## Contents

### SECTION 1
Introduction to Drug Therapy

1. **Introduction to Pharmacology**
   - A Message to Students 2
   - Overview 2
   - Sources of Drugs 3
   - Drug Classifications and Prototypes 3
   - Drug Names 3
   - Drug Marketing 3
   - Pharmacoeconomics 4
   - Prescription and Nonprescription Drugs 4
   - Drug Approval Processes 4
   - Sources of Drug Information 7
   - Strategies for Studying Pharmacology 7

2. **Basic Concepts and Processes**
   - Overview 9
   - Cellular Physiology 9
   - Drug Transport Through Cell Membranes 10
   - Pharmacokinetics 10
   - Pharmacodynamics 15
   - Variables That Affect Drug Actions 17
   - Tolerance and Cross-Tolerance 20
   - Adverse Effects of Drugs 20

3. **Administering Medications**
   - Overview 29
   - General Principles of Accurate Drug Administration 29
   - Legal Responsibilities 30
   - Medication Errors 30
   - Medication Systems 31
   - Medication Orders 31
   - Drug Preparations and Dosage Forms 32
   - Calculating Drug Dosages 34
   - Routes of Administration 35

4. **Nursing Process in Drug Therapy**
   - Overview 47
   - Nursing Process in Drug Therapy 48
   - Integrating Nursing Process, Critical Paths and Drug Therapy 51
   - General Principles of Drug Therapy 59
SECTION 2
Drugs Affecting the Central Nervous System ............ 71

5 Physiology of the Central Nervous System ................. 72
Characteristics and Functions of the Central Nervous System 72
Drugs Affecting the Central Nervous System 77

6 Opioid Analgesics and Opioid Antagonists ................. 79
Overview 79
Pain 79
Endogenous Analgesia System 80
Opioid Analgesics 80
Individual Drugs 82
Principles of Therapy 89

7 Analgesic–Antipyretic–Anti-inflammatory and Related Drugs .... 99
Overview 99
Pain, Fever, and Inflammation 100
Mechanism of Action 100
Indications for Use 102
Contraindications to Use 103
Subgroups and Individual Drugs 104
Principles of Therapy 114

8 Antianxiety and Sedative-Hypnotic Drugs ................. 124
Overview 124
Anxiety 125
Sleep and Insomnia 125
Drugs Used to Treat Anxiety and Insomnia 126
Principles of Therapy 134

9 Antipsychotic Drugs ........................................... 144
Psychosis 144
Schizophrenia 145
Antipsychotic Drugs 145
Principles of Therapy 152

10 Drugs for Mood Disorders: Antidepressants and Mood Stabilizers .... 163
Mood Disorders 163
Antidepressant Drugs 165
Types of Antidepressants and Individual Drugs 166
Principles of Therapy 171

11 Antiseizure Drugs ............................................ 182
Seizure Disorders 182
Antiseizure Drugs 183
Individual Antiseizure Drugs 184
Principles of Therapy 193
12 **Antiparkinson Drugs** .................................................. 202
Parkinson’s Disease 202
Antiparkinson Drugs 202
Individual Antiparkinson Drugs 203
Principles of Therapy 207

13 **Skeletal Muscle Relaxants** .......................................... 213
Skeletal Muscle Relaxants 213
Individual Drugs 214
Principles of Therapy 217

14 **Anesthetics** .............................................................. 220
General Anesthesia 220
Regional Anesthesia 221
Adjuncts to Anesthesia 221
Individual Anesthetic Agents 222
Principles of Therapy 222

15 **Substance Abuse Disorders** ....................................... 236
Substance Abuse 236
Dependence 236
Central Nervous System Depressants 237
Central Nervous System Stimulants 243
Principles of Therapy 249

16 **Central Nervous System Stimulants** ........................... 251
Uses 251
Types of Stimulants 252
Individual Central Nervous System Stimulants 252
Principles of Therapy 255

SECTION 3
**Drugs Affecting the Autonomic Nervous System** .... 260

17 **Physiology of the Autonomic Nervous System** ............ 261
Autonomic Nervous System 261
Characteristics of Autonomic Drugs 266

18 **Adrenergic Drugs** .................................................... 268
Description 268
Individual Adrenergic Drugs 272
Principles of Therapy 275

19 **Antiadrenergic Drugs** ............................................... 283
Description 283
Individual Antiadrenergic Drugs 285
Principles of Therapy 290
20 Cholinergic Drugs ................................................. 298
  Description 298
  Individual Cholinergic Drugs 299
  Principles of Therapy 303

21 Anticholinergic Drugs ........................................... 308
  Description 308
  Individual Anticholinergic Drugs 310
  Principles of Therapy 314

SECTION 4
Drugs Affecting the Endocrine System ................. 320

22 Physiology of the Endocrine System .................... 321
  Overview 321
  Endocrine System–Nervous System Interactions 321
  General Characteristics of Hormones 322
  General Characteristics of Hormonal Drugs 324

23 Hypothalamic and Pituitary Hormones .................. 325
  Overview 325
  Therapeutic Limitations 327
  Individual Hormonal Agents 328
  Principles of Therapy 331

24 Corticosteroids .................................................. 334
  Overview 334
  Endogenous Corticosteroids 334
  Exogenous Corticosteroids (Glucocorticoid Drugs) 337
  Principles of Therapy 343

25 Thyroid and Antithyroid Drugs ............................. 353
  Overview 353
  Thyroid Disorders 354
  Individual Drugs 356
  Principles of Therapy 360

26 Hormones That Regulate Calcium and Bone Metabolism .... 366
  Overview 366
  Drugs Used for Calcium and Bone Disorders 368
  Principles of Therapy 375

27 Antidiabetic Drugs .............................................. 382
  Overview 382
  Endogenous Insulin 382
  Diabetes Mellitus 384
  Hypoglycemic Drugs 385
  Principles of Therapy 394
28  *Estrogens, Progestins, and Hormonal Contraceptives* ............... 409
  Overview 409
  Estrogens 410
  Progesterone 410
  Estrogens and Progestins Used as Drugs 411
  Individual Estrogens, Progestins, and Combination Products 413
  Principles of Therapy 418

29  *Androgens and Anabolic Steroids* ........................................ 425
  Overview 425
  Testosterone 425
  Anabolic Steroids 426
  Abuse of Androgenic and Anabolic Steroid Drugs 426
  Androgens and Anabolic Steroids Used As Drugs 427
  Principles of Therapy 429

SECTION 5
*Nutrients, Fluids, and Electrolytes* ......................................... 433

30  *Nutritional Support Products and Drugs for Obesity* ............... 434
  Overview 434
  Nutritional Deficiency States 434
  Nutritional Products 435
  Pancreatic Enzymes 435
  Obesity 436
  Principles of Therapy 442

31  *Vitamins* ........................................................................... 453
  Overview 453
  Description and Uses 454
  Vitamin Supplements 454
  Principles of Therapy 460

32  *Minerals and Electrolytes* ...................................................... 469
  Overview 469
  Minerals as Nutrients 470
  Individual Agents Used In Mineral–Electrolyte Imbalances 470
  Principles of Therapy 483

SECTION 6
*Drugs Used to Treat Infections* ................................................... 493

33  *General Characteristics of Antimicrobial Drugs* ...................... 494
  Overview 494
  Microorganisms and Infections 494
  Host Defense Mechanisms 499
  Characteristics of Anti-infective Drugs 500
  Principles of Therapy 502
34 Beta-Lactam Antibacterials: Penicillins, Cephalosporins, and Others ........................................... 510
   Overview 510
   Penicillins 511
   Cephalosporins 517
   Carbapenems 518
   Monobactam 519
   Principles of Therapy 519

35 Aminoglycosides and Fluoroquinolones ................................................................. 527
   Overview 527
   Aminoglycosides 527
   Fluoroquinolones 530
   Principles of Therapy 531

36 Tetracyclines, Sulfonamides, and Urinary Agents ...................................................... 537
   Overview 537
   Principles of Therapy 543

37 Macrolides and Miscellaneous Antibacterials ......................................................... 548
   Overview 548
   Macrolides 548
   Miscellaneous Antibacterial Drugs 550
   Principles of Therapy 552

38 Drugs for Tuberculosis and Mycobacterium avium Complex (MAC) Disease ........ 559
   Overview 559
   Epidemiology of Tuberculosis 560
   Drug-Resistant Tuberculosis 561
   Preventing the Development and Spread of Tuberculosis 561
   Antitubercular Drugs 561
   Treatment of Active Tuberculosis 567
   Mycobacterium avium Complex Disease 567
   Principles of Therapy 568

39 Antiviral Drugs ........................................................................................................... 576
   Overview 576
   Principles of Therapy 585

40 Antifungal Drugs ......................................................................................................... 595
   Overview 595
   Fungal Infections 596
   Principles of Therapy 606

41 Antiparasitics .............................................................................................................. 614
   Overview 614
   Protozoal Infections 614
   Helminthiasis 616
   Scabies and Pediculosis 616
   Antiparasitic Drugs 617
   Principles of Therapy 623
**SECTION 7**
**Drugs Affecting Hematopoiesis and the Immune System** .......................... 627

42  **Physiology of the Hematopoietic and Immune Systems**  .......... 628
    Overview  628
    Hematopoietic Cytokines  628
    Overview of Body Defense Mechanisms  630
    Immunity  631
    Immune Cells  632
    Patient-Related Factors That Influence Immune Function  637
    Immune Disorders  638
    Drugs That Alter Hematopoietic and Immune Responses  638

43  **Immunizing Agents** .......................................................... 640
    Overview  640
    Immunization  641
    Agents for Active Immunity  641
    Agents for Passive Immunity  641
    Individual Immunizing Agents  642
    Principles of Therapy  648

44  **Hematopoietic and Immunostimulant Drugs** ......................... 657
    Overview  657
    General Characteristics of Hematopoietic and Immunostimulant Drugs  657
    Principles of Therapy  663

45  **Immunosuppressants** .................................................... 671
    Overview  671
    Autoimmune Disorders  672
    Tissue and Organ Transplantation  674
    Immunosuppressant Drugs  675
    Principles of Therapy  682

**SECTION 8**
**Drugs Affecting the Respiratory System** ............................ 693

46  **Physiology of the Respiratory System** .............................. 694
    Overview  694
    Summary  696
    Disorders of the Respiratory System  696
    Drug Therapy  696

47  **Drugs for Asthma and Other Bronchoconstrictive Disorders**  .... 697
    Overview  697
    Drug Therapy  700
    Principles of Therapy  706
## CONTENTS

### 48 Antihistamines and Allergic Disorders ............................. 715
  Overview 715  
  Histamine and Its Receptors 715  
  Hypersensitivity (Allergic) Reactions 716  
  Antihistamines 718  
  Principles of Therapy 723

### 49 Nasal Decongestants, Antitussives, and Cold Remedies .......... 728
  Overview 728  
  The Common Cold 728  
  Sinusitis 729  
  Common Signs and Symptoms of Respiratory Disorders 729  
  Drugs for Respiratory Disorders 729  
  Individual Drugs 730  
  Principles of Therapy 733

### SECTION 9  
**Drugs Affecting the Cardiovascular System**  ............. 738

### 50 Physiology of the Cardiovascular System  ..................... 739
  Overview 739  
  Heart 739  
  Blood Vessels 740  
  Blood 741  
  Cardiovascular Disorders 742  
  Drug Therapy in Cardiovascular Disorders 742

### 51 Drug Therapy of Heart Failure  ................................. 743
  Overview 743  
  Drug Therapy 744  
  Principles of Therapy 750

### 52 Antidysrhythmic Drugs  ........................................... 758
  Overview 758  
  Cardiac Electrophysiology 758  
  Cardiac Dysrhythmias 759  
  Antidysrhythmic Drugs 760  
  Classifications and Individual Drugs 760  
  Principles of Therapy 767

### 53 Antianginal Drugs  .................................................. 774
  Overview 774  
  Antianginal Drugs 777  
  Principles of Therapy 782

### 54 Drugs Used in Hypotension and Shock  .......................... 788
  Overview 788  
  Antishock Drugs 789  
  Individual Drugs 789  
  Principles of Therapy 792
55 **Antihypertensive Drugs** ................................. 797
  Overview  797
  Regulation of Arterial Blood Pressure  797
  Hypertension  798
  Antihypertensive Drugs  801
  Individual Drugs  803
  Principles of Therapy  804

56 **Diuretics** ..................................................... 818
  Overview  818
  Renal Physiology  818
  Alterations in Renal Function  821
  Diuretic Drugs  821
  Principles of Therapy  824

57 **Drugs That Affect Blood Coagulation** ................. 832
  Overview  832
  Hemostasis  833
  Clot Lysis  833
  Thrombotic and Thromboembolic Disorders  833
  Drugs Used in Thrombotic and Thromboembolic Disorders  835
  Principles of Therapy  843

58 **Drugs for Dyslipidemia** ................................. 851
  Overview  851
  Atherosclerosis  851
  Blood Lipids  852
  Dyslipidemia  853
  Initial Management of Dyslipidemia  853
  Drug Therapy of Dyslipidemia  854
  Principles of Therapy  857

**SECTION 10**
**Drugs Affecting the Digestive System** ................. 863

59 **Physiology of the Digestive System** ...................... 864
  Overview  864
  Organs of the Digestive System  864
  Secretions of the Digestive System  866
  Effects of Drugs on the Digestive System  866

60 **Drugs Used for Peptic Ulcer and Acid Reflux Disorders**  .................................................................................. 867
  Overview  867
  Peptic Ulcer Disease  867
  Types of Drugs  869
  Principles of Therapy  875
61  Laxatives and Cathartics ................................. 883
   Overview  883
   Defecation  883
   Laxatives and Cathartics  884
   Principles of Therapy  887

62  Antidiarrheals ........................................... 892
   Overview  892
   Antidiarrheal Drugs  893
   Principles of Therapy  897

63  Antiemetics ................................................. 902
   Overview  902
   Antiemetic Drugs  903
   Principles of Therapy  907

SECTION 11
Drugs Used in Special Conditions .......................... 912

64  Drugs Used in Oncologic Disorders ........................ 913
   Overview  913
   Normal and Malignant Cells  913
   Cancer  914
   Antineoplastic Drugs  916
   Individual Drugs  919
   Cytoprotectant Drugs  919
   Principles of Therapy  920

65  Drugs Used in Ophthalmic Conditions .................... 935
   Overview  935
   Disorders of the Eye  936
   Types of Ophthalmic Drugs  937
   Ophthalmic Drug Therapy  937
   Individual Drugs  937
   Principles of Therapy  938

66  Drugs Used in Dermatologic Conditions .................. 949
   Overview  949
   Disorders of the Skin  950
   Types of Dermatologic Drugs  952
   Individual Drugs  953
   Principles of Therapy  957
67 Drug Use During Pregnancy and Lactation .......................... 965
   Overview 965
   Pregnancy and Lactation 965
   Maternal–Placental–Fetal Circulation 966
   Drug Effects on the Fetus 966
   Fetal Therapeutics 970
   Maternal Therapeutics 970
   Abortifacients 973
   Tocolytics 973
   Drugs Used During Labor and Delivery at Term 974
   Neonatal Therapeutics 975
   Principles of Therapy 976

APPENDIX A
   Recently Approved and Miscellaneous Drugs ......................... 981

APPENDIX B
   The International System of Units ................................. 983

APPENDIX C
   Therapeutic Serum Drug Concentrations for Selected Drugs ...... 984

APPENDIX D
   Canadian Drug Laws and Standards ............................. 985

APPENDIX E
   Canadian Drug Names ............................................ 986

INDEX ............................................................. 995
PURPOSE

The basic precepts underlying previous editions of *Clinical Drug Therapy* continue to guide the writing of this seventh edition. The overall purpose is to promote safe, effective, and rational drug therapy by:

- Providing information that accurately reflects current practices in drug therapy.
- Facilitating the acquisition, comprehension, and application of knowledge related to drug therapy. Application requires knowledge about the drug and the client receiving it.
- Identifying knowledge and skills the nurse can use to smooth the interface between a drug and the client receiving it.

GOALS AND RESPONSIBILITIES OF NURSING CARE RELATED TO DRUG THERAPY

- Preventing the need for drug therapy, when possible, by promoting health and preventing conditions that require drug therapy.
- Using appropriate and effective nonpharmacologic interventions instead of, or in conjunction with, drug therapy when indicated. When used with drug therapy, such interventions may promote lower drug dosage, less frequent administration, and fewer adverse effects.
- Enhancing therapeutic effects by administering drugs accurately and considering clients’ individual characteristics that influence responses to drug therapy.
- Preventing or minimizing adverse drug effects by knowing the major adverse effects associated with particular drugs, identifying clients with characteristics that may increase risks of experiencing adverse effects, and actively monitoring for the occurrence of adverse effects. When adverse effects occur, early recognition allows interventions to minimize their severity. Because all drugs may cause adverse effects, nurses must maintain a high index of suspicion that symptoms, especially new ones, may be drug-induced.
- Teaching clients and caregivers about accurate administration of medications, nonpharmacologic treatments to use with or instead of pharmacologic treatments, and when to contact a health care provider.

ORGANIZATIONAL FRAMEWORK

The content of *Clinical Drug Therapy* is organized in 11 sections, primarily by therapeutic drug groups and their effects on particular body systems. This approach helps the student make logical connections between major drug groups and the conditions for which they are used. It also provides a foundation for learning about new drugs, most of which fit into known groups.

The first section contains the basic information required to learn, understand, and apply drug knowledge. The chapters in this section include drug names, classifications, prototypes, costs, laws and standards, schedules of controlled substances, drug approval processes, and learning strategies (Chapter 1); cellular physiology, drug transport, pharmacokinetic processes, the receptor theory of drug action, types of drug interactions, and factors that influence drug effects on body tissues (Chapter 2); dosage forms and routes and methods of accurate drug administration (Chapter 3); and guidelines for using the nursing process in drug therapy and general principles of drug therapy (Chapter 4).

Most drug sections include an initial chapter that reviews the physiology of a body system followed by several chapters that discuss drug groups used to treat disorders of that body system. The seven physiology review chapters are designed to facilitate understanding of drug effects on a
body system. These include the central nervous system; the autonomic nervous system; and the en-
docrine, hematopoietic, immune, respiratory, cardiovascular, and digestive systems. Other chapters
within each section emphasize therapeutic classes of drugs and prototypical or commonly used
individual drugs, those used to treat common disorders, and those likely to be encountered in
clinical nursing practice. Drug chapter content is presented in a consistent format and includes
a description of a condition for which a drug group is used; a general description of a drug group,
including mechanism(s) of action, indications for use, and contraindications; and descriptions and
tables of individual drugs, with recommended dosages and routes of administration.
Additional clinically relevant information is presented under the headings of Nursing Process,
Principles of Therapy, and Nursing Actions.

The Nursing Process section emphasizes the importance of the nursing process in drug therapy,
including assessment of the client’s condition in relation to the drug group, nursing diagnoses, ex-
pected outcomes, needed interventions, and evaluation of the client’s progress toward expected out-
comes. Client teaching guidelines are displayed separately from other interventions to emphasize
their importance.

The Principles of Therapy section presents guidelines for individualizing drug therapy in spe-
cific populations (eg, children, older adults, clients with renal or hepatic impairments). General prin-
ciples are included in Chapter 4; specific principles related to drug groups are included in the chapters
where those drug groups are discussed. This approach, rather than separate chapters on pediatric and
geriatric pharmacology, for example, was chosen because knowledge about a drug is required be-
fore that knowledge can be applied to a specific population with distinctive characteristics and needs
in relation to drug therapy.

Each drug chapter includes a Nursing Actions display that provides specific nursing respon-
sibilities related to drug administration and client observation.

Other drug sections include products used to treat nutritional, infectious, oncologic, oph-
thalmic, and dermatologic disorders.

NEW FEATURES AND CONTENT

• Updated Drug Information. More than 100 new drugs have been added. Some are addi-
tions to well-known drug groups, such as the angiotensin II receptor antagonists (Chapter
55); antidiabetic drugs (Chapter 27); antiretroviral drugs (Chapter 39); and drugs that affect
blood coagulation (Chapter 57). Others represent advances in the drug therapy of some dis-
ease processes, such as newer anti-cancer agents (Chapter 64).

In addition, continuing trends in drug dosage formulations are reflected in the increased
numbers of fixed-dose combination drug products, long-acting preparations, and nasal or oral
inhalation products.

• Major Revision of Many Chapters. Chapter revisions reflect current practices in drug ther-
apy, integrate new drugs, explain the major characteristics of new drug groups, provide in-
creased information about pharmacokinetics and toxicology, and add content related to
herbal and dietary supplements when relevant to chapter content.

• Herbal and Dietary Supplements. Commonly used products are introduced in Chapter 4
and included in selected later chapters. Safety aspects are emphasized.

• New Tables. These include the conversion of all remaining drug monographs to a tabular for-
mat for drug dosages, tables of pharmacokinetic data for selected drug groups, a table of com-
monly overdosed drugs and their antidotes, and a table of commonly used herbal supplements.

• New Illustrations. Several new illustrations have been developed, primarily to enhance un-
derstanding of drug actions.

• New Boxed Displays. These include information to promote understanding of drug therapy
for selected conditions.

IMPORTANT RECURRING FEATURES

• Readability. Since the first edition of Clinical Drug Therapy was published in 1983, many
students and faculty have commented about the book’s clear presentation style.
• **Organizational Framework.** The book’s organizational framework allows it to be used effectively as both a textbook and as a reference. As a textbook, students can read chapters in their entirety to learn the characteristics of major drug classes, their prototypical drugs or commonly used representatives, their uses and effects in prevention or treatment of disease processes, and their implications for nursing practice. As a reference book, students can readily review selected topics for classroom use or clinical application. Facilitating such uses are a consistent format and frequent headings that allow the reader to identify topics at a glance.

• **Four-Color Design.** The striking design enhances liveliness of the text and promotes student interest and interactivity.

• **Interactive Displays.** Presented in consistent formats and colors throughout the text, these displays heighten student attention and emphasize critical thinking and clinical decision-making skills. Drug-related chapters contain two or more of the following displays: an opening critical thinking scenario, a knowledge application situation, a medication error prevention exercise, and an ethical/legal dilemma. The solutions to the knowledge application situations and the medication error prevention exercises appear at the ends of chapters.

• **Chapter Objectives.** Learning objectives at the beginning of each chapter focus the student’s attention on important chapter content.

• **Client Teaching Guidelines.** This feature is designed to meet several goals. One is to highlight the importance of teaching clients and caregivers how to manage drug therapy at home, where most medications are taken. This is done by separating teaching from other nursing interventions. Another goal is to promote active and knowledgeable client participation in drug therapy regimens, which helps to maximize therapeutic effects and minimize adverse effects. In addition, written guidelines allow clients and caregivers to have a source of reference when questions arise in the home setting. A third goal is to make client teaching easier and less time consuming. Using the guidelines as a foundation, the nurse can simply add or delete information according to a client’s individual needs. To assist both the nurse and client further, the guidelines contain minimal medical jargon.

• **Principles of Therapy.** This unique section describes important drug-related and client-related characteristics that need to be considered in drug therapy regimens. Such considerations can greatly increase safety and therapeutic effects, and all health care providers associated with drug therapy should be aware of them. Most chapters contain principles with the headings of Use in Children, Use in Older Adults, Use in Renal Impairment, Use in Hepatic Impairment, and Home Care to denote differences related to age, developmental level, pathophysiology, and the home care setting. Some chapters include principles related to Genetic and Ethnic Considerations, Use in Critical Illness, and Management of Drug Toxicity or Drug Withdrawal.

• **Nursing Actions Displays.** These displays emphasize nursing interventions during drug therapy within the following categories: Administer accurately, Observe for therapeutic effects, Observe for adverse effects, and Observe for drug interactions. The inclusion of rationales for interventions provides a strong knowledge base and scientific foundation for clinical practice and critical thinking.

• **Review and Application Exercises.** Located at the end of each chapter, these questions encourage students to rehearse clinical application strategies in a nonclinical, nonstressful, nondistracting environment. They also promote self-testing in chapter content and can be used to promote classroom discussion. Answers to these exercises can be found on the connection companion Website http://connection.lww.com/go/abrams7e.

• **Appendices.** These include recently approved and miscellaneous drugs, the International System of Units, therapeutic serum drug concentrations for selected drugs, Canadian drug laws and standards, and Canadian drug names.

• **Extensive Index.** Listings of generic and trade names of drugs, nursing process, and other topics provide rapid access to desired information.

**ANCILLARY PACKAGE**

Nursing students must develop skills in critical thinking, information processing, decision making, collaboration, and problem solving. How can a teacher assist students to develop these skills in relation to drug therapy? The goal of the ancillary package is to assist both student and teacher in this development.
The Study Guide engages the student’s interest and active participation by providing a variety of learning exercises and opportunities to practice cognitive skills. Worksheets promote the learning of concepts, principles, and characteristics and uses of major drug groups. The worksheets can be completed independently, by a small group as an in-class learning activity, or by the instructor, with answers elicited from the class as a whole. Clinical challenge scenarios promote appropriate data collection, critical analysis of both drug-related and client-related data, and application of the data in patient care.

The connection companion Website http://connection.lww.com/go/abrams7e provides online updates for faculty and students, links to newly-approved drugs, answers to the chapter questions for review and application, and more.

The free Back of Book CD-ROM is an invaluable learning tool that provides 3-D animated depictions of pharmacology concepts, video on preventing medication errors, NCLEX-style review questions, and monographs of the 100 most commonly prescribed drugs.

The Instructor’s Resource CD-ROM facilitates use of the text in designing and implementing courses of study. To fulfill this purpose, the CD-ROM contains an Instructor’s Manual, an Electronic Testbank, and PowerPoint Slides.

The Instructor’s Manual includes the following:
- General observations and comments about teaching and learning pharmacology in relation to nursing
- A sample syllabus for a separate three-credit hour, one-semester pharmacology course that may be taught in a traditional classroom or a nontraditional online setting
- General teaching strategies for classroom or online teaching, with a listing of additional requirements for an online course (eg, a computer network and software such as WebCT or Blackboard; student computer skills and access to a computer; interactivity between students and faculty and among students; student preparation and participation; an online mechanism for submitting assignments, taking tests, and receiving grades; and modified teaching strategies)
- Specific teaching strategies for classroom, online, small group, and clinical teaching of content in each chapter
- A list of major topics; text locations of objectives, displays, and selected elements; terms and concepts; and selected individual drugs for each drug-related chapter of the text
- Suggestions for designing an independent study course for RNs seeking a BSN
- Suggestions for including pharmacology content in the nursing courses of an integrated curriculum.
- Discussion/solutions of Clinical Challenges from the Study Guide
- Drug Jeopardy Game, with a description and sample questions and answers

The Brownstone® Testbank includes approximately 1,000 multiple-choice test items in NCLEX format, a Test Generator, and Grade Book. These materials can assist the instructor in evaluating students’ knowledge of drug information and their ability to apply that information in client care.

PowerPoint slides include text and art from Clinical Drug Therapy to provide significant classroom or online teaching support.

These varied materials allow each instructor to choose or adapt those relevant to his or her circumstances. The author and publisher hope the materials are truly helpful in easing the day-to-day rigors of teaching pharmacology, and invite comments from instructors regarding the materials.

Anne Collins Abrams, RN, MSN
Contributors

Sondra G. Ferguson, RN, MSN, CS, ANP, APRN, BC
Assistant Professor of Nursing
Berea College
Berea, Kentucky
Chapters 50, 51, 55, 57, 58

Tracey Goldsmith, PharmD
Independent Legal and Healthcare Consultant
Magnolia, Texas
Chapters 33–37
Note: These chapters were reviewed by John Mohr, PharmD, Clinical Specialist, Infectious Diseases, Memorial Hermann Hospital, Houston, Texas

Constance J. Hirnle, RN, MN
Nursing Development Specialist
Virginia Mason Medical Center
Seattle, Washington
and
Lecturer, Biobehavioral Nursing and Health Systems
University of Washington
Seattle, Washington
Chapter Opening Critical Thinking Scenarios, Nursing Notes:
Apply Your Knowledge, How Can You Avoid This Medication Error?, and Ethical/Legal Dilemma

Carol Ann Barnett Lammon, RN, PhD
Assistant Professor of Nursing
Capstone College of Nursing
University of Alabama
Tuscaloosa, Alabama
Chapter 17–21

Sandra Smith Pennington, RN, PhD
Associate Professor of Nursing
Berea College
Berea, Kentucky
Chapters 50, 52, 53, 54, 56

Frank Romanelli, PharmD, BCSP
Assistant Professor
College of Pharmacy and College of Health Sciences
University of Kentucky
Lexington, Kentucky
Chapters 39 and 41
**NEW** Drugs at a Glance tables give students characteristics, and routes and dosage ranges in an easy-to-read format.

**chapter 37**

**Macrolides and Miscellaneous Antibacterials**

**Objectives**
- Discuss mechanisms and specific uses of macrodilide antibiotics.
- Compare and contrast macrodilides with other classes of antibiotics.
- Apply antivirus and anti-bacterial therapy in related clinical situations.

**Critical Thinking Scenario**

You are an infection control nurse and you are providing diabetes care to patients with diabetic ketoacidosis (DKA). The patient, who has type 1 diabetes, has been hospitalized with DKA. The patient’s glucose level is 500 mg/dL, and the patient is also being treated with vancomycin.

**Chapter Objectives**
- Let students know what they’re going to learn in each and every chapter.
- Critical Thinking Scenarios at the beginning of each chapter help students prepare for using their knowledge in the real world.
- Prototype drugs are highlighted in the text for the first time.
How Can You Avoid This Medication Error? gives students examples of common mistakes, and helps them avoid them in the future.

Client Teaching Guidelines gives students specific information they may need to educate patients.

Nursing Notes: Apply Your Knowledge asks students a specific question about information from the chapter.

Drug Selection

1. Type of cancer is a major factor. Therefore, prostate cancer in elderly men is ideal for certain drugs that have lower levels of activity against the tumor.

2. Age of patient is another consideration. Younger patients may tolerate higher doses of chemotherapy than older patients.

3. Gender of patient is also taken into account. Women generally have lower levels of the enzyme that metabolizes certain drugs, which can affect their response to treatment.

4. Genetic factors are important. For example, some patients may have a higher risk of developing certain side effects due to variations in their genetic makeup.

5. Drug interactions are significant. Some medications may increase or decrease the effectiveness of other drugs, either by blocking their absorption or enhancing their metabolism.

Drug Administration

1. Oral route is preferred, but other routes may be necessary for certain drugs. For example, intravenous routes are used for drugs that require rapid administration or for patients unable to take oral medication.

2. Medication schedules vary depending on the drug. For some drugs, once-daily dosing is sufficient, while others require more frequent administration.

3. Patient compliance is crucial. Patients must be educated about their medication regimen and the importance of adhering to it.

4. Home health visits may be beneficial for patients receiving home infusion therapy.

Clinical Drug Therapy material helps students think about drug therapy in terms of the nursing process.

Nursing Process

1. Assessment involves gathering data about the patient, including their medical history, current symptoms, and other relevant factors.

2. Planning involves developing a plan of care based on the assessment findings.

3. Implementation involves carrying out the plan of care, which may include administering medications, monitoring for adverse effects, and providing education.

4. Evaluation involves reviewing the outcomes of the nursing care provided and making any necessary adjustments to the plan of care.
NEW® Herbal and Dietary Supplement Content is highlighted so students are aware of how these alternative therapies may affect traditional medications.

Home Care content is highlighted in the text.

Nursing Actions give students specific instructions on administration of drugs, with rationales for each step.

Nursing Notes and How Can You Avoid This Medication Error? answers are provided at the end of the chapter so students can think on their own, and compare their answers to the ones within the text.

Review and Application Exercises gives students the opportunity to review what they just learned.
Reviewers

Sarah P. Delaware, RN, BSN, MSN
Assistant Professor of Nursing
Truman State University
Nursing Program
Kirksville, Missouri

Mary Elliott, RN, BScN, MEd
Professor
Humber College of Applied Arts and Technology
Etobicoke, Ontario
Canada

Christine Hobbs, RN, BSN
Nursing Instructor
Southwest Virginia Community College
Grundy, Virginia

Mary Jo Kirkpatrick, RN, MSN
Director, Associate of Science in Nursing
Mississippi University for Women
Columbus, Mississippi

Dorothy Mathers, RN, MSN
Associate Professor of Nursing
Pennsylvania College of Technology
Williamsport, Pennsylvania

Peggy Przybycien, RN, MS
Associate Professor of Nursing
Onondaga Community College
Syracuse, New York

Deanna L. Reising, RN, CS, PhD
Assistant Professor
Indiana University School of Nursing
Bloomington, Indiana

Judy M. Truttman, RNC, BSN, MSN
Nursing Instructor
Northeast Wisconsin Technical College
Green Bay, Wisconsin

Denise R. York, RNC, MS, MEd, CNS
Associate Professor
Columbus State Community College
Columbus, Ohio
section 1

Introduction to Drug Therapy
Introduction to Pharmacology

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Differentiate between pharmacology and drug therapy.
2. Differentiate between generic and trade names of drugs.
3. Define a prototypical drug.
4. Select authoritative sources of drug information.
5. Discuss major drug laws and standards.
6. Differentiate the main categories of controlled substances in relation to therapeutic use and potential for abuse.
7. Discuss nursing responsibilities in handling controlled substances correctly.
8. Discuss the role of the Food and Drug Administration.
9. Analyze the potential impact of drug costs on drug therapy regimens.
10. Develop personal techniques for learning about drugs and using drug knowledge in client care.

Critical Thinking Scenario

This is your first semester of clinical nursing. This quarter you will be taking a basic nursing theory course, a skills laboratory, and pharmacology. You anticipate that pharmacology will be challenging. To increase your clinical knowledge and ensure that you will be a safe practitioner, you want to develop a strong foundation in pharmacology.

Reflect on:

- List successful strategies you have used in the past to learn difficult material. Reflect on which strategies might be helpful this semester.
- Assess support for your learning at your school (e.g., learning center, peer tutors, student study groups) and develop a plan to use them.
- Review your course syllabus and pharmacology text. Develop a learning plan (e.g., readings, assignments, study times for major tests) and enter this plan into your calendar.

A MESSAGE TO STUDENTS

You’ve probably been taking medicines and seeing other people take medicines most of your life. Perhaps you’ve given medicines to your children, parents, grandparents, or others. Have you ever wondered why it’s usually okay to give children Tylenol but not aspirin? Why a lot of middle-aged and older people take an aspirin a day? Why people with high blood pressure, heart failure, or diabetes take ACE inhibitors and what ACE inhibitors are? When an antibiotic should NOT be prescribed for an infection?

You are embarking on an exciting journey of discovery as you begin or continue your study of pharmacology. Much of what you learn will apply to your personal and family life as well as your professional life as a nurse. The purpose of this book is to help you learn about medicines and the why, what, how, when, and where they are used in daily life. Bon voyage!!

OVERVIEW

Pharmacology is the study of drugs (chemicals) that alter functions of living organisms. Drug therapy, also called pharmacotherapy, is the use of drugs to prevent, diagnose, or treat signs, symptoms, and disease processes. When prevention or cure is not a reasonable goal, relief of symptoms can greatly improve quality of life and ability to function in activities of daily living. Drugs given for therapeutic purposes are usually called medications.
Medications may be given for various reasons. In many instances, the goal of drug therapy is to lessen disease processes rather than cure them. To meet this goal, drugs may be given for local or systemic effects. Drugs with local effects, such as sunscreen lotions and local anesthetics, act mainly at the site of application. Those with systemic effects are taken into the body, circulated through the bloodstream to their sites of action in various body tissues, and eventually eliminated from the body. Most drugs are given for their systemic effects. Drugs may also be given for relatively immediate effects (eg, in acute problems such as pain or infection) or long-term effects (eg, to relieve signs and symptoms of chronic disorders). Many drugs are given for their long-term effects.

**SOURCES OF DRUGS**

Where do medications come from? Historically, drugs were mainly derived from plants (eg, morphine), animals (eg, insulin), and minerals (eg, iron). Now, most drugs are synthetic chemical compounds manufactured in laboratories. Chemists, for example, can often create a useful new drug by altering the chemical structure of an existing drug (eg, adding, deleting, or altering a side-chain). Such techniques and other technological advances have enabled the production of new drugs as well as synthetic versions of many drugs originally derived from plants and animals. Synthetic drugs are more standardized in their chemical characteristics, more consistent in their effects, and less likely to produce allergic reactions. Semisynthetic drugs (eg, many antibiotics) are naturally occurring substances that have been chemically modified.

Biotechnology is also an important source of drugs. This process involves manipulating deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) and recombining genes into hybrid molecules that can be inserted into living organisms (Escherichia coli bacteria are often used) and repeatedly reproduced. Each hybrid molecule produces a genetically identical molecule, called a clone. Cloning makes it possible to identify the DNA sequence in a gene and produce the protein product encoded by a gene, including insulin and several other body proteins. Cloning also allows production of adequate amounts of the drug for therapeutic or research purposes.

**DRUG NAMES**

Individual drugs may have several different names, but the two most commonly used are the generic name and the trade name (also called the brand or proprietary name). The generic name (eg, amoxicillin) is related to the chemical or official name and is independent of the manufacturer. The generic name often indicates the drug group (eg, drugs with generic names ending in “cillin” are penicillins). The trade name is designated and patented by the manufacturer. For example, amoxicillin is manufactured by several pharmaceutical companies, some of which assign a specific trade name (eg, Amoxil, Trimox) and several of which use only the generic name. In drug literature, trade names are capitalized and generic names are lowercase unless in a list or at the beginning of a sentence. Drugs may be prescribed and dispensed by generic or trade name.

**DRUG MARKETING**

A new drug is protected by patent for 14 years, during which it can be marketed only by the pharmaceutical manufacturer that developed it. This is seen as a return on the company’s investment in developing a drug, which may require years of work and millions of dollars, and an incentive for developing other drugs. Other pharmaceutical companies cannot manufacture and market the drug. However, for new drugs that are popular and widely used, other companies often produce similar drugs, with different generic and trade names. For example, the marketing of fluoxetine (Prozac) led to the introduction of similar drugs from different companies, such as citalopram (Celexa), fluvoxamine (Luvox), paroxetine (Paxil), and sertraline (Zoloft). Prozac was approved in 1987 and went off patent in 2001, meaning that any pharmaceutical company could then manufacture and market the generic formulation of fluoxetine. Generic drugs are required to be therapeutically equivalent and are much less expensive than trade name drugs.
PHARMACOECONOMICS

Pharmacoeconomics involves the costs of drug therapy, including those of purchasing, dispensing (eg, salaries of pharmacists, pharmacy technicians), storage, administration (eg, salaries of nurses, costs of supplies), laboratory and other tests used to monitor client responses, and losses from expiration. Length of illness or hospitalization is also considered.

Costs are increasingly being considered a major factor in choosing medications, and research projects that compare costs have greatly increased in recent years. The goal of most studies is to define drug therapy regimens that provide the desired benefits at the least cost. For drugs or regimens of similar efficacy and toxicity, there is considerable pressure on prescribers (eg, from managed care organizations) to prescribe less costly drugs.

PRESCRIPTION AND NONPRESCRIPTION DRUGS

Legally, American consumers have two routes of access to therapeutic drugs. One route is by prescription or order from a licensed health care provider, such as a physician, dentist, or nurse practitioner. The other route is by over-the-counter (OTC) purchase of drugs that do not require a prescription. Both of these routes are regulated by various drug laws. Acquiring and using prescription drugs for nontherapeutic purposes, by persons who are not authorized to have the drugs or for whom they are not prescribed, is illegal.

American Drug Laws and Standards

Current drug laws and standards have evolved over many years. Their main goal is to protect the public by ensuring that drugs marketed for therapeutic purposes, whether prescription or OTC, are safe and effective. Their main provisions are summarized in Table 1–1.

The Food, Drug, and Cosmetic Act of 1938 was especially important because this law and its amendments regulate the manufacture, distribution, advertising, and labeling of drugs. It also confers official status on drugs listed in The United States Pharmacopeia. The names of these drugs may be followed by the letters USP. Official drugs must meet standards of purity and strength as determined by chemical analysis or animal response to specified doses (bioassay). The Durham-Humphrey Amendment designated drugs that must be prescribed by a physician and dispensed by a pharmacist. The Food and Drug Administration (FDA) is charged with enforcing the law. In addition, the Public Health Service regulates vaccines and other biologic products, and the Federal Trade Commission can suppress misleading advertisements of nonprescription drugs.

Another important law, the Comprehensive Drug Abuse Prevention and Control Act, was passed in 1970. Title II of this law, called the Controlled Substances Act, regulates the manufacture and distribution of narcotics, stimulants, depressants, hallucinogens, and anabolic steroids. These drugs are categorized according to therapeutic usefulness and potential for abuse (Box 1–1) and labeled as controlled substances (eg, morphine, a Schedule II drug, is labeled C–II).

The Drug Enforcement Administration (DEA) is charged with enforcing the Controlled Substances Act. Individuals and companies legally empowered to handle controlled substances must be registered with the DEA, keep accurate records of all transactions, and provide for secure storage. Physicians are assigned a number by the DEA and must include the number on all prescriptions they write for a controlled substance. Prescriptions for Schedule II drugs cannot be refilled; a new prescription is required. Nurses are responsible for storing controlled substances in locked containers, administering them only to people for whom they are prescribed, recording each dose given on agency narcotic sheets and on the client’s medication administration record, maintaining an accurate inventory, and reporting discrepancies to the proper authorities.

In addition to federal laws, state laws also regulate the sale and distribution of controlled drugs. These laws may be more stringent than federal laws; if so, the stricter laws usually apply.

Canadian Drug Laws and Standards

Canada and its provinces have laws and standards that parallel those of the United States, particularly those related to controlled substances (see Appendix D).

Nursing Notes: Apply Your Knowledge

Using this text and a drug handbook, or the Physicians’ Desk Reference (PDR), look up the following drugs: meperidine and diazepam. Indicate the controlled substance category for each drug. From the information you obtained in researching the drug, reflect on why each drug was placed in the assigned category. How did the resources you used differ in the organization and depth of information provided about drugs?

DRUG APPROVAL PROCESSES

The FDA is responsible for assuring that new drugs are safe and effective before approving the drugs and allowing them to be marketed. The FDA reviews research studies (usually conducted or sponsored by a pharmaceutical company) about proposed new drugs; the organization does not test the drugs.

Before passage of the Food, Drug, and Cosmetic Act, many drugs were marketed without confirmation of safety or
TABLE 1–1 American Drug Laws and Amendments

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Main Provision(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1906</td>
<td>Pure Food and Drug Act</td>
<td>Established official standards and requirements for accurate labeling of drug products</td>
</tr>
<tr>
<td>1912</td>
<td>Sherley Amendment</td>
<td>Prohibited fraudulent claims of drug effectiveness</td>
</tr>
<tr>
<td>1914</td>
<td>Harrison Narcotic Act</td>
<td>Restricted the importation, manufacture, sale, and use of opium, cocaine, marijuana, and other drugs that the act defined as narcotics</td>
</tr>
<tr>
<td>1938</td>
<td>Food, Drug, and Cosmetic Act</td>
<td>• Required proof of safety from the manufacturer before a new drug could be marketed&lt;br&gt;• Authorized factory inspections&lt;br&gt;• Established penalties for fraudulent claims and misleading labels</td>
</tr>
<tr>
<td>1945</td>
<td>Amendment</td>
<td>Required governmental certification of biologic products, such as insulin and antibiotics</td>
</tr>
<tr>
<td>1952</td>
<td>Durham-Humphrey Amendment</td>
<td>Designated drugs that must be prescribed by a physician and dispensed by a pharmacist (eg, controlled substances, drugs considered unsafe for use except under supervision by a health care provider, and drugs limited to prescription use under a manufacturer’s new drug application)</td>
</tr>
<tr>
<td>1962</td>
<td>Kefauver-Harris Amendment</td>
<td>• Required a manufacturer to provide evidence (from well-controlled research studies) that a drug was effective for claims and conditions identified in the product’s labeling&lt;br&gt;• Gave the federal government the authority to standardize drug names</td>
</tr>
<tr>
<td>1970</td>
<td>Comprehensive Drug Abuse Prevention and Control Act; Title II, Controlled Substances Act</td>
<td>• Regulated distribution of narcotics and other drugs of abuse&lt;br&gt;• Categorized these drugs according to therapeutic usefulness and potential for abuse</td>
</tr>
<tr>
<td>1978</td>
<td>Drug Regulation Reform Act</td>
<td>• Established guidelines for research studies and data to be submitted to the FDA by manufacturers&lt;br&gt;• Shortened the time required to develop and market new drugs</td>
</tr>
<tr>
<td>1983</td>
<td>Orphan Drug Act</td>
<td>• Decreased taxes and competition for manufacturers who would produce drugs to treat selected serious disorders affecting relatively few people</td>
</tr>
<tr>
<td>1987</td>
<td></td>
<td>• Established new regulations designed to speed up the approval process for high-priority medications</td>
</tr>
<tr>
<td>1992</td>
<td>Prescription Drug User Fee Act</td>
<td>• Allowed the FDA to collect user fees from pharmaceutical companies, with each new drug application, to shorten the review time (eg, by hiring more staff)&lt;br&gt;• Specified a review time of 12 months for standard drugs and 6 months for priority drugs</td>
</tr>
<tr>
<td>1997</td>
<td>FDA Modernization Act</td>
<td>• Updated regulation of biologic products&lt;br&gt;• Increased client access to experimental drugs and medical devices&lt;br&gt;• Accelerated review of important new drugs&lt;br&gt;• Allowed drug companies to disseminate information about off-label (non–FDA-approved) uses and costs of drugs&lt;br&gt;• Extended user fees</td>
</tr>
</tbody>
</table>

FDA, Food and Drug Administration.

BOX 1–1 CATEGORIES OF CONTROLLED SUBSTANCES

**Schedule I**
Drugs that are not approved for medical use and have high abuse potentials: heroin, lysergic acid diethylamide (LSD), peyote, mescaline, tetrahydrocannabinol, marijuana.

**Schedule II**
Drugs that are used medically and have high abuse potentials: opioid analgesics (eg, codeine, hydromorphone, methadone, meperidine, morphine, oxycodone, oxymorphone), central nervous system (CNS) stimulants (eg, cocaine, methamphetamine, methylphenidate), and barbiturate sedative-hypnotics (amobarbital, pentobarbital, secobarbital).

**Schedule III**
Drugs with less potential for abuse than those in Schedules I and II, but abuse may lead to psychological or physical dependence: an- drogens and anabolic steroids, some CNS stimulants (eg, benzphetamine), and mixtures containing small amounts of controlled substances (eg, codeine, barbiturates not listed in other schedules).

**Schedule IV**
Drugs with some potential for abuse: benzodiazepines (eg, diazepam, lorazepam, temazepam), other sedative-hypnotics (eg, phenobarbital, chloral hydrate), and some prescription appetite suppressants (eg, mazindol, phenetermine).

**Schedule V**
Products containing moderate amounts of controlled substances. They may be dispensed by the pharmacist without a physician’s prescription but with some restrictions regarding amount, record keeping, and other safeguards. Included are antidiarrheal drugs, such as diphenoxylate and atropine (Lomotil).
Testing and Clinical Trials

The testing process begins with animal studies to determine potential uses and effects. The next step involves FDA review of the data obtained in the animal studies. The drug then undergoes clinical trials in humans. Most clinical trials use a randomized, controlled experimental design that involves selection of subjects according to established criteria, random assignment of subjects to experimental groups, and administration of the test drug to one group and a control substance to another group.

In Phase I, a few doses are given to a few healthy volunteers to determine safe dosages, routes of administration, absorption, metabolism, excretion, and toxicity. In Phase II, a few doses are given to a few subjects with the disease or symptom for which the drug is being studied, and responses are compared with those of healthy subjects. In Phase III, the drug is given to a larger and more representative group of subjects. In double-blind, placebo-controlled designs, half the subjects receive the new drug and half receive a placebo, with neither subjects nor researchers knowing who receives which formulation. In crossover studies, subjects serve as their own controls; each subject receives the experimental drug during half the study and a placebo during the other half. Other research methods include control studies, in which some clients receive a known drug rather than a placebo, and subject matching, in which clients are paired with others of similar characteristics. Phase III studies help to determine whether the potential benefits of the drug outweigh the risks.

In Phase IV, the FDA evaluates the data from the first three phases for drug safety and effectiveness, allows the drug to be marketed for general use, and requires manufacturers to continue monitoring the drug's effects. Some adverse drug effects may become evident during the postmarketing phase as the drug is more widely used. Several drugs have been withdrawn in recent years, partly or mainly because of the increased postmarketing surveillance. Critics contend that changes enacted to streamline the approval process have allowed unsafe drugs to be marketed; proponents claim that the faster review process helps clients with serious diseases to gain effective treatment more quickly.

The FDA has increased efforts to monitor marketed drugs more closely in recent years, especially for their adverse effects. One such effort involves contracts with some commercial companies that provide access to databases containing information on the actual use of prescription drugs in adults and children. Examples of information include how long nonhospitalized patients stay on prescribed medications, which combinations of medications are being prescribed to patients, and the use of prescription drugs in hospitalized children. Individual patients are not identified in these databases.

Food and Drug Administration Approval

The FDA approves many new drugs annually. In 1992, procedures were changed to accelerate the approval process, especially for drugs used to treat acquired immunodeficiency syndrome. Since then, new drugs are categorized according to their review priority and therapeutic potential. “1P” status indicates a new drug reviewed on a priority basis and with some therapeutic advantages over similar drugs already available; “1S” status indicates standard review and drugs with few, if any, therapeutic advantages (ie, the new drug is similar to one already available). Most newly approved drugs are “1S” prescription drugs.

The FDA also approves drugs for OTC availability, including the transfer of drugs from prescription to OTC status, and may require additional clinical trials to determine safety and effectiveness of OTC use. Numerous drugs have been transferred from prescription to OTC status in recent years and the trend is likely to continue. For drugs taken orally, indications for use may be different, and recommended doses are usually lower for the OTC formulation. For example, for OTC ibuprofen, which is available under its generic and several trade names (eg, Advil) in 200-mg tablets and used for pain, fever, and dysmenorrhea, the recommended dose is usually 200 to 400 mg three or four times daily. With prescription ibuprofen, Motrin is the common trade name and dosage may be 400, 600, or 800 mg three or four times daily.

FDA approval of a drug for OTC availability involves evaluation of evidence that the consumer can use the drug safely, using information on the product label, and shifts primary responsibility for safe and effective drug therapy from health care professionals to consumers. With prescription drugs, a health care professional diagnoses the condition, often with the help of laboratory and other diagnostic tests, and determines a need for the drug. With OTC drugs, the client must make these decisions, with or without consultation with a health care provider. Questions to be answered include the following:

1. Can consumers accurately self-diagnose the condition for which a drug is indicated?
2. Can consumers read and understand the label well enough to determine the dosage, interpret warnings and contraindications and determine whether they apply, and recognize drugs already being taken that might interact adversely with the drug being considered?
3. Is the drug effective when used as recommended?
4. Is the drug safe when used as instructed?

Having drugs available OTC has potential advantages and disadvantages for consumers. Advantages include greater autonomy; faster and more convenient access to effective treatment; possibly earlier resumption of usual activities of daily living; fewer visits to a health care provider; and possibly increased efforts by consumers to learn about their symptoms/conditions and recommended treatments. Disadvantages include inaccurate self-diagnoses and potential risks of choosing a wrong or contraindicated drug, delaying treatment by a health care professional, and developing adverse drug reactions and interactions.

When a drug is switched from prescription to OTC status, pharmaceutical companies’ sales and profits increase and insurance companies’ costs decrease. Costs to consumers may increase because health insurance policies do not cover OTC drugs. For the year 2000, it was estimated that Americans spent more than $19 billion on OTC drugs.

**SOURCES OF DRUG INFORMATION**

There are many sources of drug data, including pharmacology textbooks, drug reference books, journal articles, and Internet sites. For the beginning student of pharmacology, a textbook is usually the best source of information because it describes groups of drugs in relation to therapeutic uses. Drug reference books are most helpful in relation to individual drugs. Two authoritative sources are the American Hospital Formulary Service and Drug Facts and Comparisons. The former is published by the American Society of Health-System Pharmacists and updated periodically. The latter is published by the Facts and Comparisons division of Lippincott Williams & Wilkins and updated monthly (looseleaf edition) or annually (hardbound edition). A widely available but less authoritative source is the Physicians’ Desk Reference (PDR). The PDR, published yearly, is a compilation of manufacturers’ package inserts for selected drugs.

Numerous drug handbooks (eg, Lippincott’s Nursing Drug Guide, published annually) and pharmacologic, medical, and nursing journals also contain information about drugs. Journal articles often present information about drug therapy for clients with specific disease processes and may thereby facilitate application of drug knowledge in clinical practice. Helpful Internet sites include the Food and Drug Administration (http://www.fda.gov), and RxMed (http://www.rxmed.com).

**STRATEGIES FOR STUDYING PHARMACOLOGY**

1. *Concentrate on therapeutic classifications and their prototypes.* For example, morphine is the prototype of opioid analgesics (see Chap. 6). Understanding morphine makes learning about other opioid analgesics easier because they are compared with morphine.

**Nursing Notes: Apply Your Knowledge**

Answer: Meperidine (Demerol) is an opioid analgesic that is used to manage severe pain. Its abuse potential is high and it is therefore given a Schedule II classification. Diazepam (Valium) is an antianxiety agent that has some potential for abuse, so it is listed as a Schedule IV drug. Different references give you different information and are organized differently. A nursing textbook of pharmacology is comprehensive and gives you enough information to understand how drugs work. It is the best resource to use when you are first learning about drugs. Drug handbooks are helpful when you are trying to research specific information about a specific drug. They are arranged alphabetically and assume you have a basic understanding of pharmacology. The PDR is available in many health care facilities. It provides the reader with drug inserts from the manufacturer and color photographs of many medications. It is published annually, so it is a good resource for new drugs. Much information is provided, but without prioritization (eg, any reported side effect is given rather than identifying the most common or most serious side effects), which can make it difficult for a beginning student to use effectively.
Review and Application Exercises

1. What is the difference between local and systemic effects of drugs?
2. Can a client experience systemic effects of local drugs and local effects of systemic drugs? Why or why not?
3. Why is it helpful for nurses to know the generic names of commonly used medications?
4. Why is it helpful to study prototypes of drug groups?
5. List at least three strategies for studying pharmacology.
6. List at least three authoritative sources of drug information.

SELECTED REFERENCES


Basic Concepts and Processes

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss cellular physiology in relation to drug therapy.
2. Describe the main pathways and mechanisms by which drugs cross biologic membranes and move through the body.
3. Describe each process of pharmacokinetics.
4. Discuss the clinical usefulness of measuring serum drug levels.
5. Describe major characteristics of the receptor theory of drug action.
6. Differentiate between agonist drugs and antagonist drugs.
7. Describe drug-related and client-related variables that affect drug actions.
8. Discuss mechanisms and potential effects of drug–drug interactions.
9. Identify signs and symptoms that may occur with adverse drug effects on major body systems.
10. Discuss general management of drug overdose and toxicity.
11. Discuss selected drug antidotes.

Critical Thinking Scenario
Mrs. Green, an 89-year-old widow, lives alone and has recently started taking many heart medications. She prides herself on being independent and able to manage on her own despite failing memory and failing health. When you visit as a home health nurse, you assess therapeutic and adverse effects of her medications.

Reflect on:
- Considering Mrs. Green’s age, what factors might alter the pharmacokinetics (absorption, distribution, metabolism, excretion) of the drugs she takes? What data will you collect to determine her risk?
- What psychosocial factors could affect the therapeutic and adverse effects of Mrs. Green’s medications? What data will be important to collect before developing a plan for Mrs. Green?
- When clients are taking many medications, the risk for drug interactions and toxicity increases. Describe how you will develop a plan to research possible drug interactions for any client.

OVERVIEW
All body functions and disease processes and most drug actions occur at the cellular level. Drugs are chemicals that alter basic processes in body cells. They can stimulate or inhibit normal cellular functions and activities; they cannot add functions and activities. To act on body cells, drugs given for systemic effects must reach adequate concentrations in blood and other tissue fluids surrounding the cells. Thus, they must enter the body and be circulated to their sites of action (target cells). After they act on cells, they must be eliminated from the body.

How do systemic drugs reach, interact with, and leave body cells? How do people respond to drug actions? The answers to these questions are derived from cellular physiology, pathways and mechanisms of drug transport, pharmacokinetics, pharmacodynamics, and other basic concepts and processes. These concepts and processes form the foundation of rational drug therapy and the content of this chapter.

CELLULAR PHYSIOLOGY
Cells are dynamic, busy, “factories” (Fig. 2–1; Box 2–1). That is, they take in raw materials, manufacture various products required to maintain cellular and bodily functions, and deliver those products to their appropriate destinations in the body. Although cells differ from one tissue to another, their common characteristics include the ability to:
SECTION 1 INTRODUCTION TO DRUG THERAPY

• Exchange materials with their immediate environment
• Obtain energy from nutrients
• Synthesize hormones, neurotransmitters, enzymes, structural proteins, and other complex molecules
• Duplicate themselves (reproduce)
• Communicate with each other via various biologic chemicals, such as neurotransmitters and hormones

DRUG TRANSPORT THROUGH CELL MEMBRANES

Drugs, as well as physiologic substances such as hormones and neurotransmitters, must reach and interact with or cross the cell membrane in order to stimulate or inhibit cellular function. Most drugs are given for effects on body cells that are distant from the sites of administration (ie, systemic effects). To move through the body and reach their sites of action, metabolism, and excretion (Fig. 2–2), drug molecules must cross numerous cell membranes. For example, molecules of most oral drugs must cross the membranes of cells in the gastrointestinal (GI) tract, liver, and capillaries to reach the bloodstream, circulate to their target cells, leave the bloodstream and attach to receptors on cells, perform their action, return to the bloodstream, circulate to the liver, reach drug-metabolizing enzymes in liver cells, re-enter the bloodstream (usually as metabolites), circulate to the kidneys, and be excreted in urine. Several transport pathways and mechanisms are used to move drug molecules through the body (Fig. 2–3 and Box 2–2).

PHARMACOKINETICS

Pharmacokinetics involves drug movement through the body (ie, “what the body does to the drug”) to reach sites of action, metabolism, and excretion. Specific processes are absorption, distribution, metabolism (biotransformation), and excretion. Overall, these processes largely determine serum drug levels, onset, peak and duration of drug actions, drug half-life, therapeutic and adverse drug effects, and other important aspects of drug therapy.

Absorption

Absorption is the process that occurs from the time a drug enters the body to the time it enters the bloodstream to be circulated. Onset of drug action is largely determined by the rate of absorption; intensity is determined by the extent of absorption. Numerous factors affect the rate and extent of drug absorption, including dosage form, route of administration, blood flow to the site of administration, GI function, the presence of food or other drugs, and other variables. Dosage form is a major determinant of a drug’s bioavailability (the portion of a dose that reaches the systemic circulation and is available to act on body cells). An intravenous drug is virtually 100% bioavailable; an oral drug is virtually always less than 100% bioavailable because some is not absorbed from the GI tract and some goes to the liver and is partially metabolized before reaching the systemic circulation.

Most oral drugs must be swallowed, dissolved in gastric fluid, and delivered to the small intestine (which has a large surface area for absorption of nutrients and drugs) before they are absorbed. Liquid medications are absorbed faster than tablets or capsules because they need not be dissolved. Rapid movement through the stomach and small intestine may increase drug absorption by promoting contact with absorptive mucous membrane; it also may decrease absorption because some drugs may move through the small intestine too rapidly to be absorbed. For many drugs, the presence of food in the stomach slows the rate of absorption and may decrease the amount of drug absorbed.

Drugs injected into subcutaneous (SC) or intramuscular (IM) tissues are usually absorbed more rapidly than oral drugs because they move directly from the injection site to the bloodstream. Absorption is rapid from IM sites because muscle tissue has an abundant blood supply. Drugs injected intravenously (IV) do not need to be absorbed because they are placed directly into the bloodstream.

Other absorptive sites include the skin, mucous membranes, and lungs. Most drugs applied to the skin are given for local effects (eg, sunscreens). Systemic absorption is minimal from intact skin but may be considerable when the skin is inflamed or damaged. Also, a number of drugs have been formulated in adhesive skin patches for absorption through the skin (eg, clonidine, estrogen, fentanyl, nitroglycerin, scopolamine). Some drugs applied to mucous membranes also are given for local effects. However, systemic absorption occurs from the mucosa of the oral cavity, nose, eye, vagina, and rectum. Drugs absorbed through mucous membranes may pass directly into the bloodstream. The lungs have a large surface area for absorption of anesthetic gases and a few other drugs.
Protoplasms comprises the internal environment of body cells. It is composed of water, electrolytes (potassium, magnesium, phosphate, sulfate, and bicarbonate), proteins, lipids, and carbohydrates.

Water makes up 70% to 85% of most cells; cellular enzymes, electrolytes, and other chemicals are dissolved or suspended in the water.

Electrolytes provide chemicals for cellular reactions and are required for some processes (e.g., transmission of electrochemical impulses in nerve and muscle cells).

Proteins comprise 10% to 20% of the cell mass. They consist of “physical” proteins that form the structure of cells and “chemical” proteins that function mainly as enzymes within the cell. These enzymatic proteins come into direct contact with other substances in the cell fluid and catalyze chemical reactions within the cell.

Lipids, mainly phospholipids and cholesterol, form the membranes that separate structures inside the cell and the cell itself from surrounding cells and body fluids.

Carbohydrates play a minor role in cell structure, but a major role in cell nutrition. Glucose is present in extracellular fluid and readily available to supply the cell’s need for energy. In addition, a small amount of carbohydrate is stored within the cell as glycogen, a storage form of glucose that can be rapidly converted when needed.

The nucleus might be called the “manager” of cellular activities because it regulates the type and amount of proteins, enzymes, and other substances to be produced.

The cytoplasm surrounds the nucleus and contains the working units of the cell.

The endoplasmic reticulum (ER) contains ribosomes, which synthesize enzymes and other proteins. These include enzymes that synthesize glycogen, triglycerides, and steroids and those that detoxify drugs and other chemicals. The ER is important in the production of hormones by glandular cells and the production of plasma proteins and drug-metabolizing enzymes by liver cells.

The Golgi complex stores hormones and other substances produced by the ER. It also packages these substances into secretory granules, which then move out of the Golgi complex into the cytoplasm and, after an appropriate stimulus, are released from the cell through the process of exocytosis.

Mitochondria generate energy for cellular activities and require oxygen.

Lysosomes are membrane-enclosed vesicles that contain enzymes capable of digesting nutrients (proteins, carbohydrates, fats), damaged cellular structures, foreign substances (e.g., bacteria), and the cell itself. When a cell becomes worn out or damaged, the membrane around the lysosome breaks and the enzymes (hydrolases) are released. However, lysosomal contents also are released into extracellular spaces, destroying surrounding cells. Normally, the enzymes are activated by enzyme inhibitors and excessive tissue destruction is prevented.

The cell membrane, a complex structure composed of phospholipids, proteins, cholesterol and carbohydrates, separates intracellular contents from the extracellular environment, provides receptors for hormones and other biologically active substances, participates in electrical events that occur in nerve and muscle cells, and helps regulate growth and proliferation.

The cell membrane, which covers the entire surface of the cell, consists of a thin, double layer of lipids interspersed with proteins (see Fig. 2–3). The lipid layer is composed of phospholipid (fatty acid and phosphate) molecules. The phosphate end of each phospholipid molecule, located on the external surface and in contact with the tissue fluids surrounding the cell, is soluble in water. The fatty acid end of the phospholipid molecule, located in the middle of the membrane, is soluble only in fat. Thus, this portion of the membrane allows easy penetration of fat-soluble substances such as oxygen and alcohol, but is impermeable to water-soluble substances such as ions and glucose.

Cell membrane proteins, most of which are combined with a carbohydrate as glycoproteins, include integral and peripheral proteins. Integral proteins penetrate through the entire membrane so that each end is available to interact with other substances. The protein portion protrudes on the intracellular side of the cell membrane; the glyco portion protrudes to the outside of the cell, dangling outward from the cell surface. Some of these proteins provide structural channels or pores through which water and water-soluble substances (e.g., sodium, potassium, and calcium ions) can diffuse between extracellular and intracellular fluids. Others act as carriers to transport substances that otherwise could not penetrate the lipid layer of the membrane. Still others act as enzymes to catalyze chemical substances that otherwise could not penetrate the lipid layer of the membrane. Still others act as enzymes to catalyze chemical reactions within the cell. Peripheral proteins do not penetrate the cell membrane. They are usually attached to the intracellular side of the membrane and to integral proteins. These proteins function as enzymes and other substances that regulate intracellular function.

Cell membrane carbohydrates occur mainly in combination with proteins (glycoproteins) or lipids (glycolipids). Glycoproteins composed of carbohydrate around a small, inner core of protein (called proteoglycans) are often attached to and cover the entire outside surface of the cell. As a result, the carbohydrate molecules are free to interact with extracellular substances and perform several important functions. First, many have a negative electrical charge which gives most cells an overall negative surface charge that repels other negatively charged substances. Second, the “carbohydrate coat” of some cells attaches to the carbohydrate coat of other cells and thereby connects cells to each other. Third, many of the carbohydrates act as receptor molecules for binding hormones (e.g., insulin). The receptor–hormone combination then activates the attached inner core of protein to perform its enzymatic or other functions in the cell.
**Distribution**

*Distribution* involves the transport of drug molecules within the body. Once a drug is injected or absorbed into the bloodstream, it is carried by the blood and tissue fluids to its sites of pharmacologic action, metabolism, and excretion. Most drug molecules enter and leave the bloodstream at the capillary level, through gaps between the cells that form capillary walls. Distribution depends largely on the adequacy of blood circulation. Drugs are distributed rapidly to organs receiving a large blood supply, such as the heart, liver, and kidneys. Distribution to other internal organs, muscle, fat, and skin is usually slower.

An important factor in drug distribution is *protein binding* (Fig. 2–4). Most drugs form a complex with plasma proteins, mainly albumin, which act as carriers. Drug molecules bound to plasma proteins are pharmacologically inactive because the large size of the complex prevents their leaving the bloodstream through the small openings in capillary walls and reaching their sites of action, metabolism, and excretion. Only the free or unbound portion of a drug acts on body cells. As the free drug acts on cells, the decrease in plasma drug levels causes some of the bound drug to be released.

Protein binding allows part of a drug dose to be stored and released as needed. Some drugs also are stored in muscle, fat, or other body tissues and released gradually when plasma drug levels fall. These storage mechanisms maintain lower, more even blood levels and reduce the risk of toxicity. Drugs that are highly bound to plasma proteins or stored extensively in other tissues have a long duration of action.

Drug distribution into the central nervous system (CNS) is limited because the blood–brain barrier, which is composed of capillaries with tight walls, limits movement of drug molecules into brain tissue. This barrier usually acts as a selectively permeable membrane to protect the CNS. However, it also can make drug therapy of CNS disorders more difficult because drugs must pass through cells of the capillary wall rather than between cells. As a result, only drugs that are lipid soluble or have a transport system can cross the blood–brain barrier and reach therapeutic concentrations in brain tissue.

Drug distribution during pregnancy and lactation is also unique (see Chap. 67). During pregnancy, most drugs cross the placenta and may affect the fetus. During lactation, many drugs enter breast milk and may affect the nursing infant.

**Metabolism**

*Metabolism* is the method by which drugs are inactivated or biotransformed by the body. Most often, an active drug is changed into one or more inactive metabolites, which are

![Cell membrane](image)

Lipid-soluble drugs dissolve in the lipid layer of the cell membrane and diffuse into or out of the cell.

![Gated channels](image)

Gated channels regulate movement of ions.

![Carrier proteins](image)

Carrier proteins attach to drug molecules and move them across cell membranes.
BOX 2–2 DRUG TRANSPORT PATHWAYS AND MECHANISMS

Pathways
There are three main pathways of drug movement across cell membranes. The most common pathway is direct penetration of the membrane by lipid-soluble drugs, which are able to dissolve in the lipid layer of the cell membrane. Most systemic drugs are formulated to be lipid soluble so they can move through cell membranes, even oral tablets and capsules that must be sufficiently water soluble to dissolve in the aqueous fluids of the stomach and small intestine.

A second pathway involves passage through protein channels that go all the way through the cell membrane. Only a few drugs are able to use this pathway because most drug molecules are too large to pass through the small channels. Small ions (eg, sodium and potassium) use this pathway, but their movement is regulated by specific channels with a gating mechanism. The gate is a flap of protein that opens for a few milliseconds to allow ion movement across the cell membrane, then closes (ie, blocks the channel opening) to prevent additional ion movement. On sodium channels, the gates are located on the outside of the cell membrane; when the gates open, sodium ions (Na⁺) move from extracellular fluid into the cell. On potassium channels, the gates are located on the inside of the cell membrane; when the gates open, potassium ions (K⁺) move from the cell into extracellular fluid.

The stimulus for opening and closing the gates may be voltage gating or chemical (also called ligand) gating. With voltage gating, the electrical potential across the cell membrane determines whether the gate is open or closed. With chemical gating, a chemical substance (a ligand) binds with the protein forming the channel and changes the shape of the protein to open or close the gate. Chemical gating (eg, by neurotransmitters such as acetylcholine) is very important in the transmission of signals from one nerve cell to another and from nerve cells to muscle cells to cause muscle contraction.

Mechanisms
Once absorbed into the body, drugs are transported to and from target cells by such mechanisms as passive diffusion, facilitated diffusion, and active transport.

Passive diffusion, the most common mechanism, involves movement of a drug from an area of higher concentration to one of lower concentration. For example, after oral administration, the initial concentration of a drug is higher in the gastrointestinal tract than in the blood. This promotes movement of the drug into the bloodstream. When the drug is circulated, the concentration is higher in the blood than in body cells, so that the drug moves (from capillaries) into the fluids surrounding the cells or into the cells themselves. Passive diffusion continues until a state of equilibrium is reached between the amount of drug in the tissues and the amount in the blood.

Facilitated diffusion is a similar process, except that drug molecules combine with a carrier substance, such as an enzyme or other protein.

In active transport, drug molecules are moved from an area of lower concentration to one of higher concentration. This process requires a carrier substance and the release of cellular energy.

The third pathway involves carrier proteins that transport molecules from one side of the cell membrane to the other. All of the carrier proteins are selective in the substances they transport; a drug’s structure determines which carrier will transport it. These transport systems are an important means of moving drug molecules through the body. They are used, for example, to carry oral drugs from the intestine to the bloodstream, to carry hormones to their sites of action inside body cells, and to carry drug molecules from the blood into renal tubules.

Bloodstream

![Diagram of drug transport](Image)

Figure 2-4 Plasma proteins, mainly albumin (A), act as carriers for drug molecules (D). Bound drug (A–D) stays in bloodstream and is pharmacologically inactive. Free drug (D) can leave the bloodstream and act on body cells.

Most drugs are lipid soluble, a characteristic that aids their movement across cell membranes. However, the kidneys, which are the primary excretory organs, can excrete only water-soluble substances. Therefore, one function of metabolism is to convert fat-soluble drugs into water-soluble metabolites. Hepatic drug metabolism or clearance is a major mechanism for terminating drug action and eliminating drug molecules from the body.

Most drugs are metabolized by enzymes in the liver (called the cytochrome P450 [CYP] or the microsomal enzyme system); red blood cells, plasma, kidneys, lungs, and GI mucosa also contain drug-metabolizing enzymes. The cytochrome P450 system consists of 12 groups or families, nine of which metabolize endogenous substances and three of which metabolize drugs. The three groups that metabolize drugs are labeled CYP1, CYP2 and CYP3. Of the many drugs metabolized by the liver, the CYP3 group of enzymes is thought to metabolize about 50%, the CYP2 group about 45%, and the CYP1 group about 5%. Individual members of the groups, each of which metabolizes specific drugs, are further categorized. For example, many drugs are metabolized by CYP2D6, CYP2C9, or CYP3A4 enzymes.

These enzymes, located within hepatocytes, are complex proteins with binding sites for drug molecules (and endogenous substances). They catalyze the chemical reactions of oxidation, reduction, hydrolysis, and conjugation with endogenous sub-
stances, such as glucuronic acid or sulfate. With chronic administration, some drugs stimulate liver cells to produce larger amounts of drug-metabolizing enzymes (a process called enzyme induction). Enzyme induction accelerates drug metabolism because larger amounts of the enzymes (and more binding sites) allow larger amounts of a drug to be metabolized during a given time. As a result, larger doses of the rapidly metabolized drug may be required to produce or maintain therapeutic effects. Rapid metabolism may also increase the production of toxic metabolites with some drugs, (eg, acetaminophen). Drugs that induce enzyme production also may increase the rate of metabolism for endogenous steroidal hormones (eg, cortisol, estrogens, testosterone, and vitamin D). However, enzyme induction does not occur for 1 to 3 weeks after an inducing agent is started, because new enzyme proteins must be synthesized. Rifampin, an antituberculosis drug, is a strong inducer of CYP 1A and 3A enzymes.

Metabolism also can be decreased or delayed in a process called enzyme inhibition, which most often occurs with concurrent administration of two or more drugs that compete for the same metabolizing enzymes. In this case, smaller doses of the slowly metabolized drug may be needed to avoid adverse reactions and toxicity from drug accumulation. Enzyme inhibition occurs within hours or days of starting an inhibiting agent. Cimetidine, a gastric acid suppressor, inhibits several CYP enzymes (eg, 1A2, 2C, and 3A) and can greatly decrease drug metabolism. The rate of drug metabolism also is reduced in infants (their hepatic enzyme system is immature), in people with impaired blood flow to the liver or severe hepatic or cardiovascular disease, and in people who are malnourished or on low-protein diets.

When drugs are given orally, they are absorbed from the GI tract and carried to the liver through the portal circulation. Some drugs are extensively metabolized in the liver, with only part of a drug dose reaching the systemic circulation for distribution to sites of action. This is called the first-pass effect or presystemic metabolism.

**Excretion**

Excretion refers to elimination of a drug from the body. Effective excretion requires adequate functioning of the circulatory system and of the organs of excretion (kidneys, bowel, lungs, and skin). Most drugs are excreted by the kidneys and eliminated unchanged or as metabolites in the urine. Some drugs or metabolites are excreted in bile, then eliminated in feces; others are excreted in bile, reabsorbed from the small intestine, returned to the liver (called enterohepatic recirculation), metabolized, and eventually excreted in urine. Some oral drugs are not absorbed and are excreted in the feces. The lungs mainly remove volatile substances, such as anesthetic gases. The skin has minimal excretory function. Factors impairing excretion, especially severe renal disease, lead to accumulation of numerous drugs and may cause severe adverse effects if dosage is not reduced.

**Serum Drug Levels**

A serum drug level is a laboratory measurement of the amount of a drug in the blood at a particular time (Fig. 2–5). It reflects dosage, absorption, bioavailability, half-life, and the rates of metabolism and excretion. A minimum effective concentration (MEC) must be present before a drug exerts its pharmacologic action on body cells; this is largely determined by the drug dose and how well it is absorbed into the bloodstream. A toxic concentration is an excessive level at which toxicity occurs. Toxic concentrations may stem from a single large dose, repeated small doses, or slow metabolism that allows the drug to accumulate in the body. Between these low and high concentrations is the therapeutic range, which is the goal of drug therapy—that is, enough drug to be beneficial, but not enough to be toxic.

For most drugs, serum levels indicate the onset, peak, and duration of drug action. When a single dose of a drug is given, onset of action occurs when the drug level reaches the MEC. The drug level continues to climb as more of the drug is absorbed, until it reaches its highest concentration and peak drug action occurs. Then, drug levels decline as the drug is eliminated (ie, metabolized and excreted) from the body. Although there may still be numerous drug molecules in the body, drug action stops when drug levels fall below the MEC. The duration of action is the time during which serum drug levels are at or above the MEC. When multiple doses of a drug are given (eg, for chronic, long-lasting conditions), the goal is usually to give sufficient doses often enough to maintain serum drug levels in the therapeutic range and avoid the toxic range.

In clinical practice, measuring serum drug levels is useful in several circumstances:

- When drugs with a low or narrow therapeutic index are given. These are drugs with a narrow margin of safety because their therapeutic doses are close to their toxic doses (eg, digoxin, aminoglycoside antibiotics, lithium, theophylline).
- To document the serum drug levels associated with particular drug dosages, therapeutic effects, or possible adverse effects.
- To monitor unexpected responses to a drug dose. This could be either a lack of therapeutic effect or increased adverse effects.
- When a drug overdose is suspected.

**Serum Half-Life**

Serum half-life, also called elimination half-life, is the time required for the serum concentration of a drug to decrease by 50%. It is determined primarily by the drug’s rates of metabolism and excretion. A drug with a short half-life requires more frequent administration than one with a long half-life.

When a drug is given at a stable dose, four or five half-lives are required to achieve steady-state concentrations and develop equilibrium between tissue and serum concentra-
Because maximal therapeutic effects do not occur until equilibrium is established, some drugs are not fully effective for days or weeks. To maintain steady-state conditions, the amount of drug given must equal the amount eliminated from the body. When a drug dose is changed, an additional four to five half-lives are required to re-establish equilibrium; when a drug is discontinued, it is eliminated gradually over several half-lives.

**PHARMACODYNAMICS**

Pharmacodynamics involves drug actions on target cells and the resulting alterations in cellular biochemical reactions and functions (ie, “what the drug does to the body”). As previously stated, all drug actions occur at the cellular level.

**Receptor Theory of Drug Action**

Like the physiologic substances (eg, hormones and neurotransmitters) that normally regulate cell functions, most drugs exert their effects by chemically binding with receptors at the cellular level (Fig. 2–6). Receptors are mainly proteins located on the surfaces of cell membranes or within cells. Specific receptors include enzymes involved in essential metabolic or regulatory processes (eg, dihydrofolate reductase, acetylcholinesterase); proteins involved in transport (eg, sodium–potassium adenosine triphosphatase) or structural processes (eg, tubulin); and nucleic acids (eg, DNA) involved in cellular protein synthesis, reproduction, and other metabolic activities.

When drug molecules bind with receptor molecules, the resulting drug–receptor complex initiates physiochemical reactions that stimulate or inhibit normal cellular functions. One type of reaction involves activation, inactivation, or other alterations of intracellular enzymes. Because almost all cellular functions are catalyzed by enzymes, drug-induced changes can markedly increase or decrease the rate of cellular metabolism. For example, an epinephrine–receptor complex increases the activity of the intracellular enzyme adenylyl cyclase, which then causes the formation of cyclic adenosine 3’,5’-monophosphate (cAMP) and a consequent increase in cellular metabolic activity.

**Nursing Notes: Apply Your Knowledge**

A client has a drug level of 100 units/mL. The drug’s half-life is 1 hour. If concentrations above 25 units/mL are toxic and no more drug is given, how long will it take for the blood level to reach the nontoxic range?
also interact with receptors to stimulate or inhibit cellular function. Drug molecules (Da and Db) also interact with receptors to stimulate or inhibit cellular function. Additional elements and characteristics of the receptor theory include the following:

1. The site and extent of drug action on body cells are determined primarily by specific characteristics of receptors and drugs. Receptors vary in type, location, number, and functional capacity. For example, many different types of receptors have been identified. Most types occur in most body tissues, such as receptors for epinephrine and norepinephrine (whether received from stimulation of the sympathetic nervous system or administration of drug formulations) and receptors for hormones, including growth hormone, thyroid hormone, and insulin. Some occur in fewer body tissues, such as receptors for opiates and benzodiazepines in the brain and subgroups of receptors for epinephrine in the heart (beta₁-adrenergic receptors) and lungs (beta₂-adrenergic receptors). Receptor type and location influence drug action. The receptor is often described as a lock into which the drug molecule fits as a key, and only those drugs able to bond chemically to the receptors in a particular body tissue can exert pharmacologic effects on that tissue. Thus, all body cells do not respond to all drugs, even though virtually all cell receptors are exposed to any drug molecules circulating in the bloodstream.

2. When drug molecules chemically bind with cell receptors, the pharmacologic effects are those due to either agonism or antagonism. Agonists are drugs that produce effects similar to those produced by naturally occurring hormones, neurotransmitters, and other substances. Agonists may accelerate or slow normal cellular processes, depending on the type of receptor activated. For example, epinephrine-like drugs act on the heart to increase the heart rate, and acetylcholine-like drugs act on the heart to slow the heart rate; both are agonists. Antagonists are drugs that inhibit cell function by occupying receptor sites. This prevents natural body substances or other drugs from occupying the receptor sites and activating cell functions. Once drug action occurs, drug molecules may detach from receptor molecules (ie, the chemical binding is reversible), return to the bloodstream, and circulate to the liver for metabolism and the kidneys for excretion.

3. Receptors are dynamic cellular components that can be synthesized by body cells and altered by endogenous substances and exogenous drugs. For example, prolonged stimulation of body cells with an excitatory agonist usually reduces the number or sensitivity of receptors. As a result, the cell becomes less responsive to the agonist (a process called receptor desensitization.

**Figure 2–6** Cell membrane contains receptors for physiologic substances such as hormones (H) and neurotransmitters (NT). These substances stimulate or inhibit cellular function. Drug molecules (Da and Db) also interact with receptors to stimulate or inhibit cellular function.
or down-regulation). Prolonged inhibition of normal cellular functions with an antagonist may increase receptor number or sensitivity. If the antagonist is suddenly reduced or stopped, the cell becomes excessively responsive to an agonist (a process called receptor up-regulation). These changes in receptors may explain why some drugs must be tapered in dosage and discontinued gradually if withdrawal symptoms are to be avoided.

**Nonreceptor Drug Actions**

Relatively few drugs act by mechanisms other than combination with receptor sites on cells. These include:

1. Antacids, which act chemically to neutralize the hydrochloric acid produced by gastric parietal cells and thereby raise the pH of gastric fluid
2. Osmotic diuretics (eg, mannitol), which increase the osmolarity of plasma and pull water out of tissues into the bloodstream
3. Drugs that are structurally similar to nutrients required by body cells (eg, purines, pyrimidines) and that can be incorporated into cellular constituents, such as nucleic acids. This interferes with normal cell functioning. Several anticancer drugs act by this mechanism.
4. Metal chelating agents, which combine with toxic metals (eg, lead) to form a complex that can be more readily excreted.

**VARIABLES THAT AFFECT DRUG ACTIONS**

Expected responses to drugs are largely based on those occurring when a particular drug is given to healthy adult men (18 to 65 years of age) of average weight (150 lb [70 kg]). However, other groups of people (eg, women, children, older adults, different ethnic or racial groups, and clients with diseases or symptoms that the drugs are designed to treat) receive drugs and respond differently than healthy adult men. Therefore, current clinical trials are including more representatives of these groups. In any client, however, responses may be altered by both drug- and client-related variables, some of which are described in the following sections.

**Drug-Related Variables**

**Dosage**

Although the terms dose and dosage are often used interchangeably, dose indicates the amount to be given at one time and dosage refers to the frequency, size, and number of doses. Dosage is a major determinant of drug actions and responses, both therapeutic and adverse. If the amount is too small or administered infrequently, no pharmacologic action occurs because the drug does not reach an adequate concentration at target cells. If the amount is too large or administered too often, toxicity (poisoning) may occur. Because dosage includes the amount of the drug and the frequency of administration, overdosage may occur with a single large dose or with chronic ingestion of smaller amounts. Doses that produce signs and symptoms of toxicity are called toxic doses. Doses that cause death are called lethal doses.

Dosages recommended in drug literature are usually those that produce particular responses in 50% of the people tested. These dosages usually produce a mixture of therapeutic and adverse effects. The dosage of a particular drug depends on many characteristics of the drug (reason for use, potency, pharmacokinetics, route of administration, dosage form, and others) and of the recipient (age, weight, state of health, and function of cardiovascular, renal, and hepatic systems). Thus, the recommended dosages are intended only as guidelines for individualizing dosages.

**Route of Administration**

Routes of administration affect drug actions and responses largely by influencing absorption and distribution. For rapid drug action and response, the IV route is most effective because the drug is injected directly into the bloodstream. For some drugs, the IM route also produces drug action within a few minutes because muscles have a large blood supply. The oral route usually produces slower drug action than parenteral routes. Absorption and action of topical drugs vary according to the drug formulation, whether the drug is applied to skin or mucous membranes, and other factors.

**Drug–Diet Interactions**

Food may alter the absorption of oral drugs. In many instances, food slows absorption by slowing gastric emptying time and altering GI secretions and motility. When tablets or capsules are taken with or soon after food, they dissolve more slowly; therefore, drug molecules are delivered to absorptive sites in the small intestine more slowly. Food also may decrease absorption by combining with a drug to form an insoluble drug–food complex. In other instances, however, certain drugs or dosage forms are better absorbed with certain types of meals. For example, a fatty meal increases the absorption of some sustained-release forms of theophylline. Interactions that alter drug absorption can be minimized by spacing food and medications.

In addition, some foods contain substances that react with certain drugs. One such interaction occurs between tyramine-containing foods and monoamine oxidase (MAO) inhibitor drugs. Tyramine causes the release of norepinephrine, a strong vasoconstrictive agent, from the adrenal medulla and sympathetic neurons. Normally, norepinephrine is active for only a few milliseconds before it is inactivated by MAO. However, because MAO inhibitor drugs prevent inactivation of norepinephrine, ingesting tyramine-containing foods with an MAO inhibitor may produce severe hypertension or intracranial
Drug–Drug Interactions

The action of a drug may be increased or decreased by its interaction with another drug in the body. Most interactions occur whenever the interacting drugs are present in the body; some, especially those affecting the absorption of oral drugs, occur when the interacting drugs are given at or near the same time. The basic cause of many drug–drug interactions is altered drug metabolism. For example, drugs metabolized by the same enzymes may compete for enzyme binding sites and there may not be enough binding sites for two or more drugs. Also, some drugs induce or inhibit the metabolism of other drugs. Protein binding is also the basis for some important drug–drug interactions. A drug with a strong attraction to protein-binding sites may displace a less tightly bound drug. The displaced drug then becomes pharmacologically active, and the overall effect is the same as taking a larger dose of the displaced drug.

Increased Drug Effects

Interactions that can increase the therapeutic or adverse effects of drugs are as follows:

1. **Additive effects** occur when two drugs with similar pharmacologic actions are taken.
   
   Example: ethanol + sedative drug → increased sedation

2. **Synergism or potentiation** occurs when two drugs with different sites or mechanisms of action produce greater effects when taken together than either does when taken alone.

   Example: acetaminophen (non-opioid analgesic) + codeine (opioid analgesic) → increased analgesia

3. **Interference** by one drug with the metabolism or elimination of a second drug may result in intensified effects of the second drug.

   Example: cimetidine inhibits CYP 1A, 2C, and 3A drug-metabolizing enzymes in the liver and therefore interferes with the metabolism of many drugs (eg, benzodiazepine antianxiety and hypnotic drugs, calcium channel blockers, tricyclic antidepressants, some antidysrhythmics, beta blockers and antiseizure drugs, theophylline, and warfarin). When these drugs are given concurrently with cimetidine, they are likely to cause adverse and toxic effects.

4. **Displacement** of one drug from plasma protein-binding sites by a second drug increases the effects of the displaced drug. This increase occurs because the molecules of the displaced drug, freed from their bound form, become pharmacologically active.

   Example: aspirin (an anti-inflammatory/analgesic/antipyretic agent) + warfarin (an anticoagulant) → increased anticoagulant effect

Decreased Drug Effects

Interactions in which drug effects are decreased are grouped under the term antagonism. Examples of such interactions are as follows:

1. In some situations, a drug that is a specific antidote is given to antagonize the toxic effects of another drug.

   Example: naloxone (a narcotic antagonist) + morphine (a narcotic or opioid analgesic) → relief of opioid-induced respiratory depression. Naloxone molecules displace morphine molecules from their receptor sites on nerve cells in the brain so that the morphine molecules cannot continue to exert their depressant effects.

2. Decreased intestinal absorption of oral drugs occurs when drugs combine to produce nonabsorbable compounds.

   Example: aluminum or magnesium hydroxide (antacids) + oral tetracycline (an antibiotic) → binding of tetracycline to aluminum or magnesium, causing decreased absorption and decreased antibiotic effect of tetracycline

3. Activation of drug-metabolizing enzymes in the liver increases the metabolism rate of any drug metabolized primarily by that group of enzymes. Several drugs (eg, phenytoin, rifampin), ethanol, and cigarette smoking are known enzyme inducers.

   Example: phenobarbital (a barbiturate) + warfarin (an anticoagulant) → decreased effects of warfarin

4. Increased excretion occurs when urinary pH is changed and renal reabsorption is blocked.

   Example: sodium bicarbonate + phenobarbital → increased excretion of phenobarbital. The sodium bicar-
In general, people heavier than average need larger doses, provided that their renal, hepatic, and cardiovascular functions are adequate. Recommended doses for many drugs are listed in terms of grams or milligrams per kilogram of body weight.

**Genetic and Ethnic Characteristics**

Drugs are given to elicit certain responses that are relatively predictable for most drug recipients. When given the same drug in the same dose, however, some people experience inadequate therapeutic effects, and others experience unusual or exaggerated effects, including increased toxicity. These interindividual variations in drug response are often attributed to genetic or ethnic differences in drug pharmacokinetics or pharmacodynamics. As a result, there is increased awareness that genetic and ethnic characteristics are important factors and that diverse groups must be included in clinical trials.

**Genetics**

A person’s genetic characteristics may influence drug action in several ways. For example, genes determine the types and amounts of proteins produced in the body. When most drugs enter the body, they interact with proteins (eg, in plasma, tissues, cell membranes, and drug receptor sites) to reach their sites of action, and with other proteins (eg, drug-metabolizing enzymes in the liver and other organs) to be biotransformed and eliminated from the body. Genetic characteristics that alter any of these proteins can alter drug pharmacokinetics or pharmacodynamics.

One of the earliest genetic variations to be identified derived from the observation that some people taking usual doses of isoniazid (an antitubercular drug), hydralazine (an antihypertensive agent), or procainamide (an antidysrhythmic) showed no therapeutic effects, whereas toxicity developed in other people. Research established that these drugs are normally metabolized by acetylation, a chemical conjugation process in which the drug molecule combines with an acetyl group of acetyl coenzyme A. The reaction is catalyzed by a hepatic drug-metabolizing enzyme called acetyltransferase. It was further established that humans may acetylate the drug rapidly or slowly, depending largely on genetically controlled differences in acetylator activity. Clinically, rapid acetylators may need larger-than-usual doses to achieve therapeutic effects, and slow acetylators may need smaller-than-usual doses to avoid toxic effects. In addition, several genetic variations of the cytochrome P450 drug-metabolizing system have been identified. Specific variations may influence any of the chemical processes by which drugs are metabolized.

As another example of genetic variation in drug metabolism, some people lack the plasma pseudocholinesterase enzyme that normally inactivates succinylcholine, a potent muscle relaxant used in some surgical procedures. These people may experience prolonged paralysis and apnea if given succinylcholine.

Other people are deficient in glucose-6-phosphate dehydrogenase, an enzyme normally found in red blood cells and

**Client-Related Variables**

**Age**

The effects of age on drug action are most pronounced in neonates, infants, and older adults. In children, drug action depends largely on age and developmental stage. During pregnancy, drugs cross the placenta and may harm the fetus. Fetuses have no effective mechanisms for metabolizing or eliminating drugs because their liver and kidney functions are immature. Newborn infants (birth to 1 month) also handle drugs inefficiently. Drug distribution, metabolism, and excretion differ markedly in neonates, especially premature infants, because their organ systems are not fully developed.

Older infants (1 month to 1 year) reach approximately adult levels of protein binding and kidney function, but liver function and the blood–brain barrier are still immature.

Children (1 to 12 years) experience a period of increased activity of drug-metabolizing enzymes so that some drugs are rapidly metabolized and eliminated. Although the onset and duration of this period are unclear, a few studies have been done with particular drugs. Theophylline, for example, is cleared much faster in a 7-year-old child than in a neonate or adult (18 to 65 years). After approximately 12 years of age, healthy children handle drugs similarly to healthy adults.

In older adults (65 years and older), physiologic changes may alter all pharmacokinetic processes. Changes in the GI tract include decreased gastric acidity, decreased blood flow, and decreased motility. Despite these changes, however, there is little difference in absorption. Changes in the cardiovascular system include decreased cardiac output and therefore slower distribution of drug molecules to their sites of action, metabolism, and excretion. In the liver, blood flow and metabolizing enzymes are decreased. Thus, many drugs are metabolized more slowly, have a longer action, and are more likely to accumulate with chronic administration. In the kidneys, there is decreased blood flow, decreased glomerular filtration rate, and decreased tubular secretion of drugs. All of these changes tend to slow excretion and promote accumulation of drugs in the body. **Impaired kidney and liver function greatly increase the risks of adverse drug effects.** In addition, older adults are more likely to have acute and chronic illnesses that require multiple drugs or long-term drug therapy. Thus, possibilities for interactions among drugs and between drugs and diseased organs are greatly multiplied.

**Body Weight**

Body weight affects drug action mainly in relation to dose. The ratio between the amount of drug given and body weight influences drug distribution and concentration at sites of action.
other body tissues. These people may have hemolytic anemia when given antimalarial drugs, sulfonamides, analgesics, antipyretics, and other drugs.

**Ethnicity**

Most drug information has been derived from clinical drug trials using white men; few subjects of other ethnic groups are included. Interethnic variations became evident when drugs and dosages developed for white people produced unexpected responses, including toxicity, when given to other ethnic groups.

One common interethnic variation is that African Americans are less responsive to some antihypertensive drugs than are white people. For example, angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking drugs are less effective as single-drug therapy. In general, African American hypertensive clients respond better to diuretics or calcium channel blockers than to ACE inhibitors and beta blockers. Another interethnic variation is that Asians usually require much smaller doses of some commonly used drugs, including beta blockers and several psychotropic drugs (eg, alprazolam, an antianxiety agent, and haloperidol, an antipsychotic). Some documented interethnic variations are included in later chapters.

**Gender**

Except during pregnancy and lactation, gender has been considered a minor influence on drug action. Most research studies related to drugs have involved men, and clinicians have extrapolated the findings to women. Several reasons have been advanced for excluding women from clinical drug trials, including the risks to a fetus if a woman becomes pregnant and the greater complexity in sample size and data analysis. However, because differences between men and women in responses to drug therapy are being identified, the need to include women in drug studies is evident.

Some gender-related differences in responses to drugs may stem from hormonal fluctuations in women during the menstrual cycle. Although this area has received little attention in research studies and clinical practice, altered responses have been demonstrated in some women taking clonidine, an antihypertensive; lithium, a mood-stabilizing agent; phenytoin, an anticonvulsant; propranolol, a beta-adrenergic blocking drug used in the management of hypertension, angina pectoris, and migraine; and antidepressants. In addition, a significant percentage of women with arthritis, asthma, depression, diabetes mellitus, epilepsy, and migraine experience increased symptoms premenstrually. The increased symptoms may indicate a need for adjustments in their drug therapy regimens. Women with clinical depression, for example, may need higher doses of antidepressant medications premenstrually, if symptoms exacerbate, and lower doses during the rest of the menstrual cycle.

Another example is that women with schizophrenia require lower dosages of antipsychotic medications than men. If given the higher doses required by men, women are likely to have adverse drug reactions.

**Pathologic Conditions**

Pathologic conditions may alter pharmacokinetic processes (Table 2–1). In general, all pharmacokinetic processes are decreased in cardiovascular disorders characterized by decreased blood flow to tissues, such as heart failure. In addition, the absorption of oral drugs is decreased with various GI disorders. Distribution is altered in liver or kidney disease and other conditions that alter plasma proteins. Metabolism is decreased in malnutrition (eg, inadequate protein to synthesize drug-metabolizing enzymes) and severe liver disease; it may be increased in conditions that generally increase body metabolism, such as hyperthyroidism and fever. Excretion is decreased in kidney disease.

**Psychological Considerations**

Psychological considerations influence individual responses to drug administration, although specific mechanisms are unknown. An example is the *placebo response*. A placebo is a pharmacologically inactive substance. Placebos are used in clinical drug trials to compare the medication being tested with a “dummy” medication. Interestingly, recipients often report both therapeutic and adverse effects from placebos.

Attitudes and expectations related to drugs in general, a particular drug, or a placebo influence client response. They also influence compliance or the willingness to carry out the prescribed drug regimen, especially with long-term drug therapy.

**TOLERANCE AND CROSS-TOLERANCE**

Drug tolerance occurs when the body becomes accustomed to a particular drug over time so that larger doses must be given to produce the same effects. Tolerance may be acquired to the pharmacologic action of many drugs, especially opioid analgesics, alcohol, and other CNS depressants. Tolerance to pharmacologically related drugs is called cross-tolerance. For example, a person who regularly drinks large amounts of alcohol becomes able to ingest even larger amounts before becoming intoxicated—this is tolerance to alcohol. If the person is then given sedative-type drugs or a general anesthetic, larger-than-usual doses are required to produce a pharmacologic effect—this is cross-tolerance.

Tolerance and cross-tolerance are usually attributed to activation of drug-metabolizing enzymes in the liver, which accelerates drug metabolism and excretion. They also are attributed to decreased sensitivity or numbers of receptor sites.

**ADVERSE EFFECTS OF DRUGS**

As used in this book, the term adverse effects refers to any undesired responses to drug administration, as opposed to therapeutic effects, which are desired responses. Most drugs produce a mixture of therapeutic and adverse effects; all drugs can produce adverse effects. Adverse effects may produce es-
TABLE 2–1  Effects of Pathologic Conditions on Drug Pharmacokinetics

<table>
<thead>
<tr>
<th>Pathologic Conditions</th>
<th>Pharmacokinetic Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiovascular disorders that impair the pumping ability of the heart, decrease cardiac output, or impair blood flow to body tissues (eg, acute myocardial infarction, heart failure, hypotension, and shock)</td>
<td>Absorption of oral, subcutaneous, intramuscular, and topical drugs is erratic because of decreased blood flow to sites of drug administration. Distribution is impaired because of decreased blood flow to body tissues and thus to sites of drug action. Metabolism and excretion are impaired because of decreased blood flow to the liver and kidneys. CNS impairment may alter pharmacokinetics indirectly by causing hypo- or hypertention and acid–base imbalances. Also, cerebral irritation may occur with head injuries and lead to stimulation of the sympathetic nervous system and increased cardiac output. Increased blood flow may accelerate all pharmacokinetic processes. With faster absorption and distribution, drug action may be more rapid, but faster metabolism and excretion may shorten duration of action.</td>
</tr>
<tr>
<td>Central nervous system (CNS) disorders that alter respiration or circulation (eg, brain trauma or injury, brain ischemia from inadequate cerebral blood flow, drugs that depress or stimulate brain function)</td>
<td>Symptoms of impaired GI function commonly occur with both GI and non-GI disorders. As a result, many patients cannot take oral medications. Those who are able to take oral drugs may experience impaired absorption because of: Vomiting or diarrhea. Concurrent administration of drugs that raise the pH of gastric fluids (eg, antacids, histamine-2 blockers, proton pump inhibitors). Concurrent administration of foods or tube feeding solutions that decrease drug absorption. Crushing tablets or opening capsules to give a drug through a GI tube.</td>
</tr>
<tr>
<td>Gastrointestinal (GI) disorders that interfere with GI function or blood flow (eg, trauma or surgery of the GI tract, abdominal infection, paralytic ileus, pancreatitis)</td>
<td>Absorption of oral drugs is variable. It may be increased because GI hypermotility rapidly delivers drug molecules to sites of absorption in the small intestine and the drugs tend to be absorbed more rapidly from inflamed tissue. It may be decreased because hypermotility and diarrhea may move the drug through the GI tract too rapidly to be adequately absorbed.</td>
</tr>
<tr>
<td>Inflammatory bowel disorders (eg, Crohn’s disease, ulcerative colitis)</td>
<td>Impaired circulation may decrease all pharmacokinetic processes, as described previously. The main effect is on metabolism. Hypothyroidism slows metabolism, which prolongs drug action and slows elimination from the body. Hyperthyroidism accelerates metabolism, producing a shorter duration of action and a faster elimination rate. As a thyroid disorder is treated and thyroid function returns to normal, the rate of drug metabolism also returns to normal. Thus, dosages of drugs that are extensively metabolized need adjustments according to the level of thyroid function.</td>
</tr>
<tr>
<td>Endocrine disorders that impair function or change hormonal balance</td>
<td>Increase adrenal function (ie, increased amounts of circulating catecholamines and cortisol) affects drug action by increasing cardiac output, redistributing cardiac output (more blood flow to the heart and brain, less to kidneys, liver, and GI tract), causing fluid retention, and increasing blood volume. Stress also changes plasma protein levels, which can affect the unbound portion of a drug dose. Decreased adrenal function causes hypotension and shock, which impairs all pharmacokinetic processes.</td>
</tr>
<tr>
<td>Adrenal disorders resulting from the underlying illness or the stress response that accompanies illness</td>
<td>Increased adrenal function (ie, increased amounts of circulating catecholamines and cortisol) affects drug action by increasing cardiac output, redistributing cardiac output (more blood flow to the heart and brain, less to kidneys, liver, and GI tract), causing fluid retention, and increasing blood volume. Stress also changes plasma protein levels, which can affect the unbound portion of a drug dose. Decreased adrenal function causes hypotension and shock, which impairs all pharmacokinetic processes.</td>
</tr>
<tr>
<td>Hepatic disorders that impair hepatic function and blood flow (eg, hepatitis, cirrhosis)</td>
<td>Most drugs are eliminated from the body by hepatic metabolism, renal excretion or both. Hepatic metabolism depends on hepatic blood flow, hepatic enzyme activity, and plasma protein binding. Increased hepatic blood flow increases delivery of drug molecules to hepatocytes, where metabolism occurs, and thereby accelerates drug metabolism. Decreased hepatic blood flow slows metabolism. Severe liver disease or cirrhosis may impair all pharmacokinetic processes. Absorption of oral drugs may be decreased in cirrhosis because of edema in the GI tract. Distribution may be altered by changes in plasma proteins. The impaired liver may be unable to synthesize adequate amounts of plasma proteins, especially albumin. Also, liver impairment leads to inadequate metabolism and accumulation of substances (eg, serum bilirubin) that can displace drugs from protein-binding sites. With decreased protein binding, the serum concentration of active drug is increased and the drug is distributed to sites of action and elimination more rapidly. Thus, onset of drug action may be faster, peak blood levels may be higher and cause adverse effects, and the duration of action may be shorter because the drug is metabolized and excreted more quickly. With cirrhosis, oral drugs are distributed directly into the systemic circulation rather than going through the portal circulation and the liver first. This shunting of blood around the liver means that oral drugs that are normally extensively metabolized during their first pass through the liver (eg, propranolol) must be given in reduced doses to prevent high blood levels and toxicity. Metabolism may be impaired by hepatic and nonhepatic disorders that reduce hepatic blood flow. In addition, an impaired liver may not be able to synthesize adequate amounts of drug-metabolizing enzymes.</td>
</tr>
</tbody>
</table>

(continued)
TABLE 2–1 Effects of Pathologic Conditions on Drug Pharmacokinetics (continued)

<table>
<thead>
<tr>
<th>Pathologic Conditions</th>
<th>Pharmacokinetic Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Excretion</strong> may be increased when protein binding is impaired because larger amounts of free drug are circulating in the bloodstream and being delivered more rapidly to sites of metabolism and excretion. The result is a shorter drug half-life and duration of action. Excretion is decreased when the liver is unable to metabolize lipid-soluble drugs into water-soluble metabolites that can be excreted by the kidneys. ARF and CRF can interfere with all pharmacokinetic processes. Absorption of oral drugs may be decreased indirectly by changes that often occur with renal failure (eg, delayed gastric emptying, changes in gastric pH, GI symptoms such as vomiting and diarrhea). Also, in the presence of generalized edema, edema of the GI tract may impair absorption. In CRF, gastric pH may be increased by administration of oral alkalinizing agents (eg, sodium bicarbonate, citrate) and the use of antacids for phosphate-binding effects. This may decrease absorption of oral drugs that require an acidic environment for dissolution and absorption and increase absorption of drugs that are absorbed from a more alkaline environment. <strong>Distribution</strong> of many drugs may be altered by changes in extracellular fluid volume (ECF), plasma protein binding, and tissue binding. Water-soluble drugs are distributed throughout the ECF, including edema fluid, which is usually increased in renal impairment because the kidney’s ability to eliminate water and sodium is impaired. Drug binding with albumin, the main drug-binding plasma protein for acidic drugs, is usually decreased with renal impairment. Protein binding may be decreased because of less albumin or decreased binding capacity of albumin for a drug. Reasons for decreased albumin include hypermetabolic states (eg, stress, trauma, sepsis) in which protein breakdown exceeds protein synthesis, nephrotic states in which albumin is lost in the urine, and liver disease that decreases hepatic synthesis of albumin. Reasons for reduced binding capacity include structural changes in the albumin molecule or uremic toxins that compete with drugs for binding sites. When less drug is bound to albumin, the higher serum drug levels of unbound or active drug can result in drug toxicity. In addition, more unbound drug is available for distribution into tissues and sites of metabolism and excretion so that faster elimination can decrease drug half-life and therapeutic effects. For basic drugs (eg, clindamycin, propafenone), alpha1-acid glycoprotein (AAG) is the main binding protein. The amount of AAG increases in some patients, including those with renal transplants and those receiving hemodialysis. If these patients are given a basic drug, a larger amount is bound and a smaller amount is free to exert a pharmacologic effect. Finally, some conditions that often occur in renal impairment (eg, metabolic acidosis, respiratory alkalosis, others) may alter tissue distribution of some drugs. For example, digoxin can be displaced from tissue-binding sites by metabolic products that cannot be adequately excreted by impaired kidneys. <strong>Metabolism</strong> can be increased, decreased, or unaffected by renal impairment. One factor is alteration of drug metabolism in the liver. In uremia, reduction and hydrolysis reactions may be slower, but oxidation by cytochrome P450 enzymes and conjugation with glucuronide or sulfate usually proceed at normal rates. Another factor is the inability of impaired kidneys to eliminate drugs and pharmacologically active metabolites, which may lead to accumulation and adverse drug reactions with long-term drug therapy. Metabolites may have pharmacologic activity similar to or different from that of the parent drug. A third factor may be impaired renal metabolism of drugs. Although the role of the kidneys in excretion of drugs and drug metabolites is well known, their role in drug metabolism has received little attention. The kidney itself contains many of the same metabolizing enzymes found in the liver, including renal cytochrome P450 enzymes, which metabolize a variety of chemicals and drugs. <strong>Excretion</strong> of many drugs and metabolites is reduced by renal impairment. The kidneys normally excrete both the parent drug and metabolites produced by the liver and other tissues. Processes of renal excretion include glomerular filtration, tubular secretion, and tubular reabsorption, all of which may be affected by renal impairment. If the kidneys are unable to excrete drugs and metabolites, some of which may be pharmacologically active, these substances may accumulate and cause adverse or toxic effects. Respiratory impairment may indirectly affect drug metabolism. For example, hypoxemia leads to decreased enzyme production in the liver, decreased efficiency of the enzymes that are produced, and decreased oxygen available for drug biotransformation. Mechanical ventilation leads to decreased blood flow to the liver.</td>
<td></td>
</tr>
</tbody>
</table>
Adverse effects may occur with almost any drug, especially if the dosage is large. Common or serious adverse effects include the following:

1. **CNS effects** may result from CNS stimulation (e.g., agitation, confusion, delirium, disorientation, hallucinations, psychosis, seizures) or CNS depression (dizziness, drowsiness, impaired level of consciousness, sedation, coma, impaired respiration and circulation). CNS effects may occur with many drugs, including most therapeutic groups, substances of abuse, and over-the-counter preparations.

2. **Gastrointestinal effects** (anorexia, nausea, vomiting, constipation, diarrhea) are among the most common adverse reactions to drugs. Nausea and vomiting occur with many drugs from local irritation of the gastrointestinal tract or stimulation of the vomiting center in the brain. Diarrhea occurs with drugs that cause local irritation or increase peristalsis. More serious effects include bleeding or ulceration (most often with aspirin and nonsteroidal anti-inflammatory agents) and severe diarrhea/colitis (most often with antibiotics).

3. **Hematologic effects** (blood coagulation disorders, bleeding disorders, bone marrow depression, anemias, leukopenia, agranulocytosis, thrombocytopenia) are relatively common and potentially life threatening. Excessive bleeding is most often associated with anticoagulants and thrombolytics; bone marrow depression is usually associated with antineoplastic drugs.

4. **Hepatotoxicity** (hepatitis, liver dysfunction or failure, biliary tract inflammation or obstruction) is potentially life threatening. Because most drugs are metabolized by the liver, the liver is especially susceptible to drug-induced injury. Drugs that are hepatotoxic include acetaminophen (Tylenol), isoniazid (INH), methotrexate (Mexate), phenytoin (Dilantin), and aspirin and other salicylates. In the presence of drug- or disease-induced liver damage, the metabolism of many drugs is impaired. Consequently, drugs metabolized by the liver tend to accumulate in the body and cause adverse effects. Besides hepatotoxicity, many drugs produce abnormal values in liver function tests without producing clinical signs of liver dysfunction.

5. **Nephrotoxicity** (nephritis, renal insufficiency or failure) occurs with several antimicrobial agents (e.g., gentamicin and other aminoglycosides), nonsteroidal anti-inflammatory agents (e.g., ibuprofen and related drugs), and others. It is potentially serious because it may interfere with drug excretion, thereby causing drug accumulation and increased adverse effects.

6. **Hypersensitivity or allergy** may occur with almost any drug in susceptible clients. It is largely unpredictable and unrelated to dose. It occurs in those who have previously been exposed to the drug or a similar substance (antigen) and who have developed antibodies. When readministered, the drug reacts with the antibodies to cause cell damage and the release of histamine and other intracellular substances. These substances produce reactions ranging from mild skin rashes to anaphylactic shock. Anaphylactic shock is a life-threatening hypersensitivity reaction characterized by respiratory distress and cardiovascular collapse. It occurs within a few minutes after drug administration and requires emergency treatment with epinephrine. Some allergic reactions (e.g., serum sickness) occur 1 to 2 weeks after the drug is given.

7. **Drug fever** is a fever associated with administration of a medication. Drugs can cause fever by several mechanisms, including allergic reactions, damaging body tissues, increasing body heat or interfering with its dissipation, or acting on the temperature-regulating center in the brain. The most common mechanism is an allergic reaction. Fever may occur alone or with other allergic manifestations (e.g., skin rash, hives, joint and muscle pain, enlarged lymph glands, eosinophilia) and its pattern may be low grade and continuous or spiking and intermittent. It may begin within hours after the first dose if the client has taken the drug before, or within approximately 10 days of continued administration if the drug is new to the client. If the causative drug is discontinued, fever usually subsides within 48 to 72 hours unless
drug excretion is delayed or significant tissue damage has occurred (eg, hepatitis).

Many drugs have been implicated as causes of drug fever, including most antimicrobials, several cardiovascular agents (eg, beta blockers, hydralazine, methyldopa, procainamide, quinidine), drugs with anticholinergic properties (eg, atropine, some antihistamines, phenothiazine antipsychotic agents, and tricyclic antidepressants), and some anticonvulsants.

8. **Idiosyncrasy** refers to an unexpected reaction to a drug that occurs the first time it is given. These reactions are usually attributed to genetic characteristics that alter the person’s drug-metabolizing enzymes.

9. **Drug dependence** (see Chap. 15) may occur with mind-altering drugs, such as opioid analgesics, sedative-hypnotic agents, antianxiety agents, and CNS stimulants. Dependence may be physiologic or psychological. Physiologic dependence produces unpleasant physical symptoms when the dose is reduced or the drug is withdrawn. Psychological dependence leads to excessive preoccupation with drugs and drug-seeking behavior.

10. **Carcinogenicity** is the ability of a substance to cause cancer. Several drugs are carcinogens, including some hormones and anticancer drugs. Carcinogenicity apparently results from drug-induced alterations in cellular DNA.

11. **Teratogenicity** is the ability of a substance to cause abnormal fetal development when taken by pregnant women. Drug groups considered teratogenic include analgesics, diuretics, antiepileptic drugs, antihistamines, antibiotics, antiemetics, and others.

### Toxic Effects of Drugs

Drug toxicity (also called poisoning, overdose, or intoxication) results from excessive amounts of a drug and may cause reversible or irreversible damage to body tissues. It is a common problem in both adult and pediatric populations. It may result from a single large dose or prolonged ingestion of smaller doses. It may involve alcohol or prescription, over-the-counter, or illicit drugs. Poisoned patients may be seen in essentially any setting (eg, inpatient hospital units, patients’ homes, long-term care facilities), but are especially likely to be encountered in hospital emergency departments.

In some cases, the patient or someone accompanying the patient may know the toxic agent (eg, accidental overdose of a therapeutic drug, use of an illicit drug, a suicide attempt). Often, however, multiple drugs have been ingested, the causative drug or drugs are unknown, and the circumstances may involve traumatic injury or impaired mental status that make the patient unable to provide useful information. Clinical manifestations are often nonspecific for drug overdoses and may indicate other disease processes. Because of the variable presentation of drug intoxication, health care providers must have a high index of suspicion so that toxicity can be rapidly recognized and treated.

### Drug Overdose: General Management

Most poisoned or overdosed clients are treated in emergency rooms and discharged to their homes. A few are admitted to intensive care units (ICUs), often because of unconsciousness and the need for endotracheal intubation and mechanical ventilation. Unconsciousness is a major toxic effect of several commonly ingested substances such as benzodiazepine antianxiety and sedative agents, tricyclic antidepressants, ethanol, and opiates. Serious cardiovascular effects (eg, cardiac arrest, dysrhythmias, circulatory impairment) are also common and warrant admission to an ICU.

The main goals of treatment for a poisoned patient are supporting and stabilizing vital functions (ie, airway, breathing, circulation), preventing further damage from the toxic agent by reducing additional absorption or increasing elimination, and administering specific antidotes when available and indicated. General aspects of care are described below; selected antidotes are listed in Table 2–2; and specific aspects of care are described in relevant chapters.

1. For patient who are seriously ill on first contact, enlist help for more rapid assessment and treatment. In general, starting treatment as soon as possible after drug ingestion leads to better patient outcomes.

2. The first priority is support of vital functions, as indicated by a rapid assessment of the patient’s condition (eg, vital signs, level of consciousness). In serious poisonings, an electrocardiogram is indicated and findings of severe toxicity (eg, dysrhythmias, ischemia) justify more aggressive and invasive care. Standard cardiopulmonary resuscitation (CPR) measures may be needed to maintain breathing and circulation. An intravenous (IV) line is usually needed to administer fluids and drugs, and invasive treatment or monitoring devices may be inserted.

Endotracheal intubation and mechanical ventilation are often required to maintain breathing (in unconscious patients), correct hypoxemia, and protect the airway. Hypoxemia must be corrected quickly to avoid brain injury, myocardial ischemia, and cardiac dysrhythmias. Ventilation with positive end expiratory pressure (PEEP) should be used cautiously in hypotensive patients because it decreases venous return to the heart and worsens hypotension.

Serious cardiovascular manifestations often require pharmacologic treatment. Hypotension and hypoperfusion may be treated with inotropic and vasopressor drugs. Dysrhythmias are treated according to Advanced Cardiac Life Support (ACLS) protocols.

Recurring seizures or status epilepticus require treatment with anticonvulsant drugs.

3. For unconscious patients, as soon as an IV line is established, some authorities recommend a dose of naloxone (2 mg IV) for possible narcotic overdose.
<table>
<thead>
<tr>
<th>Overdosed Drug (Poison)</th>
<th>Antidote</th>
<th>Route and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (see Chap. 7)</td>
<td>Acetylcysteine (Mucomyst)</td>
<td>PO 140 mg/kg initially, then 70 mg/kg q4h for 17 doses</td>
<td>Dilute 20% solution to a 5% solution with a cola or other soft drink for oral administration</td>
</tr>
<tr>
<td>Anticholinergics (atropine; see Chap. 21)</td>
<td>Physostigmine</td>
<td>IV, IM 2 mg. Give IV slowly, over at least 2 min.</td>
<td>Infrequently used because of its toxicity</td>
</tr>
<tr>
<td>Benzodiazepines (see Chap. 8)</td>
<td>Flumazenil</td>
<td>IV 0.2 mg over 30 sec; if no response, may give 0.3 mg. Additional doses of 0.5 mg may be given at 1-min intervals up to a total amount of 3 mg</td>
<td>Should not be given to patients with overdose of unknown drugs or drugs known to cause seizures in overdose (eg, cocaine, lithium)</td>
</tr>
<tr>
<td>Beta blockers (see Chap. 19)</td>
<td>Glucagon</td>
<td>IV 50–150 mcg/kg (5–10 mg for adults) over 1 min initially, then 2–5 mg/h by continuous infusion as needed</td>
<td>Glucagon increases myocardial contractility; not FDA-approved for this indication</td>
</tr>
<tr>
<td>Calcium channel blockers (see Chaps. 53, 55)</td>
<td>Calcium gluconate 10%</td>
<td>IV 1 g over 5 min; may be repeated</td>
<td>Increases myocardial contractility</td>
</tr>
<tr>
<td>Cholinergics (see Chap. 20)</td>
<td>Atropine</td>
<td>Adults: IV 2 mg, repeated as needed. Children: IV 0.05 mg/kg, up to 2 mg.</td>
<td>If poisoning is due to organophosphates (eg, insecticides), pralidoxime may be given with the atropine</td>
</tr>
<tr>
<td>Digoxin (see Chap. 51)</td>
<td>Digoxin immune fab (Digibind)</td>
<td>IV 40 mg (1 vial) for each 0.6 mg of digoxin ingested. Reconstitute each vial with 4 mL Water for Injection, then dilute with sterile isotonic saline to a convenient volume and give over 30 min, through a 0.22-micron filter. If cardiac arrest seems imminent, may give the dose as a bolus injection.</td>
<td>Recommended for severe toxicity; reverses cardiac and extracardiac symptoms in a few minutes. Note: Serum digoxin levels increase after antidote administration, but the drug is bound and therefore inactive.</td>
</tr>
<tr>
<td>Heparin (see Chap. 57)</td>
<td>Protamine sulfate</td>
<td>IV 1 mg/100 units of heparin, slowly, over at least 10 min. A single dose should not exceed 50 mg.</td>
<td>Indicated for serum iron levels &gt;500 mg/dL or serum levels &gt;350 mg/dL with GI or cardiovascular symptoms. Can bind and remove a portion of an ingested dose; urine becomes red as iron is excreted</td>
</tr>
<tr>
<td>Iron (see Chap. 32)</td>
<td>Deferoxamine</td>
<td>IM 1 g q8h PRN. IV 15 mg/kg/h if hypotensive</td>
<td>Can also be given IM, SC, or by endotracheal tube</td>
</tr>
<tr>
<td>Isoniazid (INH)</td>
<td>Pyridoxine</td>
<td>IV 1 g per gram of INH ingested, at rate of 1 g q2–3 min. If amount of INH unknown, give 5 g; may be repeated.</td>
<td>Indicated for management of seizures and correction of acidosis</td>
</tr>
<tr>
<td>Lead</td>
<td>Succimer</td>
<td>Children: PO 10 mg/kg q8h for 5 days.</td>
<td></td>
</tr>
<tr>
<td>Opioid analgesics (Chap. 6)</td>
<td>Naloxone (Narcan)</td>
<td>Adults: IV 0.4–2 mg PRN. Children: IV 0.1 mg/kg per dose.</td>
<td>Can also be given IM, SC, or by endotracheal tube</td>
</tr>
<tr>
<td>Phenothiazine antipsychotic agents (see Chap. 9)</td>
<td>Diphenhydramine (Benadryl)</td>
<td>Adults: IV 50 mg. Children: IV 1–2 mg/kg, up to a total of 50 mg.</td>
<td>Given to relieve extrapyramidal symptoms (movement disorders)</td>
</tr>
<tr>
<td>Thrombolytics (see Chap. 57)</td>
<td>Aminocaproic acid (Amicar)</td>
<td>PO, IV infusion, 5 g initially, then 1–1.25 g/h for 8 h or until bleeding is controlled. Maximum dose, 30 g/24h.</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
and thiamine (100 mg IV) for possible brain dysfunction due to thiamine deficiency. In addition, a fingerstick blood glucose test should be done and, if hypoglycemia is indicated, 50% dextrose (50 ml IV) should be given.

4. Once the patient is out of immediate danger, a thorough physical examination and efforts to determine the drug(s), the amounts, and the time lapse since exposure are needed. If the patient is unable to supply needed information, interview anyone else who may be able to do so. Ask about the use of prescription, over-the-counter, alcohol, and illicit substances.

5. There are no standard laboratory tests for poisoned patients. The client’s condition and the clinician’s judgment determine which laboratory tests are needed, although baseline tests of liver and kidney function are usually indicated. Specimens of blood, urine, or gastric fluids may be obtained for laboratory analysis.

Screening tests for toxic substances are not very helpful because test results may be delayed, many substances are not detected, and the results rarely affect initial treatment. Initial treatment should never be delayed to obtain results of a toxicology screen. Identification of an unknown drug or poison is often based on the patient’s history and signs and symptoms, with specific tests as confirmation.

Serum drug levels are needed when acetaminophen, alcohol, digoxin, lithium, aspirin, or theophylline is known to be an ingested drug, to assist with treatment.

6. For orally ingested drugs, gastrointestinal (GI) decontamination has become a controversial topic. For many years, standard techniques for removing drugs from the GI tract included ipecac syrup for alert patients, to induce emesis; gastric lavage for patients with decreased levels of consciousness; activated charcoal to adsorb the ingested drug in the GI tract; and a cathartic (usually 70% sorbitol) to accelerate elimination of the adsorbed drug. More recently, whole bowel irrigation (WBI) was introduced as an additional technique.

Currently, there are differences of opinion regarding whether and when these techniques are indicated. These differences led to the convening of a consensus group of toxicologists from the American Academy of Clinical Toxicology (AACT) and the European Association of Poison Centres and Clinical Toxicologists (EAPCCT). This group issued treatment guidelines that have also been endorsed by other toxicology organizations. Generally, the recommendations state that none of the aforementioned techniques should be used routinely and that adequate data to support or exclude their use are often lacking. Opinions expressed by the consensus group and others are described below:

**Ipecac.** Usage in hospital settings has declined. Its use may delay administration or reduce effectiveness of activated charcoal, oral antidotes, and whole bowel irrigation. It is contraindicated in patients who are less than fully alert (because of the danger of aspiration). Ipecac may be used to treat mild poisonings in the home, especially in children. Parents should call a poison control center or a health care provider before giving ipecac. If used, it is most beneficial if administered within an hour after ingestion of a toxic drug dose.

**Gastric lavage.** Its usefulness is being increasingly questioned. It is contraindicated in less than alert patients unless the patient has an endotracheal tube in place (to prevent aspiration).

It may be beneficial in serious overdoses if performed within an hour of drug ingestion. If the ingested agent delays gastric emptying (eg, tricyclic antidepressants and other drugs with anticholinergic effects), the time limit may be extended. When used after ingestion of pills or capsules, the tube lumen should be large enough to allow removal of pill fragments.

**Activated charcoal.** Sometimes called the universal antidote, it is useful in many poisoning situations. It is being used alone for mild or moderate overdoses and with gastric lavage in serious poisonings. It effectively adsorbs many toxins and rarely causes complications. It is most beneficial when given within an hour of ingestion of a potentially toxic amount of a drug known to bind to charcoal. Its effectiveness decreases with time and there are inadequate data to support or exclude its use later than 1 hour after ingestion.

Activated charcoal is usually mixed in water (about 50 g or 10 heaping tablespoons in 8 oz. water) to make a slurry, which is gritty and unpleasant to

---

**TABLE 2–2 Antidotes for Overdoses of Selected Therapeutic Drugs (continued)**

<table>
<thead>
<tr>
<th>Overdosed Drug (Poison)</th>
<th>Antidote</th>
<th>Route and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tricyclic antidepressants (see Chap. 10)</td>
<td>Sodium bicarbonate</td>
<td>IV 1–2 mEq/kg initially, then continuous IV drip to maintain serum pH of 7.5</td>
<td>To treat cardiac dysrhythmias, conduction disturbances, and hypotension</td>
</tr>
<tr>
<td>Warfarin (see Chap. 57)</td>
<td>Vitamin K₁</td>
<td>PO 5–10 mg daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV (severe overdose) continuous infusion at rate no faster than 1 mg/min</td>
<td></td>
</tr>
</tbody>
</table>
swallow. It is often given by GI tube. The charcoal blackens later bowel movements. Adverse effects include pulmonary aspiration and impaction of the charcoal–drug complex.

If used with whole bowel irrigation, activated charcoal should be given before the WBI solution is started. If given during WBI, the binding capacity of the charcoal is decreased.

**Cathartic.** It is not recommended alone and its use with activated charcoal has produced conflicting data. If used, it should be limited to a single dose to minimize adverse effects.

**Whole bowel irrigation (WBI).** This technique is most useful for removing toxic ingestions of long-acting, sustained-release drugs (eg, many beta blockers, calcium channel blockers, and theophylline preparations); enteric coated drugs; and toxins that do not bind well with activated charcoal (eg, iron, lithium, lead). It may also be helpful in removing packets of illicit drugs, such as cocaine or heroin. When given, polyethylene glycol solution (eg, Colyte) 1–2 liters/hour to a total of 10 liters is recommended.

WBI is contraindicated in patients with serious bowel disorders (eg, obstruction, perforation, ileus), hemodynamic instability, or respiratory impairment (unless intubated).

7. Urinary elimination of some drugs and toxic metabolites can be accelerated by changing the pH of urine (eg, acidifying with amphetamine overdose; alkalinizing with salicylate overdose), diuresis, or hemodialysis. Hemodialysis is the treatment of choice in severe lithium and aspirin (salicylate) poisoning.

8. Administer specific antidotes when available and indicated by the client’s clinical condition. Available antidotes vary widely in effectiveness. Some are very effective and rapidly reverse toxic manifestations (eg, naloxone for opiates, flumazenil for benzodiazepines, specific Fab fragments for digoxin). Others are less effective (eg, deferoxamine for acute iron ingestion) or potentially toxic themselves (eg, physostigmine for tricyclic antidepressant overdose).

When an antidote is used, its half-life relative to the toxin’s half-life must be considered. For example, the half-life of naloxone, a narcotic antagonist, is relatively short compared with the half-life of the longer-acting opiates such as methadone. Similarly, flumazenil has a shorter half-life than most benzodiazepines. Thus, repeated doses of these agents may be needed to prevent recurrence of the toxic state.

---

**How Can You Avoid This Medication Error?**

**Answer:** Grapefruit juice interacts with many medications, including felodipine. The drug level of felodipine increases because the grapefruit juice inhibits the isozyme of cytochrome P450, which is important in the metabolism of felodipine. As the blood level increases, serious toxic effects can occur. Other juices do not impact cytochrome P450 so it would be safe to have Mrs. Beecher take her medication with another type of juice or water. Notify the physician regarding Mrs. Beecher’s hypotension and the drug–food interaction. If Mrs. Beecher remains on felodipine, she must be cautioned to eliminate grapefruit juice from her diet.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Half-life is the time required for the serum concentration of a drug to decrease by 50%. After 1 hour, the serum concentration would be 50 units/mL (100/2). After 2 hours, the serum concentration would be 25 units/mL (50/2) and reach the nontoxic range.

---

**SELECTED REFERENCES**


Ms. Mabel Zack is transferred to your rehabilitation facility after a cerebral vascular accident (stroke) 2 weeks ago. When you review her chart, it indicates she has right-sided hemiparesis, memory deficits, and dysphagia (difficulty swallowing). Reflect on:

Outline appropriate assessments to determine if it is safe to give Ms. Zack oral medications.

If a swallowing evaluation indicates that Ms. Zack can take medications orally, what precautions can you take to help ensure her safety?

How might you individualize your teaching plan, considering Ms. Zack’s memory deficits?

Drugs given for therapeutic purposes are called medications. Giving medications to clients is an important nursing responsibility in many health care settings, including ambulatory care, hospitals, long-term care facilities, and clients’ homes. The basic requirements for accurate drug administration are often called the “five rights”: giving the right drug, in the right dose, to the right client, by the right route, at the right time. These “rights” require knowledge of the drugs to be given and the clients who are to receive them as well as specific nursing skills and interventions. When one of these rights is violated, medication errors can occur. Nurses need to recognize circumstances in which errors are likely to occur and intervene to prevent errors and protect clients. This chapter is concerned with safe and accurate medication administration.

Follow the “five rights” consistently.

Learn essential information about each drug to be given (eg, indications for use, contraindications, therapeutic effects, adverse effects, and any specific instructions about administration).

Interpret the prescriber’s order accurately (ie, drug name, dose, frequency of administration). Question the prescriber if any information is unclear or if the drug seems inappropriate for the client’s condition.

Read labels of drug containers for the drug name and concentration (usually in mg per tablet, capsule, or milliliter of solution). Many medications are available in different dosage forms and concentrations; it is extremely important that the correct ones be used.
How Can You Avoid This Medication Error?

You are administering 6 AM medications to a client on a medical unit. You enter Mr. Gonzalez’s room, gently shake him awake, and call him by name. He slowly awakens and appears groggy. You explain that you just gave medications to Mr. Sanchez. He slowly awakens and appears groggy. You explain that you just gave medications to Mr. Sanchez.

You enter Mr. Gonzales’ room, gently shake him awake, and call him by name. He slowly awakens and appears groggy. You explain that you just gave medications to Mr. Sanchez.

LEGAL RESPONSIBILITIES

Registered and licensed practical nurses are legally empowered, under state nurse practice acts, to give medications ordered by licensed physicians and dentists. In some states, nurse practitioners may prescribe medications.

When giving medications, the nurse is legally responsible for safe and accurate administration. This means the nurse may be held liable for not giving a drug or for giving a wrong drug or a wrong dose. In addition, the nurse is expected to have sufficient drug knowledge to recognize and question erroneous orders. If, after questioning the prescriber and seeking information from other authoritative sources, the nurse considers that giving a drug is unsafe, the nurse must refuse to give the drug. The fact that a physician wrote an erroneous order does not excuse the nurse from legal liability if he or she carries out that order.

The nurse also is legally responsible for actions delegated to people who are inadequately prepared for or legally barred from administering medications (such as nursing assistants). However, certified medical assistants (CMAs) administer medications in physicians’ offices and certified medication aides (nursing assistants with a short course of training, also called CMAs,) often administer medications in long-term care facilities.

The nurse who consistently follows safe practices in giving medications does not need to be excessively concerned about legal liability. The basic techniques and guidelines described in this chapter are aimed at safe and accurate preparation and administration; most errors result when these practices are not followed.

Legal responsibilities in other aspects of drug therapy are less tangible and clear-cut. However, in general, nurses are expected to monitor clients’ responses to drug therapy (eg, therapeutic and adverse effects) and to teach clients safe and effective self-administration of drugs when indicated. These aspects are described more fully in Chapter 4.

MEDICATION ERRORS

Increasing attention is being paid to the number and consequences of medication errors. In one study of 1116 hospitals, medication errors (a total of 430,586) were reported in approximately 5% of admitted patients. In 913 of those hospitals, over 17,000 errors (0.25% of admitted patients) re-
portedly caused adverse client outcomes (usually described as serious illness, conditions that prolong hospitalization or require additional treatment, or death). Other studies have reported that common errors include giving an incorrect dose, not giving an ordered drug, and giving an unordered drug. Specific drugs often associated with errors include insulin, heparin, and warfarin.

There are several steps and numerous people involved in getting each dose of a medication to the intended client. Each step or person has a potential for contributing to a medication error (Box 3–1). All health care providers involved in drug therapy must be extremely vigilant in all phases of drug administration.

## MEDICATION SYSTEMS

Each agency has a system for distributing drugs. The unit-dose system, in which most drugs are dispensed in single-dose containers for individual clients, is widely used. Drug orders are checked by a pharmacist or pharmacy technician, who then places the indicated number of doses in the client’s medication drawer at scheduled intervals. When a dose is due, the nurse removes the medication and takes it to the client. Unit-dose wrappings of oral drugs should be left in place until the nurse is in the presence of the client and ready to give the medication. Each dose of a drug must be recorded on the client’s medication administration record (MAR) as soon as possible after administration.

Increasingly, agencies are using automated, computerized, locked cabinets for which each nurse on a unit has a password or code for accessing the cabinet and obtaining a drug dose. These automated systems maintain an inventory and drugs are restocked as needed.

Controlled drugs, such as opioid analgesics, are usually kept as a stock supply in a locked drawer or automated cabinet and replaced as needed. Each dose is signed for and recorded on the client’s MAR. Each nurse must comply with legal regulations and agency policies for dispensing and recording controlled drugs.

### MEDICATION ORDERS

Medication orders should include the full name of the client; the generic or trade name of the drug; the dose, route, and frequency of administration; and the date, time, and signature of the prescriber, usually a physician.

Most orders in a health care agency are handwritten on an order sheet in the client’s medical record or typed into a com-

## BOX 3–1 SOURCES OF MEDICATION ERRORS

Medication errors may occur during any phase of drug therapy, including prescribing, dispensing, and administration. The main purpose of including potential sources of errors here is to increase the ability of health care providers to recognize risky situations and to prevent errors when possible.

**Health Care Providers**

**Prescribers** may write orders illegibly; order a drug that is not indicated by the client’s condition; fail to order a drug that is indicated; fail to consider the client’s age, size, kidney function, liver function, and disease process when selecting a drug or dosage; fail to consider other medications the client is taking, including prescription and over-the-counter drugs; lack sufficient knowledge about the drug; fail to monitor for, or instruct others to monitor for, effects of administered drugs; and fail to discontinue drugs appropriately. **Pharmacists** may not know the client’s condition or recognize an inappropriate or erroneous physician’s order. They may dispense incorrect medications, mislabel containers, or fail to ask outpatients about other drugs being taken. **Nurses** may have inadequate knowledge about a drug or about the client receiving the drug; not follow the “five rights”: fail to question the medication order when indicated.

**Clients/Consumers**

People may take drugs from several prescribers; fail to inform one physician about drugs prescribed by another; get prescriptions filled at more than one pharmacy; fail to get prescriptions filled or refilled; underuse or overdose an appropriately prescribed drug; take drugs left over from a previous illness or prescribed for someone else; fail to follow instructions for drug administration or storage; fail to keep appointments for follow-up care; and fail to ask for information about prescription and nonprescription drugs when needed.

**Drugs**

Drugs may have similar names that can lead to erroneous prescribing, dispensing, or administration. For example, the anti-seizure drug Lamictal (generic name, lamotrigine) has been confused with Lamisil, an antifungal drug, lamivudine, an antiviral drug, and others. As a result, the FDA-proposed labeling changes to make the differences more noticeable. The FDA is also looking at proposed trade names of new drugs prior to marketing, to see if they are likely to be confused with older drugs, and increasing surveillance of medication errors attributed to drug name confusion.

In addition to similar names, many drugs, especially those produced by the same manufacturer, have similar packaging. This can lead to errors if container labels are not read carefully, especially if the products are shelved or stored next to each other.

Long-acting oral dosage forms with various, sometimes unclear indicators (eg, LA, XL, XR), may be crushed, chewed, or otherwise broken so that the long-acting feature is destroyed. This can cause an overdose.

**Circumstances**

Prescribers, pharmacists, and nurses may have a heavy workload, with resultant rushing of prescribing, dispensing, or administering medications. They may also experience distractions by interruptions, noise, and other events in the work environment that make it difficult to pay needed attention to the medication-related task.
puter. Occasionally, verbal or telephone orders are acceptable. These are written on the client’s order sheet, signed by the person taking the order, and later countersigned by the prescriber. Once the order is written, a copy is sent to the pharmacy, where the order is recorded and the drug is dispensed to the appropriate client care unit. In many agencies, pharmacy staff prepare a computer-generated MAR for each 24-hour period.

For clients in ambulatory care settings, the procedure is essentially the same for drugs to be given immediately. For drugs to be taken at home, written prescriptions are given. In addition to the previous information, a prescription should include instructions for taking the drug (eg, dose and frequency) and whether the prescription can be refilled. Prescriptions for Schedule II controlled drugs cannot be refilled.

To interpret medication orders accurately, the nurse must know commonly used abbreviations for routes, dosages, and times of drug administration (Table 3–1). If the nurse cannot read the physician’s order or if the order seems erroneous, he or she must question the order before giving the drug.

### TABLE 3–1 / Common Abbreviations

<table>
<thead>
<tr>
<th>Routes of Drug Administration</th>
<th>_Common Abbreviations_</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>OD</td>
<td>right eye*</td>
</tr>
<tr>
<td>GS</td>
<td>left eye*</td>
</tr>
<tr>
<td>OU</td>
<td>both eyes*</td>
</tr>
<tr>
<td>PO</td>
<td>by mouth, oral</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>SL</td>
<td>sublingual</td>
</tr>
<tr>
<td>Drug Dosages</td>
<td></td>
</tr>
<tr>
<td>cc</td>
<td>cubic centimeter</td>
</tr>
<tr>
<td>g</td>
<td>gram</td>
</tr>
<tr>
<td>gr</td>
<td>grain</td>
</tr>
<tr>
<td>gt</td>
<td>drop†</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>oz</td>
<td>ounce</td>
</tr>
<tr>
<td>tbsp</td>
<td>tablespoon</td>
</tr>
<tr>
<td>tsp</td>
<td>teaspoon</td>
</tr>
</tbody>
</table>

**Times of Drug Administration**

| ac                           | before meals             |
| ad lib                       | as desired               |
| bid                          | twice daily              |
| hs                           | bedtime                  |
| pc                           | after meals              |
| PRN                          | when needed              |
| qd                           | every day, daily         |
| q4h                          | every four hours         |
| qid                          | four times daily         |
| qod                          | every other day          |
| stat                         | immediately              |
| tid                          | three times daily        |

*Because of errors made with the abbreviations, some authorities recommend spelling out the site (eg, right eye).

drops = gtt.

---

### DRUG PREPARATIONS AND DOSAGE FORMS

Drug preparations and dosage forms vary according to the drug’s chemical characteristics, reason for use, and route of administration. Some drugs are available in only one dosage form; others are available in several forms. Characteristics of various dosage forms are described below and in Table 3–2.

Dosage forms of systemic drugs include liquids, tablets, capsules, suppositories, and transdermal and pump delivery systems. Systemic liquids are given orally (PO) or by injection. Those given by injection must be sterile.

Tablets and capsules are given PO. Tablets contain active drug plus binders, colorants, preservatives, and other substances. Capsules contain active drug enclosed in a gelatin capsule. Most tablets and capsules dissolve in the acidic fluids of the stomach and are absorbed in the alkaline fluids of the upper small intestine. Enteric-coated tablets and capsules are coated with a substance that is insoluble in stomach acid. This delays dissolution until the medication reaches the intestine, usually to avoid gastric irritation or to keep the drug from being destroyed by gastric acid. Tablets for sublingual or buccal administration must be specifically formulated for such use.

Several controlled-release dosage forms and drug delivery systems are available and more continue to be developed. These formulations maintain more consistent serum drug levels and allow less frequent administration, which is more convenient for clients. Oral tablets and capsules are called by a variety of names (eg, timed release, sustained release, extended release) and their names usually include SR, XL, or other indications that they are long-acting formulations. Most of these formulations are given once or twice daily. Some drugs (eg, alendronate for osteoporosis and fluoxetine for major depression) are available in formulations that deliver a full week’s dosage in one oral tablet. Because controlled-release tablets and capsules contain high amounts of drug intended to be absorbed slowly and act over a prolonged period of time, they should never be broken, opened, crushed, or chewed. Such an action allows the full dose to be absorbed immediately and constitutes an overdose, with potential organ damage or death.

Transdermal (skin patch) formulations include systemically absorbed clonidine, estrogen, fentanyl, nitroglycerin, and scopalamine. These medications are slowly absorbed from the skin patches over varying periods of time (eg, 1 week for clonidine and estrogen). Pump delivery systems may be external or implanted under the skin and refillable or long acting without refills. Pumps are used to administer insulin, opioid analgesics, antineoplastics, and other drugs.

Solutions, ointments, creams, and suppositories are applied topically to skin or mucous membranes. They are formulated for the intended route of administration. For example, several drugs are available in solutions for nasal or oral inhalation; they are usually self-administered as a spray into the nose or mouth.

Many combination products containing fixed doses of two or more drugs are also available. Commonly used combinations include analgesics, antihypertensive drugs, and cold remedies. Most are oral tablets, capsules, or solutions.
### TABLE 3–2 Drug Dosage Forms

<table>
<thead>
<tr>
<th>Dosage Forms and Their Routes of Administration</th>
<th>Characteristics</th>
<th>Considerations/Precautions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tablets</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular: PO, GI tube (crushed and mixed with water)</td>
<td>• Contain active drug plus binders, dyes, preservatives</td>
<td>8 oz of water recommended when taken orally, to promote dissolution and absorption</td>
</tr>
<tr>
<td>Chewable: PO</td>
<td>• Dissolve in gastric fluids</td>
<td>Colors and flavors appeal to children; keep out of reach to avoid accidental overdose.</td>
</tr>
<tr>
<td>Enteric coated: PO</td>
<td>• Colorful and flavored, mainly for young children who are unable to swallow or who refuse regular tablets</td>
<td><em>Do not crush; instruct clients not to chew or crush.</em></td>
</tr>
<tr>
<td>Extended release (XL): PO</td>
<td>• Dissolve in small intestine rather than stomach; mainly used for medications that cause gastric irritation</td>
<td><em>Warning: Crushing to give orally or through a GI tube administers an overdose, with potentially serious adverse effects or death!! Never crush; instruct clients not to chew or crush.</em></td>
</tr>
<tr>
<td>Sublingual: Under the tongue</td>
<td>• Dissolve relatively large doses of active drug</td>
<td>Few medications formulated for administration by these routes</td>
</tr>
<tr>
<td>Buccal: Held in cheek</td>
<td>• Medication absorbed directly into the bloodstream and exerts rapid systemic effects</td>
<td></td>
</tr>
<tr>
<td><strong>Capsules</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular: PO</td>
<td>• Contain active drug, fillers, and preservatives in a gelatin capsule</td>
<td>As with oral tablets, 8 oz of fluid recommended to promote dissolution of capsule and absorption of medication</td>
</tr>
<tr>
<td>Extended release (XL): PO</td>
<td>• Gelatin capsules dissolve in gastric fluid and release medication</td>
<td><em>Warning: Emptying a capsule to give the medication orally or through a GI tube administers an overdose, with potentially serious adverse effects or death!! Instruct clients not to bite, chew or empty these capsules.</em></td>
</tr>
<tr>
<td><strong>Solutions</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral: PO, GI tube</td>
<td>• Absorbed rapidly because they do not need to be dissolved</td>
<td>Use of appropriate measuring devices and accurate measurement are extremely important.</td>
</tr>
<tr>
<td>Parenteral: IV, IM SC, intradermal</td>
<td>• Medications and all administration devices must be sterile</td>
<td>Use of appropriate equipment (eg, needles, syringes, IV administration sets) and accurate measurement are extremely important. Insulin syringes should always be used for insulin and tuberculin syringes are recommended for measuring small amounts of other drugs.</td>
</tr>
<tr>
<td><strong>Suspensions</strong></td>
<td>• IV produces rapid effects; SC is used mainly for insulin and heparin; IM is used for only a few drugs; intradermal is used mainly to inject skin test material rather than therapeutic drugs.</td>
<td></td>
</tr>
<tr>
<td>PO, SC (NPH and Lente insulins)</td>
<td>• These are particles of active drug suspended in a liquid; the liquid must be rotated or shaken before measuring a dose.</td>
<td>Drug particles settle to the bottom on standing. If not remixed, the liquid vehicle is given rather than the drug dose.</td>
</tr>
<tr>
<td><strong>Dermatologic Creams, Lotions, Ointments</strong></td>
<td>• Most are formulated for minimal absorption through skin and local effects at the site of application; medications in skin patch formulations are absorbed and exert systemic effects.</td>
<td>Formulations vary with intended uses and are not interchangeable. When removed from the client, skin patches must be disposed of properly to prevent someone else from being exposed to the active drug remaining in the patch.</td>
</tr>
<tr>
<td><strong>Solutions and Powders for Oral or Nasal Inhalation, Including Metered Dose Inhalers (MDIs)</strong></td>
<td>• Oral inhalations are used mainly for asthma; nasal sprays for nasal allergies (allergic rhinitis)</td>
<td>Several research studies indicate that patients often do not use MDIs correctly and sometimes are incorrectly taught by health care providers. Correct use is essential to obtaining therapeutic effects and avoiding adverse effects.</td>
</tr>
<tr>
<td><strong>Eye Solutions and Ointments</strong></td>
<td>• Effective with less systemic effect than oral drugs</td>
<td>Can be systemically absorbed and cause systemic adverse effects</td>
</tr>
<tr>
<td><strong>Throat Lozenges</strong></td>
<td>• Deliver a specified dose per inhalation</td>
<td></td>
</tr>
<tr>
<td><strong>Ear Solutions</strong></td>
<td>Should be sterile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Most are packaged in small amounts, to be used by a single patient</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Used for cough and sore throat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Used mainly for ear infections</td>
<td></td>
</tr>
</tbody>
</table>

*(continued)*
CALCULATING DRUG DOSAGES

When calculating drug doses, the importance of accuracy cannot be overemphasized. Accuracy requires basic skills in mathematics, knowledge of common units of measurement, and methods of using data in performing calculations.

Systems of Measurement

The most commonly used system of measurement is the metric system, in which the meter is used for linear measure, the gram for weight, and the liter for volume. One milliliter (mL) equals 1 cubic centimeter (cc), and both equal 1 gram (g) of water. The apothecary system, now obsolete and rarely used, has units called grains, minims, drams, ounces, pounds, pints, and quarts. The household system, with units of drops, teaspoons, tablespoons, and cups, is infrequently used in health care agencies but may be used at home. Table 3–3 lists equivalent measurements within and among these systems. Equivalents are approximate.

A few drugs are ordered and measured in terms of units or milliequivalents (mEq). Units express biologic activity in animal tests (ie, the amount of drug required to produce a particular response). Units are unique for each drug. For example, concentrations of insulin and heparin are both expressed in units, but there is no relation between a unit of insulin and a unit of heparin. These drugs are usually ordered in the number of units per dose (eg, NPH insulin 30 units subcutaneously [SC] every morning, or heparin 5000 units SC q12h) and labeled in number of units per milliliter (U 100 insulin contains 100 units/mL; heparin may have 1000, 5000, or 10,000 units/mL). Milliequivalents express the ionic activity of a drug. Drugs such as potassium chloride are ordered and labeled in the number of milliequivalents per dose, tablet, or milliliter.

Mathematical Calculations

Most drug orders and labels are expressed in metric units of measurement. If the amount specified in the order is the same as that on the drug label, no calculations are required, and preparing the right dose is a simple matter. For example, if the order reads “ibuprofen 400 mg PO” and the drug label reads “ibuprofen 400 mg per tablet,” it is clear that one tablet is to be given.

What happens if the order calls for a 400-mg dose and 200-mg tablets are available? The question is, “How many 200-mg tablets are needed to give a dose of 400 mg?” In this case, the answer can be readily calculated mentally to indicate two tablets. This is a simple example that also can be used to illustrate mathematical calculations. This problem can be solved by several acceptable methods; the following formula is presented because of its relative simplicity for students lacking a more familiar method.

\[
\frac{D}{H} = \frac{X}{V}
\]

\[
D = \text{desired dose (dose ordered, often in milligrams)}
\]
\[
H = \text{on-hand or available dose (dose on the drug label, often in mg per tablet, capsule, or milliliter)}
\]
\[
X = \text{unknown (number of tablets, in this example)}
\]
\[
V = \text{unit (one tablet, here)}
\]
Cross multiply:

\[
\frac{400 \text{ mg}}{200 \text{ mg}} = \frac{X \text{ tablet}}{1 \text{ tablet}}
\]

\[200X = 400\]

\[X = \frac{400}{200} = 2 \text{ tablets}\]

What happens if the order and the label are written in different units? For example, the order may read “amoxicillin 0.5 g” and the label may read “amoxicillin 500 mg/capsule.” To calculate the number of capsules needed for the dose, the first step is to convert 0.5 g to the equivalent number of milligrams, or convert 500 mg to the equivalent number of grams. The desired or ordered dose and the available or label dose must be in the same units of measurement. Using the equivalents (ie, 1 g = 1000 mg) listed in Table 3–2, an equation can be set up as follows:

\[
\frac{1 \text{ g}}{1000 \text{ mg}} = \frac{0.5 \text{ g}}{X \text{ mg}}
\]

\[X = 0.5 \times 1000 = 500 \text{ mg}\]

The next step is to use the new information in the formula, which then becomes:

\[
\frac{D}{H} = \frac{X}{V}
\]

\[
\frac{500 \text{ mg}}{500 \text{ mg}} = \frac{X \text{ capsules}}{1 \text{ capsule}}
\]

\[500X = 500\]

\[X = \frac{500}{500} = 1 \text{ capsule}\]

The same procedure and formula can be used to calculate portions of tablets or dosages of liquids. These are illustrated in the following problems:

1. Order: 25 mg PO
   Label: 50-mg tablet

\[
\frac{25 \text{ mg}}{50 \text{ mg}} = \frac{X \text{ tablet}}{1 \text{ tablet}}
\]

\[50X = 25\]

\[X = \frac{25}{50} = 0.5 \text{ tablet}\]

2. Order: 25 mg IM
   Label: 50 mg in 1 cc

\[
\frac{25 \text{ mg}}{50 \text{ mg}} = \frac{X \text{ cc}}{1 \text{ cc}}
\]

\[50X = 25\]

\[X = \frac{25}{50} = 0.5 \text{ cc}\]

3. Order: 4 mg IV
   Label: 10 mg/mL

\[
\frac{4 \text{ mg}}{10 \text{ mg}} = \frac{X \text{ mL}}{1 \text{ mL}}
\]

\[10X = 4\]

\[X = \frac{4}{10} = 0.4 \text{ mL}\]

4. Order: Heparin 5000 units
   Label: Heparin 10,000 units/mL

\[
\frac{5000 \text{ units}}{10,000 \text{ units}} = \frac{X \text{ mL}}{1 \text{ mL}}
\]

\[10,000X = 5000\]

\[X = \frac{5000}{10,000} = 0.5 \text{ mL}\]

5. Order: KCl 20 mEq
   Label: KCl 10 mEq/5 mL

\[
\frac{20 \text{ mEq}}{10 \text{ mEq}} = \frac{X \text{ mL}}{5 \text{ mL}}
\]

\[10X = 100\]

\[X = \frac{100}{10} = 10 \text{ mL}\]

**ROUTES OF ADMINISTRATION**

Routes of administration depend on drug characteristics, client characteristics, and desired responses. The major routes are oral, parenteral, and topical. Each has advantages, disadvantages, indications for use, and specific techniques of administration (Table 3–4). The term parenteral refers to any route other than gastrointestinal (enteral), but is commonly used to indicate SC, IM, and IV injections. Injections require special drug preparations, equipment, and techniques. General characteristics are described below; specific considerations for the intravenous route are described in Box 3–2.

**Drugs for Injection**

Parenteral drugs must be prepared, packaged, and administered in ways to maintain sterility. Vials are closed glass or plastic containers with rubber stoppers through which a sterile needle can be inserted for withdrawing medication. Single-dose vials usually do not contain a preservative and must be discarded after a dose is withdrawn; multiple-dose vials contain a preservative and may be reused if aseptic technique is maintained.

Ampules are sealed glass containers, the tops of which must be broken off to allow insertion of a needle and withdrawal of the medication. Broken ampules and any remaining medication are discarded; they are no longer sterile and
<table>
<thead>
<tr>
<th>Route and Description</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>• Simple and can be used by most people&lt;br&gt; • Convenient; does not require complex equipment&lt;br&gt; • Relatively inexpensive</td>
<td>• Amount of drug acting on body cells is unknown because varying portions of a dose are absorbed and some drug is metabolized in the liver before reaching the bloodstream for circulation&lt;br&gt; • Slow drug action&lt;br&gt; • Irritation of gastrointestinal mucosa by some drugs</td>
<td>The oral route should generally be used when possible, considering the client’s condition and ability to take or tolerate oral drugs.</td>
</tr>
<tr>
<td>GI tubes (eg, nasogastric, gastrostomy)</td>
<td>• Allows use of GI tract in clients who cannot take oral drugs&lt;br&gt; • Can be used over long periods of time, if necessary&lt;br&gt; • May avoid or decrease injections</td>
<td>• With nasogastric tubes, medications may be aspirated into the lungs&lt;br&gt; • Small-bore tubes often become clogged&lt;br&gt; • Requires special precautions to give correctly and avoid complications</td>
<td>Liquid preparations are preferred over crushed tablets and emptied capsules, when available&lt;br&gt; Tube should be rinsed before and after instilling medication. The SC route is commonly used for only a few drugs because many drugs are irritating to SC tissues. Such drugs may cause pain, necrosis and abscess formation if injected SC. It is very important to use anatomic landmarks when selecting IM injection sites.</td>
</tr>
<tr>
<td>Subcutaneous (SC) injection—&lt;br&gt; injection of drugs under the skin, into the underlying fatty tissue</td>
<td>• Relatively painless&lt;br&gt; • Very small needles can be used&lt;br&gt; • Insulin and heparin, commonly used medications that often require multiple daily injections, can be given SC</td>
<td>• Only a small amount of drug (up to 1 mL) can be given&lt;br&gt; • Drug absorption is relatively slow&lt;br&gt; • Only a few drugs can be given SC</td>
<td></td>
</tr>
<tr>
<td>Intramuscular (IM) injection—&lt;br&gt; injection of drugs into selected muscles</td>
<td>• May be used for several drugs&lt;br&gt; • Drug absorption is rapid because muscle tissue has an abundant blood supply&lt;br&gt; • Bypasses barriers to drug absorption that occur with other routes&lt;br&gt; • Rapid drug action&lt;br&gt; • Larger amounts can be given than by SC and IM routes&lt;br&gt; • Allows slow administration when indicated</td>
<td>• A relatively small amount of drug (up to 3 mL) can be given&lt;br&gt; • Risks of damage to blood vessels or nerves if needle is not positioned correctly&lt;br&gt; • High potential for adverse reactions from rapid drug action and possible complications of IV therapy (ie, bleeding, infection, fluid overload, extravasation)&lt;br&gt; • Phlebitis commonly occurs and increases risks of thrombosis&lt;br&gt; • Phlebitis and thrombosis cause discomfort or pain, may take days or weeks to subside, and limit the veins available for future therapy</td>
<td>The nurse should wear latex gloves to start IV infusions, for protection against exposure to bloodborne pathogens. Phlebitis and thrombosis result from injury to the endothelial cells that form the inner lining (intima) of veins and may be caused by repeated venipunctures, the IV catheter, hypertonic IV fluid, or irritating drugs.</td>
</tr>
<tr>
<td>Intravenous (IV) injection—&lt;br&gt; injection of a drug into the bloodstream</td>
<td>• Allows medications to be given to a patient who cannot take fluids or drugs by GI tract&lt;br&gt; • Bypasses barriers to drug absorption that occur with other routes&lt;br&gt; • Rapid drug action&lt;br&gt; • Larger amounts can be given than by SC and IM routes&lt;br&gt; • Allows slow administration when indicated&lt;br&gt; • Time and skill required for venipuncture and maintaining an IV line&lt;br&gt; • Once injected, drug cannot be retrieved if adverse effects or overdoses occur&lt;br&gt; • High potential for adverse reactions from rapid drug action and possible complications of IV therapy (ie, bleeding, infection, fluid overload, extravasation)&lt;br&gt; • Phlebitis commonly occurs and increases risks of thrombosis&lt;br&gt; • Phlebitis and thrombosis cause discomfort or pain, may take days or weeks to subside, and limit the veins available for future therapy</td>
<td>• Some drugs irritate skin or mucous membranes and cause itching, rash, or discomfort&lt;br&gt; • With inflamed, abraded, or damaged skin, drug absorption is increased and systemic adverse effects may occur&lt;br&gt; • Application to mucous membranes may cause systemic adverse effects (eg, beta blocker eye drops, used to treat glaucoma, can cause bradycardia just as oral beta blockers can)&lt;br&gt; • Specific drug preparations must be used for the various routes (ie, dermatologics for skin; ophthalmics for eyes; sublingual, buccal, vaginal, and rectal preparations for those sites).</td>
<td>When available and effective, topical drugs are often preferred over oral or injected drugs, because of fewer and/or less severe systemic adverse effects.</td>
</tr>
<tr>
<td>Topical administration—&lt;br&gt; application to skin or mucous membranes. Application to mucous membranes includes drugs given by nasal or oral inhalation; by instillation into the lungs, eyes, or nose; and by insertion under the tongue (sublingual), into the cheek (buccal), and into the vagina or rectum.</td>
<td>• With application to intact skin, most medications act at the site of application, with little systemic absorption or systemic adverse effects.&lt;br&gt; • Some drugs are given topically for systemic effects (eg, medicated skin patches). Effects may last several days and the patches are usually convenient for clients.&lt;br&gt; • With application to mucous membranes, most drugs are well and rapidly absorbed</td>
<td>• Some drugs irritate skin or mucous membranes and cause itching, rash, or discomfort&lt;br&gt; • With inflamed, abraded, or damaged skin, drug absorption is increased and systemic adverse effects may occur&lt;br&gt; • Application to mucous membranes may cause systemic adverse effects (eg, beta blocker eye drops, used to treat glaucoma, can cause bradycardia just as oral beta blockers can)&lt;br&gt; • Specific drug preparations must be used for the various routes (ie, dermatologics for skin; ophthalmics for eyes; sublingual, buccal, vaginal, and rectal preparations for those sites).</td>
<td>When available and effective, topical drugs are often preferred over oral or injected drugs, because of fewer and/or less severe systemic adverse effects.</td>
</tr>
</tbody>
</table>
Methods

**IV injection or IV push** is the direct injection of a medication into the vein. The drug may be injected through an injection site on IV tubing or an intermittent infusion device. Most IV push medications should be injected slowly. The time depends on the particular drug, but is often 2 minutes or longer for a dose. Rapid injection should generally be avoided because the drug produces high blood levels and is quickly circulated to the heart and brain, where it may cause adverse or toxic effects. Although IV push may be useful with a few drugs or in emergency situations, slower infusion of more dilute drugs is usually preferred.

**Intermittent infusion** is administration of intermittent doses, often diluted in 50 to 100 mL of fluid and infused over 30–60 minutes. The drug dose is usually prepared in a pharmacy and connected to an IV administration set that controls the amount and flow rate. Intermittent infusions are often connected to an injection port on a primary IV line, through which IV fluids are infusing continuously. The purpose of the primary IV line may be to provide fluids to the client or to keep the vein open for periodic administration of medications. The IV fluids are usually stopped for the medication infusion, then restarted. Drug doses may also be infused through an intermittent infusion device (eg, a heparin lock) to conserve veins and allow freedom of motion between drug doses. The devices decrease the amount of IV fluids given to patients who do not need them (ie, who are able to ingest adequate amounts of oral fluids) and those who are at risk of fluid overload, especially children and older adults.

An intermittent infusion device may be part of an initial IV line or used to adapt a continuous IV for intermittent use. The devices include a heparin lock or a resealable adapter added to a peripheral or central IV catheter. These devices must be flushed routinely to maintain patency. If the IV catheter has more than one lumen, all must be flushed, whether being used or not. Saline is probably the most commonly used flushing solution; heparin may also be used if recommended by the device’s manufacturer or required by institutional policy. For example, heparin (3 to 5 mL of 100 units/mL, after each use or monthly if not in use) is recommended for implanted catheters.

**Continuous infusion** indicates medications mixed in a large volume of IV fluid and infused continuously, over several hours. For example, vitamins and minerals (eg, potassium chloride) are usually added to liters of IV fluids. Greater dilution of the drug and administration over a longer time decreases risks of accumulation and toxicity, as well as venous irritation and thrombophlebitis.

Equipment

Equipment varies considerably from one health care agency to another. Nurses must become familiar with the equipment available in their work setting, including IV catheters, types of IV tubing, needles and needleless systems, types of volume control devices, and electronic infusion devices (IV pumps).

**Catheters** vary in size (both gauge and length), design and composition (eg, polyvinyl chloride, polyurethane, silicone). The most common design type is over the needle; the needle is used to start the IV, then it is removed. When choosing a catheter to start an IV, one that is much smaller than the lumen of the vein is recommended. This allows good blood flow and rapidly dilutes drug solutions as they enter the vein. This, in turn, prevents high drug concentrations and risks of toxicity. Also, once a catheter is inserted, it is very important to tape it securely so that it does not move around. Movement of the catheter increases venous irritation and risks of thrombophlebitis and infection. If signs of venous irritation and inflammation develop, the catheter should be removed and a new one inserted at another site. Additional recommendations include application of a topical antibiotic or antiseptic ointment at the IV site after catheter insertion, a sterile occlusive dressing over the site, and limiting the duration of placement to a few days.

Many medications are administered through peripherally inserted central catheters (PICC lines) or central venous catheters, in which the catheter tips are inserted into the superior vena cava, next to the right atrium of the heart. Central venous catheters may have single, double, or triple lumens. Other products, which are especially useful for long-term IV drug therapy, include a variety of implanted ports, pumps, and reservoirs.

If a catheter becomes clogged, do not irrigate it. Doing so may push a clot into the circulation and result in a pulmonary embolus, myocardial infarction, or stroke. It may also cause septicemia, if the clot is infected.

**Needleless systems** are one of the most important advances in IV therapy. Most products have a blunt-tipped plastic insertion device and an injection port that opens. These systems greatly decrease needle-stick injuries and exposure to blood-borne pathogens.

**Electronic infusion devices** allow amounts and flow rates of IV drug solutions to be set and controlled by a computer. Although the devices save nursing time, because the nurse does not need to count drops and continually adjust flow rates, probably the biggest advantage is the steady rate of drug administration. The devices are used in most settings where IV drugs and IV fluids are administered, but they are especially valuable in pediatrics, where very small amounts of medication and IV fluid are needed, and in intensive care units, where strong drugs and varying amounts of IV fluid are usually required. Several types of pumps are available, even within the same health care agency. It is extremely important that nurses become familiar with the devices used in their work setting, so they can program them accurately and determine whether or not they are functioning properly (ie, delivering medications as ordered).

Site Selection

IV needles are usually inserted into a vein on the hand or forearm; IV catheters may be inserted in a peripheral site or centrally (the catheter tip ends in the superior vena cava, near the right atrium of the heart, and medications and fluids are rapidly diluted and flow directly into the heart). In general, recommendations are:

- **Start at the most distal location.** This conserves more proximal veins for later use, if needed. Veins on the back of the hand and on the forearm are often used. These sites usually provide more comfort and freedom of movement for clients than other sites.
- **Use veins with a large blood volume flowing through them when possible.** Many drugs cause irritation and phlebitis in small veins.

(continued)
When possible, avoid the antecubital vein on the inner surface of the elbow, veins over or close to joints, and veins on the inner aspect of the wrists. Reasons include the difficulty of stabilizing and maintaining an IV line at these sites. In addition, the antecubital vein is often used to draw blood samples for laboratory analysis and inner wrist venipunctures are very painful. Do not perform venipuncture in foot or leg veins. The risks of serious or fatal complications are too high.

- Rotate sites when long-term use (more than a few days) of IV fluid or drug therapy is required. Venous irritation occurs with longer duration of site use and with the administration of irritating drugs or fluids. When it is necessary to change an IV site, use the opposite arm if possible.

**Drug Preparation**

Most IV drugs are prepared for administration in pharmacies and this is the safest practice. When a nurse must prepare a medication, considerations include the following:

- Only drug formulations manufactured for IV use should be given IV. Other formulations contain various substances that are not sterile, pure enough, or soluable enough to be injected into the bloodstream. In recent years, there have been numerous reports of medication errors resulting from IV administration of drug preparations intended for oral use!! Such errors can and should be prevented. For example, when liquid medications intended for oral use are measured or dispensed in a syringe (as they often are for children, adults with difficulty in swallowing tablets and capsules, or for administration through a gastrointestinal [GI] tube), the syringe should have a blunt tip that will not connect to or penetrate IV tubing injection sites.

- Use sterile technique during all phases of IV drug preparation.

- Follow the manufacturer’s instructions for mixing and diluting IV medications. Some liquid IV medications need to be diluted prior to IV administration and powdered medications must be reconstituted appropriately (eg, the correct amount of the recommended diluent added). The diluent recommended by the drug’s manufacturer should be used because different drugs require different diluents. In addition, be sure any reconstituted drug is completely dissolved to avoid particles that may be injected into the systemic circulation and lead to thrombus formation or embolism. A filtered aspiration needle should be used when withdrawing medication from a vial or ampule, to remove any particles in the solution. The filter needle should then be discarded, to prevent filtered particles from being injected when the medication is added to the IV fluid. Filters added to IV tubing also help to remove particles.

- Check the expiration date on all IV medications. Many drugs have a limited period of stability after they are reconstituted or diluted for IV administration.

- IV medications should be compatible with the infusing IV fluids. Most are compatible with 5% dextrose in water or saline solutions.

- If adding a medication to a container of IV fluid, invert the container to be sure the additive is well mixed with the solution.

- For any IV medication that is prepared or added to an IV bag, label the medication vial or IV bag with the name of the patient, drug, dosage, date, time of mixing, expiration date, and the preparer’s signature.

**Drug Administration**

- Most IV medications are injected into a self-sealing site in any of several IV set-ups, including a scalp–vein needle and tubing, a plastic catheter connected to a heparin lock or other intermittent infusion device, or IV tubing and a plastic bag containing IV fluid.

- Before injecting any IV medication, be sure the IV line is open and functioning properly (eg, catheter not clotted, IV fluid not leaking into surrounding tissues, phlebitis not present). If leakage occurs, some drugs are very irritating to subcutaneous tissues and may cause tissue necrosis.

- Maintain sterility of all IV fluids, tubings, injection sites, drug solutions, and equipment coming into contact with the IV system. Because medications and fluids are injected directly into the bloodstream, breaks in sterile technique can lead to serious systemic infections (septicemia) and death.

- When two or more medications are to be given one after the other, flush the IV tubing and catheter (with the infusing IV fluid or with sterile 0.9% sodium chloride injection) so that the drugs do not come into contact with each other.

- If a medication is to be injected or infused through an intermittent infusion device containing heparin, the drug should be compatible with heparin or the device should be irrigated with sterile saline before and after medication administration. After irrigation, heparin then needs to be reinstilled. This is not a common event, because most heparin locks and other intermittent infusion devices are now filled with saline rather than heparin.

- In general, administer slowly to allow greater dilution of the drug in the bloodstream. Most drugs given by IV push (direct injection) can be given over 2–5 minutes and most drugs diluted in 50–100 mL of IV fluid can be infused in 30–60 minutes.

- When injecting or infusing medications into IV solutions that contain other additives (eg, vitamins, insulin, minerals such as potassium or magnesium), be sure the medications are compatible with the other substances. Consult compatibility charts (usually available on nursing units) or pharmacists when indicated.

- IV flow rates are usually calculated in mL/hour and drops per minute. Required information includes the amount of solution or medication to be infused, the time or duration of the infusion, and the drop factor of the IV administration set to be used. The drop factor of macrodrip sets may be 10, 15, or 20 drops per milliliter, depending on the manufacturer. Most agencies use mainly one manufacturer’s product. The drop factor of all microdrip sets is 60 drops per mL. Following is a sample calculation:

  **Order:** Cefazolin 1 g IV q8h

  **Label:** Cefazolin 1 g in 100 mL of 0.9% sodium chloride injection; infuse over 60 minutes

  **Solution:** Divide 100 by 60 to determine mL/min (1.66). Multiply 1.66 by the drop factor to determine drops/min (eg, with a drop factor of 20 drops/mL, 33 drops/min would deliver the dose). Count drops and regulate the flow rate manually or program an IV pump to deliver the dose.
Nursing Notes: Apply Your Knowledge

Your client has a nasogastric feeding tube in place. You will be administering morning medications, including 4 tablets, 1 capsule, and 10 cc of an elixir. Describe how you will safely administer medications through a feeding tube to this client.

cannot be reused. When vials or ampules contain a powder form of the drug, a sterile solution of water or 0.9% sodium chloride must be added and the drug dissolved before withdrawal. Use a filter needle to withdraw the medication from an ampule or vial because broken glass or rubber fragments may need to be removed from the drug solution. Replace the filter needle with a regular needle before injecting the client.

Many injectable drugs (eg, morphine, heparin), are available in prefilled syringes with attached needles. These units are inserted into specially designed holders and used like other needle/syringe units.

Equipment for Injections

Sterile needles and syringes are used to measure and administer parenteral medications; they may be packaged together or separately. Needles are available in various gauges and lengths. The term gauge refers to lumen size, with larger numbers indicating smaller lumen sizes. For example, a 25-gauge needle is smaller than an 18-gauge needle. Choice of needle gauge and length depends on the route of administration, the viscosity (thickness) of the solution to be given, and the size of the client. Usually, a 25-gauge, ½-inch needle is used for SC injections and a 22- or 20-gauge, 1½-inch needle for IM injections. Other needle sizes are available for special uses, such as insulin or intradermal injections. When needles are used, avoid recapping them and dispose of them in appropriate containers. Such containers are designed to prevent accidental needle-stick injuries to health care and housekeeping personnel.

Sites for Injections

Common sites for subcutaneous injections are the upper arms, abdomen, back, and thighs (Fig. 3–1). Sites for intramuscular injections are the deltoid, dorsogluteal, ventrogluteal, and vastus lateralis muscles. These sites must be selected by first identifying anatomic landmarks (Fig. 3–2). Common sites for intravenous injections are the veins on the back of the hands and on the forearms (Fig. 3–3). Other sites (eg, subclavian and jugular veins) are also used, mainly in critically ill clients. Additional parenteral routes include injection into layers of the skin (intradermal), arteries (intra-arterial), joints (intra-articular), and cerebrospinal fluid (intrathecal). Nurses may administer drugs intradermally or intra-arterially (if an established arterial line is present); physicians administer intra-articular and intrathecal medications.

In many settings, needleless systems are being used. These involve a plastic tip on the syringe that can be used to enter vials and injection sites on IV tubing. Openings created by the tip reseal themselves. Needleless systems were developed because of the risk of injury and spread of blood-borne pathogens, such as the viruses that cause acquired immunodeficiency syndrome and hepatitis B.

Syringes also are available in various sizes. The 3-mL size is probably used most often. It is usually plastic and is available with or without an attached needle. Syringes are calibrated so that drug doses can be measured accurately. However, the calibrations vary according to the size and type of syringe.

Insulin and tuberculin syringes are used for specific purposes. Insulin syringes are calibrated to measure up to 100 units of insulin. Safe practice requires that only insulin syringes be used to measure insulin and that they be used for no other drugs. Tuberculin syringes have a capacity of 1 mL. They should be used for small doses of any drug because measurements are more accurate than with larger syringes.
**Figure 3-2** IM injection sites. (A) Placement of the needle for insertion into the deltoid muscle. The area of injection is bounded by the lower edge of the acromion on the top to a point on the side of the arm opposite the axilla on the bottom. The side boundaries of the rectangular site are parallel to the arm and one third and two thirds of the way around the side of the arm. (B) Proper placement of the needle for an intramuscular injection into the dorsogluteal site. It is above and outside a diagonal line drawn from the greater trochanter of the femur to the posterior superior iliac spine. Notice how this site allows the nurse to avoid entering an area near the sciatic nerve and the superior gluteal artery. (C) Placement of the needle for insertion into the ventrogluteal area. Notice how the nurse’s palm is placed on the greater trochanter and the index finger on the anterior superior iliac spine. The middle finger is spread posteriorly as far as possible along the iliac crest. The injection is made in the middle of the triangle formed by the nurse’s fingers and the iliac crest. (D) Placement of the needle for insertion into the vastus lateralis. It is usually easier to have the client lying on his or her back. However, the client may be sitting when using this site for intramuscular injections. It is a suitable site for children when the nurse grasps the muscle in her hand to concentrate the muscle mass for injection.
CHAPTER 3 ADMINISTERING MEDICATIONS

Figure 3-3 Veins of the hand and forearm that may be used to administer intravenous fluids and medications.

Drug Administration

NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
1. Follow general rules for administering medications safety and effectively. | To prevent errors in selecting ordered drugs, calculating dosages, and identifying clients.
   a. Prepare and give drugs in well-lighted areas, as free of interruptions and distractions as possible. | To prevent infection and cross-contamination.
   b. Wash hands before preparing medications and, if needed, during administration. | To prevent infection. Sterile technique involves using sterile needles and syringes, using sterile drug solutions, not touching sterile objects to any unsterile objects, and cleansing injection sites with an antiseptic.
   c. Use sterile technique in preparing and administering injections. | For accurate drug administration. Most nursing texts instruct the nurse to read a drug label three times: when removing the container, while measuring the dose, and before returning the container.
   d. Read the medication administration record (MAR) carefully. Read the label on the drug container, and compare with the MAR in terms of drug, dosage or concentration, and route of administration. | To prevent accidental or deliberate ingestion by anyone other than the intended person. Also, to prevent contamination or spilling of medications.
   e. Do not leave medications unattended. | (continued)
### NURSING ACTIONS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>f.</td>
<td>Identify the client, preferably by comparing the identification wristband to the medication sheet.</td>
</tr>
<tr>
<td>g.</td>
<td>Identify yourself, if indicated, and state your reason for approaching the client. For example, “I’m . . . I have your medication for you.”</td>
</tr>
<tr>
<td>h.</td>
<td>Position the client appropriately for the intended route of administration.</td>
</tr>
<tr>
<td>i.</td>
<td>Do not leave medications at the bedside as a general rule. Common exceptions are antacids, nitroglycerin, and eye medications.</td>
</tr>
<tr>
<td>j.</td>
<td>Do not give a drug when signs and symptoms of toxicity are present. Notify the physician, and record that the drug was omitted and why.</td>
</tr>
<tr>
<td>k.</td>
<td>Record drug administration (or omission) as soon as possible and according to agency policies.</td>
</tr>
<tr>
<td>l.</td>
<td>If it is necessary to omit a scheduled dose for some reason, the decision to give the dose later or omit it depends largely on the drug and frequency of administration. Generally, give drugs ordered once or twice daily at a later time. For others, omit the one dose, and give the drug at the next scheduled time.</td>
</tr>
<tr>
<td>m.</td>
<td>For medications ordered as needed (PRN), assess the client’s condition; check the physician’s orders or MAR for the name, dose, and frequency of administration; and determine the time of the most recently administered dose.</td>
</tr>
<tr>
<td>n.</td>
<td>For narcotics and other controlled substances, sign drugs out on separate narcotic records according to agency policies.</td>
</tr>
<tr>
<td>o.</td>
<td>If, at any time during drug preparation or administration, any question arises regarding the drug, the dose, or whether the client is supposed to receive it, check the original physician’s order. If the order is not clear, call the physician for clarification before giving the drug.</td>
</tr>
<tr>
<td>2.</td>
<td>For oral medications:</td>
</tr>
<tr>
<td>a.</td>
<td>With adults</td>
</tr>
<tr>
<td>(1)</td>
<td>To give tablets or capsules, open the unit-dose wrapper, place medication in a medicine cup, and give the cup to the client. For solutions, hold the cup at eye level, and measure the dosage at the bottom of the meniscus. For suspensions, shake or invert containers to mix the medication before measuring the dose.</td>
</tr>
<tr>
<td>(2)</td>
<td>Have the client in a sitting position when not contraindicated.</td>
</tr>
<tr>
<td>(3)</td>
<td>Give before, with, or after meals as indicated by the specific drug.</td>
</tr>
<tr>
<td>(4)</td>
<td>Give most oral drugs with a full glass (8 oz) of water or other fluid.</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>f.</td>
<td>This is the best way to verify identity. Calling by name, relying on the name on a door or bed, and asking someone else are unreliable methods, although they must be used occasionally when the client lacks a name band.</td>
</tr>
<tr>
<td>g.</td>
<td>Explaining actions helps to decrease client anxiety and increase cooperation in taking prescribed medication.</td>
</tr>
<tr>
<td>h.</td>
<td>To prevent complications, such as aspiration of oral drugs into the lungs</td>
</tr>
<tr>
<td>i.</td>
<td>To promote comfort of the client and to ensure drug administration</td>
</tr>
<tr>
<td>j.</td>
<td>To prevent omitting or losing the drug or hoarding of the drug by the client</td>
</tr>
<tr>
<td>k.</td>
<td>Additional doses of a drug increase toxicity. However, drugs are not omitted without a careful assessment of the client’s condition and a valid reason.</td>
</tr>
<tr>
<td>l.</td>
<td>To maintain an accurate record of drugs received by the client</td>
</tr>
<tr>
<td>m.</td>
<td>Clients may be unable to take the drug at the scheduled time because of diagnostic tests or many other reasons. A temporary change in the time of administration—usually for one dose only—may be necessary to maintain therapeutic effects.</td>
</tr>
<tr>
<td>n.</td>
<td>Administration of PRN medications requires nursing assessment and decision making. Analgesics, antiemetics, and antipyretics are often ordered PRN.</td>
</tr>
<tr>
<td>o.</td>
<td>To meet legal requirements for dispensing controlled substances</td>
</tr>
<tr>
<td>p.</td>
<td>To promote safety and prevent errors. The same procedure applies when the client questions drug orders at the bedside. For example, the client may state he has been receiving different drugs or different doses.</td>
</tr>
<tr>
<td>(continued)</td>
<td></td>
</tr>
<tr>
<td>NURSING ACTIONS</td>
<td>RATIONALE/EXPLANATION</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td><strong>b. With children, liquids or chewable tablets are usually given.</strong>&lt;br&gt;(1) Measure and give liquids to infants with a dropper or syringe, placing medication on the tongue or buccal mucosa and giving slowly.&lt;br&gt;(2) Medications are often mixed with juice, applesauce, or other vehicle.</td>
<td>Children under 5 years of age are often unable to swallow tablets or capsules. For accurate measurement and administration. Giving slowly decreases risks of aspiration.</td>
</tr>
<tr>
<td><strong>c. Do not give oral drugs if the client is:</strong>&lt;br&gt;(1) NPO (receiving nothing by mouth)&lt;br&gt;(2) Vomiting&lt;br&gt;(3) Excessively sedated or unconscious</td>
<td>Oral drugs and fluids may interfere with diagnostic tests or be otherwise contraindicated. Most drugs can be given after diagnostic tests are completed. If the client is having surgery, preoperative drug orders are cancelled. New orders are written postoperatively. Oral drugs and fluids increase vomiting. Thus, no benefit results from the drug. Also, fluid and electrolyte problems may result from loss of gastric acid. To avoid aspiration of drugs into the lungs owing to impaired ability to swallow</td>
</tr>
<tr>
<td><strong>3. For medications given by nasogastric tube:</strong>&lt;br&gt;a. Use a liquid preparation when possible. If necessary, crush a tablet or empty a capsule into about 30 mL of water and mix well. <strong>Do not crush enteric-coated or sustained-release products, and do not empty sustained-release capsules.</strong>&lt;br&gt;b. Use a clean bulb syringe or other catheter-tipped syringe.&lt;br&gt;c. Before instilling medication, aspirate gastric fluid or use another method to check tube placement.&lt;br&gt;d. Instill medication by gravity flow, and follow it with at least 50 mL of water. Do not allow the syringe to empty completely between additions.&lt;br&gt;e. Clamp off the tube from suction or drainage for at least 30 minutes.</td>
<td>Particles of tablets or powders from capsules may obstruct the tube lumen. Altering sustained-release products increases risks of overdosage and adverse effects. The syringe allows aspiration and serves as a funnel for instillation of medication and fluids into the stomach. To be sure the tube is in the stomach Gravity flow is safer than applying pressure. Water “pushes” the drug into the stomach and rinses the tube, thereby maintaining tube patency. Additional water or other fluids may be given according to fluid needs of the client. Add fluids to avoid instilling air into the stomach unnecessarily, with possible client discomfort. To avoid removing the medication from the stomach</td>
</tr>
<tr>
<td><strong>4. For subcutaneous (SC) injections:</strong>&lt;br&gt;a. Use only sterile drug preparations labeled or commonly used for SC injections.&lt;br&gt;b. Use a 25-gauge, $\frac{3}{4}$-inch needle for most SC injections.&lt;br&gt;c. Select an appropriate injection site, based on client preferences, drug characteristics, and visual inspection of possible sites. In long-term therapy, such as with insulin, rotate injection sites. Avoid areas with lumps, bruises, or other lesions.&lt;br&gt;d. Cleanse the site with an alcohol sponge.&lt;br&gt;e. Tighten the skin or pinch a fold of skin and tissue between thumb and fingers.&lt;br&gt;f. Hold the syringe like a pencil, and insert the needle quickly at a 45-degree angle. Use enough force to penetrate the skin and subcutaneous tissue in one smooth movement.</td>
<td>Many parenteral drugs are too irritating to subcutaneous tissue for use by this route. This size needle is effective for most clients and drugs. These techniques allow the client to participate in his or her care; avoid tissue damage and unpredictable absorption, which occur with repeated injections in the same location; and increase client comfort and cooperation. To prevent infection Either is acceptable for most clients. If the client is obese, tightening the skin may be easier. If the client is very thin, the tissue fold may keep the needle from hitting bone. To give the drug correctly with minimal client discomfort.</td>
</tr>
</tbody>
</table>
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
g. Release the skin so that both hands are free to manipulate the syringe. Pull back gently on the plunger (aspirate). If no blood enters the syringe, inject the drug. If blood is aspirated into the syringe, remove the needle, and reprepare the medication. | To prevent accidental injection into the bloodstream. Blood return in the syringe is an uncommon occurrence.
h. Remove the needle quickly and apply gentle pressure for a few seconds. | To prevent bleeding

5. **For intramuscular (IM) injections:**

a. Use only drug preparations labeled or commonly used for IM injections. Check label instructions for mixing drugs in powder form.
b. Use a 1 1/2-inch needle for most adults and a 3/4- to 1 1/2-inch needle for children, depending on the size of the client.
c. Use the smallest-gauge needle that will accommodate the medication. A 22-gauge is satisfactory for most drugs; a 20-gauge may be used for viscous medications.
d. Select an appropriate injection site, based on client preferences, drug characteristics, anatomic landmarks, and visual inspection of possible sites. Rotate sites if frequent injections are being given, and avoid areas with lumps, bruises, or other lesions.
e. Cleanse the site with an alcohol sponge.
f. Tighten the skin, hold the syringe like a pencil, and insert the needle quickly at a 90-degree angle. Use enough force to penetrate the skin and subcutaneous tissue into the muscle in one smooth motion.
g. Aspirate (see 4g, SC injections).
h. Remove the needle quickly and apply pressure for several seconds. | Some parenteral drug preparations cannot be given safely by the IM route.
A long needle is necessary to reach muscle tissue, which underlies subcutaneous fat.
To decrease tissue damage and client discomfort
To increase client comfort and participation and to avoid tissue damage. Identification of anatomic landmarks is mandatory for safe administration of IM drugs.
To prevent infection
To give the drug correctly with minimal client discomfort
To prevent bleeding

6. **For intravenous (IV) injections:**

a. Use only drug preparations that are labeled for IV use.
b. Check label instructions for the type and amount of fluid to use for dissolving or diluting the drug.
c. Prepare drugs just before use, as a general rule. Also, add drugs to IV fluids just before use.
d. For venipuncture and direct injection into a vein, apply a tourniquet, select a site in the arm, cleanse the skin with an antiseptic (eg, povidone-iodine or alcohol), insert the needle, and aspirate a small amount of blood into the syringe to be sure that the needle is in the vein. Remove the tourniquet, and inject the drug slowly. Remove the needle and apply pressure until there is no evidence of bleeding. | Others are not pure enough for safe injection into the bloodstream or are not compatible with the blood pH (7.35–7.45).
Some drugs require special preparation techniques to maintain solubility or pharmacologic activity. Most drugs in powder form can be dissolved in sterile water or sodium chloride for injection. Most drug solutions can be given with dextrose or dextrose and sodium chloride IV solutions.
Some drugs are unstable in solution. In some agencies, drugs are mixed and added to IV fluids in the pharmacy. This is the preferred method because sterility can be better maintained.
For safe and accurate drug administration with minimal risk to the client. The length of time required to give the drug depends on the specific drug and the amount. Slow administration, over several minutes, allows immediate discontinuation if adverse effects occur.
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>e.</th>
<th>For administration by an established IV line:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Check the infusion for patency and flow rate. Check the venipuncture site for signs of infiltration and phlebitis before each drug dose.</td>
</tr>
<tr>
<td>(2)</td>
<td>For direct injection, cleanse an injection site on the IV tubing, insert the needle, and inject the drug slowly.</td>
</tr>
<tr>
<td>(3)</td>
<td>To use a volume-control set, fill it with 50–100 mL of IV fluid, and clamp it so that no further fluid enters the chamber and dilutes the drug. Inject the drug into an injection site after cleansing the site with an alcohol sponge and infuse, usually in 1 hour or less. Once the drug is infused, add solution to maintain the infusion.</td>
</tr>
<tr>
<td>(4)</td>
<td>To use a “piggyback” method, add the drug to 50–100 mL of IV solution in a separate container. Attach the IV tubing and a needle. Insert the needle in an injection site on the main IV tubing after cleansing the site. Infuse the drug over 15–60 minutes, depending on the drug.</td>
</tr>
</tbody>
</table>

| f. | When more than one drug is to be given, flush the line between drugs. Do not mix drugs in syringes or in IV fluids unless the drug literature states that the drugs are compatible. |

<table>
<thead>
<tr>
<th>7.</th>
<th>For application to skin:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Use drug preparations labeled for dermatologic use. Cleanse the skin, remove any previously applied medication, and apply the drug in a thin layer. For broken skin or open lesions, use sterile gloves, tongue blade, or cotton-tipped applicator to apply the drug.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8.</th>
<th>For instillation of eye drops:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Use drug preparations labeled for ophthalmic use. Wash your hands, open the eye to expose the conjunctival sac, and drop the medication into the sac, not on the eyeball, without touching the dropper tip to anything. Provide a tissue for blotting any excess drug. If two or more eye drops are scheduled at the same time, wait 1–5 minutes between instillations. With children, prepare the medication, place the child in a head-lowered position, steady the hand holding the medication on the child’s head, gently retract the lower lid, and instill the medication into the conjunctival sac.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9.</th>
<th>For instillation of nose drops and nasal sprays:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Have the client hold his or her head back, and drop the medication into the nostrils. Give only as ordered. With children, place in a supine position with the head lowered, instill the medication, and maintain the position for 2–3 minutes. Then, place the child in a prone position.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>10.</th>
<th>For instillation of ear medications:</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>Open the ear canal by pulling the ear up and back for adults, down and back for children, and drop the medication on the side of the canal.</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

<table>
<thead>
<tr>
<th>e.</th>
<th>The solution must be flowing freely for accurate drug administration. If infiltration or phlebitis is present, do not give the drug until a new IV line is begun.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Most tubings have injection sites to facilitate drug administration.</td>
<td></td>
</tr>
<tr>
<td>This method is used for administration of antibiotics on an intermittent schedule. Dilution of the drug decreases adverse effects.</td>
<td></td>
</tr>
<tr>
<td>This method is also used for intermittent administration of antibiotics and other drugs. Whether a volume-control or piggyback apparatus is used depends on agency policy and equipment available.</td>
<td></td>
</tr>
<tr>
<td>Physical and chemical interactions between the drugs may occur and cause precipitation, inactivation, or increased toxicity. Most nursing units have charts depicting drug compatibility, or information may be obtained from the pharmacy.</td>
<td></td>
</tr>
<tr>
<td>To promote therapeutic effects and minimize adverse effects</td>
<td></td>
</tr>
<tr>
<td>Ophthalmic preparations must be sterile to avoid infection. Blot any excess drug from the inner canthus near the nose to decrease systemic absorption of the drug.</td>
<td></td>
</tr>
<tr>
<td>Careful positioning and restraint to avoid sudden movements are necessary to decrease risks of injury to the eye.</td>
<td></td>
</tr>
<tr>
<td>When nose drops are used for rhinitis and nasal congestion accompanying the common cold, overuse results in a rebound congestion that may be worse than the original symptom.</td>
<td></td>
</tr>
<tr>
<td>To straighten the canal and promote maximal contact between medication and tissue</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Nursing Actions

<table>
<thead>
<tr>
<th>Action</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
</table>
| 11. For rectal suppositories:  
   a. Lubricate the end with a water-soluble lubricant, wear a glove or finger cot, and insert into the rectum the length of the finger. Place the suppository next to the mucosal wall. If the client prefers and is able, provide supplies for self-administration.  
   b. If the client prefers and is able, provide supplies for self-administration. | To promote absorption. Allowing self-administration may prevent embarrassment to the client. Be sure the client knows the correct procedure. |
| 12. For vaginal medications:  
   a. Use gloves or an applicator for insertion. If an applicator is used, wash thoroughly with soap and water after each use. If the client prefers and is able, provide supplies for self-administration. | Some women may be embarrassed and prefer self-administration. Be sure the client knows the correct procedure. |

### How Can You Avoid This Medication Error?

**Answer:** This medication error occurred because the medication was given to the wrong client. The nurse did not check the client’s name band and relied on the client to respond to her calling his name. In this situation, the client had been asleep and may have been responding simply to being awakened. Also, language and culture may have been a factor. Accurate identification of the client is imperative, especially when the client may be confused or unable to respond appropriately.

### Nursing Notes: Apply Your Knowledge

**Answer:** First check tube placement by aspirating gastric content or instilling air into the stomach (listen with a stethoscope for a swishing sound over the gastric area). Use liquid preparations when possible. When a liquid formulation is not available, crush a tablet or empty a capsule into 15 to 30 mL of warm water and mix well. Note: Do not crush enteric-coated or sustained-release products because this alters their rate of absorption and could be dangerous to the client.

To administer, flush the feeding tube with tap water, draw medication into a syringe, and slowly instill the medication into the tube, then flush the tube again. Preferably, give each medication separately and rinse the tube between medications. When all medications are given, flush the tube with 50 mL of water unless the client is on a fluid restriction. Small feeding tubes occlude very easily and must be rinsed well to prevent clogging.

### Review and Application Exercises

1. *When giving an oral medication, what are some interventions to aid absorption and hasten therapeutic effects?*

### SELECTED REFERENCES


Nursing Process in Drug Therapy

**Critical Thinking Scenario**
You are making the first home visit for an elderly client with arthritis and hypertension who is taking the following medications:
- Ibuprofen 800 mg every 4 hours
- Prednisone 5 mg daily
- Lasix 20 mg twice a day
- Captopril 25 mg twice a day
- Pepcid 20 mg at bedtime

Look up each of these medications. Note the drug class and why you think this client is taking them. Are these acceptable doses for elderly clients? What criteria will you use to determine therapeutic effects for each drug? Note any side effects that are likely for each drug and what assessment data will be important to collect.

**OVERVIEW**

Drug therapy involves the use of drugs to prevent or treat disease processes and manifestations. It may save lives, improve the quality of life, and otherwise benefit recipients. It also may cause adverse effects. Adverse effects and failure to achieve therapeutic effects may occur with correct use, but they are more likely to occur with incorrect use. Physicians, pharmacists, clients, and nurses all have important roles to play in the safe and effective use of drugs.

For the nurse, drug therapy is one of many responsibilities in client care. To fulfill this responsibility, the nurse must be knowledgeable about pharmacology (drugs and their effects on the body), physiology (normal body functions), and pathophysiology (alterations in mental and physical functions due to disease processes), and must be adept at using all steps of the nursing process.

Chapter 1 included general information about drugs and suggested strategies for studying pharmacology. Chapter 2 described cellular physiology and concepts and processes essential to understanding drug effects in humans. Chapter 3 emphasized drug preparation and administration. Although the importance of safe and accurate administration cannot be overemphasized, this is only one aspect of the nursing process.
in drug therapy. The nurse also must monitor responses to drug therapy, both therapeutic and adverse, and teach clients about drugs, both prescribed and OTC. To help the nurse continue to acquire knowledge and skills related to drug therapy, this chapter includes nursing process guidelines, general principles of drug therapy, and general nursing actions. Guidelines, principles, and actions related to specific drug groups and individual drugs are included in appropriate chapters throughout this text.

**NURSING PROCESS IN DRUG THERAPY**

The nursing process is a systematic way of gathering and using information to plan and provide individualized client care and to evaluate the outcomes of care. It involves both cognitive and psychomotor skills. Knowledge and skill in the nursing process are required for drug therapy, as in other aspects of client care. The five steps of the nursing process are assessment, nursing diagnosis, planning and establishing goals for nursing care, interventions, and evaluation. One might say that assessment and interventions are the “action” phases whereas analysis of assessment data and establishing nursing diagnoses and goals are “thinking” phases. However, knowledge and informed, rational thinking should underlie all data collection, decision-making, and interventions.

**Assessment**

Assessment involves collecting data about client characteristics known to affect drug therapy. This can be done by observing and interviewing the client, interviewing family members or others involved in client care, completing a physical assessment, reviewing medical records for pertinent laboratory and diagnostic test reports, and other methods. Although listed as the important first step in the nursing process, assessment is actually a component of all steps and occurs with every contact with the client. For example, the initial assessment needs to be especially thorough because the information gained may guide the care provided by oneself, other nurses, and other health care providers (eg, dietitians, pharmacists). All available sources of assessment data should be used (eg, client, family members, medical records). Later assessments of a client’s condition and response to treatment are ongoing; they provide a basis for decisions about continuing or revising nursing care. Some guidelines for obtaining needed assessment data are described below.

- On initial contact with a client, before drug therapy is started, assess age, weight, health status, pathologic conditions, and ability to function in usual activities of daily living. The effects of these client-related factors on drug therapy are discussed in Chapter 2.
- Assess for previous and current use of prescription, nonprescription, and nontherapeutic (eg, alcohol, caffeine, nicotine, cocaine, marijuana) drugs. A medication history (Box 4–1) is useful, or the information can be incorporated into any data collection tool.

Specific questions and areas of assessment include:

- What are current drug orders?
- What does the client know about current drugs? Is teaching needed?
- What drugs has the client taken before? Include any drugs taken regularly, such as those taken for chronic illnesses (eg, hypertension, diabetes mellitus, arthritis). It also may be helpful to ask about nonprescription drugs for headache, colds, indigestion, or constipation, because some people do not think of these preparations as drugs.
- Has the client ever had an allergic reaction to a drug? If so, what signs and symptoms occurred? This information is necessary because many people describe minor nausea and other symptoms as allergic reactions. Unless the reaction is further explored, the client may have therapy withheld inappropriately.
- What are the client’s attitudes about drugs? Try to obtain information to help assess whether the client takes drugs freely or reluctantly, is likely to comply with a prescribed drug regimen, or is likely to abuse drugs.
- If long-term drug therapy is likely, can the client afford to buy medications? Is transportation available for obtaining medications or seeing a health care provider for monitoring and follow-up care?
- Can the client communicate his or her needs, such as requesting medication? Can he or she swallow oral medications?
- Are any other conditions present that influence drug therapy? For example, all seriously ill clients should be assessed for risk factors and manifestations of impaired function of vital organs. Early recognition and treatment may prevent or decrease organ impairment.
- Assess for previous or current use of herbal or dietary supplements (eg, echinacea, gingko, glucosamine/chondroitin). If so, ask for names, how much and how often taken, for how long, their reason for use, and perceived benefits or adverse effects.
- In addition to nursing assessment data, use progress notes, laboratory reports, and other sources as available and relevant. As part of the initial assessment, obtain baseline data on measurements to be used in monitoring therapeutic or adverse effects. Specific data to be acquired depend on the medication and the client’s condition. Laboratory tests of liver, kidney, and bone marrow function are often helpful because some drugs may damage these organs. Also, if liver or kidney damage exists, drug metabolism or excretion may be altered. Some specific laboratory tests include serum potassium levels before diuretic therapy, culture and susceptibility studies before antimicrobial therapy, and blood clotting tests before anticoagulant therapy. Other data that may
be relevant include physical assessment data, vital signs, weight, and urine output.

• Seek information about ordered drugs, if needed.

Once assessment data are obtained, they need to be analyzed for their relevance to the client’s current condition and nursing care needs. In general, nurses must provide care based on available information while knowing that assessment data are always relatively incomplete. As a result, continued assessment is needed. With later contacts and after drug therapy is begun, assess the client’s response in relation to therapeutic and adverse effects, ability and willingness to take the drugs as prescribed, and other aspects of safe and effective drug therapy.

Nursing Diagnoses

These statements, as developed by the North American Nursing Diagnosis Association, describe client problems or needs and are based on assessment data. They should be individualized according to the client’s condition and the drugs prescribed. Thus, the nursing diagnoses needed to adequately
reflect the client’s condition vary considerably. Because almost any nursing diagnosis may apply in specific circumstances, this text emphasizes those diagnoses that generally apply to any course of drug therapy.

- Deficient Knowledge: Drug therapy regimen (eg, drug ordered, reason for use, expected effects, and monitoring of response by health care providers, including diagnostic tests and office visits)
- Deficient Knowledge: Safe and effective self-administration (when appropriate)
- Risk for Injury related to adverse drug effects
- Noncompliance: Overuse
- Noncompliance: Underuse

**Planning/Goals**

This step involves stating the expected outcomes of the prescribed drug therapy. As a general rule, goals should be stated in terms of client behavior, not nurse behavior. For example, the client will:

- Receive or take drugs as prescribed
- Experience relief of signs and symptoms
- Avoid preventable adverse drug effects
- Avoid unnecessary drug ingestion
- Self-administer drugs safely and accurately
- Verbalize essential drug information
- Keep appointments for monitoring and follow-up
- Use any herbal and dietary supplements with caution
- Report the use of herbal and dietary supplements to health care providers

**Interventions**

This step involves implementing planned activities and actually includes any task performed on a client’s behalf. Areas of nursing intervention may include assessment, drug administration, teaching about medications, solving problems related to drug therapy, promoting compliance with the prescribed drug therapy regimen, identifying barriers to compliance, identifying resources (eg, financial assistance for obtaining medications), and others.

*General interventions* include promoting health, preventing or decreasing the need for drug therapy, and using nondrug measures to enhance therapeutic effects or to decrease adverse effects. Some examples include:

- Promoting healthful lifestyles in terms of nutrition, fluids, exercise, rest, and sleep
- Handwashing and other measures to prevent infection
- Positioning
- Assisting to cough and deep breathe
- Ambulating
- Applying heat or cold
- Increasing or decreasing sensory stimulation
- Scheduling activities to allow periods of rest or sleep
- Recording vital signs, fluid intake, urine output, and other assessment data

- Implementing specific interventions indicated by a particular drug or the client’s condition. For example, weighing seriously ill clients helps in calculating dosages of several drugs and in assessing changes in clients’ fluid balance or nutritional status; ensuring that blood samples for serum drug levels are drawn at correct times in relation to drug administration helps to increase the usefulness and accuracy of these tests in monitoring the client’s condition; and, in clients at risk for developing acute renal failure (ARF), ensuring adequate fluid intake and blood pressure and avoiding or following safety precautions with nephrotoxic drugs (eg, aminoglycoside antibiotics) helps to prevent ARF.

Client teaching as a nursing intervention is presented separately to emphasize its importance. Teaching about drug therapy is essential because most medications are self-administered and clients need information and assistance to use therapeutic drugs safely and effectively. When medications are given by another caregiver, rather than self-administered, the caregiver needs to understand about the medications. Adequate knowledge and preparation are required to fulfill teaching responsibilities. Teaching aids to assist the nurse in this endeavor include Box 4–2: Preparing to teach a client or caregiver: Client Teaching Guidelines: Safe and effective use of prescription medications; and Client Teaching Guidelines: Safe and effective use of over-the-counter (OTC) medications. Later drug-related chapters contain client teaching guidelines for the drugs discussed in particular chapters.

Other nursing interventions presented in a separate section of most chapters are the actions needed once a drug is ordered (ie, accurate administration, assessing for therapeutic and adverse effects, observing for drug interactions). These are presented under the heading of “Nursing Actions,” and rationales for the interventions are included.

In addition, nursing interventions are integrated with background information and client characteristics to assist in individualizing care. These are presented under the heading of “Principles of Therapy.” General principles or guidelines are included in this chapter; those related to particular drug groups are included in later chapters.

**Evaluation**

This step involves evaluating the client’s status in relation to stated goals and expected outcomes. Some outcomes can be evaluated within a few minutes of drug administration (eg, relief of acute pain after administration of an analgesic). Most, however, require much longer periods of time, often extending from hospitalization and direct observation by the nurse to self-care at home and occasional contact with a health care provider.

With the current emphasis on outpatient treatment and short hospitalizations, the client is likely to experience brief contacts with many health care providers rather than extensive contacts with a few health care providers. These factors, plus a client’s usual reluctance to admit noncompliance, con-
These difficulties can be managed by using appropriate techniques and criteria of evaluation. Techniques include directly observing the client’s status; interviewing the client or others about the client’s response to drug therapy; and checking appropriate medical records, including medication records and laboratory and other diagnostic test reports. With outpatients, “pill counts” may be done to compare doses remaining with the number prescribed during a designated time. These techniques may be used at every contact with a client, if appropriate.

General criteria include progress toward stated outcomes, such as relief of symptoms, accurate administration, avoidance of preventable adverse effects, compliance with instructions, and others. Specific criteria indicate the parameters that must be measured to evaluate responses to particular drugs (eg, blood sugar with antidiabetic drugs, blood pressure with antihypertensive drugs).

**INTEGRATING NURSING PROCESS, CRITICAL PATHS AND DRUG THERAPY**

In many agencies, nursing responsibilities related to drug therapy are designated in critical paths (also called clinical pathways or care maps). Critical paths are guidelines for the care of
Safe and Effective Use of Prescription Medications

General Considerations

✔ Use drugs cautiously and only when necessary because all drugs affect body functions and may cause adverse effects.

✔ Use non-drug measures, when possible, to prevent the need for drug therapy or to enhance beneficial effects and decrease adverse effects of drugs.

✔ Do not take drugs left over from a previous illness or prescribed for someone else and do not share prescription drugs with anyone else. The likelihood of having the right drug in the right dose is remote and the risk of adverse effects is high in such circumstances.

✔ Keep all health care providers informed about all the drugs being taken, including over-the-counter (OTC) products and herbal or dietary supplements. One way to do this is to keep a written record of all current medicines, including their names and doses and how they are taken. It is a good idea to carry a copy of this list at all times. This information can help avoid new prescriptions or OTC drugs that have similar effects or cancel each other’s effects.

✔ Take drugs as prescribed and for the length of time prescribed; notify a health care provider if unable to obtain or take a medication. Therapeutic effects greatly depend on taking medications correctly. Altering the dose or time may cause underdosage or overdosage. Stopping a medication may cause a recurrence of the problem for which it was given or withdrawal symptoms. Some medications need to be tapered in dosage and gradually discontinued. If problems occur with taking the drug, report them to the prescribing physician rather than stopping the drug. Often, an adjustment in dosage or other aspect of administration may solve the problem.

✔ Follow instructions for follow-up care (e.g., office visits, laboratory or other diagnostic tests that monitor therapeutic or adverse effects of drugs). Some drugs require more frequent monitoring than others. However, safety requires periodic checks with essentially all medications. With long-term use of a medication, responses may change over time with aging, changes in kidney function, and so on.

✔ Take drugs in current use when seeing a physician for any health-related problem. It may be helpful to remind the physician periodically of the medications being taken and ask if any can be discontinued or reduced in dosage.

✔ Get all prescriptions filled at the same pharmacy, when possible. This is an important safety factor in helping to avoid several prescriptions of the same or similar drugs and to minimize undesirable interactions of newly prescribed drugs with those already in use.

✔ Report any drug allergies to all health care providers and wear a medical identification emblem that lists allergens.

✔ Ask questions (and write down the answers) about newly prescribed medications, such as:

- What is the medicine’s name?
- What is it supposed to do (i.e., what symptoms or problems will it relieve)?
- How and when do I take it, and for how long?
- Should it be taken with food or on an empty stomach?
- While taking this medicine, should I avoid certain foods, beverages, other medications, certain activities? (For example, alcoholic beverages and driving a car should be avoided with medications that cause drowsiness or decrease alertness.)
- Will this medication work safely with the others I’m already taking?
- What side effects are likely and what do I do if they occur?
- Will the medication affect my ability to sleep or work?
- What should I do if I miss a dose?
- Is there a drug information sheet I can have?

✔ Store medications out of reach of children and never refer to medications as “candy”, to prevent accidental ingestion.

✔ Develop a plan for renewing or refilling prescriptions so that the medication supply does not run out when the prescribing physician is unavailable or the pharmacy is closed.

✔ When taking prescription medications, talk to a doctor, pharmacist, or nurse before starting an OTC medication or herbal or dietary supplement. This is a safety factor to avoid undesirable drug interactions.

✔ Inform health care providers if you have diabetes or kidney or liver disease. These conditions require special precautions with drug therapy.

✔ If pregnant, consult your obstetrician before taking any medications prescribed by another physician.

✔ If breast-feeding, consult your obstetrician or pediatrician before taking any medications prescribed by another physician.

Self-Administration

✔ Develop a routine for taking medications (e.g., at the same time and place each day). A schedule that minimally disrupts usual household activities is more convenient and more likely to be followed accurately.

✔ Take medications in a well-lighted area and read labels of containers to ensure taking the intended drug. Do not take medications if you are not alert or cannot see clearly.

✔ Most tablets and capsules should be taken whole. If unable to take them whole, ask a health care provider before splitting, chewing, or crushing tablets or taking the medication out of capsules. Some long-acting preparations are dangerous if altered so that the entire dose is absorbed at the same time.

✔ As a general rule, take oral medications with 6–8 oz of water, in a sitting or standing position. The water helps tablets and capsules dissolve in the stomach, “dilutes” the drug so that it is less likely to upset the stomach, and promotes absorption of the drug into the bloodstream. The upright position helps the drug reach the stomach rather than getting stuck in the throat or esophagus.
Safe and Effective Use of Prescription Medications (Continued)

✔ Take most oral drugs at evenly spaced intervals around the clock. For example, if ordered once daily, take about the same time every day. If ordered twice daily or morning and evening, take about 12 hours apart.

✔ Follow instructions about taking a medication with food or on an empty stomach, about taking with other medications, or taking with fluids other than water. Prescription medications often include instructions to take on an empty stomach or with food. If taking several medications, ask a health care provider whether they may be taken together or at different times. For example, an antacid usually should not be taken at the same time as other oral medications because the antacid decreases absorption of many other drugs.

✔ If a dose is missed, most authorities recommend taking the dose if remembered soon after the scheduled time and omitting the dose if it is not remembered for several hours. If a dose is omitted, the next dose should be taken at the next scheduled time. Do not double the dose.

✔ If taking a liquid medication (or giving one to a child), measure with a calibrated medication cup or measuring spoon. A dose cannot be measured accurately with household teaspoons or tablespoons because they are different sizes and deliver varying amounts of medication. If the liquid medication is packaged with a measuring cup that shows teaspoons or tablespoons, that should be used to measure doses, for adults or children. This is especially important for young children because most of their medications are given in liquid form.

✔ Use other types of medications according to instructions. If not clear how a medication is to be used, be sure to ask a health care provider. Correct use of oral or nasal inhalers, eye drops, and skin medications is essential for therapeutic effects.

✔ Report problems or new symptoms to a health care provider.

✔ Store medications safely, in a cool, dry place. Do not store them in a bathroom; heat, light, and moisture may cause them to decompose. Do not store them near a dangerous substance, which could be taken by mistake. Keep medications in the container in which they were dispensed by the pharmacy, where the label identifies it and gives directions. Do not put several different tablets or capsules in one container. Although this may be more convenient, especially when away from home for work or travel, it is never a safe practice because it increases the likelihood of taking the wrong drug.

✔ Discard outdated medications; do not keep drugs for long periods. Drugs are chemicals that may deteriorate over time, especially if exposed to heat and moisture. In addition, having many containers increases the risks of medication errors and adverse drug interactions.

Herbal and Dietary Supplements

In recent years, an additional nursing concern has emerged in the form of herbal and dietary supplements. These supplements are increasingly being used, and clients who take them are likely to be encountered in any clinical practice setting. Herbal medicines, also called botanicals, phytochemicals, and nutraceuticals, are derived from plants; other dietary supplements may be derived from a variety of sources. The 1994 Dietary Supplement Health and Education Act (DSHEA) defined a dietary supplement as “a vitamin, a mineral, an herb or other botanical used to supplement the diet.” Under this law, herbs can be labeled according to their possible effects on the human body, but the products cannot claim to diagnose, prevent, relieve, or cure illnesses.
Some suggestions and guidelines include the following:

- Their knowledge in all steps of the nursing process (see below).
- Need to have an adequate knowledge base and to incorporate therapeutic effects or increase adverse effects. In general, nurses monitor from a health care provider when indicated and that the use of supplements may keep the client from seeking treatment for their condition.
- Safe and effective drug therapy? Two major concerns are that herbal and dietary supplements, and in combination with other products on particular consumers, in combination with other products. Overall, the effects of these products have not been studied sufficiently to evaluate their safety or effectiveness; most available information involves testimonials from family members, friends, or celebrities. With the continued caution that relatively little reliable information is known about these products, several resources are provided in this text, including:
- Table 4–1 describes some commonly used herbal and dietary supplements. In later chapters, when information is available and deemed clinically relevant, selected herbal and dietary supplements with some scientific support for their use are described in more detail. For example, in Chapter 7, some products reported to be useful in relieving pain, fever, inflammation, or migraine, are described.
- Client teaching guidelines. In this chapter, general information is provided (see Client Teaching Guidelines: General information about herbal and dietary supplements). In later chapters, guidelines may emphasize avoidance or caution in using supplements.

### CLIENT TEACHING GUIDELINES

Safe and Effective Use of Over-the-Counter (OTC) Medications

- Read product labels carefully. The labels contain essential information about the name, ingredients, indications for use, usual dosage, when to stop using the medication or when to see a doctor, possible side effects, and expiration dates.
- Use a magnifying glass, if necessary, to read the fine print.
- If you do not understand the information on labels, ask a physician, pharmacist, or nurse.
- Do not take OTC medications longer or in higher doses than recommended.
- Note that all OTC medications are not safe for everyone. Many OTC medications warn against use with certain illnesses (eg, hypertension, thyroid disorders). Consult a health care provider before taking the product if you have one of the contraindicated conditions.
- If taking any prescription medications, consult a health care provider before taking any nonprescription drugs to avoid undesirable drug interactions and adverse effects. Some specific precautions include the following:
  - Avoid alcohol if taking antihistamines, cough or cold remedies containing dextromethorphan, or sleeping pills. Because all these drugs cause drowsiness, combining any of them with alcohol may result in excessive, potentially dangerous, sedation.
  - Avoid OTC sleeping aids if you are taking a prescription sedative-type drug (eg, for nervousness or depression).
  - Ask a health care provider before taking products containing aspirin if you are taking an anticoagulant (eg, Coumadin).
  - Ask a health care provider before taking other products containing aspirin if you are already taking a regular dose of aspirin to prevent blood clots, heart attack, or stroke. Aspirin is commonly used for this purpose, often in doses of 81 mg (a child’s dose) or 325 mg.
- Do not take a laxative if you have stomach pain, nausea, or vomiting, to avoid worsening the problem.
- Do not take a nasal decongestant (eg, Sudafed), a multisymptom cold remedy containing pseudoephedrine (eg, Actifed, Sinutab), an antihistamine-decongestant combination (eg, Claritin D), or the herbal medicine ephedra (Ma Huang) if you are taking a prescription medication for high blood pressure. Such products can raise blood pressure and decrease or cancel the blood pressure–lowering effect of the prescription drug. This could lead to severe hypertension and stroke.
- Store OTC drugs in a cool, dry place, in their original containers; check expiration dates periodically and discard those that have expired.
- If pregnant, consult your obstetrician before taking any OTC medications.
- If breast-feeding, consult your pediatrician or family doctor before taking any OTC medications.
- For children, follow any age limits on the label.
- Measure liquid OTC medications with the measuring device that comes with the product (some have a dropper or plastic cup calibrated in milliliters, teaspoons, or tablespoons). If such a device is not available, use a measuring spoon. It is not safe to use household teaspoons or tablespoons because they are different sizes and deliver varying amounts of medication. Accurate measurement of doses is especially important for young children because most of their medications are given in liquid form.
- Do not assume continued safety of an OTC medication you have taken for years. Older people are more likely to have adverse drug reactions and interactions because of changes in heart, kidneys, and other organs that occur with aging and various disease processes.
- Note tamper-resistant features and do not buy products with damaged packages.

Specific human diseases unless approved by the FDA. Most products have not been studied sufficiently to evaluate their safety or effectiveness; most available information involves self-reports of a few people. Overall, the effects of these products on particular consumers, in combination with other herbal and dietary supplements, and in combination with pharmaceutical drugs, are essentially unknown.

What is the nursing role in relation to these products and safe and effective drug therapy? Two major concerns are that use of supplements may keep the client from seeking treatment from a health care provider when indicated and that the products may interact with prescription drugs to decrease therapeutic effects or increase adverse effects. In general, nurses need to have an adequate knowledge base and to incorporate their knowledge in all steps of the nursing process (see below). Some suggestions and guidelines include the following:

- Seek information from authoritative, objective sources rather than product labels, advertisements, or personal
<table>
<thead>
<tr>
<th>Name</th>
<th>Characteristics</th>
<th>Uses</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Black cohosh</td>
<td>• Thought to relieve menopausal symptoms by suppressing the release of luteinizing hormone (LH) from the pituitary gland and dysmenorrhea by relaxing uterine muscle &lt;br&gt; • Well tolerated; may cause occasional stomach upset. In overdose may cause nausea, vomiting, dizziness, visual disturbances, and reduced pulse rate &lt;br&gt; • Most clinical trials done with Remefemin, in small numbers of women; other trade names include Estroven and Femtrol</td>
<td>• Most often used to relieve symptoms of menopause (eg, flushes, vaginal dryness, irritability) &lt;br&gt; • May also relieve premenstrual syndrome (PMS) and dysmenorrhea</td>
<td>• No apparent advantage over traditional estrogen replacement therapy (ERT) &lt;br&gt; • May be useful when ERT is contraindicated for a client or the client refuses ERT &lt;br&gt; • Recommended dose is 1 tab standardized to contain 20 mg of herbal drug, twice daily &lt;br&gt; • Not recommended for use longer than 6 months because long-term effects are unknown &lt;br&gt; • Apparently has no effect on endometrium, so progesterone not needed in women with an intact uterus</td>
</tr>
<tr>
<td>Capsaicin</td>
<td>(see Chap. 6) • Derived from cayenne pepper &lt;br&gt; • Pain with first application &lt;br&gt; • Adverse effects include skin irritation, itching, redness, and stinging</td>
<td>Capsaicin is a topical analgesic that may inhibit the synthesis, transport, and release of substance P, a peripheral neurotransmitter of pain. &lt;br&gt; Used to treat pain associated with neuralgia, neuropathy, and osteoarthritis. &lt;br&gt; Self-defense as the active ingredient in “pepper spray”</td>
<td>Applied topically Few studies and little data to support use and effectiveness in GI disorders</td>
</tr>
<tr>
<td>Chamomile</td>
<td>• Usually ingested as a tea &lt;br&gt; • May cause contact dermatitis &lt;br&gt; • May cause severe hypersensitivity reactions, including anaphylaxis, in people allergic to ragweed, asters, and chrysanthemums &lt;br&gt; • May delay absorption of oral medications &lt;br&gt; • May increase risks of bleeding (contains coumarins, the substances from which warfarin, an oral anticoagulant, is derived)</td>
<td>Used mainly for antispasmodic effects in the gastrointestinal (GI) tract; may relieve abdominal cramping</td>
<td></td>
</tr>
<tr>
<td>Chondroitin</td>
<td>(see Chap. 7) • Derived from the trachea cartilage of cattle slaughtered for food &lt;br&gt; • Usually taken with glucosamine &lt;br&gt; • Adverse effects minor, may include GI upset, nausea, and headache</td>
<td>Arthritis</td>
<td>Several studies support use</td>
</tr>
<tr>
<td>Creatine</td>
<td>• An amino acid produced in liver and kidneys and stored in muscles &lt;br&gt; • Causes weight gain, usually within 2 weeks of starting use &lt;br&gt; • Legal and available in health food stores as a powder to be mixed with water or juice, a liquid, as tablets and capsules</td>
<td>• Athletes take creatine supplements to gain extra energy, to train longer and harder, and improve performance</td>
<td>• Not recommended for use by children because studies have not been done and effects in children are unknown &lt;br&gt; • Nurses and parents need to actively discourage children and adolescents from using creatine supplements</td>
</tr>
<tr>
<td>Echinacea</td>
<td>• Many species but E. purpurea most often used medicinally &lt;br&gt; • Effects on immune system include stimulation of phagocytes and monocytes &lt;br&gt; • Contraindicated in persons with immune system disorders because stimulation of the immune system may aggravate autoimmune disorders &lt;br&gt; • Hepatotoxic with long-term use</td>
<td>• Most often used for the common cold, but also advertised for many other uses (immune system stimulant, anti-infective)</td>
<td>• Hard to interpret validity of medicinal claims because various combinations of species and preparations used in reported studies &lt;br&gt; • A few studies support use in common cold, with reports of shorter durations and possibly decreased severity of symptoms</td>
</tr>
</tbody>
</table>

(continued)
### Table 4-1: Herbal and Dietary Supplements (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Characteristics</th>
<th>Uses</th>
<th>Remarks</th>
</tr>
</thead>
</table>
| Ephedra (Ma Huang)  | • Acts the same as the adrenergic drugs ephedrine and pseudo-ephedrine, which are cardiac and central nervous system (CNS) stimulants as well as decongestants and bronchodilators (see Chap. 18)  
• Commonly found in herbal weight-loss products  
• May cause or aggravate hypertension, cardiac dysrhythmias, nervousness, nausea, vomiting, tremor, headache, seizures, strokes, myocardial infarctions  
• May increase effects of other cardiac and CNS stimulants and cause potentially life-threatening illnesses  
• May decrease effects of anti-hypertensive medications  
• May increase clotting time and risk of bleeding  
• May cause hypersensitivity reactions in people allergic to ragweed, asters, chrysanthemums, or daisies  
• May cause withdrawal syndrome if use is stopped abruptly | Anorexiant for weight loss, decongestant, bronchodilator, stimulant | The Food and Drug Administration (FDA) has issued warnings against use of ephedra because of potentially severe adverse effects, including death.  
• Although not recommended for use by anyone, ephedra is considered especially hazardous for people with conditions that might be aggravated (eg, hypertension, seizures, cardiac palpitations) or who take medications associated with significant drug interactions (eg, decreased therapeutic effects or increased adverse effects). |
| Feverfew (see Chap. 7) | • May increase clotting time and risk of bleeding  
• May cause hypersensitivity reactions in people allergic to ragweed, asters, chrysanthemums, or daisies  
• May cause withdrawal syndrome if use is stopped abruptly | Migraines, menstrual irregularities, arthritis | Some studies support use in migraine |
| Garlic              | • Active ingredient is thought to be allicin  
• Has antiplatelet activity and may increase risk of bleeding; should not be used with anticoagulants  
• May decrease blood sugar and cholesterol  
• Adverse effects include allergic reactions (asthma, dermatitis), dizziness, irritation of GI tract, nausea, vomiting | Used mainly to lower serum cholesterol levels, although a recent study did not support its effectiveness for this purpose  
• Also used for antihypertensive and antibiotic effects, but there is little reliable evidence for such use | Medicinal effects probably exaggerated, especially those of deodorized supplements |
| Ginger              | • Inhibits platelet aggregation; may increase clotting time  
• Gastroprotective effects in animal studies | Used mainly to treat nausea, including motion sickness and postoperative nausea | Should not be used for morning sickness associated with pregnancy—may increase risk of miscarriage |
| Ginkgo biloba       | • Reportedly increases blood flow to the brain; improves memory and decreases dizziness and ringing in the ears (tinnitus)  
• Improves blood flow to legs and decreases intermittent claudication associated with peripheral arterial insufficiency  
• Antioxidant  
• Inhibits platelet aggregation  
• Adverse effects include GI upset, headache, bleeding, allergic skin reaction  
• May increase risks of bleeding with any drug that has antiplatelet effects (eg, aspirin and other non-steroidal anti-inflammatory drugs [NSAIDs], warfarin, heparin, clopidogrel) | Used mainly to improve memory and cognitive function in people with Alzheimer’s disease; may be useful in treating peripheral arterial disease | Some studies indicate slight improvement in Alzheimer’s disease. Whether this shows clinically significant benefits is still unclear. A disadvantage is a delayed response, up to 6 or 8 weeks, and a recommendation to use no longer than 3 months.  
• In European studies, patients with intermittent claudication showed significant improvement. |
<table>
<thead>
<tr>
<th>Name</th>
<th>Characteristics</th>
<th>Uses</th>
<th>Remarks</th>
</tr>
</thead>
</table>
| Ginseng | • Active ingredients called ginsenosides or panaxosides  
• Has a variety of pharmacologic effects that vary with dose and duration of use (e.g., inhibits platelet aggregation; may depress or stimulate central nervous system [CNS], thus possible mood elevating, anti-stress, antidepressive, and sedative effects; decreases blood glucose and cholesterol)  
• Adverse effects include hypertension, diarrhea, nervousness, depression, headache, anorexia, insomnia, skin rashes, chest pain, epistaxis, headache, impotence, nausea, palpitations, pruritus, vaginal bleeding, and vomiting  
• May increase risks of bleeding with any drug that has antiplatelet effects (e.g., aspirin and other NSAIDs, warfarin, heparin, clopidogrel)  
• Increases risk of hypoglycemic reactions if taken concurrently with insulin or oral antidiabetic agents  
• Should not be taken concurrently with other herbs or drugs that inhibit monoamine oxidase (e.g., St. John’s wort, phenelzine, selegiline, tranylcypromine); headache, mania, and tremors may occur  
• Usually used with chondroitin  
• Has beneficial effects on cartilage  
• Adverse effects mild, may include GI upset, drowsiness  
• Produces mild euphoria and sedation; may have antiseizure effects  
• May act similarly to benzodiazepines, by enhancing effects of GABA (an inhibitory neurotransmitter in the CNS)  
• Adverse effects include impaired coordination, gait, and judgment; pupil dilation  
• Chronic heavy use may cause hematologic abnormalities (e.g., decreased platelets, lymphocytes, plasma proteins, bilirubin and urea), weight loss, and hepatotoxicity  
• May increase effects of alcohol and other CNS depressants (any herb or drug that causes drowsiness and sedation); such combinations should be avoided | Used to increase stamina, strength, endurance, and mental acuity. Also to promote sleep and relieve depression | A few small studies in humans support benefits of ginseng in improving psychomotor and cognitive functioning and sleep. However, more well-controlled studies are needed before the herb can be recommended for these uses.  
• A ginseng abuse syndrome, with symptoms of insomnia, hypotonia, and edema, has been reported. Caution clients to avoid ingesting excessive amounts.  
• Diabetics should use ginseng very cautiously, if at all, because of its hypoglycemic effect alone and apparent ability to increase the hypoglycemic effects of insulin and oral antidiabetic drugs. If a client insists on using, urge him or her to check blood glucose frequently until ginseng’s effects on blood sugar are known.  
• Instruct clients with cardiovascular disease, diabetes mellitus, or hypertension to check with their primary physician before taking ginseng.  
• Instruct any client taking ginseng to avoid long-term use. Siberian ginseng should not be used longer than 3 weeks.  
• Use as a calming agent is supported by limited evidence from a few small clinical trials; other therapeutic claims are poorly documented  
• Should be used cautiously by people with renal disease, thrombocytopenia, or neutropenia  
• Should be avoided by people with hepatic disease, during pregnancy and lactation, and in children under 12 years old | Arthritis | Several studies support use |
| Glucosamine (see Chap. 7) | | | |
| Kava (see Chap. 8) | | | |
### TABLE 4–1 Herbal and Dietary Supplements (continued)

<table>
<thead>
<tr>
<th>Name</th>
<th>Characteristics</th>
<th>Uses</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melatonin (Chap. 8)</td>
<td>• Several studies of effects on sleep, energy level, fatigue, mental alertness, and mood indicate some improvement, compared with placebo &lt;br&gt; • Contraindicated in persons with hepatic insufficiency (especially cirrhosis, because of slowed melatonin clearance), a history of cerebrovascular disease, depression, or neurologic disorders &lt;br&gt; • Adverse effects include altered sleep patterns, confusion, headache, itching, sedation, tachycardia &lt;br&gt; • Melatonin used mainly for treatment of insomnia and prevention and treatment of jet lag</td>
<td>• Should not be combined with monoamine oxidase inhibitor (MAOI) or selective serotonin reuptake inhibitor (SSRI) antidepressants; unsafe when combined with ephedra &lt;br&gt; • Can decrease effectiveness of birth control pills, antineoplastic drugs, antivirals used to treat acquired immunodeficiency syndrome (AIDS), and organ transplant drugs (eg, cyclosporine)</td>
<td>Patients with renal impairment should use cautiously</td>
</tr>
<tr>
<td>Saint John’s wort (Chap. 10)</td>
<td>• Active component thought to be hypericin, but at least 10 potentially active components have been identified &lt;br&gt; • Thought to act similarly to fluoxetine (Prozac), which increases serotonin in the brain &lt;br&gt; • Studies (most lasting 6 months or less) indicate improvement in mild to moderate depression &lt;br&gt; • Apparently not effective in major or serious depression &lt;br&gt; • Adverse effects include photosensitivity (especially in fair-skinned persons), dizziness, GI upset, fatigue and confusion &lt;br&gt; • May interact with numerous drugs to increase their effects, probably by inhibiting their metabolism. These include antidepressants, adrenergics and others</td>
<td>Used mainly for treatment of depression</td>
<td></td>
</tr>
<tr>
<td>Saw palmetto</td>
<td>• Action unknown; may have antiandrogenic effects &lt;br&gt; • Generally well tolerated; adverse effects usually minor but may include GI upset, headache. Diarrhea may occur with high doses</td>
<td>Used mainly to relieve urinary symptoms in men with benign prostatic hyperplasia (BPH)</td>
<td>• Reportedly effective in doses of 320 mg/day for 1–3 months &lt;br&gt; • Men should have a prostate specific antigen (PSA) test (a blood test for prostate cancer) before starting saw palmetto, because the herb can reduce levels of PSA and produce a false-negative result. &lt;br&gt; • Should not be combined with sedative drugs and should not be used regularly &lt;br&gt; • Many extract products contain 40–60% alcohol and may not be appropriate for all patients &lt;br&gt; • Most studies flawed—experts do not believe there is sufficient evidence to support the use of saw palmetto for treatment of benign prostatic hyperplasia (BPH)</td>
</tr>
<tr>
<td>Valerian (Chap. 8)</td>
<td>• Sedative effects may be due to increasing GABA in the brain &lt;br&gt; • Adverse effects with acute overdose or chronic use include blurred vision, drowsiness, dizziness, excitability, headache, hypersensitivity reactions, insomnia, nausea. Also, risk of liver damage from combination products containing valerian and from overdoses averaging 2.5 g &lt;br&gt; • May cause additive sedation if combined with other CNS depressants; these combinations should be avoided</td>
<td>Used mainly to promote sleep and allay anxiety and nervousness. Also has muscle relaxant effects</td>
<td>• Reportedly effective in doses of 320 mg/day for 1–3 months &lt;br&gt; • Men should have a prostate specific antigen (PSA) test (a blood test for prostate cancer) before starting saw palmetto, because the herb can reduce levels of PSA and produce a false-negative result. &lt;br&gt; • Should not be combined with sedative drugs and should not be used regularly &lt;br&gt; • Many extract products contain 40–60% alcohol and may not be appropriate for all patients &lt;br&gt; • Most studies flawed—experts do not believe there is sufficient evidence to support the use of saw palmetto for treatment of benign prostatic hyperplasia (BPH)</td>
</tr>
</tbody>
</table>
Herbal and dietary products are chemicals that have drug-like effects in people. Unfortunately, their effects are largely unknown and may be dangerous for some people because there is little reliable information about them. For most products, little research has been done to determine either their benefits or their adverse effects. The safety and effectiveness of these products are not documented or regulated by laws designed to protect consumers, as are pharmaceutical drugs. As a result, the types and amounts of ingredients may not be standardized or even identified on the product label. In fact, most products contain several active ingredients and it is often not known which ingredient has the desired pharmacologic effect. In addition, components and active ingredients of plants can vary considerably, depending on the soil, water, and climate where the plants are grown.

These products can be used more safely if they are manufactured by a reputable company that states the ingredients are standardized (meaning that the dose of medicine in each tablet or capsule is the same).

The product label should also state specific percentages, amounts, and strengths of active ingredients. With herbal medicines especially, different brands of the same herb vary in the amounts of active ingredients per recommended dose. Dosing is also difficult because a particular herb may be available in several different dosage forms (e.g., tablet, capsule, tea, extract) with different amounts of active ingredients.

These products are often advertised as “natural.” Many people interpret this to mean the products are safe and better than synthetic or man-made products. This is not true; “natural” does not mean safe, especially when taken concurrently with other herals, dietary supplements, or drugs.

When taking herbal or dietary supplements, follow the instructions on the product label. Inappropriate use or taking excessive amounts may cause dangerous side effects. Inform health care providers when taking any kind of herbal or dietary supplement, to reduce risks of severe adverse effects or drug–supplement interactions.

Most herbal and dietary supplements should be avoided during pregnancy or lactation and in young children.

The American Society of Anesthesiologists recommends that all herbal products be discontinued 2–3 weeks before any surgical procedure. Some products (e.g., echinacea, ephedra, feverfew, garlic, gingko, ginseng, kava, valerian and St. John’s wort) can interfere with or increase the effects of some drugs, affect blood pressure or heart rhythm, or increase risks of bleeding; some have unknown effects when combined with anesthetics, other perioperative medications, and surgical procedures.

Store herbal and dietary supplements out of the reach of children.

- Teach clients about these products and their possible interactions with each other and with their prescription drugs (when such information is available).
4. Drug effects on quality of life should be considered in designing a drug therapy regimen. Quality-of-life issues are also being emphasized in research studies, with expectations of measurable improvement as a result of drug therapy.

**General Drug Selection and Dosage Considerations**

Numerous factors must be considered when choosing a drug and dosage range for a particular client, including the following:

1. For the most part, use as few drugs in as few doses as possible. Minimizing the number of drugs and the frequency of administration increases client compliance with the prescribed drug regimen and decreases risks of serious adverse effects, including hazardous drug–drug interactions. There are notable exceptions to this basic rule. For example, multiple drugs are commonly used to treat severe hypertension or serious infections.
2. Although individual drugs allow greater flexibility of dosage than fixed-dose combinations, fixed-dose combinations are increasingly available and commonly used, mainly because clients are more likely to take them. Also, many of the combination products are formulated to be long acting, which also promotes compliance.
3. The least amount of the least potent drug that yields therapeutic benefit should be given to decrease adverse reactions. For example, if a mild non-opioid and a strong opioid analgesic are both ordered, give the non-opioid drug if it is effective in relieving pain.
4. In drug literature, recommended dosages are listed in amounts likely to be effective for most people. However, they are only guidelines to be interpreted according to the client’s condition. For example, clients with serious illnesses may require larger doses of some drugs than clients with milder illnesses; clients with severe kidney disease often need much smaller doses of renally excreted drugs.
5. A drug can be started rapidly or slowly. If it has a long half-life and optimal therapeutic effects do not usually occur for several days or weeks, the physician may order a limited number of relatively large (loading) doses followed by a regular schedule of smaller (maintenance) doses. When drug actions are not urgent, therapy may be initiated with a maintenance dose.
6. In general, different salts of the same drug rarely differ pharmacologically. Hydrochloride, sulfate, and sodium salts are often used. Pharmacists and chemists choose salts on the basis of cost, convenience, solubility, and stability. For example, solubility is especially important with parenteral drugs; taste is a factor with oral drugs. Dermatologic drugs are often formulated in different salts and dosage forms, however, according to their intended uses (eg, application to intact skin or the mucous membranes of the eye, nose, mouth, vagina, or rectum).

**Drug Therapy in Children**

Drug therapy in neonates (birth to 1 month), infants (1 month to 1 year), and children (approximately 1 to 12 years) requires special consideration because of the child’s changing size, developmental level, and organ function. Physiologic differences alter drug pharmacokinetics (Table 4–2), and drug therapy is less predictable than in adults. Neonates are especially vulnerable to adverse drug effects because of their immature liver and kidney function; neonatal therapeutics are discussed further in Chapter 67.

Most drug use in children is empiric in nature because few studies have been done in that population. For many drugs, manufacturers’ literature states that “safety and effectiveness for use in children have not been established.” Most drugs given to adults also are given to children, and general principles, techniques of drug administration, and nursing process guidelines apply. Additional principles and guidelines include the following:

1. All aspects of pediatric drug therapy must be guided by the child’s age, weight, and level of growth and development.
2. Choice of drug is often restricted because many drugs commonly used in adult drug therapy have not been sufficiently investigated to ensure safety and effectiveness in children.
3. Safe therapeutic dosage ranges are less well defined for children than for adults. Some drugs are not recommended for use in children, and therefore dosages have not been established. For many drugs, doses for children are extrapolated from those established for adults. When pediatric dosage ranges are listed in drug literature, these should be used. Often, however, they are expressed in the amount of drug to be given per kilogram of body weight or square meter of body surface area, and the amount needed for a specific dose must be calculated as a fraction of the adult dose. The following methods are used for these calculations:
   a. Clark’s rule is based on weight and is used for children at least 2 years of age:
   \[
   \text{Weight (in pounds)} \times \frac{150}{150} = \text{child’s dose}
   \]
   b. Calculating dosage based on body surface area is considered a more accurate method than those based on other characteristics. Body surface area, based on

**Nursing Notes: Apply Your Knowledge**

You are assigned to care for a low-birth-weight infant, who has been started on digoxin to treat congenital heart problems until corrective surgery can be performed. The digoxin dosage seems very low to you. What factors might you consider before questioning the physician regarding the dosage that was ordered?
Physiologic Characteristics | Pharmacokinetic Consequences
--- | ---
Increased thinness and permeability of skin in neonates and infants | Increased absorption of topical drugs (e.g., corticosteroids may be absorbed sufficiently to suppress adrenocortical function)
Immature blood–brain barrier in neonates and infants | Increased distribution of drugs into the central nervous system because myelination (which creates the blood–brain barrier to the passage of drugs) is not mature until approximately 2 years of age
Increased percentage of body water (70% to 80% in neonates and infants, compared with 50% to 60% in children older than 2 years of age and adults) | Usually increased volume of distribution in infants and young children, compared with adults. This would seem to indicate a need for larger doses. However, prolonged drug half-life and decreased rate of drug clearance may offset. The net effect is often a need for decreased dosage.
Altered protein binding until approximately 1 year of age, when it reaches adult levels | The amount and binding capacity of plasma proteins may be reduced. This may result in a greater proportion of unbound or pharmacologically active drug and greater risks of adverse drug effects. Dosage requirements may be decreased or modified by other factors. Drugs with decreased protein binding in neonates, compared with older children and adults, include ampicillin (Omnipen, others), diazepam (Valium), digoxin (Lanoxin), lidocaine (Xylocaine), nafcillin (Unipen), phenobarbital, phenytoin (Dilantin), salicylates (eg, aspirin), and theophylline (Theolair).
Decreased glomerular filtration rate in neonates and infants, compared with older children and adults. Kidney function develops progressively during the first few months of life and is fairly mature by 1 year of age. | In neonates and infants, slowed excretion of drugs eliminated by the kidneys. Dosage of these drugs may need to be decreased, depending on the infant’s age and level of growth and development.
Decreased activity of liver drug-metabolizing enzyme systems in neonates and infants | Decreased capacity for biotransformation of drugs. This results in slowed metabolism and elimination, with increased risks of drug accumulation and adverse effects.
Increased activity of liver drug-metabolizing enzyme systems in children | Increased capacity for biotransformation of some drugs. This results in a rapid rate of metabolism and elimination. For example, theophylline is cleared about 30% faster in a 7-year-old child than in an adult and approximately four times faster than in a neonate.

**TABLE 4–2 Neonates, Infants, and Children: Physiologic Characteristics and Pharmacokinetic Consequences**

height and weight, is estimated using a nomogram (Fig. 4–1). Use the estimated body surface area in the following formula to calculate the child’s dose:

\[
\text{Body surface area} \, (\text{in square meters}) = \frac{1.73 \, \text{square meters}}{\text{height} \, (\text{in meters})^2} \times \text{weight} \, (\text{in kilograms})
\]

c. Dosages obtained from these calculations are approximate and must be individualized. These doses can be used initially and then increased or decreased according to the child’s response.
4. Use the oral route of drug administration when possible. Try to obtain the child’s cooperation; never force oral medications because forcing may lead to aspiration.
5. If intramuscular injections are required in infants, use the thigh muscles because the deltoid muscles are quite small and the gluteal muscles do not develop until the child is walking.
6. For safety, keep all medications in childproof containers, out of reach of children, and do not refer to medications as “candy.”

**Drug Therapy in Older Adults**

Aging is a continuum; precisely when a person becomes an “older adult” is not clearly established, but in this book people 65 years of age and older are so categorized. In this population, general nursing process guidelines and principles of drug therapy apply. In addition, adverse effects are likely because of physiologic changes associated with aging (Table 4–3), pathologic changes due to disease processes, multiple drug therapy for acute and chronic disorders, impaired memory and cognition, and difficulty in complying with drug orders. Overall, the goal of drug therapy may be “care” rather than “cure,” with efforts to prevent or control symptoms and maintain the client’s ability to function in usual activities of daily living.

Additional principles include the following:

1. Although age in years is an important factor, older adults are quite heterogeneous in their responses to drug therapy and responses differ widely within the same age group. Responses also differ in the same person over time. Physiologic age (ie, organ function) is more important than chronologic age.
2. It may be difficult to separate the effects of aging from the effects of disease processes or drug therapy, particularly long-term drug therapy. Symptoms attributed to aging or disease may be caused by medications. This occurs because older adults are usually less able to metabolize and excrete drugs efficiently. As a result, drugs are more likely to accumulate.
3. Medications—both prescription and nonprescription drugs—should be taken only when necessary.
4. Any prescriber should review current medications, including nonprescription drugs, before prescribing...
new drugs. In addition, unnecessary drugs should be discontinued. Some drugs, especially with long-term use, need to be tapered in dosage and discontinued gradually to avoid withdrawal symptoms.

5. When drug therapy is required, the choice of drug should be based on available drug information regarding effects in older adults.

6. The basic principle of giving the smallest effective number of drugs applies especially to older adults. A regimens of several drugs increases the incidence of adverse reactions and potentially hazardous drug interactions. In addition, many older adults are unable to self-administer more than three or four drugs correctly.

7. All drugs should be given for the shortest effective time. This interval is not established for most drugs, and many drugs are continued for years. Health care providers must reassess drug regimens periodically to see whether drugs, dosages, or other aspects need to be revised. This is especially important when a serious illness or significant changes in health status have occurred.

8. The smallest number of effective doses should be prescribed. This allows less disruption of usual activities and promotes compliance with the prescribed regimen.

9. When any drug is started, the dosage should usually be smaller than for younger adults. The dosage can then be increased or decreased according to response. If an increased dosage is indicated, increments should be
TABLE 4–3  Older Adults: Physiologic Characteristics and Pharmacokinetic Consequences

<table>
<thead>
<tr>
<th>Physiologic Characteristics</th>
<th>Pharmacokinetic Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased gastrointestinal secretions and motility</td>
<td>Minimal effects on absorption of most oral drugs; effects on extended-release formulations are unknown</td>
</tr>
<tr>
<td>Decreased cardiac output</td>
<td>• Slower absorption from some sites of administration (eg, gastrointestinal tract, subcutaneous or muscle tissue); effects on absorption from skin and mucous membranes are unknown</td>
</tr>
<tr>
<td></td>
<td>• Decreased distribution to sites of action in tissues, with potential for delaying the onset and reducing the extent of therapeutic effects</td>
</tr>
<tr>
<td>Decreased blood flow to the liver and kidneys</td>
<td>Delayed metabolism and excretion, which may lead to drug accumulation and increased risks of adverse or toxic effects</td>
</tr>
<tr>
<td>Decreased total body water and lean body mass per kg of weight; increased body fat</td>
<td>Water-soluble drugs (eg, ethanol, lithium) are distributed into a smaller area, with resultant higher plasma concentrations and higher risks of toxicity with a given dose. Fat-soluble drugs (eg, diazepam) are distributed to a larger area, accumulate in fat, and have a longer duration of action in the body.</td>
</tr>
<tr>
<td>Decreased serum albumin</td>
<td>Decreased availability of protein for binding and transporting drug molecules. This increases serum concentration of free, pharmacologically active drug, especially for those that are normally highly protein bound (eg, aspirin, warfarin). This may increase risks of adverse effects. However, the drug also may be metabolized and excreted more rapidly, thereby offsetting at least some of the risks. In addition, drug interactions occur with co-administration of multiple drugs that are highly protein bound. The drugs compete for protein-binding sites and are more likely to cause adverse effects with decreased levels of serum albumin. As above, the result is larger concentrations of free drug.</td>
</tr>
<tr>
<td>Decreased blood flow to the liver; decreased size of the liver; decreased number and activity of the cytochrome P450 (CYP) oxidative drug-metabolizing enzymes</td>
<td>Slowed metabolism and detoxification of many drugs, with increased risks of drug accumulation and toxic effects. Numerous drugs metabolized by the CYP enzymes are often prescribed for older adults, including beta blockers, calcium channel blockers, antimicrobials, the statin cholesterol-lowering drugs, and antiulcer drugs. Metabolism of drugs metabolized by conjugative reactions (eg, acetaminophen, diazepam, morphine, steroids) does not change significantly with aging.</td>
</tr>
<tr>
<td>Decreased blood flow to the kidneys, decreased number of functioning nephrons, decreased glomerular filtration rate, and decreased tubular secretion</td>
<td>• Impaired drug excretion, prolonged half-life, and increased risks of toxicity • Age-related alterations in renal function are consistent and well described. When renal blood flow is decreased, less drug is delivered to the kidney for elimination. Renal mass is also decreased and older adults may be more sensitive to drugs that further impair renal function (eg, nonsteroidal anti-inflammatory drugs such as ibuprofen, which older adults often take for pain or arthritis).</td>
</tr>
</tbody>
</table>

10. Use nondrug measures to decrease the need for drugs and to increase their effectiveness or decrease their adverse effects. For example, insomnia is a common complaint among older adults. Preventing it (eg, by avoiding caffeine-containing beverages and excessive napping) is much safer than taking sedative-hypnotic drugs.

11. For people receiving long-term drug therapy at home, use measures to help them take drugs safely and effectively.
   a. If vision is impaired, label drug containers with large lettering for easier readability. A magnifying glass also may be useful.
   b. Be sure the client can open drug containers. For example, avoid childproof containers for an older adult with arthritic hands.
   c. Several devices may be used to schedule drug doses and decrease risks of omitting or repeating doses. These include written schedules, calendars, and charts. Also available are drug containers with doses prepared and clearly labeled as to the day and time each dose is to be taken. With the latter system, the client can tell at a glance whether a dose has been taken.
   d. Enlist family members or friends when necessary.

12. When a client acquires new symptoms or becomes less capable of functioning in usual activities of daily living, consider the possibility of adverse drug effects. Often, new signs and symptoms are attributed to aging or disease. They may then be ignored or treated by prescribing a new drug, when stopping or reducing the dose of an old drug is the indicated intervention.

Drug Therapy in Renal Impairment

Many clients have or are at risk for impaired renal function. Clients with disease processes such as diabetes, hypertension, or heart failure may have renal insufficiency on first contact, and this may be worsened by illness, major surgery or trauma, or administration of nephrotoxic drugs. In clients with nor-
nal renal function, renal failure may develop from depletion of intravascular fluid volume, shock due to sepsis or blood loss, seriously impaired cardiovascular function, major surgery, nephrotoxic drugs, or other conditions. Acute renal failure (ARF) may occur in any illness in which renal blood flow or function is impaired. Chronic renal failure (CRF) usually results from disease processes that destroy renal tissue.

With ARF, renal function may recover if the impairment is recognized promptly, contributing factors are eliminated or treated effectively, and medication dosages are adjusted according to the extent of renal impairment. With CRF, effective treatment can help to conserve functioning nephrons and delay progression to end-stage renal disease (ESRD). If ESRD develops, dialysis or transplantation is required.

In relation to drug therapy, the major concern with renal impairment is the high risk of drug accumulation and adverse effects because the kidneys are unable to excrete drugs and drug metabolites. Guidelines have been established for the use of many drugs; health care providers need to know and use these recommendations to maximize the safety and effectiveness of drug therapy. Some general guidelines are listed here; specific guidelines for particular drug groups are included in appropriate chapters.

1. Drug therapy must be especially cautious in clients with renal impairment because of the risks of drug accumulation and adverse effects. When possible, nephrologists should design drug therapy regimens. However, all health care providers need to be knowledgeable about risk factors for development of renal impairment, illnesses and their physiologic changes (eg, hemodynamic, renal, hepatic, and metabolic alterations) that affect renal function, and the effects of various drugs on renal function.

2. Renal status should be monitored in any client with renal insufficiency or risk factors for development of renal insufficiency. Signs and symptoms of ARF include decreased urine output (<600 mL/24 hours), increased blood urea nitrogen or increased serum creatinine (>2 mg/dL or an increase of ≥20.5 mg/dL over a baseline value of <3.0 mg/dL). In addition, an adequate fluid intake is required to excrete drugs by the kidneys. Any factors that deplete extracellular fluid volume (eg, inadequate fluid intake; diuretic drugs; loss of body fluids with blood loss, vomiting, or diarrhea) increase the risk of worsening renal impairment in clients who already have impairment or of causing impairment in those who previously had normal function.

3. Clients with renal impairment may respond to a drug dose or serum concentration differently than clients with normal renal function because of the physiologic and biochemical changes. Thus, drug therapy must be individualized according to the extent of renal impairment. This is usually determined by measuring serum creatinine, which is then used to calculate creatinine clearance as a measure of the glomerular filtration rate (GFR). Because serum creatinine is determined by muscle mass as well as the GFR, the serum creatinine measurement cannot be used as the sole indicator of renal function unless the client is a young, relatively healthy, well-nourished person with a sudden acute illness. Estimations of creatinine clearance are more accurate for clients with stable renal function (ie, stable serum creatinine) and average muscle mass (for their age, weight, and height). Estimations are less accurate for emaciated and obese clients and for those with changing renal function, as often occurs in acute illness. If a fluctuating serum creatinine is used to calculate the GFR, an erroneous value will be obtained. If a client is oliguric (<400 mL urine/24 hours), for example, the creatinine clearance should be estimated to be less than 10 mL/minute, regardless of the serum creatinine concentration.

Serum creatinine is also a relatively unreliable indicator of renal function in elderly or malnourished clients. Because these clients usually have diminished muscle mass, they may have a normal serum level of creatinine even if their renal function and GFR are markedly reduced.

Some medications can increase serum creatinine levels and create a false impression of renal failure. These drugs, which include cimetidine and trimethoprim, interfere with secretion of creatinine into kidney tubules. As a result, serum creatinine levels are increased without an associated decrease in renal function.

4. Drug selection should be guided by baseline renal function and the known effects of drugs on renal function, when possible. Many commonly used drugs may adversely affect renal function, including nonsteroidal anti-inflammatory drugs such as prescription or OTC ibuprofen (Motrin, Advil). Some drugs are excreted exclusively (eg, aminoglycoside antibiotics, lithium) and most are excreted primarily or to some extent by the kidneys. Some drugs are contraindicated in renal impairment (eg, tetracyclines except doxycycline); others can be used if safety guidelines are followed (eg, reducing dosage, monitoring serum drug levels and renal function tests, avoiding dehydration). Drugs known to be nephrotoxic should be avoided when possible. In some instances, however, there are no effective substitutes and nephrotoxic drugs must be given. Some commonly used nephrotoxic drugs include aminoglycoside antibiotics, amphotericin B, and cisplatin.

5. Dosage of many drugs needs to be decreased in renal failure, including aminoglycoside antibiotics, most cephalosporin antibiotics, fluoroquinolones, and digoxin. For some drugs, a smaller dose or a longer interval between doses is recommended for clients with moderate (creatinine clearance 10 to 50 mL/minute) or severe renal insufficiency (creatinine clearance < 10 mL/minute). However, for many commonly used drugs, the most effective dosage adjustments are based on the client’s clinical responses and serum drug levels.

For clients receiving renal replacement therapy (eg, hemodialysis or some type of filtration), the treatment removes variable amounts of drugs that are...
usually excreted through the kidneys. With some drugs, such as many antimicrobials, a supplemental dose may be needed to maintain therapeutic blood levels of drug.

**Drug Therapy in Hepatic Impairment**

Most drugs are eliminated from the body by hepatic metabolism, renal excretion, or both. Hepatic metabolism depends mainly on blood flow and enzyme activity in the liver and protein binding in the plasma. Clients at risk for impaired liver function include those with primary liver disease (eg, hepatitis, cirrhosis) and those with disease processes that impair blood flow to the liver (eg, heart failure, shock, major surgery, or trauma) or hepatic enzyme production. An additional factor is hepatotoxic drugs. Fortunately, although the liver is often damaged, it has a great capacity for cell repair and may be able to function with as little as 10% of undamaged hepatic cells.

In relation to drug therapy, acute liver impairment may interfere with drug metabolism and elimination, whereas chronic cirrhosis or severe liver impairment may affect all pharmacokinetic processes. It is difficult to predict the effects of drug therapy because of wide variations in liver function and few helpful diagnostic tests. In addition, with severe hepatic impairment, extrahepatic sites of drug metabolism (eg, intestine, kidneys, lungs) may become more important in eliminating drugs from the body. Thus, guidelines for drug selection, dosage, and duration of use are not well established. Some general guidelines for increasing drug safety and effectiveness are listed here; known guidelines for particular drug groups are included in appropriate chapters.

1. During drug therapy, clients with impaired liver function require close monitoring for signs and symptoms (eg, nausea, vomiting, jaundice, liver enlargement) and abnormal results of laboratory tests of liver function (see 4, below).

2. **Drug selection** should be based on knowledge of drug effects on hepatic function. Hepatotoxic drugs should be avoided when possible. If they cannot be avoided, they should be used in the smallest effective doses, for the shortest effective time. Commonly used hepatotoxic drugs include acetaminophen, isoniazid, and cholesterol-lowering statins. Alcohol is toxic to the liver by itself and increases the risks of hepatotoxicity with other drugs.

   In addition to hepatotoxic drugs, many other drugs can cause or aggravate liver impairment by decreasing hepatic blood flow and drug-metabolizing capacity. For example, epinephrine and related drugs may cause vasoconstriction in the hepatic artery and portal vein, the two main sources of the liver’s blood supply. Beta-adrenergic blocking agents decrease hepatic blood flow by decreasing cardiac output. Several drugs (eg, cimetidine, fluoxetine, ketoconazole) inhibit hepatic metabolism of many coadministered drugs. The consequence may be toxicity from the inhibited drugs if the dose is not decreased.

3. **Dosage** should be reduced for drugs that are extensively metabolized in the liver because, if doses are not reduced, serum drug levels are higher, elimination is slower, and toxicity is more likely to occur in a client with hepatic disease. For example, lidocaine is normally rapidly deactivated by hepatic metabolism. If blood flow is impaired so that lidocaine molecules in the blood are unable to reach drug-metabolizing liver cells, more drug stays in the bloodstream longer. Also, some oral drugs are normally extensively metabolized during their “first pass” through the liver, so that a relatively small portion of an oral dose reaches the systemic circulation. With cirrhosis, the blood carrying the drug molecules is shunted around the liver so that oral drugs go directly into the systemic circulation. Some drugs whose dosages should be decreased in hepatic failure include cefoperazone, cimetidine, clindamycin, diazepam, labetalol, lorazepam, meperidine, morphine, phenytoin, propranolol, quinidine, ranitidine, theophylline, and verapamil.

4. Liver function tests should be monitored in clients with or at risk for liver impairment, especially when clients are receiving potentially hepatotoxic drugs. Indicators of hepatic impairment include serum bilirubin levels above 4 to 5 mg/dL, a prothrombin time greater than 1.5 times control, a serum albumin below 2.0 g/dL, and elevated serum alanine (ALT) and aspartate (AST) aminotransferases. In some clients, abnormal liver function test results may occur without indicating severe liver damage and are often reversible.

**Drug Therapy in Critical Illness**

The term *critical illness*, as used here, denotes the care of clients who are experiencing acute, serious, or life-threatening illness. Critically ill clients are at risk for multiple organ failure, including cardiovascular, renal, and hepatic impairments that influence all aspects of drug therapy. Overall, critically ill clients exhibit varying degrees of organ dysfunction and their conditions tend to change rapidly, so that drug pharmacokinetics and pharmacodynamics vary widely. Although blood volume is often decreased, drug distribution is usually increased because of less protein binding and increased extracellular fluid. Drug elimination is usually impaired because of decreased blood flow and decreased function of the liver and kidneys.

Although critical care nursing is a specialty area of practice and much of critical care is performed in an intensive care unit (ICU), nurses in numerous other settings also care for these clients. For example, nurses in emergency departments often initiate and maintain treatment for several hours; nurses on other hospital units care for clients who are transferred to or from ICUs; and, increasingly, clients formerly cared for in
an ICU are on medical-surgical hospital units, in long-term care facilities, or even at home. Moreover, increasing numbers of nursing students are introduced to critical care during their educational programs, many new graduates seek employment in critical care settings, and experienced nurses may transfer to an ICU. Thus, all nurses need to know about drug therapy in critically ill clients. Some general guidelines to increase safety and effectiveness of drug therapy in critical illness are listed here; more specific guidelines related to particular drugs are included in the appropriate chapters.

1. Drug therapy in clients who are critically ill is often more complex, more problematic, and less predictable than in most other populations. One reason is that clients often have multiple organ impairments that alter drug effects and increase the risks of adverse drug reactions. Another reason is that critically ill clients often require aggressive treatment with large numbers, large doses, and combinations of highly potent medications. Overall, therapeutic effects may be decreased and risks of adverse reactions and interactions may be increased because the client’s body may be unable to process or respond to drugs effectively.

In this at-risk population, safe and effective drug therapy requires that all involved health care providers be knowledgeable about common critical illnesses, the physiologic changes (eg, hemodynamic, renal, hepatic, and metabolic alterations) that can be caused by the illnesses, and the drugs used to treat the illnesses. Nurses need to be especially diligent in administering drugs and vigilant in observing client responses.

2. Drugs used in critical illness represent most drug classifications and are also discussed in other chapters. Commonly used drugs include analgesics, antimicrobials, cardiovascular agents, gastric acid suppressants, neuromuscular blocking agents, and sedatives.

3. In many instances, the goal of drug therapy is to support vital functions and relieve life-threatening symptoms until healing can occur or definitive treatment can be instituted.

4. Drug selection should be guided by the client’s clinical status (eg, symptoms, severity of illness) and organ function, especially cardiovascular, renal, and hepatic functions.

5. Route of administration should also be guided by the client’s clinical status. Most drugs are given intravenously (IV) because critically ill clients are often unable to take oral medications and require many drugs, rapid drug action, and relatively large doses. In addition, the IV route achieves more reliable and measurable blood levels.

When a drug is given IV, it reaches the heart and brain quickly because the sympathetic nervous system and other homeostatic mechanisms attempt to maintain blood flow to the heart and brain at the expense of blood flow to other organs such as the kidneys, gastrointestinal (GI) tract, liver, and skin. As a result, cardiovascular and central nervous system (CNS) effects may be faster, more pronounced, and longer lasting than usual. If the drug is a sedative, effects may include excessive sedation and cardiac depression.

If the client is able to take oral medications, this is probably the preferred route. However, many factors may interfere with drug effects (eg, impaired function of the GI tract, heart, kidneys, or liver) and drug–drug and drug–diet interactions may occur if precautions are not taken. For example, ant ulcer drugs, which are often given to prevent stress ulcers and GI bleeding, may decrease absorption of other drugs.

For clients who receive oral medications or nutritional solutions through a nasogastric, gastrostomy, or jejunostomy tube, there may be drug–food interactions that impair drug absorption. In addition, crushing tablets or opening capsules to give a drug by a GI tube may alter the absorption and chemical stability of the drug.

Sublingual, oral inhalation, and transdermal medications may be used effectively in some critically ill clients. However, few drugs are available in these formulations.

For clients with hypotension and shock, drugs usually should not be given orally, subcutaneously, intramuscularly, or by skin patch because shock impairs absorption from their sites of administration, distribution to body cells is unpredictable, the liver cannot metabolize drugs effectively, and the kidneys cannot excrete drugs effectively.

6. Dosage requirements may vary considerably among clients and within the same client at different times during an illness. A standard dose may be effective, subtherapeutic, or toxic. Thus, it is especially important that initial dosages are individualized according to the severity of the condition being treated and client characteristics such as age and organ function, and that maintenance dosages are titrated according to client responses and changes in organ function (eg, as indicated by symptoms or laboratory tests).

7. With many drugs, the timing of administration may be important in increasing therapeutic effects and decreasing adverse effects. Once-daily drug doses should be given at approximately the same time each day; multiple-daily doses should be given at approximately even intervals around the clock.

8. Weigh clients when possible, initially and periodically, because dosage of many drugs is based on weight. In addition, periodic weights help to assess clients for loss of body mass or gain in body water, both of which affect the pharmacokinetics of the drugs administered.

9. Laboratory tests are often needed before and during drug therapy of critical illnesses to assess the client’s
condition (eg, cardiovascular, renal and hepatic functions, fluid and electrolyte balance) and response to treatment. Other tests may include measurement of serum drug levels. The results of these tests may indicate that changes are needed in drug therapy.

10. Serum protein levels should be monitored in critically ill clients because drug binding may be significantly altered. Serum albumin, which binds acidic drugs such as phenytoin and diazepam, is usually decreased during critical illness for a variety of reasons, including inadequate production by the liver. If there is not enough albumin to bind a drug, blood levels are higher and may cause adverse effects. Also, unbound molecules are metabolized and excreted more readily so that therapeutic effects may be decreased.

Alpha1-acid glycoprotein binds basic drugs and its synthesis may increase during critical illness. As a result, the bound portion of a dose increases for some drugs (eg, meperidine, propranolol, imipramine, lidocaine) and therapeutic blood levels may not be achieved unless higher doses are given. In addition, these drugs are eliminated more slowly than usual.

Home Care

Home care is an expanding area of health care. This trend evolved from efforts to reduce health care costs, especially the costs of hospitalization. The consequences of this trend include increased outpatient care and brief hospitalizations for severe illness or major surgery. In both instances, clients of all age groups are often discharged to their homes for follow-up care and recovery. Skilled nursing care, such as managing medication regimens, is often required during follow-up. Most general principles and nursing responsibilities related to drug therapy apply in home care as in other health care settings. Some additional principles and factors include the following:

1. Clients may require short- or long-term drug therapy. In most instances, the role of the nurse is to teach the client or caregiver to administer medications and monitor their effects.

2. In a client’s home, the nurse is a guest and must work within the environment to establish rapport, elicit cooperation, and provide nursing care. The initial contact is usually by telephone, and one purpose is to schedule a home visit, preferably at a convenient time for the client and caregiver. In addition, state the main purpose of the visit and approximately how long the visit will be. Establish a method for contact in case the appointment must be canceled by either party.

3. Assess the client’s attitude toward the prescribed medication regimen and his or her ability to provide self-care. If the client is unable, who will be the primary caregiver for medication administration and observing for medication effects? What are the learning needs of the client or caregiver in relation to the medication regimen?

4. Ask to see all prescribed and OTC medications the client takes, and ask how and when the client takes each one. With this information, the nurse may be able to reinforce the client’s compliance or identify potential problem areas (eg, differences between instructions and client usage of medications, drugs with opposing or duplicate effects, continued use of medications that were supposed to be discontinued, drugs discontinued because of adverse effects).

5. Ask if the client takes any herbal medicines or dietary supplements. If so, try to determine the amount, frequency, duration of use, reasons for use, and perceived beneficial or adverse effects. Explain that the nurse needs this information because some herbs and dietary supplements may cause various health problems or react adversely with prescription or OTC medications.

6. Assess the environment for potential safety hazards (eg, risk of infection with corticosteroids and other immunosuppressants, risk of falls and other injuries with opioid analgesics and other drugs with sedating effects). In addition, assess the client’s ability to obtain medications and keep appointments for follow-up visits to health care providers.

7. Provide whatever information and assistance is needed for home management of the drug therapy regimen. Most people are accustomed to taking oral drugs, but they may need information about timing in relation to food intake, whether a tablet can be crushed, when to omit the drug, and other aspects. With other routes, the nurse may initially need to demonstrate administration or coach the client or caregiver through each step. Demonstrating and having the client or caregiver do a return demonstration is a good way to teach psychomotor skills such as giving a medication through a GI tube, preparing and administering an injection, or manipulating an intravenous infusion pump.

8. In addition to safe and accurate administration, teach the client and caregiver to observe for beneficial and adverse effects. If side effects occur, teach them how to manage minor ones and which ones to report to a health care provider.

9. Between home visits, the home care nurse can maintain contact with clients and caregivers to monitor progress, answer questions, identify problems, and provide reassurance. Clients and caregivers should be given a telephone number to call with questions about medications, side effects, and so forth. The nurse may wish to schedule a daily time for receiving and making nonemergency calls. For clients and nurses with computers and Internet access, electronic mail may be a convenient and efficient method of communication.
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Prepare medications for administration.</td>
<td>If giving medications to a group of patients, start preparing about 30 minutes before the scheduled administration time when possible, to avoid rushing and increasing the risk of errors.</td>
</tr>
<tr>
<td>a. Assemble appropriate supplies and equipment.</td>
<td>Medications and supplies are usually kept on a medication cart in a hospital or long-term care facility.</td>
</tr>
<tr>
<td>b. Calculate doses when indicated.</td>
<td>Except for very simple calculations, use pencil and paper to decrease the risk of errors. If unsure about the results, ask a colleague or a pharmacist to do the calculation. Compare results. Accuracy is vital.</td>
</tr>
<tr>
<td>c. Check vital signs when indicated.</td>
<td>Check blood pressure (recent recordings) before giving antihypertensive drugs. Check temperature before giving an antipyretic.</td>
</tr>
<tr>
<td>d. Check laboratory reports when indicated.</td>
<td>Commonly needed reports include serum potassium levels before giving diuretics; prothrombin time or international normalized ratio (INR) before giving Coumadin; culture and susceptibility reports before giving an antibiotic.</td>
</tr>
<tr>
<td>e. Check drug references when indicated.</td>
<td>This is often needed to look up new or unfamiliar drugs; other uses include assessing a drug in relation to a particular client (e.g., Is it contraindicated? Is it likely to interact with other drugs the client is taking? Does the client’s ordered dose fit within the dosage range listed in the drug reference? Can a tablet be crushed or a capsule opened without decreasing therapeutic effects or increasing adverse effects?)</td>
</tr>
<tr>
<td>2. Administer drugs accurately (see Chap. 3).</td>
<td>These rights are ensured if the techniques described in Chapter 3 are consistently followed. The time may vary by approximately 30 minutes. For example, a drug ordered for 9 AM can be usually given between 8:30 AM and 9:30 AM. No variation is allowed in the other rights.</td>
</tr>
<tr>
<td>a. Practice the five rights of drug administration (right drug, right client, right dose, right route, and right time).</td>
<td>For example, sterile equipment and techniques are required for injection of any drug.</td>
</tr>
<tr>
<td>b. Use correct techniques for different routes of administration.</td>
<td>Some drugs require specific techniques of preparation and administration.</td>
</tr>
<tr>
<td>c. Follow label instructions regarding mixing or other aspects of giving specific drugs.</td>
<td>Antacids decrease absorption of many oral drugs.</td>
</tr>
<tr>
<td>d. In general, do not give antacids with any other oral drugs. When both are ordered, administer at least 2 hours apart.</td>
<td>In general, the nurse should know the expected effects and when they are likely to occur. Specific observations depend on the specific drug or drugs being given.</td>
</tr>
<tr>
<td>2. Observe for therapeutic effects.</td>
<td>All drugs are potentially harmful, although the incidence and severity of adverse reactions vary among drugs and clients. People most likely to have adverse reactions are those with severe liver or kidney disease, those who are very young or very old, those taking several drugs, and those receiving large doses of any drug. Specific adverse effects for which to observe depend on the drugs being given.</td>
</tr>
<tr>
<td>a. Look for improvement in signs and symptoms, laboratory or other diagnostic test reports, or ability to function.</td>
<td>(continued)</td>
</tr>
<tr>
<td>b. Ask questions to determine whether the client is feeling better.</td>
<td></td>
</tr>
<tr>
<td>3. Observe for adverse effects.</td>
<td></td>
</tr>
<tr>
<td>a. Look for signs and symptoms of new problems or worsening of previous disorders. If noted, compare the client’s symptoms with your knowledge base about adverse effects associated with the drugs or consult a drug reference.</td>
<td></td>
</tr>
<tr>
<td>b. Check laboratory (e.g., complete blood count [CBC], electrolytes, blood urea nitrogen and serum creatinine, liver function tests) and other diagnostic test reports for abnormal values.</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS

<table>
<thead>
<tr>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Assess for decreasing ability to function at previous levels.</td>
</tr>
<tr>
<td>d. Ask questions to determine how the client is feeling and whether he or she is having difficulties that may be associated with drug therapy.</td>
</tr>
</tbody>
</table>

4. Observe for drug interactions.

| a. Consider a possible interaction when a client does not experience expected therapeutic effects or develops adverse effects. |
| b. Look for signs and symptoms of new problems or worsening of previous ones. If noted, compare the client’s symptoms with your knowledge base about interactions associated with the drugs or consult a drug reference to validate your observations. |

---

**How Can You Avoid This Medication Error?**

**Answer:** The nurse administered the wrong dose of medication to Jamie. Thirty cc would provide the entire daily dose of amoxicillin, rather than 100 mg, which should be administered every 8 hours. Carefully reread the order and recalculate the dosage ordered. Unit dosing can help double-check calculations and avoid errors.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** With infants, especially low-birth-weight infants, the danger of potential drug toxicity is high. This is especially true for a drug like digoxin that has a narrow therapeutic range. Decreased protein binding may result in higher blood levels of digoxin, causing toxicity. Also, excretion is reduced because the liver and kidneys are often immature in the low-birth-weight infant. It is prudent, especially with the very young and the very old, to start drug doses low and increase if necessary. It is never wrong to discuss your concerns with the physician, especially if your assessment reveals that therapeutic effects have not occurred (eg, worsening congestive heart failure).

---

**Review and Application Exercises**

1. Why do nurses need to know the therapeutic and adverse effects of the drugs they give?
2. Given a newly assigned client, what information is needed about present and previous medications or herbal and dietary supplements?

---

**SELECTED REFERENCES**


Drugs Affecting the Central Nervous System
Physiology of the Central Nervous System

Objectives

After studying this chapter, the student will be able to:

1. Describe the process of neurotransmission.
2. Describe major neurotransmitters and their roles in nervous system functioning.
3. Discuss signs and symptoms of central nervous system (CNS) depression.
4. Discuss general types and characteristics of CNS depressant drugs.

The central nervous system (CNS), composed of the brain and spinal cord, acts as the control center for regulating physical and mental body processes. Afferent or sensory neurons carry messages to the CNS; efferent or motor neurons carry messages away from the CNS. More specifically, the CNS constantly receives information about blood levels of oxygen and carbon dioxide, body temperature, and sensory stimuli and sends messages to effector organs to adjust the environment toward homeostasis. It is also concerned with higher intellectual functions (e.g., thought, learning, reasoning, problem solving, memory) and with muscle function, both skeletal and smooth.

The CNS has complex interactions with other parts of the body, and components of the CNS have complex interactions with each other. Although various components of brain function are often studied individually, it is the overall coordination of the “mind/body” connections that produces mental and physical health. A lack of coordination or imbalances among the components may lead to mental or physical disorders. Thus, emotions can strongly influence neural control of body function, and alterations in neural functions can strongly influence mood and behavior.

More specific characteristics are reviewed to aid understanding of drugs that act by altering CNS functions.

Characteristics and Functions of the Central Nervous System

Neurons

The CNS is composed mainly of two types of cells: the glia protect, support, and nourish the neuron; the neuron is the basic functional unit. Most neurons are composed of a cell body, a dendrite, and an axon. Nerve cell bodies usually occur in groups or clusters, called ganglia or nuclei. A cluster of cell bodies or nuclei with the same function is called a center (e.g., the vasomotor and respiratory centers in the medulla oblongata). A dendrite has a branching structure with many synapses or sites for receiving stimuli or messages, which are then conducted toward the cell body. An axon is a finger-like projection that carries impulses away from the cell body. The end of the axon branches into presynaptic fibers that end with small, knob-like structures called vesicles. These structures project into the synapse and contain the granules where neurotransmitters are stored. Many axons are covered by a fatty substance called myelin. The myelin cover or sheath protects and insulates the axon. An axon together with its myelin sheath is called a nerve fiber. Nerve fibers involved in the transmission of the same type of impulses (e.g., pain signals) are found together in a common pathway or tract.

Neurons must be able to communicate with other neurons and body tissues. This communication involves a complex network of electrical and chemical signals that receive, interpret, modify, and send messages. Characteristics that allow neurons to communicate with other cells include excitability (the ability to produce an action potential or be stimulated) and conductivity (the ability to convey electrical impulses). More specific components of the communication network include neurotransmitters, synapses, and receptors (described below).

Neurotransmitters

Neurotransmitters are chemical substances that carry messages from one neuron to another, or from a neuron to other body tissues, such as cardiac or skeletal muscle. They are
synthesized and stored in presynaptic nerve terminals and released in response to an electrical impulse (action potential) arriving at the end of the first neuron (presynaptic fiber). The basis for the action potential is the transient opening of ion channels. The entry of calcium ions is required for neurotransmitter release from storage sites in small sacs called synaptic vesicles. Storage of neurotransmitters allows them to be available quickly when needed and to avoid degradation by enzymes in the nerve terminal.

When released from the synaptic vesicles, molecules of neurotransmitter cross the synapse, bind to receptors in the cell membrane of the postsynaptic neuron (Fig. 5–1), and excite or inhibit postsynaptic neurons. Free neurotransmitter molecules (ie, those not bound to receptors) are rapidly removed from the synapse by three mechanisms: transportation back into the presynaptic nerve terminal (reuptake) for reuse, diffusion into surrounding body fluids, or destruction by enzymes (eg, acetylcholine is degraded by cholinesterase; norepinephrine is metabolized by monoamine oxidase and catecholomethyl transferase).

Three main types of neurotransmitters are amines, amino acids, and peptides, all of which are derived from body proteins. Most acute CNS responses are caused by small-molecule, rapidly acting neurotransmitters, such as acetylcholine, the amines (dopamine, norepinephrine, serotonin), and amino acids (aspartate, gamma-aminobutyric acid [GABA], glutamate, and glycine). Most prolonged CNS responses are caused by large-molecule, slowly acting neurotransmitters, such as the neuropeptide hormones (eg, adrenocorticotropic hormone [ACTH or corticotropin] and antidiuretic hormone [ADH]), substance P, and others. Prolonged effects are thought to involve closure of calcium channels, changes in cellular metabolism, changes in activation or deactivation of specific genes in the cell nucleus, and alterations in the numbers of excitatory or inhibitory postsynaptic membrane receptors. Some peptides (eg, ADH) serve as chemical messengers in both the nervous system and the endocrine system. Substance P plays a role in transmitting pain signals from peripheral tissues to the CNS and the stress response to noxious stimuli.

Several factors affect the availability and function of neurotransmitters. One factor is the availability of precursor proteins and enzymes required to synthesize particular neurotransmitters. Another factor is the number and binding capacity of receptors in the cell membranes of presynaptic and postsynaptic nerve endings. Other important factors include acid–base imbalances (acidosis decreases and alkalois increases synaptic transmission); hypoxia, which causes CNS depression (coma occurs within seconds without oxygen); and drugs, which may alter neurotransmitter synthesis, release, degradation, or binding to receptors to cause either CNS stimulation or depression.

**Synapses**

Neurons in a chain are separated by a microscopic gap called a synapse or synaptic cleft. Synapses may be electrical, in which sodium and potassium ions can rapidly conduct an electrical impulse from one neuron to another, or chemical, in which a neurotransmitter conducts the message to the next neuron. The chemical synapse is more commonly used to communicate with other neurons or target cells. Neurotransmitter release and removal occur in the synapses.

**Receptors**

Receptors are proteins embedded in the cell membranes of neurons. In the CNS, most receptors are on postsynaptic neurons, but some are on presynaptic nerve terminals. For most receptors, several subtypes have been identified, for which specific characteristics and functions have not yet been delineated. A neurotransmitter must bind to receptors to exert an effect on the next neuron in the chain. Some receptors act rapidly to open ion channels; others interact with a variety of intracellular proteins to initiate a second messenger system. For example, when norepinephrine binds with alpha- or beta-adrenergic receptors, intracellular events include activation of the enzyme adenylyl cyclase and the production of cyclic adenosine monophosphate (cAMP). In this case, the cAMP is a second messenger that activates cellular functions and the physiologic responses controlled by the alpha- and beta-adrenergic receptors. A neurotransmitter–receptor complex may have an excitatory or inhibitory effect on the postsynaptic neuron.

Receptors increase in number and activity (up-regulation) when there is underactivity at the synapse. They decrease in number and activity (down-regulation) when there is overactivity. Like other protein molecules in the body, receptors are constantly being synthesized and degraded. More specifically, it is believed that receptor proteins are constantly being formed by the endoplasmic reticulum–Golgi apparatus and inserted into presynaptic and postsynaptic membranes. If the

---

**Figure 5–1** Neurotransmission in the central nervous system. Neurontransmitter molecules (eg, norepinephrine and acetylcholine), released by the presynaptic nerve, cross the synapse and bind with receptor proteins in the cell membrane of the postsynaptic nerve.
synapses are overused and excessive amounts of neurotransmitter combine with receptor proteins, it is then postulated that many of the receptor proteins are inactivated and removed from the synaptic membrane. Thus, synaptic fatigue and downgrading or upgrading of receptors work with other control mechanisms of the nervous system to readjust abnormally stimulated or depressed nerve function toward normal.

**Neurotransmission Systems**

Neurons function through communication networks that may be called neurotransmission systems, the major elements of which are neurotransmitters, synapses, and receptors. Although neurotransmitters, synapses, and receptors are discussed separately here, it is the interaction among these elements that promotes order or disorder in the body’s physical and mental processes. Although many details of neuronal function remain elusive, a great deal of knowledge has been gained. For example, numerous neurotransmitters and subtypes of receptors have been identified and characterized. Major neurotransmission systems are the cholinergic, dopaminergic, GABA-ergic, noradrenergic, and serotonergic networks.

The **cholinergic system** uses acetylcholine as its neurotransmitter. Acetylcholine, the first substance to be designated as a neurotransmitter in the CNS, is located in many areas of the brain, with especially high concentrations in the motor cortex and basal ganglia. It is also a neurotransmitter in the autonomic nervous system and at peripheral neuromuscular junctions. Acetylcholine exerts excitatory effects at synapses and nerve–muscle junctions and inhibitory effects at some peripheral sites, such as organs supplied by the vagus nerve. In the CNS, acetylcholine is associated with level of arousal, memory, motor conditioning, and speech.

The **dopaminergic system** uses dopamine as its neurotransmitter. Dopamine is derived from tyrosine, an amino acid, and is a precursor substance in the synthesis of norepinephrine and epinephrine. Dopamine makes up more than half the catecholamine content in the brain and is found in the substantia nigra, the midbrain, and the hypothalamus, with high concentrations in the substantia nigra and basal ganglia. Much of the information about dopamine is derived from studies of antipsychotic drugs (see Chap. 9) and Parkinson's disease, a disorder caused by destruction of dopamine-producing neurons in the substantia nigra. Dopamine also occurs outside the brain, in renal and mesenteric blood vessels.

In the CNS, dopamine is thought to be inhibitory in the basal ganglia but may be excitatory in other areas. Repeated stimulation of dopamine receptors decreases their numbers (down-regulation) and their sensitivity to dopamine (desensitization). Prolonged blockade of dopamine receptors increases their numbers and sensitivity to dopamine. Some receptors (called autoreceptors) occur on the presynaptic nerve terminal. When released, dopamine stimulates these receptors and a negative feedback system is initiated that inhibits further dopamine synthesis and release.

Two groups of dopamine receptors have been identified. They are differentiated by the intracellular events that follow dopamine–receptor binding. One group includes D1 and D5 receptors, which activate adenyl cyclase to produce cAMP. The other group includes D2, D3, and D4 receptors. D2 receptors have been described most thoroughly; they are thought to inhibit activation of adenyl cyclase and subsequent production of cAMP, suppress calcium ion currents, and activate potassium ion currents. D1 and D2 receptor functions have not been delineated. Overall, dopamine actions at the cellular level depend on the subtype of receptor to which it binds and the simultaneous effects of other neurotransmitters at the same target neurons.

The **GABA-ergic system** uses GABA as its neurotransmitter. GABA is synthesized in the brain (cerebellum, basal ganglia, and cerebral cortex) and spinal cord in abundant amounts. It is the major inhibitory neurotransmitter in the CNS, with a role in many neuronal circuits (estimated at nearly one third of CNS synapses). GABA receptors have been divided into two main types, A and B. The GABA<sub>A</sub> receptor is a chloride ion channel that opens when GABA is released from presynaptic neurons. GABA<sub>B</sub> has not been delineated, but it is thought to function in the regulation of ion channels and biochemical pathways. There is evidence of multiple subtypes of GABA receptors and important functional differences among them.

The **noradrenergic system** uses norepinephrine as its neurotransmitter and extends to virtually every area of the brain. Like dopamine, norepinephrine is a catecholamine synthesized from tyrosine. It is found in relatively large amounts in the hypothalamus and the limbic system and in smaller amounts in most areas of the brain, including the reticular formation. Norepinephrine is mainly an excitatory neurotransmitter that stimulates the brain to generalized increased activity. However, it is inhibitory in a few areas because of inhibitory receptors at some nerve synapses.

Norepinephrine receptors in the CNS, as in the sympathetic nervous system, are divided into alpha- and beta-adrenergic receptors and their subtypes. Activation of alpha<sub>1</sub>, beta<sub>1</sub>, and beta<sub>2</sub> receptors is thought to stimulate activity of intracellular adenyl cyclase and the production of cAMP. Activation of alpha<sub>2</sub> receptors is associated with inhibition of adenyl cyclase activity and decreased production of cAMP. However, the effects of norepinephrine–alpha<sub>2</sub> receptor coupling are thought to stem mainly from activation of receptor-operated potassium ion channels and suppression of voltage-operated calcium ion channels. These effects on ion channels may increase membrane resistance to stimuli and inhibit the firing of CNS neurons. In addition, alpha<sub>2</sub> receptors on the presynaptic nerve ending are believed to regulate norepinephrine release. In other words, when high levels of extracellular norepinephrine act on presynaptic alpha<sub>2</sub> receptors, the effect is similar to that of a negative feedback system that inhibits the release of norepinephrine. Overall, the noradrenergic system is associated with mood, motor activity, regulation of arousal, and reward. It is thought to play an important role in producing rapid-eye-movement (REM) sleep, during which dreaming occurs.
The **serotonergic system** uses **serotonin** (also called 5-hydroxytryptamine or 5-HT) as its neurotransmitter. Serotonin-synthesizing neurons are widely distributed in the CNS, beginning in the midbrain and projecting into the thalamus, hypothalamus, cerebral cortex, and spinal cord. Because serotonin is synthesized from the amino acid tryptophan, the amount of tryptophan intake in the diet and the enzyme tryptophan hydroxylase control the rate of serotonin production. CNS serotonin is usually an inhibitory neurotransmitter and is associated with mood, the sleep–wake cycle, habituation, and sensory perceptions, including inhibition of pain pathways in the spinal cord. Serotonin is thought to produce sleep by inhibiting CNS activity and arousal.

Serotonin receptors are found in regions of the CNS that are associated with mood and anxiety and are also thought to be involved in temperature regulation. Activation of some receptors leads to hyperpolarization and neuronal inhibition. Several subtypes of serotonin receptors have been identified, some of which are linked to inhibition of adenyl cyclase activity or to regulation of potassium or calcium ion channels.

Serotonin is also found outside the CNS, mainly in mast cells of the lungs and platelets. It plays a major role in the blood coagulation process, during which it is released from platelets and causes vasoconstriction. It may also be involved in the vascular spasm associated with some pulmonary allergic reactions (during which it is released from mast cells) and migraine headaches. However, peripheral serotonin cannot cross the blood–brain barrier.

The **amino acid system** includes several amino acids that may serve as both structural components for protein synthesis and neurotransmitters. Amino acids were recognized as neurotransmitters relatively recently, and their roles and functions in this regard have not been completely elucidated. A summary of their characteristics follows.

**Aspartate** is an excitatory neurotransmitter found in high concentrations in the brain. Aspartate and glutamate are considered the major fast-acting, excitatory neurotransmitters in the brain.

**Glycine** is an inhibitory neurotransmitter found in the brain stem and spinal cord. Glycine receptors have many of the features described for GABA<sub>A</sub> receptors; subtypes have been identified but their functions are unknown.

**Glutamate** is considered the most important excitatory neurotransmitter in the CNS. It occurs in high concentrations in virtually every area of the CNS, including the cerebral cortex, basal ganglia, limbic structures, and hippocampus. Several subtypes of glutamate receptors have been identified, each with a unique distribution in the CNS. The functions of these receptor subtypes have not been established, but research suggests that the N-methyl-D-aspartate (NMDA) glutamate receptor subtype plays a role in memory.

Although some glutamate is apparently necessary for normal neurotransmission, brief exposure of neurons to high concentrations can lead to neuronal cell death. Events leading to neuronal death are triggered by excessive activation of NMDA receptors and movement of calcium ions into the neurons. This process may be similar to the neurotoxicity associated with brain injury (eg, from ischemia, hypoglycemia, or hypoxia), where increased release and impaired reuptake of glutamate lead to excessive stimulation of glutamate receptors and subsequent cell death. Altered glutamate metabolism may also lead to the formation of free radicals, which are implicated in neuronal cell death associated with some neurodegenerative diseases and toxic chemicals, including some drugs of abuse.

## Neurotransmission Systems in Selected Central Nervous System Disorders

Abnormalities in neurotransmission systems (eg, dysfunction or destruction of the neurons that normally produce neurotransmitters; altered receptor response to neurotransmitters) are implicated in many CNS disorders. For example, decreased acetylcholine is a characteristic of Alzheimer’s disease; dopamine abnormalities occur in psychosis and Parkinson’s disease; GABA abnormalities occur in anxiety, hyperarousal states, and seizure disorders; glutamate has been implicated in the pathogenesis of epilepsy, schizophrenia, stroke, and Huntington’s disease; and serotonin abnormalities are thought to be involved in mental depression and sleep disorders.

Although most research has focused on single neurotransmitters and their respective receptors, CNS function in both health and disease is probably determined by interactions among neurotransmission systems. In health, for example, complex mechanisms regulate the amounts and binding capacities of neurotransmitters and receptors, as well as the balance between excitatory and inhibitory forces. When abnormalities occur in any of these elements, the resulting dysregulation and imbalances lead to signs and symptoms of CNS disorders. Overall, then, neurotransmission systems function interdependently; one system may increase, decrease, or otherwise modify the effects of another system.

Except for mental depression, most psychiatric symptoms result from CNS stimulation and usually involve physical and mental hyperactivity. Such hyperactivity reflects a wide range of observable behaviors and nonobservable thoughts and feelings. In most people, manifestations may include pleasant feelings of mild euphoria and high levels of enthusiasm, energy, and productivity. In people with psychiatric illnesses, such as severe anxiety or psychosis, manifestations include unpleasant feelings of tension, psychomotor agitation, nervousness, and decreased ability to rest and sleep, even when very tired. Many psychiatric disorders, therapeutic drugs, and drugs of abuse may cause varying degrees of CNS stimulation. In general, the pathogenesis of excessive CNS stimulation may involve one or more of the following mechanisms:

1. Excessive amounts of excitatory neurotransmitters (eg, norepinephrine, glutamate)
2. Increased numbers or sensitivity of excitatory receptors
3. Insufficient amounts of inhibitory neurotransmitters (eg, GABA)
4. Decreased numbers or sensitivity of inhibitory receptors
**Cerebral Cortex**

The cerebral cortex is involved in all conscious processes, such as learning, memory, reasoning, verbalization, and voluntary body movements. Some parts of the cortex receive incoming nerve impulses and are called sensory areas; other parts send impulses to peripheral structures and are called motor areas. Around the sensory and motor areas are the “association” areas, which occupy the greater portion of the cortex. These areas analyze the information received by the sensory areas and decide on the appropriate response. In some instances, the response may be to store the perception in memory; in others, it may involve stimulation of motor centers to produce movement or speech.

**Thalamus**

The thalamus receives impulses carrying sensations such as heat, cold, pain, and muscle position sense. These sensations produce only a crude awareness at the thalamic level. They are relayed to the cerebral cortex, where they are interpreted regarding location, quality, intensity, and significance. The thalamus also relays motor impulses from the cortex to the spinal cord.

**Hypothalamus**

The hypothalamus has extensive neurologic and endocrine functions. In the CNS, it is connected with the thalamus, medulla oblongata, spinal cord, reticular activating system, and limbic system. In the autonomic nervous system, it is the center for motor control. In the endocrine system, the hypothalamus controls the secretion of all pituitary hormones. It is anatomically connected to the posterior pituitary gland, and it regulates the activity of the anterior pituitary. It constantly collects information about the internal environment of the body and helps maintain homeostasis by making continuous adjustments in water balance, body temperature, hormone levels, arterial blood pressure, heart rate, gastrointestinal motility, and other body functions. The hypothalamus is stimulated or inhibited by nerve impulses from different portions of the nervous system and by concentrations of nutrients, electrolytes, water, and hormones in the blood. Specific neuroendocrine functions include:
1. Producing oxytocin and ADH, which are stored in the posterior pituitary gland and released in response to nerve impulses from the hypothalamus. Oxytocin initiates uterine contractions to begin labor and delivery and helps to release milk from breast glands during breastfeeding. ADH helps maintain fluid balance by controlling water excretion. ADH secretion is controlled by the osmolarity of the extracellular fluid. When osmolarity is high, more ADH is secreted. This means that water is retained in the body to dilute the extracellular fluid and return it toward normal or homeostatic levels. When osmolarity is low, less ADH is secreted, and more water is excreted in the urine.
2. Regulating body temperature. When body temperature is elevated, sweating and dilation of blood vessels in the skin lower the temperature. When body temperature is low, sweating ceases and vasoconstriction occurs. When heat loss is decreased, the temperature is raised.
3. Assisting in regulation of arterial blood pressure by its effects on the vasomotor center. The vasomotor center in the medulla oblongata and pons maintains a state of partial contraction in blood vessels (vasomotor tone). The hypothalamus can exert excitatory or inhibitory effects on the vasomotor center, depending on which portions of the hypothalamus are stimulated. When nerve impulses from the hypothalamus excite the vasomotor center, vasomotor tone or vasoconstriction is increased, and blood pressure is raised. When the impulses from the hypothalamus inhibit the vasomotor center, vasomotor tone or vasoconstriction is decreased, with the overall effect of relative vasodilation and lowering of arterial blood pressure.
4. Regulating anterior pituitary hormones, including thyroid-stimulating hormone, ACTH, and growth hormone. The hypothalamus secretes “releasing factors,” which cause the anterior pituitary to secrete these hormones. There is a hypothalamic releasing factor for each hormone. The hypothalamic factor called prolactin-inhibiting factor inhibits secretion of prolactin, another anterior pituitary hormone.
5. Regulating food and water intake by the hypothalamic thirst, appetite, hunger, and satiety centers.
6. Regulating the physical changes associated with emotions (eg, increased blood pressure and heart rate). The hypothalamus, thalamus, and cerebral cortex interact to produce the feelings associated with emotions.

**Medulla Oblongata**

The medulla oblongata contains groups of neurons that form the vital cardiac, respiratory, and vasomotor centers. For example, if the respiratory center is stimulated, respiratory rate and depth are increased. If the respiratory center is depressed, respiratory rate and depth are decreased. The medulla also contains reflex centers for coughing, vomiting, sneezing, swallowing, and salivating.

The medulla and pons varoli also contain groups of neurons from which originate cranial nerves 5 through 12. Together with the midbrain, these structures form the brainstem.

**Reticular Activating System**

The reticular activating system is a network of neurons that extends from the spinal cord through the medulla and pons to the thalamus and hypothalamus. It receives impulses from all parts of the body, evaluates the significance of the impulses,
and decides which impulses to transmit to the cerebral cortex. It also excites or inhibits motor nerves that control both reflex and voluntary movement. Stimulation of these neurons produces wakefulness and mental alertness; depression causes sedation and loss of consciousness.

**Limbic System**

The limbic system borders and interconnects with the thalamus, hypothalamus, basal ganglia, hippocampus, amygdala, and septum. It participates in regulation of feeding behavior, the sleep–wake cycle, emotions (e.g., pleasure, fear, anger, sadness), and behavior (e.g., aggression, laughing, crying). Many nerve impulses from the limbic system are transmitted through the hypothalamus; thus, physiologic changes in blood pressure, heart rate, respiration, and hormone secretion occur in response to the emotions.

**Cerebellum**

The cerebellum, which is connected with motor centers in the cerebral cortex and basal ganglia, coordinates muscular activity. When several skeletal muscles are involved, some are contracted and some are relaxed for smooth, purposeful movements. It also helps to maintain balance and posture by receiving nerve impulses from the inner ear that produce appropriate reflex responses.

**Basal Ganglia**

The basal ganglia are concerned with skeletal muscle tone and orderly activity. Normal function is influenced by dopamine, a neurotransmitter produced in several areas of the brain. Degenerative changes in one of these areas, the substantia nigra, cause dopamine to be released in decreased amounts. This process is a factor in the development of Parkinson’s disease, which is characterized by rigidity and increased muscle tone.

**Pyramidal and Extrapyramidal Systems**

The pyramidal and extrapyramidal systems are pathways out of the cerebral cortex. In the pyramidal or corticospinal tract, nerve fibers originate in the cerebral cortex, go down the brain stem to the medulla, where the fibers cross, and continue down the spinal cord, where they end at various levels. Impulses are then carried from the spinal cord to skeletal muscle. Because the fibers cross in the medulla, impulses from the right side of the cerebral cortex control skeletal muscle movements of the left side of the body, and impulses from the left control muscle movements of the right side.

In the extrapyramidal system, fibers originate mainly in the premotor area of the cerebral cortex and travel to the basal ganglia and brain stem. The fibers are called extrapyramidal because they do not enter the medullary pyramids and cross over. Pyramidal and extrapyramidal systems intermingle in the spinal cord; disease processes affecting higher levels of the CNS involve both tracts.

**Brain Metabolism**

To function correctly, the brain must have an adequate and continuous supply of oxygen, glucose, and thiamine. Oxygen is carried to the brain by the carotid and vertebral arteries. The brain requires more oxygen than any other organ. Cerebral cortex cells are very sensitive to lack of oxygen (hypoxia), and interruption of blood supply causes immediate loss of consciousness. Brain stem cells are less sensitive to hypoxia. People in whom hypoxia is relatively prolonged may survive, although they may have irreversible brain damage.

Glucose is required as an energy source for brain cell metabolism. Hypoglycemia (low blood sugar) may cause mental confusion, dizziness, convulsions, loss of consciousness, and permanent damage to the cerebral cortex.

Thiamine is required for production and use of glucose. Thiamine deficiency can reduce glucose use by approximately half and can cause degeneration of the myelin sheaths of nerve cells. Such degeneration in central neurons leads to a form of encephalopathy known as Wernicke-Korsakoff syndrome. Degeneration in peripheral nerves leads to polyneuritis and muscle atrophy, weakness, and paralysis.

**Spinal Cord**

The spinal cord is continuous with the medulla oblongata and extends down through the vertebral column to the sacral area. It consists of 31 segments, each of which is the point of origin for a pair of spinal nerves. The cord is a pathway between the brain and the peripheral nervous system. It carries impulses to and from the brain, along sensory and motor nerve fibers, and is a center for reflex actions. Reflexes are involuntary responses to certain nerve impulses received by the spinal cord (e.g., the knee-jerk and pupillary reflexes).

**DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM**

Drugs affecting the CNS, sometimes called centrally active drugs, are broadly classified as depressants or stimulants. CNS depressant drugs (e.g., antipsychotics, opioid analgesics, sedative-hypnotics) produce a general depression of the CNS when given in sufficient dosages. Mild CNS depression is characterized by lack of interest in surroundings and inability to focus on a topic (short attention span). As depression progresses, there is drowsiness or sleep, decreased
muscle tone, decreased ability to move, and decreased perception of sensations such as pain, heat, and cold. Severe CNS depression produces unconsciousness or coma, loss of reflexes, respiratory failure, and death.

Central nervous system stimulants produce a variety of effects. Mild stimulation is characterized by wakefulness, mental alertness, and decreased fatigue. Increasing stimulation produces hyperactivity, excessive talking, nervousness, and insomnia. Excessive stimulation can cause convulsive seizures, cardiac dysrhythmias, and death. Because it is difficult to avoid excessive, harmful CNS stimulation by these drugs, CNS stimulants are less useful for therapeutic purposes than are CNS depressants.

**Review and Application Exercises**

1. Where are neurotransmitters synthesized and stored?
2. What events occur at the synapse between two neurons?
3. Once a neurotransmitter is released and acts on receptors, how are the remaining molecules inactivated?
4. What are the main functions of acetylcholine, dopamine, GABA, norepinephrine, and serotonin?
5. What part of the brain is concerned mainly with thoughts, reasoning, and learning?
6. What part of the brain contains vital respiratory and cardiovascular centers?
7. How would you expect a person with CNS depression to look and behave?
8. How would you expect a person with excessive CNS stimulation to look and behave?

**SELECTED REFERENCES**

Opioid (Narcotic) Analgesics

General Considerations

- Use nonpharmacologic treatments of pain (eg, exercise, heat and cold applications) instead of or along with analgesics, when effective.
- For pain that is not relieved by nondrug treatments, a non-narcotic analgesic (eg, acetaminopen or ibuprofen) may be taken.
- For pain that is not relieved by a non-narcotic analgesic, a narcotic may be alternated with a non-narcotic analgesic or a combination product containing a narcotic and non-narcotic may be effective. Use of a narcotic analgesic for acute pain is acceptable and unlikely to lead to addiction.
- Most combination products (eg, Lorcet, Lortab, Percocet, Vicodin, Tylenol No. 3) contain acetaminopen and there is a risk of liver failure from high doses of acetaminopen or from lower doses in people who already have liver damage (eg, alcohol abusers). The maximum recommended daily dose, whether taken alone or in a combination product, is 4000 milligrams (eg, 8 tablets or capsules containing 500 mg each or 12 tablets containing 325 mg each). If unsure whether a combination product contains acetaminopen, ask a health care provider.
- For acute episodes of pain, most opioids may be taken as needed; for chronic pain, the drugs should be taken on a regular schedule, around the clock.
- When a choice of analgesics is available, use the least amount of the mildest drug that is likely to be effective in a particular situation.
- Take only as prescribed. If desired effects are not achieved, report to the physician. Do not increase the dose and do not take medication more often than prescribed. Although these principles apply to all medications, they are especially important with opioid analgesics because of potentially serious adverse reactions, including drug dependence, and because analgesics may mask pain for which medical attention is needed.
- Do not drink alcohol or take other drugs that cause drowsiness (eg, some antihistamines, sedative-type drugs for nervousness or anxiety, sleeping pills) while taking opioid analgesics. Combining drugs with similar effects may lead to excessive sedation, even coma, and difficulty in breathing.

Self-administration

- Take oral narcotics with 6–8 oz of water, with or after food to reduce nausea.
- Do not crush or chew long-acting tablets (eg, MS Contin, Oxycontin). The tablets are formulated to release the active drug slowly, over several hours. Crushing or chewing causes immediate release of the drug, with a high risk of overdose and adverse effects, and shortens the duration of action.
- Omit one or more doses if severe adverse effects occur (eg, excessive drowsiness, difficulty in breathing, severe nausea, vomiting, or constipation) and report to a health care provider.

Do not smoke, cook, drive a car, or operate machinery when drowsy or dizzy or when vision is blurred from medication.

Stay in bed at least 30–60 minutes after receiving an opioid analgesic by injection. Injected drugs may cause dizziness, drowsiness, and falls when walking around. If it is necessary to get out of bed, ask someone for assistance.

When hospitalized, ask the physician or nurse about potential methods of pain management. For example, if anticipating surgery, ask how postoperative pain will be handled, how you need to report pain and request pain medication, and so on. It is better to take adequate medication and be able to cough, deep breathe, and ambulate than to avoid or minimize pain medication and be unable to perform activities that promote recovery and healing. Do not object to having bedrails up and asking for assistance to ambulate when receiving a strong narcotic analgesic. These are safety measures to prevent falls or other injuries because these analgesics may cause drowsiness, weakness, unsteady gait, and blurred vision.

Constipation is a common adverse effect of opioid analgesics. It may be prevented or managed by eating high-fiber foods, such as whole-grain cereals, fruits, and vegetables; drinking 2–3 quarts of fluid daily; and being as active as tolerated. For someone unable to take these preventive measures, Metamucil daily or a mild laxative every other day may be needed.

Do not crush or chew long-acting tablets (eg, MS Contin, Oxycontin). The tablets are formulated to release the active drug slowly, over several hours. Crushing or chewing causes immediate release of the drug, with a high risk of overdose and adverse effects, and shortens the duration of action.

A technique called patient-controlled analgesia (PCA) allows self-administration. One device consists of a syringe of diluted drug connected to an IV line and infusion pump; another device uses a specially designed IV bag and special tubing. These devices deliver a dose when the client pushes a button. Some PCA pumps can
Critical Thinking Scenario
You are working in an emergency room when parents bring in their 2-year-old son who has just ingested half a bottle of acetaminophen (Tylenol). His parents have recently come to this country from Mexico and speak very little English. The child does not appear acutely ill and the parents become very upset when the physician wants to admit the child.

Reflect on:
- Why is Tylenol overdose potentially so serious for this young child?
- What would emergency and follow-up treatment for Tylenol overdose be?
- How has this child’s developmental stage increased the likelihood for accidental poisoning?
- Develop a teaching plan for this family to prevent recurrence.

Overview
The analgesic–antipyretic–anti-inflammatory drug group includes chemically and pharmacologically diverse drugs that share the ability to relieve pain, fever, and inflammation, symptoms associated with many injuries and illnesses. Drugs discussed in this chapter include aspirin (acetylsalicylic acid or ASA); the prototype, aspirin-related drugs that are often called nonsteroidal anti-inflammatory drugs (NSAIDs, eg, ibuprofen); acetaminophen; and drugs used to prevent or treat gout and migraine.

Aspirin, NSAIDs, and acetaminophen can also be called antiprostaglandin drugs, because they inhibit the synthesis of prostaglandins. Prostaglandins are chemical mediators found in most body tissues; they help regulate many cell functions and participate in the inflammatory response. They are formed when cellular injury occurs and phospholipids in cell membranes release arachidonic acid. Arachidonic acid is then metabolized by cyclooxygenase enzymes to produce prostaglandins, which act briefly in the area where they are produced and are then inactivated. Prostaglandins exert various and opposing effects in different body tissues (Table 7–1).
SECTION 2 DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM

To aid understanding of prostaglandins, their roles in pain, fever, and inflammation are described in the following section.

### PAIN, FEVER, AND INFLAMMATION

**Pain** is the sensation of discomfort, hurt, or distress. It is a common human ailment and may occur with tissue injury and inflammation. Prostaglandins sensitize pain receptors and increase the pain associated with other chemical mediators such as bradykinin and histamine (Box 7–1).

**Fever** is an elevation of body temperature above the normal range. Body temperature is controlled by a regulating center in the hypothalamus. Normally, there is a balance between heat production and heat loss so that a constant body temperature is maintained. When there is excessive heat production, mechanisms to increase heat loss are activated. As a result, blood vessels dilate, more blood flows through the skin, sweating occurs, and body temperature usually stays within normal range. When fever occurs, the heat-regulating center in the hypothalamus is reset so that it tolerates a higher body temperature. Fever may be produced by dehydration, inflammation, infectious processes, some drugs, brain injury, or diseases involving the hypothalamus. Prostaglandin formation is stimulated by such circumstances and, along with bacterial toxins and other substances, prostaglandins act as pyrogens (fever-producing agents).

**Inflammation** is the normal body response to tissue damage from any source and it may occur in any tissue or organ. It is an attempt by the body to remove the damaging agent and repair the damaged tissue. Local manifestations are redness, heat, edema, and pain. Redness and heat result from vasodilation and increased blood supply; edema results from leakage of blood plasma into the area; and pain occurs when pain receptors on nerve endings are stimulated by heat, edema, pressure, chemicals released by the damaged cells, and prostaglandins. Systemic manifestations include leukocytosis, increased erythrocyte sedimentation rate, fever, headache, loss of appetite, lethargy or malaise, and weakness. Both local and systemic manifestations vary according to the cause and extent of tissue damage. In addition, inflammation may be acute or chronic.

Because inflammation may be a component of virtually any illness, anti-inflammatory drugs are needed when the inflammatory response is inappropriate, abnormal, or persistent, or destroys tissue. Common conditions that are characterized by pain, fever, and inflammation, and for which the drugs discussed in this chapter are used, are described in Box 7–2.

### MECHANISM OF ACTION

Aspirin, NSAIDs, and acetaminophen inactivate cyclooxygenases, the enzymes required for prostaglandin formation (Fig. 7–1). Two forms of cyclooxygenase, called COX-1 and COX-2, have been identified. Aspirin and traditional NSAIDs inhibit both COX-1 and COX-2 enzymes.

COX-1 is normally synthesized continuously and present in all tissues and cell types, especially platelets, endothelial cells, the gastrointestinal (GI) tract, and the kidneys. Prostaglandins produced by COX-1 are important in numerous homeostatic functions and are associated with protective effects on the stomach and kidneys. In the stomach, they decrease gastric acid secretion, increase mucus secretion, and regulate blood circulation. In the kidneys, these prostaglandins help to maintain adequate blood flow and function. In the cardiovascular system, the prostaglandins help regulate vascular tone (ie, vasodilatation and vasoconstriction) and platelet function. Drug-induced inhibition of these prostaglandins results in the adverse effects associated with aspirin and related drugs, especially gastric irritation, ulceration, and bleeding. Inhibition of COX-1 activity in platelets may be more responsible for GI bleeding than inhibition in gastric mucosa.

COX-2 is also normally present in several tissues (eg, brain, bone, kidneys, GI tract, and the female reproductive system). However, it is thought to occur in small amounts or to be in-

---

### TABLE 7–1 Prostaglandins

<table>
<thead>
<tr>
<th>Prostaglandin</th>
<th>Locations</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>D₂</td>
<td>Airways, brain, mast cells</td>
<td>• Bronchoconstriction</td>
</tr>
<tr>
<td>E₂</td>
<td>Brain, kidneys, vascular smooth muscle cells, platelets</td>
<td>• Bronchodilation</td>
</tr>
<tr>
<td>F₂</td>
<td>Airways, eyes, uterus, vascular smooth muscle</td>
<td>• Gastroprotection</td>
</tr>
<tr>
<td>I₂ (Prostacyclin)</td>
<td>Brain, endothelium, kidneys, platelets</td>
<td>• Increased activity of GI smooth muscle</td>
</tr>
<tr>
<td>Thromboxane A₂</td>
<td>Kidneys, macrophages, platelets, vascular smooth muscle</td>
<td>• Increased sensitivity to pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased body temperature</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vasodilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Bronchoconstriction</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased activity of GI smooth muscle</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased uterine contraction (eg, menstrual cramps)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Decreased platelet aggregation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Gastroprotection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vasodilation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased platelet aggregation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vasoconstriction</td>
</tr>
</tbody>
</table>
**BOX 7–1 CHEMICAL MEDIATORS OF INFLAMMATION AND IMMUNITY**

*Bradykinin* is a kinin in body fluids that becomes physiologically active with tissue injury. When tissue cells are damaged, white blood cells (WBCs) increase in the area and ingest damaged cells to remove them from the area. When the WBCs die, they release enzymes that activate kinitins. The activated kinitins increase and prolong the vasodilation and increased vascular permeability caused by histamine. They also cause pain by stimulating nerve endings for pain in the area. Thus, bradykinin may aggravate and prolong the erythema, heat, and pain of local inflammatory reactions. It also increases mucous gland secretion.

**Complement** is a group of plasma proteins essential to normal inflammatory and immunologic processes. More specifically, complement destroys cell membranes of body cells (eg, red blood cells, lymphocytes, platelets) and pathogenic microorganisms (eg, bacteria, viruses). The system is initiated by an antigen–antibody reaction or by tissue injury. Components of the system (called C1 through C9) are activated in a cascade type of reaction in which each component becomes a proteolytic enzyme that splits the next component in the series. Activation yields products with profound inflammatory effects. C3a and C5a, also called anaphylatoxins, act mainly by liberating histamine from mast cells and platelets, and their effects are therefore similar to those of histamine. C3a causes or increases smooth muscle contraction, vascular permeability, degranulation of mast cells and basophils, and secretion of lysosomal enzymes by leukocytes. C5a performs the same functions as C3a and also promotes movement of WBCs into the injured area (chemotaxis). In addition, it activates the lipoxygenase pathway of arachidonic acid metabolism in neutrophils and macrophages, thereby inducing formation of leukotrienes and other substances that increase vascular permeability and chemotaxis.

In the immune response, the complement system breaks down antigen–antibody complexes, especially those in which the antigen is a microbial agent. It enables the body to produce inflammation and localize an infective agent. More specific reactions include increased vascular permeability, chemotaxis, and opsonization (coating a microbe or other antigen so it can be more readily phagocytized).

**Cytokines** may act on the cells that produce them, on surrounding cells, or on distant cells if sufficient amounts reach the bloodstream. Thus, cytokines act locally and systemically to produce inflammatory and immune responses, including increased vascular permeability and chemotaxis of macrophages, neutrophils, and basophils. Two major types of cytokines are interleukins (produced by leukocytes) and interferons (produced by T lymphocytes or fibroblasts). Interleukin-1 (IL-1) mediates several inflammatory responses, including fever, and IL-2 (also called T-cell growth factor) is required for the growth and function of T lymphocytes. Interferons are cytokines that protect nearby cells from invasion by intra-cellular microorganisms, such as viruses and rickettsiae. They also limit the growth of some cancer cells.

**Histamine** is formed (from the amino acid histidine) and stored in most body tissue, with high concentrations in mast cells, basophils, and platelets. Mast cells, which are abundant in skin and connective tissue, release histamine into the vascular system in response to stimuli (eg, antigen–antibody reaction, tissue injury, and some drugs). Once released, histamine is highly vasoactive, causing vasodilation (increasing blood flow to the area and producing hypotension) and increasing permeability of capillaries and venules (producing edema). Other effects include contracting smooth muscles in the bronchi (producing bronchoconstriction and respiratory distress), gastrointestinal (GI) tract, and uterus; stimulating salivary, gastric, bronchial, and intestinal secretions; stimulating sensory nerve endings to cause pain and itching; and stimulating movement of eosinophils into injured tissue. Histamine is the first chemical mediator released in the inflammatory response and immediate hypersensitivity reactions (anaphylaxis).

When histamine is released from mast cells and basophils, it diffuses rapidly into other tissues. It then acts on target tissues through both histamine-1 (H1) and histamine-2 (H2) receptors. H1 receptors are located mainly on smooth muscle cells in blood vessels and the respiratory and GI tracts. When histamine binds with these receptors, resulting events include contraction of smooth muscle, increased vascular permeability, production of nasal mucus, stimulation of sensory nerves, pruritus, and dilation of capillaries in the skin. H2 receptors are also located in the airways, GI tract, and other tissues. When histamine binds to these receptors, there is increased secretion of gastric acid by parietal cells in the stomach mucosal lining, increased mucus secretion and bronchodilation in the airways, contraction of esophageal muscles, tachycardia, inhibition of lymphocyte function, and degranulation of basophils (with additional release of histamine and other mediators) in the bloodstream. In allergic reactions, both types of receptors mediate hypotension (in anaphylaxis), skin flushing, and headache. The peak effects of histamine occur within 1 to 2 minutes of its release and may last as long as 10 minutes, after which it is inactivated by histaminase (produced by eosinophils) or N-methyltransferase.

**Platelet-activating factor (PAF),** like prostaglandins and leukotrienes, is derived from arachidonic acid metabolism and has multiple inflammatory activities. It is produced by mast cells, neutrophils, monocytes, and platelets. Because these cells are widely distributed, PAF effects can occur in virtually every organ and tissue. Besides causing platelet aggregation, PAF activates neutrophils, attracts eosinophils, increases vascular permeability, causes vasodilation, and causes IL-1 and tumor necrosis factor–alpha (TNF-alpha) to be released. PAF, IL-1, and TNF-alpha can induce each other’s release.
Box 7–2  Selected Conditions for Which Aspirin, Other NSAIDs, and Acetaminophen Are Commonly Used

<table>
<thead>
<tr>
<th>Condition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bursitis</td>
<td>Inflammation of a bursa (a cavity in connective tissue that contains synovial fluid; the fluid reduces friction between tendons and bones or ligaments). Common forms include acute painful shoulder, “tennis elbow,” “housemaid’s knee,” and bursions.</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>Pain associated with menstruation; thought to be caused by prostaglandins that increase contractility of the uterine muscle.</td>
</tr>
<tr>
<td>Gout</td>
<td>A disorder characterized by an inability to metabolize uric acid, a waste product of protein metabolism. The resulting hyperuricemia may be asymptomatic or may lead to urate deposits in various tissues. In the musculoskeletal system, often in the feet, urate deposits produce periodic episodes of severe pain, edema, and inflammation (gouty arthritis). In the kidneys, urate deposits may form renal calculi or cause other damage.</td>
</tr>
<tr>
<td>Migraine</td>
<td>A type of headache characterized by periodic attacks of pain, nausea, and increased sensitivity to light and sound. The pain is often worse on one side of the head, throbbing or pulsating in nature, moderate or severe in intensity, and disruptive of usual activities of daily living. The etiology is unknown, but one theory is that certain circumstances cause an imbalance of chemicals (e.g., serotonin, prostaglandins) in the brain. This imbalance results in vasodilation, release of inflammatory mediators, and irritation of nerve endings. Numerous circumstances have been implicated as “triggers” for the chemical imbalance and migraine, including alcohol (especially red wine), some foods (e.g., chocolate, aged cheeses), some medications (e.g., anti-hypertensives, oral contraceptives), irregular patterns of eating and sleeping, and physical and emotional stress. Migraine occurs more often in women than men and may be associated with menes.</td>
</tr>
<tr>
<td>Osteoarthritis (OA)</td>
<td>A disease that affects the cartilage of weight-bearing joints and produces pain, usually aggravated by movement, decreased range of motion, and progressive loss of mobility. As joint cartilage deteriorates over time, there is less padding and lubricating fluid, underlying bone is exposed, and friction and abrasion lead to inflammation of the synovial membrane lining of the joint. The joint becomes unstable, more susceptible to injury, and less efficient in repairing itself. Knee OA, a common type, often develops from repeated joint injury or repetitive motion. Pain in and around the knee occurs early in the disease process; joint stiffness, edema, and deformity occur as the disease advances.</td>
</tr>
<tr>
<td>Rheumatoid arthritis (RA)</td>
<td>A chronic, painful, inflammatory disorder that affects hingelike joints, tissues around these joints, and eventually other body organs (systemic effects). It is considered an autoimmune disorder in which the body attacks its own tissues. Juvenile rheumatoid arthritis is a chronic, inflammatory, systemic disease that may cause joint or connective tissue damage and visceral lesions throughout the body. Onset may occur before 16 years of age.</td>
</tr>
</tbody>
</table>

Aspirin and traditional NSAIDs also have antiplatelet effects that differ in mechanism and extent. When aspirin is absorbed into the bloodstream, the acetyl portion dissociates, then binds irreversibly to platelet COX-1. This action prevents synthesis of thromboxane A₂, a prostaglandin derivative, and thereby inhibits platelet aggregation. A small single dose (325 mg) irreversibly acetylates circulating platelets within a few minutes, and effects last for the lifespan of the platelets (7 to 10 days). Most other NSAIDs bind reversibly with platelet COX-1 so that antiplatelet effects occur only while the drug is present in the blood. Thus, aspirin has greater effects, but all the drugs except acetaminophen and the COX-2 inhibitors inhibit platelet aggregation, interfere with blood coagulation, and increase the risk of bleeding.

**Indications for Use**

These drugs are widely used to prevent and treat mild to moderate pain and/or inflammation associated with musculoskeletal disorders (e.g., osteoarthritis, tendinitis, gout), headache, dysmenorrhea, minor trauma (e.g., athletic injuries such as sprains), minor surgery (e.g., dental extraction, epistotomy), and other acute and chronic conditions. Despite many similarities, however, aspirin and other NSAIDs differ in their approved uses. Although aspirin is effective in many disorders, its usage has declined for most indications, largely because of adverse effects on the gastrointestinal system.
tract and the advent of newer drugs. At the same time, low-dose aspirin is increasingly prescribed for clients at risk of myocardial infarction or stroke from thrombosis. This indication stems from its antiplatelet activity and resultant effects on blood coagulation (ie, decreased clot formation). Some NSAIDs such as ibuprofen (Motrin) and related drugs are widely used as anti-inflammatory agents and analgesics; ketorolac (Toradol), which can be given orally and parenterally, is used only as an analgesic. Most of the other NSAIDs are too toxic to use as analgesics and antipyretics. They are used primarily in rheumatoid arthritis and other musculoskeletal disorders that do not respond to safer drugs. Celecoxib (Celebrex) is also used to treat familial adenomatous polyposis, in which the drug reduces the number of polyps and may decrease risks of colon cancer. Several NSAIDs are formulated as eye drops for use in treating eye disorders (see Chap. 65).

Acetaminophen, which differs chemically from aspirin and other NSAIDs, is commonly used as an aspirin substitute for pain and fever, but it lacks anti-inflammatory and antiplatelet effects.

**CONTRAINDICATIONS TO USE**

Contraindications to aspirin and nonselective NSAIDs include peptic ulcer disease, gastrointestinal (GI) or other bleeding disorders, history of hypersensitivity reactions, and impaired renal function. In people who are allergic to aspirin, nonaspirin NSAIDs also are contraindicated because hypersensitivity reactions may occur with any drugs that inhibit prostaglandin synthesis. In children and adolescents, aspirin is contraindicated in the presence of viral infections such as influenza or chickenpox because of its association with Reye’s syndrome. Selective COX-2 inhibitors are contraindicated for clients with a history of peptic ulcers, GI bleeding, asthma, an allergic reaction to other NSAIDs, or severe renal impairment. In addition, celecoxib and valdecoxib are contraindicated in clients
who are allergic to sulfonamides and ketorolac is contraindicated in clients at risk of excessive bleeding. Thus, ketorolac should not be administered during labor and delivery; before or during any major surgery; with suspected or confirmed cerebrovascular bleeding; or to clients who are currently taking aspirin or other NSAIDs.

Over-the-counter (OTC) products containing these drugs are contraindicated for chronic alcohol abusers because of possible liver damage (with acetaminophen) or stomach bleeding (with aspirin, ibuprofen, ketoprofen, or naproxen). The Food and Drug Administration (FDA) requires an alcohol warning on the labels of all OTC pain relievers and fever reducers. This warning states that people who drink three or more alcoholic drinks daily should ask their doctors before taking the products.

[Image 45x732 to 75x784]

**SUBGROUPS AND INDIVIDUAL DRUGS**

Sub-groups and selected individual drugs are described below; indications for use, trade names, and dosage ranges of individual drugs are listed in Drugs at a Glance: Analgesic, Antipyretic, Anti-inflammatory Drugs.

**Aspirin** is the prototype of the analgesic–antipyretic–anti-inflammatory drugs and the most commonly used salicylate. Because it is a nonprescription drug and is widely available, people tend to underestimate its usefulness. It is effective in pain of low to moderate intensity, especially that involving the skin, muscles, joints, and other connective tissue. It is useful in inflammatory disorders, such as arthritis, but many people prefer drugs that cause less gastric irritation.

Regular aspirin tablets are well absorbed after oral administration; their action starts within 15 to 30 minutes, peaks in 1 to 2 hours, and lasts 4 to 6 hours. Taking aspirin with food slows absorption, but also decreases gastric irritation. Absorption of enteric-coated aspirin and rectal suppositories is slower and less complete.

Aspirin is distributed to all body tissues and fluids, including fetal tissues, breast milk, and the central nervous system (CNS). The highest concentrations are found in the plasma, liver, heart, and lungs. In plasma, aspirin binds to albumin (75 to 90%). Aspirin has a short half-life of 15–20 minutes because it is rapidly converted to salicylic acid, an active metabolite. Salicylic acid has a half-life of 2 to 3 hours at low doses and 6 to 12 hours at therapeutic anti-inflammatory doses. It undergoes oxidation and conjugation in the liver and its metabolites are excreted through the kidneys. In alkaline urine (eg, pH of 8), renal excretion of salicylate is greatly increased.

Aspirin is a home remedy for headaches, colds, influenza and other respiratory infections, muscular aches, and fever. It can be purchased in plain, chewable, enteric-coated, and effervescent tablets and rectal suppositories. It is not marketed in liquid form because it is unstable in solution.

**Diflunisal** (Dolobid) is a salicylic acid derivative that differs chemically from aspirin. It is reportedly equal or superior to aspirin in mild to moderate pain, rheumatoid arthritis, and osteoarthritis. Compared with aspirin, it has less antipyretic effect, causes less gastric irritation, and has a longer duration of action.

**NSAIDs**

**Propionic acid derivatives** include fenoprofen (Nalfon), flurbiprofen (Ansaid), ibuprofen (Motrin, Advil), ketoprofen (Orudis), naproxen (Naprosyn), and oxaprozin (Daypro). In addition to their use as anti-inflammatory agents, some are used as analgesics and antipyretics. Ibuprofen, ketoprofen, and naproxen are available OTC, with recommended doses smaller and durations of use shorter than those for prescription formulations. Although these drugs are usually better tolerated than aspirin, they are much more expensive and may cause all the adverse effects associated with aspirin and other prostaglandin inhibitors.

**Ibuprofen**, a commonly used drug, is well absorbed with oral administration. Its action starts in about 30 minutes, peaks in 1 to 2 hours, and lasts 4 to 6 hours. The drug is highly bound (about 99%) to plasma proteins and has a half-life of about 2 hours. It is metabolized in the liver and excreted through the kidneys. It is available by prescription and OTC, in tablets, chewable tablets, capsules, oral suspension, and oral drops, for use by adults and children.

**Acetic acid derivatives** include indomethacin (Indocin), sulindac (Clinoril), and tolmetin (Tolectin). These drugs have strong anti-inflammatory effects and more severe adverse effects than the propionic acid derivatives. Potentially serious adverse effects include GI ulceration, bone marrow depression, hemolytic anemia, mental confusion, depression, and psychosis. These effects are especially associated with indomethacin; the other drugs were developed in an effort to find equally effective but less toxic derivatives of indomethacin. Although adverse reactions occur less often with sulindac and tolmetin, they are still common.

In addition to other uses, intravenous (IV) indomethacin is approved for treatment of patent ductus arteriosus in premature infants. (The ductus arteriosus joins the pulmonary artery to the aorta in the fetal circulation. When it fails to close, blood is shunted from the aorta to the pulmonary artery, causing severe cardiopulmonary problems.)

Other drugs related to this group are etodolac (Lodine), ketorolac (Toradol), and nabumetone (Relafen). Etodolac reportedly causes less gastric irritation, especially in older adults at high risk for GI bleeding. Ketorolac is used only for pain, and although it can be given orally, its unique characteristic is that it can be given by injection. Parenteral ketorolac reportedly compares with morphine and other opioids in analgesic effectiveness for moderate or severe pain. However, its use is limited to 5 days because it increases the risk of bleeding. Hematomas and wound bleeding have been reported with postoperative use.

**Oxicam** drugs include meloxicam (Mobic) and piroxicam (Feldene). Meloxicam has a serum half-life of 15 to 20 hours (text continues on page 108)
### Drugs at a Glance: Analgesic, Antipyretic, Anti-inflammatory Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acetaminophen</strong> (Tylenol, others)</td>
<td>Pain, Fever</td>
<td>Adults: PO 325–650 mg q4–6h, or 1000 mg three or four times per day; maximum 4 g/d</td>
<td>Warning: Overdoses may cause fatal liver damage. Maximum recommended dose for adults is 4 g/d from all sources. Parents and caregivers should ask pediatricians about the amounts of acetaminophen children may take safely.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Children: PO 10 mg/kg or according to age as follows: 0–3 mo: 40 mg; 4–11 mo: 80 mg; 1–2 y: 120 mg; 2–3 y: 160 mg; 4–5 y: 240 mg; 6–8 y: 320 mg; 9–10 y: 400 mg; 11 y: 480 mg. Doses may be given q4–6h to a maximum of 5 doses in 24 h.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rectal suppository: 650 mg q4–6h, maximum of 6 in 24 h</td>
<td></td>
</tr>
<tr>
<td><strong>Aspirin</strong></td>
<td>Pain, Fever, Osteoarthritis (OA), rheumatoid arthritis (RA), Prophylaxis of myocardial infarction (MI), transient ischemic attacks (TIAs) and stroke in men, Rheumatic fever</td>
<td>Pain, Fever: PO 325–650 mg q4h PRN; usual single dose, 650 mg</td>
<td>Therapeutic serum level of salicylate is 100–300 mcg/mL for treatment of arthritis and rheumatic fever; toxicity occurs at levels above 300 mcg/mL.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OA, RA: PO 2–6 g/d in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prophylaxis of MI, TIA, and stroke: PO 81–325 mg/d</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acute rheumatic fever: PO 5–8 g/d, in divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>TIAs, PO 1300 mg/d in divided doses (650 mg twice a day or 325 mg four times a day)</td>
<td></td>
</tr>
<tr>
<td><strong>Celecoxib</strong> (Celebrex)</td>
<td>Osteoarthritis, Rheumatoid arthritis, Familial adenomatous polyposis (FAP)</td>
<td>OA: PO 100 mg twice daily or 200 mg once daily</td>
<td>Dosage not established</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RA: PO 100–200 mg twice daily</td>
<td>200-mg doses should be taken with food</td>
</tr>
<tr>
<td><strong>Diclofenac potassium</strong> (Cataflam)</td>
<td>Osteoarthritis, Rheumatoid arthritis</td>
<td>OA: PO 100–150 mg/d in divided doses (eg, 50 mg two or three times or 75 mg twice or 100 mg once daily)</td>
<td>Dosage not established</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RA: PO 150–200 mg/d in two, three or four divided doses</td>
<td>Diclofenac potassium is available only in 50-mg immediate-release tablets. It may be used for all indications.</td>
</tr>
<tr>
<td><strong>Diclofenac sodium</strong> (Voltaren, Voltaren XR)</td>
<td>Osteoarthritis, Rheumatoid arthritis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Analgesic, Antipyretic, Anti-inflammatory Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diflunisal (Dolobid)</td>
<td>Ankylosing spondylitis (AS) Pain, dysmenorrhea</td>
<td>Adults: FO 100–125 mg/d in four or five divided doses (eg, 25 mg four or five times daily) Pain, dysmenorrhea: (diclofenac potassium only) PO 50 mg three times daily</td>
<td>Not recommended for use in children &lt;12 years of age</td>
</tr>
<tr>
<td>Etodolac (Lodine, Lodine XL)</td>
<td>Osteoarthritis Rheumatoid arthritis Pain</td>
<td>OA, RA: PO 500–1000 mg/d, in two divided doses, increased to a maximum of 1500 mg/d if necessary Pain: PO 500–1000 mg initially, then 250–500 mg q8–12h</td>
<td>Dosage not established Available in immediate-release and extended-release (XL) tablets of various strengths. The immediate-release forms should be used to treat acute pain.</td>
</tr>
<tr>
<td>Fenoprofen (Nalfon)</td>
<td>Osteoarthritis Rheumatoid arthritis Pain</td>
<td>OA, RA: PO 300–600 mg three or four times per day Pain: PO 200 mg q4–6h PRN Maximum, 3200 mg/d</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Flurbiprofen (Ansaid)</td>
<td>Osteoarthritis Rheumatoid arthritis Pain</td>
<td>OA, RA: PO 200–300 mg/d in two, three, or four divided doses</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Ibuprofen (Advil, Motrin, PediaCare)</td>
<td>Osteoarthritis Rheumatoid arthritis Pain, dysmenorrhea Fever</td>
<td>OA, RA: PO 300–600 mg 3 or 4 times per day; maximum, 2400 mg/d Pain, dysmenorrhea: PO 400 mg q4–6h PRN Maximum, 3200 mg/d</td>
<td>1–12 y: Fever, initial temperature 39.2°C (102.5°F) or less, PO 5 mg/kg q6–8h; initial temperature above 39.2°C (102.5°F), PO 10 mg/kg q6–8h; maximum dose, 40 mg/kg/d Juvenile arthritis, PO 20–40 mg/kg/d, in three or four divided doses</td>
</tr>
<tr>
<td>Indomethacin (Indocin, Indocin SR)</td>
<td>Osteoarthritis Rheumatoid arthritis Ankylosing spondylitis Tendinitis Bursitis Acute painful shoulder Acute gout Closure of patent ductus arteriosus (IV only)</td>
<td>PO, rectal suppository, 75 mg/d initially, increased by 25 mg/d at weekly intervals to a maximum of 150–200 mg/d, if necessary Premature infants with patent ductus arteriosus, IV 0.2–0.3 mg/kg q12h for a total of three doses</td>
<td>The sustained-release form is not recommended for acute gouty arthritis.</td>
</tr>
<tr>
<td>Generic/Trade Name</td>
<td>Indications for Use</td>
<td>Routes and Dosage Ranges</td>
<td>Comments</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------</td>
<td>--------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Ketoprofen (Orudis, Oruvail)</strong></td>
<td>Pain, dysmenorrhea, OA, RA</td>
<td>PO 25–50 mg q6–8h PRN</td>
<td>Do not give to children &lt;16 years unless directed by a physician.</td>
</tr>
<tr>
<td></td>
<td>Osteoarthritis</td>
<td>PO 150–300 mg/d in three or four divided doses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
<td>Sustained-release (Oruvail SR), 200 mg once daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximum, 300 mg/d for regular formulation; 200 mg/d for extended release; 100–150 mg/d for clients with impaired renal function</td>
<td></td>
</tr>
<tr>
<td><strong>Ketorolac (Toradol)</strong></td>
<td>Moderately severe, acute pain, for short term (up to 5 days) treatment</td>
<td>IV, IM 30 mg q8h PRN to a maximum of 120 mg/d</td>
<td>Treatment is started with one or more injected doses, followed by oral doses when the client is able to take them. Maximum duration of both injected and oral doses, 5 days.</td>
</tr>
<tr>
<td><strong>Meloxicam (Mobic)</strong></td>
<td>Osteoarthritis</td>
<td>PO 7.5 once daily; increased to 15 mg once daily if necessary</td>
<td>May be taken without regard to meals</td>
</tr>
<tr>
<td><strong>Nabumetone (Relafen)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis</td>
<td>PO 1000–2000 mg/day in one or two doses</td>
<td></td>
</tr>
<tr>
<td><strong>Naproxen (Naprosyn)</strong></td>
<td>Osteoarthritis</td>
<td>Naproxen: PO 250–500 mg twice daily</td>
<td></td>
</tr>
<tr>
<td><strong>Naproxen sodium (Aleve, Anaprox, Naprelan)</strong></td>
<td>Rheumatoid arthritis, Juvenile arthritis, Ankylosing spondylitis, Pain, Dysmenorrhea, Bursitis, Tendinitis, Acute gout</td>
<td>Gout: PO 750 mg initially, then 250 mg q8h until symptoms subside</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximum, 1250 mg/d</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Naproxen sodium: Pain, dysmenorrhea, acute tendinitis, bursitis: PO 550 mg q12h or 275 mg q6–8h</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maximum, 1375 mg/d</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>OA, RA, AS: PO 275–550 mg twice a day</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acute gout: PO 825 mg initially, then 275 mg q8h until symptoms subside</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Controlled-release (Naprelan), 750–1000 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>
and is excreted about equally through urine and feces. Piroxicam has a half-life of about 50 hours. The long half-lives allow the drugs to be given once daily, but optimal efficacy may not occur for 1 to 2 weeks.  

**Diclofenac sodium** (Voltaren) is chemically different from but pharmacologically similar to other NSAIDs. Formulations are delayed or extended-release and onset of action is therefore delayed. Peak action occurs in about 2 hours and effects last 12 to 15 hours. As a result, the potassium salt may be given for rapid relief of pain and primary dysmenorrhea. Diclofenac has a serum half-life of about 2 hours and is excreted mainly in the urine.

**Cyclooxygenase-2 inhibitors** block production of prostaglandins associated with pain and inflammation without blocking those associated with protective effects on gastric mucosa. Thus, they produce less gastric irritation than aspirin and other NSAIDs. In addition, they are not associated with increased risks of bleeding because they do not have the antiplatelet effects of aspirin and other NSAIDs. Despite the relative safety of these drugs, there have been a few cases reported in which hypertension was acutely worsened by the drugs (blood pressure returned to previous levels when the drugs were discontinued; the drugs do not raise blood pressure in normotensive clients) and some clients receiving a COX-2 inhibitor had a small increase in the incidence of myocardial infarction and stroke due to thrombosis, compared with clients receiving a nonselective NSAID (naproxen) or placebo. These concerns are being investigated.

**Celecoxib** (Celebrex) is well absorbed with oral administration; peak plasma levels and peak action occur approximately 3 hours after an oral dose. This drug is highly protein bound (97%) and its serum half-life is about 11 hours. It is metabolized by the cytochrome P450 enzymes in the liver to inactive metabolites that are then excreted in the urine. A small amount is excreted unchanged in the urine. Rofecoxib (Vioxx) acts within 45 minutes and peaks in 2 to 3 hours. It is 87% protein bound and has a half-life of 17 hours. It is metabolized in the liver and excreted in urine and feces. Valdecoxib (Bextra) is a newer COX-2 inhibitor; others are being developed.

---

### Drugs at a Glance: Analgesic, Antipyretic, Anti-inflammatory Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxaprozin (Daypro)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis</td>
<td>PO 600–1200 mg once daily Maximum, 1800 mg/d or 26 mg/kg/d, whichever is lower, in divided doses</td>
<td>Lower doses recommended for patients with low body weight or milder disease</td>
</tr>
<tr>
<td><strong>Piroxicam (Feldene)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis</td>
<td>PO 20 mg/d or 10 mg twice daily</td>
<td>Dosage not established</td>
</tr>
<tr>
<td><strong>Rofecoxib (Vioxx)</strong></td>
<td>Osteoarthritis, Pain, Dysmenorrhea</td>
<td>PO 12.5–25 mg once daily Acute pain, dysmenorrhea: PO 50 mg once daily as needed</td>
<td>Dosage not established</td>
</tr>
<tr>
<td><strong>Sulindac (Clinoril)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis, Ankylosing spondylitis, Bursitis, Tendinitis, Acute painful shoulder, Acute gout</td>
<td>PO 150–200 mg twice a day; maximum, 400 mg/d Acute gout, acute painful shoulder: PO 200 mg twice a day until pain and inflammation subside (eg, 7–14 d), then reduce dosage or discontinue</td>
<td>Dosage not established</td>
</tr>
<tr>
<td><strong>Tolmetin (Tolectin)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis, Juvenile rheumatoid arthritis</td>
<td>PO 400 mg three times daily initially, increased to 1800 mg/d if necessary Juvenile RA: PO 20 mg/kg/d in three or four divided doses</td>
<td></td>
</tr>
<tr>
<td><strong>Valdecoxib (Bextra)</strong></td>
<td>Osteoarthritis, Rheumatoid arthritis, Dysmenorrhea</td>
<td>PO 10 mg once daily Dysmenorrhea: PO 20 mg twice daily as needed</td>
<td>Dosage not established</td>
</tr>
</tbody>
</table>
Acetaminophen (also called APAP, an abbreviation for N-Acetyl-P-Aminophenol) is a nonprescription drug commonly used as an aspirin substitute because it does not cause nausea, vomiting, or GI bleeding, and it does not interfere with blood clotting. It is equal to aspirin in analgesic and antipyretic effects, but it lacks anti-inflammatory activity.

Acetaminophen is well absorbed with oral administration and peak plasma concentrations are reached within 30 to 120 minutes. Duration of action is 3 to 4 hours. Acetaminophen is metabolized in the liver; approximately 94% is excreted in the urine as inactive glucuronate and sulfate conjugates. Approximately 4% is metabolized to a toxic metabolite, which is normally inactivated by conjugation with glutathione and excreted in urine. With usual therapeutic doses, a sufficient amount of glutathione is available in the liver to detoxify acetaminophen. In acute or chronic overdose situations, however, the supply of glutathione may become depleted. In the absence of glutathione, the toxic metabolite combines with liver cells and causes damage or fatal liver necrosis. In people who abuse alcohol, usual therapeutic doses may cause or increase liver damage. The probable mechanism for increased risk of hepatotoxicity in this population is that ethanol induces drug-metabolizing enzymes in the liver. The resulting rapid metabolism of acetaminophen produces enough toxic metabolite to exceed the available glutathione.

Acetaminophen is available in tablet, liquid, and rectal suppository forms and is in numerous combination products marketed as analgesics and cold remedies. It is often prescribed with codeine, hydrocodone, or oxycodone for added analgesic effects.

### Drugs Used in Gout and Hyperuricemia

Individual drugs are described below; dosages are listed in Drugs at a Glance: Drugs for Gout.

**Allopurinol** (Zyloprim) is used to prevent or treat hyperuricemia, which occurs with gout and with antineoplastic drug therapy. Uric acid is formed by purine metabolism and an enzyme called xanthine oxidase. Allopurinol prevents formation of uric acid by inhibiting xanthine oxidase. It is especially useful in chronic gout characterized by tophi (deposits of uric acid crystals in the joints, kidneys, and soft tissues) and impaired renal function. The drug promotes resorption of urate deposits and prevents their further development. Acute attacks of gout may result when urate deposits are mobilized. These may be prevented by concomitant administration of colchicine until serum uric acid levels are lowered.

**Colchicine** is an anti-inflammatory drug used to prevent or treat acute attacks of gout. In acute attacks, it is the drug of choice for relieving joint pain and edema. Colchicine decreases inflammation by decreasing the movement of leukocytes into body tissues containing urate crystals. It has no analgesic or antipyretic effects.

**Probenecid** (Benemid) increases the urinary excretion of uric acid. This uricosuric action is used therapeutically to treat hyperuricemia and gout. It is not effective in acute attacks of gouty arthritis but prevents hyperuricemia and tophi associated with chronic gout. Probenecid may precipitate acute gout until serum uric acid levels are within the normal range; concomitant administration of colchicine prevents this effect. (Probenecid also is used with penicillin, most often in treating sexually transmitted diseases. It increases blood levels and prolongs the action of penicillin by decreasing the rate of urinary excretion.)

**Sulfinpyrazone** (Anturane) is a uricosuric agent similar to probenecid. It is not effective in acute gout but prevents or decreases tissue changes of chronic gout. Colchicine is usually given during initial sulfinpyrazone therapy to prevent acute gout.

### Drugs at a Glance: Drugs for Gout

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allopurinol</strong> (Zyloprim)</td>
<td>Adults</td>
</tr>
<tr>
<td>Mild gout, PO 200–400 mg/d</td>
<td></td>
</tr>
<tr>
<td>Severe gout, PO 400–600 mg/d</td>
<td></td>
</tr>
<tr>
<td>Hyperuricemia in clients with renal insufficiency, PO 100–200 mg/d</td>
<td></td>
</tr>
<tr>
<td><strong>Colchicine</strong></td>
<td>Acute attacks, PO 0.5 mg q1h until pain is relieved or toxicity (nausea, vomiting, diarrhea) occurs; 3-d interval between courses of therapy</td>
</tr>
<tr>
<td>IV 1–2 mg initially, then 0.5 mg q3–6h until response is obtained; maximum total dose 4 mg</td>
<td></td>
</tr>
<tr>
<td>Prophylaxis, PO 0.5–1 mg/d</td>
<td></td>
</tr>
<tr>
<td><strong>Probenecid</strong> (Benemid)</td>
<td>PO 250 mg twice a day for 1 wk, then 500 mg twice a day</td>
</tr>
<tr>
<td><strong>Sulfinpyrazone</strong> (Anturane)</td>
<td>PO 100–200 mg twice a day, gradually increased over 1 wk to a maximum of 400–800 mg/d</td>
</tr>
</tbody>
</table>

### Drugs for Migraine

Individual drugs are described below; dosages are listed in Drugs at a Glance: Drugs for Migraine.

**Almotriptan** (Axert), **frovatriptan** (Frova), **naratriptan** (Amerge), **rizatriptan** (Maxalt), **sumatriptan** (Imitrex), and **zolmitriptan** (Zomig), called “triptans,” were developed...
They are called selective serotonin 5-HT receptor agonists specifically for the treatment of moderate or severe migraines.

### Serotonin agonists (Triptans)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Almotriptan</strong> (Axert)</td>
<td>PO 6.25 mg, repeat after 2 h if necessary; Maximum, 12.5 mg/24h</td>
</tr>
<tr>
<td><strong>Naratriptan</strong> (Amerge)</td>
<td>PO 1–2.5 mg as a single dose; repeat in 4 h if necessary; Maximum, 5 mg/d</td>
</tr>
<tr>
<td><strong>Rizatriptan</strong> (Maxalt)</td>
<td>PO 5–10 mg as a single dose; repeat after 2 h if necessary; Maximum dose, 30 mg/d</td>
</tr>
<tr>
<td><strong>Sumatriptan</strong> (Imitrex)</td>
<td>PO 25–100 mg as a single dose. Maximum dose, 300 mg/d; SC 6 mg as a single dose. Maximum, 12 mg/d</td>
</tr>
<tr>
<td><strong>Zolmitriptan</strong> (Zomig)</td>
<td>PO 1.25–2.5 mg as a single dose; may repeat after 2 h if necessary. Maximum dose, 10 mg/d</td>
</tr>
</tbody>
</table>

### Ergot Preparations

**Ergotamine tartrate** (Ergomar) PO, sublingually, 1–2 mg at onset of migraine, then 2 mg q30 min, if necessary, to a maximum of 6 mg/24 h or 10 mg/wk

**Ergotamine tartrate and caffeine** (Cafergot)

**Adults:** PO 2 tablets at onset of migraine, then 1 tablet q30 min, if necessary, up to 6 tablets per attack or 10 tablets/wk

**Children:** PO 0.5–1 tablet initially, then 0.5 tablet q30 min, if necessary, to a maximum of three tablets

**Dihydroergotamine mesylate** (DHE 45)

**IM** 1 mg at onset of migraine, may be repeated hourly, if necessary, to a total of 3 mg

**IV** 1 mg, repeated, if necessary, after 1 h; maximum dose 2 mg. Do not exceed 6 mg/wk.

Specifically for the treatment of moderate or severe migraines. They are called selective serotonin 5-HT receptor agonists because they act on a specific subtype of serotonin receptor to increase serotonin (5-hydroxytryptamine or 5-HT) in the brain. They relieve migraine by constricting blood vessels. Because of their vasoconstrictive properties, the drugs are contraindicated in clients with a history of angina pectoris, myocardial infarction, or uncontrolled hypertension. The drugs vary in onset of action, with subcutaneous sumatriptan acting the most rapidly and starting to relieve migraine headache within 10 minutes. Most clients get relief within 1 to 2 hours with all of the oral drugs. The drugs are metabolized in the liver by monoamine oxidase or cytochrome P450 enzymes; specifically for the treatment of moderate or severe migraines. They are called selective serotonin 5-HT receptor agonists because they act on a specific subtype of serotonin receptor to increase serotonin (5-hydroxytryptamine or 5-HT) in the brain.

### Ergotamine tartrate

Ergotamine tartrate (Ergomar) is an ergot alkaloid used only in the treatment of migraine. Ergot preparations relieve migraine by constricting blood vessels. Ergotamine is most effective when given sublingually or by inhalation at the onset of headache. When given orally, ergotamine is erratically absorbed, and therapeutic effects may be delayed for 20 to 30 minutes. Ergotamine is contraindicated during pregnancy and in the presence of severe hypertension, peripheral vascular disease, coronary artery disease, renal or hepatic disease, and severe infections.

**Ergotamine tartrate and caffeine** (Cafergot) is a commonly used antimigraine preparation. Caffeine reportedly increases the absorption and vasoconstrictive effects of ergotamine. Dihydroergotamine mesylate (DHE 45) is a semisynthetic derivative of ergotamine that is less toxic and less effective than the parent drug.

**Herbal and Dietary Supplements**

In addition to the drugs described above, many herbal medicines are used to relieve pain and/or inflammation. For most of these (eg, comfrey, marigold, peppermint, primrose), such usage is anecdotal and unsupported by clinical studies. For a few supplements, there is some evidence of effectiveness with few adverse effects; these are described below.

**Chondroitin sulfate** (CS), a supplement extracted from animal cartilage or manufactured synthetically and used to treat arthritis, is thought to delay the breakdown of joint cartilage (by inhibiting elastase, a proteolytic enzyme found in synovial membranes), to stimulate synthesis of new cartilage (by stimulating chondrocytes to produce collagen and proteoglycan), and to promote the “shock-absorbing” quality of cartilage (by retaining water).

Chondroitin is a normal component of joint cartilage, which contains water (65 to 80%), collagen, proteoglycans, and chondrocytes that produce new collagen and proteoglycans. CS was first used as a dietary supplement because studies suggested that it would promote healing of cartilage damaged by inflammation or injury. The daily dose is based on the client’s weight: under 120 lbs, 800 mg CS; 120 to 200 lbs, 1200 mg CS; over 200 lbs, 1600 mg CS. CS is usually taken with food, in two to four divided doses.

Proponents of CS cite clinical trials that indicate beneficial effects. For example, one study cited by Fetrow and Avila compared CS with diclofenac sodium, an NSAID, in 146 clients with osteoarthritis of the knee. The authors concluded that the NSAID relieved pain faster but the effects of CS lasted longer, up to 3 months after treatment. Proponents also tout the safety of CS in comparison with the adverse effects of NSAIDs. The main adverse effects are reportedly minor stomach upset. In addition, there is a theoretical risk of bleeding because of the
General Considerations

Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin) are used to relieve pain, fever, and inflammation. Aspirin is as effective as the more costly NSAIDs, but is more likely to cause stomach irritation and bleeding problems. This advantage of NSAIDs may be minimal if high doses are taken.

Because these drugs are so widely used and available, there is a high risk of overdosing on different products containing the same drug or products containing similar drugs. Knowing drug names, reading product labels, and using the following precautions can increase safety in using these drugs:

1. If you are taking aspirin or an NSAID regularly for pain or inflammation, generally avoid taking additional aspirin in over-the-counter (OTC) aspirin or products containing aspirin (eg, Alka-Seltzer, Anacin, Arthritis Pain Formula, Ascriptin, Bufferin, Doan’s Pills/Caplets, Ecotrin, Excedrin, Midol, Vanquish). There are two exceptions if you are taking a small dose of aspirin daily (usually 81–325 mg), to prevent heart attack and stroke. First, you should continue taking the aspirin if Celebrex, Vioxx, or Bextra is prescribed. Second, it is generally safe to take occasional doses of aspirin or an NSAID for pain or fever.

2. If you are taking any prescription NSAID regularly, avoid OTC products containing ibuprofen (eg, Advil, Dristan Sinus, Midol IB, Motrin IB, Sine-Aid IB), ketoprofen (Actron, Orudis KT), or naproxen (Aleve). Also, do not combine the OTC products with each other or with aspirin. These drugs are available as both prescription and OTC products. OTC ibuprofen is the same medication as prescription Motrin; OTC naproxen is the same as prescription Naprosyn; OTC ketoprofen is the same as prescription Orudis. Recommended doses are smaller for OTC products than for prescription drugs. However, any combination of these drugs could constitute an overdose.

With NSAIDs, if one is not effective, another one may work because people vary in responses to the drugs. Improvement of symptoms depends on the reason for use. When taken for pain, the drugs usually act within 30 to 60 minutes; when taken for inflammatory disorders, such as arthritis, improvement may occur within 24 to 48 hours with aspirin and 1 to 2 weeks with other NSAIDs.

Taking a medication for fever is not usually recommended unless the fever is high or is accompanied by other symptoms. Fever is one way the body fights infection.

Do not take OTC ibuprofen more than 3 days for fever or 10 days for pain. If these symptoms persist or worsen, or if new symptoms develop, contact a health care provider.

Avoid aspirin for approximately 2 weeks before and after major surgery or dental work to decrease the risk of excessive bleeding. If pregnant, do not take aspirin for approximately 2 weeks before the estimated delivery date.

Inform any health care provider if taking aspirin, ibuprofen, or any other NSAID regularly.

Inform health care providers if you have ever had an allergic reaction (eg, asthma, difficulty in breathing, hives) or severe GI symptoms (eg, ulcer, bleeding) after taking aspirin, ibuprofen, or similar drugs.

Avoid or minimize alcoholic beverages because alcohol increases gastric irritation and risks of bleeding. The Food and Drug Administration requires an alcohol warning on the labels of OTC pain and fever relievers and urges people who drink three or more alcoholic drinks every day to ask their doctors before using the products.

To avoid accidental ingestion and aspirin poisoning, store aspirin in a closed childproof container and keep out of children’s reach.

Self-Administration

Take aspirin, ibuprofen, and other NSAIDs with a full glass of liquid and food to decrease stomach irritation. Rofecoxib (Vioxx) and meloxicam (Mobic) may be taken without regard to food.

Swallow enteric-coated aspirin (eg, Ecotrin) whole; do not chew or crush. The coating is applied to decrease stomach irritation by making the tablet dissolve in the intestine. Also, do not take with an antacid, which can cause the tablet to dissolve in the stomach.

Swallow any long-acting pills or capsules whole; do not chew or crush. These include diclofenac sodium (Voltaren or Voltaren XR); diflunisal (Dolobid); etodolac (Lodine XL); ketoprofen or Oruvail extended release capsules; naproxen delayed-release (EC-Naprosyn) or controlled-release (Naprelan) tablets.

Note: These are prescription drugs and most are also available in short-acting products; if unsure whether the medicine you are taking is long-acting, ask a health care provider.

Drink 2–3 quarts of fluid daily when taking an NSAID regularly. This decreases gastric irritation and helps to maintain good kidney function.

Report signs of bleeding (eg, nose bleed, vomiting blood, bruising, blood in urine or stools), difficulty breathing, skin rash or hives, ringing in ears, dizziness, severe stomach upset, or swelling and weight gain.

Acetaminophen

Acetaminophen is often the initial drug of choice for relieving mild-to-moderate pain and fever because it is effective and does not cause gastric irritation or bleeding. It may be taken on an empty stomach.

Acetaminophen is an effective aspirin substitute for pain or fever but not for inflammation or preventing heart attack or stroke.

Acetaminophen is available in its generic form and with many OTC brand names (eg, Tylenol). Most preparations...
Joint connective tissue. With osteoarthritis (OA), glucosamine is an essential structural component of the cartilage matrix. Thus, all consumers should read product labels carefully to avoid taking the drug in several products, with potential overdoses.

- **Do not exceed recommended doses.** For occasional pain or fever, 650–1000 mg may be taken three or four times daily. For daily, long-term use (eg, in osteoarthritis), do not take more than 4000 mg (eg, eight 500 mg or extra-strength tablets or capsules) daily. Larger doses may cause life-threatening liver damage. People who have hepatitis or other liver disorders and those who ingest alcoholic beverages frequently should take no more than 2000 mg daily.
- **Do not exceed recommended duration of use** (longer than 5 days in children, 10 days in adults, or 3 days for fever in adults and children) without consulting a physician.
- **Avoid or minimize alcoholic beverages** because alcohol increases risk of liver damage. The Food and Drug Administration requires an alcohol warning on the labels of OTC pain relievers because alcoholic beverages frequently are taken with them.

Glucosamine, a synthetic supplement, is also taken for arthritis. Glucosamine is an essential structural component of joint connective tissue. With osteoarthritis (OA), glucosamine production is decreased, synovial fluid becomes thin and less effective in lubricating the joint, and joint cartilage deteriorates. The rationale for taking supplementary glucosamine is to reduce cartilage breakdown and improve cartilage production and repair.

Some studies indicate that glucosamine may decrease mild to moderate OA pain in some patients, possibly as well as NSAIDs; other studies indicate little or no benefit when glucosamine is compared with placebo. There is controversy about glucosamine’s ability to affect cartilage structure and delay joint deterioration. Most studies are criticized as being too small, of too short duration, and of having flawed designs. A study of 212 patients with knee OA indicated that long-term use of glucosamine improves symptoms and prevents changes in joint structure. These patients took 1500 mg of glucosamine sulfate or placebo once a day for 3 years; radiographs of the knees were taken before starting glucosamine and after 1 and 3 years of treatment. The researchers concluded that significant improvement of symptoms and less joint deterioration occurred in clients receiving glucosamine.

Glucosamine is available as a hydrochloride salt and as a sulfate salt. Most studies have been done with glucosamine sulfate (GS), which is the preferred form. Dosage is based on the client’s weight: under 120 lbs, 1000 mg GS; 120 to 200 lbs, 1500 mg GS; over 200 lbs, 2000 mg GS. The total daily dosage is usually taken with food in two to four divided doses.
There are no known contraindications to the use of glucosamine, but it should be avoided during pregnancy and lactation and in children, because effects are unknown. Adverse effects include GI upset (eg, epigastric pain, heartburn, nausea, constipation, diarrhea), drowsiness, headache, and skin rash. No interactions with OTC or prescription drugs have been reported.

**Glucosamine and chondroitin** can each be used alone, but are more often taken in combination, with the same dosages as listed above. Use of this combination greatly increased after it was highly praised in *The Arthritis Cure* by J. Theodosakis.

As with studies of the individual components, many of the studies involving glucosamine and chondroitin are flawed. The American College of Rheumatology and the Arthritis Foundation do not recommend the use of these supplements because they do not believe reported research studies adequately demonstrate significant relief of symptoms or slowing of the disease process. These organizations say longer clinical trials with larger groups of people are needed. When questioned by clients, some physicians suggest taking the supplement for 3 months (glucosamine 500 mg and chondroitin 400 mg 3 times a day) and decide for themselves whether their symptoms improve (eg, less pain, improved ability to walk) and whether they want to continue.

### Nursing Process

#### Assessment

- Assess for signs and symptoms of pain, such as location, severity, duration, and factors that cause or relieve the pain (see Chap. 6).
- Assess for fever (thermometer readings above 99.6°F [37.3°C] are usually considered fever). Hot, dry skin; flushed face; reduced urine output; and concentrated urine may accompany fever if the person also is dehydrated.
- Assess for inflammation. Local signs are redness, heat, edema, and pain or tenderness; systemic signs include fever, elevated white blood cell count (leukocytosis), and weakness.
- With arthritis or other musculoskeletal disorders, assess for pain and limitations in activity and mobility.
- Ask about use of OTC analgesic, antipyretic, or anti-inflammatory drugs and herbal or dietary supplements.
- Ask about allergic reactions to aspirin or NSAIDs.
- Assess for history of peptic ulcer disease, GI bleeding, or kidney disorders.
- With migraine, assess severity and patterns of occurrences.

#### Nursing Diagnoses

- Acute Pain
- Chronic Pain

- Activity Intolerance related to pain
- Risk for Poisoning: Acetaminophen overdose
- Risk for Injury related to adverse drug effects (GI bleeding, renal insufficiency)
- Deficient Knowledge: Therapeutic and adverse effects of commonly used drugs
- Deficient Knowledge: Correct use of OTC drugs for pain, fever, and inflammation

### Planning/Goals

**The client will:**

- Experience relief of discomfort with minimal adverse drug effects
- Experience increased mobility and activity tolerance
- Inform health care providers if taking aspirin or an NSAID regularly
- Self-administer the drugs safely
- Avoid overuse of the drugs
- Use measures to prevent accidental ingestion or overdose, especially in children
- Experience fewer and less severe attacks of migraine

### Interventions

Implement measures to prevent or minimize pain, fever, and inflammation:

- Treat the disease processes (eg, infection, arthritis) or circumstances (eg, impaired blood supply, lack of physical activity, poor positioning or body alignment) thought to be causing pain, fever, or inflammation
- Treat pain as soon as possible; early treatment may prevent severe pain and anxiety and allow the use of milder analgesic drugs. Use distraction, relaxation techniques, other nonpharmacologic techniques along with drug therapy, when appropriate.
- With acute musculoskeletal injuries (eg, sprains), cold applications can decrease pain, swelling, and inflammation. Apply for approximately 20 minutes, then remove.
- Assist clients with migraine to identify and avoid “triggers.” Assist clients to drink 2 to 3 L of fluid daily when taking an NSAID regularly. This decreases gastric irritation and helps to maintain good kidney function. With long-term use of aspirin, fluids help to prevent precipitation of salicylate crystals in the urinary tract. With antigout drugs, fluids help to prevent precipitation of urate crystals and formation of urate kidney stones. Fluid intake is especially important initially when serum uric acid levels are high and large amounts of uric acid are being excreted.

### Evaluation

- Interview and observe regarding relief of symptoms.
- Interview and observe regarding mobility and activity levels.
- Interview and observe regarding safe, effective use of the drugs.
- Select drugs appropriately.
CLIENT TEACHING GUIDELINES

Drugs for Migraine

General Considerations
✔ Try to identify and avoid situations known to precipitate acute attacks of migraine.
✔ For mild or infrequent migraine attacks, acetaminophen, aspirin, or another nonsteroidal anti-inflammatory drug may be effective.
✔ For moderate to severe migraine attacks, the drug of first choice is probably sumatriptan (Imitrex) or a related drug, if not contraindicated (eg, by heart disease or hypertension). However, one of these drugs should not be taken if an ergot preparation has been taken within the previous 24 hours.
✔ If you have frequent or severe migraine attacks, consult a physician about medications to prevent or reduce the frequency of acute attacks.
✔ Never take an antimigraine medication prescribed for someone else or allow someone else to take yours. The medications used to relieve acute migraine can constrict blood vessels, raise blood pressure, and cause serious adverse effects.

Self-administration
✔ Take medication at onset of pain, when possible, to prevent development of more severe symptoms.
✔ With triptans, take oral drugs (except for rizatriptan orally disintegrating tablets) with fluids. If symptoms recur, a second dose may be taken. However, do not take a second dose of sumatriptan or zolmitriptan sooner than 2 hours after the first dose, or a second dose of naratriptan sooner than 4 hours after the first dose. Do not take more than 12.5 mg of almotriptan, 7.5 mg of frovatriptan, 5 mg of naratriptan, or 10 mg of zolmitriptan in any 24-hour period.
✔ Rizatriptan is available in a regular tablet, which can be taken with fluids, and in an orally disintegrating tablet, which can be dissolved on the tongue and swallowed without fluids. The tablet should be removed from its package with dry hands and placed on the tongue immediately.
✔ Sumatriptan can be taken by mouth, injection, or nasal spray. Instructions should be strictly followed for the prescribed method of administration. For the nasal spray, the usual dose is one spray into one nostril. If symptoms return, a second spray may be taken 2 hours or longer after the first spray. Do not take more than 40 mg of nasal spray or 200 mg orally or by injection in any 24-hour period. If self-administering injectable sumatriptan, be sure to give in fatty tissue under the skin. This drug must not be taken intravenously; serious, potentially fatal reactions may occur.
✔ If symptoms of an allergic reaction (eg, shortness of breath, wheezing, heart pounding, swelling of eyelids, face or lips, skin rash, or hives) occur after taking a triptan drug, tell your prescribing physician immediately and do not take any additional doses without specific instructions to do so.
✔ With ergot preparations, report signs of poor blood circulation, such as tingling sensations or coldness, numbness, or weakness of the arms and legs. These are symptoms of ergot toxicity. To avoid potentially serious adverse effects, do not exceed recommended doses.

PRINCIPLES OF THERAPY

Guidelines for Therapy With Aspirin

When pain, fever, or inflammation is present, aspirin is effective across a wide range of clinical conditions. Like any other drug, aspirin must be used appropriately to maximize therapeutic benefits and minimize adverse reactions. Some guidelines include the following:

1. For pain, aspirin is useful alone when the discomfort is of low to moderate intensity. For more severe pain, aspirin may be combined with an oral opioid (eg, codeine) or given between opioid doses. Aspirin and opioid analgesics act by different mechanisms, so such use is rational. For acute pain, aspirin is taken when the pain occurs and is often effective within a few minutes. For chronic pain, a regular schedule of administration, such as every 4 to 6 hours, is more effective.

2. For fever, aspirin is effective if drug therapy is indicated. In children, however, aspirin is contraindicated because of its association with Reye’s syndrome.

3. For inflammation, aspirin is useful in both short- and long-term therapy of conditions characterized by pain and inflammation, such as rheumatoid arthritis or osteoarthritis. Although effective, the high doses and frequent administration required for anti-inflammatory effects increase the risks of GI upset, ulceration, and bleeding.

4. For acute pain or fever, plain aspirin tablets are preferred. For chronic pain, long-term use in arthritis, and daily use for antiplatelet effects, enteric-coated tablets may be better tolerated. Rectal suppositories are sometimes used when oral administration is contraindicated.

5. Aspirin dosage depends mainly on the condition being treated. Low doses are used for antiplatelet effects in preventing arterial thrombotic disorders such as myocardial infarction or stroke. Lower-than-average doses are needed for clients with low serum albumin levels because a larger proportion of each dose is free to exert pharmacologic activity. Larger doses are needed for anti-inflammatory effects than for analgesic and antipyretic effects.
6. In general, clients taking low-dose aspirin to prevent myocardial infarction or stroke should continue the aspirin if prescribed a COX-2 inhibitor NSAID. The COX-2 inhibitors have little effect on platelet function.

**Toxicity: Salicylate Poisoning**

Salicylate intoxication (salicylism) may occur with an acute overdose or chronic use of therapeutic doses, especially the higher doses taken for anti-inflammatory effects. Chronic ingestion of large doses saturates a major metabolic pathway, thereby slowing drug elimination, prolonging the serum half-life, and causing drug accumulation.

**Prevention**

To decrease risks of toxicity, plasma salicylate levels should be measured when an acute overdose is suspected and periodically when large doses of aspirin are taken long term. Therapeutic levels are 150 to 300 mcg/mL. Signs of salicylate toxicity occur at serum levels > 200 mcg/mL; severe toxic effects may occur at levels > 400 mcg/mL.

**Recognition: Signs and Symptoms**

Manifestations of salicylism include nausea, vomiting, fever, fluid and electrolyte deficiencies, tinnitus, decreased hearing, visual changes, drowsiness, confusion, hyperventilation, and others. Severe central nervous system dysfunction (eg, delirium, stupor, coma, seizures) indicates life-threatening toxicity.

**Treatment**

In mild salicylism, stopping the drug or reducing the dose is usually sufficient. In severe salicylate overdose, treatment is symptomatic and aimed at preventing further absorption from the GI tract; increasing urinary excretion; and correcting fluid, electrolyte, and acid–base imbalances. When the drug may still be in the GI tract, gastric lavage and activated charcoal help reduce absorption. Intravenous (IV) sodium bicarbonate produces an alkaline urine in which salicylates are more rapidly excreted, and hemodialysis effectively removes salicylates from the blood. IV fluids are indicated when high fever or dehydration is present. The specific content of IV fluids depends on the serum electrolyte and acid–base status.

**Guidelines for Therapy With NSAIDs**

Nonaspirin NSAIDs are widely used and preferred by many people because of less gastric irritation and GI upset, compared with aspirin. Many NSAIDs are prescription drugs used primarily for analgesia and anti-inflammatory effects in arthritis and other musculoskeletal disorders. However, several are approved for more general use as an analgesic or antipyretic. Ibuprofen, ketoprofen, and naproxen are available by prescription and OTC. Clients must be instructed to avoid combined use of prescription and nonprescription NSAIDs because of the high risk of adverse effects. NSAIDs commonly cause gastric mucosal damage, and prolonged use may lead to gastric ulceration and bleeding. Because NSAIDs lead to renal impairment in some clients, blood urea nitrogen and serum creatinine should be checked approximately 2 weeks after starting any of the agents.

NSAIDs inhibit platelet activity only while drug molecules are in the bloodstream, not for the life of the platelet (approximately 1 week) as aspirin does. Thus, they are not prescribed therapeutically for antiplatelet effects.

**Effects of NSAIDs on Other Drugs**

NSAIDs decrease effects of ACE inhibitors, beta blockers, and diuretics. With ACE inhibitors, there are decreased antihypertensive effects, probably because of sodium and water retention. With beta blockers, decreased antihypertensive effects are attributed to NSAID inhibition of renal prostaglandin synthesis, which allows unopposed pressor systems to produce hypertension. With diuretics, decreased effects on hypertension and edema are attributed to retention of sodium and water.

NSAIDs increase effects of a variety of drugs. With anticoagulants, prothrombin time may be prolonged and risks of bleeding are increased by NSAID-induced gastric irritation and antiplatelet effects. With cyclosporine, nephrotoxicity associated with both drugs may be increased. With digoxin, ibuprofen and indomethacin may increase serum levels. With phenytoin, serum drug levels and pharmacologic effects, including adverse or toxic effects, may be increased. With lithium, serum drug levels and risk of toxicity may be increased (except with sulindac, which has no effect or may decrease serum lithium levels). With methotrexate, risks of toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity) may be increased. Celecoxib and meloxicam apparently do not increase methotrexate toxicity.

**Guidelines for Therapy With Acetaminophen**

Acetaminophen is effective and widely used for the treatment of pain and fever. Two major advantages over aspirin are that acetaminophen does not cause gastric irritation or increase the risk of bleeding. It is the drug of choice for children with febrile illness (because of the association of aspirin with Reye’s syndrome), elderly adults with impaired renal function (because aspirin and NSAIDs may cause further impairment), and pregnant women (because aspirin is associated with several maternal and fetal disorders, including bleeding).

Despite its high degree of safety when used appropriately, acetaminophen is probably not the drug of choice for people with hepatitis or other liver disorders or those who drink substantial amounts of alcoholic beverages. The major drawback to acetaminophen use is potentially fatal liver damage with overdose. The kidneys and myocardium may also be damaged.
Toxicity: Acetaminophen Poisoning

Poisoning may occur with a single large dose (possibility as little as 6 g, but usually 10–15 g), or chronic ingestion of excessive doses (5 to 8 g/day for several weeks or 3 to 4 g/day for 1 year). Potentially fatal hepatotoxicity is the main concern and is most likely to occur with doses of 20 g or more. Metabolism of acetaminophen produces a toxic metabolite that is normally inactivated by combining with glutathione. In overdose situations, the supply of glutathione is depleted and the toxic metabolite accumulates and directly damages liver cells. Acute renal failure may also occur.

Prevention

The recommended maximum daily dose is 4 g for adults; additional amounts constitute an overdose. Ingestion of an overdose may be accidental or intentional. A contributing factor may be that some people think the drug is so safe that they can take any amount without harm. Another may be that people take the drug in several formulations without calculating or realizing that they are taking potentially harmful amounts. For example, numerous brand names of acetaminophen are available OTC and acetaminophen is an ingredient in many prescription and OTC combination products (eg, Percocet; OTC cold, flu, headache, and sinus remedies). For chronic alcohol abusers, short-term ingestion of usual therapeutic doses may cause hepatotoxicity and it is recommended that they ingest no more than 2 g daily. If they ingest three or more alcoholic drinks daily, they should avoid acetaminophen or ask a physician before using even small doses. Another recommendation is to limit duration of use (5 days or less in children, 10 days or less in adults, and 3 days in both adults and children when used to reduce fever) unless directed by a physician.

Because of multiple reports of liver damage from acetaminophen poisoning, the FDA may strengthen the warning on products containing acetaminophen and emphasize that the maximum dose of 4 g daily, from all sources, should not be exceeded.

Recognition: Signs and Symptoms

Early symptoms (12 to 24 hours after ingestion) are nonspecific (eg, anorexia, nausea, vomiting, diaphoresis) and may not be considered serious or important enough to report or seek treatment. At 24 to 48 hours, symptoms may subside but tests of liver function (eg, AST, ALT, bilirubin, prothrombin time) begin to show increased levels. Later manifestations may include jaundice, vomiting, and CNS stimulation with excitement and delirium, followed by vascular collapse, coma, and death. Peak hepatotoxicity occurs in 3 to 4 days; recovery in nonfatal overdoses occurs in 7 to 8 days.

Plasma acetaminophen levels should be obtained when an overdose is known or suspected, preferably within 4 hours after ingestion and every 24 hours for several days. Minimal hepatotoxicity is associated with plasma levels of <120 mcg/mL at 4 hours after ingestion or <30 mcg/mL at 12 hours after ingestion. With blood levels >300 mcg/mL at 4 hours after ingestion, about 90% of clients develop liver damage.

Guidelines for Treating Arthritis

The primary goals of treatment are to control pain and inflammation and to minimize immobilization and disability. Rest, exercise, physical therapy, and drugs are used to attain these goals. Few of these measures prevent or slow joint destruction.

Osteoarthritis (OA)

The main goal of drug therapy is relief of pain. Acetaminophen is probably the initial drug of choice. For clients whose pain is inadequately relieved by acetaminophen, an NSAID is usually given. Ibuprofen and other propionic acid derivatives are often used, although available NSAIDs have comparable effectiveness. A drug may be given for 2 or 3 weeks on a trial basis. If therapeutic benefits occur, the drug may be continued; if no benefits seem evident or toxicity occurs, another drug may be tried. A COX-2 inhibitor may be preferred for clients at high risk of GI ulceration and bleeding. NSAIDs are usually given in analgesic doses for OA, rather than the larger anti-inflammatory doses given for rheumatoid arthritis.

Additional treatments for knee OA include topical capsaicin; oral chondroitin and glucosamine; intra-articular injections of corticosteroids (see Chap. 24) or hyaluronic acid (eg, Synvisc, a product that helps restore the “shock-absorbing”

Nursing Notes: Apply Your Knowledge

Mrs. Whynn, a 73-year-old widow, has severe osteoarthritis. To control the pain, she takes ibuprofen 400 mg every 4 hours while awake and prednisone 5 mg daily. Also, she swims and uses moist heat to decrease stiffness and discomfort. Lately, she has been feeling weak and tired. She has also experienced dizziness when getting up from bed, and today she fainted. She asks you if this could be related to the medications she is taking and what she should do.
ability of joint structures). Clients who continue to have severe pain and functional impairment despite medical treatment may need knee replacement surgery.

**Rheumatoid Arthritis (RA)**

Acetaminophen may relieve pain; aspirin or another NSAID may relieve pain and inflammation. Aspirin is effective but many people are unable to tolerate the adverse effects associated with anti-inflammatory doses. When aspirin is used, dosage usually ranges between 2 and 6 g daily but should be individualized to relieve symptoms, maintain therapeutic salicylate blood levels, and minimize adverse effects. For people who cannot take aspirin, another NSAID may be given. For those who cannot take aspirin or a nonselective NSAID because of gastric irritation, peptic ulcer disease, bleeding disorders, or other contraindications, a selective COX-2 inhibitor NSAID may be preferred. NSAIDs are usually given in larger, anti-inflammatory doses for RA, rather than the smaller, analgesic doses given for OA.

Second-line drugs, for moderate or severe RA, include corticosteroids and immunosuppressants (see Chap. 45). The goal of treatment with corticosteroids is to relieve symptoms; the goal with immunosuppressants is to relieve symptoms and also slow tissue damage (so-called disease-modifying effects). Both groups of drugs may cause serious adverse effects, including greatly increased susceptibility to infection. Methotrexate (MTX), which is also used in cancer chemotherapy, is given in smaller doses for RA. It is unknown whether MTX has disease-modifying effects or just improves symptoms and quality of life. About 75% of clients have a beneficial response, with improvement usually evident within 4 to 8 weeks (ie, less morning stiffness, pain, joint edema, and fatigue).

Three newer immunosuppressants used to treat RA are etanercept (Enbrel), infliximab (Remicade), and leflunomide (Arava). Clinical improvement usually occurs within a few weeks. One of these drugs may be used alone or given along with methotrexate in clients whose symptoms are inadequately controlled by methotrexate alone.

**Perioperative Use of Aspirin and Other NSAIDs**

Aspirin should generally be avoided for 1 to 2 weeks before and after surgery because it increases the risk of bleeding. Most other NSAIDs should be discontinued approximately 3 days before surgery; nabumetone and piroxicam have long half-lives and must be discontinued approximately 1 week before surgery. After surgery, especially after relatively minor procedures, such as dental extractions and episiotomies, several of the drugs are used to relieve pain. Caution is needed because of increased risks of bleeding, and the drugs should not be given if there are other risk factors for bleeding. In addition, ketorolac, the only injectable NSAID, has been used in more extensive surgeries. Although the drug has several advantages over opioid analgesics, bleeding and hematomas may occur.

**Use of Acetaminophen, Aspirin, and Other NSAIDs in Cancer Pain**

Cancer often produces chronic pain from tumor invasion of tissues or complications of treatment (chemotherapy, surgery, or radiation). As with acute pain, these drugs prevent sensitization of peripheral pain receptors by inhibiting prostaglandin formation. They are especially effective for pain associated with bone metastases. For mild pain, acetaminophen or an NSAID may be used alone; for moderate to severe pain, these drugs may be continued and an opioid analgesic added. Non-opioid and opioid analgesics can be given together or alternated; a combination of analgesics is often needed to provide optimal pain relief. Aspirin is contraindicated for the client receiving chemotherapy that depresses the bone marrow because of the high risk of thrombocytopenia and bleeding.

**Use of Acetaminophen, Aspirin, and Other NSAIDs in Children**

Acetaminophen is usually the drug of choice for pain or fever in children. Children seem less susceptible to liver toxicity than adults, apparently because they form less of the toxic metabolite during metabolism of acetaminophen. However, there is a risk of overdose and hepatotoxicity because acetaminophen is a very common ingredient in OTC cold, flu, fever, and pain remedies. An overdose can occur with large doses of one product or smaller amounts of several different products. In addition, toxicity has occurred when parents or caregivers have given the liquid concentration intended for children to infants. The concentrations are different and cannot be given interchangeably. Infants’ doses are measured with a dropper; children’s doses are measured by teaspoon. Caution parents and caregivers to ask pediatricians for written instructions on giving acetaminophen to their children, to read the labels of all drug products very carefully, and avoid giving children acetaminophen from multiple sources.

Ibuprofen also may be given for fever. Aspirin is not recommended because of its association with Reye’s syndrome, a life-threatening illness characterized by encephalopathy, hepatic damage, and other serious problems. Reye’s syndrome usually occurs after a viral infection, such as influenza or chickenpox, during which aspirin was given for fever. For children with juvenile rheumatoid arthritis, aspirin, ibuprofen, naproxen, or tolmetin may be given. Pediatric indications for use and dosages have not been established for most of the other drugs.

When an NSAID is given during late pregnancy to prevent premature labor, the fetus’s kidneys may be adversely affected. When one is given shortly after birth to close a patent ductus arteriosus, the neonate’s kidneys may be adversely affected.
Use of Acetaminophen, Aspirin, and Other NSAIDs in Older Adults

Acetaminophen is usually safe in recommended doses unless liver damage is present or the person is a chronic alcohol abuser. Aspirin is usually safe in the small doses prescribed for prevention of myocardial infarction and stroke (antiplatelet effects). Aspirin and other NSAIDs are probably safe in therapeutic doses for occasional use as an analgesic or antipyretic. However, older adults have a high incidence of musculoskeletal disorders (eg, osteoarthritis), and an NSAID is often prescribed. Long-term use increases the risk of serious GI bleeding. Small doses, gradual increments, and taking the drug with or a full glass of water may decrease GI effects. COX-2 inhibitor NSAIDs may be especially beneficial in older adults because they are less likely to cause gastric ulceration and bleeding. Older adults also are more likely than younger adults to acquire nephrotoxicity with NSAIDs, especially with high doses or long-term use, because the drugs may reduce blood flow to the kidneys.

Guidelines for Treating Hyperuricemia and Gout

Opinions differ regarding treatment of asymptomatic hyperuricemia. Some authorities do not think drug therapy is indicated; others think that lowering serum uric acid levels may prevent joint inflammation and renal calculi. Allopurinol, probenecid, or sulfapyrazone may be given for this purpose. Colchicine also should be given for several weeks to prevent acute attacks of gout while serum uric acid levels are being lowered. During initial administration of these drugs, a high fluid intake (to produce approximately 2000 mL of urine per day) and alkaline urine are recommended to prevent renal calculi. Urate crystals are more likely to precipitate in acid urine.

Guidelines for Treating Migraine

For infrequent or mild migraine attacks, acetaminophen, aspirin, or other NSAIDs may be effective. For example, NSAIDs are often effective in migraines associated with menstruation. For moderate to severe migraine attacks, sumatriptan and related drugs are effective and they cause fewer adverse effects than ergot preparations. They are usually well tolerated; adverse effects are relatively minor and usually brief. However, because they are strong vasoconstrictors, they should not be taken by people with coronary artery disease or hypertension. They are also expensive compared with other antimigraine drugs. If an ergot preparation is used, it should be given at the onset of headache, and the client should lie down in a quiet, darkened room.

For frequent (two or more per month) or severe migraine attacks, prophylactic therapy is needed. Those for whom the triptans and ergot preparations are contraindicated for acute attacks and those whose attacks are predictable (eg, perimenstrual) may also need drug therapy to reduce the incidence and severity of acute attacks. Numerous medications have been used for prophylaxis, including aspirin (650 mg bid) and NSAIDs (ibuprofen 300 to 600 mg tid; ketoprofen 50 to 75 mg bid or tid; naproxen 250 to 750 mg daily or 250 mg tid). When used to prevent migraine associated with menses, they should be started approximately 1 week before and continued through the menstrual period. Although these drugs are usually well tolerated, long-term use is not recommended because of GI and renal toxicity associated with chronic inhibition of prostaglandin production. Other prophylactic drugs include propranolol and other beta-adrenergic blocking agents (see Chap. 19).

Use in Renal Impairment

Acetaminophen, aspirin, and other NSAIDs can cause or aggravate renal impairment even though they are eliminated mainly by hepatic metabolism. Acetaminophen is normally metabolized in the liver to metabolites that are excreted through the kidneys; these metabolites may accumulate in renal failure. In addition, acetaminophen is nephrotoxic in overdose because it forms a metabolite that attacks kidney cells and may cause necrosis. Aspirin is nephrotoxic in high doses, and protein binding of aspirin is reduced in renal failure so that blood levels of active drug are higher. In addition, aspirin and other NSAIDs can decrease blood flow in the kidneys by inhibiting synthesis of prostaglandins that dilate renal blood vessels. When renal blood flow is normal, these prostaglandins have limited activity. When renal blood flow is decreased, however, their synthesis is increased and they protect the kidneys from ischemia and hypoxia by antagonizing the vasoconstrictive effects of angiotensin II, norepinephrine, and other substances. Thus, in clients who depend on prostaglandins to maintain an adequate renal blood flow, the prostaglandin-blocking effects of aspirin and NSAIDs result in constriction of renal arteries and arterioles, decreased renal blood flow, decreased glomerular filtration rate, and retention of salt and water. NSAIDs can also cause kidney damage by other mechanisms, including a hypersensitivity reaction that leads to acute renal failure, manifested by proteinuria, hematuria, or pyuria. Biopsy reports usually indicate inflammatory reactions such as glomerulonephritis or interstitial nephritis.

People at highest risk from the use of these drugs are those with pre-existing renal impairment; those older than 50 years of age; those taking diuretics; and those with hypertension, diabetes, or heart failure. Measures to prevent or minimize renal damage include avoiding nephrotoxic drugs when possible, treating the disorders that increase risk of renal damage, stopping the NSAID if renal impairment occurs, monitoring renal function, reducing dosage, and maintaining hydration.

The role of COX-2 inhibitor NSAIDs in renal impairment is not clear. Although it was hoped that these drugs would have protective effects on the kidneys as they do on the stomach, studies indicate that their effects on the kidneys are similar to those of the older NSAIDs.
Use in Hepatic Impairment

Except for acetaminophen, the effects of NSAIDs on liver function and the effects of hepatic impairment on most NSAIDs are largely unknown. Because the drugs are metabolized in the liver, they should be used with caution and in lower doses in people with impaired hepatic function or a history of liver disease. For example, some authorities recommend a maximum daily dose of 2 g for people with hepatitis (compared with a maximum daily dose of 4 g for people who do not have impaired liver function).

Acetaminophen can cause fatal liver necrosis in overdose because it forms a metabolite that can destroy liver cells. The hepatotoxic metabolite is formed more rapidly when drug-metabolizing enzymes in the liver have been stimulated by ingestion of alcohol, cigarette smoking, and drugs such as anticonvulsants and others. Thus, alcoholics are at high risk of hepatotoxicity with usual therapeutic doses.

In cirrhotic liver disease, naproxen and sulindac may be metabolized more slowly and aggravate hepatic impairment if dosage is not reduced. In liver impairment, blood levels of oral sumatriptan and related antimigraine drugs may be high because less drug is metabolized on its first pass through the liver and a higher proportion of a dose reaches the systemic circulation. Thus, the drugs should be used cautiously, possibly in reduced dosage.

Use in Critical Illness

Acetaminophen, aspirin, and other NSAIDs are infrequently used during critical illness, partly because they are usually given orally and many clients are unable to take oral medications. Pain is more likely to be treated with injectable opioid analgesics in this population. Acetaminophen may be given by rectal suppository for pain or fever in clients who are unable to take oral drugs.

These drugs may be risk factors for renal or hepatic impairment or bleeding disorders. For example, if a client has a history of taking aspirin, including the low doses prescribed for antithrombotic effects, there is a risk of bleeding from common therapeutic (eg, IM injections, venipuncture, inserting urinary catheters or GI tubes) or diagnostic procedures (eg, drawing blood, angiography). If a client has been taking an NSAID regularly, he or she may be more likely to experience renal failure if the critical illness causes dehydration or requires treatment with one or more nephrotoxic drugs. If a client presents with acute renal failure, NSAID ingestion must be considered as a possible cause. If a client is known to drink alcoholic beverages and take acetaminophen, he or she may be more likely to experience impaired liver function.

Home Care

Home use of acetaminophen and NSAIDs is extremely widespread. Many people are aware of the drugs’ beneficial effects in relieving pain, but they may not be adequately informed about potential problems associated with use of the drugs. Thus, the home care nurse may need to assist clients in perceiving a need for additional information and provide that information. Specific suggestions include reading and following instructions on labels of OTC analgesics, not exceeding recommended dosages without consulting a health care provider, avoiding multiple sources of acetaminophen or NSAIDs (eg, multiple OTC NSAIDs or an OTC and a prescription NSAID). In addition, adverse drug effects should be reviewed with clients, and clients should be assessed for characteristics (eg, older age group, renal impairment, overuse of the drugs) that increase the risks of adverse effects.

NURSING ACTIONS

**Analgesic–Antipyretic–Anti-inflammatory and Related Drugs**

**NURSING ACTIONS**

1. **Administer accurately**

   a. Give aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) with a full glass of water or other fluid and with or just after food.

   b. Do not crush tablets or open capsules of long-acting dosage forms and instruct patients not to crush or chew the products. Examples include:

      1. Enteric-coated aspirin (eg, Ecotrin)
      2. Diclofenac sodium (Voltaren or Voltaren XR).
      3. Diflunisal (Dolobid)
      4. Etodolac (Lodine XL)
      5. Indomethacin or Indocin SR

   To decrease gastric irritation. Even though food delays absorption and decreases peak plasma levels of some of the drugs, it is probably safer to give them with food. Rofecoxib and meloxicam may be given without regard to food.

   Breaking the tablets or capsules allows faster absorption, destroys the long-acting feature, and increases risks of adverse effects and toxicity from overdose.

   (continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6) Ketoprofen or Oruvail extended-release capsules</td>
<td>To prevent development of more severe symptoms.</td>
</tr>
<tr>
<td>(7) Naproxen delayed-release (EC-Naprosyn) or naproxen sodium controlled-release (Naprelan)</td>
<td></td>
</tr>
<tr>
<td>c. Give antimigraine preparations at the onset of headache.</td>
<td></td>
</tr>
</tbody>
</table>

2. Observe for therapeutic effects

a. When drugs are given for pain, observe for decreased or absent manifestations of pain.

b. When drugs are given for fever, record temperature every 2 to 4 hours, and observe for a decrease.

c. When drugs are given for arthritis and other inflammatory disorders, observe for decreased pain, edema, redness, heat, and stiffness of joints. Also observe for increased joint mobility and exercise tolerance.

d. When colchicine is given for acute gouty arthritis, observe for decreased pain and inflammation in involved joints.

e. When allopurinol, probenecid, or sulfinpyrazone is given for hyperuricemia, observe for normal serum uric acid level (approximately 2–8 mg/100 mL).

f. When the above drugs are given for chronic gout, observe for decreased size of tophi, absence of new tophi, decreased joint pain and increased joint mobility, and normal serum uric acid levels.

g. When triptans or ergot preparations are given in migraine headache, observe for relief of symptoms.

3. Observe for adverse effects

a. With analgesic–antipyretic–anti-inflammatory and antigout agents, observe for:

1. Gastrointestinal problems—anorexia, nausea, vomiting, diarrhea, bleeding, ulceration

2. Hematologic problems—petechiae, bruises, hematuria, melena, epistaxis, and bone marrow depression (leukopenia, thrombocytopenia, anemia)

3. Central nervous system effects—headache, dizziness, fainting, ataxia, insomnia, confusion, drowsiness

4. Skin rashes, dermatitis

5. Hypersensitivity reactions with dyspnea, bronchospasm, skin rashes

6. Tinnitus, blurred vision

7. Nephrotoxicity—decreased urine output, increased blood urea nitrogen (BUN), increased serum creatinine, hyperkalemia, retention of sodium and water with resultant edema

These are common reactions, more likely with aspirin, indomethacin, piroxicam, sulindac, tolmetin, colchicine, and sulfinpyrazone and less likely with acetaminophen, celecoxib, diflunisal, etodolac, fenuprofen, ibuprofen, naproxen, rofecoxib, and valdecoxib.

Bone marrow depression is more likely to occur with colchicine.

These effects are relatively common with indomethacin and may occur with most of the other drugs, especially with high dosages.

These effects may simulate asthma in people who are allergic to aspirin and aspirin-like drugs. Most likely to occur in patients with a history of nasal polyps, asthma, or rhinitis. May result in severe symptoms, including potentially fatal bronchospasm.

Tinnitus (ringing or roaring in the ears) is a classic sign of aspirin overdose (salicylate intoxication). It occurs with NSAIDs as well, especially with overdosage.

More likely to occur in people with preexisting renal impairment, especially when fluid intake is decreased or fluid loss is increased. Older adults are at greater risk because of decreased renal blood flow and increased incidence of congestive heart failure and diuretic therapy. Renal damage is usually reversible when the drug is discontinued.

(continued)
### NURSING ACTIONS

| (8) Cardiovascular effects—increased hypertension |
| (9) Hepatotoxicity—liver damage or failure |

**b. With triptan antimigraine drugs, observe for:**

1. Chest tightness or pain, hypertension, dizziness, nausea, fatigue, paresthesias

**c. With ergot antimigraine drugs, observe for:**

1. Nausea, vomiting, diarrhea

(2) Symptoms of ergot poisoning (ergotism)—coolness, numbness, and tingling of the extremities, headache, vomiting, dizziness, thirst, convulsions, weak pulse, confusion, angina-like chest pain, transient tachycardia or bradycardia, muscle weakness and pain, cyanosis, gangrene of the extremities

3. Hypertension

4. Hypersensitivity reactions—local edema and pruritus, anaphylactic shock

### RATIONALE/EXPLANATION

Long known to occur with older NSAIDs, probably due to retention of sodium and water. A few cases have been reported with COX-2 inhibitors, mechanism unknown.

Occurs mainly with acetaminophen, in overdose or in people with underlying liver disease

Most adverse effects are mild and transient. However, because of their vasoconstrictive effects, they may cause or aggravate angina pectoris and hypertension.

These drugs have a direct effect on the vomiting center of the brain and stimulate contraction of gastrointestinal smooth muscle.

The ergot alkaloids are highly toxic; poisoning may be acute or chronic. Acute poisoning is rare; chronic poisoning is usually a result of overdosage. Circulatory impairments may result from vasoconstriction and vascular insufficiency. Large doses also damage capillary endothelium and may cause thrombosis and occlusion. Gangrene of extremities rarely occurs with usual doses unless peripheral vascular disease or other contraindications are also present.

Blood pressure may rise as a result of generalized vasoconstriction induced by the ergot preparation.

Allergic reactions are relatively uncommon.

Acidify urine and thereby decrease the urinary excretion rate of salicylates

Increases gastric irritation and occult blood loss

Increase risk of bleeding substantially. People taking anticoagulants should avoid aspirin and aspirin-containing products.

Additive analgesic effects because of different mechanisms of action. Aspirin or an NSAID can often be used with these drugs to provide adequate pain relief without excessive doses and sedation.

Additive gastric irritation and possible ulcerogenic effects

Inhibits liver enzymes that normally metabolize celecoxib; increases serum celecoxib levels

Increase rate of renal excretion

This drug, a prostaglandin, was developed specifically to prevent aspirin and NSAID-induced gastric ulcers.

Induces drug-metabolizing enzymes in the liver and decreases blood levels of fenoprofen. Dosage of fenoprofen may need to be increased if phenobarbital is started or decreased if phenobarbital is discontinued.

Induces drug-metabolizing enzymes in the liver and decreases blood levels of rofecoxib

(continued)
## NURSING ACTIONS

<table>
<thead>
<tr>
<th>f.</th>
<th>Drugs that <em>increase</em> effects of indomethacin:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1) Anticoagulants, oral</td>
</tr>
<tr>
<td></td>
<td>(2) Corticosteroids</td>
</tr>
<tr>
<td></td>
<td>(3) Salicylates</td>
</tr>
<tr>
<td></td>
<td>(4) Heparin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>g.</th>
<th>Drugs that <em>decrease</em> effects of indomethacin:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1) Antacids</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>h.</th>
<th>Drugs that <em>decrease</em> effects of allopurinol, probenecid, and sulfinpyrazone:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1) Alkalinizing agents (eg, sodium bicarbonate)</td>
</tr>
<tr>
<td></td>
<td>(2) Colchicine</td>
</tr>
<tr>
<td></td>
<td>(3) Diuretics</td>
</tr>
<tr>
<td></td>
<td>(4) Salicylates</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>i.</th>
<th>Drugs that <em>increase</em> effects of ergot preparations:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1) Vasoconstrictors (eg, ephedrine, epinephrine, phenylephrine)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>j.</th>
<th>Drugs that <em>increase</em> the effects of triptan antimigraine drugs:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(1) Monoamine oxidase inhibitors (MAOIs)</td>
</tr>
<tr>
<td></td>
<td>(2) Ergot preparations</td>
</tr>
</tbody>
</table>

## RATIONALE/EXPLANATION

- **f.** Increase risk of gastrointestinal bleeding. Indomethacin causes gastric irritation and is considered an ulcerogenic drug.
- **g.** Delay absorption from the gastrointestinal tract.
- **h.** Decrease risks of renal calculi from precipitation of uric acid crystals. Alkalinizing agents are recommended until serum uric acid levels return to normal.
- **i.** Additive vasoconstriction with risks of severe, persistent hypertension and intracranial hemorrhage.
- **j.** Increase serum levels of triptans and may cause serious adverse effects, including cardiac arrhythmias and myocardial infarction. **Triptans and MAOIs must not be taken concurrently; a triptan should not be taken for at least 2 weeks after an MAOI is discontinued.** Triptans and ergot preparations should not be taken concurrently or within 24 hours of each other, because severe hypertension and stroke may occur.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** The symptoms may be related to her medications, but you need to collect more information before you can be sure. A very common side effect of aspirin (and all nonsteroidal anti-inflammatory drugs) is gastric irritation that can cause gastrointestinal ulceration and bleeding. Blood loss is often gradual, so patients get used to the fatigue. When patients become volume depleted secondary to the blood loss, they can exhibit signs of dizziness and syncope. Take Mrs. Whynn’s postural blood pressure. Refer her to her physician, who will test her stool for blood, and if blood is present, will do some diagnostic tests. Most important, to prevent falls and accidental injury, make sure Mrs. Whynn seeks care promptly.

---

**Review and Application Exercises**

1. How do aspirin and other NSAIDs produce analgesic, antipyretic, anti-inflammatory, and antiplatelet effects?
2. What adverse effects occur with aspirin and other NSAIDs, especially with daily ingestion?
3. Compare and contrast the uses and effects of aspirin, ibuprofen, and acetaminophen.
4. For a 6-year-old child with fever, would aspirin or acetaminophen be preferred? Why?
5. For a 50-year-old adult with rheumatoid arthritis, would aspirin, another NSAID, or acetaminophen be preferred? Why?
6. For a 75-year-old adult with osteoarthritis and a long history of “stomach trouble,” would aspirin, another NSAID, or acetaminophen be preferred? Why?

7. What are some nursing interventions to decrease the adverse effects of aspirin, other NSAIDs, and acetaminophen?

8. When teaching a client about home use of aspirin, other NSAIDs, and acetaminophen, what information must be included?

9. What is the rationale for using acetylcysteine in the treatment of acetaminophen toxicity?

10. What is the rationale for combining opioid and non-opioid analgesics in the treatment of moderate pain?

11. If you were a client, what information do you think would be most helpful in home management of migraine?

SELECTED REFERENCES


**Drug facts and comparisons.** (Updated monthly). St. Louis: Facts and Comparisons.


 CLIENT TEACHING GUIDELINES
Antianxiety and Sedative-Hypnotic Drugs

General Considerations

- “Nerve pills” and “sleeping pills” can relieve symptoms temporarily but they do not cure or solve the underlying problems. With rare exceptions, these drugs are recommended only for short-term use. For long-term relief, counseling or psychotherapy may be more beneficial because it can help you learn other ways to decrease your nervousness and difficulty in sleeping.

- Use nondrug measures to promote relaxation, rest, and sleep when possible. Physical exercise, reading, craft work, stress management, and relaxation techniques are safer than any drug.

- Try to identify and avoid factors that cause nervousness or insomnia, such as caffeine-containing beverages and stimulant drugs. This may prevent or decrease the severity of nervousness or insomnia so that sedative-type drugs are not needed. If the drugs are used, these factors can cancel or decrease the drugs’ effects. Stimulant drugs include asthma and cold remedies and appetite suppressants.

- Most “nerve pills” and “sleeping pills” belong to the same chemical group and have similar effects, including the ability to decrease nervousness, cause drowsiness, and cause dependence. Thus, there is no logical reason to take a combination of the drugs for anxiety, or to take one drug for daytime sedation and another for sleep. Ativan, Xanax, Valium, and Restoril are commonly used examples of this group, but there are several others as well.

- Inform all health care providers when taking a sedative-type medication, preferably by the generic and trade names. This helps avoid multiple prescriptions of drugs with similar effects and reduces the risk of serious adverse effects from overdose.

- Do not perform tasks that require alertness if drowsy from medication. The drugs often impair mental and physical functioning, especially during the first several days of use, and thereby make routine activities potentially hazardous. Avoid smoking, ambulating without help, driving a car, operating machinery, and other potentially hazardous tasks. These activities may lead to falls or other injuries if undertaken while alertness is impaired.

- Avoid alcohol and other depressant drugs (eg, over-the-counter [OTC] antihistamines and sleeping pills, narcotic analgesics, sedating herbs such as kava and valerian, and the dietary supplement melatonin) while taking any antianxiety or sedative-hypnotic drugs (except buspirone). An antihistamine that causes drowsiness is the active ingredient in OTC sleep aids (eg, Compoz, Nytol, Sominex, Unisom) and many pain reliever products with “PM” as part of their names (eg, Tylenol PM). Because these drugs depress brain functioning when taken alone, combining them produces additive depression and may lead to excessive drowsiness, difficulty breathing, traumatic injuries, and other potentially serious adverse drug effects.

- Store drugs safely, out of reach of children and adults who are confused or less than alert. Accidental or intentional ingestion may lead to serious adverse effects. Also, do not keep the drug container at the bedside, because a person sedated by a previous dose may take additional doses.

- Do not share these drugs with anyone else. These mind-altering, brain-depressant drugs should be taken only by those people for whom they are prescribed.

- Do not stop taking a Valium-related drug abruptly. Withdrawal symptoms can occur. When being discontinued, dosage should be gradually reduced, as directed and with the supervision of a health care provider.

- Do not take “sleeping pills” every night. These drugs lose their effectiveness in 2–4 weeks if taken nightly, and cause sleep disturbances when stopped.

- Alprazolam (Xanax), is sometimes confused with ranitidine (Zantac), a drug for heartburn and peptic ulcers.

Self-Administration

- Follow instructions carefully about how much, how often, and how long to take the drugs. These drugs produce more beneficial effects and fewer adverse reactions when used in the smallest effective doses and for the shortest duration feasible in particular circumstances. All of the Valium-related drugs, zaleplon (Sonata), and zolpidem (Ambien) can cause physical dependence, which may eventually cause worse problems than the original anxiety or insomnia.

- Take sleeping pills just before going to bed so that you are lying down when the expected drowsiness occurs.

- Omit one or more doses if excessive drowsiness occurs to avoid difficulty breathing, falls, and other adverse drug effects.

- Take oral benzodiazepines with a glass of water; they may be taken with food if stomach upset occurs.

- Take buspirone on a daily schedule. It is not fully effective until after 3–4 weeks of regular use; it is ineffective for occasional use.

- Take zolpidem on an empty stomach, at bedtime, because the drug acts quickly to cause drowsiness.

PRINCIPLES OF THERAPY

Use in Anxiety Disorders

Antianxiety drugs are not recommended for treating everyday stress and anxiety. Some authorities believe such use promotes reliance on drugs and decreases development of healthier coping mechanisms. For severe anxiety associated with a temporary stressful situation, an anxiolytic drug may be beneficial for short-term, “as-needed” use; prolonged drug therapy is not recommended. These drugs are most clearly indicated when anxiety causes disability and interferes with job performance, interpersonal relationships, and other activities of daily living. The drugs are not recommended for long-term
drugs can be given. When treatment is initiated with oral doses, usually controlled within 48 to 72 hours, after which oral doses. Thus, usual IM doses are approximately half the intramuscular (IM) doses avoid first-pass metabolism and produce serum drug levels approximately double those of oral doses. In contrast, significant portion of a dose does not reach the systemic circulation and low serum drug levels are produced. In contrast, undergo extensive first-pass metabolism in the liver so that a significant portion of a dose does not reach the systemic circulation and low serum drug levels are produced. In contrast, intramuscular (IM) doses avoid first-pass metabolism and produce serum drug levels approximately double those of oral doses. Thus, usual IM doses are approximately half the oral doses.

Initial drug therapy for acute psychotic episodes may require IM administration and hospitalization; symptoms are usually controlled within 48 to 72 hours, after which oral drugs can be given. When treatment is initiated with oral drugs, divided daily doses are recommended. For maintenance therapy, once daily dosing is usually preferred. A single bedtime dose is effective for most clients. This schedule increases compliance with prescribed drug therapy, allows better nighttime sleep, and decreases hypotension and day-

**CLIENT TEACHING GUIDELINES**

Antipsychotic Drugs

**General Considerations**

- Ask about the planned drug therapy regimen, including the desired results, when results can be expected, and the tentative length of drug therapy.
- Maintain an adequate supply of medication to ensure regular administration. Consistent blood levels are necessary to control symptoms and prevent recurring episodes of acute illness and hospitalization.
- Do not allow the client to drive a car, operate machinery, or perform activities that require alertness when drowsy from medication. Drowsiness, slowed thinking, and impaired muscle coordination are especially likely during the first 2 weeks of drug therapy but tend to decrease with time.
- Report unusual side effects and all physical illnesses, because changes in drug therapy may be indicated.
- Try to prevent the client from taking unprescribed medications, including those available without prescription or those prescribed for another person, to prevent undesirable drug interactions. Alcohol and sleeping pills should be avoided because they may cause excessive drowsiness and decreased awareness of safety hazards in the environment.
- Keep all physicians informed about all the medications being taken by the client, to decrease risks of undesirable drug interactions.

- These drugs should be tapered in dosage and discontinued gradually; they should not be stopped abruptly.

**Medication Administration**

Assist or prompt the client to:

- Take medications in the correct doses and at the correct times, to maintain blood levels and beneficial effects.
- Avoid taking these medications with antacids. If an antacid is needed (eg, for heartburn), it should be taken 1 hour before or 2 hours after the antipsychotic drug. Antacids decrease absorption of these drugs from the intestine.
- Lie down for approximately an hour after receiving medication, if dizziness and faintness occur.
- Practice good oral hygiene, including dental checkups, thorough and frequent toothbrushing, drinking fluids, and frequent mouth rinsing. Mouth dryness is a common side effect of the drugs. Although it is usually not serious, dry mouth can lead to mouth infections and dental cavities.
- Minimize exposure to sunlight, wear protective clothing, and use sunscreen lotions. Sensitivity to sunlight occurs with some of the drugs and may produce a sunburn-type skin reaction.
- Avoid exposure to excessive heat. Some of these medications may cause fever and heat prostration with high environmental temperatures. In hot weather or climates, keep the client indoors and use air conditioning or fans during the hours of highest heat levels.

**Nursing Notes: Apply Your Knowledge**

You are assigned to care for John Chou, hospitalized 2 weeks ago and started on fluphenazine hydrochloride (Prolixin) to treat acute psychotic symptoms. During your assessment, John appears restless, unable to sit still, and uncoordinated. He also has a fine hand tremor. How would you interpret these data?
Drugs for Mood Disorders: Antidepressants and Mood Stabilizers

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe major features of depression and bipolar disorder.
2. Discuss characteristics of antidepressants in terms of mechanism of action, indications for use, adverse effects, principles of therapy, and nursing process implications.
3. Compare and contrast selective serotonin re-uptake inhibitors with tricyclic antidepressants.
4. Discuss selected characteristics of bupropion, mirtazapine, nefazodone, and venlafaxine.
5. Describe the use of lithium in bipolar disorder.
6. Discuss interventions to increase safety of lithium therapy.
7. Describe the nursing role in preventing, recognizing, and treating overdoses of antidepressant drugs and lithium.
8. Analyze important factors in using antidepressant drugs and lithium in special populations.

Critical Thinking Scenario

Betty McGrath, 73 years of age, was recently widowed. She depended on her husband to handle their finances, maintain their home, and make major decisions. She enjoyed the role of homemaker and never worked outside the home. Her children live out of state, but they write and call often. Betty’s daughter calls you because she is concerned about her mother. Mrs. McGrath seems to be losing weight, stays home most of the time, complains she feels very tired, and sleeps much more than usual. She is also reluctant to go out with friends or visit her children.

- List factors that might increase Mrs. McGrath’s risk for depression.
- What symptoms does Mrs. McGrath have that may indicate she is depressed?
- What additional data would support a diagnosis of depression?
- At this point, what suggestions would you have for Mrs. McGrath and her daughter?

MOOD DISORDERS

Mood disorders include depression, dysthymia, bipolar disorder, and cyclothymia (Box 10–1). Depression is estimated to affect 5% to 10% of adults in the United States and to be increasing in children and adolescents. It is associated with impaired ability to function in usual activities and relationships. The average depressive episode lasts about 5 months, and having one episode is a risk factor for developing another episode. Depression and antidepressant drug therapy are emphasized in this chapter; bipolar disorder and mood stabilizing drugs are also discussed.

Etiology

Despite extensive study and identification of numerous potential contributory factors, the etiology of depression is unclear. It is likely that depression results from interactions among several complex factors. Two of the major theories of depression pathogenesis are described below.

Monoamine Neurotransmitter Dysfunction

Depression is thought to result from a deficiency of norepinephrine and/or serotonin. This hypothesis stemmed from...
studies demonstrating that antidepressant drugs increase the amounts of one or both of these neurotransmitters in the central nervous system (CNS) synapse by inhibiting their reuptake into the presynaptic neuron. Serotonin received increased attention after the selective serotonin reuptake inhibitor (SSRI) antidepressants were marketed. Serotonin helps regulate several behaviors that are disturbed in depression, such as mood, sleep, appetite, energy level, and cognitive and psychomotor functions.

Emphasis shifted toward receptors because the neurotransmitter view did not explain why the amounts of neurotransmitter increased within hours after single doses of a drug, but relief of depression occurred only after weeks of drug therapy. Researchers identified changes in norepinephrine and serotonin receptors with chronic antidepressant drug therapy. Studies demonstrated that chronic drug administration (ie, increased neurotransmitter in the synapse for several weeks) results in fewer receptors on the postsynaptic membrane. This down-regulation of receptors, first noted with beta-adrenergic receptors, corresponds with therapeutic drug effects. All known treatments for depression lead to the down-regulation of beta receptors and occur in the same period as the behavioral changes associated with antidepressant drug therapy.

Alpha2-adrenergic receptors (called autoreceptors), located on presynaptic nerve terminals, may also play a role. When these receptors are stimulated, they inhibit the release of norepinephrine. There is evidence that alpha2 receptors are also down-regulated by antidepressant drugs, thus allowing increased norepinephrine release. With serotonin receptors, available antidepressants may increase the sensitivity of postsynaptic receptors and decrease the sensitivity of presynaptic receptors.

Physiologically, presynaptic receptors regulate the release and reuptake of neurotransmitters; postsynaptic receptors participate in the transmission of nerve impulses to target tissues. It seems apparent that long-term administration of antidepressant drugs produces complex changes in the sensitivities of both presynaptic and postsynaptic receptor sites.

Overall, there is increasing awareness that balance, integration, and interactions among norepinephrine, serotonin, and possibly other neurotransmission systems (eg, dopamine, acetylcholine) are probably more important etiologic factors than single neurotransmitter or receptor alterations. For example, animal studies indicate that serotonin is required for optimal functioning of the neurons that produce norepinephrine. Changes in neurons may also play a major role.

**Neuroendocrine Factors**

In addition to monoamine neurotransmission systems, researchers have identified non-monoamine systems that influence neurotransmission and are significantly altered in depression. A major non-monoamine is corticotropin releasing factor, or hormone (CRF or CRH), whose secretion is increased in depression. CRF-secreting neurons are widespread in the CNS, and CRF apparently functions as a neuro-
transmitter and mediator of the endocrine, autonomic, immune, and behavioral responses to stress as well as a releasing factor for corticotropin. Hypothalamic CRF is part of the hypothalamic-pituitary-adrenal (HPA) axis, which becomes hyperactive in depression. As a result, there is increased secretion of CRF by the hypothalamus, adrenocorticotropic hormone (ACTH) by the anterior pituitary, and cortisol by the adrenal cortex. The increased cortisol (part of the normal physiologic response to stress) is thought to decrease the numbers or sensitivity of cortisol receptors (down-regulation) and lead to depression. This view is supported by animal studies indicating that antidepressant drugs restore the ability of cortisol receptors to bind with cortisol. This alteration of cortisol receptors takes about two weeks, the approximate time interval required for the drugs to improve symptoms of depression. Extrahypothalamic CRF is also increased in depression. Secretion of both hypothalamic and extrahypothalamic CRF apparently returns to normal with recovery from depression.

Other neuroendocrine factors in depression are thought to include abnormalities in the secretion and function of thyroid and growth hormones.

**Additional Factors**

Additional factors thought to play a role in the etiology of depression include the immune system, genetic factors, and environmental factors.

Immune cells (eg, T lymphocytes and B lymphocytes) produce cytokines (eg, interleukins, interferons, and tumor necrosis factor), which affect neurotransmission. Possible mechanisms of cytokine-induced depression include increased CRF and activation of the HPA axis, alteration of monoamine neurotransmitters in several areas of the brain, or cytokines functioning as neurotransmitters and exerting direct effects on brain function.

Genetic factors are considered important mainly because close relatives of a depressed person are more likely to experience depression.

Environmental factors include stressful life events, which apparently change brain structure and function and contribute to the development of depression in some people. Changes have been identified in CRF, the HPA axis, and the noradrenergic neurotransmission system, all of which are activated as part of the stress response. These changes are thought to cause a hypersensitive or exaggerated response to later stressful events, including mild stress or daily life events. Most studies have involved early life trauma such as physical or sexual abuse in childhood.

**Bipolar Disorder**

Like depression, mania and hypomania may result from abnormal functioning of neurotransmitters or receptors, such as a relative excess of excitatory neurotransmitters (eg, norepinephrine) or a relative deficiency of inhibitory neurotransmitters (eg, gamma-aminobutyric acid [GABA]). Drugs that stimulate the CNS can cause manic and hypomanic behaviors that are easily confused with schizophreniform psychoses.

**ANTIDEPRESSANT DRUGS**

Drugs used in the pharmacologic management of depressive disorders are derived from several chemical groups. Older antidepressants include the tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAOIs). Newer drugs include the selective serotonin reuptake inhibitors (SSRIs) and several individual drugs that differ from TCAs, MAOIs, and SSRIs. General characteristics of antidepressants include the following:

- All are effective in relieving depression, but they differ in their adverse effects.
- All must be taken for 2 to 4 weeks before depressive symptoms improve.
- They are given orally, absorbed from the small bowel, enter the portal circulation, and circulate through the liver, where they undergo extensive first-pass metabolism before reaching the systemic circulation.
- They are metabolized by the cytochrome P450 enzymes in the liver. Many antidepressants and other drugs are metabolized by the 2D6 or 3A4 subgroup of the enzymes. Thus, antidepressants may interact with each other and with a wide variety of drugs that are normally metabolized by the same subgroups of enzymes.

**Mechanisms of Action**

Although their actions are still being studied in relation to newer information about brain function and the etiology of mood disorders, antidepressant drugs apparently normalize abnormal neurotransmission systems in the brain by altering the amounts of neurotransmitters and the number or sensitivity of receptors. They may also modify interactions among neurotransmission systems and affect endocrine function (eg, the HPA axis and cortisol activity).

After neurotransmitters are released from presynaptic nerve endings, the molecules that are not bound to receptors are normally inactivated by reuptake into the presynaptic nerve fibers that released them or metabolized by monoamine oxidase (MAO). Most antidepressants prevent the reuptake of multiple neurotransmitters; SSRIs selectively inhibit the reuptake of serotonin. MAOIs prevent the metabolism of neurotransmitter molecules. These mechanisms thereby increase the amount of neurotransmitter available to bind to receptors.

With chronic drug administration, receptors adapt to the presence of increased neurotransmitter by decreasing their number or sensitivity to the neurotransmitter. More specifically, norepinephrine receptors, especially postsynaptic beta receptors and presynaptic alpha2 receptors, are down-regulated. The serotonin, receptor, a postsynaptic receptor, and cortisol (glucocorticoid) receptors may also be down-regulated.
Thus, antidepressant effects are attributed to changes in receptors rather than changes in neurotransmitters. Although some of the drugs act more selectively on one neurotransmission system than another initially, this selectivity seems to be lost with chronic administration.

With lithium, the exact mechanism of action is unknown. However, it is known to affect the synthesis, release, and reuptake of several neurotransmitters in the brain, including acetylcholine, dopamine, GABA, and norepinephrine. For example, the drug may increase the activity of GABA, an inhibitory neurotransmitter. It also stabilizes postsynaptic receptor sensitivity to neurotransmitters, probably by competing with calcium, magnesium, potassium, and sodium ions for binding sites.

### Indications for Use

Antidepressant drug therapy may be indicated if depressive symptoms persist at least 2 weeks, impair social relationships or work performance, and occur independently of life events. In addition, antidepressants are increasingly being used for treatment of anxiety disorders. TCAs may be used in children and adolescents in the management of enuresis (bedwetting and involuntary urination resulting from a physical or psychological disorder). In this setting, a TCA may be given after physical causes (eg, urethral irritation, excessive intake of fluids) have been ruled out. TCAs are also commonly used in the treatment of neuropathic pain. MAOIs are considered third-line drugs, largely because of their potential for serious interactions with certain foods and other drugs.

### Contraindications to Use

Antidepressant drugs are contraindicated or must be used with caution in clients with acute schizophrenia; mixed mania and depression; suicidal tendencies; severe renal, hepatic, or cardiovascular disease; narrow-angle glaucoma; and seizure disorders.

### Types of Antidepressants and Individual Drugs

Additional characteristics of antidepressants and lithium are described in the following sections; names, indications for use, and dosage ranges of individual drugs are listed in Drugs at a Glance: Antidepressant Agents.

### Tricyclic Antidepressants

Tricyclic antidepressants (TCAs), of which imipramine is the prototype, are similar drugs that produce a high incidence of adverse effects such as sedation, orthostatic hypotension, cardiac dysrhythmias, anticholinergic effects (eg, blurred vision, dry mouth, constipation, urinary retention), and weight gain. They are well absorbed after oral administration, but first-pass metabolism by the liver results in blood level variations of 10- to 30-fold among people given identical doses. Once absorbed, these drugs are widely distributed in body tissues and metabolized by the liver to active and inactive metabolites. Because of adverse effects on the heart, especially in overdose, baseline and follow-up electrocardiograms (ECGs) are recommended for all clients. Amitriptyline (Elavil) is a commonly used TCA.

### Selective Serotonin Reuptake Inhibitors (SSRIs)

Selective serotonin reuptake inhibitors (SSRIs), of which fluoxetine (Prozac, Sarafem) is the prototype, produce fewer serious adverse effects than the TCAs. They are well absorbed with oral administration, undergo extensive first-pass metabolism in the liver, are highly protein bound (95%), and have a half-life of 24 to 72 hours, which may lead to accumulation with chronic administration. Fluoxetine also forms an active metabolite with a half-life of 7 to 9 days. Thus, steady-state blood levels are achieved slowly, over several weeks, and drug effects decrease slowly (over 2 to 3 months) when fluoxetine is discontinued. Sertraline (Zoloft) and citalopram (Celexa) also have active metabolites, but fluoxetine and paroxetine (Paxil) are more likely to accumulate. Paroxetine, sertraline, and fluvoxamine (Luvox) reach steady-state concentrations in 1 to 2 weeks. SSRIs are usually given once daily.

Because SSRIs are highly bound to plasma proteins, the drugs compete with endogenous compounds and other medications for binding sites. Because they are highly lipid soluble, they accumulate in the CNS and other adipose-rich tissue.

Adverse effects include a high incidence of gastrointestinal symptoms (eg, nausea, diarrhea, weight loss) and sexual dysfunction (eg, delayed ejaculation in men and impaired orgasmic ability in women). Most also cause some degree of CNS stimulation (eg, anxiety, nervousness, insomnia), which is most prominent with fluoxetine.

Serious, sometimes fatal, reactions have occurred from combined therapy with an SSRI and an MAOI, and the drugs should not be given concurrently or within 2 weeks of each other. If a client on an SSRI is to be transferred to an MAOI, most SSRIs should be discontinued at least 14 days before starting the MAOI; fluoxetine should be discontinued at least 5 weeks before starting an MAOI.

### Monoamine Oxidase Inhibitors

MAOIs are infrequently used, mainly because they may interact with some foods and drugs to produce severe hypertension and possible heart attack or stroke. Foods that interact contain tyramine, a monoamine precursor of norepinephrine. Normally, tyramine is deactivated in the gastrointestinal tract and liver so that large amounts do not
<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tricyclic Antidepressants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline (Elavil)</td>
<td>Depression</td>
<td>PO 50–100 mg once daily at bedtime, gradually increased to 150 mg daily if necessary. IM 80–120 mg daily in 4 divided doses. <strong>Adolescents and older adults:</strong> PO 10 mg 3 times daily and 20 mg at bedtime.</td>
</tr>
<tr>
<td>Amoxapine (Asendin)</td>
<td>Depression</td>
<td>PO 50 mg 2 or 3 times daily, increased to 100 mg 2 or 3 times daily by end of 1 week. Give maintenance dose in a single dose at bedtime. <strong>Older adults:</strong> PO 25 mg 2 or 3 times daily, increased to 50 mg 2 or 3 times daily by end of 1 week. Give maintenance dose in a single dose at bedtime.</td>
</tr>
<tr>
<td>Clomipramine (Anafranil)</td>
<td>Obsessive-compulsive disorder</td>
<td>PO 25 mg daily, increased to 100 mg daily by end of 2 weeks, in divided doses, with meals. Give maintenance dose in a single dose at bedtime. Maximum dose, 250 mg daily. <strong>Children and adolescents:</strong> PO 25 mg daily, increased to 3 mg/kg or 100 mg, whichever is smaller, over 2 weeks. Give maintenance dose in a single dose at bedtime. Maximum dose, 3 mg/kg or 200 mg, whichever is smaller.</td>
</tr>
<tr>
<td>Desipramine (Norpramin)</td>
<td>Depression</td>
<td>PO 100–200 mg daily in divided doses or as a single daily dose. Give maintenance dose once daily. Maximum dose, 300 mg/d. <strong>Adolescents and older adults:</strong> PO 25–100 mg daily in divided doses or as a single daily dose. Maximum dose, 150 mg/d.</td>
</tr>
<tr>
<td>Doxepin (Sinequan)</td>
<td>Depression</td>
<td>PO 75–150 mg daily, in divided doses or a single dose at bedtime. Maximum dose, 300 mg/d.</td>
</tr>
<tr>
<td>Imipramine (Tofranil)</td>
<td>Depression</td>
<td>PO 75 mg daily in 3 divided doses, gradually increased to 200 mg daily if necessary. Maintenance dose, 75–150 mg daily. <strong>Adolescents and older adults:</strong> PO 30–40 mg daily in divided doses, increased to 100 mg daily if necessary. <strong>Children &gt;6 y:</strong> Enuresis, PO 25–50 mg 1 hour before bedtime.</td>
</tr>
<tr>
<td>Nortriptyline (Aventyl, Pamelor)</td>
<td>Depression</td>
<td>PO 25 mg 3 or 4 times daily or in a single dose (75–100 mg) at bedtime. Maximum dose, 150 mg/d. <strong>Adolescents and older adults:</strong> 30–50 mg/d, in divided doses or a single dose once daily. Maximum dose, 60 mg.</td>
</tr>
<tr>
<td>Protriptyline (Vivactil)</td>
<td>Depression</td>
<td>PO 15–40 mg daily in 3 or 4 divided doses. Maximum dose, 60 mg. <strong>Adolescents and older adults:</strong> PO 5 mg 3 times daily, increase gradually if necessary. PO 75 mg daily, in divided doses or a single dose at bedtime, increased to 150 mg/d if necessary. Maximum dose, 200 mg/d.</td>
</tr>
<tr>
<td>Trimipramine maleate (Surmontil)</td>
<td>Depression</td>
<td>PO 75 mg daily in 3 divided doses, gradually increased to 200 mg daily if necessary. Maintenance dose, 75–150 mg daily. <strong>Adolescents and older adults:</strong> PO 50 mg daily, increased to 100 mg/d if necessary. <strong>Children &gt;6 y:</strong> Enuresis, PO 25–50 mg 1 hour before bedtime.</td>
</tr>
<tr>
<td><strong>Selective Serotonin Reuptake Inhibitors (SSRIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Citalopram (Celexa)</td>
<td>Depression</td>
<td>PO 20 mg once daily, morning or evening, increased to 40 mg daily in 1 week, if necessary. <strong>Elderly/hepatic impairment:</strong> PO 20 mg daily.</td>
</tr>
<tr>
<td>Fluoxetine (Prozac, Sarafem)</td>
<td>Depression, Obsessive-compulsive disorder, Bulimia nervosa, Premenstrual dysphoric disorder (Sarafem)</td>
<td>PO 20 mg once daily in the morning, increased after several weeks if necessary. Give doses larger than 20 mg once in the morning or in 2 divided doses, morning and noon; maximum daily dose 80 mg. Prozac weekly (delayed-release capsules), PO 90 mg once each week, starting 7 days after the last 20-mg dose.</td>
</tr>
<tr>
<td>Fluvoxamine (Luvox)</td>
<td>Obsessive-compulsive disorder</td>
<td>PO 50 mg once daily at bedtime, increased in 50-mg increments every 4–7 days if necessary. For daily amounts above 100 mg, give in 2 divided doses. Maximum dose, 300 mg/d. <strong>Children 8–17 y:</strong> PO 25 mg once daily at bedtime, increased in 25-mg increments every 4–7 days if necessary. For daily amounts above 50 mg, give in 2 divided doses. Maximum dose 200 mg/d.</td>
</tr>
<tr>
<td>Paroxetine (Paxil, Paxil CR)</td>
<td>Depression, Generalized anxiety disorder, Obsessive-compulsive disorder, Panic disorder, Social anxiety disorder</td>
<td>PO 20 mg once daily in the morning, increased at 1 week or longer intervals, if necessary; usual range, 20–50 mg/d; maximum dose, 60 mg/d. Controlled-release tablets, PO 25 mg once daily in the morning, increased up to 62.5 mg/d if necessary. <strong>Elderly or debilitated adults:</strong> PO 10 mg once daily, increased if necessary. Maximum dose, 40 mg. <strong>Severe renal or hepatic impairment:</strong> Same as for older adults.</td>
</tr>
</tbody>
</table>

(continued)
reach the systemic circulation. However, when deactivation is blocked by MAOIs, tyramine is absorbed systemically and transported to adrenergic nerve terminals, where it causes a sudden release of large amounts of norepinephrine. Foods that should be avoided include aged cheeses and meats, concentrated yeast extracts, sauerkraut, and fava beans. Drugs that should be avoided include CNS stimulants (eg, amphetamines, cocaine), adrenergics (eg, pseudoephedrine), antidepressants (SSRIs, venlafaxine), buspirone, levodopa, and meperidine.

**Miscellaneous Antidepressants**

**Bupropion** (Wellbutrin, Zyban) inhibits the reuptake of dopamine, norepinephrine, and serotonin. It was marketed with warnings related to seizure activity. Seizures are most likely to occur with doses above 450 mg/day and in clients known to have a seizure disorder.

After an oral dose, peak plasma levels are reached in about 2 hours. The average drug half-life is about 14 hours. The drug is metabolized in the liver and excreted primarily in the urine. Several metabolites are pharmacologically active. Dosage should be reduced with impaired hepatic or renal function. Acute episodes of depression usually require several months of drug therapy. Bupropion is also used as a smoking cessation aid.

Bupropion has few adverse effects on cardiac function and does not cause orthostatic hypotension or sexual dysfunction. In addition to seizures, however, the drug has CNS stimulant effects (agitation, anxiety, excitement, increased motor activity, insomnia, restlessness) that may require a sedative during the first few days of administration. These effects may increase the risk of abuse. Other common adverse effects include dry mouth, headache, nausea and vomiting, and constipation.

**Maprotiline** is similar to the TCAs in therapeutic and adverse effects.
Mirtazapine (Remeron) blocks presynaptic alpha-adrenergic receptors (which increases the release of norepinephrine), serotonin receptors, and histamine H1 receptors. Consequently, the drug decreases anxiety, agitation, insomnia, and migraine headache as well as depression.

The drug is well absorbed after oral administration, and peak plasma levels occur within 2 hours after an oral dose. It is metabolized in the liver, mainly to inactive metabolites. Common adverse effects include drowsiness (with accompanying cognitive and motor impairment), increased appetite, weight gain, dizziness, dry mouth, and constipation. It does not cause sexual dysfunction.

Mirtazapine should not be taken concurrently with other CNS depressants (eg, alcohol or benzodiazepine antianxiety or hypnotic agents) because of additive sedation. In addition, it should not be taken concurrently with an MAOI or for 14 days after stopping an MAOI. An MAOI should not be started until at least 14 days after stopping mirtazapine.

Nefazodone (Serzone) inhibits the neuronal reuptake of serotonin and norepinephrine, thereby increasing the amount of these neurotransmitters in the brain. It is contraindicated in pregnancy and liver damage and should be used with caution in people with cardiovascular or cerebrovascular disorders, dehydration, hypovolemia, mania, hypomania, suicidal ideation, hepatic cirrhosis, electroconvulsive therapy, debilitation, and lactation. It has a long half-life (2 to 3 days) and crosses the placenta. It is metabolized in the liver and produces two active metabolites. It is excreted in breast milk, urine, and feces.

Adverse effects resemble those of SSRIs and TCAs, including agitation, confusion, dizziness, GI symptoms (nausea, vomiting, diarrhea), headache, insomnia, orthostatic hypotension, sedation, and skin rash. Because of its association with liver failure, serum levels of liver enzymes (eg, aspartate and alanine aminotransferases [AST and ALT]) should be measured before starting nefazodone therapy, periodically during therapy, and immediately when symptoms of liver dysfunction (eg, anorexia, nausea, vomiting, dark urine) develop.

Nefazodone should not be taken with an MAOI because of the risk of severe toxic effects. If a client on nefazodone is to be transferred to an MAOI, the nefazodone should be discontinued at least 7 days before starting the MAOI; if a client on an MAOI is to be transferred to nefazodone, the MAOI should be discontinued at least 14 days before starting nefazodone. Other potentially serious drug interactions include increased CNS depression with general anesthetics and decreased metabolism of drugs metabolized by the cytochrome P450 3A4 enzymes, which are inhibited by nefazodone.

Trazodone (Desyrel) is used more often for sedation and sleep than for depression because high doses (>300 mg/day) are required for antidepressant effects and these amounts cause excessive sedation for many clients. It is often given concurrently with a stimulating antidepressant, such as bupropion, fluoxetine, sertraline, or venlafaxine.

Trazodone is well absorbed with oral administration, and peak plasma concentrations are obtained within 30 minutes to 2 hours. It is metabolized by the liver and excreted primarily by the kidneys. Adverse effects include sedation, dizziness, edema, cardiac dysrhythmias, and priapism (prolonged and painful penile erection).

Venlafaxine (Effexor) inhibits the reuptake of norepinephrine, serotonin, and dopamine, thereby increasing the activity of these neurotransmitters in the brain. The drug crosses the placenta and may enter breast milk. It is metabolized in the liver and excreted in urine. It is contraindicated during pregnancy, and women should use effective birth control methods while taking this drug. Adverse effects include CNS (anxiety, dizziness, dreams, insomnia, nervousness, somnolence, tremors), GI (anorexia, nausea, vomiting, constipation, diarrhea), cardiovascular (hypertension, tachycardia, vasodilation), genitourinary (abnormal ejaculation, impotence, urinary frequency), and dermatologic (sweating, rash, pruritus) symptoms. Venlafaxine does not interact with drugs metabolized by the cytochrome P450 system, but it should not be taken concurrently with MAOIs because of increased serum levels and risks of toxicity. If a client on venlafaxine is to be transferred to an MAOI, the venlafaxine should be discontinued at least 7 days before starting the MAOI; if a client on an MAOI is to be transferred to venlafaxine, the MAOI should be discontinued at least 14 days before starting venlafaxine.

Mood-Stabilizing Agents

Lithium carbonate (Eskalith) is a naturally occurring metallic salt that is used in bipolar disorder, mainly to treat and prevent manic episodes. It is well absorbed after oral administration, with peak serum levels in 1 to 3 hours after a dose and steady-state concentrations in 5 to 7 days. Serum lithium concentrations should be monitored frequently because they vary widely among clients taking similar doses and because of the narrow range between therapeutic and toxic levels.

Lithium is not metabolized by the body; it is entirely excreted by the kidneys, so adequate renal function is a prerequisite for lithium therapy. Approximately 80% of a lithium dose is reabsorbed in the proximal renal tubules. The amount of reabsorption depends on the concentration of sodium in the proximal renal tubules. A deficiency of sodium causes more lithium to be reabsorbed and increases the risk of lithium toxicity; excessive sodium intake causes more lithium to be excreted (ie, lithium diuresis) and may lower serum lithium levels to nontherapeutic ranges.

Before lithium therapy is begun, baseline studies of renal, cardiac, and thyroid status should be obtained because adverse drug effects involve these organ systems. Baseline electrolyte studies are also necessary.

Anticonvulsants (see Chap. 11) are also used as mood stabilizing agents in bipolar disorder, because they modify nerve cell function. Carbamazepine (Tegretol) and valproate (Depakene) are commonly used. Newer drugs (eg, gabapentin, lamotrigine, topiramate, oxcarbazepine) are being used and studied regarding their effects in bipolar disorder, but none are FDA-approved for this purpose. Thus far, most of the drugs seem to have some beneficial effects but additional studies are needed.
**Herbal Supplement**

**St. John’s wort** (Hypericum perforatum) is an herb that is widely self-prescribed for depression. Several studies, most of which used about 900 mg daily of a standardized extract, indicate its usefulness in mild to moderate depression, with fewer adverse effects than antidepressant drugs. A 3-year, multicenter study by the National Institutes of Health concluded that the herb is not effective in major depression.

Antidepressant effects are attributed mainly to hypercin, although several other active components have also been identified. The mechanism of action is unknown, but the herb is thought to act similarly to antidepressant drugs. Some herbalists refer to St. John’s wort as “natural Prozac.”

Adverse effects, which are usually infrequent and mild, include constipation, dizziness, dry mouth, fatigue, GI distress, nausea, photosensitivity, restlessness, skin rash, and sleep disturbances. These symptoms are relieved by stopping the herb.

Drug interactions may be extensive. St. John’s wort should not be combined with alcohol, antidepressant drugs (eg, MAOIs, SSRIs, TCAs), nasal decongestants or other over-the-counter cold and flu medications, bronchodilators, opioid analgesics, or amino acid supplements containing phenylalanine and tyrosine. All of these interactions may result in hypertension, possibly severe.

Most authorities agree that there is insufficient evidence to support the use of St. John’s wort for mild to moderate depression and that more studies are needed in order to confirm the herb’s safety and effectiveness. Most of the previous studies were considered flawed.

Overall, both consumers and health care professionals seem to underestimate the risks of taking this herbal supplement. For clients who report use of St. John’s wort, teach them to purchase products from reputable sources because the amount and type of herbal content may vary among manufacturers; to avoid taking antidepressant drugs, alcohol, and cold and flu medications while taking St. John’s wort; to avoid the herb during pregnancy, because effects are unknown; and to use sunscreen lotions and clothing to protect themselves from sun exposure.

**Nursing Process**

**Assessment**

Assess the client’s condition in relation to depressive disorders.

- Identify clients at risk for current or potential depression. Areas to assess include health status, family and social relationships, and work status. Severe or prolonged illness, impaired interpersonal relationships, inability to work, and job dissatisfaction may precipitate depression. Depression also occurs without an identifiable cause.

**Planning/Goals**

The client will:

- Experience improvement of mood and depressive state
- Receive or self-administer the drugs correctly
- Be kept safe while sedated during therapy with the TCAs and related drugs
- Be assessed regularly for suicidal tendencies. If present, caretakers will implement safety measures.
- Be cared for by staff in areas of nutrition, hygiene, exercise, and social interactions when unable to provide self-care
- Resume self-care and other usual activities
- Avoid preventable adverse drug effects

**Interventions**

Use measures to prevent or decrease the severity of depression. General measures include supportive psychotherapy and reduction of environmental stress. Specific measures include the following:

- Support the client’s usual mechanisms for handling stressful situations, when feasible. Helpful actions may involve relieving pain or insomnia, scheduling rest periods, and increasing or decreasing socialization.
- Call the client by name, encourage self-care activities, allow him or her to participate in setting goals and making
decisions, and praise efforts to accomplish tasks. These actions promote a positive self-image.

- When signs and symptoms of depression are observed, initiate treatment before depression becomes severe. Institute suicide precautions for clients at risk. These usually involve close observation, often on a one-to-one basis, and removal of potential weapons from the environment. For clients hospitalized on medical-surgical units, transfer to a psychiatric unit may be needed.

**Evaluation**

- Observe for behaviors indicating lessened depression.
- Interview regarding feelings and mood.
- Observe and interview regarding adverse drug effects.
- Observe and interview regarding suicidal thoughts and behaviors.

**PRINCIPLES OF THERAPY**

**Drug Selection**

Because the available drugs seem similarly effective, the choice of an antidepressant depends on the client’s age, medical conditions, previous history of drug response, if any, and the specific drug’s adverse effects. Cost also needs to be considered. The newer drugs are much more expensive than the TCAs. However, they may be more cost effective overall because TCAs are more likely to cause serious adverse effects, they require monitoring of plasma drug levels and ECGs, and clients are more likely to stop taking them. Additional guidelines for choosing a drug include the following:

1. The SSRIs are the drugs of first choice. These drugs are effective and usually produce fewer and milder adverse effects than other drugs. Guidelines for choosing one SSRI over another have not been established.
2. With TCAs, initial selection may be based on the client’s previous response or susceptibility to adverse effects. For example, if a client (or a close family member) responded well to a particular drug in the past, that is probably the drug of choice for repeated episodes of depression. The response of family members to individual drugs may be significant because there is a strong genetic component to depression and drug response. If therapeutic effects do not occur within 4 weeks, the TCA probably should be discontinued or changed, because some clients tolerate or respond better to one TCA than to another. For a potentially suicidal client, an SSRI or another newer drug is preferred over a TCA because the TCAs are much more toxic in overdoses.
3. MAOIs are third-line drugs for the treatment of depression because of their potential interactions with other drugs and certain foods. An MAOI is most likely to be prescribed when the client does not respond to other antidepressant drugs or when electroconvulsive therapy is refused or contraindicated.
4. Criteria for choosing bupropion, mirtazapine, nefazodone, and venlafaxine are not clearly defined. Bupropion does not cause orthostatic hypotension or sexual dysfunction. Mirtazapine decreases anxiety, agitation, migraines, and insomnia, as well as depression. In addition, it does not cause sexual dysfunction or clinically significant drug–drug interactions. Nefazodone has sedating and anxiolytic properties that may be useful for clients with severe insomnia, anxiety, and agitation. However, it has been associated with liver failure and probably should not be given to clients with significant liver impairment. In addition, serum nefazodone levels are increased in clients with cirrhosis, and the drug inhibits cytochrome P450 3A4 enzymes that metabolize many drugs. Venlafaxine has stimulant effects, increases blood pressure, and causes sexual dysfunction, but does not cause significant drug–drug interactions.
5. For clients with cardiovascular disorders, most antidepressants can cause hypotension, but the SSRIs, bupropion, nefazodone, and venlafaxine are rarely associated with cardiac dysrhythmias. Venlafaxine and MAOIs can increase blood pressure.
6. For clients with seizure disorders, bupropion, clomipramine, and maprotiline should be avoided; SSRIs, MAOIs, and desipramine are less likely to cause seizures.
7. For clients with diabetes mellitus, SSRIs may have a hypoglycemic effect and bupropion and venlafaxine have little effect on blood sugar levels.
8. Lithium is the drug of choice for clients with bipolar disorder. When used therapeutically, lithium is effective in controlling mania in 65% to 80% of clients. When used prophylactically, the drug decreases the frequency and intensity of manic cycles. Carbamazepine (Tegretol), an anticonvulsant, may be as effective as lithium as a mood-stabilizing agent. It is often used in clients who do not respond to lithium, although it is not FDA approved for that purpose.

**Dosage and Administration**

Dosage of antidepressant drugs should be individualized according to clinical response. Antidepressant drug therapy is usually initiated with small, divided doses that are gradually increased until therapeutic or adverse effects occur. Specific guidelines for dosage include the following:

1. With SSRIs, nefazodone, and venlafaxine, therapy is begun with once-daily oral administration of the manufacturer’s recommended dosage. Dosage may be increased after 3 or 4 weeks if depression is not relieved. With nefazodone, an optimal response may require 300 mg to 500 mg daily. As with most other drugs, smaller doses may be indicated in older adults and clients taking multiple medications.
CLIENT TEACHING GUIDELINES
Antidepressants and Lithium

General Considerations
✔ Take antidepressants as directed to maximize therapeutic benefits and minimize adverse effects. Do not alter doses when symptoms subside. Antidepressants are usually given for several months, perhaps years; lithium therapy may be lifelong.
✔ Therapeutic effects (relief of symptoms) may not occur for 2 to 4 weeks after drug therapy is started. As a result, it is very important not to think the drug is ineffective and stop taking it prematurely.
✔ Do not take other prescription or over-the-counter drugs without consulting a health care provider, including over-the-counter cold remedies. Potentially serious drug interactions may occur.
✔ Do not take the herbal supplement St. John’s wort while taking a prescription antidepressant drug. Serious interactions may occur.
✔ Inform any physician, surgeon, dentist or nurse practitioner about the antidepressant drugs being taken. Potentially serious adverse effects or drug interactions may occur if certain other drugs are prescribed.
✔ Avoid activities that require alertness and physical coordination (eg, driving a car, operating other machinery) until reasonably sure the medication does not make you drowsy or impair your ability to perform the activities safely.
✔ Avoid alcohol and other central nervous system depressants (eg, any drugs that cause drowsiness). Excessive drowsiness, dizziness, difficulty breathing, and low blood pressure may occur, with potentially serious consequences.
✔ Learn the name and type of a prescribed antidepressant drug to help avoid undesirable interactions with other drugs or a physician prescribing other drugs with similar effects. There are several different types of antidepressant drugs, with different characteristics and precautions for safe and effective usage.
✔ Bupropion is a unique drug prescribed for depression (brand name, Wellbutrin) and for smoking cessation (brand name, Zyban). It is extremely important not to increase the dose or take the two brand names at the same time (as might happen with different physicians or filling prescriptions at different pharmacies). Overdoses may cause seizures, as well as other adverse effects. When used for smoking cessation, Zyban is recommended for up to 12 weeks if progress is being made. If significant progress is not made by approximately 7 weeks, it is considered unlikely that longer drug use will be helpful.
✔ Do not stop taking any antidepressant drug without discussing it with a health care provider. If a problem occurs, the type of drug, the dose, or other aspects may be changed to solve the problem and allow continued use of the medication.
✔ Counseling, support groups, relaxation techniques, and other nonmedication treatments are recommended along with drug therapy.

Self-administration
✔ With a selective serotonin reuptake inhibitor (eg, Celexa, Paxil, Prozac, Zoloft), take in the morning because the drug may interfere with sleep if taken at bedtime. In addition, notify a health care provider if a skin rash or other allergic reaction occurs. Allergic reactions are uncommon but may require that the drug be discontinued.
✔ With a tricyclic antidepressant (eg, amitriptyline), take at bedtime to aid sleep and decrease side effects. Also, report urinary retention, fainting, irregular heartbeat, seizures, restlessness, and mental confusion. These are potentially serious adverse drug effects.
✔ With nefazodone (Serzone) and venlafaxine (Effexor), take as directed or ask for instructions. These drugs are often taken twice daily. Notify a health care provider if a skin rash or other allergic reaction occurs. An allergic reaction may require that the drug be discontinued.
✔ With bupropion, take two or three times daily, as prescribed.
✔ With lithium, several precautions are needed for safe use:
   1. Take with food or milk or soon after a meal to decrease stomach upset.
   2. Do not alter dietary salt intake. Decreased salt intake (eg, low-salt diet) increases risk of adverse effects from lithium. Increased intake may decrease therapeutic effects.
   3. Drink 8 to 12 glasses of fluids daily; avoid excessive intake of caffeine-containing beverages. Caffeine has a diuretic effect and dehydration increases lithium toxicity.
   4. Minimize activities that cause excessive perspiration. Loss of salt in sweat increases the risk of adverse effects from lithium.
   5. Report for measurements of lithium blood levels as instructed, and do not take the morning dose of lithium until the blood sample has been obtained. Regular measurements of blood lithium levels are necessary for safe and effective lithium therapy. Accurate measurement of serum drug levels requires that blood be drawn approximately 12 hours after the previous dose of lithium.
   6. If signs of overdose occur (eg, vomiting, diarrhea, unsteady walking, tremor, drowsiness, muscle weakness), stop taking lithium and contact the prescribing physician or other health care provider.
Once symptoms of mania are controlled, lithium doses should be lowered. Serum lithium levels should be measured at least every 3 months during long-term maintenance therapy.

**Duration of Drug Therapy**

Guidelines for the duration of antidepressant drug therapy are not well established, and there are differences of opinion. Some authorities recommend 9 months of treatment after symptoms subside for a first episode of depression, 5 years after symptoms subside for a second episode, and long-term therapy after a third episode. One argument for long-term maintenance therapy is that depression tends to relapse or recur, and successive episodes often are more severe and more difficult to treat.

Maintenance therapy for depression requires close supervision and periodic reassessment of the client’s condition and response. With the use of TCAs for acute depression, low doses have been given for several months, followed by gradual tapering of the dose and drug discontinuation. However, recent studies indicate that full therapeutic doses (if clients can tolerate the adverse effects) for up to 5 years are effective in preventing recurrent episodes. The long-term effects of SSRIs and newer agents have not been studied.

With lithium, long-term therapy is the usual practice because of a high recurrence rate if the drug is discontinued. When lithium is discontinued, most often because of adverse effects or the client’s lack of adherence to the prescribed regimen, gradually tapering the dose over 2 to 4 weeks delays recurrence of symptoms.

**Effects of Antidepressants on Other Drugs**

The SSRIs are strong inhibitors of the cytochrome P450 enzyme system, which metabolizes many drugs, especially those metabolized by the 1A2, 2D6, and 3A4 groups of enzymes. Inhibiting the enzymes that normally metabolize or inactivate a drug produces the same effect as an excessive dose of the inhibited drug. As a result, serum drug levels and risks of adverse effects are greatly increased. Specific interactions include the following:

- Fluvoxamine inhibits both 1A2 and 3A4 enzymes. Inhibition of 1A2 enzymes slows metabolism of acetaminophen, caffeine, clozapine, haloperidol, olanzapine, tacrine, theophylline, tricyclic antidepressants, and warfarin. Inhibition of 3A4 enzymes slows metabolism of benzodiazepines (alprazolam, midazolam, triazolam), calcium channel blockers (diltiazem, nifedipine, verapamil), cyclosporine, erythromycin, protease inhibitors (anti-AIDS drugs, indinavir, ritonavir, saquinavir), steroids, tamoxifen, warfarin, and zolpidem.
- Fluoxetine, paroxetine, and sertraline inhibit 2D6 enzymes and slow metabolism of bupropion, codeine,
Toxicity of Antidepressants and Lithium: Recognition and Management

Some antidepressant drugs are highly toxic and potentially lethal when taken in large doses. Toxicity is most likely to occur in depressed clients who intentionally ingest large amounts of drug in suicide attempts and in young children who accidentally gain access to medication containers. Measures to prevent acute poisoning from drug overdose include dispensing only a few days’ supply (ie, 5 to 7 days) to clients with suicidal tendencies and storing the drugs in places inaccessible to young children. General measures to treat acute poisoning include early detection of signs and symptoms, stopping the drug, and instituting treatment if indicated. Specific measures include the following:

SSRI overdose: Symptoms include nausea, vomiting, agitation, restlessness, hypomania, and other signs of CNS stimulation. Management includes symptomatic and supportive treatment, such as maintaining an adequate airway and ventilation and administering activated charcoal.

TCA overdose: Symptoms occur 1 to 4 hours after drug ingestion and consist primarily of CNS depression and cardiovascular effects (eg, nystagmus, tremor, restlessness, seizures, hypotension, dysrhythmias, myocardial depression).Death usually results from cardiac, respiratory, and circulatory failure. Management of TCA toxicity consists of providing gastric lavage and giving activated charcoal to reduce drug absorption, establishing and maintaining a patent airway, performing continuous ECG monitoring of comatose clients or those with respiratory insufficiency or wide QRS intervals, giving intravenous fluids and vasopressors for severe hypotension, and giving intravenous phenytoin (Dilantin) or fosphenytoin (Cerebyx) or a parenteral benzodiazepine (eg, lorazepam) if seizures occur.

MAOI overdose: Symptoms occur 12 hours or more after drug ingestion and consist primarily of adrenergic effects (eg, tachycardia, increased rate of respiration, agitation, tremors, convulsive seizures, sweating, heart block, hypotension, delirium, coma). Management consists of diuresis, acidification of urine, or hemodialysis to remove the drug from the body.

Bupropion overdose: Symptoms include agitation and other mental status changes, nausea and vomiting, and seizures. General treatment measures include hospitalization, decreasing absorption (eg, giving activated charcoal to conscious clients), and supporting vital functions. If seizures occur, an intravenous benzodiazepine (eg, lorazepam) is the drug of first choice.

Nefazodone or venlafaxine overdose: Symptoms include increased incidence or severity of adverse effects, with nausea, vomiting, and drowsiness most often reported. Hypotension and excessive sedation may occur with nefazodone, seizures and diastolic hypertension with venlafaxine. There are no specific antidotes; treatment is symptomatic and supportive.

Lithium overdose: Toxic manifestations occur with serum lithium levels above 2.5 mEq/L and include nystagmus, tremors, oliguria, confusion, impaired consciousness, visual or tactile hallucinations, choreiform movements, convulsions, coma, and death. Treatment involves supportive care to maintain vital functions, including correction of fluid and electrolyte imbalances. With severe overdoses, hemodialysis is preferred because it removes lithium from the body.

Prevention and Management of Withdrawal Symptoms

Withdrawal symptoms have been reported with sudden discontinuation of most antidepressant drugs. In general, symptoms occur more rapidly and may be more intense with drugs having a short half-life. As with other psychotropic drugs, these drugs should be tapered in dosage and discontinued gradually unless severe drug toxicity, anaphylactic reactions, or other life-threatening conditions are present. Most antidepressants may be tapered and discontinued over approximately 1 week without serious withdrawal symptoms. For a client on maintenance drug therapy, the occurrence of withdrawal symptoms may indicate that the client has omitted doses or stopped taking the drug.

The most clearly defined withdrawal syndromes are associated with SSRIs and TCAs. With SSRIs, withdrawal symptoms include dizziness, nausea, and headache and last from several days to several weeks. More serious symptoms may include aggression, hypomania, mood disturbances, and suicidal tendencies. Fluoxetine has a long half-life and has not been associated with withdrawal symptoms. Other SSRIs have short half-lives and may cause withdrawal reactions if stopped abruptly. Paroxetine, which has a half-life of approximately 24 hours and does not produce active metabolites, may be associated with relatively severe withdrawal symptoms even when discontinued gradually, over 7 to 10 days. Symptoms
may include a flu-like syndrome with nausea, vomiting, fatigue, muscle aches, dizziness, headache, and insomnia. The short-acting SSRIs should be tapered in dosage and gradually discontinued to prevent or minimize withdrawal reactions.

With TCAs, the main concern is over those with strong anticholinergic effects. When stopped abruptly, especially with high doses, these drugs can cause symptoms of excessive cholinergic activity (ie, hypersalivation, diarrhea, urinary urgency, abdominal cramping, and sweating). A recommended rate for tapering TCAs is approximately 25 to 50 mg every 2 to 3 days.

**Genetic or Ethnic Considerations**

Antidepressant drug therapy for nonwhite populations in the United States is based primarily on dosage recommendations, pharmacokinetic data, and adverse effects derived from white recipients. However, several studies document differences in drug effects in nonwhite populations. The differences are mainly attributed to genetic or ethnic variations in drug-metabolizing enzymes in the liver. Although all ethnic groups are genetically heterogeneous and individual members may respond differently, health care providers need to consider potential differences in responses to drug therapy.

1. **African Americans** tend to have higher plasma levels for a given dose, respond more rapidly, experience a higher incidence of adverse effects, and metabolize TCAs more slowly than whites. To decrease adverse effects, initial doses may need to be lower than those given to whites and later doses should be titrated according to clinical response and serum drug levels. In addition, baseline and periodic ECGs are recommended to detect adverse drug effects on the heart. Studies have not been done with newer antidepressants. With lithium, African Americans report more adverse reactions than whites and may need smaller doses.

2. **Asians** tend to metabolize antidepressant drugs slowly and therefore have higher plasma drug levels for a given dose than whites. Most studies have been done with TCAs and a limited number of Asian subgroups. Thus, it cannot be assumed that all antidepressant drugs and all people of Asian heritage respond the same. To avoid drug toxicity, initial doses should be approximately half the usual doses given to whites and later doses should be titrated according to clinical response and serum drug levels. This recommendation is supported by a survey from several Asian countries that reported the use of much smaller doses of TCAs than in the United States. In addition, in Asians as in African Americans, baseline and periodic ECGs are recommended to detect adverse drug effects on the heart. Studies have not been done with newer antidepressants. With lithium, there are no apparent differences between effects in Asians and whites.

3. **Hispanics’** responses to antidepressant drugs are largely unknown. Few studies have been done, with some reporting a need for lower doses of TCAs and greater susceptibility to anticholinergic effects, whereas others report no differences between Hispanics and whites.

**Use in Perioperative Periods**

Antidepressants must be used very cautiously, if at all, perioperatively because of the risk of serious adverse effects and adverse interactions with anesthetics and other commonly used drugs. MAOIs are contraindicated and should be discontinued at least 10 days before elective surgery. TCAs should be discontinued several days before elective surgery and resumed several days after surgery. SSRIs and miscellaneous antidepressants have not been studied in relation to perioperative use; however, it seems reasonable to discontinue the drugs when feasible because of potential adverse effects, especially on the cardiovascular system and CNS. It is usually recommended that antidepressants be tapered in dosage and gradually discontinued. Lithium should be stopped 1 to 2 days before surgery and resumed when full oral intake of food and fluids is allowed. Lithium may prolong the effects of anesthetics and neuromuscular blocking drugs.

**Use in Children**

Depression commonly occurs in children and adolescents and antidepressant drugs are widely prescribed. However, drug therapy is largely empiric and of unproven effectiveness. Although some antidepressants are approved for other uses in children (eg, two SSRIs, fluvoxamine and sertraline, are approved for treatment of obsessive-compulsive disorder, and some TCAs are approved for treatment of enuresis), none is approved for treatment of depression. Moreover, the long-term effects of antidepressant drugs on the developing brain are unknown. Overall, there are few reliable data or guidelines for the use of antidepressants in children and adolescents. Considerations include the following:

1. For most children and adolescents, it is probably best to reserve drug therapy for those who do not respond to nonpharmacologic treatment and those whose depression is persistent or severe enough to impair function in usual activities of daily living.

2. For adolescents, it may be important to discuss sexual effects because the SSRIs and venlafaxine cause a high incidence of sexual dysfunction (eg, anorgasmia,
doses may be prudent. The weight loss often associated with may be eliminated more slowly, and smaller or less frequent their effects in older adults are not well delineated, SSRIs adverse effects in older adults as in younger adults. Although these drugs produce similar adverse effects (improvement of mood, increased energy and motivation) from the adverse effects of behavioral activation (agitation, hypomania, restlessness).

4. TCAs are not recommended for use in children younger than 12 years of age except for short-term treatment of enuresis in children older than 6 years of age. However, they are used to treat depression, mainly amitriptyline, desipramine, imipramine, and nortriptyline. Because of potentially serious adverse effects, blood pressure, ECGs, and plasma drug levels should be monitored. There is evidence that children metabolize TCAs faster than adults, and withdrawal symptoms (eg, increased GI motility, malaise, headache) are more common in children than in adults.

Divided doses may be better tolerated and minimize withdrawal symptoms. When a TCA is used for enuresis, effectiveness may decrease over time, and no residual benefits continue once the drug is stopped. Common adverse effects include sedation, fatigue, nervousness, and sleep disorders. A TCA probably is not a drug of first choice for adolescents because TCAs are more toxic in overdose than other antidepressants and suicide is a leading cause of death in adolescents.

5. Safety and effectiveness have not been established for amoxapine and MAOIs in children younger than 16 years of age or for bupropion, mirtazapine, nefazodone, and venlafaxine in children younger than 18 years of age.

6. Lithium is not approved for use in children younger than 12 years of age, but it has been used to treat bipolar disorder and aggressiveness. Children normally excrete lithium more rapidly than adults. As with adults, initial doses should be relatively low and gradually increased according to regular measurements of serum drug levels.

Use in Older Adults

SSRIs are the drugs of choice in older adults as in younger ones because they produce fewer sedative, anticholinergic, cardiotoxic, and psychomotor adverse effects than the TCAs and related antidepressants. These drugs produce similar adverse effects in older adults as in younger adults. Although their effects in older adults are not well delineated, SSRIs may be eliminated more slowly, and smaller or less frequent doses may be prudent. The weight loss often associated with SSRIs may be undesirable in older adults. Nefazodone and venlafaxine may also be used in older adults, with smaller initial doses and increments recommended.

TCAs may cause or aggravate conditions that are common in older adults (eg, cardiac conduction abnormalities, urinary retention, narrow-angle glaucoma). In addition, impaired compensatory mechanisms make older adults more likely to experience anticholinergic effects, confusion, hypotension, and sedation. If a TCA is chosen for an older adult, nortriptyline or desipramine is preferred. In addition, any TCA should be given in small doses initially and gradually increased over several weeks, if necessary, to achieve therapeutic effects. Initial and maintenance doses should be small because the drugs are metabolized and excreted more slowly than in younger adults. Initial dosage should be decreased by 30% to 50% to avoid serious adverse reactions; increments should be small. Vital signs, serum drug levels, and ECGs should be monitored regularly.

MAOIs may be more likely to cause hypertensive crises in older adults because cardiovascular, renal, and hepatic functions are often diminished.

With lithium, initial doses should be low and increased gradually, according to regular measurements of serum drug levels.

Use in Renal Impairment

Antidepressants should be used cautiously in the presence of severe renal impairment. Mild or moderate impairment has few effects, but severe impairment may increase plasma levels and adverse effects of virtually all antidepressants. Thus, small initial doses, slow increases, and less frequent dosing are indicated.

Lithium is eliminated only by the kidneys and it has a very narrow therapeutic range. If given to a client with renal impairment or unstable renal function, the dose must be markedly reduced and plasma lithium levels must be closely monitored.

Use in Hepatic Impairment

Hepatic impairment leads to reduced first-pass metabolism of most antidepressant drugs, with resultant higher plasma levels. The drugs should be used cautiously in clients with severe liver impairment. Cautious use means lower doses, longer intervals between doses, and slower dose increases than usual.

Fluoxetine and sertraline are less readily metabolized to their active metabolites with hepatic impairment. In clients with cirrhosis, for example, the average half-life of fluoxetine may increase from 2 to 3 days to more than 7 days, and that of norfluoxetine, the active metabolite, from 7 to 9 days to 12 days. Clearance of sertraline is also decreased in clients with cirrhosis. Paroxetine has a short half-life and no active metabolites, but increased plasma levels can occur with severe hepatic impairment.
Tricyclic antidepressants are also less readily metabolized with severe hepatic impairment (eg, severe cirrhosis). This increases the risk of adverse effects such as sedation and hypotension.

Nefazodone has been associated with a few cases of liver failure and should not be given to clients with severe liver impairment. In addition, blood levels of nefazodone are higher in clients with cirrhosis.

Use in Critical Illness

Critically ill clients may be receiving an antidepressant drug when the critical illness develops or may need a drug to combat the depression that often develops with major illness. The decision to continue or start an antidepressant drug should be based on a thorough assessment of the client’s condition, other drugs being given, potential adverse drug effects, and other factors. If an antidepressant is given, its use must be cautious and slow and the client’s responses carefully monitored because critically ill clients are often frail and unstable, with multiple organ dysfunctions.

Home Care

Whatever the primary problem for which a home care nurse is visiting a client, he or she must be vigilant for signs and symptoms of major depression. Depression often accompanies any serious physical illness and may occur in many other circumstances as well. The main role of the nurse may be in recognizing depressive states and referring clients for treatment. If an antidepressant medication was recently started, the nurse may need to remind the client that it usually takes 2 to 4 weeks to feel better; the nurse should encourage the client to continue taking the medication. Also, the nurse needs to observe the client’s response and assess for suicidal thoughts or plans.

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>Antidepressants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NURSING ACTIONS</strong></td>
<td><strong>RATIONALE/EXPLANATION</strong></td>
</tr>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
</tbody>
</table>
  a. Give most selective serotonin reuptake inhibitors (SSRIs) once daily in the morning; citalopram and sertraline may be given morning or evening.  
  b. Mix sertraline oral concentrate (20 mg/mL) in 4 oz of water, ginger ale, lemon/lime soda, lemonade, or orange juice only; give immediately after mixing.  
  c. Give tricyclic antidepressants (TCAs) and mirtazapine at bedtime.  
  d. Give venlafaxine and lithium with food. | To prevent insomnia  
Manufacturer’s recommendation  
To aid sleep and decrease daytime sedation  
To decrease gastrointestinal (GI) effects (eg, nausea and vomiting) Therapeutic effects occur 2 to 4 weeks after drug therapy is started. |
| 2. Observe for therapeutic effects |  
  a. With antidepressants for depression, observe for statements of feeling better or less depressed; increased appetite, physical activity, and interest in surroundings; improved sleep patterns; improved appearance; decreased anxiety; decreased somatic complaints.  
  b. With antidepressants for anxiety disorders, observe for decreased symptoms of the disorders (see Chap. 8)  
  c. With lithium, observe for decreases in manic behavior and mood swings. | Therapeutic effects do not occur until approximately 7 to 10 days after therapeutic serum drug levels (1–1.5 mEq/L with acute mania; 0.6–1.2 mEq/L for maintenance therapy) are attained. In mania, a benzodiazepine or an antipsychotic drug is usually given to reduce agitation and control behavior until the lithium takes effect. |

(continued)
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>3. Observe for adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a.</strong> With SSRIs nefazodone and venlafaxine, observe for dizziness, headache, nervousness, insomnia, nausea, diarrhea, dizziness, dry mouth, sedation, skin rash, sexual dysfunction.</td>
</tr>
<tr>
<td><strong>b.</strong> With TCAs, observe for:</td>
</tr>
<tr>
<td>(1) Central nervous system (CNS) effects—drowsiness, dizziness, confusion, poor memory</td>
</tr>
<tr>
<td>(2) Cardiovascular effects—cardiac arrhythmias, tachycardia, orthostatic hypotension</td>
</tr>
<tr>
<td>(3) GI effects—nausea, dry mouth, constipation</td>
</tr>
<tr>
<td>(4) Other effects—blurred vision, urinary retention, sexual dysfunction, weight gain</td>
</tr>
<tr>
<td><strong>c.</strong> With monoamine oxidase inhibitors (MAOIs), observe for blurred vision, constipation, dizziness, dry mouth, hypotension, urinary retention, hypoglycemia.</td>
</tr>
<tr>
<td><strong>d.</strong> With bupropion, observe for seizure activity, CNS stimulation (agitation, insomnia, hyperactivity, hallucinations, delusions), headache, nausea and vomiting, and weight loss.</td>
</tr>
<tr>
<td><strong>e.</strong> With mirtazapine, observe for sedation, confusion, dry mouth, constipation, nausea and vomiting, hypotension, tachycardia, urinary retention, photosensitivity, skin rash, weight gain.</td>
</tr>
<tr>
<td><strong>f.</strong> With nefazodone, observe for:</td>
</tr>
<tr>
<td>(1) CNS effects—anxiety, drowsiness, dizziness, headache, insomnia</td>
</tr>
<tr>
<td>(2) GI effects—nausea, vomiting, diarrhea, dry mouth, anorexia, constipation</td>
</tr>
<tr>
<td>(3) Cardiovascular effect—orthostatic hypotension</td>
</tr>
<tr>
<td>(4) Hepatic effect—liver failure (anorexia, nausea, vomiting, abdominal pain, dark urine, jaundice)</td>
</tr>
<tr>
<td><strong>g.</strong> With lithium, observe for:</td>
</tr>
<tr>
<td>(1) Metallic taste, hand tremors, nausea, polyuria, polydipsia, diarrhea, muscular weakness, fatigue, edema, and weight gain</td>
</tr>
<tr>
<td>(2) More severe nausea and diarrhea, vomiting, ataxia, incoordination, dizziness, slurred speech, blurred vision, tinnitus, muscle twitching and tremors, increased muscle tone</td>
</tr>
<tr>
<td>(3) Leukocytosis</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

GI upset and diarrhea are common with SSRIs; GI upset, diarrhea, and orthostatic hypotension are common with nefazodone; GI upset, diarrhea, agitation, and insomnia are common with venlafaxine. Although numerous adverse effects may occur, they are usually less serious than those occurring with most other antidepressants. Compared with the TCAs, SSRIs and other newer drugs are less likely to cause significant sedation, hypotension, and cardiac arrhythmias but are more likely to cause nausea, nervousness, and insomnia.

Most adverse effects result from anticholinergic or antiadrenergic activity. Cardiovascular effects are most serious in overdose.

Anticholinergic effects are common. Hypoglycemia results from a drug-induced reduction in blood sugar.

Adverse effects are most likely to occur if recommended doses are exceeded. Note that bupropion has few, if any, effects on cardiac conduction and does not cause orthostatic hypotension.

Common effects are drowsiness, dizziness, and weight gain. Has CNS depressant and anticholinergic effects.

Most clients who take lithium experience adverse effects. Symptoms listed in (1) are common, occur at therapeutic serum drug levels (0.8–1.2 mEq/L), and usually subside during the first few weeks of drug therapy. Symptoms listed in (2) occur at higher serum drug levels (1.5–2.5 mEq/L). Nausea may be decreased by giving lithium with meals. Propranolol (Inderal), 20–120 mg daily, may be given to control tremors. Severe adverse effects may be managed by decreasing lithium dosage, omitting a few doses, or discontinuing the drug temporarily. Toxic symptoms occur at serum drug levels above 2.5 mEq/L.

Lithium mobilizes white blood cells (WBCs) from bone marrow to the bloodstream. Maximum increase in WBCs occurs in 7 to 10 days.
### Nursing Actions

<table>
<thead>
<tr>
<th>4. Observe for drug interactions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Drugs that increase effects of SSRIs:</strong></td>
<td>Drug interactions with the SSRIs vary with individual drugs. May increase serum drug levels of SSRIs by slowing their metabolism</td>
</tr>
<tr>
<td>(1) Cimetidine</td>
<td>SSRIs and MAOIs should not be given concurrently or close together because serious and fatal reactions have occurred. The reaction, attributed to excess serotonin and called the serotonin syndrome, may cause hyperthermia, muscle spasm, agitation, delirium, and coma. To avoid this reaction, an SSRI should not be started for at least 2 weeks after an MAOI is discontinued, and an MAOI should not be started for at least 2 weeks after an SSRI has been discontinued (5 weeks with fluoxetine, because of its long half-life).</td>
</tr>
<tr>
<td>(2) MAOIs</td>
<td></td>
</tr>
<tr>
<td><strong>b. Drugs that decrease effects of SSRIs:</strong></td>
<td>These drugs induce liver enzymes that accelerate the metabolism of the SSRIs. This is an antihistamine with antiserotonin effects.</td>
</tr>
<tr>
<td>(1) Carbamazepine, phenytoin, rifampin</td>
<td>See SSRIs, above. These drugs and MAOIs should not be given concurrently or close together because serious and fatal reactions have occurred. Mirtazapine should be stopped at least 14 days and nefazodone or venlafaxine at least 7 days before starting an MAOI, and an MAOI should be stopped at least 14 days before starting mirtazapine, nefazodone or venlafaxine.</td>
</tr>
<tr>
<td>(2) Cyproheptadine</td>
<td></td>
</tr>
<tr>
<td><strong>c. Drugs that increase the effects of mirtazapine, nefazodone, and venlafaxine:</strong></td>
<td>Additive effects on cardiac conduction, increasing risk of heart block</td>
</tr>
<tr>
<td>(1) MAOIs</td>
<td>Additive anticholinergic effects (eg, dry mouth, blurred vision, urinary retention, constipation)</td>
</tr>
<tr>
<td><strong>d. Drugs that increase effects of TCAs:</strong></td>
<td>Additive anticholinergic effects</td>
</tr>
<tr>
<td>(1) Antiarrhythmics (eg, quinidine, disopyramide, procainamide)</td>
<td>Additive hypotension</td>
</tr>
<tr>
<td>(2) Antihistamines, atropine, and other drugs with anticholinergic effects</td>
<td>Increases risks of toxicity by decreasing hepatic metabolism and increasing blood levels of TCAs</td>
</tr>
<tr>
<td>(3) Antihypertensives</td>
<td>Additive sedation and CNS depression</td>
</tr>
<tr>
<td>(4) Cimetidine</td>
<td>TCAs should not be given with MAOIs or within 2 weeks after an MAOI drug; hyperpyrexia, convulsions, and death have occurred with concurrent use. Inhibit metabolism of TCAs</td>
</tr>
<tr>
<td>(5) CNS depressants (eg, alcohol, benzodiazepine anti-anxiety and hypnotic agents, opioid analgesics)</td>
<td>These drugs induce drug-metabolizing enzymes in the liver, which increases the rate of TCA metabolism and elimination from the body.</td>
</tr>
<tr>
<td>(6) MAOIs</td>
<td>Additive anticholinergic effects</td>
</tr>
<tr>
<td>(7) SSRIs</td>
<td>Hypertensive crisis and stroke may occur.</td>
</tr>
<tr>
<td><strong>e. Drugs that decrease effects of TCAs:</strong></td>
<td>(continued)</td>
</tr>
<tr>
<td>(1) Carbamazepine, phenytoin, rifampin, nicotine (cigarette smoking)</td>
<td></td>
</tr>
<tr>
<td><strong>f. Drugs that increase effects of MAOIs:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Anticholinergic drugs (eg, atropine, antipsychotic agents, TCAs)</td>
<td></td>
</tr>
<tr>
<td>(2) Adrenergic agents (eg, epinephrine, phenylephrine), alcohol (some beers and wines), levodopa, meperidine</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Review and Application Exercises

1. During the initial assessment of any client, what kinds of appearances or behaviors may indicate depression?

2. Is antidepressant drug therapy indicated for most episodes of temporary sadness? Why or why not?

3. What are the major groups of antidepressant drugs?

4. How do the drugs act to relieve depression?

5. When a client begins antidepressant drug therapy, why is it important to explain that relief of depression may not occur for a few weeks?

6. What are common adverse effects of TCAs, and how may they be minimized?

7. What is the advantage of giving a TCA at bedtime rather than in the morning?

8. For a client taking an MAOI, what information would you provide for preventing a hypertensive crisis?

9. How do the SSRIs differ from TCAs?

10. How do the newer drugs, mirtazapine, nefazodone, and venlafaxine, compare with the SSRIs in terms of adverse effects and adverse drug–drug interactions?

11. List the main elements of treatment for antidepressant overdoses.

12. What are common adverse effects of lithium, and how may they be minimized?

13. What is the nurse’s role in assessing and managing depression in special populations? In the home setting?

### How Can You Avoid This Medication Error?

**Answer:** Do not leave medications at the bedside of a client. Often they can be forgotten or taken away with the food tray. Missing a dose of a medication can affect therapeutic blood levels. In this situation, special care should be taken to supervise all medications. Depressed clients could save up medication to commit suicide by overdosing. The risk for this increases as the antidepressant drugs start to work, giving the client more energy to carry out suicidal actions. Wake Jane up and firmly encourage her to take her medications as you watch.

### Nursing Notes: Apply Your Knowledge

**Answer:** Prozac has a long half-life (24 to 72 hours), so it takes longer than a week to reach steady state. The dosage is usually not increased for 3 to 4 weeks. It is important to teach all clients beginning therapy with antidepressants that they may not see significant improvement in their depression for a number of weeks. Ms. Jordan’s sleeping difficulty could be a symptom of her depression or a side effect of the Prozac. If it is a drug side effect, it might help to take the drug in the morning.

### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>g. Drugs that increase effects of lithium:</td>
<td></td>
</tr>
<tr>
<td>(1) Angiotensin-converting enzyme inhibitors (eg, captopril)</td>
<td>Decrease renal clearance of lithium and thus increase serum lithium levels and risks of toxicity.</td>
</tr>
<tr>
<td>(2) Diuretics (eg, furosemide, hydrochlorothiazide)</td>
<td>Increase neurotoxicity and cardiotoxicity of lithium by increasing excretion of sodium and potassium and thereby decreasing excretion of lithium.</td>
</tr>
<tr>
<td>(3) Nonsteroidal anti-inflammatory drugs</td>
<td>Decrease renal clearance of lithium and thus increase serum levels and risks of lithium toxicity.</td>
</tr>
<tr>
<td>(4) Phenothiazines</td>
<td>Increased risk of hyperglycemia</td>
</tr>
<tr>
<td>(5) TCAs</td>
<td>May increase effects of lithium and are sometimes combined with lithium for this purpose. These drugs also may precipitate a manic episode and increase risks of hypothyroidism.</td>
</tr>
<tr>
<td>h. Drugs that decrease effects of lithium:</td>
<td></td>
</tr>
<tr>
<td>(1) Acetazolamide, sodium chloride (in excessive amounts), drugs with a high sodium content (eg, ticarcillin), theophylline</td>
<td>Increase excretion of lithium</td>
</tr>
</tbody>
</table>

### Selected References

chapter 11

Antiseizure Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify types and potential causes of seizures.
2. Discuss major factors that influence choice of an antiseizure drug for a client with a seizure disorder.
3. Differentiate characteristics and effects of commonly used antiseizure drugs.
4. Differentiate between older and newer antiseizure drugs.
5. Compare advantages and disadvantages between monotherapy and combination drug therapy for seizure disorders.
6. Apply the nursing process with clients receiving antiepileptic drugs.
7. Describe strategies for prevention and treatment of status epilepticus.
8. Discuss the use of antiseizure drugs in special populations.

Critical Thinking Scenario
You are caring for 6-month-old Jamie, who was just diagnosed with tonic-clonic seizures. He was started on valproic acid (Depakene) 30 mg qid and has only had one seizure during his 4-day hospitalization. He will be discharged today to his single, teenaged mother, who will be the primary caregiver.

Reflect on:
- How you would feel as a new parent if your infant were diagnosed with a seizure disorder. What would be your most significant fears?
- Given 15 minutes for discharge teaching, prioritize your teaching plan, considering the following: safe administration of an anticonvulsant medication to a 6-month-old; methods to avoid skipping doses, which could increase risk of seizures; management of Jamie during a seizure to ensure safety.

SEIZURE DISORDERS

Antiseizure drugs are also called antiepileptic drugs (AEDs) or anticonvulsants. The terms seizure and convulsion are often used interchangeably, although they are not the same. A seizure involves a brief episode of abnormal electrical activity in nerve cells of the brain that may or may not be accompanied by visible changes in appearance or behavior. A convulsion is a tonic-clonic type of seizure characterized by spasmodic contractions of involuntary muscles.

Seizures may occur as single events in response to hypoglycemia, fever, electrolyte imbalances, overdoses of numerous drugs (eg, amphetamine, cocaine, isoniazid, lidocaine, lithium, methylphenidate, antipsychotics, theophylline), and withdrawal of alcohol or sedative-hypnotic drugs. In these instances, treatment of the underlying problem or temporary use of an AED may relieve the seizures.

Epilepsy

When seizures occur in a chronic, recurrent pattern, the disorder is called epilepsy, and drug therapy is usually required. Epilepsy is characterized by abnormal and excessive electrical discharges of nerve cells. It is diagnosed by clinical signs and symptoms of seizure activity and by the presence of abnormal brain wave patterns on the electroencephalogram. The cause is unknown in 60% to 80% of children and adolescents and 50% of older adults. When epilepsy begins in infancy, causes include developmental defects, metabolic disease, or birth injury. Fever is a common cause during late infancy and early childhood, and inherited forms usually begin in childhood or adolescence. When epilepsy begins in adulthood, it is often caused by an acquired neurologic disorder (eg, head injury, stroke, brain tumor) or alcohol and other drug effects. The incidence of epilepsy is
higher in young children and older adults than in other age groups.

Epilepsy is broadly classified as partial and generalized seizures. Partial seizures begin in a specific area of the brain and often indicate a localized brain lesion such as birth injury, trauma, stroke, or tumor. They produce symptoms ranging from simple motor and sensory manifestations to more complex abnormal movements and bizarre behavior. Movements are usually automatic, repetitive, and inappropriate to the situation, such as chewing, swallowing, or aversive movements. Behavior is sometimes so bizarre that the person is diagnosed as psychotic or schizophrenic. In simple partial seizures, consciousness is not impaired; in complex partial seizures, the level of consciousness is decreased.

Generalized seizures are bilateral and symmetric and have no discernible point of origin in the brain. The most common type is the tonic-clonic or major motor seizure. The tonic phase involves sustained contraction of skeletal muscles; abnormal postures, such as opisthotonos; and absence of respiration, during which the person becomes cyanotic. The clonic phase is characterized by rapid rhythmic and symmetric jerking movements of the body. Tonic-clonic seizures are sometimes preceded by an aura, a brief warning, such as a flash of light or a specific sound. In children, febrile seizures (ie, tonic-clonic seizures that occur in the absence of other identifiable causes) are the most common form of epilepsy.

Another type of generalized seizure is the absence seizure, characterized by abrupt alterations in consciousness that last only a few seconds. The person may have a blank, staring expression with or without blinking of the eyelids, twitching of the head or arms, and other motor movements. Other types of generalized seizures include the myoclonic type (contraction of a muscle or group of muscles) and the akinetic type (absence of movement). Some people are subject to mixed seizures.

Status epilepticus is a life-threatening emergency characterized by generalized tonic-clonic convulsions lasting for several minutes or occurring at close intervals during which the client does not regain consciousness. Hypotension, hypoxia, and cardiac dysrhythmias may also occur. There is a high risk of permanent brain damage and death unless prompt, appropriate treatment is instituted. In a person taking medications for a diagnosed seizure disorder, the most common cause of status epilepticus is abruptly stopping AEDs. In other clients, regardless of whether they have a diagnosed seizure disorder, causes of status epilepticus include brain trauma or tumors, systemic or central nervous system (CNS) infections, alcohol withdrawal, and overdoses of drugs (eg, cocaine, theophylline).

**Mechanisms of Action**

Although the exact mechanism of action is unknown for most AEDs, the drugs are thought to suppress seizures by decreasing movement of ions into nerve cells, altering the activity of neurotransmitters (eg, GABA, glutamate), or a combination of these mechanisms. Because movement of sodium and calcium ions is required for normal conduction of nerve impulses, blocking these ions decreases responsiveness to stimuli and results in stabilized, less excitable cell membranes. Increasing the activity of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the brain, and decreasing the activity of glutamate, the major excitatory neurotransmitter, also decrease nerve cell excitability. The actions of both sodium channel blockers (eg, phenytoin, oxcarbazepine) and GABA enhancers (eg, benzodiazepines and most of the newer AEDs) raise the amount of stimulation required to produce a seizure (called the seizure threshold). Overall, the drugs are thought to stabilize neuronal membranes and decrease neuronal firing in response to stimuli. Some seem able to suppress abnormal neuronal firing without suppressing normal neurotransmission.

**Indications for Use**

The major clinical indication for AEDs is the prevention or treatment of seizures, especially the chronic recurring seizures of epilepsy. Indications for particular drugs depend on the types and severity of seizures involved. For example, most of the newer drugs are indicated for use with one or two other AEDs to treat more severe seizure disorders that do not respond to a single drug. However, oxcarbazepine is approved for monotherapy and studies indicate that most of the other newer drugs may be effective as monotherapy in some types of seizures.

In addition to maintenance treatment of epilepsy, AEDs also are used to stop acute, tonic-clonic convulsions and status epilepticus. The drug of choice for this purpose is an intravenous (IV) benzodiazepine, usually lorazepam. Once acute seizure activity is controlled, a longer-acting drug, such as...
phenytoin or fosphenytoin, is given to prevent recurrence. AEDs are also used prophylactically in clients with brain trauma from injury or surgery.

In addition to treatment of seizure disorders, AEDs are used to treat bipolar disorder (eg, carbamazepine and valproate) although they are not FDA-approved for this purpose. They are also used in the management of chronic neuropathic pain, although few studies validate their effectiveness for this purpose. Carbamazepine is approved for treatment of the pain associated with trigeminal neuralgia. Gabapentin is also being used, but it is not approved for this indication and is not considered better than carbamazepine. Some of the newer AEDs are being tested for effectiveness in relation to bipolar, neuropathic pain, and other disorders. Because the drugs are being used for other indications than seizure disorders, some people suggest they be called neuromodulators or neurostabilizers rather than AEDs or anticonvulsants.

**Contraindications to Use**

AEDs are contraindicated or must be used with caution in clients with CNS depression. Phenytoin, carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, and valproate are contraindicated in clients who have experienced a hypersensitivity reaction to the particular drug (usually manifested by a skin rash, arthralgia, and other symptoms). Phenytoin, carbamazepine, ethosuximide, lamotrigine, topiramate and zonisamide are contraindicated or must be used cautiously in clients with hepatic or renal impairment. Additional contraindications include phenytoin with sinus bradycardia or heart block; carbamazepine with bone marrow depression (eg, leukopenia, agranulocytosis); and tiagabine and valproic acid with liver disease. All of the drugs must be used cautiously during pregnancy because they are teratogenic in animals.

**INDIVIDUAL ANTISEIZURE DRUGS**

Most AEDs are well absorbed with oral administration and are usually given by this route. Most are metabolized in the liver; a few are eliminated mainly through the kidneys. Most produce ataxia (impaired muscular coordination such as a staggering gait when trying to walk), confusion, dizziness, and drowsiness as common adverse effects; some may cause serious or life-threatening adverse effects such as cardiac dysrhythmias, bone marrow depression, or pancreatitis. Because the drugs are so diverse, they cannot be adequately discussed as groups. Consequently, the drugs are described individually; types of seizures for which the drugs are used and dosages are listed in Drugs at a Glance: Antiseizure Drugs.

Phenytoin (Dilantin), the prototype, is one of the oldest and most widely used AEDs. It is often the initial drug of choice, especially in adults. In addition to treatment of seizure disorders, it is sometimes used to treat cardiac dysrhythmias.

With oral phenytoin, the rate and extent of absorption vary with the drug formulation. Prompt-acting forms reach peak plasma levels in 2 to 3 hours, and long-acting forms in about 12 hours. Intramuscular phenytoin is poorly absorbed and not recommended. Phenytoin is highly bound (90%) to plasma proteins. It is metabolized in the liver to inactive metabolites that are excreted in the urine.

The most common adverse effects of phenytoin affect the CNS (eg, ataxia, drowsiness, lethargy) and gastrointestinal (GI) tract (nausea, vomiting). Gingival hyperplasia, an overgrowth of gum tissue, is also common, especially in children. Serious reactions are uncommon but may include allergic reactions, hepatitis, nephritis, bone marrow depression, and mental confusion.

Phenytoin may interact with many other drugs, mainly because it induces drug-metabolizing enzymes in the liver. Thus, it can increase the metabolism of itself and many other drugs, both AEDs and non-AEDs. Also, many other drugs can affect phenytoin metabolism and protein binding.

Phenytoin is available in generic and brand name capsules, a chewable tablet, an oral suspension, and an injectable solution. The injectable solution is highly irritating to tissues and special techniques are required when the drug is given intravenously (IV). Clients should not switch between generic and trade name formulations of phenytoin because of differences in absorption and bioavailability. If a client is stabilized on a generic formulation and switches to Dilantin, there is a risk of higher serum phenytoin levels and toxicity. If a client takes Dilantin and switches to a generic form, there is a risk of lower serum phenytoin levels, loss of therapeutic effectiveness, and seizures. There may also be differences in bioavailability among generic formulations manufactured by different companies.

Fosphenytoin (Cerebyx) is a prodrug formulation that is rapidly hydrolyzed to phenytoin after IV or intramuscular (IM) injection. It is approved for treatment of status epilepticus and for short-term use in clients who cannot take oral phenytoin. In contrast to other preparations of injectable phenytoin, fosphenytoin causes minimal tissue irritation, can be diluted with 5% dextrose or 0.9% sodium chloride solution, and can be given IV more rapidly. The manufacturer recommends that all dosages be expressed in phenytoin equivalents (PE). Fosphenytoin is available in 2-mL and 10-mL vials with 50 mg PE/mL (fosphenytoin 50 mg PE = phenytoin 50 mg). For IV administration, fosphenytoin can be diluted to a concentration of 1.5–25 mg PE/mL, and infused at a maximal rate of 150 mg PE/minute.

Carbamazepine (Tegretol) is used, in addition to seizure disorders, to treat trigeminal neuralgia and bipolar disorder. It is given orally and peak blood levels are reached in about 1.5 hours with the liquid suspension, 4 to 5 hours with conventional tablets, and 3 to 12 hours with extended-release forms (tablets and capsules). It is metabolized in the liver to an active metabolite. Because it induces its own metabolism, its half-life shortens with chronic administration. Carbamazepine is contraindicated in clients with previous bone growth of gum tissue, is also common, especially in children. Serious reactions are uncommon but may include allergic reactions, hepatitis, nephritis, bone marrow depression, and mental confusion.

Phenytoin may interact with many other drugs, mainly because it induces drug-metabolizing enzymes in the liver. Thus, it can increase the metabolism of itself and many other drugs, both AEDs and non-AEDs. Also, many other drugs can affect phenytoin metabolism and protein binding.

Phenytoin is available in generic and brand name capsules, a chewable tablet, an oral suspension, and an injectable solution. The injectable solution is highly irritating to tissues and special techniques are required when the drug is given intravenously (IV). Clients should not switch between generic and trade name formulations of phenytoin because of differences in absorption and bioavailability. If a client is stabilized on a generic formulation and switches to Dilantin, there is a risk of higher serum phenytoin levels and toxicity. If a client takes Dilantin and switches to a generic form, there is a risk of lower serum phenytoin levels, loss of therapeutic effectiveness, and seizures. There may also be differences in bioavailability among generic formulations manufactured by different companies.

Fosphenytoin (Cerebyx) is a prodrug formulation that is rapidly hydrolyzed to phenytoin after IV or intramuscular (IM) injection. It is approved for treatment of status epilepticus and for short-term use in clients who cannot take oral phenytoin. In contrast to other preparations of injectable phenytoin, fosphenytoin causes minimal tissue irritation, can be diluted with 5% dextrose or 0.9% sodium chloride solution, and can be given IV more rapidly. The manufacturer recommends that all dosages be expressed in phenytoin equivalents (PE). Fosphenytoin is available in 2-mL and 10-mL vials with 50 mg PE/mL (fosphenytoin 50 mg PE = phenytoin 50 mg). For IV administration, fosphenytoin can be diluted to a concentration of 1.5–25 mg PE/mL, and infused at a maximal rate of 150 mg PE/minute.

Carbamazepine (Tegretol) is used, in addition to seizure disorders, to treat trigeminal neuralgia and bipolar disorder. It is given orally and peak blood levels are reached in about 1.5 hours with the liquid suspension, 4 to 5 hours with conventional tablets, and 3 to 12 hours with extended-release forms (tablets and capsules). It is metabolized in the liver to an active metabolite. Because it induces its own metabolism, its half-life shortens with chronic administration. Carbamazepine is contraindicated in clients with previous bone
### Drugs at a Glance: Antiseizure Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Types of Seizures Used to Treat</th>
<th>Routes and Dosage Ranges</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine (Tegretol)</td>
<td>Partial, generalized tonic-clonic, and mixed seizures</td>
<td><strong>Epilepsy, PO 200 mg twice daily, increased gradually to 600–1200 mg daily if needed, in 3 or 4 divided doses</strong></td>
<td>• Available in oral and chewable tablets, extended-release tablets and capsules, and a suspension of 100 mg/5 mL.</td>
</tr>
<tr>
<td>Clonazepam (Klonopin)</td>
<td>Myoclonic or akinetic seizures, alone or with other AEDs; possibly effective in generalized tonic-clonic and psychomotor seizures</td>
<td><strong>PO 1.5 mg/d, increased by 0.5 mg/d every 3–7 days if necessary; maximum dose, 20 mg/d</strong></td>
<td>Schedule IV drug</td>
</tr>
<tr>
<td>Clorazepate (Tranxene)</td>
<td>Partial seizures, with other AEDs</td>
<td><strong>PO maximal initial dose 7.5 mg 3 times daily; increased by 7.5 mg every week, if necessary; maximum dose, 90 mg/d</strong></td>
<td>Schedule IV drug</td>
</tr>
<tr>
<td>Diazepam (Valium)</td>
<td>Acute convulsive seizures, status epilepticus</td>
<td><strong>IV 5–10 mg no faster than 2 mg/min; repeat every 5–10 min if needed; maximum dose, 30 mg. Repeat in 2–4 hours if necessary; maximum dose, 100 mg/24 h.</strong></td>
<td>Schedule IV drug</td>
</tr>
<tr>
<td>Ethosuximide (Zarontin)</td>
<td>Absence seizures; also may be effective in myoclonic and akinetic epilepsy</td>
<td><strong>PO initially 500 mg/d, increased by 250 mg weekly until seizures are controlled or toxicity occurs; maximum dose, 1500 mg/d</strong></td>
<td>Available in oral capsules and syrup</td>
</tr>
<tr>
<td>Fosphenytoin (Cerebyx)</td>
<td>Status epilepticus and short-term use in clients who cannot take oral phenytoin</td>
<td><strong>Nonemergent seizures, IV, IM loading dose 1–20 mg PE/kg; maintenance dose 4–6 mg PE/kg/d; status epilepticus, IV 15–20 mg PE/kg, at a rate of 100–150 mg PE/min</strong></td>
<td>Therapeutic serum drug level is 40–80 mcg/mL. Much easier to give IV than phenytoin; can also be given IM</td>
</tr>
<tr>
<td>Gabapentin (Neurontin)</td>
<td>Partial seizures, with other AEDs</td>
<td><strong>PO 900 mg daily, in 3 divided doses; increased up to 1800 mg/d if necessary. Intervals between doses should not exceed 12 h.</strong></td>
<td>Does not cause significant drug-drug interactions</td>
</tr>
</tbody>
</table>

(continued)
### Lamotrigine (Lamictal)

<table>
<thead>
<tr>
<th>Types of Seizures Used to Treat</th>
<th>Routes and Dosage Ranges</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial seizures, with other AEDs</td>
<td>Renal impairment: Crcl &gt;60 mL/min, 400 mg 3 times daily (1200 mg/d); Crcl 30–60 mL/min, 300 mg 2 times daily (600 mg/d); Crcl 15–30 mL/min, 300 mg once daily; Crcl &lt;15 mL/min, 300 mg every other day. For patients on hemodialysis, 200–300 mg after each 4 h of hemodialysis.</td>
<td>Valproic acid slows lamotrigine’s metabolism by approximately 50%. If lamotrigine is combined with other AEDs plus valproic acid, dosage must be substantially reduced.</td>
</tr>
<tr>
<td>Lennox-Gastaut syndrome, with other AEDs</td>
<td>With AEDs other than valproic acid: PO 50 mg once daily for 2 wk, then 50 mg twice daily (100 mg/d) for 2 wk, then increase by 100 mg/d at weekly intervals to a maintenance dose. Usual maintenance dose, 300–500 mg/d in 2 divided doses.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>With AEDs including valproic acid: PO 25 mg every other day for 2 wk, then 25 mg once daily for 2 wk, then increase by 25 to 50 mg/d every 1–2 wk to a maintenance dose. Usual maintenance dose, 100–150 mg/d in 2 divided doses.</td>
<td></td>
</tr>
</tbody>
</table>

### Levetiracetam (Keppra)

<table>
<thead>
<tr>
<th>Types of Seizures Used to Treat</th>
<th>Routes and Dosage Ranges</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Partial seizures, with other AEDs</td>
<td>PO 500 mg twice daily initially, increased by 1000 mg/d every 2 wk, if necessary. Maximum dose, 3000 mg daily</td>
<td>A newer drug that may have several advantages over older agents</td>
</tr>
<tr>
<td></td>
<td>Renal Impairment: Crcl &gt;80, 500–1500 mg; Crcl 50–80, 500–1000 mg; Crcl 30–50, 250–750 mg; Crcl &lt;30, 250–500 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td>End-stage renal disease, on hemodialysis, 500–1000 mg, with a supplemental dose of half the total daily dose (250–500 mg)</td>
<td></td>
</tr>
<tr>
<td>Generic/Trade Name</td>
<td>Types of Seizures Used to Treat</td>
<td>Routes and Dosage Ranges</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Lorazepam (Ativan)</strong></td>
<td>Acute convulsive seizures, status epilepticus</td>
<td>IV 2–10 mg, diluted in an equal amount of sterile water for injection, 0.9% sodium chloride injection, or 5% dextrose in water, and injected over 2 min</td>
</tr>
<tr>
<td><strong>Oxcarbazepine (Trileptal)</strong></td>
<td>Partial seizures, as monotherapy or with other AEDs in adults, with other AEDs in children 4–16 years old</td>
<td>PO 600 mg twice daily (1200 mg/d) Severe renal impairment (Crcl &lt;30 mL/min), PO 300 mg twice daily (600 mg/d) and increased slowly until response achieved</td>
</tr>
<tr>
<td><strong>Phenobarbital</strong></td>
<td>Generalized tonic-clonic and partial seizures</td>
<td>PO 100–300 mg daily in 2–3 divided doses</td>
</tr>
<tr>
<td><strong>Phenytoin (prototype; Dilantin)</strong></td>
<td>Generalized tonic-clonic and some partial seizures Prevention and treatment of seizures occurring during or after neurosurgery</td>
<td>PO 100 mg three times daily initially; 300 mg (long-acting) once daily as maintenance IV 100 mg q6–8h; maximum 50 mg/min</td>
</tr>
<tr>
<td><strong>Tiagabine (Gabitril)</strong></td>
<td>Partial seizures, with other AEDs</td>
<td>PO 4 mg daily for 1 wk, increased by 4–8 mg/wk until desired effect; maximum dose 56 mg/d in 2–4 divided doses</td>
</tr>
<tr>
<td><strong>Topiramate (Topamax)</strong></td>
<td>Partial seizures, with other AEDs</td>
<td>PO 25–50 mg daily, increased by 25–50 mg per week until response. Usual dose, 400 mg daily in 2 divided doses</td>
</tr>
</tbody>
</table>
Valproic acid (Depakene capsules); Sodium valproate (Depakene syrup, Depacon injection); Divalproex sodium (Depakote enteric-coated tablets)

Zonisamide (Zonegran)

AED, antiepileptic drug; PE, phenytoin equivalent; Crcl, creatinine clearance.

1. Therapeutic serum levels are 50–100 mcg/mL (SI units 350–700 µmol/L). 
2. Note: Dosage ranges are the same for the different formulations; doses are in valproic acid equivalents. 
3. Do not give IV >14 days; switch to oral product when possible. Several formulations of valproic acid are available in the United States. These products may contain valproic acid as the acid, as the sodium salt (sodium valproate), or a combination of the two (divalproex sodium).

### Drugs at a Glance: Antiseizure Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Types of Seizures Used to Treat</th>
<th>Routes and Dosage Ranges</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valproic acid (Depakene capsules); Sodium valproate (Depakene syrup, Depacon injection); Divalproex sodium (Depakote enteric-coated tablets)</td>
<td>Absence, mixed, and complex partial seizures</td>
<td>PO 10–15 mg/kg/d, increase weekly by 5–10 mg/kg/d, until seizures controlled, adverse effects occur, or the maximum dose (60 mg/kg/d) is reached. Give amounts &gt;250 mg/d in divided doses. Usual daily dose, 1000–1600 mg, in divided doses IV client’s usual dose, diluted in 5% dextrose or 0.9% sodium chloride injection</td>
<td>PO 15–30 mg/kg/d</td>
</tr>
<tr>
<td>Zonisamide (Zonegran)</td>
<td>Partial seizures, with other AEDs</td>
<td>PO 100–200 mg daily as a single dose or as 2–3 divided doses; increase by 100 mg/d every 1–2 wk if necessary; maximum dose, 600 mg daily</td>
<td>PO 15–30 mg/kg/d</td>
</tr>
</tbody>
</table>

AED, antiepileptic drug; PE, phenytoin equivalent; Crcl, creatinine clearance.

### Absence, mixed, and complex partial seizures

#### Partial seizures, with other AEDs

#### PO

**Gabapentin** (Neurontin) is used with other AEDs for treatment of partial seizures. It is 60% absorbed with usual doses, circulates largely in a free state because of minimal binding to plasma proteins, is not appreciably metabolized, and is eliminated by the kidneys as unchanged drug. The elimination half-life is 5 to 7 hours with normal renal function and up to 50 hours with impaired renal function, depending on creatinine clearance.

Adverse effects include dizziness, drowsiness, fatigue, loss of muscle coordination, tremor, nausea, vomiting, abnormal vision, gingivitis, and pruritus. Most adverse effects subside spontaneously or with dosage reduction. Gabapentin reportedly does not cause significant drug–drug interactions. Because the drug is eliminated only by the kidneys, dosage must be reduced in clients with renal impairment.
**Lamotrigine** (Lamictal) is used with other AEDs for treatment of partial seizures. It is thought to reduce the release of glutamate, an excitatory neurotransmitter, in the brain. It is well absorbed after oral administration, with peak plasma levels reached in 1.5 to 4.5 hours. Lamotrigine is about 55% bound to plasma proteins. It is metabolized in the liver to an inactive metabolite and eliminated mainly in the urine.

Adverse effects include dizziness, drowsiness, headache, ataxia, blurred or double vision, nausea and vomiting, and weakness. Because a serious skin rash may occur, especially in children, lamotrigine should not be given to children younger than 16 years of age and should be discontinued at the first sign of skin rash in an adult. Skin rash is more likely to occur with concomitant valproic acid therapy, high lamotrigine starting dose, and rapid titration rate. It may resolve if lamotrigine is discontinued, but it progresses in some clients to a more severe form, such as Stevens-Johnson syndrome.

Lamotrigine has little effect on the metabolism of other AEDs, but other AEDs affect lamotrigine’s metabolism. Phenytoin, carbamazepine, and phenobarbital induce drug-metabolizing enzymes in the liver and accelerate lamotrigine’s metabolism. Valproic acid inhibits those enzymes and thereby slows lamotrigine’s metabolism by approximately 50%. If lamotrigine is combined with other AEDs plus valproic acid, dosage must be substantially reduced. To discontinue, dosage should be tapered over at least 2 weeks.

**Levetiracetam** (Keppra) is a newer drug approved for treatment of partial seizures, in combination with other AEDs. It is chemically unrelated to other AEDs and its mechanism of action is unknown. It inhibits abnormal neuronal firing but does not affect normal neuronal excitability or function.

Levetiracetam is well and rapidly absorbed with oral administration; peak plasma levels occur in about one hour. Food reduces peak plasma levels by 20% and delays them to 1.5 hours, but does not affect the extent of drug absorption. The drug is minimally bound (10%) to plasma proteins and reaches steady-state plasma concentrations after 2 days of twice daily administration. This rapid attainment of therapeutic effects is especially useful for patients with frequent or severe seizures.

Most of a dose (66%) is eliminated by the kidneys as unchanged drug. Dosage must be reduced with impaired renal function. The drug is not metabolized by the liver and does not affect the hepatic metabolism of other drugs. Thus, it has a low potential for drug interactions. It was well tolerated in clinical trials and the incidence of adverse events was similar to that of placebo. Common adverse effects include drowsiness, dizziness, and fatigue; others include decreases in red and white blood cell counts, double vision, amnesia, anxiety, ataxia, emotional lability, hostility, nervousness, paresthesia, pharyngitis, and rhinitis.

Overall, levetiracetam has pharmacokinetic and other characteristics that may make it especially useful in clients who require combination antiepileptic drug therapy, who take drugs with increased potential for drug interactions, or who have impaired liver function.

**Oxcarbazepine** (Trileptal) is a newer drug that is structurally related to carbamazepine. It is approved for both monotherapy and adjunctive (with other AEDs) therapy in adults with partial seizures and for adjunctive therapy only in children. For patients receiving carbamazepine or oxcarbazepine, either drug may be substituted for the other without tapering the dose of one or gradually increasing the dose of the other. However, the equivalent dose of oxcarbazepine is 50% higher than the carbamazepine dosage. In older adults, the recommended equivalent oxcarbazepine dosage is 20% higher than the carbamazepine dosage.

The drug is well absorbed with oral administration, with peak plasma levels in about 5 hours. Most effects are attributed to an active metabolite produced during first-pass metabolism in the liver; the metabolite is 40% protein bound. The elimination half-life is 2 hours for oxcarbazepine and 9 hours for the metabolite. The metabolite is conjugated with glucuronic acid in the liver and excreted in the urine, along with a small amount of unchanged drug. Dosage must be reduced in patients with severe renal impairment (ie, creatinine clearance < 30 mL/min).

In clinical trials, adverse effects were similar in adult and pediatric patients and when oxcarbazepine was used alone or with other AEDs. They included cardiac dysrhythmias, drowsiness, dizziness, hypotension, nausea, vomiting, skin rash, and hyponatremia. Because of the risk of hyponatremia, oxcarbazepine should be used with caution in clients taking other drugs that decrease serum sodium levels, and serum sodium levels should be monitored periodically during maintenance therapy. Some studies indicate that skin reactions occur less often with oxcarbazepine than with carbamazepine.

Several drug–drug interactions may occur with oxcarbazepine. The drug inhibits cytochrome P450 2C19 enzymes and induces 3A4 enzymes to influence the metabolism of other drugs metabolized by these enzymes. For example, oxcarbazepine increases metabolism of estrogens and may decrease the effectiveness of oral contraceptives and postmenopausal estrogen replacement therapy. In addition, other drugs that induce cytochrome P450 enzymes, including phenytoin, may reduce plasma levels of the active metabolite by about one third; drugs that inhibit these enzymes (eg, cimetidine, erythromycin) do not significantly affect the elimination of oxcarbazepine or its metabolite.

**Phenobarbital** is a long-acting barbiturate that is used alone or with another AED (most often phenytoin). Its use has declined with the advent of other AEDs that cause less sedation and cognitive impairment. CNS depression and other adverse effects associated with barbiturates may occur, but drug dependence and barbiturate intoxication are unlikely with usual antiepileptic doses. Because phenobarbital has a long half-life (50 to 140 hours), it takes 2 to 3 weeks to reach therapeutic serum levels and 3 to 4 weeks to reach a steady-state concentration. It is metabolized in the liver; about 25% is eliminated unchanged in the urine. It induces drug-metabolizing enzymes in the liver and thereby accelerates the metabolism of most AEDs when given with them. Effects on other drugs begin 1 or 2 weeks after phenobarbital therapy is started.
**Tiagabine** (Gabitril), which may increase GABA levels in the brain, is used with other AEDs in clients with partial seizures. After oral administration, tiagabine is well absorbed; peak plasma levels occur in about 45 minutes if taken on an empty stomach and 2.5 hours if taken with food. It is highly protein bound (96%) and is extensively metabolized in the liver, by the cytochrome P450 3A family of enzymes. Only 1% of the drug is excreted unchanged in the urine and the metabolites are excreted in urine and feces. The elimination half-life is 4 to 7 hours in clients receiving enzyme-inducing AEDs (eg, phenytoin, carbamazepine). Clients with impaired liver function may need smaller doses because the drug is cleared more slowly. CNS effects (eg, confusion, impaired concentration or speech) are the most common adverse effects. GI upset and a serious skin rash may also occur.

**Topiramate** (Topamax), which has a broad spectrum of antiseizure activity, may act by increasing the effects of GABA and other mechanisms. It is rapidly absorbed and produces peak plasma levels in about 2 hours after oral administration. The average elimination half-life is about 21 hours, and steady-state concentrations are reached in about 4 days with normal renal function. It is 20% bound to plasma proteins. It is not extensively metabolized and is primarily eliminated unchanged through the kidneys. For clients with a creatinine clearance below 70 mL/minute, dosage should be reduced by one half.

The most common adverse effects are ataxia, drowsiness, dizziness, and nausea. Renal stones may also occur. Interventions to help prevent renal stones include maintaining an adequate fluid intake, avoiding concurrent use of topiramate with other drugs associated with renal stone formation or increased urinary pH (eg, triamterene, zonisamide), and avoiding topiramate in people with conditions requiring fluid restriction (eg, heart failure) or a history of renal stones.

Additive CNS depression may occur with alcohol and other CNS depressant drugs.

**Valproic acid** preparations (Depakene, Depacon, Depakote) are chemically unrelated to other AEDs. They are thought to enhance the effects of GABA in the brain. They are also used to treat manic reactions in bipolar disorder and to prevent migraine headaches.

Valproic acid preparations are well absorbed after oral administration and produce peak plasma levels in 1 to 4 hours (15 minutes to 2 hours with the syrup). They are highly bound (90%) to plasma proteins. They are primarily metabolized in the liver and metabolites are excreted through the kidneys.

These preparations produce less sedation and cognitive impairment than phenytoin and phenobarbital. Although they are uncommon, potentially serious adverse effects include hepatotoxicity and pancreatitis. The drugs are contraindicated in people who have had hypersensitivity reactions to any of the preparations and people with hepatic disease or impaired hepatic function.

Valproic acid (Depakene) is available in capsules; sodium valproate is a syrup formulation. Divalproex sodium (Depakote) contains equal parts of valproic acid and sodium valproate and is available as delayed-release tablets and sprinkle capsules. Depacon is an injectable formulation of valproate. Dosages of all formulations are expressed in valproic acid equivalents.

**Zonisamide** (Zonegran) is chemically a sulfonamide (and contraindicated for use in clients who are allergic to sulfonamides). It is approved for adjunctive treatment of partial seizures and may also be effective for monotherapy and generalized seizures. It is thought to act by inhibiting the entry of sodium and calcium ions into nerve cells.

Zonisamide is well absorbed with oral administration and produces peak plasma levels in 2 to 6 hours. It is 40% bound to plasma proteins and also binds extensively to red blood cells. Its elimination half-life is about 63 hours in plasma and >100 hours in red blood cells. It is metabolized by the cytochrome P450 3A enzymes and perhaps other pathways. It is excreted in the urine as unchanged drug (35%) and metabolites (65%). Clients with impaired renal function may require lower doses or a slower titration schedule.

Adverse effects include drowsiness, dizziness, ataxia, confusion, abnormal thinking, nervousness, and fatigue, which can be reduced by increasing dosage gradually, over several weeks. There is also a risk of kidney stones, which is higher in clients with an inadequate fluid intake or who also take topiramate or triamterene. Skin rash, including the life-threatening Stevens-Johnson syndrome, has been observed.

Drugs that induce the cytochrome P450 enzymes (eg, carbamazepine, phenytoin) increase the metabolism of zonisamide and reduce its half-life. However, administration with cimetidine, which inhibits the cytochrome P450 enzymes, does not seem to inhibit zonisamide metabolism or increase its half-life. Zonisamide apparently does not induce or inhibit the cytochrome P450 enzymes and therefore has little effect on the metabolism of other drugs.

---

**Nursing Process**

**Assessment**

Assess client status in relation to seizure activity and other factors:

- If the client has a known seizure disorder and is taking antiseizure drugs, helpful assessment data can be obtained by interviewing the client. Some questions and guidelines include the following:
  - How long has the client had the seizure disorder?
  - How long has it been since seizure activity occurred, or what is the frequency of seizures?
  - Does any particular situation or activity precipitate a seizure?
  - How does the seizure affect the client? For example, what parts of the body are involved? Does he or she lose consciousness? Is he or she drowsy and tired afterward?
• Which antiseizure drugs are taken? How do they affect the client? How long has the client taken the drugs? Is the currently ordered dosage the same as what the client has been taking? Does the client usually take the drugs as prescribed, or does he or she find it difficult to do so?
• What other drugs are taken? This includes both prescription and nonprescription drugs, as well as those taken regularly or periodically. This information is necessary because many drugs interact with antiseizure drugs to decrease seizure control or increase drug toxicity.
• What is the client’s attitude toward the seizure disorder? Clues to attitude may include terminology, willingness or reluctance to discuss the seizure disorder, compliance or rejection of drug therapy, and others.
• Check reports of serum drug levels for abnormal values.
• Identify risk factors for seizure disorders. In people without previous seizure activity, seizure disorders may develop with brain surgery, head injury, hypoxia, hypoglycemia, drug overdose (CNS stimulants, such as amphetamines or cocaine, or local anesthetics, such as lidocaine), and withdrawal from CNS depressants, such as alcohol and barbiturates.
• To observe and record seizure activity accurately, note the location (localized or generalized); specific characteristics of abnormal movements or behavior; duration; concomitant events, such as loss of consciousness and loss of bowel or bladder control; and postseizure behavior.
• Assess for risk of status epilepticus. Risk factors include recent changes in antiseizure drug therapy, chronic alcohol ingestion, use of drugs known to cause seizures, and infection.

Nursing Diagnoses
• Ineffective Coping related to denial of the disease process and need for long-term drug therapy
• Deficient Knowledge: Disease process
• Deficient Knowledge: Drug effects
• Risk for Injury: Trauma related to ataxia, dizziness, confusion
• Risk for Injury: Seizure activity or drug toxicity
• Noncompliance: Underuse of medications

Planning/Goals
The client will:
• Take medications as prescribed
• Experience control of seizures
• Avoid serious adverse drug effects
• Verbalize knowledge of the disease process and treatment regimen
• Avoid discontinuing antiseizure medications abruptly
• Keep follow-up appointments with health care providers

Interventions
Use measures to minimize seizure activity. Guidelines include the following:
• Help the client identify conditions under which seizures are likely to occur. These precipitating factors, to be avoided or decreased when possible, may include ingestion of alcoholic beverages or stimulant drugs; fever; severe physical or emotional stress; and sensory stimuli, such as flashing lights and loud noises. Identification of precipitating factors is important because lifestyle changes (reducing stress, reducing alcohol and caffeine intake, increasing exercise, improving sleep and diet) and treatment of existing disorders can reduce the frequency of seizures.
• Assist the client in planning how to get enough rest and exercise and eat a balanced diet, if needed.
• Discuss the seizure disorder, the plan for treatment, and the importance of complying with prescribed drug therapy with the client and family members.
• Involve the client in decision making when possible.
• Inform the client and family that seizure control is not gained immediately when drug therapy is started. The goal is to avoid unrealistic expectations and excessive frustration while drugs and dosages are being changed in an effort to determine the best regimen for the client.
• Discuss social and economic factors that promote or prevent compliance.
• Protect a client experiencing a generalized tonic-clonic seizure by:
  • Placing a pillow or piece of clothing under the head if injury could be sustained from the ground or floor.
  • Not restraining the client’s movements; fractures may result.
  • Loosening tight clothing, especially around the neck and chest, to promote respiration.
• Turning the client to one side so that accumulated secretions can drain from the mouth and throat when convulsive movements stop. The cyanosis, abnormal movements, and loss of consciousness that characterize a generalized tonic-clonic seizure can be quite alarming to witnesses. Most of these seizures, however, subside within 3 or 4 minutes, and the person starts responding and regaining normal skin color. If the person has one seizure after another (status epilepticus), has trouble breathing or continued cyanosis, or has sustained an injury, further care is needed, and a physician should be notified immediately.
• When risk factors for seizures, especially status epilepticus, are identified, try to prevent or minimize their occurrence.

Evaluation
• Interview and observe for decrease in or absence of seizure activity.
• Interview and observe for avoidance of adverse drug effects, especially those that impair safety.
• When available, check laboratory reports of serum drug levels for therapeutic ranges or evidence of underdosing or overdosing.
SECTION 2 DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM

General Considerations
- Take the medications as prescribed. This is extremely important. These drugs must be taken regularly to maintain blood levels adequate to control seizure activity. At the same time, additional doses must not be taken because of increased risks of serious adverse reactions.
- Do not suddenly stop taking any antiseizure medication. Severe, even life-threatening, seizures may occur if the drugs are stopped abruptly.
- Discuss any problems (e.g., seizure activity, excessive drowsiness, other adverse effects) associated with an antiseizure medication with the prescribing physician or other health care professional. Adjusting dosage or time of administration may relieve the problems.
- Do not drive a car, operate machinery, or perform other activities requiring physical and mental alertness when drowsy from antiseizure medications. Excessive drowsiness, decreased physical coordination, and decreased mental alertness increase the likelihood of injury.
- Do not take other drugs without the physician’s knowledge and inform any other physician or dentist about taking antiseizure medications. There are many potential drug interactions in which the effects of the antiseizure drug or other drugs may be altered when drugs are given concomitantly.
- Do not take any other drugs that cause drowsiness, including over-the-counter antihistamines and sleep aids.
- Carry identification, such as a MedicAlert device, with the name and dose of the medication being taken. This is necessary for rapid and appropriate treatment in the event of a seizure, accidental injury, or other emergency situation.
- Notify your physician if you become pregnant or intend to become pregnant during therapy. Oxcarbazepine (Trileptal) decreases the effectiveness of oral contraceptive drugs.
- Notify your physician if you are breast-feeding or intend to breast-feed during therapy.

Self-administration
- Take most antiseizure medications with food or a full glass of fluid. This will prevent or decrease nausea, vomiting, and gastric distress, which are adverse reactions to most of these drugs. Levetiracetam (Keppra), oxcarbazepine (Trileptal), topiramate (Topamax), and zonisamide (Zonegran) may be taken with or without food.
- When taking generic phenytoin or the Dilantin brand of phenytoin:
  1. Do not switch from a generic to Dilantin, or vice versa, without discussing with the prescribing physician.
- There are differences in formulations that may upset seizure control and cause adverse effects.
- Ask your physician if you should take (or give a child) supplements of folic acid, calcium, vitamin D, or vitamin K. These supplements may help to prevent some adverse effects of phenytoin.
- Brush and floss your teeth and have regular dental care to prevent or delay a gum disorder called gingival hyperplasia.
- If you have diabetes, you may need to check your blood sugar more often or take a higher dose of your antidiabetic medication. Phenytoin may inhibit the release of insulin and increase blood sugar.
- Notify your physician or another health care professional if you develop a skin rash, severe nausea and vomiting, swollen glands, bleeding, swollen or tender gums, yellowish skin or eyes, joint pain, unexplained fever, sore throat, unusual bleeding or bruising, persistent headache, or any indication of infection or bleeding, and if you become pregnant.
- If you are taking phenytoin liquid suspension or giving it to a child, mix it thoroughly immediately before use and measure it with a calibrated medicine cup or a measuring teaspoon. Do not use regular teaspoons because they hold varying amounts of medication.
- If you are taking oxcarbazepine liquid suspension or giving it to a child, mix it thoroughly immediately before use. Measure it with the syringe supplied by the manufacturer and squirt the medication directly into the mouth. Store the suspension at room temperature and use the bottle within 7 weeks or discard the amount remaining. It is helpful to write the date opened and the expiration date on the container.
- With valproic acid, the regular capsule should not be opened and the tablet should not be crushed for administration. The sprinkle capsule may be opened and the contents sprinkled on soft food for administration. The syrup formulation may be diluted in water or milk but should not be mixed in carbonated beverages.
- Swallow tablets or capsules of valproic acid (Depakene or Depakote) whole; chewing or crushing may cause irritation of the mouth and throat.
- Taking valproic acid at bedtime may reduce dizziness and drowsiness.
- Lamotrigine may cause photosensitivity. When outdoors, wear protective clothing and sunscreen.
- If taking lamotrigine, notify the physician immediately if a skin rash or decreased seizure control develops.

CLIENT TEACHING GUIDELINES
Antiseizure Medications

- ✔ Take the medications as prescribed. This is extremely important. These drugs must be taken regularly to maintain blood levels adequate to control seizure activity. At the same time, additional doses must not be taken because of increased risks of serious adverse reactions.
- ✔ Do not suddenly stop taking any antiseizure medication. Severe, even life-threatening, seizures may occur if the drugs are stopped abruptly.
- ✔ Discuss any problems (e.g., seizure activity, excessive drowsiness, other adverse effects) associated with an antiseizure medication with the prescribing physician or other health care professional. Adjusting dosage or time of administration may relieve the problems.
- ✔ Do not drive a car, operate machinery, or perform other activities requiring physical and mental alertness when drowsy from antiseizure medications. Excessive drowsiness, decreased physical coordination, and decreased mental alertness increase the likelihood of injury.
- ✔ Do not take other drugs without the physician’s knowledge and inform any other physician or dentist about taking antiseizure medications. There are many potential drug interactions in which the effects of the antiseizure drug or other drugs may be altered when drugs are given concomitantly.
- ✔ Do not take any other drugs that cause drowsiness, including over-the-counter antihistamines and sleep aids.
- ✔ Carry identification, such as a MedicAlert device, with the name and dose of the medication being taken. This is necessary for rapid and appropriate treatment in the event of a seizure, accidental injury, or other emergency situation.
- ✔ Notify your physician if you become pregnant or intend to become pregnant during therapy. Oxcarbazepine (Trileptal) decreases the effectiveness of oral contraceptive drugs.
- ✔ Notify your physician if you are breast-feeding or intend to breast-feed during therapy.

Self-administration
- ✔ Take most antiseizure medications with food or a full glass of fluid. This will prevent or decrease nausea, vomiting, and gastric distress, which are adverse reactions to most of these drugs. Levetiracetam (Keppra), oxcarbazepine (Trileptal), topiramate (Topamax), and zonisamide (Zonegran) may be taken with or without food.
- ✔ When taking generic phenytoin or the Dilantin brand of phenytoin:
  1. Do not switch from a generic to Dilantin, or vice versa, without discussing with the prescribing physician.
- ✔ There are differences in formulations that may upset seizure control and cause adverse effects.
- ✔ Ask your physician if you should take (or give a child) supplements of folic acid, calcium, vitamin D, or vitamin K. These supplements may help to prevent some adverse effects of phenytoin.
- ✔ Brush and floss your teeth and have regular dental care to prevent or delay a gum disorder called gingival hyperplasia.
- ✔ If you have diabetes, you may need to check your blood sugar more often or take a higher dose of your antidiabetic medication. Phenytoin may inhibit the release of insulin and increase blood sugar.
- ✔ Notify your physician or another health care professional if you develop a skin rash, severe nausea and vomiting, swollen glands, bleeding, swollen or tender gums, yellowish skin or eyes, joint pain, unexplained fever, sore throat, unusual bleeding or bruising, persistent headache, or any indication of infection or bleeding, and if you become pregnant.
- ✔ If you are taking phenytoin liquid suspension or giving it to a child, mix it thoroughly immediately before use and measure it with a calibrated medicine cup or a measuring teaspoon. Do not use regular teaspoons because they hold varying amounts of medication.
- ✔ If you are taking oxcarbazepine liquid suspension or giving it to a child, mix it thoroughly immediately before use. Measure it with the syringe supplied by the manufacturer and squirt the medication directly into the mouth. Store the suspension at room temperature and use the bottle within 7 weeks or discard the amount remaining. It is helpful to write the date opened and the expiration date on the container.
- ✔ With valproic acid, the regular capsule should not be opened and the tablet should not be crushed for administration. The sprinkle capsule may be opened and the contents sprinkled on soft food for administration. The syrup formulation may be diluted in water or milk but should not be mixed in carbonated beverages.
- ✔ Swallow tablets or capsules of valproic acid (Depakene or Depakote) whole; chewing or crushing may cause irritation of the mouth and throat.
- ✔ Taking valproic acid at bedtime may reduce dizziness and drowsiness.
- ✔ Lamotrigine may cause photosensitivity. When outdoors, wear protective clothing and sunscreen.
- ✔ If taking lamotrigine, notify the physician immediately if a skin rash or decreased seizure control develops.
Ms. Hammerly is admitted to your unit for neurosurgery in the morning. She is NPO after midnight. The nurse holds all medications, including her antiseizure medication, which is usually taken at midnight and 6 AM. In the morning, Ms. Hammerly’s surgery is delayed so you decide to help her with her shower. While showering, Ms. Hammerly experiences a generalized seizure.

**CHAPTER 11 ANTISEIZURE DRUGS**

**How Can You Avoid This Medication Error?**

Ms. Hammerly is admitted to your unit for neurosurgery in the morning. She is NPO after midnight. The nurse holds all medications, including her antiseizure medication, which is usually taken at midnight and 6 AM. In the morning, Ms. Hammerly’s surgery is delayed so you decide to help her with her shower. While showering, Ms. Hammerly experiences a generalized seizure.

**PRINCIPLES OF THERAPY**

**Therapeutic Goal**

Drug therapy is the main treatment of epilepsy for clients of all ages. The goal is to control seizure activity with minimal adverse drug effects. To meet this goal, therapy must be individualized. In most clients, treatment with a single AED is sufficient to meet this goal. In 20% to 30% of clients, however, two or more AEDs are required. In general, combination therapy is associated with more severe adverse effects, interactions between AEDs, poor compliance, and higher costs.

**Drug Selection**

1. **Type of seizure** is a major factor. Therefore, an accurate diagnosis is essential before drug therapy is started. In general, AEDs with activity against both partial-onset and generalized seizures include lamotrigine, levetiracetam, topiramate, valproic acid, and zonisamide. Drugs considered most useful for partial seizures include carbamazepine, gabapentin, oxcarbazepine, phenobarbital, phenytoin, and tiagabine. For absence seizures, ethosuximide is the drug of choice; clonazepam and valproate are also effective. For mixed seizures, a combination of drugs is usually necessary.

   Guidelines for newer drugs are evolving as research studies are done and clinical experience with their use increases. Most of these agents are approved for combination therapy with other AEDs in clients whose seizures are not adequately controlled with a single drug. Oxcarbazepine is approved for monotherapy of partial seizures; some of the other drugs are also thought to be effective as monotherapy.

2. **Adverse drug effects** may be the deciding factor in choosing an AED because most types of seizures can be treated effectively by a variety of drugs. The use of carbamazepine and valproic acid increased largely because they cause less sedation and cognitive and psychomotor impairment than phenobarbital and phenytoin, although they may cause other potentially serious adverse effects. Most of the newer AEDs reportedly cause fewer adverse effects and are better tolerated than the older drugs although they may also cause potentially serious adverse effects. Fewer and milder adverse effects can greatly increase a client’s willingness to comply with the prescribed regimen and attain seizure control.

3. **Monotherapy versus combination therapy**. A single drug (monotherapy) is recommended when possible. If effective in controlling seizures, monotherapy has the advantages of fewer adverse drug effects, fewer drug–drug interactions, lower costs, and usually greater client compliance. If the first drug, in adequate dosage, fails to control seizures or causes unacceptable adverse effects, then another agent should be tried as monotherapy. Most practitioners recommend sequential trials of two to three agents as monotherapy before considering combination therapy.

   When substituting one AED for another, the second drug should be added and allowed to reach therapeutic blood levels before the first drug is gradually decreased in dosage and discontinued. This is not necessary when substituting oxcarbazepine for carbamazepine or vice versa, because the drugs are similar.

   When monotherapy is ineffective, a second, and sometimes a third, drug may be added. If combination therapy is ineffective, the clinician may need to reassess the client for type of seizure, medical conditions or drug–drug interactions that aggravate the seizure disorder or decrease the effectiveness of AEDs, and compliance with the prescribed drug therapy regimen.

4. **Dosage forms** may increase seizure control, client convenience, and compliance. For example, extended release or long-acting dosage forms can maintain more consistent serum drug levels and decrease frequency of administration. Most of the AEDs are available in oral tablets or capsules; a few are available as oral liquids or injectable solutions.

5. **Cost** should be considered because this may be a major factor in client compliance. Although the newer drugs are generally effective and better tolerated than older agents, they are also quite expensive. Costs, which depend on manufacturers’ wholesale prices and pharmacies’ markups as well as prescribed dose amounts and other factors, may vary among pharmacies and change over time. However, the following list of costs per month allow comparisons among AEDs and may be useful in clinical practice. Costs of older drugs are carbamazepine ($54 to $81), ethosuximide ($105 to $158), phenobarbital ($2 to $5), phenytoin ($26 to $35), and valproate ($80 to $280). Costs of newer drugs are gabapentin ($139 to $354), lamotrigine ($196 to $289), levetiracetam ($105 to $315), oxcarbazepine ($97 to $358), tiagabine ($99 to $190), topiramate ($88 to $354), and zonisamide ($100 to $201). When possible, prescribers can encourage compliance by choosing drugs that are covered by clients’ insurance plans or, for uninsured clients, choosing less expensive drug therapy regimens.

6. **Pregnancy risk**. Sexually active adolescent girls and women of childbearing potential who require an AED must be evaluated and monitored very closely because...
all of the drugs are considered teratogenic. In general, infants exposed to one AED have a significantly higher risk of birth defects than those not exposed and infants exposed to two or more AEDs have a significantly higher risk than those exposed to one AED.

**Drug Dosage**

The dosage of most drugs is determined empirically by observation of seizure control and adverse effects.

1. Usually, larger doses are needed for a single drug than for multiple drugs; for people with a large body mass (assuming normal liver and kidney function); and in cases involving trauma, surgery, and emotional stress.

2. Smaller doses are usually required when liver disease is present and when multiple drugs are being given. Smaller doses of gabapentin, levetiracetam, and topiramate must be given in the presence of renal impairment, and smaller doses of lamotrigine must be given when combined with valproic acid and another AED.

3. For most drugs, initial doses are relatively low; doses are gradually increased until seizures are controlled or adverse effects occur. Then, doses may be lowered to the minimum effective level, to decrease adverse effects. Adverse effects are more likely to occur during initiation of treatment and, if treatment is started too aggressively, clients may be unwilling to continue a particular medication even if doses are reduced in amount or frequency of administration.

   When one AED is being substituted for another, dosage of the one being added is gradually increased while the one being discontinued is gradually decreased. The first drug is usually stopped when therapeutic effects or therapeutic serum drug levels of the second drug are attained.

   When an AED is being discontinued, its dosage should always be tapered gradually, usually over 1 to 3 months. Abruptly stopping an AED may exacerbate seizures or cause status epilepticus.

4. When fosphenytoin is substituted for oral phenytoin, the same total daily dosage (in PE) may be given IV or IM.

5. For patients receiving carbamazepine or oxcarbazepine therapy, either agent may be substituted for the other without gradual reduction or titration of the dose. For most patients, the equivalent oxcarbazepine dosage is 50% higher than the carbamazepine dosage. When switching between agents in older adults, the recommended equivalent oxcarbazepine dosage is 20% higher than the carbamazepine dosage.

**Monitoring Antiepileptic Drug Therapy**

1. The effectiveness of drug therapy is evaluated primarily by client response in terms of therapeutic or adverse effects.

2. Periodic measurements of serum drug levels are recommended, especially when multiple AEDs are being given. This helps to document blood levels associated with particular drug dosages, seizure control, or adverse drug effects; to assess and document therapeutic failures; to assess for drug malabsorption or client non-compliance; to guide dosage adjustments; and to evaluate possible drug-related adverse effects.

   To be useful, serum drug levels must be interpreted in relation to clinical responses because there are wide variations among clients receiving similar doses, probably owing to differences in hepatic metabolism. In other words, doses should not be increased or decreased solely to maintain a certain serum drug level. In addition, the timing of blood samples in relation to drug administration is important. For routine monitoring, blood samples should generally be obtained in the morning, before the first daily dose of an AED.

3. Several antiseizure drugs have the potential for causing blood, liver, or kidney disorders. For this reason, it is usually recommended that baseline blood studies (complete blood count, platelet count) and liver function tests (eg, bilirubin, serum protein, aspartate aminotransferase) be performed before drug therapy starts and periodically thereafter.

   When drug therapy fails to control seizures, there are several possible causes. A common one is the client’s failure to take the antiseizure drug as prescribed. Other causes include incorrect diagnosis of the type of seizure, use of the wrong drug for the type of seizure, inadequate drug dosage, and too-frequent changes or premature withdrawal of drugs. Additional causes may include drug overdoses (eg, theophylline) and severe electrolyte imbalances (eg, hyponatremia) or use of alcohol or recreational drugs.

### Duration and Discontinuation of Therapy

Antiseizure drug therapy may be discontinued for some clients, usually after a seizure-free period of at least 2 years. Although opinions differ about whether, when, and how the drugs should be discontinued, studies indicate that medications can be stopped in approximately two thirds of clients whose epilepsy is completely controlled with drug therapy.

---

**Nursing Notes: Apply Your Knowledge**

You are a nurse working in a clinic. Mr. Eng, an epileptic for the last 10 years, comes into the clinic complaining of problems with poor coordination and fatigue. His speech also seems somewhat slurred. His seizures have been well controlled on phenytoin (Dilantin) 300 mg hs. His Dilantin level is drawn and is 19 mcg/mL. How should you proceed?

1. The effectiveness of drug therapy is evaluated primarily by client response in terms of therapeutic or adverse effects.

2. Periodic measurements of serum drug levels are recommended, especially when multiple AEDs are being given. This helps to document blood levels associated with particular drug dosages, seizure control, or adverse drug effects; to assess and document therapeutic failures; to assess for drug malabsorption or client non-compliance; to guide dosage adjustments; and to evaluate possible drug-related adverse effects.

   To be useful, serum drug levels must be interpreted in relation to clinical responses because there are wide variations among clients receiving similar doses, probably owing to differences in hepatic metabolism. In other words, doses should not be increased or decreased solely to maintain a certain serum drug level. In addition, the timing of blood samples in relation to drug administration is important. For routine monitoring, blood samples should generally be obtained in the morning, before the first daily dose of an AED.

   When drug therapy fails to control seizures, there are several possible causes. A common one is the client’s failure to take the antiseizure drug as prescribed. Other causes include incorrect diagnosis of the type of seizure, use of the wrong drug for the type of seizure, inadequate drug dosage, and too-frequent changes or premature withdrawal of drugs. Additional causes may include drug overdoses (eg, theophylline) and severe electrolyte imbalances (eg, hyponatremia) or use of alcohol or recreational drugs.

---
Advantages of discontinuation include avoiding adverse drug effects and decreasing costs; disadvantages include recurrence of seizures, with possible status epilepticus. Even if drugs cannot be stopped completely, periodic attempts to decrease the number or dosage of drugs are probably desirable to minimize adverse reactions. Discontinuing drugs, changing drugs, or changing dosage must be done gradually over 2 to 3 months for each drug and with close medical supervision because sudden withdrawal or dosage decreases may cause status epilepticus. Only one drug should be reduced in dosage or gradually discontinued at a time.

**Drug Therapy for Status Epilepticus**

An IV benzodiazepine (eg, lorazepam 0.1 mg/kg at 2 mg/minute) is the drug of choice for rapid control of tonic-clonic seizures. However, seizures often recur unless the benzodiazepine is repeated or another, longer-acting drug is given, such as IV phenytoin (20 mg/kg at 50 mg/minute) or fosphenytoin (20 mg/kg phenytoin equivalents at 150 mg/minute). Further treatments are based on the patient’s response to these medications. Because there is a risk of significant respiratory depression with IV benzodiazepines, personnel and supplies for emergency resuscitation must be readily available.

**Toxicity of Antiseizure Drugs: Recognition and Management**

Signs and symptoms of overdose and toxicity are usually extensions of known adverse effects. Severe overdoses disturb vital functions (eg, CNS depression with confusion, impaired consciousness and possible coma, respiratory depression; cardiovascular problems such as dysrhythmias and hypotension) and are life-threatening. Fatalities have been reported with most antiseizure drugs. If toxicity is suspected, a serum drug level is indicated for those drugs with established therapeutic ranges. There are no specific antidotes and treatment is symptomatic and supportive (ie, gastric lavage and activated charcoal, if indicated, to prevent absorption of additional drug. An endotracheal tube should be inserted prior to lavage, to prevent aspiration). Activated charcoal is not effective in adsorbing topiramate and is not recommended for topiramate overdose. Hemodialysis is effective in removing drugs that are poorly bound to plasma proteins and that are excreted mainly or partly by the kidneys (eg, gabapentin, levetiracetam, topiramate, valproate). Vital signs, electrocardiogram (ECG), level of consciousness, pupillary reflexes, and urine output should be monitored.

**Effects of Antiepileptic Drugs on Non-Antiepileptic Drugs**

Antiepileptic drugs may have clinically significant interactions with many non-AEDs. Because the drugs depress the CNS and cause drowsiness, their combination with any other CNS depressant drugs may cause excessive sedation and other adverse CNS effects. They may also decrease the effects of numerous other drugs, mainly by inducing drug-metabolizing enzymes in the liver. Enzyme induction means the affected drugs are metabolized and eliminated more quickly. In some cases, larger doses of the affected drugs are needed to achieve therapeutic effects.

*Phenytoin* reduces the effects of cardiovascular drugs (eg, amiodarone, digoxin, disopyramide, dopamine, mexitilene, quinidine), female sex hormones (estrogens, oral contraceptives, levonorgestrel), adrenal corticosteroids, antipsychotic drugs (eg, phenothiazines, haloperidol), oral antidiabetic agents (eg, sulfonylureas), doxycycline, furosemide, levodopa, methadone, and theophylline. With acetaminophen, phenytoin decreases therapeutic effects, but may increase the risk of hepatotoxicity by accelerating production of the metabolite that damages the liver. The consequence of increasing metabolism of oral contraceptives may be unintended pregnancy; the consequence of decreasing the effects of sulfonylureas may be greater difficulty in controlling blood sugar levels in diabetic clients who require both drugs.

*Carbamazepine* reduces the effects of tricyclic antidepressants, oral anticoagulants, oral contraceptives, bupropion, cyclosporine, doxycycline, felodipine, and haloperidol. The effects on acetaminophen are the same as those of phenytoin (see above).

*Topiramate* decreases effects of digoxin and oral contraceptives.

Few interactions have been reported with the newer drugs. *Levetiracetam* does not induce or inhibit hepatic metabolism of drugs and risks of interactions are minimal. *Oxcarbazepine* decreases effectiveness of felodipine and oral contraceptives (a barrier type of contraception is recommended during oxcarbazepine therapy). *Zonisamide* interacts with other AEDs but no interactions have been reported with non-AEDs. More interactions with these drugs may be observed with longer clinical use.

**Use in Children**

Oral drugs are absorbed slowly and inefficiently in newborns. If an antiseizure drug is necessary during the first 7 to 10 days of life, IM phenobarbital is effective. Metabolism and excretion also are delayed during the first 2 weeks of life, but rates become more rapid than those of adults by 2 to 3 months of age. In infants and children, oral drugs are rapidly absorbed and have short half-lives. This produces therapeutic serum drug levels earlier in children than in adults. Rates of metabolism and excretion also are increased. Consequently, children require higher doses per kilogram of body weight than adults.

The rapid rate of drug elimination persists until approximately 6 years of age, then decreases until it stabilizes around the adult rate by age 10 to 14 years. AEDs must be used cautiously to avoid excessive sedation and interference with learning and social development.
With the newer AEDs, there is little information about their effects in children. Most of the drugs (eg, gabapentin, lamotrigine, oxcarbazepine, tiagabine, and topiramate) are approved for use in children; levetiracetam and zonisamide are not approved for use in children. Oxcarbazepine is metabolized faster in children younger than 8 years of age; the rate of metabolism is similar to that in adults after 8 years. Several studies indicated that oxcarbazepine is effective in monotherapy and combination therapy, with relatively few and mild adverse effects.

**Use in Older Adults**

Seizure disorders commonly occur in older adults and require drug therapy. Older adults often have multiple medical conditions, take multiple drugs, and have decreases in protein binding and liver and kidney function. As a result, older adults are at high risk of adverse drug effects and adverse drug–drug interactions with AEDs. For example, reduced levels of serum albumin may increase the active portion of highly protein bound AEDs (eg, phenytoin, valproic acid) and increase risks for adverse effects even when total serum drug concentrations are normal. Similarly, decreased elimination by the liver and kidneys may lead to drug accumulation, with subsequent risks of dizziness, impaired coordination, and injuries due to falls.

In addition to the ataxia, confusion, dizziness, and drowsiness that may occur with most AEDs, older adults are also more likely to develop some adverse effects associated with specific drugs. For example, with carbamazepine, they may develop hyponatremia, especially if they also take sodium-losing diuretics (eg, furosemide, hydrochlorothiazide), or cardiac dysrhythmias, especially if they have underlying heart disease. Older adults with preexisting heart disease should have a thorough cardiac evaluation before starting carbamazepine therapy. These effects may also occur with oxcarbazepine. With valproic acid, older adults may develop a tremor that is difficult to diagnose because of its gradual onset and similarity to the tremor occurring with Parkinson’s disease. The tremor is often dose-related and reverses when the drug is reduced in dosage or discontinued.

Most of these potential problems can be averted or minimized by using AEDs very cautiously in older adults. In general, small initial doses, slow titration to desired doses, and small maintenance doses are needed. Using controlled-release formulations, when available, to minimize peak plasma concentrations, may also be helpful. In addition, frequent assessment of clients for adverse effects and periodic monitoring of serum drug levels, liver function, and kidney function are indicated.

**Use in Renal Impairment**

*Phenytoin* is used in patients with severe renal impairment requires markedly reduced dosage, close monitoring of plasma drug levels, and frequent observation for toxic effects. Smaller doses of *gabapentin*, *levetiracetam*, *oxcarbazepine*, *topiramate*, and *zonisamide* must be given in the presence of renal impairment because these drugs are eliminated primarily through the kidneys. Dosage of oxcarbazepine should be decreased by 50% in patients with creatinine clearance <30 mL/minute. Zonisamide should not be given to patients with renal failure and should be discontinued in patients who develop acute renal failure or increased serum creatinine and blood urea nitrogen during therapy. Elimination of tiagabine is not significantly affected by renal insufficiency, renal failure, or hemodialysis, and dose adjustment for renal dysfunction is not necessary. Renal stones have been reported with topiramate and zonisamide.

**Use in Hepatic Impairment**

Most AEDs are metabolized in the liver and may accumulate in the presence of liver disease or impaired function. The drugs should be used cautiously. *Tiagabine* is cleared more slowly in clients with liver impairment. Increased plasma levels of unbound tiagabine, increased elimination half-life, and increased frequency of neurologic adverse effects (eg, ataxia, dizziness, drowsiness, tremor) have been observed in clients with mild and moderate hepatic insufficiency. Doses may need to be reduced or given at less frequent intervals. *Topiramate* may also be cleared more slowly even though it is eliminated mainly through the kidneys and does not undergo significant hepatic metabolism. It should be used with caution in the presence of hepatic impairment.

*Valproic acid* is a hepatotoxic drug and contraindicated for use in hepatic impairment. No dosage adjustment is indicated with levetiracetam, oxcarbazepine, or zonisamide.

**Use in Critical Illness**

*Phenytoin* is often used to prevent or treat seizure disorders in critically ill clients, including those with head injuries. Phenytoin therapy can best be monitored by measuring free serum phenytoin concentrations, but laboratories usually report the total serum drug concentration. In some clients, a low total phenytoin level may still be therapeutic and a dosage increase is not indicated. The occurrence of nystagmus (abnormal movements of the eyeball) indicates phenytoin toxicity: the drug should be reduced in dosage or discontinued until serum levels decrease. Because phenytoin is extensively metabolized in the liver, clients with severe illnesses may metabolize the drug more slowly and therefore experience toxicity.

For clients in critical care units for other disorders, a history of long-term AED therapy may be a risk factor for seizures, including status epilepticus, if the drug is stopped abruptly. At the same time, continuing an AED may complicate drug therapy of other conditions because of adverse
effects and potential drug-drug interactions. For example, phenytoin decreases the effects of dopamine, a drug often used to treat hypotension and shock in critical care units. In addition, phenytoin decreases ventricular automaticity and should not be used in critically ill clients with sinus bradycardia or heart block.

### Home Care

The home care nurse must work with clients and family members to implement and monitor AED therapy. When an AED is started, a few weeks may be required to titrate the dosage and determine whether the chosen drug is effective in controlling seizures. The nurse can play an important role by clinical assessment of the client, interviewing the family about the occurrence of seizures (a log of date, time, duration, and characteristics of seizures can be very helpful), ensuring that the client keeps appointments for serum drug levels and follow-up care, and encouraging compliance with the prescribed regimen. With long-term use of the drugs, the nurse must monitor the client for therapeutic and adverse drug effects, especially with changes in drugs or dosages. With any evidence that the client is not taking medication as directed, the nurse may need to review the potential loss of seizure control and potential for status epilepticus.

### Nursing Actions

<table>
<thead>
<tr>
<th>Antiseizure Drugs</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td>To maintain therapeutic blood levels of drugs</td>
</tr>
<tr>
<td>a. Give on a regular schedule about the same time each day.</td>
<td>Most antiseizure drugs cause some gastric irritation, nausea, or vomiting. Taking the drugs with food or fluid helps decrease gastrointestinal side effects.</td>
</tr>
<tr>
<td>b. Give most oral antiseizure drugs after meals or with a full glass of water or other fluid; levetiracetam, oxcarbazepine, topiramate, and zonisamide may be taken with or without food.</td>
<td>In suspensions, particles of drug are suspended in water or other liquid. On standing, drug particles settle to the bottom of the container. Shaking the container is necessary to distribute drug particles in the liquid vehicle. If the contents are not mixed well every time a dose is given, the liquid vehicle will be given initially, and the concentrated drug will be given later. That is, underdosage will occur at first, and little if any therapeutic benefit will result. Overdosage will follow, and the risks of serious toxicity are greatly increased. Using the same measuring container ensures consistent dosage. Calibrated medication cups or measuring teaspoons or tablespoons are acceptable. Regular household teaspoons and tablespoons used for eating and serving are not acceptable because sizes vary widely.</td>
</tr>
<tr>
<td>c. To give phenytoin:</td>
<td>Phenytoin solution is highly alkaline (pH approximately 12) and physically incompatible with other drugs. A precipitate occurs if mixing is attempted.</td>
</tr>
<tr>
<td>(1) Shake oral suspensions of the drug vigorously before pouring and always use the same measuring equipment.</td>
<td>Phenytoin cannot be diluted or given in IV fluids other than normal saline because it precipitates within minutes. Slow administration and dilution decrease local venous irritation from the highly alkaline drug solution. Rapid administration must be avoided because it may produce myocardial depression, hypotension, cardiac arrhythmias, and even cardiac arrest.</td>
</tr>
<tr>
<td>(2) Do not mix parenteral phenytoin in the same syringe with any other drug.</td>
<td>The dose is expressed in phenytoin equivalents (PE; fosphenytoin 50 mg PE = phenytoin 50 mg).</td>
</tr>
<tr>
<td>(3) Give phenytoin as an undiluted (IV) bolus injection at a rate not exceeding 50 mg/min, then flush the IV line with normal saline or dilute in 50–100 mL of normal saline (0.9% NaCl) and administer over approximately 30–60 minutes.</td>
<td></td>
</tr>
<tr>
<td>“piggybacked” into a primary IV line, the primary IV solution must be normal saline or the line must be flushed with normal saline before and after administration of phenytoin. An in-line filter is recommended.</td>
<td></td>
</tr>
<tr>
<td>d. To give IV fosphenytoin:</td>
<td></td>
</tr>
<tr>
<td>(1) Check the physician’s order and the drug concentration carefully.</td>
<td>(continued)</td>
</tr>
</tbody>
</table>
### Nursing Actions

| (2) | Dilute the dose in 5% dextrose or 0.9% sodium chloride solution to a concentration of 1.5 mg PE/mL to 25 mg PE/mL and infuse no faster than 150 mg PE/min. |
| (3) | Consult a pharmacist or the manufacturer’s literature if any aspect of the dose or instructions for administration are unclear. |
| e. | To give carbamazepine and phenytoin suspensions by nasogastric (NG) feeding tube, dilute with an equal amount of water, and rinse the NG tube before and after administration. |
| f. | To give oxcarbazepine suspension, use the 10-mL oral dosing syringe provided by the manufacturer with each bottle. Also check expiration date. |

### Rationale/Explanation

- The drug is preferably diluted in the pharmacy and labeled with the concentration and duration of the infusion. For a 100-mg PE dose, diluting with 4 mL yields the maximum concentration of 25 mg PE/mL; this amount could be infused in about 1 min at the maximal recommended rate. A 1-g loading dose could be added to 50 mL of 0.9% sodium chloride and infused in approximately 10 min at the maximal recommended rate. |
- To avoid error |
- Absorption is slow and decreased, possibly because of drug adherence to the NG tube. Dilution and tube irrigation decrease such adherence. |
- For accurate measurement and a reminder that the suspension is given orally only. The suspension is stored at room temperature and must be used within 7 weeks after opening the bottle. |
- Therapeutic effects begin later with antiseizure drugs than with most other drug groups because the antiseizure drugs have relatively long half-lives. Optimum therapeutic benefits of phenytoin occur approximately 7–10 days after drug therapy is started. |
- IV lorazepam is the drug of choice for controlling an acute convulsion. |
- These effects are common, especially during the first week or two of drug therapy. |
- These common effects of oral drugs can be reduced by taking the drugs with food or a full glass of water. |
- These may occur with almost all the antiseizure drugs. Some are mild; some are potentially serious but rare. These skin reactions are usually sufficient reason to discontinue the drug. About 25–30% of patients with allergic reactions to carbamazepine are likely to be allergic to oxcarbazepine. |
- Most antiseizure drugs decrease blood levels of folic acid, which may progress to megaloblastic anemia. The other disorders indicate bone marrow depression and are potentially life threatening. They do not usually occur with phenytoin, but may infrequently occur with most other antiseizure drugs. |
- This is not likely to be a significant adverse reaction except when a depressant drug, such as lorazepam, is given IV to control acute seizures, such as status epilepticus. Even then, respiratory depression can be minimized by avoiding overdosage and rapid administration. |
- Hepatic damage may occur with phenytoin, and fatal hepatotoxicity has been reported with valproic acid. |
- Occurs often with phenytoin, especially in children. It may be prevented or delayed by vigorous oral hygiene. |
- May occur when antiseizure drugs are taken in high doses and over long periods (continued)
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>Action</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>i. Hyponatremia</td>
<td>May occur with carbamazepine and oxcarbazepine, especially if taken concurrently with sodium-losing diuretics (e.g., furosemide, hydrochlorothiazide). Usually transient and levels return to normal with fluid restriction or dose reduction.</td>
</tr>
<tr>
<td>j. Lymphadenopathy resembling malignant lymphoma</td>
<td>This reaction has occurred with several antiseizure drugs, most often with phenytoin.</td>
</tr>
<tr>
<td>k. Pancreatitis</td>
<td>Life-threatening pancreatitis has occurred after short- and long-term therapy with valproic acid. Patients should be monitored for the development of acute abdominal pain, nausea, and vomiting.</td>
</tr>
<tr>
<td>l. Kidney stones</td>
<td>May occur with topiramate and zonisamide. Inadequate fluid intake or concurrent administration of triamterene may increase risk.</td>
</tr>
</tbody>
</table>

### 4. Observe for drug interactions

<table>
<thead>
<tr>
<th>Type</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Drugs that increase effects of antiseizure drugs:</td>
<td>Additive CNS depression</td>
</tr>
<tr>
<td>(1) CNS depressants—alcohol, sedating antihistamines, benzodiazepines, opioid analgesics, sedatives</td>
<td>Additive or synergistic effects. The drugs are often given in combination, to increase therapeutic effects.</td>
</tr>
<tr>
<td>(2) Most other antiseizure drugs</td>
<td>These drugs may lower the seizure threshold and precipitate seizures. Dosage of antiseizure drugs may need to be increased.</td>
</tr>
<tr>
<td>b. Drugs that decrease effects of antiseizure drugs:</td>
<td>These drugs inhibit themselves and other antiseizure drugs by activating liver enzymes and accelerating the rate of drug metabolism.</td>
</tr>
<tr>
<td>(1) Tricyclic antidepressants, antipsychotic drugs</td>
<td>These drugs increase phenytoin toxicity by inhibiting hepatic metabolism of phenytoin or by displacing it from plasma protein-binding sites.</td>
</tr>
<tr>
<td>(2) Carbamazepine, phenytoin, and other enzyme inducers</td>
<td>These drugs decrease effects of phenytoin by decreasing absorption, accelerating metabolism, or by unknown mechanisms.</td>
</tr>
<tr>
<td>c. Additional drugs that alter effects of phenytoin and fosphenytoin:</td>
<td>Phenytoin and phenobarbital have complex interactions with unpredictable effects. Although phenobarbital induces drug metabolism in the liver and may increase the rate of metabolism of other anticonvulsant drugs, its interaction with phenytoin differs. Phenobarbital apparently decreases serum levels of phenytoin and perhaps its half-life. Still, the anticonvulsant effects of the two drugs together are greater than those of either drug given alone. The interaction apparently varies with dosage, route, time of administration, the degree of liver enzyme induction already present, and other factors. Thus, whether a significant interaction will occur in a client is unpredictable. Probably the most important clinical implication is that close observation of the client is necessary when either drug is being added or withdrawn.</td>
</tr>
<tr>
<td>(1) Alcohol (acute ingestion), allopurinol, amiodarone, benzodiazepines, chlorpheniramine, cimetidine, fluconazole, fluoxetine, isoniazid, metronidazole, miconazole, omeprazole, paroxetine, sertraline, and trimethoprim increase effects.</td>
<td>These drugs increase phenytoin toxicity by inhibiting hepatic metabolism of phenytoin or by displacing it from plasma protein-binding sites.</td>
</tr>
<tr>
<td>(2) Alcohol (chronic ingestion), antacids, antineoplastics, folic acid, pyridoxine, rifampin, sulfa salt, and theophylline decrease effects.</td>
<td>These drugs decrease effects of phenytoin by decreasing absorption, accelerating metabolism, or by unknown mechanisms.</td>
</tr>
<tr>
<td>(3) Phenobarbital has variable interactions with phenytoin.</td>
<td>Phenytoin and phenobarbital have complex interactions with unpredictable effects. Although phenobarbital induces drug metabolism in the liver and may increase the rate of metabolism of other anticonvulsant drugs, its interaction with phenytoin differs. Phenobarbital apparently decreases serum levels of phenytoin and perhaps its half-life. Still, the anticonvulsant effects of the two drugs together are greater than those of either drug given alone. The interaction apparently varies with dosage, route, time of administration, the degree of liver enzyme induction already present, and other factors. Thus, whether a significant interaction will occur in a client is unpredictable. Probably the most important clinical implication is that close observation of the client is necessary when either drug is being added or withdrawn.</td>
</tr>
<tr>
<td>d. Additional drugs that alter effects of carbamazepine:</td>
<td>Most of these drugs inhibit the cytochrome P450 enzymes (1A2, 2C8, and/or 3A4 groups) that normally metabolize carbamazepine, thereby increasing blood levels of carbamazepine. Valproic acid inhibits an epoxide hydrolase enzyme and causes an active metabolite to accumulate. Toxicity may result even if carbamazepine blood levels are at therapeutic concentrations.</td>
</tr>
<tr>
<td>(1) Cimetidine, clarithromycin, diltiazem, erythromycin, isoniazid, valproic acid, and verapamil increase effects.</td>
<td>(continued)</td>
</tr>
</tbody>
</table>


**NURSING ACTIONS**

<table>
<thead>
<tr>
<th></th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Alcohol, phenytoin, and phenobarbital decrease effects.</td>
<td>These drugs increase activity of hepatic drug-metabolizing enzymes, thereby decreasing blood levels of carbamazepine.</td>
</tr>
<tr>
<td>e. Drugs that alter the effects of gabapentin:</td>
<td>Reduce absorption of gabapentin. Gabapentin should be given at least 2 hours after a dose of an antacid to decrease interference with absorption.</td>
</tr>
<tr>
<td>(1) Antacids</td>
<td>Valproic acid inhibits the liver enzymes that metabolize lamotrigine, thereby increasing blood levels and slowing metabolism of lamotrigine. As a result, lamotrigine dosage must be substantially reduced when the drug is given in a multidrug regimen that includes valproic acid.</td>
</tr>
<tr>
<td>f. Drugs that alter effects of lamotrigine:</td>
<td>These drugs induce drug-metabolizing enzymes in the liver and thereby increase the rate of metabolism of themselves and of lamotrigine.</td>
</tr>
<tr>
<td>(1) Valproic acid increases effects.</td>
<td>These drugs induce drug-metabolizing enzymes in the liver and thereby increase the metabolism and hasten the elimination of oxcarbazepine.</td>
</tr>
<tr>
<td>(2) Carbamazepine, phenytoin, and phenobarbital decrease effects.</td>
<td>May increase plasma levels of phenobarbital as much as 40%, probably by inhibiting liver metabolizing enzymes.</td>
</tr>
<tr>
<td>g. Drugs that decrease effects of oxcarbazepine</td>
<td>Inhibits drug-metabolizing enzymes, thereby slowing elimination from the body and increasing blood levels of valproic acid</td>
</tr>
<tr>
<td>(1) Phenobarbital, phenytoin, valproic acid, verapamil</td>
<td>Displace valproic acid from binding sites on plasma proteins, thereby increasing the serum level of unbound valproic acid</td>
</tr>
<tr>
<td>h. Drug that increase the effects of phenobarbital:</td>
<td>These drugs induce drug-metabolizing enzymes in the liver and thereby increase the metabolism and hasten the elimination of zonisamide.</td>
</tr>
<tr>
<td>(1) Valproic acid</td>
<td>These drugs are benzodiazepines, discussed in Chapter 8.</td>
</tr>
<tr>
<td>i. Additional drugs that increase effects of valproate:</td>
<td>How Can You Avoid This Medication Error?</td>
</tr>
<tr>
<td>(1) Cimetidine</td>
<td>Answer: Blood levels need to remain within a therapeutic range to prevent seizures. Even missing two doses could affect this level. Frequently, surgery patients are permitted to take medications with a sip of water, even when they are NPO. Good judgment requires a nurse to check with the physician when significant medications are withheld.</td>
</tr>
<tr>
<td>(2) Salicylates</td>
<td>Review and Application Exercises</td>
</tr>
<tr>
<td>j. Drugs that decrease effects of zonisamide</td>
<td>Answer: Although Mr. Eng’s Dilantin level falls within the high end of normal (10–20 mcg/mL), his symptoms indicate phenytoin toxicity. Laboratory values are guides for appropriate dosing, but it is important that treatment be based on clinical data. Mr. Eng should be referred to his physician for evaluation of Dilantin toxicity and adjustment of Dilantin dosage.</td>
</tr>
<tr>
<td>(1) Carbamazepine, phenytoin, phenobarbital</td>
<td>1. For a client with a newly developed seizure disorder, why is it important to verify the type of seizure by electroencephalogram before starting antiseizure drug therapy?</td>
</tr>
<tr>
<td>k. Interactions with clonazepam, lorazepam, and diazepam</td>
<td>2. What are the indications for use of the major AEDs?</td>
</tr>
</tbody>
</table>

**Nursing Notes: Apply Your Knowledge**

Answer: Although Mr. Eng’s Dilantin level falls within the high end of normal (10–20 mcg/mL), his symptoms indicate phenytoin toxicity. Laboratory values are guides for appropriate dosing, but it is important that treatment be based on clinical data. Mr. Eng should be referred to his physician for evaluation of Dilantin toxicity and adjustment of Dilantin dosage.

Answer: Blood levels need to remain within a therapeutic range to prevent seizures. Even missing two doses could affect this level. Frequently, surgery patients are permitted to take medications with a sip of water, even when they are NPO. Good judgment requires a nurse to check with the physician when significant medications are withheld.
8. What is the treatment of choice for an acute convulsion or status epilepticus?

9. Why is it important when teaching clients to emphasize that none of the AEDs should be stopped abruptly?

10. How can a home care nurse monitor AED therapy during a home visit?

SELECTED REFERENCES


PARKINSON’S DISEASE

Parkinson’s disease (also called parkinsonism) is a chronic, progressive, degenerative disorder of the central nervous system (CNS) characterized by abnormalities in movement and posture (tremor, bradykinesia, joint and muscular rigidity). It occurs equally in men and women, usually between 50 and 80 years of age. Classic parkinsonism probably results from destruction or degenerative changes in dopamine-producing nerve cells. The cause of the nerve cell damage is unknown; age-related degeneration, genetics, and exposure to toxins (eg, carbon monoxide, organophosphate pesticides) are possible etiologic factors. Early-onset parkinsonism (before 45 years) is thought to have a genetic component. Signs and symptoms of the disease also may occur with other CNS diseases, brain tumors, and head injuries and with the use of typical or traditional antipsychotic drugs (eg, phenothiazines). Use of the newer “atypical” antipsychotic drugs may reduce the incidence of drug-induced parkinsonism.

The basal ganglia in the brain normally contain substantial amounts of the neurotransmitters dopamine and acetylcholine. The correct balance of dopamine and acetylcholine is important in regulating posture, muscle tone, and voluntary movement. People with Parkinson’s disease have an imbalance in these neurotransmitters, resulting in a decrease in inhibitory brain dopamine and a relative increase in excitatory acetylcholine. Imbalances of other neurotransmitters (eg, gamma aminobutyric acid [GABA], glutamate, norepinephrine, and serotonin) also occur.

ANTIPARKINSON DRUGS

Drugs used in Parkinson’s disease increase levels of dopamine (levodopa, dopamine agonists, monoamine oxidase [MAO] inhibitors, catechol-O-methyltransferase [COMT] inhibitors) or inhibit the actions of acetylcholine (anticholinergic agents) in the brain. Thus, the drugs help adjust the balance of neurotransmitters.
Dopaminergic Drugs

Levodopa, carbidopa, amantadine, bromocriptine, pergolide, pramipexole, ropinirole, selegiline, entacapone, and tolcapone increase dopamine concentrations in the brain and exert dopaminergic activity, directly or indirectly. Levodopa is the mainstay of drug therapy for idiopathic parkinsonism. Carbidopa is used only in conjunction with levodopa. The other drugs are used as adjunctive agents, usually with levodopa.

Anticholinergic Drugs

Anticholinergic drugs are discussed in Chapter 21 and are described here only in relation to their use in the treatment of Parkinson’s disease. Only anticholinergic drugs that are centrally active (ie, those that penetrate the blood–brain barrier) are useful in treating parkinsonism. Atropine and scopolamine are centrally active but are not used because of a high incidence of adverse reactions. In addition to the primary anticholinergic drugs, an antihistamine (diphenhydramine) is used for parkinsonism because of its strong anticholinergic effects.

Mechanisms of Action

Dopaminergic drugs increase the amount of dopamine in the brain by various mechanisms. Amantadine increases dopamine release and decreases dopamine reuptake by presynaptic nerve fibers. Bromocriptine, pergolide, pramipexole, and ropinirole are dopamine agonists that directly stimulate postsynaptic dopamine receptors. Levodopa is a precursor substance that is converted to dopamine. Selegiline blocks one of the enzymes (MAO-B) that normally inactivates dopamine. Entacapone and tolcapone block another enzyme (COMT) that normally inactivates dopamine and levodopa. Anticholinergic drugs decrease the effects of acetylcholine. This decreases the apparent excess of acetylcholine in relation to the amount of dopamine.

Indications for Use

Entacapone, levodopa, pergolide, pramipexole, ropinirole, selegiline, and tolcapone are indicated for the treatment of idiopathic or acquired parkinsonism; carbidopa is used only to decrease peripheral breakdown of levodopa. Some of the other drugs have additional uses. For example, amantadine is also used to prevent and treat influenza A viral infections. Bromocriptine is also used in the treatment of amenorrhea and galactorrhea associated with hyperprolactinemia.

Anticholinergic drugs are used in idiopathic parkinsonism to decrease salivation, spasticity, and tremors. They are used primarily for people who have minimal symptoms or who cannot tolerate levodopa, or in combination with other antiparkinson drugs. Anticholinergic agents also are used to relieve symptoms of parkinsonism that can occur with the use of antipsychotic drugs. If used for this purpose, a course of therapy of approximately 3 months is recommended because symptoms usually subside by then even if the antipsychotic drug is continued.

Contraindications to Use

Levodopa is contraindicated in clients with narrow-angle glaucoma, hemolytic anemia, severe angina pectoris, transient ischemic attacks, or a history of melanoma or undiagnosed skin disorders, and in clients taking MAO inhibitor drugs. In addition, levodopa must be used with caution in clients with severe cardiovascular, pulmonary, renal, hepatic, or endocrine disorders. Bromocriptine and pergolide are ergot derivatives and therefore are contraindicated in people hypersensitive to ergot alkaloids or those with uncontrolled hypertension. Selegiline, entacapone, and tolcapone are contraindicated in people with hypersensitivity reactions to the drugs. Tolcapone is contraindicated in people with impaired liver function.

Anticholinergic drugs are contraindicated in clients with glaucoma, gastrointestinal obstruction, prostatic hypertrophy, urinary bladder neck obstruction, and myasthenia gravis. The drugs must be used cautiously in clients with cardiovascular disorders (eg, tachycardia, dysrhythmias, hypertension) and liver or kidney disease.

INDIVIDUAL ANTIPARKINSON DRUGS

Dopaminergic antiparkinson drugs are described in this section; names, routes, and dosage ranges are listed in Drugs at a Glance: Antiparkinson Drugs.

Levodopa (Larodopa, Dopar) is the most effective drug available for the treatment of Parkinson’s disease. It relieves all major symptoms, especially bradykinesia and rigidity. Although levodopa does not alter the underlying disease process, it may improve a client’s quality of life.

Levodopa acts to replace dopamine in the basal ganglia of the brain. Dopamine cannot be used for replacement therapy because it does not penetrate the blood–brain barrier. Levodopa readily penetrates the CNS and is converted to dopamine by the enzyme amino acid decarboxylase (AADC). The dopamine is stored in presynaptic dopaminergic neurons and functions like endogenous dopamine. In advanced stages of Parkinson’s disease, there are fewer dopaminergic neurons and thus less storage capacity for dopamine derived from levodopa. As a result, levodopa has a shorter duration of action and drug effects “wear off” between doses.

In peripheral tissues (eg, liver, kidney, gastrointestinal tract), levodopa is extensively metabolized by decarboxylase, whose concentration is greater in peripheral tissues than in the brain. It is metabolized to a lesser extent by the enzyme COMT. Consequently, most levodopa is metabolized in peripheral tissues and large amounts are required to obtain therapeutic levels of dopamine in the brain. Peripheral metabolism of levodopa can be reduced (and the amounts
Diphenhydramine (Benadryl)
Tolcapone (Tasmar)
Selegiline (Symmetrel)
Trihexyphenidyl (Trihexy)
Procyclidine (Kemadrin)
Ropinirole (Requip)
Pramipexole (Mirapex)
Pergolide (Permax)
Levodopa/carbidopa (Sinemet)
Amantadine (Symmetrel)
Bromocriptine (Parlodel)
Entacapone (Comtan)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levodopa (Larodopa)</td>
<td>PO 0.5–1 g/d initially in 3 or 4 divided doses, increase gradually by no more than 0.75 g/d, every 3–7 d. The rate of dosage increase depends mainly on the client’s tolerance of adverse effects, especially nausea and vomiting. Average maintenance dose, 3–6 g/d; maximum dose, 8 g/d. Dosage must be reduced when carbidopa is also given (see carbidopa, below).</td>
</tr>
<tr>
<td>Carbhidopa (Lodosyn)</td>
<td>PO 70–100 mg/d, depending on dosage of levodopa; maximum dose, 200 mg/d</td>
</tr>
<tr>
<td>Levodopa/carbidopa (Sinemet)</td>
<td>PO 70–100 mg/d, depending on dosage of levodopa; maximum dose, 200 mg/d</td>
</tr>
<tr>
<td>Clients not receiving levodopa: PO 1 tab of 25 mg carbidopa/100 mg levodopa 3 times daily or 1 tab of 10 mg carbidopa/100 mg levodopa 3 or 4 times daily, increased by 1 tablet every day or every other day until a dosage of 8 tablets daily is reached. Sinemet CR PO 1 tab twice daily at least 6 h apart initially, increased up to 8 tablets daily and q4h intervals if necessary.</td>
<td></td>
</tr>
<tr>
<td>Amantadine (Symmetrel)</td>
<td>PO 100 mg twice a day</td>
</tr>
<tr>
<td>Bromocriptine (Parlodel)</td>
<td>PO 1.25 mg twice a day with meals, increased by 2.5 mg/d every 2–4 wk if necessary for therapeutic benefit. Reduce dose gradually if severe adverse effects occur.</td>
</tr>
<tr>
<td>Entacapone (Comtan)</td>
<td>PO 200 mg with each dose of levodopa/carbidopa, up to 8 times (1600 mg) daily</td>
</tr>
<tr>
<td>Pergolide (Permax)</td>
<td>PO 50 mg 2–4 times daily, increased to 8 tablets daily and q4h intervals if necessary</td>
</tr>
<tr>
<td>Pramipexole (Mirapex)</td>
<td>PO wk 1, 0.125 mg 3 times daily; wk 2, 0.25 mg 3 times daily; wk 3, 0.5 mg 3 times daily; wk 4, 0.75 mg 3 times daily; wk 5, 1 mg 3 times daily; wk 6, 1.25 mg 3 times daily; wk 7, 1.5 mg 3 times daily</td>
</tr>
<tr>
<td>Renal impairment: Creatinine clearance (Crcl) &gt; 60 mL/min, 0.125 mg 3 times daily initially, up to a maximum of 1.5 mg 3 times daily; Crcl 35–59 mL/min, 0.125 mg 2 times daily initially, up to a maximum of 1.5 mg 2 times daily; Crcl 15–34 mL/min, 0.125 mg once daily, up to a maximum of 1.5 mg once daily</td>
<td></td>
</tr>
<tr>
<td>Ropinirole (Requip)</td>
<td>PO wk 1, 0.125 mg 3 times daily; wk 2, 0.25 mg 3 times daily; wk 3, 0.5 mg 3 times daily; wk 4, 0.75 mg 3 times daily; wk 5, 1 mg 3 times daily; wk 6, 1.25 mg 3 times daily; wk 7, 1.5 mg 3 times daily</td>
</tr>
<tr>
<td>Selegiline (Eldepryl)</td>
<td>PO 10 mg carbidopa/100 mg levodopa 3 or 4 times daily, increased by 1 tablet every day or every other day</td>
</tr>
<tr>
<td>Tolcapone (Tasmar)</td>
<td>PO wk 1, 0.125 mg 3 times daily; wk 2, 0.25 mg 3 times daily; wk 3, 0.5 mg 3 times daily; wk 4, 0.75 mg 3 times daily; wk 5, 1 mg 3 times daily; wk 6, 1.25 mg 3 times daily; wk 7, 1.5 mg 3 times daily</td>
</tr>
<tr>
<td>Discontinue levodopa at least 8 h before starting Sinemet. PO 1 tab of 25 mg carbidopa/100 mg levodopa 3 or 4 times daily for clients taking &gt;1500 mg levodopa or 1 tab of 25 mg carbidopa/100 mg levodopa for clients taking &lt;1500 mg levodopa</td>
<td></td>
</tr>
<tr>
<td>PO 0.5–1 mg at bedtime initially, gradually increased to 4–6 mg daily if necessary</td>
<td></td>
</tr>
<tr>
<td>PO 2 mg 3–4 times daily</td>
<td></td>
</tr>
<tr>
<td>PO 25 mg 3 times daily, gradually increased to 50 mg 4 times daily if necessary</td>
<td></td>
</tr>
<tr>
<td>Adults: Drug-induced extrapyramidal reactions, IM, IV 10–50 mg; maximal single dose, 100 mg; maximal daily dose, 400 mg</td>
<td></td>
</tr>
<tr>
<td>Children: Drug-induced extrapyramidal reactions, IM 5 mg/kg per day; maximal daily dose, 300 mg</td>
<td></td>
</tr>
<tr>
<td>PO 1–2 mg daily initially, gradually increased to 12–15 mg daily, until therapeutic or adverse effects occur</td>
<td></td>
</tr>
</tbody>
</table>

Levodopa is well absorbed from the small intestine after oral administration, reaches peak serum levels within 30 to 90 minutes, and has a short serum half-life (1 to 3 hours). Absorption is decreased by delayed gastric emptying, hyperacidity of gastric secretions, and competition with amino acids (from digestion of protein foods) for sites of absorption in the small intestine. Levodopa is metabolized to 30 or more metabolites, some of which are pharmacologically active and probably contribute to drug toxicity; the metabolites are excreted primarily in the urine, usually within 24 hours.

Because of side effects and recurrence of parkinsonian symptoms after a few years of levodopa therapy, levodopa is often reserved for clients with significant symptoms and functional disabilities. In addition to treating Parkinson’s disease, levodopa also may be useful in other CNS disorders in which symptoms of parkinsonism occur (eg, juvenile Huntington’s chorea, chronic manganese poisoning). Levodopa relieves only parkinsonian symptoms in these conditions.
Carbidopa (Lodosyn) inhibits the enzyme AADC. As a result, less levodopa is decarboxylated in peripheral tissues; more levodopa reaches the brain, where it is decarboxylated to dopamine; and much smaller doses of levodopa can be given. Carbidopa does not penetrate the blood–brain barrier. Although carbidopa is available alone, it is most often given in a levodopa/carbidopa fixed-dose combination product called Sinemet.

Amantadine (Symmetrel) is a synthetic antiviral agent initially used to prevent infection from influenza A virus. Amantadine increases the release and inhibits the reuptake of dopamine in the brain, thereby increasing dopamine levels. The drug relieves symptoms rapidly, within 1 to 5 days, but it loses efficacy with approximately 6 to 8 weeks of continuous administration. Consequently, it is usually given for 2- to 3-week periods during initiation of drug therapy with longer-acting agents (eg, levodopa), or when symptoms worsen. Amantadine is often given in conjunction with levodopa. Compared with other antiparkinson drugs, amantadine is considered less effective than levodopa but more effective than anticholinergic agents.

Amantadine is well absorbed from the gastrointestinal tract and has a relatively long duration of action. It is excreted unchanged in the urine. Dosage must be reduced with impaired renal function to avoid drug accumulation.

Bromocriptine (Parlodel) and pergolide (Permax) are ergot derivatives that directly stimulate dopamine receptors in the brain. They are used in the treatment of idiopathic Parkinson’s disease, with levodopa/carbidopa, to prolong effectiveness and allow reduced dosage of levodopa. Pergolide has a longer duration of action than bromocriptine and may be effective in some clients unresponsive to bromocriptine. Adverse effects are similar for the two drugs.

Entacapone (Comtan) and tolcapone (Tasmar) are COMT inhibitors. COMT plays a role in brain metabolism of dopamine and metabolizes approximately 10% of peripheral levodopa. By inhibiting COMT, entacapone and tolcapone increase levels of dopamine in the brain and relieve symptoms more effectively and consistently. Although the main mechanism of action seems to be inhibiting the metabolism of levodopa in the bloodstream, the drugs may also inhibit COMT in the brain and prolong the activity of dopamine at the synapse. These drugs are used only in conjunction with levodopa/carbidopa, and dosage of levodopa must be reduced.

Entacapone is well absorbed with oral administration and reaches a peak plasma level in 1 hour. It is highly protein bound (98%), has a half-life of about 2.5 hours, and is metabolized in the liver to an inactive metabolite. Dosage must be reduced by 50% in the presence of impaired liver function. The parent drug and the metabolite are 90% excreted through the biliary tract and feces; 10% is excreted in the urine. Adverse effects include confusion, dizziness, drowsiness, hallucinations, nausea, and vomiting. These can be reduced by lowering the dose of either levodopa or entacapone. Although there were few instances of liver enzyme elevation or hemoglobin decreases during clinical trials, it is recommended that liver enzymes and red blood cell counts be done periodically.

Tolcapone is also well absorbed with oral administration. Its elimination half-life is 2 to 3 hours and it is metabolized in the liver. Diarrhea was a common adverse effect during clinical trials. Because of several reports of liver damage and deaths from liver failure, tolcapone should be used only in clients who do not respond to other drugs. When used, liver aminotransferase enzymes (serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) should be monitored every 2 weeks for 1 year, then every 4 weeks for 6 months, then every 2 months. Tolcapone should be discontinued if ALT and AST are elevated, if symptoms of liver failure occur (anorexia, abdominal tenderness, dark urine, jaundice, clay-colored stools), or if parkinsonian symptoms do not improve after 3 weeks of taking tolcapone.

Pramipexole (Mirapex) and ropinirole (Requip) are newer drugs that also stimulate dopamine receptors in the brain. They are approved for both beginning and advanced stages of Parkinson’s disease. In early stages, one of the drugs can be used alone to improve motor performance, to improve ability to participate in usual activities of daily living, and to delay levodopa therapy. In advanced stages, one of the drugs can be used with levodopa and perhaps other antiparkinson drugs to provide more consistent relief of symptoms between doses of levodopa and allow reduced dosage of levodopa. These drugs are not ergot derivatives and may not cause some adverse effects associated with bromocriptine and pergolide (eg, pulmonary and peritoneal fibrosis and constriction of coronary arteries).

Pramipexole is rapidly absorbed with oral administration. Peak serum levels are reached in 1 to 3 hours after a dose and steady-state concentrations in about 2 days. It is less than 20% bound to plasma proteins and has an elimination half-life of 8 to 12 hours. Most of the drug is excreted unchanged in the urine; only 10% of the drug is metabolized. As a result, renal failure may cause higher-than-usual plasma levels and possible toxicity, but hepatic disease is unlikely to alter drug effects.

Ropinirole is also well absorbed with oral administration. It reaches peak serum levels in 1–2 hours and steady-state concentrations within 2 days. It is 40% bound to plasma proteins and has an elimination half-life of 6 hours. It is metabolized by the cytochrome P450 enzymes in the liver to inactive metabolites, which are excreted through the kidneys. Less than 10% of ropinirole is excreted unchanged in the urine. Thus, liver failure may decrease metabolism, allow drug accumulation, and increase adverse effects. Renal failure does not appear to alter drug effects.

Selegiline (Eldepryl) increases dopamine in the brain by inhibiting its metabolism by MAO. MAO exists in two types,
Nursing Notes: Apply Your Knowledge

Mr. Simmons has had Parkinson’s disease for 4 years and, despite treatment with Sinemet, his functional abilities continue to decline. His physician prescribes a tricyclic antidepressant. He comes to the clinic 3 weeks later complaining of constipation and difficulty voiding. Are these symptoms related to his medications?

MAO-A and MAO-B, both of which are found in the CNS and peripheral tissues. They are differentiated by their relative specificities for individual catecholamines. MAO-A acts more specifically on tyramine, norepinephrine, epinephrine, and serotonin. It is the main subtype in gastrointestinal mucosa and the liver and is responsible for metabolizing dietary tyramine. If MAO-A is inhibited in the intestine, tyramine in various foods is absorbed systemically rather than deactivated. As a result, there is excessive stimulation of the sympathetic nervous system and severe hypertension and stroke can occur. This life-threatening reaction can also occur with medications that are normally metabolized by MAO.

MAO-B metabolizes dopamine; in the brain, most MAO activity is due to type B. At oral doses of 10 mg/day or less, selegiline inhibits MAO-B selectively and is unlikely to cause severe hypertension and stroke. At doses higher than 10 mg/day, however, selectivity is lost and metabolism of both MAO-A and MAO-B is inhibited. Doses above 10 mg/day should be avoided in Parkinson’s disease. Selegiline inhibition of MAO-B is irreversible and drug effects persist until more MAO is synthesized in the brain, which may take several months.

In early Parkinson’s disease, selegiline may be effective as monotherapy. In advanced disease, it is given to enhance the effects of levodopa. Its addition aids symptom control and allows the dosage of levodopa/carbidopa to be reduced.

Nursing Process

Assessment

Assess for signs and symptoms of Parkinson’s disease and drug-induced extrapyramidal reactions. These may include the following, depending on the severity and stage of progression:

- Excessive salivation and drooling
- Dysphagia
- Excessive sweating
- Constipation from decreased intestinal motility
- Mental depression from self-consciousness and embarrassment over physical appearance and activity limitations. The intellect is usually intact until the late stages of the disease process.

Nursing Diagnoses

- Bathing/Grooming Self Care Deficit related to tremors and impaired motor function
- Impaired Physical Mobility related to alterations in balance and coordination
- Disturbed Body Image related to disease and disability
- Deficient Knowledge: Safe usage and effects of antiparkinson drugs
- Imbalanced Nutrition: Less Than Body Requirements related to difficulty in chewing and swallowing food
- Risk for Injury: Dizziness, hypotension related to adverse drug effects

Planning/Goals

The client will:

- Experience relief of excessive salivation, muscle rigidity, spasticity, and tremors
- Experience improved motor function, mobility, and self-care abilities
- Experience improvement of self-concept and body image
- Increase knowledge of the disease process and drug therapy
- Take medications as instructed
- Avoid falls and other injuries from the disease process or drug therapy.

Interventions

Use measures to assist the client and family in coping with symptoms and maintaining function. These include the following:

- Provide physical therapy for heel-to-toe gait training, widening stance to increase balance and base of support, other exercises.
- Encourage ambulation and frequent changes of position, assisted if necessary.
- Help with active and passive range-of-motion exercises.
- Encourage self-care as much as possible. Cutting meat; opening cartons; giving frequent, small meals; and allowing privacy during mealtime may be helpful. If the client has difficulty chewing or swallowing, chopped or soft foods may be necessary. Velcro-type fasteners or zippers are easier to handle than buttons. Slip-on shoes are easier to manage than laced ones.
- Spend time with the client and encourage socialization with other people. Victims of Parkinson’s disease tend to become withdrawn, isolated, and depressed.
CHAPTER 12 ANTIPARKINSON DRUGS

PRINCIPLES OF THERAPY

Goals of Treatment

The goals of antiparkinson drug therapy are to control symptoms, maintain functional ability in activities of daily living, minimize adverse drug effects, and slow disease progression.

Drug Selection

Choices of antiparkinson drugs depend largely on the type of parkinsonism (idiopathic or drug induced) and the severity of symptoms. In addition, because of difficulties with levodopa therapy (eg, adverse effects, loss of effectiveness in a few years, possible acceleration of the loss of dopaminergic neurons in the brain), several drug therapy strategies and combinations are used to delay the start of levodopa therapy and, once started, to reduce levodopa dosage.

1. For drug-induced parkinsonism or extrapyramidal symptoms, an anticholinergic agent is the drug of choice.
2. For early idiopathic parkinsonism, when symptoms and functional disability are relatively mild, several drugs may be used as monotherapy.
   a. An anticholinergic agent may be the initial drug of choice in clients younger than 60 years of age, especially when tremor is the major symptom. An anticholinergic relieves tremor in approximately 50% of clients.
   b. Amantadine may be useful in relieving bradykinesia or tremor.
   c. A dopamine agonist may improve functional disability related to bradykinesia, rigidity, impaired physical dexterity, impaired speech, shuffling gait, and tremor.
3. For advanced idiopathic parkinsonism, a combination of medications is used. Two advantages of combination therapy are better control of symptoms and reduced dosage of individual drugs.
   a. An anticholinergic agent may be given with levodopa alone or with a levodopa/carbidopa combination.
   b. Amantadine may be given in combination with levodopa or other antiparkinson agents.
   c. A dopamine agonist is usually given with levodopa/carbidopa. The combination provides more effective relief of symptoms and allows lower dosage of levodopa. Although all four of the available dopamine agonists are similarly effective, the newer agents (pramipexole and ropinirole) may cause fewer or less severe adverse effects than bromocriptine and pergolide.

CLIENT TEACHING GUIDELINES

Antiparkinson Drugs

General Considerations

- Beneficial effects of antiparkinson drugs may not occur for a few weeks or months; do not stop taking them before they have had a chance to work.
- Do not take other drugs without the physician’s knowledge and consent. This is necessary to avoid adverse drug interactions. Prescription and nonprescription drugs may interact with antiparkinson drugs to increase or decrease effects.
- Avoid driving an automobile or operating other potentially hazardous machinery if vision is blurred or drowsiness occurs with levodopa.
- Change positions slowly, especially when assuming an upright position, and wear elastic stockings, if needed, to prevent dizziness from a drop in blood pressure.

Self- or Caregiver Administration

- Take antiparkinson drugs with or just after food intake to prevent or reduce anorexia, nausea, and vomiting.
- Do not crush or chew Sinemet CR. It is formulated to be released slowly; crushing or chewing destroys this feature.
- Take or give selegiline in the morning and at noon. This schedule decreases stimulating effects that may interfere with sleep if the drug is taken in the evening.
- Decrease excessive mouth dryness by maintaining an adequate fluid intake (2000–3000 mL daily if not contraindicated) and using sugarless chewing gum and hard candies. Both anticholinergics and levodopa may cause mouth dryness. This is usually a therapeutic effect in Parkinson’s disease. However, excessive mouth dryness causes discomfort and dental caries.
- Report adverse effects. Adverse effects can often be reduced by changing drugs or dosages. However, some adverse effects usually must be tolerated for control of disease symptoms.
d. The levodopa/carbidopa combination is probably the most effective drug when bradykinesia and rigidity become prominent. However, because levodopa becomes less effective after approximately 5 to 7 years, many clinicians use other drugs first and reserve levodopa for use when symptoms become more severe.

e. Selegiline may be given with levodopa/carbidopa. Although evidence is limited and opinions differ, selegiline may have a neuroprotective effect and slow the loss of dopaminergic neurons in the brain.

f. Entacapone is used only with levodopa/carbidopa. However, in contrast to AADC inhibitors, which increase the bioavailability of levodopa without increasing its plasma half-life, simultaneous administration of COMT and AADC inhibitors significantly increases the plasma half-life of levodopa. Tolcapone should be used only when other drugs are ineffective, because of its association with liver failure.

Selegiline and entacapone may both be used with levodopa/carbidopa because entacapone acts peripherally and selegiline acts in the brain. Inhibition of levodopa/dopamine metabolism is a valuable addition to levodopa as an exogenous source of dopamine.

4. When changes are made in a drug therapy regimen, one change at a time is recommended so that effects of the change are clear.

**Drug Dosage**

The dosage of antiparkinson drugs is highly individualized. The general rule is to start with a low initial dose and gradually increase the dosage until therapeutic effects, adverse effects, or maximum drug dosage is achieved. Additional guidelines include the following.

1. The optimal dose is the lowest one that allows the patient to function adequately. Optimal dosage may not be established for 6 to 8 weeks with levodopa.

2. Doses need to be adjusted as parkinsonism progresses.

3. Dosage must be individualized for levodopa and carbidopa. Only 5% to 10% of a dose of levodopa reaches the CNS, even with the addition of carbidopa. When carbidopa is given with levodopa, the dosage of levodopa must be reduced by approximately 75%. A daily dose of approximately 70 to 100 mg of carbidopa is required to saturate peripheral amino acid decarboxylase.

A levodopa/carbidopa combination is available in three dosage formulations (10 mg carbidopa/100 mg levodopa, 25 mg carbidopa/100 mg levodopa, and 25 mg carbidopa/250 mg levodopa) of immediate-release tablets (Sinemet) and two dosage formulations (25 mg carbidopa/100 mg levodopa, 50 mg carbidopa/200 mg levodopa) of sustained-release tablets (Sinemet CR). Various preparations can be mixed to administer optimal amounts of each ingredient. Sinemet CR is not as well absorbed as the short-acting form, and a client being transferred to Sinemet CR needs a dosage increase of approximately one third.

4. With levodopa, dosage should be gradually increased to the desired therapeutic level. In addition, therapeutic effects may be increased and adverse effects decreased by frequent administration of small doses.

5. With pramipexole and ropinirole, dosage is started at low levels and gradually increased over several weeks. When the drugs are discontinued, they should be tapered in dosage over 1 week. With pramipexole, lower doses are indicated in older adults and those with renal impairment; with ropinirole, lower doses may be needed with hepatic impairment.

6. When combinations of drugs are used, dosage adjustments of individual components are often necessary. When levodopa is added to a regimen of anticholinergic drug therapy, for example, the anticholinergic drug need not be discontinued or reduced in dosage. However, when a dopaminergic drug is added to a regimen containing levodopa/carbidopa, dosage of levodopa/carbidopa must be reduced.

**Use in Children**

Safety and effectiveness for use in children have not been established for most antiparkinson drugs, including the centrally acting anticholinergics (all ages), levodopa (<12 years), and bromocriptine (<15 years). However, anticholinergics are sometimes given to children who have drug-induced extrapyramidal reactions.

Because parkinsonism is a degenerative disorder of adults, antiparkinson drugs are most likely to be used for other purposes in children. Amantadine for influenza A prevention or treatment is not recommended for neonates or infants younger than 1 year of age but may be given to children 9 to 12 years of age.

**Use in Older Adults**

Dosage of amantadine may need to be reduced because the drug is excreted mainly through the kidneys and renal function is usually decreased in older adults. Dosage of levodopa/carbidopa may need to be reduced because of an age-related decrease in peripheral AADC, the enzyme that carbidopa inhibits.

Anticholinergic drugs may cause blurred vision, dry mouth, tachycardia, and urinary retention. They also decrease sweating and may cause fever or heatstroke. Fever may occur in any age group, but heatstroke is more likely to occur in older adults, especially with cardiovascular disease, strenuous activity, and high environmental temperatures. When centrally active anticholinergics are given for Parkinson’s disease, agitation, mental confusion, hallucinations, and psychosis may occur. In addition to the primary anticholinergics, many other drugs have significant anticholinergic activity. These include some...
antihistamines, including those in over-the-counter cold remedies and sleep aids; tricyclic antidepressants; and phenothiazine antipsychotic drugs. When an anticholinergic is needed by an older adult, dosage should be minimized, combinations of drugs with anticholinergic effects should be avoided, and clients should be closely monitored for adverse drug effects.

Older clients are at increased risk of having hallucinations with dopamine agonist drugs. In addition, pramipexole dosage may need to be reduced in older adults with impaired renal function.

**Use in Renal Impairment**

Amantadine is excreted primarily by the kidneys and should be used with caution in clients with renal failure. With pramipexole, clearance is reduced in clients with moderate or severe renal impairment and lower initial and maintenance doses are recommended. With ropinirole and entacapone, no dosage adjustments are needed for renal impairment.

**Use in Hepatic Impairment**

Ropinirole should be used cautiously in hepatic impairment and dosage may need to be reduced. With tolcapone, elevated liver enzymes and a few deaths from liver failure have been reported. In clients with noncirrhotic liver disease, dosage reductions are not needed. In clients with hepatic cirrhosis, however, tolcapone metabolism is impaired and plasma drug levels are high. Dosage should be reduced and maintenance dosage should be less than the 600 mg daily recommended for noncirrhotic clients. In addition, liver transaminase enzymes should be monitored frequently. Although liver failure has not been associated with entacapone, periodic measurements of liver transaminase enzymes are recommended.

**Home Care**

The home care nurse can help clients and caregivers understand that the purpose of drug therapy is to control symptoms and that noticeable improvement may not occur for several weeks. Also, the nurse can encourage clients to consult physical therapists, speech therapists, and dietitians to help maintain their ability to perform activities of daily living. In addition, teaching may be needed about preventing or managing adverse drug effects. Caregivers may need to be informed that most activities (eg, eating, dressing) take longer and require considerable effort by clients with parkinsonism.

---

### Nursing Actions

#### Antiparkinson Drugs

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
<tr>
<td>a. Give most antiparkinson drugs with or just after food; entacapone can be given without regard to meals.</td>
<td>To prevent or reduce nausea and vomiting</td>
</tr>
<tr>
<td>b. Do not crush Sinemet CR and instruct clients not to chew the tablet.</td>
<td>Crushing and chewing destroys the controlled-release feature of the formulation.</td>
</tr>
<tr>
<td>c. Do not give levodopa with iron preparations or multivitamin-mineral preparations containing iron.</td>
<td>Iron decreases absorption of levodopa.</td>
</tr>
<tr>
<td>d. Give selegiline in the morning and at noon.</td>
<td>To decrease central nervous system (CNS) stimulating effects that may interfere with sleep if the drug is taken in the evening.</td>
</tr>
</tbody>
</table>

2. Observe for therapeutic effects

a. With anticholinergic agents, observe for decreased tremor, salivation, drooling, and sweating.

b. With levodopa and dopaminergic agents, observe for improvement in mobility, balance, posture, gait, speech, handwriting, and self-care ability. Drooling and seborrhea may be abolished, and mood may be elevated. Decreased salivation and sweating are therapeutic effects when these drugs are used in Parkinson’s disease, but they are adverse effects when the drugs are used in other disorders. Therapeutic effects are usually evident within 2–3 weeks, as levodopa dosage approaches 2–3 g/d, but may not reach optimum levels for 6 months.

(continued)
### Nursing Actions

<table>
<thead>
<tr>
<th>3. Observe for adverse effects</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. With anticholinergic drugs, observe for atropine-like effects,</strong> such as:</td>
<td></td>
</tr>
<tr>
<td>(1) Tachycardia and palpitations</td>
<td>These effects may occur with usual therapeutic doses but are not likely to be serious except in people with underlying heart disease.</td>
</tr>
<tr>
<td>(2) Excessive CNS stimulation (tremor, restlessness, confusion, hallucinations, delirium)</td>
<td>This effect is most likely to occur with large doses of trihexyphenidyl (Artane) or benztropine (Cogentin). It may occur with levodopa.</td>
</tr>
<tr>
<td>(3) Sedation and drowsiness</td>
<td>These are most likely to occur with benztropine. The drug has anti-histaminic and anticholinergic properties, and sedation is attributed to the antihistamine effect.</td>
</tr>
<tr>
<td>(4) Constipation, impaction, paralytic ileus</td>
<td>These effects result from decreased gastrointestinal motility and muscle tone. They may be severe because decreased intestinal motility and constipation also are characteristics of Parkinson’s disease; thus, additive effects may occur.</td>
</tr>
<tr>
<td>(5) Urinary retention</td>
<td>This reaction is caused by loss of muscle tone in the bladder and is most likely to occur in elderly men who have enlarged prostate glands.</td>
</tr>
<tr>
<td>(6) Dilated pupils (mydriasis), blurred vision, photophobia</td>
<td>Ocular effects are due to paralysis of accommodation and relaxation of the ciliary muscle and the sphincter muscle of the iris.</td>
</tr>
<tr>
<td><strong>b. With levodopa, observe for:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Anorexia, nausea, and vomiting</td>
<td>These symptoms usually disappear after a few months of drug therapy. They may be minimized by giving levodopa with food, gradually increasing dosage, administering smaller doses more frequently or adding carbidopa so that dosage of levodopa can be reduced.</td>
</tr>
<tr>
<td>(2) Orthostatic hypotension—check blood pressure in both sitting and standing positions q4h while the client is awake.</td>
<td>This effect is common during the first few weeks but usually subsides eventually. It can be minimized by arising slowly from supine or sitting positions and by wearing elastic stockings.</td>
</tr>
<tr>
<td>(3) Cardiac arrhythmias (tachycardia, premature ventricular contractions) and increased myocardial contractility</td>
<td>Levodopa and its metabolites stimulate beta-adrenergic receptors in the heart. People with pre-existing coronary artery disease may need a beta-adrenergic blocking agent (eg, propranolol) to counteract these effects.</td>
</tr>
<tr>
<td>(4) Dyskinesia—involuntary movements that may involve only the tongue, mouth, and face or the whole body</td>
<td>Dyskinesia eventually develops in most people who take levodopa. It is related to duration of levodopa therapy rather than dosage. Carbidopa may heighten this adverse effect, and there is no way to prevent it except by decreasing levodopa dosage. Many people prefer dyskinesia to lowering drug dosage and subsequent return of the parkinsonism symptoms.</td>
</tr>
<tr>
<td>(5) CNS stimulation—restlessness, agitation, confusion, delirium</td>
<td>This is more likely to occur with levodopa/carbidopa combination drug therapy.</td>
</tr>
<tr>
<td>(6) Abrupt swings in motor function (on–off phenomenon)</td>
<td>This fluctuation may indicate progression of the disease process. It often occurs after long-term levodopa use.</td>
</tr>
<tr>
<td><strong>c. With amantadine, observe for:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) CNS stimulation—insomnia, hyperexcitability, ataxia, dizziness, slurred speech, mental confusion, hallucinations</td>
<td>Compared with other antiparkinson drugs, amantadine produces few adverse effects. The ones that occur are mild, transient, and reversible. However, adverse effects increase if daily dosage exceeds 200 mg.</td>
</tr>
<tr>
<td>(2) Livedo reticularis—patchy, bluish discoloration of skin on the legs</td>
<td>This is a benign but cosmetically unappealing condition. It usually occurs with long-term use of amantadine and disappears when the drug is discontinued.</td>
</tr>
</tbody>
</table>
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
d. With bromocriptine and pergolide, observe for:
(1) Nausea
(2) Confusion and hallucinations
(3) Hypotension
These symptoms are usually mild and can be minimized by starting with low doses and increasing the dose gradually until the desired effect is achieved. If adverse effects do occur, they usually disappear with a decrease in dosage.
e. With pramipexole and ropinirole, observe for:
(1) Nausea
(2) Confusion, hallucinations
(3) Dizziness, drowsiness
(4) Dyskinesias
(5) Orthostatic hypotension
These effects occurred more commonly than others during clinical trials.
f. With selegiline, observe for:
(1) CNS effects—agitation, ataxia, bradykinesia, confusion, dizziness, dyskinesias, hallucinations, insomnia
(2) Nausea, abdominal pain
These effects occurred more commonly than others during clinical trials.
g. With entocapone and tolcapone, observe for:
(1) Anorexia, nausea, vomiting, diarrhea, constipation
(2) Dizziness, drowsiness
(3) Dyskinesias and dystonias
(4) Hallucinations
(5) Orthostatic hypotension
These drugs have anticholinergic properties and produce additive anticholinergic effects.
4. Observe for drug interactions
a. Drugs that increase effects of anticholinergic drugs:
(1) Antihistamines, disopyramide (Norpace), thiothixene (Navane), phenothiazines, and tricyclic antidepressants
These drugs have anticholinergic properties and produce additive anticholinergic effects.
b. Drugs that decrease effects of anticholinergic drugs:
(1) Cholinergic agents
These drugs counteract the inhibition of gastrointestinal motility and tone, which is a side effect of anticholinergic drug therapy.
c. Drugs that increase effects of levodopa:
(1) Amantadine, anticholinergic agents, bromocriptine, carbidopa, entacapone, pergolide, pramipexole, ropinirole, selegiline, tolcapone
These drugs are often used in combination for treatment of Parkinson's disease.
(2) Tricyclic antidepressants
These drugs potentiate levodopa effects and increase the risk of cardiac arrhythmias in people with heart disease.
(3) Monoamine oxidase type A (MAO-A) inhibitors, including isocarboxazid (Marplan), phenelzine (Nardil), and tranylcypromine (Parnate)
The combination of a catecholamine precursor (levodopa) and MAO-A inhibitors that decrease metabolism of catecholamines can result in excessive amounts of dopamine, epinephrine, and norepinephrine. Heart palpitations, headache, hypertensive crisis, and stroke may occur. Levodopa and MAO-A inhibitors should not be given concurrently. Also, levodopa should not be started within 3 weeks after an MAO-A inhibitor is discontinued. Effects of MAO-A inhibitors persist for 1–3 weeks after their discontinuation. These effects are unlikely to occur with selegiline, an MAO-B inhibitor, which more selectively inhibits the metabolism of dopamine. However, selectivity may be lost at doses higher than the recommended 10 mg/d. Selegiline is used with levodopa.
NURSING ACTIONS

**d.** Drugs that decrease effects of levodopa:

1. Anticholinergics

2. Alcohol, benzodiazepines (e.g., diazepam [Valium]), antiemetics, antipsychotics such as phenothiazines, haloperidol (Haldol), and thiothixene (Navane)

3. Oral iron preparations

4. Pyridoxine (vitamin B<sub>6</sub>)

**RATIONALE/EXPLANATION**

Although anticholinergics are often given with levodopa for increased antiparkinson effects, they also may decrease effects of levodopa by delaying gastric emptying. This causes more levodopa to be metabolized in the stomach and decreases the amount available for absorption from the intestine.

The mechanisms by which most of these drugs decrease effects of levodopa are not clear. Phenothiazines block dopamine receptors in the basal ganglia.

Iron binds with levodopa and reduces levodopa absorption, possibly by as much as 50%.

Pyridoxine stimulates decarboxylase, the enzyme that converts levodopa to dopamine. As a result, more levodopa is metabolized in peripheral tissues, and less reaches the CNS, where antiparkinson effects occur. This interaction does not occur when carbidopa is given with levodopa.

**e.** Drugs that decrease effects of dopaminergic antiparkinson drugs:

1. Antipsychotic drugs

2. Metoclopramide

These drugs are dopamine antagonists and therefore inhibit the effects of dopamine agonists.

---

**How Can You Avoid This Medication Error?**

**Answer:** This medication error occurred because the wrong dose of levodopa was given to Mr. Evans. When administering a combination product, it is important that the dosage be correct for each medication. In this situation, the Sinemet provided contained 25 mg of carbidopa and 250 mg of levodopa. When administering Sinemet 25/250, you give the patient 250 mg of levodopa rather than the 100 mg that was ordered. Call the pharmacy and request that Sinemet 25/100 be provided.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Yes. Both Sinemet and tricyclic antidepressants have anticholinergic side effects, including urinary retention and constipation. When these medications are given together, enhanced anticholinergic effects are seen. Tachycardia and palpiations can also occur. Refer Mr. Simmons to his physician to see if another antidepressant with fewer anticholinergic side effects could be used.

---

**Review and Application Exercises**

1. Which neurotransmitter is deficient in idiopathic and drug-induced parkinsonism?
2. How do the antiparkinson drugs act to alter the level of the deficient neurotransmitter?

---

**SELECTED REFERENCES**


Skeletal Muscle Relaxants

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss common symptoms/disorders for which skeletal muscle relaxants are used.
2. Differentiate uses and effects of selected drugs.
3. Describe nonpharmacologic interventions to relieve muscle spasm and spasticity.
4. Apply the nursing process with clients experiencing muscle spasm or spasticity.

Critical Thinking Scenario
John Moore was in an automobile accident 5 days ago, sustaining trauma to his back and shoulder. Although no bones were broken, he continues to have pain and muscle spasms. His physician orders Tylox PRN for the pain and cyclobenzaprine (Flexeril) tid for muscle spasms.

Reflect on:
- Why are two different medications ordered to manage John’s discomfort?
- What nonpharmacologic treatments can be used to promote comfort?
- What teaching needs to be done before sending John home?

SKELETAL MUSCLE RELAXANTS

Skeletal muscle relaxants are used to decrease muscle spasm or spasticity that occurs in certain neurologic and musculoskeletal disorders. (Neuromuscular blocking agents used as adjuncts to general anesthesia for surgery are discussed in Chap. 14.)

Muscle Spasm

Muscle spasm or cramp is a sudden, involuntary, painful muscle contraction that occurs with trauma or an irritant. Spasms may involve alternating contraction and relaxation (clonic) or sustained contraction (tonic). Muscle spasm may occur with musculoskeletal trauma or inflammation (eg, sprains, strains, bursitis, arthritis). It is also encountered with acute or chronic low back pain, a common condition that is primarily a disorder of posture.

Spasticity

Spasticity involves increased muscle tone or contraction and stiff, awkward movements. It occurs with neurologic disorders such as spinal cord injury and multiple sclerosis.

In patients with spinal cord injury, spasticity requires treatment when it impairs safety, mobility, and the ability to perform activities of daily living (eg, self-care in hygiene, eating, dressing, and work or recreational activities). Stimuli that precipitate spasms vary from one individual to another and may include muscle stretching, bladder infections or stones, constipation and bowel distention, or infections. Each person needs to be assessed for personal precipitating factors, so they can be avoided when possible. Treatment measures include passive range-of-motion and muscle-stretching exercises and antispasmodic medications (eg, baclofen, dantrolene).

Multiple sclerosis (MS) is a major cause of neurologic disability among young and middle-aged adults, occurs more often in women than in men, and has a pattern of exacerbations and remissions. It is considered an autoimmune disorder that occurs in genetically susceptible individuals, although its cause is unknown. It involves destruction of portions of the myelin sheath that covers nerves in the brain, spinal cord, and optic nerve. Myelin normally insulates the neuron from electrical activity and conducts electrical impulses rapidly along nerve fibers. When myelin is destroyed (a process called demyelination, which probably results from inflammation), fibrotic lesions are formed and nerve conduction is slowed or blocked around the lesions. Lesions in various states of development (eg, acute, subacute, and
chronic) often occur at multiple sites in the CNS. Muscle weakness and other symptoms vary according to the location and duration of the myelin damage.

In recent years, researchers have discovered that nerve cells can be repaired (remyelinated) if the process that damaged the myelin is stopped before the oligodendrocytes (the cells that form myelin) are destroyed. Other researchers are trying to develop methods for enhancing nerve conduction velocity in demyelinated nerves. For example, exposure to cold by wearing a cooling vest or exercising in cool water temporarily increases the rate of nerve conduction and improves symptoms in some people. Avoiding environmental heat and conditions that cause fever may also help because an elevated body temperature slows nerve conduction and often aggravates MS symptoms.

The person with minimal symptoms does not require treatment, but should be encouraged to maintain a healthy lifestyle. Those with more extensive symptoms should try to avoid emotional stress, environmental temperature extremes, infections, and excessive fatigue. Physical therapy may help maintain muscle tone, and occupational therapy may help maintain ability to perform activities of daily living.

Drug therapy for MS may involve several types of medications for different types and stages of the disease. Acute exacerbations are treated with corticosteroids (see Chap. 24), interferon beta (Avonex, Betaseron) or glatiramer (Copaxone) is given to prevent relapses, immunosuppressive drugs (eg, methotrexate) are used to treat progressive disease, and symptoms are treated with a variety of drugs, including antidepressants for depression and skeletal muscle relaxants for spasticity.

Spasticity may be controlled with the use of baclofen, tizanidine, or dantrolene. In some cases, decreasing spasticity may not be desirable because clients with severe leg weakness may require some degree of spasticity to ambulate. In cases of severe spasticity, baclofen may be given intrathecally through an implanted subcutaneous pump.

**Mechanism of Action**

All skeletal muscle relaxants except dantrolene are centrally active drugs. Pharmacologic action is usually attributed to general depression of the central nervous system (CNS), but may involve blockage of nerve impulses that cause increased muscle tone and contraction. It is unclear whether relief of pain results from sedative effects, muscular relaxation, or a placebo effect. In addition, although parenteral administration of some drugs (eg, diazepam, methocarbamol) relieves pain associated with acute musculoskeletal trauma or inflammation, it is uncertain whether oral administration of usual doses exerts a beneficial effect in acute or chronic disorders.

Baclofen and diazepam increase the effects of gamma-aminobutyric acid, an inhibitory neurotransmitter, and tizanidine inhibits motor neurons in the brain. Dantrolene is the only skeletal muscle relaxant that acts peripherally on the muscle it-
adverse effects include drowsiness, dizziness, confusion, constipation, fatigue, headache, hypotension, insomnia, nausea, and weakness. When discontinued, dosage should be tapered and the drug withdrawn over 1 to 2 weeks.

Carisoprodol (Soma) is used to relieve discomfort from acute, painful, musculoskeletal disorders. It is not recommended for long-term use and, if used long term or in high doses, it can cause physical dependence (ie, symptoms of withdrawal if stopped abruptly). The drug is contraindicated in clients with intermittent porphyria, a rare metabolic disorder characterized by acute abdominal pain and neurologic symptoms. Oral drug acts within 30 minutes, peaks in 1 to 2 hours and lasts 4 to 6 hours. It is metabolized in the liver and has a half-life of 8 hours. Common adverse effects include drowsiness, dizziness, and impaired motor coordination.

Chlorphenesin (Maolate) is used to relieve discomfort from acute, painful, musculoskeletal disorders. Oral drug effects peak in 1 to 3 hours and last 8 to 12 hours; half-life is 3.5 hours. The drug is metabolized in the liver and excreted in urine. Common adverse effects are drowsiness, dizziness, confusion, nausea.

Cyclobenzaprine (Flexeril) has the same indication for use as carisoprodol and chlorphenesin, above. It is contraindicated in clients with cardiovascular disorders (eg, recent myocardial infarction, dysrhythmias, heart block) or hyperthyroidism. Oral drug acts in 1 hour, peaks in 4 to 6 hours and lasts 12 to 18 hours.
24 hours; half-life is 1 to 3 days. Duration of use should not exceed 3 weeks. Common adverse effects are drowsiness, dizziness, and anticholinergic effects (eg, dry mouth, constipation, urinary retention, tachycardia).

**Dantrolene** (Dantrium) acts directly on skeletal muscle to inhibit muscle contraction. It is used to relieve spasticity in neurologic disorders (eg, multiple sclerosis, spinal cord injury) and to prevent or treat malignant hyperthermia, a rare but life-threatening complication of anesthesia characterized by hypercarbia, metabolic acidosis, skeletal muscle rigidity, fever, and cyanosis. For preoperative prophylaxis in people with previous episodes of malignant hyperthermia, the drug is given orally for 1 to 2 days before surgery. For intraoperative malignant hyperthermia, the drug is given intravenously. After an occurrence during surgery, the drug is given orally for 1 to 3 days to prevent recurrence of symptoms.

Oral drug acts slowly, peaks in 4 to 6 hours and lasts 8 to 10 hours. IV drug acts rapidly, peaks in about 5 hours and lasts 6 to 8 hours. Common adverse effects include drowsiness, dizziness, diarrhea, and fatigue. The most serious adverse effect is potentially fatal hepatitis, with jaundice and other symptoms that usually occur within 1 month of starting drug therapy. Liver function tests should be monitored periodically in all clients receiving dantrolene. These adverse effects do not occur with short-term use of IV drug for malignant hyperthermia.

**Metaxalone** (Skelaxin) is used to relieve discomfort from acute, painful, musculoskeletal disorders. It is contraindicated in clients with anemias or severe renal or hepatic impairment. Oral drug acts within 60 minutes, peaks in 2 hours and lasts 4 to 6 hours. It has a half-life of 2 to 3 hours, is metabolized in the liver, and is excreted in urine. Common adverse effects include drowsiness, dizziness, and nausea; hepatotoxicity and hemolytic anemia may also occur. Liver function should be monitored during therapy.

**Methocarbamol** (Robaxin) is used to relieve discomfort from acute, painful, musculoskeletal disorders; it may also be used to treat tetanus. Parenteral drug is contraindicated in clients with renal impairment because the solution contains polyethylene glycol. Oral drug acts within 30 minutes and peaks in 2 hours; parenteral drug acts rapidly but peak and duration of action are unknown. The drug has a half-life of 1 to 2 hours, is metabolized in the liver, and is excreted in urine and feces. Common adverse effects with oral drug include drowsiness, dizziness, and nausea; constipation and hypotension. It is given orally and its action starts within 30 to 60 minutes, peaks in 1 to 2 hours, and lasts 3 to 4 hours. Its half-life is 3 to 4 hours; it is metabolized in the liver and excreted in urine. Common adverse effects include drowsiness, constipation, dry mouth, nausea, tachycardia, and urinary retention.

**Tizanidine** (Zanaflex) is an alpha2 adrenergic agonist, similar to clonidine, that is used to treat spasticity in clients with multiple sclerosis, spinal cord injury, or brain trauma. It should be used cautiously with renal or hepatic impairment and hypotension. It is given orally and its action starts within 30 to 60 minutes, peaks in 1 to 2 hours, and lasts 4 to 4 hours. Its half-life is 3 to 4 hours; it is metabolized in the liver and excreted in urine. Common adverse effects include drowsiness, dizziness, constipation, dry mouth, and hypotension. Hypotension may be significant and occur at usual doses. It may also cause psychotic symptoms, including hallucinations.

---

**Nursing Notes: Apply Your Knowledge**

Sarah Johnson is experiencing severe muscle spasms. Her physician orders Valium 50 mg to be given IV stat. Your stock supply has 10 mg Valium in 2-cc vial. Discuss how you will safely administer this medication.

---

**Nursing Process**

**Assessment**

Assess for muscle spasm and spasticity.
- With muscle spasm, assess for:
  - Pain. This is a prominent symptom of muscle spasm and is usually aggravated by movement. Try to determine the location as specifically as possible, as well as the intensity, duration, and precipitating factors (eg, traumatic injury, strenuous exercise).
  - Accompanying signs and symptoms, such as bruises (ecchymoses), edema, or signs of inflammation (redness, heat, edema, tenderness to touch)
- With spasticity, assess for pain and impaired functional ability in self-care (eg, eating, dressing). In addition, severe spasticity interferes with ambulation and other movements as well as exercises to maintain joint and muscle mobility.

**Nursing Diagnoses**

- Pain related to muscle spasm
- Impaired Physical Mobility related to spasm and pain
- Bathing/Hygiene Self-Care Deficit related to spasm and pain
- Deficient Knowledge: Nondrug measures to relieve muscle spasm, pain, and spasticity and safe usage of skeletal muscle relaxants
CHAPTER 13  SKELETAL MUSCLE RELAXANTS

PRINCIPLES OF THERAPY

Goal of Treatment

The goal of treatment is to relieve pain, muscle spasm, and muscle spasticity without impairing the ability to perform self-care activities of daily living.

Planning/Goals

The client will:

- Experience relief of pain and spasm
- Experience improved motor function
- Increase self-care abilities in activities of daily living
- Take medications as instructed
- Use nondrug measures appropriately
- Be safeguarded when sedated from drug therapy

Interventions

Use adjunctive measures for muscle spasm and spasticity:

- Physical therapy (massage, moist heat, exercises)
- Bed rest for acute muscle spasm
- Relaxation techniques
- Correct posture and lifting techniques (e.g., stooping rather than bending to lift objects, holding heavy objects close to the body, not lifting excessive amounts of weight)
- Regular exercise and use of warm-up exercises. Strenuous exercise performed on an occasional basis (e.g., weekly or monthly) is more likely to cause acute muscle spasm.

Evaluation

- Interview and observe for relief of symptoms.
- Interview and observe regarding correct usage of medications and nondrug therapeutic measures.

Drug Selection

Choice of a skeletal muscle relaxant depends mainly on the disorder being treated:

1. For acute muscle spasm and pain, an oral or parenteral drug may be given. The drugs cause sedation and other adverse effects and are recommended for short-term use. Cyclobenzaprine should not be used longer than 3 weeks.
2. Parenteral agents are preferred for orthopedic procedures because they have greater sedative and pain-relieving effects.
3. Baclofen (Lioresal) is approved for treatment of spasticity in people with multiple sclerosis. It is variably effective, and its clinical usefulness may be limited by adverse reactions.
4. None of the skeletal muscle relaxants has been established as safe for use during pregnancy and lactation.
5. For children, the choice of drug should be limited to those with established pediatric dosages.

Use in Children

For most of the drugs, safety and effectiveness for use in children 12 years of age and younger have not been established. The drugs should be used only when clearly indicated, for short periods, when close supervision is available for monitoring drug effects (especially sedation), and when mobility and alertness are not required.

Use in Older Adults

Any CNS depressant or sedating drugs should be used cautiously in older adults. Risks of falls, mental confusion, and other adverse effects are higher because of impaired drug metabolism and excretion.

CLIENT TEACHING GUIDELINES

Skeletal Muscle Relaxants

General Considerations

- Use nondrug measures, such as exercises and applications of heat and cold, to decrease muscle spasm and spasticity.
- Avoid activities that require mental alertness or physical coordination (e.g., driving an automobile, operating potentially dangerous machinery) if drowsy from medication.
- Do not take other drugs without the physician’s knowledge, including nonprescription drugs. The major risk occurs with concurrent use of alcohol, antihistamines, sleeping aids, or other drugs that cause drowsiness.
- Avoid herbal preparations that cause drowsiness or sleep, including kava and valerian.

Self-Administration

- Take the drugs with milk or food, to avoid nausea and stomach irritation.
- Do not stop drugs abruptly. Dosage should be decreased gradually, especially with baclofen (Lioresal), carisoprodol (Soma), and cyclobenzaprine (Flexeril). Suddenly stopping baclofen may cause hallucinations; stopping the other drugs may cause fatigue, headache, and nausea.
**Use in Renal Impairment**

The drugs should be used cautiously in clients with renal impairment; dosage of baclofen must be reduced.

**Use in Hepatic Impairment**

Dantrolene may cause potentially fatal hepatitis, with jaundice and other symptoms that usually occur within 1 month of starting drug therapy. Liver function tests should be monitored periodically in all clients receiving dantrolene.

Metaxalone and tizanidine can cause liver damage. Thus, liver function should be assessed before starting either drug and periodically during treatment. If liver damage occurs, the drugs should be stopped. The drugs should not be given to clients with preexisting liver disease.

**Home Care**

The home care nurse is likely to be involved with the use of baclofen, dantrolene, or tizanidine in chronic spastic disorders. Clients may need continued assessment of drug effects, monitoring of functional abilities, assistance in arranging blood tests of liver function, and other care. Caregivers may need instruction about nonpharmacologic interventions to help prevent or relieve spasticity.

---

### Skeletal Muscle Relaxants

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give baclofen, chlorphenesin, metaxalone with milk or food.</td>
<td>To decrease gastrointestinal distress</td>
</tr>
<tr>
<td>b. Do not mix parenteral diazepam in a syringe with any other drugs.</td>
<td>Diazepam is physically incompatible with other drugs.</td>
</tr>
<tr>
<td>c. Inject intravenous (IV) diazepam directly into a vein or the injection site nearest the vein (during continuous IV infusions) at a rate of approximately 2 mg/min.</td>
<td>Diazepam may cause a precipitate if diluted. Avoid contact with IV solutions as much as possible. A slow rate of injection minimizes the risks of respiratory depression and apnea.</td>
</tr>
<tr>
<td>d. Avoid extravasation with IV diazepam, and inject intramuscular (IM) diazepam deeply into a gluteal muscle.</td>
<td>To prevent or reduce tissue irritation</td>
</tr>
<tr>
<td>e. With IV methocarbamol, inject or infuse slowly.</td>
<td>Rapid administration may cause bradycardia, hypotension, and dizziness.</td>
</tr>
<tr>
<td>f. With IV methocarbamol, have the client lie down during and at least 15 minutes after administration.</td>
<td>To minimize orthostatic hypotension and other adverse drug effects</td>
</tr>
<tr>
<td>g. Avoid extravasation with IV methocarbamol, and give IM methocarbamol deeply into a gluteal muscle. (Dividing the dose and giving two injections is preferred.)</td>
<td>Parenteral methocarbamol is a hypertonic solution that is very irritating to tissues. Thrombophlebitis may occur at IV injection sites, and sloughing of tissue may occur at sites of extravasation or IM injections.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. When the drug is given for acute muscle spasm, observe for:</td>
<td>Therapeutic effects usually occur within 30 minutes after IV injection of diazepam or methocarbamol.</td>
</tr>
<tr>
<td>(1) Decreased pain and tenderness</td>
<td></td>
</tr>
<tr>
<td>(2) Increased mobility</td>
<td></td>
</tr>
<tr>
<td>(3) Increased ability to participate in activities of daily living</td>
<td></td>
</tr>
<tr>
<td>b. When the drug is given for spasticity in chronic neurologic disorders, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Increased ability to maintain posture and balance</td>
<td></td>
</tr>
<tr>
<td>(2) Increased ability for self-care (eg, eating and dressing)</td>
<td></td>
</tr>
<tr>
<td>(3) Increased tolerance for physical therapy and exercises</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### NURSING ACTIONS

3. Observe for adverse effects
   a. With centrally active agents, observe for:
      1. Drowsiness and dizziness
      2. Blurred vision, lethargy, flushing
      3. Nausea, vomiting, abdominal distress, constipation or diarrhea, ataxia, areflexia, flaccid paralysis, respiratory depression, tachycardia, hypotension
      4. Hypersensitivity—skin rash, pruritus
      5. Psychological or physical dependence with diazepam and other antianxiety agents
   b. With a peripherally active agent (dantrolene), observe for:
      1. Drowsiness, fatigue, lethargy, weakness, nausea, vomiting
      2. Headache, anorexia, nervousness
      3. Hepatotoxicity

4. Observe for drug interactions
   a. Drugs that increase effects of skeletal muscle relaxants:
      1. Central nervous system (CNS) depressants (alcohol, antianxiety agents, antidepressants, antihistamines, antipsychotic drugs, sedative-hypnotics)
      2. Monoamine oxidase inhibitors
      3. Antihypertensive agents

### RATIONALE/EXPLANATION

These are the most common adverse effects.
These effects occur more often with IV administration of drugs. They are usually transient.
These effects are most likely to occur with large oral doses.
The drug should be discontinued if hypersensitivity reactions occur. Serious allergic reactions (eg, anaphylaxis) are rare.
Most likely to occur with long-term use of large doses
Adverse effects are usually transient.
These effects are the most common.
Less common effects
This potentially serious adverse effect is most likely to occur in people older than 35 years of age who have taken the drug 60 days or longer. Women over age 35 years who take estrogens have the highest risk. Hepatotoxicity can be prevented or minimized by administering the lowest effective dose, monitoring liver enzymes (aspartate aminotransferase and alanine aminotransferase) during therapy, and discontinuing the drug if no beneficial effects occur within 45 days.
Additive CNS depression with increased risks of excessive sedation and respiratory depression or apnea
May potentiate effects by inhibiting metabolism of muscle relaxants
Increased hypotension, especially with tizanidine

### Nursing Notes: Apply Your Knowledge

**Answer:** Check this order with the physician. Normal IV Valium dosage is 5–10 mg every 3–4 hours. A 50-mg dose is unsafe and should not be given. Any time you have to administer 10 cc IV push you should question whether the dose is appropriate.

### Review and Application Exercises

1. How do skeletal muscle relaxants act to relieve spasm and pain?
2. What are the indications for the use of skeletal muscle relaxants?
3. What are the contraindications to the use of these drugs?
4. What are the major adverse effects of these drugs, and how can they be minimized?
5. What are some nonpharmacologic interventions to use instead of or along with the drugs?

### SELECTED REFERENCES


Anesthesia means loss of sensation with or without loss of consciousness. Anesthetic drugs are given to prevent pain and promote relaxation during surgery, childbirth, some diagnostic tests, and some treatments. They interrupt the conduction of painful nerve impulses from a site of injury to the brain. The two basic types of anesthesia are general and regional.

**GENERAL ANESTHESIA**

General anesthesia is a state of profound central nervous system (CNS) depression, during which there is complete loss of sensation, consciousness, pain perception, and memory. It has three components: hypnosis, analgesia, and muscle relaxation. Several different drugs are usually combined to produce desired levels of these components without excessive CNS depression. This so-called balanced anesthesia also allows lower dosages of potent general anesthetics.

General anesthesia is usually induced with a fast-acting drug (eg, propofol or thiopental) given intravenously and is maintained with a gas mixture of anesthetic agent and oxygen given by inhalation. The intravenous (IV) agent produces rapid loss of consciousness and provides a pleasant induction and recovery. Its rapid onset of action is attributed to rapid circulation to the brain and accumulation in the neuronal tissue of the cerebral cortex.

The drugs are short acting because they are quickly redistributed from the brain to highly perfused organs (eg, heart, liver, kidneys) and muscles, and then to fatty tissues. Because they are slowly released from fatty tissues back into the bloodstream, anesthesia, drowsiness, and cardiopulmonary depression persist into the postoperative period. Duration of action can be prolonged and accumulation is more likely to occur with repeated doses or continuous IV infusion.

An anesthetic barbiturate or propofol may be used alone for anesthesia during brief diagnostic tests or surgical procedures. Barbiturates are contraindicated in patients with acute intermittent porphyria, a rare hereditary disorder characterized by recurrent attacks of physical and mental disturbances.
Inhalation anesthetics vary in the degree of CNS depression produced and thereby vary in the rate of induction, anesthetic potency, degree of muscle relaxation, and analgesic potency. CNS depression is determined by the concentration of the drug in the CNS. Drug concentration, in turn, depends on the rate at which the drug is transported from the alveoli to the blood, transported past the blood–brain barrier to reach the CNS, redistributed by the blood to other body tissues, and eliminated by the lungs. Depth of anesthesia can be regulated readily by varying the concentration of the inhaled anesthetic gas. General inhalation anesthetics should be given only by specially trained people, such as anesthesiologists and nurse anesthetists, and only with appropriate equipment.

**REGIONAL ANESTHESIA**

Regional anesthesia involves loss of sensation and motor activity in localized areas of the body. It is induced by application or injection of local anesthetic drugs. The drugs act to decrease the permeability of nerve cell membranes to ions, especially sodium. This action stabilizes and reduces excitability of cell membranes. When excitability falls low enough, nerve impulses cannot be initiated or conducted by the anesthetized nerves. As a result, the drugs prevent the cells from responding to pain impulses and other sensory stimuli.

Some local anesthetic is absorbed into the bloodstream and circulated through the body, especially when injected or applied to mucous membrane. The rate and amount of absorption depend mainly on the drug dose and blood flow to the site of administration. The highest concentrations are found in organs with a large blood supply (eg, brain, heart, liver, lungs). Systemic absorption accounts for most of the potentially serious adverse effects (eg, CNS stimulation or depression, decreased myocardial conduction and contractility, bradycardia, hypotension) of local anesthetics. Epinephrine, a vasoconstrictor, is often added to a local anesthetic to slow systemic absorption, prolong anesthetic effects, and control bleeding. Anesthetic effects dwindle and end as drug molecules diffuse out of neurons into the bloodstream. The drugs are then transported to the liver for metabolism, mainly to inactive metabolites. The metabolites are excreted in the urine, along with a small amount of unchanged drug.

Regional anesthesia is usually categorized according to the site of application. The area anesthetized may be the site of application, or it may be distal to the point of injection. Specific types of anesthesia attained with local anesthetic drugs include the following:

1. Topical or surface anesthesia involves applying local anesthetics to skin or mucous membrane. Such application makes sensory receptors unresponsive to pain, itching, and other stimuli. Local anesthetics for topical use are usually ingredients of various ointments, solutions, or lotions designed for use at particular sites. For example, preparations are available for use on eyes, ears, nose, oral mucosa, perineum, hemorrhoids, and skin.
2. Infiltration involves injecting the local anesthetic solution directly into or very close to the area to be anesthetized.
3. Peripheral nerve block involves injecting the anesthetic solution into the area of a larger nerve trunk or a nerve plexus at some access point along the course of a nerve distant from the area to be anesthetized.
4. Field block anesthesia involves injecting the anesthetic solution around the area to be anesthetized.
5. Spinal anesthesia involves injecting the anesthetic agent into the cerebrospinal fluid, usually in the lumbar spine. The anesthetic blocks sensory impulses at the root of peripheral nerves as they enter the spinal cord. Spinal anesthesia is especially useful for surgery involving the lower abdomen and legs.

The body area anesthetized is determined by the level to which the drug solution rises in the spinal canal. This, in turn, is determined by the site of injection, the position of the client, and the specific gravity, amount, and concentration of the injected solution.

Solutions of local anesthetics used for spinal anesthesia are either hyperbaric or hypobaric. Hyperbaric or heavy solutions are diluted with dextrose, have a higher specific gravity than cerebrospinal fluid, and gravitate toward the head when the client is tilted in a head-down position. Hypobaric or light solutions are diluted with distilled water, have a lower specific gravity than cerebrospinal fluid, and gravitate toward the lower (caudal) end of the spinal canal when the client is tilted in a head-down position.

6. Epidural anesthesia, which involves injecting the anesthetic into the epidural space, is used most often in obstetrics during labor and delivery. This route is also used to provide analgesia (often with a combination of a local anesthetic and an opioid) for clients with postoperative or other pain.

The extent and duration of anesthesia produced by injection of local anesthetics depend on several factors. In general, large amounts, high concentrations, or injections into highly vascular areas (eg, head and neck, intercostal and paracervical sites) produce peak plasma levels rapidly. Duration depends on the chemical characteristics of the drug used and the rate at which it leaves nerve tissue. When a vasoconstrictor drug, such as epinephrine, has been added, onset and duration of anesthesia are prolonged because of slow absorption and elimination of the anesthetic agent. Epinephrine also controls bleeding in the affected area.

**ADJUNCTS TO ANESTHESIA**

Several nonanesthetic drugs are used as adjuncts or supplements to anesthetic drugs. Most are discussed elsewhere and are described here only in relation to anesthesia. Drug groups include antianxiety agents and sedative-hypnotics (see Chap. 8), anticholinergics (see Chap. 21), and opioid antagonists (see Chap. 6). The neuromuscular blocking agents are described in this chapter.

Goals of preanesthetic medication include decreased anxiety without excessive drowsiness, client amnesia for the peri-
operative period, reduced requirement for inhalation anesthetic, reduced adverse effects associated with some inhalation anesthetics (eg, bradycardia, coughing, salivation, postanesthetic vomiting), and reduced perioperative stress. Various regimens, usually of two or three drugs, are used.

**Antianxiety Agents and Sedative-Hypnotics**

Antianxiety agents and sedative-hypnotics are given to decrease anxiety, promote rest, and increase client safety by allowing easier induction of anesthesia and smaller doses of anesthetic agents. These drugs may be given the night before to aid sleep and 1 or 2 hours before the scheduled procedure. Hypnotic doses are usually given for greater sedative effects. A benzodiazepine such as diazepam (Valium) or midazolam (Versed) is often used. Midazolam has a rapid onset and short duration of action, causes amnesia, produces minimal cardiovascular side effects, and reduces the dose of opioid analgesics required during surgery. It is often used in ambulatory surgical or invasive diagnostic procedures and regional anesthesia.

**Anticholinergics**

Anticholinergic drugs are given to prevent vagal effects associated with general anesthesia and surgery (eg, bradycardia, hypotension). Vagal stimulation occurs with some inhalation anesthetics; with succinylcholine, a muscle relaxant; and with surgical procedures in which there is manipulation of the pharynx, trachea, peritoneum, stomach, intestine, or other viscera and procedures in which pressure is exerted on the eyeball. Useful drugs are atropine and glycopyrrolate (Robinul).

**Opioid Analgesics**

Opioid analgesics induce relaxation and pain relief in the preanesthetic period. These drugs potentiate the CNS depression produced by other drugs, and less anesthetic agent is required. Morphine and fentanyl may be given in anesthetic doses in certain circumstances.

**Neuromuscular Blocking Agents**

Neuromuscular blocking agents cause muscle relaxation, the third component of general anesthesia, and allow the use of smaller amounts of anesthetic agent. Artificial ventilation is necessary because these drugs paralyze muscles of respiration as well as other skeletal muscles. The drugs do not cause sedation; therefore, unless the recipients are unconscious, they can see and hear environmental activities and conversations.

There are two types of neuromuscular blocking agents: depolarizing and nondepolarizing. Succinylcholine is the only commonly used depolarizing drug. Like acetylcholine, the drug combines with cholinergic receptors at the motor endplate to produce depolarization and muscle contraction initially. Repolarization and further muscle contraction are then inhibited as long as an adequate concentration of drug remains at the receptor site.

Muscle paralysis is preceded by muscle spasms, which may damage muscles. Injury to muscle cells may cause postoperative muscle pain and release potassium into the circulation. If hyperkalemia develops, it is usually mild and insignificant but may cause cardiac dysrhythmias or even cardiac arrest in some situations. Succinylcholine is normally deactivated by plasma pseudocholinesterase. There is no antidote except reconstituted fresh-frozen plasma that contains pseudocholinesterase.

Nondepolarizing neuromuscular blocking agents prevent acetylcholine from acting at neuromuscular junctions. Consequently, the nerve cell membrane is not depolarized, the muscle fibers are not stimulated, and skeletal muscle contraction does not occur. The prototype drug is tubocurarine, the active ingredient of curare, a naturally occurring plant alkaloid that causes skeletal muscle relaxation or paralysis. Anticholinesterase drugs, such as neostigmine (Prostigmin; see Chap. 20), are antidotes and can be used to reverse muscle paralysis.

Several newer, synthetic nondepolarizing agents are available and are preferred over succinylcholine in most instances. The drugs vary in onset and duration of action. Some have short elimination half-lives (eg, mivacurium, rocuronium) that allow spontaneous recovery of neuromuscular function when an IV infusion is discontinued. With these agents, administration of a reversal agent may be unnecessary. The drugs also vary in routes of elimination, with most involving both hepatic and renal mechanisms. In clients with renal or hepatic impairment, the parent drug or its metabolites may accumulate and cause prolonged paralysis. As a result, neuromuscular blocking agents should be used very cautiously in clients with renal or hepatic impairment.

**INDIVIDUAL ANESTHETIC AGENTS**

General anesthetics are listed in Table 14–1, neuromuscular blocking agents in Table 14–2, and local anesthetics in Table 14–3.

**PRINCIPLES OF THERAPY**

**Preanesthetic Medications**

Principles for using preanesthetic drugs (antianxiety agents, anticholinergics, opioid analgesics) are the same when these drugs are given before surgery as at other times. They are ordered by an anesthesiologist and the choice of a particular drug depends on several factors. Some client-related factors include age; the specific procedure to be performed and its
## TABLE 14–1  General Anesthetics

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Inhalation Anesthetics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Desflurane (Suprane)</strong></td>
<td>Similar to isoflurane</td>
<td>Used for induction and maintenance of general anesthesia</td>
</tr>
<tr>
<td><strong>Enflurane (Ethrane)</strong></td>
<td>Nonexplosive, nonflammable volatile liquid; similar to halothane but may produce better analgesia and muscle relaxation; sensitizes heart to catecholamines—increases risk of cardiac dysrhythmias; renal or hepatic toxicity not reported</td>
<td>A frequently used agent</td>
</tr>
<tr>
<td><strong>Halothane (Fluothane)</strong></td>
<td>Nonexplosive, nonflammable volatile liquid</td>
<td>Halothane has largely been replaced by newer agents with increased efficacy, decreased adverse effects, or both.</td>
</tr>
<tr>
<td></td>
<td>Advantages:</td>
<td>It may be used in balanced anesthesia with other agents. Although quite potent, it may not produce adequate analgesia and muscle relaxation at a dosage that is not likely to produce significant adverse effects. Therefore, nitrous oxide is given to increase analgesic effects; a neuromuscular blocking agent is given to increase muscle relaxation; and an IV barbiturate is used to produce rapid, smooth induction, after which halothane is given to maintain anesthesia.</td>
</tr>
<tr>
<td></td>
<td>1. Produces rapid induction with little or no excitement; rapid recovery with little excitement or nausea and vomiting</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Does not irritate respiratory tract mucosa; therefore does not increase saliva and tracheobronchial secretions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Depresses pharyngeal and laryngeal reflexes, which decreases risk of laryngospasm and bronchospasm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disadvantages:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Depresses contractility of the heart and vascular smooth muscle, which causes decreased cardiac output, hypotension, and bradycardia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Circulatory failure may occur with high doses.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Causes cardiac dysrhythmias. Bradycardia is common; ventricular dysrhythmias are uncommon unless ventilation is inadequate.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Sensitizes heart to catecholamines; increases risk of cardiac dysrhythmias</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5. Depresses respiration and may produce hypoxemia and respiratory acidosis (hypercarbia)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6. Depresses functions of the kidneys, liver, and immune system</td>
<td></td>
</tr>
<tr>
<td></td>
<td>7. May cause jaundice and hepatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>8. May cause malignant hyperthermia</td>
<td></td>
</tr>
<tr>
<td><strong>Isoflurane (Forane)</strong></td>
<td>Similar to halothane but less likely to cause cardiovascular depression and ventricular dysrhythmias. Isoflurane may cause malignant hyperthermia but apparently does not cause hepatotoxicity.</td>
<td>Used for induction and maintenance of general anesthesia</td>
</tr>
<tr>
<td><strong>Nitrous oxide</strong></td>
<td>Nonexplosive gas; good analgesic, weak anesthetic; one of oldest and safest anesthetics; causes no appreciable damage to vital organs unless hypoxia is allowed to develop and persist; administered with oxygen to prevent hypoxia; rapid induction and recovery. Note: Nitrous oxide is an incomplete anesthetic; that is, by itself, it cannot produce surgical anesthesia.</td>
<td>Used in balanced anesthesia with IV barbiturates, neuromuscular blocking agents, opioid analgesics, and more potent inhalation anesthetics. It is safer for prolonged surgical procedures (see “Characteristics”). It is used alone for analgesia in dentistry, obstetrics, and brief surgical procedures.</td>
</tr>
<tr>
<td><strong>Sevoflurane (Ultane)</strong></td>
<td>Similar to isoflurane</td>
<td>Used for induction and maintenance of general anesthesia</td>
</tr>
<tr>
<td><strong>General Intravenous Anesthetics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Alfentanil (Alfenta)</strong></td>
<td>Opioid analgesic–anesthetic related to fentanyl and sufentanil. Rapid acting.</td>
<td>May be used as a primary anesthetic or an analgesic adjunct in balanced anesthesia</td>
</tr>
<tr>
<td><strong>Etomidate (Amidate)</strong></td>
<td>A nonanalgesic hypnotic used for induction and maintenance of general anesthesia</td>
<td>May be used with nitrous oxide and oxygen in maintenance of general anesthesia for short operative procedures such as uterine dilation and curettage</td>
</tr>
</tbody>
</table>

(continued)
Thiopental sodium (Sufenta) should be corrected before anesthesia, when possible. General organ system (cardiovascular, respiratory, renal) is present, it nistic, or therapeutic procedure. If a medical disorder of a vital severity of illness, presence of chronic diseases, and any other disorders are also involved, the risks of anesthesia and surgery are greatly increased. Because of the risks, general anesthetics and neuromuscular blocking agents should be given only by people with special training in correct usage and only in locations where staff, equipment, and drugs are available for emergency use or cardiopulmonary resuscitation.

**General Anesthesia**

General anesthesia can be used for almost any surgical, diagnostic, or therapeutic procedure. If a medical disorder of a vital organ system (cardiovascular, respiratory, renal) is present, it should be corrected before anesthesia, when possible. General anesthesia and major surgical procedures have profound effects on normal body functioning. When alterations due to other disorders are also involved, the risks of anesthesia and surgery are greatly increased. Because of the risks, general anesthetics and neuromuscular blocking agents should be given only by people with special training in correct usage and only in locations where staff, equipment, and drugs are available for emergency use or cardiopulmonary resuscitation.

**Regional and Local Anesthesia**

Regional or local anesthesia is usually safer than general anesthesia because it produces fewer systemic effects. For
### Table 14–3: Local Anesthetics

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Articaine</strong> (Septocaine, Septodont)</td>
<td>Newer drug, formulated with epinephrine; Effects occur in 1–6 min and last 1 hour</td>
<td>Local infiltration and nerve block for dental and periodontal procedures or oral surgery</td>
</tr>
<tr>
<td><strong>Benzocaine</strong> (Americaine)</td>
<td>Poorly water soluble; Minimal systemic absorption; Available in numerous preparations, including aerosol sprays, throat lozenges, rectal suppositories, lotions, and ointments</td>
<td>Topical anesthesia of skin and mucous membrane to relieve pain and itching of sunburn, other minor burns and wounds, skin abrasions, earache, hemorrhoids, sore throat, and other conditions</td>
</tr>
<tr>
<td><strong>Bupivacaine</strong> (Marcaine)</td>
<td>Given by injection; May cause systemic toxicity; Effects occur in 5 min and last 2–4 hours with injection, 10–20 min and 3–5 hours with epidural administration</td>
<td>Regional anesthesia by infiltration, nerve block, and epidural anesthesia during childbirth. It is not used for spinal anesthesia.</td>
</tr>
<tr>
<td><strong>Butamben</strong> (Butesin)</td>
<td>Applied topically to skin only</td>
<td>Used mainly in minor burns and skin irritations</td>
</tr>
<tr>
<td><strong>Chloroprocaine</strong> (Nesacaine)</td>
<td>Related to procaine, but its potency is greater and duration of action is shorter</td>
<td>Regional anesthesia by infiltration, nerve block, and epidural anesthesia</td>
</tr>
<tr>
<td><strong>Cocaine</strong></td>
<td>A naturally occurring plant alkaloid; Readily absorbed through mucous membranes; A Schedule II controlled substance with high potential for abuse, largely because of euphoria and other central nervous system (CNS) stimulatory effects; produces psychic dependence and tolerance with prolonged use</td>
<td>Topical anesthesia of ear, nose, and throat</td>
</tr>
<tr>
<td><strong>Dibucaine</strong> (Nupercainal)</td>
<td>May cause local allergic reactions; Effects occur in &lt;15 min and last 3–4 hours</td>
<td>Topical anesthesia of skin and mucous membranes</td>
</tr>
</tbody>
</table>

*All the nondepolarizing agents may cause hypotension; effects of the drugs can be reversed by neostigmine (Prostigmin).*

### Table 14–2: Neuromuscular Blocking Agents (Skeletal Muscle Relaxants)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Uses</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Depolarizing Type</strong></td>
<td></td>
<td>All types of surgery and brief procedures, such as endoscopy and endotracheal intubation</td>
</tr>
<tr>
<td>Succinylcholine (Anectine)</td>
<td>Short acting after single dose; action can be prolonged by repeated injections or continuous intravenous infusion. Malignant hyperthermia may occur.</td>
<td></td>
</tr>
<tr>
<td><strong>Nondepolarizing Type</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atracurium (Tracrium)</td>
<td>Intermediate acting*</td>
<td>Adjunct to general anesthesia</td>
</tr>
<tr>
<td>Cisatracurium (Nimbex)</td>
<td>Intermediate acting*</td>
<td>Same as rocuronium, below</td>
</tr>
<tr>
<td>Vecuronium (Norcuron)</td>
<td>Intermediate acting*</td>
<td>Adjunct to general anesthesia</td>
</tr>
<tr>
<td>Pancuronium (Pavulon)</td>
<td>Short acting*</td>
<td>Mainly during surgery after general anesthesia has been induced; occasionally to aid endotracheal intubation or mechanical ventilation</td>
</tr>
<tr>
<td>Pipecuronium (Arduan)</td>
<td>Long acting*</td>
<td>Adjunct to general anesthesia; recommended only for procedures expected to last 90 minutes or longer</td>
</tr>
<tr>
<td>Rocuronium (Zemuron)</td>
<td>Intermediate acting*</td>
<td>Adjunct to general anesthesia to aid endotracheal intubation and provide muscle relaxation during surgery or mechanical ventilation</td>
</tr>
<tr>
<td>Tubocurarine</td>
<td>Long acting; the prototype of nondepolarizing drugs*</td>
<td>Adjunct to general anesthesia; occasionally to facilitate mechanical ventilation</td>
</tr>
</tbody>
</table>

*All the nondepolarizing agents may cause hypotension; effects of the drugs can be reversed by neostigmine (Prostigmin).*
SECTION 2 DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM

Example, spinal anesthesia is often the anesthesia of choice for surgery involving the lower abdomen and lower extremities, especially in people who are elderly or have chronic lung disease. A major advantage of spinal anesthesia is that it causes less CNS and respiratory depression. Guidelines for injections of local anesthetic agents include the following:

1. Local anesthetics should be injected only by people with special training in correct usage and only in locations where staff, equipment, and drugs are available for emergency use or cardiopulmonary resuscitation.

2. Choice of a local anesthetic depends mainly on the reason for use or the type of regional anesthesia desired. Lidocaine, one of the most widely used, is available in topical and injectable forms.

3. Except with IV lidocaine for cardiac dysrhythmias, local anesthetic solutions must not be injected into blood vessels because of the high risk of serious adverse reactions involving the cardiovascular system and CNS. To prevent accidental injection into a blood vessel, needle placement must be verified by aspirat-
You are working in a busy postanesthesia recovery unit (PACU), caring for two patients recovering from general anesthesia. You have been asked to extend your shift because someone has called in sick. You are preparing some intravenous morphine to administer to one patient, but before you administer the morphine, you are interrupted twice. After you finally administer the drug, you realize that you administered it to the wrong patient.

**How Can You Avoid This Medication Error?**

**Nursing Process**

**Preoperative Assessment**
- Assess nutritional status.
- Assess use of prescription and nonprescription drugs, especially those taken within the past 3 days.
- Ask about the use of herbal drugs during the previous week, especially those that are likely to cause perioperative complications. For example, ephedra increases risks of cardiac dysrhythmias, hypertension, myocardial infarction, and stroke; feverfew, garlic, ginkgo, and ginseng can increase risks of bleeding; kava and valerian can increase effects of sedatives.
- Ask about drug allergies. If use of local or regional anesthesia is anticipated, ask if the client has ever had an allergic reaction to a local anesthetic.
- Assess for risk factors for complications of anesthesia and surgery (cigarette smoking, obesity, limited exercise or activity, chronic cardiovascular, respiratory, renal, or other disease processes).
- Assess the client’s understanding of the intended procedure, attitude toward anesthesia and surgery, and degree of anxiety and fear.
- Assess ability and willingness to participate in postoperative activities to promote recovery.
- Assess vital signs, laboratory data, and other data as indicated to establish baseline measurements for monitoring changes.

**Postoperative Assessment**
- During the immediate postoperative period, assess vital signs and respiratory and cardiovascular function every 5 to 15 minutes until reactive and stabilizing. Effects of anesthetics and adjunctive medications persist into postanesthesia recovery.
- Continue to assess vital signs, fluid balance, and laboratory and other data.
- Assess for signs of complications (eg, fluid and electrolyte imbalance, respiratory problems, thrombophlebitis, wound infection).

**Nursing Diagnoses**
- Risk for Injury: Trauma related to impaired sensory perception and impaired physical mobility from anesthetic or sedative drugs
- Risk for Injury: CNS depression with premedications and general anesthetics
- Pain related to operative procedure
- Decreased Cardiac Output related to effects of anesthetics, other medications, and surgery
- Risk for Ineffective Breathing Patterns related to respiratory depression
- Anxiety or Fear related to anticipated surgery and possible outcomes

**Planning/Goals**

*The client will:*
- Receive sufficient emotional support and instruction to facilitate a smooth preoperative and postoperative course
- Be protected from injury and complications while self-care ability is impaired
- Have emergency supplies and personnel available if needed
- Have postoperative discomfort managed appropriately

**Interventions**

Preoperatively, assist the client to achieve optimal conditions for surgery. Some guidelines include the following:
- Provide foods and fluids to improve or maintain nutritional status (eg, those high in protein, vitamin C and other vitamins, and electrolytes to promote healing).
- Help the client maintain exercise and activity, when feasible. This helps promote respiratory and cardiovascular function and decreases anxiety.
- Explain the expected course of events of the perioperative period (eg, specific preparations for surgery, close observation and monitoring during postanesthesia recovery, approximate length of stay).
- Assist clients with measures to facilitate recovery postoperatively (eg, coughing and deep-breathing exercises, leg exercises and early ambulation, maintaining fluid balance and urine output).
- Explain how postoperative pain will be managed. This is often a major source of anxiety.

Postoperatively, the major focus is on maintaining a safe environment and vital functions. Specific interventions include:
- Observe and record vital signs, level of consciousness, respiratory and cardiovascular status, wound status, and elimination frequently until sensory and motor functions return, then periodically until discharge.
- Maintain IV infusions. Monitor the site, amount, and type of fluids. If potential problems are identified (eg, hypovolemia or hypervolemia), intervene to prevent them from becoming actual problems.
- Give pain medication appropriately as indicated by the client’s condition.
- Help the client to turn, cough, deep breathe, exercise legs, ambulate, and perform other self-care activities until he or she can perform them independently.
- Use sterile technique in wound care.
- Initiate discharge planning for a smooth transition to home care.
With preanesthetic, sedative-type medications, stay in bed with the siderails up and use the call light if help is needed. You may fall or otherwise injure yourself if you get out of bed without assistance.

Do not try to perform activities requiring mental alertness and physical coordination while drowsy or less than alert from general anesthesia, sedation, or pain medication.

After surgery, take enough pain medication to allow ambulation, movement, coughing and deep breathing, and other exercises to promote recovery. In most instances, you will receive pain medication by injection (often intravenously) for 2 or 3 days, then by mouth.

Follow instructions and try to cooperate with health care personnel in activities to prevent postoperative complications, including respiratory and wound infections.

After a local anesthetic is injected for dental or other oral surgery procedures, do not eat, chew, or drink hot liquids until the anesthetic has completely worn off. Such activities can lead to injuries.
Use in Children

Compared with adults, children are at greater risk of complications (eg, laryngospasm, bronchospasm, aspiration) and death from anesthesia. Thus, whoever administers anesthetics to children should be knowledgeable about anesthetics and their effects in children. In addition, the nurse who cares for a child before, during, and after surgical or other procedures that require anesthesia or sedation must be skilled in using the nursing process with children.

1. Halothane has been commonly used. It causes bronchodilation and does not irritate respiratory mucosa, features that make it especially useful for children with asthma, cystic fibrosis, or other bronchospastic disorders. However, the drug dilates blood vessels in the brain and increases intracranial pressure, so it may not be indicated in clients who already have increased intracranial pressure or mass lesions. Halothane may also sensitize the myocardium to epinephrine, although children are less likely than adults to have ventricular dysrhythmias.

2. Sevoflurane, a newer agent, may have some advantages over halothane in pediatric anesthesia. It allows a faster induction and emergence, does not stimulate the sympathetic nervous system or potentiate cardiac dysrhythmias, and produces a minimal increase in intracranial pressure. However, it is much more expensive than halothane.

3. Propofol is approved for use in children 3 years of age and older. It has a rapid onset; a rapid metabolism rate; and a smooth emergence with little mental confusion, sedation, or nausea. It also decreases cerebral blood flow and intracranial pressure, making it useful in neurosurgery. In addition, propofol is widely used for sedation with diagnostic tests or special procedures that require children to be sedated and immobile. Propofol may be given by injection for induction and an IV infusion pump for maintenance of anesthesia or sedation.

Adverse effects include respiratory depression, hypertension, and pain with injection. Slow titration of dosage, a large-bore IV catheter, adding lidocaine, and slow drug injection into a rapidly flowing IV can minimize these effects. In addition, the formulation now contains an antimicrobial agent, which should reduce risks of infection.

4. In general, infants and children have a higher anesthetic requirement, relative to size and weight, than healthy adults.

5. Some agencies allow parents to be present during induction of general anesthesia. This seems to reduce anxiety for both parents and children.

6. With muscle relaxants, the choice depends on the type of surgery and anesthesia, contraindications to a particular agent, the presence of client conditions that affect or preclude use of a particular drug, and the preference of the anesthesiologist. For short surgical procedures, intermediate-acting nondepolarizing agents (eg, atracurium, mivacurium) are commonly used. Succinylcholine, formerly a commonly used agent, is now contraindicated for routine, elective surgery in children and adolescents. This precaution stems from reports of several deaths associated with the use of succinylcholine in children with previously undiagnosed skeletal muscle myopathy. However, succinylcholine is still indicated in children who require emergency intubation or rapid securing of the airway (eg, laryngospasm, full stomach) and for intramuscular administration when a suitable vein is unavailable.

7. Children are more likely to have postoperative nausea and vomiting than adults.

8. Local anesthetics usually have the same uses, precautions, and adverse effects in children as in adults. Safety and efficacy of bupivacaine, dyclonine, and tetra- caine have not been established in children younger than 12 years of age. Benzocaine should not be used in infants younger than 1 year of age. Dosages in children
should be reduced according to age, body weight, and physical condition.

With topical applications to intact skin, there is greater systemic absorption and risk of toxicity in infants. A mixture of lidocaine and prilocaine (Eutectic Mixture of Local Anesthetics [EMLA]) was formulated to penetrate intact skin, provide local anesthesia, and decrease pain of vaccinations and venipuncture. The cream is applied at the injection site with an occlusive dressing at least 60 minutes before vaccination or venipuncture.

For topical application to mucous membranes, low concentrations of local anesthetics should be used. EMLA cream should not be used on mucous membranes (or abraded skin). These drugs are readily absorbed through mucous membranes and may cause systemic toxicity.

### Use in Older Adults

Older adults often have physiologic changes and pathologic conditions that make them more susceptible to adverse effects of anesthetics, neuromuscular blocking agents, and adjunctive medications. Thus, lower doses of these agents are usually needed. With propofol, delayed excretion and a longer half-life lead to higher peak plasma levels. Higher plasma levels can cause hypotension, apnea, airway obstruction, and oxygen desaturation if dosage is not reduced. Long-term infusion may result in accumulation in body fat and prolonged elimination.

With injections of a local anesthetic, repeated doses may cause accumulation of the drug or its metabolites and increased risks of adverse effects. Because cardiovascular homeostatic mechanisms are often impaired, older adults may be at risk for decreased cardiac output, hypotension, heart block, and cardiac arrest.

### Use in Renal Impairment

Most inhalation general anesthetic agents can be used in clients with renal impairment because they are eliminated mainly by exhalation from the lungs. However, they reduce renal blood flow, glomerular filtration, and urine volume, as do IV general anesthetics.

Most neuromuscular blocking agents are metabolized or excreted in urine to varying extents. Thus, renal effects vary among the drugs, and several may accumulate in the presence of renal impairment because of delayed elimination. With atracurium, which is mainly metabolized by the liver with a small amount excreted unchanged in urine, short-term use of bolus doses does not impair renal function. With long-term infusion, however, metabolism of atracurium produces a metabolite (laudanosine) that accumulates in renal failure and may cause neurotoxicity. With succinylcholine, liver metabolism produces active metabolites, some of which are excreted through the kidneys. These metabolites can accumulate and cause hyperkalemia in clients with renal impairment. Thus, renal impairment may lead to accumulation of neuromuscular blocking agents or their metabolites. The drugs should be used very cautiously in clients with renal impairment.

### Use in Hepatic Impairment

Most inhalation general anesthetics are minimally metabolized in the liver and therefore are unlikely to accumulate with short-term usage. However, all general anesthetics reduce blood flow to the liver, and the liver’s ability to metabolize other drugs may be impaired. Propofol is metabolized mainly in the liver to inactive metabolites, which are then excreted by the kidneys. Propofol clearance may be slower because of decreased hepatic blood flow.

Neuromuscular blocking agents vary in the extent to which they are metabolized in the liver. For example, atracurium, rocuronium, and vecuronium are eliminated mainly by the liver. They may accumulate with hepatic impairment because of delayed elimination. Succinylcholine is also metabolized in the liver and should be used very cautiously in clients with hepatic impairment.

With local anesthetics, injections of the amide type (eg, lidocaine), which are metabolized primarily in the liver, are more likely to reach high plasma levels and cause systemic toxicity in clients with hepatic disease. The drugs should be used cautiously, in minimally effective doses, in such clients. In addition, clients with severe hepatic impairment are more likely to acquire toxic plasma concentrations of lidocaine and prilocaine from topical use of EMLA because of impaired ability to metabolize the drug.

### Use in Critical Illness

Propofol, neuromuscular blocking agents, and local anesthetics are commonly used in intensive care units. These drugs should be administered and monitored only by health care personnel who are skilled in the management of critically ill clients, including cardiopulmonary resuscitation and airway management. Critical care nurses must often care for clients receiving IV infusions of the drugs and titrate dosage and flow rate to achieve desired effects and minimize adverse effects.

Propofol is an anesthetic used in subanesthetic doses for short-term sedation of clients who are intubated and mechanically ventilated. It has a rapid onset of action, and clients awaken within a few minutes of stopping drug administration. It is given by continuous IV infusion in doses of 5 to 50 mcg/kg/min. Doses can be increased in small amounts every 5 to 10 minutes to achieve sedation and decreased in small amounts every 5 to 10 minutes to allow awakening. The rate of infusion should be individualized and titrated to clinical response. As a general rule, the rate should be slower in older adults, clients receiving other CNS depressant drugs (eg, opioids or benzodiazepines), and critically ill clients. In addition, the level of sedation may be adjusted to the client’s condition and needs, such as a lighter level during visiting hours or a deeper level during painful procedures. Propofol
lacks analgesic effects, so analgesia must be provided for patients in pain or those having painful procedures. It also has antiemetic properties.

During propofol infusion, vital functions need to be assessed and monitored at regular intervals. For neurologic assessment, dosage is decreased every 12 or 24 hours to maintain light sedation. The drug should not be stopped because rapid awakening may be accompanied by anxiety, agitation, and resistance to mechanical ventilation. After assessment, the dose is increased until the desired level of sedation occurs. For hemodynamic and respiratory assessment, vital signs, electrocardiograms, pulmonary capillary wedge pressures, arterial blood gas levels, oxygen saturation, and other measurements are needed. Because propofol is expensive, some clinicians recommend that its use be limited to 24 to 48 hours.

Neuromuscular blocking agents are used to facilitate mechanical ventilation, control increased intracranial pressure, and treat status epilepticus. Clients requiring prolonged use of neuromuscular blocking agents usually have life-threatening illnesses such as adult respiratory distress syndrome, systemic inflammatory response syndrome, or multiple organ dysfunction syndrome.

The most commonly used are the nondepolarizing agents (eg, atracurium, vecuronium), which are given by intermittent bolus or continuous infusion. When the drugs are used for extended periods, clients are at risk for development of complications of immobility such as atelectasis, pneumonia, muscle wasting, and malnutrition. In addition, the drugs may accumulate, prolong muscle weakness, and make weaning from a ventilator more difficult. Accumulation results mainly from delayed elimination.

Local anesthetics should be used with caution in critically ill clients, especially those with impaired cardiovascular function such as dysrhythmias, heart block, hypotension, or shock. Repeated doses may cause accumulation of the drug or its metabolites or slow its metabolism. Reduced doses are indicated to decrease adverse effects; if a local anesthetic (eg, bupivacaine) is infused epidurally with an opioid analgesic (eg, fentanyl), dosage of both agents must be reduced to decrease risks of respiratory arrest. In addition to usual uses of local anesthetics, lidocaine is often given in coronary care units to decrease myocardial irritability and prevent or treat ventricular tachydysrhythmias (see Chap. 52).

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td>Drug administration in relation to anesthesia refers primarily to preanesthetic or postanesthetic drugs because physicians, dentists, and nurse anesthetists administer anesthetic drugs. In addition, critical care nurses may administer propofol or a neuromuscular blocking agent to patients being mechanically ventilated. Timing is important. It is better if these medications are administered so that peak sedative effects occur before administration of anesthetics to avoid excessive central nervous system (CNS) depression. If they are given too early, the client may be sedated longer than necessary, and the risk of postanesthetic respiratory and circulatory complications is increased. Also, medication effects may wear off before induction of anesthesia. If they are given too late, the client may suffer needless anxiety and not be relaxed and drowsy when anesthesia is being initiated. Preanesthetic medications are often ordered “on call” rather than for a specific time, and the client may or may not become sedated before being transported to the surgery suite. A precipitate may develop, or one of the drugs may be inactivated or altered when combined. Although larger amounts are sometimes given, probably no more than 2 to 3 mL should be given intramuscularly (IM) for both drug absorption and client comfort. Approximately 1.25 mL (20 minims) is the upper limit for subcutaneous injections.</td>
</tr>
<tr>
<td>a. Schedule the administration of preanesthetic medications so that their peak effects are reached at the optimal time, if possible.</td>
<td>The drug can irritate peripheral veins. An infusion pump is required for accurate administration and dosage titration.</td>
</tr>
<tr>
<td>b. If a combination of injectable preanesthetic medications is ordered, do not mix in the same syringe and give as one injection unless the drugs are known to be compatible and the total volume is approximately 2 mL. For example, atropine and glycopyrrolate (Robinul) are compatible with morphine. If compatibility is unknown, give two or more injections if necessary. Do not mix the drugs.</td>
<td>(continued)</td>
</tr>
<tr>
<td>c. With propofol intravenous (IV) infusion:</td>
<td>In continuing</td>
</tr>
</tbody>
</table>
### Nursing Actions

<table>
<thead>
<tr>
<th><strong>NURSING ACTIONS</strong></th>
<th><strong>RATIONALE/EXPLANATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Do not mix with other drugs before administration.</td>
<td>Propofol is an emulsion that is incompatible with other drugs.</td>
</tr>
<tr>
<td>(3) Dilute with 5% dextrose injection and do not dilute to a concentration of &lt;2 mg/mL.</td>
<td>Manufacturer’s recommendation</td>
</tr>
<tr>
<td>(4) Propofol is compatible with 5% dextrose, lactated Ringer’s, lactated Ringer’s and 5% dextrose, 5% dextrose and 0.45% sodium chloride, and 5% dextrose and 0.2% sodium chloride IV solutions</td>
<td>Strict aseptic administration and maintenance techniques are needed because of the potential for microbial contamination.</td>
</tr>
<tr>
<td>(5) Change IV tubing and propofol solution every 6 hours if manufactured IV solution is not used. If manufactured solution is used and the nurse only has to access the bag of fluid, change IV tubing every 12 hours.</td>
<td>These drugs can cause cardiovascular collapse, hypotension, and respiratory failure.</td>
</tr>
<tr>
<td><strong>d.</strong> Have drugs and equipment for resuscitation readily available in any location where propofol, neuromuscular blocking agents, or local anesthetics are being used.</td>
<td>Although the physician is responsible for drugs he or she administers, the nurse often assists by obtaining and perhaps holding the drug vial while the physician aspirates drug solution into a syringe.</td>
</tr>
<tr>
<td><strong>e.</strong> If assisting a physician in injecting a local anesthetic solution, show the drug container to the physician and verbally verify the name of the drug, the percentage concentration, and whether the solution is plain or contains epinephrine.</td>
<td>Accuracy of administration is essential so that adverse reactions can be avoided or treated appropriately if they do occur. The incidence of adverse reactions increases with the amount and concentration of local anesthetic solution injected. Also, adverse reactions to epinephrine may occur.</td>
</tr>
<tr>
<td><strong>f.</strong> When applying local anesthetics for topical or surface anesthesia, be certain to use the appropriate preparation of the prescribed drug.</td>
<td>Most preparations are used in particular conditions or bodily locations. For example, lidocaine viscous is used only as an oral preparation for anesthesia of the mouth and throat. Other preparations are used only on the skin.</td>
</tr>
</tbody>
</table>

2. Observe for therapeutic effects

| **a.** When adjunctive drugs are given for preanesthetic medication, observe for relaxation, drowsiness, and relief of pain. | Therapeutic effects depend on the type of drug and the reason for use. |
| **b.** When local anesthetic drugs are applied for surface anesthesia, observe for relief of the symptom for which the drug was ordered, such as sore mouth or throat, pain in skin or mucous membrane, and itching of hemorrhoids. | Depending on dose and client condition, these effects are usually evident within 20 to 30 minutes after the drugs are given. |
| **c.** When propofol is used for sedation in an intensive care unit, observe for lack of agitation and movement, tolerance of mechanical ventilation, and arousability for neurologic assessment when drug dosage is reduced by slowing the IV infusion rate. | Relief is usually obtained within a few minutes. Ask the client if the symptom has been relieved, and if not, assess the situation to determine whether further action is needed. |
| **d.** When a neuromuscular blocking agent is used in an intensive care unit, observe for tolerance of mechanical ventilation. | Serious adverse effects are most likely to occur during and within a few hours after general anesthesia and major surgery. During general anesthesia, the anesthesiologist monitors the client’s condition constantly to prevent, detect, or treat hypoxia, hypotension, cardiac dysrhythmias, and other problems. The nurse observes for adverse effects in the preanesthetic and postanesthetic periods. |

3. Observe for adverse effects

| **a.** With preanesthetic drugs, observe for excessive sedation. | The often-used combination of an opioid analgesic and a sedative-type drug produces additive CNS depression. |
| **b.** After general anesthesia and during propofol administration in intensive care units, observe for: | The early recovery period is normally marked by a progressive increase in alertness, responsiveness, and movement. |
| (1) Excessive sedation—delayed awakening, failure to respond to verbal or tactile stimuli | (continued) |
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>(2) Respiratory problems—laryngospasm, hypoxia, hypercarbia</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(3) Cardiovascular problems—hypotension, tachycardia and other cardiac arrhythmias, fluid and electrolyte imbalances</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(4) Other problems—restlessness, nausea, and vomiting. With ketamine, unpleasant dreams or hallucinations also may occur.</th>
</tr>
</thead>
</table>

#### c. After regional anesthesia, observe for:

<table>
<thead>
<tr>
<th>(1) CNS stimulation at first (hyperactivity, excitement, seizure activity) followed by CNS depression</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(2) Cardiovascular depression—hypotension, arrhythmias</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(3) Headache and urinary retention with spinal anesthesia</th>
</tr>
</thead>
</table>

#### 4. Observe for drug interactions

**a. Drugs that increase effects of general anesthetic agents:**

<table>
<thead>
<tr>
<th>(1) Antibiotics—aminoglycosides (gentamicin and related drugs)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(2) Antihypertensives</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(3) Catecholamines—dopamine, epinephrine, isoproterenol, norepinephrine</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(4) CNS depressants—alcohol, antianxiety agents, anti-convulsants, antidepressants, antihistamines, antipsychotics, barbiturates, opioid analgesics, sedative-hypnotics</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(5) Corticosteroids</th>
</tr>
</thead>
</table>

Laryngospasm may occur after removal of the endotracheal tube used to administer general anesthesia. Hypoxia and hypercarbia indicate inadequate ventilation and may result from depression of the respiratory center in the medulla oblongata, prolonged paralysis of respiratory muscles with muscle relaxant drugs, or retention of respiratory tract secretions due to a depressed cough reflex. Vital signs are often unstable during the early recovery period and therefore need to be checked frequently. Extreme changes must be reported to the surgeon or the anesthesiologist. These problems are most likely to occur while general anesthesia is being administered and progressively less likely as the patient recovers or awakens. Restlessness may be caused by the anesthetic, pain, or hypoxia and should be assessed carefully before action is taken. For example, if caused by hypoxia but interpreted as being caused by pain, administration of analgesics would aggravate hypoxia. These symptoms are more likely to occur with large doses, high concentrations, injections into highly vascular areas, or accidental injection into a blood vessel. Local anesthetics depress myocardial contractility and the cardiac conduction system. These effects are most likely to occur with high doses. Doses used for spinal or epidural anesthesia usually have little effect on cardiovascular function. Headache is more likely to occur if the person does not lie flat for 8 to 12 hours after spinal anesthesia is given. Urinary retention may occur in anyone but is more likely in older men with enlarged prostate glands. For interactions involving preanesthetic medications, see Anti-anxiety and Sedative-Hypnotics Drugs (Chap. 8), Anticholinergic Drugs (Chap. 21), and Opioid Analgesics and Opioid Antagonists (Chap. 6).

These antibiotics inhibit neuromuscular transmission. When they are combined with general anesthetics, additive muscle relaxation occurs with increased likelihood of respiratory paralysis and apnea. Additive hypotension, shock, and circulatory failure may occur. Increased likelihood of cardiac arrhythmias. Halothane and a few rarely used general anesthetics sensitize the myocardium to the effects of catecholamines. If they are combined, ventricular tachycardia or ventricular fibrillation may occur. Such a combination is contraindicated. CNS depressants include many different drug groups and hundreds of individual drugs. Some are used therapeutically for their CNS depressant effects; others are used mainly for other purposes, and CNS depression is a side effect. Any combination of these drugs with each other or with general anesthetic agents produces additive CNS depression. Extreme caution must be used to prevent excessive CNS depression. Additive hypotension may occur during and after surgery because of adrenocortical atrophy and reduced ability to respond to stress. For clients who have been receiving corticosteroids, most physicians recommend administration of hydrocortisone before, during, and, in decreasing doses, after surgery.

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6) Monoamine oxidase (MAO) inhibitors—isocarboxazid, isoniazid, procarbazine, tranylcypromine, others</td>
<td>Additive CNS depression. These drugs should be discontinued at least 10 days to 3 weeks before elective surgery. If emergency surgery is required, clients taking MAO inhibitors should not be given general anesthesia. Although they may be given spinal anesthesia, there is increased risk of hypotension. They should not be given local anesthetic solutions to which epinephrine has been added.</td>
</tr>
<tr>
<td>(7) Neuromuscular blocking agents</td>
<td>Additive relaxation of skeletal muscles. These drugs are given for this therapeutic effect so that smaller amounts of general anesthetics may be given.</td>
</tr>
<tr>
<td>b. Drugs that decrease effects of general anesthetics:</td>
<td>Few drugs actually decrease effects of general anesthetics. When clients are excessively depressed and hypotension, cardiac dysrhythmias, respiratory depression, and other problems develop, the main treatment is stopping the anesthetic and supporting vital functions rather than giving additional drugs. Effects of general inhalation anesthetics decrease rapidly once administration is discontinued. Effects of IV anesthetics decrease more slowly.</td>
</tr>
<tr>
<td>(1) Alcohol</td>
<td>Alcohol is a CNS depressant, and acute ingestion has an additive CNS depressant effect with general anesthetic agents. With chronic ingestion, however, tolerance to the effects of alcohol and general anesthetics develops; that is, larger amounts of general anesthetic agents are required in clients who have acquired tolerance to alcohol.</td>
</tr>
<tr>
<td>(2) Atropine</td>
<td>Atropine is often given as preanesthetic medication to prevent reflex bradycardia, which may occur with general inhalation anesthetics.</td>
</tr>
<tr>
<td>c. Drugs that increase effects of local anesthetics:</td>
<td>Additive depression and increased risk of hypotension and arrhythmias</td>
</tr>
<tr>
<td>(1) Cardiovascular depressants—general anesthetics, propranolol (Inderal)</td>
<td>Additive CNS depression with high doses</td>
</tr>
<tr>
<td>(2) CNS depressants</td>
<td>Epinephrine is often used in dental anesthesia to prolong anesthetic effects by delaying systemic absorption of the local anesthetic drug. It is contraindicated for this use, however, in clients with hyperthyroidism or severe heart disease or those receiving adrenergic blocking agents for hypertension.</td>
</tr>
<tr>
<td>(3) Epinephrine</td>
<td>Apnea may be prolonged by the combination of a local anesthetic agent and succinylcholine.</td>
</tr>
<tr>
<td>(4) Succinylcholine (Anectine)</td>
<td>These are seldom necessary or desirable. If overdosage of local anesthetics occurs, treatment is mainly symptomatic and supportive.</td>
</tr>
<tr>
<td>d. Drugs that decrease effects of local anesthetics:</td>
<td>This drug may be given to treat acute convulsions resulting from toxicity of local anesthetic drugs.</td>
</tr>
<tr>
<td>(1) Succinylcholine (Anectine)</td>
<td>These drugs can cause neuromuscular blockade on their own. If given with other blocking agents, additive blockade and increased risk of respiratory depression and apnea occur.</td>
</tr>
<tr>
<td>e. Drugs that increase effects of neuromuscular blocking agents (muscle relaxants):</td>
<td>Additive muscle relaxation</td>
</tr>
<tr>
<td>(1) Aminoglycoside antibiotics (eg, gentamicin)</td>
<td>Drugs that produce hypokalemia potentiate skeletal muscle relaxants</td>
</tr>
<tr>
<td>(2) General anesthetics</td>
<td>Additive muscle relaxation</td>
</tr>
<tr>
<td>(3) Thiazide diuretics (eg, hydrochlorothiazide)</td>
<td></td>
</tr>
<tr>
<td>(4) Others (clindamycin, lithium, magnesium sulfate, quinidine, procainamide, verapamil)</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
NURSING ACTIONS

<table>
<thead>
<tr>
<th>f. Drugs that decrease effects of neuromuscular blocking agents:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Anticholinesterase drugs (eg, neostigmine)</td>
</tr>
<tr>
<td>(2) Enzyme inducers (eg, carbamazepine, phenytoin)</td>
</tr>
</tbody>
</table>

RATIONALE/EXPLANATION

These drugs often are used to reverse the effects of the non-depolarizing agents. They do not reverse the effects of succinylcholine and may potentiate them instead.

These drugs may increase metabolism of neuromuscular blocking agents so that drug onset of action is delayed and duration of action is shorter.

---

**Review and Application Exercises**

1. When assessing a client before, during, or after general anesthesia, what are important factors to consider?

2. What are major adverse effects of general anesthetics and neuromuscular blocking agents?

3. What interventions are needed to ensure client safety during recovery from general anesthesia?

4. When assessing a client before, during, or after local or regional anesthesia, what are important factors to consider?

5. What are major adverse effects of local anesthetic agents?

6. What interventions are needed to ensure client safety during recovery from local or regional anesthesia?

7. What are the main elements of drug administration and client assessment when propofol or a neuromuscular blocking agent is used in critical care settings?

---

**SELECTED REFERENCES**


A buse of alcohol and other drugs is a significant health, social, economic, and legal problem. Substance abuse is often associated with substantial damage to the abuser and society (e.g., crime, child and spouse abuse, traumatic injury, death). As used in this chapter, substance abuse is defined as self-administration of a drug for prolonged periods or in excessive amounts to the point of producing physical or psychological dependence and reduced ability to function as a productive member of society.

Critical Thinking Scenario
You are a school nurse working in a middle school. Just after lunch, an 8th grader approaches you saying he is very worried about his friend. After lunch, on a dare, his friend drank over half a bottle of vodka and no one has been able to wake him up.

Reflect on:

Prioritize your assessment when you reach the intoxicated youth.

List factors, especially during the adolescent period, that increase the likelihood a person will experiment with or abuse alcohol.

Discuss important follow-up with this adolescent and his family after the incident.

**Objectives**

**AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:**

1. Identify risk factors for development of drug dependence.
2. Describe the effects of alcohol, cocaine, marijuana, and nicotine on selected body organs.
3. Compare and contrast characteristics of dependence associated with alcohol, benzodiazepines, cocaine, and opiates.
4. Describe specific antidotes for overdoses of central nervous system (CNS) depressant drugs and the circumstances indicating their use.
5. Outline major elements of treatment for overdoses of commonly abused drugs that do not have antidotes.
6. Describe interventions to prevent or manage withdrawal reactions associated with barbiturates, benzodiazepines, cocaine and other CNS stimulants, ethanol, and opiates.

**SUBSTANCE ABUSE**

Abuse of alcohol and other drugs is a significant health, social, economic, and legal problem. Substance abuse is often associated with substantial damage to the abuser and society (e.g., crime, child and spouse abuse, traumatic injury, death). As used in this chapter, substance abuse is defined as self-administration of a drug for prolonged periods or in excessive amounts to the point of producing physical or psychological dependence and reduced ability to function as a productive member of society.

Most drugs of abuse are those that affect the CNS and alter the state of consciousness. These include prescription and non-prescription and legal and illegal drugs. Commonly abused drugs include CNS depressants (e.g., alcohol, antianxiety/sedative-hypnotic agents, opioid analgesics), CNS stimulants (e.g., amphetamines, cocaine, nicotine), and other mind-altering drugs (e.g., marijuana, “ecstasy”). Although these drugs produce different effects, they are associated with feelings of pleasure, positive reinforcement, and compulsive self-administration. Most are also associated with tolerance if used repeatedly. This means that the body adjusts to the drugs so that higher doses are needed to achieve feelings of pleasure or stave off withdrawal symptoms.

**DEPENDENCE**

Characteristics of drug dependence include craving a drug, often with unsuccessful attempts to decrease its use; compulsive drug-seeking behavior; physical dependence (withdrawal symptoms if drug use is stopped); and continuing to take a drug despite adverse consequences (e.g., drug-related illnesses, mental or legal problems, job loss or decreased ability to function in an occupation, impaired family relationships).

Psychological dependence involves feelings of satisfaction and pleasure from taking the drug. These feelings, per-
ceived as extremely desirable by the drug-dependent person, contribute to acute intoxication, development and maintenance of drug abuse patterns, and return to drug-taking behavior after periods of abstinence.

Physical dependence involves physiologic adaptation to chronic use of a drug so that unpleasant symptoms occur when the drug is stopped or its action is antagonized by another drug. The withdrawal or abstinence syndrome produces specific manifestations according to the type of drug and does not occur as long as adequate dosage is maintained. Attempts to avoid withdrawal symptoms reinforce psychological dependence and promote continuing drug use and relapses to drug-taking behavior. Tolerance is often an element of drug dependence, and increasing doses are therefore required to obtain psychological effects or avoid physical withdrawal symptoms. A person may be dependent on more than one drug.

Drug dependence is a complex phenomenon of unknown cause. One view is that drugs stimulate or inhibit neurotransmitters in the brain to produce pleasure and euphoria or to decrease unpleasant feelings such as anxiety. The specific drug and the amount, frequency, and route of administration are also important. In addition to drug effects, other influencing factors include a person’s psychological and physiologic characteristics and environmental or circumstantial characteristics. Peer pressure is often an important factor in initial and continuing drug ingestion. A genetic factor seems evident in alcohol abuse: Studies indicate that children of abusers are at risk of becoming abusers themselves, even if reared away from the abusing parent. Additional general characteristics of substance abuse and dependence include the following:

- Substance abuse involves all socioeconomic levels and almost all age groups, from school-aged children to elderly adults. Patterns of abuse may vary in age groups. For example, adolescents and young adults may be more likely to use illicit drugs and older adults are more likely to abuse alcohol and prescription drugs. Health care professionals (eg, physicians, pharmacists, nurses) are also considered at high risk for development of substance abuse disorders, at least partly because of easy access.
- A person who abuses one drug is likely to abuse others.
- Multiple drugs are often abused concurrently. Alcohol, for example, is often used with other drugs of abuse, probably because it is legal and readily available. In addition, alcohol, marijuana, opioids, and sedatives are often used to combat the anxiety and nervousness induced by cocaine and other CNS stimulants.
- Drug effects vary according to the type of substance being abused, the amount, route of administration, duration of use, and phase of substance abuse (eg, acute intoxication, withdrawal syndromes, organ damage, and medical illness). Thus, acute intoxication often produces profound behavioral changes and chronic abuse often leads to serious organ damage and impaired ability to function in work, family, or social settings. Withdrawal symptoms are characteristic for particular types of drugs and are usually opposite the effects originally produced. For example, withdrawal symptoms of alcohol and sedative-type drugs are mainly agitation, nervousness, and hyperactivity.
- Alcohol and other drug abusers are not reliable sources of information about the types or amounts of drugs used. Most abusers understate the amount and frequency of substance use; heroin addicts may overstate the amount used in attempts to obtain higher doses of methadone. In addition, those who use illegal street drugs may not know what they have taken because of varying purity, potency, additives, names, and substitutions of one drug for another.
- Substance abusers rarely seek health care unless circumstances force the issue. Thus, most substance abuse comes to the attention of health care professionals when the abuser experiences a complication such as acute intoxication, withdrawal, or serious medical problems resulting from chronic drug overdose, misuse, or abuse.
- Smoking or inhaling drug vapors is a preferred route of administration for cocaine, marijuana, and nicotine because the drugs are rapidly absorbed from the large surface area of the lungs. Then, they rapidly circulate to the heart and brain without dilution by the systemic circulation or metabolism by enzymes. With crack cocaine, inhaling vapors from the heated drug produces blood levels comparable to those obtained with intravenous (IV) administration.
- Substance abusers who inject drugs intravenously are prey to serious problems because they use impure drugs of unknown potency, contaminated needles, poor hygiene, and other dangerous practices. Specific problems include overdoses, death, and numerous infections (eg, hepatitis, human immunodeficiency virus infection, endocarditis, phlebitis, and cellulitis at injection sites).

Many drugs are abused for their mind-altering properties. Most of these have clinical usefulness and are discussed elsewhere: Antianxiety and Sedative-Hypnotic Drugs (see Chap. 8), Opioid Analgesics and Opioid Antagonists (see Chap. 6), and Central Nervous System Stimulants (see Chap. 16). This chapter describes commonly abused substances, characteristics and treatment of substance-related disorders, and drugs used to treat substance-related disorders (see Drugs at a Glance: Drugs Used to Treat Substance Abuse Disorders).

### CENTRAL NERVOUS SYSTEM DEPRESSANTS

CNS depressants are drugs that slow down or “depress” brain activity. They include alcohol, antianxiety and sedative-hypnotic agents, and opiates.

**Alcohol (Ethanol)**

Alcohol is the most abused drug in the world. It is legal and readily available, and its use is accepted in most societies. There is no clear dividing line between use and abuse, but
# Drugs at a Glance: Drugs Used to Treat Substance Abuse Disorders

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bupropion</strong> <em>(Zyban)</em></td>
<td>Smoking cessation</td>
<td>PO 150 mg once daily for 3 days, then increase to 150 mg twice daily, at least 8 hours apart. Maximum dose, 300 mg/d</td>
<td></td>
</tr>
<tr>
<td><strong>Chlordiazepoxide</strong> <em>(Librium)</em></td>
<td>Alcohol detoxification; benzodiazepine withdrawal</td>
<td>PO 50 mg q6–8h initially, then tapered over 1–2 wk</td>
<td>Unlabeled uses, May cause hypotension</td>
</tr>
<tr>
<td><strong>Clonidine</strong> <em>(Catapres)</em></td>
<td>Alcohol withdrawal; opiate withdrawal</td>
<td>Alcohol withdrawal PO 0.3–0.6 mg q6h Opiate withdrawal PO 2 mcg/kg 3 times daily for 7–10 days</td>
<td></td>
</tr>
<tr>
<td><strong>Disulfiram</strong> <em>(Antabuse)</em></td>
<td>Chronic alcohol abuse, to prevent continued alcohol ingestion</td>
<td>PO 125–500 mg daily</td>
<td>Limited effectiveness because many alcoholics will not take the drug; should not be given until at least 12 h after alcohol ingestion</td>
</tr>
<tr>
<td><strong>Flumazenil</strong> <em>(Romazicon)</em></td>
<td>Acute intoxication or overdose of benzodiazepine anxiolytic or sedative-hypnotic drugs</td>
<td>IV 0.1–0.2 mg/min up to 1 mg</td>
<td>May precipitate acute withdrawal symptoms</td>
</tr>
<tr>
<td><strong>Haloperidol</strong> <em>(Haldol)</em></td>
<td>Psychotic symptoms associated with acute intoxication with cocaine and other central nervous system (CNS) stimulants</td>
<td>IM 2–5 mg every 30 min to 6 h PRN for psychotic behavior</td>
<td>Other antipsychotic agents may also be used</td>
</tr>
<tr>
<td><strong>Levomethadyl</strong> <em>(LAAM)</em> <em>(Orlaam)</em></td>
<td>Maintenance therapy of heroin addiction</td>
<td>PO 60–100 mg 3 times weekly</td>
<td>Reportedly as effective and well accepted by heroin addicts as methadone</td>
</tr>
<tr>
<td><strong>Lorazepam</strong> <em>(Ativan)</em></td>
<td>Excessive CNS stimulation associated with acute intoxication with cocaine and other CNS stimulants, hallucinogens, marijuana, inhalants, and phencyclidine; alcohol withdrawal</td>
<td><strong>Agitation</strong>, IM q30 min–6 h PRN; alcohol withdrawal halucinations or seizures, IM 2 mg, repeated if necessary; benzodiazepine withdrawal, PO 2 mg q6–8h initially, then tapered over 1–2 wk</td>
<td>1 wk of tapering usually adequate for withdrawal from short-acting benzodiazepines; 2 wk needed for long-acting benzodiazepines</td>
</tr>
<tr>
<td><strong>Methadone</strong></td>
<td>Opiate withdrawal; maintenance therapy of heroin addiction</td>
<td>Withdrawal, PO 20–80 mg daily initially, reduced by 5–10 mg daily over 7–10 days; maintenance PO 20–80 mg daily</td>
<td>Maintenance doses of 60–80 mg daily more effective than 20–30 mg daily in decreasing heroin use</td>
</tr>
<tr>
<td><strong>Naloxone</strong> <em>(Narcan)</em></td>
<td>Acute intoxication or overdose of opiates (heroin, morphine, others)</td>
<td>IV 0.4–2 mg q3min</td>
<td>May precipitate acute withdrawal symptoms</td>
</tr>
<tr>
<td><strong>Naltrexone</strong> <em>(ReVia)</em></td>
<td>Opiate dependence; alcohol dependence</td>
<td>PO 50 mg daily</td>
<td>With opiate dependence, should not be started until patient is opioid-free for at least 7 d</td>
</tr>
<tr>
<td><strong>Nicotine</strong> <em>(Habitrol, Nicotrol, Nicoderm CQ, Nicorette, Nicotrol Inhaler, Nicotrol NS)</em></td>
<td>Aid smoking cessation by relieving nicotine withdrawal symptoms</td>
<td><strong>Transdermal patches, Habitrol, Nicoderm</strong>: 21 mg/d for 6 wk; 14 mg/d for 2 wk; 7 mg/d for 2 wk  <strong>Nicotrol patch</strong>: 15 mg/16 hours for 6 wk  <strong>Nicotrol chewing gum</strong>: 1 piece every 1–2 h for wks 1–6; 1 piece every 2–4 h for wks 7–9; 1 piece every 4–8 h for wks 10–12  <strong>Nicotrol inhaler, 6–12 cartridges/d</strong> for 3 mo, then gradually taper dosage over 6–12 wk, then discontinue  <strong>Nicotrol nasal spray</strong>: 1 spray to each nostril, every 1–2 h, to a maximum of 80 sprays (40 mg) per day for heavy smokers. Taper by using less often or spraying 1 nostril per dose.</td>
<td>Should not be used while continuing to smoke because of high risk of serious adverse effects. Used patches contain enough nicotine to be toxic to children and pets; they should be discarded in a safe manner</td>
</tr>
</tbody>
</table>
rather a continuum of progression over several years. Alcohol exerts profound metabolic and physiologic effects on all organ systems (Box 15–1). Some of these effects are evident with acute alcohol intake, whereas others become evident with chronic intake of substantial amounts. Alcohol is thought to exert its effects on the CNS by enhancing the activity of gamma-aminobutyric acid, an inhibitory neurotransmitter, or by inhibiting the activity of glutamate, an excitatory neurotransmitter.

When alcohol is ingested orally, a portion is inactivated in the stomach (by the enzyme alcohol dehydrogenase) and not absorbed systemically. Women have less enzyme activity than men and therefore absorb approximately 30% more alcohol than men when comparable amounts are ingested according to weight and size. As a result, women are especially vulnerable to adverse effects of alcohol, including more rapid intoxication from smaller amounts of alcohol and earlier development of hepatic cirrhosis and other complications of alcohol abuse.

In men and women, alcohol is absorbed partly from the stomach but mostly from the upper small intestine. It is rapidly absorbed when the stomach and small intestine are empty. Food delays absorption by diluting the alcohol and delaying gastric emptying. Once absorbed, alcohol is quickly distributed to all body tissues, partly because it is lipid soluble and crosses cell membranes easily. The alcohol concentration in the brain rapidly approaches that in the blood, and CNS effects usually occur within a few minutes. These effects depend on the amount ingested, how rapidly it was ingested, whether the stomach was empty, and other factors.

**BOX 15–1 EFFECTS OF ALCOHOL ABUSE**

**Central and Peripheral Nervous System Effects**
Sedation ranging from drowsiness to coma; impaired memory, learning, and thinking processes; impaired motor coordination, with ataxia or staggering gait, altered speech patterns, poor task performance, and hypoactivity or hyperactivity; mental depression, anxiety, insomnia; impaired interpersonal relationships; brain damage, polyneuritis and Wernicke-Korsakoff syndrome.

**Hepatic Effects**
Induces drug-metabolizing enzymes that accelerate metabolism of alcohol and many other drugs and produces tolerance and cross-tolerance; eventually damages the liver enough to impair drug metabolism, leading to accumulation and toxic effects; decreases use and increases production of lactate, leading to lactic acidosis, decreased renal excretion of uric acid, and secondary hyperuricemia; decreases use and increases production of lipids, leading to hyperlipidemia and fatty liver. Fatty liver causes accumulation of fat and protein, leading to hepatomegaly; eventually produces severe liver injury characterized by necrosis and inflammation (alcoholic hepatitis) or by fibrous bands of scar tissue that irreversibly alter structure and function (cirrhosis).

The incidence of liver disease correlates with the amount of alcohol consumed and the progression of liver damage is attributed directly to ethanol or indirectly to the metabolic changes produced by ethanol.

**Gastrointestinal Effects**
Slowed gastric emptying time; increased intestinal motility, which probably contributes to the diarrhea that often occurs with alcoholism; damage to the epithelial cells of the intestinal mucosa; multiple nutritional deficiencies, including protein and water-soluble vitamins, such as thiamine, folic acid, and vitamin B₁₂; pancreatic disease, which contributes to malabsorption of fat, nitrogen, and vitamin B₁₂.

**Cardiovascular Effects**
Damage to myocardial cells; cardiomyopathy manifested by cardiomegaly, edema, dyspnea, abnormal heart sounds, and electrocardiographic changes indicating left ventricular hypertrophy, abnormal T waves, and conduction disturbances; possible impairment of coronary blood flow and myocardial contractility.

**Hematologic Effects**
Bone marrow depression due to alcohol or associated conditions, such as malnutrition, infection, and liver disease; several types of anemia including megaloblastic anemia from folic acid deficiency, sideroblastic anemia (sideroblasts are precursors of red blood cells) probably from nutritional deficiency, hemolytic anemia from abnormalities in the structure of red blood cells, iron deficiency anemia usually from gastrointestinal bleeding, and anemias from hemodilution, chronic infection, and fatty liver and bone marrow failure associated with cirrhosis; thrombocytopenia and decreased platelet aggregation from folic acid deficiency, hypersplenism, and other factors; decreased numbers and impaired function of white blood cells, which lead to decreased resistance to infection.

**Endocrine Effects**
Increased release of cortisol and catecholamines and decreased release of aldosterone from the adrenal glands; hypogonadism, gynecomastia, and feminization in men with cirrhosis due to decreased secretion of male sex hormones; degenerative changes in the anterior pituitary gland; decreased secretion of antidiuretic hormone from the posterior pituitary; hypoglycemia due to impaired glucose synthesis or hyperglycemia due to glycogenolysis.

**Skeletal Effects**
Impaired growth and development, which is most apparent in children born to alcoholic mothers. Fetal alcohol syndrome is characterized by low birth weight and length and by birth defects, such as cleft palate and cardiac septal defects. Impairment of growth and motor development persists in the postnatal period, and mental retardation becomes apparent. Other effects include decreased bone density, osteoporosis, and increased susceptibility to fractures; osteonecrosis due to obstructed blood supply; hypocalcemia, which leads to bone resorption and decreased skeletal mass; hypomagnesemia, which may further stimulate bone resorption; hypophosphatemia, probably from inadequate dietary intake of phosphorus.

**Muscular Effects**
Acute myopathy, which may be manifested by acute pain, tenderness, edema, and hyperkalemia; chronic myopathy, which may involve muscle weakness, atrophy, episodes of acute myopathy associated with a drinking spree, and elevated creatine phosphokinase.
Effects with acute intoxication usually progress from a feeling of relaxation to impaired mental and motor functions to stupor and sleep. Excited behavior may occur because of depression of the cerebral cortex, which normally controls behavior. The person may seem more relaxed, talkative, and outgoing or more impulsive and aggressive because inhibitions have been lessened.

The rate of alcohol metabolism largely determines the duration of CNS effects. Most alcohol is oxidized in the liver to acetaldehyde, which can be used for energy or converted to fat and stored. When metabolized to acetaldehyde, alcohol no longer exerts depressant effects on the CNS. Although the rate of metabolism differs with acute ingestion or chronic intake and some other factors, it is approximately 120 mg/kg of body weight or 10 mL/hour. This is the amount of alcohol contained in approximately 2/3 oz of whiskey, 3 to 4 oz of wine, or 8 to 12 oz of beer. Alcohol is metabolized at the same rate regardless of the amount present in body tissues.

In older adults, the pharmacokinetics of alcohol are essentially the same as for younger adults. However, equivalent amounts of alcohol produce higher blood levels in older adults because of changes in body composition (eg, a greater proportion of fatty tissue).

**Alcohol Interactions With Other Drugs**

Alcohol may cause several potentially significant interactions when used with other drugs. These interactions often differ between acute and chronic ingestion. *Acute ingestion* inhibits drug-metabolizing enzymes. This slows the metabolism of some drugs, thereby increasing their effects and the likelihood of toxicity. *Chronic ingestion* induces metabolizing enzymes. This increases the rate of metabolism and decreases drug effects. Long-term ingestion of large amounts of alcohol, however, causes liver damage and impaired ability to metabolize drugs.

Because so many variables influence alcohol’s interactions with other drugs, it is difficult to predict effects of interactions in particular people. However, some important interactions include those with other CNS depressants, antihypertensive agents, antidiabetic agents, oral anticoagulants, and disulfiram. These are summarized as follows:

- With other CNS depressants (eg, sedative-hypnotics, opioid analgesics, antianxiety agents, antipsychotic agents, general anesthetics, and tricyclic antidepressants), alcohol potentiates CNS depression and increases risks of excessive sedation, respiratory depression, impaired mental and physical functioning, and other effects. Combining alcohol with these drugs may be lethal and should be avoided.
- With antihypertensive agents, alcohol potentiates vasodilation and hypotensive effects.
- With oral antidiabetic drugs, alcohol potentiates hypoglycemic effects.
- With oral anticoagulants (eg, warfarin), alcohol interactions vary. *Acute ingestion* increases anticoagulant effects and the risk of bleeding. *Chronic ingestion* decreases anticoagulant effects by inducing drug-metabolizing enzymes in the liver and increasing the rate of warfarin metabolism. However, if chronic ingestion has caused liver damage, metabolism of warfarin may be slowed. This increases the risk of excessive anticoagulant effect and bleeding.
  - With disulfiram (Antabuse), alcohol produces significant distress (flushing, tachycardia, bronchospasm, sweating, nausea and vomiting). This reaction may be used to treat alcohol dependence.
  - A disulfiram-like reaction also may occur with other drugs, including several cephalosporin antibiotics (cefamandole, cefonicid, cefoperazone, ceforanide, cefotetan), chlorpropamide (Diabinese), tolbutamide (Orinase), and metronidazole (Flagyl).

**Alcohol Dependence**

Alcohol dependence involves acute or chronic consumption of alcohol in excess of the limits accepted by the person’s culture, at times considered inappropriate by that culture, and to the extent that physical health and social relationships are impaired. Psychological dependence, physical dependence, tolerance, and cross-tolerance (with other CNS depressants) are prominent characteristics.

Acute intoxication impairs thinking, judgment, and psychomotor coordination. These impairments lead to poor work performance, accidents, and disturbed relationships with other people. Conscious control of behavior is lost, and exhibitionism, aggressiveness, and assaultiveness often result. Chronic ingestion affects essentially all body systems and may cause severe organ damage and mental problems. Effects are summarized in Box 15–1.

Signs and symptoms of alcohol withdrawal include agitation, anxiety, tremors, sweating, nausea, tachycardia, fever, hyperreflexia, postural hypotension, and, if severe, convulsions and delirium. Delirium tremens, the most serious form of alcohol withdrawal, is characterized by confusion, disorientation, delusions, visual hallucinations, and other signs of acute psychosis. The intensity of the alcohol withdrawal syndrome varies with the duration and amount of alcohol ingestion. Withdrawal symptoms start within a few hours after a person’s last drink and last for several days.

**Treatment of Alcohol Dependence**

Alcohol dependence is a progressive illness, and early recognition and treatment are desirable. The alcohol-dependent person is unlikely to seek treatment for alcohol abuse unless an acute situation forces the issue. He or she is likely, however, to seek treatment for other disorders, such as nervousness, anxiety, depression, insomnia, and gastroenteritis. Thus, health professionals may recognize alcohol abuse in its early stages if they are aware of indicative assessment data.

If the first step of treatment is recognition of alcohol abuse, the second step is probably confronting the client with evidence of alcohol abuse and trying to elicit cooperation. Unless
the client admits that alcohol abuse is a problem and agrees to participate in a treatment program, success is unlikely. The client may fail to make return visits or may seek treatment elsewhere. If the client agrees to treatment, the three primary approaches are psychological counseling, referral to a self-help group such as Alcoholics Anonymous, and drug therapy.

Acute intoxication with alcohol does not usually require treatment. If the client is hyperactive and combative, a sedative-type drug may be given. The client must be closely observed because sedatives potentiate alcohol, and excessive CNS depression may occur. If the client is already sedated and stuporous, he or she can be allowed to sleep off the alcohol effects. If the client is comatose, supportive measures are indicated. For example, respiratory depression may require insertion of an artificial airway and mechanical ventilation.

Benzodiazepine antianxiety agents are the drugs of choice for treating alcohol withdrawal syndromes. They can help the client participate in rehabilitation programs and can be gradually reduced in dosage and discontinued. They provide adequate sedation and have a significant anticonvulsant effect. Some physicians prefer a benzodiazepine with a long half-life (eg, diazepam or chlordiazepoxide) whereas others prefer one with a short half-life (eg, lorazepam or oxazepam). Lorazepam and oxazepam are less likely to accumulate and may be best for older adults or patients with hepatic disease. Alcoholic patients usually require high doses of benzodiazepines because of the drugs’ cross-tolerance with alcohol. Seizures require treatment if they are repeated or continuous. Antiseizure drugs need not be given for more than a few days unless the person has a preexisting seizure disorder. Clonidine may be given to reduce symptoms (eg, hyperactivity, tremors) associated with excessive stimulation of the sympathetic nervous system. Midazolam or propofol may be useful for treating delirium tremens because their doses can be easily titrated to manage the symptoms.

Drug therapy for maintenance of sobriety is limited, mainly because of poor compliance. The two drugs approved for this purpose are disulfiram (Antabuse) and naltrexone (ReVia). Disulfiram interferes with hepatic metabolism of alcohol and allows accumulation of acetaldehyde. If alcohol is ingested during disulfiram therapy, acetaldehyde causes nausea and vomiting, dyspnea, hypotension, tachycardia, syncope, blurred vision, headache, and confusion. Severe reactions include respiratory depression, cardiovascular collapse, cardiac arrhythmias, myocardial infarction, congestive heart failure, unconsciousness, convulsions, and death. The severity of reactions varies but is usually proportional to the amounts of alcohol and disulfiram taken. The duration of the reaction varies from a few minutes to several hours, as long as alcohol is present in the blood. Ingestion of prescription and over-the-counter medications that contain alcohol may cause a reaction in the disulfiram-treated alcoholic. Disulfiram alone may produce adverse reactions of drowsiness, fatigue, impotence, headache, and dermatitis. These are more likely to occur during the first 2 weeks of treatment, after which they usually subside. Disulfiram also interferes with the metabolism of phenytoin and warfarin, which may increase blood levels of the drugs and increase their toxicity. Because of these reactions, disulfiram must be given only with the client’s full consent, cooperation, and knowledge.

Naltrexone is an opiate antagonist that reduces craving for alcohol and increases abstinence rates when combined with psychosocial treatment. A possible mechanism is blockade of the endogenous opioid system, which is thought to reinforce alcohol craving and consumption. The most common adverse effect is nausea; others include anxiety, dizziness, drowsiness, headache, insomnia, nervousness, and vomiting. Naltrexone is hepatotoxic in high doses and contraindicated in patients with acute hepatitis or liver failure.

In addition to drug therapy to treat withdrawal and maintain sobriety, alcohol abusers often need treatment of coexisting psychiatric disorders, such as depression. Antidepressant drugs seem to decrease alcohol intake as well as relieve depression.

## Barbiturates and Benzodiazepines

Barbiturates are old drugs that are rarely used therapeutically but remain drugs of abuse. Overdoses may cause respiratory depression, coma, and death. Withdrawal is similar to alcohol withdrawal and may be more severe. Seizures and death can occur. With short-acting barbiturates such as pentobarbital (Nembutal) and secobarbital (Seconal), withdrawal symptoms begin 12 to 24 hours after the last dose and peak at 24 to 72 hours. With phenobarbital, symptoms begin 24 to 48 hours after the last dose and peak in 5 to 8 days.

Benzodiazepines are widely used for antianxiety and sedative-hypnotic effects (see Chap. 8) and are also widely abused, mainly by people who also abuse alcohol or other drugs. Benzodiazepines rarely cause respiratory depression or death, even in overdose, unless taken with alcohol or other drugs. They may, however, cause oversedation, memory impairment, poor motor coordination, and confusion. Withdrawal reactions can be extremely uncomfortable. Symptoms begin 12 to 24 hours after the last dose of a short-acting drug such as alprazolam (Xanax), and peak at 24 to 72 hours. With long-acting drugs such as diazepam (Valium) and chlordiazepoxide (Librium), symptoms begin 24 to 48 hours after the last dose and peak within 5 to 8 days.

Combining any of these drugs with each other or with alcohol can cause serious depression of vital functions and death. Unfortunately, abusers often combine drugs in their quest for a greater “high” or to relieve the unpleasant effects of CNS stimulants and other street drugs.

## Barbiturate and Benzodiazepine Dependence

This type of dependence resembles alcohol dependence in symptoms of intoxication and withdrawal. Other characteristics include physical dependence, psychological dependence, tolerance, and cross-tolerance. Signs and symptoms of withdrawal include anxiety, tremors and muscle twitch-
ing, weakness, dizziness, distorted visual perceptions, nausea and vomiting, insomnia, nightmares, tachycardia, weight loss, postural hypotension, generalized tonic-clonic seizures, and delirium that resembles the delirium tremens of alcoholism or a major psychotic episode. Convulsions are more likely to occur during the first 48 hours of withdrawal and delirium after 48 to 72 hours. Signs and symptoms of withdrawal are less severe with the benzodiazepines than with the barbiturates.

**Treatment of Barbiturate or Benzodiazepine Abuse**

Treatment may involve overdose and withdrawal syndromes. Overdose produces intoxication similar to that produced by alcohol. There may be a period of excitement and emotional lability followed by progressively increasing signs of CNS depression (eg, impaired mental function, muscular incoordination, and sedation). Treatment is unnecessary for mild overdose if vital functions are adequate. The client usually sleeps off the effects of the drug. The rate of recovery depends primarily on the amount of drug ingested and its rate of metabolism. More severe overdoses cause respiratory depression and coma.

There is no antidote for barbiturate overdose; treatment is symptomatic and supportive. The goals of treatment are to maintain vital functions until the drug is metabolized and eliminated from the body. Insertion of an artificial airway and mechanical ventilation often are necessary. Gastric lavage may help if started within approximately 3 hours of drug ingestion. If the person is comatose, a cuffed endotracheal tube should be inserted and the cuff inflated before lavage to prevent aspiration. Diuresis helps to eliminate the drugs and can be induced by IV fluids or diuretic drugs. Hemo dialysis also removes most of these drugs and may be used with high serum drug levels or failure to respond to other treatment measures. Hypotension and shock are usually treated with IV fluids.

These treatments were formerly used for benzodiazepine overdoses and may still be needed in some cases (eg, overdoses involving multiple drugs). However, a specific antidote is now available to reverse sedation, coma, and respiratory depression. Flumazenil (Romazicon) competes with benzodiazepines for benzodiazepine receptors. The drug has a short duration of action, and repeated IV injections are usually needed. Recipients must be closely observed because symptoms of overdose may recur when the effects of a dose of flumazenil subside and because the drug may precipitate acute withdrawal symptoms (eg, agitation, confusion, seizures) in benzodiazepine abusers.

Treatment of withdrawal may involve administration of a benzodiazepine or phenobarbital to relieve acute signs and symptoms, then tapering the dose until the drug can be discontinued. Barbirate and benzodiazepine withdrawal syndromes can be life threatening. The person may experience cardiovascular collapse, generalized tonic-clonic seizures, and acute psychotic episodes. These can be prevented by gradually withdrawing the offending drug. If they do occur, each situation requires specific drug therapy and supportive measures. Withdrawal reactions should be supervised and managed by experienced people, such as health care professionals or staff at detoxification centers.

**Opiates**

Opiates are potent analgesics and extensively used in pain management (see Chap. 6). They are also commonly abused. Because therapeutic opiates are discussed elsewhere, the focus here is heroin. Heroin, a semisynthetic derivative of morphine, is a common drug of abuse. It is a Schedule I drug in the United States and is not used therapeutically.

Heroin may be taken by IV injection, smoking, or nasal application (snorting). IV injection produces intense euphoria, which occurs within seconds, lasts a few minutes, and is followed by a period of sedation. Effects diminish over approximately 4 hours, depending on the dose. Addicts may inject several times daily, cycling between desired effects and symptoms of withdrawal. Tolerance to euphoric effects develops rapidly, leading to dosage escalation and continued use to avoid withdrawal. Like other opiates, heroin causes severe respiratory depression with overdose and produces a characteristic abstinence syndrome.

**Opiate Dependence**

Opiates produce tolerance and high degrees of psychological and physical dependence. Most other drugs that produce dependence do so with prolonged usage of large doses, but morphine-like drugs produce dependence with repeated administration of small doses. Medical usage of these drugs produces physical dependence and tolerance but rarely leads to use or abuse for mind-altering effects. Thus, “addiction” should not be an issue when the drugs are needed for pain management in patients with cancer or other severe illnesses.

Acute effects of opiate administration vary according to dosage, route of administration, and physical and mental characteristics of the user. They may produce euphoria, sedation, analgesia, respiratory depression, postural hypotension, vasodilation, pupil constriction, and constipation.

**Treatment of Opiate Dependence**

Treatment may be needed for overdose or withdrawal syndromes. Overdose may produce severe respiratory depression and coma. Insertion of an endotracheal tube and mechanical ventilation may be required. Drug therapy consists of an opioid antagonist to reverse opioid effects. Giving an opioid antagonist can precipitate withdrawal symptoms. If there is no response to the opioid antagonist, the symptoms may be caused by depressant drugs other than opiates. In addition to profound respiratory depression, pulmonary edema, hypoglycemia, pneumonia, cellulitis, and other infections often accompany opiate overdose and require specific treatment measures.
Signs and symptoms of withdrawal can be reversed immediately by giving the drug producing the dependence. Therapeutic withdrawal, which is more comfortable and safer, can be managed by gradually reducing dosage over several days. Clonidine, an antihypertensive drug, is sometimes used to relieve withdrawal symptoms associated with sympathetic nervous system overactivity.

Ideally, the goal of treatment for opiate abuse is abstinence from further opiate usage. Because this goal is rarely met, long-term drug therapy may be used to treat heroin dependence. One method uses opioid substitutes to prevent withdrawal symptoms and improve a lifestyle that revolves around obtaining, using, and recovering from a drug. Methadone has long been used for this purpose, usually a single, daily, oral dose given in a methadone clinic. Proponents say that methadone blocks euphoria produced by heroin, acts longer, and reduces preoccupation with drug use. This allows a more normal lifestyle for the client and reduces morbidity and mortality associated with the use of illegal and injected drugs. Also, because methadone is free, the heroin addict does not commit crimes to obtain drugs. Opponents say that methadone maintenance only substitutes one type of drug dependence for another. In addition, a substantial percentage of those receiving methadone maintenance therapy abuse other drugs, including cocaine.

Another drug approved for maintenance therapy is levomethadyl acetate hydrochloride, also called LAAM. LAAM (Orlaam) is a synthetic, Schedule II opioid indicated only for the treatment of opiate dependence. It is metabolized to long-acting, potent metabolites. After oral administration, effects occur within 90 minutes, peak in about 4 hours, and last about 72 hours. Its main advantage over methadone is that it can be given three times weekly rather than daily. However, if given on a Monday/Wednesday/Friday schedule, the Friday dose may need to be larger to prevent withdrawal symptoms until the Monday dose can be given. Also, initial dosage needs careful titration to prevent withdrawal symptoms but avoid overdosage when peak effects occur. Patients must be informed about the delayed effects of the drug and the risks of overdosage if they take other opiates. LAAM has proarrhythmic effects and an electrocardiogram should be done prior to starting the drug and periodically during therapy.

A third treatment option is naltrexone (ReVia), an opioid antagonist that prevents opiates from occupying receptor sites and thereby prevents their physiologic effects. Used to maintain opiate-free states in the opiate addict, it is recommended for use in conjunction with psychological counseling to promote client motivation and compliance. If the patient taking naltrexone has mild or moderate pain, nonopioid analgesics (eg, acetaminophen or a nonsteroidal anti-inflammatory drug) should be given. If the patient has severe pain and requires an opioid, it should be given in a setting staffed and equipped for cardiopulmonary resuscitation because respiratory depression may be deeper and more prolonged than usual. In addition, patients needing elective surgery and opioid analgesics should be instructed to stop taking naltrexone at least 72 hours before the scheduled procedure.

Amphetamines and Related Drugs

Amphetamines and related drugs (see Chap. 16) are used therapeutically for narcolepsy and attention deficit-hyperactivity disorder (ADHD). Except for the use of methylphenidate in treating ADHD, however, the drugs are more important as drugs of abuse than therapeutic agents.

Amphetamine-Type Dependence

Amphetamines and related drugs (eg, methylphenidate) produce stimulation and euphoria, effects often sought by drug users. The user may increase the amount and frequency of administration to reach or continue the state of stimulation. One of the drugs, methamphetamine, may be chemically treated to produce potent crystals (called “ice”), which are then heated and the vapors smoked or inhaled. Psychological effects of amphetamines are similar to those produced by cocaine and are largely dose related. Small amounts produce mental alertness, wakefulness, and increased energy. Large amounts may cause psychosis (eg, hallucinations and paranoid delusions). Tolerance develops to amphetamines.

Acute ingestion of these drugs masks underlying fatigue or depression; withdrawal allows these conditions to emerge in an exaggerated form. The resulting exhaustion and depression reinforce the compulsion to continue using the drugs. Users may take them alone or to counteract the effects of other drugs. In the latter case, these drugs may be part of a pattern of polydrug use in which CNS depressants, such as alcohol or sedative-type drugs (“downers”), are alternated with CNS stimulants, such as amphetamines (“uppers”).

Treatment of Amphetamine-Type Abuse

Treatment of amphetamine-type abuse is mainly concerned with overdosage because these drugs do not produce physical dependence and withdrawal as alcohol, opiates, and sedative-hypnotic drugs do. Because amphetamines delay gastric emptying, gastric lavage may be helpful even if several hours have passed since drug ingestion. The client is likely to be hyperactive, agitated, and hallucinating (toxic psychosis) and may have tachycardia, fever, and other symptoms. Symptomatic treatment includes sedation, lowering of body temperature, and administration of an antipsychotic drug. Sedative-type drugs must be used with great caution, however, because depression and sleep usually follow amphetamine use, and these after-effects can be aggravated by sedative administration.

Cocaine

Cocaine is a popular drug of abuse. It produces powerful CNS stimulation by preventing reuptake of neurotransmitters (eg, dopamine, norepinephrine, serotonin), which increases...
and prolongs neurotransmitter effects. Cocaine is commonly inhaled (snorted) through the nose; “crack” is heated and the vapors inhaled. Acute use of cocaine or crack produces intense euphoria, increased energy and alertness, sexual arousal, tachycardia, increased blood pressure, and restlessness followed by depression, fatigue, and drowsiness as drug effects wear off. Overdose can cause cardiac dysrhythmias, convulsions, myocardial infarction, respiratory failure, stroke, and death, even in young, healthy adults and even with initial exposure. Both acute and chronic use produce numerous physiologic effects (Box 15–2).

**Cocaine Dependence**

Cocaine-induced euphoria is intense but brief and often leads to drug ingestion every few minutes as long as the drug is available. Cocaine is not thought to produce physical dependence, although fatigue, depression, drowsiness, dysphoria, and intense craving occur as drug effects dissipate. Crack is a strong, inexpensive, extremely addicting, and widely used form of cocaine. It is prepared by altering cocaine hydrochloride with chemicals and heat to form rock-like formations of cocaine base. The process removes impurities and results in a very potent drug. When the drug is heated and the vapors inhaled, crack acts within a few seconds. It reportedly can cause psychological dependence with one use.

**Treatment of Cocaine Abuse**

Drug therapy is largely symptomatic. Thus, agitation and hyperactivity may be treated with a benzodiazepine antianxiety agent; psychosis may be treated with haloperidol or other antipsychotic agent; cardiac dysrhythmias may be treated with usual antidysrhythmic drugs; myocardial infarction may be treated by standard methods; and so forth. Initial detoxification and long-term treatment are best accomplished in centers or units that specialize in substance abuse disorders.

Long-term treatment of cocaine abuse usually involves psychotherapy, behavioral therapy, and 12-step programs. In addition, many patients need treatment for coexisting psychiatric disorders.

**Nicotine**

Nicotine, one of many active ingredients in tobacco products, is the ingredient that promotes compulsive use, abuse, and dependence. Inhaling smoke from a cigarette produces CNS stimulation in a few seconds. The average cigarette contains approximately 6 to 8 mg of nicotine and delivers approximately 1 mg of nicotine systemically to the smoker (most is burned or dissipated as “sidestream” smoke). Nicotine obtained from chewing tobacco produces longer-lasting effects because it is more slowly absorbed than inhaled nicotine. Nicotine produces its effects by increasing levels of dopamine and other substances in the brain.

Nicotine is readily absorbed through the lungs, skin, and mucous membranes. It is extensively metabolized, mainly in the liver, and its metabolites are eliminated by the kidneys. It is also excreted in breast milk of nursing mothers. Adverse effects include nausea in new smokers at low blood levels and in experienced smokers at blood levels higher than their accustomed levels. Nicotine poisoning can occur in infants and children from ingestion of tobacco products, skin contact with nicotine transdermal patches, or chewing nicotine gum. Poisoning may also occur with accidental ingestion of pesticide sprays containing nicotine. Oral ingestion usually causes vomiting, which limits the amount of nicotine absorbed. Toxic effects of a large dose may include hypertension, cardiac dysrhythmias, convulsions, coma, respiratory arrest, and paralysis of skeletal muscle. With chronic tobacco use, nicotine is implicated in the vascular disease and sudden cardiac death associated with smoking. However, the role of nicotine in the etiology of other disorders (eg, cancer and pulmonary

### BOX 15–2  PHYSIOLOGIC AND BEHAVIORAL EFFECTS OF COCAINE ABUSE

| Central Nervous System Effects | Cerebral infarct, subarachnoid and other hemorrhages; excessive central nervous system stimulation, manifested by anxiety, agitation, delirium, hyperactivity, irritability, insomnia, anorexia and weight loss; psychosis with paranoid delusions and hallucinations that may be indistinguishable from schizophrenia; seizures. |
| Cardiovascular Effects | Dysrhythmias, including tachycardia, premature ventricular contractions, ventricular tachycardia and fibrillation, and asystole; cardiopathy; myocardial ischemia and acute myocardial infarction; hypertension; stroke; rupture of the aorta; constriction of coronary and peripheral arteries. |
| Respiratory Effects | With snorting of cocaine, rhinitis, rhinorrhea, and damage (ulceration, perforation, necrosis) of the nasal septum from vasoconstriction and ischemia. With inhalation of crack cocaine vapors, respiratory symptoms occur in up to 25% of users and may include bronchitis, bronchospasm, cough, dyspnea, pneumonia, pulmonary edema, and fatal lung hemorrhage. |
| Gastrointestinal Effects | Nausea; weight loss; intestinal ischemia, possible necrosis. |
| Genitourinary Effects | Delayed orgasm for men and women; difficulty in maintaining erection. |
| Effects of Intravenous Use | Hepatitis; human immunodeficiency virus infection; endocarditis; cellulitis; abscesses. |
disease) associated with chronic use of tobacco is unknown. Effects are summarized in Box 15–3.

**Nicotine Dependence**

Like alcohol and opiate dependence, nicotine dependence is characterized by compulsive use and the development of tolerance and physical dependence. Mental depression is also associated with nicotine dependence. It is unknown whether depression leads to smoking or develops concomitantly with nicotine dependence. Cigarette smokers may smoke to obtain the perceived pleasure of nicotine’s effects, avoid the discomfort of nicotine withdrawal, or both. Evidence indicates a compulsion to smoke when blood levels of nicotine become low. Abstinence from smoking leads to signs and symptoms of withdrawal (eg, anxiety, irritability, difficulty concentrating, restlessness, headache, increased appetite, weight gain, sleep disturbances), which usually begin within 24 hours of the last exposure to nicotine.

**Treatment of Nicotine Dependence**

Most tobacco users who quit do so on their own. For those who are strongly dependent and unable or unwilling to quit on their own, there are two main methods of treatment. One method is the use of bupropion, an antidepressant (see Chap. 10). The antidepressant formulation is marketed as Wellbutrin; the smoking-cessation formulation is Zyban, a sustained-release tablet. The other method is nicotine replacement therapy with drug formulations of nicotine. These products prevent or reduce withdrawal symptoms, but they do not produce the subjective effects or peak blood levels seen with cigarettes.

Nicotine is available in transdermal patches, chewing gum, an oral inhaler, and a nasal spray. The gum, inhaler, and spray are used intermittently during the day; the transdermal patch is applied once daily. Transdermal patches produce a steady blood level of nicotine and patients seem to use them more consistently than they use the other products. The patches and gum are available over the counter; the inhaler and nasal spray require a prescription. The products are contraindicated in people with significant cardiovascular disease (angina pectoris, dysrhythmias, or recent myocardial infarction). Adverse effects include soreness of mouth and throat (with gum), nausea, vomiting, dizziness, hypertension, dysrhythmias, confusion, and skin irritation at sites of transdermal patch application.

Nicotine products are intended to be used for limited periods of 3 to 6 months, with tapering of dosage and discontinuation. Although they are effective in helping smokers achieve abstinence, many resume smoking.

Overall, treatment regimens that combine counseling and behavioral therapy with drug therapy are more successful than those using drug therapy alone. In addition, a combination of Zyban and nicotine transdermal patches is sometimes used and may be more effective than either drug alone.

**Marijuana**

Marijuana and other cannabis preparations are obtained from *Cannabis sativa*, the hemp plant, which grows in most parts of the world, including the entire United States. Marijuana and hashish are the two cannabis preparations used in the United States. Marijuana is obtained from leaves and stems; hashish, prepared from plant resin, is 5 to 10 times as potent as commonly available marijuana. These cannabis preparations contain several related compounds called cannabinoids. Delta-9-tetrahydrocannabinol (Δ9-THC) is the main psychoactive ingredient, but metabolites and other constituents also may exert pharmacologic activity. The mechanism of action is unknown, although specific cannabinoid receptors have been identified in several regions of the brain. The endogenous substances that react with these receptors have not been determined.

Cannabis preparations are difficult to classify. Some people call them depressants; some call them stimulants; and others label them as mind-altering, hallucinogenic, psychotomimetic, or unique in terms of fitting into drug categories. It is also difficult to predict the effects of these drugs. Many factors apparently influence a person’s response. One factor is the amount of active ingredients, which varies with the climate and soil where the plants are grown and with the method of preparation. Other factors include dose, route of administration, personality variables, and the environment in which the drug is taken.

Marijuana can be taken orally but is more often smoked and inhaled through the lungs. It is more potent and more rapid in its actions when inhaled. After smoking, subjective

---

**Central Nervous System Effects**

- Central nervous system stimulation with increased alertness, possibly feelings of enjoyment, decreased appetite, tremors, convulsions at high doses.

**Cardiovascular Effects**

- Cardiac stimulation with tachycardia, vasoconstriction, increased blood pressure, increased force of myocardial contraction, and increased cardiac workload.

**Gastrointestinal Effects**

- Increases secretion of gastric acid; increases muscle tone and motility; nausea and vomiting; aggravates gastroesophageal and peptic ulcer disease.
morning glory seeds. It is very potent, and small doses can
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
and body temperature, as well as pupil dilation. Adverse re-
actions, including increased blood pressure, heart rate,
and body temperature, as well as pupil dilation. Adverse re-
actions include self-injury and possibly suicide, violent be-
havior, psychotic episodes, “flashbacks” (a phenomenon
characterized by psychological effects and hallucinations
that may recur days, weeks, or months after the drug is
taken), and possible chromosomal damage resulting in birth
defects.

**MDMA** (3,4 methylenedioxymethamphetamine), com-
monly called “ecstasy,” is an illegal, Schedule I derivative of
amphetamine that produces hallucinogenic and stimulant ef-
facts when taken orally. It is usually taken by adolescents and
young adults, often at dance parties called “raves,” and its use
is reportedly increasing. Users report increased energy and
perception, euphoria, and feelings of closeness to others.
These effects occur within an hour after oral ingestion and
last 6 to 8 hours.

Although users apparently think this is a safe drug, evi-
dence indicates it is extremely dangerous. Adverse effects in-
clude cardiac dysrhythmias, coma, dehydration, delirium,
hypertension, hyperthermia, hyponatremia, rhabdomyolysis,
seizures, tachycardia, and death. These effects have occurred
with a single use. Even without these life-threatening adverse
effects, drug use is usually followed by several days of de-
pression, sadness, low energy, and a decreased ability to feel
emotions or pleasure.

Another major concern is the drug’s neurotoxicity. Early
effects include spasmodic jerking, involuntary jaw clench-
ing, and teeth grinding. Long-term or permanent changes
may result from damage to the nerve cells in the brain that
transmit serotonin. MDMA floods the brain with high
amounts of serotonin, which is important in emotion, mood,
and memory. As a result, repeated use of MDMA may lead
towards mood swings, irritability, and depression. In some
people, these effects may persist even after the drug is no
longer being used.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
to new, strange sensations and experiences. LSD is usually
distributed as a yellow or orange powder, which is dissolved
in liquid and ingested orally.

**MDMA** (3,4 methylenedioxymethamphetamine), commonly
called “ecstasy,” is an illegal, Schedule I derivative of
amphetamine that produces hallucinogenic and stimulant ef-
facts when taken orally. It is usually taken by adolescents and
young adults, often at dance parties called “raves,” and its use
is reportedly increasing. Users report increased energy and
perception, euphoria, and feelings of closeness to others.
These effects occur within an hour after oral ingestion and
last 6 to 8 hours.

Although users apparently think this is a safe drug, evi-
dence indicates it is extremely dangerous. Adverse effects in-
clude cardiac dysrhythmias, coma, dehydration, delirium,
hypertension, hyperthermia, hyponatremia, rhabdomyolysis,
seizures, tachycardia, and death. These effects have occurred
with a single use. Even without these life-threatening adverse
effects, drug use is usually followed by several days of de-
pression, sadness, low energy, and a decreased ability to feel
emotions or pleasure.

Another major concern is the drug’s neurotoxicity. Early
effects include spasmodic jerking, involuntary jaw clench-
ing, and teeth grinding. Long-term or permanent changes
may result from damage to the nerve cells in the brain that
transmit serotonin. MDMA floods the brain with high
amounts of serotonin, which is important in emotion, mood,
and memory. As a result, repeated use of MDMA may lead
towards mood swings, irritability, and depression. In some
people, these effects may persist even after the drug is no
longer being used.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
ment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
ment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
tment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
tment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
tment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,
hallucinations, delusions, depersonalization, pupil dilation,
elevated body temperature, and elevated blood pressure.

**LSD** (lysergic acid diethylamide) is a synthetic derivative
of lysergic acid, a compound in ergot and some varieties of
morning glory seeds. It is very potent, and small doses can

**Marijuana Dependence**

Tolerance and psychological dependence do not usually de-
velop with occasional use but may occur with chronic use;
physical dependence rarely occurs. There is no specific treat-
tment other than abstinence.

**Hallucinogens**

Hallucinogenic drugs include a variety of substances that
cause mood changes, anxiety, distorted sensory perceptions,

<table>
<thead>
<tr>
<th>BOX 15-4</th>
<th>EFFECTS OF MARIJUANA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Nervous System Effects</strong></td>
<td>Impaired memory; perceptual and sensory distortions; disturbances in time perception; mood alteration; restlessness; depersonalization; panic reactions; paranoid ideation; impaired performance on cognitive, perceptual, and psychomotor tasks; drowsiness with high doses.</td>
</tr>
<tr>
<td><strong>Cardiovascular Effects</strong></td>
<td>Hypertension; bradycardia; peripheral vasoconstriction; orthostatic hypotension and tachycardia at high doses.</td>
</tr>
<tr>
<td><strong>Respiratory Effects</strong></td>
<td>Irritation and cellular changes in bronchial mucosa; bronchospasm; impaired gas exchange; aspergillosis in immunocompromised people; possibly increased risk of mouth, throat, and lung cancer (some known carcinogens are much higher in marijuana smoke than in tobacco smoke).</td>
</tr>
<tr>
<td><strong>Musculoskeletal Effects</strong></td>
<td>Ataxia; impaired coordination; increased reaction time.</td>
</tr>
<tr>
<td><strong>Miscellaneous Effects</strong></td>
<td>Constipation, decreased libido, thirst, decreased intraocular pressure.</td>
</tr>
</tbody>
</table>
to depression, insomnia, memory impairment, and low energy or passivity.

In addition to adverse effects of MDMA, users also need to be concerned about the actual product they are taking. There have been numerous reports of other drugs (e.g., LSD, methamphetamine, ketamine, or phencyclidine [PCP]) being sold as ecstasy. All of these drugs may have serious adverse effects as well.

MDMA is not thought to cause dependence or withdrawal syndromes. Emergency treatment of MDMA abuse usually involves decreasing the high body temperature, replacing fluids and electrolytes, and monitoring for cardiovascular complications.

Mescaline is an alkaloid of the peyote cactus. It is the least active of the commonly used psychotomimetic agents but produces effects similar to those of LSD. It is usually ingested in the form of a soluble powder or capsule.

Phencyclidine (PCP) produces excitement, delirium, hallucinations, and other profound psychological and physiologic effects, including a state of intoxication similar to that produced by alcohol; altered sensory perceptions; impaired thought processes; impaired motor skills; psychotic reactions; sedation and analgesia; nystagmus and diplopia; and pressor effects that can cause hypertensive crisis, cerebral hemorrhage, convulsions, coma, and death. Death from overdose also has occurred as a result of respiratory depression. Bizarre murders, suicides, and self-mutilations have been attributed to the schizophrenic reaction induced by PCP, especially in high doses. The drug also produces flashbacks.

Phencyclidine is usually distributed in liquid or crystal form and can be ingested, inhaled, or injected. It is usually sprayed or sprinkled on marijuana or herbs and smoked. Probably because it is cheap, easily synthesized, and readily available, PCP is often sold as LSD, mescaline, cocaine, or THC (the active ingredient in marijuana). It is also added to low-potency marijuana without the user’s knowledge. Consequently, the drug user may experience severe and unexpected reactions, including death.

Hallucinogen Dependence

Tolerance develops, but there is no apparent physical dependence or abstinence syndrome. Psychological dependence probably occurs but is usually not intense. Users may prefer one of these drugs, but they apparently do without or substitute another drug if the one they favor is unavailable. A major danger with these drugs is their ability to impair judgment and insight, which can lead to panic reactions in which users may try to injure themselves (e.g., by running into traffic).

Treatment of Hallucinogen Abuse

There is no specific treatment for hallucinogen dependence. Those who experience severe panic reactions may be kept in a safe, supportive environment until drug effects wear off or may be given a sedative-type drug.

Volatile Solvents (Inhalants)

These drugs include acetone, toluene, and gasoline. These solvents may be constituents of some types of glue, plastic cements, aerosol sprays, and other products. Some general inhalation anesthetics, such as nitrous oxide, have also been abused to the point of dependence. Volatile solvents are most often abused by preadolescents and adolescents who squeeze glue into a plastic bag, for example, and sniff the fumes. Suffocation sometimes occurs when the sniffer loses consciousness while the bag covers the face.

These substances produce symptoms comparable with those of acute alcohol intoxication, including initial mild euphoria followed by ataxia, confusion, and disorientation. Some substances in gasoline and toluene also may produce symptoms similar to those produced by the hallucinogens, including euphoria, hallucinations, recklessness, and loss of self-control. Large doses may cause convulsions, coma, and death. Substances containing gasoline, benzene, or carbon tetrachloride are especially likely to cause serious damage to the liver, kidneys, and bone marrow.

These substances produce psychological dependence, and some produce tolerance. There is some question about whether physical dependence occurs. If it does occur, it is considered less intense than the physical dependence associated with alcohol, barbiturates, and opiates.
clients may refuse to answer or give answers that contradict other assessment data. Denial of excessive drinking and of problems resulting from alcohol use is a prominent characteristic of alcoholism; underreporting the extent of drug use is common in other types of drug abuse as well. Useful information includes each specific drug, the amount, the frequency of administration, and the duration of administration. If answers to general questions reveal problem areas, such as long-term use of alcohol or psychotropic drugs, more specific questions can be formulated to assess the scope and depth of the problem. It may be especially difficult to obtain needed information about illegal “street drugs,” most of which have numerous, frequently changed names. For nurses who often encounter substance abusers, efforts to keep up with drug names and terminology may be helpful.

- Interview the client regarding alcohol and other drug use to help determine immediate and long-term nursing care needs. For example, information may be obtained that would indicate the likelihood of a withdrawal reaction, the risk of increased or decreased effects of a variety of drugs, and the client’s susceptibility to drug abuse. People who abuse one drug are likely to abuse others, and abuse of multiple drugs is a more common pattern than abuse of a single drug. These and other factors aid effective planning of nursing care.

- Assess behavior that may indicate drug abuse, such as alcohol on the breath, altered speech patterns, staggering gait, hyperactivity or hypovigilance, and other signs of excessive central nervous system (CNS) depression or stimulation. Impairments in work performance and in interpersonal relationships also may be behavioral clues.

- Assess for disorders that may be caused by substance abuse. These disorders may include infections, liver disease, accidental injuries, and psychiatric problems of anxiety or depression. These disorders may be caused by other factors, of course, and are nonspecific.

- Check laboratory reports, when available, for abnormal liver function test results, indications of anemia, abnormal white blood cell counts, abnormal electrolytes (hypocalcemia, hypomagnesemia, and acidosis are common in alcoholics), and alcohol and drug levels in the blood.

**Nursing Diagnoses**

- Ineffective Coping related to reliance on alcohol or other drugs
- Risk for Injury: Adverse effects of abused drug(s)
- Disturbed Thought Processes related to use of psychoactive drugs
- Risk for Other- or Self-Directed Violence related to disturbed thought processes, impaired judgment, and impulsive behavior
- Imbalanced Nutrition: Less Than Body Requirements related to drug effects and drug-seeking behavior
- Dysfunctional Family Processes: Alcoholism
- Risk for Injury: Infection, hepatitis, AIDS related to use of contaminated needles and syringes for IV drugs

**Planning/Goals**

- Safety will be maintained for clients impaired by alcohol and drug abuse.
- Information will be provided regarding drug effects and treatment resources.
- The client’s efforts toward stopping drug usage will be recognized and reinforced.

**Interventions**

- Administer prescribed drugs correctly during acute intoxication or withdrawal.
- Decrease environmental stimuli for the person undergoing drug withdrawal.
- Record vital signs; cardiovascular, respiratory, and neurologic functions; mental status; and behavior at regular intervals.
- Support use of resources for stopping drug abuse (psychotherapy, treatment programs).
- Request patient referrals to psychiatric/mental health physicians, nurse clinical specialists, or self-help programs when indicated.
- Use therapeutic communication skills to discuss alcohol or other drug-related health problems, health-related benefits of stopping substance use or abuse, and available services or treatment options.
- Teach nondrug techniques for coping with stress and anxiety.
- Provide positive reinforcement for efforts toward quitting substance abuse.
- Inform smokers with young children in the home that cigarette smoke can precipitate or aggravate asthma and upper respiratory disorders in children.
- Inform smokers with nonsmoking spouses or other members of the household that “second-hand” smoke can increase the risks of cancer and lung disease in the nonsmokers as well as the smoker.
- For smokers who are concerned about weight gain if they quit smoking, emphasize that the health benefits of quitting far outweigh the disadvantages of gaining a few pounds, and discuss ways to control weight without smoking.

**Evaluation**

- Observe for improved behavior (eg, less impulsiveness, improved judgment and thought processes, commits no injury to self or others).
- Observe for use or avoidance of nonprescribed drugs while hospitalized.
- Interview to determine the client’s insight into personal problems stemming from drug abuse.
- Verify enrollment in a treatment program.
- Observe for appropriate use of drugs to decrease abuse of other drugs.
CHAPTER 15 SUBSTANCE ABUSE DISORDERS

PRINCIPLES OF THERAPY

Prevention of Alcohol and Other Drug Abuse

Use measures to prevent substance abuse. Although there are difficulties in trying to prevent conditions for which causes are not known, some of the following community-wide and individual measures may be helpful:

1. Decrease the supply or availability of commonly abused drugs. Most efforts at prevention have tried to reduce the supply of drugs. For example, laws designate certain drugs as illegal and provide penalties for possession or use of these drugs. Other laws regulate circumstances in which legal drugs, such as opioid analgesics and barbiturates, may be used. Also, laws regulate the sale of alcoholic beverages.

2. Decrease the demand for drugs. Because this involves changing attitudes, it is very difficult but more effective in the long run. Many current attitudes seem to promote drug use, misuse, and abuse, including:
   a. The belief that a drug is available for every mental and physical discomfort and should be taken in preference to tolerating even minor discomfort. Consequently, society has a permissive attitude toward taking drugs, and this attitude is probably perpetuated by physicians who are quick to prescribe drugs and nurses who are quick to administer them. Of course, there are many appropriate uses of drugs, and clients certainly should not be denied their benefits. The difficulties emerge when there is excessive reliance on drugs as chemical solutions to problems that are not amenable to chemical solutions.
   b. The widespread acceptance and use of alcohol. In some groups, every social occasion is accompanied by alcoholic beverages of some kind.
   c. The apparently prevalent view that drug abuse refers only to the use of illegal drugs and that using alcohol or prescription drugs, however inappropriately, does not constitute drug abuse.
   d. The acceptance and use of illegal drugs in certain subgroups of the population. This is especially prevalent in high school and college students.

3. Each person must take personal responsibility for drinking alcoholic beverages and taking mind-altering drugs. Initially, conscious, voluntary choices are made to drink or not to drink, to take a drug or not to take it. This period varies somewhat, but drug dependence develops in most instances only after prolonged use. When mind-altering drugs are prescribed for a legitimate reason, the client must use them in prescribed doses and preferably for a short time.

4. Physicians can help prevent drug abuse by prescribing drugs appropriately, prescribing mind-altering drugs in limited amounts and for limited periods, using nondrug measures when they are likely to be effective, educating clients about the drugs prescribed for them, participating in drug education programs, and recognizing, as early as possible, clients who are abusing or are likely to abuse drugs.

5. Nurses can help prevent drug abuse by administering drugs appropriately, using nondrug measures when possible, teaching clients about drugs prescribed for them, and participating in drug education programs. Some resources for information and educational materials include the following:
   - National Institute on Drug Abuse
     6001 Executive Blvd
     Bethesda, MD 20892-9561
     Phone: (301) 443-1124
     www.nida.nih.gov
   - National Clearinghouse for Alcohol and Drug Abuse
     Information (NCADI)
     Center for Substance Abuse Prevention
     5600 Fishers Lane
     Rockwall II
     Rockville, MD 20857
     Phone: (301) 443-0365
     E-Mail: nnadal@samhsa.gov
     www.health.org

6. Parents can help prevent drug abuse in their children by minimizing their own use of drugs and by avoiding heavy cigarette smoking. Children are more likely to use illegal drugs if their parents have a generally permissive attitude about drug taking, if either parent takes mind-altering drugs regularly, and if either parent is a heavy cigarette smoker.

7. Pregnant women should avoid alcohol, nicotine, and other drugs of abuse because of potentially harmful effects on the fetus.

Treatment Measures for Substance Abuse

Treatment measures for alcohol and other drug abuse are not very successful. Even people who have been institutionalized...
and achieved a drug-free state for prolonged periods are apt to resume their drug-taking behavior when released from the institution. So far, voluntary self-help groups, such as Alcoholics Anonymous and Narcotics Anonymous, have been more successful than health professionals in dealing with drug abuse. Health professionals are more likely to be involved in acute situations, such as intoxication or overdose, withdrawal syndromes, or various medical-surgical conditions. As a general rule, treatment depends on the type, extent, and duration of drug-taking behavior and the particular situation for which treatment is needed. Some general management principles include the following:

1. Psychological rehabilitation efforts should be part of any treatment program for a drug-dependent person. Several approaches may be useful, including psychotherapy, voluntary groups, and other types of emotional support and counseling.

2. Drug therapy is limited in treating drug dependence for several reasons. First, specific antidotes are available only for benzodiazepines (flumazenil) and opioid narcotics (naloxone). Second, there is a high risk of substituting one abused drug for another. Third, there are significant drawbacks to giving CNS stimulants to reverse effects of CNS depressants, and vice versa. Fourth, there is often inadequate information about the types and amounts of drugs taken.

3. Despite these drawbacks, however, there are some clinical indications for drug therapy, including treatment of overdose or withdrawal syndromes. Even when drug therapy is indicated, there are few guidelines for optimal use. Doses, for example, must often be estimated initially and then titrated accordingly to response.

4. General care of clients with drug overdose is primarily symptomatic and supportive. The aim of treatment is usually to support vital functions, such as respiration and circulation, until the drug is metabolized and eliminated from the body. For example, respiratory depression from an overdose of a CNS depressant drug may be treated by inserting an artificial airway and mechanical ventilation. Removal of some drugs can be hastened by hemodialysis.

5. Treatment of substance abuse may be complicated by the presence of other disorders. For example, depression is common and may require antidepressant drug therapy.

**Review and Application Exercises**

1. Why is it important to assess each client in relation to alcohol and other substance abuse?
2. What are signs and symptoms of overdose with alcohol, benzodiazepine antianxiety or hypnotic agents, cocaine, and opiates?
3. What are general interventions for treatment of drug overdoses?
4. What are specific antidotes for opiate and benzodiazepine overdoses, and how are they administered?
5. Which commonly abused drugs may produce life-threatening withdrawal reactions if stopped abruptly?
6. How can severe withdrawal syndromes be prevented, minimized, or safely managed?
7. What are the advantages of treating substance abuse disorders in centers established for that purpose?

**SELECTED REFERENCES**


Critical Thinking Scenario
Mrs. Williams comes to your office with her 6-year-old son. She complains that he is a very active child who always seems to be getting into mischief. She likes a clean, orderly house and he likes to make messes. He seems to be doing OK in school, although she would like to see his grades improve. She was talking to a neighbor, who encouraged her to talk with a physician about prescribing Ritalin, because her son may have attention deficit-hyperactivity disorder (ADHD).

Reflect on:
- What advice you would have for Mrs. Williams.
- Possible therapeutic effects if the boy has ADHD.
- Possible negative effects if the boy does not have ADHD.

Central Nervous System Stimulants

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe general characteristics of central nervous system (CNS) stimulant drugs.
2. Discuss reasons for decreased use of amines for therapeutic purposes.
3. Discuss the rationale for treating attention deficit-hyperactivity disorder with CNS stimulant drugs.
4. Identify effects and sources of caffeine.
5. Identify nursing interventions to prevent, recognize, and treat stimulant overdose.

Narcolepsy
Narcolepsy is a sleep disorder characterized by daytime “sleep attacks” in which the victim goes to sleep at any place or any time. Signs and symptoms also include excessive daytime drowsiness, fatigue, muscle weakness and hallucinations at onset of sleep, and disturbances of nighttime sleep patterns. The hazards of drowsiness during normal waking hours and suddenly going to sleep in unsafe environments restrict activities of daily living.

Narcolepsy affects men and women equally and usually starts during teenage or young adult years. Its cause is unknown; sleep studies are required for an accurate diagnosis. In addition to drug therapy, prevention of sleep deprivation, regular sleeping and waking times, avoiding shift work, and short naps may be helpful in reducing daytime sleepiness.

Attention Deficit-Hyperactivity Disorder
ADHD is reportedly the most common psychiatric or neurobehavioral disorder in children. It occurs before 7 years of age and is characterized by persistent hyperactivity, a short attention span, difficulty completing assigned tasks or schoolwork, restlessness, and impulsiveness. Such behaviors make it difficult for the child to get along with others (eg, family members, peer groups, teachers) and to function in situations requiring more controlled behavior (eg, classrooms).

Formerly thought to disappear with adolescence, ADHD is now thought to continue into adolescence and adulthood in one third to two thirds of clients. In adolescents and adults, impulsiveness and inattention continue but hyperactivity is
not a prominent feature. A major criterion for diagnosing later ADHD is a previous diagnosis of childhood ADHD. Some studies indicate that children with ADHD are more likely to have learning disabilities, mood disorders, and substance abuse disorders as adolescents and adults as well as continuing difficulties in structured settings such as school or work.

**TYPES OF STIMULANTS**

Most CNS stimulants act by facilitating initiation and transmission of nerve impulses that excite other cells. The drugs are somewhat selective in their actions at lower doses but tend to involve the entire CNS at higher doses. The major groups are amphetamines and related drugs, analeptics, and xanthines.

**Amphetamines** increase the amounts of norepinephrine, dopamine, and possibly serotonin in the brain, thereby producing mood elevation or euphoria, increasing mental alertness and capacity for work, decreasing fatigue and drowsiness, and prolonging wakefulness. Larger doses, however, produce signs of excessive CNS stimulation, such as restlessness, hyperactivity, agitation, nervousness, difficulty concentrating on a task, and confusion. Overdoses can produce convulsions and psychotic behavior. Amphetamines also stimulate the sympathetic nervous system, resulting in increased heart rate and blood pressure, pupil dilation (mydriasis), slowed gastrointestinal motility, and other symptoms. In ADHD, the drugs reduce behavioral symptoms and may improve cognitive performance.

Amphetamines are Schedule II drugs under the Controlled Substances Act and have a high potential for drug abuse and dependence. Prescriptions for them are nonrefillable. These drugs are widely sold on the street and commonly abused (see Chap. 15).

**Amphetamine-related drugs** (methylphenidate and dexamphetamine) have essentially the same effects as the amphetamines and are also Schedule II drugs.

**Analeptics** are infrequently used (see doxapram and modafinil, below).

**Xanthines** stimulate the cerebral cortex, increasing mental alertness and decreasing drowsiness and fatigue. Other effects include myocardial stimulation with increased cardiac output and heart rate, diuresis, and increased secretion of pepsin and hydrochloric acid. Large doses can impair mental and physical functions by producing restlessness, nervousness, anxiety, agitation, insomnia, cardiac dysrhythmias, and gastritis.

**Indications for Use**

Amphetamines and methylphenidate are used in the treatment of narcolepsy and ADHD. Dexmethylphenidate is indicated only for ADHD. One analeptic is used occasionally to treat respiratory depression; the other one is approved only for treatment of narcolepsy. Caffeine (a xanthine) is an ingredient in nonprescription analgesics and stimulants that promote wakefulness (eg, No-Doz). A combination of caffeine and sodium benzoate is occasionally used as a respiratory stimulant in neonates.

**Contraindications to Use**

Central nervous system stimulants cause cardiac stimulation and thus are contraindicated in clients with cardiovascular disorders (eg, angina, dysrhythmias, hypertension) that are likely to be aggravated by the drugs. They also are contraindicated in clients with anxiety or agitation, glaucoma, or hyperthyroidism. They are usually contraindicated in clients with a history of drug abuse.

**INDIVIDUAL CENTRAL NERVOUS SYSTEM STIMULANTS**

Individual drugs are described below; dosages are listed in Drugs at a Glance: Central Nervous System Stimulants.

**Amphetamines and Related Drugs**

**Amphetamine**, dextroamphetamine (Dexedrine), and methamphetamine (Desoxyn) are closely related drugs that share characteristics of the amphetamines as a group. They are more important as drugs of abuse than as therapeutic agents.

**Methylphenidate** (Ritalin) is chemically related to amphetamines and produces similar actions and adverse effects. It is well absorbed with oral administration. In children, peak plasma levels occur in about 2 hours with immediate-release tablets and about 5 hours with extended-release tablets. Half-life is 1 to 3 hours, but pharmacologic effects last 4 to 6 hours. Most of a dose is metabolized in the liver and excreted in urine.

**Dexmethylphenidate** (Focalin) is very similar to methylphenidate and the amphetamines. It is well absorbed with oral administration and reaches peak plasma levels in 1 to 1.5 hours. It is metabolized in the liver and excreted in urine.

**Analeptics**

**Doxapram** (Dopram) is occasionally used by anesthesiologists and pulmonary specialists as a respiratory stimulant. Although it increases tidal volume and respiratory rate, it also increases oxygen consumption and carbon dioxide production. Limitations include a short duration of action (5 to 10 minutes after a single intravenous [IV] dose) and therapeutic dosages near or overlapping those that produce convulsions. Endotracheal intubation and mechanical ventilation are safer and more effective in relieving respiratory depression from depressant drugs or other causes.

**Modafinil** (Provigil) is a newer drug for treatment of narcolepsy. Its ability to promote wakefulness is similar to that of amphetamines and methylphenidate, but its mechanism of action is unknown. Like other CNS stimulants, it also has
psychoactive and euphoric effects that alter mood, perception, and thinking. It is a Schedule IV drug. It is rapidly absorbed (food may delay absorption), reaches peak plasma levels in 2 to 4 hours, is 60% bound to plasma proteins, and is 90% metabolized by the liver to metabolites that are then excreted in urine. Steady-state concentrations are reached in 2 to 4 days and half-life with chronic use is about 15 hours.

Modafinil is not recommended for patients with a history of left ventricular hypertrophy or ischemic changes on electrocardiograms. Adverse effects include anxiety, chest pain, dizziness, dyspnea, dysrhythmias, headache, nausea, nervousness, and palpitations. Interactions with other drugs include decreased effects of cyclosporine and oral contraceptives and increased effects of phenytoin, tricyclic antidepressants, and warfarin. Dosage should be reduced by 50% with severe hepatic impairment; effects of severe renal impairment are unknown.

### Xanthines

**Caffeine** has numerous pharmacologic actions, including CNS stimulation, diuresis, hyperglycemia, cardiac stimulation, coronary and peripheral vasodilation, cerebrovascular vasconstriction, skeletal muscle stimulation, increased secretion of gastric acid and pepsin, and bronchodilation from relaxation of smooth muscle. In low to moderate amounts, caffeine increases alertness and capacity for work and decreases fatigue. Large amounts cause excessive CNS stimulation with anxiety, agitation, diarrhea, insomnia, irritability, nausea, nervousness,
premature ventricular contractions, hyperactivity and restlessness, tachycardia, tremors, and vomiting. Toxic amounts may cause delirium and seizures. With large amounts or chronic use, caffeine has been implicated as a causative or aggravating factor in cardiovascular disease (hypertension, dysrhythmias), gastrointestinal disorders (esophageal reflux, peptic ulcers), reproductive disorders, osteoporosis (may increase loss of calcium in urine), carcinogenicity, psychiatric disturbances, and drug abuse liability. Caffeine produces tolerance to its stimulating effects, and psychological dependence or habituation occurs.

Pharmaceutical preparations include an oral preparation and a solution for injection. Caffeine is usually prescribed as caffeine citrate for oral use and caffeine and sodium benzoate for parenteral use because these forms are more soluble than caffeine itself. It is an ingredient in some nonprescription analgesic preparations and may increase analgesia. It is combined with an ergot alkaloid to treat migraine headaches (eg, Cafergot) and is the active ingredient in nonprescription stimulant (antisleep) preparations. A combination of caffeine and sodium benzoate is used as a respiratory stimulant in neonatal apnea unresponsive to other therapies.

Caffeine is a frequently consumed CNS stimulant worldwide, and most is consumed from dietary sources (eg, coffee, tea, and cola drinks). The caffeine content of coffee and tea beverages is determined by the particular coffee bean or tea leaf and the method of preparation. Because of the widespread ingestion of caffeine-containing beverages and the wide availability of over-the-counter products that contain caffeine, toxicity may result from concomitant consumption of caffeine from several sources. Some authorities recommend that normal, healthy, nonpregnant adults consume no more than 250 mg of caffeine daily. Sources and amounts of caffeine are summarized in Table 16–1.

**Theophylline** preparations are xanthines used in the treatment of respiratory disorders, such as asthma and bronchitis. In these conditions, the desired effect is bronchodilation and improvement of breathing; CNS stimulation is then an adverse effect (see Chap. 47).

### Herbal and Dietary Supplements

**Guarana** is made from the seeds of a South American shrub. The main active ingredient is caffeine, which is present in greater amounts than in coffee beans or dried tea leaves. Guarana is widely used as a source of caffeine by soft drink manufacturers. It is also used as a flavoring agent and an ingredient in herbal stimulant and weight-loss products, usually in combination with ephedra (ma huang), energy drinks, vit-
amin supplements, candies, and chewing gums. The product, which may also contain theophylline and theobromine, is also available in teas, extracts, elixirs, capsules, and tablets of various strengths. In general, the caffeine content of a guarana product is unknown and guarana may not be listed as an ingredient. As a result, consumers may not know how much caffeine they are ingesting in products containing guarana.

As with caffeine from other sources, guarana may cause excessive nervousness and insomnia. It is contraindicated during pregnancy and lactation and should be used cautiously, if at all, in people who are sensitive to the effects of caffeine or who have cardiovascular disease. Overall, the use of guarana as a CNS stimulant and weight-loss aid is not recommended and should be discouraged.

PRINCIPLES OF THERAPY

Appropriate Use

Stimulant drugs are often misused and abused by people who want to combat fatigue and delay sleep, such as long-distance drivers, students, and athletes. Use of amphetamines or other stimulants for this purpose is not justified. These drugs are dangerous for drivers and those involved in similar activities, and they have no legitimate use in athletics.

When a CNS stimulant is prescribed, giving the smallest effective dose and limiting the number of doses obtained with one prescription decrease the likelihood of drug dependence or diversion (drug use by people for whom the drug is not prescribed).

Toxicity of CNS Stimulants: Recognition and Management

Overdoses may occur with acute or chronic ingestion of large amounts of a single stimulant, combinations of stimulants, or concurrent ingestion of a stimulant and another drug that slows the metabolism of the stimulant. Signs of toxicity may include severe agitation, cardiac dysrhythmias, combativeness, confusion, delirium, hallucinations, high body temperature, hyperactivity, hypertension, insomnia, irritability, nervousness, panic states, restlessness, tremors, seizures, coma, circulatory collapse, and death.

Treatment is largely symptomatic and supportive. In general, place the client in a cool room, monitor cardiac function and temperature, and minimize external stimulation. Gastric lavage may be helpful if done within 4 hours of ingestion of the stimulant. After emptying the stomach, activated charcoal (1 g/kg) may be given. With amphetamines, urinary acidification, IV fluids, and IV diuretics (eg, furosemide or mannitol) hasten drug excretion. IV diazepam or lorazepam can be given to calm agitation, hyperactivity, or seizures; haloperidol may be given for symptoms of psychosis. If cardiovascular collapse occurs, fluid replacement and vasopressors may be necessary.
be used. If a long-acting form of the stimulant drug has been ingested, saline cathartics may be useful to remove undissolved drug granules.

With caffeine, ingestion of 15 to 30 mg/kg (1 to 2 g for a person of 70 kg or 150 lbs) may cause myocardial irritability, muscle tremors or spasms, and vomiting. Oral doses of 5 g or more may cause death. Signs of toxicity are correlated with serum levels of caffeine. Several cups of coffee may produce levels of 5 to 10 mcg/mL and symptoms of agitation and tremors. Cardiac dysrhythmias and seizures occur at higher levels. Additional manifestations of caffeine toxicity include opisthotonus, decerebrate posturing, muscle hypertonicity, rhabdomyolysis with subsequent renal failure, pulmonary edema, hyperglycemia, hypokalemia, leukocytosis, ketosis, and metabolic acidosis.

Treatment is symptomatic and supportive, with gastric lavage and activated charcoal if indicated. IV diazepam or lorazepam may be used to control seizures. Hemodialysis is indicated if the serum caffeine concentration is > 100 mcg/mL or if life-threatening seizures or cardiac dysrhythmias occur.

**Effects of CNS Stimulants on Other Drugs**

**Caffeine** may increase adverse effects of clozapine and theophylline by decreasing their metabolism and increasing their blood levels. It may increase effects of aspirin by increasing aspirin absorption. It may decrease effects of lithium by increasing lithium clearance. **Dexmethylphenidate** and methylphenidate may increase effects of phenytoin and antidepressants (selective serotonin reuptake inhibitors and tricyclics), and they may decrease effects of antihypertensive drugs. **Modafinil** may increase effects of clomipramine, phenytoin, tricyclic antidepressants, and warfarin. It may decrease effects of cyclosporine and oral contraceptives.

**Use in Children**

Central nervous system stimulants are not recommended for ADHD in children younger than 6 years of age. When used, dosage should be carefully titrated and monitored to avoid excessive CNS stimulation, anorexia, and insomnia. Suppression of weight and height have been reported, and growth should be monitored at regular intervals during drug therapy. In children with psychosis or Tourette syndrome, CNS stimulants may exacerbate symptoms.

In ADHD, careful documentation of baseline symptoms over approximately 1 month is necessary to establish the diagnosis and evaluate outcomes of treatment. This can be done by videotapes of behavior; observations and ratings by clinicians familiar with ADHD; and by interviewing the child, parents, or caretakers. Some authorities believe that this condition is overdiagnosed and that stimulant drugs are prescribed unnecessarily. **Guidelines for treatment of ADHD** include the following:

1. Counseling and psychotherapy (eg, parental counseling or family therapy) are recommended along with drug therapy for effective treatment and realistic expectations of outcomes.
2. Young children may not require treatment until starting school. Then, the goal of drug therapy is to control symptoms, facilitate learning, and promote social development.

3. Drug therapy is indicated when symptoms are moderate to severe; are present for several months; and interfere in social, academic, or behavioral functioning. When possible, drug therapy should be omitted or reduced in dosage when children are not in school.

4. Methylphenidate is the most commonly used drug. It is usually given daily, including weekends, for the first 3 to 4 weeks to allow caregivers to assess beneficial and adverse effects. Desirable effects may include improvement in behavior, attention span, and quality and quantity of school work, and better relationships with other children and family members. Adverse effects include appetite suppression and weight loss, which may be worse during the first 6 months of therapy.

5. Drug holidays (stopping drug administration) are controversial. Some clinicians say they are indicated only if no significant problems occur during the drug-free period and are not recommended for most children. Other clinicians believe they are desirable when children are not in school (eg, summer) and necessary periodically to re-evaluate the child’s condition. Dosage adjustments are often needed at least annually as the child grows and hepatic metabolism slows. In addition, the drug-free periods decrease weight loss and growth suppression.

### Use in Older Adults

CNS stimulants should be used cautiously in older adults. As with most other drugs, slowed metabolism and excretion increase the risks of accumulation and toxicity. Older adults are likely to experience anxiety, nervousness, insomnia, and mental confusion from excessive CNS stimulation. In addition, older adults often have cardiovascular disorders (eg, angina, dysrhythmias, hypertension) that may be aggravated by the cardiac-stimulating effects of the drugs, including dietary caffeine. In general, reduced doses are safer in older adults.

### NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give amphetamines and methylphenidate early in the day, at least 6 hours before bedtime.</td>
<td>To avoid interference with sleep. If insomnia occurs, give the last dose of the day at an earlier time or decrease the dose.</td>
</tr>
<tr>
<td>b. For children with attention deficit-hyperactivity disorder (ADHD), give amphetamines and methylphenidate about 30 minutes before meals.</td>
<td>To minimize the drugs’ appetite-suppressing effects and risks of interference with nutrition and growth.</td>
</tr>
<tr>
<td>c. Do not crush or open and instruct clients not to bite or chew long-acting forms of methylphenidate (Concerta, Metadate CD, Metadate ER, Ritalin SR).</td>
<td>Breaking the tablets or capsules destroys the extended-release feature and allows the drug to be absorbed faster. An overdose may result.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td>Therapeutic effects depend on the reason for use.</td>
</tr>
<tr>
<td>a. Fewer “sleep attacks” with narcolepsy</td>
<td></td>
</tr>
<tr>
<td>b. Improved behavior and performance of cognitive and psychomotor tasks with ADHD</td>
<td></td>
</tr>
<tr>
<td>c. Increased mental alertness and decreased fatigue</td>
<td></td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td>Adverse effects may occur with acute or chronic ingestion of any CNS stimulant drugs.</td>
</tr>
<tr>
<td>a. Excessive central nervous system (CNS) stimulation—hyperactivity, nervousness, insomnia, anxiety, tremors, convulsions, psychotic behavior</td>
<td>These reactions are more likely to occur with large doses.</td>
</tr>
<tr>
<td>b. Cardiovascular effects—tachycardia, other dysrhythmias, hypertension</td>
<td></td>
</tr>
<tr>
<td>c. Gastrointestinal effects—anorexia, gastritis, weight loss, nausea, diarrhea, constipation</td>
<td>These reactions are caused by the sympathomimetic effects of the drugs.</td>
</tr>
</tbody>
</table>

(continued)
### SECTION 2 DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM

#### NURSING ACTIONS

<table>
<thead>
<tr>
<th>4. Observe for drug interactions</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Drugs that increase the effects of CNS stimulants:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Other CNS stimulant drugs</td>
<td>Such combinations are potentially dangerous and should be avoided or minimized.</td>
</tr>
<tr>
<td>(2) Albuterol and related antiasthmatic drugs, pseudoephedrine</td>
<td>These drugs cause CNS and cardiac stimulating effects.</td>
</tr>
<tr>
<td><strong>b. Drugs that decrease effects of CNS stimulants:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) CNS depressants</td>
<td>IV diazepam or lorazepam may be used to decrease agitation, hyperactivity, and seizures occurring with stimulant overdose.</td>
</tr>
<tr>
<td><strong>c. Drugs that increase effects of amphetamines:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Alkalinizing agents (eg, antacids)</td>
<td>Drugs that increase the alkalinity of the gastrointestinal tract increase intestinal absorption of amphetamines, and urinary alkalinizers decrease urinary excretion. Increased absorption and decreased excretion serve to potentiate drug effects.</td>
</tr>
<tr>
<td>(2) Monoamine oxidase (MAO) inhibitors</td>
<td>Potentiate amphetamines by slowing drug metabolism. These drugs thereby increase the risks of headache, subarachnoid hemorrhage, and other signs of a hypertensive crisis. The combination may cause death and should be avoided.</td>
</tr>
<tr>
<td><strong>d. Drugs that decrease effects of amphetamines:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Acidifying agents</td>
<td>Urinary acidifying agents (eg, ammonium chloride) increase urinary excretion and lower blood levels of amphetamines. Decreased absorption and increased excretion serve to decrease drug effects.</td>
</tr>
<tr>
<td>(2) Antipsychotic agents</td>
<td>Decrease or antagonize the excessive CNS stimulation produced by amphetamines. Chlorpromazine (Thorazine) or haloperidol (Haldol) is sometimes used in treating amphetamine overdose.</td>
</tr>
<tr>
<td><strong>e. Drugs that increase effects of modafinil:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Itraconazole, ketoconazole</td>
<td>These drugs inhibit cytochrome P450 3A4 enzymes that partly metabolize modafinil.</td>
</tr>
<tr>
<td><strong>f. Drugs that decrease effects of modafinil:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Carbamazepine, phenytoin, rifampin</td>
<td>These drugs induce cytochrome P450 3A4 enzymes that partly metabolize modafinil.</td>
</tr>
<tr>
<td><strong>g. Drugs that increase effects of caffeine:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Enoxacin, fluvoxamine, mexilene, theophylline</td>
<td>These drugs inhibit the cytochrome P450 1A2 enzymes that participate in the metabolism of caffeine. Decreased metabolism may increase adverse effects.</td>
</tr>
<tr>
<td>(2) Cimetidine, oral contraceptives</td>
<td>May impair caffeine metabolism.</td>
</tr>
<tr>
<td><strong>h. Drugs that decrease effects of caffeine:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Carbamazepine, phenytoin, rifampin</td>
<td>These drugs induce drug-metabolizing enzymes, thereby decreasing blood levels and increasing clearance of caffeine.</td>
</tr>
</tbody>
</table>
Review and Application Exercises

1. What kinds of behaviors may indicate narcolepsy?
2. What kinds of behaviors may indicate ADHD?
3. What is the rationale for treating narcolepsy and ADHD with CNS stimulants?
4. What are the major adverse effects of CNS stimulants, and how may they be minimized?
5. Do you think children taking CNS stimulants for ADHD should have drug-free periods? Justify your answer.

SELECTED REFERENCES


Drugs Affecting the Autonomic Nervous System
Physiology of the Autonomic Nervous System

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify physiologic effects of the sympathetic nervous system.
2. Differentiate subtypes and functions of sympathetic nervous system receptors.
3. Identify physiologic effects of the parasympathetic nervous system.
4. Differentiate subtypes and functions of parasympathetic nervous system receptors.
5. Describe signal transduction and the intracellular events that occur when receptors of the autonomic nervous system are stimulated.
6. State names and general characteristics of drugs affecting the autonomic nervous system.

AUTONOMIC NERVOUS SYSTEM

The nervous system is composed of two main divisions, the central nervous system (CNS) and the peripheral nervous system (Fig. 17–1). The central nervous system includes the brain and spinal cord. The peripheral nervous system includes all the neurons and ganglia found outside the CNS. The peripheral nervous system is subdivided into the afferent neurons and efferent neurons. Afferent neurons carry sensory input from the periphery to the CNS and modify motor output through the action of reflex arcs. The efferent neurons carry motor signals from the CNS to the peripheral areas of the body. The efferent portion of the peripheral nervous system is further subdivided into the somatic and autonomic nervous system (ANS). The somatic nervous system innervates skeletal muscles and controls voluntary movement. The ANS, without conscious thought or effort, controls involuntary activities in the visceral organs of the body such as the heart, smooth muscle, and secretory glands. These functions can be broadly described as activities designed to maintain a constant internal environment (homeostasis), to respond to stress or emergencies, and to repair body tissues. The ANS is regulated by centers in the CNS, including the hypothalamus, brain stem, and spinal cord. The autonomic nervous system is subdivided into the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).

Nerve impulses are generated and transmitted to body tissues in the sympathetic and parasympathetic nervous systems as they are in the CNS (see Chap. 5). Autonomic nerve impulses are carried through preganglionic fibers, ganglia, and postganglionic fibers. Preganglionic impulses travel from the CNS along the preganglionic nerves to ganglia. Ganglia are composed of the terminal end of the preganglionic nerve and clusters of postganglionic cell bodies. A neurotransmitter is released from the terminal end of the preganglionic nerve allowing the nervous impulse to bridge the synapse between the preganglionic and postganglionic nerve. The postganglionic impulses travel from ganglia to effector tissues of the heart, blood vessels, glands, other visceral organs, and smooth muscle (Fig. 17–2).

The main neurotransmitters of the ANS are acetylcholine and norepinephrine (see Chap. 5). Acetylcholine is synthesized from acetylcoenzyme A and choline and released at preganglionic fibers of both the SNS and PNS and at postganglionic fibers of the PNS. Acetylcholine is also released from postganglionic sympathetic neurons that innervate the sweat glands and from motor neurons of the somatic nervous system that innervate the skeletal muscles. The nerve fibers that secrete acetylcholine are called cholinergic fibers. Norepinephrine is synthesized from the amino acid tyrosine by a series of enzymatic conversions that also produce dopamine and epinephrine (ie, tyrosine → dopamine → norepinephrine → epinephrine). Norepinephrine is the end product, except in the adrenal medulla, where most of the norepinephrine is converted to epinephrine. Norepinephrine is released at most postganglionic fibers of the
Figure 17-1  Divisions of the human nervous system.

Figure 17-2  Organization of the autonomic and somatic nervous systems.
reaction. Specific body responses include:

whether real or imaginary, is often called the vigorous muscle activity in response to a perceived threat, emotions, and temperature extremes. Increased capacity for

The SNS is stimulated by physical or emotional stress, such as strenuous exercise or work, pain, hemorrhage, intense emotions, and temperature extremes. Increased capacity for vigorous muscle activity in response to a perceived threat, whether real or imaginary, is often called the fight-or-flight reaction. Specific body responses include:

1. Increased arterial blood pressure and cardiac output
2. Increased blood flow to the brain, heart, and skeletal muscles; decreased blood flow to viscera, skin, and other organs not needed for fight-or-flight
3. Increased rate of cellular metabolism—increased oxygen consumption and carbon dioxide production
4. Increased breakdown of muscle glycogen for energy
5. Increased blood sugar
6. Increased mental activity and ability to think clearly
7. Increased muscle strength
8. Increased rate of blood coagulation
9. Increased rate and depth of respiration
10. Pupil dilation to aid vision

11. Increased sweating. (Note that acetylcholine is the neurotransmitter for this sympathetic response. This is a deviation from the normal postganglionic neurotransmitter, which is norepinephrine.)

These responses are protective mechanisms designed to help the person cope with the stress or get away from it. The intensity and duration of responses depend on the amounts of norepinephrine and epinephrine present. Norepinephrine is synthesized in adrenergic nerve endings and released into the synapse when adrenergic nerve endings are stimulated. It exerts intense but brief effects on presynaptic and postsynaptic adrenergic receptors. Most of the norepinephrine is taken up again by the nerve endings and reused as a neurotransmitter. This reuptake can be inhibited by cocaine and tricyclic antidepressant medications and is responsible for the activation of the sympathetic nervous system seen with these drugs. The remainder of the norepinephrine, which was not taken back into the nerve endings, diffuses into surrounding tissue fluids and blood, or it is metabolized by monoamine oxidase (MAO) or catechol-O-methyltransferase (COMT).

Norepinephrine also functions as a hormone, along with epinephrine. In response to adrenergic nerve stimulation, norepinephrine and epinephrine are secreted into the bloodstream by the adrenal medullae and transported to all body tissues. They are continually present in arterial blood in amounts that vary according to the degree of stress present and the ability of the adrenal medullae to respond to stimuli. The larger proportion of the circulating hormones (approximately 80%) is epinephrine. These catecholamines exert the same effects as those caused by direct stimulation of the SNS. However, the effects last longer because the hormones are removed from the blood more slowly. These hormones are metabolized mainly in the liver by the enzymes MAO and COMT.

Dopamine is also an adrenergic neurotransmitter and catecholamine. In the brain, dopamine is essential for normal function (see Chap. 5); in peripheral tissues, its main effects are on the heart and blood vessels of the renal system and viscera.

**Sympathetic Nervous System**

The SNS is stimulated by physical or emotional stress, such as strenuous exercise or work, pain, hemorrhage, intense emotions, and temperature extremes. Increased capacity for vigorous muscle activity in response to a perceived threat, whether real or imaginary, is often called the fight-or-flight reaction. Specific body responses include:

- Increased arterial blood pressure and cardiac output
- Increased blood flow to the brain, heart, and skeletal muscles; decreased blood flow to viscera, skin, and other organs not needed for fight-or-flight
- Increased rate of cellular metabolism—increased oxygen consumption and carbon dioxide production
- Increased breakdown of muscle glycogen for energy
- Increased blood sugar
- Increased mental activity and ability to think clearly
- Increased muscle strength
- Increased rate of blood coagulation
- Increased rate and depth of respiration
- Pupil dilation to aid vision

**Adrenergic Receptors**

When norepinephrine and epinephrine act on body cells that respond to sympathetic nerve or catecholamine stimulation, they interact with two distinct adrenergic receptors, alpha and beta. Norepinephrine acts mainly on alpha receptors; epinephrine acts on both alpha and beta receptors. These receptors have been further subdivided into alpha, alpha, beta, and beta receptors. A beta receptor has been identified, and animal studies suggest that drugs targeted to this receptor may augment heat production, produce lipolysis (thermogenesis), and increase energy expenditure. Several compounds are being tested to treat obesity, hyperglycemia, and the problem of insulin resistance in diabetes. There are no beta agonist compounds approved by the Food and Drug Administration for human use.

When dopamine acts on body cells that respond to adrenergic stimulation, it can activate alpha and beta receptors as well as dopaminergic receptors. Only dopamine can activate
Dopaminergic receptors. Dopamine receptors are located in the brain, in blood vessels of the kidneys and other viscera, and probably in presynaptic sympathetic nerve terminals. Activation (agonism) of these receptors may result in stimulation or inhibition of cellular function. Like alpha and beta receptors, dopamine receptors are divided into several subtypes (D₁ to D₅), and specific effects depend on which subtype of receptor is activated. Table 17–1 describes the location of adrenergic receptors in the body and the response that occurs when each receptor is stimulated.

The intracellular events (of signal transduction) after stimulation of adrenergic receptors are thought to include the following mechanisms:

- **Alpha₁ receptors:** The binding of adrenergic substances to receptor proteins in the cell membrane of smooth muscle cells is thought to open ion channels, allow calcium ions to move into the cell, and produce muscle contraction (e.g., vasoconstriction, gastrointestinal and bladder sphincter contraction).
- **Alpha₂ receptors:** In the brain, some of the norepinephrine released into the synaptic cleft between neurons returns to the nerve endings from which it was released and stimulates presynaptic alpha₂ receptors. This negative feedback causes less norepinephrine to be released by subsequent nerve impulses. The result is decreased sympathetic outflow and an antiadrenergic effect. The

---

**Figure 17–3** Signal transduction mechanism for an adrenergic beta receptor. Epinephrine (1), the “first messenger,” interacts with a beta receptor (2). This hormone-receptor complex activates a G protein, which reacts with a guanosine triphosphate (GTP) (3). The activated G protein then activates the enzyme adenyl cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), the “second messenger.” (5) cAMP activates enzymes, which bring about the biologic responses to epinephrine (6).
probable mechanism is that the calcium required for neurotransmitter release from storage vesicles is prevented from entering the presynaptic nerve cell. Also, cyclic adenosine monophosphate (cAMP) is decreased.

- **Beta_1, beta_2, and beta_3 receptors:** Activation of these receptors stimulates activity of adenyl cyclase, an enzyme in cell membranes. Adenyl cyclase, in turn, stimulates formation of cyclic adenosine monophosphate (cAMP). cAMP serves as a second messenger and can initiate several different intracellular actions, with specific actions depending on the type of cell. cAMP is rapidly degraded by an enzyme called phosphodiesterase to 5’ adenosine monophosphate (AMP). Drugs such as theophylline inhibit phosphodiesterase and increase cAMP concentrations, resulting in bronchodilation (see Chap. 47).

- **Dopaminergic receptors D_1 and D_2:** Activation of these receptors is thought to stimulate the production of cAMP, as does activation of beta_1 and beta_2 receptors.

- **Dopaminergic receptor D_3:** Activation of this receptor is thought to inhibit formation of cAMP and to alter calcium and potassium ion currents. D_1 and D_2 receptors are subgrouped with D_3 receptors, but the effects of their activation have not been clearly delineated.

The number and the binding activity of receptors is dynamic and may be altered. These phenomena are most clearly understood with beta receptors. For example, when chronically exposed to high concentrations of substances that stimulate their function, the receptors decrease in number and become less efficient in stimulating adenyl cyclase. The resulting decrease in beta-adrenergic responsiveness is called desensitization or down-regulation of receptors.

Conversely, when chronically exposed to substances that block their function, the receptors may increase in number and become more efficient in stimulating adenyl cyclase. The resulting increase in beta-adrenergic responsiveness (called hypersensitization or up-regulation) may lead to an exaggerated response when the blocking substance is withdrawn.

### TABLE 17–1 Adrenergic Receptors

<table>
<thead>
<tr>
<th>Type</th>
<th>Location</th>
<th>Effects of Stimulation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha_1</td>
<td>Blood vessels, kidney</td>
<td>Vasosconstriction</td>
</tr>
<tr>
<td></td>
<td>Intestinal smooth muscle, liver</td>
<td>Decreased renin secretion</td>
</tr>
<tr>
<td></td>
<td>Genitourinary smooth muscle</td>
<td>Relaxation</td>
</tr>
<tr>
<td></td>
<td>Eye (radial muscle)</td>
<td>Glycogenolysis, glucoseogenesis</td>
</tr>
<tr>
<td>Alpha_2</td>
<td>Vascular smooth muscle, platelets</td>
<td>Inhibit release of norepinephrine</td>
</tr>
<tr>
<td></td>
<td>Platelets</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td></td>
<td>Pancreatic beta cells, heart</td>
<td>Increased heart rate</td>
</tr>
<tr>
<td>Beta_1</td>
<td>Heart</td>
<td>Increased renin release</td>
</tr>
<tr>
<td></td>
<td>Kidney</td>
<td>Bronchodilation</td>
</tr>
<tr>
<td>Beta_2</td>
<td>Bronchioles</td>
<td>Vasodilation</td>
</tr>
<tr>
<td></td>
<td>Blood vessels</td>
<td>Decreased motility and tone</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal tract, liver</td>
<td>Glycogenolysis, glucoseogenesis</td>
</tr>
<tr>
<td></td>
<td>Urinary bladder, kidney</td>
<td>Relaxed detrusor muscle</td>
</tr>
<tr>
<td>Dopamine</td>
<td>Blood vessels of kidney, heart</td>
<td>Vasodilation</td>
</tr>
</tbody>
</table>

### Parasympathetic Nervous System

Functions stimulated by the PNS are often described as resting, reparative, or vegetative functions. They include digestion, excretion, cardiac deceleration, anabolism, and near vision.

Approximately 75% of all parasympathetic nerve fibers are in the vagus nerves. These nerves supply the thoracic and abdominal organs; their branches go to the heart, lungs, esophagus, stomach, small intestine, the proximal half of the colon, the liver, gallbladder, pancreas, and the upper portions of the ureters. Other parasympathetic fibers supply pupillary sphincters and circular muscles of the eye; lacrimal, nasal, submaxillary, and parotid glands; descending colon and rectum; lower portions of the ureters and bladder; and genitalia.

Specific body responses to parasympathetic stimulation include:

1. Dilation of blood vessels in the skin
2. Release of nitrous oxide (NO) (previously called endothelium-derived relaxing factor [EDRF]) from the endothelium of blood vessels, resulting in decreased platelet aggregation, decreased inflammation, relaxation of vascular endothelium, and dilation of blood vessels
3. Decreased heart rate, possibly bradycardia
4. Increased secretion of digestive enzymes and motility of the gastrointestinal tract
5. Constriction of smooth muscle of bronchi
6. Increased secretions from glands in the lungs, stomach, intestines, and skin (sweat glands)
7. Constricted pupils (from contraction of the circular muscle of the iris) and accommodation to near vision (from contraction of the ciliary muscle of the eye)
8. Contraction of smooth muscle in the urinary bladder
9. Contraction of skeletal muscle
10. No apparent effects on blood coagulation, blood sugar, mental activity, or muscle strength

These responses are regulated by acetylcholine, a neurotransmitter in the brain, ANS, and neuromuscular junctions. Acetylcholine is formed in cholinergic nerve endings from choline and acetylcoenzyme A; the reaction is catalyzed by
choline acetyltransferase. After its release from the nerve ending, acetylcholine acts briefly (milliseconds), then is rapidly metabolized by acetylcholinesterase (an enzyme present in the nerve ending and on the surface of the receptor organ). Acetylcholinesterase splits the active acetylcholine into inactive acetate and choline; the choline is taken up again by the presynaptic nerve terminal and reused. Acetylcholine exerts excitatory effects at nerve synapses and nerve–muscle junctions and inhibitory effects at some peripheral sites such as the heart.

**Cholinergic Receptors**

When acetylcholine acts on body cells that respond to parasympathetic nerve stimulation, it interacts with two types of cholinergic receptors: nicotinic and muscarinic. Nicotinic receptors are located in motor nerves and skeletal muscle. When they are activated by acetylcholine, the cell membrane depolarizes and produces muscle contraction. Muscarinic receptors are located in most internal organs, including the cardiovascular, respiratory, gastrointestinal, and genitourinary systems. When muscarinic receptors are activated by acetylcholine, the affected cells may be excited or inhibited in their functions. These receptors have been further subdivided, with two types of nicotinic and five types of muscarinic receptors identified.

Although the subtypes of cholinergic receptors have not been as well characterized as those of the adrenergic receptors, the intracellular events (of signal transduction) after stimulation are thought to include the following mechanisms:

- **Muscarnic1 receptors**: Activation of these receptors results in a molecular response similar to M1 receptor activation. The receptor has been identified in central nervous system tissues; however, its function has not been delineated.
- **Muscarnic2 receptors**: These receptors are located on autonomic ganglia and the adrenal medulla. Activation results in enhanced transmission of nerve impulses at all parasympathetic and sympathetic ganglia, and release of epinephrine from the adrenal medulla.
- **Muscarnic3 receptors**: These are located at neuromuscular junctions in skeletal muscle. Their activation causes muscle contraction.
- **Muscarnic4 receptors**: These receptors are located on presynaptic nerve fibers in the brain and spinal cord. Their activation promotes the release of acetylcholine in the cerebral cortex.

**CHARACTERISTICS OF AUTONOMIC DRUGS**

Many drugs are used clinically because of their ability to stimulate or block activity of the SNS or PNS. Drugs that stimulate activity act like endogenous neurotransmitter substances; drugs that block activity prevent the action of both endogenous substances and stimulating drugs.

Drugs that act on the ANS usually affect the entire body rather than certain organs and tissues. Drug effects depend on which branch of the ANS is involved and whether it is stimulated or inhibited by drug therapy. Thus, knowledge of the physiology of the ANS is required if drug effects are to be understood and predicted. In addition, it is becoming increasingly important to understand receptor activity and the consequences of stimulation or inhibition. More drugs are being developed to stimulate or inhibit particular subtypes of receptors. This is part of the continuing effort to design drugs that act more selectively on particular body tissues and decrease adverse effects on other body tissues. For example, drugs such as terbutaline have been developed to stimulate beta2 receptors in the respiratory tract and produce bronchodilation (a desired effect) with decreased stimulation of beta1 receptors in the heart (an adverse effect).

The terminology used to describe autonomic drugs is often confusing because different terms are used to refer to the same phenomenon. Thus, **sympathomimetic**, **adrenergic**, and **alpha**- and **beta-adrenergic agonists** are used to describe a drug that has the same effects on the human body as stimulation of the SNS. **Parasympathomimetic, cholinomimetic, and cholinergic** are used to describe a drug that has the same effects on the body as stimulation of the PNS. There are also drugs that oppose or block stimulation of these systems. **Sympatholytic, antiadrenergic**, and **alpha- and beta-adrenergic blocking drugs** inhibit sympathetic stimulation. **Parasympatholytic, anticholinergic, and cholinergic blocking drugs** inhibit parasympathetic stimulation. This book uses the terms **adrenergic, antiadrenergic, cholinergic, and anticholinergic** when describing medications.
**Review and Application Exercises**

1. What are the major differences between the sympathetic and parasympathetic branches of the ANS?
2. What are the major SNS and PNS neurotransmitters?
3. What are the locations and functions of SNS receptors?
4. What is meant when drugs are described as adrenergic, sympathomimetic, antiadrenergic, sympatholytic, cholinergic, or anticholinergic?

**SELECTED REFERENCES**


268

Adrenergic Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify effects produced by stimulation of alpha- and beta-adrenergic receptors.
2. List characteristics of adrenergic drugs in terms of effects on body tissues, indications for use, adverse effects, nursing process implications, principles of therapy, and observation of client responses.
3. Discuss use of epinephrine to treat anaphylactic shock, acute bronchospasm, and cardiac arrest.
4. Identify clients at risk of experiencing adverse effects with adrenergic drugs.
5. List commonly used over-the-counter preparations and herbal preparations that contain adrenergic drugs.
6. Discuss principles of therapy and nursing process for using adrenergic drugs in special populations.
7. Describe signs and symptoms of toxicity due to noncatecholamine adrenergic drugs.
8. Discuss treatment of overdose with noncatecholamine adrenergic drugs.
9. Teach the client about safe, effective use of adrenergic drugs.

Critical Thinking Scenario
Jill, 8 years old, is brought to the clinic for allergy desensitization. She is starting on a new concentration of allergy extract today. After her injection, as usual, you ask her to remain in the waiting room for 30 minutes. After 20 minutes, her mother comes to get you. Jill is restless, her voice is high-pitched, she feels odd, and her respiration rate has increased to 30 breaths per minute.

Reflect on:
▶ What data would you collect next?
▶ How could you differentiate anaphylaxis from anxiety?
▶ If Jill were experiencing an anaphylactic reaction, what would be the treatment of choice?

DESCRIPTION
Adrenergic (sympathomimetic) drugs produce effects similar to those produced by stimulation of the sympathetic nervous system (see Chap. 17) and therefore have widespread effects on body tissues. Some of the drugs are exogenous formulations of naturally occurring neurotransmitters and hormones such as norepinephrine (Levophed), epinephrine (Adrenalin), and dopamine (Intropin). Other adrenergic medications such as phenylephrine (Neo-Synephrine), pseudoephedrine (Sudafed), and isoproterenol (Isuprel) are synthetic chemical relatives of naturally occurring neurotransmitters and hormones.

Specific effects of adrenergic medications depend mainly on the client’s health status when a drug is given and the type of adrenergic receptor activated by the drug. Major therapeutic uses and adverse effects stem from drug effects on the heart, blood vessels, and lungs. The drugs discussed in this chapter (epinephrine, ephedrine, pseudoephedrine, isoproterenol, and phenylephrine) are those with multiple effects and clinical uses (Drugs at a Glance: Selected Adrenergic Drugs). Because epinephrine, ephedrine, and pseudoephedrine stimulate both alpha- and beta-adrenergic receptors, these drugs have widespread effects on body tissues and multiple clinical uses. Isoproterenol stimulates beta-adrenergic receptors (both beta1 and beta2) and may be used in the treatment of several clinical conditions. Phenylephrine stimulates alpha-adrenergic receptors and is used to induce vasoconstriction in several conditions.

Other adrenergic drugs are selective for specific adrenergic receptors, or are given topically to produce more localized therapeutic effects and fewer systemic adverse effects.
## Drugs at a Glance: Selected Adrenergic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Use</th>
<th>Preparations, Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Epinephrine** (Adrenalin) | Bronchodilator | **Aqueous epinephrine**  
1 mg/mL (**1:1000**):  
IM, SC: 0.1–0.5 mg q 15 min to 4h if needed  
Do not exceed 1 mg in a single dose  
**IV injection** (**1:1000**):  
Dilute 1 mg with 10 mL NaCl injection for a final concentration of 1:10,000 or 0.1 mg/mL.  
Give 0.1–2.25 mg (1–2.5 mL) of this solution. Single dose maximum: 1 mg (10 mL) |
| **Cardiac arrest** | **Aqueous epinephrine**  
1 mg/mL (**1:1000**):  
**IV injection**: 1 mg q 3–5 min. Higher doses (up to 0.2 mg/kg) may be used if 1 mg dose fails.  
**Continuous infusion**: Add 30 mg epinephrine to 250/ml NS or D5W, run at 100 mL/h and titrate to response.  
**Endotracheally**: 2.0–2.5 mg of **1:1000** solution diluted in 10 ml NS. | **Aqueous epinephrine**  
0.1 mg/mL (**1:10,000**):  
Give 0.01 mg/kg (0.1 mL/kg) q 3–5 min.  
**Subsequent doses**: **Aqueous epinephrine**  
1 mg/mL (**1:1000**):  
Give 0.1 mg/kg (0.1 mg/kg) up to 0.2 mg/kg (0.2 mL/kg)  
**Endotracheally**: 0.1 mg/kg of **1:1000** solution q 3–5 min until IV access is established. |
| **Allergic reaction/anaphylaxis** | **Aqueous epinephrine 1 mg/mL (1:1000)**:  
IM, SC: 0.1–0.5 mg q 20 min to q4h. Do not exceed 1 mg in a single dose. | **Aqueous epinephrine 1 mg/mL (1:1000)**:  
IV: 0.01 mg q20 min to q4h. Do not exceed 0.5 mg in a single dose. |
| **Ophthalmic agent** | **Epinephrine HCl 0.1%, 0.5%, 1%, and 2%**  
1–2 drops in eyes 1–2 times/day |  |
| **Nasal agent for hemostasis** | **Epinephrine Nasal Solution 0.1% (1:1000)**:  
1–2 drops per nostril q4–6h. |  |
| **Ephedrine** | Asthma | PO 25–50 mg q4h  
6–12 y: PO 6.25–12.5 mg q4–6h. 2–6 y: PO 0.3–0.5 mg/kg q4–6h. |
| | Hypotension | IM, SC: 25–50 mg  
IV push: 5–25 mg/dose slowly, repeated q 5–10 min as needed then q3–4 h.  
Do not exceed 150 mg/24h. |
| | Nasal congestion | PO 25–50 mg q4h.  
0.25% nasal spray or 1% nasal jelly. |
| **Pseudoephedrine** (Sudafed) | Nasal congestion |  
Give 30–60 mg PO q4–6h or 120 mg sustained release formula q12h. Do not exceed 240 mg/24h.  
6–12 y: PO 30 mg q6h. Do not exceed 120 mg/24h.  
2–5 y: PO 14 mg q6h. Do not exceed 60 mg/24h. |
These drugs have relatively restricted clinical indications and are discussed more extensively elsewhere (Drugs Used in Hypotension and Shock, Chap. 54; Drugs for Asthma and Other Bronchoconstrictive Disorders, Chap. 47; Nasal Decongestants, Antitussives, and Cold Remedies, Chap. 49; and Drugs Used in Ophthalmic Conditions, Chap. 65). Table 18–1 lists commonly used adrenergic drugs in relation to adrenergic receptor activity and clinical use.

### Mechanisms of Action and Effects

Adrenergic (sympathomimetic) drugs have three mechanisms of action. For the most part, adrenergic drugs interact directly with postsynaptic alpha,- or beta-adrenergic receptors on the surface membrane of body cells (Fig. 18–1). The drug–receptor complex then alters the cell membrane’s permeability to ions or extracellular enzymes. The influx of these molecules stimulates intracellular metabolism and production of other enzymes, structural proteins, energy, and other products required for cell function and reproduction. Epinephrine, isoproterenol, norepinephrine, and phenylephrine are examples of direct-acting adrenergic drugs.

Some adrenergic drugs exert indirect effects on adrenergic receptors. Indirect adrenergic effects may be produced by drugs such as amphetamines that increase the amount of norepinephrine released into the synapse from storage sites in nerve endings (Fig. 18–2A). Norepinephrine then stimulates the alpha and beta receptors, producing sympathetic effects in the body. Inhibition of norepinephrine reuptake from the synapse is another mechanism that will produce indirect adrenergic effects. Remember that norepinephrine reuptake...
is the major way that sympathetic nerve transmission is terminated. Drugs such as tricyclic antidepressants and cocaine will block norepinephrine reuptake, resulting in stimulation of alpha- and beta-adrenergic receptors (Fig. 18–2B). The third mechanism of adrenergic drug action is called mixed acting and is a combination of direct and indirect receptor stimulation. Ephedrine and pseudoephedrine are examples of mixed-acting adrenergic drugs. Drugs that activate alpha2 receptors on presynaptic nerve fibers do not produce a sympathetic effect. These drugs inhibit the release of the neurotransmitter norepinephrine into synapses of the sympathetic nervous system and therefore exert a sympatholytic or antiadrenergic response in the body. Although activation of alpha receptors in the periphery is not of clinical significance, activation of alpha2 receptors in the central nervous system by medications is useful in treating hypertension (see Chap. 19 and Chap. 55).

Because most body tissues have both alpha and beta receptors, the effect produced by an adrenergic drug depends on the type of receptor activated and the number of affected receptors in a particular body tissue. Some drugs act on both types of receptors; some act more selectively on certain subtypes of receptors. Activation of alpha2 receptors in blood vessels results in vasoconstriction, which then raises blood pressure and decreases nasal congestion. Activation of beta2 receptors in the heart results in cardiac stimulation (increased force of myocardial contraction and increased heart rate). Activation of beta2 receptors in the lungs results in bronchodilation and activation of beta2 receptors in blood vessels results in vasodilation (increased blood flow to the heart, brain, and skeletal muscles, the tissues needed to aid the “fight-or-flight” response). Many newer adrenergic drugs (eg, beta2 receptor agonists used as bronchodilators in asthma and other bronchoconstrictive disorders) were developed specifically to be more selective.

In addition to the cardiac, vascular, and pulmonary effects, other effects of adrenergic drugs include contraction of gastrointestinal (GI) and urinary sphincters, lipolysis, decreased GI tone, changes in renin secretion, uterine relaxation, hepatic glycogenolysis and gluconeogenesis, and decreased secretion of insulin.

### Indications for Use

Clinical indications for the use of adrenergic drugs stem mainly from their effects on the heart, blood vessels, and bronchi. They are often used as emergency drugs in the treatment of acute cardiovascular, respiratory, and allergic disorders.
In cardiac arrest and Stokes-Adams syndrome (heart block), they may be given as cardiac stimulants. In hypotension and shock, they may be given to increase blood pressure. In hemorrhagic or hypovolemic shock, the drugs are second-line agents that may be used if adequate fluid volume replacement does not restore sufficient blood pressure and circulation to maintain organ perfusion.

In bronchial asthma and other obstructive pulmonary diseases, the drugs are given as bronchodilators to relieve bronchoconstriction and bronchospasm. In upper respiratory infections, including the common cold and sinusitis, they may be given orally or applied topically to the nasal mucosa for decongestant effects.

In allergic disorders, the drugs are given for vasoconstricting or decongestant effects to relieve edema in the respiratory tract, skin, and other tissues. Thus, they may be used to treat allergic rhinitis, acute hypersensitivity (anaphylactoid reactions to drugs, animal serums, insect stings, and other allergens), serum sickness, urticaria, and angioneurotic edema. Other clinical uses include relaxation of uterine musculature and inhibition of uterine contractions in preterm labor. They also may be added to intraspinal and local anesthetics to prolong anesthesia. Topical uses include application to skin and mucous membranes for vasoconstriction and hemostatic effects, and to the eyes for vasoconstriction and mydriasis.

**Contraindications to Use**

Contraindications to using adrenergic drugs include cardiac dysrhythmias, angina pectoris, hypertension, hyperthyroidism, and cerebrovascular disease because stimulation of the sympathetic nervous system worsens these conditions. Adrenergic drugs are also contraindicated for persons with narrow-angle glaucoma because they result in mydriasis, closure of the filtration angle of the eye, and increased intraocular pressure. Hypersensitivity to an adrenergic drug or any component (some preparations contain sulfites, to which some people are allergic) is also a contraindication for their use. Adrenergic drugs are contraindicated with local anesthesia of distal areas with a single blood supply (e.g., fingers, toes, nose, ears) because of potential tissue damage and sloughing from vasoconstriction. They should not be given during the second stage of labor because they may delay progression. The drugs should be used with caution in clients with anxiety, insomnia, and psychiatric disorders because of their stimulant effects on the central nervous system (CNS) and in older adults because of their cardiac- and CNS-stimulating effects.

**INDIVIDUAL ADRENERGIC DRUGS**

**Epinephrine** (Adrenalin) is the prototype of adrenergic drugs. When it is given systemically, the effects may be therapeutic or adverse, depending on the reason for use and route of administration. Specific effects include:

1. Increased systolic blood pressure, due primarily to increased force of myocardial contraction and vasoconstriction in skin, mucous membranes, and kidneys
2. Vasodilation and increased blood flow to skeletal muscles, heart, and brain
3. Vasoconstriction in peripheral blood vessels. This allows shunting of blood to the heart and brain, with increased perfusion pressure in the coronary and cerebral
circulations. This action is thought to be the main beneficial effect in cardiac arrest and cardiopulmonary resuscitation (CPR).
4. Increased heart rate and possibly arrhythmias due to stimulation of conducting tissues in the heart. Reflex bradycardia may occur when blood pressure is raised.
5. Relaxation of GI smooth muscle
6. Relaxation or dilation of bronchial smooth muscle
7. Increased glucose, lactate, and fatty acids in the blood due to metabolic effects
8. Inhibition of insulin secretion
9. Miscellaneous effects, including increased total leukocyte count, increased rate of blood coagulation, and decreased intraocular pressure in wide-angle glaucoma.

When given locally, the main effect is vasoconstriction.

Epinephrine stimulates both alpha and beta receptors. At usual doses, beta-adrenergic effects on the heart and vascular and other smooth muscles predominate. However, at high doses, alpha-adrenergic effects (eg, vasoconstriction) predominate. The effects and clinical indications for epinephrine, the prototype of adrenergic drugs, are the same as for most adrenergic drugs. In addition, epinephrine is the adrenergic drug of choice for relieving the acute bronchospasm and laryngeal edema of anaphylactic shock, the most serious allergic reaction. Epinephrine is used in cardiac arrest for its cardiac stimulant and peripheral vasoconstrictive effects. It also is added to local anesthetics for vasoconstrictive effects, which prolong the action of the local anesthetic drug, prevent systemic absorption, and minimize bleeding.

Epinephrine should be used with caution in infants and children; syncope has occurred with use in asthmatic children. Epinephrine is the active ingredient in over-the-counter (OTC) inhalation products for asthma (AsthmaNefrin, Primatene Mist, Bronkaid Mist, others). People who have heart disease or are elderly should not use these products on a regular basis. These preparations have a short duration of action, and effects last less than 60 minutes. Ephedrine is excreted unchanged in the urine. Acidic urine increases the rate of drug elimination.

Epinephrine can be given orally or parenterally. When given orally, therapeutic effects occur within 1 hour and last 3 to 5 hours. When given SC, it acts in approximately 20 minutes and effects last approximately 60 minutes; with intramuscular administration, it acts in approximately 10 to 20 minutes and effects last less than 60 minutes. Ephedrine is excreted unchanged in the urine. Acidic urine increases the rate of drug elimination.

Epinephrine is a common ingredient in OTC anti-asthma tablets (Bronkaid, Primatene, others). The tablets contain 12.5 to 25 mg of ephedrine and 100 to 130 mg of theophylline, a xanthine bronchodilator. Other clinical uses include shock associated with spinal or epidural anesthesia, Stokes-Adams syndrome (sudden attacks of unconsciousness caused by heart block), allergic disorders, nasal congestion, and eye disorders.

Pseudoephedrine (Sudafed) is a related drug with similar actions. It is used for bronchodilating and nasal decongestant effects. Pseudoephedrine is given orally and is available OTC alone and as an ingredient in several multi-ingredient sinus, allergy, and cold remedies. Pseudoephedrine is eliminated primarily in the urine. Its elimination may be slowed by alkaline urine, which promotes drug reabsorption in the renal tubules.

Isoproterenol (Isuprel) is a synthetic catecholamine that acts on beta₁- and beta₂-adrenergic receptors. Its main actions are to stimulate the heart, dilate blood vessels in skeletal muscle, and relax bronchial smooth muscle. Compared with epinephrine, its cardiac stimulant effects are similar, but it does not affect alpha receptors and therefore does not cause vasoconstriction. It is well absorbed when given by injection or as an aerosol. However, absorption is unreliable with sublingual and oral preparations, so their use is not

---

**TABLE 18–2  Epinephrine Concentrations and Administration Routes**

<table>
<thead>
<tr>
<th>Final Concentration</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% (1:100)</td>
<td>Inhalation</td>
</tr>
<tr>
<td>0.5% (1:200)</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>0.1% (1:1000)</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>0.01% (1:10,000)</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>0.001% (1:100,000)</td>
<td>Intradermal (in combination with local anesthetics)</td>
</tr>
</tbody>
</table>
recommended. It is metabolized more slowly than epinephrine by the enzyme catechol-O-methyltransferase (COMT). It is not well metabolized by monoamine oxidase (MAO), which may account for its slightly longer duration of action than epinephrine. Isoproterenol may be used as a cardiac stimulant in heart block and cardiogenic shock and as a bronchodilator in respiratory conditions characterized by bronchospasm. However, beta₂-selective agonists (eg, albuterol, others) are preferred for bronchodilating effects because they cause less cardiac stimulation. Too-frequent use of inhaled isoproterenol may lead to tolerance and decreased bronchodilating effects.

**Phenylephrine** (Neo-Synephrine, others) is a synthetic drug that acts on alpha-adrenergic receptors to produce vasoconstriction. Vasoconstriction decreases cardiac output and renal perfusion and increases peripheral vascular resistance and blood pressure. There is little cardiac stimulation because phenylephrine does not activate beta receptors in the heart or beta₂ receptors in blood vessels. Phenylephrine may be given to raise blood pressure in hypotension and shock. Compared with epinephrine, phenylephrine produces longer-lasting elevation of blood pressure (20 to 50 minutes with injection). When given systemically, phenylephrine produces a reflex bradycardia. This effect may be used therapeutically to relieve paroxysmal atrial tachycardia. However, other medications such as calcium channel blockers (see Chap. 53) are more likely to be used for this purpose. Other uses of phenylephrine include local application for nasal decongestant and mydriatic effects. Various preparations are available for different uses. Phenylephrine is often an ingredient in prescription and nonprescription cold and allergy remedies. It is excreted primarily in the urine.

**Phenylpropanolamine** (PPA) is an indirect-acting adrenergic drug that was a common ingredient in OTC cold and allergy remedies and appetite suppressants. The Food and Drug Administration recently removed phenylpropanolamine from the market due to its association with severe hypertension and the occurrence of strokes. Nurses should instruct patients to check the labels on OTC medications and discard those containing PPA.

---

### Nursing Process

#### Assessment

Assess the client’s status in relation to the following conditions:

- **Allergic disorders.** It is standard procedure to question a client about allergies on initial contact or admission to a health care agency. If the client reports a previous allergic reaction, try to determine what caused it and what specific symptoms occurred. It may be helpful to ask if swelling, breathing difficulty, or hives (urticaria) occurred. With anaphylactic reactions, severe respiratory distress (from bronchospasm and laryngeal edema) and profound hypotension (from vasodilation) may occur.

- **Asthma.** If the client is known to have asthma, assess the frequency of attacks, the specific signs and symptoms experienced, the precipitating factors, the actions taken to obtain relief, and the use of bronchodilators or other medications on a long-term basis. With acute bronchospasm, respiratory distress is clearly evidenced by loud, rapid, gasping, wheezing respirations. Acute asthma attacks may be precipitated by exposure to allergens or respiratory infections. When available, check arterial blood gas reports for the adequacy of oxygen–carbon dioxide gas exchange. Hypoxemia (\(\downarrow\)P\(_{O_2}\)), hypercarbia (\(\uparrow\)P\(_{CO_2}\)), and acidosis (\(\downarrow\)pH) may occur with acute bronchospasm.

- **Chronic obstructive pulmonary disorders.** Emphysema and chronic bronchitis are characterized by bronchoconstriction and dyspnea with exercise or at rest. Check arterial blood gas reports when available. Hypoxemia, hypercarbia, and acidosis are likely with chronic bronchoconstriction. Acute bronchospasm may be superimposed on the chronic bronchoconstrictive disorder, especially with a respiratory infection.

- **Cardiovascular status.** Assess for conditions that are caused or aggravated by adrenergic drugs (eg, angina, hypertension, tachyarrhythmias).

#### Interventions

Use measures to prevent or minimize conditions for which adrenergic drugs are required:

- Decrease exposure to allergens. Allergens include cigarette smoke, foods, drugs, air pollutants, plant pollens, insect venoms, and animal dander. Specific allergens must be determined for each person.
• For clients with chronic lung disease, use measures to prevent respiratory infections. These include interventions to aid removal of respiratory secretions, such as adequate hydration, ambulation, deep-breathing and coughing exercises, and chest physiotherapy. Immunizations with pneumococcal pneumonia vaccine (a single dose) and influenza vaccine (annually) are also strongly recommended.
• When administering substances known to produce hypersensitivity reactions (penicillin and other antibiotics, allergy extracts, vaccines, local anesthetics), observe the recipient carefully for at least 30 minutes after administration. Have adrenergic and other emergency drugs and equipment readily available in case a reaction occurs.
• Use noninvasive interventions in addition to adrenergic medications when treating shock and hypotension. These include applying external pressure over a bleeding site to control hemorrhage and placing the patient in modified Trendelenburg position (patient supine with legs markedly elevated and head and shoulders only slightly elevated) to improve venous return and blood pressure.

Evaluation
• Observe for increased blood pressure and improved tissue perfusion when a drug is given for hypotension and shock or anaphylaxis.
• Interview and observe for improved breathing and arterial blood gas reports when a drug is given for bronchoconstriction or anaphylaxis.
• Interview and observe for decreased nasal congestion.

PRINCIPLES OF THERAPY

Drug Selection and Administration

The choice of drug, dosage, and route of administration depends largely on the reason for use. IV or SC epinephrine is the drug of choice in anaphylactic shock. Isoproterenol by oral inhalation may be used for producing bronchodilation. However, a selective beta2 agonist is preferred because it causes less cardiac stimulation. Adrenergic drugs are given IV only for emergencies, such as cardiac arrest, severe arterial hypotension, circulatory shock, and anaphylactic shock. No standard doses of individual adrenergic drugs are always effective; the dosage must be individualized according to the client’s response. This is especially true in emergencies, but it also applies to long-term use.

Use in Specific Situations

Because adrenergic drugs are often used in crises, they must be readily available in all health care settings (e.g., hospitals, long-term care facilities, physicians’ offices). All health care personnel should know where emergency drugs are stored.

Anaphylaxis

Epinephrine is the drug of choice for the treatment of anaphylaxis. It relieves bronchospasm, laryngeal edema, and hypotension. In conjunction with its alpha (vasoconstriction) and beta (cardiac stimulation, bronchodilation) effects, epinephrine acts as a physiologic antagonist of histamine and other bronchoconstricting and vasodilating substances released during anaphylactic reactions. People susceptible to severe allergic responses should carry a syringe of epinephrine at all times. Epipen and Epipen Jr. are prefilled, auto-injection syringes for self-administration of epinephrine in an emergency situation.

Victims of anaphylaxis who have been taking beta-adrenergic blocking drugs (e.g., propranolol [Inderal]) do not respond as readily to epinephrine as those not taking a beta blocker. Larger doses of epinephrine and large amounts of IV fluids may be required. Adjunct medications that may be useful in treating severe cases of anaphylaxis include corticosteroids, norepinephrine, and aminophylline. Antihistamines are not very useful because histamine plays a minor role in causing anaphylaxis, compared with leukotrienes and other inflammatory mediators.

Cardiopulmonary Resuscitation

Epinephrine is often administered during CPR. Its most important action is constriction of peripheral blood vessels, which shunts blood to the central circulation and increases blood flow to the heart and brain. In the past it was considered the drug of choice to treat cardiac arrest. The most recent Advanced Cardiac Life Support (ACLS) guidelines for health professionals (2000) classify epinephrine as a class indeterminate for the treatment of defibrillation-resistant ventricular tachycardia and ventricular fibrillation during cardiac arrest. Class indeterminate means a treatment is promising but lacks research evidence of benefit. Vasopressin is the alternative pressor to epinephrine that may be used in this situation. Vasopressin is listed as class IIb, which means the usefulness of the drug is supported by fair to good research. Class IIb drugs are considered optional or alternative interventions by the majority of experts in treatment of cardiac arrest. When treating defibrillation-resistant ventricular tachycardia or ventricular fibrillation, vasopressin is given as a single dose of 40 units IV (see Chap. 23). Epinephrine is still considered the drug of choice to treat cardiac arrest in nonventricular tachycardia/fibrillation cases such as pulseless electrical activity (PEA) and asystole. Epinephrine is beneficial in these situations because it stimulates electrical and mechanical activity and produces myocardial contraction.

The specific effects of epinephrine depend largely on the dose and route of administration. The optimal dose in CPR has not been established. ACLS guidelines recommend epinephrine 1 mg IV every 3 to 5 minutes. If this fails, higher doses of epinephrine (up to 0.2 mg/kg) are acceptable, but not recommended. In fact, there is growing evidence that higher doses of epinephrine may be harmful.

CHAPTER 18 ADRENERGIC DRUGS
276
SECTION 3 DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM

CLIENT TEACHING GUIDELINES
Adrenergic Drugs

General Considerations
✔ Take no other medications without the physician’s knowledge and approval. Many over-the-counter (OTC) cold remedies and appetite suppressants contain adrenergic drugs. Use of these along with prescribed adrenergic drugs can result in overdose and serious cardiovascular or central nervous system problems. In addition, adrenergic drugs interact with numerous other drugs to increase or decrease effects; some of these interactions may be life threatening.
✔ Herbal preparations of ephedra or ma huang contain derivatives of ephedrine and should not be taken with other adrenergic medications. Excessive central nervous system and cardiovascular stimulation may result.
✔ Tell your health care provider if you are pregnant, breastfeeding, taking any other prescription or OTC drugs, or if you are allergic to sulfite preservatives.
✔ Use these drugs only as directed. The potential for abuse is high, especially for the client with asthma or other chronic lung disease who is seeking relief from labored breathing. Some of these drugs are prescribed for long-term use, but excessive use does not increase therapeutic effects. Instead, it causes tolerance and decreased benefit from usual doses and increases the incidence and severity of adverse reactions.
✔ Frequent cardiac monitoring, checks of flow rate, blood pressure, and urine output are necessary if you are receiving intravenous adrenergic drugs to stimulate your heart or raise your blood pressure. These measures increase the safety and benefits of drug therapy rather than indicate the presence of a critical condition. Ask your nurse if you have concerns about your condition.
✔ You may feel anxious or tense; have difficulty sleeping; and experience palpitations, blurred vision, headache, tremor, dizziness, and pallor. These are effects of the medication. Use of relaxation techniques to promote rest and decrease muscle tension may be helpful.
✔ Use caution when driving or performing activities requiring alertness, dexterity, and good vision.
✔ Report adverse reactions such as fast pulse, palpitations, and chest pain so that drug dosage can be reevaluated and therapy changed if needed.

Self-administration
✔ Do not use topical decongestants longer than 3 to 5 days. Long-term use may be habit forming. Burning on use and rebound congestion after the dose wears off are common. Stop using the medication gradually.
✔ Stinging may occur when using ophthalmic preparations. Do not let the tip of the applicator touch your eye or anything else during administration of the medication, to avoid contamination. Do not wear soft contact lenses while using ophthalmic adrenergic drugs; discoloration of the lenses may occur. Report blurred vision, headache, palpatations, and muscle tremors to your health care provider.
✔ Follow guidelines for use of your inhaler. Do not increase the dosage or frequency; tolerance may occur. Report chest pain, dizziness, or failure to obtain relief of symptoms. Saliva and sputum may be discolored pink with isoproterenol.
✔ Learn to self-administer an injection of epinephrine if you have severe allergies. Always carry your injection kit with you. Seek immediate medical care after self-injection of epinephrine.
✔ If you are diabetic, monitor your glucose levels carefully because adrenergic medications may elevate them.

Hypotension and Shock

In hypotension and shock, initial efforts involve identifying and treating the cause when possible. Such treatments include placing the patient in the recumbent position, blood transfusions, fluid and electrolyte replacement, treatment of infection, and use of positive inotropic drugs to treat heart failure. If these measures are ineffective in raising the blood pressure enough to maintain perfusion to vital organs such as the brain, kidneys and heart, vasopressor drugs may be used. The usual goal of vasopressor drug therapy is to maintain tissue perfusion and a mean arterial pressure of at least 80 to 100 mm Hg.

Nursing Notes: Apply Your Knowledge

Jack Newton, a healthy 46-year-old, develops seasonal allergies. He self-medicates his allergy symptoms with over-the-counter ephedrine (Bronkaid) for approximately 4 weeks before going to his physician. When the nurse takes his vital signs, he is surprised that his blood pressure is 160/92 and his pulse is 102. How does ephedrine, an adrenergic agent, relieve allergy symptoms? What side effects are common?

How Can You Avoid This Medication Error?

You are working in a clinic when a patient has a sudden, severe episode of laryngeal edema and hypotension. The physician shouts an order for epinephrine 0.1 mg IV stat. Your stock supply provides epinephrine 1 mg/mL. You draw up 1 mL into a syringe and hand it to the physician for IV administration.
**Nasal Congestion**

Adrenergic drugs are given topically and systemically to constrict blood vessels in nasal mucosa and decrease the nasal congestion associated with the common cold, allergic rhinitis, and sinusitis. Topical agents are effective, undergo little systemic absorption, are available OTC, and are widely used. However, overdose leads to decreased effectiveness (tolerance), irritation and ischemic changes in the nasal mucosa, and rebound congestion. These effects can be minimized by using small doses only when necessary and for no longer than 3 to 5 days.

Oral agents have a slower onset of action than topical ones but may last longer. They also may cause more adverse effects. Adverse effects may occur with usual therapeutic doses and are especially likely with high doses. The most problematic adverse effects are cardiac and CNS stimulation. Commonly used oral agents are pseudoephedrine and ephedrine. Pseudoephedrine seems to be the safest in relation to risks of hypertension and cerebral hemorrhage (stroke). Ephedrine may cause hypertension even in normotensive people, with higher risks in hypertensive people. Hypertensive clients should avoid these drugs if possible.

**Toxicity of Adrenergics: Recognition and Management**

Unlike catecholamines, which are quickly cleared from the body, excessive use of noncatecholamine adrenergic drugs (phenylephrine, ephedrine, and pseudoephedrine) can lead to overdose and toxicity. These drugs are an ingredient in OTC products such as nasal decongestants, cold preparations, and appetite suppressants. Ephedrine and ephedra-containing herbal preparations (eg, ma huang and herbal ecstasy) are often abused as an alternative to amphetamines or to aid in rapid weight loss.

Phenylephrine and ephedrine have a narrow therapeutic index with toxic doses only two to three times greater than the therapeutic dose. Pseudoephedrine toxicity occurs with doses four to five times greater than the normal therapeutic dose.

The primary clinical manifestation of noncatecholamine adrenergic drug toxicity is severe hypertension, which may lead to headache, confusion, seizures, and intracranial hemorrhage. Reflex bradycardia and atioventricular block also have been associated with phenylephrine toxicity.

Treatment involves maintaining an airway and assisting with ventilation if needed. Activated charcoal may be administered early in treatment. Hypertension is aggressively treated with vasodilators such as phentolamine or nitroprusside. Beta blockers are not used alone to treat hypertension without first administering a vasodilator, to avoid a paradoxical increase in blood pressure.

Dialysis and hemoperfusion are not effective in clearing these drugs from the body. Urinary acidification may enhance elimination of ephedrine and pseudoephedrine; however, this technique is not routinely used because of the risk of renal damage from myoglobin deposition in the kidney.

**Use in Children**

Adrenergic agents are used to treat asthma, hypotension, shock, cardiac arrest, and anaphylaxis in children. However, guidelines for safe and effective use of adrenergic drugs in children are not well established. Children are very sensitive to drug effects, including cardiac and CNS stimulation, and recommended doses usually should not be exceeded.

The main use of epinephrine in children is for treatment of bronchospasm due to asthma or allergic reactions. Parenteral epinephrine may cause syncope when given to asthmatic children. Isoproterenol is rarely given parenterally, but if given, the first dose should be approximately half that of an adult’s, and later doses should be based on the response to the first dose. There is little reason to use the inhalation route because in children, as in adults, selective beta2 agonists such as albuterol are preferred for bronchodilation in asthma.

Phenylephrine is most often used to relieve congestion of the upper respiratory tract and may be given topically, as nose drops. Doses must be carefully measured. Rebound nasal congestion occurs with overuse.

**Use in Older Adults**

Adrenergic agents are used to treat asthma, hypotension, shock, cardiac arrest, and anaphylaxis in older adults. These drugs stimulate the heart to increase rate and force of contraction and blood pressure. Because older adults often have chronic cardiovascular conditions (eg, angina, dysrhythmias, congestive heart failure, coronary artery disease, hypertension, peripheral vascular disease) that are aggravated by adrenergic drugs, careful monitoring by the nurse is required.

Adrenergic drugs are often prescribed as bronchodilators and decongestants in older adults. Therapeutic doses increase the workload of the heart and may cause symptoms of impaired cardiovascular function; overdoses may cause severe cardiovascular dysfunction, including life-threatening dysrhythmias. The drugs also cause CNS stimulation. With therapeutic doses, anxiety, restlessness, nervousness, and insomnia often occur in older adults. Overdoses may cause hallucinations, convulsions, CNS depression, and death.

Adrenergics are ingredients in OTC asthma remedies, cold remedies, nasal decongestants, and appetite suppressants. Cautious use of these preparations is required for older adults. They should not be taken concurrently with prescription adrenergic drugs because of the high risk of overdose and toxicity.

Ophthalmic preparations of adrenergic drugs also should be used cautiously. For example, phenylephrine is used as a vasoconstrictor and mydriatic. Applying larger-than-recommended doses to the normal eye or usual doses to the traumatized, inflamed, or diseased eye may result in enough systemic absorption of the drug to cause increased blood pressure and other adverse effects.
Use in Renal Impairment

Adrenergic drugs exert effects on the renal system that may cause problems for clients with renal impairment. For example, adrenergic drugs with alpha activity cause constriction of renal arteries, thereby diminishing renal blood flow and urine production. These drugs also constrict urinary sphincters, causing urinary retention and painful urination, especially in men with prostatic hyperplasia.

Many adrenergic drugs and their metabolites are eliminated by the renal system. In the presence of renal disease, these compounds may accumulate and cause increased adverse effects.

Use in Hepatic Impairment

The liver is rich in the enzymes MAO and COMT, which are responsible for metabolism of circulating epinephrine and other adrenergic drugs (eg, norepinephrine, dopamine, and isoproterenol). However, other tissues in the body also possess these enzymes and are capable of metabolizing natural and synthetic catecholamines. Any unchanged drug can be excreted in the urine. Many noncatecholamine adrenergic drugs are excreted largely unchanged in the urine. Therefore, liver disease is not usually considered a contraindication to administering adrenergic drugs.

Use in Critical Illness

Adrenergic drugs are an important component of the emergency drug box. They are essential for treating hypotension, shock, asystole and other dysrhythmias, acute bronchospasm, and anaphylaxis. Although they may save the life of a critically ill client, use of adrenergic drugs may result in secondary health problems that require monitoring and intervention. These include:

1. Potential for the vasopressor action of adrenergic drugs to result in diminished renal perfusion and decreased urine output
2. Potential for adrenergic drugs with beta₁ activity to induce irritable cardiac dysrhythmias
3. Potential for adrenergic drugs with beta₁ activity to increase myocardial oxygen requirement
4. Potential for adrenergic drugs with vasopressor action to decrease perfusion to the liver, with subsequent liver damage
5. Hyperglycemia, hypokalemia, and hypophosphatemia due to beta₁-adrenergic effects
6. Severe hypertension and reflex bradycardia
7. Tissue necrosis after extravasation

Occurrence of any of these adverse effects may complicate the already complex care of the critically ill client. Careful assessment and prompt nursing intervention are essential in caring for the critically ill client experiencing these health problems.

Home Care

Adrenergic drugs are often used in the home setting. Frequently prescribed drugs include bronchodilators and nasal decongestants. OTC drugs with the same effects are also commonly used for asthma, allergic rhinitis, cold symptoms, and appetite suppression for weight control. A major function of the home care nurse is to teach clients to use the drugs correctly (especially metered-dose inhalers), to report excessive CNS or cardiac stimulation to a health care provider, and not to take OTC drugs or herbal preparations with the same or similar ingredients as prescription drugs.

Excessive adverse effects are probably most likely to occur in children and older adults. Older adults often have other illnesses that may be aggravated by adrenergic drugs, or take other drugs, whose effects may be altered by concomitant use of adrenergics.

**Adrenergic Drugs**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td>The many different preparations and concentrations available for various routes of administration increase the risk of medication error unless extreme caution is used. Preparations for intravenous, subcutaneous, inhalation, ophthalmic, or nasal routes must be used by the designated route only.</td>
</tr>
<tr>
<td>a. Check package inserts or other references if not absolutely sure about the preparation, concentration, or method of administration for an adrenergic drug.</td>
<td>The tuberculin syringe is necessary for accurate measurement of the small doses usually given (often less than 0.5 mL). Aspiration is necessary to avoid inadvertent IV administration of the larger, undiluted amount of drug intended for subcutaneous use. Massaging the injection site accelerates drug absorption and thus relief of symptoms.</td>
</tr>
<tr>
<td>b. To give epinephrine subcutaneously, use a tuberculin syringe, aspirate, and massage the injection site.</td>
<td><em>(continued)</em></td>
</tr>
</tbody>
</table>
### NURSING ACTIONS

| c. | For inhalation, be sure to use the correct drug concentration, and use the nebulizing device properly. |
| d. | Do not give epinephrine and isoproterenol at the same time or within 4 hours of each other. |
| e. | For IV injection of epinephrine, dilute 1 ml of 1:1000 solution with 10 mL of sodium chloride injection, or use a commercial preparation of 1:10,000 concentration. For IV infusion of epinephrine, dilute 1 mg in 250 mL D5W. Administer in intensive care, when possible, using an infusion pump and a central IV line. Use parenteral solutions of epinephrine only if clear. Epinephrine is unstable in alkaline solutions. |
| f. | For IV infusion of isoproterenol and phenylephrine:  
(1) Administer in an intensive care unit when possible.  
(2) Use only clear drug solutions  
(3) Dilute isoproterenol in 500 mL of 5% dextrose injection. Phenylephrine can be diluted in 5% dextrose injection or 0.9% sodium chloride solution. Do not add the drug until ready to use.  
(4) Use an infusion device to regulate flow rate accurately.  
(5) Use a “piggyback” IV apparatus.  
(6) Start the adrenergic drug solution slowly and increase flow rate according to the client’s response (eg, blood pressure, color, mental status). Slow or discontinue gradually as well. |
| g. | When giving adrenergic drugs as eye drops or nose drops, do not touch the dropper to the eye or nose. |

### RATIONALE/EXPLANATION

Inhalation medications are often administered by clients themselves or by respiratory therapists if intermittent positive-pressure breathing is used. The nurse may need to demonstrate and supervise self-administration initially.

Both of these drugs are potent cardiac stimulants, and the combination could cause serious cardiac arrhythmias. However, they have synergistic bronchodilating effects, and doses can be alternated and given safely if the drugs are given no more closely together than 4 hours.

Dilution increases safety of administration. A solution that is brown or contains a precipitate should not be used. Discoloration indicates chemical deterioration of epinephrine. Do not administer at same time sodium bicarbonate is being administered.

These drugs are given IV in emergencies, during which the client’s condition must be carefully monitored. Frequent recording of blood pressure and pulse and continuous electrocardiographic monitoring are needed.

A brownish color or precipitate indicates deterioration, and such solutions should not be used.

Mixing solutions when ready for use helps to ensure drug stability. Note that drug concentration varies with the amount of drug and the amount of IV solution to which it is added.

Flow rate usually requires frequent adjustment according to blood pressure measurements. An infusion device helps to regulate drug administration, so wide fluctuations in blood pressure are avoided.

Only one bottle contains an adrenergic drug, and it can be regulated or discontinued without disruption of the primary IV line.

To avoid abrupt changes in circulation and blood pressure Contaminated droppers can be a source of bacterial infection.

These depend on the reason for use.

Indicates prevention or relief of bronchospasm. Acute bronchospasm is usually relieved within 5 minutes by injected or inhaled epinephrine or inhaled isoproterenol.

Epinephrine injection usually relieves laryngeal edema and bronchospasm within 5 minutes and lasts for approximately 20 minutes.

These are indicators of improved circulation.

(continued)
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
d. When a drug is given nasally for decongestant effects, observe for decreased nasal congestion and ability to breathe through the nose.  
e. When given as eye drops for vasoconstrictor effects, observe for decreased redness. When giving for mydriatic effects, observe for pupil dilation.

3. **Observe for adverse effects**

a. Cardiovascular effects—cardiac dysrhythmias, hypertension  
   - Tachycardia and hypertension are common; if severe or prolonged, myocardial ischemia or heart failure may occur. Premature ventricular contractions and other serious dysrhythmias may occur. Propranolol (Inderal) or another beta blocker may be given to decrease heart rate and hypertension resulting from overdosage of adrenergic drugs. Phentolamine (Regitine) may be used to decrease severe hypertension.

b. Excessive central nervous system (CNS) stimulation—nervousness, anxiety, tremor, insomnia  
   - These effects are more likely to occur with ephedrine or high doses of other adrenergic drugs. Sometimes, a sedative-type drug is given concomitantly to offset these effects.

c. Rebound nasal congestion, rhinitis, possible ulceration of nasal mucosa  
   - These effects occur with excessive use of nasal decongestant drugs.

4. **Observe for drug interactions**

a. Drugs that *increase* effects of adrenergic drugs:
   
   1. Anesthetics, general (eg, halothane)  
   2. Anticholinergics (eg, atropine)  
   3. Antidepressants, tricyclic (eg, amitriptyline [Elavil])  
   4. Antihistamines  
   5. Cocaine  
   6. Digoxin  
   7. Doxapram (Dopram)  
   8. Ergot alkaloids  
   9. Monoamine oxidase (MAO) inhibitors (eg, isocarboxazid [Marplan])

   - Most of these drugs increase incidence or severity of adverse reactions.

   - Increased risk of cardiac dysrhythmias. Potentially hazardous.  
   - Increased bronchial relaxation. Also increased mydriasis and therefore contraindicated with narrow-angle glaucoma.  
   - Increased pressor response with intravenous epinephrine  
   - May increase pressor effects  
   - Increases pressor and mydriatic effects by inhibiting uptake of noradrenaline by nerve endings. Cardiac dysrhythmias, convulsions, and acute glaucoma may occur.  
   - Sympathomimetics, especially beta-adrenergics like epinephrine and isoproterenol, increase the likelihood of cardiac dysrhythmias due to ectopic pacemaker activity.  
   - Increased pressor effect  
   - Increased vasoconstriction. Extremely high blood pressure may occur. There also may be decreased perfusion of fingers and toes.  
   - Contraindicated. The combination may cause death. When these drugs are given concurrently with adrenergic drugs, there is danger of cardiac dysrhythmias, respiratory depression, and acute hypertensive crisis with possible intracranial hemorrhage, convulsions, coma, and death. Effects of MAO inhibitors may not occur for several weeks after treatment is started and may last up to 3 weeks after the drug is stopped. Every client taking MAO inhibitors should be warned against taking any other medication without the advice of a physician or pharmacist.
**Review and Application Exercises**

1. How do adrenergic drugs act to relieve symptoms of acute bronchospasm, anaphylaxis, cardiac arrest, hypotension and shock, and nasal congestion?

2. Which adrenergic receptors are stimulated by administration of epinephrine?

3. Why is it important to have epinephrine and other adrenergic drugs readily available in all health care settings?

4. Which adrenergic drug is the drug of choice to treat acute anaphylactic reactions?

5. Why is inhaled epinephrine not a drug of choice for long-term treatment of asthma and other bronchoconstrictive disorders?

6. What are the major adverse effects of adrenergic drugs?

7. Why are clients with cardiac arrhythmias, angina pectoris, hypertension, or diabetes mellitus especially likely to experience adverse reactions to adrenergic drugs?

8. For a client who reports frequent use of OTC asthma remedies and cold remedies, what teaching is needed to increase client safety?

9. Mentally rehearse nursing interventions for various emergency situations (anaphylaxis, acute respiratory distress, cardiac arrest) in terms of medications and equipment needed and how to obtain them promptly.

10. What signs and symptoms occur with overdose of non-catecholamine adrenergic drugs? What interventions are needed to treat the toxicity?

**SELECTED REFERENCES**


Antiadrenergic Drugs

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. List characteristics of antiadrenergic drugs in terms of effects on body tissues, indications for use, nursing process implications, principles of therapy, and observation of client response.

2. Discuss alpha1-adrenergic blocking agents and alpha2-adrenergic agonists in terms of indications for use, adverse effects, and selected other characteristics.

3. Compare and contrast beta-adrenergic blocking agents in terms of cardioselectivity, indications for use, adverse effects, and selected other characteristics.

4. Teach clients about safe, effective use of antiadrenergic drugs.

5. Discuss principles of therapy and nursing process for using antiadrenergic drugs in special populations.

Critical Thinking Scenario

Joe Moore, 56 years of age, comes to the clinic with complaints of chest pain with exertion. His vital signs are blood pressure (BP) 194/88, pulse 92, respiration 18. His primary provider prescribes a selective beta blocker, atenolol (Tenormin), and schedules a follow-up visit in 2 weeks.

Reflect on:

✓ Why a beta blocker is ordered for this patient.
✓ What are the advantages of using a selective rather that a nonselective beta blocker?
✓ What side effects are likely when a patient is started on atenolol?
✓ Describe a teaching plan for this patient.

DESCRIPTION

Antiadrenergic or sympatholytic drugs decrease or block the effects of sympathetic nerve stimulation, endogenous catecholamines (eg, epinephrine), and adrenergic drugs. The drugs are chemically diverse and have a wide spectrum of pharmacologic activity, with specific effects depending mainly on the client’s health status when a drug is given and the drug’s binding with particular adrenergic receptors. Included here are clonidine and related centrally active antiadrenergic drugs, which are used primarily in the treatment of hypertension, and peripherally active agents (alpha- and beta-adrenergic blocking agents), which are used to treat various cardiovascular and other disorders. A few uncommonly used antiadrenergic drugs for hypertension are included in Chapter 55.

A basal level of sympathetic tone is necessary to maintain normal body functioning, including regulation of blood pressure, blood glucose, and stress response. Therefore, the goal of antiadrenergic drug therapy is to suppress pathologic stimulation, not the normal, physiologic response to activity, stress, and other stimuli.

Mechanisms of Action and Effects

Antiadrenergic effects can occur either when alpha, or beta receptors are blocked by adrenergic antagonists or when presynaptic alpha, receptors are stimulated by agonist drugs (see Chap. 17). Most antiadrenergic drugs have antagonist (blocking) effects in which they combine with alpha1, beta1, beta2, or a combination of receptors in peripheral tissues and prevent adrenergic (sympathomimetic) effects. Clonidine and related drugs have agonist effects at presynaptic alpha2 receptors in the brain. This results in a negative feedback type of mechanism that decreases the release of additional norepinephrine. Thus, the overall effect is decreased sympathetic outflow...
from the brain and antiadrenergic effects on peripheral tissues (i.e., decreased activation of alpha and beta receptors by norepinephrine throughout the body).

**Alpha-Adrenergic Agonists and Blocking Agents**

*Alpha₂-adrenergic agonists* inhibit the release of norepinephrine in the brain, thereby decreasing the effects of sympathetic nervous system stimulation throughout the body. A major clinical effect is decreased blood pressure. Although clinical effects are attributed mainly to drug action at presynaptic alpha₂ receptors in the brain, postsynaptic alpha₂ receptors in the brain and peripheral tissues (e.g., vascular smooth muscle) may also be involved. Activation of alpha₂ receptors in the pancreatic islets suppresses insulin secretion.

*Alpha₁-adrenergic blocking agents* occupy alpha₁-adrenergic receptor sites in smooth muscles and glands innervated by sympathetic nerve fibers. These drugs act primarily in the skin, mucosa, intestines, lungs, and kidneys to prevent alpha-mediated vasoconstriction. Specific effects include dilation of arterioles and veins, increased local blood flow, decreased blood pressure, constriction of pupils, and increased motility of the gastrointestinal tract. Alpha-adrenergic antagonists may activate reflexes that oppose the fall in blood pressure by increasing heart rate and cardiac output and causing fluid retention.

The drugs also can prevent alpha-mediated contraction of smooth muscle in nonvascular tissues. For example, benign prostatic hyperplasia (BPH) is characterized by obstructed urine flow because the enlarged prostate gland presses on the urethra. Alpha blocking agents can decrease urinary retention and improve urine flow by inhibiting contraction of muscles in the prostate and urinary bladder.

*Nonselective alpha-adrenergic blocking agents* occupy peripheral alpha₁ receptors to cause vasodilation and alpha₂ receptors to cause cardiac stimulation. Consequently, decreased blood pressure is accompanied by tachycardia and perhaps other dysrhythmias.

**Beta-Adrenergic Blocking Drugs**

*Beta-adrenergic blocking agents* occupy beta-adrenergic receptor sites and prevent the receptors from responding to sympathetic nerve impulses, circulating catecholamines, and beta-adrenergic drugs (Fig. 19–1). Specific effects include:

1. Decreased heart rate (negative chronotropy)
2. Decreased force of myocardial contraction (negative inotropy)
3. Decreased cardiac output at rest and with exercise
4. Slowed conduction through the atrioventricular (AV) node (negative dromotropy)
5. Decreased automaticity of ectopic pacemakers
6. Decreased renin secretion from the kidneys
7. Decreased blood pressure in supine and standing positions. This effect occurs primarily in people with hypertension.
8. Bronchoconstriction from blockade of beta₂ receptors in bronchial smooth muscle. This effect occurs primarily in people with asthma or other chronic lung diseases.
9. Less effective metabolism of glucose (decreased glycogenolysis) when needed by the body, especially in people taking beta-blocking agents along with antidiabetic drugs. These clients may experience more severe and prolonged hypoglycemia. In addition, early symptoms of hypoglycemia (e.g., tachycardia) may be blocked, delaying recognition of the hypoglycemia.
10. Decreased production of aqueous humor in the eye
11. Chronic use of beta blockers is associated with increased very–low-density lipoprotein (VLDL) and decreased high-density lipoprotein (HDL) cholesterol. These changes pose a potential risk for patients with cardiovascular disease.
12. Diminished portal vein pressure in patients with cirrhosis

**Indications for Use**

*Alpha-Adrenergic Agonists and Blocking Agents*

Alpha₂ agonists are used in the treatment of hypertension. Clonidine, administered by the epidural route, is also approved for the relief of severe pain in cancer patients. Investigational uses of clonidine include treatment of alcohol withdrawal and opioid dependence, treatment of drug-induced akathisia, tic
disorders, postmenopausal hot flashes, adjunct medication during anesthesia, treatment of migraines, and attention deficit-hyperactivity disorder. Clonidine has not received approval by the Food and Drug Administration (FDA) for these purposes.

Alpha-adrenergic blocking agents are used in the treatment of hypertension, BPH, vasospastic disorders, and persistent pulmonary hypertension in the newborn. Nonselective alpha-blocking agents are not used as antihypertensive drugs except in hypertension caused by excessive catecholamines. Excessive catecholamines may result from overdosage of adrenergic drugs or from pheochromocytoma, a rare tumor of the adrenal medulla that secretes epinephrine and norepinephrine and causes hypertension, tachycardia, and cardiac dysrhythmias. Although the treatment of choice for pheochromocytoma is surgical excision, alpha-adrenergic blocking drugs are useful adjuncts. They are given before and during surgery, usually in conjunction with beta blockers. Nonselective alpha blockers also are used in vascular diseases characterized by vasospasm, such as Raynaud’s disease and frostbite, in which they improve blood flow. Phentolamine (Regitine) also can be used to prevent tissue necrosis from extravasation of potent vasoconstrictors (eg, norepinephrine, dopamine) into subcutaneous tissues.

**Beta-Adrenergic Blocking Drugs**

Clinical indications for use of beta-blocking agents are mainly cardiovascular disorders (ie, angina pectoris, cardiac tachyarrhythmias, hypertension, myocardial infarction, congestive heart failure, and glaucoma).

In angina, beta blockers decrease myocardial contractility, cardiac output, heart rate, and blood pressure. These effects decrease myocardial oxygen demand (cardiac workload), especially in response to activity, exercise, and stress. In dysrhythmias, drug effects depend on the sympathetic tone of the heart (ie, the degree of adrenergic stimulation of the heart that the drug must block or overcome). The drugs slow the sinus rate and prolong conduction through the AV node, thereby slowing the ventricular response rate to supraventricular tachyarrhythmias.

In hypertension, the actions by which the drugs lower blood pressure are unclear. Possible mechanisms include reduced cardiac output, inhibition of renin, and inhibition of sympathetic nervous system stimulation in the brain. However, the drugs effective in hypertension do not consistently demonstrate these effects—in other words, a drug may lower blood pressure without reducing cardiac output or inhibiting renin, for example. After myocardial infarction, the drugs help protect the heart from reinfarction and decrease mortality rates over several years. A possible mechanism is preventing or decreasing the incidence of catecholamine-induced dysrhythmias. In congestive heart failure (CHF), beta blockers have a limited role and require careful monitoring on the part of the physician and the nurse. Administration of beta blockers may acutely worsen the condition of persons with congestive heart failure by blocking the sympathetic stimulation that helps to maintain cardiac output. However, in selected patients who are able to tolerate the effects of beta blockers, the drugs are beneficial. For these patients, beta blockers decrease the risk of sudden cardiac death and may reduce ventricular remodeling that accompanies CHF and leads to further deterioration of cardiac function.

In glaucoma, the drugs reduce intraocular pressure by binding to beta-adrenergic receptors in the ciliary body of the eye and decreasing formation of aqueous humor.

**Propranolol** (Inderal) is the prototype of beta-adrenergic blocking agents. It is also the oldest and most extensively studied beta blocker. In addition to its use in the treatment of hypertension, dysrhythmias, angina pectoris, and myocardial infarction, propranolol is used to treat a wide variety of other conditions. In hypertrophic obstructive cardiomyopathy, it is used to improve exercise tolerance by increasing stroke volume. In pheochromocytoma, it is used in conjunction with an alpha-blocking agent to counter the effect of excessive catecholamine secretion, preventing tachycardia and dysrhythmias. Propranolol is useful in treating dissecting aortic aneurysms by decreasing systolic blood pressure. Propranolol decreases heart rate, cardiac output, and tremor in patients with hyperthyroidism. It is also useful, by an unknown mechanism, for the prevention of migraine headaches. Propranolol is not helpful in acute attacks of migraine headaches. The drug also relieves palpitation and tremor associated with anxiety and stage fright, but it is not approved for clinical use as an antianxiety drug. Some patients experiencing alcohol withdrawal may also benefit from the administration of propranolol.

In cirrhosis of the liver, research indicates that propranolol may decrease the incidence of the initial episode of bleeding esophageal varices, prevent rebleeding episodes, and decrease the mortality rate due to hemorrhage.

**Contraindications to Use**

Alpha, agonists are contraindicated in clients with hypersensitivity to the drugs, and methyldopa is also contraindicated in clients with active liver disease. Alpha-adrenergic blocking agents are contraindicated in angina pectoris, myocardial infarction, and stroke. Beta-adrenergic blocking agents are contraindicated in bradycardia, heart block, and asthma and other allergic or pulmonary conditions characterized by bronchoconstriction. Although new research has shown that beta blockers can be beneficial to selected clients with mild to moderate chronic heart failure, the drugs have not been proven safe for people older than 80 years of age or those with severe heart failure.

**INDIVIDUAL ANTIADRENERGIC DRUGS**

These drugs are described in the following sections. Trade names, clinical indications, and dosage ranges are listed in Drugs at a Glance: Alpha-Adrenergic Agonists and Blocking
Alpha-Adrenergic Agonists and Blocking Agents

Alpha₂-adrenergic agonists include clonidine, guanabenz, guanfacine, and methyldopa. These drugs produce similar therapeutic and adverse effects but differ in their pharmacokinetics and frequency of administration. Oral clonidine reduces blood pressure within 1 hour, reaches peak plasma levels in 3 to 5 hours, and has a plasma half-life of approximately 12 to 16 hours (longer with renal impairment). Approximately half the oral dose is metabolized in the liver; the remainder is excreted unchanged in urine. With transdermal clonidine, therapeutic plasma levels are reached in 2 to 3 days and last 1 week. Guanabenz action occurs within 1 hour, peaks within 2 to 4 hours, and lasts 6 to 8 hours. It is metabolized extensively; very little unchanged drug is excreted in urine. Guanfacine is well absorbed and widely distributed, with approximately 70% bound to plasma proteins. Peak plasma levels occur in 1 to 4 hours and the half-life is 10 to 30 hours. Approximately half is metabolized and the metabolites and unchanged drug are excreted in urine. Because of its longer half-life, guanfacine can be given once daily. Methyldopa is an older drug with low to moderate absorption, peak plasma levels in 2 to 4 hours, and peak antihypertensive effects in approximately 2 days. When discontinued, blood pressure rises in approximately 2 days. Intravenous administration reduces blood pressure in 4 to 6 hours and lasts 10 to 16 hours. Methyldopa is metabolized to some extent in the liver but is largely excreted in urine. In clients with renal impairment, blood pressure–lowering effects may be pronounced and pro-

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alpha₂-Agonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine (Catapres)</td>
<td>Hypertension</td>
<td>PO 0.1 mg 2 times daily initially, gradually increased if necessary. Average maintenance dose, 0.2–0.8 mg/d. Transdermal 0.1-mg patch every 7 d initially; increase every 7–14 d to 0.2 mg or 0.3 mg if necessary. Maximum dose, two 0.3-mg patches every 7 d.</td>
</tr>
<tr>
<td>Guanabenz (Wytensin)</td>
<td>Hypertension</td>
<td>PO 4 mg twice daily, increased by 4–8 mg/d every 1–2 wk if necessary to a maximal dose of 32 mg twice daily.</td>
</tr>
<tr>
<td>Guanfacine (Tenex)</td>
<td>Hypertension</td>
<td>PO 1 mg daily at bedtime, increased to 2 mg after 3–4 wk, then to 3 mg if necessary. Adults: PO 250 mg 2 or 3 times daily initially, increased gradually at intervals of not less than 2 d until blood pressure is controlled or a daily dose of 3 g is reached. Children: PO 10 mg/kg/d in 2 to 4 divided doses initially, increased or decreased according to response. Maximal dose, 65 mg/kg/d or 3 g daily, whichever is less.</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>Hypertension</td>
<td>PO 1 mg once daily initially, increased to 2 mg, then to 4, 8, and 16 mg if necessary.</td>
</tr>
</tbody>
</table>

| **Alpha₁-Blocking Agents** |                      |                          |
| Doxazosin (Cardura)       | Hypertension, BPH    | PO 1 mg once daily initially, increased to 2 mg, then to 4, 8, and 16 mg if necessary. |
| Prazosin (Minipress)      | Hypertension, BPH    | PO 1 mg 2 to 3 times daily initially, increased if necessary to a total daily dose of 20 mg in divided doses. Average maintenance dose, 6–15 mg/d. |
| Tamsulosin HCl (Flomax)   | BPH                  | PO 0.4 mg/d after same meal each day. Dose may be increased if needed after 2–4 wk trial period. |
| Terazosin (Hytrin)        | Hypertension         | PO 1 mg at bedtime initially, increased gradually to maintenance dose, usually 1–5 mg once daily, 1–5 mg once daily |
| Tolazoline (Priscoline)   | Vasospastic disorders | SC, IM, IV 10–50 mg q6h |

| **Nonselective Alpha-Blocking Agents** |                      |                          |
| Phenoxycyanurate (Dibenzyline) | Hypertension caused by pheochromocytoma, Raynaud’s disorder, Frostbite | PO 10 mg daily initially, gradually increased by 10 mg every 4 d until therapeutic effects are obtained or adverse effects become intolerable; optimum dosage level usually reached in 2 wk; usual maintenance dose 20–60 mg/d. Before and during surgery for pheochromocytoma: IV, IM 5–20 mg as needed to control blood pressure. |
| Phentolamine (Regitine)      | Hypertension caused by pheochromocytoma, Prevention of tissue necrosis from extravasation of vasoconstrictive drugs | Prevention of tissue necrosis: IV 10 mg in each liter of IV solution containing a potent vasoconstrictor. Treatment of extravasation: SC 5–10 mg in 10 mL saline, infiltrated into the area within 12 h |

BPH, benign prostatic hyperplasia; IM, intramuscular; IV, intravenous; PO, oral; SC, subcutaneous.
## Drugs at a Glance: Beta-Adrenergic Blocking Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nonselective Blocking Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carteolol (Cartrol, Ocupress)</td>
<td>Hypertension, Glaucoma</td>
<td>PO: Initially, 2.5 mg once daily, gradually increased to a maximum daily dose of 10 mg if necessary. Usual maintenance dose, 2.5–5 mg once daily. Extend dosage interval to 48 h for a creatinine clearance of 20–60 mL/min and to 72 h for a creatinine clearance below 20 mL/min. Topically to affected eye, 1 drop twice daily.</td>
</tr>
<tr>
<td>Levobunolol (Betagan)</td>
<td>Glaucoma</td>
<td>Topically to each eye, 1 drop once or twice daily.</td>
</tr>
<tr>
<td>Metipranolol (OptiPranolol)</td>
<td>Glaucoma</td>
<td>PO 20 mg once daily</td>
</tr>
<tr>
<td>Penbutolol (Levatol)</td>
<td>Hypertension</td>
<td>PO 40 mg twice daily initially, may be increased to 120–240 mg daily in divided doses. Maximal daily dose, 640 mg. Sustained release capsules, PO 80 mg once daily, may be increased to 120–160 mg once daily.</td>
</tr>
<tr>
<td>Propranolol (Inderal)</td>
<td>Hypertension</td>
<td>PO 20–40 mg daily initially, may be increased to 120–240 mg daily in divided doses. Maximal daily dose, 320 mg. Sustained release, PO 80–160 mg once daily.</td>
</tr>
<tr>
<td>Nadolol (Corgard)</td>
<td>Hypertension, Angina pectoris</td>
<td>Hypertension, PO 40 mg once daily initially, gradually increased. Usual daily maintenance dose, 80–320 mg. Angina, PO 40 mg once daily initially, increased by 40–80 mg at 3- to 7-d intervals. Usual daily maintenance dose, 80–240 mg. PO 5 mg twice daily initially, increased by 10 mg every 3–4 wk, to a maximal daily dose of 60 mg if necessary.</td>
</tr>
<tr>
<td>Pindolol (Visken)</td>
<td>Hypertension</td>
<td>Hypertension, PO 10 mg twice daily initially, increased at 7-d intervals to a maximum of 60 mg/d in 2 divided doses; usual maintenance dose, 20–40 mg daily. Myocardial infarction, PO 10 mg twice daily.</td>
</tr>
<tr>
<td>Sotalol (Betapace)</td>
<td>Cardiac dysrhythmias</td>
<td>Hypertension, PO 180–240 mg daily in 3 or 4 divided doses. Maximal daily dose, 240 mg.</td>
</tr>
<tr>
<td>Timolol (Blocadren, Timoptic)</td>
<td>Hypertension, Myocardial infarction, Glaucoma</td>
<td>PO 20–40 mg daily in 3 or 4 divided doses. Sustained release, PO 80–160 mg once daily. PO 80–240 mg daily in divided doses. Sustained release, PO 80 mg once daily.</td>
</tr>
<tr>
<td><strong>Cardioselective Blocking Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acebutolol (Sectral)</td>
<td>Hypertension, Ventricular dysrhythmias</td>
<td>Hypertension, PO 400 mg daily in 1 or 2 doses; usual maintenance dose, 400–800 mg daily. Dysrhythmias, PO 400 mg daily in 2 divided doses; usual maintenance dose, 600–1200 mg daily.</td>
</tr>
<tr>
<td>Atenolol (Tenormin)</td>
<td>Hypertension, Angina pectoris, Myocardial infarction</td>
<td>Hypertension, PO 50–100 mg daily. Angina, PO 50–100 mg daily, increased to 200 mg daily if necessary. Myocardial infarction, IV 5 mg over 5 min, then 5 mg 10 min later, then 50 mg PO 10 min later, then 50 mg 12 h later. Thereafter, PO 100 mg daily, in 1 or 2 doses, for 6–9 d or until discharge from hospital.</td>
</tr>
<tr>
<td>Betaxolol (Betoptic, Kerlone)</td>
<td>Glaucoma</td>
<td>Topically to each eye, 1 drop twice daily.</td>
</tr>
<tr>
<td>Bisoprolol (Zebeta)</td>
<td>Hypertension</td>
<td>Hypertension, PO 10–20 mg daily.</td>
</tr>
<tr>
<td>Esmolol (Brevibloc)</td>
<td>Hypertension, Supraventricular tachyarrhythmias</td>
<td>IV 50–200 mcg/kg per minute; average dose, 100 mcg/kg per minute, titrated to effect with close monitoring of client’s condition.</td>
</tr>
<tr>
<td>Metoprolol (Lopressor)</td>
<td>Hypertension, Myocardial infarction</td>
<td>Hypertension, PO 100 mg daily in single or divided doses, increased at 7-d or longer intervals; usual maintenance dose, 100–450 mg/d. Myocardial infarction, early treatment, IV 5 mg every 2 min for total of 3 doses (15 mg), then 50 mg PO q6h for 48 h, then 100 mg PO twice daily. Myocardial infarction, late treatment, PO 100 mg twice daily, at least 3 months, up to 1–3 y.</td>
</tr>
</tbody>
</table>

(continued)
Alpha-Beta-blocking Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carvedilol (Coreg)</td>
<td>Hypertension</td>
<td>PO 6.25 mg twice daily for 7–14 d, then increase to 12.5 mg twice daily if necessary (maximum dose).</td>
</tr>
<tr>
<td></td>
<td>Congestive heart failure</td>
<td>PO 100 mg twice daily for 7–14 d, then increase to 25 mg twice daily if necessary (maximum dose).</td>
</tr>
<tr>
<td>Labetalol (Trandate, Normodyne)</td>
<td>Hypertension, including hypertensive emergencies</td>
<td>IV 20 mg over 2 min then 40–80 mg every 10 min until desired blood pressure achieved or 300 mg given</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV infusion 2 mg/min (eg, add 200 mg of drug to 250 mL 5% dextrose solution for a 2 mg/3 mL concentration)</td>
</tr>
</tbody>
</table>

Nonselective alpha-adrenergic blocking agents include phenoxybenzamine and phentolamine. Phenoxybenzamine (Dibenzylidine) is long acting; the effects of a single dose persist for 3 to 4 days. Phentolamine (Regitine) is similar to phenoxybenzamine but more useful clinically. Phentolamine is short acting; effects last only a few hours and can be reversed by an alpha-adrenergic stimulant drug, such as norepinephrine (Levophed).

**Beta-Adrenergic Blocking Drugs**

Numerous beta-blocking agents are marketed in the United States. Although they produce similar effects, they differ in several characteristics, including clinical indications for use, receptor selectivity, intrinsic sympathomimetic activity, membrane-stabilizing ability, lipid solubility, routes of excretion, routes of administration, and duration of action.

**Clinical Indications**

Most beta blockers are approved for the treatment of hypertension. A beta blocker may be used alone or with another antihypertensive drug, such as a diuretic. Labetalol is also approved for treatment of hypertensive emergencies. Atenolol, metoprolol, nadolol, and propranolol are approved as antianginal agents; acebutolol, esmolol, propranolol, and sotalol are approved as antiarrhythmic agents. Atenolol, metoprolol, propranolol, and timolol are used to prevent myocardial infarction or reinfarction. Betaxolol, carteolol, and timolol are used for hypertension and glaucoma; levobunolol and metipranolol are used only for glaucoma.

Beta blockers have traditionally been considered contraindicated in clients with heart failure because of their ability to decrease cardiac function. A growing number of studies, however, are showing that beta blockers are useful not only in the treatment of mild to moderate cases of chronic heart failure but in reducing the risk of sudden death in these clients. The only beta blocker approved by the FDA to treat heart failure is carvedilol. Treatment should begin with a low dose of the beta blocker, administered concurrently with an angiotensin-converting enzyme (ACE) inhibitor. The purpose of the ACE inhibitor is to counteract any initial worsen-
Receptor Selectivity

Carteolol, levobunolol, metipranolol, penbutolol, nadolol, pindolol, propranolol, sotalol, and timolol are nonselective beta blockers. The term nonselective indicates that the drugs block both beta1 (cardiac) and beta2 (mainly smooth muscle in the bronchi and blood vessels) receptors. Blockade of beta2 receptors is associated with adverse effects such as bronchodilatation, peripheral vasoconstriction, and interference with glycojenolysis.

Acebutolol, atenolol, betaxolol, bisoprolol, esmolol, and metoprolol are cardioselective agents, which means they have more effect on beta1 receptors than on beta2 receptors. As a result, they may cause less bronchospasm, less impairment of glucose metabolism, and less peripheral vascular insufficiency. These drugs are preferred when beta blockers are needed by clients with asthma or other bronchospastic pulmonary disorders, diabetes mellitus, or peripheral vascular disorders. However, cardioselectivity is lost at higher doses because most organs have both beta1 and beta2 receptors rather than one or the other exclusively.

Labetalol and carvedilol block alpha receptors to cause vasodilation and beta1 and beta2 receptors to cause all the effects of the nonselective agents. Both alpha- and beta-adrenergic blocking actions contribute to antihypertensive effects, but it is unclear whether these drugs have any definite advantage over other beta blockers. They may cause less bradycardia but more postural hypotension than other beta-blocking agents, and they may cause less reflex tachycardia than other vasodilators.

Intrinsic Sympathomimetic Activity

Drugs with this characteristic (ie, acebutolol, carteolol, penbutolol, and pindolol) have a chemical structure similar to that of catecholamines. As a result, they can block some beta receptors and stimulate others. Consequently, these drugs are less likely to cause bradycardia and may be useful for clients experiencing bradycardia with other beta blockers.

Membrane-Stabilizing Activity

Several beta blockers have a membrane-stabilizing effect sometimes described as quinidine-like (ie, producing myocardial depression). Because the doses required to produce this effect are much higher than those used for therapeutic effects, this characteristic is considered clinically insignificant.

Lipid Solubility

The more lipid-soluble beta blockers were thought to penetrate the central nervous system (CNS) more extensively and cause adverse effects such as confusion, depression, hallucinations, and insomnia. Some clinicians state that this characteristic is important only in terms of drug usage and excretion in certain disease states. Thus, a water-soluble, renally excreted beta blocker may be preferred in clients with liver disease and a lipid-soluble, hepatically metabolized drug may be preferred in clients with renal disease.

Routes of Elimination

Most beta-blocking agents are metabolized in the liver. Atenolol, carteolol, nadolol, and an active metabolite of acebutolol are excreted by the kidneys; dosage must be reduced in the presence of renal failure.

Routes of Administration

Most beta blockers can be given orally. Atenolol, esmolol, labetalol, metoprolol, and propranolol also can be given intravenously, and ophthalmic solutions are applied topically to the eye. Betaxolol, carteolol, and timolol are available in oral and ophthalmic forms.

Duration of Action

Acebutolol, atenolol, bisoprolol, carteolol, penbutolol, and nadolol have long serum half-lives and can usually be given once daily. Carvedilol, labetalol, metoprolol, pindolol, sotalol, and timolol are usually given twice daily. Propranolol required administration several times daily until development of a sustained-release capsule allowed once-daily dosing.

How Can You Avoid This Medication Error?

In the bronchi and blood vessels) receptors. Blockade of beta 2 because most organs have both beta1 and beta 2 receptors disorders. However, cardioselectivity is lost at higher doses pulmonary disorders, diabetes mellitus, or peripheral vascular needed by clients with asthma or other bronchospastic pul-
sufficiency. These drugs are preferred when beta blockers are ment of glucose metabolism, and less peripheral vascular in-
geneolysis.
As a result, they may cause less bronchospasm, less impair-
gent of muscle in the bronchi and blood vessels) receptors. Blockade of beta2 receptors is associated with adverse effects such as bron-
choconstriction, peripheral vasoconstriction, and interference with glycojenolysis.

Acebutolol, atenolol, betaxolol, bisoprolol, esmolol, and metoprolol are cardioselective agents, which means they have more effect on beta1 receptors than on beta2 receptors. As a result, they may cause less bronchospasm, less impairment of glucose metabolism, and less peripheral vascular insufficiency. These drugs are preferred when beta blockers are needed by clients with asthma or other bronchospastic pulmonary disorders, diabetes mellitus, or peripheral vascular disorders. However, cardioselectivity is lost at higher doses because most organs have both beta1 and beta2 receptors rather than one or the other exclusively.

Labetalol and carvedilol block alpha receptors to cause vasodilation and beta1 and beta2 receptors to cause all the effects of the nonselective agents. Both alpha- and beta-adrenergic blocking actions contribute to antihypertensive effects, but it is unclear whether these drugs have any definite advantage over other beta blockers. They may cause less bradycardia but more postural hypotension than other beta-blocking agents, and they may cause less reflex tachycardia than other vasodilators.

Intrinsic Sympathomimetic Activity

Drugs with this characteristic (ie, acebutolol, carteolol, penbutolol, and pindolol) have a chemical structure similar to that of catecholamines. As a result, they can block some beta receptors and stimulate others. Consequently, these drugs are less likely to cause bradycardia and may be useful for clients experiencing bradycardia with other beta blockers.

Membrane-Stabilizing Activity

Several beta blockers have a membrane-stabilizing effect sometimes described as quinidine-like (ie, producing myocardial depression). Because the doses required to produce this effect are much higher than those used for therapeutic effects, this characteristic is considered clinically insignificant.
is stimulated by physical and emotional stress, efforts to decrease stress may indirectly decrease the need for drugs to antagonize sympathetic effects. Such efforts may include the following:

- Helping the client stop or decrease cigarette smoking. Nicotine stimulates the CNS and the sympathetic nervous system to cause tremors, tachycardia, and elevated blood pressure.
- Teaching measures to relieve pain, anxiety, and other stresses
- Counseling regarding relaxation techniques
- Helping the client avoid temperature extremes
- Helping the client avoid excessive caffeine in coffee or other beverages
- Helping the client develop a reasonable balance among rest, exercise, work, and recreation
- Recording vital signs at regular intervals in hospitalized clients to monitor for adverse effects
- Helping with activity or ambulation as needed to prevent injury from dizziness

**Evaluation**

- Observe for decreased blood pressure when antiadrenergic drugs are given for hypertension.
- Interview regarding decreased chest pain when beta blockers are given for angina.
- Interview and observe for signs and symptoms of adverse drug effects (eg, edema, tachycardia with alpha agonists and blocking agents; bradycardia, congestive heart failure, bronchoconstriction with beta blockers).
- Interview regarding knowledge and use of drugs.
dine, for example, the dose should be gradually reduced over 2 to 4 days.

4. When phenoxybenzamine is given on a long-term basis, dosage must be carefully individualized. Because the drug is long acting and accumulates in the body, dosage is small initially and gradually increased at intervals of approximately 4 days. Several weeks may be required for full therapeutic benefit, and drug effects persist for several days after the drug is discontinued. If circulatory shock develops from overdosage or hypersensitivity, norepinephrine (Levophed) can be given to overcome the blockade of alpha-adrenergic receptors in arterioles and to raise blood pressure. Epinephrine is contraindicated because it stimulates both alpha- and beta-adrenergic receptors, resulting in increased vasodilation and hypotension.

Beta-Adrenergic Blocking Drugs

1. For most people, a nonselective beta blocker that can be taken once or twice daily is acceptable. For others, the

CLIENT TEACHING GUIDELINES
Alpha₂ Agonists and Alpha-Blocking Agents

General Considerations

- Have your blood pressure checked regularly. Report high or low values to your health care provider.
- The adverse reactions of palpitations, weakness, and dizziness usually disappear with continued use. However, they may recur with conditions promoting vasodilation (dosage increase, exercise, high environmental temperatures, ingesting alcohol or a large meal).
- To prevent falls and injuries, if the above reactions occur, sit down or lie down immediately and flex arms and legs. Change positions slowly, especially from supine to standing.
- Do not drive a car or operate machinery if drowsy or dizzy from medication.
- Do not stop the drugs abruptly. Hypertension, possibly severe, may develop.

With methyldopa, report any signs of abdominal pain, nausea, vomiting, diarrhea, or jaundice to your health care provider. Regular blood tests are needed to make sure the medication is working as it should.

Do not take over-the-counter or other medications without the physician’s knowledge. Many drugs interact to increase or decrease the effects of antiadrenergic drugs.

Self-Administration

- Sedation and first-dose syncope may be minimized by taking all or most of the prescribed dose at bedtime.
- When using the clonidine transdermal patch, select a hairless area on the upper arm or torso for the application. The patch is changed once a week.
- Avoid alcohol use with these medications because excessive drowsiness may occur.

CLIENT TEACHING GUIDELINES
Beta-Blocking Agents

General Considerations

- Count your pulse daily and report to a health care provider if under 50 for several days in succession. This information helps to determine if the drug therapy needs to be altered to avoid more serious adverse effects.
- Report weight gain (more than 2 pounds within a week), ankle edema, shortness of breath, or excessive fatigue. These are signs of heart failure. If they occur, the drug will be stopped.
- Report fainting spells, excessive weakness, or difficulty in breathing. Beta-blocking drugs decrease the usual adaptive responses to exercise or stress. Syncope may result from hypotension, bradycardia, or heart block; its occurrence probably indicates stopping or decreasing the dose of the drug.

- Do not stop the drugs abruptly. Stopping the drugs suddenly may cause or aggravate chest pain (angina).
- Do not take over-the-counter or other medications without the physician’s knowledge. Many drugs interact to increase or decrease the effects of beta-blocking agents.

Self-Administration

- Consistently take the drug at the same time each day with or without food. This maintains consistent therapeutic blood levels.
- Do not crush or chew long-acting forms of these medications.
choice of a beta-blocking agent depends largely on the client’s condition and response to the drugs. For example, cardioselective drugs are preferred for clients with pulmonary disorders and diabetes mellitus; a drug with intrinsic sympathomimetic activity may be preferred for those who experience significant bradycardia with beta blockers lacking this property.

2. Dosage of beta-blocking agents must be individualized because of wide variations in plasma levels from comparable doses. Variations are attributed to initial metabolism in the liver, the extent of binding to plasma proteins, and the degree of beta-adrenergic stimulation that the drugs must overcome. In general, low doses should be used initially and increased gradually until therapeutic or adverse effects occur. Adequacy of dosage or extent of beta blockade can be assessed by determining whether the heart rate increases in response to exercise.

3. When a beta blocker is used to prevent myocardial infarction (MI), it should be started as soon as the client is hemodynamically stable after a definite or suspected acute MI. The drug should be continued for at least 2 years. Studies have shown that such use of a beta blocker may reduce mortality by as much as 25%. However, many post-MI patients still do not receive a prescription for this medication.

4. Beta-blocking drugs should not be discontinued abruptly. Long-term blockade of beta-adrenergic receptors increases the receptors’ sensitivity to epinephrine and norepinephrine when the drugs are discontinued. There is a risk of severe hypertension, angina, dysrhythmias, and myocardial infarction from the increased or excessive sympathetic nervous system stimulation. Thus, dosage should be tapered and gradually discontinued to allow beta-adrenergic receptors to return to predrug density and sensitivity. An optimal tapering period has not been defined. Some authorities recommend 1 to 2 weeks; others recommend reducing dosage over approximately 10 days to 30 mg/day of propranolol (or an equivalent amount of other drugs) and continuing this amount at least 2 weeks before the drug is stopped completely.

5. Opinions differ regarding use of beta blockers before anesthesia and major surgery. On the one hand, the drugs block arrhythmogenic properties of some general inhalation anesthetics; on the other hand, there is a risk of excessive myocardial depression. If feasible, the drug may be tapered gradually and discontinued (at least 48 hours) before surgery. If the drug is continued, the lowest effective dosage should be given. If emergency surgery is necessary, the effects of beta blockers can be reversed by administration of beta receptor stimulants, such as dobutamine or isoproterenol.

6. Various drugs may be used to treat adverse effects of beta blockers. Atropine can be given for bradycardia, digoxin and diuretics for heart failure, vasopressors for hypotension, and bronchodilator drugs for bronchoconstriction.

Genetic or Ethnic Considerations

Most studies involve adults with hypertension and compare drug therapy responses between African Americans and whites. Findings indicate that monotherapy with alpha blockers and combination therapy with alpha and beta blockers is equally effective in the two groups. However, monotherapy with beta blockers is less effective in African Americans than in whites. When beta blockers are used in African Americans, they should usually be part of a multidrug treatment regimen, and higher doses may be required. In addition, labetalol, an alpha and beta blocker, has been shown to be more effective in the African-American population than propranolol, timolol, or metoprolol.

Several studies indicate that Asians achieve higher blood levels of beta blockers with given doses and, in general, need much smaller doses than whites. This increased sensitivity to the drugs may result from slower metabolism and excretion.

Use in Children

Most alpha-adrenergic agonists and blocking agents have not been established as safe and effective in children. Tolazoline (Priscoline), however, is an alpha blocker that is useful in the treatment of persistent pulmonary hypertension of the newborn. The vasodilatory effects reduce pulmonary pressure and decrease the workload of the right ventricle. Vital signs should be carefully monitored because hypotension or hypertension, tachycardia, and dysrhythmias may occur. Ephedrine should be used in the treatment of hypotension, should it occur, rather than epinephrine or norepinephrine. The child should also be monitored for peptic ulcer formation. Prophylaxis against stress ulcers should be considered.

Beta-adrenergic blocking agents are used in children for disorders similar to those occurring in adults. However, safety and effectiveness have not been established and manufacturers of most of the drugs do not recommend pediatric use or doses. The drugs are probably contraindicated in young children with resting heart rates below 60 beats per minute.

When a beta blocker is given, general guidelines include the following:

1. Dosage should be adjusted for body weight.
2. Monitor responses closely. Children are more sensitive to adverse drug effects than adults.
3. If beta blockers are given to infants (up to 1 year of age) with immature liver function, blood levels may be higher and accumulation is more likely even when doses are based on weight.
4. When monitoring responses, remember that heart rate and blood pressure vary among children according to age and level of growth and development. They also differ from those of adults.
5. Children are more likely to have asthma than adults. Thus, they may be at greater risk of drug-induced bronchoconstriction.

Propranolol is probably the most frequently used beta blocker in children. Intravenous administration is not recommended. The drug is given orally for hypertension, and dosage
should be individualized. The usual dosage range is 2 to 4 mg/kg/day in two equal doses. Dosage calculated from body surface area is not recommended because of excessive blood levels of drug and greater risk of toxicity. As with adults, dosage should be tapered gradually over 1 to 3 weeks. The drug should not be stopped abruptly.

**Use in Older Adults**

α₁-adrenergic agonists (clonidine and related drugs) may be used to treat hypertension in older adults; α₁-adrenergic antagonists (prazosin and related drugs) may be used to treat hypertension and BPH. Dosage of these drugs should be reduced because older adults are more likely to experience adverse drug effects, especially with impaired renal or hepatic function. As with other populations, these drugs should not be stopped suddenly. Instead, they should be tapered in dosage and discontinued gradually, over 1 to 2 weeks.

Beta-adrenergic blocking agents are commonly used in older adults for angina, dysrhythmias, hypertension, and glaucoma. With hypertension, beta blockers are not recommended for monotherapy because older adults may be less responsive than younger adults. Thus, the drugs are probably most useful as second drugs (with diuretics) in clients who require multiple drug therapy and clients who also have angina pectoris or another disorder for which a beta blocker is indicated.

Whatever the circumstances for using beta blockers in older adults, use them cautiously and monitor responses closely. Older adults are likely to have disorders that place them at high risk of adverse drug effects, such as heart failure and other cardiovascular conditions, renal or hepatic impairment, and chronic pulmonary disease. Thus, they may experience bradycardia, bronchoconstriction, and hypotension to a greater degree than younger adults. Dosage usually should be reduced because of decreased hepatic blood flow and subsequent slowing of drug metabolism. As with administration in other populations, beta blockers should be tapered in dosage and discontinued over 1 to 3 weeks to avoid myocardial ischemia and other potentially serious adverse cardiovascular effects.

**Use in Renal Impairment**

Centrally acting α₂ agonists such as clonidine, guanabenz, and methyldopa are eliminated by a combination of liver metabolism and renal excretion. Renal impairment may result in slower excretion of these medications with subsequent accumulation and increased adverse effects.

α₁-adrenergic antagonists such as prazosin, terazosin, doxazosin, and tamsulosin are eliminated primarily by liver metabolism and biliary excretion. Therefore, renal impairment is not a contraindication to use of these medications. Tolazoline, however, is excreted by the kidney and reduced dosages should be considered in the presence of renal impairment.

Many beta blockers are eliminated primarily in the urine and pose potentially serious problems for the client with renal failure. In renal failure, dosage of acebutolol, atenolol, carte-

olol, and nadolol must be reduced because they are eliminated mainly through the kidneys. The dosage of acebutolol and nadolol should be reduced if creatinine clearance is under 50 mL/minute; dosage of atenolol should be decreased if the creatinine clearance is under 35 mL/minute. With carteolol, the same amount is given per dose, but the interval between doses is extended to 48 hours for a creatinine clearance of 20 to 60 mL/minute and to 72 hours for a creatinine clearance below 20 mL/minute.

**Use in Liver Impairment**

Caution must be used when administering centrally acting α₁-adrenergic agonists such as clonidine, guanabenz, and methyldopa to clients with liver impairment. These medications rely on hepatic metabolism as well as renal elimination to clear the body. Liver impairment may result in increased drug levels and adverse effects. In the presence of hepatic disease (eg, cirrhosis) or impaired blood flow to the liver (eg, reduced cardiac output from any cause), dosage of some beta blockers such as propranolol, metoprolol, and timolol should be substantially reduced because these drugs are extensively metabolized in the liver. The use of atenolol or nadolol is preferred in liver disease because both are eliminated primarily by the kidneys.

**Use in Critical Illness**

Antiadrenergic drugs are one of several families of medications that may be used to treat urgent or malignant hypertension. An α₁ agonist such as clonidine might be prescribed under such conditions. A loading dose of clonidine 0.2 mg followed by 0.1 mg hourly until the diastolic pressure falls below 110 mm Hg may be administered. Do not exceed 0.7 mg when using clonidine to treat malignant hypertension.

Beta blockers may be used in the treatment of acute myocardial infarction. Early administration of a beta blocker after an acute myocardial infarction results in a lower incidence of reinfarction, ventricular dysrhythmias, and mortality. These results have been demonstrated with several different agents; however, those with intrinsic sympathomimetic activity are not prescribed for this purpose. Clients must be carefully monitored for hypotension and heart failure when receiving beta blockers after a myocardial infarction.

**Home Care**

Antiadrenergic drugs are commonly used in the home setting, mainly to treat chronic disorders in adults. With α₁-adrenergic blocking agents, the home care nurse may need to
teach clients ways to avoid orthostatic hypotension. Most clients probably take these medications for hypertension. However, some older men with BPH take one of these drugs to aid urinary elimination. For an older man taking one of these drugs, the home care nurse must assess the reason for use to teach the client and monitor for drug effects.

With beta-adrenergic blocking agents, the home care nurse may need to assist clients and caregivers in assessing for therapeutic and adverse drug effects. It is helpful to have the client or someone else in the household count and record the radial pulse daily, preferably about the same time interval before or after taking a beta blocker. Several days of a slow pulse should probably be reported to the health care provider who prescribed the beta blocker, especially if the client also has excessive fatigue or signs of heart failure.

If wheezing respirations (indicating bronchoconstriction) develop in a client taking a nonselective beta blocker, the client or the home care nurse must consult the prescribing physician about changing to a cardioselective beta blocker. If a client has diabetes mellitus, the home care nurse must interview and observe the client for alterations in blood sugar control, especially increased episodes of hypoglycemia. If a client has hypertension, the home care nurse must teach the client to avoid over-the-counter (OTC) asthma and cold remedies, decongestants, appetite suppressants, and herbal preparations such as ma huang, black cohosh and St. John’s wart because these drugs act to increase blood pressure and may reduce the benefits of antiadrenergic medications. In addition, OTC analgesics such as ibuprofen, ketoprofen, and naproxen may raise blood pressure by causing retention of sodium and water.

### Antiadrenergic Drugs

#### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td>To minimize daytime drowsiness and sedation</td>
</tr>
<tr>
<td>a. With alpha₂ agonists:</td>
<td>To promote effectiveness and safe usage</td>
</tr>
<tr>
<td>(1) Give all or most of a dose at bedtime, when possible.</td>
<td></td>
</tr>
<tr>
<td>(2) Apply the clonidine skin patch to a hairless, intact area on the upper arm or torso; then apply adhesive overlay securely. Do not cut or alter the patch. Remove a used patch and fold its adhesive edges together before discarding. Apply a new patch in a new site.</td>
<td></td>
</tr>
<tr>
<td>b. With alpha₁ -blocking agents:</td>
<td>To prevent fainting from severe orthostatic hypotension</td>
</tr>
<tr>
<td>(1) Give the first dose of doxazosin, prazosin, or terazosin at bedtime.</td>
<td></td>
</tr>
<tr>
<td>c. With beta-adrenergic blocking agents:</td>
<td>To monitor therapeutic effects and the occurrence of adverse reactions. Some clients with heart rates between 50 and 60 beats per minute may be continued on a beta blocker if hypotension or escape arrhythmias do not develop.</td>
</tr>
<tr>
<td>(1) Check blood pressure and pulse frequently, especially when dosage is being increased.</td>
<td>Specific instructions vary with individual drugs.</td>
</tr>
<tr>
<td>(2) See Drugs at a Glance: Beta-Adrenergic Blocking Agents and manufacturers’ literature regarding IV administration.</td>
<td></td>
</tr>
<tr>
<td>2. Observe for therapeutic effects</td>
<td>With most of the drugs, blood pressure decreases within a few hours. However, antihypertensive effects with clonidine skin patches occur 2–3 days after initial application (overlap with oral clonidine or other antihypertensive drugs may be needed) and persist 2–3 days when discontinued.</td>
</tr>
<tr>
<td>a. With alpha₂ agonists and alpha-blocking agents:</td>
<td>The client may report a larger stream, less nocturnal voiding, and more complete emptying of the bladder.</td>
</tr>
<tr>
<td>(1) With hypertension, observe for decreased blood pressure.</td>
<td>Because symptoms of pheochromocytoma are caused by excessive sympathetic nervous system stimulation, blocking stimulation with these drugs produces a decrease or absence of symptoms.</td>
</tr>
<tr>
<td>(2) With benign prostatic hyperplasia, observe for improved urination.</td>
<td>These conditions are characterized by vasospasm, which diminishes blood flow to the affected part. The drugs improve blood flow by vasodilation.</td>
</tr>
<tr>
<td>(3) In pheochromocytoma, observe for decreased pulse rate, blood pressure, sweating, palpitations, and blood sugar.</td>
<td></td>
</tr>
<tr>
<td>(4) In Raynaud’s disease or frostbite, observe affected areas for improvement in skin color and temperature and in the quality of peripheral pulses.</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### NURSING ACTIONS

#### 3. Observe for adverse effects

**a. With alpha-agonists and alpha-blocking agents:**

1. Hypotension
2. Sedation, drowsiness
3. Tachycardia
4. Edema

**b. With beta-blocking agents:**

1. Bradycardia and heart block
2. Congestive heart failure—edema, dyspnea, fatigue
3. Bronchospasm—dyspnea, wheezing
4. Fatigue and dizziness, especially with activity or exercise
5. Central nervous system (CNS) effects—depression, insomnia, vivid dreams, and hallucinations

#### 4. Observe for drug interactions

**a. Drugs that increase effects of alpha-antiadrenergic agents:**

1. Other antihypertensive drugs
2. CNS depressants
3. Nonsteroidal anti-inflammatory drugs
4. Epinephrine

**b. Drugs that decrease effects of alpha-antiadrenergic agents:**

1. Alpha adrenergics (eg, norepinephrine [Levophed])
2. Estrogens, oral contraceptives, nonsteroidal anti-inflammatory drugs

**c. Drugs that increase effects of beta-adrenergic blocking agents (eg, propranolol):**

1. Other antihypertensives

---

### RATIONALE/EXPLANATION

Adverse effects are usually extensions of therapeutic effects. Hypotension may range from transient postural hypotension to a more severe hypotensive state resembling shock. “First-dose syncope” may occur with prazosin and related drugs. Sedation can be minimized by increasing dosage slowly and giving all or most of the daily dose at bedtime. Tachycardia occurs as a reflex mechanism to increase blood supply to body tissues in hypotensive states. These drugs promote retention of sodium and water. Concomitant diuretic therapy may be needed to maintain antihypertensive effects with long-term use.

These are extensions of the therapeutic effects, which slow conduction of electrical impulses through the atrioventricular node, particularly in clients with compromised cardiac function. Caused by reduced force of myocardial contraction. Caused by drug-induced constriction of bronchi and bronchioles. It is more likely to occur in people with bronchial asthma or other obstructive lung disease. These symptoms occur because the usual sympathetic nervous system stimulation in response to activity or stress is blocked by drug action. The mechanism by which these effects are produced is unknown.

Additive antihypertensive effects Additive sedation and drowsiness Additive sodium and water retention, possible edema

Epinephrine increases the hypertensive effects of phenoxybenzamine and phentolamine and should not be given to treat shock caused by these drugs. Because epinephrine stimulates both alpha- and beta-adrenergic receptors, the net effect is vasodilation and a further drop in blood pressure.

Norepinephrine is a strong vasoconstricting agent and is the drug of choice for treating shock caused by overdosage of, or hypersensitivity to, phenoxybenzamine or phentolamine. These drugs may cause sodium and fluid retention and thereby decrease antihypertensive effects of alpha-antiadrenergic drugs.

Synergistic antihypertensive effects. Clients who do not respond to beta blockers or vasodilators alone may respond well to the combination. Also, beta blockers prevent reflex tachycardia, which usually occurs with vasodilator antihypertensive drugs.

(continued)
**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>(2) Phenoxybenzamine or phen tolamine</th>
<th>(2) Phenoxybenzamine or phentolamine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3) Cimetidine, furosemide</td>
<td>Synergistic effects to prevent excessive hypertension before and during surgical excision of pheochromocytoma</td>
</tr>
<tr>
<td>(4) Digoxin</td>
<td>Increase plasma levels by slowing hepatic metabolism</td>
</tr>
<tr>
<td>(5) Phenytoin</td>
<td>Additive bradycardia, heart block</td>
</tr>
<tr>
<td>(6) Quinidine</td>
<td>Potentiates cardiac depressant effects of propranolol</td>
</tr>
<tr>
<td>(7) Verapamil, IV</td>
<td>The combination may be synergistic in treating cardiac arrhythmias. However, additive cardiac depressant effects also may occur (brady-cardia, decreased force of myocardial contraction [negative inotropy], decreased cardiac output).</td>
</tr>
</tbody>
</table>

**d. Drugs that decrease effects of beta-adrenergic blocking agents:**

| (1) Antacids                          | Decrease absorption of several oral beta blockers |
| (2) Atropine                          | Increases heart rate and may be used to counteract excessive bradycardia caused by beta blockers |
| (3) Isoproterenol                     | Stimulates beta-adrenergic receptors and therefore antagonizes effects of beta-blocking agents. Isoproterenol also can be used to counteract excessive bradycardia. |

---

**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>(2) Phenoxybenzamine or phentolamine</th>
<th>Synergistic effects to prevent excessive hypertension before and during surgical excision of pheochromocytoma</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3) Cimetidine, furosemide</td>
<td>Increase plasma levels by slowing hepatic metabolism</td>
</tr>
<tr>
<td>(4) Digoxin</td>
<td>Additive bradycardia, heart block</td>
</tr>
<tr>
<td>(5) Phenytoin</td>
<td>Potentiates cardiac depressant effects of propranolol</td>
</tr>
<tr>
<td>(6) Quinidine</td>
<td>The combination may be synergistic in treating cardiac arrhythmias. However, additive cardiac depressant effects also may occur (brady-cardia, decreased force of myocardial contraction [negative inotropy], decreased cardiac output).</td>
</tr>
</tbody>
</table>

**d. Drugs that decrease effects of beta-adrenergic blocking agents:**

| (1) Antacids                          | Decrease absorption of several oral beta blockers |
| (2) Atropine                          | Increases heart rate and may be used to counteract excessive bradycardia caused by beta blockers |
| (3) Isoproterenol                     | Stimulates beta-adrenergic receptors and therefore antagonizes effects of beta-blocking agents. Isoproterenol also can be used to counteract excessive bradycardia. |

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Although she is probably not allergic to the Inderal, this new medication is responsible for her breathing difficulties. Inderal is a nonselective beta blocker, which means that it blocks beta₁ and beta₂ receptors. Blocking the beta₂ receptor causes bronchial constriction. Clients with asthma are likely to become symptomatic when this occurs. Selective beta blockers, which primarily block beta₁ receptors, should be used for any clients with a history of asthma or chronic obstructive pulmonary disease. In high doses, even selective beta blockers can cause bronchoconstriction in high-risk patients.

**How Can You Avoid This Medication Error?**

**Answer:** This would be a lethal mistake. Inderal is greatly affected by the first-pass effect, so the normal IV dose is significantly less than the normal oral dose. When a patient is NPO, an order must be obtained to change the route of administration. The nurse should question administering 20 cc of a medication IV push. Normal IV push doses are usually 1 to 2 cc.

**Review and Application Exercises**

1. How do alpha₂ agonists and alpha₁-blocking agents decrease blood pressure?
2. What are safety factors in administering and monitoring the effects of alpha₁ agonists and alpha₁-blocking agents?
3. Why should a client be cautioned against stopping alpha₂ agonists and alpha₁-blocking agents abruptly?
4. What are the main mechanisms by which beta blockers relieve angina pectoris?
5. How are beta blockers thought to be “cardioprotective” in preventing repeat myocardial infarctions?
6. What are some noncardiovascular indications for the use of propranolol?
7. What are the main differences between cardioselective and nonselective beta blockers?
8. Why are cardioselective beta blockers preferred for clients with asthma or diabetes mellitus?
9. List at least five adverse effects of beta blockers.
10. Explain the drug effects that contribute to each adverse reaction.
11. What signs, symptoms, or behaviors would lead you to suspect adverse drug effects?
12. Do the same adverse effects occur with beta blocker eye drops that occur with systemic drugs? If so, how may they be prevented or minimized?
13. What information needs to be included in teaching clients about beta blocker therapy?
14. What is the risk of abruptly stopping a beta blocker drug rather than tapering the dose and gradually discontinuing, as recommended?
15. How can beta blockers be both therapeutic and nontherapeutic for heart failure?

**SELECTED REFERENCES**


CHAPTER 19 ANTIADRENERGIC DRUGS


## Cholinergic Drugs

### Objectives

**AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:**

1. Describe effects and indications for use of selected cholinergic drugs.
2. Discuss drug therapy of myasthenia gravis.
3. Discuss the use of cholinergic drug therapy for paralytic ileus and urinary retention.
5. Describe major nursing care needs of clients receiving cholinergic drugs.
6. Describe signs, symptoms, and treatment of overdose with cholinergic drugs.
7. Discuss atropine and pralidoxime as antidotes for cholinergic drugs.
8. Discuss principles of therapy for using cholinergic drugs in special populations.
9. Teach clients about safe, effective use of cholinergic drugs.

### Critical Thinking Scenario

Jamie, a 14-year-old, was diagnosed with myasthenia gravis 3 years ago and has been well managed on neostigmine (Prostigmin), an anticholinesterase agent. His mother calls the clinic and, clearly upset, reports the following symptoms that Jamie is experiencing: severe headache, drooling, and one fainting episode. Jamie states he “just doesn’t feel right.”

**Reflect on:**
- Review the underlying pathophysiology of myasthenia gravis. Explain how Prostigmin alters neurotransmitters to manage this condition. (Hint: Think first how the parasympathetic nervous system is altered and how balance could be restored.)
- Contrast the symptoms of cholinergic crisis (too much Prostigmin) with myasthenic crisis (undertreatment). Which seems to fit with Jamie’s symptoms?
- What additional data would you collect to help arrive at a diagnosis before treatment?
- Discuss appropriate medical and pharmacologic management of Jamie.

### Description

Cholinergic drugs, also called parasympathomimetics and cholinomimetics, stimulate the parasympathetic nervous system in the same manner as acetylcholine (see Chap. 17). Some drugs act directly to stimulate cholinergic receptors; others act indirectly by slowing acetylcholine metabolism (by the enzyme acetylcholinesterase) at autonomic nerve synapses and terminals. Selected drugs are discussed here in relation to their use in myasthenia gravis, Alzheimer’s disease, and atony of the smooth muscle of the gastrointestinal and urinary systems, which results in paralytic ileus and urinary retention, respectively.

In normal neuromuscular function, acetylcholine is released from nerve endings and binds to nicotinic receptors on cell membranes of muscle cells to cause muscle contraction. Myasthenia gravis is an autoimmune disorder in which autoantibodies are thought to destroy nicotinic receptors for acetylcholine on skeletal muscle. As a result, acetylcholine is less able to stimulate muscle contraction and muscle weakness occurs.

In normal brain function, acetylcholine is an essential neurotransmitter and plays an important role in cognitive functions, including memory storage and retrieval. Alzheimer’s disease, the most common type of dementia in adults, is characterized by abnormalities in the cholinergic, serotoninergic, noradrenergic, and glutamatergic neurotransmission systems (see Chap. 5). In the cholinergic system, there is a substantial loss of neurons that secrete acetylcholine in the brain and decreased activity of choline acetyltransferase, the enzyme required for synthesis of acetylcholine.
Acetylcholine stimulates cholinergic receptors in the gut to promote normal secretory and motor activity. Cholinergic stimulation results in increased peristalsis and relaxation of the smooth muscle in sphincters to facilitate movement of flatus and feces. The secretory functions of the salivary and gastric glands are also stimulated.

Acetylcholine stimulates cholinergic receptors in the urinary system to promote normal urination. Cholinergic stimulation results in contraction of the detrusor muscle and relaxation of the urinary sphincter to facilitate emptying the urinary bladder.

**Mechanisms of Action and Effects**

*Direct-acting cholinergic drugs* are synthetic derivatives of choline. Most direct-acting cholinergic drugs are quaternary amines, carry a positive charge, and are lipid insoluble. They do not readily enter the central nervous system; thus, their effects occur primarily in the periphery. These drugs can exert their therapeutic effects because they are highly resistant to metabolism by acetylcholinesterase, the enzyme that normally metabolizes acetylcholine. Their action is longer than that of acetylcholine. They have widespread systemic effects when they combine with muscarinic receptors in cardiac muscle, smooth muscle, exocrine glands, and the eye (Fig. 20–1). Specific effects include:

1. Decreased heart rate, vasodilation, and unpredictable changes in blood pressure
2. Increased tone and contractility in gastrointestinal (GI) smooth muscle, relaxation of sphincters, increased salivary gland and GI secretions
3. Increased tone and contractility of smooth muscle (detrusor) in the urinary bladder and relaxation of the sphincter
4. Increased tone and contractility of bronchial smooth muscle
5. Increased respiratory secretions
6. Constriction of pupils (miosis) and contraction of ciliary muscle, resulting in accommodation for near vision

*Indirect-acting cholinergic* or *anticholinesterase drugs* decrease the inactivation of acetylcholine in the synapse by the enzyme acetylcholinesterase. Acetylcholine can then accumulate in the synapse and enhance the activation of postsynaptic muscarinic and nicotinic receptors (Fig. 20–2). This improves cholinergic neurotransmission in the brain and the force of muscle contraction in peripheral tissues.

Anticholinesterase drugs are classified as either reversible or irreversible inhibitors of acetylcholinesterase. The reversible inhibitors exhibit a moderate duration of action and have several therapeutic uses, as described later. The irreversible inhibitors produce prolonged effects and are highly toxic. These agents are used primarily as poisons (ie, insecticides and nerve gases). Their only therapeutic use is in the treatment of glaucoma (see Chap. 65).

**Indications for Use**

Cholinergic drugs have limited but varied uses. A direct-acting drug, bethanechol, is used to treat urinary retention due to urinary bladder atony and postoperative abdominal distention due to paralytic ileus. The anticholinesterase agents are used in the diagnosis and treatment of myasthenia gravis and to reverse the action of nondepolarizing neuromuscular blocking agents (eg, tubocurarine and related drugs) used in surgery (see Chap. 14). The drugs do not reverse the neuromuscular blockade produced by depolarizing agents, such as succinylcholine. In addition, tacrine, donepezil, and rivastigmine are anticholinesterase agents approved for treatment of Alzheimer’s disease. Cholinergic drugs may also be used to treat glaucoma (see Chap. 65).

**Contraindications to Use**

These drugs are contraindicated in urinary or GI tract obstruction, asthma, peptic ulcer disease, coronary artery disease, hyperthyroidism, pregnancy, and inflammatory abdominal conditions. Tacrine is also contraindicated in previous users in whom jaundice or a serum bilirubin level above 3 mg/dL developed.

**INDIVIDUAL CHOLINERGIC DRUGS**

These drugs are described in the following sections. Trade names, clinical indications, and dosage ranges are listed in Drugs at a Glance: Selected Cholinergic Drugs.
Direct-Acting Cholinergics

Bethanechol (Urecholine) is a synthetic derivative of choline. Because the drug produces smooth muscle contractions, it should not be used in obstructive conditions of the urinary or gastrointestinal tracts. Because oral bethanechol is not well absorbed from the GI tract, oral doses are much larger than subcutaneous (SC) doses. Bethanechol is not given by the intramuscular (IM) or intravenous (IV) route because it results in severe adverse effects due to excessive cholinergic stimulation.

Reversible Indirect-Acting Cholinergics (Anticholinesterases)

Neostigmine (Prostigmin) is the prototype anticholinesterase agent. It is used for long-term treatment of myasthenia gravis and as an antidote for tubocurarine and other nondepolarizing skeletal muscle relaxants used in surgery. Neostigmine, like bethanecol, is a quaternary amine and carries a positive charge. This reduces its lipid solubility and results in poor absorption from the GI tract. Consequently, oral doses are much larger than parenteral doses. When it is used for long-term treatment of myasthenia gravis, resistance to its action may occur and larger doses may be required.

Edrophonium (Tensilon) is a short-acting cholinergic drug used to diagnose myasthenia gravis, to differentiate between myasthenic crisis and cholinergic crisis, and to reverse the neuromuscular blockade produced by nondepolarizing skeletal muscle relaxants. It is given IM or IV by a physician who remains in attendance. Atropine, an antidote, and life support equipment, such as ventilators and endotracheal tubes, must be available when the drug is given.

Ambenonium (Mytelase) is a long-acting drug used for the treatment of myasthenia gravis. It is used less often than neostigmine and pyridostigmine. It may be useful in clients who are allergic to bromides, however, because the other drugs are both bromide salts. Ambenonium may be useful for myasthenic clients on ventilators because it is less likely to increase respiratory secretions than other anticholinesterase drugs.

Physostigmine salicylate (Antilirium) is the only anticholinesterase capable of crossing the blood–brain barrier. Unlike other drugs in this group, physostigmine is not a quaternary amine, does not carry a positive charge, and therefore is more lipid soluble. It is sometimes used as an antidote for overdosage of anticholinergic drugs, including atropine, antihistamines, tricyclic antidepressants, and phenothiazine antipsychotics. However, its potential for causing serious adverse effects limits its usefulness. Some preparations of physostigmine are also used in the treatment of glaucoma (see Chap. 65).

Pyridostigmine (Mestinon) is similar to neostigmine in actions, uses, and adverse effects. It may have a longer duration of action than neostigmine and is the maintenance drug of choice for clients with myasthenia gravis. An added advantage is the availability of a slow-release form, which is effective for 8 to 12 hours. When this form is taken at bedtime, the client does not have to take other medications during the night and does not awaken too weak to swallow.

Donepezil (Aricept) is used to treat mild to moderate Alzheimer’s disease. In long term studies, donepezil delayed the progression of the disease for up to 55 weeks. Donepezil increases acetylcholine in the brain by inhibiting its metabolism. The drug is well absorbed after oral administration and absorption is unaffected by food. It is highly bound (96%) to
### Drugs at a Glance: Selected Cholinergic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Direct-Acting Cholinergics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bethanechol (Urecholine)</td>
<td>PO 10–50 mg bid to qid, maximum single dose not to exceed 50 mg. SC: 2.5–5 mg tid or qid. DO NOT give IM or IV.</td>
<td>Safety and efficacy not established &lt; 8 yrs. PO: 0.6 mg/kg tid to qid. SC: 0.2 mg/kg tid to qid. DO NOT give IM or IV.</td>
</tr>
<tr>
<td><strong>Indirect-Acting Cholinergics (Anticholinesterase Drugs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ambenonium (Mytelase)</td>
<td>PO 5–25 mg tid to qid</td>
<td>Safety and efficacy not established. Diagnosis of myasthenia gravis Infants: 0.5 mg IV. &lt;34 kg: 1 mg IV. May titrate up to 5 mg if no response. &gt;34 kg: 2 mg IV. May titrate up to 10 mg if no response. IM &lt;34 kg: give 2 mg. &gt;34 kg: give 5 mg.</td>
</tr>
<tr>
<td>Edrophonium (Tension)</td>
<td>IV route preferred: 2 mg IV over 15–30 sec. 8 mg IV given 45 seconds later if no response. Test dose may be repeated in 30 min. IM route: 10 mg. May follow up with an additional 2 mg 30 min later if no response. Differentiation or myasthenic crisis from cholinergic crisis 1 mg IV, may repeat in 1 min. BE PREPARED to intubate.</td>
<td>Prevention/treatment of postop retention Safety and efficacy not established Treatment of myasthenia gravis PO 0.3–0.6 mg/kg q3–4h SC, IV, IM 0.01–0.04 mg/kg/dose q2–3h as needed</td>
</tr>
<tr>
<td>Neostigmine (Prostigmin)</td>
<td>0.022 mg/kg IM Antidote for nondepolarizing neuromuscular blockers Give atropine sulfate 0.6–1.2 mg IV several min before slow IV injection of neostigmine 0.5–2 mg. Repeat as needed, total dose not to exceed 5 mg.</td>
<td>Diagnosis of myasthenia gravis 0.04 mg/kg IM Antidote for nondepolarizing neuromuscular blockers Give 0.008–0.025 mg/kg atropine sulfate IV several min before slow IV injection of neostigmine 0.07–0.08 mg/kg.</td>
</tr>
<tr>
<td>Physostigmine (Antilirium)</td>
<td>IM, IV 0.5–2 mg. Give IV slowly, no faster than 1 mg/min to avoid adverse effects of bradycardia, respiratory distress, and seizures.</td>
<td>Prevention/treatment of postop retention Safety and efficacy not established</td>
</tr>
<tr>
<td>Pyridostigmine (Mestinon)</td>
<td>PO 60 mg tid initially, individualize dose to control symptoms. Average dose in 24 h: 600 mg. Range in 24 h: 60–1500 mg. IM, IV slowly: 1/30th the oral dose</td>
<td>PO 7 mg/kg/day divided into 5 or 6 doses. Neonates of mothers with myasthenia gravis who have difficulty with sucking/breathing/swallowing: 0.05–0.15 mg/kg IM. Change to syrup as soon as possible.</td>
</tr>
<tr>
<td><strong>Indirect-Acting Cholinergics for Alzheimer’s Disease</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donepezil (Aricept)</td>
<td>PO 5 mg daily hs for 4–6 wk, then increase to 10 mg qd if needed.</td>
<td></td>
</tr>
<tr>
<td>Galantamine (Reminyl)</td>
<td>PO 8 mg/day initially, increase to 16 mg/day after 4 wks if needed. May continue to increase q 4 wks up to maximum dose 24 mg/day.</td>
<td></td>
</tr>
<tr>
<td>Rivastigmine (Exelon)</td>
<td>PO 1.5 mg bid with food initially. May titrate to higher doses at 1.5 mg intervals q 2 wks to a maximum dose of 12 mg/day.</td>
<td></td>
</tr>
<tr>
<td>Tacrine (Cognex)</td>
<td>PO 40 mg/d (10 mg qid) for 6 wks. If aminotransferase levels are satisfactory after weekly monitoring, may increase the dose to 80 mg/d (20 mg/qid). If liver function remains normal, may increase daily dose by 10 mg q 6 wks to a total of 120–160 mg/d.</td>
<td></td>
</tr>
</tbody>
</table>

Plasma proteins. It is metabolized in the liver to several metabolites, some of which are pharmacologically active; metabolites and some unchanged drug are excreted mainly in urine. Adverse effects include nausea, vomiting, diarrhea, bradycardia, and possible aggravation of asthma, peptic ulcer disease, and chronic obstructive pulmonary disease. Unlike tacrine, donepezil does not cause liver toxicity.

**Galantamine (Reminyl)** is the newest long-acting anticholinesterase agent approved by the Food and Drug Administration for the treatment of Alzheimer’s disease. Its pharmacokinetics and side effect profile are similar to donepezil and rivastigmine.

**Rivastigmine (Exelon)** is a long-acting central anticholinesterase agent approved for the treatment of Alzheimer’s...
The drug is discontinued. These patients return to normal liver function values when alanine aminotransferase (ALT) values of three times normal. Ninety percent of patients receiving low-dose tacrine therapy experience elevated alanine aminotransferase. Approximately 30% of patients receiving low-dose tacrine therapy have light-colored stools (jaundice) that may indicate hepatotoxicity. Approximately 30% of patients receiving low-dose tacrine therapy experience elevated alanine aminotransferase (ALT) values of three times normal. Ninety percent of these patients return to normal liver function values when the drug is discontinued.

**Nursing Notes: Apply Your Knowledge**

Jill and her boyfriend ate mushrooms they picked while hiking. They were admitted to the hospital later that afternoon with acute cholinergic poisoning. Describe the signs and symptoms they likely exhibited. What antidote do you think was given, and why?

**Assessment**

Assess the client’s condition in relation to disorders for which cholinergic drugs are used:

- In clients known to have myasthenia gravis, assess for muscle weakness. This may be manifested by ptosis (drooping) of the upper eyelid and diplopia (double vision) caused by weakness of the eye muscles. More severe disease may be indicated by difficulty in chewing, swallowing, and speaking; accumulation of oral secretions, which the client may be unable to expectorate or swallow; decreased skeletal muscle activity, including impaired chest expansion; and eventual respiratory failure.
- In clients with possible urinary retention, assess for bladder distention, time and amount of previous urination, and fluid intake.
- In clients with possible paralytic ileus, assess for presence of bowel sounds, abdominal distention, and elimination pattern.
- In clients with Alzheimer’s disease, assess for abilities and limitations in relation to memory, cognitive functioning, self-care activities, and preexisting conditions that may be aggravated by a cholinergic drug.

**Interventions**

- Use measures to prevent or decrease the need for cholinergic drugs. Ambulation, adequate fluid intake, and judicious use of opioid analgesics or other sedative-type drugs help prevent postoperative urinary retention. In myasthenia gravis, muscle weakness is aggravated by exercise and improved by rest. Therefore, scheduling activities to avoid excessive fatigue and to allow adequate rest periods may be beneficial.
- With drug therapy for Alzheimer’s disease, assist and teach caregivers to:
  - Maintain a quiet, stable environment and daily routines to decrease confusion (eg, verbal or written reminders, simple directions, adequate lighting, calendars, and personal objects within view and reach).
  - Avoid altering dosage or stopping the drug without consulting the prescribing physician.
  - Be sure that clients keep appointments for supervision and blood tests.
  - Report signs and symptoms (ie, skin rash, jaundice, light-colored stools) that may indicate hepatotoxicity for clients taking tacrine.
  - Notify surgeons about tacrine therapy. Exaggerated muscle relaxation may occur if succinylcholine-type drugs are given.
  - Do not give cholinergic drugs for bladder atony and urinary retention or paralytic ileus in the presence of an obstruction.
  - For long-term use, assist clients and families to establish a Schedule of drug administration that best meets the client’s needs.

**Nursing Diagnoses**

- Impaired gas exchange related to increased respiratory secretions, bronchospasm, and/or respiratory paralysis
- Ineffective Breathing Pattern related to bronchoconstriction
- Ineffective Airway Clearance related to increased respiratory secretions
- Self Care Deficit related to muscle weakness cognitive impairment, or diplopia
- Deficient Knowledge: Drug administration and effects

**Planning/Goals**

The client will:

- Verbalize or demonstrate correct drug administration
- Improve in self-care abilities
- Regain usual patterns of urinary and bowel elimination
- Maintain effective oxygenation of tissues
- Report adverse drug effects
- For clients with myasthenia gravis, at least one family member will verbalize or demonstrate correct drug administration, symptoms of too much or too little drug, and emergency care procedures.
- For clients with dementia, a caregiver will verbalize or demonstrate correct drug administration and knowledge of adverse effects to be reported to a health care provider.
Use in Myasthenia Gravis

Guidelines for the use of anticholinesterase drugs in myasthenia gravis include the following:

1. Drug dosage should be increased gradually until maximal benefit is obtained. Larger doses are often required with increased physical activity, emotional stress, and infections, and sometimes premenstrually.
2. Some clients with myasthenia gravis cannot tolerate optimal doses of anticholinesterase drugs unless atropine is given to decrease the severity of adverse reactions due to muscarinic activation. However, atropine should be given only if necessary because it may mask the sudden increase of side effects. This increase is the first sign of overdose.
3. Drug dosage in excess of the amount needed to maintain muscle strength and function can produce a cholinergic crisis. A cholinergic crisis is characterized by excessive stimulation of the parasympathetic nervous system. If early symptoms are not treated, hypotension and respiratory failure may occur. At high doses, anticholinesterase drugs weaken rather than strengthen skeletal muscle contraction because excessive amounts of acetylcholine accumulate at motor endplates and reduce nerve impulse transmission to muscle tissue.

- Treatment for cholinergic crisis includes withdrawal of anticholinesterase drugs, administration of atropine, and measures to maintain respiration.
- Endotracheal intubation and mechanical ventilation
may be necessary due to profound skeletal muscle weakness (including muscles of respiration), which is not counteracted by atropine.

b. Differentiating myasthenic crisis from cholinergic crisis may be difficult because both are characterized by respiratory difficulty or failure. It is necessary to differentiate between them, however, because they require opposite treatment measures. Myasthenic crisis requires more anticholinesterase drug, whereas cholinergic crisis requires discontinuing any anticholinesterase drug the client has been receiving. The physician may be able to make an accurate diagnosis from signs and symptoms and their timing in relation to medication; that is, signs and symptoms having their onset within approximately 1 hour after a dose of anticholinesterase drug are more likely to be caused by cholinergic crisis (too much drug). Signs and symptoms beginning 3 hours or more after a drug dose are more likely to be caused by myasthenic crisis (too little drug).

c. If the differential diagnosis cannot be made on the basis of signs and symptoms, the client can be intubated, mechanically ventilated, and observed closely until a diagnosis is possible. Still another way to differentiate between the two conditions is for the physician to inject a small dose of IV edrophonium. If the edrophonium causes a dramatic improvement in breathing, the diagnosis is myasthenic crisis; if it makes the client even weaker, the diagnosis is cholinergic crisis. Note, however, that edrophonium or any other pharmacologic agent should be administered only after endotracheal intubation and controlled ventilation have been instituted.

4. Some people acquire partial or total resistance to anticholinesterase drugs after taking them for months or years. Therefore, do not assume that drug therapy that is effective initially will continue to be effective over the long-term course of the disease.

Use in Children

Bethanechol is occasionally used to treat urinary retention and paralytic ileus, but safety and effectiveness for children younger than 8 years of age have not been established. Neostigmine is used to treat myasthenia gravis and to reverse neuromuscular blockade after general anesthesia but is not recommended for urinary retention. Pyridostigmine may be used in the neonate of a mother with myasthenia gravis to be used in the neonate of a mother with myasthenia gravis to prevent contractures and improve muscle strength. Other indirect-acting cholinergic drugs are used only in the treatment of myasthenia gravis. Precautions and adverse effects are the same for children as for adults.

Use in Older Adults

Indirect-acting cholinergic drugs may be used in myasthenia gravis, Alzheimer’s disease, or overdoses of atropine and other centrally acting anticholinergic drugs (eg, those used for parkinsonism). Older adults are more likely to experience adverse drug effects because of age-related physiologic changes and superimposed pathologic conditions.

Use in Renal Impairment

Because bethanechol and other cholinergic drugs increase pressure in the urinary tract by stimulating detrusor muscle contraction and relaxation of urinary sphincters, they are contraindicated for clients with urinary tract obstructions or weaknesses in the bladder wall. Administering a cholinergic drug to these people might result in rupture of the bladder. Some aspects of the pharmacokinetics of cholinergic drugs are unknown. Many of the drugs are degraded enzymatically by cholinesterases. However, a few (eg, neostigmine and pyridostigmine) undergo hepatic metabolism and tubular excretion in the kidneys. Renal impairment may result in accumulation and increased adverse effects, especially with chronic use.

Use in Hepatic Impairment

The hepatic metabolism of neostigmine and pyridostigmine may be impaired by liver disease, resulting in increased adverse effects.

Tacrine is contraindicated in liver disease. Approximately 20% to 50% of clients experience an increase in liver aminotransferase levels after beginning therapy with tacrine. Most enzyme elevation occurs in the first 18 weeks of therapy and is more common in female clients. When tacrine is started, serum ALT should be monitored weekly for 18 weeks. Then, if values are within normal limits and signs of liver damage do not occur, the test can be done every 3 months. Immediate withdrawal of the medication usually restores liver enzymes to normal levels with no permanent liver injury.

Use in Critical Illness

Cholinergic drugs have several specific uses in critical illness. These include:

1. Use of neostigmine, pyridostigmine, and edrophonium to reverse neuromuscular blockade (skeletal muscle paralysis) caused by nondepolarizing muscle relaxants.
2. Anticholinesterase drugs are used to treat myasthenic crisis and improve muscle strength.
3. Physostigmine may be used in severe cases as an antidote to anticholinergic poisoning with drugs such as atropine or tricyclic antidepressants.

Toxicity of Cholinergic Drugs: Recognition and Management

Atropine, an anticholinergic (antimuscarinic) drug, is a specific antidote to cholinergic agents. The drug and equipment for in-
jection should be readily available whenever cholinergic drugs are given. It is important to note that atropine reverses only the muscarinic effects of cholinergic drugs, primarily in the heart, smooth muscle, and glands. Atropine does not interact with nicotinic receptors and therefore can not reverse the nicotinic effects of skeletal muscle weakness or paralysis due to overdose of the indirect cholinergic drugs.

Management of Mushroom Poisoning

Muscarinic receptors in the parasympathetic nervous system were given their name because they can be stimulated by muscarine, an alkaloid that is found in small quantities in the Amanita muscaria mushroom. Some mushrooms found in North America, such as the Clitocybe and Inocybe mushrooms, however, contain much larger quantities of muscarine. Accidental or intentional ingestion of these mushrooms results in intense cholinergic stimulation (cholinergic crisis) and is potentially fatal. Atropine is the specific antidote for mushroom poisoning.

Toxicity of Irreversible Anticholinesterase Agents: Recognition and Management

Most irreversible anticholinesterase agents are highly lipid soluble and can enter the body by a variety of routes including the eye, skin, respiratory system and gastrointestinal tract. Since they readily cross the blood–brain barrier, their effects are seen peripherally as well as centrally.

Exposure to toxic doses of irreversible anticholinesterase agents, such as organophosphate insecticides (malathion, parathion) or nerve gases (sarin, tabun, soman), produces a cholinergic crisis characterized by excessive cholinergic (muscarinic) stimulation and neuromuscular blockade. This cholinergic crisis occurs because the irreversible anticholinesterase poison binds to the enzyme acetylcholinesterase and inactivates it. Consequently, acetylcholine remains in cholinergic synapses and causes excessive stimulation of muscarinic and nicotinic receptors.

Emergency treatment includes decontamination procedures such as removing contaminated clothing, flushing the poison from skin and eyes, and using activated charcoal and lavage to remove ingested poison from the GI tract. Pharmacologic treatment includes administering atropine to counteract the muscarinic effects of the poison (eg, salivation, urination, defecation, bronchial secretions, laryngospasm, bronchospasm).

To relieve the neuromuscular blockade produced by nicotinic effects of the poison, a second drug, pralidoxime, is needed. Pralidoxime (Protopam), a cholinesterase reactivator, is a specific antidote for overdose with irreversible anticholinesterase agents. Pralidoxime treats toxicity by causing the anticholinesterase poison to release the enzyme acetylcholinesterase. The reactivated acetylcholinesterase can then degrade excess acetylcholine at the cholinergic synapses, including the neuromuscular junction. Because pralidoxime cannot cross the blood–brain barrier, it is effective only in the peripheral areas of the body. Pralidoxime must be given as soon after the poisoning as possible. If too much time passes, the bond between the irreversible anticholinesterase agent and acetylcholinesterase becomes stronger and pralidoxime is unable to release the enzyme from the poison. Treatment of anticholinesterase overdose may also require diazepam or lorazepam to control seizures. Mechanical ventilation may be necessary to treat respiratory paralysis.

Home Care

Medications to treat long-term conditions such as myasthenia gravis or Alzheimer’s disease are often administered in the home setting. The person using the drugs may have difficulty with self-administration. The client with myasthenia gravis may have diplopia or diminished muscle strength that make it difficult to self-administer medications. The client with Alzheimer’s disease may have problems with remembering to take medications and may easily underdose or overdose himself or herself. It is important to work with responsible family members in such cases to ensure accurate drug administration.

Nursing Notes: Apply Your Knowledge

Answer: Excessive stimulation of the parasympathetic nervous system causes decreased heart rate and cardiac contractility, hypotension, bronchial constriction, excessive saliva and mucus production, nausea, vomiting, diarrhea, and abdominal cramping. Because these symptoms are a result of excessive stimulation of cholinergic receptors, treatment includes administration of an anticholinergic drug such as atropine.
### Cholinergic Drugs

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong>&lt;br&gt;a. Give oral bethanechol before meals.</td>
<td>If these drugs are given after meals, nausea and vomiting may occur because the drug stimulates contraction of muscles in the GI tract. IM and IV injections may cause acute, severe hypotension and circulatory failure. Cardiac arrest may occur. For consistent blood levels and control of symptoms.</td>
</tr>
<tr>
<td>b. Give parenteral bethanechol by the subcutaneous route only.</td>
<td>Food decreases absorption and decreases serum drug levels by 30% or more. Regular intervals increase therapeutic effects and decrease adverse effects.</td>
</tr>
<tr>
<td>c. With pyridostigmine and other drugs for myasthenia gravis, give at regularly scheduled intervals.</td>
<td>These are indicators of increased GI muscle tone and motility.</td>
</tr>
<tr>
<td>d. Give tacrine on an empty stomach, 1 hour before or 2 hours after a meal, if possible, at regular intervals around the clock (eg, q6h). Give with meals if GI upset occurs.</td>
<td>With neostigmine, onset of action is 2–4 hours after oral administration and 10–30 minutes after injection. Duration is approximately 3–4 hours. With pyridostigmine, onset of action is approximately 30–45 minutes after oral use, 15 minutes after IM injection, and 2–5 minutes after IV injection. Duration is approximately 4–6 hours. The long-acting form of pyridostigmine lasts 8–12 hours. Improved functioning is most likely to occur in patients with mild to moderate dementia.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong>&lt;br&gt;a. When the drug is given for postoperative hypoperistalsis, observe for bowel sounds, passage of flatus through the rectum, or a bowel movement.</td>
<td>Adverse effects occur with usual therapeutic doses but are more likely with large doses. They are caused by stimulation of the parasympathetic nervous system.</td>
</tr>
<tr>
<td>b. When bethanechol or neostigmine is given for urinary retention, micturition usually occurs within approximately 60 minutes. If it does not, urinary catheterization may be necessary.</td>
<td>Adverse effects occur with usual therapeutic doses but are more likely with large doses. They are caused by stimulation of the parasympathetic nervous system.</td>
</tr>
<tr>
<td>c. When the drug is given in myasthenia gravis, observe for increased muscle strength as shown by:&lt;br&gt;1. Decreased or absent ptosis of eyelids&lt;br&gt;2. Decreased difficulty with chewing, swallowing, and speech&lt;br&gt;3. Increased skeletal muscle strength, increased tolerance of activity, less fatigue</td>
<td>These may be detected early by regular assessment of blood pressure and heart rate. Bradycardia is probably the most likely dysrhythmia to occur. GI effects commonly occur.</td>
</tr>
<tr>
<td>d. With cholinergic drugs to treat Alzheimer’s disease (tacrine, donepezil, galantamine, and rivastigmine) observe for improvement in memory and cognitive functioning in activities of daily living.</td>
<td>Skin rashes are most likely to occur from formulations of neostigmine or pyridostigmine that contain bromide.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong>&lt;br&gt;a. Central nervous system effects—convulsions, dizziness, drowsiness, headache, loss of consciousness</td>
<td></td>
</tr>
<tr>
<td>b. Respiratory effects—increased secretions, bronchospasm, laryngospasm, respiratory failure</td>
<td></td>
</tr>
<tr>
<td>c. Cardiovascular effects—dysrhythmias (bradycardia, tachycardia, atrioventricular block), cardiac arrest, hypotension, syncope</td>
<td></td>
</tr>
<tr>
<td>d. GI effects—nausea and vomiting, diarrhea, increased peristalsis, abdominal cramping, increased secretions (ie, saliva, gastric and intestinal secretions)</td>
<td></td>
</tr>
<tr>
<td>e. Other effects—increased frequency and urgency of urination, increased sweating, miosis, skin rash</td>
<td></td>
</tr>
</tbody>
</table>
CHAPTER 20 CHOLINERGIC DRUGS

Review and Application Exercises

1. What are the actions of cholinergic drugs?
2. Which neurotransmitter is involved in cholinergic (parasympathetic) stimulation?
3. When a cholinergic drug is given to treat myasthenia gravis, what is the expected effect?
4. What is the difference between cholinergic crisis and myasthenic crisis? How are they treated?
5. When tacrine is given to treat Alzheimer’s disease, what is the desired effect?
6. Is a cholinergic drug the usual treatment of choice for urinary bladder atony or hypotonicity? Why or why not?
7. What are the adverse effects of cholinergic drugs?
8. How are overdoses of cholinergic drugs treated?

SELECTED REFERENCES


chapter 21

Anticholinergic Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. List characteristics of anticholinergic drugs in terms of effects on body tissues, indications for use, nursing process implications, observation of client response, and teaching clients.

2. Discuss atropine as the prototype of anticholinergic drugs.

3. Discuss clinical disorders/symptoms for which anticholinergic drugs are used.

4. Describe the mechanism by which atropine relieves bradycardia.

5. Review anticholinergic effects of antipsychotics, tricyclic antidepressants, and antihistamines.

6. Discuss principles of therapy and nursing process for using anticholinergic drugs in special populations.

7. Describe the signs and symptoms of atropine or anticholinergic drug overdose and its treatment.

8. Teach clients about the safe, effective use of anticholinergic drugs.

Critical Thinking Scenario
George Wilson, 76 years of age, has been treated for depression with amitriptyline (Elavil) for 5 years. He is admitted to the hospital for elective surgery, after which he becomes acutely confused. The physician prescribes haloperidol (Haldol) PRN to control severe agitation. You note in the drug reference text that both these medications have anticholinergic side effects.

Reflect on:
- Important assessments to detect anticholinergic effects.
- How anticholinergic side effects can be especially significant for the elderly.
- Developing a plan to minimize or manage anticholinergic effects for this client.

DESCRIPTION
Anticholinergic drugs, also called cholinergic blocking and parasympatholytic agents, block the action of acetylcholine on the parasympathetic nervous system (PNS). Most anticholinergic drugs interact with muscarinic cholinergic receptors in the brain, secretory glands, heart, and smooth muscle and are also called antimuscarinic agents. A few anticholinergic drugs, when given at high doses, are also able to block nicotinic receptors in autonomic ganglia and skeletal muscles. Glycopyrrolate (Robinul) is an example of such a medication. The prototype anticholinergic drug is atropine, and this drug class includes belladonna alkaloids, their derivatives, and many synthetic substitutes.

Most anticholinergic medications are either tertiary amines or quaternary amines in their chemical structure. Tertiary amines are uncharged lipid-soluble molecules. Atropine and scopolamine are tertiary amines and therefore are able to cross cell membranes readily. They are well absorbed from the gastrointestinal (GI) tract and conjunctiva and they cross the blood–brain barrier. Tertiary amines are excreted in the urine. Some belladonna derivatives and synthetic anticholinergics are quaternary amines. These drugs carry a positive charge and are lipid insoluble. Consequently, they do not readily cross cell membranes. They are poorly absorbed from the GI tract and do not cross the blood–brain barrier. Quaternary amines are excreted largely in the feces. Table 21–1 lists common tertiary amine and quaternary amine anticholinergic drugs.

Mechanism of Action and Effects
These drugs act by occupying receptor sites at parasympathetic nerve endings, thereby leaving fewer receptor sites free to respond to acetylcholine (Fig. 21–1). Parasympathetic response is absent or decreased, depending on the number of
receptors blocked by anticholinergic drugs and the underlying degree of parasympathetic activity. Since cholinergic muscarinic receptors are widely distributed in the body, anticholinergic drugs produce effects in a variety of locations, including the central nervous system, heart, smooth muscle, glands, and the eye.

Specific effects on body tissues and organs include:

1. **Central nervous system (CNS) stimulation followed by depression**, which may result in coma and death. This is most likely to occur with large doses of anticholinergic drugs that cross the blood–brain barrier (atropine, scopolamine, and antiparkinson agents).

2. **Decreased cardiovascular response to parasympathetic (vagal) stimulation that slows heart rate**. Atropine is the anticholinergic drug most often used for its cardiovascular effects. According to Advanced Cardiac Life Support (ACLS) protocol (2000), atropine is the drug of choice to treat symptomatic sinus bradycardia. Low doses (<0.5 mg) may produce a slight and temporary decrease in heart rate; however, moderate to large doses (0.5 to 1 mg) increase heart rate by blocking parasympathetic vagal stimulation. Although the increase in heart rate may be therapeutic in bradycardia, it can be an adverse effect in patients with other types of heart disease because atropine increases the myocardial oxygen demand. Atropine usually has little or no effect on blood pressure. Large doses cause facial flushing because of dilation of blood vessels in the neck.

3. **Bronchodilation and decreased respiratory tract secretions**. Bronchodilating effects result from blocking the bronchoconstrictive effects of acetylcholine. When anticholinergic drugs are given systemically, respiratory secretions decrease and may become viscous, resulting in mucus plugging of small respiratory passages. Administering the medications by inhalation decreases this effect while preserving the beneficial bronchodilation effect.

4. **Antispasmodic effects in the GI tract due to decreased muscle tone and motility**. The drugs have little inhibitory effect on gastric acid secretion with usual doses and insignificant effects on pancreatic and intestinal secretions.

5. **Mydriasis and cycloplegia in the eye**. Normally, anticholinergics do not change intraocular pressure, but with narrow-angle glaucoma, they may increase intraocular pressure and precipitate an episode of acute glaucoma. When the pupil is fully dilated, photophobia may be bothersome, and reflexes to light and accommodation may disappear.

6. **Miscellaneous effects** include decreased secretions from salivary and sweat glands; relaxation of ureters, urinary bladder, and the detrusor muscle; and relaxation of smooth muscle in the gallbladder and bile ducts.

The clinical usefulness of anticholinergic drugs is limited by their widespread effects. Consequently, several synthetic drugs have been developed in an effort to increase selectivity of action on particular body tissues, especially to retain the antispasmodic and antisecretory effects of atropine while eliminating its adverse effects. This effort has been less than successful—all the synthetic drugs produce atropine-like adverse effects when given in sufficient dosage.

One group of synthetic drugs is used for antispasmodic effects in GI disorders. Another group of synthetic drugs includes centrally active anticholinergics used in the treatment of Parkinson’s disease (see Chap. 12). They balance the relative cholinergic dominance that causes the movement disorders associated with parkinsonism.

### Indications for Use

Anticholinergic drugs are used for disorders in many body systems. Clinical indications for use of anticholinergic drugs include GI, genitourinary, ophthalmic and respiratory dis-
orders, bradycardia, and Parkinson’s disease. They also are used before surgery and bronchoscopy. Drugs at a Glance: Selected Anticholinergic Drugs describes the therapeutic use, dosage and route of administration of selected anticholinergic medications.

- **GI disorders** in which anticholinergics have been used include peptic ulcer disease, gastritis, pylorospasm, diverticulitis, ileitis, and ulcerative colitis. These conditions are often characterized by excessive gastric acid and abdominal pain because of increased motility and spasm of GI smooth muscle. In peptic ulcer disease, more effective drugs have been developed, and anticholinergics are rarely used. The drugs are weak inhibitors of gastric acid secretion even in maximal doses (which usually produce intolerable adverse effects). Although they do not heal peptic ulcers, they may relieve abdominal pain by relaxing GI smooth muscle.

Anticholinergics may be helpful in treating irritable colon or colitis, but they may be contraindicated in chronic inflammatory disorders (eg, diverticulitis, ulcerative colitis) or acute intestinal infections (eg, bacterial, viral, amebic). Other drugs are used to decrease diarrhea and intestinal motility in these conditions.

- In **genitourinary disorders**, anticholinergic drugs may be given for their antispasmodic effects on smooth muscle to relieve the symptoms of urinary incontinence and frequency that accompany an overactive bladder. In infections such as cystitis, urethritis, and prostatitis, the drugs decrease the frequency and pain of urination. The drugs are also given to increase bladder capacity in enuresis, paraplegia, or neurogenic bladder.

- In **ophthalmology**, anticholinergic drugs are applied topically for mydriatic and cycloplegic effects to aid examination or surgery. They are also used to treat some inflammatory disorders. Anticholinergic preparations used in ophthalmology are discussed further in Chapter 65.

- In **respiratory disorders** characterized by bronchoconstriction (ie, asthma, chronic bronchitis), ipratropium (Atrovent) may be given by inhalation for bronchodilating effects (see Chap. 47).

- In **cardiology**, atropine may be given to increase heart rate in bradycardia and heart block characterized by hypotension and shock.

- In **Parkinson’s disease**, anticholinergic drugs are given for their central effects in decreasing salivation, spasticity, and tremors. They are used mainly in clients who have minimal symptoms, who do not respond to levodopa, or who cannot tolerate levodopa because of adverse reactions or contraindications. An additional use of anticholinergic drugs is to relieve Parkinson-like symptoms that occur with older antipsychotic drugs.

- Before **surgery**, anticholinergics are given to prevent vagal stimulation and potential bradycardia, hypotension, and cardiac arrest. They are also given to reduce respiratory tract secretions, especially in head and neck surgery and bronchoscopy.

---

### Contraindications to Use

Contraindications to the use of anticholinergic drugs include any condition characterized by symptoms that would be aggravated by the drugs. Some of these are prostatic hypertrophy, myasthenia gravis, hyperthyroidism, glaucoma, tachyarrhythmias, myocardial infarction, and heart failure unless bradycardia is present. They should not be given in hiatal hernia or other conditions contributing to reflux esophagitis because the drugs delay gastric emptying, relax the cardioesophageal sphincter, and increase esophageal reflux.

---

### INDIVIDUAL ANTICHOLINERGIC DRUGS

#### Belladonna Alkaloids and Derivatives

**Atropine**, the prototype of anticholinergic drugs, produces the same effects, has the same clinical indications for use, and has the same contraindications as those described earlier. In addition, it is used as an antidote for an overdose of cholinergic drugs and exposure to insecticides that have cholinergic effects.

Atropine is a naturally occurring belladonna alkaloid that can be extracted from the belladonna plant or prepared synthetically. It is usually prepared as atropine sulfate, a salt that is very soluble in water. It is well absorbed from the GI tract and distributed throughout the body. It crosses the blood–brain barrier to enter the CNS, where large doses produce stimulant effects and toxic doses produce depressant effects. Atropine is also absorbed systemically when applied locally to mucous membranes. The drug is rapidly excreted in the urine. Pharmacologic effects are of short duration except for ocular effects, which may last for several days.

**Belladonna tincture** is a mixture of alkaloids in an aqueous-alcohol solution. It is most often used in GI disorders for antispasmodic effect. It is an ingredient in several drug mixtures.

**Homatropine hydrobromide** (Homapin) is a semisynthetic derivative of atropine used as eye drops to produce mydriasis and cycloplegia. Homatropine may be preferable to atropine because ocular effects do not last as long.

**Hyoscine** (Anaspaz) is a belladonna alkaloid used in GI and genitourinary disorders characterized by spasm, increased secretion, and increased motility. It has the same effects as other atropine-like drugs.

**Ipratropium** (Atrovent) is an anticholinergic drug chemically related to atropine. When given as a nasal spray, it is useful in treating rhinorrhea due to allergy or the common cold. When given as an inhalation treatment or aerosol to patients with chronic obstructive pulmonary disease (COPD), it is beneficial as a bronchodilator. An advantage of administration of anticholinergic drugs by the respiratory route over systemic administration is less thickening of respiratory secretions and reduced incidence of mucus-pluged airways.

**Scopolamine** is similar to atropine in uses, adverse effects, and peripheral effects but different in central effects.
# Drugs at a Glance: Selected Anticholinergic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Belladonna Alkaloids and Derivatives</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Atropine</strong></td>
<td>Systemic use</td>
<td>PO, IM, SC, IV 0.4–0.6 mg</td>
<td>PO, IM, SC, IV: 7–16 lbs: 0.1 mg 16–24 lbs: 0.15 mg 24–40 lbs: 0.2 mg 40–65 lbs: 0.3 mg 65–90 lbs: 0.4 mg &gt;90 lbs 0.4–0.6 mg</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>IM, SC, or IV 0.4–0.6 mg prior to induction. Use 0.4-mg dose with cyclopropane anesthesia.</td>
<td>0.1 mg (newborn) to 0.6 mg (12 y) given SC 30 min prior to surgery.</td>
</tr>
<tr>
<td></td>
<td>Bradyarrhythmias</td>
<td>IV 0.4–1 mg (up to 2 mg) q1–2h PRN.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antidote for cholinergic poisoning</td>
<td>IV titrate large doses of 2–3 mg as needed until signs of atropine toxicity appear and cholinergic crisis is controlled.</td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmic atropine (Isopto-Atropine)</strong></td>
<td>Mydriatic/cycloplegia/ inflammation of uveal tract</td>
<td>For refraction: Instill 1–2 drops of 1% solution into eye(s) 1 h before refraction. For uveitis: Instill 1–2 drops of 1% solution into eye(s) qid.</td>
<td>For refraction: Instill 1–2 drops of 0.5% solution bid for 1–3 days before procedure.</td>
</tr>
<tr>
<td><strong>Homatropine (Homapin)</strong></td>
<td>Mydriatic/cycloplegia/ inflammation of uveal tract</td>
<td>For refraction: Instill 1–2 drops of 2% solution or 1 drop 5% solution into eye before procedure. May repeat at 5–10 min intervals as needed. For uveitis: Instill 1–2 drops of 2% or 5% solution bid to tid or every 3–4 h as needed.</td>
<td>For refraction: Instill 1 drop of 2% solution into eye before procedure. May repeat q 10 min as needed. For uveitis: Instill 1 drop of 2% solution bid to tid.</td>
</tr>
<tr>
<td><strong>Hyoscyamine (Anaspaz)</strong></td>
<td>Antispasmodic Antisecretory for gastrointestinal (GI) and genitourinary (GU) disorders</td>
<td>PO, SL 0.125–0.25 mg tid or qid, ac and hs. PO (timed-release formula): 0.375–0.75 q12h. IM, IV, SC: 0.25–0.5 mg q6h.</td>
<td>Children 2–10 y: PO 0.062–0.125 mg q 6–8h. Children &lt;2 y: half of the previous dose.</td>
</tr>
<tr>
<td><strong>Ipratropium (Atrovent)</strong></td>
<td>Bronchodilation</td>
<td>2 puffs (36 mcg) of aerosol qid. Additional inhalations may be needed. Do not exceed 12 puffs/24h. Solution for inhalation: 500 mcg, tid–qid.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nasal spray for rhinorrhea</td>
<td>2 sprays/nostril of 0.03% spray bid–tid. 2 sprays/nostril of 0.06% spray tid–qid.</td>
<td>2 sprays/nostril of 0.03% spray bid–tid.</td>
</tr>
<tr>
<td><strong>Scopolamine</strong></td>
<td>Systemic use</td>
<td>PO 0.4–0.8 mg qd. SC, IM 0.32–0.65 mg IV 0.32–0.65 mg diluted in sterile water for injection.</td>
<td>Not approved for PO use &lt;6 y. Parenteral: 0.006 mg/kg. Maximum dose: 0.3 mg.</td>
</tr>
<tr>
<td></td>
<td>Antiemetic</td>
<td>Transdermal: Apply disc 4 h before antiemetic effect is needed. Replace q 3 days.</td>
<td>Not approved in children.</td>
</tr>
<tr>
<td></td>
<td>Mydriatic/cycloplegia/ inflammation of uveal tract</td>
<td>For refraction: Instill 1–2 drops into eye 1 h before refracting. For uveitis: Instill 1–2 drops into eye(s) up to tid.</td>
<td>Same as adult dose</td>
</tr>
</tbody>
</table>

(continued)
## Drugs at a Glance: Selected Anticholinergic Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antisecretory/Antispasmodic Anticholinergics for GI Disorders</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dicyclomine hydrochloride (Bentyl)</td>
<td>Antisecretory/antispasmodic</td>
<td>PO 20–40 mg ac &amp; hs IM 20 mg ac &amp; hs</td>
<td>&lt; 12 y: not recommended</td>
</tr>
<tr>
<td>Glycopyrrolate (Robinul)</td>
<td>Antisecretory/antispasmodic</td>
<td>PO 1–2 mg bid–tid IM, IV 0.1–0.2 mg IM 0.004 mg/kg 30–60 min before anesthesia</td>
<td>&lt; 2 y: 0.004 mg/lb IM 30–60 min before anesthesia. 2–12 y: 0.002–0.004 mg/lb IM 30–60 min before anesthesia.</td>
</tr>
<tr>
<td>Mepenzolate (Cantil)</td>
<td>Antisecretory/antispasmodic Preanesthetic</td>
<td>PO 25–50 mg qid ac &amp; hs</td>
<td></td>
</tr>
<tr>
<td>Methscopolamine (Pamine)</td>
<td>Antisecretory/antispasmodic</td>
<td>PO 2.5–5 mg 30 min ac &amp; hs</td>
<td>200 mcg/kg ac &amp; hs</td>
</tr>
<tr>
<td>Propantheline bromide (Pro-Banthine)</td>
<td>Antisecretory/antispasmodic</td>
<td>PO 7.5–15 mg 30 min ac &amp; hs</td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergics Used in Parkinson’s Disease</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benztropine (Cogentin)</td>
<td>Parkinsonism</td>
<td>PO, IM, IV 0.5–1 mg hs. May increase up to 6 mg given hs or in 2–4 divided doses. <strong>For acute dystonia:</strong> IM, IV 1–2 mg. May repeat if needed. <strong>For prevention:</strong> PO 1–2 mg.</td>
<td></td>
</tr>
<tr>
<td>Biperiden (Akineton)</td>
<td>Parkinsonism</td>
<td>PO 2 mg tid–qid. Maximum dose 16 mg/day.</td>
<td></td>
</tr>
<tr>
<td>Procyclidine (Kemadrin)</td>
<td>Parkinsonism</td>
<td>PO 2.5 mg tid pc. May increase to 5 mg tid.</td>
<td></td>
</tr>
<tr>
<td>Trihexyphenidyl (Trihexy)</td>
<td>Parkinsonism</td>
<td>PO 1–2 mg. Increase by 2 mg increments at 3–5-d intervals until a total of 6–10 mg is given qd in divided doses 3–4 times/d at mealtimes and bedtimes. Drug-induced extrapyramidal symptoms</td>
<td>PO 1 mg initially. Increase as needed to control symptoms.</td>
</tr>
<tr>
<td><strong>Urinary Antispasmodics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flavoxate (Urispas)</td>
<td></td>
<td>PO 100–200 mg tid–qid. Reduce when symptoms improve.</td>
<td>&lt;12 y: safety and efficacy not established</td>
</tr>
<tr>
<td>Oxybutynin (Ditropan and Ditropan XL)</td>
<td></td>
<td>PO 5 mg bid or tid. Maximum dose 5 mg qid. Extended-release 5 mg PO qd up to 30 mg/d.</td>
<td>&gt;5 y: 5 mg PO bid. Maximum dose 5 mg tid.</td>
</tr>
<tr>
<td>Tolterodine (Detrol and Detrol LA)</td>
<td></td>
<td>PO 2 mg bid. May decrease to 1 mg when symptoms improve. Reduce doses to 1 mg PO bid in presence of hepatic impairment.</td>
<td>Safety and efficacy not established.</td>
</tr>
</tbody>
</table>

ac, before meals; hs, bedtime; pc, after meals.
When given parenterally, scopolamine depresses the CNS and causes amnesia, drowsiness, euphoria, relaxation, and sleep. Effects of scopolamine appear more quickly and disappear more readily than those of atropine. Scopolamine also is used in motion sickness. It is available as oral tablets and as a transdermal adhesive disc that is placed behind the ear. The disc (Transderm-V) protects against motion sickness for 72 hours.

**Centrally Acting Anticholinergics Used in Parkinson’s Disease**

Older anticholinergic drugs such as atropine are rarely used to treat Parkinson’s disease because of their undesirable peripheral effects (eg, dry mouth, blurred vision, photophobia, constipation, urinary retention, and tachycardia). Newer, centrally acting synthetic anticholinergic drugs are more selective for muscarinic receptors in the CNS and are designed to produce fewer side effects.

Trihexyphenidyl (Trihexy) is used in the treatment of parkinsonism and extrapyramidal reactions caused by some antipsychotic drugs. Trihexyphenidyl relieves smooth muscle spasm by a direct action on the muscle and by inhibiting the PNS. The drug supposedly has fewer side effects than atropine, but approximately half the recipients report mouth dryness, blurring of vision, and other side effects common to anticholinergic drugs. Trihexyphenidyl requires the same precautions as other anticholinergic drugs and is contraindicated in glaucoma. Biperiden (Akineton) and procyclidine (Kemadrin) are chemical derivatives of trihexyphenidyl and have similar actions.

Benztropine (Cogentin) is a synthetic drug with both anticholinergic and antihistaminic effects. Its anticholinergic activity approximates that of atropine. A major clinical use is to treat acute dystonic reactions caused by antipsychotic drugs and to prevent their recurrence in clients receiving long-term antipsychotic drug therapy. It also may be given in small doses to supplement other antiparkinson drugs. In full dosage, adverse reactions are common.

**Urinary Antispasmodics**

Flavoxate (Urispas) was developed specifically to counteract spasm in smooth muscle tissue of the urinary tract. It has anticholinergic, local anesthetic, and analgesic effects. Thus, the drug relieves dysuria, urgency, frequency, and pain with genitourinary infections, such as cystitis and prostatitis.

Oxybutynin (Ditropan and Ditropan XL) has direct antispasmodic effects on smooth muscle and anticholinergic effects. It increases bladder capacity and decreases frequency of voiding in clients with neurogenic bladder. Oxybutynin is now available in an extended-release form for once a day dosing.

Tolterodine (Detrol and Detrol LA) is a competitive antimuscarinic, anticholinergic agent that inhibits bladder contraction, decreases detrusor muscle pressure, and delays the urge to void. It is used to treat urinary frequency, urgency, and urge incontinence. Tolterodine is more selective for muscarinic receptors in the urinary bladder than other areas of the body, such as the salivary glands, and therefore anticholinergic side effects are less marked. Reduced doses (of 1 mg) are recommended for those with hepatic dysfunction. Tolterodine is also available in an extended-release form.

**Nursing Process**

**Assessment**

- Assess the client’s condition in relation to disorders for which anticholinergic drugs are used (ie, check for bradycardia or heart block, diarrhea, dysuria, abdominal pain, and other disorders). If the client reports or medical records indicate a specific disorder, assess for signs and symptoms of that disorder (eg, Parkinson’s disease).
- Assess for disorders in which anticholinergic drugs are contraindicated (eg, glaucoma, prostatic hypertrophy, reflux esophagitis, myasthenia gravis, hyperthyroidism).
- Assess use of other drugs with anticholinergic effects, such as antihistamines (histamine-1 receptor antagonists [see Chap. 48]), antipsychotic agents, and tricyclic antidepressants.

**Nursing Diagnoses**

- Impaired Urinary Elimination: Decreased bladder tone and urine retention
- Constipation related to slowed GI function
- Disturbed Thought Processes: Confusion, disorientation, especially in older adults
- Deficient Knowledge: Drug effects and accurate usage
- Risk for Injury related to drug-induced blurred vision and photophobia
- Risk for Noncompliance related to adverse drug effects
- Risk for Altered Body Temperature: Hyperthermia

**How Can You Avoid This Medication Error?**

Sam Miller is admitted for elective surgery. He has a history of heart disease, glaucoma, and benign prostatic hyperplasia (BPH). After surgery, a scopolamine patch is prescribed to control nausea. You administer the patch, as ordered, placing it on his chest in a nonhairy area.

Scott Andrews is scheduled for a bronchoscopy. Before this procedure, you have been ordered to give him Valium and atropine. Explain the rationale of giving an anticholinergic agent as a preoperative medication.
SECTION 3 DRUGS AFFECTING THE AUTONOMIC NERVOUS SYSTEM

314

PRINCIPLES OF THERAPY

Use in Specific Conditions

Renal or Biliary Colic

Atropine is sometimes given with morphine or meperidine to relieve the severe pain of renal or biliary colic. It acts mainly to decrease the spasm-producing effects of the opioid analgesics. It has little antispasmodic effect on the involved muscles and is not used alone for this purpose.

Preoperative Use in Clients With Glaucoma

Glaucoma is usually listed as a contraindication to anticholinergic drugs because the drugs impair outflow of aqueous humor and may cause an acute attack of glaucoma (increased intraocular pressure). However, anticholinergic drugs can be given safely before surgery to clients with open-angle glaucoma (80% of clients with primary glaucoma) if they are receiving miotic drugs, such as pilocarpine. If anticholinergic preoperative medication is needed in clients predisposed to angle closure, the hazard of causing acute glaucoma can be minimized by also giving pilocarpine eye drops and acetazolamide (Diamox).

Interventions

Use measures to decrease the need for anticholinergic drugs. For example, with peptic ulcer disease, teach the client to avoid factors known to increase gastric secretion and GI motility (alcohol; cigarette smoking; caffeine-containing beverages, such as coffee, tea, and cola drinks; ulcerogenic drugs, such as aspirin). Late evening snacks also should be avoided because increased gastric acid secretion occurs approximately 90 minutes after eating and may cause pain and awakening from sleep. Although milk was once considered an “ulcer food,” it contains protein and calcium, which promote acid secretion, and is a poor buffer of gastric acid. Thus, drinking large amounts of milk should be avoided.

Evaluation

• Interview and observe in relation to safe, accurate drug administration.
• Interview and observe for relief of symptoms for which the drugs are given.
• Interview and observe for adverse drug effects.

Gastrointestinal Disorders

When anticholinergic drugs are given for GI disorders, larger doses may be given at bedtime to prevent pain and awakening during sleep.

Parkinsonism

When these drugs are used in parkinsonism, small doses are given initially and gradually increased. This regimen decreases adverse reactions.

Extrapyramidal Reactions

When used in drug-induced extrapyramidal reactions (parkinson-like symptoms), these drugs should be prescribed only if symptoms occur. They should not be used routinely to prevent extrapyramidal reactions because fewer than half the clients taking antipsychotic drugs experience such reactions. Most drug-induced reactions last approximately 3 months and do not recur if anticholinergic drugs are discontinued at that time. (An exception is tardive dyskinesia, which does not respond to anticholinergic drugs and may be aggravated by them.)

Muscarinic Agonist Poisoning

Atropine is the antidote for poisoning by muscarinic agonists such as certain species of mushrooms, cholinergic agonist drugs, cholinesterase inhibitor drugs, and insecticides containing organophosphates. Symptoms of muscarinic poisoning include salivation, lacrimation, visual disturbances, bronchospasm, diarrhea, bradycardia, and hypotension. Atropine blocks the poison from interacting with the muscarinic receptor, thus reversing the toxic effects.

Asthma

Oral anticholinergics are not used to treat asthma and other chronic obstructive pulmonary diseases because of their tendency to thicken secretions and form mucus plugs in airways. Ipratropium (Atrovent) may be given by inhalation to produce bronchodilation without thickening of respiratory secretions.

Toxicity of Anticholinergics: Recognition and Management

Overdosage of atropine or other anticholinergic drugs produces the usual pharmacologic effects in a severe and exaggerated form. The anticholinergic overdose syndrome is characterized by hyperthermia; hot, dry, flushed skin; dry mouth; mydriasis; delirium; tachycardia; ileus; and urinary retention. Myoclonic movements and choreoathetosis may be seen. Seizures, coma, and respiratory arrest may also occur. Treatment involves use of activated charcoal to absorb ingested poison. Hemodialysis, hemoperfusion, peritoneal dialysis, and repeated doses of charcoal are not effective in removing anticholinergic agents.

Planning/Goals

The client will:
• Receive or self-administer the drugs correctly
• Experience relief of symptoms for which anticholinergic drugs are given
• Be assisted to avoid or cope with adverse drug effects on vision, thought processes, bowel and bladder elimination, and heat dissipation

Gastrointestinal Disorders

When anticholinergic drugs are given for GI disorders, larger doses may be given at bedtime to prevent pain and awakening during sleep.

Parkinsonism

When these drugs are used in parkinsonism, small doses are given initially and gradually increased. This regimen decreases adverse reactions.

Extrapyramidal Reactions

When used in drug-induced extrapyramidal reactions (parkinson-like symptoms), these drugs should be prescribed only if symptoms occur. They should not be used routinely to prevent extrapyramidal reactions because fewer than half the clients taking antipsychotic drugs experience such reactions. Most drug-induced reactions last approximately 3 months and do not recur if anticholinergic drugs are discontinued at that time. (An exception is tardive dyskinesia, which does not respond to anticholinergic drugs and may be aggravated by them.)

Muscarinic Agonist Poisoning

Atropine is the antidote for poisoning by muscarinic agonists such as certain species of mushrooms, cholinergic agonist drugs, cholinesterase inhibitor drugs, and insecticides containing organophosphates. Symptoms of muscarinic poisoning include salivation, lacrimation, visual disturbances, bronchospasm, diarrhea, bradycardia, and hypotension. Atropine blocks the poison from interacting with the muscarinic receptor, thus reversing the toxic effects.

Asthma

Oral anticholinergics are not used to treat asthma and other chronic obstructive pulmonary diseases because of their tendency to thicken secretions and form mucus plugs in airways. Ipratropium (Atrovent) may be given by inhalation to produce bronchodilation without thickening of respiratory secretions.

Toxicity of Anticholinergics: Recognition and Management

Overdosage of atropine or other anticholinergic drugs produces the usual pharmacologic effects in a severe and exaggerated form. The anticholinergic overdose syndrome is characterized by hyperthermia; hot, dry, flushed skin; dry mouth; mydriasis; delirium; tachycardia; ileus; and urinary retention. Myoclonic movements and choreoathetosis may be seen. Seizures, coma, and respiratory arrest may also occur. Treatment involves use of activated charcoal to absorb ingested poison. Hemodialysis, hemoperfusion, peritoneal dialysis, and repeated doses of charcoal are not effective in removing anticholinergic agents.
Physostigmine salicylate (Antilirium), an acetylcholinesterase inhibitor, is a specific antidote. It is usually given intravenously (IV) at a slow rate of injection. Adult dosage is 2 mg (no more than 1 mg/minute); child dosage is 0.5 to 1 mg (no more than 0.5 mg/minute). Rapid administration may cause bradycardia, hypersalivation (with subsequent respiratory distress), and seizures. Repeated doses may be given if life-threatening dysrhythmias, convulsions, or coma occur.

Diazepam (Valium) or a similar drug may be given for excessive CNS stimulation (delirium, excitement). Ice bags, cooling blankets, and tepid sponge baths may help reduce fever. Artificial ventilation and cardiopulmonary resuscitative measures are used if excessive depression of the CNS causes coma and respiratory failure. Infants, children, and the elderly are especially susceptible to the toxic effects of anticholinergic agents.

Use in Children

Systemic anticholinergics, including atropine, glycopyrrolate (Robinul), and scopolamine, are given to children of all ages for essentially the same effects as for adults. Most of the antisecretory, antispasmodic agents for gastrointestinal disorders are not recommended for children. With the urinary antispasmodics, flavoxate is not recommended for children younger than 12 years, oxybutynin is not recommended for children younger than 5 years of age, and the safety and efficacy of tolterodine are not established in children.

The drugs cause the same adverse effects in children as in adults. However, they may be more severe because children are especially sensitive to the drugs. Facial flushing is common in children, and a skin rash may occur.

Ophthalmic anticholinergic drugs are used for cycloplegia and mydriasis before eye examinations and surgical procedures (see Chap. 65). They should be used only with close medical supervision. Cyclopentolate (Cyclogyl) and tropicamide (Mydriacyl) have been associated with behavioral disturbances and psychotic reactions in children. Tropicamide also has been associated with cardiopulmonary collapse.

Use in Older Adults

Anticholinergic drugs are given for the same purposes as in younger adults. In addition to the primary anticholinergic drugs, many others that are commonly prescribed for older adults have high anticholinergic activity. These include many antihistamines (histamine-1 receptor antagonists), tricyclic antidepressants, and antipsychotic drugs.
Older adults are especially likely to have significant adverse reactions because of slowed drug metabolism and the frequent presence of several disease processes. Some common adverse effects and suggestions for reducing their impact are:

- **Blurred vision.** The client may need help with ambulation, especially with stairs or other potentially hazardous environments. Remove obstacles and hazards when possible.
- **Confusion.** Provide whatever assistance is needed to prevent falls and other injuries.
- **Heat stroke.** Help to avoid precipitating factors, such as strenuous activity and high environmental temperatures.
- **Constipation.** Encourage or assist with an adequate intake of high-fiber foods and fluids and adequate exercise when feasible.
- **Urinary retention.** Encourage adequate fluid intake and avoid high doses of the drugs. Men should be examined for prostatic hypertrophy.
- **Hallucinations and other psychotic symptoms.** These are most likely to occur with the centrally active anticholinergics given for Parkinson’s disease or drug-induced extrapyramidal effects, such as trihexyphenidyl or benztropine. Dosage of these drugs should be carefully regulated and supervised.

### Use in Renal Impairment

Anticholinergic agents that have a tertiary amine structure, such as atropine, are eliminated by a combination of hepatic metabolism and renal excretion. In the presence of renal impairment, they may accumulate and cause increased adverse effects. Quaternary amines are eliminated largely in the feces and are less affected by renal impairment.

### Use in Hepatic Impairment

Because some anticholinergic drugs are metabolized by the liver, they may accumulate and cause adverse effects in the presence of hepatic impairment. Tolterodine is an example of such a medication. In the presence of liver impairment, dosages should be reduced and given less frequently.

### Use in Critical Illness

Atropine is an important drug in the emergency drug box. According to ACLS guidelines, atropine is the first drug to be administered in the emergency treatment of bradyarrhythmias. Atropine 0.5 to 1 mg should be administered IV every 5 minutes and may be repeated up to 2 to 3 mg (0.03 to 0.04 mg/kg total dose). For clients with asystole, 1 mg of atropine is administered IV and repeated every 3 to 5 minutes if asystole persists, up to 0.04 mg/kg. Administration of atropine in doses less than 0.5 mg should be avoided because this may result in a paradoxical bradycardia. Atropine may be administered by endotracheal tube in clients without an intravenous access. The recommended dose is 2 to 3 mg diluted in 10 mL normal saline.

### Abuse of Anticholinergic Agents

Anticholinergic drugs have potential intoxicating effects. Abuse of these drugs may produce euphoria, disorientation, hallucinations, and paranoia in addition to the classic anticholinergic adverse reactions.

### Home Care

Anticholinergic medications are commonly used in home care with children and adults. Children and older adults are probably most likely to experience adverse effects of these drugs and should be monitored carefully. With elderly clients, the home care nurse needs to assess medication regimens for combinations of drugs with anticholinergic effects, especially if mental confusion develops or worsens. The home care nurse may also need to teach elderly clients or caregivers that the drugs prevent sweating and heat loss and increase risks of heat stroke if precautions to avoid overheating are not taken.
**CHAPTER 21 ANTICHOLINERGIC DRUGS**

## Anticholinergic Drugs

### NURSING ACTIONS

1. **Administer accurately**
   - a. For gastrointestinal disorders, give most oral anticholinergic drugs approximately 30 min before meals and at bedtime.
   - b. When given before surgery, parenteral preparations of atropine can be mixed in the same syringe with several other common preoperative medications, such as meperidine (Demerol), morphine, oxymorphone (Numorphan), and promethazine (Phenergan).
   - c. When applying topical atropine solutions or ointment to the eye, be sure to use the correct concentration and blot any excess from the inner canthus.
   - d. If propantheline is to be given intravenously, dissolve the 30-mg dose of powder in no less than 10 mL of sterile water for injection.
   - e. Instruct clients to swallow oral propantheline tablets, not to chew them.
   - f. Parenteral glycopyrrolate can be given through the tubing of a running intravenous infusion of physiologic saline or lactated Ringer’s solution.
   - g. Do not crush extended-release forms of anticholinergic drugs such as Detrol LA and Ditropan XL.

2. **Observe for therapeutic effects**
   - a. When a drug is given for peptic ulcer disease or other gastrointestinal disorders, observe for decreased abdominal pain.
   - b. When the drug is given for diagnosing or treating eye disorders, observe for pupil dilation (mydriasis) and blurring of vision (cycloplegia).
   - c. When the drug is given for symptomatic bradycardia, observe for increased pulse rate.
   - d. When the drug is given for urinary tract disorders, such as cystitis or enuresis, observe for decreased frequency of urination. When the drug is given for renal colic due to stones, observe for decreased pain.
   - e. When the centrally acting anticholinergics are given for Parkinson’s disease, observe for decrease in tremor, salivation, and drooling.

### RATIONALE/EXPLANATION

To allow the drugs to reach peak antisecretory effects by the time ingested food is stimulating gastric acid secretion. Bedtime administration helps prevent awakening with abdominal pain.

The primary reason for mixing medications in the same syringe is to decrease the number of injections and thus decrease client discomfort. Note, however, that extra caution is required when mixing drugs to be sure that the dosage of each drug is accurate. Also, if any question exists regarding compatibility with another drug, it is safer not to mix the drugs, even if two or three injections are required.

Atropine ophthalmic preparations are available in several concentrations (usually 1%, 2%, and 3%). Excess medication should be removed so the drug will not enter the nasolacrimal (tear) ducts and be absorbed systemically through the mucous membrane of the nasopharynx or be carried to the throat and swallowed.

Parenteral administration is reserved for clients who cannot take the drug orally.

The tablets have a hard sugar coating to mask the bitter taste of the drug.

Crushing long-acting medications may result in high blood levels of the medication and increased adverse effects.

Therapeutic effects depend primarily on the reason for use. Thus, a therapeutic effect in one condition may be a side effect or an adverse reaction in another condition.

Relief of abdominal pain is due to the smooth muscle relaxant or antispasmodic effect of the drug.

Note that these ocular effects are side effects when the drugs are given for problems not related to the eyes.

These drugs increase heart rate by blocking action of the vagus nerve.

Anticholinergic drugs decrease muscle tone and spasm in the smooth muscle of the ureters and urinary bladder.

Decreased salivation is a therapeutic effect with parkinsonism but an adverse reaction in most other conditions.

(continued)
### Nursing Actions

<table>
<thead>
<tr>
<th>3. Observe for adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Tachycardia</td>
</tr>
<tr>
<td>b. Excessive central nervous system (CNS) stimulation (tremor, restlessness, confusion, hallucinations, delirium) followed by excessive CNS depression (coma, respiratory depression)</td>
</tr>
<tr>
<td>c. Sedation and amnesia with scopolamine or benztropine (Cogentin)</td>
</tr>
<tr>
<td>d. Constipation or paralytic ileus</td>
</tr>
<tr>
<td>e. Decreased oral and respiratory tract secretions, which cause mouth dryness and thick respiratory secretions</td>
</tr>
<tr>
<td>f. Urinary retention</td>
</tr>
<tr>
<td>g. Hot, dry skin; fever; heat stroke</td>
</tr>
<tr>
<td>h. Ocular effects—mydriasis, blurred vision, photophobia</td>
</tr>
</tbody>
</table>

### Rationale/Explanation

- **3. Observe for adverse effects**
- **a. Tachycardia**
  - These depend on reasons for use and are dose related. Tachycardia may occur with usual therapeutic doses because anticholinergic drugs block vagal action, which normally slows heart rate. Tachycardia is not likely to be serious except in clients with underlying heart disease. For example, in clients with angina pectoris, prolonged or severe tachycardia may increase myocardial ischemia to the point of causing an acute attack of angina (chest pain) or even myocardial infarction. In clients with congestive heart failure, severe or prolonged tachycardia can increase the workload of the heart to the point of causing acute heart failure or pulmonary edema.

- **b. Excessive central nervous system (CNS) stimulation**
  - These effects are more likely to occur with large doses of atropine because atropine crosses the blood-brain barrier. Large doses of trihexyphenidyl (Trihexy) also may cause CNS stimulation. This may be a therapeutic effect but becomes an adverse reaction if severe or if the drug is given for another purpose. Benztropine has anticholinergic and antihistaminic properties. Apparently, drowsiness and sedation are caused by the antihistaminic component.

- **c. Sedation and amnesia**
  - These effects are the result of decreased gastrointestinal motility and muscle tone. Constipation is more likely with large doses or parenteral administration. Paralytic ileus is not likely unless the drugs are given to clients who already have decreased gastrointestinal motility.

- **d. Constipation or paralytic ileus**
  - These effects are due to decreased sweating and impairment of the normal heat loss mechanism. Fever may occur with any age group. Heat stroke is more likely to occur with cardiovascular disease, strenuous physical activity, and high environmental temperatures, especially in elderly people.

- **e. Decreased oral and respiratory tract secretions**
  - Mouth dryness is more annoying than serious in most cases and is caused by decreased salivation. However, clients with chronic lung disease, who usually have excessive secretions, tend to retain them with the consequence of frequent respiratory tract infections.

- **f. Urinary retention**
  - This reaction is caused by loss of bladder tone and is most likely to occur in elderly men with enlarged prostate glands. Thus, the drugs are usually contraindicated with prostatic hypertrophy.

- **g. Hot, dry skin; fever; heat stroke**
  - These effects are due to decreased sweating and impairment of the normal heat loss mechanism. Fever may occur with any age group. Heat stroke is more likely to occur with cardiovascular disease, strenuous physical activity, and high environmental temperatures, especially in elderly people.

- **h. Ocular effects—mydriasis, blurred vision, photophobia**
  - These are adverse effects when anticholinergic drugs are given for conditions not related to the eyes.

### Observe for drug interactions

- **a. Drugs that increase effects of anticholinergic drugs**
  - These drugs have anticholinergic properties and produce additive anticholinergic effects.

- **b. Drugs that decrease effects of anticholinergic drugs**
  - These drugs counteract the inhibition of gastrointestinal motility and tone induced by atropine. They are sometimes used in atropine overdose.
**CHAPTER 21 ANTICHolinERGIC DRUGS**

**Review and Application Exercises**

1. How do anticholinergic drugs exert their therapeutic effects?
2. What are indications for use and contraindications for anticholinergic drugs?
3. What is the effect of anticholinergic drugs on heart rate, and what is the mechanism for this effect?
4. Under what circumstances is it desirable to administer atropine before surgery, and why?
5. What are adverse effects of anticholinergic drugs?
6. What treatment measures are indicated for a client with an overdose of a drug with anticholinergic effects?
7. Name two other commonly used drug groups that have anticholinergic effects.
8. What nursing observations and interventions are needed to increase client safety and comfort during anticholinergic drug therapy?

**SELECTED REFERENCES**


Drugs Affecting the Endocrine System
Physiology of the Endocrine System

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss the relationship between the endocrine system and the central nervous system.
2. Describe general characteristics and functions of hormones.
3. Differentiate steroid and protein hormones in relation to site of action and pharmacokinetics.
4. Discuss hormonal action at the cellular level.
5. Describe the second messenger roles of cyclic adenosine monophosphate and calcium within body cells.
6. Differentiate between physiologic and pharmacologic doses of hormonal drugs.

OVERVIEW

The endocrine system participates in the regulation of essentially all body activities, including metabolism of nutrients and water, reproduction, growth and development, and adapting to changes in internal and external environments. The major organs of the endocrine system are the hypothalamus, pituitary, thyroid, parathyroids, pancreas, adrenals, ovaries, and testes. These tissues function through hormones, substances that are synthesized and secreted into body fluids by one group of cells and have physiologic effects on other body cells. Hormones act as chemical messengers to transmit information between body cells and organs. Most hormones from the traditional endocrine glands are secreted into the bloodstream and act on distant organs.

In addition to the major endocrine organs, other tissues also produce hormones. These endocrine-like cells intermingle with nonendocrine cells in various organs. Their hormones are secreted into tissue fluids and act locally on nearby cells, as in the following examples:

- Gastrointestinal mucosa produces hormones that are important in the digestive process (eg, gastrin, entero-gastrone, secretin, and cholecystokinin).
- The kidneys produce erythropoietin, a hormone that stimulates the bone marrow to produce red blood cells.
- White blood cells produce cytokines that function as messengers among leukocytes in inflammatory and immune processes.
- Many body tissues produce prostaglandins and leukotrienes, which have a variety of physiologic effects.

Neoplasms also may produce hormones. In endocrine tissues, neoplasms may be an added source of the hormone normally produced by the organ. In nonendocrine tissues, various hormones may be produced. For example, lung tumors may produce corticotropin (adrenocorticotropic hormone [ACTH]), antidiuretic hormone, or parathyroid hormone; kidney tumors may produce parathyroid hormone. The usual effects are those of excess hormone secretion.

This chapter focuses on the traditional endocrine organs and their hormones. Specific organs are discussed in the following chapters; general characteristics of the endocrine system and hormones are described in the following sections and in Box 22–1.

ENDOCRINE SYSTEM–NERVOUS SYSTEM INTERACTIONS

The endocrine and nervous systems are closely connected, anatomically and physiologically, and work in harmony to integrate and regulate body functions. In general, the nervous system regulates rapid muscular and sensory activities by secreting substances that act as neurotransmitters, circulating hormones, and local hormones (eg, norepinephrine, epinephrine). The endocrine system regulates slow metabolic activities by secreting hormones that control cellular metabolism, transport of substances across cell membranes, and other functions (eg, reproduction, growth and development, secretion).

The main connecting link between the nervous system and the endocrine system is the hypothalamus, which responds to nervous system stimulation by producing hormones. Thus, secretion of almost all hormones from the pituitary gland is controlled by the hypothalamus. Special nerve fibers originating in the hypothalamus and ending in the posterior pituitary gland control secretions of the posterior pituitary. The hypothalamus secretes hormones called releasing and in-
Hormones must be continuously inactivated to prevent their accumulation and excessive effects. Several mechanisms operate to eliminate hormones from the body. The water-soluble, protein-derived hormones have a short duration of action and are inactivated by enzymes mainly in the liver and kidneys. The lipid-soluble steroid and thyroid hormones have a longer duration of action because they are bound to plasma proteins. Once released by the plasma proteins, these hormones are conjugated in the liver to inactive products before being excreted in the bile.
forms and then excreted in bile or urine. A third, less common mechanism is inactivation by enzymes at receptor sites on target cells.

**Hormone Action at the Cellular Level**

Hormones modify rather than initiate cellular reactions and functions. Once hormone molecules reach a responsive cell, they bind with receptors in the cell membrane (eg, catecholamines and protein hormones) or inside the cell (eg, steroid and thyroid hormones). The number of hormone receptors and the affinity of the receptors for the hormone are the major determinants of target cell response to hormone action.

The main target organs for a given hormone contain large numbers of receptors. However, the number of receptors may be altered by various conditions. For example, receptors may be increased (called up-regulation) when there are low levels of hormone. This allows the cell to obtain more of the needed hormone than it can obtain with fewer receptors. Receptors may be decreased (called down-regulation) when there are excessive amounts of hormone. This mechanism protects the cell by making it less responsive to excessive hormone levels. Receptor up-regulation and down-regulation occur with chronic exposure to abnormal levels of hormones. In addition, receptor proteins may be decreased by inadequate formation or antibodies that destroy them. Thus, receptors are constantly being synthesized and degraded, so the number of receptors may change within hours. Receptor affinity for binding with hormone molecules probably changes as well.

After binding occurs, the resulting hormone–receptor complex initiates intracellular biochemical reactions, depending on the particular hormone and the type of cell. Many hormones act as a “first messenger” to the cell, and the hormone–receptor complex activates a “second messenger.” The second messenger then activates intracellular structures to produce characteristic cellular functions and products. Steroid hormones from the adrenal cortex, ovaries, and testes stimulate target cells to synthesize various proteins (eg, enzymes, transport and structural proteins) needed for normal cellular function.

**Second Messenger Systems**

Three major second messenger systems, cyclic adenosine monophosphate (cAMP), calcium–calmodulin, and phospholipid products, are described in this section.

Cyclic AMP is the second messenger for many hormones, including corticotropin, catecholamines, glucagon, thyroid-stimulating hormone, follicle-stimulating hormone, luteinizing hormone, parathyroid hormone, secretin, and antidiuretic hormone. It is formed by the action of the enzyme adenyl cyclase on adenosine triphosphate, a component of all cells and the main source of energy for cellular metabolism. Once formed, cAMP activates a series of enzyme reactions that alter cell function. The amount of intracellular cAMP is increased by hormones that activate adenyl cyclase (eg, the pituitary hormones, calcitonin, glucagon, parathyroid hormone) and decreased by hormones that inactivate adenyl cyclase (eg, angiotensin, somatostatin). Cyclic AMP is inactivated by phosphodiesterase enzymes.

Calcium is the second messenger for angiotensin II, a strong vasoconstrictor that participates in control of arterial blood pressure, and for gonadotropin-releasing hormone. The postulated sequence of events is that hormone binding to receptors increases intracellular calcium. The calcium binds with an intracellular regulatory protein called calmodulin. The calcium–calmodulin complex activates protein kinases, which then regulate contractile structures of the cell, cell membrane permeability, and intracellular enzyme activity. Specific effects include contraction of smooth muscle, changes in the secretions produced by secreting cells, and changes in ciliary action in the lungs.

Phospholipid products are mainly involved with local hormones. Phospholipids are major components of the cell membrane portion of all body cells. Some local hormones activate cell membrane receptors and transform them into phospholipase C, an enzyme that causes some of the phospholipids in cell membranes to split into smaller molecules (eg, inositol triphosphate and diacylglycerol). These products then act as second messengers to intracellular structures. Inositol triphosphate mobilizes intracellular calcium ions and the calcium ions then fulfill their functions as second messengers, as described previously. Diacylglycerol activates an enzyme, protein kinase C, that is important in cell reproduction. Also, the lipid component of diacylglycerol is arachidonic acid, the precursor for prostaglandins, leukotrienes, and other local hormones with extensive effects.

**Steroid Stimulation of Protein Synthesis**

Steroid hormones are lipid soluble and therefore cross cell membranes easily. Once inside the cell cytoplasm, the hormone molecules bind with specific receptor proteins. The hormone–receptor complex then enters the nucleus of the cell where it activates nucleic acids (DNA and RNA) and the genetic code to synthesize new proteins.

**Hormonal Disorders**

Abnormal secretion and function of hormones, even minor alterations, can impair physical and mental health. Malfunction of an endocrine organ is usually associated with hyposecretion, hypersecretion, or inappropriate secretion of its hormones. Any malfunction can produce serious disease or death.

**Hypofunction**

Hypofunction may be associated with a variety of circumstances, including the following:

1. A congenital defect may result in the absence of an endocrine gland, the presence of an abnormally developed
SECTION 4 DRUGS AFFECTING THE ENDOCRINE SYSTEM

Hyperfunction

Hyperfunction is usually characterized by excessive hormone production. Excessive amounts of hormone may occur from excessive stimulation and enlargement of the endocrine gland, from a hormone-producing tumor of the gland, or from a hormone-producing tumor of nonendocrine tissues (eg, some primary lung tumors produce antidiuretic hormone and adrenocorticotropic hormone).

GENERAL CHARACTERISTICS OF HORMONAL DRUGS

1. Hormones given for therapeutic purposes include natural hormones from human or animal sources and synthetic hormones. Many of the most important hormones have been synthesized, and these preparations may have more potent and prolonged effects than the naturally occurring hormones.
2. Hormones are given for physiologic or pharmacologic effects. Physiologic use involves giving small doses as a replacement or substitute for the amount secreted by a normally functioning endocrine gland. Such use is indicated only when a gland cannot secrete an adequate amount of hormone. Examples of physiologic use include insulin administration in diabetes mellitus and adrenal corticosteroid administration in Addison’s disease. Pharmacologic use involves relatively large doses for effects greater than physiologic effects. For example, adrenal corticosteroids are widely used for anti-inflammatory effects in endocrine and nonendocrine disorders.
3. Hormones are powerful drugs that produce widespread therapeutic and adverse effects.
4. Administration of one hormone may alter effects of other hormones. These alterations result from the complex interactions among hormones.
5. Hormonal drugs are more often given for disorders resulting from endocrine gland hypofunction than for those related to hyperfunction.

SELECTED REFERENCES

OBJECTIVE 1. Describe clinical uses of selected hormones.

OBJECTIVE 2. Differentiate characteristics and functions of anterior and posterior pituitary hormones.

OBJECTIVE 3. Discuss limitations of hypothalamic and pituitary hormones as therapeutic agents.

OBJECTIVE 4. State major nursing considerations in the care of clients receiving specific hypothalamic and pituitary hormones.

Critical Thinking Scenario

John, 11 years of age, is brought to the pediatric nurse practitioner for his annual sports physical. His mother voices concerns about John’s short stature and questions you about the use of growth hormone. You note that John is in the 25th percentile for height and the 50th percentile for weight.

Reflect on:
- Additional assessment questions to ask John and his mother.
- Factors that might influence their desire for increased height and the use of growth hormone to accomplish this.
- If John uses growth hormone, outline some of the disadvantages and side effects.

Hypothalamic and Pituitary Hormones

OVERVIEW

The hypothalamus and pituitary gland (Fig. 23–1) interact to control most metabolic functions of the body and to maintain homeostasis. They are anatomically connected by the hypophyseal stalk. The hypothalamus controls secretions of the pituitary gland. The pituitary gland, in turn, regulates secretions or functions of other body tissues, called target tissues. The pituitary gland is actually two glands, each with different structures and functions. The anterior pituitary is composed of different types of glandular cells that synthesize and secrete different hormones. The posterior pituitary is anatomically an extension of the hypothalamus and is composed largely of nerve fibers. It does not manufacture any hormones itself but stores and releases hormones synthesized in the hypothalamus.

Hypothalamic Hormones

The hypothalamus produces a releasing hormone or an inhibiting hormone that corresponds to each of the major hormones of the anterior pituitary gland.

Corticotropin-releasing hormone or factor (CRH or CRF) causes release of corticotropin (also called adrenocorticotropic hormone or ACTH), in response to stress and threatening stimuli. CRH is secreted most often during sleep and its secretion is influenced by several neurotransmitters. Acetylcholine and serotonin stimulate secretion; gamma-aminobutyric acid (GABA) and norepinephrine inhibit secretion. The ability of CRH to stimulate corticotropin secretion is increased by vasopressin and decreased or prevented by somatostatin and elevated levels of glucocorticoids. CRH can be used in the diagnosis of Cushing’s disease, a disorder characterized by excess cortisol.

Growth hormone-releasing hormone (GHRH) causes release of growth hormone in response to low blood levels of the hormone. Found in the pancreas as well as the hypothalamus, GHRH structurally resembles a group of hormones that includes glucagon, secretin, vasoactive intestinal peptide, and gastric inhibitory peptide. Secretion of hypothalamic GHRH is stimulated by dopamine, norepinephrine, epinephrine, GABA, acetylcholine, and serotonin. The stimulatory effect of GHRH on secretion of growth hormone is blocked by somatostatin. GHRH may be used to...
test pituitary function and to stimulate growth in children with GHRH deficiency.

**Growth hormone release-inhibiting hormone** (somatostatin) inhibits release of growth hormone. Although originally isolated from the hypothalamus, it is found in many tissues. It is distributed throughout the brain and spinal cord, where it functions as a neurotransmitter. It is also found in the intestines and the pancreas (where it regulates secretion of insulin and glucagon). Somatostatin secretion is increased by several neurotransmitters, including acetylcholine, dopamine, epinephrine, GABA, and nor-epinephrine.

In addition to inhibiting growth hormone, somatostatin also inhibits other functions, including secretion of corticotropin, thyroid-stimulating hormone (TSH or thyrotropin), prolactin, pancreatic secretions (eg, insulin, glucagon), gastrointestinal (GI) secretions (gastrin, cholecystokinin, secretin, vasoactive intestinal peptide), GI motility, bile flow, and mesenteric blood flow. Hypothalamic somatostatin blocks the action of GHRH and decreases thyrotropin-releasing hormone (TRH)-induced release of TSH. Growth hormone stimulates secretion of somatostatin, and somatostatin’s effects on TSH may contribute to TSH deficiency in children being treated with growth hormone. A long-acting somatostatin analog, octreotide (Sandostatin), may be used to treat acromegaly and TSH-secreting pituitary tumors.

**Thyrotropin-releasing hormone** (TRH) causes release of thyroid-stimulating hormone (TSH or thyrotropin) in response to stress, such as exposure to cold. TRH may be used in diagnostic tests of pituitary function and hyperthyroidism.

**Gonadotropin-releasing hormone** (GnRH) causes release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Several synthetic equivalents of GnRH are used clinically.

**Prolactin-releasing factor** is active during lactation after childbirth.

**Prolactin-inhibitory factor** (PIF) is active at times other than during lactation.

**Anterior Pituitary Hormones**

The anterior pituitary gland produces seven hormones. Two of these, growth hormone and prolactin, act directly on their
target tissues; the other five act indirectly by stimulating target tissues to produce other hormones.

**Corticotropin**, also called ACTH, stimulates the adrenal cortex to produce corticosteroids. Secretion is controlled by the hypothalamus and by plasma levels of cortisol, the major corticosteroid. When plasma levels are adequate for body needs, the anterior pituitary does not release corticotropin (negative feedback mechanism).

**Growth hormone**, also called somatotropin, stimulates growth of body tissues. It promotes an increase in cell size and number, including growth of muscle cells and lengthening of bone, largely by affecting metabolism of carbohydrate, protein, fat, and bone tissue. For example, it regulates cell division and protein synthesis required for normal growth. In children, levels of growth hormone rise rapidly during adolescence, peak in the 20s, then start to decline. Deficient growth hormone in children produces dwarfism, a condition marked by severely decreased linear growth and, frequently, severely delayed mental, emotional, dental, and sexual growth as well. Deficient hormone in adults (less than expected for age) can cause increased fat, reduced skeletal and heart muscle mass, reduced strength, reduced ability to exercise, and worsened cholesterol levels (ie, increased low-density lipoprotein [LDL] cholesterol and decreased high-density lipoprotein [HDL] cholesterol), which increase risk factors for cardiovascular disease.

Excessive growth hormone in preadolescent children produces gigantism, resulting in heights of 8 or 9 feet if untreated. Excessive growth hormone in adults produces acromegaly, develops gigantism, resulting in heights of 8 or 9 feet if untreated. This is a condition characterized by increased fat, reduced skeletal and heart muscle mass, reduced strength, reduced ability to exercise, and worsened cholesterol levels (ie, increased low-density lipoprotein [LDL] cholesterol and decreased high-density lipoprotein [HDL] cholesterol), which increase risk factors for cardiovascular disease.

**Thyrotropin** (also called TSH) regulates secretion of thyroid hormones. Thyrotropin secretion is controlled by a negative feedback mechanism in proportion to metabolic needs. Thus, increased thyroid hormones in body fluids inhibit secretion of thyrotropin by the anterior pituitary and of TRH by the hypothalamus.

**FSH**, one of the gonadotropins, stimulates functions of sex glands. It is produced by the anterior pituitary gland of both sexes, beginning at puberty. FSH acts on the ovaries in a cyclical fashion during the reproductive years, stimulating growth of ovarian follicles. These follicles then produce estrogen, which prepares the endometrium for implantation of a fertilized ovum. FSH acts on the testes to stimulate the production and growth of sperm (spermatogenesis), but it does not stimulate secretion of male sex hormones. Drug preparations of FSH include urofollitropin (Fertinex), follitropin alfa (Gonal-F), and follitropin beta (Follistim). These drugs are used to stimulate ovarian function in the treatment of infertility.

**LH** (also called interstitial cell-stimulating hormone) is another gonadotropin that stimulates hormone production by the gonads of both sexes. In women, LH is important in the maturation and rupture of the ovarian follicle (ovulation). After ovulation, LH acts on the cells of the collapsed corpus to produce the corpus luteum, which then produces progesterone during the last half of the menstrual cycle. When blood progesterone levels rise, a negative feedback effect is exerted on hypothalamic and anterior pituitary secretion of gonadotropins.

Decreased pituitary secretion of LH causes the corpus luteum to die and stop producing progesterone. Lack of progesterone causes slough and discharge of the endometrial lining as menstrual flow. (Of course, if the ovum has been fertilized and attached to the endometrium, menstruation does not occur.) In men, LH stimulates the Leydig’s cells in the spaces between the seminiferous tubules. These cells then secrete androgens, mainly testosterone.

**Prolactin** plays a part in milk production by nursing mothers. It is not usually secreted in nonpregnant women because of the hypothalamic hormone PIF. During late pregnancy and lactation, various stimuli, including suckling, inhibit the production of PIF, and thus prolactin is synthesized and released.

**Melanocyte-stimulating hormone** plays a role in skin pigmentation, but its function in humans is not clearly delineated.

### Posterior Pituitary Hormones

The posterior pituitary gland stores and releases two hormones that are synthesized by nerve cells in the hypothalamus.

**Antidiuretic hormone** (ADH), also called vasopressin, functions to regulate water balance. When ADH is secreted, it makes renal tubules more permeable to water. This allows water in renal tubules to be reabsorbed into the plasma and so conserves body water. In the absence of ADH, little water is reabsorbed, and large amounts are lost in the urine.

Antidiuretic hormone is secreted when body fluids become concentrated (high amounts of electrolytes in proportion to the amount of water) and when blood volume is low. In the first instance, ADH causes reabsorption of water, dilution of extracellular fluids, and restoration of normal osmotic pressure. In the second instance, ADH raises blood volume and arteriolar blood pressure toward homeostatic levels.

**Oxytocin** functions in childbirth and lactation. It initiates uterine contractions at the end of gestation to induce childbirth, and it causes milk to move from breast glands to nipples so the infant can obtain the milk by suckling.

### Therapeutic Limitations

There are few therapeutic uses for hypothalamic hormones and pituitary hormones. Most hypothalamic hormones are used to diagnose pituitary insufficiency. Pituitary hormones are not used extensively because most conditions in which they are indicated are uncommon; other effective agents are available for some uses; and deficiencies of target gland hormones (eg, corticosteroids, thyroid hormones, male or female sex hormones) are usually more effectively treated with those hormones than with anterior pituitary hormones that stimulate their secretion. However, the hormones perform important functions when used in particular circumstances, and drug formulations of most hormones have been synthesized for these purposes.
INDIVIDUAL HORMONAL AGENTS

Selected drugs are described below. Indications for use, routes, and dosage ranges are listed in Drugs at a Glance: Hypothalamic and Pituitary Agents.

Hypothalamic Hormones

**Gonadorelin** (Factrel), **goserelin** (Zoladex), histrelin (Supprelin), **leuprolide** (Lupron), **nafarelin** (Synarel), and **tripletorelin** (Trelstar) are equivalent to gonadotropin-releasing hormone. After initial stimulation of LH and FSH secretion, chronic administration of therapeutic doses inhibits gonadotropin secretion. This action results in decreased production of testosterone and estrogen, which is reversible when drug administration is stopped. In males, testosterone is reduced to castrate levels. In premenopausal females, estrogens are reduced to postmenopausal levels. These effects occur within 2 to 4 weeks after drug therapy is begun. In children with central precocious puberty (CPP), gonadotropins (testosterone in males, estrogen in females) are reduced to prepubertal levels.

The drugs cannot be given orally because they would be destroyed by enzymes in the GI tract. Most are given by injection and are available in depot preparations that can be given once monthly or less often. Adverse effects are basically those of testosterone or estrogen deficiency. When given for prostate cancer, the drugs may cause increased bone pain and increased difficulty in urinating during the first few weeks of treatment. The drugs may also cause or aggravate depression.

**Octreotide** (Sandostatin) has pharmacologic actions similar to those of somatostatin. Indications for use include acromegaly, in which it reduces blood levels of growth hormone and insulin-like growth factor-1; carcinoid tumors, in which it inhibits diarrhea and flushing; and in vasoactive intestinal peptide tumors, in which it relieves diarrhea (by decreasing GI secretions and motility). It is also used to treat diarrhea in acquired immunodeficiency syndrome and other conditions. The drug is most often given subcutaneously (SC) and may be self-administered. The long-acting formulation (Sandostatin LAR Depot) must be given intramuscularly (IM) in a gluteal muscle of the hip. Dosage should be reduced for older adults.

Anterior Pituitary Hormones

**Corticotropin** (ACTH, Acthar), which is obtained from animal pituitary glands, is mainly of historical interest. For therapeutic purposes, it has been replaced by adrenal corticosteroids. It may be used occasionally as a diagnostic test to differentiate primary adrenal insufficiency (Addison’s disease, which is associated with atrophy of the adrenal gland) from secondary adrenal insufficiency caused by inadequate pituitary secretion of corticotropin. However, **cosyntropin** (Cortrosyn), a synthetic formulation, is more commonly used to test for suspected adrenal insufficiency.

**Growth hormone** is synthesized from bacteria by recombinant DNA technology. Somatropin (Humatrope) and somatrem (Protropin) are therapeutically equivalent to endogenous growth hormone produced by the pituitary gland. The main clinical use of the drugs is for children whose growth is impaired by a deficiency of endogenous hormone. The drugs are ineffective when impaired growth results from other causes or after puberty, when epiphyses of the long bones have closed. They are also used to treat short stature in children that is associated with chronic renal failure or Turner syndrome (a genetic disorder that occurs in girls). In adults, the drugs may be used to treat deficiency states (eg, those caused by disease, surgery, or radiation of the pituitary gland) or the tissue wasting associated with acquired immunodeficiency syndrome. In general, dosage should be individualized according to response. Excessive administration can cause excessive growth (gigantism).

**Human chorionic gonadotropin** (HCG; Chorex, others) produces physiologic effects similar to those of the naturally occurring LH. In males, it is used to evaluate the ability of Leydig’s cells to produce testosterone, to treat hypogonadism due to pituitary deficiency, and to treat cryptorchidism (undescended testicle) in preadolescent boys. In women, HCG is used in combination with menotropins to induce ovulation in the treatment of infertility. Excessive doses or prolonged administration can lead to sexual precocity, edema, and breast enlargement caused by oversecretion of testosterone and estrogen.

**Menotropins** (Pergonal), a gonadotropin preparation obtained from the urine of postmenopausal women, contains both FSH and LH. It is usually combined with HCG to induce ovulation in the treatment of infertility caused by lack of pituitary gonadotropins.

**Thyrotropin** (Thytropar) is used as a diagnostic agent to distinguish between primary hypothyroidism (caused by a thyroid disorder) and secondary hypothyroidism (caused by pituitary malfunction). If thyroid hormones in serum are elevated after the administration of thyrotropin, then the hypothyroidism is secondary to inadequate pituitary function. Thyrotropin must be used cautiously in clients with coronary artery disease, congestive heart failure, or adrenocortical insufficiency. **Thyrotropin alfa** (Thyrogen) is a synthetic formulation of TSH used to treat thyroid cancer.

Posterior Pituitary Hormones

**Desmopressin** (DDAVP, Stimate), lyspressin, and vasopressin (Pitressin) are synthetic equivalents of antidiuretic hormone (ADH). A major clinical use is the treatment of neurogenic diabetes insipidus, a disorder characterized by a deficiency of ADH and the excretion of large amounts of dilute urine. Diabetes insipidus may be idiopathic, hereditary, or acquired as a result of trauma, surgery, tumor, infection, or other conditions that impair the function of the hypothalamus or posterior pituitary.
### Drugs at a Glance: Hypothalamic and Pituitary Agents

<table>
<thead>
<tr>
<th>Generic/Trade Names</th>
<th>Indications for Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypothalamic Hormones</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gonadorelin</strong> (Factrel)</td>
<td>Diagnostic test of gonadotropin functions of the anterior pituitary</td>
<td>SC, IV 100 mcg</td>
<td></td>
</tr>
<tr>
<td><strong>Goserelin</strong> (Zoladex)</td>
<td>Endometriosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metastatic breast cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prostate cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Leuprolide</strong> (Lupron)</td>
<td>Advanced prostatic cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Central precocious puberty (CPP) in children</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endometriosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uterine fibroid tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nafarelin</strong> (Synarel)</td>
<td>Endometriosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Central precocious puberty in children</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Octreotide</strong> (Sandostatin)</td>
<td>Acromegaly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carcinoid tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vasoactive intestinal peptide tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anterior Pituitary Hormones</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Corticotropin</strong> (ACTH, Acthar Gel)</td>
<td>Stimulate synthesis of hormones by the adrenal cortex</td>
<td>Therapeutic use, IM, SC 20 units four times daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic test of adrenal function</td>
<td>Diagnostic use, IV infusion, 10–25 units in 500 mL of 5% dextrose or 0.9% sodium chloride solution, over 8 hours Acthar Gel, IM 40–80 units q24–72h</td>
<td></td>
</tr>
<tr>
<td><strong>Cosyntropin</strong> (Cortrosyn)</td>
<td>Diagnostic test in suspected adrenal insufficiency</td>
<td>IM, IV 0.25 mg (equivalent to 25 units ACTH)</td>
<td></td>
</tr>
<tr>
<td><strong>Growth hormone:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Somatrem</strong> (Protropin)</td>
<td>Promote growth in children whose growth is impaired by a deficiency of endogenous growth hormone</td>
<td>Somatrem IM, up to 0.1 mg/kg three times per week</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preadolescent boys: Cryptorchidism and male hypogonadism, IM 500–4000 units 2–3 times per week for several weeks</td>
<td>Preadolescent boys: Cryptorchidism and hypogonadism, IM 500–4000 units 2–3 times per week for several weeks</td>
<td></td>
</tr>
<tr>
<td><strong>Somatropin</strong> (Genotropin, Humatrop, Nordotropin, Nutropin, Serostim)</td>
<td>Cryptorchidism</td>
<td>To induce ovulation, IM 5000–10,000 units in one dose, 1 d after treatment with menotropins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diagnostic test of testosterone production</td>
<td>To induce ovulation, IM 5000–10,000 units in one dose, 1 d after treatment with menotropins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induce ovulation in the treatment of infertility</td>
<td>To induce ovulation, IM 5000–10,000 units in one dose, 1 d after treatment with menotropins</td>
<td></td>
</tr>
<tr>
<td><strong>Choriogonadotropin alfa</strong> (Ovidrel)</td>
<td>Cryptorchidism and male hypogonadism, IM 500–4000 units 2–3 times per week for several weeks</td>
<td>Preadolescent boys: Cryptorchidism and hypogonadism, IM 500–4000 units 2–3 times per week for several weeks</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td></td>
</tr>
<tr>
<td><strong>Menotropins</strong> (Pergonal)</td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td>Combined with HCG to induce ovulation in treatment of infertility caused by lack of pituitary gonadotropins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td>IM 1 ampule (75 units FSH and 75 units LH) daily for 9–12 d, followed by HCG to induce ovulation</td>
<td></td>
</tr>
</tbody>
</table>

*(continued)*
### Drugs at a Glance: Hypothalamic and Pituitary Agents (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Names</th>
<th>Indications for Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyrotropin alfa (Thyrogen)</td>
<td>Diagnostic test of thyroid function</td>
<td>IM 0.9 mg every 24 h for 2 doses or every 72 h for 3 doses</td>
<td>&lt;16 y: Dosage not established</td>
</tr>
<tr>
<td>Posterior Pituitary Hormones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Desmopressin (DDAVP, Stimate)</td>
<td>Neurogenic diabetes insipidus Hemostasis (parenteral only) in spontaneous, trauma-induced and perioperative bleeding</td>
<td>Diabetes insipidus, intranasally 0.1–0.4 mL/d, usually in two divided doses</td>
<td>3 mo–2 y: Diabetes insipidus, intranasally 0.05–0.3 mL/d in 1–2 doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hemophilia A, von Willebrand’s disease, IV 0.3 mcg/kg in 50 mL sterile saline, infused over 15–30 min</td>
<td>Weight &gt;10 kg: Hemophilia A, von Willebrand’s disease, same as adult dosage</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Weight ≤10 kg: Hemophilia A, von Willebrand’s disease, IV 0.3 mcg/kg in 10 mL of sterile saline</td>
</tr>
<tr>
<td>Lypressin</td>
<td>Diabetes insipidus</td>
<td>Intranasal spray, one or two sprays to one or both nostrils, 3–4 times per day</td>
<td></td>
</tr>
<tr>
<td>Vasopressin (Pitressin)</td>
<td>Diabetes insipidus</td>
<td>IM, SC, intranasally on cotton pledgets, 0.25–0.5 mL (5–10 units) 2–3 times per day</td>
<td>IM, SC, intranasally on cotton pledgets, 0.125–0.5 mL (2.5–10 units) 3–4 times per day</td>
</tr>
<tr>
<td>Oxytocin (Pitocin)</td>
<td>Induce labor Control postpartum bleeding</td>
<td>Induction of labor, IV 1-mL ampule (10 units) in 1000 mL of 5% dextrose injection (10 units/1000 mL = 10 milliunits/mL), infused at 0.2–2 milliunits/min initially, then regulated according to frequency and strength of uterine contractions</td>
<td>Prevention or treatment of postpartum bleeding, IV 10–40 units in 1000 mL of 5% dextrose injection, infused at 125 mL/h (40 milliunits/min) or 0.6–1.8 units (0.06–0.18 mL) diluted in 3–5 mL sodium chloride injection and injected slowly; IM 0.3–1 mL (3–10 units)</td>
</tr>
</tbody>
</table>

Lypressin is used only for controlling the excessive water loss of diabetes insipidus. Parenteral desmopressin is also used as a hemostatic in clients with hemophilia A or mild to moderate von Willebrand’s disease (type 1). The drug is effective in controlling spontaneous or trauma-induced bleeding and intraoperative and postoperative bleeding when given 30 minutes before the procedure. Vasopressin is also used in the treatment of bleeding esophageal varices because of its vasoconstrictive effects. Desmopressin and lypressin may be inhaled intranasally; vasopressin must be injected.

**Oxytocin (Pitocin)** is a synthetic drug that exerts the same physiologic effects as the posterior pituitary hormone. Thus, it promotes uterine contractility and is used clinically to induce labor and in the postpartum period to control bleeding. Oxytocin must be used only when clearly indicated and when the recipient can be supervised by well-trained personnel, as in a hospital.

---

### Nursing Process

#### Assessment

Assess for disorders for which hypothalamic and pituitary hormones are given:

- For children with impaired growth, assess height and weight (actual and compared with growth charts) and diagnostic x-ray reports of bone age.
- For clients with diabetes insipidus, assess baseline blood pressure, weight, ratio of fluid intake to urine output, urine specific gravity, and laboratory reports of serum electrolytes.
- For clients with diarrhea, assess number and consistency of stools per day as well as hydration status.
CHAPTER 23 HYPOTHALAMIC AND PITUITARY HORMONES

PRINCIPLES OF THERAPY

1. Hypothalamic hormones are rarely used in most clinical practice settings. The drugs should be prescribed by physicians who are knowledgeable about endocrinology and administered according to current manufacturers’ literature.

2. Most drug therapy with pituitary hormones is given to replace or supplement naturally occurring hormones in situations involving inadequate function of the pituitary gland (hypopituitarism). Conditions resulting from excessive amounts of pituitary hormones (hyperpituitarism) are more often treated with surgery or irradiation.

3. Diagnosis of suspected pituitary disorders should be thorough to promote more effective treatment, including drug therapy.

4. Even though manufacturers recommend corticotropin for treatment of disorders that respond to glucocorticoids, corticotropin is less predictable and less convenient than glucocorticoids and has no apparent advantages over them.

5. Dosage of any pituitary hormone must be individualized because responsiveness of affected tissues varies.

6. Because the hormones are proteins, they must be given by injection or nasal inhalation. If taken orally, they would be destroyed by proteolytic enzymes in the GI tract.

7. An increasing concern is inappropriate use of growth hormone. Young athletes may use the drug for bodybuilding and to enhance athletic performance. If so, they are likely to use relatively high doses. In addition, the highest levels of physiologic hormone are secreted during adolescence. The combination of high pharmacologic and high physiologic amounts increases risks of health problems from excessive hormone. Also, there is little evidence that hormone use increases muscle mass or strength beyond that achieved with exercise alone.

Middle-aged and older adults may use growth hormone to combat the effects of aging, such as decreased energy, weaker muscles and joints, and wrinkled skin. One source of the product is apparently “anti-aging” clinics. Although it is not illegal for physicians to prescribe growth hormone for these populations, such use is unproven in safety and effectiveness. Endocrinologists emphasize that optimal adult levels of growth hormone are unknown and using the drug to slow aging is unproven and potentially dangerous because the long-term effects are unknown.

Possible adverse effects, especially with high doses or chronic use, include acromegaly, diabetes, hypertension, and increased risk of serious cardiovascular disease (eg, heart failure). There is also concern about a possible link between growth hormone, which stimulates tumor growth, and cancer. Growth hormone stimulates the release of insulin-like growth factor-1 (IGF-1, also called somatomedin), a substance which circulates in the blood and stimulates cell division. Most tumor cells have receptors that recognize IGF-1, bind it, and allow it to enter the cell, where it could trigger uncontrolled cell division. This concern may be greater for middle-aged and older adults, because malignancies are more common in these groups than in adolescents and young adults.

Nursing Diagnoses
- Deficient Knowledge: Drug administration and effects
- Altered Growth and Development
- Anxiety related to multiple injections
- Risk for Injury: Adverse drug effects

Planning/Goals
The client will:
- Experience relief of symptoms without serious adverse effects
- Take or receive the drug accurately
- Comply with procedures for monitoring and follow-up

Interventions
- For children receiving growth hormone, assist the family to set reasonable goals for increased height and weight and to comply with accurate drug administration and follow-up procedures (periodic x-rays to determine bone growth and progress toward epiphyseal closure, recording height and weight at least weekly).
- For clients with diabetes insipidus, assist them to develop a daily routine to monitor their response to drug therapy (eg, weigh themselves, monitor fluid intake and urine output for approximately equal amounts, or check urine specific gravity [should be at least 1.015] and replace fluids accordingly).

Evaluation
- Interview and observe for compliance with instructions for taking the drug(s).
- Observe for relief of symptoms for which pituitary hormones were prescribed.

Nursing Notes: Apply Your Knowledge
After surgery for a brain tumor, you note that Mr. Willis has excessive, dilute urine output (8000 mL/24 h). The physician diagnoses deficient antidiuretic hormone production and prescribes lypressin (Diapid), a synthetic vasopressin. What assessment data will indicate that this medication is effective?
### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong>&lt;br&gt;a. Read the manufacturer’s instructions and drug labels carefully before drug preparation and administration.</td>
<td>These hormone preparations are given infrequently and often require special techniques of administration.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong>&lt;br&gt;a. With gonadorelin and related drugs, observe for ovulation or decreased symptoms of endometriosis and absence of menstruation.</td>
<td>Therapeutic effects vary widely, depending on the particular pituitary hormone given and the reason for use.</td>
</tr>
<tr>
<td>b. With corticotropin, therapeutic effects stem largely from increased secretion of adrenal cortex hormones, especially the glucocorticoids, and include anti-inflammatory effects (see Chap. 24).</td>
<td>Therapeutic effects depend on the reason for use. Note that different formulations are used to stimulate ovulation and treat endometriosis.</td>
</tr>
<tr>
<td>c. With chorionic gonadotropin and menotropins given in cases of female infertility, ovulation and conception are therapeutic effects.</td>
<td>Corticotropin is usually not recommended for the numerous non-endocrine inflammatory disorders that respond to glucocorticoids. Administration of glucocorticoids is more convenient and effective than administration of corticotropin.</td>
</tr>
<tr>
<td>d. With chorionic gonadotropin given in cryptorchidism, the therapeutic effect is descent of the testicles from the abdomen to the scrotum.</td>
<td></td>
</tr>
<tr>
<td>e. With growth hormone, observe for increased skeletal growth and development.</td>
<td>Indicated by appropriate increases in height and weight.</td>
</tr>
<tr>
<td>f. With antidiuretics (desmopressin, lypressin, and vasopressin), observe for decreased urine output, increased urine specific gravity, decreased signs of dehydration, decreased thirst.</td>
<td>These effects indicate control of diabetes insipidus.</td>
</tr>
<tr>
<td>g. With oxytocin given to induce labor, observe for the beginning or the intensifying of uterine contractions.</td>
<td>Octreotide is often used to control diarrhea associated with a number of conditions.</td>
</tr>
<tr>
<td>h. With oxytocin given to control postpartum bleeding, observe for a firm uterine fundus and decreased vaginal bleeding.</td>
<td>Systemic reactions occur infrequently.</td>
</tr>
<tr>
<td>i. With octreotide given for diarrhea, observe for decreased number and fluidity of stools.</td>
<td>Although adverse effects occur in about 50% of patients, they are usually minor and of short duration.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong>&lt;br&gt;a. With gonadorelin, observe for headache, nausea, lightheadedness, and local edema, pain and pruritus after subcutaneous injections.</td>
<td>These adverse reactions are in general the same as those produced by adrenal cortex hormones. Severity of adverse reactions tends to increase with dosage and duration of corticotropin administration.</td>
</tr>
<tr>
<td>b. With protirelin, observe for hypotension, nausea, headache, lightheadedness, anxiety, drowsiness.</td>
<td>Sexual precocity results from stimulation of excessive testosterone secretion at an early age.</td>
</tr>
<tr>
<td>c. With corticotropin, observe for sodium and fluid retention, edema, hypokalemia, hyperglycemia, osteoporosis, increased susceptibility to infection, myopathy, behavioral changes.</td>
<td>Adverse effects are not common. Another adverse effect may be development of antibodies to the drug, but this does not prevent its growth-stimulating effects.</td>
</tr>
<tr>
<td>d. With human chorionic gonadotropin given to preadolescent boys, observe for sexual precocity, breast enlargement, and edema.</td>
<td>Adverse effects can be minimized by frequent pelvic examinations to check for ovarian enlargement and by laboratory measurement of estrogen levels. Multiple gestation (mostly twins) is a possibility and is related to ovarian overstimulation.</td>
</tr>
<tr>
<td>e. With growth hormone, observe for mild edema, headache, localized muscle pain, weakness, hyperglycemia.</td>
<td>(continued)</td>
</tr>
<tr>
<td>f. With menotropins, observe for symptoms of ovarian hyperstimulation, such as abdominal discomfort, weight gain, ascites, pleural effusion, oliguria, and hypotension.</td>
<td></td>
</tr>
</tbody>
</table>
### NURSING ACTIONS

g. With desmopressin, observe for headache, nasal congestion, nausea, and increase blood pressure. A more serious adverse reaction is water retention and hyponatremia.

h. With lypressin, observe for headache and congestion of nasal passages, dyspnea and coughing (if the drug is inhaled), and water intoxication if excessive amounts of lypressin or fluid are taken.

i. With vasopressin, observe for water intoxication; chest pain, myocardial infarction, increased blood pressure; abdominal cramps, nausea, and diarrhea.

j. With oxytocin, observe for excessive stimulation or contractility of the uterus, uterine rupture, and cervical and perineal lacerations.

k. With octreotide, observe for arrhythmias, bradycardia, diarrhea, headache, hyperglycemia, injection site pain, and symptoms of gallstones.

4. Observe for drug interactions

   a. Drugs that increase effects of vasopressin:
      - General anesthetics, chlorpropamide (Diabinese)

   b. Drug that decreases effects of vasopressin:
      - Lithium

   c. Drugs that increase effects of oxytocin:
      - (1) Estrogens
      - (2) Vasoconstrictors or vasoconstrictors (e.g., ephedrine, epinephrine, norepinephrine)

### RATIONALE/EXPLANATION

Adverse reactions usually occur only with high dosages and tend to be relatively mild. Water intoxication (headache, nausea, vomiting, confusion, lethargy, coma, convulsions) may occur with any antidiuretic therapy if excessive fluids are ingested.

Adverse effects are usually mild and occur infrequently with usual doses.

With high doses, vasopressin constricts blood vessels, especially coronary arteries, and stimulates smooth muscle of the gastrointestinal tract. Special caution is necessary in clients with heart disease, asthma, or epilepsy.

Severe adverse reactions are most likely to occur when oxytocin is given to induce labor and delivery.

These are more common effects, especially in those receiving octreotide for acromegaly.

### Nursing Notes: Apply Your Knowledge

**Answer:** Lypressin replaces the antidiuretic hormone that acts to decrease urine output. If this medication is effective, you would expect to see a decrease in urine output. The urine will appear less dilute (may be pale yellow rather than clear) and have a higher specific gravity. Keep accurate intake and output records on Mr. Willis, record daily weights, and monitor specific gravity.

### Review and Application Exercises

1. What hormones are secreted by the hypothalamus and pituitary, and what are their functions?
2. What are the functions and clinical uses of ADH and growth hormone?

### SELECTED REFERENCES

Corticosteroids

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review physiologic effects of endogenous corticosteroids.
2. Discuss clinical indications for use of exogenous corticosteroids.
3. Differentiate between physiologic and pharmacologic doses of corticosteroids.
4. Differentiate between short-term and long-term corticosteroid therapy.
5. List at least 10 adverse effects of long-term corticosteroid therapy.
6. Explain the pathophysiologic basis of adverse effects.
7. State the rationale for giving corticosteroids topically when possible rather than systemically.
8. Use other drugs and interventions to decrease the need for corticosteroids.
9. Discuss the use of corticosteroids in selected populations and conditions.
10. Apply the nursing process with a client receiving long-term systemic corticosteroid therapy, including teaching needs.

Critical Thinking Scenario

Sally, 15 years of age, was hospitalized with ulcerative colitis 2 days ago. When you enter her room, she is crying and does not look up. You sit down quietly beside her. Finally, she begins to tell you her fears. “The doctor says I have to go on steroids for my ulcerative colitis. I remember this girl in middle school who had a kidney transplant and had to take steroids. She gained lots of weight and her face became round and fat. I don’t want that to happen to me.”

Reflect on:

- The developmental level of a 15-year-old.
- The impact a chronic illness or long-term use of corticosteroids would have for an adolescent.
- What you could say in this situation that might be helpful. Provide rationale.
- What you should not say in this situation. Provide rationale.

OVERVIEW

Corticosteroids, also called glucocorticoids or steroids, are hormones produced by the adrenal cortex. These hormones affect almost all body organs and are extremely important in maintaining homeostasis when secreted in normal amounts. Disease results from inadequate or excessive secretion. Exogenous corticosteroids are used as drugs in a variety of disorders. Their use must be closely monitored because the drugs produce profound therapeutic and adverse effects. To understand the effects of corticosteroids used as drugs, it is necessary to understand physiologic effects and other characteristics of the endogenous hormones.

ENDOGENOUS CORTICOSTEROIDS

The adrenal cortex produces approximately 30 steroid hormones, which are divided into glucocorticoids, mineralocorticoids, and adrenal sex hormones. Glucocorticoids are important in metabolic, inflammatory, and immune processes. Mineralocorticoids are important in maintaining fluid and electrolyte balance. The adrenal sex hormones have little effect on normal body function.

Chemically, all corticosteroids are derived from cholesterol and have similar chemical structures. Despite their similarities, however, slight differences cause them to have different functions.
**Secretion of Corticosteroids**

Corticosteroid secretion is controlled by the hypothalamus, anterior pituitary, and adrenal cortex (the hypothalamic–pituitary–adrenal, or HPA, axis). Various stimuli (eg, low plasma levels of corticosteroids, pain, anxiety, trauma, illness, anesthesia) activate the system. These stimuli cause the hypothalamus to secrete corticotropin-releasing hormone (CRH). CRH stimulates the anterior pituitary to secrete corticotropin, and corticotropin stimulates the adrenal cortex to secrete corticosteroids.

The rate of corticosteroid secretion is usually maintained within relatively narrow limits but changes according to need. When plasma corticosteroid levels rise to an adequate level, secretion of corticosteroids slows or stops. The mechanism by which the hypothalamus and anterior pituitary are informed that no more corticosteroids are needed is called a negative feedback mechanism.

This negative feedback mechanism is normally very important, but it does not work during stress responses. The stress response activates the sympathetic nervous system (SNS) to produce more epinephrine and norepinephrine and the adrenal cortex to produce as much as 10 times the normal amount of cortisol. The synergistic interaction of these hormones increases the person’s ability to respond to stress. However, the increased SNS activity continues to stimulate cortisol production and overrules the negative feedback mechanism. Excessive and prolonged corticosteroid secretion damages body tissues.

Corticosteroids are secreted directly into the bloodstream. Cortisol is approximately 90% bound to plasma proteins (80% to an alpha globulin called transcortin or cortisol-binding globulin and 10% to albumin). This high extent of protein binding slows cortisol movement out of the plasma, so that it has a relatively long plasma half-life of 60 to 90 minutes. The remaining 10% is unbound and biologically active. In contrast, aldosterone is only 60% bound to plasma proteins and has a short half-life of 20 minutes. In general, protein binding functions as a storage area from which the hormones are released as needed. This promotes more consistent blood levels and more uniform distribution to the tissues.

Corticosteroids are metabolized in the liver (mainly by cytochrome P450 3A4 enzymes) and conjugated to inactive metabolites. About 25% of the metabolites are excreted in the bile, then in the feces. The other 75% enter the circulation and are excreted by the kidneys. Metabolism is slowed by hepatic disease, and excretion is slowed by renal disease. In these conditions, corticosteroids may accumulate and cause signs and symptoms of hypercorticism.

**Glucocorticoids**

The term corticosteroids actually means all secretions of the adrenal cortex, but it is most often used to designate the glucocorticoids. Glucocorticoids include cortisol, corticosterone, and cortisone. Cortisol accounts for at least 95% of glucocorticoid activity, and approximately 15 to 20 mg are secreted daily. Corticosterone has a small amount of activity, and approximately 1.5 to 4 mg are secreted daily. Cortisone has little activity and is secreted in minute quantities. Glucocorticoids are secreted cyclically, with the largest amount being produced in the early morning and the smallest amount during the evening hours (in people with a normal day–night schedule). At the cellular level, glucocorticoids account for most of the characteristics and physiologic effects of the corticosteroids (Box 24–1).

**Mineralocorticoids**

Mineralocorticoids play a vital role in maintaining fluid and electrolyte balance. Aldosterone is the main mineralocorticoid and is responsible for approximately 90% of mineralocorticoid activity. Characteristics and physiologic effects of aldosterone are summarized in Box 24–2.

**Adrenal Sex Hormones**

The adrenal cortex secretes male (androgens) and female (estrogens and progesterone) sex hormones. The adrenal sex hormones are insignificant compared with those produced by the testes and ovaries. Adrenal androgens, secreted continuously in small quantities by both sexes, are responsible for most of the physiologic effects exerted by the adrenal sex hormones. They increase protein synthesis (anabolism), which increases the mass and strength of muscle and bone tissue; they affect development of male secondary sex characteristics; and they increase hair growth and libido in women. Excessive secretion of adrenal androgens in women causes masculinizing effects (eg, hirsutism, acne, breast atrophy, deepening of the voice, and amenorrhea). Female sex hormones are secreted in small amounts and normally exert few physiologic effects. Excessive secretion may produce feminizing effects in men (eg, breast enlargement, decreased hair growth, voice changes).

**Disorders of the Adrenal Cortex**

Disorders of the adrenal cortex involve increased or decreased production of corticosteroids, especially cortisol as the primary glucocorticoid and aldosterone as the primary mineralocorticoid. These disorders include the following:

- **Primary adrenocortical insufficiency (Addison’s disease)** is associated with destruction of the adrenal cortex by disorders such as tuberculosis, cancer, or hemorrhage; with atrophy of the adrenal cortex caused by autoimmune disease or prolonged administration of exogenous corticosteroids; and with surgical excision of the adrenal glands. In this condition, there is inadequate production of both cortisol and aldosterone.
- **Secondary adrenocortical insufficiency**, produced by inadequate secretion of corticotropin, is most often caused by prolonged administration of corticosteroid
BOX 24-1 EFFECTS OF GLUCOCORTICOIDs ON BODY PROCESSES AND SYSTEMS

**Carbohydrate Metabolism**
- ↑Formation of glucose (gluconeogenesis) by breaking down protein into amino acids. The amino acids are then transported to the liver, where they are acted on by enzymes that convert them to glucose. The glucose is then returned to the circulation for use by body tissues or storage in the liver as glycogen.
- ↓Cell use of glucose, especially in muscle cells. This is attributed to a defect of insulin on the proteins that normally transport glucose into cells and by numbers and functional capacity of insulin receptors.
- Both the ↑production and ↓use of glucose promote higher levels of glucose in the blood (hyperglycemia) and may lead to diabetes mellitus. These actions also increase the amount of glucose stored as glycogen in the liver, skeletal muscles, and other tissues.

**Protein Metabolism**
- ↑Breakdown of protein into amino acids (catabolic effect); ↑rate of amino acid transport to the liver and conversion to glucose.
- ↓Rate of new protein formation from dietary and other amino acids (antianabolic effect)
- The combination of ↑breakdown of cell protein and ↓protein synthesis leads to protein depletion in virtually all body cells except those of the liver. Thus, glycogen stores in the body are ↑and protein stores are ↓.

**Lipid Metabolism**
- ↑Breakdown of adipose tissue into fatty acids; the fatty acids are transported in the plasma and used as a source of energy by body cells.
- ↑Oxidation of fatty acids within body cells

**Inflammatory and Immune Responses**
- ↓Inflammatory response. Inflammation is the normal bodily response to tissue damage and involves three stages. First, a large amount of plasma-like fluid leaks out of capillaries into the damaged area and becomes clotted. Second, leukocytes migrate into the area. Third, tissue healing occurs, largely by growth of fibrous scar tissue. Normal or physiologic amounts of glucocorticoids probably do not significantly affect inflammation and healing, but large amounts of glucocorticoids inhibit all three stages of the inflammatory process.
  - More specifically, corticosteroids stabilize lysosomal membranes (and thereby prevent the release of inflammatory proteolytic enzymes), ↓capillary permeability (and thereby ↓leakage of fluid and proteins into the damaged tissue), ↓the accumulation of neutrophils and macrophages at sites of inflammation (and thereby impair phagocytosis of pathogenic microorganisms and waste products of cellular metabolism), and ↓production of inflammatory chemicals, such as interleukin-1, prostaglandins, and leukotrienes, by injured cells.
- ↓Immune response. The immune system normally protects the body from foreign invaders, and several immune responses overlap inflammatory responses, including phagocytosis. In addition, the immune response stimulates the production of antibodies and activated lymphocytes to destroy the foreign substance. Glucocorticoids impair protein synthesis, including the production of antibodies; ↓the numbers of circulating lymphocytes, eosinophils, and macrophages; and ↓amounts of lymphoid tissue. These effects help to account for the immunosuppressive and antiallergic actions of the glucocorticoids.

**Cardiovascular System**
- Help to regulate arterial blood pressure by modifying vascular smooth muscle tone, by modifying myocardial contractility, and by stimulating renal mineralocorticoid and glucocorticoid receptors.
- ↑The response of vascular smooth muscle to the pressor effects of catecholamines and other vasoconstrictive agents.

**Nervous System**
- Physiologic amounts help to maintain normal nerve excitability; pharmacologic amounts ↓nerve excitability, slow activity in the cerebral cortex, and alter brain wave patterns.
- ↓Secretion of corticotropin-releasing hormone by the hypothalamus and of corticotropin by the anterior pituitary gland. This results in suppression of further glucocorticoid secretion by the adrenal cortex (negative feedback system).

**Musculoskeletal System**
- Maintain muscle strength when present in physiologic amounts but cause muscle atrophy (from protein breakdown) when present in excessive amounts.
- ↓Bone formation and growth and ↑bone breakdown. Glucocorticoids also ↓intestinal absorption and ↑renal excretion of calcium. These effects contribute to bone demineralization (osteoporosis) in adults and to ↓linear growth in children.

**Respiratory System**
- Maintain open airways. Glucocorticoids do not have direct bronchodilating effects, but help to maintain and restore responsiveness to the bronchodilating effects of endogenous catecholamines, such as epinephrine.
- Stabilize mast cells and other cells to inhibit the release of bronchoconstrictive and inflammatory substances, such as histamine.

**Gastrointestinal System**
- ↓Viscosity of gastric mucus. This effect may ↓protective properties of the mucus and contribute to the development of peptic ulcer disease.

---

drugs. This condition is largely a glucocorticoid deficiency; mineralocorticoid secretion is not significantly impaired.

- **Congenital adrenogenital syndromes and adrenal hyperplasia** result from deficiencies in one or more enzymes required for cortisol production. Low plasma levels of cortisol lead to excessive corticotropin secretion, which then leads to excessive adrenal secretion of androgens and hyperplasia.
- **Androgen-producing tumors** of the adrenal cortex, which are usually benign, produce masculinizing effects.
- **Adrenocortical hyperfunction** (Cushing’s disease) may result from excessive corticotropin or a primary adrenal tumor. Adrenal tumors may be benign or malignant.
Benign tumors often produce one corticosteroid normally secreted by the adrenal cortex, but malignant tumors often secrete several corticosteroids.

- **Hyperaldosteronism** is a rare disorder caused by adenoma or hyperplasia of the adrenal cortex cells that produce aldosterone. It is characterized by hypokalemia, hypernatremia, hypertension, thirst, and polyuria.

### EXOGENOUS CORTICOSTEROIDS (GLUCOCORTICOID DRUGS)

When corticosteroids are administered from sources outside the body, they are given mainly for replacement or therapeutic purposes. Replacement involves small doses to correct a deficiency state and restore normal function. Therapeutic purposes involve relatively large doses to exert pharmacologic effects. Drug effects involve extension of the physiologic effects of endogenous corticosteroids and new effects that do not occur with small, physiologic doses. The most frequently desired effects are anti-inflammatory, immunsuppressive, antiallergic, and antistress. These are glucocorticoid effects. Mineralocorticoid and androgenic effects are usually considered adverse reactions. Additional characteristics of therapeutic corticosteroids include the following:

- All adrenal corticosteroids are available as drug preparations, as are many synthetic derivatives developed by altering the basic steroid molecule in efforts to increase therapeutic effects while minimizing adverse effects. These efforts have been most successful in decreasing mineralocorticoid activity.
- The drugs are palliative; they control many symptoms but do not cure underlying disease processes. In chronic disorders, they may enable a client to continue the usual activities of daily living and delay disability. However, the disease may continue to progress and long-term use of systemic corticosteroids inevitably produces serious adverse effects.
- Drug effects vary, so a specific effect may be considered therapeutic in one client but adverse in another. For example, an increased blood sugar level is therapeutic for the client with adrenocortical insufficiency or an islet cell adenoma of the pancreas, but an adverse reaction for most clients, especially for those with diabetes mellitus. In addition, some clients respond more favorably or experience adverse reactions more readily than others taking equivalent doses. This is partly caused by individual differences in the rate at which corticosteroids are metabolized.
- Administration of exogenous corticosteroids suppresses the HPA axis. This decreases secretion of corticotropin, which, in turn, causes atrophy of the adrenal cortex and decreased production of endogenous adrenal corticosteroids. Daily administration of physiologic doses (15 to 20 mg of hydrocortisone or its equivalent) or administration of pharmacologic doses (more than 15 to 20 mg of hydrocortisone or its equivalent) for approximately 2 weeks suppresses the HPA axis. HPA recovery usually occurs within a few weeks or months after corticosteroids are discontinued, but may take 9 to 12 months. During that time, supplemental corticosteroids are usually needed during stressful situations (eg, fever, illness, surgical procedures) to improve the client’s ability to respond to stress and prevent acute adrenocortical insufficiency.
- **Hydrocortisone**, the exogenous equivalent of endogenous cortisol, is the prototype of corticosteroid drugs. When a new corticosteroid is developed, it is compared with hydrocortisone to determine its potency in producing anti-inflammatory and antiallergic responses, increasing deposition of liver glycogen, and suppressing secretion of corticotropin.
- Anti-inflammatory activity of glucocorticoids is approximately equal when the drugs are given in equivalent doses (hydrocortisone 20 mg; prednisone and prednisolone 5 mg; methylprednisolone and triamcinolone 4 mg; dexamethasone 0.75 mg; and betamethasone 0.6 mg). Mineralocorticoid activity is high in cortisone (which is rarely used), intermediate in hydrocortisone, prednisolone, and prednisone, and low in newer agents.
- Many glucocorticoids are available for use in different clinical problems, and routes of administration vary. Several of these drugs can be given by more than one route; others can be given only orally or topically. For example, in recent years there have been several formulations developed for oral inhalation in the treatment of...
of asthma and for nasal inhalation in the treatment of allergic rhinitis.

For intramuscular or intravenous injections, sodium phosphate or sodium succinate salts are used because they are most soluble in water. For intra-articular or intralesional injections, acetate salts are used because they have low solubility in water and provide prolonged local action.

- Duration of action also varies and is only known for oral drugs. Betamethasone and dexamethasone last 48 hours, methylprednisolone, prednisolone, prednisone and triamcinolone last 18 to 36 hours, and hydrocortisone lasts 18 hours.

**Mechanisms of Action**

Like endogenous glucocorticoids, exogenous drug molecules act at the cellular level by binding to glucocorticoid receptors in target tissues. The drugs are lipid soluble and easily diffuse through the cell membranes of target cells. Once inside the cell, they bind with receptors in intracellular cytoplasm. The drug–receptor complex then moves to the cell nucleus, where it interacts with DNA to stimulate or suppress gene transcription.

Glucocorticoid drugs increase or decrease transcription of many genes to alter the synthesis of proteins that regulate their many physiologic effects (eg, enzymes, transport proteins, structural proteins). Metabolic effects do not occur for at least 45 to 60 minutes because of the time required for protein synthesis. Several hours or days may be needed for full production of proteins.

Because the genes vary in different types of body cells, glucocorticoid effects also vary, depending on the specific cells being targeted. For example, supraphysiologic concentrations of glucocorticoids induce the synthesis of lipolytic and proteolytic enzymes and other specific proteins in various tissues. Overall, corticosteroids have multiple mechanisms of action and effects (Fig. 24–11), including the following:

- **Inhibiting arachidonic acid metabolism.** Normally, when a body cell is injured or activated by various stimuli, the enzyme phospholipase A₂ causes the phospholipids in cell membranes to release arachidonic acid. Free arachidonic acid is then metabolized to produce proinflammatory prostaglandins (see Chap. 7) and leukotrienes. At sites of tissue injury or inflammation, corticosteroids induce the synthesis of proteins that suppress the activation of phospholipase A₂. This action, in turn, decreases the release of arachidonic acid and the formation of prostaglandins and leukotrienes.

- **Strengthening or stabilizing biologic membranes.** Two biologic membranes are especially important in inflammatory processes. Stabilization of cell membranes inhibits the release of arachidonic acid and production of prostaglandins and leukotrienes, as described above. Stabilization of lysosomal membranes inhibits release of bradykinin, histamine, enzymes, and perhaps other substances from lysosomes. (Lysosomes are intracellular structures that contain inflammatory chemical mediators and enzymes that destroy cellular debris and phagocytized pathogens.) This reduces capillary permeability and thus prevents leakage of fluid into the injured area and development of edema. It also reduces the chemicals that normally cause vasodilation and tissue irritation.

- **Inhibiting the production of interleukin-1, tumor necrosis factor, and other cytokines.** This action also contributes to the anti-inflammatory and immunosuppressant effects of glucocorticoids.

- **Impairing phagocytosis.** The drugs inhibit the ability of phagocytic cells to leave the bloodstream and move into the injured or inflamed tissue.

- **Impairing lymphocytes.** The drugs inhibit the ability of these immune cells to increase in number and perform their functions.

- **Inhibiting tissue repair.** The drugs inhibit the growth of new capillaries, fibroblasts, and collagen needed for tissue repair.

**Indications for Use**

Corticosteroids are extensively used to treat many different disorders. Except for replacement therapy in deficiency states, the use of corticosteroids is largely empiric. Because the drugs affect virtually every aspect of inflammatory and immune responses, they are used in the treatment of a broad spectrum of diseases with an inflammatory or immunologic component.

Corticosteroid preparations applied topically in ophthalmic and dermatologic disorders are discussed in Chapters 65 and 66, respectively. The corticosteroids discussed in this chapter (Drugs at a Glance: Corticosteroids) are primarily those given orally, intramuscularly, intravenously, topically by oral or nasal inhalation, or by local injection in potentially serious or disabling disorders. These disorders include the following:

- **Allergic** or hypersensitivity disorders, such as allergic reactions to drugs, serum and blood transfusions, and dermatoses with an allergic component

- **Collagen** disorders, such as systemic lupus erythematous, scleroderma, and periarteritis nodosa. Collagen is the basic structural protein of connective tissue, tendons, cartilage, and bone, and it is therefore present in almost all body tissues and organ systems. The collagen disorders are characterized by inflammation of various body tissues. Signs and symptoms depend on which body tissues or organs are affected and the severity of the inflammatory process.

- **Dermatologic** disorders that may be treated with systemic corticosteroids include acute contact dermatitis, erythema multiforme, herpes zoster (prophylaxis of postherpetic neuralgia), lichen planus, pemphigus, skin rashes caused by drugs, and toxic epidermal necrolysis.

- **Endocrine** disorders, such as adrenocortical insufficiency and congenital adrenal hyperplasia. Cortico-
steroids are given to replace or substitute for the natural hormones (both glucocorticoids and mineralocorticoids) in cases of insufficiency and to suppress corticotropin when excess secretion causes adrenal hyperplasia. These conditions are rare and account for a small percentage of corticosteroid usage.

- **Gastrointestinal** disorders, such as ulcerative colitis and regional enteritis (Crohn’s disease)
- **Hematologic** disorders, such as idiopathic thrombocytopenic purpura or acquired hemolytic anemia
- **Hepatic** disorders characterized by edema, such as cirrhosis and ascites
- **Neoplastic** disease, such as acute and chronic leukemias, Hodgkin’s disease, other lymphomas, and multiple myeloma. The effectiveness of corticosteroids in these conditions probably stems from their ability to suppress lymphocytes and other lymphoid tissue.
- **Neurologic** conditions, such as cerebral edema, brain tumor, and myasthenia gravis
- **Ophthalmic** disorders, such as optic neuritis, sympathetic ophthalmia, and chorioretinitis
- **Organ or tissue transplants and grafts** (eg, kidney, heart, bone marrow). Corticosteroids suppress cellular and humoral immune responses (see Chap. 42) and help prevent rejection of transplanted tissue. Drug therapy is usually continued as long as the transplanted tissue is in place.
- **Renal** disorders characterized by edema, such as the nephrotic syndrome
- **Respiratory** disorders, such as asthma, status asthmaticus, chronic obstructive pulmonary disease (COPD), and inflammatory disorders of nasal mucosa (rhinitis). In asthma, corticosteroids increase the number of beta-adrenergic receptors and increase or restore responsiveness of beta receptors to beta-adrenergic bronchodilating drugs. In asthma, COPD, and rhinitis, the drugs decrease mucus secretion and inflammation.
- **Rheumatic** disorders, such as ankylosing spondylitis, acute and chronic bursitis, acute gouty arthritis, rheumatoid arthritis, and osteoarthritis
- **Shock**. Corticosteroids are clearly indicated only for shock resulting from adrenocortical insufficiency (adisonian or adrenal crisis), which may mimic hypovolemic or septic shock. Studies indicate that the drugs are not beneficial in treating septic shock. In anaphylactic shock resulting from an allergic reaction, corticosteroids may increase or restore cardiovascular responsiveness to adrenergic drugs.

**Contraindications to Use**

Corticosteroids are contraindicated in systemic fungal infections and in people who are hypersensitive to drug formula-
## Drugs at a Glance: Corticosteroids*

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticoids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone oral inhalation (Vanceril)</td>
<td>2 inhalations (84 mcg) 3–4 times daily (maximal daily dose, 20 inhalations or 840 mcg)</td>
<td>6–12 y: 1–3 inhalations (42–84 mcg) 3–4 times daily (maximal daily dose, 10 inhalations or 420 mcg) &gt;12 y: 1 inhalation (42 mcg) in each nostril 2–4 times daily (total dose 168–336 mcg/d) 6–12 y: 1 inhalation in each nostril 3 times daily (252 mcg/d) &lt;6 y: Not recommended</td>
</tr>
<tr>
<td>Nasal inhalation (Vancenase)</td>
<td>1 inhalation (42 mcg in each nostril) 2–4 times daily (total dose 168–336 mcg/d)</td>
<td></td>
</tr>
<tr>
<td>Betamethasone (Celestone)</td>
<td>PO 0.6–7.2 mg daily initially, gradually reduced to lowest effective dose</td>
<td>Betamethasone acetate and sodium phosphate (Celestone Soluspan) Intra-articular injection 0.25–2 mL</td>
</tr>
<tr>
<td>Budesonide oral inhalation (Pulmicort Turbuhaler, Pulmicort Respules)</td>
<td>Turbuhaler, 200–400 mcg twice daily</td>
<td>Turbuhaler, &gt;6 y: 200 mcg twice daily Respules, 12 mo–8 y: 0.5 mg daily in one single or two divided doses &gt; 6 y: Same as adults</td>
</tr>
<tr>
<td>Nasal inhalation (Rhinocort)</td>
<td>256 mcg daily initially (2 sprays each nostril morning and evening or 4 sprays each nostril every morning). When symptoms are controlled, reduce dosage to lowest effective maintenance dose.</td>
<td></td>
</tr>
<tr>
<td>Oral capsule (Entocort EC)</td>
<td>Crohn’s disease, PO 9 mg once daily in the morning, for up to 8 wk</td>
<td></td>
</tr>
<tr>
<td>Cortisone (Cortone)</td>
<td>PO 25–300 mg daily, individualized for condition and response</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone (Decadron)</td>
<td>PO 0.75–9 mg daily in 2–4 doses; higher ranges for serious diseases</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone acetate</td>
<td>IM 8–16 mg (1–2 mL) in single dose, repeated every 1–3 wk if necessary</td>
<td></td>
</tr>
<tr>
<td>Dexamethasone sodium phosphate</td>
<td>IM, IV 0.5–9 mg, depending on severity of disease</td>
<td></td>
</tr>
<tr>
<td>Flunisolide oral inhalation (Aerobid)</td>
<td>2 inhalations (500 mcg) twice daily</td>
<td>6–15 y: Same as adults</td>
</tr>
<tr>
<td>Nasal inhalation (Nasalide)</td>
<td>2 sprays (50 mcg) in each nostril twice daily (200 mcg/d); maximal daily dose 8 sprays in each nostril (400 mcg/d)</td>
<td>6–14 y: 1 spray (25 mcg) in each nostril 3 times daily or 2 sprays (50 mcg) in each nostril 2 times daily (150–200 mcg/d); maximal daily dose 4 sprays in each nostril (200 mcg/d) ≥12 y: 100 mcg daily (1 spray per nostril once daily)</td>
</tr>
<tr>
<td>Fluticasone (Flonase) nasal inhalation</td>
<td>200 mcg daily initially (2 sprays each nostril once daily or 1 spray each nostril twice daily). After a few days, reduce dosage to 100 mcg daily (1 spray each nostril once daily) for maintenance therapy.</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone (Hydrocortone, Cortef)</td>
<td>PO 20–240 mg daily, depending on condition and response</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone sodium phosphate</td>
<td>IV, IM, SC 15–240 mg daily in 2 divided doses</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone sodium succinate</td>
<td>IV, IM 100–400 mg initially, repeated at 2, 4, or 6 hour intervals if necessary</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone retention enema (Cortenema)</td>
<td>Rectally, one enema (100 mg) nightly for 21 d or until optimal response</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone acetate intrarectal foam (Cortifoam)</td>
<td>1 applicatorful 1–2 times daily for 2–3 wks, then once every 2–3 days if needed</td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone (Medrol)</td>
<td>PO 4–48 mg daily initially, gradually reduced to lowest effective level</td>
<td>Infants and children: IV, IM not less than 0.5 mg/kg/24 hours</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate (Solu-Medrol)</td>
<td>IV, IM 10–40 mg initially, adjusted to condition and response</td>
<td>&gt;12 y: Same as adults 3–11 y: 1 spray (50 mcg) in each nostril once daily (100 mcg/d)</td>
</tr>
<tr>
<td>Methylprednisolone acetate (Depo-Medrol)</td>
<td>IM 40–120 mg once daily</td>
<td></td>
</tr>
<tr>
<td>Mometasone (Nasonex)</td>
<td>2 sprays (50 mcg/spray) in each nostril once daily (200 mcg/d)</td>
<td></td>
</tr>
</tbody>
</table>

*For detailed dosage information, please refer to the full text of the document.*
tions. They should be used with caution in clients at risk for infections (they may decrease resistance), clients with infections (they may mask signs and symptoms so that infections become more severe before they are recognized and treated), diabetes mellitus (they cause or increase hyperglycemia), peptic ulcer disease, inflammatory bowel disorders, hypertension, congestive heart failure, and renal insufficiency.

**Drugs at a Glance: Corticosteroids* (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prednisolone (Delta-Cortef)</td>
<td>PO 5–60 mg daily initially, adjusted for maintenance</td>
<td>6–12 y: 1–2 inhalations (100–200 mcg) 3–4 times daily or 4 inhalations (400 mcg) 2 times daily</td>
</tr>
<tr>
<td>Prednisolone acetate</td>
<td>IM 4–60 mg daily initially, adjusted for maintenance</td>
<td>≥6 y: 2 sprays (110 mcg) in each nostril once daily (220 mcg/day) initially, reduce to 1 spray per nostril once daily (110 mcg/day)</td>
</tr>
<tr>
<td>Prednisolone sodium phosphate (Hydeltrasol)</td>
<td>PO 5–60 mg daily initially, reduced for maintenance</td>
<td></td>
</tr>
<tr>
<td>Prednisone (Deltasone)</td>
<td>PO 4–48 mg daily initially, reduced for maintenance</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone (Aristocort, Kenacort)</td>
<td>IM 2.5–60 mg daily, depending on the disease. Reduce dosage and start oral therapy when feasible.</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone acetonide (Kenalog-40)</td>
<td>2 inhalations (200 mcg) 3–4 times daily or 4 inhalations (400 mcg) 2 times daily</td>
<td></td>
</tr>
<tr>
<td>Oral inhalation (Azmacort)</td>
<td>6–12 y: 1–2 inhalations (100–200 mcg) 3–4 times daily or 4 inhalations (400 mcg) 2 times daily</td>
<td></td>
</tr>
<tr>
<td>Nasal inhalation (Nasacort)</td>
<td>2 sprays (110 mcg) in each nostril once daily (total dose 220 mcg/d). May increase to maximal daily dose of 440 mcg if indicated.</td>
<td>≥6 y: 2 sprays (110 mcg) in each nostril once daily (220 mcg/day) initially, reduce to 1 spray per nostril once daily (110 mcg/day)</td>
</tr>
<tr>
<td>Triamcinolone diacetate (Aristocort Forte)</td>
<td>IM 20–80 mg initially</td>
<td></td>
</tr>
<tr>
<td>Mineralocorticoid</td>
<td></td>
<td>PO 0.05–0.1 mg daily</td>
</tr>
<tr>
<td>Fludrocortisone (Florinef)</td>
<td>Chronic adrenocortical insufficiency, PO 0.1 mg daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Salt-losing adrenogenital syndromes, PO 0.1–0.2 mg daily</td>
<td></td>
</tr>
</tbody>
</table>

*Ophthalmic and dermatologic preparations are discussed in Chapters 65 and 66, respectively.

Kim Wilson, 62 years of age, was admitted for elective abdominal surgery. Her medication history reveals daily use of prednisone. Individualize a postoperative plan of care for Kim considering her chronic steroid use.

This may include diagnostic tests for diabetes mellitus, tuberculosis, and peptic ulcer disease because these conditions may develop from or be exacerbated by administration of corticosteroid drugs. If one of these conditions is present, corticosteroid therapy must be altered and other drugs given concomitantly.

- If acute infection is found on initial assessment, it should be treated with appropriate antibiotics either before corticosteroid drugs are started or concomitantly with corticosteroid therapy. This is necessary because corticosteroids may mask symptoms of infection and impair healing. Thus, even minor infections can become serious if left untreated during corticosteroid therapy. If infection occurs during long-term corticosteroid therapy, appropriate antibiotic therapy (as determined by culture of the causative microorganism and antibiotic sensitivity studies) is again indicated. Also, increased doses of corticosteroids are usually indicated to cope with the added stress of the infection.

**Assessment Related to Previous or Current Corticosteroid Therapy**

Initial assessment of every client should include information about previous or current treatment with systemic corticosteroids. This can usually be determined by questioning the client or reviewing medical records.

- If the nurse determines that the client has taken corticosteroids in the past, additional information is needed about the specific drug and dosage taken, the purpose and length
• Excess Fluid Volume related to sodium and water
• Imbalanced Nutrition: More Than Body Requirements
• Imbalanced Nutrition: Less Than Body Requirements

Nursing Diagnoses
- Disturbed Body Image related to cushingoid changes in appearance
- Imbalanced Nutrition: Less Than Body Requirements related to protein and potassium losses
- Imbalanced Nutrition: More Than Body Requirements related to sodium and water retention
- Excess Fluid Volume related to sodium and water retention

Planning/Goals
The client will:
- Receive or take the drug correctly
- Receive and practice measures to decrease the need for corticosteroids and minimize adverse effects
- Be monitored regularly for adverse drug effects
- Keep appointments for follow-up care
- Be assisted to cope with body image changes
- Verbalize or demonstrate essential drug information

Interventions
For clients on long-term, systemic corticosteroid therapy, use supplementary drugs as ordered and nondrug measures to decrease dosage and adverse effects of corticosteroid drugs. Some specific measures include the following:
- Help clients to set reasonable goals of drug therapy. For example, partial relief of symptoms may be better than complete relief if the latter requires larger doses or longer periods of treatment with systemic drugs.
- In clients with bronchial asthma and COPD, other treatment measures should be continued during corticosteroid therapy. With asthma, the corticosteroid needs to be given on a regular schedule; inhaled bronchodilators can usually be taken as needed.
- In clients with rheumatoid arthritis, rest, physical therapy, and salicylates or other nonsteroid anti-inflammatory drugs are continued. Systemic corticosteroid therapy is reserved for severe, acute exacerbations when possible.
- Help clients to identify stressors and to find ways to modify or avoid stressful situations when possible. For example, most clients probably do not think of extreme heat or cold or minor infections as significant stressors. They can be, however, for people taking corticosteroid drugs. This assessment of potential stressors must be individualized because a situation viewed as stressful by one client may not be stressful to another.
- Encourage activity, if not contraindicated, to slow demineralization of bone (osteoporosis). This is especially important in postmenopausal women who are not taking replacement estrogens, because they are very susceptible to osteoporosis. Walking is preferred if the client is able. Range-of-motion exercises are indicated in immobilized or bedfast people. Also, bedfast clients taking corticosteroid drugs should have their positions changed fre-
Risk–Benefit Factors

1. Because systemic corticosteroid drugs can cause serious adverse reactions, indications for their clinical use should be as clear-cut as possible. They are relatively safe for short-term treatment of self-limiting conditions, such as allergic reactions or acute exacerbations of chronic conditions. Long-term use of pharmacologic doses (eg, more than 5 mg of prednisone daily) produces adverse reactions. For this reason, long-term corticosteroid therapy should be reserved for life-threatening conditions or severe, disabling symptoms that do not respond to treatment with more benign drugs or other measures.

2. The goal of corticosteroid therapy is usually to reduce symptoms to a tolerable level. Total suppression of symptoms may require excessively large doses and produce excessive adverse effects.

Evaluation

• Interview and observe for relief of symptoms for which corticosteroids were prescribed.
• Interview and observe for accurate drug administration.
• Interview and observe for use of nondrug measures indicated for the condition being treated.
• Interview and observe for adverse drug effects on a regular basis.
• Interview regarding drug knowledge and effects to be reported to health care providers.

Drug Selection

Choice of corticosteroid drug is influenced by many factors, including the purpose for use, characteristics of specific drugs, desired route of administration, characteristics of individual clients, and expected adverse effects. Some guidelines for rational drug choice include the following:

1. **Adrenocortical insufficiency**, whether caused by Addison’s disease, adrenalectomy, or inadequate corticotropin, requires replacement of both glucocorticoids and mineralocorticoids. Hydrocortisone and cortisone are usually the drugs of choice because they have greater mineralocorticoid activity compared with other corticosteroids. If additional mineralocorticoid activity is required, fludrocortisone can be given.

2. **Nonendocrine disorders**, in which anti-inflammatory, antiallergic, antistress, and immunosuppressive effects are desired, can be treated by a corticosteroid drug with primarily glucocorticoid activity. Prednisone is often the glucocorticoid of choice.

3. **Respiratory disorders**. Beclomethasone (Vanceril, Vancenase), budesonide (Pulmicort, Rhinocort), flunisolide (Aerobid, Nasalide), fluticasone (Flonase, Flovent), mometasone (Nasonex), and triamcinolone (Azmacort, Nasacort) are corticosteroids formulated to be given by oral or nasal inhalation. Their use replaces, prevents, delays, or decreases use of systemic drugs and thereby decreases risks of serious adverse effects. However, high doses or frequent use may suppress adrenocortical function.

4. **Cerebral edema** associated with brain tumors, craniotomy, or head injury. Dexamethasone (parenterally or orally) is considered the corticosteroid of choice because it is thought to penetrate the blood–brain barrier more readily and achieve higher concentrations in cerebrospinal fluids and tissues. It also has minimal sodium- and water-retaining properties. With brain tumors, the drug is more effective in metastatic lesions than glioblastomas than astrocytomas and meningiomas.

5. **Acute, life-threatening situations** require a drug that can be given parenterally, usually intravenously (IV). This limits the choice of drugs because not all are available in injectable preparations. Hydrocortisone, dexamethasone, and methylprednisolone are among those that may be given parenterally.

Dosage Factors

Dosage of corticosteroid drugs must be individualized because it is influenced by many factors, such as the specific drug to be given, the desired route of administration, the reason for use, expected adverse effects, and client characteristics. In general, the smallest effective dose should be given for the shortest effective time. Dosage guidelines include the following:

1. Dosage must be individualized according to the severity of the disorder being treated, whether the disease is
General Considerations

In most instances, corticosteroids are used to relieve symptoms; they do not cure the underlying disease process. However, they can improve comfort and quality of life.

When taking an oral corticosteroid (eg, prednisone) for longer than 2 weeks, it is extremely important to take the drug as directed. Missing a dose or two, stopping the drug, changing the amount or time of administration, or taking extra drug (except as specifically directed during stress situations) or any other alterations may result in complications. Some complications are relatively minor; several are serious, even life threatening. When these drugs are being discontinued, the dosage is gradually reduced over several weeks. They must not be stopped abruptly.

Avoid exposure to infection when possible. Avoid crowds, including physicians, other medical workers, and institutions. Corticosteroids increase the ability to provide appropriate treatment. However, they can improve comfort and quality of life.

Muscle weakness and fatigue or disease symptoms may occur when drug dosage is reduced, withdrawn, or omitted (eg, the nondrug day of alternate-day therapy). Although these symptoms may cause some discomfort, they should be tolerated if possible rather than increasing the corticosteroid dose. If severe, of course, dosage or time of administration may have to be changed.

Remind the client about corticosteroid therapy. Corticosteroids increase the ability to provide appropriate treatment. However, they can improve comfort and quality of life. Ask the physician about the amount and kind of activity or exercise needed. As a general rule, being as active as possible helps to prevent or delay osteoporosis, a common adverse effect. However, increased activity may not be desirable for everyone. A client with rheumatoid arthritis, for example, may become too active when drug therapy relieves joint pain and increases mobility.

Follow instructions for other measures used in treatment of the particular condition (eg, other drugs and physical therapy for rheumatoid arthritis). Such measures may allow smaller doses of corticosteroids and decrease adverse effects.

Because the corticosteroid impairs the ability to respond to stress, dosage may need to be temporarily increased with illness, surgery, or other stressful situations. Clarify with the physician predictable sources of stress and the amount of drug to be taken if the stress cannot be avoided.

In addition to stressful situations, report sore throat, fever, or other signs of infection; weight gain of 5 lbs. or more in a week; or swelling in the ankles or elsewhere. These symptoms may indicate adverse drug effects and changes in corticosteroid therapy may be indicated.

Dietary changes may be helpful in reducing some adverse effects of corticosteroid therapy. Decreasing salt intake (eg, by not adding table salt to foods and avoiding obviously salty foods, such as many snack foods and prepared sandwich meats) may help decrease swelling. Eating high-potassium foods, such as citrus fruits and juices or bananas, may help prevent potassium loss. An adequate intake of calcium, protein, and vitamin D (meat and dairy products are good sources) may help to prevent or delay osteoporosis. Vitamin C (eg, from citrus fruits) may help to prevent excessive bruising.

Do not object when your physician reduces your dose of oral corticosteroid, with the goal of stopping the drug entirely or continuing with a smaller dose. Long-term therapy should be used only when necessary because of the potential for serious adverse effects, and the lowest effective dose should be given.

With local applications of corticosteroids, there is usually little systemic absorption and few adverse effects, compared with oral or injected drugs. When effective in relieving symptoms, it is better to use a local than a systemic corticosteroid. In some instances, combined systemic and local application allows administration of a lesser dose of the systemic drug.

(continued)
CLIENT TEACHING GUIDELINES
Long-term Corticosteroids (Continued)

Commonly used local applications are applied topically to skin disorders, by oral inhalation for asthma, and by nasal inhalation for allergic rhinitis. Although long-term use is usually well tolerated, systemic toxicity can occur if excess corticosteroid is inhaled or if occlusive dressings are used over skin lesions. Thus, a corticosteroid for local application must be applied correctly and not overused. Corticosteroids are not the same as the steroids often abused by athletes and body builders. Those are anabolic steroids derived from testosterone, the male sex hormone.

Self- or Caregiver Administration

- Take an oral corticosteroid with a meal or snack to decrease gastrointestinal upset.
- If taking the medication once a day or every other day, take before 9 am; if taking multiple doses, take at evenly spaced intervals throughout the day.
- Report to the physician if unable to take a dose orally because of vomiting or some other problem. In some circumstances, the dose may need to be given by injection.
- If taking an oral corticosteroid in tapering doses, be sure to follow instructions exactly to avoid adverse effects.

When applying a corticosteroid to skin lesions, do not apply more often than ordered and do not cover with an occlusive dressing unless specifically instructed to do so.

- With an intranasal corticosteroid, use on a regular basis (usually once or twice daily) for the best anti-inflammatory effects.
- With an oral inhalation corticosteroid, use on a regular schedule for anti-inflammatory effects. The drugs are not effective in relieving acute asthma attacks or shortness of breath and should not be used “as needed” for that purpose. Use metered-dose inhalers as follows (unless instructed otherwise by a health care provider):
  1. Shake canister thoroughly.
  2. Place canister between lips (both open and pursed lips have been recommended) or outside lips.
  3. Exhale completely.
  4. Activate canister while taking a slow, deep breath.
  5. Hold breath for 10 seconds or as long as possible.
  6. Wait at least 1 minute before taking additional inhalations.
  7. Rinse mouth after inhalations to decrease the incidence of oral thrush (a fungal infection).
  8. Rinse mouthpiece at least once per day.

acute or chronic, and the client’s response to drug therapy. If life-threatening disease is present, high doses are usually given until acute symptoms subside. Then, dosage is gradually reduced until a maintenance dose is determined or the drug is discontinued. If the disease is not life threatening, the physician may still choose to prescribe relatively high doses initially and then reduce them. Dosages should be gradually reduced (tapered) over several days.

2. Physiologic doses (approximately 15 to 20 mg of hydrocortisone or its equivalent daily) are given to replace or substitute for endogenous adrenocortical hormone. Pharmacologic doses (supraphysiologic amounts) are usually required for anti-inflammatory, antiallergic, antistress, and immunosuppressive effects.

3. Compared with hydrocortisone, newer drugs are more potent on a weight basis but are equipotent in anti-inflammatory effects when given in equivalent doses. Statements of equivalency with hydrocortisone are helpful in evaluating new drugs, comparing different drugs, and changing drugs or dosages. However, dosage equivalents apply only to drugs given orally or IV.

4. Dosage for children is calculated according to severity of disease rather than weight.

5. For people receiving chronic corticosteroid therapy, dosage must be increased during periods of stress. Although an event that is stressful for one client may not be stressful for another, some common sources of stress for most people include surgery and anesthesia, infections, anxiety, and extremes of temperature. Some guidelines for corticosteroid dosage during stress include the following:

   a. During minor or relatively mild illness (eg, viral upper respiratory infection, any febrile illness, strenuous exercise, gastroenteritis with vomiting and diarrhea, minor surgery), doubling the daily maintenance dose is usually adequate. Once the stress period is over, dosage may be reduced abruptly to the usual maintenance dose.

   b. During major stress or severe illness, even larger doses are necessary. For example, a client undergoing abdominal surgery may require 300 to 400 mg of hydrocortisone on the day of surgery. This dose can gradually be reduced to usual maintenance doses within approximately 5 days if postoperative recovery is uncomplicated. As a general rule, it is better to administer excessive doses temporarily than to risk inadequate doses and adrenal insufficiency. The client also may require sodium chloride and fluid replacement, antibiotic therapy if infection is present, and supportive measures if shock occurs.

   An acute stress situation of short duration, such as traumatic injury or invasive diagnostic tests (eg, angiography), can usually be treated with a single dose of approximately 100 mg of hydrocortisone immediately after the injury or before the diagnostic test.
c. Many chronic diseases that require long-term corticosteroid therapy are characterized by exacerbations and remissions. Dosage of corticosteroids usually must be increased during acute flare-ups of disease symptoms but can then be decreased gradually to maintenance levels.

6. With long-term corticosteroid therapy, periodic attempts to reduce dosage are desirable to decrease adverse effects. One way is to reduce the dose gradually until symptoms worsen, indicating the minimally effective dose.

**Route of Administration**

Corticosteroid drugs can be given by several different routes to achieve local or systemic effects. When feasible, they should be given locally rather than systemically to prevent or decrease systemic toxicity. When corticosteroids must be given systemically, the oral route is preferred. Parenteral administration is indicated only for clients who are seriously ill or unable to take oral medications.

**Scheduling Guidelines**

Scheduling of drug administration is more important with corticosteroids than with most other drug classes. Most adverse effects occur with long-term administration of high doses. A major adverse reaction is suppression of the HPA axis and subsequent loss of adrenocortical function. Although opinions differ, the following schedules are often recommended to prevent or minimize HPA suppression:

1. **Short-term use (approximately 1 week) in acute situations:** Corticosteroids can be given in relatively large, divided doses for approximately 48 to 72 hours until the acute situation is brought under control. After acute symptoms subside or 48 to 72 hours have passed, the dosage is tapered so that a slightly smaller dose is given each day until the drug can be discontinued completely. Such a regimen may be useful in allergic reactions, contact dermatitis, exacerbations of chronic conditions (eg, bronchial asthma), and stressful situations such as surgery.

2. **Replacement therapy in cases of chronic adrenocortical insufficiency:** Daily administration is required. The entire daily dose can be taken each morning, between 6 and 9 AM. This schedule simulates normal endogenous corticosteroid secretion.

3. **Other chronic conditions:** Alternate-day therapy (ADT), in which a double dose is taken every other morning, is usually preferred. This schedule allows rest periods so that adverse effects are decreased while anti-inflammatory effects continue.
   a. ADT seems to be as effective as more frequent administration in most clients with bronchial asthma, ulcerative colitis, and other conditions for which long-term corticosteroid therapy is prescribed.

b. ADT is used only for maintenance therapy (ie, clinical signs and symptoms are controlled initially with more frequent drug administration). ADT can be started once symptoms have subsided and stabilized.

c. ADT does not retard growth in children, as do other schedules.

d. ADT probably decreases susceptibility to infection.

e. Intermediate-acting glucocorticoids (eg, prednisone, prednisolone, and methylprednisolone), are the drugs of choice for ADT. Long-acting agents (eg, betamethasone, dexamethasone) are not recommended because of their prolonged suppression of adrenocortical function.

f. ADT is not usually indicated in clients who have received long-term corticosteroid therapy. First, these clients already have maximal HPA suppression, so a major advantage of ADT is lost. Second, if they are transferred to ADT, recurrence of symptoms and considerable discomfort may occur on days when drugs are omitted. Clients with severe disease and very painful or disabling symptoms also may experience severe discomfort with ADT.

**Use in Specific Conditions**

**Allergic Rhinitis**

Allergic rhinitis (also called seasonal rhinitis or hay fever and perennial rhinitis) is a common problem for which corticosteroids are given by nasal spray, once or twice daily. Therapeutic effects usually occur within a few days with regular use. Systemic adverse effects are minimal with recommended doses but may occur with higher doses, including adrenocortical insufficiency from HPA suppression.

**Arthritis**

Corticosteroids are the most effective drugs for rapid relief of the pain, edema, and restricted mobility associated with acute episodes of joint inflammation. They are usually given on a short-term basis. When inflammation is limited to three or fewer joints, the preferred route of drug administration is by injection directly into the joint. Intra-articular injections relieve symptoms in approximately 2 to 8 weeks, and several formulations are available for this route. However, these drugs do not prevent disease progression and joint destruction. As a general rule, a joint should not be injected more often than three times yearly because of risks of infection and damage to intra-articular structures from the injections and from overuse when pain is relieved.

**Asthma**

Corticosteroids are commonly used in the treatment of asthma for anti-inflammatory and other effects. In acute asthma attacks or status asthmaticus unrelieved by an inhaled beta-adrenergic bronchodilator, high doses of systemic corticosteroids are given orally or IV along with the bronchodilator for approximately 5 to 10 days. Although
these high doses suppress the HPA axis, the suppression only lasts for 1 to 3 days and other serious adverse effects are avoided. Thus, systemic corticosteroids are used in short courses as needed and not for long-term treatment. People who regularly use inhaled corticosteroids also need high doses of systemic drugs during acute attacks because aerosols are not effective. As soon as acute symptoms subside, dosage should be tapered to the lowest effective maintenance dose or the drug should be discontinued.

In chronic asthma, inhaled corticosteroids are drugs of first choice. This recommendation evolved from increased knowledge about the importance of inflammation in the pathophysiology of asthma and the development of aerosol corticosteroids that are effective with minimal adverse effects. Inhaled drugs may be given alone or with systemic drugs. In general, inhaled corticosteroids can replace oral drugs when daily dosage of the oral agent has been tapered to 10 to 15 mg of prednisone or the equivalent dosage of other agents. When a client is being switched from an oral to an inhaled corticosteroid, the inhaled drug should be started during tapering of the oral drug, approximately 1 or 2 weeks before discontinuing or reaching the lowest anticipated dose of the oral drug. When a client requires a systemic corticosteroid, coadministration of an aerosol allows smaller doses of the systemic corticosteroid. Although the inhaled drugs can cause suppression of the HPA axis and adrenocortical function, especially at higher doses, they are much less likely to do so than systemic drugs.

In addition to their anti-inflammatory effects, corticosteroids also increase the effects of adrenergic bronchodilators that are given in asthma and other disorders to prevent or treat bronchoconstriction and bronchospasm. They perform this important function by increasing the number and responsiveness of beta-adrenergic receptors and preventing the tolerance usually associated with chronic administration of adrenergic bronchodilators. Research studies indicate increased responsiveness to beta-adrenergic bronchodilators within 2 hours and increased numbers of beta receptors within 4 hours of corticosteroid administration.

Cancer

Corticosteroids are commonly used in the treatment of lymphomas, lymphocytic leukemias, and multiple myeloma. In these disorders, corticosteroids inhibit cell reproduction and are cytotoxic to lymphocytes. In addition to their anticancer effects in hematologic malignancies, corticosteroids are beneficial in treatment of several signs and symptoms that often accompany cancer. Although the mechanisms of action are unknown and drug/dosage regimens vary widely, corticosteroids are used to treat anorexia, nausea and vomiting, cerebral edema and inflammation associated with brain metastases or radiation of the head, spinal cord compression, pain and edema related to pressure on nerves or bone metastases, graft-versus-host disease after bone marrow transplantation, and other disorders. Clients tend to feel better when taking corticosteroids, although the basic disease process may be unchanged. The following are some guidelines for corticosteroid therapy of cancer and associated symptoms:

Primary central nervous system (CNS) lymphomas. Formerly considered rare tumors of older adults, these tumors are being diagnosed more often in younger clients. They are usually associated with chronic immunosuppression from immunosuppressant drugs or from acquired immunodeficiency syndrome (AIDS). Many of these lymphomas are very sensitive to corticosteroids and therapy is indicated once the diagnosis is established. Other CNS tumors. Corticosteroid therapy may be useful in both supportive and definitive treatment of brain and spinal cord tumors; neurologic signs and symptoms often improve dramatically within 24 to 48 hours. Corticosteroids help to relieve symptoms by controlling edema around the tumor, at operative sites, and at sites receiving radiation therapy. Some clients can be tapered off corticosteroids after surgical or radiation therapy; others require continued therapy to manage neurologic symptoms. Adverse effects of long-term corticosteroid therapy may include mental changes ranging from mild agitation to psychosis and steroid myopathy (muscle weakness and atrophy), which may be confused with tumor progression. Mental symptoms usually improve if drug dosage is reduced and resolve if the drug is discontinued; steroid myopathy may persist for weeks or months.

Chemotherapy-induced emesis. Corticosteroids have strong antiemetic effects; the mechanism is unknown. One effective regimen combines an oral or IV dose of dexamethasone (10 to 20 mg) with a serotonin antagonist or metoclopramide and is given immediately before the chemotherapeutic drug. This regimen is the treatment of choice for chemotherapy with cisplatin, which is a strongly emetic drug.

Chronic Obstructive Pulmonary Disease

Corticosteroids are more helpful in acute exacerbations than in stable disease. However, oral corticosteroids may improve pulmonary function and symptoms in some clients. For a client with inadequate relief from a bronchodilator, a trial of a corticosteroid (eg, prednisone 20 to 40 mg each morning for 5 to 7 days) may be justified. Treatment should be continued only if there is significant improvement. As in other conditions, the lowest effective dose is needed to minimize adverse drug effects.

Inhaled corticosteroids can also be tried. They produce minimal adverse effects, but their effectiveness in COPD has not been clearly demonstrated.

Inflammatory Bowel Disease

Crohn’s disease and ulcerative colitis often require periodic corticosteroid therapy. With moderate Crohn’s disease, clients are usually given oral prednisone, 40 mg daily, until symptoms subside. With severe disease, clients often require hospitalization, IV fluids for hydration, and parenteral corticosteroids until symptoms subside. An oral form of budesonide (Entocort EC) is a newer drug for Crohn’s disease. The capsule dissolves in the small intestine and acts locally before being absorbed.
into the bloodstream and transported to the liver for metabolism. It has fewer adverse effects than systemic corticosteroids, but is also less effective and more expensive.

With ulcerative colitis, corticosteroids are usually used when aminosalicylates (eg, mesalamine) are not effective or when symptoms are more severe. Initially, hydrocortisone enemas may be effective. If not effective, oral prednisone 20 to 60 mg daily may be given until symptoms subside. In clients with severe disease, oral prednisone may be required initially. Once remission of symptoms is achieved, the dose can be tapered by 2.5 to 5 mg/day each week to a dose of 20 mg. Then, tapering may be slowed to 2.5 to 5 mg/day every other week. As with Crohn’s disease, clients with severe ulcerative colitis often require hospitalization and parenteral corticosteroids. One regimen uses IV hydrocortisone 300 mg/day or the equivalent dose of another drug. When the client’s condition improves, oral prednisone can replace the IV corticosteroid.

**Prevention of Acute Adrenocortical Insufficiency**

Suppression of the HPA axis may occur with corticosteroid therapy and may lead to life-threatening inability to increase cortisol secretion when needed to cope with stress. It is most likely to occur with abrupt withdrawal of systemic corticosteroid drugs. The risk of HPA suppression is high with systemic drugs given for more than a few days, although clients vary in degree and duration of suppression with comparable doses, and the minimum dose and duration of therapy that cause suppression are unknown.

When the drugs are given for replacement therapy, adrenal insufficiency is lifelong and drug administration must be continued. When the drugs are given for purposes other than replacement and then discontinued, the HPA axis usually recovers within several weeks to months, but may take a year. Several strategies have been developed to minimize HPA suppression and risks of acute adrenal insufficiency, including:

- Administer a systemic corticosteroid during high-stress situations (eg, moderate or severe illness, trauma, or surgery) to clients who have received pharmacologic doses for 2 weeks within the previous year or who receive long-term systemic therapy (ie, are steroid dependent).
- Give short courses of systemic therapy for acute disorders, such as asthma attacks, then decrease the dose or stop the drug within a few days.
- Gradually taper the dose of any systemic corticosteroid. Although specific guidelines for tapering dosage have not been developed, higher doses and longer durations of administration in general require slower tapering, possibly over several weeks. The goal of tapering may be to stop the drug or to decrease the dosage to the lowest effective amount.
- Use local rather than systemic therapy when possible, alone or in combination with low doses of systemic drugs. Numerous preparations are available for local application, including aerosols for oral or nasal inhalation, formulations for topical application to the skin, eyes, and ears, and drugs for intra-articular injections.
- Use ADT, which involves titrating the daily dose to the lowest effective maintenance level, then giving a double dose every other day.

**Use in Children**

Corticosteroids are used for the same conditions in children as in adults; a common use is for treatment of asthma. With severe asthma, continual corticosteroid therapy may be required. A major concern with children is growth retardation, which can occur with small doses and administration by inhalation. One 12-month study of 343 children with asthma, aged 4 to 11 years, concluded that fluticasone (Flonase) caused less growth inhibition and was more effective in improving lung function than beclomethasone (Vanceril). Many children have a growth spurt when the drug is discontinued, but drug effects on adult stature are unknown.

Parents and health care providers can monitor drug effects by recording height and weight weekly. ADT is less likely to impair normal growth and development than daily administration. In addition, for both systemic and inhaled corticosteroids, each child’s dose should be titrated to the lowest effective amount.

**Use in Older Adults**

Corticosteroids are used for the same conditions in older adults as in younger ones. Older adults are especially likely to have conditions that are aggravated by the drugs (eg, congestive heart failure, hypertension, diabetes mellitus, arthritis, osteoporosis, increased susceptibility to infection, and concomitant drug therapy that increases risks of gastrointestinal ulceration and bleeding). Consequently, risk–benefit ratios of systemic corticosteroid therapy should be carefully considered, especially for long-term therapy.

When used, lower doses are usually indicated because of decreased muscle mass, plasma volume, hepatic metabolism, and renal excretion in older adults. In addition, therapeutic and adverse responses should be monitored regularly by a health care provider (eg, blood pressure, serum electrolytes, and blood glucose levels at least every 6 months). As in other populations, adverse effects are less likely to occur with oral or nasal inhalations than with oral drugs.

---

**How Can You Avoid This Medication Error?**

Jane Wright has been receiving high-dose corticosteroid therapy (hydrocortisone 80 mg bid) for the last month. You receive an order to taper the steroid dose as follows: decrease hydrocortisone dose 20 mg each day for 3 days, then decrease by 10 mg per day and give only qd. You are caring for Jane on the third day after this order was written. You administer 40 mg for her morning dose.
Use in Renal Impairment

Systemic corticosteroids should be used with caution because of slowed excretion, with possible accumulation and signs and symptoms of hypercorticism. In renal transplantation, corticosteroids are extensively used, along with other immunosuppressive drugs, to prevent or treat rejection reactions. In these clients, as in others, adverse effects of systemic corticosteroids may include infections, hypertension, glucose intolerance, obesity, cosmetic changes, bone loss, growth retardation in children, cataracts, pancreatitis, peptic ulcerations, and psychiatric disturbances. Dosages should be minimized and the drugs can be withdrawn in some clients.

Use in Hepatic Impairment

Metabolism of corticosteroids is slowed by severe hepatic disease, so that corticosteroids may accumulate and cause signs and symptoms of hypercorticism. In addition, clients with liver disease should be given prednisolone rather than prednisone. Liver metabolism of prednisone is required to convert it to its active form, prednisolone. The single dose of prednisone is not harmful. Adrenal insufficiency is being increasingly recognized in this population and clients should be assessed for it, if indicated. In addition, corticosteroid therapy increases the risks of pulmonary infection.

Use in Critical Illness

Corticosteroids have been extensively used in the treatment of serious illness, with much usage empiric. Some guidelines regarding their use in various critical illnesses include the following:

Adrenal insufficiency is the most clear-cut indication for use of a corticosteroid, and even a slight impairment of the adrenal response during severe illness can be lethal if corticosteroid therapy is not provided. For example, hypotension is a common symptom in critically ill clients and hypotension caused by adrenal insufficiency may mimic either hypovolemic or septic shock. If adrenal insufficiency is the cause of the hypotension, administration of corticosteroids can eliminate the need for vasopressor drugs to maintain adequate tissue perfusion.

However, adrenal insufficiency may not be recognized because hypotension and other symptoms also occur with many illnesses. The normal response to critical illness (eg, pain, hypovolemia) is increased and prolonged secretion of cortisol. If this does not occur, or if too little cortisol is produced, a state of adrenal insufficiency exists. One way to evaluate a client for adrenal insufficiency is a test in which a baseline serum cortisol level is measured, after which corticotropin is given IV to stimulate cortisol production, and the serum cortisol level is measured again in approximately 30 to 60 minutes. Test results are hard to interpret in seriously ill clients, though, because serum cortisol concentrations that would be normal in normal subjects may be low in this population. In addition, a lower-than-expected rise in serum cortisol levels may indicate a normal HPA axis that is already maximally stimulated, or interference with the ability of the adrenal cortex to synthesize cortisol. Thus, a critically ill client may have a limited ability to increase cortisol production in response to stress. In any client suspected of having adrenal insufficiency, a single IV dose of corticosteroid seems justified. If the client does have adrenal insufficiency, the dose may prevent immediate death and allow time for other diagnostic and therapeutic measures. If the client does not have adrenal insufficiency, the single dose is not harmful.

Acute respiratory failure in clients with COPD. Some studies support the use of IV methylprednisolone. Thus, if other medications do not produce adequate bronchodilation, it seems reasonable to try an IV corticosteroid during the first 72 hours of the illness. However, corticosteroid therapy increases the risks of pulmonary infection.

Adult respiratory distress syndrome (ARDS). Although corticosteroids have been widely used, several well-controlled studies demonstrate that the drugs are not beneficial in early treatment or in prevention of ARDS. Thus, corticosteroids should be used in these clients only if there are other specific indications.

Sepsis. Large, well-controlled, multicenter studies have shown no beneficial effect from the use of corticosteroids in gram-negative bacteremia, sepsis, or septic shock. In addition, the drugs do not prevent development of ARDS or multiple organ dysfunction syndrome or decrease mortality in clients with sepsis. In addition, clients receiving corticosteroid therapy for other conditions are at risk for development of sepsis because the drugs impair the ability of white blood cells to leave the bloodstream and reach a site of infection.

AIDS. Adrenal insufficiency is being increasingly recognized in this population and clients should be assessed and treated for it, if indicated. In addition, corticosteroid therapy improves survival and decreases risks of respiratory failure with pneumocystosis, a common cause of death in clients with AIDS. The recommended regimen is prednisone 40 mg twice daily for 5 days, then 40 mg once daily for 5 days, then 20 mg daily until completion of treatment for pneumocystosis. The effect of corticosteroids on risks for development of other opportunistic infections or neoplasms is unknown.

Home Care

Corticosteroids are extensively used in the home setting, by all age groups, for a wide variety of disorders, and by most routes of administration. Because of potentially serious adverse effects, especially with oral drugs, it is extremely important that these drugs be used as prescribed. A major responsibility of the home care nurse is to teach, demonstrate, supervise, monitor, or do whatever is needed to facilitate correct use. In addition, the home care nurse needs to teach clients and caregivers interventions to minimize adverse effects of these drugs.

Use in Renal Impairment

Systemic corticosteroids should be used with caution because of slowed excretion, with possible accumulation and signs and symptoms of hypercorticism. In renal transplantation, corticosteroids are extensively used, along with other immunosuppressive drugs, to prevent or treat rejection reactions. In these clients, as in others, adverse effects of systemic corticosteroids may include infections, hypertension, glucose intolerance, obesity, cosmetic changes, bone loss, growth retardation in children, cataracts, pancreatitis, peptic ulcerations, and psychiatric disturbances. Dosages should be minimized and the drugs can be withdrawn in some clients.

Use in Hepatic Impairment

Metabolism of corticosteroids is slowed by severe hepatic disease, so that corticosteroids may accumulate and cause signs and symptoms of hypercorticism. In addition, clients with liver disease should be given prednisolone rather than prednisone. Liver metabolism of prednisone is required to convert it to its active form, prednisolone. The single dose of prednisone is not harmful. Adrenal insufficiency is being increasingly recognized in this population and clients should be assessed for it, if indicated. In addition, corticosteroid therapy increases the risks of pulmonary infection.

Use in Critical Illness

Corticosteroids have been extensively used in the treatment of serious illness, with much usage empiric. Some guidelines regarding their use in various critical illnesses include the following:

Adrenal insufficiency is the most clear-cut indication for use of a corticosteroid, and even a slight impairment of the adrenal response during severe illness can be lethal if corticosteroid therapy is not provided. For example, hypotension is a common symptom in critically ill clients and hypotension caused by adrenal insufficiency may mimic either hypovolemic or septic shock. If adrenal insufficiency is the cause of the hypotension, administration of corticosteroids can eliminate the need for vasopressor drugs to maintain adequate tissue perfusion.

However, adrenal insufficiency may not be recognized because hypotension and other symptoms also occur with many illnesses. The normal response to critical illness (eg, pain, hypovolemia) is increased and prolonged secretion of cortisol. If this does not occur, or if too little cortisol is produced, a state of adrenal insufficiency exists. One way to evaluate a client for adrenal insufficiency is a test in which a baseline serum cortisol level is measured, after which corticotropin is given IV to stimulate cortisol production, and the serum cortisol level is measured again in approximately 30 to 60 minutes. Test results are hard to interpret in seriously ill clients, though, because serum cortisol concentrations that would be normal in normal subjects may be low in this population. In addition, a lower-than-expected rise in serum cortisol levels may indicate a normal HPA axis that is already maximally stimulated, or interference with the ability of the adrenal cortex to synthesize cortisol. Thus, a critically ill client may have a limited ability to increase cortisol production in response to stress. In any client suspected of having adrenal insufficiency, a single IV dose of corticosteroid seems justified. If the client does have adrenal insufficiency, the dose may prevent immediate death and allow time for other diagnostic and therapeutic measures. If the client does not have adrenal insufficiency, the single dose is not harmful.

Acute respiratory failure in clients with COPD. Some studies support the use of IV methylprednisolone. Thus, if other medications do not produce adequate bronchodilation, it seems reasonable to try an IV corticosteroid during the first 72 hours of the illness. However, corticosteroid therapy increases the risks of pulmonary infection.

Adult respiratory distress syndrome (ARDS). Although corticosteroids have been widely used, several well-controlled studies demonstrate that the drugs are not beneficial in early treatment or in prevention of ARDS. Thus, corticosteroids should be used in these clients only if there are other specific indications.

Sepsis. Large, well-controlled, multicenter studies have shown no beneficial effect from the use of corticosteroids in gram-negative bacteremia, sepsis, or septic shock. In addition, the drugs do not prevent development of ARDS or multiple organ dysfunction syndrome or decrease mortality in clients with sepsis. In addition, clients receiving corticosteroid therapy for other conditions are at risk for development of sepsis because the drugs impair the ability of white blood cells to leave the bloodstream and reach a site of infection.

AIDS. Adrenal insufficiency is being increasingly recognized in this population and clients should be assessed and treated for it, if indicated. In addition, corticosteroid therapy improves survival and decreases risks of respiratory failure with pneumocystosis, a common cause of death in clients with AIDS. The recommended regimen is prednisone 40 mg twice daily for 5 days, then 40 mg once daily for 5 days, then 20 mg daily until completion of treatment for pneumocystosis. The effect of corticosteroids on risks for development of other opportunistic infections or neoplasms is unknown.

Home Care

Corticosteroids are extensively used in the home setting, by all age groups, for a wide variety of disorders, and by most routes of administration. Because of potentially serious adverse effects, especially with oral drugs, it is extremely important that these drugs be used as prescribed. A major responsibility of the home care nurse is to teach, demonstrate, supervise, monitor, or do whatever is needed to facilitate correct use. In addition, the home care nurse needs to teach clients and caregivers interventions to minimize adverse effects of these drugs.
### Corticosteroid Drugs

#### NURSING ACTIONS

<table>
<thead>
<tr>
<th>1. Administer accurately</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a.</strong> Read the drug label carefully to be certain of having the correct preparation for the intended route of administration.</td>
<td>Many corticosteroid drugs are available in several different preparations. For example, hydrocortisone is available in formulations for intravenous (IV) or intramuscular (IM) administration, for intra-articular injection, and for topical application in creams and ointments of several different strengths. These preparations cannot be used interchangeably without causing potentially serious adverse reactions and decreasing therapeutic effects. Some drugs are available for only one use. For example, several preparations are for topical use only; beclomethasone is prepared only for oral and nasal inhalation.</td>
</tr>
<tr>
<td><strong>b.</strong> With oral corticosteroids,</td>
<td>Early morning administration causes less suppression of hypothalamic–pituitary–adrenal (HPA) function.</td>
</tr>
<tr>
<td>(1) Give single daily doses or alternate day doses between 6 and 9 AM</td>
<td>To avoid adverse effects</td>
</tr>
<tr>
<td>(2) Give multiple doses at evenly spaced intervals.</td>
<td>To decrease gastrointestinal (GI) upset</td>
</tr>
<tr>
<td>(3) If dosage is being tapered, follow the exact schedule.</td>
<td>This drug is formulated to dissolve in the intestine and have local anti-inflammatory effects. Biting or chewing allows it to dissolve in the stomach.</td>
</tr>
<tr>
<td>(4) Give with meals or snacks.</td>
<td>The antacids decrease absorption of corticosteroids, with possible reduction of therapeutic effects.</td>
</tr>
<tr>
<td>(5) With oral budesonide (Entocort EC), ask the client to swallow the drug whole, without biting or chewing.</td>
<td>Most of the injectable formulations are suspensions, which need to be mixed well for accurate dosage.</td>
</tr>
<tr>
<td>(6) Do <strong>not</strong> give these drugs with an antacid containing aluminum or magnesium (eg, Maalox, Mylanta).</td>
<td>To increase safety of administration</td>
</tr>
<tr>
<td><strong>c.</strong> For IV or IM administration:</td>
<td>These drugs are given by metered dose inhalers or nasal sprays, and correct usage of the devices is essential to drug administration and therapeutic effects.</td>
</tr>
<tr>
<td>(1) Shake the medication vial well before withdrawing medication.</td>
<td>The primary objective of corticosteroid therapy is to relieve signs and symptoms, because the drugs are not curative. Therefore, therapeutic effects depend largely on the reason for use.</td>
</tr>
<tr>
<td>(2) Give a direct IV injection over at least 1 min.</td>
<td>These signs and symptoms of impaired metabolism do not occur with adequate replacement of corticosteroids.</td>
</tr>
</tbody>
</table>

**d.** For oral or nasal inhalation of a corticosteroid, check the instruction leaflet that accompanies the inhaler. | | |

2. Observe for therapeutic effects | |
| **a.** With adrenocortical insufficiency, observe for absence or decrease of weakness, weight loss, anorexia, nausea, vomiting, hyperpigmentation, hypotension, hypoglycemia, hyponatremia, and hyperkalemia. | |
| **b.** With rheumatoid arthritis, observe for decreased pain and edema in joints, greater capacity for movement, and increased ability to perform usual activities of daily living. | |
| **c.** With asthma and chronic obstructive pulmonary disease, observe for decrease in respiratory distress and increased tolerance of activity. | |
| **d.** With skin lesions, observe for decreasing inflammation. | |
| **e.** When the drug is given to suppress the immune response to organ transplants, therapeutic effect is the absence of signs and symptoms indicating rejection of the transplanted tissue. | |

(continued)
### NURSING ACTIONS

#### 3. Observe for adverse effects

- **a.** Adrenocortical insufficiency—fainting, weakness, anorexia, nausea, vomiting, hypotension, shock, and if untreated, death

- **b.** Adrenocortical excess (hypercorticism or Cushing’s disease)
  1. “Moon face,” “buffalo hump” contour of shoulders, obese trunk, thin extremities
  2. Diabetes mellitus—glycosuria, hyperglycemia, polyuria, polydipsia, polyphagia, impaired healing, and other signs and symptoms
  3. Central nervous system effects—euphoria, psychological dependence, nervousness, insomnia, depression, personality and behavioral changes, aggravation of preexisting psychiatric disorders
  4. Musculoskeletal effects—osteoporosis, pathologic fractures, muscle weakness and atrophy, decreased linear growth in children
  5. Cardiovascular, fluid, and electrolyte effects—fluid retention, edema, hypertension, congestive heart failure, hypernatremia, hypokalemia, metabolic alkalosis
  6. Gastrointestinal effects—nausea, vomiting, possible peptic ulcer disease, increased appetite, obesity
  7. Increased susceptibility to infection and delayed wound healing
  8. Menstrual irregularities, acne, excessive facial hair
  9. Ocular effects—increased intraocular pressure, glaucoma, cataracts
  10. Integumentary effects—skin becomes reddened, thinner, has stretch marks, and is easily injured

#### 4. Observe for drug interactions

- **a.** Drugs that *increase* effects of corticosteroids:
  1. Estrogens, oral contraceptives, ketoconazole, macrolide antibiotics (eg, erythromycin)
  2. Diuretics (eg, furosemide, thiazides)

- **b.** Drugs that *decrease* effects of corticosteroids:
  1. Antacids, cholestyramine
  2. Carbamazepine, phenytoin, rifampin

### RATIONALE/EXPLANATION

These are uncommon with replacement therapy but common with long-term administration of the pharmacologic doses used for many disease processes. Adverse reactions may affect every body tissue and organ.

This reaction is likely to occur in clients receiving daily corticosteroid drugs who encounter stressful situations. It is caused by drug-induced suppression of the HPA axis, which makes the client unable to respond to stress by increasing adrenocortical hormone secretion.

Most adverse effects result from excessive corticosteroids.

Corticosteroid drugs can cause hyperglycemia and diabetes mellitus or aggravate preexisting diabetes mellitus by their effects on carbohydrate metabolism.

Some clients enjoy the drug-induced euphoria so much that they resist attempts to withdraw the drug or decrease its dosage.

Deminerlization of bone produces thin, weak bones that fracture easily. Fractures of vertebrae, long bones, and ribs are relatively common, especially in postmenopausal women and immobilized clients. Myopathy results from abnormal protein metabolism. Decreased growth in children results from impaired bone formation and protein metabolism.

Caused by suppression of normal inflammatory and immune processes and impaired protein metabolism

Caused by excessive sex hormones, primarily androgens

These drugs apparently inhibit the enzymes that normally metabolize corticosteroids in the liver.

Increase hypokalemia

Decrease absorption

These drugs induce microsomal enzymes in the liver and increase the rate at which corticosteroids are metabolized or deactivated.
Nursing Notes: Apply Your Knowledge

Answer: Kim’s prednisone should not be stopped before surgery. In fact, the dose may be increased because of the physiologic stress of the surgery. Check with the surgeon to clarify preoperative and postoperative steroid orders. Side effects of steroid use are significant for the postoperative patient. Wound healing is delayed because the inflammatory response is impaired. Carefully inspect the incision for dehiscence and know that staples or sutures may remain in place for a longer period of time. Signs of infection (fever, elevated white blood cell count, purulent drainage) may be absent or diminished even when an infection is present. Assess for fluid and electrolyte imbalances (sodium and fluid retention) during the postoperative period, as well as gastrointestinal irritation.

How Can You Avoid This Medication Error?

Answer: By the third day, the dose should be 20 mg (first day 60 mg; second day 40 mg), so this medication error occurred because the wrong dose was administered. This taper order is not written clearly. Clarify with the physician the dosage for each day and have him or her write the order indicating the dosage for day 1, day 2, day 3, and so forth. When administering a dose that is adjusted daily, it helps to look at how much was administered the previous days to double-check the dosage to be administered.

Review and Application Exercises

1. What are the main characteristics and functions of cortisol?
2. What is the difference between glucocorticoid and mineralocorticoid components of corticosteroids?
3. How do glucocorticoids affect body metabolism?
4. What is meant by the HPA axis?
5. What are the mechanisms by which exogenous corticosteroids may cause adrenocortical insufficiency and excess?
6. What adverse effects are associated with chronic use of systemic corticosteroids?
7. For a client on long-term systemic corticosteroid therapy, why is it important to taper the dose and gradually discontinue the drug rather than stop it abruptly?
8. Why is alternate-day administration of a systemic corticosteroid preferred when possible?
9. What are the main differences between administering corticosteroids in adrenal insufficiency and in other disorders?
10. When a corticosteroid is given by inhalation to clients with asthma, what is the expected effect?

SELECTED REFERENCES

Budesonide (Entocort EC) for Crohn’s disease (2002). The Medical Letter on Drugs and Therapeutics, 44, 6–8.
Critical Thinking Scenario
Mary Sanchez, 55 years of age, is diagnosed with chronic (Hashimoto’s) thyroiditis and is to begin treatment with levothyroxine (Synthroid) 0.1 mg daily. You are the nurse in the clinic and responsible for teaching Ms. Sanchez about her hypothyroidism and thyroid replacement therapy.

Reflect on:
- Signs and symptoms of hypothyroidism and its impact on functional abilities.
- Priority information that should be given to Ms. Sanchez during the brief (10-minute) time allotted.
- How you will need to individualize teaching if Ms. Sanchez’s ability to speak and read English is limited.
- Necessary follow-up for Ms. Sanchez’s hypothyroidism and drug management.

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe physiologic effects of thyroid hormone.
2. Identify subclinical, symptomatic, and severe effects of inadequate or excessive thyroid hormone.
3. Describe characteristics, uses, and effects of thyroid drugs.
4. Describe characteristics, uses, and effects of antithyroid drugs.
5. Discuss the influence of thyroid and antithyroid drugs on the metabolism of other drugs.
6. Teach clients self-care activities related to the use of thyroid and antithyroid drugs.

OVERVIEW
The thyroid gland produces three hormones: thyroxine, triiodothyronine, and calcitonin. Thyroxine contains four atoms of iodine and is also called T4. Triiodothyronine contains three atoms of iodine and is called T3. Compared with thyroxine, triiodothyronine is more potent and has a more rapid onset but shorter duration of action. Despite these minor differences, the two hormones produce the same physiologic effects and have the same actions and uses. Calcitonin functions in calcium metabolism and is discussed in Chapter 26.

Production of thyroxine and triiodothyronine depends on the presence of iodine and tyrosine in the thyroid gland. Plasma iodide is derived from dietary sources and from the metabolic breakdown of thyroid hormone, which allows some iodine to be reused. The thyroid gland extracts iodide from the circulating blood, concentrates it, and secretes enzymes that change the chemically inactive iodide to free iodine atoms. Tyrosine is an amino acid derived from dietary protein. It forms the basic structure of thyroglobulin. In a series of chemical reactions, iodine atoms become attached to tyrosine to form the thyroid hormones T3 and T4. Once formed, the hormones are stored within the chemically inactive thyroglobulin molecule.

Thyroid hormones are released into the circulation when the thyroid gland is stimulated by thyroid-stimulating hormone (thyrotropin or TSH) from the anterior pituitary gland. Because the thyroglobulin molecule is too large to cross cell membranes, proteolytic enzymes break down the molecule so the active hormones can be released. After their release from thyroglobulin, the hormones become largely bound to plasma proteins. Only the small amounts left unbound are biologically active. The bound thyroid hormones are released to tissue cells very slowly. Once in the cells, the hormones combine with intracellular proteins so they are again stored. They are released slowly within the cell and used over a period of days or weeks. Once used by the cells, the thyroid hormones release the iodine atoms. Most of the iodine is reabsorbed and used to produce new thyroid hormones; the remainder is excreted in the urine.

Thyroid hormones control the rate of cellular metabolism and thereby influence the functioning of virtually every cell.
THYROID DISORDERS

Thyroid disorders requiring drug therapy are goiter, hypothyroidism, and hyperthyroidism. Hypothyroidism and hyperthyroidism produce opposing effects on body tissues, depending on the levels of circulating thyroid hormone. Specific effects and clinical manifestations are listed in Table 25–1.

Simple Goiter

Simple goiter is an enlargement of the thyroid gland resulting from iodine deficiency. Inadequate iodine decreases thyroid hormone production. To compensate, the anterior pituitary gland secretes more TSH, which causes the thyroid to enlarge and produce more hormone. If the enlarged gland secretes enough hormone, thyroid function is normal and the main consequences of the goiter are disfigurement, psychological distress, dyspnea, and dysphagia. If the gland cannot secrete enough hormone despite enlargement, hypothyroidism results. Simple or endemic goiter is a common condition in some geographic areas. It is uncommon in the United States, largely because of the widespread use of iodized table salt.

Treatment of simple goiter involves giving iodine preparations and thyroid hormones to prevent further enlargement and promote regression in gland size. Large goiters may require surgical excision.

Hypothyroidism

Primary hypothyroidism occurs when disease or destruction of thyroid gland tissue causes inadequate production of thyroid hormones. Common causes of primary hypothyroidism include chronic (Hashimoto’s) thyroiditis, an autoimmune disorder, and treatment of hyperthyroidism with antithyroid drugs, radiation therapy, or surgery. Other causes include previous radiation to the thyroid area of the neck and treatment with amiodarone, lithium, or iodine. Secondary hypothyroidism occurs when there is decreased TSH from the anterior pituitary gland.

Congenital hypothyroidism (cretinism) occurs when a child is born without a thyroid gland or with a poorly functioning gland. Cretinism is uncommon in the United States but may occur with a lack of iodine in the mother’s diet. Symptoms are rarely present at birth but develop gradually during infancy and early childhood and include poor growth and development, lethargy and inactivity, feeding problems, slow pulse, subnormal temperature, and constipation. If the disorder is untreated until the child is several months old, permanent mental retardation is likely to result.

Adult hypothyroidism (myxedema) may be subclinical or clinical and occurs much more often in women than in men. Subclinical hypothyroidism, which is the most common thyroid disorder, involves a mildly elevated serum TSH and normal serum thyroxine levels. It is usually asymptomatic. Clinical hypothyroidism produces variable signs and symptoms, depending on the amount of circulating thyroid hormone. Initially, manifestations are mild and vague. They usually increase in incidence and severity over time as the thyroid gland gradually atrophies and functioning glandular tissue is replaced by nonfunctioning fibrous connective tissue (see Table 25–1).

Myxedema coma is severe, life-threatening hypothyroidism characterized by coma, hypothermia, cardiovascular collapse, hypoventilation, and severe metabolic disorders such as hypokalemia, hypoglycemia, and lactic acidosis. Predisposing factors include exposure to cold, infection, trauma, respiratory disease, and administration of central nervous system (CNS) depressant drugs (eg, anesthetics, analgesics, sedatives). A person with severe hypothyroidism cannot metabolize and excrete the drugs.

Treatment

Regardless of the cause of hypothyroidism and the age at which it occurs, the specific treatment is replacement of thyroid hormone from an exogenous source. Synthetic levothyroxine is the drug of choice. In patients with subclinical hypothyroidism, levothyroxine should be given if the serum TSH level is higher than 10 microunits/L. There is some difference of opinion about treatment for TSH values between 5 and 10 microunits/L. Two arguments for treatment of subclinical hypothyroidism are the high rate of progression to symptomatic hypothyroidism and improvement of cholesterol metabolism (eg, low-density lipoprotein [LDL] or “bad” cholesterol is reduced).

In patients with symptomatic hypothyroidism, levothyroxine therapy is definitely indicated. In addition to improvement of metabolism, treatment may also improve cardiac function, energy level, mood, muscle function, and fertility. In myxedema coma, levothyroxine or liothyronine is given intravenously, along with interventions to relieve precipitating factors and to support vital functions until the thyroid hormone becomes effective, often within 24 hours.
Hyperthyroidism

Hyperthyroidism is characterized by excessive secretion of thyroid hormone. It may be associated with Graves’ disease, nodular goiter, thyroiditis, overtreatment with thyroid drugs, functioning thyroid carcinoma, and pituitary adenoma that secretes excessive TSH. Hyperthyroidism usually involves an enlarged thyroid gland that has an increased number of cells and an increased rate of secretion. The hyperplastic thyroid gland may secrete 5 to 15 times the normal amount of thyroid hormone. As a result, body metabolism is greatly increased. Specific physiologic effects and clinical manifesta-

<table>
<thead>
<tr>
<th>Thyroid Disorders and Their Effects on Body Systems</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiovascular Effects</strong></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td>Increased capillary fragility</td>
<td>Tachycardia</td>
</tr>
<tr>
<td>Decreased cardiac output</td>
<td>Increased cardiac output</td>
</tr>
<tr>
<td>Decreased blood pressure</td>
<td>Increased blood volume</td>
</tr>
<tr>
<td>Decreased heart rate</td>
<td>Increased systolic blood pressure</td>
</tr>
<tr>
<td>Cardiac enlargement</td>
<td>Cardiac dysrhythmias</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>Anemia</td>
<td>More rapid development of atherosclerosis and its complications (eg, coronary artery and peripheral vascular disease)</td>
</tr>
<tr>
<td><strong>Central Nervous System Effects</strong></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td>Apathy and lethargy</td>
<td>Nervousness</td>
</tr>
<tr>
<td>Emotional dullness</td>
<td>Emotional instability</td>
</tr>
<tr>
<td>Slow speech, perhaps slurring and hoarseness as well</td>
<td>Restlessness</td>
</tr>
<tr>
<td>Hypoactive reflexes</td>
<td>Anxiety</td>
</tr>
<tr>
<td>Forgetfulness and mental sluggishness</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Excessive drowsiness and sleeping</td>
<td>Hyperactive reflexes</td>
</tr>
<tr>
<td><strong>Metabolic Effects</strong></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td>Intolerance of cold</td>
<td>Intolerance of heat</td>
</tr>
<tr>
<td>Subnormal temperature</td>
<td>Low-grade fever</td>
</tr>
<tr>
<td>Increased serum cholesterol</td>
<td>Weight loss despite increased appetite</td>
</tr>
<tr>
<td>Weight gain</td>
<td><strong>Gastrointestinal Effects</strong></td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>Increased appetite</td>
</tr>
<tr>
<td>Constipation</td>
<td>Abdominal cramps</td>
</tr>
<tr>
<td></td>
<td>Diarrhea</td>
</tr>
<tr>
<td></td>
<td>Nausea and vomiting</td>
</tr>
<tr>
<td><strong>Muscular Effects</strong></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td>Weakness</td>
<td>Weakness</td>
</tr>
<tr>
<td>Fatigue</td>
<td>Fatigue</td>
</tr>
<tr>
<td>Vague aches and pains</td>
<td>Muscle atrophy</td>
</tr>
<tr>
<td></td>
<td>Tremors</td>
</tr>
<tr>
<td><strong>Integumentary Effects</strong></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td>Dry, coarse, and thickened skin</td>
<td>Moist, warm, flushed skin due to vasodilation and increased sweating</td>
</tr>
<tr>
<td>Puffy appearance of face and eyelids</td>
<td>Hair and nails soft</td>
</tr>
<tr>
<td>Dry and thinned hair</td>
<td><strong>Reproductive Effects</strong></td>
</tr>
<tr>
<td>Thick and hard nails</td>
<td>Amenorrhea or oligomenorrhea</td>
</tr>
<tr>
<td></td>
<td><strong>Hyperthyroidism</strong></td>
</tr>
<tr>
<td><strong>Miscellaneous Effects</strong></td>
<td>Dyspnea</td>
</tr>
<tr>
<td>Increased susceptibility to infection</td>
<td>Polyuria</td>
</tr>
<tr>
<td>Increased sensitivity to narcotics, barbiturates, and anesthetics due to slowed metabolism of these drugs</td>
<td>Hoarse, rapid speech</td>
</tr>
<tr>
<td></td>
<td>Increased susceptibility to infection</td>
</tr>
<tr>
<td></td>
<td>Excessive perspiration</td>
</tr>
<tr>
<td></td>
<td>Localized edema around the eyeballs, which produces characteristic eye changes, including exophthalmos</td>
</tr>
</tbody>
</table>
tions of hyperthyroidism are listed in Table 25–1. These effects vary, depending on the amount of circulating thyroid hormone, and they usually increase in incidence and severity with time if hyperthyroidism is not treated.

Subclinical hyperthyroidism is defined as a reduced TSH (below 0.1 microunit/L) and normal thyroxine and triiodothyronine levels. The most common cause is excess thyroid hormone therapy. Subclinical hyperthyroidism is a risk factor for osteoporosis in postmenopausal women who do not take estrogen replacement therapy, because it leads to reduced bone mineral density. It also greatly increases the risk of atrial fibrillation in clients over 60 years of age.

Thyroid storm or thyrotoxic crisis is a rare but severe complication characterized by extreme symptoms of hyperthyroidism, such as severe tachycardia, fever, dehydration, heart failure, and coma. It is most likely to occur in clients with hyperthyroidism that has been inadequately treated, especially when stressful situations occur (eg, trauma, infection, surgery, emotional upsets).

**Treatment**

Treatment of hyperthyroidism depends on the cause. If the cause is an adenoma or multinodular goiter, surgery or radioactive iodine therapy is recommended, especially in older clients. If the cause is excessive levothyroxine dosage for hypothyroidism, the dose should be reduced. If the cause is Graves’ disease, treatment may involve antithyroid drugs, radioactive iodine, surgery, or a combination of these methods. The drugs act by decreasing production or release of thyroid hormones. Radioactive iodine emits rays that destroy thyroid gland tissue. Subtotal thyroidectomy involves surgical excision of thyroid tissue. All these methods reduce the amount of thyroid hormones circulating in the bloodstream.

The antithyroid drugs include the thioamide derivatives (propylthiouracil and methimazole) and iodine preparations. The thioamide drugs inhibit synthesis of thyroid hormone, are inexpensive and relatively safe, and they do not damage the thyroid gland. These drugs may be used as the primary treatment (for which they may be given 6 months to 2 years) or to decrease blood levels of thyroid hormone before radioactive iodine therapy or surgery.

Radioactive iodine is a frequently used treatment. It is safe, effective, inexpensive, and convenient. One disadvantage is hypothyroidism, which usually develops within a few months and requires lifelong thyroid hormone replacement therapy. Another disadvantage is the delay in therapeutic benefits. Results may not be apparent for 3 months or longer, during which time severe hyperthyroidism must be brought under control with one of the thioamide antithyroid drugs. Other iodine preparations are not used in long-term treatment of hyperthyroidism. They are indicated when a rapid clinical response is needed, as in thyroid storm and acute hyperthyroidism, or to prepare a hyperthyroid person for thyroidectomy. A thioamide drug is given to produce a euthyroid state, and an iodine preparation is given to reduce the size and vascularity of the thyroid gland to reduce the risk of excessive bleeding.

Iodine preparations inhibit the release of thyroid hormones and cause them to be stored within the gland. They reduce blood levels of thyroid hormones more quickly than thioamide drugs or radioactive iodine. Maximal effects are reached in approximately 10 to 15 days of continuous therapy, and this is probably the primary advantage. Disadvantages, however, include the following:

- They may produce goiter, hyperthyroidism, or both.
- They cannot be used alone. Therapeutic benefits are temporary, and symptoms of hyperthyroidism may reappear and even be intensified if other treatment methods are not also used.
- Radioactive iodine cannot be used effectively for a prolonged period in a client who has received iodine preparations. Even if the iodine preparation is discontinued, the thyroid gland is saturated with iodine and does not attract enough radioactive iodine for treatment to be effective. Also, if radioactive iodine is given later, acute hyperthyroidism is likely to result because the radioactive iodine causes the stored hormones to be released into the circulation.
- Although giving a thioamide drug followed by an iodine preparation is standard preparation for thyroidectomy, the opposite sequence of administration is unsafe. If the iodine preparation is given first and followed by propylthiouracil or methimazole, the client is likely to experience acute hyperthyroidism because the thioamide causes release of the stored thyroid hormones.

Subtotal thyroidectomy is effective in relieving hyperthyroidism but also has several disadvantages. First, preparation for surgery requires several weeks of drug therapy. Second, there are risks involved in anesthesia and surgery and potential postoperative complications. Third, there is a high risk of eventual hypothyroidism. For these reasons, surgery is usually used for clients with large goiters or contraindications to other treatments.

Propranolol is used as an adjunctive drug in the treatment of hyperthyroidism. It relieves tachycardia, cardiac palpitations, excessive sweating, and other symptoms. Propranolol is especially helpful during the several weeks required for therapeutic results from antithyroid drugs or from radioactive iodine administration.

**INDIVIDUAL DRUGS**

The drugs are described in the following section; dosages are listed in Drugs at a Glance: Drugs for Hypothyroidism and Hyperthyroidism.

**Thyroid Agents (Drugs Used in Hypothyroidism)**

**Levothyroxine** (Synthroid, Levothroid), a synthetic preparation of thyroxine (T₄), is the drug of choice for long-term
treatment of hypothyroidism. It is a potent form that contains a uniform amount of hormone and can be given parenterally. Compared with liothyronine, levothyroxine has a slower onset and longer duration of action.

Levothyroxine absorption with oral administration varies from 48% to 79% of the dose administered. Taking the medication on an empty stomach increases absorption; malabsorption syndromes cause excessive fecal loss. Most (99%) of the circulating levothyroxine is bound to serum proteins, including thyroid-binding globulin as well as thyroid-binding prealbumin and albumin. Levothyroxine has a long half-life of about 6 to 7 days in euthyroidism, but is prolonged to 9 to 10 days in hypothyroidism and shortened to 3 to 4 days in hyperthyroidism.

Much of the levothyroxine is converted to liothyronine (T₃) in peripheral tissues. This conversion (ie, removal of an iodine atom, called deiodination) occurs at several locations, including the liver, kidneys, and other tissues. Some of the
hormone is conjugated with glucuronide or sulfate and excreted in the bile and intestine.

Liothyronine (Cytomel, Triostat) is a synthetic preparation of T₃. Compared with levothyroxine, liothyronine has a more rapid onset and a shorter duration of action. Consequently, it may be more likely to produce high concentrations in blood and tissues and cause adverse reactions. Also, it requires more frequent administration if used for long-term treatment of hypothyroidism. Only the intravenous (IV) formulation (Triostat) is used in treating myxedema coma.

Liotrix (Euthroid, Thyrolar) contains levothyroxine and liothyronine in a 4:1 ratio, resembling the composition of natural thyroid hormone. Euthroid and Thyrolar are available in strengths ranging from 15 to 180 mg in thyroid equivalency.

**Antithyroid Agents**
(Drugs Used in Hyperthyroidism)

Propylthiouracil (PTU) is the prototype of the thioamide antithyroid drugs. It can be used alone to treat hyperthyroidism, as part of the preoperative preparation for thyroidectomy, before or after radioactive iodine therapy, and in the treatment of thyroid storm or thyrotoxic crisis. Propylthiouracil acts by inhibiting production of thyroid hormones and peripheral conversion of T₄ to the more active T₃. It does not interfere with release of thyroid hormones previously produced and stored. Thus, therapeutic effects do not occur for several days or weeks until the stored hormones have been used.

PTU is well absorbed with oral administration, and peak plasma levels occur within 30 minutes. Plasma half-life is 1 to 2 hours. However, duration of action depends on the half-life within the thyroid gland rather than plasma half-life. Because this time is relatively short, also, the drug must be given every 8 hours. PTU is metabolized in the liver and excreted in urine.

Methimazole (Tapazole) is similar to PTU in actions, uses, and adverse reactions. It is also well absorbed with oral administration and rapidly reaches peak plasma levels.

Strong iodine solution (Lugol’s solution) and saturated solution of potassium iodide (SSKI) are iodine preparations sometimes used in short-term treatment of hyperthyroidism. The drugs inhibit release of thyroid hormones, causing them to accumulate in the thyroid gland. Lugol’s solution is usually used to treat thyrotoxic crisis and to decrease the size and vascularity of the thyroid gland before thyroidectomy. SSKI is more often used as an expectorant but may be given as preparation for thyroidectomy. Iodine preparations should not be followed by propylthiouracil, methimazole, or radioactive iodine because the latter drugs cause release of stored thyroid hormone and may precipitate acute hyperthyroidism.

Sodium iodide ¹³¹I (Iodotope) is a radioactive isotope of iodine. The thyroid gland cannot differentiate between regular iodide and radioactive iodide, so it picks up the radioactive iodide from the circulating blood. As a result, small amounts of radioactive iodide can be used as a diagnostic test of thyroid function, and larger doses are used therapeutically to treat hyperthyroidism. Therapeutic doses act by emitting beta and gamma rays, which destroy thyroid tissue and thereby decrease production of thyroid hormones. It is also used to treat thyroid cancer.

Radioactive iodide is usually given in a single dose on an outpatient basis. For most clients, no special radiation precautions are necessary. If a very large dose is given, the client may be isolated for 8 days, which is the half-life of radioactive iodide. Therapeutic effects are delayed for several weeks or up to 6 months. During this time, symptoms may be controlled with thioamide drugs or propranolol. Radioactive iodide is usually given to middle-aged and elderly people; it is contraindicated during pregnancy and lactation.

Propranolol (Inderal) is an antiadrenergic, not an antithyroid, drug. It does not affect thyroid function, hormone secretion, or hormone metabolism. It is most often used to treat cardiovascular conditions, such as dysrhythmias, angina pectoris, and hypertension. When given to clients with hyperthyroidism, propranolol blocks beta-adrenergic receptors in various organs and thereby controls symptoms of hyperthyroidism resulting from excessive stimulation of the sympathetic nervous system. These symptoms include tachycardia, palpitations, excessive sweating, tremors, and nervousness. Propranolol is useful for controlling symptoms during the delayed response to thioamide drugs and radioactive iodine, before thyroidectomy, and in treating thyrotoxic crisis. When the client becomes euthyroid and hyperthyroid symptoms are controlled by definitive treatment measures, propranolol should be discontinued.

**Nursing Notes: Apply Your Knowledge**

Ms. Sanchez has been taking Synthroid for approximately 2 years. She switched to a generic brand of levothyroxine 2 months ago. When she returns to the clinic, she is complaining of fatigue, weight gain, dry skin, and cold intolerance. What do you suggest?

**How Can You Avoid This Medication Error?**

Gina Sinatro takes Synthroid 0.1 mg once daily. The drug label lists Synthroid 100 mcg per tablet. To administer the morning dose, the nurse gives Ms. Sinatro 10 tablets.

**Nursing Process**

**Assessment**
- Assess for signs and symptoms of thyroid disorders (see Table 25-1). During the course of treatment with thyroid or antithyroid drugs, the client’s blood level of thyroid
hormone may range from low to normal to high. At either end of the continuum, signs and symptoms may be dramatic and obvious. As blood levels change toward normal as a result of treatment, signs and symptoms become less obvious. If presenting signs and symptoms are treated too aggressively, they may change toward the opposite end of the continuum and indicate adverse drug effects. Thus, each client receiving a drug that alters thyroid function must be assessed for indicators of hypothyroidism, euthyroidism, and hyperthyroidism.

- Check laboratory reports for serum TSH (normal = 0.5 to 4.1 μU/mL) when available. An elevated serum TSH is the first indication of primary hypothyroidism and commonly occurs in middle-aged women, even in the absence of other signs and symptoms. Serum TSH is used to monitor response to drugs that alter thyroid function.

Nursing Diagnoses
- Decreased Cardiac Output related to disease- or drug-induced thyroid disorders
- Imbalanced Nutrition: Less Than Body Requirements with hyperthyroidism
- Imbalanced Nutrition: More Than Body Requirements with hyperthyroidism
- Ineffective Thermoregulation related to changes in metabolism rate and body heat production
- Deficient Knowledge: Disease process and drug therapy

Planning/Goals
The client will:
- Achieve normal blood levels of thyroid hormone
- Receive or take drugs accurately
- Experience relief of symptoms of hypothyroidism or hyperthyroidism
- Be assisted to cope with symptoms until therapy becomes effective
- Avoid preventable adverse drug effects
- Be monitored regularly for therapeutic and adverse effects of drug therapy

Interventions
Use nondrug measures to control symptoms, increase effectiveness of drug therapy, and decrease adverse reactions. Some areas for intervention include the following:
- Environmental temperature. Regulate for the client’s comfort, when possible. Clients with hypothyroidism are very intolerant of cold owing to their slow metabolism rate. Chilling and shivering should be prevented because of added strain on the heart. Provide blankets and warm clothing as needed. Clients with hyperthyroidism are very intolerant of heat and perspire excessively owing to their rapid metabolism rate. Provide cooling baths and lightweight clothing as needed.
- Diet. Despite a poor appetite, hypothyroid clients are often overweight because of slow metabolism rates. Thus, a low-calorie, weight-reduction diet may be indicated. In addition, an increased intake of high-fiber foods is usually needed to prevent constipation as a result of decreased gastrointestinal secretion and motility. Despite a good appetite, hyperthyroid clients are often underweight because of rapid metabolism rates. They often need extra calories and nutrients to prevent tissue breakdown. These can be provided by extra meals and snacks. The client may wish to avoid highly seasoned and high-fiber foods because they may increase diarrhea.
- Fluids. With hypothyroidism, clients need an adequate intake of low-calorie fluids to prevent constipation. With hyperthyroidism, clients need large amounts of fluids (3000–4000 mL/day) unless contraindicated by cardiac or renal disease. The fluids are needed to eliminate heat and waste products produced by the hypermetabolic state. Much of the client’s fluid loss is visible as excessive perspiration and urine output.
- Activity. With hypothyroidism, encourage activity to maintain cardiovascular, respiratory, gastrointestinal, and musculoskeletal function. With hyperthyroidism, encourage rest and quiet, nonstrenuous activity. Because clients differ in what they find restful, this must be determined with each one. A quiet room, reading, and soft music may be helpful. Mild sedatives are often given. The client is caught in the dilemma of needing rest because of the high metabolic rate but being unable to rest because of nervousness and excitement.
- Skin care. Hypothyroid clients are likely to have edema and dry skin. When edema is present, inspect pressure points, turn often, and avoid trauma when possible. Edema increases risks of skin breakdown and decubitus ulcer formation. Also, increased capillary fragility increases the likelihood of bruising from seemingly minor trauma. When skin is dry, use soap sparingly and lotions and other lubricants freely.
- Eye care. Hyperthyroid clients may have exophthalmos. In mild cases, use measures to protect the eye. For example, dark glasses, local lubricants, and patching of the eyes at night may be needed. Diuretic drugs and elevating the head of the bed may help reduce periorbital edema and eyeball protrusion. If the eyelids cannot close, they are sometimes taped shut to avoid corneal abrasion. In severe exophthalmos, the preceding measures are taken and large doses of corticosteroids are usually given.

Evaluation
- Interview and observe for compliance with instructions for taking medications.
- Observe for relief of symptoms.
- Check laboratory reports for normal blood levels of TSH or thyroid hormones.
- Interview and observe for adverse drug effects.
- Check appointment records for compliance with follow-up procedures.
SECTION 4 DRUGS AFFECTING THE ENDOCRINE SYSTEM

CLIENT TEACHING GUIDELINES
Levothyroxine

General Considerations
- Thyroid hormone is required for normal body functioning and for life. When a person's thyroid gland is unable to produce enough thyroid hormone, levothyroxine is used as a synthetic substitute. Thus, levothyroxine therapy for hypothyroidism is lifelong; stopping it may lead to life-threatening illness.
- Periodic tests of thyroid function are needed.
- Dosage adjustments are made according to clinical response and results of thyroid function tests.
- Do not switch from one brand name to another; effects may be different.
- Levothyroxine stimulates the central nervous system and the heart; excessive stimulation may occur if it is taken with other stimulating drugs. Thus, you should consult a health care provider before taking over-the-counter drugs that stimulate the heart or cause nervousness (e.g., asthma remedies, cold remedies, decongestants). In addition, you should avoid the herb ephedra (also called ma huang and not recommended for anyone to take; it may increase blood pressure and cause heart attack or stroke) and probably limit your intake of caffeine-containing beverages to 2 to 3 servings daily.

Self-Administration
- Take every morning, on an empty stomach, for best absorption. Also, do not take the drug with an antacid (e.g., Tums, Maalox), an iron preparation, or sucralfate (Carafate). These drugs decrease absorption of levothyroxine. If necessary to take one of these drugs, take levothyroxine 2 hours before or 4 to 6 hours after the other drug.
- Take about the same time each day for more consistent blood levels and more normal body metabolism.
- Report chest pain, heart palpitations, nervousness, or insomnia. These adverse effects result from excessive stimulation and may indicate that drug dosage or intake of other stimulants needs to be reduced.

PRINCIPLES OF THERAPY

Thyroid Drugs

Drug Selection
Levothyroxine is the drug of choice for thyroid hormone replacement because of uniform potency, once-daily dosing, and low cost. The goal of treatment with levothyroxine is to restore euthyroidism and normal metabolism.

Dosage Factors
Dosage is influenced by the choice of drug, the client’s age and general condition, severity and duration of hypothyroidism, and clinical response to drug therapy. Specific factors include the following:

1. Dosage must be individualized to approximate the amount of thyroid hormone needed to make up the deficit in endogenous hormone production. As a general rule, initial dosage is relatively small. Dosage is

CLIENT TEACHING GUIDELINES
Propylthiouracil or Methimazole

General Considerations
- These drugs are sometimes called antithyroid drugs because they are given to decrease the production of thyroid hormone by an overactive thyroid gland.
- These drugs must be taken for 1 year or longer to decrease thyroid hormone levels to normal.
- Periodic tests of thyroid function and drug dosage adjustments are needed.
- Ask the prescribing physician if it is necessary to avoid or restrict amounts of seafood or iodized salt. These sources of iodide may need to be reduced or omitted during antithyroid drug therapy.

Self-Administration
- Take at regular intervals around the clock, usually every 8 hours.
- Report fever, sore throat, unusual bleeding or bruising, headache, skin rash, yellowing of the skin, or vomiting. If these adverse effects occur, drug dosage may need to be reduced or the drug may need to be discontinued.
- Consult a health care provider before taking over-the-counter drugs. Some drugs contain iodide, which can increase the likelihood of goiter and the risk of adverse effects from excessive doses of iodide (e.g., some cough syrups, asthma medications, and multivitamins may contain iodide).
gradually increased at approximately 2-week intervals until symptoms are relieved and a normal serum TSH level (0.5 to 4.7 microunits per liter) is re-established. Maintenance dosage for long-term therapy is based on the client’s clinical status and periodic measurement of serum TSH.

2. Infants requiring thyroid hormone replacement need relatively large doses. After thyroid drugs are started, the maintenance dosage is determined by periodic radioimmunoassay of serum thyroxine levels and by periodic radiographs to follow bone development.

3. Clients who are elderly or have cardiovascular disease require cautious treatment because of a high risk of adverse effects on the cardiovascular system. Thus, they are given smaller initial doses and smaller increments at longer intervals than younger adults.

Hypothyroidism and the Metabolism of Other Drugs

Changes in the rate of body metabolism affect the metabolism of many drugs. Most drugs given to a client with hypothyroidism have a prolonged effect because drug metabolism in the liver is delayed and the glomerular filtration rate of the kidneys is decreased. Also, drug absorption from the intestine or a parenteral injection site may be slowed. As a result, dosage of many other drugs should be reduced, including digoxin and insulin. In addition, people with hypothyroidism are especially likely to experience respiratory depression and myxedema coma with opioid analgesics and other sedating drugs. These drugs should be avoided when possible. However, when necessary, they are given very cautiously and in dosages of approximately one third to one half the usual dose. Even then, clients must be observed very closely for respiratory depression.

Once thyroid replacement therapy is started and stabilized, the client becomes euthyroid, has a normal rate of metabolism, and can tolerate usual doses of most drugs if other influencing factors are not present. On the other hand, excessive doses of thyroid drugs may produce hyperthyroidism and a greatly increased rate of metabolism. In this instance, larger doses of most other drugs are necessary to produce the same effects. Rather than increasing dosage of other drugs, however, dosage of thyroid drugs should be reduced so the client is euthyroid again.

Duration of Replacement Therapy

Thyroid replacement therapy in the client with hypothyroidism is lifelong. Medical supervision is needed frequently during early treatment and at least annually after the client’s condition has stabilized and maintenance dosage has been determined.

Adrenal Insufficiency

When hypothyroidism and adrenal insufficiency coexist, the adrenal insufficiency should be treated with a corticosteroid drug before starting thyroid replacement. Thyroid hormones increase tissue metabolism and tissue demands for adrenocortical hormones. If adrenal insufficiency is not treated first, administration of thyroid hormone may cause acute adrenocortical insufficiency, a life-threatening condition.

Antithyroid Drugs

Dosage Factors

Dosage of the thioamide antithyroid drugs is relatively large until a euthyroid state is reached, usually in 6 to 8 weeks. A maintenance dose, in the smallest amount that prevents recurrent symptoms of hyperthyroidism, is then given for 1 year or longer. Dosage should be decreased if the thyroid gland enlarges or signs and symptoms of hypothyroidism occur.

Duration of Antithyroid Therapy

No clear-cut guidelines exist regarding duration of antithyroid drug therapy because exacerbations and remissions occur. It is usually continued until the client is euthyroid for 6 to 12 months. Diagnostic tests to evaluate thyroid function or a trial withdrawal then may be implemented to determine whether the client is likely to remain euthyroid without further drug therapy. If the drug is to be discontinued, this is usually done gradually over weeks or months.

Use in Pregnancy

Iodine preparations and thioamide antithyroid drugs are contraindicated during pregnancy because they can lead to goiter and hypothyroidism in the fetus or newborn.

Hyperthyroidism and the Metabolism of Other Drugs

Treatment of hyperthyroidism changes the rate of body metabolism, including the rate of metabolism of many drugs. During the hyperthyroid state, drug metabolism may be very rapid, and higher doses of most drugs may be necessary to achieve therapeutic results. When the client becomes euthyroid, the rate of drug metabolism is decreased. Consequently, doses of all medications should be evaluated and probably reduced to avoid severe adverse effects.

Iodine Ingestion and Hyperthyroidism

Iodine is present in foods (especially seafood) and in contrast dyes used for gallbladder and other radiologic procedures. Ingestion of large amounts of iodine from these sources may result in goiter and hyperthyroidism.

Use in Children

For hypothyroidism in children, replacement therapy is required because thyroid hormone is essential for normal growth
and development. As in adults, levothyroxine is the drug of choice in children and dosage needs may change with growth. For congenital hypothyroidism (cretinism), drug therapy should be started within 6 weeks of birth and continued for life. Initially, the recommended dose is 10 to 15 mcg/kg/day. Then, maintenance doses for long-term therapy vary with the child’s age and weight, usually decreasing over time to a typical adult dose at 11 to 20 years of age. To monitor drug effects on growth, height and weight should be recorded and compared with growth charts at regular intervals. Adverse drug effects are similar to those seen in adults, and children should be monitored closely.

For hyperthyroidism in children, propylthiouracil or methimazole is used. Potential risks of adverse effects are similar to those in adults. Because radioactive iodine may cause cancer and chromosome damage in children, it should be used only for hyperthyroidism that cannot be controlled by other antithyroid drugs or surgery.

Use in Older Adults

Signs and symptoms of thyroid disorders may mimic those of other disorders that often occur in older adults (eg, congestive heart failure). Therefore, a thorough physical examination and diagnostic tests of thyroid function are necessary before starting any type of treatment.

For hypothyroidism, levothyroxine is given. Thyroid replacement hormone increases the workload of the heart and may cause serious adverse effects in older adults, especially those with cardiovascular disease. Cardiac effects also may be increased in clients receiving bronchodilators or other cardiac stimulants. To decrease adverse effects, the drugs should be given in small initial dosages (eg, 25 mcg/day) and increased by 25 mcg/day at monthly intervals until euthyroidism is attained and a maintenance dose established. Periodic measurements of serum TSH levels are indicated to monitor drug therapy, and doses can be adjusted when indicated.

Blood pressure and pulse should be monitored regularly. As a general rule, the drug should not be given if the resting heart rate is more than 100 beats per minute.

For hyperthyroidism, propylthiouracil or methimazole may be used, but radioactive iodine is often preferred because it is associated with fewer adverse effects than other antithyroid drugs or surgery. Clients should be monitored closely for hypothyroidism, which usually develops within a year after receiving treatment for hyperthyroidism.

## Thyroid and Antithyroid Drugs

### NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a. With thyroid drugs:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Administer in a single daily dose, on an empty stomach (eg, before breakfast).</td>
<td>Fasting increases drug absorption; early administration allows peak activity during daytime hours and is less likely to interfere with sleep.</td>
</tr>
<tr>
<td>(2) Check the pulse rate before giving the drug. If the rate is over 100 per minute or if any changes in cardiac rhythm are noted, consult the physician before giving the dose.</td>
<td>Tachycardia or other cardiac dysrhythmias may indicate adverse cardiac effects. Dosage may need to be reduced or the drug stopped temporarily.</td>
</tr>
<tr>
<td>(3) To give levothyroxine to an infant or young child, the tablet may be crushed and a small amount of formula or water added. Once mixed, administer soon, by spoon or dropper. Do not store the liquid very long. The crushed tablet may also be sprinkled on a small amount of food (eg, cereal or applesauce).</td>
<td>Accurate and consistent administration is vital to promoting normal growth and development.</td>
</tr>
<tr>
<td>(4) Do not switch among various brands or generic forms of the drug.</td>
<td>Differences in bioavailability have been identified among products. Changes in preparations may alter dosage and therefore symptom control.</td>
</tr>
<tr>
<td><strong>b. With antithyroid and iodine drugs:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Administer q8h.</td>
<td>All these drugs have rather short half-lives and must be given frequently and regularly to maintain therapeutic blood levels. In addition, if iodine preparations are not given every 8 h, symptoms of hyperthyroidism may recur.</td>
</tr>
<tr>
<td>(2) Dilute iodine solutions in a full glass of fruit juice or milk, if possible, and have the client drink the medication through a straw.</td>
<td>Dilution of the drug reduces gastric irritation and masks the unpleasant taste. Using a straw prevents staining the teeth.</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>2. Observe for therapeutic effects</td>
<td></td>
</tr>
<tr>
<td>a. With thyroid drugs, observe for:</td>
<td>Therapeutic effects result from a return to normal metabolic activities and relief of the symptoms of hypothyroidism. Therapeutic effects may be evident as early as 2 or 3 d after drug therapy is started or delayed up to approximately 2 wk. All signs and symptoms of myxedema should disappear in approximately 3 to 12 wk.</td>
</tr>
<tr>
<td>(1) Increased energy and activity level, less lethargy and fatigue</td>
<td></td>
</tr>
<tr>
<td>(2) Increased alertness and interest in surroundings</td>
<td></td>
</tr>
<tr>
<td>(3) Increased appetite</td>
<td></td>
</tr>
<tr>
<td>(4) Increased pulse rate and temperature</td>
<td></td>
</tr>
<tr>
<td>(5) Decreased constipation</td>
<td></td>
</tr>
<tr>
<td>(6) Reversal of coarseness and other changes in skin and hair</td>
<td></td>
</tr>
<tr>
<td>(7) With cretinism, increased growth rate (record height periodically)</td>
<td>These tests are often elevated with myxedema and may return to normal when thyroid replacement therapy is begun.</td>
</tr>
<tr>
<td>(8) With myxedema, diuresis, weight loss, and decreased edema</td>
<td>With propylthiouracil and methimazole, some therapeutic effects are apparent in 1 or 2 wk, but euthyroidism may not occur for 6 or 8 wk.</td>
</tr>
<tr>
<td>(9) Decreased serum cholesterol and possibly decreased creatine phosphokinase, lactate dehydrogenase, and aspartate aminotransferase</td>
<td>With iodine solutions, therapeutic effects may be apparent within 24 h. Maximal effects occur in approximately 10 to 15 d. However, therapeutic effects may not be sustained. Symptoms may reappear if the drug is given longer than a few weeks, and they may be more severe than initially.</td>
</tr>
<tr>
<td>b. With antithyroid and iodine drugs, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Slower pulse rate</td>
<td>Most adverse reactions stem from excessive doses, and signs and symptoms produced are the same as those occurring with hyperthyroidism. Excessive thyroid hormones make the heart work very hard and fast in attempting to meet tissue demands for oxygenated blood and nutrients. Symptoms of myocardial ischemia occur when the myocardium does not get an adequate supply of oxygenated blood. Symptoms of congestive heart failure occur when the increased cardiac workload is prolonged. Cardiovascular problems are more likely to occur in clients who are elderly or who already have heart disease.</td>
</tr>
<tr>
<td>(2) Slower speech</td>
<td>Leukopenia may be difficult to evaluate because it may occur with hyperthyroidism and with antithyroid drugs. Agranulocytosis occurs rarely but is the most severe adverse reaction; the earliest symptoms are likely to be sore throat and fever. If these occur, report them to the physician immediately.</td>
</tr>
<tr>
<td>(3) More normal activity level (slowing of hyperactivity)</td>
<td></td>
</tr>
<tr>
<td>(4) Decreased nervousness</td>
<td></td>
</tr>
<tr>
<td>(5) Decreased tremors</td>
<td></td>
</tr>
<tr>
<td>(6) Improved ability to sleep and rest</td>
<td></td>
</tr>
<tr>
<td>(7) Weight gain</td>
<td></td>
</tr>
<tr>
<td>3. Observe for adverse effects</td>
<td></td>
</tr>
<tr>
<td>a. With thyroid drugs, observe for tachycardia and other cardiac dysrhythmias, angina pectoris, myocardial infarction, congestive heart failure, nervousness, hyperactivity, insomnia, diarrhea, abdominal cramps, nausea and vomiting, weight loss, fever, intolerance to heat.</td>
<td></td>
</tr>
<tr>
<td>b. With propylthiouracil and methimazole, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Hypothyroidism—bradycardia, congestive heart failure, anemia, coronary artery and peripheral vascular disease, slow speech and movements, emotional and mental dullness, excessive sleeping, weight gain, constipation, skin changes, and others</td>
<td>Leukopenia may be difficult to evaluate because it may occur with hyperthyroidism and with antithyroid drugs. Agranulocytosis occurs rarely but is the most severe adverse reaction; the earliest symptoms are likely to be sore throat and fever. If these occur, report them to the physician immediately.</td>
</tr>
<tr>
<td>(2) Blood disorders—leukopenia, agranulocytosis, hypoprothrombinemia</td>
<td></td>
</tr>
<tr>
<td><strong>NURSING ACTIONS</strong></td>
<td><strong>RATIONALE/EXPLANATION</strong></td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>(3) Integumentary system—skin rash, pruritus, alopecia</td>
<td>Adverse effects are uncommon with short-term use.</td>
</tr>
<tr>
<td>(4) Central nervous system (CNS)—headache, dizziness, loss of sense of taste, drowsiness, paresthesias</td>
<td></td>
</tr>
<tr>
<td>(5) Gastrointestinal system—nausea, vomiting, abdominal discomfort, gastric irritation, cholestatic hepatitis</td>
<td></td>
</tr>
<tr>
<td>(6) Other—lymphadenopathy, edema, joint pain, drug fever</td>
<td></td>
</tr>
<tr>
<td>e. With iodine preparations, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Iodism—metallic taste, burning in mouth, soreness of gums, excessive salivation, gastric or respiratory irritation, rhinitis, headache, redness of conjunctiva, edema of eyelids</td>
<td>Allergic reactions rarely occur.</td>
</tr>
<tr>
<td>(2) Hypersensitivity—acneiform skin rash, pruritus, fever, jaundice, angioedema, serum sickness</td>
<td></td>
</tr>
<tr>
<td>(3) Goiter with hypothyroidism</td>
<td>Uncommon but may occur in adults and newborns whose mothers have taken iodides for long periods</td>
</tr>
<tr>
<td>4. Observe for drug interactions</td>
<td></td>
</tr>
<tr>
<td>a. Drugs that <em>increase</em> effects of thyroid hormones:</td>
<td></td>
</tr>
<tr>
<td>(1) Activating antidepressants (eg, bupropian, venlafaxine), adrenergic antiasthmatic drugs (eg, albuterol, epinephrine), nasal decongestants</td>
<td>These drugs may cause CNS and cardiovascular stimulation when taken alone. When combined with thyroid hormones, excessive cardiovascular stimulation may occur and cause myocardial ischemia, cardiac dysrhythmias, hypertension, and other adverse cardiovascular effects. Excessive CNS stimulation may produce anxiety, nervousness, hyperactivity, and insomnia.</td>
</tr>
<tr>
<td>b. Drugs that <em>decrease</em> effects of thyroid hormones:</td>
<td></td>
</tr>
<tr>
<td>(1) Antacids, cholestyramine, iron, sucralfate</td>
<td>Decrease absorption of levothyroxine; give levothyroxine 2 hours before or 4 to 6 hours after one of these drugs</td>
</tr>
<tr>
<td>(2) Antihypertensives</td>
<td>Decrease cardiac stimulating effects</td>
</tr>
<tr>
<td>(3) Estrogens, including oral contraceptives containing estrogens</td>
<td>Estrogens increase thyroxine-binding globulin, thereby increasing the amount of bound, inactive levothyroxine in clients with hypothyroidism. This decreased effect does not occur in clients with adequate thyroid hormone secretion because the increased binding is offset by increased T4 production. Women taking oral contraceptives may need larger doses of thyroid hormone replacement than would otherwise be needed.</td>
</tr>
<tr>
<td>(4) Propranolol (Inderal)</td>
<td>This drug decreases cardiac effects of thyroid hormones. It is used in hyperthyroidism to reduce tachycardia and other symptoms of excessive cardiovascular stimulation.</td>
</tr>
<tr>
<td>(5) Phenytoin, rifampin</td>
<td>Induce enzymes that metabolize (inactivate) levothyroxine more rapidly</td>
</tr>
<tr>
<td>c. Drug that <em>increases</em> effects of antithyroid drugs:</td>
<td></td>
</tr>
<tr>
<td>(1) Lithium</td>
<td>Acts synergistically to produce hypothyroidism</td>
</tr>
</tbody>
</table>
CHAPTER 25  THYROID AND ANTITHYROID DRUGS

Review and Application Exercises

1. Where is TSH produced, and what is its function?
2. What is the role of thyroid hormones in maintaining body functions?
3. What signs and symptoms are associated with hypothyroidism?
4. In primary hypothyroidism, are blood levels of TSH increased or decreased?
5. What is the drug of first choice for treating hypothyroidism?
6. What are adverse effects of drug therapy for hypothyroidism?
7. What signs and symptoms are associated with hyperthyroidism?
8. Which drugs reduce blood levels of thyroid hormone in hyperthyroidism, and how do they act?
9. What are adverse effects of drug therapy for hyperthyroidism?
10. When propranolol is used in the treatment of hyperthyroidism, what are its expected effects?
11. What is the effect of thyroid disorders on metabolism of other drugs?

SELECTED REFERENCES


Nursing Notes: Apply Your Knowledge

Answer: For most drugs, substituting generic brands is safe and economical. For some drugs, the bioavailability (amount of drug absorbed into the bloodstream) differs for generic brands. This sometimes occurs with thyroid preparations. Ms. Sanchez is experiencing signs of hypothyroidism because her blood levels have fallen below the therapeutic range since she started taking generic thyroid. In this situation, the cost benefit of taking generic drugs may be offset by the higher dose required to achieve therapeutic levels.

How Can You Avoid This Medication Error?

Answer: To convert from milligrams to micrograms, use the conversion factor of 1 mg = 1000 mcg. When doing the computation, 0.1 mg converts to 100 mcg, and thus one tablet should have been administered. Always question the dosage when more than 2 tablets are given.
Hormones That Regulate Calcium and Bone Metabolism

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe the roles of parathyroid hormone, calcitonin, and vitamin D in regulating calcium metabolism.
2. Identify populations at risk for development of hypocalcemia.
3. Discuss prevention and treatment of hypocalcemia and osteoporosis.
4. Identify clients at risk for development of hypercalcemia.
5. Discuss recognition and management of hypercalcemia as a medical emergency.
6. Discuss the use of calcium and vitamin D supplements, calcitonin, and bisphosphonate drugs in the treatment of osteoporosis.

Critical Thinking Scenario
You are working at a community center, providing health promotion and disease prevention programs for older adults who live independently in the community. You are planning an osteoporosis prevention workshop.

Reflect on:
- Risk factors for osteoporosis.
- Nonpharmacologic management strategies to reduce osteoporosis risk.
- Methods to increase calcium intake via diet or medications.
- Benefits of estrogen replacement therapy for postmenopausal women.
- How medication classes, such as bisphosphonates and selective estrogen receptor modulators, work to prevent osteoporosis in high-risk people.

OVERVIEW
Calcium and bone metabolism are regulated by three hormones: parathyroid hormone (PTH), calcitonin, and vitamin D, which act to maintain normal serum levels of calcium. When serum calcium levels are decreased, hormonal mechanisms are activated to raise them; when they are elevated, mechanisms act to lower them (Fig. 26–1). Overall, the hormones alter absorption of dietary calcium from the gastrointestinal tract, movement of calcium from bone to serum, and excretion of calcium through the kidneys.

Disorders of calcium and bone metabolism include hypocalcemia, hypercalcemia, osteoporosis, Paget’s disease, and bone breakdown associated with breast cancer and multiple myeloma. Drugs used to treat these disorders are mainly those to alter serum calcium levels or to strengthen bone. To aid understanding of these drugs, characteristics of the hormones, calcium, phosphorus, bone metabolism, and selected disorders are described.

Parathyroid Hormone
Parathyroid hormone secretion is stimulated by low serum calcium levels and inhibited by normal or high levels (a negative feedback system). Because phosphate is closely related to calcium in body functions, PTH also regulates phosphate metabolism. In general, when serum calcium levels go up, serum phosphate levels go down, and vice versa. Thus, an inverse relationship exists between calcium and phosphate.

When the serum calcium level falls below the normal range, PTH raises the level by acting on bone, intestines, and kidneys. In bone, breakdown is increased, so that calcium moves from bone into the serum. In the intestines, there is
increased absorption of calcium ingested in food (PTH activates vitamin D, which increases intestinal absorption). In the kidneys, there is increased reabsorption of calcium in the renal tubules and less urinary excretion. The opposite effects occur with phosphate (ie, PTH decreases serum phosphate and increases urinary phosphate excretion).

Disorders of parathyroid function are related to deficient production of PTH (hypoparathyroidism) or excessive production (hyperparathyroidism). Hypoparathyroidism is most often caused by removal of or damage to the parathyroid glands during neck surgery. Hyperparathyroidism is most often caused by a tumor or hyperplasia of a parathyroid gland. It also may result from ectopic secretion of PTH by malignant tumors (eg, carcinomas of the lung, pancreas, kidney, ovary, prostate gland, or bladder). Clinical manifestations and treatment of hypoparathyroidism are the same as those of hypocalcemia; clinical manifestations of hyperparathyroidism are those of hypercalcemia.

**Calcitonin**

Calcitonin is a hormone from the thyroid gland whose secretion is controlled by the concentration of ionized calcium in the blood flowing through the thyroid gland. When the serum level of ionized calcium is increased, secretion of calcitonin is increased. The function of calcitonin is to lower serum calcium in the presence of hypercalcemia, which it does by decreasing movement of calcium from bone to serum and increasing urinary excretion of calcium. Calcitonin’s action is rapid but of short duration. Thus, it has little effect on long-term calcium metabolism.

**Vitamin D (Calciferol)**

Vitamin D is a fat-soluble vitamin that includes both ergocalciferol (obtained from foods) and cholecalciferol (formed by exposure of skin to sunlight). It functions as a hormone and plays an important role in calcium and bone metabolism. The main action of vitamin D is to raise serum calcium levels by increasing intestinal absorption of calcium and mobilizing calcium from bone. It also promotes bone formation by providing adequate serum concentrations of minerals. Vitamin D is not physiologically active in the body. It must be converted to an intermediate metabolite in the liver, then to an active metabolite (1,25-dihydroxyvitamin D or calcitriol) in the kidneys. PTH and adequate he-
Bone disorders. Calcium and vitamin D supplements are
used to treat hypocalcemia and to prevent and treat osteo-
porosis. These agents are described in the following sec-
tions; names and dosages of individual drug preparations
are listed in Drugs at a Glance: Calcium and Vitamin D
Preparations. Drugs used for hypercalcemia include bis-
phosphonates, calcitonin, corticosteroids, 0.9% sodium
chloride intravenous (IV) infusion, and others. Those used
for osteoporosis inhibit bone breakdown and demineraliza-
tion and include bisphosphonates, calcitonin, estrogens,
and antiestrogens. These drugs are described in the follow-
ing sections; indications for use and dosages are listed in Drugs
at a Glance: Drugs Used in Hypercalcemia and Selected
Bone Disorders.

Calcium and Phosphorus

Calcium and phosphorus are discussed together because they
are closely related physiologically. These mineral nutrients
are found in many of the same foods, from which they are ab-
sorbed together. They are regulated by PTH and excreted
through the kidneys. They are both required in cellular struc-
ture and function and, as calcium phosphate, in formation and
maintenance of bones and teeth. Their characteristics and
functions are summarized in Box 26–1.

Bone Metabolism

Bone is mineralized connective tissue that functions as struc-
tural support and a reservoir for calcium, phosphorus, magne-
sium, sodium, and carbonate. The role of bone in maintaining
serum calcium levels takes precedence over its structural func-
tion (that is, bone may be weakened or destroyed as calcium
leaves bone and enters serum).

Bone tissue is constantly being formed and broken down in
a process called remodeling. During childhood, adoles-
cence, and early adulthood, formation usually exceeds break-
down (resorption) as the person attains adult height and peak
bone mass. After approximately 35 years of age, resorption is
greater than formation. Hormonal deficiencies, some diseases,
and some medications (eg, glucocorticoids) can also increase
resorption, resulting in loss of bone mass and osteoporosis.

Calcium and Bone Disorders

The calcium disorders are hypocalcemia and hypercal-
cemia, either of which can be life threatening. The bone dis-
orders discussed in this chapter are those characterized by
increased resorption of calcium and loss of bone mass.
These disorders weaken bone and lead to fractures, pain,
and disability. Calcium and selected bone disorders are
described in Box 26–2.

DRUGS USED FOR CALCIUM
AND BONE DISORDERS

Drugs from several groups are used to treat calcium and
bone disorders. Calcium and vitamin D supplements are
Calcium is required for building and maintaining bones and teeth. Bone calcium is composed mainly of calcium phosphate and calcium carbonate. In addition to these bound forms, a small amount of calcium is available for exchange with serum. This acts as a reserve supply of calcium. Calcium is constantly shifting between bone and serum as bone is formed and broken down. When serum calcium levels become low, calcium moves into serum.

Requirements and Sources
The calcium requirement of normal adults is approximately 1000 mg daily. Increased daily amounts are needed by growing children (1200 mg), pregnant or lactating women (1200 mg), and postmenopausal women who do not take replacement estrogens (1500 mg to prevent osteoporosis).

The best sources of calcium are milk and milk products. Three 8-oz glasses of milk daily contain approximately the amount needed by healthy adults. Calcium in milk is readily used by the body because milk also contains lactose and vitamin D, both of which are involved in calcium absorption. Other sources of calcium include vegetables (eg, broccoli, spinach, kale, mustard greens) and seafood (eg, clams, oysters).

Phosphorus
Phosphorus is one of the most important elements in normal body function. Most phosphorus is combined with calcium in bones and teeth as calcium phosphate (approximately 80%). The remainder is distributed in every body cell and in extracellular fluid. It is combined with carbohydrates, lipids, proteins, and various other compounds.

Phosphorus is obtained from the diet, and approximately 70% of dietary phosphorus is absorbed from the gastrointestinal (GI) tract. The most efficient absorption occurs when calcium and phosphorus are ingested in approximately equal amounts. Because this equal ratio is present in milk, milk is probably the best source of phosphorus. In general, factors that increase or decrease calcium absorption act the same way on phosphorus absorption. Vitamin D enhances, but is not essential for, phosphorus absorption. Large amounts of calcium or aluminum in the GI tract may combine with phosphate to form insoluble compounds and thereby decrease absorption of phosphorus.

Phosphorus is lost from the body primarily in urine. In people with acute or chronic renal failure, phosphorus intake is restricted because excretion is impaired.

Functions
Phosphorus, most of which is located intracellularly as the phosphate ion, performs many metabolic functions:

- It is an essential component of deoxyribonucleic acid, ribonucleic acid, and other nucleic acids in body cells. Thus, it is required for cell reproduction and body growth.
- It combines with fatty acids to form phospholipids, which are components of all cell membranes in the body. This reaction also prevents buildup of excessive amounts of free fatty acids.
- It forms a phosphate buffer system, which helps to maintain acid–base balance. When excess hydrogen ions are present in kidney tubules, phosphate combines with them and allows their excretion in urine. At the same time, bicarbonate is retained by the kidneys and contributes to alkalinity of body fluids. Although there are other buffering systems in the body, failure of the phosphate system leads to metabolic acidosis (retained hydrogen ions or acid and lost bicarbonate ions or base).
- It is necessary for cellular use of glucose and production of energy.
- It is necessary for proper function of several B vitamins (ie, the vitamins function as coenzymes in various chemical reactions only when combined with phosphate).

Requirements and Sources
Daily requirements for phosphorus are approximately 800 mg for normal adults and 1200 mg for growing children and pregnant or lactating women. Phosphorus is widely available in foods. Good sources are milk and other dairy products, meat, poultry, fish, eggs, and nuts. There is little risk of phosphorus deficiency with an adequate intake of calcium and protein.
Hypocalcemia

Hypocalcemia is an abnormally low blood calcium level (ie, <8.5 mg/dL). It may be caused by inadequate intake of calcium and vitamin D, numerous disorders (eg, diarrhea or malabsorption syndromes that cause inadequate absorption of calcium and vitamin D, hypoparathyroidism, renal failure, severe hypomagnesemia, hypermagnesemia, acute pancreatitis, rhabdomyolysis, tumor lysis syndrome, vitamin D deficiency), and several drugs (eg, cisplatin, cytosine arabinoside, foscarnet, ketoconazole, pentamidine, and agents used to treat hypercalcemia). Hypocalcemia associated with renal failure is caused by two mechanisms. First, inability to excrete phosphate in urine leads to accumulation of phosphate in the blood (hyperphosphatemia). Because phosphate levels are inversely related to calcium levels, hyperphosphatemia induces hypocalcemia. Second, when kidney function is impaired, vitamin D conversion to its active metabolite is impaired. This results in decreased intestinal absorption of calcium.

Clinical manifestations are characterized by increased neuromuscular irritability, which may progress to tetany. Tetany is characterized by numbness and tingling of the lips, fingers, and toes; twitching of facial muscles; spasms of skeletal muscle; carpopedal spasm; laryngospasm; and convulsions. In young children, hypocalcemia may be manifested by convulsions rather than tetany and erroneously diagnosed as epilepsy. This may be a serious error because anticonvulsant drugs used for epilepsy may further decrease serum calcium levels. Severe hypocalcemia may cause lethargy or confusion.

Hypercalcemia

Hypercalcemia is an abnormally high blood calcium level (ie, >10.5 mg/dL). It may be caused by hyperparathyroidism, hyperthyroidism, malignant neoplasms, vitamin D or vitamin A intoxication, aluminum intoxication, prolonged immobilization, adrenocortical insufficiency, and ingestion of thiazide diuretics, estrogens, and lithium. Cancer is a common cause, especially carcinomas (of the breast, lung, head and neck, or kidney) and multiple myeloma. Cancer stimulates bone breakdown, which increases serum calcium levels. Increased urine output leads to fluid volume deficit. This leads, in turn, to increased reabsorption of calcium in renal tubules and decreased renal excretion of calcium. Decreased renal excretion potentiates hypercalcemia.

Clinical manifestations are caused by the decreased ability of nerves to respond to stimuli and the decreased ability of muscles to contract and relax. Hypercalcemia has a depressant effect on nerve and muscle function. Gastrointestinal problems with hypercalcemia include anorexia, nausea, vomiting, constipation, and abdominal pain. Central nervous system problems include apathy, depression, poor memory, headache, and drowsiness. Severe hypercalcemia may produce lethargy, syncope, disorientation, hallucinations, coma, and death. Other signs and symptoms include weakness and decreased tone in skeletal and smooth muscle, dysphagia, polyuria, polyphagia, and cardiac dysrhythmias. In addition, calcium may be deposited in various tissues, such as the conjunctiva, cornea, and kidneys. Calcium deposits in the kidneys (renal calculi) may lead to irreversible damage and impairment of function.

Osteoporosis

Osteoporosis is characterized by decreased bone density (osteopenia) and weak, fragile bones that often lead to fractures, pain, and disability. Although any bones may be affected, common fracture sites are the vertebral bodies of the lower back and lumbar spine, wrists, and hips.

Risk factors include female sex, advanced age, small stature, lean body mass, white or Asian race, positive family history, low calcium intake, menopause, sedentary lifestyle, nulliparity, smoking, excessive ingestion of alcohol or caffeine, high protein intake, high phosphate intake, hyperthyroidism, and chronic use of certain medications (eg, corticosteroids, phenytoin). Postmenopausal women who do not take estrogen replacement therapy are at high risk because of estrogen deficiency, age-related bone loss, and a low peak bone mass. Osteoporosis occurs in men but less often than in women. Both men and women who take high doses of corticosteroids are at high risk because the drugs demineralize bone. In addition, renal transplant recipients can acquire osteoporosis from corticosteroid therapy, decreased renal function, increased parathyroid hormone secretion, and calcitriol immunosuppressant therapy.

Osteopenia or early osteoporosis may be present and undetected unless radiography or a bone density measurement is done. If detected, treatment is needed to slow bone loss. If undetected or untreated, clinical manifestations of osteoporosis include shortened stature (a measurable loss of height), back pain, spinal deformity, or a fracture. Fractures often occur with common bending or lifting movements or falling.

Paget’s Disease

Paget's disease is an inflammatory skeletal disease that affects older people. Its etiology is unknown. It is characterized by a high rate of bone turnover and results in bone deformity and pain. It is treated with non-narcotic analgesics and drugs that decrease bone resorption (eg, bisphosphonates, calcitonin).

Calcium Preparations

For acute, symptomatic hypocalcemia, a calcium salt (usually calcium gluconate) is given IV. For asymptomatic, less severe, or chronic hypocalcemia, an oral preparation (eg, calcium carbonate or citrate) is given. These preparations differ mainly in the amounts of calcium they contain and the routes by which they may be given.

Even when serum calcium levels are normal, calcium supplements may be needed by people who do not get enough calcium in their diets. Most diets are thought to be deficient in calcium for all age groups, but especially for young women and older adults. Calcium supplements are also used in the prevention and treatment of osteoporosis.

Corticosteroids

Glucocorticoids (see Chap. 24) are used in the treatment of hypercalcemia due to malignancies or vitamin D intoxication. These drugs lower serum calcium by inhibiting cytokine release, by direct cytolytic effects on some tumor...
cells, by inhibiting calcium absorption from the intestine, and by increasing calcium excretion in the urine. Hydrocortisone or prednisone is often used; serum calcium levels decrease in approximately 5 to 10 days. After the serum calcium level stabilizes, dosage should be gradually reduced to the minimum needed to control symptoms of hypercalcemia. High dosage or prolonged administration leads to serious adverse effects.

**Estrogens and Antiestrogens**

Estrogens are discussed here in relation to osteoporosis; see Chapter 28 for other uses and dosages. Estrogen replacement therapy (ERT) is beneficial for preventing postmenopausal osteoporosis. It is most beneficial immediately after menopause, when a period of accelerated bone loss occurs. Mechanisms by which ERT protects against bone loss and fractures are thought to include decreased bone breakdown, increased calcium absorption from the intestine, and increased calcitriol (the active form of vitamin D) concentration. Progestins have been used with estrogens in women with an intact uterus because of the increased risk of endometrial cancer with estrogen therapy alone. However, estrogen and estrogen-progestin combinations are no longer recommended because adverse effects are thought to outweigh benefits.

Raloxifene (Evista) and tamoxifen (Nolvadex) act like estrogen in some body tissues and prevent the action of estrogen in other body tissues. Raloxifene is classified as a selective estrogen receptor modulator and is approved for prevention of postmenopausal osteoporosis. It has estrogenic effects in bone tissue, thereby decreasing bone breakdown and increasing bone mass density. It has antiestrogen effects in uterine and breast tissue. Tamoxifen, which is classified as an antiestrogen, is used to prevent and treat breast cancer. It also has estrogenic effects and can be used to prevent osteoporosis and cardiovascular disease, although it is not approved for these uses. Tamoxifen may help prevent osteoporosis in

---

**Drugs at a Glance: Calcium and Vitamin D Preparations**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oral Calcium Products</strong></td>
<td></td>
</tr>
<tr>
<td>Calcium acetate (25% calcium) (PhosLo)</td>
<td>PO 2–4 tablets with each meal</td>
</tr>
<tr>
<td>Calcium carbonate precipitated (40% calcium) (Os-Cal, Tums)</td>
<td>PO 1–1.5 g 3 times daily with meals (maximal dose, 8 g daily)</td>
</tr>
<tr>
<td>Calcium citrate (21% calcium) (Citracal)</td>
<td>PO 1–2 tablets (200 mg calcium per tablet) 2–4 times daily</td>
</tr>
<tr>
<td>Calcium gluconate (9% calcium)</td>
<td>PO 1–2 g 3 or 4 times daily</td>
</tr>
<tr>
<td>Calcium lactate (13% calcium)</td>
<td>PO 1 g 3 three times daily with meals</td>
</tr>
<tr>
<td>Tricalcium phosphate (39% calcium) (Posture)</td>
<td>PO 1–2 tablets (600 mg calcium per tablet) 2–4 times daily</td>
</tr>
<tr>
<td><strong>Parenteral Calcium Products</strong></td>
<td></td>
</tr>
<tr>
<td>Calcium chloride (10 mL of 10% solution contains 273 mg [13.6 mEq] of calcium)</td>
<td>IV 500 mg–1 g (5–10 mL of 10% solution) every 1–3 d, depending on clinical response or serum calcium measurements</td>
</tr>
<tr>
<td>Calcium gluceptate 1.1 g/5 mL (5 mL contains 90 mg [4.5 mEq] of calcium)</td>
<td>IV 5–20 mL (90–360 mg calcium); IM 2–5 mL</td>
</tr>
<tr>
<td>Calcium gluconate (10 mL of 10% solution contains 93 mg [4.65 mEq] of calcium)</td>
<td>IV 5–20 mL of 10% solution</td>
</tr>
<tr>
<td><strong>Vitamin D Preparations</strong></td>
<td></td>
</tr>
<tr>
<td>Calcifediol (Calderol)</td>
<td>Dialysis patients, PO 50–100 mcg daily</td>
</tr>
<tr>
<td>Calcitriol (Rocaltril, Calcijex)</td>
<td>Dialysis patients, hypoparathyroidism, PO 0.25 mcg daily initially, then adjusted according to serum calcium levels (usual daily maintenance dose 0.5–1 mcg)</td>
</tr>
<tr>
<td>Cholecalciferol (Delta-D)</td>
<td>PO 400–1000 IU daily</td>
</tr>
<tr>
<td>Dihydrotachysterol (HytaKerol)</td>
<td>PO 0.75–2.5 mg daily for several days, then decreased (average daily maintenance dose, 0.6 mg)</td>
</tr>
<tr>
<td>Doxercalciferol (Hectorol)</td>
<td>Dialysis patients, PO 10 mcg three times weekly initially, increased if necessary. Maximum dose, 20 mcg three times weekly</td>
</tr>
<tr>
<td>Ergocalciferol (Calciferol, Drisdol)</td>
<td>Hypoparathyroidism, PO 50,000–200,000 units daily initially (average daily maintenance dose, 25,000–100,000 units)</td>
</tr>
<tr>
<td>Paricalcitol (Zemplar)</td>
<td>Dialysis patients, 0.04–0.1 mcg/kg every other day initially; increased by 2–4 mcg at 2- to 4-week intervals, if necessary. Reduce dosage or stop therapy if hypercalcemia occurs.</td>
</tr>
</tbody>
</table>
### Drugs at a Glance: Drugs Used in Hypercalcemia and Selected Bone Disorders

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bisphosphonates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alendronate (Fosamax)</td>
<td>Osteoporosis: Prevention and treatment in post-menopausal women</td>
<td>Osteoporosis: Postmenopausal women: Prevention, PO 5 mg once daily or 35 mg once weekly; treatment, PO 10 mg once daily or 70 mg once weekly Men, 10 mg once daily; Glucocorticoid-induced, 5 mg once daily Paget’s disease, PO 40 mg daily for 6 mo; repeated if necessary</td>
</tr>
<tr>
<td>Etidronate (Didronel)</td>
<td>Paget’s disease Hypercalcemia of malignancy Heterotopic ossification</td>
<td>Paget’s disease, PO 5–10 mg/kg/d up to 6 mo or 11–20 mg/kg/d up to 3 mo; may be repeated after 3 mo if symptoms recur Heterotopic ossification: with spinal cord injury, PO 20 mg/kg/d for 2 wk, then 10 mg/kg/d for 10 wk; with total hip replacement, PO 20 mg/kg/d for 1 mo before and 3 mo after surgery Hypercalcemia of malignancy, IV 7.5 mg/kg/d, in at least 250 mL of 0.9% sodium chloride solution and infused over at least 2 h, daily for 3–7 d</td>
</tr>
<tr>
<td>Pamidronate (Aredia)</td>
<td>Hypercalcemia of malignancy Osteolytic lesions of breast cancer metastases or multiple myeloma Paget’s disease</td>
<td>Hypercalcemia, IV 60 mg over 4 h; 90 mg over 24 h Osteolytic bone lesions, breast cancer IV 90 mg over 2 h every 3–4 wk; multiple myeloma, IV 90 mg over 4 h once monthly</td>
</tr>
<tr>
<td>Risedronate (Actonel)</td>
<td>Osteoporosis, postmenopausal and glucocorticoid-induced, prevention and treatment Paget’s disease</td>
<td>Paget’s disease, IV 30 mg over 4 h, daily for 3 doses Prevention and treatment of osteoporosis, PO 5 mg once daily or 35 mg once weekly</td>
</tr>
<tr>
<td>Tiludronate (Skelid)</td>
<td>Paget’s disease</td>
<td>Paget’s disease, PO 30 mg once daily for 2 mo</td>
</tr>
<tr>
<td>Zoledronate (Zometa)</td>
<td>Hypercalcemia of malignancy</td>
<td>PO 400 mg once daily for 3 mo IV 4 mg over 15 min or longer</td>
</tr>
<tr>
<td><strong>Calcitonin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcitonin-human (Cibacalcin)</td>
<td>Paget’s disease</td>
<td>SC 0.5 mg/d Hypercalcemia, SC, IM 4 IU/kg q12h; can be increased after 1 or 2 d to 8 IU/kg q12h; maximum dose, 8 IU/kg q6h</td>
</tr>
<tr>
<td>Calcitonin-salmon (Calcimar, Miacalcin)</td>
<td>Hypercalcemia Paget’s disease Postmenopausal osteoporosis</td>
<td>Paget’s disease, SC, IM 50–100 IU/d Postmenopausal osteoporosis, SC, IM 100 IU/d; nasal spray (Miacalcin) 200 IU/d</td>
</tr>
<tr>
<td><strong>Parathyroid Hormone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teriparatide (Forteo)</td>
<td>Osteoporosis</td>
<td>SC 20 mcg daily</td>
</tr>
<tr>
<td><strong>Miscellaneous Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Furosemide (Lasix)</td>
<td>Hypercalcemia</td>
<td>Adults: IV 80–100 mg q2h until a diuretic response is obtained or other treatment measures are initiated Children: IV 20–40 mg q4h until a diuretic response is obtained or other treatment measures are initiated PO 1–2 tablets three or four times daily, or contents of 1 capsule mixed with 75 mL of water four times daily</td>
</tr>
<tr>
<td>Phosphate salts (NeutraPhos)</td>
<td>Hypercalcemia</td>
<td>Prednisone PO 20–50 mg bid (or equivalent dose of another glucocorticoid) for 5–10 d, then tapered to the minimum dose required to prevent hypercalcemia</td>
</tr>
<tr>
<td>Prednisone or Hydrocortisone</td>
<td>Hypercalcemia</td>
<td>Hydrocortisone IM, IV 100–500 mg/d 4–6 L/d</td>
</tr>
<tr>
<td><strong>0.9% Sodium chloride injection</strong></td>
<td>Acute hypercalcemia</td>
<td></td>
</tr>
</tbody>
</table>
clients with breast cancer. In postmenopausal osteoporosis, these drugs may be used instead of estrogen therapy.

**Parathyroid Hormone**

Teriparatide (Forteo) is a recombinant DNA version of parathyroid hormone. It is approved for the treatment of osteoporosis in women. Other drugs for osteoporosis slow bone loss; teriparatide increases bone formation by increasing the number of bone-building cells (osteoblasts). It also increases serum levels of calcium and calcitriol (a metabolite of vitamin D that promotes absorption and use of calcium in bone-building). In clinical trials, it increased vertebral bone mineral density and decreased vertebral fractures. It is recommended for use in patients with severe osteoporosis or those who have not responded adequately to other treatments, partly because osteosarcoma developed in some animals given high doses for long periods. None developed in humans during clinical trials, but the longest of these trials was two years.

Teriparatide is rapidly and well absorbed with subcutaneous injection. Bioavailability is 95% and peak serum levels occur in 30 minutes. The drug is metabolized and excreted through the liver, kidneys, and bone. It is not expected to accumulate in bone or other tissues, to interact significantly with other drugs, or to require dosage adjustment with renal or hepatic impairment. Adverse effects include nausea, headache, back pain, dizziness, syncope, and leg cramps.

**Vitamin D Preparations**

Vitamin D is used in chronic hypocalcemia if calcium supplements alone cannot maintain serum calcium levels within normal range. It is also used to prevent deficiency states and treat hypoparathyroidism and osteoporosis. Although authorities agree that dietary intake is better than supplements, some suggest a vitamin D supplement for people who ingest less than the recommended amount (400 IU daily for those aged 6 months to 24 years; 200 IU for those 25 years of age and older). In addition, the recommended amount for older adults may be too low, especially for those who receive little exposure to sunlight, and dosage needs for all age groups may be greater during winter, when there is less sunlight. If used, vitamin D supplements should be taken cautiously and not overused; excessive amounts can cause serious problems, including hypercalcemia.

**Miscellaneous Drugs for Hypercalcemia**

Furosemide (Lasix) is a loop diuretic (see Chap. 56) that increases calcium excretion in urine by preventing its reabsorption in renal tubules. Although it can be given IV for rapid effects in acute hypercalcemia, opinions seem divided regarding its use. Some recommend its use once extracellular fluid volume has been restored and saline diuresis occurs with IV infusion of several liters of 0.9% sodium chloride. Others recommend its use only if evidence of fluid overload or heart failure develops. Thiazide diuretics are contraindicated in clients with hypercalcemia because they decrease urinary excretion of calcium.

**Phosphate salts** (Neutra-Phos) inhibit intestinal absorption of calcium and increase deposition of calcium in bone. Oral salts are effective in the treatment of hypercalcemia of any etiology. A potential adverse effect of phosphates is calcification of soft tissues due to deposition of calcium phosphate. This can lead to severe impairment of function in the kidneys and other organs. Phosphates should be given only when hypercalcemia is accompanied by hypophosphatemia (serum phosphorus < 3 mg/dL) and renal function is normal, to minimize the risk of soft tissue calcification. Serum calcium, phosphorus, and creatinine should be monitored frequently and the dose should be reduced if serum phosphorus exceeds 4.5 mg/dL or the product of serum calcium and phosphorus (measured in milligrams per deciliter) exceeds 60. Neutra-Phos is an oral combination of sodium phosphate and potassium phosphate.

**Sodium chloride (0.9%) injection** (normal saline) is an IV solution containing water, sodium, and chloride. It is included here because it is the treatment of choice for hypercalcemia and is usually effective. The sodium contained in the solution inhibits the reabsorption of calcium in renal tubules and thereby increases urinary excretion of calcium. The solution also relieves the dehydration caused by vomiting and polyuria, and it dilutes the calcium concentration of serum and urine. Several liters are given daily. The client should be monitored closely for signs of fluid overload and serum calcium, magnesium, and potassium levels should be measured every 6 to 12 hours. Large amounts of magnesium and potassium are lost in the urine and adequate replacement is essential.

**Nursing Notes: Apply Your Knowledge**

Ms. Sadie Evans had a subtotal thyroidectomy 2 days ago. When you perform your morning assessment, she complains of tingling in her fingers. What additional data should be collected at this time?

with...
10.5 mg/dL (SI units 2.2 to 2.6 mmol/L). Approximately half of the total serum calcium (eg, 4 to 5 mg/dL) should be free ionized calcium, the physiologically active form. To interpret serum calcium levels accurately, serum albumin levels and acid–base status must be considered. Low serum albumin decreases the total serum level of calcium by decreasing the amount of calcium that is bound to protein. However, the ionized concentration is normal. Metabolic and respiratory alkalosis increase binding of calcium to serum proteins, thereby maintaining normal total serum calcium but decreasing the ionized values. Conversely, metabolic and respiratory acidosis decrease binding and therefore increase the concentration of ionized calcium.

- Check for Chvostek’s sign: Tap the facial nerve just below the temple, in front of the ear. If facial muscles twitch, hyperirritability of the nerve and potential tetany are indicated.
- Check for Trousseau’s sign: Constrict blood circulation in an arm (usually with a blood pressure cuff) for 3 to 5 minutes. This produces ischemia and increased irritability of peripheral nerves, which causes spasms of the lower arm and hand muscles (carpopedal spasm) if tetany is present.
- Assess for conditions in which hypercalcemia is likely to occur (eg, cancer, prolonged immobilization, vitamin D overdose).
- Observe for signs and symptoms of hypercalcemia in clients at risk. Electrocardiogram changes indicative of hypercalcemia include a shortened Q-T interval and an inverted T wave.
- Assess for risk factors and manifestations of osteoporosis, especially in postmenopausal women and men and women on chronic corticosteroid therapy:
  - If risk factors are identified, ask if preventive measures are being used (eg, increasing calcium intake, exercise, medications)
  - If the client is known to have osteoporosis, ask about duration and severity of symptoms, age of onset, location, whether fractures have occurred, what treatments have been done, and response to treatments.
  - If Paget’s disease is suspected, assess for an elevated serum alkaline phosphatase and abnormal bone scan reports.

**Nursing Diagnoses**

- Deficient Knowledge: Recommended daily amounts and dietary sources of calcium and vitamin D
- Deficient Knowledge: Disease process and drug therapy for osteoporosis
- Risk for Injury: Tetany, sedation, seizures from hypercalcemia
- Risk for Injury: Hypercalcemia related to overuse of supplements; hypocalcemia from aggressive treatment of hypercalcemia

**Planning/Goals**

*The client will:*

- Achieve and maintain normal serum levels of calcium
- Increase dietary intake of calcium-containing foods to prevent or treat osteoporosis
- Use calcium or vitamin D supplements in recommended amounts
- Comply with instructions for safe drug use
- Be monitored closely for therapeutic and adverse effects of drugs used to treat hypercalcemia
- Comply with procedures for follow-up treatment of hypocalcemia, hypercalcemia, or osteoporosis
- Avoid preventable adverse effects of treatment for acute hypocalcemia or hypercalcemia

**Interventions**

Assist all clients in meeting the recommended daily requirements of calcium and vitamin D. With an adequate protein and calcium intake, enough phosphorus also is obtained.

- The best dietary source is milk and other dairy products, including yogurt.
- Unless contraindicated by the client’s condition, recommend that adults drink at least two 8-oz glasses of milk daily. This furnishes approximately half the daily calcium requirement; the remainder will probably be obtained from other foods.
- Children need approximately four glasses of milk or an equivalent amount of calcium in milk and other foods to support normal growth and development.
- Pregnant and lactating women also need approximately four glasses of milk or their equivalents to meet increased needs. Vitamin and mineral supplements are often prescribed during these periods.
- Postmenopausal women who take estrogens need at least 1000 mg daily. Those who do not take estrogens need at least 1500 mg.
- For clients who avoid or minimize their intake of dairy products because of the calories, identify low-calorie alternatives, such as skim milk and low-fat yogurt.
- Milk that has been fortified with vitamin D is the best food source. Exposure of skin to sunlight is also needed to supply adequate amounts of vitamin D.
- For people who are unable or unwilling to ingest sufficient calcium, a supplement may be needed to prevent osteoporosis.

Assist clients with hypercalcemia to decrease formation of renal calculi by forcing fluids to approximately 3000 to 4000 mL/day and preventing urinary tract infections.

**Evaluation**

- Check laboratory reports of serum calcium levels for normal values.
- Interview and observe for relief of symptoms of hypocalcemia, hypercalcemia, or osteoporosis.
- Interview and observe intake of calcium-containing foods.
- Question about normal calcium requirements and how to meet them.
- Interview and observe for accurate drug usage and compliance with follow-up procedures.
- Interview and observe for therapeutic and adverse drug effects.
CHAPTER 26 HORMONES THAT REGULATE CALCIUM AND BONE METABOLISM

PRINCIPLES OF THERAPY

Management of Hypocalcemia

Treatment of hypocalcemia includes giving a calcium preparation and perhaps vitamin D.

1. Acute, severe hypocalcemia is a medical emergency and requires IV administration of calcium, usually 10 to 20 mL of 10% calcium gluconate (1 to 2 g of calcium). Doses may be repeated, a continuous infusion may be given, or oral supplements may be used to avoid symptoms of hypocalcemia and maintain normal serum calcium levels (as measured every 4 to 6 hours). Once the condition is stabilized, treatment is aimed toward the underlying cause or preventing recurrence. Serum magnesium levels should also be measured, and, if hypomagnesemia is present, it must be treated before treatment of hypocalcemia can be effective.

2. For less acute situations or for long-term treatment of chronic hypocalcemia, oral calcium supplements are preferred. Vitamin D is given also if a calcium preparation alone cannot maintain serum calcium levels within a normal range.

3. Calcium deficits caused by inadequate dietary intake affect bone tissue rather than serum calcium levels. Calcium supplements can decrease bone loss and fractures, especially in women. Calcium carbonate contains the most elemental calcium by weight (40%) and is inexpensive. It is available in the nonprescription antacid called Tums. Calcium citrate is reportedly better absorbed than calcium carbonate.

4. If hypocalcemia is caused by diarrhea or malabsorption, treatment of the underlying condition decreases loss of calcium from the body and increases absorption.

5. When vitamin D is given to treat hypocalcemia, dosage is determined by frequent measurement of serum calcium levels. Usually, higher doses are given initially and lower doses for maintenance therapy.

6. Calcium salts and vitamin D are combined in many over-the-counter preparations promoted as dietary supplements (Table 26–1). These preparations contain variable amounts of calcium and vitamin D. Calcium 600 mg and vitamin D 200 IU once or twice daily are

CLIENT TEACHING GUIDELINES

Drugs for Osteoporosis

General Considerations

✔ Osteoporosis involves weak bones that fracture easily and may cause pain and disability.

✔ Important factors in prevention and treatment include an adequate intake of calcium and vitamin D (from the diet, from supplements, or a combination of both sources), regular weight-bearing exercise, and drugs that can slow bone loss.

✔ It is better to obtain calcium and vitamin D from foods such as milk and other dairy products. Approximately 1000 to 1500 mg of calcium and 400 IU of vitamin D are recommended daily.

✔ If unable to get sufficient dietary calcium and vitamin D, consider supplements of these nutrients. Consult a health care provider about the types and amounts. For example, a daily multivitamin and mineral supplement may contain adequate amounts when added to dietary intake. If taking other supplements, avoid those containing bone meal because they may contain lead and other contaminants that are toxic to the human body. Do not take more than the recommended amounts of supplements; overdose can cause serious, life-threatening problems.

✔ The main drugs approved for prevention and treatment of osteoporosis are the bisphosphonates (eg, Fosamax, Actonel). These drugs help prevent the loss of calcium from bone, thereby strengthening bone and reducing the risks of fractures.

✔ For people at high risk for development of osteoporosis (eg, postmenopausal women, men and women who take an oral or inhaled corticosteroid such as prednisone or fluticasone [Flonase]), or those being treated for osteoporosis, a baseline measurement of bone mineral density and periodic follow-up measurements are needed. This is a noninvasive test that does not involve any injections or device insertions.

Self-Administration

✔ If taking a calcium supplement, calcium carbonate 500 mg twice daily is often recommended. This can be obtained from an inexpensive over-the-counter antacid called Tums, which contains 200 mg of calcium per tablet.

✔ Do not take a calcium supplement with an iron preparation, tetracycline, ciprofloxacin, or phenytoin. Instead, take the drugs at least 2 hours apart to avoid calcium interference with absorption of the other drugs.

✔ If taking both a calcium supplement and a bisphosphonate, take the calcium at least 2 hours after the bisphosphonate. Calcium, antacids, and other drugs interfere with absorption of bisphosphonate.

✔ Take bisphosphonates with 6 to 8 oz of water at least 30 minutes before any food, other fluid, or other medication. Beverages other than water and foods decrease absorption and effectiveness.

✔ Take a bisphosphonate in an upright position and do not lie down for at least 30 minutes. This helps prevent esophageal irritation and stomach upset.
often recommended for postmenopausal women with osteoporosis. In general, intake of calcium should not exceed 2500 mg daily, from all sources, and intake of vitamin D should not exceed 400 IU daily. These mixtures are not indicated for maintenance therapy in chronic hypocalcemia.

7. Calcium preparations and digoxin have similar effects on the myocardium. Therefore, if calcium is given to a digitalized client, the risks of digitalis toxicity and cardiac dysrhythmias are increased. This combination must be used very cautiously.

8. Oral calcium preparations decrease effects of oral tetracycline drugs by combining with the antibiotic and preventing its absorption. They should not be given at the same time or within 2 to 3 hours of each other.

Management of Hypercalcemia

Clients at risk for hypercalcemia should be monitored for early signs and symptoms so treatment can be started before severe hypercalcemia develops. Treatment depends largely on the cause and severity.

1. When hypercalcemia is caused by a tumor of parathyroid tissue, the usual treatment is surgical excision. When it is caused by malignant tumor, treatment of the tumor with surgery, irradiation, or chemotherapy may reduce production of PTH. When it is caused by excessive intake of vitamin D, the vitamin D preparation should be stopped immediately.

2. Acute hypercalcemia is a medical emergency. It is treated with interventions that increase calcium excretion in the urine and decrease resorption of calcium from bone into the serum. For severe symptoms or a serum calcium level above 12 mg/dL, the priority is rehydration. This need can be met by IV saline infusion (0.9% or 0.45% NaCl) 4000 mL/day or more if kidney function is adequate. After rehydration, furosemide may be given IV to increase renal excretion of calcium and prevent fluid overload. Because sodium, potassium, and water are also lost in the urine, these must be replaced in the IV fluids.

With mild hypercalcemia, most clients respond to the aforementioned treatment, and further drug therapy is not needed. With moderate to severe hypercalcemia, pamidronate or zoledronate may be the drug of choice. When pamidronate is given in a single IV infusion containing 60 or 90 mg, serum calcium levels decrease within 2 days, reach their lowest levels in approximately 7 days, and remain lower for 2 weeks or longer. Treatment can be repeated if hypercalcemia recurs. Zoledronate can be given over 15 minutes and effects may last longer than those of pamidronate. Adverse effects of the two drugs are similar. Phosphates should not be used unless hypophosphatemia is present. They are also contraindicated in clients with persistent urinary tract infections and an alkaline urine because calcium phosphate kidney stones are likely to form in such cases.

3. Chronic hypercalcemia requires treatment of the underlying disease process and measures to control serum calcium levels (eg, a high fluid intake and mobilization to help retain calcium in bone). Oral phosphate administration may help if other measures are ineffective.

4. Serum calcium levels should be measured periodically to monitor effects of therapy.

5. For clients with severely impaired renal function in whom hypercalcemia develops, hemodialysis or peritoneal dialysis with a calcium-free solution is effective and safe.

6. For clients receiving a calcium channel blocker (see Chap. 53), the drug may be less effective in the presence of hypercalcemia.

Prevention of Osteoporosis

Preventive measures should be implemented for all age groups to avoid or slow bone loss.

1. In all age groups, preventive efforts include a consistently adequate dietary intake of calcium to promote normal bone development and maintenance. In children, adolescents, and young adults, an adequate calcium intake promotes bone growth and peak bone mass. A well-stocked “reservoir” means that, in later years when bone loss exceeds formation, more bone can be lost before osteoporosis develops. In postmenopausal women and men older than 40 years of age, an adequate calcium intake may slow the development of osteoporosis and fractures. Although dietary intake is much preferred, a supplement may be needed to ensure a daily intake of 1000 to 1500 mg, especially in adolescent girls, frail elderly, and those receiving corticosteroids.

2. Regular exercise is also important in all age groups. Vigorous, weight-bearing exercise helps to promote and maintain strong bone; inactivity promotes bone weakening and loss.
3. Women who smoke should be encouraged to stop. Smoking decreases the amount of active estrogen in the body and thus accelerates bone loss.
4. Alendronate (Fosamax) and risedronate (Actonel) are approved by the Food and Drug Administration (FDA) for prevention of osteoporosis. With alendronate, recommended dosage is smaller for prevention than for treatment.
5. Raloxifene (Evista) is approved for prevention of postmenopausal osteoporosis in women who are unable or unwilling to take ERT.
6. An adequate intake of vitamin D helps to prevent osteoporosis, but supplementation is probably not indicated unless a deficiency can be demonstrated. Serum calcitriol can be measured in clients at risk for vitamin D deficiency, including elderly adults and those on chronic corticosteroid therapy.
7. Preventive measures are needed for clients on chronic corticosteroid therapy (eg, prednisone 7.5 mg daily, equivalent amounts of other systemic drugs, or high doses of inhaled drugs). For both men and women, most of the preceding guidelines apply (eg, calcium supplements, regular exercise, a bisphosphonate drug). In addition, low doses and nonsystemic routes help prevent osteoporosis and other adverse effects. For men, corticosteroids decrease testosterone levels by approximately one half, and replacement therapy may be needed.

**Management of Osteoporosis**

Once bone loss is evident (from diagnostic tests of bone density or occurrence of fractures), several interventions may help slow further skeletal bone loss or prevent fractures. Most drugs used to treat osteoporosis decrease the rate of bone breakdown and thus slow the rate of bone loss; a newer drug, teriparatide (Forteo), actually increases bone formation.

1. As with prevention, those diagnosed with osteoporosis need adequate calcium and vitamin D (at least the recommended dietary allowance), whether obtained from the diet or from supplements. Pharmacologic doses of vitamin D are sometimes used to treat clients with serious osteoporosis. If such doses are used, caution should be exercised because excessive amounts of vitamin D can cause hypercalcemia and hypercalciuria.
2. Regular exercise is needed. Numerous studies indicate that regular physical activity helps to reduce bone loss and fractures.
3. Women who smoke should be encouraged to stop because smoking has effects similar to those of menopause (estrogen deficiency and accelerated bone loss).
4. Alendronate (Fosamax), 10 mg daily or 70 mg weekly, and risedronate (Actonel), 5 mg daily, are Food and Drug Administration (FDA) approved for treatment of osteoporosis in postmenopausal women. The drugs can increase bone mineral density, reduce risks of vertebral fractures, and slow progression of vertebral deformities and loss of height. One of these drugs is often used in combination with estrogen and calcium and vitamin D supplements.
5. Treatment of men is similar to that of women except that testosterone replacement may be needed.
6. With corticosteroid-induced osteoporosis, multiple treatment measures may be needed, including increased dietary and supplemental calcium and possibly vitamin D supplementation, hormone replacement, corticosteroid dosage reduction, exercise, and a bisphosphonate or calcitonin to slow skeletal bone loss.

**Use in Children**

Hypocalcemia is uncommon in children. However, inadequate calcium in the diet is thought to be common, especially in girls. Inadequate calcium and exercise in children are risk factors for eventual osteoporosis. If hypocalcemia or dietary calcium deficiency develops, principles of using calcium or vitamin D supplements are the same as those in adults. Children should be monitored closely for signs and symptoms of adverse effects, including hypercalcemia. Hypercalcemia is probably most likely to occur in children with a malignant tumor. Guidelines for treating hypercalcemia in children are essentially the same as those for adults, with drug dosages adjusted. Safety, effectiveness, and dosages of etidronate, pamidronate, and zoledronate have not been established.

**Use in Older Adults**

Hypocalcemia is uncommon because calcium moves from bone to blood to maintain normal serum levels. However, calcium deficiency commonly occurs because of long-term dietary deficiencies of calcium and vitamin D, impaired absorption of calcium from the intestine, lack of exposure to sunlight, and impaired liver or kidney metabolism of vitamin D to its active form. These and other factors lead to demineralization and weakening of bone (osteoporosis) and an increased risk of fractures. Postmenopausal women are at high risk for development of osteoporosis. Although osteoporosis also develops in older men, it occurs less often, at a later age, and to a lesser extent.

---

**How Can You Avoid This Medication Error?**

Mrs. Wenzel, an 86-year-old nursing home resident, has been taking alendronate (Fosamax), 10 mg ac breakfast for her severe osteoporosis. You approach Mrs. Wenzel before breakfast to administer the Fosamax. She states, “I’m feeling so tired this morning, I think I will just skip breakfast and sleep a little longer this morning.” You encourage her to take her Fosamax anyway because it is important to prevent fractures. She does so with a sip of water and sends you on your way.
than in older women. Both men and women who take corticosteroids are at risk of developing osteoporosis. The risk is higher with systemic corticosteroids but may also occur with oral or nasal inhalation, especially at higher doses. In general, all older adults need to continue their dietary intake of dairy products and other calcium-containing foods. Older adults with osteoporosis or risk factors for developing osteoporosis may need calcium supplements, and a bisphosphonate or calcitonin to prevent or treat the disorder.

With hypercalcemia, treatment usually requires large amounts of IV 0.9% sodium chloride (eg, 150 to 200 mL/hour). Older adults often have chronic cardiovascular disorders that may be aggravated by this treatment. They should be monitored closely for signs of fluid overload, congestive heart failure, pulmonary edema, and hypertension.

Use in Renal Impairment

Clients with renal impairment or failure often have disordered calcium and bone metabolism. Calcium acetate may be used to prevent or treat hyperphosphatemia. The calcium reduces blood levels of phosphate by reducing its absorption from foods. That is, calcium binds with dietary phosphate to produce calcium phosphate, which is insoluble and excreted in feces. If vitamin D therapy is needed to treat osteomalacia associated with renal impairment, calcitriol (Rocaltrol) or dihydrotachysterol (Hytakerol) is preferred. Calcitriol is the active form of vitamin D and thus requires no metabolism; dihydrotachysterol is a synthetic compound that is metabolized in the liver but not in the kidneys.

None of the bisphosphonate drugs is recommended for use in severe renal impairment (eg, serum creatinine > 5 mg/dL or creatinine clearance < 30 mL/minute). With alendronate, dosage does not need to be reduced in mild to moderate impairment (eg, creatinine clearance 35 to 60 mL/minute). Etidronate should be used cautiously with mild renal impairment and is contraindicated with severe renal impairment. Pamidronate and zoledronate are nephrotoxic and renal function should be closely monitored during their use.

Teriparatide (Forteo), a form of parathyroid hormone, apparently does not require dosage adjustment in renal impairment.

Use in Hepatic Impairment

If vitamin D therapy is needed for a client with impaired liver function, calcifediol (Calderol) is preferred because it does not require liver metabolism.

The bisphosphonates are not metabolized in the liver and are unlikely to affect liver function. Teriparatide (Forteo), a form of parathyroid hormone, apparently does not require dosage adjustment in hepatic impairment.

Home Care

The home care nurse has an excellent opportunity to promote health and prevent illness related to calcium and bone disorders. All members of a household should be assessed in relation to calcium and vitamin D intake because an adequate amount of these nutrients is needed throughout life. Children, adolescent girls, and older women often have inadequate intakes, with risks of having or developing osteoporosis. Teaching may be needed about dietary and supplemental sources of these nutrients, as well as the adverse effects of excessive amounts. Teaching or other assistance may also be needed by clients who are receiving medications to prevent or treat osteoporosis.

If assisting in the care of any seriously ill client, the nurse should also be able to recognize and obtain immediate treatment for hypocalcemia or hypercalcemia. For example, hypercalcemia may occur in clients with cancer, especially cancers involving bone.
# Drugs Used in Calcium and Bone Disorders

## NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
</table>

### 1. Administer accurately

**a.** With calcium preparations:

1. Give oral preparations with or after meals.
2. Give intravenous (IV) preparations slowly (0.5–2 mL/min), check pulse and blood pressure closely, and monitor the electrocardiogram (ECG) if possible.
3. Do not mix IV preparations with any other drug in the same syringe.

**b.** With bisphosphonates:

1. Give alendronate and risedronate with 6–8 oz of plain water, at least 30 min before the first food, beverage, or medication of the day.
2. Give oral etidronate on an empty stomach, as a single dose or in divided doses. Avoid giving within 2 h of ingesting dairy products, antacids, or vitamin or mineral preparations.
3. Give IV etidronate, pamidronate, and zoledronate according to the manufacturers’ instructions.

**c.** Give calcitonin at bedtime.

**d.** With phosphate salts, mix powder forms with water for oral administration. See package inserts for specific instructions.

### 2. Observe for therapeutic effects

**a.** With calcium preparations, observe for:

1. Relief of symptoms of neuromuscular irritability and tetany, such as decreased muscle spasms and decreased paresthesias
2. Serum calcium levels within the normal range (8.5–10.5 mg/dL)
3. Absence of Chvostek’s and Trousseau’s signs

**b.** With alendronate or risedronate for osteoporosis, observe for improved bone mass density and absence of fractures.

**c.** With calcitonin, corticosteroids, pamidronate, or zoledronate for hypercalcemia, observe for:

1. Decreased serum calcium level
2. Decreased signs and symptoms of hypercalcemia

### 3. Observe for adverse effects

**a.** With calcium preparations, observe for hypercalcemia:

1. GI effects—anorexia, nausea, vomiting, abdominal pain, constipation
2. Central nervous system effects—apathy, poor memory, depression, drowsiness, disorientation

To increase absorption

These solutions may cause dysrhythmias and hypotension if injected rapidly. They are also irritating to tissues.

Calcium reacts with some other drugs and forms a precipitate.

To promote absorption and decrease esophageal and gastric irritation

If gastrointestinal (GI) symptoms occur with the single dose, divided doses may relieve them. Substances containing calcium or other minerals decrease absorption of etidronate.

These drugs require reconstitution, diluting with IV fluids, and specific time intervals of administration.

To decrease nausea and discomfort from flushing

Early osteopenia and osteoporosis are asymptomatic. Measurement of bone mass density is the only way to quantify bone loss.

Calcitonin lowers serum calcium levels in about 2 h after injection and effects last 6–8 h. Corticosteroids require 10–14 days to lower serum calcium. Bisphosphonates lower serum calcium levels within 2 days, but may require a week or more to produce normal serum calcium levels.

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3) Other effects—weakness and decreased tone in skeletal and smooth muscles, dysphagia, polyuria, polydipsia, cardiac dysrhythmias</td>
<td>This is most likely to occur with chronic ingestion of high doses daily. In children, accidental ingestion may lead to acute toxicity.</td>
</tr>
<tr>
<td>(4) Serum calcium &gt;10.5 mg/dL.</td>
<td>Adverse effects are usually minor with the doses taken for prevention or treatment of osteoporosis, if the drugs are taken as directed. More severe effects may occur with the higher doses taken for Paget’s disease.</td>
</tr>
<tr>
<td>(5) ECG changes indicating hypercalcemia (a prolonged Q-T interval and an inverted T wave)</td>
<td>Adverse effects are usually mild and transient. Nasal administration produces greater client compliance than injections, with few adverse effects.</td>
</tr>
<tr>
<td><strong>b.</strong> With vitamin D preparations, observe for hypervitaminosis D and hypercalcemia (see above).</td>
<td>Hypocalcemia may occur with vigorous treatment of hypercalcemia. This can be minimized by monitoring serum calcium levels frequently and adjusting drug dosages and other treatments.</td>
</tr>
<tr>
<td><strong>c.</strong> With alendronate and risedronate, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) GI effects—abdominal distention, acid regurgitation, dysphagia, esophagitis, flatulence</td>
<td></td>
</tr>
<tr>
<td>(2) Other effects—headache, musculoskeletal pain, decreased serum calcium and phosphate</td>
<td></td>
</tr>
<tr>
<td><strong>d.</strong> With calcitonin, observe for nausea, vomiting, tissue irritation at administration sites, and allergic reactions.</td>
<td></td>
</tr>
<tr>
<td><strong>e.</strong> With drug therapy of hypercalcemia, observe for hypocalcemia.</td>
<td></td>
</tr>
<tr>
<td><strong>f.</strong> With pamidronate and zoledronate, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) GI effects—anorexia, nausea, vomiting, constipation</td>
<td>Adverse effects are more frequent and more severe at higher doses. The drug is nephrotoxic and should not be used in clients with renal failure.</td>
</tr>
<tr>
<td>(2) Cardiovascular effects—fluid overload, hypertension</td>
<td></td>
</tr>
<tr>
<td>(3) Electrolyte imbalances—hypokalemia, hypomagnesemia, hypophosphatemia</td>
<td></td>
</tr>
<tr>
<td>(4) Musculoskeletal effects—muscle and joint pain</td>
<td></td>
</tr>
<tr>
<td>(5) Miscellaneous effects—fever, tissue irritation at IV insertion site, pain, anemia</td>
<td></td>
</tr>
<tr>
<td><strong>g.</strong> With etidronate, observe for anorexia, nausea, diarrhea, bone pain, fever, fluid overload, and increased serum creatinine.</td>
<td></td>
</tr>
<tr>
<td><strong>h.</strong> With phosphates, observe for nausea, vomiting, and diarrhea.</td>
<td></td>
</tr>
</tbody>
</table>

4. **Observe for drug interactions**

   **a.** Drugs that increase effects of calcium:
   
   (1) Vitamin D
   
   (2) Thiazide diuretics
   
   **b.** Drugs that decrease effects of calcium: Corticosteroids (prednisone, others), calcitonin, and phosphates
   
   **c.** Drugs that increase effects of vitamin D: Thiazide diuretics
   
   **d.** Drugs that decrease effects of vitamin D:
   
   (1) Phenytoin
   
   (2) Cholestyramine resin (Questran)

   | (continued) |
381

**NURSING ACTIONS**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(3)</td>
<td>Mineral oil</td>
</tr>
<tr>
<td>e.</td>
<td>Drugs that decrease effects of alendronate and other oral bisphosphonates: Antacids and calcium supplements</td>
</tr>
<tr>
<td>f.</td>
<td>Drugs that alter effects of calcitonin:</td>
</tr>
<tr>
<td></td>
<td>(1) Testosterone and other androgens increase effects.</td>
</tr>
<tr>
<td></td>
<td>(2) Parathyroid hormone decreases effects.</td>
</tr>
<tr>
<td>g.</td>
<td>Drugs that decrease effects of phosphate salts: Antacids containing aluminum and magnesium</td>
</tr>
</tbody>
</table>

**RATIONALE/EXPLANATION**

Mineral oil is a fat and therefore combines with fat-soluble vitamins, such as vitamin D, and prevents their absorption from the gastrointestinal tract.

These drugs interfere with absorption of bisphosphonates and should be taken at least 2 h after a bisphosphonate.

Androgens and calcitonin have additive effects on calcium retention and inhibition of bone resorption (movement of calcium from bone to serum).

Parathyroid hormone antagonizes or opposes calcitonin. Aluminum and magnesium may combine with phosphate and thereby prevent its absorption and therapeutic effect.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Tingling may be a symptom of hypocalcemia. Hypocalcemia can occur in Ms. Evans because, during her thyroid surgery, the parathyroid glands that maintain calcium balance could have been damaged or inadvertently removed. Assess Chvostek’s sign by tapping on Ms. Evans’ face just above the temple, observing for twitching, which indicates hypocalcemia. Trousseau’s sign can be assessed by constricting circulation in the arm by inflicting a blood pressure cuff and observing for spasms of the lower arm and hand. Serum calcium levels should be obtained and compared with previous readings. Normal values are 8.5 to 10.5 mg/dL and must be adjusted when albumin levels are low. Report hypocalcemia or signs of tetany to the physician so that calcium replacement can be promptly administered.

**How Can You Avoid This Medication Error?**

**Answer:** It is very important to administer Fosomax with the patient in an upright sitting position, on an empty stomach with a full glass of water. Mrs. Wenzel had not eaten breakfast, so absorption of the Fosomax was good. But because Mrs. Wenzel swallowed the Fosomax with only a sip of water while she was in bed (probably not in an upright position), the potential for esophagitis was increased. Esophagitis, sometimes resulting in ulceration of the esophagus, can occur when the drug does not completely pass through the esophagus into the stomach. Since this complication can be very serious, it is important to always administer Fosomax with a full glass of water and have the patient remain sitting or standing for at least 30 minutes after administration. Lying down can increase the chance of gastric reflux. Do not chew the tablet. The physician should be notified if the patient experiences increased heartburn, pain upon swallowing, or difficulty swallowing.

---

**Review and Application Exercises**

1. What are the major physiologic functions of calcium?
2. What is the normal serum level of calcium?

---

**SELECTED REFERENCES**

Antidiabetic Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe major effects of endogenous insulin on body tissues.
2. Discuss insulins and insulin analogs in terms of characteristics and uses.
3. Discuss the relationships among diet, exercise, and drug therapy in controlling diabetes.
4. Differentiate types of oral antidiabetic agents in terms of mechanisms of action, indications for use, adverse effects, and nursing process implications.
5. Explain the benefits of maintaining glycemic control in preventing complications of diabetes.
6. State reasons for combinations of insulin and oral agents or different types of oral agents.
7. Assist clients or caregivers in learning how to manage diabetes care, including administration of antidiabetic medications.
8. Collaborate with nurse diabetes educators, dietitians, and others in teaching self-care activities to clients with diabetes.
10. Discuss dietary and herbal supplements that affect blood sugar and diabetes control.

Critical Thinking Scenario
You are assigned to care for Ellen Rodriguez, a 13-year-old, who was admitted to the intensive care unit 12 hours ago in acute ketoacidosis. Her blood glucose level has stabilized after emergency treatment. She lives with her mother (a single parent) and five younger siblings in public housing within the Latino community. The diagnosis of diabetes mellitus is completely unexpected. Her mother asks why Ellen has to take shots, because her aunt did just fine on pills.

Ellen will be discharged in 2 to 3 days on insulin, glucose monitoring before meals and at bedtime, and a diabetic diet. Use the following questions to think about and plan Ellen’s care.

► Visualize yourself as Ellen and try to verbalize how you might feel. Now visualize yourself as Ellen’s mother and again try to explain how you are feeling. Compare and contrast these two pictures.
► Reflect on developmental and socioeconomic factors that need to be considered when planning Ellen’s care.
► Role play how you might answer Ellen’s mother’s question concerning why her daughter needs to inject insulin rather than take pills to manage her diabetes.
► Before discharge, you have three teaching sessions of approximately 30 minutes each. Prioritize essential teaching and describe your teaching plan for Ellen.
► Discuss appropriate postdischarge follow-up to continue diabetic teaching and monitor compliance with prescribed management strategies.

OVERVIEW
Insulin and oral agents are the two types of drugs used to lower blood glucose in diabetes mellitus. To assist readers in understanding the clinical use of these drugs, characteristics of endogenous insulin, diabetes, and the drugs are described.

ENDOGENOUS INSULIN
Insulin is a protein hormone secreted by beta cells in the pancreas. The average adult pancreas secretes 40 to 60 units of insulin daily. This includes a basal amount of 1 to 2 units/hour and additional amounts (4 to 6 units/hour) after meals or when the blood sugar exceeds 100 mg/dL. In a fasting state, serum
insulin levels are low and stored glucose and amino acids are used for energy needs of tissues that require glucose. After a meal, serum insulin levels increase and peak in a few minutes, then decrease to baseline levels in 2 to 3 hours.

Insulin is secreted into the portal circulation and transported to the liver, where about half is used or degraded. The other half reaches the systemic circulation, where it circulates mainly in an unbound form and is transported to body cells.

At the cellular level (Fig. 27–1), insulin binds with and activates receptors on the cell membranes of about 80% of body cells. Liver, muscle, and fat cells have many insulin receptors and are primary tissues for insulin action. After insulin–receptor binding occurs, cell membranes become highly permeable to glucose and allow rapid entry of glucose into the cells. The cell membranes also become more permeable to amino acids, fatty acids, and electrolytes such as potassium, magnesium, and phosphate ions. Cellular metabolism is altered by the movement of these substances into the cells, activation of some enzymes and inactivation of others, movement of proteins between intracellular compartments, changes in the amounts of proteins produced, and perhaps other mechanisms. Overall, the changes in cellular metabolism stimulate anabolic effects (eg, utilization and storage of glucose, amino acids, and fatty acids) and inhibit catabolic processes (eg, breakdown of glycogen, fat, and protein). After binding to insulin and entering the cell, receptors may be degraded or recycled back to the cell surface.

Insulin is cleared from circulating blood in 10 to 15 minutes because of rapid binding to peripheral tissues or metabolic breakdown. The insulin that does not combine with receptors is metabolized in the liver, kidneys, plasma, and muscles. In the kidneys, insulin is filtered by the glomeruli and reabsorbed by the tubules, which also degrade it. Severe renal impairment slows the clearance of insulin from the blood.

Insulin plays a major role in metabolism of carbohydrate, fat, and protein (Box 27–1). These foodstuffs are broken down into molecules of glucose, lipids, and amino acids, respectively. The molecules enter the cells and are converted to energy for cellular activities. The energy can be used immediately or converted to storage forms for later use. When carrying out its metabolic functions, the overall effect of insulin is to lower blood glucose levels, primarily by the following mechanisms:

1. In the liver, insulin acts to decrease breakdown of glycogen (glycogenolysis), formation of new glucose from fatty acids and amino acids (gluconeogenesis), and formation of ketone bodies (ketogenesis). At the same time, it acts to increase synthesis and storage of glycogen and fatty acids.
2. In adipose tissue, insulin acts to decrease breakdown of fat (lipolysis) and to increase production of glycerol and fatty acids.
3. In muscle tissue, insulin acts to decrease protein breakdown and amino acid output and to increase amino acid uptake, protein synthesis, and glycogen synthesis.

**Regulation of Insulin Secretion**

Insulin, the only hormone that decreases blood sugar, regulates the amount of glucose available for cellular metabolism and energy needs, during both fasting and feeding. Insulin
secretion involves coordination of various nutrients, hormones, the autonomic nervous system, and other factors.

Glucose is the major stimulus of insulin secretion; others include amino acids, fatty acids, ketone bodies, and stimulation of beta2-adrenergic receptors or vagal nerves. Oral glucose is more effective than intravenous glucose because glucose or food in the digestive tract induces the release of gastrointestinal (GI) hormones (eg, gastrin, secretin, cholecystokinin, gastric inhibitory peptide) and stimulates vagal activity. Other hormones that raise blood glucose levels and stimulate insulin secretion include cortisol, glucagon, growth hormone, epinephrine, estrogen, and progesterone. Excessive, prolonged endogenous secretion or administration of pharmacologic preparations of these hormones can exhaust the ability of pancreatic beta cells to produce insulin and thereby cause or aggravate diabetes mellitus.

Factors that inhibit insulin secretion include stimulation of pancreatic alpha2-adrenergic receptors and stress conditions such as hypoxia, hypothermia, surgery, or severe burns.

**DIABETES MELLITUS**

Diabetes mellitus is a chronic systemic disease characterized by metabolic and vascular abnormalities. Metabolic problems occur early in the disease process and are related to changes in the metabolism of carbohydrate, fat, and protein. A major clinical manifestation of disordered metabolism is hyperglycemia.

Vascular problems include atherosclerosis throughout the body and changes in small blood vessels, which especially affect the retina and kidney. Clinical manifestations of vascular disorders may include hypertension, myocardial infarction, stroke, retinopathy, blindness, nephropathy, and peripheral vascular disease.

### Classifications

The two major classifications are type 1 and type 2. Although both are characterized by hyperglycemia, they differ in onset, course, pathology, and treatment. Other types of diabetes may be induced by disease processes, certain drugs, and pregnancy.

**Type 1**

Type 1 diabetes, a common chronic disorder of childhood, results from an autoimmune disorder that destroys pancreatic beta cells. Symptoms usually develop when 10% to 20% of functioning beta cells remain, but may occur at any time if acute illness or stress increases the body’s demand for insulin beyond the capacity of the remaining beta cells to secrete insulin. Eventually, all the beta cells are destroyed and no insulin is produced.

Type 1 may occur at any age but usually starts between 4 and 20 years. The peak incidence for girls is 10 to 12 years, for boys, 12 to 14 years. Type 1 usually has a sudden onset; produces severe symptoms; is difficult to control; produces a high incidence of complications, such as diabetic ketoacidosis (DKA) and renal failure; and requires administration of exogenous insulin. About 10% of people with diabetes have type 1.

**Type 2**

Type 2 is characterized by hyperglycemia and insulin resistance. The hyperglycemia results from increased production of glucose by the liver and decreased uptake of glucose in liver, muscle and fat cells. Insulin resistance means that higher-than-usual concentrations of insulin are required. Thus, insulin is
Dehydration also occurs because high blood levels increase thirst (polydipsia) and, if fluid intake is inadequate, output (polyuria). The excessive loss of fluid in urine leads to the renal tubule. This results in a greatly increased urine volume. In older people, the kidneys may be less able to excrete glucose in urine at much lower or even normal blood glucose levels. In children, glucose tends to appear in urine at increased blood glucose levels. In older people, the kidneys may be less able to excrete excess glucose in urine. As a result, blood glucose levels may be high with little or no glucose in the urine.

When large amounts of glucose are present in urine, water is pulled into the renal tubule. This results in a greatly increased urine volume (polyuria). The excessive loss of fluid in urine leads to increased thirst (polydipsia) and, if fluid intake is inadequate, to dehydration. Dehydration also occurs because high blood glucose levels increase osmotic pressure in the bloodstream, and fluid is pulled out of the cells in the body's attempt to regain homeostasis.

Polyphagia (increased appetite) occurs because the body cannot use ingested foods. People with uncontrolled diabetes lose weight because of abnormal metabolism.

### Complications

Complications of diabetes mellitus are common and potentially disabling or life threatening. Diabetes is a leading cause of myocardial infarction, stroke, blindness, leg amputation, and kidney failure. These complications result from hyperglycemia and other metabolic abnormalities that accompany a lack of effective insulin. The metabolic abnormalities associated with hyperglycemia can cause early, acute complications, such as DKA or hyperosmolar hyperglycemic nonketotic coma (Box 27–2). Eventually, metabolic abnormalities lead to damage in blood vessels and other body tissues. For example, atherosclerosis develops earlier, progresses more rapidly, and becomes more severe in people with diabetes. Microvascular changes lead to nephropathy, retinopathy, and peripheral neuropathy. Other complications include musculoskeletal disorders, increased numbers and severity of infections, and complications of pregnancy.

### HYPOGLYCEMIC DRUGS

#### Insulin

Insulin is described in this section, and individual insulins are listed in Drugs at a Glance: Insulins.

- Exogenous insulin used to replace endogenous insulin has the same effects as the pancreatic hormone.
- Insulin and its analogs (structurally similar chemicals) lower blood glucose levels by increasing glucose uptake by body cells, especially skeletal muscle and fat cells, and by decreasing glucose production in the liver.
- The main clinical indication for insulin is treatment of diabetes mellitus. Insulin is the only effective treatment for type 1 because pancreatic beta cells are unable to secrete endogenous insulin and metabolism is severely impaired. Insulin is required for clients with type 2 who cannot control their disease with diet, weight control, and oral agents. It may be needed by anyone with diabetes during times of stress, such as illness, infection, or surgery. Insulin is also used to control diabetes induced by chronic pancreatitis, surgical excision of pancreatic tissue, hormones and other drugs, and pregnancy (gestational diabetes). In nondiabetic clients, insulin is used to prevent or treat hyperglycemia induced by intravenous (IV) hyperalimentation solutions and to treat hyperkalemia. In hyperkalemia, an IV infusion of insulin and dextrose solution causes potassium to move from the blood into the cells; it does not eliminate potassium from the body.
**Diabetic Ketoacidosis (DKA)**

This life-threatening complication occurs with severe insulin deficiency. In the absence of insulin, glucose cannot be used by body cells for energy and fat is mobilized from adipose tissue to furnish a fuel source. The mobilized fat circulates in the bloodstream, from which it is extracted by the liver and broken down into glycerol and fatty acids. The fatty acids are further changed in the liver to ketones (eg, acetoacetic acid, acetone), which then enter the bloodstream and are circulated to body cells for metabolic conversion to energy, carbon dioxide, and water.

The ketones are produced more rapidly than body cells can use them and their accumulation produces acidemia (a drop in blood pH and an increase in blood hydrogen ions). The body attempts to buffer the acidic hydrogen ions by exchanging them for intracellular potassium ions. Hydrogen ions enter body cells, and potassium ions leave the cells to be excreted in the urine. Another attempt to remove excess acid involves the lungs. Deep, labored respirations, called Kussmaul respirations, eliminate more carbon dioxide and prevent formation of carbonic acid. A third attempt to regain homeostasis involves the kidneys, which excrete some of the ketones, thereby producing acetone in the urine.

DKA worsens as the compensatory mechanisms fail. Clinical signs and symptoms become progressively more severe. Early ones include blurred vision, anorexia, nausea and vomiting, thirst, and polyuria. Later ones include drowsiness, which progresses to stupor and coma, Kussmaul breathing, dehydration and other signs of fluid and electrolyte imbalances, and decreased blood pressure, increased pulse, and other signs of shock.

Two major causes of DKA are omission of insulin and illnesses such as infection, trauma, myocardial infarction, or stroke.

**Hyperosmolar Hyperglycemic Nonkетotic Coma (HHNC)**

HHNC is another type of diabetic coma that is potentially life threatening. It is relatively rare and carries a high mortality rate. The term *hyperosmolar* refers to an excessive amount of glucose, electrolytes, and other solutes in the blood in relation to the amount of water.

Like DKA, HHNC is characterized by hyperglycemia, which leads to osmotic diuresis and resultant thirst, polyuria, dehydration, and electrolyte losses, as well as neurologic signs ranging from drowsiness to stupor to coma. Additional clinical problems may include hypovolemic shock, thrombosis, renal problems, or stroke. In contrast to DKA, hyperosmolar coma occurs in people with previously unknown or mild diabetes, usually after an illness; occurs in hyperglycemic conditions other than diabetes (eg, severe burns, corticosteroid drug therapy); and does not cause ketosis.

---

- The only clear-cut contraindication to the use of insulin is hypoglycemia, because of the risk of brain damage (Box 27–3). Pork insulin is contraindicated in clients allergic to the animal protein.
- Available insulins are pork insulin and human insulin. Pork insulin differs from human insulin by one amino acid. Human insulin is synthetized in the laboratory with recombinant DNA techniques using strains of *Escherichia coli* or by modifying pork insulin to replace the single different amino acid. The name human insulin means that the synthetic product is identical to endogenous insulin (ie, has the same number and sequence of amino acids). It is not derived from the human pancreas.
- Insulin analogs are synthetized in the laboratory by altering the type or sequence of amino acids in insulin molecules. Insulin lispro (Humalog) and insulin aspart (Novolog) are short-acting products. Lispro, the first analog to be marketed, is identical to human insulin except for the reversal of two amino acids (lysine and proline). It is absorbed more rapidly and has a shorter half-life after subcutaneous (SC) injection than regular human insulin. As a result, it is similar to physiologic insulin secretion after a meal, more effective at decreasing postprandial hyperglycemia, and less likely to cause hypoglycemia before the next meal. Injection just before a meal produces hypoglycemic effects similar to those of an injection of conventional regular insulin given 30 minutes before a meal. Aspart has an even more rapid onset and shorter duration of action. In contrast, insulin glargine is a long-acting preparation used to provide a basal amount of insulin through 24 hours, similar to normal, endogenous insulin secretion.
- Insulin cannot be given orally because it is a protein that is destroyed by proteolytic enzymes in the GI tract. It is given only parenterally, most often SC. However, a nasal spray formulation is being developed.
- Insulins differ in onset and duration of action. They are usually categorized as short, intermediate, or long acting. Short-acting insulins have a rapid onset and a short duration of action. Intermediate- and long-acting insulins (except for insulin glargine) are modified by adding protamine (a large, insoluble protein), zinc, or both to slow absorption and prolong drug action. Several mixtures of an intermediate- and a short-acting insulin are available and commonly used.
- U-100, the main insulin concentration in the United States, contains 100 units of insulin per milliliter of solution. It can be accurately measured only in a syringe designed for use with U-100 insulin.
- Subcutaneous insulin is absorbed most rapidly when injected into the abdomen, followed by the upper arm, thigh, and buttocks. Absorption is delayed or decreased by injection into SC tissue with lipodystrophy or other lesions, by circulatory problems such as edema or hypotension, by insulin-binding antibodies (which develop after 2 or 3 months of insulin administration), and by injecting cold (ie, refrigerated) insulin.
- Temperature extremes can cause loss of potency. Insulin retains potency up to 36 months under refrigeration and 18 to 24 months at room temperature. At high temperatures (eg, 100°F or 37.8°C), insulin loses potency in about 2 months. If frozen, insulin clumps or precipitates, cannot be measured accurately, and should be discarded.
# Drugs at a Glance: Insulins

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
<th>Action (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting Insulin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin injection (Regular Iletin II, Humulin R, Novolin R)</td>
<td>1. A clear liquid solution with the appearance of water 2. The hypoglycemic drug of choice for diabetics experiencing acute or emergency situations, diabetic ketoacidosis, hyperosmolar non-ketotic coma, severe infections or other illnesses, major surgery, and pregnancy 3. The only insulin preparation that can be given IV</td>
<td>SC, dosage individualized according to blood glucose levels. For sliding scale, 5–20 units before meals and bedtime, depending on blood glucose levels IV, dosage individualized. For ketoacidosis, regular insulin may be given by direct injection, intermittent infusion, or continuous infusion. One regimen involves an initial bolus injection of 10–20 units followed by a continuous low-dose infusion of 2–10 units/h, based on hourly blood and urine glucose levels</td>
<td>( \frac{1}{2} )–1 2–3 5–7</td>
</tr>
<tr>
<td><strong>Intermediate-acting Insulins</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isophane insulin suspension (NPH, NPH Iletin II, Humulin N, Novolin N)</td>
<td>1. Commonly used for long-term administration 2. Modified by addition of protamine (a protein) and zinc 3. A suspension with a cloudy appearance when correctly mixed in the drug vial 4. Given only SC 5. Not recommended for use in acute situations 6. Hypoglycemic reactions are more likely to occur during mid-to-late afternoon</td>
<td>SC, dosage individualized. Initially, 7–26 units may be given once or twice daily.</td>
<td>1–1½ 8–12 18–24</td>
</tr>
<tr>
<td><strong>Long-acting Insulin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Extended insulin zinc suspension (Humulin U, Ultralente)</td>
<td>1. Modified by addition of zinc and formation of large crystals, which are slowly absorbed 2. Hypoglycemic reactions are frequent and likely to occur during sleep.</td>
<td>SC, dosage individualized. Initially, 7–26 units may be given once daily</td>
<td>4–8 10–30 36 plus</td>
</tr>
<tr>
<td><strong>Insulin Mixtures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NPH 70%</td>
<td>1. Stable mixture</td>
<td>SC, dosage individualized</td>
<td></td>
</tr>
<tr>
<td>Regular 30% (Humulin 70/30, Novolin 70/30)</td>
<td>2. Onset, peak, and duration of action same as individual components See Humulin 70/30, above</td>
<td>SC, dosage individualized</td>
<td></td>
</tr>
<tr>
<td>NPH 50%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regular 50% (Humulin 50/50)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Insulin Analogs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin lispro (Humalog)</td>
<td>1. A synthetic insulin of recombinant DNA origin, created by reversing two amino acids 2. Has a faster onset and a shorter duration of action than human regular insulin 3. Intended for use with a longer-acting insulin</td>
<td>SC, dosage individualized, 15 min before meals</td>
<td>( \frac{1}{2} )–1½ 6–8</td>
</tr>
</tbody>
</table>

(continued)
Oral Hypoglycemic Drugs

There are five types of oral antidiabetic agents, all of which may be used to treat type 2 diabetes that is not controlled by diet and exercise. The drugs lower blood sugar by different mechanisms (Fig. 27–2) and may be used in various combinations for additive effects. Some are also combined with insulin. These drugs are further described below and in Drugs at a Glance: Oral Drugs for Diabetes Mellitus.

Sulfonylureas

- The sulfonylureas are the oldest and largest group of oral agents. They lower blood glucose mainly by increasing secretion of insulin. They may also increase peripheral use of glucose, decrease production of glucose in the liver, increase the number of insulin receptors, or alter postreceptor actions to increase tissue responsiveness to insulin. Because the drugs stimulate pancreatic beta cells to produce more insulin, they are effective only when functioning pancreatic beta cells are present.
- First-generation drugs (eg, acetohexamide, chlorpropamide, tolazamide, and tolbutamide) have largely been replaced by the second generation and are not discussed further. The second-generation drugs, glipizide, glyburide, and glimepiride, are similar in therapeutic and adverse effects. The main adverse effect is hypoglycemia (see Box 27–3).
- The sulfonylureas are chemically related to sulfonamide antibacterial drugs; well absorbed with oral administration; more than 90% bound to plasma proteins; and metabolized in the liver to inactive metabolites, which are excreted mainly by the kidneys (except for glyburide, which is excreted about equally in urine and bile).
- A sulfonylurea may be given alone or with most other antidiabetic drugs in the treatment of type 2 diabetes, including insulin, acarbose, miglitol, metformin, pioglitazone, or rosiglitazone.
- Sulfonylureas are contraindicated in clients with hypersensitivity to them, with severe renal or hepatic impairment, and during pregnancy. They are unlikely to be effective during periods of stress, such as major surgery, severe illness, or infection. Insulin is usually required in these circumstances.

Alpha-Glucosidase Inhibitors

- Acarbose and miglitol inhibit alpha-glucosidase enzymes (eg, sucrase, maltase, amylase) in the GI tract and thereby delay digestion of complex carbohydrates into glucose and other simple sugars. As a result, glucose absorption is delayed and there is a smaller increase in blood glucose levels after a meal.
- The drugs are metabolized in the GI tract by digestive enzymes and intestinal bacteria. Some of the metabolites are absorbed systemically and excreted in urine; plasma concentrations are increased in the presence of renal impairment.
- One of the drugs may be combined with insulin or an oral agent, usually a sulfonylurea.
- These drugs are contraindicated in clients with hypersensitivity, DKA, hepatic cirrhosis, inflammatory or malabsorptive intestinal disorders, and severe renal impairment.

Biguanide

- Metformin increases the use of glucose by muscle and fat cells, decreases hepatic glucose production, and decreases intestinal absorption of glucose. It is preferably called an antihyperglycemic rather than a hypoglycemic agent because it does not cause hypoglycemia, even in large doses, when used alone.
- It is absorbed from the small intestine, circulates without binding to plasma proteins, and has a serum half-life of 1.3 to 4.5 hours. It is not metabolized in the liver and is excreted unchanged in the urine.
- Metformin may be used alone or in combination with insulin or other oral agents. It is widely prescribed as the initial drug in obese clients with newly diagnosed type 2 diabetes, largely because it does not cause weight gain as most other oral agents do.
- It is contraindicated in clients with diabetes complicated by fever, severe infections, severe trauma, major surgery, acidosis, or pregnancy (insulin is indicated in these conditions). It is also contraindicated in clients with serious hepatic or renal impairment, cardiac or respiratory insufficiency, hypoxia, or a history of lactic acidosis because these conditions may increase production of lactate and the risk of potentially fatal lactic acidosis.
Hypoglycemia may occur with insulin or oral sulfonylureas. When hypoglycemia is suspected, the blood glucose level should be measured if possible, although signs and symptoms and the plasma glucose level at which they occur vary from person to person. Hypoglycemia is a blood glucose below 60 to 70 mg/dL and is especially dangerous at approximately 40 mg/dL or below. Central nervous system effects may lead to accidental injury or permanent brain damage; cardiovascular effects may lead to cardiac dysrhythmias or myocardial infarction. Causes of hypoglycemia include:

- Intensive insulin therapy (ie, continuous subcutaneous [SC] infusion or three or more injections daily).
- Omitting or delaying meals
- An excessive or incorrect dose of insulin or an oral agent that causes hypoglycemia
- Altered sensitivity to insulin
- Decreased clearance of insulin or an oral agent (eg, with renal insufficiency)
- Decreased glucose intake
- Decreased production of glucose in the liver
- Giving an insulin injection intramuscularly (IM) rather than SC
- Drug interactions that decrease blood glucose levels
- Increased physical exertion
- Ethanol ingestion

**Hormones That Raise Blood Sugar**

Normally, when hypoglycemia occurs, several hormones (glucagon, epinephrine, growth hormone, and cortisol) work to restore and maintain blood glucose levels. Glucagon and epinephrine, the dominant counter-regulatory hormones, act rapidly because they are activated as soon as blood glucose levels start declining. Growth hormone and cortisol act more slowly, about 2 hours after hypoglycemia occurs.

People with diabetes who develop hypoglycemia may have impaired secretion of these hormones, especially those with type 1 diabetes. Decreased secretion of glucagon is often evident in clients who have had diabetes for 5 years or longer. Decreased secretion of epinephrine also occurs in people who have been treated with insulin for several years. Decreased epinephrine decreases tachycardia, a common sign of hypoglycemia, and may delay recognition and treatment.

**The Conscious Client**

Treatment of hypoglycemic reactions consists of immediate administration of a rapidly absorbed carbohydrate. For the conscious client who is able to swallow, the carbohydrate is given orally. Foods and fluids that provide approximately 15 g of carbohydrate include:

- Two sugar cubes or 1 to 2 teaspoons of sugar, syrup, honey, or jelly
- Two or three small pieces of candy or eight Lifesaver candies
- 4 oz of fruit juice, such as orange, apple, or grape
- 4 oz of ginger ale
- Coffee or tea with 2 teaspoons of sugar added
- Commercial glucose products (eg, Glutose, B-D Glucose).

These products must be swallowed to be effective. Symptoms usually subside within 15 to 20 minutes. If they do not subside, the client should take another 10 to 15 g of oral carbohydrate. If acarbose or miglitol has been taken with insulin or a sulfonylurea and a hypoglycemic reaction occurs, glucose (oral or intravenous [IV]) or glucagon must be given for treatment. Sucrose (table sugar) and other oral carbohydrates do not relieve hypoglycemia because the presence of acarbose or miglitol prevents their digestion and absorption from the gastrointestinal tract.

**The Unconscious Client**

For the unconscious client, carbohydrate cannot be given orally because of the risks of aspiration. Therefore, the treatment choices are parenteral glucose or glucagon.

If the client is in a health care facility where medical help is readily available, IV glucose in a 25% or 50% solution is the treatment of choice. It acts rapidly to raise blood glucose levels and arouse the client. If the client is at home or elsewhere, glucagon may be given if available and there is someone to inject it. A family member or roommate may be taught to give glucagon SC or IM. It can also be given IV. The usual adult dose is 0.5 to 1 mg. Glucagon is a pancreatic hormone that increases blood sugar by converting liver glycogen to glucose. It is effective only when liver glycogen is present. Some clients cannot respond to glucagon because glycogen stores are depleted by such conditions as starvation, adrenal insufficiency, or chronic hypoglycemia. The hyperglycemic effect of glucagon occurs more slowly than that of IV glucose and is of relatively brief duration. If the client does not respond to one or two doses of glucagon within 20 minutes, IV glucose is indicated.

Caution is needed in the treatment of hypoglycemia. Although the main goal of treatment is to relieve hypoglycemia and restore the brain’s supply of glucose, a secondary goal is to avoid overtreatment and excessive hyperglycemia. The client having a hypoglycemic reaction should not use it as an excuse to eat high-caloric foods or large amounts of food. Health care personnel caring for the client should avoid giving excessive amounts of glucose.

**Posthypoglycemia Care**

Once hypoglycemia is relieved, the person should have a snack or a meal. Slowly absorbed carbohydrate and protein foods, such as milk, cheese, and bread, are needed to replace glycogen stores in the liver and to prevent secondary hypoglycemia from rapid use of the carbohydrates given earlier. In addition, the episode needs to be evaluated for precipitating factors so that these can be minimized to prevent future episodes. Repeated episodes mean that the therapeutic regimen and client compliance must be re-evaluated and adjusted if indicated.

**Glitazones**

- These drugs, pioglitazone and rosiglitazone, are also called thiazolidinediones or TZDs and insulin sensitizers.
- They decrease insulin resistance, a major factor in the pathophysiology of type 2 diabetes. The drugs stimulate receptors on muscle, fat, and liver cells. This stimulation increases or restores the effectiveness of circulating insulin and results in increased uptake of glucose by peripheral tissues and decreased production of glucose by the liver.
- The drugs may be used as monotherapy with diet and exercise or in combination with insulin, metformin, or a sulfonylurea.
The drugs are contraindicated in clients with active liver disease or a serum alanine aminotransferase (ALT) > 2.5 times the upper limit of normal. They are also contraindicated in clients who are hypersensitive to them.

The drugs should be used very cautiously, if at all, in clients at risk of developing congestive heart failure. Glitazones increase plasma volume and may cause fluid retention and heart failure. In one study, heart failure developed in 4.5% of glitazone users within 10 months and 12.4% within 36 months. In people who did not take a glitazone, 2.6% developed heart failure within 10 months and 8.4% within 36 months.

Meglitinides

- Nateglinide and repaglinide are nonsulfonylureas that lower blood sugar by stimulating pancreatic secretion of insulin.
- They can be used as monotherapy with diet and exercise or in combination with metformin.
- The drugs are well absorbed from the GI tract; peak plasma level occurs within 1 hour. They have a plasma half-life of 1 to 1.5 hours and are highly bound (>98%) to plasma proteins. They are metabolized in the liver; metabolites are excreted in urine and feces.
- Repaglinide is metabolized and removed from the bloodstream within 3 to 4 hours after a dose, nateglinide within about 6 hours. This decreases the workload of pancreatic beta cells (ie, decreases duration of beta cell stimulation), allows serum insulin levels to return to normal before the next meal, and decreases risks of hypoglycemic episodes.

These drugs should be taken just before or up to 30 minutes before a meal. If a meal is skipped, the drug dose should be skipped; if a meal is added, a drug dose should be added.

HERBAL AND DIETARY SUPPLEMENTS

With most herbs and dietary supplements, even the commonly used ones (eg, echinacea, St. John’s wort), the effects on blood glucose levels are unknown; well-controlled, long-term studies of effects have not been done; and interactions with antidiabetic drugs are unknown. Thus, anyone with diabetes who wishes to take an herbal or dietary supplement should consult a health care provider, read product labels carefully, seek the most authoritative information available, and monitor blood glucose closely when starting the supplement. Described below are some products that reportedly affect blood sugar and should be used cautiously, if at all, by clients with diabetes.

Supplements That May Increase Blood Glucose Levels

- **Bee pollen** may cause hyperglycemia and decrease the effects of antidiabetic medications. It should not be used by people with diabetes.
- **Ginkgo biloba** extract is thought to increase blood sugar in clients with diabetes by increasing hepatic metabolism of insulin and oral hypoglycemic drugs, thereby
## Drugs at a Glance: Oral Drugs For Diabetes Mellitus

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sulfonylureas, Second Generation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glimepiride (Amaryl)</td>
<td>Onset of action about 1 h; peak, 2–3 h</td>
<td>PO, initially 1–2 mg once daily, with breakfast or first main meal. Maximum starting dose 2 mg or less. Maintenance dose 1–4 mg once daily. After a dose of 2 mg is reached, increase dose in increments of 2 mg or less at 1- to 2-week intervals, based on blood glucose levels. Maximum recommended dose, 8 mg once daily. In combination with insulin, PO 8 mg once daily with the first main meal.</td>
</tr>
<tr>
<td>Glipizide (Glucotrol)</td>
<td>Onset of action, approximately 1–1.5 h; duration 10–16 h</td>
<td>PO, initially 5 mg daily in a single dose, 30 min before breakfast. Maximum dose, 40 mg daily. In elderly, may start with 2.5 mg daily</td>
</tr>
<tr>
<td>Glyburide (DiaBeta, Micronase, Glynase Pres Tab)</td>
<td>Onset of action approximately 2–4 h; duration 24 h. Glynase is better absorbed, acts faster (onset about 1 h; duration 24 h), and is given in smaller doses than other forms of glyburide.</td>
<td>PO, initially 2.5–5 mg daily in a single dose, with breakfast. Maximum dose, 20 mg daily. Glynase PO initially 1.5–3 mg daily with breakfast. Maximum dose, 12 mg daily.</td>
</tr>
<tr>
<td><strong>Alpha-Glucosidase Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acarbose (Precose)</td>
<td>Delays digestion of carbohydrate foods when acarbose and food are present in gastrointestinal (GI) tract at the same time</td>
<td>PO, initially 25 mg, three times daily with first bite of main meals; increase at 4- to 8-week intervals to a maximum dose of 50 mg three times daily (for patients weighing under 60 kg) if necessary, depending on 1-h postprandial blood glucose levels and tolerance. Clients weighing more than 60 kg may need doses up to 100 mg three times daily (the maximum dose).</td>
</tr>
<tr>
<td>Miglitol (Glyset)</td>
<td>Delays digestion of carbohydrates in the GI tract</td>
<td>PO, initially 25 mg three times daily with the first bite of each main meal, gradually increased if necessary. Maximum dose, 100 mg three times daily</td>
</tr>
<tr>
<td><strong>Biguanide</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metformin (Glucophage)</td>
<td>Older adults are at higher risk for development of lactic acidosis, a rare but potentially fatal reaction. Thus, smaller doses and monitoring of renal function are recommended.</td>
<td>PO, initially 500 mg twice daily, with morning and evening meals; increase dose in increments of 500 mg/d every 2–3 weeks if necessary, up to a maximum of 3000 mg daily, based on patient tolerance and blood glucose levels. In elderly patients, do not increase to maximum dose.</td>
</tr>
<tr>
<td><strong>Glitazones</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pioglitazone (Actos)</td>
<td>Increases effects of insulin; may be used alone or with insulin, metformin, or a sulfonlurea</td>
<td>PO 15–30 mg once daily</td>
</tr>
<tr>
<td>Rosiglitazone (Avandia)</td>
<td>Increases effects of insulin; may be used alone or with metformin</td>
<td>PO 4–8 mg once daily , in one dose or two divided doses</td>
</tr>
<tr>
<td><strong>Meglitinides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nateglinide (Starlix)</td>
<td>Onset of action, within 20 min; peak, 1 h; duration, 3–4 h</td>
<td>PO 120 mg three times daily, 1–30 min before meals. Omit dose if skip a meal.</td>
</tr>
<tr>
<td>Repaglinide (Prandin)</td>
<td>Onset of action, within 30 min; peak, 1 h; duration approximately 3–4 h</td>
<td>PO 1–2 mg 15–30 min. before each meal; increased to 4 mg before meals if necessary. Maximum dose, 16 mg daily. Omit a dose if skip a meal; add a dose if add a meal.</td>
</tr>
<tr>
<td><strong>Combination Drug</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glyburide/metformin (Glucovance)</td>
<td>Available in preparations with 1.25 mg glyburide and 250 mg metformin; 2.5 mg glyburide and 500 mg metformin; or 5 mg glyburide and 500 mg metformin</td>
<td>Initially, PO 1.25 mg/250 mg once or twice daily with meals. Patients previously treated with glyburide or other sulfonylurea plus metformin: Initially, PO 2.5 or 5 mg/500 mg twice daily with meals, not to exceed previous doses of separate drugs.</td>
</tr>
</tbody>
</table>

*See Appendix A for additional combination drugs.
Jean Watson, a 52-year-old type 2 diabetic, has been managed for the last 3 years on 500 mg of metformin (Glucophage) bid. Her blood glucose usually is under 200 mg/dL. Mrs. Watson is scheduled for an intravenous pyelogram (IVP) to evaluate a series of recent urinary tract infections. When Mrs. Watson comes in for her test, she mentions that her blood glucose was elevated that morning, so she took her metformin as usual with a sip of water but did not eat breakfast as instructed. You note this in the chart and proceed to prepare her for the IVP.

making the drugs less effective. It is not recommended for use.

Glucosamine, as indicated by animal studies, may cause impaired beta cell function and insulin secretion similar to that observed in humans with type 2 diabetes. Long-term effects in humans are unknown, but the product is considered potentially harmful to people with diabetes or impaired glucose tolerance (prediabetes). Adverse effects on blood sugar and drug interactions with antidiabetic medications have not been reported. However, blood sugar should be monitored carefully. With chondroitin, which is often taken with glucosamine for osteoarthritis, there is no information about effects on blood sugar, use by diabetic clients, or interactions with antidiabetic drugs.

Supplements that May Decrease Blood Glucose Levels

Basil, which is commonly used in cooking, is also available as an herbal supplement. The amounts used in cooking are unlikely to affect blood sugar, but larger amounts may cause hypoglycemia or increase the hypoglycemic effects of insulin and oral antidiabetic drugs. The use of supplemental amounts should probably be avoided by people with diabetes. If used, blood glucose levels should be closely monitored.

Bay leaf is commonly used in cooking (it should be removed from the food before eating) and is also available as an extract made with ground leaves. It increases the effects of insulin and is sometimes recommended by nutritionists for diabetic diets. If used, blood glucose levels should be monitored closely.

Chromium is a trace mineral required for normal glucose metabolism. It may increase production of insulin receptors and insulin binding to the receptors, thereby increasing insulin effectiveness, lowering blood glucose levels, and decreasing insulin requirements in people with diabetes. It also may have beneficial effects on serum cholesterol levels. However, evidence for these effects is inconsistent, with some supporting and some negating the use of chromium supplements.

Chromium deficiency, considered rare in the United States, may play a role in the development of diabetes and atherosclerosis. If so, beneficial effects of a supplement may be more evident in a deficiency state. In one study of pregnant women and older adults with marginal levels of chromium, administration of a supplement improved glucose tolerance. At present, there is insufficient evidence to recommend routine chromium supplementation in diabetics. In nondiabetics, chromium supplements do not have hypoglycemic effects.

Echinacea. Some clinical trials have been done, but people with diabetes were excluded. A conclusion was that diabetics should not take the drug.

Garlic. Some sources report no known effects on blood glucose; others report a decrease in animals and humans. Some researchers also reported increased serum insulin and improvement in liver glycogen storage after garlic administration. There is a potential for additive hypoglycemic effects with antidiabetic drugs, although no apparent interactions have been reported.

Ginseng. Several studies (generally small and not well-designed) indicate that ginseng lowers blood glucose levels in both diabetic and nondiabetic subjects. It may be useful in preventing diabetes or complications of diabetes. However, larger and longer studies are needed before general use can be recommended for diabetics or nondiabetics. For nondiabetics who use ginseng, the herb may need to be taken with a meal to prevent unintentional hypoglycemia. For diabetics, use of ginseng should be very cautious (if at all), with frequent monitoring of blood glucose and signs of hypoglycemia, because of possible additive effects with antidiabetic medications. Its use should also be accompanied by proper diet, physical activity, and antidiabetic medication.

Glucosmannan, which is promoted as a diet aid and laxative, has hypoglycemic effects and should be avoided or used very cautiously by people with diabetes. If used, blood sugar should be monitored closely and lower doses of antidiabetic drugs may be needed.

Guar gum is a type of fiber that becomes gel-like upon contact with liquids (eg, like Metamucil). It is used as a thickening agent in foods and drugs and is an ingredient in some over-the-counter weight loss products. It should be used cautiously, if at all, by people with diabetes because it has hypoglycemic effects and slows gastrointestinal motility. Several cases of esophageal and intestinal obstruction have been reported with weight loss products.

Nursing Process

Assessment
Assess the client’s knowledge, attitude, and condition in relation to diabetes, the prescribed treatment plan, and complications. Assessment data should include past manifestations
of the disease process and the client’s response to them, present status, and potential problem areas.

- **Historic data** include age at onset of diabetes, prescribed control measures and their effectiveness, the ease or difficulty of complying with the prescribed treatment, occurrence of complications such as ketoacidosis, and whether other disease processes have interfered with diabetes control.

- **Assess the client’s current status**, in relation to the following areas:
  - **Diet.** Ask about the prescribed nutritional plan, who prepares the food, what factors help in following the diet, what factors interfere with following the diet, the current weight, and whether there has been a recent weight change. Also ask if herbal or other dietary supplements are used. If so, list each one by name and frequency of use. If a nutritionist is available, ask one to assess the client’s dietary practice and needs.
  - **Activity.** Ask the client to describe usual activities of daily living, including those related to work, home, and recreation and whether he or she participates in a regular exercise program. If so, ask for more information about what, how often, how long, and so forth. If not, teaching is needed because exercise is extremely important in diabetes management.
  - **Medication.** If the client takes insulin, ask what kind, how much, who administers it, usual time of administration, sites used for injections, if a hypoglycemic reaction to insulin has ever been experienced, and if so, how it was handled. This information helps to assess knowledge, usual practices, and teaching needs. If the client takes an oral antidiabetic drug, ask the name, dosage, and time taken.
  - **Monitoring methods.** Testing the blood for glucose and the urine for ketones (eg, when blood sugar is elevated or when ill and unable to eat) are the two main methods of self-monitoring glycemic control. Ask about the method used, the frequency of testing, and the pattern of results. If possible, observe the client performing and interpreting an actual test to assess accuracy.
  - **Skin and mucous membranes.** Inspect for signs of infection and other lesions. Infections often occur in the axillary and groin areas because these areas have large numbers of microorganisms. Periodontal disease (pyorrhea) may be manifested by inflammation and bleeding of the gums. Women with diabetes are susceptible to monilial vaginitis and infections under the breasts. Check the sites of insulin injection for atrophy (dimpling or indentation), hypertrophy (nodules or lumps), and fibrosis (hardened areas). Check the lower leg for brown spots; these are caused by small hemorrhages into the skin and may indicate widespread changes in the blood vessels.

Problems are especially likely to develop in the feet from infection, trauma, pressure, vascular insufficiency, and neuropathy. Therefore, inspect the feet for calluses, ulcers, and signs of infection. When such problems develop, sensory impairment from neuropathy may delay detection and impaired circulation may delay healing. Check pedal pulses, color, and temperature in both feet to evaluate arterial blood flow. Ankle edema may indicate venous insufficiency or impaired cardiac function.

- **Eyes.** Ask about difficulties with vision and if eyes are examined regularly. Diabetic clients are prone to development of retinopathy, cataracts, and possibly glaucoma.

- **Cardiovascular system.** Clients with diabetes have a high incidence of atherosclerosis, which makes them susceptible to hypertension, angina pectoris, myocardial infarction, peripheral vascular disease, and stroke. Therefore, check blood pressure and ask about chest pain and pain in the legs with exercise (intermittent claudication).

- **Genitourinary system.** People with diabetes often have kidney and bladder problems. Assess for signs of urinary tract infection; albumin, white blood cells, or blood in urine; edema; increased urination at night; difficulty voiding; generalized itching; fatigue; and muscular weakness. Impotence may develop in men and is attributed to neuropathy.

- **Assess blood sugar reports for abnormal levels.** Two or more fasting blood glucose levels greater than 126 mg/dL or two random levels greater than 200 mg/dL are diagnostic of diabetes. Decreased blood sugar levels are especially dangerous at 40 mg/dL or below.

- **Assess the glycosylated hemoglobin (also called glycated hemoglobin and HbA1c) level when available.** This test indicates glucose bound to hemoglobin in red blood cells (RBCs) when RBCs are exposed to hyperglycemia. The binding is irreversible and lasts for the lifespan of RBCs (approximately 120 days). The test reflects the average blood sugar during the previous 2 to 3 months. The goal is usually less than 7% (the range for people without diabetes is approximately 4% to 6%). The test should be done every 3 to 6 months.

  Test results are not affected by several factors that alter blood sugar levels, such as time of day, food intake, exercise, recently administered antidiabetic drugs, emotional stress, or client cooperation. The test is especially useful with children, those whose diabetes is poorly controlled, those who do not test blood glucose regularly, and those who change their usual habits before a scheduled appointment with a health care provider so that their blood sugar control appears better than it actually is.

**Nursing Diagnoses**

- Ineffective Tissue Perfusion, peripheral, related to atherosclerosis and vascular impairment
- Disturbed Sensory Perception, visual and tactile, related to impaired vision or neuropathy
- Ineffective Coping related to chronic illness and required treatment
• Anxiety: Managing a chronic illness, finger sticks, insulin injections
• Risk for Injury: Trauma, infection, hypoglycemia, hyperglycemia
• Noncompliance related to inability or unwillingness to manage the disease process and required treatment
• Deficient Knowledge: Disease process and management; administration and effects of antidiabetic drugs; interrelationships among diet, exercise, and antidiabetic drugs; and management of hypoglycemia, “sick days,” and other complications

Planning/Goals
The client will:
• Learn self-care activities
• Manage drug therapy to prevent or minimize hypoglycemia and other adverse effects
• Develop a consistent pattern of diet and exercise
• Use available resources to learn about the disease process and how to manage it
• Take antidiabetic drugs accurately
• Self-monitor blood glucose and urine ketones appropriately
• Keep appointments for follow-up and monitoring procedures by a health care provider

Interventions
Use nondrug measures to improve control of diabetes and to help prevent complications.
• Assist the client in maintaining the prescribed diet. Specific measures vary but may include teaching the client and family about the importance of diet, referring the client to a dietitian, and helping the client identify and modify factors that decrease compliance with the diet. If the client is obese, assist in developing a program to lose weight and then maintain weight at a more nearly normal level.
• Assist the client to develop and maintain a regular exercise program.
• Perform and interpret blood tests for glucose accurately, and assist clients and family members to do so. Self-monitoring of blood glucose levels allows the client to see the effects of diet, exercise, and hypoglycemic medications on blood glucose levels and may promote compliance.

Several products are available for home glucose monitoring. All involve obtaining a drop of capillary blood from a finger with a sterile lancet. The blood is placed on a semipermeable membrane that contains a reagent. The amount of blood glucose can be read with various machines (eg, glucometers).
• Test urine for ketones when the client is sick, when blood glucose levels are above 200 mg/dL, and when episodes of nocturnal hypoglycemia are suspected. Also teach clients and family members to test urine when indicated.
• Promote early recognition and treatment of problems by observing for signs and symptoms of urinary tract infection, peripheral vascular disease, vision changes, ketoacidosis, hypoglycemia, and others. Teach clients and families to observe for these conditions and report their occurrence.
• Discuss the importance of regular visits to health care facilities for blood sugar measurements, weights, blood pressure measurements, and eye examinations.
• Perform and teach correct foot care. Have the client observe the following safeguards: avoid going barefoot, to prevent trauma to the feet; wear correctly fitted shoes; wash the feet daily with warm water, dry well, inspect for any lesions or pressure areas, and apply lanolin if the skin is dry; wear cotton or wool socks because they are more absorbent than synthetic materials; cut toenails straight across and only after the feet have been soaked in warm water and washed thoroughly. Teach the client to avoid use of hot water bottles or electric heating pads, cutting toenails if vision is impaired, use of strong antiseptics on the feet, and cutting corns or calluses. Also teach the client to report any lesions on the feet to the physician.
• Help clients keep up with newer developments in diabetes care by providing information, sources of information, consultations with specialists, and other resources. However, do not overwhelm a newly diagnosed diabetic client with excessive information or assume that a long-term diabetic client does not need information.

Evaluation
• Check blood sugar reports regularly for normal or abnormal values.
• Check glycosylated hemoglobin reports when available.
• Interview and observe for therapeutic and adverse responses to antidiabetic drugs.
• Interview and observe for compliance with prescribed treatment.
• Interview clients and family members about the frequency and length of hospitalizations for diabetes mellitus.

PRINCIPLES OF THERAPY

Goals of Therapy
For most clients, the goals of treatment are to maintain blood glucose at normal or near-normal levels; promote normal metabolism of carbohydrate, fat, and protein; prevent acute and long-term complications; and prevent hypoglycemic episodes.

There is strong evidence that strict control of blood sugar delays the onset and slows progression of complications of diabetes. In addition to glycemic control, other measures can be used to help prevent end-stage renal disease. Administration of angiotensin-converting enzyme (ACE) inhibitors (eg, captopril) has protective effects on the kidneys in both type 1 and type 2 diabetes and in both normotensive and hypertensive people. Although ACE inhibitors are also used in the treatment of hypertension, their ability to delay nephropathy seems to be independent of antihypertensive effects. Additional measures to preserve renal function include effective treatment of...
General Considerations

- Wear or carry diabetic identification (e.g., a Medic-Alert necklace or bracelet) at all times, to aid treatment if needed.
- Learn as much as you can about diabetes and its management. Few other diseases require as much adaptation in activities of daily living, and you must be well informed to control the disease, minimize complications, and achieve an optimal quality of life. Although much information is available from health care providers (physicians, nurses, nurse diabetes educators, nutritionists), an additional major resource is the American Diabetes Association
  1660 Duke St.
  Alexandria, VA 22314
  1-800-ADA-DISC
  http://www.diabetes.org
- In general, a consistent schedule of diet, exercise, and medication produces the best control of blood sugar levels and the least risk of complications.
- Diet, weight control, and exercise are extremely important in managing diabetes. Maintaining normal weight and avoiding excessive caloric intake decrease the need for medication and decrease the workload of the pancreas. Exercise helps body tissues use insulin better, which means that glucose moves out of the bloodstream and into muscles and other body tissues. This promotes more normal blood glucose levels and decreases long-term complications of diabetes.
- Take any antidiabetic medication as prescribed. If unable to take a medication, notify a health care provider. To control blood sugar most effectively, medications are balanced with diet and exercise. If you take insulin, you need to know what type(s) you are taking, how to obtain more, and how to store it. Regular and NPH insulins and mixtures (e.g., Humulin) are available over-the-counter; Humalog, NovoLog, and Lantus require a prescription. Keep several days’ supply of insulin and syringes on hand to allow for weather or other conditions that might prevent replacement of insulin or other supplies when needed.
- You need to know the signs and symptoms of high blood sugar (hyperglycemia): increased blood glucose and excessive thirst, hunger, and urine output. Persistent hyperglycemia may indicate a need to change some aspect of the treatment program, such as diet or medication.
- You need to know the symptoms of low blood sugar (hypoglycemia): sweating, nervousness, hunger, weakness, tremors, and mental confusion. Hypoglycemia may indicate too much medication or exercise or too little food. Treatment is a rapidly absorbed source of sugar, which usually reverses symptoms within 10 to 20 minutes. If you are alert and able to swallow, take 4 oz of fruit juice, 4 to 6 oz of a sugar-containing soft drink, a piece of fruit or ½ cup of raisins, two to three glucose tablets (5 grams each), a tube of glucose gel, 1 cup of skim milk, tea or coffee with 2 teaspoons of sugar, or eight LifeSaver candies. Avoid taking so much sugar that hyperglycemia occurs.
- If you take acarbose (Precose) or miglitol (Glyset) along with insulin, glimepiride (Amaryl), glipizide (Glucotrol), or glyburide (DiaBeta, Glynase, Micronase) and a hypoglycemic reaction occurs, you must take some form of glucose (or glucagon) for treatment. Sucrose (table sugar) and other oral carbohydrates do not relieve hypoglycemia because the presence of acarbose or miglitol prevents their digestion and absorption from the gastrointestinal (GI) tract.
- You need to have a family member or another person able to recognize and manage hypoglycemia in case you are unable to obtain or swallow a source of glucose. If you take insulin, glucagon should be available in the home and a caregiver should know how to give it.
- The best way to prevent, delay, or decrease the severity of diabetes complications is to maintain blood sugar at a normal or near-normal level. Other measures include regular visits to health care providers, preferably a team of specialists in diabetes care; regular vision and glaucoma testing; and special foot care. In addition, if you have hypertension, treatment can help prevent heart attacks and strokes.
- Take only drugs prescribed by a physician who knows you have diabetes. Avoid other prescriptions and over-the-counter drugs unless these are discussed with the physician treating the diabetes because adverse reactions and interactions may occur. For example, nasal decongestants (alone or in cold remedies) and asthma medications may cause tachycardia and nervousness, which may be interpreted as hypoglycemia. In addition, liquid cold remedies and cough syrups may contain sugar and raise blood glucose levels.
- If you wish to take any kind of herbal or dietary supplement, you should discuss this with the health care provider who is managing your diabetes. There has been little study of these preparations in relation to diabetes; many can increase or decrease blood sugar and alter diabetes control. If you start a supplement, you need to check your blood sugar frequently to see how it affects your blood glucose level.
- Test blood regularly for glucose. A schedule individualized to your needs is best. Testing should be done more often when medication dosages are changed or when you are ill.
- Reduce insulin dosage or eat extra food if you expect to exercise more than usual. Specific recommendations should be individualized and worked out with health care providers in relation to the type of exercise.
- Ask for written instructions about managing "sick days" and call your physician if unsure about what you need to do. Although each person needs individualized instructions, some general guidelines include the following:
- Continue your antidiabetic medications unless instructed otherwise. Additional insulin also may be needed, especially if ketosis develops. Ketones (acetone) in the urine indicate insulin deficiency or insulin resistance.

(continued)
CHAPTER 4 DRUGS AFFECTING THE ENDOCRINE SYSTEM

396

SECTION 4 DRUGS AFFECTING THE ENDOCRINE SYSTEM

the abdomen and the thighs. Insulin is absorbed fastest from the abdomen. Do not inject insulin within 2 inches of the “belly button” or into any skin lesions.

If it is necessary to mix two insulin preparations, ask for specific instructions about the technique and then follow it consistently. There is a risk of inaccurate dosage of both insulins unless measured very carefully. Commercial mixtures are also available for some combinations.

Change insulin dosage only if instructed to do so and the circumstances are specified.

Carry sugar, candy, or a commercial glucose preparation for immediate use if a hypoglycemic reaction occurs.

Take oral drugs as directed. Recommendations usually include the following:

- Take glipizide or glyburide approximately 30 minutes before meals; take glimepiride with breakfast or the first main meal.
- Take acarbose or miglitol with the first bite of each main meal. The drugs need to be in the GI tract with food because they act by decreasing absorption of sugar in the food. Starting with a small dose and increasing it gradually helps to prevent bloating, “gas pains,” and diarrhea.
- Take metformin (Glucophage) with meals to decrease stomach upset.
- Take repaglinide (Prandin) or nateglinide (Starlix) about 15 to 30 minutes before meals (2, 3, or 4 times daily). Doses may vary from 0.5 to 4.0 mg, depending on fasting blood glucose levels. Dosage changes should be at least 1 week apart. If you skip a meal, you should skip that dose of repaglinide or nateglinide; if you eat an extra meal, you should take an extra dose.
- Take pioglitazone (Actos) and rosiglitazone (Avandia) without regard to meals.

If you take glimepiride, glipizide, glyburide, or repaglinide, alone or in combination with other antidiabetic drugs, be prepared to handle hypoglycemic reactions (as with insulin, above). Acarbose, miglitol, metformin, pioglitazone, and rosiglitazone do not cause hypoglycemia when taken alone. Do not skip meals and snacks. This increases the risk of hypoglycemic reactions.

If you exercise vigorously, you may need to decrease your dose of antidiabetic drug or eat more. Ask for specific instructions related to the type and frequency of the exercise.

**Self-Administration**

- Use correct techniques for injecting insulin:
  - Follow instructions for times of administration as nearly as possible. Different types of insulin have different onsets, peaks, and durations of action. Accurate timing (eg, in relation to meals), can increase beneficial effects and decrease risks of hypoglycemic reactions.
  - Wash hands; wash injection site, if needed.
  - Draw up insulin in a good light, being very careful to draw up the correct dose. If you have trouble seeing the syringe markers, get a magnifier or ask someone else to draw up the insulin. Prefilled syringes or cartridges for pen devices are also available.
  - Instructions may vary about cleaning the top of the insulin vial and the injection site with an alcohol swab and about pulling back on the plunger after injection to see if any blood enters the syringe. These techniques have been commonly used, but many diabetes experts do not believe they are necessary.
  - Inject straight into the fat layer under the skin, at a 90-degree angle. If very thin, pinch up a skin-fold and inject at a 45-degree angle.
  - Rotate injection sites. Your health care provider may suggest a rotation plan. Many people rotate between the abdomen and the thighs. Insulin is absorbed fastest from the abdomen. Do not inject insulin within 2 inches of the “belly button” or into any skin lesions.
  - Rest, keep warm, do not exercise, and keep someone with you if possible.
  - If unable to eat solid food, take easily digested liquids or semiliquid foods. About 15 g of carbohydrate every 1 to 2 hours is usually enough and can be provided by ½ cup of apple juice, applesauce, cola, cranberry juice, eggnog, Cream of Wheat cereal, custard, vanilla ice cream, regular gelatin, or frozen yogurt.
  - Drink 2 to 3 quarts of fluids daily, especially if you have a fever. Water, tea, broths, clear soups, diet soda, or carbohydrate-containing fluids are acceptable.
  - Record the amount of fluid intake as well as the number of times you urinate, vomit, or have loose stools.
  - Seek medical attention if a premeal blood glucose level is more than 250 mg/dL, if urine acetone is present, if you have fever above 100°F, if you have several episodes of vomiting or diarrhea, or if you have difficulty in breathing, chest pain, severe abdominal pain, or severe dehydration.
  - Test urine for ketones when the blood glucose level exceeds 250 mg/dL or with each urination. If unable to test urine, have someone else do it.
hypertension, limited intake of dietary protein, prompt treatment of urinary tract infections, and avoidance of nephrotoxic drugs when possible.

Treatment Regimens

When possible, it is desirable to have an interdisciplinary diabetes care team (eg, physician, nurse diabetes educator, dietitian, and perhaps others) work with the client to design, monitor, and revise an individualized treatment plan. This is especially important for clients with newly diagnosed diabetes to assist them in learning to manage their disease and make appropriate lifestyle changes.

The best regimen for a particular client depends on the type of diabetes, the client’s age and general condition, and the client’s ability and willingness to comply with the prescribed therapy. In type 1 diabetes, the only effective treatment measures are insulin, diet, and exercise. In type 2, the initial treatment of choice is diet, exercise, and weight control. If this regimen is ineffective, oral agents or insulin may be added.

Guidelines for Insulin Therapy

Choice of Preparation

When insulin therapy is indicated, the physician may choose from several preparations that vary in composition, onset, duration of action, and other characteristics. Some factors to be considered include the following:

- Human insulin is preferred for newly diagnosed type 1 diabetes, gestational diabetes, poorly controlled diabetes, clients having surgery or an illness that requires short-term insulin therapy, and clients with insulin allergy.
- Regular insulin (insulin injection) has a rapid onset of action and can be given IV. Therefore, it is the insulin of choice during acute situations, such as DKA, severe infection or other illness, and surgical procedures.
- Isophane insulin (NPH) is often used for long-term insulin therapy. For many clients, a combination of NPH and a short-acting insulin provides more consistent control of blood glucose levels. Although several regimens are used, a common one is a mixture of regular and NPH insulins administered before the morning and evening meals. A commercial mixture is more convenient and probably more accurate than a mixture prepared by a client or caregiver, if the proportions of insulins are appropriate for the client.
- Insulin lispro or aspart may be used instead of SC regular insulin in most situations, but safe usage requires both health care providers and clients to be aware of differences. Insulin aspart is also approved for use in external insulin pumps that administer a subcutaneous continuous infusion.
- Insulin glargine may be used to provide a basal amount of insulin over 24 hours, with a short-acting insulin at meal times.

Dosage Factors

Dosage of insulin must be individualized according to blood glucose levels. The goal is to alleviate symptoms of hyperglycemia and re-establish metabolic balance without causing hypoglycemia. An initial dose of 0.5 to 1 unit/kg/day may be started and then adjusted to maintain blood glucose levels (tested before meals and at bedtime) of 80 to 140 mg/dL in adults (100 to 200 mg/dL in children younger than 5 years). However, many factors influence blood glucose response to exogenous insulin and therefore influence insulin requirements.

- Factors that increase insulin requirements include weight gain; increased caloric intake; pregnancy; decreased activity; acute infections; hyperadrenocorticism (Cushing’s disease); primary hyperparathyroidism; acromegaly; hypokalemia; and drugs such as corticosteroids, epinephrine, levothyroxine, and thiazide diuretics. Clients who are obese may require 2 units/kg/day because of resistance to insulin in peripheral tissues.
- Factors that decrease insulin requirements include weight reduction; decreased caloric intake; increased physical activity; development of renal insufficiency; stopping administration of corticosteroids, epinephrine, levothyroxine, and diuretics; hypothyroidism; hypopituitarism; recovery from hyperparathyroidism; recovery from acute infections; and the “honeymoon period,” which may occur with type 1 diabetes.

People who need less than 0.5 unit/kg/day may produce some endogenous insulin or their tissues may be more responsive to insulin because of exercise and good physical conditioning. Renal insufficiency decreases dosage requirements because less insulin is metabolized in the kidneys than with normal renal function. The honeymoon period, characterized by temporary recovery of beta cell function and production of insulin, may occur after diabetes is first diagnosed. Insulin requirements may decrease rapidly, and if the dosage is not decreased, severe hypoglycemic reactions may occur.

In acute situations, dosage of regular insulin needs frequent adjustments based on measurements of blood glucose. When insulin is given IV in a continuous infusion, 20% to 30% binds to the IV fluid container and the infusion tubing.

Dosage of insulin for long-term therapy is determined by blood glucose levels at various times of the day and adjusted when indicated (eg, because of illness or changes in physical activity). Titration of insulin dosage may be

Nursing Notes: Apply Your Knowledge

Your patient is managing his diabetes with the following split-dose insulin regimen:

Before breakfast (8 AM) 32 units of NPH
Before dinner (6 PM) 10 units of NPH

Using Drugs at a Glance: Insulins, calculate when this patient is most likely to experience hypoglycemia.
Timing of Insulin Administration

Many clients who take insulin need at least two injections daily to control hyperglycemia. A common regimen is one half to two thirds of the total daily dose in the morning, before breakfast, and the remaining one half or one third before the evening meal or at bedtime. With regular insulin before meals, it is very important that the medication be injected 30 to 45 minutes before meals so that the insulin will be available when blood sugar increases after meals. With insulin lispro or aspart before meals, it is important to inject the medication about 15 minutes before eating. If the client does not eat within 15 minutes, hypoglycemia may occur. Insulin glargine should be given at bedtime.

Selection of Subcutaneous Sites for Insulin Injections

Several factors affect insulin absorption from injection sites, including the site location, environmental temperature, and exercise or massage. Studies indicate that insulin is absorbed fastest from the abdomen, followed by the deltoid, thigh, and hip. Because of these differences, many clinicians recommend rotating injection sites within areas. This technique decreases rotations between areas and promotes more consistent blood glucose levels. With regard to temperature, insulin is absorbed more rapidly in warmer sites and environments. In relation to exercise, people who exercise should avoid injecting insulin into SC tissue near the muscles to be used. The increased blood flow that accompanies exercise promotes rapid absorption and may lead to hypoglycemia.

Timing of Food Intake

Clients receiving insulin need food at the peak action time of the insulin and at bedtime. The food is usually taken as a between-meal and a bedtime snack. These snacks help prevent hypoglycemic reactions between meals and at night. When hypoglycemia occurs during sleep, recognition and treatment may be delayed. This delay may allow the reaction to become more severe.

Use With Oral Antidiabetic Drugs

Insulin has been used successfully with all currently available types of oral agents (alpha-glucosidase inhibitors, biguanide, glitazones, meglitinides, and sulfonylureas).

Management of Diabetic Ketoacidosis

Insulin therapy is a major component of any treatment for DKA. Clients with DKA have a deficiency in the total amount of insulin in the body and a resistance to the action of the insulin that is available, probably owing to acidosis, hyperosmolality, infection, and other factors. To be effective, insulin therapy must be individualized according to frequent measurements of blood glucose. Low doses, given by continuous IV infusion, are preferred in most circumstances.

Additional measures include identification and treatment of conditions that precipitate DKA, administration of IV fluids to correct hyperosmolality and dehydration, administration of potassium supplements to restore and maintain normal serum potassium levels, and administration of sodium bicarbonate to correct metabolic acidosis. Infection is one of the most common causes of DKA. If no obvious source of infection is identified, cultures of blood, urine, and throat swabs are recommended. When infection is identified, antibacterial drug therapy may be indicated.

Intravenous fluids, the first step in treating DKA, usually consist of 0.9% sodium chloride, an isotonic solution. Hypotonic solutions are usually avoided because they allow intracellular fluid shifts and may cause cerebral, pulmonary, and peripheral edema.

Although serum potassium levels may be normal at first, they fall rapidly after insulin and IV fluid therapy are begun. Decreased serum potassium levels are caused by expansion of extracellular fluid volume, movement of potassium into cells, and continued loss of potassium in the urine as long as hyperglycemia persists. For these reasons, potassium supplements are usually added to IV fluids. Because both hypokalemia and hyperkalemia can cause serious cardiovascular disturbances, dosage of potassium supplements must be based on frequent measurements of serum potassium levels. Also, continuous or frequent electrocardiogram monitoring is recommended.

Severe acidosis can cause serious cardiovascular disturbances, which usually stem from peripheral vasodilation and decreased cardiac output with hypotension and shock. Acidosis usually can be corrected by giving fluids and insulin; sodium bicarbonate may be given if the pH is less than 7.2. If used, sodium bicarbonate should be given slowly and cautiously. Rapid alkalinization can cause potassium to move into body cells faster than it can be replaced IV. The result may be severe hypokalemia and cardiac dysrhythmias. Also, giving excessive amounts of sodium bicarbonate can produce alkalosis.

Treatment of the Unconscious Client

When a person with diabetes becomes unconscious and it is unknown whether the unconsciousness is caused by DKA or
by hypoglycemia, the client should be treated for hypoglycemia. If hypoglycemia is the cause, giving glucose may avert brain damage. If DKA is the cause, giving glucose does not harm the client. Sudden unconsciousness in a client who takes insulin is most likely to result from an insulin reaction; DKA usually develops gradually over several days or weeks.

**Hyperosmolar Hyperglycemic Nonketotic Coma (HHNC)**

Treatment of HHNC is similar to that of DKA in that insulin, IV fluids, and potassium supplements are major components. Regular insulin is given by continuous IV infusion, and dosage is individualized according to frequent measurements of blood glucose levels. IV fluids are given to correct the profound dehydration and hyperosmolality, and potassium is given IV to replace the large amounts lost in urine during a hyperglycemic state.

**Perioperative Insulin Therapy**

Clients with diabetes who undergo major surgery have increased risks of both surgical and diabetic complications. Risks associated with surgery and anesthesia are greater if diabetes is not well controlled and complications of diabetes (eg, hypertension, nephropathy, vascular damage) are already evident. Hyperglycemia and poor metabolic control are associated with increased susceptibility to infection, poor wound healing, and fluid and electrolyte imbalances. Risks of diabetic complications are increased because the stress of surgery increases insulin requirements and may precipitate DKA. Metabolic responses to stress include increased secretion of catecholamines, cortisol, glucagon, and growth hormone, all of which increase blood glucose levels. In addition to hyperglycemia, protein breakdown, lipolysis, ketogenesis, and insulin resistance occur. The risk of hypoglycemia is also increased.

The goals of treatment are to avoid hypoglycemia, severe hyperglycemia, ketoacidosis, and fluid and electrolyte imbalances. In general, mild hyperglycemia (eg, blood glucose levels between 150 and 250 mg/dL) is considered safer for the client than hypoglycemia, which may go unrecognized during anesthesia and surgery. Because surgery is a stressful event that increases blood glucose levels and the body’s need for insulin, insulin therapy is usually required.

The goal of insulin therapy is to avoid ketosis from inadequate insulin and hypoglycemia from excessive insulin. Specific actions depend largely on the severity of diabetes and the type of surgical procedure. Diabetes should be well controlled before any type of surgery. Minor procedures usually require little change in the usual treatment program; major operations usually require a different medication regimen.

In general, regular, short-acting insulin is used with major surgery or surgery requiring general anesthesia. For clients who use an intermediate-acting insulin, a different regimen using regular insulin in doses approximating the usual daily requirement is needed. For clients who usually manage their diabetes with diet alone or with diet and oral medications, insulin therapy may be started. Human insulin is preferred for temporary use to minimize formation of insulin antibodies. Small doses are usually required.

For elective major surgery, clients should be scheduled early in the day to avoid prolonged fasting. In addition, most authorities recommend omitting usual doses of insulin on the day of surgery and oral antidiabetic medications for 1 or 2 days before surgery. While the client is receiving nothing by mouth, before and during surgery, IV insulin is usually given. Along with the insulin, clients need adequate sources of carbohydrate. This is usually supplied by IV solutions of 5% or 10% dextrose.

After surgery, IV insulin and dextrose may be continued until the client is able to eat and drink. Regular insulin also can be given SC every 4 to 6 hours, with frequent blood glucose measurements. Oral fluids and foods that contain carbohydrate should be resumed as soon as possible. When meals are fully tolerated, the preoperative insulin or oral medication regimen can be resumed. Additional regular insulin can be given for elevated blood glucose and ketones, if indicated.

**Guidelines for Using Oral Antidiabetic Drugs**

**Sulfonylureas**

- Sulfonylureas are not effective in all clients with type 2 diabetes and many clients experience primary or secondary treatment failure. Primary failure involves a lack of initial response to the drugs. Secondary failure means that a therapeutic response occurs when the drugs are first given, but the drugs eventually become ineffective. Reasons for secondary failure may include decreased compliance with diet and exercise instructions, failure to take the drugs as prescribed, or decreased ability of the pancreatic beta cells to produce more insulin in response to the drugs.
- These drugs must be used cautiously in clients with impaired renal or hepatic function.
- Dosage of sulfonylureas is usually started low and increased gradually until the fasting blood glucose is 110 mg/dL or less. The lowest dose that achieves normal fasting and postprandial blood sugar levels is recommended.
- Sulfonylureas are not recommended for use during pregnancy because of risks of fetal hypoglycemia and death, congenital anomalies, and overt diabetes in women with gestational diabetes (because the drugs stimulate an already overstimulated pancreas).

**Alpha-Glucosidase Inhibitors**

- These drugs do not alter insulin secretion or cause hypoglycemia.
- Acarbose and miglitol should be taken at the beginning of a meal so they will be present in the GI tract with food and able to delay digestion of carbohydrates.
Combination drug therapy is an increasing trend in type 2 diabetes that is not controlled by diet, exercise, and single-drug therapy. Useful combinations include drugs with different mechanisms of action, and several rational combinations are currently available. Most studies have involved combinations of two drugs; some three-drug combinations are also being used. All combination therapy should be monitored with periodic measurements of fasting plasma glucose and glycosylated hemoglobin levels. If adequate glycemic control is not achieved, oral drugs may need to be discontinued and insulin therapy started. Two-drug combinations include the following:

- **Insulin plus a sulfonylurea.** Advantages include lower fasting blood glucose levels, decreased glycosylated hemoglobin levels, increased secretion of endogenous insulin, smaller daily doses of insulin, and no significant change in body weight. The role of insulin analogs in combination therapy is not clear. One regimen, called BIDS, uses bedtime insulin, usually NPH, with a daytime sulfonylurea, usually glyburide.
- **Insulin plus a glitazone.** Glitazones increase the effectiveness of insulin, whether endogenous or exogenous.
- **Sulfonylurea plus acarbose or miglitol.** This combination is Food and Drug Administration (FDA) approved for clients who do not achieve adequate glycemic control with one of the drugs alone.
- **Sulfonylurea plus metformin.** Glimepiride is FDA approved for this combination.
- **Sulfonylurea plus a glitazone.** The sulfonylurea increases insulin and the glitazone increases insulin effectiveness.
- **Metformin plus a meglitinide.** If one of the drugs alone does not produce adequate glycemic control, the other one may be added. Dosage of each drug should be titrated to the minimal dose required to achieve the desired effects.

**Effects of Illness on Diabetes Care**

Illness may affect diabetes control in several ways. First, it causes a stress response. Part of the stress response is increased secretion of glucagon, epinephrine, growth hormone, and cortisol, hormones that raise blood glucose levels (by stimulating gluconeogenesis and inhibiting insulin action) and cause ketosis (by stimulating lipolysis and ketogenesis). Second, if the illness makes a person unable or unwilling to eat, hypoglycemia can occur. Third, if the illness affects GI function (eg, causes vomiting or diarrhea), the person may be unable to drink enough fluids to prevent dehydration and electrolyte imbalance. In addition, hyperglycemia induces an osmotic diuresis that increases dehydration and electrolyte imbalances.

As a result of these potentially serious effects, an illness that would be minor in people without diabetes may become a major illness or medical emergency in people with diabetes. Everyone involved should be vigilant about recognizing and seeking prompt treatment for any illness. In addition, clients with diabetes (or their caregivers) should be taught how to adjust their usual regimens to maintain metabolic balance and prevent severe complications. The main goal during illness is to prevent complications such as severe hyperglycemia, dehydration, and DKA.
Use in Children

Diabetes, one of the most common chronic disorders of childhood, usually appears after 4 years of age and peaks in incidence at 10 to 12 years for girls and 12 to 14 years for boys.

Type 1 Diabetes

Insulin is the only drug indicated for use; it is required as replacement therapy because affected children cannot produce insulin. Factors that influence management and insulin therapy include the following:

- Effective management requires a consistent schedule of meals, snacks, blood glucose monitoring, insulin injections and dose adjustments, and exercise. Insulin injections must be given three or four times per day. A healthful, varied diet, rich in whole grains, fruits and vegetables and limited in simple sugars, is recommended. In addition, food intake must be synchronized with insulin injections and usually involves three meals and three snacks, all at regularly scheduled times.

- Such a schedule is difficult to maintain in children, but extremely important in promoting normal growth and development. A major factor in optimal treatment is a supportive family in which at least one member is thoroughly educated about the disease and its management. Less-than-optimal treatment can lead to stunted growth; delayed puberty; and early development of complications such as retinopathy, nephropathy, or neuropathy.

- Infections and other illnesses may cause wide fluctuations in blood glucose levels and interfere with metabolic control. For example, some infections cause hypoglycemia; others, especially chronic infections, may cause hyperglycemia and insulin resistance and may precipitate ketoacidosis. As a result, insulin requirements may vary widely during illness episodes and should be based on blood glucose and urine ketone levels. Hypoglycemia often develops in young children, partly because of anorexia and smaller glycogen reserves.

- During illness, children are highly susceptible to dehydration, and an adequate fluid intake is very important. Many clinicians recommend sugar-containing liquids (eg, regular sodas, clear juices, regular gelatin desserts) if blood glucose values are lower than 250 mg/dL. When blood glucose values are above 250 mg/dL, diet soda, unsweetened tea, and other fluids without sugar should be given.

- For infants and toddlers who weigh less than 10 kg or require less than 5 units of insulin per day, a diluted insulin can be used because such small doses are hard to measure in a U-100 syringe. The most common dilution is U-10, and a diluent is available from insulin manufacturers. Vials of diluted insulin should be clearly labeled and discarded after 1 month.

- Rotation of injection sites is important in infants and young children because of the relatively small areas for injection at each anatomic site and to prevent lipodystrophy.

- Young children usually adjust to injections and blood glucose monitoring better when the parents express less anxiety about these vital procedures.

- Avoiding hypoglycemia is a major goal in infants and young children because of potentially damaging effects on growth and development. For example, the brain and spinal cord do not develop normally without an adequate supply of glucose. Animal studies indicate that prolonged hypoglycemia results in decreased brain weight, numbers of neurons, and protein content. Myelinization of nerve cells is also decreased. Because complex motor and intellectual functions require an intact central nervous system, frequent, severe, or prolonged hypoglycemia can be a serious problem in infants, toddlers, and preschoolers.

- In addition, recognition of hypoglycemia may be delayed because signs and symptoms are vague and the children may be unable to communicate them to parents or caregivers. Because of these difficulties, most pediatric diabetologists recommend maintaining blood glucose levels between 100 and 200 mg/dL to prevent hypoglycemia. In addition, the bedtime snack and blood glucose measurement should never be skipped.

- Signs and symptoms of hypoglycemia in older children are similar to those in adults (eg, hunger, sweating, tachycardia). In young children, hypoglycemia may be manifested by changes in behavior, including severe hunger, irritability, and lethargy. In addition, mental functioning may be impaired in all age groups, even with mild hypoglycemia. Anytime hypoglycemia is suspected, blood glucose should be tested.

- Adolescents may resit adhering to their prescribed treatment regimens, and effective management may be especially difficult during this developmental period. Adolescents and young adults may delay, omit, or decrease dosage of insulin to fit in socially (eg, by eating more, sleeping in, or drinking alcohol) or to control their weight. Omitting or decreasing insulin dosage may lead to repeated episodes of ketoacidosis. Also, adolescent females may develop eating disorders.

- A good resource is the Juvenile Diabetes Foundation (JDF), a not-for-profit health agency with support groups and other activities for families affected by diabetes.

Juvenile Diabetes Foundation International
120 Wall Street
New York, NY 10005-4001
1-800-JDF-CURE
1-800-223-1138

Type 2 Diabetes

Type 2 diabetes is being increasingly identified in children. This trend is attributed mainly to obesity and inadequate exercise because most children with type 2 are seriously overweight and have poor eating habits. In addition, most are
members of high-risk ethnic groups (eg, African American, Native American, or Hispanic) and have relatives with diabetes. These children are at high risk for development of serious complications during early adulthood, such as myocardial infarction during their fourth decade. Management involves exercise, weight loss, and a more healthful diet.

**Use in Older Adults**

General precautions for safe and effective use of antidiabetic drugs apply to older adults, including close monitoring of blood glucose levels. In addition, older adults may have impaired vision or other problems that decrease their ability to perform needed tasks (eg, self-administration of insulin, monitoring blood glucose levels, managing diet and exercise). They also may have other disorders that may complicate management of diabetes. For example, renal insufficiency may increase risks of adverse effects with antidiabetic drugs; treatment with thiazide diuretics, corticosteroids, estrogens, and other drugs may cause hyperglycemia, thereby increasing dosage requirements for antidiabetic drugs.

With oral sulfonylureas, drugs with a short duration of action and inactive metabolites are considered safer, especially in older adults because they have a longer half-life and may accumulate. With metformin, dosage should be based on periodic tests of renal function and the drug should be stopped if renal impairment occurs or if serum lactate increases. In addition, dosage should not be titrated to the maximum amount recommended for younger adults. With the glitazones, dosage increments should be made very slowly, because the drugs act locally, within the GI tract.

**Use in Renal Impairment**

**Insulin.** Frequent monitoring of blood glucose levels and dosage adjustments may be needed. It is difficult to predict dosage needs, and this may lead to higher blood levels of insulin if dosage is not reduced. On the other hand, muscles and possibly other tissues are less sensitive to insulin, and this insulin resistance may result in increased blood glucose level if dosage is not increased. Overall, vigilance is required to prevent dangerous hypoglycemia, especially in clients whose renal function is unstable or worsening.

**Oral drugs. Sulfonylureas** and their metabolites are excreted mainly by the kidneys; renal impairment may lead to accumulation and hypoglycemia. They should be used cautiously, with close monitoring of renal function, in clients with mild to moderate renal impairment, and are contraindicated in severe renal impairment. **Alpha-glucosidase inhibitors** are excreted by the kidneys and accumulate in clients with renal impairment. However, dosage reduction is not helpful because the drugs act locally, within the GI tract. **Metformin** requires assessment of renal function before starting and at least annually during long-term therapy. It should not be given initially if renal impairment is present; it should be stopped if renal impairment occurs during treatment. **Meglitinides** do not require initial dosage adjustments, but increments should be made cautiously in clients with renal impairment or renal failure requiring hemodialysis.

**Use in Hepatic Impairment**

**Insulin.** There may be higher blood levels of insulin in clients with hepatic impairment because less insulin may be degraded. Careful monitoring of blood glucose levels and insulin dosage reductions may be needed to prevent hypoglycemia.

**Oral drugs. Sulfonylureas** should be used cautiously and dosage should be monitored. They are metabolized in the liver and hepatic impairment may result in higher serum drug levels and inadequate release of hepatic glucose in response to hypoglycemia. With glipizide, initial dosage should be reduced in clients with liver failure. Glyburide may cause hypoglycemia in clients with liver disease. **Alpha-glucosidase inhibitors** require no precautions with hepatic impairment because acarbose is metabolized in the GI tract and miglitol is not metabolized. **Metformin** is not recommended for use in clients with clinical or laboratory evidence of hepatic impairment because risks of lactic acidosis may be increased. **Meglitinides** should be used cautiously and dosage increments should be made very slowly, because serum drug levels are higher, for a longer period of time, in clients with moderate to severe hepatic impairment. **Glitazones** have been associated with hepatotoxicity and require monitoring of liver enzymes. The drugs should not be given to clients with active liver disease or a serum alanine aminotransferase (ALT) >2.5 times the upper limit of normal. Once glitazone therapy is initiated, liver enzymes should be measured every 2 months for 1 year, then periodically.

**Use in Critical Illness**

Insulin is more likely to be used in critical illness than any of the oral agents. Reasons include greater ability to titrate dosage needs in clients who are often debilitated and unstable, with varying degrees of cardiovascular, liver, and kidney dysfunction.
impairment. One important consideration with IV insulin therapy is that 30% or more of a dose may adsorb into containers of IV fluid or infusion sets. In addition, many critically ill clients are unable to take oral drugs.

Overall, critically ill clients are at risk for serious hypoglycemia, especially if they are debilitated, sedated, or unable to recognize and communicate symptoms. Vigilant monitoring is essential for any client who has diabetes and a critical illness.

Home Care

Most diabetes care is delivered in ambulatory care settings or in the home, and any client with diabetes may need home care. Hospitalization usually occurs only for complications, and clients are quickly discharged if possible. The home care nurse may need to assist clients of multiple age groups to learn self-care and assist caregivers to support clients’ efforts or actively participate in diabetes management. Some aspects of the nursing role include mobilizing and coordinating health care providers and community resources, teaching and supporting clients and caregivers, monitoring the client’s health status and progress in disease management, and preventing or solving problems.

The person with diabetes has a tremendous amount of information to learn about living with this disease on a day-to-day basis. For most clients, the goal of diabetes education is self-care in terms of diet, exercise, medication administration, blood glucose monitoring, and prevention, recognition, and treatment of complications. For some clients, a parent or caregiver may assume most of the responsibility for diabetes management. Because of the amount and complexity of information, a multidisciplinary health care team that includes a nurse diabetes educator is preferred in home care as in other settings. The role of the home care nurse may include initial teaching or reinforcement and follow-up of teaching done by others.

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With insulin:</td>
<td>Cold insulin is more likely to cause lipodystrophy, local sensitivity reactions, discomfort, and delayed absorption. Insulin preparations are stable for months at room temperature if temperature extremes are avoided. Extremes of temperature decrease insulin potency and cause clumping of the suspended particles of modified insulins. This clumping phenomenon causes inaccurate dosage even if the volume is accurately measured. For accurate measurement of the prescribed dose.</td>
</tr>
<tr>
<td>(1) Store the insulin vial in current use and administer insulin at room temperature. Refrigerate extra vials.</td>
<td></td>
</tr>
<tr>
<td>(2) Avoid freezing temperatures (32°F) or high temperatures (95°F or above).</td>
<td></td>
</tr>
<tr>
<td>(3) Use only an insulin syringe calibrated to measure U-100 insulin.</td>
<td></td>
</tr>
<tr>
<td>(4) With NPH and Lente insulins, be sure they are mixed to a uniform cloudy appearance before drawing up a dose.</td>
<td>These insulin preparations are suspensions, and the components separate on standing. Unless the particles are resuspended in the solution and distributed evenly, dosage will be inaccurate.</td>
</tr>
<tr>
<td>(5) When regular and NPH insulins must be mixed, prepare as follows:</td>
<td>The insulins must be drawn up in the same sequence every time. Regular insulin should always be drawn up first, to avoid contamination of the regular insulin with the NPH. Because regular insulin combines with excess protamine in NPH, the concentration of regular insulin is changed when they are mixed. Following the same sequence also leaves the same type of insulin in the needle and syringe (dead space) every time. Although dead space is not usually a significant factor with available insulin syringes, it may be with small doses.</td>
</tr>
<tr>
<td>(a) Draw into the insulin syringe the amount of air equal to the total amount of both insulins.</td>
<td></td>
</tr>
<tr>
<td>(b) Draw up the regular insulin first. Inject the equivalent portion of air, and aspirate the ordered dose.</td>
<td></td>
</tr>
<tr>
<td>(c) With the NPH vial, insert the remaining air (avoid injecting regular insulin into the NPH vial), and aspirate the ordered dose.</td>
<td></td>
</tr>
<tr>
<td>(d) Expel air bubbles, if present, and verify that the correct dosage is in the syringe.</td>
<td></td>
</tr>
</tbody>
</table>
### Nursing Actions

<table>
<thead>
<tr>
<th>(e)</th>
<th>Administer combined insulins <strong>consistently</strong> within 15 min of mixing or after a longer period; that is, do not give one dose within 15 min of mixing and another 2 h or days after mixing.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6)</td>
<td>Rotate injection sites systematically, within the same anatomic area (e.g., abdomen) until all sites are used. Avoid random rotation between the abdomen and thigh or arm, for example.</td>
</tr>
<tr>
<td>(7)</td>
<td>Inject insulin at a 90-degree angle into a subcutaneous pocket created by raising subcutaneous tissue away from muscle tissue. Avoid intramuscular injection.</td>
</tr>
<tr>
<td>(8)</td>
<td>With insulin analogs, give aspart within 5 to 10 minutes of starting a meal; give lispro within 15 minutes before or immediately after a meal; give glargine once daily at bedtime.</td>
</tr>
<tr>
<td></td>
<td><strong>b.</strong> With oral sulfonylureas: Give glipizide or glyburide 30 minutes before breakfast and the evening meal. Give glimepiride with breakfast.</td>
</tr>
<tr>
<td></td>
<td><strong>c.</strong> With acarbose and miglitol: Give at the beginning of each main meal, three times daily.</td>
</tr>
<tr>
<td></td>
<td><strong>d.</strong> With metformin: Give with meals.</td>
</tr>
<tr>
<td></td>
<td><strong>e.</strong> With pioglitazone and rosiglitazone: Give once daily, without regard to meals.</td>
</tr>
<tr>
<td></td>
<td><strong>f.</strong> With repaglinide and nateglinide: Give 15 to 30 min before meals (2, 3, or 4 times daily). If the client does not eat a meal, omit that dose; if the client eats an extra meal, give an extra dose.</td>
</tr>
</tbody>
</table>

#### Rationale/Explanation

<table>
<thead>
<tr>
<th>(e)</th>
<th>Regular insulin combines with excess protamine when mixed with NPH insulin. This reaction occurs within 15 min of mixing and alters the amount of regular insulin present. After 15 min, the mixture is stable for approximately 1 month at room temperature and 3 months when refrigerated. Thus, to administer the same dose consistently, the mixture must be given at approximately the same time interval after mixing.</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6)</td>
<td>Frequent injection in the same site can cause tissue fibrosis, erratic absorption, and deposits of unabsorbed insulin. Also, if insulin is usually injected into fibrotic tissue where absorption is slow, injection into healthy tissue may result in hypoglycemia because of more rapid absorption. Further, deposits of unabsorbed insulin may initially lead to hyperglycemia. If dosage is increased to control the apparent hyperglycemia, hypoglycemia may occur.</td>
</tr>
<tr>
<td>(7)</td>
<td>Rates of absorption differ among anatomic sites, and random rotation increases risks of hypoglycemic reactions.</td>
</tr>
<tr>
<td>(8)</td>
<td>Injection into a subcutaneous pocket is thought to produce less tissue irritation and better absorption than injection into subcutaneous tissue. Intramuscular injection should not be used because of rapid absorption.</td>
</tr>
<tr>
<td></td>
<td><strong>Manufacturers’ recommendations.</strong> Aspart and lispro act rapidly; glargine is long-acting.</td>
</tr>
</tbody>
</table>

#### 2. Observe for therapeutic effects

<table>
<thead>
<tr>
<th>a.</th>
<th>Improved blood glucose levels (fasting, preprandial, and postprandial) and glycosylated hemoglobin levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>b.</td>
<td>Absent or decreased ketones in urine (N = none)</td>
</tr>
<tr>
<td>c.</td>
<td>Absent or decreased pruritus, polyuria, polydipsia, polyphagia, and fatigue</td>
</tr>
<tr>
<td>d.</td>
<td>Decreased complications of diabetes</td>
</tr>
</tbody>
</table>

*continued*
### Nursing Actions

#### 3. Observe for adverse effects

**a.** With insulin, sulfonylureas, and meglitinides:

1. **Hypoglycemia**
   - (a) Sympathetic nervous system (SNS) activation—tachycardia, palpitations, nervousness, weakness, hunger, perspiration
   - (b) Central nervous system impairment—mental confusion, incoherent speech, blurred or double vision, headache, convulsions, coma

2. **Weight gain**

**b.** With insulin:

1. Local insulin allergy—erythema, induration, itching at injection sites
2. Systemic allergic reactions—skin rash, dyspnea, tachycardia, hypotension, angioedema, anaphylaxis
3. Lipodystrophy—atrophy and “dimpling” at injection site; hypertrophy at injection site

**c.** With sulfonylureas:

1. Hypoglycemia and weight gain—see above
2. Allergic skin reactions—skin rash, urticaria, erythema, pruritus
3. GI upset—nausea, heartburn
4. Miscellaneous—fluid retention and hyponatremia; facial flushing if alcohol is ingested; hematologic disorders (hemolytic or aplastic anemia, leukopenia, thrombocytopenia, others)

**d.** With acarbose and miglitol: GI symptoms—bloating, flatulence, diarrhea, abdominal pain

**e.** With metformin:

1. GI effects—anorexia, nausea, vomiting, diarrhea, abdominal discomfort, decreased intestinal absorption of folate and vitamin B<sub>12</sub>
2. Allergic skin reactions—eczema, pruritus, erythema, urticaria
3. Lactic acidosis—drowsiness, malaise, respiratory distress, bradycardia and hypotension (if severe), blood lactate levels above 5 mmol/L, blood pH below 7.35

---

### Rationale/Explanation

Hypoglycemia is more likely to occur with insulin than with oral agents and at peak action times of the insulin being used (eg, 2 to 3 h after injection of regular insulin; 8 to 12 h after injection of NPH or Lente insulin).

The SNS is activated as part of the stress response to low blood glucose levels. Epinephrine and other hormones act to raise blood glucose levels.

There is an inadequate supply of glucose for normal brain function.

This effect may decrease compliance with drug therapy, especially in adolescent and young adult females.

Uncommon with human insulin

Uncommon; if a severe systemic reaction occurs, skin testing and desensitization are usually required.

These changes in subcutaneous fat occur from too-frequent injections into the same site. They are uncommon with human insulin.

Hypoglycemia occurs less often with oral agents than with insulin. It is more likely to occur in patients who are elderly, debilitated, or who have impaired renal and hepatic function.

These reactions may subside with continued use of the drug. If they do not subside, the drug should be discontinued.

These are the most commonly reported adverse effects. If severe, reducing drug dosage usually relieves them.

These are less common adverse effects.

These are commonly reported. They are caused by the presence of undigested carbohydrate in the lower GI tract. They can be decreased by low doses initially and gradual increases.

GI symptoms are common adverse effects. They may be minimized by taking the drug with meals and increasing dosage slowly.

A rare but serious adverse effect (approximately 50% fatal). Most likely with renal or hepatic impairment, advanced age, or hypoxia. This is a medical emergency that requires hospitalization for treatment.

Hemodialysis is effective in correcting acidosis and removing metformin.

Lactic acidosis may be prevented by monitoring plasma lactate levels and stopping the drug if they exceed 3 mmol/L. Other rea-
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>f. With pioglitazone and rosiglitazone:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Upper respiratory infections—pharyngitis, sinusitis</td>
</tr>
<tr>
<td>(2) Liver damage or failure</td>
</tr>
<tr>
<td>(3) Fluid retention, edema, and congestive heart failure</td>
</tr>
<tr>
<td>(4) Weight gain</td>
</tr>
<tr>
<td>(5) Headache</td>
</tr>
<tr>
<td>(6) Anemia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>g. With nateglinide and repaglinide:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Hypoglycemia</td>
</tr>
<tr>
<td>(2) Rhinitis, respiratory infection, influenza symptoms</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

- **With pioglitazone and rosiglitazone:**
  - Few cases of liver failure have been reported, but the drugs are related to troglitazone (Rezulin), a drug that was taken off the market because of hepatotoxicity. Monitoring of liver enzymes is recommended during therapy.
  - Several reports indicate increased risks of developing or worsening heart failure.

- **With nateglinide and repaglinide:**
  - If occurs, usually of mild to moderate intensity
  - These were the most commonly reported during clinical drug trials.

### 4. Observe for drug interactions

#### a. Drugs that increase effects of insulin:
- (1) ACE inhibitors (eg, captopril)
- (2) Alcohol
- (3) Anabolic steroids
- (4) Antidiabetic drugs, oral
- (5) Antimicrobials (sulfonamides, tetracyclines)
- (6) Beta-adrenergic blocking agents (eg, propranolol)

#### b. Drugs that decrease effects of insulin:
- (1) Adrenergics (eg, albuterol, epinephrine, others)
- (2) Corticosteroids (eg, prednisone)
- (3) Estrogens and oral contraceptives
- (4) Glucagon
- (5) Levothyroxine (Synthroid)
- (6) Phenytoin (Dilantin)
- (7) Propranolol (Inderal)
- (8) Thiazide diuretics (eg, hydrochlorothiazide)

#### c. Drugs that increase effects of sulfonylureas:
- (1) Acarbose, miglitol, metformin, pioglitazone, rosiglitazone

One of these drugs may be used concomitantly with a sulfonylurea to improve glycemic control in patients with type 2 diabetes. There is an increased risk of hypoglycemia with the combinations.

(continued)
### CHAPTER 27  ANTIDIABETIC DRUGS

#### NURSING ACTIONS

| (2) Alcohol (acute ingestion) | Additive hypoglycemia |
| (3) Cimetidine (Tagamet) | May inhibit metabolism of sulfonylureas, thereby increasing and prolonging hypoglycemic effects |
| (4) Insulin | Additive hypoglycemia |

**d. Drugs that decrease effects of sulfonylureas:**

| (1) Alcohol | Heavy, chronic intake of alcohol induces metabolizing enzymes in the liver. This accelerates metabolism of sulfonylureas, shortens their half-lives, and may produce hyperglycemia. |
| (2) Beta-blocking agents | Decrease hypoglycemic effects, possibly by decreasing release of insulin in the pancreas |
| (3) Corticosteroids, diuretics, epinephrine, estrogens, and oral contraceptives | These drugs have hyperglycemic effects. |
| (4) Glucagon | Raises blood glucose levels. It is used to treat severe hypoglycemia induced by insulin or oral antidiabetic agents. |
| (5) Nicotinic acid | Large doses have a hyperglycemic effect. |
| (6) Phenyltoin (Dilantin) | Inhibits insulin secretion and has hyperglycemic effects |
| (7) Rifampin | Increases the rate of metabolism of sulfonylureas by inducing liver-metabolizing enzymes |
| (8) Thyroid preparations | Antagonize the hypoglycemic effects of oral antidiabetic drugs |

**e. Drugs that decrease effects of acarbose and miglitol:**

| (1) Digestive enzymes | Decrease effects and should not be used concomitantly |
| (2) Intestinal adsorbents (eg, charcoal) | Decrease effects and should not be used concomitantly |

**f. Drugs that increase effects of metformin:**

| (1) Alcohol | Increases risk of hypoglycemia and lactic acidosis. Patients should avoid acute and chronic ingestion of excessive alcohol. |
| (2) Cimetidine | Increases risk of hypoglycemia. Cimetidine interferes with metabolism and increases blood levels of metformin. |
| (3) Furosemide | Increases blood levels of metformin |
| (4) Sulfonylurea hypoglycemic agents | The combination of these drugs is used to improve control of hyperglycemia in type 2 diabetes but it also increases risk of hypoglycemia. |

**g. Drugs that increase effects of pioglitazone:**

| (1) Erythromycin, ketoconazole and related drugs | Inhibit cytochrome P450 3A4 enzymes that partially metabolize pioglitazone and may increase adverse effects. This interaction not reported with rosiglitazone, which is metabolized mainly by 2C8 and 2C9 enzymes. |

**h. Drugs that increase effects of nateglinide and repaglinide:**

| (1) Nonsteroidal anti-inflammatory drugs and other agents that are highly bound to plasma proteins | May displace drugs from binding sites, therefore increasing their blood levels |
| (2) Beta blockers | May inhibit hepatic metabolism of repaglinide and nateglinide and increase their blood levels |
| (3) Cimetidine, erythromycin, ketoconazole, miconazole | |
| (4) Sulfonylamides | |

**i. Drugs that decrease effects of nateglinide and repaglinide:**

| (1) Adrenergics, corticosteroids, estrogens, niacin, oral contraceptives, thiazide diuretics | May cause hyperglycemia |
| (2) Carbamazepine, rifampin | Induce drug-metabolizing enzymes in the liver, which leads to faster inactivation |
Nursing Notes: Apply Your Knowledge

Answer: NPH is an intermediate-acting insulin that usually peaks 8 to 12 hours after administration. Hypoglycemia is most likely to occur before meals. The morning NPH is most likely to cause hypoglycemia before dinner and the evening NPH is likely to cause hypoglycemia after midnight, so diabetics need to eat an evening snack.

How Can You Avoid This Medication Error?

Answer: Metformin (Glucophage) should be discontinued a few days before any diagnostic procedure involving a contrast medium to decrease the chance of lactic acidosis, a potentially lethal side effect. The incidence of lactic acidosis increases when renal insufficiency is present. Urinary tract infections can contribute to renal damage. Documenting in Mrs. Watson’s chart that she has taken her metformin is good but this is not enough because the physician may overlook reading it in the chart. The physician should be notified because it would be prudent to reschedule Mrs. Watson’s IVP.

Review and Application Exercises

1. What is the function of insulin in normal cellular metabolism?
2. What are the effects of insulin, cortisol, epinephrine, glucagon, and growth hormone on blood glucose levels?
3. What are the major differences between type 1 and type 2 diabetes?
4. What is the rationale for maintaining near-normal blood glucose levels? What is the major risk?
5. At what blood glucose range is brain damage most likely to occur?
6. Compare regular, NPH, and Lente insulins in terms of onset, peak, and duration of action.
7. Describe major characteristics and uses of insulin analogs.
8. In a diabetic client with typical signs and symptoms, distinguish between manifestations of hyperglycemia and hypoglycemia.
9. Contrast the five types of oral hypoglycemic agents in terms of mechanisms of action, indications for use, contraindications to use, and adverse effects.
10. For an adult client newly diagnosed with type 2 diabetes, outline interventions to assist the client in learning self-care.
11. Prepare a teaching plan for a client starting insulin therapy and for a client starting an oral hypoglycemic drug.
12. For a diabetic client who reports using dietary and herbal supplements, analyze specific supplements in relation to their potential impact on blood sugar control.

SELECTED REFERENCES

Estrogens, Progestins, and Hormonal Contraceptives

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss the effects of endogenous estrogens and progestins.
2. Describe the benefits and risks of postmenopausal hormone replacement therapy (HRT).
3. Describe adverse effects associated with estrogens, progestins, and hormonal contraceptives.
4. Apply nursing process with clients taking estrogens, progestins, and hormonal contraceptives.

Critical Thinking Scenario

Sally Chow, a perimenopausal woman has concerns about hormone replacement therapy (HRT). She seeks information from you to help her make an informed choice whether to use HRT.

Reflect on:

- Benefits of HRT for the postmenopausal woman.
- Possible adverse effects of HRT for the postmenopausal woman.
- Teaching strategies helpful in teaching Ms. Chow about HRT.
- As a nurse, your role in assisting Ms. Chow in her decision-making process.

Overview

Estrogens and progestins are female sex hormones produced primarily by the ovaries and secondarily by the adrenal cortices in nonpregnant women. Small amounts of estrogens are also synthesized in the liver, kidney, brain, skeletal muscle, testes, and adipose tissue. In normal premenopausal women, estrogen synthesis in adipose tissue may be a significant source of the hormone. Some evidence indicates that a minimum body weight (about 105 lbs.) and fat content (16% to 24%) are required for initiation and maintenance of the menstrual cycle. This view is supported by the observation that women with anorexia nervosa, chronic disease, or malnutrition and those who are long-distance runners usually have amenorrhea. With anorexia nervosa, regaining weight and body mass usually reestablishes normal menstrual patterns.

Small amounts of progesterone are secreted by the testes and adrenal glands. In men and in postmenopausal women, the peripheral sites produce all endogenous estrogen. Almost no progesterone is synthesized in postmenopausal women.

As with other steroid hormones, estrogens and progestins are synthesized from cholesterol. The ovaries and adrenal glands can manufacture cholesterol or extract it from the blood. Through a series of chemical reactions, cholesterol is converted to progesterone and then to androgens, testosterone, and androstenedione. The ovaries use these male sex hormones to produce estrogens. After formation, the hormones are secreted into the bloodstream in response to stimulation by the anterior pituitary gonadotropic hormones, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). In the bloodstream, the hormones combine with serum proteins and are transported to target tissues where they enter body cells. They cross cell membranes easily because of their steroid structure and lipid solubility. Once inside the cells, the hormones bind to estrogen or progesterin receptors and regulate intracellular protein synthesis. Estrogen can enhance target tissue responses to progesterone by increasing progesterone receptors. Progesterone seems to inhibit tissue responses to estrogen by decreasing estrogen receptors.
Three ovarian estrogens (estradiol, estrone, and estriol) are secreted in significant amounts. Estradiol is the major estrogen because it exerts more estrogenic activity than the other two estrogens combined. The main function of the estrogens is to promote growth in tissues related to reproduction and sexual characteristics in women. More specific effects of estrogens on body tissues are described in Box 28–1.

In nonpregnant women, between puberty and menopause, estrogens are secreted in a monthly cycle called the menstrual cycle. During the first half of the cycle, before ovulation, estrogens are secreted in progressively larger amounts. During the second half of the cycle, estrogens and progesterone are secreted in increasing amounts until 2 to 3 days before the onset of menstruation. At that time, secretion of both hormones decreases abruptly. When the endometrial lining of the uterus loses its hormonal stimulation, it is discharged vaginally as menstrual flow.

During pregnancy, the placenta produces large amounts of estrogen, mainly estriol. The increased estrogen causes enlargement of the uterus and breasts, growth of glandular tissue in the breasts, and relaxation of ligaments and joints in the pelvis. All these changes are necessary for the growth and birth of the fetus.

Finally, estrogens are deactivated in the liver, partly or mainly by cytochrome P450 3A4 enzymes. The estrogens are then conjugated with glucuronic acid or sulfuric acid, which makes them water soluble and readily excreted through the kidneys. Metabolites are also formed in the gastrointestinal tract, brain, skin, and other steroid target tissues. Most of the conjugates are excreted in urine; some are excreted in bile and recirculated to the liver or excreted in feces.

**PROGESTERONE**

Progesterone is a progestin concerned almost entirely with reproduction. In the nonpregnant woman, progesterone is secreted by the corpus luteum during the last half of the menstrual cycle, which occurs after ovulation. This hormone continues the changes in the endometrial lining of the uterus begun by estrogens during the first half of the menstrual cycle. These changes provide for implantation and nourishment of a fertilized ovum. When fertilization does not take place, the estrogen and progesterone levels decrease and menstruation occurs.

If the ovum is fertilized, progesterone acts to maintain the pregnancy. The corpus luteum produces progesterone during the first few weeks of gestation. Then, the placenta produces the progesterone needed to maintain the endometrial lining of the uterus. In addition to its effects on the uterus, progesterone prepares the breasts for lactation by promoting development of milk-producing cells. Milk is not secreted, however, until the cells are further stimulated by prolactin from the anterior pituitary gland.

**BOX 28–1  EFFECTS OF ENDOGENOUS ESTROGENS**

<table>
<thead>
<tr>
<th><strong>Breasts</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Stimulate growth at puberty by causing deposition of fat, formation of connective tissue, and construction of ducts. These ducts become part of the milk-producing apparatus after additional stimulation by progesterone.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Sexual Organs</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Enlarge the fallopian tubes, uterus, vagina, and external genitalia at puberty, when estrogen secretion increases greatly.</td>
</tr>
<tr>
<td>• Cause the endometrial lining of the uterus to proliferate and develop glands that later nourish the implanted ovum when pregnancy occurs.</td>
</tr>
<tr>
<td>• Increase resistance of the epithelial lining of the vagina to trauma and infection.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Skeleton</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Stimulate skeletal growth so that, beginning at puberty, height increases rapidly for several years. Estrogen then causes the epiphyses to unite with the shafts of the long bones, and linear growth is halted. This effect of estrogen is stronger than the similar effect of testosterone in the male. Consequently, women stop growing in height several years earlier than men and on the average are shorter than men.</td>
</tr>
<tr>
<td>• Conserve calcium and phosphorus for healthy bones and teeth. This action promotes bone formation and decreases bone loss.</td>
</tr>
<tr>
<td>• Broaden the pelvis in preparation for childbirth.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Skin and Subcutaneous Tissue</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Increase vascularity in the skin. This leads to greater skin warmth and likelihood of bleeding in women.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Anterior Pituitary Gland</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Decrease pituitary secretion of follicle-stimulating hormone and increase secretion of luteinizing hormone when blood levels are sufficiently high (negative feedback mechanism).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Metabolism</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Affect metabolism of both reproductive and nonreproductive tissues. Estrogen receptors are found in female reproductive organs, breast tissue, bone, the brain, liver, heart, and blood vessels. They are also found in various tissues in men.</td>
</tr>
<tr>
<td>• Increase protein anabolism, bone growth, and epiphyseal closure in young girls.</td>
</tr>
<tr>
<td>• Decrease bone resorption.</td>
</tr>
<tr>
<td>• Increase sodium and water retention, serum triglycerides, and high-density lipoproteins (HDL or “good” cholesterol).</td>
</tr>
<tr>
<td>• Decrease low-density lipoproteins (LDL or “bad” cholesterol).</td>
</tr>
<tr>
<td>• Increase the amount of cholesterol in bile and thereby increase gallstone formation.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Blood Coagulation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Enhance coagulation by increasing blood levels of several clotting factors, including prothrombin and factors VII, IX, and X, and probably increase platelet aggregation.</td>
</tr>
</tbody>
</table>
Estrogens and Progestins

Anterior pituitary gland. Progesterone also may help maintain pregnancy by decreasing uterine contractility. This, in turn, decreases the risk of spontaneous abortion.

Progesterone, in general, has opposite effects on lipid metabolism compared with estrogen. That is, progestins decrease high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol, both of which increase risks of cardiovascular disease. Physiologic progesterone increases insulin levels but does not usually impair glucose tolerance. However, long-term administration of potent synthetic progestins, such as norgestrel, may decrease glucose tolerance and make diabetes mellitus more difficult to control. Like estrogen, progesterone is metabolized in the liver.

**Mechanisms of Action**

The precise mechanisms by which estrogens and progestins produce their effects are unknown. Estrogens circulate in the bloodstream to target cells, where they enter the cells and combine with receptor proteins in cell cytoplasm. The estrogen–receptor complex is then transported to the cell nucleus where it interacts with deoxyribonucleic acid (DNA) to produce ribonucleic acid (RNA) and new DNA. These substances stimulate cell reproduction and production of various proteins. Progestins also diffuse freely into cells, where they bind to progesterone receptors.

Hormonal contraceptives act by several mechanisms. First, they inhibit hypothalamic secretion of gonadotropin-releasing hormone, which inhibits pituitary secretion of FSH and LH. When these gonadotropic hormones are absent, ovulation and, therefore, conception cannot occur. Second, the drugs produce cervical mucus that resists penetration of spermatozoa into the upper reproductive tract. Third, the drugs interfere with endometrial maturation and reception of ova that are released and fertilized. These overlapping mechanisms make the drugs highly effective in preventing pregnancy.

**Indications for Use**

**Estrogens**

- **As replacement therapy in deficiency states.** Deficiency states usually result from hypofunction of the pituitary gland or the ovaries and may occur anytime during the life cycle. For example, in the adolescent girl with delayed sexual development, estrogen can be given to produce the changes that normally occur at puberty. In the woman of reproductive age (approximately 12 to 50 years), estrogen replacement is usually given to prevent osteoporosis.
45 years of age), estrogens are occasionally used in menstrual disorders, including amenorrhea and abnormal uterine bleeding due to estrogen deficiency.

- **As a component in birth control pills and other contraceptive preparations.** An estrogen, when combined with a progestin, is used widely in the 12- to 45-year age group to control fertility. If pregnancy does occur, estrogens are contraindicated because their use during pregnancy has been associated with the occurrence of vaginal cancer in female offspring and possible harmful effects on male offspring.

- **Menopause.** Estrogens are prescribed to relieve symptoms of estrogen deficiency (eg, atrophic vaginitis and vasomotor instability, which produces “hot flashes”) and to prevent or treat osteoporosis. When estrogen is prescribed for women with a uterus, a progestin is also given to prevent endometrial cancer. Such usage is usually called estrogen replacement therapy (ERT) or HRT.

  In addition, ERT and HRT have been used long-term for cardioprotective effects because it was believed that the drugs decreased myocardial infarctions and deaths from cardiovascular disease. This view was based largely on observational studies that indicated that postmenopausal women had a much higher risk of heart disease than did premenopausal women. The difference was attributed to decreased hormone production at menopause. The drugs are now recommended for short-term use (eg, 2 years) to relieve menopausal symptoms, but not for long-term use for cardioprotective effects. A recent well-done study indicated that risks are greater than benefits for combined estrogen-progestin therapy (Box 28–2).

  The part of the study concerned with estrogen replacement only is scheduled to be completed in 2005. The early part of the study did not indicate significantly increased risks with estrogen replacement after hysterectomy.

**Progestins**

Progestins are most often used in combination with an estrogen in contraceptive products. They also are used to suppress

---

**BOX 28–2 HORMONE REPLACEMENT THERAPY IN POSTMENOPAUSAL WOMEN**

**Background**

For many years, postmenopausal women have been treated with estrogen replacement therapy (ERT) to manage symptoms of menopause. In addition, estrogen was thought to have cardioprotective effects, partly because the incidence of heart attacks in women increased substantially after menopause and became similar to the incidence in men. Several studies also indicated beneficial effects in preventing osteoporosis, a common disorder in postmenopausal women. As a result of these observations, the use of ERT evolved from management of menopausal symptoms to prevention of cardiovascular disease and osteoporosis. Other benefits were also attributed to ERT. Because estrogen alone increases risks of endometrial cancer in women with an intact uterus, a progestin was added.

**Estrogen-Progestin Combinations**

Combined estrogen/progestin hormone replacement therapy became the standard of care for women with an intact uterus and was widely prescribed for its perceived benefits in maintaining women’s health. In 2002, the prevailing opinion changed dramatically to indicate that combined estrogen/progestin therapy should not be used to prevent cardiovascular disease in healthy postmenopausal women, because risks were greater than benefits.

This opinion resulted largely from the Women’s Health Initiative (WHI), a randomized, controlled study involving >16,000 women with an intact uterus. The published report of the Writing Group for the Women’s Health Initiative Investigators revealed that risks from long-term use of an estrogen-progestin combination (Prempro) outweighed its benefits. This part of the study was stopped after an average follow-up period of 5 years (8 years planned), because of a higher incidence of invasive breast cancer. Results also indicated increased risks of heart attacks, strokes, and blood clotting disorders and decreased risks of osteoporotic fractures and colon cancers.

Data analysis indicated that in 10,000 women taking the drug combination, there would be seven more coronary heart disease events, eight more strokes, eight more pulmonary emboli, eight more invasive breast cancers, six fewer colorectal cancers, and five fewer hip fractures. Although these numbers are not large and the risk is relatively small, the investigators concluded that the drug combination produced more harm than benefit and should not be started or continued to prevent coronary heart disease (CHD) in healthy women.

The WHI study was done with healthy women, to see if the drugs would prevent CHD from developing. The Heart and Estrogen/ Progestin Replacement Studies, HERS and HERS II, involved postmenopausal women with intact uteri who already had CHD. Results indicated that the drug combination (estrogen 0.625 mg and medroxyprogesterone 2.5 mg) conferred no benefit in relation to preventing serious cardiovascular events and actually increased risks during the first year of therapy. As with healthy women, the conclusion was that the hormones should not be started or continued in women with CHD for preventive purposes.

For individual women, the benefits in reducing symptoms of menopause, fractures from osteoporosis, and colon cancer must be weighed against the increased risks of CHD, thromboembolic stroke, venous thromboembolism, breast cancer, and cholecystitis. Thromboembolic disorders are most likely to occur during the first year of use; risks of developing breast cancer and gallbladder disease increase with the duration of drug use. If the combined drugs are prescribed to relieve menopausal symptoms in women who have not had a hysterectomy, they should probably be used for 1 to 2 years, then discontinued.

**Estrogen Alone**

For postmenopausal women who have had a hysterectomy and thus do not need a progestin to prevent endometrial cancer, estrogen alone is used to prevent or treat symptoms of menopause. In addition, estrogen is generally thought to have beneficial effects on serum cholesterol and bone density. However, there has been considerable debate about possible increases in breast cancer risks. Overall, benefits versus risks have not yet been well delineated. The part of the WHI study concerning the use of estrogen alone in hysterectomized women continues. To date, no alarming results have developed; the study is scheduled for completion in 2005. There are currently no new recommendations for or against the use of estrogen alone in women who have had a hysterectomy. Individual women and their health care providers must weigh risks versus benefits.
ovarian function in dysmenorrhea, endometriosis, and uterine bleeding. These uses of progestins are extensions of the physiologic actions of progesterone on the neuroendocrine control of ovarian function and on the endometrium. For approximately 20 to 25 years, progestins were used in combination with estrogen for long-term HRT in postmenopausal women with intact uteri. With HRT, the purpose of a progestin is to prevent endometrial cancer, which can occur with unopposed estrogenic stimulation. Currently, however, the combination is not recommended for long-term use because a research study indicated that the adverse effects outweigh the beneficial effects (see Box 28–2).

**Hormonal Contraceptives**

The primary clinical indication for the use of hormonal contraceptives is to control fertility and prevent pregnancy. Some products are used for contraception after unprotected sexual intercourse. These preparations also are used to treat menstrual disorders (eg, amenorrhea, dysmenorrhea).

**Contraindications to Use**

Because of their widespread effects on body tissues and reported adverse reactions, estrogens, progestins, and hormonal contraceptives are contraindicated in:

- Known or suspected pregnancy, because damage to the fetus may result
- Thromboembolic disorders, such as thrombophlebitis, deep vein thrombosis, or pulmonary embolism
- Known or suspected cancers of breast or genital tissues, because the drugs may stimulate tumor growth. An exception is the use of estrogens for treatment of metastatic breast cancer in women at least 5 years postmenopause.
- Undiagnosed vaginal or uterine bleeding
- Fibroid tumors of the uterus
- Active liver disease or impaired liver function
- History of cerebrovascular disease, coronary artery disease, thrombophlebitis, hypertension, or conditions predisposing to these disease processes
- Women older than 35 years of age who smoke cigarettes. These women have a greater risk of thromboembolic disorders if they take hormonal contraceptives, possibly because of increased platelet aggregation with estrogen ingestion and cigarette smoking. In addition, estrogen increases hepatic production of blood clotting factors.
- Family history of breast or reproductive system cancer

**INDIVIDUAL ESTROGENS, PROGESTINS, AND COMBINATION PRODUCTS**

Clinical indications, routes of administration, and dosages are discussed in the estrogens and progestins Drugs at a Glance tables. Combination noncontraceptive products are listed in Drugs at a Glance: Noncontraceptive Estrogen-Progesterin Combinations, and hormonal contraceptive agents are listed in Table 28–1.

(text continues on page 417)
### Drugs at a Glance: Estrogens (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Menopausal Symptoms</th>
<th>Female Hypogonadism</th>
<th>Prevention of Osteoporosis</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estradiol (Estrace)</td>
<td>PO 1–2 mg daily for 3 wk, then 1 wk off or daily Monday through Friday, none on Saturday or Sunday</td>
<td></td>
<td>PO 0.5 mg daily for 23 d and no drug for 5 d each month</td>
<td>Atrophic vaginitis, cream, 2-4 g daily for 2 wk, then 1-2 g daily for 2 wk, then 1 g 1–3 times weekly; vaginal ring (Estring), 1 every 3 mo</td>
</tr>
<tr>
<td>Estradiol cypionate (Depo-Estradiol)</td>
<td>IM 1–5 mg every 3–4 wk</td>
<td>IM 1.5–2 mg at monthly intervals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol hemihydrate (Vagifem)</td>
<td>Topically to skin, 1 patch one or two times weekly for 3 wk followed by 1 wk off (cyclically)</td>
<td>Same as for menopause</td>
<td>0.05 mg daily</td>
<td></td>
</tr>
<tr>
<td>Estradiol transdermal system (Estraderm)</td>
<td>PO 0.02–0.05 mg daily, cyclically</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estradiol valerate (Delestrogen)</td>
<td>IM 10–20 mg every 4 wk</td>
<td>IM 10–20 mg every 4 wk</td>
<td></td>
<td>Atrophic vaginitis, 1 tablet, inserted into vagina, daily for 2 wk, then twice weekly</td>
</tr>
<tr>
<td>Estrone</td>
<td>PO 0.5 mg daily for 23 d and no drug for 5 d each month</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estropipate (Ogen)</td>
<td>PO 1.25–7.5 mg daily for 3 wk, followed by an 8- to 10-d rest period. Repeat as needed.</td>
<td>PO 0.625 mg daily 25 d, no drug 6 d each month</td>
<td></td>
<td>Ovarian failure: same dosage as for female hypogonadism Atrophic vaginitis: topically, 1–2 g vaginal cream daily</td>
</tr>
<tr>
<td>Ethinyl estradiol (Estinyl)</td>
<td>PO 0.02–0.05 mg daily, cyclically</td>
<td>PO 0.05 mg one to three times daily for 2 wk with addition of progestin for last 2 wk of month</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Drugs at a Glance: Progestins

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Menstrual Disorders</th>
<th>Endometriosis</th>
<th>Endometrial Cancer</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxyprogesterone caproate (Hylutin)</td>
<td>Amenorrhea, dysfunctional uterine bleeding: IM 375 mg. If no bleeding after 21 d, begin cyclic therapy with estradiol and repeat every 4 wk for 4 cycles</td>
<td>PO 1.25–7.5 mg daily for 3 wk, followed by an 8- to 10-d rest period. Repeat as needed.</td>
<td>PO 0.625 mg daily 25 d, no drug 6 d each month</td>
<td>Uterine adenocarcinoma: IM 1 g or more initially; repeat one or more times each week (maximum, 7 g/wk). Stop when relapse occurs or after 12 wk with no response. Test for endogenous estrogen production: IM 250 mg, repeated in 4 wk. Bleeding 7–14 d after injection indicates endogenous estrogen.</td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Progestins (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Menstrual Disorders</th>
<th>Endometriosis</th>
<th>Endometrial Cancer</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medroxyprogesterone acetate (Depo-Provera, Provera)</td>
<td>Dysfunctional uterine bleeding: PO 5–10 mg daily for 5–10 d beginning on 16th or 21st d of cycle</td>
<td>IM 400–1000 mg weekly until improvement, then 400 mg monthly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Megestrol acetate (Megace)</td>
<td>Amenorrhea: PO 5–10 mg daily for 5–10 d</td>
<td>PO 40–320 mg daily in 4 divided doses for at least 2 mo</td>
<td>Breast cancer: PO 160 mg daily in 4 divided doses for at least 2 mo</td>
<td></td>
</tr>
<tr>
<td>Norethindrone acetate (Aygestin)</td>
<td>Amenorrhea, dysfunctional uterine bleeding: PO 2.5–10 mg daily, starting on 5th d of menstrual cycle and ending on 25th d</td>
<td>PO 5 mg daily for 2 wk, increased by 2.5 mg daily every 2 wk to dose of 15 mg. Then give 10–15 mg daily for maintenance.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progesterone</td>
<td>Amenorrhea, dysfunctional uterine bleeding: IM 5–10 mg for 6–8 consecutive d</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Drugs at a Glance: Noncontraceptive Estrogen-Progesterin Combinations

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Estrogen</th>
<th>Progesterin</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activeelle</td>
<td>Estradiol 1 mg</td>
<td>Norethindrone 0.5 mg</td>
<td>Menopausal symptoms; prevention of osteoporosis</td>
<td>PO 1 tablet daily</td>
</tr>
<tr>
<td>Combi-Patch</td>
<td>Estradiol 0.05 mg</td>
<td>Norethindrone 0.14 mg or 0.25 mg</td>
<td>Estrogen deficiency states due to menopause, hypogonadism, castration, or primary ovarian failure</td>
<td>1 transdermal patch twice weekly</td>
</tr>
<tr>
<td>Femhrt</td>
<td>Ethinyl estradiol 5 mcg</td>
<td>Norethindrone 1 mg</td>
<td>Menopausal symptoms; prevention of osteoporosis</td>
<td>PO 1 tablet daily</td>
</tr>
<tr>
<td>Ortho-Prefest</td>
<td>Estradiol 1 mg*</td>
<td>Norgestimate 0.09 mg</td>
<td>Menopausal symptoms; prevention of osteoporosis</td>
<td>PO 1 tablet estrogen-only (pink) daily for 3 d, then 1 combination tablet (white) daily for 3 d. Repeat this 6-d regimen continuously, without interruption.</td>
</tr>
<tr>
<td>Premphase</td>
<td>Conjugated estrogens 0.625 mg*</td>
<td>Medroxyprogesterone 5 mg</td>
<td>Menopausal symptoms; prevention of osteoporosis</td>
<td>PO 1 tablet of estrogen-only once daily on d 1–14, then 1 combination tablet once daily on d 15–28</td>
</tr>
<tr>
<td>Prempro</td>
<td>Conjugated estrogens 0.625 mg</td>
<td>Medroxyprogesterone 2.5 or 5 mg</td>
<td>Menopausal symptoms; prevention of osteoporosis</td>
<td>PO 1 tablet once daily</td>
</tr>
</tbody>
</table>

*Also available with estrogen only.
### TABLE 28–1  Oral and Other Contraceptives

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Phase</th>
<th>Estrogen (mcg)</th>
<th>Progestin (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Monophasics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alesse</td>
<td></td>
<td>Ethinyl estradiol 20</td>
<td>Levonorgestrel 0.1</td>
</tr>
<tr>
<td>Apri</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Desogestrel 0.15</td>
</tr>
<tr>
<td>Aviane</td>
<td></td>
<td>Ethinyl estradiol 20</td>
<td>Levonorgestrel 0.1</td>
</tr>
<tr>
<td>Brevicon</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.1</td>
</tr>
<tr>
<td>Demulen 1/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Ethynodiol 1</td>
</tr>
<tr>
<td>Demulen 1/50</td>
<td></td>
<td>Ethinyl estradiol 50</td>
<td>Ethynodiol 1</td>
</tr>
<tr>
<td>Desogen</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Desogestrel 0.15</td>
</tr>
<tr>
<td>Levlen</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Levonorgestrel 0.15</td>
</tr>
<tr>
<td>Levite</td>
<td></td>
<td>Ethinyl estradiol 20</td>
<td>Levonorgestrel 0.1</td>
</tr>
<tr>
<td>Levora</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Levonorgestrel 0.15</td>
</tr>
<tr>
<td>Loestrin 21 1.5/30</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1.5</td>
</tr>
<tr>
<td>Loestrin Fe 1/20</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1.5</td>
</tr>
<tr>
<td>Loestrin 1.5/30</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1.5</td>
</tr>
<tr>
<td>Lo/Oral</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 0.3</td>
</tr>
<tr>
<td>Low-Orgestrel</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 0.3</td>
</tr>
<tr>
<td>Microgestin Fe 1/20</td>
<td></td>
<td>Ethinyl estradiol 20</td>
<td>Noretindrone 1.5</td>
</tr>
<tr>
<td>Microgestin Fe 1.5/30</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1.5</td>
</tr>
<tr>
<td>Modicon</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Necon 0.5/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Necon 1/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Necon 1/50</td>
<td></td>
<td>Mestranol 50</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Nordette</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Levonorgestrel 0.15</td>
</tr>
<tr>
<td>Norinyl 1 + 35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Norinyl 1 + 50</td>
<td></td>
<td>Mestranol 50</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Nortrel 0.5/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Nortrel 1/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ogestrel</td>
<td></td>
<td>Ethinyl estradiol 50</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Ortho-Cept</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Desogestrel 0.15</td>
</tr>
<tr>
<td>Ortho-Cyclen</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Norgestimate 0.25</td>
</tr>
<tr>
<td>Ortho-Novum 1/35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ortho-Novum 1/50</td>
<td></td>
<td>Mestranol 50</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ovcon-35</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.4</td>
</tr>
<tr>
<td>Ovcon-50</td>
<td></td>
<td>Ethinyl estradiol 50</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ovral-28</td>
<td></td>
<td>Ethinyl estradiol 50</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td>Yasmin</td>
<td></td>
<td>Ethinyl estradiol 30</td>
<td>Drospirenone 3</td>
</tr>
<tr>
<td>Zovia 1/35E</td>
<td></td>
<td>Ethinyl estradiol 35</td>
<td>Ethynodiol 1</td>
</tr>
<tr>
<td>Zovia 1/50E</td>
<td></td>
<td>Ethinyl estradiol 50</td>
<td>Ethynodiol 1</td>
</tr>
<tr>
<td><strong>Biphasics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jenest-28</td>
<td>I: 10 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td></td>
<td>II: 11 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Mircette</td>
<td>II: 21 d</td>
<td>Ethinyl estradiol 20</td>
<td>Desogestrel 0.15</td>
</tr>
<tr>
<td>Necon 10/11</td>
<td>I: 10 d</td>
<td>Ethinyl estradiol 10</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td></td>
<td>II: 11 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ortho-Novum 10/11</td>
<td>I: 10 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td></td>
<td>II: 11 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td><strong>Triphasics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Estrostep 21</td>
<td>I: 5 d</td>
<td>Ethinyl estradiol 20</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td></td>
<td>II: 7 d</td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td></td>
<td>III: 9 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Estrostep Fe</td>
<td>I: 5 d</td>
<td>Ethinyl estradiol 20</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td></td>
<td>II: 7 d</td>
<td>Ethinyl estradiol 30</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td></td>
<td>III: 9 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ortho-Novum 7/7/7</td>
<td>I: 7 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.5</td>
</tr>
<tr>
<td></td>
<td>II: 7 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 0.75</td>
</tr>
<tr>
<td></td>
<td>III: 7 d</td>
<td>Ethinyl estradiol 35</td>
<td>Noretindrone 1</td>
</tr>
<tr>
<td>Ortho Tri-Cyclen</td>
<td>I: 7 d</td>
<td>Ethinyl estradiol 35</td>
<td>Norgestimate 0.18</td>
</tr>
<tr>
<td></td>
<td>II: 9 d</td>
<td>Ethinyl estradiol 35</td>
<td>Norgestimate 0.215</td>
</tr>
<tr>
<td></td>
<td>III: 5 d</td>
<td>Ethinyl estradiol 35</td>
<td>Norgestimate 0.25</td>
</tr>
</tbody>
</table>
Herbal and Dietary Supplements

**Black Cohosh** is an herb used to self-treat symptoms of menopause. It is reportedly effective in relieving vasomotor instability. Most information is derived from small German studies using Remifemin, the brand name of a standardized extract that is marketed as an alternative to estrogen therapy for menopausal symptoms. The product apparently does not affect the endometrium or estrogen-dependent cancers; its effects on bone and osteoporosis are unknown. Animal studies indicate binding to estrogen receptors and suppression of LH. A study of posthysterectomy patients indicated no advantage of the herb over conventional ERT. Other trade names include Estroven, Femtrol, and GNC Menopause Formula.

Adverse effects may include nausea, vomiting, dizziness, hypotension, and visual disturbances. Blood pressure should be monitored closely in hypertensive clients, because the herb may increase the hypotensive effects of antihypertensive drugs. Black cohosh is contraindicated in pregnancy and not recommended for use longer than 6 months for menopausal symptoms.

Overall, this herb may be useful in clients who refuse estrogen or have conditions in which estrogen is contraindicated. If Remifemin is taken, the recommended dose is 1 tablet (standardized to contain 20 mg of herbal drug) twice daily. Other dosage forms are available, and dosage depends on the method of preparation.

---

### Nursing Process

#### Assessment

Before drug therapy is started, clients need a thorough history and physical examination, including measurements of blood pressure, serum cholesterol, and triglycerides. These parameters must be monitored periodically as long as the drugs are taken.

- **Assess for conditions in which estrogens and progestins are used** (eg, menstrual disorders, menopausal symptoms).
- **Assess for conditions that increase risks of adverse effects or are contraindications for hormonal therapy** (eg, thromboembolic disorders, pregnancy).
- **Record blood pressure with each outpatient contact or regularly with hospitalized clients. Increases are likely in premenopausal women, especially with oral contraceptives, but are unlikely in women who are postmenopausal who are receiving physiologic replacement doses.**
- **Check laboratory reports of cholesterol and triglyceride levels when available.**
- **Assess diet and presence of cigarette smoking. A high-fat diet increases the risks of gallbladder disease and perhaps other problems; cigarette smoking increases risks of thromboembolic disorders in women older than 35 years of age who take oral contraceptives.**
- **Assess the client’s willingness to comply with instructions about drug therapy and follow-up procedures.**
Drug Selection Factors

Choice of preparation depends on the reason for use, desired route of administration, and duration of action. Conjugated estrogen (eg, Premarin) is a commonly used oral estrogen and medroxyprogesterone (eg, Provera) is a commonly used oral progestin.

The choice of combination contraceptive product may be determined by the progestin component. Some progestins are more likely to cause weight gain, acne, and changes in blood lipids that increase risks of myocardial infarction or stroke. These adverse effects are attributed mainly to the androgenic activity of the progestin, and some progestins have more androgenic effects than others. Progestins with minimal androgenic activity are desogestrel and norgestimate; those with intermediate activity include norethindrone and ethynodiol; norgestrel has high androgenic effects. In addition, there are long-acting progestin contraceptive preparations such as IM depot medroxyprogesterone (Depo-Provera) that lasts 3 months per injection, intrauterine progesterone that lasts 1 year, and levonorgestrel subcutaneous implants (Norplant) that last 5 years.

Dosage Factors

Although dosage needs vary with clients and the conditions for which the drugs are prescribed, a general rule is to use the smallest effective dose for the shortest effective time. Estrogens are often given cyclically. In one regimen, the drug is taken for 3 weeks, then omitted for 1 week; in another, it is omitted the first 5 days of each month. These regimens more closely resemble normal secretion of estrogen and avoid prolonged stimulation of body tissues. A progestin may be added for 10 days each month.

Effects of Estrogens and Oral Contraceptives on Other Drugs

These drugs may interact with several drugs or drug groups to increase or decrease their effects. Most interactions have been reported with oral contraceptives.

Estrogens may decrease the effectiveness of sulfonylurea antidiabetic drugs (probably by increasing their metabolism); warfarin, an oral anticoagulant (by increasing hepatic production of several clotting factors); and phenytoin, an anticonvulsant (possibly by increasing fluid retention). Estrogens may increase the adverse effects and risks of toxicity with corticosteroids, ropinirole, and tacrine by inhibiting their metabolism. Ropinirole and tacrine should not be used concurrently with an estrogen.

Oral contraceptives decrease effects of some benzodiazepines (eg, lorzepam, oxazepam, temazepam), insulin, sulfonylurea antidiabetic drugs, and warfarin. If one of these drugs is taken concurrently with an oral contraceptive, increased dosage may be needed for therapeutic effects. Contra-
CHAPTER 28 ESTROGENS, PROGESTINS, AND HORMONAL CONTRACEPTIVES

CHAPTER 28 ESTROGENS, PROGESTINS, AND HORMONAL CONTRACEPTIVES

CHAPTER 28 ESTROGENS, PROGESTINS, AND HORMONAL CONTRACEPTIVES

CHAPTER 28 ESTROGENS, PROGESTINS, AND HORMONAL CONTRACEPTIVES

CLIENT TEACHING GUIDELINES

Hormone Replacement Therapy

General Considerations

✔ Estrogen replacement therapy relieves symptoms of menopause and helps to prevent or treat osteoporosis.

✔ Maintain medical supervision at least annually to check blood pressure, breasts, pelvis, and other areas for possible adverse reactions when these drugs are taken for long periods.

✔ Women who have not had a hysterectomy should take both estrogen and progestin; the progestin component (eg, Provera) prevents endometrial cancer, an adverse effect of estrogen-only therapy. However, a well-done study reported in 2002 concluded that risks of adverse effects with estrogen–progestin combinations are greater than previously believed. Women with an intact uterus who are considering hormone replacement therapy (eg, for severe symptoms of menopause) should discuss their individual risks and potential benefits with their health care providers.

✔ Combined estrogen–progestin therapy may increase blood sugar levels in women with diabetes. This effect is attributed to progestin and is unlikely to occur with estrogen only therapy.

✔ Women with diabetes should report increased blood glucose levels.

Self-Administration

✔ Take estrogens and progestins with food or at bedtime to decrease nausea, a common adverse reaction.

✔ Apply skin patch estrogen (eg, Estraderm) to clean, dry skin, preferably the abdomen. Press the patch tightly for 10 seconds to get a good seal and rotate sites so that at least a week passes between applications to a site.

✔ Weigh weekly and report sudden weight gain. Fluid retention and edema may occur and produce weight gain.

✔ Report any unusual vaginal bleeding.

CLIENT TEACHING GUIDELINES

Oral Contraceptives

General Considerations

✔ Seek information about the use of oral contraceptives.

✔ Oral contraceptives are very effective at preventing pregnancy, but they do not prevent transmission of sexually transmitted diseases (eg, acquired immunodeficiency syndrome, chlamydia, gonorrhea).

✔ See a health care provider every 6 to 12 months for blood pressure measurement, breast and pelvic examinations, and other care as indicated. This is very important to monitor for adverse drug effects such as high blood pressure, gallbladder disease, and blood clotting disorders.

✔ Do not smoke cigarettes. Cigarette smoking increases risks of blood clots in the legs, lungs, heart, or brain. The blood clots may cause heart attack, stroke, or other serious diseases.

✔ Several medications may reduce the effectiveness of oral contraceptives (ie, increase the likelihood of pregnancy). These include several antibiotics (eg, ampicillin, clarithromycin and similar drugs, rifampin, penicillin V, sulfonamides [eg, Bactrim], tetracyclines, and antiseizure medications [eg, carbamazepine, oxcarbazepine, phenytoin, topiramate]). Inform all health care providers who prescribe medications for you that you are taking a birth control pill.

✔ Be prepared to use an additional or alternative method of birth control if a dose is missed, if you are unable to take the oral contraceptive because of illness, or if you have an infection for which an antibiotic is prescribed. For example, use a different method of birth control while taking an antibiotic and for the remainder of that cycle.

✔ Avoid pregnancy for approximately 3 to 6 months after the drugs are stopped.

Self-Administration

✔ Take oral contraceptives with meals or food or at bedtime to decrease nausea. (If using Ortho Evra, a contraceptive skin patch that lasts a week, follow package instructions for correct application.)

✔ Take about the same time every day to maintain effective blood levels and establish a routine so that missed doses are less likely. Missing one dose may allow pregnancy to occur. If you forget to take one pill, take it as soon as you remember. If you do not remember until the next scheduled pill, you can take two pills at once. If you miss two pills in a row, you may take two pills for the next 2 days. If you miss more than two pills, notify your health care provider.

✔ Use sunscreen and protective clothing when outdoors. The drugs may cause photosensitivity, with increased likelihood of sunburn after short periods of exposure.

✔ Weigh weekly and report sudden weight gain. The drugs may cause fluid retention; decreasing salt intake may be helpful.

✔ Report any unusual vaginal bleeding; calf tenderness, redness, or swelling; chest pain; weakness or numbness in an arm or leg; or sudden difficulty with seeing or talking.
Emergency (Postcoital) Contraception

Emergency contraception (ie, high doses of estrogen and progestin) may be used to avoid pregnancy after unprotected sexual intercourse, especially for victims of rape or incest or women whose physical or mental health is threatened by pregnancy. It is most effective if started within 24 hours and no later than 72 hours after exposure. The drugs are believed to act mainly by inhibiting ovulation.

Although Preven (levonorgestrel 0.25 mg and ethinyl estradiol 0.05 mg) is the only drug approved by the Food and Drug Administration (FDA) for postcoital contraception, multiple tablets of several birth control pills are also effective. The drugs are given in 2 doses, 12 hours apart. Amounts include 4 tablets of Levlen, Lo-Ovral, Nordette, Triphasil, or Tri-Levlen, 2 tablets of Ovral, and 5 tablets of Alesse. These are high doses and common adverse effects are nausea and vomiting. Antiemetic medication or repeating vomited doses may be needed. Women who take a hormonal contraceptive should probably ask the prescriber about possible postcoital use.

Menopause

Menopause usually occurs in women who are 48 to 55 years of age. A woman who has not menstruated for a full year is considered menopausal, although symptoms of estrogen deficiency and irregular periods start approximately 4 years before final cessation. Physiologic menopause results from the gradual cessation of ovarian function and the resultant decrease in estrogen levels. Surgical menopause results from excision of both ovaries and the sudden loss of ovarian estrogen. Although estrogens from the adrenal cortex and other sites are still produced, the amount is insufficient to prevent estrogen deficiency.

ERT prevents vasomotor instability (“hot flashes”) and other menopausal symptoms. A commonly prescribed regimen...
is a conjugated estrogen (eg, Premarin) 0.625 mg to 1.25 mg daily for 25 days of each month, with a progestin, such as Provera, 10 mg daily for 10 days of each month, on days 15 to 25 of the cycle. The main function of the progestin is to decrease the risk of endometrial cancer; thus, women who have had a hysterectomy do not need it. Another regimen uses estradiol as a transdermal patch (Estraderm), which releases the drug slowly, provides more consistent blood levels than oral formulations, and is applied weekly. A newer synthetic conjugated estrogen (Cenestin) is also approved for short-term treatment of hot flashes and sweating; it is not approved for long-term use in preventing osteoporosis in postmenopausal women.

**Use in Older Adults**

The short-term use (1 to 2 years) of estrogens or estrogens and progestins in postmenopausal women may be indicated for management of menopausal symptoms. Long-term use of an estrogen/progestin combination is no longer recommended for most women, because of potentially serious adverse effects. Long-term use of estrogen alone is being investigated.

**Use in Hepatic Impairment**

Estrogens are contraindicated in impaired liver function, liver disease, or liver cancer. Impaired liver function may lead to impaired estrogen metabolism, with resultant accumulation and adverse effects. In addition, women who have had jaundice during pregnancy have an increased risk of recurrence if they take an estrogen-containing contraceptive. Any client in whom jaundice develops when taking estrogen should stop the drug. Because jaundice may indicate liver damage, the cause should be investigated.

Progestins are contraindicated in clients with impaired liver function or liver disease.

**Home Care**

Estrogens, progestins, and hormonal contraceptives are usually self-administered at home. The home care nurse may encounter clients or family members taking one of the drugs when visiting the home for another purpose. Teaching or assisting clients to take the drugs as prescribed may be needed. In addition, clients may need encouragement to keep appointments for follow-up supervision and blood pressure monitoring. When visiting families that include adolescent girls or young women, the nurse may need to teach about birth control or preventing osteoporosis by improving diet and exercise patterns. With families that include postmenopausal women, the nurse may need to teach about nonhormonal strategies for preventing or treating osteoporosis and cardiovascular disease.

---

**Prevention and Treatment of Osteoporosis**

Estrogen or estrogen/progestin therapy is effective and has been widely used to prevent or treat osteoporosis and prevent fractures in postmenopausal women (see Chap. 26). Estrogenic effects in preventing bone loss include decreased bone resorption (breakdown), increased intestinal absorption of calcium, and increased calcitriol concentration. Calcitriol is the active form of vitamin D, which is required for absorption of calcium.

These hormones may be used less often for osteoporosis in future for two main reasons. First, recent evidence (see Box 28–2) indicates that the risks of estrogen/progestin hormonal therapy outweigh the benefits. The effects of estrogen alone are not yet known. Second, there are other effective measures for prevention and treatment of osteoporosis, including calcium and vitamin D supplements, bisphosphonate drugs (eg, alendronate and risedronate), and weight-bearing exercise.

**Use in Children**

There is little information about the effects of estrogens in children, and the drugs are not indicated for use. Because the drugs cause epiphyseal closure, they should be used with caution before completion of bone growth and attainment of adult height. When hormonal contraceptives are given to adolescent girls, the smallest effective doses should be used, as in other populations.

---

**NURSING ACTIONS**

**Estrogens, Progestins, and Hormonal Contraceptives**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give oral estrogens, progestins, and contraceptive preparations after meals or at bedtime.</td>
<td>To decrease nausea, a common adverse reaction</td>
</tr>
<tr>
<td>b. With aqueous suspensions to be given intramuscularly, roll the vial between the hands several times.</td>
<td>To be sure that drug particles are evenly distributed through the liquid vehicle</td>
</tr>
</tbody>
</table>

(continued)
### NURSING ACTIONS

**c.** Give oil preparations deeply into a large muscle mass, preferably gluteal muscles.

**d.** With estradiol skin patches, apply to clean dry skin of the abdomen, buttocks, upper inner thigh, or upper arm. Avoid breasts, waistline areas, and areas exposed to sunlight. Press with palm of hand for about 10 seconds. Rotate sites.

**e.** With Combi-Patch, apply to clean dry skin of the lower abdomen; rotate sites.

**f.** With Ortho Evra patch, apply to abdomen, buttocks, upper torso (except breasts), or upper outer arm.

### RATIONALE/EXPLANATION

To facilitate effective absorption and adherence to the skin and avoid skin irritation.

Manufacturer’s recommendation. Rotating sites decreases skin irritation.

Therapeutic effects vary, depending on the reason for use.

### 2. Observe for therapeutic effects

**a.** With estrogens:

1. When given for menopausal symptoms, observe for decrease in hot flashes and vaginal problems.
2. When given for amenorrhea, observe for menstruation.
3. When given for female hypogonadism, observe for menstruation, breast enlargement, axillary and pubic hair, and other secondary sexual characteristics.
4. When given to prevent or treat osteoporosis, observe for improved bone density tests and absence of fractures.

**b.** With progestins:

1. When given for menstrual disorders, such as abnormal uterine bleeding, amenorrhea, dysmenorrhea, pre-menstrual discomfort, and endometriosis, observe for relief of symptoms.

### 3. Observe for adverse effects

**a.** With estrogens:

1. Menstrual disorders—breakthrough bleeding, dysmenorrhea, amenorrhea
2. Gastrointestinal system—nausea, vomiting, abdominal cramps, bloating
3. Gallbladder disease
4. Cardiovascular system—thromboembolic conditions such as thrombophlebitis, pulmonary embolism, cerebral thrombosis, and coronary thrombosis; edema and weight gain
5. Central nervous system—headache, migraine, dizziness, mental depression
6. Cancer—endometrial and possibly breast cancer

Estrogen drugs may alter hormonal balance.

Nausea commonly occurs but usually subsides within 1 to 2 wk of continued therapy. When high doses of estrogens are used as postcoital contraceptives, nausea and vomiting may be severe enough to require administration of antiemetic drugs.

Postmenopausal women taking an estrogen are 2 to 4 times more likely than nonusers to require surgery for gallbladder disease.

Estrogens promote blood clotting by stimulating hepatic production of four clotting factors (II, VII, IX, X). Thromboembolic disorders are most likely to occur in women older than 35 y who take oral contraceptives and smoke cigarettes, postmenopausal women taking long-term estrogen and progestin therapy, and men or women who receive large doses of estrogens for cancer treatment. Edema and weight gain are caused by fluid retention.

Estrogens may cause or aggravate migraine in some women; the mechanism is unknown.

When estrogens are used alone in postmenopausal women, they cause endometrial hyperplasia and may cause endometrial cancer. Women with an intact uterus should also be given a progestin, which opposes the effects of estrogen on the endometrium.

(continued)
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
b. With progestins: | 
(1) Menstrual disorders—breakthrough bleeding | Opinions differ regarding estrogens as a cause of breast cancer. Most studies indicate little risk; a few indicate some risk, especially with high doses for prolonged periods (ie, 10 y or longer). However, estrogens do stimulate growth in breast cancers that have estrogen receptors.
(2) Cardiovascular system—decreased high-density lipoprotein and increased low-density lipoprotein cholesterol | Irregular vaginal bleeding is a common adverse effect that decreases during the first year of use. This is a major reason that some women do not want to take progestin-only contraceptives.
(3) Gastrointestinal system—nausea, increased or decreased weight | These adverse effects on plasma lipids potentially increase the risks of cardiovascular disease.
(4) Central nervous system—drowsiness, insomnia, mental depression | Nausea may be decreased by taking with food.
(5) Miscellaneous effects—edema, weight gain | Nausea can be minimized by taking the drugs with food or at bedtime.

c. Combined estrogen and progestin oral contraceptives: | 
(1) Gastrointestinal effects—nausea, others | These effects occurred with earlier oral contraceptives, which contained larger amounts of estrogen than those currently used, and are much less common in most people who take low-dose preparations. However, for women older than 35 y who smoke, there is an increased risk of myocardial infarction and other cardiovascular disorders even with low-dose pills.
(2) Cardiovascular effects—thromboembolism, myocardial infarction, stroke, hypertension | Women who use oral contraceptives or estrogen–progestin hormone replacement therapy are several times more likely to develop gallbladder disease than nonusers. This is attributed to increased concentration of cholesterol in bile acids, which leads to decreased solubility and increased precipitation of stones.
(3) Gallbladder disease—cholelithiasis and cholecystitis | 
(4) Miscellaneous—edema, weight gain, headache | 

4. Observe for drug interactions | 
a. Drugs that decrease effects of estrogens, progestins, and oral contraceptives: | 
(1) Anticonvulsants—carbamazepine, oxcarbazepine, phenytoin, topiramate | Decrease effects by inducing enzymes that accelerate metabolism of estrogens and progestins.
(2) Antimicrobials | Most interactions with antimicrobials have been reported with oral contraceptives. Rifampin induces drug-metabolizing enzymes that accelerate drug inactivation. Other antimicrobials act mainly by disrupting the normal bacterial flora of the gastrointestinal tract and decreasing enterohepatic recirculation of estrogens. This action may decrease effectiveness of contraceptives or cause breakthrough bleeding. To prevent pregnancy from occurring during antimicrobial therapy, a larger dose of oral contraceptive or an additional or alternative form of birth control is probably advisable.
(a) Antibacterials—ampicillin, macrolides (erythromycin, clarithromycin, dirithromycin), metronidazole, penicillin V, rifampin, sulfonamides, tetracyclines, trimethoprim | 
(b) Antifungals—fluconazole, itraconazole, ketoconazole | 
(c) Antivirals—efavirenz, ritonavir, lopinavir/ritonavir combination |
Answer: Factors such as the number of doses omitted and the time of the month such omission occurred may affect whether skipped doses could alter therapeutic drug levels. If Jane remembers a skipped dose within hours, instruct her just to take the pill late. If a longer period of time elapses (eg, over 48 hours), instruct Jane not to take all the missed doses at once and to check with her health care provider. Alternative forms of birth control may be required for the rest of the cycle.

Teach Jane to take her birth control pills at the same time each day, in association with a daily task or ritual (eg, after breakfast, after brushing teeth before bed). Advise her to notify any health care provider that she is taking birth control pills when other medications are prescribed. Drug interactions can occur with some other drugs. Antibiotics, which childbearing women may often require, can decrease the effectiveness of oral contraceptives.

How Can You Avoid This Medication Error?

Answer: The nurse has provided adequate patient teaching concerning Tami’s antibiotic, but the nurse has not advised her regarding the drug–drug interaction between ampicillin and oral contraceptives. Taking both of these drugs together will decrease the effectiveness of the oral contraceptives and could result in an unplanned pregnancy. Tami needs to use additional contraceptive protection during the month she is taking the antibiotic. She also needs to know that birth control pills will not protect against sexually transmitted disease.

Review and Application Exercises

1. What are the reproductive and nonreproductive functions of estrogens?
2. What are the functions of progestins?
3. What is considered the major mechanism of action of hormonal contraceptives?
4. What are the adverse effects of hormonal contraceptives, and how can they be prevented or minimized?
5. Outline the points you would make for and against HRT for a postmenopausal woman.
6. Prepare a teaching plan for perimenopausal or postmenopausal woman about nonpharmacologic measures to manage menopausal symptoms and prevent osteoporosis.

SELECTED REFERENCES

Androgens and Anabolic Steroids

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss effects of endogenous androgens.
2. Discuss uses and effects of exogenous androgens and anabolic steroids.
3. Describe potential consequences of abusing androgens and anabolic steroids.
4. Counsel clients about the physiologic effects of the dietary supplements androstenedione and dehydroepiandrosterone (DHEA).

Critical Thinking Scenario
You are a nurse working in a rural high school. The wrestling coach asks you to talk with his wrestling team about anabolic steroids.

Reflect on:
- Why adolescents might want to use anabolic steroids.
- Potential dangers of anabolic steroid use.
- Confusion regarding the difference between anabolic steroids and corticosteroids.
- Strategies that might be effective in limiting the use of anabolic steroids among young athletes.

OVERVIEW
Androgens are male sex hormones secreted by the testes in men, the ovaries in women, and the adrenal cortices of both sexes. Like the female sex hormones, the naturally occurring male sex hormones are steroids synthesized from cholesterol. The sex organs and adrenal glands can produce cholesterol or remove it from the blood. Cholesterol then undergoes a series of conversions to progesterone, androgenic prehormones, and testosterone. The androgens produced by the ovaries have little androgenic activity and are used mainly as precursor substances for the production of naturally occurring estrogens. The adrenal glands produce several androgens, including androstenedione and dehydroepiandrosterone (DHEA). Androstenedione and DHEA are weak androgens with little masculinizing effect that are mainly converted to estrogens.

TESTOSTERONE
Testosterone is normally the only important male sex hormone. It is secreted by the Leydig’s cells in the testes in response to stimulation by luteinizing hormone from the anterior pituitary gland. The main functions of testosterone are related to the development of male sexual characteristics, reproduction, and metabolism (Box 29–1).

About 97% of the testosterone secreted by the testes binds to plasma albumin or to sex hormone–binding globulin and circulates in the blood for 30 minutes to several hours. The bound testosterone is either transferred to the tissues or broken down into inactive products that are excreted. Much of the testosterone that transfers to tissues undergoes intracellular conversion to dihydrotestosterone, especially in the external genitalia of the male fetus and the prostate gland in the adult male. The dihydrotestosterone combines with receptor proteins in the cytosol; the steroid–receptor combination then migrates to the cell nucleus where it induces transcription of DNA and RNA and stimulates production of proteins. Almost all testosterone effects result from the increased formation of proteins throughout the body, especially in the cells of target organs and tissues responsible for development of male sexual characteristics.

The portion of testosterone that does not become attached to tissues is converted into androsterone and DHEA by the liver. These are conjugated with glucuronic or sulfuric acid and excreted in the bile or urine.
ANABOLIC STEROIDS

Anabolic steroids are synthetic drugs with increased anabolic activity and decreased androgenic activity compared with testosterone. They were developed during attempts to modify testosterone so that its tissue-building and growth-stimulating effects could be retained while its masculinizing effects could be eliminated or reduced.

ABUSE OF ANDROGENIC AND ANABOLIC STEROID DRUGS

Androgens and anabolic steroids are widely abused in attempts to enhance muscle development, muscle strength, and athletic performance. Because of their abuse potential, the drugs are Schedule III controlled substances. Although non-prescription sales of the drugs are illegal, they apparently are easily obtained.

Athletes are considered a high-risk group because some start taking the drugs in their early teenage years and continue for years. The number of teens taking anabolic steroids is thought to be small in comparison with the number using marijuana, amphetamines, and other illegal drugs. However, the number is also thought to be increasing, and long-term effects may be as bad as the effects that occur with use of other illegal drugs. Although steroids have a reputation for being dangerous to adult athletes, such as bodybuilders and football players, they are considered even more dangerous for teens because teens are still growing. Anabolic steroids can stop bone growth and damage the heart, kidneys, and liver of adolescents. In addition to those who take steroids to enhance athletic performance, some males take the drugs to produce a more muscular appearance and impress females. Steroid abusers usually take massive doses and often take several drugs or combine injectable and oral drugs for maximum effects. The large doses produce potentially serious adverse effects in several body tissues:

- **Cardiovascular disorders** include hypertension, decreased high-density blood lipoproteins (HDL) and increased low-density lipoproteins (LDL), all of which promote heart attacks and strokes.
- **Liver disorders** include benign and malignant neoplasms, cholestatic hepatitis and jaundice, and peliosis hepatis, a disorder in which blood-filled cysts develop in the liver and may lead to hemorrhage or liver failure.
Central nervous system disorders include aggression, hostility, combativeness, and dependence characterized by preoccupation with drug use, inability to stop taking the drugs, and withdrawal symptoms similar to those that occur with alcohol, cocaine, and narcotics. In some cases, psychosis may develop.

Reproductive system disorders include decreased testicular function (eg, decreased secretion of endogenous testosterone and decreased formation of sperm), testicular atrophy, and impotence in men. They include amenorrhea in women.

Metabolic disorders include atherosclerosis-promoting changes in cholesterol metabolism and retention of fluids, with edema and other imbalances. Fluid and electrolyte retention contribute to the increased weight associated with drug use.

Dermatologic disorders include moderate to severe acne in both sexes, depending on drug dosage. Many of these adverse effects persist several months after the drugs are stopped and may be irreversible. Names of anabolic steroids include nandrolone (Deca-Durabolin), oxandrolone (Oxandrin), oxymetholone (Anadrol-50), and Stanazolol (Winstrol).

**Mechanism of Action**

Like other steroid drugs, androgenic and anabolic drugs penetrate the cell membrane and bind to receptor proteins in the cell cytoplasm. The steroid–receptor complex is then transported to the nucleus, where it activates ribonucleic and deoxyribonucleic acid production and stimulates cellular synthesis of protein.
**Indications for Use**

With male sex hormones, the most clear-cut indication for use is to treat androgen deficiency states (e.g., hypogonadism, cryptorchidism, impotence, oligospermia) in boys and men. Hypogonadism may result from hypothalamic-pituitary or testicular dysfunction. In prepubertal boys, administration of the drugs stimulates the development of masculine characteristics. In postpubertal men who become androgen deficient, the hormones re-establish and maintain masculine characteristics and functions.

In women, danazol (Danocrine) may be used to prevent or treat endometriosis or fibrocystic breast disease. Anabolic steroids are more often abused for body-building purposes than used for therapeutic effects.

Although some drug literature still lists metastatic breast cancer and some types of anemia as indications for use, androgens have largely been replaced by newer drugs for these purposes. In breast cancer, for example, androgens are second-line hormonal agents, after anti-estrogens (e.g., tamoxifen). In anemia associated with renal failure, synthetic erythropoietin is more effective and likely to be used.

**Contraindications to Use**

Androgens and anabolic steroids are contraindicated during pregnancy (because of possible masculinizing effects on a female fetus), in clients with preexisting liver disease, and in men with prostate gland disorders. Men with enlarged prostates may have additional enlargement, and men with prostatic cancer may experience tumor growth. Although not contraindicated in children, these drugs must be used very cautiously and with x-rays approximately every 6 months to evaluate bone growth.

**Individual Androgens**

Clinical indications, routes, and dosage ranges are listed in Drugs at a Glance: Androgens.

**HERBAL OR DIETARY SUPPLEMENTS**

Androstenedione and DHEA, androgens produced by the adrenal cortex, are also available as over-the-counter (OTC) dietary supplements. They are marketed as safe, natural, alternative androgens for building muscles. These products, which have weak androgenic activity, act mainly as precursors for the production of sex hormones. Androstenedione, for example, may be converted to testosterone by way of an enzyme found in most body tissues. However, it may also be converted to estrogens and the testosterone that is produced may be further converted to estrogen (estradiol). In one study, young men with normal serum testosterone levels were given an androstenedione supplement for 8 weeks. The researchers found little effect on serum testosterone levels or muscle development with resistance training. They also found increased serum levels of estrone and estradiol, which indicate that a significant proportion of the androstenedione was converted to estrogens. Thus, taking a supplement for masculinizing effects may produce feminizing effects instead.

DHEA is available alone as oral capsules or tablets and in a topical cream with vitamins and herbs. Most DHEA prod-

---

**Drugs at a Glance: Androgens**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Hypogonadism</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Testosterone cypionate</strong> (Depo-Testosterone)</td>
<td>IM 50–200 mg every 2–4 wk</td>
<td><strong>Breast cancer:</strong> PO 250 mg four times daily</td>
</tr>
<tr>
<td><strong>Testosterone enanthate</strong> (Delatestryl)</td>
<td>IM 50–200 mg every 2–4 wk</td>
<td><strong>Cryptorchidism:</strong> PO 30 mg daily; buccal tablets, 15 mg daily</td>
</tr>
<tr>
<td><strong>Testosterone gel</strong> (Androgel 1%)</td>
<td>5 g (50 mg of drug) once daily to skin of shoulders and upper arms or abdomen</td>
<td><strong>Endometriosis:</strong> PO 800 mg daily in two divided doses for 3–9 mo</td>
</tr>
<tr>
<td><strong>Testosterone pellets</strong></td>
<td>SC 150–450 mg every 3–6 mo</td>
<td><strong>Fibrocystic breast disease:</strong> PO 100–400 mg daily in two divided doses for 3–6 mo</td>
</tr>
<tr>
<td><strong>Testosterone transdermal systems</strong> (Androderm, Testoderm)</td>
<td>Apply two Androderm systems (dose of 5 mg) nightly to back, abdomen, upper arm or thigh; apply Testoderm (one 6-mg system) to scrotal sac daily</td>
<td>Delayed puberty, SC lower dosage range, for a limited duration (eg, every 3 mo for 2–3 doses)</td>
</tr>
<tr>
<td><strong>Testolactone</strong> (Teslac)</td>
<td>PO 5–20 mg daily</td>
<td></td>
</tr>
<tr>
<td><strong>Fluoxymesterone</strong> (Halotestin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methyltestosterone</strong> (Methitest, others)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Danazol</strong> (Danocrine)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IM, intramuscular; PO, oral.
ucts of plant origin are produced in Europe and China. They are marketed with numerous claims for health benefits, including inhibition of aging, atherosclerosis, cancer, diabetes mellitus, and osteoporosis. Most claims stem from laboratory and animal studies. A few small human studies have been done, most of which used a dose of 50 mg daily. Overall, there is no conclusive evidence that DHEA supplementation will prevent or treat such conditions. In addition, long-term effects in humans are unknown.

DHEA is contraindicated in men with prostate cancer or benign prostatic hypertrophy (BPH) and in women with estrogen-responsive breast or uterine cancer, because DHEA may stimulate growth of these tissues. Clients older than 40 years of age should be aggressively screened for hormonally sensitive cancers before taking DHEA.

Adverse effects of DHEA include aggressiveness, hirsutism, insomnia, and irritability. Whether large doses of the OTC products can produce some of the serious side effects associated with standard anabolic steroids is unknown.

**Nursing Process**

**Assessment**

Before drug therapy is started, clients need a thorough history and physical examination. Periodic monitoring of the client’s condition is needed throughout drug therapy.

- Assess for conditions in which androgens are used (eg, deficiency states).
- Assess for conditions that increase risks of adverse effects or are contraindications (eg, pregnancy, liver disease, prostatic hypertrophy).
- Check laboratory reports of liver function tests (the drugs may cause cholestatic jaundice and liver damage), serum electrolytes (the drugs may cause sodium and water retention), and serum lipids (the drugs may increase levels and aggravate atherosclerosis).
- Assess weight and blood pressure regularly. These may be elevated by retention of sodium and water with resultant edema, especially in clients with congestive heart failure.
- For children, check x-ray reports of bone growth status initially and approximately every 6 months while the drugs are being taken.
- Assess the client’s attitude toward taking male sex hormones.
- Assess the client’s willingness to comply with instructions for taking the drugs and follow-up procedures.

**Nursing Diagnoses**

- Disturbed Body Image related to masculinizing effects and menstrual irregularities
- Deficient Knowledge: Physiologic and psychological consequences of overuse and abuse of the drugs to enhance athletic performance

**PRINCIPLES OF THERAPY**

**Duration of Therapy**

Drug therapy with androgens may be short or long term, depending on the condition in question, the client’s response to treatment, and the incidence of adverse reactions. If feasible, intermittent rather than continuous therapy is recommended.

**Effects of Androgens and Anabolic Steroids on Other Drugs**

Androgens may increase effects of cyclosporine and warfarin, apparently by slowing their metabolism and increasing their concentrations in the blood. These combinations should be

**Planning/Goals**

*The client will:*

- Use the drugs for medical purposes only
- Receive or take the drugs as prescribed
- Avoid abuse of drugs or dietary supplements for body building
- Be counseled regarding effects of overuse and abuse if identified as being at risk (eg, athletes, especially weight lifters and football players)
- Avoid preventable adverse drug effects
- Comply with monitoring and follow-up procedures

**Interventions**

- Assist clients to use the drug correctly.
- Assist clients to reduce sodium intake if edema develops.
- Record weight and blood pressure at regular intervals.
- Participate in school or community programs to inform children, parents, coaches, athletic trainers, and others of the risks of inappropriate use of androgens, anabolic steroids, and related dietary supplements.
avoided if possible. However, if required, serum creatinine and
cyclosporine levels should be monitored with cyclosporine and
prothrombin time or international normalized ratio (INR) with
warfarin.

Androgens also increase effects of sulfonylurea anti-
diabetic drugs. Concurrent use should be avoided if possible.
If required, smaller doses of sulfonylureas may be needed,
blood glucose levels should be monitored closely, and clients
should be assessed for signs of hypoglycemia. Danazol in-
hibits metabolism of carbamazepine and increases risks of
toxicity. Concurrent use should be avoided.

Use in Children

The main indication for use of androgens is for boys with es-
tablished deficiency states. Because the drugs cause epiphyseal
closure, hands and wrists should be x-rayed every 6 months
to detect bone maturation and prevent loss of adult height.
Stimulation of skeletal growth continues for approximately
6 months after drug therapy is stopped. If premature puberty
occurs (precocious sexual development, enlarged penis), the
drug should be stopped. The drugs may cause or aggravate
acne. Scrupulous skin care and other antiacne treatment may
be needed, especially in adolescent boys.

Use in Older Adults

The main indication for use of androgens is a deficiency state
in men. Older adults often have hypertension and other cardio-
vascular disorders that may be aggravated by the sodium and
water retention associated with androgens and anabolic
steroids. In men, the drugs may increase prostate size and in-
terfere with urination, increase risk of prostatic cancer, and
cause excessive sexual stimulation and priapism.

Use in Hepatic Impairment

Androgens and anabolic steroids are contraindicated in clients
with preexisting liver disease. Prolonged use of high doses may
cause potentially life-threatening conditions such as peliosis
hepatis, hepatic neoplasms, and hepatocellular carcinoma. In
addition, androgen therapy should be discontinued if cholesta-
tic hepatitis with jaundice occurs, or if liver function tests be-
come abnormal. Drug-induced jaundice is reversible when the
medication is stopped.
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
<tr>
<td>a. Give intramuscular preparations of testosterone, other androgens and anabolic steroids deeply, preferably in the gluteal muscle.</td>
<td>To decrease gastrointestinal disturbances</td>
</tr>
<tr>
<td>b. Give oral preparations before or with meals, in divided doses.</td>
<td></td>
</tr>
<tr>
<td>c. For buccal preparations:</td>
<td></td>
</tr>
<tr>
<td>(1) Give in divided doses.</td>
<td>Buccal preparations must be absorbed through the mucous membranes.</td>
</tr>
<tr>
<td>(2) Place the tablet between the cheek and gum.</td>
<td></td>
</tr>
<tr>
<td>(3) Instruct the client not to swallow the tablet and not to drink, chew, or smoke until the tablet is completely absorbed.</td>
<td></td>
</tr>
<tr>
<td>d. With transdermal systems:</td>
<td></td>
</tr>
<tr>
<td>(1) Apply 2 Androderm systems nightly to clean, dry skin on back, abdomen, upper arm, or thigh. Do not apply to scrotum. Rotate sites, with 7 days between applications to a site. Press firmly into place for adherence.</td>
<td>Manufacturer’s recommendation. Clients may prefer self-application. Skin should be clean, dry, and intact; hands should be washed after application; and showering and swimming should be avoided for at least 1 hour and preferably 4 to 6 hours after application.</td>
</tr>
<tr>
<td>(2) Apply 1 Testoderm system to clean, dry scrotal skin (shaved, for best adherence) once daily.</td>
<td></td>
</tr>
<tr>
<td>(3) Apply Androgel 1% to shoulders and upper arms or abdomen, once daily, preferably in the morning.</td>
<td></td>
</tr>
<tr>
<td>e. Inject testosterone pellets (Testopel) subcutaneously.</td>
<td></td>
</tr>
<tr>
<td>2. Observe for therapeutic effects</td>
<td></td>
</tr>
<tr>
<td>a. When the drug is given for hypogonadism, observe for masculinizing effects, such as growth of sexual organs, deepening of voice, growth of body hair, and acne.</td>
<td></td>
</tr>
<tr>
<td>b. When the drug is given for anabolic effects, observe for increased appetite, euphoria, or statements of feeling better.</td>
<td></td>
</tr>
<tr>
<td>3. Observe for adverse reactions</td>
<td></td>
</tr>
<tr>
<td>a. Virilism or masculinizing effects:</td>
<td></td>
</tr>
<tr>
<td>(1) In adult men with adequate secretion of testosterone—priapism, increased sexual desire, reduced sperm count, and prostate enlargement</td>
<td>More likely in clients who are elderly or who have heart or kidney disease</td>
</tr>
<tr>
<td>(2) In prepubertal boys—premature development of sex organs and secondary sexual characteristics, such as enlargement of the penis, priapism, pubic hair</td>
<td></td>
</tr>
<tr>
<td>(3) In women—masculinizing effects include hirsutism, deepening of the voice, menstrual irregularities</td>
<td>More likely in women with advanced breast cancer</td>
</tr>
<tr>
<td>b. Jaundice—dark urine, yellow skin and sclera, itching</td>
<td></td>
</tr>
<tr>
<td>c. Edema</td>
<td></td>
</tr>
<tr>
<td>d. Hypercalcemia</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
1. How does testosterone promote development of male sexual characteristics?
2. What is the major clinical indication for therapeutic use of testosterone and related androgens?
3. What is the difference between androgenic activity and anabolic activity?
4. What are the adverse effects of using large doses of anabolic steroids in body-building efforts?
5. If your 14-year-old brother said some friends were telling him to take drugs to increase muscle development and athletic ability, how would you reply? Justify your answer.

**SELECTED REFERENCES**


Nutrients, Fluids, and Electrolytes
Critical Thinking Scenario

Jamie, 2 months of age, had a gastrostomy tube placed after surgical repair of his esophagus. He is being sent home with his parents to receive tube feedings for a period of 6 to 8 weeks.

Reflect on:
- Questions and anxieties the parents may have.
- Potential impact on infant–parent bonding.
- Compare and contrast how tube feedings are the same and different for an infant and adult.
- Review priority teaching needs for Jamie’s parents before discharge.

Objectives

After studying this chapter, the student will be able to:

1. Assess clients for risk factors and manifestations of fluid imbalances, undernutrition, and obesity.
2. Evaluate the types and amounts of nutrients provided in commercial products for oral and tube feedings.
3. Collaborate with nutritionists and physicians in designing and implementing nutritional support measures for undernourished or malnourished clients.
4. Minimize complications of enteral and parenteral nutrition.
5. Monitor laboratory reports that indicate nutritional status.
7. Assist clients who are overweight or obese to develop and maintain a safe and realistic weight loss program.

Nutritional Support Products and Drugs for Obesity

Overview

Water, carbohydrates, proteins, fats, vitamins, and minerals are required for human nutrition, to promote or maintain health, to prevent illness, and to promote recovery from illness or injury. The first four nutrients are discussed in this chapter; vitamins and minerals are discussed in the following chapters.

Water, carbohydrates, proteins, and fats are necessary for life. Water is required for cellular metabolism and excretion of metabolic waste products; 2000 to 3000 mL are needed daily. Proteins are basic anatomic and physiologic components of all body cells and tissues; the recommended amount for adults is 50 to 60 g daily. Carbohydrates and fats serve primarily as sources of energy for cellular metabolism. Energy is measured in kilocalories (kcal) per gram of food oxidized in the body. Carbohydrates and proteins supply 4 kcal/g; fats supply 9 kcal/g.

Although recommended amounts of these nutrients can be used as rough estimates of clients’ nutritional needs, actual requirements vary widely, depending on age, gender, size, illness, and other factors. Thus, nutritional care should be individualized. Although physicians usually order diets and nutritionists advise about dietary matters, it is often the nurse who must implement or assist others to implement nutritional care. Consequently, this chapter discusses the use of products to improve nutritional status in clients with deficiency states and special needs. It also discusses obesity and drugs to aid weight loss.

Nutritional Deficiency States

Nutritional deficiencies result from inadequate amounts of water, carbohydrates, proteins, or fats. Treatment of deficiency states may lead to excess states. Causes and symptoms
of water imbalances are listed in Table 30–1; those of protein-calorie imbalances are listed in Table 30–2.

Nurses encounter many clients who are unable to ingest adequate fluid and food because of illness. Debilitating illnesses such as cancer, acquired immunodeficiency syndrome, and chronic lung, kidney, or cardiovascular disorders often interfere with appetite and gastrointestinal (GI) function. Therapeutic drugs often cause anorexia, nausea, vomiting, diarrhea, or constipation. Nutritional deficiencies may impair the function of essentially every body organ, impair wound healing, and increase risks of infection.

**NUTRITIONAL PRODUCTS**

Numerous products are available to supplement or substitute for dietary intake in clients who cannot ingest, digest, absorb, or use nutrients. For example, liquid enteral formulas are available for oral or tube feedings. Many are nutritionally complete, except for water, when given in sufficient amounts. Additional water must be given to meet fluid needs. Some products contain extra protein, fiber, calories, or other nutrients. Most oral products are available in several flavors and contain 1 kcal/mL; some contain 1.5 or 2 kcal/mL.

<table>
<thead>
<tr>
<th>TABLE 30–1</th>
<th>Water Imbalances</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Water Deficit</strong></td>
<td>Causes</td>
</tr>
<tr>
<td>1. Inadequate fluid intake, most likely to occur in people who are comatose, unable to swallow, or otherwise incapacitated</td>
<td>1. Thirst</td>
</tr>
<tr>
<td>2. Excessive fluid loss due to vomiting, diarrhea, fever, diuretic drug therapy, high environmental temperatures, strenuous physical activity, or excessive sweating</td>
<td>2. Oliguria and concentrated urine</td>
</tr>
<tr>
<td>3. A combination of 1 and 2</td>
<td>3. Weakness</td>
</tr>
<tr>
<td><strong>Water Excess</strong></td>
<td>Causes</td>
</tr>
<tr>
<td>1. Excessive intake, most likely to occur with excessive amounts or rapid infusion of intravenous fluids</td>
<td>1. Drowsiness</td>
</tr>
<tr>
<td>2. Impaired excretion of fluids due to endocrine, renal, cardiovascular, or central nervous system disorders</td>
<td>2. Weakness and lethargy</td>
</tr>
<tr>
<td></td>
<td>3. Weight gain</td>
</tr>
<tr>
<td></td>
<td>4. Edema</td>
</tr>
<tr>
<td></td>
<td>5. Disorientation</td>
</tr>
<tr>
<td></td>
<td>6. Circulatory overload and pulmonary edema if water excess is severe or develops rapidly</td>
</tr>
<tr>
<td></td>
<td>7. Low serum sodium and hematocrit</td>
</tr>
<tr>
<td></td>
<td>8. Disordered brain function</td>
</tr>
<tr>
<td></td>
<td>10. Coma</td>
</tr>
<tr>
<td></td>
<td>11. Starvation</td>
</tr>
<tr>
<td></td>
<td>12. Starvation</td>
</tr>
</tbody>
</table>

Some products are formulated for clients with particular organ impairments (eg, renal insufficiency) or disease processes (eg, diabetes mellitus), and some are contraindicated for clients with particular organ impairments or disease processes. Clients and caregivers who purchase the products over-the-counter should read labels carefully or consult a nutritionist.

**TABLE 30–2 Carbohydrate, Protein, and Fat Imbalances**

<table>
<thead>
<tr>
<th>Protein-Calorie Deficit</th>
<th>Causes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Inadequate intake of protein, carbohydrate, and fat</td>
<td>Signs and Symptoms</td>
</tr>
<tr>
<td>2. Impaired ability to digest, absorb, or use nutrients</td>
<td>1. Weight loss with eventual loss of subcutaneous fat and muscle mass</td>
</tr>
<tr>
<td>3. Excessive losses</td>
<td>2. Increased susceptibility to infection</td>
</tr>
<tr>
<td>1. Excessive intake, especially of carbohydrates and fats</td>
<td>3. Weakness and fatigability</td>
</tr>
<tr>
<td></td>
<td>4. Dry, scaly skin</td>
</tr>
<tr>
<td></td>
<td>5. Impaired healing</td>
</tr>
<tr>
<td></td>
<td>7. Edema</td>
</tr>
<tr>
<td></td>
<td>8. Decreased hemoglobin</td>
</tr>
<tr>
<td></td>
<td>10. Disordered brain function</td>
</tr>
<tr>
<td></td>
<td>11. Coma</td>
</tr>
<tr>
<td></td>
<td>12. Starvation</td>
</tr>
</tbody>
</table>

**PANCREATIC ENZYMES**

Pancreatin and pancrelipase are commercial preparations of pancreatic enzymes (eg, lipase, protease, and amylase). The preparations are used to aid digestion and absorption of dietary carbohydrate, protein, and fat in conditions characterized by pancreatic enzyme deficiency. These conditions...
include cystic fibrosis, chronic pancreatitis, pancreatectomy, and pancreatic obstruction. Dosages of the enzymes are listed in Drugs at a Glance: Pancreatic Enzymes.

**OBESITY**

Overweight and obesity are widespread and increasing in the United States, in both children and adults. They are considered major public health problems because of their association with high rates of morbidity and mortality. Overweight is defined as a body mass index (BMI) of 25 to 29.9 kg/m²; obesity is defined as a BMI of 30 kg/m² or more. The BMI reflects weight in relation to height and is a better indicator than weight alone.* The desirable range for BMI is 18.5 to 24.9 kg/m², with any values below 18.5 indicating underweight and any values of 25 or above indicating excessive weight.

Obesity may occur in any group but is more likely to occur in women, minority groups, and poor people. It results from consistent ingestion of more calories than are used, and it substantially increases risks for development of cardiovascular disease (eg, hypertension, angina pectoris, myocardial infarction, stroke), diabetes mellitus, dyslipidemias (eg, increased

---

**TABLE 30–3  Intravenous Fluids**

<table>
<thead>
<tr>
<th>Type/Characteristics</th>
<th>Uses</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dextrose Injection</strong></td>
<td>To provide water and calories</td>
<td>The dextrose in D₂W is rapidly used, leaving “free” water for excreting waste products, maintaining renal function, and maintaining urine output.</td>
</tr>
<tr>
<td>Available in preparations containing 2.5%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, and 70% dextrose</td>
<td>Treat hypoglycemia (eg, insulin overdose)</td>
<td></td>
</tr>
<tr>
<td>The most frequently used concentration is 5% dextrose in water (D₂W) or sodium chloride injection. 5% dextrose in water is isotonic with blood. It provides water and 170 kcal/L. 10% dextrose solution provides twice the calories in the same volume of fluid but is hypertonic and therefore may cause phlebitis. Except for 25% or 50% solutions sometimes used to treat hypoglycemia, the higher concentrations are used in parenteral nutrition. They are hypertonic and must be given through a central or subclavian catheter.</td>
<td>As a component of parenteral nutritional mixtures</td>
<td></td>
</tr>
<tr>
<td><strong>Dextrose and Sodium Chloride Injection</strong></td>
<td>Maintenance fluids, usually with added potassium chloride, in clients who cannot eat or drink</td>
<td></td>
</tr>
<tr>
<td>Available in several concentrations</td>
<td>Replacement fluids when large amounts are lost</td>
<td></td>
</tr>
<tr>
<td>Frequently used are 5% dextrose in 0.225% (also called D₂₅/₄ normal saline) and 5% dextrose in 0.45% sodium chloride (D₂₅/₂ normal saline)</td>
<td>To keep IV lines open</td>
<td></td>
</tr>
<tr>
<td>These provide approximately 170 kcal/L, water, sodium, and chloride.</td>
<td>Administration of IV medications</td>
<td></td>
</tr>
<tr>
<td><strong>Crystalline Amino Acid Solutions (Aminosyn, Fremaime)</strong></td>
<td>As a component of peripheral or central IV parenteral nutrition, with concentrated dextrose solutions</td>
<td>Special formulations are available for use in patients with renal or hepatic failure.</td>
</tr>
<tr>
<td>Contain essential and nonessential amino acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fat Emulsions (Intralipid, Liposyn)</strong></td>
<td>As a component of peripheral or central total parenteral nutrition</td>
<td>More calories can be supplied with a fat emulsion than with dextrose-protein solutions alone.</td>
</tr>
<tr>
<td>Provide concentrated calories and essential fatty acids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Available in 10% and 20% emulsions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>500 mL of 10% emulsion provides 550 calories.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*BMI = \[ \frac{\text{Weight (pounds)}}{\text{Height (inches)}} \times 704.5 \]

Example: A person who weighs 150 lbs. and is 5’5” (65 inches) tall:  

\[ \text{BMI} = \frac{150 \text{ lbs}}{65 \text{ in}} \times 704.5 \frac{\text{lbs}}{\text{in} \times 704.5} = \frac{105,675}{4225} = 25 \]
### TABLE 30–4 Representative Enteral Formulas for Infants, Children, and Adults

<table>
<thead>
<tr>
<th>Name/Characteristics</th>
<th>Uses</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Infants and Children</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Enfamil, Enfamil Premature</em></td>
<td>Alone for bottle-fed infants; as a supplement for breast-fed infants</td>
<td>Formulas are similar to human breast milk.</td>
</tr>
<tr>
<td></td>
<td>Alone for bottle-fed or tube-fed premature infants</td>
<td>Nutritional needs of preterm infants differ from those of full-term infants.</td>
</tr>
<tr>
<td><em>Lofenlac</em></td>
<td>For infants and children with phenylketonuria (a metabolic disorder</td>
<td>Inadequate for complete nutrition and growth.</td>
</tr>
<tr>
<td></td>
<td>in which phenylalanine cannot be metabolized normally)</td>
<td>It is recommended that 85% of a child’s protein needs be supplied with Lofenlac and the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>remaining with foods containing phenylalanine, which is an essential amino acid.</td>
</tr>
<tr>
<td><em>Nursoy, ProSobee, Soyalac</em></td>
<td>As milk substitutes for infants who are allergic to milk</td>
<td>Provide all other essential nutrients for normal growth and development.</td>
</tr>
<tr>
<td><em>Nutramigen</em></td>
<td>Infants and children who are allergic to ordinary food proteins or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>have diarrhea or other GI problems</td>
<td></td>
</tr>
<tr>
<td><em>PediaSure</em></td>
<td>Children 1–6 years of age</td>
<td></td>
</tr>
<tr>
<td><em>Precision diets</em></td>
<td>These formulas can be given to children if the amount is calculated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to provide recommended amounts of nutrients for the particular age</td>
<td></td>
</tr>
<tr>
<td></td>
<td>group.</td>
<td></td>
</tr>
<tr>
<td><em>Pregestimil</em></td>
<td>For infants with severe malabsorption disorders</td>
<td></td>
</tr>
<tr>
<td><em>Vivonex</em></td>
<td>For children with GI disorders</td>
<td></td>
</tr>
<tr>
<td><em>Adults</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Amin-Aid</em></td>
<td>As a source of protein for clients with acute or chronic renal</td>
<td>2000 mL daily meets basic nutritional needs for adults.</td>
</tr>
<tr>
<td></td>
<td>failure</td>
<td>Limit use in clients with severe hepatic cirrhosis because it may precipitate encephalopa-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>thy and coma.</td>
</tr>
<tr>
<td><em>Ensure, Isocal, Osmolite</em></td>
<td>As the sole source of nutrients or a supplement when food intake is</td>
<td>Although useful as a caloric substitute for dietary fat (1 tbsp provides 115 kcal), it</td>
</tr>
<tr>
<td></td>
<td>decreased or does not meet nutritional needs</td>
<td>does not promote absorption of fat-soluble vitamins or provide essential fatty acids as</td>
</tr>
<tr>
<td></td>
<td></td>
<td>the long-chain triglycerides do.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Individualize amounts by calories needed and tolerance.</td>
</tr>
<tr>
<td><em>MCT Oil</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increase caloric intake in clients on protein-, electrolyte-, or fat-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>restricted diets</td>
<td></td>
</tr>
<tr>
<td><em>Polycose</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>For clients with fat malabsorption problems, as the complete diet,</td>
<td>May induce coma in clients with severe hepatic cirrhosis.</td>
</tr>
<tr>
<td></td>
<td>as a beverage with meals, or as an addition to various recipes</td>
<td></td>
</tr>
<tr>
<td><em>Portagen</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>These preparations are ingested or given by tube slowly over 4 hours. The carbohydrate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>content may produce hyperglycemia; therefore, they should not be used in clients with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>diabetes mellitus.</td>
</tr>
<tr>
<td><em>Precision diets</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(continued)
triglycerides and low-density lipoprotein (LDL) cholesterol; decreased high-density lipoprotein (HDL) cholesterol, some types of cancer (eg, breast, prostate, endometrium, and colon), gallbladder disease, sleep apnea, and osteoarthritis of the knees. These disorders are mainly attributed to the multiple metabolic abnormalities associated with obesity. Abdominal fat out of proportion to total body fat (also called central obesity), which often occurs in men, is considered a greater risk factor for disease and death than lower body obesity. Many people consider obesity a chronic disease.

**Childhood Obesity**

Overweight and obesity are common and increasing among children, especially those with overweight parents. Overweight is defined as a BMI above the 85th percentile for the age group. Studies indicate that obesity in childhood and adolescence is predictive of obesity and increased health risks in adulthood. In addition, more children are developing type 2 diabetes, which was formerly believed to occur only in adults. The increase in obesity and type 2 diabetes is mainly attributed to poor eating habits and too little exercise.

**Drugs for Obesity**

Drug therapy for obesity (Drugs at a Glance: Drugs for Obesity) has a problematic history because available drugs had potentially serious adverse effects, were recommended only for short-term use, and weight was rapidly regained when the drugs were stopped. Two widely used drugs, fenfluramine and dexfenfluramine, were taken off the market in 1997 because of their association with diseased heart valves and pulmonary hypertension. More recently, phenylpropanolamine (PPA) was taken off the market because of its association with hypertension and hemorrhagic strokes. PPA was the active ingredient in some over-the-counter diet aids (eg, Dexatrim, Acutrim) as well as the nasal decongestant component of many multisymptom cold remedies.

Older drugs include amphetamines and similar drugs. Amphetamines (see Chap. 16) are not recommended because they are controlled substances (see Schedule II) with a high potential for abuse and dependence. Benzphetamine, diethylpropion, phendimetrazine, and phentermine are adrenergic drugs (see Chap. 18) that stimulate the release of norepinephrine and dopamine in the brain. This action in nerve terminals of the hypothalamic feeding center suppresses appetite. Other drug actions that may contribute to decreased appetite and weight loss include increasing energy and decreasing gastric secretion.

**TABLE 30–4**

<table>
<thead>
<tr>
<th>Name/Characteristics</th>
<th>Uses</th>
<th>Comments</th>
</tr>
</thead>
</table>
| **Pulmocare, Nutrivent**
These products are high in fat and low in carbohydrates because fat metabolism produces less carbon dioxide than carbohydrate metabolism. | Clients with chronic obstructive pulmonary disease or respiratory insufficiency | Clients with impaired breathing have difficulty eliminating carbon dioxide, a waste product of carbohydrate metabolism. When carbon dioxide accumulates in the body, it may produce respiratory acidosis and respiratory failure. |
| **Sustacal**
Nutritionally complete
May be given orally or by tube feeding | As the complete diet or to supplement other sources of nutrients | The amount, concentration, and rate of administration can be adjusted to meet nutritional needs and tolerance. |
| **TraumaCal, Vivonex**
Nutritionally complete, high-protein formulas with easily assimilated amino acids and other nutrients
Can be used for oral or tube feedings | Clients with hypermetabolic states (eg, severe burns, trauma, or sepsis), to help meet nutritional needs and promote healing | |

**Drugs at a Glance: Pancreatic Enzymes**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Route and Dosage Ranges</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreatin (Creon, others)</td>
<td>PO 1 or 2 capsules or tablets with meals or snacks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancrelipase (Viokase, others)</td>
<td>PO 1 to 3 capsules or tablets before or with meals or snacks; or 1 or 2 packets of powder with meals or snacks</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO 1 or 2 capsules or tablets with each meal, increased in amount or frequency if necessary and if adverse effects do not occur</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**How Can You Avoid This Medication Error?**

Pancrelipase, a pancreatic enzyme, 2 capsules ac is ordered for John Smily. His meal times are breakfast 8:00 AM, lunch 12:00, and dinner 6:00 PM. You administer his morning dose of Pancrelipase at 9:15 AM.
These drugs are central nervous system (CNS) and cardiovascular stimulants and are contraindicated in cardiovascular disease, hyperthyroidism, glaucoma, and agitated states. In addition, they are promoted for short-term use (8 to 12 weeks), weight is usually rapidly regained when the drugs are stopped, and they are controlled substances. Overall, their use as appetite suppressants is not recommended.

Phentermine (Ionamin, others) is the most frequently prescribed adrenergic anorexiant. Its use should be limited to patients with a BMI >30 kg/m², or >27 kg/m² if the client also has risk factors or other health problems that are aggravated by excessive weight. Its use is contraindicated in clients with hypertension or other cardiovascular disease and in those with a history of drug abuse. Phenetermine is pharmacologically and chemically similar to amphetamines; physical and psychological dependence may occur. The drug should also be used cautiously in clients with anxiety or agitation because of CNS stimulant effects. The most commonly reported adverse effects are nervousness, dry mouth, constipation, and hypertension.

Sibutramine (Meridia) was approved by the Food and Drug Administration (FDA) in late 1997 and became the most commonly prescribed antiobesity drug. This drug inhibits the reuptake of serotonin and norepinephrine in the brain, thereby increasing the amounts of these neurotransmitters. Clinical effects include increased satiety, decreased food intake, and a faster metabolism rate. Sibutramine is approved by the FDA for long-term use, but its effects are mostly unknown beyond one year. The drug increases blood pressure and heart rate and is contraindicated in cardiovascular disorders (eg, hypertension, dysrhythmias). It should be used cautiously in clients who take other medications that increase blood pressure and pulse rate. It should also be used cautiously in clients with impaired hepatic function, narrow-angle glaucoma (may cause mydriasis), or a history of substance abuse or dependency.

Orlistat (Xenical) is the most frequently prescribed fat blocker. This drug inhibits the reuptake of serotonin and norepinephrine in the brain, thereby increasing the amounts of these neurotransmitters. Clinical effects include increased satiety, decreased food intake, and a faster metabolism rate. Orlistat is approved by the FDA for long-term use, but its effects are mostly unknown beyond one year. The drug increases blood pressure and heart rate and is contraindicated in cardiovascular disorders (eg, hypertension, dysrhythmias). It should be used cautiously in clients who take other medications that increase blood pressure and pulse rate. It should also be used cautiously in clients with impaired hepatic function, narrow-angle glaucoma (may cause mydriasis), or a history of substance abuse or dependency.

Orlistat (Xenical) is the most frequently prescribed fat blocker. This drug inhibits the reuptake of serotonin and norepinephrine in the brain, thereby increasing the amounts of these neurotransmitters. Clinical effects include increased satiety, decreased food intake, and a faster metabolism rate. Orlistat is approved by the FDA for long-term use, but its effects are mostly unknown beyond one year. The drug increases blood pressure and heart rate and is contraindicated in cardiovascular disorders (eg, hypertension, dysrhythmias). It should be used cautiously in clients who take other medications that increase blood pressure and pulse rate. It should also be used cautiously in clients with impaired hepatic function, narrow-angle glaucoma (may cause mydriasis), or a history of substance abuse or dependency.

Orlistat (Xenical) is the most frequently prescribed fat blocker. This drug inhibits the reuptake of serotonin and norepinephrine in the brain, thereby increasing the amounts of these neurotransmitters. Clinical effects include increased satiety, decreased food intake, and a faster metabolism rate. Orlistat is approved by the FDA for long-term use, but its effects are mostly unknown beyond one year. The drug increases blood pressure and heart rate and is contraindicated in cardiovascular disorders (eg, hypertension, dysrhythmias). It should be used cautiously in clients who take other medications that increase blood pressure and pulse rate. It should also be used cautiously in clients with impaired hepatic function, narrow-angle glaucoma (may cause mydriasis), or a history of substance abuse or dependency.

Drugs at a Glance: Drugs for Obesity

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Route and Dosage Range (Adults)</th>
<th>Controlled Substance Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Appetite Suppressants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzphetamine (Didrex)</td>
<td>PO 25–50 mg once daily initially, increased up to 3 times daily if indicated</td>
<td>Schedule III</td>
</tr>
<tr>
<td>Diethylpropion (Tenuate)</td>
<td>Immediate release tablets, PO 25 mg 3 times daily</td>
<td>Schedule IV</td>
</tr>
<tr>
<td></td>
<td>Controlled release tablets, PO 75 mg once daily in midmorning</td>
<td></td>
</tr>
<tr>
<td>Phendimetrazine (Bontril)</td>
<td>Immediate release tablets, PO 35 mg 2 or 3 times daily, 1 h before meals</td>
<td>Schedule III</td>
</tr>
<tr>
<td></td>
<td>Sustained-release capsules, PO 105 mg once daily, 30–60 min before the first morning meal</td>
<td></td>
</tr>
<tr>
<td>Phentermine hydrochloride (Adipex)</td>
<td>PO 8 mg 3 times daily or 15–37.5 mg daily in the morning</td>
<td>Schedule IV</td>
</tr>
<tr>
<td>Phentermine resin (Ionamin)</td>
<td>PO 15–30 mg once daily in the morning</td>
<td></td>
</tr>
<tr>
<td>Sibutramine (Meridia)</td>
<td>PO 10–15 mg once daily, in the morning, with or without food</td>
<td>Schedule IV</td>
</tr>
<tr>
<td><strong>Fat Blocker</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orlistat (Xenical)</td>
<td>PO 1 capsule with each main meal, up to 3 capsules daily</td>
<td></td>
</tr>
</tbody>
</table>
In March 2002, a consumer group petitioned the FDA to take sibutramine off the market, saying the drug’s risks outweigh its benefits. At the time, the FDA had received reports of 25 deaths worldwide of people who were taking the drug. It was unknown whether the deaths were related to the use of sibutramine. The majority of the deaths (16) were related to cardiac problems. The manufacturer reported knowledge of 32 deaths of people taking sibutramine but stated there was no evidence that the drug was to blame.

Orlistat (Xenical) differs from other antiobesity drugs because it decreases absorption of dietary fat from the intestine (by inhibiting gastric and pancreatic lipase enzymes that normally break down fat into absorbable triglycerides). The drug blocks absorption of approximately 30% of the fat ingested in a meal. Decreased fat absorption leads to decreased caloric intake, resulting in weight loss and improved serum cholesterol values (eg, decreases total and LDL cholesterol levels). The improvement in cholesterol is believed to be independent of weight loss effects.

Orlistat is not absorbed systemically, and its action occurs in the GI tract. Consequently, it does not cause systemic adverse effects or drug interactions as do phenetermine and sibutramine. Its main disadvantages are frequent administration (3 times daily) and GI symptoms (abdominal pain, oily spotting, fecal urgency, flatulence with discharge, fatty stools, fecal incontinence, and increased defecation). Adverse GI effects occur in almost all orlistat users but usually subside after approximately 4 weeks. In addition, the drug prevents absorption of the fat-soluble vitamins A, D, E, and K. As a result, people taking orlistat should also take a daily multivitamin containing these vitamins. The multivitamin should be taken 2 hours before or after the orlistat dose. If taken at the same time, the orlistat prevents absorption of the fat-soluble vitamins.

Orlistat is intended for people who are clinically obese, not for those wanting to lose a few pounds. In addition, high-fat foods still must be decreased because total caloric intake is a major determinant of weight and adverse effects (eg, diarrhea and fatty, malodorous stools) worsen with high fat consumption. Long-term effects of orlistat are unknown, although one study reported safe and effective use for 2 years. In addition to weight loss and reduced cholesterol levels, clinical trials found a reduction in other risk factors associated with obesity, such as hypertension, hyperglycemia, and excessive waist circumference.

**HERBAL AND DIETARY SUPPLEMENTS**

Many people use herbal or dietary supplements for weight loss, even though reliable evidence of both safety and effectiveness is generally lacking. Some herbal products claim to decrease appetite and increase the rate at which the body burns calories. However, their effectiveness varies and, in most cases, there is no scientific evidence that they work at all. Most supplements for weight loss contain cardiovascular and CNS stimulants that may cause serious, even life-threatening, adverse effects.

In a survey of college students, researchers asked about the use of nonvitamin, nonmineral dietary supplements. Almost half (48.5%) of the 272 respondents reported that they took such a product during the previous year. Although echinacea, ginseng, and St. John’s wort were more frequently used, 27 students took weight loss products. Of these, 81.5% had a BMI in the acceptable range, and 11 of the 19 participants who reported an adverse reaction continued to take the products.

In general, many consumers do not appreciate the benefits of proven weight management techniques (ie, appropriate diet and exercise) or the potential risks of taking weight loss products. Selected products are described in the following section.

Ephedra (ma huang) is an herb in many weight loss products (eg, Metabolife, Herbalife, others). It is not recommended for use by anyone because it is a strong cardiovascular and CNS stimulant that increases risks of heart attack, seizure, stroke, and sudden death. Many ephedra-containing products also contain caffeine, which can further increase cardiovascular and CNS stimulation.

Glucomannan expands on contact with body fluids. It is included in weight loss regimens because of its supposed ability to produce feelings of stomach fullness, causing a person to eat less. It also has a laxative effect. There is little evidence to support its use as a weight loss aid. Products containing glucomannan should not be used by people with diabetes; it may cause hypoglycemia alone and increases hypoglycemic effects of antidiabetic medications.

Guarana, a major source of commercial caffeine, is found in weight loss products as well as caffeine-containing soft drinks, bodybuilding supplements, smoking cessation products, vitamin supplements, candies, and chewing gums. Caffeine is the active ingredient; the amount varies among products, and caffeine content of any particular product cannot be accurately predicted. Guarana is promoted to decrease appetite and increase energy and mental alertness. It is contraindicated in clients with dysrhythmias and may aggravate gastroesophageal reflux disease (GERD) and peptic ulcer disease.

Adverse effects include diuresis, cardiovascular symptoms (premature ventricular contractions, tachycardia), CNS symptoms (agitation, anxiety, insomnia, seizures, tremors), and GI symptoms (nausea, vomiting, diarrhea). Such effects are more likely to occur with higher doses or concomitant use of guarana and other sources of caffeine. Adverse drug-drug interactions include additive CNS and cardiovascular stimulation with beta adrenergic agonists (eg, epinephrine, albuterol and related drugs, pseudoephedrine) and theophylline. In addition, concurrent use of cimetidine, fluoroquinolones, or oral contraceptives may increase or prolong serum caffeine levels and subsequent adverse effects.

Guar gum is a dietary fiber included in weight loss products because it is bulk forming, produces feelings of fullness, and may decrease appetite. It may cause esophageal or intestinal obstruction if not taken with an adequate amount of water and may interfere with the absorption of other drugs if taken at the same time. Adverse effects include nausea, diarrhea, flatulence, and abdominal discomfort.
Hydroxycitric acid (HCA, found in CitriMax) apparently suppresses appetite in animals, but there are no reliable studies that indicate its effectiveness in humans. Laxative and diuretic herbs (eg, aloe, rhubarb root, buckthorn, cascara, senna, parsley, juniper, and dandelion leaves) are found in several products such as Super Dieter’s Tea, Trim-Maxx Tea, and Water Pill. These products cause a significant loss of body fluids, not fat. Adverse effects may include low serum potassium levels, with subsequent cardiac dysrhythmias and other heart problems. In addition, long-term use of laxatives may lead to loss of normal bowel function and the necessity for continued use (ie, laxative dependency). LipoKinetix, a combination dietary supplement, was recently associated with severe hepatotoxicity in 7 young (ages 20 to 32 years), previously healthy people who developed acute hepatitis. There were 4 women and 3 men. Five Japanese patients were diagnosed in 1 month or less; two white bodybuilders were diagnosed within 3 months. Three people were taking only LipoKinetix; four were also taking other supplements, which they resumed later without recurrence of hepatitis. All reported taking LipoKinetix according to the manufacturer’s instructions; all recovered after the product was discontinued.

LipoKinetix contains norephedrine, caffeine, sodium usniate, 3,5-diiodothyronine, and yohimbe. The ingredient(s) responsible for the hepatotoxicity was unknown. The reactions were considered idiosyncratic, and no other cause of the hepatitis was found.

With the observation that the five Japanese developed hepatotoxicity more rapidly than the two Caucasians, there is a possibility that Asians are less able to metabolize and excrete this product. As discussed in the early chapters of this text, smaller doses of several prescription drugs are needed in this population because of genetic or ethnic differences in metabolism. This principle may also apply to some herbal and dietary supplements and should be considered in teaching clients of Asian descent.

Nursing Process

Assessment
Assess each client for current or potential nutritional disorders. Some specific assessment factors include the following:

- What are usual drinking and eating patterns? Does fluid intake seem adequate? Does food intake seem adequate in terms of normal nutrition? Is the client financially able to purchase sufficient food? What are fluid and food likes and dislikes?
- Does the client know the basic foods for normal nutrition? Does the client view nutrition as important in maintaining health?
- Does the client appear underweight? Has there been a recent change in weight (eg, unintended weight loss)? If the client is underweight, assess for contributing factors (eg, appetite; ability to obtain, cook, or chew food). Calculate or estimate the BMI; a BMI less than 18.5 kg/m² indicates undernutrition.
- Does the client appear overweight? If so, calculate the BMI or use the information in Table 30-5 to estimate the BMI. If the BMI is 25 kg/m² or above, ask the client if there are concerns about weight, if there are health problems caused or aggravated by excessive weight, if there is interest in a weight-management program to improve health, and what methods, over-the-counter products, or herbal or dietary supplements, if any, have been used to reduce weight. The nurse must be very tactful in eliciting information and assessing whether a client would like assistance with weight management. If the nurse–client contact stems from a health problem caused or aggravated by excessive weight, the client may be more motivated to lose weight and improve health.
- Does the client have symptoms, disease processes, treatments, medications, or diagnostic tests that are likely to interfere with nutrition? For example, many illnesses and oral medications cause anorexia, nausea, vomiting, and diarrhea.
- Are any conditions present that increase or decrease nutritional requirements?
- Check available reports of laboratory tests, such as serum albumin, complete blood count, and blood glucose. Nutritional disorders, as well as many other disorders, may cause abnormal values.

Nursing Diagnoses

- Imbalanced Nutrition: Less Than Body Requirements related to inadequate intake or impaired ability to digest nutrients
- Imbalanced Nutrition: More Than Body Requirements related to excessive intake
- Deficient Fluid Volume related to inadequate intake
- Excess Fluid Volume related to excessive intake
- Diarrhea related to enteral nutrition
- Feeding Self Care Deficit
- Disturbed Body Image related to excessive weight loss or weight gain
- Deficient Knowledge: Nutritional needs and weight management

Planning/Goals

The client will:

- Improve nutritional status in relation to body needs
- Maintain fluid and electrolyte balance
- Avoid complications of enteral nutrition, including aspiration, diarrhea, deficient or excess fluid volume, and infection
- Avoid complications of parenteral nutrition, including deficient or excess fluid volume and infection
- Identify the types and amounts of foods to meet nutritional needs
- Avoid overuse of anorexiant drugs
- Avoid unproven weight-loss dietary supplements
Interventions

Implement measures to prevent nutritional disorders by promoting a well-balanced diet for all clients. Depending on the client’s condition, diet orders, food preferences, knowledge and attitudes about nutrition, and other factors, specific activities may include the following:

- Provide food and fluid the client is willing and able to take, at preferred times when possible.
- Assist the client to a sitting position, cut meat, open containers, feed the client, and perform other actions if indicated.
- Treat symptoms or disorders that are likely to interfere with nutrition, such as pain, nausea, vomiting, or diarrhea.
- Consult with the physician or dietitian when needed, especially when special diets are ordered. Compliance is improved when the ordered diet differs as little as possible from the usual diet. Also, preferred foods often may be substituted for disliked ones.
- Promote exercise and activity. For undernourished clients, this may increase appetite, improve digestion, and aid bowel elimination. For overweight and obese clients, exercise may decrease appetite and distract from eating behaviors as well as increase calorie expenditure.
- Minimize the use of sedative-type drugs when appropriate. Although no one should be denied pain relief, strong analgesics and other sedatives may cause drowsiness and decreased desire or ability to eat and drink as well as constipation and a feeling of fullness.
- Weigh clients at regular intervals. Calculate or estimate the BMI when indicated.
- Use available resources to individualize nutritional care according to the client’s clinical status and needs. For example, in hospitalized clients who are able to eat, consult a nutritionist about providing foods the client is able and willing to take. In hospitalized or outpatient clients who need a nutritional supplement, consult a nutritionist about choices, amounts, and costs.
- For clients receiving parenteral nutrition, monitor weight, fluid intake, urine output, vital signs, blood glucose, serum electrolytes, and complete blood count daily or weekly, according to the client’s status and whether hospitalized or at home.

Evaluation

- Observe undernourished clients for quantity and quality of nutrient intake, weight gain, and improvement in laboratory tests of nutritional status (eg, serum proteins, blood sugar, electrolytes).
- Observe overweight or obese clients for food intake, weight loss, and appropriate use of exercise and anorexiant drugs.
- Observe children for quantity and quality of food intake and appropriate increases in height and weight.
- Interview and observe for signs and symptoms of complications of enteral and parenteral nutrition.

PRINCIPLES OF THERAPY

Managing Fluid Disorders

Fluid Deficiency

Treatment of fluid deficiency is aimed toward increasing intake or decreasing loss, depending on causative factors. The safest and most effective way of replacing body fluids is to give oral fluids when possible. Water is probably best, at least initially. Fluids containing large amounts of carbohydrate, fat, or protein are hypertonic and may increase fluid volume deficit if taken without sufficient water. If the client cannot take oral food or fluids for a few days or can take only limited amounts, IV fluids can be used to provide complete or supplemental amounts of fluids. Frequently used solutions include 5% dextrose in water or sodium chloride.

To meet fluid needs over a longer period, a nasogastric or other GI tube may be used to administer fluids. Fluid needs must be assessed carefully for the client receiving food and fluid only by tube. Additional water is needed after or between tube feedings. Another way of meeting long-term fluid needs when the GI tract cannot be used is parenteral nutrition. These IV solutions provide other nutrients as well as fluids.

Optimal amounts of fluid may vary greatly. For most clients, 2000 to 3000 mL daily are adequate. A person with severe heart failure or oliguric kidney disease needs smaller amounts, but someone with fever or extra losses (eg, vomiting, diarrhea) needs more.

Fluid Excess

Treatment of fluid excess is aimed toward decreasing intake and increasing loss. In acute circulatory overload or pulmonary edema, the usual treatment is to stop fluid intake (if the client is receiving IV fluids, slow the rate but keep the vein open for medication) and administer an IV diuretic. Because fluid excess may be a life-threatening emergency, prevention is better than treatment.

Managing Nutritional Deficiencies

Undernutrition impairs the function of essentially every body organ, impairs wound healing, and increases risks of infection. The goal of treatment is to provide an adequate quantity and quality of nutrients to meet tissue needs. Requirements for nutrients vary with age, level of activity, level of health or illness, and other factors that must be considered when designing appropriate therapy.

Enteral Nutrition: Oral Feedings

The safest and most effective way of increasing nutritional intake is by oral feedings, when feasible. High-protein, high-calorie foods can be included in many diets and given as between-meal or bedtime snacks. If the client cannot ingest enough food and fluid, many of the commercial nutritional preparations can be given as between-meal supplements to
increase intake of protein and calories. These preparations vary in taste and acceptability. Measures to improve taste may include chilling, serving over ice, freezing, or mixing with fruit juice or another beverage. Specific methods depend on the client’s taste preferences and the available formulas. Refer to instructions, usually on the labels, for appropriate diluting and mixing of beverages. Pudding formulations of several oral supplements are available and may be preferred by some clients.

**Enteral Nutrition: Tube Feedings**

When oral feeding is contraindicated but the GI tract is functioning, tube feeding is usually preferred over IV fluids, especially for long-term use. First, tube feeding is usually safer, more convenient, and more economic. Second, it helps to prevent GI atrophy, maintain GI function, and maintain immune system function. Third, several tubes and placement sites are available. For example, a nasogastric tube may be used for approximately 4 weeks. For long-term feedings, a gastrostomy tube may be placed percutaneously (called percutaneous endoscopic gastrostomy) or surgically. Nasointestinal tubes are recommended for clients at risk of aspiration from gastric feedings or with gastric disorders. Except for gastrostomy tubes, the tubes should be soft and small bore to decrease trauma.

When tube feedings are the client’s only source of nutrients, they should be nutritionally complete and given in amounts calculated to provide adequate water, protein,
Other guidelines include the following:

- Any weight loss program should include a nutritionally adequate diet with decreased calories and increased exercise. The recommended rate of weight loss is approximately 2 lb weekly.
- Regular physical examinations and follow-up care are needed during weight loss programs.
- Diet and exercise are recommended for people who want to lose a few pounds. Medications to aid weight loss are usually recommended only for people whose health is endangered (ie, those who are overweight and have other risk factors for heart disease and those who are obese).
- Read package inserts and other available information about the drug being taken, who should not take the drug, instructions and precautions for safe usage, and so forth. Keep the material for later reference if questions arise. If unclear about any aspect of the information, consult a health care provider before taking the drug.
- Appetite-suppressant drugs must be used correctly to avoid potentially serious adverse effects. Because these drugs stimulate the heart and the brain, adverse effects may include increased blood pressure, fast heart beat, irregular heart beat, heart attack, stroke, dizziness, nervousness, insomnia (if taken late in the day), and mental confusion. In addition, prolonged use of prescription drugs may lead to psychological dependence.
- Avoid over-the-counter decongestants, allergy, asthma, and cold remedies and weight loss herbal or dietary supplements when taking a prescription appetite suppressant. The combination can cause serious adverse effects from excessive heart and brain stimulation.
- Inform health care providers when taking an appetite suppressant, mainly to avoid other drugs with similar effects.
- Orlistat (Xenical) is not an appetite suppressant and does not cause heart or brain stimulation. It works in the intestines to prevent the fats in foods from being absorbed. It should be taken with a low-fat diet. Adverse effects include fatty stools and bloating.

### General Considerations

- In addition to feeling better, health benefits of weight loss may include reduced blood pressure, reduced blood fats, less likelihood of having a heart attack or stroke, and less risk for development of diabetes mellitus.
- Although tube feeding formulas vary in the volume needed for adequate intake of nutrients, any of the complete formulas can be used effectively.
- Most formulas provide 1 kcal/mL so that caloric intake can be quickly calculated. Water can be given with, after, or between regular feedings and with medications, according to the client’s fluid needs.
- Other than problems resulting from hypertonic solutions and inadequate fluid intake (diarrhea, fluid volume deficit, hypernatremia), a major complication of tube feeding is aspiration of the formula into the lungs. This is more likely to occur with unconscious clients. It can be prevented by correctly positioning clients, verifying tube placement (before every intermittent feeding and approximately every 4 hours with continuous feedings), and giving feedings slowly.

### Self-Administration

- Take appetite suppressants in the morning to decrease appetite during the day and avoid interference with sleep at night.
- Do not crush or chew sustained-release products.
- With sibutramine (Meridia):
  - Take once daily, with or without food.
  - Have blood pressure and heart rate checked at regular intervals (the drug increases them).
  - Notify a health care provider if a skin rash, hives, or other allergic reaction occurs.
- With orlistat:
  - Take one capsule with each main meal or up to 1 hour after a meal, up to 3 capsules daily. If you miss a meal or eat a non-fat meal, you may omit a dose of orlistat.
  - Take a multivitamin containing fat-soluble vitamins (A,D,E, and K) daily, at least 2 hours before or after taking orlistat. Orlistat prevents absorption of fat-soluble vitamins from food or multivitamin preparations if taken at the same time.

- A common practice has been to initiate feedings with small amounts of diluted solution (ie, half strength), then increase to larger amounts and full strength. The rationale is to decrease the diarrhea and dehydration that may ensue when hypertonic solutions are given and water is drawn into the GI tract. Some authorities question the value of this regimen and prefer starting with small amounts of full-strength formulas. Isocal and Osmolite are isotonic and should be given full strength. Most formulas provide 1 kcal/mL so that caloric intake can be quickly calculated. Water can be given with, after, or between regular feedings and with medications, according to the client’s fluid needs.
**Parenteral Nutrition: Intravenous Feedings**

Parenteral feedings are indicated when the GI tract is non-functioning, when enteral feedings would aggravate conditions such as inflammatory bowel diseases or pancreatitis, and when nutritional needs cannot be met by enteral feedings. For short-term use (eg, 3 to 5 days) of IV fluids, the goal is to provide adequate amounts of fluids and electrolytes and enough carbohydrate to minimize oxidation of body protein and fat for energy. The choice of specific solution depends on individual needs, but it should contain at least 5% dextrose. A frequently used solution is 5% dextrose in 0.22% sodium chloride, 2000 to 3000 mL/24 hours. Potassium chloride is often added, and vitamins may be added. These solutions are nutritionally inadequate.

For long-term IV feedings (weeks to months), the goal is to provide all nutrients required for normal body functioning, including tissue growth and repair. Basic nutritional solutions provide water, carbohydrate, protein, vitamins, and minerals. Calories are usually supplied by dilution of concentrated glucose solutions. Hypertonic solutions are given in a central vein so they can be diluted rapidly. Central parenteral nutrition requires special techniques to increase safety and decrease complications. For example, a physician must insert the central IV catheter, and placement must be verified by a chest x-ray. Complications include air embolism and pneumothorax. Peripheral nutrition solutions are less hypertonic because they contains 5% or 10% dextrose. They can be given alone or in combination with oral or enteral feedings to increase nutrient intake.

Intravenous fat emulsions provide calories and essential fatty acids. These solutions are isotonic and may be given centrally or peripherally. When given peripherally, they are confused with the nutrition solution. The fat emulsion is believed to protect the vein and decrease phlebitis.

Guidelines for administration of central and peripheral parenteral nutrition include the following:

- **Administer with an infusion pump to control the flow rate accurately.** The solution must be given at a consistent rate so nutrients can be used and complications prevented. The initial flow rate is usually 50 mL/hour; flow rate is then increased as tolerated to meet nutritional requirements (approximately 1500 to 3000 mL/day). With home administration, the entire daily amount may be infused overnight.
- **To prevent infection, several measures are indicated.** First, the IV catheter must be inserted with aseptic technique. Second, all solutions must be prepared aseptically in a pharmacy under a laminar-flow hood. Third, use an appropriate in-line filter. Fourth, change solution containers, administration sets, and dressings at the venipuncture site on a regular schedule, according to agency policies. Protocols for dressing changes usually include cleansing around the catheter with povidone-iodine solution (Betadine), applying povidone-iodine ointment, and reapplying an occlusive dressing. Sterile technique is used throughout.
- **“Piggyback”** fat emulsions into the IV line beyond the filter.

**Managing Overweight or Obese Clients**

The general goals of weight management are to assist clients to prevent further weight gain, lose weight, and maintain a lower body weight more conducive to health. People who want to lose a few pounds should be encouraged to decrease caloric intake and increase exercise. For people with a BMI of 27 kg/m², treatment is recommended for those with two or more risk factors (eg, hypertension, dyslipidemia, diabetes) or a high waist circumference (central obesity). For people with a BMI of 30 kg/m² or above, treatment is recommended. Considerations include the following:

- **Any weight reduction program needs to include a reduced-calorie diet and physical activity.** Diets should consist of nutritionally sound foods in balanced meals. “Fad” diets are potentially hazardous to health and should be avoided. Exercise increases use of calories and helps to preserve lean body mass during weight loss. It may also help to prevent the decreased metabolic rate that usually occurs with low-calorie diets.
- **Emphasize health benefits of weight reduction.** There is strong evidence that weight loss reduces risk factors for cardiovascular disease, including blood pressure, serum triglycerides, and total and LDL cholesterol. It also increases HDL cholesterol. In addition, in overweight and obese people without diabetes, weight loss reduces blood glucose levels and the risk for development of type 2 diabetes. For people who already have type 2 diabetes, weight loss reduces blood levels of glucose and glycosylated hemoglobin. These effects make the diabetes easier to manage, reduce complications of diabetes, and may allow smaller doses of antidiabetic medications. In general, modest weight losses of only 5 to 10 lbs lower blood pressure and blood lipids and improve insulin resistance and glucose tolerance.
- **Clients in a weight loss regimen should have regular measurements of body weight, BMI, blood pressure, blood lipids, and other factors as indicated.**
- **Provide psychological support and positive reinforcement for efforts toward weight management.**
- **There is increasing consensus that obesity is a chronic disease and that obese people should take weight loss medications on a long-term basis.** Usually, however, the

---

**Nursing Notes: Apply Your Knowledge**

You receive the following order for Mrs. Leader’s tube feedings: ½ strength Ensure, 2000 mL daily. The Ensure is supplied in 240-cc cans. How will you dilute this formula, and at what rate will you set the infusion pump?
medications are recommended only in clients whose health is significantly endangered by obesity.

- When drug therapy is indicated, a single drug in the lowest effective dose is recommended. As with most other drugs, low doses decrease risks of adverse drug effects.
- A client taking an appetite suppressant who has not lost 4 lbs during the first month of treatment is unlikely to benefit from longer use of the drug.
- Maximum weight loss usually occurs during the first 6 months of drug therapy. With most available drugs, use for this long is an unlabeled use of the drug.
- After a weight loss regimen of a few months, some experts recommend letting the body adjust to the lower weight before attempting additional losses. Thus, a weight maintenance program, possibly with continued drug therapy, is indicated.
- The National Institutes of Health do not recommend combining weight loss medications except in the context of clinical trials. This recommendation may change with orlistat, which works in the intestines and is not systemically absorbed.

### Nutritional Support and Obesity in Children

Children in general need increased amounts of water, protein, carbohydrate, and fat in proportion to their size to support growth and increased physical activity. However, reports of childhood obesity and inadequate exercise abound and are steadily increasing. Therefore, the goal of nutritional support is to meet needs without promoting obesity.

With tube feedings, to prevent nausea and regurgitation, the recommended rate of administration is no more than 5 mL every 5 to 10 minutes for premature and small infants and 10 mL/minute for older infants and children. Preparation of formulas, positioning of children, and administration are the same as for adults to prevent aspiration, diarrhea, and infection.

Parenteral nutrition may be indicated in infants and children who cannot eat or be fed enterally. With newborns, especially preterm and low-birth-weight infants, parenteral nutrition is needed within approximately 3 days of birth because they have little nutritional reserve. However, lipid emulsions should be given cautiously in preterm infants because deaths have been attributed to increased serum levels of lipids and free fatty acids. With other infants and children, parenteral nutrition may be used during medical illnesses or perioperative conditions to improve or maintain nutritional status. Overall, benefits include weight gain, increased height, increased liver synthesis of plasma proteins, and improved healing and recovery.

Treatment of childhood obesity should focus on normalizing food intake, especially fat intake, and increasing physical activity. One study indicates more success when caregivers work with the parents rather than the children themselves. None of the available weight loss drugs is indicated for use in children.

Emphasis is being placed on prevention of obesity, especially in children, adolescents, and young adults. The main elements are a more active lifestyle, a low-fat diet, regular meals, avoidance of snacking, drinking water instead of calorie-containing beverages, and decreasing the time spent watching television.

### Nutritional Support and Obesity in Older Adults

Older adults are at risk for development of deficits and excesses in fluid volume. Inadequate intake is common and may result from numerous causes (eg, impaired thirst mechanism, impaired ability to obtain and drink fluids, inadequate water with tube feedings). Increased losses also occur with diuretic drugs, which are commonly prescribed for older adults. Fluid volume excess is most likely to occur with large amounts or rapid administration of IV fluids, especially in older adults with impaired cardiovascular function.

Older adults also are at risk of undernutrition in terms of protein, carbohydrate, and fat intake. Inadequate intake may result from the inability to obtain and prepare food, as well as disease processes that interfere with the ability to digest and use nutrients. When alternative feeding methods (tube feedings, IV fluids) are used, careful assessment of nutritional status is required to avoid deficits or excesses. Overweight and obesity are also common among older adults. Although caloric needs are usually decreased, primarily because of slowed metabolism and decreased physical activity, most people continue usual eating patterns. With the high incidence of atherosclerosis and cardiovascular disease in older adults, it is especially important that fat intake be reduced. Anorexiant drugs should be used very cautiously, if at all, because older adults often have cardiovascular, renal, or hepatic impairments that increase risks of adverse drug effects. The use of orlistat in older adults has not been studied.

### Use in Renal Impairment

Because the kidneys excrete water and waste products of food metabolism, clients with renal impairment often have accumulation of water and urea nitrogen. As a result, these clients have special needs in relation to nutritional support. The needs differ with acute renal failure (ARF) and chronic renal failure (CRF).

With ARF, clients usually have major physiologic stress (eg, serious illness, sepsis, major surgery) that leads to metabolic disorders. These disorders include glucose intolerance (hyperglycemia and peripheral insulin resistance); accumulation of urea nitrogen, the end product of protein metabolism; and increased serum triglyceride levels from disordered fat metabolism. With CRF, clients are not usually as stressed as those with ARF. However, they often have multiple metabolic and fluid and electrolyte disorders. Those on dialysis have impaired host defense mechanisms and increased risk of infection.
Undernourished clients have increased morbidity and mortality. Some considerations in nutritional support of clients with ARF and CRF are listed in the following sections.

**Acute Renal Failure**

- In early ARF, dietary protein is usually restricted to 20 to 30 g/day to minimize urea nitrogen production.
- In oliguric ARF, small volumes of concentrated nutrients with minimal sodium are needed.
- In nonoliguric ARF, large amounts of sodium may be lost in urine and sodium replacement may be needed.
- Enteral nutrition is preferred, if possible. However, most clients are unable to tolerate enteral feedings because they are critically ill.
- Parenteral nutrition formulas should be carefully calculated according to nutritional status and metabolic disorders. Several amino acid solutions are formulated for clients with renal failure (eg, Aminosyn-RF, Aminess, NephrAmine, RenAmin). In addition, clients with ARF often have hyperkalemia, hyperphosphatemia, and hypermagnesemia, so that potassium, phosphorus, and magnesium should be omitted until serum levels return to normal.
- Intravenous fat emulsions should not be given to clients with ARF if serum triglyceride levels exceed 300 mg/dL.

**Chronic Renal Failure**

- Enteral nutritional support is usually indicated because the GI tract is functional. Normal amounts of protein (eg, 1 g/kg/day) may be given. The former recommendation that protein restriction delayed progression of renal failure and the need for dialysis is not supported by newer data.
- High-calorie, low-electrolyte enteral formulations are usually indicated. Nepro is a formulation for clients receiving dialysis; Suplena, which is lower in protein and some electrolytes than Nepro, may be used in clients who are not receiving dialysis.
- If parenteral nutrition is needed, solutions should be carefully formulated according to nutritional status, the extent of metabolic disorders, and whether the client is receiving dialysis. Several amino acid solutions are formulated for clients with renal failure (eg, Aminosyn-RF, Aminess, NephrAmine, RenAmin).
- Serum triglyceride levels should be measured before IV fat emulsions are given. Many clients with CRF have hypertriglyceridemia, which would be worsened by fat emulsions, possibly leading to pancreatitis.

In relation to drugs for weight loss and obesity, little information is available about their use in clients with renal impairment. With sibutramine, dosage reductions are not recommended with mild to moderate impairment because the drug and its active metabolites are eliminated by the liver. However, some inactive metabolites are also formed and these are excreted renally. The drug is contraindicated in clients with severe renal impairment.

**Use in Hepatic Impairment**

The liver is extremely important in digestion and metabolism of carbohydrates, proteins, and fat, as well as storage of nutrients. Thus, clients with impaired hepatic function are often undernourished, with impaired metabolism of foodstuffs, vitamin deficiencies, and fluid and electrolyte imbalances. Depending on the disease process and the extent of liver impairment, these clients have special needs in relation to nutritional support.

- Clients with alcoholic hepatitis or cirrhosis have a high rate of metabolism and therefore need foods to supply extra energy. However, metabolic disorders interfere with the liver’s ability to process and use foodstuffs.
- Disorders of glucose metabolism are common. Clients with cirrhosis often have hyperglycemia. Clients with severe hepatitis often have hypoglycemia because of impaired hepatic production of glucose and possibly impaired hepatic metabolism of insulin.
- Protein restriction is usually needed in clients with cirrhosis to prevent or treat hepatic encephalopathy, which is caused by excessive protein or excessive production of ammonia (from protein breakdown in the GI tract). For clients able to tolerate enteral feedings (usually by GI tube), Hepatic Aid II is formulated for clients with liver failure. When peripheral or central parenteral nutrition is necessary for clients with hepatic failure and hepatic encephalopathy, HepatAmine, a special formulation of amino acids, may be used. Other amino acid preparations are contraindicated in clients with hepatic encephalopathy and coma.
- Enteral and parenteral fat preparations must be used cautiously. Medium-chain triglycerides (eg, MCT oil), which are used to provide calories in other malnourished clients, may lead to coma in clients with advanced cirrhosis. Clients who require parenteral nutrition may develop high serum triglyceride levels and pancreatitis if given usual amounts of IV fat emulsions. If serum triglyceride levels exceed 300 mg/dL, fat emulsions should be used only to prevent a deficiency of essential fatty acids.
- Sodium and fluid restrictions are often needed to decrease edema.

In relation to drugs for weight loss and obesity, little information is available about their use in clients with hepatic impairment. Because sibutramine is metabolized in the liver, it is contraindicated in clients with severe hepatic impairment.

**Use in Critical Illness**

Critically ill clients often have organ failures that alter their ability to use and eliminate essential nutrients. Thus, their
nutritional needs vary with the type and extent of organ impairment. In addition to renal and hepatic impairments, which were discussed, clients with pulmonary failure, cardiac failure, and multiple organ dysfunction syndrome (MODS) have specific needs in relation to nutritional support.

**Pulmonary Impairment**
- In clients with chronic obstructive pulmonary disease (COPD), major concerns are weight loss and decreasing the work of breathing. Weight loss is attributed mainly to hyperactive metabolism. However, increasing caloric intake in these clients must be done cautiously because overfeeding leads to increased carbon dioxide (CO₂) production, increased work of breathing, and perhaps respiratory acidosis. Thus, excessive carbohydrate in enteral or parenteral feedings may cause respiratory failure.
- Enteral nutrition is preferred if the GI tract is functional and accessible. Nutrient and Pulmocare are enteral products for clients with COPD or respiratory failure and mechanical ventilation. They contain less carbohydrate and more fat than other products.
- Clients need adequate amounts of protein, but too much can increase the work of breathing and lead to muscle fatigue and respiratory failure. Moderate amounts (1 to 1.5 g/kg/day) are recommended for clients with stable COPD. Higher amounts are usually needed by clients with sepsis and respiratory failure who require mechanical ventilation.
- Enteral formulas with more concentrated calories (eg, 2 kcal/mL) may be useful for clients with adult respiratory distress syndrome (ARDS), pulmonary edema, or other conditions requiring fluid restriction.
- Parenteral nutrition is often needed because clients with pulmonary failure from severe pneumonia or septicemia may have a prolonged ileus and be unable to tolerate enteral feedings. As with enteral feedings, excessive carbohydrate must be avoided.
- Intravenous fat emulsions should be infused slowly, over 24 hours. Rapid infusion may lead to pulmonary vasoconstriction.
- Excessive amounts of sodium and fluids should be avoided with both enteral and parenteral nutrition because they may worsen impaired pulmonary function.

**Cardiac Impairment**
- Undernutrition may lead to decreased cardiac output and stroke volume, with resultant hypotension and bradycardia.
- Excessive amounts of nutrients or fluids may worsen heart failure by increasing cardiac workload.
- Restricting sodium and fluid intake and increasing serum albumin may decrease edema and prevent or treat congestive heart failure, which commonly occurs in clients with impaired cardiac function. Also, loop diuretics are often given to increase excretion of sodium and water.
- With enteral nutrition, concentrated products (eg, 1.5 to 2 kcal/mL) provide more calories and help with fluid restrictions.
- Parenteral nutrition is usually needed only when a superimposed illness prevents use of the GI tract. Excessive amounts of sodium and fluid or rapid administration may precipitate or worsen heart failure and should be avoided. If IV fat emulsions are used, they should be given over 24 hours because faster infusion may depress myocardial function.

**Multiple Organ Dysfunction Syndrome**
- Clients with MODS, who are usually in critical care units, require nutritional support because they have high rates of metabolism and tissue breakdown (catabolism). However, nutritional support is complex because a client may have a combination of renal, hepatic, pulmonary, and cardiac impairments. Thus, it must be individualized according to the type and extent of organ impairment.
- Clients often have an ileus and GI dysfunction so that they require parenteral nutrition.
- Usual amounts of glucose are usually recommended. Clients with oliguric ARF or ARDS as part of their MODS need concentrated nutrients because fluid intake must be limited.
- During the severe physiologic stress of MODS, clients need higher-than-usual amounts of protein (eg, 1.5 to 2.5 g/kg/day) for growth, tissue maintenance and repair, and enzyme and hormone production. However, many clients may not be able to tolerate this amount because of organ impairments. For example, clients with ARF and dialysis or severe hepatic failure usually have protein intake restricted.
- Intravenous fat emulsions, a readily used source of energy, should provide 20% to 30% of calories. They also provide essential fatty acids. Some clients with MODS already have high serum triglyceride levels and are at risk for development of acute pancreatitis and further organ impairment. In these clients, IV fat emulsions are usually avoided until serum triglyceride levels are less than 300 mg/dL. In clients with MODS who receive IV fat emulsions, serum triglyceride levels should be monitored at least weekly.

### Home Care

The home care nurse is involved with nutritional matters in almost any home care setting. Because nutrition is so important to health, the home care nurse should take advantage of any opportunity for health promotion in this area. Health promotion may involve assessing the nutritional status of all members of the household, especially children, older adults, and those with obvious deficiencies or excesses, and providing counseling or other assistance to improve nutritional status.
For clients receiving tube feedings at home, the home care nurse may teach about the goals of treatment, administration, preparation or storage of solutions, equipment (eg, obtaining, cleaning), and monitoring responses (eg, weight, urine output).

For clients receiving parenteral nutrition at home, solutions, infusion pumps, and other equipment are often obtained from a pharmacy, home health agency, or independent company. The home care nurse may not be involved in the initial setup but is likely to participate in ongoing client care, monitoring of client responses, and supporting caregivers. In addition, the home care nurse may need to coordinate activities among physicians, IV therapy personnel, and other health care providers.

### Nutritional Products and Drugs for Obesity

#### NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td>Chilling (or freezing) may improve formula taste and decrease formula odor. A straw directs the formula toward the back of the throat and decreases its contact with taste buds. A closed container also decreases odor. Giving between meals may have less effect on appetite at mealtimes.</td>
</tr>
<tr>
<td>a. For oral supplemental feedings:</td>
<td>Some can be mixed with fruit juice, milk, tea, or coffee, which may improve taste and acceptability.</td>
</tr>
<tr>
<td>(1) Chill liquids or pour over ice and give through a straw, from a closed container, between meals.</td>
<td>To administer sufficient fluids without a rapid flow rate. Rapid flow rates or large amounts of IV fluids can cause circulatory overload and pulmonary edema. In addition, hyperglycemia and osmotic diuresis may occur with hyperalimentation solutions.</td>
</tr>
<tr>
<td>(2) Mix powders or concentrated liquid preparations in preferred beverages if not contraindicated.</td>
<td>Lipid emulsions should not be filtered.</td>
</tr>
<tr>
<td>b. For intravenous (IV) feedings:</td>
<td>To prevent infection</td>
</tr>
<tr>
<td>(1) Administer fluids at the prescribed flow rate. Use an infusion control device for hyperalimentation solutions.</td>
<td>To avoid physical or chemical incompatibility</td>
</tr>
<tr>
<td>(2) With IV fat emulsions, connect to the primary IV line beyond the filter; start slowly (0.5–1 mL/min) for approximately 30 minutes. If no adverse effects occur, increase rate to a maximum of 125 mL/h for the 10% solution or 60 mL/h for a 20% solution.</td>
<td>To avoid incompatibilities and possible precipitation or inactivation of the drug or fluid components</td>
</tr>
<tr>
<td>(3) Use sterile technique when changing containers, tubings, or dressings.</td>
<td>To decrease risks of aspirating formula into lungs</td>
</tr>
<tr>
<td>(4) When adding drugs, use sterile technique, and add only those drugs known to be compatible with the IV solution.</td>
<td>To prevent aspiration or accidental instillation of feedings into lungs</td>
</tr>
<tr>
<td>(5) Do not administer antibiotics or other drugs through central venous catheters.</td>
<td>Cold formulas may cause abdominal cramping.</td>
</tr>
<tr>
<td>c. For tube feedings:</td>
<td>To avoid gastric distention, possible vomiting, and aspiration into lungs</td>
</tr>
<tr>
<td>(1) Have the client sitting, if possible.</td>
<td>Rapid administration may cause nausea, vomiting, and other symptoms.</td>
</tr>
<tr>
<td>(2) Check tube placement before each feeding by aspirating stomach contents or instilling air into the tube while listening over the stomach with a stethoscope.</td>
<td>Most tube feeding formulas are milk based and provide a good culture medium for bacterial growth. Clean technique, not sterile technique, is required.</td>
</tr>
<tr>
<td>(3) Give the solution at room temperature.</td>
<td>(continued)</td>
</tr>
<tr>
<td>(4) If giving by intermittent instillation, do not give more than 500 mL per feeding, including water for rinsing the tube.</td>
<td></td>
</tr>
<tr>
<td>(5) Give by gravity flow (over 30–60 minutes) or infusion pump.</td>
<td></td>
</tr>
<tr>
<td>(6) With continuous feedings, change containers and tubing daily. With intermittent bolus feedings, rinse all equipment after each use, and change at least every 24 hours.</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
(7) Give an adequate amount of water, based on assessment of fluid needs. This may be done by mixing water with the tube feeding formula, giving it after the tube feeding, or giving it between feedings. | To avoid dehydration and promote fluid balance. Most clients receiving 1500 to 2000 mL of tube feeding formula daily will need 1000 mL or more of water daily.
(8) Rinse nasogastric tubes with at least 50 to 100 mL water after each bolus feeding or administration of medications through the tube. | To keep the tube patent and functioning. This water is included in calculation of fluid intake.
(9) When medications are ordered by tube, liquid preparations are preferred over crushed tablets or powders emptied from capsules. | Tablets or powders may stick in the tube lumen. This may mean the full dose of the medication does not reach the stomach. Also, the tube is likely to become obstructed.
d. With pancreatic enzymes, give before or with meals or food. | To obtain therapeutic effects, these agents must be in the small intestine when food is present.
e. With adrenergic anorexiants:
   (1) Give single-dose drugs in the early morning. | For maximum appetite-suppressant effects during the day
   (2) Give multiple-dose preparations 30–60 minutes before meals and the last dose of the day about 6 h before bedtime. | For maximum appetite-suppressant effects at mealtime and to avoid interference with sleep from the drug’s stimulating effects on the central nervous system (CNS)
f. With sibutramine, give once daily, in the morning | The drug needs to be in the gastrointestinal tract when fat-containing foods are eaten to prevent fat absorption.
g. With orlistat, give 1 capsule with each main meal or up to 1 h after a meal, up to 3 capsules daily. If a meal is missed or contains no fat, the dose can be omitted. | The recommended rate of weight loss is approximately 2 to 3 lb weekly.
2. Observe for therapeutic effects
   a. With water and other fluids, observe for fluid balance (amber-colored urine, approximately 1500 mL daily; moist mucous membranes in the oral cavity; adequate skin turgor). | Therapeutic effects depend on the reason for use (ie, prevention or treatment of undernutrition).
b. With nutritional formulas given orally or by tube feeding, observe for weight gain and increased serum albumin. For infants and children receiving milk substitutes, observe for decreased diarrhea and weight gain. | These are indications of improved metabolism, nitrogen balance, and nutritional status. When parenteral hyperalimentation is used for gastrointestinal malabsorption syndromes, diarrhea and other symptoms are usually relieved when oral feedings are stopped.
c. With parenteral hyperalimentation, observe for weight maintenance or gain and normal serum levels of glucose, electrolytes, and protein. | The pancreatic enzymes function the same way as endogenous enzymes to aid digestion of carbohydrate, protein, and fat.
d. With pancreatic enzymes, observe for decreased diarrhea and steatorrhea. | The recommended rate of weight loss is approximately 2 to 3 lb weekly.
e. With anorexiant drugs and orlistat, observe for decreased caloric intake and weight loss. | Fluid excess is most likely to occur with rapid administration or large amounts of IV fluids, especially in people who are elderly or have congestive heart failure.
3. Observe for adverse effects
   a. With fluids, observe for peripheral edema, circulatory overload, and pulmonary edema (severe dyspnea, crackles). | These adverse reactions are usually attributed to the hyperosmolality or hypertonicity of the preparations. They can be prevented or minimized by starting with small amounts of formula, given slowly.
b. With commercial nutritional formulas (except Osmolite and Isocal), observe for hypotension, tachycardia, increased urine output, dehydration, nausea, vomiting, or diarrhea. | These signs and symptoms indicate complications of therapy. Except for infection, they are likely to occur when the solution is given in a concentration or at a rate that delivers more glucose than can be used. This produces hyperglycemia, which in turn causes excessive amounts of fluid to be excreted in the urine (osmotic diuresis). Hyperglycemic, hyperosmolar, nonketotic coma also may occur.
c. With parenteral hyperalimentation, observe for elevated blood and urine glucose levels, signs of infection (fever, inflammation at the venipuncture site), concentrated urine or high specific gravity (≥1.035), hypertension, dyspnea. | Thrombophlebitis and sepsis are the most frequent adverse effects.
d. With IV fat emulsions, observe for signs of fat embolism (dyspnea, fever, chills, pain in the chest and back), phlebitis from vein irritation, and sepsis from contamination. Hyperlipidemia and hepatomegaly also may occur. | (continued)
### Nursing Actions

**e.** With anorexiant drugs, observe for:

1. Nervousness, insomnia, hyperactivity
2. Hypertension
3. Development of tolerance to appetite-suppressant effects
4. Signs of psychological drug dependence

**f.** With orlistat, observe for abdominal cramping, gas pains, diarrhea, and fatty stools.

### Rationale/Explanation

- These adverse effects are caused by excessive stimulation of the CNS. They are more likely to occur with large doses or too frequent administration.
- Anorexiant drugs stimulate the sympathetic nervous system and may cause or aggravate hypertension.
- This usually occurs within 4 to 6 weeks and is an indication for discontinuing drug administration. Continued administration does not maintain appetite-suppressant effects but increases incidence of adverse effects. In addition, taking large doses of the drug does not restore appetite-suppressant effects.
- More likely with large doses or long-term use
- These effects commonly occur and worsen with a high intake of dietary fat. The drug should not be used as an excuse for eating large amounts of fatty foods.

### 4. Observe for drug interactions with weight loss drugs

- **a.** Drugs that *increase* effects of anorexiants:
  1. Antidepressants, tricyclic
  2. Other CNS stimulants
  3. Other sympathomimetic drugs (eg, epinephrine)

- **b.** Drugs that *decrease* effects of anorexiants:
  1. Antihypertensive drugs
  2. CNS depressants (eg, alcohol)

- **c.** Drugs that *increase* effects of sibutramine
  1. Adrenergics (eg, epinephrine, pseudoephedrine)
  2. Antidepressants (tricyclics [TCAs; eg, amitriptyline], selective serotonin reuptake inhibitors [SSRIs; eg, fluoxetine])
  3. Antifungals (eg, itraconazole, ketoconazole)
  4. Antimigraine triptans (eg, sumatriptan)
  5. Lithium

- **d.** Drugs that *decrease* effects of pancreatic enzymes
  1. Antacids with calcium carbonate or magnesium hydroxide

### Nursing Notes: Apply Your Knowledge

**Answer:** To obtain a 1/2 strength solution, the formula has to be diluted with an equal amount of water, so you will add 240 cc of tap water to 1 can of Ensure. The infusion rate is for 2000 mL per 24 hours, which calculates to an hourly rate of 83 mL/hour. Set the infusion pump to deliver 83 mL/hour.

**How Can You Avoid This Medication Error?**

**Answer:** Pancreatic enzymes are usually given before meals, so that the medication will be in the small intestine to aid digestion. Giving this drug at the wrong time (more than 1 hour after eating breakfast) decreases drug effectiveness. Review your abbreviations to ensure that you can interpret drug orders correctly. Organize your day so that ac medications can be administered before eating.
Review and Application Exercises

1. Differentiate clients who are at high risk for development of fluid imbalances.
2. When assessing a client’s fluid balance, what signs and symptoms indicate deficient or excess fluid volume?
3. What are pharmacologic and nonpharmacologic interventions to restore fluid balance when an imbalance occurs?
4. For clients who are unable to ingest food, which nutrients can be provided with IV nutritional formulas?
5. What is the role of lipid emulsions in parenteral nutrition?
6. In an infant receiving parenteral nutrition, what is the best way to assess the adequacy of nutritional status?
7. In an outpatient or home care client with a protein-calorie deficit and various commercial nutritional formulas: Analyze the types and amounts of nutrients provided. Choose a supplement to recommend to the client or caregiver. Designate the amount to be taken daily for optimum nutritional status. Suggest ways to increase palatability and client ingestion of the nutrients.
8. With an overweight or obese client who wants to lose weight, what are some nursing interventions to assist and support the client?
9. With critically ill clients, what special needs must be considered in relation to nutritional support?

SELECTED REFERENCES


Critical Thinking Scenario
You have been asked to speak with a group of senior citizens, living independently in a retirement community, about vitamins and health. You have a group of approximately 25 who signed up for this talk as part of a general education series on “Staying Fit and Healthy After 65.”

Reflect on:
- Teaching strategies that might enhance learning, considering the size of the group and the age of the participants.
- Review important vitamins, their benefits, and Recommended Dietary Allowances (RDAs).
- Review dietary sources to meet daily requirements.
- Problem-solve which nonprescription vitamins are indicated and cost-effective.
- Review potential problems in megadosing.

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review functions and food sources of essential vitamins.
2. Differentiate between maintenance and therapeutic doses of vitamins.
3. Identify clients at risk for development of vitamin deficiency or excess.
4. Delineate circumstances in which therapeutic vitamins are likely to be needed.
5. Describe adverse effects associated with overdose of fat-soluble and selected water-soluble vitamins.
6. Discuss the rationale for administering vitamin K to newborns.

Vitamins

OVERVIEW

Vitamins are required for normal body metabolism, growth, and development. They are components of enzyme systems that release energy from proteins, fats, and carbohydrates. They also are required for formation of red blood cells, nerve cells, hormones, genetic materials, bones, and other tissues. They are effective in small amounts and are mainly obtained from foods or supplements. Most nutritionists agree that a varied and well-balanced diet provides an adequate intake of vitamins for most people and that dietary sources of vitamins are in general preferred to supplement sources. However, studies indicate that most adults and children do not consume enough fruits, vegetables, cereal grains, dairy products, and other foods to consistently meet their vitamin requirements. In addition, some conditions increase requirements above the usual recommended amounts (eg, pregnancy, lactation, various illnesses).

Historically, the major concern in relation to vitamins was sufficient intake to promote health and prevent deficiency diseases. Nutritional goals for vitamin intake were established by the Food and Nutrition Board of the National Academy of Sciences as Recommended Dietary Allowances (RDAs). The RDAs were designed to meet the daily needs of healthy children and adults; those used in recent years were established in 1989. These RDAs are in the process of being replaced by standards called the Dietary Reference Intakes (DRIs; Box 31–1). As with the RDAs, the DRIs will be revised periodically according to newer information. For example, research studies demonstrated that folic acid can prevent neural tube birth defects such as spina bifida. As a result, in 1998, the DRI was increased from 180 to 200 mcg for most adults to 400 mcg. In addition, the Food and Drug Administration (FDA) mandated that folic acid be added to cereal grain foods, in an amount estimated to add 100 mcg of folic acid to the average daily diet.
Vitamins are usually classified as fat soluble (A, D, E, K) and water soluble (B complex, C). Fat-soluble vitamins are absorbed from the intestine with dietary fat, and absorption requires the presence of bile salts and pancreatic lipase. These vitamins are relatively stable in cooking. Water-soluble vitamins are readily absorbed but are also readily lost by improper cooking and storage. Vitamin D is discussed in Chapter 26 because of its major role in bone metabolism.

Table 31–1 summarizes the characteristics, functions, recommended amounts, and food sources of vitamins. Deficiency states occur with inadequate intake or disease processes that interfere with absorption or use of vitamins. Excess states occur with excessive intake of fat-soluble vitamins because these vitamins accumulate in the body. Excess states do not occur with dietary intake of water-soluble vitamins because these vitamins are rapidly excreted in the urine. However, excess states may occur with vitamin supplements that exceed recommended amounts. Causes and clinical manifestations of vitamin disorders are listed in Table 31–2.

### Vitamin Supplements

Vitamin supplements may be prescribed by health care providers, but most are self-prescribed. Preparations may contain one or several vitamins. The only clear-cut indications for these products are prevention and treatment of vitamin deficiencies. Because vitamins are essential nutrients, some
# TABLE 31–1  Vitamins as Nutrients

<table>
<thead>
<tr>
<th>Vitamin/Function</th>
<th>Recommended Daily Intakes for Individuals</th>
<th>Dietary Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fat-Soluble Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin A (Retinol)</td>
<td>DRIs*: Females: 14 y and older, 700 mcg; pregnancy, 750–770 mcg; lactation, 1200–1300 mcg; Males: 14 y and older, 900 mcg</td>
<td>Preformed vitamin A—meat, butter and fortified margarine, egg yolk, whole milk, cheese made from whole milk</td>
</tr>
<tr>
<td></td>
<td>Infants (Als): 0–6 mo, 400 mcg; 6–12 mo, 500 mcg; Children: 1–3 y, 300 mcg; 4–8 y, 400 mcg; 9–13 y, 600 mcg</td>
<td>Carotenoids—turnip and collard greens, carrots, sweet potatoes, squash, apricots, peaches, cantaloupe</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>RDAs: Females: 14 y and older, 15 mcg; pregnancy, 15 mcg; lactation, 19 mcg; Males: 14 y and older, 15 mcg; Children: 1–3 y, 6 mcg; 4–8 y, 7 mg; 9–13 y, 11 mcg</td>
<td>Cereals, green leafy vegetables, egg yolk, milk fat, butter, meat, vegetable oils</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Activates precursor proteins, found in the liver, into clotting factors II, VII, IX, and X.</td>
<td>Green leafy vegetables (spinach, kale, cabbage, lettuce), cauliflower, tomatoes, wheat bran, cheese, egg yolk, liver</td>
</tr>
<tr>
<td>Vitamin D (see Chap. 26)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Water-Soluble Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-COMPLEX VITAMINS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biotin</td>
<td>DRIs: Females: 14–18 y, 25 mcg; 19 y and older, 30 mcg; pregnancy, 30 mcg; lactation, 35 mcg; Males: 4–18 y, 25 mcg; 19 y and older, 30 mcg; Infants: 0–6 mo, 5 mcg; 7–12 mo, 6 mcg; Children: 1–3 y, 8 mcg; 4–8 y, 12 mcg; 9–13 y, 20 mcg</td>
<td>Meat, especially liver, egg yolk, nuts, cereals, most vegetables</td>
</tr>
<tr>
<td>Cyanocobalamin (vitamin B12)</td>
<td>RDAs: Females: 14 y and older, 2.4 mcg; pregnancy, 2.6 mcg; lactation, 2.8 mcg; Males: 14 y and older, 2.4 mcg; Children: 1–3 y, 0.9 mcg; 4–8 y, 1.2 mcg; 9–13 y, 1.8 mcg; Infants (Als): 0–6 mo, 0.4 mcg; 7–12 mo, 0.5 mcg</td>
<td>Meat, especially liver, eggs, fish, cheese</td>
</tr>
<tr>
<td>Folic acid (folate)</td>
<td>RDAs: Females: 14 y and older, 400 mcg; pregnancy, 600 mcg; lactation, 500 mcg; Males: 14 y and older, 400 mcg; Children: 1–3 y, 150 mcg; 4–8 y, 200 mcg; 9–13 y, 300 mcg; Infants (Als): 0–6 mo, 65 mcg; 7–12 mo, 80 mcg</td>
<td>Liver, kidney beans, fresh green vegetables (spinach, broccoli, asparagus), fortified grain products (eg, breads, cereals, rice). Since 1998, the Food and Drug Administration has required the addition of folic acid to grain products.</td>
</tr>
<tr>
<td>Niacin (vitamin B3)</td>
<td>DRIs: Females: 14 y and older, 14 mg; pregnancy, 18 mg; lactation, 17 mg; Males: 14 y and older, 16 mg; Children: 1–3 y, 6 mg; 4–8 y, 8 mg; 9–13 y, 12 mg; Infants (Als): 0–6 mo, 2 mg; 7–12 mo, 4 mg</td>
<td>Meat, poultry, fish, peanuts</td>
</tr>
<tr>
<td>Pantothenic acid (vitamin B5)</td>
<td>Als: Females: 14–18 y, 25 mcg; 19 y and older, 30 mcg; pregnancy, 30 mcg; lactation, 35 mcg; Males: 4–18 y, 25 mcg; 19 y and older, 30 mcg; Infants: 0–6 mo, 5 mcg; 7–12 mo, 6 mcg</td>
<td>Eggs, liver, salmon, yeast, cauliflower, broccoli, lean beef, potatoes, tomatoes</td>
</tr>
</tbody>
</table>

(continued)
people believe that large amounts (megadoses) promote health and provide other beneficial effects. However, excessive intake of vitamins causes harmful effects and “megavitamins” should never be self-prescribed. Additional characteristics include the following:

- Vitamins from supplements exert the same physiologic effects as those obtained from foods.
- Vitamin supplements do not require a prescription.
- Vitamin products vary widely in number, type, and amount of specific ingredients. They cannot be used interchangeably or indiscriminately with safety.
- Preparations promoted for use as dietary supplements may contain 50% to 100% of the amounts recommended for daily intake. In healthy people who eat a well-balanced diet, nutrient needs may be exceeded.
- Preparations for therapeutic use may contain 300% to 500% of the amounts recommended for daily intake in normal circumstances. These should not contain more than recommended amounts of vitamin D, folic acid, and vitamin A.
- Synthetic vitamins have the same structure and function as natural vitamins derived from plant and animal sources. Contrary to some claims, natural vitamins are no better than synthetic vitamins and are more expensive.
- Multivitamin preparations often contain minerals as well, usually in smaller amounts than those recommended for daily intake. Large doses of minerals are toxic (see Chap. 32).
- Vitamins are often marketed in combination products with each other (eg, antioxidant vitamins) and with

### Table 31-1 Vitamins as Nutrients (continued)

<table>
<thead>
<tr>
<th>Vitamin/Function</th>
<th>Recommended Daily Intakes for Individuals</th>
<th>Dietary Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pyridoxine (vitamin B6)</strong>/A coenzyme in many metabolic processes; functions in metabolism of carbohydrate, protein, and fat; required for formation of tryptophan and conversion of tryptophan to niacin; as part of the enzyme phospholysase, helps release glycogen from the liver and muscle tissue; functions in metabolism of the central nervous system; helps maintain cellular immunity</td>
<td>DRIs</td>
<td>Yeast, wheat germ, liver and other glandular meats, whole grain cereals, potatoes, legumes</td>
</tr>
<tr>
<td></td>
<td><strong>Females:</strong> 14–18 y, 1.2 mg; 19–50 y, 1.3 mg; 51–70 and older, 1.5 mg; pregnancy, 1.9 mg; lactation, 2.0 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Males:</strong> 14–50 y, 1.3 mg; 51–70 y and older, 1.7 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children:</strong> 1–3 y, 0.5 mg; 4–8 y, 0.6 mg; 9–13 y, 1.0 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Infants (AIs):</strong> 0–6 mo, 0.1 mg; 7–12 mo, 0.3 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Riboflavin (vitamin B2)</strong>/Serves as a coenzyme in metabolism; necessary for growth; may function in production of corticosteroids and red blood cells and gluconeogenesis</td>
<td>DRIs</td>
<td>Milk, cheddar and cottage cheeses, meat, eggs, green leafy vegetables</td>
</tr>
<tr>
<td></td>
<td><strong>Females:</strong> 14–18 y, 1.0 mg; 19 y and older, 1.1 mg; pregnancy, 1.4 mg; lactation, 1.6 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Males:</strong> 14 y and older, 1.3 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children:</strong> 1–3 y, 0.5 mg; 4–8 y, 0.6 mg; 9–13 y, 0.9 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Infants (AIs):</strong> 0–6 mo, 0.3 mg; 7–12 mo, 0.4 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Thiamine (vitamin B1)</strong>/A coenzyme in carbohydrate metabolism and essential for energy production</td>
<td>DRIs</td>
<td>Meat, poultry, fish, egg yolk, dried beans, whole-grain cereal products, peanuts</td>
</tr>
<tr>
<td></td>
<td><strong>Females:</strong> 14–18 y, 1.0 mg; 19 y and older, 1.1 mg; pregnancy, 1.4 mg; lactation, 1.4 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Males:</strong> 14 y and older, 1.2 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children:</strong> 1–3 y, 0.5 mg; 4–8 y, 0.6 mg; 9–13 y, 0.9 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Infants (AIs):</strong> 0–6 mo, 0.2 mg; 7–12 mo, 0.3 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin C (ascorbic acid)</strong>/Essential for collagen formation (collagen is a fibrous protein in connective tissue throughout the body, including skin, ligaments, cartilage, bone, and teeth) Required for wound healing and tissue repair, metabolism of iron and folic acid, synthesis of fats and proteins, preservation of blood vessel integrity, and resistance to infection</td>
<td>DRIs</td>
<td>Fruits and vegetables, especially citrus fruits and juices</td>
</tr>
<tr>
<td></td>
<td><strong>Females:</strong> 14–18 y, 65 mg; 19 y and older, 75 mg; pregnancy, 80–85 mg; lactation, 115–120 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Males:</strong> 14–18 y, 75 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Children:</strong> 1–3 y, 15 mg; 4–8 y, 25 mg; 9–13 y, 45 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Infants (AIs):</strong> 0–6 mo, 40 mg; 7–12 mo, 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

*DRIs are expressed in retinol activity equivalents (RAEs), which include both preformed vitamin A and carotenoids. 1 RAE = 1 mcg retinol or 12 mcg beta carotene.
†Vitamin E activity is expressed in milligrams of alpha-tocopherol equivalents (alpha TE).
### Table 31–2: Vitamin Imbalances

<table>
<thead>
<tr>
<th></th>
<th>Deficiency States</th>
<th>Excess States</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fat-Soluble Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin A</strong></td>
<td>Rarely caused by inadequate dietary intake in the United States. May occur during periods of rapid growth, with GI disorders affecting its absorption or conversion, and with liver disorders limiting conversion of beta carotene to the active form or storage of vitamin A.</td>
<td>Excessive intake of vitamin A, which is unlikely with dietary intake but can occur with overuse of vitamin A supplements.</td>
</tr>
<tr>
<td></td>
<td>Night blindness</td>
<td>Anorexia</td>
</tr>
<tr>
<td></td>
<td>Xerophthalmia, which</td>
<td>Vomiting</td>
</tr>
<tr>
<td></td>
<td>may progress to corneal ulceration and blindness</td>
<td>Irritability</td>
</tr>
<tr>
<td></td>
<td>Changes in skin and mucous membranes that lead to skin lesions and infections, respiratory tract infections, and urinary calculi</td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Skin changes (dryness, itching, desquamation, dermatitis)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin E</strong></td>
<td>Deficiency is rare.</td>
<td>Excessive intake of vitamin E, which is rare with dietary intake but can occur with overuse of vitamin E supplements.</td>
</tr>
<tr>
<td></td>
<td>Abnormal bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(melena, hematemesis, hematuria, epistaxis, petechiae, ecchymoses, hypovolemic shock)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vitamin K</strong></td>
<td>Inadequate intake, absorption, or use. Rarely caused by inadequate intake after infancy. Occurs commonly in newborns owing to lack of dietary intake of vitamin K and lack of intestinal synthesis of the vitamin during the first week of life. After infancy, deficiency usually results from diseases that interfere with absorption (biliary tract and GI disorders) or use (hepatic cirrhosis and hepatitis). In alcoholics, deficiency commonly occurs and probably results from decreased intake and impaired use. Drug-induced deficiency occurs with oral coumarin</td>
<td>Unlikely to occur from dietary intake; may occur when vitamin K is given as an antidote for oral anticoagulants</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abnormal bleeding</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(melena, hematemesis, hematuria, epistaxis, petechiae, ecchymoses, hypovolemic shock)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 31–2 Vitamin Imbalances (continued)

<table>
<thead>
<tr>
<th>Deficiency States</th>
<th>Excess States</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Causes</strong></td>
<td><strong>Signs and Symptoms</strong></td>
</tr>
<tr>
<td><strong>Vitamin D</strong></td>
<td></td>
</tr>
<tr>
<td>See Chapter 26.</td>
<td></td>
</tr>
<tr>
<td><strong>WATER-SOLUBLE VITAMINS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Biotin</strong></td>
<td>Inadequate intake or impaired absorption. Biotin deficiency is rare.</td>
</tr>
<tr>
<td></td>
<td>Usually impaired absorption from a lack of hydrochloric acid or intrinsic factor in the stomach</td>
</tr>
<tr>
<td><strong>Cyanocobalamin</strong> <em>(vitamin B₁₂)</em></td>
<td>Megaloblastic or pernicious anemia: Decreased numbers of RBCs Abnormally large, immature RBCs Fatigue Dyspnea With severe deficiency, leukopenia, thrombocytopenia, cardiac arrhythmias, heart failure, or infections may occur. Neurologic signs and symptoms: Paresthesias in hands and feet; unsteady gait Depressed deep-tendon reflexes With severe deficiency, loss of memory, confusion, delusions, hallucinations, and psychosis may occur. Nerve damage may be irreversible.</td>
</tr>
<tr>
<td><strong>Folic acid</strong></td>
<td>Inadequate diet Impaired absorption (intestinal disorders) Greatly increased requirements (pregnancy, lactation, hemolytic anemias) Ingestion of folate antagonist drugs (eg, methotrexate) Alcoholism is a common cause. It interferes with intake and absorption.</td>
</tr>
<tr>
<td><strong>Niacin</strong> <em>(vitamin B₃)</em></td>
<td>Inadequate diet or impaired absorption</td>
</tr>
</tbody>
</table>
### TABLE 31–2	Vitamin Imbalances (continued)

<table>
<thead>
<tr>
<th>Deficiency States</th>
<th>Excess States</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Causes</strong></td>
<td><strong>Signs and Symptoms</strong></td>
</tr>
<tr>
<td>Gl problems (stomatitis, glossitis, enteritis, diarrhea)</td>
<td>Central nervous system problems (headache, dizziness, insomnia, depression, memory loss)</td>
</tr>
<tr>
<td>With severe deficiency, delusions, hallucinations, and impairment of peripheral motor and sensory nerves may occur.</td>
<td></td>
</tr>
<tr>
<td>No deficiency state established</td>
<td>Skin and mucous membrane lesions (seborrheic dermatitis, intertrigo, glossitis, stomatitis)</td>
</tr>
<tr>
<td>Inadequate intake or impaired absorption</td>
<td>Neurologic problems (convulsions, peripheral neuritis, mental depression)</td>
</tr>
<tr>
<td>Inadequate diet, especially among pregnant women and infants; impaired absorption due to GI disorders</td>
<td>Glositis and stomatitis</td>
</tr>
<tr>
<td>Alcoholism</td>
<td>Seborrheic dermatitis</td>
</tr>
<tr>
<td>Inadequate intake or impaired absorption</td>
<td>Eye disorders (burning, itching, lacrimation, photophobia, vascularization of the cornea)</td>
</tr>
<tr>
<td>Inadequate dietary intake (most likely in infants, older adults, indigent people, and alcoholics)</td>
<td>Mild deficiency—fatigue, anorexia, retarded growth, mental depression, irritability, apathy, lethargy</td>
</tr>
<tr>
<td>Increased requirements (people who smoke cigarettes, take oral contraceptives, or have acute or chronic illness)</td>
<td>Severe deficiency—scurvy and adverse effects on most body tissues (gingivitis; bleeding of gums, skin, joints, and other areas; disturbances of bone growth; anemia; and loosening of teeth). If not treated, coma and death may occur.</td>
</tr>
<tr>
<td>Megadoses that are abruptly discontinued may cause a rebound deficiency. Deficiency also may occur in infants whose mothers took megadoses during pregnancy.</td>
<td></td>
</tr>
</tbody>
</table>
| GI, gastrointestinal; RBCs, red blood cells.
Selected preparations of individual vitamins are listed in Drugs at a Glance: Vitamin Drug Preparations.

**Nursing Process**

**Assessment**
Assess each client for current or potential vitamin disorders during an overall assessment of nutritional status. Specific assessment factors related to vitamins include the following:

- Deficiency states are more common than excess states.
- People with other nutritional deficiencies are likely to have vitamin deficiencies as well.
- Deficiencies of water-soluble vitamins (B complex and C) are more common than those of fat-soluble vitamins.
- Vitamin deficiencies are usually multiple and signs and symptoms often overlap, especially with B-complex deficiencies.
- Vitamin requirements are increased during infancy, pregnancy, lactation, fever, hyperthyroidism, and many illnesses. Thus, a vitamin intake that is normally adequate may be inadequate in certain circumstances.
- Vitamin deficiencies are likely to occur in people who are poor, elderly, chronically or severely ill, or alcoholic.
- Vitamin excess states are rarely caused by excessive dietary intake but may occur with use of vitamin drug preparations, especially if megadoses are taken.

**Nursing Diagnoses**
- Imbalanced Nutrition: Less Than Body Requirements related to vitamin deficiency
- Imbalanced Nutrition: More Than Body Requirements related to vitamin excess with overuse of supplements
- Risk for Injury related to vitamin deficiency or overdose
- Deficient Knowledge: Importance of adequate vitamin intake in normal body functioning
- Deficient Knowledge Deficit: Dietary and supplemental sources of various vitamins

**Planning/Goals**
*The client will:*
- Ingest appropriate amounts and sources of dietary vitamins
- Select and use vitamin supplements appropriately
- Avoid megadoses of vitamin supplements
- Avoid symptoms of vitamin deficiency or overdose

**Interventions**
Implement measures to prevent vitamin disorders; the safest and most effective way to prevent vitamin deficiencies is by increasing dietary intake of vitamins:
- A well-balanced, varied diet that is adequate in proteins and calories is adequate in vitamins for most people. Exceptions are those who have increased requirements or conditions that interfere with absorption or use of vitamins.
- Assist clients to increase dietary vitamin intake. Water-soluble vitamins are often destroyed by cooking or discarded in cooking water. Eating raw fruits and vegetables prevents loss of vitamins during cooking. When fruits and vegetables are cooked, vitamin losses can be minimized by using small amounts of water, steaming or microwave cooking for short periods, and keeping cooking utensils covered. In addition to cooking losses, vitamin C is lost with exposure of foods to air. Consequently, fruits and vegetables, including juices, should be kept covered during storage.
- When vitamin deficiency stems from inadequate dietary intake, correcting the diet is preferred over administering supplemental vitamins when feasible. Increasing fruit and vegetable intake to at least five servings daily is a recommended alternative to a vitamin supplement. For vitamin A deficiency, increasing daily intake of plant and animal sources may be sufficient. For vitamin C deficiency, citrus juices and fruits can be used therapeutically. When folic acid deficiency anemia stems from dietary lack, one fresh, uncooked fruit or vegetable or one glass of fruit juice added to the daily diet will probably correct the deficiency (except during pregnancy, when folate requirements are increased).
- Clients receiving only intravenous (IV) fluids or a clear liquid diet for more than 2 or 3 days need replacement vitamins.
- When requirements are increased or absorption is decreased, supplements may be needed to prevent deficiencies. Assist clients in choosing and using vitamin supplements, because they differ widely in the amount and type of vitamins contained. Recommendations should be based on DRIs and usual eating habits.
- An oral multivitamin preparation containing no more than the recommended daily intake may be beneficial for most people, but it is not a substitute for an adequate diet.

**Evaluation**
- Interview about and observe the amount and type of food intake.
- Interview about and observe for signs of vitamin deficiency or overdose.

**PRINCIPLES OF THERAPY**

**Managing Vitamin Disorders**

Vitamin disorders should be recognized as early as possible and appropriate treatment initiated. Early recognition and treatment can prevent a mild deficiency or excess from becoming severe. General guidelines include the following:
- For deficiency states, oral vitamin preparations are preferred when possible. They are usually effective (except
### Drugs at a Glance: Vitamin Drug Preparations

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fat-Soluble Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitamin A (also called retinol)</td>
<td><em>Deficiency:</em> PO, IM 100,000 IU daily for 3 d, then 50,000 IU daily for 2 wk, then 10,000–20,000 IU daily for another 2 mo.</td>
<td>IM administration indicated when oral not feasible, as in anorexia, nausea, vomiting, pre-operative and postoperative conditions, or malabsorption syndromes. With xerophthalmia, vitamin E 40 IU should be coadministered to increase effectiveness of the retinol. Should not be given IV because IV use has been associated with 38 infant deaths. Do not give IV; serious, anaphylaxis-like reactions have occurred.</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>PO 100–400 IU daily</td>
<td></td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Anticoagulant-induced prothrombin deficiency, PO, SC, IM 2.5–10 mg initially, repeat after 6–8 h (injected dose) or 12–48 h (oral dose) if needed (ie, if prothrombin time still prolonged)</td>
<td></td>
</tr>
<tr>
<td>Phytonadione (Mephyton, Aqua-Mephyton)</td>
<td>Hypoprothrombinemia due to other causes, PO, SC, IM 2.5–25 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Water-Soluble Vitamins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B-Complex Vitamins</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium pantothenate (B₅)</td>
<td>Total parenteral nutrition, IV 15 mg daily</td>
<td>Deficiency states seen only with severe, multiple B-complex deficiency states. Oral drug, alone or in multivitamin preparations, is given for nutritional deficiencies. Parenteral B₁₂ should be given for pellagra. Intronasal drug should not be used if rhinitis, nasal congestion, or upper respiratory infection is present. Oral administration preferred unless severe intestinal malabsorption is present.</td>
</tr>
<tr>
<td>Cyanocobalamin (B₁₂)</td>
<td>PO 100–250 mcg daily IM 30 mcg daily for 5–10 d, then 100–200 mcg monthly</td>
<td></td>
</tr>
<tr>
<td>Nascobal</td>
<td>Intranasal gel, 1 spray (500 mcg) in one nostril, once per wk</td>
<td></td>
</tr>
<tr>
<td>Folic acid</td>
<td>Deficiency, megaloblastic anemia PO, SC, IM, IV up to 1 mg daily until symptoms decrease and blood tests are normal, then maintenance dose of 0.4 mg daily</td>
<td>Safety and effectiveness not established for amounts exceeding the RDA. To reduce flushing with larger doses, start with smaller doses and gradually increase them.</td>
</tr>
<tr>
<td>Niacin (nicotinic acid), niacinamide (nicotinamide)</td>
<td>Deficiency, PO 50–100 mg daily Pellagra, PO Up to 500 mg daily Hyperlipidemia, PO 2–6 g daily (maximum dose, 6 g/d)</td>
<td>Usually given with isoniazid, an antitubercular drug, to prevent peripheral neuropathy. Deficiency rarely occurs alone; more likely with other vitamin deficiency states. Deficiency is common in alcoholics.</td>
</tr>
<tr>
<td>Pyridoxine (B₆)</td>
<td>Deficiency, PO, IM, IV 2–5 mg daily Anemia, peripheral neuritis, 50–200 mg daily</td>
<td>Safety and effectiveness not established for amounts exceeding the RDA.</td>
</tr>
<tr>
<td>Riboflavin</td>
<td>Deficiency, PO 5–10 mg daily In total parenteral nutrition, 3.6 mg/d</td>
<td>Deficiency rarely occurs alone; more likely with other vitamin deficiency states.</td>
</tr>
<tr>
<td>Thiamine (B₁)</td>
<td>Deficiency, PO 10–30 mg daily; IM 10–20 mg 3 times daily for 2 wk, supplemented with 5–10 mg orally; IV 50–100 mg/d</td>
<td>Deficiency is common in alcoholics.</td>
</tr>
</tbody>
</table>

(continued)
Disorders of Fat-Soluble Vitamins A and K

- With vitamin A deficiency, increase intake of foods containing vitamin A or beta carotene when feasible. Use a single, pure form of vitamin A rather than a multivitamin, unless multiple deficiencies are present. Give doses no larger than 25,000 U daily unless a severe deficiency is present. Give orally if not contraindicated; give intramuscularly if gastrointestinal (GI) absorption is severely impaired or ocular symptoms are severe. With vitamin A excess, immediately stop known sources of the vitamin.
- With vitamin K deficiency, bleeding may occur spontaneously or in response to trauma. Thus, administration of vitamin K and measures to prevent bleeding are indicated. If the deficiency is not severe, oral vitamin K may be given for a few days until serum prothrombin activity returns to a normal range. In obstructive jaundice, bile salts must be given at the same time as oral vitamin K, or vitamin K must be given parenterally. In malabsorption syndromes or diarrhea, parenteral administration is probably necessary. A single dose of vitamin K may be sufficient.

  With severe bleeding, vitamin K may be given intravenously. IV vitamin K must be given slowly to decrease risks of hypotension and shock. Unfortunately, a therapeutic response does not occur for at least 4 hours. For more rapid control of bleeding, transfusions of plasma or whole blood are needed. When bleeding is caused by an oral anticoagulant drug, avoid overdoses of vitamin K. Oral anticoagulants such as warfarin (Coumadin) are usually given for thromboembolic disorders. Giving vitamin K as an antidote to control bleeding reestablishes the risks of thrombi. Measures to prevent bleeding include avoiding trauma, injections, and drugs that may cause bleeding.

Disorders of B-Complex Vitamins

- Most deficiencies of B-complex vitamins are multiple rather than single. Also, many of these vitamins are obtained from the same foods. Treating deficiencies consists of increasing intake of foods containing B-complex vitamins or giving multivitamin preparations. Most preparations contain all the B vitamins; other vitamins may also be included.
- If a single deficiency seems predominant, that vitamin may be given alone or along with a multivitamin preparation. For example, folic acid deficiency is much less widespread than formerly, but may still occur. It is attributed to inadequate dietary intake, loss in cooking and food processing, and intestinal disorders that inhibit absorption. In addition, folic acid is depleted by alcohol and several medications, including antibiotics containing trimethoprim (eg, Bactrim), phenytoin, methotrexate, and oral contraceptives.

  Thiamine deficiency is common in alcoholics. Reasons include inadequate dietary intake and the use of large amounts of thiamine to metabolize ethanol.
- Some uncommon types of anemia occur with deficiencies of certain B vitamins. One type occurs with pyridoxine deficiency and is relieved by administration of pyridoxine. Megaloblastic anemias, characterized by abnormally large, immature red blood cells, occur with

### How Can You Avoid This Medication Error?

You receive an order for K 5 mg IM STAT for a patient. You see KCl in your stock supply that comes in 10 mEq/10 mL. You proceed to draw up and administer 5 mL of KCl IM to the patient.
Vitamins are required for normal body metabolism and functioning. For the most part, they must be obtained from the diet or from vitamin supplements.

The safest and most effective way to obtain needed vitamins is to eat a varied, well-balanced diet. A healthful diet supplies vitamins, minerals, protein, water, fiber, and probably other elements yet to be discovered. Thus, vitamin supplements cannot substitute for a healthy diet. Vitamin content of foods, especially B vitamins and vitamin C, can be increased by avoiding prolonged cooking.

Although diseases caused by vitamin deficiencies are uncommon in the United States, studies indicate that fewer than 25% of adults meet recommendations for dietary intake of vitamins.

An adequate vitamin intake, especially from the recommended minimum of five daily servings of fruits and vegetables, may help prevent heart disease and cancer.

People who are healthy and who eat a well-balanced diet do not need to take a daily multivitamin supplement. However, a supplement is needed by pregnant women and people who smoke, ingest large amounts of alcohol, have impaired immune systems, or are elderly.

Avoid large doses of vitamins. They will not promote health, strength, or youth. In addition, excessive amounts of B vitamins and vitamin C are eliminated in urine and can cause adverse effects (eg, large doses of vitamin C can cause kidney stones; niacin (B₃) can cause stomach upset, flushing, skin rashes, itching, and aggravation of asthma and gout; pyridoxine (B₆) may cause numbness in limbs and difficulty in walking). Excessive amounts of vitamins A, D, E, and K are stored in the body and often lead to toxic effects. For example, high doses of vitamin A can result in headaches, diarrhea, nausea, loss of appetite, dry, itching skin, and elevated blood calcium. Excessive doses during pregnancy may cause birth defects.

Although natural vitamins are advertised as being better than synthetic vitamins, there is no evidence to support this claim. The two types are chemically identical and used in the same way by the human body. Natural vitamins are usually much more expensive than synthetic vitamins.

Sexually active women of childbearing potential need an adequate intake of folic acid to prevent severe birth defects in infants. To help prevent birth defects from folic acid deficiency, the Food and Drug Administration requires that folic acid be added to breads and cereal grain products. This is estimated to add about 100 mcg of folic acid to the daily diet of most people. However, the recommended daily intake for adults is 400 mcg.

Vitamins from supplements exert the same physiologic effects as those obtained from foods.

Multivitamin preparations often contain minerals as well, usually in smaller amounts than those recommended for daily intake. Large doses of minerals are toxic.

Self-Administration

If supplementary vitamins are taken, it is probably advisable to consult a health care provider. Available preparations differ widely in amounts and types of vitamin content. As a general rule, a multivitamin that contains no more than 100% of the recommended dietary allowance (RDA) for any vitamin is recommended because additional vitamins are obtained from food. In addition, the product should not contain more than recommended amounts of vitamin D and vitamin A because of possible adverse effects.

When choosing a vitamin supplement, compare ingredients and costs. Store brands are usually effective and less expensive than name brands.

Vitamin C supplements are available in tablet and powder forms of various dosages. Vitamin C is commonly included in multivitamin and other preparations sold as antioxidant supplements. In 2000, the RDA was increased from 60 mg daily to 75 mg for adult women and 90 mg for adult men. Large doses (eg, 1000 mg or more daily) may cause adverse effects and should be avoided. An adequate amount of vitamin C can also be obtained by eating at least five servings of fruit and vegetables daily.

Take oral niacin preparations, except for timed-release forms, with or after meals or at bedtime to decrease stomach irritation. In addition, sit or lie down for approximately 30 minutes after taking a dose. Niacin causes blood vessels to dilate and may cause facial flushing, dizziness, and falls. Facial flushing can be decreased by aspirin 325 mg, taken 30 to 60 minutes before a dose of niacin. Itching, tingling, and headache may also occur. These effects usually subside with continued use of niacin.

Swallow extended-release products whole; do not break, crush, or chew them. Breaking the product delivers the entire dose at once and may cause adverse effects.

Take prescribed vitamins as directed and for the appropriate time. In pernicious anemia, vitamin B₁₂ injections must be taken for the remainder of life. In pregnancy and lactation, vitamin supplements are usually taken only during this period of increased need.

Swallow vitamin E capsules whole; do not crush or chew.
Disorders of Vitamin C

Treatment of vitamin C deficiency involves increased intake of vitamin C from dietary or pharmaceutical sources. Vitamin C is available alone for oral, intramuscular (IM), or IV administration. It is also an ingredient in most multivitamin preparations for oral or parenteral use.

From 1989 until 2000, the RDA for vitamin C was 60 mg daily. In 2000, it was changed to 75 mg for most adult women and 90 mg for most adult men. Some nutritionists recommend 120 mg/day; others recommend approximately 200 mg/day from five servings of fruits and vegetables or 100 mg/day of a vitamin C supplement. An additional recommendation is to limit intake to less than 1 g/day.

Plasma levels of vitamin C are usually low in patients who are smokers, are postoperative, or have illnesses such as sepsis, human immunodeficiency virus infection, pancreatitis, adult respiratory distress syndrome, or other critical illnesses requiring intensive care. The significance of low plasma levels and whether increased levels would decrease smoking-related diseases or have beneficial effects in other illnesses is unknown. In addition, there are few data relating plasma levels to susceptibility to the common cold and other infections.

With excessive intake of vitamin C supplements (1 g or more daily), the main concern is formation of calcium oxalate kidney stones and potential obstruction or other renal damage. There is no known benefit of such large amounts, and their use should be discouraged.

Effects of Vitamins on Other Drugs

Folic acid decreases effects of phenytoin, probably by accelerating phenytoin metabolism, and may decrease absorption and effects of zinc. Niacin may increase the risk of rhabdomyolysis (a life-threatening breakdown of skeletal muscle) with statin cholesterol-lowering drugs. Vitamin A, in large doses, and possibly vitamin E may increase the anticoagulant effect of warfarin. Vitamin C, 1 g daily or more, may decrease metabolism and increase the effects of estrogens and oral contraceptives. It is recommended that the daily dose of vitamin C not exceed 100 mg, to prevent this interaction.

Use in Children

Children need sufficient amounts of all required vitamins to support growth and normal body functioning. For healthy children consuming a well-balanced diet, vitamin supplements are probably not needed. However, if supplements are given, considerations include the following:

- Dosages should not exceed recommended amounts. There is a risk of overdose by children and their parents. Because of manufacturers’ marketing strategies, many supplements are available in flavors and shapes (eg, cartoon characters, animals) designed to appeal to children. Because younger children may think of these supplements as candy and take more than recommended, they should be stored out of reach and dispensed by an adult. Parents may lack knowledge of nutrition or be concerned about the adequacy of a child’s diet. Their wish to promote health may lead them to give unneeded supplements or to give more than recommended amounts. Parents may need information about the potential hazards of acute and chronic vitamin overdoses.
- The content of supplements for infants and children younger than 4 years is regulated by the FDA; the content of preparations for older children is not regulated.
- Supplements given to children and adolescents should in general provide RDA or DRI levels of vitamins. Supplements containing 25% to 50% of the recommended amount minimize risks of deficiency states; those containing 100% of the recommended amount meet nutritional needs without producing excess states.
- Except for single supplements of vitamin K and vitamin E in infants, multivitamin products are commonly used. For infants, liquid formulations usually include vitamins A, D, C, and B complex. Folic acid is not included because it is unstable in liquid form. For older children, chewable tablets usually contain vitamins A, D, C, and B complex, including folic acid.
- A single IM dose of vitamin K is given to newborn infants to prevent hemorrhagic disease of newborns.
- Preterm infants need proportionately more vitamins than term infants because their growth rate is faster and their absorption of vitamins from the intestine is less complete. A multivitamin product containing the equivalent of RDAs for term infants is recommended.
- Tolerable upper intake levels (ULs) have been established for some vitamins, and these maximum daily

Nursing Notes: Apply Your Knowledge

Jim Bagley, 40 years of age, was just diagnosed with pernicious anemia. Jim asks you why he must take shots rather than vitamin pills. You are assigned to provide his IM injection of vitamin B₁₂ and provide patient teaching. Discuss how you will proceed.
amounts should not be exceeded. For infants (birth to 12 months), the only UL is for vitamin D (25 mcg). For other children, ULs vary according to age, as follows.

<table>
<thead>
<tr>
<th>Vitamin</th>
<th>1–3 Y</th>
<th>4–8 Y</th>
<th>9–13 Y</th>
<th>14–18 Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>D</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
<td>50 mg</td>
</tr>
<tr>
<td>E</td>
<td>200 mg</td>
<td>300 mg</td>
<td>600 mg</td>
<td>800 mg</td>
</tr>
<tr>
<td>C</td>
<td>400 mg</td>
<td>650 mg</td>
<td>1200 mg</td>
<td>1800 mg</td>
</tr>
<tr>
<td>Folate</td>
<td>300 mcg</td>
<td>400 mcg</td>
<td>600 mcg</td>
<td>800 mcg</td>
</tr>
<tr>
<td>Niacin</td>
<td>10 mg</td>
<td>15 mg</td>
<td>20 mg</td>
<td>30 mg</td>
</tr>
<tr>
<td>Pyridoxine</td>
<td>30 mg</td>
<td>40 mg</td>
<td>60 mg</td>
<td>80 mg</td>
</tr>
</tbody>
</table>

### Use in Older Adults

Vitamin requirements are the same as for younger adults. However, deficiencies are common in older adults, especially of vitamins A and D, cyanocobalamin (B12), folic acid, riboflavin, and thiamine. With vitamin B12, for example, it is estimated that older adults absorb only 10% to 30% of the amount found in food. Other factors may also contribute to deficiencies, including limited income, anorexia, lack of teeth or ill-fitting dentures, drugs that decrease absorption of dietary nutrients, and disease processes that interfere with the ability to obtain, prepare, or eat adequate amounts of a variety of foods.

Every older adult should be assessed regarding vitamin intake (from foods and supplements) and use of drugs that interact with dietary nutrients. For most older adults, a daily multivitamin is probably desirable, even for those who seem healthy and able to eat a varied, well-balanced diet. In addition, requirements may be increased during illnesses, especially those affecting GI function. Overdoses, especially of the fat-soluble vitamins A and D, may cause toxicity and should be avoided. Tolerable ULs for older adults have been established for some vitamins (D, 50 mcg; E, 1000 mcg; C, 2000 mg; folate, 1000 mcg; niacin, 35 mg; pyridoxine, 100 mg), and these amounts should not be exceeded.

### Use in Preventing Cancer

Vitamin A, its precursor beta carotene, and vitamin C are the main vitamins associated with prevention of cancer. Anticancer effects are attributed to antioxidant activity. Vitamin A and beta carotene may reduce cancers of the lung, breast, oral mucosa, esophagus, and bladder. Although vitamin A supplements are not recommended, increasing dietary intake of fruits and vegetables is desirable. It is unknown whether anticancer effects stem from beta carotene or other components of fruits and vegetables.

With vitamin C, several studies indicate that diets with 200 mg or more from fruits and vegetables (five or more servings daily) are associated with reduced cancer risk, especially for cancers of the GI tract (eg, oral cavity, esophagus, stomach, and colon) and lung. However, in other studies, vitamin C supplements did not decrease the occurrence of stomach or colorectal cancer. Thus, the cancer-preventing effects of fruits and vegetables may be associated with factors other than vitamin C (eg, interactions between vitamin C and other components of these foods, food components other than vitamin C, or because people who eat fruits and vegetables also participate in other health-promoting activities).

### Use in Preventing Cardiovascular Disease

Folic acid and vitamin C are believed to have cardioprotective effects. Folic acid is important in the metabolism of homocysteine, a toxic amino acid and a major risk factor for heart disease. Homocysteine is normally produced during metabolism of methionine, another amino acid. Several B vitamins, including folic acid, are required for the metabolism of homocysteine to a nontoxic substance, and an increased blood level of homocysteine occurs with folic acid deficiency. Excessive homocysteine damages the endothelial lining of arteries and leads to plaque formation, arteriosclerosis, and thrombosis. Folic acid supplements can prevent or delay these effects by lowering blood levels of homocysteine. Although the FDA requirement that folic acid be added to cereal grain foods may be helpful, the folic acid intake that helps prevent cardiovascular disease is thought to be higher.

Vitamin C is thought to help prevent cardiovascular disease by its antioxidant effects. The atherogenic effects of blood lipids, especially low-density lipoprotein (LDL) cholesterol (see Chap. 58), are attributed to their chemical breakdown or oxidation. Vitamin C may help to prevent oxidation of LDL cholesterol. Overall, however, the effects of vitamin C on prevention of coronary artery disease (CAD) are unclear. Some studies indicate an increased risk for CAD only with a severe vitamin C deficiency and that vitamin C has little effect on ischemic heart disease and stroke after adjustment for other risk factors. More research is needed before vitamin C supplements are recommended for cardioprotective effects. However, fruits and vegetables are natural sources of antioxidants and increased intake may be beneficial.

For a number of years, vitamin E was thought to have antioxidant, cardioprotective effects similar to those of vitamin C. However, several studies failed to support this view.

### Use in Renal Impairment

Patients with renal impairment usually have special needs in relation to vitamin intake because of difficulties in ingesting or using these nutrients. Considerations include:

- In patients with acute renal failure who are unable to eat an adequate diet, a vitamin supplement to meet DRIs is recommended. Large doses of vitamin C should be avoided because urinary excretion is impaired. In addition, oxalate (a product of vitamin C catabolism) may precipitate in renal tubules or form calcium oxalate stones, obstruct urine flow, and worsen renal function.
- In patients with chronic renal failure (CRF), deficiencies of water-soluble vitamins are common because many
foods that contain these vitamins are restricted because of their potassium content. In addition, vitamin C is reabsorbed from renal tubules by a specific transport protein. When the transport protein becomes saturated, vitamin C is excreted in urine. The optimal replacement dose is unknown but probably should not exceed 200 mg/day (to avoid increased oxalate and possible stones).

A multivitamin product with essential vitamins, including vitamin C 70 to 100 mg, pyridoxine 5 to 10 mg, and folic acid 1 mg, is recommended for daily use. Because patients with CRF often have increased vitamin A concentrations, vitamin A should be omitted or reduced in dosage for those requiring parenteral nutrition.

### Use in Hepatic Impairment

Vitamin deficiencies commonly occur in patients with chronic liver disease because of poor intake and malabsorption. With hepatic failure, hepatic stores of vitamin A, pyridoxine, folic acid, riboflavin, pantothenic acid, vitamin B₁₂, and thiamine are depleted. Folic acid deficiency may lead to megaloblastic anemia. Thiamine deficiency may lead to Wernicke’s encephalopathy. Therapeutic doses of vitamins should be given for documented deficiency states.

Niacin is contraindicated in liver disease because it may increase liver enzymes (alanine and aspartate aminotransferase, alkaline phosphatase) and bilirubin and cause further liver damage. Long-acting dosage forms may be more hepatotoxic than the fast-acting forms.

### Use in Critical Illness

Patients with critical illnesses often experience vitamin deficiencies unless they are prevented by early supplementation. Patients receiving enteral nutrition should usually be given DRI-equivalent amounts of all vitamins. Those with intestinal resections (short bowel syndrome) may be able to take most vitamins orally or by GI tube. However, they usually need injections of vitamin B₁₂ because they are unable to absorb it from the GI tract. Those with fat malabsorption syndromes need supplements of the fat-soluble vitamins A, D, E, and K.

For patients receiving parenteral nutrition, guidelines for daily vitamin supplementation have been developed by the Nutrition Advisory Group of the American Medical Association (NAG-AMA). These guidelines are based on the DRIs for healthy people; vitamin requirements for patients who are critically ill or have specific organ failures are unclear.

Several parenteral multivitamin formulations meet the NAG-AMA guidelines for adults and children. Those for adults do not contain vitamin K, which is usually injected weekly. The usual dose is 2 to 4 mg, but some clinicians give 5 to 10 mg. Vitamin K is included in pediatric parenteral nutrition solutions.

### Home Care

The home care nurse needs to assess household members and the home setting for indications of vitamin deficiencies or use of supplements, especially megadoses. If actual or potential difficulties are found, the nurse may need to counsel household members about dietary sources of vitamins and adverse effects of excessive vitamin intake.

---

**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td>To increase therapeutic effects and avoid adverse reactions</td>
</tr>
<tr>
<td>a. With fat-soluble vitamins:</td>
<td>Mineral oil absorbs the vitamins and thus prevents their systemic absorption.</td>
</tr>
<tr>
<td>(1) Give as directed.</td>
<td>Vitamin K is given to clients with hypoprothrombinemia, which causes a bleeding tendency. Thus, any injection may cause trauma and bleeding at the injection site.</td>
</tr>
<tr>
<td>(2) Do not give oral preparations at the same time as mineral oil.</td>
<td>Intravenous phytonadione may cause hypotension and shock from an anaphylactic type of reaction.</td>
</tr>
<tr>
<td>(3) For subcutaneous or intramuscular administration of vitamin K, aspirate carefully to avoid intravenous injection, apply gentle pressure to the injection site, and inspect the site frequently. For intravenous injection, vitamin K may be given by direct injection or diluted in intravenous fluids (eg, 5% dextrose in water or saline).</td>
<td></td>
</tr>
<tr>
<td>(4) Administer intravenous vitamin K slowly, at a rate not to exceed 1 mg/min, whether diluted or undiluted.</td>
<td></td>
</tr>
<tr>
<td>b. With B-complex vitamins:</td>
<td></td>
</tr>
<tr>
<td>(1) Give parenteral cyanocobalamin (vitamin B₁₂) intramuscularly or deep subcutaneously.</td>
<td>(continued)</td>
</tr>
</tbody>
</table>
(2) Give oral niacin preparations, except for timed-release forms, with or after meals or at bedtime. Have the client sit or lie down for about 1/2 hour after administration.

(3) Give intramuscular thiamine deeply into a large muscle mass. Avoid the intravenous route.

2. Observe for therapeutic effects (mainly decreased signs and symptoms of deficiency)

a. With vitamin A, observe for improved vision, especially in dim light or at night, less dryness in eyes and conjunctiva (xerophthalmia), improvement in skin lesions.

b. With vitamin K, observe for decreased bleeding and more nearly normal blood coagulation tests (e.g., prothrombin time).

c. With B-complex vitamins, observe for decreased or absent stomatitis, glossitis, cheilosis, seborrheic dermatitis, neurologic problems (neuritis, convulsions, mental deterioration, psychotic symptoms), cardiovascular problems (edema, heart failure), and eye problems (itching, burning, photophobia).

d. With vitamin B₁₂ and folic acid, observe for increased appetite, strength and feeling of well-being, increased reticulocyte counts, and increased numbers of normal red blood cells, hemoglobin, and hematocrit.

e. With vitamin C, observe for decreased or absent malaise, irritability, and bleeding tendencies (easy bruising of skin, bleeding gums, nosebleeds, and so on).

3. Observe for adverse reactions

a. With vitamin A, observe for signs of hypervitaminosis A (anorexia, vomiting, irritability, headache, skin changes [dryness, dermatitis, itching, desquamation], fatigue, pain in muscles, bones, and joints, and other clinical manifestations, and serum levels of vitamin A above 1200 U/dL).

b. With vitamin K, observe for hypotension and signs of anaphylactic shock with intravenous phytonadione.

c. With B-complex vitamins, observe for hypotension and anaphylactic shock with parenteral niacin, thiamine, cyanocobalamin, and folic acid; anorexia, nausea, vomiting and diarrhea, and postural hypotension with oral niacin.

d. With vitamin C megadoses, observe for diarrhea and rebound deficiency if stopped abruptly.

4. Observe for drug interactions

a. Fat-soluble vitamins:

1. Bile salts increase effects.

2. Laxatives, especially mineral oil, decrease effects.

3. Antibiotics may decrease effects.

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Give oral niacin preparations, except for timed-release forms, with or after meals or at bedtime. Have the client sit or lie down for about 1/2 hour after administration.</td>
<td>To decrease anorexia, nausea, vomiting, diarrhea, and flatulence. Niacin causes vasodilation, which may result in dizziness, hypotension, and possibly injury from falls. Vasodilation occurs within a few minutes and may last 1 hour.</td>
</tr>
<tr>
<td>(3) Give intramuscular thiamine deeply into a large muscle mass. Avoid the intravenous route.</td>
<td>To decrease pain at the injection site. Hypotension and anaphylactic shock have occurred with rapid intravenous administration and large doses.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects (mainly decreased signs and symptoms of deficiency)</strong></td>
<td>Night blindness is usually relieved within a few days. Skin lesions may not completely disappear for several weeks. Blood coagulation tests usually improve within 4 to 12 hours. Deficiencies of B-complex vitamins commonly occur together and produce many similar manifestations. Therapeutic effects may be quite rapid and dramatic. The client usually feels better within 24 to 48 hours, and normal red blood cells begin to appear. Anemia is decreased within approximately 2 weeks, but 4 to 8 weeks may be needed for complete blood count to return to normal.</td>
</tr>
<tr>
<td>a. With vitamin A, observe for improved vision, especially in dim light or at night, less dryness in eyes and conjunctiva (xerophthalmia), improvement in skin lesions.</td>
<td>Severity of manifestations depends largely on dose and duration of excess vitamin A intake. Very severe states produce additional clinical signs, including enlargement of liver and spleen, altered liver function, increased intracranial pressure, and other neurologic manifestations. Vitamin K rarely produces adverse reactions. Giving intravenous phytonadione slowly may prevent adverse reactions. Adverse reactions are generally rare. They are unlikely with B-complex multivitamin preparations. They are most likely to occur with large intravenous doses and rapid administration. Adverse reactions are rare with usual doses and methods of administration.</td>
</tr>
<tr>
<td>b. With vitamin K, observe for decreased bleeding and more nearly normal blood coagulation tests (e.g., prothrombin time).</td>
<td>Increase intestinal absorption Mineral oil combines with fat-soluble vitamins and prevents their absorption if both are taken at the same time. Excessive or chronic laxative use decreases intestinal absorption. With vitamin K, antibiotics decrease production by decreasing intestinal bacteria. With others, antibiotics may cause diarrhea and subsequent malabsorption.</td>
</tr>
<tr>
<td>c. With B-complex vitamins, observe for decreased or absent stomatitis, glossitis, cheilosis, seborrheic dermatitis, neurologic problems (neuritis, convulsions, mental deterioration, psychotic symptoms), cardiovascular problems (edema, heart failure), and eye problems (itching, burning, photophobia).</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

Nursing Notes: Apply Your Knowledge

Answer: Explain to Jim that injections are required for pernicious anemia because the parietal cells in the lining of his stomach fail to secrete intrinsic factor, which is required for intestinal absorption of B12. Monthly injection of B12 will be required for the rest of his life. Later, Jim may want to learn how to administer his own injections. Provide Jim with teaching pamphlets about pernicious anemia and encourage him to ask questions.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?

Answer: You need to clarify this order with the physician before you proceed, clarifying whether vitamin K or KCl is ordered. It is likely the intended drug is vitamin K because it is ordered in milligrams and given IM. KCl is usually ordered in mEq and never given IM or IV push. Also, 5 mL is a very large dose to administer IM.

How Can You Avoid This Medication Error?
Critical Thinking Scenario
Minnie Pearl, 62 years of age, has been started on a thiazide diuretic to remove excess fluid and decrease the workload on her heart. Potassium supplements have been ordered to prevent hypokalemia.

Reflect on:
- How diuretics might alter electrolyte balance.
- What laboratory values are important to monitor for Ms. Pearl (review normal values).
- Why potassium supplements are especially important for cardiac patients on diuretics that are not potassium sparing.
- Important dietary teaching to help ensure electrolyte balance.

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss functions and food sources of major minerals.
2. Identify clients at risk for development of selected mineral and electrolyte imbalances.
3. Describe signs, symptoms, and treatment of sodium, potassium, and magnesium imbalances.
4. Describe signs, symptoms, and treatment of iron deficiency anemia.
5. Discuss the chelating agents used to remove excessive copper, iron, and lead from body tissues.
6. Apply nursing process skills to prevent, recognize, or treat mineral or electrolyte imbalances.

OVERVIEW

Minerals and electrolytes are essential constituents of bone, teeth, cell membranes, connective tissue, and many essential enzymes. They function to maintain fluid, electrolyte, and acid–base balance; maintain osmotic pressure; maintain nerve and muscle function; assist in transfer of compounds across cell membranes; and influence the growth process.

Minerals occur in the body and foods mainly in ionic form. Ions are electrically charged particles. Metals (eg, sodium, potassium, calcium, magnesium) form positive ions or cations; nonmetals (eg, chlorine, phosphorus, sulfur) form negative ions or anions. These cations and anions combine to form compounds that are physiologically inactive and electrically neutral. When placed in solution, such as a body fluid, the components separate into electrically charged particles called electrolytes. For example, sodium and chlorine combine to form sodium chloride (NaCl or table salt). In a solution, NaCl separates into Na⁺ and Cl⁻ ions. (The plus sign after Na means that Na is a cation; the minus sign after Cl means that Cl is an anion.) At any given time, the body must maintain an equal number of positive and negative charges. Therefore, the ions are constantly combining and separating to maintain electrical neutrality or electrolyte balance.

These electrolytes also maintain the acid–base balance of body fluids, which is necessary for normal body functioning. When foods are digested in the body, they produce mineral residues that react chemically as acids or bases. Acids are usually anions, such as chloride, bicarbonate, sulfate, and phosphate. Bases are usually cations, such as sodium, potassium, calcium, and magnesium. If approximately equal amounts of cations and anions are present in the mineral residue, the residue is essentially neutral, and the pH of body fluids does not require adjustment. If there is an excess of cations (base), the body must draw on its anions (acid) to combine with the cations, render them physiologically inactive, and restore the normal pH of the blood. Excess cations are excreted in the urine, mainly in combination with the anion phosphate. If there is an excess of anions (acid), usually sulfate or phosphate, they
combine with hydrogen ions or other cations and are excreted in the urine.

**MINERALS AS NUTRIENTS**

There are 22 minerals considered necessary for human nutrition. They are mainly obtained from foods or supplements. In general, nutritionists agree that a varied and well-balanced diet provides an adequate intake of minerals for most people and that dietary sources of minerals are preferred to supplement sources. However, several studies indicate that most adults and children do not ingest sufficient dietary calcium and that iron deficiency anemia is common in some populations. In addition, some conditions increase requirements (eg, pregnancy, lactation, various illnesses) and some drug–drug interactions decrease absorption or use of minerals.

Nutritional goals for mineral intake (as for vitamin intake) were established by the Food and Nutrition Board of the National Academy of Sciences as Recommended Dietary Allowances (RDAs). Although the RDAs have been extensively used to guide nutrient intake, it should be noted that they were mainly established to prevent deficiencies and that they were extrapolated from studies of healthy adults. Thus, they may not be appropriate for all age groups such as young children and older adults. Current RDAs, which were established in 1989, are in the process of being revised and replaced by standards called the Dietary Reference Intakes (DRIs; see Chap. 31). Thus far, DRIs have been established for calcium, phosphorus, magnesium, iron, fluoride, and selenium.

The DRIs consist of four subtypes of nutrient recommendations. The estimated average requirement (EAR) is the amount estimated to provide adequate intake in 50% of healthy persons in a specific group; the RDA is the average amount estimated to meet the needs of approximately 98% of healthy children and adults in a specific age and gender group; adequate intake (AI) is the amount thought to be sufficient when there is not enough scientific information to estimate an average requirement; the tolerable upper intake level (UL) is the maximum daily intake considered unlikely to pose a health risk in healthy persons of a specified group. The UL should not be exceeded. With minerals for adults, ULs have been established for calcium (2.5 g), phosphorus (3 to 4 g), magnesium (350 mg), fluoride (10 mg), and selenium (400 mcg). Except for magnesium, which is set for supplements only and excludes food and water sources, the stated amounts include those from both foods and supplements.

The current DRIs were established in 1997, 1998, and 2000; additional ones are expected to be established. Once established, DRIs will be periodically reviewed and updated by the Food and Nutrition Board of the Institute of Medicine and the National Academy of Science.

**Macronutrients**

Some minerals (calcium, phosphorus, sodium, potassium, magnesium, chlorine, sulfur) are required in relatively large amounts (>100 mg) and thus are sometimes called *macronutrients*. Calcium and phosphorus are discussed in Chapter 26. Sulfur is a component of cellular protein molecules, several amino acids, B vitamins, insulin, and other essential body substances. No RDA has been established; the dietary source is protein foods. The other macronutrients are described here in terms of characteristics; functions; DRIs, RDAs, or AIs; and food sources (Table 32–1). Imbalances of macronutrients are classified as deficiency states and excess states. Sodium imbalances (hyponatremia and hypernatremia) are described in Table 32–2, potassium imbalances (hypokalemia and hyperkalemia) in Table 32–3, magnesium imbalances (hypomagnesemia and hypermagnesemia) in Table 32–4, and chloride imbalances (hypochloremic metabolic alkalosis and hyperchloremic metabolic acidosis) in Table 32–5. Each imbalance is described in terms of causes, pathophysiology, and clinical signs and symptoms.

**Micronutrients**

The other 15 minerals are required in small amounts (<100 mg) and are often called *micronutrients* or *trace elements*. Eight trace elements (chromium, cobalt, copper, fluoride, iodine, iron, selenium, and zinc) have relatively well-defined roles in human nutrition (Table 32–6). Because of their clinical importance, iron imbalances are discussed separately in Table 32–7. Other trace elements (manganese, molybdenum, nickel, silicon, tin, and vanadium) are present in many body tissues. Some are components of enzymes and may be necessary for normal growth, structure, and function of connective tissue. For most of these, requirements are unknown, and states of deficiency or excess have not been identified in humans.

**INDIVIDUAL AGENTS USED IN MINERAL–ELECTROLYTE IMBALANCES**

Several pharmacologic agents are used to prevent or treat mineral–electrolyte imbalances. Usually, neutral salts of minerals (eg, potassium chloride) are used in deficiency states, and nonmineral drug preparations are used in excess states. Selected individual drugs are described in the follow sections; routes and dosage ranges are listed in Drugs at a Glance: Individual Agents Used in Mineral–Electrolyte and Acid–Base Imbalances.

**Alkalinizing Agent**

Sodium bicarbonate has long been used to treat metabolic acidosis, which occurs with severe renal disease, diabetes mellitus, circulatory impairment due to hypotension, shock or fluid volume deficit, and cardiac arrest. The drug dissociates into sodium and bicarbonate ions; the bicarbonate ions combine with free hydrogen ions to form carbonic acid. This
### TABLE 32–1  Minerals and Electrolytes

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Functions</th>
<th>Recommended Daily Intake (RDAs or DRIs)</th>
<th>Food Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sodium</strong></td>
<td>Assists in regulating osmotic pressure, water balance, conduction of electrical impulses in nerves and muscles, electrolyte and acid–base balance</td>
<td>Approximately 2 g (estimated)</td>
<td>Present in most foods. Proteins contain relatively large amounts, vegetables and cereals contain moderate to small amounts, fruits contain little or no sodium. Major source in the diet is table salt added to food in cooking, processing, or seasoning. One teaspoon contains 2.3 g of sodium. Water in some areas may contain significant amounts of sodium.</td>
</tr>
<tr>
<td>Major cation in extracellular body fluids (blood, lymph, tissue fluid)</td>
<td>Influences permeability of cell membranes and assists in movement of substances across cell membranes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Small amount in intracellular fluid</td>
<td>Participates in many intracellular chemical reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Large amounts in saliva, gastric secretions, bile, pancreatic and intestinal secretions</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **Potassium** | Within cells, helps to maintain osmotic pressure, fluid and electrolyte balance, and acid–base balance | Approximately 40 mEq | Present in most foods, including meat, whole-grain breads or cereals, bananas, citrus fruits, tomatoes, and broccoli |
| Major cation in intracellular body fluids | In extracellular fluid, functions with sodium and calcium to regulate neuromuscular excitability. Potassium is required for conduction of nerve impulses and contraction of skeletal and smooth muscle. It is especially important in activity of the myocardium. Participates in carbohydrate and protein metabolism. Helps transport glucose into cells and is required for glycogen formation and storage. Required for synthesis of muscle proteins | | |
| Present in all body fluids | | | |
| Eliminated primarily in urine. Normally functioning kidneys excrete excessive amounts of potassium, but they cannot conserve potassium when intake is low or absent. The kidneys excrete 10 mEq or more daily in the absence of intake. Potassium excretion is influenced by acid–base balance and aldosterone secretion. A small amount is normally lost in feces and sweat. | | |

| **Magnesium** | Required for conduction of nerve impulses and contraction of muscle | Adults (DRIs): Males 19–30 y, 400 mg; 31–70 y, 320 mg; females 19–30 y, 310 mg; 31–70 y, 320 mg; pregnancy, 350–360 mg; lactation, 310–320 mg | Present in many foods; diet adequate in other respects contains adequate magnesium. Good food sources include nuts, cereal grains, dark green vegetables, and seafoods. |
| A cation occurring primarily in intracellular fluid | Especially important in functions of cardiac and skeletal muscles Serves as a component of many enzymes Essential for metabolism of carbohydrate and protein | Upper limit (UL) or maximum intake from pharmaceutical preparations, 350 mg (does not include intake from food and water), Infants (Als): 0-6 mo, 30 mg; 7-12 mo, 75 mg Other children (RDAs): 1–3 y, 80 mg; 4–8 y, 130 mg; 9–13 y, 240 mg; 14–18 y, 410 mg | |
| Widely distributed in the body, approximately half in bone tissue and the remainder in soft tissue and body fluids | | | |
| Most dietary magnesium is not absorbed from the gastrointestinal tract and is excreted in feces. | | | |
| | | | |

(continued)
TABLE 32–1  Minerals and Electrolytes (continued)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Functions</th>
<th>Recommended Daily Intake (RDAs or DRIs)</th>
<th>Food Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chloride</strong></td>
<td>Functions with sodium to help maintain osmotic pressure and water balance</td>
<td>80–110 mEq</td>
<td>Most dietary chloride is ingested as sodium chloride (NaCl), and foods high in sodium are also high in chloride.</td>
</tr>
<tr>
<td>Ionized form of element chlorine</td>
<td>Forms hydrochloric acid (HCl) in gastric mucosal cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The main anion of extracellular fluid</td>
<td>Helps regulate electrolyte and acid–base balance by competing with bicarbonate ions for sodium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Almost all chloride is normally excreted by the kidneys.</td>
<td>Participates in a homeostatic buffering mechanism in which chloride shifts in and out of red blood cells in exchange for bicarbonate</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RDAs, recommended dietary allowances; DRIs, dietary reference intakes.

action reduces the number of free hydrogen ions and thereby raises blood pH toward normal (7.35 to 7.45). However, the drug is not usually recommended now unless the acidosis is severe (e.g., pH <7.1), or clinical shock is present. Even then, use must be based on frequent measurements of arterial blood gases and careful titration to avoid inducing alkalosis. Alkalosis makes the myocardium more sensitive to stimuli and increases the occurrence of dysrhythmias. It also alters the oxyhemoglobin dissociation curve so less oxygen is released and hypoxemia becomes even more severe. Thus, drug administration may be more harmful than helpful. In most instances, treating the underlying cause of the acidosis is safer and more effective. For example, in diabetic ketoacidosis, fluid replacement and insulin may be effective. In cardiac arrest, interventions to maintain circulation and ventilation are more effective in alleviating acidosis.

TABLE 32–2  Sodium Imbalances

<table>
<thead>
<tr>
<th>Causes</th>
<th>Pathophysiology</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hyponatremia</strong></td>
<td>1. Decreased serum sodium</td>
<td>1. Serum sodium &lt;135 mEq/L</td>
</tr>
<tr>
<td>1. Inadequate intake. Unusual but may occur with sodium restricted diets and diuretic drug therapy or when water only is ingested after water and sodium are lost (e.g., excessive sweating)</td>
<td>2. Decreased plasma volume and cardiac output</td>
<td>2. Hypotension and tachycardia</td>
</tr>
<tr>
<td>2. Excessive losses with vomiting, GI suction, diarrhea, excessive water enemas, excessive perspiration, burn wounds, and adrenal insufficiency states (e.g., Addison’s disease)</td>
<td>3. Decreased blood flow to kidneys, decreased glomerular filtration rate, and decreased ability of kidneys to excrete water</td>
<td>3. Oliguria and increased BUN</td>
</tr>
<tr>
<td>3. Excessive dilution of body fluids with water</td>
<td>4. Overhydration and swelling of brain cells (cerebral edema), Leads to impaired neurologic and muscular functions.</td>
<td>4. Headache, dizziness, weakness, lethargy, restlessness, confusion, delirium, muscle tremors, convulsions, ataxia, aphasia</td>
</tr>
<tr>
<td><strong>Hypernatremia</strong></td>
<td>1. Increased serum sodium</td>
<td>5. Anorexia, nausea, and vomiting are common; abdominal cramps and paralytic ileus may develop.</td>
</tr>
<tr>
<td>1. Deficiency of water in proportion to the amount of sodium present. Water deficiency results from lack of intake or excessive losses (diarrhea, diuretic drugs, excessive sweating).</td>
<td>2. Hypernatremia due to water deficiency decreases fluid volume in extracellular fluid and intracellular fluid compartments (dehydration).</td>
<td>1. Serum sodium &gt;145 mEq/L</td>
</tr>
<tr>
<td>2. Excessive intake of sodium. An uncommon cause of hypernatremia because the thirst mechanism is normally activated, and water intake is increased.</td>
<td>3. Hypernatremia due to sodium gain increases extracellular fluid volume and decreases intracellular fluid volume as water is pulled out of cells.</td>
<td>2. Lethargy, disorientation, hyperactive reflexes, muscle rigidity, tremors and spasms, irritability, coma, cerebral hemorrhage, subdural hematoma</td>
</tr>
<tr>
<td>3. Sodium retention due to hyperaldosteronism and Cushing’s disease</td>
<td>4. Fever, dry skin, and dry mucous membranes</td>
<td>3. Hypotension</td>
</tr>
<tr>
<td></td>
<td>5. Oliguria, concentrated urine with a high specific gravity, and increased BUN</td>
<td>4. Fever, dry skin, and dry mucous membranes</td>
</tr>
</tbody>
</table>

BUN, blood urea nitrogen; GI, gastrointestinal.
**Hypokalemia**

1. Inadequate intake. Uncommon in clients who can eat; may occur in those unable to eat or receiving only potassium-free intravenous fluids for several days.
2. Excessive losses from the gastrointestinal tract (vomiting, gastric suction, diarrhea, overuse of laxatives and enemas) or urinary tract (polyuria from diuretics, drugs, renal disease, excessive aldosterone)
3. Movement of potassium out of serum and into cells. This occurs with administration of insulin and glucose in treatment of diabetic ketoacidosis and in metabolic alkalosis.

**Hyperkalemia**

2. Impaired excretion due to renal insufficiency, oliguria, potassium-sparing diuretics, aldosterone deficiency, or adrenocortical deficiency
3. Combination of the above factors. Non-food sources of potassium include potassium supplements, salt substitutes, transfusions of old blood, and potassium salts of penicillin (penicillin G potassium contains 1.7 mEq potassium per 1 million units).
4. Movement of potassium from cells into serum with burns, crushing injuries, and acidosis

**Potassium Imbalances**

<table>
<thead>
<tr>
<th>Causes</th>
<th>Pathophysiology</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypokalemia</strong></td>
<td>1. Decreased serum potassium 2. Impaired cardiac conduction 3. Decreased strength of myocardial contraction and decreased cardiac output. Decreased response to catecholamines and other substances that normally raise blood pressure. 4. Neurologic changes due to impaired conduction of nerve impulses 5. Impaired function of skeletal, smooth, and cardiac muscle, most likely with serum potassium &lt;2.5 mEq/L. Electrical impulses are slowed until muscle contraction cannot occur. 6. Slowed gastric emptying and decreased intestinal motility, probably caused by muscle weakness 7. Decreased ability of kidneys to concentrate urine and excrete acid. Decreased glomerular filtration rate with prolonged potassium deficiency. 8. Impaired carbohydrate metabolism and decreased secretion of insulin</td>
<td>1. Serum potassium &lt;3.5 mEq/L 2. Arrhythmias and ECG changes (depressed ST segment; flattened or inverted T wave; increased amplitude of P wave; prolonged P-R interval; prolonged QRS complex with normal shape and size). Premature atrial and ventricular beats or atrioventricular block may occur, usually in people taking digoxin. Death from cardiac arrest may occur. 3. Postural hypotension 4. Confusion, memory impairment, lethargy, apathy, drowsiness, irritability, delirium 5. Muscle weakness and possibly paralysis. Weakness of leg muscles usually occurs first. Then weakness ascends to include respiratory muscles and cause respiratory insufficiency. 6. Abdominal distention, constipation, paralytic ileus 7. Polyuria, polydipsia, nocturia. Prolonged deficiency may increase serum creatinine and blood urea nitrogen 8. Hyperglycemia</td>
</tr>
<tr>
<td><strong>Hyperkalemia</strong></td>
<td>1. Increased serum potassium 2. Impaired conduction of nerve impulses and muscle contraction 3. Impaired cardiac conduction. Hyperkalemia “anesthetizes” nerve and muscle cells so electrical current cannot be built up to a sufficient level (repolarization) for an electrical impulse to be initiated and conducted.</td>
<td>1. Serum potassium &gt;5 mEq/L 2. Muscle weakness, possibly paralysis and respiratory insufficiency 3. Cardiotoxicity, with arrhythmias or cardiac arrest. Cardiac effects are not usually severe until serum levels are 7 mEq/L or above. ECG changes include a high, peaked T wave, prolonged P-R interval, absence of P waves, and prolonged QRS complex.</td>
</tr>
</tbody>
</table>

Sodium bicarbonate also is used to alkalinize the urine. Alkalinization increases solubility of uric acid and sulfonamide drugs and increases excretion of some acidic drugs (eg, salicylates, phenobarbital) when taken in overdose.

Oral sodium bicarbonate is well absorbed; action begins rapidly, peaks in about 30 minutes, and lasts 1 to 3 hours. Intravenous (IV) drug acts and peaks rapidly.

**Cation Exchange Resin**

**Sodium polystyrene sulfonate** (Kayexalate) is a cation exchange resin used for treatment of hyperkalemia. Given orally or rectally, the resin acts in the colon to release sodium and combine with potassium. Potassium is then eliminated from the body in the feces. Each gram of resin removes approximately 1 mEq of potassium. Because the resin requires several hours to lower serum potassium levels, it is more likely to be used after other measures (eg, insulin and glucose infusions) have lowered serum levels. Insulin and glucose lower serum potassium levels by driving potassium into the cells. They do not remove potassium from the body.

**Chelating Agents (Metal Antagonists)**

- **Deferoxamine** (Desferal), a chelating agent for iron, is the only drug available for removing excess iron from
the body. When given orally within a few hours after oral ingestion of iron preparations, deferoxamine combines with the iron in the bowel lumen and prevents its absorption. When given parenterally, it removes iron from storage sites (eg, ferritin, hemosiderin) and combines with the iron to produce a water-soluble compound that can be excreted by the kidneys. The drug can remove 10 to 50 mg of iron per day. The urine becomes reddish brown from the iron content.

The major indication for use of deferoxamine is acute iron intoxication. It is also used in hemochromatosis due to blood transfusions or hemosiderosis due to certain hemolytic anemias. In these chronic conditions characterized by accumulation of iron in tissues, phlebotomy may be more effective in removing iron. Deferoxamine is more likely to be used in clients who are too anemic or hypoproteinemic to tolerate the blood loss.

### Table 32–4: Magnesium Imbalances

<table>
<thead>
<tr>
<th>Causes</th>
<th>Pathophysiology</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypomagnesemia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Inadequate dietary intake or prolonged administration of magnesium-free intravenous fluids</td>
<td>1. Decreased serum magnesium</td>
<td>1. Serum magnesium &lt;1.5 mEq/L</td>
</tr>
<tr>
<td>2. Decreased absorption, as occurs with alcoholism</td>
<td>2. Impaired conduction of nerve impulses and muscle contraction</td>
<td>2. Confusion, restlessness, irritability, vertigo, ataxia, seizures</td>
</tr>
<tr>
<td>3. Excessive losses with diuretic drugs, diarrhea, or diabetic acidosis</td>
<td></td>
<td>3. Muscle tremors, carpopedal spasm, nystagmus, generalized spasticity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4. Tachycardia, hypotension, premature atrial and ventricular beats</td>
</tr>
<tr>
<td><strong>Hypermagnesemia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Renal failure</td>
<td>1. Increased serum magnesium</td>
<td>1. Serum magnesium &gt;2.5 mEq/L</td>
</tr>
<tr>
<td>2. Impaired renal function accompanied by excessive intake of magnesium salts in antacids or cathartics</td>
<td>2. Depressant effects on central nervous and neuromuscular systems, which block transmission of electrical impulses</td>
<td>2. Skeletal muscle weakness and paralysis, cardiac arrhythmias, hypotension, respiratory insufficiency, drowsiness, lethargy, coma</td>
</tr>
<tr>
<td>3. Overtreatment of magnesium deficiency</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 32–5: Chloride Imbalances

<table>
<thead>
<tr>
<th>Causes</th>
<th>Pathophysiology</th>
<th>Signs and Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypochloremic Metabolic Alkalosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Excessive losses of chloride from vomiting, gastric suctioning, diuretic drug therapy, diabetic ketoacidosis, excessive perspiration, or adrenocortical insufficiency</td>
<td>1. Decreased serum chloride</td>
<td>1. Serum chloride &lt;95 mEq/L; arterial blood pH &gt;7.45</td>
</tr>
<tr>
<td>2. Excessive ingestion of bicarbonate or base</td>
<td>2. When chloride is lost, the body retains bicarbonate to maintain electroneutrality in extracellular fluids. The result is metabolic alkalosis, a relative deficiency of acid, and a relative excess of base. Hypokalemia is often present as well.</td>
<td>2. Paresthesias of face and extremities</td>
</tr>
<tr>
<td></td>
<td>3. Hyperexcitability of the nervous system</td>
<td>3. Muscle spasms and tetany, which cannot be distinguished from the tetany produced by hypocalcemia</td>
</tr>
<tr>
<td></td>
<td>4. Retention of carbon dioxide (acid) as a compensatory attempt to restore acid–base balance</td>
<td>4. Slow, shallow respirations</td>
</tr>
<tr>
<td></td>
<td>5. Fluid loss and decreased plasma volume</td>
<td>5. Dehydration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6. Hypotension</td>
</tr>
<tr>
<td><strong>Hyperchloremic Metabolic Acidosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Most often caused by dehydration</td>
<td>1. Increased serum chloride</td>
<td>1. Serum chloride &gt;103 mEq/L; arterial blood pH &lt;7.35</td>
</tr>
<tr>
<td>2. Deficient bicarbonate</td>
<td>2. In dehydration, the kidneys reabsorb water in an attempt to relieve the fluid deficit. Large amounts of chloride are reabsorbed along with the water. The result is metabolic acidosis, a relative excess of acid, and a relative deficiency of base. Central nervous system depression</td>
<td>2. Lethargy, stupor, disorientation, and coma if acidosis is not treated</td>
</tr>
<tr>
<td>3. Hyperparathyroidism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Respiratory alkalosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Excessive administration of sodium chloride or ammonium chloride</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE 32–6  Selected Trace Elements

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Functions</th>
<th>Recommended Dietary Daily Intake (RDAs, DRIs, or AI*)</th>
<th>Food Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chromium</strong></td>
<td>Aids glucose use by increasing effectiveness of insulin and facilitating transport of glucose across cell membranes</td>
<td>Not established</td>
<td>Brewer’s yeast and whole wheat products</td>
</tr>
<tr>
<td>Deficiency produces impaired glucose tolerance (hyperglycemia, glycosuria), impaired growth and reproduction, and decreased life span.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cobalt</strong></td>
<td>A component of vitamin $B_{12}$, which is required for normal function of all body cells and for maturation of red blood cells</td>
<td>Approximately 1 mg in the form of vitamin $B_{12}$</td>
<td>Animal foods, including liver, muscle meats, and shellfish. Fruits, vegetables, and cereals contain no cobalt as vitamin $B_{12}$.</td>
</tr>
<tr>
<td>1. Stored in the liver, spleen, kidneys, and pancreas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Excreted mainly in urine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Deficiency of vitamin $B_{12}$ produces pernicious anemia.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Excess state not established for humans. In animals, excess cobalt produces polycythemia, bone marrow hyperplasia, and increased blood volume.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Copper</strong></td>
<td>1. A component of many enzymes</td>
<td>Not established; estimated at approximately 2 mg</td>
<td>Many foods, including liver, shellfish, nuts, cereals, poultry, dried fruits</td>
</tr>
<tr>
<td>1. Found in the brain, liver, heart, kidneys, bone, and muscle</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Eliminated in urine, sweat, feces, and menstrual flow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Deficiency occurs with lack of food intake, malabsorption syndromes, and prolonged administration of copper-free IV hyperalimentation solutions</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Signs and symptoms of deficiency include decreased serum levels of copper and ceruloplasmin (a plasma protein that transports copper); decreased iron absorption; anemia from impaired erythropoiesis; leukopenia. Death can occur. In infants, three deficiency syndromes have been identified. One is characterized by anemia, a second by chronic malnutrition and diarrhea, and a third (Menke’s syndrome) by retarded growth and progressive mental deterioration.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Copper excess (hypercupremia) may occur in women who take oral contraceptives or who are pregnant and in clients with infections or liver disease. Wilson’s disease is a rare hereditary disorder characterized by accumulation of copper in vital organs (brain, liver, kidneys). Signs and symptoms vary according to affected organs.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Fluoride</strong></td>
<td>1. Present in water, soil, plants, and animals in small amounts. Often added to community supplies of drinking water.</td>
<td>Adults (AIs): males 19–70 y, 4 mg; females 19–70 y, 3 mg; pregnancy and lactation, 5 mg</td>
<td>Beef, canned salmon, eggs. Very little in milk, cereal grains, fruits, and vegetables. Fluoride content of foods depends on fluoride content of soil where they are grown.</td>
</tr>
<tr>
<td>2. Accumulates in the body until approximately 50–60 years of age</td>
<td>Infants (AIs): 0–6 mo, 0.01 mg; 7–12 mo, 0.5 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Fluoride deficiency is indicated by dental caries and possibly a greater incidence of osteoporosis.</td>
<td>Other children (AIs): 1–3 y, 0.7 mg; 4–8 y, 1 mg; 9–13 y, 2 mg; 14–18 y, 3 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fluoride excess results in mottling of teeth and osteosclerosis.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. A component of tooth enamel</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Strengthens bones, probably by promoting calcium retention in bones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Adequate intake before ages 50–60 years may decrease osteoporosis and fractures during later years.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE 32–6 Selected Trace Elements (continued)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Functions</th>
<th>Recommended Dietary Daily Intake (RDAs, DRIs, or Al*)</th>
<th>Food Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Iodine</strong></td>
<td>Essential component of thyroid hormones</td>
<td>Adults (RDAs): males and females, 19–51+, 150 mcg;</td>
<td>Seafood is the best source. In vegetables, iodine content varies with the amount of iodine in soil where grown. In milk and eggs, content depends on the amount present in animal feed.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>pregnancy, 175 mcg; lactation, 200 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 40 mcg; 6–12 mo, 50 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td></td>
</tr>
<tr>
<td>1. Iodine deficiency causes thyroid gland enlargement and may cause hypothyroidism</td>
<td></td>
<td>Adult (RDAs): males 19–51+, 10 mg; females 19–50, 15</td>
<td>Liver and other organ meats, lean meat, shellfish, dried beans and vegetables, egg yolks, dried fruits, molasses, whole grain and enriched breads. Milk and milk products contain essentially no iron.</td>
</tr>
<tr>
<td>2. Iodine excess (iodism) produces edema, fever, conjunctivitis, lymphadenopathy, stomatitis, vomiting, and coryza. Iodism is unlikely with dietary intake but may occur with excessive intake of drugs containing iodine.</td>
<td></td>
<td>mg; 51+, 10 mg; pregnancy, 30 mg; lactation, 15 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 6 mg; 6–12 mo, 10 mg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td></td>
</tr>
<tr>
<td><strong>Iron</strong></td>
<td>Essential component of hemoglobin, myoglobin, and several enzymes</td>
<td>Adult (RDAs): males and females, 19–51+, 150 mcg;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>pregnancy, 175 mcg; lactation, 200 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 40 mcg; 6–12 mo, 50 mcg</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td>1. Nearly 75% of body iron is in hemoglobin in red blood cells; approximately 25% is stored in the liver, bone marrow, and spleen as ferritin and hemosiderin; the remaining small amount is in myoglobin and enzymes or bound to transferrin in plasma.</td>
<td>2. Hemoglobin is required for transport and use of oxygen by body cells; myoglobin aids oxygen transport and use by muscle cells; enzymes are important for cellular metabolism.</td>
<td>Adult (RDAs): males 19–51+, 10 mg; females 19–50, 15 mg; 51+, 10 mg; pregnancy, 30 mg; lactation, 15 mg</td>
<td></td>
</tr>
<tr>
<td>2. Absorption from foods is approximately 10%.</td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 6 mg; 6–12 mo, 10 mg</td>
<td></td>
</tr>
<tr>
<td>A. Factors that increase absorption:</td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td>(1) Presence of dietary ascorbic acid</td>
<td></td>
<td>males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td></td>
</tr>
<tr>
<td>(2) Acidity of gastric fluids increases solubility of dietary iron.</td>
<td></td>
<td>Adult (RDAs): males and females, 19–51+, 150 mcg;</td>
<td></td>
</tr>
<tr>
<td>(3) Presence of calcium. Calcium combines with phosphate, oxalate, and phylate. If this reaction does not occur, iron combines with these substances and produces non-absorbable compounds.</td>
<td></td>
<td>pregnancy, 175 mcg; lactation, 200 mcg</td>
<td></td>
</tr>
<tr>
<td>(4) Physiologic states that increase iron absorption include periods of increased blood formation, such as pregnancy and growth. Also, more iron is absorbed when iron deficiency is present.</td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 40 mcg; 6–12 mo, 50 mcg</td>
<td></td>
</tr>
<tr>
<td>B. Factors that decrease absorption:</td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td>(1) Lack of hydrochloric acid in the stomach or administra-</td>
<td></td>
<td>males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td></td>
</tr>
<tr>
<td>tion of antacids, which produces an alkaline environment</td>
<td></td>
<td>Adult (RDAs): males and females, 19–51+, 150 mcg;</td>
<td></td>
</tr>
<tr>
<td>(2) Combination of iron with phosphates, oxalates, or phytates in the intestine. This results in non-absorbable compounds.</td>
<td></td>
<td>pregnancy, 175 mcg; lactation, 200 mcg</td>
<td></td>
</tr>
<tr>
<td>(3) Increased motility of the intestines, which decreases absorption of iron by decreasing contact time with the mucosa</td>
<td></td>
<td><strong>Infants:</strong> 0–6 mo, 6 mg; 6–12 mo, 10 mg</td>
<td></td>
</tr>
<tr>
<td>(4) Steatorrhea or any malabsorption disorder</td>
<td></td>
<td><strong>Other Children:</strong> 1–10 y, 10 mg;</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td></td>
</tr>
</tbody>
</table>
CHAPTER 32 MINERALS AND ELECTROLYTES

Penicillamine (Cuprimine) chelates copper, zinc, mercury, and lead to form soluble complexes that are excreted in the urine. The main therapeutic use is to remove excess copper in clients with Wilson’s disease (see Table 32–6). It also can be used prophylactically, before clinical manifestations occur, in clients in whom this hereditary condition is likely to develop. Penicillamine may be used to treat cystinuria, a hereditary metabolic disorder characterized by large amounts of cystine in the urine and renal calculi. It may be used in lead poisoning and in severe rheumatoid arthritis that does not respond to conventional treatment measures.

Succimer (Chemet) chelates lead to form water-soluble complexes that are excreted in the urine. It is used to treat lead poisoning in children with blood levels above 45 mcg/100 mL. After oral administration, peak blood levels are reached in 1 to 2 hours. The drug is metabolized in the liver and excreted in urine and feces, with a half-life of 2 days. The most common adverse effects are anorexia, nausea, vomiting, and diarrhea.

Iron Preparations

Iron preparations are used to prevent or treat iron deficiency anemia. For prevention, they are often given during periods of increased requirements (eg, childhood, pregnancy). Oral ferrous salts (sulfate, gluconate, fumarate) are preferred, because they are well absorbed. Action starts in about 4 days, peaks in 7 to 10 days, and lasts 2 to 4 months. The drugs are not metabolized; a portion of a dose is lost daily in feces. Otherwise, the iron content is recycled and its half-life is unknown. Sustained-release or enteric-coated formulations are not as well absorbed as other preparations. Available ferrous salts differ in the amount of elemental iron they contain.

Adverse effects include nausea and other gastrointestinal (GI) symptoms from GI irritation. Oral preparations also discolor feces, producing a black-green color that may be mistaken for blood in the stool. Iron preparations are contraindicated in clients with peptic ulcer disease, inflammatory intestinal disorders, anemias other than iron deficiency anemia.

### Table 32–6 Selected Trace Elements (continued)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Functions</th>
<th>Recommended Dietary Daily Intake (RDAs, DRIs, or AI*)</th>
<th>Food Sources</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selenium</td>
<td>Important for function of myocardium and probably other muscles</td>
<td>Adults (RDAs): males and females, 19–&gt;70 y, 55 mcg; pregnancy 60 mcg; lactation 70 mcg Infants (AIs): 0-6 mo, 15 mcg; 7-12 mo, 20 mcg Other children (RDAs): 1–3 y, 20 mcg; 4–8 y, 30 mcg; 9–13 y, 40 mcg; 14–18 y, 55 mcg</td>
<td>Fish, meat, breads, and cereals</td>
</tr>
<tr>
<td>Zinc</td>
<td>1. A component of many enzymes that are essential for normal metabolism (eg, carbonic anhydrase, lactic dehydrogenase, alkaline phosphatase). 2. Necessary for normal cell growth, synthesis of nucleic acids (RNA and DNA), and synthesis of carbohydrates and proteins 3. May be essential for use of vitamin A</td>
<td>Adults (RDAs): males 19–51+ y, 15 mg; females, 19–51+ y, 12 mg; pregnancy 15 mg; lactation, 16–19 mg Infants: 0–6 mo, 40 mcg; 6–12 mo, 50 mcg Other children: 1–10 y, 10 mg; males, 11–18 y, 12 mg; females 11–18 y, 15 mg</td>
<td>Animal proteins, such as meat, liver, eggs, and seafood. Wheat germ is also a good source.</td>
</tr>
</tbody>
</table>

*RDAs, recommended dietary allowances; DRIs, dietary reference intakes; AIs, adequate intake.
mia, multiple blood transfusions, hemochromatosis, and hemosiderosis.

- **Ferrous sulfate** (Feosol), which contains 20% elemental iron (eg, 65 mg per 325-mg tablet), is the prototype and the usual preparation of choice. **Ferrous gluconate** (Fergon) may be less irritating to GI mucosa and therefore better tolerated than ferrous sulfate. It contains 12% elemental iron (eg, 36 mg per 325-mg tablet). **Ferrous fumarate** (Feostat) contains 33% elemental iron (eg, 33 mg per 100-mg tablet). As with dietary iron, only a portion is absorbed from pharmaceutical preparations, and relatively large doses are needed to supply the 10 to 15 mg needed daily by most adults and children. Small amounts of iron are lost daily (about 0.5 to 1 mg) in urine, sweat, and sloughing of intestinal mucosal cells. Somewhat larger amounts (1 to 2 mg daily) are lost during menstruation. Thus, women of child-bearing potential need larger amounts of iron than children, men, and postmenopausal women. Women who are pregnant have the greatest requirement and usually need an iron supplement. Although most iron products are available over the counter, their use should be discussed with a health care provider because of the toxicity that may occur with iron accumulation in body tissues.

- **Iron dextran injection** (InFeD) is a parenteral form of iron useful in treating iron deficiency anemia when oral supplements are not feasible. One milliliter equals 50 mg of elemental iron. Reasons for using iron dextran injection include peptic ulcer or inflammatory bowel disease that is likely to be aggravated by oral iron preparations, the client’s inability or unwillingness to take oral preparations, and a shortage of time for correcting the iron deficiency (eg, late pregnancy or preoperative status). A major advantage of parenteral iron is that body iron stores can be replenished rapidly.

  Drug action has a slow onset and peaks in 1 to 2 weeks. As with iron from dietary sources or supplements, iron dextran is minimally eliminated from the body. The preparation is contraindicated in people with anemias not associated with iron deficiency and those with hypersensitivity to the drug (fatal anaphylactoid reactions have occurred). Dosage is calculated for individual clients according to severity of anemia (eg, hemoglobin level) and weight (see the manufacturer’s literature). A small IV test dose should be given before a therapeutic dose. The drug is usually given IV but may be given intramuscularly (IM).

**Magnesium Preparations**

Magnesium oxide or hydroxide may be given for mild hypomagnesemia in asymptomatic clients. **Magnesium sulfate** is given parenterally for moderate to severe hypomagnesemia, convulsions associated with pregnancy (eclampsia), and prevention of hypomagnesemia in total parenteral nutrition. Therapeutic effects in these conditions are attributed to the drug’s depressant effects on the central nervous system and smooth, skeletal, and cardiac muscle. Oral magnesium salts may cause diarrhea; their uses as antacids and cathartics are discussed in Chapters 60 and 61, respectively. Magnesium preparations are contraindicated in clients who have impaired renal function or who are comatose. Oral preparations of magnesium oxide or hydroxide act in 3 to 6 hours, are mini-
### Drugs at a Glance: Individual Agents Used in Mineral–Electrolyte and Acid–Base Imbalances

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications for Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkalizing Agent</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>Metabolic acidosis</td>
<td>PO 325 mg to 2 g, up to 4 times daily; maximum daily dose, 16 g for adults &lt;60 y, 8 g for adults &gt;60 y</td>
<td>IV dosage individualized according to arterial blood gases</td>
</tr>
<tr>
<td></td>
<td>Urine alkalinization</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>IV dosage individualized according to arterial blood gases</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cation Exchange Resin</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium polystyrene sulfonate</td>
<td>Treatment of hyperkalemia</td>
<td>PO 15 g in 100–200 mL of water and 70% sorbitol, 1–4 times daily Rectally (retention enema): 30–50 g in 100–200 mL of water and 70% sorbitol q6h</td>
<td></td>
</tr>
<tr>
<td>(Kayexalate)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chelating Agents (Metal Antagonists)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Deferoxamine (Desferal)</td>
<td>Acute iron intoxication</td>
<td>PO 4–8 g, within a few hours of oral ingestion of iron preparations IM 1 g initially, then 500 mg q4h for 2 doses, then 500 mg q4–12h if needed; maximum dose, 6 g/24h IV infusion (for patients in shock) 1 g slowly (not to exceed 15 mg/kg/h), then 500 mg q4h for 2 doses, then 500 mg q4–12h if necessary; maximum dose, 6 g/24h</td>
<td>Same as adults</td>
</tr>
<tr>
<td></td>
<td>Hemochromatosis due to blood transfusions</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemosiderosis due to hemolytic anemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillamine (Cuprimine)</td>
<td>Wilson’s disease</td>
<td>Wilson’s disease, PO 250 mg 4 times daily, increased gradually if necessary, up to 2 g daily</td>
<td>Older children: same as adults Infants &gt;6 mo and young children: Wilson’s disease, PO 250 mg daily, dissolved in fruit juice</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
<td>Rheumatoid arthritis, PO 125–250 mg/d for 4 wk, increased by 125–250 mg/d at 1- to 3-mo intervals, if necessary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cystinuria</td>
<td>Usual maintenance dose, 500–750 mg/d; maximum dose, 1000–1500 mg/d</td>
<td></td>
</tr>
<tr>
<td>Succimer (Chemet)</td>
<td>Lead poisoning</td>
<td></td>
<td>PO 10 mg/kg or 350 mg/m² q8h for 5 days, then q12h for 14 days (total of 19 days of drug administration) For young children who cannot swallow capsules, the capsule contents can be sprinkled on soft food or given with a spoon.</td>
</tr>
<tr>
<td><strong>Iron Preparations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous gluconate (Fergon)</td>
<td>Iron deficiency anemia</td>
<td>PO 320–640 mg (40–80 mg elemental iron) 3 times daily</td>
<td>PO 100–300 mg (12.5–37.5 mg elemental iron) 3 times daily Infants: PO 100 mg or 30 drops of elixir initially, gradually increased to 300 mg or 5 mL of elixir daily (15–37.5 mg elemental iron), in divided doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrous sulfate (Feosol)</td>
<td>Iron deficiency anemia</td>
<td>PO 325 mg–1.2 g (60–240 mg elemental iron) daily in 3 or 4 divided doses</td>
<td>6–12 y: PO 120–600 mg (24–120 mg elemental iron) daily, in divided doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>&lt;6 y: 300 mg (60 mg elemental iron) daily, in divided doses</td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Individual Agents Used in Mineral–Electrolyte and Acid–Base Imbalances (continued)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Iron dextran injection</strong> (InFeD)</td>
<td>Iron deficiency anemia</td>
<td>Dosage is calculated for individual clients according to hemoglobin and weight (see manufacturer’s literature). A small test dose is required before therapeutic doses are given.</td>
</tr>
<tr>
<td><strong>Magnesium Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnesium oxide</td>
<td>Prevent or treat hypomagnesemia</td>
<td>Hypomagnesemia, PO magnesium oxide 250–500 mg 3–4 times daily, milk of magnesia 5 mL 4 times daily, or a magnesium-containing antacid 15 mL 3 times daily; IM (magnesium sulfate) 1–2 g (2–4 mL of 50% solution) 1–2 times daily based on serum magnesium levels</td>
</tr>
<tr>
<td>Magnesium hydroxide</td>
<td>Treat hypertension or convulsions associated with toxemia of pregnancy or acute nephritis in children</td>
<td></td>
</tr>
<tr>
<td>Magnesium sulfate</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Potassium Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium chloride (KCl)</td>
<td>Prevent or treat hypokalemia</td>
<td>PO 15–20 mEq 2–4 times daily IV 40–100 mEq/24 h, depending on serum potassium levels. KCl must be diluted in dextrose or NaCl IV solution for IV use. Maximum for serum K⁺ &gt;2.5 mEq: diluted 40 mEq/L, infused 10 mEq/h to maximum dose of 200 mEq in 24 h Maximum for serum K⁺ &lt;2.5 mEq: diluted 80 mEq/L, infused 40 mEq/h to maximum dose of 400 mEq in 24 h</td>
</tr>
<tr>
<td><strong>Sodium Preparations</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium chloride (NaCl) injection</td>
<td>Hyponatremia</td>
<td>IV 1500–3000 mL of 0.22% or 0.45% solution/24 h depending on the client’s fluid needs; approximately 50 mL/h to keep IV lines open</td>
</tr>
<tr>
<td><strong>Zinc Preparation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zinc sulfate</td>
<td>Prevent or treat zinc deficiency</td>
<td>PO 25–50 mg elemental zinc (eg, zinc sulfate 110–220 mg) daily</td>
</tr>
<tr>
<td><strong>Multiple Mineral–Electrolyte Preparations</strong></td>
<td>Prevent or treat fluid and electrolyte deficiencies</td>
<td>IV 2000–3000 mL/24 h, depending on individual fluid and electrolyte needs</td>
</tr>
</tbody>
</table>
mally absorbed systemically, and are excreted in urine. With magnesiu
m sulfate, oral preparations act in 1 to 2 hours and last 3
to 4 hours; IM injections act in 1 hour and last 3 to 4 hours;
and IV administration produces immediate action that lasts
about 30 minutes. The products are excreted in urine.

Potassium Preparations

Potassium chloride (KCl) is the drug of choice for preventing or treating hypokalemia because potassium and chloride deficiencies often occur together. It may be prescribed for clients who are receiving potassium-losing diuretics (eg, hydrochlorothiazide, furosemide), those who are receiving digoxin (hypokalemia increases risks of digoxin toxicity), and those who are receiving only IV fluids because of surgical procedures, GI disease, or other conditions. KCl also may be used to replace chloride in hypochloremic metabolic alkalosis. It is contraindicated in clients with renal failure and in those receiving potassium-saving diuretics, such as triamterene, spironolactone, or amiloride.

Potassium chloride can be given orally or IV. Oral preparations act slowly and peak in 1 to 2 hours; IV preparations act rapidly. KCl is excreted in urine; half-life is unknown. Oral preparations are recommended when feasible, but one disadvantage of oral liquids is an unpleasant taste. This has led to production of various flavored powders, liquids, and effervescent tablets (eg, Kay Ciel Elixir, K-Lor, Klorvess). Tablets containing a wax matrix (eg, Slow-K) are effective and better tolerated by most clients than liquid formulations. IV preparations of KCl must be diluted before administration to prevent hyperkalemia, cardiotoxicity, and severe pain at the injection site. Dosage must be individualized according to serum potassium levels; the usual range is 20 to 60 mEq per 24 hours.

Sodium Preparations

Sodium chloride (NaCl) injection is available in several concentrations and sizes for IV use. Commonly used concentrations are 0.45% (hypotonic solution) and 0.9% (isotonic). NaCl is also available in combination with dextrose. Five percent dextrose in 0.22% NaCl and 5% dextrose in 0.45% NaCl are often used for IV fluid therapy. They contain 38.5 and 77 mEq/L, respectively, of sodium and chloride. Isotonic or 0.9% sodium chloride contains 154 mEq of both sodium and chloride. This solution may be used to treat hyponatremia.

How Can You Avoid This Medication Error?

Jean Watson, a postoperative patient, has a low serum potassium on her second postoperative day (2.1 mEq/L), and her physician orders an additional 20 mEq of KCl to be added to her IV bag. Currently, she has 1000 cc 5% D/.45% NaCl with 20 mEq KCl hanging with 200 cc left in the bag and infusing at 125 cc/hour. You draw up the 20 mEq of KCl and add it to the current infusion without changing the infusion rate.

Zinc Preparations

Zinc sulfate is available in tablets containing 110 or 220 mg of zinc sulfate (equivalent to 25 and 50 mg of elemental zinc, respectively) and in other preparations and strengths. It is also an ingredient in several vitamin–mineral combination products. Zinc sulfate is given orally as a dietary supplement to prevent or treat zinc deficiency. It has a slow onset of action and a delayed peak. It is metabolized in the liver and excreted in feces; its half-life is unknown.

Multiple Mineral–Electrolyte Preparations

There are numerous commercially prepared electrolyte solutions for IV use. One group provides maintenance amounts of fluids and electrolytes when oral intake of food and fluids is restricted or contraindicated. These solutions differ slightly in the number and amount of particular electrolytes. A second group provides replacement amounts of electrolytes (mainly sodium and chloride) when electrolytes are lost from the body in abnormal amounts. These preparations are available from several different manufacturers; health care agencies use one manufacturer’s products for the most part.

Oral electrolyte solutions (eg, Pedialyte) contain several electrolytes and a small amount of dextrose. They are used to supply maintenance amounts of fluids and electrolytes when oral intake is restricted. They are especially useful in children for treatment of diarrhea and may prevent severe fluid and electrolyte depletion. The amount given must be carefully prescribed and calculated to avoid excessive intake. They should not be used in severe circumstances in which IV fluid and electrolyte therapy is indicated. They must be used cautiously with impaired renal function. They should not be mixed with other electrolyte-containing fluids, such as milk or fruit juices.

Nursing Process

Assessment

Assess each client for current or potential mineral–electrolyte or acid–base disorders. Specific assessment factors include the following:

• Deficiency states are probably more common than excess states unless a mineral–electrolyte supplement is being taken. However, deficiencies and excesses may be equally harmful, and both must be assessed.

• Clients with other nutritional deficiencies are likely to have mineral–electrolyte deficiencies as well. Moreover, deficiencies are likely to be multiple, with overlapping signs and symptoms.

• Many drugs influence gains and losses of minerals and electrolytes, including diuretics and laxatives.
• Minerals and electrolytes are lost with gastric suction, polyuria, diarrhea, excessive perspiration, and other conditions.
• Assess laboratory reports when available.
  • Check the complete blood count for decreased red blood cells, hemoglobin, and hematocrit. Reduced values may indicate iron deficiency anemia, and further assessment is needed.
  • Check serum electrolyte reports for increases or decreases. All major minerals can be measured in clinical laboratories. The ones usually measured are sodium, chloride, and potassium; carbon dioxide content, a measure of bicarbonate, is also assessed. Normal values vary to some extent with the laboratory and the method of measurement, but a general range of normal values is sodium, 135 to 145 mEq/L; chloride, 95 to 105 mEq/L; potassium, 3.5 to 5 mEq/L; and carbon dioxide, 22 to 26 mEq/L.

Nursing Diagnoses
• Imbalanced Nutrition: Less Than Body Requirements related to mineral–electrolyte deficiency
• Imbalanced Nutrition: More Than Body Requirements related to excessive intake of pharmaceutical preparations
• Risk for Injury related to mineral–electrolyte deficiency or overdose
• Deficient Knowledge: Dietary sources and importance of mineral–electrolyte nutrients in normal body functioning

Planning/Goals
The client will:
• Have an adequate dietary intake of minerals and electrolytes
• Avoid mineral–electrolyte supplements unless recommended by a health care provider
• Participate in follow-up procedures and laboratory tests as requested when mineral–electrolyte drugs are prescribed
• Take mineral–electrolyte drugs as prescribed
• Avoid adverse effects of drug preparations

Interventions
Implement measures to prevent mineral–electrolyte disorders:
• Promote a varied diet. A diet adequate in protein and calories usually provides adequate minerals and electrolytes. An exception is iron, which is often needed as a dietary supplement in women and children.
• If assessment data reveal potential development of a disorder, start preventive measures as soon as possible. For clients able to eat, foods high in iron may delay onset of iron deficiency anemia, foods high in potassium may prevent hypokalemia with diuretic therapy, and salty foods along with water help to prevent problems associated with excessive heat and perspiration. For people unable to eat, IV fluids and electrolytes are usually given. In general, oral food intake or tube feeding is preferable to IV therapy.
• Treat underlying disorders that contribute to the mineral–electrolyte deficiency or excess. Measures to relieve anorexia, nausea, vomiting, diarrhea, pain, and other symptoms help to increase intake or decrease output of certain minerals. Measures to increase urine output, such as forcing fluids, help to increase output of some minerals in the urine and therefore prevent excess states from developing.
• Mineral supplements are in general, recommended only for current or potential deficiencies because all are toxic in excessive amounts. When deficiencies are identified, treat with foods when possible. Next, use oral mineral supplements. Use parenteral supplements only for clear-cut indications because they are potentially the most hazardous.
• For clients who have nasogastric tubes to suction, irrigate the tubes with isotonic sodium chloride solution. The use of tap water is contraindicated because it is hypotonic and would pull electrolytes into the stomach. Electrolytes are then lost in the aspirated and discarded stomach contents. For the same reason, only small amounts of ice chips or water are allowed per hour. Clients often request ice chips or water frequently and in larger amounts than desirable; the nurse must explain the reason for the restrictions.
• Assist clients to keep appointments for periodic blood tests and other follow-up procedures when mineral–electrolyte supplements are prescribed.

Evaluation
• Interview about and observe the amount and type of food intake in relation to required minerals and electrolytes.
• Interview and observe for signs of mineral–electrolyte deficiency or excess.

Herbal and Dietary Supplements
Many people take mineral preparations as dietary supplements, usually in a multivitamin-mineral combination. Nutritionists usually recommend dietary intake of nutrients rather than pharmaceutical supplements. In addition, some studies indicate that the people most likely to take dietary supplements are those who have an adequate diet. In deciding whether to take mineral supplements or advise clients to take them, health care providers should consider the following factors:
• Supplements do not compensate for an inadequate diet.
• In general, recommended daily doses should not be exceeded because all minerals are toxic at high doses.
• Multivitamin-mineral combinations recommended for age and gender groups contain different amounts of some minerals (eg, postmenopausal women need less iron than younger women). This should be considered in choosing a product.
• Iron supplements other than those in multivitamin-mineral combinations are usually intended for temporary use in the presence of deficiency or a period of increased need (eg, pregnancy). They should not be taken otherwise because of the risk of accumulation and toxicity.
CHAPTER 32 MINERALS AND ELECTROLYTES

Most adolescent and adult females probably benefit from a calcium supplement to achieve the recommended amount (1000 to 1300 mg daily). The amounts consumed in dairy products and other foods should be considered and the UL of 2500 mg daily should not be exceeded.

Although selenium is being promoted as an antioxidant that decreases cardiovascular disease and cancer, there is limited evidence of such benefits and extra selenium intake is not currently recommended for anyone.

Although zinc is being promoted for treatment of the common cold and to promote wound healing, there is insufficient evidence to support such uses. With colds, zinc reportedly helps some people and does not help others. With wounds, zinc is reportedly beneficial only if the client has a zinc deficiency. More studies are needed before supplemental zinc can be recommended for general use.

PRINCIPLES OF THERAPY

Prevention of an Excess State

When a mineral is given to correct a deficiency state, there is a risk of producing an excess state. Because both deficiency and excess states may be harmful, the amount of mineral supplement should be titrated closely to the amount needed by the body. Larger doses are needed to treat deficiency states than are needed to prevent deficiencies from developing. In addition to producing potential toxicity, large doses of one mineral may cause a relative deficiency of another mineral or nutrient.

Drug Selection

Oral drug preparations are preferred, when feasible, for preventing or treating mineral disorders. They are safer, less likely to produce toxicity, more convenient to administer, and less expensive than parenteral preparations.

Management of Sodium Disorders

Hyponatremia

Treatment of hyponatremia is aimed at restoring normal levels of serum sodium. This can be done with isotonic NaCl solution when hyponatremia is caused by sodium depletion and with restriction of water when hyponatremia is caused by fluid volume excess (water intoxication).
**Hypokalemia**

Treatment of hypokalemia requires administration of sodium-free fluids, either orally or IV, until serum sodium levels return to normal. Milder states usually respond to increased water intake through the GI tract; more severe hypokalemia requires IV administration of 5% dextrose in water.

**Management of Potassium Disorders**

**Hypokalemia**

1. Assess for conditions contributing to hypokalemia, and attempt to eliminate them or reduce their impact. Such conditions are usually inadequate intake, excessive loss, or some combination of the two.
2. Assess the severity of the hypokalemia. This is best done on the basis of serum potassium levels and clinical manifestations. Serum potassium levels alone are inadequate because they may not accurately reflect depletion of body potassium.
3. Potassium supplements are indicated in the following circumstances:
   a. When serum potassium level is below 3 mEq/L on repeated measurements, even if the client is asymptomatic
   b. When serum potassium is 3 to 3.5 mEq/L and clear-cut symptoms or electrocardiographic (ECG) changes indicate hypokalemia. Some clinicians advocate treatment in the absence of symptoms.
   c. In clients receiving digoxin, if necessary to maintain serum potassium levels above 3.5 mEq/L. This is indicated because hypokalemia increases digoxin toxicity.
4. When potassium supplements are necessary, oral administration is preferred when possible.
5. Potassium chloride is the drug of choice in most instances. Liquids, powders, and effervescent tablets for oral use must be diluted in at least 4 oz of water or juice to improve taste and decrease gastric irritation. Controlled-release tablets or capsules with KCl in a wax matrix or microencapsulated form are preferred by most clients.
6. Intravenous KCl is indicated when a client cannot take an oral preparation or has severe hypokalemia. The serum potassium level should be measured, total body deficit estimated, and adequate urine output established before IV potassium therapy begins.
   a. Intravenous KCl must be well diluted to prevent sudden hyperkalemia, cardiotoxic effects, and phlebitis at the venipuncture site. The usual dilution is KCl 20 to 60 mEq/1000 mL of IV fluid for maintenance and 10 mEq/50 mL or 20 mEq/100 mL for replacement.
   b. Dosage must be individualized. Clients receiving only IV fluids are usually given 40 to 60 mEq of KCl daily. This can be given safely with 20 mEq KCl/L of fluids and a flow rate of 100 to 125 mL/hour. In severe deficits, a higher concentration and a higher flow rate may be necessary. In these situations, an infusion pump to control flow rate accurately and continuous cardiac monitoring for detection of hyperkalemia are necessary. Also, serum potassium levels must be checked frequently and dosage adjusted if indicated. For serum potassium levels above 2.5 mEq/L, no more than 200 mEq of KCl should be given within 24 hours.
   c. Do not administer potassium-containing IV solutions into a central venous catheter. There is a risk of hyperkalemia and cardiac arrhythmias or arrest because there is limited time for the solution to be diluted in the blood returning to the heart.
   d. In critical situations, KCl usually should be given in sodium chloride solutions rather than dextrose solutions. Administering dextrose solutions may increase hypokalemia by causing some potassium to leave the serum and enter cells.

**Hyperkalemia**

1. Eliminate any exogenous sources of potassium, such as potassium supplements, penicillin G potassium, salt substitutes, and blood transfusion with old blood.
2. Treat acidosis, if present, because potassium leaves cells and enters the serum with acidosis.
3. Use measures that antagonize the effects of potassium, that cause potassium to leave the serum and reenter cells, and that remove potassium from the body. Appropriate measures are determined mainly by serum potassium levels and ECG changes. Continuous cardiac monitoring is required.
   - Severe hyperkalemia (serum potassium above 7 mEq/L and ECG changes indicating hyperkalemia) requires urgent treatment. Immediate IV administration of sodium bicarbonate 45 mEq, over a 5-minute period, causes rapid movement of potassium into cells. This can be repeated in a few minutes if ECG changes persist.
   - Calcium gluconate 10%, 5 to 10 mL IV, is also given early in treatment to decrease the cardiotoxic effects of hyperkalemia. It is contraindicated if the client is receiving digoxin, and it cannot be added to fluids containing sodium bicarbonate because insoluble precipitates are formed.
   - The next step is IV infusion of glucose and insulin. This also causes potassium to move into cells, although not as quickly as sodium bicarbonate.
4. When hyperkalemia is less severe or when it has been reduced by the aforementioned measures, sodium polystyrene sulfonate, a cation exchange resin, can be given orally or rectally to remove potassium from the body. Each gram of the resin combines with 1 mEq potassium, and both are excreted in feces. The resin is usually mixed with water and sorbitol, a poorly absorbed,
osmotically active alcohol that has a laxative effect. The sorbitol offsets the constipating effect of the resin and aids in its expulsion. Oral administration is preferred, and several doses daily may be given until serum potassium is normal. When given as an enema, the solution must be retained from 1 to several hours, or repeated enemas must be given for therapeutic effect.

5. If the preceding measures fail to reduce hyperkalemia, peritoneal dialysis or hemodialysis may be used.

Management of Magnesium Disorders

Hypomagnesemia

1. Prevent hypomagnesemia, when possible, by giving parenteral fluids with magnesium when the fluids are the only source of nutrients. Multiple-electrolyte IV solutions contain magnesium chloride or acetate, and magnesium can be added to solutions for total parenteral nutrition.

2. For mild, asymptomatic hypomagnesemia, oral magnesium preparations may be given. For moderate to severe and symptomatic hypomagnesemia, parenteral (IV or IM) magnesium sulfate may be given daily as long as hypomagnesemia persists or continuing losses occur. Initial dosage may be larger, but the usual maintenance dose is approximately 8 mEq daily. A 10% solution is available in 10-mL vials that contain 8 mEq of magnesium sulfate for adding to IV solutions. A 50% solution is available in 2-mL vials (8 mEq) for IM administration.

3. Check serum magnesium levels daily.

Hypermagnesemia

1. Stop any source of exogenous magnesium, such as magnesium sulfate or magnesium-containing antacids, cathartics, or enemas.

2. Have calcium gluconate available for IV administration. It is an antidote for the sedative effects of magnesium excess.

3. Increase urine output by increasing fluid intake, if feasible. This increases removal of magnesium from the body in urine.

4. Clients with chronic renal failure are the most likely to become hypermagnesemic. They may require peritoneal dialysis or hemodialysis to lower serum magnesium levels.

Nursing Notes: Apply Your Knowledge

After surgery, George Lee will be taking ferrous sulfate, 325 mg tid with meals. The pharmacy supplies him with 325-mg tablets. Review important points to focus in your teaching plan before discharge.

Management of Iron Deficiency and Excess

Iron Deficiency Anemia

1. Anemia is a symptom, not a disease. Therefore, the underlying cause must be identified and eliminated, if possible.

2. Assess the client’s intake of and attitude toward foods with high iron content. Encourage increased dietary intake of these foods.

3. Use oral iron preparations when possible. They are safe, effective, convenient to administer, and relatively inexpensive. Ferrous sulfate is usually the drug of choice for oral iron therapy. Slow-release or enteric-coated products decrease absorption of iron but may cause less gastric irritation.

4. Dosage is calculated in terms of elemental iron. Iron preparations vary greatly in the amount of elemental iron they contain. Ferrous sulfate, for example, contains 20% iron; thus, each 325-mg tablet furnishes about 65 mg of elemental iron. With the usual regimen of 1 tablet 3 times daily, a daily dose of 195 mg of elemental iron is given. For most clients, probably half that amount would correct the deficiency. However, tablets are not manufactured in sizes to allow this regimen, and liquid preparations are not popular with clients. Thus, relatively large doses may be just as effective, especially if GI symptoms become a problem with higher dosages. Whatever the dose, only about 10% to 15% of the iron is absorbed. Most of the remainder is excreted in feces, which turn dark green or black.

5. Oral iron preparations are better absorbed if taken on an empty stomach. However, because gastric irritation is a common adverse reaction, they are more often given with or immediately after meals.

6. Although normal hemoglobin levels return after approximately 2 months of oral iron therapy, an additional 6-month period of drug therapy is recommended to replenish the body’s iron stores.

7. Reasons for failure to respond to iron therapy include continued blood loss, failure to take the drug as prescribed, or defective iron absorption. These factors must be reevaluated if no therapeutic response is evident within 3 to 4 weeks after drug therapy is begun.

8. Parenteral iron is indicated when oral preparations may further irritate a diseased GI tract, when the client is unable or unwilling to take the oral drugs, or when the anemia must be corrected rapidly.

9. For severe iron deficiency anemia, blood transfusions may be most effective.

Iron Excess

1. Acute iron overdosage requires treatment as soon as possible, even if overdosage is only suspected and the amount taken is unknown. It is unnecessary to wait until the serum iron level is measured.
If treatment is begun shortly after oral ingestion of iron, induced vomiting or aspiration of stomach contents by nasogastric tube is helpful. This can be followed by lavage with 1% sodium bicarbonate solution to form insoluble iron carbonate compounds. The next step is to instill in the stomach 5 to 8 g of deferoxamine (Desferal) dissolved in 50 mL of distilled water to bind the iron remaining in the GI tract and prevent its absorption. Finally, deferoxamine is given IM or IV to bind with iron in tissues and allow its excretion in the urine. Throughout the treatment period, supportive measures may be needed for GI hemorrhage, acidosis, and shock.

2. For chronic iron overload or hemochromatosis, the first step in treatment is to stop the source of iron, if possible. Phlebotomy is the treatment of choice for most clients because withdrawal of 500 mL of blood removes about 250 mg of iron. Phlebotomy may be needed as often as weekly and for as long as 2 to 3 years. For clients resistant to or intolerant of phlebotomy, deferoxamine can be given. Ten to 50 mg of iron are excreted daily in the urine with deferoxamine administration.

**Management of Acid–Base Disorders**

**Metabolic Acidosis**

1. Assess the presence and severity of acidosis by measuring arterial blood gases. Results reflecting acidosis are decreased pH (<7.35) and decreased bicarbonate (<22 mEq/L).
2. Assess and treat the underlying condition, such as diabetic ketoacidosis.
3. If this does not relieve acidosis or if acidosis is severe (arterial blood pH < 7.2), sodium bicarbonate may be given parenterally to alkalinize the blood. It can be given by direct injection into a vein or as a continuous IV infusion. Ampules and prefilled syringes are available in 8.4% solution (50 mL contains 50 mEq) or 7.5% solution (50 mL contains 44.6 mEq). IV solutions of 5% and 1.4% sodium bicarbonate are also available in 500-mL bottles.
4. Monitor arterial blood gases and serum potassium levels frequently. Overtreatment of acidosis with sodium bicarbonate produces alkalosis. Serum potassium levels may change from high to normal levels initially (because acidosis causes potassium to be drawn into the bloodstream) to severely low levels as potassium reenters cells with treatment of acidosis. Thus, potassium replacement is likely to be needed during treatment of acidosis.
5. During severe acidosis, effective ventilation measures are needed, along with sodium bicarbonate to remove carbon dioxide from the blood.
6. In lactic acidosis, larger doses of sodium bicarbonate may be required than in other types of acidosis. This is because of continued production of large amounts of lactic acid by body metabolism.
7. Chronic metabolic acidosis may occur with chronic renal failure. Sodium bicarbonate or citrate (which is converted to bicarbonate in the body) can be given orally in a dose sufficient to maintain a normal serum bicarbonate level.

**Metabolic Alkalosis**

1. Assess the presence and severity of the alkalosis by measuring arterial blood gases. Values indicating alkalosis are increased pH (>7.45) and increased bicarbonate (>26 mEq/L).
2. Assess and treat the underlying condition. Often, volume depletion and hypochloremia are present and can be corrected with isotonic 0.9% NaCl solution. If hypokalemia and hypochloremia are present, KCl will likely replace both deficits.

**Effects of Minerals on Other Drugs**

Iron salts may decrease absorption of levodopa, levothyroxine, methyldopa, penicillamine, fluoroquinolones, and tetracyclines.

Magnesium salts may decrease absorption and therapeutic effects of digoxin, fluoroquinolones, nitrofurantoin, penicillamine, and tetracyclines. Zinc salts may decrease absorption of fluoroquinolones and most tetracyclines (doxycycline is apparently not affected).

**Use in Children**

Children need sufficient amounts of minerals and electrolytes to support growth and normal body functioning. In the healthy child, a varied, well-balanced diet is usually preferred over supplements. However, iron deficiency is common in young children and teenage girls, and an iron supplement is often needed. Guidelines include the following:

1. In children who eat poorly, a combined vitamin/mineral supplement every other day may be reasonable. In areas where water is not fluorinated, a combined vitamin/mineral supplement containing fluoride may be indicated for infants and children. Fluoride must be prescribed by a physician, dentist, or nurse practitioner.
   Children must be guarded against excessive fluoride ingestion and possible toxicity. Fluoride supplements are used more often than formerly and numerous preparations are available for oral (tablets, chewable tablets, solutions) or topical (liquid rinse solutions or gels) uses. Supplements used by children or adults should be kept out of the reach of children; supplements prescribed for children should be used only with adult supervision; and children using topical preparations should be reminded to spit them out and not to swallow them.
2. If supplements are given, dosages should be discussed with a health care provider and usually should not ex-
ceed recommended amounts for particular age groups. All minerals and electrolytes are toxic in overdose and may cause life-threatening adverse effects. All such drugs should be kept out of reach of young children and should never be referred to as “candy.”

3. If KCl and other electrolyte preparations are used to treat deficiency states in children, serum electrolyte levels must be monitored. In addition, doses must be carefully measured and given no more often than prescribed to avoid toxicity.

4. Accidental ingestion of iron-containing medications and dietary supplements is a common cause of poisoning death in children younger than 6 years of age. To help combat accidental poisoning, products containing iron must be labeled with a warning and products with 30 mg or more of iron (eg, prenatal products) must be packaged as individual doses. All iron-containing preparations should be stored in places that are inaccessible to young children.

5. Tolerable ULs for children have been established for some minerals and these maximum daily amounts should not be exceeded. They are listed in the following table. The ULs for magnesium indicate maximum intake from pharmaceutical preparations; they do not include intake from food and water.

<table>
<thead>
<tr>
<th>Mineral</th>
<th>Birth–6 months</th>
<th>7–12 months</th>
<th>1–3 years</th>
<th>4–8 years</th>
<th>9–13 years</th>
<th>14–18 years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Calcium</td>
<td>No data</td>
<td>No data</td>
<td>2.5 g</td>
<td>2.5 g</td>
<td>2.5 g</td>
<td>2.5 g</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>No data</td>
<td>No data</td>
<td>3 g</td>
<td>3 g</td>
<td>4 g</td>
<td>4 g</td>
</tr>
<tr>
<td>Fluoride</td>
<td>0.7 mg</td>
<td>0.9 mg</td>
<td>1.3 mg</td>
<td>2.2 mg</td>
<td>10 mg</td>
<td>10 mg</td>
</tr>
<tr>
<td>Magnesium</td>
<td>No data</td>
<td>No data</td>
<td>65 mg</td>
<td>110 mg</td>
<td>350 mg</td>
<td>350 mg</td>
</tr>
<tr>
<td>Selenium</td>
<td>45 mcg</td>
<td>60 mcg</td>
<td>90 mcg</td>
<td>150 mcg</td>
<td>280 mcg</td>
<td>400 mcg</td>
</tr>
</tbody>
</table>

Use in Older Adults

Mineral–electrolyte requirements are the same as for younger adults, but deficiencies of calcium and iron are common in older adults. Numerous factors may contribute to deficiencies, including limited income, anorexia, lack of teeth or ill-fitting dentures, drugs that decrease absorption of dietary nutrients, and disease processes that interfere with the ability to obtain, prepare, or eat adequate amounts of a variety of foods. Diuretic drugs, frequently prescribed for cardiovascular disorders in older adults, may cause potassium deficiency unless serum levels are carefully monitored and preventive measures taken.

Excess states also may occur in older adults. For example, decreased renal function promotes retention of magnesium and potassium. Hyperkalemia also may occur with the use of potassium supplements or salt substitutes. All minerals and electrolytes are toxic in overdose. Tolerable ULs for older adults (>65 years) have been established for calcium (2.5 g), phosphorus (3 to 4 g), fluoride (10 mg), magnesium (350 mg), and selenium (400 mcg), and these maximum daily amounts should not be exceeded.

Every older adult should be assessed carefully regarding nutritional status and use of drugs that interact with dietary nutrients. Serum levels of minerals and electrolytes should be monitored carefully during illness, and measures taken to prevent either deficiency or excess states.

Use in Renal Impairment

Several mineral–electrolyte products are contraindicated in clients with renal impairment, including magnesium and potassium chloride (severe impairment with oliguria or azotemia), because of potential accumulation and toxicity. Frequent measurements of serum electrolyte levels may be indicated.

In clients with chronic renal failure who are on hemodialysis and receiving supplemental erythropoietin therapy, two iron preparations have been developed to treat iron deficiency anemia. Sodium ferric gluconate complex (Ferrlecit) and iron sucrose (Venfor) may be given IV during dialysis.

Use in Hepatic Impairment

Iron dextran must be used with extreme caution in clients with impaired hepatic function. Also, overdoses of chromium and copper are hepatotoxic and should be avoided.

Use in Critical Illness

Electrolyte and acid–base imbalances often occur in critically ill clients and are usually treated as in other clients, with close monitoring of serum electrolyte levels and avoiding excessive amounts of replacement products.

Use in Home Care

The home care nurse has the opportunity to assess household members and the environment for indications of mineral–electrolyte deficiency or excess. Depending on assessment data, teaching may be needed about dietary sources of these nutrients, when mineral supplements are indicated or should be avoided, and safety factors related to iron supplements or exposure to lead in homes with small children.
1. Administer accurately
   a. Give oral mineral–electrolyte preparations with food or immediately after meals.
   b. Give intravenous (IV) preparations slowly, as a general rule.
   c. Do not mix minerals and electrolytes with any other drug in a syringe.
   d. For IV infusion, most minerals and electrolytes are compatible with solutions of dextrose or sodium chloride. Do not mix with other solutions until compatibility is determined.
   e. For IV sodium chloride (NaCl) solutions:
      (1) Give fluids at the prescribed flow rate.
   f. For potassium supplements:
      (1) Mix liquids, powders, and effervescent tablets in at least 4 oz of juice, water, or carbonated beverage.
      (2) Give oral preparations with or after meals.
      (3) Never give undiluted potassium chloride (KCl) IV.
      (4) Dilute IV KCl 20 to 60 mEq in 1000 ml of IV solution, such as dextrose in water. Be sure that KCl is mixed well with the IV solution.
      (5) Usually, give potassium-containing IV solutions at a rate that administers approximately 10 mEq/h or less.
      (6) For life-threatening arrhythmias caused by hypokalemia, potassium can be replaced with 20 to 40 mEq/h with appropriate cardiac monitoring.
   g. For magnesium sulfate (MgSO₄):
      (1) Read the drug label carefully to be sure you have the correct preparation for the intended use.
      (2) For intramuscular administration, small amounts of 50% solution are usually used (1 g MgSO₄ = 2 mL of 50% solution).
      (3) For IV use, a 5% or 10% solution is used for direct injection, intermittent infusion, or continuous infusion. Whatever concentration is used, administer no more than 150 mg/min (1.5 mL/min of 10% solution; 3 mL/min of 5% solution).

   To decrease gastric irritation. Iron and possibly some other agents are better absorbed when taken on an empty stomach. However, they are better tolerated when taken with food.

   The primary danger of rapid IV injection or infusion is a transient excess in serum, which may cause cardiac arrhythmias or other serious problems.

   High risk of physical incompatibility and precipitation of drugs

   To avoid physical incompatibility and precipitation of contents

   Flow rates depend largely on reasons for use. For example, if a client is receiving no oral fluids (NPO) or only small amounts, the flow rate is often 100 to 125 mL/h or 2400 to 3000 mL/24 h. If used as a vehicle for IV antibiotics, the rate is often 50 mL/h or keep open rate (KOR). If the client is dehydrated, 150 to 200 mL/h may be given for a few hours or until a certain amount has been given. (Restrictions in time or amount are necessary to avoid circulatory overload or pulmonary edema.)

   To dilute, disguise the unpleasant taste, and decrease gastric irritation

   To decrease gastric irritation

   Transient hyperkalemia may cause life-threatening cardiotoxicity. Severe pain and vein sclerosis also may result.

   Dilution decreases risks of hyperkalemia and cardiotoxicity. It also prevents or decreases pain at the infusion site.

   This is the safest amount and rate of potassium administration. It is also usually effective.

   Risks of hyperkalemia and life-threatening cardiotoxicity are greatly increased with high concentrations or rapid flow rates. Constant electrocardiogram monitoring is the best way to detect hyperkalemia.

   MgSO₄ is available in concentrations of 10%, 25%, and 50% and in sizes of 2-, 10-, and 20-mL ampules, as well as a 30-mL multidose vial.
### NURSING ACTIONS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>h.</td>
<td>For sodium bicarbonate (NaHCO&lt;sub&gt;3&lt;/sub&gt;):</td>
</tr>
<tr>
<td></td>
<td>(1) Read the label carefully to be sure you have the correct solution.</td>
</tr>
<tr>
<td></td>
<td>(2) Inject directly into the vein or into the tubing of a flowing IV infusion solution in emergencies, such as cardiac arrest.</td>
</tr>
<tr>
<td></td>
<td>(3) In nonemergency situations, titrate flow rate of infusions according to arterial blood gases.</td>
</tr>
<tr>
<td></td>
<td>(4) Flush IV lines before and after injecting and do not add any other medications to an IV containing NaHCO&lt;sub&gt;3&lt;/sub&gt;.</td>
</tr>
<tr>
<td></td>
<td>(5) Monitor arterial blood gases for increased pH after each 50 to 100 mEq of NaHCO&lt;sub&gt;3&lt;/sub&gt;.</td>
</tr>
<tr>
<td>i.</td>
<td>For iron preparations:</td>
</tr>
<tr>
<td></td>
<td>(1) Dilute liquid iron preparations, give with a straw, and have the client rinse the mouth afterward</td>
</tr>
<tr>
<td></td>
<td>(2) To give iron dextran intramuscularly, use a 2- to 3-inch needle and Z-track technique to inject the drug into the upper outer quadrant of the buttock.</td>
</tr>
<tr>
<td></td>
<td>(3) To give iron dextran IV (either directly or diluted in sodium chloride solution and given over several hours), do not use the multidose vial.</td>
</tr>
<tr>
<td>j.</td>
<td>Refer to the individual drugs or package literature for instructions regarding administration of deferoxamine, penicillamine, and multiple electrolyte solutions.</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NaHCO&lt;sub&gt;3&lt;/sub&gt; is available in several concentrations and sizes, such as 50-mL ampules or prefilled syringes with 50 mEq drug (8.4% solution) or 44.6 mEq drug (7.5% solution), or 500-mL bottles with 297.7 mEq drug (5% solution) or 83 mEq drug (1.4% solution).</td>
<td></td>
</tr>
<tr>
<td>To avoid iatrogenic alkalosis</td>
<td></td>
</tr>
<tr>
<td>NaHCO&lt;sub&gt;3&lt;/sub&gt; is highly alkaline and may cause precipitation of other drugs.</td>
<td></td>
</tr>
<tr>
<td>To avoid overtreatment and metabolic alkalosis</td>
<td></td>
</tr>
<tr>
<td>To prevent temporary staining of teeth</td>
<td></td>
</tr>
<tr>
<td>To prevent discomfort and staining of subcutaneous tissue and skin</td>
<td></td>
</tr>
<tr>
<td>The multidose vial contains phenol as a preservative and is not suitable for IV use. Ampules of 2 mL or 5 mL are available without preservative.</td>
<td></td>
</tr>
</tbody>
</table>

2. Observe for therapeutic effects

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td>With NaCl, observe for decreased symptoms of hyponatremia and increased serum sodium level.</td>
</tr>
<tr>
<td>b.</td>
<td>With KCl or other potassium preparations, observe for decreased signs of hypokalemia and increased serum potassium levels.</td>
</tr>
<tr>
<td>c.</td>
<td>With MgSO&lt;sub&gt;4&lt;/sub&gt;, observe for decreased signs of hypomagnesemia, increased serum magnesium levels, or control of convulsions.</td>
</tr>
<tr>
<td>d.</td>
<td>With zinc sulfate (ZnSO&lt;sub&gt;4&lt;/sub&gt;), observe for improved wound healing.</td>
</tr>
<tr>
<td>e.</td>
<td>With sodium bicarbonate (NaHCO&lt;sub&gt;3&lt;/sub&gt;), observe for decreased manifestations of acidosis and a rise in blood pH and bicarbonate levels.</td>
</tr>
<tr>
<td>f.</td>
<td>With iron preparations, observe for:</td>
</tr>
<tr>
<td></td>
<td>(1) Increased vigor and feeling of well-being</td>
</tr>
<tr>
<td></td>
<td>(2) Improved appetite</td>
</tr>
<tr>
<td></td>
<td>(3) Less fatigue</td>
</tr>
<tr>
<td></td>
<td>(4) Increased red blood cells, hemoglobin, and hematocrit</td>
</tr>
<tr>
<td></td>
<td>(5) With parenteral iron, observe for an average increase in hemoglobin of 1 g/wk.</td>
</tr>
</tbody>
</table>

Therapeutic effects should be evident within a few hours.

Therapeutic effects are usually evident within a month unless other problems are also present (eg, vitamin deficiency, achlorhydria, infection, malabsorption).
### Nursing Actions

<table>
<thead>
<tr>
<th>3. Observe for adverse effects</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Mineral–electrolyte excess states:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) With NaCl injection, observe for hypernatremia and circulatory overload.</td>
<td>These are likely to occur with excessive dosages of supplements. They can usually be prevented by using relatively low doses in nonemergency situations and by frequent monitoring of serum levels of electrolytes and iron.</td>
</tr>
<tr>
<td>(2) With potassium preparations, observe for hyperkalemia.</td>
<td>This is most likely to occur with rapid IV administration, high dosages or concentrations, or in the presence of renal insufficiency and decreased urine output.</td>
</tr>
<tr>
<td>(3) With magnesium preparations, observe for hypermagnesemia.</td>
<td>See potassium preparations, above.</td>
</tr>
<tr>
<td>(4) With NaHCO₃, observe for metabolic alkalosis.</td>
<td>This is most likely to occur when large amounts of NaHCO₃ are given IV.</td>
</tr>
<tr>
<td><strong>b. Gastrointestinal (GI) symptoms—anorexia, nausea, vomiting, diarrhea, and abdominal discomfort from gastric irritation</strong></td>
<td></td>
</tr>
<tr>
<td><strong>c. Cardiovascular symptoms:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Cardiac arrhythmias</td>
<td>Potentially fatal arrhythmias may occur with hyperkalemia or hypermagnesemia.</td>
</tr>
<tr>
<td>(2) Hypotension, tachycardia, other symptoms of shock</td>
<td>May occur with deferoxamine and iron dextran injections</td>
</tr>
<tr>
<td>(3) Circulatory overload and possible pulmonary edema</td>
<td>Most likely to occur with large amounts of NaCl or NaHCO₃</td>
</tr>
<tr>
<td><strong>d. With Kayexalate, observe for hypokalemia, hypocalcemia, hypomagnesemia, and edema.</strong></td>
<td>Although this drug is used to treat hyperkalemia, it removes calcium and magnesium ions as well as potassium ions. Because it acts by trading sodium for potassium, the sodium retention may lead to edema.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. Observe for drug interactions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a. Drugs that increase effects of minerals and electrolytes and related drugs:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Alkalining agents (sodium bicarbonate): effects are increased by antacids, such as magnesium hydroxide, calcium carbonate, and aluminum hydroxide.</td>
<td>Small amounts of antacids may be absorbed to produce additive effects.</td>
</tr>
<tr>
<td>(2) Cation exchange resin (Kayexalate): diuretics increase potassium loss; other sources of sodium increase the likelihood of edema.</td>
<td>Additive effects</td>
</tr>
<tr>
<td>(3) Iron salts:</td>
<td></td>
</tr>
<tr>
<td>(a) Allopurinol (Zyloprim)</td>
<td>This drug may increase the concentration of iron in the liver. It should not be given concurrently with any iron preparation.</td>
</tr>
<tr>
<td>(b) Ascorbic acid (vitamin C)</td>
<td>In large doses of 1 g or more, ascorbic acid increases absorption of iron by acidifying secretions.</td>
</tr>
<tr>
<td>(4) Potassium salts:</td>
<td></td>
</tr>
<tr>
<td>(a) Angiotensin-converting enzyme (ACE) inhibitors (eg, captopril)</td>
<td>May increase risks of hyperkalemia</td>
</tr>
<tr>
<td>(b) Potassium-saving diuretics (spironolactone, triamterene, amiloride)</td>
<td>These drugs should not be given with a potassium supplement because of additive risks of producing life-threatening hyperkalemia.</td>
</tr>
</tbody>
</table>
**NURSING ACTIONS**

(c) Salt substitutes

(d) Penicillin G potassium

**RATIONALE/EXPLANATION**

These contain potassium rather than sodium and may cause hyperkalemia if given with potassium supplements.

This potassium salt of penicillin contains 1.7 mEq of potassium per 1 million units. It may produce hyperkalemia if given in combination with potassium supplements.

**b. Drugs that decrease effects of minerals and electrolytes and related drugs:**

1. Alkalinizing agents: effects are decreased by acidifying drugs.

2. Oral iron salts:
   - (a) Antacids
   - (b) Caffeine
   - (c) Cimetidine (Tagamet)
   - (d) Pancreatic extracts

3. Potassium salts:
   - (a) Calcium gluconate
   - (b) Sodium polystyrene sulfonate (Kayexalate)

Acidifying drugs neutralize effects of alkalinizing agents.

Decrease absorption. Iron is best absorbed in an acidic environment and antacids increase alkalinity.

Decreases absorption. An iron preparation and a caffeine-containing substance (eg, coffee) should be separated by at least 2 hours.

Decrease absorption

Decrease absorption

Decreases cardiotoxic effects of hyperkalemia and is therefore useful in the treatment of hyperkalemia

Used in treatment of hyperkalemia because it removes potassium from the body

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Ferrous sulfate is an iron preparation that helps restore iron levels possibly depleted by blood loss during surgery. Take 1 tablet with meals to avoid gastric irritation, which can occur if taken on an empty stomach. Warn Mr. Lee that iron will turn his stool black or dark green and is very constipating. Because constipation may be a factor during the postoperative period because of other factors, a stool softener and laxatives may be needed to promote optimal bowel function.

---

**How Can You Avoid This Medication Error?**

**Answer:** This could cause hyperkalemia that might be lethal for the patient. Adding KCl to an IV bag with only 200 cc remaining would create a solution too concentrated to administer IV. Also, adding KCl to an existing IV should be avoided whenever possible because if the potassium is not mixed adequately with the solution in the bag, a concentrated, potentially lethal dose could be infused. It would be prudent in this situation to waste the 200 cc of IV fluid in the bag that is hanging and hang a new 1000-cc bag with the additional 20 mEq of KCl added. This IV will have 40 mEq of KCL per 1000 cc, which can be safely given at 125 cc/hour. It would be safest to administer the IV through an infusion pump so sudden infusion of excess IV fluid can be avoided.

---

**Review and Application Exercises**

1. What are the major roles of minerals and electrolytes in normal body functioning?
2. How would you assess a client for hypokalemia?
3. When a client is given potassium supplements for hypokalemia, how do you monitor for therapeutic and adverse drug effects?
4. Identify client populations at risk for development of hyperkalemia.
5. List interventions to decrease risks for development of hyperkalemia.
6. If severe hyperkalemia develops, how is it treated?
7. What are some causes of iron deficiency anemia?
8. In a client with iron deficiency anemia, what information could you provide about good food sources of iron?
9. What are advantages and disadvantages of iron supplements?

**SELECTED REFERENCES**


section 6

Drugs Used to Treat Infections
chapter 33

General Characteristics of Antimicrobial Drugs

Objectives
After studying this chapter, the student will be able to:

1. Identify populations who are at increased risk for development of infections.
2. Discuss common pathogens and methods of infection control.
3. Assess clients for local and systemic signs of infection.
4. Discuss common and potentially serious adverse effects of antimicrobial drugs.
5. Identify clients at increased risk for adverse drug reactions.
6. Discuss ways to increase benefits and decrease hazards of antimicrobial drug therapy.
7. Discuss ways to minimize emergence of drug-resistant microorganisms.
8. State appropriate nursing implications for a client receiving an antimicrobial drug.
9. Discuss important elements of using antimicrobial drugs in children, older adults, those with renal or hepatic impairment, and those with critical illness.

Overview
Antimicrobial drugs are used to prevent or treat infections caused by pathogenic (disease-producing) microorganisms. The human body and the environment contain many microorganisms, most of which live in a state of balance with the human host and do not cause disease. When the balance is upset and infection occurs, characteristics of the infecting microorganism(s) and the adequacy of host defense mechanisms are major factors in the severity of the infection and the person’s ability to recover. Conditions that impair defense mechanisms increase the incidence and severity of infections and impede recovery. In addition, use of antimicrobial drugs may lead to serious infections caused by drug-resistant microorganisms. To help prevent infectious diseases and participate effectively in antimicrobial drug therapy, the nurse must be knowledgeable about microorganisms, host responses to microorganisms, and antimicrobial drugs.

Microorganisms and Infections
In an infection, microorganisms initially attach to host cell receptors (i.e., proteins, carbohydrates, lipids). For example, some bacteria have hair-like structures that attach them to skin and mucous membranes. Most microorganisms preferentially attach themselves to particular body tissues. The microorganisms may then invade tissues, multiply, and produce infection. A major characteristic of microorganisms is their ability to survive in various environments. Bacteria, for example, may form mutant strains, alter their structures and functions, or become embedded in a layer of mucus. These adaptations may protect them from normal body defense mechanisms and antimicrobial drugs. Drug-resistant bacterial strains can be produced in the presence of antimicrobial drugs. Classifications, normal microbial flora, and common pathogenic microorganisms are described in the following sections.

Classifications
Bacteria are subclassified according to whether they are aerobic (require oxygen) or anaerobic (cannot live in the presence of oxygen), their reaction to Gram’s stain (gram positive or gram negative), and their shape (e.g., cocci, bacilli).

Viruses are intracellular parasites that survive only in living tissues. They are officially classified according to their structures, but are more commonly described according to origin and the disorders or symptoms they produce. Human pathogens include adenoviruses, herpesviruses, and retroviruses (see Chap. 39).

Fungi are plant-like organisms that live as parasites on living tissue or as saprophytes on decaying organic matter. Approximately 50 species are pathogenic in humans (see Chap. 40).
Normal Microbial Flora

The human body normally has areas that are sterile and areas that are colonized with microorganisms. Sterile areas are body fluids and cavities, the lower respiratory tract (trachea, bronchi, lungs), much of the gastrointestinal (GI) and genitourinary tracts, and the musculoskeletal system. Colonized areas include the skin, upper respiratory tract, and colon.

Normal skin flora includes staphylococci, streptococci, diphtheroids, and transient environmental organisms. The upper respiratory tract contains staphylococci, streptococci, pneumococci, diphtheroids, and Hemophilus influenzae. The external genitalia contain skin organisms; the vagina contains lactobacilli, Candida, and Bacteroides. The colon contains Escherichia coli, Klebsiella, Enterobacter, Proteus, Pseudomonas, Bacteroides, clostridia, lactobacilli, streptococci, and staphylococci. Microorganisms that are part of the normal flora and nonpathogenic in one area of the body may be pathogenic in other parts of the body; for example, E. coli often cause urinary tract infections.

Normal flora protects the human host by occupying space and consuming nutrients. This interferes with the ability of potential pathogens to establish residence and proliferate. If the normal flora is suppressed by antimicrobial drug therapy, potential pathogens may thrive. For example, the yeast, Candida albicans, is a normal resident of the vagina and intestinal tract. An antibacterial drug may destroy the normal bacterial flora without affecting the fungal organism. As a result, C. albicans can proliferate and cause infection. Much of the normal flora can cause disease under certain conditions, especially in elderly, debilitated, or immunosuppressed people. Normal bowel flora also synthesizes vitamin K and vitamin B complex.

Infectious Diseases

Colonization involves the presence of normal microbial flora or transient environmental organisms that do not harm the host. Infectious disease involves the presence of a pathogen plus clinical signs and symptoms indicative of an infection. Accurate assessment and documentation of symptoms can aid diagnosis of infectious diseases.

Laboratory Identification of Pathogens

Laboratory tests of infected fluids or tissues can identify probable pathogens. Bacteria can be identified based on Gram’s stain and culture. Gram’s stain identifies microscopic appearance, including shape and color of the organisms. Culture involves growing a microorganism in the laboratory. Growth on selective culture media will characterize color, shape, and texture of the growing colonies. Identification of other microorganisms (eg, intracellular pathogens such as chlamydiae and viruses) may require different techniques. Serology identifies infectious agents indirectly by measuring the antibody level (titer) in the serum of a diseased host. A tentative diagnosis can be made if the antibody level against a specific pathogen rises during the acute phase of the disease and falls during convalescence. Detection of antigens uses features of culture and serology but reduces the time required for diagnosis. Another technique to identify an organism involves polymerase chain reaction (PCR), which can detect whether DNA for a specific organism is present in a sample.

Common Human Pathogens

Common human pathogens are viruses, gram-positive enterococci, streptococci and staphylococci, and gram-negative intestinal organisms (E. coli, Bacteroides, Klebsiella, Proteus, Pseudomonas species, and others; Box 33–1). These microorganisms are usually spread by direct contact with an infected person or contaminated hands, food, water, or objects.

“Opportunistic” microorganisms are usually normal endogenous or environmental flora and nonpathogenic. They become pathogens, however, in hosts whose defense mechanisms are impaired. Opportunistic infections are likely to occur in people with severe burns, cancer, indwelling intravenous (IV) or urinary catheters, and antibiotic or corticosteroid drug therapy. Opportunistic bacterial infections, often caused by drug-resistant microorganisms, are usually serious and may be life threatening. Fungi of the Candida genus, especially C. albicans, may cause life-threatening bloodstream or deep tissue infections, such as abdominal abscesses. Viral infections may cause fatal pneumonia in people with renal or cardiac disorders and in bone marrow transplant recipients.

Community-Acquired Versus Nosocomial Infections

Infections are often categorized as community acquired or hospital acquired (nosocomial). Because the microbial environments differ, the two types of infections often have different etiologies and require different antimicrobial drugs. As a general rule, community-acquired infections are less severe and easier to treat. Nosocomial infections may be more severe and difficult to manage because they often result from drug-resistant microorganisms and occur in people whose resistance to disease is impaired. Drug-resistant strains of staphylococci, Pseudomonas, and Proteus are common causes of nosocomial infections.

Antibiotic-Resistant Microorganisms

The increasing prevalence of bacteria resistant to the effects of antibiotics, in both community-acquired and nosocomial infections, is a major public health concern (Box 33–2). Antibiotic resistance occurs in most human pathogens. Infections caused by drug-resistant organisms often require more toxic and expensive drugs, lead to prolonged illness or hospitalization, and increase mortality rates.

Resistant microorganisms grow and multiply when susceptible organisms (eg, normal flora) are suppressed by antimicrobial drugs or when normal body defenses are impaired

(text continues on page 499)
**BOX 33–1 COMMON BACTERIAL PATHOGENS**

**Gram-Positive Bacteria**

**Staphylococci**

_S. aureus_ organisms are part of the normal microbial flora of the skin and upper respiratory tract and also are common pathogens. Some people carry (are colonized with) the organism in the anterior nares. The organisms are spread mainly by direct contact with people who are infected or who are carriers. The hands of health care workers are considered a major source of indirect spread and nosocomial infections. The organisms also survive on inanimate surfaces for long periods of time.

_S. aureus_ organisms cause boils, carbuncles, burn and surgical wound infections, and internal abscesses. Burns or surgical wounds often become infected from clients’ own nasal carriage or from health care personnel. The organisms cannot penetrate intact skin or mucous membranes. However, they can penetrate damaged tissues and produce exotoxins that destroy erythrocytes, leukocytes, platelets, fibroblasts, and other human cells. Also, many strains produce enterotoxins that cause food poisoning when ingested. The enterotoxins survive heating at temperatures high enough to kill the organisms, so reheating foods does not prevent food poisoning.

High-risk groups for staphylococcal infections include newborns, the elderly, and those who are malnourished, diabetic, or obese. In children, staphylococcal infections of the respiratory tract are most common in those younger than 2 years of age. In adults, staphylococcal pneumonia often occurs in people with chronic lung disease or as a secondary bacterial infection after influenza. The influenza virus destroys the ciliated epithelium of the respiratory tract and thereby aids bacterial invasion.

_Staphylococcus_ species, non-aureus (SSNA), describes a group of organisms that are also part of the normal microbial flora of the skin and mucosal surfaces and are increasingly common pathogens. The most common member of this group involved in infections is _Staphylococcus epidermidis_. However, not all laboratories routinely further identify the specific organism when SSNA is identified, and microbiology laboratory reports may just report SSNA. For this discussion, we will use the term SSNA unless a specific reference needs to be made to _Staphylococcus epidermidis_.

Infections due to SSNA are associated with the use of treatment devices such as intravascular catheters, prosthetic heart valves, cardiac pacemakers, orthopedic prostheses, cerebrospinal fluid shunts, and peritoneal catheters. SSNA infections include endocarditis, bacteremia, and other serious infections and are especially hazardous to neutropenic and immunocompromised clients. Treatment usually requires removal of any infected medical device as well as appropriate antibiotic therapy.

**Streptococci**

Certain streptococci are part of the normal microbial flora of the throat and nasopharynx in many healthy people. Infections are usually spread by inhalation of droplets from the upper respiratory tracts of carriers or people with infections. However, these organisms do not cause disease unless the mucosal barrier is damaged by trauma, previous infection, or surgical manipulation. Such damage allows the organisms to enter the bloodstream and gain access to other parts of the body. For example, the organisms may cause endocarditis if they reach damaged heart valves.

_S. pneumoniae_ organisms, often called pneumococci, are common bacterial pathogens. They cause pneumonia, sinusitis, otitis media, and meningitis. Pneumococcal pneumonia usually develops when the mechanisms that normally expel organisms inhaled into the lower airway (ie, the mucociliary blanket and cough reflex) are impaired by viral infection, smoking, immobility, or other insults. When _S. pneumoniae_ reach the alveoli, they proliferate, cause acute inflammation, and spread rapidly to involve one or more lobes. Alveoli fill with proteinaceous fluid, neutrophils, and bacteria. When the pneumonia resolves, there is usually no residual damage to the pulmonary parenchyma. Elderly adults have high rates of illness and death from pneumococcal pneumonia, which can often be prevented by pneumococcal vaccine. Pneumococcal vaccine (see Chap. 43) contains 23 strains of the pneumococci that cause most of the serious infections.

Pneumococcal sinusitis and otitis media usually follow a viral illness, such as the common cold. The viral infection injures the protective ciliated epithelium and fills the air spaces with nutrient-rich tissue fluid, in which the pneumococci thrive. _S. pneumoniae_ cause approximately 35% of cases of bacterial sinusitis. In young children, upper respiratory tract infections may be complicated by acute sinusitis. With otitis media, most children have repeated episodes by 6 years of age and the pneumococci causes approximately half of these cases. Recurrent otitis media during early childhood may result in reduced hearing acuity. Otitis media rarely occurs in adults.

Pneumococcal meningitis may develop from sinus or middle ear infections or an injury that allows organisms from the nasopharynx to enter the meninges. _S. pneumoniae_ are a common cause of bacterial meningitis in adults. Other potential secondary complications include septicemia, endocarditis, pericarditis, and empyema.

Susceptible pneumococcal infections may be treated with penicillin G. For people who are allergic to penicillin, a cephalosporin or a macrolide may be effective.

_S. pneumoniae_ organisms are developing resistance such that empiric treatment must be based on the likelihood of drug-resistant _S. pneumoniae_ (DRSP). Rates of DRSP vary by locale; if high, the organisms will be resistant to penicillin and also cross-resistant to other alternatives such as second- and third-generation cephalosporins and possibly macrolides. Alternatives include fluoroquinolones, vancomycin, and chloramphenicol. Empiric treatment of meningitis where _S. pneumoniae_ is known or suspected should include a third-generation cephalosporin (ceftriaxone or cefotaxime plus vancomycin. Empiric treatment for pneumonia should include a fluoroquinolone or a macrolide in those areas with high penicillin and cephalosporin resistance rates.

_S. pyogenes_ (beta-hemolytic streptococcus) are often part of the normal flora of the skin and oropharynx. The organisms spread from person to person by direct contact with oral or respiratory secretions. They cause severe pharyngitis (“strep throat”), scarlet fever, rheumatic fever, and endocarditis. With streptococcal pharyngitis, people remain infected with the organism for weeks after symptoms resolve and thus serve as a reservoir for infection.

**Enterococci**

Enterococci are normal flora in the human intestine but are also found in soil, food, water, and animals. Although the genus _Enterococcus_ contains approximately 12 species, the main pathogens are _E. faecalis_ and _E. faecium_. Most enterococcal infections occur in hospitalized patients, especially those in critical care units. Risk factors for nosocomial infections include serious underlying disease, prior surgery, renal impairment, and the presence of urinary or vascular catheters. These organisms, especially _E. faecalis_, are usually secondary invaders in urinary tract or wound infections. Enterococci may also cause endocarditis. This serious infection occurs most often in people with underlying heart disease, such as an injured
valve. When the organisms reach a heart valve, they multiply and release emboli of foreign particles into the bloodstream. Symptoms of endocarditis include fever, heart murmurs, enlarged spleen, and anemia. This infection is diagnosed by isolating enterococci from blood cultures. If not treated promptly and appropriately, often with ampicillin and gentamicin, enterococcal endocarditis may be fatal.

**Gram-Negative Bacteria**

**Bacteroides**

*Bacteroides* are anaerobic bacteria normally found in the digestive, respiratory, and genital tracts. They are the most common bacteria in the colon, where they greatly outnumber *Escherichia coli*. *B. fragilis*, the major human pathogen, causes intra-abdominal and pelvic abscesses (eg, after surgery or trauma that allows fecal contamination of these tissues), brain abscesses (eg, from bacteremia or spread from a middle ear or sinus infection), and bacteremia, which may spread the organisms throughout the body.

**Escherichia coli**

*E. coli* inhabit the intestinal tract of humans and animals. They are normally nonpathogenic in the intestinal tract but common pathogens in other parts of the body. They may be beneficial by synthesizing vitamins and by competitively discouraging growth of potential pathogens.

*E. coli* cause most urinary tract infections. They also cause pneumonia and sepsis in immunocompromised hosts and meningitis and sepsis in newborns. *E. coli* pneumonia often occurs in debilitated patients after colonization of the oropharynx with organisms from their endogenous microbial flora. In healthy people, the normal gram-positive organisms of oral cavities attach to material that coats the surface of oral mucosa and prevents transient *E. coli* from establishing residence. Debilitated or severely ill people produce an enzyme that destroys the material that allows gram-positive flora to adhere to oral mucosa. This allows *E. coli* (and other gram-negative enteric bacteria) to compete successfully with the normal gram-positive flora and colonize the oropharynx. Then, droplets of the oral flora are aspirated into the respiratory tract, where impaired protective mechanisms allow survival of the aspirated organisms.

*E. coli* also cause enteric gram-negative sepsis, which is acquired from the normal enteric bacterial flora. When *E. coli* and other enteric organisms reach the bloodstream of healthy people, host defenses eliminate the organisms. When the organisms reach the bloodstream of people with severe illnesses and conditions such as neutropenia, the host is unable to mount adequate defenses and sepsis occurs. In neonates, *E. coli* are the most common gram-negative organisms causing nosocomial septic shock and meningitis.

In addition, *E. coli* often cause diarrhea and dysentery. One strain, called O157:H7, causes hemorrhagic colitis, a disease characterized by severe abdominal cramps, copious bloody diarrhea, and hemolytic-uremic syndrome (hemolytic anemia, thrombocytopenia, and acute renal failure). Hemolytic-uremic syndrome occurs most often in children. The main reservoir of this strain is the intestinal tract of animals, especially cattle, and several epidemics have been associated with ingestion of undercooked ground beef. Other sources include contaminated water and milk and person-to-person spread. Because it cannot survive in nature, the presence of *E. coli* in milk or water indicates fecal contamination.

**Klebsiella**

*Klebsiella* organisms, which are normal bowel flora, may infect the respiratory tract, urinary tract, bloodstream, burn wounds, and meninges, most often as opportunistic infections in debilitated persons. *K. pneumoniae* are a common cause of pneumonia, especially in people with pulmonary disease, bacteremia, and sepsis.

**Proteus**

*Proteus* organisms are normally found in the intestinal tract and in decaying matter. They most often cause urinary tract and wound infections but may infect any tissue, especially in debilitated people. Infection usually occurs with antibiotic therapy, which decreases drug-sensitive bacteria and allows drug-resistant bacteria to proliferate.

**Pseudomonas**

*Pseudomonas* organisms are found in water, soil, skin, and intestines. They are found in the stools of some healthy people and possibly 50% of hospital patients. *P. aeruginosa*, the species most often associated with human disease, can cause infections of the respiratory tract, urinary tract, wounds, burns, meningees, eyes, and ears. Because of its resistance to many antibiotics, it can cause severe infections in people receiving antibiotic therapy for burns, wounds, and cystic fibrosis. *P. aeruginosa* colonizes the respiratory tract of most clients with cystic fibrosis and infects approximately 25% of burn patients. Infection is more likely to occur in hosts who are very young or very old or who have impaired immune systems. Sources of infection include catheterization of the urinary tract, trauma or procedures involving the brain or spinal cord, and contamination of respiratory ventilators.

*P. cepacia* infections are increasing, especially in patients with burns, cystic fibrosis, debilitation, or immunosuppression. These infections are especially difficult to treat because the organism is resistant to many of the antibiotics used to treat other gram-negative infections.

**Serratia**

*S. marcescens* organisms are found in infected people, water, milk, feces, and soil. They cause serious nosocomial infections of the urinary tract, respiratory tract, skin, burn wounds, and bloodstream. They also may cause hospital epidemics and produce drug-resistant strains. High-risk patients include newborns, the debilitated, and the immunosuppressed.

**Salmonella**

Approximately 1400 species have been identified; several are pathogenic to humans. The organisms cause gastroenteritis, typhoid fever, septicemia, and a severe, sometimes fatal type of food poisoning. The primary reservoir is the intestinal tract of many animals. Humans become infected through ingestion of contaminated water or food. Water becomes polluted by introduction of feces from any animal excreting salmonellae. Infection by food usually results from ingestion of contaminated meat or by hands transferring organisms from an infected source. In the United States, undercooked poultry and eggs are common sources.

*Salmonella* enterocolitis is a common cause of food-borne outbreaks of gastroenteritis. Diarrhea usually begins several hours after ingesting contaminated food and may continue for several days, along with nausea, vomiting, headache, and abdominal pain.

**Shigella**

*Shigella* species cause gastrointestinal problems ranging from mild diarrhea to severe bacillary dysentery. Humans, who seem to be the only natural hosts, become infected after ingestion of contaminated food or water. Effects of shigellosis are attributed to the loss of fluids, electrolytes, and nutrients and to the ulceration that occurs in the colon wall.
Methicillin-Resistant Staphylococcus Species
Penicillin-resistant staphylococci developed in the early days of penicillin use because the organisms produced beta-lactamase enzymes (penicillinases) that destroyed penicillin. Methicillin was one of five drugs developed to resist the action of beta-lactamase enzymes and thus be effective in treating staphylococcal infections. Eventually, strains of *S. aureus* became resistant to these drugs as well. The mechanism of resistance in methicillin-resistant *S. aureus* (MRSA) is alteration of penicillin-binding proteins (PBPs). PBPs, the target sites of penicillins and other beta-lactam antibiotics, are proteins required for maintaining integrity of bacterial cell walls. Susceptible *S. aureus* have five PBPs called 1, 2, 3, 3a or 3′, and 4. Beta-lactam antibiotics bind to these enzymes and produce defective bacterial cell walls, which kill the organisms. MRSA have an additional PBP called 2a or 2′. Methicillin cannot bind effectively to the PBPs and inhibit bacteria cell wall synthesis except with very high drug concentrations. Consequently, minimum inhibitory concentrations (MICs) of methicillin increased to high levels that were difficult to achieve.

The term MRSA is commonly used but misleading because the organisms are widely resistant to penicillins (including all of the antistaphylococcal penicillins, not just methicillin) and cephalosporins. Many strains of MRSA are also resistant to erythromycin, clindamycin, tetracycline, and the aminoglycosides. MRSA frequently colonize nasal passages of health care workers and are increasing as a cause of nosocomial infections, especially in critical care units. In addition, the incidence of methicillin-resistant *S. epidermidis* (MRSE, often reported as methicillin-resistant SSNA) isolates is increasing.

A major reason for concern about infections caused by MRSA and MRSE is that vancomycin is the drug of choice for treatment. However, vancomycin has been used extensively to treat infections caused by *S. epidermidis* and enterococci, and vancomycin resistance is increasing in those species. Because resistance genes from the other organisms can be transferred to *S. aureus*, vancomycin-resistant *S. aureus* may develop. Vancomycin-resistant enterococci (VRE) are discussed later.

Penicillin-Resistant Streptococcus pneumoniae (Pneumococci)
Penicillin has long been the drug of choice for treating pneumococcal infections (eg, community-acquired pneumonia, bacteremia, meningitis, and otitis media in children). However, penicillin-resistant strains and multidrug-resistant strains are being identified with increasing frequency. Risk factors for the development of resistant strains include frequent antibiotic use and prophylactic antibiotics. Once developed, resistant strains spread to other people, especially in children’s day care centers and in hospital settings. Children in day care centers are often colonized or infected with antibiotic-resistant *S. pneumoniae*. This is attributed to a high incidence of otitis media, which is often treated with a penicillin or cephalosporin. Resistant strains in adults and elderly clients are often associated with previous use of a penicillin or cephalosporin and hospitalization.

*S. pneumoniae* are thought to develop resistance to penicillin by decreasing the ability of their PBPs to bind with penicillin (and other beta-lactam antibiotics). Organisms displaying high-level penicillin resistance may be cross-resistant to second- and third-generation cephalosporins, amoxicillin/clavulanate, and the macrolides azithromycin and clarithromycin. In pneumococcal infections resistant to penicillins and cephalosporins, vancomycin, quinolones, and macrolides are drugs of choice. To decrease spread of resistant *S. pneumoniae*, the Centers for Disease Control and Prevention (CDC) have proposed:

- Improved surveillance to delineate prevalence by geographic area and assist clinicians in choosing appropriate antimicrobial therapy.
- Rational use of antimicrobials to reduce exposures to drug-resistant pneumococci. For example, prophylactic antibiotic therapy for otitis media may increase colonization and infection of young children with resistant organisms.
- Pneumococcal vaccination for people older than 2 years of age with increased risk of pneumococcal infection, and for all people older than 65 years of age.

Vancomycin-Resistant Enterococci
Enterococci have intrinsic and acquired resistance to many antibacterial drugs. For example, penicillins and cephalosporins inhibit rather than kill the organisms at achievable concentrations, and aminoglycosides are ineffective if used alone. As a result, standard treatment of an enterococcal infection outside of the urinary tract has involved a combination of ampicillin and gentamicin or streptomycin. This combination is often successful because the ampicillin damages the bacterial cell wall and allows the aminoglycoside to penetrate the bacterial cell. For ampicillin-allergic clients, vancomycin is given with an aminoglycoside.

This treatment is becoming less effective because some strains of enterococci have developed resistance to ampicillin, gentamicin, and vancomycin. The incidence of multidrug-resistant enterococci and VRE has increased in recent years. Two major types (Van A and Van B) of VRE have been described, with different patterns of antimicrobial susceptibility. Van B is susceptible to teicoplanin; Van A is resistant to teicoplanin but may be susceptible to minocycline, ciprofloxacin, or quinupristin/dalfopristin (Synercid).

A major contributing factor to VRE is increased use of vancomycin to prevent or treat other infections such as staphylococcal (MRSA and MRSE) infections and antibiotic-associated (pseudomembranous) colitis (caused by toxins released by *Clostridium difficile* organisms). Therefore, to decrease the spread of VRE, the CDC recommends limiting the use of vancomycin. Specific recommendations include avoiding or minimizing use in routine surgical prophylaxis, empiric therapy for febrile patients with neutropenia (unless the prevalence of MRSA or MRSE is high), systemic or local prophylaxis for intravascular catheter infection or colonization, selective decontamination of the gastrointestinal tract, eradication of MRSA colonization, primary treatment of antibiotic-associated colitis, and routine prophylaxis for very low birth weight infants or patients on continuous ambulatory peritoneal dialysis. Thorough handwashing and environmental cleaning are also important because VRE can survive for long periods on hands, gloves, stethoscopes, and environmental surfaces. Personnel should remove or change gloves after contact with clients known to be colonized or infected with VRE. Stethoscopes should be used only with an infected patient or cleaned thoroughly between patients if used for both VRE-infected and uninfected patients.
by immunosuppressive disorders or drugs. They may emerge during or after antimicrobial drug therapy. Contributing factors include:

1. **Widespread use of antimicrobial drugs, especially broad-spectrum agents.** Antibiotics affect the bacteria for which they are prescribed, transient organisms, other pathogens, and normal flora. When the normal flora is suppressed, space and nutrients become available to support the growth of organisms resistant to the effects of that antibiotic. The resistant organisms soon become the predominant strain. Once established, resistant bacteria can cause superinfection in the original host, spread to other hosts, and even spread their resistance properties for that antibiotic to other species of bacteria. In addition to resistance to the effects of one antibiotic, cross-resistance to similar antibiotics also occurs because most antibiotics are variations of a few basic types.

2. **Interrupted or inadequate antimicrobial treatment of infections.** Clients often stop taking a prescribed antibiotic when symptoms subside or they feel better. In such circumstances, only the most susceptible bacteria are affected and resistant organisms can become established residents.

3. **Type of bacteria.** Both gram-positive and gram-negative bacteria are producing more antibiotic-resistant strains. Gram-positive organisms include staphylococci, streptococci, and enterococci. Gram-negative bacteria associated with high rates of antibiotic resistance include *Pseudomonas aeruginosa* and *Serratia, Enterobacter,* and *Acinetobacter* species. These organisms are inherently resistant to penetration of antibiotics and acquire resistance by multiple mechanisms. One mechanism is an outer membrane with openings (porins) that regulate passage of antibiotics. Some gram-negative bacteria (eg, *E. coli*) have more permeable porins than others (eg, *P. aeruginosa*). Thus, *P. aeruginosa* organisms are generally resistant to many antibiotics.

4. **Type of infection.** Infections often associated with high rates of resistance include lower respiratory tract infections and those associated with cystic fibrosis or osteomyelitis. These infections are often difficult to treat because they tend to recur; involve multiple, gram-negative, or resistant organisms; and involve anatomic locations that antibiotics do not penetrate well.

5. **Condition of the host.** Clients who are malnourished, severely ill, immunosuppressed, or receiving mechanical ventilation are at high risk for infections, including those caused by antibiotic-resistant organisms.

6. **Location or setting.** Resistant organisms are especially likely to emerge in critical care units and large teaching hospitals, where seriously ill clients often require extensive antibiotic therapy. The constant presence of antibiotics provides strong pressures for selection and replication of resistant organisms.

Resistant organisms and the antibiotics to which they develop resistance vary in geographic areas, communities, and hospitals according to the use of particular antibiotics. Nationally, resistant bacterial strains of major concern include penicillin-resistant *Streptococcus pneumoniae,* methicillin-resistant *Staphylococcus aureus* and *Staphylococcus epidermidis,* vancomycin-resistant enterococcus, and multidrug-resistant tuberculosis (MDR-TB). Actually, all of these organisms are resistant to multiple antibiotics. The first three are described in Box 33–2; MDR-TB is discussed in Chapter 38. Viruses and fungi also develop resistance to antimicrobial drugs, as discussed in Chapters 39 and 40.

### Mechanisms of Resistance

Bacteria have developed numerous ways to acquire resistance to antimicrobial drugs, including:

- Production of enzymes that inactivate the drugs. For example, beta-lactamase enzymes change the chemical structure of penicillins and cephalosporins by opening the beta-lactam ring and preventing the antibiotic from binding with its target site (called penicillin-binding proteins) in the bacterial cell wall.
- Genetic mutations that change antibiotic target sites or change the genetic code to produce new targets. These changes decrease bacterial susceptibility to an antibiotic, largely by altering binding sites.
- Changing their metabolic pathways to bypass antibiotic activity.
- Changing their cell walls to produce porins that prevent penetration of the drug.
- Acquiring the ability to pump drug molecules out of the cell. Multiple, nonspecific efflux systems become activated to remove foreign chemicals.
- Transferring genetic material (DNA or plasmids) between microorganisms. Bacteria have efficient mechanisms for genetic exchange that allow them to spread antibiotic resistance from one bacterial strain to another, including different species or types of bacteria. Thus, when a new antibiotic is used, resistance may rapidly appear and be disseminated to multiple bacteria.

### HOST DEFENSE MECHANISMS

Although the numbers and virulence of microorganisms help to determine whether a person acquires an infection, another major factor is the host’s ability to defend itself against the would-be invaders.

Major defense mechanisms of the human body are intact skin and mucous membranes, various anti-infective secretions, mechanical movements, phagocytic cells, and the immune and inflammatory processes. The skin prevents penetration of foreign particles, and its secretions and normal bacterial flora inhibit growth of pathogenic microorganisms. Secretions of the GI, respiratory, and genitourinary tracts (eg, gastric acid, mucus) kill, trap, or inhibit growth of microorganisms. Coughing, swallowing, and peristalsis help to remove foreign particles and pathogens trapped in mucus, as does the movement of cilia. Phagocytic cells in various organs and tissues engulf and digest...
SECTION 6 DRUGS USED TO TREAT INFECTIONS

pathogens and cellular debris. The immune system produces lymphocytes and antibodies (see Chap. 42). The inflammatory process is the body’s response to injury by microorganisms, foreign particles, chemical agents, or physical irritation of tissues. Inflammation localizes, destroys, dilutes, or removes the injurious agent so tissue healing can occur.

Many factors impair host defense mechanisms and predispose to infection by disease-producing microorganisms:
- Breaks in the skin and mucous membranes related to trauma, inflammation, open lesions, or insertion of prosthetic devices, tubes, and catheters for diagnostic or therapeutic purposes
- Impaired blood supply
- Neutropenia and other blood disorders
- Malnutrition
- Poor personal hygiene
- Suppression of normal bacterial flora by antimicrobial drugs
- Suppression of the immune system and the inflammatory response by immunosuppressive drugs, cytotoxic antineoplastic drugs, and adrenal corticosteroids
- Diabetes mellitus and other chronic diseases
- Advanced age

CHARACTERISTICS OF ANTI-INFECTIVE DRUGS

Terms and Concepts

Several terms are used to describe these drugs. *Anti-infective* and *antimicrobial* include antibacterial, antiviral, and antifungal drugs; *antibacterial* and *antibiotic* usually refer only to drugs used in bacterial infections. Most of the drugs in this section are antibacterials. Antiviral and antifungal drugs are discussed in Chapters 39 and 40, respectively.

Additional terms for antibacterial drugs include *broad spectrum*, for those effective against several groups of microorganisms, and *narrow spectrum*, for those effective against a few groups. The action of an antibacterial drug is usually described as *bactericidal* (kills the microorganism) or *bacteriostatic* (inhibits growth of the microorganism). Whether a drug is bactericidal or bacteriostatic often depends on its concentration at the infection site and the susceptibility of the microorganism to the drug. Successful treatment with bacteriostatic antibiotics depends on the ability of the host’s immune system to eliminate the inhibited bacteria and an adequate duration of drug therapy. Stopping an antibiotic prematurely can result in rapid resumption of bacterial growth. Bactericidal drugs are preferred in serious infections, especially in people with impaired immune function.

Mechanisms of Action

Most antibiotics act on a specific target in the bacterial cell (Fig. 33–1). Almost any structure unique to bacteria, such as proteins or nucleic acids, can be a target for antibiotics. Specific mechanisms include the following:

1. Inhibition of bacterial cell wall synthesis or activation of enzymes that disrupt bacterial cell walls (eg, penicillins, cephalosporins, vancomycin)
2. Inhibition of protein synthesis by bacteria or production of abnormal bacterial proteins (eg, aminoglycosides, clindamycin, erythromycin, tetracyclines). These drugs bind irreversibly to bacterial ribosomes, intracellular structures that synthesize proteins. When antimicrobial drugs are bound to the ribosomes, bacteria cannot synthesize the proteins necessary for cell walls and other structures.
3. Disruption of microbial cell membranes (eg, antifungals)
4. Inhibition of organism reproduction by interfering with nucleic acid synthesis (eg, fluoroquinolones, rifampin, anti–acquired immunodeficiency syndrome antivirals)
5. Inhibition of cell metabolism and growth (eg, sulfonamides, trimethoprim)

Indications for Use

Antimicrobial drugs are used to treat and prevent infections. Because laboratory tests (except Gram’s stain and a rapid test for group A streptococci) to identify causative organisms usually take 24 hours or longer, empiric therapy against the most likely pathogens is often begun. Once organisms are identified, more specific therapy is instituted. Prophylactic therapy is recommended to prevent:

1. Group A streptococcal infections and possibly rheumatic fever, rheumatic heart disease, and glomerulonephritis. Penicillin is commonly used.
2. Bacterial endocarditis in clients with cardiac valvular disease who are having dental, surgical, or other invasive procedures
3. Tuberculosis. Isoniazid (see Chap. 38) is used.
4. Perioperative infections in high-risk clients (eg, those whose resistance to infection is lowered because of age, poor nutrition, disease, or drugs) and for high-risk surgical procedures (eg, cardiac or GI surgery, certain orthopedic procedures, organ transplants)
5. Sexually transmitted diseases (eg, gonorrhea, syphilis, chlamydial infections) after exposure has occurred
6. Recurrent urinary tract infections in premenopausal, sexually active women. A single dose of trimethoprim-sulfamethoxazole, cinoxacin, or cephalexin, taken after sexual intercourse, is often effective.

Planning/Goals
The client will:
• Receive antimicrobial drugs accurately when given by health care providers or caregivers
• Take drugs as prescribed and for the length of time prescribed when self-administered as an outpatient
• Experience decreased fever, white blood cell (WBC) count, and other signs and symptoms of infection
• Be monitored regularly for therapeutic and adverse drug effects
• Be safeguarded against nosocomial infections by health care providers

Assessment
Assess for current or potential infection:
• General signs and symptoms of infection are the same as those of inflammation, although the terms are not synonymous. Inflammation is the normal response to any injury; infection requires the presence of a microorganism. The two often occur together. Inflammation may weaken tissue, allowing microorganisms to invade and cause infection. Infection (tissue injury by microorganisms) arouses inflammation. Local signs include redness, heat, edema, and pain; systemic signs include fever and leukocytosis. Specific manifestations depend on the site of infection. Common sites are the respiratory tract, surgical or other wounds, and the genitourinary tract.
• Assess each client for the presence of factors that increase risks of infection (see the section on Host Defense Mechanisms, earlier).
• Assess culture reports for causative organisms.
• Assess susceptibility reports for appropriate antibacterial drug therapy.
• Assess clients for drug allergies. If present, ask about specific signs and symptoms.
• Assess baseline data about renal and hepatic function and other factors that aid monitoring for therapeutic and adverse drug effects.
• Assess for characteristics that increase risks of adverse drug effects.

Nursing Diagnoses
• Fatigue related to infection
• Activity Intolerance related to fatigue
• Diarrhea related to antimicrobial therapy
• Imbalanced Nutrition: Less Than Body Requirements related to anorexia, nausea, and vomiting associated with antimicrobial therapy
• Risk for Injury related to infection or adverse drug effects
• Risk for Infection related to emergence of drug-resistant microorganisms
• Deficient Knowledge: Methods of preventing infections

Interventions
• Use measures to prevent and minimize the spread of infection.
• Wash hands thoroughly and often. This is probably the most effective method of preventing infections.
• Support natural defense mechanisms by promoting general health measures (eg, nutrition, adequate fluid intake, rest, exercise).
• Keep the client’s skin clean and dry, especially the hands, underarms, groin, and perineum, because these areas harbor large numbers of microorganisms. Also, take care to prevent trauma to the skin and mucous membrane. Damaged tissues are susceptible to infection.
• Treat all body fluids (eg, blood, aspirates from abdomen or chest) and body substances (eg, sputum, feces, urine, wound drainage) as infectious. Major elements of standard precautions to prevent transmission of hepatitis B, human immunodeficiency virus, and other pathogens include wearing gloves when likely to be exposed to any of these materials and thorough handwashing when the gloves are removed. Rigorous and consistent use of the recommended precautions helps to protect health care providers and clients.
• Implement isolation procedures appropriately.
• To prevent spread of respiratory infections, have clients wash hands after coughing, sneezing, or contact with infected people; cover mouth and nose with tissues when sneezing or coughing and dispose of tissues by placing them in a paper bag and burning it; expectorate sputum (swallowing may cause reinfection); avoid crowds when possible, especially during influenza season (approximately November through February); and recommend annual influenza vaccine to high-risk populations (eg, people with chronic diseases such as diabetes and heart, lung, or renal problems; older adults; and health care personnel who are likely to be exposed). Pneumo-
coccal vaccine (see Chap. 43) is recommended as a single dose for the same populations.

- Assist or instruct clients at risk about pulmonary hygiene measures to prevent accumulation or promote removal of respiratory secretions. These measures include ambulating, turning, coughing and deep-breathing exercises, and incentive spirometry. Retained secretions are good culture media for bacterial growth.

- Use sterile technique when changing any dressing. If a wound is not infected, sterile technique helps prevent infection; if the wound is already infected, sterile technique avoids introducing new bacteria. For all but the smallest of dressings without drainage, remove the dressing with clean gloves, discard it in a moisture-proof bag, and wash hands before putting on sterile gloves to apply the new dressing.

- To minimize spread of staphylococcal infections, infected personnel with skin lesions should not work until lesions are healed; infected clients should be isolated. Personnel with skin lesions probably spread more staphylococci than clients because personnel are more mobile.

- For clients with infections, monitor temperature for increased or decreased fever, and monitor WBC count for decrease.

- For clients receiving antimicrobial therapy, maintain a total fluid intake of approximately 3000 mL/24 hours, if not contraindicated by the client’s condition. An adequate intake and avoidance of fluid volume deficit may help to decrease drug toxicity, especially with aminoglycoside antibiotics. On the other hand, a client receiving IV antibiotics, with 50 to 100 mL of fluid per dose, may be at risk for development of fluid volume overload.

- Assist clients with handwashing, maintaining nutrition and fluid balance, getting adequate rest, and handling secretions correctly. These measures help the body to fight the infection, prevent further infection, and enhance the effectiveness of anti-infective drugs.

- Assist clients in using antimicrobial drugs safely and effectively.

**Evaluation**

- Interview and observe for compliance with instructions for using antimicrobial drugs.
- Observe for adverse drug effects.
- Interview and observe for practices to prevent infection.

## PRINCIPLES OF THERAPY

### Treating Infection

The goal of treatment is to eradicate the causative microorganism and return the host to full physiologic functioning. This differs from the goal of most drug therapy, which is to relieve signs and symptoms rather than cure the underlying disorder.

### Rational Use of Antimicrobial Drugs

Antimicrobials are among the most frequently used drugs worldwide. Their success in saving lives and decreasing severity and duration of infectious diseases has encouraged their extensive use. Authorities believe that much antibiotic use involves overuse, misuse, or abuse of the drugs. That is, an antibiotic is not indicated at all or the wrong drug, dose, route, or duration is prescribed. Inappropriate use of antibiotics increases adverse drug effects, infections with drug-resistant microorganisms, and health care costs. In addition, it decreases the number of effective drugs for serious or antibiotic-resistant infections.

Guidelines to promote more appropriate use of the drugs include:

1. Avoid the use of broad-spectrum antibacterial drugs to treat trivial or viral infections; use narrow-spectrum agents when likely to be effective.
2. Give antibacterial drugs only when a significant bacterial infection is diagnosed or strongly suspected or when there is an established indication for prophylaxis. These drugs are ineffective and should not be used to treat viral infections.
3. Minimize antimicrobial drug therapy for fever unless other clinical manifestations or laboratory data indicate infection.
4. Use the drugs along with other interventions to decrease microbial proliferation, such as universal precautions, medical isolation techniques, frequent and thorough handwashing, and preoperative skin and bowel cleansing.
5. Follow recommendations of the Centers for Disease Control and Prevention for prevention and treatment of infections, especially those caused by drug-resistant organisms (eg, gonorrhea, penicillin-resistant streptococcal infections, methicillin-resistant staphylococcal infections, vancomycin-resistant enterococcal infections, and MDR-TB).

### Collection of Specimens

Collect specimens for culture and Gram’s stain before giving the first dose of an antibiotic. For best results, specimens must be collected accurately and taken directly to the laboratory. If analysis is delayed, contaminants may overgrow pathogenic microorganisms.

### Drug Selection

Once an infection requiring treatment is diagnosed, numerous factors influence the choice of an antimicrobial drug or combination of drugs.
**Initial, empiric therapy.** Because most laboratory tests to definitively identify causative organisms and to determine susceptibility to antibiotics require 48 to 72 hours, the physician usually prescribes for immediate administration a drug that is likely to be effective. This empiric therapy is based on an informed estimate of the most likely pathogen, given the client’s signs and symptoms and apparent site of infection. A single broad-spectrum antibiotic or a combination of drugs is often chosen.  

**Culture and susceptibility studies** allow the therapist to “match the drug to the bug.” Culture identifies the causative organism; susceptibility tests determine which drugs are likely to be effective against the organism. Culture and susceptibility studies are especially important with suspected gram-negative infections because of the high incidence of drug-resistant microorganisms. However, drug-resistant gram-positive organisms are being identified with increasing frequency.  

When a specific organism is identified by a laboratory culture, tests can be performed to measure the organism’s susceptibility to particular antibiotics. Laboratory reports indicate whether the organism is susceptible (S) or resistant (R) to the tested drugs. One indication of susceptibility is the minimum inhibitory concentration (MIC). The MIC is the lowest concentration of an antibiotic that prevents visible growth of microorganisms. Some laboratories report MIC instead of, or in addition to, susceptible (S) or resistant (R). Susceptible organisms have low or moderate MICs that can be attained by giving usual doses of an antimicrobial agent. For the drug to be effective, serum and tissue concentrations should usually exceed the MIC of the organism for a period of time. How much and how long drug concentrations need to exceed the MIC depend on the drug class and the bacterial species. With beta-lactam agents (eg, penicillins, cephalosporins), the drug concentration usually needs to be maintained above the MIC of the infecting organism for a majority of the dosing interval. With the aminoglycosides (eg, gentamicin, oth-
ers), the drug concentration does not need to be maintained above the MIC for the entire dosing interval. Aminoglycosides have a postantibiotic effect, defined as a persistent effect of an antimicrobial on bacterial growth after brief exposure of the organisms to a drug. Some studies demonstrate that large doses of aminoglycosides, given once daily, are as effective as more frequent dosing and may cause less nephrotoxicity. Resistant organisms have high MICs and may require higher concentrations of drug than can be achieved in the body, even with large doses. In some cases the minimum bactericidal concentration (MBC) is reported, indicating no growth of the organism in the presence of a particular antibiotic. The MBC is especially desirable for infected hosts with impaired immune functions.

Clients’ responses to antimicrobial therapy cannot always be correlated with the MIC of an infecting pathogen. Thus, reports of drug susceptibility testing must be applied in the context of the site of infection, the characteristics of the drug, and the clinical status of the client.

Knowledge of antibiotic resistance patterns in the community and agency. Because these patterns change, continuing efforts must be made. Pseudomonas aeruginosa is resistant to many antibiotics. Those strains resistant to gentamicin may be susceptible to amikacin, ceftazidime, imipenem, or aztreonam. Some gram-negative organisms have become increasingly resistant to aminoglycosides, third-generation cephalosporins, and aztreonam, but may be susceptible to imipenem.

Knowledge of the organisms most likely to infect particular body tissues. For example, urinary tract infections are often caused by E. coli, and a drug effective against this organism is indicated.

A drug’s ability to penetrate infected tissues. Several antimicrobials are effective in urinary tract infections because they are excreted in the urine. However, the choice of an effective antimicrobial drug may be limited in infections of the brain, eyes, gallbladder, or prostate gland because many drugs are unable to reach therapeutic concentrations in these tissues.

A drug’s toxicity and the risk-to-benefit ratio. In general, the least toxic drug should always be used. However, for serious infections, more toxic drugs may be necessary.

Drug costs. If an older, less expensive drug meets the criteria for rational drug selection and is likely to be effective in a given infection, it should be used as opposed to a more expensive agent. For hospitals and nursing homes, personnel costs in relation to preparation and administration should be considered as well as purchasing costs.

Antibiotic Combination Therapy

Antimicrobial drugs are often used in combination. Indications for combination therapy may include:

- Infections caused by multiple microorganisms (eg, abdominal and pelvic infections)
- Nosocomial infections, which may be caused by many different organisms
- Serious infections in which a combination is synergistic (eg, an aminoglycoside and an antipseudomonal penicillin for pseudomonal infections)
- Likely emergence of drug-resistant organisms if a single drug is used (eg, tuberculosis). Although drug combinations to prevent resistance are widely used, the only clearly effective use is for treatment of tuberculosis.
- Fever or other signs of infection in clients whose immune systems are suppressed. Combinations of antibacterial plus antiviral and/or antifungal drugs may be needed.

Dosage

Dosage (amount and frequency of administration) should be individualized according to characteristics of the causative organism, the chosen drug, and the client’s size and condition (eg, type and severity of infection, ability to use and excrete the chosen drug). For example, dosage may need to be increased for more resistant organisms such as Pseudomonas and for infections in which antibiotics have difficulty penetrating to the site of infection (eg, meningitis). Dosage must often be reduced if the client has renal impairment or other disorders that delay drug elimination.

Route of Administration

Most antimicrobial drugs are given orally or IV for systemic infections. The route of administration depends on the client’s condition (eg, location and severity of the infection, ability to take oral drugs) and the available drug dosage forms. In serious infections, the IV route is preferred for most drugs.

Duration of Therapy

Duration of therapy varies from a single dose to years, depending on the reason for use. For most acute infections, the average duration is approximately 7 to 10 days or until the recipient has been afebrile and asymptomatic for 48 to 72 hours.

Perioperative Use

When used to prevent infections associated with surgery, a single dose of an antimicrobial is usually given within 2 hours before the first incision. This provides effective tissue concentration during the procedure. If contamination occurs, the client should be treated for an infection. The choice of drug depends on the pathogens most likely to colonize the operative area. For most surgeries involving an incision through the skin, a first-generation cephalosporin such as cefazolin (Kefzol) with activity against Staphylococcus aureus or Streptococcus species
is commonly used. Repeated doses may be given during surgery for procedures of long duration, procedures involving insertion of prosthetic materials, and contaminated or infected operative sites. Postoperative antimicrobials are indicated with contaminated surgeries, traumatic wounds or ruptured viscera.

**Use in Children**

Antimicrobial drugs are commonly used in hospitals and ambulatory settings for respiratory infections, otitis media, and other infections. General principles of pediatric (see Chap. 4) and antimicrobial drug therapy apply. Other guidelines include the following:

1. **Penicillins and cephalosporins** are considered safe for most age groups. However, they are eliminated more slowly in neonates because of immature renal function and must be used cautiously and dosed appropriately for age. As with other classes of drugs, many penicillins and cephalosporins have not been Food and Drug Administration (FDA) approved for use in children (usually under the age of 12 years). However, pediatric specialty references reflect the growing body of experience in using these drugs in younger children.

2. **Erythromycin**, oral azithromycin (Zithromax), and clarithromycin (Biaxin) are considered safe. Dirithromycin (Dynabac) has not been FDA approved in children younger than 12 years of age.

3. **Aminoglycosides** (eg, gentamicin) may cause nephrotoxicity and ototoxicity in any client population. Neonates are at high risk because of immature renal function.

4. **Tetracyclines** are contraindicated in children younger than 8 years of age because of drug effects on teeth and bone (see Chap. 36).

5. **Clindamycin** (Cleocin) is given to neonates and infants, liver and kidney function should be monitored.

6. **Fluoroquinolones** (eg, ciprofloxacin [Cipro]) are contraindicated for use in children (<18 years of age) because weight-bearing joints have been impaired in young animals given the drugs. However, if fluoroquinolones are the only therapeutic option for a resistant pathogen, the prescriber may decide to use a fluoroquinolone in children. The following formula may be used to estimate CrCl:

   Male: Weight in kilograms × (140 − age), divided by 72 × serum creatinine (in milligrams per 100 mL)

   Female: 0.85 × above value

   Dosage may be reduced by giving smaller individual doses, by increasing the time interval between doses, or both.

   **Use in Older Adults**

   Antimicrobial drugs are commonly used in all health care settings for infections in older adults as in younger adults. General principles of geriatric (see Chap. 4) and antimicrobial drug therapy apply. Other guidelines include the following:

   1. **Penicillins** are usually safe. However, hyperkalemia may occur with large IV doses of penicillin G potassium (1.7 mEq potassium per 1 million units), and hypernatremia may occur with ticarcillin (Ticar), which contains 10.2 mEq sodium per gram. Hyperkalemia and hypernatremia are more likely to occur with impaired renal function.

   2. **Cephalosporins** (eg, cefazolin) are considered safe but may cause or aggravate renal impairment, especially when other nephrotoxic drugs are used concurrently. Dosage of most cephalosporins should be reduced in the presence of renal impairment (see Chap. 34).

   3. **Macrolides** (eg, erythromycin) are usually safe. Dosage of clarithromycin should be reduced with severe renal impairment.

   4. **Aminoglycosides** (eg, gentamicin) are contraindicated in the presence of impaired renal function if less toxic drugs are effective against causative microorganisms. Older adults are at high risk of nephrotoxicity and ototoxicity from these drugs. Interventions to decrease adverse drug effects are described in Chapter 35.

   5. **Clindamycin** may cause diarrhea and should be used with caution in the presence of GI disease, especially colitis.

   6. **Trimethoprim/sulfamethoxazole** (Bactrim, Septra) may be associated with an increased risk of severe adverse effects in older adults, especially those with impaired liver or kidney function. Severe skin reactions and bone marrow depression are the most frequently reported severe reactions.

   7. **Tetracyclines** (except doxycycline) and nitrofurantoin (Macrodantin) are contraindicated in the presence of impaired renal function if less toxic drugs are effective against causative organisms.

   **Use in Renal Impairment**

   Antimicrobial drug therapy requires close monitoring in clients with renal impairment. Many drugs are excreted primarily by the kidneys; some are nephrotoxic and may further damage the kidneys. In the presence of renal impairment, drugs may accumulate and produce toxic effects. Thus, dosage reductions are necessary for some drugs. Methods of calculating dosage are usually based on rates of creatinine clearance (CrCl). For some antibiotics, such as the aminoglycosides and vancomycin, serum drug concentrations should also be used to individualize dosage.

   The following formula may be used to estimate CrCl:

   Male: Weight in kilograms × (140 − age), divided by 72 × serum creatinine (in milligrams per 100 mL)

   Female: 0.85 × above value

   Dosage may be reduced by giving smaller individual doses, by increasing the time interval between doses, or both.
Anti-infective drugs can be categorized as follows in relation to renal impairment:

1. Drugs that should be avoided in severe renal impairment (i.e., CrCl < 15–30 mL/minute) unless the infecting organism is sensitive only to a particular drug (e.g., tetracyclines except doxycycline, fluconosine).
2. Drugs that may exacerbate renal impairment and should not be used if safer alternatives are available. If used, dosage must be carefully adjusted, renal function must be closely monitored, and the client must be closely observed for adverse effects. These drugs include aminoglycosides, amphotericin B, and the fluoroquinolones. Serum drug concentrations are recommended for monitoring aminoglycoside antibiotics.
3. Drugs that require dosage reduction in severe renal impairment. These include penicillin G, ampicillin, most cephalosporins, fluoroquinolones, and trimethoprim/sulfamethoxazole.
4. Drugs that require little or no dosage adjustment. These include chloramphenicol, clindamycin, dicloxacillin, doxycycline, erythromycin, isoniazid, nafcillin, and rifampin.

An additional factor is important in clients with acute or chronic renal failure who are receiving hemodialysis or peritoneal dialysis: Some drugs are removed by dialysis, and an extra dose may be needed during or after dialysis. Clients with acute renal failure receiving continuous renal replacement therapy (CRRT) may also require adjustments in drug doses. Generally, CRRT is more effective at removing drugs than hemodialysis and peritoneal dialysis. Reference texts or scientific articles should be consulted to determine appropriate doses of antibiotics in these clients.

**Use in Hepatic Impairment**

Antimicrobial therapy in clients with liver impairment is not well defined. Some drugs are metabolized by the liver (e.g., cefoperazone, chloramphenicol, clindamycin, erythromycin), and dosage must be reduced in clients with severe liver impairment. Some are associated with elevations of liver enzymes and/or hepatotoxicity (e.g., certain fluoroquinolones, tetracyclines, isoniazid, rifampin). Laboratory monitoring may be helpful in high-risk populations.

Penicillins and other beta-lactam drugs rarely cause jaundice, hepatitis, or liver failure. However, acute liver injuries have been reported with the combination of amoxicillin/clavulanate (Augmentin), and some cases of cholestatic jaundice have been reported with ticarcillin/clavulanate (Timentin). Hepatotoxicity is attributed to the clavulanate component. These drugs are contraindicated in clients who have had cholestatic jaundice or hepatic dysfunction associated with their use and must be used with caution in clients with hepatic impairment.

Some fluoroquinolones have been associated with liver-enzyme abnormalities and hepatotoxicity (e.g., hepatitis, liver impairment or failure). The drugs should be used cautiously in clients with or at risk for development of impaired liver function. The drug should be stopped if jaundice or any other symptoms of liver dysfunction develop. If trovafloxacin is used at all, the restrictions established by the FDA (see Chap. 35) should be strictly followed.

**Use in Critical Illness**

Antimicrobials are frequently given in critical care units. Many clients have multiple organ impairments or chronic diseases with a superimposed acute illness or injury (e.g., surgery, trauma, burns). Thus, antimicrobial therapy is often more aggressive, complex, and expensive in critically ill clients than in other clients. In addition, measurement of plasma drug levels and dosage adjustment are often necessary to accommodate the changing physiology of a critically ill client. Drug levels are usually measured after four or five doses are given so that steady-state concentrations have been reached.

Clients in critical care units are at high risk for acquiring nosocomial pneumonia because of the severity of their illness, duration of hospitalization, and antimicrobial drug therapy. The strongest predisposing factor is mechanical ventilation, which bypasses airway defenses against movement of microorganisms from the upper to the lower respiratory tract. Organisms often associated with nosocomial pneumonia are S. aureus and gram-negative bacilli. Bacterial pneumonia is usually treated with a broad-spectrum antibiotic until culture and susceptibility reports become available. Selection of antibacterial drugs may be difficult because of frequent changes in antibiotic resistance patterns.

**Home Care**

Infections are among the most common illnesses in all age groups, and they are often treated by antibiotic therapy at home, with medications administered by the client or a family member caregiver. If a home care nurse is involved, responsibilities may include teaching family members how to administer antibiotics (e.g., teaching a parent how to store and measure a liquid antibiotic), care for the person with an infection, and protect other people in the environment from the infection. General infection control practices include frequent and thorough handwashing, use of gloves when indicated, and appropriate handling and disposal of body substances (e.g., blood, urine, feces, sputum, vomitus, wound drainage).

Increasingly, IV antibiotics are being given in the home. Any client who needs more than a few days of IV antibiotic therapy may be a candidate for home care. Some infections that require relatively long-term IV antibiotic therapy include endocarditis, osteomyelitis, and some surgical wound infections. Numerous people and agencies may be involved in providing this service. First, the client and family need to be able and willing to manage some aspects of therapy and to provide space for necessary supplies. Second, arrangements must be made for procuring equipment, supplies, and medication. In some areas, nurses employed by equipment companies help families prepare and use IV infusion pumps. Medication is usually obtained from a local pharmacy in a unit-dose package ready for administration.
The role of the home care nurse includes teaching the client and caregiver to store and administer the medication, monitor the IV site, monitor the infection, manage problems, and report client responses. Specific responsibilities may vary according to drug administration intermittently or by continuous infusion, whether the client has a peripheral or central IV line, and other factors. The family should be provided with detailed instructions and emergency telephone numbers of the home care nurse, the pharmacy, and the supply company.

### Antimicrobial Drugs

#### Nursing Actions

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td>To maintain therapeutic blood levels</td>
</tr>
<tr>
<td>a. Schedule at evenly spaced intervals around the clock.</td>
<td>To decrease binding to foods and inactivation by gastric acid</td>
</tr>
<tr>
<td>b. Give most oral antimicrobials on an empty stomach, approximately 1 h before or 2 h after meals.</td>
<td>Several antimicrobial drugs are marketed in powder forms because they are unstable in solution. When mixed, measured amounts of diluent must be added for drug dissolution and the appropriate concentration. Parenteral solutions are usually prepared in the pharmacy. Most solutions require refrigeration to prolong stability. None of the solutions should be used after the expiration date because drug decomposition is likely.</td>
</tr>
<tr>
<td>c. For oral and parenteral solutions from powder forms, follow label instructions for mixing and storing. Check expiration dates.</td>
<td>To avoid chemical and physical incompatibilities that may cause drug precipitation or inactivation</td>
</tr>
<tr>
<td>d. Give parenteral antimicrobial solutions alone; do not mix with any other drug in a syringe or intravenous (IV) solution.</td>
<td>To decrease tissue irritation</td>
</tr>
<tr>
<td>e. Give intramuscular (IM) antimicrobials deeply into large muscle masses (preferably gluteal muscles), and rotate injection sites.</td>
<td>Most antimicrobials that are given IV can be given by intermittent infusion. Although instructions vary with specific drugs, most reconstituted drugs can be further diluted with 50 to 100 mL of IV fluid (D&lt;sub&gt;5&lt;/sub&gt;W, NS, D&lt;sub&gt;5&lt;/sub&gt;-1/2% or D&lt;sub&gt;5&lt;/sub&gt;-1/2% NaCl). Dilution and slow administration minimize vascular irritation and phlebitis. Flushing ensures that the entire dose is given and prevents contact between drugs in the tubing.</td>
</tr>
<tr>
<td>f. For IV administration, use dilute solutions, give direct injections slowly and intermittent infusions over 30 to 60 min. After infusions, flush the IV tubing with at least 10 mL of IV solution. For children, check references about individual drugs to avoid excessive concentrations and excessive fluids.</td>
<td>Signs and symptoms of inflammation and infection usually subside within approximately 48 h after antimicrobial therapy is begun. Although systemic manifestations of infection are similar regardless of the cause, local manifestations vary with the type or location of the infection.</td>
</tr>
</tbody>
</table>

2. Observe for therapeutic effects

a. With local infections, observe for decreased redness, edema, heat, and pain.

b. With systemic infections, observe for decreased fever and white blood cell count, increased appetite, and reports of feeling better.

c. With wound infections, observe for decreased signs of local inflammation and decreased drainage. Drainage also may change from purulent to serous.

d. With respiratory infections, observe for decreased dyspnea, coughing, and secretions. Secretions may change from thick and colored to thin and white.

e. With urinary tract infections, observe for decreased urgency, frequency, and dysuria. If urinalysis is done, check the laboratory report for decreased bacteria and white blood cells.

f. Absence of signs and symptoms of infection when given prophylactically.

3. Observe for adverse effects

a. Hypersensitivity

Reactions are more likely to occur in those with previous hypersensitivity reactions and those with a history of allergy, asthma, or hay fever.

(continued)
<table>
<thead>
<tr>
<th><strong>NURSING ACTIONS</strong></th>
<th><strong>RATIONALE/EXPLANATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Anaphylaxis—hypotension, respiratory distress, urticaria, angioedema, vomiting, diarrhea</td>
<td>Hypersensitivity may occur with most antimicrobial drugs but is more common with penicillins. Anaphylaxis may occur with oral administration but is more likely with parenteral administration and may occur within 5 to 30 min of injection. Hypotension results from vasodilation and circulatory collapse. Respiratory distress results from bronchospasm or laryngeal edema.</td>
</tr>
<tr>
<td>(2) Serum sickness—chills, fever, vasculitis, generalized lymphadenopathy, joint edema and inflammation, bronchospasm, urticaria</td>
<td>This is a delayed allergic reaction, occurring 1 wk or more after the drug is started. Signs and symptoms are caused by inflammation.</td>
</tr>
<tr>
<td>(3) Acute interstitial nephritis (AIN), hematuria, oliguria, proteinuria, pyuria</td>
<td>AIN is considered a hypersensitivity reaction that may occur with many antimicrobials, including penicillins, cephalosporins, aminoglycosides, sulfonamides, tetracyclines, and others. It is usually reversible if the causative agent is promptly stopped.</td>
</tr>
<tr>
<td><strong>b. Superinfection</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Recurrence of systemic signs and symptoms (eg, fever, malaise)</td>
<td></td>
</tr>
<tr>
<td>(2) New localized signs and symptoms—redness, heat, edema, pain, drainage, cough</td>
<td></td>
</tr>
<tr>
<td>(3) Stomatitis or “thrush”—sore mouth; white patches on oral mucosa; black, furry tongue</td>
<td>From overgrowth of fungi</td>
</tr>
<tr>
<td>(4) Pseudomembranous colitis—severe diarrhea characterized by blood, pus, and mucus in stools</td>
<td>May occur with most antibiotics, but is most often associated with ampicillin, the cephalosporins, and clindamycin. These and other antibiotics suppress normal bacterial flora and allow the overgrowth of <em>Clostridium difficile</em>. The organism produces a toxin that kills mucosal cells and produces superficial ulcerations that are visible with sigmoidoscopy. Discontinuing the drug and giving metronidazole or oral vancomycin are curative measures. However, relapses may occur.</td>
</tr>
<tr>
<td>(5) Monilial vaginitis—rash in perineal area, itching, vaginal discharge</td>
<td>From overgrowth of yeast organisms</td>
</tr>
<tr>
<td><strong>c. Phlebitis at IV sites; pain at IM sites</strong></td>
<td>Many antimicrobial parenteral solutions are irritating to body tissues. These often occur with oral antimicrobials, probably from irritation of gastric mucosa.</td>
</tr>
<tr>
<td><strong>d. Nausea and vomiting</strong></td>
<td>Commonly occurs, caused by irritation of gastrointestinal mucosa and changes in intestinal bacterial flora; and may range from mild to severe. Pseudomembranous colitis is one type of severe diarrhea.</td>
</tr>
<tr>
<td><strong>e. Diarrhea</strong></td>
<td>More likely to occur in clients who are elderly or who have impaired renal function.</td>
</tr>
<tr>
<td><strong>f. Nephrotoxicity</strong></td>
<td>Aminoglycosides are the antimicrobial agents most often associated with ATN.</td>
</tr>
<tr>
<td>(1) See AIN, earlier</td>
<td>More likely with large IV doses of penicillins or cephalosporins, especially in clients with impaired renal function.</td>
</tr>
<tr>
<td>(2) Acute tubular necrosis (ATN)—increased blood urea nitrogen and serum creatinine, decreased creatinine clearance, fluid and electrolyte imbalances</td>
<td>More often associated with penicillins and cephalosporins.</td>
</tr>
<tr>
<td><strong>g. Neurotoxicity</strong></td>
<td>See following chapters. The most significant interactions are those that alter effectiveness or increase drug toxicity.</td>
</tr>
<tr>
<td>—confusion, hallucinations, neuromuscular irritability, convulsive seizures</td>
<td></td>
</tr>
<tr>
<td><strong>h. Bleeding</strong>—hypoprothrombinemia, platelet dysfunction</td>
<td></td>
</tr>
</tbody>
</table>
**Review and Application Exercises**

1. How does the body defend itself against infection?

2. When assessing a client, what signs and symptoms may indicate an infectious process?

3. Do all infections require antimicrobial drug therapy? Why or why not?

4. With antimicrobial drug therapy, what is meant by the terms *bacteriostatic, bactericidal, antimicrobial spectrum of activity,* and *minimum inhibitory concentration?*

5. Why is it important to identify the organism causing an infection?

6. Why are infections of the brain, eye, and prostate gland more difficult to treat than infections of the GI, respiratory, and urinary tracts?

7. What factors promote the development of drug-resistant microorganisms, and how can they be prevented or minimized?

8. What are common adverse effects associated with antimicrobial drug therapy?

9. When teaching a client about a prescribed antibiotic, a common instruction is to take all the medicine and not to stop prematurely. Why is this information important?

10. When a dose of an antibiotic is prescribed to prevent postoperative infection, should it be given before, during, or after surgery? Why?

11. What special precautions are needed for clients with renal or hepatic impairment or critical illness?

**SELECTED REFERENCES**


Critical Thinking Scenario
Kurt, 5 months of age, is brought to the urgent care center at 4 am. He has had a cold for 3 days and started to run a high temperature (over 39°C) last evening. His parents are visibly upset and worried. He has been crying continuously for the last 8 hours and appears to be in pain. The physician examines him and tells the parents he has a middle ear infection, for which he prescribes amoxicillin 200 mg q8h for 10 days.

Reflect on:
- Factors contributing to the increased incidence of ear infections in this age group.
- Why amoxicillin is a good choice for treatment. (Hint: think of the spectrum of coverage.)
- Important teaching to limit the potential for antimicrobial resistance.
- Factors in the situation that may make learning difficult for the parents, and how you will individualize teaching.

Overview
Beta-lactam antibacterials derive their name from the beta-lactam ring that is part of their chemical structure. An intact beta-lactam ring is essential for antibacterial activity. Several gram-positive and gram-negative bacteria produce beta-lactamase enzymes that disrupt the beta-lactam ring and inactivate the drugs. This is a major mechanism by which microorganisms acquire resistance to beta-lactam antibiotics.

Penicillinase and cephalosporinase are beta-lactamase enzymes that act on penicillins and cephalosporins, respectively. Despite the common element of a beta-lactam ring, characteristics of beta-lactam antibiotics differ widely because of variations in their chemical structures. The drugs may differ in antimicrobial spectrum of activity, routes of administration, susceptibility to beta-lactamase enzymes, and adverse effects. Beta-lactam antibiotics include penicillins, cephalosporins, carbapenems, and monobactams, which are...
described in the following sections. Pharmacokinetic characteristics of selected drugs are listed in Table 34–1 and routes and dosage ranges are listed in the Drugs at a Glance tables.

### Mechanism of Action

Beta-lactam antibacterial drugs inhibit synthesis of bacterial cell walls by binding to proteins (penicillin-binding proteins) in bacterial cell membranes. This binding produces a defective cell wall that allows intracellular contents to leak out, destroying the microorganism. In sub-bactericidal concentrations, the drugs may inhibit growth, decrease viability, and alter the shape and structure of organisms. The latter characteristic may help to explain the development of mutant strains of microorganisms exposed to the drugs. Beta-lactam antibiotics are most effective when bacterial cells are dividing.

#### PENICILLINS

The penicillins are effective, safe, and widely used antimicrobial agents. The group includes natural extracts from the *Penicillium* mold and several semisynthetic derivatives. When penicillin G, the prototype, was introduced, it was

*(text continues on page 515)*
### Drugs at a Glance: Penicillins

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Penicillins G and V</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin G potassium and sodium (Pfizerpen)</td>
<td>IM 300,000–8 million U daily IV 6–20 million U daily by continuous or intermittent infusion q2–4h. Up to 60 million U daily have been given in certain serious infections.</td>
<td>IM, IV 50,000–300,000 U/kg/d in divided doses q4h</td>
</tr>
<tr>
<td>Penicillin G benzathine (Bicillin)</td>
<td>IM 1.2–2.4 million U in a single dose Prophylaxis of recurrent rheumatic fever, IM 1.2 million U q3–4 wk Treatment of syphilis, IM 2.4 million U (1.2 million U in each buttock) in a single dose</td>
<td>IM 50,000 U/kg in one dose Prophylaxis of recurrent rheumatic fever, IM same as adult</td>
</tr>
<tr>
<td>Penicillin G procaine (Wycillin)</td>
<td>IM 600,000–2.4 million U daily in one or two doses</td>
<td>IM 300,000 U/day in divided doses q12h</td>
</tr>
<tr>
<td>Penicillin V (Veeptids)</td>
<td>PO 125–500 mg 4–6 times daily</td>
<td>Same as adults Infants: PO 15–50 mg/kg/d in 3–6 divided doses</td>
</tr>
</tbody>
</table>

| **Penicillinase-Resistant (Antistaphylococcal) Penicillins** | | |
| Dicloxacillin | PO 250 mg q6h | Weight ≥ 40 kg: Same as adults Weight < 40 kg: 25 mg/kg/d in four divided doses q6h |
| Nafcillin | IM 500 mg q4–6h IV 500 mg–2 g in 15–30 mL sodium chloride injection, infused over 5–10 min, q4h; maximal daily dose, 18 g for serious infections | IM, IV 50–200 mg/kg/d in four to six divided doses q4–6h |
| Oxacillin | PO, IM, IV 500 mg–1 g q4–6h. For direct IV injection, the dose should be well diluted and given over 10–15 min. | Weight > 40 kg: Same as adults Weight ≤ 40 kg: PO, IM, IV 50–100 mg/kg/d in four divided doses q6h |

| **Ampicillins** | | |
| Ampicillin (Principen) | PO, IM, IV 250–500 mg q6h. In severe infections, doses up to 2 g q4h may be given IV. | Weight > 20 kg: Same as adults Weight ≤ 20 kg: PO, IM, IV 50–200 mg/kg/d in divided doses q6h |
| Amoxicillin (Amoxil) | PO 250–500 mg q8h | Weight > 20 kg: Same as adults Weight ≤ 20 kg: 20–40 mg/kg/d in divided doses q8h |

| **Extended-Spectrum (Antipseudomonal) Penicillins** | | |
| Carbenicillin indanyl sodium (Geocillin) | PO 382–764 mg four times daily | PO 30–50 mg/kg/d in divided doses q6h |
| Ticarcillin (Ticar) | IM, IV 1–3 g q6h. IM injections should not exceed 2 g/injection. | Weight < 40 kg: 100–300 mg/kg/d q6–8h |
| Mezlocillin (Mezlin) | IM, IV 200–300 mg/kg/d in four to six divided doses. Usual adult dosage, 3 g q4h or 4 g q6h | Age 1 mo–12 y: 150–300 mg/kg/d in six divided doses, q4h |
| Piperacillin (Pipracil) | IV, IM 200–300 mg/kg/d in divided doses q4–6h. Usual adult dosage, 3–4 g q4–6h; maximal daily dose, 24 g | Age < 12 y: Dosage not established |

| **Penicillin/Beta-Lactamase Inhibitor Combinations** | | |
| Ampicillin/sulbactam (Unasyn) | IM, IV 1.5–3 g q6h | Weight ≥ 40 kg: same as adults Weight < 40 kg: 300 mg/kg/day in divided doses q6h |
| Amoxicillin clavulanate (Augmentin) | PO 250–500 mg q8h or 875 mg q12h | Weight < 40 kg: 20–40 mg/kg/d in divided doses q8h Weight ≥ 40 kg: same as adults |
| Piperacillin/tazobactam (Zosyn) | IV 2.25–4.5 g q6–8h | IV 100–300 mg/kg/d in divided doses q4–6h |
| Ticarcillin/clavulanate (Timentin) | IV 3.1 g q4–6h | Weight < 60 kg: 200–300 mg/kg/d in divided doses q4–6h |
## Drugs at a Glance: Oral Cephalosporins

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefadroxil (Duricef, Ultracef)</td>
<td>A derivative of cephalaxin that has a longer half-life and can be given less often</td>
<td>PO 1–2 g twice daily</td>
<td>30 mg/kg/d in two doses q12h</td>
</tr>
<tr>
<td>Cephalexin (Keflex)</td>
<td>First oral cephalosporin; still used extensively</td>
<td>PO 250–500 mg q6h, increased to 4 g q6h if necessary in severe infections</td>
<td>PO 25–50 mg/kg/d in divided doses q6h</td>
</tr>
<tr>
<td>Cephradine (Anspor, Velosef)</td>
<td>Essentially the same as cephalexin, except it also can be given parenterally</td>
<td>PO 250–500 mg q6h, up to 4 g daily in severe infections</td>
<td>PO 25–50 mg/kg/d in divided doses q6h. In severe infections, up to 100 mg/kg/d may be given.</td>
</tr>
<tr>
<td><strong>Second Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefaclor (Ceclor)</td>
<td>More active against <em>H. influenzae</em> and <em>E. coli</em> than first-generation drugs</td>
<td>PO 250–500 mg q8h</td>
<td>PO 20–40 mg/kg/d in three divided doses q8h</td>
</tr>
<tr>
<td>Cefprozil (Cefzil)</td>
<td>Similar to cefaclor</td>
<td>PO 250–500 mg q12–24h</td>
<td>PO 15 mg/kg q12h</td>
</tr>
<tr>
<td>Cefuroxime (Ceftin)</td>
<td>1. Can also be given parenterally 2. Available only in tablet form 3. The tablet may be crushed and added to a food (eg, applesauce), but the crushed tablet leaves a strong, bitter, persistent aftertaste.</td>
<td>PO 250 mg q12h; severe infections, 500 mg q12h; urinary tract infection, 125 mg q12h</td>
<td>&gt;12 y, same as adults; &gt;12 y, 125 mg q12h; &lt;12 y, 250 mg q12h</td>
</tr>
<tr>
<td>Loracarbef (Lorabid)</td>
<td>A synthetic drug similar to cefaclor</td>
<td>PO 200–400 mg q12h</td>
<td>PO 15–30 mg/kg/d in divided doses q12h</td>
</tr>
<tr>
<td><strong>Third Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefdinir (Omnicef)</td>
<td>Indicated for bronchitis, pharyngitis, and otitis media caused by streptococci or <em>H. influenzae</em></td>
<td>PO 300 mg q12h or 600 mg q24h for 10 d</td>
<td>≥13 y: PO Same as adults 6 mo–12 y: PO 7 mg/kg q12h or 14 mg/kg q24h for 10 d</td>
</tr>
<tr>
<td>Cefditoren pivoxil (Spectracef)</td>
<td>Indicated for pharyngitis, bacterial exacerbations of chronic bronchitis, and skin/skin structure infections</td>
<td>Bronchitis or pharyngitis, PO 400 mg twice daily (q12h) for 10 days Skin infections, PO 200 mg twice daily for 10 days Renal impairment: CrCl 30–49 mL/min, PO 200 mg twice daily CrCl &lt;30 mL/min, PO 200 mg once daily</td>
<td>≥12 y: Same as adults</td>
</tr>
<tr>
<td>Cefixime (Suprax)</td>
<td>First oral third-generation drug</td>
<td>PO 200 mg q12h or 400 mg q24h</td>
<td>PO 4 mg/kg q12h or 8 mg/kg q24h; give adult dose to children 50 kg of weight or ≥12 y PO 5 mg/kg q12h</td>
</tr>
<tr>
<td>Cefpodoxime (Vantin)</td>
<td>Similar to cefixime except has some activity against staphylococci (except methicillin-resistant <em>S. aureus</em>)</td>
<td>PO 200–400 mg q12h</td>
<td>Give 10 mg/kg (400 mg or adult dose) to children ≤13 y with skin and soft-tissue infections Oral suspension with 90 mg/5 mL 10 kg: 5 mL daily 20 kg: 10 mL daily 40 kg: 20 mL daily Above 45 kg: Same as adults</td>
</tr>
<tr>
<td>Cefdituten (Cedax)</td>
<td>1. Indicated for bronchitis, otitis media, pharyngitis, or tonsillitis caused by streptococci or <em>H. influenzae</em>. 2. Can be given once daily 3. Available in a capsule for oral use and an oral pediatric suspension that comes in two concentrations (90 mg/5 mL and 180 mg/5 mL).</td>
<td>PO 400 mg daily for 10 d Renal impairment: CrCl 30–49 mL/min, 200 mg q24h CrCl 5–29 mL/min, 100 mg q24h</td>
<td>Oral suspension with 180 mg/5 mL 10 kg: 2.5 mL daily 20 kg: 5 mL daily 40 kg: 10 mL daily Above 45 kg: Same as adults</td>
</tr>
</tbody>
</table>

CrCl, creatinine clearance.
## Drugs at a Glance: Parenteral Cephalosporins

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First Generation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefazolin (Kefzol, Ancef)</td>
<td>Active against streptococci, staphylococci, Neisseria, Salmonella, Shigella, Escherichia, Klebsiella, Listeria, Bacillus, Hemophilus influenzae, Coynebacterium diphtheriae, Proteus mirabilis, and Bacteroides (except B. fragilis)</td>
<td>IM, IV 250 mg–1 g q6–8h</td>
</tr>
<tr>
<td>Cephradine (Anspor, Velosef)</td>
<td>No significant differences from cefazolin except it also can be given orally</td>
<td>IV, IM 500 mg–1 g q4–6h, up to 12 g daily, IV, in serious infections</td>
</tr>
<tr>
<td>Cephapirin (Cefadyl)</td>
<td>No significant differences from cefazolin</td>
<td>IV, IM 500 mg–1 g 2–4 times daily, depending on severity of infection</td>
</tr>
<tr>
<td><strong>Second Generation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefmetazole (Zefazone)</td>
<td>Similar to cefoxitin in antibacterial spectrum and clinical use</td>
<td>IV 2 g q6–12h for 5–14 d Surgical prophylaxis, IV 1 or 2 g 30–90 min before surgery</td>
</tr>
<tr>
<td>Cefonocid (Monocid)</td>
<td>1. Antimicrobial spectrum similar to other second-generation cephalosporins 2. Has a long half-life and can therefore be given once daily 3. Not approved for use in children</td>
<td>IV, IM 1–2 g q12h for 5–10 d; maximum dose, 3 g q12h in life-threatening infections Perioperative prophylaxis, IV 1–2 g 30–60 min before procedure</td>
</tr>
<tr>
<td>Cefotetan (Cefotan)</td>
<td>1. Effective against most organisms except Pseudomonas 2. Highly resistant to beta-lactamase enzymes</td>
<td>IV, IM 1–2 g q6–8h Surgical prophylaxis, IV 1 or 2 g 30–90 min before surgery</td>
</tr>
<tr>
<td>Cefoxitin (Mefoxin)</td>
<td>1. The first cephamycin (derived from a different fungus than cephalosporins) 2. A major clinical use may stem from increased activity against B. fragilis, an organism resistant to most other antimicrobial drugs</td>
<td>IV 1–2 g q4–6h Surgical prophylaxis, IV 1 or 2 g 30–90 min before surgery</td>
</tr>
<tr>
<td>Cefuroxime (Ceftin, Kefurox, Zinacef)</td>
<td>1. Similar to other second-generation cephalosporins 2. Penetrates cerebrospinal fluid in presence of inflamed meninges</td>
<td>IV, IM, 750 mg–1.5 g q8h Surgical prophylaxis, IV 1.5 g 30–60 min before initial skin incision</td>
</tr>
<tr>
<td><strong>Third Generation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cefoperazone (Cefobid)</td>
<td>1. Active against gram-negative and gram-positive organisms, including gram-negative organisms resistant to earlier cephalosporins 2. Excreted primarily in bile; half-life prolonged in hepatic failure</td>
<td>IV, IM 2–4 g/d in divided doses q8–12h</td>
</tr>
<tr>
<td>Cefotaxime (Claforan)</td>
<td>1. Antibacterial activity against most gram-positive and gram-negative bacteria, including several strains resistant to other antibiotics. 2. Recommended for serious infections caused by susceptible microorganisms</td>
<td>IV, IM 1 g q6–8h; maximum dose, 12 g/24h</td>
</tr>
</tbody>
</table>
**Drugs at a Glance: Parenteral Cephalosporins (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Ceftazidime**      | 1. Active against gram-positive and gram-negative organisms  
| (Fortaz)             | 2. Especially effective against gram-negative organisms, including *P. aeruginosa* and other bacterial strains resistant to aminoglycosides  
|                      | 3. Indicated for serious infections caused by susceptible organisms        | IV, IM 1 g q8–12h                                               |
| **Ceftizoxime**      | 1. Broader gram-negative and anaerobic activity, especially against *B. fragilis*  
| (Cefizox)            | 2. More active against Enterobacteriaceae than cefoperazone  
|                      | 3. Dosage must be reduced with even mild renal insufficiency (CrCl < 80 mL/min) | IV, IM 1–2 g q8–12h                                            |
| **Ceftriaxone**      | 1. First third-generation cephalosporin approved for once-daily dosing  
| (Rocephin)           | 2. Antibacterial activity against most gram-positive and gram-negative bacteria, including several strains resistant to other antibiotics | IV, IM 1–2 g once daily (q24h)                                 |
| **Fourth Generation**|                                                                                  |                                                 |
| **Cefepime**         | 1. Indicated for urinary tract infections caused by *Escherichia coli* or *Klebsiella pneumoniae*; skin and soft tissue infections caused by susceptible streptococci or staphylococci; pneumonia caused by *Streptococcus pneumoniae* or *Pseudomonas aeruginosa*; complicated intra-abdominal infection and empiric therapy of febrile, neutropenic clients  
| (Maxipime)           | 2. Dosage must be reduced with renal impairment.                             | IV 0.5–2 g q12h                                            |
|                      |                                                                                  | IM 0.5–1 g q12h                                               |
|                      |                                                                                  | Renal impairment:                                          |
|                      |                                                                                  | CrCl 30–60 mL/min, 0.5–2 g q24h; CrCl 11–29 mL/min, 0.5–1 g q24h; CrCl ≤ 10 mL/min, 250–500 mg q24h |

CrCl, creatinine clearance.

**Indications for Use**

Clinical indications for use of penicillins include bacterial infections caused by susceptible microorganisms. As a class, penicillins usually are more effective in infections caused by gram-positive bacteria than those caused by gram-negative bacteria. However, their clinical uses vary significantly according to the subgroup or individual drug and microbial patterns of resistance. The drugs are often useful in skin/soft tissue, respiratory, gastrointestinal, and genitourinary infections caused by susceptible microorganisms. Penicillins are widely distributed and achieve therapeutic concentrations in most body fluids, including joint, pleural, and pericardial fluids and bile. Therapeutic levels are not usually obtained in intraocular and cerebrospinal fluids (CSF) unless inflammation is present because normal cell membranes act as barriers to drug penetration. Penicillins are rapidly excreted by the kidneys and produce high drug concentrations in the urine (an exception is nafcillin, which is excreted by the liver).

The most serious, and potentially fatal, adverse effect of the penicillins is hypersensitivity. Seizures, interstitial nephritis, and nephropathy may also occur.
infections. However, the incidence of resistance among streptococci, staphylococci, and other microorganisms continues to grow.

Contraindications to Use

Contraindications include hypersensitivity or allergic reactions to any penicillin preparation. An allergic reaction to one penicillin means the client is allergic to all members of the penicillin class. The potential for cross-allergenicity with cephalosporins and carbapenems exists, so other alternatives should be selected in penicillin-allergic clients when possible.

Subgroups and Individual Penicillins

Penicillins G and V

Penicillin G, the prototype, remains widely used because of its effectiveness and minimal toxicity. Many strains of staphylococci and gonococci have acquired resistance to penicillin G, preventing its use for treatment of infections caused by these organisms. Some strains of streptococci have acquired resistance to penicillin G, although the drug is still effective in many streptococcal infections. Thus, it is often the drug of choice for the treatment of streptococcal pharyngitis; for prevention of rheumatic fever, a complication of streptococcal pharyngitis; and for prevention of bacterial endocarditis in people with diseased heart valves who undergo dental or some surgical procedures.

Several preparations of penicillin G are available for intravenous (IV) and intramuscular (IM) administration. They cannot be used interchangeably. Only aqueous preparations can be given IV. Preparations containing benzathine or procaine can be given only IM. Long-acting repository forms have additives that decrease their solubility in tissue fluids and delay their absorption.

Penicillin V is derived from penicillin G and has the same antibacterial spectrum. It is not destroyed by gastric acid and is given only by the oral route. It is well absorbed and produces therapeutic blood levels.

Penicillinase-Resistant (Antistaphylococcal) Penicillins

This group includes four drugs (cloxacillin, dicloxacillin, nafcillin, and oxacillin) that are effective in some infections caused by staphylococci resistant to penicillin G. An older member of this group, methicillin, is no longer marketed for clinical use. However, susceptibility of bacteria to the antistaphylococcal penicillins is determined by exposing the bacteria to methicillin (methicillin-susceptible or -resistant) or oxacillin (oxacillin-susceptible or -resistant) in bacteriology laboratories.

These drugs are formulated to resist the penicillinases that inactivate other penicillins. They are recommended for use in known or suspected staphylococcal infections, except for methicillin-resistant Staphylococcus aureus (MRSA) infections. Although called “methicillin-resistant,” these staphylococcal microorganisms are also resistant to other antistaphylococcal penicillins.

Aminopenicillins

Ampicillin is a broad-spectrum, semisynthetic penicillin that is bactericidal for several types of gram-positive and gram-negative bacteria. It has been effective against enterococci, Proteus mirabilis, Salmonella, Shigella, and Escherichia coli, but resistant forms of these organisms are increasing. It is ineffective against penicillinase-producing staphylococci and gonococci.

Ampicillin is excreted mainly by the kidneys; thus, it is useful in urinary tract infections (UTI). Because some is excreted in bile, it is useful in biliary tract infections not caused by biliary obstruction. It is used in the treatment of bronchitis, sinusitis, and otitis media.

Amoxicillin is similar to ampicillin except it is only available orally. It is better absorbed and produces therapeutic blood levels more rapidly than oral ampicillin. It also causes less gastrointestinal distress.

Extended-Spectrum (Antipseudomonal) Penicillins

The drugs in this group (carbenicillin, ticarcillin, mezlocillin, and piperacillin) have a broad spectrum of antimicrobial ac-
activity, especially against gram-negative organisms such as *Pseudomonas* and *Proteus* species and *E. coli*. For pseudomonal infections, one of these drugs is usually given concomitantly with an aminoglycoside or a fluoroquinolone (see Chap. 35). Carbenicillin is available as an oral formulation for UTI or prostatitis caused by susceptible pathogens. The other drugs are usually given by intermittent IV infusion, although most can be given IM.

**Penicillin/Beta-Lactamase Inhibitor Combinations**

Beta-lactamase inhibitors are drugs with a beta-lactam structure but little antibacterial activity. They bind and inactivate the beta-lactamase enzymes produced by many bacteria (eg, *E. coli*, *Klebsiella*, *Enterobacter*, and *Bacteroides* species, and *S. aureus*). When combined with a penicillin, the beta-lactamase inhibitor protects the penicillin from destruction by the enzymes and extends the penicillin’s spectrum of antimicrobial activity. Thus, the combination drug may be effective in infections caused by bacteria that are resistant to a beta-lactam antibiotic alone. Clavulanate, sulbactam, and tazobactam are the beta-lactamase inhibitors available in combinations with penicillins.

**Unasyn** is a combination of ampicillin and sulbactam available in vials with 1 g of ampicillin and 0.5 g of sulbactam or 2 g of ampicillin and 1 g of sulbactam. **Augmentin** contains amoxicillin and clavulanate. It is available in 250-, 500-, and 875-mg tablets, each of which contains 125 mg of clavulanate. Thus, two 250-mg tablets are not equivalent to one 500-mg tablet. **Timentin** is a combination of ticarcillin and clavulanate in an IV formulation containing 3 g ticarcillin and 100 mg clavulanate. **Zosyn** is a combination of piperacillin and tazobactam in an IV formulation. Three dosage strengths are available, with 2 g piperacillin and 0.25 g tazobactam, 3 g piperacillin and 0.375 g tazobactam, or 4 g piperacillin and 0.5 g tazobactam.

**CEPHALOSPORINS**

Cephalosporins are a widely used group of drugs that are derived from a fungus. Although technically cefoxitin and ceftotan (cephamycins derived from a different fungus) and loracarbef (a carbacephem) are not cephalosporins, they are categorized with the cephalosporins because of their similarities to the group. Cephalosporins are broad-spectrum agents with activity against both gram-positive and gram-negative bacteria. Compared with penicillins, they are in general less active against gram-positive organisms but more active against gram-negative ones.

Once absorbed, cephalosporins are widely distributed into most body fluids and tissues, with maximum concentrations in the liver and kidneys. Many cephalosporins do not reach therapeutic levels in CSF; exceptions are cefuroxime, a second-generation drug, and the third-generation agents. These drugs reach therapeutic levels when meninges are inflamed. Most cephalosporins are excreted through the kidneys. Exceptions include cefoperazone, which is excreted in bile, and ceftriaxone, which undergoes dual elimination via the biliary tract and kidneys. Cefotaxime is primarily metabolized in the liver to an active metabolite, desacetylcefotaxime, which is eliminated by the kidneys.

**First-Generation Cephalosporins**

The first cephalosporin, cephalothin, is no longer available for clinical use. However, it is used for determining susceptibility to first-generation cephalosporins, which have essentially the same spectrum of antimicrobial activity. These drugs are effective against streptococci, staphylococci (except methicillin-resistant *S. aureus*), Neisseria, Salmonella, Shigella, Escherichia, Klebsiella, and Bacillus species, Corynebacterium diphtheriae, Proteus mirabilis, and Bacteroides species (except *Bacteroides fragilis*). They are not effective against *Enterobacter*, *Pseudomonas*, and *Serratia* species.

**Second-Generation Cephalosporins**

Second-generation cephalosporins are more active against some gram-negative organisms than the first-generation drugs. Thus, they may be effective in infections resistant to other antibiotics, including infections caused by *Hemophilus influenzae*, and *Klebsiella* species, *E. coli*, and some strains of *Proteus*. Because each of these drugs has a different antimicrobial spectrum, susceptibility tests must be performed for each drug rather than for the entire group, as may be done with first-generation drugs. Cefoxitin (Mefoxin), for example, is active against *B. fragilis*, an anaerobic organism resistant to most drugs.

**Third-Generation Cephalosporins**

Third-generation cephalosporins further extend the spectrum of activity against gram-negative organisms. In addition to activity against the usual enteric pathogens (eg, *E. coli*, *Proteus* and *Klebsiella* species), they are also active against several strains resistant to other antibiotics and to first- and second-generation cephalosporins. Thus, they may be useful in infections caused by unusual strains of enteric organisms such as *Citrobacter*, *Serratia*, and *Providencia*. Another difference is that third-generation cephalosporins penetrate inflamed meninges to reach therapeutic concentrations in CSF. Thus, they may be useful in meningal infections caused by common pathogens, including *H. influenzae*, *Neisseria meningitidis*, and *Streptococcus pneumoniae*. Although some of the drugs are active against *Pseudomonas* organisms, drug-resistant strains may emerge when a cephalosporin is used alone for treatment of pseudomonal infection.

Overall, cephalosporins gain gram-negative activity and lose gram-positive activity as they move from the first to
the third generation. The second- and third-generation drugs are more active against gram-negative organisms because they are more resistant to the beta-lactamase enzymes (cephalosporinases) produced by some bacteria to inactivate cephalosporins.

Fourth-Generation Cephalosporins

Fourth-generation cephalosporins have a greater spectrum of antimicrobial activity and greater stability against breakdown by beta-lactamase enzymes compared with third-generation drugs. Cefepime is the first fourth-generation cephalosporin to be developed. It is active against both gram-positive and gram-negative organisms. With gram-positive organisms, it is active against streptococci and staphylococci (except for methicillin-resistant staphylococci). With gram-negative organisms, its activity against Pseudomonas aeruginosa is similar to that of ceftazidime and its activity against Enterobacteriaceae is greater than that of third-generation cephalosporins. Moreover, cefepime retains activity against strains of Enterobacteriaceae and P. aeruginosa that have acquired resistance to third-generation agents.

Indications for Use

Clinical indications for the use of cephalosporins include surgical prophylaxis and treatment of infections of the respiratory tract, skin and soft tissues, bones and joints, urinary tract, brain and spinal cord, and bloodstream (septicaemia). In most infections with streptococci and staphylococci, penicillins are more effective and less expensive. In infections caused by methicillin-resistant S. aureus, cephalosporins are not clinically effective even if in vitro testing indicates susceptibility. Infections caused by Neisseria gonorrhoeae, once susceptible to penicillin, are now preferentially treated with a third-generation cephalosporin such as ceftriaxone. Cefepime is indicated for use in severe infections of the lower respiratory and urinary tracts, skin and soft tissue, female reproductive tract, and in febrile neutropenic clients. It may be used as monotherapy for all infections caused by susceptible organisms except P. aeruginosa; a combination of drugs should be used for serious pseudomonal infections.

Contraindications to Use

A major contraindication to the use of a cephalosporin is a previous severe anaphylactic reaction to a penicillin. Because cephalosporins are chemically similar to penicillins, there is a risk of cross-sensitivity. However, incidence of cross-sensitivity is low, especially in clients who have had delayed reactions (eg, skin rash) to penicillins. Another contraindication is cephalosporin allergy. Immediate allergic reactions with anaphylaxis, bronchospasm, and urticaria occur less often than delayed reactions with skin rash, drug fever, and eosinophilia.

How Can You Avoid This Medication Error?

Glen Riley returns to your busy surgical unit with the following antibiotic order: Cefuroxime 1 g q12h. The antibiotic comes from the pharmacy labeled “cefuroxime 1 g q12h (0900 & 2100). Infuse 50 cc over 30 minutes.” You hook up the antibiotic and set the hour rate for 100 cc/hour.

CARBAPENEMS

Carbapenems are broad-spectrum, bactericidal, beta-lactam antimicrobials. Like other beta-lactam drugs, they inhibit synthesis of bacterial cell walls by binding with penicillin-binding proteins. The group consists of three drugs.

Imipenem/cilastatin (Primaxin) is given parenterally and distributed in most body fluids. Imipenem is rapidly broken down by an enzyme (dehydropeptidase) in renal tubules and therefore reaches only low concentrations in urine. Cilastatin was synthesized to inhibit the enzyme and reduce potential renal toxicity of the antibacterial agent. Recommended doses indicate the amount of imipenem; the solution contains an equivalent amount of cilastatin.

The drug is effective in infections caused by a wide range of bacteria, including penicillinase-producing staphylococci, E. coli, Proteus species, Enterobacter–Klebsiella–Serratia species, P. aeruginosa, and Enterococcus faecalis. Its main indication for use is treatment of infections caused by organisms resistant to other drugs. Adverse effects are similar to those of other beta-lactam antibiotics, including the risk of cross-sensitivity in clients with penicillin hypersensitivity. Central nervous system toxicity, including seizures, has been reported. Seizures are more likely in clients with a seizure disorder or when recommended doses are exceeded; however, they have occurred in other clients as well. To prepare the solution for IM injection, lidocaine, a local anesthetic, is added to decrease pain. This solution is contraindicated in people allergic to this type of local anesthetic or who have severe shock or heart block.

Meropenem (Merrem) has a broad spectrum of antibacterial activity and may be used as a single drug for empiric therapy before causative microorganisms are identified. It is effective against penicillin-susceptible staphylococci and S. pneumoniae, most gram-negative aerobes (eg, E. coli, H. influenzae, Klebsiella pneumoniae, P. aeruginosa), and some anaerobes, including B. fragilis. It is indicated for use in intra-abdominal infections and bacterial meningitis caused by susceptible organisms. Compared with imipenem, meropenem costs more and seems to offer no clinical advantages. Adverse effects are similar to those of imipenem.

Ertapenem (Invanz) also has a broad spectrum of anti-bacterial activity, although more limited than imipenem and meropenem. It is approved for complicated intra-abdominal, skin and skin structure, acute pelvic, and urinary tract infections. It can be used to treat community-acquired pneumonia caused by penicillin-susceptible S. pneumoniae. Unlike imipenem and meropenem, ertapenem does not have in vitro
activity against *Pseudomonas aeruginosa* and *Acinetobacter baumannii*.

Ertapenem shares the adverse effect profile of the other carbapenems. Lidocaine is also used in preparation of the solution for IM injection, and the same cautions should be used as with imipenem.

**MONOBACTAM**

Aztreonam (Azactam) is active against gram-negative bacteria, including Enterobacteriaceae and *P. aeruginosa*, and many strains that are resistant to multiple antibiotics. Activity against gram-negative bacteria is similar to that of the aminoglycosides, but the drug does not cause kidney damage or hearing loss. Aztreonam is stable in the presence of beta-lactamase enzymes. Because gram-positive and anaerobic bacteria are resistant to aztreonam, the drug’s ability to preserve normal gram-positive and anaerobic flora may be an advantage over most other antimicrobial agents.

Indications for use include infections of the urinary tract, lower respiratory tract, skin and skin structures, as well as intra-abdominal and gynecologic infections and septicemia. Adverse effects are similar to those for penicillin, including possible hypersensitivity reactions.

**PRINCIPLES OF THERAPY**

**Guidelines Related to Hypersensitivity to Penicillins**

1. Before giving the initial dose of any penicillin preparation, ask the client if he or she has ever taken penicillin and, if so, whether an allergic reaction occurred. Penicillin is the most common cause of drug-induced anaphylaxis, a life-threatening hypersensitivity reaction, and a person known to be hypersensitive should be given another type of antibiotic.

2. In the rare instance in which penicillin is considered essential, a skin test may be helpful in assessing hypersensitivity. Benzylpenicilloyl polylysine (Pre-Pen) or a dilute solution of the penicillin to be administered (10,000 units/mL) may be applied topically to a skin scratch made with a sterile needle. If the scratch test is negative (no urticaria, erythema, or pruritus), the preparation may be injected intradermally. Allergic reactions, including fatal anaphylactic shock, have occurred with skin tests and after negative skin tests. If the scratch test is positive, desensitization can be accomplished by giving gradually increasing doses of penicillin.

3. Because anaphylactic shock may occur with administration of the penicillins, especially by parenteral routes, emergency drugs and equipment must be readily available. Treatment may require parenteral epinephrine, oxygen, and insertion of an endotracheal or tracheostomy tube if laryngeal edema occurs.

**Drug Selection**

Choice of a beta-lactam antibacterial depends on the organism causing the infection, severity of the infection, and other factors. With penicillins, penicillin G or amoxicillin is the drug of choice in many infections; an antipseudomonal peni-
Second-generation cephalosporins are also often used for surgical prophylaxis, especially with prosthetic implants, because gram-positive organisms such as staphylococci cause most post-implant infections. They may also be used alone for treatment of infections caused by susceptible organisms in body sites where drug penetration and host defenses are adequate. Cefazolin (Keftzol) is a frequently used parenteral agent. It reaches a higher serum concentration, is more protein bound, and has a slower rate of elimination than other first-generation drugs. These factors prolong serum half-life, so cefazolin can be given less frequently. Cefazolin may also be administered IM.

Second-generation cephalosporins are also often used for surgical prophylaxis, especially for gynecologic and colo-rectal surgery. They are also used for treatment of intra-abdominal infections such as pelvic inflammatory disease, diverticulitis, penetrating wounds of the abdomen, and other infections caused by organisms inhabiting pelvic and colorectal areas.

Third-generation cephalosporins are recommended for serious infections caused by susceptible organisms that are resistant to first- and second-generation cephalosporins. They are often used in the treatment of infections caused by E. coli, Proteus, Klebsiella, and Serratia species, and other Enterobacteriaceae, especially when the infections occur in body sites not readily reached by other drugs (eg, CSF, bone) and in clients with immunosuppression. Although effective against many Pseudomonas strains, these drugs should not be used alone in treating pseudomonal infections because drug resistance develops.

Fourth-generation drugs are most useful in serious gram-negative infections, especially infections caused by organisms resistant to third-generation drugs. Cefepime has the same indications for use as ceftazidime, a third-generation drug.

**Route of Administration and Dosage**

Choice of route and dosage depends largely on the seriousness of the infection being treated. For serious infections, beta-lactam antibacterials are usually given IV in large doses. With penicillins, most must be given every 4 to 6 hours to maintain therapeutic blood levels because the kidneys rapidly excrete them. The oral route is often used, especially for less serious infections and for long-term prophylaxis of rheumatic fever; the IM route is rarely used in hospitalized clients but may be used in ambulatory settings. With cephalosporins, a
few are sufficiently absorbed for oral administration; these are most often used in mild infections and UTI. Although some cephalosporins can be given IM, the injections cause pain and induration. Cefazolin is preferred for IM administration because it is less irritating to tissues.

Use of Penicillins in Specific Situations

Streptococcal Infections

Clinicians need to perform culture and susceptibility studies and know local patterns of streptococcal susceptibility or resistance before prescribing penicillins for streptococcal infections. When used, penicillins should be given for the full prescribed course to prevent complications such as rheumatic fever, endocarditis, and glomerulonephritis.

With Probenecid

Probenecid (Benemid) can be given concurrently with penicillins to increase serum drug levels. Probenecid acts by blocking renal excretion of the penicillins. This action may be useful when high serum levels are needed with oral penicillins or when a single large dose is given IM for prevention or treatment of syphilis.

With an Aminoglycoside

A penicillin is often given concomitantly with an aminoglycoside for serious infections, such as those caused by *P. aeruginosa*. The drugs should not be admixed in a syringe or an IV solution because the penicillin inactivates the aminoglycoside.

Perioperative Use of Cephalosporins

Some cephalosporins are used in surgical prophylaxis. The particular drug depends largely on the type of organism likely to be encountered in the operative area. First-generation drugs, mainly cefazolin, are used for procedures associated with gram-positive postoperative infections, such as prosthetic implant surgery. Second-generation cephalosporins (mainly cefotetan and cefoxitin) are often used for abdominal procedures, especially gynecologic and colorectal surgery, in which enteric gram-negative postoperative infections may occur. Third-generation drugs should not be used for surgical prophylaxis because they are less active against staphylococci than cefazolin, the gram-negative organisms they are most useful against are rarely encountered in elective surgery, widespread usage for prophylaxis promotes emergence of drug-resistant organisms, and they are very expensive.

When used perioperatively, a cephalosporin should be given within 2 hours before the first skin incision is made so the drug has time to reach therapeutic serum and tissue concentrations. A single dose is usually sufficient, although clients undergoing a surgical procedure exceeding 3 hours should receive additional doses at 3-hour intervals. Postoperative doses are rarely necessary, but, if used, should generally not exceed 24 hours.

Use in Children

Penicillins and cephalosporins are widely used to treat infections in children and are generally safe. They should be used cautiously in neonates because immature kidney function
slows their elimination. Dosages should be based on age, weight, severity of the infection being treated, and renal function. Specialized pediatric dosing references can provide guidance to dosing of most beta-lactams based on the child’s age and weight.

### Use in Older Adults

Beta-lactam antibacterials are relatively safe, although decreased renal function, other disease processes, and concurrent drug therapies increase the risks of adverse effects in older adults. With penicillins, hyperkalemia may occur with large IV doses of penicillin G potassium and hypernatremia may occur with ticarcillin (Ticar). Hypernatremia is less likely with other antipseudomonal penicillins such as mezlocillin and piperacillin. Cephalosporins may aggravate renal impairment, especially when other nephrotoxic drugs are used concurrently. Dosage of most cephalosporins must be reduced in the presence of renal impairment, depending on creatinine clearance.

With aztreonam, imipenem/cilastatin, and meropenem, dose and frequency of administration are determined by renal status as indicated by creatinine clearance.

### Use in Renal Impairment

Beta-lactam antimicrobials are excreted mainly by the kidneys and may accumulate in the presence of renal impairment. Dosage of many beta-lactams must be decreased according to creatinine clearance (CrCl) levels. In addition, some of the drugs are nephrotoxic. References should be consulted to determine dosages recommended for various levels of creatinine clearance. Additional considerations are included in the following sections.

### Penicillins

- Dosage of penicillin G, carbenicillin, mezlocillin, piperacillin, piperacillin/tazobactam, and ticarcillin should be reduced.
- Clients on hemodialysis usually need an additional dose after treatment because hemodialysis removes substantial amounts and produces subtherapeutic serum drug levels.
- Carbenicillin, which is used to treat UTIs, does not reach therapeutic levels in urine in clients with severe renal impairment (CrCl < 10 mL/minute).
- Nephropathy, such as interstitial nephritis, although infrequent, has occurred with all penicillins. It is most often associated with high doses of parenteral penicillins and is attributed to hypersensitivity reactions. Manifestations include fever, skin rash, eosinophilia, and possibly increased levels of blood urea nitrogen and serum creatinine.
- Electrolyte imbalances, mainly hypernatremia and hyperkalemia, may occur. Hypernatremia is most likely to occur when ticarcillin (5.6 mEq sodium/g) is given to clients with renal impairment or congestive heart failure. Hyperkalemic metabolic acidosis may also occur with ticarcillin because potassium loss is enhanced by high sodium intake. Hyperkalemia may occur with large IV doses of penicillin G potassium (1.7 mEq/1 million units).

### Cephalosporins

- Reduce dosage because usual doses may produce high and prolonged serum drug levels. In renal failure (CrCl < 20 to 30 mL/minute), dosage of all cephalosporins except cefoperazone should be reduced. Cefoperazone is excreted primarily through the bile and therefore does not accumulate with renal failure.
- Cefotaxime is converted to active metabolites that are normally eliminated by the kidneys. These metabolites accumulate and may cause toxicity in clients with renal impairment.

### Aztreonam

- After an initial loading dose, reduce dosage by 50% or more in clients with CrCl levels of 30 mL/minute or less. Give at the usual intervals of 6, 8, or 12 hours.
- For serious or life-threatening infections in clients on hemodialysis, give 12.5% of the initial dose after each hemodialysis session, in addition to maintenance doses.

### Carbapenems

- Dosage of imipenem should be reduced in most clients with renal impairment and the drug is contraindicated in clients with severe renal impairment (CrCl of 5 mL/minute or less) unless hemodialysis is started within 48 hours. For clients already on hemodialysis, the drug may cause seizures and should be used very cautiously, if at all.
- Dosage of meropenem should be reduced with renal impairment (CrCl < 50 mL/minute).
- Dosage of ertapenem should be reduced to 500 mg daily with renal impairment (CrCl < 30 mL/minute). For clients on hemodialysis, administer the daily dose after dialysis.

### Use in Hepatic Impairment

A few beta-lactam antibiotics may cause or aggravate hepatic impairment. Amoxicillin/clavulanate (Augmentin) should be used with caution in clients with hepatic impairment. It is contraindicated in clients who have had cholestatic jaundice and hepatic dysfunction with previous use of the drug. Cholestatic liver impairment usually subsides when the drug is stopped. Hepatotoxicity is attributed to the clavulinate component and has also occurred with ticarcillin/clavulanate (Timentin).
Cefoperazone is excreted mainly in bile and its serum half-life increases in clients with hepatic impairment or biliary obstruction. Adverse effects include cholestasis, jaundice, and hepatitis. Serum drug levels should be monitored if high doses are given (>4 g).

Aztreonam, imipenem, meropenem, and ertapenem may cause abnormalities in liver function test results (ie, elevated aspartate and alanine aminotransferase and alkaline phosphatase), but hepatitis and jaundice rarely occur.

**Use in Critical Illness**

Beta-lactam antimicrobials are commonly used in critical care units to treat pneumonia, bloodstream, wound, and other infections.

Because clients often have multiorganism or nosocomial infections, the beta-lactam drugs are often given concomitantly with other antimicrobial drugs. Because clients are seriously ill, renal, hepatic, and other organ functions should be monitored and drug dosages should be reduced when indicated.

With penicillins, the extended-spectrum drugs (eg, piperacillin) and penicillin–β-lactamase inhibitor combinations (eg, Unasyn) are most likely to be used. With cephalosporins, third-generation drugs are commonly used and usually given by intermittent IV infusions every 8 or 12 hours. Currently, possible advantages of continuous infusion are being studied. Blood levels of cephalosporins and penicillins need to be maintained above the minimum inhibitory concentration for microorganisms causing the infection being treated. Thus, continuous infusions may be of benefit with serious infections, especially those caused by relatively resistant organisms such as *Pseudomonas* or *Acinetobacter*.

**Home Care**

Many beta-lactam antibiotics are given in the home setting. With oral agents, the role of the home care nurse is mainly to teach accurate administration and observation for therapeutic and adverse effects. With liquid suspensions for children, shaking to resuspend medication and measuring with a measuring spoon or calibrated device are required for safe dosing. Household spoons should not be used because they vary widely in capacity. General guidelines for IV therapy are discussed in Chapter 33; specific guidelines depend on the drug being given.

**NURSING ACTIONS**

<table>
<thead>
<tr>
<th><strong>Beta-Lactam Antibacterials</strong></th>
<th><strong>RATIONALE/EXPLANATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NURSING ACTIONS</strong></td>
<td></td>
</tr>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With penicillins:</td>
<td></td>
</tr>
<tr>
<td>(1) Give most oral penicillins on an empty stomach, approximately 1 h before or 2 h after a meal. Penicillin V, amoxicillin, and amoxicillin/clavulanate may be given without regard to meals.</td>
<td>To decrease binding to foods and inactivation by gastric acid. The latter three drugs are not significantly affected by food.</td>
</tr>
<tr>
<td>(2) Give oral drugs with a full glass of water, preferably; do not give with orange juice or other acidic fluids.</td>
<td>To promote absorption and decrease inactivation, which may occur in an acidic environment</td>
</tr>
<tr>
<td>(3) Give intramuscular (IM) penicillins deeply into a large muscle mass.</td>
<td>To decrease tissue irritation</td>
</tr>
<tr>
<td>(4) For intravenous (IV) administration, usually dilute reconstituted penicillins in 50 to 100 mL of 5% dextrose or 0.9% sodium chloride injection and infuse over 30 to 60 min.</td>
<td>To minimize vascular irritation and phlebitis</td>
</tr>
<tr>
<td>(5) Give reconstituted ampicillin IV or IM within 1 h.</td>
<td>The drug is stable in solution for a limited time, after which effectiveness is lost.</td>
</tr>
<tr>
<td>b. With cephalosporins:</td>
<td></td>
</tr>
<tr>
<td>(1) Give most oral drugs with food or milk.</td>
<td>To decrease nausea and vomiting. Food delays absorption but does not affect the amount of drug absorbed. An exception is the pediatric suspension of ceftibuten, which must be given at least 2 h before or 1 h after a meal.</td>
</tr>
<tr>
<td>(2) Give IM drugs deeply into a large muscle mass.</td>
<td>The drugs are irritating to tissues and cause pain, induration, and possibly sterile abscess. The IM route is rarely used.</td>
</tr>
</tbody>
</table>

(continued)
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>Action</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3) For IV administration, usually dilute reconstituted drugs in 50 to 100 mL of 5% dextrose or 0.9% sodium chloride injection and infuse over 30 min.</td>
<td><strong>RATIONALE/EXPLANATION</strong> These drugs are irritating to veins and cause thrombophlebitis. This can be minimized by using small IV catheters, large veins, adequate dilution, slow infusion rates, and changing venipuncture sites. Thrombophlebitis is more likely to occur with doses of more than 6 g/d for longer than 3 d.</td>
</tr>
<tr>
<td><strong>c. With carbapenems:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) For IV imipenem/cilastatin, mix reconstituted solution in 100 mL of 0.9% NaCl or 5% dextrose injection. Give 250- to 500-mg doses over 20 to 30 min; give 1-g doses over 40 to 60 min.</td>
<td>Manufacturer’s recommendations</td>
</tr>
<tr>
<td>(2) For IM imipenem, inject deeply into a large muscle mass with a 21-gauge, 2-inch needle.</td>
<td></td>
</tr>
<tr>
<td>(3) For IV meropenem, give as an injection (5–20 mL) over 3 to 5 min or as an infusion over 15 to 30 min.</td>
<td></td>
</tr>
<tr>
<td>(4) For IV ertapenem, infuse over 30 min.</td>
<td></td>
</tr>
<tr>
<td><strong>d. With aztreonam:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) For IM administration, add 3 mL diluent per gram of drug, and inject into a large muscle mass.</td>
<td></td>
</tr>
<tr>
<td>(2) For IV injection, add 6 to 10 mL sterile water, and inject into vein or IV tubing over 3 to 5 min.</td>
<td></td>
</tr>
<tr>
<td>(3) For IV infusion, mix in at least 50 mL of 0.9% NaCl or 5% dextrose injection per gram of drug and give over 20 to 60 min.</td>
<td></td>
</tr>
<tr>
<td><strong>e. With imipenem/cilastatin:</strong></td>
<td></td>
</tr>
<tr>
<td>IV: Mix reconstituted solution in 100 mL of 0.9% NaCl or 5% dextrose injection. Give 250- to 500-mg doses over 20 to 30 min; give 1-g doses over 40 to 60 min. IM: Inject deeply into a large muscle mass with a 21-gauge, 2-inch needle.</td>
<td></td>
</tr>
</tbody>
</table>

### 2. Observe for therapeutic effects

- a. Decreased signs of local and systemic infection
- b. Decreased signs and symptoms of the infection for which the drug is given
- c. Absence of signs and symptoms of infection when given prophylactically

### 3. Observe for adverse effects

- a. Hypersensitivity—anaphylaxis, serum sickness, skin rash, urticaria
- b. Phlebitis at IV sites and pain at IM sites
- c. Superinfection
- d. Nausea and vomiting
- e. Diarrhea, colitis, pseudomembranous colitis

See Nursing Actions in Chapter 33 for signs and symptoms. Reactions are more likely to occur in those with previous hypersensitivity reactions and those with a history of allergy, asthma, or hay fever. Anaphylaxis is more likely with parenteral administration and may occur within 5 to 30 min of injection.

Parenteral solutions are irritating to body tissue. See Chapter 33 for signs and symptoms.

May occur with all beta-lactam drugs, especially with high oral doses. Diarrhea commonly occurs with beta-lactam drugs and may range from mild to severe. The most severe form is pseudomembranous colitis, which is more often associated with amoxicillin and the cephalosporins than other beta-lactams.

(continued)
## NURSING ACTIONS

<table>
<thead>
<tr>
<th>f. Nephrotoxicity</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Acute interstitial nephritis (AIN)—hematuria, oliguria, proteinuria, pyuria</td>
<td>AIN may occur with any of the beta-lactams, especially with high parenteral doses of penicillins.</td>
</tr>
<tr>
<td>(2) Increased blood urea nitrogen and serum creatinine; casts in urine</td>
<td>More likely with cephalosporins, especially in clients who are elderly or have impaired renal function, unless dosage is reduced</td>
</tr>
<tr>
<td>g. Neurotoxicity—confusion, hallucinations, neuromuscular irritability, convulsive seizures</td>
<td>More likely with large IV doses of penicillins or cephalosporins, especially in clients with impaired renal function</td>
</tr>
<tr>
<td>h. Coagulation disorders and bleeding from hypoprothrombinemia or platelet dysfunction</td>
<td>Ticarcillin may cause decreased platelet aggregation. Cefmetazole, cefoperazone, cefotetan, and ceftriaxone may cause hypoprothrombinemia (by killing intestinal bacteria that normally produce vitamin K or a chemical structure that prevents activation of prothrombin) or platelet dysfunction. Bleeding can be treated by giving vitamin K. Vitamin K does not restore normal platelet function or normal bacterial flora in the intestines.</td>
</tr>
</tbody>
</table>

## 4. Observe for drug interactions

<table>
<thead>
<tr>
<th>a. Drugs that increase effects of penicillins:</th>
<th>Synergistic activity against <em>Pseudomonas</em> organisms when given concomitantly with extended-spectrum (antipseudomonal) penicillins</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Gentamicin and other aminoglycosides</td>
<td>Synergistic activity against enterococci that cause subacute bacterial endocarditis, brain abscess, meningitis, or urinary tract infection</td>
</tr>
<tr>
<td>(2) Probenecid (Benemid)</td>
<td>Synergistic activity against <em>S. aureus</em> when used with nafcillin</td>
</tr>
<tr>
<td>b. Drugs that decrease effects of penicillins:</td>
<td>Decreases renal excretion of penicillins, thus elevates and prolongs penicillin blood levels</td>
</tr>
<tr>
<td>(1) Acidifying agents (ascorbic acid, cranberry juice, orange juice)</td>
<td>Most oral penicillins are destroyed by acids, including gastric acid. Amoxicillin and penicillin V are acid stable.</td>
</tr>
<tr>
<td>(2) Erythromycin</td>
<td>Erythromycin inhibits the bactericidal activity of penicillins against most organisms but potentiates activity against resistant strains of <em>S. aureus</em>.</td>
</tr>
<tr>
<td>(3) Tetracyclines</td>
<td>These bacteriostatic antibiotics slow multiplication of bacteria and thereby inhibit the penicillins, which act against rapidly multiplying bacteria.</td>
</tr>
<tr>
<td>c. Drugs that increase effects of cephalosporins:</td>
<td>Increased renal toxicity</td>
</tr>
<tr>
<td>(1) Loop diuretics (furosemide, ethacrynic acid)</td>
<td>Additive renal toxicity especially in older clients, those with renal impairment, those receiving high dosages, and those receiving probenecid</td>
</tr>
<tr>
<td>(2) Gentamicin and other aminoglycoside antibiotics</td>
<td>Increases blood levels by decreasing renal excretion of the cephalosporins. This may be a desirable interaction to increase blood levels and therapeutic effectiveness or allow smaller doses.</td>
</tr>
<tr>
<td>(3) Probenecid</td>
<td>Tetracyclines are bacteriostatic and slow the rate of bacterial reproduction. Cephalosporins are bactericidal and are most effective against rapidly multiplying bacteria. Thus, tetracyclines should not be given concurrently with cephalosporins.</td>
</tr>
<tr>
<td>d. Drugs that decrease effects of cephalosporins:</td>
<td>These drugs decrease absorption of cefditoren (Spectracef). Give the drugs at least 2 hours apart.</td>
</tr>
<tr>
<td>(1) Tetracyclines</td>
<td>(continued)</td>
</tr>
<tr>
<td>(2) Antacids containing aluminum or magnesium (eg, Mylanta) and histamine H₂ antagonists (eg, cimetidine, ranitidine)</td>
<td>(continued)</td>
</tr>
</tbody>
</table>
**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>e. Drugs that increase effects of carbapenems</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Probenecid</td>
</tr>
<tr>
<td>(2) Cyclosporine</td>
</tr>
</tbody>
</table>

| f. Drugs that alter effects of aztreonam    |

**RATIONALE/EXPLANATION**

Probenecid minimally increases serum drug levels of carbapenems, but it is not recommended for concomitant use with any of the drugs.

May increase central nervous system (CNS) adverse effects of imipenem.

Few documented, clinically significant interactions reported, but potential interactions are those that occur with other beta-lactam antibiotics.

---

**How Can You Avoid This Medication Error?**

**Answer:** You have just administered the wrong medication to this patient. Although the names are similar (many cephalosporin names sound and look alike), these are two different drugs. Cefuroxime is a second-generation cephalosporin and cefizoxime is a third-generation cephalosporin, meaning their bacterial coverage and pharmacokinetics are different. When the dispensed medication is not identical to the prescribed medication, check with the pharmacist to see if the substitution is appropriate or if it is a mistake.

**Nursing Notes: Apply Your Knowledge**

**Answer:** Ms. Driver may be experiencing anaphylaxis. Although she did not state an allergy to cephalosporin antibiotics, 5% to 10% of people allergic to penicillin may have a cross-sensitivity to cephalosporins because structurally all beta-lactams are similar. Stop the infusing cefotetan but keep the IV line open because you may need to give emergency drugs IV if her condition worsens. Take her vital signs, administer oxygen, and have someone stay with her while you contact the physician. Make sure that you have epinephrine on hand.

**Review and Application Exercises**

1. How do beta-lactam drugs act against bacteria?
2. What adverse effects are associated with beta-lactam drugs, and how may they be prevented or minimized?
3. What are beta-lactamase enzymes, and what do they do to beta-lactam antibacterial drugs?

4. How are penicillins and other beta-lactam drugs excreted?
5. What are the main differences between penicillin G or V and antistaphylococcal and antipseudomonal penicillins?
6. What is the reason for combining clavulanate, sulbactam, or tazobactam with a penicillin?
7. When giving injections of penicillin in an outpatient setting, it is recommended to keep clients in the area and observe them for at least 30 minutes. Why?
8. When probenecid is given concurrently with a penicillin, what is its purpose?
9. What are the signs and symptoms of anaphylaxis?
10. For clients with renal impairment, which drugs in this chapter require reduced dosages?
11. Which drugs from this chapter may cause pseudomembranous (antibiotic-associated) colitis?
12. What are the signs, symptoms, and treatment of pseudomembranous colitis?

**SELECTED REFERENCES**


chapter 35

Aminoglycosides and Fluoroquinolones

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe characteristics of aminoglycosides in relation to effectiveness, safety, spectrum of antimicrobial activity, indications for use, administration, and observation of client responses.
2. Discuss factors influencing selection and dosage of aminoglycosides.
3. State the rationale for the increasing use of single daily doses.
4. Discuss the importance of serum drug levels during aminoglycoside therapy.
5. Describe measures to decrease nephrotoxicity and ototoxicity with aminoglycosides.
6. Describe characteristics, uses, adverse effects, and nursing process implications of fluoroquinolones.
7. Discuss principles of using aminoglycosides in renal impairment and critical illness.

Critical Thinking Scenario
George Masury, accompanied by his wife Jennie, visits his primary care provider complaining of upper respiratory symptoms. George and Jennie have been married for 52 years and Jennie has always cared for George when he was sick and helped make decisions for him. George is hard of hearing, has some “forgetfulness,” and does not talk very much. His physician prescribes ciprofloxacin (Cipro) 250 mg bid for 10 days.

Reflect on:
- How you will include George and Jennie in the teaching session.
- Essential information to teach about Cipro.
- Teaching strategies to individualize for hearing deficits and memory deficits.
- How you will evaluate George and Jennie’s learning and their ability to comply with the newly prescribed medication.

OVERVIEW

The aminoglycosides have been widely used to treat serious gram-negative infections for many years. The quinolones are also older drugs originally used only for treatment of urinary tract infections (see Chap. 36). The fluoroquinolones are synthesized by adding a fluorine molecule to the quinolone structure. This addition increases drug activity against gram-negative microorganisms, broadens the antimicrobial spectrum to include several other microorganisms, and allows use of the drugs in treating systemic infections. General characteristics, mechanisms of action, indications for and contraindications to use, nursing process implications, and principles of therapy for these drugs are described in this chapter. Individual drugs, with routes of administration and dosage ranges, are listed in the Drugs at a Glance tables.

AMINOGLYCOSES

Aminoglycosides are bactericidal agents with similar pharmacologic, antimicrobial, and toxicologic characteristics. They are used to treat infections caused by gram-negative microorganisms such as Pseudomonas and Proteus species, Escherichia coli, and Klebsiella, Enterobacter, and Serratia species.

These drugs are poorly absorbed from the gastrointestinal (GI) tract. Thus, when given orally, they exert local effects in the GI tract. They are well absorbed from intramuscular injection sites and reach peak effects in 30 to 90 minutes if circula-
## Drugs at a Glance: Aminoglycosides

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin (Amikin)</td>
<td>Retains a broader spectrum of antibacterial activity than other aminoglycosides because it resists degradation by most enzymes that inactivate gentamicin and tobramycin. Major clinical use is in infections caused by organisms resistant to other aminoglycosides (e.g., <em>Pseudomonas</em>, <em>Proteus</em>, <em>Escherichia coli</em>, <em>Klebsiella</em>, <em>Enterobacter</em>, <em>Serratia</em>), whether community or hospital acquired.</td>
<td>IM, IV 15 mg/kg q24h, 7.5 mg/kg q12h, or 5 mg/kg q8h. Older children: Same as adults. Neonates: IM, IV 10 mg/kg initially, then 7.5 mg/kg q12h.</td>
</tr>
<tr>
<td>Gentamicin (Garamycin)</td>
<td>Effective against several gram-negative organisms, although some strains have become resistant. Acts synergistically with antipseudomona penicillins against <em>Pseudomonas aeruginosa</em> and with ampicillin or vancomycin against enterococci.</td>
<td>IV, IM 3–7 mg/kg q24h, 1.5–2.5 mg/kg q12h, or 1–1.7 mg/kg q8h. Infants and neonates: IV, IM 7.5 mg/kg/d in three divided doses, q8h. Premature infants and neonates: IV, IM 5 mg/kg/d in two divided doses, q12h. IV, IM same as adults.</td>
</tr>
<tr>
<td>Kanamycin (Kantrex)</td>
<td>Occasionally used to decrease bowel organisms before surgery, treat hepatic coma, or to treat multidrug-resistant tuberculosis.</td>
<td>Suppression of intestinal bacteria. Hepatic coma PO 8–12 g daily in divided doses.</td>
</tr>
<tr>
<td>Neomycin</td>
<td>Given orally or topically only because too toxic for systemic use. Although poorly absorbed from GI tract, toxic levels may accumulate in presence of renal failure. Used topically, often in combination with other drugs, to treat infections of the eye, ear, and skin (burns, wounds, ulcers, dermatoses). When used for wound or bladder irrigations, systemic absorption may occur if the area is large or if drug concentration exceeds 0.1%.</td>
<td>Suppression of intestinal bacteria (with erythromycin 1 g) PO 1 g at 19, 18, and 9 h before surgery (three doses). Hepatic coma PO 4–12 g daily in divided doses.</td>
</tr>
<tr>
<td>Netilmicin (Netromycin)</td>
<td>Similar to gentamicin in antimicrobial spectrum, but is reportedly less active against <em>P. aeruginosa</em>.</td>
<td>IM, IV 4–6.5 mg/kg/d in two or three divided doses, q8–12h. Infants and children (6 wk to 12 y): 5.5 to 8 mg/kg/d in 2 or 3 divided doses, q8–12h. Neonates (&lt;6 wk): 4–6.5 mg/kg/d, in two divided doses, q12h.</td>
</tr>
<tr>
<td>Paromomycin (Humatin)</td>
<td>Acts against bacteria and amebae in the intestinal lumen. Used to treat hepatic coma and intestinal amebiasis. It is not effective in amebic infections outside the intestine. Usually not absorbed from GI tract and unlikely to cause ototoxicity and nephrotoxicity associated with systemically absorbed aminoglycosides. However, systemic absorption may occur in the presence of inflammatory or ulcerative bowel disease.</td>
<td>Intestinal amebiasis PO 25–35 mg/kg/d, in three divided doses, with meals, for 5–10 d. Repeat after 2 wk, if necessary. Hepatic coma PO 4 g/d in divided doses for 5–6 d. Intestinal amebiasis, same as adults.</td>
</tr>
</tbody>
</table>
CHAPTER 35 AMINOGLYCOSIDES AND FLUOROQUINOLONES

**Drugs at a Glance: Aminoglycosides (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Streptomycin</td>
<td>May be used in a four- to six-drug regimen for treatment of multidrug-resistant tuberculosis</td>
<td><strong>Adults</strong>&lt;br&gt;IM 15 mg/kg/d (maximum 1 g) or 25–30 mg/kg two or three times weekly (maximum 1.5 g per dose)</td>
</tr>
<tr>
<td>Tobramycin (Nebcin)</td>
<td>Similar to gentamicin in antibacterial spectrum, but may be more active against <em>Pseudomonas</em> organisms. Often used with other antibiotics for septicemia and infections of burn wounds, other soft tissues, bone, the urinary tract and the central nervous system.</td>
<td><strong>Adults</strong>&lt;br&gt;IV, IM 3–5 mg/kg q24h, 1.5–2.5 mg/kg q12h, or 1–1.7 mg/kg q8h</td>
</tr>
</tbody>
</table>

After intravenous (IV) administration, peak effects occur within 30 to 60 minutes. Plasma half-life is 2 to 4 hours with normal renal function. After parenteral administration, aminoglycosides are widely distributed in extracellular fluid and reach therapeutic levels in blood, urine, bone, inflamed joints, and pleural and ascitic fluids. They accumulate in high concentrations in the kidney and inner ear. They are poorly distributed to the central nervous system, intraocular fluids, and respiratory tract secretions. Injected drugs are not metabolized; they are excreted unchanged in the urine, primarily by glomerular filtration. Oral drugs are excreted in feces.

**Drugs at a Glance: Fluoroquinolones**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cinoxacin (Cinobac)</td>
<td>1. Used only for UTI&lt;br&gt;2. Effective against most gram-negative bacteria that commonly cause UTI (<em>Escherichia coli</em>, <em>Klebsiella</em>, <em>Enterobacter</em>, <em>Proteus</em>)</td>
<td><strong>Adults</strong>&lt;br&gt;PO 1 g daily in two to four divided doses for 7–14 d</td>
</tr>
<tr>
<td>Ciprofloxacin (Cipro)</td>
<td>1. Effective in respiratory, urinary tract, gastrointestinal tract, and skin and soft tissue infections as well as sexually transmitted diseases caused by chlamydiae and gonorrhea organisms&lt;br&gt;2. Used as one of four to six drugs in treatment of multidrug-resistant tuberculosis</td>
<td><strong>Adults</strong>&lt;br&gt;PO 250–750 mg q12h&lt;br&gt;IV 200–400 mg q8–12h</td>
</tr>
<tr>
<td>Enoxacin (Penetrex)</td>
<td>Used only for UTI and uncomplicated gonorrhea</td>
<td><strong>Adults</strong>&lt;br&gt;UTI, PO 200–400 mg q12h for 7–14 d&lt;br&gt;Gonorrhea, PO 400 mg as a single dose</td>
</tr>
<tr>
<td>Gatifloxacin (Tequin)</td>
<td>Indicated for pneumonia, bronchitis, sinusitis, skin and soft tissue infections, urinary infections, pyelonephritis, and gonorrhea</td>
<td><strong>Adults</strong>&lt;br&gt;PO, IV 250–750 mg once daily. Infuse IV dose slowly over 60 min</td>
</tr>
<tr>
<td>Levofloxacin (Levaquin)</td>
<td>A broad-spectrum agent effective for treatment of bronchitis, cystitis, pneumonia, sinusitis, skin and skin structure infections, and pyelonephritis</td>
<td><strong>Adults</strong>&lt;br&gt;PO 400 mg once daily&lt;br&gt;Preoperatively, PO 400 mg as a single dose, 1–6 h before surgery</td>
</tr>
<tr>
<td>Lomefloxacin (Maxaquin)</td>
<td>Approved for bronchitis, urinary infections, and transurethral surgical procedures</td>
<td><strong>Adults</strong>&lt;br&gt;PO 400 mg twice daily&lt;br&gt;PO, IV 200–400 mg q12h for 3–10 d&lt;br&gt;Gonorrhea, PO 400 mg as a single dose&lt;br&gt;PO 400 mg as loading dose, then 200 mg once daily for 10 d&lt;br&gt;Renal impairment (creatinine clearance &lt;50 mL/min), PO 400 mg as loading dose, then 200 mg q48h for a total of 9 d of therapy</td>
</tr>
<tr>
<td>Moxifloxacin (Avelox)</td>
<td>Indicated for pneumonia, sinusitis, bronchitis, skin and soft tissue infections</td>
<td><strong>Adults</strong>&lt;br&gt;PO, IV 400 mg once daily. Infuse IV dose slowly over 60 min</td>
</tr>
<tr>
<td>Norfloxacin (Noroxin)</td>
<td>Used only for UTI and uncomplicated gonorrhea</td>
<td><strong>Adults</strong>&lt;br&gt;PO 400 mg twice daily&lt;br&gt;PO, IV 200–400 mg q12h for 3–10 d&lt;br&gt;Gonorrhea, PO 400 mg as a single dose</td>
</tr>
<tr>
<td>Ofloxacin (Floxin)</td>
<td>See ciprofloxacin, above</td>
<td><strong>Adults</strong>&lt;br&gt;PO 400 mg as loading dose, then 200 mg once daily for 10 d</td>
</tr>
<tr>
<td>Sparfloxacin (Zagam)</td>
<td>Indicated for community-acquired pneumonia caused by <em>Chlamydia pneumoniae</em>, <em>Streptococcus pneumoniae</em>, <em>Actinobacillus pleuropneumoniae</em>, or <em>pneumoniae</em>, and acute bacterial exacerbations of chronic bronchitis caused by above organisms, <em>Klebsiella pneumoniae</em>, or <em>Staphylococcus aureus</em></td>
<td><strong>Adults</strong>&lt;br&gt;PO 400 mg once daily&lt;br&gt;Preoperatively, PO 400 mg as a single dose, 1–6 h before surgery</td>
</tr>
</tbody>
</table>
Mechanism of Action

Aminoglycosides penetrate the cell walls of susceptible bacteria and bind irreversibly to 30S ribosomes, intracellular structures that synthesize proteins. As a result, the bacteria cannot synthesize the proteins necessary for their function and replication.

Indications for Use

The major clinical use of parenteral aminoglycosides is to treat serious systemic infections caused by susceptible aerobic gram-negative organisms. Many hospital-acquired infections are caused by gram-negative organisms. These infections have become more common with control of other types of infections, widespread use of antimicrobial drugs, and diseases (eg, acquired immunodeficiency syndrome [AIDS]) or treatments (eg, radical surgery and therapy with antineoplastic or immunosuppressive drugs) that lower host resistance. Although they can occur anywhere, infections due to gram-negative organisms commonly involve the respiratory and genitourinary tracts, skin, wounds, bowel, and bloodstream. Any infection with gram-negative organisms may be serious and potentially life threatening. Management is difficult because the organisms are in general less susceptible to antibacterial drugs, and drug-resistant strains develop rapidly. In pseudomonal infections, an aminoglycoside is often given concurrently with an antipseudomonal penicillin (eg, piperacillin) for synergistic therapeutic effects. The penicillin-induced breakdown of the bacterial cell wall makes it easier for the aminoglycoside to reach its site of action inside the bacterial cell. However, the drugs are chemically and physically incompatible. Therefore, they should not be mixed in a syringe or an IV fluid because the aminoglycoside will be deactivated.

A second clinical use is for treatment of tuberculosis. Streptomycin was often used before the development of isoniazid and rifampin. Now, it may be used for treatment of tuberculosis resistant to other antituberculdrugs. Multidrug-resistant strains of the tuberculosis organism, including strains resistant to both isoniazid and rifampin, are being identified with increasing frequency. This development is leading some authorities to recommend an aminoglycoside as part of a four- to six-drug regimen.

A third clinical use is for synergistic action when combined with ampicillin, penicillin G, or vancomycin in the treatment of enterococcal infections. Regimens for enterococcal infections, particularly meningitis or endocarditis, should include gentamicin in divided doses rather than once-daily dosing. Some enterococcal strains are resistant to gentamicin, however, and microbiology results should be reviewed for each patient.

A final clinical use is oral administration to suppress intestinal bacteria. Neomycin and kanamycin may be given before bowel surgery and to treat hepatic coma. In hepatic coma, intestinal bacteria produce ammonia, which enters the bloodstream and causes encephalopathy. Drug therapy to suppress intestinal bacteria decreases ammonia production. Paromomycin is used mainly in the treatment of intestinal amebiasis.

Contraindications to Use

Aminoglycosides are contraindicated in infections for which less toxic drugs are effective. The drugs are nephrotoxic and ototoxic and must be used very cautiously in the presence of renal impairment. Dosages are adjusted according to serum drug levels and creatinine clearance. The drugs must also be used cautiously in clients with myasthenia gravis and other neuromuscular disorders because muscle weakness may be increased.

FLUOROQUINOLONES

Fluoroquinolones are synthetic bactericidal drugs with activity against gram-negative and gram-positive organisms. They may allow oral ambulatory treatment of infections that previously required parenteral therapy and hospitalization. Most are given orally, after which they are well absorbed, achieve therapeutic concentrations in most body fluids, and are metabolized to some extent in the liver. The kidneys are the main route of elimination, with approximately 30% to 60% of an oral dose excreted unchanged in the urine. Dosage should be reduced in renal impairment.

Mechanism of Action

The drugs act by interfering with deoxyribonucleic acid (DNA) gyrase, an enzyme required for synthesis of bacterial DNA and therefore required for bacterial growth and replication.

Indications for Use

Fluoroquinolones are indicated for various infections caused by aerobic gram-negative and other microorganisms. Thus, they may be used to treat infections of the respiratory, genitourinary, and GI tracts as well as infections of bones, joints, skin, and soft tissues. Additional uses include treatment of gonorrhea, multidrug-resistant tuberculosis (see Chap. 38), Mycobacterium avium complex (MAC) infections in clients with AIDS, and fever in neutropenic cancer clients. Indications vary with individual drugs and are listed in Drugs at a Glance: Fluoroquinolones.

Contraindications to Use

Fluoroquinolones are contraindicated in clients who have experienced a hypersensitivity reaction and in children younger than 18 years of age, if other alternatives are available. Lim-
ated data are available on the safety of fluoroquinolones in pregnant or lactating women; they should not be used unless the benefits outweigh the potential risks.

**PRINCIPLES OF THERAPY**

### Choice of Drug

The choice of aminoglycoside depends on local susceptibility patterns and specific organisms causing an infection. Gentamicin is often given for systemic infections if resistant microorganisms have not developed in the clinical setting. If gentamicin-resistant organisms have developed, amikacin or tobramycin may be given because they are usually less susceptible to drug-destroying enzymes. In terms of toxicity, the aminoglycosides cause similar effects.

The choice of fluoroquinolone is also determined by local susceptibility patterns and specific organisms because individual drugs differ somewhat in their antimicrobial spectra. The drugs cause similar adverse effects.

### Dosage of Aminoglycosides

Dosage of aminoglycosides must be carefully regulated because therapeutic doses are close to toxic doses. Two major dosing schedules are used, one involving multiple daily doses and one involving a single daily dose. The multiple-dose regimen has been used traditionally and guidelines are well defined. The single-dose regimen is being used increasingly, and guidelines are still evolving as studies and clinical experience accumulate. These two regimens are described in the following sections.

#### Multiple Daily Dosing

1. **An initial loading dose**, based on client weight and the desired peak serum concentration, is given to achieve therapeutic serum concentrations rapidly. If the client is obese, lean or ideal body weight should be used because aminoglycosides are not significantly distributed in body fat. In clients with normal renal function, the recommended loading dose for gentamicin, tobramycin, and netilmicin is 1.5 to 2 mg/kg of body weight; for amikacin the loading dose is 5 to 7.5 mg/kg.

2. **Maintenance doses** are based on serum drug concentrations. Peak serum concentrations should be assessed 30 to 60 minutes after drug administration (5 to 8 mcg/mL for gentamicin and tobramycin, 20 to 30 mcg/mL for amikacin, 4 to 12 mcg/mL for netilmicin). Measurement of both peak and trough levels helps to maintain therapeutic serum levels without excessive toxicity. For gentamicin and tobramycin, peak levels above 10 to 12 mcg/mL and trough levels above 2 mcg/mL for prolonged periods have been associated with nephrotoxicity. For accuracy, blood samples must be drawn at the correct times and the timing of drug administration and blood sampling must be accurately documented.

3. **With impaired renal function**, dosage of aminoglycosides must be reduced. Methods of adjusting dosage include lengthening the time between doses or reducing doses. References should be consulted for specific

---

**Nursing Process**

General aspects of the nursing process as described in Chapter 33 apply to the client receiving aminoglycosides and fluoroquinolones. In this chapter, only those aspects related specifically to these drugs are included.

### Assessment

With aminoglycosides, assess for the presence of factors that predispose to nephrotoxicity or ototoxicity:

- Check laboratory reports of renal function (e.g., serum creatinine, creatinine clearance, blood urea nitrogen [BUN]) for abnormal values.
- Assess for impairment of balance or hearing, including audiometry reports if available.
- Analyze current medications for drugs that interact with aminoglycosides to increase risks of nephrotoxicity or ototoxicity.

With fluoroquinolones, assess for the presence of factors that increase risks of adverse drug effects (e.g., impaired renal function, inadequate fluid intake, frequent or prolonged exposure to sunlight in usual activities of daily living):

- Assess laboratory tests (e.g., complete blood counts and tests of renal and hepatic function) for abnormal values.

### Planning/Goals

The client will:

- Receive aminoglycoside dosages that are individualized by age, weight, renal function, and serum drug levels
- Have serum aminoglycoside levels monitored when indicated
- Have renal function tests performed regularly during aminoglycoside and fluoroquinolone therapy
- Be well hydrated during aminoglycoside and fluoroquinolone therapy
- Be observed regularly for adverse drug effects

### Interventions

- With aminoglycosides, weigh clients accurately (dosage is based on weight), monitor laboratory reports of BUN, serum creatinine, serum drug levels, and urinalysis for abnormal values.
- Force fluids to at least 2000 to 3000 mL daily if not contraindicated. Keeping the client well hydrated reduces risks of nephrotoxicity with aminoglycosides and crystalluria with fluoroquinolones.
- Avoid concurrent use of other nephrotoxic drugs when possible.

### Evaluation

- Interview and observe for improvement in the infection being treated.
- Interview and observe for adverse drug effects.
SECTION 6 DRUGS USED TO TREAT INFECTIONS

SECTION 6 DRUGS USED TO TREAT INFECTIONS

recommends on adjusting aminoglycoside doses for renal impairment.

4. In urinary tract infections, smaller doses can be used than in systemic infections because the aminoglycosides reach high concentrations in the urine.

Single Daily Dosing

The use of once-daily (or extended interval) aminoglycoside dosing is increasing. This dosing method uses high doses (eg, gentamicin, 7 mg/kg) to produce high initial drug concentrations, but a repeat dose is not administered until the serum concentration is quite low. Most clients can be successfully managed with one daily dose using this approach. However, certain populations require more than one daily dose, but still require fewer daily doses than are necessary in multiple dosing strategies (thus extended interval).

This practice evolved from increased knowledge about the concentration-dependent bactericidal effects and postantibiotic effects of aminoglycosides. Concentration-dependent bactericidal effects mean that the drugs kill more microorganisms with a large dose and high peak serum concentrations. Postantibiotic effects mean that aminoglycosides continue killing microorganisms even with low serum concentrations. These characteristics allow administration of high doses to achieve high peak serum concentrations and optimal killing of microorganisms. The longer interval until the next dose allows the client to eliminate the drug to very low serum concentrations for approximately 6 hours. During this low-drug period, the postantibiotic effect is active while there is minimal drug accumulation in body tissues. Reported advantages of this regimen include increased bactericidal effects, less nephrotoxicity, reduced need for serum drug concentration data, and reduced nursing time for administration.

Dosage of Fluoroquinolones

Recommended dosages of fluoroquinolones should not be exceeded in any clients, and dosages should be reduced in the presence of renal impairment.

Guidelines for Reducing Toxicity of Aminoglycosides

In addition to the preceding recommendations, guidelines to decrease the incidence and severity of adverse effects include the following:

1. Identify clients at high risk for adverse effects (eg, neonates, older adults, clients with renal impairment, clients with disease processes or drug therapies that impair blood circulation and renal function).

2. Keep clients well hydrated to decrease drug concentration in serum and body tissues. The drugs reach higher

3. Avoid exposure to sunlight during and for several days after taking one of these drugs. Stop taking the drug and notify the prescribing physician if skin burning, redness, swelling, rash, or itching occurs. Sunscreen lotions do not prevent photosensitivity reactions.

4. Be very careful if driving or doing other tasks requiring alertness or physical coordination. These drugs may cause dizziness or lightheadedness.

5. Drink 2 to 3 quarts of fluid daily if able. This helps to prevent kidney problems.

6. Do not take antacids containing magnesium or aluminum (eg, Mylanta or Maalox) or any products containing iron or zinc at the same time, within 4 hours before, or within 2 hours after a dose of the antibiotic.

Nursing Notes: Apply Your Knowledge

William Howles, 82 years of age, has been receiving gentamicin for the last 3 days to treat a serious wound infection. Peak and trough blood levels have been drawn and you receive the following results: peak 7 mcg/mL and trough 4 mcg/mL (normal: peak 5 to 8 mcg/mL and trough < 2 mcg/mL). How will you interpret these results, and what, if any, action will you take?

How Can You Avoid This Medication Error?

You try to call Mr. Howles’ physician with the abnormal laboratory results. The gentamicin peak level is normal but the trough level is high (4 mcg/mL rather than less than 2 mcg/mL) and both his blood urea nitrogen and creatinine are elevated. It is now time to give the next dose of gentamicin. You decide to give one half the ordered dose because his trough level was twice the normal value.
concentrations in the kidneys and inner ears than in other body tissues. This is a major factor in nephrotoxicity and ototoxicity. The goal of an adequate fluid intake is to decrease the incidence and severity of these adverse effects.

3. Use caution with concurrent administration of diuretics. Diuretics may increase the risk of nephrotoxicity by decreasing fluid volume, thereby increasing drug concentration in serum and tissues. Dehydration is most likely to occur with loop diuretics such as furosemide.

4. Give the drug for no longer than 10 days unless necessary for treatment of certain infections. Clients are most at risk when high doses are given for prolonged periods.

5. Detect adverse effects early and reduce dosage or discontinue the drug. Changes in renal function tests that indicate nephrotoxicity may not occur until the client has received an aminoglycoside for several days. If nephrotoxicity occurs, it is usually reversible if the drug is stopped. Early ototoxicity is detectable only with audiometry and is generally not reversible.

**Use in Children**

Aminoglycosides must be used cautiously in children as with adults. Dosage must be accurately calculated according to weight and renal function. Serum drug concentrations must be monitored and dosage adjusted as indicated to avoid toxicity. Neonates may have increased risk of nephrotoxicity and ototoxicity because of their immature renal function. Neomycin is not recommended for use in infants and children. Fluoroquinolones are not recommended for use in children if other alternatives are available because they have been associated with permanent damage in cartilage and joints in some animal studies.

**Use in Older Adults**

With aminoglycosides, advanced age is considered a major risk factor for development of toxicity. Because of impaired renal function, other disease processes (eg, diabetes), and multiple-drug therapy, older adults are at high risk for development of aminoglycoside-induced nephrotoxicity and ototoxicity. However, the drugs are commonly used in older adults for infections caused by organisms resistant to other antibacterials. Aminoglycosides should not be given to older adults with impaired renal function if less toxic drugs are effective against causative organisms. When the drugs are given, extreme caution is required. Interventions to decrease the incidence and severity of adverse drug effects are listed in the section on Guidelines for Reducing Toxicity of Aminoglycosides. These interventions are important with any client receiving an aminoglycoside, but are especially important with older adults. In addition, prolonged therapy (>1 week) increases risk of toxicity and should be avoided when possible.

Fluoroquinolones are commonly used in older adults for the same indications as in younger adults. In older adults with normal renal function, the drugs should be accompanied by an adequate fluid intake and urine output to prevent drug crystals from forming in the urinary tract. In addition, urinary alkalinizing agents, such as calcium-containing antacids, should be avoided because drug crystals form more readily in alkaline urine. In those with impaired renal function, a common condition in older adults, the drugs should be used cautiously and in reduced dosages.

**Use in Renal Impairment**

Aminoglycosides and fluoroquinolones are nephrotoxic and must be used very cautiously in clients with renal impairment. Both aminoglycosides and fluoroquinolones require dosage adjustments in renal impairment. Dosage guidelines have been established according to creatinine clearance and often involve lower dosages and prolonged intervals between doses (eg, 36 to 72 hours). Guidelines for reducing nephrotoxicity of aminoglycosides are as listed previously. With fluoroquinolones, reported renal effects include azotemia, crystalluria, hematuria, interstitial nephritis, nephropathy, and renal failure. Nephrotoxicity occurs less often than with aminoglycosides, and most cases of acute renal failure have occurred in older adults. It is unknown whether renal failure is caused by hypersensitivity or a direct toxic effect. Crystalluria rarely occurs in acidic urine but may occur in alkaline urine. Guidelines for reducing nephrotoxicity include lower dosages, longer intervals between doses, adequate hydration, and avoiding substances that alkalinize the urine.

**Use in Hepatic Impairment**

With aminoglycosides, hepatic impairment is not a significant factor because the drugs are excreted through the kidneys. With fluoroquinolones, however, hepatotoxicity has been observed with some of the drugs. Clinical manifestations range from abnormalities in liver enzyme test results to hepatitis, liver necrosis, or hepatic failure. Because of serious hepatotoxicity with trovafloxacin, the Food and Drug Administration issued a public health advisory to use the drug only for serious infections, give initial doses in an inpatient setting, administer no longer than 14 days, and discontinue the drug if liver dysfunction occurs.

**Use in Critical Illness**

Aminoglycosides and fluoroquinolones are often used in critically ill clients because this population has a high incidence of serious infections. Aminoglycosides are usually given with
other antimicrobials to provide broad-spectrum activity. In critical care units, as in other settings, there is increased use of once-daily dosing. Because critically ill clients are at high risk for development of nephrotoxicity and ototoxicity with aminoglycosides, guidelines for safe drug usage should be strictly followed.

Because fluoroquinolones may be nephrotoxic and hepatotoxic, renal and hepatic function should be monitored during therapy. Fluoroquinolones are usually infused IV in critically ill clients. However, administration orally or by GI tube (eg, nasogastric, gastrostomy, or jejunostomy) may be feasible in some clients. Concomitant administration of antacids or enteral feedings decreases absorption.

**Home Care**

Parenteral aminoglycosides are usually given in a hospital setting. Oral fluoroquinolones are often self-administered at home. The role of the home care nurse is primarily to teach clients or caregivers how to take the drugs effectively and to observe for adverse drug effects.

---

### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Aminoglycosides and Fluoroquinolones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With aminoglycosides:</td>
<td></td>
</tr>
<tr>
<td>(1) For intravenous (IV) administration, dilute the drug in 50 to 100 mL of 5% dextrose or 0.9% sodium chloride injection and infuse over 30 to 60 min. The concentration of gentamicin solution should not exceed 1 mg/mL.</td>
<td>To achieve therapeutic blood levels</td>
</tr>
<tr>
<td>(2) Give intramuscular aminoglycosides in a large muscle mass, and rotate sites.</td>
<td>To avoid local tissue irritation. This is less likely to occur with aminoglycosides than with most other antibiotics.</td>
</tr>
<tr>
<td>b. With fluoroquinolones:</td>
<td></td>
</tr>
<tr>
<td>(1) Give norfloxacin and enoxacin 1 h before or 2 h after a meal. Do not give ofloxacin with food. Ciprofloxacin, lomefloxacin, and sparfloxacin may be given without regard to food intake.</td>
<td>To promote therapeutic plasma drug levels. Food in the gastrointestinal (GI) tract interferes with absorption of most oral fluoroquinolones.</td>
</tr>
<tr>
<td>(2) Give IV infusions over 60 min.</td>
<td>To decrease vein irritation and phlebitis</td>
</tr>
<tr>
<td>(3) When giving ciprofloxacin IV into a primary IV line (eg, using piggyback or Y connector), stop the primary solution until ciprofloxacin is infused.</td>
<td>To avoid physical or chemical incompatibilities</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td>See Chapter 33</td>
</tr>
<tr>
<td>a. Decreased signs and symptoms of the infection for which the drug is being given</td>
<td>Adverse effects are more likely to occur with parenteral administration of large doses for prolonged periods. However, they may occur with oral administration in the presence of renal impairment and with usual therapeutic doses.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td>Renal damage is most likely to occur in clients who are elderly, receive high doses or prolonged therapy, have prior renal damage, or receive other nephrotoxic drugs. This is the most serious adverse reaction. Risks of kidney damage can be minimized by using the drugs appropriately, detecting early signs of renal impairment, and keeping clients well hydrated.</td>
</tr>
<tr>
<td>a. With aminoglycosides, observe for:</td>
<td>This results from damage to the eighth cranial nerve. Incidence of ototoxicity is increased in older clients and those with previous auditory damage, high doses or prolonged duration, and concurrent use of other ototoxic drugs.</td>
</tr>
<tr>
<td>(1) Nephrotoxicity—casts, albumin, red or white blood cells in urine, decreased creatinine clearance, increased serum creatinine, increased blood urea nitrogen.</td>
<td></td>
</tr>
<tr>
<td>(2) Ototoxicity—deafness or decreased hearing, tinnitus, dizziness, ataxia</td>
<td></td>
</tr>
</tbody>
</table>

*(continued)*
### NURSING ACTIONS

| (3) Neurotoxicity—respiratory paralysis and apnea |
| (4) Hypersensitivity—skin rash, urticaria |
| (5) Nausea, vomiting, diarrhea, peripheral neuritis, paresthesias |

**b. With fluoroquinolones, observe for:**

| (1) Hepatotoxicity (abnormal liver enzyme tests, hepatitis, hepatic failure) |
| (2) Allergic reactions (anaphylaxis, urticaria) |
| (3) Nausea, vomiting, diarrhea, pseudomembranous colitis |
| (4) Headache, dizziness |
| (5) Crystalluria |
| (6) Photosensitivity (skin redness, rash, itching) |
| (7) Other |

### RATIONALE/EXPLANATION

- **This is caused by neuromuscular blockade and is more likely to occur after rapid IV injection, administration to a client with myasthenia gravis, or concomitant administration of general anesthetics or neuromuscular blocking agents (eg, succinylcholine, tubocurarine). This effect also may occur if an aminoglycoside is administered shortly after surgery, owing to the residual effects of anesthetics or neuromuscular blockers. Neostigmine or calcium may be given to counteract apnea.**

- **This is an uncommon reaction except with topical neomycin, which may cause sensitization in as many as 10% of recipients.**

- **Uncommon with parenteral aminoglycosides. Diarrhea often occurs with oral administration.**

- **Hepatotoxicity has been observed with most of the drugs.**

- **Trovafloxacin use is restricted because of liver damage and failure.**

- **Uncommon, but some fatalities have been reported.**

- **Nausea is the most common GI symptom.**

- **Uncommon, but may occur with an inadequate fluid intake.**

- **May occur with most fluoroquinolones with exposure to sunlight.**

- **Adverse effects involving most body systems have been reported with one or more of the fluoroquinolones. Most have a low incidence (<1%) of occurrence.**

- **The listed drugs increase toxicity.**

- **These drugs are nephrotoxic alone and may increase nephrotoxicity of aminoglycosides.**

- **Increased ototoxicity.**

- **Increased neuromuscular blockade with possible paralysis of respiratory muscles and apnea.**

- **Cimetidine inhibits hepatic metabolism and probenecid inhibits renal excretion of fluoroquinolones. These actions may increase serum drug levels.**

- **These drugs interfere with absorption of fluoroquinolones from the GI tract.**

- **These drugs may decrease serum levels of fluoroquinolones.**

- **These drugs should not be taken together or within 1 h of each other.**

### 4. Observe for drug interactions

**a. Drugs that increase effects of aminoglycosides:**

- (1) Amphotericin B, cephalosporins, cisplatin, cyclosporine, enflurane, vancomycin
- (2) Loop diuretics (furosemide, bumetanide)
- (3) Neuromuscular blocking agents (eg, pancuronium, vecuronium)

**b. Drugs that increase effects of fluoroquinolones:**

- Cimetidine, probenecid

**c. Drugs that decrease effects of fluoroquinolones:**

- (1) Antacids, iron preparations, sucralfate, zinc preparations
- (2) Antineoplastic drugs
- (3) Bismuth subsalicylate (eg, Pepto-Bismol) decreases enoxacin absorption if given with or within 1 h after enoxacin.
- (4) Nitrofurantoin may decrease the antibacterial effect of norfloxacin in the urinary tract
**Nursing Notes: Apply Your Knowledge**

**Answer:** Peak and trough gentamicin levels are obtained to assess whether the proper dosage is being administered and to avoid toxicity that can cause permanent damage to renal function and hearing. Peak (highest) blood levels should be drawn 30 to 60 minutes after administering the drug and trough (lowest) blood level should be drawn just before the dose is administered. The laboratory results indicate that the peak level is normal but the trough level is high (4 mcg/mL rather than less than 2 mcg/mL). Dosage will need to be decreased to avoid renal damage. Considering Mr. Howles’ age, he may have some renal impairment already that has decreased the rate of gentamicin excretion. Check to see if Mr. Howles’ creatinine and blood urea nitrogen levels are elevated, which would indicate renal insufficiency. Notify the physician of the test result so that the gentamicin dose can be adjusted.

**How Can You Avoid This Medication Error?**

**Answer:** A nurse may change the dose of a medication only if she has prescriptive authority (eg, ARNP). This is not indicated in this situation. Your concerns are valid regarding aminoglycoside toxicity for this patient. It would be prudent to place another call to the physician and hold the gentamicin until you hear from her or him.

**Review and Application Exercises**

1. Why must aminoglycosides be given parenterally for systemic infections?
2. How are aminoglycosides excreted?
3. What are risk factors for aminoglycoside-induced nephrotoxicity and ototoxicity?
4. How would you assess a client for nephrotoxicity or ototoxicity?
5. What is the reason for giving an aminoglycoside and an antipseudomonal penicillin in the treatment of serious infections caused by *Pseudomonas aeruginosa*?
6. Why should an aminoglycoside and an antipseudomonal penicillin *not* be combined in a syringe or IV fluid for administration?
7. Which laboratory tests need to be monitored regularly for a client receiving a systemic aminoglycoside?
8. What is the rationale for giving an oral aminoglycoside to treat hepatic coma?
9. What are the main clinical uses of fluoroquinolones?
10. What are adverse effects of fluoroquinolones, and how may they be prevented or minimized?
11. Why is it important to maintain an adequate fluid intake and urine output with the fluoroquinolones?
12. Why are fluoroquinolones not preferred drugs for children?

**SELECTED REFERENCES**


chapter 36

Tetracyclines, Sulfonamides, and Urinary Agents

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss major characteristics and clinical uses of tetracyclines.
2. Recognize doxycycline as the tetracycline of choice for use in clients with renal failure.
3. Discuss characteristics, clinical uses, adverse effects, and nursing implications of selected sulfonamides.
4. Recognize trimethoprim-sulfamethoxazole as a combination drug that is commonly used for urinary tract and systemic infections.
6. Teach clients strategies for preventing, recognizing, and treating urinary tract infections.

Critical Thinking Scenario

Faye Sullivan, 15 years of age, comes to the walk-in clinic with symptoms of urgency, frequency, and dysuria. A routine urinalysis indicates the presence of infection. The urinary tract infection (UTI) is treated with Bactrim for 10 days.

Reflect on:

- Factors that increase the incidence of UTI for adolescent girls.
- Important information to include when teaching Faye about Bactrim therapy.
- Strategies to prevent future UTIs.
- Data to collect to determine if Faye's UTI is responding to treatment.

OVERVIEW

Tetracyclines and sulfonamides are older, broad-spectrum, bacteriostatic drugs that are rarely used for systemic infections because of microbial resistance and the development of more effective or less toxic drugs. However, the drugs are useful in selected infections. Urinary antiseptics are used only in urinary tract infections (UTI). These drugs are described later in this chapter and listed in the Drugs at a Glance tables.

The tetracyclines are similar in pharmacologic properties and antimicrobial activity. They are effective against a wide range of gram-positive and gram-negative organisms, although they are usually not drugs of choice. Bacterial infections caused by Brucella and Vibrio cholerae are still treated by tetracyclines. The drugs also remain effective against rickettsiae, chlamydia, mycoplasma, some protozoa, spirochetes, and others. They are widely distributed into most body tissues and fluids. The older tetracyclines are excreted mainly in urine; doxycycline is eliminated in urine and feces, and minocycline is eliminated mainly by the liver.

Sulfonamides are bacteriostatic against a wide range of gram-positive and gram-negative bacteria, although increasing resistance is making them less useful. Susceptibility should be documented, but sulfonamides may be active against Streptococcus pyogenes, some staphylococcal strains, Haemophilus influenzae, Nocardia, Chlamydia trachomatis, and toxoplasmosis. The combination of trimethoprim-sulfamethoxazole is useful in UTIs due to Enterobacteriaceae, bronchitis, and Pneumocystis carinii infection (in high doses). Individual drugs vary in extent of systemic absorption and clinical indications. Some are well absorbed and can be used in systemic infections; others are poorly absorbed and exert more local effects.
Urinary antiseptics may be bactericidal for sensitive organisms in the urinary tract because they are concentrated in renal tubules and reach high levels in urine. They are not used in systemic infections because they do not attain therapeutic plasma levels. An additional drug, phenazopyridine, is given to relieve pain associated with UTI. It has no antibacterial activity.

### Mechanisms of Action

Tetracyclines penetrate microbial cells by passive diffusion and an active transport system. Intracellularly, they bind to 30S ribosomes, like the aminoglycosides, and inhibit microbial protein synthesis. Sulfonamides act as antimetabolites of para-aminobenzoic acid (PABA), which microorganisms require to produce folic acid; folic acid, in turn, is required for the production of bacterial intracellular proteins. Sulfonamides enter into the reaction instead of PABA, compete for the enzyme involved, and cause formation of nonfunctional derivatives of folic acid. Thus, sulfonamides halt multiplication of new bacteria but do not kill mature, fully formed bacteria. With the exception of the topical sulfonamides used in burn therapy, the presence of pus, serum, or necrotic tissue interferes with sulfonamide action because these materials contain PABA. Some bacteria can change their metabolic pathways to use precursors or other forms of folic acid and thereby develop resistance to the antibacterial action of sulfonamides. Once resistance to one sulfonamide develops, cross-resistance to others is common.

### Indications for Use

A tetracycline is the drug of choice or alternate (sometimes as part of combination therapy) in a few infections (eg, brucellosis, chancroid, cholera, granuloma inguinale, psittacosis, Rocky Mountain spotted fever, syphilis, trachoma, typhus, gastroenteritis due to *Vibrio cholerae* or *Helicobacter pylori*). They are also useful in some animal bites and Lyme disease. Other drugs (eg, penicillins) are usually preferred in gram-positive infections, and most gram-negative organisms are resistant to tetracyclines. However, a tetracycline may be used if bacterial susceptibility is confirmed. Specific clinical indications for tetracyclines include:

1. Treatment of uncomplicated urethral, endocervical, or rectal infections caused by *Chlamydia* organisms.
### Drugs at a Glance: Sulfonamide Preparations

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Single Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Sulfadiazine       | 1. A short-acting, rapidly absorbed, rapidly excreted agent for systemic infections  
2. The addition of folinic acid may be recommended | Nocardiosis  
Toxoplasmosis | PO 2–8 gm daily | >2 mo: PO 75 mg/kg initially, then 150 mg/kg/d in four to six divided doses; maximal daily dose, 6 g |
|                    |                | Urinary tract infections | PO 500 mg–1 g three or four times daily | >2 mo: PO 30–45 mg/kg/d in 4 divided doses |
| Sulfamethizole (Thiosulfil) | A highly soluble, rapidly absorbed, and rapidly excreted agent that is similar to sulfisoxazole in actions and uses | Systemic infections  
Urinary tract infections | PO 2 g initially, then 1–2 g two or three times daily | >2 mo: PO 50–60 mg/kg initially, then 30 mg/kg q12h; maximal daily dose, 75 mg/kg |
| Sulfamethoxazole (Gantanol) | 1. Similar to sulfisoxazole in therapeutic effects but absorbed and excreted more slowly. More likely to produce excessive blood levels and crystalluria than sulfisoxazole.  
2. An ingredient in mixtures with trimethoprim (see Combination Agent, below) | Ulcerative colitis  
Rheumatoid arthritis | Ulcerative colitis, PO 3–4 g daily in divided doses initially; 2 g daily in four doses for maintenance; maximal daily dose, 8 g  
Rheumatoid arthritis, PO 2 g daily in divided doses | PO 40–60 mg/kg/d in three to six divided doses initially, followed by 30 mg/kg/d in four divided doses |
| Sulfapyridine | 1. Poorly absorbed  
2. Does not alter normal bacterial flora in the intestine. Effectiveness in ulcerative colitis may be due to antibacterial (sulfapyridine) and anti-inflammatory (aminosalicylic acid) metabolites. | Urinary tract infections  
Vaginitis  
Ocular infections | PO 2–4 g initially, then 4–8 g daily in four to six divided doses  
Intravaginally: 2.5–5 g of vaginal cream (10%) twice daily | >2 mo: PO 75 mg/kg of body weight initially, then 150 mg/kg/d in four to six divided doses; maximal daily dose, 6 g |
| Sulfisoxazole | 1. Rapidly absorbed, rapidly excreted:  
2. Highly soluble and less likely to cause crystalluria than most other sulfonamides | Acute and chronic urinary tract infections  
Acute exacerbations of chronic bronchitis  
Acute otitis media caused by susceptible strains of Hemophilus influenzae and S. pneumoniae  
Shigellosis  
Infection by Pneumocystis carinii (prevention and treatment)  
Intravenous preparation indicated for P. carinii pneumonia, severe urinary tract infections, and shigellosis | Urinary tract infections, trimethoprim 160 mg and sulfamethoxazole 800 mg PO q12h for 10–14 d  
Shigellosis, same dose as above for 5 d  
Severe urinary tract infections, PO 8–10 mg (trimethoprim component) per kg/d in two to four divided doses, up to 14 d  
P. carinii pneumonia, IV 15–20 mg (trimethoprim component) per kg/d in three or four divided doses, q6–8h up to 14 d | Urinary tract infections, otitis media, and shigellosis, PO 8 mg/kg trimethoprim and 40 mg/kg sulfamethoxazole in two divided doses q12h for 10 d  
Severe urinary tract infections, IV 8–10 mg (trimethoprim component)/kg in two to four divided doses q6–8h or q12h up to 14 d  
P. carinii pneumonia, IV 15–20 mg (trimethoprim component) per kg/d in three or four divided doses, q6–8h up to 14 d |
| **Combination Agent** |                |                      |        |          |
| Trimeprin-sulfamethoxazole (Bactrim, Septra, others) | 1. May exhibit synergistic effectiveness against many organisms (verify susceptibility first), including streptococci (S. viridans); staphylococci (S. epidermidis, S. aureus); Escherichia coli; Salmonella; Shigella Serratia; Klebsiella; Nocardia; and others. Most strains of Pseudomonas are resistant.  
2. The two drugs have additive antibacterial effects because they interfere with different steps in bacterial synthesis and activation of folic acid, an essential nutrient. | Acute and chronic urinary tract infections  
Acute exacerbations of chronic bronchitis  
Acute otitis media caused by susceptible strains of Hemophilus influenzae and S. pneumoniae  
Infection by Pneumocystis carinii (prevention and treatment)  
Severe urinary tract infections, and shigellosis | | |
### Drugs at a Glance: Sulfonamide Preparations (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mafenide (Sulfamylon)</td>
<td>1. Effective against most gram-negative and gram-positive organisms, especially <em>Pseudomonas</em>&lt;br&gt;2. Application causes pain and burning.&lt;br&gt;3. Mafenide is absorbed systemically and may produce metabolic acidosis.</td>
<td>Prevention of bacterial colonization and infection of severe burn wounds&lt;br&gt;Topical application to burned area, once or twice daily, in a thin layer&lt;br&gt;Same as mafenide. Usually the preferred drug.</td>
</tr>
<tr>
<td>Silver sulfadiazine (Silvadene)</td>
<td>1. Effective against most <em>Pseudomonas</em> species, the most common pathogen in severe burn sepsis, <em>E. coli, Klebsiella, Proteus,</em> staphylococci, and streptococci&lt;br&gt;2. Application is painless.&lt;br&gt;3. Does not cause electrolyte or acid–base imbalances&lt;br&gt;4. Significant amounts may be absorbed systemically with large burned areas and prolonged use.</td>
<td>Same as mafenide&lt;br&gt;Same as mafenide&lt;br&gt;Same as mafenide</td>
</tr>
</tbody>
</table>
## Drugs at a Glance: Miscellaneous Drugs for Urinary Tract Infections

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Fosfomycin** *(Monurol)* | 1. Broad-spectrum, long-acting agent  
2. Most common adverse effects are diarrhea and headache. | Adults: PO 3 g in a single dose, taken with or without food. Powder should be mixed with one-half cup of water and drunk immediately.  
Children: Dosage not established |
| **Methenamine mandelate** *(Mandelamine)* | 1. Antibacterial activity only at a urine pH <5.5. In acidic urine, the drug forms formaldehyde, which is the antibacterial component. Acidification of urine (eg, with ascorbic acid) is usually needed.  
2. Formaldehyde is active against several gram-positive and gram-negative organisms, including *Escherichia coli*. It is most useful for long-term suppression of bacteria in chronic, recurrent infections.  
3. It is not indicated in acute infections.  
4. Contraindicated in renal failure | Adults: PO 1 g four times daily  
Children: Age 6–12 y: PO 500 mg four times daily  
Age <6 y: PO 50 mg/kg/d, in 3 divided doses |
| **Methanamine-hippurate** *(Hiprex)* | See methenamine mandelate, above | |
| **Nalidixic acid** *(NegGram)* | 1. Prototype of quinolones  
2. Active against most gram-negative organisms that cause UTI, but rarely used because organisms develop resistance rapidly and other effective drugs are available. | Adults: PO 1 g twice daily  
Children: PO 500 mg–1 g twice daily |
| **Nitrofurantoin** *(Furadantin, Macrobid)* | 1. Antibacterial activity against *E. coli* and most other organisms that cause UTI.  
2. Used for short-term treatment of UTI or long-term suppression of bacteria in chronic, recurrent UTI.  
3. Bacterial resistance develops slowly and to a limited degree.  
4. Contraindicated in severe renal disease | Adults: PO 50–100 mg four times daily  
Prophylaxis of recurrent UTI in women, PO 50–100 mg at bedtime  
Children: PO 4 g daily in four divided doses for 1–2 wk, then 2 g/d if long-term treatment is required |
| **Phenazopyridine** *(Pyridium)* | 1. An azo dye that acts as a urinary tract analgesic and relieves symptoms of dysuria, burning, and frequency and urgency of urination, which occur with UTI.  
2. It has no anti-infective action.  
3. It turns urine orange-red, which may be mistaken for blood.  
4. It is contraindicated in renal insufficiency and severe hepatitis. | Adults: PO 200 mg three times daily after meals  
Children: 6–12 y: PO 12 mg/kg/d, in three divided doses |
| **Trimethoprim** *(Proloprim, Trimpex)* | 1. A folate antagonist drug with anti-bacterial effects  
2. Available as a single agent for treatment of UTI caused by susceptible strains of *E. coli*, and other gram-negative organisms  
3. Most often used in a fixed-dose combination with sulfamethoxazole (Bactrim, Septra)  
4. Contraindicated in clients with hypersensitivity to trimethoprim or megaloblastic anemia due to folate deficiency.  
5. Rash and pruritus are the most common adverse effects. Nausea, vomiting, thrombocytopenia, and leukopenia occasionally occur. | Adults: PO 100 mg q12h for 10 d |

*PO, oral; UTI, urinary tract infection.*
2. Adjunctive treatment, with other antimicrobials, in the treatment of pelvic inflammatory disease and sexually transmitted diseases.

3. Long-term treatment of acne. Tetracyclines interfere with the production of free fatty acids and decrease Corynebacterium in sebum. These actions decrease the inflammatory, pustular lesions associated with severe acne.

4. As a substitute for penicillin in penicillin-allergic clients. Tetracyclines may be effective in treating syphilis when penicillin cannot be given. They should not be substituted for penicillin in treating streptococcal pharyngitis because microbial resistance is common, and tetracyclines do not prevent rheumatic fever. In addition, they should not be substituted for penicillin in any serious staphylococcal infection because microbial resistance commonly occurs.

5. Doxycycline may be used to prevent traveler’s diarrhea due to enterotoxigenic strains of E. coli.

6. Demeclocycline may be used to inhibit antidiuretic hormone in the management of chronic inappropriate antidiuretic hormone secretion.

Sulfonamides are commonly used to treat UTI (eg, acute and chronic cystitis, asymptomatic bacteriuria) caused by E. coli and Proteus or Klebsiella organisms. In acute pyelonephritis, other agents are preferred. Additional uses include ulcerative colitis and uncommon infections such as chancroid, lymphogranuloma venereum, nocardiosis, toxoplasmosis, and trachoma. Topical sulfonamides are used in prevention of burn wound infections and in treatment of ocular, vaginal, and other soft tissue infections. For specific clinical indications of individual drugs, see Drugs at a Glance: Sulfonamide Preparations.

Urinary antiseptics are used only for UTI.

Contraindications to Use

Both tetracyclines and sulfonamides are contraindicated in clients with renal failure. Tetracyclines are also contraindicated in pregnant women and in children up to 8 years of age. In the fetus and young child, tetracyclines are deposited in bones and teeth along with calcium. If given during active mineralization of these tissues, tetracyclines can cause permanent brown coloring (mottling) of tooth enamel and can depress bone growth. With the exception of doxycycline, they should not be used in renal failure because accumulation may increase the likelihood of liver toxicity. Increased photosensitivity is a common side effect, and clients should be warned to take precautions against sunburn while on these drugs. Sulfonamides are also contraindicated in late pregnancy, lactation, children younger than 2 months of age (except for treatment of congenital toxoplasmosis), and people who have had hypersensitivity reactions to them or to chemically related drugs (eg, thiazide diuretics or antidiabetic sulfonlyureas). Sulfasalazine (Azulfidine) is contraindicated in people who are allergic to salicylates and people with intestinal or urinary tract obstruction.

Nursing Process

General aspects of the nursing process in antimicrobial drug therapy, as described in Chapter 33, apply to the client receiving tetracyclines, sulfonamides, and urinary antiseptics. In this chapter, only those aspects related specifically to these drugs are included.

Assessment

With tetracyclines, assess for conditions in which the drugs must be used cautiously or are contraindicated, such as impaired renal or hepatic function.

With sulfonamides, assess for signs and symptoms of disorders for which the drugs are used:

- For UTI, assess urinalysis reports for white blood cells and bacteria, urine culture reports for type of bacteria, and symptoms of dysuria, frequency, and urgency of urination.
- For burns, assess the size of the wound, amount and type of drainage, presence of edema, and amount of eschar.
- Ask clients specifically if they have ever taken a sulfonamide and, if so, whether they had an allergic reaction.

With urinary antiseptics, assess for signs and symptoms of UTI.

Nursing Diagnoses

- Risk for Injury: Hypersensitivity reaction, kidney, liver, or blood disorders with sulfonamides
- Deficient Knowledge: Correct administration and use of tetracyclines, sulfonamides, and urinary antiseptics

Planning/Goals

The client will:

- Receive or self-administer the drugs as directed
- Receive prompt and appropriate treatment if adverse effects occur

Interventions

- During tetracycline therapy for systemic infections, monitor laboratory tests of renal function for abnormal values.
- During sulfonamide therapy, encourage sufficient fluids to produce a urine output of at least 1200 to 1500 mL daily. A high fluid intake decreases the risk of crystalluria (precipitation of drug crystals in the urine).
- Avoid urinary catheterization when possible. If catheterization is necessary, use sterile technique. The urinary tract is normally sterile except for the lower third of the urethra. Introduction of any bacteria into the bladder may cause infection.
- A single catheterization may cause infection. With indwelling catheters, bacteria colonize the bladder and produce infection within 2 to 3 weeks, even with meticulous care.
- When indwelling catheters must be used, measures to decrease UTI include using a closed drainage system; keeping the perineal area clean; forcing fluids, if not con-
PRINCIPLES OF THERAPY

Tetracyclines

1. Culture and susceptibility studies are needed before tetracycline therapy is started because many strains of organisms are either resistant or vary greatly in drug susceptibility. Cross-sensitivity and cross-resistance are common among tetracyclines.

2. The oral route of administration is usually effective and preferred. Intravenous (IV) therapy is used when oral administration is contraindicated or for initial treatment of severe infections.

3. Tetracyclines decompose with age, exposure to light, and extreme heat and humidity. Because the breakdown products may be toxic, it is important to store these drugs correctly. Also, the manufacturer’s expiration dates on containers should be noted and outdated drugs should be discarded.

Sulfonamides and Urinary Antiseptics

1. With systemically absorbed sulfonamides, an initial loading dose may be given to produce therapeutic blood levels (12 to 15 mg/100 mL) more rapidly. The amount is usually twice the maintenance dose.

2. Urine pH is important in drug therapy with sulfonamides and urinary antiseptics.
   a. With sulfonamide therapy, alkaline urine increases drug solubility and helps prevent crystalluria. It also increases the rate of sulfonamide excretion and the concentration of sulfonamide in the urine. The urine can be alkalined by giving sodium bicarbonate. Alkalinization is not needed with sulfisoxazole (because the drug is highly soluble) or sulfonamides used to treat intestinal infections or burn wounds (because there is little systemic absorption).
   b. With mandelamine therapy, urine pH must be acidic (<5.5) for the drug to be effective. At a higher pH, mandelamine does not hydrolyze to formaldehyde, the antibacterial component. Urine can be acidified by concomitant administration of ascorbic acid.

3. Urine cultures and sensitivity tests are indicated in suspected UTI because of wide variability in possible pathogens and their susceptibility to antibacterial drugs. The best results are obtained with drug therapy indicated by the microorganisms isolated from each client.

Evaluation

1. Observe for improvement in signs of the infection for which drug therapy was given.
2. Interview and observe for adverse drug effects.

Use in Children

Tetracyclines should not be used in children younger than 8 years of age because of their effects on teeth and bones. In teeth, the drugs interfere with enamel development and may cause a permanent yellow, gray, or brown discoloration. In bone, the drugs form a stable compound in bone-forming tissue and may interfere with bone growth.

Systemic sulfonamides are contraindicated during late pregnancy, lactation, and in children younger than 2 months. If a fetus or young infant receives a sulfonamide by placental transfer, in breast milk, or by direct administration, the drug displaces bilirubin from binding sites on albumin. As a result, bilirubin may accumulate in the bloodstream (hyperbilirubinemia) and central nervous system (kernicterus) and cause life-threatening toxicity.

Sulfonamides are often used to treat UTI in children older than 2 months. Few data are available regarding the effects of long-term or recurrent use of sulfamethoxazole in children younger than 6 years of age with chronic renal disease. Sulfamethoxazole is often given in combination with trimethoprim (Bactrim, Septra), although trimethoprim has not been established as safe and effective in children younger than 12 years of age.

Some clinicians recommend that asymptomatic bacteriuria be treated in children younger than 5 years of age to decrease risks of long-term renal damage. Treatment is the same as for symptomatic UTI.

Use in Older Adults

A major concern with the use of tetracyclines and sulfonamides in older adults is renal impairment, which commonly...
clients with renal impairment. As with younger adults, a fluid intake of 2 L daily is needed to reduce formation of crystals and stones in the urinary tract.

With the combination of sulfamethoxazole and trimethoprim (Bactrim, Septra), older adults are at increased risk for severe adverse effects. Severe skin reactions and bone marrow depression are most often reported. Folic acid deficiency may also occur because both of the drugs interfere with folic acid metabolism.

### Use in Renal Impairment

As discussed previously, most tetracyclines are contraindicated in clients with renal impairment. High concentrations of tetracyclines inhibit protein synthesis in human cells. This antianabolic effect increases tissue breakdown (catabolism) and the amount of waste products to be excreted by the kidneys. The increased workload can be handled by normally functioning kidneys, but waste products are retained when renal function is impaired. This leads to azotemia, increased blood urea nitrogen, hyperphosphatemia, hyperkalemia, and acidosis. If a tetracycline is necessary because of an organism’s sensitivity or the host’s inability to take other antimicrobial drugs, doxycycline or minocycline may be given.

Systemic sulfonamides should probably be avoided in clients with renal impairment, if other effective drugs are available. Acute renal failure (ARF) has occurred when the drugs or their metabolites precipitated in renal tubules and caused obstruction. ARF is rarely associated with newer sulfonamides, which are more soluble than older ones, but has increased with the use of sulfadiazine to treat toxoplasmosis in clients with acquired immunodeficiency syndrome (AIDS). Preventive measures include a fluid intake of 2 to 3 L daily.

---

### CLIENT TEACHING GUIDELINES

#### Oral Sulfonamides

##### General Considerations

- Sulfonamides inhibit rather than kill bacteria. Thus, it is especially important to take them as prescribed, for the length of time prescribed.
- These drugs increase sensitivity to sunlight and risks of sunburn. Avoid sunlamps, tanning beds, and intense or prolonged exposure to sunlight; if unable to avoid exposure, wear protective clothing and a sunblock preparation.
- Notify the prescribing physician if you have blood in urine, skin rash, difficulty in breathing, fever, or sore throat. These symptoms may indicate adverse drug effects and the need to change or stop the drug.

##### Self-Administration

- Take oral sulfonamides on an empty stomach with at least 8 oz of water.
- With oral suspensions, shake well, refrigerate after opening, and discard the unused portion after 14 days.
- Drink 2 to 3 quarts of fluid daily, if able. A good fluid intake helps the drugs to be more effective, especially in urinary tract infections, and decreases the likelihood of damaging the kidneys.
Use in Hepatic Impairment

Tetracyclines are contraindicated in pregnant women because they may cause fatal hepatic necrosis in the mother. They must be used cautiously in the presence of liver or kidney impairment. Because tetracyclines are metabolized in the liver, hepatic impairment or biliary obstruction slows drug elimination. In clients with renal impairment, high IV doses (>2 g/day) have been associated with death from liver failure. If necessary in clients with known or suspected renal and hepatic impairment, renal and liver function test results should be monitored. In addition, serum tetracycline levels should not exceed 15 mcg/mL, and other hepatotoxic drugs should be avoided.

Sulfonamides cause cholestatic jaundice in a small percentage of clients and should be used with caution in clients with hepatic impairment.

Use in Critical Illness

Tetracyclines may be used to treat sepsis caused by rickettsial, chlamydial, or mycoplasma infection and pulmonary infection caused by *Mycoplasma pneumoniae* or *Legionella pneumophila*.

When necessary, doxycycline is the drug of choice because it can be given to clients with renal impairment, a common problem in critical care settings.

Sulfonamides are rarely used in critical care settings except for the combination of trimethoprim and sulfamethoxazole (eg, Bactrim) and the topical silver sulfadiazine (Silvadene) used to treat burn wounds. Bactrim may be used to treat *Pneumocystis carinii* pneumonia. Although often given IV in critical care settings, oral or nasogastric tube administration may be used in selected clients (eg, clients with AIDS and respiratory failure).

---

**Nursing Notes: Apply Your Knowledge**

You are working in a nursing home, caring for an elderly, incontinent client who has an indwelling urinary catheter. You notice her urine is cloudy with lots of sediment and it has a strong, foul odor. The client is afebrile and is not complaining of any pain. Analyze these data and discuss how you will proceed.

**Nursing Actions**

1. **Administer accurately**
   a. With tetracyclines:
      (1) Give oral drugs with food that does not contain dairy products; do not give with or within 2 h of dairy products, antacids, or iron supplements.
      (2) For intravenous (IV) administration, dilute with an appropriate type and amount of IV solution, and infuse over 1–4 h.
   b. With sulfonamides:
      (1) Give oral drugs before or after meals, with a full glass of water.
      (2) Infuse IV trimethoprim-sulfamethoxazole (diluted in 125 mL of 5% dextrose in water) over 60–90 min. Do not mix with other drugs or solutions and flush IV lines to remove any residual drug.
      (3) For topical sulfonamides to burn wounds, apply a thin layer with a sterile gloved hand after the surface has been cleansed of previously applied medication.
   c. Give nitrofurantoin with or after meals.
2. **Observe for therapeutic effects**
   a. With tetracyclines, observe for decreased signs and symptoms of the infection for which the drug is being given.

   To decrease nausea and other gastrointestinal (GI) symptoms. Tetracyclines combine with metallic ions (eg, aluminum, calcium, iron, magnesium) and are not absorbed.
   Rapid administration should be avoided. IV doses are usually mixed in hospital pharmacies.
   Absorption is better when taken on an empty stomach; however, taking with food decreases GI upset.
   Manufacturer’s recommendations

   Burn wounds may be cleansed by whirlpool, shower, or spot cleansing with sterile saline, gauze pads, and gloves.
   Food decreases nausea, vomiting and diarrhea.
   Therapeutic effects depend on the reason for use.
### Nursing Actions

| b. | With sulfonamides, observe for decreased symptoms of urinary tract infection (UTI), decreased diarrhea when given for ulcerative colitis or bacillary dysentery, lack of fever and wound drainage and evidence of healing in burn wounds. |
| c. | With urinary antiseptics, observe for decreased symptoms of UTI. |

### Rationale/Explanation

Topical sulfonamides for burns are used to prevent rather than treat infection.

### 3. Observe for adverse effects

| a. Nausea, vomiting, diarrhea |
| b. Hematologic disorders—anemia, neutropenia, thrombocytopenia |
| c. Hypersensitivity—anaphylaxis, skin rash, urticaria, serum sickness |
| d. Photosensitivity—sunburn reaction |
| e. Thrombophlebitis at IV infusion sites |
| f. Nephrotoxicity—increased blood urea nitrogen and serum creatinine, hematuria, proteinuria, crystalluria |
| g. Hepatotoxicity—elevated aspartate aminotransferase and other enzymes |
| h. Superinfection—sore mouth, white patches on oral mucosa, black, furry tongue, diarrhea, skin rash, itching in the perineal area, pseudomembranous colitis |

This can be prevented or minimized by avoiding exposure to sunlight or other sources of ultraviolet light, wearing protective clothing and using sunscreen lotions.

### 4. Observe for drug interactions

| a. Drugs that decrease effects of tetracyclines: |
| 1. Aluminum, calcium, iron, or magnesium preparations (eg, antacids, ferrous sulfate) |
| 2. Cathartics |
| 3. Barbiturates, carbamazepine, phenytoin, rifampin |
| b. Drugs that increase effects of sulfonamides: |
| 1. Alkalizing agents (eg, sodium bicarbonate) |
| 2. Methenamine compounds, urinary acidifiers (eg, ascorbic acid) |
| 3. Salicylates (eg, aspirin), nonsteroidal anti-inflammatory drugs (eg, ibuprofen), oral anticoagulants, phenytoin, methotrexate |
| c. Drugs that alter effects of nitrofurantoin: |
| 1. Antacids |
| 2. Acidifying agents |

These metals combine with oral tetracyclines to produce insoluble, nonabsorbable compounds that are excreted in feces.

Increase rate of urinary excretion, thereby raising levels of sulfonamides in the urinary tract and increasing effectiveness in UTIs

Meticulous oral and perineal hygiene helps prevent these problems. The drug should be stopped if severe diarrhea occurs, with blood, mucus, or pus in stools.

These drugs induce drug-metabolizing enzymes in the liver and may speed up metabolism of doxycycline.

These drugs increase the risk of nephrotoxicity and should not be used with sulfonamides. They may cause precipitation of sulfonamide with resultant blockage of renal tubules.

Meticulous oral and perineal hygiene helps prevent these problems. The drug should be stopped if severe diarrhea occurs, with blood, mucus, or pus in stools.

These drugs increase antibacterial activity of nitrofurantoin by decreasing renal excretion. Nitrofurantoin is most active against organisms causing UTI when urine pH is 5.5 or less.

May decrease absorption
CHAPTER 36 TETRACYCLINES, SULFONAMIDES, AND URINARY AGENTS

2. What are potentially serious adverse effects of tetracyclines?
3. What is the rationale for long-term, low-dose administration of a tetracycline for acne?
4. Which tetracyclines may be given to clients with renal impairment?
5. Why are sulfonamides often effective in UTI?
6. What are major adverse effects of sulfonamides, and how may they be prevented or minimized?
7. What is the rationale for combining sulfamethoxazole and trimethoprim?
8. What are important characteristics of urinary antiseptics?

SELECTED REFERENCES


Macrolides and Miscellaneous Antibacterials

Objectives

After studying this chapter, the student will be able to:

1. Discuss characteristics and specific uses of macrolide antibacterials.
2. Compare and contrast macrolides with other commonly used antibacterial drugs.
3. Apply principles of using macrolides in selected client situations.
4. Discuss characteristics and clinical indications for using chloramphenicol, clindamycin, linezolid, metronidazole, quinupristin/dalfopristin, and vancomycin.
5. Discuss the roles of metronidazole and oral vancomycin in the treatment of pseudomembranous colitis.

Critical Thinking Scenario

You are an infection control nurse who will be providing long-term care nurses with an update on methicillin-resistant Staphylococcus aureus (MRSA). Because MRSA has been a significant problem over the last decade, especially in long-term care facilities, your goal is to increase knowledge about the development of drug resistance and appropriate measures to prevent spread of this organism.

Reflect on:

- Factors that promote resistance to antibiotics.
- Why vancomycin may be the drug of choice for MRSA.
- What risks are involved when vancomycin is used consistently to treat MRSA.
- What infection control practices are necessary to limit the spread of MRSA and other resistant organisms.

OVERVIEW

The drugs described in this chapter are heterogeneous in their antimicrobial spectra, characteristics, and clinical uses. Some are used often; some are used only in specific circumstances. The macrolides and selected miscellaneous drugs are described in the following sections; names, routes, and dosage ranges of individual drugs are listed in the Drugs at a Glance tables.

MACROLIDES

The macrolides, which include erythromycin, azithromycin (Zithromax), clarithromycin (Biaxin), and dirithromycin (Dynabac), have similar antibacterial spectra and mechanisms of action. They are widely distributed into body tissues and fluids and may be bacteriostatic or bactericidal, depending on drug concentration in infected tissues. They are effective against gram-positive cocci, including group A streptococci, pneumococci, and most staphylococci. They are also effective against species of Corynebacterium, Treponema, Neisseria, and Mycoplasma and against some anaerobic organisms such as Bacteroides and Clostridia. Azithromycin and clarithromycin also are active against the atypical mycobacteria that cause Mycobacterium avium complex (MAC) disease. MAC disease is an opportunistic infection that occurs mainly in people with advanced human immunodeficiency virus infection.

Erythromycin, the prototype, is now used less often because of microbial resistance, numerous drug interactions, and the development of newer macrolides. Erythromycin is metabolized in the liver and excreted mainly in bile; approximately 20% is excreted in urine. Depending on the specific salt
formulation used, food can have a variable effect on the absorption of oral erythromycin. Compared with erythromycin, the newer drugs require less frequent administration and cause less nausea, vomiting, and diarrhea. Azithromycin and dirithromycin are excreted mainly in bile, and clarithromycin is metabolized to an active metabolite in the liver, which is then excreted in urine.

Erythromycin is available in several preparations. Ophthalmic and topical preparations are discussed in Chapters 65 and 66.

A relative of the macrolides, telithromycin (Ketek), is the first of a new class of antibiotics, named the ketolides. Telithromycin and a similar drug have not yet received Food and Drug Administration (FDA) approval for marketing. These drugs are expected to offer better activity against multidrug-resistant strains of *Streptococcus pneumoniae*, an increasingly common cause of infections in children and adults.

### Mechanism of Action

The macrolides enter microbial cells and attach to 50S ribosomes, thereby inhibiting microbial protein synthesis.

### Indications for Use

The macrolides are widely used for treatment of respiratory tract and skin/soft tissue infections caused by streptococci and staphylococci. Erythromycin is also used as a penicillin substitute in clients who are allergic to penicillin; for prevention of rheumatic fever, gonorrhea, syphilis, pertussis, and chlamy-
dial conjunctivitis in newborns (ophthalmic ointment); and to treat other infections (eg, Legionnaire’s disease, genitourinary infections caused by *Chlamydia trachomatis*, intestinal amebiasis caused by *Entamoeba histolytica*). In addition, azithromycin is approved for treatment of urethritis and cervicitis by *C. trachomatis* organisms, and is being used for the prevention and treatment of MAC disease. Clarithromycin is approved for prevention and treatment of MAC disease. For prevention, clarithromycin may be used alone; for treatment, it is combined with one or two other drugs (eg, ethambutol or rifabutin) to prevent the emergence of drug-resistant organisms. Clarithromycin is also used to treat *Helicobacter pylori* infections associated with peptic ulcer disease.

**Contraindications to Use**

Macrolides are contraindicated in people who have had hypersensitivity reactions. They are also contraindicated or must be used with caution in clients with pre-existing liver disease.

### MISCELLANEOUS ANTIBACTERIAL DRUGS

- **Chloramphenicol** (Chloromycetin) is a broad-spectrum, bacteriostatic antibiotic that is active against most gram-positive and gram-negative bacteria, rickettsiae, chlamydiae, and treponemes. It acts by interfering with microbial protein synthesis. It is well absorbed and diffuses well into body tissues and fluids, including cerebrospinal fluid (CSF), but low drug levels are obtained in urine. It is metabolized in the liver and excreted in the urine.

  Chloramphenicol is rarely used in infections caused by gram-positive organisms because of the effectiveness and low toxicity of penicillins, cephalosporins, and macrolides. Each of the alternate classes of antibiotics has a more favorable safety profile and should be considered first, before chloramphenicol. It is indicated for use in serious infections for which no adequate substitute drug is available. Specific infections include meningococcal, pneumococcal, or *Haemophilus* meningitis in...
• **Linezolid** (Zyvox) is a member of the oxazolidinone class, a newer class of antibiotics. It is active against aerobic gram-positive bacteria, in which it acts by inhibiting protein synthesis. The drug is well absorbed orally, distributes widely, and undergoes hepatic elimination. Its effects in pregnancy and in children are largely unknown.

Linezolid is indicated for septicemia, pneumonia (both community acquired and nosocomial) and skin and skin structure infections. The drug is bacteriostatic against enterococci (including faecalis and faecium) and staphylococci (including methicillin-resistant strains), and bactericidal for most streptococci.

Myelosuppression (eg, anemia, leukopenia, pancytopenia, thrombocytopenia) is a serious adverse effect. The client’s complete blood count should be monitored; if myelosuppression occurs, linezolid should be discontinued. Myelosuppression usually improves with drug discontinuation. Pseudomembranous colitis may also occur. Mild cases usually resolve with drug discontinuation; moderate or severe cases may require fluid and electrolyte replacement and an antibacterial drug that is effective against *Clostridium difficile* organisms. Hypertension may occur with the concomitant ingestion of linezolid and adrenergic drugs or large amounts of tyramine-containing foods (eg, aged cheeses, tap beers, red wines, sauerkraut, soy sauce).

• **Metronidazole** (Flagyl) is effective against anaerobic bacteria, including gram-negative bacilli such as *Bacteroides*, gram-positive bacilli such as *Clostridia*, and some gram-positive cocci. It is also effective against protozoa that cause amebiasis, giardiasis, and trichomoniasis (see Chap. 41).

Clinical indications for use include prevention or treatment of anaerobic bacterial infections (eg, in colorectal surgery and intra-abdominal infections) and treatment of *Clostridium difficile* infections associated with pseudomembranous colitis. It is contraindicated during the first trimester of pregnancy and must be used with caution in clients with CNS or blood disorders.

Metronidazole is carcinogenic in rodents, if given in high doses for prolonged periods, but there is no evidence that people treated with therapeutic doses have increased risks for development of cancer. The drug is widely distributed in body fluids and tissues, metabolized in the liver, and excreted mostly (60% to 80%) in urine, with a small amount excreted in feces.

• **Quinupristin/dalfopristin** (Synercid) belongs to a class of antimicrobials referred to as streptogramins. Both components are active antimicrobials that affect bacterial ribosomes to decrease protein synthesis. The combination is bacteriostatic against *Enterococcus faecium* (including vancomycin-resistant strains) and bactericidal against both methicillin-susceptible and methicillin-resistant strains of staphylococci. It is not active against *Enterococcus faecalis*. The combination undergoes biliary excretion and fecal elimination.

Quinupristin/dalfopristin is indicated for skin and skin structure infections caused by *Staphylococcus aureus* or group A streptococcus. It is also used for treatment of clients with serious or life-threatening infections associated with vancomycin-resistant *Enterococcus faecium* (VREF) bacteremia.

Quinupristin/dalfopristin is a strong inhibitor of cytochrome P450 3A4 enzymes and therefore interferes with the metabolism of drugs such as cyclosporine, antitremovirals, carbamazepine, and many others. Toxicity may occur with the inhibited drugs.

• **Spectinomycin** (Trobicin) is used for treatment of gonococcal exposure or infection in people who are allergic to or unable to take preferred drugs (the cephalosporins ceftriaxone or cefixime, or the fluoroquinolones ciprofloxacin or ofloxacin). It may be used during pregnancy when clients cannot tolerate cephalosporins and when fluoroquinolones are contraindicated. Spectinomycin has no activity against infections caused by *Chlamydia* organisms, which often accompany gonorrhea.

• **Vancomycin** is active only against gram-positive microorganisms. It acts by inhibiting cell wall synthesis.
Vancomycin is indicated only for the treatment of severe infections. Parenteral vancomycin has been used extensively to treat infections caused by MRSA and methicillin-resistant staphylococcal species non-aureus (SSNA, including *Staphylococcus epidermidis*) and endocarditis caused by *Streptococcus viridans* (in clients allergic to or with infections resistant to penicillins and cephalosporins) or *Enterococcus faecalis* (with an aminoglycoside). *Streptococcus pneumoniae* remain susceptible to vancomycin, although vancomycin-tolerant strains have been identified. The drug has also been widely used for prophylaxis of gram-positive infections in clients who are at high-risk of developing MRSA infections (e.g., those with diabetes, previous hospitalization, or MRSA in their nasal passages) and who require placement of long-term intravascular catheters and other invasive treatment or monitoring devices. Oral vancomycin has been used extensively to treat staphylococcal enterocolitis and pseudomembranous colitis caused by *C. difficile*.

Partly because of this widespread use, vancomycin-resistant enterococci (VRE) are being encountered more often, especially in critical care units, and treatment options for infections caused by these organisms are limited. To decrease the spread of VRE, the Centers for Disease Control and Prevention recommend limiting the use of vancomycin. Specific recommendations include avoiding or minimizing use in empiric treatment of febrile clients with neutropenia (unless the prevalence of MRSA or SSNA is high); initial treatment for *C. difficile* colitis (metronidazole is preferred); and prophylaxis for surgery, low-birth-weight infants, intravascular catheter colonization or infection, and peritoneal dialysis.

For systemic infections, vancomycin is given intravenously (IV) and reaches therapeutic plasma levels within 1 hour after infusion. It is very important to give IV infusions slowly, over 1 to 2 hours, to avoid an adverse reaction characterized by hypotension and flushing and skin rash. This reaction, sometimes called *red man syndrome*, is attributed to histamine release. Vancomycin is excreted through the kidneys; dosage should be reduced in the presence of renal impairment. For bacterial colitis, vancomycin is given orally because it is not absorbed from the GI tract and acts within the bowel lumen. Large amounts of vancomycin are excreted in the feces after oral administration.

**Nursing Process**

**Assessment**
- Assess for infections that macrolides and the designated miscellaneous drugs are used to prevent or treat.
- Assess each client for signs and symptoms of the specific current infection.
- Assess culture and susceptibility reports when available.

**How Can You Avoid This Medication Error?**

Your patient has vancomycin 1 g IV ordered for 0900. The pharmacy sends up a 250-cc IV bag with 1 g of vancomycin, to infuse over 1 hour. Your IV drip rate is 10 drops/cc. You calculate and regulate the IV rate at 42 drops per minute. When you return in 30 minutes, the entire 250 cc has infused into the patient and he appears very flushed and complains of feeling hot.

**PRINCIPLES OF THERAPY**

**Culture and Susceptibility Studies**

Culture and susceptibility reports and local susceptibility patterns should be reviewed to determine if an antibiotic-resistant pathogen is present in the client. This is particularly important before starting vancomycin, quinupristin/dalfopristin, or line-
zolid. These drugs have relatively narrow spectra of activity and appropriate indications for their use should be observed to decrease the likelihood of resistance.

Effects of Macrolides on Other Drugs

Erythromycin interferes with the elimination of several drugs, especially those metabolized by the cytochrome P450 enzymes in the liver. As a result, the affected drugs are eliminated more slowly, their serum levels are increased, and they are more likely to cause adverse effects and toxicity unless dosage is reduced. Interacting drugs include alfentanil (Alfenta), bromocriptine (Parlodel), carbamazepine (Tegretol), cyclosporine (Sandimmune), digoxin (Lanoxin), disopyramide (Norpace), methylprednisolone (Medrol), theophylline (Theo-Dur), triazolam (Halcion), and warfarin (Coumadin). These drugs represent a variety of drug classes. Erythromycin is contraindicated in clients who are receiving fluoroquinolone antibacterials (eg, ciprofloxacin) because serious ventricular dysrhythmias and fatalities have been reported.

The newer macrolides have fewer effects on other drugs, but some differences are apparent. Clarithromycin, for example, increases carbamazepine levels, but azithromycin does not.

Preventing Toxicity With Chloramphenicol

Blood dyscrasias (potentially serious and life-threatening) have occurred in clients taking chloramphenicol. Irreversible bone marrow depression may appear weeks or months after therapy. A dose-related reversible bone marrow depression usually responds to discontinuation of the drug. Clients should be monitored with a complete blood count, platelet count, reticulocyte count, and serum iron every 2 days. In addition, periodic measurements of serum drug levels are recommended. Therapeutic levels are 10 to 20 mcg/mL.

Preventing Toxicity With Clindamycin

If diarrhea develops in a client receiving clindamycin, the drug should be stopped. If the diarrhea is severe and persistent, stools should be checked for white blood cells, blood, and mucus, and the presence of Clostridium difficile toxin. Proctoscopy can be done to more definitively determine whether the client has pseudomembranous colitis, a potentially fatal adverse reaction. If lesions are seen on proctoscopy, the drug should be stopped immediately. Although pseudomembranous colitis may occur with any antibiotic, it has often been associated with clindamycin therapy.

Nursing Notes: Apply Your Knowledge

After gynecologic surgery, Susan Miller contracts a serious wound infection. She is treated with IV clindamycin and IV gentamicin. After 5 days of treatment, Ms. Miller develops severe diarrhea (12 watery, bloody stools per day) and feels dizzy and weak, especially when getting out of bed. She is afebrile. Based on these assessment data, how should you proceed?
Use in Children

Erythromycin is usually considered safe for treatment of infections caused by susceptible organisms. Azithromycin and clarithromycin are used in young children for some infections (eg, pharyngitis/tonsillitis and acute otitis media). Safety and effectiveness of dirithromycin have not been established for children younger than 12 years of age.

Dosage of chloramphenicol must be reduced in premature infants and in full-term infants less than 2 weeks of age because impaired metabolism may lead to accumulation and adverse effects. Clindamycin should be given to neonates and infants only if clearly indicated, and then liver and kidney function must be monitored. Diarrhea and pseudomembranous colitis may occur with topical clindamycin for treatment of acne. The safety and efficacy of metronidazole have been established in children only for the treatment of amebiasis. Vancomycin is often used in children, including preterm and full-term neonates, for the same indications as in adults. Monitoring serum drug levels is recommended with IV vancomycin.

With the newer drugs, linezolid and quinupristin/dalfopristin, there has been little experience with their use in children, and pediatric dosages have not been identified.

Use in Older Adults

Erythromycin is generally considered safe. Because it is metabolized in the liver and excreted in bile, it may be useful in clients with impaired renal function. Dosage reductions are not indicated with azithromycin and dirithromycin, but may be needed if clarithromycin is given to older adults with severe renal impairment. Dosage of vancomycin should be adjusted for impaired renal function in older adults as in other age groups.

Quinupristin/dalfopristin and linezolid do not require dosage adjustment in older adults. The miscellaneous drugs are used in older adults for the same indications as in younger adults.

Use in Renal Impairment

With the macrolides, dosage of erythromycin does not need reduction because it is excreted mainly by the liver. With the newer drugs, there are no data about azithromycin dosage in renal impairment and no dosage reduction is recommended for dirithromycin. However, clarithromycin dosage should be halved or the dosing interval doubled in clients with severe renal impairment (creatinine clearance [CrCl] <30 mL/minute). In addition, the combination of clarithromycin and ranitidine bismuth citrate therapy (Tritec; used to treat peptic ulcers associated with H. pylori infection) is not recommended in clients with severe renal impairment (CrCl <25 mL/minute).

Dosage of clindamycin does not need reduction in renal impairment because it is excreted primarily by the liver. Dosage of vancomycin should be reduced because it is excreted mainly by the kidneys and accumulates in renal impairment. In addition, vancomycin may be nephrotoxic with IV administration, high serum concentrations, prolonged therapy, use in elderly or neonates, and concomitant use of other nephrotoxic drugs. Thus, in addition to reduced dosage, renal function and serum drug levels should be monitored (therapeutic levels are 10 to 25 mcg/mL). Dosage of quinupristin/dalfopristin and linezolid does not need to be reduced in clients with renal failure.

Use in Hepatic Impairment

Erythromycin should be used cautiously, if at all, in clients with hepatic impairment. It is metabolized in the liver to an active metabolite that is excreted in the bile. Avoiding the drug or dosage reduction may be needed in liver failure. It has also been associated with cholestatic hepatitis, most often with the estolate formulation (eg, Ilosone). Symptoms, which may include nausea, vomiting, fever, and jaundice, usually occur after 1 to 2 weeks of drug administration and subside when the drug is stopped.

Other macrolides vary in their hepatic effects. Azithromycin is mainly eliminated unchanged in bile and could accumulate with impaired liver function. It should be used with caution. Clarithromycin is metabolized in the liver to an active metabolite that is then excreted through the kidneys. Dosage reduction is not recommended for clients with hepatic impairment and normal renal function but is required with severe renal impairment (see Use in Renal Impairment). Dirithromycin is metabolized in the liver to an active metabolite that is then excreted in bile and feces. No dosage reduction is recommended for mild hepatic impairment. Because effects in moderate to severe hepatic impairment have not been studied, the drug should be used only if absolutely necessary.

Clindamycin, chloramphenicol, and metronidazole should be used cautiously, if at all, in the presence of liver disease. Because these drugs are eliminated through the liver, they may accumulate and cause toxic effects. When feasible, other drugs should be substituted. If no effective substitutes are available, dosage should be reduced. With quinupristin/dalfopristin and linezolid, there are currently no recommendations to alter dosage in hepatic impairment.

Use in Critical Illness

Erythromycin is seldom used in critical care settings, partly because broader spectrum bactericidal drugs are usually needed in critically ill clients, and partly because it inhibits liver metabolism and slows elimination of several other drugs. For a critically ill client who needs a macrolide antibiotic, one of the newer drugs is preferred because they have broader spectra of antibacterial activity and fewer effects on the metabolism of other drugs.

Clindamycin should be used only when necessary (ie, for serious infections caused by susceptible anaerobes) because
critically ill clients may develop hepatic impairment and pseudomembranous colitis (also called antibiotic-associated colitis). These clients are at high risk for development of pseudomembranous colitis because they often receive aggressive antibiotic therapy with multiple or broad-spectrum antibacterial drugs that destroy normal bowel microorganisms. Metronidazole is often used in critically ill clients with mixed infections. These clients are at risk for drug toxicity from accumulation of active metabolites. Vancomycin penetrates tissues well in critically ill clients and achieves therapeutic levels well above the minimum inhibitory concentration for most staphylococci and enterococci. Plasma drug levels and renal function should be monitored. Although usually given by IV infusion, vancomycin is given orally to treat pseudomembranous colitis. Quinupristin/dalfopristin and linezolid are often used in critically ill clients because infections with resistant pathogens commonly occur in this population.

**Home Care**

Most of the macrolides and miscellaneous drugs may be taken in the home setting. The role of the home care nurse is generally the same as with other antibiotic therapy; that is, the nurse may need to teach clients or caregivers about drug administration and expected effects. For clients taking oral metronidazole or vancomycin for pseudomembranous colitis, stool specimens may need to be collected and tested in the laboratory for *C. difficile* organisms or toxins.

---

### NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
<tr>
<td><strong>a.</strong> Give oral erythromycin preparations according to manufacturers’ instructions, with 6 to 8 oz of water, at evenly spaced intervals, around the clock.</td>
<td>Some should be taken on an empty stomach; some can be taken without regard to meals. Adequate water aids absorption; regular intervals help to maintain therapeutic blood levels.</td>
</tr>
<tr>
<td><strong>b.</strong> With azithromycin, give the oral suspension on an empty stomach, 1 h before or 2 h after a meal. Give tablets without regard to meals. Do not give oral azithromycin with aluminum- or magnesium-containing antacids.</td>
<td>Food decreases absorption of the suspension; antacids decrease absorption of tablets and the suspension</td>
</tr>
<tr>
<td><strong>c.</strong> With clarithromycin, give regular tablets and the oral suspension with or without food. Give the extended-release tablets (Biaxin XL) with food. Shake the suspension well before measuring the dose.</td>
<td>Manufacturer’s recommendations. All suspensions should be mixed well to measure accurately.</td>
</tr>
<tr>
<td><strong>d.</strong> With dirithromycin, give with food or within 1 h after a meal.</td>
<td>The IV formulation has limited stability in solution, and instructions must be followed carefully to achieve therapeutic effects. Also, instructions differ for intermittent and continuous infusions. IV erythromycin is the treatment of choice for Legionnaire’s disease. Otherwise, it is rarely used.</td>
</tr>
<tr>
<td><strong>f.</strong> With chloramphenicol:</td>
<td>To increase absorption and maintain therapeutic blood levels</td>
</tr>
<tr>
<td>(1) Give oral drug 1 h before or 2 h after meals, q6h around the clock. If gastrointestinal (GI) upset occurs, give with food.</td>
<td>To avoid esophageal irritation</td>
</tr>
<tr>
<td>(2) Mix IV chloramphenicol in 50–100 mL of 5% dextrose in water and infuse over 15–30 min.</td>
<td>Refrigeration is not required for drug stability and may thicken the solution, making it difficult to measure and pour accurately.</td>
</tr>
<tr>
<td><strong>g.</strong> With clindamycin:</td>
<td>To decrease pain, induration, and abscess formation</td>
</tr>
<tr>
<td>(1) Give capsules with a full glass of water.</td>
<td>(continued)</td>
</tr>
<tr>
<td>(2) Do not refrigerate reconstituted oral solution.</td>
<td></td>
</tr>
<tr>
<td>(3) Give intramuscular injections deeply, and rotate sites. Do not give more than 600 mg in a single injection.</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS | RATIONALE/EXPLANATION
---|---
(4) For IV administration, dilute 300 mg in 50 mL of IV fluid and give over 10 min, or dilute 600 mg in 100 mL and give over 20 min. *Do not* give clindamycin undiluted or by direct injection.

**h.** With linezolid:
1. Give oral tablets and suspension without regard to meals.
2. For IV administration, the drug is compatible with 5% dextrose, 0.9% sodium chloride, and Lactated Ringer’s solutions.
3. Infuse the drug over 30–120 minutes. If other drugs are being given through the same IV line, flush the line with one of the above solutions before and after linezolid administration.

**i.** With IV metronidazole, check the manufacturer’s instructions.

**j.** With quinupristin/dalfopristin:
1. Give IV, mixed in a minimum of 250 mL of 5% dextrose solution and infused over 60 min.
2. *Do not* mix the drug or flush the IV line with saline- or heparin-containing solutions.

**k.** With vancomycin, dilute 500-mg doses in 100 mL and 1-g doses in 200 mL of 0.9% NaCl or 5% dextrose injection and infuse over at least 60 min.

2. **Observe for therapeutic effects**
   a. Decreased local and systemic signs of infection
   b. Decreased signs and symptoms of the specific infection for which the drug is being given

3. **Observe for adverse effects**
   a. With macrolides:
      1. Nausea, vomiting, diarrhea
      2. With IV erythromycin, phlebitis at the IV infusion site
      3. Hepatotoxicity—nausea, vomiting, abdominal cramps, fever, leukocytosis, abnormal liver function, cholestatic jaundice
      4. Allergic reactions (anaphylaxis, skin rash, urticaria)
   b. With chloramphenicol:
      1. Bone marrow depression (anemia, leukopenia, thrombocytopenia)
      2. Clinical signs of infection or bleeding
   c. With clindamycin:
      1. Nausea, vomiting, diarrhea

Dilution decreases risks of phlebitis. Cardiac arrest has been reported with bolus injections of clindamycin.

Manufacturer’s recommendations

The drug requires specific techniques for preparation and administration.

Dilution in at least 250 mL of IV solution decreases venous irritation. A central venous catheter may also be used for drug administration to decrease irritation.

The drug is incompatible with saline- and heparin-containing solutions.

To decrease hypotension and flushing (ie, “red man syndrome”) that may occur with more rapid IV administration. This reaction is attributed to histamine release and may be prevented by prior administration of diphenhydramine, an antihistamine. Dilution also decreases pain and phlebitis at the injection site.

These are the most frequent adverse reactions, reportedly less common with azithromycin and clarithromycin than with erythromycin.

The drug is very irritating to body tissues. Phlebitis can be minimized by diluting the drug well, infusing it slowly, and not using the same vein more than 48–72 h, if possible.

More likely to occur with the estolate formulation of erythromycin; less likely to occur with the newer macrolides than with erythromycin

Potentially serious but infrequent

Blood dyscrasias are the most serious adverse reaction to chloramphenicol.

These are the most frequent adverse effects and may be severe enough to require stopping the drug.
### NURSING ACTIONS

**d. With linezolid:**
- (1) Nausea, vomiting, diarrhea
- (2) Bone marrow depression (anemia, leukopenia, thrombocytopenia)
- (3) Pseudomembranous colitis (PMC)

**e. With metronidazole:**
- (1) Central nervous system effects—convulsive seizures, peripheral paresthesias, ataxia, confusion, dizziness, headache
- (2) GI effects—nausea, vomiting, diarrhea
- (3) Dermatologic effects—skin rash, pruritus, thrombophlebitis at infusion sites

**f. With quinupristin/dalfopristin:**
- (1) IV infusion site reactions (pain, edema, inflammation)
- (2) Nausea, vomiting, diarrheae

**g. With vancomycin:**
- (1) Nephrotoxicity—oliguria, increased blood urea nitrogen and serum creatinine
- (2) Otoxicity—hearing loss, tinnitus
- (3) Red man syndrome—hypotension, skin flushing

### RATIONALE/EXPLANATION

- May occur with most antibiotics but is more common with oral clindamycin. It is caused by *Clostridium difficile*. The organism produces a toxin that kills mucosal cells and produces superficial ulcerations that are visible with sigmoidoscopy. Discontinuing the drug and giving oral metronidazole are curative measures.

- These are common effects.

- Complete blood cell counts (CBCs) are recommended weekly to monitor for myelosupression. If it occurs, the drug should be discontinued.

- May occur with linezolid as with other antibiotics. If it occurs, the drug should be discontinued.

- Convulsions and peripheral neuropathy may be serious effects; GI effects are most common.

- The most common adverse effects during clinical trials. Moderate to severe venous irritation can occur with administration through peripheral veins. This can be prevented by infusion through a central venous IV line.

- These effects occurred in 2.7% to 4.6% of subjects in clinical trials. Most other adverse effects occurred in fewer than 1%.

- Uncommon. Most likely to occur with large doses, concomitant administration of an aminoglycoside antibiotic, or pre-existing renal impairment. Usually resolves when vancomycin is discontinued.

- Most likely to occur in people with renal impairment or a pre-existing hearing loss.

- Occurs with rapid infusion of IV vancomycin. Can be prevented by adequate dilution and infusing over 1–2 h or premedicating with diphenhydramine (an antihistamine).

- The combination is effective against some strains of resistant *Staphylococcus aureus*.

- The combination is effective against the enterococcus in bacteremia, brain abscess, endocarditis, meningitis, and urinary tract infection.

- Probably inhibits metabolism of clarithromycin

- These agents raise gastric pH and slightly increase absorption of dirithromycin.

- Antacids decrease peak serum levels

*(continued)*
**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>e. Drugs that decrease effects of chloramphenicol:</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Enzyme inducers (eg, rifampin)</td>
<td>Reduce serum levels, probably by accelerating liver metabolism of chloramphenicol</td>
</tr>
<tr>
<td>f. Drugs that decrease effects of clindamycin:</td>
<td></td>
</tr>
<tr>
<td>(1) Erythromycin</td>
<td></td>
</tr>
<tr>
<td>(2) Kaolin-pectin</td>
<td></td>
</tr>
<tr>
<td>g. Drug that increases effects of metronidazole:</td>
<td></td>
</tr>
<tr>
<td>(1) Cimetidine</td>
<td>Inhibits hepatic metabolism of metronidazole</td>
</tr>
<tr>
<td>h. Drugs that decrease effects of metronidazole:</td>
<td></td>
</tr>
<tr>
<td>(1) Enzyme inducers (phenobarbital, phenytoin, prednisone, rifampin)</td>
<td>These drugs induce hepatic enzymes and decrease effects of metronidazole by accelerating its rate of hepatic metabolism.</td>
</tr>
</tbody>
</table>

**How Can You Avoid This Medication Error?**

**Answer:** This error occurred because the drug infused too rapidly. Although the IV rate was calculated correctly, the IV could have been positional, which could have caused the sudden infusing of medication. When giving a medication such as this, it is best to use an IV controller pump to regulate the infusion rate. The rapid infusion of vancomycin caused the flushing, which is sometimes referred to as the “red man effect.” This is not an allergic reaction, but is caused by histamine release and vasodilation when infusion is too fast. This reaction can be limited by slowing the infusion or premedication with an antihistamine.

**Nursing Notes: Apply Your Knowledge**

**Answer:** Diarrhea is a side effect of many antibiotics. When diarrhea is severe, it is important to determine if the cause is pseudomembranous colitis, which is caused when antibiotics suppress the growth of normal flora and allow the overgrowth of *Clostridium difficile*. This organism produces a toxin that kills mucosal cells and creates ulcerations. Pseudomembranous colitis is often associated with the use of clindamycin. Contact the physician for an order for a *C. difficile* (C-diff) stool toxin assay. Treatment includes metronidazole (Flagyl) or oral vancomycin. Ms. Miller’s dizziness may be caused by volume depletion. Adequate fluids must be restored to prevent shock.

**SELECTED REFERENCES**


**Review and Application Exercises**

1. Why is erythromycin called a penicillin substitute?
2. What are adverse effects with erythromycin, and how may they be prevented or minimized?
Drugs for Tuberculosis and Mycobacterium avium Complex (MAC) Disease

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe characteristics of latent, active, and drug-resistant tuberculosis infections.
2. Identify populations at high risk for developing tuberculosis.
3. List characteristics, uses, effects, and nursing implications of using primary antitubercular drugs.
4. Describe the rationale for multiple drug therapy in treatment of tuberculosis.
5. Discuss ways to increase adherence to antitubercular drug therapy regimens.
6. Differentiate the advantages and disadvantages of directly observed therapy (DOT).
7. Describe factors affecting the use of primary, secondary, and other drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB).
8. Describe Mycobacterium avium complex disease and the drugs used to prevent or treat it.

Critical Thinking Scenario
John Phillips, a homeless person with a history of drug and alcohol abuse, comes to the emergency department with a productive cough, complaints of night sweats, and fatigue. The physician suspects tuberculosis (TB) and orders a purified protein derivative (PPD) skin test, chest x-ray, and sputum for acid-fast bacilli.

Reflect on:
- The necessary infection control measures to use before TB is confirmed or ruled out.
- Why multidrug treatment would be important if TB is confirmed.
- Factors that affect compliance with drug treatment for John Phillips and a plan to improve and monitor compliance.
- How long Mr. Phillips will require drug treatment, and how you can evaluate when the TB is cured.

OVERVIEW

Tuberculosis (TB) is an infectious disease that usually affects the lungs (>80% of cases) but may involve most parts of the body, including lymph nodes, pleurae, bones, joints, kidneys, and the gastrointestinal (GI) tract. It is caused by Mycobacterium tuberculosis, the tubercle bacillus. In general, these bacilli multiply slowly; they may lie dormant in the body for many years; they resist phagocytosis and survive in phagocytic cells; and they develop resistance to antitubercular drugs.

Tuberculosis commonly occurs in many parts of the world and causes many deaths annually. In the United States, active disease has waned to a historical low level. However, there are now large numbers of people with inactive or latent tuberculosis infection. Contributing factors include increased exposure during a resurgence of active disease between 1985 and 1992, immigration from countries where the disease is common, and increasing numbers of people with conditions or medications that depress the immune system.
There are four distinct phases in the initiation and progression of tuberculosis (Fig. 38–1):

1. **Transmission** occurs when an uninfected person inhales infected airborne particles that are exhaled by an infected person. Major factors affecting transmission are the number of bacteria expelled by the infected person and the closeness and duration of the contact between the infected and the uninfected person.

2. **Primary infection.** It is estimated that 30% of persons exposed to tuberculosis bacilli become infected and develop a mild, pneumonia-like illness that is often undiagnosed. About 6 to 8 weeks after exposure, those infected have positive reactions to tuberculin skin tests. Within approximately 6 months of exposure, spontaneous healing occurs as the bacilli are encapsulated in calcified tubercles.

3. **Latent tuberculosis infection (LTBI).** In most people who become infected with TB bacteria, the immune system is able to stop bacterial growth. The bacteria become inactive, but they remain alive in the body and can become active later. People with inactive or latent TB infection have no symptoms, do not feel sick, do not spread TB to others, usually have a positive skin test reaction, and can develop active TB disease years later if the latent infection is not effectively treated. In many people with LTBI, the infection remains inactive throughout their lives. In others, the TB bacteria become active and cause tuberculosis, usually when a person’s immune system becomes weak as a result of disease, immunosuppressive drugs, or aging.

4. **Active tuberculosis** usually results from reactivation of latent infection, although new infection can also occur. Both reactivated and new infections are more likely to occur in people whose immune systems are depressed by disease (eg, human immunodeficiency virus [HIV] infection, diabetes mellitus, cancer) or drug therapy (eg, for cancer or organ transplantation). Among people with LTBI, signs and symptoms of active disease (eg, cough...
that is persistent and often productive of sputum, chest pain, chills, fever, hemoptysis, night sweats, weight loss, weakness, lack of appetite, a positive skin test, abnormal chest radiograph, and/or positive sputum smear or culture) are estimated to develop in 5% within 2 years and in another 5% after 2 years. Among people with both LTBI and HIV infection, LTBI progresses to active disease more rapidly (approximately 10% each year), is more severe, and often involves extrapulmonary sites.

**DRUG-RESISTANT TUBERCULOSIS**

In addition to LTBI, a major concern among public health and infectious disease experts is an increase in drug-resistant infections. A major factor in drug-resistant infections is poor patient adherence to prescribed antitubercular drug therapy.

Drug-resistant mutants of *M. tuberculosis* microorganisms are present in any infected person. When infected people receive antitubercular drugs, drug-resistant mutants continue to appear and reproduce in the presence of the drugs. These strains may become predominant as the drugs eliminate susceptible strains and provide more space and nutrients for resistant strains. Most drug-resistant strains develop when previously infected clients do not take the drugs and doses prescribed for the length of time prescribed. However, drug-resistant strains can also be spread from one person to another and cause new infections, especially in people whose immune systems are suppressed.

Multidrug-resistant tuberculosis (MDR-TB) indicates organisms that are resistant to both isoniazid (INH) and rifampin, the most effective drugs available, with or without resistance to other antitubercular drugs. MDR-TB is associated with rapid progression, with 4 to 16 weeks from diagnosis to death, and high death rates (50% to 80%). It is also difficult and expensive to treat.

**PREVENTING THE DEVELOPMENT AND SPREAD OF TUBERCULOSIS**

Recommendations for tuberculosis control have changed considerably in recent years. Current recommendations from the Centers for Disease Control and Prevention (CDC), the American Thoracic Society (ATS), and the Infectious Diseases Society of America (IDSA) emphasize continued treatment of active disease and expanded efforts to identify and treat latent infection (LTBI). For identification, tuberculin skin testing is recommended only for high-risk groups (Box 38–1). When LTBI is found in these groups, it should be treated to eradicate this reservoir of infection (Box 38–2).

Recommendations for treatment are also changing, as authorities strive to design more effective regimens and overcome barriers to their effective implementation. One major change is increasing use of short-course regimens. Numerous studies indicate that these regimens are effective for many people. In addition, patients are more likely to complete a shorter course of therapy, which reduces the occurrence of drug-resistant TB.

Although local health departments are largely responsible for TB control programs, some authorities urge increased testing and treatment in primary care settings and settings where high-risk groups are found (eg, homeless shelters). In addition, they urge recognition and effective management of language, social, economic, transportation, and other barriers that limit access to health care and inhibit diagnosis and treatment.

Nurses have important roles to play in TB control. Some of the roles include performing and reading tuberculin skin tests; managing TB clinics; tracking contacts of patients with active disease; assessing clients, homes, and other settings for risk factors; educating patients and families about the tuberculosis infection and its treatment; administering or directing the administration of antitubercular drugs (eg, directly observed therapy [DOT]); and maintaining records (eg, skin tests performed, positive results, patients starting or completing drug therapy, and adherence or lack of adherence to prescribed treatment regimens).

**ANTITUBERCULAR DRUGS**

Antitubercular drugs are divided into primary and secondary agents. The main primary drugs (eg, isoniazid, rifampin, and pyrazinamide) are used to treat latent, active, and drug-resistant TB infection when possible. Ethambutol and streptomycin are also considered primary drugs. Because of their varied characteristics, the primary drugs are described individually below and their dosages are listed in Drugs at a Glance: Primary Antitubercular Drugs.

Secondary drugs are used only for clients who are unable to tolerate primary drugs or clients who are infected with organisms that are resistant to primary drugs. In general, they are less effective, more toxic, or both.

**Primary Antitubercular Drugs**

**Isoniazid** (INH), the most commonly used antitubercular drug, is bactericidal, relatively inexpensive and nontoxic, and can be given orally or by injection. Although it can be used alone for treatment of LTBI, it must be used with other antitubercular drugs for treatment of active disease.

INH penetrates body cells and mycobacteria, kills actively growing intracellular and extracellular organisms, and inhibits the growth of dormant organisms in macrophages and tuberculous lesions. Its mechanism of action is inhibiting formation of cell walls in mycobacteria.

INH is well absorbed from the GI tract, with peak serum concentrations occurring 1 to 2 hours after a 300-mg dose. It (text continues on page 564)
Purpose
To identify people with latent tuberculosis infection (LTBI) who are at high risk for developing active tuberculosis and who would benefit by treatment of LTBI, if detected.

Who Should Be Tested?
Numerous high-risk groups have been identified, including persons with the following circumstances or conditions:
- Recent infection with *Mycobacterium tuberculosis* organisms
- Close contact with someone diagnosed with infectious pulmonary TB
- Immigration from areas of the world with high rates of TB. For about 5 years, immigrants have incidence rates similar to those of their countries of origin and are thought to have become infected in their native countries. After 5 years, rates become similar to those of the general U.S. population.
- Belonging to younger age groups. Young children (eg, <5 years) with a positive skin test are at high risk for progression to active disease. The risk is also increased in adolescents and young adults.
- Belonging to older age groups, especially if also living or working in institutions with high-risk populations (eg, hospitals, homeless shelters, correctional facilities, nursing homes, residential homes for patients with AIDS).
- Being homeless
- Being an injection drug user
- Having HIV infection or AIDS. HIV infection greatly increases the risk for progression of LTBI to active TB.
- Having chest radiographs that show fibrotic lesions in the lungs. Such lesions are likely to stem from prior, untreated, healed TB.
- Being underweight, especially if more than 10% to 15% under ideal weight.
- Having silicosis (a pulmonary disorder caused by inhalation of dust particles from mining or stonecutting). People with silicosis and a positive tuberculin test are about 30 times more likely to develop active disease than the general population.
- Having chronic renal failure and being on hemodialysis. These people are 2 to 4 times more likely to develop active disease than the general population.
- Having diabetes mellitus. These people are 10 to 25 times more likely to develop active disease than the general population.
- Having chest radiographs that show fibrotic lesions in the lungs. Such lesions are likely to stem from prior, untreated, healed TB.
- Having diabetes mellitus. These people are 2 to 4 times more likely to develop active TB than those without diabetes, and the risk is probably greater in those with insulin-dependent or poorly controlled diabetes.
- Having a history of gastrectomy (which is often accompanied by weight loss and malabsorption), jejunoileal bypass, renal or cardiac transplantation, carcinoma of the head or neck, lung cancer, lymphoma, or leukemia.
- Receiving high-dose corticosteroid therapy (eg, prednisone >15 mg/d or equivalent amounts of other drugs for several weeks). These people may be at risk for reactivation of TB, but the exact risk is unknown. Lower doses and intermittent administration of corticosteroids are not associated with TB.

Where Should Testing Be Done?
Traditionally, local health departments have been responsible for testing, interpreting, and providing follow-up care; some institutions have tested residents and employees, and some large businesses have tested employees. More recently, the Centers for Disease Control (CDC) and other authorities have recommended that more testing be done in primary care settings and any other locations where high risk individuals are. Such testing sites include neighborhood health centers, jails, homeless shelters, inner-city sites, methadone clinics, syringe and needle-exchange programs, and other community-based social service organizations. In the latter situations, local health departments are urged to assist local providers in developing, implementing, and evaluating TB screening programs appropriate for their communities.

Test Interpretation
Positive reactions differ according to the amount of induration (a nodule or area of hardened tissue, not to be confused with the area of redness, which may be larger than the area of induration) and characteristics of the group being tested, as follows:
- **Induration of 5 mm or more.** Persons at highest risk (eg, close contacts of someone with active, infectious TB; those with HIV infection or risk factors for HIV infection; and those with chest radiographs that are consistent with previous TB).
- **Induration of 10 mm or more.** Persons at high risk (eg, those with conditions or characteristics such as diabetes mellitus; silicosis; immunosuppressive drug therapy; leukemia, lymphoma, head or neck cancer; chronic renal failure; gastronomy; jejunoileal bypass; low body weight; injecting drug users known to be seronegative for HIV infection; recent immigrants from countries that have high TB rates; residents and employees of prisons, long-term care institutions, and other congregate settings for high-risk populations; low-income groups; high-risk racial and ethnic groups; migrant farm workers; and infants, children, and adolescents exposed to adults in high-risk categories).
- **Induration of 15 mm or more.** Persons who are at low risk for developing TB and do not meet the criteria listed for the above groups. Routine testing is not recommended for low-risk groups.
- **False-positive reactions.** These may occur with infections caused by nontuberculous strains of mycobacteria or a previous intradermal injection of Bacille Calmette-Guérin (BCG), a live attenuated strain derived from *Mycobacterium bovis*. In many parts of the world, BCG is used as a vaccine against tuberculosis, especially in children. There is currently no reliable way to differentiate tuberculosis reactions caused by vaccination with BCG from those caused by infection with *M. tuberculosis*. However, large areas of induration (>20 mm) are unlikely to result from BCG.
- **False-negative reactions.** These may occur with HIV infection or other conditions that suppress the immune system and inhibit the ability to react to the tuberculin antigen. Thus, a negative skin test may occur in the presence of tuberculosis infection.
Recommended Regimens for Adults

Isoniazid (INH) daily or twice weekly for 9 months is the preferred regimen, including persons with HIV infection or radiographic evidence of prior TB.

Isoniazid daily or twice weekly for 6 months. The main advantage of this regimen over the 9-month schedule is greater adherence because of the shorter length. It is also less costly. This regimen may be used for HIV-negative adults with normal chest radiographs; it is not recommended for HIV-positive persons, those <18 years of age, or those with fibrotic lesions on chest radiographs.

Rifampin and pyrazinamide (RIF-PZA) daily or twice weekly for 2 months. This regimen may be used for contacts of patients with INH-resistant TB and for those who are unlikely to complete a longer course of treatment. Rifampin is contraindicated in HIV-positive patients who are receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors, because rifampin greatly stimulates metabolism and decreases the effectiveness of the antiviral drugs. Rifabutin, which causes less enzyme induction than rifampin, may be substituted in some cases. Pyrazinamide is contraindicated during pregnancy.

This regimen was revised in 2001 because of several reports of liver failure and death. To reduce the risks of liver injury, the American Thoracic Society and the CDC, with the endorsement of the Infectious Diseases Society of America, issued new recommendations for choosing patients and for more intensive clinical and laboratory monitoring, as follows:

1. The RIF-PZA regimen is not recommended for persons who have underlying liver disease or who have had INH-associated liver injury. It should be used with caution in patients who take other hepatotoxic medications or use alcohol, even if alcohol use is stopped during treatment. Persons being considered for treatment with this regimen should be informed about potential hepatotoxicity and asked whether they have had liver disease or adverse effects from INH.

2. The RIF-PZA regimen is recommended mainly for clients who are unlikely to complete longer courses of treatment and who can be monitored closely. (For other adults not infected with HIV, the 9-month daily regimen of INH is preferred, with 4 months of daily RIF as an acceptable alternative.)

3. The RIF-PZA regimen does increase risks of hepatotoxicity in clients with HIV infection. Still, INH daily for 9 months is the treatment of choice for HIV-infected persons with LTBI when completion of treatment can be assured.

4. Increase safety by limiting the pyrazinamide dose to <20 mg/kg/d and a maximum of 2 g/d; giving no more than a 2-week supply of rifampin and pyrazinamide at a time; and assessing patients at 2, 4, and 6 weeks of treatment for adherence, tolerance, and adverse effects, and at 8 weeks to document treatment completion. For non-English-speaking clients, health care providers who speak the clients’ language should instruct them to stop taking the drugs immediately and seek medical care if abdominal pain, emesis, jaundice, or other symptoms of hepatitis develop. Provider continuity is recommended for monitoring.

5. Perform liver function tests (eg, serum aspartate and alanine aminotransferases [AST and ALT] and bilirubin) at baseline and at 2, 4, and 6 weeks. RIF-PZA treatment should be stopped and not resumed if enzyme levels are higher than five times the upper limit of normal in an asymptomatic person, are higher than normal range if symptoms of hepatitis are present, or if a serum bilirubin is above normal range.

Rifampin daily for 4 months. This regimen is used mainly for clients who cannot tolerate INH or pyrazinamide.

Special Populations

1. Pregnant women. The preferred regimen for treatment of LTBI is INH, administered daily or twice weekly for 9 or 6 months. Pregnant women taking INH should also take pyridoxine supplementation. For HIV-positive women with higher risks of progression to active TB, treatment should not be delayed; for those with lower risks, some experts recommend waiting until after delivery to start treatment. In general, INH, rifampin, and ethambutol have good safety records in pregnancy. Pyrazinamide and streptomycin are contraindicated during pregnancy.

2. Children and adolescents. INH daily or twice weekly for 9 months is recommended. Infants and children under 5 years of age with LTBI are at high risk for progression to disease. They are also more likely than older children and adults to develop life-threatening forms of TB, including meningeval and disseminated disease. INH therapy appears to be more effective for children than adults, and the risk for INH-related hepatitis is minimal in infants, children, and adolescents, who generally tolerate the drug better than adults. Routine administration of pyridoxine is not recommended for children taking INH, but should be given to breast-feeding infants, children and adolescents with pyridoxine-deficient diets, and children who experience paresthesias when taking INH.

Although few studies have been done in infants, children, and adolescents, rifampin alone, rifampin with INH, and rifampin with pyrazinamide have been used to treat LTBI with effectiveness. Although the optimal length of rifampin therapy in children with LTBI is unknown, the American Academy of Pediatrics recommends 6 months.

There have been no reported studies of any regimen for treatment for LTBI in HIV-infected children. The American Academy of Pediatrics recommends INH for 9 months; most experts recommend routine monitoring of serum liver enzyme concentrations and pyridoxine administration.

3. Contacts of patients with drug-susceptible TB and positive skin-test reactions (>5 mm) should be treated with one of the recommended regimens described above, regardless of age.

4. Contacts of patients with INH-resistant, rifampin-susceptible TB should generally be given rifampin and pyrazinamide for 2 months. For patients with intolerance to pyrazinamide, rifampin alone for 4 months is recommended. If rifampin cannot be used, rifabutin can be substituted.

5. Contacts of patients with multidrug-resistant (MDR)-TB who are at high risk for developing active TB are generally given pyrazinamide and ethambutol or pyrazinamide and a fluoroquinolone (levofloxacin, ofloxacin, or sparfloxacin) for 6 to 12 months. Immunocompetent contacts may be observed without treatment or treated for 6 months; immunocompromised contacts (eg, HIV-infected persons) should be treated for 12 months.

For children exposed to MDR-TB, pyrazinamide and ethambutol are recommended for 9 to 12 months if the isolate is susceptible to both drugs. If these drugs cannot be used, two other (continued)
drugs to which the infecting organism is likely susceptible should be given. Fluoroquinolones are contraindicated in children.

6. HIV-infected persons. With INH, the 9-month regimen is recommended. With rifampin, the drug is contraindicated or should be used with caution in persons who are taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors (NNRTIs). Rifapentin can be substituted for rifampin in some circumstances, but it should not be used with hard-gel saquinavir or delavirdine and must be used cautiously with soft-gel saquinavir and nevirapine because data are limited. Dosage of rifapentin needs to be reduced to one half the usual daily dose (ie, from 300 mg/d to 150 mg/d) with indinavir, nelfinavir, or amprenavir and to one fourth the usual dose (ie, 150 mg every other day or 3 times a week) with ritonavir. Usual dosage (300 mg/d) can be given with nevirapine and 450 mg or 600 mg/d are needed with efavirenz. Rifapentine is not recommended as a substitute for rifampin because its safety, effectiveness, and interactions with anti-HIV medication have not been established.

7. BCG-vaccinated persons. A history of Bacille Calmette-Guérin (BCG) vaccination should not influence the decision to treat LTBI.

**Additional Recommendations**

1. Before beginning treatment for LTBI, active TB should be ruled out by history, physical examination, chest radiography, and bacteriologic studies, if indicated.

2. Allow patients to participate in choosing a treatment regimen, when feasible, by discussing options and characteristics of each (eg, the length and complexity, possible adverse effects, and potential drug interactions).

3. Directly observed therapy (DOT) should be used consistently with intermittent regimens (eg, twice weekly) and when possible with 2-month regimens and in certain settings (eg, institutional settings, community outreach programs, and for persons living in households with patients who are receiving home-based DOT for active TB).

4. Try to ensure completion of treatment. This is determined by the total number of doses administered as well as the duration of therapy. For daily INH, the 9-month regimen should include at least 270 doses in 12 months and the 6-month regimen should include at least 180 doses in 9 months. For twice-weekly INH, the 9-month regimen should include at least 76 doses in 12 months and the 6-month regimen should include at least 52 doses in 9 months. For the 2-month regimen of daily rifampin (or rifabutin) and pyrazinamide, at least 60 doses should be given in 3 months. For the 4-month regimen of daily rifampin alone, at least 120 doses should be given in 6 months.

These schedules allow minor interruptions in therapy although, ideally, patients should receive medication on a regular schedule until the course of therapy is completed. When doses are missed, the duration of therapy should be lengthened. When restarting therapy after interruptions, the original regimen may be continued as long as needed to complete the recommended duration of the particular regimen or a new regimen may be needed if interruptions were frequent or prolonged. If treatment is interrupted for longer than 2 months, the client should be reassessed for active TB before restarting drug therapy.

### Drugs at a Glance: Primary Antitubercular Drugs

<table>
<thead>
<tr>
<th>Name/Route</th>
<th>Dosage Ranges (Maximum dose)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Isoniazid (INH)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO or IM</td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>5 mg/kg</td>
<td>15 mg/kg</td>
</tr>
<tr>
<td></td>
<td>(300 mg)</td>
<td>(900)</td>
</tr>
<tr>
<td><strong>Rifampin (Rifadin)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PO or IV infusion</td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>10 mg/kg</td>
<td>10 mg/kg</td>
</tr>
<tr>
<td></td>
<td>(600 mg)</td>
<td>(600 mg)</td>
</tr>
<tr>
<td><strong>Pyrazinamide</strong></td>
<td>PO</td>
<td>PO</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>15–30 mg/kg</td>
<td>50–70 mg/kg</td>
</tr>
<tr>
<td></td>
<td>(2 g)</td>
<td>(4 g)</td>
</tr>
<tr>
<td><strong>Streptomycin</strong></td>
<td>IM</td>
<td>IM</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>15 mg/kg</td>
<td>25–30 mg/kg</td>
</tr>
<tr>
<td></td>
<td>(1 g)</td>
<td>(1.5 g)</td>
</tr>
<tr>
<td><strong>Ethambutol</strong></td>
<td>(Myambutol)</td>
<td>PO</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>15–25 mg/kg</td>
<td>50 mg/kg</td>
</tr>
<tr>
<td></td>
<td>(2.5 g)</td>
<td>(2.5 g)</td>
</tr>
<tr>
<td><strong>Rifabutin</strong></td>
<td>(Mycobutin)</td>
<td>PO</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>300 mg</td>
<td>Not established</td>
</tr>
<tr>
<td><strong>Rifapentine</strong></td>
<td>(Priftin) PO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>Children</td>
</tr>
<tr>
<td></td>
<td>DAILY</td>
<td>TWICE/WEEK</td>
</tr>
<tr>
<td></td>
<td>150 mg twice a week for 2 mo, then once a week for 4 mo</td>
<td>Not established</td>
</tr>
</tbody>
</table>
penetrates and reaches therapeutic concentrations in essentially all body fluids and cavities. Its half-life is 1 to 4 hours. It is acetylated in the liver to acetylsalicylic acid, which is excreted by the kidneys. Metabolism of INH is genetically determined; some people are “slow acetylators” and others are “rapid acetylators.” A person’s rate of acetylation may be significant in determining response to INH. Slow acetylators have less N-acetyltransferase, the acetylating enzyme, in their livers. In these clients, INH is more likely to accumulate to toxic concentrations and the development of peripheral neuropathy is more likely. However, there is no significant difference in the clinical effectiveness of INH. Rapid acetylators may require unusually high doses of INH. They also may be more susceptible to serious liver injury because of rapid formation of hepatotoxic metabolites. The drug is excreted in urine.

Potentially serious adverse effects include hepatotoxicity and peripheral neuropathy. Hepatotoxicity may be manifested by symptoms of hepatitis (eg, anorexia, nausea, fatigue, malaise, and jaundice) or elevated liver enzymes. The drug should be stopped if hepatitis develops or liver enzymes (eg, alanine [ALT] and aspartate aminotransferases [AST]) are more than five times the normal values. Hepatitis is more likely to occur during the first 8 weeks of INH therapy and in people who use alcohol. Clients receiving INH should be monitored monthly for signs and symptoms of hepatitis. Because of the risk of hepatotoxicity, INH should be used cautiously in clients with preexisting liver disease. Peripheral neuropathy may be manifested by numbness and tingling in the hands and feet. It is most likely to occur in clients who are malnourished or elderly, or who have alcoholism, diabetes mellitus, or uremia. Pyridoxine 25 to 50 mg daily is usually given with INH to minimize peripheral neuropathy.

**Rifampin** is a rifamycin drug that is bactericidal for both intracellular and extracellular tuberculosis organisms. It kills mycobacteria by inhibiting synthesis of ribonucleic acid (RNA) and thereby causing defective, nonfunctional proteins to be produced. Its ability to penetrate intact cells contributes to its effectiveness in tuberculosis because mycobacteria are harbored in host cells. Rifampin and INH are synergistic in combination and eliminate tuberculosis bacilli from sputum and produce clinical improvement faster than any other drug regimen, unless organisms resistant to one or both drugs are causing the disease.

Rifampin is well absorbed with oral administration and diffuses well into body tissues and fluids, with highest concentrations in the liver, lungs, gallbladder, and kidneys. Peak serum concentration occurs in 1 to 3 hours with oral administration and immediately with IV administration. It is metabolized in the liver and excreted primarily in bile; a small amount is excreted in urine. Its elimination half-life is approximately 3 hours with a 300-mg dose and approximately 5 hours with a 600-mg dose. Because it is a strong inducer of drug-metabolizing enzymes, its half-life becomes shorter with continued use. The drug causes a harmless red-orange discoloration of body secretions, including urine, tears, saliva, sputum, perspiration, and feces. It may permanently stain soft contact lenses.

Adverse effects include GI upset, skin rashes, hepatitis, and a harmless red-orange discoloration of urine, tears, sweat, and other body fluids. Soft contact lenses may be permanently stained. Rifampin has many interactions with other drugs. It induces hepatic microsomal enzymes and accelerates the metabolism of numerous other drugs, thereby decreasing their serum concentrations, half-lives, and therapeutic effects. Affected drugs include acetaminophen, anti-AIDS drugs (protease inhibitors and nonnucleoside reverse transcriptase inhibitors; see Chap. 39), benzodiazepines, corticosteroids, cyclosporine, estrogens, fluconazole, ketoconazole, mexiletine, methadone, metoprolol, phenytoin, propranolol, quinidine, oral contraceptives, oral sulfonylureas, theophylline, verapamil, and warfarin. With warfarin, decreased anticoagulant effect occurs approximately 5 to 8 days after rifampin is started and lasts for 5 to 7 days after rifampin is stopped. With methadone, concurrent administration with rifampin may precipitate signs and symptoms of opiate withdrawal unless methadone dosage is increased.

**Rifabutin** (Mycobutin) is another rifamycin that is active against mycobacteria. Its mechanism of action is the same as that of rifampin, so that most rifampin-resistant strains are also resistant to rifabutin. Its two main uses are in patients with HIV infection, to treat *Mycobacterium avium complex (MAC)* disease, and to substitute for rifampin in patients who need both antitubercular and certain antiviral drugs. The major advantages of rifabutin over rifampin are a longer serum half-life (45 hours, on average) and reduced hepatic induction of microsomal metabolism. Rifabutin has no advantage over rifampin in treatment of tuberculosis but may be given concurrently with INH to clients who need prophylaxis against both *M. tuberculosis* and *M. avium*.

Rifabutin is well absorbed from the GI tract; a dose of 300 mg produces peak serum concentration in 23 hours. It is extensively metabolized in the liver (and to a lesser extent in the intestinal wall); it is excreted in urine and bile.

Like rifampin, rifabutin and its metabolites may cause a harmess red-orange discoloration of urine, feces, saliva, sputum, perspiration, and tears. Soft contact lenses may be permanently stained. Adverse effects include GI upset (nausea, vomiting, diarrhea), hepatitis, muscular aches, neutropenia, skin rash, and uveitis (an eye disorder characterized by inflammation, pain, and impaired vision). Hepatotoxicity is rare. Adverse effects increase when rifabutin is administered unusually high doses of INH. They also may be more susceptible to serious liver injury because of rapid formation of hepatotoxic metabolites. The drug is excreted in urine.

**Nursing Notes: Apply Your Knowledge**

Christine Sommers, during chemotherapy for breast cancer, experienced symptoms of tuberculosis (TB) and had an abnormal chest x-ray. Sputum results are not yet available, but treatment with isoniazid and rifampin is started. Ms. Sommers voices anxiety about taking medications that are “toxic” and have so many side effects. How can you individualize your teaching for Ms. Sommers?
with a drug that inhibits cytochrome P4503A4 enzymes (eg, clarithromycin) and inhibits rifabutin metabolism. Safety and effectiveness in children have not been established.

Also similar to rifampin, but to a lesser extent, rifabutin induces drug-metabolizing enzymes in the liver and accelerates the metabolism of numerous drugs. This action decreases concentration and clinical efficacy of beta blockers, corticosteroids, cyclosporine, digoxin, hormonal contraceptives, itraconazole and ketoconazole, methadone, nonnucleoside reverse transcriptase inhibitors, oral hypoglycemic agents, phenytoin, protease inhibitors, theophylline, warfarin, and zidovudine. If these drugs are administered with rifabutin, their dosage may need to be increased.

**Rifapentine** (Priftin) is similar to rifampin in effectiveness, adverse effects, and enzyme induction activity. It is indicated for use in the treatment of pulmonary tuberculosis and must be used with at least one other drug to which the causative organisms are susceptible. The main advantage over rifampin is less frequent administration (once or twice weekly). Its action has a slow onset and peaks in 5 to 6 hours. It is metabolized in the liver and excreted in urine and feces. It has a half-life of 14 hours.

**Ethambutol** (Myambutol) is a tuberculostatic drug that inhibits synthesis of RNA and thus interferes with mycobacterial protein metabolism. It may be a component in a four-drug regimen for initial treatment of active tuberculosis that may be caused by drug-resistant organisms. When culture and susceptibility reports become available (usually several weeks), ethambutol may be stopped if the causative organisms are susceptible to INH and rifampin or continued if the organisms are resistant to INH or rifampin and susceptible to ethambutol. Ethambutol is not recommended for young children (eg, <5 years of age) whose visual acuity cannot be monitored, but may be considered for children of any age when organisms are susceptible to ethambutol and resistant to other drugs. Mycobacterial resistance to ethambutol develops slowly.

Ethambutol is well absorbed from the GI tract, even when given with food. Dosage is determined by body weight and should be changed during treatment if significant changes in weight occur. To obtain therapeutic serum levels, the total daily dose is given at one time. Drug action has a rapid onset, peaks in 2 to 4 hours and lasts 20 to 24 hours. The drug has a half-life of 3 to 4 hours, is metabolized in the liver, and is excreted primarily by the kidneys, either unchanged or as metabolites. Dosage must be reduced with impaired renal function.

A major adverse effect is optic neuritis, an inflammatory, demyelinating disorder of the optic nerve that decreases visual acuity and ability to differentiate red from green. Tests of visual acuity and red-green discrimination are recommended before starting ethambutol and periodically during therapy. If optic neuritis develops, the drug should be promptly stopped. Recovery usually occurs when ethambutol is discontinued.

**Pyrazinamide** is used with INH and rifampin for the first 2 months of treating active TB and with rifampin alone for treatment of latent infection. It is bactericidal against actively growing mycobacteria in macrophages, but its exact mechanism of action is unknown. It is well absorbed from the GI tract and penetrates most body fluids and tissues, including macrophages containing TB organisms. Its action has a rapid onset and peaks in 2 hours. It is metabolized in the liver and excreted mainly through the kidneys. Its half-life is 9 to 10 hours.

The most common adverse effect is GI upset; the most severe adverse effect is hepatotoxicity, and the drug should not be given to a client with preexisting liver impairment unless it is considered essential. Clients without liver impairment should be assessed for symptoms of liver dysfunction every 2 weeks during the usual 8 weeks of therapy. If symptoms occur, liver enzymes (ALT and AST) should be measured. If significant liver damage is indicated, pyrazinamide should be stopped.

Pyrazinamide inhibits urate excretion. This characteristic causes hyperuricemia in most clients and may cause acute attacks of gout, but these are uncommon.

**Streptomycin**, an aminoglycoside antibiotic (see Chap. 35), acts only against extracellular organisms; it does not penetrate macrophages and tuberculous lesions. It may be used in a regimen of 4 drugs to treat active TB when the susceptibility of the causative organism is unknown or in a regimen of 4 to 6 drugs in the treatment of tuberculosis suspected or known to be resistant to INH, rifampin, or both. It may be discontinued when cultures become negative or after a few months of therapy.

### Combination Primary Drugs

Rifamate and Rifater are combination products developed to increase convenience to clients and promote adherence to the prescribed drug therapy regimen (for drug-susceptible tuberculosis). Each Rifamate tablet contains INH 150 mg and rifampin 300 mg, and 2 tablets daily provide the recommended doses for a 6-month, short-course treatment regimen. Rifater contains INH 50 mg, rifampin 120 mg, and pyrazinamide 300 mg and is approved for the first 2 months of a 6-month, short-course treatment regimen. Dosage depends on weight, with 4 tablets daily for clients weighing 44 kg or less, 5 tablets daily for those weighing 45 to 54 kg, and 6 tablets daily for those weighing 55 kg or more.

### Secondary Antitubercular Drugs

Para-aminosalicylic acid (PAS), capreomycin (Capastat), cycloserine (Seromycin), and ethionamide (Trecator SC) are diverse drugs that share tuberculostatic properties. They are indicated for use only when other agents are contraindicated or in disease caused by drug-resistant organisms. They must be given concurrently with other drugs to inhibit emergence of resistant mycobacteria. PAS is available only on special order from the manufacturer.
Other Drugs Used in Multidrug-Resistant Tuberculosis

Amikacin and kanamycin are aminoglycoside antibiotics with activity against mycobacteria. Although they are not usually considered antitubercular drugs, one may be a component of a 4- to 6-drug regimen to treat suspected or known MDR-TB. Similarly, the fluoroquinolones (eg, levofloxacin, ofloxacin, sparfloxacin) have antimycobacterial activity and may be used to treat MDR-TB.

TREATMENT OF ACTIVE TUBERCULOSIS

Adequate drug therapy of clients with active disease usually produces improvement within 2 to 3 weeks, with decreased fever and cough, weight gain and improved well-being, and improved chest x-rays. Treatment should generally be continued for at least 6 months, or 3 months after cultures become negative. Most clients have negative sputum cultures within 3 to 6 months. If the client is symptomatic or the culture is positive after 3 months, noncompliance or drug resistance must be considered. Cultures that are positive after 6 months often include drug-resistant organisms, and an alternative drug therapy regimen is needed. With the increasing prevalence of MDR-TB, guidelines for treatment have changed and continue to evolve in the attempt to promote client adherence and to manage MDR-TB, two of the major problems in drug therapy of tuberculosis,

- The most commonly used regimen consists of INH, rifampin, and pyrazinamide daily for 2 months, followed by INH and rifampin (daily, 2 times weekly, or 3 times weekly) for 4 additional months. If 4% or more of the tuberculosis isolates in the community are INH-resistant organisms, ethambutol or streptomycin should also be given until susceptibility reports become available. If the causative strain of *M. tuberculosis* is susceptible to INH, rifampin, and pyrazinamide, the regimen is continued as with the 3-drug regimen described and the fourth drug (ethambutol or streptomycin) is discontinued. If rifampin is not used, an 18-month course of therapy is considered the minimum. In the absence of drug resistance, INH and rifampin in a 9-month regimen are effective; adding pyrazinamide for the initial 2 months of therapy allows the regimen to be shortened to 6 months.
- For INH-resistant TB, the recommended regimen is rifampin, pyrazinamide, and ethambutol for 6 months. For rifampin-resistant TB, recommended regimens are INH and ethambutol for 18 months or INH, pyrazinamide, and streptomycin for 9 months. For MDR-TB, a 5- or 6-drug regimen, individualized according to susceptibility reports and containing at least 3 drugs to which the organism is susceptible, should be instituted. Such regimens include primary and secondary antitubercular drugs as well as other drugs with activity against *M. tuberculosis*, such as amikacin, kanamycin, levofloxacin, ofloxacin, or sparfloxacin. Some clinicians include at least one injectable agent. The drugs should be given for 1 to 2 years after cultures become negative, preferably with direct observation. Intermittent administration is not recommended for MDR-TB.
- In the intermittent schedules, health care providers (or other responsible adults) either administer the drugs or observe the client taking them (called DOT). This method was developed for clients unable or unwilling to self-administer the drugs independently. DOT increases adherence to and completion of prescribed courses of treatment. It is considered desirable for all treatment regimens and mandatory for intermittent regimens (eg, 2 or 3 times weekly) and regimens for MDR-TB.
- During pregnancy, a 3-drug regimen of INH, rifampin, and ethambutol is usually used, with close monitoring of liver function tests. Pyrazinamide and streptomycin should not be used during pregnancy.

Mycobacterium avium Complex Disease

*Mycobacterium avium* and *Mycobacterium intracellulare* are different types of mycobacteria that resemble each other so closely they are usually grouped together as MAC. These atypical mycobacteria are found in water and soil throughout the United States. The organisms are thought to be transmitted by inhalation of droplets of contaminated water; there is no evidence of spread to humans from animals or other humans.

*M. avium* complex rarely causes significant disease in immunocompetent people but causes an opportunistic pulmonary infection in approximately 50% of clients with advanced HIV infection. Symptoms include a productive cough, weight loss, hemoptysis, and fever. As the disease becomes disseminated through the body, chronic lung disease develops and the organism is found in the blood, bone marrow, liver, lymph nodes, and other body tissues.

The main drugs used in prevention of MAC disease are the macrolides, azithromycin and clarithromycin (see Chap. 37),

Nursing Notes: Ethical/Legal Dilemma

Hong Pham was recently diagnosed with active tuberculosis (TB). His physician is discussing treatment options through a translator. Mr. Pham is against taking medications (isoniazid, rifampin, and ethambutol) that the doctor is prescribing, requesting that he be allowed to cure the TB with herbal remedies.

Reflect on:
- Mr. Pham’s right to refuse treatment.
- The role culture may play in Mr. Pham’s decision.
- The rights of the general public to be protected from infectious disease.
- How to work with Mr. Pham to resolve this conflict.
and rifabutin (described in previous section). Prophylactic drug therapy is recommended to be lifelong. For treatment, a 3-drug regimen of a macrolide (azithromycin 250 mg daily or clarithromycin 1000 mg daily), rifabutin (300 mg daily), and ethambutol (25 mg/kg/d for 2 months, then 15 mg/kg/d) is often used. The drugs may also be given 2 or 3 times weekly. Drug dosages are the same for intermittent regimens except that the larger dose of ethambutol is continued throughout. Streptomycin 500 to 1000 mg twice weekly is usually added for the initial 3 months of treatment when extensive MAC disease is present.

**Nursing Diagnoses**

- Anxiety or Fear related to chronic illness and long-term drug therapy
- Deficient Knowledge: Disease process and need for treatment
- Noncompliance related to adverse drug effects and need for long-term treatment
- Deficient Knowledge: Consequences of noncompliance with the drug therapy regimen
- Risk for Injury: Adverse drug effects

**Planning/Goals**

The client will:

- Take drugs as prescribed
- Keep appointments for follow-up care
- Report adverse drug effects
- Act to prevent spread of tuberculosis

**Interventions**

Assist clients to understand the disease process and the necessity for long-term treatment and follow-up. This is extremely important for the client and the community, because lack of knowledge and failure to comply with the therapeutic regimen lead to disease progression and spread. The American Lung Association publishes many helpful pamphlets, written for the general public, that can be obtained from a local chapter and given to clients and their families. Do not use these as a substitute for personal contact, however.

Use measures to prevent the spread of tuberculosis:

- Isolate suspected or newly diagnosed hospitalized clients in a private room for 2 or 3 weeks, until drug therapy has rendered them noninfectious.
- Wear masks with close contact, and wash hands thoroughly afterward.
- Have clients wear masks when out of the room for diagnostic tests.
- Assist clients to take antitubercular drugs as prescribed, for the length of time prescribed.

**Evaluation**

- Observe for improvement in signs and symptoms of tuberculosis and MAC disease.
- Interview and observe for adverse drug effects; check laboratory reports of hepatic and renal function, when available.
- Question regarding compliance with instructions for taking antitubercular and anti-MAC drugs.

**PRINCIPLES OF THERAPY**

**Drug-Susceptible Tuberculosis**

1. Sputum culture and susceptibility reports require 6 to 8 weeks because the tubercle bacillus multiplies slowly. Consequently, initial drug therapy is based on other factors, such as the extent of disease, whether the
CLIENT TEACHING GUIDELINES
Isoniazid, Rifampin, and Pyrazinamide

ptune with positive skin tests to prevent development of active disease. Vitamin B₆ (pyridoxine) is usually given along with the INH to prevent leg numbness and tingling. Take INH and pyridoxine in a single dose once daily. Take on an empty stomach if possible; if stomach upset occurs, the drugs may be taken with food.

For treatment of active disease, INH, rifampin, and pyrazinamide are usually given daily or twice weekly for 2 months; then the pyrazinamide is stopped and the others are continued for an additional 4 months.

For treatment of inactive or latent tuberculosis infection, various regimens of INH alone, rifampin and pyrazinamide, or rifampin alone may be used. Any one of these regimens can be effective in preventing active disease if the drugs are taken correctly and for the time prescribed.

INH, rifampin, and pyrazinamide can all cause liver damage. As a result, you should avoid alcoholic beverages and watch for signs and symptoms of hepatitis (eg, nausea, yellowing of skin or eyes, dark urine, light-colored stools). If such symptoms occur, you should stop taking the drugs and report the symptoms to the nurse or physician managing the tuberculosis infection immediately. Blood tests of liver function will also be ordered. In some cases, liver failure has occurred, most often when clients continued to take the medications for a week or longer after symptoms of liver damage occurred.

Rifampin should be taken in a single dose, once daily or twice weekly, on an empty stomach, 1 hour before or 2 hours after a meal.

Rifampin causes a reddish discoloration of urine, tears, saliva, and other body secretions. This is harmless, except that soft contact lenses may be permanently stained.

Use all available resources to learn about tuberculosis and the medications used to prevent or treat the infection. This is extremely important because the information can help you understand the reasons long-term treatment and follow-up care are needed. In addition to personal benefit, taking medications as prescribed can help your family and community by helping to prevent spread of tuberculosis. The American Lung Association publishes many helpful pamphlets that are available from local health departments and health care providers. Additional information is available on the Internet. Some sites that provide reliable information include the Centers for Disease Control and Prevention (CDC) Division of Tuberculosis Elimination (DTBE) at http://www.cdc.gov/nchstp/tb/dtbe.html; and the National Tuberculosis Center at http://www.nationaltbcenter.edu/resource.html.

Learn how to prevent spread of tuberculosis:

- Cover mouth and nose when coughing or sneezing. This prevents expelling tuberculosis germs into the surrounding air, where they can be inhaled by and infect others.
- Cough and expectorate sputum into at least two layers of tissue. Place the used tissues in a waterproof bag, and dispose of the bag, preferably by burning.
- Wash hands after coughing or sneezing.
- A nourishing diet and adequate rest help healing of infection.
- Periodic visits to a health care provider are needed for follow-up care and to monitor medications.
- The importance of taking medications as prescribed cannot be overemphasized. If not taken in the doses and for the length of time needed, there is a high likelihood for development of tuberculosis infection that is resistant to the most effective antituberculosis drugs. If this happens, treatment is much longer, very expensive, and requires strong drugs that cause more adverse effects. In addition, this very serious infection can be spread to family members and other close contacts. Thus, avoiding drug-resistant tuberculosis should be a strong incentive to complete the full course of treatment.
- Rifampin decreases the effectiveness of oral contraceptive tablets; a different type of contraception should be used during rifampin therapy.

Multidrug-Resistant Tuberculosis

1. Multidrug-resistant strains may occur anywhere. However, in the United States, they have been most evident in populations with AIDS, in closed environments (eg, hospitals, prisons, long-term care facilities, homeless shelters), and in large urban areas.

2. Drug therapy regimens for people exposed to someone with MDR-TB or suspected of having MDR-TB should be designed in consultation with infectious disease specialists.
3. Treatment of MDR-TB requires concurrent administration of more drugs (eg, 4 to 6), for a longer period of time (eg, 2 years or longer), than for drug-susceptible tuberculosis. The specific regimen is derived from cultures of infecting strains and susceptibility tests with primary, secondary, and other drugs with antimycobacterial activity. It should include 2 or 3 drugs to which the isolate is sensitive and that the client has not taken before. The fluoroquinolones are not recommended for use in children.

4. All drug therapy for suspected or known MDR-TB should involve daily administration and DOT.

5. Treatment is extremely expensive, even in the non-HIV population, and costs many thousand dollars more than the treatment of drug-susceptible TB.

**Increasing Adherence to Antituberculosis Drug Therapy**

Failure to complete treatment regimens is a major problem in TB management because it increases the spread of the disease and the amount of drug-resistant disease in a community. There is more difficulty with getting clients to complete treatment for latent infection than for active disease. Identifying and treating LTBI requires several steps, including administering and reading skin tests, obtaining medical evaluations of infected persons, and initiating, monitoring, and completing treatment. Nonadherence is common in all of these aspects. Numerous strategies have been proposed to increase adherence, including:

1. **Patient/family/contact education.** This may be especially important with treatment of LTBI. Most people are more motivated to take medications and schedule follow-up care when they have symptoms than when they feel well and have no symptoms. The importance of treatment for the future health of the individual, significant others, and the community must be emphasized. In addition, clients should be informed about common and potential adverse effects of drug therapy and what to do if they occur.

2. **Providing support services and resources.** These require substantial financial resources and may include more workers to provide DOT therapy at the client’s location; flexible clinic hours; reducing waiting times for patients; and assisting clients with child care, transportation, or other social service needs that encourage them to initiate and continue treatment. Lack of these services (eg, clinics far from clients’ homes, with inconvenient hours, long waiting times, and unsupportive staff) may deter clients from being evaluated for a positive skin test, initiating treatment, or completing the prescribed treatment and follow-up care.

3. **Individualizing treatment regimens,** when possible, to increase client convenience and minimize disruption of usual activities of daily living. Short-course regimens, intermittent dosing (eg, 2 or 3 times weekly rather than daily), and fixed-dose combinations of drugs (eg, Rifater or Rifamate) reduce the number of pills and the duration of therapy.

4. **Promoting communication and continuity of care.** With clients for whom English is not their primary language, it is desirable to have a health care worker who speaks their language or who belongs to their ethnic group. This worker may be able to more effectively teach clients and others, elicit cooperation with treatment, administer DOT, and be a consistent support person.

**Monitoring Antitubercular Drug Therapy**

There are two main methods of monitoring client responses to treatment, clinical and laboratory. The current trend seems to be increasing clinical monitoring and decreasing laboratory monitoring.

1. **Clinical monitoring** is indicated for all patients. It includes teaching clients about signs and symptoms of adverse drug effects and which effects require stopping drug therapy and obtaining medical care (eg, hepatotoxicity). It also includes regular assessment by a health care provider. Clinical monitoring should be repeated at each monthly visit. Patients should be assessed for signs of liver disease (eg, loss of appetite, nausea, vomiting, dark urine, jaundice, numbness or tingling of the hands and feet, fatigue, abdominal tenderness, easy bruising or bleeding) at least monthly if receiving INH alone or rifampin alone and at 2, 4, and 8 weeks if receiving rifampin and pyrazinamide. In addition to detecting adverse effects, these ongoing contacts are opportunities to reinforce teaching, assess adherence with therapy since the last visit, and observe for drug interactions. A standardized interview form may be helpful in eliciting appropriate information.

2. **Laboratory monitoring** mainly involves liver function tests (ALT and AST and bilirubin). Baseline measurements are indicated for patients with possible liver disorders, those infected with HIV, women who are pregnant or early postpartum (within 3 months of delivery), those with a history of liver disease (eg, hepatitis B or C, alcoholic hepatitis or cirrhosis), those who use alcohol regularly, and those with risk factors for liver disease. Monitoring during therapy is indicated for patients who have abnormal baseline values or other risk factors for liver disease and those who develop symptoms of liver damage. Some clinicians recommend that INH be stopped for transaminase levels over 3 times the upper limit of normal if associated with symptoms and five times the upper limit of normal if the patient is asymptomatic.
Effects of Antitubercular Drugs on Other Drugs

Isoniazid (INH) increases risks of toxicity with several drugs, apparently by inhibiting their metabolism and increasing their blood levels. These include acetaminophen, carbamazepine, haloperidol, ketoconazole, phenytoin (effects of rifampin are opposite to those of INH and tend to predominate if both drugs are given with phenytoin), and vincristine. INH increases the risk of hepatotoxicity with most of these drugs; concurrent use should be avoided when possible or blood levels of the inhibited drug should be monitored. With vincristine, INH may increase peripheral neuropathy.

The rifamycins (rifampin, rifabutin, rifapentine) induce cytochrome P450 drug-metabolizing enzymes and therefore accelerate the metabolism and decrease the effectiveness of many drugs. Rifampin is the strongest inducer and may decrease the effects of angiotensin converting enzyme (ACE) inhibitors, anticoagulants, antidyssrhythmics, some antifungals (eg, fluconazole), anti-HIV protease inhibitors (eg, amprenavir, indinavir, nelfinavir, ritonavir), anti-HIV nonnucleoside reverse transcriptase inhibitors (NNRTIs; delavirdine, efavirenz, nevirapine), benzodiazepines, beta blockers, corticosteroids, cyclosporine, digoxin, diltiazem, doxycycline, estrogens and oral contraceptives, fexofenadine, fluoroquinolones, fluvalastatin, haloperidol, lamotrigine, losartan, macrolide antibiotics, narcotic analgesics (eg, methadone, morphine), nifedipine, ondansetron, phenytoin, propafenone, rifampin, sirolimus, sulfonylureas (eg, glyburide), tacrolimus, tamoxifen, theophylline, thyroid hormones, toremifene, tricyclic antidepressants, verapamil, zaleplon, zidovudine, and zolpidem.

Rifabutin is reportedly a weaker enzyme inducer and may be substituted for rifampin in some cases. It is probably substituted most often for clients who require anti-HIV medications.

Pyrazinamide may decrease effects of allopurinol and cyclosporine.

Use in Human Immunodeficiency Virus (HIV) Infection

Tuberculosis is a common opportunistic infection in people with advanced HIV infection and may develop from an initial infection or reactivation of an old infection. For treatment of latent infection (LTBI) in clients with positive skin tests, 9 months of INH or 2 months of rifampin and pyrazinamide are effective. Both regimens may be given daily or twice weekly. Several cases of serious liver damage and a few deaths have been reported with the rifampin/pyrazinamide combination. Monitoring of liver function is recommended at weeks 2, 4, and 8 of the combination.

Treatment of active disease is similar to that of persons who do not have HIV infection. Those with HIV infection who adhere to standard treatment regimens do not have an increased risk of treatment failure or relapse. Thus, these clients are usually treated with antitubercular drugs for 6 months as are HIV-seronegative clients. The regimen may be longer if the bacteriologic (eg, negative cultures) or clinical response (eg, improvement in symptoms) is slow or inadequate.

A major difficulty with treatment of TB in clients with HIV infection is that rifampin interacts with many protease inhibitors (PIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs). If the drugs are given concurrently, rifampin decreases blood levels and therapeutic effects of the anti-HIV drugs. Rifabutin has fewer interactions and may be substituted for rifampin. The PIs indinavir and nelfinavir and most of the NNRTIs can be used with rifabutin. Ritonavir (PI) and delavirdine (NNRTI) should not be used with rifabutin. Also, amprenavir and indinavir increase risks of rifabutin toxicity. Dosage of rifabutin should be decreased if given with one of these drugs.

Use in Children

Tuberculosis occurs in children of all ages. Infants and preschool children are especially in need of early recognition and treatment because they can rapidly progress from primary infection to active pulmonary disease and perhaps to extrapulmonary involvement. Tuberculosis is usually discovered during examination of a sick child or investigation of the contacts of someone with newly diagnosed active tuberculosis. Most children are infected in their homes. Children in close contact with a case of tuberculosis should receive skin testing, a physical examination, and a chest x-ray.

For treatment of latent infection, only one of the four regimens currently recommended for adults (INH for 9 months) is recommended for those under 18 years of age. For treatment of active disease, the prescribed regimens are similar to those used for adults. That is, the same primary drugs are used and may be given daily, twice weekly, or 3 times weekly with child-appropriate reductions in dosage. If the drug-susceptibility patterns of the M. tuberculosis strain causing the index case are known, the child is treated with those drugs; if this information is not available, the pattern of drug resistance in the community where the child likely became infected should be the guide for selecting the drug therapy regimen. As in adults, drug-susceptible tuberculosis is treated with INH, rifampin, and pyrazinamide for 2 months. Then, pyrazinamide is stopped and the INH and rifampin are continued for 4 more months. If drug-resistant organisms have been identified in the community, a fourth drug, ethambutol or streptomycin, should be given until the client’s culture and susceptibility reports become available. If pyrazinamide is not given, INH and rifampin are recommended for 9 months. When INH or rifampin cannot be used, therapy should continue for 12 to 24 months.

Drug-resistant TB in children is usually acquired from an adult family member or other close contact with active, drug-resistant disease. For children exposed to MDR-TB, there is no proven preventive therapy. Several regimens are used empirically, including ethambutol and pyrazinamide or ethionamide and cycloserine. When INH and rifampin cannot be
given because of MDR-TB, drug therapy should continue for 24 months after sputum smears or cultures become negative. Fluoroquinolones (eg, levofloxacin, ofloxacin) are used for treatment of MDR-TB in adults, but are not recommended for use in children. Clients with MDR-TB may require months of treatment before sputum smears become negative, and they are infectious during this period. To guide dosage and minimize adverse drug effects, serum drug levels should be measured periodically, especially in clients with GI, renal or hepatic disease, or with advanced HIV infection.

In children with HIV infection, the American Academy of Pediatrics recommends 3 drugs for at least 12 months. If drug-resistant or extrapulmonary disease is suspected, 4 drugs are indicated.

Overall, as with adults, drug therapy regimens vary with particular circumstances and continue to evolve. Health care providers must follow current recommendations of pediatric infectious disease specialists.

Use in Older Adults

Although INH is the drug of choice for treatment of latent infection, its use is controversial in older adults. Because risks of drug-induced hepatotoxicity are higher in this population, some clinicians believe those with positive skin tests should have additional risk factors (eg, recent skin test conversion, immunosuppression, or previous gastrectomy) before receiving INH. When INH is given, people who drink alcoholic beverages daily are most likely to sustain serious liver impairment.

For treatment of active disease caused by drug-susceptible organisms, INH, rifampin, and pyrazinamide are given, as in younger adults. Because all three drugs may cause hepatotoxicity, liver function tests should be monitored and the drugs discontinued if signs and symptoms of hepatotoxicity occur. For treatment of suspected or known MDR-TB, four to six drugs are used.

Use in Renal Impairment

Rifampin is mainly eliminated by the liver. However, up to 30% of a dose is excreted by the kidneys and dose reduction may be needed in clients with renal impairment. In addition, dosage of amikacin, capreomycin, cycloserine, ethambutol, fluoroquinolones, and streptomycin should be reduced in clients with impaired renal function. Cycloserine is contraindicated in severe renal impairment.

Use in Hepatic Impairment

Most antitubercular drugs are metabolized in the liver and several (eg, INH, rifampin, and pyrazinamide) are hepatotoxic. Moreover, they are often used concomitantly, which increases risks of hepatotoxicity. To detect hepatotoxicity as early as possible, clients should be thoroughly instructed to report any signs of liver damage and health care providers who administer DOT or have any client contact should observe for and ask about symptoms. For clients at risk of developing hepatotoxicity, serum ALT and AST should be measured before starting and periodically during drug therapy. If hepatitis occurs, these enzymes usually increase before other signs and symptoms develop.

With INH, mild increases in AST and ALT occur in approximately 10% to 20% of clients but are not considered significant and usually resolve without stopping the drug. Hepatitis and liver damage are more likely to occur during the first 8 weeks of INH therapy and in middle-aged and older adults. Clients should be assessed monthly for symptoms of hepatitis (anorexia, nausea, fatigue, malaise, and jaundice). If symptoms occur or if AST and ALT increase significantly (more than five times the normal values), INH should be discontinued. INH should be used cautiously in clients with preexisting liver disease.

With rifampin, liver damage is most likely to occur with preexisting liver disease or concurrent use of other hepatotoxic drugs. Clients should be monitored at least monthly for symptoms of hepatotoxicity. AST and ALT may be measured before starting rifampin and periodically during rifampin therapy. If signs of liver damage occur, the drug should be stopped, serum AST and ALT should be measured, and medical evaluation should be done.

With pyrazinamide, the drug should not be given to a client with preexisting liver impairment unless it is considered absolutely essential. For clients without liver impairment, clinical monitoring for signs and symptoms of hepatotoxicity are recommended every 2 weeks. Serum ALT and AST may also be measured periodically. If significant symptoms or elevations of serum ALT and AST occur, the drug must be stopped.

Home Care

The home care nurse has major roles to play in the health care of clients, families, and communities. With individual clients receiving antitubercular drugs for latent or active infection, the home care nurse needs to assist in taking the drugs as directed. Specific interventions vary widely and may include administering the drugs (DOT); teaching about the importance of taking the drugs and the possible consequences of not taking them (ie, more severe disease, longer treatment regimens with more toxic drugs, spreading the disease to others); monitoring for adverse drug effects and assisting the client to manage them or reporting them to the drug prescriber; assisting in obtaining the drugs and keeping follow-up appointments for blood tests and chest x-rays; and others. Family members may also need teaching related to preventing spread of the disease and assisting the client to obtain adequate treatment. In relation to community needs, the nurse needs to be active in identifying cases, investigating contacts of newly diagnosed cases, and promoting efforts to manage tuberculosis effectively.
### Antitubercular Drugs

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a.</strong> Give isoniazid (INH), ethambutol, and rifampin in a single dose once daily, twice a week, or 3 times a week.</td>
<td>A single dose with the resulting higher blood levels is more effective. Also, less frequent administration is more convenient for clients and more likely to be completed.</td>
</tr>
<tr>
<td><strong>b.</strong> Give INH and rifampin on an empty stomach, 1 h before or 2 h after a meal, with a full glass of water. INH may be given with food if GI upset occurs.</td>
<td>Food delays absorption.</td>
</tr>
<tr>
<td><strong>c.</strong> Give parenteral INH by deep IM injection into a large muscle mass, and rotate injection sites.</td>
<td>To decrease local pain and tissue irritation. Used only when clients are unable to take the medication orally.</td>
</tr>
<tr>
<td><strong>d.</strong> Give IV rifampin by infusion, over 1 to 3 h, depending on dose and volume of IV solution.</td>
<td>For a 600-mg dose, reconstitute with 10 mL sterile water for injection; withdraw the entire amount and add it to 500 mL 5% Dextrose or 0.9% Sodium chloride solution; infuse over 3 h.</td>
</tr>
<tr>
<td><strong>e.</strong> Give rifabutin 300 mg once daily; if GI upset occurs, may give 150 mg twice daily.</td>
<td>Manufacturer’s recommendation</td>
</tr>
<tr>
<td><strong>f.</strong> Give rifapentine on an empty stomach when possible; may give with food if GI upset occurs.</td>
<td>Usually given twice weekly for 2 mo, with 72 h between doses, then once weekly for 4 mo, along with other anti-TB drugs, for treatment of active TB.</td>
</tr>
<tr>
<td><strong>g.</strong> Give secondary anti-TB drugs daily. See drug literature for specific instructions.</td>
<td>These drugs are used only to treat TB infection caused by organisms that are resistant to the primary anti-TB drugs. Therapeutic effects are usually apparent within the first 2 or 3 wk of drug therapy for active disease.</td>
</tr>
</tbody>
</table>

| **2. Observe for therapeutic effects** | |
| **a.** With latent infection, observe for the absence of signs and symptoms. | These symptoms are likely to occur with any of the oral antitubercular drugs. |
| **b.** With active disease, observe for clinical improvement (eg, decreased cough, sputum, fever, night sweats, and fatigue; increased appetite, weight, and feeling of well-being; negative sputum smear and culture; improvement in chest radiographs). | |

| **3. Observe for adverse effects** | |
| **a.** Nausea, vomiting, diarrhea | |
| **b.** Neurotoxicity: | A major adverse reaction to aminoglycoside antibiotics |
| (1) Eighth cranial nerve damage—vertigo, tinnitus, hearing loss | The major adverse reaction to ethambutol |
| (2) Optic nerve damage—decreased vision and color discrimination | Often occurs with INH but can be prevented by administering pyridoxine (vitamin B6). Also may occur with ethambutol. |
| (3) Peripheral neuritis—tingling, numbness, paresthesias | More often associated with INH, but similar changes may occur with ethambutol. |
| (4) Central nervous system changes—confusion, convulsions, depression | May occur with INH, rifampin, and pyrazinamide, especially if the client already has liver damage. Report these symptoms to the prescribing physician immediately, to prevent possible liver failure and death. |
| **c.** Hepatotoxicity—increased serum ALT, AST, and bilirubin; jaundice; and other symptoms of hepatitis (eg, anorexia, nausea, vomiting, abdominal pain) | A major adverse reaction to aminoglycosides |
| **d.** Nephrotoxicity—increased blood urea nitrogen and serum creatinine, cells in urine, oliguria | (continued)
**Review and Application Exercises**

1. How do tuberculosis infections differ from other bacterial infections?
2. Why are clients with AIDS at high risk for development of tuberculosis?
3. What are the main risk factors for development of drug-resistant tuberculosis?
4. Who should receive INH to prevent tuberculosis? Who should not be given INH? Why?
5. When INH is given alone for treatment of latent infection (LTBI), how long should it be taken?
6. If you worked in a health department with clients on INH for treatment of LTBI, what are some interventions to promote client adherence to the drug regimen?
7. Why is active, symptomatic tuberculosis always treated with multiple drugs?

**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypersensitivity reactions are more likely to occur between the third and eighth weeks of drug therapy. Early detection and drug discontinuation are necessary to prevent progressive worsening of the client’s condition. Severe reactions can be fatal.</td>
</tr>
<tr>
<td>The color change is harmless, but clients should avoid wearing soft contact lenses during therapy.</td>
</tr>
<tr>
<td>Women who take rifampin should use a different form of birth control.</td>
</tr>
<tr>
<td>Potentiate antitubercular effects and risks of hepatotoxicity. These drugs are always used in combinations of two or more for treatment of active tuberculosis.</td>
</tr>
<tr>
<td>Increases risk of hepatotoxicity, even if use is stopped during INH therapy.</td>
</tr>
<tr>
<td>Accelerates metabolism of INH to hepatotoxic metabolites and increases risk of hepatotoxicity.</td>
</tr>
<tr>
<td>Increases risk of peripheral neuropathy; avoid the combination if possible.</td>
</tr>
<tr>
<td>Decreases risk of peripheral neuritis.</td>
</tr>
<tr>
<td>May decrease absorption.</td>
</tr>
</tbody>
</table>

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** First, it is important that you hear Ms. Sommers’ concerns and acknowledge them. To comply with treatment, Ms. Sommers needs to see that the benefits are greater than the risks. Provide Ms. Sommers with specific information concerning side effects and how they will be monitored. Peripheral neuropathy and hepatotoxicity are significant side effects. Tell Ms. Sommers to alert you about tingling in her feet or hands. Vitamin B6 tablets can be given to decrease this side effect. Liver function is monitored by watching for symptoms such as jaundice and fatigue and by assessing laboratory results (liver enzymes, bilirubin levels). Warn Ms. Sommers that her urine and other body fluids may turn red, but this is not harmful in any way. Ms. Sommers should also check with her doctor before taking over-the-counter medications because drug interactions with TB medications are common. Provide Ms. Sommers with written material and encourage her to call if she has any questions.
8. In a client with tuberculosis newly started on drug therapy, how could you explain the emergence of drug-resistant organisms and the importance of preventing this problem?

9. What are advantages and disadvantages of short-course (6 to 9 months) treatment programs?

10. What adverse effects are associated with INH, rifampin, pyrazinamide, and ethambutol, and how may they be prevented or minimized?

SELECTED REFERENCES


Antiviral Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe characteristics of viruses and common viral infections.
2. Discuss difficulties in developing and using antiviral drugs.
3. Identify clients at risk for development of systemic viral infections.
4. Differentiate types of antiviral drugs used for herpes infections, human immunodeficiency virus (HIV) infections, influenza A, and respiratory syncytial virus infections.
5. Describe commonly used antiviral drugs in terms of indications for use, adverse effects, and nursing process implications.
6. Discuss the rationale for using combinations of drugs in treating HIV infection.
7. Discuss guidelines for using antiviral drugs in special populations.
8. Teach clients techniques to prevent viral infections.

Critical Thinking Scenario
Mark, a 32-year-old bisexual man, was recently diagnosed with human immunodeficiency virus (HIV) infection with a CD4+ cell count of less than 200. He is started on aggressive drug therapy with Combivir, a reverse transcriptase inhibitor combination, and nelfinavir, a protease inhibitor. Each day he takes 12 pills at a cost of approximately $450.00/week.

Reflect on:
- What is the expected outcome of antiviral therapy in a person infected with HIV?
- Does this patient have the acquired immunodeficiency syndrome (AIDS)?
- Is the HIV-infected person still able to spread the infection to others while on antiviral treatment?
- Who should be responsible for the cost of treatment if private insurance lapses when Mark is no longer able to work?

OVERVIEW
Viruses produce many diseases, including acquired immunodeficiency syndrome (AIDS), hepatitis, pneumonia, and other disorders that affect almost every body system. Many potentially pathogenic viral strains exist. For example, more than 150 viruses infect the human respiratory tract, including approximately 100 types of rhinovirus that cause the common cold. Viruses can be spread by secretions from infected people, ingestion of contaminated food or water, breaks in skin or mucous membrane, blood transfusions, sexual contact, pregnancy, breast-feeding, and organ transplantation. Viral infections vary from mild, localized disease with few symptoms to severe systemic illness and death. Severe infections are more common when host defense mechanisms are impaired by disease or drugs. Additional characteristics of viruses and viral infections are described in the following paragraphs; selected infections are described in Box 39–1.

1. Viruses are intracellular parasites that can live and reproduce only while inside other living cells. They gain entry to human host cells by binding to receptors on cell membranes. All human cells do not have receptors for all viruses; cells that lack receptors for a particular virus are resistant to infection by that virus. Thus, the locations and numbers of the receptors determine which host cells can be infected by a virus. For example, the mucous membranes lining the tracheobronchial tree have receptors for the influenza A virus, and certain white blood cells (eg, helper T lymphocytes) have CD4 molecules, which are the receptors for the human immunodeficiency virus (HIV).
Herpesvirus Infections

Cytomegalovirus Disease and Retinitis

Cytomegalovirus (CMV) infection is extremely common, and most people become infected by adulthood. Infection is usually asymptomatic in healthy, immunocompetent adults. Like other herpesviruses, CMV can cause a primary infection, then remain latent in body tissues, probably for life. This means the virus can be shed in secretions of an asymptomatic host and spread to others by contact with infected saliva, blood, urine, semen, breast milk, and cervical secretions. It also means the virus may lead to an opportunistic infection when the host becomes immunsuppressed. During pregnancy, CMV is transmitted to the fetus across the placenta and may cause infection in the brain, inner ears, eyes, liver, and bone marrow. Learning disabilities and mental retardation can result from congenital CMV infection. Children spread the virus to each other in saliva or urine, while adolescents and adults transmit the virus mainly through sexual contact.

Major populations at risk for the development of CMV infection are patients with cancer who receive immunosuppressant drugs; organ transplant recipients, who must receive immunosuppressant drugs to prevent their body’s rejection of the transplanted organ; and those with advanced human immunodeficiency virus (HIV) infection. Systemic CMV infection occurs mainly from reactivation of endogenous virus, although it may occur from an exogenous source. Active CMV infection may cause cellular necrosis and inflammation in various body tissues. Common manifestations of disease include pneumonia, hepatitis, encephalitis, adrenal insufficiency, gastrointestinal inflammation, and gastric ulcerations.

In the eye, CMV infection produces retinitis, usually characterized by blurred vision and decreased visual acuity. Visual impairment is progressive and irreversible and, if untreated, may result in blindness. CMV retinitis may also indicate systemic CMV infection or may be entirely asymptomatic.

Genital Herpes Infection

Genital herpes infection is caused by the herpes simplex virus (HSV) and produces recurrent, painful, blister-like eruptions of the skin and mucous membranes. The virus is usually transmitted from person to person by direct contact with open lesions or secretions, including genital secretions. Primary infection occurs at a site of viral entry, where the virus infects epithelial cells, produces progeny viruses, and eventually causes cell death. After primary infection, latent virus may become dormant within sensory nerve cells. In response to various stimuli, such as intense sunlight, emotional stress, febrile illness, or menstruation, this latent virus may become reactivated and lead to viral reproduction and shedding.

In the fetus, HSV may be transmitted from an infected birth canal, and neonatal herpes is a serious complication of maternal genital herpes. Neonatal herpes usually becomes evident within the first week of life and may be manifested by the typical clusters of blister-like lesions on skin or mucous membranes. Irritability, lethargy, jaundice, altered blood clotting, respiratory distress, seizures, or coma may also occur. The lesions may heal in 1 to 2 weeks, but clinicians should be aware that neonatal herpes carries a high mortality rate. In immunosuppressed patients, HSV infection may result in severe, systemic disease.

Herpes Zoster

Herpes zoster is caused by the varicella-zoster virus, which is highly contagious and present worldwide. Most children in the United States are infected by early school age. The virus produces chickenpox on first exposure and is spread from person to person by the respiratory route or by contact with secretions from skin lesions. Recovery from the primary infection leaves latent infection in nerve cells. Reactivation of the latent infection (usually later in life) causes herpes zoster (more commonly known as “shingles”), a localized cluster of painful, blister-like skin eruptions. The skin lesions have the same appearance as those of chickenpox and genital herpes. Over several days, the vesicles become pustules, then rupture and heal. Because the virus remains in sensory nerve cells, pain can persist for months after the skin lesions heal. Most cases of herpes zoster infection occur among the elderly and the immunocompromised.

Human Immunodeficiency Virus Infection

HIV infection is caused by a retrovirus that attacks the immune system. Two types of HIV virus have been identified, HIV-1 and HIV-2. Most infections in the United States are caused by HIV-1; HIV-2 infections occur mainly in Africa. HIV binds to a receptor protein located on the surface of CD4+ cells (also called T lymphocytes or helper T cells). The binding of HIV to CD4+ cells and its impending replication will eventually result in cell death. CD4+ cells play pivotal roles in controlling and regulating immune function. The destruction of CD4+ cells eventually results in impairment of the immune system and resultant acquisition of opportunistic infections.

Progression of HIV-1 infection to acquired immunodeficiency syndrome (AIDS) occurs in phases of disease development. The initial phase of infection is characterized by influenza-like symptoms (eg, fever, chills, muscle aches) that may last several weeks. During this time, the virus undergoes rapid and significant replication. The next phase is characterized by a dramatic decline in the rate of viral replication, attributed to a partially effective immune response. During this phase no visible manifestations of HIV infection may be present. Despite the lack of symptoms, replication of HIV continues and antibodies may be detected in the serum (seroconversion). During this period, which may last 10 years, the person is seropositive (HIV+) and infectious but asymptomatic. Eventually, the immune system is substantially damaged and the rate of viral reproduction accelerates. When viral load and immunodeficiency reach significant levels, the illness is termed AIDS. This phase is characterized by decreased CD4+ cell counts, loss of immune responses, and onset of opportunistic infections such as Pneumocystis carinii pneumonia.

HIV can spread to a new host during any phase of infection. The virus is most commonly spread by sexual intercourse, injection of intravenous drugs with contaminated needles, mucous membrane contact with infected blood or body fluids, and perinatally from mother to fetus. Although the virus is found in most body fluids, infection has primarily been associated with exposure to blood, semen, or vaginal secretions. The virus is not spread through casual contact. Health care workers have been infected by needlestick injuries and should be aware that postexposure prophylaxis is available and may significantly reduce the risk of transmission in these cases.

Respiratory Syncytial Virus Infection

The respiratory syncytial virus (RSV) is a highly contagious virus that is present worldwide and infects most children by school age. Epidemics of RSV infection often occur in nurseries, day care centers, and pediatric hospital units during winter months. This virus infects and destroys respiratory epithelium in the bronchi, bronchioles, and alveoli. It is spread by respiratory droplets and secre-
2. Once inside host cells, viruses use cellular metabolic activities for their own survival and replication. Viral replication involves dissolution of the protein coating and exposure of the genetic material (deoxyribonucleic acid [DNA] or ribonucleic acid [RNA]). With DNA viruses, the viral DNA enters the host cell’s nucleus, where it becomes incorporated into the host cell’s chromosomal DNA. Then, host cell genes are coded to produce new viruses. In addition, the viral DNA incorporated with host DNA is transmitted to the host’s daughter cells during host cell mitosis and becomes part of the inherited genetic information of the host cell and its progeny. With RNA viruses (eg, HIV), viral RNA must be converted to DNA by an enzyme called reverse transcriptase before replication can occur.

Once new viruses are formed, they are released from the infected cell by budding out and breaking off from the cell membrane (leaving the host cell intact) or by causing lysis of the cell. When the cell is destroyed, the viruses are released into the blood and surrounding tissues, from which they can transmit the viral infection to other host cells.

3. Viruses induce antibodies and immunity. Antibodies are proteins that defend against microbial or viral invasion. They are very specific (ie, an antibody protects only against a specific virus or other antigen). For instance, in a person who has had measles, antibody protection (immunity) develops against future infection by the measles virus, but immunity does not develop against other viral infections, such as chickenpox or hepatitis.

The protein coat of the virus allows the immune system of the host to recognize the virus as a “foreign invader” and to produce antibodies against it. This system works well for most viruses but does not work for the influenza A virus, which can alter its protein covering so much and so often that the immune system does not recognize it as foreign to the body. Thus, last year’s antibody cannot recognize and neutralize this year’s virus.

Antibodies against infecting viruses can prevent the viruses from reaching the bloodstream or, if they are already in the bloodstream, prevent their invasion of host cells. Once the virus has penetrated the cell, it is protected from antibody action and the host depends on cell-mediated immunity (lymphocytes and macrophages) to eradicate the virus along with the cell harboring it.

4. Viral infection may occur without signs and symptoms of illness. If illness does occur, the clinical course is usually short and self-limited. Recovery occurs as the virus is eliminated from the body. Some viruses (eg, herpesviruses) can survive in host cells for many years and cause a chronic, latent infection that periodically becomes reactivated. Also, autoimmune diseases may be caused by viral alteration of host cells so that lymphocytes recognize the host’s own tissues as being foreign.

5. Symptoms usually associated with acute viral infections are called “constitutional symptoms” and include fever, headache, cough, malaise, muscle pain, nausea and vomiting, diarrhea, insomnia, and photophobia. White blood cell counts usually remain normal. Other signs and symptoms vary with the type of virus and body organs involved.

### Antiviral Drugs

Few antiviral drugs were available before the AIDS epidemic. Since then, numerous drugs have been developed to treat HIV infection and opportunistic viral infections that occur in hosts whose immune systems are suppressed by AIDS or immunosuppressant drugs given to organ transplant recipients. Drug therapy for viral infections is still limited, however, because drug development is difficult. Viruses use the metabolic and reproductive mechanisms of host cells for their own vital functions, and few drugs inhibit viruses without being excessively toxic to host tissues. Most of these agents inhibit viral reproduction but do not eliminate viruses from tissues. Available drugs are expensive, relatively toxic, and effective in a limited number of infections. Some may be useful in treating an established infection if given promptly and in chemoprophylaxis if given before or soon after exposure. Protection conferred by chemoprophylaxis is immediate but lasts only while the drug is being taken. Subgroups of antiviral drugs are described in the following sections; additional characteristics and dosage ranges are listed in the Drugs at a Glance tables.
## Drugs at a Glance: Drugs for Prevention or Treatment of Selected Viral Infections

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Herpes Virus Infections</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acyclovir (Zovirax)</td>
<td>Oral mucocutaneous lesions (eg, cold sores, fever blisters) Genital herpes Herpes simplex encephalitis Varicella (chickenpox) in immunocompromised hosts Herpes zoster (shingles) in normal and immunocompromised hosts</td>
<td><strong>Adults</strong>: Genital herpes, PO 200 mg q4h, five times daily for 10 d for initial infection; 400 mg two times daily to prevent recurrence of chronic infection; 200 mg q4h five times daily for 5 d to treat recurrence Herpes zoster, PO 800 mg q4h five times daily for 7–10 d Chickenpox, PO 20 mg/kg (maximum dose 800 mg) four times daily for 5 d Mucosal and cutaneous herpes simplex virus (HSV) infections in immunocompromised hosts (ICH), IV 5 mg/kg infused at constant rate over 1 h, q8h for 7 d Varicella-zoster infections in ICH, IV 10 mg/kg, infused as above, q8h for 7 d HSV encephalitis, IV 10 mg/kg infused as above, q8h for 10 d <strong>Children</strong>: (&lt;12\ y): IV 250 mg/m² q8h for 7 d</td>
</tr>
<tr>
<td>Cidofovir (Vistide)</td>
<td>Treatment of CMV retinitis in persons with AIDS</td>
<td><strong>Adults</strong>: CMV retinitis, IV 60 mg/kg q8h for 2–3 wk, depending on clinical response, then 90–120 mg/kg/d for maintenance HSV infections, IV 40 mg/kg q8–12h for 2–3 wk or until lesions are healed <strong>Children</strong>: Dosage not established</td>
</tr>
<tr>
<td>Famciclovir (Famvir)</td>
<td>Acute herpes zoster Genital herpes, recurrent episodes</td>
<td><strong>Adults</strong>: Topically to lesions q3h, six times daily for 7 d</td>
</tr>
<tr>
<td>Foscarnet (Foscavir)</td>
<td>Treatment of CMV retinitis in persons with AIDS Treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised clients</td>
<td><strong>Adults</strong>: IV infusion, 5 mg/kg over 1 h, every 2 wk</td>
</tr>
<tr>
<td>Ganciclovir (Cytovene)</td>
<td>CMV retinitis in immunocompromised clients Prevention of CMV disease in clients with organ transplants or advanced HIV infection</td>
<td><strong>Adults</strong>: Reduce dosage with impaired renal function</td>
</tr>
<tr>
<td>Trifluridine (Viroptic)</td>
<td>Keratoconjunctivitis caused by herpes viruses</td>
<td><strong>Adults</strong>: Topically to eye, 1% opthalmic solution, 1 drop q2h while awake (maximum 9 drops/d) until re-epithelialization of corneal ulcer occurs; then 1 drop q4h (maximum 5 drops/d) for 7 d</td>
</tr>
<tr>
<td>Valacyclovir (Valtrex)</td>
<td>Herpes zoster and recurrent genital herpes in immunocompetent clients</td>
<td><strong>Adults</strong>: Recurrent genital herpes, PO 500 mg q12h daily for 5 d Reduce dosage with renal impairment (creatinine clearance (&lt;50\ \text{mL/min}))</td>
</tr>
<tr>
<td>Vidarabine (Vira-A)</td>
<td>Keratoconjunctivitis caused by herpes viruses</td>
<td><strong>Adults</strong>: IV 15 mg/kg/d dissolved in 2500 mL of fluid and given over 12–24 h daily for 10 d Topically to eye, 3% ophthalmic ointment, applied q3h until re-epithelialization, then twice daily for 7 d</td>
</tr>
<tr>
<td><strong>Influenza Virus Infection</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amantadine (Symmetrel)</td>
<td>Prevention or treatment of influenza A infection</td>
<td><strong>Adults</strong>: PO 200 mg once daily or 100 mg twice daily Reduce dosage with renal impairment (creatinine clearance (&lt;50\ \text{mL/min}))</td>
</tr>
</tbody>
</table>

(continued)
Drugs for Herpesvirus Infections

Acyclovir, famciclovir, and valacyclovir penetrate virus-infected cells, become activated by an enzyme, and inhibit viral DNA reproduction. They are used in the treatment of herpes simplex and herpes zoster infections. Acyclovir is used to treat genital herpes, in which it decreases viral shedding and the duration of skin lesions and pain. It does not eliminate inactive virus in the body and thus does not prevent recurrence of the disease unless oral drug therapy is continued. Acyclovir is also used for treatment of herpes simplex infections in immunocompromised clients. Prolonged or repeated courses of acyclovir therapy may result in the emergence of acyclovir-resistant viral strains, especially in immunocompromised clients. Acyclovir can be given orally, intravenously (IV), or applied topically to lesions. IV use is recommended for severe genital herpes in nonimmunocompromised patients and any herpes infections in immunocompromised patients. Oral and IV acyclovir are excreted mainly in urine, and dosage should be decreased in patients who are elderly or have renal impairment.

Famiclovir and valacyclovir are oral drugs for herpes zoster and recurrent genital herpes. Famiclovir is metabolized to penciclovir, its active form, and excreted mainly in the urine. Valacyclovir is metabolized to acyclovir by enzymes in the liver and/or intestine and is eventually excreted in the urine. As with acyclovir, dosage of these drugs must be reduced in the presence of renal impairment.

Cidofovir, foscarnet, ganciclovir, and valganciclovir also inhibit viral reproduction after activation by a viral enzyme found in virus-infected cells. The drugs are used to treat cytomegalovirus (CMV) retinitis most commonly in patients with AIDS. In addition, foscarnet is used to treat acyclovir-resistant mucocutaneous herpes simplex infections in people with impaired immune functions. Valganciclovir and ganciclovir are used to prevent CMV disease, mainly in patients with organ transplants or HIV infection. Dosage of these drugs must be reduced with renal impairment. Ganciclovir causes granulocytopenia and thrombocytopenia in approximately 20% to 40% of recipients. These hematologic effects often occur during the first 2 weeks of therapy but may occur at any time. If severe bone marrow depression occurs, ganciclovir should be discontinued. Recovery usually occurs within a week of stopping the drug. Foscarnet and cidofovir should be used cautiously in patients with renal disease.

Trifluridine and vidarabine are applied topically to treat keratoconjunctivitis and corneal ulcers caused by the herpes simplex virus (herpetic keratitis). Trifluridine should not be used longer than 21 days because of possible ocular toxicity. Vidarabine also is given IV to treat herpes zoster infections in patients whose immune systems are impaired and encephalitis caused by herpes simplex viruses. IV dosage must be reduced with impaired renal function.

**Drugs for HIV Infection and AIDS (Antiretrovirals)**

Four classes of drugs currently exist for the management of HIV infection: nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors. Each class inhibits enzymes required for viral replication in human host cells (Fig. 39–1). To increase effectiveness and decrease viral mutations and emergence of drug-resistant viral strains, the drugs are used in combination. All of the drugs can cause serious adverse effects and require intensive monitoring.

**Nucleoside Reverse Transcriptase Inhibitors**

The NRTIs are structurally similar to specific DNA components (adenosine, cytosine, guanosine, or thymidine) and thus easily enter human cells and viruses in human cells. For example, zidovudine, the prototype, is able to substitute for...
### Drugs at a Glance: Drugs for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nucleoside Reverse Transcriptase Inhibitors (NRTIs)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Zidovudine (AZT, ZVD, Retrovir) | Prototype NRTI  
Well absorbed with oral administration  
Metabolized in the liver to an inactive metabolite, which is excreted in urine  
Often causes severe anemia and granulocytopenia, which may require stopping the drug, giving blood transfusions, or giving filgrastim or sargramostim to hasten bone marrow recovery  
May also cause peripheral neuropathy and pancreatitis | PO 300 mg twice daily | 3 mo to 12 y: 180 mg/m² q6h (not to exceed 200 mg q6h)  
Neonate born of HIV-infected mother who took the drug during pregnancy, labor, and delivery, PO 2 mg/kg q6h starting within 12 h of birth and continuing until 6 wk of age. If unable to take oral drug, give 1.5 mg/kg IV q6h, infused over 30 min. | |
| Abacavir (Ziagen) | Well absorbed with oral administration  
Approximately 50% bound to plasma proteins  
Metabolized to inactive metabolites that are excreted in urine and feces  
May cause serious hypersensitivity reactions | PO 300 mg twice daily | >3 mo: PO 8 mg/kg twice daily (maximum dose, 300 mg twice daily) |
| Didanosine (ddl, Videx, Videx EC) | Used for patients who do not respond to or cannot tolerate zidovudine | PO 200 mg twice daily or 400 mg (enteric coated) once daily | <0.4 m² BSA: PO 25 mg q12h  
0.5–0.7 m² BSA: PO 50 mg q12h  
0.8–1 m² BSA: PO 75 mg q12h  
1.1–1.4 m² BSA: PO 100 mg q12h | |
| Lamivudine (Epivir) | Used to treat advanced HIV infection and chronic hepatitis B  
Well absorbed with oral administration and mainly eliminated unchanged in urine  
Dosage should be reduced with renal impairment | PO 150 mg twice daily  
Weight <50 kg (110 lbs): PO 2 mg/kg twice daily | 3 mo to 12 y: PO 4 mg/kg twice daily  
12–16 y: PO same as adults | |
| Stavudine (Zerit) | Used to treat adults who do not improve with or do not tolerate other anti-HIV medications  
May be useful against zidovudine-resistant strains of HIV  
Approximately 40% is eliminated through the kidneys, and dosage should be reduced with renal impairment  
May cause peripheral neuropathy | Weight ≥60 kg, PO 40 mg q12h  
Weight <60 kg, PO 30 mg q12h | Dosage not established | |
| Zalcitabine (Hivid) | Used with zidovudine to treat advanced HIV infection in adults whose condition continues to deteriorate while receiving zidovudine  
May cause peripheral neuropathy | PO 0.75 mg q6h (2.25 mg/d) with zidovudine 200 mg q8h (600 mg/d) | Dosage not established | |
| Zidovudine and Lamivudine (Combivir) | Combination product to reduce pill burden  
May cause peripheral neuropathy | One capsule twice daily | Dosage not established | |
| Zidovudine, Lamivudine, and Abacavir (Trizivir) | Combination product to reduce pill burden | One capsule twice daily | Dosage not established | |

### Nucleotide Reverse Transcriptase Inhibitors

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
</table>
| Tenofovir DF (Viread) | Used for salvage therapy after multiple drug failures.  
Efficacious against hepatitis B. | 300 mg once daily | Dosage not established |
## Drugs at a Glance: Drugs for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Delavirdine (Rescriptor)</td>
<td>Used with NRTIs and protease inhibitors</td>
<td><strong>PO 400 mg (four 100-mg tablets) three times daily</strong></td>
</tr>
<tr>
<td></td>
<td>Well absorbed with oral administration and metabolized in the liver</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induces drug-metabolizing enzymes in the liver and increases metabolism of itself and other drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Common adverse effects are nausea and skin rash.</td>
<td></td>
</tr>
<tr>
<td>Efavirenz (Sustiva)</td>
<td>May cause CNS side effects</td>
<td><strong>PO 600 mg at bedtime</strong></td>
</tr>
<tr>
<td></td>
<td>Well absorbed with oral administration and metabolized in the liver</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induces drug-metabolizing enzymes in the liver and increases metabolism of itself and other drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adverse effects include severe skin reactions and hepatotoxicity.</td>
<td></td>
</tr>
<tr>
<td>Nevirapine (Viramune)</td>
<td>Well absorbed with oral administration and metabolized in the liver</td>
<td><strong>PO 200 mg once daily for 2 wk, then 200 mg twice daily</strong></td>
</tr>
<tr>
<td></td>
<td>Induces drug-metabolizing enzymes in the liver and increases metabolism of itself and other drugs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adverse effects include severe skin reactions and hepatotoxicity.</td>
<td></td>
</tr>
<tr>
<td><strong>Protease Inhibitors</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amprenavir (Agenerase)</td>
<td>Well absorbed after oral administration</td>
<td><strong>PO 1200 mg (eight 150-mg capsules) twice daily</strong></td>
</tr>
<tr>
<td></td>
<td>Oral solution less bioavailable than capsules, thus the two dosage forms are not equivalent on a milligram basis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Highly bound to plasma proteins</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Metabolized in liver; small amount of unchanged drug excreted in urine and feces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>May cause serious skin reactions</td>
<td></td>
</tr>
<tr>
<td>Indinavir (Crixivan)</td>
<td>Well absorbed and approximately 60% bound to plasma proteins.</td>
<td><strong>PO 800 mg (two 400-mg capsules) q8h</strong></td>
</tr>
<tr>
<td></td>
<td>Metabolized in the liver and excreted mainly in feces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>May cause GI upset and kidney stones</td>
<td></td>
</tr>
<tr>
<td>Nelfinavir (Viracept)</td>
<td>Metabolized in the liver</td>
<td><strong>1250 mg twice daily</strong></td>
</tr>
<tr>
<td></td>
<td>Most common adverse effect is diarrhea, which can be controlled with over-the-counter drugs such as loperamide.</td>
<td></td>
</tr>
<tr>
<td>Ritonavir (Norvir)</td>
<td>Metabolized in the liver</td>
<td><strong>PO 600 mg twice daily</strong></td>
</tr>
<tr>
<td></td>
<td>May cause GI upset</td>
<td></td>
</tr>
<tr>
<td>Saquinavir (Fortovase)</td>
<td>Not well absorbed, undergoes first-pass metabolism in the liver, and is highly bound to plasma proteins</td>
<td><strong>PO 1200 mg (six 200-mg tablets) three times daily</strong></td>
</tr>
<tr>
<td></td>
<td>Metabolized in the liver and excreted mainly in feces</td>
<td></td>
</tr>
<tr>
<td></td>
<td>May cause GI upset</td>
<td></td>
</tr>
<tr>
<td></td>
<td>May produce fewer drug interactions than indinavir and ritonavir</td>
<td></td>
</tr>
<tr>
<td>Kaletra (Lopinavir and Ritonavir)</td>
<td>Combination product composed of two protease inhibitors</td>
<td><strong>3 capsules twice daily</strong></td>
</tr>
<tr>
<td></td>
<td>Ritonavir boosts lopinavir levels manifold</td>
<td></td>
</tr>
</tbody>
</table>

BSA, body surface area
CHAPTER 39 ANTIVIRAL DRUGS

583

thymidine. In infected cells, these drugs inhibit reverse transcriptase, an enzyme required by retroviruses to convert RNA to DNA and allow replication. The drugs are more active in preventing acute infection than in treating chronically infected cells. Thus, they slow progression but do not cure HIV infection or prevent transmission of the virus through sexual contact or blood contamination.

Zidovudine, the first NRTI to be developed, is still widely used. However, zidovudine-resistant viral strains are common. Other NRTIs are usually given in combination with zidovudine or as a substitute for zidovudine in patients who are unable to take or do not respond to zidovudine.

**Nucleotide Reverse Transcriptase Inhibitors**

This class of antiretroviral drugs is the newest and currently includes one agent. These drugs, like the NRTIs, inhibit the reverse transcriptase enzyme. However, they differ structurally from the NRTIs, and this difference helps them to circumvent acquired drug resistance. The drugs are partially activated and begin inhibiting HIV replication soon after ingestion. Tenofovir is the first available drug from this class; it can be dosed once daily. Tenofovir has also demonstrated efficacy in the treatment of hepatitis B.

**Non-nucleoside Reverse Transcriptase Inhibitors**

The NNRTIs inhibit viral replication in infected cells by directly binding to reverse transcriptase and preventing its function. They are used in combination with NRTIs to treat patients with advanced HIV infection. Because the two types of drugs inhibit reverse transcriptase by different mechanisms, they have synergistic antiviral effects. NNRTIs are also used with other antiretroviral drugs because drug-resistant strains emerge rapidly when the drugs are used alone.

**Protease Inhibitors**

Protease inhibitors exert their effects against HIV at a different phase of its life cycle than reverse transcriptase inhibitors. Protease is an HIV enzyme required to process viral protein precursors into mature viral particles that are capable of infecting other cells. The drugs inhibit the enzyme by binding to the protease-active site. This inhibition causes the production of immature, noninfectious viral particles. These drugs are active in both acutely and chronically infected cells because they block viral maturation.

Most protease inhibitors are metabolized in the liver by the cytochrome P450 enzyme system and should be used cautiously in patients with impaired liver function. They should be used cautiously in pregnant women because few data exist. It is unknown whether the drugs are excreted in breast milk, but this may be irrelevant because the Centers for Disease Control and Prevention (CDC) advise women with HIV infection to avoid breast-feeding because HIV may be transmitted to an uninfected infant. Safety and efficacy of protease inhibitors in children have not been established.

**Nursing Notes: Apply Your Knowledge**

Nick, a 19-year-old college student, is diagnosed with genital herpes at the student health center. Acyclovir 200 mg q4h is prescribed for 10 days. In addition, acyclovir 400 mg is ordered bid to control recurrence of symptoms when lesions appear. What client teaching will Nick need at this time?
with resistant strains developing in approximately half of the recipients within a year of drug therapy. In relation to drug interactions, protease inhibitors interfere with metabolism, increase plasma concentrations, and increase risks of toxicity of numerous other drugs metabolized by the cytochrome P450 (CYP450) enzymes in the liver.

Ritonavir is the most potent CYP450 inhibitor among the protease inhibitor class. It may increase plasma concentrations of amiodarone, bepridil, bupropion, clozapine, flecainide, meperidine, piroxicam, propafenone, propoxyphene, quinidine, and rifabutin. None of these drugs should be given concomitantly with ritonavir because high plasma concentrations may cause cardiac dysrhythmias, hematoLOGII abnormalities, seizures, and other potentially serious adverse effects. In addition, ritonavir may increase sedation and respiratory depression when used concurrently with benzodiazepines (eg, alprazolam, diazepam) and zolpidem.

Indinavir increases plasma concentrations of several of the same drugs listed previously and should not be given concomitantly with them because of potential cardiac arrhythmias or prolonged sedation. Saquinavir may produce fewer interactions because it inhibits the cytochrome P450 enzyme system to a lesser extent than indinavir and ritonavir. However, if saquinavir is given with clindamycin, quinidine, triazolam, or a calcium channel blocker, patients should be monitored closely for increased plasma levels and adverse drug effects.

Amprenavir is a sulfonamide and should be used with caution in clients known to be allergic to sulfonamides. The likelihood of cross-sensitivity reactions between amprenavir and other sulfonamides is unknown. The drug formulation contains high concentrations of vitamin E, and patients using this drug should be cautioned against taking any additional vitamin E supplements. Amprenavir should be discontinued with the occurrence of severe skin rashes or moderate rashes with systemic symptoms.

**Combination Drugs**

In HIV infection, as in many other conditions, the use of combination drugs is increasing. Antiretroviral drug regimens are complex and involve the ingestion of many pills daily. Adherence to the regimens is difficult but critical in preventing the development of drug resistance. Combination products decrease the “pill burden” and promote adherence. Combivir (lamivudine and zidovudine), Trizivir (abacavir, lamivudine, and zidovudine), and Kaletra (lopinavir and ritonavir) are currently available. Kaletra is a combination of two protease inhibitors in which ritonavir is added to increase serum concentrations of lopinavir. Lopinavir is not available as a single agent.

**Drugs for Influenza A**

Amantadine and rimantadine inhibit replication of the influenza A virus and are used to prevent or treat influenza A infections. Postexposure prophylaxis with either drug protects contacts of people with influenza A infections. Seasonal prophylaxis may be used in high-risk patients if the influenza vaccine cannot be given or may be ineffective. In epidemics, one of the drugs is recommended for patients at high risk who have not been vaccinated. The high-risk population includes older adults, those who have chronic lung disease, and those who have immunodeficiency disorders. During an epidemic, amantadine or rimantadine may be given for approximately 2 weeks if the client is vaccinated at the beginning of drug therapy or approximately 4 to 8 weeks if the client is unvaccinated. Protection is lost within a few days after drug therapy is stopped. For treatment of influenza A infection, either drug may shorten the illness if started soon after onset and continued for 5 days. The drugs may also decrease viral shedding and spread.

Amantadine and rimantadine are well absorbed after oral administration. Amantadine is excreted in the urine unchanged. It accumulates in the body of elderly adults and others with impaired renal function, and dosage therefore should be reduced in these groups. Rimantadine is extensively metabolized, with small amounts excreted in the urine. The most common adverse effects of the drugs are gastrointestinal (GI) (anorexia, nausea) and central nervous system (CNS) (nervousness, lightheadedness, difficulty concentrating) symptoms. CNS effects are more likely to occur with amantadine than rimantadine, and high plasma levels of amantadine have been associated with delirium, hallucinations, seizures, coma, and cardiac dysrhythmias. Amantadine has also been associated with exacerbations of preexisting seizure disorders and psychiatric symptoms. Amantadine is teratogenic in animals, and neither drug has been established as safe for pregnant women.

Amantadine is also used in the treatment of Parkinson’s disease and for extrapyramidal symptoms associated with the use of certain antipsychotic drugs (see Chap. 12).

Oseltamivir (Tamiflu) and zanamivir (Relenza) are approved for treatment of influenza A or B in clients with symptoms for 2 days or less. They are used for 5 days. Oseltamivir is an oral drug; zanamivir is a powder form for oral inhalation with a device called a Diskhaler. Zanamivir may cause bronchospasm in clients with asthma or chronic obstructive pulmonary disease.

**Drug for Respiratory Syncytial Virus**

**Respiratory Tract Infections**

Ribavirin is used for the treatment of bronchiolitis or pneumonia caused by the respiratory syncytial virus (RSV). It is used in hospitalized infants and young children and given by inhalation with the Viratek Small Particle Aerosol Generator. The drug is not recommended for clients on ventilators because it precipitates and may block breathing tubes, including endotracheal tubes. Deterioration of pulmonary function is a common adverse effect. The drug is absorbed systemically after administration by aerosol. Most infants and chil-
dren with RSV infections have mild, self-limited disease that does not involve the lower respiratory tract and therefore does not require hospitalization or ribavirin therapy.

### Nursing Process

#### Assessment
- Assessment varies with the type of viral infection and may include signs and symptoms of influenza or other viral infections of the respiratory tract, genital herpes, viral infections of the eye, or other conditions.
- Assess renal function and adequacy of fluid intake.
- With HIV infection, assess baseline data to assist in monitoring response to drug therapy. Baseline data may include vital signs, weight and nutritional status, signs and symptoms of the disease, signs and symptoms of opportunistic infections associated with the disease and immunosuppression, and available reports of laboratory tests (eg, complete blood count, CD4+ lymphocyte counts, plasma levels of viral RNA, blood urea nitrogen and serum creatinine, liver function tests).

#### Nursing Diagnoses
- Anxiety related to a medical diagnosis of HIV infection, genital herpes, or CMV retinitis
- Altered Sexuality Patterns related to sexually transmitted viral infections (HIV infection, genital herpes)
- Disturbed Body Image related to sexually transmitted infection
- Social Isolation related to a medical diagnosis of HIV infection or genital herpes
- Deficient Knowledge: Disease process and methods of spread; availability of vaccines and other prophylactic interventions
- Risk for Injury: Recurrent infection; adverse drug effects or interactions; infections and other problems associated with compromised immune systems in HIV infection

#### Planning/Goals

*The client will:*
- Receive or take antiviral drugs as prescribed
- Be safeguarded against new or recurrent infection
- Act to prevent spread of viral infection to others and recurrence in self
- Avoid preventable adverse drug effects
- Receive emotional support and counseling to assist in coping with HIV infection or genital herpes

#### Interventions
- Follow recommended policies and procedures for preventing spread of viral infections.
- Assist clients in learning ways to control spread and recurrence of viral infection.
- Assist clients to maintain immunizations against viral infections.

#### Evaluation
- Observe for improvement in signs and symptoms of the viral infection for which a drug is given.
- Interview outpatients regarding their compliance with instructions for taking antiviral drugs.
- Interview and observe for use of infection control measures.
- Interview and observe for adverse drug effects.
- Observe the extent and severity of any symptoms in clients with HIV infection.

### PRINCIPLES OF THERAPY

#### Prevention of Viral Infections

General preventive measures include vaccination, hand washing, teaching infected clients to cover their mouth and nose when coughing or sneezing, treatment of symptoms, and recognition and treatment of complications. Of the sexually transmitted viral infections, genital herpes can be prevented by avoiding sex when skin lesions are present and using condoms; HIV infection can be prevented by the consistent use of condoms and use of clean needles by IV drug abusers.

#### Viral Vaccines

Viral vaccines are used to produce active immunity in patients before exposure or to control epidemics of viral disease in a community. Vaccines for prevention of poliomyelitis, measles, rubella, mumps, smallpox, chickenpox, and yellow fever and for protection against influenza and rabies are available (see Chap. 43). Live attenuated viral vaccines are generally safe and nontoxic. However, they should not be used in patients who are pregnant, immunodeficient, receiving corticosteroids, antineoplastic or immunosuppressive drugs, or irradiation. Influenza vaccines prevent infection in most patients. If infection does occur, less virus is shed in respiratory secretions. Thus, vaccination reduces transmission of influenza by decreasing the number of susceptible people and by decreasing transmission by immunized people who still become infected. The multiplicity of rhinoviruses (common cold), enteroviruses, and respiratory viruses hinders development of practical, specific vaccines for these common diseases.
Use of Antibacterial Drugs in Viral Infections

Antibacterial drugs should not be used to treat viral infections. They do have a role, however, in treating bacterial complications of viral infections. For example, bacterial pneumonia may develop as a complication of influenza.

Use of Antiretroviral Drugs in HIV Infection

1. The goals of drug therapy include prolonging and improving quality of life, decreasing viral load to undetectable levels in plasma (<400 copies/mL) as long as possible, halting disease progression, and restoring immune function.
2. Treatment of HIV infection is complex, and recommendations change often as new drugs and research reports become available. Thus, when possible, clinicians with expertise in the care of HIV-infected clients should prescribe, supervise, and monitor drug therapy. Clinicians caring for HIV-seropositive patients should always consult current treatment guidelines before initiating therapy.
3. Drug therapy requires substantial commitment of time and energy by therapists and their patients. Therapists must keep abreast of new developments and monitor patients’ responses; patients must be willing to adhere to complex regimens and manage or tolerate adverse drug effects. Nonadherence may lead to a lack of effectiveness or emergence of drug-resistant viral strains. Thus, therapists and patients need to discuss benefits and risks and participate in decision making.
4. Drug therapy is usually initiated early in the course of infection. The initial infection is manifested by an illness similar to influenza, with fever, chills, and muscle aches that may last for several weeks. This period is usually followed by a quiescent phase, which may last up to 10 years, during which there may be no clinical manifestations. This phase was once thought to indicate viral latency and inactivity. However, research has shown that the initial infection is characterized by explosive viral growth and spread to body tissues, especially the lymphoid system. The period after the initial infection is characterized by a partially effective immune system response, which decreases viral replication. However, some viral replication and destruction of lymphoid tissue continue during this period. Early treatment reduces viral load and may delay progression of the disease and development of clinical signs and symptoms.
5. Guidelines for drug therapy in adults and adolescents, as developed by the Panel on Clinical Practices for Treatment of HIV Infection (convened by the Department of Health and Human Services and the Henry J. Kaiser Family Foundation), include the following:
   a. Treatment is recommended for symptomatic patients, patients with CD4+ cell counts <350 cells/mm³, or patients with viral loads >30,000–55,000 copies/mL.
   b. Combination antiretroviral therapy is standard of care. A commonly used 3-drug regimen includes 2 NRTIs and a protease inhibitor. Other options include 2 NRTIs and 1 NNRTI (most commonly efavirenz) or 3 NRTIs (one of which should be abacavir). The choice of specific drugs must be accomplished with consideration of the patient’s health status, adverse drug effects, and potential drug interactions. For example, anorexia may prevent patients from following dietary recommendations to promote absorption of some protease inhibitors;
CLIENT TEACHING GUIDELINES
Antiretroviral Drugs

General Considerations

✔ Prevention is better than treatment, partly because medications used to treat viral infections may cause serious adverse effects. Thus, whenever possible, techniques to prevent viral infections, should be employed.
✔ Frequent and thorough hand washing helps prevent most infections.
✔ Maintain immunizations against viral infections as indicated.
✔ Always practice safer sex by using a condom.
✔ In cases of IV drug abuse, use or promote the use of clean needles.

 Drugs may relieve symptoms but do not cure HIV infection, prevent transmission of the virus, or prevent other illnesses associated with advanced HIV infection.

Effective treatment of HIV infection requires close adherence to drug therapy regimens involving several drugs and daily doses. Missing as few as one or two doses can decrease blood levels of antiretroviral drugs and result in increased HIV replication and selection for drug-resistant viral strains.

It is generally recommended that herbal products not be used with antiretroviral medications. The protease inhibitors are particularly sensitive to the effects of herbal remedies, and the use of these products may result in decreased serum levels. In controlled clinical trials, St. John’s wort and garlic reduced serum levels of specific protease inhibitors. Echinacea should also be avoided because it may stimulate viral replication.

Request information about adverse effects associated with the specific drugs you are taking and what you should do if they occur. Adverse effects vary among the drugs; some are potentially serious.

Have regular blood tests including viral load, CD4+ cell count, complete blood count, and others as indicated (eg, tests of kidney and liver function).

Keep your health care providers informed about all medications being taken; do not take any other drugs (including drugs of abuse, herbal preparations, vitamin/mineral supplements, nonprescription drugs) without consulting a health care provider. These preparations may make antiretroviral medications less effective or more toxic.

If amprenavir is prescribed:

✔ Tell the prescriber if you are allergic to sulfa drugs (eg, Bactrim). Amprenavir is a sulfonamide; it is unknown whether people allergic to sulfa drugs are allergic to amprenavir.

✔ Women who take hormonal contraceptives may need to use a second form of contraception.

✔ Do not take vitamin E supplements because amprenavir capsules and oral solution contain more than the recommended daily amount of vitamin E.

✔ With nelfinavir, women using oral contraceptives may need to use a second form of contraception.

Self-Administration

✔ Take the medications exactly as prescribed. Do not change doses or stop the medications without consulting a health care provider. If a dose is missed, do not double the next dose. The drugs must be taken consistently to suppress HIV infection and minimize adverse drug effects.

✔ These medications vary in their interactions with food and should be taken appropriately for optimal benefit. Unless otherwise instructed, take the drugs as follows:

- **Abacavir, amprenavir, Combivir, delavirdine, efavirenz, famciclovir, lamivudine, nevirapine, stavudine, tenofovir**, and **valacyclovir** may be taken with or without food. However, do not take abacavir, amprenavir, or efavirenz with a high-fat meal. Also, if taking an antacid or didanosine, take **amprenavir** at least 1 hour before or after a dose of antacid or didanosine.

- **Take didanosine and indinavir** on an empty stomach. This usually means 1 hour before or 2 hours after a meal. Although indinavir is best absorbed if taken on an empty stomach, with water, it may also be taken with skim milk, juice, coffee, tea, or a light meal (eg, toast, cereal). If you are taking indinavir and didanosine, the drugs should be taken at least 1 hour apart on an empty stomach.

- **Take ganciclovir, Kaletra, nelfinavir**, and **ritonavir** with food. The oral solution of ritonavir may be mixed with chocolate milk to improve the taste.

- **Take saquinavir** within 2 hours after a meal.

- **Delavirdine** tablets may be mixed in water by adding four tablets to at least 3 oz of water, waiting a few minutes, and then stirring. Drink the mixture promptly, rinse the glass, and swallow the rinse to be sure the entire dose is taken.

- **To give nelfinavir** to infants and young children, the oral powder can be mixed with a small amount of water, milk, or formula. Once mixed, the entire amount must be taken to obtain the full dose. Acidic foods or juices (eg, apple sauce, orange juice, apple juice) should not be used because they produce a bitter taste.

bone marrow suppression induced by zidovudine may make the drug intolerable; specific combinations of NRTIs may increase neuropathy; and multiple drug interactions may occur, especially between protease inhibitors and many other drugs. Because of the high risk of drug interactions, patients considering new drugs (including over-the-counter, herbal, or other preparations) should discuss the potential effects on their anti-HIV drug regimen with a health care provider.
Therapy with a single anti-HIV medication should never be used, except with the possible exception of pregnancy, to reduce perinatal transmission.

c. When initiating drug therapy, medications should be started concurrently and in full therapeutic doses.

d. Potentially serious drug interactions, especially between protease inhibitors and other agents, are extensive and often require drug substitution or dose reduction to avoid toxicity. Patients should be assessed for signs and symptoms of adverse drug effects at least twice during the first month of treatment and approximately every 3 months during therapy.

e. Effective drug therapy usually produces significantly reduced plasma HIV RNA levels by 2 months and undetectable levels (<400 copies/mL) by 4 to 6 months. Failure to obtain an undetectable viral load may result from nonadherence, inadequate drugs or doses, drug-resistant viral strains, and a number of other factors.

f. Laboratory tests are used to determine when to initiate drug therapy and to assess adherence and response to therapy. Viral load is a measure of the number of HIV RNA particles within the blood; it does not measure viral levels in tissues, where viral reproduction may be continuing. Measurement is recommended at the time of diagnosis and subsequently every 3 to 4 months in untreated patients. In treated clients, HIV RNA levels should be drawn before and 2 to 8 weeks after starting drug therapy, then every 3 to 4 months. Serial measurements should be done in the same laboratory because slight variations may occur among different tests and techniques.

CD4+ cell counts are also assessed and used to monitor effective drug therapy. CD4+ cell counts should be measured at the time of diagnosis and approximately every 3 to 6 months thereafter. Complete blood counts, tests of renal and hepatic function, and other tests are also recommended.

g. Clients receiving drug therapy for advanced HIV infection should continue medications during an opportunistic infection or malignancy, unless there are significant drug intolerances, toxicities, or interactions.

h. Reasons for temporary interruption of therapy include intolerable adverse effects, drug interactions, and unavailability of drug. Although interruptions increase the risk of drug resistance, the time interval between stopping drug therapy and the development of drug resistance is unknown. If one antiretroviral drug must be stopped for a prolonged period, then all medications should be discontinued. Continuing one or two drugs may select for drug-resistant strains.

i. Updated treatment guidelines are readily available via the Internet at http://www.hivatis.org.

**Use in Children**

The use of systemic antiviral drugs may be difficult in children because several of the available agents have not been tested in this group, are not available in pediatric formulations, and/or do not have pediatric dosages.

Amantadine may be given to prevent or treat influenza A in children 1 year of age or older, and rimantadine is given only for prevention in children. The optimal dose and duration of amantadine or rimantadine therapy have not yet been established.

Cidofovir is highly nephrotoxic and should probably not be used in children because of long-term risks of carcinogenicity and reproductive toxicity.

Consistent with most other viral infections, few guidelines exist regarding the use of anti-HIV drugs in children. Most HIV infections in children result from perinatal transmission, and HIV testing should be a part of routine perinatal care. HIV-seropositive females should receive zidovudine to prevent perinatal transmission. At 14 to 34 weeks of gestation, zidovudine should be administered at a dose of 100 mg PO 5 times a day until delivery. At delivery, a loading dose of 2 mg/kg should be administered, followed by 1 mg/kg/hour until birth. The infant is then administered zidovudine 2 mg/kg every 6 hours for the first 6 weeks of life. If perinatal infection occurs, the infant usually develops symptoms (eg, an opportunistic infection or failure to thrive) within the first 3 to 8 months of life. Zidovudine, which is approved for treatment of HIV infection in children, is usually the drug of choice. As in adults, anemia and neutropenia are common adverse effects of zidovudine.

**Nursing Notes: Ethical/Legal Dilemma**

John was diagnosed with acquired immunodeficiency syndrome 2 years ago and has been aggressively treated with many different drug protocols. Despite aggressive therapy, his condition continues to deteriorate and his physician initiates discussions regarding end-of-life issues. John’s last hope seems to be a new investigational drug that is being studied at the University.

**Reflect on:**

- How research methods will necessarily exclude some hopeful participants.
- Should the Food and Drug Administration process for new drug approval be altered when drugs are being developed to treat terminal conditions?
- When a client feels his or her chance for survival without a drug are limited, is informed consent for study participation really possible?
Abacavir can be used in patients 3 months to 13 years of age; amprenavir can be used in children 4 to 16 years of age; didanosine is an alternative for children who do not respond to zidovudine; nelfinavir may be used in children 2 years of age and older; and delavirdine and zalcitabine may be used in adolescents. Safety and effectiveness of several drugs have not been established (eg, famciclovir, indinavir, and stavudine for any age group; ritonavir for those younger than 12 years of age; and saquinavir for those younger than 16 years). Kaletra can be used for children 6 months or older.

Use in Older Adults

Antiviral drug selection and dosing should proceed cautiously in the elderly, who often have impaired organ function, concomitant diseases, and/or other drug therapy. Most systemic antiviral drugs are excreted by the kidneys and renal impairment is common in older adults. Therefore, greater risks of toxicity exist. These risks may be minimized by dose reduction when indicated by decreased creatinine clearance (CrCl). When amantadine is given to prevent or treat influenza A, dosage should be reduced with renal impairment, and older adults should be closely monitored for CNS (eg, hallucinations, depression, confusion) and cardiovascular effects (eg, congestive heart failure, orthostatic hypotension).

There is little information regarding the effects of anti-HIV medications in older adults. As potent antiretroviral therapy continues to extend the lifespans of HIV-seropositive patients, clinicians can expect to encounter greater numbers of older adults on these medications. As a general rule, renal impairment may necessitate adjustment of NRTI and NNRTI doses, while hepatic impairment will affect dosing of protease inhibitors.

Use in Renal Impairment

Antiviral drugs should be used cautiously in clients with impaired renal function because some are nephrotoxic, most are eliminated by the kidneys, and many require dosage reductions because their elimination may be decreased. All patients with renal impairment should be monitored closely for abnormal renal function tests and drug-related toxicity. Renal effects and guidelines for usage of selected drugs are described in the following sections.

Nephrotoxic Drugs

- **Acyclovir** may precipitate in renal tubules and cause renal impairment with high doses of oral drug or IV administration (eg, to treat acute herpes zoster). This is most likely to occur in patients who are dehydrated and may be minimized by maintaining a high urine output. Although patients on hemodialysis usually need reduced doses, an additional dose is needed after dialysis because treatment removes up to 51% of serum acyclovir.
- **Cidofovir** is nephrotoxic in approximately 50% of clients. It is contraindicated in clients who are taking other nephrotoxic drugs or who have abnormal renal function tests (eg, baseline serum creatinine >1.5 mg/dL, CrCl ≤ 55 mL/minute, or proteinuria ≥2+). Acute renal failure has occurred and renal function may not return to baseline after drug discontinuation. Guidelines to minimize nephrotoxicity include avoidance of higher-than-recommended doses, rates of infusion, and frequencies of administration; prehydration with IV 0.9% sodium chloride injection; administration of probenecid with each infusion; monitoring serum creatinine and urine protein 48 hours before each dose; and dose adjustment when indicated.
- **Foscarnet** may cause or worsen renal impairment and should be used with caution in all patients. Manifestations of renal impairment are most likely to occur during the second week of induction therapy but may occur any time during treatment. Renal impairment may be minimized by monitoring renal function (eg, at baseline, 2 to 3 times weekly during induction, and at least every 1 to 2 weeks during maintenance therapy) and reducing dosage accordingly. The drug should be stopped if CrCl drops below 0.4 mL/minute/kg. Adequate hydration should also be maintained throughout the course of drug therapy.
- **Indinavir** may cause nephrolithiasis, flank pain, and hematuria. Symptoms usually subside with increased hydration and drug discontinuation. To avoid nephrolithiasis, patients on indinavir should consume six to eight full eight ounce glasses of water or other appropriate fluid per day.

Drugs That Require Dosage Reduction

- **Amantadine, famciclovir, ganciclovir, lamivudine, stavudine, valacyclovir,** and **zalcitabine** are eliminated mainly through the kidneys. In patients with renal impairment, they may accumulate, produce higher blood levels, have longer half-lives, and cause toxicity. For all of these drugs except famciclovir, dosage should be reduced with CrCl levels below 50 mL/minute. With famciclovir, dosage should be decreased with CrCl below 60 mL/minute. For patients receiving hemodialysis, dosages should be calculated according to CrCl, with daily doses given after dialysis. Prescribers should consult manufacturers’ recommendations for specific dosing recommendations.
- **Zidovudine** dosage should be decreased in cases of severe renal impairment. Zidovudine is mainly metabolized in the liver to an inactive metabolite that is then eliminated renally (approximately 60% to 75% of a dose); another 20% is excreted as unchanged drug in the urine. Thus, mild to moderate renal impairment does not
lead to drug accumulation or a need for reduced dosage. With severe impairment, however, drug half-life is prolonged, possibly because some metabolism occurs in the kidneys as well as the liver. Also, patients with renal impairment may be more likely to experience zidovudine-induced hematologic adverse effects because of decreased production of erythropoietin. Because of these factors, it is recommended that the daily dosage be reduced by approximately 50% in patients with severe renal impairment (CrCl <25 mL/minute) and patients on hemodialysis.

- **Didanosine** doses are approximately 60% excreted in the urine as unchanged drug. The remainder is metabolized in the liver to several metabolites, including one with antiviral activity. In patients with severe renal impairment, didanosine is eliminated slowly and has a longer half-life. Thus, dosage reduction is indicated to prevent drug accumulation and toxic effects in patients with renal impairment. Also, standard didanosine tablets, unlike the enteric-coated formulation (didanosine EC), contain sodium and magnesium, which may accumulate in patients with reduced renal function.

**Other Drugs**

**Delavirdine, nelfinavir, nevirapine, ritonavir, and saquinavir** are primarily metabolized by the liver and are unlikely to require dosage reductions in cases of impaired renal function.

**Use in Hepatic Impairment**

The antiviral drugs of most concern in hepatic impairment are the anti-HIV agents, especially the protease inhibitors. Although most antiretroviral drugs have not been studied in clients with hepatic impairment, several are primarily metabolized in the liver and may produce high blood levels and cause adverse effects in the presence of liver dysfunction. In addition, clients with HIV infection may have concomitant liver disease that further impairs hepatic metabolism and elimination of the drugs. Although few guidelines are available, dosages should be individualized according to the severity of hepatic impairment and HIV infection, other drug therapies (for HIV infection, opportunistic infections, or other conditions), additional risk factors for drug toxicity, and the potential for drug interactions. In addition, all clients with hepatic impairment should be monitored closely for abnormal liver function tests (LFTs) and drug-related toxicity. Hepatic effects and considerations for usage of selected drugs are as follows:

- **Amprenavir, delavirdine, didanosine, nelfinavir, nevirapine, ritonavir, saquinavir, and tenofovir** may need dosage reductions in patients with impaired hepatic function.
- **Nevirapine** may cause abnormal LFTs, and a few cases of fatal hepatitis have been reported. If moderate or severe LFT abnormalities occur, nevirapine administration should be discontinued until LFTs return to baseline. If liver dysfunction recurs when the drug is resumed, nevirapine should be discontinued permanently.
- **Zidovudine** is eliminated slowly and has a longer half-life in patients with moderate to severe liver disease. Thus, daily doses should be reduced by 50% in patients with hepatic impairment.

**Home Care**

Most antiviral drugs are self-administered or dosed by caregivers in the home setting. Precautions to prevent viral infections from occurring or spreading are important because of the close contacts among members of a household. The home care nurse may be required to teach infection control precautions and to assess the immunization status of all household members. If immunizations are indicated, the nurse may need to teach, encourage, provide, or facilitate their administration.

Home care of patients with HIV infection may include a variety of activities such as assisting with drug therapy for HIV or opportunistic infections, coordinating medical and social services, managing symptoms of infection or adverse drug effects, and preventing or minimizing opportunistic infections. Nurses may also be involved in disease state education of both patients and their families. As part of home care, the nurse should be prepared to triage and refer patients to hospitalization or hospice when indicated.
1. Administer accurately
   a. Give oral drugs as recommended in relation to meals:
      (1) Give abacavir, amprenavir, delavirdine, efavirenz, famciclovir, lamivudine, nevirapine, stavudine, tenofovir and valacyclovir with or without food. However, do not give abacavir, amprenavir, or efavirenz with a high-fat meal. Also, if the patient is taking an antacid or didanosine, give amprenavir at least 1 h before or after a dose of antacid or didanosine.
      (2) Give didanosine and indinavir on an empty stomach, 1 h before or 2 h after a meal. Although indinavir is best absorbed if taken on an empty stomach, with water, it may also be taken with skim milk, juice, coffee, tea or a light meal (eg, toast, cereal). If the patient is taking indinavir and didanosine, the drugs should be given at least 1 h apart on an empty stomach.
      (3) Give ganciclovir, nelfinavir, Kaletra, and ritonavir with food. The oral solution of ritonavir may be mixed with chocolate milk to improve the taste.
      (4) Give saquinavir within 2 h after a meal.
   b. Delavirdine tablets may be mixed in water by adding four tablets to at least 3 oz of water, waiting a few minutes, and then stirring. Have the client drink the mixture promptly, rinse the glass, and swallow the rinse to be sure the entire dose is taken.
   c. To give nelfinavir to infants and young children, the oral powder can be mixed with a small amount of water, milk, or formula. Once mixed, the entire amount must be taken to obtain the full dose.
   d. Give intravenous (IV) acyclovir, cidofovir, foscarnet, and ganciclovir over 1 h.
   e. With cidofovir therapy, give probenecid 2 g 3 h before cidofovir, 1 g 2 h before cidofovir, and 1 g 8 h after completion of the cidofovir infusion
   f. When applying topical acyclovir, wear a glove to apply.
   g. With administering ribavirin, follow the manufacturer’s instructions.

2. Observe for therapeutic effects
   a. With acyclovir for genital herpes, observe for fewer recurrences when given for prophylaxis; observe for healing of lesions and decreased pain and itching when given for treatment.
   b. With amantadine, observe for absence of symptoms when given for prophylaxis of influenza A and decreased fever, cough, muscle aches, and malaise when given for treatment.
   c. With cidofovir, ganciclovir or foscarnet for cytomegalovirus retinitis, observe for improved vision.
   d. With ophthalmic drugs, observe for decreased signs of eye infection.

(continued)
e. With antiretroviral drugs, observe for improved clinical status (fewer signs and symptoms) and improved laboratory markers (eg, decreased viral load, increased CD4+ cell count)

3. Observe for adverse effects

a. General effects—anorexia, nausea, vomiting, diarrhea, fever, headache

b. With IV acyclovir—phlebitis at injection site, skin rash, urticaria, increased blood urea nitrogen or serum creatinine, encephalopathy manifested by confusion, coma, lethargy, seizures, tremors

c. With topical acyclovir—burning or stinging and pruritus

d. With amantadine and rimantadine—central nervous system (CNS) effects with anxiety, ataxia, dizziness, hyperexcitability, insomnia, mental confusion, hallucinations, slurred speech

e. With didanosine, zalcitabine, and zidovudine—peripheral neuropathy (numbness, burning, pain in hands and feet), pancreatitis (abdominal pain, severe nausea and vomiting, elevated serum amylase)

f. With ganciclovir and foscarnet—bone marrow depression (anemia, leukopenia, neutropenia, thrombocytopenia), renal impairment (increased serum creatinine and decreased creatinine clearance), neuropathy

g. With indinavir, ritonavir, and saquinavir—circumoral and peripheral paresthesias, debilitation, fatigue

h. With lamivudine and stavudine—peripheral neuropathy, flu-like syndrome (fever, malaise, muscle and joint aches or pain), dizziness, insomnia, depression

i. With ophthalmic antiviral drugs—pain, itching, edema, or inflammation of the eyelids

j. With ribavirin—increased respiratory distress

k. With zidovudine—bone marrow depression (BMD; anemia, leukopenia, granulocytopenia, thrombocytopenia); anemia and neutropenia in newborn infants

4. Observe for drug interactions

These effects occur with most systemic antiviral drugs and may range from mild to severe.

Encephalopathy is rare but potentially serious; other effects commonly occur.

These effects are usually transient.

CNS symptoms are reportedly more likely with zalcitabine amantadine than with rimantadine and may be similar to those caused by atropine and CNS stimulants. Adverse reactions are more likely to occur in older adults and those with renal impairment.

Peripheral neuropathy is more likely with and the drug should be discontinued if symptoms occur. Pancreatitis may be more likely with didanosine, especially in those with previous episodes, alcohol consumption, elevated serum triglycerides, or advanced HIV infection. Didanosine should be stopped promptly if symptoms of pancreatitis occur.

Renal impairment may be more likely to occur with foscarnet.

The most frequent adverse effects are the general ones listed above. Most are relatively mild.

These symptoms result from tissue irritation or hypersensitivity reactions.

Pulmonary function may deteriorate.

Anemia may occur within 2–4 wk of starting the drug; granulocytopenia is more likely after 6–8 wk. A complete blood count should be performed every 2 wk. Colony-stimulating factors have been used to aid recovery of bone marrow function. Blood transfusions may be given for anemia.

The hematologic effects on newborn infants may occur when the mothers received zidovudine during pregnancy.

Antiviral drugs are often given concomitantly with each other and with many other drugs, especially those used to treat opportunistic infections and other illnesses associated with HIV infection and organ transplantation. In general, combinations of drugs that cause similar, potentially serious adverse effects (eg, bone marrow depression, peripheral neuropathy) should be avoided, when possible.

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a.</strong> Drugs that increase effects of acyclovir:</td>
<td>May increase blood levels of acyclovir by slowing its renal excretion</td>
</tr>
<tr>
<td>(1) Probenecid</td>
<td>Severe drowsiness and lethargy may occur.</td>
</tr>
<tr>
<td>(2) Zidovudine</td>
<td>These drugs add to the anticholinergic effects (eg, blurred vision, mouth dryness, urine retention, constipation, tachycardia) of the antiviral agents.</td>
</tr>
<tr>
<td>b. Drugs that increase effects of amantadine and rimantadine:</td>
<td>These drugs add to the CNS-stimulating effects (eg, confusion, insomnia, nervousness, hyperexcitability) of the antiviral agents.</td>
</tr>
<tr>
<td>(1) Anticholinergics—atropine, first-generation antihistamines, antipsychotics, tricyclic antidepressants</td>
<td>These drugs are nephrotoxic and increase risks of nephrotoxicity.</td>
</tr>
<tr>
<td>(2) CNS stimulants</td>
<td>Increased risk of seizures; avoid the combination if possible.</td>
</tr>
<tr>
<td>c. Drugs that increase effects of cidofovir and foscarnet:</td>
<td>Increased serum creatinine and potential nephrotoxicity</td>
</tr>
<tr>
<td>(1) Aminoglycoside antibiotics, amphotericin B, didanosine, IV pentamidine</td>
<td>May increase blood levels of cidofovir by decreasing its renal excretion</td>
</tr>
<tr>
<td>d. Drugs that increase effects of ganciclovir:</td>
<td>Increase blood levels of ganciclovir, probably by decreasing its metabolism and elimination</td>
</tr>
<tr>
<td>(1) Imipenem/cilastatin</td>
<td>Didanosine increases gastric pH and decreases absorption of indinavir. If the two drugs are given concurrently, give at least 1 h apart, on an empty stomach.</td>
</tr>
<tr>
<td>(2) Nephrotoxic drugs (eg, amphotericin B, cyclosporine)</td>
<td>Decreases blood levels of indinavir</td>
</tr>
<tr>
<td>(3) Probenecid</td>
<td>These drugs speed up metabolism of indinavir by inducing hepatic drug-metabolizing enzymes.</td>
</tr>
<tr>
<td>e. Drugs that increase effects of indinavir:</td>
<td>Increase blood levels of indinavir, probably by decreasing its metabolism and elimination</td>
</tr>
<tr>
<td>(1) Clarithromycin, ketoconazole, quinidine, zidovudine.</td>
<td>Didanosine increases gastric pH and decreases absorption of indinavir. If the two drugs are given concurrently, give at least 1 h apart, on an empty stomach.</td>
</tr>
<tr>
<td>f. Drugs that decrease effects of indinavir:</td>
<td>Decreases blood levels of indinavir</td>
</tr>
<tr>
<td>(1) Didanosine</td>
<td>These drugs speed up metabolism of indinavir by inducing hepatic drug-metabolizing enzymes.</td>
</tr>
<tr>
<td>(2) Fluconazole</td>
<td>Decrease elimination of lamivudine</td>
</tr>
<tr>
<td>(3) Rifampin, rifabutin</td>
<td>Increase blood levels, probably by slowing metabolism of ritonavir</td>
</tr>
<tr>
<td>g. Drug that increases the effects of lamivudine:</td>
<td>Accelerates metabolism of ritonavir by inducing drug-metabolizing enzymes in the liver</td>
</tr>
<tr>
<td>(1) Trimethoprim/sulfamethoxazole</td>
<td>Increases blood levels of saquinavir</td>
</tr>
<tr>
<td>h. Drugs that increase the effects of ritonavir:</td>
<td>Accelerate metabolism of ritonavir by inducing drug-metabolizing enzymes in the liver</td>
</tr>
<tr>
<td>(1) Clarithromycin, fluconazole, fluoxetine:</td>
<td>Zalcitabine and these drugs are associated with peripheral neuropathy; concomitant use increases risks of this adverse effect.</td>
</tr>
<tr>
<td>i. Drug that decreases the effects of ritonavir:</td>
<td>Increase blood levels of zalcitabine by decreasing its elimination</td>
</tr>
<tr>
<td>(1) Rifampin</td>
<td>Increased risk of pancreatitis. If IV pentamidine is used to treat Pneumocystis carinii pneumonia, zalcitabine should be interrupted.</td>
</tr>
<tr>
<td><strong>l.</strong> Drugs that increase the effects of zalcitabine:</td>
<td>(continued)</td>
</tr>
<tr>
<td>(1) Chloramphenicol, cisplatin, didanosine, ethionamide, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, vincristine</td>
<td></td>
</tr>
<tr>
<td>(2) Cimetidine, probenecid</td>
<td></td>
</tr>
<tr>
<td>(3) Pentamidine (IV)</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS

m. Drugs that decrease effects of zalcitabine:
   (1) Antacids, metoclopramide

n. Drugs that increase effects of zidovudine:
   (1) Doxorubicin, vincristine, vinblastine
   (2) Amphotericin B, flucytosine
   (3) Ganciclovir and pentamidine
   (4) Probenecid, trimethoprim

o. Drugs that decrease effects of zidovudine:
   (1) Rifampin, rifabutin

p. Drugs that decrease effects of Kaletra:
   (1) Efavirenz
   (2) Nevirapine

RATIONALE/EXPLANATION

Decrease absorption. Do not give antacids at the same time as zalcitabine.

Increased bone marrow depression, including neutropenia
Increased nephrotoxicity
Increased neutropenia
May increase blood levels of zidovudine, probably by decreasing renal excretion

Accelerate metabolism of zidovudine

Dosage of Kaletra may need to be increased if it is given concomitantly with one of these drugs.

Nursing Notes: Apply Your Knowledge

Answer: Nick may feel embarrassed or ashamed about this diagnosis and reluctant to ask questions. If his stress level is high, he may not comprehend everything that is said. Provide written information for his future reference. Stress that genital herpes is a sexually transmitted disease that can be controlled but not cured with the acyclovir. He should complete the entire 10-day prescription, then take 400 mg bid for recurrences. Factors such as illness, emotional stress, or intense sunlight can increase recurrence. Because genital herpes is not cured, it is important to use a condom to prevent transmission of herpes to a sexual partner. The diagnosis of herpes is stressful and affects future life decisions. Listen to Nick’s concerns and offer counseling.

SELECTED REFERENCES

chapter 40

Antifungal Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT SHOULD BE ABLE TO:

1. Describe characteristics of fungi and fungal infections.
2. Discuss antibacterial drug therapy and immunosuppression as risk factors for development of fungal infections.
3. Describe commonly used antifungal drugs in terms of indications for use, adverse effects, and nursing process implications.
4. Differentiate between adverse effects associated with systemic and topical antifungal drugs.
5. Differentiate among formulations of amphotericin B.
6. Teach clients about prevention and treatment of fungal infections.

Critical Thinking Scenario
John Morgan, 79 years of age, is diagnosed with prostate cancer. He has been receiving chemotherapy for the last 3 months. After his third course of treatment, he becomes neutropenic and an infection develops that is treated with two broad-spectrum antibiotics.

Reflect on:
- Why John is at risk for a fungal infection.
- Why a fungal infection in John is likely to be serious and systemic.
- What assessments you will make to detect a fungal infection.

OVERVIEW

Fungi are molds and yeasts that are widely dispersed in the environment and are either saprophytic (ie, obtain food from dead organic matter) or parasitic (ie, obtain nourishment from living organisms). Molds are multicellular organisms comprised of colonies of tangled strands. They form a fuzzy coating on various surfaces (eg, the mold that forms on spoiled food and the mildew that forms on clothing in damp environments). Yeasts are unicellular organisms. Some fungi, called dermatophytes, can grow only at the cooler temperatures of body surfaces. Other fungi, called dimorphic, can grow as molds outside the body and as yeasts in the warm temperatures of the body. As molds, these fungi produce spores that can persist indefinitely in the environment and be carried by the wind to distant locations. When these mold spores enter the body, most often by inhalation, they rapidly become yeasts that can invade body tissues. Dimorphic fungi include a number of human pathogens such as those that cause blastomycosis, histoplasmosis, and coccidioidomycosis.

Fungi that are pathogenic in humans exist in soil, decaying plants, and other environmental habitats or as part of the endogenous human flora. For example, Candida albicans organisms are part of the normal microbial flora of the skin, mouth, gastrointestinal (GI) tract, and vagina. Growth of Candida organisms is normally restrained by intact immune mechanisms and bacterial competition for nutrients. When these restraining forces are altered (eg, by suppression of the immune system or antibacterial drug therapy), fungal overgrowth and opportunistic infection can occur. In addition, some fungi have characteristics that enhance their ability to cause disease. Cryptococcus neoformans organisms, for example, can become encapsulated, which allows them to evade the normal immune defense mechanism of phagocytosis. Aspergillus organisms produce protease, an enzyme that allows them to destroy structural proteins and penetrate body tissues.

Structurally, fungi are larger and more complex than bacteria. They have a thick, rigid cell wall, of which one of the components is a polysaccharide called glucan. Glucan is formed by the fungal enzyme, beta-(1,3)-D-glucan synthetase. Fungi also
having a cell membrane composed of lipids, glycoproteins, and sterols. One of the sterols is ergosterol, a lipid that is similar to the cholesterol component of human cell membranes. Within the cell membrane, structures are essentially the same as those in human cells (e.g., a nucleus, mitochondria, Golgi apparatus, ribosomes attached to endoplasmic reticulum, and a cytoskeleton with microtubules and filaments).

### FUNGAL INFECTIONS

Fungal infections (mycoses) may be mild and superficial or life-threatening and systemic. Dermatophytes cause superficial infections of the skin, hair, and nails. They obtain nourishment from keratin, a protein in skin, hair, and nails. Dermatophytic infections include tinea pedis (athlete’s foot) and tinea capitis (ringworm of the scalp) (see Chap. 66).

Most fungal infections occur in healthy people but are more severe and invasive in immunocompromised hosts. For example, *C. albicans* organisms often cause superficial mucosal infections (e.g., oral, intestinal, or vaginal candidiasis) with antibacterial drug therapy. In immunocompromised hosts, candidal infections are more likely to be deep, widespread, and caused by non-albicans species. Other fungi that cause serious infections are not part of the body’s normal flora. Instead, they grow in soil and decaying organic matter. Most invasive fungal infections are acquired by inhalation of airborne spores from contaminated soil and severity of disease increases with intensity of exposure. Infections such as histoplasmosis, coccidioidomycosis, and blastomycosis usually occur as pulmonary disease but may be systemic. Other serious, systemic infections include aspergillosis, cryptococcosis, and sporotrichosis.

Serious, systemic fungal infections commonly occur and are increasing in incidence, largely because of human immunodeficiency virus (HIV) infections, the use of immunosuppressant drugs to treat clients with cancer or organ transplants, the use of indwelling intravenous (IV) catheters for prolonged drug therapy or parenteral nutrition, implantation of prosthetic devices, and widespread use of broad-spectrum antibacterial drugs. Characteristics of selected fungal infections are described in Box 40–1.

### Antifungal Drugs

Development of drugs that are effective against fungal cells without being excessively toxic to human cells has been limited because fungal cells are very similar to human cells. Available antifungal drugs, which differ in their chemical structures and mechanisms of action, produce their therapeutic effects by disrupting the structure and function of various fungal cell components (Fig. 40–1).

Polymers (e.g., amphotericin B) and azoles (e.g., fluconazole) act on ergosterol to disrupt fungal cell membranes. Amphotericin B (and nystatin) binds to ergosterol and forms holes in the membrane, causing leakage of the fungal cell contents and lysis of the cell. The azole drugs bind to a cytochrome P450 enzyme (14-alpha demethylase) that is required for synthesis of ergosterol from lanosterol, a precursor. This action causes production of a defective cell membrane, which also allows leakage of ergosterol from the membrane, and destruction of the cell. Both types of drugs also affect cholesterol in human cell membranes, and this characteristic is considered primarily responsible for the drugs’ toxicities.

Echinocandins or glucan synthesis inhibitors (e.g., caspofungin) are a new class of antifungal drugs that disrupt fungal cell walls rather than fungal cell membranes. They act by inhibiting beta-(1,3)-D-glucan synthetase, an enzyme required for synthesis of glucan. Glucan is an essential polysaccharide in the fungal cell wall; its depletion leads to leakage of cellular contents and cell death. Because human cells do not contain cell walls, these drugs are less toxic than the polyene and azole antifungals.

Drugs for superficial fungal infections of skin and mucous membranes are usually applied topically. Numerous preparations are available, many without a prescription. Drugs for systemic infections are given IV or orally. Patients with HIV infection need aggressive treatment of primary fungal infections and prolonged or lifelong secondary prophylaxis. Patients with prolonged or severe neutropenia secondary to treatment with cytotoxic cancer drugs also require aggressive treatment of fungal infections, because they are at high risk for acute, life-threatening, systemic mycoses such as candidiasis and aspergillosis. Selected antifungal drugs are further described in the following sections. In addition, pharmacokinetic characteristics of selected drugs are listed in Table 40–1; clinical indications for use and dosage ranges are listed in Drugs at a Glance: Selected Antifungal Drugs.

### Polymers

**Amphotericin B** is active against most types of pathogenic fungi, including those that cause aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, cryptococcosis, histoplasmosis, and sporotrichosis. The drug is fungicidal or fungistatic depending on the concentration in body fluids and on the susceptibility of the causative fungus. Amphotericin B is highly toxic to humans and is therefore recommended only for serious, potentially fatal fungal infections, in which it is usually the initial drug of choice. The drug is usually given for 4 to 12 weeks but may be needed longer by some clients.

Lipid formulations were developed to decrease adverse effects, especially nephrotoxicity. Compared to the original deoxycholate formulation (Fungizone), these mixtures of amphotericin B with lipids penetrate and reach higher concentrations in diseased tissues (e.g., those infected or inflamed). This increases therapeutic effects. At the same time, lipid formulations do not penetrate normal tissues well and therefore reach lower concentrations in normal tissues. This decreases adverse effects and also allows higher doses to be given. Although these products cause much less nephrotoxicity, chills, and fever, they are much more expensive than the deoxycholate formulation. As a result, they are usually recommended for use only in clients who cannot tolerate the
Aspergillosis, the most common invasive mold infection worldwide, occurs in debilitated and immunocompromised people, including those with leukemia, lymphoma, or acquired immunodeficiency syndrome (AIDS), and those with neutropenia from a disease process or drug therapy. Invasive aspergillosis is characterized by inflammatory granulomatous lesions, which may develop in the bronchi, lungs, ear canal, skin, or mucous membranes of the eye, nose, or urethra. It may extend into blood vessels, which leads to infection of the brain, heart, kidneys, and other organs. Invasive aspergillosis is a serious illness associated with thrombosis, ischemic infarction of involved tissues, and progressive disease. It is often fatal.

Allergic bronchopulmonary aspergillosis, an allergic reaction to inhaled aspergillus spores, may develop in people with asthma and cause bronchoconstriction, wheezing, dyspnea, cough, muscle aches, and fever. The condition is aggravated if the spores germinate and grow in the airways, thereby producing chronic exposure to the antigen and permanent fibrotic damage.

Aspergillus mold may be found in soil, decaying plant matter, cellars, potted plants, peppers and spices, showerheads, hot water faucets, public buildings, and private homes. It is estimated to comprise about 40% of the fungal flora in homes and hospitals. It has also been found in library books, on soft contact lenses, and in food. In neutropenic patients, ingestion of cereals, powdered milk, tea, and soy sauce has been linked to aspergillosis. A few cases in immunocompromised patients have been associated with marijuana smoking and the organism can infect peanuts, cashews, and coffee beans. Large numbers of spores are released into the air during soil excavations (eg, for construction or renovation of buildings) or handling of decaying organic matter and carried into most human environments. There are several species that cause invasive disease in humans but A. fumigatus is the most common (about 90% of cases). A. fumigatus reproduces by releasing spores, which are small enough to reach the alveoli when inhaled. Most aspergillus organisms (80% to 90%) enter the body through the respiratory system, and pulmonary aspergillosis is acquired by inhalation of the spores. Other potential entry sites include damaged skin (eg, burn wounds, intravenous catheter insertion sites), operative wounds, the cornea, and the ear.

Aspergillosis in hospitalized patients has long been attributed to entry of outside air containing aspergillus spores into hospital ventilation systems. Consequently, preventive measures have focused on removing aspergillus spores from the air and preventing exposure by using high efficiency particle air (HEPA) filtration, laminar air flow, and positive pressure systems in rooms used by high-risk patients (eg, those with bone marrow or organ transplants). Specific recommendations are to place HEPA filters where outside air enters patient rooms; position air intake and exhaust ports so that room air enters from one side of the room, flows across the room, and exits on the opposite side; and maintain room air pressure above that of the corridor so that corridor air cannot enter the room. In addition, monitor filtration systems (eg, regular preventive maintenance and checking of pressures and airflow) and construct windows, doors, and air entry and exit ports to seal patients’ rooms and prevent air leaks. Doors to patients’ rooms should be kept closed as much as possible.

Despite the use of the above measures, the incidence of aspergillosis continued to increase and researchers began looking for other sources of infection. One recent study identified a hospital water system as a source of exposure. More airborne particles containing aspergillus were found in bathrooms than in patient rooms and hallways and A. fumigatus organisms isolated from a patient with aspergillosis were identical to those recovered from the shower wall in the patient’s room. The researchers concluded that the hospital water supply can be a source of nosocomial aspergillosis. Another study investigated the spread of invasive aspergillosis in an intensive care unit for liver transplant patients. The index case developed a wound infection 11 days after liver transplantation. Two other patients in the unit developed invasive pulmonary aspergillosis. The researchers concluded that Aspergillus organisms can form spores in infected wounds and that debriding and dressing those wounds may result in aerosolization of spores and airborne person-to-person transmission. With these organisms, inhalation of spores and direct inoculation of tissues by spores are common routes of infection. Health care providers, especially those who work with immunocompromised patients, should be aware of this potential risk. Hospitalized patients with wound or skin infections caused by Aspergillus species should have their lesions covered with a clean dressing and disruptions minimized. If this is not feasible, the patient should be placed in a private room with monitored negative room air pressure and HEPA filtration of the room air, if available. These recommendations may also be helpful with lung transplant recipients who develop tracheobronchial aspergillosis and may potentially be a source of airborne Aspergillus organisms.

Blastomycosis is initiated by inhalation of spores from a fungus that grows in soil and decaying organic matter. The organism is widespread in the southeastern United States, Minnesota, Wisconsin, Michigan, and New York. Sporadic cases most often occur in adult males who have extensive exposure to woods and streams with vocational or recreational activities. The infection may be asymptomatic or produce pulmonary symptoms resembling pneumonia, tuberculosis, or lung cancer. It may also be systemic and involve other organs, especially the skin and bone. Skin lesions (eg, pustules, ulcerations, abscesses) may progress over a period of years and eventually involve large areas of the body. Bone invasion, with arthritis and bone destruction, occurs in 25% to 50% of clients.

Blastomycosis can occur in healthy people with sufficient exposure but is usually more severe and more likely to involve multiple organ involvement and CNS disease in immunocompromised clients. However, it infrequently occurs in patients with HIV infection.

Candidiasis is a yeast infection that often occurs in clients with malignant lymphomas, diabetes mellitus, or AIDS and in clients receiving antibiotic, antineoplastic, corticosteroid, and immunosuppressant drug therapy. Candida organisms are found in soil, on inanimate objects, in hospital environments, and in food. In the human body, they are found on diseased skin and along the entire gastrointestinal (GI) tract, in sputum, along the female genital tract, and in the urine of patients with indwelling bladder catheters. Most infections arise from the normal endogenous organisms, often from the GI tract or skin, and are caused by Candida albicans. Oral, intestinal, vaginal, and systemic candidiasis can occur. Early recognition and treatment of local infections may prevent systemic candidiasis.

- Oral candidiasis (thrush) is characterized by painless white plaques on oral and pharyngeal mucosa. It often occurs in (continued)
newborn infants who become infected during passage through an infected or colonized vagina. In older children and adults, thrush may occur as a complication of diabetes mellitus, as a result of poor oral hygiene, or after taking antibiotics or corticosteroids. It may also occur as an early manifestation of AIDS.

- **Gastrointestinal candidiasis** most often occurs after prolonged broad-spectrum antibacterial therapy, which destroys a large part of the normal flora of the intestine. The main symptom is diarrhea.

- **Vaginal candidiasis** commonly occurs in women who are pregnant, have diabetes mellitus, or take oral contraceptives or antibacterial drugs. The main symptom is a yellowish vaginal discharge. The infection may produce inflammation of the perineal area and spread to the buttocks and thighs. The organism is difficult to eradicate, and many women have recurrent infections.

- **Skin candidiasis** usually occurs in people with continuously moist skinfolds or moist surgical dressings. The organism also may cause diaper rash and perineal rashes. Skin lesions are red and macerated.

- **Systemic or invasive candidiasis** occurs when the organism gets into the bloodstream and is circulated throughout the body, with the brain, heart, kidneys, and eyes as the most common sites of infection. It often occurs as a nosocomial infection in clients with serious illnesses or drug therapies that suppress their immune systems and may be fatal. Invasive infections may be present in any organ and may produce such disorders as urinary tract infection, endocarditis, and meningitis. It is usually diagnosed by positive cultures of blood or tissue. Signs and symptoms depend on the severity of the infection and the organs affected.

    The incidence of severe candidal infections has increased in recent years, in part because of increased numbers of neutropenic and immunodeficient patients. In addition, the frequent use of strong, broad-spectrum antibiotics leads to extensive candidal colonization in debilitated patients and the widespread use of medical devices (eg, intravascular catheters, monitoring equipment, endotracheal tubes, and urinary catheters) allows the organisms to reach sites that are normally sterile. People who use intravenous drugs also develop invasive candidiasis because the injections inoculate the fungi directly into the bloodstream.

    The incidence of invasive infections caused by non-albicans Candida species also seems to be increasing. These infections are related to the widespread use of antifungal drugs such as fluconazole. In general, non-albicans candidal infections are less susceptible to azole antifungal drugs (eg, fluconazole,itraconazole) and are more difficult to treat effectively with the currently available agents.

- **Coccidioidomycosis** is caused by an organism that grows as a mold in soil and decay organic matter and is commonly found in the southwestern United States and northern Mexico. Infection results from inhalation of spores that convert to yeasts in the warm environment of the body and often cause asymptomatic or mild respiratory infection. However, the organism may cause acute pulmonary infection with fever, chest pain, cough, headache, and loss of appetite. Radiographs may show small nodules in the lung like those seen in tuberculosis. In some cases, chronic disease develops in which the organisms remain localized and cause large, organism-filled cavities in the lung. These cavities may become fibrotic and eventually require surgical excision. In a few cases, severe, disseminated disease occurs, either soon after the primary infection or after years of chronic pulmonary disease. Disseminated coccidioidomycosis may produce an acute or chronic meningitis or a generalized disease with lesions in many internal organs. Skin lesions appear as granulomas that may eventually heal or become ulcerations. Most clients with primary infection recover without treatment; clients with disseminated disease require prolonged chemotherapy.

    Coccidioidomycosis may occur in healthy or immunocompromised people but is more severe and more likely to become systemic in immunocompromised clients. For example, clients with AIDS who live in endemic areas are highly susceptible to this infection. The severity of the disease also increases with intensity of exposure.

    **Cryptococcosis** is caused by inhalation of spores of Cryptococcus neoformans, an organism found worldwide. *C. neoformans* organisms grow most abundantly in bird excreta, especially pigeon droppings. They have also been isolated from nonavian sources such as fruits, vegetables, and dairy products.

    When cryptococcosis occurs in healthy people, the primary infection is localized in the lungs, is asymptomatic or produces mild symptoms, and heals without treatment. However, pneumonia may occur and lead to spread of the organisms by the bloodstream. When cryptococcosis occurs in immunocompromised people, it is likely to be more severe and to become disseminated to the CNS, skin, and other body organs. People with AIDS are highly susceptible and cryptococcosis is the fourth most frequent opportunistic infection in this population. Infection most often affects the lungs and CNS. Cryptococcal pneumonia in patients with AIDS has a mortality rate of 40% or more. Cryptococcal meningitis, the most common manifestation of disseminated disease, often produces abscesses in the brain. Clinical manifestations include headache, dizziness, and neck stiffness, and the condition is often mistaken for brain tumor. Later symptoms include coma, respiratory failure, and death if the meningitis is not treated effectively.

    **Histoplasmosis** is a common fungal infection that occurs worldwide, especially in the central and mideastern United States. The causative fungus is found in soil and organic debris around chicken houses, bird roosts, and caves inhabited by bats. Exposure to spores may result from activities such as demolishing or remodeling old buildings, clearing brush from urban parks, or cleaning chicken coops. Spores can be picked up by the wind and spread over large areas. Histoplasmosis develops when the spores are inhaled into the lungs, where they rapidly develop into the tissue-invasive yeast cells that reach the bloodstream and become distributed throughout the body. In most cases, the organisms are destroyed or encapsulated by the host’s immune system. The lung lesions heal by fibrosis and calcification and resemble the lesions of tuberculosis.

    Clinical manifestations may vary widely. In people with normal immune responses, manifestations can be correlated with the extent of exposure. Most infections are asymptomatic or produce minimal symptoms for which treatment is not sought. When symptoms occur, they usually resemble an acute, influenza-like respiratory infection and improve within a few weeks. However, people exposed to large amounts of spores may have a high fever and severe pneumonia, which usually resolves with a low mortality rate. Some people, most often adult men with underlying emphysema or...
older formulation or who are at risk for developing nephrotoxicity. The various lipid preparations differ in their characteristics and cannot be used interchangeably.

Amphotericin B is not well absorbed orally and must be given intravenously for systemic infections. After infusion, the drug is rapidly taken up by the liver and other organs. It is then slowly released back into the bloodstream. Despite its long-term use, little is known about its distribution and metabolic pathways. Drug concentrations in most body fluids (eg, pleural, peritoneal, synovial, aqueous, and vitreous humors) are higher in the presence of inflammation (about two thirds of serum levels). Concentrations in cerebrospinal fluid (CSF) are low with or without inflammation. The drug has an initial serum half-life of 24 hours, which represents redistribution from the bloodstream to tissues. This is followed by a second elimination phase, with a half-life of approximately 15 days, which represents elimination from tissue storage sites. Most of the drug is thought to be metabolized in the tissues; about 5% of the active drug is excreted daily in the urine. After administration is stopped, amphotericin B can be detected in the urine for several weeks.

(text continues on page 602)

Figure 40–1  Actions of antifungal drugs on fungal cells.
### TABLE 40–1 Pharmacokinetics of Systemic Antifungal Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Protein Binding (%)</th>
<th>Half-life</th>
<th>Metabolism/Excretion</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphotericin B deoxycholate (Fungizone)</td>
<td>&gt;90</td>
<td>24 h, then 15 d</td>
<td>Tissues/urine</td>
<td>IV 20–30 min, 1–2 h, 20–24 h</td>
</tr>
<tr>
<td>Fluconazole (Diflucan)</td>
<td>11–12</td>
<td>30 h</td>
<td>PO slow</td>
<td>1–2 h, 2–4 d</td>
</tr>
<tr>
<td>Flucytosine (Ancobon)</td>
<td>Minimal</td>
<td>2–4 h</td>
<td>PO rapid</td>
<td>1 h, 2–4 d</td>
</tr>
<tr>
<td>Itraconazole (Sporanox)</td>
<td>99</td>
<td>21 h, then 64 h</td>
<td>PO Varies</td>
<td>2 h, 10–12 h</td>
</tr>
<tr>
<td>Ketoconazole (Nizoral)</td>
<td>99</td>
<td>8 h</td>
<td>IV Slow</td>
<td>4 h, 4–6 d</td>
</tr>
<tr>
<td>Terbinafine (Lamisil)</td>
<td>99</td>
<td>36 h</td>
<td>IV rapid</td>
<td>1–4 h, End of infusion</td>
</tr>
</tbody>
</table>

### Drugs at a Glance: Selected Antifungal Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amphotericin B deoxycholate (Fungizone)</td>
<td>Serious, systemic fungal infections (eg, candidiasis, histoplasmosis)</td>
<td>IV, individualized according to disease severity and client tolerance. Initial dose often 0.25 mg/kg/d, gradually increased to 0.5–1 mg/kg/d, infused over 2–6 h. Topically to skin lesions two to four times daily for 1–4 wk Oral suspension (100 mg/mL), 1 mL “swish and swallow” 4 times daily</td>
</tr>
<tr>
<td>Liposomal amphotericin B (AmBisome)</td>
<td>Systemic infections in clients who do not tolerate Fungizone Empiric treatment of presumed fungal infections in febrile, neutropenic clients</td>
<td>IV 5 mg/kg/d Same as adults</td>
</tr>
<tr>
<td>Anfotericin B lipid complex (Abelcet)</td>
<td>Systemic infections in clients who do not tolerate Fungizone</td>
<td>IV 3–5 mg/kg/d Same as adults</td>
</tr>
<tr>
<td>Butenafine (Mentax)</td>
<td>Tinea infections</td>
<td>Topically to skin lesions 1–2 times daily for 1–4 wk Safety and efficacy not established for children &lt;12 y</td>
</tr>
<tr>
<td>Butoconazole (Femstat, Gynazol)</td>
<td>Vaginal candidiasis</td>
<td>Intravaginally, once daily for 3 d Safety and efficacy not established</td>
</tr>
<tr>
<td>Caspofungin (Cancidas)</td>
<td>Invasive aspergillosis</td>
<td>IV infusion over 1 h, 70 mg initially, then 50 mg daily Hepatic impairment, 70 mg initially, then 35 mg daily Safety and efficacy not established</td>
</tr>
<tr>
<td>Ciclopirox (Loprox)</td>
<td>Tinea infections, cutaneous candidiasis</td>
<td>Topically to skin lesions, twice daily for 2–4 wk Safety and efficacy not established</td>
</tr>
<tr>
<td>Clotrimazole (Lotrimin, Mycelex, Gyne-Lotrimin)</td>
<td>Cutaneous dermatophytosis; oral, cutaneous, and vaginal candidiasis</td>
<td>Orally, 1 troche dissolved in mouth five times daily Safety and efficacy not established</td>
</tr>
<tr>
<td>Econazole (Spectazole)</td>
<td>Tinea infections, cutaneous candidiasis</td>
<td>Topically to skin lesions, once or twice daily for 2–4 wk Safety and efficacy not established</td>
</tr>
<tr>
<td>Fluconazole (Diflucan)</td>
<td>Oropharyngeal, esophageal, vaginal, and systemic candidiasis Prevention of candidiasis after bone marrow transplantation Cryptococcal meningitis</td>
<td>Oropharyngeal candidiasis, PO, IV 200 mg first day, then 100 mg daily for 2 wk Dosage not established</td>
</tr>
<tr>
<td>Fluconazole (Diflucan)</td>
<td>Oropharyngeal candidiasis, PO, IV 6 mg/kg first day, then 3 mg/kg/d for at least 2 wk</td>
<td>Oropharyngeal candidiasis, PO, IV 200 mg first day, then 100 mg daily for at least 3 wk</td>
</tr>
<tr>
<td>Generic/Trade Name</td>
<td>Clinical Indications</td>
<td>Routes and Dosage Ranges</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Flucytosine (Ancobon)</strong></td>
<td>Systemic mycoses due to <em>Candida</em> species or <em>Cryptococcus neoformans</em></td>
<td>PO 50–150 mg/kg/d in divided doses q6h</td>
</tr>
<tr>
<td><strong>Griseofulvin (Fulvicin)</strong></td>
<td>Dermatophytosis (skin, hair, nails)</td>
<td>Microsize, PO 500 mg–1 g daily in divided doses q6h</td>
</tr>
<tr>
<td><strong>Haloprogin (Halotex)</strong></td>
<td>Dermatophytosis, mainly tinea pedis (athlete’s foot), cutaneous candidiasis</td>
<td>Topically to skin, 1% cream or solution twice daily for 2–4 wk</td>
</tr>
<tr>
<td><strong>Itraconazole (Sporanox)</strong></td>
<td>Systemic fungal infections, including aspergillosis, in neutropenic and immunocompromised hosts Onychomycosis Tinea infections</td>
<td>Systemic infection, PO 200 mg once or twice daily for 3 mo Blastomycosis, histoplasmosis, aspergillosis, IV 200 mg twice daily for 4 doses, then 200 mg/d Fingernail onychomycosis, PO 200 mg twice daily for 1 wk, no drug for 3 wk, then repeat dosage for 1 wk Oral solution, 100–200 mg daily (10–20 mL), swish and swallow 3 times daily for 3–5 d Tinea infections, PO 100–200 mg daily for 1–4 wk</td>
</tr>
<tr>
<td><strong>Ketoconazole (Nizoral)</strong></td>
<td>Candidiasis, histoplasmosis, coccidioidomycosis Cutaneous candidiasis Tinea infections</td>
<td>PO 200 mg once daily, increased to 400 mg once daily if necessary in severe infections</td>
</tr>
<tr>
<td><strong>Miconazole (Monistat)</strong></td>
<td>Dermatophytosis, cutaneous and vulvovaginal candidiasis</td>
<td>Topically, once daily for 2–6 wk Intravaginally, vaginal cream, once daily at bedtime for 3–7 d; vaginal suppository, once daily at bedtime (1 d for 1200 mg; 3 d for 200 mg; 7 d for 100 mg) Topically, twice daily for 2–4 wk</td>
</tr>
<tr>
<td><strong>Naftifine (Naftin)</strong></td>
<td>Tinea infections (athlete’s foot, jock itch, ringworm)</td>
<td>Topically, once daily (cream) or twice daily (gel)</td>
</tr>
<tr>
<td><strong>Natamycin (Natacyn)</strong></td>
<td>Fungal infections of the eye</td>
<td>Topically. 1 drop q1–2h for 3–4 d, then 1 drop 6–8 times daily for 14–24 d</td>
</tr>
<tr>
<td><strong>Nystatin (Mycostatin)</strong></td>
<td>Candidiasis of skin, mucous membrane, and intestinal tract</td>
<td>Oral or intestinal infection, PO tablets 1–2 (500,000–1,000,000 units) 3 times daily; oral suspension, 4–6 mL (400,000–600,000 units) 4 times daily; oral troches 1–2 (200,000–400,000 units) 4–5 times daily Topically to skin lesions, 2–3 times daily Intravaginally, 1 vaginal tablet once daily for 14 d</td>
</tr>
</tbody>
</table>
Drugs at a Glance: Selected Antifungal Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Indications</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxiconazole (Oxistat)</td>
<td>Tinea infections</td>
<td>Topically to skin lesions, once or twice daily for 2–4 wk</td>
<td>Safety and efficacy not established</td>
</tr>
<tr>
<td>Sulconazole (Exelderm)</td>
<td>Tinea infections</td>
<td>Topically to skin lesions, once or twice daily for 3–4 wk</td>
<td>Safety and efficacy not established for children &lt;12 y</td>
</tr>
<tr>
<td>Terbinafine (Lamisil)</td>
<td>Tinea infections, Onychomycosis of fingernails or toenails</td>
<td>Tinea infections, topically to skin, once or twice daily for at least 1 wk and no longer than 4 wk</td>
<td>For children &lt;12 y</td>
</tr>
<tr>
<td>Terconazole (Terazol)</td>
<td>Vaginal candidiasis</td>
<td>Intravaginally, 1 applicator once daily at bedtime for 7 doses (0.4% cream) or 3 doses (0.8% cream)</td>
<td>Topically to skin lesions, twice daily for 2–6 wk</td>
</tr>
<tr>
<td>Tioconazole (Vagistat)</td>
<td>Vaginal candidiasis</td>
<td>Vaginal suppository, 1 daily at bedtime for 3 d</td>
<td>Topically to skin lesions, 3 times daily</td>
</tr>
<tr>
<td>Tolnaftate (Tinactin)</td>
<td>Cutaneous mycoses (dermatophytosis) (eg, athlete’s foot), cutaneous candidiasis</td>
<td>Topically to skin lesions, twice daily for 2–4 wk</td>
<td>Same as for adults</td>
</tr>
<tr>
<td>Triacetin (Fungoid)</td>
<td>Dermatophytosis (Fungoid)</td>
<td>Topically to skin twice daily for 2–4 wk</td>
<td>Same as for adults</td>
</tr>
<tr>
<td>Zinc undecylenate (Desenex)</td>
<td>Dermatophytosis</td>
<td>Same as for adults</td>
<td>Same as for adults</td>
</tr>
</tbody>
</table>

Adverse effects include an infusion reaction characterized by fever, chills, and tachypnea. This reaction does not represent drug hypersensitivity. It is usually managed by premedication with acetaminophen, diphenhydramine (an antihistamine), or the addition of hydrocortisone to the IV infusion fluids. Chills, which occur despite premedication, can be treated with meperidine. Nephrotoxicity is the most common and the most serious long-term adverse effect. The drug apparently damages the kidneys by constricting afferent renal arterioles and reducing blood flow to the kidneys. Several measures may decrease nephrotoxicity, such as keeping the client well hydrated, giving 0.9% sodium chloride IV solution prior to drug administration, and avoiding the concomitant administration of other nephrotoxic drugs (eg, aminoglycoside antibiotics) or diuretics. Increasing the dosing interval to every other day has also been proposed, but this lessens nephrotoxicity only if the total dose of the drug is reduced. Hypokalemia and hypomagnesemia also occur and may require oral or IV replacement. Additional adverse effects include anorexia, nausea, vomiting, anemia, and phlebitis or thrombophlebitis at peripheral infusion sites. A central vein is preferred for administration.

Nystatin has the same mechanism of action as amphotericin B. However, it is used only for topical therapy of oral, intestinal, and vaginal candidiasis because it is too toxic for systemic use. Although given orally for oral or intestinal infections, the drug is not absorbed systemically and it is excreted in the feces after oral use. With oral use, adverse effects include nausea, vomiting, and diarrhea; with vaginal application, adverse effects include local irritation and burning.

Azoles

The azoles comprise the largest group of commonly used antifungal agents. Many of these are used topically and some are available without a prescription for dermatologic (see Chap. 66) or vaginal use (eg, butoconazole, clotrimazole, miconazole, terconazole, tioconazole). The ones discussed in this chapter are used systemically or both topically and systemically. In serious, invasive fungal infections, these drugs are often used long term following initial treatment with amphotericin B. However, their use as initial treatment for some systemic infections is increasing. Ketoconazole, the first azole, is chemically an imidazole; fluconazole and itraconazole are triazoles. The triazoles have replaced ketoconazole for most uses because they have a broader spectrum of antifungal activity, better absorption, better drug distribution in body tissues,

Amphotericin B is ordered for Harry Little, who has aspergillosis. You collect the following information before administering the medication: blood pressure 110/68, pulse 92, respiratory rate 18, temperature 37.8°C. Laboratory test results include K+ 3.2 mEq/L, Na+ 140 mEq/L, hemoglobin 14 g/dL, hematocrit 43%, blood urea nitrogen (BUN) 48 mg/dL, and creatinine 3.5 mg/dL. You have an order to premedicate Mr. Little with meperidine and diphenhydramine IV, which you do. He has a central line and the IV amphotericin is diluted in 500 cc, to run over 2 hours. You set the IV infusion pump for 250 cc/hour after you check the site and see that there is no redness.
fewer adverse effects, and fewer drug interactions. Several newer triazoles are being developed. All azoles are contra-indicated during pregnancy. Teratogenicity has occurred in animals and fetal malformations have been reported in women who took fluconazole during pregnancy.

**Ketoconazole** (Nizoral) was an important antifungal agent when it was first introduced. It had several advantages over amphotericin B in that it could be given orally, on an outpatient basis, and was somewhat less toxic. Little absorption occurs with topical use. Adverse effects include nausea, vomiting, hypersensitivity reactions (including anaphylaxis), pruritus with oral use, and irritation, stinging, and itching with local application. A major disadvantage that evolved during several years of use includes many interactions with other drugs in which ketoconazole decreases the metabolism and increases the risks of toxicity with affected drugs. The drug also requires gastric acid for tablet dissolution and drug absorption. Consequently, administration is problematic for patients with achlorhydria and those receiving drugs that decrease gastric acidity (eg, antacids, histamine H₂ blockers, proton pump inhibitors). These drugs must be given at least 2 hours after ketoconazole. In addition, the drug has been associated with hepatotoxicity. As a result of these difficulties and the development of the triazole drugs, ketoconazole has largely been replaced by fluconazole and itraconazole for systemic fungal infections. It is still used for some patients who require long-term therapy, because it is much less expensive than fluconazole or itraconazole. It may also be used with cyclosporine and tacrolimus because it increases blood levels of these immunosuppressant drugs and allows smaller dosages in patients with organ transplants.

**Fluconazole** (Diflucan) is a synthetic, broad-spectrum agent that is effective for candidiasis, cryptococcosis, and coccidioidomycosis and may be used as first-line or second-line (after amphotericin B) therapy. It is also used for long-term maintenance therapy of cryptococcal meningitis in clients with AIDS, after initial use of amphotericin B. It is effective in treatment of candidal infections. A single oral dose of 150 mg is given for vaginal candidiasis. However, more infections with resistant strains of *Candida* organisms are being seen with the extensive use of fluconazole during recent years. Aspergillosis does not respond to fluconazole therapy, and fluconazole has less activity against blastomycosis and histoplasmosis than itraconazole.

Fluconazole can be given orally or intravenously and, except for a more rapid onset with IV use, pharmacokinetics (and dosage) are similar with the two routes. Oral drug does not require gastric acid for absorption and the drug reaches therapeutic levels in most body fluids and tissues, including normal and inflamed meninges. With a one-time loading dose of twice the usual daily dose, steady-state blood levels are reached in about 2 days; without a loading dose, 5 to 10 days are required. Once daily dosing may be effective in some clients with normal renal function. Most of the drug is excreted as unchanged drug in urine; dosage may need to be reduced in clients with impaired renal function.

Fluconazole is usually well tolerated. Adverse effects, including nausea, vomiting, diarrhea, abdominal pain, headache, and skin rash, have been reported in fewer than 3% of patients. In addition, elevation of liver enzymes and hepatic necrosis have been reported and alopecia often occurs in clients receiving prolonged, high-dose treatment.

Fluconazole increases the effects of several drugs, including cyclosporine, phenytoin, oral sulfonylureas, and warfarin, but apparently has fewer interactions than ketoconazole and itraconazole.

**Itraconazole** (Sporanox) is a synthetic, broad-spectrum agent similar to fluconazole. It is a drug of choice for blastomycosis, histoplasmosis, and sporotrichosis and is useful in treating aspergillosis. It may be most useful for long-term suppression of disseminated histoplasmosis in patients with AIDS and for nonmeningeal, non-life-threatening blastomycosis. It is probably the drug of choice for all forms of sporotrichosis except meningitis. It may also be used to treat vaginal candidiasis, tinea infections, dermatophytic infections, and onychomycosis. It is contraindicated for the treatment of dermatophytic infections and onychomycosis in patients with congestive heart failure.

Itraconazole can be given orally or IV. However, both the oral capsule and suspension require a low gastric pH for drug dissolution and absorption. The suspension is better absorbed than the capsule. Drug absorption is especially problematic in patients with HIV infection who have achlorhydria and in those receiving a concurrent antacid, histamine H₂ antagonist, or proton pump inhibitor. Serum levels should be measured to ensure adequate absorption. Drug concentrations are higher in visceral organs than in serum; little drug appears in urine or CSF.

The drug is well tolerated in usual doses but may cause nausea and gastric distress. Higher doses may cause impotence, hypokalemia, hypertension, edema, and congestive heart failure. Itraconazole has significant interactions with several commonly prescribed drugs. Drugs that increase the pH of gastric acid (eg, antacids, histamine H₂ blockers, proton pump inhibitors) decrease absorption of itraconazole and should be given at least 2 hours after itraconazole. Drugs that induce drug-metabolizing enzymes (eg, carbamazepine, phenytoin, rifampin) decrease serum levels and therapeutic effectiveness of itraconazole. Itraconazole increases serum levels of cyclosporine, digoxin, oral sulfonylureas, and warfarin. It decreases serum levels of carbamazepine, phenytoin, and rifampin.

**Miscellaneous Antifungal Drugs**

**Caspofungin** (Cancidas) is the first echinocandin antifungal drug; others are being developed. These drugs are usually fungicidal but they do not act as rapidly as amphotericin B. They are active against *Candida* organisms, including azole-resistant strains, *Aspergillus* organisms, and the organisms that cause blastomycosis and histoplasmosis. They lack activity against *Cryptococcus* species. These drugs inhibit beta-(1,3)-D-glucan synthase, the enzyme responsible for incorporation
of glucose into the glucan fibrils that compose the walls of most fungi. Depletion of glucan in the fungal cell wall leads to leakage of cellular contents and cell death. Because human cells do not have cell walls or contain beta glucan, these drugs are less toxic than other systemic antifungal drugs. At present, caspofungin is indicated for treatment of invasive aspergillosis in clients who cannot take or do not respond to amphotericin B or itraconazole. It has not been studied for initial treatment of invasive aspergillosis.

Caspofungin is given IV and is highly bound to plasma albumin. After a single 1-hour infusion, plasma levels decline in three main phases. A short alpha phase occurs immediately after infusion; an intermediate beta phase has a half-life of 8 to 11 hours; and a longer gamma phase has a half-life of 40 to 50 hours. There is minimal biotransformation or excretion during the first 30 hours after infusion, then the drug is metabolized slowly and excreted in feces and urine.

Caspofungin is usually well tolerated with doses of 50 mg/day. Adverse effects occur in fewer than 3% of recipients and include nausea, vomiting, and infusion site complications. With doses of 50 to 70 mg daily, adverse effects include fever, headache, nausea, phlebitis or thrombophlebitis at infusion sites, and abnormal laboratory reports (eg, decreased white blood cells, hemoglobin and hematocrit; increased serum potassium and liver aminotransferase enzymes). Dosage must be reduced with moderate hepatic impairment (eg, after a 70-mg loading dose, a 35-mg daily dose is recommended rather than the 50-mg daily recommended for clients with normal liver function). The drug has not been studied in clients with severe hepatic impairment. No dosage adjustment is needed for renal impairment.

Cyclosporine increases the effects of caspofungin, including potential liver damage. Concomitant use is not recommended unless potential benefits outweigh potential risks. Drugs that decrease effects include anti-HIV drugs (eg, efavirenz, nelbuvir, nevirapine), anticonvulsants (eg, carbamazepine, phenytoin), dexamethasone, and rifampin. Concurrent administration may significantly reduce caspofungin blood levels and therapeutic effectiveness unless dosage is increased (eg, from the usual 50 mg to 70 mg daily).

Flucytosine is a nucleoside analog that is converted to 5-fluorouracil inside the fungal cell. The 5-fluorouracil is then metabolized to products that interfere with the synthesis of fungal RNA and DNA. Flucytosine has little activity against molds or dimorphic fungi and is mainly used for yeast infections. It has significant activity against Candida and Cryptococcus neoformans organisms. Flucytosine is not used alone because drug resistance develops. It is most often used in combination with amphotericin B to treat systemic candidiasis and cryptococcal meningitis. The combination allows smaller doses of amphotericin B and prevents emergence of flucytosine resistance. If high doses of amphotericin B are used, flucytosine adds no additional benefit.

Flucytosine is well absorbed with oral use and widely distributed into most body fluids, including urine, aqueous humor, bronchial secretions, and CSF. Levels in CSF reach 60% to 80% of serum levels. More than 90% of each dose is excreted unchanged in urine. Dosage must be reduced and serum drug levels monitored in the presence of impaired renal function.

Flucytosine causes fewer adverse effects than amphotericin B and the azole antifungals, but may be associated with GI upset (nausea, vomiting, diarrhea) and bone marrow depression (eg, leukopenia, thrombocytopenia), especially when given concurrently with amphotericin B. AIDS patients with systemic fungal infections do not tolerate flucytosine well because of their baseline leukopenia. Adverse effects are attributed to conversion of flucytosine to toxic metabolites in human cells.

Griseofulvin (Fulvicin) has long been used orally for dermatophyte infections of the scalp and nails and for skin eruptions that were too extensive to be treated with topical agents alone. The drug acts by interfering with cell division and reproduction in actively growing fungal cells. In infections of keratinized tissues, the drug binds to keratin (a protein in hair, nails, and the epidermis of the skin). Over time, the infected tissues are shed and replaced by uninfected tissues. Dermatophytic infections (eg, ringworm) of skin usually improve in 3 to 8 weeks. A year or more may be needed to eliminate onychomycosis of toenails. As a result, griseofulvin is being used less often and itraconazole, which is effective with shorter courses of therapy, is being used more often. Griseofulvin is contraindicated for patients with liver disease.

Oral griseofulvin is poorly absorbed; absorption is improved by reducing the particle size (micrsize or ultramicrosize formulations are available) and by taking the drug with fatty meals. Doses are about 30% lower with the ultramicrosized formulation because it is better absorbed than the microsized formulation.

Griseofulvin is usually well tolerated. Common adverse effects include GI upset (eg, nausea, vomiting, diarrhea), fatigue, headache, insomnia, and skin rash. Hepatotoxicity may also occur. Griseofulvin may decrease the effects of cyclosporine, oral contraceptives, salicylates, and warfarin. Warfarin doses may need to be increased and an alternative method of contraception may be needed during griseofulvin therapy.

Terbinafine (Lamisil) is a synthetic allylamine with a broad spectrum of antifungal activity. It inhibits an enzyme (squalene epoxidase) needed for synthesis of ergosterol, a structural component of fungal cell membranes. Terbinafine has fungicidal activity against dermatophytes and has been used primarily for topical treatment of ringworm infections and oral treatment of onychomycosis (fungal infection of nails). Therapeutic effects may not be evident until months after drug therapy is stopped, because of the time required for growth of healthy nail. Because of its activity against Candida, Aspergillus, and possibly other fungal organisms, terbinafine is being evaluated for possible use in invasive mycoses.

Oral terbinafine is about 70% absorbed, but first-pass metabolism reduces bioavailability to approximately 40%. The drug is extensively metabolized to inactive metabolites and excreted in the urine.

Adverse effects with topical terbinafine are minimal. Common effects with oral use are headache, diarrhea, and abdominal discomfort. Oral drug may also cause skin reactions
and liver failure with long-term therapy of onychomycosis. Hepatotoxicity is uncommon, but has occurred in people with and without preexisting liver disease and has led to liver transplant or death. Terbinafine is not recommended for patients with chronic or active liver disease and serum aminotransferases (ALT and AST) should be checked before starting the drug.

**Nursing Process**

**Assessment**
Assess for fungal infections. Specific signs and symptoms vary with location and type of infection as well as the immune state of the client.
- Superficial lesions of skin, hair, and nails are usually characterized by pain, burning, and itching. Some lesions are moist; others are dry and scaling. They also may appear inflamed or discolored.
- Candidiasis occurs in warm, moist areas of the body. Skin lesions are likely to occur in perineal and intertriginous areas. They are usually moist, inflamed, pruritic areas with papules, vesicles, and pustules. Oral lesions are white patches that adhere to the buccal mucosa. Vaginal infection causes a cheesy vaginal discharge, burning, and itching. Intestinal infection causes diarrhea. Systemic infection causes chills and fever, myalgia, arthralgia, and prostration.
- Blastomycosis, coccidioidomycosis, and histoplasmosis may be asymptomatic or mimic influenza, pneumonia, or tuberculosis, with cough, fever, malaise, and other pulmonary manifestations. Severe histoplasmosis may also cause fever, anemia, enlarged spleen and liver, leukopenia, and gastrointestinal tract ulcers.
- Cryptococcosis may involve the lungs, skin, and other body organs. In clients with AIDS or other immunosuppressant disorders, it often involves the central nervous system (CNS) and produces mental status changes, headache, dizziness, and neck stiffness.
- Sporotrichosis involves the skin and lymph nodes. It usually produces small nodules that look like insect bites initially and ulcerations later. Nodules and ulcers also may develop in local lymphatic channels and nodes. The infection can spread to other parts of the body in immunocompromised clients.
- Systemic mycoses produce severe symptoms and may be life-threatening. They are confirmed by recovery of organisms from specimens of body tissues or fluids.

**Nursing Diagnoses**
- Risk for Injury related to fungal infection
- Deficient Knowledge: Prevention of fungal infection; accurate drug usage
- Noncompliance related to the need for long-term therapy
- Risk for Injury: Adverse drug effects with systemic antifungal drugs

**Planning/Goals**
*The client will:*
- Take or receive systemic antifungal drugs as prescribed
- Apply topical drugs accurately
- Act to prevent recurrence of fungal infection
- Avoid preventable adverse effects from systemic drugs

**Interventions**
- Use measures to prevent spread of fungal infections:
  - Observe universal precautions while assessing or providing care to clients with skin lesions. Superficial infections (eg, ringworm) are highly contagious and can be spread by sharing towels and hairbrushes. Systemic mycoses are not usually considered contagious.
  - Decrease client exposure to environmental fungi. For inpatients who are neutropenic or otherwise immunocompromised, do not allow soil-containing plants in the room and request regular cleaning and inspection of air-conditioning systems. Aspergillosis has occurred after inhalation of airborne mold spores from air-conditioning units and hospital water supplies. For outpatients, assist to identify and avoid areas of potential exposure (eg, soil contaminated by chicken, bird, or bat droppings; areas where buildings are being razed, constructed, or renovated). If exposure is unavoidable, instruct to spray areas with water to minimize airborne spores and to wear disposable clothing and a face mask. For clients at risk of exposure to sporotrichosis (eg, those who garden or work in plant nurseries), assist to identify risk factors and preventive measures (eg, wearing gloves and long sleeves).
- For obese clients with skin candidiasis, apply dry padding to intertriginous areas to help prevent irritation and candidal growth.
- For clients with oropharyngeal ulcerations, provide soothing oral hygiene, nonacidic fluids, and soft, bland foods.
- For clients with systemic fungal infections, monitor respiratory, cardiovascular, and neurologic status at least every 8 hours. Provide comfort measures and medications (eg, analgesics, antihistamines, antipyretics, antiemetics) for clients receiving IV amphotericin B.

**Evaluation**
- Observe for relief of symptoms for which an antifungal drug was prescribed.
- Interview outpatients regarding their compliance with instructions for using antifungal drugs.
- Interview and observe for adverse drug effects with systemic antifungal agents.

**Nursing Notes: Apply Your Knowledge**
Harold Johnson has oral candidiasis and is being treated with nystatin 5 cc, S & S, after meals and at bedtime. What nursing considerations are important to ensure therapeutic effect?
With vaginal antifungal preparations:
- Read instructions carefully, with prescribed and over-the-counter drugs.
- Insert high into the vagina (except during pregnancy).
- Continue use through menstruation.
- Wear a minipad to avoid staining clothing; do not use a tampon.
- Wash applicator with mild soap and rinse thoroughly after each use.
- Avoid sexual intercourse while using the drug.

With flucytosine, take capsules a few at a time over 15 minutes to decrease nausea and vomiting.
With oral ketoconazole, take with food to decrease gastrointestinal upset. However, do not take with antacids or drugs such as ranitidine (Zantac) or omeprazole (Prilosec). If one of these drugs is required, take it approximately 2 hours after a dose of ketoconazole.
With itraconazole capsules, take after a full meal for best absorption. With the oral suspension, take on an empty stomach, usually by swishing in the mouth and then swallowing it.
With nystatin suspension for mouth lesions (thrush), swish the medication around in the mouth for a few minutes (to increase drug contact with the lesions), then swallow the medication.
With oral fluconazole (Diflucan), itraconazole (Sporanox), ketoconazole (Nizoral), or terbinafine (Lamisil), notify a healthcare provider of unusual fatigue, loss of appetite, nausea, vomiting, jaundice, dark urine, pale stools, fever, abdominal pain, or diarrhea. These may be signs of liver damage or other adverse drug effects. Drug therapy may need to be discontinued.
With griseofulvin, avoid prolonged exposure to sunlight or sunlamps; the drug may cause photosensitivity.

**General Considerations**
- If you have a condition or take a medicine that suppresses your immune system (eg, bone marrow or organ transplant, leukemia, lymphoma, diabetes mellitus, HIV infection, cancer chemotherapy, corticosteroid therapy), you need to avoid exposure to molds and fungi when possible. For example, aspergillus organisms, which can be in the air, dust, soil, and other environments, can cause serious illness and death. To minimize exposure, you should avoid areas of building construction or renovation, avoid cleaning carpets or potentially moldy areas, and avoid potted plants and live flowers.
- With skin lesions, wash hands often and do not share towels, hairbrushes, or other personal items.
- With vaginal yeast infections, do not use over-the-counter medications repeatedly without consulting a physician or other health care provider. Recurrent infections may indicate inadequate treatment, reinfection, or a bacterial infection (for which an antifungal drug is not effective), and a different treatment may be needed.
- With histoplasmosis and other potentially serious fungal infections, avoid or minimize future exposure to chicken, pigeon, and bat excreta.
- For people who work with plants (eg, roses, sphagnum moss) or baled hay, sporotrichosis can be prevented by wearing gloves and long sleeves and avoiding injuries that cause breaks in the skin.

**Self-Administration**
- Use antifungal drugs as prescribed.
- With topical skin preparations, wash and dry the area before each application of medication.

**CLIENT TEACHING GUIDELINES**

### Oral and Topical Antifungal Drugs

**General Considerations**
- If you have a condition or take a medicine that suppresses your immune system (eg, bone marrow or organ transplant, leukemia, lymphoma, diabetes mellitus, HIV infection, cancer chemotherapy, corticosteroid therapy), you need to avoid exposure to molds and fungi when possible. For example, aspergillus organisms, which can be in the air, dust, soil, and other environments, can cause serious illness and death. To minimize exposure, you should avoid areas of building construction or renovation, avoid cleaning carpets or potentially moldy areas, and avoid potted plants and live flowers.
- With skin lesions, wash hands often and do not share towels, hairbrushes, or other personal items.
- With vaginal yeast infections, do not use over-the-counter medications repeatedly without consulting a physician or other health care provider. Recurrent infections may indicate inadequate treatment, reinfection, or a bacterial infection (for which an antifungal drug is not effective), and a different treatment may be needed.
- With histoplasmosis and other potentially serious fungal infections, avoid or minimize future exposure to chicken, pigeon, and bat excreta.
- For people who work with plants (eg, roses, sphagnum moss) or baled hay, sporotrichosis can be prevented by wearing gloves and long sleeves and avoiding injuries that cause breaks in the skin.

**Self-Administration**
- Use antifungal drugs as prescribed.
- With topical skin preparations, wash and dry the area before each application of medication.

**PRINCIPLES OF THERAPY**

### Nonpharmacologic Treatment

Some fungal infections are asymptomatic or resolve spontaneously without treatment. In addition, candidal infections of blood or urine often respond to the removal of predisposing factors, such as antibacterial drugs, corticosteroids or other immunosuppressive drugs, and indwelling IV or bladder catheters.

### Choice of Drug

Drug therapy for potentially serious fungal infections should be planned in consultation with an infectious disease specialist when possible. In general, drug selection is determined mainly by the type of fungal infection. For example, drugs that are effective in candidiasis are not usually effective in dermatophytic infections, and vice versa. For serious infections, amphotericin B is usually the first drug of choice, especially for invasive aspergillosis and systemic infections in immunocompromised hosts. However, fluconazole and itraconazole are increasingly being used for first-line treatment of some infections. If anazole drug has equivalent effectiveness in a particular infection, it may be preferred over amphotericin B because it is easier to administer and less toxic. The systemic azoles are also used for initial therapy in less acutely ill patients and as long-term treatment after a brief initial course of amphotericin B. However, all azoles are contraindicated during pregnancy. The newer drug, caspofungin, is currently approved only for second-line treatment of invasive aspergillosis.

### Dosage and Routes of Administration

Dosages depend on illness severity, with high amounts required for systemic infections, especially in immunocompromised hosts.
Routes are determined mainly by location and severity of infection. For example, local infections can often be treated by topical applications, whereas more serious or systemic infections require oral or IV routes.

**Duration of Therapy**

When antifungal drug therapy is required, it is usually long term, over weeks to months. In some cases, it may be years or lifelong. If drug therapy is stopped too soon, relapse of the infection commonly occurs. However, in clients with AIDS, who often require long-term antifungal drug therapy, drug-resistant infections may develop. Fluconazole-resistant candidiasis is becoming increasingly recognized in this population. Clients with impaired immune responses often become reinfected after effective antifungal drug therapy and may require repeated courses of therapy.

**Drugs Used in Specific Infections**

- **Aspergillosis.** Itraconazole for approximately 1 year may be effective in mild to moderate infection. Amphotericin B is indicated for serious invasive disease, and large doses are required. Caspofungin may be used in clients who cannot tolerate or do not respond to itraconazole or amphotericin B.
- **Blastomycosis.** Amphotericin B is the drug of first choice for seriously ill clients. Itraconazole may also be used, alone for at least 6 months or after a course of amphotericin B.
- **Candidiasis.** Oral candidiasis is often treated with nystatin suspension, which is swished in the mouth to allow medication contact with the mucosa and then swallowed. Other options include nystatin or clotrimazole troches, dissolved slowly in the mouth; oral fluconazole or itraconazole; and low-dose amphotericin B IV for 1 to 2 weeks. Vaginal candidiasis may be treated with a single oral dose of fluconazole or multiple doses of vaginal tablets, creams, or suppositories containing butoconazole, clotrimazole, miconazole, nystatin, terconazole, or tioconazole. Some of these preparations are available over the counter. One concern about self-treatment with nonprescription products is an incorrect diagnosis. Antifungal preparations do not help a bacterial vaginal infection. Pregnant clients should consult their obstetricians before using these drugs. Gastrointestinal candidiasis is usually treated with oral nystatin, fluconazole, or itraconazole. Systemic candidiasis is usually treated with amphotericin B. If the CNS is involved, flucytosine is used in conjunction with amphotericin B, although some strains of *C. albicans* are resistant to flucytosine. Oral or IV fluconazole or itraconazole may also be used.
- **Coccidioidomycosis.** Amphotericin B is preferred for severe or disseminated disease and is usually given for 1 to 3 months. For milder infections, an oral azole (eg, fluconazole) may be given. Azole therapy is usually continued for more than 6 months after the disease becomes inactive. Some clients may require long-term therapy with itraconazole.
- **Cryptococcosis.** A combination of amphotericin B and flucytosine for 2 to 6 weeks is the initial treatment of first choice. This may be followed by 6 months of oral fluconazole for treatment of meningitis.
- **Histoplasmosis.** Amphotericin B is the drug of choice for treating moderate to severe disease in immunocompromised hosts. Itraconazole may be given, usually for 6 to 12 months, for mild disease in immunocompetent hosts. Relapses may occur.
- **Sporotrichosis.** Itraconazole, for 3 to 6 months, is probably the drug of choice for localized lymphocutaneous infection. Amphotericin B is used to treat pulmonary, disseminated, and relapsing infections.

**Characteristics and Usage of Amphotericin B**

Amphotericin B has long been the gold standard of drug therapy for serious fungal infections. However, its use is problematic because of different preparations, special requirements for administration, and toxicity. These aspects are summarized as follows:

- **Preparations.** The deoxycholate preparation (Fungizone), often called conventional amphotericin B, is the oldest, most widely used form. Lipid preparations were developed to decrease the toxicity of the deoxycholate form, and three are currently available. These preparations have similar antifungal spectra, but they differ from the deoxycholate formulation and from each other in other respects. The cholesteryl form (Amphotec) and the lipid complex form (Abelcet) have longer half-lives than the liposomal form (Ambisome). Because they are less toxic to normal tissues, these formulations can be given in higher doses than Fungizone.

  The lipid formulations are indicated for clients who are unable to tolerate or do not respond to conventional amphotericin B. For example, these formulations may be useful for clients with renal impairment. Their main drawback is that they are expensive.

- **Administration.** These drugs should be reconstituted and prepared for IV administration in a pharmacy. If not prepared in a pharmacy, the manufacturer’s instructions should be followed for each preparation. Additional factors include the following:
  - A test dose is usually recommended to assess the client’s tolerance of the drug. Some authorities question the need for a test dose.
  - Maintenance doses can be doubled and infused on alternate days. However, a single daily dose of Fungizone should not exceed 1.5 mg/kg; overdoses can result in cardiorespiratory arrest.
Small initial doses (eg, 5 to 10 mg/day) are recommended for clients with impaired cardiovascular or renal function or a severe reaction to the test dose.

Larger doses of lipid preparations are needed to achieve therapeutic effects similar to those of the deoxycholate preparation.

Administer through a separate IV line when possible. If injecting into an existing IV line, the line should be flushed with 5% dextrose solution before and after drug administration (both deoxycholate and lipid formulations).

An in-line filter may be used with Fungizone and AmBisome but should not be used with Abelcet or Amphotec.

Prepared solutions should be infused within 8 hours of reconstitution.

**Decreasing adverse effects.** Several recommendations for reducing toxicity of IV amphotericin B have evolved, but most of them have not been tested in controlled studies. Recommendations to decrease nephrotoxicity are listed in the section on Use in Renal Impairment: those to decrease fever and chills include premedication with acetaminophen, diphenhydramine, IV corticosteroid, and meperidine; and those to decrease phlebitis at injection sites include administering on alternate days, adding 500 to 2000 units of heparin to the infusion, rotating infusion sites, administering through a large central vein, removing the needle after infusion, and using a pediatric scalp vein needle. A test dose is often given, but this does not reliably predict or rule out anaphylaxis, which is a rare adverse effect of both conventional and lipid formulations.

Supplemental potassium may be used to treat hypokalemia, and recombinant erythropoietin may be used to treat anemia if the client has a low plasma level of erythropoietin.

**Effects of Antifungals on Other Drugs**

**Amphotericin B** increases effects of cyclosporine (nephrotoxicity), digoxin (risk of hypokalemia and resultant cardiac dysrhythmias), nephrotoxic drugs (eg, aminoglycoside antibiotics), skeletal muscle relaxants (amphotericin B-induced hypokalemia may enhance muscle relaxation), and thiazide and loop diuretics (risk of hypokalemia). Serum potassium levels should be monitored.

**Azoles** inhibit the metabolism of many drugs (by inhibiting cytochrome P450 drug-metabolizing enzymes in the liver and small intestine, especially 3A4 enzymes) and therefore increase their effects and risks of toxicity. These drugs include benzodiazepines (alprazolam, midazolam, triazolam), calcium channel blockers (felodipine, nifedipine), cyclosporine, phenytoin, statin cholesterol-lowering drugs (lovastatin, simvastatin), sulfonylureas, tacrolimus, theophylline, warfarin, vincristine, and zidovudine.

Although the main concern about azole drug interactions is increased toxicity of inhibited drugs, ketoconazole is being given concurrently with cyclosporine and tacrolimus to decrease dosages and costs of the immunosuppressant drugs. There may also be a reduced risk of fungal infections, which commonly occur in people with impaired immune systems.

Fluconazole is apparently a less potent inhibitor of CYP3A4 enzymes than ketoconazole and itraconazole. As a result, drug interactions with fluconazole are of lesser magnitude and usually occur only with dosages of 200 mg/day or more. However, fluconazole is a strong inhibitor of CYP2C9 enzymes and concurrent administration of losartan, phenytoin, sulfamethoxazole, or warfarin results in greater risks of toxicity with the inhibited drugs.

**Caspofungin** decreases serum levels of tacrolimus; serum levels of tacrolimus should be monitored with concurrent use of the two drugs. **Terbinafine** is a strong inhibitor of CYP2D6 and may increase the effects of propafenone, an antidysrhythmic; metoprolol, a beta blocker; and desipramine and nortriptyline, tricyclic antidepressants. **Griseofulvin** decreases the effects of cyclosporine, oral contraceptives, salicylates, and warfarin, probably by inducing hepatic drug-metabolizing enzymes and accelerating their metabolism.

**Use in Children**

Guidelines for the use of topical antifungal drugs in children are generally the same as those for adults. With most oral and parenteral agents, safety, effectiveness, and guidelines for use have not been established. In addition, some agents have no established dosages and others have age restrictions. Despite these limitations, most oral and parenteral drugs have been used successfully to treat children with serious fungal infections, without unusual or severe adverse effects. These include conventional and lipid formulations of amphotericin B, fluconazole, itraconazole, and ketoconazole. As in other populations receiving these drugs, children should receive the lowest effective dosage and be monitored closely for adverse effects. The safety and efficacy of caspofungin in children have not been established.

**Use in Older Adults**

Specific guidelines for the use of antifungal drugs have not been established. The main concern is with oral or parenteral drugs because topical agents produce few adverse effects.

Virtually all adults receiving IV amphotericin B experience adverse effects. With the impaired renal and cardiovascular functions that usually accompany aging, older adults are especially vulnerable to serious adverse effects. They must be monitored closely to reduce the incidence and severity of nephrotoxicity, hypokalemia, and other adverse drug reactions. Lipid formulations are less nephrotoxic than the conventional deoxycholate formulation and may be preferred for older adults. Azole drugs should probably be stopped if
hypertension, edema, or hypokalemia occur. In addition, itraconazole has been associated with heart failure, a common condition in older adults.

**Use in Clients With Cancer**

Clients with cancer are at high risk for development of serious, systemic fungal infections. In clients receiving cytotoxic anticancer drugs, antifungal therapy is often used to prevent or treat infections caused by *Candida* and *Aspergillus* organisms. For prophylaxis, topical, oral, or IV agents are given before and during periods of drug-induced neutropenia, often to prevent recurrence of infection that occurred during previous neutropenic episodes. For treatment, oral or IV drugs may be given at the onset of fever and neutropenia, when fever persists or recurs in a neutropenic client despite appropriate antimicrobial therapy, or when maintenance therapy is needed after acute treatment of coccidioidomycosis, cryptococcosis, or histoplasmosis. These infections often relapse if antifungal drugs are discontinued. Clients must be closely monitored for adverse effects of antifungal drugs.

**Use in Renal Impairment**

*Amphotericin B* deoxycholate (Fungizone), the conventional formulation, is nephro toxic. Renal impairment occurs in most clients (up to 80%) within the first 2 weeks of therapy but usually subsides with dosage reduction or drug discontinuation. Permanent impairment occurs in a few clients. Recommendations to decrease nephrotoxicity include hydrating clients with a liter of 0.9% sodium chloride solution IV and monitoring serum creatinine and blood urea nitrogen (BUN) at least weekly. If the BUN exceeds 40 mg/dL or the serum creatinine exceeds 3 mg/dL, the drug should be stopped or dosage should be reduced until renal function recovers. Another strategy is to give a lipid formulation (eg, Abelcet, AmBisome, or Amphotec), which is less nephro toxic. For clients who already have renal impairment or other risk factors for development of renal impairment, a lipid formulation is indicated. Renal function should still be monitored frequently.

*Caspofungin* does not require dosage reduction for renal impairment and is not removed by hemodialysis. *Fluconazole* is mainly excreted in the urine as unchanged drug. For clients with a creatinine clearance (CrCl) above 50 mL/minute, full dosage may be given. For those with CrCl of 50 mL/minute or less, dosage should be reduced by one-half. However, for clients receiving hemodialysis, an extra dose may be needed because 3 hours of hemodialysis lowers plasma drug levels by approximately 50%. *Itraconazole* can be given to clients with mild to moderate renal impairment but is contraindicated in those with a CrCl of 30 mL/minute or less. It is not removed by hemodialysis.

*Flucytosine* is excreted renally and may accumulate in renal impairment. Accumulation may increase BUN and serum creatinine and lead to renal failure unless dosage is reduced. Plasma drug levels should be monitored and dosage should be adjusted to maintain blood levels below 100 mcg/mL. *Terbinafine* clearance is reduced by 50% in clients with significant renal impairment (CrCl of 50 mL/minute or less). Its use is not recommended.

**Use in Hepatic Impairment**

Although the main concern with *amphotericin B* is nephrotoxicity, it is recommended that liver function tests be monitored during use. *Caspofungin* dosage must be reduced with moderate hepatic impairment; the drug has not been studied in clients with severe hepatic impairment.

The azole antifungals may cause hepatotoxicity; hepatitis especially occurs with all of the drugs. Hepatic aminotransferases (ALT, AST) and serum bilirubin should be checked before drug use, after several weeks of drug use, and every 1 to 2 months during long-term therapy. Asymptomatic, reversible elevations in ALT and AST may occur. However, if AST and ALT increase to more than 3 times the normal range, the azole should be discontinued. Hepatotoxicity may be reversible if drug therapy is stopped.

With *fluconazole*, hepatic dysfunction may range from mild elevations in ALT and AST to clinical hepatitis, cholestasis, hepatic failure, and death. Fatal hepatic damage has occurred primarily in clients with serious underlying conditions, such as AIDS or malignancy, and with multiple concomitant medications. *Itraconazole* is relatively contraindicated in clients with increased liver enzymes, active liver disease, or a history of liver damage with other drugs. It should be given only if expected benefits outweigh risks of liver injury. Plasma levels of itraconazole should be monitored and dosage adjusted if indicated. *Ketoconazole* may cause serious hepatic impairment, including toxic hepatitis.

*Griseofulvin* may cause hepatotoxicity, especially if given in large doses for prolonged periods. *Terbinafine* has been associated with a few cases of liver failure, and its clearance is reduced by 50% in clients with hepatic cirrhosis. Its use is not recommended for patients with chronic or active liver disease and liver function tests should be done in all patients before starting therapy. Hepatotoxicity has been reported in patients with and without preexisting liver disease.

**Use in Critical Illness**

Amphotericin B, fluconazole, and itraconazole are the drugs most often used for serious fungal infections. *Amphotericin B* penetrates tissues well, except for CSF, and only small amounts are excreted in urine. With prolonged administration, the half-life increases from 1 to 15 days. Hemodialysis does not remove the drug. Lipid formulations may be preferred in critically ill clients because of less nephrotoxicity. *Fluconazole* penetrates tissues well, including CSF. Although IV administration may be necessary in many critically ill clients, the
drug is well absorbed when administered orally or by nasogastric tube. Significantly impaired renal function may require reduced dose and impaired hepatic function may require discontinuation. When *itraconazole* is used in critically ill clients, a loading dose of 200 mg 3 times daily (600 mg/day) may be given for the first 3 days. Treatment should be continued for at least 3 months; inadequate treatment may lead to recurrent infection.

### Home Care

Antifungal drugs may be taken at home by a variety of routes. For topical and oral routes, the role of the home care nurse may be teaching correct usage and encouraging clients to persist with the long-term treatment usually required. With IV antifungal drugs for serious infections, the home care nurse may need to assist in managing the environment, administering the drug, and monitoring for adverse effects. Because these patients’ immune functions are often severely suppressed, protective interventions are needed. These may include teaching about frequent and thorough handwashing by clients, all members of the household, and visitors; safe food preparation and storage; removing potted plants and fresh flowers; and avoiding activities that generate dust in the patient’s environment. In addition, air conditioning and air filtering systems should be kept meticulously clean and any plans for renovations should be postponed or canceled.

### NURSING ACTIONS

#### Antifungal Drugs

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong>&lt;br&gt;a. Give IV amphotericin B according to manufacturers’ recommendations for each product:</td>
<td>Test doses and all other solutions should be prepared in the pharmacy.</td>
</tr>
<tr>
<td>(1) Follow recommendations for administration of test doses.</td>
<td>Administration times can vary according to patient tolerance.</td>
</tr>
<tr>
<td>(2) Use an infusion pump.</td>
<td></td>
</tr>
<tr>
<td>(3) Use a separate intravenous (IV) line if possible; if necessary to use an existing line, flush with 5% dextrose in water before and after each infusion.</td>
<td></td>
</tr>
<tr>
<td>(4) Fungizone IV—give in 5% dextrose in water, over 2–6 h; use an in-line filter; do not mix with other IV medications.</td>
<td></td>
</tr>
<tr>
<td>(5) Abelcet—give IV over approximately 2 h; if infusion time exceeds 2 h, shake the container q2h to mix contents; do not use an in-line filter.</td>
<td></td>
</tr>
<tr>
<td>(6) AmBisome—infuse over 2 h or longer; may use an in-line filter.</td>
<td></td>
</tr>
<tr>
<td>(7) Amphotec—refrigerate after reconstitution and use within 24 h; infuse over at least 2 h; do not use an in-line filter.</td>
<td></td>
</tr>
<tr>
<td>(8) Apply cream or lotion liberally to skin lesions and rub in gently.</td>
<td></td>
</tr>
<tr>
<td>b. Give azoles according to manufacturers’ recommendations:</td>
<td></td>
</tr>
<tr>
<td>(1) With IV fluconazole, follow instructions for preparation carefully; give as a continuous infusion at a maximum rate of 200 mg/h.</td>
<td>To resuspend medication in the liquid vehicle and ensure accurate dosage</td>
</tr>
<tr>
<td>(2) Shake the oral suspension of fluconazole thoroughly before measuring the dose.</td>
<td>To decrease GI upset and increase absorption. The oral solution is used to treat oropharyngeal and esophageal candidiasis, and correct administration enhances contact with mucosal lesions.</td>
</tr>
<tr>
<td>(3) Give itraconazole capsules after a full meal; give the oral solution on an empty stomach and ask the client to swish the medication around in the mouth, then swallow the medication.</td>
<td></td>
</tr>
</tbody>
</table>
**NURSING ACTIONS**

4. Give ketoconazole tablets with food. However, do not give with antacids or other gastric acid suppressants. If such drugs are required, give them 2 h after a dose of ketoconazole.

c. With IV caspofungin, infuse over approximately 1 hour. Be sure it is added to 0.9% sodium chloride solutions only (dextrose solutions should be avoided). Do not mix or co-infuse with any other medications.

d. With flucytosine, have the client take 1 or 2 capsules at a time over 15 min.

**RATIONALE/EXPLANATION**

Food decreases GI upset. Antacids and other drugs that suppress gastric acid decrease absorption because the drug is dissolved and absorbed only in an acidic environment.

Caspofungin should be prepared in a pharmacy according to the manufacturer’s instructions. The drug is available in single-dose vials of 50 mg or 70 mg. It must be reconstituted with 0.9% sodium chloride solution, then added to 250 mL of 0.9% sodium chloride solution.

To decrease nausea and vomiting

Most antifungal drug therapy is long-term, over weeks, months, or years. With skin infections, optimal therapeutic effects may occur 2–4 wks after drug therapy is stopped. With nail infections, optimal effects may occur 6–9 mo after drug therapy is stopped.

**2. Observe for therapeutic effects**

a. Decreased fever and malaise with systemic mycoses

b. Healing of lesions on skin and mucous membranes

c. Diminished diarrhea with intestinal candidiasis

d. Decreased vaginal discharge and discomfort with vaginal candidiasis

**3. Observe for adverse effects**

a. With IV amphotericin B, observe for fever, chills, anorexia, nausea, vomiting, renal damage (elevated blood urea nitrogen and serum creatinine), hypokalemia, hypomagnesemia, headache, stupor, coma, convulsions, anemia from bone marrow depression, phlebitis at venipuncture sites, and anaphylaxis.

b. With fluconazole, itraconazole, or ketoconazole, observe for unusual fatigue, loss of appetite, nausea, vomiting, jaundice, dark urine, pale stools, fever, abdominal pain, or diarrhea. With ketoconazole, observe for nausea, vomiting, pruritus, and abdominal pain.

c. With caspofungin 50 mg daily, observe for nausea, vomiting, and phlebitis at infusion sites. With larger doses (50–70 mg daily), observe for the above plus fever, headache, and abnormal laboratory reports (eg, decreased white blood cells, hemoglobin, and hematocrit; increased serum potassium and liver amino transferase enzymes).

d. With flucytosine, observe for nausea, vomiting, and diarrhea.

e. With griseofulvin, observe for GI symptoms, hypersensitivity (urticaria, photosensitivity, skin rashes, angioedema), headache, mental confusion, fatigue, dizziness, peripheral neuritis, and blood dyscrasias (leukopenia, neutropenia, granulocytopenia).

f. With oral terbinafine, observe for diarrhea, dyspepsia, headache, skin rash or itching, and liver enzyme abnormalities.

g. With topical drugs, observe for skin rash and irritation.

Amphotericin B is a highly toxic drug and most recipients develop adverse reactions, including some degree of renal damage. Antipyretic and antiemetic drugs may be given to help minimize adverse reactions and promote patient comfort. Adequate hydration and lipid formulations may decrease renal damage. Anaphylaxis is uncommon; however, appropriate treatment medications and supplies should be available during infusions. If severe respiratory distress occurs, the drug infusion should be stopped immediately and no additional doses should be given.

These may be signs of liver damage or other adverse effects. Drug therapy may need to be discontinued. With ketoconazole, GI upset occurs in about 20% of clients taking 200 mg daily and in 50% or more of clients taking 400 mg daily.

The drug is usually well tolerated.

These are common effects. Hepatic, renal, and hematologic functions also may be affected.

The incidence of serious reactions is very low.

Elevated liver enzymes (AST and ALT) may indicate liver damage and may occur in clients with or without pre-existing liver disease.

Adverse reactions are usually minimal with topical drugs, although hypersensitivity may occur.

(continued)
4. Observe for drug interactions

a. Drugs that increase effects of amphotericin B:
   (1) Antineoplastic drugs
   (2) Corticosteroids
   (3) Zidovudine
   (4) Nephrotoxic drugs (eg, aminoglycoside antibiotics, cyclosporine)

b. Drug that increases effects of fluconazole:
   (1) Hydrochlorothiazide

c. Drugs that decrease effects of fluconazole:
   (1) Cimetidine
   (2) Rifampin

d. Drugs that decrease effects of itraconazole and ketoconazole:
   (1) Antacids, histamine H₂ antagonists, proton pump inhibitors
   (2) Phenytoin, rifampin

e. Drug that increases effects of caspofungin:
   (1) Cyclosporine

f. Drugs that decrease effects of caspofungin:
   (1) Enzyme inducers (efavirenz, nelfinavir, nevirapine, dexamethasone, carbamazepine, phenytoin, rifampin)

g. Drugs that decrease effects of griseofulvin:
   (1) Enzyme inducers (eg, rifampin)

h. Drug that increases effects of terbinafine:
   (1) Cimetidine

i. Drug that decreases effects of terbinafine:
   (1) Rifampin

May increase risks of nephrotoxicity, hypotension, and bronchospasm
May potentiate hypokalemia and precipitate cardiac dysfunction. Increases renal and hematologic adverse effects of the liposomal formulation of amphotericin B. Renal and hematologic functions should be monitored closely.
Increase nephrotoxicity
Increases serum levels of fluconazole, attributed to decreased renal excretion
Decreased absorption
Accelerated metabolism from enzyme induction
These drugs decrease gastric acid, which inhibits absorption of itraconazole and ketoconazole. If one of these drugs is required, it should be given at least 2 h after the azole drug.
Decrease serum levels, probably from accelerated metabolism
Increases serum levels
Decrease serum levels by accelerating caspofungin metabolism. The daily dose of caspofungin may need to be increased to 70 mg/d (instead of 50 mg/d) if given with one of these drugs.
Enzyme inducers inhibit effects of griseofulvin by increasing its rate of metabolism.
Slows metabolism and elimination of terbinafine so that serum levels are increased
Causes rapid clearance of terbinafine

Answer: Nystatin works topically to treat fungal infestation in the oral cavity. “S & S” means “swish and swallow.” To ensure that nystatin remains in contact with the oral mucosa for as long as possible, it should be administered after meals and all other medications. Instruct the patient not to drink anything for 30 minutes.

Answer: Amphotericin B is very nephrotoxic. You should not administer it to Mr. Little when his BUN is 48 mg/dL and his creatinine is 3.5 mg/dL because both values indicate renal impairment. Notify his physician of these laboratory data to see if he or she would like to decrease the dose.
Review and Application Exercises

1. What environmental factors predispose clients to development of fungal infections?
2. What signs and symptoms occur with candidiasis, and how would you assess for these?
3. Which fungal infections often mimic other respiratory infections?
4. What are the clinical indications for use of IV amphotericin B?
5. What are nursing interventions to decrease adverse effects of IV amphotericin B?
6. What are the differences between amphotericin B deoxycholate and the lipid formulations?
7. What are the clinical indications for use of oral antifungal drugs?
8. What are some early indications that a client is developing nephrotoxicity or hepatotoxicity?
9. Which population groups are at high risk of developing serious fungal infections and what can be done to protect them?

SELECTED REFERENCES


Drug facts and comparisons. (Updated monthly.) St. Louis: Facts and Comparisons.


Antiparasitics

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe environmental and other major factors in prevention and recognition of selected parasitic diseases.
2. Discuss assessment and treatment of pinworm infestations and pediculosis in school-age children.
3. Discuss the drugs used to treat Pneumocystis carinii pneumonia in clients with acquired immunodeficiency syndrome.
4. Teach preventive interventions to clients planning travel to a malarious area.

Critical Thinking Scenario
You are the school nurse in an elementary school. There is an outbreak of head lice in one of the fourth grade classrooms. Four girls are affected. You are responsible for identifying infested students and developing prevention programs.

Reflect on:
- How infested children feel.
- How the parents feel when they find out their child has head lice.
- Appropriate infection control measures to prevent the spread of head lice to other children in the classroom or family members.
- Teaching about the safe use of topical agents such as Nix.

OVERVIEW
A parasite is a living organism that survives at the expense of another organism, called the host. Parasitic infestations are common human ailments worldwide. The effects of parasitic diseases on human hosts vary from minor to major and life threatening. Parasitic diseases in this chapter are those caused by protozoa, helminths (worms), scabies, and pediculi (lice). Protozoa and helminths can infect the digestive tract and other body tissues; scabies and pediculi affect the skin.

PROTOZOAL INFECTIONS

Amebiasis

Amebiasis is a common disease in Africa, Asia, and Latin America, but it can occur in any geographic region. In the United States it is most likely to occur in residents of institutions for the mentally retarded, homosexual and bisexual men, and residents or travelers in countries with poor sanitation.

Amebiasis is caused by the pathogenic protozoan Entamoeba histolytica, which exists in two forms. The cystic form is inactive and resistant to a number of factors, including drugs, heat, cold, and drying. The cystic form can survive outside the body for long periods. Amebiasis is transmitted by the fecal–oral route, such as ingesting food or water contaminated with human feces containing amebic cysts. Once ingested, some cysts open in the ileum to release amebae, which produce trophozoites. Other cysts remain intact to be expelled in feces and continue the chain of infection. Trophozoites are active amebae that feed, multiply, move about, and produce clinical manifestations of amebiasis. Trophozoites produce an enzyme that allows them to invade body tissues. They may form erosions and ulcerations in the intestinal wall with resultant diarrhea (this form of the disease is called intestinal amebiasis or amebic dysentery), or they may penetrate blood vessels and be carried to other organs, where they form abscesses. These abscesses are usually
found in the liver (hepatic amebiasis), but also may occur in the lungs or brain.

Drugs used to treat amebiasis (amebicides) are classified according to their site of action. For example, iodoquinol is an intestinal amebicide because it acts within the lumen of the bowel; chloroquine is a tissue or extraintestinal amebicide because it acts within the liver or other tissues. Metronidazole (Flagyl) is effective in both intestinal and extraintestinal amebiasis. No amebicides are currently recommended for prophylaxis of amebiasis.

**Giardiasis**

Giardiasis is caused by *Giardia lamblia*, a common intestinal parasite. It is spread by food or water contaminated with human feces containing encysted forms of the organism or by contact with infected people or animals. Person-to-person spread often occurs among children in day care centers, institutionalized people, and homosexual or bisexual men. The organism is also found in people who camp or hike in wilderness areas or who drink untreated well water in areas where sanitation is poor. Giardiasis may affect children more than adults and may cause community outbreaks of diarrhea.

Giardial infections occur 1 to 2 weeks after ingestion of the cysts and may be asymptomatic or produce diarrhea and abdominal cramping and distention. If untreated, giardiasis may resolve spontaneously or progress to a chronic disease with anorexia, nausea, malaise, weight loss, and continued diarrhea with large, foul-smelling, light-colored, fatty stools. Deficiencies of vitamin B₁₂ and fat-soluble vitamins may occur. Adults and children older than 8 years with symptomatic giardiasis should be treated with oral metronidazole.

**Malaria**

Malaria is a common cause of morbidity and mortality in many parts of the world, especially in tropical regions. In the United States, malaria is rare and affects travelers or immigrants from malarious areas.

Malaria is caused by four species of protozoa of the genus *Plasmodium*. The human being is the only natural reservoir of these parasites. All types of malaria are transmitted only by *Anopheles* mosquitoes. *Plasmodium vivax*, *Plasmodium malariae*, and *Plasmodium ovale* cause recurrent malaria by forming reservoirs in the human host. In these types of malaria, signs and symptoms may occur months or years after the initial attack. *Plasmodium falciparum* causes the most life-threatening type of malaria but does not form a reservoir. This type of malaria may be cured and prevented from recurring.

Plasmodia have a life cycle in which one stage of development occurs within the human body. When a mosquito bites a person with malaria, it ingests blood that contains gametocytes (male and female forms of the protozoan parasite). From these forms, sporozoites are produced and transported to the mosquito’s salivary glands. When the mosquito bites the next person, the sporozoites are injected into that person’s bloodstream. From the bloodstream, the organisms lodge in the liver and other tissues, where they reproduce and form merozoites. The liver cells containing the parasite eventually rupture and release the merozoites into the bloodstream, where they invade red blood cells. After a period of growth and reproduction, merozoites rupture red blood cells, invade other erythrocytes, form gametocytes, and continue the cycle. After several cycles, clinical symptoms of malaria manifest secondary to the large parasite burden. The characteristic cycles of chills and fever correspond to the release of merozoites from erythrocytes.

Antimalarial drugs act at different stages in the life cycle of plasmodial parasites. Some drugs (eg, chloroquine) are effective against erythrocytic forms and are therefore useful in preventing or treating acute attacks of malaria. These drugs do not prevent infection with the parasite, but they do prevent clinical manifestations. Other drugs (eg, primaquine) act against exoerythrocytic or tissue forms of the parasite to prevent initial infection and recurrent attacks or to cure some types of malaria. Combination drug therapy, administered concomitantly or consecutively, is common with antimalarial drugs.

**Pneumocystosis**

Pneumocystosis is caused by *Pneumocystis carinii*, a parasitic organism once considered a protozoan but now considered a fungus. Sources and routes of spread have not been clearly delineated. It is apparently widespread in the environment, and most people are exposed at an early age. Infections are mild or asymptomatic in immunocompetent people. However, the organism can form cysts in the lungs, persist for long periods, and become activated in immunocompromised hosts. Activation produces *P. carinii* pneumonia (PCP), an acute, life-threatening respiratory infection characterized by cough, fever, dyspnea, and presence of the organism in sputum. Groups at risk include human immunodeficiency syndrome (HIV) seropositive persons; those receiving corticosteroids or antineoplastics and other immunosuppressive drugs; and caregivers of infected people. PCP is a common cause of death in people with AIDS.

**Toxoplasmosis**

Toxoplasmosis is caused by *Toxoplasma gondii*, a parasite spread by ingesting undercooked meat or other food containing encysted forms of the organism, by contact with feces from infected cats, and by congenital spread from mothers with acute infection. Once infected, the organism may persist in tissue cysts for the life of the host. However, symptoms rarely occur unless the immune system is impaired or becomes impaired at a later time. Although symptomatic infection may occur in anyone with immunosuppression (eg, people with cancer or organ transplantation), it is especially common and
serious in people with AIDS, in whom it often causes encephalitis and death.

**Trichomoniasis**

The most common form of trichomoniasis is a vaginal infection caused by *Trichomonas vaginalis*. The disease is usually spread by sexual intercourse. Antitrichomonal drugs may be administered systemically (ie, metronidazole) or applied locally as douche solutions or vaginal creams.

**HELMINTHIASIS**

Helminthiasis, or infestation with parasitic worms, is a common finding in many parts of the world. Helminths are most often found in the gastrointestinal (GI) tract. However, several types of parasitic worms penetrate body tissues to produce larvae that migrate to the blood, lymph channels, lungs, liver, and other body tissues. Helminthic infections are described in Box 41–1.

Drugs used for treatment of helminthiasis are called *anthelmintics*. Most anthelmintics act locally to kill or cause expulsion of parasitic worms from the intestines; some anthelmintics act systemically against parasites that have penetrated various body tissues. The goal of anthelmintic therapy may be to eradicate the parasite completely or to decrease the magnitude of infestation (“worm burden”).

**SCABIES AND PEDICULOSIS**

Scabies and pediculosis are parasitic infestations of the skin. Scabies is caused by the itch mite (*Sarcoptes scabiei*), which burrows into the skin and lays eggs that hatch in 4 to 8 days. The burrows may produce visible skin lesions, most often between the fingers and on the wrists.

Pediculosis may be caused by one of three types of lice. Pediculosis capitis (head lice) is the most common type of pediculosis in the United States. It is diagnosed by finding louse eggs (nits) attached to hair shafts close to the scalp. Pediculosis corporis (body lice) is diagnosed by finding lice in clothing, especially in seams. Body lice can transmit typhus and other diseases. Pediculosis pubis (pubic or crab lice) is diagnosed by the presence of nits in the pubic and genital areas. Occasionally, pubic lice may infest the axillae, mustache, or eyelashes. Pediculosis may infect persons of any socioeconomic status. Although scabies and pediculosis are caused by different parasites, the conditions have several common characteristics:

- They are more likely to occur in areas of poverty, overcrowding, and poor sanitation. However, they may occur in any geographic area and socioeconomic group.
- They are highly communicable and transmitted by direct contact with an infected person or the person’s personal effects (eg, clothing, combs and hairbrushes, bed linens).
- Pruritus is usually the major symptom. It results from an allergic reaction to parasite secretions and excrement. In
addition to the intense discomfort associated with pruritus, scratching is likely to cause skin excoriation with secondary bacterial infection and formation of vesicles, pustules, and crusts.

- They are treated with many of the same topical medications.

## ANTIPARASITIC DRUGS

Antiparasitic drugs include amebicides, antimalarials, other antiprotozoal agents, anthelmintics, scabicides, and pediculicides. Their descriptions are in the following text and are also listed in Drugs at a Glance: Antiparasitics.

### Amebicides

**Chloroquine** (Aralen) is used primarily for its antimalarial effects. When used as an amebicide, the drug is effective in extraintestinal amebiasis (ie, hepatic amebiasis) but usually ineffective in intestinal amebiasis. The phosphate salt is given orally. When the oral route is contraindicated, severe nausea and vomiting occur, or the infection is severe, the hydrochloride salt can be given intramuscularly. Treatment is usually combined with an intestinal amebicide.

**Iodoquinol** (Yodoxin) is an iodine compound that acts against active amebae (trophozoites) in the intestinal lumen. It may be used alone in asymptomatic intestinal amebiasis to decrease the number of amebic cysts passed in the feces. When given for symptomatic intestinal amebiasis (eg, amebic dysentery), it is usually given with other amebicides in concurrent or alternating courses. Iodoquinol is ineffective in amebic hepatitis and abscess formation. Its use is contraindicated with iodine allergy and liver disease.

**Metronidazole** (Flagyl) is effective against protozoa that cause amebiasis, giardiasis, and trichomoniasis and against anaerobic bacilli, such as *Bacteroides* and *Clostridia* (see Chap. 37). In amebiasis, metronidazole is amebicidal at intestinal and extraintestinal sites of infection. It is a drug of choice for all forms of amebiasis except asymptomatic intestinal amebiasis (in which amebic cysts are expelled in the feces). In trichomoniasis, metronidazole is the only systemic trichomonacide available and it is more effective than any locally active agent. Because trichomoniasis is transmitted by sexual intercourse, partners should be treated simultaneously to prevent reinfection.

Metronidazole is usually contraindicated during the first trimester of pregnancy and must be used with caution in patients with central nervous system (CNS) or blood disorders. Patients should also avoid all forms of ethanol while on this medication.

**Tetracycline** and **doxycycline** are antibacterial drugs (see Chap. 36) that act against amebae in the intestinal lumen by altering the bacterial flora required for amebic viability. One of these drugs may be used with other amebicides in the treatment of all forms of amebiasis except asymptomatic intestinal amebiasis.

### Antimalarial Agents

**Chloroquine** is a widely used antimalarial agent. It acts against erythrocytic forms of plasmodial parasites to prevent or treat malarial attacks. When used for prophylaxis, it is given before, during, and after travel or residence in endemic areas. When used for treatment of malaria caused by *P. vivax*, *P. malariae*, or *P. ovale*, chloroquine relieves symptoms of the acute attack. However, the drug does not prevent recurrence of malarial attacks because it does not act against the tissue (exoerythrocytic) forms of the parasite. When used for treatment of malaria caused by *P. falciparum*, chloroquine relieves symptoms of the acute attack and eliminates the parasite from the body because *P. falciparum* does not have tissue reservoirs. Concern about chloroquine-resistant strains of *P. falciparum* has developed in many areas.

Chloroquine is also used in protozoal infections other than malaria, including extraintestinal amebiasis and giardiasis. It should be used with caution in patients with hepatic disease or severe neurologic, GI, or blood disorders.

**Hydroxychloroquine** (Plaquenil) is a derivative of chloroquine with essentially the same actions, uses, and adverse effects as chloroquine. It has also been used to treat rheumatoid arthritis and lupus erythematosus.

**Chloroquine with primaquine** is a mixture available in tablets containing chloroquine phosphate 500 mg (equivalent to 300 mg of chloroquine base) and primaquine phosphate 79 mg (equivalent to 45 mg of primaquine base). This combination is effective for prophylaxis of malaria and may be more acceptable to clients. It also may be more convenient for use in children because no pediatric formulation of primaquine is available.

**Halofantrine** (Halfan) is indicated for treatment of malaria caused by *P. falciparum* or *P. vivax*, including chloroquine- or multidrug-resistant strains.

**Mefloquine** (Lariam) is used to prevent *P. falciparum* malaria, including chloroquine-resistant strains, and to treat acute malaria caused by *P. falciparum* or *P. vivax*.

**Primaquine** is used to prevent the initial occurrence of malaria; to prevent recurrent attacks of malaria caused by *P. vivax*, *P. malariae*, and *P. ovale*; and to achieve “radical cure” of these three types of malaria. (Radical cure involves eradicating the exoerythrocytic forms of the plasmodium and preventing the survival of the blood forms.) The clinical usefulness of primaquine stems primarily from its ability to destroy tissue (exoerythrocytic) forms of the malarial parasite. Primaquine is especially effective in *P. vivax* malaria. Thus far, plasmodial strains causing the three relapsing types of malaria have not developed resistance to primaquine. When used to prevent initial occurrence of malaria (causal prophylaxis), primaquine is given concurrently with a suppressive agent (eg, chloroquine or hydroxychloroquine) after the patient has returned from a malarious area. Primaquine is not effective for treatment of acute attacks of malaria.

**Pyrimethamine** (Daraprim) is a folic acid antagonist used to prevent malaria caused by susceptible strains of plasmodia.
### Drugs at a Glance: Antiparasitic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amebicides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine (Aralen)</td>
<td>Extraintestinal amebiasis</td>
<td>Phosphate, PO 1 g/d for 2 d, then 500 mg/d for 2 to 3 wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hydrochloride, IM 200 to 250 mg/d for 10 to 12 d</td>
</tr>
<tr>
<td>Iodoquinol (Yodoxin)</td>
<td>Intestinal amebiasis</td>
<td>PO 40 mg/kg/d in three divided doses for 20 d (maximum dose, 2 g/d); repeat after 2 to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3 wk if necessary</td>
</tr>
<tr>
<td>Metronidazole (Flagyl)</td>
<td>Intestinal and extraintestinal</td>
<td>Amebiasis, PO 500 to 750 mg three times daily for 5–10 d</td>
</tr>
<tr>
<td></td>
<td>amebiasis</td>
<td>Giardiasis, PO 250 mg three times daily for 7 d</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trichomoniasis, PO 250 mg three times daily for 7 d, 1 g twice daily for 1 d, or 2 g</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in a single dose. Repeat after 4 to 6 wk, if necessary.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gardnerella vaginalis vaginitis, PO 500 mg twice daily for 7 d</td>
</tr>
<tr>
<td>Tetracycline (Sumycin) and</td>
<td>Intestinal amebiasis</td>
<td>PO 250–500 mg q6h, up to 14 d</td>
</tr>
<tr>
<td>doxycycline (Vibramycin)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antimalarial Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine phosphate and</td>
<td>Prevention and treatment of</td>
<td>Prophylaxis, PO 5 mg/kg (chloroquine base) weekly (maximum of 300 mg weekly), starting</td>
</tr>
<tr>
<td>chloroquine hydrochloride</td>
<td>malaria</td>
<td>2 wk before entering a malarious area and continuing for 8 wk after return</td>
</tr>
<tr>
<td>(Aralen)</td>
<td></td>
<td>Treatment, PO 1 g (600 mg of base) initially, then 500 mg (300 mg of base) after 6 to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8 h, then 500 mg daily for 2 d (total of 2.5 g in four doses)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment of malarial attacks, (hydrochloride) IM 250 mg (equivalent to 200 mg of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>chloroquine base) initially, repeated after 6 h if necessary, to a maximal dose of 800</td>
</tr>
<tr>
<td></td>
<td></td>
<td>mg of chloroquine base in 24 h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prophylaxis, PO 5 mg/kg, not to exceed 310 mg (of hydroxychloroquine base), once</td>
</tr>
<tr>
<td></td>
<td></td>
<td>weekly for 2 wk before entry to and 8 wk after return from malarious areas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment of acute malarial attacks, PO 620 mg initially, then 310 mg 6 h later, and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>310 mg/d for 2 d (total of four doses)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO 1 tablet weekly for 2 wk before entering and 8 wk after leaving malarious areas</td>
</tr>
<tr>
<td>Hydroxychloroquine (Plaquenil)</td>
<td>Erythrocytic malaria</td>
<td>Prophylaxis, PO 5 mg/kg (of hydroxychloroquine base) once weekly for 2 wk before entry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to and 8 wk after return from malarious areas</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment of acute malarial attacks, PO 10 mg/kg initially, then 5 mg/kg 6 h later,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and 5 mg/kg/d for two doses (total of four doses)</td>
</tr>
<tr>
<td>氯喹 含普奎明</td>
<td>Prophylaxis of malaria</td>
<td>PO same as adults for children weighing &gt;45 kg: 1/2 tablet for children weighing 25–45</td>
</tr>
<tr>
<td></td>
<td></td>
<td>kg. For younger children, a suspension is prepared (eg, 40 mg of chloroquine and 6 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>of primaquine in 5 mL). Dosages are then 2.5 mL for children weighing 5 to 7 kg, 5 mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>for 8 to 11 kg, 7.5 mL for 12 to 15 kg, 10 mL for 16 to 20 kg, and 12.5 mL for 21 to</td>
</tr>
<tr>
<td></td>
<td></td>
<td>24 kg. Dosages are given weekly for 2 wk before entering and 8 wk after leaving</td>
</tr>
<tr>
<td></td>
<td></td>
<td>malarious areas.</td>
</tr>
</tbody>
</table>
### Drugs at a Glance: Antiparasitic Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Atovaquone/Proguanil (Malarone)</strong></td>
<td>Prevention and treatment of malaria</td>
<td>Prophylaxis, one tablet daily 1–2 days before and 7 d after travel. Treatment, 4 tablets daily for 3 d.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>11–40 kg: Prophylaxis, 1 to 3 pediatric tablets 1–2 d before and 7 d after travel. Treatment, 1–4 adult tablets every day for 3 d</td>
</tr>
<tr>
<td><strong>Halofantrine (Halfan)</strong></td>
<td>Treatment of malaria, including chloroquine- or multidrug-resistant strains.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PO 500 mg q6h for three doses, repeat in 1 wk for clients without previous exposure to malaria (eg, travelers)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>&lt;40 kg: PO 8 mg/kg according to the schedule for adults</td>
<td></td>
</tr>
<tr>
<td><strong>Mefloquine (Lariam)</strong></td>
<td>Prevention and treatment of malaria</td>
<td>Treatment, 1250 mg (5 tablets) as a single dose</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prophylaxis, PO 1/4 tablet for 15–19 kg weight; 1/2 tablet for 20–30 kg; 3/4 tablet for 31–45 kg; and 1 tablet for &gt;45 kg, according to the schedule for adults</td>
</tr>
<tr>
<td><strong>Primaquine</strong></td>
<td>Prevention of malaria</td>
<td>PO 0.3 mg of base/kg/d for 14 d, according to the schedule for adults, or 0.9 mg of base/kg/wk for 8 wk</td>
</tr>
<tr>
<td></td>
<td>PO 25 mg once weekly, starting 2 wk before entering and continuing for 8 wk after returning from malarious areas</td>
<td></td>
</tr>
<tr>
<td><strong>Pyrimethamine (Daraprim)</strong></td>
<td>Prevention of malaria</td>
<td>PO 25 mg once weekly, as for adults, for children &gt;10 y; 6.25–12.5 mg once weekly for children &lt;10 y</td>
</tr>
<tr>
<td></td>
<td>PO 25 mg once weekly, starting 2 wk before entering and continuing for 8 wk after returning from malarious areas</td>
<td></td>
</tr>
<tr>
<td><strong>Quinine (Quinamm)</strong></td>
<td>Treatment of malaria</td>
<td>PO 25 mg/kg/d in divided doses q8h for 10–14 d</td>
</tr>
<tr>
<td></td>
<td>PO 650 mg q8h for 10–14 d</td>
<td></td>
</tr>
</tbody>
</table>

### Anti–Pneumocystis carinii Agents

| **Trimethoprim–sulfamethoxazole or TMP-SMX (Bactrim, others)** | Prevention and treatment of Pneumocystis carinii pneumonia (PCP) | Prophylaxis, PO 1 double-strength tablet (160 mg TMP and 800 mg SMX) q24h |
|                                                              | Treatment, IV 15–20 mg/kg/d (based on trimethoprim) q6–8 h, for up to 14 d; PO 15–20 mg/kg TMP/100 mg/kg SMX per day, in divided doses, q6h, for 14–21 d |
|                                                              | Prophylaxis, PO 15 mg/m² TMP/750 mg/m² SMX per d, in divided doses q12h, on 3 consecutive days per week. Maximum daily dose, 320 mg TMP/1600 mg SMX. Treatment, IV 15–20 mg/kg/d (based on trimethoprim) q6–8 h, for up to 14 d; PO 15–20 mg/kg TMP/100 mg/kg SMX per day, in divided doses, q6h, for 14–21 d |

| **Atovaquone (Mepron)** | Prevention and treatment of PCP in people who are unable to take TMP-SMX | Prevention, PO 1500 mg once daily with a meal |
|                         | Treatment, PO 750 mg twice daily with food for 21 d |
| **Pentamidine (Pentam 300, NebuPent)** | Prevention and treatment of PCP | Treatment, IM, IV 4 mg/kg once daily for 14 d |
|                          | Prophylaxis, inhalation, 300 mg every 4 wk |
| **Dapsone (Avlosulfon)** | Prevention of PCP | PO 100 mg daily |
| **Trimetrexate (Neutrexin)** | Treatment of PCP in immunocompromised clients who are unable to take TMP-SMX | IV infusion 45 mg/m² daily, over 60–90 min, for 21 d (with leucovorin, PO, IV 20 mg/m² q6h for 24 d; give IV doses over 5–10 min) |

(continued)
It is sometimes used with a sulfonamide and quinine to treat chloroquine-resistant strains of *P. falciparum*. Folic acid antagonists and sulfonamides act synergistically against plasmodia because they block different steps in the synthesis of folic acid, a nutrient required by the parasites.

**Quinine** (Quinamm) is derived from the bark of the cinchona tree. Quinine was the primary antimalarial drug for many years but has been largely replaced by synthetic agents that cause fewer adverse reactions. However, it may still be used in the treatment of chloroquine-resistant *P. falciparum* malaria, usually in conjunction with pyrimethamine and a sulfonamide. Quinine also relaxes skeletal muscles and has been used for prevention and treatment of nocturnal leg cramps.

**Malarone** is a new combination antimalarial medication containing 250 mg of atovaquone and 100 mg of proguanil per tablet. This product may be used for both the prevention and treatment of malarial infections, particularly those caused...
by *P. falciparum*. The drug also seems to be effective in chloroquine-resistant areas and is devoid of many of the side effects of mefloquine. Two drugs are combined to inhibit separate pathways involved in the synthesis of nucleic acids by the offending parasite. The drug should be taken daily with food or milk starting 1 to 2 days before entering an endemic area and for 7 days upon return.

**Anti-Pneumocystis carinii Agents**

**Trimethoprim-sulfamethoxazole** (TMP-SMX, Bactrim, others) (see Chap. 36) is the drug of choice for prevention and treatment of PCP. Prophylaxis is indicated for adults and adolescents with HIV and CD4+ cell counts <200; organ transplant recipients; patients with leukemia or lymphoma who are receiving cytotoxic chemotherapy; and for patients receiving high doses of corticosteroids (equivalent to 20 mg or more daily of prednisone) for prolonged periods of time.

Common adverse effects include nausea, vomiting, and skin rash. These effects are more common in patients who are HIV seropositive.

**Atovaquone** (Mepron) is used for both prophylaxis and treatment of PCP in people who are unable to take TMP-SMX. Adverse effects include nausea, vomiting, diarrhea, fever, insomnia, and elevated hepatic enzymes.

**Dapsone** may be used for the prophylaxis of PCP infection in HIV-seropositive patients who are unable to tolerate TMP-SMX. Patients who are glucose-6-phosphate dehydrogenase (G6PD) deficient will develop hemolytic anemia and therefore this laboratory parameter should be assessed before initiating therapy. Common side effects include nausea/vomiting and rash.

**Trimetrexate** (Neutrexin) is a folate antagonist (which must be used with leucovorin rescue) approved only for treatment of moderate to severe PCP in immunocompromised patients, including those with advanced HIV infection who are unable to take TMP-SMX. Hematologic toxicity is the main dose-limiting adverse effect. To minimize hematologic effects, leucovorin should be given daily during trimetrexate therapy and for 72 hours after the last trimetrexate dose. Dosage of trimetrexate must be reduced, and dosage of leucovorin must be increased with significant neutropenia or thrombocytopenia.

**Pentamidine** (Pentam 300, NebuPent) may be used both for prophylaxis and treatment of PCP infection. Pentamidine interferes with production of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) by the organism. The drug is given parenterally for treatment of PCP and by inhalation for prophylaxis. It is excreted by the kidneys and accumulates in the presence of renal failure, so dosage should be reduced in patients with renal impairment. Clinicians should also be aware that the intravenous (IV) form of pentamidine is particularly panureotoxic. With parenteral pentamidine, appropriate tests should be performed before, during, and after treatment (e.g., complete blood count, platelet count, serum creatinine, blood urea nitrogen, blood glucose, serum calcium, and electrocardiogram).

**Anthelmintics**

**Mebendazole** (Vermox) is a broad-spectrum anthelmintic used in the treatment of parasitic infections by hookworms, pinworms, roundworms, and whipworms. It is also useful but less effective in tapeworm infection. Mebendazole kills helminths by preventing uptake of the glucose necessary for parasitic metabolism. The helminths become immobilized and die slowly, so they may be expelled from the GI tract up to 3 days after drug therapy is completed. Mebendazole acts locally in the GI tract, and less than 10% of the drug is absorbed systemically.

Mebendazole is usually the drug of choice for single or mixed infections caused by the aforementioned parasitic worms. The drug is contraindicated during pregnancy because of teratogenic effects in rats; it is relatively contraindicated in children younger than 2 years of age because it has not been extensively investigated for use in this age group.

**Pyrantel** (Antiminth) is effective in infestations of roundworms, pinworms, and hookworms. The drug acts locally to paralyze worms in the intestinal tract. Pyrantel is poorly absorbed from the GI tract, and most of an administered dose may be recovered in feces. Pyrantel is contraindicated in pregnancy and is not recommended for children younger than 1 year of age.

**Thiabendazole** (Mintezol) is most effective against threadworms and pinworms. It is useful but less effective against hookworms, roundworms, and whipworms. Because of the broad spectrum of anthelmintic activity, thiabendazole may be especially useful in mixed parasitic infections. In trichinosis, thiabendazole decreases symptoms and eosinophilia but does not eliminate larvae from muscle tissues. The mechanism of anthelmintic action is uncertain but probably involves interference with parasitic metabolism. The drug is relatively toxic compared with other anthelmintic agents.

Thiabendazole is a drug of choice for threadworm infestations. For other types of helminthiasis, it is usually considered an alternative drug. It is rapidly absorbed after oral administration and most of the drug is excreted in urine within 24 hours. It should be used with caution in clients with liver or kidney disease.

**Ivermectin** (Stromectol) is used for numerous parasitic infections and is most active against strongyloidiasis. Ivermectin has also been used for the oral treatment of resistant lice. The drug has relatively few side effects but may cause some nausea and vomiting.

**Scabicides and Pediculicides**

**Permethrin** is the drug of choice for both pediculosis and scabies. Although a single application eliminates parasites and
oVa, two applications are generally recommended. For pediculosis, permethrin is available as a 1% over-the-counter liquid (Nix). For scabies, a 5% cream permethrin cream (Elimite) is available by prescription. For scabies, a single application of 5% permethrin cream is considered curative. Permethrin is safer than other scabicides and pediculicides, especially for infants and children.

Permethrin is derived from a chrysanthemum plant, and people with a history of allergy to ragweed or chrysanthemum flowers should use it cautiously. The most frequent adverse effect is pruritus.

To avoid reinfection, close contacts should be treated simultaneously. With pediculosis, clothing and bedding should be sterilized by boiling or steaming and seams of clothes should be examined to verify that all lice are eliminated.

**Gamma benzene hexachloride (Lindane)** is a second-line drug for scabies and pediculosis. It may be used for people who have hypersensitivity reactions or resistance to treatment with permethrin. It is applied topically, and substantial amounts are absorbed through intact skin. CNS toxicity has been reported with excessive use, especially in infants and children. The drug is available in a 1% concentration in a cream, lotion, and shampoo.

**Malathion** (Ovide) is a pediculicide particularly used in the treatment of head lice, and **Pyrethrin** preparations (eg, Barc, RID) are available over the counter as gels, shampoos, and liquid suspensions for treatment of pediculosis. **Crotamiton** (Eurax) is sometimes used as a 10% cream or lotion for scabies.

**Nursing Process**

**Assessment**

Assess for conditions in which antiparasitic drugs are used.

- Assess for exposure to parasites. Although exposure is influenced by many variables (eg, geographic location, personal hygiene, environmental sanitation), some useful questions may include the following:
  - Does the person live in an institution, an area of poor sanitation, an underdeveloped country, a tropical region, or an area of overcrowded housing? These conditions predispose to parasitic infestations with lice, scabies, protozoa, and worms.
  - Are parasitic diseases present in the person’s environment? For example, head lice, scabies, and pinworm infestations often affect school children and their families.
  - Has the person recently traveled (within the previous 1 to 3 weeks) in malarious regions? If so, were prophylactic measures used appropriately?
  - With vaginal trichomoniasis, assess in relation to sexual activity. The disease is spread by sexual intercourse, and sexual partners need simultaneous treatment to prevent reinfection.
- With pubic (crab) lice, assess sexual activity. Lice may be transmitted by sexual and other close contact and by contact with infested bed linens.
- Assess for signs and symptoms. These vary greatly, depending on the type and extent of parasitic infestation.
  - **Amebiasis.** The person may be asymptomatic, have nausea, vomiting, diarrhea, abdominal cramping, and weakness, or experience symptoms from ulcerations of the colon or abscesses of the liver (amebic hepatitis) if the disease is severe, prolonged, and untreated. Amebiasis is diagnosed by identifying cysts or trophozoites of *E. histolytica* in stool specimens.
  - **Malaria.** Initial symptoms may resemble those produced by influenza (eg, headache, myalgia). Characteristic paroxysms of chills, fever, and copious perspiration may not be present in early malaria. During acute malarial attacks, the cycles occur every 36 to 72 hours. Additional symptoms include nausea and vomiting, splenomegaly, hepatomegaly, anemia, leukopenia, thrombocytopenia, and hyperbilirubinemia. Malaria is diagnosed by identifying the plasmodial parasite in peripheral blood smears (by microscopic examination).
  - **Trichomoniasis.** Women usually have vaginal burning, itching, and yellowish discharge; men may be asymptomatic or have symptoms of urethritis. The condition is diagnosed by finding *T. vaginalis* organisms in a wet smear of vaginal exudate, semen, prostatic fluid, or urinary sediment (by microscopic examination). Cultures may be necessary.
  - **Helminthiasis.** Light infestations may be asymptomatic. Heavy infestations produce symptoms according to the particular parasitic worm. Hookworm, roundworm, and threadworm larvae migrate through the lungs and may cause symptoms of pulmonary congestion. The hookworm may cause anemia by feeding on blood from the intestinal mucosa; the fish tapeworm may cause megaloblastic or pernicious anemia by absorbing folic acid and vitamin B₁₂. Large masses of roundworms or tape-worms may cause intestinal obstruction. The major symptom usually associated with pinworms is intense itching in the perianal area (pruritus ani). Helminthiasis is diagnosed by microscopic identification of parasites or ova in stool specimens. Pinworm infestation is diagnosed by identifying ova on anal swabs, obtained by touching the sticky side of cellophane tape to the anal area. (Early-morning swabs are best because the female pinworm deposits eggs during sleeping hours.)
  - **Scabies and pediculosis.** Pruritus is usually the primary symptom. Secondary symptoms result from scratching and often include skin excoriation and infection (ie, vesicles, pustules, and crusts). Pediculosis is diagnosed by visual identification of lice or ova (nits) on the client’s body or clothing.
Nursing Diagnoses
- Deficient Knowledge: Management of disease process and prevention of recurrence
- Deficient Knowledge: Accurate drug administration
- Imbalanced Nutrition: Less Than Body Requirements related to parasitic disease or drug therapy
- Self-Esteem Disturbance related to a medical diagnosis of parasitic infestation
- Noncompliance related to need for hygiene and other measures to prevent and treat parasitic infestations

Planning/Goals
The client will:
- Experience relief of symptoms for which antiparasitic drugs were taken
- Self-administer drugs accurately
- Avoid preventable adverse effects
- Act to prevent recurrent infestation
- Keep appointments for follow-up care

Interventions
Use measures to avoid exposure to or prevent transmission of parasitic diseases.
- Environmental health measures include the following:
  - Sanitary sewers to prevent deposition of feces on surface soil and the resultant exposure to helminths
  - Monitoring of community water supplies, food-handling establishments, and food-handling personnel
  - Follow-up examination and possibly treatment of household and other close contacts of people with helminthiasis, amebiasis, trichomoniasis, scabies, and pediculosis
  - Mosquito control in malarious areas and prophylactic drug therapy for travelers to malarious areas. In addition, teach travelers to decrease exposure to mosquito bites (eg, wear long-sleeved, dark clothing; use an effective insect repellent such as DEET; and sleep in well-screened rooms or under mosquito netting). These measures are especially needed at dusk and dawn, the maximal feeding times for mosquitoes.
- Personal and other health measures include the following:
  - Maintain personal hygiene (ie, regular bathing and shampooing, handwashing before eating or handling food and after defecation or urination).
  - Avoid raw fish and undercooked meat. This is especially important for anyone with immunosuppression.
  - Avoid contaminating streams or other water sources with feces.
  - Control flies and avoid foods exposed to flies.
  - With scabies and pediculosis infestations, drug therapy must be accompanied by adjunctive measures to avoid reinfection or transmission to others. For example, close contacts should be examined carefully and treated if indicated. Clothes, bed linens, and towels should be washed and dried on hot cycles. Clothes that cannot be washed should be dry cleaned. With head lice, combs and brushes should be cleaned and disinfected; carpets and upholstered furniture should be vacuumed.
  - With pinworms, clothing, bed linens, and towels should be washed daily on hot cycles. Toilet seats should be disinfected daily.
  - Ensure follow-up measures, such as stool specimens, vaginal examinations, anal swabs, smears, and cultures.
  - With vaginal infections, avoid sexual intercourse, or have the male partner use a condom.

Evaluation
- Interview and observe for relief of symptoms.
- Interview outpatients regarding compliance with instructions for taking antiparasitic drugs and measures to prevent recurrence of infestation.
- Interview and observe for adverse drug effects.
- Interview and observe regarding food intake or changes in weight.

PRINCIPLES OF THERAPY
1. Antiparasitic drugs should be used along with personal and public health control measures to prevent the spread of parasitic infestations. Specific measures vary according to the type of organism, the environment, and the host.
2. Many of the drugs described in this chapter are quite toxic; they should be used only when clearly indicated (ie, laboratory documentation of parasitic infection).

Use in Children
Children often receive an antiparasitic drug for head lice or worm infestations. These products should be used exactly as directed and with appropriate precautions to prevent reinfection. Malaria is usually more severe in children than in adults, and children should be protected from exposure when possible. When chemoprophylaxis or treatment for malaria is indicated, the same drugs are used for children as

Nursing Notes: Apply Your Knowledge
You are a nurse in a travel clinic. Sally and Bill, college students, plan to spend part of their summer vacation traveling in Africa. You update their immunizations and then talk with them about malaria prevention. The physician has written a prescription for chloroquine phosphate and primaquine, 1 tablet every week. What information would you include in your teaching?
for adults, with appropriate dosage adjustments. An exception is that tetracyclines should not be given to children younger than 8 years of age.

**Use in Older Adults**

Older adults are more likely to experience adverse effects of antiparasitic drugs because they often have impaired renal and hepatic function.

**Home Care**

Most antiparasitic drugs are given primarily in the home setting. The home care nurse may need to examine close contacts of the infected person and assess his or her need for treatment, assist parents and clients so that drugs are used appropriately, and teach personal and environmental hygiene measures to prevent reinfection. When children have parasitic infestations, the home care nurse may need to collaborate with day care centers and schools to prevent or control outbreaks.

---

**CLIENT TEACHING GUIDELINES**

**Antiparasitic Drugs**

**General Considerations**

- Use measures to prevent parasitic infection or reinfection:
  - Support public health measures to maintain a clean environment (ie, sanitary sewers, clean water, regulation of food-handling establishments and food-handling personnel).
  - When traveling to wilderness areas or to tropical or underdeveloped countries, check with the local health department about precautions needed to avoid parasitic infections.
  - Practice good hand washing and other personal hygienic practices.
  - When a family member or other close contact contracts a parasitic infection, be sure appropriate treatment and follow-up care are completed.
  - Avoid raw fish and undercooked meat.
  - With vaginal infections, avoid sexual intercourse, or use a condom.

**Self- or Caregiver Administration**

- Use antiparasitic drugs as prescribed; their effectiveness depends on accurate use.

**NURSING ACTIONS**

**Antiparasitics**

1. **Administer accurately**
   a. Give atovaquone, chloroquine and related drugs, iodoquinol, and oral metronidazole with or after meals.
   b. With pentamidine:
      1. For intravenous administration, dissolve the calculated dose in 3–5 mL of sterile water or 5% dextrose in water. Dilute further with 50–250 mL of 5% dextrose solution and infuse over 60 min.
   c. Give anthelmintics without regard to mealtimes or food ingestion. Mebendazole tablets may be chewed, swallowed, or crushed and mixed with food.

   **RATIONALE/EXPLANATION**
   - Food improves absorption of atovaquone and decreases gastrointestinal (GI) irritation of the other drugs.
   - Food in the GI tract does not decrease effectiveness of most anthelmintics.

   (continued)
### NURSING ACTIONS

#### d. For pediculicides and scabicides, follow the label or manufacturer’s instructions.

#### 2. Observe for therapeutic effects

- **a.** With chloroquine for acute malaria, observe for relief of symptoms and negative blood smears.
- **b.** With amebicides, observe for relief of symptoms and negative stool examinations.

- **c.** With anti-

#### Pneumocystis carinii agents for prophylaxis, observe for absence of symptoms; when used for treatment, observe for decreased fever, cough, and respiratory distress.

- **d.** With anthelmintics, observe for relief of symptoms, absence of the parasite in blood or stool for three consecutive examinations, or a reduction in the number of parasitic ova in the feces.

- **e.** With pediculicides, inspect affected areas for lice or nits.

#### 3. Observe for adverse effects

- **a.** With amebicides, observe for anorexia, nausea, vomiting, epigastric burning, diarrhea.
  
  (1) With iodoquinol, observe for agitation, amnesia, peripheral neuropathy, and optic neuropathy.

- **b.** With antimalarial agents, observe for nausea, vomiting, diarrhea, pruritus, skin rash, headache, central nervous system (CNS) stimulation.
  
  (1) With pyrimethamine, observe for anemia, thrombocytopenia, and leukopenia.
  
  (2) With quinine, observe for signs of cinchonism (headache, tinnitus, decreased auditory acuity, blurred vision).

- **c.** With metronidazole, observe for convulsions, peripheral paresthesias, nausea, diarrhea, unpleasant taste, vertigo, headache, and vaginal and urethral burning sensation.

- **d.** With parenteral pentamidine, observe for leukopenia, thrombocytopenia, hypoglycemia, hyperglycemia, hypocalcemia, hypokalemia, hypotension, acute renal failure.

- **e.** With aerosolized pentamidine, observe for fatigue, shortness of breath, bronchospasm, cough, dizziness, rash, anorexia, nausea, vomiting, chest pain.

- **f.** With atovaquone, observe for nausea, vomiting, diarrhea, fever, headache, skin rash.

- **g.** With trimetrexate, observe for anemia, neutropenia, thrombocytopenia, increased bilirubin and liver enzymes (aspartate and alanine aminotransferases, alkaline phosphatase), fever, skin rash, pruritus, nausea, vomiting, hyponatremia, hypocalcemia.

- **h.** With topical antitrichomonal agents, observe for hypersensitivity reactions (eg, rash, inflammation), burning, and pruritus.

### RATIONALE/EXPLANATION

- Instructions vary among preparations.

- Fever and chills usually subside within 24–48 h, and blood smears are negative for plasmodia within 24–72 h.

- Relief of symptoms does not indicate cure of amebiasis; laboratory evidence is required. Stool specimens should be examined for amebic cysts and trophozoites periodically for approximately 6 mo.

- The goal of anthelmintic drug therapy may be complete eradication of the parasite or reduction of the “worm burden.”

- For most clients, one treatment is effective. For others, a second treatment may be necessary.

- GI effects may occur with all amebicides.

- These effects are most likely to occur with large doses or long-term drug administration.

- These effects may occur with most antimalarial agents. However, adverse effects are usually mild because small doses are used for prophylaxis, and the larger doses required for treatment of acute malarial attacks are given only for short periods.

- This drug interferes with folic acid metabolism.

- These effects occur with usual therapeutic doses of quinine. They do not usually necessitate discontinuance of quinine therapy.

- CNS effects are most serious; GI effects are most common.

- Severe hypotension may occur after a single parenteral dose. Deaths from hypotension, hypoglycemia, and cardiac arrhythmias have been reported.

- These are the most common adverse effects.

- Hypersensitivity reactions are the major adverse effects. Other effects are minor and rarely require that drug therapy be discontinued.

(continued)
NURSING ACTIONS | RATIONALE/EXPLANATION
---|---
1. With permethrin, observe for pruritus, burning, or tingling; with Lindane, observe for CNS stimulation (nervousness, tremors, insomnia, convulsions). | Antihistamines or topical corticosteroids may be used to decrease itching. CNS toxicity is more likely to occur with excessive use of Lindane (ie, increased amounts, leaving in place longer than prescribed, or applying more frequently than prescribed).

4. Observe for drug interactions | Few clinically significant drug interactions occur because many antiparasitic agents are administered for local effects in the GI tract or on the skin. Most of the drugs also are given for short periods.

a. Drugs that alter effects of chloroquine: | Inhibit chloroquine by increasing the rate of urinary excretion

(1) Acidifying agents (eg, ascorbic acid) | Potentiate chloroquine by decreasing the rate of urinary excretion

(2) Alkalinizing agents (eg, sodium bicarbonate) | Increase risk of toxicity and retinal damage by inhibiting metabolism.

(3) Monoamine oxidase inhibitors | These drugs induce hepatic enzymes and decrease effects of metronidazole by accelerating its rate of hepatic metabolism.

b. Drugs that alter effects of metronidazole: | May increase effects by inhibiting hepatic metabolism of metronidazole.

(1) Phenobarbital, phenytoin | Although few interactions have been reported, any enzyme-inducing drug can potentially decrease effects of atovaquone and trimetrexate by accelerating their metabolism in the liver.

(2) Cimetidine | 

c. Drugs that decrease effects of atovaquone and trimetrexate: Rifampin and other drugs that induce CYP450 drug-metabolizing enzymes in the liver | 

Nursing Notes: Apply Your Knowledge

Answer: Explain that malaria is transmitted by mosquito bites, and thus it is important to limit exposure to mosquitoes (by using insect repellant, wearing long pants and long-sleeve shirts, sleeping in screened or well-netted areas). Mosquitoes are most active at dusk and dawn, so prevention is especially important at these times. Prophylactic medications must be started 2 weeks before entering infested areas and continued for 8 weeks after return. The medication should be taken on the same day of the week at approximately the same time. If acute symptoms appear (headache, malaise, fever, chills), additional medication can be taken to treat the infection. Clear, written instructions regarding the dosage should be provided.

SELECTED REFERENCES


section 7

Drugs Affecting Hematopoiesis and the Immune System
chapter 42

Physiology of the Hematopoietic and Immune Systems

Objectives

After studying this chapter, the student will be able to:

1. Review hematopoiesis, body defense mechanisms, and immune mechanisms.
2. Differentiate between cellular and humoral types of immunity.
3. Describe the antigen–antibody reaction.
4. Discuss roles of various white blood cells in the immune response.
5. Describe the functions and roles of cytokines and hematopoietic growth factors.
6. Discuss therapeutic uses of selected cytokines.

Overview

All blood cells originate in bone marrow in stem cells that are capable of becoming different types of blood cells. As these pluripotent stem cells reproduce, some reproduced cells are exactly like the original pluripotent cells and are retained in bone marrow to maintain a continuing supply. However, most reproduced stem cells differentiate to form other types of cells. The early offspring are committed to become a particular type of cell, and a committed stem cell that will produce a cell type is called a colony-forming unit (CFU), such as CFU-erythrocyte or CFU-granulocyte. Hematopoietic growth factors or cytokines control the reproduction, growth, and differentiation of stem cells and CFUs. They also initiate the processes required to produce fully mature cells.

Hematopoietic Cytokines

Cytokines (Table 42–1) are substances produced by bone marrow stromal cells, activated helper T cells, activated macrophages, and other cells. They regulate many cellular activities by acting as chemical messengers among cells. Some cytokines are growth factors that induce proliferation and differentiation of blood cells. These cytokines comprise a large group of proteins that are structurally and functionally diverse. They were initially named and defined by their action on one type of blood cell, but some of them act on multiple types of blood cells. The term cytokine includes lymphokines secreted by lymphocytes and monokines secreted by monocytes and macrophages. The terms lymphokines and monokines are still used, but they are misleading because secretion of many lymphokines and monokines is not limited to lymphocytes and monocytes as these terms imply. In general, secretion of cytokines occurs after activation of a particular cell and lasts a few hours to a few days. Although several cells can secrete cytokines, helper T cells and macrophages are the main producers.

Cytokines act by binding to receptors on the membranes of numerous types of target cells. A cytokine may bind to receptors on the membrane of the same cell that secreted it (autocrine action), it may bind to receptors on a target cell near the cell that produced it (paracrine action), and, occasionally, it may bind to target cells in distant parts of the body (endocrine or hormonal action). After binding, the cytokine-receptor complex triggers signal-transduction pathways that alter gene expression in the target cells. Overall, cytokines are involved in numerous physiologic responses, including hematopoiesis, cellular proliferation and differentiation, inflammation, wound healing, and cellular and humoral immunity.

Cytokine actions and functions are affected by several factors. First, although the immune response to an antigen may include the production of cytokines, cytokines do not act in response to specific antigens. Instead, they affect whatever cells they encounter that have cytokine receptors and are able to respond. Cytokine receptors are often expressed on a cell only after that cell has interacted with an antigen, so that cytokine activation is limited to antigen-activated lymphocytes. Second, the actions of most cytokines have been determined in laboratories by analysis of the effects of recombinant cytokines, often at nonphysiologic concentrations, and added individually to in vitro systems. Within the human body,
### Table 42-1: Hematopoietic and Immune Cytokines

<table>
<thead>
<tr>
<th>Type/Name</th>
<th>Main Source</th>
<th>Main Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colony-Stimulating Factors (CSFs)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G-CSF</td>
<td>Leukocytes</td>
<td>Stimulates growth of bone marrow</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Generates neutrophils</td>
</tr>
<tr>
<td>M-CSF</td>
<td></td>
<td>Generates and stimulates growth of macrophages</td>
</tr>
<tr>
<td>GM-CSF</td>
<td></td>
<td>Stimulates growth of monocyte-macrophages</td>
</tr>
<tr>
<td>Erythropoietin</td>
<td>Kidneys</td>
<td>Stimulates production of red blood cells by bone marrow</td>
</tr>
<tr>
<td>Thrombopoietin</td>
<td>Liver and kidneys</td>
<td>Stimulates production of platelets by bone marrow</td>
</tr>
<tr>
<td><strong>Interferons (IFN)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-alpha</td>
<td>Leukocytes</td>
<td>Inhibits viral replication in uninfected cells (antiviral effects)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Has antiproliferative and immunomodulating effects</td>
</tr>
<tr>
<td>IFN-beta</td>
<td>Fibroblasts</td>
<td>Inhibits viral replication in uninfected cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helps to regulate immune cell functions</td>
</tr>
<tr>
<td>IFN-gamma</td>
<td>Circulating T cells and natural</td>
<td>Induces cell membrane antigens (eg, major histocompatibility complex)</td>
</tr>
<tr>
<td></td>
<td>killer (NK) cells</td>
<td>Acts on B cells to alter antibody production</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influences functions of basophils and mast cells by increasing their ability to release histamine and decreasing their capacity for growth</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Helps regulate delayed-type hypersensitivity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May have greater antitumor, cytolytic, and immunomodulatory effects than IFN-alpha or beta</td>
</tr>
<tr>
<td><strong>Interleukins (IL)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-1</td>
<td>Monocytes</td>
<td>Stimulates growth of blood cells, especially B and T lymphocytes</td>
</tr>
<tr>
<td></td>
<td>Monocyte-macrophages</td>
<td>Enhances interactions between monocytes and lymphocytes</td>
</tr>
<tr>
<td></td>
<td>B cells, vascular endothelial cells, other cell types</td>
<td>Interacts with tumor necrosis factor to induce other growth factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Promotes chemotaxis and inflammation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acts on hypothalamus to cause fever</td>
</tr>
<tr>
<td>IL-2</td>
<td>T lymphocytes</td>
<td>Activates and promotes growth of T cells, B cells, and NK cells</td>
</tr>
<tr>
<td></td>
<td>Helper T cells</td>
<td>Augments production of other cytokines, such as interferon-gamma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Influences the expression of histocompatibility antigens</td>
</tr>
<tr>
<td>IL-3 (multi-CSF)</td>
<td>T lymphocytes</td>
<td>May inhibit granulocyte–macrophage colony formation and erythropoiesis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates bone marrow; growth factor for all blood cells</td>
</tr>
<tr>
<td>IL-4</td>
<td>Helper T cells</td>
<td>Stimulates growth and histamine secretion of mast cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates growth of T and B cells, mast cells, and NK cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates activation and differentiation of B cells; promotes production of immunoglobulins</td>
</tr>
<tr>
<td>IL-5</td>
<td>Helper T cells</td>
<td>Increases phagocytic activity of macrophages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates B-cell growth, differentiation, and antibody secretion</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates eosinophils</td>
</tr>
<tr>
<td>IL-6</td>
<td>Fibroblasts and others</td>
<td>Acts on myeloid stem cells to stimulate growth and differentiation of B and T cells, megakaryocyte, and granulocyte-macrophages</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Promotes differentiation of B cells into plasma cells; then stimulates plasma cells to produce antibodies</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Interacts with other growth factors to stimulate growth and differentiation of T cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Enhances inflammatory responses</td>
</tr>
<tr>
<td>IL-7</td>
<td>Stromal cells of bone marrow</td>
<td>Acts on lymphoid stem cells to generate pre-B and pre-T cells, stimulate lymphocyte growth, and activate B and T cells</td>
</tr>
<tr>
<td>IL-8</td>
<td>Macrophages and others</td>
<td>Acts on resting T cells to increase expression of IL-2 and its receptor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Regulates growth and movement of neutrophils and lymphocytes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Induces immediate inflammatory responses (eg, acts on neutrophils to attract them to sites of cell injury, promote their adherence to vascular endothelium, and promote their movement from the bloodstream into tissues)</td>
</tr>
<tr>
<td>IL-9</td>
<td>T lymphocytes</td>
<td>Stimulates production of red blood cells, platelets, and helper T cells</td>
</tr>
<tr>
<td>IL-10</td>
<td>T and B lymphocytes, macrophages</td>
<td>Acts on macrophages to inhibit cytokine production and on antigen-presenting cells to reduce expression of class II MHC genes</td>
</tr>
<tr>
<td>IL-11</td>
<td>Stromal cells of bone marrow</td>
<td>Stimulates growth and differentiation of megakaryocytes, B cells and blast cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stimulates hepatocytes to produce acute-phase proteins (eg, fibrinogen and C-reactive protein, as part of the inflammatory response)</td>
</tr>
<tr>
<td>IL-12</td>
<td>Lymphocytes</td>
<td>Stimulates activation and proliferation of T lymphocytes and NK cells</td>
</tr>
<tr>
<td></td>
<td>Macrophages and B cells</td>
<td>Acts synergistically with IL-2 to stimulate cytotoxic T cells</td>
</tr>
</tbody>
</table>

(continues)
however, cytokines rarely, if ever, act alone. Instead, a target cell is exposed to an environment containing a mixture of cytokines, which may have synergistic or antagonistic effects on each other. Third, cytokines often induce the synthesis of other cytokines. The resulting actions and interactions among cytokines may profoundly alter physiologic responses. Fourth, proteins that act as cytokine antagonists are found in the bloodstream and other extracellular fluids. These proteins may bind directly to a cytokine and inhibit its activity or bind to a cytokine receptor but fail to activate the cell.

The main groups of cytokines (also called biologic response modifiers) are categorized as colony-stimulating factors (CSFs), interferons, and interleukins.

### Colony-Stimulating Factors

As their name indicates, CSFs stimulate the production of red blood cells (erythropoietin), platelets (thrombopoietin), granulocytes (G-CSF), granulocyte–macrophages (GM-CSF), and monocyte–macrophages (M-CSF). In addition to granulocytes (neutrophils, basophils, and eosinophils), G-CSF also affects other blood cells (eg, erythrocytes, platelet precursors, and macrophages). Interleukin-3 (IL-3) is sometimes called multi-CSF because it stimulates the production of all types of blood cells.

### Interferons

Interferons “interfere” with the ability of viruses in infected cells to replicate and spread to uninfected cells. They also inhibit reproduction and growth of other cells, including tumor cells, and activate natural killer cells. These antiproliferative and immunomodulatory activities play important roles in normal host defense mechanisms.

### Interleukins

Interleukins (ILs) were initially named because they were thought to be produced by and to act only on leukocytes and lymphocytes. However, they can be produced by body cells other than leukocytes and they can act on nonhematopoietic cells. Interleukins 1 through 18 have been identified. Especially important ILs include IL-3 (stimulates growth of stem cell precursors of all blood cells), IL-2 (stimulates T and B lymphocytes), IL-12 (stimulates hematopoietic cells and lymphocytes), and IL-11 (stimulates platelets and other cells). Interleukin action may occur only when combined with another factor, may be suppressive rather than stimulatory (eg, IL-10), or may involve a specific function (eg, IL-8 mainly promotes movement of leukocytes into injured tissues as part of the inflammatory response).

### OVERVIEW OF BODY DEFENSE MECHANISMS

The immune system is one of several mechanisms that protects the body from potentially harmful substances, including pathogenic microorganisms. The body’s primary external defense mechanism is intact skin, which prevents entry of foreign substances and produces secretions that inhibit microbial growth. The mucous membranes lining the gastrointestinal (GI) and respiratory tracts are internal defense mechanisms that act as
molecules or markers are encoded by a group of genes called the major histocompatibility complex (MHC). MHC markers are essential to immune system function because they regulate the antigens to which a person responds and allow immune cells (eg, lymphocytes and macrophages) to recognize and communicate with each other. Nonself or foreign antigens are also recognized by distinctive molecules, called epitopes, on their surfaces. Epitopes vary widely in type, number, and ability to elicit an immune response.

A normally functioning immune system does not attack body tissues labeled as self but attacks nonself substances. In most instances, a normally functioning immune system is highly desirable. With organ or tissue transplants, however, the system responds appropriately but undesirably when it attacks the nonself grafts. An abnormally functioning immune system causes numerous diseases. When the system is hyperactive, immunodeficiency disorders develop in which the person is highly susceptible to infectious and neoplastic diseases. When the system is hyperactive, it perceives ordinarily harmless environmental substances (eg, foods, plant pollens) as harmful and induces allergic reactions. When the system is inappropriately activated (it loses its ability to distinguish between self and nonself, so an immune response is aroused against the host’s own body tissues), the result is autoimmune disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Many other disorders, including diabetes mellitus, myasthenia gravis, and inflammatory bowel diseases, are thought to involve autoimmune mechanisms. To aid understanding of the immune response and drugs used to alter immune response, more specific characteristics, processes, and functions of the immune system are described.

### Types of Immunity

**Innate immunity**, which is not produced by the immune system, includes the general protective mechanisms described.

**Acquired immunity** develops during gestation or after birth and may be active or passive. **Active immunity** is produced by the person’s own immune system in response to a disease caused by a specific antigen or administration of an antigen (eg, a vaccine) from a source outside the body, usually by injection. The immune response stimulated by the antigen produces activated lymphocytes and antibodies against the antigen. When an antigen is present for the first time, production of antibodies requires several days. As a result, the serum concentration of antibodies does not reach protective levels for approximately 7 to 10 days, and the disease develops in the host. When the antigen is eliminated, the antibody concentration gradually decreases over several weeks.

The duration of active immunity may be brief (eg, to influenza viruses), or it may last for years or a lifetime. **Long-term active immunity has a unique characteristic called memory.** When the host is re-exposed to the antigen, lymphocytes are activated and antibodies are produced rapidly, and the host does not contract the disease. This characteristic

---

**IMMUNITY**

Immunity indicates protection from a disease, and the major function of the immune system is to detect and eliminate foreign substances that may cause tissue injury or disease. To perform this function, the immune system must be able to differentiate body tissues (self) from foreign substances (nonself). Self tissues are recognized by distinctive protein molecules on the surface membranes of body cells. These physical barriers and produce mucus that traps foreign substances so they may be expelled from the body. Mucous membranes also produce other secretions (eg, gastric acid) that kill ingested microorganisms. Additional internal mechanisms include the normal microbial population, which is usually nonpathogenic and controls potential pathogens, and secretions (eg, perspiration, tears, and saliva) that contain lysozyme, an enzyme that destroys the cell walls of gram-positive bacteria.

If a foreign substance gets through the aforementioned defenses to penetrate body tissues and cause cellular injury, an inflammatory response begins immediately. Cellular injury may be caused by chemicals, hypoxia, ischemia, microorganisms, excessive heat or cold, radiation, and nutritional deficiencies or excesses. The cellular response to injury involves inflammation, a generalized reaction to any tissue damage. Inflammation is an attempt to remove the damaging agent and repair the damaged tissue. The hemodynamic aspect of inflammation includes vasodilation, which increases blood supply to the injured area, and increased capillary permeability, which allows fluid to leak into tissue spaces. The cellular aspect involves the movement of white blood cells (WBCs) into the area of injury. WBCs are attracted to the injured area by bacteria, tissue debris, plasma protein fractions (complement), and other substances in a process called chemotaxis. Once they reach the area, they phagocytize causative agents and tissue debris.

The final defense mechanism is the immune response, and development of an effective response involves lymphoid cells, inflammatory cells, and hematopoietic cells. Immune responses, which occur more slowly than inflammatory responses, stimulate production of antibodies and activated lymphocytes to destroy foreign invaders and mutant body cells.

Inflammatory and immune responses interact in complex ways and share a number of processes, including phagocytosis. They produce their effects indirectly, through interactions among cytokines and other chemical mediators. Cytokines induce WBC replication, phagocytosis, antibody production, fever, inflammation, and tissue repair. Other chemical mediators (eg, histamine, prostaglandins) are synthesized or released by mast cells, basophils, and other cells. Once activated, mediators may exert their effects on tissues locally or at distant target sites. They also may induce or enhance other mediators. Little information is available about the chemical mediators of chronic inflammation, but immunologic mechanisms are thought to play an important role.
allows “booster” doses of antigen to increase antibody levels and maintain active immunity against some diseases.

Passive immunity occurs when antibodies are formed by the immune system of another person or animal and transferred to the host. For example, an infant is normally protected for several months by maternal antibodies received through the placenta during gestation. Also, antibodies previously formed by a donor can be transferred to the host by an injection of immune serum. These antibodies act against antigens immediately. Passive immunity is short-term, lasting only a few weeks or months.

Cellular and Humoral Immunity

Types of acquired immunity have traditionally been separated into cellular immunity (mainly involving activated T lymphocytes in body tissues) and humoral immunity (mainly involving B lymphocytes and antibodies in the blood). However, it is now known that the two types are closely connected, that virtually all antigens elicit both cellular and humoral responses, and that most humoral (B cell) responses require cellular (T cell) stimulation.

Although most humoral immune responses occur when antibodies or B cells encounter antigens in blood, some occur when antibodies or B cells encounter antigens in other body fluids (eg, tears, sweat, saliva, mucus, and breast milk). The antibodies in body fluids other than blood are produced by a part of humoral immunity sometimes called the secretory or mucosal immune system. The B cells of the mucosal system migrate through lymphoid tissues of tear ducts, salivary glands, breasts, bronchi, intestines, and genitourinary structures. The antibodies (mostly immunoglobulin A [IgA], some IgM and IgG) secreted at these sites act locally rather than systemically. This local protection combats foreign substances, especially pathogenic microorganisms, that are inhaled, swallowed, or otherwise come in contact with external body surfaces. When the foreign substances bind to local antibodies, they are unable to attach to and invade mucosal tissue.

Antigens

Antigens are the foreign (nonself) substances (eg, microorganisms, other proteins, or polysaccharides) that initiate immune responses. Antigens have specific sites that interact with immune cells to induce the immune response. The number of antigenic sites on a molecule depends largely on its molecular weight. Large protein and polysaccharide molecules are complete antigens because of their complex chemical structures and multiple antigenic sites. Smaller molecules (eg, animal danders, plant pollens, and most drugs) are incomplete antigens (called haptens) and cannot act as antigens by themselves. However, they have antigenic sites and can combine with carrier substances to become antigenic. Antigens also may be called immunogens. In discussions of allergic conditions, antigens are often called allergens.

Immune Responses to Antigens

The immune response involves antigens that induce the formation of antibodies or activated T lymphocytes. The initial response occurs when an antigen is first introduced into the body. B lymphocytes recognize the antigen as foreign and develop antibodies against it. Antibodies are proteins called immunoglobulins that interact with specific antigens.

Antigen–antibody interactions may result in formation of antigen–antibody complexes, agglutination or clumping of cells, neutralization of bacterial toxins, destruction of pathogens or cells, attachment of antigen to immune cells, coating of the antigen so that it is more readily phagocytized (opsonization), or activation of complement (a group of plasma proteins activated by recognition of an antigen–antibody complex, bacteria, or viruses and essential to normal inflammatory and immunologic responses). Activated complement stimulates chemotaxis (of monocytes, neutrophils, basophils, and eosinophils) and the release of hydrolytic enzymes, actions that result in the destruction or inactivation of the invading antigen. With a later exposure to the antigen, antibody is rapidly produced. The number of exposures required to produce enough antibodies to bind a significant amount of antigen is unknown. Thus, an allergic reaction may occur with the second exposure or after several exposures, when sufficient antibodies have been produced.

Antigen–T lymphocyte interactions stimulate production and function of other T lymphocytes and help to regulate antibody production by B lymphocytes. T cells are involved in delayed hypersensitivity reactions, rejection of tissue or organ transplantats, and responses to neoplasms and some infections.

Immune cells (Fig. 42–1) are WBCs found throughout the body in lymphoid tissues (bone marrow, spleen, thymus, tonsils and adenoids, Peyer’s patches in the small intestine, lymph nodes, and blood and lymphatic vessels that transport the cells). When exposure to an antigen occurs and an immune response is aroused, WBCs move toward the antigen in a process called chemotaxis. Once WBCs reach the area, they phagocytize the antigen. Specific WBCs are granulocytes (neutrophils, eosinophils, basophils), and nongranulocytes (monocytes and lymphocytes). Although all WBCs play a role, neutrophils, monocytes, and lymphocytes are especially important in phagocytic and immune processes. Granulocytes often contain inflammatory mediators or digestive enzymes in their cytoplasm.

Neutrophils, the body’s main defense against pathogenic bacteria, are the major leukocytes in the bloodstream. Substances (eg, complement) released from infected or inflamed tissue cause neutrophils to migrate to the affected tissue. These WBCs arrive first, usually within 90 minutes of injury. They localize the area of injury and phagocytize organisms or particles by releasing digestive enzymes and oxidative metabolites that kill engulfed pathogens or destroy other types of foreign particles. The number of neutrophils increases greatly during
**Figure 42-1** Hematopoiesis and formation of immune cells.
the inflammatory process. These cells circulate in the bloodstream for approximately 10 hours, then move into tissues where they live for 1 to 3 days.

Eosinophils increase during allergic reactions and parasitic infections. In parasitic infections, they bind to and kill the parasites. In hypersensitivity reactions, they produce enzymes that inactivate histamine and leukotrienes and may produce other enzymes that destroy antigen–antibody complexes. Despite these generally beneficial effects, eosinophils also may aggravate tissue damage by releasing cytotoxic substances. Basophils release histamine, a major chemical mediator in inflammatory and immediate hypersensitivity reactions.

Monocytes arrive several hours after injury and influx of neutrophils into the area; they usually replace neutrophils as the predominant WBC within 48 hours. Monocytes are the largest WBCs, and their life span is much longer than that of the neutrophils. Monocytes can phagocytize larger sizes and amounts of foreign material than neutrophils. In addition to their activity in the bloodstream, monocytes can leave blood vessels and enter tissue spaces (and then are called fixed tissue macrophages), although they can again become mobile and reenter the bloodstream in some circumstances. Tissue macrophages are widely distributed in connective tissue and other areas (eg, Kupffer’s cells in the liver, alveolar macrophages in the lungs, others in the lymph nodes and spleen) and form the mononuclear phagocyte system. Both mobile and fixed monocyte–macrophages are important in inflammatory processes and both can initiate the immune response by activating lymphocytes. They perform this function as part of phagocytosis, in which they engulf a circulating antigen (eg, foreign material and cellular debris), break it into fragments, and return antigenic fragments to the cell surface. The antigenic fragments are recognized as foreign material by circulating T and B lymphocytes, and an immune response is initiated. Because the monocytes prepare the antigen to interact with T and B lymphocytes, they are called antigen-processing and antigen-presenting cells.

Lymphocytes are the main immunocytes, and those in tissues are in dynamic equilibrium with those in circulating blood. These cells continuously travel through blood and lymph vessels from one lymphoid organ to another. The three types of lymphocytes are natural killer cells, T cells, and B cells.

Natural killer cells, so called because they do not need to interact with a specific antigen to become activated, destroy infectious microorganisms and malignant cells by releasing powerful chemicals. T cells are involved in both cell-mediated and humoral immunity and are especially able to combat intracellular infections (eg, virus-infected cells). B cells are involved in humoral immunity; they secrete antibodies that can neutralize pathogens before their entry into host cells. Both T and B cells must be activated by antigens before they can fulfill their immune functions, and both have proteins on their cell membrane surfaces that act as receptors for antigens.

Each T or B lymphocyte reacts only with a specific type of antigen and is capable of forming only one type of antibody or one type of T cell. When a specific antigen attaches to cell membrane receptors to form an antigen–antibody complex, the complex activates the lymphocyte to form tremendous numbers of duplicate lymphocytes (clones) that are exactly like the parent cell. Clones of a B lymphocyte eventually secrete antibodies that circulate throughout the body. Clones of a T lymphocyte are sensitized or activated T cells that are released into lymphatic ducts, carried to the blood, circulated through all tissue fluids, then returned to lymphatic ducts and recirculated. Additional participants in the activation process are phagocytic macrophages and helper T cells, which secrete cytokines that regulate the growth, reproduction, and function of lymphocytes.

**T Lymphocytes**

T lymphocytes are the primary regulators of immune responses because they direct the activities of B cells and macrophages. They originate in pluripotential stem cells in the bone marrow and differentiate into immune cells in the thymus gland. The thymus produces a substance called thymosin, which is necessary for T-cell maturation. When T cells bind with an antigen, specific genes are activated to produce substances that direct T-cell proliferation and differentiation. One such substance is IL-2, which stimulates T-cell deoxyribonucleic acid replication and mitosis. Cell division is necessary for production of large numbers of antigen-reactive cells and for cellular changes associated with the different subgroups of T cells. Specific types and functions of T cells include the following:

- **Helper T cells** (also called T<sub>H</sub> or CD4<sup>+</sup> cells), the largest subgroup, regulate virtually all immune functions by producing protein substances called cytokines (formerly called lymphokines to denote cytokines produced by lymphocytes). The cytokines stimulate the growth of bone marrow and other cells of the immune system (eg, cytotoxic T cells and B cells). They also activate macrophages and facilitate phagocytosis. Important cytokines include IL-2, -3, -4, -5, and -6, GM-CSF, and interferon gamma. The devastating effects of acquired immunodeficiency syndrome (AIDS) result primarily from the ability of the human immunodeficiency virus to destroy helper T cells.

  Subsets of helper T cells have recently been identified as T<sub>H</sub>1 and T<sub>H</sub>2. Both secrete IL-3 and GM-CSF but differ in the other cytokines they secrete. The T<sub>H</sub>1 subset is responsible for many cell-mediated functions (eg, delayed-type hypersensitivity reactions and activation of cytotoxic T cells) and for the production of immunoglobulin G antibodies that promote opsonization of antigens. These cells are also associated with excessive inflammation and tissue injury. The T<sub>H</sub>2 subset stimulates the activation and differentiation of eosinophils and stimulates B cells (eg, to produce im-
muno\(\text{g}l\)obulins such as IgM and IgE). These cells are also associated with hypersensitivity reactions.

- **Cytotoxic T cells** (also called \(T_c\) or CD8+ cells) are recruited and activated by helper T cells. More specifically, helper T cells secrete IL-2, which is necessary for activation and proliferation (clonal expansion) of cytotoxic T cells. Once activated by antigen and IL-2, cytotoxic T cells bind to antigens on the surfaces of target cells. After binding to antigen, the T cells are thought to destroy target cells by one or more of three mechanisms. One mechanism involves the formation of holes in the target cell membrane that allow fluids to enter and swell the cell until it bursts. Another is the insertion of enzymes that break down or digest the cell. A third mechanism is to induce apoptosis (programmed cell death). Once these cytotoxic cells have damaged the target cells, they can detach themselves and attack other target cells.

  Cytotoxic T cells are especially lethal to virus-infected cells because virus particles become entrapped in the membranes of the cells and act as strong antigens that attract the T cells. These cells persist in tissues for months, even after destruction of all the invaders that elicited the original cytotoxic activity. Thus, cytotoxic T cells are especially important in killing body cells that have been invaded by foreign microorganisms or cells that have become malignant. Cytotoxic T cells also play a role in the destruction of transplanted organs and delayed hypersensitivity reactions.

  An additional type of T cells, called suppressor T cells, has been postulated to exist and to function by stopping the immune response (ie, decreasing the activities of B cells and other T cells) when an antigen has been destroyed. This activity is considered important in preventing further tissue damage. For example, in autoimmune disorders, suppressor T cell function is impaired and extensive tissue damage may result. However, efforts to clone these cells have been unsuccessful and some immunologists believe that suppressor activity is performed by subsets of helper T cells or cytotoxic T cells rather than a different type of T cell.

**B Lymphocytes**

B lymphocytes originate in stem cells in the bone marrow, differentiate into cells capable of forming antibodies (also in the bone marrow), and migrate to the spleen, lymph nodes, or other lymphoid tissue. In lymphoid tissue, the cells may be dormant until exposed to an antigen. In response to an antigen and IL-2 from helper T cells, B cells multiply rapidly, enlarge, and differentiate into plasma cells, which then produce antibodies (immunoglobulins [IGs]) to oppose the antigen. Immunoglobulins are secreted into lymph and transported to the bloodstream for circulation throughout the body. There are five main classes of immunoglobulins:

- **IgG** is the most abundant immunoglobulin, constituting approximately 80% of the antibodies in human serum. It protects against bacteria, toxins, and viruses as it circulates in the bloodstream. Molecules of IgG combine with molecules of antigen, and the antigen–antibody complex activates complement. Activated complement causes an inflammatory reaction, promotes phagocytosis, and inactivates or destroys the antigen. IgG also crosses the placenta to provide maternally acquired antibodies (passive immunity) to the infant.

- **IgA** is the main immunoglobulin in mucous membranes and body secretions. It is found in saliva, breast milk, and nasal, respiratory, prostatic and vaginal secretions. It protects against pathogens and other antigens that gain access to these areas. For example, it prevents attachment of viruses and bacteria to mucous membranes.

- **IgM** constitutes approximately 10% of serum antibodies. It protects against bacteria, toxins, and viruses that gain access to the bloodstream and is important in early immune responses. It acts only in the bloodstream because its large molecular size prevents its movement or transport through capillary walls. It activates complement to destroy microorganisms.

- **IgE** binds to mast cells and basophils. It is present in body fluids and readily enters body tissues. It is involved in parasitic infections and hypersensitivity reactions, including anaphylaxis. IgE sensitizes mast cells, which then release histamine and other chemical mediators that cause bronchoconstriction, edema, urticaria, and other manifestations of allergic reactions. IgE does not activate complement. The production of IgE is stimulated by T lymphocytes and interleukins 4, 5, and 6 and inhibited by the interferons. Small amounts of IgE are present in the serum of nonallergic people; larger amounts are produced by people with allergies.

- **IgD** is found on the cell membranes of B lymphocytes. It functions in recognition of antigens and differentiation and maturation of B lymphocytes.

**Immune System Cytokines**

Cytokines (Fig. 42–2) are the primary means of communication between immune cells and other tissues and organs of the body. They also regulate the intensity and duration of the immune response by stimulating or inhibiting the activation, proliferation, and/or differentiation of various cells and by regulating the secretion of antibodies or other cytokines. Although the hematopoietic cytokines described include the immune system cytokines, the emphasis here is on those that affect immune cells. It is thought that cytokines formed by activated macrophages enter the bone marrow, where they induce the synthesis and release of other cytokines.
Figure 42-2  Macrophage and T cell cytokines, their target cells, and the products of target cells. These elements overlap and interact to regulate the immune response.

IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; $T_H$, helper T cell; $T_C$, cytotoxic T cells; CSF, colony-stimulating factor.
that activate resting stem cells to produce more granulocytes and monocyte–macrophages. Newly formed granulocytes and monocytes leave the bone marrow and enter the circulating blood in approximately 3 days.

Cytokine binding to target cells elicits wide-ranging effects, including increased expression of cytokine receptors and increased production of other cytokines. In general, the cytokines secreted by antigen-activated lymphocytes can affect the activity of most cells involved in the immune response. For example, cytokines produced by activated helper T cells influence the activity of B cells, cytotoxic T cells, natural killer cells, macrophages, granulocytes, and hematopoietic stem cells. As a result, a network of interacting cells is activated.

Some cytokines enhance macrophage activity by two main mechanisms. First, they cause macrophages to accumulate in damaged tissues by delaying or stopping macrophage migration from the area. Second, they increase the capacity and effectiveness of phagocytosis. Some cytokines, especially IL-2, directly stimulate helper T cells and enhance their antigenic activity. They also enhance the antiantigenic activity of the entire immune system. Interleukins 4, 5, and 6 are especially important in B-cell activities.

Tumor necrosis factors (TNF) are produced by activated macrophages and other cells and act on many immune and nonimmune target cells. They participate in the inflammatory response and cause hemorrhagic necrosis in several types of tumor cells. TNF-alpha is structurally the same as cachectin, a substance associated with debilitation and weight loss in patients with cancer. TNF-beta is also called lymphotoxin.

PATIENT-RELATED FACTORS THAT INFLUENCE IMMUNE FUNCTION

Age

Immune Function During Fetal and Neonatal Periods

During the first few months of gestation, the fetal immune system is deficient in antibody production and phagocytic activity. During the last trimester, the fetal immune system may be able to respond to infectious antigens, such as cytomegalovirus, rubella virus, and Toxoplasma. However, most fetal protection against infectious microorganisms is by maternal antibodies that reach the fetal circulation through the placenta. In the placenta, maternal blood and fetal blood are separated only by a layer of specialized cells called trophoblasts. Because antibodies are too large to diffuse across the trophoblastic layer, they are actively transported from the maternal to the fetal circulation by the trophoblastic cells.

At birth, the neonatal immune system is still immature, but IgG levels (from maternal blood) are near adult levels in umbilical cord blood. However, the source of maternal antibodies is severed at birth. Antibody titers in infants decrease over approximately 6 months as maternal antibodies are catabolized. Although the infant does start producing IgG, the rate of production is lower than the rate of breakdown of maternal antibodies. Cell-mediated immunity is probably completely functional at birth.

Immune Function in Older Adults

Both humoral and cell-mediated immune functions decline with aging, and this decline is probably a major factor in the older adult’s increased susceptibility to infections and tumors. The regulation of immunologic functions also declines with age, which may account for the greater frequency of autoimmune diseases in this age group. Lymphocytes are less able to proliferate in response to antigenic stimulation, and a relative state of immunodeficiency prevails. With T lymphocytes, function is impaired, and the numbers in peripheral blood may be decreased. The functional impairment includes decreased activity of helper T cells. With B lymphocytes, the numbers probably do not decrease, but the cells are less able to form antibodies in response to antigens. Abnormal antibody production results from impaired function of B cells and helper T cells. In addition, older adults have increased blood levels of antibodies against their own tissues (autoantibodies).

Impaired immune mechanisms have several implications for clinicians who care for elderly patients, including the following:

- Older adults are more likely to contract infections and less able to recover from them. Therefore, older adults need protective measures, such as rigorous personal hygiene; good nutrition; adequate exercise, rest, and sleep; minimal exposure to potential pathogens, when possible; and appropriate immunizations (eg, influenza, pneumonia, tetanus). When an infection develops in older adults, signs and symptoms (eg, fever and drainage) may be absent or less pronounced than in younger adults.

- Older adults have impaired immune responses to antigens. Thus, achieving protective antibody titers may require higher doses of immunizing antigens in older adults than in younger adults.

- Older adults often exhibit a less intense positive reaction in skin tests for tuberculosis (indicating a decreased delayed hypersensitivity response).

Nutritional Status

Nutritional status can have profound effects on immune function. Adequate nutrient intake contributes to immunocompetence (ability of the immune system to function effectively). Malnutrition contributes to immunodeficiency. A severe lack of calories or protein decreases numbers and functions of T cells, complement activity, neutrophil chemotaxis, and phagocytosis. An inadequate zinc intake can depress the functions of T and B cells. Zinc is a cofactor for many enzymes,
some of which are found in lymphocytes and are required for lymphocyte function. Zinc deficiency also may result from inadequate absorption in the GI tract or excessive losses in urine, feces, or through the skin with such disorders as chronic renal disease, chronic diarrhea, burns, or severe psoriasis. Vitamin deficiencies may also depress T- and B-cell function because several (eg, A, E, folic acid, pantothenic acid, and pyridoxine) also are enzyme cofactors in lymphocytes.

**Stress**

There is evidence that stress depresses immune function and therefore increases risks for development of infection and cancer. The connection between the stress response and the immune response is thought to involve neuroendocrine mechanisms. The stress response is characterized by increased activity of catecholamine neurotransmitters in the central and autonomic nervous systems (eg, norepinephrine, epinephrine) and increased secretion of cortisol from the adrenal cortex. Cortisol and other corticosteroids are well known to suppress immune function and are used therapeutically for that purpose. The immune response is affected by these neuroendocrine influences on lymphoid organs and lymphocyte functions because lymphocytes have receptors for many neurotransmitters and hormones.

**IMMUNE DISORDERS**

Dysfunction of the immune system is related to many different disease processes, including allergic, autoimmune, immunodeficiency, and neoplastic disorders. Each of these is described in the following list to assist in understanding the use of drugs to alter immune functions:

- In *allergic disorders*, the body erroneously perceives normally harmless substances (eg, foods, pollens) as antigens and mounts an immune response. More specifically, IgE binds to antigen on the surface of mast cells and causes the release of chemical mediators (eg, histamine) that produce the allergic manifestations. This reaction may cause tissue damage ranging from mild skin rashes to life-threatening anaphylaxis.
- In *autoimmune disorders*, the body erroneously perceives its own tissues as antigens and elicits an immune response, often inflammatory in nature. Hashimoto’s thyroiditis, multiple sclerosis, myasthenia gravis, rheumatoid arthritis, scleroderma, systemic lupus erythematosus (SLE), and type 1 diabetes mellitus are considered autoimmune disorders. Most of these disorders occur more often in women than men, possibly because of hormonal differences.

Autoimmune processes may damage virtually every body tissue, and various mechanisms have been proposed to explain their development. Some evidence exists for different mechanisms, and it is probable that autoimmunity develops from several events rather than a single one.

- In *immunodeficiency disorders*, the body is especially susceptible to infections and neoplastic diseases. AIDS is a major immunodeficiency disorder that decreases the numbers and almost all functions of T lymphocytes and several functions of B lymphocytes and monocytes. Immunodeficiency also is induced by severe malnutrition, cancer, and immunosuppressant drugs.
- In *neoplastic disease*, immune cells lose their ability to destroy mutant cells or early malignant cells. This effect could result from immunodeficiency states or from cancer cells that are overwhelming in number or highly malignant. Mutant cells constantly occur during cell division, but few survive or lead to cancer. Most mutant cells simply die; some survive but retain the normal controls that prevent excessive growth; and some are destroyed by immune processes activated by abnormal proteins found in most mutant cells.

**DRUGS THAT ALTER HEMATOPOIETIC AND IMMUNE RESPONSES**

Several hematopoietic and immune cytokines have been synthesized for therapeutic purposes. Hematopoietic agents are used to prevent or treat symptoms (eg, anemia, neutropenia) caused by disease processes or their treatments.

Drugs that modify the immune system are used to prevent or treat infections, treat immunodeficiency disorders and cancer, and to prevent or treat rejection of transplanted tissues or organs.

Methods include administering exogenous antigens (eg, immunizations and desensitization procedures), strengthening antigens (eg, an antigen that is too weak to elicit an immune response), or suppressing the normal response to an antigen. In desensitization procedures, weak extracts of antigenic substances (eg, foods, plant pollens, penicillin) are prepared as drugs and administered in small, increasing amounts so the patient develops a tolerance for the substances and avoids serious allergic reactions.

Overall, drugs can be given to stimulate immune responses (immunizing agents [see Chap. 43]; stimulate hematopoiesis and immune responses [see Chap. 44]); or suppress normal immune responses (immunosuppressants [see Chap. 45]).

**Review and Application Exercises**

1. What is the difference between innate and acquired immunity?
2. What are methods of producing active acquired immunity?
3. Which WBCs are phagocytes?
4. Describe phagocytosis.
5. Where are T lymphocytes formed, and what are their functions?
6. Where are B lymphocytes formed, and what are their functions?
7. What are antigens, and how do they elicit an immune response?
8. What are cytokines, and how do they function in the immune response?
9. What is complement, and how does it function in the immune response?
10. What are the main consequences of immunodeficiency states?

SELECTED REFERENCES
A young couple brings their 6-week-old infant to the clinic for a well-baby check and her required “shots.” First, you examine the baby and talk with the couple about how new parenthood is going. Both seem very motivated to be good parents. They have lots of questions and ask whether all those shots are really necessary. The mother admits that she has always been afraid of shots and just can’t watch her baby be hurt.

Reflect on:
- How you can acknowledge the mother’s concerns without minimizing her feelings.
- Basic information regarding immunizations that every new parent should have.
- Teaching regarding what the parents may expect for 2 to 3 days after the injection and appropriate symptom management.
- The importance of keeping up-to-date immunization records.


discuss common characteristics of immunizations.

2. Discuss the importance of immunizations in promoting health and preventing disease.

3. Identify authoritative sources for immunization information.

4. Identify immunizations recommended for children.

5. Identify immunizations recommended for adults.

6. Discuss ways to promote immunization of all age groups.

7. Teach parents about recommended immunizations and record keeping.

Critical Thinking Scenario

A young couple brings their 6-week-old infant to the clinic for a well-baby check and her required “shots.” First, you examine the baby and talk with the couple about how new parenthood is going. Both seem very motivated to be good parents. They have lots of questions and ask whether all those shots are really necessary. The mother admits that she has always been afraid of shots and just can’t watch her baby be hurt.

Reflect on:
- How you can acknowledge the mother’s concerns without minimizing her feelings.
- Basic information regarding immunizations that every new parent should have.
- Teaching regarding what the parents may expect for 2 to 3 days after the injection and appropriate symptom management.
- The importance of keeping up-to-date immunization records.

OVERVIEW

Immune responses and types of immunity are described in Chapter 42. Many antigens that activate the immune response are microorganisms that cause infectious diseases. Early scientists observed that people who contracted certain diseases were thereafter protected despite repeated exposure to the disease. As knowledge evolved, it was discovered that protection stemmed from body substances called antibodies, and that antibodies could also be induced by deliberate, controlled exposure to the antigen. Subsequently, immunization techniques were developed.

Although immunizations against some diseases have long been used, the development of immunizing agents and recommendations for their use continue. Some recommendations and changes of recent years are summarized as follows:
- The American Academy of Pediatrics (www.aap.org) recommends that only the inactivated polio vaccine (IPV) be used in the United States. The oral vaccine used for many years contained live virus and caused viral shedding and a few cases of polio. The main disadvantages of IPV are that it must be injected and it is more expensive.
- Hepatitis B virus (HBV) infection can cause serious liver diseases such as acute and chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Chronic carriers of HBV may be asymptomatic reservoirs for viral transmission. Children who become infected are at high risk of becoming chronically infected. Because of these circumstances, hepatitis B vaccine is now recommended for all newborns and for unimmunized children before starting school, as well as other at-risk groups. Overall, the goal is to achieve universal immunization, decrease transmission, and eradicate the disease.
- Everyone should be immunized against diphtheria and tetanus every 7 to 10 years for life.
- Strategies to promote immunization continue to evolve. One strategy is to combine vaccines so that only one in-
jection is required when the need and time for multiple vaccines coincide. In addition to the long-used, measles-mumps-rubella (MMR) and diphtheria-tetanus-pertussis (DTaP) combinations, available combinations include Haemophilus b (Hib) with hepatitis B (Comvax), DTaP with Haemophilus b (DTaP-HIB; TriHIBit), and hepatitis A and hepatitis B (Twinrix). Another strategy is to give multiple vaccines (in separate syringes, at different sites) at one visit to a health care provider when feasible. For example, several vaccines are recommended to be given at the same time for routine immunization of infants and young children. In addition, influenza and pneumococcal vaccines can be administered concurrently, and at least one study indicates that varicella and MMR can be given at the same office visit.

- Two vaccines were developed, marketed, then withdrawn from the market. Rotavirus vaccine was withdrawn because of adverse effects, and Lyme disease vaccine was apparently withdrawn because of infrequent use.

**IMMUNIZATION**

Immunization or vaccination involves administration of an antigen to induce antibody formation (for active immunity) or serum from immune people (for passive immunity). Preparations used for immunization are biologic products prepared by pharmaceutical companies and regulated by the Food and Drug Administration (FDA).

**AGENTS FOR ACTIVE IMMUNITY**

The biologic products used for active immunity are vaccines and toxoids. Vaccines are suspensions of microorganisms or their antigenic products that have been killed or attenuated (weakened or reduced in virulence) so that they can induce antibody formation while preventing or causing very mild forms of the disease. Many vaccines produce long-lasting immunity. Attenuated live vaccines produce immunity, usually lifelong, that is similar to that produced by natural infection. However, there is a small risk of producing disease with live vaccines, especially in people with impaired immune function. Vaccines developed with recombinant deoxyribonucleic acid (DNA) technology have a low risk for causing active disease.

Toxoids are bacterial toxins or products that have been modified to destroy toxicity while retaining antigenic properties (ie, ability to induce antibody formation). Immunization with toxoids is not permanent; scheduled repeat doses (boosters) are required to maintain immunity.

Additional components of vaccines and toxoids may include aluminum phosphate, aluminum hydroxide, or calcium phosphate. Products containing aluminum should be given intramuscularly only because they cannot be given intravenously and greater tissue irritation occurs with subcutaneous injections. These additives are used to delay absorption and increase antigenicity.

For maximum effectiveness, vaccines and toxoids must be given before exposure to the pathogenic microorganism. They should also be given by the recommended route to ensure the desired immunologic response.

**Indications for Use**

Clinical indications for use of vaccines and toxoids include the following:

1. Routine immunization of all children against diphtheria, Haemophilus b infection, hepatitis B, mumps, pertussis, pneumococcal infection, poliomyelitis, rubella (German measles), rubeola (red measles), tetanus, and varicella.
2. Immunization of adolescents and adults against diphtheria and tetanus.
3. Immunization of prepubertal girls or women of childbearing age against rubella. Rubella during the first trimester of pregnancy is associated with a high incidence of birth defects in the newborn.
4. Immunization of people at high risk of serious morbidity or mortality from a particular disease. For example, hepatitis B, influenza, and pneumococcal vaccines are recommended for selected groups of people.
5. Immunization of adults and children at high risk of exposure to a particular disease. For example, some diseases (eg, yellow fever) rarely occur in most parts of the world. Thus, immunization is recommended only for people who live in or travel to geographic areas where the disease can be contracted.

**Contraindications to Use**

Vaccines and toxoids are usually contraindicated during febrile illnesses; immunosuppressive drug therapy (see Chap. 45); immunodeficiency states; leukemia, lymphoma, or generalized malignancy; and pregnancy.

**AGENTS FOR PASSIVE IMMUNITY**

Immune serums are the biologic products used for passive immunity. They are used to provide temporary immunity in people exposed to or experiencing a particular disease. The goal of therapy is to prevent or modify the disease process (ie, decrease the incidence and severity of symptoms).

Immune globulin products are made from the serum of individuals with high concentrations of the specific antibody or immunoglobulin (Ig) required. They may consist of whole serum or the immunoglobulin portion of serum in which the specific antibodies are concentrated. Immunoglobulin fractions are preferred over whole serum because they are more likely to be effective. Plasma used to prepare these products is negative for hepatitis B surface antigen (HbsAg). Hyperimmune serums are available for cytomegalovirus, hepatitis
Obtain recommended immunizations for children and self
Keep appointments for immunizations

**Interventions**

Use measures to prevent infectious diseases, and provide information about the availability of immunizing agents. General measures include those to promote health and resistance to disease (eg, nutrition, rest, and exercise). Additional measures include the following:

- Education of the public, especially parents of young children, regarding the importance of immunizations to personal and public health. Include information about the diseases that can be prevented and where immunizations can be obtained.
- Assisting clients in developing a system to maintain immunization records for themselves and their children. This is important because immunizations are often obtained at different places and over a period of years. Written, accurate, up-to-date records help to prevent diseases and unnecessary immunizations.
- Prevention of disease transmission. The following are helpful measures:
  - Hand washing (probably the most effective method)
  - Avoiding contact with people who have known or suspected infectious diseases, when possible
  - Using isolation techniques when appropriate
  - Using medical and surgical aseptic techniques
- For someone exposed to rubella, administration of measles vaccine within 48 hours to prevent the disease
- For someone with a puncture wound or a dirty wound, administration of tetanus immune globulin to prevent tetanus, a life-threatening disease
- For someone with an animal bite, washing the wound immediately with large amounts of soap and water. Health care should then be sought. Administration of rabies vaccine may be needed to prevent rabies, a life-threatening disease.
- Explaining to the client that contracting rubella or undergoing rubella immunization during pregnancy, especially during the first trimester, may cause severe birth defects in the infant. The goal of immunization is to prevent congenital rubella syndrome. Current recommendations are to immunize children against rubella at 12 to 15 months of age.
  
  It is recommended that previously unimmunized girls 11 to 13 years of age be immunized. Further, nonpregnant women of childbearing age should have rubella antibody tests. If antibody concentrations are low, the women should be immunized. Pregnancy should be avoided for 3 months after immunization.

**Evaluation**

- Interview and observe for symptoms.
- Interview and observe for adverse drug effects.
- Check immunization records when indicated.
### Drugs at a Glance: Vaccines and Toxoids for Active Immunity

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccines</strong></td>
<td></td>
<td></td>
<td>Adults</td>
</tr>
<tr>
<td><strong>Haemophilus b (Hib) conjugate vaccine</strong> (ActHIB, HibTITER, PedvaxHIB)</td>
<td>Formed by conjugating a derivative of the organism with a protein. The protein increases antigenicity.</td>
<td>To prevent infection with Hib, a common cause of serious bacterial infections, including meningitis, in children younger than 5 y</td>
<td>HibTITER, age 2–5 mo, IM 0.5 mL every 2 mo for 3 doses; age 15 mo, 0.5 mL as a single booster dose Age 7–11 mo, IM 0.5 mL every 2 mo for two doses; age 15 mo, 0.5 mL as a single booster dose Age 12–14 mo, IM 0.5 mL as single dose; age 15 mo, 0.5 mL as a single booster dose, at least 2 mo after the first dose Age 15–59 mo, IM 0.5 mL as a single dose (no booster dose) Pedvax Hib age 2–6 mo, IM 0.5 mL every 2 mo for two doses; age 12 mo, 0.5 mL as a booster dose Age 7–11 mo, IM 0.5 mL every 2 mo for two doses; age 15 mo, 0.5 mL as booster dose Age 12–14 mo, IM 0.5 mL as single dose; age 15 mo, 0.5 mL as a single booster dose, at least 2 mo after the first dose Age 15–59 mo, IM 0.5 mL as a single dose (no booster dose) ProHIBit, age 15–59 mo, IM 0.5 mL at 2, 4, and 12–15 months of age</td>
</tr>
<tr>
<td><strong>Haemophilus b (Hib) conjugate vaccine with hepatitis B vaccine</strong> (Comvax)</td>
<td>May be given at the same time as DTaP, measles, mumps, rubella (MMR), injected polio vaccine (IPV), but with separate syringes and in separate sites</td>
<td>Routine immunization of children 6 wk to 15 mo of age born to HBsAg-negative mothers</td>
<td>Havrix, IM in deltoid, 1440 units initially and 6–12 mo later (total of 2 doses) Vaqta, IM in deltoid, 50 units initially and 6–12 mo later (total of 2 doses)</td>
</tr>
<tr>
<td><strong>Hepatitis A vaccine</strong> (Havrix, Vaqta)</td>
<td>Inactivated whole virus More than 90% effective Duration of protection unknown Contraindicated during febrile illness, immunosuppression</td>
<td>Workers in day care centers, laboratories, food-handling establishments; homosexual men; IV drug users; military personnel; travelers to areas where hepatitis A is endemic; community residents during an outbreak; people with chronic liver disease (eg, hepatitis B or C, cirrhosis)</td>
<td>Havrix, 2–18 y, IM, 360 units initially, 1 mo later, and 6–12 mo later (total of 3 doses) or 720 units initially and 6–12 mo later (total of 2 doses) Vaqta, IM, 25 units initially and 6–18 mo later (total of 2 doses)</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Hepatitis B vaccine (recombinant)**    | Prepared by inserting the gene coding for production of hepatitis B surface antigen (HBsAg) into yeast cells  
Contains no blood or blood products  
Approximately 96% effective in children and young adults; approximately 88% effective in adults >40 y  
Duration of protection unknown; can measure serum antibody levels periodically (protective levels approximately 10 million units/mL) | Pre-exposure immunization of high-risk groups, such as health care providers (nurses, physicians, dentists, laboratory workers); clients with cancer, organ transplants, hemodialysis, immunosuppressant drug therapy, or multiple infusions of blood or blood products; male homosexuals; IV drug abusers; household contacts of HBV carriers; residents and staff of institutions for mentally handicapped people  
Persons requiring post-exposure vaccine include infants born to carrier mothers, people with accidental exposure of skin or mucous membrane to infected blood (eg, needlestick injuries), and household contacts or sexual partners of persons with acute hepatitis B infection | Adults  
20 y and older: Engerix, IM, 20 mcg (1 mL) initially and 1 mo and 6 mo later (3 doses)  
Predialysis and dialysis clients, IM, 40 mcg (2 mL) initially and 1, 2, and 6 mo later (4 doses)  
Recombivax, IM, 10 mcg (1 mL) initially and 1 mo and 6 mo later (3 doses)  
Predialysis and dialysis clients, IM, 40 mcg (1 mL) initially and 1 mo and 6 mo later (3 doses)  
Neonates to 19 y: Engerix, IM, 10 mcg (0.5 mL), initially and 1 mo and 6 mo later (3 doses)  
Neonates to 19 y: Recombivax, IM, 5 mcg (0.5 mL) initially and 1 mo and 6 mo later (3 doses)  
Alternative for ages  
11–15 y: IM 10 mcg (1 mL) initially and at 4 to 6 mo (2 doses)                                                                                     |
| **Hepatitis A, inactivated, and Hepatitis B, recombinant** (Twinrix) | Contains 720 units of hepatitis A and 20 mcg of hepatitis B antigens per mL                                                                                                                                                                                                  | Adults exposed to hepatitis A or B (eg, medical personnel, staff in institutional settings such as day care centers, prisons)  
Adults at risk of exposure, including travelers to areas of high incidence; people with chronic liver disease; laboratory workers, police, emergency medical personnel, sanitation workers | IM 1 mL initially, and 1 and 6 mo later (total of 3 doses)                                                                                                               |
### Drugs at a Glance: Vaccines and Toxoids for Active Immunity (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Influenza vaccine</strong>&lt;br&gt;(Fluzone, FluShield, Fluvirin)</td>
<td>Inactivated strains of A and B influenza viruses, reformulated annually to include current strains&lt;br&gt;Provides protective antibody concentrations for about 6 months&lt;br&gt;Grown in chick embryos; therefore, contraindicated in clients who are highly allergic to eggs</td>
<td>Recommended annually for health care providers; all adults &gt;65 y; and people in chronic care facilities or chronically ill with pulmonary, cardiovascular, or renal disorders, diabetes mellitus, or adrenocortical insufficiency&lt;br&gt;Also recommended for pregnant women in their second or third trimester</td>
<td>IM 0.5 mL in a single dose&lt;br&gt;SC 0.5 mL in a single dose&lt;br&gt;&lt;3 y: IM, 0.25 mL, 1 dose if previously vaccinated; 2 doses at least 1 mo apart if first vaccination&lt;br&gt;3–8 y: IM, 0.5 mL, 1 dose if previously vaccinated; 2 doses at least 1 mo apart if first vaccination&lt;br&gt;9 y and older: IM, 0.5 mL in a single dose</td>
</tr>
<tr>
<td><strong>Measles vaccine</strong>&lt;br&gt;(Attenuvax)</td>
<td>Preparation of live, attenuated measles (rubeola) virus&lt;br&gt;Protects approximately 95% of recipients for several years or lifetime&lt;br&gt;Usually given with mumps and rubella vaccines.&lt;br&gt;A combination product containing all three antigens is available and preferred.&lt;br&gt;Measles vaccine should not be given for 3 mo after administration of immune serum globulin, plasma, or whole blood</td>
<td>Routine immunization of children up to 1 y of age&lt;br&gt;Immunization of adults not previously immunized</td>
<td>SC 0.5 mL in a single dose&lt;br&gt;SC, same as adults</td>
</tr>
<tr>
<td><strong>Measles and rubella vaccine</strong>&lt;br&gt;(M-R-Vax II)</td>
<td>Mixture of live, attenuated rubeola virus (Attenuvax) and rubella (German measles) virus</td>
<td>Immunization of 15-mo-old children against rubeola and rubella</td>
<td>SC, total volume of reconstituted vial</td>
</tr>
<tr>
<td><strong>Measles, mumps, and rubella vaccine</strong>&lt;br&gt;(M-M-R II)</td>
<td>Mixture of rubeola, rubella, and mumps vaccines Preferred over single immunizing agents</td>
<td>Immunization from age 15 mo to puberty</td>
<td>SC 0.5 mL</td>
</tr>
<tr>
<td><strong>Meningitis vaccine</strong>&lt;br&gt;(Menomune-A/C&lt;br&gt;Menomune-A/C/Y/W-135)</td>
<td>Suspension prepared from Neisseria meningitidis&lt;br&gt;Protective levels of antibody usually achieved 7–10 d after immunization</td>
<td>Immunization of people at risk in epidemic or endemic areas&lt;br&gt;Type A only should be given to infants and children &lt;2 y</td>
<td>SC 0.5 mL</td>
</tr>
<tr>
<td><strong>Mumps vaccine</strong>&lt;br&gt;(Mumpsvax)</td>
<td>Suspension of live, attenuated mumps virus&lt;br&gt;Provides immunity in about 97% of children and 93% of adults for at least 10 y&lt;br&gt;Most often given in combination with measles and rubella vaccines</td>
<td>Routine immunization of children up to 1 y old and adults</td>
<td>SC 0.5 mL in a single dose&lt;br&gt;(reconstituted vaccine retains potency for 8 h if refrigerated. Discard if not used within 8 h.)&lt;br&gt;&gt;1 y: same as adults (vaccination not indicated in children &lt;1 y)</td>
</tr>
</tbody>
</table>

(continued)
## Drugs at a Glance: Vaccines and Toxoids for Active Immunity (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumococcal vaccine, polyvalent (Pneumovax 23, Pnu-Immune 23)</td>
<td>Consists of 23 strains of pneumococci, which cause approximately 85%–90% of the serious pneumococcal infections in the United States. Protection begins about 3 wk after vaccination and lasts years. Not recommended for children &lt;2 y because they may be unable to produce adequate antibody levels.</td>
<td>Adults with chronic disorders associated with increased risk of pneumococcal infection (eg, cardiovascular or pulmonary disease, diabetes mellitus, Hodgkin’s disease, multiple myeloma, cirrhosis, alcohol dependence, renal failure, immunosuppression). Adults 65 y and older who are otherwise healthy. Children 2 y and older with chronic disease associated with increased risk of pneumococcal infection (eg, asplenia, nephrotic syndrome, immunosuppression).</td>
<td>SC IM 0.5 mL as a single dose. Same as adults</td>
</tr>
<tr>
<td>Pneumococcal 7-valent conjugate vaccine (Prevnar)</td>
<td>Contains 7 Streptococcus pneumoniae antigens conjugated to a protein to increase antigenicity.</td>
<td>Active immunization to prevent invasive pneumococcal infections in young children.</td>
<td>Birth–6 mo: IM 0.5 mL at 2, 4, and 6 mo and at 12–15 mo (4 doses). 7–11 mo: IM 0.5 mL initially, at least 4 wk later, and after 1 y birthday (3 doses). 12–23 mo: IM 0.5 mL initially and at least 2 mo later (2 doses). 24 mo–9 y: IM 0.5 mL in a single dose. SC, 0.5 mL at 2, 4, 6–18 mo, and 4–6 y of age (4 doses) or at 2 and 4 mo (2 doses).</td>
</tr>
<tr>
<td>Poliomyelitis vaccine, inactivated (IPV) (IPOL)</td>
<td>A suspension of inactivated poliovirus types I, II, and III.</td>
<td>Routine immunization of infants. Immunization of adults not previously immunized and at risk of exposure (eg, health care or laboratory workers).</td>
<td>SC, 0.5 mL monthly for 2 doses, then a third dose 6–12 mo later.</td>
</tr>
<tr>
<td>Rabies vaccine (human diploid cell rabies vaccine [HDCV]) (Imovax)</td>
<td>An inactivated virus vaccine. Immunity develops in 7–10 d and lasts 1 y or longer. Preexposure prophylaxis in people at high risk of exposure (veterinarians, animal handlers, laboratory personnel who work with rabies virus). Postexposure prophylaxis in people who have been bitten by potentially rabid animals or who have skin scratches or abrasions exposed to animal saliva (eg, animal licking of wound), urine, or blood.</td>
<td>Preexposure prophylaxis, IM, 1.0 mL for 3 doses. The second dose is given 1 wk after the first; the third dose is given 3–4 wk after the first. Then, booster doses (1 mL) every 2–5 y based on antibody titers. Postexposure, IM, 1 mL for 5 doses. After the initial dose, other doses are given 3, 7, 14, and 28 d later. Rabies immunoglobulin is administered at the same time as the initial dose of HDCV vaccine.</td>
<td>Same as adults</td>
</tr>
</tbody>
</table>
**Drugs at a Glance: Vaccines and Toxoids for Active Immunity (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rubella vaccine</strong> (Meruvax II)</td>
<td>Sterile suspension of live, attenuated rubella virus Protects about 95% of recipients at least 15 y, probably for lifetime Should not be given for 3 mo after receiving immune serum globulin, plasma, or whole blood Usually given with measles and mumps vaccines</td>
<td>Routine immunization of children 1 y and older Initial or repeat immunization of adolescent girls or women of child-bearing age if serum antibody levels are low</td>
<td>Adults: SC 0.5 mL in a single dose Children: SC, same as adults</td>
</tr>
<tr>
<td><strong>Rubella and mumps vaccine</strong> (Biavax II)</td>
<td>A mixture of mumps and rubella virus strains Less frequently used than measles, mumps, and rubella vaccine</td>
<td>Immunization of children</td>
<td>Up to 1 y: SC, total volume of reconstituted vial</td>
</tr>
<tr>
<td><strong>Tuberculosis vaccine</strong> (Bacillus Calmette-Guérin) (TICE BCG)</td>
<td>Suspension of attenuated tubercle bacilli Converts negative tuberculin reactors to positive reactors. Therefore, precludes use of the tuberculin skin test for screening or early diagnosis of tuberculosis. Contraindicated in clients with impaired immune responses</td>
<td>People at high risk for exposure, including newborns of women with tuberculosis</td>
<td>Percutaneous, by multiple puncture disk, 0.2–0.3 mL Newborns: percutaneous, by multiple puncture disk, 0.1 mL &gt;1 mo, same as adults</td>
</tr>
<tr>
<td><strong>Typhoid vaccine</strong> (Vivotif Berna, Typhim Vi)</td>
<td>Suspension of attenuated or killed typhoid bacilli Protects &gt;70% of recipients</td>
<td>High-risk people (household contacts of typhoid carriers or people whose occupation or travel predisposes to exposure)</td>
<td>Adults: SC, 0.5 mL for two doses at least 4 wk apart, then a booster dose of 0.5 mL (or 0.1 mL intradermal) at least every 3 y for repeated or continued exposure Age 6 mo–10 y: SC 0.25 mL for 2 doses, at least 4 wk apart, then a booster dose of 0.25 mL (or 0.1 mL intradermal) every 3 y if indicated &gt;6 y: PO same as adults 1–12 y: SC 0.5 mL in a single dose Adolescents, 13 y and older: SC, 0.5 mL, followed by a second dose of 0.5 mL 4–8 wk after the first dose</td>
</tr>
<tr>
<td><strong>Varicella virus vaccine</strong> (Varivax)</td>
<td>Contains live, attenuated varicella virus Contraindicated in people with hematologic or lymphatic malignancy, immunosuppression, febrile illness, or pregnancy</td>
<td>Immunization of children 12 mo and older Immunization of adults</td>
<td>Adults: SC 0.5 mL, followed by a second dose of 0.5 mL 4–8 wk after the first dose</td>
</tr>
<tr>
<td><strong>Yellow fever vaccine</strong> (YF-Vax)</td>
<td>Suspension of live, attenuated yellow fever virus Protects about 95% of recipients for 10 y or longer</td>
<td>Laboratory personnel at risk of exposure Travel to endemic areas (Africa, South America)</td>
<td>Adults: SC 0.5 mL; booster dose of 0.5 mL every 10 y if in endemic areas</td>
</tr>
</tbody>
</table>

(continued)
## Drugs at a Glance: Vaccines and Toxoids for Active Immunity (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Toxoids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Tripedia, Certiva, Infanrix)</td>
<td>The pertussis component is acellular bacterial particles, which decrease the adverse effects associated with the whole-cell vaccine used formerly</td>
<td>Active immunization of children aged 6 wk to 7 y</td>
<td>IM 0.5 mL at approximately 2, 4, 6, and 18 mo of age</td>
<td></td>
</tr>
<tr>
<td>Diphtheria and tetanus toxoids and acellular pertussis and Hemophilus influenzae type B conjugate vaccines (DTaP-HIB) (TriHIBit)</td>
<td>A combination product, to decrease the number of injections and increase compliance</td>
<td>Active immunization of children 15–18 mo of age who have been previously immunized against diphtheria, tetanus, and pertussis</td>
<td>IM 0.5 mL within 30 min or less after reconstitution</td>
<td></td>
</tr>
<tr>
<td>Diphtheria and tetanus toxoids adsorbed (pediatric type)</td>
<td>Also called DT</td>
<td>Routine immunization of infants and children 6 y and younger in whom pertussis vaccine is contraindicated (ie, those who have adverse reactions to initial doses of DTP)</td>
<td>Infants and children 6 y and younger: IM 0.5 mL for 2 doses at least 4 wk apart, followed by a reinforcing dose 1 y later and at the time the child starts school</td>
<td></td>
</tr>
<tr>
<td>Tetanus toxoid, adsorbed</td>
<td>Preparation of detoxified products of Clostridium tetani</td>
<td>Routine immunization of infants and young children</td>
<td>Primary immunization in adults not previously immunized, IM 0.5 mL for 3 doses, initially, 4–8 wk later, then at 6–12 mo. Then, 0.5 mL booster dose every 10 y. Prophylaxis, IM 0.5 mL if wound severely contaminated and no booster dose received for 5 y; 0.5 mL if wound is clean and no booster dose received for 10 y</td>
<td>Primary immunization and prophylaxis, same as adults</td>
</tr>
<tr>
<td>Tetanus and diphtheria toxoids, adsorbed (adult type)</td>
<td>Also called Td</td>
<td>Primary immunization or booster doses in adults and children &gt;6 y of age</td>
<td>IM 0.5 mL for 2 doses, at least 4 wk apart, followed by a reinforcing dose 6–12 mo later and every 10 y thereafter</td>
<td>&gt;6 y: same as adults</td>
</tr>
</tbody>
</table>

### PRINCIPLES OF THERAPY

#### Keeping Up-to-Date with Immunization Recommendations

Recommendations regarding immunizations change periodically as additional information and new immunizing agents become available. Consequently, health care providers should update their knowledge at least annually. The best source of information regarding current recommendations is the Centers for Disease Control and Prevention (CDC), whose headquarters are in Atlanta, Georgia (Internet address: http://www.cdc.gov).

The main source of CDC recommendations is the Advisory Committee on Immunization Practices (ACIP, accessible at www.cdc.gov/nip/acip), which consists of 15 experts appointed by the Secretary of the U.S. Department of Health and Human Services to advise the Secretary, the Assistant Secretary for Health, and the CDC on strategies to prevent vaccine-preventable diseases. Other sources of information include the American Academy of Pediatrics (accessible at www.aap.org) and the American Academy of Family Physicians (accessible...
### Drugs at a Glance: Immune Serums for Passive Immunity

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cytomegalovirus immune globulin, IV, human (CMV-IGIV) (CytoGam)</strong></td>
<td>Contains antibodies against CMV</td>
<td>Treat CMV infection in renal, liver, and bone marrow transplant recipients</td>
<td>Post-transplantation, IV infusion, 150 mg/kg within 72 h, then 100–150 mg/kg at 2, 4, 6, and 8 wk, then 50–100 mg/kg at 12 and 16 wk</td>
</tr>
<tr>
<td><strong>Hepatitis B immune globulin, human (H-BIG, BayHep B, Nabi-HB)</strong></td>
<td>A solution of immunoglobulins that contains antibodies to hepatitis B surface antigen (HBsAg)</td>
<td>To prevent hepatitis after exposure. Neonates born to HBsAg positive or unknown status mothers are given HBIG and the first dose of hepatitis B vaccine within 12 h of birth.</td>
<td>Adults and children: IM, 0.06 mL/kg (usual adult dose is 3–5 mL) as soon as possible after exposure, preferably within 7 d. Repeat dose in 1 mo.</td>
</tr>
<tr>
<td><strong>Immune globulin (human) (IG; IGIM) (BayGam)</strong></td>
<td>Given IM only</td>
<td>To decrease the severity of hepatitis A, measles, and varicella after exposure</td>
<td>Adults and children: exposure to hepatitis A, IM, 0.02 mL/kg Exposure to measles, IM, 0.25 mL/kg given within 6 d of exposure Exposure to varicella, IM, 0.6–1.2 mL/kg Exposure to rubella (pregnant women only), IM, 0.55 mL/kg Immunoglobulin deficiency, IM, 1.3 mL/kg initially, then 0.6 mL/kg every 3–4 wk</td>
</tr>
<tr>
<td><strong>Immune globulin IV (IGIV) (Gamimune N, Gammagard, GammaP IV, Iveegam, Polygam S/D, Panglobulin, Sandoglobulin, Venoglobulin-S)</strong></td>
<td>Given IV only</td>
<td>To treat immunoglobulin deficiency Adjunct to antibiotics in severe bacterial infections and burns To lessen possibility of fetal damage in pregnant women exposed to rubella virus (however, routine use in early pregnancy is not recommended)</td>
<td>Gamimune: IV infusion, 100–200 mg/kg once a month. May be given more often or increased to 400 mg/kg if clinical response or serum level of IgG is insufficient. ITP, IV infusion, 400 mg/kg daily for 5 consecutive d</td>
</tr>
<tr>
<td><strong>Rabies immune globulin (human) (Hyperab, Imogam)</strong></td>
<td>Gamma globulin obtained from plasma of people hyperimmunized with rabies vaccine Not useful in treatment of clinical rabies infection</td>
<td>Postexposure prevention of rabies, in conjunction with rabies vaccine</td>
<td>Adults and children: IM, 20 units/kg (half the dose may be infiltrated around the wound) as soon as possible after possible exposure (eg, animal bite)</td>
</tr>
<tr>
<td><strong>Respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV) (RespiGam)</strong></td>
<td>Reduces severity of RSV illness and the incidence and duration of hospitalization in high-risk infants May cause fluid overload Not established as safe and effective in children with congenital heart disease</td>
<td>Prevention of serious RSV infections in high-risk children &lt;2 y (ie, those with bronchopulmonary dysplasia or history of premature birth [gestation of 35 wk or less]) Treatment of RSV lower respiratory tract infections in hospitalized infants and young children</td>
<td>Children: IV infusion via infusion pump, 1.5 mL/kg/h for 15 min then 3 mL/kg/h for 15 min, then 6 mL/kg/h until the infusion is completed, then once monthly, if tolerated. Maximum monthly dose, 750 mg/kg</td>
</tr>
</tbody>
</table>

(continued)
## Drugs at a Glance: Immune Serums for Passive Immunity (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rho(D) immune globulin (human)</strong> (Gamulin Rh, HypRho-D, RhoGAM)</td>
<td>Prepared from fractionated human plasma A sterile concentrated solution of specific immunoglobulin (IgG) containing anti-Rh(D)</td>
<td>To prevent sensitization in a subsequent pregnancy to the Rh(D) factor in an Rh-negative mother who has given birth to an Rh-positive infant by an Rh-positive father Also available in microdose form (MICRhoGAM) for the prevention of maternal Rh immunization after abortion or miscarriage up to 12 wk gestation</td>
<td>Obstetric use: inject contents of 1 vial IM for every 15 mL fetal packed red cell volume within 72 h after delivery, miscarriage, or abortion Consult package instructions for blood typing and drug administration procedures.</td>
</tr>
<tr>
<td><strong>Tetanus immune globulin (human)</strong> (Hyper-Tet)</td>
<td>Solution of globulins from plasma of people hyperimmunized with tetanus toxoid Tetanus toxoid (Td) should also be given to initiate active immunization if minor wound and &gt;10 y since Td, if major wound and &gt;5 y since Td, or if Td primary immunization series was incomplete</td>
<td>To prevent tetanus in clients with wounds possibly contaminated with <em>Clostridium tetani</em> and whose immunization history is uncertain or incomplete Treatment of tetanus infection</td>
<td>Adults and children: prophylaxis, IM, 250 units as a single dose Treatment of clinical disease IM 3000–6000 units in a single dose</td>
</tr>
<tr>
<td><strong>Varicella-zoster immune globulin (human)</strong> (VZIG) (Varicella-zoster immune globulin)</td>
<td>The globulin fraction of human plasma Antibodies last 1 mo or longer.</td>
<td>Postexposure to chickenpox or shingles, to prevent or decrease severity of infections in children &lt;15 y of age who have not been immunized or who are immunodeficient because of illness or drug therapy Infants born to mothers who develop varicella 5 d before or 2 d after delivery and premature infants &lt;28 wk gestation</td>
<td>IM 125 units/10 kg up to a maximum of 625 units within 48 h after exposure if possible; may be given up to 96 h after exposure. Minimal dose, 125 units</td>
</tr>
</tbody>
</table>

CMV, cytomegalovirus; IgG, immunoglobulin G; RSV, respiratory syncytial virus; HBsAg, hepatitis B surface antigen.

### CLIENT TEACHING GUIDELINES

#### Vaccinations

- Appropriate vaccinations should be maintained for adults as well as for children. Consult a health care provider periodically because recommendations and personal needs change fairly often.
- Maintain immunization records for yourself and your children. This is important because immunizations are often obtained at different places and over a period of years. Written, accurate, up-to-date records help to prevent diseases and unnecessary immunizations.
- If a physician recommends an immunization and you do not know whether you have had the immunization or the disease, it is probably safer to take the immunization than to risk having the disease. Immunization after a previous immunization or after having the disease usually is not harmful.
- To avoid rubella-induced abnormalities in fetal development, women of childbearing age who receive a rubella immunization must avoid becoming pregnant (ie, must use effective contraceptive methods) for 3 months.
- Women of childbearing age who receive a varicella immunization must avoid becoming pregnant (ie, must use effective contraceptive methods) for 3 months.
- Most vaccines cause fever and soreness at the site of injection. Acetaminophen (Tylenol) can be taken two to three times daily for 24 to 48 hours (by adults and children) to decrease fever and discomfort.
- After receiving varicella vaccine (to prevent chickenpox), avoid close contact with newborns, pregnant women, and anyone whose immune system is impaired. Also, use effective methods of contraception to avoid pregnancy for at least 3 months after immunization. Vaccinated people may transmit the vaccine virus to susceptible close contacts. Effects of the vaccine on the fetus are unknown, but fetal harm has occurred with natural varicella infection during pregnancy.
- After receiving a vaccine, stay in the area for approximately 30 minutes. If an allergic reaction is going to occur, it will usually do so within that time.
CHAPTER 43 IMMUNIZING AGENTS

at www.aafp.org). Local health departments can also be consulted on routine immunizations and those required for foreign travel. These sources can also provide information on new vaccine release, vaccine supply, and statements on usage of specific vaccines.

Storage of Vaccines

To maintain effectiveness of vaccines and other biologic preparations, the products must be stored properly. Most products require refrigeration at 2°C to 8°C (35.6°F to 46.4°F); some (eg, MMR) require protection from light. Manufacturers’ instructions for storage should be strictly followed.

Vaccine Shortages

During 2000 to 2002, approximately, shortages of several vaccines occurred. Some shortages were localized, some were widespread. These shortages interrupted the recommended schedules for many immunizations, especially those for routine immunizations of children. Long-term consequences of altered immunization schedules are largely unknown.

During the shortages, public health officials regularly issued updates on availability and priorities for usage among at-risk populations. One postulated reason for the shortages was the withdrawal of some manufacturers from vaccine production, probably because of relatively low profits and difficulties in complying with FDA regulations for manufacturing them. For example, a regulation requiring removal of thiomersal, a mercury-based preservative, resulted in the need for single-dose vials rather than multiple-dose vials and a smaller amount of marketable product from the same amount of vaccine. Mercury is toxic to humans, especially to infants.

Use in Children

Routine immunization of children has greatly reduced the prevalence of many common childhood diseases. However, many children are not being immunized appropriately, and diseases for which vaccines are available still occur. Standards of practice, aimed toward increasing immunizations, have been established and are supported by most pediatric provider groups (Box 43–1).

Guidelines for children whose immunizations begin in early infancy are given in the following list. Different schedules are recommended for children 1 to 5 years of age and for those older than 6 years of age who are being immunized for the first time.

BOX 43–1 STANDARDS FOR PEDIATRIC IMMUNIZATION PRACTICES

The following standards are recommended for use by all health professionals in the public and private sector who administer vaccines to or manage immunization services for infants and children.

- Standard 1. … Immunization services are readily available.
- Standard 2. … There are no barriers or unnecessary prerequisites to the receipt of vaccines.
- Standard 3. … Immunization services are available free or for a minimal fee.
- Standard 4. … Providers use all clinical encounters to screen and, when indicated, immunize children.
- Standard 5. … Providers educate parents and guardians about pediatric immunizations in general terms.
- Standard 6. … Providers question parents or guardians about contraindications and, before immunizing a child, inform them in specific terms about the risks and benefits of the immunizations their child is to receive.
- Standard 7. … Providers follow only true contraindications.
- Standard 8. … Providers administer simultaneously all vaccine doses for which a child is eligible at the time of each visit.
- Standard 9. … Providers use accurate and complete recording procedures.
- Standard 10. … Providers coschedule immunization appointments in conjunction with appointments for other child health services.
- Standard 11. … Providers report adverse events after immunization promptly, accurately, and completely.
- Standard 12. … Providers operate a tracking system.
- Standard 13. … Providers adhere to appropriate procedures for vaccine management.
- Standard 14. … Providers conduct semiannual audits to assess immunization coverage levels and to review immunization records in the patient population they serve.
- Standard 15. … Providers maintain up-to-date, easily retrievable medical protocols at all locations where vaccines are administered.
- Standard 17. … Vaccines are administered by properly trained individuals.
- Standard 18. … Providers receive ongoing education and training on current immunization recommendations.
1. Hepatitis B vaccine to all newborns with a second dose 4 weeks after the first dose, a third dose at least 8 weeks after the third dose or 16 weeks after the first dose. The last dose in the series (third or fourth dose) should not be given before 6 months of age. This schedule is for monovalent vaccine (hepatitis B vaccine only) and infants whose mothers were negative for HbsAg. If a combined hepatitis B, Haemophilus influenzae B vaccine is used (eg, the combination can be used for all but the first dose in newborns), the second dose should not be given before 6 weeks of age. Also, if the mother’s HbsAg status is positive or unknown, newborns should be given hepatitis B vaccine within 12 hours of birth, along with a dose of hepatitis B immune globulin (HBIG).

The annual “Recommended Childhood Immunization Schedule” of the American Academy of Pediatrics (AAP), the CDC Advisory Committee on Immunization Practices (ACIP), and the American Academy of Family Physicians (AAFP) is issued in January of each year. The 2002 schedule places more emphasis on giving hepatitis B vaccine to all infants before hospital discharge to “1) safeguard against maternal hepatitis B testing errors and test reporting failures; 2) protect neonates discharged to households in which hepatitis B chronic carriers other than the mother may reside; and 3) enhance the completion of the childhood immunization series.”

2. DTaP (diphtheria and tetanus toxoids, acellular pertussis vaccine) at 2 months, 4 months, 6 months, 15 to 18 months, and 4 to 6 years of age.

3. Haemophilus influenzae type b vaccine (Hib) at 2, 4, 6, and 12 to 15 months of age. There are three Hib conjugate vaccines approved for use in infants. If Pedvax-HIB or ComVax is given at 2 and 4 months of age, a dose at 6 months is not needed. DTaP/Hib combination products should not be used for primary immunization at 2, 4, or 6 months but can be used as boosters after any Hib vaccine.

4. Inactivated poliovirus vaccine (IPV) injection at 2 and 4 months of age, at 6 to 18 months, and at 4 to 6 years of age. Oral polio vaccine (OPV) is no longer recommended for use in the United States.

5. MMR at 12 to 15 months of age, as a combined vaccine. These vaccines are given later than DTaP and IPV because sufficient antibodies may not be produced until passive immunity acquired from the mother dissipates (at 12 to 15 months of age).

6. Pneumococcal 7-valent conjugate vaccine (Prevnar) to all children at 2 to 23 months of age and pneumococcal polyvalent vaccine (Pneumovax 23 or Pnu-Imune 23) for children 2 years and older with chronic illnesses that increase their risk for developing serious pneumococcal infections.

7. Varicella at 12 to 18 months and again at approximately 12 years of age.

8. For children with chronic illnesses such as asthma, heart disease, diabetes, and others, influenza vaccine is recommended annually after 6 months of age.

9. For children with human immunodeficiency virus (HIV) infection, live viral and bacterial vaccines (MMR, varicella, bacillus Calmette-Guérin) are contraindicated because they may cause the disease rather than prevent it. However, immunizations with DTaP, IPV, and Hib are recommended even though they may be less effective than in children with competent immune systems. Also recommended are annual administration of influenza vaccine for children over 6 months of age and one-time administration of pneumococcal vaccine for children older than 2 years of age.

Use in Healthy Adolescents, Young Adults, and Middle-Aged Adults

Adolescents who received all primary immunizations as infants and young children should have hepatitis B vaccine (if not received earlier) and a tetanus-diphtheria booster (adult type) at 14 to 16 years of age and every 10 years thereafter. Young adults who are health care workers, are sexually active, or belong to high-risk groups should have hepatitis B vaccine if not previously received; a tetanus-diphtheria booster every 10 years; MMR if not pregnant and rubella titer is inadequate or proof of immunization is unavailable; and varicella. In addition, young adults who are health care providers should have influenza vaccine annually. Middle-aged adults should maintain immunizations against tetanus; high-risk groups (eg, those with chronic illness) and health care providers should receive hepatitis B once (if not previously taken) and influenza vaccine annually.

Use in Older Adults

Annual influenza vaccine and one-time administration of pneumococcal vaccine at 65 years of age are recommended.

Nursing Notes: Ethical/Legal Dilemma

Jim and Sue bring in their newborn for a well-child examination. When you bring up the immunization schedule for infants, they voice concerns about the safety of some immunizations. They further explain that they read an article outlining several cases that involved serious complications (deaths and lifelong disabilities) after infant immunizations.

Reflect on:

• Additional information you might want to collect from the parents.
• How you feel as a health care provider when people select not to participate in widely accepted health practices.
• How you can help these parents make an informed decision.
• How you can support these parents in their decision, even if it is different from what you personally would choose.
for healthy older adults and those with chronic respiratory, cardiovascular, and other diseases. As with younger adults, immunization for most other diseases is recommended for older adults at high risk of exposure.

**Use in Immunosuppression**

Compared to healthy, immunocompetent individuals, the antibody response to immunization is usually adequate but reduced in immunosuppressed persons. With hepatitis A and B vaccines, larger doses may be required. Also, with hepatitis B vaccine, antibody concentrations should be measured and booster doses given if antibody concentrations fall.

Live bacterial (BCG, oral typhoid) or viral vaccines (MMR, varicella, yellow fever) should generally not be given to people with HIV infection, other immune diseases, or impaired immune systems due to leukemia, lymphoma, systemic corticosteroid or anticancer drugs, or radiation therapy. The bacteria or viruses may be able to reproduce and cause active infection in these people. Persons with asymptomatic HIV infection should receive inactivated vaccines. If an immunosuppressed person is exposed to measles or varicella, immune globulin or varicella-zoster immune globulin may be given for passive immunization.

For children with HIV infection, the AAP and ACIP recommend administration of most routine immunizations (DTaP, IPV, MMR, Hib) regardless of symptoms and administration of influenza and pneumococcal vaccines if symptomatic. Varicella vaccine is not recommended.

**Use in Cancer**

For patients with active malignant disease, live vaccines should not be given. Although killed vaccines and toxoids may be given, antibody production may be inadequate to provide immunity. When possible, patients should receive needed immunizations 2 weeks before or 3 months after immunosuppressive radiation or chemotherapy treatments. For example, patients with Hodgkin’s lymphoma who are more than 2 years old should be immunized with pneumococcal and Hib vaccines 10 to 14 days before therapy is started. In addition, patients who have not received chemotherapy for 3 to 4 weeks may have an adequate antibody response to influenza vaccine.

---

**NURSING ACTIONS**

**NURSING ACTIONS**

1. Administer accurately
   a. Read the package insert, and check the expiration date on all biologic products (eg, vaccines, toxoids, and human immune serums).

   b. Check the child’s temperature before giving diphtheria, tetanus, and pertussis (DTP) vaccine.

   c. Give DTP in the lateral thigh muscle of the infant.

   d. With measles, mumps, rubella (MMR) vaccine, use only the diluent provided by the manufacturer, and administer the vaccine subcutaneously (SC) within 8 h after reconstitution.

   e. Give hepatitis B vaccine IM in the anterolateral thigh of infants and young children and in the deltoid of older children and adults. Although the IM route is preferred, the drug can be given SC in people at high risk of bleeding from IM injections (eg, clients with hemophilia).

   f. Give IM human immune serum globulin with an 18- to 20-gauge needle, preferably in gluteal muscles. If the dose is 5 mL or more, divide it and inject it into two or more IM sites. Follow manufacturer’s instruction for preparation and administration of IV formulations.

   g. Aspirate carefully before IM or SC injection of any immunizing agent.

   Concentration, dosage, and administration of biologic products often vary with the products. Fresh products are preferred; avoid administration of expired products. Also, use reconstituted products within designated time limits because they are usually stable for only a few hours.

   If the temperature is elevated, do not give the vaccine.

   The vastus lateralis is the largest skeletal muscle mass in the infant and the preferred site for all intramuscular (IM) injections.

   The reconstituted preparation is stable for approximately 8 h. If not used within 8 h, discard the solution.

   Higher blood levels of protective antibodies are produced when the vaccine is given in the thigh or deltoid than when it is given in the buttocks, probably because of injection into fatty tissue rather than gluteal muscles.

   To promote absorption and minimize tissue irritation and other adverse reactions

   To avoid inadvertent IV administration and greatly increased risks of severe adverse effects

   (continued)
### Nursing Actions

| h. | Have aqueous epinephrine 1:1000 readily available before administering any vaccine. |
| k. | After administration of an immunizing agent in a clinic or office setting, have the client stay in the area for at least 30 min. |

2. **Observe for therapeutic effects**
   - a. Absence of diseases for which immunized
   - b. Decreased incidence and severity of symptoms when given to modify disease processes

3. **Observe for adverse effects**
   - a. General reactions
     - (1) Pain, tenderness, redness at injection sites
     - (2) Fever, malaise, muscle aches
     - (3) Anaphylaxis (cardiovascular collapse, shock, laryngeal edema, urticaria, angioneurotic edema, severe respiratory distress)
     - (4) Serum sickness (urticaria, fever, arthralgia, enlarged lymph nodes)
   - b. With DtaP
     - (1) Soreness, erythema, edema at injection sites
     - (2) Anorexia, nausea
     - (3) Severe fever, encephalopathy, seizures
   - c. With *Haemophilus influenzae* b vaccine—pain and erythema at injection sites
   - d. With hepatitis B vaccine
     - (1) Injection site soreness, erythema, induration
     - (2) Fever
     - (3) Anaphylaxis
   - e. With influenza vaccine
     - (1) Pain, induration, and erythema at injection sites
     - (2) Flu-like symptoms—chills, fever, malaise, muscle aches
     - (3) Febrile seizures

### Rationale/Explanations

- For immediate treatment of allergic reactions
- To observe for allergic reactions, which usually occur within 30 min

Most adverse effects are mild and transient. However, serious reactions occasionally occur. The risk of serious adverse effects from immunization is usually much smaller than the risk of the disease immunized against.

Adverse effects may be caused by the immunizing agent or by foreign protein incorporated with the immunizing agent (e.g., egg protein in viral vaccines grown in chick embryos).

Local tissue irritation may occur with injected immunizing agents. These adverse effects commonly occur with vaccines and toxoids. They rarely occur with human immune sera given for passive immunity.

Anaphylaxis occasionally occurs with immunizing agents. It is a medical emergency that requires immediate treatment with SC epinephrine (0.5 mL for adults; 0.01 mL/kg for children). Anaphylaxis is most likely to occur within 30 min after immunizing agents are injected.

Serum sickness is a delayed hypersensitivity reaction that occurs several days or weeks after an injection of serum. Treatment is symptomatic. Symptoms are usually relieved by acetaminophen, antihistamines, and corticosteroids.

These effects are common.

These are rare adverse reactions and less likely to occur with the acellular pertussis component now used. If they occur, they are thought to be caused by the pertussis antigen, and further administration of pertussis vaccine or DTP may be contraindicated.

These effects occur in about 25% of recipients but are usually mild and resolve within 24 hours.

Soreness and fever commonly occur and can be relieved by acetaminophen or ibuprofen. Anaphylaxis and other severe reactions rarely occur.

Adverse effects can be minimized by administering acetaminophen at the time of immunization and at 4, 8, and 12 h later. Injection site reactions and flu-like symptoms may start within 12 h after vaccination. Febrile seizures have been reported in children, but are uncommon.

(continued)
### NURSING ACTIONS

<table>
<thead>
<tr>
<th>f. With MMR vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Mild symptoms of measles—cough, fever up to 39.4°C (102°F), headache, malaise, photophobia, skin rash, sore throat</td>
</tr>
<tr>
<td>(2) Febrile seizures</td>
</tr>
<tr>
<td>(3) Arthralgia (joint pain)</td>
</tr>
<tr>
<td>(4) Anaphylaxis in recipients who are allergic to eggs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>g. With pneumococcal vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Local effects—soreness, induration, and erythema at injection sites</td>
</tr>
<tr>
<td>(2) Systemic effects—chills, fever, headache, muscle aches, nausea, photophobia, weakness</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>h. With polio vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Soreness at injection sites</td>
</tr>
<tr>
<td>(2) Fever</td>
</tr>
<tr>
<td>(3) Anaphylaxis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>i. With varicella vaccine</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Early effects—transient soreness or erythema at injection sites</td>
</tr>
<tr>
<td>(2) Late effect—a mild, maculopapular skin rash with a few lesions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>j. With immune globulin intravenous (IGIV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>chills, dizziness, dyspnea, fever, flushing, headache, nausea, urticaria, vomiting, tightness in chest, pain in chest, hip or back</td>
</tr>
</tbody>
</table>

4. Observe for drug interactions

<table>
<thead>
<tr>
<th>a. Drugs that decrease effects of vaccines in general: immunosuppressants (eg, corticosteroids, antineoplastic drugs, phenytoin [Dilantin])</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>b. Drugs that decrease effects of measles and MMR vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Immunosuppressants</td>
</tr>
<tr>
<td>(2) Immune globulins (eg, RIG, RSV-IGIV, VZIG, IGIV)</td>
</tr>
</tbody>
</table>

### RATIONALE/EXPLANATION

These symptoms may occur 6–11 d after immunization.

These are rare, but more likely to occur in children <2 years of age. Joint pain has been reported in as many as 25% of adult females 2–6 wk after receiving rubella vaccine.

The measles and mumps viruses used in MMR vaccine are grown in chick embryo cell cultures. Recipients who are allergic to eggs should be observed for 90 min after the vaccine is injected. MMR vaccine should be given only in a setting where personnel and equipment are available to treat anaphylaxis.

Local effects occur in 40–90% of recipients; systemic effects occur less frequently.

Adverse effects are usually mild. Anaphylaxis rarely occurs. However, if it occurs within 24 h after administration of polio vaccine, no additional doses of the vaccine should be given.

Injection site reactions occur in 20–35% of recipients; a skin rash develops in a few (about 8%) recipients within a month. Those who develop the rash from the vaccine have milder symptoms of shorter duration than those who develop varicella naturally.

These effects occur in as many as 10% of recipients and are related to the rate of infusion. If they occur, the infusion should be stopped until the symptoms subside and restarted at a slower rate. The symptoms can also be prevented or minimized by pre-infusion administration of acetaminophen and diphenhydramine or a corticosteroid.

Vaccines may be contraindicated in clients receiving immunosuppressive drugs. These clients cannot produce sufficient amounts of antibodies for immunity and may develop the illness produced by the particular organism contained in the vaccine. The disease is most likely to occur with the live virus vaccines (measles, mumps, rubella). Similar effects occur when the client is receiving irradiation and phenytoin, an anticonvulsant drug that suppresses both cellular and humoral immune responses.

May decrease effectiveness of immunization; patients may remain susceptible to measles despite immunization.

To avoid inactivation of the attenuated virus, give measles or MMR vaccine at least 14–30 d before or 6–8 wk after the immune globulin. Alternatively, may check antibody titers or repeat the measles vaccine dose 3 mo after immune globulin administration.

(continued)
NURSING ACTIONS          RATIONALE/EXPLANATION

(3) Interferon
   c. Drugs that decrease effects of meningococcal vaccine
      (1) Measles vaccine
   d. With varicella vaccine, salicylates may increase risk of Reye’s syndrome.

May inhibit antibody response to the vaccine
These vaccines should be given at least 1 mo apart.
Aspirin and other salicylates should be avoided for 6 wk after vaccine administration because of potential Reye’s syndrome, which has been reported with salicylate use after natural varicella infection.

Nursing Notes: Apply Your Knowledge

Answer: Ask the patient how long ago she received a tetanus booster. Lifelong immunity is not provided for tetanus, necessitating booster injections every 10 years. Adults often do not keep good immunization records. If the patient is not absolutely sure she has had a recent booster injection, a tetanus immunization should be given. Tetanus is common with puncture wounds and can be lethal.

8. Why should live vaccines not be given to people whose immune systems are suppressed by drugs or diseases?

SELECTED REFERENCES

Hematopoietic and Immunostimulant Drugs

Objectives

**AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:**

1. Describe the goals and methods of enhancing hematopoietic and immune functions.
2. Discuss the use of hematopoietic agents in the treatment of anemia and thrombocytopenia.
3. Discuss the use of filgrastim and sargramostim in neutropenia and bone marrow transplantation.
4. Describe the adverse effects and nursing process implications of administering filgrastim and sargramostim.
5. Discuss interferons in terms of clinical uses, adverse effects, and nursing process implications.

Critical Thinking Scenario

Mrs. Reynolds, a 67-year-old who has had chronic renal failure for the last 7 years, is severely anemic. Her physician prescribes epoetin alfa (Epogen) to stimulate red blood cell production. You are responsible for teaching her about the drug, including subcutaneous administration.

Reflect on:

- Review why renal failure causes anemia and how Epogen works to increase red blood cell counts.
- What assessment data should you collect before teaching Mrs. Reynolds self-injection technique?
- How will you evaluate whether the Epogen is working? Consider decreased symptoms of anemia and expected changes in laboratory values.

OVERVIEW

Enhancing a person’s own body systems to fight infection and cancer is a concept that continues to evolve. Hematopoietic and immunostimulant drugs (also called biologic response modifiers) are given to restore normal function or increase the ability of the immune system to eliminate potentially harmful invaders. Those available for therapeutic use include colony-stimulating factors (CSF; eg, darbepoetin alfa, epoetin alfa, filgrastim, sargramostim), several interferons, and two interleukins. These drugs, which are the primary focus of this chapter, are described in the following sections and in Drugs at a Glance: Hematopoietic and Immunostimulant Agents.

Bacillus Calmette-Guérin (BCG) vaccine, used in the treatment of bladder cancer, is also discussed. Other drugs with immunostimulant properties are discussed in other chapters. These include traditional immunizing agents (see Chap. 43); levamisole (Ergamisol), which restores functions of macrophages and T cells and is used with fluorouracil in the treatment of intestinal cancer (see Chap. 64); and antiviral drugs used in the treatment of acquired immunodeficiency syndrome (AIDS) (see Chap. 39). Levamisole and antiviral drugs are more accurately called immunorestoratives because they help a compromised immune system regain normal function rather than stimulating “supranormal” function. In AIDS, the human immunodeficiency virus (HIV) causes immune system malfunction, so the antiviral drugs indirectly improve immunologic function.

GENERAL CHARACTERISTICS OF HEMATOPOIETIC AND IMMUNOSTIMULANT DRUGS

1. Most hematopoietic and immunostimulant drugs are facsimiles of natural endogenous protein substances called cytokines (see Chap. 42). Techniques of molecule-
### Drugs at a Glance: Hematopoietic and Immunostimulant Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hematopoietic Agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Darbepoetin alfa (Aranesp)</td>
<td>Anemia associated with chronic renal failure (CRF)</td>
<td>SC, IV, 0.45 mcg/kg once weekly, adjusted to achieve and maintain hemoglobin level no greater than 12 g/dL</td>
<td>Main advantage over epoetin alfa is that it is given less often</td>
</tr>
<tr>
<td>Epoetin alfa (Epogen, Procrit)</td>
<td>Prevention and treatment of anemia associated with CRF, zidovudine therapy, or anticancer chemotherapy; Reduction of blood transfusions in anemic clients undergoing elective noncardiac, nonvascular surgery</td>
<td>CRF IV, SC 50–100 units/kg 3 times weekly to achieve or maintain a hematocrit of 30%–36%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Most patients need an iron supplement during epoetin alfa therapy.</td>
</tr>
</tbody>
</table>

| **Colony-Stimulating Factors (CSF)** | | | |
| Filgrastim (G-CSF) (Neupogen) | To prevent infection in patients with neutropenia induced by cancer chemotherapy or bone marrow transplantation; To mobilize stem cells from bone marrow to peripheral blood, where they can be collected and reinfused after chemotherapy that depresses bone marrow function; To treat severe chronic neutropenia | Myelosuppressive chemotherapy, SC injection, IV infusion over 15–30 min, or continuous SC or IV infusion 5 mg/kg/d, up to 2 wk until ANC reaches 10,000/mm³ |
| | | Bone marrow transplantation, IV or SC infusion, 10 mcg/kg/d initially, then titrated according to neutrophil count (5 mcg/kg/d if ANC >1000/mm³ for 3 consecutive days; stop drug if >1000/mm³ for 6 d. If ANC drops below 1000/mm³, restart filgrastim at 5 mcg/kg/d). |
| | | Collection of peripheral stem cells, SC, 10 mcg/kg/d for 6–7 d, with collection on the last 3 d of drug administration |
| | | Severe, chronic neutropenia, SC 5 or 6 mcg/kg, once or twice daily, depending on clinical response and ANC |
| | | Do not give 24 h before or after a dose of cytotoxic chemotherapy. |
| | | Dosage may be increased if indicated by neutrophil count. |
| | | Stop the drug if ANC exceeds 10,000/mm³. |
| Pegfilgrastim (Neulasta) | To prevent infection in patients with neutropenia induced by cancer chemotherapy | SC 6 mg once per chemotherapy cycle. Do not give between 14 d before and 24 h after cytotoxic chemotherapy. |
| Sargramostim (GM-CSF) (Leukine) | After bone marrow transplantation to promote bone marrow function or to treat graft failure or delayed function; Mobilization of stem cells in peripheral blood so they can be collected. | Bone marrow reconstitution, IV infusion over 2 h, 250 mcg/m²/d, starting 2–4 h after bone marrow infusion, and continuing for 21 d |
| | | Graft failure or delay, IV infusion over 2 h, 250 mcg/m²/d, for 14 d |
| | | Course of treatment may be repeated after 7 d off therapy if engraftment has not occurred. |
| | | Mobilization of stem cells, SC or IV over 24 h, 250 mcg/m²/d |
## Interleukins

### Aldesleukin (interleukin-2) (Proleukin)
- **Indications for Use**: Metastatic renal cell carcinoma in adults *
- **Routes and Dosage Ranges**: IV infusion over 15 min 600,000 IU or 0.037 mg/kg q8h for 14 doses: after 9 d, repeat q8h for 14 doses
- **Comments**: Adverse reactions are common and may be serious or fatal. Drug administration must be interrupted or stopped for serious toxicity. Start 6–24 h after completion of chemotherapy and continue until postnadir platelet count is 50,000 cells/mm³ or higher, usually 10–21 d. Discontinue oprelvekin at least 2 d before the next cycle of chemotherapy.

### Oprelvekin (Neumega)
- **Indications for Use**: Prevention of severe thrombocytopenia with antineoplastic chemotherapy that depresses bone marrow function in clients with nonmyeloid malignancies
- **Routes and Dosage Ranges**: SC, 50 mcg/kg once daily

## Interferons

### Interferon alfa-2a (Roferon-A)
- **Indications for Use**: Chronic hepatitis C in adults *
- **Routes and Dosage Ranges**: Chronic hepatitis C SC, IM 3 million IU 3 times weekly for 48–52 wk
- **Comments**: Give SC only when using a prefilled syringe; SC recommended for patients with platelet counts <50,000/mm³ or who are at risk for bleeding

### Interferon alfa-2b (Intron A)
- **Indications for Use**: Chronic hepatitis B SC, IM, 5 million IU daily or 10 million IU 3 times weekly (total of 30–35 million IU per wk) for 16 wk
- **Routes and Dosage Ranges**: Chronic hepatitis B SC, IM, 5 million IU daily or 10 million IU 3 times weekly (total of 30–35 million IU per wk) for 16 wk
- **Comments**: Omit single doses or reduce dosage by 50% if severe adverse reactions occur.
lar biology are used to delineate the type and sequence of amino acids and to identify the genes responsible for producing the substances. These genes are then inserted into bacteria (usually Escherichia coli) or yeasts capable of producing the substances exogenously. Cloning of the genes that encode interferons, for example, has made it possible to produce large amounts of these substances for research and clinical use. Some interferons (eg, interferon beta-1b) are synthetic versions of deoxyribonucleic acid (DNA) recombinant products.

2. Despite extensive research efforts, relatively few cytokine-like drugs are available for clinical use. One of the difficulties in using cytokines is maintaining effective dose levels over treatment periods of weeks or months. During a “natural” immune response, interacting body cells produce adequate concentrations of cytokines around target cells. However, achieving adequate local concentrations from injected, exogenous cytokines is difficult.

A second difficulty is that some of the drugs have a short half-life and require frequent administration. Some newer formulations (eg, darbepoetin alfa, pegfilgrastim, and peginterferon alfa 2b) can be given less often. An additional consideration is that the substances are powerful biologic response modifiers and they can cause unanticipated adverse effects.

3. Exogenous drug preparations have the same mechanisms of action as the endogenous products described in Chapter 42. Thus, CSF bind to receptors on the cell surfaces of immature blood cells in the bone marrow and increase the number, maturity, and functional ability of the cells. Interferons, called alfa, beta, or gamma according to specific characteristics, also bind to specific cell surface receptors and alter intracellular activities. In viral infections, they induce enzymes that inhibit protein synthesis and degrade viral ribonucleic acid. As a result, viruses are less able to enter uninfected cells, reproduce, and release new viruses.
In addition to their antiviral effects, interferons also have antiproliferative and immunoregulatory activities. They can increase expression of major histocompatibility complex (MHC) molecules, augment the activity of natural killer (NK) cells, increase the effectiveness of antigen presenting cells in inducing the proliferation of cytotoxic T cells, aid the attachment of cytotoxic T cells to target cells, and inhibit angiogenesis. Because of these characteristics, the interferons are used mainly to treat viral infections and cancers. In chronic hepatitis C, interferon improves liver function in approximately 50% of clients, but relapse often occurs when drug therapy is stopped. In multiple sclerosis, the action of interferon beta is unknown. The drugs are being investigated for additional uses. Systemic interferons are usually well absorbed, widely distributed, and eliminated primarily by the kidneys.

4. In cancer, the exact mechanisms by which interferons and interleukins exert antineoplastic effects are unknown. However, their immunostimulant effects are thought to enhance activities of immune cells (ie, NK cells, T cells, B cells, and macrophages), induce tumor cell antigens (which make tumor cells more easily recognized by immune cells), or alter the expression of oncogenes (genes that can cause a normal cell to change to a cancer cell). BCG vaccine is thought to act against cancer of the urinary bladder by stimulating the immune system and eliciting a local inflammatory response, but its exact mechanism of action is unknown.

5. They are given by subcutaneous (SC) or intravenous (IV) injection because they are proteins that would be destroyed by digestive enzymes if given orally. Darbepoetin alfa (Aranesp), epoetin alfa (Epogen), filgrastim (Neupogen), oprelvekin (Neumega), and the interferons are often self- or caregiver-administered to ambulatory clients.

6. They may produce adverse effects so that clients do not feel better when taking one of these drugs.

7. The combination of injections and adverse effects may lead to noncompliance in taking the drugs as prescribed.

8. All of the drugs are contraindicated for use in clients who have had organ transplantation or those with serious cardiovascular disease (eg, an abnormal thallium stress test, which reflects coronary artery disease) or serious pulmonary disease (eg, abnormal pulmonary function tests). It is contraindicated for repeated courses of therapy in clients who have had serious toxicity during earlier courses, including the following:

- Cardiac—dysrhythmias unresponsive to treatment or ventricular tachycardia lasting for five beats or more, recurrent episodes of chest pain with electrocardiographic evidence of angina or myocardial infarction, pericardial tamponade
- Gastrointestinal—bleeding requiring surgery; bowel ischemia or perforation
- Respiratory—intubation required longer than 72 hours
- Central nervous system—coma or toxic psychosis lasting longer than 72 hours; repetitive or hard to control seizures

Filgrastim and sargramostim are drug formulations of granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF), respectively, produced by recombinant DNA technology. They are used to stimulate blood cell production by the bone marrow in clients with bone marrow transplantation or chemotherapy-induced neutropenia. They can greatly reduce the incidence and severity of infections. GM-CSF is also being used to promote growth of blood vessels (angiogenesis) in clients with ischemic heart disease. The drug apparently promotes growth of arterioles around blocked areas in coronary arteries. It may be more effective than drugs that stimulate capillary growth, because arterioles are larger and can carry more blood.

**Characteristics of Individual Drugs**

**Hematopoietic Agents**

Darbepoetin alfa and epoetin alfa are drug formulations of erythropoietin, a hormone from the kidney that stimulates bone marrow production of red blood cells. They are used to prevent or treat anemia in several conditions. In chronic renal failure, epoetin has a serum half-life of 4 to 13 hours and produces detectable blood levels of erythropoietin within 24 hours with IV administration. With SC administration, peak serum levels occur within 5 to 24 hours and then decline slowly. Darbepoetin has a much longer half-life (about 49 hours) in patients with chronic renal failure, and peak plasma levels occur in about 34 hours.

**Interleukins**

Aldesleukin (Proleukin) is a recombinant DNA version of interleukin-2 (IL-2). It differs from native IL-2 but has the same biologic activity (eg, activates cellular immunity; produces tumor necrosis factor, IL-1, and interferon gamma; and inhibits tumor growth). It is used to treat metastatic renal cell carcinoma and melanoma and is being investigated for use in other types of cancer. The drug is given by IV infusion, after which it is rapidly distributed to extravascular, extracellular spaces and eliminated by metabolism in the kidneys.

Aldesleukin is contraindicated for initial use in clients who have had organ transplantation or those with serious cardiovascular disease (eg, an abnormal thallium stress test, which reflects coronary artery disease) or serious pulmonary disease (eg, abnormal pulmonary function tests). It is contraindicated for repeated courses of therapy in clients who had serious toxicity during earlier courses, including the following:

- Cardiac—dysrhythmias unresponsive to treatment or ventricular tachycardia lasting for five beats or more, recurrent episodes of chest pain with electrocardiographic evidence of angina or myocardial infarction, pericardial tamponade
- Gastrointestinal—bleeding requiring surgery; bowel ischemia or perforation
- Respiratory—intubation required longer than 72 hours
- Central nervous system—coma or toxic psychosis lasting longer than 72 hours; repetitive or hard to control seizures

**Interferons**

Interferons alfa-2a and alfa-2b, structurally the same except for one amino acid, are used to treat hairy cell leukemia (a type
of B-cell leukemia known as hairy cell because the cells are covered with fine hair-like structures) and Kaposi’s sarcoma associated with AIDS. Interferon alfa-2b is also approved for the treatment of viral infections, such as chronic hepatitis and condylomata acuminata (genital warts associated with infection by human papillomavirus). Interferon alfa-n1 and alfacon-1 are newer drugs approved for treatment of chronic hepatitis C, a condition that can lead to liver failure. Interferon gamma is used to treat chronic granulomatous disease, which involves impaired phagocytosis of ingested microbes and frequent infections. Drug therapy reduces the incidence and severity of infections. Interferon beta is used for multiple sclerosis, an autoimmune neurologic disorder in which the drug reduces progression of neurologic dysfunction, prolongs remissions, and reduces the severity of relapses.

Interferons are being investigated for additional uses, especially in cancer and viral infections, including AIDS. In cancer, for example, interferon alfa has demonstrated antitumor effects in non-Hodgkin’s lymphoma, chronic myelogenous leukemia, multiple myeloma, malignant melanoma, and renal cell carcinoma. Common solid tumors of the breast, lung, and colon are unresponsive. Interferon alfa-2b is being combined with ribavirin, another antiviral drug, to increase effectiveness in chronic hepatitis C. In condylomata, interferon alfa-2b is injected directly into the lesions for several weeks, and most of the lesions disappear completely. In chronic myelogenous leukemia (CML), 70% response rates have been reported and some patients undergo complete remission.

Although the main adverse effects of interferons are flulike symptoms, these drugs may also cause or aggravate serious, life-threatening neuropsychiatric (including depression and some reports of suicide), autoimmune, ischemic, and infectious disorders. These effects usually resolve when the drug is discontinued but some may persist for months. Patients receiving the drugs should be closely monitored through clinical and laboratory examinations.

Bacillus Calmette-Guérin

Bacillus Calmette-Guérin vaccine is a suspension of attenuated Mycobacterium bovis, long used as an immunizing agent against tuberculosis. The drug’s immunostimulant properties stem from its ability to stimulate cell-mediated immunity. It is used as a topical agent to treat superficial cancers of the urinary bladder, in which approximately 80% of clients achieve a therapeutic response. BCG is contraindicated in immunosuppressed clients because the live tubercular organisms may cause tuberculosis in this high-risk population.

**Nursing Process**

**Assessment**

- Assess the client’s status in relation to conditions for which hematopoietic and immunostimulant drugs are used (eg, infection, neutropenia, cancer).

- Assess nutritional status, including appetite and weight.
- Assess functional abilities in relation to activities of daily living (ADLs).
- Assess adequacy of support systems for outpatients (eg, transportation for clinic visits).
- Assess ability and attitude toward planned drug therapy and associated monitoring and follow-up.
- Assess coping mechanisms of client and significant others in stressful situations.
- Assess client for factors predisposing to infection (eg, skin integrity, invasive devices, cigarette smoking).
- Assess environment for factors predisposing to infection (eg, family or health care providers with infections).
- Assess baseline values of laboratory and other diagnostic test reports to aid monitoring of responses to hematopoietic and immunostimulant drug therapy.

**Nursing Diagnoses**

- Risk for Injury: Infection related to drug-induced neutropenia, immunosuppression, malnutrition, chronic disease; bleeding related to anemia or thrombocytopenia
- Risk for Injury: Adverse drug effects
- Activity Intolerance related to weakness, fatigue from debilitating disease, or drug therapy
- Anxiety related to the diagnosis of cancer, hepatitis, multiple sclerosis, or HIV infection
- Deficient Knowledge: Disease process; hematopoietic and immunostimulant drug therapy

**Planning/Goals**

**The client will:**

- Participate in interventions to prevent or decrease infection
- Remain afebrile during immunostimulant therapy
- Experience increased immunocompetence as indicated by increased white blood cell (WBC) count (if initially leukopenic) or tumor regression
- Avoid preventable infections
- Experience relief or reduction of disease symptoms
- Maintain independence in ADLs when able; be assisted appropriately when unable
- Maintain adequate levels of nutrition and fluids, rest and sleep, and exercise
- Maintain or increase appetite and weight if initially anorexic and underweight
- Learn to self-administer medications accurately when indicated

**Interventions**

- Practice and promote good hand washing techniques by clients and all others in contact with the client.
- Use sterile technique for all injections, IV site care, wound dressing changes, and any other invasive diagnostic or therapeutic measures.
- Screen staff and visitors for signs and symptoms of infection; if infection is noted, do not allow contact with the client.
- Allow clients to participate in self-care and decision making when possible and appropriate.
Use isolation procedures when indicated, usually when the neutrophil count is below 500/mm³.

Promote adequate nutrition, with nutritious fluids, supplements, and snacks when indicated.

Promote adequate rest, sleep, and exercise (eg, schedule frequent rest periods, avoid interrupting sleep when possible, individualize exercise or activity according to the client’s condition).

Inform clients about diagnostic test results, planned changes in therapeutic regimens, and evidence of progress.

Allow family members or significant others to visit clients when feasible.

Monitor complete blood count (CBC) and other diagnostic test reports for normal or abnormal values.

Schedule and coordinate drug administration, diagnostic tests, and other elements of care to conserve clients’ energy and decrease stress.

Consult other health care providers (eg, physician, dietitian, social worker) on the client’s behalf when indicated.

Assist clients to learn ways to prevent or reduce the incidence of infections (eg, meticulous personal hygiene, avoiding contact with infected people).

Assist clients to learn ways to enhance immune mechanisms and other body defenses by healthy lifestyle habits, such as a nutritious diet, adequate rest and sleep, and avoidance of tobacco and alcohol.

Assist clients or caregivers in learning how to prepare and inject darbepoetin alfa, epoetin alfa, filgrastim, an interferon, or oprelvekin, when indicated.

Evaluation

Determine the number and type of infections that have occurred in neutropenic clients.

Compare current CBC reports with baseline values for changes toward normal levels (eg, WBC count 5000 to 10,000/mm³).

Compare weight and nutritional status with baseline values for maintenance or improvement.

Observe and interview for decreased numbers or severity of disease symptoms.

Observe for increased energy and ability to participate in ADLs.

Observe and interview outpatients regarding compliance with follow-up care.

Observe and interview regarding the mental and emotional status of the client and family members.

**PRINCIPLES OF THERAPY**

**Inpatient Versus Outpatient Settings for Drug Administration**

Choosing inpatient or outpatient administration of hematopoietic and immunostimulant therapy depends on many factors, including the condition of the client, route of drug administration, expected duration of therapy, and potential severity of adverse drug reactions. Most of these drugs are proteins, and anaphylactic or other allergic reactions may occur, especially with parenteral administration. Thus, initial doses should be given where appropriate supplies and personnel are available to treat allergic reactions.

Darbepoetin alfa, epoetin alfa, filgrastim, interferons, and oprelvekin may be taken at home if the client or a caregiver can prepare and inject the medication. Because severe, life-threatening adverse effects may occur with high-dose aldesleukin, this drug should be given only in a hospital with intensive care facilities, under the supervision of health care providers experienced in critical care.

**Dosage**

With darbepoetin alfa and epoetin alfa, dosage is adjusted according to response. With darbepoetin, dosage is adjusted to achieve and maintain a hemoglobin value of approximately 12 g/dL. With epoetin, dosage is adjusted to achieve and maintain a hematocrit value of 30% to 36%. Dosage should be reduced when the hematocrit approaches 36% or increases >4 points in any 2-week period. Dosage should be increased if hematocrit does not increase by 5 to 6 points after 8 weeks of drug therapy and is below the recommended range. When doses are changed, measurable differences in hematocrit do not occur for 2 to 6 weeks because of the time required for maturation of RBCs and their release into the circulation. Thus, the hematocrit should be checked twice weekly for at least 2 to 6 weeks after any dosage change. In general, dose adjustments should not be made more often than once monthly.

Optimal dosages for interferons and aldesleukin have not been established. For clients who experience severe adverse reactions with interferon alfa, dosage should be reduced by 50% or administration stopped until the reaction subsides. For clients who experience severe reactions to aldesleukin, dosage reduction is not recommended. Instead, one or more doses should be withheld, or the drug should be discontinued. Withhold the dose for cardiac arrhythmias, hypotension, chest pain, agitation or confusion, sepsis, renal impairment (oliguria, increased serum creatinine), hepatic impairment (encephalopathy, increasing ascites), positive stool guaiac test, or severe dermatitis, until the condition is resolved. The drug should be discontinued for the occurrence of any of the conditions listed as contraindications for repeat courses of aldesleukin therapy (eg, sustained ventricular tachycardia, angina, myocardial infarction, pulmonary intubation, renal dialysis, coma, and GI bleeding).

**Laboratory Monitoring**

With darbepoetin and epoetin, iron stores (eg, transferrin saturation and serum ferritin) should be measured before and periodically during treatment. Virtually all patients eventually require supplemental iron. Check hemoglobin...
In cancer chemotherapy, many therapeutic drugs cause bone marrow depression and result in anemia and neutropenia. Neutropenic clients are at high risk for development of infections, often from the normal microbial flora of the client’s body or environmental microorganisms, and they may involve bacteria, fungi, and viruses. The client is most vulnerable to infection when the neutrophil count falls below 500/mm³. Filgrastim helps to prevent infection by reducing the incidence, severity, and duration of neutropenia associated with several chemotherapy regimens. Most clients taking filgrastim have fewer days of fever, infection, and antimicrobial drug therapy. In addition, by promoting bone marrow recovery after a course of cytotoxic antineoplastic drugs, filgrastim also may allow higher doses or more timely administration of subsequent antitumor drugs.

When filgrastim is given to prevent infection in neutropenic clients with cancer, the drug should be started at least 24 hours after the last dose of the antineoplastic agent. It should then be continued during the period of maximum bone marrow suppression and the lowest neutrophil count (nadir) and during bone marrow recovery. CBC and platelet counts should be performed twice weekly during therapy, and the drug should be stopped if the neutrophil count exceeds 10,000/mm³. When sargramostim is given to clients with cancer who have had bone marrow transplantation, the drug should be started 2 to 4 hours after the bone marrow infusion and at least 24 hours after the last dose of antineo-

### Uses in Clients With Cancer

#### Colony-Stimulating Factors

Filgrastim and sargramostim are used to restore, promote, or accelerate bone marrow function in clients with cancer who are undergoing chemotherapy or bone marrow transplantation. In cancer chemotherapy, many therapeutic drugs cause bone marrow depression and result in anemia and neutropenia. Neutropenic clients are at high risk for development of infections, often from the normal microbial flora of the client’s body or environmental microorganisms, and they may involve bacteria, fungi, and viruses. The client is most vulnerable to infection when the neutrophil count falls below 500/mm³. Filgrastim helps to prevent infection by reducing the incidence, severity, and duration of neutropenia associated with several chemotherapy regimens. Most clients taking filgrastim have fewer days of fever, infection, and antimicrobial drug therapy. In addition, by promoting bone marrow recovery after a course of cytotoxic antineoplastic drugs, filgrastim also may allow higher doses or more timely administration of subsequent antitumor drugs.

When filgrastim is given to prevent infection in neutropenic clients with cancer, the drug should be started at least 24 hours after the last dose of the antineoplastic agent. It should then be continued during the period of maximum bone marrow suppression and the lowest neutrophil count (nadir) and during bone marrow recovery. CBC and platelet counts should be performed twice weekly during therapy, and the drug should be stopped if the neutrophil count exceeds 10,000/mm³. When sargramostim is given to clients with cancer who have had bone marrow transplantation, the drug should be started 2 to 4 hours after the bone marrow infusion and at least 24 hours after the last dose of antineo-
plastic chemotherapy or 12 hours after the last radiotherapy treatment. CBC should be done twice weekly during therapy, and the neutrophil count should not exceed approximately 20,000/mm³.

Epoetin alfa may be used to prevent or treat anemia in clients with cancer. An adequate intake of iron is required for drug effectiveness. In addition to dietary sources, a supplement is usually necessary.

**Interleukins**

Aldesleukin is a highly toxic drug and contraindicated in clients with preexisting serious cardiovascular or pulmonary impairment. Therefore, when it is used to treat metastatic renal cell carcinoma, clients must be carefully selected, evaluated, and monitored. The drug is most effective in clients with prior nephrectomy and low tumor burden. Still, only approximately 15% to 25% of clients experience therapeutic responses.

Measures to decrease toxicity are also needed. One strategy is to give the drug by continuous infusion rather than bolus injection. Another is to use cancer-fighting T cells found within tumors. These T cells, called tumor-infiltrating lymphocytes, can be removed from the tumors, incubated in vitro with aldesleukin, and reinjected into the client. Tumor-infiltrating lymphocytes return to the tumor and are more active in killing malignant cells than untreated T cells. This technique allows lower and therefore less toxic doses of aldesleukin. Corticosteroids can also decrease toxicity, but their use is not recommended because they also decrease the antineoplastic effects of aldesleukin.

In addition, any preexisting infection should be treated and resolved before initiating aldesleukin therapy because the drug may impair neutrophil function and increase the risk of infections, including sepsis and bacterial endocarditis. Clients with indwelling central IV devices should be given prophylactic antibacterials that are effective against Staphylococcus aureus (eg, nafcillin, vancomycin).

Oprelvekin may be used to prevent or treat thrombocytopenia and risks of bleeding in clients with cancer.

**Interferons**

In hairy cell leukemia, interferons normalize WBC counts in 70% to 90% of clients, with or without prior splenectomy. Drug therapy must be continued indefinitely to avoid relapse, which usually develops rapidly after the drug is discontinued.

In AIDS-related Kaposi’s sarcoma, larger doses are required than in other clinical uses, with resultant increases in toxicity. Interferon alfa is recommended for clients with CD4 cell counts higher than 200/mL (CD4 cells are the helper T cells attacked by the AIDS virus), who have no systemic symptoms, and who have had no opportunistic infections. Approximately 40% of these clients achieve a therapeutic response that lasts 1 to 2 years. In addition to antineoplastic effects, data indicate that viral replication is suppressed in responding clients. Research studies suggest that a combination of interferon alfa and zidovudine, an antiviral drug used in the treatment of AIDS, may have synergistic antineoplastic and antiviral effects. Lower doses of interferon must be used when the drug is combined with zidovudine, to minimize neutropenia.

**Bacillus Calmette-Guérin**

Bacillus Calmette-Guérin, when instilled into the urinary bladder of clients with superficial bladder cancer, causes remission in up to 82% of clients for an average of 4 years. Early, successful treatment of carcinoma in situ also prevents development of invasive bladder cancer. A specific protocol has been developed for administration of BCG solution, and it should be followed accurately.

**Use in Bone Marrow and Stem Cell Transplantation**

Filgrastim and sargramostim are used to treat clients who undergo bone marrow transplantation for Hodgkin’s disease, non-Hodgkin’s lymphoma, or acute lymphoblastic leukemia. Before receiving a bone marrow transplant, the client’s immune system is suppressed by anticancer drugs or irradiation. After transplantation, it takes 2 to 4 weeks for the engrafted bone marrow cells to mature and begin producing blood cells. During this time, the client has virtually no functioning granulocytes and is at high risk for infection. Sargramostim promotes engraftment and function of the transplanted bone marrow, thereby decreasing risks of infection. If the graft is successful, the granulocyte count starts to rise in approximately 2 weeks. Sargramostim also is used to treat graft failure.

In stem cell transplantation, filgrastim or sargramostim is used to stimulate the movement of hematopoietic stem cells from the bone marrow to circulating blood, where they can be readily collected (in a process called peripheral blood progenitor cell collection). Transplantation of large numbers of stem cells can lead to more rapid engraftment and recovery, with less risk of transplant failure and complications.

**Use in Children**

There has been limited experience with hematopoietic and immunostimulant drugs in children (younger than 18 years of age), and the drugs’ safety and effectiveness have not been
established. *Filgrastim* and *sargramostim* have been used in children with therapeutic and adverse effects similar to those in adults. In clinical trials, filgrastim produced a greater incidence of subclinical spleen enlargement in children than in adults, but whether this affects growth and development or has other long-term consequences is unknown. *Oprelvekin* has been given to a few children with adverse effects similar to those observed in adults. Reports indicate that tachycardia occurs more often in children and that larger doses are needed (eg, a dose of 75 to 100 mcg/kg in children produces similar plasma levels to a dose of 50 mcg/kg in adults). Long-term effects on growth and development are unknown.

Little information is available about the use of interferons in children. *Interferon alfacon-1* (Infergen) is not recommended for use in children.

### Use in Older Adults

In general, hematopoietic and immunostimulant agents have the same uses and responses in older adults as in younger adults. As with many other drugs, older adults may be at greater risk of adverse effects, especially if large doses are used. *Oprelvekin* should be used with caution in clients with a history of or risk factors for atrial fibrillation or flutter; these arrhythmias occurred in approximately 10% of clients during clinical trials. In addition, older adults are more likely to have fluid retention, with resultant symptoms of peripheral edema, dyspnea on exertion, and dilutional anemia.

### Use in Renal Impairment

Except for darbepoetin alfa and epoetin alfa, which are used to treat anemia in clients with chronic renal failure, little information is available about the use of hematopoietic and immunostimulant drugs in clients with renal impairment. In some clients with preexisting renal impairment, sargramostim increased serum creatinine. Values declined to baseline levels when the drug was stopped or its dosage reduced. Renal function tests are recommended every 2 weeks in clients with preexisting impairment.

With aldesleukin, renal impairment occurs during therapy. This impairment may be increased if other nephrotoxic drugs are taken concomitantly. In addition, drug-induced renal impairment may delay elimination of other medications and increase risks of adverse effects.

### Use in Hepatic Impairment

In some clients with preexisting hepatic impairment, sargramostim increased serum bilirubin and liver enzymes. Values declined to baseline levels when the drug was stopped or its dosage reduced. Hepatic function tests are recommended every 2 weeks in clients with preexisting impairment.

With aldesleukin, hepatic impairment occurs during therapy. This impairment may be increased if other hepatotoxic drugs are taken concomitantly. In addition, drug-induced hepatic impairment may delay metabolism and elimination of other medications and increase risks of adverse effects.

Interferons may aggravate hepatic impairment. Interferons alfa-2b, alfacon-1, and alfa-n1 are contraindicated in clients with decompensated liver disease (ie, signs and symptoms such as jaundice, ascites, bleeding disorders, or decreased serum albumin), autoimmune hepatitis, a history of autoimmune disease, or post-transplantation immunosuppression. Worsening of liver disease, with jaundice, hepatic encephalopathy, hepatic failure, and death, has occurred in these clients. The drugs should be discontinued in clients with signs and symptoms of liver failure.

### Home Care

Darbepoetin alfa (Aranesp), epoetin alfa (Epogen), filgrastim (Neupogen, Neulasta), oprelvekin (Neumega), and the interferons are often self-administered or given by a caregiver to chronically ill clients. The home care nurse may need to teach clients or caregivers accurate drug preparation and injection techniques, as well as proper disposal of needles and syringes. Assistance may also be needed in obtaining appropriate laboratory tests (eg, CBC, platelet count, tests of renal or hepatic function) to monitor clients’ responses to the medications. Other interventions depend on the drug being taken. For example, epoetin alfa is not effective unless sufficient iron is present, and most clients need an iron supplement. When an iron preparation is prescribed, the home care nurse may need to emphasize the importance of taking it. With filgrastim, the nurse may need to help the client and family with techniques to reduce exposure to infection.
### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give darbepoetin alfa intravenously (IV) or subcutaneously (SC) once weekly</td>
<td>For hospitalized clients, the drugs may be prepared for administration in a pharmacy. When nurses prepare the drugs, they should consult the manufacturer’s instructions. Outpatients may be taught self-administration techniques.</td>
</tr>
<tr>
<td>b. Give epoetin alfa IV or SC; do not shake the vial; and discard any remainder of multidose vials 21 d after opening.</td>
<td>For clients with chronic renal failure on hemodialysis, epoetin alfa can be given by bolus injection at the end of dialysis. For other patients with an IV line, the drug can be given IV. For patients without an IV line or who are ambulatory, the drug is injected SC. Shaking can inactivate the medication; the manufacturer does not ensure sterility or stability of multidose vials after 21 days. Manufacturer’s recommendations</td>
</tr>
<tr>
<td>c. Give filgrastim (Neupogen) according to indication for use:</td>
<td>This drug has limited uses and is rarely given. Thus, most nurses will need to review instructions each time.</td>
</tr>
<tr>
<td>(1) With cancer chemotherapy, give by SC bolus injection, IV infusion over 15–30 min, or continuous SC or IV infusion</td>
<td>Available drugs have similar names but often differ in indications for use, dosages, and routes of administration.</td>
</tr>
<tr>
<td>(2) For bone marrow transplantation, give by IV infusion over 4 h or by continuous IV or SC infusion</td>
<td>Manufacturer’s recommendation</td>
</tr>
<tr>
<td>(3) For collection of stem cells, give as a bolus or a continuous infusion</td>
<td></td>
</tr>
<tr>
<td>(4) For chronic neutropenia, give SC</td>
<td></td>
</tr>
<tr>
<td>d. Give pegfilgrastim (Neulasta) SC only</td>
<td>Manufacturer’s recommendation</td>
</tr>
<tr>
<td>e. Give sargramostim by IV infusion over 2 h, after reconstitution with 1 mL sterile water for injection and addition to 0.9% sodium chloride.</td>
<td></td>
</tr>
<tr>
<td>f. With aldesleukin, review institutional protocols or the manufacturer’s instructions for administration.</td>
<td></td>
</tr>
<tr>
<td>g. With interferons,</td>
<td></td>
</tr>
<tr>
<td>(1) Read drug labels carefully to ensure having the correct drug preparation.</td>
<td></td>
</tr>
<tr>
<td>(2) Give most interferons SC, 3 times weekly, on a regular schedule (eg, Mon., Weds., and Fri.), at about the same time of day, at least 48 h apart.</td>
<td></td>
</tr>
<tr>
<td>(3) Inject interferon for condylomata intralesionally into the base of each wart with a small-gauge needle. For large warts, inject at several points</td>
<td></td>
</tr>
<tr>
<td>h. With intravesical <em>Bacillus Calmette-Guérin</em> (BCG):</td>
<td></td>
</tr>
<tr>
<td>(1) Reconstitute solution (see Drugs at a Glance: Hematopoietic and Immunostimulant Agents).</td>
<td>Reconstituted solution should be used immediately or refrigerated. Discard if not used within 2 h.</td>
</tr>
<tr>
<td>(2) Wear gown and gloves.</td>
<td></td>
</tr>
<tr>
<td>(3) Insert a sterile urethral catheter and drain bladder.</td>
<td></td>
</tr>
<tr>
<td>(4) Instill medication slowly by gravity.</td>
<td></td>
</tr>
<tr>
<td>(5) Remove catheter.</td>
<td></td>
</tr>
<tr>
<td>(6) Have the patient lie on abdomen, back, and alternate sides for 15 min in each position. Then, allow to ambulate but ask to retain solution for a total of 2 h before urinating, if able.</td>
<td></td>
</tr>
<tr>
<td>(continued)</td>
<td></td>
</tr>
</tbody>
</table>
### Nursing Actions

| (7) Dispose of all equipment in contact with BCG solution appropriately. |
| (8) Do not give if catheterization causes trauma (eg, bleeding), and wait 1 wk before a repeat attempt. |

#### Rationale/Explanation

BCG contains live mycobacterial organisms and is therefore infectious material.

### Observe for Therapeutic Effects

#### a. With darbepoetin alfa and epoetin alfa, observe for increased red blood cells, hemoglobin, and hematocrit.

#### b. With oprelvekin, observe for maintenance of a normal or near-normal platelet count when used to prevent thrombocytopenia and an increased platelet count or fewer platelet transfusions when used to treat thrombocytopenia.

#### c. With aldesleukin, observe for tumor regression (improvement in signs and symptoms).

#### d. With parenteral interferons, observe for improvement in signs and symptoms.

#### e. With intralesional interferon, observe for disappearance of genital warts.

### Observe for Adverse Effects

#### a. With darbepoetin alfa and epoetin alfa, observe for nausea, vomiting, diarrhea, arthralgias, and hypertension.

#### b. With oprelvekin, observe for atrial fibrillation or flutter, dyspnea, edema, fever, mucositis, nausea, neutropenia, tachycardia, vomiting.

#### c. With filgrastim, observe for bone pain, erythema at SC injection sites, and increased serum lactate dehydrogenase, alkaline phosphatase, and uric acid levels.

#### d. With sargramostim, observe for bone pain, fever, headache, muscle aches, generalized maculopapular skin rash, and fluid retention (peripheral edema, pleural effusion, pericardial effusion).

#### e. With interferons, observe for acute flu-like symptoms (eg, fever, chills, fatigue, muscle aches, headache), chronic fatigue, depression, leukopenia, and increased liver enzymes. Anemia and depressed platelet and WBC counts may also occur but are infrequent.

The drugs are usually well tolerated, with adverse effects similar to those of placebo and which may result from the underlying disease processes.

In clinical trials, most adverse events were mild or moderate in severity and reversible after stopping drug administration. Atrial arrhythmias are more likely to occur in older adults. Dyspnea and edema are attributed to fluid retention.

Bone pain reportedly occurs in 20% to 25% of patients and can be treated with acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID).

Pleural and pericardial effusions are more likely at doses greater than 20 mcg/kg/d. Adverse effects occur more often with sargramostim than filgrastim.

Acute effects occur in most patients, increasing with higher doses and decreasing with continued drug administration. Most symptoms can be relieved by acetaminophen. Fatigue and depression occur with long-term administration and are dose-limiting effects.
Nursing Notes: Apply Your Knowledge

**Answer:** G-CSF is given to decrease the length and severity of bone marrow suppression after chemotherapy. Laboratory values (white blood cell count and differential) evaluate the degree of bone marrow suppression and whether G-CSF is effective. In this situation, the nadir (lowest neutrophil count) should be above 1000/mm³ and should last for less than 6 days. Although bone marrow suppression can affect red blood cells and platelets, white blood cells (neutrophils) are most significant because a low neutrophil count increases infection risk. Infection in a neutropenic patient can be life-threatening.

### Chapter 44 Hematopoietic and Immunostimulant Drugs

#### Review and Application Exercises

1. What are the hematopoietic, colony-stimulating cytokines, and how do they function in the body?
2. What are adverse effects of filgrastim and sargramostim, and how may they be prevented or minimized?
3. What are the clinical uses of pharmaceutical interleukins and interferons?
4. What are the adverse effects of interleukins and interferons, and how can they be prevented or minimized?
5. Describe the clinical uses of hematopoietic and immunostimulant drugs in the treatment of anemia, neutropenia, thrombocytopenia, cancer, and bone marrow transplantation.

### Nursing Actions

#### Rationale/Explanation

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>f.</strong> With aldesleukin, observe for capillary leak syndrome (hypotension, shock, angina, myocardial infarction, arrhythmias, edema, respiratory distress, gastrointestinal bleeding, renal insufficiency, mental status changes). Other effects may involve most body systems, such as chills and fever, blood (anemia, thrombocytopenia, eosinophilia), central nervous system (CNS) (seizures, psychiatric symptoms), skin (erythema, burning, pruritus), hepatic (cholestasis), endocrine (hypothyroidism), and bacterial infections. In addition, drug-induced tumor breakdown may cause hypocalcemia, hyperkalemia, hyperphosphatemia, hyperuricemia, renal failure, and electrocardiogram changes.</td>
<td>Adverse effects are frequent, often serious, and sometimes fatal. Most subside within 2 to 3 d after stopping the drug. Capillary leak syndrome, which may begin soon after treatment starts, is characterized by a loss of plasma proteins and fluids into extravascular space. Signs and symptoms result from decreased organ perfusion, and most patients can be treated with vasopressor drugs, cautious fluid replacement, diuretics, and supplemental oxygen.</td>
</tr>
<tr>
<td><strong>g.</strong> With intravesical BCG, assess for symptoms of bladder irritation (eg, frequency, urgency, dysuria, hematuria) and systemic symptoms of fever, chills, and malaise.</td>
<td>These effects occur in more than 50% of patients, usually starting a few hours after administration and lasting 2 to 3 d. They can be decreased by phenazopyridine (Pyridium), a urinary tract analgesic; propantheline (Pro-Banthine) or oxybutynin (Ditropan), antispasmodics; and acetaminophen (Tylenol) or ibuprofen (Motrin), analgesic–antipyretic agents.</td>
</tr>
</tbody>
</table>

### 4. Observe for drug interactions

#### a. Drugs that increase effects of sargramostim:

1. Corticosteroids, lithium

#### b. Drugs that increase effects of aldesleukin:

1. Aminoglycoside antibiotics (eg, gentamicin, others)
2. Antihypertensives
3. Antineoplastics (eg, asparaginase, doxorubicin, methotrexate)
4. Opioid analgesics
5. NSAIDs (eg, ibuprofen)
6. Sedative-hypnotics

#### d. Drugs that decrease effects of aldesleukin:

1. Corticosteroids

These drugs have myeloproliferative (bone marrow stimulating) effects of their own, which may add to those of sargramostim. All of the listed drug groups may potentiate adverse effects of aldesleukin.

- Increased nephrotoxicity
- Increased hypotension
- Increased toxic effects on bone marrow, heart, and liver. Aldesleukin is usually given as a single antineoplastic agent; its use in combination with other antineoplastic drugs is being evaluated.
- Increased CNS adverse effects
- Increased nephrotoxicity
- Increased CNS adverse effects

These drugs should not be given concurrently with aldesleukin, because they decrease the drug’s therapeutic anticancer effects.
SELECTED REFERENCES


Immunosuppressants

**Objectives**

After studying this chapter, the student will be able to:

1. Describe characteristics and consequences of immunosuppression.
2. Discuss characteristics and uses of major immunosuppressant drugs in autoimmune disorders and organ transplantation.
3. Identify adverse effects of immunosuppressant drugs.
4. Discuss nursing interventions to decrease adverse effects of immunosuppressant drugs.
5. Teach clients, family members, and caregivers about safe and effective immunosuppressant drug therapy.
6. Assist clients and family members to identify potential sources of infection in the home care environment.

**Critical Thinking Scenario**

Jane Reily, 46 years of age, is scheduled to have a kidney transplant this week. After transplantation, she will be on a regimen of immunosuppressive drugs, including corticosteroids and cyclosporine. You are responsible for Ms. Reily’s teaching.

Reflect on:

- Why lifelong immunosuppression is necessary after an organ transplant.
- What symptoms Ms. Reily might experience if she rejects her transplanted kidney.
- How you will teach Ms. Reily to reduce her risk of infection.
- What lifelong measures for medical follow-up and management are necessary for a transplant recipient.

**OVERVIEW**

Immunosuppressant drugs interfere with the production or function of immune cells. The drugs are used to decrease an inappropriate or undesirable immune response. The immune response is normally a protective mechanism (see Chap. 42) that helps the body defend itself against potentially harmful external (e.g., microorganisms) and internal agents (e.g., cancer cells). However, numerous disease processes are thought to be caused or aggravated when the immune system perceives the person’s own body tissues as harmful invaders and tries to eliminate them. This inappropriate activation of the immune response is a major factor in a growing list of serious diseases believed to involve autoimmune processes, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and others.

An appropriate but undesirable immune response is elicited when foreign tissue is transplanted into the body. If the immune response is not sufficiently suppressed, the body reacts as with other antigens and attempts to destroy (reject) the foreign organ or tissue. Although numerous advances have been made in transplantation technology, the immune response remains a major factor in determining the success or failure of transplantation.

Most of the available immunosuppressant drugs inhibit the immune response in a general or nonspecific manner. However, the number of drugs that suppress the immune response to specific antigens is increasing. Drugs used therapeutically as immunosuppressants comprise a diverse group, several of which also are used for other purposes. These include corticosteroids (see Chap. 24) and certain cytotoxic antineoplastic drugs (see Chap. 64). These drugs are discussed here primarily in relation to their effects on the immune response. The drugs used to treat autoimmune disorders or to prevent or treat transplant rejection reactions are the main focus of this chapter (Fig. 45–1). These drugs are described in the following sections and in Drugs at a Glance: Immunosuppressants. To aid understanding of im-
Autoimmune disorders occur when a person’s immune system loses its ability to differentiate between antigens on its own cells (called self-antigens or autoantigens) and antigens on foreign cells. As a result, an undesirable immune response is aroused against host tissues. In most instances, the autoantigen is a protein. Thus, in rheumatoid arthritis, the antigen is a protein found in joint tissue.

The mechanisms by which autoantigens are altered to elicit an immune response are unclear. Genetic susceptibility and possible “triggering” events such as damage by microorganisms or trauma, similarity in appearance between autoantigens and foreign antigens, or a linkage between a foreign antigen and an autoantigen may be involved. Once an autoantigen is changed and perceived as foreign or “non-self,” the immune response may involve T lymphocytes in direct destruction of tissue, production of proinflammatory cytokines that recruit and activate phagocytes, and stimulation of antibody production.

**AUTOIMMUNE DISORDERS**
### Drugs at a Glance: Immunosuppressants

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Contraindications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Azathioprine</strong> (Imuran)</td>
<td>Prevent renal transplant rejection</td>
<td>Pregnancy</td>
<td>Renal transplant: PO, IV</td>
</tr>
<tr>
<td></td>
<td>Severe rheumatoid arthritis unresponsive to other treatment</td>
<td>Allergy to azathioprine</td>
<td>3–5 mg/kg/d initially, decreased (1–3 mg/kg/d) for maintenance and in presence of renal impairment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Rheumatoid arthritis: PO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 mg/kg/d (50–100 mg), increased by 0.5 mg/kg/d after 8 wk, then every 5 wk to a maximum dose of 2.5 mg/kg/d. Decrease dosage for maintenance.</td>
</tr>
<tr>
<td><strong>Basiliximab</strong> (Simulect)</td>
<td>Prevent renal transplant rejection</td>
<td>Hypersensitivity to any components of the drug formulation</td>
<td>Adults: IV 20 mg within 2 h before transplantation and 20 mg 4 d after transplantation (total of two doses).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Children (2–15 y): IV 12 mg/m² up to a maximum of 20 mg for two doses as for adults</td>
</tr>
<tr>
<td><strong>Cyclosporine</strong> (Sandimmune, Neoral)</td>
<td>Prevent rejection of solid organ (eg, heart, kidney, liver) transplant</td>
<td>Allergy to cyclosporine or polyoxyethylated castor oil (in IV preparation only)</td>
<td>Sandimmune, PO 15 mg/kg 4–12 h before transplant surgery, then 15 mg/kg once daily for 1–2 wk, then decrease by 5% per week to a maintenance dose of 5–10 mg/kg/d.</td>
</tr>
<tr>
<td></td>
<td>Prevent and treat graft-versus-host disease in bone marrow transplantation</td>
<td>Cautious use during pregnancy or lactation</td>
<td>Neoral, PO, the first dose in clients with new transplants is the same as the first oral dose of Sandimmune; later doses are titrated according to the desired cyclosporine blood level.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IV 5–6 mg/kg infused over 2–6 h</td>
</tr>
<tr>
<td><strong>Daclizumab</strong> (Zenapax)</td>
<td>Prevent renal transplant rejection</td>
<td>Hypersensitivity to any components of the drug formulation</td>
<td>IV 1 mg/kg over 15 min. First dose within 24 h before transplantation, then a dose every 14 d for four doses (total of five doses).</td>
</tr>
<tr>
<td><strong>Etanercept</strong> (Enbrel)</td>
<td>Rheumatoid arthritis</td>
<td>Sepsis</td>
<td>Adults: SC 25 mg twice weekly, 72–96 h apart</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypersensitivity to any components of the drug formulation</td>
<td>Children (4–17 y): SC 0.4 mg/kg up to a maximum of 25 mg per dose, twice weekly, 72–96 h apart</td>
</tr>
<tr>
<td><strong>Infliximab</strong> (Remicade)</td>
<td>Crohn’s disease, moderate to severe or fistulizing</td>
<td>Hypersensitivity to mouse proteins or any other components of the formulation</td>
<td>Crohn’s disease, moderate to severe: IV infusion 5 mg/kg as a single dose.</td>
</tr>
<tr>
<td></td>
<td>Rheumatoid arthritis</td>
<td></td>
<td>Crohn’s disease, fistulizing: IV infusion 5 mg/kg initially and 2 and 6 wk later (total of three doses).</td>
</tr>
<tr>
<td><strong>Leflunomide</strong> (Arava)</td>
<td>Rheumatoid arthritis</td>
<td>Hypersensitivity to any components of the drug formulation</td>
<td>PO 100 mg once daily for 3 d, then 20 mg once daily</td>
</tr>
<tr>
<td><strong>Lymphocyte immune globulin, antithymocyte globulin (Equine)</strong> (Atgam)</td>
<td>Prevent or treat renal transplant rejection</td>
<td>Allergy to horse serum or prior allergic reaction to Atgam</td>
<td>IV 15 mg/kg/d for 14 d, then every other day for 14 d (21 doses).</td>
</tr>
<tr>
<td><strong>Methotrexate</strong> (MTX) (Rheumatrex)</td>
<td>Severe rheumatoid arthritis unresponsive to other therapy</td>
<td>Allergy to methotrexate</td>
<td>PO 7.5 mg/wk as single dose, or 2.5 mg q12h for three doses once weekly</td>
</tr>
</tbody>
</table>

(continued)
of B lymphocytes to produce autoantibodies that produce inflammation and tissue damage.

In addition to the factors that activate an immune response, there are also factors that prevent the immune system from “turning off” the abnormal immune or inflammatory process. One of these factors may be a deficient number of suppressor T cells. At present, it is unclear whether suppressor T cells are a separate group or a subpopulation of helper or cytotoxic T cells with suppressive functions.

### TISSUE AND ORGAN TRANSPLANTATION

Tissue and organ transplantation usually involves replacing diseased host tissue with healthy donor tissue. The goal of such treatment is to save or enhance the quality of the host’s life. Skin and renal grafts are commonly and successfully performed; heart, liver, lung, pancreas, and bone marrow transplantations are increasing. Although numerous factors affect graft survival, including the degree of matching between donor tissues and recipient tissues, drug-induced immunosuppression is a major part of transplantation technology. The goal is to provide adequate, but not excessive, immunosuppression. If immunosuppression is inadequate, graft rejection reactions occur with solid organ transplantation, and graft-versus-host disease (GVHD) occurs with bone marrow transplantation. If immunosuppression is excessive, the client develops serious infections and other adverse effects because the drug actions that slow the proliferation of activated lymphocytes also affect any rapidly dividing nonimmune cells (eg, epithelial cells of the gastrointestinal [GI] tract and hematopoietic stem cells of the bone marrow). Serious complications can occur.

#### Rejection Reactions With Solid Organ Transplantation and Host-Versus-Graft Disease

A rejection reaction occurs when the host’s immune system is stimulated to destroy the transplanted organ. The immune cells of the transplant recipient attach to the donor cells of the transplanted organ and react against the antigens of the donor organ. The rejection process involves T and B lymphocytes, antibodies, multiple cytokines, and inflammatory mediators. In general, T cell activation and proliferation are more important in the rejection reaction than B cell activation and formation of antibodies. Cytotoxic and helper T cells are activated; activated helper T cells stimulate B cells to produce antibodies and lead to a delayed hypersensitivity reaction. The initial target of the recipient antibodies is the blood vessels of the transplanted organ. The antibodies can injure the transplanted organ by activating complement, producing antigen–antibody complexes, or causing antibody-mediated tissue breakdown. This reaction can destroy the solid organ graft within 2 weeks.

### Drugs at a Glance: Immunosuppressants (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Contraindications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muromonab-CD3 (Orthoclone OKT3)</td>
<td>Treatment of renal cardiac and hepatic transplant rejection</td>
<td>Allergy to muromonab-CD3 Signs of fluid overload (eg, heart failure, weight gain during week before starting drug therapy) Cautious use during pregnancy</td>
<td>IV 5 mg bolus injection once daily for 10–14 d</td>
</tr>
<tr>
<td>Mycophenolate mofetil (CellCept)</td>
<td>Prevent renal cardiac and hepatic transplant rejection</td>
<td>Hypersensitivity to the drug or any component of the product</td>
<td>Renal transplantation: PO, IV 1 g twice daily Cardiac and hepatic transplantation: PO, IV 1.5 g twice daily Adults: PO 6 mg as soon after transplantation as possible, then 2 mg daily Children &gt;13 y: PO 3 mg/m² as loading dose, then 1 mg/m² daily.</td>
</tr>
<tr>
<td>Sirolimus (Rapamune)</td>
<td>Prevent renal transplant rejection</td>
<td>Hypersensitivity to any component of the drug formulation</td>
<td></td>
</tr>
<tr>
<td>Tacrolimus (Prograf)</td>
<td>Prevent liver, kidney, and heart transplant rejection</td>
<td>Hypersensitivity to the drug or the castor oil used in the IV formulation</td>
<td>PO 150–200 mcg/kg/d, in two divided doses q12h, with the first dose 8–12 h after stopping the IV infusion Children: IV 50–100 mcg/kg/d PO 200–300 mcg/kg/d</td>
</tr>
</tbody>
</table>
unless the recipient’s immune system is adequately suppressed by immunosuppressant drugs.

Rejection reactions are designated as hyperacute, acute, or chronic, depending on the time elapsed between transplantation and rejection. Hyperacute reactions occur within 24 hours. This rare type of reaction occurs in recipients who have previously formed antibodies against antigens in the graft. The antibodies bind to the graft and induce intense inflammation with extensive infiltration of neutrophils into the grafted tissue. The inflammatory reaction causes massive blood clots within the capillaries and prevents vascularization and function of the graft. Acute reactions, which may occur from 10 days to a few months after transplantation, mainly involve a cellular response with the proliferation of T lymphocytes. Characteristics include signs of organ failure and vasculitis lesions that often lead to arterial narrowing or obliteration. Treatment with immunosuppressant drugs is usually effective in ensuring short-term survival of the transplant, but does not prevent chronic rejection. Chronic reactions, which may occur after months or years of normal function, are caused by both cellular and humoral immunity and do not respond to increased immunosuppressive drug therapy. Characteristics include fibrosis of blood vessels and progressive failure of the transplanted organ.

Rejection reactions produce general manifestations of inflammation and specific manifestations depending on the organ involved. With renal transplantation, for example, acute rejection reactions produce fever, flank tenderness over the graft organ site, and symptoms of renal failure (eg, increased serum creatinine, decreased urine output, edema, weight gain, hypertension). Chronic rejection reactions are characterized by a gradual increase in serum creatinine levels over approximately 4 to 6 months.

**Bone Marrow Transplantation and Graft-Versus-Host Disease**

With bone marrow transplantation, the donor bone marrow mounts an immune response (mainly by stimulating T lymphocytes) against antigens on the host’s tissues, producing GVHD. Tissue damage is produced directly by the action of cytotoxic T cells or indirectly through the release of inflammatory mediators such as complement and cytokines such as tumor necrosis factor (TNF)-alpha and interleukins.

Acute GVHD occurs in 30% to 50% of clients, usually within 6 weeks. Signs and symptoms include delayed recovery of blood cell production in the bone marrow, skin rash, liver dysfunction (indicated by increased alkaline phosphatase, aminotransferases, and bilirubin), and diarrhea. The skin reaction is usually a pruritic maculopapular rash that begins on the palms and soles and may extend over the entire body. Liver involvement can lead to bleeding disorders and coma.

Chronic GVHD occurs when symptoms persist or occur 100 days or more after transplantation. It is characterized by abnormal humoral and cellular immunity, severe skin disorders, and liver disease. Chronic GVHD appears to be an autoimmune disorder in which activated T cells perceive autoantigens as foreign antigens.

**IMMUNOSUPPRESSANT DRUGS**

Drugs used as immunosuppressants are diverse agents with often overlapping mechanisms of actions and effects. Older drugs generally depress the immune system (ie, suppress the immune response to all antigens). This greatly increases risks of serious infections with bacteria, viruses, fungi, or protozoa, at any time during the immunosuppressed state. In addition, many immunosuppressant drugs slow the proliferation of activated lymphocytes and damage rapidly dividing nonimmune cells (eg, mucosal, intestinal, and bone marrow hematopoietic stem cells). As a result, serious or life-threatening complications can occur. For example, patients on long-term immunosuppressant drug therapy (eg, with autoimmune disorders and organ transplantation) are at increased risk of cancer (especially lymphoma), hypertension, and metabolic bone disease.

For many reasons, including adverse effects of older drugs and the efforts to develop more effective agents, extensive research has been done to develop drugs that modify the immune response (often called immunomodulators or biologic response modifiers). As a result, several drugs with more specific immunosuppressive actions have been approved in recent years. Most are used in combination with older immunosuppressants for synergistic effects.

Immunosuppressants are discussed here as corticosteroids, cytotoxic antiproliferative agents, conventional antirejection agents, antibody preparations, and miscellaneous drugs. This grouping is rather arbitrary because most of the drugs could also fit in one or more other categories (eg, the cytotoxic drugs and most of the antibody preparations are also antirejection drugs; some of the drugs can also be called anticytokines because they block the actions of cytokines such as interleukin-2 [IL-2] and TNF). It is hoped that the chosen groupings will assist the reader in differentiating drug sources, effects, and clinical uses.

**Corticosteroids**

Corticosteroids are potent anti-inflammatory drugs that act to suppress the immune response at many levels. In many disorders, they relieve signs and symptoms by decreasing the accumulation of lymphocytes and macrophages and the production of cell-damaging cytokines at sites of inflammatory reactions. Because inflammation is a common response to chemical mediators or antigens that cause tissue injury, the anti-inflammatory and immunosuppressive actions of corticosteroids often overlap and are indistinguishable. Despite this somewhat arbitrary separation, corticosteroid effects on the immune response are emphasized here. In general, the drugs suppress growth of all lymphoid tissue and therefore decrease formation and function of antibodies and T cells. For patients with transplanted tissues, a corticosteroid is usually given with
other agents (eg, azathioprine) to prevent acute episodes of graft rejection. Specific effects include the following:

- Increased numbers of circulating neutrophils (more are released from bone marrow and fewer leave the circulation to enter inflammatory exudates). In terms of neutrophil functions, corticosteroids increase chemotaxis and release of lysosomal enzymes.
- Decreased numbers of circulating basophils, eosinophils, and monocytes. The reduced availability of monocytes is considered a major factor in the anti-inflammatory activity of corticosteroids. Functions of monocyte–macrophages are also impaired. Corticosteroids suppress phagocytosis and initial antigen processing (necessary to initiate an immune response), impair migration to areas of tissue injury, and block the differentiation of monocytes to macrophages.
- Decreased numbers of circulating lymphocytes (immune cells), resulting from impaired production (ie, inhibition of deoxyribonucleic acid [DNA], ribonucleic acid [RNA], and protein synthesis), sequestration in lymphoid tissues, or lysis of the cells. T cells are markedly reduced; B cells are moderately reduced.
- Impaired function of cellular (T-cell) and humoral (B-cell) immunity. Corticosteroids inhibit the production of immunostimulant cytokines (eg, IL-1 and IL-2) required for activation and clonal expansion of lymphocytes and cytotoxic cytokines, such as TNF and interferons. When administered for 2 to 3 weeks, the drugs also inhibit immune reactions to antigenic skin tests and reduce serum concentrations of some antibodies (immunoglobulins [Ig] G and A but not IgM).

### Cytotoxic, Antiproliferative Agents

Cytotoxic, antiproliferative drugs damage or kill cells that are able to reproduce, such as immunologically competent lymphocytes. These drugs are used primarily in cancer chemotherapy. However, in small doses, some also exhibit immunosuppressive activities and are used to treat autoimmune disorders (eg, methotrexate) and to prevent rejection reactions in organ transplantation (azathioprine). These drugs cause generalized suppression of the immune system and can kill lymphocytes and nonlymphoid proliferating cells (eg, bone marrow blood cells, GI mucosal cells, and germ cells in gonads).

**Azathioprine** is an antimetabolite that interferes with production of DNA and RNA and thus blocks cellular reproduction, growth, and development. Once ingested, azathioprine is metabolized by the liver to 6-mercaptopurine, a purine analog. The purine analog is then incorporated into the DNA of proliferating cells in place of the natural purine bases, leading to the production of abnormal DNA. Rapidly proliferating cells are most affected, including T and B lymphocytes, which normally reproduce rapidly in response to stimulation by an antigen. The drug acts especially on T cells to block cell division, clonal proliferation, and differentiation.

Azathioprine is well absorbed after oral administration, with peak serum concentrations in 1 to 2 hours and a half-life of less than 5 hours. The mercaptopurine resulting from initial biotransformation is inactivated mainly by the enzyme xanthine oxidase. Impaired liver function may decrease metabolism of azathioprine to its active metabolite and therefore decrease pharmacologic effects.

The drug is used mainly to prevent organ graft rejection and has little effect on acute rejection reactions. It is also used to treat severe rheumatoid arthritis not responsive to conventional treatment. When used to prevent graft rejection, azathioprine is used lifelong. Dosage varies among transplantation centers and types of transplants, but depends largely on white blood cell (WBC) and platelet counts.

**Methotrexate** is a folate antagonist. It inhibits dihydrofolate reductase, the enzyme that converts dihydrofolate to the tetrahydrofolate required for biosynthesis of DNA and cell reproduction. The resultant DNA impairment inhibits production and function of immune cells, especially T cells. Methotrexate has long been used in the treatment of cancer. Other uses have evolved from its immunosuppressive effects, including treatment of autoimmune or inflammatory disorders, such as severe arthritis and psoriasis, that do not respond to other treatment measures. It is also used (with cyclosporine) to prevent GVHD associated with bone marrow transplantation, but it is not approved by the Food and Drug Administration for this purpose. Lower doses are given for these conditions than for cancers, and adverse drug effects are fewer and less severe.

**Mycophenolate** is similar to azathioprine. It is used for prevention and treatment of rejection reactions with renal, cardiac, and hepatic transplantation. It inhibits proliferation and function of T and B lymphocytes. It has synergistic effects with corticosteroids and cyclosporine and is used in combination with these drugs.

After oral or intravenous (IV) administration, the drug is rapidly broken down to mycophenolic acid, the active component. Mycophenolic acid is further metabolized to inactive metabolites that are eliminated in bile and urine. Neutropenia and thrombocytopenia may occur but are less common and less severe than with azathioprine. Infections with mycophenolate occur at approximately the same rate as with other immunosuppressant drugs. Because of its lesser toxicity, mycophenolate may be preferred over azathioprine, at least in clients who are unable to tolerate azathioprine.

### Conventional Antirejection Agents

Cyclosporine, tacrolimus, and sirolimus are fungal metabolites with strong immunosuppressive effects. Cyclosporine and tacrolimus are chemically unrelated but have a similar action. They inhibit the synthesis of a cytokine, IL-2, which is required for activation of T cells and B cells. Sirolimus is structurally similar to tacrolimus. It inhibits T cell activation and proliferation in response to several ILs (eg, IL-2, IL-4, and IL-15). It also inhibits antibody production. Sirolimus and
tacrolimus may have stronger immunosuppressant activity than cyclosporine.

By inhibiting helper T cell proliferation and cytokine expression, these three drugs reduce the activation of various cells involved in graft rejection, including cytotoxic T cells, natural killer cells, macrophages, and B cells. Consequently, they have become a mainstay of heart, liver, kidney, and bone marrow transplantation.

**Cyclosporine** is used to prevent rejection reactions and prolong graft survival after solid organ transplantation (eg, kidney, liver, heart, lung), or to treat chronic rejection in clients previously treated with other immunosuppressive agents. The drug inhibits both cellular and humoral immunity but affects T lymphocytes more than B lymphocytes. With T cells, cyclosporine reduces proliferation of helper and cytotoxic T cells and synthesis of several cytokines (eg, IL-2, interferons). With B cells, cyclosporine reduces production and function to some extent, but considerable activity is retained.

Transplant rejection reactions mainly involve cellular immunity or T cells. With cyclosporine-induced deprivation of IL-2, T cells stimulated by the graft antigen do not undergo clonal expansion and differentiation, and graft destruction is inhibited. In addition to its use in solid organ transplantation, cyclosporine is used to prevent and treat GVHD, a potential complication of bone marrow transplantation. In GVHD, T lymphocytes from the transplanted marrow of the donor mount an immune response against the tissues of the recipient.

Absorption of cyclosporine is slow and incomplete with oral administration. The drug is highly bound to plasma proteins (90%), and approximately 50% is distributed in erythrocytes, so drug levels in whole blood are significantly higher than those in plasma. Peak plasma levels occur 4 to 5 hours after a dose, and the elimination half-life is 10 to 27 hours. Cyclosporine is metabolized in the liver and excreted in bile; less than 10% is excreted unchanged in urine.

Because the drug is insoluble in water, other solvents are used in commercial formulations. Thus, it is prepared in alcohol and olive oil for oral administration and in alcohol and polyoxyethylated castor oil for IV administration. Anaphylactic reactions, attributed to the castor oil, have occurred with the IV formulation. Neoral is a microemulsion formulation of cyclosporine that is better absorbed than oral Sandimmune. The two formulations are not equivalent and cannot be used interchangeably. Neoral is available in capsules and an oral solution; Sandimmune is available in capsules, oral solution, and an IV solution.

Nephrotoxicity is a major adverse effect. Acute nephrotoxicity commonly occurs and, in some cases, progresses to chronic nephrotoxicity and kidney failure.

**Sirolimus** is used to prevent renal transplant rejection. It acts by inhibiting T-cell activation. It is given concomitantly with a corticosteroid and cyclosporine. It may have synergistic effects with cyclosporine because it has a different mechanism of action. However, the two drugs are metabolized by the same cytochrome P450 3A4 enzymes and cyclosporine increases blood levels of sirolimus, possibly to toxic levels. Consequently, the drugs should not be given at the same time; sirolimus should be taken 4 hours after a dose of cyclosporine. Sirolimus is contraindicated in patients who are allergic to the drug or who are pregnant or breast-feeding.

Sirolimus is well absorbed with oral administration. Its action has a rapid onset and peaks within 1 hour. It has a long half-life of 62 hours. It is metabolized in the liver and excreted mainly in feces (>90%), with a small amount eliminated in urine (<3%).

Reported adverse effects include abdominal pain, acne, anemia, constipation, diarrhea, edema, headache, hepatotoxicity, hypercholesterolemia, hypertension, insomnia, leukopenia, nausea, nephrotoxicity, skin rash, thrombocytopenia, and tremor. Because of the high risk of infection, with sirolimus as with other immunosuppressant drugs, antimicrobial prophylaxis is recommended for cytomegalovirus (CMV) infection for 3 months and *Pneumocystis carinii* pneumonia for 1 year after transplantation.

**Tacrolimus** (formerly FK506) is similar to cyclosporine in its mechanisms of action, pharmacokinetic characteristics, and adverse effects. It prevents rejection of transplanted organs by inhibiting growth and proliferation of T lymphocytes. Although survival of clients and grafts is approximately the same as with cyclosporine, potential advantages of tacrolimus include less corticosteroid therapy and shorter, less costly hospitalizations.

Tacrolimus is not well absorbed orally, so higher oral doses than IV doses must be given to obtain similar blood levels. With IV administration, action onset is rapid and peak action occurs in 1 to 2 hours; with oral administration, onset varies and peak action occurs in 1.5 to 3.5 hours. The drug is well distributed through the body and reaches higher concentrations in erythrocytes than in plasma. It is metabolized in the liver and intestine to several metabolites, which are excreted in bile and urine. It has a half-life of 6 hours. Impaired liver function may slow its metabolism and elimination.

Dosage ranges of tacrolimus vary according to clinical response, adverse effects, and blood concentrations. Serum drug levels are routinely monitored, with therapeutic ranges approximately 10 to 20 ng/mL for 6 months after transplantation, then 5 to 15 ng/mL. Children with transplants metabolize tacrolimus more rapidly than adults with transplants, on a body weight basis. Thus, children require higher doses, based on milligrams per kilogram, to maintain similar plasma drug levels. Dosage does not need to be reduced in renal insufficiency because there is little renal elimination of the drug.

There are numerous potential drug interactions that increase or decrease blood levels and effects of tacrolimus. Because tacrolimus is metabolized mainly by the cytochrome P450 enzymes that metabolize cyclosporine, drug interactions known to alter cyclosporine effects are likely to alter tacrolimus effects. In addition, tacrolimus is a macrolide and may have drug interactions similar to those occurring with erythromycin. Erythromycin is known to increase blood levels and risks of toxicity of several drugs, including oral anticoagulants, digoxin, and theophylline.

The role of tacrolimus in transplantation immunosuppression is not well defined. Because successful liver and intesti-
nal transplantations have been attributed to the drug, some people suggest that tacrolimus may replace cyclosporine as the immunosuppressant of choice for new clients. It may also be useful for clients who do not respond to cyclosporine. In renal transplantation, its role is less clear because high success rates have been achieved with cyclosporine. However, cyclosporine is given with corticosteroids and tacrolimus may allow corticosteroids to be reduced or stopped, thereby decreasing the adverse effects of long-term corticosteroid therapy. Nephrotoxicity occurs at an approximately equal rate with both drugs.

Antibody Preparations

Antibody preparations are produced in the laboratory or derived from animals injected with human lymphoid tissue to stimulate an immune response. Such preparations are being extensively used or investigated for use in cancer, transplantation rejection, drug toxicity, Crohn’s disease, rheumatoid arthritis, and other diseases. They are also being used in diagnostic imaging technology.

The antibodies may be nonspecific polyclonal or specific monoclonal. Polyvalent preparations are a mixture of antibodies (e.g., IgA, IgD, IgE, IgG, or IgM) produced by several clones of B lymphocytes. Each clone produces a structurally and functionally different antibody, even though the humoral immune response was induced by a single antigen. Monoclonal antibodies are produced in the laboratory by procedures that isolate and clone individual B lymphocytes, resulting in the production of completely identical antibody molecules. The antigen to which the desired antibody will respond is first injected into a mouse. The mouse mounts an immune response in which its B lymphocytes are stimulated to produce a specific antibody against that antigen. The B lymphocytes are then recovered from the spleen of the mouse and mixed with myeloma cells (a cell line that can live forever in culture) in polyethylene glycol. This treatment results in fusion of the cells and produces an antibody-secreting hybridoma, which can be cloned to produce large amounts of the desired antibody. The antibodies can be isolated from the culture and prepared for clinical use. Because the antibodies are proteins and would be destroyed if taken orally, they must be given by injection.

Older animal-derived antibodies (e.g., LIG-ATG, muromonab-CD3) are themselves antigenic; they usually elicit human antibodies against the animal cells within 2 weeks. Newer murine (mouse-derived) antibodies (e.g., basiliximab) have had human antibodies added by recombinant DNA technology and are less likely to elicit an immune response. However, because the products are proteins, there is some risk of hypersensitivity reactions.

Because they are derived from one cell line or clone, monoclonal antibodies can be designed to suppress the specific components of the immune system that are causing tissue damage in particular disorders. They cause cell destruction by eliciting an antigen–antibody reaction, activating complement, or targeting molecules on the cell surface that are necessary for growth or differentiation of that cell.

Note that the generic names of monoclonal antibodies used as drugs end in *mab* and thus identify their origin.

**Polyvalent Antibody**

**Lymphocyte Immune Globulin, Antithymocyte Globulin**

Lymphocyte immune globulin, antithymocyte globulin (LIG, ATG [or Atgam]) is a nonspecific antibody with activity against all blood cells, although it acts mainly against T lymphocytes. LIG, ATG is obtained from the serum of horses immunized with human thymus tissue or T lymphocytes. It contains antibodies that destroy lymphoid tissues and decrease the number of circulating T cells, thereby suppressing cellular and humoral immune responses. In addition to its high concentration of antibodies against T lymphocytes, the preparation contains low concentrations of antibodies against other blood cells. A skin test is recommended before administration to determine whether the client is allergic to horse serum. Because there is a high risk of anaphylactic reactions in recipients previously sensitized to horse serum, clients with positive skin tests should be desensitized before drug therapy is begun. LIG, ATG may be given for a few weeks to treat rejection reactions after solid organ transplantation, and it may be used to treat aplastic anemia.

**Monoclonal Antibodies**

**Basiliximab** (Simulect) and **daclizumab** (Zenapax) are similar drugs. They are humanized IgE (i.e., a combination of human and murine antibodies). They are called IL-2 receptor antagonists because they bind to IL-2 receptors on the surface of activated lymphocytes. This action inhibits the ability of IL-2 to stimulate proliferation and cytokine production of lymphocytes, a critical component of the cellular immune response involved in allograft rejection. The drugs are used to prevent organ rejection in clients receiving renal transplants and are given in combination with cyclosporine and a corticosteroid. In clinical trials, adverse effects were consistent with those of transplant status, underlying disease, and concomitant immunosuppressive and other drug therapy. They were also similar to those reported with placebo (i.e., basiliximab or daclizumab + cyclosporine and a corticosteroid vs. placebo + cyclosporine and a corticosteroid).

**Infliximab** (Remicade) is a humanized IgG monoclonal antibody used to treat rheumatoid arthritis and Crohn’s disease. It inhibits a cytokine, TNF-alpha, from binding to its receptors and thus neutralizes its actions. Biologic activities attributed to TNF-alpha include induction of other proinflammatory cytokines (e.g., IL-1 and IL-6), increasing leukocyte migration into sites of injury or inflammation and stimulating neutrophil and eosinophil activity. Infliximab’s ability to neutralize TNF-alpha accounts for its anti-inflammatory effects. (It does not neutralize TNF-beta, a related cytokine that uses the same receptors.)
In Crohn’s disease, elevated concentrations of TNF-alpha have been found in clients’ stools and correlate with episodes of increased disease activity. Infliximab reduces infiltration of inflammatory cells, production of TNF-alpha in inflamed areas of the intestine, and the number of cells that can produce TNF-alpha. It is indicated for clients with moderate to severe disease who do not respond adequately to conventional treatment measures and for those with draining enterocutaneous fistulas.

Infliximab therapy (ie, anti-TNF therapy) may lead to the formation of autoimmune antibodies and hypersensitivity reactions. Dyspnea, hypotension, and urticaria have occurred. The drug should be administered in settings in which personnel and supplies (eg, epinephrine, antihistamines, corticosteroids) are available for treatment of hypersensitivity reactions, and should be discontinued if severe reactions occur. In addition, infections developed in approximately 21% of clients in clinical trials and the drug may aggravate congestive heart failure.

Muromonab-CD3 (Orthoclone OKT3) is a monoclonal antibody that acts against an antigenic receptor called CD3, which is found on the surface membrane of most T cells in blood and body tissues. CD indicates clusters of differentiation, or groups of cells with the same surface markers (antigenic receptors). The CD3 molecule is associated with the antigen recognition structure of T cells and is essential for T-cell activation. Muromonab-CD3 binds with its antigen (CD3) and therefore blocks all known functions of T cells containing the CD3 molecule. Because rejection reactions are mainly T-cell–mediated immune responses against antigenic (nonself) tissues, the drug’s ability to suppress such reactions accounts for its therapeutic effects in treating renal, cardiac, and hepatic transplant rejection. It is usually given for 10 to 14 days. After treatment, CD3-positive T cells reappear rapidly and reach pretreatment levels within 1 week. The drug’s name is derived from its source (murine or mouse cells) and its action (monoclonal antibody against the CD3 antigen). Because the drug is a protein and induces antibodies in most clients, decreased effectiveness and serious allergic reactions may occur if it is readministered later. Second courses of treatment must be undertaken cautiously.

Miscellaneous Immunosuppressants

Etanercept (Enbrel) is a manufactured TNF receptor that binds with TNF and prevents it from binding with its “normal” receptors on cell surfaces. This action inhibits TNF activity in inflammatory and immune responses.

Tumor necrosis factor is a naturally occurring cytokine that enhances leukocyte migration into areas of tissue injury and induces the production of other cytokines, such as IL-6. In rheumatoid arthritis, TNF is increased in joint synovial fluid and considered important in joint inflammation and destruction.

The biologic activity of TNF requires its binding to TNF-alpha or TNF-beta receptors on cell surfaces. Etanercept inhibits binding of both TNF-alpha and TNF-beta to cell surface TNF receptors and thereby inactivates TNF.

Etanercept is used to treat moderate to severe rheumatoid arthritis in adults and children who have not received adequate relief of symptoms with other treatments. It can be used in combination with methotrexate in clients who do not respond adequately to methotrexate alone.

Leflunomide (Arava) has antiinflammatory and antinflammatory activities that are attributed to its effects on the immune system. The drug inhibits the synthesis of pyrimidines, which are components of DNA and RNA and therefore important in cell reproduction and growth. Leflunomide is used to treat rheumatoid arthritis in adults. In addition to relieving signs and symptoms, it also slows the progressive destruction of joint tissues.

After oral administration, leflunomide is metabolized to an active metabolite (called M1) that exerts almost all of the drug’s effects. M1 has a half-life of about 2 weeks, and a loading dose is usually given for 3 days to achieve therapeutic blood levels more rapidly. It is highly bound to albumin and eventually eliminated by further metabolism and renal or biliary excretion. Some of the M1 excreted in bile is reabsorbed, and this contributes to its long half-life. Most adverse effects in clinical trials were similar to those of placebos.

Nursing Process

Assessment

- Assess clients receiving or anticipating immunosuppressant drug therapy for signs and symptoms of current infection or factors predisposing them to potential infection (eg, impaired skin integrity, invasive devices, cigarette smoking).
- Assess the environment for factors predisposing to infection (eg, family or health care providers with infections, contact with young children, and potential exposure to childhood infectious diseases).
- Assess nutritional status, including appetite and weight.
- Assess baseline values of laboratory and other diagnostic test results to aid monitoring of responses to immunosuppressant drug therapy. With pretransplantation clients, this includes assessing for impaired function of the diseased organ and for abnormalities that need treatment before surgery.
- Assess adequacy of support systems for transplantation recipients.
- Assess post-transplantation clients for surgical wound healing, manifestations of organ rejection, and adverse effects of immunosuppressant drugs.
- Assess clients with autoimmune disorders (eg, rheumatoid arthritis, Crohn’s disease) for manifestations of the disease process and responses to drug therapy.
Nursing Diagnoses
- Risk for Injury: Adverse drug effects
- Risk for Injury: Infection and cancer related to immunosuppression and increased susceptibility
- Deficient Knowledge: Disease process and immunosuppressant drug therapy
- Anxiety related to the diagnosis of serious disease or need for organ transplantation
- Social Isolation related to activities to reduce exposure to infection

Planning/Goals
The client will:
- Participate in decision making about the treatment plan
- Receive or take immunosuppressant drugs correctly
- Participate in interventions to prevent infection (eg, maintain good hygiene, avoid known sources of infection) while immunosuppressed
- Experience relief or reduction of disease symptoms
- Maintain adequate levels of nutrition and fluids, rest and sleep, and exercise
- Be assisted to cope with anxiety related to the disease process and drug therapy
- Keep appointments for follow-up care
- Have adverse drug effects prevented or recognized and treated promptly
- Maintain diagnostic test values within acceptable limits
- Maintain family and other emotional or social support systems
- Receive optimal instructions and information about the treatment plan, self-care in activities of daily living, reporting adverse drug effects, and other concerns
- Before and after tissue or organ transplantation, receive appropriate care, including prevention or early recognition and treatment of rejection reactions

Interventions
- Practice and emphasize good personal hygiene and hand washing techniques by clients and all others in contact with clients.
- Use sterile technique for all injections, IV site care, wound dressing changes, and any other invasive diagnostic or therapeutic measures.
- Screen staff and visitors for signs and symptoms of infection; if infection is noted, do not allow contact with the client.
- Report fever and other manifestations of infection immediately.
- Allow clients to participate in decision making when possible and appropriate.
- Use isolation techniques according to institutional policies, usually after transplantation or when the neutrophil count is below 500/mm³.
- Assist clients to maintain adequate nutrition, rest and sleep, and exercise.
- Inform clients about diagnostic test results, planned changes in therapeutic regimens, and evidence of progress.
- Allow family members or significant others to visit clients when feasible.
- Monitor complete blood count (CBC) and other diagnostic test results related to blood, liver, and kidney function throughout drug therapy. Specific tests vary with the client’s health or illness status and the immunosuppressant drugs being taken.
- Schedule and coordinate drug administration to maximize therapeutic effects and minimize adverse effects.
- Consult other health care providers (eg, physician, dietitian, social worker) on the client’s behalf when indicated. Multi-disciplinary consultation is essential for transplantation clients and desirable for clients with autoimmune disorders.
- Assist clients in learning strategies to manage day-to-day activities during long-term immunosuppression.

Evaluation
- Interview and observe for accurate drug administration.
- Interview and observe for personal hygiene practices and infection-avoiding maneuvers.
- Interview and observe for therapeutic and adverse drug effects with each client contact.
- Interview regarding knowledge and attitude toward the drug therapy regimen, including follow-up care and symptoms to report to health care providers.
- Determine the number and types of infections that have occurred in the neutropenic client.
- Compare current CBC and other reports with baseline values for acceptable levels, according to the client’s condition.
- Observe and interview outpatients regarding compliance with follow-up care.
- Interview and observe for organ function and absence of rejection reactions in post-transplantation clients.

Nursing Notes: Ethical/Legal Dilemma
Anne Robins, a chronic alcoholic for many years, has just received a liver transplant. She will have to be on very expensive immunosuppressive medications for the rest of her life. She has private insurance, but there is some question whether it will cover the cost of her medications.

Reflect on:
- Do you think medical insurance companies should include expensive medications, which must be taken for life, in their benefit package?
- Explore the impact on Ms. Robins and her family if this benefit is denied.
- Explore the impact on insurance rates for other plan members who are healthy and require no long-term management if this benefit is included.
- Should Ms. Robins’ history of alcoholism affect any decision that is made?
CLIENT TEACHING GUIDELINES
Immunosuppressant Drugs

General Considerations
✔ People taking medications that suppress the immune system are at high risk for development of infections. As a result, clients, caregivers, and others in the client’s environment need to wash their hands often and thoroughly, practice meticulous personal hygiene, avoid contact with infected people, and practice other methods of preventing infection.
✔ Report adverse drug effects (eg, signs or symptoms of infection such as sore throat or fever, decreased urine output if taking cyclosporine, easy bruising or bleeding if taking azathioprine or methotrexate) to a health care provider.
✔ Try to maintain healthy lifestyle habits, such as a nutritious diet, adequate rest and sleep, and avoiding tobacco and alcohol. These measures enhance immune mechanisms and other body defenses.
✔ Carry identification that lists the drugs being taken; the dosage; the physician’s name, address, and telephone number; and instructions for emergency treatment. This information is needed if an accident or emergency situation occurs.
✔ Inform all health care providers that you are taking these drugs.
✔ Maintain regular medical supervision. This is extremely important for detecting adverse drug reactions, evaluating disease status, evaluating drug responses and indications for dosage change, and having blood tests or other monitoring tests when needed.
✔ Take no other drugs, prescription or nonprescription, without notifying the physician who is managing immunosuppressant therapy. Immunosuppressant drugs may influence reactions to other drugs, and other drugs may influence reactions to the immunosuppressants. Thus, taking other drugs may decrease therapeutic effects or increase adverse effects. In addition, vaccinations may be less effective, and some should be avoided while taking immunosuppressant drugs.
✔ People of reproductive capability who are sexually active should practice effective contraceptive techniques during immunosuppressive drug therapy. With methotrexate, use contraception during, and for at least 3 months (men) or 6 months (women) after stopping the drug. With mycophenolate, effective contraception should be continued for 6 weeks after the drug is stopped. With sirolimus, effective contraception must be used before, during, and for 12 weeks after drug therapy. The drug was toxic to embryos and fetuses in animal studies.
✔ Wear protective clothing and use sunscreens to decrease exposure of skin to sunlight and risks of skin cancers. Also, methotrexate and sirolimus increase sensitivity to sunlight and may increase sunburn.

Self-Administration
✔ Follow instructions about taking the drugs. This is vital to achieving beneficial effects and decreasing adverse effects. If unable to take a medication, report to the prescribing physician or other health care provider; do not stop unless advised to do so. For transplant recipients, missed doses may lead to transplant rejection; for clients with autoimmune diseases, missed doses may lead to acute flare-ups of symptoms. In addition, take at approximately the same time each day to maintain consistent drug levels in the blood.
✔ Take oral azathioprine in divided doses, after meals, to decrease stomach upset.
✔ With cyclosporine, use the same oral solution consistently. The two available solutions (Neoral and Sandimmune) are not equivalent and cannot be used interchangeably. If a change in formulation is necessary, it should be made cautiously and only under supervision of the prescribing physician.

Measure oral cyclosporine solution with the dosing syringe provided; add to orange or apple juice that is at room temperature (avoid grapefruit juice); stir well and drink at once (do not allow diluted solution to stand before drinking). Use a glass container, not plastic. Rinse the glass with more diluent to ensure the total dose is taken. Do not rinse the dosing syringe with water or other cleaning agents. Take on a consistent schedule with regard to time of day and meals.

These are the manufacturer’s recommendations. Mixing with orange or apple juice improves taste; grapefruit juice should not be used because it affects metabolism of cyclosporine. The amount of fluid should be large enough to increase palatability, especially for children, but small enough to be consumed quickly. Rinsing ensures the entire dose is taken.

Take mycophenolate on an empty stomach; food decreases the amount of active drug by 40%. Do not crush mycophenolate tablets and do not open or crush the capsules.

Take sirolimus consistently with or without food; do not mix or take the drug with grapefruit juice. Grapefruit juice inhibits metabolism and increases adverse effects. If also taking cyclosporine, take the sirolimus 4 hours after a dose of cyclosporine.

If taking the oral solution, use the syringe that comes with the medication to measure and withdraw the dose from the bottle. Empty the dose into a glass or plastic container with at least 2 oz (¼ cup or 60 mL) of water or orange juice. Do not use any other liquid to dilute the drug. Stir the mixture vigorously, and drink it immediately. Refill the container with at least 4 oz (1/2 cup or 120 mL) of water or orange juice, stir vigorously, and drink at once.

Take tacrolimus with food to decrease stomach upset.

If giving or taking an injected drug (eg, etanercept), be sure you understand how to mix and inject the medication correctly. For example, with etanercept, rotate injection sites, give a new injection at least 1 inch from a previous injection site, and do not inject the medication into areas where the skin is tender, bruised, red, or hard. When possible, practice the required techniques and perform at least the first injection under supervision of a qualified health care professional.
PRINCIPLES OF THERAPY

Risk–Benefit Factors

Immunosuppression is a serious, life-threatening condition that may result from disease processes or drug therapy. At the same time, immunosuppressant drugs are used to treat serious illnesses, and their use may be required. Rational use of these drugs requires thorough assessment of a client’s health or illness status, clear-cut indications for use, a lack of more effective and safer alternative treatments, analysis of potential risks versus potential benefits, cautious administration, and vigilant monitoring of the client’s response. If a decision is then made that immunosuppressant drug therapy is indicated and benefits outweigh risks, the therapeutic plan must be discussed with the client (ie, reasons, expected benefits, consequences for the client’s health, behavior, and lifestyle).

In addition to the specific risks or adverse effects of individual immunosuppressant drugs, general risks of immunosuppression include infection and cancer. Infection is a major cause of morbidity and mortality, especially in clients who are neutropenic (neutrophil count <1000/mm³) from cytotoxic immunosuppressant drugs or who have had bone marrow or solid organ transplantation. For the latter group, who must continue lifelong immunosuppression to avoid graft rejection, serious infection is a constant hazard. Extensive efforts are made to prevent infections; if these efforts are unsuccessful and infections occur, they may be fatal unless recognized promptly and treated vigorously. Common infections are bacterial (gram-positive, such as Staphylococcus aureus or S. epidermidis, and gram-negative, such as Escherichia coli, Klebsiella, and Pseudomonas species), fungal (candidiasis, aspergillosis), or viral (cytomegalovirus, herpes simplex, or herpes zoster).

Cancer, most commonly lymphoma or skin cancer, may result from immunosuppression. The normal immune system is thought to recognize and destroy malignant cells as they develop, as long as they can be differentiated from normal cells. With immunosuppression, the malignant cells are no longer destroyed and thus are allowed to proliferate.

The consequences of immunosuppression may be lessened by newer drugs that target specific components of the immune response rather than causing general suppression of multiple components. However, there is apparently still some risk of infection and malignancy.

Use in Transplantation

The use of immunosuppressant drugs in transplantation continues to evolve as new drugs, combinations of drugs, and other aspects are developed and tested. Specific protocols vary among transplantation centers and types of transplants. As a general rule, immunosuppressant drugs used in transplantation are often used in highly technical, complex circumstances to manage life-threatening illness. Consequently, except for corticosteroids, the drugs should be used only by specialist physicians who are adept in their management. In addition, all health care providers need to review research studies and other current literature regularly for ways to maximize safety and effectiveness and minimize adverse effects of immunosuppression.

Combinations of Immunosuppressant Drugs

Most immunosuppressants are used to prevent rejection of transplanted tissues. The rejection reaction involves T and B lymphocytes, multiple cytokines, and inflammatory mediators. Thus, drug combinations are rational because they act on different components of the immune response and often have overlapping and synergistic effects. They may also allow lower doses of individual drugs, which usually cause fewer or less severe adverse effects. For example, most organ transplantation centers use a combination regimen (eg, azathioprine, a corticosteroid, and either cyclosporine, sirolimus, or tacrolimus) for prevention and treatment of rejection reactions. Once the transplanted tissue is functioning and rejection has been successfully prevented or treated, it often is possible to maintain the graft with fewer drugs or lower drug dosages. Some recommendations to increase safety or effectiveness of drug combinations include the following:

- Lymphocyte immune globulin, antithymocyte globulin is usually given with azathioprine and a corticosteroid.
- Azathioprine is usually given with cyclosporine and prednisone.
- Basiliximab and daclizumab are given with cyclosporine and a corticosteroid.
- Corticosteroids may be given alone or included in multi-drug regimens with cyclosporine and muromonab-CD3. A corticosteroid should always accompany cyclosporine administration to enhance immunosuppression. In prophylaxis of organ transplant rejection, the combination seems more effective than azathioprine alone or azathioprine and a corticosteroid. A corticosteroid may not be required, at least long-term, with tacrolimus.
- Cyclosporine should be used cautiously with immunosuppressants other than corticosteroids to decrease risks of excessive immunosuppression and its complications.
- Methotrexate may be used alone or with cyclosporine for prophylaxis of GVHD after bone marrow transplantation.
- Muromonab-CD3 may be given cautiously with reduced numbers or dosages of other immunosuppressants. When co-administered with prednisone and azathioprine, the maximum daily dose of prednisone is 0.5 mg/kg, and the maximum for azathioprine is 25 mg. When muromonab-CD3 is co-administered with cyclosporine, cyclosporine dosage should be reduced or the drug temporarily discontinued. If discontinued, cyclosporine is restarted 3 days before completing the course of muromonab-CD3 therapy, to resume a maintenance level of immunosuppression.
Mycophenolate is used with cyclosporine and a corticosteroid. It may be used instead of azathioprine.

Sirolimus is used with cyclosporine and a corticosteroid.

Tacrolimus is substituted for cyclosporine in some long-term immunosuppressant regimens. An advantage of tacrolimus is that corticosteroid therapy can often be discontinued, with the concomitant elimination of the adverse effects associated with the long-term use of corticosteroids.

Dosage Factors

Immunosuppressant drugs are relatively toxic, and adverse effects occur more often and are more severe with higher doses. Thus, the general principle of using the smallest effective dose for the shortest period of time is especially important with immunosuppressant drug therapy. Dosage must be individualized according to the client’s clinical response (ie, improvement in signs and symptoms or occurrence of adverse effects). Factors to be considered in drug dosage decisions include the following:

- Azathioprine dosage should be reduced or the drug discontinued if severe bone marrow depression occurs (eg, reduced red blood cells, WBCs, and platelets on complete blood count [CBC]). If it is necessary to stop the drug, administration may be resumed at a smaller dosage once the bone marrow has recovered. With renal transplant recipients, the dosage required to prevent rejection and minimize toxicity varies. When given long-term for maintenance of immunosuppression, the lowest effective dose is recommended. If given concomitantly with muromonab-CD3, the dosage is reduced to 25 mg/day.

- Corticosteroid dosages vary among transplantation centers. The highest doses are usually given immediately after transplantation and during treatment of acute graft rejection reactions. Doses are usually tapered by 6 months after the transplantation, and long-term maintenance doses of prednisone are usually under 10 mg/day. Doses of corticosteroids may also be reduced when the drugs are given in combination with other immunosuppressants. For some clients, the drugs may be discontinued.

- Cyclosporine dosage should be individualized according to drug concentration in blood, serum creatinine, and the client’s clinical status. Higher doses are given for approximately 3 months post-transplantation and may be given IV for a few days after surgery (at one third the oral dosage). Higher doses are also given when cyclosporine is used with one other drug than when it is used with two other drugs. After a few months, the dose is reduced for long-term maintenance of immunosuppression after solid organ transplantation.

When a client receiving cyclosporine is given muromonab-CD3, cyclosporine is stopped temporarily or given in reduced doses.

- Dosage of mycophenolate, Muromonab-CD3, sirolimus, and tacrolimus should follow established recommendations.

Drug Administration Schedules

The effectiveness of immunosuppressant therapy may be enhanced by appropriate timing of drug administration. For example, corticosteroids are most effective when given just before exposure to the antigen, whereas the cytotoxic agents (eg, azathioprine, methotrexate) are most effective when given soon after exposure (ie, during the interval between exposure to the antigen and the production of sensitized T cells or antibodies). The newer drugs, basiliximab and daclizumab, are started a few hours before transplantation and continued for a few doses afterward.

Type of Transplant

Cardiac transplant recipients are usually given azathioprine, cyclosporine, and prednisone. Tacrolimus may be used instead of cyclosporine. Because rejection reactions are more likely to occur during the first 6 months after transplantation, transvenous endomyocardial biopsies are performed at regular intervals up to a year, then as needed according to the client’s clinical status.

Renal transplant recipients receive variable immunosuppressive drug therapy, depending on the time interval since the transplant surgery. For several days post-transplantation, high doses of IV methylprednisolone are usually given. The dose is tapered and discontinued as oral prednisone is initiated.

Cyclosporine may not be used because of its unpredictable absorption and its nephrotoxicity. If used, it is given in low doses. If not used, adequate immunosuppression must be maintained with other agents. Whichever drugs are used in the immediate postoperative period and up to 3 months post-transplantation, high doses are required to prevent organ rejection. These high doses may result in serious complications, such as infection and corticosteroid-induced diabetes. Doses are usually reduced if clients have serious adverse effects (eg, opportunistic infections, nephrotoxicity, or hepatotoxicity).

After approximately 3 months, maintenance immunosuppressant therapy usually consists of azathioprine and prednisone alone or with cyclosporine or tacrolimus. Doses are gradually decreased over 6 to 12 months, and some drugs may be discontinued (eg, prednisone, when tacrolimus is given). In addition, cyclosporine may be discontinued if chronic nephrotoxicity or severe hypertension occurs.

Liver transplant recipients may be given various drugs, and there are several effective regimens. Most regimens use methylprednisolone initially, with cyclosporine or tacrolimus; some include azathioprine or mycophenolate. At some centers, corticosteroids are eventually discontinued and clients are maintained on tacrolimus alone. Treatment of rejection reactions also varies among liver transplantation centers and centers.
may include the addition of high-dose corticosteroids and muromonab-CD3 or LIG, ATG for 7 to 14 days. In addition, clients on tacrolimus may be given higher doses. Those on cyclosporine usually do not receive higher doses because of nephrotoxicity.

An additional consideration is that liver and biliary tract functions vary among clients. As a result, the pharmacokinetics of some immunosuppressant drugs are altered. Cyclosporine has been studied most in this setting. When liver function is impaired, for example, oral cyclosporine is poorly absorbed and higher oral doses or IV administration are required to maintain adequate blood levels. When liver function and bile flow are restored, absorption of oral cyclosporine is greatly improved and dosage must be substantially reduced to maintain stable blood concentrations. Absorption of other lipid-soluble drugs is also improved. In addition, serum albumin levels are usually decreased for months after transplantation, producing higher blood levels of drugs that normally bind to albumin.

Still another consideration is that neurologic adverse effects (eg, ataxia, psychosis, seizures) occur in almost half of liver transplant recipients. These effects have been associated with corticosteroids, cyclosporine, muromonab-CD3, and tacrolimus.

Bone marrow transplant recipients are usually given cyclosporine and a corticosteroid.

**Laboratory Monitoring**

With azathioprine, bone marrow depression (eg, severe leukopenia or thrombocytopenia) may occur. To monitor bone marrow function, CBC and platelet counts should be checked weekly during the first month, every 2 weeks during the second and third months, then monthly. If dosage is changed or a client’s health status worsens at any time during therapy, more frequent blood tests are needed.

With oral cyclosporine, blood levels are monitored periodically for low or high values. Subtherapeutic levels may lead to organ transplant rejection. They are more likely to occur with the Sandimmune formulation than with Neoral because Sandimmune is poorly absorbed. High levels increase adverse effects. The blood levels are used to regulate dosage. In addition, renal (serum creatinine, blood urea nitrogen) and liver (bilirubin, aminotransferase enzymes) function tests should be performed regularly to monitor for nephrotoxicity and hepatotoxicity.

With leflunomide, renal and liver function tests should be done periodically.

With methotrexate, CBC and platelet counts and renal and liver function tests should be done periodically.

With muromonab-CD3, WBC and differential counts should be performed periodically.

With mycophenolate, a CBC is recommended weekly during the first month, twice monthly during the second and third months, and monthly during the first year.

With sirolimus, serum drug levels should be monitored in patients who are likely to have altered drug metabolism (eg, those 13 years and older who weigh less than 40 kg, those with impaired hepatic function, and those who also are receiving enzyme-inducing or inhibiting drugs). Trough concentrations of 15 ng/mL or more are associated with increased frequency of adverse effects. In addition, tests related to hyperlipidemia and renal function should also be performed periodically.

With tacrolimus, periodic measurements of serum creatinine, potassium, and glucose are recommended to monitor for the adverse effects of nephrotoxicity, hyperkalemia, and hyperglycemia.

**Use in Children**

Most immunosuppressants are used in children for the same disorders and with similar effects as in adults. Corticosteroids impair growth in children. As a result, some transplantation centers avoid prednisone therapy until a rejection episode occurs. When prednisone is used, administering it every other day may improve growth rates. Cyclosporine has been safely and effectively given to children as young as 6 months of age, but extensive studies have not been performed. Muromonab-CD3 has been used successfully in children as young as 2 years of age; however, safety and efficacy for use in children have not been established. Mycophenolate has been used in a few children undergoing renal transplantation. In children with impaired renal function, recommended doses of mycophenolate cause a high incidence of adverse effects. Thus, dosage should be adjusted for the level of renal function. Tacrolimus has been used in children younger than 12 years of age who were undergoing liver transplantation. This usage indicates that children require higher doses to maintain therapeutic blood levels than adults because they metabolize the drug more rapidly.

Little information is available about the use of newer immunosuppressants in children. Safety and effectiveness have not been established for basiliximab, daclizumab, infliximab, or leflunomide. Leflunomide is not recommended for children under 18 years of age. Etanercept is approved for clients 4 to 17 years of age with juvenile rheumatoid arthritis. In clinical trials, effects in children were similar to those in adults. Most children in a 3-month study had an infection while receiving etanercept. The infections were usually mild and consistent.
with those commonly seen in outpatient pediatric settings. Children reported abdominal pain, nausea, vomiting, and headache more often than adults. Other medications (eg, a corticosteroid, methotrexate, a nonsteroidal anti-inflammatory drug, or an analgesic) may be continued during treatment.

**Use in Older Adults**

Immunosuppressants are used for the same purposes and produce similar therapeutic and adverse effects in older adults as in younger adults. Because older adults often have multiple disorders and organ impairments, it is especially important that drug choices, dosages, and monitoring tests are individualized. In addition, infections occur more commonly in older adults, and this tendency may be increased with immunosuppressant therapy.

**Use in Renal Impairment**

- **Azathioprine** metabolites are excreted in urine but they are inactive, and the dose does not need to be reduced in clients with renal impairment.
- **Cyclosporine** is nephrotoxic but commonly used in clients with renal and other transplants. Nephrotoxicity has been noted in 25% of renal, 38% of cardiac, and 37% of liver transplant recipients, especially with high doses. It usually subsides with decreased dosage or stopping the drug.

  In renal transplant recipients, when serum creatinine and blood urea nitrogen levels remain elevated, a complete evaluation of the client must be done to differentiate cyclosporine-induced nephrotoxicity from a transplant rejection reaction (although up to 20% of clients may have simultaneous nephrotoxicity and rejection). If renal function is deteriorating from cyclosporine, dosage reduction may be needed. If dosage reduction does not improve renal function, another immunosuppressant is preferred.

  If renal function is deteriorating from a rejection reaction, decreasing cyclosporine dosage would increase the severity of the reaction. With severe rejection that does not respond to treatment with corticosteroids and monoclonal antibodies, it is preferable to allow the kidney transplant to be rejected and removed rather than increase cyclosporine dosage to high levels in an attempt to reverse the rejection.

  To decrease risks of nephrotoxicity, dosage is adjusted according to cyclosporine blood levels and renal function test results, and other nephrotoxic drugs should be avoided. An additional factor is the potential for significant drug interactions with microsomal enzyme inhibitors and inducers. Drugs that inhibit hepatic metabolism (eg, cimetidine) raise cyclosporine blood levels, whereas those that stimulate metabolism decrease levels.

- **Methotrexate** is mainly excreted in urine, so its half-life is prolonged in clients with renal impairment, with risks of accumulation to toxic levels and additional renal damage. However, the risks are less with the small doses used for treatment of rheumatoid arthritis than for the high doses used in cancer chemotherapy. To decrease these risks, adequate renal function should be documented before the drug is given and clients should be well hydrated.

- **Muromonab-CD3** has caused increased serum creatinine and decreased urine output in a few clients during the first 1 to 3 days of use. This was attributed to the release of cytokines with resultant renal function impairment or delayed renal allograft function. The renal function impairment was reversible. Overall, there is little information about the use of this drug in clients with renal impairment.

- **Mycophenolate** produces higher plasma levels in renal transplant recipients with severe, chronic renal impairment than in clients with less severe renal impairment and healthy volunteers. Doses higher than 1 g twice a day should be avoided in these clients. There is no information about mycophenolate use in cardiac transplant recipients with severe, chronic renal impairment.

- **Sirolimus** is eliminated mainly in feces, with less than 3% eliminated in urine. Dosage does not need to be reduced with renal impairment.

- **Tacrolimus** is often associated with high rates of nephrotoxicity when given IV, so oral dosing is preferred. Renal impairment does not increase drug half-life.

Little information is available about the use of basiliximab, etanercept, infliximab, or leflunomide in clients with renal impairment. However, leflunomide metabolites are partly excreted renally and the drug should be used cautiously. Daclizumab dosage does not need to be adjusted with renal impairment.

**Use in Hepatic Impairment**

- **Azathioprine** is normally metabolized to its active metabolite in the liver. As a result, pharmacologic action is decreased in clients with hepatic impairment. When azathioprine is used in liver transplantation, clients sometimes experience hepatotoxicity characterized by cholestasis, peliosis hepatis, nodular regenerative hyperplasia, and veno-occlusive disease. Liver function usually improves within a week if azathioprine is discontinued.

  Little information is available about the use of basiliximab, etanercept, infliximab, or leflunomide in clients with hepatic impairment. When azathioprine is used in liver transplantation, clients sometimes experience hepatotoxicity characterized by cholestasis, peliosis hepatis, nodular regenerative hyperplasia, and veno-occlusive disease. Liver function usually improves within a week if azathioprine is discontinued.

- **Cyclosporine** reportedly causes hepatotoxicity (eg, elevated serum aminotransferases and bilirubin) in approximately 4% of renal and liver transplant recipients and 7% of cardiac transplant recipients. This is most likely to occur during the first month of therapy, when high doses of cyclosporine are usually given, and usually subsides with reduced dosage.
• **Methotrexate** is metabolized in the liver and may cause hepatotoxicity, even in the low doses used in rheumatoid arthritis and psoriasis. Several studies indicate that these clients eventually sustain liver changes that may include fatty deposits, lobular necrosis, fibrosis, and cirrhosis. Progression to cirrhosis may be related to the deposition of methotrexate and its metabolites in the liver. Many clinicians recommend serial liver biopsies for clients on long-term, low-dose methotrexate (eg, after each cumulative dose of 1 to 1.5 g) because fibrosis and cirrhosis may not produce clinical manifestations.

In addition, in clients with or without initial liver impairment, liver function tests should be performed to monitor clients for hepatotoxicity and to guide drug dosage. In general, methotrexate dosage should be decreased by 25% if bilirubin (normal = 0.1 to 1.0 mg/dL) is between 3 and 5 mg/dL or aspartate aminotransferase (AST) (normal = 10 to 40 IU/L) is above 180 IU/L, and the drug should be omitted if bilirubin is above 5 mg/dL.

• **Muromonab-CD3** may cause a transient increase in liver aminotransferase enzymes (eg, AST, alanine aminotransferase [ALT]) with the first few doses. Overall, however, there is little information about drug effects or use in clients with liver impairment.

• **Mycophenolate** is metabolized in the liver to an active metabolite that is further metabolized to inactive metabolites. Liver impairment presumably could interfere with these processes and affect both action and elimination. However, there is little information about its use in clients with hepatic impairment.

• **Sirolimus** is extensively metabolized in the liver and may accumulate in the presence of hepatic impairment. The maintenance dose should be reduced by 35%; it is not necessary to reduce the loading dose.

• **Tacrolimus** is metabolized in the liver by the microsomal P450 enzyme system. Impaired liver function may decrease presystemic (first-pass) metabolism of oral tacrolimus and produce higher blood levels. Also, the elimination half-life is significantly longer for IV or oral drug. As a result, dosage must be decreased in clients with impaired liver function.

An additional factor is the potential for significant drug interactions with microsomal enzyme inhibitors and inducers. Drugs that inhibit hepatic metabolism (eg, cimetidine) raise tacrolimus blood levels, whereas those that stimulate metabolism decrease levels.

There is no information about the use of basiliximab, daclizumab, etanercept, or infliximab in clients with liver impairment. **Leflunomide** may be hepatotoxic in clients with normal liver function and is not recommended for use in clients with liver impairment or positive serology tests for hepatitis B or C. Considerations and guidelines include the following:

1. Leflunomide is metabolized to an active metabolite. The site of metabolism is unknown but thought to be the liver and the wall of the intestine. With liver impairment, less formation of the active metabolite may result in reduced therapeutic effect.

2. The active metabolite is further metabolized and excreted through the kidneys and biliary tract. Some of the drug excreted in bile is reabsorbed. Leflunomide’s long half-life is attributed to this biliary recycling.

3. The role of the liver in drug metabolism and excretion in bile increases risks of hepatotoxicity. The drug increased liver enzymes (mainly AST and ALT) in clinical trials. Most elevations were mild and usually subsided with continued therapy. Higher elevations were infrequent and subsided if dosage was reduced or the drug was discontinued. It is recommended that liver enzymes, especially ALT, be measured before starting leflunomide, every month during therapy until stable, then as needed.

4. When ALT elevation is more than twice the upper limits of normal (ULN), leflunomide dosage should be reduced to 10 mg/day (half the usual daily maintenance dose). If ALT levels are more than twice but not more than three times the ULN and persist despite dosage reduction, liver biopsy is recommended if continued drug use is desired. If elevations are more than three times the ULN and persist despite dosage reduction and cholestyramine (see later), leflunomide should be discontinued. ALT levels should be monitored and cholestyramine readministered as indicated.

5. When leflunomide is stopped, a special procedure is recommended to eliminate the drug (otherwise it could take as long as 2 years). The procedure involves administration of cholestyramine (see Chap. 58) 8 g three times daily for 11 days (the 11 days do not need to be consecutive unless blood levels need to be lowered rapidly). If plasma levels are still above the goal level of less than 0.02 mcg/mL, additional cholestyramine may be needed.

### Home Care

With clients who are taking immunosuppressant drugs, a major role of the home care nurse is to assess the environment for potential sources of infection, assist clients and other members of the household to understand the client’s susceptibility to infection, and teach ways to decrease risks of infection. Although infections often develop from the client’s own body flora, other potential sources include people with infections, caregivers, water or soil around live plants, and raw fruits and vegetables. Meticulous environmental cleaning, personal hygiene, and hand washing are required. In addition, the nurse may need to assist with clinic visits for monitoring and follow-up care.
### Immunosuppressants

#### NURSING ACTIONS

<table>
<thead>
<tr>
<th>1. Administer accurately</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>a. For prepared intravenous (IV) solutions, check for appropriate dilution, discoloration, particulate matter, and expiration time. If okay, give by infusion pump, for the recommended time.</td>
<td></td>
</tr>
<tr>
<td>b. Give oral azathioprine in divided doses, after meals; give IV drug by infusion, usually over 30 to 60 min.</td>
<td></td>
</tr>
<tr>
<td>c. With basiliximab, infuse through a peripheral or central vein over 20–30 min. Use the reconstituted solution within 4 h at room temperature or 24 h if refrigerated.</td>
<td></td>
</tr>
<tr>
<td>d. With IV cyclosporine, infuse over 2–6 h.</td>
<td></td>
</tr>
<tr>
<td>e. With oral cyclosporine solutions, measure doses with the provided syringe; add to room temperature orange or apple juice (avoid grapefruit juice); stir well and have the patient drink at once (do not allow diluted solution to stand before drinking). Use a glass container, not plastic. Rinse the glass with more juice to ensure the total dose is taken. Do not rinse the dosing syringe with water or other cleaning agents. Give on a consistent schedule in relation to time of day and meals.</td>
<td></td>
</tr>
<tr>
<td>f. Infuse reconstituted and diluted daclizumab through a peripheral or central vein over 15 min. Once mixed, use within 4 h or refrigerate up to 24 h.</td>
<td></td>
</tr>
<tr>
<td>g. With etanercept, slowly inject 1 mL of the supplied Sterile Bacteriostatic Water for Injection into the vial, without shaking (to avoid excessive foaming). Give subcutaneously, rotating sites so that a new dose is injected at least 1 inch from an old site and never into areas where the skin is tender, bruised, red, or hard.</td>
<td></td>
</tr>
<tr>
<td>h. Infuse reconstituted and diluted infliximab over approximately 2 h, starting within 3 h of preparation (contains no antibacterial preservatives).</td>
<td></td>
</tr>
<tr>
<td>i. Give lymphocyte immune globulin, antithymocyte globulin (diluted to a concentration of 1 mg/mL) into a large or central vein, using an in-line filter and infusion pump, over at least 4 h. Once diluted, use within 24 h.</td>
<td></td>
</tr>
<tr>
<td>j. Give muromonab-CD3 in an IV bolus injection once daily. Do not give by IV infusion or mix with other drug solutions.</td>
<td></td>
</tr>
<tr>
<td>k. Infuse IV mycophenolate over approximately 2 h, within 4 h of solution preparation (contains no antibacterial preservatives).</td>
<td></td>
</tr>
<tr>
<td>l. Give oral mycophenolate on an empty stomach. Do not crush the tablets, do not open or crush the capsules, and ask clients to swallow the capsules whole, without biting or chewing.</td>
<td></td>
</tr>
</tbody>
</table>

#### RATIONALE/EXPLANATION

- **IV drugs should be reconstituted and diluted in a pharmacy, and the manufacturers’ instructions should be followed exactly. Once mixed, most of these drugs are stable only for a few hours and some do not contain preservatives.**
  - To decrease nausea and vomiting with oral drug
  - The first dose is given within 2 h before transplantation surgery and the second dose 4 d after transplantation.
  - IV drug is given to patients who are unable to take it orally; resume oral administration when feasible.
  - These are the manufacturers’ recommendations. Mixing with orange or apple juice improves taste; grapefruit juice should not be used because it affects metabolism of cyclosporine.
  - The amount of fluid should be large enough to increase palatability, especially for children, but small enough to be consumed quickly. Rinsing ensures the entire dose is taken.
  - Oral cyclosporine may be given to clients who have had an anaphylactic reaction to the IV preparation, because the reaction is attributed to the oil diluent rather than the drug.
  - The first dose is given approximately 24 h before transplantation, followed by a dose every 2 wk for four doses (total of five doses).
  - This drug may be administered at home, by a client or a caregiver, with appropriate instructions and supervised practice in mixing and injecting the drug.
- **Infliximab should be prepared in a pharmacy because special equipment is required for administration.**
  - Manufacturer’s recommendations. Using a high-flow vein decreases phlebitis and thrombosis at the IV site. The filter is used to remove any insoluble particles.
  - Manufacturer’s recommendations
  - The IV drug must be reconstituted and diluted with 5% dextrose to a concentration of 6 mg/mL (1 g in 140 mL or 1.5 g in 210 mL).
  - Handle the drug cautiously to avoid contact with skin and mucous membranes. If such contact occurs, wash thoroughly with soap and water; rinse eyes with plain water.
  - Food decreases absorption. Avoid inhaling the powder from the capsules or getting on skin or mucous membranes. Such contacts produced teratogenic effects in animals.

(continued)
### Nursing Actions

**m.** With sirolimus, give 4 h after a dose of cyclosporine; give consistently with or without food; and do not give with grapefruit juice.

With oral sirolimus solution, use the amber oral dose syringe to withdraw a dose from the bottle; empty the dose into a glass or plastic container with at least 60 mL of water or orange juice (do not use any other diluent); stir the mixture vigorously and ask the patient to drink it immediately; refill the container with at least 120 mL of water or orange juice; stir vigorously and ask the patient to drink all of the fluid.

**n.** Give IV tacrolimus as a continuous infusion by infusion pump.

**o.** Give the first dose of oral tacrolimus 8–12 h after stopping the IV infusion.

### Rationale/Explanation

Serum drug levels of sirolimus are increased if the two drugs are taken at the same time; consistent timing in relation to food provides more consistent absorption and blood levels; grapefruit juice inhibits the enzymes that metabolize sirolimus, thereby increasing blood levels of drug and increasing risks of toxicity

Manufacturer’s recommendations

Oral tacrolimus can usually be substituted for IV drug 2–3 d after transplantation.

With azathioprine, therapeutic effects usually occur after 6–8 wk. If no response occurs within 12 wk, other treatment measures are indicated. With methotrexate, therapeutic effects usually occur within 3–6 wk.

Frequency and severity increase with higher drug dosages. Risks are high in immunosuppressed clients. Infections may be caused by almost any microorganism and may affect any part of the body, although respiratory and urinary tract infections may occur more often.

The incidence of adverse effects is high in renal transplant recipients. Dosage reduction or stopping azathioprine may be indicated.

Can be reduced by dividing the daily dosage and giving after meals GI symptoms were often reported in clinical trials. Although adverse effects involving all body systems were reported, the number and type were similar for basiliximab, daclizumab, and placebo groups. All patients were also receiving cyclosporine and a corticosteroid.

This is a major adverse effect, and it may produce signs and symptoms that are difficult to distinguish from those caused by renal graft rejection. Rejection usually occurs within the first month after surgery. If it occurs, dosage must be reduced and the patient observed for improved renal function.

Also, note that graft rejection and drug-induced nephrotoxicity may be present simultaneously. The latter may be decreased by reducing dosage. Nephrotoxicity often occurs 2–3 mo after transplantation and results in a stable but decreased level of renal function (BUN of 35–45 mg/dL and serum creatinine of 2.0–2.5 mg/dL).

*(continued)*
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Hepatotoxicity (increased serum enzymes and bilirubin)</td>
<td>The reported incidence is less than 8% after kidney, heart, or liver transplantation. It usually occurs during the first month, when high doses are used, and decreases with dosage reduction.</td>
</tr>
<tr>
<td>(3) Hypertension</td>
<td>This is especially likely to occur in clients with heart transplants and may require antihypertensive drug therapy. Do not give a potassium-sparing diuretic as part of the antihypertensive regimen because of increased risk of hyperkalemia.</td>
</tr>
<tr>
<td>(4) Anaphylaxis (with IV cyclosporine) (urticaria, hypotension or shock, respiratory distress)</td>
<td>This is rare but may occur. The allergen is thought to be the polyoxyethylated castor oil because people who had allergic reactions with the IV drug have later taken oral doses without allergic reactions. During IV administration, observe the client continuously for the first 30 min and often thereafter. Stop the infusion if a reaction occurs, and give emergency care (eg, epinephrine 1:1000).</td>
</tr>
<tr>
<td>(5) Central nervous system (CNS) toxicity (confusion, depression, hallucinations, seizures, tremor)</td>
<td>These effects are relatively uncommon and may be caused by factors other than cyclosporine (eg, nephrotoxicity).</td>
</tr>
<tr>
<td>(6) Other (gingival hyperplasia, hirsutism)</td>
<td>Gingival hyperplasia can be minimized by thorough oral hygiene.</td>
</tr>
<tr>
<td>e. With infliximab, observe for:</td>
<td>The drug was, in general, well tolerated in clinical trials, with the number and type of most adverse effects similar to those occurring with placebo.</td>
</tr>
<tr>
<td>(1) Infusion reactions (fever, chills, pruritus, urticaria, chest pain)</td>
<td></td>
</tr>
<tr>
<td>(2) GI upset (nausea, vomiting, abdominal pain)</td>
<td></td>
</tr>
<tr>
<td>(3) Respiratory symptoms (bronchitis, chest pain, coughing, dyspnea)</td>
<td></td>
</tr>
<tr>
<td>f. With leflunomide, observe for:</td>
<td>An uncommon but serious allergic reaction to the animal protein in the drug that may occur anytime during therapy. If it occurs, stop the drug infusion, inject 0.3 mL epinephrine 1:1000, and provide other supportive emergency care as indicated.</td>
</tr>
<tr>
<td>(1) GI upset (nausea, diarrhea)</td>
<td>Fever occurs in approximately 50% of clients; it may be decreased by premedicating with acetaminophen, an antihistamine, or a corticosteroid.</td>
</tr>
<tr>
<td>(2) Hepatotoxicity (elevation of transaminases)</td>
<td></td>
</tr>
<tr>
<td>(3) Skin (alopecia, rash)</td>
<td></td>
</tr>
<tr>
<td>g. With lymphocyte immune globulin, antithymocyte globulin, observe for:</td>
<td>Monitor complete blood count (CBC) regularly. Bone marrow depression is less likely to occur with the small doses used for inflammatory disorders than with doses used in cancer chemotherapy.</td>
</tr>
<tr>
<td>(1) Anaphylaxis (chest pain, respiratory distress, hypotension, or shock)</td>
<td>Long-term, low-dose methotrexate may produce fatty changes, fibrosis, necrosis, and cirrhosis in the liver.</td>
</tr>
<tr>
<td>(2) Chills and fever</td>
<td>This reaction is attributed to the release of cytokines by activated lymphocytes or monocytes. Symptoms may range from “flu-like” to a less frequent but severe, shock-like reaction that may include serious cardiovascular and CNS disorders.</td>
</tr>
<tr>
<td>h. With methotrexate, observe for:</td>
<td>(continued)</td>
</tr>
<tr>
<td>(1) GI disorders (nausea, vomiting, diarrhea, ulcers, bleeding)</td>
<td></td>
</tr>
<tr>
<td>(2) Bone marrow depression (anemia, neutropenia, thrombocytopenia)</td>
<td></td>
</tr>
<tr>
<td>(3) Hepatotoxicity (yellow discoloration of skin or eyes, dark urine, elevated liver aminotransferases)</td>
<td></td>
</tr>
<tr>
<td>i. With muromonab-CD3, observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) An acute reaction called the cytokine release syndrome (high fever, chills, chest pain, dyspnea, hypertension, nausea, vomiting, diarrhea)</td>
<td></td>
</tr>
<tr>
<td>(continued)</td>
<td></td>
</tr>
<tr>
<td>NURSING ACTIONS</td>
<td>RATIONALE/EXPLANATION</td>
</tr>
<tr>
<td>-----------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>(2) Hypersensitivity (edema, difficulty in swallowing or breathing, skin rash, urticaria, rapid heart beat)</td>
<td>Symptoms usually occur within 30–60 min after administration of a dose, especially the first dose, and may last several hours. The reaction usually subsides with later doses, but may recur with dosage increases or restarting after a period without the drug.</td>
</tr>
<tr>
<td>(3) Nausea, vomiting, diarrhea</td>
<td>Patients experiencing a hypersensitivity reaction should receive immediate treatment.</td>
</tr>
<tr>
<td><strong>j. With mycophenolate, observe for:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) GI effects (nausea, vomiting, diarrhea)</td>
<td>GI effects are more likely when mycophenolate is started and may subside if dosage is reduced.</td>
</tr>
<tr>
<td>(2) Hematologic effects (anemia, neutropenia)</td>
<td>Monitor CBC reports regularly. Up to 2% of renal and 2.8% of cardiac transplant recipients taking mycophenolate have severe neutropenia (absolute neutrophil count &lt;500/mm³). The neutropenia may be related to mycophenolate, concomitant medications, viral infections, or a combination of these causes. If a client has neutropenia, interrupt drug administration or reduce the dose and initiate appropriate treatment as soon as possible.</td>
</tr>
<tr>
<td>(3) CNS effects (dizziness, headache, insomnia)</td>
<td></td>
</tr>
<tr>
<td><strong>k. With sirolimus, observe for:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) GI effects—abdominal pain, nausea, vomiting, constipation, diarrhea, hepatotoxicity</td>
<td></td>
</tr>
<tr>
<td>(2) Hematologic effects—anemia, leukopenia, thrombocytopenia, hypercholesterolemia</td>
<td></td>
</tr>
<tr>
<td>(3) Cardiovascular effects—edema, hypertension</td>
<td></td>
</tr>
<tr>
<td>(4) CNS effects—insomnia, headache, tremor</td>
<td>Most reactions were common (ie, occurred in &gt;10% of recipients). However, patients were also receiving cyclosporine and a corticosteroid.</td>
</tr>
<tr>
<td><strong>l. With tacrolimus, observe for:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Nephrotoxicity—increased serum creatinine, decreased urine output</td>
<td>Nephrotoxicity has occurred in one third or more of liver transplant recipients who received tacrolimus. The risk is greater with higher doses.</td>
</tr>
<tr>
<td>(2) Neurotoxicity—minor effects include insomnia, mild tremors, headaches, photophobia, nightmares; major effects include confusion, seizures, coma, expressive aphasia, psychosis, and encephalopathy.</td>
<td>Neurologic symptoms are common and occur in approximately 10%–20% of clients receiving tacrolimus.</td>
</tr>
<tr>
<td>(3) Infection—cytomegalovirus (CMV) infection and others</td>
<td>CMV infection commonly occurs.</td>
</tr>
<tr>
<td>(4) Hyperglycemia</td>
<td>Glucose intolerance may require insulin therapy.</td>
</tr>
<tr>
<td><strong>4. Observe for drug interactions</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a. Drugs that increase effects of azathioprine:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Allopurinol</td>
<td>Inhibits hepatic metabolism, thereby increasing pharmacologic effects. If the two drugs are given concomitantly, the dose of azathioprine should be reduced drastically to 25%–35% of the usual dose.</td>
</tr>
<tr>
<td>(2) Corticosteroids</td>
<td>Increased immunosuppression and risk of infection</td>
</tr>
<tr>
<td><strong>b. Drugs that increase effects of cyclosporine:</strong></td>
<td></td>
</tr>
<tr>
<td>(1) Aminoglycoside antibiotics (eg, gentamicin), antifungals (eg, amphotericin B)</td>
<td>Increased risk of nephrotoxicity. Avoid other nephrotoxic drugs when possible.</td>
</tr>
<tr>
<td>(2) Antifungals (fluconazole, itraconazole), calcium channel blockers (diltiazem, nicardipine, verapamil), macrolide antibiotics (erythromycin, clarithromycin), cimetidine</td>
<td>Decreased hepatic metabolism, increased serum drug levels, and increased risk of toxicity</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Drugs that <em>decrease</em> effects of cyclosporine:</td>
<td>Enzyme-inducing drugs stimulate hepatic metabolism of cyclosporine, thereby reducing blood levels. If concurrent administration is necessary, monitor cyclosporine blood levels to avoid subtherapeutic levels and decreased effectiveness.</td>
</tr>
<tr>
<td>(1) Enzyme inducers, including anticonvulsants (carbamazepine, phenytoin), rifampin, trimethoprim-sulfamethoxazole</td>
<td></td>
</tr>
<tr>
<td>d. Drugs that <em>increase</em> effects of leflunomide:</td>
<td>Rifampin induces liver enzymes and accelerates metabolism of leflunomide to its active metabolite.</td>
</tr>
<tr>
<td>(1) Rifampin</td>
<td>Additive hepatotoxicity</td>
</tr>
<tr>
<td>(2) Hepatotoxic drugs (eg, methotrexate)</td>
<td></td>
</tr>
<tr>
<td>e. Drugs that <em>decrease</em> effects of leflunomide:</td>
<td>These drugs may be used to lower blood levels of leflunomide.</td>
</tr>
<tr>
<td>(1) Charcoal</td>
<td></td>
</tr>
<tr>
<td>(2) Cholestyramine</td>
<td></td>
</tr>
<tr>
<td>f. Drugs that <em>increase</em> effects of methotrexate:</td>
<td>Probenecid, salicylates, and sulfonamides may increase both therapeutic and toxic effects. The mechanism is unknown, but may involve slowing of methotrexate elimination through the kidneys or displacement of methotrexate from plasma protein-binding sites.</td>
</tr>
<tr>
<td>(1) Probenecid</td>
<td>NSAIDS are often used concomitantly with methotrexate by clients with rheumatoid arthritis. There may be an increased risk of GI ulceration and bleeding.</td>
</tr>
<tr>
<td>(2) Salicylates</td>
<td>Procarbazine may increase nephrotoxicity; hepatotoxic drugs increase hepatotoxicity.</td>
</tr>
<tr>
<td>(3) Sulfonamides</td>
<td></td>
</tr>
<tr>
<td>(4) Nonsteroidal anti-inflammatory drugs (NSAIDs)</td>
<td></td>
</tr>
<tr>
<td>(5) Procarbazine</td>
<td></td>
</tr>
<tr>
<td>(6) Alcohol and other hepatotoxic drugs</td>
<td></td>
</tr>
<tr>
<td>g. Drug that <em>decreases</em> effects of methotrexate:</td>
<td>Methotrexate acts by blocking folic acid. Its effectiveness is decreased by folic acid supplementation, alone or in multivitamin preparations.</td>
</tr>
<tr>
<td>(1) Folic acid</td>
<td></td>
</tr>
<tr>
<td>h. Drugs that <em>increase</em> effects of mycophenolate:</td>
<td>Increase blood levels of mycophenolate, probably by decreasing renal excretion</td>
</tr>
<tr>
<td>(1) Acyclovir, ganciclovir</td>
<td>Increase blood levels</td>
</tr>
<tr>
<td>(2) Probenecid, salicylates</td>
<td></td>
</tr>
<tr>
<td>i. Drug that <em>decreases</em> effects of mycophenolate:</td>
<td>Decreases absorption</td>
</tr>
<tr>
<td>(1) Cholestyramine</td>
<td></td>
</tr>
<tr>
<td>j. Drugs that <em>increase</em> effects of sirolimus:</td>
<td>Increases blood levels of sirolimus and should not be given at same time (give sirolimus 4 h after a dose of cyclosporine)</td>
</tr>
<tr>
<td>(1) Cyclosporine</td>
<td>These drugs inhibit metabolism of sirolimus, which increases blood levels and risks of toxicity.</td>
</tr>
<tr>
<td>(2) CYP3A4 enzyme inhibitors—Azole antifungal drugs (eg, fluconazole, itraconazole), calcium channel blockers (eg, diltiazem, nicardipine, verapamil), macrolide antibiotics (eg, erythromycin, clarithromycin), protease inhibitors (eg, ritonavir, indinavir), cimetidine</td>
<td></td>
</tr>
<tr>
<td>k. Drugs that <em>decrease</em> effects of sirolimus:</td>
<td>These drugs speed up the metabolism and elimination of sirolimus.</td>
</tr>
<tr>
<td>(1) Enzyme inducers—Anticonvulsants (eg, carbamazepine, phenytoin), rifamycins (eg, rifampin, rifabutin, rifapentine), St. John’s wort</td>
<td></td>
</tr>
<tr>
<td>(continued)</td>
<td></td>
</tr>
</tbody>
</table>
**NURSING ACTIONS**

1. Drugs that *increase* effects of tacrolimus:
   - (1) Nephrotoxic drugs (eg, aminoglycoside antibiotics, amphotericin B, cisplatin, NSAIDs)
   - (2) Antifungals (clotrimazole, fluconazole, itraconazole); erythromycin and other macrolides; calcium channel blockers (diltiazem, verapamil), cimetidine, danazol, methylprednisolone, metoclopramide
   - (3) Angiotensin-converting enzyme inhibitors, potassium supplements

2. Drugs that *decrease* effects of tacrolimus:
   - (1) Antacids
   - (2) Enzyme inducers—carbamazepine, phenytoin, rifampin, rifabutin

**RATIONALE/EXPLANATION**

- Increased risk of nephrotoxicity
  
  Increased risk of hyperkalemia. Serum potassium levels should be monitored closely.

  With oral tacrolimus, antacids adsorb the drug or raise the pH of gastric fluids and increase its degradation. If ordered concomitantly, an antacid should be given at least 2 h before or after tacrolimus.

- Induction of drug-metabolizing enzymes in the liver may accelerate metabolism of tacrolimus and decrease its blood levels.

**Nursing Notes: Apply Your Knowledge**

**Answer:** Complete a total body assessment, looking for signs of infection. It is important to note that patients taking immunosuppressive drugs do not mount an effective immune response in the presence of infection. Her temperature, even though it is a low-grade fever, is very significant and supports that an infection might be present. Signs of organ rejection include fever, flank pain, and signs that indicate the kidney is no longer functioning well (increased creatinine and blood urea nitrogen [BUN], decreased urine output, weight gain). Provide Ms. Reily’s transplant surgeon with the data you have collected. He or she will order laboratory tests, including white blood cell count and differential, creatinine, BUN, and a cyclosporine level.

**Selected References**


**Review and Application Exercises**

1. List clinical indications for use of immunosuppressant drug therapy.
2. How do the different types of drugs exert their immunosuppressant effects?
3. What are major adverse effects of immunosuppressant drugs?
4. When assessing a client receiving one or more immunosuppressant drugs, what specific signs and symptoms indicate adverse drug effects?
5. For a client taking one or more immunosuppressant drugs, prepare a teaching plan related to safe and effective drug therapy.
Drugs Affecting the Respiratory System
chapter 46

Physiology of the Respiratory System

Objectives
After studying this chapter, the student will be able to:

1. Review roles and functions of the main respiratory tract structures in oxygenation of body tissues.
2. Describe the role of carbon dioxide in respiration.
3. List common signs and symptoms affecting respiratory function.
4. Identify general categories of drugs used to treat respiratory disorders.

Overview

The respiratory system helps meet the basic human need for oxygen (O₂). Oxygen is necessary for the oxidation of foodstuffs, by which energy for cellular metabolism is produced. When the oxygen supply is inadequate, cell function is impaired; when oxygen is absent, cells die. Permanent brain damage occurs within 4 to 6 minutes of anoxia. In addition to providing oxygen to all body cells, the respiratory system also removes carbon dioxide (CO₂), a major waste product of cell metabolism. Excessive accumulation of CO₂ damages or kills body cells.

The efficiency of the respiratory system depends on the quality and quantity of air inhaled, the patency of air passageways, the ability of the lungs to expand and contract, and the ability of O₂ and CO₂ to cross the alveolar–capillary membrane. In addition to the respiratory system, the circulatory, nervous, and musculoskeletal systems have important functions in respiration. Additional characteristics of the respiratory system and the process of respiration are described in the following sections.

Respiration

Respiration is the process of gas exchange by which O₂ is obtained and CO₂ is eliminated. This gas exchange occurs between the lung and the blood across the alveolar–capillary membrane and between the blood and body cells. More specifically, the four parts of respiration are:

• Ventilation—the movement of air between the atmosphere and the alveoli of the lungs
• Perfusion—blood flow through the lungs
• Diffusion—the process by which O₂ and CO₂ are transferred between alveoli and blood and between blood and body cells
• Regulation of breathing by the respiratory muscles and nervous system

Respiratory Tract

The respiratory tract is a series of branching tubes with progressively smaller diameters. These tubes (nose, pharynx, larynx, trachea, bronchi, and bronchioles) function as air passageways and air “conditioners” that filter, warm, and humidify incoming air. Most of the conditioning is done by the ciliated mucous membrane that lines the entire respiratory tract, except the pharynx and alveoli. Cilia are tiny, hair-like projections that sweep mucus toward the pharynx to be expectorated or swallowed. The mucous membrane secretes mucus, which forms a protective blanket and traps foreign particles, such as bacteria and dust.

When air is inhaled through the nose, it is conditioned by the nasal mucosa. When the nasal passages are blocked, the mouth serves as an alternate airway. The oral mucosa may warm and humidify air but cannot filter it.

Pharynx, Larynx, and Trachea

Air passes from the nasal cavities to the pharynx (throat). Pharyngeal walls are composed of skeletal muscle, and their lining is composed of mucous membrane. The pharynx contains the palatine tonsils, which are large masses of lymphatic tissue. The pharynx is a passageway for food, fluids, and air. Food and fluids go from the pharynx to the esophagus, and air passes from the pharynx into the trachea.

The larynx is composed of nine cartilages joined by ligaments and controlled by skeletal muscles. It contains the vocal cords and forms the upper end of the trachea. It closes
on swallowing to prevent aspiration of food and fluids into
the lungs.

The trachea is the passageway between the larynx and the
main stem bronchi. It is a cartilaginous tube lined with cili-
ated epithelium and mucus-secreting cells. Cilia and mucus
help to protect and defend the lungs.

**Lungs**

The lungs begin where the trachea divides into the right and
left main stem bronchi and contain the remaining respiratory
structures. They are divided into five lobes, each with a sec-
dondary bronchus. The lobes are further subdivided into bron-
chopulmonary segments supplied by smaller bronchi. The
bronchopulmonary segments contain lobules, which are the
functional units of the lung (the site where gas exchange takes
place). Each lobule is supplied by a bronchiole, an arteriole,
a venule, and a lymphatic vessel. Blood enters the lobules
through a pulmonary artery and exits through a pulmonary
vein. Lymphatic structures surround the lobule and aid in the
removal of plasma proteins and other particles from interstitial
spaces.

The mainstem bronchi branch into smaller bronchi, then
into bronchioles. Bronchioles are approximately the size of
a pencil lead and do not contain cartilage or mucus-secreting
glands. The walls of the bronchioles contain smooth mus-
cle, which is controlled by the autonomic nervous system.
Stimulation of parasympathetic nerves causes constriction;
stimulation of sympathetic nerves causes relaxation or
dilation.

The epithelial lining of the bronchioles becomes thinner with
progressive branchings until only one cell layer is apparent. The
bronchioles give rise to the alveoli, which are grape-like clus-
ters of air sacs surrounded by capillaries.

The alveoli are composed of two types of cells. Type I
cells are flat, thin epithelial cells that fuse with capillaries to
form the alveolar–capillary membrane across which gas ex-
change occurs. Oxygen enters the bloodstream to be trans-
ported to body cells; CO₂ enters the alveoli to be exhaled from
the lungs. Type II cells produce surfactant, a lipoprotein
substance that decreases the surface tension in the alveoli and
aids lung inflation. The alveoli also contain macrophages that
help to protect and defend the lungs.

The lungs are encased in a membrane called the pleura,
which is composed of two layers. The inner layer, which
adheres to the surface of the lung, is called the visceral
pleura. The outer layer, which lines the thoracic cavity, is
called the parietal pleura. The potential space between the
layers is called the pleural cavity. It contains fluid that
allows the layers to glide over each other and minimizes
friction.

The lungs expand and relax in response to changes in pres-
sure relationships (intrapulmonic and intrapleural pressures).
Elastic tissue in the bronchioles and alveoli allows the lungs
to stretch or expand to accommodate incoming air. This abil-
ity is called compliance. The lungs also recoil (like a stretched
rubber band) to expel air. Some air remains in the lungs after
expiration, which allows gas exchange to continue between respirations.

In addition to exchanging O₂ and CO₂, the lungs synthesize,
store, release, remove, metabolize, or inactivate a variety of
biologically active substances. These substances, which may be
locally released or carried in blood or tissue fluids, partici-
pate in both physiologic and pathologic processes. Specific sub-
stances that may be released from the lungs include biogenic
amines (eg, catecholamines, histamine, serotonin), arachi-
donic acid metabolites (eg, prostaglandins, leukotrienes),
angiotensin-converting enzyme, and heparin. The amines are
important in regulating smooth muscle tone (ie, constriction
or dilation) in the airways and blood vessels. Prostaglandins
and leukotrienes are important in inflammatory processes.
Angiotensin-converting enzyme converts angiotensin I to
angiotensin II, which is important in regulating blood pres-
sure. Heparin helps to dissolve blood clots, especially in the
capillaries, where small clots are trapped. The lungs also
process peptides, lipids, hormones, and drugs and inactivate
bradykinin.

**Lung Circulation**

The pulmonary circulatory system transports O₂ and CO₂.
After oxygen enters the bloodstream across the alveolar–
capillary membrane, it combines with hemoglobin in red
blood cells for transport to body cells, where it is released. Car-
bon dioxide combines with hemoglobin in the cells for return
to the lungs and elimination from the body.

The lungs receive the total cardiac output of blood and are
supplied with blood from two sources, the pulmonary
and bronchial circulations. The pulmonary circulation pro-
vides for gas exchange as the pulmonary arteries carry un-
oxigenated blood to the lungs and the pulmonary veins
return oxygenated blood to the heart. The bronchial arter-
ies arise from the thoracic aorta and supply the air passages
and supporting structures. The bronchial circulation also
warms and humidifies incoming air and can form new ves-
sels and develop collateral circulation when normal vessels
are blocked (eg, in pulmonary embolism). The latter ability
helps to keep lung tissue alive until circulation can be
restored.

Capillaries in the lungs are lined by a single layer of ep-
ithelial cells called endothelium. Once thought to be a pas-
sive conduit for blood, it is now known that the endothelium
performs several important functions. First, it forms a bar-
rier that prevents leakage of water and other substances into
lung tissue. Second, it participates in the transport of respir-
atory gases, water, and solutes. Third, it secretes vasodi-
lating substances such as nitric oxide and prostacyclin.
Nitric oxide also regulates smooth muscle tone in the
bronchi, and prostacyclin also inhibits platelet aggregation.
When pulmonary endothelium is injured (eg, by endotoxins
or drugs such as bleomycin, an anticancer drug), these func-
tions are impaired.
Nervous System

The nervous system regulates the rate and depth of respiration by the respiratory center in the medulla oblongata, the pneumotaxic center in the pons, and the apneustic center in the reticular formation. The respiratory center is stimulated primarily by increased CO₂ in the fluids of the center. (However, excessive CO₂ depresses the respiratory center.) When the center is stimulated, the rate and depth of breathing are increased, and excessive CO₂ is exhaled. A lesser stimulus to the respiratory center is decreased oxygen in arterial blood.

The nervous system also operates several reflexes important to respiration. The cough reflex is especially important because it helps protect the lungs from foreign particles, air pollutants, bacteria, and other potentially harmful substances. A cough occurs when nerve endings in the respiratory tract mucosa are stimulated by dryness, pressure, cold, irritant fumes, and excessive secretions.

Musculoskeletal System

The musculoskeletal system participates in chest expansion and contraction. Normally, the diaphragm and external intercostal muscles expand the chest cavity and are called muscles of inspiration. The abdominal and internal intercostal muscles are the muscles of expiration.

SUMMARY

Overall, normal respiration requires:
1. Atmospheric air containing at least 21% O₂.
2. Adequate ventilation. Ventilation, in turn, requires patent airways, expansion and contraction of the chest, expansion and contraction of the lungs, and maintenance of a normal range of intrapulmonic and intrapleural pressures.
3. Adequate diffusion of O₂ and CO₂ through the alveolar–capillary membrane. Factors influencing diffusion include the thickness and surface area of the membrane and pressure differences between gases on each side of the membrane.
4. Adequate perfusion or circulation of blood and sufficient hemoglobin to carry needed O₂.

In addition, normal breathing occurs 16 to 20 times per minute and is quiet, rhythmic, and effortless. Approximately 500 mL of air is inspired and expired with a normal breath (tidal volume); deep breaths or “sighs” occur 6 to 10 times per hour to ventilate more alveoli. Fever, exercise, pain, and emotions such as anger increase respirations. Sleep or rest and various medications, such as antianxiety drugs, sedatives, and opioid analgesics, slow respiration.

DISORDERS OF THE RESPIRATORY SYSTEM

The respiratory system is subject to many disorders that interfere with respiration and other lung functions. These disorders may be caused by agents that reach the system through inhaled air or through the bloodstream and include respiratory tract infections, allergic disorders, inflammatory disorders, and conditions that obstruct airflow (eg, excessive respiratory tract secretions, asthma, and other chronic obstructive pulmonary diseases). Injury to the lungs by various disorders (eg, anaphylaxis, asthma, mechanical stimulation such as hyperventilation, pulmonary thromboembolism, pulmonary edema, acute respiratory distress syndrome) is associated with the release of histamine and other biologically active chemical mediators from the lungs. These mediators often cause inflammation and constriction of the airways.

The ciliated epithelial cells of the larger airways, the type I epithelial cells of the alveoli, and the capillary endothelial cells of the alveolar area are especially susceptible to injury. Once injured, cellular functions are impaired (eg, decreased mucociliary clearance). Common signs and symptoms of respiratory disorders include cough, increased secretions, mucosal congestion, and bronchospasm. Severe disorders or inadequate treatment may lead to cell necrosis or respiratory failure.

DRUG THERAPY

In general, drug therapy is more effective in relieving respiratory symptoms than in curing the underlying disorders that cause the symptoms. Major drug groups used to treat respiratory symptoms are bronchodilating and anti-inflammatory agents (see Chap. 47), antihistamines (see Chap. 48), and nasal decongestants, antitussives, and cold remedies (see Chap. 49).

Review and Application Exercises

1. What is the main function of the respiratory system?
2. Where does the exchange of oxygen and carbon dioxide occur?
3. List factors that stimulate rate and depth of respiration.
4. List factors that depress rate and depth of respiration.
5. What are common signs and symptoms of respiratory disorders for which drug therapy is often used?

SELECTED REFERENCES

Drugs for Asthma and Other Bronchoconstrictive Disorders

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe the main pathophysiologic characteristics of asthma and other bronchoconstrictive disorders.
2. Discuss the uses and effects of bronchodilating drugs, including adrenergics, ipratropium, and theophylline.
3. Differentiate between short-acting and long-acting inhaled beta₂-adrenergic agonists in terms of uses and nursing process implications.
4. Discuss the uses of anti-inflammatory drugs, including corticosteroids, leukotriene modifiers, and mast cell stabilizers.
5. Discuss reasons for using inhaled drugs when possible.
6. Differentiate between “quick relief” and long-term control of asthma symptoms.
7. Discuss the use of antiasthmatic drugs in special populations.
8. Teach clients self-care and long-term control measures.

Critical Thinking Scenario
Gwen, a 12-year-old middle schooler, was recently diagnosed with asthma. She uses two inhalers four times a day, in addition to using a rescue inhaler during periods of dyspnea. She also is taking peak flow measurements. As the school nurse, you are responsible for overseeing Gwen’s care while she is in school.

Reflect on:
- The developmental level of 12-year-olds. How might this affect Gwen’s feelings about having asthma and complying with treatment?
- What asthma triggers might be present in the school environment?
- School regulations usually require that all medication be kept in the nurse’s office. What impact might this have if Gwen experiences an asthma attack?
- Develop an educational program on asthma for middle schoolers. How might Gwen and other students with asthma participate?

OVERVIEW
The drugs described in this chapter are used to treat respiratory disorders characterized by bronchoconstriction, inflammation, mucosal edema, and excessive mucus production (asthma, bronchitis, and emphysema). Asthma is emphasized because of its widespread prevalence, especially in urban populations. Compared with whites, African Americans and Hispanics have a higher prevalence and African Americans have a higher death rate from asthma. However, the differences are usually attributed to urban living and lesser access to health care rather than race or ethnic group. Occupational asthma (ie, asthma resulting from repeated and prolonged exposure to industrial inhalants) is also a major health problem. Persons with occupational asthma often have symptoms while in the work environment, with improvement on days off and during vacations. Symptoms sometime persist after termination of exposure. Asthma may occur at any age but is especially common in children and older adults. Children who are exposed to allergens and airway irritants such as tobacco smoke during infancy are at high risk for development of asthma.
Asthma

Asthma is an airway disorder characterized by bronchoconstriction, inflammation, and hyperreactivity to various stimuli. Resultant symptoms include dyspnea, wheezing, chest tightness, cough, and sputum production. Wheezing is a high-pitched, whistling sound caused by turbulent airflow through an obstructed airway. Thus, any condition that produces significant airway occlusion can cause wheezing. However, a chronic cough may be the only symptom for some people. Symptoms vary in incidence and severity from occasional episodes of mild respiratory distress, with normal functioning between “attacks,” to persistent, daily, or continual respiratory distress if not adequately controlled. Inflammation and damaged airway mucosa are chronically present, even when clients appear symptom free.

Acute symptoms of asthma may be precipitated by numerous stimuli, and hyperreactivity to such stimuli may initiate both inflammation and bronchoconstriction. Viral infections of the respiratory tract are often the causative agents, especially in infants and young children whose airways are small and easily obstructed. Asthma symptoms may persist for days or weeks after the viral infection resolves. In about 25% of patients with asthma, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can precipitate an attack. Some patients are allergic to sulfites and may experience life-threatening asthma attacks if they ingest foods processed with these preservatives (eg, beer, wine, dried fruit). The Food and Drug Administration (FDA) has banned the use of sulfites on foods meant to be served raw, such as open salad bars. Patients with severe asthma should be cautioned against ingesting food and drug products containing sulfites or metabisulfites.

Gastroesophageal reflux disease (GERD), a common disorder characterized by heartburn and esophagitis, is also associated with asthma. Asthma that worsens at night may be associated with nighttime acid reflux. The reflux of acidic gastric contents into the esophagus is thought to initiate a vagally mediated, reflex type of bronchoconstriction. (Asthma may also aggravate GERD, because antiasthma medications that dilate the airways also relax muscle tone in the gastrointestinal sphincter and may increase acid reflux.) Additional precipitants may include allergens (eg, pollens, molds, others), airway irritants and pollutants (eg, chemical fumes, cigarette smoke, automobile exhaust), cold air, and exercise. Acute episodes of asthma may last minutes to hours.

Bronchoconstriction (also called bronchospasm) involves strong muscle contractions that narrow the airways. Airway smooth muscle extends from the trachea through the bronchioles. It is wrapped around the airways in a spiral pattern, and contraction causes a sphincter-type of action that can completely occlude the airway lumen. Bronchoconstriction is aggravated by inflammation, mucosal edema, and excessive mucus and may be precipitated by the numerous stimuli described above.

When lung tissues are exposed to causative stimuli, mast cells release substances that cause bronchoconstriction and inflammation. Mast cells are found throughout the body in connective tissues and are abundant in tissues surrounding capillaries in the lungs. When sensitized mast cells in the lungs or eosinophils in the blood are exposed to allergens or irritants, multiple cytokines and other chemical mediators (eg, acetylcholine, cyclic guanosine monophosphate [GMP], histamine, interleukins, leukotrienes, prostaglandins, and serotonin) are synthesized and released. These chemicals act directly on target tissues of the airways, causing smooth muscle constriction, increased capillary permeability and fluid leakage, and changes in the mucus-secreting properties of the airway epithelium.

Bronchoconstrictive substances are antagonized by cyclic adenosine monophosphate (cyclic AMP). Cyclic AMP is an intracellular substance that initiates various intracellular activities, depending on the type of cell. In lung cells, cyclic AMP inhibits release of bronchoconstrictive substances and thus indirectly promotes bronchodilation. In mild to moderate asthma, bronchoconstriction is usually recurrent and reversible, either spontaneously or with drug therapy. In advanced or severe asthma, airway obstruction becomes less reversible and worsens because chronically inflamed airways undergo structural changes (eg, fibrosis, enlarged smooth muscle cells, and enlarged mucous glands), called “airway remodeling,” that inhibit their function.

National Asthma Education and Prevention Program (NAEPP)

Because of asthma’s significance as a public health problem, the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) established the NAEPP. The NAEPP assembled a group of experts who established “Guidelines for the Diagnosis and Management of Asthma.” These guidelines (Box 47–1) were updated in 1997 and selected aspects, mainly related to children, were updated in 2002. The guidelines are the current “standard of care” for adults and children with asthma. Additional information can be obtained from:

NHLBI Health Information Network
P.O. Box 30105
Bethesda, MD 20824-0105
Phone: (301) 592-8573
Fax: (301) 592-8563
Web: http://www.nhlbi.nih.gov

Chronic Bronchitis and Emphysema

Chronic bronchitis and emphysema, commonly called chronic obstructive pulmonary disease (COPD), usually develop after long-standing exposure to airway irritants such as cigarette smoke. In these conditions, bronchoconstriction and inflammation are more constant and less reversible than with asthma. Anatomic and physiologic changes occur over several years and lead to increasing dyspnea and activity intolerance. These conditions usually affect middle-aged or older adults.
**General Recommendations**

- Establish and teach patients/parents/caregivers about quick relief measures and long-term control measures. Assist to identify and control environmental factors that aggravate asthma.
- For acute attacks, gain control as quickly as possible (a short course of systemic corticosteroid may be needed); then step down to the least medication necessary to maintain control.
- Review the treatment regimen every 1 to 6 months. If control is adequate and goals are being met, the treatment regimen need not be changed. For example, frequent or increasing use of a short-acting beta2 agonist (>2 times a week with intermittent asthma; daily or increasing use with persistent asthma) may indicate the need to initiate or increase long-term control therapy. However, first reassess patients’ medication techniques (eg, correct use of inhalers), adherence, and environmental control measures.

**Goals of Therapy**

1. Minimal or no chronic symptoms day or night
2. Minimal or no exacerbations
3. No limitations on activities; for children, no school/parent’s work missed
4. Minimal use of short-acting inhaled beta2 agonist (<1 time per day, <1 canister/month)
5. Minimal or no adverse effects from medications

**Quick Relief for Acute Exacerbations**

- **Adults and children > 5 years:** Short-acting, inhaled, beta2 agonist, 2–4 puffs as needed. If symptoms are severe, patients may need up to 3 treatments at 20-minute intervals or a nebulizer treatment. A short course of a systemic corticosteroid may also be needed.
- **Children 5 years and younger:** Short-acting beta2 agonist by nebulizer or face mask and spacer or holding chamber. Alternative: oral beta2 agonist. With viral respiratory infections, the beta2 agonist may be needed q4–6h up to 24 hours or longer and a systemic corticosteroid may be needed.

**Long-term Control**

- **Step 1 Mild Intermittent** (symptoms 2 days/week or less or 2 nights/month or less): No daily medication needed; treat acute exacerbations with an inhaled beta2 agonist and possibly a short course of a systemic corticosteroid.
- **Step 2 Mild Persistent** (symptoms >2/week but <1x/day or >2 nights/month):
  - **Adults and children > 5 years:** Low-dose inhaled corticosteroid. Alternatives: cromolyn or nedocromil, a leukotriene modifier, or sustained-release theophylline to maintain a serum drug level of 5–15 mcg/mL.
  - **Children 5 years and younger:** Administer the inhaled corticosteroid by a nebulizer or metered-dose inhaler (MDI) with a holding chamber. Alternatives: cromolyn (via nebulizer or MDI with holding chamber) or a leukotriene modifier.
- **Step 3 Moderate Persistent** (symptoms daily and >1 night/week):
  - **Adults and children > 5 years:** Low- to medium-dose inhaled corticosteroid and a long-acting beta2 agonist. Alternatives: increase corticosteroid dose or continue low to medium dose of corticosteroid and add a leukotriene modifier or theophylline.
  - **Children < 5 years:** Low-dose inhaled corticosteroid and a long-acting beta2 agonist or medium dose inhaled corticosteroid.
- **Step 4 Severe Persistent** (symptoms continual during daytime hours and frequent at night):
  - **Adults and children > 5 years:** High-dose inhaled corticosteroid and long-acting beta2 agonist and, if necessary, a systemic corticosteroid (2 mg/kg/d, not to exceed 60 mg/d). Reduce systemic corticosteroid when possible.
  - **Children < 5 years:** Same as for adults and older children.

**Definitions**

Asthma is “a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role, in particular, mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, and epithelial cells.”

**Low (L), Medium (M), and High (H) Doses of Inhaled Corticosteroids:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Adults (mcg)</th>
<th>Children (12 y and younger) (mcg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone (42 or 84 mcg/puff)</td>
<td>L: 168–504</td>
<td>L: 84–336</td>
</tr>
<tr>
<td></td>
<td>M: 504–840</td>
<td>M: 336–672</td>
</tr>
<tr>
<td></td>
<td>H: &gt;840</td>
<td>H: &gt;672</td>
</tr>
<tr>
<td></td>
<td>H: &gt;480</td>
<td>H: &gt;320</td>
</tr>
<tr>
<td>Budesonide (200 mcg/ inhalation)</td>
<td>L: 200–600</td>
<td>L: 200–400</td>
</tr>
<tr>
<td></td>
<td>M: 600–1200</td>
<td>M: 400–800</td>
</tr>
<tr>
<td></td>
<td>H: &gt;1200</td>
<td>H: &gt;800</td>
</tr>
<tr>
<td>Budesonide inhalation suspension for nebulization (child dose only)</td>
<td>L: 0.5 mg</td>
<td>M: 1.0 mg</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H: 2.0 mg</td>
</tr>
<tr>
<td>Flunisolide (250 mcg/puff)</td>
<td>L: 500–1000</td>
<td>L: 500–750</td>
</tr>
<tr>
<td></td>
<td>H: &gt;2000</td>
<td>H: &gt;1250</td>
</tr>
<tr>
<td>Fluticasone aerosol (44, 110, or 220 mcg/puff)</td>
<td>L: 88–264</td>
<td>L: 88–176</td>
</tr>
<tr>
<td></td>
<td>H: &gt;660</td>
<td>H: &gt;440</td>
</tr>
<tr>
<td>Fluticasone powder (50, 100, or 250 mcg/puff)</td>
<td>L: 100–300</td>
<td>L: 100–200</td>
</tr>
<tr>
<td></td>
<td>M: 300–600</td>
<td>M: 200–400</td>
</tr>
<tr>
<td></td>
<td>H: &gt;600</td>
<td>H: &gt;400</td>
</tr>
<tr>
<td>Triamcinolone acetate (100 mcg/puff)</td>
<td>L: 400–1000</td>
<td>L: 400–800</td>
</tr>
<tr>
<td></td>
<td>H: &gt;2000</td>
<td>H: &gt;1200</td>
</tr>
</tbody>
</table>

*Adapted from NAEPP Expert Panel Report 2 (NIH Publication No. 97-4051, 1997) and the Update on Selected Topics 2002 (NIH Publication No. 02-5075).
Two major groups of drugs used to treat asthma, acute and chronic bronchitis, and emphysema are bronchodilators and anti-inflammatory drugs. Bronchodilators are used to prevent and treat bronchoconstriction; anti-inflammatory drugs are used to prevent and treat inflammation of the airways. Reducing inflammation also reduces bronchoconstriction by decreasing mucosal edema and mucus secretions that narrow airways and by decreasing airway hyperreactivity to various stimuli. The drugs are described in the following sections; pharmacokinetic characteristics of inhaled drugs are listed in Table 47–1 and dosage ranges are listed in Drugs at a Glance: Bronchodilating Drugs and Drugs at a Glance: Anti-inflammatory Antiasthmatic Drugs.

**Bronchodilators**

**Adrenergics**

Adrenergic drugs (see Chap. 18) stimulate beta₂-adrenergic receptors in the smooth muscle of bronchi and bronchioles. The receptors, in turn, stimulate the enzyme adenylyl cyclase to increase production of cyclic AMP. The increased cyclic AMP produces bronchodilation. Some beta-adrenergic drugs (eg, epinephrine) also stimulate beta₁-adrenergic receptors in the heart to increase the rate and force of contraction. Cardiac stimulation is an adverse effect when the drugs are given for bronchodilation. These drugs are contraindicated in clients with cardiac tachydysrhythmias and severe coronary artery disease; they should be used cautiously in clients with hypertension, hyperthyroidism, diabetes mellitus, and seizure disorders.

Epinephrine may be injected subcutaneously in an acute attack of bronchoconstriction, with therapeutic effects in approximately 5 minutes and lasting for approximately 4 hours. However, an inhaled selective beta₂ agonist is the drug of choice in this situation. Epinephrine is also available without prescription in a pressurized aerosol form (eg, Primatene). Almost all over-the-counter aerosol products promoted for use in asthma contain epinephrine. These products are often abused and may delay the client from seeking medical attention. Clients should be cautioned that excessive use may produce hazardous cardiac stimulation and other adverse effects.

**Albuterol**, **bitolterol**, **levalbuterol**, and **pirbuterol** are short-acting beta₂-adrenergic agonists used for prevention and treatment of bronchoconstriction. These drugs act more selectively on beta₂ receptors and cause less cardiac stimulation than epinephrine. Most often taken by inhalation, they are also the most effective bronchodilators and the treatment of first choice to relieve acute asthma. Because the drugs can be effectively delivered by aerosol or nebulization, even to young children and patients on mechanical ventilation, there is seldom a need to give epinephrine or other nonselective adrenergic drugs by injection.

The beta₂ agonists are usually self-administered by metered-dose inhalers (MDIs). Although most drug references still list a regular dosing schedule (eg, every 4 to 6 hours), asthma experts recommend that the drugs be used when needed (eg, to treat acute dyspnea or prevent dyspnea during exercise). If these drugs are overused, they lose their bronchodilating effects because the beta₂-adrenergic receptors become unresponsive to stimulation. This tolerance does not occur with the long-acting beta₂ agonists.

**Formoterol** and **salmeterol** are long-acting beta₂-adrenergic agonists used only for prophylaxis of acute bronchoconstriction. They are not effective in acute attacks because they have a slower onset of action than the short-acting drugs (up to 20 minutes for salmeterol). Effects last

<table>
<thead>
<tr>
<th>TABLE 47–1</th>
<th>Pharmacokinetics of Selected Inhaled Antiasthma Medications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Generic Name</strong></td>
<td><strong>Action</strong></td>
</tr>
<tr>
<td><strong>Adrenergics</strong></td>
<td></td>
</tr>
<tr>
<td>Albuterol</td>
<td>5</td>
</tr>
<tr>
<td>Bitolterol</td>
<td>2–4</td>
</tr>
<tr>
<td>Levalbuterol</td>
<td>5</td>
</tr>
<tr>
<td>Pirbuterol</td>
<td>5</td>
</tr>
<tr>
<td>Salmeterol</td>
<td>13–20</td>
</tr>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
</tr>
<tr>
<td>Ipratropium</td>
<td>15</td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone</td>
<td>Rapid</td>
</tr>
<tr>
<td>Budesonide</td>
<td>Immediate</td>
</tr>
<tr>
<td>Flunisolide</td>
<td>Slow</td>
</tr>
<tr>
<td>Fluticasone</td>
<td>Slow</td>
</tr>
</tbody>
</table>

ND, not determined.
### Drugs at a Glance: Bronchodilating Drugs

**Generic/Trade Name** | **Routes and Dosage Ranges** (Adults) | **Children**
--- | --- | ---

**Bronchodilators**

**ADRENERGICS**

**Epinephrine** *(Adrenalin, Bronkaid)*
- Aqueous solution (epinephrine 1:1000), SC 0.2–0.5 mL; dose may be repeated after 20 min if necessary
- Inhalation by inhaler, one or two inhalations 4–6 times per day
- Inhalation by nebulizer, 0.25–0.5 mL of 2.25% racemic epinephrine in 2.5 mL normal saline

**Albuterol** *(Proventil, Ventolin, AccuNeb, Volmax, Proventil Repetab)*
- Inhalation aerosol: 4 y and older (12 y and older for Proventil), same as adults
- Nebulizer solution, 12 y and older, same as adults; 2–12 y (AccuNeb), 1.25 mg 3–4 times daily, as needed, over 5–15 min
- Regular tablets: 12 y and older, same as adults; 6–12 y, 2 mg 3–4 times daily
- Extended release tablets: 12 y and older, same as adults; 6–12 y: PO 4 mg q12h initially; increase if necessary to a maximum of 24 mg/d, in divided doses, q12h (both Volmax and Proventil Repetab)

**Bitolterol** *(Tornalate)*
- Aerosol, two inhalations (0.37 mg/puff) at least 1–3 min apart, followed by a third if necessary; nebulizing solution, 1 mg via intermittent flow, 2.5 mg via continuous flow
- Aerosol, prophylaxis, two inhalations q8h; maximum recommended dose, three inhalations q6h or two inhalations q4h

**Formoterol** *(Foradil)*
- Oral inhalation by special inhaler (Aerolizer), 12 mcg (contents of 1 capsule) twice daily, q12h

**Isoproterenol** *(Isuprel)*
- Inhalation by nebulizer, 0.25–0.5 mL of 1:200 Isuprel solution in 2.5 mL saline
- Inhalation by inhaler,* one or two inhalations (0.075–0.125 mg/puff) four times per day; maximum dose, three inhalations per attack of bronchospasm

**Levalbuterol** *(Xopenex)*
- Nebulizer, 0.63–1.25 mg 3 times daily, q6–8h

**Metaproterenol** *(Alupent)*
- Inhalation,* 1–3 puffs (0.65 mg/dose), 4 times per day; maximum dose, 12 inhalations/d
- PO 10–20 mg q6–8h

**Pirbuterol** *(Maxair)*
- Inhalation,* two puffs (0.4 mg/dose), 4–6 times per day; maximum dose, 12 inhalations/d

**Salmeterol** *(Serevent)*
- Aerosol: 2 inhalations (42 mcg), q12h
- Inhalation powder: 1 inhalation (50 mcg) q12h

**Terbutaline** *(Brethine)*
- PO 2.5–5 mg q6–8h; maximum dose, 15 mg/d
- SC 0.25 mg, repeated in 15–30 min if necessary, q4–6h
- Inhalation,* two inhalations (400 mcg/dose) q4–6h

**ANTICHOLINERGIC**

**Ipratropium bromide** *(Atrovent)*
- Two inhalations (36 mcg) from the metered-dose inhaler 4 times per day

**Xanthines**

**Short-acting theophylline** *(Aminophylline)*
- PO, 500 mg initially, then 200–300 mg q6–8h; IV infusion, 6 mg/kg over 30 min, then 0.1–1.2 mg/kg/h

**Long-acting theophylline** *(Theo-Dur, others)*
- PO, 150–300 mg q8–12h; maximal dose 13 mg/kg or 900 mg daily, whichever is less

**PO, 7.5 mg/kg initially, then 5–6 mg/kg q6–8h; IV infusion, 6 mg/kg over 30 min, then 0.6–0.9 mg/kg/h
- PO, 100–200 mg q8–12h; maximal dose, 24 mg/kg/d

(continued)
12 hours and the drugs should not be taken more frequently. If additional bronchodilating medication is needed, a short-acting agent (eg, albuterol) should be used.

**Isoproterenol** is a short-acting bronchodilator and cardiac stimulant. When used for treatment of bronchospasm, isoproterenol is given by inhalation, alone or in combination with other agents.

**Metaproterenol** is a relatively selective, intermediate-acting beta-2-adrenergic agonist that may be given orally or by MDI. It is used to treat acute bronchospasm and to prevent

---

### Drugs at a Glance: Bronchodilating Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Combination Drugs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluticasone/Salmeterol (Advair)</td>
<td>Oral inhalation, one inhalation, twice daily</td>
<td>12 y and older: same as adults</td>
</tr>
<tr>
<td>Ipratropium/Albuterol (Combivent, DuoNeb)</td>
<td>Aerosol: two inhalations 4 times daily</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Ipratropium/Albuterol (Combivent, DuoNeb)</td>
<td>Nebulizing solution: 1 vial 4 times daily, increased to 6 times daily if necessary</td>
<td></td>
</tr>
</tbody>
</table>

*Short-acting adrenergic bronchodilators are used mainly by inhalation, as needed, rather than on a regular schedule.*

---

### Drugs at a Glance: Anti-Inflammatory Antiasthmatic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone (Beclovent, Vanceril)</td>
<td>Oral inhalation, two inhalations (0.84 mg/dose) three or four times daily; maximum, 20 inhalations/24 h</td>
<td>6–12 y: Oral inhalation, one or two inhalations three or four times per day; maximum dose, 10 inhalations/24 h</td>
</tr>
<tr>
<td>Budesonide (Pulmocort Turbuhaler)</td>
<td>Oral inhalation, 200–400 mcg twice daily</td>
<td>≥6 y: Oral inhalation 200 mcg twice daily</td>
</tr>
<tr>
<td>Flunisolide (AeroBid)</td>
<td>Oral inhalation, two inhalations (0.50 mg/dose) twice daily, morning and evening; maximum dose, four inhalations twice daily (2 mg)</td>
<td>6–15 y: Oral inhalation, two inhalations twice daily</td>
</tr>
<tr>
<td>Fluticasone aerosol (Flovent)</td>
<td>Aerosol, 220–440 mcg twice daily</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Fluticasone powder (Flovent Rotadisk)</td>
<td>Powder, 100–500 mcg twice daily</td>
<td>4–11 y: Powder, 50–100 mcg twice daily</td>
</tr>
<tr>
<td>Hydrocortisone sodium phosphate and sodium succinate</td>
<td>IV 100–200 mg q4–6h initially, then decreased or switched to an oral dosage form</td>
<td>IV 1–5 mg/kg q4–6h</td>
</tr>
<tr>
<td>Methylprednisolone sodium succinate</td>
<td>IV 10–40 mg q4–6h for 48–72 h</td>
<td>IV 0.5 mg/kg q4–6h</td>
</tr>
<tr>
<td>Prednisone</td>
<td>PO 20–60 mg/d</td>
<td>PO 2 mg/kg/d initially</td>
</tr>
<tr>
<td>Triamcinolone (Azmacort)</td>
<td>Oral inhalation, two inhalations 3 or 4 times per day; maximum dose, 16 inhalations/24 h</td>
<td>6–12 y: one or two inhalations 3 or 4 times per day; maximum dose, 12 inhalations/24 h</td>
</tr>
</tbody>
</table>

**Leukotriene Modifiers**

<table>
<thead>
<tr>
<th>Montelukast (Singulair)</th>
<th>PO 10 mg once daily in the evening or at bedtime</th>
<th>15 y and older: Same as adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>6–14 y: PO 5 mg once daily in the evening</td>
<td>2–5 y: 4 mg once daily</td>
<td></td>
</tr>
<tr>
<td>Zafirlukast (Accolate)</td>
<td>PO 20 mg twice daily, 1 h before or 2 h after a meal</td>
<td>12 y and older: Same as adults</td>
</tr>
<tr>
<td>5–11 y: PO 10 mg twice daily</td>
<td>12 y and older: Same as adults</td>
<td></td>
</tr>
<tr>
<td>Zileuton (Zyflo)</td>
<td>PO 600 mg 4 times daily</td>
<td>&lt;12 y: Dosage not established</td>
</tr>
</tbody>
</table>

**Mast Cell Stabilizers**

<table>
<thead>
<tr>
<th>Cromolyn (Intal)</th>
<th>Nebulizer solution, oral inhalation, 20 mg 4 times daily</th>
<th>2 y and older: Same as adults</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerosol spray, oral inhalation, two sprays 4 times daily</td>
<td>5 y and older: Same as adults</td>
<td></td>
</tr>
<tr>
<td>Inhalation, 4 mg q6–12h</td>
<td>&gt;12 y: Same as adults</td>
<td></td>
</tr>
<tr>
<td>Nedocromil (Tilade)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---
exercise-induced asthma. In high doses, metaproterenol loses some of its selectivity and may cause cardiac and central nervous system (CNS) stimulation.

**Terbutaline** is a relatively selective beta₂-adrenergic agonist that is a long-acting bronchodilator. When given subcutaneously, terbutaline loses its selectivity and has little advantage over epinephrine. Muscle tremor is the most frequent side effect with this agent.

**Anticholinergics**

Anticholinergics (see Chap. 21) block the action of acetylcholine in bronchial smooth muscle when given by inhalation. This action reduces intracellular GMP, a bronchoconstrictive substance.

*Ipratropium* was formulated to be taken by inhalation for maintenance therapy of bronchoconstriction associated with chronic bronchitis and emphysema. Improved pulmonary function usually occurs in a few minutes. Ipratropium acts synergistically with adrenergic bronchodilators and may be used concomitantly. It improves lung function about 10% to 15% over an inhaled beta₂ agonist alone. Ipratropium may also be used to treat rhinorrhea associated with allergic rhinitis and the common cold. It is available as a nasal spray for such usage. Ipratropium is poorly absorbed and produces few systemic effects. However, cautious use is recommended in clients with narrow-angle glaucoma and prostatic hypertrophy. The most common adverse effects are cough, nervousness, nausea, gastrointestinal upset, headache, and dizziness.

**Xanthines**

The main xanthine used clinically is theophylline. Despite many years of use, the drug’s mechanism of action is unknown. Various mechanisms have been proposed, such as inhibiting phosphodiesterase enzymes that metabolize cyclic AMP, increasing endogenous catecholamines, inhibiting calcium ion movement into smooth muscle, inhibiting prostaglandin synthesis and release, or inhibiting the release of bronchoconstrictive substances from mast cells and leukocytes. In addition to bronchodilation, other effects that may be beneficial in asthma and COPD include inhibiting pulmonary edema by decreasing vascular permeability, increasing the ability of cilia to clear mucus from the airways, strengthening contractions of the diaphragm, and decreasing inflammation. Theophylline also increases cardiac output, causes peripheral vasodilation, exerts a mild diuretic effect, and stimulates the CNS. The cardiovascular and CNS effects are adverse effects. Serum drug levels should be monitored to help regulate dosage and avoid adverse effects. Theophylline preparations are contraindicated in clients with acute gastritis and peptic ulcer disease; they should be used cautiously in those with cardiovascular disorders that could be aggravated by drug-induced cardiac stimulation.

Theophylline was formerly used extensively in the prevention and treatment of bronchoconstriction associated with asthma, bronchitis, and emphysema. Now, it is considered a second-line agent that may be added in severe disease inadequately controlled by first-line drugs. Numerous dosage forms of theophylline are available. Theophylline ethylenediamine (aminophylline) contains approximately 85% theophylline and is the only formulation that can be given intravenously (IV). However, IV aminophylline is not recommended for emergency treatment of acute asthma because studies indicate little, if any, added benefit in adults or children. Oral theophylline preparations may be used for long-term treatment. Most formulations contain anhydrous theophylline (100% theophylline) as the active ingredient, and sustained-action tablets (eg, Theo-Dur, Theobid) are more commonly used than other formulations. Theophylline is metabolized in the liver; metabolites and some unchanged drug are excreted through the kidneys.

**Anti-inflammatory Agents**

**Corticosteroids**

Corticosteroids (see Chap. 24) are used in the treatment of acute and chronic asthma and other bronchoconstrictive disorders, in which they have two major actions. First, they suppress inflammation in the airways by inhibiting the following processes: movement of fluid and protein into tissues; migration and function of neutrophils and eosinophils; synthesis of histamine in mast cells; and production of proinflammatory substances (eg, prostaglandins, leukotrienes, several interleukins, and others). Beneficial effects of suppressing airway inflammation include decreased mucus secretion, decreased edema of airway mucosa, and repair of damaged epithelium, with subsequent reduction of airway reactivity. A second action is to increase the number and sensitivity of beta₂-adrenergic receptors, which restores or increases the effectiveness of beta₂-adrenergic bronchodilators. The number of beta₂ receptors increases within approximately 4 hours, and improved responsiveness to beta₂ agonists occurs within approximately 2 hours.

In acute, severe asthma, a systemic corticosteroid in relatively high doses is indicated in patients whose respiratory distress is not relieved by multiple doses of an inhaled beta₂ agonist (eg, every 20 minutes for 3 to 4 doses). The corticosteroid may be given IV or orally, and IV administration offers no therapeutic advantage over oral administration. Once the drug is started, pulmonary function usually improves in 6 to 8 hours. Most patients achieve substantial benefit within 48 to 72 hours and the drug is usually continued for 7 to 10 days. Multiple doses are usually given because studies indicate that maintaining the drug concentration at steroid receptor sites in the lung is more effective than high single doses. High single or pulse doses do not increase therapeutic effects; they may increase risks of developing myopathy and other adverse effects, however. In some infants and young children
with acute, severe asthma, oral prednisone for 3 to 10 days has relieved symptoms and prevented hospitalization.

In chronic asthma, a corticosteroid is usually taken by inhalation, on a daily schedule. It is often given concomitantly with one or more bronchodilators and may be given with another anti-inflammatory drug such as a leukotriene modifier or a mast cell stabilizer. In some instances, the other drugs allow smaller doses of the corticosteroid. For acute flare-ups of symptoms during treatment of chronic asthma, a systemic corticosteroid may be needed temporarily to regain control.

In early stages of the progressive disease, patients with COPD are unlikely to need corticosteroid therapy. In later stages, however, they usually need periodic short-course therapy for episodes of respiratory distress. When needed, the corticosteroid is given orally or parenterally because effectiveness of inhaled corticosteroids has not been established in COPD. In end-stage COPD, patients often become “steroid-dependent” and require daily doses because any attempt to reduce dosage or stop the drug results in respiratory distress. Such patients experience numerous serious adverse effects of prolonged systemic corticosteroid therapy.

Corticosteroids should be used with caution in clients with peptic ulcer disease, inflammatory bowel disease, hypertension, congestive heart failure, and thromboembolic disorders. However, they cause fewer and less severe adverse effects when taken in short courses or by inhalation than when taken systemically for long periods of time.

Beclomethasone, budesonide, flunisolide, fluticasone, and triamcinolone are topical corticosteroids for inhalation. Topical administration minimizes systemic absorption and adverse effects. These preparations may substitute for or allow reduced dosage of systemic corticosteroids. In people with asthma who are taking an oral corticosteroid, the oral dosage is reduced slowly (over weeks to months) when an inhaled corticosteroid is added. The goal is to give the lowest oral dose necessary to control symptoms. Beclomethasone, flunisolide, and fluticasone also are available in nasal solutions for treatment of allergic rhinitis, which may play a role in bronchoconstriction. Because systemic absorption occurs in clients using inhaled corticosteroids (about 20% of a dose), high doses should be reserved for those otherwise requiring oral corticosteroids.

Hydrocortisone, prednisone, and methylprednisolone are given to clients who require systemic corticosteroids. Prednisone is given orally; hydrocortisone and methylprednisolone may be given IV to patients who are unable to take an oral medication.

**Leukotriene Modifiers**

Leukotrienes are strong chemical mediators of bronchoconstriction and inflammation, the major pathologic features of asthma. They can cause sustained constriction of bronchioles and immediate hypersensitivity reactions. They also increase mucus secretion and mucosal edema in the respiratory tract. Leukotrienes are formed by the lipoxygenase pathway of arachidonic acid metabolism (Fig. 47–1) in response to cellular injury. They are designated by LT, the letter B, C, D, or E, and the number of chemical bonds in their structure (eg, LTB4, LTC4, and LTE4, also called slow releasing substances of anaphylaxis or SRS-A, because they are released more slowly than histamine).

Leukotriene modifier drugs were developed to counteract the effects of leukotrienes and are indicated for long-term treatment of asthma in adults and children. The drugs help prevent acute asthma attacks induced by allergens, exercise, cold air, hyperventilation, irritants, and aspirin or NSAIDs. They are not effective in relieving acute attacks. However, they may be continued concurrently with other drugs during acute episodes.

The leukotriene modifiers include three agents with two different mechanisms of action. Zileuton inhibits lipoxygenase and thereby reduces formation of leukotrienes; montelukast and zafirlukast are leukotriene receptor antagonists. Zileuton is used infrequently because it requires multiple daily dosing, may cause hepatotoxicity, and may inhibit the metabolism of drugs metabolized by the cytochrome P450 3A4 enzymes. Zafirlukast and montelukast improve symptoms and pulmonary function tests (PFTs), decrease nighttime symptoms, and decrease the use of beta; agonist drugs. They are effective with oral administration, can be taken once or twice a day, can be used with bronchodilators and corticosteroids, and elicit a high degree of patient adherence and satisfaction. However, they are less effective than low doses of inhaled corticosteroids.

Montelukast and zafirlukast are well absorbed with oral administration. They are metabolized in the liver by the cytochrome P450 enzyme system and may interact with other drugs metabolized by this system. Most metabolites are excreted in the feces. Zafirlukast is excreted in breast milk and should not be taken during lactation. The most common adverse effects reported in clinical trials were headache, nausea, diarrhea, and infection.

Zileuton is well absorbed, highly bound to serum albumin (93%), and metabolized by the cytochrome P450 liver enzymes; metabolites are excreted mainly in urine. It is contraindicated in clients with active liver disease or substantially elevated liver enzymes (three times the upper limit of normal values). When used, hepatic aminotransferase enzymes should be monitored during therapy and the drug should be discontinued if enzyme levels reach five times the normal values or if symptoms of liver dysfunction develop. Elevation of liver enzymes was the most serious adverse effect during clinical trials; other adverse effects include headache, pain, and nausea. In addition, zileuton increases serum concentrations of propranolol, theophylline, and warfarin.

**Mast Cell Stabilizers**

**Cromolyn and nedocromil** stabilize mast cells and prevent the release of bronchoconstrictive and inflammatory substances when mast cells are confronted with allergens and other stimuli. The drugs are indicated only for prophylaxis
of acute asthma attacks in clients with chronic asthma; they are not effective in acute bronchospasm or status asthmaticus and should not be used in these conditions. Use of one of these drugs may allow reduced dosage of bronchodilators and corticosteroids.

The drugs are taken by inhalation. Cromolyn is available in a metered-dose aerosol and a solution for use with a power-operated nebulizer. A nasal solution is also available for prevention and treatment of allergic rhinitis. Nedocromil is available in a metered-dose aerosol.

Mast cell stabilizers are contraindicated in clients who are hypersensitive to the drugs. They should be used with caution in clients with impaired renal or hepatic function. Also, the propellants in the aerosols may aggravate coronary artery disease or dysrhythmias.

**Herbal and Dietary Supplements**

Numerous preparations are promoted to relieve symptoms of asthma and patients with asthma are increasingly using alternative and complementary therapies. Some herbs have a pharmacologic basis for effect. However, most are less potent or more toxic than traditional asthma medications. For example, caffeine is a xanthine and therefore has bronchodilating effects similar to, but weaker than, those of theophylline. Caffeine-containing products, including coffee and tea, may slightly enhance bronchodilation. However, they also increase the adverse effects associated with adrenergic bronchodilators or theophylline (eg, symptoms of excessive cardiac and CNS stimulation such as tachycardia, dysrhythmias, insomnia, nervousness). Ephedra (ma huang), an adrenergic-type product, may also have bronchodilating effects. However, it also causes excessive cardiac and CNS stimulation, and deaths have been reported. It is not recommended for any use by anyone.

In general, herbal and dietary therapies in asthma, as in other disorders, have not been studied in controlled clinical trials and should be avoided. Because asthma can result in death in a matter of minutes, patients should be counseled not to use dietary or herbal supplements in place of prescribed bronchodilating and anti-inflammatory medications. Delays in appropriate treatment can have serious, even fatal, consequences.

**Nursing Process**

**Assessment**

Assess the client’s pulmonary function:

- General assessment factors include rate and character of respiration, skin color, arterial blood gas analysis, and
pulmonary function tests. Abnormal breathing patterns (eg, rate below 12 or above 24 per minute, dyspnea, cough, orthopnea, wheezing, "noisy" respirations) may indicate respiratory distress. Severe respiratory distress is characterized by tachypnea, dyspnea, use of accessory muscles of respiration, and hypoxia. Early signs of hypoxia include mental confusion, restlessness, anxiety, and increased blood pressure and pulse rate. Late signs include cyanosis and decreased blood pressure and pulse. Hypoxemia is confirmed if arterial blood gas analysis shows decreased partial pressure of oxygen (Po2).

- In acute bronchospasm, a medical emergency, the client is in obvious and severe respiratory distress. A characteristic feature of bronchospasm is forceful expiration or wheezing.
- If the client has chronic asthma, try to determine the frequency and severity of acute attacks, factors that precipitate or relieve acute attacks, antiasthmatic medications taken occasionally or regularly, allergies, and condition between acute attacks, such as restrictions in activities of daily living due to asthma.
- If the client has chronic bronchitis or emphysema, assess for signs of respiratory distress, hypoxia, cough, amount and character of sputum, exercise tolerance (eg, dyspnea on exertion, dyspnea at rest), medications, and nondrug treatment measures (eg, breathing exercises, chest physiotherapy).

**Nursing Diagnoses**

- Impaired Gas Exchange related to bronchoconstriction and excessive mucus production
- Activity Intolerance related to impaired gas exchange and fatigue
- Risk for Injury: Severe bronchospasm with asthma and adverse effects with antiasthmatic drugs
- Noncompliance: Overuse of adrenergic bronchodilators
- Deficient Knowledge: Factors precipitating bronchoconstriction and strategies to avoid precipitating factors.
- Deficient Knowledge: Accurate self-administration of drugs, including use of inhalers

**Planning/Goals**

*The client will:*

- Self-administer bronchodilating and other drugs accurately
- Experience relief of symptoms
- Avoid preventable adverse drug effects
- Avoid overusing bronchodilating drugs
- Avoid exposure to stimuli that cause bronchospasm when possible
- Avoid respiratory infections when possible

**Interventions**

Use measures to prevent or relieve bronchoconstriction when possible. General measures include those to prevent respiratory disease or promote an adequate airway. Some specific measures include the following:

- Use mechanical measures for removing excessive respiratory tract secretions and preventing their retention. Effective measures include coughing, deep breathing, percussion, and postural drainage.
- Help the client identify and avoid exposure to conditions that precipitate bronchoconstriction. For example, allergens may be removed from the home, school, or work environment; cigarette smoke should be avoided when possible. When bronchospasm is precipitated by exercise, prophylaxis by prior inhalation of bronchodilating agents is better than avoiding exercise, especially in children.
- Assist clients with asthma to identify early signs of difficulty, including increased need for beta-adrenergic agonists, activity limitations, and waking at night with asthma symptoms.
- Monitor peak expiratory flow rate (PEFR) when indicated. Portable meters are available for use in clinics, physicians’ offices, and clients’ homes. This is an objective measure of airflow/airway obstruction and helps to evaluate the client’s treatment regimen.
- Assist clients with moderate to severe asthma in obtaining meters and learning to measure PEFR. Clients with a decreased PEFR may need treatment to prevent acute, severe respiratory distress.
- Assist clients and at least one family member in managing acute attacks of bronchoconstriction, including when to seek emergency care.
- Try to prevent or reduce anxiety, which may aggravate bronchospasm. Stay with the client during an acute asthma attack if feasible. Clients experiencing severe and prolonged bronchospasm (status asthmaticus) should be admitted or transferred to a hospital intensive care unit.
- With any clients who smoke cigarettes, encourage cessation of smoking and provide information, resources, and assistance in doing so. Emphasize the health benefits of improved respiratory function.

**Evaluation**

- Observe for relief of symptoms and improved arterial blood gas values.
- Interview and observe for correct drug administration, including use of inhalers.
- Interview and observe for tachydysrhythmias, nervousness, insomnia, and other adverse drug effects.
- Interview about and observe behaviors to avoid stimuli that cause bronchoconstriction and respiratory infections.

**PRINCIPLES OF THERAPY**

**Drug Selection and Administration**

Choice of drug and route of administration are determined largely by the severity of the disease process and the client’s response to therapy. Some guidelines include the following:
CLIENT TEACHING GUIDELINES

Antiasthmatic Drugs

General Considerations

- Asthma and other chronic lung diseases are characterized by constant inflammation of the airways and periodic or persistent labored breathing from constriction or narrowing of the airways. Antiasthmatic drugs are often given in combination to combat these problems. Thus, it is extremely important to know the type and purpose of each drug.

- Except for the short-acting, inhaled bronchodilators (eg, albuterol), antiasthmatic medications are used long term to control symptoms and prevent acute asthma attacks. This means they must be taken on a regular schedule and continued when symptom free.

- When an asthma attack (ie, acute bronchospasm with shortness of breath, wheezing respirations, cough) occurs, the only fast-acting, commonly used medication to relieve these symptoms is an inhaled, short-acting bronchodilator (eg, albuterol). Other inhaled and oral drugs are not effective and should not be used.

- Try to prevent symptoms. For example, respiratory infections can precipitate difficulty in breathing. Avoiding infections (eg, by good handwashing, avoiding people with infections, annual influenza vaccinations, and other measures) can prevent acute asthma attacks. If you are allergic to tobacco smoke, perfume, or flowers, try to avoid or minimize exposure.

- A common cause of acute asthma attacks is not taking medications correctly. Some studies indicate that one third to two thirds of clients with asthma do not comply with instructions for using their medications. Factors that contribute to noncompliance with drug therapy include long-term use, expense, and adverse effects. If you have difficulty taking medications as prescribed, discuss the situation with a health care provider. Cheaper medications or lower doses may be effective alternatives. Just stopping the medications may precipitate acute breathing problems.

- If unable to prevent symptoms, early recognition and treatment may help prevent severe distress and hospitalizations. Signs of impending difficulty include increased needs for bronchodilator inhalers, activity limitations, waking at night because of asthma symptoms, and variability in the peak expiratory flow rate (PEFR), if you use a PEFR meter at home. The first treatment is to use a short-acting, inhaled bronchodilator. If this does not improve breathing, seek emergency care.

- Keep adequate supplies of medications on hand. Missing a few doses of long-term control or “preventive” medications may precipitate an acute asthma attack; not using an inhaled bronchodilator for early breathing difficulty may lead to more severe problems and the need for emergency treatment or hospitalization.

- Be sure you can use your metered-dose inhalers correctly. According to several research studies, many patients do not.

- Drinking 2 to 3 quarts of fluids daily helps thin secretions in the throat and lungs and makes them easier to remove.

- Avoid tobacco smoke and other substances that irritate breathing passages (eg, aerosol hair spray, antiperspirants, cleaning products, and automobile exhaust) when possible.

- Avoid excessive intake of caffeine-containing fluids such as coffee, tea, and cola drinks. These beverages may increase bronchodilatation but also may increase heart rate and cause palpitations, nervousness, and insomnia with bronchodilating drugs.

- Take influenza vaccine annually and pneumococcal vaccine at least once if you have chronic lung disease.

- Inform all health care providers about the medications you are taking and do not take over-the-counter drugs or herbal supplements without consulting a health care provider. Some drugs can decrease beneficial effects or increase adverse effects of antiasthmatic medications. For example, over-the-counter nasal decongestants, asthma remedies, cold remedies, and antisleep medications can increase the rapid heartbeat, palpitations, and nervousness often associated with bronchodilators. With herbal remedies, none are as effective as standard antiasthmatic medication, and they may cause serious or life-threatening adverse effects. Preparations containing ephedra (also called ma huang or herbal ecstasy) are especially dangerous and not recommended for use by anyone, for any purpose.

Self-Administration

- Follow instructions carefully. Better breathing with minimal adverse effects depends on accurate use of prescribed medications. If help is needed with metered-dose inhalers, consult a health care provider.

- Use short-acting bronchodilator inhalers as needed, not on a regular schedule. If desired effects are not achieved or if symptoms worsen, inform the prescribing physician. Do not increase dosage or frequency of taking medication. Overuse increases adverse drug effects and decreases drug effectiveness.

- If taking formoterol or salmeterol, which are long-acting, inhaled bronchodilators, do not use more often than every 12 hours. If constricted breathing occurs, use a short-acting bronchodilator inhaler between doses of a long-acting drug. Salmeterol does not relieve acute shortness of breath because it takes approximately 20 minutes to start acting and 1 to 4 hours to achieve maximal bronchodilating effects.

- If taking an oral or inhaled corticosteroid, take on a regular schedule, approximately the same time each day. The purpose of these drugs is to relieve inflammation in the airways and prevent acute respiratory distress. They are not effective unless taken regularly.

- If taking oral theophylline, take fast-acting preparations before meals with a full glass of water, at regular intervals around the clock. If gastrointestinal upset occurs, take with food. Take long-acting preparations every 8 to 12 hours; do not chew or crush.

(continued)
A selective, short-acting, inhaled beta₂-adrenergic agonist (eg, albuterol) is the initial drug of choice for acute bronchospasm.

Because aerosol products act directly on the airways, drugs given by inhalation can usually be given in smaller doses and produce fewer adverse effects than oral or parenteral drugs.

Ipratropium, the anticholinergic bronchodilator, is most useful in the long-term management of COPD. It is ineffective in relieving acute bronchospasm by itself, but it adds to the bronchodilating effects of adrenergic drugs.

Theophylline is used less often than formerly and is now considered a second-line drug. When used, it is usually given orally in an extended-release formulation for chronic disorders, such as COPD. IV aminophylline is no longer used to treat acute asthma attacks.

Cromolyn and nedocromil are used prophylactically; they are ineffective in acute bronchospasm.

Because inflammation has been established as a major component of asthma, an inhaled corticosteroid is being used early in the disease process, often with a bronchodilator or mast cell stabilizer. In acute episodes of bronchoconstriction, a corticosteroid is often given orally or IV for several days.

In chronic disorders, inhaled corticosteroids should be taken on a regular schedule. These drugs may be effective when used alone or with relatively small doses of an oral corticosteroid. Optimal schedules of administration are not clearly established, but more frequent dosing (eg, every 6 hours) may be more effective than less frequent dosing (eg, every 12 hours), even if the total amount is the same. As with systemic glucocorticoid therapy, the recommended dose is the lowest amount required to control symptoms. High doses suppress adrenocortical function, but much less than systemic drugs. Small doses may impair bone metabolism and predispose adults to osteoporosis by decreasing calcium deposition and increasing calcium resorption from bone. In children, chronic administration of corticosteroids may retard growth. Local adverse effects (oropharyngeal candidiasis, hoarseness) can be decreased by reducing the dose, administering less often, rinsing the mouth after use, or using a spacer device. These measures decrease the amount of drug deposited in the oral cavity. The inhaled drugs are well tolerated with chronic use.

Keith Wilson, 66 years of age, has worsening chronic obstructive pulmonary disease. At his last office visit, his physician added ipratropium bromide (Atrovent) and beclomethasone (Vanceril) to his beta-adrenergic (Alupent) inhaler. He visits the office complaining of severe dyspnea. You quickly grab his Atrovent inhaler to administer a PRN dose and try to get him to relax. What drug error has occurred, and how could this error be avoided?

How Can You Avoid This Medication Error?

Take zafirlukast 1 hour before or 2 hours after a meal; montelukast and zileuton may be taken with or without food. Take montelukast in the evening or at bedtime. This schedule provides maximum beneficial effects during the night and early morning, when asthma symptoms often occur or worsen.

Use inhalers correctly:
1. Shake well immediately before each use.
2. Remove the cap from the mouthpiece.
3. Exhale to the end of a normal breath.
4. With the inhaler in the upright position, place the mouthpiece just inside the mouth, and use the lips to form a tight seal or hold the mouthpiece approximately two finger-widths from the open mouth.

While pressing down on the inhaler, take a slow, deep breath for 3 to 5 seconds, hold the breath for approximately 10 seconds, and exhale slowly.

Wait 3 to 5 min before taking a second inhalation of the drug.

Rinse the mouth with water after each inhalation.

Rinse the mouthpiece and store the inhaler away from heat.

If you have difficulty using an inhaler, ask your physician about a spacer device (a tube attached to the inhaler that makes it easier to use).

How Can You Avoid This Medication Error?

Take zafirlukast 1 hour before or 2 hours after a meal; montelukast and zileuton may be taken with or without food. Take montelukast in the evening or at bedtime. This schedule provides maximum beneficial effects during the night and early morning, when asthma symptoms often occur or worsen.

Use inhalers correctly:
1. Shake well immediately before each use.
2. Remove the cap from the mouthpiece.
3. Exhale to the end of a normal breath.
4. With the inhaler in the upright position, place the mouthpiece just inside the mouth, and use the lips to form a tight seal or hold the mouthpiece approximately two finger-widths from the open mouth.

While pressing down on the inhaler, take a slow, deep breath for 3 to 5 seconds, hold the breath for approximately 10 seconds, and exhale slowly.

Wait 3 to 5 min before taking a second inhalation of the drug.

Rinse the mouth with water after each inhalation.

Rinse the mouthpiece and store the inhaler away from heat.

If you have difficulty using an inhaler, ask your physician about a spacer device (a tube attached to the inhaler that makes it easier to use).
added to the regimen to further control symptoms and reduce the need for corticosteroids and inhaled bronchodilators.

8. Multidrug regimens are commonly used and one advantage is that smaller doses of each agent can usually be given. This may decrease adverse effects and allow dosages to be increased when exacerbation of symptoms occurs. Available combination inhalation products include Combivent (albuterol and ipratropium) and Advair (salmeterol and fluticasone). Advair, which was developed to treat both inflammation and bronchoconstriction, was more effective than the individual components at the same doses and as effective as concurrent use of the same drugs at the same doses. In addition, the combination reduced the corticosteroid dose by 50% and was more effective than higher doses of fluticasone alone in reducing asthma exacerbations. The combination improved symptoms within 1 week. Additional combination products are likely to be marketed and may improve patient compliance with prescribed drug therapy.

Dosage Factors

Dosage of antiasthmatic drugs must be individualized to attain the most therapeutic effects and the fewest adverse effects. Larger doses of bronchodilators and corticosteroids (inhaled, systemic, or both) are usually required to relieve the symptoms of acute, severe bronchoconstriction or status asthmaticus. Then, doses should be reduced to the smallest effective amounts for long-term control.

Dosage of theophylline preparations should be based mainly on serum theophylline levels (therapeutic range is 5 to 15 mcg/mL; toxic levels are 20 mcg/mL or above). Blood for serum levels should be drawn 1 to 2 hours after immediate-release dosage forms and about 4 hours after sustained-release forms. In addition, children and cigarette smokers usually need higher doses to maintain therapeutic blood levels because they metabolize theophylline rapidly, and clients with liver disease, congestive heart failure, chronic pulmonary disease, or acute viral infections usually need smaller doses because these conditions impair theophylline metabolism. For obese clients, theophylline dosage should be calculated on the basis of lean or ideal body weight because theophylline is not highly distributed in fatty tissue.

Toxicity of Antiasthmatic Drugs

Signs and symptoms of overdose and toxicity are probably most likely to occur when clients with acute or chronic bronchoconstrictive disorders overuse bronchodilators in their efforts to relieve dyspnea. General management of acute poisoning includes early recognition of signs and symptoms, stopping the causative drug, and instituting other treatment measures as indicated. Specific measures include the following:

• **Bronchodilator overdose.** With inhaled or systemic adrenergic bronchodilators, major adverse effects are excessive cardiac and CNS stimulation. Symptoms of cardiac stimulation include angina, tachycardia, and palpitations; serious dysrhythmias and cardiac arrest have also been reported. Symptoms of CNS stimulation include agitation, anxiety, insomnia, seizures, and tremors. Severe overdoses may cause delirium, collapse, and coma. In addition, hypokalemia, hyperglycemia, and hypotension or hypertension may occur. Management includes discontinuing the causative medications and using general supportive measures (measles, gastric lavage, or activated charcoal may be useful with oral drugs). For cardiac symptoms, monitor blood pressure, pulse, and electrocardiogram. Cautious use of a beta-adrenergic blocking drug (eg, propranolol) may be indicated. However, a nonselective beta blocker may induce bronchoconstriction.

• **Theophylline overdose.** Signs and symptoms include anorexia, nausea, vomiting, agitation, nervousness, insomnia, tachycardia and other dysrhythmias, and tonic-clonic convulsions. Ventricular dysrhythmias or convulsions may be the first sign of toxicity. Serious adverse effects rarely occur at serum drug levels below 20 mcg/mL. Overdoses with sustained-release preparations may cause a dramatic increase in serum drug concentrations much later (12 hours or longer) than the immediate-release preparations. Early treatment helps but does not prevent these delayed increases in serum drug levels.

In patients without seizures, induce vomiting unless the level of consciousness is impaired. In these patients, precautions to prevent aspiration are needed, especially in children. If overdose is identified within an hour of drug ingestion, gastric lavage may be helpful if unable to induce vomiting or vomiting is contraindicated. Administration of activated charcoal and a cathartic is also recommended, especially for overdoses of sustained-release formulations.

In patients with seizures, treatment includes securing the airway, giving oxygen, injecting IV diazepam (0.1 to 0.3 mg/kg, up to 10 mg), monitoring vital signs, maintaining blood pressure, providing adequate hydration, and monitoring serum theophylline levels until below 20 mcg/mL. Also, symptomatic treatment of dysrhythmias may be needed.

• **Leukotriene modifiers and mast cell stabilizers.** These drugs seem relatively devoid of serious toxicity. There have been few reports of toxicity in humans and little clinical experience in managing it. If toxicity occurs, general supportive and symptomatic treatment is indicated.
Use in Children

The American Academy of Pediatrics endorses the clinical practice guidelines established by the National Asthma Education and Prevention Program (see Box 47–1). In general, antiasthmatic medications are used in children and adolescents for the same indications as for adults. With adrenergic bronchodilators, recommendations for use vary according to route of administration, age of the child, and specific drug formulations. However, even infants and young children can be treated effectively with aerosolized or nebulized drugs. In addition, some oral drugs can be given to children as young as 2 years and most can be given to children 6 to 12 years of age.

With theophylline, use in children should be closely monitored because dosage needs and rates of metabolism vary widely. In children younger than 6 months, especially premature infants and neonates, drug elimination may be prolonged because of immature liver function. Except for preterm infants with apnea, theophylline preparations are not recommended for use in this age group. Children 6 months to 16 years of age, approximately, metabolize theophylline more rapidly than younger or older clients. Thus, they may need higher doses than adults in proportion to size and weight. If the child is obese, the dosage should be calculated on the basis of lean or ideal body weight because the drug is not highly distributed in fatty tissue. Long-acting dosage forms are not recommended for children younger than 6 years of age. Children may become hyperactive and disruptive from the CNS-stimulating effects of theophylline. Tolerance to these effects usually develops with continued use of the drug.

Corticosteroids are being used earlier in children as in adults and inhaled corticosteroids are first-line drugs for treatment of persistent bronchoconstrictive disorders. The effectiveness and safety of inhaled corticosteroids in children older than 3 years of age is well established; few data are available on the use of inhaled drugs in those younger than 3 years. Major concerns about long-term use in children include decreased adrenal function, growth, and bone mass. Most are given by inhalation, and dosage, type of inhaler device, and characteristics of individual drugs influence the extent and severity of these systemic effects.

Adrenal insufficiency is most likely to occur with systemic or high doses of inhaled corticosteroids. Dose-related inhibition of growth has been reported in short and intermediate studies but long-term studies have found few, if any, decreases in expected adult height. Inhaled corticosteroids have not been associated with significant decreases in bone mass but more studies of high doses and of drug therapy in adolescents are needed. Bone growth should be monitored closely in children taking corticosteroids. Although inhaled corticosteroids are the most effective anti-inflammatory medications available for asthma, high doses in children are still of concern. The risk of high doses is especially great in children with other allergic conditions that require topical corticosteroid drugs. The risk can be decreased by using the lowest effective dose, administration techniques that minimize swallowed drug, and other antiasthmatic drugs to reduce corticosteroid dose.

Leukotriene modifiers have not been extensively studied in children and adolescents. With montelukast, the 10-mg film-coated tablet is recommended for adolescents 15 years of age and older and a 4-mg chewable tablet is recommended for children 2 to 5 years of age. Safety and effectiveness of zafirlukast in children younger than 12 years have not been established.

Cromolyn aerosol solution may be used in children 5 years of age and older, and nebulizer solution is used with children 2 years and older. Nedocromil is not established as safe and effective in children younger than 12 years of age.

Use in Older Adults

Older adults often have chronic pulmonary disorders for which bronchodilators and antiasthmatic medications are used. As with other populations, administering the medications by inhalation and giving the lowest effective dose decrease adverse effects. The main risks with adrenergic bronchodilators are excessive cardiac and CNS stimulation.

Theophylline use must be carefully monitored because drug effects are unpredictable. On the one hand, cigarette smoking and drugs that stimulate drug-metabolizing enzymes in the liver (eg, phenobarbital, phenytoin) increase the rate of metabolism and therefore dosage requirements. On the other hand, impaired liver function, decreased blood flow to the liver, and some drugs (eg, cimetidine, erythromycin) impair metabolism and therefore decrease dosage requirements. Adverse effects include cardiac and CNS stimulation. Safety can be increased by measuring serum drug levels and adjusting dosage to maintain therapeutic levels of 5 to 15 mcg/mL. If the client is obese, dosage should be based on lean or ideal body weight because theophylline is not highly distributed in fatty tissue.

Corticosteroids increase the risks of osteoporosis and cataracts in older adults. Leukotriene modifiers usually are well

Nursing Notes: Apply Your Knowledge

Gwen, a 7th grader, comes to the health center at the middle school in moderate respiratory distress. Her respiratory rate is 36 and you hear audible wheezing without a stethoscope. Her inhalers (albuterol and Vanceril) are kept in the health center for administration during school hours. Gwen has not been in to use her inhalers for the last week. What is most important to do now to treat Gwen’s asthma attack? What assessments/interventions might be important to assist Gwen in long-term management of her asthma?
tolerated by older adults, with pharmacokinetics and effects similar to those in younger adults. With zafirlukast, however, blood levels are higher and elimination is slower than in younger adults. Zileuton is contraindicated in older adults with underlying hepatic dysfunction.

**Use in Renal Impairment**

Bronchodilating and anti-inflammatory drugs can usually be given without dosage adjustments in clients with impaired renal function. Beta agonists may be given by inhalation or parenteral routes. Theophylline can be given in usual doses, but serum drug levels should be monitored. Most corticosteroids are eliminated by hepatic metabolism, and dosage reductions are not needed in clients with renal impairment. No data are available about the use of montelukast, and no dosage adjustments are recommended for zafirlukast or zileuton.

Cromolyn is eliminated by renal and biliary excretion; the drug should be given in reduced doses, if at all, in clients with renal impairment.

**Use in Hepatic Impairment**

Montelukast and zafirlukast produce higher blood levels and are eliminated more slowly in clients with hepatic impairment. However, no dosage adjustment is recommended for clients with mild to moderate hepatic impairment. Zileuton is associated with hepatotoxicity and contraindicated in clients with active liver disease or aminotransferase elevations of three times the upper limit of normal or higher. Recommendations to avoid hepatotoxicity include measuring hepatic aminotransferases (eg, alanine aminotransferase) before starting zileuton, once a month for the first 3 months of therapy, every 2 to 3 months for the remainder of the first year, and periodically thereafter. The drug should be discontinued if symptoms of liver dysfunction develop (eg, right upper quadrant pain, nausea, fatigue, pruritus, jaundice, or flu-like symptoms) or aminotransferase levels increase to more than five times the upper limit of normal.

Cromolyn is eliminated by renal and biliary excretion; the drug should be given in reduced doses, if at all, in clients with hepatic impairment.

**Use in Critical Illness**

Acute, severe asthma (status asthmaticus) is characterized by severe respiratory distress and requires emergency treatment. Beta₂ agonists should be given in high doses and as often as every 20 minutes for 1 to 2 hours (by MDIs with spacer devices or by compressed-air nebulization). However, high doses of nebulized albuterol have been associated with tachycardia, hypokalemia, and hyperglycemia. Once symptoms are controlled, dosage can usually be reduced and dosing intervals extended. High doses of systemic corticosteroids are also given for several days, IV or orally. If the patient is able to take an oral drug, there is no therapeutic advantage to IV administration.

When respiratory function improves, efforts to prevent future episodes are needed. These efforts may include identifying and avoiding suspected triggers, evaluation and possible adjustment of the client’s treatment regimen, and assessment of the client’s adherence to the prescribed regimen.

**Home Care**

All of the drugs discussed in this chapter are used in the home setting. A major role of the home care nurse is to assist clients in using the drugs safely and effectively. Several studies have indicated that many people do not use MDIs and other inhalation devices correctly. The home care nurse needs to observe a client using an inhalation device when possible. If errors in technique are assessed, teaching or reteaching may be needed. With inhaled medications, a spacer device may be useful, especially for children and older adults, because less muscle coordination is required to administer a dose. Adverse effects may be minimized as well.

For clients with asthma, especially children, assess the environment for potential triggers of acute bronchospasm, such as cigarette smoking. In addition, assist clients to recognize and treat (or get help for) exacerbations before respiratory distress becomes severe.

With theophylline, the home care nurse needs to assess the client and the environment for substances that may affect metabolism of theophylline and decrease therapeutic effects or increase adverse effects. In addition, the nurse needs to reinforce the importance of not exceeding the prescribed dose, not crushing long-acting formulations, reporting adverse effects, and keeping appointments for follow-up care.
### Drugs for Asthma and Other Bronchoconstrictive Disorders

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Be sure clients have adequate supplies of inhaled bronchodilators and corticosteroids available for self-administration. Observe technique of self-administration for accuracy and assist if needed.</td>
<td>To promote dissolution and absorption. Taking with food may decrease nausea and vomiting.</td>
</tr>
<tr>
<td>b. Give immediate-release oral theophylline before meals with a full glass of water, at regular intervals around the clock. If gastrointestinal upset occurs, give with food.</td>
<td>Sustained-release drug formulations should never be chewed or crushed because doing so causes immediate release of potentially toxic doses.</td>
</tr>
<tr>
<td>c. Give sustained-release theophylline q8–12h, with instructions not to chew or crush.</td>
<td>The bioavailability of zafirlukast is reduced approximately 40% if taken with food. Food does not significantly affect the bioavailability of montelukast and zileuton.</td>
</tr>
<tr>
<td>d. Give zafirlukast 1 h before or 2 h after a meal; montelukast and zileuton may be given with or without food.</td>
<td>This schedule provides high drug concentrations during the night and early morning, when asthma symptoms tend to occur or worsen.</td>
</tr>
<tr>
<td>e. Give montelukast in the evening or at bedtime</td>
<td></td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. Decreased dyspnea, wheezing, and respiratory secretions</td>
<td>Relief of bronchospasm and wheezing should be evident within a few minutes after giving subcutaneous epinephrine, IV aminophylline, or aerosolized adrenergic bronchodilators.</td>
</tr>
<tr>
<td>b. Reduced rate and improved quality of respirations</td>
<td></td>
</tr>
<tr>
<td>c. Reduced anxiety and restlessness</td>
<td></td>
</tr>
<tr>
<td>d. Therapeutic serum levels of theophylline (5–15 µg/mL)</td>
<td></td>
</tr>
<tr>
<td>e. Improved arterial blood gas levels (normal values: PO₂ 80 to 100 mm Hg; PCO₂ 35 to 45 mm Hg; pH, 7.35 to 7.45)</td>
<td></td>
</tr>
<tr>
<td>f. Improved exercise tolerance</td>
<td></td>
</tr>
<tr>
<td>g. Decreased incidence and severity of acute attacks of bronchospasm with chronic administration of drugs</td>
<td></td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. With adrenergic bronchodilators, observe for tachycardia, arrhythmias, palpitations, restlessness, agitation, insomnia.</td>
<td>These signs and symptoms result from cardiac and central nervous system (CNS) stimulation.</td>
</tr>
<tr>
<td>b. With ipratropium, observe for cough or exacerbation of symptoms.</td>
<td>Ipratropium produces few adverse effects because it is not absorbed systemically.</td>
</tr>
<tr>
<td>c. With xanthine bronchodilators, observe for tachycardia, arrhythmias, palpitations, restlessness, agitation, insomnia, nausea, vomiting, convulsions.</td>
<td>Theophylline causes cardiac and CNS stimulation. Convulsions occur at toxic serum concentrations (&gt;20 mcg/mL). They may occur without preceding symptoms of toxicity and may result in death. IV diazepam (Valium) may be used to control seizures. Theophylline also stimulates the chemoreceptor trigger zone in the medulla oblongata to cause nausea and vomiting.</td>
</tr>
<tr>
<td>d. With inhaled corticosteroids, observe for hoarseness, cough, throat irritation, and fungal infection of mouth and throat.</td>
<td>Inhaled corticosteroids are unlikely to produce the serious adverse effects of long-term systemic therapy (see Chap. 24). These drugs are usually well tolerated. A highly elevated ALT and liver dysfunction are more likely to occur with zileuton.</td>
</tr>
<tr>
<td>e. With leukotriene inhibitors, observe for headache, infection, nausea, pain, elevated liver enzymes (eg, alanine aminotransferase [ALT]), and liver dysfunction.</td>
<td>Some of the cardiovascular effects are thought to be caused by the propellants used in the aerosol preparation.</td>
</tr>
<tr>
<td>f. With cromolyn, observe for dysrhythmias, hypotension, chest pain, restlessness, dizziness, convulsions, CNS depression, anorexia, nausea and vomiting. Sedation and coma may occur with overdosage.</td>
<td></td>
</tr>
</tbody>
</table>

*(continued)*
CHAPTER 47 DRUGS FOR ASTHMA AND OTHER BRONCHOCONSTRICTIVE DISORDERS

713

Review and Application Exercises

1. What are some causes of bronchoconstriction, and how can they be prevented or minimized?
2. How do beta-adrenergic agonists act as bronchodilators?
3. What adverse effects are associated with bronchodilators, and how can they be prevented or minimized?
4. What is the therapeutic range of serum theophylline levels, and why should they be monitored?
5. For what effects are corticosteroids used in the treatment of bronchoconstrictive respiratory disorders?
6. For what effects are leukotriene modifiers used in the treatment of asthma?
7. How do cromolyn and nedocromil act to prevent acute asthma attacks?
8. What are the main elements of treating respiratory distress from acute bronchospasm?

How Can You Avoid This Medication Error?

Answer: Only short-acting beta-adrenergic bronchodilators should be used for acute dyspnea. Alupent, not Atrovent, is indicated. When patients have more than one inhaler, they should be taught which inhaler to use in emergency situations. The canister should be a different color (many manufacturers consider this) or clearly marked with tape, so that quick identification can occur in an emergency. Additional teaching may be indicated for the nurse and the patient regarding the action of each inhaler.

Nursing Notes: Apply Your Knowledge

Answer: First, have Gwen sit in a private area. An asthma attack can be very embarrassing for a middle-schooler and stress can increase her respiratory distress. Gwen needs to use her rescue inhaler now. Albuterol, a beta2 agonist, will work quickly to dilate constricted bronchioles. Repeat if necessary. If Gwen’s respiratory distress is not reversed by using the inhaler, the nurse should call 911 for emergency back-up. Asthma can be lethal.

Plan follow-up with Gwen and her family at a later time to determine factors that may have contributed to Gwen’s asthma attack. Have Gwen demonstrate using her inhalers so you can assess her technique. Question her regarding compliance with the medication regimen. Ask to see her peak flow log to assess whether she has been consistently monitoring her asthma control. Assess potential triggers that may have contributed to this attack (new pets, exposure to other allergens) and individualize teaching.

SELECTED REFERENCES


Critical Thinking Scenario
You are working at the college health center. John, a freshman, comes to the clinic complaining of seasonal pollen allergies that have worsened significantly since his relocation at college. He has been self-treating with over-the-counter (OTC) medications a friend in the dorms gave him.

Reflect on:
- Assessment of John’s allergy history and factors that may have increased John’s allergic response
- Appropriate teaching about the allergic response and how antihistamines work
- Informed use of OTC allergy medications to manage symptoms, including side effects and interactions
- Nonpharmacologic methods to prevent or limit allergic reactions

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Delineate effects of histamine on selected body tissues.
2. Differentiate histamine receptors.
3. Describe the types of hypersensitivity or allergic reactions.
4. Discuss allergic rhinitis, allergic contact dermatitis, and drug allergies as conditions for which antihistamines are commonly used.
5. Identify the effects of histamine that are blocked by histamine-1 receptor antagonist drugs.
7. Describe antihistamines in terms of indications for use, adverse effects, and nursing process implications.
8. Discuss the use of antihistamines in special populations.

OVERVIEW
Antihistamines are drugs that antagonize the action of histamine. Thus, to understand the use of these drugs, it is necessary to understand histamine and its effects on body tissues, characteristics of allergic reactions, and selected conditions for which antihistamines are used.

HISTAMINE AND ITS RECEPTORS
Histamine is the first chemical mediator to be released in immune and inflammatory responses. It is synthesized and stored in most body tissues, with high concentrations in tissues exposed to environmental substances (e.g., the skin and mucosal surfaces of the eye, nose, lungs, and gastrointestinal [GI] tract). It is also found in the central nervous system (CNS). In these tissues, histamine is located mainly in secretory granules of mast cells (tissue cells surrounding capillaries) and basophils (circulating blood cells).

Histamine is discharged from mast cells and basophils in response to certain stimuli (e.g., allergic reactions, cellular injury, extreme cold). Once released, it diffuses rapidly into other tissues, where it interacts with histamine receptors on target organs, called H1 and H2. H1 receptors are located mainly on smooth muscle cells in blood vessels and the respiratory and GI tracts. When histamine binds with these receptors and stimulates them, effects include:
- Contraction of smooth muscle in the bronchi and bronchioles (producing bronchoconstriction and respiratory distress)
- Stimulation of vagus nerve endings to produce reflex bronchoconstriction and cough
- Increased permeability of veins and capillaries, which allows fluid to flow into subcutaneous tissues and form edema
- Increased secretion of mucous glands. Mucosal edema and increased nasal mucus produce the nasal congestion characteristic of allergic rhinitis and the common cold.
- Stimulation of sensory peripheral nerve endings to cause pain and pruritus. Pruritus is especially prominent with allergic skin disorders.
- Dilatation of capillaries in the skin, to cause flushing
  When H2 receptors are stimulated, the main effects are increased secretion of gastric acid and pepsin, increased rate and force of myocardial contraction, and decreased immunologic and proinflammatory reactions (eg, decreased release of histamine from basophils, decreased movement of neutrophils and basophils into areas of injury, inhibited T- and B-lymphocyte function). Stimulation of both H1 and H2 receptors causes peripheral vasodilation (with hypotension, headache, and skin flushing) and increases bronchial, intestinal, and salivary secretion of mucus.

**HYPERSENSITIVITY (ALLERGIC) REACTIONS**

Hypersensitivity or allergic reactions are immune responses (see Chap. 42) in which a person’s body overreacts to an environmental or ingested substance that does not cause a reaction in most people. That is, the person is hypersensitive or allergic to the substance (called an antigen or allergen). Allergic reactions may result from specific antibodies, sensitized T lymphocytes, or both, formed during exposure to an antigen.

### Types of Allergic Reactions

- **Type I** (also called immediate hypersensitivity because it occurs within minutes of exposure to the antigen) is an immunoglobulin E (IgE)-induced response that causes release of histamine and other mediators. For example, anaphylaxis is a type I response that may be mild (characterized mainly by urticaria, other dermatologic manifestations, or rhinitis) or severe and life threatening (characterized by respiratory distress and cardiovascular collapse). It is uncommon and does not occur on first exposure to an antigen; it occurs with a second or later exposure, after antibody formation was induced by an earlier exposure. Severe anaphylaxis (sometimes called anaphylactic shock; see Chap. 54) is characterized by cardiovascular collapse from profound vasodilation and pooling of blood in the splanchnic system so that the patient has severe hypotension and functional hypovolemia. Respiratory distress often occurs from laryngeal edema and bronchoconstriction. Urticaria often occurs because the skin has many mast cells to release histamine. Anaphylaxis is a systemic reaction that usually involves the respiratory, cardiovascular, and dermatologic systems. Severe anaphylaxis may be fatal if not treated promptly and effectively.

- **Type II** responses are mediated by IgG or IgM. They produce direct damage to the cell surface. These cytotoxic reactions include blood transfusion reactions, hemolytic disease of newborns, autoimmune hemolytic anemia, and some drug reactions.
- **Type III** is an IgG- or IgM-mediated reaction characterized by formation of antigen–antibody complexes that induce an acute inflammatory reaction in the tissues. *Serum sickness*, the prototype of these reactions, occurs when excess antigen combines with antibodies to form immune complexes. The complexes then diffuse into affected tissues, where they cause tissue damage by activating the complement system and initiating the inflammatory response. If small amounts of immune complexes are deposited locally, the antigenic material can be phagocytized and digested by white blood cells and macrophages without tissue destruction. If large amounts are deposited locally or reach the bloodstream and become deposited in blood vessel walls, the lysosomal enzymes released during phagocytosis may cause permanent tissue destruction.
- **Type IV** hypersensitivity (also called delayed hypersensitivity because it usually occurs several hours or days after exposure to the antigen) is a cell-mediated response in which sensitized T lymphocytes react with an antigen to cause inflammation mediated by release of lymphokines, direct cytotoxicity, or both.

**Allergic Rhinitis**

Allergic rhinitis is inflammation of nasal mucosa caused by a type I hypersensitivity reaction to inhaled allergens. It is a very common disorder characterized by nasal congestion, itching, sneezing, and watery drainage. Itching of the throat, eyes, and ears often occurs as well.

There are two types of allergic rhinitis. Seasonal disease (often called hay fever) produces acute symptoms in response to the protein components of airborne pollens from trees, grasses and weeds, mainly in spring or fall. Perennial disease produces chronic symptoms in response to nonseasonal allergens such as dust mites, animal dander, and molds. Actually, mold spores can cause both seasonal and perennial allergies because they are present year round, with seasonal increases. Some people have both types, with chronic symptoms plus acute seasonal symptoms.

People with a personal or family history of other allergic disorders are likely to have allergic rhinitis. Once the nasal mucosa is inflamed, symptoms can be worsened by nonallergenic irritants such as tobacco smoke, strong odors, air pollution, and climatic changes.

Allergic rhinitis is an immune response in which normal nasal breathing and filtering of air brings inhaled antigens into contact with mast cells and basophils in nasal mucosa, blood vessels, and submucosal tissues. With initial exposure, the inhaled antigens are processed by lymphocytes that pro-
duce IgE, an antigen-specific antibody that binds to mast cells. With later exposures, the IgE interacts with inhaled antigens and triggers the breakdown of the mast cell. This breakdown causes the release of histamine and other inflammatory mediators such as prostaglandins and leukotrienes (Fig. 48–1). These mediators, of which histamine may be the most important, dilate and engorge blood vessels to produce nasal congestion, stimulate secretion of mucus, and attract inflammatory cells (eg, eosinophils, lymphocytes, monocytes, macrophages). In people with allergies, mast cells and basophils are increased in both number and reactivity. Thus, they may be capable of releasing large amounts of histamine and other mediators.

Allergic rhinitis that is not effectively treated may lead to chronic fatigue, impaired ability to perform usual activities of daily living, difficulty sleeping, sinus infections, postnasal drip, cough, and headache. In addition, this condition is a strong risk factor for asthma.

**Allergic Contact Dermatitis**

Allergic contact dermatitis is a type IV hypersensitivity reaction resulting from direct contact with antigens to which a person has previously become sensitized (eg, poison ivy or poison oak, cosmetics, hair dyes, metals, drugs applied topically to the skin). This reaction, which may be acute or chronic, usually occurs more than 24 hours after re-exposure to an antigen and may last from days to weeks.

Affected areas of the skin are usually inflamed, warm, edematous, intensely pruritic, and tender to touch. Skin lesions are usually erythematous macules, papules, and vesicles (blisters) that may drain, develop crusts, and become infected. Lesion location may indicate the causative antigen.

**Allergic Drug Reactions**

Virtually any drug may induce an immunologic response in susceptible people, and any body tissues may be affected. Allergic drug reactions are complex and diverse and may include any of the types of hypersensitivity described previously. A single drug may induce one or more of these states and multiple symptoms. There are no specific characteristics that identify drug-related reactions, although some reactions commonly attributed to drugs (eg, skin rashes, drug fever, hematologic reactions, hepatic reactions) rarely occur with plant pollens and other naturally occurring antigens. Usually, however, the body responds to a drug as it does to other foreign materials (antigens). In addition, some reactions may be caused by coloring agents, preservatives, and other additives rather than the drug itself.

![Figure 48–1. Type I hypersensitivity reaction: allergic rhinitis. (A) The first exposure of mast cells in nasal mucosa to inhaled antigens (eg, pollens from weeds, grasses, trees) leads to the formation of immunoglobulin E (IgE) antibody molecules. These molecules then bind to the surface membranes of mast cells. This process sensitizes mast cells to the effects of inhaled antigens (allergens). (B) When sensitized mast cells are re-exposed to inhaled pollens or other antigens, they release histamine and other chemical mediators which then act on nasal mucosa to produce characteristic symptoms of allergic rhinitis.](image-url)
Allergic drug reactions should be considered when new signs and symptoms develop or when they differ from the usual manifestations of the illness being treated, especially if a reaction:

- Follows ingestion of a drug, especially one known to produce allergic reactions
- Is unpredictable and occurs in only a few clients when many clients receive the suspected drug
- Occurs approximately 7 to 10 days after initial exposure to the suspected drug (to allow antibody production)
- Follows a previous exposure to the same or similar drug (sensitizing exposure)
- Occurs minutes or hours after a second or subsequent exposure
- Occurs after small doses (reduces the likelihood that the reaction is due to dose-related drug toxicity)
- Occurs with other drugs that are chemically or immunologically similar to the suspected drug
- Produces signs and symptoms that differ from the usual pharmacologic actions of the suspected drug
- Produces signs and symptoms usually considered allergic in nature (eg, anaphylaxis, urticaria, serum sickness)
- Produces similar signs and symptoms to previous allergic reactions to the same or a similar drug
- Increases eosinophils in blood or tissue
- Resolves within a few days of discontinuing the suspected drug

Virtually all drugs have been implicated in anaphylactic reactions. Penicillins and other antimicrobials, radiocontrast media, aspirin and other nonsteroidal anti-inflammatory drugs, and antineoplastics such as asparaginase and cisplatin are more common offenders. Less common causes include anesthetics (local and general), opioid analgesics, skeletal muscle relaxants used with general anesthetics, and vaccines. Approximately 10% of severe anaphylactic reactions are fatal. In many cases, it is unknown whether clinical manifestations are immunologic or nonimmunologic in origin.

**Serum sickness** is a delayed hypersensitivity reaction most often caused by drugs, such as antimicrobials. In addition, many drugs that produce anaphylaxis also produce serum sickness. With initial exposure to the antigen, symptoms usually develop within 7 to 10 days and include urticaria, lymphadenopathy, myalgia, arthralgia, and fever. The reaction usually resolves within a few days but may be severe or even fatal. With repeated exposure to the antigen, after prior sensitization of the host, accelerated serum sickness may develop within 2 to 4 days, with similar but often more severe signs and symptoms.

**Systemic lupus erythematosus** (SLE) is an autoimmune disorder that may be induced by hydralazine, procainamide, isoniazid, and other drugs. Clinical manifestations vary greatly, depending on the location and severity of the inflammatory and immune processes, and may include skin lesions, fever, pneumonia, anemia, arthralgia, arthritis, nephritis and others. Drug-induced lupus produces less renal and CNS involvement than idiopathic SLE.

**Fever** often occurs with allergic drug reactions. It may occur alone, with a skin rash and eosinophilia, or with other drug-induced allergic reactions such as serum sickness, SLE, vasculitis, and hepatitis.

**Dermatologic conditions** (eg, skin rash, urticaria, inflammation) commonly occur with allergic drug reactions and may be the first and most visible manifestations.

### Pseudoallergic Drug Reactions

Pseudoallergic drug reactions resemble immune responses (because histamine and other chemical mediators are released) but they do not produce antibodies or sensitized T lymphocytes. **Anaphylactoid reactions** are like anaphylaxis in terms of immediate occurrence, symptoms, and life-threatening severity. The main difference is that they are not antigen–antibody reactions and therefore may occur on first exposure to the causative agent. The drugs bind directly to mast cells, activate the cells, and cause the release of histamine and other vasoactive chemical mediators. Contrast media for radiologic diagnostic tests are often implicated.

### Antihistamines

The term antihistamines generally indicates classic or traditional drugs. With increased knowledge about histamine receptors, these drugs are often called H1 receptor antagonists. These drugs prevent or reduce most of the physiologic effects that histamine normally induces at H1 receptor sites. Thus, they:

- Inhibit smooth muscle constriction in blood vessels and the respiratory and GI tracts
- Decrease capillary permeability
- Decrease salivation and tear formation

The drugs are similar in effectiveness as histamine antagonists but differ in adverse effects. These are the antihistamines discussed in this chapter. Cimetidine (Tagamet), ranitidine (Zantac), famotidine (Pepcid), and nizatidine (Axid) are H2 receptor antagonists or blocking agents used to prevent or treat peptic ulcer disease. These are discussed in Chapter 60. Selected H1 antagonists are described in the following sections and in Drugs at a Glance: Commonly Used Antihistamines.

### First-Generation H1 Receptor Antagonists

These chemically diverse antihistamines (also called nonselective or sedating agents) bind to both central and peripheral H1 receptors and can cause CNS depression or stimulation. They usually cause CNS depression (drowsiness, sedation) with therapeutic doses and may cause CNS stimulation (anxiety, agitation) with excessive doses, especially in children. They also have substantial anticholinergic effects (eg, cause dry mouth, urinary retention, constipation, blurred vision).
# Drugs at a Glance: Commonly Used Antihistamines

## First Generation

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Azelastine</strong> (Astelin)</td>
<td>Allergic rhinitis</td>
<td>Nasal inhalation, two sprays per nostril q12h</td>
</tr>
<tr>
<td>Chlorpheniramine (Chlor-Trimeton)</td>
<td>Allergic rhinitis</td>
<td>PO 4 mg q4–6h; maximal dose, 24 mg in 24h</td>
</tr>
<tr>
<td>Clemastine (Tavist)</td>
<td>Allergic rhinitis</td>
<td>PO 1.34 mg twice daily, increased up to a maximum of 8.04 mg daily, if necessary</td>
</tr>
<tr>
<td><strong>Cyproheptadine</strong> (Periactin)</td>
<td>Hypersensitivity reactions (allergic rhinitis, conjunctivitis, dermatitis)</td>
<td>PO 4 mg q8h initially, increase if necessary. Maximal dose 0.5 mg/kg/d</td>
</tr>
<tr>
<td><strong>Dexchlorpheniramine</strong> (Polaramine)</td>
<td>Hypersensitivity reactions (allergic rhinitis, conjunctivitis, dermatitis)</td>
<td>Regular tablets and syrup, PO 2 mg q4–6h</td>
</tr>
<tr>
<td>Diphenhydramine (Benadryl)</td>
<td>Hypersensitivity reactions (allergic rhinitis, conjunctivitis, dermatitis)</td>
<td>Hypersensitivity reaction, motion sickness, parkinsonism, PO 25–50 mg q4–8h; IV or deep IM 10–50 mg, increased if necessary to a maximal daily dose of 400 mg</td>
</tr>
<tr>
<td>Hydroxyzine (Vistaril, Atarax)</td>
<td>Pruritus</td>
<td>PO 25 mg q6–8h; IM 25–100 mg as needed</td>
</tr>
<tr>
<td>Phenindamine (Nolahist)</td>
<td>Allergic rhinitis</td>
<td>PO 25 mg q4–6h; maximal dose 150 mg in 24 h</td>
</tr>
<tr>
<td>Promethazine (Phenergan)</td>
<td>Hypersensitivity reactions (allergic rhinitis, conjunctivitis, dermatitis)</td>
<td>PO, IM, rectally, 25 mg q4–6h as needed</td>
</tr>
<tr>
<td>Tripelemamine (PBZ)</td>
<td>Hypersensitivity reactions (allergic rhinitis, conjunctivitis, dermatitis)</td>
<td>PO 25–50 mg q4–6h Extended-release tablets, PO 100 mg q12h</td>
</tr>
</tbody>
</table>

(continued)
Drugs at a Glance: Commonly Used Antihistamines (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Second Generation</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cetirizine (Zyrtec)</td>
<td>Allergic rhinitis</td>
<td>PO 5–10 mg once daily</td>
<td>≥6 y: Same as adults</td>
</tr>
<tr>
<td></td>
<td>Chronic idiopathic urticaria</td>
<td>Renal or hepatic impairment: PO 5 mg once daily</td>
<td></td>
</tr>
<tr>
<td>Desloratadine (Clarinex)</td>
<td>Allergic rhinitis</td>
<td>PO 5 mg once daily</td>
<td>12 y and older: Same as adults</td>
</tr>
<tr>
<td></td>
<td>Chronic idiopathic urticaria</td>
<td>Renal and hepatic impairment: PO 5 mg every other day</td>
<td>&lt;12 y: Dosage not established</td>
</tr>
<tr>
<td>Fexofenadine (Allegra)</td>
<td>Allergic rhinitis</td>
<td>PO 60 mg twice daily</td>
<td>≥12 y: Same as adults</td>
</tr>
<tr>
<td></td>
<td>Chronic idiopathic urticaria</td>
<td>Renal impairment: PO 60 mg once daily</td>
<td>6–11 y: PO 30 mg twice daily</td>
</tr>
<tr>
<td>Loratadine (Clarith)</td>
<td>Allergic rhinitis</td>
<td>PO 10 mg once daily</td>
<td>≥6 y: Same as adults</td>
</tr>
<tr>
<td></td>
<td>Chronic idiopathic urticaria</td>
<td>Renal or hepatic impairment: PO 10 mg every other day</td>
<td></td>
</tr>
</tbody>
</table>

**Brompheniramine, chlorpheniramine** (Chlor-Trimeton), and **dextchlorpheniramine** (Polaramine) cause minimal drowsiness. **Diphenhydramine** (Benadryl), the prototype of first-generation antihistamines, causes a high incidence of drowsiness and anticholinergic effects. **Hydroxyzine** (Vistaril) and **promethazine** (Phenergan) are strong CNS depressants and cause extensive drowsiness.

First-generation antihistamines are usually well absorbed after oral administration. Immediate-release oral forms act within 15 to 60 minutes and last 4 to 6 hours. Enteric-coated or sustained-release preparations last 8 to 12 hours. Most drugs are given orally; a few may be given parenterally. These drugs are primarily metabolized by the liver, with metabolites and small amounts of unchanged drug excreted in urine within 24 hours. Several of these drugs are available without prescription. **Brompheniramine** is available only in multi-ingredient preparations (eg, several Dimetapp formulations); **chlorpheniramine** and **diphenhydramine** are available alone and in combination with adrenergic nasal decongestants, analgesics, and allergy, cold, and sinus remedies.

**Second-Generation H1 Receptor Antagonists**

Second-generation H1 antagonists (also called selective or nonsedating agents) were developed mainly to produce less sedation than the first-generation drugs. They cause less CNS depression because they are selective for peripheral H1 receptors and do not cross the blood–brain barrier. These drugs have been available only by prescription. However, the manufacturer of loratadine (Clarith) has received Food and Drug Administration (FDA) approval of over-the-counter (OTC) sales. Proponents of OTC availability usually argue that the drugs are safer than the first-generation drugs that have been available OTC for many years.

**Azelastine** (Astelin) is the only antihistamine formulated as a nasal spray for topical use. When applied to nasal mucosa, it produces peak levels in 2 to 3 hours and lasts 12 to 24 hours. It is metabolized in the liver to an active metabolite and is excreted mainly in feces. The other drugs are well absorbed with oral administration and have a rapid onset of action. **Cetirizine** (Zyrtec) is an active metabolite of hydroxyzine that causes less drowsiness than hydroxyzine. It reaches maximal serum concentration in 1 hour and is about 93% protein bound. About half of a dose is metabolized in the liver; the other half is excreted unchanged in the urine. **Fexofenadine** (Allegra) reaches peak serum concentrations in about 2.5 hours, is 60% to 70% protein bound, and 95% is excreted unchanged in bile and urine. **Loratadine** (Clarith) effects occur within 1 to 3 hours, reach a maximum in 8 to 12 hours, and last 24 hours or longer. It is metabolized in the liver and its long duration of action is due, in part, to an active metabolite. Loratadine’s patent expired in December, 2002, clearing the way for generic formulations. **Desloratadine** (Clarinex), an active metabolite of loratadine and marketed by the manufacturer of Claritin, seems to offer no advantage over loratadine or other second-generation drugs.

**Mechanism of Action**

Antihistamines are structurally related to histamine and occupy the same receptor sites as histamine, which prevents histamine from acting on target tissues (Fig. 48–2). Thus, the drugs are effective in inhibiting vascular permeability, edema formation, bronchoconstriction, and pruritus associated with histamine release. They do not prevent histamine release or reduce the amount released.

**Indications for Use**

Antihistamines are used for a variety of allergic and nonallergic disorders to prevent or reverse target organ inflammation and its effects on organ function. The drugs can relieve symptoms but do not relieve the hypersensitivity.
**Allergic rhinitis.** Of people with seasonal allergic rhinitis, 75% to 95% experience some relief of sneezing, rhinorrhea, nasal congestion, and conjunctivitis with the use of antihistamines. People with perennial allergic rhinitis usually experience decreased nasal congestion and drying of nasal mucosa. However, many people require an additional drug to relieve symptoms. Cromolyn, ipratropium, and several corticosteroids are available in intranasal preparations for this purpose. These drugs, with dosage ranges for adults and children, are listed in Drugs at a Glance: Intranasal Drugs for Allergic Rhinitis.

**Anaphylaxis.** Antihistamines are helpful in treating urticaria and pruritus but are not effective in treating bronchoconstriction and hypotension. Epinephrine, rather than an antihistamine, is the drug of choice for treating severe anaphylaxis.

**Allergic conjunctivitis.** This condition, which is characterized by redness, itching, and tearing of the eyes, is often associated with allergic rhinitis. Antihistamine eye medications may be given (see Chap. 65).

**Drug allergies and pseudoallergies.** Antihistamines may be given to prevent or treat reactions to drugs. When used for prevention, they should be given before exposure (e.g., before a diagnostic test that uses an iodine preparation as a contrast medium; before an IV infusion of amphotericin B). When antihistamines are used for treatment, giving the antihistamine and stopping the causative drug usually relieve signs and symptoms within a few days.

**Transfusions of blood and blood products.** Premedication with an antihistamine is often used to prevent allergic reactions.

**Dermatologic conditions.** Antihistamines are the drugs of choice for treatment of allergic contact dermatitis and acute urticaria (a vascular reaction of the skin characterized by papules or wheals and severe itching, often called hives). Urticaria often occurs because the skin has many mast cells to release histamine. Other indications for use include drug-induced skin reactions, pruritus ani, and pruritus vulvae. Systemic drugs are used; topical preparations are not recommended because they

![Figure 48-2](image-url)
Drugs at a Glance: Intranasal Drugs for Allergic Rhinitis

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticholinergic</strong></td>
<td></td>
</tr>
<tr>
<td>Ipratropium (Atrovent nasal spray)</td>
<td>2 sprays (42 mcg or 84 mcg) per nostril 2–4 times daily</td>
</tr>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
</tr>
<tr>
<td>Beclomethasone (Beconase, Vancenase)</td>
<td>1 inhalation (42 mcg) in each nostril 2–4 times daily</td>
</tr>
<tr>
<td>Budesonide (Rhinocort)</td>
<td>256 mcg daily as 2 sprays per nostril twice daily or 4 sprays per nostril once daily</td>
</tr>
<tr>
<td>Flunisolide (Nasalide, Nasarel)</td>
<td>2 sprays (50 mcg) in each nostril 2 times daily, increase to 3 times daily if necessary</td>
</tr>
<tr>
<td>Fluticasone (Fionase)</td>
<td>2 sprays (50 mcg each) per nostril once daily (200 mcg daily)</td>
</tr>
<tr>
<td>Mometasone (Nasonex)</td>
<td>2 sprays (50 mcg each) per nostril once daily (200 mcg daily)</td>
</tr>
<tr>
<td>Triamcinolone (Nasacort, Nasacort AQ)</td>
<td>2 sprays (55 mcg/spray) in each nostril once daily</td>
</tr>
<tr>
<td><strong>Mast Cell Stabilizer</strong></td>
<td></td>
</tr>
<tr>
<td>Cromolyn (Nasalcrom)</td>
<td>1 spray in each nostril 3–6 times daily, q4–6h</td>
</tr>
</tbody>
</table>

often induce skin rashes themselves. With pruritus, oral cyproheptadine (Periactin) and hydroxyzine (Atarax) are especially effective.

• **Miscellaneous.** Some antihistamines are commonly used for nonallergic disorders, such as motion sickness, nausea and vomiting (eg, promethazine, hydroxyzine; see Chap. 63), and sleep (eg, diphenhydramine). The active ingredient in OTC sleep aids (eg, Compoz, Sominex) is a sedating antihistamine. Antihistamines are also common ingredients in OTC cold remedies (see Chap. 49).

**Contraindications to Use**

Antihistamines are contraindicated or must be used with caution in clients with hypersensitivity to the drugs, narrow-angle glaucoma, prostatic hypertrophy, stenosing peptic ulcer, and bladder neck obstruction, and during pregnancy.

• Assess every client for a potential hypersensitivity reaction. For example, it is standard practice on first contact to ask a client if he or she has any food, drug, or other allergies. The health care provider is likely to get more complete information by asking clients about allergic reactions to specific drugs (eg, antibiotics such as penicillin, local anesthetics) rather than asking if they are allergic to or cannot take any drugs.

If a drug allergy is identified, ask about specific signs and symptoms as well as any drugs currently taken. With previous exposure and sensitization to the same or a similar drug, immediate allergic reactions may occur. With a new drug, antibody formation and allergic reactions usually require a week or longer. Most reactions appear within a month of starting a drug.

When a suspected allergic reaction occurs (eg, skin rash, fever, edema, dyspnea), interview the client or consult medical records about the drug, dose, route, and time of administration. In addition, evaluate all the drugs a client is taking as a potential cause of the reaction. This assessment may involve searching drug literature to see if the suspected drug is associated with allergic reactions and discussion with physicians and pharmacists.

**Nursing Diagnoses**

• Risk for Injury related to drowsiness with first-generation antihistamines
• Deficient Knowledge: Safe and accurate drug use
• Deficient Knowledge: Strategies for minimizing exposure to allergens and irritants

**Nursing Process**

**Assessment**

• Assess the client’s condition in relation to disorders for which antihistamines are used. For the client with known allergies, try to determine the factors that precipitate or relieve allergic reactions and specific signs and symptoms experienced during a reaction.
Planning/Goals

The client will:
• Experience relief of symptoms
• Take antihistamines accurately
• Avoid hazardous activities if sedated from antihistamines
• Avoid preventable adverse drug effects
• Avoid taking sedative-type antihistamines with alcohol or other sedative drugs

Interventions

• For clients with known allergies, assist in identifying and avoiding precipitating factors when possible. If it is a drug allergy, encourage the client to carry a medical alert device that identifies the drug.
• Monitor the client closely for excessive drowsiness during the first few days of therapy with antihistamines known to cause sedation.
• Encourage a fluid intake of 2000 to 3000 mL daily, if not contraindicated.
• Because antihistamines are most effective before exposure to the stimulus that causes histamine release, assist clients in learning when to take the drugs (eg, during seasons of high pollen and mold counts).
• When indicated, obtain an order and administer an antihistamine before situations known to elicit allergic reactions (eg, blood transfusions, diagnostic tests that involve contrast media).
• For clients who have experienced an allergic or pseudoallergic drug reaction, assist them in learning about the drug thought responsible (including the generic and commonly used trade names), suitable alternatives for future drug therapy, and potential sources of the drug.

Evaluation

• Observe for relief of symptoms.
• Interview and observe for correct drug usage.
• Interview and observe for excessive drowsiness.

PRINCIPLES OF THERAPY

Prevention of Histamine-Releasing Reactions

When possible, avoiding exposure to known allergens can prevent allergic reactions. If antihistamine therapy is required, it is more effective if started before exposure to allergens because the drugs can then occupy receptor sites before histamine is released.

Drug Selection and Usage

• Choosing an antihistamine is based on the desired effect, duration of action, adverse effects, and other characteristics of available drugs. For most people, a second-generation drug is the first drug of choice. However, they are quite expensive. If costs are prohibitive for a client, a first-generation drug may be used with minimal daytime sedation if taken at bedtime or in low initial doses, with gradual increases over a week or two. Azelastine nasal spray also causes little sedation, but it leaves an unpleasant taste. Overall, safety should be the determining factor. Some studies have shown cognitive and performance impairment with the first-generation drugs even when the person does not feel drowsy or impaired.

• For treatment of acute allergic reactions, a rapid-acting agent of short duration is preferred.
• For chronic allergic symptoms (eg, allergic rhinitis), long-acting preparations provide more consistent relief. A client may respond better to one antihistamine than to another. Thus, if one does not relieve symptoms or produces excessive sedation, another may be effective.
• For treatment of the common cold, studies have demonstrated that antihistamines do not relieve symptoms and are not recommended. However, an antihistamine is often included in prescription and OTC combination products for the common cold.

Use in Children

First-generation antihistamines (eg, diphenhydramine) may cause drowsiness and decreased mental alertness in children as in adults. Young children may experience paradoxical excitement. These reactions may occur with therapeutic dosages. In overdose, hallucinations, convulsions, and death may occur. Close supervision and appropriate dosages are required for safe drug usage in children.

Diphenhydramine is not recommended for use in newborn infants (premature or full-term) or children with chickenpox or a flu-like infection. When used in young children, doses should be small because of drug effects on the brain and nervous system. Promethazine should not be used in children with hepatic disease, Reye’s syndrome, a history of sleep apnea, or a family history of sudden infant death syndrome.

The second-generation drugs vary in recommendations for use according to age groups. Cetirizine and loratadine may be used in children 2 years and older. Syrup formulations are available for use in younger children. Azelastine may be used in children 5 years and older; fexofenadine may be used in children 6 years of age and older; and desloratadine may be used in children 12 years and older.

Use in Older Adults

First-generation antihistamines (eg, diphenhydramine) may cause confusion (with impaired thinking, judgment, and memory), dizziness, hypotension, sedation, syncope,
unsteady gait, and paradoxical CNS stimulation in older adults. These effects, especially sedation, may be misinterpreted as senility or mental depression. Older men with prostatic hypertrophy may have difficulty voiding while taking these drugs. Some of these adverse reactions derive from anticholinergic effects of the drugs and are likely to be more severe if the client is also taking other drugs with anticholinergic effects (eg, tricyclic antidepressants, older antipsychotic drugs, some antiparkinson drugs). Despite the increased risk of adverse effects, however, diphenhydramine is sometimes prescribed as a sleep aid for occasional use in older adults. As with many other drugs, smaller-than-usual dosages are indicated.

In general, second-generation antihistamines should be used for older adults. They are much safer because they do not impair consciousness, thinking, or ability to perform activities of daily living (eg, driving a car or operating various machines).

**Use in Renal Impairment**

Little information is available about using antihistamines in clients with impaired renal function. With diphenhydramine, the dosing interval should be extended to 12 to 18 hours in clients with severe kidney failure. With cetirizine (5 mg once daily), desloratadine (5 mg every other day), fexofenadine (60 mg once daily), and loratadine (10 mg every other day), recommended doses for initial use are approximately one half of those used for young and middle-
Use in Hematologic Impairment

Little information is available about using antihistamines in clients with impaired hematologic function. With diphenhydramine, single doses are probably safe but the effects of multiple doses have not been studied in this population. With promethazine, cholestatic jaundice has been reported and the drug should be used with caution. With cetirizine (5 mg once daily) and loratadine (10 mg every other day), smaller-than-usual doses are recommended. No data are available regarding use of azelastine. However, because the drug is metabolized in the liver and excreted mainly in feces, cautious use and a possible dosage reduction may be needed with hepatic impairment.

Use in Critical Illness

Antihistamines are not often used in the treatment of clients with critical illness. Most are given orally, and many critically ill clients are unable to take oral drugs. Diphenhydramine may be given by injection, usually as a single dose, to a client who is having a blood transfusion or a diagnostic test, to prevent allergic reactions. Hydroxyzine or promethazine may be given by injection for nausea and vomiting or to provide sedation but are not usually the first drugs of choice for these indications.

Home Care

Antihistamines are often taken in the home setting, especially for allergic rhinitis and other allergic disorders. Most people are familiar with the uses and side effects of antihistamines. The home care nurse is unlikely to be involved in antihistamine drug therapy unless visiting a client for other care and purposes. If a first-generation drug is being used, the home care nurse needs to assess for drowsiness and safety hazards in the environment (eg, operating a car or other potentially hazardous machinery). In most people, tolerance develops to the sedative effects within a few days if they are not taking other sedative-type drugs or alcoholic beverages.

If a client has an allergic disorder, the home care nurse may need to assist in identifying and alleviating environmental allergens (eg, cigarette smoke, animal dander, dust mites).

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
<tr>
<td>a. Give most oral antihistamines with food; give loratadine on an empty stomach; give cetirizine with or without food.</td>
<td>To decrease gastrointestinal (GI) effects of the drugs</td>
</tr>
<tr>
<td>b. Give intramuscular antihistamines deeply into a large muscle mass.</td>
<td>To decrease tissue irritation</td>
</tr>
<tr>
<td>c. Inject intravenous (IV) antihistamines slowly, over a few minutes.</td>
<td>Severe hypotension may result from rapid IV injection.</td>
</tr>
<tr>
<td>d. When a drug is used to prevent motion sickness, give it 30–60 min before travel.</td>
<td>Therapeutic effects depend on the reason for use.</td>
</tr>
<tr>
<td>2. Observe for therapeutic effects</td>
<td></td>
</tr>
<tr>
<td>a. A verbal statement of therapeutic effect (relief of symptoms)</td>
<td></td>
</tr>
<tr>
<td>b. Decreased nausea and vomiting when given for antiemetic effects</td>
<td></td>
</tr>
<tr>
<td>c. Decreased dizziness and nausea when taken for motion sickness</td>
<td></td>
</tr>
<tr>
<td>d. Drowsiness or sleep when given for sedation</td>
<td></td>
</tr>
<tr>
<td>3. Observe for adverse effects</td>
<td></td>
</tr>
<tr>
<td>a. First-generation drugs</td>
<td></td>
</tr>
<tr>
<td>(1) Sedation</td>
<td>Drowsiness due to central nervous system (CNS) depression is the most common adverse effect.</td>
</tr>
</tbody>
</table>

(continued)
NURSING ACTIONS

(2) Paradoxical excitation—restlessness, insomnia, tremors, nervousness, palpitations
(3) Convulsive seizures
(4) Dryness of mouth, nose, and throat, blurred vision, urinary retention, constipation
(5) GI distress—anorexia, nausea, vomiting

b. Second-generation drugs
(1) Drowsiness
(2) Dry mouth
(3) Fatigue
(4) Headache
(5) GI upset

4. Observe for drug interactions

a. Drugs that increase effects of first-generation antihistamines:
(1) Alcohol and other CNS depressants (eg, antianxiety and antipsychotic agents, opioid analgesics, sedative-hypnotics)
(2) Monoamine oxidase inhibitors
(3) Tricyclic antidepressants

b. Drugs that increase effects of loratadine:
(1) Macrolide antibacterials (azithromycin, clarithromycin, erythromycin)
(2) Azole antifungals (fluconazole, itraconazole, ketoconazole, miconazole)
(3) Cimetidine

c. Drugs that may decrease effects of fexofenadine:
(1) Rifampin

RATIONALE/EXPLANATION

This reaction is more likely to occur in children. It may result from the anticholinergic effects of antihistamines.
Antihistamines, particularly the phenothiazines, may lower the seizure threshold.
Due to anticholinergic effects
Adverse effects are few and mild.
Drowsiness and dry mouth are more likely to occur with cetirizine; headache is more likely to occur with loratadine; desloratadine and fexofenadine reportedly produce minimal adverse effects.

Note: No documented drug interactions have been reported with intranasal azelastine or oral cetirizine or desloratadine.
Additive CNS depression. Concomitant use may lead to drowsiness, lethargy, stupor, respiratory depression, coma, and death.
Inhibit metabolism of antihistamines, leading to an increased duration of action; increased incidence and severity of sedative and anticholinergic adverse effects.
Additive anticholinergic side effects
All of these drugs increase plasma levels of loratadine by decreasing its metabolism.

Rifampin may induce enzymes that accelerate metabolism of fexofenadine.

Nursing Notes: Apply Your Knowledge

Answer: Benadryl, an antihistamine, blocks histamine receptors, thus decreasing histamine-induced symptoms such as rash, pruritus, cough, and swelling. If an allergic, histamine-related response occurs, the symptoms will be less severe if Benadryl has been previously administered. If a severe allergic reaction involving bronchospasm and hypotension occurs, epinephrine should be administered to reverse these potentially life-threatening symptoms.

How Can You Avoid This Medication Error?

Answer: Mrs. Doe needs to induce her son to vomit to prevent additional absorption of the cold remedy. Syrup of ipecac can be used to promote vomiting, which usually occurs 20 to 30 minutes after ingestion. If vomiting cannot be induced, instruct Mrs. Doe to bring her son to the urgent care center where gastric lavage can be used to empty the stomach.

Question Mrs. Doe regarding the time that has elapsed since ingestion, the amount of the medication ingested, medications contained in the cold remedy, and any symptoms her son is exhibiting. Teaching is essential to prevent future accidental poisonings. All medication, even OTC and herbal remedies, must be kept out of reach of all children and have childproof tops. Toddlers are especially prone to accidental poisoning because they are inquisitive, like to put things in their mouths, and cannot understand the danger such a situation poses. Children need constant supervision and should not be left alone. Make sure that Mrs. Doe has syrup of ipecac on hand and the phone number of the poison control center posted.
Review and Application Exercises

1. Describe several factors that cause histamine release from cells.

2. What signs and symptoms are produced by the release of histamine?

3. How do antihistamines act to block the effects of histamine?

4. Differentiate between H₁ and H₂ receptor antagonists in terms of pharmacologic effects and clinical indications for use.

5. In general, when should an antihistamine be taken to prevent or treat allergic disorders?

6. Compare and contrast the first- and second-generation antihistamines.

SELECTED REFERENCES


Nasal Decongestants, Antitussives, and Cold Remedies

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe characteristics of selected upper respiratory disorders and symptoms.
2. Review decongestant and adverse effects of adrenergic drugs.
3. Describe general characteristics and effects of antitussive agents.
4. Discuss the advantages and disadvantages of using combination products in treatment of the common cold.
5. Evaluate over-the-counter allergy, cold, cough, and sinus remedies for personal or clients’ use.

Critical Thinking Scenario

New parents bring their 5-month-old into the clinic with symptoms of a cold. The mother states her daughter has a slight fever, a runny nose, and a cough. The baby has had difficulty sleeping and has been keeping the mother awake with her fussing. The baby’s appetite has also decreased.

Reflect on:

- Worries and concerns new parents are likely to have about their sick infant.
- The effectiveness of an infant’s immune system in resisting infection.
- How nasal stuffiness may affect smaller anatomic structures of the infant.
- Nonpharmacologic interventions to decrease cold symptoms.

OVERVIEW

The drugs discussed in this chapter are used to treat upper respiratory disorders and symptoms such as the common cold, sinusitis, nasal congestion, cough, and excessive secretions. Some of these diverse drugs are discussed more extensively in other chapters; they are discussed here in relation to their use in upper respiratory conditions.

THE COMMON COLD

The common cold, a viral infection of the upper respiratory tract, is the most common respiratory tract infection. Adults usually have 2 to 4 colds per year; schoolchildren may have as many as 10 per year. A cold often begins with dry, stuffy feelings in the nose and throat, an increased amount of clear nasal secretions, and tearing of the eyes. As the mucous membranes of the nose and throat become more inflamed, other common symptoms include cough, increased nasal congestion and drainage, sore throat, hoarseness, headache, and general malaise. Colds can be caused by many types of virus, most often the rhinovirus. Shedding of these viruses by infected people, mainly from nasal mucosa, can result in rapid spread to other people.

The major mode of transmission is contamination of skin or environmental surfaces. The infected person, with viruses on the hands from contact with nasal secretions (e.g., sneezing, coughing), touches various objects (e.g., doorknobs, faucet handles, telephones). The uninfected person touches these contaminated surfaces with the fingers and then transfers the viruses by touching nasal or eye mucosal membranes. The viruses can enter the body through mucous membranes. Cold viruses can survive for several hours on the skin and hard surfaces, such as wood and plastic. There may also be airborne spread from sneezing and coughing, but this source...
is considered secondary. Once the viruses gain entry, the incubation period is about 5 days, the most contagious period is about 3 days after symptoms begin, and the cold usually lasts about 7 days. Because of the way cold viruses are spread, frequent and thorough handwashing (by both infected and uninfected people) is the most important protective and preventive measure.

**SINUSITIS**

Sinusitis is inflammation of the paranasal sinuses, air cells that connect with the nasal cavity and are lined by similar mucosa. As in other parts of the respiratory tract, ciliated mucous membranes help move fluid and microorganisms out of the sinuses and into the nasal cavity. This movement becomes impaired when sinus openings are blocked by nasal swelling, and the impairment is considered a major cause of sinus infections. Another contributing factor is a lower oxygen content in the sinuses, which aids the growth of microorganisms and impairs local defense mechanisms. Rhinitis (inflammation and congestion of nasal mucosa) and upper respiratory tract infections are the most common causes of sinusitis. Symptoms may include moderate to severe headache, tenderness or pain in the affected sinus area, and fever.

**COMMON SIGNS AND SYMPTOMS OF RESPIRATORY DISORDERS**

- **Nasal congestion** is manifested by obstructed nasal passages (“stuffy nose”) and nasal drainage (“runny nose”). It is a prominent symptom of the common cold and rhinitis (including allergic rhinitis; see Chap. 48). Nasal congestion results from dilation of the blood vessels in the nasal mucosa and engorgement of the mucous membranes with blood. At the same time, nasal membranes are stimulated to increase mucus secretion. Related symptomatic terms are rhinorrhea (secretions discharged from the nose) and rhinitis (inflammation of nasal mucosa, usually accompanied by nasal congestion, rhinorrhea, and sneezing).

- **Cough** is a forceful expulsion of air from the lungs. It is normally a protective reflex for removing foreign bodies, environmental irritants, or accumulated secretions from the respiratory tract. The cough reflex involves central and peripheral mechanisms. Centrally, the cough center in the medulla oblongata receives stimuli and initiates the reflex response (deep inspiration, closed glottis, buildup of pressure within the lungs, and forceful exhalation). Peripherally, cough receptors in the pharynx, larynx, trachea, or lungs may be stimulated by air, dryness of mucous membranes, or excessive secretions. A cough is productive when secretions are expectorated; it is non-productive when it is dry and no sputum is expectorated.

Cough is a prominent symptom of respiratory tract infections (eg, the common cold, influenza, bronchitis, pharyngitis) and chronic obstructive pulmonary diseases (eg, emphysema, chronic bronchitis). **Increased secretions** may result from excessive production or decreased ability to cough or otherwise remove secretions from the respiratory tract. Secretions may seriously impair respiration by obstructing airways and preventing air flow to and from alveoli, where gas exchange occurs. Secretions also may cause atelectasis (a condition in which part of the lung is airless and collapses) by blocking air flow, and they may cause or aggravate infections by supporting bacterial growth.

Respiratory disorders characterized by retention of secretions include influenza, pneumonia, upper respiratory infections, acute and chronic bronchitis, emphysema, and acute attacks of asthma. Nonrespiratory conditions that predispose to secretion retention include immobility, debilitation, cigarette smoking, and postoperative status. Surgical procedures involving the chest or abdomen are most likely to be associated with retention of secretions because pain may decrease the client’s ability to cough, breathe deeply, and ambulate.

**DRUGS FOR RESPIRATORY DISORDERS**

Numerous drugs are available and widely used to treat the symptoms of respiratory disorders. Many are nonprescription drugs and can be obtained alone or in combination products. Available products include nasal decongestants, antitussives, and expectorants.

**Nasal Decongestants**

Nasal decongestants are used to relieve nasal obstruction and discharge. Adrenergic (sympathomimetic) drugs are most often used for this purpose (see Chap. 18). These agents relieve nasal congestion and swelling by constricting arterioles and reducing blood flow to nasal mucosa. Oxymetazoline (Afrin) is a commonly used nasal spray; pseudoephedrine (Sudafed) is taken orally. Rebound nasal swelling can occur with excessive or extended use of nasal sprays (eg, >7 days, perhaps sooner).

Nasal decongestants are most often used to relieve rhinitis associated with respiratory infections or allergies. They also may be used to reduce local blood flow before nasal surgery and to aid visualization of the nasal mucosa during diagnostic examinations.

These drugs are contraindicated in clients with severe hypertension or coronary artery disease because of their cardiac stimulating and vasoconstricting effects. They also are contraindicated for clients with narrow-angle glaucoma and those taking tricyclic or monoamine oxidase inhibitor antidepressants. They must be used with caution in the presence of cardiac dysrhythmias, hyperthyroidism, diabetes mellitus, glaucoma, and prostatic hypertrophy.
How Can You Avoid This Medication Error?

Mr. Fell, an elderly man with a history of hypertension and diabetes, has a cold. A resident, who does not know Mr. Fell well, prescribes pseudoephedrine (Sudafed) to relieve nasal congestion. You administer this medication as ordered. Discuss the error and the impact it will have on Mr. Fell.

Antitussives

Antitussive agents suppress cough by depressing the cough center in the medulla oblongata or the cough receptors in the throat, trachea, or lungs. Centrally acting antitussives include narcotics (eg, codeine, hydrocodone) and non-narcotics (eg, dextromethorphan). Locally acting agents (eg, throat lozenges, cough drops) may suppress cough by increasing the flow of saliva and by containing demulcents or local anesthetics to decrease irritation of pharyngeal mucosa. Flavored syrups are often used as vehicles for other drugs.

The major clinical indication for use of antitussives is a dry, hacking, nonproductive cough that interferes with rest and sleep. It is not desirable to suppress a productive cough because the secretions need to be removed. Although antitussives continue to be used and some people report beneficial effects, some research studies indicate that cough medicines are no more effective than placebos in children or adults. The American Academy of Pediatrics and several other groups advise against the use of antitussives.

Expectorants

Expectorants are agents given orally to liquefy respiratory secretions and allow for their easier removal. Guaifenesin is the most commonly used expectorant. It is available alone and as an ingredient in many combination cough and cold remedies, although research studies do not support its effectiveness and many authorities do not recommend its use.

Mucolytics

Mucolytics are administered by inhalation to liquefy mucus in the respiratory tract. Solutions of mucolytic drugs may be nebulized into a face mask or mouthpiece or instilled directly into the respiratory tract through a tracheostomy. Sodium chloride solution and acetylcysteine (Mucomyst) are the only agents recommended for use as mucolytics. Acetylcysteine is effective within 1 minute after inhalation, and maximal effects occur within 5 to 10 minutes. It is effective immediately after direct instillation. Oral acetylcysteine is widely used in the treatment of acetaminophen overdose (see Chap. 7).

Cold Remedies

Many combination products are available for treating symptoms of the common cold. Many of the products contain an antihistamine, a nasal decongestant, and an analgesic. Some contain antitussives, expectorants, and other agents as well. Many cold remedies are over-the-counter (OTC) formulations. Commonly used ingredients include chlorpheniramine (antihistamine), pseudoephedrine (adrenergic nasal decongestant), acetaminophen (analgesic and antipyretic), dextromethorphan (antitussive), and guaifenesin (expectorant). Although antihistamines are popular OTC drugs because they dry nasal secretions, they are not recommended because they can also dry lower respiratory secretions and worsen secretion retention and cough.

Many products come in several formulations, with different ingredients, and are advertised for different purposes (eg, allergy, sinus disorders, multisymptom cold and flu remedies). For example, allergy remedies contain an antihistamine; “nondrowsy” or “daytime” formulas contain a nasal decongestant, but do not contain an antihistamine; PM or “night” formulas contain a sedating antihistamine to promote sleep; pain, fever, and multisymptom formulas usually contain acetaminophen; and “maximum strength” preparations usually refer only to the amount of acetaminophen per dose, usually 1000 mg for adults. In addition, labels on OTC combination products list ingredients by generic name, without identifying the type of drug. As a result of these bewildering products, consumers, including nurses and other health care providers, may not know what medications they are taking or whether some drugs increase or block the effects of other drugs.

INDIVIDUAL DRUGS

Individual decongestants, antitussives, expectorants, and mucolytics are listed in Drugs at a Glance: Nasal Decongestants, Antitussives, and Expectorants; selected combination products are listed in Table 49–1.

Herbal and Dietary Supplements

Several supplements are commonly used to prevent or treat symptoms of the common cold. In general, there is minimal or no support for such use. Echinacea preparations differ in chemical composition depending on which of the nine species or parts of the plant (eg, leaves, roots, whole plants) are used, as well as the sea-

Nursing Notes: Apply Your Knowledge

Joan, a college student, comes to the health clinic with cold symptoms (productive cough, low-grade fever, continuous nasal discharge, and general malaise and discomfort). She states she went to the drugstore to buy some cold medicine, but there were so many different preparations that she was confused. Discuss your recommendations for Joan, with their underlying rationale. 

### Drugs at a Glance: Nasal Decongestants, Antitussives, and Expectorants

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nasal Decongestants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ephedrine sulfate 0.25% solution</td>
<td>Topically, 2–3 sprays in each nostril no more often than q4h. Maximum, 6 doses/24 h.</td>
<td>12 y and older: Same as adults</td>
</tr>
<tr>
<td>Naphazoline (Privine) 0.05% spray or drops</td>
<td>Topically, 1–2 sprays or drops no more often than q6h. Maximum, 4 doses/24 h.</td>
<td>6–11 y: 2–3 sprays in each nostril no more often than q4h. Maximum, 6 doses/24 h.</td>
</tr>
<tr>
<td>Oxymetazoline (Afrin) 0.05% spray</td>
<td>Topically, 2–3 sprays in each nostril, q10–12h. Maximum, 2 doses/24 h.</td>
<td>&lt;6 y: Not recommended</td>
</tr>
<tr>
<td>Phenylephrine (Neo-Synephrine)</td>
<td>PO 10–20 mg q4h. Maximum 120 mg/24 h. Topically, 2–3 sprays or drops of 0.25%, 0.5% or 1% solution in each nostril no more often than q4h. Maximum, 6 doses/24 h.</td>
<td>12 y and older: Same as adults</td>
</tr>
<tr>
<td>Pseudoephedrine (Sudafed, Dimetapp)</td>
<td>Regular tablets, PO 60 mg q4–6 h. Extended-release tablets, PO 120 mg q12h or 240 mg q24h. Maximum, 240 mg in 24 h.</td>
<td>6–12 y: 30 mg q4–6h. Maximum, 120 mg/24 h.</td>
</tr>
<tr>
<td>Tetrahydrozoline (Tyzine) 0.1% solution</td>
<td>Topically, 2–4 drops or 3–4 sprays in each nostril, no more often than q3h. Maximum, 8 doses/24 h.</td>
<td>2–5 y: Topically, 2–3 drops of 0.125% solution no more often than q4h. Maximum 6 doses/24 h.</td>
</tr>
<tr>
<td>Xylometazoline (Otrivin)</td>
<td>Topically, 0.1% solution, 1–3 sprays or 2–3 drops in each nostril q8–10h. Maximum, 3 doses/24 h.</td>
<td>6 y and older: Same as adults for regular and extended release tablets.</td>
</tr>
<tr>
<td><strong>Narcotic Antitussive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine</td>
<td>PO 10–20 mg q4–6h. Maximum, 120 mg/24 h.</td>
<td>6–12 y: PO 5–10 mg q4–6h. Maximum, 60 mg/24 h.</td>
</tr>
<tr>
<td><strong>Nonnarcotic Antitussive</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dextromethorphan (Benylin DM, others)</td>
<td>Liquid, lozenges, and syrup, 10–30 mg q4–8h. Maximum, 120 mg/24 h. Sustained-action liquid (Delsym), PO 60 mg q12h</td>
<td>&gt;12 y: Same as adults</td>
</tr>
<tr>
<td><strong>Expectorant</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guaifenesin (glyceryl guaiacolate) (Robitussin, others)</td>
<td>PO 100–400 mg q4h. Maximum, 2400 mg/24 h.</td>
<td>12 y and older: Same as adults</td>
</tr>
<tr>
<td><strong>Mucolytic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetylcysteine (Mucomyst)</td>
<td>Nebulization, 1–10 mL of a 20% solution or 2–20 mL of a 10% solution q2–6h. Instillation, 1–2 mL of a 10% or 20% solution q1–4h.</td>
<td>Acetaminophen overdosage, see literature</td>
</tr>
<tr>
<td></td>
<td>Acetaminophen overdosage, PO 140 mg/kg initially, then 70 mg/kg q4h for 17 doses; dilute a 10% or 20% solution to a 5% solution with cola, fruit juice, or water</td>
<td></td>
</tr>
</tbody>
</table>

Acetaminophen overdosage, see literature
Some studies indicating effectiveness of echinacea in preventing or treating colds are considered flawed in methodology, but may indicate the use of different products with different chemical components. A double-blind, placebo-controlled study showed no benefit of using echinacea for preventing the common cold or respiratory infection. However, once a cold occurred, the symptoms did not last quite as long in the echinacea group. In general, randomized, placebo-controlled research studies indicate no significant differences between echinacea groups and placebo groups in the incidence, duration, or severity of upper respiratory infections. Thus, there is no convincing evidence that echinacea is effective. Moreover, the purity and potency of echinacea products are unknown or variable among products. Although generally considered safe, allergic reactions, including anaphylaxis, have been reported.

**Vitamin C**, usually in large doses of more than 1000 mg daily, is used to reduce the incidence and severity of colds and influenza. However, such usage is not recommended or justified by clinical data. In general, high doses of vitamin C demonstrate little or no benefit in shortening the duration of symptoms or reducing viral shedding. In addition, they may cause adverse effects and about 90% of large doses is excreted in the urine. Very little is absorbed and blood levels of vitamin C are raised only slightly.

**Zinc gluconate** lozenges are marketed as a cold remedy. However, some studies indicate beneficial effects and others do not. Most of the studies suggesting benefit are considered flawed in methodology. For example, although some studies were supposed to be blind, the lozenges’ distinctive taste likely allowed the drug to be distinguished from placebo.

### Nursing Process

**Assessment**

Assess the client’s condition in relation to disorders for which the drugs are used.

- With nasal congestion, observe for decreased ability to breathe through the nose. If nasal discharge is present, note the amount, color, and thickness. Question the client about the duration and extent of nasal congestion and factors that precipitate or relieve the symptom.
CHAPTER 49 NASAL DECONGESTANTS, ANTITUSSIVES, AND COLD REMEDIES

PRINCIPLES OF THERAPY

Drug Selection and Administration

Choice of drugs and routes of administration are influenced by several client- and drug-related variables. Some guidelines include the following:

1. Single-drug formulations allow flexibility and individualization of dosage, whereas combination products may contain unneeded ingredients and are more expensive. However, many people find combination products more convenient to use.

2. With nasal decongestants, topical preparations (ie, nasal solutions or sprays) are often preferred for short-term use. They are rapidly effective because they come into direct contact with nasal mucosa. If used longer than 7 consecutive days or in excessive amounts, however, these products may produce rebound nasal congestion. Oral drugs are preferred for long-term use (>7 days). For clients with cardiovascular disease, topical nasal decongestants are usually preferred. Oral agents are usually contraindicated because of cardiovascular effects (eg, increased force of myocardial contraction, increased heart rate, increased blood pressure).

3. Antihistamines are clearly useful in allergic conditions (eg, allergic rhinitis; see Chap. 48), but their use to relieve cold symptoms is controversial. First generation antihistamines (eg, chlorpheniramine, diphenhydramine) have anticholinergic effects that may reduce sneezing, rhinorrhea, and cough. Also, their sedative effects may aid sleep. Many multi-ingredient cold remedies contain an antihistamine.

4. Cough associated with the common cold usually stems from postnasal drainage and throat irritation. Most antitussives are given orally as tablets or cough syrups. Syrups serve as vehicles for antitussive drugs and may exert antitussive effects of their own by soothing irritated pharyngeal mucosa. Dextromethorphan is the antitussive drug of choice in most circumstances and is the antitussive ingredient in almost all OTC cough remedies (often designated by DM on the product label). However, as discussed previously, some authorities question the effectiveness of antitussives and do not recommend them for use in children or adults.

5. Ipratropium (Atrovent), an anticholinergic drug, in a 0.06% nasal spray, is Food and Drug Administration (FDA) approved for treatment of rhinorrhea associated with the common cold.

6. Cromolyn, a mast cell stabilizer, used by oral or intranasal inhalation, seems effective in reducing the symptoms and duration of the common cold but it is not FDA approved for this purpose. In one study, it was used every 2 hours for the first 2 days, then 4 times daily. The nasal solution (Nasalcrom) is available OTC.

7. For treatment of excessive respiratory tract secretions, mechanical measures (eg, coughing, deep breathing,
CLIENT TEACHING GUIDELINES
Nasal Decongestants, Anticough Medications, and Multi-Ingredient Cold Remedies

General Considerations
- These drugs may relieve symptoms but do not cure the disorder causing the symptoms.
- An adequate fluid intake, humidification of the environment, and sucking on hard candy or throat lozenges can help to relieve mouth dryness and cough.
- Over-the-counter (OTC) cold remedies should not be used longer than 1 week. Do not use nose drops or sprays more often or longer than recommended. Excessive or prolonged use may damage nasal mucosa and produce chronic nasal congestion.
- Do not increase dosage if symptoms are not relieved by recommended amounts.
- See a health care provider if symptoms persist longer than 1 week.
- Read the labels of OTC allergy, cold, and sinus remedies for information about ingredients, dosages, conditions or other medications with which the drugs should not be taken, and adverse effects.
- Do not combine two drug preparations containing the same or similar active ingredients. For example, pseudoephedrine is the nasal decongestant component of most prescription and OTC sinus and multi-ingredient cold remedies. The recommended dose for immediate-release preparations is usually 30 to 60 mg of pseudoephedrine; doses in extended-release preparations are usually 120 mg. Taking more than one preparation containing pseudoephedrine (or phenylephrine, a similar drug) may increase dosage to toxic levels and cause irregular heartbeats and extreme nervousness.
- Note that many combination products contain acetaminophen or ibuprofen as pain relievers. If you are taking another form of one of these drugs (eg, Tylenol or Advil), there is a risk of overdose and adverse effects. Acetaminophen can cause liver damage; ibuprofen is a relative of aspirin that can cause gastrointestinal upset and bleeding. Thus, you need to be sure your total daily dosage is not excessive (with Tylenol, above four doses of 1000 mg each; with ibuprofen, above 2400 mg).

Self-Administration
- Take medications as prescribed or as directed on the labels of OTC preparations. Taking excessive amounts or taking recommended amounts too often can lead to serious adverse effects.
- Do not chew or crush long-acting tablets or capsules (eg, those taken once or twice daily). Such actions can cause rapid drug absorption, high blood levels, and serious adverse effects, rather than the slow absorption and prolonged action intended with these products.
- For OTC drugs available in different dosage strengths, start with lower recommended doses rather than “maximum strength” formulations or the highest recommended doses. It is safer to see how the drugs affect you, then increase doses if necessary and not contraindicated.
- With topical nasal decongestants:
  1. Use only preparations labeled for intranasal use. For example, phenylephrine (Neo-Synephrine) is available in both nasal and eye formulations. The two types of solutions cannot be used interchangeably. In addition, phenylephrine preparations may contain 0.125%, 0.25%, 0.5%, or 1% of drug. Be sure the concentration is appropriate for the person to receive it (eg, an infant, young child, or older adult).
  2. Blow the nose gently before instilling nasal solutions or sprays. This clears nasal passages and increases effectiveness of medications.
  3. To instill nose drops, lie down or sit with the neck hyperextended and instill medication without touching the dropper to the nostrils (to avoid contamination of the dropper and medication). Rinse the medication dropper after each use.
  4. For nasal sprays, sit or stand, squeeze the container once to instill medication, and rinse the spray tip after each use. Most nasal sprays are designed to deliver one dose when used correctly.
  5. If decongestant nose drops are ordered for nursing infants, give a dose 20 to 30 minutes before feeding. Nasal congestion interferes with an infant’s ability to suck.
- Take or give cough syrups undiluted and avoid eating and drinking for approximately 30 minutes. Part of the beneficial effect of cough syrups stems from soothing effects on pharyngeal mucosa. Food or fluid removes the medication from the throat.
- Report palpitations, dizziness, drowsiness, or rapid pulse. These effects may occur with nasal decongestants and cold remedies and may indicate excessive dosage.

Ambulation, chest physiotherapy, forcing fluids) are more likely to be effective than expectorant drug therapy.

Use in Children
Upper respiratory infections with nasal congestion, sore throat, cough, and increased secretions are common in children, and the drugs described in this chapter are often used. However, there are differences of opinion regarding use of the drugs and most authorities agree that more research is needed regarding dosage, safety, and effectiveness of cough and cold mixtures in children. Some considerations include the following:
- Most infections are viral in origin and antibiotics are not generally recommended. For sore throat, a throat culture for streptococcus organisms should be performed and...
the results obtained before an antibiotic is prescribed. For bronchitis, which is almost always viral, antibiotics are not usually indicated unless pneumonia is suspected or the cough lasts 10 to 14 days without improvement.

- Cough medicines are not considered effective by some authorities.
- With nasal decongestants, pseudoephedrine is considered effective in children older than 5 years of age, but research studies are inconclusive about its effectiveness in younger children. One consideration is that the low doses found in children’s preparations may be insufficient to produce therapeutic effects. As a result, some pediatricians do not recommend usage while others say the drug may be useful in some children.
- Nasal congestion may interfere with an infant’s ability to nurse. Phenylephrine nasal solution, applied just before feeding time, is usually effective. However, excessive amounts or too frequent administration of topical agents may result in rebound nasal congestion and systemic effects of cardiac and central nervous system stimulation. Therefore, the drug should be given to infants only when recommended by a pediatric specialist.
- Parents often administer a medication (eg, acetaminophen or ibuprofen) for pain and fever when a child has cold symptoms, whether the child has pain and fever or not. Some pediatricians suggest treating fevers above 101 degrees if the child seems uncomfortable but not to treat them otherwise. Parents may need to be counseled that fever is part of the body’s defense mechanism and may help the child recover from an infection.

Use in Older Adults

A major consideration is that older adults are at high risk of adverse effects from oral nasal decongestants (eg, hypertension, cardiac dysrhythmias, nervousness, insomnia). Adverse effects from topical agents are less likely, but rebound nasal congestion and systemic effects may occur with overuse. Older adults with significant cardiovascular disease should avoid the drugs. Also, as in other populations, antitussives and expectorants have questionable effectiveness.

Home Care

These drugs are used primarily in home settings and household members may ask the home care nurse for advice about OTC remedies for conditions such as allergies, colds, coughs, and sinus headaches. Before recommending a particular product, the nurse needs to assess the intended recipient for conditions or other medications that contraindicate the product’s use. For example, the nasal decongestant component may cause or aggravate cardiovascular disorders (eg, hypertension). In addition, other medications the client is taking need to be evaluated in terms of potential drug interactions with the remedy.

The home care nurse also must emphasize the need to read the label of any OTC medication for ingredients, precautions, contraindications, drug interactions, administration instructions, and so forth.

---

### Nasal Decongestants, Antitussives, and Cold Remedies

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With topical nasal decongestants:</td>
<td></td>
</tr>
<tr>
<td>(1) Use only preparations labeled for intranasal use.</td>
<td>Intranasal preparations are usually dilute, aqueous solutions prepared specifically for intranasal use. Some agents (eg, phenylephrine) are available in ophthalmic solutions as well. The two types of solutions cannot be used interchangeably. Some drug preparations are available in several concentrations. For example, phenylephrine preparations may contain 0.125%, 0.25%, 0.5%, or 1% of drug. To avoid contamination of the dropper and medication.</td>
</tr>
<tr>
<td>(2) Use the drug concentration ordered.</td>
<td></td>
</tr>
<tr>
<td>(3) For instillation of nose drops, have the client lie down or sit with the neck hyperextended. Instill medication without touching the dropper to the nares. Rinse the medication dropper after each use.</td>
<td>Most nasal sprays are designed to deliver one dose when used correctly. If necessary, secretions may be cleared and a second spray used. Correct usage and cleansing prevents contamination and infection.</td>
</tr>
<tr>
<td>(4) For nasal sprays, have the client sit, squeeze the container once to instill medication, avoid touching the spray tip to the nares, and rinse the spray tip after each use.</td>
<td>Nasal congestion interferes with an infant’s ability to suck.</td>
</tr>
<tr>
<td>(5) Give nasal decongestants to infants 20–30 min before feeding.</td>
<td></td>
</tr>
</tbody>
</table>
### Nursing Actions

**b.** Administer cough syrups undiluted and instruct the client to avoid eating and drinking for approximately 30 min.

### Rationale/Explanation

Part of the therapeutic benefit of cough syrups stems from soothing effects on pharyngeal mucosa. Food or fluid removes the medication from the pharynx.

### 2. Observe for therapeutic effects

**a.** When nasal decongestants are given, observe for decreased nasal obstruction and drainage.

**b.** With antitussives, observe for decreased coughing.

**c.** With cold and allergy remedies, observe for decreased nasal congestion, rhinitis, muscle aches, and other symptoms.

### 3. Observe for adverse effects

**a.** With nasal decongestants, observe for:

<table>
<thead>
<tr>
<th>Number</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Tachycardia, cardiac dysrhythmias, hypertension</td>
</tr>
<tr>
<td>2</td>
<td>Rebound nasal congestion, chronic rhinitis, and possible ulceration of nasal mucosa</td>
</tr>
</tbody>
</table>

**b.** With antitussives, observe for:

<table>
<thead>
<tr>
<th>Number</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Excessive suppression of the cough reflex (inability to cough effectively when secretions are present)</td>
</tr>
<tr>
<td>2</td>
<td>Nausea, vomiting, constipation, dizziness, drowsiness, pruritus, and drug dependence</td>
</tr>
<tr>
<td>3</td>
<td>Nausea, drowsiness, and dizziness with non-narcotic antitussives</td>
</tr>
</tbody>
</table>

**c.** With combination products (e.g., cold remedies), observe for adverse effects of individual ingredients (i.e., antihistamines, adrenergics, analgesics, and others)

### 4. Observe for drug interactions

**a.** Drugs that increase effects of nasal decongestants:

<table>
<thead>
<tr>
<th>Number</th>
<th>Drug Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cocaine, digoxin, general anesthetics, monoamine oxidase (MAO) inhibitors, other adrenergic drugs, thyroid preparations, and xanthenes</td>
</tr>
<tr>
<td>2</td>
<td>Antihistamines, epinephrine, ergot alkaloids, MAO inhibitors, methylphenidate</td>
</tr>
</tbody>
</table>

**b.** Drugs that increase antitussive effects of codeine:

<table>
<thead>
<tr>
<th>Number</th>
<th>Drug Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>CNS depressants (alcohol, antianxiety agents, barbiturates, and other sedative-hypnotics)</td>
</tr>
</tbody>
</table>

**c.** Drugs that alter effects of dextromethorphan:

<table>
<thead>
<tr>
<th>Number</th>
<th>Drug Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MAO inhibitors</td>
</tr>
</tbody>
</table>

These interactions are more likely to occur with oral decongestants than topically applied drugs.

Increased risks of cardiac dysrhythmias

Increased risks of hypertension due to vasoconstriction

Additive CNS depression. Codeine is given in small doses for antitussive effects, and risks of significant interactions are minimal.

This combination is contraindicated. Apnea, muscular rigidity, hyperpyrexia, laryngospasm, and death may occur.

(continued)
**NURSING ACTIONS**

**RATIONALITY/EXPLANATION**

<table>
<thead>
<tr>
<th>d. Drugs that may alter effects of combination products for coughs, colds, and allergies:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Adrenergic (sympathomimetic) agents (see Chap. 18)</td>
</tr>
<tr>
<td>(2) Antihistamines (see Chap. 48)</td>
</tr>
<tr>
<td>(3) CNS depressants (see Chaps. 6, 8, and 13)</td>
</tr>
<tr>
<td>(4) CNS stimulants (see Chap. 16)</td>
</tr>
</tbody>
</table>

Interactions depend on the individual drug components of each formulation. Risks of clinically significant drug interactions are increased with use of combination products.

---

**How Can You Avoid This Medication Error?**

**Answer:** Sudafed is an adrenergic agent whose use is contraindicated in hypertensive clients because it significantly increases blood pressure. It is the nurse’s responsibility to know the contraindications to any medication she or he administers. When requesting an order from a physician who does not know the patient well, it is helpful to briefly outline significant medical problems or medications that may interact. Because Mr. Fell’s blood pressure and pulse rate are likely to go up, monitor vital signs more frequently and request a PRN order for an antihypertensive agent if necessary.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Joan has the symptoms of a cold. Tell her to avoid combination products that may include medications she does not need and are generally more expensive. Because her cough is productive, an antitussive agent (cough suppressant) is contraindicated because expectorating retained secretions promotes recovery and prevents pneumonia and other respiratory complications. An expectorant, such as guaifenesin, may help liquefy respiratory secretions and aid their removal. A nasal decongestant could be used to decrease nasal stuffiness and discharge. Acetaminophen can be taken to reduce generalized discomfort. In addition to discussing medications, stress the importance of getting adequate rest and drinking lots of fluids.

---

**Review and Application Exercises**

1. How do adrenergic drugs relieve nasal congestion?
2. Who should usually avoid OTC nasal decongestants and cold remedies?
3. What are advantages and disadvantages of multi-ingredient cold remedies?
4. Given a client with a productive cough, what are nondrug interventions to promote removal of secretions?
5. Given a client who uses echinacea, vitamin C, or zinc lozenges and asks you what you think about the products as cold remedies, how would you reply?

---

**SELECTED REFERENCES**


Drugs Affecting the Cardiovascular System
Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review the functions of the heart, blood vessels, and blood in supplying oxygen and nutrients to body tissues.
2. Describe the role of vascular endothelium in maintaining homeostasis.
3. Discuss atherosclerosis as the basic disorder causing many cardiovascular disorders for which drug therapy is required.
4. List cardiovascular disorders for which drug therapy is a major treatment modality.
5. Identify general categories of drugs used to manage cardiovascular disorders.

OVERVIEW

The cardiovascular or circulatory system is composed of the heart, blood vessels, and blood. The general functions of the system are to carry oxygen, nutrients, hormones, antibodies, and other substances to all body cells and to remove waste products of cell metabolism (carbon dioxide and others). The efficiency of the system depends on the heart’s ability to pump blood, the patency and functions of blood vessels, and the quality and quantity of blood.

HEART

The heart is a hollow, muscular organ that functions as a two-sided pump to circulate five to six liters of blood through the body every minute. Major components and characteristics are described in the following sections.

Chambers

The heart has four chambers: two atria and two ventricles. The atria are receiving chambers. The right atrium receives deoxygenated blood from the upper part of the body by way of the superior vena cava, from the lower part of the body by way of the inferior vena cava, and from veins and sinuses within the heart itself. The left atrium receives oxygenated blood from the lungs through the pulmonary veins. The ventricles are distributing chambers. The right ventricle sends deoxygenated blood through the pulmonary circulation. It is small and thin walled because it contracts against minimal pressure. The left ventricle pumps oxygenated blood through the systemic circuit. It is much more muscular and thick walled because it contracts against relatively high pressure. The right atrium and right ventricle form one pump, and the left atrium and left ventricle form another. A muscular wall called the septum separates the right and left sides of the heart.

Layers

The layers of the heart are the endocardium, myocardium, and epicardium. The endocardium is the membrane lining the heart chambers. It is continuous with the endothelial lining of blood vessels entering and leaving the heart, and it covers the heart valves. The myocardium is the strong muscular layer of the heart that provides the pumping power for circulation of blood. The epicardium is the outer, serous layer of the heart. The heart is enclosed in a fibroserous sac called the pericardium.

Valves

Heart valves function to maintain the one-way flow of blood and prevent backflow. The mitral valve separates the left
atrium and left ventricle. The tricuspid valve separates the right atrium and right ventricle. The pulmonic valve separates the right ventricle and pulmonary artery. The aortic valve separates the left ventricle and aorta.

**Conduction System**

The heart contains special cells that can carry electrical impulses much more rapidly than ordinary muscle fibers. This special conduction system consists of the sinoatrial (SA) node, the atrioventricular node, bundle of His, right and left bundle branches, and Purkinje fibers. The SA node, the normal pacemaker of the heart, generates a burst of electrical energy approximately 60 to 100 times each minute under normal circumstances. The electrical current flows over the heart in an orderly way to produce contraction of both atria, then both ventricles.

A unique characteristic of the heart is that any cell in any chamber can generate its own electrical impulse to contract. For example, the ventricles can beat independently, but at a rate of less than 40 beats per minute. This provides a backup mechanism should the SA node fail to fire, with an inherent rate that does not compete with SA node firing. In addition, the heart does not require nervous stimulation to contract. However, the autonomic nervous system does influence heart rate. Sympathetic nerves increase heart rate (through the release of epinephrine and norepinephrine); parasympathetic nerves (by way of the vagus nerve) decrease heart rate.

**Blood Supply**

The heart receives its blood supply from the coronary arteries. Coronary arteries branch off the aorta at the aortic valve and fill during diastole, the resting or filling phase of the cardiac cycle. Coronary arteries branch into smaller arteries that supply specific parts of the myocardium, without an overlapping supply from other arterial branches. However, artery-to-artery anastomoses occur between many adjacent vessels. These anastomotic arteries may not supply sufficient blood to the heart if a major artery is suddenly occluded, but they may dilate to considerable size when disease (usually coronary atherosclerosis) develops slowly. The resultant collateral circulation may provide a sufficient blood supply for myocardial function, at least during rest.

** Blood Vessels**

There are three types of blood vessels, arteries, veins, and capillaries. Arteries and veins are similar in that they have three layers. The intima, the inner lining, is composed of a layer of endothelial cells next to the blood (to provide a smooth surface for blood circulation) and an elastic layer that joins the media. The media is the middle layer of muscle and elastic tissue. The adventitia is the outer layer of connective tissue.

Blood vessel walls are composed of two types of cells, smooth muscle cells and endothelial cells. Vascular smooth muscle functions to maintain blood pressure and blood flow. It contracts and relaxes in response to numerous stimuli, including local and circulating mediators. Contractile properties also vary among blood vessels, with some being more responsive to stimuli than others. Overall, regulation of tone in vascular smooth muscle depends on the intracellular concentration of calcium ions. Increased intracellular calcium leads to increased vascular tone. There are several mechanisms by which calcium ions can enter the cell.

Endothelial cells, once thought to be passive conduits for blood flow, are now known to perform two extremely important functions in maintaining homeostatic processes. One function is structural, in which the cells act as a permeability barrier and regulate passage of molecules and cells across the blood vessel wall. The second function is metabolic, in which the cells secrete opposing mediators that maintain a balance between bleeding and clotting of blood (including activation and inhibition of platelet functions and fibrinolysis), constriction and dilation of blood vessels, and promotion and inhibition of vascular cell growth and inflammation. Selected mediators are listed in Table 50–1; some are discussed in more detail in later chapters.

**TABLE 50–1**

<table>
<thead>
<tr>
<th>Promoting Factors</th>
<th>Inhibiting Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vasomotor Tone</strong></td>
<td></td>
</tr>
<tr>
<td>Vasodilators</td>
<td>Vasoconstrictors</td>
</tr>
<tr>
<td>Endothelial-derived hyperpolarizing factor (EDHF)</td>
<td>Angiotensin II</td>
</tr>
<tr>
<td>Nitric oxide (also called endothelial-derived relaxing factor, or EDRF)</td>
<td>Endothelin</td>
</tr>
<tr>
<td>Prostacyclin (prostaglandin I2)</td>
<td>Endothelium-derived constricting factor</td>
</tr>
<tr>
<td>Blood Coagulation</td>
<td>Platelet-derived growth factor</td>
</tr>
<tr>
<td>Procoagulants</td>
<td>Thromboxane A2</td>
</tr>
<tr>
<td>Tissue factor</td>
<td></td>
</tr>
<tr>
<td>Von Willebrand factor</td>
<td></td>
</tr>
<tr>
<td>Platelet activators</td>
<td></td>
</tr>
<tr>
<td>Platelet-activating factor</td>
<td></td>
</tr>
<tr>
<td>Von Willebrand factor</td>
<td></td>
</tr>
<tr>
<td>Profibrinolytic factors</td>
<td></td>
</tr>
<tr>
<td>Tissue plasminogen activator (t-PA)</td>
<td></td>
</tr>
<tr>
<td>Urokinase-type plasminogen activator</td>
<td></td>
</tr>
<tr>
<td>Cell Growth</td>
<td></td>
</tr>
<tr>
<td>Angiotensin II</td>
<td>Heparin</td>
</tr>
<tr>
<td>Endothelin</td>
<td>Nitric oxide</td>
</tr>
<tr>
<td>Platelet-derived growth factor</td>
<td>Prostacyclin</td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
</tr>
<tr>
<td>Proinflammatory factors</td>
<td>Anti-inflammatory factors</td>
</tr>
<tr>
<td>Cellular and intercellular</td>
<td></td>
</tr>
<tr>
<td>adhesion molecules</td>
<td></td>
</tr>
<tr>
<td>Monocyte chemotactic protein-1</td>
<td></td>
</tr>
<tr>
<td>Interleukin-8</td>
<td></td>
</tr>
</tbody>
</table>
Arteries

Arteries and arterioles contain a well-developed layer of smooth muscle (the media) and are sometimes called resistance vessels. Their efficiency depends on their patency and ability to constrict or dilate in response to various stimuli. The degree of constriction or dilation (vasomotor tone) determines peripheral vascular resistance, which is a major determinant of blood pressure.

Veins

Veins and venules have a thin media and valves that assist blood flow against gravity. They are sometimes called capacitance vessels, because blood may accumulate in various parts of the venous system. Their efficiency depends on patency, competency of valves, and the pumping action of muscles around veins.

Capillaries

Capillaries, the smallest blood vessels, connect the arterial and venous portions of the circulation. They consist of a single layer of connected endothelial cells and a few smooth muscle cells. Gases, nutrients, cells, and waste products are exchanged between blood and extracellular fluid across capillary walls. The endothelial lining acts as a semipermeable membrane to regulate the exchange of plasma solutes with extracellular fluid. Lipid-soluble materials diffuse directly through the capillary cell membrane; water and water-soluble materials enter and leave the capillary through the junctions or gaps between endothelial cells.

Lymphatics

Lymphatic vessels, which are composed mainly of endothelium, parallel the veins and empty into the venous system. They drain tissue fluid that has filtered through the endothelium of capillaries and venules from the plasma. They then carry lymphocytes, large molecules of protein and fat, microorganisms, and other materials to regional lymph nodes.

Blood

Blood functions to nourish and oxygenate body cells, protect the body from invading microorganisms, and initiate hemostasis when a blood vessel is injured. Specific functions and components are listed in the following sections.

Functions

- Transports oxygen to cells and carbon dioxide from cells to lungs for removal from the body
- Transports absorbed food products from the gastrointestinal tract to tissues; at the same time, carries metabolic wastes from tissues to the kidneys, skin, and lungs for excretion
- Transports hormones from endocrine glands to other parts of the body
- Transports leukocytes and antibodies to sites of injury, infection, and inflammation
- Assists in regulation of body temperature by transferring heat produced by cell metabolism to the skin, where it can be released
- Transports platelets to injured areas for hemostasis

Components

- **Plasma** comprises approximately 55% of the total blood volume, and it is more than 90% water. Other ingredients are
  - Serum albumin, which helps maintain blood volume by exerting colloid osmotic pressure
  - Fibrinogen, which is necessary for hemostasis
  - Gamma globulin, which is necessary for defense against microorganisms
  - Less than 1% antibodies, nutrients, metabolic wastes, respiratory gases, enzymes, and inorganic salts
- **Solid particles** or cells comprise approximately 45% of total blood volume. Cells include erythrocytes (red blood cells or RBCs); leukocytes (white blood cells or WBCs); and thrombocytes (platelets). The bone marrow produces all RBCs, 60% to 70% of WBCs, and all platelets. Lymphatic tissues (spleen and lymph nodes) produce 20% to 30% of the WBCs, and reticuloendothelial tissues (spleen, liver, lymph nodes) produce 4% to 8% of WBCs. Cell characteristics include the following:
  - Erythrocytes function primarily to transport oxygen. Almost all oxygen (95% to 97%) is transported in combination with hemoglobin; very little is dissolved in blood. The lifespan of a normal RBC is approximately 120 days.
  - Leukocytes function primarily as a defense mechanism against microorganisms. They leave the bloodstream to enter injured tissues and phagocytize the injurious agent. They also produce antibodies. The lifespan of a normal WBC is a few hours.
  - Platelets are fragments of large cells, called megakaryocytes, found in the bone marrow. Platelets are essential for blood coagulation. For example, when a blood vessel is injured, platelets adhere to each other and the edges of the injury to form a cluster of activated platelets (ie, a platelet thrombus or “plug”) that sticks to the vessel wall and prevents leakage of blood. In addition, the clustered platelets release substances (eg, adenosine diphosphate, thromboxane A2, von Willebrand factor) that promote recruitment and aggregation of new platelets. Platelets have no nucleus and cannot replicate. If not used, they circulate for approximately a week before being removed by phagocytic cells of the spleen.
CARDIOVASCULAR DISORDERS

Cardiovascular disorders, which are common causes of morbidity and mortality, often stem from blood vessel abnormalities. In turn, most vascular diseases result from the malfunction of endothelial cells or smooth muscle cells. Dysfunctional endothelium is considered a major factor in atherosclerosis, acute coronary syndromes (symptomatic myocardial ischemia, asymptomatic myocardial infarction [MI], and MI with or without ST-segment elevation), hypertension, and thromboembolic disorders. The main cause of endothelial dysfunction is injury to the blood vessel wall from trauma or disease processes. The injury alters the normal regulatory forces and leads to vasospasm, thrombosis, growth of the intimal layer of the blood vessel, rupture of atherosclerotic plaque, tissue ischemia and infarction, and dysrhythmias. Pathologic changes in the structure of the capillary and venular endothelium also result in the accumulation of excess fluid in interstitial space (edema), a common symptom of cardiovascular and other disorders.

Overall, cardiovascular disorders may involve any structure or function of the cardiovascular system. Because the circulatory system is a closed system, a disorder in one part of the system eventually disturbs the function of all other parts.

DRUG THERAPY IN CARDIOVASCULAR DISORDERS

Cardiovascular disorders usually managed with drug therapy include atherosclerosis, heart failure, cardiac dysrhythmias, ischemia, myocardial infarction, hypertension, hypotension, and shock. Peripheral vascular disease and valvular disease are usually managed surgically. Blood disorders that respond to drug therapy include certain types of anemia and coagulation disorders.

The goal of drug therapy in cardiovascular disorders is to restore homeostasis or physiologic balance between opposing factors (eg, coagulant vs. anticoagulant, vasoconstriction vs. vasodilation). Cardiovascular drugs may be given to increase or decrease cardiac output, blood pressure, and heart rate; to alter heart rhythm; increase or decrease blood clotting; alter the quality of blood; and decrease chest pain of cardiac origin. In addition, these drugs may be given for palliation of symptoms without alteration of the underlying disease process.

Review and Application Exercises

1. How does the heart muscle differ from skeletal muscle?
2. What is the normal pacemaker of the heart?
3. In what circumstances do other parts of the heart take over as pacemaker?
4. What is the effect of parasympathetic (vagal) stimulation on the heart?
5. What is the effect of sympathetic stimulation on the heart and blood vessels?
6. How does low or high blood volume influence blood pressure?
7. List five chemical mediators produced by endothelial cells and their roles in maintaining cardiovascular function.
8. How does endothelial cell dysfunction contribute to cardiovascular disorders?

SELECTED REFERENCES

Drug Therapy of Heart Failure

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe major manifestations of heart failure (HF).
2. Discuss the role of endothelial dysfunction in HF.
3. Differentiate the types of drugs used to treat HF.
4. List characteristics of digoxin in terms of effects on myocardial contractility and cardiac conduction, indications for use, principles of therapy, and nursing process implications.
5. Differentiate therapeutic effects of digoxin in HF and atrial fibrillation.
6. Differentiate digitalizing and maintenance doses of digoxin.
7. Identify therapeutic and excessive serum digoxin levels.
8. Identify clients at risk for development of digoxin toxicity.
9. Discuss interventions to prevent or minimize digoxin toxicity.
10. Explain the roles of potassium chloride, lidocaine, atropine, and digoxin immune fab in the management of digoxin toxicity.
11. Teach clients ways to increase safety and effectiveness of digoxin.
12. Discuss important elements of using digoxin in special populations.

Critical Thinking Scenario
George Sweeney, a 72-year-old retired carpenter, was recently hospitalized with heart failure and started on captopril, an angiotensin-converting enzyme (ACE) inhibitor. You are a staff nurse assigned to his care. He has many questions about his new diagnosis and the captopril.

Reflect on:
- Physiologically, what happens when the heart fails to pump adequately, and what symptoms are seen in the client?
- How ACE inhibitors decrease the workload of the heart.
- What criteria (objective and subjective) will you use to evaluate whether the ACE inhibitor is effectively managing Mr. Sweeney’s heart failure?

OVERVIEW

Heart failure (HF), also called congestive heart failure (CHF), is a common condition that occurs when the heart cannot pump enough blood to meet tissue needs for oxygen and nutrients. It may result from impaired myocardial contraction during systole (systolic dysfunction), impaired relaxation and filling of ventricles during diastole (diastolic dysfunction), or a combination of systolic and diastolic dysfunction.

Causes of Heart Failure

At the cellular level, HF stems from dysfunction of contractile myocardial cells and the endothelial cells that line the heart and blood vessels (see Chap. 50). Vital functions of the endothelium include maintaining equilibrium between vasodilation and vasoconstriction, coagulation and anticoagulation, and cellular growth promotion and inhibition. Endothelial dysfunction allows processes that narrow the blood vessel lumen (eg, buildup of atherosclerotic plaque, growth of cells, inflammation, activation of platelets) and lead to blood clot formation and vasoconstriction that further narrow the blood vessel lumen. These are major factors in coronary artery disease and hypertension, the most common conditions leading to HF.

Other causative factors include hyperthyroidism, excessive intravenous fluids or blood transfusions, and drugs that decrease the force of myocardial contraction (eg, antidysrhythmic drugs) or cause retention of sodium and water (eg, corticosteroids, estrogens, nonsteroidal anti-inflammatory agents). These
Compensatory Mechanisms

As the heart fails, the low cardiac output and inadequately filled arteries activate the neurohormonal system by several feedback mechanisms. One mechanism is increased sympathetic activity and circulating catecholamines (neurohormones), which increases the force of myocardial contraction, increases heart rate, and causes vasoconstriction. The effects of the baroreceptors in the aortic arch and carotid sinus that normally inhibit undue sympathetic stimulation are blunted in clients with HF, and the effects of the high levels of circulating catecholamines are intensified. Endothelin, a neurohormone secreted primarily by endothelial cells, is the most potent endogenous vasoconstrictor and may exert direct toxic effects on the heart and result in myocardial cell proliferation.

Another mechanism is activation of the renin–angiotensin–aldosterone system. Renin is an enzyme produced in the kidney in response to impaired blood flow and tissue perfusion. When released into the bloodstream, renin stimulates the production of angiotensin II, a powerful vasoconstrictor. Arterial vasoconstriction impairs cardiac function by increasing the resistance (afterload) against which the ventricle ejects blood. This raises filling pressures inside the heart, increases stretch and stress on the myocardial wall, and predisposes to subendocardial ischemia. In addition, clients with severe HF have constricted arterioles in cerebral, myocardial, renal, hepatic, and mesenteric vascular beds. This results in increased organ hypoperfusion and dysfunction. Venous vasoconstriction limits venous capacitance, resulting in venous congestion and increased diastolic ventricular filling pressures (preload). Angiotensin II also promotes sodium and water retention by stimulating aldosterone release from the adrenal cortex and the release of vasopressin (antidiuretic hormone) from the posterior pituitary gland.

All of these mechanisms combine to increase blood volume and pressure in the heart chambers, stretch muscle fibers, and produce dilation, hypertrophy, and changes in the shape of the heart (a process called cardiac or ventricular remodeling) that make it contract less efficiently. Overall, the compensatory mechanisms increase preload (amount of venous blood returning to the heart), workload of the heart, afterload (amount of resistance in the aorta and peripheral blood vessels that the heart must overcome to pump effectively), and blood pressure. These compensatory mechanisms that initially preserve cardiac function result in progressive deterioration of myocardial function over time.

Signs and Symptoms

Clients with compensated HF usually have no symptoms at rest and no edema; dyspnea and fatigue occur only with activities involving moderate or higher levels of exertion. Symptoms that occur with minimal exertion or at rest and are accompanied by ankle edema and distention of the jugular vein (from congestion of veins and leakage of fluid into tissues) reflect decompensation. Acute, severe cardiac decompensation is manifested by pulmonary edema, a medical emergency that requires immediate treatment. Clients with chronic HF are often described according to the New York Heart Association classification categories that separate clients into four groups according to symptoms and activity tolerance (Box 51–1). These categories are often used to help evaluate results of therapy, and to indicate a client’s functional status.

Drug Therapy

Several drugs are used to treat acute HF, and a combination of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a diuretic is first-line therapy for chronic failure. Increasingly, digoxin, a beta-adrenergic blocking agent, or spironolactone is being added to the ACE inhibitor or ARB and diuretic regimen.

Drug therapy of HF continues to evolve as the pathophysiologic mechanisms are better understood and research studies indicate more effective regimens. Combinations of drugs are commonly used in efforts to improve circulation, alter the compensatory mechanisms, and reverse heart damage. Most of the drugs used to treat HF are also used in other disorders and are discussed in other chapters; their effects in HF are described in Box 51–2. The primary focus of this chapter is inotropic agents, which include digoxin, a cardiac glycoside, and the phosphodiesterase inhibitors inamrinone and milrinone. These drugs are discussed in the following sections and in Drugs at a Glance: Drugs for Heart Failure.

---

**Box 51–1**

**NEW YORK HEART ASSOCIATION CLASSIFICATION OF PATIENTS WITH HEART DISEASE**

**Class I.** No limitations of physical activity; ordinary physical activity does not cause dyspnea, fatigue, or palpitations.

**Class II.** Slight limitations of physical activity. Patients are comfortable at rest but have dyspnea, fatigue, palpitations, or chest pain (angina) with ordinary physical activity.

**Class III.** Marked limitations of physical activity. Patients are comfortable at rest but develop symptoms with less than ordinary physical activity.

**Class IV.** Patients are unable to perform any physical activity without discomfort. Symptoms of heart failure or angina are present even at rest. If any physical activity is undertaken, discomfort increases.
Adrenergics
Dopamine or dobutamine (see Chaps. 18 and 54) may be used in acute, severe heart failure (HF) when circulatory support is required, usually in a critical care unit. Given by IV infusion, these drugs strengthen myocardial contraction (inotropic or cardiotoxic effects) and increase cardiac output. Dosage or flow rate is titrated to hemodynamic effects; minimal effective doses are recommended because of vasoconstrictive effects. The drugs also cause tachycardia and hypertension and increase cardiac workload and oxygen consumption.

Angiotensin-Converting Enzyme (ACE) Inhibitors
Captopril and other ACE inhibitors (see Chap. 55) are drugs of first choice in treating patients with all four New York Heart Association (NYHA) classifications of chronic HF. For patients with moderate or severe symptomatic HF (NYHA class III or IV), the standard of care includes an ACE inhibitor (or an ARB) and a loop diuretic, with or without digoxin.

These drugs improve cardiac function and decrease mortality. They also relieve symptoms, increase exercise tolerance, and delay further impairment of myocardial function and progression of HF (ie, ventricular remodeling). They act mainly to decrease activation of the renin–angiotensin–aldosterone system, a major pathophysiologic mechanism in HF. More specifically, the drugs prevent inactive angiotensin I from being converted to angiotensin II. Angiotensin II produces vasoconstriction and retention of sodium and water; inhibition of angiotensin II decreases vasoconstriction and retention of sodium and water. Thus, major effects of the drugs are dilation of both veins and arteries, decreased preload and afterload, decreased workload of the heart, and increased perfusion of body organs and tissues.

An ACE inhibitor is usually given in combination with a diuretic. All of the drugs have similar effects, but captopril, enalapril, lisinopril, quinapril, and ramipril are FDA-approved for treatment of HF. Some clinicians use captopril initially because it has a short half-life and is rapidly eliminated when stopped, then switch to a long-acting drug if captopril is tolerated by the client. Digoxin, a beta-adrenergic blocking agent, or spironolactone may be added to the ACE inhibitor/diuretic regimen. During ACE inhibitor therapy, clients usually need to see a health care provider frequently for dosage titration and monitoring of serum creatinine and potassium levels for increases. Elevated creatinine levels may indicate impaired renal function, in which case dosage needs to be reduced; elevated potassium levels indicate hyperkalemia, an adverse effect of the drugs.

Angiotensin Receptor Blockers (ARBs)
Losartan and other angiotensin receptor blockers (see Chap. 55) are similar to the ACE inhibitors in their effects on cardiac function, although they are not FDA approved for treatment of HF. Valsartan recently received FDA approval for management of clients with HF who are unable to tolerate an ACE inhibitor (eg, development of a cough, a common adverse effect of ACE inhibitors).

Beta-Adrenergic Blocking Agents
Although beta blockers (see Chaps. 19, 52, and 55) were formerly considered contraindicated, numerous research studies indicate they decrease morbidity (ie, symptoms and hospitalizations) and mortality in clients with chronic HF. The change evolved from a better understanding of chronic HF (ie, that it involves more than a weak pumping mechanism).

Beta blockers suppress activation of the sympathetic nervous system and the resulting catecholamine excess that eventually damages myocardial cells, reduces myocardial beta receptors, and reduces cardiac output. As a result, over time, ventricular dilatation and enlargement (ventricular remodeling) regress, the heart returns toward a more normal shape and function, and cardiac output increases. Most studies were done with clients in NYHA class II or III; effects in class IV clients are being studied.

Beta blockers are not recommended for clients in acute HF because of the potential for an initial decrease in myocardial contractility. A beta blocker is started once normal blood volume is restored and edema and other symptoms are relieved. The goal of beta blocker therapy is to shrink the ventricle back to its normal size (reverse remodeling). The beta blocker is added to the ACE inhibitor/diuretic regimen, usually near the end of a hospital stay or as outpatient therapy. Most studies have been done with bisoprolol, carvedilol, or metoprolol; it is not yet known whether some beta blockers are more effective than others. When one of the drugs is used in clients with chronic HF, recommendations include starting with a low dose (because symptoms may initially worsen in some clients), titrating the dose upward at approximately 2-week intervals, and monitoring closely. Significant hemodynamic improvement usually requires 2 to 3 months of therapy, but effects are long lasting. Beneficial effects can be measured by increases in the left ventricular ejection fraction (ie, cardiac output).

Diuretics
Diuretics (see Chap. 56) are used in treating both acute and chronic HF. Thiazides (eg, hydrochlorothiazide) can be used for mild diuretics in clients with normal renal function; loop diuretics (eg, furosemide) should be used in clients who need strong diuresis or who have impaired renal function.

In acute HF, which is characterized by fluid accumulation, a diuretic is the initial treatment. It acts to decrease plasma volume (extracellular fluid volume) and increase excretion of sodium and water, thereby decreasing preload. With early or mild HF, starting or increasing the dose of an oral thiazide may be effective. With moderate to severe HF (pulmonary edema), an IV loop diuretic is indicated. IV furosemide also has a vasodilatory effect that helps relieve vasoconstriction (afterload). Although diuretic therapy relieves symptoms, it does not improve left ventricular function and decrease mortality rates. Some clients may also need drugs to increase myocardial contractility and vasodilators to decrease preload, afterload, or both.

In chronic HF, an oral diuretic is a common component of treatment regimens. Depending on the severity of symptoms or degree of HF, the regimen may also include an ACE inhibitor or ARB, a beta blocker, and digoxin.

Potassium-sparing diuretics (eg, amiloride, triamterene) are often given concurrently with potassium-losing diuretics (eg, thiazides or loop diuretics) to help maintain normal serum potassium levels. Concomitant use of ACE inhibitors and nonsteroidal anti-inflammatory drugs and the presence of diabetes mellitus increase risks of hyperkalemia.

With all diuretic therapy, serum potassium levels must be measured periodically to monitor for hypokalemia and hyperkalemia. Both hypokalemia and hyperkalemia are cardiotoxic or impair heart function.

(continued)
receptor antagonists stem significantly from their vasodilating effects (ie, preventing or decreasing angiotensin-induced vasoconstriction). Other vasodilators may also be used. Venous dilators (eg, nitrates) decrease preload; arterial dilators (eg, hydralazine) decrease afterload. Isosorbide dinitrate and hydralazine may be combined to decrease both preload and afterload. The combination has similar effects to those of an ACE inhibitor or an ARB, but may not be as well tolerated by clients. Nitrates are discussed in Chapter 53; hydralazine and other vasodilators are discussed in Chapter 55.

Oral vasodilators usually are used in clients with chronic HF and parenteral agents are reserved for those who have severe HF or are unable to take oral medications. They should be started at low doses, titrated to desired hemodynamic effects, and discontinued slowly to avoid rebound vasoconstriction.

### Aldosterone Antagonist

Increasingly, spironolactone is also being added for clients with moderate to severe HF. Increased aldosterone, a major factor in the pathophysiology of HF, results in increased interstitial fibrosis that may decrease systolic function and increase the risk of ventricular dysrhythmias. Spironolactone is an aldosterone antagonist that reduces the aldosterone-induced retention of sodium and water and impaired vascular function. Although ACE inhibitors also decrease aldosterone initially, this effect is transient. Spironolactone is given in a daily dose of 12.5 to 25 mg, along with standard doses of an ACE inhibitor, a loop diuretic, and usually digoxin. In clients with adequate renal function (ie, serum creatinine 2.5 mg/dL or less), the addition of spironolactone usually allows smaller doses of loop diuretics and potassium supplements. Overall, studies indicate that the addition of spironolactone improves cardiac function and reduces symptoms, hospitalizations, and mortality.

### Vasodilators

Vasodilators are essential components of treatment regimens for HF, and the beneficial effects of ACE inhibitors and angiotensin
Two new classifications of drugs, human natriuretic peptides and endothelin receptor antagonists, are also presented.

**Digoxin**

**Digoxin** (Lanoxin) is the only commonly used digitalis glycoside. In the following discussion, the terms *digitalization* and *digitalis toxicity* refer to digoxin.

**General Characteristics**

When digoxin is given orally, absorption varies among available preparations. Lanoxicaps, which are liquid-filled capsules, and the elixir used for children are better absorbed than tablets. With tablets, the most frequently used formulation, differences in bioavailability are important because a person who is stabilized on one formulation may be underdosed or overdosed if another formulation is taken. Differences are attributed to the rate and extent of tablet dissolution rather than amounts of digoxin. In addition to drug dosage forms, other factors that may decrease digoxin absorption include the presence of food in the GI tract, delayed gastric emptying, malabsorption syndromes, and concurrent administration of some drugs (eg, antacids, cholestyramine).

Digoxin is distributed to most body tissues and high concentrations are found in the myocardium, brain, liver, and skeletal muscle. It also crosses the placenta, and serum levels in neonates are similar to those in the mother. Digoxin circulates mainly in a free state, with only 20% to 30% bound to serum proteins. Therapeutic serum levels of digoxin are 0.5 to 2 ng/mL; toxic serum levels are above 2 ng/mL. However, toxicity may occur at virtually any serum level.

Most (60% to 70%) of the digoxin is excreted unchanged by the kidneys. Dosage must be reduced in the presence of renal failure to prevent drug accumulation and toxicity. The remainder is metabolized or excreted by nonrenal routes.

**Mechanisms of Action**

In HF, digoxin exerts a cardiotonic or positive inotropic effect that improves the pumping ability of the heart. Increased myocardial contractility allows the ventricles to empty more completely with each heartbeat. With improved cardiac output, decreases in heart size, heart rate, end-systolic and end-diastolic pressures, vasoconstriction, sympathetic nerve stimulation, and venous congestion result. The mechanism by which digoxin increases the force of myocardial contraction is thought to be inhibition of Na,K-adenosine triphosphatase (Na,K-ATPase), an enzyme in cardiac cell membranes that decreases the movement of sodium out of myocardial cells after contraction. As a result, calcium enters the cell in exchange for sodium, causing additional calcium to be released from intracellular binding sites. With the increased intracellular concentration of free calcium ions, more calcium is available to activate the contractile proteins actin and myosin, and increase myocardial contractility. Overall, digoxin helps to relieve symptoms and decrease hospitalizations, but does not prolong survival. In HF, it is given concomitantly with a diuretic and an ACE inhibitor or ARB.

In atrial dysrhythmias, digoxin slows the rate of ventricular contraction (negative chronotropic effect). Negative chronotropic effects are probably caused by several factors. First, digoxin has a direct depressant effect on cardiac conduction tissues, especially the atrioventricular node. This action decreases the number of electrical impulses allowed to reach the ventricles from supraventricular sources. Second, digoxin indirectly stimulates the vagus nerve. Third, increased efficiency of myocardial contraction and vagal stimulation decrease compensatory tachycardia that results from the sympathetic nervous system response to inadequate circulation.

**Indications for Use**

The clinical uses of digoxin are management of HF, atrial fibrillation, and atrial flutter. Digoxin may be used in acute or chronic conditions, for digitalization, or for maintenance therapy.

**Contraindications to Use**

Digoxin is contraindicated in severe myocarditis, ventricular tachycardia, or ventricular fibrillation and must be used cautiously in clients with acute myocardial infarction, heart block, Adams-Stokes syndrome, Wolff-Parkinson-White syndrome (risk of fatal dysrhythmias), electrolyte imbalances (hypokalemia, hypomagnesemia, hypercalcemia), and renal impairment.

**Administration and Digitalization**

Digoxin is given orally or intravenously (IV). Although it can be given intramuscularly, this route is not recommended because pain and muscle necrosis may occur at injection sites. When given orally, onset of action occurs in 30 minutes to 2 hours, and peak effects occur in approximately 6 hours. When given IV, the onset of action occurs within 10 to 30 minutes, and peak effects occur in 1 to 5 hours.

In the heart, maximum drug effect occurs when a steady-state tissue concentration has been achieved. This occurs in approximately 1 week (five half-lives) unless loading doses are given for more rapid effects. Traditionally, a loading dose is called a digitalizing dose. Digitalization (administration of an amount sufficient to produce therapeutic effects) may be accomplished rapidly by giving a total dose of 0.75 to 1.5 mg.

---

**How Can You Avoid This Medication Error?**

Mr. Bello, a 75-year-old nursing home resident, currently takes digoxin 0.25 mg qd and Lasix 20 mg bid to treat his congestive heart failure. During your morning assessment he tells you his stomach is upset and he would like some Maalox. You explain that you cannot give him the Maalox with the digoxin because it will impact drug absorption. Because the digoxin is more important, he should take that first. Did this nurse make a good decision?
of digoxin in divided doses, 6 to 8 hours apart, over a 24-hour period. Because rapid digitalization engenders higher risks of toxicity, it is usually done for atrial tachydysrhythmias, with continuous cardiac monitoring, rather than for HF. Slow digitalization may be accomplished by initiating therapy with a maintenance dose of digoxin. When digoxin is discontinued, the drug is eliminated from the body in approximately 1 week.

**Digoxin Toxicity**

Digoxin has a low therapeutic index (ie, a dose adequate for therapeutic effects may be accompanied by signs of toxicity). Digoxin toxicity may result from many contributing factors:

1. Accumulation of larger-than-necessary maintenance doses
2. Rapid loading or digitalization, whether by one or more large doses or frequent administration of small doses
3. Impaired renal function, which delays excretion of digoxin
4. Age extremes (young or old)
5. Electrolyte imbalance (eg, hypokalemia, hypomagnesemia, hypercalcemia)
6. Hypoxia due to heart or lung disease, which increases myocardial sensitivity to digoxin
7. Hypothyroidism, which slows digoxin metabolism and may cause accumulation
8. Concurrent treatment with other drugs affecting the heart, such as quinidine, verapamil, or nifedipine

**Phosphodiesterase Inhibitors**

**Inamrinone** (Incor), formerly amrinone, and **milrinone IV** (Primacor) are cardiotonic-inotropic agents used in short-term management of acute, severe HF that is not controlled by digoxin, diuretics, and vasodilators. The drugs increase levels of cyclic adenosine monophosphate (cAMP) in myocardial cells by inhibiting phosphodiesterase, the enzyme that normally metabolizes cAMP. They also relax vascular smooth muscle to produce vasodilation and decrease preload and afterload. In HF, inotropic and vasodilator effects increase cardiac output. The effects of these drugs are additive to those of digoxin and may be synergistic with those of adrenergic drugs (eg, dobutamine). There is a time delay before the drugs reach therapeutic serum levels as well as inter-individual variability in therapeutic doses.

Compared with inamrinone, milrinone is more potent as an inotropic agent and causes fewer adverse effects. Both drugs are given IV by bolus injection followed by continuous infusion. Flow rate is titrated to maintain adequate circulation. Milrinone can be used alone or with other drugs such as dobutamine and nitroprusside. Its dosage should be reduced in the presence of renal impairment. Dose-limiting adverse effects of the drugs include tachycardia, atrial or ventricular dysrhythmias, and hypotension. Hypotension is more likely to occur in clients who are hypovolemic. Milrinone has a long half-life of approximately 80 hours and may accumulate with prolonged infusions.

**Human Natriuretic Peptide B-type**

**Nesiritide** (Natrecor) is the first in this new class of drugs to be used in the management of acute HF. Produced by recombinant DNA technology, nesiritide is identical to endogenous human B-type natriuretic peptide, which is secreted primarily by the ventricles in response to fluid and pressure overload. This drug acts to compensate for deteriorating cardiac function by reducing preload and afterload, increasing diuresis and secretion of sodium, suppressing the renin–angiotensin–aldosterone system, and decreasing secretion of the neurohormones endothelin and norepinephrine. Onset of action is immediate with peak effects attained in 15 minutes with a bolus dose followed by continuous IV infusion. Administration should be by a separate IV line because nesiritide is incompatible with many other drugs. Hemodynamic monitoring of pulmonary artery pressure is indicated to determine drug effectiveness. Clearance of the drug is proportional to body weight and partially by the kidneys; however, no adjustment in dosing is required for age, gender, race/ethnicity, or renal function impairment. Clinical studies have not been conducted on the use of nesiritide for more than 48 hours.

**Endothelin Receptor Antagonists**

This new class of drugs relaxes blood vessels and improves blood flow by targeting endothelin-1 (a neurohormone) that is produced in excess in heart failure. Endothelin-1 causes blood vessels to constrict, forcing the ailing heart to work harder to pump blood through the narrowed vessels. Studies indicate that endothelin antagonist drugs improve heart function, as measured by cardiac index; animal studies indicate that structural changes of heart failure (eg, hypertrophy) may be reversed by the drugs. Currently, one endothelin receptor antagonist, **bosentan** (Tracleer), is Food and Drug Administration (FDA) approved but only for treatment of pulmonary hypertension. Additional data are being collected to support specific indications for these drugs in the management of heart failure.
### Nursing Process

#### Assessment

Assess clients for current or potential HF:

- **Cardiovascular disorders:** atherosclerosis, hypertension, coronary artery disease, myocardial infarction, cardiac dysrhythmias, and cardiac valvular disease.

- **Noncardiovascular disorders:** severe infections, hyperthyroidism, pulmonary disease (eg, cor pulmonale–right-sided HF resulting from lung disease)

- **Other factors:** excessive amounts of IV fluids, rapid infusion of IV fluids or blood transfusions, advanced age

- **A combination** of any of the preceding factors

- Interview and observe for signs and symptoms of chronic HF. Within the clinical syndrome of HF, clinical manifestations vary from few and mild to many and severe, including the following:
  - **Mild HF.** Common signs and symptoms of mild HF are ankle edema, dyspnea on exertion, and fatigue with ordinary physical activity. Edema results from increased venous pressure, which allows fluids to leak into tissues; dyspnea and fatigue result from tissue hypoxia.
  - **Moderate or severe HF.** More extensive edema, dyspnea, and fatigue at rest are likely to occur. Additional signs and symptoms include orthopnea, postprandial dyspnea, and cough (from congestion of the respiratory tract with venous blood); mental confusion (from cerebral hypoxia); oliguria and decreased renal function (from decreased blood flow to the kidneys); and anxiety.

- **Observe** for signs and symptoms of acute HF. Acute pulmonary edema indicates acute HF and is a medical emergency. Causes include acute myocardial infarction, cardiac dysrhythmias, severe hypertension, acute fluid or salt overload, and certain drugs (eg, quinidine and other cardiac depressants, propranolol and other antiadrenergics, and phenylephrine, norepinephrine, and other alpha-adrenergic stimulants). Pulmonary edema occurs when left ventricular failure causes blood to accumulate in pulmonary veins and tissues. As a result, the person experiences severe dyspnea, hypoxia, hypertension, tachycardia, hemoptysis, frothy respiratory tract secretions, and anxiety.

Assess clients for signs and symptoms of atrial tachydysrhythmias:

- Record the rate and rhythm of apical and radial pulses. Atrial fibrillation, the most common atrial dysrhythmia, is characterized by tachycardia, pulse deficit (faster apical rate than radial rate) and a very irregular rhythm. Fatigue, dizziness, and fainting may occur.

- Check the electrocardiogram (ECG) for abnormal P waves, rapid rate of ventricular contraction, and QRS complexes of normal configuration but irregular intervals.

Assess baseline vital signs; weight; edema; laboratory results for potassium, magnesium, and calcium levels; and other tests of cardiovascular function when available.

### Nursing Diagnoses

- **Ineffective Tissue Perfusion related to decreased cardiac output**
- **Anxiety related to chronic illness and lifestyle changes**
- **Impaired Gas Exchange related to venous congestion and fluid accumulation in lungs**
- **Imbalanced Nutrition: Less Than Body Requirements related to digoxin-induced anorexia, nausea, and vomiting**
- **Noncompliance related to the need for long-term drug therapy and regular medical supervision**
- **Deficient Knowledge: Managing drug therapy regimen safely and effectively**

### Planning/Goals

**The client will:**

- Take digoxin and other medications safely and accurately
- Experience improved breathing and less fatigue and edema
- Maintain serum digoxin levels within therapeutic ranges
- Be closely monitored for therapeutic and adverse effects, especially during digitalization, when dosage is being changed, and when other drugs are added to or removed from the management regimen
- Keep appointments for follow-up monitoring of vital signs, serum potassium levels, serum digoxin levels, and renal function

### Interventions

Use measures to prevent or minimize HF and atrial dysrhythmias. In the broadest sense, preventative measures include sensible eating habits (a balanced diet, avoiding excess saturated fat and salt, weight control), avoiding cigarette smoking, and regular exercise. In the client at risk for development of HF and dysrhythmias, preventative measures include the following:

- **Treatment of hypertension**
- **Avoidance of hypoxia**
- **Weight control**
- **Avoidance of excess sodium in the diet**
- **Avoidance of fluid overload, especially in elderly clients**
- **Maintenance of management programs for HF, atrial dysrhythmias, and other cardiovascular or noncardiovascular disorders**

Monitor vital signs, weight, urine output, and serum potassium regularly, and compare with baseline values.
Monitor ECG when available, and compare with baseline or previous tracings.

Evaluation
- Interview and observe for relief of symptoms (weight loss, increased urine output, less extremity edema, easier breathing, improved activity tolerance and self-care ability, slower heart rate).
- Observe serum drug levels for normal or abnormal values, when available.
- Interview regarding compliance with instructions for taking the drug.
- Interview and observe for adverse drug effects, especially cardiac dysrhythmias.

PRINCIPLES OF THERAPY

Goals of Management

The goals for clients with asymptomatic (compensated) HF are to maintain function as nearly normal as possible and to prevent symptomatic (acute, congestive, or decompensated) HF, hospitalizations, and death. When symptoms or decompensation occurs, the goals are to relieve symptoms, restore function, and prevent progressive cardiac deterioration.

Nonpharmacologic Management Measures

1. Prevent or treat conditions that precipitate cardiac decompensation and failure (eg, fluid and sodium retention, factors that impair myocardial contractility or increase cardiac workload).
2. Restrict dietary sodium intake to reduce edema and other symptoms and allow a decrease in diuretic dosage. For most clients, sodium restriction need not be severe. A common order, “no added salt,” may be accomplished by avoiding obviously salty foods (eg, ham, potato chips, snack foods) and by not adding salt during cooking or eating. For clients with more severe HF, dietary intake may be more restricted (eg, no more than 2 g daily). A major source of sodium intake is table salt: A level teaspoonful contains 2300 mg of sodium.
3. If hyponatremia (serum sodium <130 mEq/L) develops from sodium restrictions and diuretic therapy, fluids may need to be restricted (eg, 1.5 L/day or less) until the serum sodium level increases. Severe hyponatremia (<125 mEq/L) may lead to dysrhythmias.
4. For clients who are obese, weight loss is desirable to decrease systemic vascular resistance and myocardial oxygen demand.
5. Reduce physical activity in clients with symptomatic HF. This decreases the workload and oxygen consumption of the myocardium. If bed rest is instituted, antithrombotic measures such as compression stockings/devices or heparin therapy should be prescribed to prevent deep vein thrombosis.
6. Administer oxygen, if needed, to relieve dyspnea, improve oxygen delivery, reduce the work of breathing, and decrease constriction of pulmonary blood vessels (which is a compensatory measure in clients with hypoxemia).

Pharmacologic Management

A combination of drugs is the standard of care for both acute and chronic HF. Specific drug components depend on the client’s symptoms and hemodynamic status.

1. For acute HF, the first drugs of choice may include an IV loop diuretic, a cardiotonic-inotropic agent (eg, digoxin, dobutamine, or milrinone), and vasodilators (eg, nitroglycerin and hydralazine or nitroprusside). This combination reduces preload and afterload and increases myocardial contractility.
2. For chronic HF, an ACE inhibitor or ARB and a diuretic are the basic standard of care. Digoxin, a beta-adrenergic blocking agent, and spironolactone may also be added. Although the use of digoxin in clients with normal sinus rhythm has been questioned, studies indicate improved ejection fraction and exercise tolerance in clients who receive digoxin. In addition, in clients stabilized on digoxin, a diuretic, and an ACE inhibitor or ARB, symptoms worsen if digoxin is discontinued.

Overall, these drugs improve clients’ quality of life by decreasing their symptoms and increasing their ability to function in activities of daily living. They also decrease hospitalizations and deaths from HF.
3. Electrolyte balance must be monitored and maintained during digoxin therapy, particularly normal serum levels of potassium (3.5 to 5 mEq/L), magnesium (1.5 to 2.5 mg/100 mL), and calcium (8.5 to 10 mg/100 mL). Hypokalemia and hypomagnesemia increase cardiac excitability and ectopic pacemaker activity, leading to dysrhythmias; hypercalcemia enhances the effects of digoxin. These electrolyte abnormalities increase the risk of digoxin toxicity. Hypocalcemia increases excitability of nerve and muscle cell membranes and causes myocardial contraction to be weak (leading to a decrease in digoxin effect).

In acute HF, there is a high risk of hypokalemia because large doses of potassium-losing diuretics are often given. Serum potassium levels should be monitored regularly and supplemental potassium may be needed. In chronic HF, hypokalemia may be less likely to occur than formerly because lower doses of potassium-losing diuretics are usually being given. In addition, there may be more extensive use of potassium-sparing diuretics (eg, amiloride or triamterene) and spironolactone. Note, however, that hyperkalemia must also be prevented because it is cardiotoxic.
CLIENT TEACHING GUIDELINES
Digoxin

General Considerations
- This drug is prescribed for two types of heart disease. One type is heart failure, in which digoxin strengthens your heartbeat and helps to relieve such symptoms as ankle swelling, shortness of breath, and fatigue. The other type is a fast heartbeat called atrial fibrillation, in which digoxin slows the heartbeat and decreases symptoms such as fatigue. Because these are chronic conditions, digoxin therapy is usually long term. Ask your health care provider why you are being given digoxin and what effects you can expect, both beneficial and adverse.

- It is extremely important to take digoxin (and other cardiovascular medications) as prescribed, usually once daily. The drug must be taken regularly to maintain therapeutic blood levels, but overuse can cause serious adverse effects.

- Precautions to increase the drug’s safety and effectiveness include the following:
  - As a general rule, do not miss a dose. It is helpful to develop a routine of taking the medication at approximately the same time each day and maintaining a written record, such as a dated checklist. If you forget a dose at the usual time and remember it within a few hours (approximately 6), go ahead and take the daily dose. Do not take an extra dose. For example, do not take a double dose to make up for a missed dose.
  - Do not take other prescription or nonprescription (eg, antacids, cold remedies, diet pills) drugs without consulting the health care provider who prescribed digoxin. Many drugs interact with digoxin to increase or decrease its effects.
  - You will need periodic physical examinations, electrocardiograms, and blood tests to check digoxin and electrolyte (sodium, potassium, magnesium) levels to monitor your response to digoxin and see whether changes in dosage are needed.
  - Digoxin is often one drug in a management regimen of several drugs for heart disease. The drugs are all needed to help the heart and blood vessels work better. Together, the drugs help maintain a balance in the cardiovascular system. As a result, changing any aspect of one of the drugs can upset the balance and lead to symptoms. For example, stopping one drug because of adverse effects can lead to problems. If you think a drug needs to be stopped or its dosage reduced, talk with a health care provider. Do not make changes on your own; serious illness or even death could result.

Guidelines for Individualizing Digoxin Dosage
1. Digoxin dosages are usually stated as the average amounts needed for digitalization and maintenance therapy. These dosages must be interpreted with consideration of specific client characteristics. Digitalizing or loading doses are safe only for a short period, usually 24 hours. In addition, loading doses should be used cautiously in clients who have taken digoxin within the previous 2 or 3 weeks. Maintenance doses, which are much smaller than digitalizing doses, may be safely
used to initiate digoxin therapy and are always used for long-term therapy.

2. In general, larger doses are needed to slow the heart rate in atrial tachydysrhythmias than to increase myocardial contractility in HF. Larger doses may also be needed to reach therapeutic serum levels of digoxin in a small group of clients (about 10%) who have digoxin-metabolizing bacteria in their colons. Members of this group are at risk for development of digoxin toxicity if they are given antibacterial drugs that destroy colonic bacteria.

3. Smaller doses (loading and maintenance) should be given to clients who are elderly or have hypothyroidism. Because metabolism and excretion of digoxin are delayed in such people, the drug may accumulate and cause toxicity if dosage is not reduced. Dosage also should be reduced in clients with hypokalemia, extensive myocardial damage, or cardiac conduction disorders. These conditions increase risks of digoxin-induced dysrhythmias.

4. Dosage can be titrated according to client response. In HF, severity of symptoms, electrocardiogram (ECG), and serum drug concentrations are useful. In atrial fibrillation, dosage can be altered to produce the desired decrease in the ventricular rate of contraction. Optimal dosage is the lowest amount that relieves signs and symptoms of HF or alters heart rate and rhythm toward normal without producing toxicity.

5. IV dosage of digoxin should be 20% to 30% less than oral dosage.

6. Digoxin dosage must be reduced by approximately half in clients with renal failure, to avoid drug accumulation and toxicity. Dosage should be based on signs and symptoms of toxicity, creatinine clearance, and serum drug levels.

7. Dosage of digoxin must be reduced by approximately half when certain drugs are given concurrently, to avoid drug accumulation and toxicity. For example, amiodarone, quinidine, nifedipine, and verapamil slow digoxin excretion and increase serum digoxin levels.

8. When a hospitalized client is unable to take a daily maintenance dose of digoxin at the scheduled time because of diagnostic tests, treatment measures, or other reasons, the dose should usually be given later rather than omitted. If the client is having surgery, the nurse often must ask the surgeon whether the drug should be given on the day of surgery (ie, orally with a small amount of water or parenterally) and if the drug should be reordered after surgery. Many clients require continued digoxin therapy. However, if a dose is missed, probably no ill effects will occur because the pharmacologic actions of digoxin persist longer than 24 hours.

**Use in Children**

Digoxin is commonly used in children for the same indications as for adults and should be prescribed or supervised by a pediatric cardiologist when possible. The response to a given dose varies with age, size, and renal and hepatic function. There may be little difference between a therapeutic dose and a toxic dose. Very small amounts are often given to children. These factors increase the risks of dosage errors in children. In a hospital setting, institutional policies may require that each dose be veri-
fied with another nurse before it is administered. ECG monitoring is desirable when digoxin therapy is started.

As in adults, dosage of digoxin should be individualized and carefully titrated. Digoxin is primarily excreted by the kidneys, and dosage must be reduced with impaired renal function. In general, divided daily doses should be given to infants and children younger than 10 years, and adult dosages adjusted to their weight should be given to children older than 10 years of age. Larger doses are usually needed to slow a too-rapid ventricular rate in children with atrial fibrillation or flutter. Differences in bioavailability of different preparations (parenterals, capsules, elixirs, and tablets) must be considered when switching from one preparation to another.

Neonates vary in tolerance of digoxin depending on their degree of maturity. Premature infants are especially sensitive to drug effects. Dosage must be reduced, and digitalization should be even more individualized and cautiously approached than in more mature infants and children. Early signs of toxicity in newborns are undue slowing of sinus rate, sinoatrial arrest, and prolongation of the PR interval.

Use in Older Adults

Digoxin is widely used and a frequent cause of adverse effects in older adults. Reduced dosages are usually required because of decreased liver or kidney function, decreased lean body weight, and advanced cardiovascular disease. All of these characteristics are common in older adults. Impaired renal function leads to slower drug excretion and increased risk of accumulation. Dosage must be reduced by approximately 50% with renal failure or concurrent administration of amiodarone, quinidine, nifedipine, or verapamil. These drugs increase serum digoxin levels and increase risks of toxicity if dosage is not reduced. The most commonly recommended dose is 0.125 mg daily. Antacids decrease absorption of oral digoxin and should not be given at the same time.

Use in Renal Impairment

Digoxin should be used cautiously, in reduced dosages, because renal impairment delays its excretion. Both loading and maintenance doses should be reduced. Clients with advanced renal impairment can achieve therapeutic serum concentrations with a dosage of 0.125 mg three to five times per week. In addition, in clients with reduced blood flow to the kidneys (eg, fluid volume depletion or acute HF), digoxin may be reabsorbed in renal tubules. As a result, less digoxin is excreted through the kidneys and maintenance doses may need even greater decreases than those calculated according to creatinine clearance. Thus, digoxin toxicity develops more often and lasts longer in renal impairment. Clients with renal impairment who are receiving digoxin, even in small doses, should be monitored closely for adverse effects, and serum digoxin levels should be monitored periodically.

There is no information available about the use of inamrinone in renal impairment. However, pharmacokinetic data indicate higher plasma levels with HF-induced reductions in renal perfusion. Also, the drug and its metabolites are excreted primarily by the kidneys.

With milrinone, which is also excreted primarily by the kidneys, renal impairment significantly increases elimination half-life, drug accumulation, and adverse effects. Dosage should be reduced according to creatinine clearance (see manufacturer’s instructions).

Use in Hepatic Impairment

Hepatic impairment has little effect on digoxin clearance, and no dosage adjustments are needed. Inamrinone is extensively metabolized in the liver and may be hepatotoxic. If significant increases in liver enzymes and clinical symptoms occur, inamrinone should be discontinued. If smaller increases in liver enzymes occur without clinical symptoms, inamrinone may be continued with reduced dosage or discontinued, depending on the client’s need for the drug.

Use in Critical Illness

Critically ill clients often have multiple cardiovascular and other disorders that require drug therapy. Acute HF may be the primary critical illness. It may also be precipitated by other illnesses or treatments that alter fluid balance, impair myocardial contractility, or increase the workload of the heart beyond its capacity to accommodate. Management is often symptomatic, with choice of drug and dosage requiring careful titration and frequent monitoring of the client’s response. Cardiotonic, diuretic, and vasodilator drugs are often required. All of the drugs should be used with caution in critically ill clients.

Herbal and Dietary Supplements

Use of nonprescription herbal and dietary supplements is frequently not reported by the client even though one third of the adults in the United States use these agents. Significant interactions can occur between supplements and prescribed drugs. Ephedra may increase cardiac stimulation and worsen dysrhythmias. Natural licorice blocks the effects of spironolactone and causes sodium retention and potassium loss, effects that may worsen heart failure and potentiate the effects of digoxin. Hawthorn should be used cautiously as it may increase the effects of ACE inhibitors and digoxin. Use of ginseng can result in digoxin toxicity. Clients may utilize herbs such as dandelion root and juniper berries for their diuretic effect. Herbal and dietary supplements should not be taken instead of prescribed drug therapies.

Home Care

Most digoxin is taken at home, and the home care nurse shares responsibility for teaching clients how to use the drug effec-
tively and circumstances to be reported to a health care provider. Accurate dosing is vitally important because under-use may cause recurrence of symptoms and overuse may cause toxicity. Either condition may be life threatening and require emergency care. The home care nurse also needs to monitor clients’ responses to the drug and changes in conditions or drug therapy that increase risks of toxicity.

When clients are receiving a combination of drugs for management of HF, the nurse needs to assist them in understanding that the different types of drugs have different actions and produce different responses. As a result, they work together to be more effective and maintain a more balanced state of cardiovascular function. Changing drugs or dosages can upset the balance and lead to acute and severe symptoms that require hospitalization and may even cause death from HF. Thus, it is extremely important that they take all the medications as prescribed. If unable to take the medications for any reason, clients or caregivers should notify the prescribing health care provider. They should be instructed not to wait until symptoms become severe before seeking care.

### Cardiotonic-Inotropic Drugs

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a. With digoxin:</strong></td>
<td>For accurate administration</td>
</tr>
<tr>
<td>(1) Read the drug label and the health care provider’s order carefully when preparing a dose.</td>
<td>Digoxin formulations vary in concentration and bioavailability and cannot be used interchangeably.</td>
</tr>
<tr>
<td>(2) Give only the ordered dosage form (eg, tablet, Lantoxicap, or elixir).</td>
<td>Bradycardia is an adverse effect.</td>
</tr>
<tr>
<td>(3) Check the apical pulse before each dose. If the rate is below 60 in adults or 100 in children, omit the dose, and notify the health care provider.</td>
<td>This may minimize gastric irritation and symptoms of anorexia, nausea, and vomiting. However, these symptoms probably arise from drug stimulation of chemoreceptors in the medulla rather than a direct irritant effect of the drug on the gastrointestinal (GI) tract.</td>
</tr>
<tr>
<td>(4) Have the same nurse give digoxin to the same clients when possible because it is important to detect changes in rate and rhythm (see Observe for therapeutic effects and Observe for adverse effects, later).</td>
<td>Digoxin should be given slowly because the diluent, propylene glycol, has toxic effects on the cardiac conduction system if given too rapidly. Digoxin may be given undiluted or diluted with a four-fold or greater volume of sterile water for injection, 0.9% sodium chloride injection, or 5% dextrose injection. If diluted, use the solution immediately.</td>
</tr>
<tr>
<td>(5) Give oral digoxin with food or after meals.</td>
<td></td>
</tr>
<tr>
<td>(6) Inject intravenous (IV) digoxin slowly (over at least 5 min).</td>
<td></td>
</tr>
<tr>
<td><strong>b. With inamrinone:</strong></td>
<td>Manufacturer’s recommendations</td>
</tr>
<tr>
<td>(1) Give undiluted or diluted to a concentration of 1 to 3 mg/mL.</td>
<td>Inamrinone may be injected into IV tubing containing a dextrose solution because contact is brief. However, a chemical interaction occurs with prolonged contact.</td>
</tr>
<tr>
<td>(2) Dilute with 0.9% or 0.45% sodium chloride solution; use the diluted solution within 24 h. Do not dilute with solutions containing dextrose.</td>
<td></td>
</tr>
<tr>
<td>(3) Give bolus injections into the tubing of an IV infusion, over 2 to 3 min.</td>
<td></td>
</tr>
<tr>
<td>(4) Administer maintenance infusions at a rate of 5 to 10 mcg/kg/min.</td>
<td></td>
</tr>
<tr>
<td><strong>c. With milrinone:</strong></td>
<td>Manufacturer’s recommendations</td>
</tr>
<tr>
<td>(1) Dilute with 0.9% or 0.45% sodium chloride or 5% dextrose solution; use the diluted solution within 24 h.</td>
<td></td>
</tr>
<tr>
<td>(2) Give the loading dose by bolus infusion over 10 min.</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
(3) Give maintenance infusions at a standard rate of 0.5 mcg/kg/min; this rate may be increased or decreased according to response. | Manufacturer’s recommendations

d. With nesiritide:
(1) Dilute with 5 mL of 0.9% or 0.45% sodium chloride or 5% dextrose solution from a 250 mL IV container; add mixed drug to the container and use diluted solution within 24 h. | Manufacturer’s recommendations

(2) Prime infusion tubing with 25 mL prior to connecting to the patient; withdraw a bolus loading dose from infusion solution. | Manufacturer’s recommendations

(3) Give a bolus injection of 2 mcg/kg over 1 minute. | Incompatible with most drugs

(4) Give the maintenance infusion at a rate of 0.01 mcg/kg/min. | 

(5) Do not mix with any other drug solution; administer through a separate line. | 

2. Observe for therapeutic effects
a. When the drugs are given in heart failure (HF), observe for:
(1) Fewer signs and symptoms of pulmonary congestion (dyspnea, orthopnea, cyanosis, cough, hemoptysis, crackles, anxiety, restlessness) | The pulmonary symptoms that develop with HF are a direct result of events initiated by inadequate cardiac output. The left side of the heart is unable to accommodate incoming blood flow from the lungs. The resulting back pressure in pulmonary veins and capillaries causes leakage of fluid from blood vessels into tissue spaces and alveoli. Fluid accumulation may result in severe respiratory difficulty and pulmonary edema, a life-threatening development. The improved strength of myocardial contraction resulting from cardiotonic-inotropic drugs reverses this potentially fatal chain of events.

(2) Decreased edema—absence of pitting, decreased size of ankles or abdominal girth, decreased weight | Diuresis and decreased edema result from improved circulation and increased renal blood flow.

(3) Increased tolerance of activity | Indicates a more adequate supply of blood to tissues

b. When digoxin is given in atrial dysrhythmias, observe for:
(1) Gradual slowing of the heart rate to 70 to 80 beats/min
(2) Elimination of the pulse deficit
(3) Change in rhythm from irregular to regular | In clients with atrial fibrillation, slowing of the heart rate and elimination of the pulse deficit are clinical indicators that digitalization has been achieved.

3. Observe for adverse effects
a. With digoxin observe for:
(1) Cardiac dysrhythmias:
   (a) Premature ventricular contractions (PVCs) | Digoxin toxicity may cause any type of cardiac dysrhythmia. These are the most serious adverse effects associated with digoxin therapy. They are detected as abnormalities in electrocardiograms and in pulse rate or rhythm.

   (b) Bradycardia | PVCs are among the most common digoxin-induced dysrhythmias. They are not specific for digoxin toxicity because there are many possible causes. They are usually perceived as “skipped” heartbeats.

   (c) Paroxysmal atrial tachycardia with heart block | Excessive slowing of the heart rate is an extension of the drug’s therapeutic action of slowing conduction through the atrioventricular (AV) node and probably depressing the sinoatrial node as well.

   ECG is necessary for identification of nodal rhythms and heart block. | (continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
</table>
| (d) AV nodal tachycardia  
(e) AV block (second- or third-degree heart block) | These GI effects commonly occur with digoxin therapy. Because they are caused at least in part by stimulation of the vomiting center in the brain, they occur with parenteral and oral administration. The presence of these symptoms raises suspicion of digitalis toxicity, but they are not specific because many other conditions may cause anorexia, nausea, and vomiting. Also, clients receiving digoxin are often taking other medications that cause these side effects, such as diuretics and potassium supplements. |
| (2) Anorexia, nausea, vomiting | These central nervous system effects are most common in older adults. |
| (3) Headache, drowsiness, confusion | These are due mainly to drug effects on the retina and may indicate acute toxicity. |
| (4) Visual disturbances (eg, blurred vision, photophobia, altered perception of colors, flickering dots) | |
| b. With inamrinone, observe for:  
(1) Thrombocytopenia | Thrombocytopenia is more likely to occur with prolonged therapy and is usually reversible if dosage is reduced or the drug is discontinued. |
| (2) Anorexia, nausea, vomiting, abdominal pain | GI symptoms can be decreased by reducing drug dosage. |
| (3) Hypotension | Hypotension probably results from vasodilatory effects of inamrinone. |
| (4) Hepatotoxicity | If marked changes in liver enzymes occur in conjunction with clinical symptoms, the drug should be discontinued. |
| c. With milrinone, observe for ventricular dysrhythmias, hypotension, and headache | Ventricular dysrhythmias reportedly occur in 12% of clients, hypotension and headache in approximately 3% of clients. |
| d. With nesiritide, observe for hypotension, headache, nausea, back pain, ventricular tachycardia, dizziness, anxiety, insomnia, bradycardia, and vomiting. | Hypotension occurs in approximately 11% of clients; headache in 8%; nausea and back pain in 4%; and other adverse effects in 1 to 3%. |
| 4. Observe for drug interactions | Most significant drug interactions increase risks of toxicity. Some alter absorption or metabolism to produce under-digitalization and decreased therapeutic effect. |
| a. Drugs that increase effects of digoxin:  
(1) Adrenergic drugs (eg, ephedrine, epinephrine, isoproterenol) | Increase risks of cardiac dysrhythmias |
| (2) Antidysrhythmics (eg, amiodarone, propafenone, quinidine) | Decrease clearance of digoxin, thereby increasing serum digoxin levels and risks of toxicity. Dosage of digoxin should be reduced if one of these drugs is given concurrently (25% with propafenone and 50% with amiodarone and quinidine). |
| (3) Anticholinergics | Increase absorption of oral digoxin by slowing transit time through the GI tract |
| (4) Calcium preparations | Increase risks of cardiac dysrhythmias. IV calcium salts are contraindicated in digitalized clients. |
| (5) Calcium channel blockers (eg, diltiazem, felodipine, nifedipine, verapamil) | Decrease clearance of digoxin, thereby increasing serum digoxin levels and risks of toxicity. Dosage of digoxin should be reduced 25% if verapamil is given concurrently. |
| b. Drugs that decrease effects of digoxin:  
(1) Antacids, cholestyramine, colestipol, laxatives, oral aminoglycosides (eg, neomycin) | Decrease absorption of oral digoxin |
**Review and Application Exercises**

1. What signs and symptoms usually occur with HF? How would you assess for these?
2. What are the physiologic effects of digoxin on the heart?
3. How does digoxin produce or assist diuresis?
4. What is digitalization?
5. Differentiate between a digitalizing dose of digoxin and a daily maintenance dose.
6. Why do nurses need to check heart rate and rhythm before giving digoxin?
7. When is it appropriate to withhold a dose of digoxin?
8. What are adverse effects associated with digoxin, and how may they be prevented or minimized?
9. For clients with renal failure who need digoxin, what are the options for safe, effective therapy?
10. Why is it important to maintain a therapeutic serum potassium level during digoxin therapy?
11. What is the specific antidote for severe digoxin toxicity?

**SELECTED REFERENCES**


Antidysrhythmic Drugs

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Differentiate between supraventricular and ventricular dysrhythmias in terms of etiology and hemodynamic effects.
2. Describe nonpharmacologic measures to prevent or minimize tachydysrhythmias.
3. Discuss the roles of beta-adrenergic blocking agents, calcium channel blockers, digoxin, and quinidine in the management of supraventricular tachydysrhythmias.
4. Discuss the effects of lidocaine in the management of ventricular tachycardia.
5. Describe adverse effects and nursing process implications related to the use of selected antidysrhythmic drugs.

Critical Thinking Scenario

Seventy-nine-year-old Elmer Fitzgerald was recently diagnosed with atrial fibrillation. His heart rate is irregularly irregular, ranging between 120 and 160 beats per minute. At times, Mr. Fitzgerald is very symptomatic, experiencing weakness, dizziness, and syncope. His health care provider prescribes verapamil, a calcium channel blocker.

Reflect on:
- The emotional impact experienced with a diagnosis of a serious cardiac problem, such as a dysrhythmia.
- How atrial fibrillation affects cardiac function and the ability to oxygenate effectively.
- How the resulting symptoms of weakness, dizziness, and syncope may affect Mr. Fitzgerald’s daily functioning.
- How verapamil acts to improve cardiac function.

OVERVIEW

Antidysrhythmic agents are diverse drugs used for prevention and management of cardiac dysrhythmias. Dysrhythmias, also called arrhythmias, are abnormalities in heart rate or rhythm. They become significant when they interfere with cardiac function and ability to perfuse body tissues. To aid in understanding of dysrhythmias and antidysrhythmic drug therapy, the physiology of cardiac conduction and contractility is reviewed.

CARDIAC ELECTROPHYSIOLOGY

The heart is an electrical pump. The “electrical” activity resides primarily in the specialized tissues that can generate and conduct an electrical impulse. Although impulses are conducted through muscle cells, the rate is much slower. The mechanical or “pump” activity resides in contractile tissue. Normally, these activities result in effective cardiac contraction and distribution of blood throughout the body. Each heartbeat or cardiac cycle occurs at regular intervals and consists of four events. These are stimulation from an electrical impulse, transmission of the electrical impulse to adjacent conductive or contractile tissue, contraction of atria and ventricles, and relaxation of atria and ventricles, during which they refill with blood in preparation for the next contraction.

Automaticity

Automaticity is the heart’s ability to generate an electrical impulse. Any part of the conduction system can spontaneously start an impulse, but the sinoatrial (SA) node normally has the highest degree of automaticity and therefore the
highest rate of spontaneous impulse formation. With its faster rate of electrical discharge or depolarization than other parts of the conduction system, the SA node serves as pacemaker and controls heart rate and rhythm.

Initiation of an electrical impulse depends on the movement of sodium and calcium ions into a myocardial cell and movement of potassium ions out of the cell. Normally, the cell membrane becomes more permeable to sodium and opens pores or channels to allow its rapid movement into the cell. Calcium ions follow sodium ions into the cell at a slower rate. As sodium and calcium ions move into cells, potassium ions move out of cells. The movement of the ions changes the membrane from its resting state of electrical neutrality to an activated state of electrical energy buildup. When the electrical energy is discharged (depolarization), muscle contraction occurs.

Some cells in the cardiac conduction system depolarize in response to the entry of calcium ions rather than entry of sodium ions. In these calcium-responsive cells, which are found mainly in the SA and atrioventricular (AV) nodes, the electrical impulse is conducted more slowly and recovery of excitability takes longer than in sodium-responsive cells. Overall, activation of the SA and AV nodes depends on a slow depolarizing current through calcium channels, and activation of the atria and ventricles depends on a rapid depolarizing current through sodium channels. These two types of conduction tissues are often called slow and fast channels, respectively, and they differ markedly in their responses to drugs that affect conduction of electrical impulses.

The ability of a cardiac muscle cell to respond to an electrical stimulus is called excitability or irritability. The stimulus must reach a certain intensity or threshold to cause contraction. After contraction, sodium and calcium ions return to the extracellular space, potassium ions return to the intracellular space, muscle relaxation occurs, and the cell prepares for the next electrical stimulus and contraction.

Following contraction there is also a period of decreased excitability (called the absolute refractory period) during which the cell cannot respond to a new stimulus. Before the resting membrane potential is reached, a stimulus greater than normal can evoke a response in the cell. This period is called the relative refractory period.

**Conductivity**

Conductivity is the ability of cardiac tissue to transmit electrical impulses. Although the electrophysiology of a single myocardial cell can assist understanding of the process, the orderly, rhythmic transmission of impulses to all cells is needed for effective myocardial contraction.

Normally, electrical impulses originate in the SA node and are transmitted to atrial muscle, where they cause atrial contraction, and then to the AV node, bundle of His, bundle branches, Purkinje fibers, and ventricular muscle, where they cause ventricular contraction. The cardiac conduction system is shown in Figure 52–1.

Cardiac dysrhythmias can originate in any part of the conduction system or from atrial or ventricular muscle. They result from disturbances in electrical impulse formation (automaticity), conduction (conductivity), or both. The characteristic of automaticity allows myocardial cells other than the SA node to depolarize and initiate the electrical impulse that culminates in atrial and ventricular contraction. This may occur when the SA node fails to initiate an impulse or does so too slowly. When the electrical impulse arises anywhere other than the SA node, it is an abnormal or ectopic focus. If the ectopic focus depolarizes at a rate faster than the SA node, the ectopic focus becomes the dominant pacemaker. Ectopic pacemakers may arise in the atria, AV node, Purkinje fibers, or ventricular muscle. They may be activated by hypoxia, ischemia, or hypokalemia. Ectopic foci indicate myocardial irritability (increased responsiveness to stimuli) and potentially serious impairment of cardiac function.

A common mechanism by which abnormal conduction causes dysrhythmias is called reentry excitation. During normal conduction, the electrical impulse moves freely down the conduction system until it reaches recently excited tissue that is refractory to stimulation. This causes the impulse to be extinguished. The SA node then recovers, fires spontaneously, and the conduction process starts over again. Reentry excitation means that an impulse continues to reenter an area of the heart rather than becoming extinguished. For this to occur, the impulse must encounter an obstacle in the normal conducting pathway. The obstacle is usually an area of damage, such as myocardial infarction. The damaged area allows conduction in only one direction and causes a circular movement of the impulse (Fig. 52–2).

Dysrhythmias may be mild or severe, acute or chronic, episodic or relatively continuous. They are clinically significant if they interfere with cardiac function (ie, the heart’s abil-
The normal heart can maintain an adequate cardiac output with ventricular rates ranging from 40 to 180 beats per minute. The diseased heart, however, may not be able to maintain an adequate cardiac output with heart rates below 60 or above 120. Dysrhythmias are usually categorized by rate, location, or patterns of conduction. Common types of dysrhythmias are described in Box 52–1.

**Antidysrhythmic Drugs**

Antidysrhythmic drugs alter the heart’s electrical conduction system. Atropine for bradydysrhythmias is discussed in Chapter 21; digoxin and its use in treating atrial fibrillation are discussed in Chapter 51. The focus of this chapter is the drugs used for tachydysrhythmias. These drugs are described in the following sections and listed in Drugs at a Glance: Antidysrhythmic Drugs.

Clinical use of antidysrhythmic drugs for tachydysrhythmias has undergone significant changes. One change is that the goal of drug therapy is to prevent or relieve symptoms or prolong survival, not just suppress dysrhythmias. This change resulted from studies in which clients treated for some dysrhythmias had a higher mortality rate than clients who did not receive antidysrhythmic drug therapy. The higher mortality rate was attributed to prodysrhythmic effects (ie, worsening existing dysrhythmias or causing new dysrhythmias). Overall, there is decreasing use of class I drugs (eg, quinidine) and increasing use of class II (beta blockers) and class III drugs (eg, amiodarone).

Another change is the greater use of nonpharmacologic management of dysrhythmias. These methods include destroying dysrhythmogenic foci in the heart with radio waves (radiofrequency catheter ablation) or surgical procedures and implanting devices for sensing, cardioverting, defibrillating, or pacing (eg, the implantable cardioverter–defibrillator or ICD).

**Indications for Use**

Antidysrhythmic drug therapy commonly is indicated in the following conditions:

1. To convert atrial fibrillation (AF) or flutter to normal sinus rhythm (NSR)
2. To maintain NSR after conversion from AF or flutter
3. When the ventricular rate is so fast or irregular that cardiac output is impaired. Decreased cardiac output leads to symptoms of decreased systemic, cerebral, and coronary circulation.
4. When dangerous dysrhythmias occur and may be fatal if not quickly terminated. For example, ventricular tachycardia may cause cardiac arrest.

**Mechanisms of Action**

Drugs used for rapid dysrhythmias mainly reduce automaticity (spontaneous depolarization of myocardial cells, including ectopic pacemakers), slow conduction of electrical impulses through the heart, and prolong the refractory period of myocardial cells so they are less likely to be prematurely activated by adjacent cells. Several different groups of drugs perform one or more of these actions. They are classified according to their mechanisms of action and effects on the conduction system, even though they differ in other respects. Additionally, some drugs have characteristics of more than one classification.

**Classifications and Individual Drugs**

**Class I Sodium Channel Blockers**

Class I drugs block the movement of sodium into cells of the cardiac conducting system. This results in a membrane-
**Sinus dysrhythmias** are usually significant only if they are severe or prolonged. Tachycardia increases the workload of the heart and may lead to heart failure or angina pectoris. Sinus tachycardia may cause anginal pain (myocardial ischemia) by two related mechanisms. One mechanism involves increased myocardial oxygen consumption. The other mechanism involves a shortened diastole so that coronary arteries may not have adequate filling time between heartbeats. Thus, additional blood flow to the myocardium is required at the same time that a decreased blood supply is delivered. Sinus tachycardia may be caused by numerous conditions such as fever, hypotension, heart failure, thyrotoxicosis, stimulation of the sympathetic nervous system (eg, stress or drugs, including asthma remedies and nasal decongestants), and lifestyle drugs such as alcohol, caffeine, and nicotine. Thus, the initial assessment of a client with sinus tachycardia should include a search for underlying causes. The rate usually may be slowed by treating the underlying cause or by stimulating the vagus nerve (eg, by carotid sinus massage or Valsalva maneuver).

Sinus bradycardia may occur with excessive vagal stimulation, deficient sympathetic tone, and sinus node dysfunction. It often occurs in healthy young adults, especially in athletes and during sleep. Other conditions associated with sinus bradycardia include hypothyroidism, hypothermia, vasovagal reactions, and with the use of drugs such as beta-adrenergic blocking agents, amiodarone, diltiazem, lithium, and verapamil. Thus, as with sinus tachycardia, efforts to identify the underlying cause are needed. Asymptomatic sinus bradycardia does not require treatment. Acute, symptomatic sinus bradycardia can be treated with atropine or a temporary pacemaker (eg, an external transthoracic, a transvenous, or an electrical cardioversion). Then, long-term drug therapy is usually given to prevent stroke or other thromboembolic complications (eg, with aspirin, warfarin, or both).

**Nodal dysrhythmias** may involve tachycardia and increased workload of the heart or bradycardia from heart block. Either tachycardia or bradycardia may decrease cardiac output. Heart block involves impaired conduction of the electrical impulse through the AV node. With first-degree heart block, conduction is slowed, but not significantly. With second-degree heart block, every second, third, or fourth atrial impulse is blocked and does not reach the ventricles (2:1, 3:1, or 4:1 block). Thus, atrial and ventricular rates differ. Second-degree heart block has been divided into two types (Mobitz type I [or Wenckebach’s phenomenon] and Mobitz type II) and may interfere with cardiac output. Mobitz type I has been associated with individuals with inferior wall myocardial infarction (MI) or digoxin toxicity and usually does not require temporary pacing because it is transient in nature. Mobitz type II occurs in clients with anterior wall MI, may progress to third-degree block, and often requires cardiac pacing because it is associated with a high mortality rate. Third-degree is the most serious type of heart block because no impulses reach the ventricles. As a result, AV dissociation occurs and the ventricles beat independently at a rate less than 40 beats/minute. This slow ventricular rate severely reduces cardiac output and hemodynamic stability.

**Ventricular dysrhythmias** include premature ventricular contractions (PVCs), ventricular tachycardia, and ventricular fibrillation. PVCs occur in healthy individuals as well as those with heart disease and may cause no symptoms or only mild palpitations. Serious PVCs often occur with ischemic heart disease, especially after acute MI. PVCs are considered serious if they produce significant symptoms (eg, anginal pain, dyspnea, or syncope), occur more than five times per minute, are coupled or grouped, are multifocal, or occur during the resting phase of the cardiac cycle (R on T phenomenon). Serious PVCs indicate a high degree of myocardial irritability and may lead to life-threatening ventricular tachycardia, ventricular fibrillation, or asystole. The goal of treatment is to decrease myocardial irritability, relieve symptoms, and prevent progression to more serious dysrhythmias.

**Ventricular tachycardia** (VT) is characterized by a ventricular rate of 160 to 250 beats/minute. It is diagnosed when three or more PVCs occur in a row at a rate greater than 100 beats/minute. VT may be sustained (lasts longer than 30 seconds or requires termination because of hemodynamic collapse) or nonsustained (stops spontaneously in less than 30 seconds). Occasional brief episodes of VT may be asymptomatic; frequent or relatively long episodes may result in hemodynamic collapse, a life-threatening situation. An acute episode most often occurs during an acute myocardial infarction. Other precipitating factors include severe electrolyte imbalances (eg, hypokalemia), hypoxemia, or digoxin toxicity. Correction of these precipitating factors usually prevents recurrences of VT. Clients with organic heart disease may have a chronic recurrent form of VT. Torsades de pointes is an especially serious type of VT that may deteriorate into ventricular fibrillation. Predisposing factors include severe bradycardia, electrolyte deficiencies (eg, hypokalemia, hypomagnesemia), and several drug groups (eg, class IA antidysrhythmics, phenothiazine antipsychotics, and tricyclic antidepressants). VT can be treated with intravenous lidocaine (a loading dose and continuous infusions), direct-current countershock, external pacing, or insertion of a transvenous pacing wire for overdrive pacing.
**Section 9: Drugs Affecting the Cardiovascular System**

Ventricular fibrillation (VF) produces no myocardial contraction so that there is no cardiac output and sudden cardiac death (SCD) occurs. Death results unless effective cardiopulmonary resuscitation or defibrillation is instituted within approximately 4 to 6 minutes. VF most often occurs in clients with ischemic heart disease, especially acute MI. Direct-current countershock and antidysrhythmic drug therapy may be used to restore a functional heart rhythm. For primary VF that occurs during the first 72 hours following an MI, antidysrhythmic drug therapy is not indicated because the VF is unlikely to recur. For VF without an identifiable or a reversible cause, successful resuscitation should be followed by long-term antidysrhythmic drug therapy or a transvenous implantable cardioverter-defibrillator (ICD). ICDs improve survival rates in sudden cardiac death (SCD) better than antidysrhythmic drug therapy. However, beta blocker therapy for the first year after a MI significantly improves survival and reduces the occurrence of SCD. Other effective treatments for VT/VF include myocardial revascularization surgery or radiofrequency catheter ablation of the dysrhythmogenic focus.

**Box 52–1: Types of Dysrhythmias (Continued)**

**DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM**

<table>
<thead>
<tr>
<th>Class I Sodium Channel Blockers</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Quinidine</strong> (Cardioquin, Quinaglute)</td>
<td>PO 200–600 mg q6h; maximum dose, 3–4 g/d</td>
<td>PO 6 mg/kg q4–6h</td>
</tr>
<tr>
<td>Maintenance dose, PO 200–600 mg q6h, or 1 or 2 extended-action tablets, 2 or 3 times per day</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM (quinidine gluconate) 600 mg initially, then 400 mg q4–6h</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Procaainamide</strong> (Pronestyl, Procanbid)</td>
<td>PO 1 g loading dose initially, then 250–500 mg q3–4h (q6h for sustained-release tablets)</td>
<td>PO 50 mg/kg/d in 4–6 divided doses</td>
</tr>
<tr>
<td>IM loading dose, 500–1000 mg followed by oral maintenance doses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV 25–50 mg/min; maximum dose, 1000 mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Disopyramide</strong> (Norpace)</td>
<td>PO loading dose, 300 mg, followed by 150 mg q6h; usual dose, PO 400–800 mg/d in 4 divided doses</td>
<td></td>
</tr>
</tbody>
</table>

**Class II Beta Blockers: Treatment of Supraventricular Tachycardia**

**Acebutolol** (Sectral) | PO 200 mg twice daily, increased gradually until optimal response is obtained (usually 600–1200 mcg/d) | | |
stabilizing effect and decreased formation and conduction of electrical impulses. This group of drugs is declining in clinical use, mainly because of prodysrhythmic effects and resultant increased mortality rates. The higher mortality rates occur most often in clients with significant structural heart disease.

### Class IA

Class IA drugs have a broad spectrum of antidysrhythmic effects and are used for both supraventricular and ventricular dysrhythmias. **Quinidine**, the prototype, reduces automatic-
Lidocaine decreases myocardial irritability (automaticity) in the ventricles. It has little effect on atrial tissue and is not useful in treating atrial dysrhythmias. It differs from quinidine in that:

1. It must be given by injection.
2. It does not decrease AV conduction or myocardial contractility with usual therapeutic doses.
3. It has a rapid onset and short duration of action. After intravenous (IV) administration of a bolus dose, therapeutic effects occur within 1 to 2 minutes and last approximately 20 minutes. This characteristic is advantageous in emergency management but limits lidocaine use to acute care settings.
4. It is metabolized in the liver. Dosage must be reduced in clients with hepatic insufficiency or heart failure to avoid drug accumulation and toxicity.
5. It is less likely to cause heart block, cardiac asystole, ventricular dysrhythmias, and heart failure.

Therapeutic serum levels of lidocaine are 2 to 5 mcg/mL. Lidocaine may be given intramuscularly (IM) in emergencies when IV administration is impossible. When given IM, therapeutic effects occur in about 15 minutes and last about 90 minutes. Lidocaine is contraindicated in clients allergic to related local anesthetics (eg, procaine). Anaphylactic reactions may occur in sensitized individuals.

Mexiletine and tocainide are oral analogs of lidocaine with similar pharmacologic actions. They are used to suppress ventricular fibrillation or ventricular tachycardia. They are well absorbed from the GI tract, and peak serum levels are obtained within 3 hours. Taking the drug with food delays but does not decrease absorption.

Phenytoin, an anticonvulsant (see Chap. 11), may be used to treat dysrhythmias produced by digoxin intoxication. Phenytoin decreases automaticity and improves conduction through the AV node. Decreased automaticity helps control dysrhythmias, whereas enhanced conduction may improve cardiac function. Further, because heart block may result from digoxin, quinidine, or procainamide, phenytoin may relieve dysrhythmias without intensifying heart block. Phenytoin is not a cardiac depressant. Its only quinidine-like action is to suppress automaticity; otherwise, it counteracts the effects of quinidine and procainamide largely by increasing the rate of conduction. Phenytoin also has a longer half-life (22 to 36 hours) than other antidysrhythmic drugs. Given IV, a therapeutic plasma level (10 to 20 mcg/mL) can be obtained rapidly. Given orally, however, the drug may not reach a steady-state concentration for approximately 1 week unless loading doses are given initially.

**Class IC**

Flecainide and propafenone are oral agents that greatly decrease conduction in the ventricles. They may initiate new dysrhythmias or aggravate preexisting dysrhythmias, sometimes causing sustained ventricular tachycardia or ventricular fibrillation. These effects are more likely to occur with high doses and rapid dose increases. The drugs are recommended for use only in life-threatening ventricular dysrhythmias.
Miscellaneous Class I Drug

Moricizine is a class I agent with properties of the other subclasses (ie, IA, IB, and IC). It is indicated for management of life-threatening ventricular dysrhythmias, such as sustained ventricular tachycardia, and contraindicated in clients with heart block, cardiogenic shock, and hypersensitivity reactions to the drug. After oral administration, onset of action occurs within 2 hours, and duration of action is 10 to 24 hours. The drug is 95% protein bound, extensively metabolized in the liver, and excreted in the urine. Because moricizine may cause new dysrhythmias or aggravate preexisting dysrhythmias, therapy should be initiated in hospitalized clients with continuous electrocardiographic (ECG) monitoring.

Class II Beta-Adrenergic Blockers

These agents (see Chap. 19) exert antidysrhythmic effects by blocking sympathetic nervous system stimulation of beta receptors in the heart and decreasing risks of ventricular fibrillation. Blockage of receptors in the SA node and ectopic pacemakers decreases automaticity, and blockage of receptors in the AV node increases the refractory period. The drugs are effective for management of supraventricular dysrhythmias and those resulting from excessive sympathetic activity. Thus, they are most often used to slow the ventricular rate of contraction in supraventricular tachydysrhythmias (eg, AF, atrial flutter, paroxysmal supraventricular tachycardia [PSVT]).

As a class, beta blockers are being used more extensively because of their effectiveness and their ability to reduce mortality in a variety of clinical settings, including post–myocardial infarction and heart failure. Reduced mortality may result from the drugs’ ability to prevent ventricular fibrillation. Only four of the beta blockers marketed in the United States are approved by the Food and Drug Administration (FDA) for management of dysrhythmias.

Acebutolol may be given orally for chronic therapy to prevent ventricular dysrhythmias, especially those precipitated by exercise. Esmolol has a rapid onset and short duration of action. It is given IV for supraventricular tachydysrhythmias, especially during anesthesia, surgery, or other emergency situations when the ventricular rate must be reduced rapidly. It is not used for chronic therapy. Propranolol may be given orally for chronic therapy to prevent ventricular dysrhythmias, especially those precipitated by exercise. It may be given IV for life-threatening dysrhythmias or those occurring during anesthesia. Sotalol is a noncardioselective beta blocker (class II) that also has properties of class III antidysrhythmic drugs. Because its class III characteristics are considered more important in its antidysrhythmic effects, it is a class III drug (see next section).

Class III Potassium Channel Blockers

These drugs act to prolong duration of the action potential, slow repolarization, and prolong the refractory period in both atria and ventricles. Although the drugs share a common mechanism of action, they are very different drugs. As with beta blockers, clinical use of class III agents is increasing because they are associated with less ventricular fibrillation and decreased mortality compared with class I drugs.

Although classified as a potassium channel blocker, amiodarone also has electrophysiologic characteristics of sodium channel blockers, beta blockers, and calcium channel blockers. Thus, it has vasodilating effects and decreases systemic vascular resistance; it prolongs conduction in all cardiac tissues and decreases heart rate; and it decreases contractility of the left ventricle.

Intravenous and oral amiodarone differ in their electrophysiologic effects. When given IV, the major effect is slowing conduction through the AV node and prolonging the effective refractory period. Thus, it is given IV mainly for acute suppression of refractory, hemodynamically destabilizing ventricular tachycardia and ventricular fibrillation. It is given orally to treat recurrent ventricular tachycardia or ventricular fibrillation and to maintain a NSR after conversion of AF and flutter. Low doses (100 to 200 mg/day) may prevent recurrence of AF with less toxicity than higher doses of amiodarone or usual doses of other agents, including quinidine.

Amiodarone is extensively metabolized in the liver and produces active metabolites. The drug and its metabolites accumulate in the liver, lung, fat, skin, and other tissues. With IV administration, the onset of action usually occurs within several hours. With oral administration, the action may be delayed from a few days up to a week or longer. Because of its long serum half-life, loading doses are usually given and higher loading doses reduce the time required for therapeutic effects. Also, effects may persist for several weeks after the drug is discontinued.

Adverse effects include hypothyroidism, hyperthyroidism, pulmonary fibrosis, myocardial depression, hypotension, bradycardia, hepatic dysfunction, central nervous system (CNS) disturbances (depression, insomnia, nightmares, hallucinations), peripheral neuropathy and muscle weakness, bluish discoloration of skin and corneal deposits that may cause photosensitivity, appearance of colored halos around lights, and reduced visual acuity. Most adverse effects are considered dose dependent and reversible.

When oral amiodarone is used long-term, it also increases the effects of numerous drugs, including anticoagulants, beta blockers, calcium channel blockers, class I antidysrhythmics (quinidine, flecainide, lidocaine, procainamide), cyclosporine, digoxin, methotrexate, phenytoin, and theophylline.

Bretylium initially increases release of catecholamines and therefore increases heart rate, blood pressure, and myocardial contractility. This is followed in a few minutes by a decrease in vascular resistance, blood pressure, and heart rate. It is used primarily in critical care settings for acute control of recurrent ventricular fibrillation, especially in clients with recent myocardial infarction. It is given by IV infusion, with a loading dose followed by a maintenance dose, or in repeated IV injections. Because it is excreted almost entirely by the kidney, drug half-life is prolonged with renal impairment.
Class IV Calcium Channel Blockers

Calcium channel blockers (see Chap. 53) block the movement of calcium into conductile and contractile myocardial cells. As antidysrhythmic agents, they act primarily against tachycardias at SA and AV nodes because the cardiac cells and slow channels that depend on calcium influx are found mainly at these sites. Thus, they reduce automaticity of the SA and AV nodes, slow conduction, and prolong the refractory period in the AV node. They are effective only in supraventricular tachycardias.

Diltiazem and verapamil are the only calcium channel blockers approved for management of dysrhythmias. Both drugs may be given IV to terminate acute PSVT, usually within 2 minutes, and in AF and flutter. They are also effective in exercise-related tachycardias. When given IV, the drugs act within 15 minutes and last up to 6 hours. Oral verapamil may be used in the chronic management of the aforementioned dysrhythmias. Diltiazem and verapamil are metabolized by the liver, and metabolites are primarily excreted by the kidneys. The drugs are contraindicated in digoxin toxicity because they may worsen heart block. If used with propranolol or digoxin, caution must be exercised to avoid further impairment of myocardial contractility. Do not use IV verapamil with IV propranolol; potentially fatal bradycardia and hypotension may occur.

Unclassified

Adenosine, a naturally occurring component of all body cells, differs chemically from other antidysrhythmic drugs but acts like the calcium channel blockers. It depresses conduction at the AV node and is used to restore NSR in clients with PSVT; it is ineffective in other dysrhythmias. The drug has a very short duration of action (serum half-life is less than 10 seconds) and a high degree of effectiveness. It must be given by a rapid bolus injection, preferably through a central venous line. If given slowly, it is eliminated before it can reach cardiac tissues and exert its action.

Magnesium sulfate is given IV in the management of several dysrhythmias, including prevention of recurrent episodes of torsades de pointes and management of digitalis-induced dysrhythmias. Its antidysrhythmic effects may derive from imbalances of magnesium, potassium, and calcium.

Hypomagnesemia increases myocardial irritability and is a risk factor for both atrial and ventricular dysrhythmias. Thus, serum magnesium levels should be monitored in clients at risk and replacement therapy instituted when indicated. However, in some instances, the drug seems to have antidysrhythmic effects even when serum magnesium levels are normal.

Nursing Process

Assessment

Assess the client’s condition in relation to cardiac dysrhythmias:

- Identify conditions or risk factors that may precipitate dysrhythmias. These include the following:
  - Hypoxia
  - Electrolyte imbalances (eg, hypokalemia, hypomagnesemia)
• Acid–base imbalances
• Ischemic heart disease (angina pectoris, myocardial infarction)
• Cardiac valvular disease
• Febrile illness
• Respiratory disorders (eg, chronic lung disease)
• Exercise
• Emotional upset
• Excessive ingestion of caffeine-containing beverages (eg, coffee, tea, colas)
• Cigarette smoking
• Drug therapy with digoxin, antidysrhythmic drugs, CNS stimulants, anorexiants, and tricyclic antidepressants
• Hyperthyroidism

Observe for clinical signs and symptoms of dysrhythmias. Mild or infrequent dysrhythmias may be perceived by the client as palpitations or skipped heartbeats. More severe dysrhythmias may produce manifestations that reflect decreased cardiac output and other hemodynamic changes, as follows:
• Hypotension, bradycardia or tachycardia, and irregular pulse
• Shortness of breath, dyspnea, and cough from impaired respiration
• Syncope or mental confusion from reduced cerebral blood flow
• Chest pain from decreased coronary artery blood flow.
• Angina pectoris or myocardial infarction may occur.
• Oliguria from decreased renal blood flow
• When electrocardiograms (ECGs) are available (eg, 12-lead ECG or continuous ECG monitoring), assess for indications of dysrhythmias.

Nursing Diagnoses
• Decreased Cardiac Output related to ineffective pumping action of the heart
• Ineffective Tissue Perfusion, cerebral and peripheral, related to compromised cardiac output or drug-induced hypotension
• Activity Intolerance related to weakness and fatigue
• Impaired Gas Exchange related to decreased tissue perfusion
• Anxiety related to potentially serious illness
• Deficient Knowledge: Pharmacologic and nonpharmacologic management of dysrhythmias
• Excess Fluid Volume: Peripheral edema and pulmonary congestion related to decreased cardiac output

Planning/Goals
The client will:
• Receive or take antidysrhythmic drugs accurately
• Avoid conditions that precipitate dysrhythmias, when feasible
• Experience improved heart rate, circulation, and activity tolerance
• Be closely monitored for therapeutic and adverse drug effects
• Avoid preventable adverse drug effects
• Have adverse drug effects promptly recognized and treated if they occur
• Keep follow-up appointments for monitoring responses to treatment measures

Interventions
Use measures to prevent or minimize dysrhythmias:
• Treat underlying disease processes that contribute to dysrhythmia development. These include cardiovascular (eg, acute myocardial infarction) and noncardiovascular (eg, chronic lung disease) disorders.
• Prevent or treat other conditions that predispose to dysrhythmias (eg, hypoxia, electrolyte imbalance).
• Help the client avoid cigarette smoking, overeating, excessive coffee drinking, and other habits that may cause or aggravate dysrhythmias. Long-term supervision and counseling may be needed.
• For the client receiving antidysrhythmic drugs, implement the preceding measures to minimize the incidence and severity of acute dysrhythmias, and help the client comply with drug therapy.
• Monitor heart rate and rhythm and blood pressure every 4 to 6 hours.
• Check laboratory reports of serum electrolytes and serum drug levels when available. Report abnormal values.

Evaluation
• Check vital signs for improved heart rate and rhythm.
• Interview and observe for relief of symptoms and improved functioning in activities of daily living.
• Interview and observe for hypotension and other adverse drug effects.
• Interview and observe for compliance with instructions for taking antidysrhythmic drugs and other aspects of care.

PRINCIPLES OF THERAPY

Nonpharmacologic Management of Dysrhythmias

Nonpharmacologic management is preferred, at least initially, for several dysrhythmias. For example, sinus tachycardia usually results from such disorders as infection, dehydration, or hypotension, and management should attempt to relieve the underlying cause. For PSVT with mild or moderate symptoms, Valsalva’s maneuver, carotid sinus massage, or other measures to increase vagal tone are preferred. For ventricular fibrillation, immediate defibrillation by electrical countershock is the initial management of choice.

In addition to these strategies, others are being increasingly used. The impetus for nonpharmacologic management developed mainly from studies demonstrating that antidysrhythmic drugs could worsen existing dysrhythmias, cause new dysrhythmias, and cause higher mortality rates in
clients receiving the drugs than clients not receiving the drugs. Current technology allows clinicians to insert pacemakers and defibrillators (e.g., ICD) to control bradydysrhythmias or tachydysrhythmias and to use radio waves (radiofrequency catheter ablation) or surgery to deactivate ectopic foci.

Pharmacologic Management of Dysrhythmias

Rational drug therapy for cardiac dysrhythmias requires accurate identification of the dysrhythmia, understanding of the basic mechanisms causing the dysrhythmia, observation of the hemodynamic and ECG effects of the dysrhythmia, knowledge of the pharmacologic actions of specific antidysrhythmic drugs, and the expectation that therapeutic effects will outweigh potential adverse effects. Even when these criteria are met, antidysrhythmic drug therapy is somewhat empiric. Although some dysrhythmias usually respond to particular drugs, different drugs or combinations of drugs are often required. General trends and guidelines for drug therapy of supraventricular and ventricular dysrhythmias are described in the following sections.

General Trends

1. There is a relative consensus of opinion among clinicians about appropriate management for acute, symptomatic dysrhythmias, in which the goals are to abolish the abnormal rhythm, restore NSR, and prevent recurrence of the dysrhythmia. There is less agreement about long-term use of the drugs, which is probably indicated only for clients who experience recurrent symptomatic episodes.

2. Class I agents do not prolong survival in any group of clients and their use is declining. For example, quinidine is no longer recommended to slow heart rate or prevent recurrence of AF. Some clinicians recommend restricting this class to clients without structural heart disease, who are less likely to experience increased mortality than others.

3. Class II and class III drugs are being used increasingly, because of demonstrated benefits in relieving symptoms and decreasing mortality rates in clients with heart disease.

Supraventricular Tachydysrhythmias

1. Propranolol and other beta blockers are being increasingly used for tachydysrhythmias, especially in clients with myocardial infarction, heart failure, or exercise-induced dysrhythmias. In addition to controlling dysrhythmias, the drugs decrease the mortality rate in these clients. Also, a beta blocker is the management of choice if a rapid heart rate is causing angina or other symptoms in a client with known coronary artery disease.

2. Atrial fibrillation is the most common dysrhythmia. Management may involve conversion to NSR by elec-
Ventricular Dysrhythmias

1. Treatment of asymptomatic PVCs and nonsustained ventricular tachycardia (formerly standard practice with lidocaine in clients post–myocardial infarction) is not recommended.

2. A beta blocker may be preferred as a first-line drug for symptomatic ventricular dysrhythmias. Amiodarone, bretylium, flecainide, propafenone, and sotalol are also used in the management of life-threatening ventricular dysrhythmias, such as sustained ventricular tachycardia. Class I agents (eg, lidocaine, mexiletine, tocainide) may be used in clients with structurally normal hearts. Lidocaine may also be used for treating digoxin-induced ventricular dysrhythmias.

3. Amiodarone, sotalol, or a beta blocker may be used to prevent recurrence of ventricular tachycardia or fibrillation in clients resuscitated from cardiac arrest.

4. Moricizine is infrequently used in the United States because of its potential for causing undesirable cardiac events. It may be used to treat life-threatening ventricular dysrhythmias (eg, sustained ventricular tachycardia) that have not responded to safer drugs.

Use in Children

Antidysrhythmic drugs are less often needed in children than in adults, and their use has decreased with increased use of catheter ablative techniques. Catheter ablation uses radio waves to destroy dysrhythmia-producing foci in cardiac tissue and reportedly causes fewer adverse effects and complications than long-term antidysrhythmic drug therapy.

Antidysrhythmic drug therapy is also less clear-cut in children. The only antidysrhythmic drug that is FDA approved for use in children is digoxin. However, pediatric cardiologists have used various drugs and developed guidelines for their use, especially dosages. As with adults, the drugs should be used only when clearly indicated, and children should be monitored closely because all of the drugs can cause adverse effects, including hypotension and new or worsened dysrhythmias.

Supraventricular tachydysrhythmias are the most common sustained dysrhythmias in children. IV adenosine, digoxin, procainamide, or propranolol can be used acutely to terminate supraventricular tachydysrhythmias. IV verapamil, which is often used in adults to terminate supraventricular tachydysrhythmias, is contraindicated in infants and small children. Although it can be used cautiously in older children, some clinicians recommend that IV verapamil be avoided in the pediatric age group.

Nursing Notes: Ethical/Legal Dilemma

You are working on a surgical unit, caring for Betty Kelman, 1 day after her major abdominal surgery. During your assessment, you notice her pulse rate is very rapid (over 150 beats/minute) and very irregular. The resident orders an electrocardiogram that identifies a serious dysrhythmia. He gives you a verbal order for lidocaine, IV push, to be followed by a continuous IV infusion. You have never given this drug before and feel uncomfortable administering it to Ms. Kelman.

Reflect on:
- Identify factors in this situation that contributed to the nurse’s reluctance to administer the drug.
- Does a nurse have a right to refuse to administer a medication?
- Explore the consequences of refusing to give this medication for the nurse, the patient, and the health care provider.
- What support structures might be available in an acute care facility for the nurse in this situation?

Nursing Notes: Apply Your Knowledge

You are working on a telemetry unit. The monitor indicates that your patient, Mr. Sweeny, is experiencing paroxysmal supraventricular tachycardia. You have a standing order to treat this dysrhythmia with a calcium channel blocker, diltiazem, 20 mg, IV push. How will you proceed to administer this medication safely?
population. Digoxin or a beta blocker may be used for long-term management of supraventricular tachydysrhythmias.

Propranolol is the beta blocker most commonly used in children. It is one of the few antidysrhythmic drugs available in a liquid solution. Propranolol has a shorter half-life (3 to 4 hours) in infants than in children older than 1 to 2 years of age and adults (6 hours). When given IV, antidysrhythmic effects are rapid, and clients require careful monitoring for bradycardia and hypotension. Esmolol is being used more frequently to treat tachydysrhythmias in children, especially those occurring after surgery.

Lidocaine may be used to treat ventricular dysrhythmias precipitated by cardiac surgery or digitalis toxicity. Class I or III drugs are usually started in a hospital setting, at lower dosage ranges, because of prodysrhythmic effects. Prodsrhythmia is more common in children with structural heart disease or significant dysrhythmias. In general, serum levels should be monitored with class IA and IC drugs and IV lidocaine. Flecainide is the class IC drug most commonly used in children. Class III drugs are used in pediatrics mainly to treat life-threatening refractory tachydysrhythmias.

As in adults, most antidysrhythmic drugs and their metabolites are excreted through the kidneys and may accumulate in children with impaired renal function.

Use in Older Adults

Cardiac dysrhythmias are common in older adults, but in general only those causing symptoms of circulatory impairment should be treated with antidysrhythmic drugs. Compared with younger adults, older adults are more likely to experience serious adverse drug effects, including aggravation of existing dysrhythmias, production of new dysrhythmias, hypotension, and heart failure. Cautious use is required, and dosage usually needs to be reduced to compensate for heart disease or impaired drug elimination processes.

Use in Renal Impairment

Antidysrhythmic drug therapy in clients with renal impairment should be very cautious, with close monitoring of drug effects (eg, plasma drug levels, ECG changes, symptoms that may indicate drug toxicity). The kidneys excrete most antidysrhythmic drugs and their metabolites. As a result, decreased renal perfusion or other renal impairment can reduce drug elimination and lead to accumulation and adverse effects if dosage is not reduced. As a general rule, dosage of bretylium, digoxin, disopyramide, flecainide, lidocaine, moricizine, procainamide, propafenone, quinidine, sotalol, and tocainide should be reduced in clients with significant impairment of renal function. Dosage of adenosine, amiodarone, ibutilide, and mexiletine does not require reduction.

Use in Hepatic Impairment

As with renal impairment, antidysrhythmic drug therapy in clients with hepatic impairment should be very cautious, with close monitoring of drug effects (eg, plasma drug levels, ECG changes, symptoms that may indicate drug toxicity).

Amiodarone may be hepatotoxic and cause serious, sometimes fatal, liver disease. Hepatic enzyme levels are often elevated without accompanying symptoms of liver impairment. However, liver enzymes should be monitored regularly, especially in clients receiving relatively high maintenance doses. If enzyme levels are above three times the normal range or double in a client whose baseline levels were elevated, dosage reduction or drug discontinuation should be considered.

Hepatic impairment increases plasma half-life of several antidysrhythmic drugs, and dosage should be reduced. These include disopyramide, flecainide, lidocaine, mexiletine, moricizine, procainamide, propafenone, quinidine, and tocainide.

Dosages of adenosine and ibutilide are unlikely to need reductions in clients with hepatic impairment.

Use in Critical Illness

Critically ill clients often have multiple cardiovascular and other disorders that increase their risks for development of acute, serious, and potentially life-threatening dysrhythmias. They may also have refractory dysrhythmias that require strong, potentially toxic antidysrhythmic drugs. Thus, antidysrhythmic drugs are often given IV in critical care settings for rapid reversal of a fast rhythm. After reversal, IV or oral drugs may be given to prevent recurrence of the dysrhythmia.

Because serious problems may stem from either dysrhythmias or their treatment, health care providers should be adept in preventing, recognizing, and treating conditions that predispose to the development of serious dysrhythmias (eg, electrolyte imbalances, hypoxia). If dysrhythmias cannot be prevented, early recognition and treatment are needed.

Overall, any antidysrhythmic drug therapy in critically ill clients is preferably performed or at least initiated in critical care units or other facilities with appropriate equipment and personnel. For example, nurses who work in emergency departments or critical care units must be certified in cardiopulmonary resuscitation and advanced cardiac life support (ACLS). With ACLS, the American Heart Association and others have developed algorithms to guide drug therapy of dysrhythmias.

Home Care

Clients receiving chronic antidysrhythmic drug therapy are likely to have significant cardiovascular disease. With each visit, the home care nurse needs to assess the client’s physical, mental, and functional status and evaluate pulse and blood pressure. In addition, clients and caregivers should be taught to report symptoms (eg, dizziness or fainting, chest pain) and avoid over-the-counter drugs unless discussed with a health care provider.
NURSING ACTIONS

Antidysrhythmic Drugs

NURSING ACTIONS

1. Administer accurately
   a. Check apical and radial pulses before each dose. Withhold the dose and report to the physician if marked changes are noted in rate, rhythm, or quality of pulses.
   b. Check blood pressure at least once daily in hospitalized clients.
   c. During intravenous (IV) administration of antidysrhythmic drugs, maintain continuous cardiac monitoring and check blood pressure about every 5 min.
   d. Give oral drugs at evenly spaced intervals.
   e. With oral amiodarone, give once daily or in two divided doses if stomach upset occurs.
   f. With IV amiodarone, mix and give loading and maintenance infusions according to the manufacturer’s instructions.
   g. Give mexiletine, quinidine, and tocainide with food.
   h. Give lidocaine parenterally only, as a bolus injection or a continuous drip. Use only solutions labeled “For cardiac dysrhythmias,” and do not use solutions containing epinephrine. Give an IV bolus over 2 min.

2. Observe for therapeutic effects
   a. Conversion to normal sinus rhythm
   b. Improvement in rate, rhythm, and quality of apical and radial pulses and the electrocardiogram (ECG)
   c. Signs of increased cardiac output—blood pressure near normal range, urine output more adequate, no complaints of dizziness.
   d. Serum drug levels (mcg/mL) within therapeutic ranges.

<table>
<thead>
<tr>
<th>Class</th>
<th>Drug</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>Quinidine</td>
<td>2–6</td>
</tr>
<tr>
<td></td>
<td>Disopyramide</td>
<td>2–8</td>
</tr>
</tbody>
</table>
|       | Proca
| IC    | Fleca
|       | Flecainide | 0.2–1 |
|       | Propafenone | 0.06–1 |
| IC    | Flecainide | 0.2–1 |
|       | Propafenone | 0.06–1 |

Chapter 52 Antidysrhythmic Drugs

RATIONAL/E

Brady

To detect hypotension, which is most likely to occur when antidy

For early detection of hypotension and impending cardiac col

To maintain adequate blood levels

Specific instructions are required for accurate mixing and admin

The drug should be given in a critical care setting, by experienced personnel, preferably through a central venous catheter.

To decrease gastrointestinal (GI) symptoms

Lidocaine solutions that contain epinephrine are used for local anesthesia only. They should never be given intravenously in cardiac dysrhythmias because the epinephrine can cause or aggravate dysrhythmias. Rapid injection (within approximately 30 sec) produces transient blood levels several times greater than therapeutic range limits. Therefore, there is increased risk of toxicity without a concomitant increase in therapeutic effectiveness.

After a single oral dose, peak plasma levels are reached in approximately 1–4 h with quinidine, procainamide, and propranolol and in 6–12 h with phenytoin. Equilibrium between plasma and tissue levels is reached in 1 or 2 d with quinidine, procainamide, and propranolol; in approximately 1 wk with phenytoin; in 1–3 wk with amiodarone; and in just a few minutes with IV lidocaine.

Serum drug levels must be interpreted in light of the client’s clinical status.

(continued)
### Nursing Actions

<table>
<thead>
<tr>
<th>Class III</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone 0.5–2.5</td>
<td>Owing to depressant effects on the cardiac conduction system</td>
</tr>
<tr>
<td>Bretylium 0.5–1.5</td>
<td>Because they affect the cardiac conduction system, antidysrhythmic drugs may worsen existing dysrhythmias or cause new dysrhythmias.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Class IV</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verapamil 0.08–0.3</td>
<td>Owing to decreased cardiac output</td>
</tr>
</tbody>
</table>

#### 3. Observe for adverse effects

a. Heart block—may be indicated on the ECG by a prolonged PR interval, prolonged QRS complex, or absence of P waves

b. Dysrhythmias—aggravation of existing dysrhythmia, tachycardia, bradycardia, premature ventricular contractions, ventricular tachycardia or fibrillation

c. Hypotension

d. Additional adverse effects with specific drugs:
   1. Disopyramide—mouth dryness, blurred vision, urinary retention, other anticholinergic effects
   2. Lidocaine—drowsiness, paresthesia, muscle twitching, convulsions, changes in mental status (eg, confusion), hypersensitivity reactions (eg, urticaria, edema, anaphylaxis)
   3. Phenytoin—nystagmus, ataxia, slurring of speech, tremors, drowsiness, confusion, gingival hyperplasia
   4. Propranolol—weakness or dizziness, especially with activity or exercise
   5. Quinidine—hypersensitivity and cinchonism (tinnitus, vomiting, severe diarrhea, vertigo, headache)
   6. Tocainide—lightheadedness, dizziness, nausea, paresthesia, tremor

#### 4. Observe for drug interactions

a. Drugs that increase effects of antidysrhythmics:
   1. Antidysrhythmic agents
   2. Antihypertensives, diuretics, phenothiazine antipsychotic agents
   3. Cimetidine

b. Drugs that decrease effects of antidysrhythmic agents:
   1. Atropine sulfate
   2. Phenytoin, rifampin

Owing to depressed effects on the cardiac conduction system

Because they affect the cardiac conduction system, antidysrhythmic drugs may worsen existing dysrhythmias or cause new dysrhythmias.

Owing to decreased cardiac output

Most adverse reactions result from drug effects on the central nervous system (CNS). Convulsions are most likely to occur with high doses. Hypersensitivity reactions may occur in individuals who are allergic to related local anesthetic agents.

CNS changes are caused by depressant effects.

The beta-adrenergic blocking action of propranolol blocks the normal sympathetic nervous system response to activity and exercise. Clients may have symptoms caused by deficient blood supply to body tissues.

These are the most frequent adverse effects. They may be reversed by decreasing dosage, administering with food, or discontinuing the drug.

These drugs may potentiate therapeutic effects or increase risk of toxicity.

When antidysrhythmic drugs are combined, there are additive cardiac depressant effects.

Increases effects by inhibiting hepatic metabolism of quinidine, procainamide, lidocaine, tocainide, flecainide, and phenytoin

Atropine is used to reverse propranolol-induced bradycardia.

Decrease effects by inducing drug-metabolizing enzymes in the liver and accelerating the metabolism of quinidine, disopyramide, and mexiletine
**Review and Application Exercises**

1. Which tissues in the heart are able to generate an electrical impulse and therefore serve as a pacemaker?

2. What risk factors predispose a client to development of dysrhythmias?

3. Name interventions that clients or health care providers can perform to decrease risks of dysrhythmias.

4. Differentiate the hemodynamic effects of common dysrhythmias.

5. What are the classes of antidysrhythmic drugs?

6. How do beta-adrenergic blocking agents act on the conduction system to slow heart rate?

7. Why are class I drugs being used less often and class II and class III drugs being used more often?

8. What are common and potentially serious adverse effects of antidysrhythmic drugs?

**SELECTED REFERENCES**


Antianginal Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe the types, causes, and effects of angina pectoris.
2. Describe general characteristics and types of antianginal drugs.
3. Discuss nitrate antianginals in terms of indications for use, routes of administration, adverse effects, nursing process implications, and drug tolerance.
4. Differentiate between short-acting and long-acting dosage forms of nitrate antianginal drugs.
5. Discuss calcium channel blockers in terms of their effects on body tissues, clinical indications for use, common adverse effects, and nursing process implications.
6. Teach clients ways to prevent, minimize, or manage acute anginal attacks.

Critical Thinking Scenario
Mrs. Sinatro, a 56-year-old housewife, experiences chest pressure after exercise. She is the mother of six and works 30 hours a week word-processing documents for a law firm. When she is told that her chest discomfort is probably secondary to coronary artery disease, she cannot believe it. She states, “I’m just too young to have heart problems!” Mrs. Sinatro is referred to her primary care health care provider and given sublingual nitroglycerin tablets to use PRN for chest pain.

Reflect on:
► What assessment questions will you ask to determine Mrs. Sinatro’s risk factors for heart disease?
► Evaluate Mrs. Sinatro’s reaction to her new diagnosis and the client teaching implications.
► What lifestyle modifications would help minimize the progression of coronary artery disease?

Overview
Angina pectoris is a clinical syndrome characterized by episodes of chest pain. It occurs when there is a deficit in myocardial oxygen supply (myocardial ischemia) in relation to myocardial oxygen demand. It is most often caused by atherosclerotic plaque in the coronary arteries but may also be caused by coronary vasospasm. The development and progression of atherosclerotic plaque is called coronary artery disease (CAD). Atherosclerotic plaque narrows the lumen, decreases elasticity, and impairs dilation of coronary arteries. The result is impaired blood flow to the myocardium, especially with exercise or other factors that increase the cardiac workload and need for oxygen.

The continuum of CAD progresses from angina to myocardial infarction. There are three main types of angina: classic angina, variant angina, and unstable angina (Box 53–1). The Canadian Cardiovascular Society classifies clients with angina according to the amount of physical activity they can tolerate before anginal pain occurs (Box 53–2). These categories can assist in clinical assessment and evaluation of therapy.

Classic anginal pain is usually described as substernal chest pain of a constricting, squeezing, or suffocating nature. It may radiate to the jaw, neck, or shoulder, down the left or both arms, or to the back. The discomfort is sometimes mistaken for arthritis, or for indigestion, as the pain may be associated with nausea, vomiting, dizziness, diaphoresis, shortness of breath, or fear of impending doom. The discomfort is usually brief, typically lasting 5 minutes or less until the balance of oxygen supply and demand is restored.

Current research indicates that gender differences exist in the type and quality of cardiac symptoms, with women reporting epigastric or back discomfort. Additionally, older adults may have atypical symptoms of CAD and may experience “silent” ischemia that may delay them from seeking professional help. Individuals with diabetes mellitus may present...
Coronary Atherosclerosis

Atherosclerosis (see Chap. 58) begins with accumulation of lipid-filled macrophages (ie, foam cells) on the inner lining of coronary arteries. Foam cells, which promote growth of atherosclerotic plaque, develop in response to elevated blood cholesterol levels. Initially, white blood cells (monocytes) become attached to the endothelium and move through the endothelial layer into subendothelial spaces, where they ingest lipid and become foam cells. These early lesions progress to fibrous plaques containing foam cells covered by smooth muscle cells and connective tissue. Advanced lesions also contain hemorrhages, ulcerations, and scar tissue. Factors contributing to plaque development and growth include endothelial injury, lipid infiltration (ie, cholesterol), recruitment of inflammatory cells (mainly monocytes and T lymphocytes), and smooth muscle cell proliferation. Endothelial injury may cause platelets to aggregate at the site of injury, form a thrombus, and release chemical mediators that cause vasoconstriction (eg, thromboxane, serotonin, platelet-derived growth factor). The disrupted plaque, thrombus, and vasoconstriction combine to obstruct blood flow further in the affected coronary artery. When the plaque injury is mild, blockage of the coronary artery may be intermittent and cause silent myocardial ischemia or episodes of anginal pain at rest. Thrombus formation and vasoconstriction may progress until the coronary artery is completely occluded, producing myocardial infarction. Endothelial injury, with subsequent thrombus formation and vasoconstriction, may also result from therapeutic procedures (eg, angioplasty, atherectomy).

The Agency for Healthcare Research and Quality, in its clinical practice guidelines for the management of angina, defines unstable angina as meeting one or more of the following criteria:

- Recent (<2 months) increase in severity as indicated by progression to at least CCSC class III severity
- Recent (<2 months) increase in severity as indicated by progression to at least CCSC class III.

However, myocardial ischemia may also be painless or silent in a substantial number of clients. Overall, the diagnosis is usually based on chest pain history, electrocardiographic evidence of ischemia, and other signs of impaired cardiac function (eg, heart failure).

Because unstable angina often occurs hours or days before acute myocardial infarction, early recognition and effective management are extremely important in preventing progression to infarction, heart failure, or sudden cardiac death.

### BOX 53–1 TYPES OF ANGINA PECTORIS

**Classic**

Classic angina (also called stable, typical, or exertional angina) occurs when atherosclerotic plaque obstructs coronary arteries and the heart requires more oxygenated blood than the blocked arteries can deliver. Chest pain is usually precipitated by situations that increase the workload of the heart, such as physical exertion, exposure to cold, and emotional upset. Recurrent episodes of classic angina usually have the same pattern of onset, duration, and intensity of symptoms. Pain is usually relieved by rest, a fast-acting preparation of nitroglycerin, or both.

**Variant**

Variant angina (also called atypical, Prinzmetal’s, or vasospastic angina) is caused by spasms of the coronary artery that decrease blood flow to the myocardium. The spasms occur most often in coronary arteries that are already partly blocked by atherosclerotic plaque. Variant angina usually occurs during rest or with minimal exercise and often occurs at night. It often occurs at the same time each day. Pain is usually relieved by nitroglycerin. Long-term management includes avoidance of conditions that precipitate vasospasm, when possible (eg, exposure to cold, smoking, and emotional stress), as well as antianginal drugs.

**Unstable**

Unstable angina (also called rest, preinfarction, and crescendo angina) is a type of myocardial ischemia that falls between classic angina and myocardial infarction. It usually occurs in clients with advanced coronary atherosclerosis and produces increased frequency, intensity, and duration of symptoms. It often leads to myocardial infarction. Unstable angina usually develops when a minor injury ruptures atherosclerotic plaque. The resulting injury to the endothelium causes platelets to aggregate at the site of injury, form a thrombus, and release chemical mediators that cause vasoconstriction (eg, thromboxane, serotonin, platelet-derived growth factor). The disrupted plaque, thrombus, and vasoconstriction combine to obstruct blood flow further in the affected coronary artery. When the plaque injury is mild, blockage of the coronary artery may be intermittent and cause silent myocardial ischemia or episodes of anginal pain at rest. Thrombus formation and vasoconstriction may progress until the coronary artery is completely occluded, producing myocardial infarction. Endothelial injury, with subsequent thrombus formation and vasoconstriction, may also result from therapeutic procedures (eg, angioplasty, atherectomy).

### BOX 53–2 CANADIAN CARDIOVASCULAR SOCIETY CLASSIFICATION OF PATIENTS WITH ANGINA PECTORIS

| Class I: | Ordinary physical activity (eg, walking, climbing stairs) does not cause angina. Angina occurs with strenuous, rapid, or prolonged exertion at work or recreation. |
| Class II: | Slight limitation of ordinary activity. Angina occurs on walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, in wind, or under emotional stress. Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions can elicit angina. |
| Class III: | Marked limitations of ordinary physical activity. Angina occurs on walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at a normal pace. |
| Class IV: | Inability to carry on any physical activity without discomfort—anginal symptoms may be present at rest. |
be the initiating factor in plaque formation because it allows monocytes, platelets, cholesterol, and other blood components to come in contact with and stimulate abnormal growth of smooth muscle cells and connective tissue in the arterial wall.

Atherosclerosis commonly develops in the coronary arteries. As the plaque lesions develop over time, they become larger and extend farther into the lumen of the artery. The lesions may develop for decades before they produce symptoms of reduced blood flow. Eventually, such events as plaque rupture, mural hemorrhage, formation of a thrombus that partly or completely occludes an artery, and vasoconstriction precipitate myocardial ischemia. Thus, serious impairment of blood flow may occur with a large atherosclerotic plaque or a relatively small plaque with superimposed vasospasm and thrombosis. If stenosis blocks approximately 80% of the artery, blood flow cannot increase in response to increased need; if stenosis blocks 90% or more of the artery, blood flow is impaired when the client is at rest.

When coronary atherosclerosis develops slowly, collateral circulation develops to increase blood supply to the heart. Collateral circulation develops from anastomotic channels that connect the coronary arteries and allow perfusion of an area by more than one artery. When one artery becomes blocked, the anastomotic channels become larger and allow blood from an unblocked artery to perfuse the area typically supplied by the occluded artery. Endothelium-derived relaxing factors such as nitric oxide (NO) can dilate collateral vessels and facilitate regional myocardial blood flow. Although collateral circulation may prevent myocardial ischemia in the client at rest, it has limited ability to increase myocardial perfusion with increased cardiac workload.

Myocardial ischemia impairs blood flow to the myocardium, especially with exercise, mental stress, exposure to cold, or other factors that increase the cardiac workload. Most individuals with myocardial ischemia have advanced coronary atherosclerosis. Hypertension is also a major risk factor for myocardial ischemia.

Myocardial Ischemia

Myocardial ischemia occurs when the coronary arteries are unable to provide sufficient blood and oxygen for normal cardiac functions. Also known as ischemic heart disease, CAD, and coronary heart disease, myocardial ischemia may present as an acute coronary syndrome with three main consequences. One consequence is unstable angina, with the occurrence of pain (symptomatic myocardial ischemia). A second is myocardial infarction (MI) that is silent or asymptomatic and diagnosed by biochemical markers only. A third is MI, with or without ST-segment elevation, which occurs when the ischemia is persistent or severe.

Resultant Cardiovascular Impairments

1. With normal cardiac function, coronary blood flow can increase to meet needs for an increased oxygen supply with exercise or other conditions that increase cardiac workload. When coronary arteries are partly blocked by atherosclerotic plaque, vasospasm, or thrombi, blood flow may not be able to increase sufficiently.

2. The endothelium of normal coronary arteries synthesizes numerous substances (see Chap. 50) that protect against vasoconstriction and vasospasm, bleeding and clotting, inflammation, and excessive cell growth. Impaired endothelium (eg, by rupture of atherosclerotic plaque or the shear force of hypertension) leads to vasoconstriction, vasospasm, clot formation, formation of atherosclerotic plaque, and growth of smooth muscle cells in blood vessel walls.

One important substance produced by the endothelium of coronary arteries is NO (also called endothelium-derived relaxing factor). NO, which is synthesized from the amino acid arginine, is released by shear stress on the endothelium, sympathetic stimulation of exercise, and interactions with acetylcholine, histamine, prostacyclin, serotonin, thrombin, and other chemical mediators. NO relaxes vascular smooth muscle and inhibits adhesion and aggregation of platelets. When the endothelium is damaged, these vasodilating and antithrombotic effects are lost. At the same time, production of strong vasoconstrictors (eg, angiotensin II, endothelin-1, thromboxane A2) is increased. In addition, inflammatory cells enter the injured area and growth factors stimulate growth of smooth muscle cells. All of these factors participate in blocking coronary arteries.

3. Sympathetic nervous system stimulation normally produces dilation of coronary arteries, tachycardia, and increased myocardial contractility to handle an increased need for oxygenated blood. Atherosclerosis of coronary arteries, especially if severe, may cause vasoconstriction as well as decrease blood flow by obstruction.

Nonpharmacologic Management of Angina

For clients at any stage of CAD development, irrespective of symptoms of myocardial ischemia, optimal management involves lifestyle changes and medications, if necessary, to control or reverse risk factors for disease progression. Risk factors are frequently additive in nature and are classified as nonmodifiable and modifiable. Nonmodifiable risk factors include age, race, gender, and family history. The risk factors that can be altered include smoking, hypertension, hyperlipidemia, obesity, sedentary lifestyle, stress, and the use of drugs that increase cardiac workload (eg, adrenergics, corticosteroids). Thus, efforts are needed to assist clients in reducing blood pressure, weight, and serum cholesterol levels, when indicated, and developing an exercise program. For clients with diabetes mellitus, glucose and blood pressure control can reduce the microvascular changes associated with the condition.

In addition, clients should avoid circumstances known to precipitate acute attacks, and those who smoke should stop. Smoking is harmful to clients because:
• Nicotine increases catecholamines which, in turn, increase heart rate and blood pressure.
• Carboxyhemoglobin, formed from the inhalation of carbon monoxide in smoke, decreases delivery of blood and oxygen to the heart, decreases myocardial contractility, and increases the risks of life-threatening cardiac dysrhythmias (eg, ventricular fibrillation) during ischemic episodes.
• Both nicotine and carbon monoxide increase platelet adhesiveness and aggregation, thereby promoting thrombosis.
• Smoking increases the risks for myocardial infarction, sudden cardiac death, cerebrovascular disease (eg, stroke), peripheral vascular disease (eg, arterial insufficiency), and hypertension. It also reduces high-density lipoprotein, the “good” cholesterol.

Additional nonpharmacologic management strategies include surgical revascularization (eg, coronary artery bypass graft) and interventional procedures that reduce blockages (eg, percutaneous transluminal coronary angioplasty [PTCA], intracoronary stents, laser therapy, and rotoblators). However, most clients still require antianginal and other cardiovascular medications to manage their disease.

### ANTIANGINAL DRUGS

Drugs used for myocardial ischemia are the organic nitrates, the beta-adrenergic blocking agents, and the calcium channel blocking agents. These drugs relieve anginal pain by reducing myocardial oxygen demand or increasing blood supply to the myocardium. Nitrates and beta blockers are described in the following sections and dosage ranges are listed in Drugs at a Glance: Nitrates and Beta Blockers. Calcium channel blockers are described in a following section; indications for use and dosage ranges are listed in Drugs at a Glance: Calcium Channel Blockers.

### Organic Nitrates

Organic nitrates relax smooth muscle in blood vessel walls. This action produces vasodilation, which relieves anginal pain.

<table>
<thead>
<tr>
<th>Drugs at a Glance: Nitrate and Beta-Blocker Antianginal Drugs</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Nitrates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nitroglycerin (Nitro-Bid, others)</td>
<td>Relieve acute angina</td>
<td>PO Immediate-release tablets, 2.5–9 mg 2 or 3 times per day</td>
</tr>
<tr>
<td></td>
<td>Prevent exercise-induced angina</td>
<td>PO Sustained-release tablets or capsules, 2.5 mg 3 or 4 times per day</td>
</tr>
<tr>
<td></td>
<td>Long-term prophylaxis to decrease the frequency and severity of acute anginal episodes</td>
<td>SL 0.15–0.6 mg PRN for chest pain</td>
</tr>
<tr>
<td>Isosorbide dinitrate (Isordil, Sorbitrate)</td>
<td>Treatment and prevention of angina</td>
<td>SL 2.5–10 mg PRN or q2–4h</td>
</tr>
<tr>
<td>Isosorbide mononitrate (Ismo, Imdur)</td>
<td>Treatment and prevention of angina</td>
<td>PO Regular tablets, 10–60 mg q4–6h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO Chewable tablets, 5–10 mg q2–3h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO Sustained-release capsules, 40 mg q6–12h</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO 20 mg twice daily, with first dose on arising and the second dose 7 h later</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PO Extended-release tablets (Imdur), 30–60 mg once daily in the morning, increased after several days to 120 mg once daily if necessary</td>
</tr>
<tr>
<td><strong>Beta Blockers</strong></td>
<td>Long-term management of angina, to reduce frequency and severity of anginal episodes</td>
<td>PO 10–80 mg 2 to 4 times per day</td>
</tr>
<tr>
<td>Propranolol (Inderal)</td>
<td>Same as propranolol</td>
<td>IV 0.5–3 mg q4h until desired response is obtained</td>
</tr>
<tr>
<td>Atenolol (Tenormin)</td>
<td>Same as propranolol</td>
<td>PO 50 mg once daily, initially, increased to 100 mg/d after 1 wk if necessary</td>
</tr>
<tr>
<td>Metoprolol (Lopressor)</td>
<td>Same as propranolol</td>
<td>PO 50 mg twice daily initially, increased up to 400 mg daily if necessary</td>
</tr>
<tr>
<td>Nadolol (Corgard)</td>
<td>Same as propranolol</td>
<td>PO 40–240 mg/d in a single dose</td>
</tr>
</tbody>
</table>
SECTION 9 DRUGS AFFECTING THE CARDIOVASCULAR SYSTEM

**Drugs at a Glance: Calcium Channel Blockers**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine (Norvasc)</td>
<td>Angina, Hypertension</td>
<td>PO 5–10 mg once daily</td>
</tr>
<tr>
<td>Bepridil (Vascor)</td>
<td>Angina</td>
<td>PO 200 mg/d initially, increased to 300 mg daily after 10 d if necessary; maximum dose, 400 mg daily</td>
</tr>
<tr>
<td>Diltiazem (Cardizem)</td>
<td>Angina, Hypertension</td>
<td>Angina or hypertension, immediate-release, PO 60–90 mg 4 times daily before meals and at bedtime</td>
</tr>
<tr>
<td></td>
<td>Atrial fibrillation and flutter, PSVT</td>
<td>Hypertension, sustained-release only, PO 120–180 mg twice daily</td>
</tr>
<tr>
<td>Felodipine (Plendil)</td>
<td>Hypertension</td>
<td>PO 5–10 mg once daily</td>
</tr>
<tr>
<td>Isradipine (DynaCirc)</td>
<td>Hypertension</td>
<td>PO 2.5–5 mg twice daily</td>
</tr>
<tr>
<td>Nicardipine (Cardene)</td>
<td>Angina, Hypertension</td>
<td>Angina, immediate-release only, PO 20–40 mg 3 times daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension, immediate-release, same as for angina, above; sustained-release, PO 30–60 mg twice daily</td>
</tr>
<tr>
<td>Nifedipine (Adalat, Procardia)</td>
<td>Angina, Hypertension</td>
<td>Angina, immediate-release, PO 10–30 mg 3 times daily; sustained-release, PO 30–60 mg once daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension, sustained-release only, 30–60 mg once daily</td>
</tr>
<tr>
<td>Nimodipine (Nimotop)</td>
<td>Subarachnoid hemorrhage</td>
<td>PO 60 mg q4h for 21 consecutive d. If patient unable to swallow, aspirate contents of capsule into a syringe with an 18-gauge needle, administer by nasogastric tube, and follow with 30 mL normal saline.</td>
</tr>
<tr>
<td>Nisoldipine (Sular)</td>
<td>Hypertension</td>
<td>PO, initially 20 mg once daily, increased by 10 mg/wk or longer intervals to a maximum of 60 mg daily. Average maintenance dose, 20–40 mg daily. Adults with liver impairment or &gt;65 y, PO, initially 10 mg once daily</td>
</tr>
<tr>
<td>Verapamil (Calan, Isoptin)</td>
<td>Angina, Atrial fibrillation or flutter, PSVT, Hypertension</td>
<td>Angina, PO 80–120 mg 3 times daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dysrhythmias, PO 80–120 mg 3 to 4 times daily; IV injection, 5–10 mg over 2 min or longer, with continuous monitoring of electrocardiogram and blood pressure</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hypertension, PO 80 mg 3 times daily or 240 mg (sustained release) once daily</td>
</tr>
</tbody>
</table>

PSVT, paroxysmal supraventricular tachycardia.

by several mechanisms. First, dilation of veins reduces venous pressure and venous return to the heart. This decreases blood volume and pressure within the heart (preload), which in turn decreases cardiac workload and oxygen demand. Second, nitrates dilate coronary arteries at higher doses and can increase blood flow to ischemic areas of the myocardium. Third, nitrates dilate arterioles, which lowers peripheral vascular resistance (afterload). This results in lower systolic blood pressure and, consequently, reduced cardiac workload. The prototype and most widely used nitrate is nitroglycerin.

Nitrates are converted to NO in vascular smooth muscle. NO activates guanylate cyclase, an enzyme that catalyzes formation of cyclic guanine monophosphate, which decreases calcium levels in vascular smooth muscle cells. Because intracellular calcium is required for contraction of vascular smooth muscle, the result of decreased calcium is vasodilation. The NO derived from nitrate medications can be considered a replacement or substitute for the NO that a damaged endothelium can no longer produce.

Clinical indications for nitroglycerin and other nitrates are management and prevention of acute chest pain caused by myocardial ischemia. For acute angina and prophylaxis before a situation deemed likely to precipitate acute angina, fast-acting preparations (sublingual or chewable tablets, transmucosal spray or tablet) are used. For management of recurrent angina, long-acting preparations (oral and sustained-release tablets or transdermal ointment and discs) are used. However, they may not be effective long-term because tolerance develops to their hemodynamic effects. Intravenous (IV) nitroglycerin is used to manage angina that is unresponsive to organic nitrates via other routes or beta-adrenergic blocking agents. It also may be used to control blood pressure in perioperative or emergency situations and to reduce preload and afterload in severe heart failure.

Contraindications include hypersensitivity reactions, severe anemia, hypotension, and hypovolemia. The drugs should be used cautiously in the presence of head injury or cerebral hemorrhage because they may increase intracranial pressure. Additionally, males taking nitroglycerin or any other nitrate should not take sildenafil (Viagra) for erectile dysfunction. Both drugs decrease blood pressure and the combined effect can produce profound, life-threatening hypotension.
Individual Nitrates

Nitroglycerin (Nitro-Bid, others), the prototype drug, is used to relieve acute angina pectoris, prevent exercise-induced angina, and decrease the frequency and severity of acute anginal episodes. Oral dosage forms are rapidly metabolized in the liver, and relatively small proportions of doses reach the systemic circulation. In addition, oral doses act slowly and do not help relieve acute chest pain.

For these reasons, several alternative dosage forms have been developed, including transmucosal tablets and sprays administered sublingually or buccally, transdermal ointments and adhesive discs applied to the skin, and an IV preparation. When given sublingually, nitroglycerin is absorbed directly into the systemic circulation. It acts within 1 to 3 minutes and lasts 30 to 60 minutes. When applied topically to the skin, nitroglycerin is also absorbed directly into the systemic circulation. However, absorption occurs at a slower rate, and topical nitroglycerin has a longer duration of action than other forms. It is available in an ointment, which is effective for 4 to 8 hours, and a transdermal disc, which is effective for about 12 hours. An IV form of nitroglycerin is used to relieve acute anginal pain that does not respond to other agents. Regardless of the route, nitroglycerin has a half-life of 1 to 5 minutes, supporting the beneficial use of transdermal patches and sustained-release tablets.

Isosorbide dinitrate (Iscordil, Sorbitrate) is used to reduce the frequency and severity of anginal episodes. When given sublingually or in chewable tablets, it acts in about 2 minutes, and its effects last 2 to 3 hours. When higher doses are given orally, more drug escapes metabolism in the liver and produces systemic effects in approximately 30 minutes. Therapeutic effects last about 4 hours after oral administration. The effective oral dose is usually determined by increasing the dose until headache occurs, indicating the maximum tolerable dose. Sustained-release capsules also are available.

Isosorbide mononitrate (Ismo, Imdur) is the metabolite and active component of isosorbide dinitrate. It is well absorbed after oral administration and almost 100% bioavailable. Unlike other oral nitrates, this drug is not subject to first-pass hepatic metabolism. Onset of action occurs within 1 hour, peak effects occur between 1 and 4 hours, and the elimination half-life is approximately 5 hours. It is used only for prophylaxis of angina; it does not act rapidly enough to relieve acute attacks.

Nursing Notes: Apply Your Knowledge

Mrs. Sinatro, a patient with newly diagnosed coronary artery disease (CAD), has been started on a nitroglycerin patch that she is to apply in the morning and remove before going to bed at night. Sublingual nitroglycerin, PRN, is ordered for episodes of chest pain. Discuss appropriate teaching for Mrs. Sinatro.

How Can You Avoid This Medication Error?

Mr. Ely has Nitropaste (nitroglycerin ointment), 1 inch, ordered every 6 hours to decrease blood pressure and control angina. The nurse carefully measures out 1 inch of ointment on the measuring paper and spreads the ointment with her finger. Before she is able to administer the medication, she feels dizzy and unwell. She hands the medication to another nurse and asks her to give it. Identify the error and how it could be prevented.

Beta-Adrenergic Blocking Agents

Beta-adrenergic blocking agents are often prescribed in a variety of clinical conditions. Their actions, uses, and adverse effects are discussed in Chapter 19. In this chapter, the drugs are discussed only in relation to their use in angina pectoris.

Sympathetic stimulation of beta, receptors in the heart increases heart rate and force of myocardial contraction, both of which increase myocardial oxygen demand and may precipitate acute anginal attacks. Beta-blocking drugs prevent or inhibit sympathetic stimulation. Thus, the drugs reduce heart rate and myocardial contractility, particularly when sympathetic output is increased during exercise. A slower heart rate may improve coronary blood flow to the ischemic area. Beta blockers also reduce blood pressure, which in turn decreases myocardial workload and oxygen demand. In angina pectoris, beta-adrenergic blocking agents are used in long-term management to decrease the frequency and severity of anginal attacks, decrease the need for sublingual nitroglycerin, and increase exercise tolerance. When a beta blocker is being discontinued after prolonged use, it should be tapered in dosage and gradually discontinued or rebound angina can occur.

These drugs should not be given to clients with known or suspected coronary artery spasms because they may intensify the frequency and severity of vasospasm. This probably results from unopposed stimulation of alpha-adrenergic receptors, which causes vasoconstriction, when beta-adrenergic receptors are blocked by the drugs. Clients who continue to smoke may have reduced efficacy with the use of beta blockers. Clients with asthma should be observed for bronchoospasm from blockage of beta, receptors in the lung. Beta blockers should be used with caution in clients with diabetes mellitus because they can conceal signs of hypoglycemia (except for sweating).

Propranolol, the prototype beta blocker, is used to reduce the frequency and severity of acute attacks of angina. It is usually added to the antianginal drug regimen when nitrates do not prevent anginal episodes. It is especially useful in preventing exercise-induced tachycardia, which can precipitate anginal attacks. Studies indicate that beta blockers are more effective than nitrates or calcium channel blockers in decreasing the likelihood of silent ischemia and improving the mortality rate after transmural MI.

Propranolol is well absorbed after oral administration. It is then metabolized extensively in the liver; a relatively small
proportion of an oral dose (approximately 30%) reaches the systemic circulation. For this reason, oral doses of propranolol are much higher than IV doses. Onset of action is 30 minutes after oral administration and 1 to 2 minutes after IV injection. Because of variations in the degree of hepatic metabolism, clients vary widely in the dosages required to maintain a therapeutic response.

Atenolol, metoprolol, and nadolol have the same actions, uses, and adverse effects as propranolol, but they have long half-lives and can be given once daily. They are excreted by the kidneys, and dosage must be reduced in clients with renal impairment.

**Calcium Channel Blocking Agents**

Calcium channel blockers act on contractile and conductive tissues of the heart and on vascular smooth muscle. For these cells to function normally, the concentration of intracellular calcium must be increased. This is usually accomplished by movement of extracellular calcium ions into the cell (through calcium channels in the cell membrane) and release of bound calcium from the sarcoplasmic reticulum in the cell. Thus, calcium plays an important role in maintaining vasomotor tone, myocardial contractility, and conduction. Calcium channel blocking agents prevent the movement of extracellular calcium into the cell. As a result, coronary and peripheral arteries are dilated, myocardial contractility is decreased, and the conduction system is depressed in relation to impulse formation (automaticity) and conduction velocity (Fig. 53–1).

In angina pectoris, the drugs improve the blood supply to the myocardium by dilating coronary arteries and decrease the workload of the heart by dilating peripheral arteries. In variant angina, calcium channel blockers reduce coronary artery vasospasm. In atrial fibrillation or flutter and other supraventricular tachydysrhythmias, diltiazem and verapamil slow the rate of ventricular response. In hypertension, the drugs lower blood pressure primarily by dilating peripheral arteries.

Calcium channel blockers are well absorbed after oral administration but undergo extensive first-pass metabolism in the liver. Most of the drugs are more than 90% protein bound and reach peak plasma levels within 1 to 2 hours (6 hours or longer for sustained-release forms). Most also have short elimination half-lives (<5 hours), so doses must be given three or four times daily unless sustained-release formulations are used. Amlodipine (30 to 50 hours), bepridil (24 hours), and felodipine (11 to 16 hours) have long elimination half-lives and therefore can be given once daily. The drugs are metabolized in the liver, and dosage should be reduced in clients with severe liver disease. Dosage reductions are not required with renal disease.

The calcium channel blockers approved for use in the United States vary in their chemical structures and effects on body tissues. Seven of these are chemically dihydropyridines, of which nifedipine is the prototype. Bepridil, diltiazem, and verapamil differ chemically from the dihydropyridines and each other. Nifedipine and related drugs act mainly on vascular smooth muscle to produce vasodilation, whereas verapamil and diltiazem have greater effects on the cardiac conduction system.

The drugs also vary in clinical indications for use; most are used for angina or hypertension, and only diltiazem and verapamil are used to manage supraventricular tachydysrhythmias. In clients with CAD, the drugs are effective as monotherapy but are commonly prescribed in combination with beta blockers. In addition, nimodipine is approved for use only in subarachnoid hemorrhage, in which it decreases spasm in cerebral blood vessels and limits the extent of brain damage. In animal studies, nimodipine exerted greater effects on cerebral arteries than on other arteries, probably because it is highly lipid soluble and penetrates the blood–brain barrier.

Contraindications include second- or third-degree heart block, cardiogenic shock, and severe bradycardia, heart failure, or hypotension. The drugs should be used cautiously with milder bradycardia, heart failure, or hypotension and with renal or hepatic impairment.
Adjunctive Antianginal Drugs

In addition to antianginal drugs, several other drugs may be used to control risk factors and prevent progression of myocardial ischemia to myocardial infarction and sudden cardiac death. These may include:

- **Aspirin.** This drug has become the standard of care because of its antiplatelet (ie, antithrombotic) effects. Recommended doses vary from 81 mg daily to 325 mg daily or every other day; apparently all doses are beneficial in reducing the possibility of myocardial reinfarction, stroke, and death. Clopidogrel (see Chap. 57), 75 mg/day, is an acceptable alternative for individuals with aspirin allergy.

- **Antilipemics.** These drugs (see Chap. 58) may be needed by clients who are unable to lower serum cholesterol levels sufficiently with a low-fat diet. Lovastatin or a related “statin” is often used. The goal is usually to reduce the serum cholesterol level below 200 mg/dL and low-density lipoprotein cholesterol to below 130 mg/dL.

- **Antihypertensives.** These drugs (see Chap. 55) may be needed for clients with hypertension. Because beta blockers and calcium channel blockers are used to manage hypertension as well as angina, one of these drugs may be effective for both disorders.

**Nursing Process**

**Assessment**
Assess the client’s condition in relation to angina pectoris. Specific assessment data vary with each client but usually should include the following:

- During the initial nursing history interview, try to answer the following questions:
  - How long has the client been taking antianginal drugs? For what purpose are they being taken (prophylaxis, treatment of acute attacks, or both)?
  - What is the frequency and duration of acute anginal attacks? Has either increased recently? (An increase could indicate worsening coronary atherosclerosis and increased risk of myocardial infarction.)
  - Do symptoms other than chest pain occur during acute attacks (eg, sweating, nausea)?
  - Are there particular activities or circumstances that provoke acute attacks? Do attacks ever occur when the client is at rest? Where does the client fit in the Canadian Cardiovascular Society classification system?
  - What measures relieve symptoms of acute angina?
  - If the client takes nitroglycerin, ask how often it is required, how many tablets are needed for relief of pain, how often the supply is replaced, and where the client stores or carries the drug.
  - Assess blood pressure and pulse, electrocardiogram (ECG) reports, serum cholesterol, and cardiac enzyme reports.

Elevated cholesterol is a significant risk factor for coronary atherosclerosis and angina and the risk is directly related to the degree of elevation. Cardiac enzyme levels, such as troponin, creatine kinase (CK), lactate dehydrogenase (LDH), and aspartate aminotransferase (AST), should all be normal in clients with angina.

- During an acute attack, assess the following:
  - Location and quality of the pain. Chest pain is non-specific. It may be a symptom of numerous disorders, such as pulmonary embolism, esophageal spasm or inflammation (heartburn), costochondritis, or anxiety. Chest pain of cardiac origin is caused by myocardial ischemia and may indicate angina pectoris or myocardial infarction.
  - Precipitating factors. For example, what was the client doing, thinking, or feeling just before the onset of chest pain?
  - Has the client had invasive procedures to diagnose or treat his or her coronary artery disease (CAD) (eg, cardiac catheterization, angioplasty, revascularization surgery)?

**Nursing Diagnoses**

- Decreased Cardiac Output related to altered stroke volume or drug therapy
- Acute pain in chest related to inadequate perfusion of the myocardium
- Activity Intolerance related to chest pain
- Noncompliance related to drug therapy and lifestyle changes
- Deficient Knowledge related to management of disease process and drug therapy
- Ineffective Individual Coping related to chronic disease process
- Sexual Dysfunction related to fear of precipitating chest pain

**Planning/Goals**
The client will:

- Receive or take antianginal drugs accurately
- Experience relief of acute chest pain
- Have fewer episodes of acute chest pain
- Have increased activity tolerance
- Identify and manage situations that precipitate anginal attacks
- Be closely monitored for therapeutic and adverse effects, especially when drug therapy is started
- Avoid preventable adverse effects
- Verbalize essential information about the disease process, needed dietary and lifestyle changes to improve health status, and drug therapy
- Recognize signs and symptoms that necessitate professional intervention
- Keep appointments for follow-up care and monitoring
Interventions

Use the following measures to prevent acute anginal attacks:

- Assist in preventing, recognizing, and managing contributory disorders, such as atherosclerosis, hypertension, hyperthyroidism, hypoxia, and anemia. For example, hypertension is a common risk factor for CAD and morbidity and mortality increase progressively with the degree of either systolic or diastolic elevation. Management of hypertension reduces morbidity and mortality rates. However, most studies indicate that the reductions stem more from fewer strokes, less renal failure, and less heart failure, than from less CAD.
- Help the client recognize and avoid precipitating factors (e.g., heavy meals, strenuous exercise) when possible. If anxiety is a factor, relaxation techniques or psychological counseling may be helpful.
- Help the client to develop a more healthful lifestyle in terms of diet and weight control, adequate rest and sleep, regular exercise, and not smoking. Ideally, these self-help interventions are practiced before illness occurs and they can help prevent or delay illness. However, most individuals are unmotivated until illness develops, and perhaps after it develops as well. These interventions are beneficial at any stage of CAD. For example, for a client who already has angina, a supervised exercise program helps to develop collateral circulation. Smoking has numerous ill effects on the client with angina and decreases effectiveness of antianginal drugs.

During an acute anginal attack in a client known to have angina or CAD:

- Assume that any chest pain may be of cardiac origin.
- Have the client lie down or sit down to reduce cardiac workload and provide rest.
- Check vital signs and compare them with baseline values.
- Record the characteristics of chest pain and the presence of other signs and symptoms.
- Have the client take a fast-acting nitroglycerin preparation (previously prescribed), up to three sublingual tablets or three oral sprays, each 5 minutes apart, as necessary.
- If chest pain is not relieved with rest and nitroglycerin, assume that a myocardial infarction has occurred until proven otherwise. In a health care setting, keep the client at rest and notify the client’s physician immediately. Outside of a health care setting, call 911 for immediate assistance.
- Leave sublingual nitroglycerin at the bedside of hospitalized clients (per hospital policy). The tablets or spray should be within reach so they can be used immediately. Record the number of tablets used daily, and ensure an adequate supply is available.

Evaluation

- Observe and interview for relief of acute chest pain.
- Observe and interview regarding the number of episodes of acute chest pain.
- Identify CAD lifestyle factors that are being successfully modified or require modification (e.g., diet, weight, activity, and smoking cessation).
- Interview regarding success and compliance with drug therapy.

PRINCIPLES OF THERAPY

Goals of Therapy

The goals of drug therapy are to relieve acute anginal pain; reduce the number and severity of acute anginal attacks; improve exercise tolerance and quality of life; delay progression of CAD; prevent myocardial infarction; and prevent sudden cardiac death.

Choice of Drug and Dosage Form

For relief of acute angina and prophylaxis before events that cause acute angina, nitroglycerin (sublingual tablets or translingual spray) is usually the primary drug of choice. Sublingual or chewable tablets of isosorbide dinitrate also may be used. For long-term prevention or management of recurrent angina, oral or topical nitrates, beta-adrenergic blocking agents, or calcium channel blocking agents are used. Combination drug therapy with a nitrate and one of the other drugs is common and effective. Clients taking one or more long-acting antianginal drugs should carry a short-acting drug as well, to be used for acute attacks.

Titration of Dosage

Dosage of all antianginal drugs should be individualized to achieve optimal benefit and minimal adverse effects. This is usually accomplished by starting with relatively small doses and increasing them at appropriate intervals as necessary. Doses may vary widely among individuals.

Tolerance to Long-Acting Nitrates

Clients who take long-acting dosage forms of nitrates on a regular schedule develop tolerance to the vasodilating (antianginal) effects of the drug. The clients more likely to develop tolerance are those on high-dose, uninterrupted therapy. Although tolerance decreases the adverse effects of hypotension, dizziness, and headache, therapeutic effects also may be decreased. As a result, episodes of chest pain may occur more often or be more severe than expected. In addition, short-acting nitrates may be less effective in relieving acute pain.

Opinions seem divided about the best way to prevent or manage nitrate tolerance. Some authorities recommend using short-acting nitrates when needed and avoiding the
Several calcium channel blockers are available in both immediate-acting and long-acting (sustained-release) forms. The brand names often differ very little (eg, Procardia—dilatrate; Procardia XL is a long-acting formulation). It is extremely important that the correct formulation is used consistently.

**Self- or Caregiver Administration**

- **Take or give as instructed; specific instructions differ with the type of antianginal drug being taken.**
- **Take or give antianginal drugs on a regular schedule, at evenly spaced intervals. This increases drug effectiveness in preventing acute attacks of angina.**
- **With nitroglycerin and other nitrate preparations:**
  - Use according to instructions for the particular dosage form. The dosage forms were developed for specific routes of administration and are not interchangeable.
  - For sublingual nitroglycerin tablets, place them under the tongue until they dissolve. Take at the first sign of an anginal attack, before severe pain develops. If chest pain is not relieved in 5 minutes, dissolve a second tablet under the tongue. If pain is not relieved within another 5 minutes, dissolve a third tablet. If pain continues or becomes more severe, notify your health care provider immediately or report to the nearest hospital emergency room. Sit down when you take the medications. This may help to relieve your pain and prevent dizziness from the drug.
  - For the translingual solution of nitroglycerin, spray onto or under the tongue; do not inhale the spray.
  - For transmucosal tablets of nitroglycerin, place them under the upper lip or between the cheek and gum and allow them to dissolve slowly over 3 to 5 hours. Do not chew or swallow the tablets.
  - Take oral nitrates on an empty stomach with a glass of water. Oral isosorbide dinitrate is available in regular and chewable tablets; be sure each type is taken appropriately. Do not crush or chew sustained-release nitroglycerin tablets.
  - For sublingual isosorbide dinitrate tablets, place them under the tongue until they dissolve.
  - If an oral nitrate and topical nitroglycerin are being used concurrently, stagger the times of administration. This minimizes dizziness from low blood pressure and headache, which are common adverse effects of nitrate drugs.
  - For nitroglycerin ointment, use the special paper to measure the dose. Place the ointment on a nonhairy part of the upper body and apply with the applicator paper. Cover the area with plastic wrap or tape. Rotate application sites (because the ointment can irritate the skin) and wipe off the previous dose before applying a new dose. Wash hands after applying the ointment.

The measured paper must be used for accurate dosage. The paper is used to apply the ointment...
### Use in Children

The safety and effectiveness of antianginal drugs have not been established for children. Nitroglycerin has been given IV for heart failure and intraoperative control of blood pressure, with the initial dose adjusted for weight and later doses titrated to response.

### Use in Older Adults

Antianginal drugs are often used because cardiovascular disease and myocardial ischemia are common problems in older adults. Adverse drug effects, such as hypotension and syncope, are likely to occur, and they may be more severe than in younger adults. Blood pressure and ability to ambulate safely should be closely monitored, especially when drug therapy is started or dosages are increased. Ambulatory clients also should be monitored for their ability to take the drugs correctly.

With calcium channel blockers, older adults may have higher plasma concentrations of verapamil, diltiazem, nifedipine, and amlodipine. This is attributed to decreased hepatic metabolism of the drugs, probably because of decreased hepatic blood flow. In addition, older adults may experience more hypotension with verapamil, nifedipine, and felodipine than younger clients. Blood pressure should be monitored with these drugs.

### Use in Renal Impairment

Little information is available about the use of antianginal drugs in clients with impaired renal function. A few studies indicate that advanced renal failure may alter the pharmacokinetics of calcium channel blockers. Although the pharmacokinetics of diltiazem and verapamil are quite similar in clients with normal and impaired renal function, caution is still advised. With verapamil, about 70% of a dose is excreted as metabolites in urine.

Dosage reductions are considered unnecessary with verapamil and diltiazem but may be needed with nifedipine and several other dihydropyridine derivatives. With nifedipine, protein binding is decreased and the elimination half-life is prolonged with renal impairment. In a few clients, reversible elevations in blood urea nitrogen and serum creatinine have occurred. With nicardipine, plasma concentrations are higher in clients with renal impairment, and dosage should be reduced. Bepridil should be used with caution because its metabolites are excreted mainly in urine.

### Use in Hepatic Impairment

Nitrates, beta blockers (see Chap. 19), and calcium channel blockers are metabolized in the liver, and all should be used with caution in clients with significant impairment of hepatic function from reduced blood flow or disease processes.

With oral nitrates, it is difficult to predict effects. On the one hand, first-pass metabolism is reduced, which increases bioavailability (amount of active drug) of a given dose. On the other hand, the nitrate reductase enzymes that normally deactivate the drug may increase if large doses are given. In this case, more enzymes are available and the drug is metabolized more rapidly, possibly reducing therapeutic effects of a given dose. Relatively large doses of oral nitrates are sometimes given to counteract the drug tolerance (reduced hemodynamic effects) associated with chronic use. In addition, metabolism of nitroglycerin and isosorbide dinitrate normally produces active metabolites. Thus, if metabolism is re-
duced by liver impairment, drug effects may be decreased and shorter in duration.

With calcium channel blockers, impairment of liver function has profound effects on the pharmacokinetics and pharmacodynamics of most of these drugs. Thus, the drugs should be used with caution, dosages should be substantially reduced, and clients should be closely monitored for drug effects (including periodic measurements of liver enzymes). These recommendations stem from the following effects:

- An impaired liver produces fewer drug-binding plasma proteins such as albumin. This means that a greater proportion of a given dose is unbound and therefore active.
- In clients with cirrhosis, bioavailability of oral drugs is greatly increased and metabolism (of both oral and parenteral drugs) is greatly decreased. Both of these effects increase plasma levels of drug from a given dose (essentially an overdose). The effects result from shunting of blood around the liver so that drug molecules circulating in the bloodstream do not come in contact with drug-metabolizing enzymes and therefore are not metabolized. For example, the bioavailability of verapamil, nifedipine, felodipine, and nisoldipine is approximately double and their clearance is approximately one third that of clients without cirrhosis.
- Although hepatotoxicity is uncommon, clinical symptoms of hepatitis, cholestasis, or jaundice and elevated liver enzymes (eg, alkaline phosphatase, creatine kinase [CK], lactate dehydrogenase [LDH], aspartate aminotransferase [AST], alanine aminotransferase [ALT]) have occurred, mainly with diltiazem, nifedipine, verapamil. These changes resolve if the causative drug is stopped.

Use in Critical Illness

Antianginal drugs have multiple cardiovascular effects and may be used alone or in combination with other cardiovascular drugs in clients with critical illness. They are probably used most often to manage severe angina, severe hypertension, or serious cardiac dysrhythmias. For example, IV nitroglycerin may be used for angina and hypertension; an IV beta blocker or calcium channel blocker may be used to improve cardiovascular function with angina, hypertension, or supraventricular tachydysrhythmias. With any of these drugs, dosage must be carefully titrated and clients must be closely monitored for hypotension and other drug effects.

In addition, absorption of oral drugs or topical forms of nitroglycerin may be impaired in clients with extensive edema, heart failure, hypotension, or other conditions that impair blood flow to the gastrointestinal tract or skin.

Home Care

The role of the home care nurse may vary, depending largely on the severity of the client’s illness. Initially, the nurse should assess the frequency and severity of anginal attacks and how the attacks are managed. In addition, the nurse can assess the home setting for lifestyle and environmental factors that may precipitate myocardial ischemia. When causative factors are identified, plans can be developed to avoid or minimize them. Other aspects of home care may include monitoring the client’s response to antianginal medications; teaching clients and caregivers how to use, store, and replace medications to ensure a constant supply; and discussing circumstances for which the client should seek emergency care.

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td>Hypotension is an adverse effect of antianginal drugs. Bradycardia is an adverse effect of propranolol and nadolol. Dosage adjustments may be necessary if these effects occur.</td>
</tr>
<tr>
<td>a. Check blood pressure and heart rate before each dose of an antianginal drug. Withhold the drug if systolic blood pressure is below 90 mm Hg. If the dose is omitted, record and report to the health care provider.</td>
<td>To increase effectiveness in preventing acute attacks of angina</td>
</tr>
<tr>
<td>b. Give antianginal drugs on a regular schedule, at evenly spaced intervals.</td>
<td>To minimize risks of additive hypotension and headache</td>
</tr>
<tr>
<td>c. If oral nitrates and topical nitroglycerin are being used concurrently, stagger times of administration.</td>
<td></td>
</tr>
<tr>
<td>d. For sublingual nitroglycerin and isosorbide dinitrate, instruct the client to place the tablets under the tongue until they dissolve.</td>
<td>Sublingual tablets of nitroglycerin are volatile. Once the bottle has been opened, they become ineffective after approximately 6 mo and should be replaced.</td>
</tr>
<tr>
<td>e. For oral isosorbide dinitrate, regular and chewable tablets are available. Be sure each type of tablet is taken appropriately.</td>
<td></td>
</tr>
<tr>
<td>f. For sublingual nitroglycerin, check the expiration date on the container.</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
NURSING ACTIONS

| g. | To apply nitroglycerin ointment, use the special paper to measure the dose. Place the ointment on a nonhairy part of the body, and apply with the applicator paper. Cover the area with plastic wrap or tape. Rotate application sites and wipe off previous ointment before applying a new dose. |
| h. | For nitroglycerin patches, apply at the same time each day to clean, dry, hairless areas on the upper body or arms. Rotate sites. Avoid applying below the knee or elbow or in areas of skin irritation or scar tissue. |
| i. | For intravenous (IV) nitroglycerin, dilute the drug and give by continuous infusion, with frequent monitoring of blood pressure and heart rate. Use only with the special administration set supplied by the manufacturer to avoid drug adsorption onto tubing. |
| j. | With IV verapamil, inject slowly, over 2–3 min. |

2. Observe for therapeutic effects

| a. | Relief of chest pain with acute attacks |
| b. | Reduced incidence and severity of acute attacks with prophylactic antianginal drugs |
| c. | Increased exercise tolerance |

3. Observe for adverse effects

| a. | With nitrates, observe for hypotension, dizziness, light-headedness, tachycardia, palpitations, and headache. |
| b. | With beta-adrenergic blocking agents, observe for hypotension, bradycardia, bronchospasm, and heart failure. |
| c. | With calcium channel blockers, observe for hypotension, dizziness, lightheadedness, weakness, peripheral edema, headache, heart failure, pulmonary edema, nausea, and constipation. Bradycardia may occur with verapamil and diltiazem; tachycardia may occur with nifedipine and nicardipine. |

4. Observe for drug interactions

| a. | Drugs that increase effects of antianginal drugs: |
| (1) | Antidysrhythmics, antihypertensive drugs, diuretics, phenothiazine antipsychotic agents |

RATIONALE/EXPLANATION

| g. | The measured paper must be used for accurate dosage. The paper is used to apply the ointment because the drug is readily absorbed through the skin. Skin contact should be avoided except on the designated area of the body. Plastic wrap or tape aids absorption and prevents removal of the drug. It also prevents soiling of clothes and linens. Application sites should be rotated because the ointment can irritate the skin. |
| h. | To promote effective and consistent drug absorption. The drug is not as well absorbed from distal portions of the extremities because of decreased blood flow. Rotation of sites decreases skin irritation. |
| i. | The drug should not be given by direct IV injection. The drug is potent and may cause hypotension. Dosage (flow rate) is adjusted according to response (pain relief or drop in systolic blood pressure of 20 mm Hg). |
| j. | To decrease hypotension and other adverse effects |

Sublingual nitroglycerin usually relieves pain within 5 min. If pain is not relieved, two additional tablets may be given, 5 min apart. If pain is not relieved after three tablets, report to the health care provider or seek emergency care. |

Adverse effects are extensions of pharmacologic action. Vasodilation causes hypotension, which in turn causes dizziness from cerebral hypoxia and tachycardia from compensatory sympathetic nervous system stimulation. Hypotension can decrease blood flow to coronary arteries and precipitate angina pectoris or myocardial infarction. Hypotension is most likely to occur within an hour after drug administration. Vasodilation also causes headache, the most common adverse effect of nitrates. |

Beta blockers lower blood pressure by decreasing myocardial contractility and cardiac output. Excessive bradycardia may contribute to hypotension and cardiac dysrhythmias. Bronchospasm is more likely to occur in clients with asthma or other chronic respiratory problems. |

Adverse effects result primarily from reduced smooth muscle contractility. These effects, except constipation, are much more likely to occur with nifedipine and other dihydropyridines. Nifedipine may cause profound hypotension, which activates the compensatory mechanisms of the sympathetic nervous system and the renin–angiotensin–aldosterone system. Peripheral edema may require the administration of a diuretic. Constipation is more likely to occur with verapamil. Diltiazem reportedly causes few adverse effects. |

Additive hypotension

(continued)
**NURSING ACTIONS**

(2) Cimetidine

(3) Digoxin

b. Drugs that decrease effects of antianginal drugs:
   (1) Adrenergic drugs (eg, epinephrine, isoproterenol)
   (2) Anticholinergic drugs
   (3) Calcium salts
   (4) Carbamazepine, phenytoin, rifampin

**RATIONALITY/EXPLANATION**

May increase beta-blocking effects of propranolol by slowing its hepatic clearance and elimination. Increases effects of all calcium channel blockers by inhibiting hepatic metabolism and increasing serum drug levels.

Additive bradycardia when given with beta-blocking agents

Adrenergic drugs, which stimulate beta receptors, can reverse bradycardia induced by beta blockers.

Drugs with anticholinergic effects can increase heart rate, offsetting slower heart rates produced by beta blockers.

May decrease therapeutic effectiveness of calcium channel blockers.

May decrease effects of calcium channel blockers by inducing hepatic enzymes and thereby increasing their rate of metabolism.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Assess Mrs. Sinatro’s knowledge about CAD and her readiness to learn about her new medications and other methods to manage this problem. Give Mrs. Sinatro written handouts about CAD and written information about her antianginal medications. Demonstrate how to apply the patch, stressing to rotate sites and not use hairy or scarred areas because they may decrease drug absorption. The patch is removed at night because the oxygen demand of the heart is usually less at rest, and continuous application can increase the development of drug tolerance. Discuss side effects, including headache and hypotension, that can cause dizziness and falls.

Teaching must include how to manage an episode of chest pain. First stress the importance of never ignoring chest pain. Some clients may deny they are experiencing chest pain and delay treatment. Tell her to rest if chest pain occurs. If pain does not subside, instruct her to place a nitroglycerin tablet under the tongue to dissolve and avoid swallowing the tablet. This can be repeated every 5 minutes up to three nitroglycerin tablets. If the pain has not subsided with rest and nitroglycerin, the client or family should call 911. The client should not drive or be driven by family to the hospital or clinic because she may be having a heart attack (myocardial infarction). The nurse should also stress the importance of keeping nitroglycerin with her at all times and making sure the prescription is refilled before it reaches the expiration date. The tablets should be kept in the original amber bottle to protect them from sunlight and stored away from moisture and excessive heat.

---

**How Can You Avoid This Medication Error?**

**Answer:** Actually, there are two errors in this situation. A nurse can only safely administer medication that she has prepared. In this situation, after the medication has been spread on the paper, the dosage will be unclear. Also, a nurse or a family member should never touch Nitropaste without wearing gloves. Hands should be washed after administration. This potent vasodilator is absorbed through the skin, causing systemic effects such as dizziness and headache.

---

**SELECTED REFERENCES**


Critical Thinking Scenario

Betty Smith is in the cardiac care unit being managed for cardiogenic shock following an acute anterior myocardial infarction (MI). She is currently on the following IV infusion: dobutamine (Dobutrex) 5 mcg/kg/min and dopamine hydrochloride (Intropin) 5 mcg/kg/min.

Reflect on:

1. Define shock. How does cardiogenic shock differ from hypovolemic shock, and how will this affect management?
2. What symptoms would likely occur when a client is experiencing cardiogenic shock?
3. Review the autonomic nervous system (ANS). Describe the ANS effects of Mrs. Smith’s medications and how they will be used to manage shock.
4. Dopamine’s effects differ depending on dosage. What effects will you most likely see in Mrs. Smith?

Drugs Used in Hypotension and Shock

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify clients at risk for development of hypovolemia and shock.
2. Identify common causes of hypotension and shock.
3. Discuss assessment of a client in shock.
4. Describe therapeutic and adverse effects of vasopressor drugs used in the management of hypotension and shock.

Types of Shock

There are three general categories of shock that are based on the circulatory mechanisms involved. These mechanisms are intravascular volume, the ability of the heart to pump, and vascular tone.

Hypovolemic shock involves a loss of intravascular fluid volume that may be due to actual blood loss or relative loss from fluid shifts within the body.

Cardiogenic shock, also called pump failure, occurs when the myocardium has lost its ability to contract efficiently and maintain an adequate cardiac output.

Distributive or vasogenic shock is characterized by severe, generalized vasodilation, which results in severe hypotension and impairment of blood flow. Distributive shock is further divided into anaphylactic, neurogenic, and septic shock.

- Anaphylactic shock results from a hypersensitivity (allergic) reaction to drugs or other substances (see Chap. 18).
- **Neurogenic shock** results from inadequate sympathetic nervous system (SNS) stimulation. The SNS normally maintains sufficient vascular tone (ie, a small amount of vasoconstriction) to support adequate blood circulation. Neurogenic shock may occur with depression of the vasomotor center in the brain or decreased sympathetic outflow to blood vessels.

- **Septic shock** can result from almost any organism that gains access to the bloodstream but is most often associated with gram-negative and gram-positive bacterial infections and fungi.

It is important to know the etiology of shock because management varies among the types. The types of shock, with their causes and symptoms, are summarized in Table 54–1.

### ANTISHOCK DRUGS

Drugs used in the management of shock are primarily the adrenergic drugs, which are discussed more extensively in Chapter 18. In this chapter, the drugs are discussed only in relation to their use in hypotension and shock. In these conditions, drugs with alpha-adrenergic activity (eg, norepinephrine, phenylephrine) are used to increase peripheral vascular resistance and raise blood pressure. Drugs with beta-adrenergic activity (eg, dobutamine, isoproterenol) are used to increase myocardial contractility and heart rate, which in turn raises blood pressure. Some drugs have both alpha- and beta-adrenergic activity (eg, dopamine, epinephrine). In many cases, a combination of drugs is used, depending on the type of shock and the client’s response to treatment. In an emergency, the drugs may be used to maintain adequate perfusion of vital organs until sufficient fluid volume is replaced and circulation is restored.

Adrenergic drugs with beta activity may be relatively contraindicated in shock states precipitated or complicated by cardiac dysrhythmias. Beta-stimulating drugs also should be used cautiously in cardiogenic shock after myocardial infarction because increased contractility and heart rate will increase myocardial oxygen consumption and extend the area of infarction.

Individual drugs are described in the following section; indications for use and dosage ranges are listed in Drugs at a Glance: Drugs Used for Hypotension and Shock.

### INDIVIDUAL DRUGS

**Dopamine** is a naturally occurring catecholamine that functions as a neurotransmitter. Dopamine exerts its actions by stimulating alpha, beta, or dopaminergic receptors, depending on the dose being used. In addition, dopamine acts indirectly by releasing norepinephrine from sympathetic nerve endings and the adrenal glands. Peripheral dopamine receptors are located in splanchnic and renal vascular beds. At low doses (0.5 to 10 mcg/kg/min), dopamine selectively stimulates dopaminergic receptors that may increase renal blood flow and glomerular filtration rate (GFR). It has long been accepted that stimulation of dopamine receptors by low doses of exogenous dopamine produces vasodilation in the renal circulation and increases urine output. More recent studies indicate that low-dose dopamine enhances renal function only when cardiac function is improved. At doses greater than 3 mcg/kg/min, dopamine binds to beta and alpha receptors and the selectivity of dopaminergic receptors is lost beyond 10 mcg/kg/min. At doses that stimulate beta receptors (3 to 20 mcg/kg/min), there is an increase in heart rate, myocardial contractility, and blood pressure. At the highest doses (20 to 50 mcg/kg/min), beta activity remains, but increasing alpha stimulation (vasoconstriction) may overcome its actions.

Dopamine is useful in hypovolemic and cardiogenic shock. Adequate fluid therapy is necessary for the maximal pressor effect of dopamine. Acidosis decreases the effectiveness of dopamine.

**Dobutamine** is a synthetic catecholamine developed to provide less vascular activity than dopamine. It acts mainly on beta1 receptors in the heart to increase the force of myocardial contraction with a minimal increase in heart rate. Dobutamine also may increase blood pressure with large doses. It is less likely to cause tachycardia, dysrhythmias, and increased myocardial oxygen demand than dopamine and isoproterenol. It is most useful in cases of shock that require increased cardiac output without the need for blood pressure support. It is recommended for short-term use only. It may be used with dopamine to augment the beta1 activity that is sometimes overridden by alpha effects when dopamine is used alone at doses greater than 10 mcg/kg/min.

Dobutamine has a short plasma half-life and therefore must be administered by continuous IV infusion. A loading...
## Drugs at a Glance: Drugs Used for Hypotension and Shock

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Dopamine (Intropin)** | Increase cardiac output  
Treat hypotension  
Increase urine output | Adults: IV 2 to 5 mcg/kg/min initially, gradually increasing to 20–50 mcg/kg/min if necessary.  
Prepare by adding 200 mg of dopamine to 250 mL of IV fluid for a final concentration of 800 mcg/mL or to 500 mL IV fluid for a final concentration of 400 mcg/mL.  
Children: Same as adults | |
| **Dobutamine (Dobutrex)** | Increase cardiac output | Adults: IV 2.5–15 mcg/kg/min, increased to 40 mcg/kg/min if necessary.  
Reconstitute the 250-mg vial with 10 mL of sterile water or 5% dextrose injection. The resulting solution should be diluted to at least 50 mL with IV solution before administering (5000 mcg/mL).  
Add 250 mg of drug to 500 mL of diluent for a concentration of 500 mcg/mL.  
Children: IV infusion, 0.025 to 0.3 mcg/kg/min  
IV direct injection, 5 to 10 mcg/kg, slowly SC, 0.01 mg/kg of 1:1000 solution | |
| **Epinephrine (Adrenalin)** | Treat anaphylactic shock  
Reverse bronchoconstriction  
Increase cardiac output  
Treat cardiac arrest | Adults: IV 1–4 mcg/min. Prepare the solution by adding 2 mg (2 mL) of epinephrine injection 1:1000 to 250 or 500 mL of IV fluid. The final concentration is 8 or 4 mcg/mL, respectively.  
IV direct injection, 100–1000 mcg of 1:10,000 injection, every 5–15 min, injected slowly. Prepare the solution by adding 1 mL epinephrine 1:1000 to 9 mL sodium chloride injection. The final concentration is 100 mcg/mL.  
Cardiac arrest, IV injection, 0.5–1.0 mg of 1:10,000 solution, repeated every 5 min as needed  
Children: IV infusion, 0.05–0.3 mcg/kg/min | |
| **Isoproterenol (Isuprel)** | Treat atropine-refractory bradycardias | Adults: IV infusion, 0.5–10 mcg/min. Prepare solution by adding 2 mg to 250 mL of IV fluid. Final concentration is 8 mcg/mL.  
Children: IV infusion, 0.05–0.3 mcg/kg/min | |
| **Metaraminol (Aramine)** | Treat hypotension due to spinal anesthesia | Adults: IM 2–10 mg  
IV injection, 0.5–5 mg  
IV infusion, add 15–500 mg of metaraminol to 250 or 500 mL of IV fluid. Adjust flow rate (dosage) to maintain the desired blood pressure.  
Children: IM 0.1 mg/kg  
IV injection, 0.01 mg/kg  
IV infusion, 1 mg/25 mL of diluent. Adjust flow rate to maintain the desired blood pressure. | |
| **Milrinone (Primacor)** | Increase cardiac output in cardiogenic shock | Adults: IV injection (loading dose), 50 mcg/kg over 10 min.  
IV infusion (maintenance, dose), 0.375–0.75 mcg/kg/min diluted in 0.9% or 0.45% sodium chloride or 5% dextrose solution. Maximum dose, 1.13 mg/kg/d.  
Children: IV infusion, 0.03–0.1 mcg/kg/min | |
| **Norepinephrine (Levophed)** | Treat hypotension  
Increase cardiac output | Adults: IV infusion, 2–4 mcg/min, to a maximum of 20 mcg/min. Prepare solution by adding 2 mg to 500 mL of IV fluid. Final concentration is 4 mcg/mL.  
Children: IV infusion, 0.03–0.1 mcg/kg/min | |
| **Phenylephrine (Neo-Synephrine)** | Treat hypotension | Adults: IV infusion, 100–180 mcg/min initially, then 40–60 mcg/min. Prepare solution by adding 10 mg of phenylephrine to 250 or 500 mL of IV fluid. Final concentration is 20 or 40 mcg/mL, respectively.  
IV injection, 0.1–0.5 mcg every 10–15 min.  
Children: SC, IM 0.5–1 mg/25 lbs | |
Epinephrine is a naturally occurring catecholamine produced by the adrenal glands. At low doses, epinephrine stimulates beta receptors, which increases cardiac output by increasing the rate and force of myocardial contractility. It also causes bronchodilation. Larger doses act on alpha receptors to increase blood pressure. Epinephrine is the drug of choice for management of anaphylactic shock because of its rapid onset of action and anti-allergic effects. It prevents the release of histamine and other mediators that cause symptoms of anaphylaxis, thereby reversing vasodilation and bronchoconstriction. In early management of anaphylaxis, it may be given subcutaneously to produce therapeutic effects within 5 to 10 minutes, with peak activity in approximately 20 minutes.

Epinephrine is also used to manage other kinds of shock and is usually given by continuous IV infusion. However, bolus doses may be given in emergencies, such as cardiac arrest. It may produce excessive cardiac stimulation, ventricular dysrhythmias, and reduced renal blood flow.

Epinephrine has an elimination half-life of about 2 minutes and is rapidly inactivated to metabolites, which are then excreted by the kidneys.

Isoproterenol is a synthetic catecholamine that acts exclusively on beta receptors to increase heart rate, myocardial contractility, and systolic blood pressure. However, it also stimulates vascular beta receptors, which causes vasodilation, and may decrease diastolic blood pressure. For this reason, isoproterenol has limited usefulness as a pressor agent. It also may increase myocardial oxygen consumption and decrease coronary artery blood flow, which in turn causes myocardial ischemia. Cardiac dysrhythmias may result from excessive beta stimulation. Because of these limitations, use of isoproterenol is limited to shock associated with slow heart rates and myocardial depression.

Metaraminol is used mainly for hypotension associated with spinal anesthesia. It acts indirectly by releasing norepinephrine from sympathetic nerve endings. Thus, its vasoconstrictive actions are similar to those of norepinephrine, except that metaraminol is less potent and has a longer duration of action.

Milrinone is discussed in Chapter 51 as a treatment for heart failure. It is also used to manage cardiogenic shock in combination with other inotropic agents or vasopressors. It increases cardiac output and decreases systemic vascular resistance without significantly increasing heart rate or myocardial oxygen consumption. The increased cardiac output improves renal blood flow, which then leads to increased urine output, decreased circulating blood volume, and decreased cardiac workload.

Norepinephrine (Levophed) is a pharmaceutical preparation of the naturally occurring catecholamine norepinephrine. It stimulates alpha-adrenergic receptors and thus increases blood pressure primarily by vasoconstriction. It also stimulates beta, receptors and therefore increases heart rate, force of myocardial contraction, and coronary artery blood flow. It is useful in cardiogenic and septic shock, but reduced renal blood flow limits its prolonged use. Norepinephrine is used mainly with patients who are unresponsive to dopamine or dobutamine. As with all drugs used to manage shock, blood pressure should be monitored frequently during infusion.

Phenylephrine (Neo-Synephrine) is an adrenergic drug that stimulates alpha-adrenergic receptors. As a result, it constricts arterioles and raises systolic and diastolic blood pressures. Phenylephrine resembles epinephrine but has fewer cardiac effects and a longer duration of action. Reduction of renal and mesenteric blood flow limit prolonged use.

### Nursing Process

#### Assessment

Assess the client’s condition in relation to hypotension and shock.

- Check blood pressure; heart rate; urine output; skin temperature and color of extremities; level of consciousness; orientation to person, place, and time; and adequacy of respiration. Abnormal values are not specific indicators of hypotension and shock, but they may indicate a need for further evaluation. In general, report blood pressure below 90/60, heart rate above 100, and urine output below 30 mL/hour.
- Assess electrocardiogram (ECG) and cardiac and hemodynamic status for indications of impaired cardiac function.
- Monitor available laboratory reports for abnormal values (eg, decreased oxygen saturation levels indicate decreased oxygenation of tissues; abnormal arterial blood gases may indicate metabolic acidosis; an increased hematocrit may indicate hypovolemia; an increased eosinophil count may indicate anaphylaxis; the presence of bacteria in blood cultures may indicate sepsis; an increased serum creatinine and blood urea nitrogen may indicate impending renal failure).

#### Nursing Diagnoses

- Decreased Cardiac Output related to altered stroke volume
- Ineffective Tissue Perfusion: Decreased related to compromised cardiac output
- Deficient Fluid Volume related to fluid loss or vasodilation
- Anxiety related to potentially life-threatening illness
Risk for Injury: Myocardial infarction, stroke, or renal damage related to decreased blood flow to vital organs

Planning/Goals
The client will:
• Have improved tissue perfusion and relief of symptoms
• Have improved vital signs
• Be guarded against recurrence of hypotension and shock if possible
• Be assessed for therapeutic and adverse effects of adrenergic drugs
• Avoid preventable adverse effects of adrenergic drugs

Interventions
Use measures to prevent or minimize hypotension and shock.
• General measures include those to maintain the airway, maintain fluid balance, control hemorrhage, manage infections, prevent hypoxia, and control other causative factors.
• Learn to recognize impending shock so management can be initiated early. Do not wait until symptoms are severe. The earlier the management, the greater the likelihood of reversing shock and preventing end-organ damage.
• Assist in recognizing and managing the underlying cause of shock in a particular client (eg, replacing fluids; preventing further loss of blood or other body fluids).

Monitor clients during shock and vasopressor drug therapy.
• Titrate adrenergic drug infusions to maintain blood pressure and tissue perfusion without causing hypertension.
• Check blood pressure and pulse constantly or at least every 5 to 15 minutes during acute shock and vasopressor drug therapy. Intra-arterial monitoring may be more reliable than cuff blood pressures in shock conditions.
• Monitor mental status, distal pulses, urine output, and skin temperature and color closely to assess tissue perfusion.
• Assess venipuncture sites frequently for signs of infiltration or extravasation. Have phenolamine (Regitine), an alpha-adrenergic blocking agent that reverses vasoconstriction, readily available in any setting where IV adrenergic drugs are used. If infiltration occurs, instill phenolamine through the IV catheter prior to removal.
• Keep family members informed about client status, management measures, including drug therapy, monitoring equipment, and the need for close observation of vital signs, IV infusion site, urine output, and so forth.

Evaluation
Observe for improved vital signs, color and temperature of skin, urine output, and mental responsiveness.

PRINCIPLES OF THERAPY

Goal of Therapy
The goal of adrenergic drug therapy in hypotension and shock is to restore and maintain adequate tissue perfusion, especially to vital organs.

Choice of Drug
The choice of drug depends primarily on the pathophysiology involved. For cardiogenic shock and decreased cardiac output, dopamine or dobutamine is given. With severe heart failure characterized by decreased cardiac output and high peripheral vascular resistance, vasodilator drugs (eg, nitroprusside, nitroglycerin) may be given along with the cardiotonic drug. The combination increases cardiac output and decreases cardiac workload by decreasing preload and afterload. However, vasodilators should not be used alone because of the risk of severe hypotension and further compromising tissue perfusion. Milrinone may be given when other drugs fail.

For distributive shock characterized by severe vasodilation and decreased peripheral vascular resistance, a vasoconstrictor or vasopressor drug, such as norepinephrine, is the drug of first choice. Drug dosage must be carefully titrated to avoid excessive vasoconstriction and hypertension, which causes impairment rather than improvement in tissue perfusion.

Guidelines for Management of Hypotension and Shock

• Vasopressor drugs are less effective in the presence of inadequate blood volume, electrolyte abnormalities, and acidosis. These conditions also must be treated if present. In addition, normalizing the blood pH and body temperature facilitates the release of oxygen from hemoglobin to the cells.
• Minimal effective doses of adrenergic drugs are recommended because of their extreme vasoconstrictive effects that can produce lactic acidosis at the cell level and create metabolic acidosis. Because catecholamine drugs have short half-lives, varying the flow rate of IV infusions can easily control dosage. Dosage and flow rate usually are titrated to maintain a low-normal blood pressure. Such titration depends on frequent and accurate blood pressure measurements.
• Septic shock due to bacterial infection requires appropriate antibiotic therapy in addition to other management measures (see Section VI). If an abscess is the source of infection, it must be surgically drained.
• Hypovolemic shock is most effectively managed by IV fluids that replace the type of fluid lost; that is, blood loss should be replaced with whole blood; gastrointestinal...
nal losses should be replaced with solutions containing electrolytes (eg, Ringer’s lactate or sodium chloride solutions with added potassium chloride).

- Cardiogenic shock may be complicated by pulmonary congestion, for which diuretic drugs are indicated and IV fluids are contraindicated (except to maintain a patent IV line).
- Anaphylactic shock is often managed by nonadrenergic drugs as well as epinephrine. For example, the histamine-induced cardiovascular symptoms (eg, vasodilation and increased capillary permeability) are thought to be mediated through both types of histamine receptors. Thus, management may include a histamine-1 receptor blocker (eg, diphenhydramine 1 mg/kg IV) and a histamine-2 receptor blocker (eg, cimetidine 4 mg/kg IV), given over at least 5 minutes. In addition, IV corticosteroids are often given, such as methylprednisolone (20 to 100 mg) or hydrocortisone (100 to 500 mg). Doses may need to be repeated every 2 to 4 hours. Corticosteroids increase tissue responsiveness to adrenergic drugs in approximately 2 hours but do not produce anti-inflammatory effects for several hours.

Use in Children

Little information is available about adrenergic drugs for the management of hypotension and shock in children. Children who lose up to one fourth of their circulating blood volume may produce minimal changes in arterial blood pressure and a relatively low heart rate. In general, management is the same as for adults, with drug dosages adjusted for weight.

Use in Older Adults

Older adults often have disorders such as atherosclerosis, peripheral vascular disease, and diabetes mellitus and may not demonstrate common symptoms of volume depletion (eg, thirst, skin turgor changes). Also, when adrenergic drugs are given, their vasoconstricting effects may decrease blood flow and increase risks of tissue ischemia and thrombosis. Careful monitoring of vital signs, skin color and temperature, urine output, and mental status is essential.

Use in Renal Impairment

Although adrenergic drugs may be lifesaving, they can reduce renal blood flow and cause renal failure because of their vasoconstrictive effects. Renal impairment may occur in clients with previously normal renal function and may be worsened in clients whose renal function is already impaired. Low-dose dopamine is commonly used to increase renal perfusion in oliguric clients, but the effectiveness of this practice is being questioned.

In men with benign prostatic hypertrophy, oliguric renal failure may need to be differentiated from post-renal failure (urinary retention) because some adrenergic drugs (eg, epinephrine, norepinephrine, phenylephrine) cause urinary retention.

Most adrenergic drugs are metabolized in the liver and the metabolites are excreted in the urine. However, little accumulation of the drugs or metabolites is likely because the drugs have short half-lives.

Use in Hepatic Impairment

Catecholamine drugs are metabolized by monoamine oxidase (MAO) and catechol-O-methyl transferase (COMT). MAO is widely distributed in most body tissues, whereas COMT is located mainly in the liver. Thus, the drugs are eliminated mainly by liver metabolism and must be used cautiously in clients with impaired liver function. Clients should be monitored closely and drug dosage should be adjusted as symptoms warrant. However, the half-life of most adrenergic drugs is very brief, and this decreases the chances of drug accumulation in hepatically impaired clients.

Use in Critical Illness

The adrenergic catecholamines (eg, dopamine, dobutamine, epinephrine, norepinephrine) are widely used in clients with a low cardiac output that persists despite adequate fluid replacement and correction of electrolyte imbalance. By improving circulation, the drugs also help to prevent tissue injury from ischemia (eg, renal failure).

Although the drugs may be used initially in almost any setting, most clients with hypotension and shock are managed in critical care units. Dobutamine and dopamine are usually the cardiotonic agents of choice in critically ill clients. Dopamine varies in clearance rate in adult and pediatric clients. However, this variance may result from the use of non–steady-state plasma concentrations in calculating the clearance rate. When a dopamine IV infusion is started, it may take 1 to 2 hours to achieve a steady-state plasma level. Relatively large doses of dopamine are given for cardiotonic and vasoconstrictive effects.

Epinephrine and norepinephrine are also widely used in critically ill clients. Recommended infusion rates in critically ill clients vary from 0.01 to 0.15 mcg/kg/min for epinephrine and from 0.06 to 0.15 mcg/kg/min for norepinephrine. All clients receiving drugs for management of hypotension and shock should be closely monitored regarding drug dosage, vital signs, relevant laboratory test results, and other indicators of clinical status. Continuous invasive hemodynamic monitoring with an arterial catheter and a pulmonary artery catheter may be indicated to titrate drug dosage and monitor the response to drug therapy. Close monitoring of the critically ill is essential as these clients often have multiple organ impairments and are clinically unstable.
Drugs Used in Hypotension and Shock

**NURSING ACTIONS**

1. **Administer accurately**
   - a. Use a large vein for the venipuncture site.
   - b. Dilute drugs for continuous infusion in 250 or 500 mL of intravenous (IV) fluid. A 5% dextrose injection is compatible with all of the drugs and is most often used. For use of other IV fluids, consult drug manufacturers’ literature. Dilute drugs for bolus injections to at least 10 mL with sodium chloride or water for injection.
   - c. Use a separate IV line or a “piggyback” IV setup.
   - d. Use an infusion pump
   - e. Discard any solution with a brownish color or precipitate.
   - f. Start the adrenergic drug slowly, and increase as necessary to obtain desired responses in blood pressure and other parameters of cardiovascular function.
   - g. Stop the drug gradually.
   - h. Manage the client, not the monitor.

2. **Observe for therapeutic effects**
   - a. Systolic blood pressure of 80–100 mm Hg
   - b. Heart rate of 60–100, improved quality of peripheral pulses
   - c. Improved urine output
   - d. Improved skin color and temperature
   - e. Pulmonary capillary wedge pressure between 15 and 20 mm Hg in cardiogenic shock

3. **Observe for adverse effects**
   - a. Bradycardia
   - b. Tachycardia
   - c. Dysrhythmias

**RATIONALE/EXPLANATION**

To decrease risks of extravasation

To avoid adverse effects, which are more likely to occur with concentrated drug solutions

This allows the adrenergic drug solution to be regulated or discontinued without disruption of other IV lines.

To administer the drug at a consistent rate and prevent wide fluctuations in blood pressure and other cardiovascular functions

Most of the solutions are stable for 24–48 h. Epinephrine and isoproterenol decompose on exposure to light, producing a brownish discoloration.

Flow rate (dosage) is titrated according to client response.

Abrupt discontinuance of pressor drugs may cause rebound hypotension.

Abnormal monitor readings (ie, blood pressure monitors) should be confirmed with a manual reading before adjusting medication dosage.

These levels are adequate for tissue perfusion. Higher levels may increase cardiac workload, resulting in reflex bradycardia and decreased cardiac output. However, higher levels may be necessary to maintain cerebral blood flow in older adults.

These indicate improved tissue perfusion and cardiovascular function.

Increased urine output indicates improved blood flow to the kidneys.

Normal pulmonary capillary wedge pressure is 6–12 mm Hg. Higher levels are required to maintain cardiac output in cardiogenic shock.

Reflex bradycardia may occur with norepinephrine, metaraminol, and phenylephrine.

This is most likely to occur with isoproterenol, but may occur with dopamine and epinephrine.

Serious dysrhythmias may occur with any of the agents used in hypotension and shock. Causes may include high doses that result in excessive adrenergic stimulation of the heart, low doses that result in inadequate perfusion of the myocardium, or the production of lactic acid by ischemic tissue.

(continued)
First, it is important to impress on Brent that anaphylactic shock is life-threatening. Explain that his allergic reaction when stung by a bee is severe and it can happen very quickly. The histamine released in the reaction affects his circulation and his breathing. When he experiences a bee sting, he should immediately take the Benadryl to decrease the amount of histamine that is released and decrease the severity of the reaction. If he experiences breathing difficulty or feels dizzy, he may need to use the Epi Pen. Instruct him to take off the cap, push the needle right through his pants into his thigh, and inject the medication. (If he has an EpiPen Auto-Injector, the medication will be dispensed automatically after the needle is inserted into the thigh.) He then needs to have someone drive him to the nearest ED.

It is important to instruct Brent to keep an EpiPen with him at all times (home, car, office) and especially when outdoors (eg, in his backpack when hiking). Family may also need to be instructed because anaphylaxis occurs very quickly and, as the patient becomes hypoxic, judgment and ability to use the EpiPen may be impaired.

**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>d. Hypertension</th>
</tr>
</thead>
<tbody>
<tr>
<td>e. Hypotension</td>
</tr>
<tr>
<td>f. Angina pectoris—chest pain, dyspnea, palpitations</td>
</tr>
<tr>
<td>g. Tissue necrosis if extravasation occurs</td>
</tr>
</tbody>
</table>

**RATIONALE/EXPLANATION**

This is most likely to occur with high doses of norepinephrine, metaraminol, and phenylephrine.

This is most likely to occur with low doses of dopamine and isoproterenol, owing to vasodilation.

All pressor agents may increase myocardial oxygen consumption and induce myocardial ischemia.

This may occur with solutions containing dopamine, norepinephrine, metaraminol, and phenylephrine, owing to local vasoconstriction and impaired blood supply. Tissue necrosis may be prevented by injecting 5–10 mg of phentolamine (Regitine) through the catheter or subcutaneously, around the area of extravasation. Phentolamine is most effective if injected within 12 h after extravasation.

**How Can You Avoid This Medication Error?**

**Answer:** Considering that extravasation of this medication can cause very significant tissue damage, this was a very poor decision. IV medications sometimes infuse at very slow rates, so that swelling is not present when the IV solution has infiltrated. It is the responsibility of the nurse to be knowledgeable regarding which drugs are vesicants and to take special precautions. Vasopressor agents significantly constrict the vessels of the surrounding tissue, thus impeding blood flow and causing necrosis. Whenever possible, infuse these medications into central lines. When extravasation occurs, phentolamine (Regitine), an alpha-adrenergic blocker, can be injected into the tissue to reverse vasoconstriction and restore blood flow.

**Review and Application Exercises**

1. **How do adrenergic drugs improve circulation in hypotension and shock?**
2. **Which adrenergic drug should be readily available for management of anaphylactic shock?**
3. What are major adverse effects of adrenergic drugs?

4. How would you assess the client for therapeutic or adverse effects of an adrenergic drug being given by continuous IV infusion?

5. Why is it important to prevent extravasation of adrenergic drug infusions into tissues surrounding the vein?

6. In hypovolemic shock, should fluid volume be replaced before or after an adrenergic drug is given? Why?

SELECTED REFERENCES


Antihypertensive Drugs

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe factors that control blood pressure.
2. Define/describe hypertension.
3. Identify clients at risk for development of hypertension and its sequelae.
4. Discuss nonpharmacologic measures to control hypertension.
5. Review the effects of alpha-adrenergic blockers, beta-adrenergic blockers, calcium channel blockers, and diuretics in hypertension.
6. Discuss angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in terms of mechanisms of action, indications for use, adverse effects, and nursing process implications.
7. Describe the rationale for using combination drugs in the management of hypertension.
8. Discuss interventions to increase therapeutic effects and minimize adverse effects of antihypertensive drugs.
9. Discuss the use of antihypertensive drugs in special populations.

Critical Thinking Scenario
Wally Ramos, a 35-year-old man, returns to the clinic for his third blood pressure check. Because his blood pressure is still elevated (178/96), the physician decides to start him on an angiotensin-converting enzyme inhibitor, captopril. He states, “I just can’t believe I have high blood pressure. I feel just fine. I have heard stories that these medications have lots of undesirable side effects.”

Reflect on:
▶ An appropriate teaching plan discussing hypertension and its effects.
▶ An appropriate teaching plan discussing nonpharmacologic strategies to decrease blood pressure.
▶ How you will address Mr. Ramos’s concerns about potential side effects.
▶ Factors that could affect compliance with antihypertensive therapy.

OVERVIEW
Antihypertensive drugs are used to treat hypertension, a common, chronic disorder affecting an estimated 50 to 60 million adults and an unknown number of children and adolescents in the United States. Hypertension increases risks of myocardial infarction, heart failure, cerebral infarction and hemorrhage, and renal disease. To understand hypertension and antihypertensive drug therapy, it is necessary first to understand the physiologic mechanisms that normally control blood pressure, characteristics of hypertension, and characteristics of antihypertensive drugs.

REGULATION OF ARTERIAL BLOOD PRESSURE
Arterial blood pressure reflects the force exerted on arterial walls by blood flow. Blood pressure normally stays relatively constant because of homeostatic mechanisms that adjust blood flow to meet tissue needs. The two major determinants of arterial blood pressure are cardiac output (systolic pressure) and peripheral vascular resistance (diastolic pressure).

Cardiac output equals the product of the heart rate and stroke volume ($CO = HR \times SV$). Stroke volume is the amount of blood ejected with each heartbeat (approximately 60 to
90 mL). Thus, cardiac output depends on the force of myocardial contraction, blood volume, and other factors. Peripheral vascular resistance is determined by local blood flow and the degree of constriction or dilation in arterioles and arteries (vascular tone).

**Autoregulation of Blood Flow**

Autoregulation is the ability of body tissues to regulate their own blood flow. Local blood flow is regulated mainly by nutritional needs of the tissue, such as lack of oxygen or accumulation of products of cellular metabolism (eg, carbon dioxide, lactic acid). Local tissues can form vasodilating and vasoconstricting substances to regulate local blood flow. Important tissue factors include histamine, bradykinin, serotonin, and prostaglandins.

Histamine is found mainly in mast cells surrounding blood vessels and released when these tissues are injured. In some tissues, such as skeletal muscle, mast cell activity is mediated by the sympathetic nervous system (SNS) and histamine is released when SNS stimulation is blocked or withdrawn. In this case, vasodilation results from increased histamine release and the withdrawal of SNS vasoconstrictor activity. Bradykinin is released from a protein in body fluids. Kinins dilate arterioles, increase capillary permeability, and constrict venules. Serotonin is released from aggregating platelets during the blood clotting process. It causes vasoconstriction and plays a major role in control of bleeding. Prostaglandins are formed in response to tissue injury and include vasodilators (eg, prostacyclin) and vasoconstrictors (eg, thromboxane A2).

An important component of regulating local blood flow is the production of several vasoactive substances by the endothelial cells that line blood vessels. Vasoconstricting substances, which increase vascular tone and blood pressure, include angiotensin II, endothelin-1, and thromboxane A2. Vasodilating substances, which decrease vascular tone and blood pressure, include nitric oxide and prostacyclin. Excessive vasoconstrictors or deficient vasodilators may contribute to the development of atherosclerosis, hypertension, and other diseases. Injury to the endothelial lining of blood vessels (eg, by the shear force of blood flow with hypertension or by rupture of atherosclerotic plaque) leads to vasoconstriction, vasoconstriction, thrombus formation, and thickening of the blood vessel wall. All of these factors make the blood flow through a narrow lumen and increase peripheral vascular resistance.

Overall, regulation of blood pressure involves a complex, interacting, overlapping network of hormonal, neural, and vascular mechanisms, and any condition that affects heart rate, stroke volume, or peripheral vascular resistance affects arterial blood pressure. Many of these mechanisms are compensatory effects that try to restore balance when hypotension or hypertension occurs. The mechanisms are further described in Box 55–1 and referred to in the following discussion of antihypertensive drugs and their actions in lowering high blood pressure.

**Response to Hypotension**

When hypotension (and decreased tissue perfusion) occurs, the SNS is stimulated, the hormones epinephrine and norepinephrine are secreted by the adrenal medulla, angiotensin II and aldosterone are formed, and the kidneys retain fluid. These compensatory mechanisms raise the blood pressure. Specific effects include:

1. Constriction of arterioles, which increases peripheral vascular resistance
2. Constriction of veins and increased venous tone
3. Stimulation of cardiac beta-adrenergic receptors, which increases heart rate and force of myocardial contraction
4. Activation of the renin–angiotensin–aldosterone mechanism

**Response to Hypertension**

When arterial blood pressure is elevated, the following sequence of events occurs:

1. Kidneys excrete more fluid (increase urine output).
3. Decreased blood volume reduces venous blood flow to the heart and therefore decreases cardiac output.
4. Decreased cardiac output reduces arterial blood pressure.
5. The vascular endothelium produces vasodilating substances (eg, nitric oxide, prostacyclin), which reduce blood pressure.

**Hypertension**

Hypertension is persistently high blood pressure that results from abnormalities in regulatory mechanisms. It is usually defined as a systolic pressure above 140 mm Hg or a diastolic pressure above 90 mm Hg on multiple blood pressure measurements.

Primary or essential hypertension (that for which no cause can be found) makes up 90% to 95% of known cases. Secondary hypertension may result from renal, endocrine, or central nervous system disorders and from drugs that stimulate the SNS or cause retention of sodium and water. Primary hypertension can be controlled with appropriate therapy; secondary hypertension can sometimes be cured by surgical therapy.

The Sixth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure, published in 1997, classified blood pressures in adults (in mm of Hg), as follows:

- Normal = systolic 130 or below; diastolic 85 or below
- High normal = systolic 130 to 139; diastolic 85 to 89
- Stage 1 hypertension (mild) = systolic 140 to 159; diastolic 90 to 99
- Stage 2 hypertension (moderate) = systolic 160 to 179; diastolic 100 to 109
Neural

Neural regulation of blood pressure mainly involves the sympathetic nervous system (SNS). In the heart, SNS neurons control heart rate and force of contraction. In blood vessels, SNS neurons control muscle tone by maintaining a state of partial contraction, with additional constriction or dilation accomplished by altering this basal state. When hypotension and inadequate tissue perfusion occur, the SNS is activated and produces secretion of epinephrine and norepinephrine by the adrenal medulla, constriction of blood vessels in the skin, gastrointestinal tract, and kidneys, and stimulation of beta-adrenergic receptors in the heart, which increases heart rate and force of myocardial contraction. All of these mechanisms act to increase blood pressure and tissue perfusion, especially of the brain and heart.

The SNS is activated by the vasomotor center in the brain, which constantly receives messages from baroreceptors and chemoreceptors located in the circulatory system. Adequate function of these receptors is essential for rapid and short-term regulation of blood pressure. The vasomotor center interprets the messages from these receptors and modifies cardiovascular functions to maintain adequate blood flow.

More specifically, baroreceptors detect changes in pressure or stretch. For example, when a person moves from a lying to a standing position, blood pressure falls and decreases stretch in the aorta and arteries. This elicits increased heart rate and vasoconstriction to restore adequate circulation. The increased heart rate occurs rapidly and blood pressure is adjusted within 1 to 2 minutes. This quick response prevents orthostatic hypotension with dizziness and possible syncope. (Antihypertensive medications may blunt this response and cause orthostatic hypotension.)

Chemoreceptors, which are located in the aorta and carotid arteries, are in close contact with arterial blood and respond to changes in the oxygen, carbon dioxide, and hydrogen ion content of blood. Although their main function is to regulate ventilation, they also communicate with the vasomotor center and can induce vasoconstriction. Chemoreceptors are stimulated when blood pressure drops to a certain point because oxygen is decreased and carbon dioxide and hydrogen ions are increased in arterial blood.

The central nervous system (CNS) also regulates vasomotor tone and blood pressure. Inadequate blood flow to the brain results in ischemia of the vasomotor center. When this occurs, neurons in the vasomotor center stimulate widespread vasoconstriction in an attempt to raise blood pressure and restore blood flow. This reaction is called the CNS ischemic response, an emergency measure to preserve blood flow to vital brain centers. If blood flow is not restored within 3 to 10 minutes, the neurons of the vasomotor center are unable to function, the impulses that maintain vascular muscle tone stop, and blood pressure drops to a fatal level.

Hormonal

The renin–angiotensin–aldosterone (RAA) system and vasopressin are important hormonal mechanisms in blood pressure regulation.

The RAA system is activated in response to hypotension and acts as a compensatory mechanism to restore adequate blood flow to body tissues. Renin is an enzyme that is synthesized, stored, and released from the kidneys in response to decreased blood pressure, SNS stimulation, or decreased sodium concentration in extracellular fluid. When released into the bloodstream, where its action lasts 30 to 60 minutes, renin converts angiotensinogen (a plasma protein) to angiotensin I. Angiotensin-converting enzyme (ACE) in the endothelium of pulmonary blood vessels then acts on angiotensin I to produce angiotensin II. Angiotensin II strongly constricts arterioles (and weakly constricts veins), increases peripheral resistance, and increases blood pressure by direct vasoconstriction, stimulation of the SNS, and stimulation of catecholamine release from the adrenal medulla. It also stimulates secretion of aldosterone from the adrenal cortex, which then causes the kidneys to retain sodium and water. Retention of sodium and water increases blood volume, cardiac output, and blood pressure.

Vasopressin, also called antidiuretic hormone or ADH, is a hormone secreted by the posterior pituitary gland that regulates reabsorption of water by the kidneys. It is released in response to decreased blood volume and decreased blood pressure. It causes retention of body fluids and vasoconstriction, both of which act to raise blood pressure.

Vascular

The endothelial cells that line blood vessels synthesize and secrete several substances that play important roles in regulating cardiovascular functions, including blood pressure. These substances normally maintain a balance between vasoconstriction and vasodilation. When the endothelium is damaged (eg, by trauma, hypertension, hypercholesterolemia, or atherosclerosis), the resulting imbalance promotes production of vasoconstricting substances and also causes blood vessels to lose their ability to relax in response to dilator substances. In addition, changes in structure of endothelial and vascular smooth muscle cells (vascular remodeling) further impair vascular functions.

Vasoconstrictors increase vascular tone (ie, constrict or narrow blood vessels so that higher blood pressure is required to pump blood to body tissues). Vasoconstricting substances produced by the endothelium include angiotensin II, endothelin-1, platelet-derived growth factor (PDGF), and thromboxane A2. Endothelin-1 is the strongest endogenous vasoconstrictor known. Angiotensin II and thromboxane A2 can also be produced by other types of cells, but endothelial cells can produce both. Thromboxane A2, a product of arachidonic acid metabolism, also promotes platelet aggregation and thrombosis.

Vasodilators decrease vascular tone and blood pressure. Major vasodilating substances produced by the endothelium include nitric oxide and prostacyclin (prostaglandin I2). Nitric oxide (NO) is a gas that can diffuse through cell membranes, trigger biochemical reactions, and then dissipate rapidly. It is formed by the action of the enzyme NO synthase on the amino acid L-arginine and continually released by normal endothelium. Its production is tightly regulated and depends on the amount of ionized calcium in the fluid portion of endothelial cells. Several substances (eg, acetylcholine, bradykinin, catecholamines, substance P, and products of aggregating platelets such as adenosine diphosphate and serotonin) act on receptors in endothelial cell membranes to increase the cytosolic concentration of ionized calcium, activate NO synthase, and increase NO production. In addition, increased blood flow or blood pressure increases shear stress at the endothelial surface and stimulates production of NO.

Once produced, endothelium-derived NO produces vasodilation primarily by activating guanylyl cyclase in vascular smooth muscle cells and increasing intracellular cyclic 3′,5′-guanosine monophosphate as a second messenger. NO also inhibits platelet aggregation and production of platelet-derived vasoconstricting substances. Because NO is released into the vessel wall (to relax (continued)
smooth muscle) and into the vessel lumen (to inactivate platelets), it is thought to have protective effects against vasoconstriction and thrombosis.

NO is also produced in leukocytes, fibroblasts, and vascular smooth muscle cells and may have pathologic effects when large amounts are produced. In these tissues, NO seems to have other functions, such as modifying nerve activity in the nervous system.

Prostacyclin is synthesized and released from endothelium in response to stimulation by several factors (e.g., bradykinin, interleukin-1, serotonin, thrombin, PDGF). It produces vasodilation by activating adenyl cyclase and increasing levels of cyclic adenosine monophosphate in smooth muscle cells. In addition, like NO, prostacyclin also inhibits platelet aggregation and production of platelet-derived vasoconstricting substances. The vasodilating effects of prostacyclin may occur independently or in conjunction with NO.

Overall, excessive vasoconstrictors or deficient vasodilators may contribute to the development of atherosclerosis, hypertension, and other diseases. Injury to the endothelial lining of blood vessels (e.g., by the shear force of blood flow with hypertension or by rupture of atherosclerotic plaque) decreases vasodilators and leads to vasoconstriction, vasospasm, thrombus formation, and thickening of the blood vessel wall. All of these factors require the blood to flow through a narrowed lumen and increase blood pressure.

Vascular Remodeling
Vascular remodeling is similar to the left ventricular remodeling that occurs in heart failure (see Chap. 51). It results from endothelial dysfunction and produces a thickening of the blood vessel wall and a narrowing of the blood vessel lumen. Thickening of the wall makes blood vessels less flexible and less able to respond to vasodilating substances. There are also changes in endothelial cell structure (i.e., the connections between endothelial cells become looser) that lead to increased permeability. The mechanisms of these vascular changes, which promote and aggravate hypertension, are described below.

As discussed in previous chapters, normal endothelium helps maintain a balance between vasoconstriction and vasodilation, procoagulation and anticoagulation, proinflammation and anti-inflammation, and progrowth and antigrowth. In the inflammatory process, normal endothelium acts as a physical barrier against the movement of leukocytes into the subendothelial space. Endothelial products such as nitric oxide may also inhibit leukocyte activity. However, inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-1 activate endothelial cells to produce adhesion molecules (which allow leukocytes to adhere to the endothelium), interleukin-8 (which attracts leukocytes to the endothelium and allows them to accumulate in subendothelial cells), and foam cells (lipid-filled monocyte/macrophages that form fatty streaks, the beginning lesions of atherosclerotic plaque). Although activation of endothelial cells may be a helpful component of the normal immune response, the resulting inflammation may contribute to disease development.

In terms of cell growth, normal endothelium limits the growth of vascular smooth muscle that underlies the endothelium and forms the vessel wall. Growth-inhibiting products of the endothelium include nitric oxide, which also inhibits platelet activation and production of growth-promoting substances. When the endothelium is damaged, endothelial cells become activated and also produce growth-promoting products. Other endothelial products (e.g., angiotensin II and endothelin-1) may also stimulate growth of vascular smooth muscle cells. Thus, damage or loss of endothelial cells stimulates growth of smooth muscle cells in the intimal layer of the blood vessel wall.

- Stage 3 hypertension (severe) = systolic 180 to 209; diastolic 110 to 119
- Stage 4 hypertension (very severe) = systolic 210 or above; diastolic 120 or above

A systolic pressure of 140 or above with a diastolic pressure below 90 is called isolated systolic hypertension and is more common in the elderly.

Hypertension profoundly alters cardiovascular function by increasing the workload of the heart and causing thickening and sclerosis of arterial walls. As a result of increased cardiac workload, the myocardium hypertrophies as a compensatory mechanism and heart failure eventually occurs. As a result of endothelial dysfunction and arterial changes (vascular remodeling), the arterial lumen is narrowed, blood supply to tissues is decreased, and risks of thrombosis are increased. In addition, necrotic areas may develop in arteries, and these may rupture with sustained high blood pressure. The areas of most serious damage are the heart, brain, kidneys, and eyes. These are often called target organs.

Initially and perhaps for years, primary hypertension may produce no symptoms. If symptoms occur, they are usually vague and nonspecific. Hypertension may go undetected, or it may be incidentally discovered when blood pressure measurements are taken as part of a routine physical examination, screening test, or assessment of other disorders. Eventually, symptoms reflect target organ damage. Hypertension is often discovered after a person experiences angina pectoris, myocardial infarction, heart failure, stroke, or renal disease.

Hypertensive emergencies are episodes of severely elevated blood pressure that may be an extension of malignant (rapidly progressive) hypertension or caused by cerebral hemorrhage, dissecting aortic aneurysm, renal disease, pheochromocytoma, or eclampsia. These require immediate management, usually intravenous (IV) antihypertensive drugs, to lower blood pressure. Symptoms include severe headache, nausea, vomiting, visual disturbances, neurologic disturbances, disorientation, and decreased level of consciousness (drowsiness, stupor, coma). Hypertensive urgencies are episodes of less severe hypertension and are often managed with oral drugs. The goal of management is to lower blood pressure within 24 hours. In most instances, it is better to lower blood pressure gradually and to avoid wide fluctuations in blood pressure.
**Antihypertensive Drugs**

Drugs used in the management of primary hypertension belong to several different groups, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), also called angiotensin II receptor antagonists (AI-IRAs), antiadrenergics, calcium channel blockers, diuretics, and direct vasodilators. In general, these drugs act to decrease blood pressure by decreasing cardiac output or peripheral vascular resistance.

**Angiotensin-Converting Enzyme Inhibitors**

Angiotensin-converting enzyme (also called kininase) is mainly located in the endothelial lining of blood vessels, which is the site of production of most angiotensin II. This same enzyme also metabolizes bradykinin, an endogenous substance with strong vasodilating properties.

ACE inhibitors block the enzyme that normally converts angiotensin I to the potent vasoconstrictor angiotensin II. By blocking production of angiotensin II, the drugs decrease vasoconstriction (having a vasodilating effect) and decrease aldosterone production (reducing retention of sodium and water). In addition to inhibiting formation of angiotensin II, the drugs also inhibit the breakdown of bradykinin, prolonging its vasodilating effects. These effects and possibly others help to prevent or reverse the remodeling of heart muscle and blood vessel walls that impairs cardiovascular function and exacerbates cardiovascular disease processes. Because of their effectiveness in hypertension and beneficial effects on the heart, blood vessels, and kidneys, these drugs are increasing in importance, number, and use. Widely used to treat heart failure and hypertension, the drugs may also decrease morbidity and mortality in other cardiovascular disorders. They improve post–myocardial infarction survival when added to standard therapy of aspirin, a beta blocker, and a thrombolytic.

ACE inhibitors may be used alone or in combination with other antihypertensive agents, such as thiazide diuretics. Although the drugs can cause or aggravate proteinuria and renal damage in nondiabetic people, they decrease proteinuria and slow the development of nephropathy in diabetic clients.

Most ACE inhibitors (captopril, enalapril, fosinopril, lisinopril, ramipril, and quinapril) also are used in the management of heart failure because they decrease peripheral vascular resistance, cardiac workload, and ventricular remodeling. Captopril and other ACE inhibitors are recommended as first-line agents for treating hypertension in diabetic clients, particularly those with type 1 diabetes and/or diabetic nephropathy, because they reduce proteinuria and slow progression of renal impairment.

ACE inhibitors are well absorbed with oral administration, produce effects within 1 hour that last approximately 24 hours, have prolonged serum half-lives with impaired renal function, and most are metabolized to active metabolites that are excreted in urine and feces. These drugs are well tolerated, with a low incidence of serious adverse effects (eg, neutropenia, agranulocytosis, proteinuria, glomerulonephritis, and angioedema). However, a persistent cough develops in approximately 10% to 20% of clients and may lead to stopping the drug. Also, acute hypotension may occur when an ACE inhibitor is started, especially in clients with fluid volume deficit. This reaction may be prevented by starting with a low dose, taken at bedtime, or by stopping diuretics and reducing dosage of other antihypertensive drugs temporarily. Hyperkalemia may develop in clients who have diabetes mellitus or renal impairment or who are taking nonsteroidal anti-inflammatory drugs, potassium supplements, or potassium-sparing diuretics.

These drugs are contraindicated during pregnancy because serious illnesses, including renal failure, have occurred in neonates whose mothers took an ACE inhibitor during the second and third trimesters.

**Angiotensin II Receptor Blockers**

Angiotensin II receptor blockers (ARBs) were developed to block the strong blood pressure–raising effects of angiotensin II. Instead of decreasing production of angiotensin II, as the ACE inhibitors do, these drugs compete with angiotensin II for tissue binding sites and prevent angiotensin II from combining with its receptors in body tissues. Although multiple types of receptors have been identified, the AT1 receptors located in brain, renal, myocardial, vascular, and adrenal tissue determine most of the effects of angiotensin II on cardiovascular and renal functions. ARBs block the angiotensin II AT1 receptors and decrease arterial blood pressure by decreasing systemic vascular resistance (Fig. 55–1).

These drugs are similar to ACE inhibitors in their effects on blood pressure and hemodynamics and are as effective as ACE inhibitors in the management of hypertension and probably heart failure. They are less likely to cause hyperkalemia than ACE inhibitors, and the occurrence of a persistent cough is rare. Overall, the drugs are well tolerated, and the incidence of most adverse effects is similar to that of placebo.

Losartan, the first ARB, is readily absorbed and rapidly metabolized by the cytochrome P450 liver enzymes to an active metabolite. Both losartan and the metabolite are highly bound to plasma albumin, and losartan has a shorter duration of action than its metabolite. When losartan therapy is started, maximal effects on blood pressure usually occur within 3 to 6 weeks. If losartan alone does not control blood pressure, a low dose of a diuretic may be added. A combination product of losartan and hydrochlorothiazide is available.

**Antiadrenergics**

Antiadrenergic (sympatholytic) drugs inhibit activity of the SNS. When the SNS is stimulated (see Chap. 17), the nerve impulse travels from the brain and spinal cord to the ganglia. From the ganglia, the impulse travels along postganglionic fibers to effector organs (eg, heart, blood vessels). Although
creased sympathetic activity. Reduced sympathetic activity results in decreased blood pressure (see Chap. 19). When the nerve impulse is inhibited or blocked at any location along its pathway, the results in orthostatic hypotension with palpitations, dizziness, and perhaps syncope 1 to 3 hours after the first dose or an increased dose. To prevent this effect, first doses and first increased doses are taken at bedtime. Another effect, associated with long-term use or higher doses, leads to sodium and fluid retention and a need for concurrent diuretic therapy. Centrally acting sympatholytics (eg, clonidine) stimulate presynaptic alpha₂ receptors in the brain and are classified as alpha₂ receptor agonists. When these drugs are taken, less norepinephrine is released and sympathetic outflow from the vasomotor center is reduced. Stimulation of presynaptic alpha₂ receptors peripherally may also contribute to the decreased sympathetic activity. Reduced sympathetic activity leads to decreased cardiac output, heart rate, peripheral vascular resistance, and blood pressure. Chronic use of clonidine and related drugs may result in sodium and fluid retention, especially with higher doses.

Beta-adrenergic blocking agents (eg, propranolol) decrease heart rate, force of myocardial contraction, cardiac output, and renin release from the kidneys. Other antiadrenergic drugs include guanethidine and related drugs, which act at postganglionic nerve endings; and two other alpha blockers (phenolamine and phenoxybenzamine), which occasionally are used in hypertension resulting from catecholamine excess. Individual antiadrenergic drugs are discussed in Chapter 19.

**Calcium Channel Blocking Agents**

Calcium channel blockers (eg, verapamil) are used for several cardiovascular disorders. The mechanism of action and use in the management of tachydysrhythmias and angina pectoris are discussed in Chapters 52 and 53. In hypertension, the drugs mainly dilate peripheral arteries and decrease peripheral vascular resistance by relaxing vascular smooth muscle.

Most of the available drugs are approved for use in hypertension. Nifedipine, a short-acting calcium channel blocker, has been used to treat hypertensive emergencies or urgencies, often by puncturing the capsule and squeezing the contents under the tongue or having the client bite and swallow the capsule. Such use is no longer recommended, because this practice is associated with an increased risk of adverse cardiovascular events precipitated by rapid and severe decrease in blood pressure.

As a group, the calcium channel blockers are well absorbed from the gastrointestinal tract following oral administration and are highly bound to protein. The drugs are metabolized in the liver and excreted in urine.

**Diuretics**

Antihypertensive effects of diuretics are usually attributed to sodium and water depletion. In fact, diuretics usually produce the same effects as severe dietary sodium restriction. In many cases of hypertension, diuretic therapy alone may lower blood pressure. When diuretic therapy is begun, blood volume and cardiac output decrease. With long-term administration of a diuretic, cardiac output returns to normal, but there is a persistent decrease in peripheral vascular resistance. This has been attributed to a persistent small reduction in extracellular water and plasma volume, decreased receptor sensitivity to vasopressor substances such as angiotensin, direct arteriolar vasodilation, and arteriolar vasodilation secondary to electrolyte depletion in the vessel wall.

In moderate or severe hypertension that does not respond to a diuretic alone, the diuretic may be continued and another antihypertensive drug added, or monotherapy with a different type of antihypertensive drug may be tried.

Thiazide diuretics (eg, hydrochlorothiazide) are most commonly used in the management of hypertension. Loop
diuretics (eg, furosemide) or potassium-sparing diuretics (eg, spironolactone) may be useful in some circumstances; see Chapter 56 for discussion of diuretic drugs.

**Vasodilators (Direct Acting)**

Vasodilator antihypertensive drugs directly relax smooth muscle in blood vessels, resulting in dilation and decreased peripheral vascular resistance. They also reduce afterload and may be used in management of heart failure. Hydralazine and minoxidil act mainly on arterioles; nitroprusside acts on arterioles and venules. These drugs have a limited effect on hypertension when used alone because the vasodilating action that lowers blood pressure also stimulates the SNS and triggers reflexive compensatory mechanisms (vasoconstriction, tachycardia, and increased cardiac output), which raise blood pressure. This effect can be prevented during long-term therapy by also giving a drug that prevents excessive sympathetic stimulation (eg, propranolol, an adrenergic blocker). These drugs also cause sodium and water retention, which may be minimized by concomitant diuretic therapy.

### INDIVIDUAL DRUGS

Diuretics are discussed in Chapter 56 and listed in Table 56–1. Antiadrenergic drugs are discussed in Chapter 19 and listed in Tables 19–1 and 19–2. Antihypertensive agents are shown in the Drugs at a Glance: Antihypertensive Drugs; antihypertensive-diuretic combination products are listed in Drugs at a Glance: Oral Antihypertensive Combination Products.

### Nursing Process

**Assessment**

Assess the client’s condition in relation to hypertension.

- Identify conditions and risk factors that may lead to hypertension. These include:
  - Obesity
  - Elevated serum cholesterol (total and low-density lipoprotein) and triglycerides
  - Cigarette smoking
  - Sedentary lifestyle
  - Family history of hypertension or other cardiovascular disease
  - African-American race
  - Renal disease (eg, renal artery stenosis)
  - Adrenal disease (eg, hypersecretion of aldosterone, pheochromocytoma)
  - Other cardiovascular disorders (eg, atherosclerosis, left ventricular hypertrophy)
  - Diabetes mellitus

- Oral contraceptives, corticosteroids, appetite suppressants, nasal decongestants, non-steroidal anti-inflammatory agents
- Neurologic disorders (eg, brain damage)
- Observe for signs and symptoms of hypertension.
- Check blood pressure accurately and repeatedly. As a rule, multiple measurements in which systolic pressure is above 140 mm Hg and/or diastolic pressure is above 90 mm Hg, are necessary to establish a diagnosis of hypertension.

  The importance of accurate blood pressure measurements cannot be overemphasized because there are many possibilities for errors. Some ways to improve accuracy and validity include using correct equipment (eg, proper cuff size), having the client rested and in the same position each time blood pressure is measured (eg, sitting or supine with arm at heart level), and using the same arm for repeated measurements.

- In most cases of early hypertension, elevated blood pressure is the only clinical manifestation. If symptoms do occur, they are usually nonspecific (eg, headache, weakness, fatigue, tachycardia, dizziness, palpitations, epistaxis).

- Eventually, signs and symptoms occur as target organs are damaged. Heart damage is often reflected as angina pectoris, myocardial infarction, or heart failure. Chest pain, tachycardia, dyspnea, fatigue, and edema may occur. Brain damage may be indicated by transient ischemic attacks or strokes of varying severity with symptoms ranging from syncope to hemiparesis. Renal damage may be reflected by proteinuria, increased blood urea nitrogen (BUN), and increased serum creatinine. Ophthalmoscopic examination may reveal hemorrhages, sclerosis of arterioles, and inflammation of the optic nerve (papilledema). Because arterioles can be visualized in the retina of the eye, damage to retinal vessels may indicate damage to arterioles in the heart, brain, and kidneys.

**Nursing Diagnoses**

- Decreased Cardiac Output related to disease process or drug therapy
- Ineffective Coping related to long-term lifestyle changes and drug therapy
- Noncompliance related to lack of knowledge about hypertension and its management, costs and adverse effects of drug therapy, and psychosocial factors
- Disturbed Body Image related to the need for long-term management and medical supervision
- Fatigue related to antihypertensive drug therapy
- Deficient Knowledge related to hypertension, antihypertensive drug therapy, and nondrug lifestyle changes
- Sexual Dysfunction related to adverse drug effects
Planning/Goals

The client will:

• Receive or take antihypertensive drugs correctly
• Be monitored closely for therapeutic and adverse drug effects, especially when drug therapy is started, when changes are made in drugs, and when dosages are increased or decreased
• Use nondrug measures to assist in blood pressure control
• Avoid, manage, or report adverse drug reactions
• Verbalize or demonstrate knowledge of prescribed drugs and recommended lifestyle changes
• Keep follow-up appointments

Interventions

Implement measures to prevent or minimize hypertension. Preventive measures are mainly lifestyle changes to reduce risk factors. These measures should be started in childhood and continued throughout life. Once hypertension is diagnosed, lifetime adherence to a therapeutic regimen may be necessary to control the disease and prevent complications. The nurse’s role is important in the prevention, early detection, and management of hypertension. Some guidelines for intervention at community, family, and personal levels include the following:

• Participate in programs to promote healthful lifestyles (eg, improving eating habits, increasing exercise, managing stress more effectively, and avoiding cigarette smoking).
• Participate in community screening programs, and make appropriate referrals when abnormal blood pressures are detected. If hypertension develops in women taking oral contraceptives, the drug should be discontinued for 3 to 6 months to see whether blood pressure decreases without antihypertensive drugs.
• Help the hypertensive client comply with prescribed therapy. Noncompliance is high among clients with hypertension. Reasons for noncompliance include lack of symptoms, lack of understanding and self-discipline to make needed lifestyle changes (eg, lose weight, stop smoking, restrict salt intake), perhaps experiencing more symptoms from medications than from hypertension, the cost of therapy, and the client’s failure to realize the importance of effective management, especially as related to prevention of major cardiovascular diseases (myocardial infarction, stroke, and death). In addition, several studies have shown that compliance decreases as the number of drugs and number of doses increase.

The nurse can help increase compliance by teaching the client about hypertension, helping the client make necessary lifestyle changes, and maintaining supportive interpersonal relationships. Losing weight, stopping smoking, and other changes are most likely to be effective if attempted one at a time.

• Use recommended techniques for measuring blood pressure. Poor techniques are too often used (eg, the client’s arm up or down rather than at heart level; cuff applied over clothing, too loosely, deflated too rapidly, or re-inflated before completely deflated; a regular-sized cuff used on large arms that need a large cuff; using the stethoscope diaphragm rather than the bell). It is disturbing to think that antihypertensive drugs may be prescribed and dosages changed on the basis of inaccurate blood pressures.

Evaluation

• Observe for blood pressure measurements within goal or more nearly normal ranges.
• Observe and interview regarding compliance with instructions about drug therapy and lifestyle changes.
• Observe and interview regarding adverse drug effects.

PRINCIPLES OF THERAPY

Therapeutic Regimens

Once the diagnosis of hypertension is established, a therapeutic regimen must be designed and implemented. The goal of management for most clients is to achieve and maintain normal blood pressure range (below 140/90 mm Hg). If this goal cannot be achieved, lowering blood pressure to any extent is still considered beneficial in decreasing the incidence of coronary artery disease and stroke.

The Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure recommends a management algorithm in which initial interventions are lifestyle modifications (ie, reduction of weight and sodium intake, regular physical activity, moderate alcohol intake, and no smoking). If these modifications do not produce goal blood pressure or substantial progress toward goal blood pressure within 3 to 6 months, antihypertensive drug therapy should be initiated and the lifestyle modifications should be continued. Although the Committee recommends monotherapy (use of one antihypertensive drug) with a diuretic or a beta blocker because research studies demonstrate reduced morbidity and mortality with these agents, a drug from another classification (eg, ACE inhibitors, ARBs, calcium channel blockers, alpha1-adrenergic blockers) may also be used effectively. Studies also indicate decreased cardiovascular morbidity and mortality with ACE inhibitors.

If the initial drug (and dose) does not produce the desired blood pressure, options for further management include increasing the drug dose, substituting another drug, or adding a second drug from a different group. If the response is still inadequate, a second or third drug may be added, including a diuretic if not previously prescribed. When current management is ineffective, reassess the client’s compliance with lifestyle modifications and drug therapy. In addition, review other factors that may decrease the therapeutic response, such as over-the-counter appetite suppressants, dietary or herbal supplements, or nasal decongestants, which raise blood pressure.
**Angiotensin-Converting Enzyme (ACE) Inhibitors**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benazepril (Lotensin)</td>
<td>PO 10 mg once daily initially, increased to 40 mg daily if necessary, in 1 or 2 doses</td>
<td>Adults: PO 1.5 mg/kg/d in divided doses, q8h; maximum dose, 6 mg/kg/d</td>
</tr>
<tr>
<td>Captopril (Capoten)</td>
<td>PO 25 mg, 2 to 3 times daily initially, gradually increased to 50, 100, or 150 mg 2 to 3 times daily, if necessary. Maximum dose, 450 mg/d.</td>
<td>Neonates: PO 0.03–0.15 mg/kg/d, q8–24h; maximum dose, 2 mg/kg/d</td>
</tr>
<tr>
<td>Enalapril (Vasotec)</td>
<td>PO 5 mg once daily, increased to 10–40 mg daily, in 1 or 2 doses, if necessary</td>
<td>PO 0.15 mg q12–24h</td>
</tr>
<tr>
<td>Fosinopril (Monopril)</td>
<td>Same as benazepril, above</td>
<td></td>
</tr>
<tr>
<td>Lisinopril (Prinivil, Zestril)</td>
<td>PO 10 mg once daily, increased to 40 mg if necessary</td>
<td></td>
</tr>
<tr>
<td>Moexipril (Univasc)</td>
<td>PO initial dose 7.5 mg (3.75 mg for those who have renal impairment or are taking a diuretic). Maintenance dose 7.5–30 mg daily, in 1 or 2 doses, adjusted according to blood pressure control</td>
<td></td>
</tr>
<tr>
<td>Quinapril (Accupril)</td>
<td>PO 10 mg once daily initially, increased to 20, 40, or 80 mg daily if necessary, in 1 or 2 doses. Wait at least 2 wk between dose increments</td>
<td></td>
</tr>
<tr>
<td>Perindopril (Aceon)</td>
<td>PO 4–16 mg daily, in 1 or 2 doses</td>
<td></td>
</tr>
<tr>
<td>Ramipril (Altace)</td>
<td>PO 2.5 mg once daily, increased to 20 mg daily if necessary, in 1 or 2 doses</td>
<td></td>
</tr>
<tr>
<td>Trandolapril (Mavik)</td>
<td>PO initial dose 1 mg once daily (0.5 mg for those who have hepatic or renal impairment or are taking a diuretic; 2 mg for African Americans). Maintenance dose 2–4 mg daily, in a single dose, adjusted according to blood pressure control</td>
<td></td>
</tr>
</tbody>
</table>

**Angiotensin II Receptor Blockers**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Candesartan (Atacand)</td>
<td>PO 16 mg once daily initially, increased if necessary to a maximum of 32 mg daily, in 1 or 2 doses</td>
<td></td>
</tr>
<tr>
<td>Eprosartan (Teveten)</td>
<td>PO 600 mg daily initially; may be increased to 800 mg daily, in 1 or 2 doses</td>
<td></td>
</tr>
<tr>
<td>Irbesartan (Avapro)</td>
<td>PO 150 mg once daily initially, increased up to 300 mg once daily, if necessary</td>
<td></td>
</tr>
<tr>
<td>Losartan (Cozaar)</td>
<td>PO 50 mg daily initially (25 mg for those who have hepatic impairment or are taking a diuretic). Maintenance dose 35–100 mg daily, in 1 or 2 doses, adjusted according to blood pressure control</td>
<td></td>
</tr>
<tr>
<td>Olmesartan (Benicar)</td>
<td>PO 20 mg daily initially, increased to 40 mg after 2 wk</td>
<td></td>
</tr>
<tr>
<td>Telmisartan (Micardis)</td>
<td>PO 40 mg daily initially, increased to a maximum of 80 mg daily if necessary</td>
<td></td>
</tr>
<tr>
<td>Valsartan (Diovan)</td>
<td>PO 80 mg daily initially, when used as monotherapy in clients who are not volume depleted. Maintenance dose may be increased. However, adding a diuretic is more effective than increasing dose beyond 80 mg,</td>
<td></td>
</tr>
</tbody>
</table>

**Antiadrenergic Agents**

**ALPHA1-BLOCKING AGENTS**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doxazosin (Cardura)</td>
<td>PO 1 mg once daily initially, increased to 2 mg, then to 4, 8, and 16 mg daily if necessary</td>
<td></td>
</tr>
<tr>
<td>Prazosin (Minipress)</td>
<td>PO 1 mg 2 to 3 times daily initially, increased if necessary to 20 mg in divided doses. Average maintenance dose, 6–15 mg daily</td>
<td></td>
</tr>
<tr>
<td>Terazosin (Hytrin)</td>
<td>PO 1 mg at bedtime initially, may be increased gradually. Usual maintenance dose, 1–5 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Antihypertensive Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALPHA2 AGONISTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine (Catapres)</td>
<td>PO 0.1 mg 2 times daily initially, gradually increased up to 2.4 mg daily, if necessary. Average maintenance dose, 0.2–0.8 mg daily</td>
<td>PO 5–25 mcg/kg/d, in divided doses, q6h; increase at 5- to 7-day intervals, if needed</td>
</tr>
<tr>
<td>Guanabenz (Wytensin)</td>
<td>PO 4 mg twice daily, increased by 4–8 mg daily every 1–2 wk if necessary to a maximum of 32 mg twice daily</td>
<td></td>
</tr>
<tr>
<td>Guanfacine (Tenex)</td>
<td>PO 1 mg daily at bedtime, increased to 2 mg after 3–4 wk, then to 3 mg if necessary</td>
<td>PO 10 mg/kg/d in 2 to 4 divided doses initially, increased or decreased according to response. Maximum dose, 65 mg/kg/d or 3 g daily, whichever is less</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>PO 250 mg 2 or 3 times daily initially, increased gradually until blood pressure is controlled or a daily dose of 3 g is reached</td>
<td></td>
</tr>
<tr>
<td><strong>POSTGANGLIONIC-ACTIVE DRUGS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guanadrel (Hylorel)</td>
<td>PO 10 mg daily initially. Usual dosage range, 20–75 mg daily in divided doses</td>
<td>PO 0.2 mg/kg/d initially, increased by the same amount every 7–10 days if necessary to a maximum dose of 3 mg/kg/d</td>
</tr>
<tr>
<td>Guanethidine sulfate (Ismelin)</td>
<td>PO 10 mg daily initially, increased every 5–7 days to a maximum daily dose of 300 mg if necessary. Usual daily dose, 25–50 mg</td>
<td></td>
</tr>
<tr>
<td><strong>BETA-ADRENERGIC BLOCKING AGENTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acebutolol (Sectral)</td>
<td>PO 400 mg once daily initially, increased to 800 mg daily if necessary</td>
<td></td>
</tr>
<tr>
<td>Atenolol (Tenormin)</td>
<td>PO 50 mg once daily initially, increased in 1–2 wk to 100 mg once daily, if necessary</td>
<td></td>
</tr>
<tr>
<td>Betaxolol (Kerlone)</td>
<td>PO 10–20 mg daily</td>
<td></td>
</tr>
<tr>
<td>Bisoprolol (Zebeta)</td>
<td>PO 5 mg once daily, increased to a maximum of 20 mg daily if necessary</td>
<td></td>
</tr>
<tr>
<td>Carteolol (Cartrol)</td>
<td>PO 2.5 mg once daily initially, gradually increased to a maximum of 10 mg daily if necessary. Usual maintenance dosage, 2.5–5 mg once daily. Extend dosage interval to 48 h for a creatinine clearance of 20–60 mL/min and to 72 h for a creatinine clearance below 20 mL/min.</td>
<td></td>
</tr>
<tr>
<td>Metoprolol (Lopressor)</td>
<td>PO 50 mg twice daily, gradually increased in weekly or longer intervals if necessary. Maximum dose, 450 mg daily</td>
<td></td>
</tr>
<tr>
<td>Nadolol (Corgard)</td>
<td>PO 40 mg daily initially, gradually increased if necessary. Average dose, 80–320 mg daily.</td>
<td></td>
</tr>
<tr>
<td>Penbutolol (Levatol)</td>
<td>PO 20 mg once daily</td>
<td></td>
</tr>
<tr>
<td>Pindolol (Visken)</td>
<td>PO 5 mg 2 or 3 times daily initially, increased by 10 mg/d at 3- to 4-wk intervals to a maximum of 60 mg daily</td>
<td></td>
</tr>
<tr>
<td>Propranolol (Inderal)</td>
<td>PO 40 mg twice daily initially, gradually increased to 160–640 mg daily</td>
<td>PO 1 mg/kg/d initially, gradually increased to a maximum of 10 mg/kg/d</td>
</tr>
<tr>
<td>Timolol (Blocadren)</td>
<td>PO 10 mg twice daily initially, increased gradually if necessary. Average daily dose, 20–40 mg; maximal daily dose, 60 mg.</td>
<td></td>
</tr>
<tr>
<td><strong>ALPHA-BETA-ADRENERGIC-BLOCKING AGENTS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carvedilol (Coreg)</td>
<td>PO 6.25 mg twice daily for 7–14 days, then increase to 12.5 mg twice daily for 7–14 days, then increase to a maximal dose of 25 mg twice daily if tolerated and needed</td>
<td></td>
</tr>
<tr>
<td>Labetalol (Trandate, Normodyne)</td>
<td>PO 100 mg twice daily, increased by 100 mg twice daily every 2–3 days if necessary. Usual maintenance dose, 200–400 mg twice daily. Severe hypertension may require 1200–2400 mg daily. IV injection, 20 mg slowly over 2 min, followed by 40–80 mg every 10 min until the desired blood pressure is achieved or 300 mg has been given.</td>
<td></td>
</tr>
</tbody>
</table>
The World Health Organization and the International Society of Hypertension guidelines for management of hypertension include considering age, ethnicity, and concomitant cardiovascular disorders when choosing an antihypertensive drug; starting with a single drug, in the lowest available dose; changing to a drug from a different group, rather than increasing dosage of the first drug or adding a second drug, if the initial drug is ineffective or not well tolerated; and using long-acting drugs (i.e., a single dose effective for 24 hours). The guidelines also note that many clients require two or more drugs to achieve adequate blood pressure control. When this is the case, fixed-dose combinations or long-acting agents may be preferred, as they decrease the number of drugs and doses that are required and may increase compliance.
# Drugs at a Glance: Oral Antihypertensive Combination Products*

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Components</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldoril</td>
<td>Angiotensin II Receptor Antagonist</td>
<td>HCTZ 15, 25, 30, or 50 mg</td>
</tr>
<tr>
<td></td>
<td>Angiotensin-Converting Enzyme Inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beta Blocker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Calcium Channel Blocker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diuretic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Non-Beta-Blocker Antiadrenergic</td>
<td>Methyldopa 250 or 500 mg</td>
</tr>
<tr>
<td></td>
<td>Dosage Ranges</td>
<td>1 tablet 2 to 3 times daily for 48 h, then adjusted according to response</td>
</tr>
<tr>
<td>Capozide</td>
<td>Captopril 25 or 50 mg</td>
<td>HCTZ 15 or 25 mg</td>
</tr>
<tr>
<td>Combipres</td>
<td></td>
<td>HCTZ 15 or 25 mg</td>
</tr>
<tr>
<td>Corzide</td>
<td>Valsartan 80 or 160 mg</td>
<td>Bendroflumethiazide 5 mg</td>
</tr>
<tr>
<td>Diovan HCT</td>
<td>Losartan 50 mg</td>
<td>HCTZ 12.5 mg</td>
</tr>
<tr>
<td>Inderide</td>
<td>Nadolol 40 or 80 mg</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Inderide LA</td>
<td>Propranolol 40 or 80 mg</td>
<td>HCTZ 12.5 mg</td>
</tr>
<tr>
<td>Lopressor HCT</td>
<td></td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Lotensin HCT</td>
<td>Lisinopril 20 mg</td>
<td>1 tablet once daily</td>
</tr>
<tr>
<td>Lotrel</td>
<td>Benazepril 5, 10, or 20 mg</td>
<td>1–2 tablets twice daily</td>
</tr>
<tr>
<td>Minizide</td>
<td>Benazepril 10 or 20 mg</td>
<td>1–2 tablets twice daily</td>
</tr>
<tr>
<td>Prinzide</td>
<td>Lisinopril 20 mg</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Tarka</td>
<td>Trandolapril 1, 2, or 4 mg</td>
<td>1 capsule 2 to 3 times daily</td>
</tr>
<tr>
<td>Tenoretic</td>
<td>Verapamil 180 or 240 mg</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Timolide</td>
<td>Atenolol 50 or 100 mg</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Vaseretic</td>
<td>Timolol 10 mg</td>
<td>1–2 tablets 1 or 2 times daily</td>
</tr>
<tr>
<td>Zestoretic</td>
<td>Enalapril</td>
<td>1 tablet daily</td>
</tr>
<tr>
<td>Ziac</td>
<td>Lisinopril 10 or 20 mg</td>
<td>1 tablet daily</td>
</tr>
</tbody>
</table>

HCTZ, hydrochlorothiazide.

*Note that one trade name product may be available in multiple formulations, with variable amounts of antihypertensive, diuretic, or both components.
CHAPTER 55 ANTIHYPERTENSIVE DRUGS

CLIENT TEACHING GUIDELINES

Antihypertensive Medications

General Considerations

- Hypertension is a major risk factor for heart attack, stroke (sometimes called brain attack), and kidney failure. Although it rarely causes symptoms unless complications occur, it can be controlled by appropriate management. Consequently, you need to learn all you can about the disease process, the factors that cause or aggravate it, and its management. In few other conditions is your knowledge and understanding about your condition as important as with hypertension.

- For many people, lifestyle changes (ie, a diet to avoid excessive salt and control weight and fat intake, regular exercise, and avoiding smoking) may be sufficient to control blood pressure. If drug therapy is prescribed, these measures should be continued.

- When drug therapy is needed, your physician will try to choose a drug and develop a regimen that works for you. There are numerous antihypertensive drugs and many can be taken once a day, which makes their use more convenient and less disruptive of your usual activities of daily living. You may need several office visits to find the right drug or combination of drugs and the right dosage. Changes in drugs or dosages may also be needed later, especially if you develop other conditions or take other drugs that alter your response to the antihypertensive drugs.

- Antihypertensive drug therapy is usually long term, may require more than one drug, and may produce side effects. You need to know the brand and generic names of any prescribed drugs and how to take each drug for optimal benefit and minimal adverse effects.

- Antihypertensive drugs must be taken as prescribed for optimal benefits, even if you do not feel well when a medication is started or when dosage is increased. No antihypertensive drug should be stopped abruptly. If problems develop, they should be discussed with the health care provider who is treating the hypertension. If treatment is stopped, blood pressure usually increases gradually as the medication(s) are eliminated from the body. Sometimes, however, blood pressure rapidly increases to pretreatment levels or even higher. With any of these situations, you are at risk of a heart attack or stroke. In addition, stopping one drug of a multidrug regimen may lead to increased adverse effects as well as decreased antihypertensive effectiveness. To avoid these problems, antihypertensive drugs should be tapered in dosage and discontinued gradually, as directed by your health care provider.

- Blood pressure measurements are the only way you can tell if your medication is working. Thus, you may want to monitor your blood pressure at home, especially when starting drug therapy, changing medications, or changing dosages. If so, a blood pressure machine may be purchased at a medical supply store. Follow instructions regarding use, take your blood pressure approximately the same time(s) each day (eg, before morning and evening meals), and keep a record to show to your health care provider.

- People sometimes feel dizzy or faint while taking antihypertensive medications. This usually means your blood pressure drops momentarily and is most likely to occur when you start a medication, increase dosage, or stand up suddenly from a sitting or lying position. This can be prevented or decreased by moving to a standing position slowly, sleeping with the head of the bed elevated, wearing elastic stockings, exercising legs, avoiding prolonged standing, and avoiding hot baths. If episodes still occur, you should sit or lie down to avoid a fall and possible injury.

- It is very important to keep appointments for follow-up care.

Self- or Caregiver Administration

- Take or give antihypertensive drugs at prescribed time intervals, about the same time each day. For example, take once-daily drugs as close to every 24 hours as you can manage; twice-a-day drugs should be taken every 12 hours. If ordered four times daily, take approximately every 6 hours. Taking doses too close together can increase dizziness, weakness, and other adverse effects. Taking doses too far apart may not control blood pressure adequately and may increase risks of heart attack or stroke.

- Take oral captopril on an empty stomach. Food decreases drug absorption.

- Take most oral antihypertensive agents with or after food intake to decrease gastric irritation. Candesartan (Atacand), irbesartan (Avapro), losartan (Cozaar), telmisartan (Micardis), and valsartan (Diovan) may be taken with or without food.

- With prazosin, doxazosin, or terazosin, take the first dose and the first increased dose at bedtime to prevent dizziness and possible fainting.

- With the clonidine skin patch, apply to a hairless area on the upper arm or torso once every 7 days. Rotate sites.

How Can You Avoid This Medication Error?

Fred Simosa, a nursing home resident, is having increasing difficulty with swallowing. You decide to crush his medications (Cardizem SR, Lasix, and Slow-K) and mix them with applesauce. What error, if any, has occurred? Reflect on potential effects of crushing these medications for this patient.

Drug Selection

Because many effective antihypertensive drugs are available, choices depend primarily on client characteristics and responses. Some general guidelines include:

- Angiotensin-converting enzyme inhibitors may be effective alone in white hypertensive clients or in combi-
nation with a diuretic in African-American hypertensive clients. They are also recommended for hypertensive adults with diabetes mellitus and kidney damage. Based on research studies that indicate reduced morbidity and mortality from cardiovascular diseases, these drugs are increasingly being prescribed as a component of a multidrug regimen.

2. **Angiotensin II receptor blockers** have therapeutic effects similar to those of ACE inhibitors, with fewer adverse effects. They may be used in most clients with hypertension.

3. **Antiadrenergics** may be effective in any hypertensive population. **Alpha agonists** and **antagonists** are most often used in multidrug regimens for stages 2, 3, or 4 hypertension, because they may cause postural hypotension and syncope. Clonidine is available in a skin patch that is applied once a week and reportedly reduces adverse effects and increases compliance. An additional advantage of transdermal clonidine is that clients who cannot take oral medications can use it. A disadvantage of this system is a delayed onset of effect (2 to 3 days), so other antihypertensive medications must also be given during the first 2 to 3 days of clonidine transdermal therapy. Other disadvantages include cost, a 20% incidence of local skin rash or irritation, and a 2- to 3-day delay in “offset” of action when transdermal therapy is discontinued.

   **Beta blockers** are the drugs of first choice for clients younger than 50 years of age with high-renin hypertension, tachycardia, angina pectoris, myocardial infarction, or left ventricular hypertrophy. Most beta blockers are approved for use in hypertension and are probably equally effective. However, the cardioselective drugs (see Chap. 19) are preferred for hypertensive clients who also have asthma, peripheral vascular disease, or diabetes mellitus.

4. **Calcium channel blockers** may be used for monotherapy or in combination with other drugs. They may be especially useful for hypertensive clients who also have angina pectoris or other cardiovascular disorders. Note that sustained-release forms of nifedipine, diltiazem, and verapamil and other long-acting drugs (eg, amlodipine, felodipine) are recommended.

5. **Diuretics** are preferred for initial therapy in older clients and African-American hypertensive clients. They should be included in any multidrug regimen for these and other populations. Thiazide and related diuretics are equally effective. Hydrochlorothiazide is commonly used.

6. **Vasodilators** are used in combination with a beta blocker and a diuretic to prevent hypotension-induced compensatory mechanisms (stimulation of the SNS and fluid retention) that raise blood pressure.

7. **Combination products** usually combine two drugs with different mechanisms of action (eg, a thiazide or related diuretic plus a beta blocker or other antiadrenergic, an ACE inhibitor, an ARB, or a calcium channel blocker). Most are available in various formulations (see Drugs at a Glance: Oral Antihypertensive Combination Products). Potential advantages of fixed-dose combination products include comparable or improved effectiveness, smaller doses of individual components, fewer adverse effects, improved compliance, and possibly decreased costs.

**Dosage Factors**

1. Dosage of antihypertensive drugs must be titrated according to individual response. Dosage should be started at minimal levels and increased if necessary. Lower doses decrease the incidence and severity of adverse effects.

2. For many clients, it may be more beneficial to change drugs or add another drug rather than increase dosage. Two or three drugs in small doses may be more effective and cause fewer adverse effects than a single drug in large doses. When two or more drugs are given, the dose of each drug may need to be reduced.

**Duration of Therapy**

Clients who maintain control of their blood pressure for 1 year or so may be candidates for reduced dosages or reduced numbers of drugs. Any such adjustments must be gradual and carefully supervised by a health care provider. Expected benefits include fewer adverse effects and greater compliance.

**Sodium Restriction**

Therapeutic regimens for hypertension include sodium restriction. Severe restrictions usually are not acceptable to clients; however, moderate restrictions (4 to 6 g of salt a day) are beneficial and more easily implemented. Avoiding heavily salted foods (eg, cured meats, sandwich meats, pretzels, and potato chips) and not adding salt to food at the table can achieve this. Research and clinical observations indicate the following:

1. Sodium restriction alone reduces blood pressure.

2. Sodium restriction potentiates the antihypertensive actions of diuretics and other antihypertensive drugs. Conversely, excessive sodium intake decreases the antihypertensive actions of all antihypertensive drugs. Clients with unrestricted salt intake who are taking thiazides may lose excessive potassium and become hypokalemic.

3. Sodium restriction may decrease dosage requirements of antihypertensive drugs, thereby decreasing the incidence and severity of adverse effects.

**Genetic/Ethnic Considerations**

For most antihypertensive drugs, there have been few research studies comparing their effects in different genetic or
Most principles of managing adult hypertension apply to managing childhood and adolescent hypertension; some additional elements include:

1. Children may have primary or secondary hypertension, but the incidence is unknown and treatment is not well defined. In recent years, increased blood pressure measurements during routine pediatric examinations have led to the discovery of significant asymptomatic hypertension and the realization that mild elevations in blood pressure are more common during childhood, especially in adolescents, than previously thought. Hypertension in children and adolescents may indicate underlying disease processes (e.g., cardiac, endocrine, renovascular, or renal parenchymal disorders) or the early onset of primary hypertension. Routine blood pressure measurement is especially important for children who are overweight or who have a hypertensive parent. Increased blood pressure in children often correlates with hypertension in young adults.

2. National norms have been established for blood pressure in children and adolescents of comparable age, body size (height and weight), and sex. Normal blood pressure is defined as systolic and diastolic values less than the 90th percentile; hypertension is defined as an average of systolic or diastolic pressures that equals or exceeds the 95th percentile on three or more occasions. Blood pressure values obtained with a child or adolescent should be compared with the norms and recorded in permanent health care records. Multiple accurate measurements are especially important in diagnosing hypertension because blood pressure may be more labile in children and adolescents.

3. Children have a greater incidence of secondary hypertension than adults. In general, the higher the blood pressure and the younger the child, the greater the likelihood of secondary hypertension. Diagnostic tests may be needed to rule out renovascular disease or coarctation of the aorta in those younger than 18 years of age with blood pressure above 140/90 mm Hg and young children with blood pressures above the 95th percentile for their age group. Oral contraceptives may cause secondary hypertension in adolescents.

4. The goals of management are to reduce blood pressure below the 95th percentile and prevent the long-term effects of persistent hypertension. As in adults, prevention of obesity, avoiding excessive sodium intake, and exercise are important nonpharmacologic measures. Obese adolescents who lose weight may lower their blood pressure, especially when they also increase physical activity.

Most children with secondary hypertension require drug therapy, which should be directed at the cause of hypertension if known. Drug therapy should be cautious and conservative because few studies have been done in children and long-term effects are unknown. The fewest drugs and the lowest doses should be used. Thus, if an initial drug is ineffective, it may be better to give a different single drug than to add a second drug to the regimen.

5. Some guidelines for choosing drugs include the following:

   a. Beta blockers are used in children of all ages; they should probably be avoided in children with resting pulse rates under 60.

   b. Thiazide diuretics may be used, and they do not commonly produce hyperglycemia, hyperuricemia, or hypercalcemia in children as they do in adults.

   c. Angiotensin II receptor blockers have not been established as safe and effective for use in children younger than 18 years of age.

   d. Although ACE inhibitors have been used to treat hypertension in children, their safety and efficacy have not been established. Most clinical experience has been with captopril, with which hemodynamic effects are stronger and last longer in newborns and young infants than in older children. Also, excessive and prolonged hypotension, with oliguria and seizures, has occurred. In general, captopril should
be used in children only when other measures for controlling blood pressure are ineffective. Also, because of teratogenic effects, these drugs should be used very cautiously, if at all, in adolescent girls who may be sexually active.

e. Calcium channel blockers are used in treating acute and chronic childhood hypertension. With chronic hypertension, immediate-release forms have a short duration of action and require frequent administration, and long-acting forms contain dosages that are not suitable for young children.

f. Hydralazine seems to be less effective in childhood and adolescent hypertension than in adult disease.

6. Although all clients with primary hypertension need regular supervision and assessment of blood pressure, this is especially important with young children and adolescents because of growth and developmental changes.

Use in Older Adults

Most principles of managing hypertension in other populations apply to older adults (>65 years). In addition, the following factors require consideration:

1. There are basically two types of hypertension in older adults. One is systolic hypertension, in which systolic blood pressure is above 160 mm Hg, but diastolic pressure is below 95 mm Hg or normal. The other type, systolic–diastolic hypertension, involves elevations of both systolic and diastolic pressures.

   Both types increase cardiovascular morbidity and mortality, especially heart failure and stroke, and should be treated.

2. Nonpharmacologic management should be tried alone or with drug therapy. For example, weight reduction and moderate sodium restriction may be the initial management of choice if the client is hypertensive and overweight.

3. If antihypertensive drug therapy is required, drugs used for younger adults may be used alone or in combination. A diuretic is usually the drug of first choice in older adults and may be effective alone. ACE inhibitors and calcium channel blocking agents may also be effective as monotherapy; beta blockers are usually less effective as monotherapy. Some ACE inhibitors (eg, lisinopril, ramipril, quinapril, moexipril) or their active metabolites produce higher plasma concentrations in older adults than in younger ones. This is attributed to decreased renal function rather than age itself. Additional guidelines include:

   a. The goal of drug therapy for systolic-diastolic hypertension is usually a systolic pressure below 140 mm Hg and a diastolic below 90 mm Hg in clients with no other complications. For those with diabetes or renal failure, the goal is a systolic pressure below 130 mm Hg and a diastolic below 85 mm Hg. However, the latter goal may be difficult for most clients to meet because it requires rather stringent lifestyle restrictions and may require two or more antihypertensive drugs.

   b. Older adults may be especially susceptible to the adverse effects of antihypertensive drugs because their homeostatic mechanisms are less efficient. For example, if hypotension occurs, the mechanisms that raise blood pressure are less efficient and syncope may occur. In addition, renal and liver function may be reduced, making accumulation of drugs more likely.

   c. Initial drug doses should be approximately half of the recommended doses for younger adults, and increases should be smaller and spaced at longer intervals. Lower drug doses (eg, hydrochlorothiazide 12.5 mg daily) are often effective and reduce risks of adverse effects.

   d. Blood pressure should be reduced slowly to facilitate adequate blood flow through arteriosclerotic vessels. Rapid lowering of blood pressure may produce cerebral insufficiency (syncope, transient ischemic attacks, stroke).

   e. A further incentive for successful management of hypertension in older clients is the benefit of reducing the incidence of dementia with antihypertensives.

   f. If blood pressure control is achieved and maintained for approximately 6 to 12 months, drug dosage should be gradually reduced, if possible.

Use in Renal Impairment

Antihypertensive drugs are frequently required by clients with renal impairment ranging from mild insufficiency to end-stage failure. A temporary decrease in renal function may occur in these clients when the blood pressure is initially lowered. Guidelines include the following:

1. In hypertensive clients with primary renal disease or diabetic nephropathy, drug therapy may slow progression of renal impairment.

2. Diuretics are usually required because sodium retention is an important element of hypertension in these clients. Thiazides are usually contraindicated because they are ineffective if serum creatinine is above 2 mg/dL. However, metolazone, a thiazide-related drug, may be used and relatively large doses may be required. Loop diuretics, such as furosemide, are more often used, and relatively large doses may be required.

3. Angiotensin-converting enzyme inhibitors are usually effective in clients with renal impairment, but responses may vary and the following factors should be considered.

   a. When a client with renal impairment is started on an ACE inhibitor, careful monitoring is required, especially during the first few weeks of therapy, to prevent irreversible renal failure. For some clients, it may not be possible to normalize blood pressure and maintain adequate renal perfusion.
b. In clients with severe atherosclerosis, especially those with unilateral or bilateral stenosis of renal arteries, ACE inhibitors can impair renal blood flow and worsen renal impairment (i.e., increase blood urea nitrogen [BUN] and serum creatinine). This may require stopping the drug. In addition, some clients without renal artery stenosis have developed increased BUN and serum creatinine levels. Although these are usually minor and transient, the drug may need to be discontinued or reduced in dosage.

c. Approximately 25% of clients taking an ACE inhibitor for heart failure experience an increase in BUN and serum creatinine levels. These clients usually do not require drug discontinuation unless they have severe, preexisting renal impairment. In clients with severe heart failure, whose renal function may depend on the activity of the renin–angiotensin–aldosterone system, management with an ACE inhibitor may worsen renal impairment. However, acute renal failure rarely occurs.

d. The mechanisms are unclear, but ACE inhibitors also have renal protective effects in hypertensive clients with some renal impairment and clients with diabetic nephropathy. A possible mechanism is less damage to the endothelium and less vascular remodeling (i.e., less narrowing of the lumen and less thickening of the wall).

e. The elimination half-life of most ACE inhibitors and their active metabolites is prolonged in clients with renal impairment. Dosage may need to be reduced with benazepril, lisinopril, quinapril, and ramipril.

4. Angiotensin II receptor blockers also inhibit the renin–angiotensin–aldosterone system and may produce effects similar to those of the ACE inhibitors. As with ACE inhibitors, some clients with severe heart failure have had oliguria or worsened renal impairment. These drugs are also likely to increase BUN and serum creatinine in clients with stenosis of one or both renal arteries.

Dosage reductions usually are not required for clients with renal impairment. However, fluid volume deficits (e.g., from diuretic therapy) should be corrected before starting the drug, and blood pressure should be monitored closely during drug therapy. Clients on hemodialysis may have orthostatic hypotension with telmisartan and possibly other drugs of this group.

5. Most beta blockers are eliminated primarily by the kidneys and serum half-life is prolonged in clients with renal impairment. Most of the drugs should be used with caution and in reduced dosages. Dosage of metoprolol does not need to be reduced. An additional consideration is that cardiac output and blood pressure should not be lowered enough to impair renal blood flow and aggravate renal impairment.

6. Calcium channel blockers are often used in clients with renal impairment because, in general, they are effective and well tolerated; they maintain renal blood flow even during blood pressure reduction in most clients; and they are mainly eliminated by hepatic metabolism. However, cautious use is still recommended because several agents produce active metabolites that are excreted by the kidneys (see section on Use in Renal Impairment, Chap. 53).

Use in Hepatic Impairment

Little information is available about the use of antihypertensive drugs in clients with impaired hepatic function. However, many of the drugs are metabolized in the liver and hepatic impairment can increase and prolong plasma concentrations.

1. Angiotensin-converting enzyme inhibitors have occasionally been associated with a syndrome that started with cholestatic jaundice and progressed to hepatic necrosis and sometimes death. The mechanism of liver impairment is unknown. Clients who have jaundice or marked elevations of hepatic enzymes while taking an ACE inhibitor should have the drug discontinued. In addition, therapeutic effects can be decreased with several of the drugs (e.g., fosinopril, quinapril, ramipril) because less of a given dose is converted to an active metabolite. Clearance of fosinopril, quinapril, and probably other ACE inhibitors that are metabolized is reduced in clients with alcoholic or biliary cirrhosis.

2. Angiotensin II receptor blockers should be used cautiously in clients with biliary tract obstruction or hepatic impairment. For some of these drugs (e.g., candesartan, irbesartan, valsartan), dosage reduction is unnecessary. However, a lower starting dose is recommended for losartan because plasma concentrations of the drug and its active metabolite are increased and clearance is decreased approximately 50%. With telmisartan, plasma concentrations are increased and bioavailability approaches 100%. In addition, the drug is eliminated mainly by biliary excretion and clients with biliary tract obstruction or hepatic impairment have reduced clearance. The drug should be used with caution, but dosage forms that allow dosage reduction below 40 mg are not available. Thus, an alternative drug should probably be considered for clients with hepatic impairment.

3. Beta blockers that normally undergo extensive first-pass hepatic metabolism (e.g., acebutolol, metoprolol, propranolol, timolol) may produce excessive blood levels in clients with cirrhosis because the blood containing the drug is shunted around the liver into the systemic circulation. Dosage should be started at a low dose and titrated carefully in these clients. Dosage of bisoprolol and pindolol should also be reduced in clients with cirrhosis or other hepatic impairment.

4. Calcium channel blockers should be used with caution, dosages should be substantially reduced, liver enzymes should be monitored periodically, and clients should be closely monitored for drug effects (see section on Use in Hepatic Impairment, Chap. 53).
Use in Critical Illness

Antihypertensive drugs are frequently prescribed for clients with critical illness and must be used cautiously, usually with reduced dosages and careful monitoring of responses. In many cases, the drugs are continued during critical illnesses caused by both cardiovascular and noncardiovascular disorders. If the client cannot take oral drugs, drug choices are narrowed because many commonly used drugs are not available in a dosage form that can be given parenterally, by gastrointestinal tube, or topically (eg, like a clonidine skin patch). Thus, clients’ drug therapy must usually be re-titrated. In one way, this may be more difficult, because critically ill clients are often unstable in their conditions and responses to drug therapy. In another way, it may be easier in a critical care unit, where hemodynamic monitoring is commonly used. The goal of management is usually to maintain adequate tissue perfusion while avoiding both hypotension and hypertension.

Antihypertensive drugs are also used to treat hypertensive urgencies and emergencies, which involve dangerously high blood pressures and actual or potential damage to target organs. Although there are risks with severe hypertension, there are also risks associated with lowering blood pressure excessively or too rapidly, including stroke, myocardial infarction, and acute renal failure. Thus, the goal of management is usually to lower blood pressure over several minutes to several hours, with careful titration of drug dosage to avoid precipitous drops.

Urgencies can be treated with oral antihypertensive agents such as *captopril* 25 to 50 mg every 1 to 2 hours or *clonidine* 0.2 mg initially, then 0.1 mg hourly until diastolic blood pressure falls below 110 mm Hg or 0.7 mg has been given.

A hypertensive emergency, defined as a diastolic pressure of 120 mm Hg or higher and target organ damage, requires an IV drug. The goal of management is usually to lower diastolic pressure to 100 to 110 mm Hg and maintain it there for several days to allow adjustment of the physiologic mechanisms that normally regulate blood pressure. Then, the blood pressure can be lowered to normotensive levels.

Several drugs can be given to treat a hypertensive emergency. *Fenoldopam* is a fast-acting drug indicated only for short-term use (<48 hours) in hospitalized clients. Dosage is calculated according to body weight and desired effects on blood pressure. Administration is by an infusion pump, with frequent monitoring of blood pressure. *Nitroglycerin* is especially beneficial in clients with both severe hypertension and myocardial ischemia. The dose is titrated according to blood pressure response and may range from 5 to 100 mcg/min. Tolerance develops to IV nitroglycerin over 24 to 48 hours. *Nitroprusside*, which has a rapid onset and short duration of action, is given as a continuous infusion at a rate of 0.5 to 8 mcg/kg/min. Intra-arterial blood pressure should be monitored during the infusion. Nitroprusside is metabolized to thiocyanate, and serum thiocyanate levels should be measured if the drug is given longer than 72 hours. The infusion should be stopped after 72 hours if the serum thiocyanate level is more than 12 mg/dL; it should be stopped at 48 hours in clients with renal impairment. Symptoms of thiocyanate toxicity (eg, nausea, vomiting, muscle twitching or spasm, and seizures) can be reversed with hemodialysis. Other drugs that may be used include IV *hydralazine*, *labetalol*, and *nicardipine*; see Drugs at a Glance: Antihypertensive Drugs.

Herbal and Dietary Supplements

Use of nonprescription herbal and dietary supplements is frequently not reported by the client even though one third of the adults in the United States use these agents. Significant interactions can occur between herbs and dietary supplements when taken with prescribed drugs. Many nonprescription medications such as antihistamine, cold/cough preparations, and weight loss products can decrease the effectiveness of antihypertensive drugs or worsen hypertension. Caffeine, by its stimulating effects, may increase blood pressure. *Ephedra* (ma huang), used to suppress appetite, treat colds, nasal congestion and asthma, and increase energy, increases blood pressure and increases risks of stroke. This product should be avoided by anyone with hypertension; it is not recommended for therapeutic use by anyone. *Yohimbe*, used to treat erectile dysfunction, is a central nervous system stimulant and can affect blood pressure.

Home Care

Antihypertensive drugs are commonly self-administered in the home setting. The home care nurse is most likely to be involved when making home visits for other reasons. Whether the client or another member of the household is taking antihypertensive medications, the home care nurse may be helpful in teaching about the drugs, monitoring for drug effects, and promoting compliance with the prescribed regimen (pharmacologic and lifestyle modifications).

Noncompliance with prescribed antihypertensive drug therapy is a major problem, and consequences may be catastrophic. The home care nurse is well situated to assess for actual or potential barriers to compliance. For example, several antihypertensive medications are quite expensive and clients may not take the drugs at all or they may take fewer than the prescribed number of doses. If the nurse’s assessment reveals this sort of situation, he or she may contact the prescribing health care provider and discuss the possibility of using less expensive drugs. If the provider is unwilling to try alternative drugs, the nurse may be able to identify resources for obtaining the needed medications.
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong>&lt;br&gt;a. Give oral captopril and moexipril on an empty stomach, 1 h before meals.&lt;br&gt;b. Give most other oral antihypertensives with or after food intake.&lt;br&gt;c. Give angiotensin II receptor blockers with or without food.&lt;br&gt;d. For intravenous injection of propranolol or labetalol, the client should be attached to a cardiac monitor. In addition, parenteral atropine and isoproterenol (Isuprel) must be readily available.&lt;br&gt;e. Give the first dose and the first increased dose of prazosin, doxazosin, and terazosin at bedtime.&lt;br&gt;f. For administration of fenoldopam and nitroprusside, use the manufacturers’ instructions to develop a unit protocol for preparation of infusion solutions, dosages, flow rates, durations of use, and monitoring of blood pressure during infusion.</td>
<td>Food decreases drug absorption.&lt;br&gt;To decrease gastric irritation.&lt;br&gt;Food does not impair drug absorption.&lt;br&gt;For early detection and management of excessive myocardial depression and dysrhythmias. Atropine may be used to treat excessive bradycardia. Isoproterenol may be used to stimulate myocardial contractility and increase cardiac output.&lt;br&gt;To prevent orthostatic hypotension and syncope.&lt;br&gt;These drugs are used to lower blood pressure rapidly in hypertensive emergencies, usually in an emergency department or critical care unit. They also have specific requirements for preparation and administration. A protocol established beforehand can save valuable time in an emergency situation.&lt;br&gt;The choice of drugs and drug dosages often requires adjustment to maximize beneficial effects and minimize adverse effects. Thus, optimal therapeutic effects may not occur immediately after drug therapy is begun.&lt;br&gt;Adverse effects are most likely to occur in clients who are elderly, have impaired renal function, and are receiving multiple antihypertensive drugs or large doses of antihypertensive drugs.&lt;br&gt;This is an extension of the expected pharmacologic action. Orthostatic hypotension results from drug blockage of compensatory reflexes (vasoconstriction, decreased venous pooling in extremities and increased venous return to the heart) that normally maintain blood pressure in the upright position. This adverse reaction may be aggravated by other conditions that cause vasodilation (eg, exercise, heat or hot weather, and alcohol consumption). Orthostatic hypotension is more likely to occur with guanethidine and methyldopa.&lt;br&gt;These effects result from decreased renal perfusion. This reaction can be prevented or minimized by concurrent administration of a diuretic.&lt;br&gt;Due to increased vagal tone and stimulation.&lt;br&gt;These effects are more likely to occur with hydralazine, methyldopa, propranolol, and captopril.&lt;br&gt;Apparenty caused by decreased levels of catecholamines and serotonin in the brain.&lt;br&gt;The drugs may cause bronchoconstriction and are contraindicated in patients with asthma and other bronchoconstrictive lung disorders.&lt;br&gt;This may be prevented by tapering dosage over several days before stopping the drug.&lt;br&gt;A chronic, nonproductive cough is a relatively common adverse effect; hyperkalemia occurs in 1%–4% of clients.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong>&lt;br&gt;a. Decreased blood pressure. The usual goal is a normal blood pressure (ie, below 140/90).</td>
<td></td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong>&lt;br&gt;a. Orthostatic hypotension, dizziness, weakness&lt;br&gt;b. Sodium and water retention, increased plasma volume, perhaps edema and weight gain&lt;br&gt;c. Prolonged atrioventricular conduction, bradycardia&lt;br&gt;d. Gastrointestinal disturbances, including nausea, vomiting, and diarrhea&lt;br&gt;e. Mental depression (with reserpine)&lt;br&gt;f. Bronchospasm (with nonselective beta blockers)&lt;br&gt;g. Hypertensive crisis (with abrupt withdrawal of clonidine or guanabenz).&lt;br&gt;h. Cough and hyperkalemia with angiotensin-converting enzyme (ACE) inhibitors</td>
<td></td>
</tr>
</tbody>
</table>
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
4. Observe for drug interactions  |  
   a. Drugs that *increase* effects of antihypertensives:  |  
      (1) Other antihypertensive agents  |  
      (2) Alcohol, other central nervous system depressants (eg, opioid analgesics, phenothiazine antipsychotics)  |  
      (3) Digoxin  |  
   b. Drugs that *decrease* effects of antihypertensives:  |  
      (1) Adrenergics  |  
      (2) Antacids  |  
      (3) Nonsteroidal anti-inflammatory drugs, oral contraceptives  |  
|  |  
Combinations of two or three drugs with different mechanisms of action are often given for their additive effects and efficacy in controlling blood pressure when a single drug is ineffective.  
These drugs have hypotensive effects when used alone and increased hypotension occurs when they are combined with antihypertensive drugs.  
Additive bradycardia with beta blockers  
These drugs stimulate the sympathetic nervous system and raise blood pressure. They include over-the-counter nasal decongestants, cold remedies, bronchodilators, and appetite suppressants.  
May decrease bioavailability of ACE inhibitors, especially captopril. Give antacids 2 h before or after ACE inhibitors.  
These drugs tend to increase blood pressure by causing retention of sodium and water.  

**How Can You Avoid This Medication Error?**  
**Answer:** If Mr. Simosa is having trouble swallowing, oral medications may not be safely taken at this time. Crushing the medications is also not indicated because Cardizem SR and Slow-K are sustained-release products. If Cardizem SR is crushed, the sustained-release properties will be lost. Immediately after administration, you will see a significant hypotensive effect because all the medication will be absorbed. Because none of the medication’s absorption will be delayed, you may see a rebound hypertension at a later time. Slow-K will also lose the ability to absorb slowly, which might cause it to be excreted by the diuretic effects of the Lasix, which is not affected by crushing.  

**Review and Application Exercises**  
1. Describe the physiologic mechanisms that control blood pressure.  
2. What are common factors that raise blood pressure?  
3. What signs and symptoms occur with hypertension, and how would you assess for them?  
4. Why is it important to measure blood pressure accurately and repeatedly?  
5. Does all hypertension require nonpharmacologic or pharmacologic treatment? Justify your answer.  
6. What are the potential consequences of untreated or inadequately treated hypertension?  
7. How do ACE inhibitors, ARBs, alpha- and beta-adrenergic blockers, calcium channel blockers, and direct vasodilators lower blood pressure?  
8. What are adverse effects of each group of antihypertensive drugs, and how may they be prevented or minimized?  
9. For a client newly diagnosed with hypertension, outline a teaching plan for lifestyle and pharmacologic interventions.  
10. List interventions by health care providers that may help hypertensive clients adhere to their management regimens and maintain quality of life.  
11. List at least two major considerations in using antihypertensive drugs in children, older adults, and clients who have renal or hepatic impairment.  
12. Mentally rehearse your assessment and interventions for a client with a hypertensive urgency or emergency.  
13. How would you assess a client being treated for hypertension for compliance with the prescribed lifestyle and drug therapy regimen?  

**SELECTED REFERENCES**  


Diuretics

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. List characteristics of diuretics in terms of mechanism of action, indications for use, principles of therapy, and nursing process implications.
2. Discuss major adverse effects of thiazide, loop, and potassium-sparing diuretics.
3. Identify clients at risk for developing adverse reactions to diuretic administration.
4. Recognize commonly used potassium-losing and potassium-sparing diuretics.
5. Discuss the rationale for using combination products containing a potassium-losing and a potassium-sparing diuretic.
6. Discuss the rationale for concomitant use of a loop diuretic and a thiazide or related diuretic.
7. Teach clients to manage diuretic therapy effectively.
8. Discuss important elements of diuretic therapy in special populations.

Critical Thinking Scenario

Jennie Masury, an 82-year-old widow, is started on a thiazide diuretic to control her hypertension. She also has a history of osteoarthritis. She lives alone with her two cats and manages independently with only a little help from her neighbors. Her children live out-of-state, but she talks with them on the phone weekly.

Reflect on:

- How diuretics work to decrease blood pressure.
- How a diuretic and its effects may affect activities and normal daily functions.
- Key factors, particularly diuretic therapy, that may pose safety risks for this widow. How might you minimize these risks?
- An appropriate teaching plan for this client regarding her diuretic therapy.

OVERVIEW

Diuretics are drugs that increase renal excretion of water, sodium, and other electrolytes, thereby increasing urine formation and output. They are important therapeutic agents widely used in the management of both edematous (eg, heart failure, renal and hepatic disease) and nonedematous (eg, hypertension, ophthalmic surgery) conditions. Diuretics are also useful in preventing renal failure by their ability to sustain urine flow. To aid understanding of diuretic drug therapy, renal physiology related to drug action and characteristics of edema are reviewed. Types of diuretics are then described, and individual drugs are listed in Drugs at a Glance: Diuretic Agents.

RENAL PHYSIOLOGY

The primary function of the kidneys is to regulate the volume, composition, and pH of body fluids. The kidneys receive approximately 25% of the cardiac output. From this large amount of blood flow, the normally functioning kidney is efficient in retaining substances needed by the body and eliminating those not needed.

The Nephron

The nephron is the functional unit of the kidney; each kidney contains approximately 1 million nephrons. Each nephron is composed of a glomerulus and a tubule (Fig. 56–1). The glomerulus is a network of capillaries that receives blood from the renal artery. Bowman’s capsule is a thin-walled structure that surrounds the glomerulus, then narrows and continues as the tubule. The tubule is a thin-walled structure of epithelial cells surrounded by peritubular capillaries. The tubule is divided into three main segments, the proximal tubule, loop of Henle, and distal tubule, which differ in structure and function. The tubules
### Drugs at a Glance: Diuretic Agents

#### Routes and Dosage Ranges

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Thiazide and Related Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bendroflumethiazide (Naturetin)</td>
<td>PO 5 mg daily initially. For maintenance, 2.5–20 mg daily or intermittently</td>
<td>PO up to 0.4 mg/kg/d initially, in 2 divided doses. For maintenance, 0.05–0.1 mg/kg/d in a single dose.</td>
</tr>
<tr>
<td>Benztiazide (Exna)</td>
<td>PO 50–200 mg daily for several days initially, depending on response. For maintenance, dosage is gradually reduced to the minimal effective amount.</td>
<td>PO 1–4 mg/kg/d initially, in 3 divided doses. For maintenance, dosage is reduced to the minimal effective amount.</td>
</tr>
<tr>
<td>Chlorothiazide (Diuril)</td>
<td>PO 500–1000 mg 1 or 2 times daily, IV 500 mg twice daily</td>
<td>PO 22 mg/kg/d in 2 divided doses</td>
</tr>
<tr>
<td>Chlorthalidone (Hygroton)</td>
<td>PO 50–200 mg daily</td>
<td>Infants &lt;6 mo, up to 33 mg/kg/d in 2 divided doses</td>
</tr>
<tr>
<td>Hydrochlorothiazide (HydroDIURIL, Esidrix, Oretic)</td>
<td>PO 25–100 mg daily</td>
<td>IV not recommended</td>
</tr>
<tr>
<td>Hydroflumethiazide (Saluron)</td>
<td>PO 25–200 mg daily</td>
<td>PO 3 mg/kg 3 times weekly, adjusted according to response</td>
</tr>
<tr>
<td>Indapamide (Lozol)</td>
<td>PO 2.5–5 mg daily</td>
<td>Infants &lt;6 mo, up to 3.3 mg/kg/d in 2 divided doses</td>
</tr>
<tr>
<td>Methylclothiazide (Enduron)</td>
<td>PO 2.5–10 mg daily</td>
<td>PO 1 mg/kg/d</td>
</tr>
<tr>
<td>Metolazone (Zaroxlyn, Mykrox)</td>
<td>PO 5–20 mg daily, depending on severity of condition and response</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Polythiazide (Renese)</td>
<td>PO 1–4 mg daily, depending on severity of condition and response</td>
<td>PO 0.02–0.08 mg/kg/d</td>
</tr>
<tr>
<td>Quinethazone (Hydromox)</td>
<td>PO 50–200 mg daily</td>
<td>Dosage not established</td>
</tr>
<tr>
<td>Trichlormethiazide (Metahydrin, Naqua)</td>
<td>PO 2–4 mg one or two times daily initially. For maintenance, 1–4 mg once daily</td>
<td>PO 0.07 mg/kg/d in single or divided doses</td>
</tr>
<tr>
<td><strong>Loop Diuretics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bumetanide (Bumex)</td>
<td>PO 0.5–2 mg daily as a single dose. May be repeated q4–6h to a maximal dose of 10 mg, if necessary. Giving on alternate days or for 3–4 d with rest periods of 1–2 d is recommended for long-term control of edema. IV, IM 0.5–1 mg, repeated in 2–3 h if necessary, to a maximal daily dose of 10 mg. Give IV injections over 1–2 min.</td>
<td>Not recommended for children &lt;18 y</td>
</tr>
<tr>
<td>Ethacrynic acid (Edecrin)</td>
<td>Edema, PO 50–100 mg daily, increased or decreased according to severity of condition and response, maximal daily dose, 400 mg. Rapid mobilization of edema, IV 50 mg or 0.5–1 mg/kg injected slowly to a maximum of 100 mg/dose</td>
<td>PO 25 mg daily</td>
</tr>
<tr>
<td>Furosemide (Lasix)</td>
<td>Edema, PO 20–80 mg as a single dose initially. If an adequate diuretic response is not obtained, dosage may be gradually increased by 20- to 40-mg increments at intervals of 6–8 h. For maintenance, dosage range and frequency of administration vary widely and must be individualized. Maximal daily dose, 600 mg. Hypertension, PO 40 mg twice daily, gradually increased if necessary. Rapid mobilization of edema, IV 20–40 mg initially, injected slowly. This dose may be repeated in 2 h. With acute pulmonary edema, initial dose is usually 40 mg, which may be repeated in 60–90 min. Acute renal failure, IV 40 mg initially, increased if necessary. Maximum dose, 1–2 g/24 h. Hypertensive crisis, IV 40–80 mg injected over 1–2 min. With renal failure, much larger doses may be needed.</td>
<td>PO 2 mg/kg/1 or 2 times daily initially, gradually increased by increments of 1–2 mg/kg per dose if necessary at intervals of 6–8 h. Maximal daily dose, 6 mg/kg</td>
</tr>
<tr>
<td>Torsemide (Demadex)</td>
<td>PO, IV 5–20 mg once daily</td>
<td>IV 1 mg/kg initially. If diuretic response is not adequate, increase dosage by 1 mg/kg no sooner than 2 h after previous dose. Maximal dose, 6 mg/kg</td>
</tr>
</tbody>
</table>

*(continued)*
are often called convoluted tubules because of their many twists and turns. The convolutions provide a large surface area that brings the blood flowing through the peritubular capillaries and the glomerular filtrate flowing through the tubular lumen into close proximity. Consequently, substances can be readily exchanged through the walls of the tubules.

The nephron functions by three processes: glomerular filtration, tubular reabsorption, and tubular secretion. These processes normally maintain the fluid volume, electrolyte concentration, and pH of body fluids within a relatively narrow range. They also remove waste products of cellular metabolism. A minimum daily urine output of approximately 400 mL is required to remove normal amounts of metabolic end products.

**Glomerular Filtration**

Arterial blood enters the glomerulus by the afferent arteriole at the relatively high pressure of approximately 70 mm Hg. This pressure pushes water, electrolytes, and other solutes out of the capillaries into Bowman’s capsule and then to the proximal tubule. This fluid, called glomerular filtrate, contains the same components as blood except for blood cells, fats, and proteins that are too large to be filtered.

The glomerular filtration rate (GFR) is about 180 L/day, or 125 mL/minute. Most of this fluid is reabsorbed as the glomerular filtrate travels through the tubules. The end product is about 2 L of urine daily. Because filtration is a nonselective process, the reabsorption and secretion processes determine the composition of the urine. Once formed, urine flows into collecting tubules, which carry it to the renal pelvis, then through the ureters, bladder, and urethra for elimination from the body.

Blood that does not become part of the glomerular filtrate leaves the glomerulus through the efferent arteriole. The efferent arteriole branches into the peritubular capillaries, which eventually empty into veins and return the blood to the systemic circulation.

**Tubular Reabsorption**

The term reabsorption, in relation to renal function, indicates movement of substances from the tubule (glomerular filtrate)
to the blood in the peritubular capillaries. Most reabsorption occurs in the proximal tubule. Almost all glucose and amino acids are reabsorbed; about 80% of water, sodium, potassium, chloride, and most other substances is reabsorbed. As a result, about 20% of the glomerular filtrate enters the loop of Henle. In the descending limb of the loop of Henle, water is reabsorbed; in the ascending limb, sodium is reabsorbed. A large fraction of the total amount of sodium (up to 30%) filtered by the glomeruli is reabsorbed in the loop of Henle. Additional sodium is reabsorbed in the distal tubule, primarily by the exchange of sodium ions for potassium ions secreted by epithelial cells of tubular walls. Final reabsorption of water occurs in the distal tubule and small collecting tubules. The remaining water and solutes are now appropriately called urine.

Antidiuretic hormone from the posterior pituitary gland promotes reabsorption of water from the distal tubules and the collecting ducts of the kidneys. This conserves water needed by the body and produces more concentrated urine. Aldosterone, a hormone from the adrenal cortex, promotes sodium–potassium exchange mainly in the distal tubule and collecting ducts. Thus, aldosterone promotes sodium reabsorption and potassium loss.

**Tubular Secretion**

The term secretion, in relation to renal function, indicates movement of substances from blood in the peritubular capillaries to glomerular filtrate flowing through the renal tubules. Secretion occurs in the proximal and distal tubules, across the epithelial cells that line the tubules. In the proximal tubule, uric acid, creatinine, hydrogen ions, and ammonia are secreted; in the distal tubule, potassium ions, hydrogen ions, and ammonia are secreted. Secretion of hydrogen ions is important in maintaining acid–base balance in body fluids.

**ALTERATIONS IN RENAL FUNCTION**

Many clinical conditions alter renal function. In some conditions, excessive amounts of substances (eg, sodium and water) are retained; in others, needed substances (eg, potassium, proteins) are eliminated. These conditions include cardiovascular, renal, hepatic, and other disorders that may be managed with diuretic drugs.

**Edema**

Edema is the excessive accumulation of fluid in body tissues. It is a symptom of many disease processes and may occur in any part of the body. Additional characteristics include the following:

1. Edema formation results from one or more of the following mechanisms that allow fluid to leave the bloodstream (intravascular compartment) and enter interstitial (third) spaces.

   a. Increased capillary permeability occurs as part of the response to tissue injury. Thus, edema may occur with burns and trauma or allergic and inflammatory reactions.

   b. Increased capillary hydrostatic pressure results from a sequence of events in which increased blood volume (from fluid overload or sodium and water retention) or obstruction of venous blood flow causes a high venous pressure and a high capillary pressure. This is the primary mechanism for edema formation in heart failure, pulmonary edema, and renal failure.

   c. Decreased plasma oncotic pressure may occur with decreased synthesis of plasma proteins (caused by liver disease or malnutrition) or increased loss of plasma proteins (caused by burn injuries or the nephrotic syndrome). Plasma proteins are important in keeping fluids within the bloodstream. When plasma proteins are lacking, fluid seeps through the capillaries and accumulates in tissues.

2. Edema interferes with blood flow to tissues. Thus, it interferes with delivery of oxygen and nutrients and removal of metabolic waste products. If severe, edema may distort body features, impair movement, and interfere with activities of daily living.

3. Specific manifestations of edema are determined by its location and extent. A common type of localized edema occurs in the feet and ankles (dependent edema), especially with prolonged sitting or standing. A less common but more severe type of localized edema is pulmonary edema, a life-threatening condition that occurs with circulatory overload (eg, of intravenous [IV] fluids or blood transfusions) or acute heart failure. Generalized massive edema (anasarca) interferes with the functions of many body organs and tissues.

**DIURETIC DRUGS**

Diuretic drugs act on the kidneys to decrease reabsorption of sodium, chloride, water, and other substances. Major subclasses are the thiazides and related diuretics, loop diuretics, and potassium-sparing diuretics, which act at different sites in the nephron (Fig. 56–2).

Major clinical indications for diuretics are edema, heart failure, and hypertension. In edematous states, diuretics mobilize tissue fluids by decreasing plasma volume. In hypertension, the exact mechanism by which diuretics lower blood pressure is unknown, but antihypertensive action is usually attributed to sodium depletion. Initially, diuretics decrease blood volume and cardiac output. With chronic use, cardiac output returns to normal, but there is a persistent decrease in plasma volume and peripheral vascular resistance. Sodium depletion may have a vasodilating effect on arterioles.
The use of diuretic agents in the management of heart failure and hypertension is discussed further in Chapters 51 and 55, respectively.

**Thiazide and Related Diuretics**

Thiazide diuretics are synthetic drugs that are chemically related to the sulfonamides and differ mainly in their duration of action. Hydrochlorothiazide is the most commonly used; chlorothiazide is the only one that can be given IV. Related diuretics are nonthiazides whose pharmacologic actions are essentially the same as those of the thiazides; they include chlorthalidone, metolazone, and quinethazone.

Thiazides and related diuretics are frequently prescribed in the long-term management of heart failure and hypertension. They act to decrease reabsorption of sodium, water, chloride, and bicarbonate in the distal convoluted tubule. Most sodium is reabsorbed before it reaches the distal convoluted tubule and only a small amount is reabsorbed at this site. Thus, these drugs are not strong diuretics. In addition, they are ineffective when immediate diuresis is required (because of their slow onset of action) and relatively ineffective with decreased renal function. They work efficiently only when urine flow is adequate.

These drugs are well absorbed, widely distributed in body fluids, and highly bound to plasma proteins. They accumulate only in the kidneys. Diuretic effects usually occur within 2 hours, peak at 4 to 6 hours, and last 6 to 24 hours. Antihypertensive effects usually last long enough to allow use of a single daily dose. Most of the drugs are excreted unchanged by the kidneys within 3 to 6 hours; some (eg, polythiazide, chlorthalidone) have longer durations of action (48 to 72 hours), attributed to slower excretion.

Thiazides and related drugs are contraindicated in clients allergic to sulfonamide drugs. They must be used cautiously during pregnancy because they cross the placenta and may have adverse effects on the fetus by compromising placental perfusion.

**Loop Diuretics**

Loop diuretics inhibit sodium and chloride reabsorption in the ascending limb of the loop of Henle, where reabsorption of most filtered sodium occurs. Thus, these potent drugs produce significant diuresis, with their sodium-losing effect up to 10 times greater than that of thiazide diuretics. Dosage can be titrated upward as needed to produce greater diuretic effects. Overall, loop diuretics are the most effective and versatile diuretics available for clinical use.

Loop diuretics may be given orally or IV. After oral administration, diuretic effects occur within 30 to 60 minutes, peak in 1 to 2 hours, and last 6 to 8 hours. After IV administration, diuretic effects occur within 5 minutes, peak within 30 minutes, and last about 2 hours. Thus, the drugs produce extensive diuresis for short periods, after which the kidney tubules regain their ability to reabsorb sodium. Actually, the kidneys reabsorb more sodium than usual during this post-diuretic phase, so a high dietary intake of sodium can cause sodium retention and reduce or cancel the diuretic-induced sodium loss. Thus, dietary sodium restriction is required to achieve optimum therapeutic benefits. The drugs are metabolized and excreted by the kidneys, and drug accumulation does not occur even with repeated doses.

Loop diuretics are the diuretics of choice when rapid effects are required (eg, in pulmonary edema) and when renal function is impaired (creatinine clearance < 30 mL/minute).
The drugs are contraindicated during pregnancy unless absolutely necessary.

Furosemide is the most commonly used loop diuretic and serves as the prototype for the group. Bumetanide may be used to produce diuresis in some clients who are allergic to or no longer respond to furosemide. It is more potent than furosemide on a weight basis, and large doses can be given in small volumes. These drugs differ mainly in potency and produce similar effects at equivalent doses (eg, furosemide 40 mg = bumetanide 1 mg).

**Potassium-Sparing Diuretics**

Sodium is normally reabsorbed in the distal tubule in exchange for potassium and hydrogen ions. Potassium-sparing diuretics act at the distal tubule to decrease sodium reabsorption and potassium excretion. This group includes three drugs. One is spironolactone, an aldosterone antagonist. Aldosterone is a hormone secreted by the adrenal cortex. It promotes retention of sodium and water and excretion of potassium by stimulating the sodium–potassium exchange mechanism in the distal tubule. Spironolactone blocks the sodium-retaining effects of aldosterone, and aldosterone must be present for spironolactone to be effective. The other two drugs, amiloride and triamterene, act directly on the distal tubule to decrease the exchange of sodium for potassium, and have similar diuretic activity.

Potassium-sparing diuretics are weak diuretics when used alone. Thus, they are usually given in combination with potassium-losing diuretics to increase diuretic activity and decrease potassium loss. They are contraindicated in the presence of renal insufficiency because their use may cause hyperkalemia through the inhibition of aldosterone and subsequent retention of potassium. Hyperkalemia is the major adverse effect of these drugs; clients receiving potassium-sparing diuretics should not be given potassium supplements and should not be encouraged to eat foods high in potassium or allowed to use salt substitutes. Salt substitutes contain potassium chloride rather than sodium chloride.

**Osmotic Diuretics**

Osmotic agents produce rapid diuresis by increasing the solute load (osmotic pressure) of the glomerular filtrate. The increased osmotic pressure causes water to be pulled from extravascular sites into the bloodstream, thereby increasing blood volume and decreasing reabsorption of water and electrolytes in the renal tubules. Mannitol is useful in managing oliguria or anuria, and it may prevent acute renal failure during prolonged surgery, trauma, or infusion of cisplatin, an antineoplastic agent. Mannitol is effective even when renal circulation and GFR are reduced (eg, in hypovolemic shock, trauma, or dehydration). Other important clinical uses of hyperosmolar agents include reduction of intracranial pressure before or after neurosurgery, reduction of intraocular pressure before certain types of ophthalmic surgery, and urinary excretion of toxic substances. Other osmotic agents are listed in Drugs at a Glance: Diuretic Agents.

**Combination Products**

Thiazide and related diuretics are available in numerous fixed-dose combinations with nondiuretic antihypertensive agents (see Chap. 55) and with potassium-sparing diuretics (Drugs at a Glance: Combination Diuretic Products). A major purpose of the antihypertensive combinations is to increase client convenience and compliance with drug therapy regimens. A major purpose of the diuretic combinations is to prevent potassium imbalances.

---

**Nursing Process**

**Assessment**

Assess the client’s status in relation to baseline data and conditions in which diuretic drugs are used.

- Useful baseline data include serum electrolytes, creatinine, glucose, blood urea nitrogen (BUN), and uric acid, because diuretics may alter these values. Other data are blood pressure readings, weight, amount and appearance of urine output, and measurement of edematous areas, such as ankles or abdomen.
- Observe for edema. Visible edema often occurs in the feet and legs of ambulatory clients. Rapid weight gain may indicate fluid retention.
- With heart failure, numerous signs and symptoms result from edema of various organs and tissues. For example, congestion in the GI tract may cause nausea and vomiting, liver congestion may cause abdominal pain and tenderness, and congestion in the lungs (pulmonary edema) causes rapid, labored breathing, hypoxemia, frothy sputum, and other manifestations of severe respiratory distress.
- Cerebral edema may be manifested by confusion, headache, dizziness, convulsions, unconsciousness, bradycardia, or failure of the pupils to react to light.
- Ascites, which occurs with hepatic cirrhosis, is an accumulation of fluid in the abdominal cavity. The abdomen appears much enlarged.
- With heart failure, fatigue and dyspnea, in addition to edema, are common symptoms.
- Hypertension (blood pressure above 140/90 mm Hg on several measurements) may be the only clinical manifestation present.

**Nursing Diagnoses**

- Excess Fluid Volume in edematous clients, related to retention of sodium and water
• Observe for increased urine output.
• Monitor serum electrolytes for normal values.
• Interview regarding compliance with instructions for diet and drug therapy.
• Monitor compliance with follow-up appointments in outpatients.

**PRINCIPLES OF THERAPY**

**Drug Selection**

The choice of diuretic drug depends primarily on the client’s condition.

1. **Thiazides and related diuretics** are the drugs of choice for most clients who require diuretic therapy, especially for long-term management of heart failure and hypertension. All the drugs in this group have similar effects. For most clients, hydrochlorothiazide is effective.

2. A **loop diuretic** (e.g., furosemide) is preferred when rapid diuretic effects are required or when renal impairment is present.

3. A **potassium-sparing diuretic** may be given concurrently with a potassium-losing diuretic to prevent or manage hypokalemia and to augment the diuretic effect. The two drugs can be given separately or in a fixed-dose combination product (see Drugs at a Glance: Combination Diuretic Products).

4. Two **potassium-losing diuretics** are sometimes given concurrently when an inadequate diuretic response occurs with one of the drugs. The combination of a loop and a thiazide diuretic has synergistic effects because the drugs act in different segments of the renal tubule. The synergistic effects probably result from the increased delivery of sodium to the distal tubule (where thiazides act) as a loop diuretic blocks sodium reabsorption in the loop of Henle. A commonly used combination is furosemide and hydrochlorothiazide (chlorothiazide can be given IV in clients who are unable to take an oral drug). Furosemide and metolazone have also been used. Because a thiazide–loop diuretic combination can induce profound diuresis, with severe sodium, potassium, and volume depletion, its use should be reserved for hospitalized clients who can be closely monitored. If used for ambulatory clients, the thiazide diuretic should be given in very low doses or only occasionally, to avoid serious adverse events.

**Dosage Factors**

Dosage of diuretics depends largely on the client’s condition and response and should be individualized to administer the minimal effective amount.
Diuretics increase urine output and are commonly used to manage hypertension, heart failure, and edema (swelling) from heart, kidney, liver, and other disorders.

While taking a diuretic drug, you need to maintain regular medical supervision so drug effects can be monitored and dosages adjusted when indicated.

Reducing sodium intake in your diet helps diuretic drugs be more effective and allows smaller doses to be taken. Smaller doses are less likely to cause adverse effects. Thus, you need to avoid excessive table salt and obviously salty foods (eg, ham, packaged sandwich meats, potato chips, dill pickles, most canned soups). These foods may aggravate edema or hypertension by causing sodium and water retention.

Diuretics may cause blood potassium imbalances, and either too little or too much damages heart function. Periodic measurements of blood potassium and other substances is one of the major reasons for regular visits to a health care provider.

Too little potassium (hypokalemia) may result from the use of potassium-losing diuretics such as hydrochlorothiazide, Lasix, and several others. To prevent or treat hypokalemia, your doctor may prescribe a potassium chloride supplement or a combination of a potassium-losing and a potassium-saving diuretic (either separately or as a combined product such as Dyazide, Maxzide, or Aldactazide). He or she may also recommend increased dietary intake of potassium-containing foods (eg, bananas, orange juice).

Too much potassium (hyperkalemia) can result from the use of potassium-saving diuretics, the overuse of potassium supplements, or from the use of salt substitutes. Potassium-saving diuretics are not a major cause of hyperkalemia because they are usually given along with a potassium-losing diuretic. If potassium supplements are prescribed, they should be taken as directed. You should not use salt substitutes without consulting your primary health care provider because they contain potassium chloride instead of sodium chloride. Hyperkalemia is most likely to occur in people with decreased kidney function, which often occurs in older adults and people with diabetes.

With diuretic therapy, you will have increased urination, which usually lasts only a few days or weeks if you do not have edema. If you do have edema (eg, in your ankles), you can expect weight loss and decreased swelling as well as increased urination. It is a good idea to check and record your weight 2–3 times per week. Rapid changes in weight often indicate gain or loss of fluid.

Some commonly used diuretics may increase blood sugar levels and cause or aggravate diabetes. If you have diabetes, you may need larger doses of your antidiabetic medications.

Diuretics may cause sensitivity to sunlight. Thus, you need to avoid prolonged exposure to sunlight, use sunscreens, and wear protective clothing.

Do not drink alcoholic beverages or take other medications without the approval of your health care provider.

If you are taking a diuretic to lower your blood pressure, especially with other antihypertensive drugs, you may feel dizzy or faint when you stand up suddenly. This can be prevented or decreased by changing positions slowly. If dizziness is severe, notify your health care provider.

Some commonly used diuretics may increase blood pressure.

Self- or Caregiver Administration

Take or give a diuretic early in the day, if ordered daily, to decrease nighttime trips to the bathroom. Fewer bathroom trips means less interference with sleep and less risk of falls. Ask someone to help you to the bathroom if you are elderly, weak, dizzy, or unsteady in walking (or use a bedside commode).

Take or give most diuretics with or after food to decrease stomach upset. Torsemide (Demadex) may be taken without regard to meals.

If you are taking digoxin, a potassium-losing diuretic, and a potassium supplement, it is very important that you take these drugs as prescribed. This is a common combination of drugs for clients with heart failure and the drugs work together to increase beneficial effects and avoid adverse effects. Stopping or changing the dose of one of these medications while continuing the others can lead to serious illness.

**CLIENT TEACHING GUIDELINES**

**Diuretics**

**General Considerations**

✔ Diuretics increase urine output and are commonly used to manage hypertension, heart failure, and edema (swelling) from heart, kidney, liver, and other disorders.

✔ While taking a diuretic drug, you need to maintain regular medical supervision so drug effects can be monitored and dosages adjusted when indicated.

✔ Reducing sodium intake in your diet helps diuretic drugs be more effective and allows smaller doses to be taken. Smaller doses are less likely to cause adverse effects. Thus, you need to avoid excessive table salt and obviously salty foods (eg, ham, packaged sandwich meats, potato chips, dill pickles, most canned soups). These foods may aggravate edema or hypertension by causing sodium and water retention.

✔ Diuretics may cause blood potassium imbalances, and either too little or too much damages heart function. Periodic measurements of blood potassium and other substances is one of the major reasons for regular visits to a health care provider.

✔ Too little potassium (hypokalemia) may result from the use of potassium-losing diuretics such as hydrochlorothiazide, Lasix, and several others. To prevent or treat hypokalemia, your doctor may prescribe a potassium chloride supplement or a combination of a potassium-losing and a potassium-saving diuretic (either separately or as a combined product such as Dyazide, Maxzide, or Aldactazide). He or she may also recommend increased dietary intake of potassium-containing foods (eg, bananas, orange juice).

✔ Too much potassium (hyperkalemia) can result from the use of potassium-saving diuretics, the overuse of potassium supplements, or from the use of salt substitutes. Potassium-saving diuretics are not a major cause of hyperkalemia because they are usually given along with a potassium-losing diuretic. If potassium supplements are prescribed, they should be taken as directed. You should not use salt substitutes without consulting your primary health care provider because they contain potassium chloride instead of sodium chloride. Hyperkalemia is most likely to occur in people with decreased kidney function, which often occurs in older adults and people with diabetes.

✔ With diuretic therapy, you will have increased urination, which usually lasts only a few days or weeks if you do not have edema. If you do have edema (eg, in your ankles), you can expect weight loss and decreased swelling as well as increased urination. It is a good idea to check and record your weight 2–3 times per week. Rapid changes in weight often indicate gain or loss of fluid.

✔ Some commonly used diuretics may increase blood sugar levels and cause or aggravate diabetes. If you have diabetes, you may need larger doses of your antidiabetic medications.

✔ Diuretics may cause sensitivity to sunlight. Thus, you need to avoid prolonged exposure to sunlight, use sunscreens, and wear protective clothing.

✔ Do not drink alcoholic beverages or take other medications without the approval of your health care provider.

✔ If you are taking a diuretic to lower your blood pressure, especially with other antihypertensive drugs, you may feel dizzy or faint when you stand up suddenly. This can be prevented or decreased by changing positions slowly. If dizziness is severe, notify your health care provider.

✔ Some commonly used diuretics may increase blood pressure.

**Self- or Caregiver Administration**

✔ Take or give a diuretic early in the day, if ordered daily, to decrease nighttime trips to the bathroom. Fewer bathroom trips means less interference with sleep and less risk of falls. Ask someone to help you to the bathroom if you are elderly, weak, dizzy, or unsteady in walking (or use a bedside commode).

✔ Take or give most diuretics with or after food to decrease stomach upset. Torsemide (Demadex) may be taken without regard to meals.

✔ If you are taking digoxin, a potassium-losing diuretic, and a potassium supplement, it is very important that you take these drugs as prescribed. This is a common combination of drugs for clients with heart failure and the drugs work together to increase beneficial effects and avoid adverse effects. Stopping or changing the dose of one of these medications while continuing the others can lead to serious illness.
1. With hydrochlorothiazide, smaller doses (e.g., 12.5 to 25 mg daily) are effective for most people and produce fewer adverse effects (e.g., hypokalemia) than larger doses. Some of the fixed-dose combinations of hydrochlorothiazide and a potassium-sparing diuretic contain 50 mg of hydrochlorothiazide. As a result, despite the convenience of a combination product, it may be better to give the drugs separately so that dosage can be titrated to the client’s needs.

2. Clients who do not achieve an adequate diuretic response with usual doses of an oral drug may need larger doses or an IV drug.

3. With torsemide, which is highly bioavailable after oral administration, oral and IV doses are equivalent and clients may be switched from one route to the other without changing dosage.

4. In liver disease, small doses of all diuretics are usually indicated because diuretic-induced electrolyte imbalances may precipitate or aggravate hepatic coma.

5. In renal disease, furosemide is often given in large doses to achieve a diuretic response. Bumetanide may be a useful alternative, because it can be given in smaller dose volumes.

6. When metolazone is given concurrently with furosemide, the initial dose is usually metolazone 2.5 to 10 mg. The dose is then doubled every 24 hours until the desired response is achieved. If an adequate diuretic effect occurs with the first dose of metolazone, the dose of furosemide can be decreased. Hydrochlorothiazide 50 mg may also be used with furosemide and may be safer than metolazone because of its shorter duration of action.

**Use in Edema**

When diuretics are used to manage clients with edema, the underlying cause of the edema should be addressed, not just the edema itself. When managing such clients, it is preferable to aim for a weight loss of approximately 2 lb (1 kg) per day. Rapid and excessive diuresis may cause dehydration and decreased blood volume with circulatory collapse. In some clients, giving a diuretic every other day or 3 to 5 days per week may be effective and is less likely to cause electrolyte imbalances.

**Use With Digoxin**

When digoxin and diuretics are given concomitantly, as is common for clients with heart failure, the risk of digoxin toxicity is increased. Digoxin toxicity is related to diuretic-induced hypokalemia. Potassium is a myocardial depressant and antidysrhythmic; it has essentially opposite cardiac effects to those of digoxin. In other words, extracellular potassium decreases the excitability of myocardial tissue, but digoxin increases excitability. The higher the serum potassium, the less effective a given dose of digoxin will be. Conversely, decreased serum potassium increases the likelihood of digoxin-induced cardiac dysrhythmias, even with small doses and therapeutic serum levels of digoxin.

Supplemental potassium chloride, a potassium-sparing diuretic, and other measures to prevent hypokalemia are often used to maintain normal serum potassium levels (3.5 to 5.0 mEq/L).

**Prevention and Management of Potassium Imbalances**

Potassium imbalances (see Chap. 32) may occur with diuretic therapy. Hypokalemia and hyperkalemia are cardiotoxic and should be prevented when possible.

1. **Hypokalemia** (serum potassium level <3.5 mEq/L) may occur with potassium-losing diuretics (e.g., hydrochlorothiazide, furosemide). Measures to prevent or manage hypokalemia include the following:
   a. Giving low doses of the diuretic (e.g., 12.5 to 25 mg daily of hydrochlorothiazide)
   b. Giving supplemental potassium, usually potassium chloride, in an average dosage range of 20 to 60 mEq daily. Sustained-release tablets are usually better tolerated than liquid preparations.
   c. Giving a potassium-sparing diuretic along with the potassium-losing drug
   d. Increasing food intake of potassium. Many texts advocate this approach as preferable to supplemental potassium or combination diuretic therapy, but its effectiveness is not clearly established. Although the
minimal daily requirement of potassium is unknown, usual recommendations are 40 to 50 mEq daily for the healthy adult. Potassium loss with diuretics may be several times this amount.

Some foods (eg, bananas) have undeserved reputations for having high potassium content; actually, large amounts must be ingested. To provide 50 mEq of potassium daily, estimated amounts of certain foods include 1000 mL of orange juice, 1600 mL of apple or grape juice, 1200 mL of pineapple juice, four to six bananas, or 30 to 40 prunes. Some of these foods are high in calories and may be contraindicated, at least in large amounts, for obese clients. Also, the amount of carbohydrate in these foods may be a concern for clients with diabetes mellitus.

e. Restricting dietary sodium intake. This reduces potassium loss by decreasing the amount of sodium available for exchange with potassium in renal tubules.

2. Hyperkalemia (serum potassium level >5 mEq/L) may occur with potassium-sparing diuretics. The following measures help prevent hyperkalemia:
   a. Avoiding use of potassium-sparing diuretics and potassium supplements in clients with renal impairment
   b. Avoiding excessive amounts of potassium chloride supplements
   c. Avoiding salt substitutes
   d. Maintaining urine output, the major route for eliminating potassium from the body

Use in Children

Although they have not been extensively studied in children, diuretics are commonly used to manage heart failure, which often results from congenital heart disease; hypertension, which is usually related to cardiac or renal dysfunction; bronchopulmonary dysplasia and respiratory distress syndrome, which are often associated with pulmonary edema; and edema, which may occur with cardiac or renal disorders such as the nephrotic syndrome.

With most thiazides, safety and effectiveness have not been established for use in children. Hydrochlorothiazide is used in doses of approximately 2.2 mg/kg/day. IV chlorothiazide usually is not recommended. Thiazides do not commonly cause hyperglycemia, hyperuricemia, or hypercalcemia in children, as they do in adults.

Although metolazone, a thiazide-related drug, is not usually recommended, it is sometimes used. Metolazone has some advantages over a thiazide because it is a stronger diuretic, causes less hypokalemia, and can produce diuresis in renal failure. In children, it is most often used with furosemide, in which case it is most effective when given 30 to 60 minutes before the furosemide.

Furosemide is the loop diuretic used most often in children. Oral therapy is preferred when feasible, and doses above 6 mg/kg/day are not recommended. In preterm infants, furosemide stimulates production of prostaglandin E2 in the kidneys and may increase the incidence of patent ductus arteriosus and neonatal respiratory distress syndrome. In neonates, furosemide may be given with indomethacin to prevent non-steroidal anti-inflammatory drug–induced nephrotoxicity during therapeutic closure of a patent ductus arteriosus. In both preterm and full-term infants, furosemide half-life is prolonged but becomes shorter as renal and hepatic functions develop.

Adverse effects of furosemide include fluid and electrolyte imbalances (eg, hypotension, hypokalemia, fluid volume deficit) and ototoxicity. Serum electrolytes should be closely monitored in children because of frequent changes in kidney function and fluid distribution associated with growth and development. Ototoxicity, which is associated with high plasma drug levels (>50 mcg/mL), can usually be avoided by dividing oral doses, and by slow injection or continuous infusion of IV doses.

Safety and effectiveness of bumetanide, ethacrynic acid, and torsemide have not been established. However, bumetanide may cause less ototoxicity and thus may be preferred for children who are taking other ototoxic drugs (eg, premature and ill neonates are often given gentamicin, an aminoglycoside antibiotic). Bumetanide may also cause less hypokalemia. The half-life of bumetanide is about 2 hours in critically ill infants and 1 hour in children.

Spironolactone is the most widely used potassium-sparing diuretic in children. It is used with other diuretics to decrease potassium loss and hypokalemia. Spironolactone accumulates in renal failure, and dosage should be reduced. It usually should not be used in severe renal failure.

Use in Older Adults

Thiazide diuretics are often prescribed for the management of hypertension and heart failure, which are common in older adults. Older adults are especially sensitive to adverse drug effects, such as hypotension and electrolyte imbalance. Thiazides may aggravate renal or hepatic impairment. With rapid or excessive diuresis, myocardial infarction, renal impairment, or cerebral thrombosis may occur from fluid volume depletion and hypotension. The smallest effective dose is recommended, usually a daily dose of 12.5 to 25 mg of hydrochlorothiazide or equivalent doses of other thiazides and related drugs. Risks of adverse effects may exceed benefits at doses of hydrochlorothiazide greater than 25 mg.

With loop diuretics, older adults are at greater risk of excessive diuresis, hypotension, fluid volume deficit, and possibly thrombosis or embolism. Rapid diuresis may cause urinary incontinence. With potassium-sparing diuretics, hyperkalemia is more likely to occur in older adults because of the renal impairment that occurs with aging.

Use in Renal Impairment

Most clients with renal impairment require diuretics as part of their drug therapy regimens. In these clients, the diuretic
response may be reduced and edema of the gastrointestinal [GI] tract may limit absorption of oral medications.

Thiazides may be useful in managing edema due to renal disorders such as nephrotic syndrome and acute glomerulonephritis. However, their effectiveness decreases as the GFR decreases, and the drugs become ineffective when the GFR is less than 30 mL/minute. The drugs may accumulate and increase adverse effects in clients with impaired renal function. Thus, renal function tests should be performed periodically. If progressive renal impairment becomes evident (eg, a rising serum creatinine or blood urea nitrogen [BUN]), a thiazide usually should be discontinued and metolazone, indapamide, or a loop diuretic may be given. Metolazone and indapamide are thiazide-related diuretics that may be effective in clients with significantly impaired renal function.

Loop diuretics are effective in clients with renal impairment. However, in chronic renal failure, they have lower peak concentrations at their site of action, which decreases diuresis. Renal elimination of the drugs is also prolonged. If renal dysfunction becomes more severe during treatment (eg, oliguria, increases in BUN or creatinine) the diuretic may need to be discontinued. If high doses of furosemide are used, a volume-controlled IV infusion at a rate of 4 mg/minute or less may be used. If IV bumetanide is given, a continuous infusion (eg, 12 mg over 12 hours) produces more diuresis than equivalent-dose intermittent injections. Continuous infusion also produces lower serum drug levels and therefore may decrease adverse effects.

Potassium-sparing diuretics are contraindicated in clients with renal impairment because of the high risk of hyperkalemia. If they are used at all, frequent monitoring of serum electrolytes, creatinine, and BUN is needed.

**Use in Hepatic Impairment**

Diuretics are often used to manage edema and ascites in clients with hepatic impairment. They must be used with caution because diuretic-induced fluid and electrolyte imbalances may precipitate or worsen hepatic encephalopathy and coma. In clients with cirrhosis, diuretic therapy should be initiated in a hospital setting, with small doses and careful monitoring. To prevent hypokalemia and metabolic alkalosis, supplemental potassium or spironolactone may be needed.

**Use in Critical Illness**

Fast-acting, potent diuretics such as furosemide and bumetanide are the most likely diuretics to be used in critically ill clients (eg, those with pulmonary edema). In clients with severe renal impairment, high doses are required to produce diuresis. Large doses may produce fluid volume depletion and worsen renal function. Although IV bolus doses of the drugs are often given, continuous IV infusions may be more effective and less likely to produce adverse effects in critically ill clients.

**Home Care**

Diuretics are often taken in the home setting. The home care nurse may need to assist clients and caregivers in using the drugs safely and effectively, monitor client responses (eg, assess nutritional status, blood pressure, weight, and use of over-the-counter medications that may aggravate edema or hypertension with each home visit), and provide information as indicated. In some cases, the home care nurse may need to assist the client in obtaining medications or blood tests (eg, serum potassium levels).

### NURSING ACTIONS

#### Diuretics

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give in the early morning if ordered daily.</td>
<td>So that peak action will occur during waking hours and not interfere with sleep</td>
</tr>
<tr>
<td>b. Take safety precautions. Keep a bedpan or urinal within reach. Keep the call light within reach, and be sure the client knows how to use it. Assist to the bathroom anyone who is elderly, weak, dizzy, or unsteady in walking.</td>
<td>Mainly to avoid falls</td>
</tr>
<tr>
<td>c. Give amiloride and triamterene with or after food</td>
<td>To decrease gastrointestinal (GI) upset</td>
</tr>
<tr>
<td>d. Give intravenous (IV) injections of furosemide and bumetanide over 1–2 min; give torsemide over 2 min.</td>
<td>To decrease or avoid high peak serum levels, which increase risks of adverse effects, including ototoxicity</td>
</tr>
<tr>
<td>e. Give high-dose furosemide continuous IV infusions at a rate of 4 mg/min or less</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
**CHAPTER 56 DIURETICS**

**NURSING ACTIONS**

2. Observe for therapeutic effects

   a. Decrease or absence of edema, increased urine output, decreased blood pressure

      (1) Weigh the client daily while edema is present and two to three times weekly thereafter. Weigh under standard conditions: early morning before eating or drinking, after urination, with the same amount of clothing, and using the same scales.

      (2) Record fluid intake and output every shift for hospitalized clients.

      (3) Observe and record characteristics of urine.

      (4) Assess for edema daily or with each client contact: ankles for the ambulatory client, sacral area and posterior thighs for clients at bed rest. Also, it is often helpful to measure abdominal girth, ankles, and calves to monitor gain or loss of fluid.

      (5) In clients with heart failure or acute pulmonary edema, observe for decreased dyspnea, crackles, cyanosis, and cough.

      (6) Record blood pressure 2 to 4 times daily when diuretic therapy is initiated.

3. Observe for adverse effects

   a. With potassium-losing diuretics (thiazides, bumetanide, furosemide, ethacrynic acid), observe for:

      (1) Hypokalemia

         (a) Serum potassium levels below 3.5 mEq/L

         (b) Electrocardiographic (ECG) changes (eg, low voltage, flattened T wave, depressed ST segment)

         (c) Cardiac dysrhythmias; weak, irregular pulse

         (d) Hypotension

         (e) Weak, shallow respirations

         (f) Anorexia, nausea, vomiting

         (g) Decreased peristalsis or paralytic ileus

         (h) Skeletal muscle weakness

         (i) Confusion, disorientation

Most oral diuretics act within 2 h; IV diuretics act within minutes. Optimal antihypertensive effects occur in approximately 2–4 wk.

Body weight is a very good indicator of fluid gain or loss. A weight change of 2.2 lb (1 kg) may indicate a gain or loss of 1000 mL of fluid. Also, weighing assists in dosage regulation to maintain therapeutic benefit without excessive or too rapid fluid loss.

Normally, oral fluid intake approximates urinary output (1500 mL/24 h). With diuretic therapy, urinary output may exceed intake, depending on the amount of edema or fluid retention, renal function, and diuretic dosage. All sources of fluid gain, including IV fluids, must be included; all sources of fluid loss (perspiration, fever, wound drainage, GI tract drainage) are important. Clients with abnormal fluid losses have less urine output with diuretic therapy. Oliguria (decreased excretion of urine) may require stopping the drug. Output greater than 100 mL/h may indicate that side effects are more likely to occur.

Dilute urine may indicate excessive fluid intake or greater likelihood of fluid and electrolyte imbalance due to rapid diuresis. Concentrated urine may mean oliguria or decreased fluid intake.

Expect a decrease in visible edema and size of measured areas. If edema reappears or worsens, a thorough reassessment of the client is in order. Questions to be answered include:

   (1) Is the prescribed diuretic being taken correctly?

   (2) What type of diuretic and what dosage is ordered?

   (3) Is there worsening of the underlying condition(s) that led to edema formation?

   (4) Has other disease developed?

Decreased fluid in the lungs leads to improved respirations as more carbon dioxide and oxygen gas exchange takes place and greater tissue oxygenation occur.

Although thiazide diuretics do not lower normal blood pressure, other diuretics may, especially with excessive or rapid diuresis. Major adverse effects are fluid and electrolyte imbalances.

Potassium is required for normal muscle function. Thus, potassium depletion causes weakness of cardiovascular, respiratory, digestive, and skeletal muscles. Clients most likely to have hypokalemia are those who are taking large doses of diuretics, potent diuretics (eg, furosemide), or adrenal corticosteroids; those who have decreased food and fluid intake; or those who have increased potassium losses through vomiting, diarrhea, chronic laxative or enema use, or GI suction. Clinically significant symptoms are most likely to occur with a serum potassium level below 3 mEq/L.

(continued)
<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Hyponatremia, hypomagnesemia, hypochloremic alkalosis, changes in serum and urinary calcium levels</td>
<td>In addition to potassium, sodium chloride, magnesium, and bicarbonate also are lost with diuresis. Thiazides and related diuretics cause hypercalcemia and hypocalciuria. They have been used to prevent calcium nephrolithiasis (kidney stones). Furosemide and other loop diuretics tend to cause hypocalcemia and hypercalciuria. Fluid volume depletion occurs with excessive or rapid diuresis. If it is prolonged or severe, hypovolemic shock may occur.</td>
</tr>
<tr>
<td>(3) Dehydration</td>
<td>Hyperglycemia is more likely to occur in clients with known or latent diabetes mellitus. Larger doses of hypoglycemic agents may be required. The hyperglycemic effect may be reversible when diuretic therapy is discontinued.</td>
</tr>
<tr>
<td>(a) Poor skin turgor, dry mucous membranes</td>
<td>Long-term use of a thiazide or loop diuretic may alter glucose metabolism. One mechanism is thought to involve diuretic-induced hypokalemia and hypomagnesemia, which then leads to decreased postprandial insulin release. Another mechanism may be development or worsening of insulin resistance.</td>
</tr>
<tr>
<td>(b) Oliguria, urine of high specific gravity</td>
<td>Because glucose intolerance is an important risk factor for coronary artery disease, diuretics should be used with caution in pre-diabetic or diabetic hypertensive clients.</td>
</tr>
<tr>
<td>(c) Thirst</td>
<td>Hyperuricemia is usually asymptomatic except for clients with gout, a predisposition toward gout, or chronic renal failure. Apparently, decreased renal excretion of uric acid allows its accumulation in the blood.</td>
</tr>
<tr>
<td>(d) Tachycardia; hypotension</td>
<td>Pulmonary edema is most likely to occur in clients with heart failure who cannot tolerate the increased blood volume produced by the drugs.</td>
</tr>
<tr>
<td>(e) Decreased level of consciousness</td>
<td>Reversible or transient hearing impairment, tinnitus, and dizziness are more common, although irreversible deafness may occur. Ototoxicity is more likely to occur with high serum drug levels (eg, high doses or use in clients with severe renal impairment) or when other ototoxic drugs (eg, aminoglycoside antibiotics) are being taken concurrently.</td>
</tr>
<tr>
<td>(f) Elevated hematocrit (above 45%)</td>
<td>Hyperkalemia is most likely to occur in clients with impaired renal function or those who are ingesting additional potassium (eg, salt substitutes)</td>
</tr>
<tr>
<td>(4) Hyperglycemia—blood glucose above 120 mg/100 mL, polyuria, polydipsia, polyphagia, glycosuria</td>
<td></td>
</tr>
<tr>
<td>(5) Hyperuricemia—serum uric acid above 7.0 mg/100 mL</td>
<td></td>
</tr>
<tr>
<td>(6) Pulmonary edema (with osmotic diuretics)</td>
<td></td>
</tr>
<tr>
<td>(7) Ototoxicity (with furosemide and ethacrynic acid)</td>
<td></td>
</tr>
<tr>
<td>b. With potassium-sparing diuretics (spironolactone, triamterene, amiloride), observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Hyperkalemia</td>
<td></td>
</tr>
<tr>
<td>(a) Serum potassium levels above 5 mEq/L</td>
<td></td>
</tr>
<tr>
<td>(b) ECG changes (ie, prolonged P-R interval; wide QRS complex; tall, peaked T wave; depressed ST segment)</td>
<td></td>
</tr>
<tr>
<td>(c) Cardiac dysrhythmias, which may progress to ventricular fibrillation and asystole</td>
<td></td>
</tr>
<tr>
<td>4. Observe for drug interactions</td>
<td></td>
</tr>
<tr>
<td>a. Drugs that increase effects of diuretics:</td>
<td></td>
</tr>
<tr>
<td>(1) Aminoglycoside antibiotics</td>
<td>Additive ototoxicity with ethacrynic acid</td>
</tr>
<tr>
<td>b. With potassium-sparing diuretics (spironolactone, triamterene, amiloride), observe for:</td>
<td></td>
</tr>
<tr>
<td>(1) Hyperkalemia</td>
<td></td>
</tr>
<tr>
<td>(a) Serum potassium levels above 5 mEq/L</td>
<td></td>
</tr>
<tr>
<td>(b) ECG changes (ie, prolonged P-R interval; wide QRS complex; tall, peaked T wave; depressed ST segment)</td>
<td></td>
</tr>
<tr>
<td>(c) Cardiac dysrhythmias, which may progress to ventricular fibrillation and asystole</td>
<td></td>
</tr>
<tr>
<td>(continued)</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
NURSING ACTIONS | RATIONALE/EXPLANATION
--- | ---
(2) Antihypertensive agents | Additive hypotensive effects. In addition, angiotensin-converting enzyme inhibitor therapy significantly increases risks of hyperkalemia with spironolactone.
(3) Corticosteroids | Additive hypokalemia
b. Drugs that decrease effects of diuretics: | These drugs cause retention of sodium and water.
(1) Nonsteroidal anti-inflammatory drugs (eg, aspirin, ibuprofen, others) | Retention of sodium and water
(2) Oral contraceptives | These drugs may antagonize hypotensive effects of diuretics by decreasing responsiveness of arterioles.
(3) Vasopressors (eg, epinephrine, norepinephrine) | 

Nursing Notes: Apply Your Knowledge

**Answer:** Assess blood pressure and compare this value with baseline blood pressure readings over the last few days. If blood pressure is significantly different from baseline (very high or greater than 180/90; very low or less than 100/60), notify the prescriber because adjustment of medications may be indicated. Postural blood pressure should be monitored because orthostatic hypotension is likely for clients on these medications. When orthostatic hypotension is present, instruct the client to rise slowly, sitting until dizziness has passed. Daily weight and intake and output records should also be assessed to evaluate whether drug therapy is effective. Check for signs of hypokalemia and serum potassium levels. This is especially important because the client is on a high dose (80 mg/day) of a potassium-wasting diuretic without potassium supplementation. Hypokalemia can increase the risk of cardiac dysrhythmias.

How Can You Avoid This Medication Error?

**Answer:** The purpose of the diuretic therapy is to pull off excessive fluid, but the assessment data gathered from Mr. Vallera (significant weight loss—almost 10 lb in 1 day; orthostatic blood pressure with elevated pulse, which indicates volume depletion; and hypokalemia) indicate that diuresis is occurring too rapidly. It is always important to evaluate assessment data before giving a medication, so that a medication can be held if the client’s condition warrants it.

Review and Application Exercises

1. What are clinical indications for the use of diuretics?
2. What is the general mechanism by which diuretics act?
3. How can you assess a client for therapeutic effects of a diuretic?
4. Compare and contrast the main groups of diuretics in terms of adverse effects.
5. Why should serum potassium levels be monitored during diuretic therapy?
6. Which prescription and over-the-counter drugs may decrease the effects of a diuretic?
7. For a client who is starting diuretic therapy, what are important points to teach the client about safe and effective drug usage?
8. For a client who is taking a potassium-losing diuretic and a potassium chloride supplement, explain the possible consequences of discontinuing one drug while continuing the other.

SELECTED REFERENCES

Drugs That Affect Blood Coagulation

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe important elements in the physiology of hemostasis and thrombosis.
2. Discuss potential consequences of blood clotting disorders.
3. Discuss characteristics and uses of anticoagulant, antiplatelet, and thrombolytic agents.
4. Compare and contrast heparin and warfarin in terms of indications for use, onset and duration of action, route of administration, blood tests used to monitor effects, and nursing process implications.
5. Teach clients on long-term warfarin therapy protective measures to prevent abnormal bleeding.
6. Discuss antiplatelet agents in terms of indications for use and effects on blood coagulation.
7. With aspirin, contrast the dose and frequency of administration for antiplatelet effects with those for analgesic, antipyretic, and anti-inflammatory effects.
8. Describe thrombolytic agents in terms of indications and contraindications for use, routes of administration, and major adverse effects.
9. Discuss the use of anticoagulant, antiplatelet, and thrombolytic drugs in special populations.
10. Describe systemic hemostatic agents for treating overdoses of anticoagulant and thrombolytic drugs.

Critical Thinking Scenario
Juan Sanchez, a 56-year-old migrant farmer without health insurance, is admitted to the hospital after an episode of syncope. He is diagnosed with atrial fibrillation and is started on a calcium channel blocker and Coumadin. Before his discharge, you are responsible for patient teaching.

Reflect on:
- Assessment data that would be helpful to individualize your teaching plan.
- Discuss the rationale for use of Coumadin for clients with atrial fibrillation.
- Identify side effects of Coumadin therapy.
- Consider strategies that might help Mr. Sanchez comply with therapy and experience limited side effects.

OVERVIEW
Anticoagulant, antiplatelet, and thrombolytic drugs are used in the prevention and management of thrombotic and thromboembolic disorders. Thrombosis involves the formation (thrombogenesis) or presence of a blood clot (thrombus) in the vascular system. Blood clotting is a normal body defense mechanism to prevent blood loss. Thus, thrombogenesis may be lifesaving when it occurs as a response to hemorrhage; however, it may be life threatening when it occurs at other times, because the thrombus can obstruct a blood vessel and block blood flow to tissues beyond the clot. When part of a thrombus breaks off and travels to another part of the body, it is called an embolus.

Atherosclerosis is the basic disease process that often leads to pathologic thrombosis. It begins with accumulation of lipid-filled macrophages (ie, foam cells) on the inner lining of arteries. Foam cells develop in response to elevated blood lipid levels and eventually become fibrous plaques (ie, foam cells covered by smooth muscle cells and connective tissue). Advanced atherosclerotic lesions also contain hemorrhages, ulcerations, and scar tissue.

Atherosclerosis can affect any organ or tissue, but often involves the arteries supplying the heart, brain, and legs. Over time, plaque lesions become larger and extend farther into the lumen of the artery. Eventually, a thrombus may develop at plaque sites and partially or completely occlude an artery. In coronary arteries, a thrombus may precipi-
tate myocardial ischemia (angina or infarction) (see Chapter 53); in carotid or cerebral arteries, a thrombus may precipitate a stroke; in peripheral arteries, a thrombus may cause intermittent claudication (pain in the legs with exercise) or acute occlusion. Thus, serious impairment of blood flow may occur with a large atherosclerotic plaque or a relatively small plaque with superimposed vasospasm and thrombosis. Consequences and clinical manifestations of thrombi and emboli depend primarily on their location and size.

Normally, thrombi are constantly being formed and dissolved (thrombolysis), but the blood stays fluid and flow is not significantly obstructed. If the balance between thrombogenesis and thrombolysis is upset, thrombotic or bleeding disorders result. Thrombotic disorders occur much more often than bleeding disorders and are emphasized in this chapter; bleeding disorders may result from excessive amounts of drugs that inhibit clotting. To aid understanding of drug therapy for thrombotic disorders, normal hemostasis, endothelial functions in relation to blood clotting, platelet functions, blood coagulation, and characteristics of arterial and venous thrombosis are described.

### HEMOSTASIS

**Hemostasis** is prevention or stoppage of blood loss from an injured blood vessel and is the process that maintains the integrity of the vascular compartment. It involves activation of several mechanisms, including vasoconstriction, formation of a platelet plug (a cluster of aggregated platelets), sequential activation of clotting factors in the blood (Table 57–1), and growth of fibrous tissue (fibrin) into the blood clot to make it more stable and to repair the tear (opening) in the damaged blood vessel. Overall, normal hemostasis is a complex process involving numerous interacting activators and inhibitors, including endothelial factors, platelets, and blood coagulation factors (Box 57–1).

### CLOTLYSIS

When a blood clot is being formed, plasminogen (an inactive protein found in many body tissues and fluids) is bound to fibrin and becomes a component of the clot. After the outward blood flow is stopped and the tear in the blood vessel repaired, plasminogen is activated by plasminogen activator (produced by endothelial cells or the coagulation cascade) to produce plasmin. Plasmin is an enzyme that breaks down the fibrin meshwork that stabilizes the clot; this fibrinolytic or thrombolytic action dissolves the clot.

### THROMBOTIC AND THROMBOEMBOLIC DISORDERS

Thrombosis may occur in both arteries and veins. Arterial thrombosis is usually associated with atherosclerotic plaque, hypertension, and turbulent blood flow. These conditions damage arterial endothelium and activate platelets to initiate the coagulation process. Arterial thrombi cause disease by obstructing blood flow. If the obstruction is incomplete or temporary, local tissue ischemia (deficient blood supply) occurs. If the obstruction is complete or prolonged, local tissue death or infarction occurs.

Venous thrombosis is usually associated with venous stasis. When blood flows slowly, thrombin and other procoagulant substances present in the blood become concentrated in local areas and initiate the clotting process. With a normal rate of blood flow, these substances are rapidly removed from the blood, primarily by Kupffer cells in the liver. A venous thrombus is less cohesive than an arterial thrombus, and an embolus can easily become detached and travel to other parts of the body.

Venous thrombi cause disease by two mechanisms. First, thrombosis causes local congestion, edema, and perhaps inflammation by impairing normal outflow of venous blood (eg, thrombophlebitis, deep vein thrombosis [DVT]). Sec-

---

**TABLE 57–1 Blood Coagulation Factors**

<table>
<thead>
<tr>
<th>Number</th>
<th>Name</th>
<th>Functions</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Fibrinogen</td>
<td>Forms fibrin, the insoluble protein strands that compose the supporting frame of a blood clot. Thrombin and calcium are required for the conversion.</td>
</tr>
<tr>
<td>II</td>
<td>Prothrombin</td>
<td>Forms thrombin, which catalyzes the conversion of fibrinogen to fibrin in the blood.</td>
</tr>
<tr>
<td>III</td>
<td>Thromboplastin</td>
<td>Converts prothrombin to thrombin in the blood.</td>
</tr>
<tr>
<td>IV</td>
<td>Calcium</td>
<td>Catalyzes the conversion of prothrombin to thrombin in the blood.</td>
</tr>
<tr>
<td>V</td>
<td>Labile factor</td>
<td>Required for formation of active thromboplastin in the blood.</td>
</tr>
<tr>
<td>VII</td>
<td>Proconvertin or stable factor</td>
<td>Accelerates action of tissue thromboplastin in the blood.</td>
</tr>
<tr>
<td>VIII</td>
<td>Antihemophilic factor</td>
<td>Promotes breakdown of platelets and formation of active platelet thromboplastin in the blood.</td>
</tr>
<tr>
<td>IX</td>
<td>Christmas factor</td>
<td>Similar to factor VIII</td>
</tr>
<tr>
<td>X</td>
<td>Stuart factor</td>
<td>Promotes action of thromboplastin in the blood.</td>
</tr>
<tr>
<td>XI</td>
<td>Plasma thromboplastin antecedent</td>
<td>Promotes platelet aggregation and breakdown, with subsequent release of platelet thromboplastin in the blood.</td>
</tr>
<tr>
<td>XII</td>
<td>Hageman factor</td>
<td>Similar to factor XI</td>
</tr>
<tr>
<td>XIII</td>
<td>Fibrin-stabilizing factor</td>
<td>Converts fibrin meshwork to the dense, tight mass of the completely formed clot in the blood.</td>
</tr>
</tbody>
</table>
The blood vessels and blood normally maintain a balance between procoagulant and antiocoagulant factors that favors anticoagulation and keeps the blood fluid. Injury to blood vessels and tissues causes complex reactions and interactions among vascular endothelial cells, platelets, and blood coagulation factors that shift the balance toward procoagulation and thrombosis.

**Endothelial Cells**

Endothelial cells play a role in all aspects of hemostasis and thrombosis. Normal endothelium helps to prevent thrombosis by producing anticoagulant factors, inhibiting platelet reactivity, and inhibiting activation of the coagulation cascade. However, endothelium promotes thrombosis when its continuity is lost (eg, the blood vessel wall is torn by rupture of atherosclerotic plaque, hypertension, trauma), its function is altered, or when blood flow is altered or becomes static. After a blood clot is formed, the endothelium also induces its dissolution and restoration of blood flow.

**Antithrombotic Functions**

- Synthesizes and releases prostacyclin (prostaglandin I₂), which inhibits platelet aggregation
- Releases endothelium-derived relaxing factor (nitric oxide), which inhibits platelet adhesion and aggregation
- Blocks platelet exposure to subendothelial collagen and other stimuli for platelet aggregation
- May inhibit platelet reactivity by inactivating adenosine diphosphate (ADP), a platelet product that promotes platelet aggregation
- Produces plasminogen activators (eg, tissue-type or tPA) in response to shear stress and such agonists as histamine and thrombin. These activators convert inactive plasminogen to plasmin, which then breaks down fibrin and dissolves blood clots (fibrinolytic effects).
- Produces thrombomodulin, a protein that helps prevent formation of intravascular thrombi by inhibiting thrombin-mediated platelet aggregation. Thrombomodulin also reacts with thrombin to activate proteins C and S, which inhibit the plasma cascade of clotting factors.

**Prothrombotic Functions**

- Produces antifibrinolytic factors. Normally, the balance between profibrinolysis and antifibrinolysis favors fibrinolysis (clot dissolution). In pathologic conditions, including atherosclerosis, fibrinolysis may be limited and thrombosis enhanced.
- In pathologic conditions, may induce synthesis of prothrombotic factors such as von Willebrand factor. Von Willebrand factor serves as a site for subendothelial platelet adhesion and as a carrier for blood coagulation factor VIII in plasma. Several disease states are associated with increased or altered production of von Willebrand factor, including atherosclerosis.
- Produces tissue factor, which activates the extrinsic coagulation pathway after exposure to oxidized low-density lipoprotein cholesterol, homocysteine, and cytokines (eg, interleukin-1, tumor necrosis factor–alpha)

**Platelets**

Platelets (also called thrombocytes) are fragments of large cells called megakaryocytes. They are produced in the bone marrow and released into the bloodstream, where they circulate for approximately 7 to 10 days before they are removed by the spleen. They contain no nuclei and therefore cannot repair or replicate themselves.

The cell membrane of a platelet contains a coat of glycoproteins that prevents the platelet from adhering to normal endothelium but allows it to adhere to damaged areas of endothelium and subendothelial collagen in the blood vessel wall. It also contains receptors for ADP, collagen, blood coagulation factors such as fibrinogen, and other substances. Breakdown of the cell membrane releases arachidonic acid (which can be metabolized to produce thromboxane A₂) and allows leakage of platelet contents (eg, thromboplastin and other clotting factors), which function to stop bleeding.

The cytoplasm of a platelet contains storage granules with ADP, fibrinogen, histamine, platelet-derived growth factor, serotonin, von Willebrand factor, enzymes that produce thromboxane A₂, and other substances. The cytoplasm also contains contractile proteins that contract storage granules so they empty their contents and help a platelet plug to retract and plug a hole in a torn blood vessel.

The only known function of platelets is hemostasis. When platelets come in contact with a damaged vascular surface, they become activated and undergo changes in structure and function. They enlarge, express receptors on their surfaces, release mediators from their storage granules, become sticky so that they adhere to endothelial and collagen cells, and form a platelet thrombus (ie, a cluster or aggregate of activated platelets) within seconds. The thrombus blocks the tear in the blood vessel and prevents further leakage of blood. Platelets usually disappear from a blood clot within 24 hours and are replaced by fibrin.

Formation of a platelet thrombus proceeds through the phases of activation, adhesion, aggregation, and procoagulation.

**Activation**

Platelet activation occurs when agonists such as thrombin, collagen, ADP, or epinephrine bind to their specific receptors on the platelet cell membrane surface. Activated platelets release von Willebrand factor, which aids platelet adhesion to blood vessel walls. They also secrete ADP and thromboxane A₂ into the blood. The ADP and thromboxane A₂ activate and recruit nearby platelets.

**Adhesion**

Platelet adhesion involves changes in platelets that allow them to adhere to endothelial cells and subendothelial collagen exposed by damaged endothelium. Adhesion is mediated by interactions between platelets and substances in the subendothelial tissues. Platelets contain binding sites for several subendothelial tissue proteins, including collagen and von Willebrand factor. In capillaries, where blood shear rates are high, platelets also can bind indirectly to collagen through von Willebrand factor. Von Willebrand factor is synthesized by endothelial cells and megakaryocytes. Although it contains binding sites for platelets and collagen, it does not normally bind with platelets until they are activated.

**Aggregation**

Aggregation involves the accumulation of platelets at a site of injury to a blood vessel wall and is stimulated by ADP, collagen, thromboxane A₂, thrombin, and other factors. It requires the binding of extracellular fibrinogen to platelet fibrinogen receptors. The fibrinogen receptor is located on a complex of two glycoproteins (GPIIb and IIIa) in the platelet cell membrane. Although many GP IIb/IIIa complexes are on the surface of each platelet, they do not function as fibrinogen receptors until the platelet is activated by an agonist. Each activated GP IIb/IIIa
HEMOSTASIS AND THROMBOSIS (Continued)

Blood Coagulation

The blood coagulation process causes hemostasis within 1 to 2 minutes. It involves sequential activation of clotting factors that are normally present in blood and tissues as inactive precursors and formation of a meshwork of fibrin strands that cements blood components together to form a stable, dense clot. Major phases include release of thromboplastin by disintegrating platelets and damaged tissue; conversion of prothrombin to thrombin, which requires thromboplastin and calcium ions; and conversion of fibrinogen to fibrin by thrombin.

Blood coagulation results from activation of the intrinsic or extrinsic coagulation pathway. Both pathways, which are activated when blood passes out of a blood vessel, are needed for normal hemostasis. The intrinsic pathway occurs in the vascular system; the extrinsic pathway occurs in the tissues. Although the pathways are initially separate, the terminal steps (ie, activation of factor X and thrombin-induced formation of fibrin) are the same.

The intrinsic pathway is activated when blood comes in contact with collagen in the injured vessel wall and coagulation factor XII interacts with biologic surfaces. The normal endothelium prevents factor XII from interacting with such surfaces. The activated form of factor XII is a protease that starts the interactions among factors involved in the intrinsic pathway (eg, prekallikrein, factor IX, factor VIII).

The extrinsic pathway is activated when blood is exposed to tissue extracts and tissue factor interacts with circulating coagulation factor VII. Activated factors VII and IX both act on factor X to produce activated factor X, which then interacts with factor V, calcium, and platelet factor 3. Platelet factor 3, a component of the platelet cell membrane, becomes available on the platelet surface only during platelet activation. The interactions among these substances lead to formation of thrombin, which then activates fibrinogen to form fibrin, and the clot is complete.

OND, embolization obstructs the blood supply when the embolus becomes lodged. The pulmonary arteries are common sites of embolization.

DRUGS USED IN THROMBOTIC AND THROMBOEMBOLIC DISORDERS

Drugs given to prevent or treat thrombosis alter some aspect of the blood coagulation process. Anticoagulants are widely used in thrombotic disorders. They are more effective in preventing venous thrombosis than arterial thrombosis. Antiplatelet drugs are used to prevent arterial thrombosis. Thrombolytic agents are used to dissolve thrombi and limit tissue damage in selected thromboembolic disorders. These drugs are described in the following sections and in Drugs at a Glance: Anticoagulant, Antiplatelet, and Thrombolytic Agents.

Anticoagulants

Anticoagulant drugs are given to prevent formation of new clots and extension of clots already present. They do not dissolve formed clots, improve blood flow in tissues around the clot, or prevent ischemic damage to tissues beyond the clot. Heparins and warfarin are commonly used anticoagulants; danaparoid and lepirudin are newer agents. Clinical indications include prevention or management of thromboembolic disorders, such as thrombophlebitis, DVT, and pulmonary embolism. The main adverse effect is bleeding.

Heparin

Heparin is a pharmaceutical preparation of the natural anticoagulant produced primarily by mast cells in pericapillary connective tissue. Endogenous heparin is found in various body tissues, most abundantly in the liver and lungs. Exogenous heparin is obtained from bovine lung or porcine intestinal mucosa and standardized in units of biologic activity.

Heparin combines with antithrombin III (a natural anticoagulant in the blood) to inactivate clotting factors IX, X, XI, and XII, inhibit the conversion of prothrombin to thrombin, and prevent thrombus formation. After thrombosis has developed, heparin can inhibit additional coagulation by inactivating thrombin, preventing the conversion of fibrinogen to
### Drugs at a Glance: Anticoagulant, Antiplatelet, and Thrombolytic Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anticoagulants</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heparin</td>
<td>Prevention and management of thromboembolic disorders (e.g., deep vein thrombosis, pulmonary embolism, atrial fibrillation with embolization)</td>
<td>Adults: IV injection, 5000 units initially, followed by 5000–10,000 units q4–6h, to a maximum dose of 25,000 units/d; IV infusion, 5000 units (loading dose), then 15–25 units/kg/h DIC, IV injection, 50–100 units/kg q4h; IV infusion, 20,000–40,000 units/d at initial rate of 0.25 units/kg/min, then adjusted according to aPTT; SC 10,000–12,000 units q8h, or 14,000–20,000 units q12h Low-dose prophylaxis, SC 5000 units 2 h before surgery, then q12h until discharged from hospital or fully ambulatory Children: DIC, IV injection, 25–50 units/kg q4h; IV infusion, 50 units/kg initially, followed by 100 units/kg q4h or 20,000 units/m² over 24 h</td>
</tr>
<tr>
<td>Argatroban (Argatroban)</td>
<td>Thrombosis prophylaxis or management in heparin-induced thrombocytopenia</td>
<td>IV continuous infusion 2 mcg/kg/min</td>
</tr>
<tr>
<td>Bivalirudin (Angiomax)</td>
<td>Clients with unstable angina undergoing PTCA</td>
<td>IV bolus dose of 1 mg/kg followed by 4 h infusion at rate of 2.5 mg/kg/min</td>
</tr>
<tr>
<td>Dalteparin (Fragmin)</td>
<td>Prophylaxis of DVT in clients having hip replacement surgery; also clients at high risk of thromboembolic disorders who are having abdominal surgery</td>
<td>Abdominal surgery, SC 2500 IU 1–2 h before surgery and then once daily for 5–10 days after surgery Hip replacement surgery, SC 2500 IU 1–2 h before surgery and the evening of surgery (at least 6 h after first dose) and then 5000 IU once daily for 5 days</td>
</tr>
<tr>
<td>Danaparoid (Orgaran)</td>
<td>Prophylaxis of DVT in clients having hip replacement surgery</td>
<td>SC 750 IU twice daily, with first dose 1–24 h before surgery, then daily for 7–14 days after surgery</td>
</tr>
<tr>
<td>Enoxaparin (Lovenox)</td>
<td>Prevention and management of DVT and pulmonary embolism Management of unstable angina, to prevent myocardial infarction</td>
<td>DVT prophylaxis in clients having hip or knee replacement surgery, SC 30 mg twice daily, with first dose within 12–24 h after surgery and continued for 7–10 days</td>
</tr>
<tr>
<td>Fondaparinux (Arixtra)</td>
<td>Prevention of DVT following hip fracture surgery or knee or hip replacement</td>
<td>Abdominal surgery, SC 40 mg once daily with first dose given 2 h before surgery, for 7–10 days DVT/pulmonary embolism management, outpatients, SC 1 mg/kg q12h; inpatients, 1 mg/kg q12h or 1.5 mg/kg q24h Unstable angina 1 mg/kg q12h in conjunction with oral aspirin (100–325 mg once daily)</td>
</tr>
<tr>
<td>Lepirudin (Refludan)</td>
<td>Heparin alternative for anticoagulation of clients with heparin-induced thrombocytopenia and associated thromboembolic disorders</td>
<td>IV injection, 0.4 mg/kg over 15–20 sec, followed by continuous IV infusion of 0.15 mg/kg for 2–10 days or longer if needed</td>
</tr>
<tr>
<td>Tinzaparin (Innohep)</td>
<td>Management of DVT, with or without PE; may be given in conjunction with warfarin</td>
<td>SC 175 anti-Xa IU/kg daily for at least 6 days and until adequately anticoagulated with warfarin</td>
</tr>
<tr>
<td>Warfarin (Coumadin)</td>
<td>Long-term prevention or management of venous thromboembolic disorders, including DVT, PE, and embolization associated with atrial fibrillation and prosthetic heart valves. May also be used after myocardial infarction to decrease reinfarction, stroke, venous thromboembolism, and death</td>
<td>PO 2–5 mg/d for 2–3 days, then adjusted according to the international normalized ratio (INR); average maintenance daily dose, 2–5 mg</td>
</tr>
<tr>
<td><strong>Antiplatelet Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>Prevention of myocardial infarction Prevention of thromboembolic disorders in patients with prosthetic heart valves or transient ischemic attacks</td>
<td>PO 81–325 mg daily</td>
</tr>
<tr>
<td>Abciximab (ReoPro)</td>
<td>Used with PTCA to prevent rethrombosis of treated arteries</td>
<td>IV bolus injection, 0.25 mg/kg 10–60 min before starting PTCA, then a continuous IV infusion of 10 mcg/min for 12 h</td>
</tr>
<tr>
<td>Anagrelide (Agrylin)</td>
<td>Essential thrombocythemia, to reduce the elevated platelet count, the risk of thrombosis, and associated symptoms</td>
<td>PO 0.5 mg 4 times daily or 1 mg twice daily initially, then titrate to lowest dose effective in maintaining platelet count &lt;600,000/mm³</td>
</tr>
</tbody>
</table>
CHAPTER 57 DRUGS THAT AFFECT BLOOD COAGULATION

fibrin, and inhibiting factor XIII (the fibrin-stabilizing factor). Other effects include inhibiting factors V and VIII and platelet aggregation.

Heparin acts immediately after intravenous (IV) injection and within 20 to 30 minutes after subcutaneous injection. It is metabolized in the liver and excreted in the urine, primarily as inactive metabolites. Heparin does not cross the placental barrier and is not secreted in breast milk, making it the anticoagulant of choice for use during pregnancy and lactation. Disadvantages of heparin are its short duration of action and the subsequent need for frequent administration, the necessity for parenteral injection (because it is not absorbed from the gastrointestinal [GI] tract), and local tissue reactions at injection sites.

Drugs at a Glance: Anticoagulant, Antiplatelet, and Thrombolytic Agents (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cilostazol (Pletal)</td>
<td>Intermittent claudication, to increase walking distance (before leg pain occurs)</td>
<td>PO 100 mg twice daily, 30 min before or 2 h after breakfast and dinner; reduce to 50 mg twice daily with concurrent use of fluconazole, itraconazole, erythromycin, or diltiazem</td>
</tr>
<tr>
<td>Clopidogrel (Plavix)</td>
<td>Reduction of atherosclerotic events (myocardial infarction, stroke, vascular death) in clients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral artery disease</td>
<td>PO 75 mg once daily with or without food</td>
</tr>
<tr>
<td>Dipyridamole (Persantine)</td>
<td>Prevention of thromboembolism after cardiac valve replacement, given with warfarin</td>
<td>PO 25–75 mg 3 times per day, 1 h before meals</td>
</tr>
<tr>
<td>Dipyridamole and Aspirin (Aggrenox)</td>
<td>Same as above</td>
<td>PO 1 capsule (200 mg extended-release dipyridamole/25 mg aspirin) twice daily</td>
</tr>
<tr>
<td>Eptifibatide (Integrilin)</td>
<td>Acute coronary syndromes, including clients who are to be managed medically and those undergoing PTCA</td>
<td>IV bolus injection, 180 mcg/kg/min, followed by continuous infusion of 2 mcg/kg/min. See manufacturer’s instructions for preparation and administration.</td>
</tr>
<tr>
<td>Ticlopidine (Ticlid)</td>
<td>Prevention of thrombosis in clients with coronary artery or cerebral vascular disease (eg, clients who have had stroke precursors or a completed thrombotic stroke)</td>
<td>PO 250 mg twice daily with food</td>
</tr>
<tr>
<td>Tirofiban (Aggrastat)</td>
<td>Acute coronary syndromes, with heparin, for clients who are to be managed medically or those undergoing PTCA</td>
<td>IV infusion, 0.4 mcg/kg/min for 30 min, then 0.1 mcg/kg/min. Patients with severe renal impairment (creatinine clearance &lt;30 mL/min) should receive half the usual rate of infusion. See manufacturer’s instructions for preparation and administration.</td>
</tr>
<tr>
<td>Treprostinil (Remodulin)</td>
<td>Pulmonary arterial hypertension</td>
<td>Continuous infusion by SC catheter and infusion pump at initial dose of 1.25 mcg/kg/min, increasing by no more than 1.25 mcg/kg/min per week for first 4 wks, and then by no more than 2.5 mcg/kg/min per week for remaining duration of infusion</td>
</tr>
</tbody>
</table>

**Thrombolytic Agents**

**Alteplase (Activase)**
- Acute ischemic stroke
- Acute myocardial infarction
- Pulmonary emboli
- IV infusion, 100 mg over 3 h (first hour, 60 mg with a bolus of 6–10 mg over 1–2 min initially; second hour, 20 mg; third hour, 20 mg)

**Drotrecogin alfa, activated (Xigris)**
- Reduction of mortality in severe sepsis
- IV infusion of 24 mcg/kg/h for 96 h

**Reteplase, recombinant (Retavase)**
- Acute myocardial infarction
- IV injection, 10 units over 2 min, repeated in 30 min. Inject into a flowing IV infusion line that contains no other medications.

**Streptokinase (Streptase)**
- Management of acute, severe pulmonary embolism or iliofemoral thromboembolitis
- Used to dissolve clots in arterial or venous cannu- 
as or catheters
- May be injected into a coronary artery to dissolve a thrombus if done within 6 h of onset of symptoms
- IV 250,000 units over 30 min, then 100,000 units/h for 24–72 h

**Tenecteplase (TNKase)**
- Acute myocardial infarction
- IV bolus dose based on weight, 30 mg (for <60 kg) not to exceed 50 mg (>90 kg)

**Urokinase (Abbokinase)**
- Coronary artery thrombi
- Pulmonary emboli
- Clearance of clogged IV catheters
- IV 4400 units/kg over 10 min, followed by continuous infusion of 4400 units/kg/h for 12 h

For clearing IV catheters, see manufacturer’s instructions

aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; DVT, deep vein thrombosis; PE, pulmonary embolism; PTCA, percutaneous transluminal coronary angioplasty or atherectomy.
Low-dose heparin prophylaxis is either ineffective or contraindicated in major orthopedic surgery, abdominal prostatectomy, and brain surgery.

Therapeutically, heparin is used for management of acute thromboembolic disorders (eg, DVT, thrombophlebitis, pulmonary embolism). In these conditions, the aim of therapy is to prevent further thrombus formation and embolization. Heparin is also used in disseminated intravascular coagulation (DIC), a life-threatening condition characterized by widespread clotting, which depletes the blood of coagulation factors. The depletion of coagulation factors then produces widespread bleeding. The goal of heparin therapy in DIC is to prevent blood coagulation long enough for clotting factors to be replenished and thus be able to control hemorrhage.

Heparin is also used to prevent clotting during cardiac and vascular surgery, extracorporeal circulation, hemodialysis, blood transfusions, and in blood samples to be used in laboratory tests.

Contraindications include GI ulcerations (eg, peptic ulcer disease, ulcerative colitis), blood dyscrasias, severe kidney or liver disease, severe hypertension, polycythemia vera, and recent surgery of the eye, spinal cord, or brain. It should be used with caution in clients with hypertension, renal or hepatic disease, alcoholism, history of GI ulcerations, drainage tubes (eg, nasogastric tubes, indwelling urinary catheters), and any occupation with high risks of traumatic injury.

Low–Molecular-Weight Heparins

Standard heparin is a mixture of high–and low–molecular-weight fractions, but most anticoagulant activity is attributed to the low–molecular-weight portion. Low–molecular-weight heparins (LMWHs) contain the low–molecular-weight fraction and are as effective as IV heparin in treating thrombotic disorders. Indications for use include prevention or management of thromboembolic complications associated with surgery or ischemic complications of unstable angina and myocardial infarction. Currently available LMWHs (dalteparin, enoxaparin, tinzaparin) differ from standard heparin and each other; they cannot be used interchangeably (ie, unit for unit).

LMWHs are given subcutaneously and do not require close monitoring of blood coagulation tests. These characteristics allow outpatient anticoagulant therapy, an increasing trend. The drugs are also associated with less thrombocytopenia than standard heparin. However, platelet counts should be monitored during therapy.

Warfarin

Warfarin is the most commonly used oral anticoagulant. It acts in the liver to prevent synthesis of vitamin K–dependent clotting factors (ie, factors II, VII, IX, and X). Warfarin is similar to vitamin K in structure and therefore acts as a competitive antagonist to hepatic use of vitamin K. Anticoagulant effects do not occur for 3 to 5 days after warfarin is started because clotting factors already in the blood follow their normal pathway of elimination. Warfarin has no effect on circulating clotting factors or on platelet function.

Warfarin is well absorbed after oral administration. It is highly bound to plasma proteins (98%), mainly albumin. It is metabolized in the liver and primarily excreted as inactive metabolites by the kidneys. Warfarin is most useful in long-term prevention or management of venous thromboembolic disorders, including DVT, pulmonary embolism, and embolization associated with atrial fibrillation and prosthetic heart valves. In addition, warfarin therapy after myocardial infarction may decrease reinfarction, stroke, venous thromboembolism, and death. Smaller doses are being used now than formerly, with similar antithrombotic effects and decreased risks of bleeding.

Like heparin, warfarin is contraindicated in clients with GI ulcerations, blood disorders associated with bleeding, severe kidney or liver disease, severe hypertension, and recent surgery of the eye, spinal cord, or brain. It should be used cautiously with mild hypertension, renal or hepatic disease, alcoholism, history of GI ulcerations, drainage tubes (eg, nasogastric tubes, indwelling urinary catheters), and occupations with high risks of traumatic injury. In addition, warfarin is contraindicated during pregnancy.

Other Anticoagulant Drugs

Danaparoid, a heparinoid, is a low–molecular weight, heparin-like drug derived from porcine mucosa. It has antithrombotic effects and is given subcutaneously to prevent postoperative thromboembolism in clients having hip replacement surgery, in the management of ischemic stroke, and as an alternative anticoagulant in clients who cannot tolerate heparin. Although related to heparin and LMWHs, it does not contain heparin and cannot be used interchangeably with standard heparin or LMWHs.
Fondaparinux produces anticoagulant effects by directly binding to circulating and clot-bound factor Xa, accelerating the activity of antithrombin and inhibiting thrombin production. It is used in the prevention of DVT in clients having surgery for hip fracture or joint replacement surgery of the knee or hip.

Lepirudin, bivalirudin, and argatroban are direct thrombin inhibitors that prevent blood coagulation by inactivating thrombin. They are used as a heparin substitute for clients who need anticoagulation but have thrombocytopenia with heparin.

**Antiplatelet Drugs**

Antiplatelet drugs prevent one or more steps in the prothrombotic activity of platelets. As described previously, platelet activity is very important in both physiologic hemostasis and pathologic thrombosis. Arterial thrombi, which are composed primarily of platelets, may form on top of atherosclerotic plaque and block blood flow in the artery. They may also form on heart walls and valves and embolize to other parts of the body.

Drugs used clinically for antiplatelet effects act by a variety of mechanisms to inhibit platelet activation, adhesion, aggregation, or procoagulant activity. These include drugs that block platelet receptors for thromboxane A2, adenosine diphosphate (ADP), glycoprotein (GP) IIb/IIIa, and phosphodiesterase.

**Thromboxane A2 Inhibitors**

Aspirin is a commonly used analgesic–antipyretic–anti-inflammatory drug (see Chap. 7) with potent antiplatelet effects. Aspirin exerts pharmacologic actions by inhibiting synthesis of prostaglandins. In this instance, aspirin acetylates cyclooxygenase, the enzyme in platelets that normally synthesizes thromboxane A2, a prostaglandin product that causes platelet aggregation. Thus, aspirin prevents formation of thromboxane A2 and thromboxane A2–induced platelet aggregation and thrombus formation. A single dose of 300 to 600 mg or multiple doses of 30 mg (eg, daily for several days) inhibit the cyclooxygenase in circulating platelets almost completely. These antithrombotic effects persist for the life of the platelet (7 to 10 days). Aspirin may be used long term for prevention of myocardial infarction or stroke, and in clients with prosthetic heart valves. It is also used for the immediate treatment of suspected or actual acute myocardial infarction, for transient ischemic attacks (TIAs), or evolving thrombotic strokes. Adverse effects are uncommon with the small doses used for antiplatelet effects. However, there is an increased risk of bleeding, including hemorrhagic stroke. Because approximately 85% of strokes are thrombotic, the benefits of aspirin or other antiplatelet agents are thought to outweigh the risks of hemorrhagic strokes (approximately 15%).

Nonsteroidal anti-inflammatory drugs (NSAIDs), including ibuprofen and many other aspirin-related drugs, inhibit cyclooxygenase reversibly. Their antiplatelet effects subside when the drugs are eliminated from the circulation and the drugs usually are not used for antiplatelet effects. However, clients who take an NSAID daily (eg, for arthritis pain) may not need to take additional aspirin for antiplatelet effects. Acetaminophen does not affect platelets in usual doses.

**Adenosine Diphosphate Receptor Antagonists**

Ticlopidine inhibits platelet aggregation by preventing ADP-induced binding between platelets and fibrinogen. This reaction inhibits platelet aggregation irreversibly, and effects persist for the lifespan of the platelet. The drug is indicated for prevention of thrombotic stroke in people who have had stroke precursor events (eg, TIA) or a completed thrombotic stroke. Ticlopidine is considered a second-line drug for clients who cannot take aspirin. The adverse effects (eg, neutropenia, diarrhea, skin rashes) and greater cost make it prohibitive for use by many clients. Contraindications include active bleeding disorders (eg, GI bleeding from peptic ulcer or intracranial bleeding), neutropenia, thrombocytopenia, severe liver disease, and hypersensitivity to the drug.

Ticlopidine is rapidly absorbed after oral administration and reaches peak plasma levels about 2 hours after a dose. It is highly protein bound (98%), extensively metabolized in the liver, and excreted in urine and feces. As with other antiplatelet drugs, there is increased risk of bleeding with ticlopidine.

Clopidogrel is chemically related to ticlopidine and causes similar effects. It is indicated for reduction of myocardial infarction, stroke, and vascular death in clients with atherosclerosis and reportedly causes fewer or less severe adverse effects than ticlopidine.

**Glycoprotein IIb/IIIa Receptor Antagonists**

Abciximab is a monoclonal antibody that prevents the binding of fibrinogen, von Willebrand factor, and other molecules to GP IIb/IIIa receptors on activated platelets. This action inhibits platelet aggregation.

Abciximab is used with percutaneous transluminal coronary angioplasty or removal of atherosclerotic plaque to prevent rethrombosis of treated arteries. It is used with aspirin and heparin and is contraindicated in clients who have recently received an oral anticoagulant or IV Dextran. Other contraindications include active bleeding, thrombocytopenia, history of a serious stroke, surgery or major trauma within the previous 6 weeks, uncontrolled hypertension, or hypersensitivity to drug components.

Eptifibatide and tirofiban inhibit platelet aggregation by preventing activation of GP IIb/IIIa receptors on the platelet surface and the subsequent binding of fibrinogen and von Willebrand factor to platelets. Antiplatelet effects occur during drug infusion and stop when the drug is stopped. The drugs are indicated for acute coronary syndrome (eg, unstable angina, myocardial infarction) in clients who are to be managed medically or by angioplasty or atherectomy.

Drug half-life is approximately 2.5 hours for eptifibatide and 2 hours for tirofiban; the drugs are cleared mainly by renal excretion. With tirofiban, plasma clearance is approxi-
mately 25% lower in older adults and approximately 50% lower in clients with severe renal impairment (creatinine clearance <30 mL/minute).

The drugs are contraindicated in clients with hypersensitivity to any component of the products; current or previous bleeding (within the previous 30 days); a history of thrombocytopenia after previous exposure to tirofiban; a history of stroke within 30 days or any history of hemorrhagic stroke; major surgery or severe physical trauma within the previous month; severe hypertension (systolic blood pressure >180 mm Hg with tirofiban or >200 mm Hg with epftifibatide, or diastolic blood pressure >110 mm Hg with either drug); a history of intracranial hemorrhage, neoplasms, arteriovenous malformation, or aneurysm; a platelet count less than 100,000 mm$^3$; serum creatinine 2 mg/dL or above (for the 180 mcg/kg bolus and the 2 mcg/kg/min infusion) or 4 mg/dL or above (for the 135 mcg/kg bolus and the 0.5 mcg/kg/min infusion); or dependency on dialysis (epftifibatide).

Bleeding is the most common adverse effect, with most major bleeding occurring at the arterial access site for cardiac catheterization. If bleeding occurs and cannot be controlled with pressure, the drug infusion and heparin should be discontinued.

These drugs should be used cautiously if given with other drugs that affect hemostasis (eg, warfarin, thrombolytics, other antiplatelet drugs).

**Phosphodiesterase Inhibitor**

Cilostazol inhibits phosphodiesterase, an enzyme that metabolizes cyclic adenosine monophosphate (cAMP). The inhibition increases intracellular cAMP, which then inhibits platelet aggregation and produces vasodilation. The drug reversibly inhibits platelet aggregation induced by various stimuli (eg, thrombin, ADP, collagen, arachidonic acid, epinephrine, and shear stress). It is indicated for management of intermittent claudication. Symptoms usually improve within 2 to 4 weeks, but may take as long as 12 weeks. The drug is contraindicated in clients with heart failure.

Cilostazol is highly protein bound (95% to 98%), mainly to albumin, extensively metabolized by hepatic cytochrome P450 enzymes, and excreted in urine (74%) and feces. The drug and two active metabolites accumulate with chronic administration and reach steady state within a few days. The most common adverse effects are diarrhea and headache.

**Miscellaneous Agents**

Anagrelide inhibits platelet aggregation induced by cAMP phosphodiesterase, ADP, and collagen. However, it is indicated only to reduce platelet counts for clients with essential thrombocytopenia (a disorder characterized by excessive numbers of platelets). Doses to reduce platelet production are smaller than those required to inhibit platelet aggregation.

Dipyridamole inhibits platelet adhesion, but its mechanism of action is unclear. It is used for prevention of thromboembolism after cardiac valve replacement and is given with warfarin.

**Thrombolytic Agents**

Thrombolytic agents are given to dissolve thrombi. They stimulate conversion of plasminogen to plasmin (also called fibrinolysin), a proteolytic enzyme that breaks down fibrin, the framework of a thrombus. The main use of thrombolytic agents is for management of acute, severe thromboembolic disease, such as myocardial infarction, pulmonary embolism, and iliofemoral thrombosis.

The goal of thrombolytic therapy is to re-establish blood flow and prevent or limit tissue damage. Heparin and warfarin are given after completion of thrombolytic therapy. Thrombolytic drugs are also used to dissolve clots in arterial or venous cannulas or catheters.

**Alteplase, reteplase, and tenecteplase** are tissue plasminogen activators used mainly in acute myocardial infarction to dissolve clots obstructing coronary arteries and re-establish perfusion of tissues beyond the thrombotic area. The drugs bind to fibrin in a clot and act locally to dissolve the clot. The most common adverse effect is bleeding, which may be internal (eg, intracranial, GI, genitourinary) or external (eg, venous or arterial puncture sites, surgical incisions). The drugs are contraindicated in the presence of bleeding, a history of stroke, central nervous system surgery or trauma within the previous 2 months, and severe hypertension.

**Streptokinase and urokinase** are enzymes that break down fibrin. They are used mainly to lyse coronary artery clots in acute myocardial infarction. Streptokinase may also be used to dissolve clots in vascular catheters and to treat acute, severe, pulmonary emboli or iliofemoral thrombophlebitis. Urokinase is recommended for use in clients allergic to streptokinase. As with other anticoagulants and thrombolytic agents, bleeding is the main adverse effect.

**Drotrecogin alfa** (Xigris) is a recombinant version of human activated protein C that is approved for use in severe sepsis or septic shock. Severe sepsis is characterized by an excessive inflammatory reaction to infection, inappropriate blood clot formation, and impaired breakdown of clots. Drotrecogin alfa is given for its thrombolytic effects, along with other therapies for inflammation and infection. The major adverse effect is bleeding.

**Drugs Used to Control Bleeding**

Anticoagulant, antiplatelet, and thrombolytic drugs profoundly affect hemostasis, and their major adverse effect is bleeding. As a result, systemic hemostatic agents (antidotes) may be needed to prevent or treat bleeding episodes. Antidotes should be used cautiously because overuse can increase risks of recurrent thrombotic disorders. The drugs are described in this section and in Drugs at a Glance: Systemic Hemostatic Drugs.
Aminocaproic acid and tranexamic acid are used to stop bleeding caused by overdoses of thrombolytic agents. Aminocaproic acid also may be used in other bleeding disorders caused by hyperfibrinolysis (e.g., cardiac surgery, blood disorders, hepatic cirrhosis, prostatectomy, neoplastic disorders). Tranexamic acid also is used for short periods (2 to 8 days) in clients with hemophilia to prevent or decrease bleeding from tooth extraction. Dosage of tranexamic acid should be reduced in the presence of moderate or severe renal impairment.

Aprotinin is a natural protease inhibitor obtained from bovine lung that has a variety of effects on blood coagulation. It inhibits plasmin and kallikrein, thus inhibiting fibrinolysis, and inhibits breakdown of blood clotting factors. It is used to decrease bleeding in selected clients undergoing coronary artery bypass surgery.

Protamine sulfate is an antidote for standard heparin and LMWHs. Because heparin is an acid and protamine sulfate is a base, protamine neutralizes heparin activity. Protamine dosage depends on the amount of heparin administered during the previous 4 hours. Each milligram of protamine neutralizes approximately 100 units of heparin or dalteparin and 1 mg of enoxaparin. A single dose should not exceed 50 mg.

The drug is given by slow IV infusion over at least 10 minutes (to prevent or minimize adverse effects of hypotension, bradycardia, and dyspnea). Protamine effects occur immediately and last for approximately 2 hours. A second dose may be required because heparin activity lasts approximately 4 hours.

Protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Thus, it should be given in settings with equipment and personnel for resuscitation and management of anaphylactic shock.

Vitamin K is the antidote for warfarin overdosage. An oral dose of 10 to 20 mg usually stops minor bleeding and returns the international normalized ratio (INR) (see section on Regulation of Heparin and Warfarin Dosage, later) to a normal range within 24 hours.

Herbal and Dietary Supplements

Many commonly used herbs and supplements have a profound effect on drugs used for anticoagulation. Multivitamin supplements may contain 25 to 28 mcg of vitamin K and should be taken consistently to avoid fluctuating vitamin K levels. Doses of vitamin C in excess of 500 mg/d may lower INR and vitamin E in excess of 400 IU/d may increase warfarin effects. Herbs commonly used that may increase the effects of warfarin include alfalfa, celery, clove, feverfew, garlic, ginger, ginkgo, ginseng, and licorice. Clients taking warfarin should be questioned carefully about their use of herbs as well as vitamin or mineral supplements.

Nursing Process

Assessment

Assess the client’s status in relation to thrombotic and thromboembolic disorders.

- Risk factors for thromboembolism include:
  - Immobility (e.g., limited activity or bed rest for more than 5 days)
  - Obesity
  - Cigarette smoking
  - History of thrombophlebitis, deep vein thrombosis (DVT), or pulmonary emboli
  - Congestive heart failure
  - Pedal edema
  - Lower limb trauma
  - Myocardial infarction
  - Atrial fibrillation
  - Mitral or aortic stenosis
  - Prosthetic heart valves
  - Abdominal, thoracic, pelvic, or major orthopedic surgery
• Atherosclerotic heart disease or peripheral vascular disease
• Use of oral contraceptives
• Signs and symptoms of thrombotic and thromboembolic disorders depend on the location and size of the thrombus.
• DVT and thrombophlebitis usually occur in the legs. The conditions may be manifested by edema (the affected leg is often measurably larger than the other) and pain, especially in the calf when the foot is dorsiflexed (Homans’ sign). If thrombophlebitis is superficial, it may be visible as a red, warm, tender area following the path of a vein.
• Pulmonary embolism, if severe enough to produce symptoms, is manifested by chest pain, cough, hemoptysis, tachypnea, and tachycardia. Massive emboli cause hypotension, shock, cyanosis, and death.
• Disseminated intravascular coagulation (DIC) is usually manifested by bleeding, which may range from petechiae or oozing from a venipuncture site to massive internal bleeding or bleeding from all body orifices.

Nursing Diagnoses
• Ineffective Tissue Perfusion related to thrombus or embolus or drug-induced bleeding
• Acute Pain related to tissue ischemia
• Impaired Physical Mobility related to bed rest and pain
• Ineffective Coping related to the need for long-term prophylaxis of thromboembolic disorders or fear of excessive bleeding
• Anxiety related to fear of myocardial infarction or stroke
• Deficient Knowledge related to anticoagulant or antiplatelet drug therapy
• Risk for Injury related to drug-induced impairment of blood coagulation

Planning/Goals
The client will:
• Receive or take anticoagulant and antiplatelet drugs correctly
• Be monitored closely for therapeutic and adverse drug effects, especially when drug therapy is started and when changes are made in drugs or dosages
• Use nondrug measures to decrease venous stasis and prevent thromboembolic disorders
• Act to prevent trauma from falls and other injuries
• Inform any health care provider when taking an anticoagulant or antiplatelet drug
• Avoid or report adverse drug reactions
• Verbalize or demonstrate knowledge of safe management of anticoagulant drug therapy
• Keep follow-up appointments for tests of blood coagulation and drug dosage regulation
• Avoid preventable bleeding episodes

Interventions
Use measures to prevent thrombotic and thromboembolic disorders.

• Have the client ambulate and exercise legs regularly, especially after surgery.
• For clients who cannot ambulate or do leg exercises, do passive range-of-motion and other leg exercises several times daily when changing the client’s position or performing other care.
• Have the client wear elastic stockings. Elastic stockings should be removed every 8 hours and replaced after inspecting the skin. Improperly applied elastic stockings can impair circulation rather than aid it. For clients on bed rest, intermittent pneumatic compression devices can also be used.
• Avoid trauma to lower extremities.
• Maintain adequate fluid intake (1500–3000 mL/day) to avoid dehydration and hemoconcentration.
• Assist clients to promote good blood circulation (eg, exercise) and avoid situations that impair circulation (eg, wearing tight clothing, crossing the legs at the knees, prolonged sitting or standing, bed rest, and placing pillows under the knees when in bed).

For the client receiving anticoagulant therapy, implement safety measures to prevent trauma and bleeding.

• For clients who cannot ambulate safely because of weakness, sedation, or other conditions, keep the call light within reach, keep bedrails elevated, and assist in ambulation.
• Provide an electric razor for shaving.
• Avoid intramuscular injections, venipunctures, and arterial punctures when possible.
• Avoid intubations when possible (eg, nasogastric tubes, indwelling urinary catheters).
• For the client receiving tirofiban or eptifibatide:
  • Monitor the femoral artery access site closely. This is the most common site of bleeding.
  • Avoid invasive procedures as much as possible (eg, arterial and venous punctures, intramuscular injections, urinary catheters, nasotracheal suction, nasogastric tubes).
  • If venipuncture must be done, avoid sites where pressure cannot be applied (eg, subclavian or jugular veins).
  • While the vascular sheath is in place, keep clients on complete bed rest with the head of the bed elevated 30 degrees and the affected limb restrained in a straight position.
  • Discontinue heparin for 3 to 4 hours and be sure the activated clotting time is less than 180 seconds or the activated partial thromboplastin time (aPTT) is below 45 seconds before removing the vascular sheath.
  • After the vascular sheath is removed, apply pressure to the site and observe closely. For outpatients, be sure there is no bleeding for at least 4 hours before hospital discharge.

For the client receiving a thrombolytic drug or a revascularization procedure for acute myocardial infarction:
• Monitor closely for bleeding.
• Assist the client and family to understand the importance of diligent efforts to reverse risk factors contributing to coronary artery disease (eg, diet and perhaps medication
to lower serum cholesterol to below 200 mg/dL and low-density lipoprotein cholesterol to below 130 mg/dL, weight reduction if overweight, control of blood pressure if hypertensive, avoidance of smoking, stress reduction techniques, exercise program designed and supervised by a health care provider).

- Assist the client and family to understand the importance of complying with medication orders to prevent reinfarction and other complications, and continued medical supervision.

**Evaluation**

- Observe for signs and symptoms of thromboembolic disorders or bleeding.
- Check blood coagulation tests for therapeutic ranges.
- Observe and interview regarding compliance with instructions about drug therapy.
- Observe and interview regarding adverse drug effects.

### PRINCIPLES OF THERAPY

**Drug Selection**

Choices of anticoagulant and antiplatelet drugs depend on the reason for use and other drug and client characteristics.

1. Heparin is the anticoagulant of choice in acute venous thromboembolic disorders because the anticoagulant effect begins immediately with IV administration.
2. Warfarin is the anticoagulant of choice for long-term maintenance therapy (ie, several weeks or months) because it can be given orally.
3. Aspirin has long been the most widely used antiplatelet drug for prevention of myocardial reinfarction and arterial thrombosis in clients with TIAs and prosthetic heart valves. However, clopidogrel may be more effective than aspirin.
4. When anticoagulation is required during pregnancy, heparin is used because it does not cross the placenta. Warfarin is contraindicated during pregnancy.
5. Various combinations of antithrombotic drugs are used concomitantly or sequentially (eg, abciximab is used with aspirin and heparin; thrombolytic drugs are usually followed with heparin and warfarin).

**Regulation of Heparin and Warfarin Dosage**

**Heparin** dosage is regulated by the activated partial thromboplastin time (aPTT), which is sensitive to changes in blood clotting factors, except factor VII. Thus, normal or control values indicate normal blood coagulation; therapeutic values indicate low levels of clotting factors and delayed blood coagulation. During heparin therapy, the aPTT should be maintained at approximately 1.5 to 2.5 times the control or baseline value. The normal control value is approximately 18 seconds. During heparin therapy, the aPTT should be maintained at approximately 1.5 to 2.5 times the control or baseline value. Therapeutic values are 45 to 70 seconds, approximately. With continuous IV infusion, blood for the aPTT may be drawn at any time; with intermittent administration, blood for the aPTT should be drawn approximately 1 hour before a dose of heparin is scheduled. Monitoring of aPTT is not necessary with low-dose standard heparin given subcutaneously for prophylaxis of thromboembolism or with the LMWHs (eg, enoxaparine).

**Warfarin** dosage is regulated according to the INR, for which therapeutic values are 2.0 to 3.0 in most conditions. An average daily dose of 4 to 5 mg maintains a therapeutic INR; stopping warfarin returns an elevated INR to normal in approximately 4 days in most clients.

The INR is based on prothrombin time (PT). PT is sensitive to changes in three of the four vitamin K–dependent coagulation factors. Thus, normal or control values indicate normal levels of these factors; therapeutic values indicate low levels of the factors and delayed blood coagulation. A normal baseline or control PT is approximately 12 seconds; a therapeutic value is approximately 1.5 times the control, or 18 seconds.

When warfarin is started, PT and INR should be assessed daily until a stable daily dose is reached (the dose that maintains PT and INR within therapeutic ranges and does not cause bleeding). Thereafter, PT and INR are determined every 2 to 4 weeks for the duration of oral anticoagulant drug therapy. If the warfarin dose is changed, PT and INR are needed more often until a stable daily dose is again established.

For many years, the PT was used to regulate warfarin dosage. PT is determined by adding a mixture of thromboplastin and calcium to citrated plasma and measuring the time (in seconds) it takes for the blood to clot. However, values vary among laboratories according to the type of thromboplastin and the instrument used to measure PT. The INR system standardizes the PT by comparing a particular thromboplastin with a standard thromboplastin designated by the World Health Organization. Advantages of the INR include consistent values among laboratories, more consistent warfarin dosage with less risk of bleeding or thrombosis, and more consistent reports of clinical trials and other research studies. Some laboratories report both PT and INR.

Warfarin dosage may need to be reduced in clients with biliary tract disorders (eg, obstructive jaundice), liver disease (eg, hepatitis, cirrhosis), malabsorption syndromes (eg, steatorrhea), and hyperthyroidism or fever. These conditions increase anticoagulant drug effects by reducing absorption of vitamin K, decreasing hepatic synthesis of blood clotting factors, or increasing the breakdown of clotting factors. Despite these influencing factors, however, the primary determinant of dosage is the PT and INR.

Warfarin interacts with many other drugs to cause increased, decreased, or unpredictable anticoagulant effects (see Nursing Actions). Thus, warfarin dosage may need to be increased or decreased when other drugs are given concomitantly. Most drugs can be given if warfarin dosage is titrated according to the PT or INR and altered appropriately when an interacting drug is added or stopped. INR or PT measurements and vigil-
General Considerations

- Antiplatelet and anticoagulant drugs are given to people who have had, or who are at risk of having, a heart attack, stroke, or other problems from blood clots. For prevention of a heart attack or stroke, you are most likely to be given an antiplatelet drug (eg, aspirin, clopidogrel) or warfarin (Coumadin). For home management of deep vein thrombosis, which usually occurs in the legs, you are likely to be given heparin injections for a few days, followed by warfarin for long-term therapy. These medications help to prevent the blood clot from getting larger, traveling to your lungs, or recurring later.

- All of these drugs can increase your risk of bleeding, so you need to take safety precautions to prevent injury.

- To help prevent blood clots from forming and decreasing blood flow through your arteries, you need to reduce risk factors that contribute to cardiovascular disease. This can be done by a low-fat, low-cholesterol diet (and medication if needed) to lower total cholesterol to below 200 mg/dL and low-density lipoprotein cholesterol to below 130 mg/dL; weight reduction if overweight; control of blood pressure if hypertensive; avoidance of smoking; stress reduction techniques; and regular exercise.

- To help prevent blood clots from forming in your leg veins, avoid or minimize situations that slow blood circulation, such as wearing tight clothing; crossing the legs at the knees; prolonged sitting or standing; and bed rest. For example, on automobile trips, stop and walk around every 1 to 2 hours; on long plane trips, exercise your feet and legs at your seat and walk around when you can.

- Following instructions regarding these medications is extremely important. Too little medication increases your risk of problems from blood clot formation; too much medication can cause bleeding.

- While taking any of these medications, you need regular medical supervision and periodic blood tests. The blood tests can help your health care provider regulate drug dosage and maintain your safety.

- You need to take the drugs as directed; avoid taking other drugs without the health care provider’s knowledge and consent; inform any health care provider (including dentists) that you are taking an antiplatelet or anticoagulant drug before any invasive diagnostic tests or treatments are begun; and keep all appointments for continuing care.

- With warfarin therapy, you need to avoid walking barefoot; avoid contact sports; use an electric razor; avoid injections when possible; and carry an identification card, necklace, or bracelet (eg, MedicAlert) stating the name of the drug and the health care provider’s name and telephone number. Also, avoid large amounts of certain vegetables (eg, broccoli, brussels sprouts, cabbage, cauliflower, chives, collard greens, kale, lettuce, mustard greens, peppers, spinach, turnips, and watercress), tomatoes, bananas, or fish; these foods contain vitamin K and may decrease anticoagulant effects.

- For home management of deep vein thrombosis, both warfarin and enoxaparin (Lovenox) are given for 3 months or longer. With Lovenox, you need an injection, usually every 12 hours. You or someone close to you may be instructed in injecting the medication, or a visiting nurse may do the injections, if necessary.

- Even if a nurse is not needed to give the injections, one will usually visit your home each day to perform a finger stick blood test. The results of this test determine your daily dose of warfarin. Once the blood test and the warfarin dose stabilize, the blood tests are done less often (eg, every 2 weeks).

- Report any sign of bleeding (eg, excessive bruising of the skin, blood in urine or stool). If superficial bleeding occurs, apply direct pressure to the site for 3 to 5 minutes or longer if necessary.

Self-Administration

- Take aspirin with food or after meals, with 8 oz of water, to decrease stomach irritation. However, stomach upset is uncommon with the small doses used for antiplatelet effects. Do not crush or chew coated tablets (long-acting preparations).

- Take cilostazol (Pletal) 30 minutes before or 2 hours after morning and evening meals for better absorption and effectiveness.

- Take ticlopidine (Ticlid) with food or after meals to decrease GI upset. Clopidogrel (Plavix) may be taken with or without food.

- With Lovenox, wash hands and cleanse skin to prevent infection; inject deep under the skin, around the navel, upper thigh, or buttocks; and change the injection site daily. If excessive bruising occurs at the injection site, rubbing an ice cube over an area before the injection may be helpful.

Thrombolytic Therapy

1. Thrombolytic therapy should be performed only by experienced personnel in an intensive care setting with cardiac and other monitoring devices in place.
2. All of the available agents are effective with recommended uses. Thus, the choice of a thrombolytic agent depends mainly on risks of adverse effects and costs. All of the drugs may cause bleeding. Alteplase may act more specifically on the fibrin in a clot and cause less systemic depletion of fibrinogen, but this agent is very expensive. Streptokinase, the least expensive agent, may cause allergic reactions because it is a foreign protein. Combination therapy (eg, with alteplase and streptokinase) may also be used.

3. Before a thrombolytic agent is begun, INR, aPTT, platelet count, and fibrinogen should be checked to establish baseline values and to determine if a blood coagulation disorder is present. Two or 3 hours after thrombolytic therapy is started, the fibrinogen level can be measured to determine if fibrinolysis is occurring. Alternatively, INR or aPTT can be checked for increased values because the breakdown products of fibrin exert anticoagulant effects.

4. Major factors in decreasing risks of bleeding are selecting recipients carefully, avoiding invasive procedures when possible, and omitting anticoagulant or antiplatelet drugs while thrombolytics are being given. If bleeding does occur, it is most likely from a venipuncture or invasive procedure site, and local pressure may control it. If bleeding cannot be controlled or involves a vital organ, the thrombolytic drug should be stopped and fibrinogen replaced with whole blood plasma or cryoprecipitate. Aminocaproic acid or tranexamic acid may also be given.

5. When the drugs are used in acute myocardial infarction, cardiac dysrrhythmias may occur when blood flow is re-established. Therefore, antidysrhythmic drugs should be readily available.

Use in Children

Little information is available about the use of anticoagulants in children. Heparin solutions containing benzyl alcohol as a preservative should not be given to premature infants because fatal reactions have been reported. When given for systemic anticoagulation, heparin dosage should be based on the child’s weight (approximately 50 units/kg). Safety and effectiveness of LMWHs (eg, enoxaparin) have not been established in children.

Warfarin is given to children after cardiac surgery to prevent thromboembolism, but doses and guidelines for safe, effective use have not been developed. Accurate drug administration, close monitoring of blood coagulation tests, safety measures to prevent trauma and bleeding, avoiding interacting drugs, and informing others in the child’s environment (eg, teachers, babysitters, health care providers) are necessary.

Antiplatelet and thrombolytic drugs have no established indications for use in children.

Use in Older Adults

Older adults often have atherosclerosis and thrombotic disorders, including myocardial infarction, thrombotic stroke, and peripheral arterial insufficiency, for which they receive an anticoagulant or an antiplatelet drug. They are more likely than younger adults to experience bleeding and other complications of anticoagulant and antiplatelet drugs. For example, aspirin or clopidogrel is commonly used to prevent thrombotic stroke, but both drugs increase risks of hemorrhagic stroke.

With standard heparin, general principles for safe and effective use apply. With LMWHs, elimination may be delayed in older adults with renal impairment and the drugs should be used cautiously. They should also be used with caution in clients taking a platelet inhibitor (eg, aspirin, clopidogrel) to prevent myocardial infarction or thrombotic stroke or an NSAID for arthritis pain. NSAIDs, which are commonly used by older adults, also have antiplatelet effects. Clients who take an NSAID daily may not need low-dose aspirin for antithrombotic effects.

With warfarin, dosage should be reduced because impaired liver function and decreased plasma proteins increase the risks of bleeding. Also, many drugs interact with warfarin to increase or decrease its effect, and older adults often take multiple drugs. Starting or stopping any drug may require that warfarin dosage be adjusted.

Use in Renal Impairment

Most anticoagulant, antiplatelet, and thrombolytic drugs may be used in clients with impaired renal function. For example, heparin and warfarin can be used in usual dosages, and thrombolytic agents (eg, streptokinase and urokinase) may be used to dissolve clots in IV catheters or vascular access sites for hemodialysis. Dosage of LMWHs should be reduced in clients with severe renal impairment (creatinine clearance <30 mL/minute) because they are excreted by the kidneys and elimination is slowed. In addition, home management of DVT with LMWHs and warfarin is contraindicated in clients with severe renal impairment. Guidelines for the use of other drugs include the following:

- **Anagrelide** may be given to clients with renal impairment (eg, serum creatinine <2 mg/dL) if potential benefits outweigh risks. Clients receiving this medication should be monitored closely for signs of renal toxicity.
- **Cilostazol** is probably safe to use in clients with mild or moderate renal impairment. However, severe renal impairment alters drug protein binding and increases blood levels of metabolites.
- **Clopidogrel** does not need dosage reduction in clients with renal impairment.
- **Danaparoid** is excreted mainly by the kidneys and dosage may need to be reduced in clients with severe renal impairment. Monitor serum creatinine during therapy.
• **Eptifibatide** does not need dosage reduction in clients with mild to moderate renal impairment. No data are available for clients with severe impairment or those on hemodialysis.

• **Lepirudin** is excreted by the kidneys and may accumulate in clients with impaired renal function. Dosage should be reduced.

• **Ticlopidine** may be more likely to cause bleeding in clients with renal impairment because the plasma drug concentration is increased and elimination is slower.

• **Tirofiban** clearance from plasma is decreased approximately 50% in clients with severe renal impairment (eg, creatinine clearance <30 mL/minute), including those receiving hemodialysis. Dosage must be reduced by approximately 50%.

### Use in Hepatic Impairment

Little information is available about the use of most anticoagulant, antiplatelet, and thrombolytic drugs in clients with impaired liver function. However, such drugs should be used very cautiously because these clients may already be predisposed to bleeding because of decreased hepatic synthesis of clotting factors. Additional considerations include the following:

• **Warfarin** is more likely to cause bleeding in clients with liver disease, because of decreased synthesis of vitamin K. In addition, warfarin is eliminated only by hepatic metabolism and may accumulate with liver impairment.

• **Low–molecular-weight heparins** are contraindicated for home management of DVT in clients with severe liver disease because of high risks of excessive bleeding.

• **Anagrelide** is metabolized in the liver and may accumulate with hepatic impairment. Clients with evidence of impairment (eg, bilirubin or aspartate aminotransferase more than 1.5 times the upper limit of normal) should receive anagrelide only if potential benefits outweigh potential risks. When anagrelide is given, clients should be closely monitored for signs of hepatotoxicity.

• **Clopidogrel** is metabolized in the liver and may accumulate with hepatic impairment. It should be used cautiously.

• **Dipyridamole** is metabolized in the liver and excreted in bile.

### Home Care

Antiplatelet agents and warfarin are used for long-term prevention or management of thromboembolism and are often taken at home. For prevention, antiplatelet agents and warfarin are usually self-administered at home, with periodic office or clinic visits for blood tests and other follow-up care.

For home management of DVT, warfarin may be self-administered, but a nurse usually visits, performs a finger stick INR, and notifies the prescriber, who then prescribes the appropriate dose of warfarin. Precautions are needed to decrease risks of bleeding. The risk of bleeding has lessened in recent years because of lower doses of warfarin. In addition, bleeding during warfarin therapy may be caused by medical conditions other than anticoagulation.

Heparin may also be taken at home. Standard heparin may be taken subcutaneously, but LMWHs for home management of venous thrombosis are becoming standard practice. Enoxaparin is approved by the Food and Drug Administration for outpatient use. Daily visits by a home care nurse may be needed if the client or a family member is unable or unwilling to inject the medication. Platelet counts should be done before and every 2 to 3 days during heparin therapy. Heparin should be discontinued if the platelet count falls below 100,000 or to less than half the baseline value.

Most home management regimens involve a structured protocol. Clients and family members should be educated about the disorder (usually DVT), including the potential consequences of either overcoagulation or undercoagulation, and the need for blood tests.

The home care nurse needs to assess clients in relation to knowledge about prescribed drugs and ability and willingness to comply with instructions for taking the drugs, obtaining blood tests when indicated, and taking safety precautions. In addition, assess the environment for risk factors for injury. Interventions vary with clients, environments, and assessment data, but may include reinforcing instructions for safe use of the drugs, assisting clients to obtain laboratory tests, and teaching how to observe for signs and symptoms of bleeding.
**NURSING ACTIONS**

**Drugs That Affect Blood Coagulation**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With standard heparin:</td>
<td></td>
</tr>
<tr>
<td>(1) When handwriting a heparin dose, write out “units” rather than using the abbreviation “U.”</td>
<td>This is a safety precaution to avoid erroneous dosage. For example, 1000 U (1000 units) may be misread as 10,000 units. Underdosage may cause thromboembolism, and overdosage may cause bleeding. In addition, heparin is available in several concentrations (1000, 2500, 5000, 10,000, 15,000, 20,000, and 40,000 units/mL).</td>
</tr>
<tr>
<td>(2) Check dosage and vial label carefully.</td>
<td></td>
</tr>
<tr>
<td>(3) For SC heparin:</td>
<td></td>
</tr>
<tr>
<td>(a) Use a 26-gauge, ½-inch needle.</td>
<td></td>
</tr>
<tr>
<td>(b) Leave a small air bubble in the syringe to follow dose</td>
<td></td>
</tr>
<tr>
<td>(c) Grasp a skinfold and inject the heparin into it, at a 90-degree angle, without aspirating.</td>
<td></td>
</tr>
<tr>
<td>(d) Do not massage site after injection</td>
<td></td>
</tr>
<tr>
<td>(4) For intermittent IV administration:</td>
<td></td>
</tr>
<tr>
<td>(a) Give by direct injection into a heparin lock or tubing injection site.</td>
<td></td>
</tr>
<tr>
<td>(b) Dilute the dose in 50 to 100 mL of any IV fluid (usually 5% dextrose in water).</td>
<td></td>
</tr>
<tr>
<td>(5) For continuous IV administration:</td>
<td></td>
</tr>
<tr>
<td>(a) Use a volume-control device and an infusion-control device.</td>
<td></td>
</tr>
<tr>
<td>(b) Add only enough heparin for a few hours. One effective method is to fill the volume-control set (eg, Volutrol) with 100 mL of 5% dextrose in water and add 5000 units of heparin to yield a concentration of 50 units/mL. Dosage is regulated by varying the flow rate. For example, administration of 1000 units/h requires a flow rate of 20 mL/h. Another method is to add 25,000 units of heparin to 500 mL of IV solution.</td>
<td></td>
</tr>
<tr>
<td>b. With low–molecular-weight heparins:</td>
<td></td>
</tr>
<tr>
<td>(1) Give by deep SC injection, into an abdominal skin fold, with the patient lying down, using the same technique as standard heparin. Do not rub the injection site.</td>
<td></td>
</tr>
<tr>
<td>(2) Rotate sites.</td>
<td></td>
</tr>
<tr>
<td>c. After the initial dose of warfarin, check the international normalized ratio (INR) before giving a subsequent dose. Do not give the dose if the INR is above 3.0. Notify the health care provider.</td>
<td></td>
</tr>
<tr>
<td>d. Give ticlopidine with food or after meals; give cilostazol 30 min before or 2 h after morning and evening meals; give clopidogrel with or without food.</td>
<td></td>
</tr>
<tr>
<td>e. With eptifibatide, tirofiban, and thrombolytic agents, follow manufacturers’ instructions for reconstitution and administration.</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th><strong>NURSING ACTIONS</strong></th>
<th><strong>RATIONALE/EXPLANATION</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a.</strong> With prophylactic heparins and warfarin, observe for the absence of signs and symptoms of thrombotic disorders.</td>
<td></td>
</tr>
<tr>
<td><strong>b.</strong> With therapeutic heparins and warfarin, observe for decrease or improvement in signs and symptoms (eg, less edema and pain with deep vein thrombosis, less chest pain and respiratory difficulty with pulmonary embolism).</td>
<td>Frequency of INR determinations varies, but the test should be done periodically in all clients taking warfarin.</td>
</tr>
<tr>
<td><strong>c.</strong> With prophylactic or therapeutic warfarin, observe for an INR between 2.0 and 3.0.</td>
<td></td>
</tr>
<tr>
<td><strong>d.</strong> With therapeutic heparin, observe for an activated partial thromboplastin time of 1.5 to 2 times the control value.</td>
<td></td>
</tr>
<tr>
<td><strong>e.</strong> With anagrelide, observe for a decrease in platelet count.</td>
<td></td>
</tr>
<tr>
<td><strong>f.</strong> With aspirin, clopidogrel, and other antiplatelet drugs, observe for the absence of thrombotic disorders (eg, myocardial infarction, stroke)</td>
<td>Platelet counts should be done every 2 days during the first week of management and weekly until a maintenance dose is reached. Counts usually begin to decrease within the first 2 wk of therapy.</td>
</tr>
<tr>
<td><strong>g.</strong> With cilostazol, observe for ability to walk farther without leg pain (intermittent claudication).</td>
<td>Improvement may occur within 2 to 4 wk or take as long as 12 wk.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td></td>
</tr>
<tr>
<td><strong>a.</strong> Bleeding:</td>
<td></td>
</tr>
<tr>
<td>(1) Record vital signs regularly.</td>
<td></td>
</tr>
<tr>
<td>(2) Check stools for blood (melena).</td>
<td></td>
</tr>
<tr>
<td>(3) Check urine for blood (hematuria).</td>
<td></td>
</tr>
<tr>
<td>(4) Inspect the skin and mucous membranes daily.</td>
<td></td>
</tr>
<tr>
<td>(5) Assess for excessive menstrual flow.</td>
<td></td>
</tr>
<tr>
<td><strong>b.</strong> Other adverse effects:</td>
<td></td>
</tr>
<tr>
<td>(1) With heparin, tissue irritation at injection sites, transient alopecia, reversible thrombocytopenia, paresthesias, and hypersensitivity</td>
<td>These effects are uncommon. They are more likely to occur with large doses or prolonged administration.</td>
</tr>
<tr>
<td>(2) With warfarin, dermatitis, diarrhea, and alopecia</td>
<td>These effects occur only occasionally. Warfarin has been given for prolonged periods without toxicity.</td>
</tr>
<tr>
<td>(3) With anagrelide, adverse cardiovascular effects (eg, tachycardia, vasodilation, heart failure)</td>
<td>These effects are most likely to occur in clients with known heart disease.</td>
</tr>
<tr>
<td>(4) With clopidogrel and ticlopidine, GI upset, skin rash, neutropenia, and thrombocytopenia</td>
<td>Neutropenia and thrombocytopenia are more likely to occur with ticlopidine than clopidogrel.</td>
</tr>
</tbody>
</table>

(continued)
### Nursing Actions

<table>
<thead>
<tr>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bleeding is most likely to occur at sites of venipuncture or other invasive procedures. Reperfusion dysrhythmias may occur when blood supply is restored to previously ischemic myocardium.</td>
</tr>
<tr>
<td>These drugs are often used concurrently or sequentially to decrease risks of myocardial infarction or stroke.</td>
</tr>
<tr>
<td>Additive anticoagulant effects and increased risks of bleeding</td>
</tr>
<tr>
<td>Some may affect blood coagulation and increase risks of bleeding</td>
</tr>
<tr>
<td>These drugs antagonize the anticoagulant effects of heparin. Mechanisms are not clear.</td>
</tr>
<tr>
<td>The antidote for heparin overdose</td>
</tr>
<tr>
<td>Mechanisms by which drugs may increase effects of warfarin include inhibiting warfarin metabolism, displacing warfarin from binding sites on serum albumin, causing antiplatelet effects, inhibiting bacterial synthesis of vitamin K in the intestinal tract, and others.</td>
</tr>
<tr>
<td>May decrease GI absorption</td>
</tr>
<tr>
<td>These drugs activate liver metabolizing enzymes, which accelerate the rate of metabolism of warfarin.</td>
</tr>
<tr>
<td>Decreases absorption</td>
</tr>
<tr>
<td>Increase synthesis and concentration of blood clotting factors</td>
</tr>
<tr>
<td>Increase synthesis of clotting factors and have thromboembolic effect</td>
</tr>
<tr>
<td>Restores prothrombin and other vitamin K–dependent clotting factors in the blood. Antidote for overdose of warfarin.</td>
</tr>
<tr>
<td>Alcohol may induce liver enzymes, which decrease effects by accelerating the rate of metabolism of the anticoagulant drug. However, with alcohol-induced liver disease (ie, cirrhosis), effects may be increased owing to impaired metabolism of warfarin.</td>
</tr>
</tbody>
</table>

### 4. Observe for Drug Interactions

- **a.** Drugs that *increase* risks of bleeding with anticoagulant, antiplatelet, and thrombolytic agents:
  - Any one of these drugs in combination with any other drug that affects hemostasis
  - A combination of these drugs

- **b.** Drugs that *increase* effects of heparins:
  - Antiplatelet drugs (eg, aspirin, clopidogrel, others)
  - Warfarin
  - Parenteral penicillins and cephalosporins

- **c.** Drugs that *decrease* effects of heparins:
  - Antihistamines, digoxin, tetracyclines
  - Protamine sulfate

- **d.** Drugs that *increase* effects of warfarin:
  - Analgesics (eg, acetaminophen, aspirin and other non-steroidal anti-inflammatory drugs)
  - Androgens and anabolic steroids
  - Antibacterial drugs (eg, aminoglycosides, erythromycin, fluoroquinolones, isoniazid, metronidazole, penicillins, cephalosporins, trimethoprim-sulfamethoxazole, tetracyclines)
  - Antifungal drugs (eg, fluconazole, ketoconazole, miconazole), including intravaginal use
  - Antiseizure drugs (eg, phenytoin)
  - Cardiovascular drugs (eg, amiodarone, beta blockers, loop diuretics, gemfibrozil, lovastatin, propafenone, quinidine)
  - Gastrointestinal drugs (eg, cimetidine, omeprazole)
  - Thyroid preparations (eg, levothyroxine)

- **e.** Drugs that *decrease* effects of warfarin:
  - Antacids and griseofulvin
  - Carbamazepine, disulfiram, rifampin
  - Cholestyramine
  - Diuretics
  - Estrogens, including oral contraceptives
  - Vitamin K

- **f.** Drug that may *increase or decrease* effects of warfarin:
  - Alcohol
NURSING ACTIONS

<table>
<thead>
<tr>
<th>g. Drugs that increase effects of cilostazol:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Diltiazem</td>
</tr>
<tr>
<td>(2) Erythomycin</td>
</tr>
<tr>
<td>(3) Itraconazole, ketoconazole</td>
</tr>
</tbody>
</table>

RATIONALE/EXPLANATION

These drugs inhibit the main cytochrome P450 enzyme (CYP3A4) that metabolizes cilostazol. Grapefruit juice also inhibits drug metabolism and should be avoided.

**Nursing Notes: Apply Your Knowledge**

**Answer:** Low-dose subcutaneous heparin is administered prophylactically to prevent deep vein thrombosis, which is associated with prolonged immobility. Activated partial thromboplastin time (aPTT) levels may be assessed before beginning therapy, but routine aPTT assessment and dosage adjustments are not required for low-dose heparin therapy. When giving the injection, take care to prevent trauma and subsequent bruising. A small, 26-gauge 1/2-inch needle is used. Leave a small air bubble in the syringe to follow the dose and lock the heparin into the subcutaneous space. The area is cleansed and grasped firmly and the needle is inserted at a 90-degree angle. Do not aspirate or rub the area because this fosters bruising. Avoid injections within 2 inches of incisions or the umbilicus and any areas that are scarred or abnormal. Although research indicates that various sites (abdomen, arms, and legs) can be used, the preferred site is the abdomen. Observe and report any signs of bleeding.

**How Can You Avoid This Medication Error?**

**Answer:** Ms. Innes’ INR is too high, which could significantly increase her risk for bleeding. Therapeutic INR levels are usually between 2 and 3. Before giving anticoagulants, it is important to check lab work (activated partial thromboplastin time for heparin, prothrombin time or INR for Coumadin) to determine whether the dose should be administered. For Ms. Innes, antibiotic therapy may have interfered with the synthesis of vitamin K in the intestine, thus increasing the risk of bleeding. Notify Ms. Innes’ physician. Because no signs of bleeding have been noted, he or she may decrease the Coumadin dosage.

**Review and Application Exercises**

1. What are the major functions of the endothelium, platelets, and coagulation factors in hemostasis and thrombosis?
2. What are the indications for use of heparin and warfarin?
3. How do heparin and warfarin differ in mechanism of action, onset and duration of action, and method of administration?
4. List interventions to protect clients from anticoagulant-induced bleeding.
5. When is it appropriate to use protamine sulfate as an antidote for heparin?
6. When is it appropriate to use vitamin K as an antidote for warfarin?
7. How do antiplatelet drugs differ from heparin and warfarin?
8. For what conditions are antiplatelet drugs indicated?
9. When is it appropriate to use a thrombolytic drug?
10. How do aminocaproic acid and tranexamic acid stop bleeding induced by thrombolytics?
11. Compare and contrast nursing care needs of clients receiving anticoagulant therapy in hospital and home settings.

**SELECTED REFERENCES**

Activated protein C (Xigris) for severe sepsis (2002, Feb. 18). The Medical Letter on Drugs and Therapeutics, 44 (1124), 17–18.
chapter 58

Drugs for Dyslipidemia

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss the role of dyslipidemia in the etiology of atherosclerosis.
2. Identify sources and functions of cholesterol and triglycerides.
3. Describe dyslipidemic drugs in terms of mechanism of action, indications for use, major adverse effects, and nursing process implications.
4. Teach clients pharmacologic and non-pharmacologic measures to prevent or reduce dyslipidemia.

Critical Thinking Scenario
During a routine physical examination, 26-year-old William Halls is diagnosed with dyslipidemia. His father died at 46 years of age of a massive myocardial infarction (MI). William jogs 3 miles three to four times a week. He eats out, mostly at fast-food places. He is very serious when he listens to the doctor explain his diagnosis. He responds by asking, “Does this mean I am going to die young like my dad?”

Reflect on:
- The emotional impact of this diagnosis for a young man, in light of his family history.
- The underlying pathophysiology of atherosclerosis. What are possible consequences of atherosclerosis other than MI?
- Ways to explain the significance of laboratory values (cholesterol, low-density lipoproteins, high-density lipoproteins, triglycerides).
- A plan for teaching and follow-up regarding lifestyle modification.

OVERVIEW

Dyslipidemic drugs are used in the management of clients with elevated blood lipids, a major risk factor for atherosclerosis and vascular disorders such as coronary artery disease, strokes, and peripheral arterial insufficiency. These drugs have proven efficacy and are being used increasingly to reduce morbidity and mortality from coronary heart disease and other atherosclerosis-related cardiovascular disorders. To understand clinical use of these drugs, it is necessary to understand atherosclerosis, characteristics of blood lipids, and types of blood lipid disorders.

ATHEROSCLEROSIS

Atherosclerosis is a major cause of ischemic heart disease (eg, angina pectoris, myocardial infarction), heart failure, stroke, peripheral vascular disease, and death (see Chapters 53 and 57). It is a systemic disease characterized by lesions in the endothelial lining of arteries throughout the body. These lesions (called fatty plaques or atheromas) start with injury to the endothelium and involve progressive accumulation of lipids (eg, cholesterol), vascular smooth muscle cells, macrophages, lymphocytes, and connective tissue proteins. Over time, the lesions interfere with nutrition of the blood vessel lining, the normally smooth endothelium becomes roughened, and thrombi, necrosis, scarring, and calcification occur. As the lesions develop and enlarge, they protrude into the lumen of the artery, reduce the size of the lumen, reduce blood flow, and may eventually occlude the artery. Severely impaired blood flow leads to damage or death of tissue supplied by the artery. Clinical manifestations vary according to the arteries involved and the extent of vessel obstruction.
**BLOOD LIPIDS**

Blood lipids, which include cholesterol, phospholipids, and triglycerides, are derived from the diet or synthesized by the liver and intestine. Most cholesterol is found in body cells, where it is a component of cell membranes and performs other essential functions. In cells of the adrenal glands, ovaries, and testes, cholesterol is required for the synthesis of steroid hormones (eg, cortisol, estrogen, progesterone, and testosterone). In liver cells, cholesterol is used to form cholic acid. The cholic acid is then conjugated with other substances to form bile salts, which promote absorption and digestion of fats. In addition, a small amount is found in blood serum. Serum cholesterol is the portion of total body cholesterol involved in formation of atherosclerotic plaques. Unless a person has a genetic disorder of lipid metabolism, the amount of cholesterol in the blood is strongly related to dietary intake of saturated fat. Phospholipids are essential components of cell membranes, and triglycerides provide energy for cellular metabolism.

**BOX 58–1 TYPES OF LIPOPROTEINS**

<table>
<thead>
<tr>
<th>Chylomicrons</th>
<th>Low-density lipoprotein (LDL) cholesterol</th>
<th>Very–low-density lipoprotein (VLDL)</th>
<th>High-density lipoprotein (HDL) cholesterol</th>
</tr>
</thead>
<tbody>
<tr>
<td>The largest lipoprotein molecules, are synthesized in the wall of the small intestine. They carry recently ingested dietary cholesterol and triglycerides that have been absorbed from the gastrointestinal tract. Hyperchylomiconemia normally occurs after a fatty meal, reaches peak levels in 3 to 4 hours, and subsides within 12 to 14 hours. Chylomicrons carry triglycerides to fat and muscle cells, where the enzyme lipoprotein lipase breaks down the molecule and releases fatty acids to be used for energy or stored as fat. This process leaves a remnant containing cholesterol, which is then transported to the liver. Thus, chylomicrons transport triglycerides to peripheral tissues and cholesterol to the liver.</td>
<td>LDL cholesterol is removed from the circulation by receptor and non-receptor mechanisms. The receptor mechanism involves the binding of LDL cholesterol to receptors on cell surface membranes. The bound LDL molecule is then engulfed into the cell, where it is broken down by enzymes and releases free cholesterol into the cytoplasm. Most LDL cholesterol receptors are located in the liver. However, nonhepatic tissues (eg, adrenal glands, smooth muscle cells, endothelial cells, and lymphoid cells) also have receptors by which they obtain the cholesterol needed for building cell membranes and synthesizing hormones. These cells can regulate their cholesterol intake by adding or removing LDL receptors.</td>
<td>VLDL contains approximately 75% triglycerides and 25% cholesterol. It transports endogenous triglycerides (those synthesized in the liver and intestine, not those derived exogenously, from food) to fat and muscle cells. Therefore, as with chylomicrons, lipoprotein lipase breaks down the molecule and releases fatty acids to be used for energy or stored as fat. The removal of triglycerides from VLDL leaves a cholesterol–rich remnant, which returns to the liver. Then the cholesterol is secreted into the intestine, mostly as bile acids, or it is used to form more VLDL and recirculated.</td>
<td>HDL is often referred to as “good cholesterol,” as it removes cholesterol from peripheral tissues and transports it to the liver for excretion, thereby promoting accumulation of cholesterol and the development of atherosclerosis. The amount of LDL cholesterol removed by nonreceptor mechanisms is increased with inadequate numbers of receptors or excessive amounts of LDL cholesterol. A high serum level of LDL cholesterol is atherogenic and a strong risk factor for coronary heart disease. The body normally attempts to compensate for high serum levels by inhibiting hepatic synthesis of cholesterol and cellular synthesis of new LDL receptors.</td>
</tr>
</tbody>
</table>

Blood lipids are transported in plasma by specific proteins called lipoproteins. Each lipoprotein contains cholesterol, phospholipid, and triglyceride bound to protein. The lipoproteins vary in density and amounts of lipid and protein. Density is determined mainly by the amount of protein, which is more dense than fat. Thus, density increases as the proportion of protein increases. The lipoproteins are differentiated according to these properties, which can be measured in the laboratory. For example, high-density lipoprotein (HDL) cholesterol contains larger amounts of protein and smaller amounts of lipid; low-density lipoprotein (LDL) cholesterol contains less protein and larger amounts of lipid. Other plasma lipoproteins are chylomicrons and very–low-density lipoproteins (VLDL). Additional characteristics of lipoproteins are described in Box 58–1.

The Third Report of The National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults classifies blood lipid levels as follows:
Total serum cholesterol (mg/dL)
Normal or desirable = less than 200
Borderline high = 200 to 239
High = 240 or above

LDL cholesterol (mg/dL)
Optimal = less than 100
Near or above optimal = 100–129
Borderline high = 130 to 159
High = 160 to 189
Very high = 190 or above

HDL cholesterol (mg/dL)
High = more than 60
Low = less than 40

Triglycerides (mg/dL)
Normal or desirable = less than 150
Borderline high = 150 to 199
High = 200 to 499
Very high = 500 or above

Overall, the most effective blood lipid profile for prevention or management of atherosclerosis and its sequelae is high HDL cholesterol, low LDL cholesterol, and low total cholesterol. A low triglyceride level is also desirable. For accurate interpretation of a client’s lipid profile, blood samples for laboratory testing of triglycerides should be drawn after the client has fasted for 12 hours. Fasting is not required for cholesterol testing.

**DYSLIPIDEMIA**

Dyslipidemia (also called hyperlipidemia) is associated with atherosclerosis and its many pathophysiologic effects (eg, myocardial ischemia and infarction, stroke, peripheral arterial occlusive disease). Ischemic heart disease has a high rate of morbidity and mortality. Elevated total cholesterol and LDL cholesterol and reduced HDL cholesterol are the abnormalities that are major risk factors for coronary artery disease. Elevated triglycerides also play a role in cardiovascular disease. For example, high blood levels reflect excessive caloric intake (excessive dietary fats are stored in adipose tissue; excessive proteins and carbohydrates are converted to triglycerides and also stored in adipose tissue) and obesity. High caloric intake also increases the conversion of VLDL to LDL cholesterol, and high dietary intake of triglycerides and saturated fat decreases the activity of LDL receptors and increases synthesis of cholesterol. Very high triglyceride levels are associated with acute pancreatitis.

Dyslipidemia may be primary (ie, genetic or familial) or secondary to dietary habits, other diseases (eg, diabetes mellitus, alcoholism, hypothyroidism, obesity, obstructive liver disease), and medications (eg, beta blockers, cyclosporine, oral estrogens, glucocorticoids, sertraline, thiazide diuretics, anti–human immunodeficiency virus protease inhibitors). Types of dyslipidemias (also called hyperlipoproteinemias because increased blood levels of lipoproteins accompany increased blood lipid levels) are described in Box 58–2. Although hypercholesterolemia is usually emphasized, hypertriglyceridemia is also associated with most types of hyperlipoproteinemia.

**INITIAL MANAGEMENT OF DYSLIPIDEMIA**

The National Cholesterol Education Program recommends management of clients according to their blood levels of total and LDL cholesterol and their risk factors for cardiovascular disease (Table 58–1). Note that both dietary and drug therapy are recommended at lower serum cholesterol levels in clients who already have cardiovascular disease or diabetes mellitus. Also, the target LDL serum level is lower in these clients. Guidelines include the following:

- Assess for, and treat, if present, conditions known to increase blood lipids (eg, diabetes mellitus, hypothyroidism).
- Stop medications known to increase blood lipids, if possible.

**BOX 58–2 TYPES OF DYSLIPIDEMIAS**

**Type I** is characterized by elevated or normal serum cholesterol, elevated triglycerides, and chylomicronemia. This rare condition may occur in infancy and childhood.

**Type IIa** (familial hypercholesterolemia) is characterized by a high level of low-density lipoprotein (LDL) cholesterol, a normal level of very–low-density lipoprotein (VLDL), and a normal or slightly increased level of triglycerides. It occurs in children and is a definite risk factor for development of atherosclerosis and coronary artery disease.

**Type IIb** (combined familial hyperlipoproteinemia) is characterized by increased levels of LDL, VLDL, cholesterol, and triglycerides and lipid deposits (xanthomas) in the feet, knees, and elbows. It occurs in adults.

**Type III** is characterized by elevations of cholesterol and triglycerides plus abnormal levels of LDL and VLDL. This type usually occurs in middle-aged adults (40 to 60 years) and is associated with accelerated coronary and peripheral vascular disease.

**Type IV** is characterized by normal or elevated cholesterol levels, elevated triglycerides, and increased levels of VLDL. This type usually occurs in adults and may be the most common form of hyperlipoproteinemia. Type IV is often secondary to obesity, excessive intake of alcohol, or other diseases. Ischemic heart disease may occur at 40 to 50 years of age.

**Type V** is characterized by elevated cholesterol and triglyceride levels with an increased level of VLDL and chylomicronemia. This uncommon type usually occurs in adults. Type V is not associated with ischemic heart disease. Instead, it is associated with fat and carbohydrate intolerance, abdominal pain, and pancreatitis, which are relieved by lowering triglyceride levels.
• Start a low-fat diet. A Step I diet contains no more than 30% of calories from fat, less than 10% of calories from saturated fats (eg, meat, dairy products), and less than 300 mg of cholesterol per day. A Step II diet contains no more than 30% of calories from fat, less than 7% of calories from saturated fat, and less than 200 mg of cholesterol per day. The Step II diet is more stringent and may be used initially in clients with more severe dyslipidemia, cardiovascular disease, or diabetes mellitus. It can decrease LDL cholesterol levels by 8% to 15%. Diets with more stringent fat restrictions than the Step II diet are not recommended because they produce little additional reduction in LDL cholesterol, they raise serum triglyceride levels, and they lower HDL cholesterol concentrations.

• Use the “Mediterranean diet,” which includes moderate amounts of monounsaturated fats (eg, canola and olive oils) and polyunsaturated fats (eg, safflower, corn, cottonseed, sesame, soybean, sunflower oils), to also decrease risks of cardiovascular disease.

• Increase dietary intake of soluble fiber (eg, psyllium preparations, oat bran, pectin, fruits and vegetables). This diet lowers serum LDL cholesterol by 5% to 10%.

• Dietary supplements (eg, Cholestain) and cholesterol-lowering margarines (eg, Benecol and Take Control) can help reduce cholesterol levels. These products are considered to be foods, not drugs, and are costly.

• Start a weight reduction diet if the client is overweight or obese. Weight loss can increase HDL and decrease LDL.

• Emphasize regular aerobic exercise (usually 30 minutes at least three times weekly). This increases blood levels of HDL.

• If the client smokes, assist to develop a cessation plan. In addition to numerous other benefits, HDL levels are higher in nonsmokers.

• If the client is postmenopausal, hormone replacement therapy can raise HDL and lower LDL.

• If the client has elevated serum triglycerides, initial management includes efforts to achieve desirable body weight, ingest low amounts of saturated fat and cholesterol, exercise regularly, stop smoking, and reduce alcohol intake, if indicated. The goal is to reduce serum triglyceride levels to 200 mg/dL or less.

• Unless lipid levels are severely elevated, a minimum of 6 months of intensive diet therapy and lifestyle modification should be undertaken before drug therapy is considered. It is essential that diet therapy continue as the benefits of diet and drug therapy are additive.

**TABLE 58–1**

National Cholesterol Education Program Recommendations for Treatment of Dyslipidemia

<table>
<thead>
<tr>
<th>Patient’s Cardiovascular Disease Status</th>
<th>Diet Therapy</th>
<th>Drug Therapy</th>
<th>Goal of Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Cholesterol (mg/dL)</td>
<td>LDL Cholesterol (mg/dL)</td>
<td>Total Cholesterol (mg/dL)</td>
</tr>
<tr>
<td>No or one risk factor</td>
<td>240</td>
<td>160</td>
<td>275</td>
</tr>
<tr>
<td>More than two risk factors</td>
<td>200</td>
<td>130</td>
<td>240</td>
</tr>
<tr>
<td>Has cardiovascular disease</td>
<td>160</td>
<td>100</td>
<td>200</td>
</tr>
</tbody>
</table>

LDL, low-density lipoprotein.

Dyslipidemic drugs are used to decrease blood lipids, to prevent or delay the development of atherosclerotic plaque, promote the regression of existing atherosclerotic plaque, and reduce morbidity and mortality from cardiovascular disease. Clinical data suggest that drug therapy may be efficacious even for those with mild to moderate elevations of LDL cholesterol. The drugs act by altering the production, metabolism, or removal of lipids and lipoproteins. Drug therapy is recommended when approximately 6 months of dietary and other lifestyle changes fail to decrease dyslipidemia to an acceptable level. It is also recommended for clients with signs and symptoms of coronary heart disease, a strong family history of coronary heart disease or dyslipidemia, or other risk factors for atherosclerotic vascular disease (eg, hypertension, diabetes mellitus, cigarette smoking). Although several dyslipidemic drugs are available, none is effective in all types of dyslipidemia. Categories of drugs are described in this section; individual drugs are listed in Drugs at a Glance: Dyslipidemic Agents.

The **HMG-CoA reductase inhibitors** or statins (eg, **lovastatin**), or statins (eg, **lovastatin**) inhibit an enzyme (hydroxymethylglutaryl-coenzyme A reductase) required for hepatic synthesis of cholesterol. By decreasing production of cholesterol, these drugs decrease total serum cholesterol, LDL cholesterol, VLDL cholesterol, and triglycerides. They reduce LDL cholesterol within 2 weeks and reach maximal effects in approximately 4 to 6 weeks. HDL cholesterol levels remain unchanged or may increase.

Overall, these drugs are useful in treating most of the major types of dyslipidemia and are the most widely used dyslipidemics. Studies indicate that these drugs can reduce the blood levels of C-reactive protein (CRP) that is associated with severe arterial inflammation that leads to heart attacks and strokes. The incidence of coronary artery disease is reduced by 25% to 60% and the risk of death from any cause by approximately 30%. They also reduce the risk of angina pectoris and peripheral arterial disease as well as the need for angioplasty and coronary artery grafting to increase or restore blood flow to the myocardium.
Absorption following oral administration varies by drug. Lovastatin and pravastatin are poorly absorbed, fluvastatin has the highest rate of absorption. Most of the statins undergo extensive first-pass metabolism by the liver, which results in low levels of drug available for general circulation. Metabolism occurs in the liver with 80% to 85% of drug metabolites excreted in feces, and the remaining excreted in urine.

Statins are usually well tolerated; the most common adverse effects (nausea, constipation, diarrhea, abdominal cramps or pain, headache, skin rash) are usually mild and transient. More serious reactions include rare occurrences of hepatotoxicity and myopathy.

Bile acid sequestrants (eg, cholestyramine) bind bile acids in the intestinal lumen. This causes the bile acids to be excreted in feces and prevents their being recirculated to the liver. Loss of bile acids stimulates hepatic synthesis of more bile acids from cholesterol. As more hepatic cholesterol is used to produce bile acids, more serum cholesterol moves into the liver to replenish the supply, thereby lowering serum cholesterol (especially LDL). LDL cholesterol levels decrease within a week of starting these drugs and reach maximal reductions within a month. When the drugs are stopped, pretreatment LDL cholesterol levels return within a month.

These drugs are used mainly to reduce LDL cholesterol further in clients who are already receiving a statin drug. The inhibition of cholesterol synthesis by a statin makes bile acid–binding drugs more effective. In addition, the combination increases HDL cholesterol and can further reduce the risk of cardiovascular disorders.

These drugs are not absorbed systemically and their main adverse effects are abdominal fullness, flatulence, and constipation. They may decrease absorption of many oral medications (eg, digoxin, folic acid, glipizide, propranolol, tetracyclines, thiazide diuretics, thyroid hormones, fat-soluble
How Can You Avoid This Medication Error?

Mrs. Gribble, a 79-year-old nursing home resident, likes to take all of her medications together. You mix up her cholestyramine (Questran) in a large glass of orange juice and give it to her with her digoxin, Lasix, captopril, and Slow-K. You monitor her pulse and blood pressure before administration and they are within normal limits. What, if any, additional precautions should be used when Questran is administered?

Nursing Process

Assessment

Assess the client’s status in relation to atherosclerotic vascular disease.

• Identify risk factors:
  • Hypertension
  • Diabetes mellitus
  • High intake of dietary fat and refined sugars
  • Obesity
  • Inadequate exercise
  • Cigarette smoking
  • Family history of atherosclerotic disorders
  • Dyslipidemia
  • Signs and symptoms depend on the specific problem:
    • Dyslipidemia is manifested by elevated serum cholesterol (>240 mg/100 mL) or triglycerides (>200 mg/100 mL), or both.
    • Coronary artery atherosclerosis is manifested by myocardial ischemia (angina pectoris, myocardial infarction).
    • Cerebrovascular insufficiency may be manifested by syncope, memory loss, transient ischemic attacks (TIAs), or strokes. Impairment of blood flow to the brain is caused primarily by atherosclerosis in the carotid, vertebral, or cerebral arteries.
    • Peripheral arterial insufficiency is manifested by impaired blood flow in the legs (weak or absent pulses; cool, pale extremities; intermittent claudication; leg pain at rest; and development of gangrene, usually in the toes because they are most distal to blood supply). This condition results from atherosclerosis in the distal abdominal aorta, the iliac arteries, and the femoral and smaller arteries in the legs.

Nursing Diagnoses

• Ineffective Tissue Perfusion: related to interruption of arterial blood flow
• Imbalanced Nutrition: More Than Body Requirements of fats and calories
• Anxiety related to risks of atherosclerotic cardiovascular disease
• Disturbed Body Image related to the need for lifestyle changes
• Noncompliance related to dietary restrictions and adverse drug reactions
• Deficient Knowledge related to drug and diet therapy of dyslipidemia

Planning/Goals

The client will:

• Take lipid-lowering drugs as prescribed
• Decrease dietary intake of saturated fats and cholesterol
• Lose weight if obese and maintain the lower weight
• Have periodic measurements of blood lipids

vitamins, and warfarin). Other drugs should be taken at least 1 hour before or 4 hours after cholestyramine or colestipol. In addition, dosage of the interactive drug may need to be changed when a bile acid sequestrant is added or withdrawn.

Fibrates are derivatives of fibric acid (eg, gemfibrozil, fenofibrate) and are similar to endogenous fatty acids. The drugs increase the oxidation of fatty acids in liver and muscle tissue and thereby decrease hepatic production of triglycerides, decrease VLDL cholesterol, and increase HDL cholesterol. These are the most effective drugs for reducing serum triglyceride levels, and their main indication for use is high serum triglyceride levels (>500 mg/dL). They are also useful for clients with low HDL cholesterol levels. In clients with coronary artery disease, management with gemfibrozil is associated with regression of atherosclerotic lesions on angiography.

These drugs are well absorbed following oral administration. Metabolism occurs in the liver and excretion is by urinary elimination. The main adverse effects are gastrointestinal discomfort and diarrhea, which may occur less often with fenofibrate than with gemfibrozil. The drugs may also increase cholesterol concentration in the biliary tract and cause gallstones. For clients receiving warfarin, warfarin dosage should be substantially decreased because fibrates displace warfarin from binding sites on serum albumin.

Niacin (nicotinic acid) decreases both cholesterol and triglycerides. It inhibits mobilization of free fatty acids from peripheral tissues, thereby reducing hepatic synthesis of triglycerides and secretion of VLDL, which leads to decreased production of LDL cholesterol. Niacin is the most effective drug for increasing the concentration of HDL cholesterol. Disadvantages of niacin are the high doses required for dyslipidemic effects and the subsequent adverse effects. Niacin commonly causes skin flushing, pruritus, and gastric irritation and may cause hyperglycemia, hyperuricemia, elevated hepatic aminotransferase enzymes, and hepatitis. Flushing can be reduced by starting with small doses, gradually increasing doses, taking doses with meals, and taking aspirin 325 mg about 30 minutes before niacin doses.

Niacin is rapidly absorbed from the gastrointestinal tract. Minimal metabolism occurs by the liver and the majority of the drug is excreted unchanged in the urine.

Niacin is most effective in preventing heart disease when used in combination with another dyslipidemic drug such as a bile acid sequestrant or a fibrate. Its use with a statin lowers serum LDL cholesterol more than either drug alone, but the combination has not been studied in relation to preventing cardiovascular disease.
• Avoid preventable adverse drug effects
• Receive positive reinforcement for efforts to lower blood lipid levels
• Feel less anxious and more in control as risks of atherosclerotic cardiovascular disease are decreased

**Interventions**

Use measures to prevent, delay, or minimize atherosclerosis.

• Help clients to control risk factors. Ideally, primary prevention begins in childhood with healthful eating habits (ie, avoiding excessive fats, meat, and dairy products; obtaining adequate amounts of all nutrients, including dietary fiber; avoiding obesity), exercise, and avoiding cigarette smoking. However, changing habits to a more healthful lifestyle is helpful at any time, before or after disease manifestations appear. Weight loss often reduces blood lipids and lipoproteins to a normal range. Changing habits is difficult for most people, even those with severe symptoms.

• Use measures to increase blood flow to tissues:
  • Exercise is helpful in developing collateral circulation in the heart and legs. Collateral circulation involves use of secondary vessels in response to tissue ischemia related to obstruction of the principal vessels. Clients with angina pectoris or previous myocardial infarction require a carefully planned and supervised program of progressive exercise. Those with peripheral arterial insufficiency usually can increase exercise tolerance by walking regularly. Distances should be determined by occurrence of pain and must be individualized.
  • Posture and position may be altered to increase blood flow to the legs in peripheral arterial insufficiency. Elevating the head of the bed and having the legs horizontal or dependent may help. Elevating the feet is usually contraindicated unless edema is present or likely to develop.
  • Although drug therapy is becoming increasingly used to prevent or manage atherosclerotic disorders, a major therapeutic option for management of occlusive vascular disease is surgical removal of atherosclerotic plaque or revascularization procedures. Thus, severe angina pectoris may be relieved by a coronary artery bypass procedure that detours blood flow around occluded vessels. This procedure also may be done after a myocardial infarction. The goal is to prevent infarction or reinfarction. TIA’s may be relieved by carotid endarterectomy; the goal is to prevent a stroke. Peripheral arterial insufficiency may be relieved by aortofemoral, femoropopliteal, or other bypass grafts that detour around occluded vessels. Although these procedures increase blood flow to ischemic tissues, they do not halt progression of atherosclerosis.

  The nursing role in relation to these procedures is to provide excellent preoperative and postoperative nursing care to promote healing, prevent infection, maintain patency of grafts, and help the client to achieve optimum function.

• Any dyslipidemic drug therapy must be accompanied by an appropriate diet; refer clients to a nutritionist. Overeating or gaining weight may decrease or cancel the lipid-lowering effects of the drugs.
• Encourage adult clients to have their serum cholesterol measured at least once every 5 years. Adults and children with a personal or family history of dyslipidemia or other risk factors should be tested more often.
• The most effective measures for preventing dyslipidemia and atherosclerosis are those related to a healthful lifestyle (diet low in cholesterol and saturated fats, weight control, exercise).
• Assist clients and family members to understand the desirability of lowering high blood lipid levels before serious cardiovascular diseases develop.

**Evaluation**

• Observe for decreased blood levels of total and low-density lipoprotein (LDL) cholesterol and triglycerides; observe for increased levels of high-density lipoprotein (HDL) cholesterol.
• Observe and interview regarding compliance with instructions for drug, diet, and other therapeutic measures.
• Observe and interview regarding adverse drug effects.
• Validate the client’s ability to identify foods high and low in cholesterol and saturated fats.

**Drug Selection**

Drug selection is based on the type of dyslipidemia and its severity. For single-drug therapy to lower cholesterol, a statin is preferred. To lower both cholesterol and triglycerides, a statin, gemfibrozil, or niacin may be used. To lower triglycerides, gemfibrozil or niacin may be used. Gemfibrozil is usually preferred for people with diabetes because niacin increases blood sugar.

When monotherapy is not effective, combination therapy is rational because the drugs act by different mechanisms. In general, a statin and a bile acid sequestrant or niacin and a bile acid sequestrant are the most effective combinations in reducing total and LDL cholesterol. A fibrate or niacin may be included when a goal of therapy is to increase levels of HDL cholesterol. However, a fibrate–statin combination should be avoided because of increased risks of severe myopathy, and a niacin–statin combination increases the risks of hepatotoxicity.

**Use in Children**

Dyslipidemia occurs in children and may lead to atherosclerotic cardiovascular disease, including myocardial infarction, in early adulthood. Dyslipidemia is diagnosed with total
General Considerations

Heart and blood vessel disease causes a great deal of illness and many deaths. The basic problem is usually atherosclerosis, in which the arteries are partly blocked by cholesterol deposits. Cholesterol, a waxy substance made in the liver, is necessary for normal body functioning. However, excessive amounts in the blood increase the likelihood of having a heart attack, stroke, or leg pain from inadequate blood flow. One type of cholesterol (low-density lipoprotein [LDL] or “bad”) attaches to artery walls, where it can enlarge over time and block blood flow. The other type (high-density lipoprotein [HDL] or “good”) carries cholesterol away from the artery and back to the liver, where it can be broken down. Thus, the healthiest blood cholesterol levels are low total cholesterol (<200 mg/dL), low LDL (<130 mg/dL) and high HDL (>35 mg/dL). High levels of blood triglycerides, another type of fat, are also unhealthy.

Dyslipidemic drugs are given to lower high concentrations of fats (total cholesterol, LDL cholesterol, and triglycerides) in your blood. The goal of management is to prevent heart attack, stroke, and peripheral arterial disease. If you already have heart and blood vessel disease, the drugs can improve your symptoms, activity level, and quality of life.

A low-fat diet is needed. This is often the first step in treating high cholesterol or triglyceride levels, and may be prescribed for 6 months or longer before drug therapy is begun. When drug therapy is prescribed, the diet should be continued. An important part is reducing the amount of saturated fat (from meats, dairy products). In addition, eating a bowl of oat cereal daily can help lower cholesterol by 5% to 10%. Diet counseling by a dietitian or nutritionist can be helpful in developing guidelines that fit your needs and lifestyle. Overeating or gaining weight may decrease or cancel the lipid-lowering effects of the drugs.

Other lifestyle changes that can help improve cholesterol levels include regular aerobic exercise (raises HDL); losing weight (raises HDL, lowers LDL, lowers triglycerides); and not smoking (HDL levels are higher in nonsmokers).

Adults should have measurements of total cholesterol and HDL cholesterol at least once every 5 years. People with a personal or family history of dyslipidemia or other risk factors for cardiovascular disease should be tested more often.

Self-Administration

Take lovastatin with food; take atorvastatin, fluvastatin, pravastatin, or simvastatin in the evening, with or without food. Food decreases stomach upset associated with lovastatin. All of these drugs may be more effective if taken in the evening or at bedtime, probably because more cholesterol is produced at nighttime and the drugs block cholesterol production.

Take fenofibrate with food; food increases drug absorption.

Take gemfibrozil on an empty stomach, 30 minutes before morning and evening meals.

Take immediate-release niacin with meals to decrease stomach upset; take timed-release niacin without regard to meals.

Mix cholestyramine powder and colestipol granules with water or other fluids, soups, cereals, or fruits such as applesauce and follow with more fluid. These drug forms should not be taken dry.

Do not take cholestyramine or colestipol with other drugs because they may prevent absorption of the other drugs. If taking other drugs, take them 1 hour before or 4 to 6 hours after cholestyramine or colestipol.

Swallow colestipol tablets whole; do not cut, crush, or chew.

Nursing Notes: Apply Your Knowledge

John Dwyer, 55 years of age, visits his primary health care provider. His cholesterol level (306 mg/dL) has been elevated for the last two visits. His health care provider prescribes niacin (nicotinic acid) to reduce his cholesterol level. Describe the data you will collect and how you will use it to individualize a teaching plan.

Atorvastatin and other statin-type dyslipidemic drugs may increase sensitivity to sunlight. Avoid prolonged exposure to the sun, use sunscreens, and wear protective clothing.

Gemfibrozil may cause dizziness or blurred vision and should be used cautiously while driving or performing other tasks that require alertness, coordination, or physical dexterity. It also may cause abdominal pain, diarrhea, nausea, or vomiting. Notify a health care provider if these symptoms become severe.

Skin flushing may occur with niacin. If it is distressing, taking one regular aspirin tablet (325 mg) 30 to 60 minutes before the niacin dose may decrease this reaction. Flushing usually decreases in a few days, but may recur when niacin dosage is increased. Ask your health care provider if there is any reason you should not take aspirin.

Cholestyramine and colestipol can cause constipation. Increasing intake of dietary fiber can help prevent this adverse effect.

Cholestyramine and colestipol can cause constipation. Increasing intake of dietary fiber can help prevent this adverse effect.
Dyslipidemic drugs are not recommended for children younger than 10 years of age. Lovastatin recently received Food and Drug Administration approval for use in children 10 to 17 years old. Oral dosing recommendations are 10 to 20 mg daily with a meal, initially, and increasing up to 40 mg daily as necessary with increases made at least 4 weeks apart. Other statin drugs are not recommended in children younger than 18 years of age, and the safety and effectiveness of the fibrates have not been established. Bile acid sequestrants are considered the drugs of choice, and niacin also may be used. Despite considerable use of bile acid sequestrants, children’s dosages have only been established for cholestyramine. Recommendations for oral dosing of cholestyramine are 240 mg/kg/day to be given in three divided doses. Niacin dosage is 55 to 87 mg/kg/d to be given orally 3 to 4 times a day with or just after meals. The long-term consequences of dyslipidemic drug therapy in children are unknown.

Use in Older Adults

As with younger adults, diet, exercise, and weight control should be tried first. When drug therapy is required, statins are effective for lowering LDL cholesterol and usually are well tolerated by older adults. However, they are expensive. Niacin and bile acid sequestrants are effective, but older adults do not tolerate their adverse effects very well. In postmenopausal women, estrogen replacement therapy increases HDL cholesterol.

Older adults often have diabetes, impaired liver function, or other conditions that raise blood lipid levels. Thus, management of secondary causes is especially important. They are also likely to have cardiovascular and other disorders that increase the adverse effects of dyslipidemic drugs. Overall, use of dyslipidemic drugs should be cautious, with close monitoring for therapeutic and adverse effects. Lower starting dosages are recommended for fenofibrate (67 mg/day), pravastatin (10 mg/day), and simvastatin (5 mg/day).

Use in Renal Impairment

Statins are metabolized by the liver and excreted partly through the kidneys (their main route of excretion is through bile). Drug plasma concentrations may be increased in clients with renal impairment and they should be used cautiously; some need reduced dosage.

- With atorvastatin, plasma levels are not affected and dosage reductions are not needed.
- With fluvastatin, because it is cleared hepatically and less than 6% of the dose is excreted in urine, dosage reduction for mild to moderate renal impairment is unnecessary. Use caution with severe impairment.
- With lovastatin, plasma concentrations are increased in clients with severe renal impairment (creatinine clearance < 30 mL/minute), and doses above 20 mg/day should be used with caution.

- With pravastatin, initiate therapy with 10 mg/day.
- With simvastatin, initiate therapy with 5 mg/day and monitor closely.

Fibrates are excreted mainly by the kidneys and therefore accumulate in the serum of clients with renal impairment. With gemfibrozil, there have been reports of worsening renal impairment in clients whose baseline serum creatinine levels were higher than 2 mg/dL. A different type of dyslipidemic drug may be preferred in these clients. Fenofibrate is contraindicated in clients with severe renal impairment, and the recommended starting dose is 67 mg/day in clients with a creatinine clearance of less than 50 mL/min. Drug and dose effects on renal function and triglyceride levels should be evaluated before dosage is increased.

Use in Hepatic Impairment

Statins are metabolized in the liver and may accumulate in clients with impaired hepatic function. They are contraindicated in clients with active liver disease or unexplained elevations of serum aspartate or alanine aminotransferase. They should be used cautiously, in reduced dosages, for clients who ingest substantial amounts of alcohol or have a history of liver disease.

Liver function tests are recommended before starting a statin, at 6 and 12 weeks after starting the drug or increasing the dose, then every 6 months. Monitor clients who have increased serum aminotransferases until the abnormal values resolve. If the increases are more than three times the upper limit of normal levels and persist, the dose should be reduced or the drug discontinued.

Fibrates may cause hepatotoxicity. Abnormal elevations of serum aminotransferases have occurred with both gemfibrozil and fenofibrate, but they usually subside when the drug is discontinued. Fenofibrate is contraindicated in severe hepatic impairment, including clients with primary biliary cirrhosis, preexisting gallbladder disease, and persistent elevations in liver function test results. In addition, hepatitis (hepatocellular, chronic active, and cholestatic) has been reported after use of fenofibrate from a few weeks to several years. Liver function tests should be monitored during the first year of drug administration. The drug should be discontinued if elevated enzyme levels persist at more than three times the normal limit.

Niacin may cause hepatotoxicity, especially with doses above 2 g daily, with timed-release preparations, and if given in combination with a statin or fibrate.

Genetic/Ethnic Considerations

Little information has been reported on racial or ethnic differences for lipid lowering drugs. Members of minority populations (eg, African Americans, Mexican Americans) are less likely to be treated than Caucasians. Despite an increased prevalence of diabetes and obesity, American Indians appear to have lower cholesterol levels than the United States popu-
lation as a whole. This suggests that diet and exercise may be more useful than lipid-lowering drugs for this group.

**Herbal and Dietary Supplements**

Use of nonprescription herbal and dietary supplements is frequently not reported by the client even though one third of the adults in the United States use these agents. Significant interactions can occur when herbs and dietary supplements are taken with prescribed drugs. Flax or flax seed is used internally as a laxative and a dyslipidemic agent. Absorption of all medications may be decreased when taken with flax, resulting in less than a therapeutic effect. Garlic is reportedly used as a dyslipidemic agent and a possible antihypertensive, but there is little scientific support for such use. Bleeding may be increased when garlic is used with anticoagulants, and insulin doses may need to be decreased as a result of the hypoglycemic effect of garlic. Green tea is commonly used for its dyslipidemic effect and the caffeinated product can be a central nervous stimulant. Soy is used as a food source and has been researched extensively. Use of soy to lower cholesterol (LDL and total cholesterol) has been documented. Significant interactions with other herbs or drugs have not been reported.

**Home Care**

For a client with dyslipidemia, the home care nurse should reinforce teaching about the role of blood lipids in causing myocardial infarction, stroke, and peripheral arterial insufficiency; the prescribed management regimen and its goals; and the importance of improving dyslipidemia in preventing or improving cardiovascular disorders. In addition, the client may need assistance in obtaining blood tests (eg, lipids and liver function tests) and dietary counseling.

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>Drugs for Dyslipidemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NURSING ACTIONS</strong></td>
<td><strong>RATIONALE/EXPLANATION</strong></td>
</tr>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give lovastatin with food; give fluvastatin on an empty stomach or at bedtime. Atorvastatin, pravastatin, or simvastatin may be given with or without food in the evening. Avoid giving with grapefruit juice. Food decreases gastrointestinal (GI) upset associated with lovastatin. These drugs are more effective if taken in the evening or at bedtime, because more cholesterol is produced by the liver at night and the drugs block cholesterol production. Grapefruit juice increases serum drug levels.</td>
<td></td>
</tr>
<tr>
<td>b. Give fenofibrate with food.</td>
<td>Food increases drug absorption.</td>
</tr>
<tr>
<td>c. Give gemfibrozil on an empty stomach, about 30 min before morning and evening meals.</td>
<td>The immediate-release formulation may cause gastric irritation.</td>
</tr>
<tr>
<td>d. Give immediate-release niacin with meals; give timed-release niacin without regard to meals.</td>
<td>These drug forms should not be taken dry.</td>
</tr>
<tr>
<td>e. Mix cholestyramine powder and colestipol granules with water or other fluids, soups, cereals, or fruits such as applesauce and follow with more fluid.</td>
<td>Cholestyramine and colestipol prevent absorption of many drugs.</td>
</tr>
<tr>
<td>f. Do not give cholestyramine or colestipol with other drugs; give them 1 h before or 4–6 h after cholestyramine or colestipol.</td>
<td></td>
</tr>
<tr>
<td>g. Instruct clients to swallow colestipol tablets whole; do not cut, crush, or chew.</td>
<td></td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. Decreased levels of total serum cholesterol, low-density lipoprotein cholesterol, and triglycerides, and increased levels of high-density lipoprotein cholesterol.</td>
<td>With statins, effects occur in 1–2 wk, with maximum effects in 4–6 wk. With fibrates and niacin, effects occur in approximately 1 mo. With cholestyramine and colestipol, maximum effects occur in approximately 1 mo.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. GI problems—nausea, vomiting, flatulence, constipation or diarrhea, abdominal discomfort</td>
<td>GI symptoms are the most common adverse effects of dyslipidemic drugs. Constipation is especially common with cholestyramine and colestipol.</td>
</tr>
</tbody>
</table>

(continued)
### RATIONALITY/EXPLANATION

- **b.** With lovastatin and related drugs, observe for GI upset (see 3a), skin rash, pruritus, and myopathy

- **c.** With nicotinic acid, flushing of the face and neck, pruritus, and skin rash may occur, as well as tachycardia, hypotension, and dizziness.

4. **Observe for drug interactions**

   - **a.** Drugs that increase effects of lovastatin and related drugs:
     1. Azole antifungals (eg, fluconazole, itraconazole)
     2. Cyclosporine
     3. Erythromycin
     4. Fibrate dyslipidemics (eg, fenofibrate, gemfibrozil)
     5. Niacin
     6. Drugs that increase effects of fluvastatin:
        a. Alcohol, cimetidine, ranitidine, omeprazole

   - **b.** Drugs that decrease effects of lovastatin and related drugs:
     1. Bile acid sequestrant dyslipidemics
     2. Antacids
     3. Isradipine
     4. Rifampin

   - **c.** Drugs that decrease effects of fibrate dyslipidemic drugs:
     1. Bile acid sequestrant dyslipidemic drugs

Adverse effects are usually mild and of short duration. A less common but potentially serious effect is liver dysfunction, usually manifested by increased levels of serum aminotransferases. Serum aminotransferases (aspartate and alanine aminotransferase) should be measured before starting the drug, every 4–6 wk during the first 3 mo, then every 6–12 wk or after dosage increases for 1 y, then every 6 mo.

These symptoms may be prominent when nicotinic acid is used to lower blood lipids because relatively high doses are required. Aspirin 325 mg, 30 min before nicotinic acid, decreases the flushing reaction.

Risk of myopathy is increased. It is recommended that statin therapy be interrupted temporarily if systemic azole antifungals are needed.

Risk of severe myopathy or rhabdomyolysis is increased.

Risk of severe myopathy or rhabdomyolysis is increased.

Risk of severe myopathy or rhabdomyolysis is increased. These drugs should not be given concurrently with statin dyslipidemic drugs.

Risk of severe myopathy or rhabdomyolysis is increased.

Increased blood levels

Decreased blood levels unless the drugs are taken 1–4 h apart

Decrease absorption of atorvastatin

This calcium channel blocker may decrease blood levels of lovastatin and its metabolites by increasing their hepatic metabolism.

Decreases blood levels of fluvastatin

Decrease absorption unless the fibrate is taken about 1 h before or 4–6 h after the bile acid sequestrant
Answer: Mr. Dwyer will need teaching regarding lifestyle modifications to reduce his cholesterol level as well as information on the niacin that has been prescribed. First, ask what he knows about high cholesterol and methods that he has used to try to decrease his cholesterol level. Make sure you include a dietary assessment, especially his knowledge of foods high in cholesterol or fat. Explore together possible ways to reduce cholesterol and fat in the diet. If he is overweight, also talk about calorie reduction. Often, people have the correct knowledge about necessary changes, but compliance with lifestyle modification is difficult. Explore his supports and provide a list of referrals for long-term follow-up. Assess his exercise pattern. Provide positive reinforcement for any exercise that he does and together develop a reasonable exercise plan.

Mr. Dwyer also needs teaching about niacin to prevent unpleasant side effects. Gradually increasing the dose can possibly limit the unpleasant side effects of flushing and pruritus, as can premedicating with aspirin. Niacin should be taken with meals. Because niacin is a vitamin, many patients may feel it is safe to increase the dose. If side effects limit compliance, discuss this with the prescriber. Many newer, more expensive antilipid agents with fewer side effects can be prescribed to lower cholesterol. It is important to stress the importance of ongoing follow-up for clients with dyslipidemia.

Answer: Questran should not be administered at the same time as other oral medications because it interferes with the absorption of many other drugs, including digoxin. Give other drugs 1 hour before or 4 to 6 hours after Questran is administered.

1. How would you describe dyslipidemia to a client?
2. What is the goal of management for dyslipidemia?

3. Differentiate lipid-lowering drugs according to their mechanisms of action.
4. What are the main nonpharmacologic measures to decrease total and LDL cholesterol and increase HDL cholesterol?
5. What are the main nonpharmacologic measures to decrease serum triglyceride levels?
Drugs Affecting the Digestive System
Physiology of the Digestive System

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review roles of the main digestive tract structures.
2. List common signs and symptoms affecting gastrointestinal functions.
3. Identify general categories of drugs used to treat gastrointestinal disorders.
4. Discuss the effects of nongastrointestinal drugs on gastrointestinal functioning.

OVERVIEW

The digestive system consists of the alimentary canal (a tube extending from the oral cavity to the anus, approximately 25 to 30 feet [7.5 to 9 m] long) and the accessory organs (salivary glands, gallbladder, liver, and pancreas). The main function of the system is to provide the body with fluids, nutrients, and electrolytes in a form that can be used at the cellular level. The system also disposes of waste products that result from the digestive process.

The alimentary canal has the same basic structure throughout. The layers of the wall are mucosa, connective tissue, and muscle. Peristalsis propels food through the tract and mixes the food bolus with digestive juices. Stimulation of the parasympathetic nervous system (by vagus nerves) increases motility and secretions. The tract has an abundant blood supply, which increases cell regeneration and healing. Blood flow increases during digestion and absorption. Blood flow decreases with strenuous exercise, sympathetic nervous system stimulation (ie, “fight or flight”), aging (secondary to decreased cardiac output and atherosclerosis), and conditions that shunt blood away from the digestive tract (eg, heart failure, atherosclerosis).

ORGANS OF THE DIGESTIVE SYSTEM

Oral Cavity

In the oral cavity, chewing mechanically breaks food into smaller particles, which can be swallowed more easily and provide a larger surface area for enzyme action. Food is also mixed with saliva, which lubricates the food bolus for swallowing and initiates the digestion of starch.

Esophagus

The esophagus is a musculofibrous tube about 10 inches (25 cm) long; its main function is to convey food from the pharynx to the stomach. It secretes a small amount of mucus and has some peristaltic movement.

Stomach

The stomach is a dilated area that serves as a reservoir. It churns and mixes the food with digestive juices, secretes mucus, hydrochloric acid, and enzymes, starts protein breakdown, and secretes intrinsic factor, which is necessary for absorption of vitamin B₁₂ from the ileum. Although there is much diffusion of water and electrolytes through the gastric mucosa in both directions, there is little absorption of these substances. Carbohydrates and amino acids are also poorly absorbed. Only a few highly lipid soluble substances, such as alcohol and some drugs, are absorbed in moderate quantities from the stomach.

The inlet of the stomach is the end of the esophagus, and the outlet is the pyloric sphincter at the beginning of the duodenum. The stomach normally holds about 1000 mL comfortably and empties in about 4 hours. Numerous factors influence the rate of gastric emptying, including the size of the pylorus, gastric motility, type of food, fluidity of chyme (the material produced by gastric digestion of food), and the state of the duodenum. Factors that cause rapid emptying include carbohydrate foods, increased motility, fluid chyme, and an empty duodenum. The stomach empties more slowly with decreased gastric tone and motility, fatty foods, chyme of excessive acidity, and a duodenum that contains fats, proteins, or chyme of excessive acidity.
When fats are present, the duodenal mucosa produces a hormone, enterogastrone, that inhibits gastric secretion and motility. This allows a longer time for the digestion of fats in the small intestine.

**Small Intestine**

The small intestine consists of the duodenum, jejunum, and ileum and is approximately 20 feet (6 m) long. The duodenum makes up the first 10 to 12 inches (25 to 30 cm) of the small intestine. The pancreatic and bile ducts empty into the duodenum at the papilla of Vater. The small intestine contains numerous glands that secrete digestive enzymes, hormones, and mucus. For the most part, digestion and absorption occur in the small intestine, including absorption of most orally administered drugs.

**Large Intestine**

The large intestine consists of the cecum, colon, rectum, and anus. The ileum opens into the cecum. The colon secretes mucus and absorbs water.

**Pancreas**

The pancreas secretes enzymes required for the digestion of carbohydrates, proteins, and fats. It also secretes insulin and glucagon, hormones that regulate glucose metabolism and blood sugar levels.

**Gallbladder**

The gallbladder is a small pouch attached to the underside of the liver that stores and concentrates bile. It has a capacity of 50 to 60 mL. The gallbladder releases bile when fats are present in the duodenum.

**Liver**

The liver is a vital organ that performs numerous functions. It receives about 1500 mL of blood per minute, or 25% to 30% of the total cardiac output. About three fourths of the blood flow is venous blood from the stomach, intestines, spleen, and pancreas (portal circulation); the remainder is arterial blood through the hepatic artery. The hepatic artery carries blood to the connective tissue of the liver and bile ducts, then empties into the hepatic sinuses. Arterial blood mixes with blood from the portal circulation. Venous blood from the liver flows into the inferior vena cava for return to the systemic circulation. The ample blood flow facilitates specific hepatic functions, which include the following:

1. **Blood reservoir.** The liver can eject 500 to 1000 mL of blood into the general circulation in response to stress, decreased blood volume, and sympathetic nervous system stimulation (eg, hemorrhagic or hypovolemic shock).

2. **Blood filter and detoxifier.** Kupffer cells in the liver phagocytize bacteria carried from the intestines by the portal vein. They also break down worn-out erythrocytes, saving iron for reuse in hemoglobin synthesis, and form bilirubin, a waste product excreted in bile. The liver metabolizes many body secretions and most drugs to prevent accumulation and harmful effects on body tissues.

   Most drugs are active as the parent compound and are metabolized in the liver to an inactive metabolite, which is then excreted by the kidneys. However, some drugs become active only after formation of a metabolite in the liver.

   The liver detoxifies or alters substances by oxidation, hydrolysis, or conjugation. Conjugation involves combining a chemical substance with an endogenous substance to produce an inactive or harmless compound. Essentially all steroid hormones, including adrenal corticosteroids and sex hormones, are at least partially conjugated in the liver and secreted into the bile. When the liver is damaged, these hormones may accumulate in body fluids and cause symptoms of hormone excess.

3. **Metabolism of carbohydrate, fat, and protein.** In carbohydrate metabolism, the liver converts glucose to glycogen for storage and reconverts glycogen to glucose when needed to maintain an adequate blood sugar concentration. Excess glucose that cannot be converted to glycogen is converted to fat. The liver also changes fructose and galactose, which cannot be used by body cells, to glucose, which provides energy for cellular metabolism. Fats are synthesized and catabolized by the liver. Amino acids from protein breakdown may be used to form glycogen, plasma proteins, and enzymes.

4. **Storage of nutrients.** In addition to glycogen, the liver also stores fat-soluble vitamins (ie, vitamins A, D, E, K), vitamin B₁₂, iron, phospholipids, cholesterol, and small amounts of protein and fat.

5. **Synthesis** of bile; serum albumin and globulin; prothrombin; fibrinogen; blood coagulation factors V, VII, VIII, IX, XI, and XII; and urea. Formation of urea removes ammonia from body fluids. Large amounts of ammonia are formed by intestinal bacteria and absorbed into the blood. If the ammonia is not converted to urea by the liver, plasma ammonia concentrations rise to toxic levels and cause hepatic coma and death.

6. **Production of body heat** by continuous cellular metabolism. The liver is the body organ with the highest rate of chemical activity during basal conditions, and it produces about 20% of total body heat.
SECRETIONS OF THE DIGESTIVE SYSTEM

Mucus

Mucus is secreted by mucous glands in every part of the gastrointestinal (GI) tract. The functions of mucus are to protect the lining of the tract from digestive juices, lubricate the food bolus for easier passage, promote adherence of the fecal mass, and neutralize acids and bases.

Saliva

Saliva consists of mucus and salivary amylase. It is produced by the salivary glands and totals about 1000 mL daily. Saliva has a slightly acidic to neutral pH (6 to 7); it lubricates the food bolus and starts starch digestion.

Gastric Juice

Gastric juice consists of mucus, digestive enzymes, hydrochloric acid, and electrolytes. The gastric glands secrete about 2000 mL of highly acidic (pH of 1 to 3) gastric juice daily. Secretion varies according to time of day, the time and type of food intake, psychological states, and other metabolic activities of the body. It is highest in the evening and lowest in the early morning. Secretion is stimulated by the parasympathetic nervous system (by the vagus nerve), the hormone gastrin, the presence of food in the mouth, and seeing, smelling, or thinking about food.

The major digestive enzyme in gastric juice is pepsin, a proteolytic enzyme (named before the “ase” system of naming enzymes) that functions best at a pH of 2 to 3. Hydrochloric acid provides the acid medium to promote pepsin activity. The major function of gastric juice is to begin digestion of proteins. There is also a weak action on fats by gastric lipase and on carbohydrates by gastric amylase. A large amount of mucus is secreted in the stomach to protect the stomach wall from the proteolytic action of pepsin. When mucus is not secreted, gastric ulceration occurs within hours.

Pancreatic Juices

Pancreatic juices are alkaline (pH 8 or above) secretions that contain amylase for carbohydrate digestion, lipase for fat digestion, and trypsin and chymotrypsin for protein digestion. They also contain large amounts of sodium bicarbonate, a base (alkali) that neutralizes the acid chyme from the stomach by reacting with hydrochloric acid. This protects the mucosa of the small intestine from the digestive properties of gastric juice. The daily amount of pancreatic secretion is about 1200 mL. The hormone cholecystokinin stimulates secretion of pancreatic juices.

Bile

Bile is an alkaline (pH about 8) secretion that is formed continuously in the liver, carried to the gallbladder by the bile ducts, and stored there. The hormone cholecystokinin causes the gallbladder to contract and release bile into the small intestine when fats are present in intestinal contents. The liver secretes about 600 mL of bile daily. This amount is concentrated to the 50- to 60-mL capacity of the gallbladder. Bile contains bile salts, cholesterol, bilirubin, fatty acids, and electrolytes. Bile salts are required for digestion and absorption of fats, including fat-soluble vitamins. Most of the bile salts are reabsorbed and reused by the liver (enterohepatic recirculation); some are excreted in feces.

EFFECTS OF DRUGS ON THE DIGESTIVE SYSTEM

The digestive system and drug therapy have a reciprocal relationship. Many common symptoms (ie, nausea, vomiting, constipation, diarrhea, abdominal pain) relate to GI dysfunction. These symptoms may result from a disorder in the digestive system, disorders in other body systems, or drug therapy. Many GI symptoms and disorders alter the ingestion, dissolution, absorption, and metabolism of drugs. Drugs may be administered to relieve these symptoms and disorders, but drugs administered for conditions unrelated to the digestive system may cause such symptoms and disorders. GI conditions may alter responses to drug therapy.

Drugs used in digestive disorders primarily alter GI secretion, absorption, or motility. They may act systemically or locally in the GI tract. The drug groups included in this section are drugs used for acid-peptic disorders, laxatives, antidiarrheals, and antiemetics. Other drug groups used in GI disorders include cholinergics (see Chap. 20), anticholinergics (see Chap. 21), corticosteroids (see Chap. 24), and antiinfective drugs (see Section VI).

Review and Application Exercises

1. What is the main function of the GI system?
2. What is the role of the parasympathetic nervous system in GI function?
3. List factors affecting GI motility and secretions.
4. Describe important GI secretions and their functions.
5. What factors stimulate or inhibit GI secretions?
6. How does the GI tract affect oral medications?
7. How do oral medications affect the GI tract?

SELECTED REFERENCES

Drugs Used for Peptic Ulcer and Acid Reflux Disorders

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Describe the main elements of peptic ulcer disease and gastroesophageal reflux disease.
2. Differentiate the types of drugs used to treat peptic ulcers and acid reflux disorders.
3. Discuss the advantages and disadvantages of proton pump inhibitors.
4. Differentiate between prescription and over-the-counter uses of histamine-2 receptor blocking agents.
5. Discuss significant drug–drug interactions with cimetidine.
6. Describe characteristics, uses, and effects of selected antacids.
7. Discuss the rationale for using combination antacid products.
8. Teach clients nonpharmacologic measures to manage peptic ulcers and gastroesophageal reflux disease.

Critical Thinking Scenario
Mrs. Greenspan, a 26-year-old homemaker, has rheumatoid arthritis that has been treated with aspirin, nonsteroidal anti-inflammatory drugs, and prednisone for the last 10 years. During the past week, Mrs. Greenspan has been feeling increasingly weak. She is dizzy when getting up and has had one episode of syncope (fainting). A work-up indicates that she has a peptic ulcer. Omeprazole, a proton pump inhibitor, is ordered.

Reflect on:
- Mrs. Greenspan’s risk factors that contributed to the development of her ulcer.
- How symptoms of weakness, dizziness, and syncope are associated with a peptic ulcer.
- How proton pump inhibitors work to heal ulcers.
- What therapies (drugs and nondrugs) can be used to prevent a recurrence of her ulcer.

OVERVIEW
Drugs to prevent or treat peptic ulcer and acid reflux disorders are comprised of several groups of drugs, most of which alter gastric acid and its effects on the mucosa of the upper gastrointestinal (UGI) tract. To aid understanding of drug effects, peptic ulcer disease and gastroesophageal reflux disease are described below; related UGI disorders are described in Box 60–1.

PEPTIC ULCER DISEASE
Peptic ulcer disease is characterized by ulcer formation in the esophagus, stomach, or duodenum, areas of the gastrointestinal (GI) mucosa that are exposed to gastric acid and pepsin. Gastric and duodenal ulcers are more common than esophageal ulcers.

Peptic ulcers are attributed to an imbalance between cell-destructive and cell-protective effects (ie, increased destructive mechanisms or decreased protective mechanisms). Cell-destructive effects include those of gastric acid (hydrochloric acid), pepsin, Helicobacter pylori (H. pylori) infection, and ingestion of nonsteroidal anti-inflammatory drugs (NSAIDs). Gastric acid, a strong acid that can digest the stomach wall, is secreted by parietal cells in the mucosa of the stomach antrum, near the pylorus. The parietal cells contain receptors for acetylcholine, gastrin, and histamine, substances that stimulate gastric acid production. Acetylcholine is released by vagus nerve endings in response to stimuli, such as thinking...
Gastritis
Gastritis, a common disorder, is an acute or chronic inflammatory reaction of gastric mucosa. Patients with gastric or duodenal ulcers usually also have gastritis. Acute gastritis (also called gastropathy) usually results from irritation of the gastric mucosa by such substances as alcohol, aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), and others. Chronic gastritis is usually caused by H. pylori infection and it persists unless the infection is treated effectively. H. pylori organisms may cause gastritis and ulceration by producing enzymes (eg, urease, others) that break down mucosa; they also alter secretion of gastric acid.

Nonsteroidal Anti-inflammatory Drug Gastropathy
NSAID gastropathy indicates damage to gastroduodenal mucosa by aspirin and other NSAIDs. The damage may range from minor superficial erosions to ulceration and bleeding. NSAID gastropathy is one of the most common causes of gastric ulcers, and it may cause duodenal ulcers as well. Many people take NSAIDs daily for pain, arthritis, and other conditions. Chronic ingestion of NSAIDs causes local irritation of gastroduodenal mucosa, inhibits the synthesis of prostaglandins (which normally protect gastric mucosa by inhibiting acid secretion, stimulating secretion of bicarbonate and mucus, and maintaining mucosal blood flow), and increases the synthesis of leukotrienes and possibly other inflammatory substances that may contribute to mucosal injury.

Stress Ulcers
Stress ulcers indicate gastric mucosal lesions that develop in patients who are critically ill from trauma, shock, hemorrhage, sepsis, burns, acute respiratory distress syndrome, major surgical procedures, or other severe illnesses. The lesions may be single or multiple ulcers or erosions. Stress ulcers are usually manifested by painless upper gastrointestinal (GI) bleeding. The frequency of occurrence has decreased, possibly because of prophylactic use of antacids and antisecretory drugs and improved management of sepsis, hypovolemia, and other disorders associated with critical illness.

Although the exact mechanisms of stress ulcer formation are unknown, several factors are thought to play a role, including mucosal ischemia, reflux of bile salts into the stomach, reduced GI tract motility, and systemic acidosis. Acidosis increases severity of lesions, and correction of acidosis decreases their formation. In addition, lesions do not form if the pH of gastric fluids is kept about 3.5 or above and lesions apparently form only when mucosal blood flow is diminished.

Zollinger-Ellison Syndrome
Zollinger-Ellison syndrome is a rare condition characterized by excessive secretion of gastric acid and a high incidence of ulcers. It is caused by gastrin-secreting tumors in the pancreas, stomach, or duodenum. Approximately two thirds of the gastrinomas are malignant. Symptoms are those of peptic ulcer disease, and diagnosis is based on high levels of serum gastrin and gastric acid. Treatment may involve long-term use of a proton pump inhibitor to diminish gastric acid, or surgical excision.
ated with *H. pylori* infection and NSAID ingestion, may occur at any age, occur about equally in men and women, are often manifested by abdominal pain, and are usually chronic in nature. They are also associated with cigarette smoking. Compared with nonsmokers, smokers are more likely to develop duodenal ulcers, their ulcers heal more slowly with treatment, and the ulcers recur more rapidly.

**Gastroesophageal Reflux Disease (GERD)**

GERD, the most common disorder of the esophagus, is characterized by regurgitation of gastric contents into the esophagus and exposure of esophageal mucosa to gastric acid and pepsin. The same amount of acid–pepsin exposure may lead to different amounts of mucosal damage, possibly related to individual variations in esophageal mucosal resistance.

Acid reflux often occurs after the evening meal and decreases during sleep. The main symptom is heartburn (pyrosis), which increases with a recumbent position or bending over. Effortless regurgitation of acidic fluid into the mouth, especially after a meal and at night, is often indicative of GERD. Depending on the frequency and extent of acid–pepsin reflux, GERD may result in mild to severe esophagitis or esophageal ulceration. Pain on swallowing usually means erosive or ulcerative esophagitis.

The main cause of GERD is thought to be an incompetent lower esophageal sphincter (LES). Normally, the LES is contracted or closed and prevents the reflux of gastric contents. It opens or relaxes on swallowing, to allow passage of food or fluid, then contracts again. Several circumstances contribute to impaired contraction of the LES and the resulting reflux, including foods (eg, fats, chocolate), fluids (alcohol, caffeinated beverages), medications (eg, beta adrenergics, calcium channel blockers, nitrates), gastric distention, cigarette smoking, and recumbent posture.

GERD occurs in men, women, and children, but is especially common during pregnancy and after 40 years of age.

**TYPES OF DRUGS**

Drugs used in the treatment of acid-peptic disorders promote healing of lesions and prevent recurrence of lesions by decreasing cell-destructive effects or increasing cell-protective effects. Several types of drugs are used, alone and in various combinations. Antacids neutralize gastric acid and decrease pepsin production; antimicrobials and bismuth can eliminate *H. pylori* infection; histamine-2 receptor antagonists (H 2 RAs) and proton pump inhibitors (PPIs) decrease gastric acid secretion; sucralfate provides a barrier between mucosal erosions or ulcers and gastric secretions; and misoprostol restores prostaglandin activity. Types of drugs and individual agents are described in the following sections; dosages are listed in Drugs at a Glance: Representative Antacid Products and Drugs at a Glance: Drugs for Acid-Peptic Disorders.

### Drugs at a Glance: Representative Antacid Products

<table>
<thead>
<tr>
<th>Trade Name</th>
<th>Components</th>
<th>Route and Dosage Ranges (Adults)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aludrox</strong></td>
<td>Magnesium Oxide</td>
<td>PO 10 mL q4h, or as needed</td>
</tr>
<tr>
<td></td>
<td>or Hydroxide</td>
<td>PO 10 mL or 600 mg 5 or 6 times daily</td>
</tr>
<tr>
<td><strong>Amphojel</strong></td>
<td>Aluminum Hydroxide</td>
<td></td>
</tr>
<tr>
<td></td>
<td>or Calcium Hydroxide</td>
<td></td>
</tr>
<tr>
<td><strong>Di-Gel</strong></td>
<td>307 mg/5 mL</td>
<td>PO 2 tsp liquid q2h, after meals or between meals, and at bedtime. Maximal dose, 20 tsp/24 h</td>
</tr>
<tr>
<td></td>
<td>300 or 600 mg/tab,</td>
<td>Do not use maximal dose longer than 2 wk.</td>
</tr>
<tr>
<td></td>
<td>320 mg/5 mL</td>
<td></td>
</tr>
<tr>
<td><strong>Gelusil</strong></td>
<td>200 mg/tab, 200 mg/tab</td>
<td>PO 10 or more mL or 2 or more tablets after meals and at bedtime or as directed by physician to a maximum of 12 tablets or tsp/24 h</td>
</tr>
<tr>
<td></td>
<td>200 mg/5 mL</td>
<td>PO 30 mL 4 times daily, after meals and at bedtime or as directed by physician; maximal dose, 16 tsp/24 h</td>
</tr>
<tr>
<td><strong>Maulox</strong></td>
<td>200 mg/5 mL</td>
<td>PO 5–10 mL or 1–2 tablets q2–4h, between meals and at bedtime or as directed by physician</td>
</tr>
<tr>
<td><strong>Mylanta</strong></td>
<td>200 mg/tab, 200 mg/5 mL</td>
<td>Same as Mylanta</td>
</tr>
<tr>
<td></td>
<td>400 mg/tab, 400 mg/5 mL</td>
<td>PO 1 tsp or 2 tablets, after meals or as directed by physician, to maximal dose of 19 tablets or 8 tsp/24 h</td>
</tr>
<tr>
<td><strong>Mylanta</strong></td>
<td>200 mg/5 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>225 mg/5 mL</td>
<td></td>
</tr>
<tr>
<td><strong>Titralac</strong></td>
<td>420 mg/tab, 1 g/5 mL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>180 mg/tab, 300 mg/5 mL</td>
<td></td>
</tr>
</tbody>
</table>
## Drugs at a Glance: Drugs for Acid-Peptic Disorders

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Routes and Dosage Ranges (Adults)</th>
</tr>
</thead>
<tbody>
<tr>
<td>**Histamine-2 Receptor</td>
<td>Treatment of peptic ulcers and GERD, to promote healing, then maintenance to prevent recurrence; Prevention of stress ulcers, GI bleeding, and aspiration pneumonitis; Treatment of Zollinger-Ellison syndrome; Treatment of heartburn</td>
<td>Cimetidine (Tagamet) Duodenal or gastric ulcer, PO 800 mg once daily at bedtime or 300 mg 4 times daily or 400 mg twice daily. Maintenance, PO 400 mg at bedtime. IV injection, 300 mg, diluted in 20 mL of 0.9% NaCl solution q6–8h. IV intermittent infusion, 300 mg diluted in 50 mL of dextrose or saline solution q6h. IM 300 mg q6–8h. GERD, PO 800 mg twice daily or 400 mg 4 times daily. Prevention of upper GI bleeding. IV continuous infusion, 50 mg/h. Heartburn, PO 200 mg once or twice daily as needed. Impaired renal function, PO, IV 300 mg q8–12h.</td>
</tr>
<tr>
<td>Antagonists</td>
<td></td>
<td>Famotidine (Pepcid) Famotidine 10 mg, calcium carbonate 800 mg, &amp; magnesium hydroxide 165 mg (Pepcid Complete) Duodenal or gastric ulcer, PO 40 mg once daily at bedtime or 20 mg twice daily for 4–8 wk; maintenance, PO 20 mg once daily at bedtime. IV injection, 20 mg q12h, diluted to 5 or 10 mL with 5% dextrose or 0.9% sodium chloride. IV infusion, 20 mg q12h, diluted with 100 mL of 5% dextrose or 0.9% sodium chloride. Impaired renal function (creatinine clearance &lt;50 mL/min), PO, IV 20 mg q24–48h. GERD PO 20 mg twice daily for 6–12 wk. Heartburn (Pepcid Complete) PO 1–2 tablets, chewed, daily as needed. Impaired renal function, PO 150 mg daily; (CrCl &lt;20 mL/min), PO 150 mg q48h.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nizatidine (Axid) Duodenal or gastric ulcer, PO 300 mg once daily at bedtime or 150 mg twice daily; maintenance, PO 150 mg once daily at bedtime. GERD, PO 150 mg twice daily. Heartburn, PO 75–150 mg twice daily as needed. Impaired renal function (creatinine clearance [CrCl] 20–50 mL/min), PO 150 mg daily; (CrCl &lt;20 mL/min), PO 150 mg q48h.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ranitidine (Zantac) Duodenal ulcer, PO 300 mg once daily at bedtime or 150 mg twice daily. IM 50 mg q6–8h. IV injection, 50 mg diluted in 20 mL of 5% dextrose or 0.9% sodium chloride solution q6–8h. IV intermittent infusion, 50 mg diluted in 100 mL of 5% dextrose or 0.9% sodium chloride solution. Gastric ulcer or GERD, PO 150 mg twice daily. Impaired renal function (CrCl &lt;50 mL/min), PO 150 mg q48h; IV, IM 50 mg q18–24h.</td>
</tr>
<tr>
<td><strong>Proton Pump Inhibitors</strong></td>
<td>Treatment of gastric and duodenal ulcers, for 4–8 wk. Treatment of GERD with erosive esophagitis for 4–8 wk to promote healing, then maintenance to prevent recurrence. Treatment of Zollinger-Ellison syndrome</td>
<td>Esomeprazole (Nexium) GERD with erosive esophagitis, PO 20–40 mg once daily for 4–8 wk; maintenance, 20 mg once daily.</td>
</tr>
</tbody>
</table>

(continued)
Antacids

Antacids are alkaline substances that neutralize acids. They react with hydrochloric acid in the stomach to produce neutral, less acidic, or poorly absorbed salts and to raise the pH (alkalinity) of gastric secretions. Raising the pH to approximately 3.5 neutralizes more than 90% of gastric acid and inhibits conversion of pepsinogen to pepsin. Commonly used antacids are aluminum, magnesium, and calcium compounds.

Antacids differ in the amounts needed to neutralize gastric acid (50 to 80 mEq of acid is produced hourly), in onset of action, and in adverse effects. Aluminum compounds have a low neutralizing capacity (ie, relatively large doses are required) and a slow onset of action. They can cause constipation. In people who ingest large amounts of aluminum-based antacids over a long period, hypophosphatemia and osteomalacia may develop because aluminum combines with phosphates in the GI tract and prevents phosphate absorption. Aluminum compounds are rarely used alone for acid-peptic disorders.

Magnesium-based antacids have a high neutralizing capacity and a rapid onset of action. They may cause diarrhea and hypermagnesemia. Calcium compounds have a rapid onset of action but may cause hypercalcemia and hypersecretion of gastric acid (“acid rebound”) due to stimulation of gastrin release, if large doses are used. Consequently, calcium compounds are rarely used in peptic ulcer disease.

Commonly used antacids are mixtures of aluminum hydroxide and magnesium hydroxide (eg, Gelusil, Mylanta, Dracapat).
Maalox). Some antacid mixtures contain other ingredients, such as simethicone or algic acid. Simethicone is an antiflatulent drug available alone as Mylicon. When added to antacids, simethicone does not affect gastric acidity. It reportedly decreases gas bubbles, thereby reducing GI distention and abdominal discomfort. Algic acid (eg, in Gaviscon) produces a foamy, viscous layer on top of gastric acid and thereby decreases backflow of gastric acid onto esophageal mucosa while the person is in an upright position.

Antacids act primarily in the stomach and are used to prevent or treat peptic ulcer disease, GERD, esophagitis, heartburn, gastritis, GI bleeding, and stress ulcers. Aluminum-based antacids also are given to clients with chronic renal failure and hyperphosphatemia to decrease absorption of phosphates in food.

Magnesium-based antacids are contraindicated in clients with renal failure.

**Helicobacter pylori Agents**

Multiple drugs are required to eradicate *H. pylori* organisms and heal related ulcers. Effective combinations include two antimicrobials and a PPI or an H$_2$RA. For the antimicrobial component, two of the following drugs—amoxicillin, clarithromycin, metronidazole, or tetracycline—are used. A single antimicrobial agent is not used because of concern about emergence of drug-resistant *H. pylori* organisms. For clients with an active ulcer, adding an antisecretory drug (ie, H$_2$RA or PPI) to an antimicrobial regimen accelerates symptom relief and ulcer healing. In addition, antimicrobial—antisecretory combinations are associated with low ulcer recurrence rates.

A bismuth preparation is added to some regimens. Bismuth exerts antibacterial effects against *H. pylori* by disrupting bacterial cell walls, preventing the organism from adhering to gastric epithelium, and inhibiting bacterial enzymatic and proteolytic activity. It also increases secretion of mucus and bicarbonate, inhibits pepsin activity, and accumulates in ulcer craters.

Although several regimens are effective in *H. pylori* infection, three-drug regimens with a PPI and two antibacterial drugs may be preferred. The regimen using metronidazole, a bismuth compound, tetracycline, and an antisecretory drug is very effective in healing ulcers. However, this regimen is not well tolerated, partly because of the multiple daily doses required. Because client compliance is a difficulty with all the *H. pylori* eradication regimens, some drug combinations are packaged as individual doses to increase convenience. For example, Helidac contains bismuth, metronidazole, and tetracycline (taken with an H$_2$RA); Prevpac contains amoxicillin, clarithromycin, and lansoprazole.

**Histamine-2 Receptor Antagonists (H$_2$RAs)**

Histamine is a substance found in almost every body tissue and released in response to certain stimuli (eg, allergic reactions, tissue injury). Once released, histamine causes contraction of smooth muscle in the bronchi, GI tract, and uterus; dilation and increased permeability of capillaries; dilation of cerebral blood vessels; and stimulation of sensory nerve endings to produce pain and itching.

Histamine also causes strong stimulation of gastric acid secretion. Vagal stimulation causes release of histamine from cells in the gastric mucosa. The histamine then acts on receptors located on the parietal cells to increase production of hydrochloric acid. These receptors are called the H$_3$ receptors.

Traditional antihistamines or H$_1$ receptor antagonists prevent or reduce other effects of histamine but do not block histamine effects on gastric acid production. The H$_3$RAs inhibit both basal secretion of gastric acid and the secretion stimulated by histamine, acetylcholine, and gastrin. They decrease the amount, acidity, and pepsin content of gastric juices. A single dose of an H$_3$RA can inhibit acid secretion for 6 to 12 hours and a continuous intravenous (IV) infusion can inhibit secretion for prolonged periods.

Clinical indications for use include prevention and treatment of peptic ulcer disease, gastroesophageal reflux disease, esophagitis, GI bleeding due to acute stress ulcers, and Zollinger-Ellison syndrome. With gastric or duodenal ulcers, healing occurs within 6 to 8 weeks; with esophagitis, healing occurs in about 12 weeks. Over-the-counter oral preparations, at lower dosage strengths, are approved for the treatment of heartburn.

There are no known contraindications, but the drugs should be used with caution in children, pregnant women, older adults, and clients with impaired renal or hepatic function. Dosage should be reduced in the presence of impaired renal function.

Adverse effects occur infrequently with usual doses and duration of treatment. They are more likely to occur with prolonged use of high doses and in older adults or those with impaired renal or hepatic function.

**Cimetidine, ranitidine, famotidine, and nizatidine** are the four available H$_3$RAs. Cimetidine was the first, and it is still widely used. It is well absorbed after oral administration. After a single dose, peak blood level is reached in 1 to 1.5 hours, and an effective concentration is maintained about 6 hours. The drug is distributed in almost all body tissues. Cimetidine should be used with caution during pregnancy because it crosses the placenta, and it should not be taken during lactation because it is excreted in breast milk. Most of an oral dose is excreted unchanged in the urine within 24 hours; some is excreted in bile and eliminated in feces. For acutely ill clients, cimetidine is given intravenously. A major disadvantage of cimetidine is that it inhibits the hepatic metabolism of numerous other drugs, thereby increasing blood levels and risks of toxicity with the inhibited drug.

Ranitidine is more potent than cimetidine on a weight basis, and smaller doses can be given less frequently. In addition, ranitidine causes fewer drug interactions than cimetidine. Oral ranitidine reaches peak blood levels 1 to 3 hours after administration, and is metabolized in the liver; approximately 30% is excreted unchanged in the urine. Parenteral ranitidine reaches peak blood levels in about 15 minutes;
65% to 80% is excreted unchanged in the urine. Famotidine and nizatidine are similar to cimetidine and ranitidine.

Compared with cimetidine, the other drugs cause similar effects except they are less likely to cause mental confusion and gynecomastia (antiandrogenic effects). In addition, they do not affect the cytochrome P450 drug-metabolizing system in the liver and therefore do not interfere with the metabolism of other drugs.

**Proton Pump Inhibitors**

PPIs are strong inhibitors of gastric acid secretion. These drugs bind irreversibly to the gastric proton pump (ie, the enzyme H⁺, K⁺-ATPase) to prevent the “pumping” or release of gastric acid from parietal cells into the stomach lumen and therefore block the final step of acid production. Inhibition of the proton pump suppresses gastric acid secretion in response to all primary stimuli, histamine, gastrin, and acetylcholine. Thus, the drugs inhibit both daytime (including meal-stimulated) and nocturnal (unstimulated) acid secretion.

Indications for use include treatment of peptic ulcer disease, erosive gastritis, GERD, and Zollinger-Ellison syndrome. PPIs are usually the drugs of choice for treatment of duodenal and gastric ulcers, GERD with erosive esophagitis, and Zollinger-Ellison syndrome. Compared with H₂RAs, PPIs suppress gastric acid more strongly and for a longer time. This effect provides faster symptom relief and faster healing in acid-related diseases. For example, healing of duodenal and gastric ulcers after 2 weeks is similar to the healing after 4 weeks of H₂RA therapy. The PPIs and H₂RAs are similarly effective in maintenance therapy of peptic ulcer disorders, with similar rates of ulcer recurrence. In clients with GERD, PPIs usually abolish symptoms within 1 to 2 weeks and heal esophagitis within 8 weeks. The drugs are also effective in maintenance therapy to prevent recurrence of esophagitis. In clients with *H. pylori*-associated ulcers, eradication of the organism with antimicrobial drugs is preferable to long-term maintenance therapy with antisecretory drugs.

The drugs usually are well tolerated; adverse effects are minimal with both short- and long-term use. Nausea, diarrhea, and headache are the most frequently reported adverse effects. However, long-term consequences of profound gastric acid suppression are unknown.

**Nursing Notes: Apply Your Knowledge**

Ellen Jones, a 54-year-old homemaker with a seizure disorder that has been well controlled on carbamazepine (Tegretol), comes to the clinic complaining of ataxia, slurred speech, and lethargy. You obtain a history and the only significant change for Ellen over the last few weeks is an episode of severe heartburn. She has been self-medicating with over-the-counter cimetidine (Tagamet) with good results. What do you think is causing Ellen’s symptoms and what action is indicated?

**Prostaglandin**

Naturally occurring prostaglandin E, which is produced in mucosal cells of the stomach and duodenum, inhibits gastric acid secretion and increases mucus and bicarbonate secretion, mucosal blood flow, and perhaps mucosal repair. It also inhibits the mucosal damage produced by gastric acid, aspirin, and NSAIDs. When synthesis of prostaglandin E is inhibited, erosion and ulceration of gastric mucosa may occur. This is the mechanism by which aspirin and other NSAIDs are thought to cause gastric and duodenal ulcers (see Chap. 7).

**Misoprostol** is a synthetic form of prostaglandin E approved for concurrent use with NSAIDs to protect gastric mucosa from NSAID-induced erosion and ulceration. It is indicated for clients at high risk of GI ulceration and bleeding, such as those taking high doses of NSAIDs for arthritis and older adults. It is contraindicated in women of childbearing potential, unless effective contraceptive methods are being used, and during pregnancy, because it may induce abortion. The most common adverse effects are diarrhea (occurs in 10% to 40% of recipients) and abdominal cramping. Older adults may be unable to tolerate misoprostol-induced diarrhea and abdominal discomfort.

**Sucralfate**

Sucralfate is a preparation of sulfated sucrose and aluminum hydroxide that binds to normal and ulcerated mucosa. It is used to prevent and treat peptic ulcer disease. It is effective even though it does not inhibit secretion of gastric acid or pepsin and it has little neutralizing effect on gastric acid. Its mechanism of action is unclear, but it is thought to act locally on the gastric and duodenal mucosa. Possible mechanisms include binding to the ulcer and forming a protective barrier between the mucosa and gastric acid, pepsin, and bile salts; neutralizing pepsin; stimulating prostaglandin synthesis in the mucosa; and exerting healing effects through the aluminum component. Sucralfate is effective in healing duodenal ulcers and in maintenance therapy to prevent ulcer...
recurrence. In general, the rates of ulcer healing with sucralfate are similar to the rates with H2RAs.

Adverse effects are low in incidence and severity because sucralfate is not absorbed systemically. Constipation and dry mouth are most often reported. The main disadvantages of using sucralfate are that the tablet is large; it must be given at least twice daily; it requires an acid pH for activation and should not be given with an antacid, H2RA, or PPI; and it may bind other drugs and prevent their absorption. In general, sucralfate should be given 2 hours before or after other drugs.

Herbal and Dietary Supplements

Several herbal supplements are promoted as aiding heartburn, gastritis, and peptic ulcer disease. Most have not been studied in humans and there is little, if any, evidence that they are either safe or effective for the proposed uses. Given the known safety and effectiveness of available drugs and the possible consequences of delaying effective treatment, the use of herbal supplements for any acid-peptic disorder should be discouraged.

Nursing Process

Assessment

Assess the client’s status in relation to peptic ulcer disease, GERD, and other conditions in which antiulcer drugs are used.

• Identify risk factors for peptic ulcer disease:
  • Cigarette smoking. Effects are thought to include stimulation of gastric acid secretion and decreased blood supply to gastric mucosa. (Nicotine constricts blood vessels.) Moreover, clients with peptic ulcers who continue to smoke heal more slowly and have more recurrent ulcers, despite usually adequate treatment, than those who stop smoking.
  • Stress, including physiologic stress (eg, shock, sepsis, burns, surgery, head injury, severe trauma, or medical illness) and psychological stress. One mechanism may be that stress activates the sympathetic nervous system, which then causes vasoconstriction in organs not needed for “fight or flight.” Thus, stress may lead to ischemia in gastric mucosa, with ulceration if ischemia is severe or prolonged.
  • Drug therapy with aspirin and other NSAIDs, corticosteroids, and antineoplastics.
  • Signs and symptoms depend on the type and location of the ulcer:
    • Periodic epigastric pain, which occurs 1 to 4 hours after eating or during the night and is often described as burning or gnawing, is a symptom of chronic duodenal ulcer.
    • Gastrointestinal (GI) bleeding occurs with acute or chronic ulcers when the ulcer erodes into a blood vessel. Clinical manifestations may range from mild (eg, occult blood in feces and eventual anemia) to severe (eg, hematemesis, melena, hypotension, and shock).
  • GERD produces heartburn (a substernal burning sensation).

Nursing Diagnoses

• Pain related to effects of gastric acid on peptic ulcers or inflamed esophageal tissues
• Imbalanced Nutrition: Less Than Body Requirements related to anorexia and abdominal discomfort
• Constipation related to aluminum- or calcium-containing antacids and sucralfate
• Diarrhea related to magnesium-containing antacids and misoprostol
• Deficient Knowledge related to drug therapy and nonpharmacologic management of GERD and peptic ulcer disease

Planning/Goals

The client will:

• Take or receive antiulcer, anti-heartburn drugs accurately
• Experience relief of symptoms
• Avoid situations that cause or exacerbate symptoms, when possible
• Be observed for GI bleeding and other complications of peptic ulcer disease and GERD
• Maintain normal patterns of bowel function
• Avoid preventable adverse effects of drug therapy

Interventions

Use measures to prevent or minimize peptic ulcer disease and gastric acid–induced esophageal disorders.

• With peptic ulcer disease, helpful interventions may include the following:
  • General health measures such as a well-balanced diet, adequate rest, and regular exercise
  • Avoiding cigarette smoking and gastric irritants (eg, alcohol, aspirin and NSAIDs, caffeine)
  • Reducing psychological stress (eg, by changing environments) or learning healthful strategies of stress management (eg, relaxation techniques, physical exercise). There is no practical way to avoid psychological stress because it is part of everyday life.
  • Long-term drug therapy with small doses of H2RAs, antacids, or sucralfate. With “active” peptic ulcer dis-
General guidelines include the following:

- Diet therapy is of minor importance in prevention or treatment of peptic ulcer disease. Some physicians prescribe no dietary restrictions, whereas others suggest avoiding or minimizing highly spiced foods, gas-forming foods, and caffeine-containing beverages.
- With heartburn and esophagitis, helpful measures are those that prevent or decrease gastroesophageal reflux of gastric contents (eg, avoiding irritant, highly spiced, or fatty foods; eating small meals; not lying down for 1 to 2 hours after eating; elevating the head of the bed; and avoiding obesity, constipation, or other conditions that increase intra-abdominal pressure).

**Evaluation**

- Observe and interview regarding drug use.
- Observe and interview regarding relief of symptoms.
- Observe for signs and symptoms of complications.
- Observe and interview regarding adverse drug effects.

### PRINCIPLES OF THERAPY

#### Drug Selection

All of the drugs used for acid-peptic disorders are effective for indicated uses; the choice of drugs may depend on etiology, acuity, severity of symptoms, cost, and convenience. General guidelines include the following:

- **Proton pump inhibitors** are the drugs of first choice in most situations. They heal gastric and duodenal ulcers more rapidly and may be more effective in erosive esophagitis, erosive gastritis, and Zollinger-Ellison syndrome than H2 RAs. They are also effective in eradicating *H. pylori* infection when combined with two antibacterial drugs. Most PPIs are given orally only; pantoprazole (Protonix IV) is a parenteral formulation. PPIs are more expensive than H2 RAs.
- **H. pylori** infection should be considered in most cases of peptic ulcer disease. If infection is confirmed by appropriate diagnostic tests, agents to eradicate the organisms should be drugs of first choice. The most recommended drug regimen is a combination of a PPI and two antibacterial drugs.
- **H2 RAs** have been replaced as first-choice drugs by the PPIs for most indications, but are still widely used. Cimetidine may be less expensive but it may cause confusion and antiandrogenic effects. It also increases the risks of toxicity with several commonly used drugs. Compared with cimetidine, other H2 RAs are more potent on a weight basis and have a longer duration of action, so they can be given in smaller, less frequent doses. In addition, they do not alter the hepatic metabolism of other drugs. Over-the-counter H2 RAs are indicated for the treatment of heartburn. In some cases, clients may depend on self-medication with over-the-counter drugs and delay seeking treatment for peptic ulcer disease or GERD. For prescription or nonprescription uses, cimetidine is preferably taken by clients who are taking no other medications.
- **Antacids** are often used as needed to relieve heartburn and abdominal discomfort. If used to treat acid-peptic disorders, they are more often used with other agents than alone and require a regular dosing schedule. The choice of antacid should be individualized to find a preparation that is acceptable to the client in terms of taste, dosage, and convenience of administration. Some guidelines include the following:
  1. Most commonly used antacids combine aluminum hydroxide and magnesium hydroxide. The combination decreases the adverse effects of diarrhea (with magnesium products) and constipation (with aluminum products). Calcium carbonate is effective in relieving heartburn, but it is infrequently used to treat peptic ulcers or GERD.
  2. Antacids may be used more often now that low doses (eg, 2 antacid tablets 4 times a day) have been shown to be effective in healing gastric and duodenal ulcers. All of the low-dose regimens contained aluminum, and the aluminum rather than acid neutralization may be the important therapeutic factor. Compared with other drugs for acid-peptic disorders, low-dose antacids are inexpensive and cause few adverse effects. In addition, tablets are as effective as liquids and usually more convenient to use.
  3. Antacids with magnesium are contraindicated in renal disease because hypermagnesemia may result; those with high sugar content are contraindicated in diabetes mellitus.
  4. Additional ingredients may be helpful to some clients. Simethicone has no effect on intragastric pH but may be useful in relieving flatulence or gastroesophageal reflux. Alginic acid may be useful in clients with daytime acid reflux and heartburn.
- **Sucralfate** must be taken before meals, and this is inconvenient for some clients.

#### Guidelines for Therapy With Proton Pump Inhibitors

1. Recommended doses of PPIs heal most gastric and duodenal ulcers in about 4 weeks. Large gastric ulcers may require 8 weeks.
2. The drugs may be used to maintain healing of gastric and duodenal ulcers and decrease risks of ulcer recurrence.
3. A PPI and two antimicrobial drugs is the most effective regimen for eradication of *H. pylori* organisms.
4. With GERD, higher doses or longer therapy may be needed for severe disease and esophagitis. Lower doses can maintain symptom relief and esophageal healing.
CLIENT TEACHING GUIDELINES
Antiulcer and Anti-Heartburn Drugs

General Considerations

These drugs are commonly used to prevent and treat peptic ulcers and heartburn. Peptic ulcers usually form in the stomach or first part of the small bowel (duodenum), where tissues are exposed to stomach acid. Two common causes of peptic ulcer disease are stomach infection with a bacterium called *Helicobacter pylori* and taking nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and many others. Heartburn (also called gastro-esophageal reflux disease) is caused by stomach acid splashing back onto the esophagus.

Peptic ulcer disease and heartburn are chronic conditions that are usually managed on an outpatient basis. Complications such as bleeding require hospitalization. Overall, these conditions can range from mild to serious, and it is important to seek information about the disease process, ways to prevent or minimize symptoms, and drug therapy.

With heartburn, try to minimize acid reflux by elevating the head of the bed; avoiding stomach distention by eating small meals; not lying down for 1 to 2 hours after eating; minimizing intake of fats, chocolate, citric juices, coffee, and alcohol; avoiding smoking (stimulates gastric acid production); and avoiding obesity, constipation, or other conditions that increase intra-abdominal pressure. In addition, take tablets and capsules with 8 oz of water and do not take medications at bedtime unless instructed to do so. Some medications (eg, tetracycline, potassium chloride tablets, iron supplements, nonsteroidal anti-inflammatory drugs [NSAIDs]) may cause “pill-induced” irritation of the esophagus (esophagitis) if not taken with enough liquid.

Most medications for peptic ulcer disease and heartburn decrease stomach acid. An exception is the antibiotics used to treat ulcers caused by *H. pylori* infection. The strongest acid reducers are omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), pantoprazole (Protonix), and rabeprazole (Aciphex). These are prescription drugs. (Omeprazole may be approved for nonprescription use.) Histamine-blocking drugs such as cimetidine (Tagamet), famotidine (Pepcid), and others are available as both prescription and over-the-counter (OTC) preparations. OTC products are indicated for heartburn, and smaller doses are taken for peptic ulcer disease. These drugs usually should not be taken longer than 2 weeks without the advice of a health care provider. The concern is that OTC drugs may delay diagnosis and treatment of potentially serious illness. In addition, cimetidine can increase toxic effects of numerous drugs and should be avoided if you are taking other medications.

Misoprostol (Cytotec) is given to prevent ulcers from NSAIDs, which are commonly used to relieve pain and inflammation with arthritis and other conditions. This drug should be taken only while taking a traditional NSAID such as ibuprofen. Related drugs such as celecoxib (Celebrex), rofecoxib (Vioxx), and valdecoxib (Bextra) are less likely to cause peptic ulcer disease. Do not take misoprostol if pregnant and do not become pregnant while taking the drug. If pregnancy occurs during misoprostol therapy, stop the drug and notify your health care provider immediately. Misoprostol can cause abdominal cramps and miscarriage.

Numerous antacid preparations are available, but they are not equally safe in all people and should be selected carefully. For example, products that contain magnesium have a laxative effect and may cause diarrhea; those that contain aluminum or calcium may cause constipation. Some commonly used antacids (eg, Maalox, Mylanta) are a mixture of magnesium and aluminum preparations, an attempt to avoid both constipation and diarrhea. People with kidney disease should not take products that contain magnesium because magnesium can accumulate in the body and cause serious adverse effects. Thus, it is important to read product labels and, if you have a chronic illness or take other medications, ask your physician or pharmacist to help you select an antacid and an appropriate dose.

Self- or Caregiver Administration

Take antiulcer drugs as directed. Underuse decreases therapeutic effectiveness; overuse increases adverse effects. For acute peptic ulcer disease or esophagitis, drugs are given in relatively high doses for 4 to 8 weeks to promote healing. For long-term maintenance therapy, dosage is reduced.

With Prilosec, Aciphex, Nexium, and Protonix, swallow the capsule whole; do not open, chew, or crush. With Prevacid, the capsule can be opened and the granules sprinkled on applesauce for patients who are unable to swallow capsules. Also, the granules are available in a packet for preparing a liquid suspension. Follow instructions for mixing the granules exactly. The granules should not be crushed or chewed.

Take cimetidine with meals or at bedtime. Take famotidine, nizatidine, and ranitidine with or without food. Do not take an antacid for 1 hour before or after taking one of these drugs.

Take sucralfate on an empty stomach at least 1 hour before meals and at bedtime. Also, do not take an antacid for 1 hour before or after taking sucralfate.

Take misoprostol with food.

For treatment of peptic ulcer disease, take antacids 1 and 3 hours after meals and at bedtime (4 to 7 doses daily), 1 to 2 hours before or after other medications. Antacids decrease absorption of many medications if taken at the same time. Also, chew chewable tablets thoroughly before swallowing, then drink a glass of water; allow effervescent tablets to dissolve completely and almost stop bubbling before drinking; and shake liquids well before measuring the dose.
Guidelines for Therapy With Histamine-2 Receptor Antagonists

1. For an acute ulcer, full dosage may be given up to 8 weeks. When the ulcer heals, dosage may be reduced by 50% for maintenance therapy to prevent recurrence.
2. For duodenal ulcers, a single evening or bedtime dose produces the same healing effects as multiple doses. Commonly used nocturnal doses are cimetidine 800 mg, ranitidine 300 mg, nizatidine 300 mg, or famotidine 40 mg.
3. For gastric ulcers, the optimal H2 RA dosage schedule has not been established. Gastric ulcers heal more slowly than duodenal ulcers and most authorities prescribe 6 to 8 weeks of drug therapy.
4. To maintain ulcer healing and prevent recurrence, long-term H2 RA therapy is often used. The drug is usually given as a single bedtime dose, but the amount is reduced by 50% (ie, cimetidine 400 mg, ranitidine 150 mg, nizatidine 150 mg, or famotidine 20 mg).
5. For Zollinger-Ellison syndrome, high doses as often as every 4 hours may be required.
6. For severe reflux esophagitis, multiple daily doses may be required for adequate symptom control.
7. Dosage of all these drugs should be reduced in the presence of impaired renal function.
8. Antacids are often given concurrently with H2 RAs to relieve pain. They should not be given at the same time (except for Pepcid Complete) because the antacid reduces absorption of the other drug. H2 RAs usually relieve pain after 1 week of administration.
9. These drugs are available in a wide array of products and precautions must be taken to ensure the correct formulation, dosage strength, and method of administration for the intended use. For example, cimetidine is available in tablets of 100, 200, 300, 400, 800 mg, an oral liquid with 300 mg/5 mL, and injectable solutions. Ranitidine is available in tablets of 75, 150, and 300 mg, effervescent tablets of 150 mg, capsules (Zantac GELdose) of 150 and 300 mg, a liquid syrup with 15 mg/mL, effervescent granules of 150 mg, and injectable solutions of 1 mg/mL and 25 mg/mL. Nizatidine is available in tablets of 75 mg and capsules of 150 and 300 mg and famotidine in tablets of 10, 20, and 40 mg, chewable tablets of 10 mg, orally disintegrating tablets (Pepcid RPD) of 20 and 40 mg, a powder for oral suspension that contains 40 mg/5 mL when reconstituted, and injection solutions of 10 mg/mL and 20 mg/50 mL.
10. All of the drugs are available by prescription and over-the-counter (OTC). When prescriptions are given, clients should be advised to avoid concomitant use of OTC versions of the same or similar drugs.

Guidelines for Therapy With Sucralfate

1. When sucralfate is used to treat an ulcer, it should be administered for 4 to 8 weeks unless healing is confirmed by radiologic or endoscopic examination.
2. When used long term to prevent ulcer recurrence, dosage should be reduced.

Guidelines for Therapy With Antacids

1. To prevent stress ulcers in critically ill clients and to treat acute GI bleeding, nearly continuous neutralization of gastric acid is desirable. Dose and frequency of administration must be sufficient to neutralize approximately 50 to 80 mEq of gastric acid each hour. This can be accomplished by a continuous intragastric drip through a nasogastric tube or by hourly administration.
2. When a client has a nasogastric tube in place, antacid dosage may be titrated by aspirating stomach contents, determining pH, and then basing the dose on the pH. (Most gastric acid is neutralized and most pepsin activity is eliminated at a pH above 3.5.)
3. When prescribing antacids to treat active ulcers, it has long been recommended to take them 1 hour and 3 hours after meals and at bedtime for greater acid neutralization. This schedule is effective but inconvenient for many clients. More recently, lower doses taken less often have been found effective in healing duodenal or gastric ulcers even though less acid neutralization occurs.
4. It was formerly thought that liquid antacid preparations were more effective. Now, tablets are considered as effective as liquids.
5. When antacids are used to relieve pain, they usually may be taken as needed. However, they should not be taken in high doses or for prolonged periods because of potential adverse effects.

Effects of Acid Suppressant Drugs on Other Drugs

Antacids may prevent absorption of most drugs taken at the same time, including benzodiazepine antianxiety drugs, corticosteroids, digoxin, H2 RAs (eg, cimetidine), iron supplements, phenothiazine antipsychotic drugs, phenytoin, fluoroquinolone antibacterials, and tetracyclines. Antacids increase absorption of a few drugs, including levodopa, quinidine, and valproic acid. These interactions can be avoided or minimized by separating administration times by 1 to 2 hours.

H2 RAs may alter the effects of several drugs. Most significant effects occur with cimetidine, which interferes with the metabolism of many commonly used drugs. Consequently, the affected drugs are eliminated more slowly, their serum levels are increased, and they are more likely to cause adverse effects and toxicity unless dosage is reduced.
Interacting drugs include antidyssrhythmics (lidocaine, propafenone, quinidine), the anticoagulant warfarin, anticonvulsants (carbamazepine, phenytoin), benzodiazepine antianxiety or hypnotic agents (alprazolam, diazepam, flurazepam, triazolam), beta-adrenergic blocking agents (labetalol, metoprolol, propranolol), the bronchodilator theophylline, calcium channel blocking agents (eg, verapamil), tricyclic antidepressants (eg, amitriptyline), and sulfonylurea antidiabetic drugs. In addition, cimetidine may increase serum levels (eg, fluorouracil, procarbazine and its active metabolite) and pharmacologic effects of other drugs (eg, respiratory depression with opioid analgesics) by unidentified mechanisms. Cimetidine also may decrease effects of several drugs, including drugs that require an acidic environment for absorption (eg, iron salts, indomethacin, fluconazole, tetracyclines) and miscellaneous drugs (eg, digoxin, tocinamide) by unknown mechanisms.

Ranitidine, famotidine, and nizatidine do not inhibit the cytochrome P450 metabolizing enzymes. Ranitidine decreases absorption of diazepam if given at the same time and increases hypoglycemic effects of glipizide. Nizatidine increases serum salicylate levels in people taking high doses of aspirin.

PPIs have relatively few effects on other drugs. Omeprazole increases blood levels of some benzodiazepines (diazepam, flurazepam, triazolam), phenytoin, and warfarin, probably by inhibiting hepatic metabolism. These interactions have not been reported with the other PPIs.

Sucralfate decreases absorption of ciprofloxacin and other fluoroquinolones, digoxin, phenytoin, and warfarin. Sucralfate binds to these drugs when both are present in the GI tract. This interaction can be avoided or minimized by giving the interacting drug 2 hours before sucralfate.

Effects of Acid Suppressant Drugs on Nutrients

Dietary folate, iron, and vitamin B₁₂ are better absorbed from an acidic environment. When gastric fluids are made less acidic by antacids, H₂ RAs, or PPIs, deficiencies of these nutrients may occur. In addition, sucralfate interferes with absorption of fat-soluble vitamins, and magnesium-containing antacids interfere with absorption of vitamin A.

Use in Children

Antacids may be given to ambulatory children in doses of 5 to 15 mL every 3 to 6 hours or after meals and at bedtime, as for adults with acid-peptic disorders. For prevention of GI bleeding in critically ill children, 2 to 5 mL may be given to infants and 5 to 15 mL to children every 1 to 2 hours. Safety and effectiveness of other antiulcer drugs have not been established for children.

Although PPIs are not approved by the Food and Drug Administration for use in children and are not available in pediatric dosage formulations, they are widely used in the treatment of peptic ulcer and gastroesophageal disease. They are also used to eradicate H. pylori organisms. Most published reports involve adult doses for children older than 3 years of age. Some clinicians titrate dosage by a child’s weight, such as an initial dose of 0.7 mg/kg/day.

Use in Older Adults

All of the antulcer, anti-heartburn drugs may be used in older adults. With antacids, smaller doses may be effective because older adults usually secrete less gastric acid than younger adults. Further, with decreased renal function, older adults are more likely to have adverse effects, such as neuromuscular effects with magnesium-containing antacids. Many physicians recommend calcium carbonate antacids (eg, Tums) as a calcium supplement to prevent or treat osteoporosis in older women.

With H₂ RAs, older adults are more likely to experience adverse effects, especially confusion, agitation, and disorientation with cimetidine. In addition, older adults often have decreased renal function, and doses need to be reduced.

Older adults often take large doses of NSAIDs for arthritis and therefore are at risk for development of acute gastric ulcers and GI bleeding. Thus, they may be candidates for treatment with misoprostol. Dosage of misoprostol may need to be reduced to prevent severe diarrhea and abdominal cramping.

PPIs and sucralfate are well tolerated by older adults. A PPI is probably the drug of choice for treating symptomatic GERD because evidence suggests that clients 60 years of age and older require stronger antisecretory effects than younger adults. No dosage reduction is recommended for older adults.

Use in Renal Impairment

A major concern with antacids is the use of magnesium-containing preparations (eg, Mylanta, Maalox). These are contraindicated in clients with impaired renal function (creatinine clearance <30 mL/minute) because 5% to 10% of the magnesium may be absorbed and accumulate to cause hypermagnesemia. In addition, antacids with calcium carbonate can cause alkalosis and raise urine pH; chronic use may cause renal stones, hypercalcemia, and renal failure.

Antacids containing aluminum hydroxide (eg, Amphogel, Rolaid) are the antacids of choice in clients with chronic renal failure. Aluminum tends not to accumulate and it binds with phosphate in the GI tract to prevent phosphate absorption and hyperphosphatemia.

With PPIs, no special precautions or dosage reductions are required in clients with renal impairment.

All of the available H₂ RAs are eliminated through the kidneys, and dosage needs to be substantially reduced in clients with renal impairment to avoid adverse effects. Cimetidine may cause mental confusion in clients with renal impairment. It also blocks secretion of creatinine in renal tubules, thereby decreasing creatinine clearance and increasing serum creatinine level. With moderate to severe renal impairment, recom-
mended dosages include cimetidine 300 mg every 12 hours, ranitidine 150 mg orally once daily or intravenously every 18 to 24 hours, and famotidine 20 mg at bedtime or every 36 to 48 hours if indicated. Dosage may be cautiously increased if necessary and if renal function is closely monitored. For clients on hemodialysis, an H2-RA should be given at the end of dialysis.

**Use in Hepatic Impairment**

PPIs are metabolized in the liver and may cause transient elevations in liver function tests. With omeprazole, bioavailability is increased because of decreased first-pass metabolism, and plasma half-life is increased. However, dosage adjustments are not recommended. Lansoprazole and rabeprazole should be used cautiously and dosage should be reduced in clients with severe liver impairment.

H2 RAs are partly metabolized in the liver and may be eliminated more slowly in clients with impaired liver function. A major concern with cimetidine is that it can inhibit hepatic metabolism of many other drugs.

**Use in Critical Illness**

Gastric acid suppressant drugs (eg, PPIs and H2 RAs) and sucralfate, are commonly used in critically ill clients. The PPIs are the strongest gastric acid suppressants and are usually well tolerated. For clients who cannot take drugs orally, pantoprazole can be given IV. The H2 RAs are used to prevent stress-induced gastric ulceration in adults and children. Except for renal impairment, in which dosage must be reduced, information about the pharmacokinetics of these drugs in critically ill clients is limited and only cimetidine and ranitidine have been studied. Compared with healthy people, critically ill clients had a longer half-life and lower clearance rate for H2 RAs. The drugs are usually given by intermittent IV infusion. Ranitidine or famotidine is preferred because critically ill clients often require numerous other drugs with which cimetidine may interact and alter effects. Nizatidine is not available in a parenteral formulation.

### Home Care

All of the antiulcer, anti-heartburn drugs are commonly taken in the home setting, usually by self-administration. The home care nurse can assist clients by providing information about taking the drugs correctly and monitoring responses. If cimetidine is being taken, the home care nurse needs to assess for potential drug–drug interactions. With OTC H2 RAs, clients should be instructed to avoid daily use of maximum doses for longer than 2 weeks. If use of antacids or OTC H2 RAs seems to be excessive or prolonged, the client should be assessed for peptic ulcer disease or GERD.

### Nursing Actions

**Antiulcer Drugs**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Administer accurately</td>
<td></td>
</tr>
<tr>
<td>a. With proton pump inhibitors:</td>
<td></td>
</tr>
<tr>
<td>(1) Give most of the drugs before food intake; give oral pantoprazole with or without food.</td>
<td>Manufacturer’s recommendations</td>
</tr>
<tr>
<td>(2) Ask clients to swallow the tablets or capsules whole, without crushing or chewing.</td>
<td>Drug formulations are delayed-release and long-acting. Opening, crushing or chewing destroys these effects.</td>
</tr>
<tr>
<td>(3) For clients who are unable to swallow capsules, the lansoprazole capsule can be opened and the granules mixed with 60 mL of orange or tomato juice or sprinkled on 1 tablespoon of applesauce, Ensure pudding, cottage cheese, or yogurt, and swallowed immediately, without chewing.</td>
<td>Manufacturer’s recommendations. Enteric-coated, delayed-release granules are in oral capsules or separate packets. Chewing or crushing destroys the coating; mixing the granules with applesauce or other acidic substances preserves the coating of the granules, allowing them to remain intact until they reach the small intestine.</td>
</tr>
<tr>
<td>(4) To give lansoprazole granules as a liquid suspension, mix 1 packet with 30 mL of water (use no other liquids), stir well, and ask the client to swallow immediately, without chewing the granules.</td>
<td></td>
</tr>
<tr>
<td>(5) Give IV pantoprazole over 15 min, injected into a dedicated line or the Y-site of an IV infusion. Use the in-line filter provided; if injecting in a Y-site, the filter should be placed below the Y-site closest to the patient. Flush the IV line with 5% dextrose, 0.9% NaCl, or lactated Ringer’s before and after pantoprazole administration.</td>
<td></td>
</tr>
</tbody>
</table>
### Nursing Actions

<table>
<thead>
<tr>
<th>b. With histamine (H₂) blockers:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Give single oral doses at bedtime; give multiple oral doses of cimetidine with meals and at bedtime and other drugs without regard to food intake.</td>
</tr>
<tr>
<td>(2) To give cimetidine or ranitidine IV, dilute in 20 mL of 5% dextrose or normal saline solution, and inject over at least 2 min. For intermittent infusion, dilute in at least 50 mL of 5% dextrose or 0.9% sodium chloride solution, and inject over 15–20 min.</td>
</tr>
<tr>
<td>(3) To give famotidine IV, dilute with 5–10 mL of 0.9% sodium chloride injection, and inject over at least 2 min. For intermittent infusion, dilute in 100 mL of 5% dextrose or 0.9% sodium chloride, and infuse over 15–30 min.</td>
</tr>
<tr>
<td>c. With antacids:</td>
</tr>
<tr>
<td>(1) Do not give doses within approximately 1 h of oral H₂ antagonists or sucralfate.</td>
</tr>
<tr>
<td>(2) Shake liquids well before measuring the dose.</td>
</tr>
<tr>
<td>(3) Instruct clients to chew antacid tablets thoroughly and follow with a glass of water.</td>
</tr>
<tr>
<td>d. Give sucralfate 1 h before meals and at bedtime.</td>
</tr>
<tr>
<td>e. Give misoprostol with food.</td>
</tr>
<tr>
<td>f. Follow package instructions for administering combination drug regimens for H. pylori infection (eg, Prevpac, Helidac).</td>
</tr>
</tbody>
</table>

### Rationale/Explanation

<table>
<thead>
<tr>
<th>b. With histamine (H₂) blockers:</th>
</tr>
</thead>
<tbody>
<tr>
<td>The drugs are effective and convenient in a single oral dose at bedtime.</td>
</tr>
<tr>
<td>c. With antacids:</td>
</tr>
<tr>
<td>Antacids decrease absorption and therapeutic effectiveness of the other drugs.</td>
</tr>
<tr>
<td>These preparations are suspensions and must be mixed thoroughly to give the correct dose.</td>
</tr>
<tr>
<td>To increase the surface area of drug available to neutralize gastric acid.</td>
</tr>
<tr>
<td>To allow the drug to form its protective coating over the ulcer before high levels of gastric acidity. Sucralfate requires an acidic environment. After it has adhered to the ulcer, antacids and food do not affect drug action.</td>
</tr>
<tr>
<td>d. Give sucralfate 1 h before meals and at bedtime.</td>
</tr>
<tr>
<td>e. Give misoprostol with food.</td>
</tr>
<tr>
<td>f. Follow package instructions for administering combination drug regimens for H. pylori infection (eg, Prevpac, Helidac).</td>
</tr>
</tbody>
</table>

### 2. Observe for Therapeutic Effects

- a. Decreased epigastric pain with gastric and duodenal ulcers; decreased heartburn with gastroesophageal reflux disorders.
- b. Decreased gastrointestinal (GI) bleeding (eg, absence of visible or occult blood in vomitus, gastric secretions, or feces).
- d. Radiologic or endoscopic reports of ulcer healing.

### 3. Observe for Adverse Effects

- a. With proton pump inhibitors, observe for headache, diarrhea, abdominal pain, nausea, and vomiting.
- b. With H₂ antagonists, observe for diarrhea or constipation, headache, dizziness, muscle aches, fatigue, skin rashes, mental confusion, delirium, coma, depression, fever.
- c. With antacids containing magnesium, observe for diarrhea and hypermagnesemia.
- d. With antacids containing aluminum or calcium, observe for constipation.

Therapeutic effects depend on the reason for use. Antacids should relieve pain within a few minutes. Proton pump inhibitors and H₂ antagonists relieve pain in 7–10 days by healing effects on peptic ulcers or esophagitis.

The minimum acceptable pH with antacid therapy is 3.5. Healing usually occurs within 4 to 8 weeks.

These effects occur infrequently and are usually well tolerated.

Adverse effects are uncommon and usually mild with recommended doses. Central nervous system effects have been associated with high doses in elderly clients or those with impaired renal function. With long-term administration of cimetidine, other adverse effects have been observed. These include decreased sperm count and gynecomastia in men and galactorrhea in women.

Diarrhea may be prevented by combining these antacids with other antacids containing aluminum or calcium. Hypermagnesemia may occur in clients with impaired renal function. These antacids should not be given to clients with renal failure.

Constipation may be prevented by combining these antacids with other antacids containing magnesium. A high-fiber diet, adequate fluid intake (2000–3000 mL daily), and exercise also help prevent constipation.
**Nursing Actions**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>e.</strong></td>
<td>With sucralfate, observe for constipation.</td>
</tr>
<tr>
<td><strong>f.</strong></td>
<td>With misoprostol, observe for diarrhea, abdominal pain, nausea, and vomiting, headache, uterine cramping, vaginal bleeding.</td>
</tr>
<tr>
<td><strong>g.</strong></td>
<td>With bismuth, observe for black stools.</td>
</tr>
</tbody>
</table>

4. **Observe for drug interactions**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>a.</strong></td>
<td>Drugs that alter effects of proton pump inhibitors:</td>
</tr>
<tr>
<td></td>
<td>(1) Clarithromycin increases effects of omeprazole.</td>
</tr>
<tr>
<td></td>
<td>(2) Sucralfate decreases effects of lansoprazole.</td>
</tr>
<tr>
<td><strong>b.</strong></td>
<td>Drugs that decrease effects of H₂ antagonists:</td>
</tr>
<tr>
<td></td>
<td>(1) Antacids</td>
</tr>
<tr>
<td><strong>c.</strong></td>
<td>Drugs that alter effects of antacids:</td>
</tr>
<tr>
<td></td>
<td>(1) Anticholinergic drugs (eg, atropine) increase effects</td>
</tr>
<tr>
<td></td>
<td>(2) Cholinergic drugs (eg, dexpanthenol [Ilopan]) decrease effects</td>
</tr>
<tr>
<td><strong>d.</strong></td>
<td>Drugs that decrease effects of sucralfate:</td>
</tr>
<tr>
<td></td>
<td>(1) Antacids</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th><strong>Rationale/Explanation</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>The drug is not absorbed systemically and constipation is the most commonly reported adverse effect.</td>
</tr>
<tr>
<td></td>
<td>Diarrhea commonly occurs and may be severe enough to indicate dosage reduction or stopping the drug.</td>
</tr>
<tr>
<td></td>
<td>This is a harmless discoloration of feces; it does not indicate GI bleeding.</td>
</tr>
<tr>
<td></td>
<td>Most significant drug interactions alter the effect of the other drug rather than that of the antiulcer or anti–gastroesophageal reflux disease (GERD) drug.</td>
</tr>
<tr>
<td></td>
<td>May increase blood levels</td>
</tr>
<tr>
<td></td>
<td>Decreases absorption of lansoprazole, which should be given about 30 min before sucralfate if both are used.</td>
</tr>
<tr>
<td></td>
<td>Antacids decrease absorption of cimetidine and probably ranitidine. The drugs should not be given at the same time.</td>
</tr>
<tr>
<td></td>
<td>May increase effects by delaying gastric emptying and by decreasing acid secretion themselves</td>
</tr>
<tr>
<td></td>
<td>May decrease effects by increasing GI motility and rate of gastric emptying</td>
</tr>
<tr>
<td></td>
<td>Antacids should not be given within 30 min before or after administration of sucralfate.</td>
</tr>
</tbody>
</table>

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** You should suspect that Ellen’s carbamazepine levels are above the therapeutic range and causing toxic effects. The most likely reason for this is the concurrent use of cimetidine because both cimetidine and carbamazepine are metabolized by the cytochrome P450 system in the liver. The physician will probably want to draw a blood level to confirm this is the cause of Ellen’s symptoms. Ellen needs to be cautioned to check with her health care provider before using over-the-counter medications because drug interactions can occur. The provider may switch Ellen to a proton pump inhibitor or a different histamine-2 receptor antagonist, such as famotidine (Pepcid) or ranitidine (Zantac) because these drugs are not metabolized through the P450 system and will not interact with her antiseizure medication.

---

**How Can You Avoid This Medication Error?**

**Answer:** Mrs. Fallot should not be given this drug with water because she has difficulty swallowing and is at risk for aspiration. Many capsules are time-released and should not be emptied prior to administration. This is not the case with lansoprazole, because the protective granules within the capsule can be preserved if given with acidic foods such as applesauce or yogurt. The granules should not be chewed. When a dispute regarding medications arises, it is wise to consult a drug resource or a pharmacist.
**Review and Application Exercises**

1. What are risk factors for peptic ulcer disease?
2. What roles do gastric acid, pepsin, *H. pylori* organisms, prostaglandins, and mucus play in peptic ulcer occurrence?
3. How do the various drug groups heal ulcers or prevent their recurrence?
4. Compare H₂RAs and PPIs in indications for use and effectiveness.
5. Compare and contrast cimetidine with other H₂ blockers.
6. What is the rationale for taking H₂ blockers at bedtime, sucralfate before meals, and antacids after meals?
7. Why are aluminum and magnesium salts often combined in antacid preparations?
8. For a client who smokes cigarettes and is newly diagnosed with peptic ulcer disease, how would you explain that smoking cessation aids ulcer healing?
9. Compare and contrast peptic ulcer disease and GERD in terms of risk factors, drug therapy, and client teaching needs.

**SELECTED REFERENCES**


Laxatives and Cathartics

**Objectives**

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Differentiate the major types of laxatives according to effects on the gastrointestinal tract.
2. Differentiate the consequences of occasional use from those of chronic use.
3. Discuss rational choices of laxatives for selected client populations or purposes.
4. Discuss bulk-forming laxatives as the most physiologic agents.
5. Discuss possible reasons for and hazards of overuse and abuse of laxatives.

**Critical Thinking Scenario**

Elmer Wong, a 67-year-old teacher, fractured his hip when he fell on a patch of ice. He is scheduled for hip surgery to repair the fracture; this will be followed by a period of rehabilitation as he regains his mobility. Mr. Wong’s history reveals he usually has a bowel movement every 2 to 3 days and occasionally uses laxatives.

Reflect on:

- Factors that increase his risk for constipation during the postoperative period.
- Expectation for postoperative bowel elimination, considering his history.
- Nonpharmacologic interventions that can promote normal bowel function during the postoperative period.
- Appropriate use of laxatives to promote normal bowel function. What kinds of laxatives are usually used, and why?

**OVERVIEW**

Laxatives and cathartics are drugs used to promote bowel elimination (defecation). The term *laxative* implies mild effects and elimination of soft, formed stool. The term *cathartic* implies strong effects and elimination of liquid or semi-liquid stool. Because the different effects depend more on the dose than on the particular drug used, the terms often are used interchangeably.

**DEFECATION**

Defecation is normally stimulated by movements and reflexes in the gastrointestinal (GI) tract. When the stomach and duodenum are distended with food or fluids, gastrocolic and duodenocolic reflexes cause propulsive movements in the colon, which move feces into the rectum and arouse the urge to defecate. When sensory nerve fibers in the rectum are stimulated by the fecal mass, the defecation reflex causes strong peristalsis, deep breathing, closure of the glottis, contraction of abdominal muscles, contraction of the rectum, relaxation of anal sphincters, and expulsion of the fecal mass.

The cerebral cortex normally controls the defecation reflex so defecation can occur at acceptable times and places. Voluntary control inhibits the external anal sphincter to allow defecation or contracts the sphincter to prevent defecation. When the external sphincter remains contracted, the defecation reflex dissipates, and the urge to defecate usually does not recur until additional feces enter the rectum or several hours later.

In people who often inhibit the defecation reflex or fail to respond to the urge to defecate, constipation develops as the reflex weakens. *Constipation* is the infrequent and painful expulsion of hard, dry stools. Although there is no “normal” number of stools because of variations in diet and other factors, most people report more than three bowel movements per week. Normal bowel elimination should produce a soft, formed stool without pain.
LAXATIVES AND CATHARTICS

Laxatives and cathartics are somewhat arbitrarily classified as bulk-forming laxatives, surfactant laxatives or stool softeners, saline cathartics, stimulant cathartics, lubricant or emollient laxatives, and miscellaneous. Individual drugs are listed in Drugs at a Glance: Laxatives and Cathartics.

Bulk-Forming Laxatives

Bulk-forming laxatives (eg, polycarbophil, psyllium seed) are substances that are largely unabsorbed from the intestine. When water is added, these substances swell and become gel-like. The added bulk or size of the fecal mass stimulates peristalsis and defecation. The substances also may act by pulling water into the intestinal lumen. Bulk-forming laxatives are the most physiologic laxatives because their effect is similar to that of increased intake of dietary fiber. They usually act within 12 to 24 hours, but may take as long as 2 to 3 days to exert their full effects.

Surfactant Laxatives (Stool Softeners)

Surfactant laxatives (eg, docusate calcium, potassium, or sodium) decrease the surface tension of the fecal mass to allow water to penetrate into the stool. They also act as a detergent to facilitate admixing of fat and water in the stool. As a result, stools are softer and easier to expel. These agents have little if any laxative effect. Their main value is to prevent straining while expelling stool. They usually act within 1 to 3 days and should be taken daily.

Saline Laxatives

Saline laxatives (eg, magnesium citrate, milk of magnesia) are not well absorbed from the intestine. Consequently, they increase osmotic pressure in the intestinal lumen and cause water to be retained. Distention of the bowel leads to increased peristalsis and decreased intestinal transit time for the fecal mass. The resultant stool is semifluid. These laxatives are used when rapid bowel evacuation is needed. With oral magnesium preparations, effects occur within 0.5 to 6 hours; with sodium phosphate–containing rectal enemas, effects occur within 15 minutes.

Saline laxatives are generally useful and safe for short-term treatment of constipation, cleansing the bowel prior to endoscopic examinations, and treating fecal impaction. However, they are not safe for frequent or prolonged usage or for certain patients because they may produce fluid and electrolyte imbalances. For example, patients with impaired renal function are at risk of developing hypermagnesemia with magnesium-containing laxatives because some of the magnesium is absorbed systemically. Patients with congestive heart failure are at risk of fluid retention and edema with sodium-containing laxatives.

Polyethylene glycol–electrolyte solution (eg, NuLytely) is a nonabsorbable oral solution that induces diarrhea within 30 to 60 minutes and rapidly evacuates the bowel, usually within 4 hours. It is a prescription drug used for bowel cleansing before GI examination (eg, colonoscopy) and is contraindicated with GI obstruction, gastric retention, colitis, or bowel perforation.

Polyethylene glycol solution (MiraLax) is an oral laxative that may be used to treat occasional constipation. Effects may require 2 to 4 days. It is a prescription drug and should not be taken longer than 2 weeks.

Stimulant Cathartics

The stimulant cathartics are the strongest and most abused laxative products. These drugs act by irritating the GI mucosa and pulling water into the bowel lumen. As a result, feces are moved through the bowel too rapidly to allow colonic absorption of fecal water, so a watery stool is eliminated. These drugs should not be used frequently or longer than 1 week because they may produce serum electrolyte and acid–base imbalances (eg, hypocalcemia, hypokalemia, metabolic acidosis or alkalosis).

Oral stimulant cathartics include bisacodyl, cascara sagrada, castor oil, and senna products. These products produce laxative effects in 6 to 12 hours. As a result, a single bedtime dose usually produces a morning bowel movement. Rectal suppository products include bisacodyl, which produces effects within 15 minutes to 2 hours, and glycerin. In addition to irritant, stimulant effects, glycerin exerts hyperosmotic effects in the colon. It usually acts within 30 minutes. Glycerin is not given orally for laxative effects.

Lubricant Laxative

Mineral oil is the only lubricant laxative used clinically. It lubricates the fecal mass and slows colonic absorption of water from the fecal mass, but the exact mechanism of action is unknown. Effects usually occur in 6 to 8 hours. Oral mineral oil may cause several adverse effects and is not recommended for long-term use. Mineral oil enemas are sometimes used to soften fecal impactions and aid their removal.

Miscellaneous Laxatives

Lactulose is a disaccharide that is not absorbed from the GI tract. It exerts laxative effects by pulling water into the intestinal lumen. It is used to treat constipation and hepatic encephalopathy. The latter condition usually results from alcoholic liver disease in which ammonia accumulates and causes stupor or coma. Ammonia is produced by metabolism of dietary...
### Drugs at a Glance: Laxatives and Cathartics

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bulk-forming Laxatives</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Methylcellulose (Citrucel)</strong></td>
<td>PO 1 heaping tbsp 1–3 times daily with water (8 oz or more)</td>
</tr>
<tr>
<td><strong>Polycarbophil (FiberCon, Mitrolan)</strong></td>
<td>PO 1 g 4 times daily or PRN with 8 oz of fluid; maximum dose, 6 g/24 h</td>
</tr>
<tr>
<td><strong>Psyllium preparations (Metamucil, EfferSyllium, Serutan, Perdiem Plain)</strong></td>
<td>PO 4–10 g (1–2 tsp) 1–3 times daily, stirred in at least 8 oz of water or other liquid</td>
</tr>
<tr>
<td><strong>Surfactant Laxatives (Stool Softeners)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Docusate sodium (Colace, Doxinate)</strong></td>
<td>PO 50–200 mg daily</td>
</tr>
<tr>
<td><strong>Docusate calcium (Surfak)</strong></td>
<td>PO 50–240 mg daily</td>
</tr>
<tr>
<td><strong>Docusate potassium (Dialose)</strong></td>
<td>PO 100–300 mg daily</td>
</tr>
<tr>
<td><strong>Saline Cathartics</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Magnesium citrate solution</strong></td>
<td>PO 200 mL at bedtime</td>
</tr>
<tr>
<td><strong>Magnesium hydroxide (milk of magnesia, magnesia magma)</strong></td>
<td>Regular liquid, PO 15–60 mL at bedtime. Concentrated liquid, PO 10–20 mL at bedtime</td>
</tr>
<tr>
<td><strong>Polyethylene glycol–electrolyte solution (PEG 3350, sodium sulfate, sodium bicarbonate, sodium chloride, potassium chloride) (GoLyte, GoLYTELY)</strong></td>
<td>For bowel cleansing before gastrointestinal examination: PO 240 mL (8 oz) every 10 min until 4 L is consumed</td>
</tr>
<tr>
<td><strong>Sodium phosphate and sodium biphosphate (Fleet Phosphosoda, Fleet Enema)</strong></td>
<td>PO 20–40 mL in 8 oz of water Rectal enema, 60–120 mL</td>
</tr>
<tr>
<td><strong>Stimulant Cathartics</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Bisacodyl (Dulcolax)</strong></td>
<td>PO 10–15 mg Rectal suppository, 10 mg</td>
</tr>
<tr>
<td><strong>Cascara sagrada</strong></td>
<td>PO, tablets, 325 mg; fluid extract, 0.5–1.5 mL; aromatic fluid extract, 5 mL</td>
</tr>
<tr>
<td><strong>Castor oil (Neoloid)</strong></td>
<td>PO 15–60 mL</td>
</tr>
<tr>
<td><strong>Glycerin</strong></td>
<td>Rectal suppository, 3 g</td>
</tr>
<tr>
<td><strong>Senna preparations (Senokot, Black Draught)</strong></td>
<td>Granules, PO 1 level tsp once or twice daily; geriatric, obstetric, gynecologic clients, PO 0.5 level tsp once or twice daily</td>
</tr>
<tr>
<td></td>
<td>Syrup, PO 2–3 tsp once or twice daily; geriatric, obstetric, gynecologic clients, 1–1½ tsp once or twice daily</td>
</tr>
<tr>
<td></td>
<td>Tablets, PO 2 tablets once or twice daily; geriatric, obstetric, gynecologic clients, 1 tablet once or twice daily</td>
</tr>
<tr>
<td></td>
<td>Suppositories, 1 suppository at bedtime</td>
</tr>
<tr>
<td><strong>Lubricant Laxative</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mineral oil (Agoral Plain, Milkinol, Fleet Mineral Oil Enema)</strong></td>
<td>PO 15–30 mL at bedtime Rectal enema, 30–60 mL</td>
</tr>
</tbody>
</table>
proteins and intestinal bacteria. Lactulose decreases production of ammonia in the intestine. The goal of treatment is usually to maintain two to three soft stools daily; effects usually occur within 24 to 48 hours. The drug should be used cautiously because it may produce electrolyte imbalances and dehydration.

**Sorbitol**

is a monosaccharide that pulls water into the intestinal lumen and has laxative effects. It is often given with sodium polystyrene sulfonate (Kayexalate), a potassium-removing resin used to treat hyperkalemia, to prevent constipation and aid expulsion of the potassium–resin complex.

**Laxative Abuse**

Laxatives and cathartics are widely available on a nonprescription basis and are among the most frequently abused drugs. One reason for overuse is the common misconception that a daily bowel movement is necessary for health and well-being, even with little intake of food or fluids. This notion may lead to a vicious cycle of events in which a person fails to have a bowel movement, takes a strong laxative, again fails to have a bowel movement, and takes another laxative before the fecal column has had time to become reestablished (2 to 3 days with normal food intake). Thus, a pattern of laxative dependence and abuse is established.

Laxatives are also abused for weight control, probably most often by people with eating disorders and those who must meet strict weight requirements (eg, some athletes). This is a very dangerous practice because it may lead to life-threatening fluid and electrolyte imbalances.

### Indications for Use

Despite widespread abuse of laxatives and cathartics, there are several rational indications for use:

1. To relieve constipation in pregnant women, elderly clients whose abdominal and perineal muscles have become weak and atrophied, children with megacolon, and clients receiving drugs that decrease intestinal motility (eg, opioid analgesics, drugs with anticholinergic effects)
2. To prevent straining at stool in clients with coronary artery disease (eg, postmyocardial infarction), hypertension, cerebrovascular disease, and hemorrhoids and other rectal conditions
3. To empty the bowel in preparation for bowel surgery or diagnostic procedures (eg, colonoscopy, barium enema)
4. To accelerate elimination of potentially toxic substances from the GI tract (eg, orally ingested drugs or toxic compounds)
5. To prevent absorption of intestinal ammonia in clients with hepatic encephalopathy
6. To obtain a stool specimen for parasitologic examination
7. To accelerate excretion of parasites after anthelmintic drugs have been administered
8. To reduce serum cholesterol levels (psyllium products)

### Contraindications to Use

Laxatives and cathartics should not be used in the presence of undiagnosed abdominal pain. The danger is that the drugs may cause an inflamed organ (eg, the appendix) to rupture and spill GI contents into the abdominal cavity with subse-
quent peritonitis, a life-threatening condition. Oral drugs also are contraindicated with intestinal obstruction and fecal impaction.

**Herbal and Dietary Supplements**

Many of the commonly used laxatives are plant-based (eg, cascara, psyllium, senna, castor oil). These have long been used and are safe and effective when used as directed.

Aloe is used most often as a topical remedy for burns and possibly other minor wounds. When used for this purpose, a gel-like liquid can be squeezed directly from a plant leaf onto the burned area. Oral aloe is sometimes used as a laxative. However, it is not recommended for this use because it is a strong stimulant laxative. With oral ingestion, aloe can cause severe cramping and other potentially serious adverse effects including hypokalemia and cardiac dysrhythmias.

**Nursing Process**

**Assessment**

Assess clients for current or potential constipation.

- Identify risk factors:
  - Diet with minimal fiber (ie, small amounts of fruits, vegetables, and whole-grain products)
  - Low fluid intake (eg, <2000 mL daily)
  - Immobility or limited activity
  - Drugs that reduce intestinal function and motility (eg, opioid analgesics, antacids containing aluminum or calcium, anticholinergics, calcium channel blockers, clozapine, diuretics, iron, phenothiazines, cholestyramine, colestipol, sulcrate, tricyclic antidepressants, vincristine). Overuse of antidiarrheal agents also may cause constipation.
  - Conditions that may reduce intestinal function and motility (eg, depression, eating disorders such as anorexia nervosa, hypothyroidism, hypercalcemia, multiple sclerosis, Parkinson disease, spinal lesions).
  - Hemorrhoids, anal fissures, or other conditions characterized by painful bowel elimination
  - Elderly or debilitated clients
  - Signs and symptoms include the following:
    - Decreased number and frequency of stools
    - Passage of dry, hard stools
    - Abdominal distention and discomfort
    - Flatulence

**Nursing Diagnoses**

- Constipation related to decreased activity, inadequate dietary fiber, inadequate fluid intake, drugs, or disease processes
- Pain (abdominal cramping and distention) related to constipation or use of laxatives
- Noncompliance with recommendations for nondrug measures to prevent or treat constipation
- Risk for Deficient Fluid Volume related to diarrhea from frequent or large doses of laxatives
- Deficient Knowledge: Nondrug measures to prevent constipation and appropriate use of laxatives

**Planning/Goals**

The client will:

- Take laxative drugs appropriately
- Use nondrug measures to promote normal bowel function and prevent constipation
- Regain normal patterns of bowel elimination
- Avoid excessive losses of fluids and electrolytes from laxative use
- Be protected from excessive fluid loss, hypotension, and other adverse drug effects, when possible
- Be assisted to avoid constipation when at risk (ie, has illness or injury that prevents activity, food and fluid intake; takes medications that decrease GI function)

**Interventions**

Assist clients with constipation and caregivers to:

- Understand the importance of diet, exercise, and fluid intake in promoting normal bowel function and preventing constipation
- Increase activity and exercise
- Increase intake of dietary fiber (vegetables, fruits, cereal grains)
- Drink at least 2000 mL of fluid daily
- Establish and maintain a routine for bowel elimination (eg, going to the bathroom immediately after breakfast)

Monitor client responses:

- Record number, amount, and type of bowel movements.
- Record vital signs. Hypotension and weak pulse may indicate deficient fluid volume.

**Evaluation**

- Observe and interview for improved patterns of bowel elimination.
- Observe for use of nondrug measures to promote bowel function.
- Observe for appropriate use of laxatives.
- Observe and interview regarding adverse effects of laxatives.

**PRINCIPLES OF THERAPY**

**Drug Selection**

Choice of a laxative or cathartic depends on the reason for use and the client’s condition.

1. For long-term use of laxatives or cathartics in clients who are elderly, unable or unwilling to eat an adequate diet, or debilitated, bulk-forming laxatives (eg, Meta-
Laxatives

General Considerations

- Diet, exercise, and fluid intake are important in maintaining normal bowel function and preventing or treating constipation.
- Eat foods high in dietary fiber daily. Fiber is the portion of plant food that is not digested. It is contained in fruits, vegetables, and whole-grain cereals and breads. Bran, the outer coating of cereal grains, such as wheat or oats, is an excellent source of dietary fiber and is available in numerous cereal products.
- Drink at least 6 to 10 glasses (8 oz each) of fluid daily if not contraindicated.
- Exercise regularly. Walking and other activities aid movement of feces through the bowel.
- Establish a regular time and place for bowel elimination. The defecation urge is usually strongest after eating and the defecation reflex is weakened or lost if repeatedly ignored.
- Laxative use should be temporary and not regular, as a general rule. Regular use may prevent normal bowel function, cause adverse drug reactions, and delay treatment for conditions that cause constipation.
- Never take laxatives when acute abdominal pain, nausea, or vomiting is present. Doing so may cause a ruptured appendix or other serious complication.
- After taking a strong laxative, it takes 2 to 3 days of normal eating to produce enough feces in the bowel for a bowel movement. Frequent use of a strong laxative promotes loss of normal bowel function, loss of fluids and electrolytes that your body needs, and laxative dependence.
- If you have chronic constipation and are unable or unwilling to eat enough fiber-containing foods in your diet, the next-best action is regular use of a bulk-forming laxative (eg, Metamucil) as a dietary supplement. These laxatives act the same way as increasing fiber in the diet and are usually best for long-term use. When taken daily, they can prevent constipation. However, they may take 2 to 3 days to work and are not effective in relieving acute constipation.
- Your urine may be discolored if you take a laxative containing senna (eg, Senokot) or cascara sagrada. The color change is not harmful.
- Some people use strong laxatives for weight control. This is an inappropriate use and a dangerous practice because it can lead to life-threatening fluid and electrolyte imbalances, including dehydration and cardiovascular problems.

Self- or Caregiver Administration

- Take all laxatives as directed and do not exceed recommended doses to avoid adverse effects.
- With bulk-forming laxatives, mix in 8 oz of fluid immediately before taking and follow with additional fluid, if able. Never take the drug dry. Adequate fluid intake is essential with these drugs.
- With bisacodyl tablets, swallow whole (do not crush or chew), and do not take within 1 hour of an antacid or milk. Avoid taking these drugs.
- Take magnesium citrate or milk of magnesia on an empty stomach with 8 oz of fluid to increase effectiveness.
- Refrigerate magnesium citrate before taking to improve taste and retain effectiveness.
- Mix lactulose with fruit juice, water, or milk, if desired, to improve taste.

Self-care guidelines for clients using laxatives are acceptable (eg, magnesium citrate, polyethylene glycol–electrolyte solution, bisacodyl). These drugs should not be used more than once per week. Frequent use is likely to produce laxative abuse.

4. Oral use of mineral oil may cause potentially serious adverse effects (decreased absorption of fat-soluble vitamins and some drugs, lipid pneumonia if aspirated into the lungs). Thus, mineral oil is not an oral laxative of choice in any condition, although occasional use in the alert client is unlikely to be harmful. It should not be used regularly. Mineral oil is probably most useful as a retention enema to soften hard, dry feces and aid in their expulsion.
5. In fecal impaction, a rectal suppository (eg, bisacodyl) or an enema (eg, oil retention or Fleet enema) is preferred. Oral laxatives are contraindicated when fecal impaction is present but may be given after the rectal mass is removed. Once the impaction is relieved, measures should be taken to prevent recurrence. If dietary and other nonpharmacologic measures are ineffective or contraindicated, use of a bulk-forming agent daily or another laxative once or twice weekly may be necessary.
6. Saline cathartics containing magnesium, phosphate, or potassium salts are contraindicated in clients with renal failure because hypermagnesemia, hyperphosphatemia, or hyperkalemia may occur.
7. Saline cathartics containing sodium salts are contraindicated in clients with edema or congestive heart failure because enough sodium may be absorbed to cause further fluid retention and edema. They also should not
be used in clients with impaired renal function or those following a sodium-restricted diet for hypertension.

8. Polyethylene glycol–electrolyte solution is formulated for rapid and effective bowel cleansing without significant changes in water or electrolyte balance.

Use in Children

As in adults, increasing fluids, high-fiber foods, and exercise is preferred when possible. For acute constipation, glycerin suppositories are often effective in infants and small children. Stool softeners may be given to older children. Children usually should not use strong, stimulant laxatives, and saline laxatives are not recommended for children younger than 2 years old. Parents should be advised not to give children any laxative more than once a week without consulting a health care provider. Polyethylene glycol–electrolyte solution is effective in treating acute iron overdose in children, although it is not approved by the Food and Drug Administration for this indication.

Use in Older Adults

Constipation is a common problem in older adults, and laxatives are often used or overused. Nondrug measures to prevent constipation (eg, increasing fluids, high-fiber foods, and exercise) are much preferred to laxatives. If a laxative is required on a regular basis, a psyllium compound (eg, Metamucil) is best because it is most physiologic in its action. If taken, it should be accompanied by a full glass of fluid. There have been reports of obstruction in the GI tract when a psyllium compound was taken with insufficient fluid. Strong stimulant laxatives should be avoided.

Use in Clients With Cancer

Many clients with cancer require moderate to large amounts of opioid analgesics for pain control. The analgesics slow GI motility and cause constipation. These clients need a bowel management program that includes routine laxative administration. Stimulant laxatives (eg, a senna preparation or bisacodyl) increase intestinal motility, which is the action that opiates suppress. These drugs may cause abdominal cramping, which may be lessened by giving small doses three or four times daily.

Use in Renal Impairment

Saline cathartics containing phosphate, sodium, magnesium, or potassium salts are usually contraindicated or must be used cautiously in the presence of impaired renal function. Ten percent or more of the magnesium in magnesium salts may be absorbed and cause hypermagnesemia; sodium phosphate and sodium biphosphate may cause hyperphosphatemia, hypernatremia, acidosis, and hypocalcemia; potassium salts may cause hyperkalemia.

Use in Hepatic Impairment

Because most laxatives are not absorbed or metabolized extensively, they can usually be used without difficulty in clients with hepatic impairment. In fact, they are used therapeutically in hepatic encephalopathy to decrease absorption of ammonia from dietary protein in the GI tract. Lactulose is usually given in dosages to produce two to three soft stools daily.

Home Care

Laxatives are commonly self-prescribed and self-administered in the home setting. The home care nurse may become involved when visiting a client for other purposes. The role of the home care nurse may include assessing usual patterns of bowel elimination, identifying clients at risk for developing constipation, promoting lifestyle interventions to prevent constipation, obtaining laxatives when indicated, and counseling about rational use of laxatives.
### Laxatives and Cathartics

#### NURSING ACTIONS

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong>&lt;br&gt;a. Give bulk-forming laxatives with at least 8 oz of water or other fluid. Mix with fluid immediately before administration.</td>
<td>To prevent thickening and expansion in the gastrointestinal (GI) tract with possible obstruction. These substances absorb water rapidly and solidify into a gelatinous mass.</td>
</tr>
<tr>
<td>b. With bisacodyl tablets, instruct the client to swallow the tablets without chewing and not to take them within an hour after ingesting milk or gastric antacids or while receiving cimetidine therapy.</td>
<td>The tablets have an enteric coating to delay dissolution until they reach the alkaline environment of the small intestine. Chewing or giving the tablets close to antacid substances or to cimetidine-treated clients causes premature dissolution and gastric irritation and results in abdominal cramping and vomiting.</td>
</tr>
<tr>
<td>c. Give saline cathartics on an empty stomach with 240 mL of fluid.</td>
<td>To increase effectiveness</td>
</tr>
<tr>
<td>d. Refrigerate magnesium citrate and polyethylene glycol-electrolyte solution before giving.</td>
<td>To increase palatability and retain potency</td>
</tr>
<tr>
<td>e. Castor oil may be chilled and followed by fruit juice or other beverage.</td>
<td>To increase palatability</td>
</tr>
<tr>
<td>f. Insert rectal suppositories to the length of the index finger, next to rectal mucosa.</td>
<td>These drugs are not effective unless they are in contact with intestinal mucosa.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong>&lt;br&gt;a. Soft to semiliquid stool</td>
<td>Therapeutic effects occur in approximately 1–3 d with bulk-forming laxatives and stool softeners; 6–8 h with bisacodyl tablets, cascara sagrada, and senna products; 15–60 min with bisacodyl and glycerin suppositories.</td>
</tr>
<tr>
<td>b. Liquid to semiliquid stool</td>
<td>Effects occur in approximately 1–3 h with saline cathartics and castor oil</td>
</tr>
<tr>
<td>c. Decreased abdominal pain when used in irritable bowel syndrome or diverticulosis</td>
<td>Pain results from straining to expel hard, dry feces.</td>
</tr>
<tr>
<td>d. Decreased rectal pain when used in clients with hemorrhoids or anal fissures</td>
<td></td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong>&lt;br&gt;a. Diarrhea—several liquid stools, abdominal cramping. Severe, prolonged diarrhea may cause hyponatremia, hypokalemia, dehydration, and other problems.</td>
<td>Diarrhea is most likely to result from strong, stimulant cathartics (eg, castor oil, bisacodyl, senna preparations) or large doses of saline cathartics (eg, milk of magnesia).</td>
</tr>
<tr>
<td>b. With bulk-forming agents, impaction or obstruction</td>
<td>Impaction or obstruction of the GI tract can be prevented by giving ample fluids with these agents and not giving the drugs to clients with known dysphagia or strictures anywhere in the alimentary canal.</td>
</tr>
<tr>
<td>c. With saline cathartics, hypermagnesemia, hyperkalemia, fluid retention, and edema</td>
<td>Hypermagnesemia and hyperkalemia are more likely to occur in clients with renal insufficiency because of impaired ability to excrete magnesium and potassium. Fluid retention and edema are more likely to occur in clients with congestive heart failure or other conditions characterized by edema. Polyethylene glycol-electrolyte solution produces the least change in water and electrolyte balance.</td>
</tr>
<tr>
<td>d. With mineral oil, lipid pneumonia and decreased absorption of vitamins A, D, E, and K</td>
<td>Lipid pneumonia can be prevented by not giving mineral oil to clients with dysphagia or impaired consciousness. Decreased absorption of fat-soluble vitamins can be prevented by not giving mineral oil with or shortly after meals or for longer than 2 wk.</td>
</tr>
</tbody>
</table>

(continued)
**Nursing Notes: Apply Your Knowledge**

**Answer:** Abdominal fullness, bloating, and seepage of liquid stool are all symptoms of fecal impaction. Fecal impaction is likely in this patient because she is taking large amounts of narcotics and is inactive. To treat the impacted stool, oil retention enemas are helpful to soften the hardened stool. Oral laxatives are usually ineffective in moving the hardened plug of feces. Frequently, manual removal of the impaction is required, especially if the patient is weak. It is very important to institute an aggressive bowel program for any patient receiving long-term narcotics for pain control. Tolerance is never developed for the constipating side effect of opioids. Bulk-forming laxatives and stool softeners should be used on a daily basis. Saline or stimulant cathartics can be administered when 2 to 3 days elapse without a bowel movement. Because impaction can occur, enemas are also used. Teaching regarding increasing fluids, fiber, and activity, within individual limitations, is also important.

**Review and Application Exercises**

1. What are risk factors for development of constipation?
2. Describe nonpharmacologic strategies to prevent constipation.
3. Which type of laxative is, in general, the most desirable for long-term use? Which is the least desirable?
4. What are the most significant adverse effects of strong laxatives?
5. If an adult client asked you to recommend an over-the-counter laxative, what information about the client’s condition would you need, and what would you recommend? Why?

**SELECTED REFERENCES**


**How Can You Avoid This Medication Error?**

**Answer:** Never recommend laxatives for a patient who is experiencing acute abdominal pain. It is important to collect more data from this patient, including a complete description of the pain (onset, locations, pattern), temperature, and other symptoms. If the patient has appendicitis, taking a laxative could cause the appendix to rupture and result in serious complications.
Antidiarraheals

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify clients at risk for development of diarrhea.
2. Discuss guidelines for assessing diarrhea.
3. Describe types of diarrhea in which antidiarrheal drug therapy may be indicated.
4. Differentiate the major types of antidiarrheal drugs.
5. Discuss characteristics, effects, and nursing process implications of commonly used antidiarrheal agents.

Critical Thinking Scenario
John Finney, a 32-year-old client with acquired immunodeficiency syndrome, is admitted to your medical unit for management of severe diarrhea. He reports having 12 to 20 liquid stools per day and feeling weak and dizzy when he gets up. This current bout of diarrhea has been continuing for 6 days, during which he has lost 18 pounds. Diphenoxylate (Lomotil) and IV fluids are ordered.

Reflect on:
- The physiologic effects of severe diarrhea.
- The impact of severe diarrhea on a person's ability to carry out normal activities.
- Appropriate nursing assessments and interventions while diarrhea continues.
- How diphenoxylate (Lomotil) works to decrease diarrhea.

OVERVIEW
Antidiarrheal drugs are used to treat diarrhea, defined as the frequent expulsion of liquid or semiliquid stools. Diarrhea is a symptom of numerous conditions that increase bowel motility, cause secretion or retention of fluids in the intestinal lumen, and cause inflammation or irritation of the gastrointestinal (GI) tract. As a result, bowel contents are rapidly propelled toward the rectum, and absorption of fluids and electrolytes is limited. Some causes of diarrhea include the following:

1. Excessive use of laxatives
2. Intestinal infections with viruses, bacteria, or protozoa. A common source of infection is ingestion of food or fluid contaminated by Salmonella, Shigella, or Staphylococcus microorganisms. So-called travelers' diarrhea is usually caused by an enteropathogenic strain of Escherichia coli.
3. Undigested, coarse, or highly spiced food in the GI tract. The food acts as an irritant and attracts fluids in a defensive attempt to dilute the irritating agent. This may result from inadequate chewing of food or lack of digestive enzymes.
4. Lack of digestive enzymes. Deficiency of pancreatic enzymes inhibits digestion and absorption of carbohydrates, proteins, and fats. Deficiency of lactase, which breaks down lactose to simple sugars (ie, glucose and galactose) that can be absorbed by GI mucosa, inhibits digestion of milk and milk products. Lactase deficiency commonly occurs among people of African and Asian descent.
5. Inflammatory bowel disorders, such as gastroenteritis, diverticulitis, ulcerative colitis, and Crohn’s disease. In these disorders, the inflamed mucous membrane secretes large amounts of fluids into the intestinal lumen, along with mucus, proteins, and blood, and absorption of water and electrolytes is impaired. In addition, when the ileum is diseased or a portion is surgically excised, large amounts of bile salts reach the colon, where they act as cathartics and cause diarrhea. Bile salts are normally reabsorbed from the ileum.
6. Drug therapy. Many oral drugs irritate the GI tract and may cause diarrhea, including acarbose, antacids that contain magnesium, antibacterials, antineoplastic agents, colchicine, laxatives, metformin, metoclopramide, misoprostol, serotonin reuptake inhibitors, tacrine, and tacrolimus. Antibacterial drugs are commonly used offenders that also may cause diarrhea by altering the normal bacterial flora in the intestine.

Antibiotic-associated colitis (also called pseudomembranous colitis and Clostridium difficile colitis) is a serious condition that results from oral or parenteral antibiotic therapy. By suppressing normal flora, antibacterials allow gram-positive, anaerobic C. difficile organisms to proliferate. The organisms produce a toxin that causes fever, abdominal pain, inflammatory lesions of the colon, and severe diarrhea with stools containing mucus, pus, and sometimes blood. Symptoms may develop within a few days or several weeks after the causative antibiotic is discontinued. Antibiotic-associated colitis is more often associated with ampicillin, cephalosporins, and clindamycin, but may occur with any antibiotic or combination of antibacterials that alters intestinal microbial flora.

7. Intestinal neoplasms. Tumors may increase intestinal motility by occupying space and stretching the intestinal wall. Diarrhea sometimes alternates with constipation in colon cancer.

8. Functional disorders. Diarrhea may be a symptom of stress or anxiety in some clients. No organic disease process can be found in such circumstances.

9. Hyperthyroidism. This condition increases bowel motility.

10. Surgical excision of portions of the intestine, especially the small intestine. Such procedures decrease the absorptive area and increase fluidity of stools.

11. Human immunodeficiency virus (HIV) infection/acquired immunodeficiency syndrome (AIDS). Diarrhea occurs in most clients with HIV infection, often as a chronic condition that contributes to malnutrition and weight loss. It may be caused by drug therapy, infection with a variety of microorganisms, or other factors.

Diarrhea may be acute or chronic and mild or severe. Most episodes of acute diarrhea are defensive mechanisms by which the body tries to rid itself of irritants, toxins, and infectious agents. These are usually self-limiting and subside within 24 to 48 hours without serious consequences. If severe or prolonged, acute diarrhea may lead to serious fluid and electrolyte depletion, especially in young children and older adults. Chronic diarrhea may cause malnutrition and anemia and is often characterized by remissions and exacerbations.

**ANTIDIARRHEAL DRUGS**

Antidiarrheal drugs include a variety of agents, most of which are discussed in other chapters. When used for treatment of diarrhea, the drugs may be given to relieve the symptom (nonspecific therapy) or the underlying cause of the symptom (specific therapy). Individual drugs are listed in Drugs at a Glance: Antidiarrheal Drugs.

**Nonspecific Therapy**

A major element of nonspecific therapy is adequate fluid and electrolyte replacement. When drug therapy is required, nonprescription antidiarrheal drugs (eg, loperamide) may be effective. **Loperamide** (Imodium) is a synthetic derivative of meperidine that decreases GI motility by its effect on intestinal muscles. Because loperamide does not penetrate the central nervous system (CNS) well, it does not cause the CNS effects associated with opioid use and lacks potential for abuse. Although adverse effects are generally few and mild, loperamide can cause abdominal pain, constipation, drowsiness, fatigue, nausea, and vomiting. For nonprescription use, dosages for adults should not exceed 8 mg/day; with supervision by a health care provider, maximum daily dosage is 16 mg/day. In general, loperamide should be discontinued after 48 hours if clinical improvement has not occurred.

Overall, opiates and opiate derivatives (see Chap. 6) are the most effective agents for symptomatic treatment of diarrhea. These drugs decrease diarrhea by slowing propulsive movements in the small and large intestines. Morphine, codeine, and related drugs are effective in relieving diarrhea but are rarely used for this purpose because of their adverse effects. Opiates have largely been replaced by the synthetic drugs diphenoxylate, loperamide, and difenoxin, which are used only for treatment of diarrhea and do not cause morphine-like adverse effects in recommended doses. Diphenoxylate and difenoxin require a prescription.

**Bismuth salts** have antibacterial and antiviral activity; bismuth subsalicylate (Pepto-Bismol, a commonly used over-the-counter drug) also has antisecretory and possibly anti-inflammatory effects because of its salicylate component.

**Octreotide** acetate is a synthetic form of somatostatin, a hormone produced in the anterior pituitary gland and in the pancreas. The drug may be effective in diarrhea because it decreases GI secretion and motility. It is used for diarrhea associated with carcinoid syndrome, intestinal tumors, HIV/AIDS, and diarrhea that does not respond to other antidiarrheal drugs.

Other nonspecific agents sometimes used in diarrhea are anticholinergics (see Chap. 21) and polycarbophil and psyllium preparations (see Chap. 61). Anticholinergic drugs, of which atropine is the prototype, are infrequently used because doses large enough to decrease intestinal motility and secretions cause intolerable adverse effects. The drugs are occasionally used to decrease abdominal cramping and pain (antispasmodic effects) associated with acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease. **Polycarbophil** (eg, FiberCon) and **psyllium** preparations (eg, Metamucil) are most often used as bulk-forming laxatives. They are occasionally used in diarrhea to decrease fluid...
# Drugs at a Glance: Antidiarrheal Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Opiate-Related Drugs</strong></td>
<td></td>
<td></td>
<td>Adults</td>
</tr>
<tr>
<td>Paregoric</td>
<td>Morphine is the active ingredient. A Schedule III drug alone and a Schedule V in the small amounts combined with other drugs. Recommended doses and short-term use do not produce euphoria, analgesia, or dependence. Overdose may cause respiratory depression and coma. Each tablet contains 1 mg of difenoxin and 0.025 mg of atropine. The atropine is added to discourage overdose and abuse for opioid effects. Contraindicated in children &lt;2 y of age and clients who are allergic to the ingredients or have hepatic impairment. A Schedule IV drug</td>
<td>Symptomatic treatment of acute diarrhea</td>
<td>PO 5–10 mL 1–4 times daily (maximum of 4 doses) until diarrhea is controlled</td>
</tr>
<tr>
<td>Difenoxin with atropine sulfate (Motofen)</td>
<td>An active metabolite of diphenoxylate Overdose may cause respiratory depression and coma. Each tablet contains 1 mg of difenoxin and 0.025 mg of atropine. The atropine is added to discourage overdose and abuse for opioid effects. Contraindicated in children &lt;2 y of age and clients who are allergic to the ingredients or have hepatic impairment. A Schedule IV drug</td>
<td>Symptomatic treatment of acute or chronic diarrhea</td>
<td>PO 2 mg initially, then 1 mg after each loose stool or 1 mg q3–4h as needed; maximum dose, 8 mg (8 tablets)/24 h</td>
</tr>
<tr>
<td>Diphenoxylate with atropine sulfate (Lomotil)</td>
<td>A derivative of meperidine (Demerol) Commonly prescribed; decreases intestinal motility In recommended doses, does not produce euphoria, analgesia, or dependence. In high doses, produces morphine-like effects, including euphoria, dependence, and respiratory depression. Naloxone (Narcan) is the antidote for overdose. Each tablet or 5 mL of liquid contains 2.5 mg of diphenoxylate and 0.025 mg of atropine. The atropine is added to discourage drug abuse. Contraindicated in severe liver disease, glaucoma, and children &lt;2 y of age. A Schedule V drug</td>
<td>Symptomatic treatment of acute or chronic diarrhea</td>
<td>PO 5 mg (2 tablets or 10 mL of liquid) 3 or 4 times daily; maximal daily dose, 20 mg</td>
</tr>
</tbody>
</table>

(continued)
**Drugs at a Glance: Antidiarrheal Drugs (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Characteristics</th>
<th>Clinical Indications</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
</table>
| **Loperamide** (Imodium)                   | A derivative of meperidine; decreases intestinal motility         | Symptomatic treatment of acute or chronic diarrhea                                  | Adults: PO 4 mg initially, then 2 mg after each loose stool to a maximal daily dose of 16 mg. For chronic diarrhea, dosage should be reduced to the lowest effective amount (average 4–8 mg daily).  
Children: 2–5 y, 13–20 kg: PO 1 mg 3 times daily; 6–8 y, 20–30 kg: PO 2 mg twice daily; 8–12 y, >30 kg: PO 2 mg 3 times daily |
| **Antibacterial Agents**                   |                                                                   |                                                                                     |                          |
| Ciprofloxacin (Cipro)                       | A fluoroquinolone (See Chap. 35)                                  | Diarrhea caused by susceptible strains of *E. coli*, *Campylobacter jejuni*, and *Shigella* species | Adults: PO 500 mg q12h for 5–7 days  
Children: Not recommended for use |
| Erythromycin (E-Mycin)                      | A macrolide (see Chap. 37)                                        | Intestinal amebiasis caused by *Entamoeba histolytica*                              | Adults: PO 250 mg 4 times daily for 10–14 days  
Children: PO 30–50 mg/kg/d, in divided doses, for 10–14 days |
| Metronidazole (Flagyl)                      | See Chap. 37                                                      | Intestinal amebiasis, *C. difficile* infection, Po 500 mg 3 times daily or 250 mg 4 times daily  
Intestinal amebiasis, Po 750 mg 3 times daily for 5 to 10 d | Adults: Dosage not established for *C. difficile* infection  
Children: Intestinal amebiasis, Po 35–50 mg/kg/24 h (maximum 750 mg/dose), in 3 divided doses for 10 d |
| **Trimethoprim-sulfamethoxazole** (TMP-SMX) (Bactrim, Septra) |                                                                   | Diarrhea caused by susceptible strains of *E. coli* or *Shigella* organisms         | Adults: PO 160 mg of TMP and 800 mg of SMX q12h for 5 d or longer  
Children: PO 8 mg/kg of TMP and 40 mg/kg of SMX daily, in divided doses, q12h, for 5 d or longer |
| **Miscellaneous Drugs**                    |                                                                   |                                                                                     |                          |
| Bismuth subsalicylate (Pepto-Bismol)        | Has antimicrobial, anti-secretory, and possibly anti-inflammatory effects | Control of diarrhea, including traveler’s diarrhea, and relief of abdominal cramping | Adults: PO 2 tablets or 30 mL every 30–60 min, if needed, up to 8 doses in 24 h  
Children: 9–12 y: PO 1 tablet or 15 mL; 6–9 y: PO ½ tablet or 10 mL; 3–6 y: PO ½ tablet or 5 mL; under <3 y, consult pediatrician |
| Cholestyramine (Questran)                  | Binds and inactivates bile salts in the intestine                 | Diarrhea due to bile salts reaching the colon and causing a cathartic effect. “Bile salt diarrhea” is associated with Crohn’s disease or surgical excision of the ileum. | Adults: PO 16–32 g/d in 120–180 mL of water, in 2–4 divided doses before or during meals and at bedtime  
Children: PO 15–30 g/d in 120–180 mL of water, in 2–4 divided doses before or during meals and at bedtime |
| Colestipol (Colestid)                       | Same as cholestyramine, above                                     | Same as cholestyramine                                                            |                          |
idity of stools. The preparations absorb large amounts of water and produce stools of gelatin-like consistency. They may cause abdominal discomfort and bloating.

Specific Therapy

Specific drug therapy for diarrhea depends on the cause of the symptom and may include the use of antibacterial, enzymatic, and bile salt–binding drugs. Antibacterial drugs are recommended for bacterial enteritis when diarrhea lasts longer than 48 hours, when the patient passes 6 or more loose stools in 24 hours, when diarrhea is associated with fever, or when blood or pus is seen in the stools. Although effective in preventing travelers’ diarrhea, antibiotics usually are not recommended because their use may promote the emergence of drug-resistant microorganisms. Although effective in reducing diarrhea due to Salmonella and E. coli intestinal infections, antibiotics may induce a prolonged carrier state during which the infection can be transmitted to other people.

Indications for Use

Despite the limitations of drug therapy in prevention and treatment of diarrhea, antidiarrheal drugs are indicated in the following circumstances:

1. Severe or prolonged diarrhea (>2 to 3 days), to prevent severe fluid and electrolyte loss
2. Relatively severe diarrhea in young children and older adults. These groups are less able to adapt to fluid and electrolyte losses.
3. In chronic inflammatory diseases of the bowel (ulcerative colitis and Crohn’s disease), to allow a more nearly normal lifestyle
4. In ileostomies or surgical excision of portions of the ileum, to decrease fluidity and volume of stool
5. HIV/AIDS-associated diarrhea
6. When specific causes of diarrhea have been determined

Contraindications to Use

Contraindications to the use of antidiarrheal drugs include diarrhea caused by toxic materials, microorganisms that penetrate intestinal mucosa (eg, pathogenic E. coli, Salmonella, Shigella), or antibiotic-associated colitis. In these circumstances, antidiarrheal agents that slow peristalsis may aggravate and prolong diarrhea. Opiates (morphine, codeine) usually are contraindicated in chronic diarrhea because of possible opiate dependence. Difenoxin, diphenoxylate, and loperamide are contraindicated in children younger than 2 years of age.

Herbal and Dietary Supplements

Several herbal remedies are promoted for treatment of diarrhea. Most include tannins, substances with astringent properties that reduce intestinal inflammation and secretions. The leaves of edible berry plants (ie, blackberry, blueberry, raspberry) are sometimes used in “tea” made by pouring boiling water over 1 to 2 teaspoons of leaves and drunk up to 6 times daily. There is little objective evidence of effectiveness or toxicity.
Nursing Process

Assessment
Assess for acute or chronic diarrhea.

- Try to determine the duration of diarrhea; number of stools per day; amount, consistency, color, odor, and presence of abnormal components (eg, undigested food, blood, pus, mucus) in each stool; precipitating factors; accompanying signs and symptoms (ie, nausea, vomiting, fever, abdominal pain or cramping); and measures used to relieve diarrhea. When possible, look at stool specimens for possible clues to causation. Blood may indicate inflammation, infection, or neoplastic disease; pus or mucus may indicate inflammation or infection. Infections caused by Shigella organisms produce blood-tinged mucus. Infections caused by Salmonella or E. coli usually produce green, liquid or semiliquid stools. Inflammatory bowel disorders often produce nonbloody mucus.

- Try to determine the cause of the diarrhea. This includes questioning about causes such as chronic inflammatory diseases of the bowel, food intake, possible exposure to contaminated food, living or traveling in areas of poor sanitation, and use of laxatives or other drugs that may cause diarrhea. When available, check laboratory reports on stool specimens (eg, culture reports).

- With severe or prolonged diarrhea, especially in young children and older adults, assess for dehydration, hypokalemia, and other fluid and electrolyte disorders.

Nursing Diagnoses
- Diarrhea related to GI infection or inflammatory disorders, other disease processes, dietary irritants, or overuse of laxatives
- Anxiety related to availability of bathroom facilities
- Deficient Fluid Volume related to excessive losses in liquid stools
- Pain (abdominal cramping) related to intestinal hypermotility and spasm
- Deficient Knowledge: Factors that cause or aggravate diarrhea and appropriate use of antidiarrheal drugs

Planning/Goals
The client will:
- Take antidiarrheal drugs appropriately
- Obtain relief from acute diarrhea (reduced number of liquid stools, reduced abdominal discomfort)
- Maintain fluid and electrolyte balance
- Maintain adequate nutritional intake
- Avoid adverse effects of antidiarrheal medications
- Reestablish normal bowel patterns after an episode of acute diarrhea
- Have fewer liquid stools with chronic diarrhea

Interventions
Use measures to prevent diarrhea:
- Prepare and store food properly and avoid improperly stored foods and those prepared under unsanitary conditions. Dairy products, cream pies, and other foods may cause diarrhea (“food poisoning”) if not refrigerated.
- Wash hands before handling any foods, after handling raw poultry or meat, and always before eating.
- Chew food well.
- Do not overuse laxatives (ie, amount per dose or frequency of use). Many over-the-counter products contain senna or other strong stimulant laxatives.

Regardless of whether antidiarrheal drugs are used, supportive therapy is required for the treatment of diarrhea. Elements of supportive care include the following:
- Replacement of fluids and electrolytes (2 to 3 quarts daily). Fluids such as weak tea, water, bouillon, clear soup, noncarbonated, caffeine-free beverages, and gelatin are usually tolerated and helpful. If the client cannot tolerate adequate amounts of oral liquids or if diarrhea is severe or prolonged, intravenous fluids may be needed (ie, solutions containing dextrose, sodium chloride, and potassium chloride).
- Avoid foods and fluids that may further irritate GI mucosa (eg, highly spiced foods or “laxative” foods, such as raw fruits and vegetables).
- Increase frequency and length of rest periods, and decrease activity. Exercise and activity stimulate peristalsis.
- If perianal irritation occurs because of frequent liquid stools, cleanse the area with mild soap and water after each bowel movement, then apply an emollient, such as white petrolatum (Vaseline).

Evaluation
- Observe and interview for decreased number of liquid or loose stools.
- Observe for signs of adequate food and fluid intake (eg, good skin turgor and urine output, stable weight).
- Observe for appropriate use of antidiarrheal drugs.
- Observe and interview for return of prediarrheal patterns of bowel elimination.
- Interview regarding knowledge and use of measures to prevent or minimize diarrhea.

PRINCIPLES OF THERAPY

Nonpharmacologic Therapy

In most cases of acute, nonspecific diarrhea in adults, fluid losses are not severe and patients need only simple replacement of fluids and electrolytes lost in the stool. Acceptable replacement fluids during the first 24 hours include 2 to 3 liters of clear liquids (eg, flat ginger ale, decaffeinated cola drinks or tea, broth, gelatin). Also, the diet should consist of bland foods.
CLIENT TEACHING GUIDELINES
Antidiarrheal Medications

General Considerations
- Taking a medication to stop diarrhea is not always needed or desirable because diarrhea may mean the body is trying to rid itself of irritants or bacteria. Treatment is indicated if diarrhea is severe, prolonged, or occurs in young children or older adults, who are highly susceptible to excessive losses of body fluids and electrolytes.
- Try to drink 2 to 3 quarts of fluid daily. This helps prevent dehydration from fluid loss in stools. Water, clear broths, and noncarbonated, caffeine-free beverages are recommended because they are unlikely to cause further diarrhea.
- Avoid highly spiced or “laxative” foods, such as fresh fruits and vegetables, until diarrhea is controlled.
- Frequent and thorough handwashing and careful food storage and preparation can help prevent diarrhea.
- Consult a health care provider if diarrhea is accompanied by severe abdominal pain or fever, lasts longer than 3 days, or if stools contain blood or mucus. These signs and symptoms may indicate more serious disorders for which other treatment measures are needed.
- Stop antidiarrheal drugs when diarrhea is controlled to avoid adverse effects such as constipation.
- Bismuth subsalicylate (Pepto-Bismol) and loperamide (Imodium A-D) are available over the counter; difenoxin (Motofen) and diphenoxylate (Lomotil) are prescription drugs.
- Difenoxin, diphenoxylate, and loperamide may cause dizziness or drowsiness and should be used with caution if driving or performing other tasks requiring alertness, coordination, or physical dexterity. In addition, alcohol and other drugs that cause drowsiness should be avoided.
- Pepto-Bismol may temporarily discolor bowel movements a grayish-black.
- Keep antidiarrheal drugs out of reach of children. Accidental overdose of Motofen may cause fatal respiratory depression.

Self- or Caregiver Administration
- Take or give antidiarrheal drugs only as prescribed or directed on nonprescription drug labels.
- Do not exceed maximal daily doses of diphenoxylate (Lomotil), loperamide, difenoxin, or paregoric.
- With liquid diphenoxylate, use only the calibrated dropper furnished by the manufacturer for accurate measurement of dosages.
- With Pepto-Bismol liquid, shake the bottle well before measuring the dose; with tablets, chew them well or allow them to dissolve in the mouth.
- Add at least 30 mL of water to each dose of paregoric to help the drug dose reach the stomach. The mixture appears milky.
- Take cholestyramine or colestipol with at least 4 oz of water. These drugs should never be taken without fluids because they may block the gastrointestinal tract. Also, do not take within 4 hours of other drugs because they may combine with and inactivate other drugs.

Drug Selection
Choice of antidiarrheal agent depends largely on the cause, severity, and duration of diarrhea.
1. For symptomatic treatment of diarrhea, difenoxin with atropine (Motofen), diphenoxylate with atropine (Lomotil), or loperamide (Imodium) is probably the drug of choice for most people.
2. In bacterial gastroenteritis or diarrhea, choice of antibacterial drug depends on the causative microorganism and susceptibility tests.
3. In ulcerative colitis, sulfonamides, adrenal corticosteroids, and other anti-inflammatory agents such as balsalazide (Colazal), mesalamine (Pentasa) and olsalazine (Dipentum) are the drugs of choice. The latter drugs are related to aspirin and nonsteroidal anti-inflammatory drugs (see Chap. 7) and are contraindicated in patients with hypersensitivity to salicylates or any other product component. They are given orally or rectally and are thought to exert topical anti-inflammatory effects in ulcerative colitis.
4. In antibiotic-associated colitis, stopping the causative drug is the initial treatment. If symptoms do not improve within 3 or 4 days, oral metronidazole or vancomycin is given for 7 to 10 days. Both are effective against C. difficile, but metronidazole is the drug of first choice and is much less expensive. Vancomycin may be given for severe disease or when metronidazole is ineffective. For approximately 6 weeks after recovery, relapse often occurs and requires retreatment. Because relapse is not due to emergence of drug-resistant strains, the same drug used for the initial bout may be used to treat the relapse.
5. In diarrhea caused by enzyme deficiency, pancreatic enzymes are given rather than antidiarrheal drugs.
6. In bile salt diarrhea, cholestyramine or colestipol may be effective.
7. Although morphine and codeine are contraindicated in chronic diarrhea, they may occasionally be used in the treatment of acute, severe diarrhea. Dosages required
for antidiarrheal effects are smaller than those required for analgesia. The following oral drugs and dosages are approximately equivalent in antidiarrheal effectiveness: 4 mg morphine, 30 mg codeine, 10 mL paregoric, 5 mg diphenoxylate, and 2 mg loperamide.

**Use in Children**

Antidiarrheal drugs, including antibiotics, are often used in children to prevent excessive losses of fluids and electrolytes. In small children, fluid volume deficit may rapidly develop with diarrhea. Drug therapy should be accompanied by appropriate fluid replacement and efforts to decrease further stimuli. Oral rehydration solutions (eg, Pedialyte solution and freezer pops) are commercially available in ready-to-use formulations in the United States. Packets of powder (containing glucose, sodium, potassium, chloride, and citrate), to be mixed with 1 liter of boiled or treated water, are available in developing countries, usually provided by the World Health Organization.

Difenoxin and diphenoxylate contain atropine, and signs of atropine overdose may occur with usual doses. Difenoxin and diphenoxylate are contraindicated in children younger than 2 years of age; loperamide should not be used in children younger than 6 years, except with a pediatrician’s supervision, and should generally not be used for longer than 2 days in older children. Loperamide is a nonprescription drug.

**Use in Older Adults**

Diarrhea is less common than constipation in older adults, but it may occur from laxative abuse and bowel cleansing procedures before GI surgery or diagnostic tests. Fluid volume deficits may rapidly develop in older adults with diarrhea. General principles of fluid and electrolyte replacement, measures to decrease GI irritants, and drug therapy apply as for younger adults. Most antidiarrheal drugs may be given to older adults, but cautious use is indicated to avoid inducing constipation.

**Use in Renal Impairment**

Difenoxin and diphenoxylate should be used with extreme caution in clients with severe hepatorenal disease because hepatic coma may be precipitated.

**Use in Hepatic Impairment**

Difenoxin and diphenoxylate should be used with extreme caution in clients with abnormal liver function test results or severe hepatorenal disease because hepatic coma may be precipitated. With loperamide, monitor clients with hepatic impairment for signs of CNS toxicity. Loperamide normally undergoes extensive first-pass metabolism, which may be lessened by liver disease. As a result, a larger portion of a dose reaches the systemic circulation and may cause adverse effects. Dosage may need to be reduced.

**Use in Immunocompromised Patients**

Diarrhea often occurs in immunocompromised patients (eg, those with AIDS, organ transplant, or anticancer chemotherapy) and may be difficult to treat with the usual antidiarrheal drugs. Octreotide may be effective, but it should be used only after other medications have failed because it is given by injection and is expensive.

**Home Care**

Prescription and over-the-counter antidiarrheal aids are often taken in the home setting. The role of the home care nurse may include advising clients and caregivers about appropriate use of the drugs, trying to identify the cause and severity of the diarrhea (ie, risk of fluid and electrolyte deficit), and teaching strategies to manage the current episode and prevent future episodes. If octreotide is taken at home, the home care nurse may need to teach the client or a caregiver how to administer subcutaneous injections.
### Nursing Actions

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. With liquid diphenoxylate, use only the calibrated dropper furnished by the manufacturer for measuring dosage.</td>
<td>For accurate measurement</td>
</tr>
<tr>
<td>b. Add at least 30 mL of water to each dose of paregoric. The mixture appears milky.</td>
<td>To add sufficient volume for the drug to reach the stomach</td>
</tr>
<tr>
<td>c. Do not exceed maximal daily doses of diphenoxylate, loperamide, difenoxin, and paregoric. Also, stop the drugs when diarrhea is controlled.</td>
<td>To decrease risks of adverse reactions, including drug dependence</td>
</tr>
<tr>
<td>d. Give cholestyramine and colestipol with at least 120 mL of water. Also, do not give within approximately 4 h of other drugs.</td>
<td>The drugs may cause obstruction of the gastrointestinal (GI) tract if swallowed in a dry state. They may combine with and inactivate other drugs.</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. Decreased number, frequency, and fluidity of stools</td>
<td>Therapeutic effects are usually evident within 24 to 48 h.</td>
</tr>
<tr>
<td>b. Decreased or absent abdominal cramping pains</td>
<td></td>
</tr>
<tr>
<td>c. Signs of normal fluid and electrolyte balance (adequate hydration, urine output, and skin turgor)</td>
<td></td>
</tr>
<tr>
<td>d. Resumption of usual activities of daily living.</td>
<td></td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. Constipation</td>
<td>Constipation is the most common adverse effect. It can be prevented by using antidiarrheal drugs only as prescribed and stopping the drugs when diarrhea is controlled.</td>
</tr>
<tr>
<td>b. Drug dependence</td>
<td>Dependence is unlikely with recommended doses but may occur with long-term use of large doses of paregoric, diphenoxylate, and difenoxin.</td>
</tr>
<tr>
<td>c. With diphenoxylate, anorexia, nausea, vomiting, dizziness, abdominal discomfort, paralytic ileus, toxic megacolon, hypersensitivity (pruritus, urticaria, angioneurotic edema), headache, and tachycardia</td>
<td>Although numerous adverse reactions have been reported, their incidence and severity are low when diphenoxylate is used appropriately.</td>
</tr>
<tr>
<td>With overdoses of a diphenoxylate–atropine or difenoxin–atropine combination, respiratory depression and coma may result from diphenoxylate or difenoxin content and anticholinergic effects (eg, dry mouth, blurred vision, urinary retention) from atropine content</td>
<td>Deliberate overdose and abuse are unlikely because of unpleasant anticholinergic effects. Overdose can be prevented by using the drug in recommended doses and only when required. Overdose can be treated with naloxone (Narcan) and supportive therapy.</td>
</tr>
<tr>
<td>d. With loperamide, abdominal cramps, dry mouth, dizziness, nausea, and vomiting</td>
<td>Abdominal cramps are the most common adverse effect. No serious adverse effects have been reported with recommended doses of loperamide. Overdose may be treated with naloxone, gastric lavage, and administration of activated charcoal.</td>
</tr>
<tr>
<td>e. With cholestyramine and colestipol, constipation, nausea, and abdominal distention</td>
<td>Adverse effects are usually minor and transient because these drugs are not absorbed from the GI tract.</td>
</tr>
<tr>
<td>f. With octreotide, diarrhea, headache, cardiac dysrhythmias, and injection site pain</td>
<td>These are commonly reported adverse effects.</td>
</tr>
<tr>
<td><strong>4. Observe for drug interactions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Few clinically significant drug interactions have been reported with commonly used antidiarrheal agents.</td>
</tr>
</tbody>
</table>
Answer: If Jan has received six 2.5-mg tablets of Lomotil, she has had a total of 15 mg, which is still under the 24-hour limit of Lomotil that was ordered (20 mg). You can safely give her another dose as ordered. Clarify the frequency specified in this order (after every bowel movement). In following this order, you might repeat doses before the previous dose has had a chance to absorb and work.

**How Can You Avoid This Medication Error?**

**Answer:** If Jan has received six 2.5-mg tablets of Lomotil, she has had a total of 15 mg, which is still under the 24-hour limit of Lomotil that was ordered (20 mg). You can safely give her another dose as ordered. Clarify the frequency specified in this order (after every bowel movement). In following this order, you might repeat doses before the previous dose has had a chance to absorb and work.

**Nursing Notes: Apply Your Knowledge**

**Answer:** First ask Mrs. Riley about her normal bowel pattern and her usual management strategies. Sometimes people think it is very important to have a bowel movement every day; thus, they take laxatives when they perceive they are constipated. Overuse or inappropriate use of laxatives can cause diarrhea. Treatment of this diarrhea can cause constipation, creating a cycle of bowel dysfunction. Try education first, explaining the importance of exercise and fiber in the diet. A bulk-forming laxative can be helpful in re-establishing a regular bowel pattern. Unless the diarrhea is severe, causing significant fluid loss and impaired ability to carry on daily activities, antidiarrheal medications should be avoided.

**SELECTED REFERENCES**


Antiemetics

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Identify clients at risk of developing nausea and vomiting.
2. Discuss guidelines for preventing, minimizing, or treating nausea and vomiting.
3. Differentiate the major types of antiemetic drugs.
4. Discuss characteristics, effects, and nursing process implications of selected antiemetic drugs.

Critical Thinking Scenario
Kelly Morgan, a 44-year-old woman, is having elective abdominal surgery. In the past, she has experienced significant postoperative nausea. Her physician orders lorazepam (Ativan), prochlorperazine (Compazine), and metoclopramide (Reglan) on a PRN basis to treat postoperative nausea and vomiting.

Reflect on:
- Factors that contribute to nausea and vomiting for the postoperative client.
- How each ordered antiemetic works to decrease nausea and vomiting.
- Why more than one antiemetic is ordered.
- How you will make decisions regarding which antiemetic medications to give Ms. Morgan.

OVERVIEW

Antiemetic drugs are used to prevent or treat nausea and vomiting. Nausea is an unpleasant sensation of abdominal discomfort accompanied by a desire to vomit. Vomiting is the expulsion of stomach contents through the mouth. Nausea may occur without vomiting, and vomiting may occur without prior nausea, but the two symptoms often occur together.

Nausea and vomiting are common symptoms experienced by virtually everyone. These symptoms may accompany almost any illness or stress situation. Causes of nausea and vomiting include the following:

1. Gastrointestinal (GI) disorders, including infection or inflammation in the GI tract, liver, gallbladder, or pancreas; impaired GI motility and muscle tone (eg, gastroparesis); and overeating or ingestion of foods or fluids that irritate the GI mucosa
2. Cardiovascular, infectious, neurologic, or metabolic disorders
3. Drug therapy. Nausea and vomiting are the most common adverse effects of drug therapy. Although the symptoms may occur with most drugs, they are especially associated with alcohol, aspirin, digoxin, anticancer drugs, antimicrobials, estrogen preparations, and opioid analgesics.
4. Pain and other noxious stimuli, such as unpleasant sights and odors
5. Emotional disturbances, physical or mental stress
6. Radiation therapy
7. Motion sickness
8. Postoperative status, which may include pain, impaired GI motility, and receiving various medications

Vomiting occurs when the vomiting center (a nucleus of cells in the medulla oblongata) is stimulated. Stimuli are relayed to the vomiting center from peripheral (eg, gastric mucosa, peritoneum, intestines, joints) and central (eg, cerebral cortex, vestibular apparatus of the ear, and neurons in the fourth ventricle, called the chemoreceptor trigger zone [CTZ]) sites. The vomiting center, CTZ, and GI tract contain benzodiazepine, cholinergic, dopamine, histamine, opiate, and serotonin receptors, which are stimulated by emetogenic drugs and toxins circulating in blood and cerebrospinal fluid. For example, in cancer chemotherapy, emetogenic drugs stimu-
late the CTZ, which then transmits signals to the vomiting center. In motion sickness, rapid changes in body motion stimulate receptors in the inner ear (vestibular branch of the auditory nerve, which is concerned with equilibrium), and nerve impulses are transmitted to the CTZ and the vomiting center.

When stimulated, the vomiting center initiates efferent impulses that cause closure of the glottis, contraction of abdominal muscles and the diaphragm, relaxation of the gastroesophageal sphincter, and reverse peristalsis, which moves stomach contents toward the mouth for ejection.

ANTIEMETIC DRUGS

Drugs used to prevent or treat nausea and vomiting belong to several different therapeutic classifications, and most have anticholinergic, antidopaminergic, antihistaminic, or antiserotonergic effects. In general, the drugs are more effective in prophylaxis than treatment. Most antiemetics prevent or relieve nausea and vomiting by acting on the vomiting center, CTZ, cerebral cortex, vestibular apparatus, or a combination of these. Major drugs are described in the following sections and in Drugs at a Glance: Antiemetic Drugs.

Phenothiazines

Phenothiazines, of which chlorpromazine (Thorazine) is the prototype, are central nervous system depressants used in the treatment of psychosis and psychotic symptoms in other disorders (see Chap. 9). These drugs have widespread effects on the body. Their therapeutic effects in nausea and vomiting (as in psychosis) are attributed to their ability to block dopamine from receptor sites in the brain and CTZ (antidopaminergic effects). When used as antiemetics, phenothiazines act on the CTZ and the vomiting center. Not all phenothiazines are effective antiemetics.

Phenothiazines are usually effective in preventing or treating nausea and vomiting induced by drugs, radiation therapy, surgery, and most other stimuli, but are usually ineffective in motion sickness. These drugs cause sedation; prochlorperazine (Compazine) and promethazine (Phenergan) are commonly used.

Antihistamines

Antihistamines are used primarily to prevent histamine from exerting its widespread effects on body tissues (see Chap. 48). Antihistamines used as antiemetic agents are the “classic” antihistamines or H1 receptor blocking agents (as differentiated from cimetidine and related drugs, which are H2 receptor blocking agents). The drugs are thought to relieve nausea and vomiting by blocking the action of acetylcholine in the brain (anticholinergic effects). Antihistamines may be effective in preventing and treating motion sickness. Not all antihistamines are effective as antiemetic agents.

Corticosteroids

Although corticosteroids are used mainly as antiallergic, anti-inflammatory, and antistress agents (see Chap. 24), they have antiemetic effects as well. The mechanism by which the drugs exert antiemetic effects is unknown; they may block prostaglandin activity in the cerebral cortex. Dexamethasone and methylprednisolone are commonly used in the management of chemotherapy-induced emesis, usually in combination with one or more other antiemetic agents. Regimens vary from a single dose before chemotherapy to doses every 4 to 6 hours for 24 to 48 hours. With this short-term use, adverse effects are mild (eg, euphoria, insomnia, mild fluid retention).

Benzodiazepine Antianxiety Drugs

These drugs (see Chap. 8) are not antiemetics, but they are often used in multidrug regimens to prevent nausea and vomiting associated with cancer chemotherapy. They produce relaxation and inhibit cerebral cortex input to the vomiting center. They are often prescribed for clients who experience anticipatory nausea and vomiting before administration of anticancer drugs. Lorazepam (Ativan) is commonly used.

5-Hydroxytryptamine3 (5-HT3 or Serotonin) Receptor Antagonists

Ondansetron (Zofran), granisetron (Kytril), and dolasetron (Anzemet) are used to prevent or treat moderate to severe nausea and vomiting associated with cancer chemotherapy, radiation therapy, and postoperative status. Some anticancer drugs apparently cause nausea and vomiting by combining with a subset of 5-HT receptors located in the CTZ and GI tract. These drugs antagonize the receptors and prevent their activation by emetogenic anticancer drugs.

These three drugs may be given intravenously or orally, and are metabolized in the liver. Adverse effects are usually mild to moderate, and common ones include diarrhea, headache, dizziness, constipation, muscle aches, and transient elevation of liver enzymes.

Ondansetron was the first drug of this group. Its half-life is 3 to 5.5 hours in most patients and 9 to 20 hours in patients with moderate or severe liver impairment. With oral drug, action begins in 30 to 60 minutes and peaks in about 2 hours. With intravenous (IV) drug, onset and peak of drug action are immediate.

Granisetron has a half-life of 6 hours with oral drug and 5 to 9 hours with IV drug; its half-life in patients with liver impairment is unknown. Action begins rapidly with IV
### Drugs at a Glance: Antiemetic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Adults</th>
<th>Children</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenothiazines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prochlorperazine (Compazine)</td>
<td>PO 5–10 mg 3 or 4 times daily (sustained-release capsule, 10 mg twice daily)</td>
<td>&gt;10 kg: PO 0.4 mg/kg/d, in 3 or 4 divided doses</td>
</tr>
<tr>
<td></td>
<td>IM 5–10 mg q3–4h to a maximum of 40 mg daily</td>
<td>IM 0.2 mg/kg as a single dose</td>
</tr>
<tr>
<td></td>
<td>Rectal suppository 25 mg twice daily</td>
<td>Rectal suppository 0.4 mg/kg/d, in 3 or 4 divided doses</td>
</tr>
<tr>
<td>Promethazine (Phenergan)</td>
<td>PO, IM, rectal suppository 12.5–25 mg q4–6h</td>
<td>&gt;3 mo: PO, IM, rectal suppository 0.25–0.5 mg/kg q4–6h</td>
</tr>
<tr>
<td><strong>Antihistamines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclizine (Marezine)</td>
<td>Motion sickness, PO 50 mg 30 min before departure, then q4–6h as needed, to a maximal daily dose of 200 mg</td>
<td>6–12 y: Motion sickness, PO 25 mg up to three times daily (maximal daily dose 75 mg)</td>
</tr>
<tr>
<td></td>
<td>IM 50 mg q4–6h as needed</td>
<td></td>
</tr>
<tr>
<td>Dimenhydrinate (Dramamine)</td>
<td>PO 50–100 mg q4–6h as needed (maximal dose, 400 mg in 24 h)</td>
<td>6–12 y: PO 25–50 mg q5–8h (maximal dose, 150 mg in 24 h)</td>
</tr>
<tr>
<td></td>
<td>IM 50 mg as needed</td>
<td>IM 1.25 mg/kg 4 times daily (maximal dose, 300 mg in 24 h)</td>
</tr>
<tr>
<td>Hydroxyzine (Vistaril)</td>
<td>IM 25–100 mg q4–6h as needed</td>
<td>IM 0.5 mg/lb q4–6h as needed</td>
</tr>
<tr>
<td>Meclozine (Antivert, Bonine)</td>
<td>Motion sickness, PO 25–50 mg 1 h before travel Vertigo 25–100 mg daily in divided doses</td>
<td>Dosage not established</td>
</tr>
<tr>
<td><strong>Prokinetic Agent</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metoclopramide (Reglan)</td>
<td>PO 10 mg 30 min before meals and at bedtime for 2–8 wk</td>
<td>Dosage not established</td>
</tr>
<tr>
<td></td>
<td>IV 2 mg/kg 30 min before injection of cisplatin and 2 h after injection of cisplatin, then 1–2 mg/kg q2–3h if needed, up to 4 doses</td>
<td></td>
</tr>
<tr>
<td><strong>5-HT3 (Serotonin) Receptor Antagonists</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dolasetron (Anzemet)</td>
<td>Prevention of PONV, PO 100 mg 2 h before surgery</td>
<td>2–16 y: Prevention of PONV, PO 1.2 mg/kg within 2 h before surgery. Maximum dose, 100 mg</td>
</tr>
<tr>
<td></td>
<td>Prevention or treatment of PONV, IV 12.5 mg as a single dose, 15 min before cessation of anesthesia or as soon as nausea or vomiting develops</td>
<td>Prevention or treatment of PONV, IV 0.35 mg/kg as a single dose, 15 min before cessation of anesthesia or as soon as nausea or vomiting develops. Maximum dose, 12.5 mg</td>
</tr>
<tr>
<td></td>
<td>Prevention of chemotherapy-induced nausea and vomiting, PO 100 mg within 1 h before chemotherapy; IV 1.8 mg/kg as a single dose approximately 30 min before chemotherapy</td>
<td>Prevention of chemotherapy-induced nausea and vomiting, PO 1.8 mg/kg within 1 h before chemotherapy, maximum dose, 100 mg; IV 1.8 mg/kg as a single dose approximately 30 min before chemotherapy, maximum dose 100 mg</td>
</tr>
<tr>
<td>Granisetron (Kytril)</td>
<td>Cancer chemotherapy, PO 1 mg twice daily, first dose approximately 1 h before emetogenic drug, second dose 12 h later, only on days receiving chemotherapy; IV 10 mg/kg infused over 5 min, 30 min before emetogenic drug, only on days receiving chemotherapy</td>
<td>2–16 y: IV 10 mg/kg</td>
</tr>
<tr>
<td>Ondansetron (Zofran)</td>
<td>Cancer chemotherapy, PO 8 mg 30 min before emetogenic drug, repeat in 8 h, then 8 mg q12h for 1–2 d</td>
<td>Cancer chemotherapy, &gt;12 y: PO 8 mg; 4–11 y: PO 4 mg 30 min before emetogenic drug, repeat in 4 and 8 h, then q8h for 1–2 d</td>
</tr>
<tr>
<td></td>
<td>IV 0.15 mg/kg for 3 doses (first 30 min before emetogenic drug, then at 4 and 8 h after the first dose) or a single dose of 32 mg 30 min before emetogenic drug</td>
<td>4–18 y: IV 0.15 mg/kg for 3 doses as for adults 2–12 y: ≤40 kg; IV 0.1 mg/kg; &gt;40 kg: IV 4 mg as a single dose</td>
</tr>
<tr>
<td></td>
<td>PONV, PO 16 mg 1 h before anesthesia or IV 4 mg just before anesthesia or postoperatively</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
injection and peaks in 30 to 45 minutes; action begins more slowly with oral drug and peaks in 60 to 90 minutes.

Dolasetron has a half-life of about 7 hours with both IV and oral drug, which is extended to 11 hours in patients with severe liver impairment. Action onset and peak occur rapidly with IV administration; onset is rapid and peak occurs in 1 to 2 hours with oral drug.

Miscellaneous Antiemetics

Dronabinol is a cannabinoid (derivative of marijuana) used in the management of nausea and vomiting associated with anticancer drugs and unrelieved by other drugs. Dronabinol causes the same adverse effects as marijuana, including psychiatric symptoms, has a high potential for abuse, and may cause a withdrawal syndrome when abruptly discontinued. As a result, it is a Schedule II drug under federal narcotic laws.

Withdrawal symptoms (eg, insomnia, irritability, restlessness, others) may occur if dronabinol is abruptly stopped. Onset occurs within 12 hours, with peak intensity within 24 hours and dissipation within 96 hours. These symptoms are most likely to occur with high doses or prolonged use. Sleep disturbances may persist for several weeks.

Metoclopramide (Reglan) is a prokinetic agent that increases GI motility and the rate of gastric emptying by increasing the release of acetylcholine from nerve endings in the GI tract (peripheral cholinergic effects). As a result, it can decrease nausea and vomiting associated with gastroparesis and other nonobstructive disorders characterized by gastric retention of food and fluids. Metoclopramide also has central antiemetic effects; it antagonizes the action of dopamine, a catecholamine neurotransmitter. Metoclopramide is given orally in diabetic gastroparesis and esophageal reflux. Large doses of the drug are given intravenously during chemotherapy with cisplatin (Platinol) and other emetogenic antineoplastic drugs.

With oral administration, action begins in 30 to 60 minutes and peaks in 60 to 90 minutes. With intramuscular (IM) use, action onset occurs in 10 to 15 minutes and peaks in 60 to 90 minutes. With IV use, action onset occurs in 1 to 3 minutes and peaks in 60 to 90 minutes. Adverse effects include sedation, restlessness, and extrapyramidal reactions (eg, akathisia, dystonia, symptoms of Parkinson’s disease).

Metoclopramide may increase the effects of alcohol and cyclosporine (by increasing their absorption) and decrease the effects of cimetidine and digoxin (by accelerating passage through the GI tract and decreasing time for absorption).

Phosphorated carbohydrate solution (Emetrol) is a hyperosmolar solution with phosphoric acid. It is thought to reduce smooth muscle contraction in the GI tract and is available over the counter.

Scopolamine, an anticholinergic drug (see Chap. 21), is effective in relieving nausea and vomiting associated with motion sickness. A transdermal patch is often used to prevent seasickness.

Indications for Use

Antiemetic drugs are indicated to prevent and treat nausea and vomiting associated with surgery, pain, motion sickness, cancer chemotherapy, radiation therapy, and other causes. Because of their adverse effects (eg, sedation, cognitive impairment), phenothiazines are mainly indicated when other antiemetic drugs are ineffective or only a few doses are needed.

Contraindications to Use

Antiemetic drugs are usually contraindicated when their use may prevent or delay diagnosis, when signs and symptoms of drug toxicity may be masked, and for routine use to prevent postoperative vomiting. Metoclopramide is relatively con-


**Herbal and Dietary Supplements**

**Ginger,** commonly used in cooking, is promoted for use in preventing nausea and vomiting associated with motion sickness, pregnancy, postoperative status, and other conditions. A few studies have investigated its antiemetic activity in humans. In one randomized, double-blind study (cited in Fetrow & Avila, p. 276), 60 women undergoing gynecologic surgery were given either 1000 mg of powdered ginger root orally, 10 mg of metoclopramide (Reglan) IV, or a placebo, 1½ hours before surgery. Results indicated that ginger was comparable to metoclopramide and that both treatments were more effective than placebo in preventing postoperative nausea and vomiting. Similar results were obtained in another study with 120 patients having gynecologic surgery; in this study, metoclopramide was given orally. Although these studies support the use of ginger, other studies do not. The general consensus seems to be that it is premature to recommend ginger for any therapeutic use until long-term, controlled studies are done.

**Nursing Process**

**Assessment**

Assess for nausea and vomiting.
- Identify risk factors (eg, digestive or other disorders in which nausea and vomiting are symptoms; drugs associated with nausea and vomiting).
- Interview regarding frequency, duration, and precipitating causes of nausea and vomiting. Also, question the client about accompanying signs and symptoms, characteristics of vomitus (amount, color, odor, presence of abnormal components, such as blood), and any measures that relieve nausea and vomiting. When possible, observe and measure the vomitus.

**Nursing Diagnoses**

- Deficient Fluid Volume related to uncontrolled vomiting
- Imbalanced Nutrition: Less Than Body Requirements related to impaired ability to ingest and digest food
- Altered Tissue Perfusion: Hypotension related to fluid volume depletion or antiemetic drug effect
- Risk for Injury related to adverse drug effects
- Deficient Knowledge related to nondrug measures to reduce nausea and vomiting and appropriate use of antiemetic drugs

**Planning/Goals**

*The client will:*
- Receive antiemetic drugs at appropriate times, by indicated routes
- Take antiemetic drugs as prescribed for outpatient use
- Obtain relief of nausea and vomiting
- Eat and retain food and fluids
- Have increased comfort
- Maintain body weight
- Maintain normal bowel elimination patterns
- Have fewer vomiting episodes and less discomfort with cancer chemotherapy or surgical procedures

**Interventions**

Use measures to prevent or minimize nausea and vomiting:
- Assist clients to identify situations that cause or aggravate nausea and vomiting.
- Avoid exposure to stimuli when feasible (eg, unpleasant sights and odors; excessive ingestion of food, alcohol, or nonsteroidal anti-inflammatory drugs).
- Because pain may cause nausea and vomiting, administration of analgesics before painful diagnostic tests and dressing changes or other therapeutic measures may be helpful.
- Administer antiemetic drugs 30 to 60 minutes before a nausea-producing event (eg, radiation therapy, cancer chemotherapy, or travel), when possible.
- Many oral drugs cause less gastric irritation, nausea, and vomiting if taken with or just after food. For any drug likely to cause nausea and vomiting, check reference sources to determine whether it can be given with food without altering beneficial effects.
- When nausea and vomiting occur, assess the client’s condition and report to the physician. In some instances, a drug (eg, digoxin, an antibiotic) may need to be discontinued or reduced in dosage. In other instances (eg, paralytic ileus, GI obstruction), preferred treatment is restriction of oral intake and nasogastric intubation.
- Eating dry crackers before rising in the morning may help prevent nausea and vomiting associated with pregnancy.
- Avoid oral intake of food, fluids, and drugs during acute episodes of nausea and vomiting. Oral intake may increase vomiting and risks of fluid and electrolyte imbalances.
- Minimize activity during acute episodes of nausea and vomiting. Lying down and resting quietly are often helpful.

Give supportive care during vomiting episodes:
- Give replacement fluids and electrolytes. Offer small amounts of food and fluids orally when tolerated and according to client preference.
- Record vital signs, intake and output, and body weight at regular intervals if nausea or vomiting occurs frequently.
- Decrease environmental stimuli when possible (eg, noise, odors). Allow the client to lie quietly in bed when nauseated. Decreasing motion may decrease stimulation of the vomiting center in the brain.
CHAPTER 63 ANTIEMETICS

PRINCIPLES OF THERAPY

Drug Selection

Choice of an antiemetic drug depends largely on the cause of nausea and vomiting and the client’s condition.

1. The 5-HT3 receptor antagonists (ondansetron, granisetron, and dolasetron) are usually the drugs of first choice for clients with chemotherapy-induced or postoperative nausea and vomiting. In chemotherapy, studies indicate greater effectiveness when combined with a corticosteroid (eg, dexamethasone).

2. Drugs with anticholinergic and antihistaminic properties are preferred for motion sickness. Antihistamines such as meclizine and dimenhydrinate are also useful for vomiting caused by labyrinthitis, uremia, or postoperative status.

3. For ambulatory clients, drugs causing minimal sedation are preferred. However, most antiemetic drugs cause some sedation in usual therapeutic doses.

4. Promethazine (Phenergan), a phenothiazine, is often used clinically for its antihistaminic, antiemetic, and sedative effects.

5. Although phenothiazines are effective antiemetic agents, they may cause serious adverse effects (eg, hypotension, sedation, anticholinergic effects, extrapyramidal reactions that simulate signs and symptoms of Parkinson’s disease). Consequently, phenothiazines other than promethazine usually should not be used, especially for pregnant, young, elderly, and postoperative clients, unless vomiting is severe and cannot be controlled by other measures.

6. Metoclopramide (Reglan) may be preferred when nausea and vomiting are associated with nonobstructive gastric retention.

Dosage and Administration Factors

Dosage and route of administration depend primarily on the reason for use.

1. Doses of phenothiazines are much smaller for antiemetic effects than for antipsychotic effects.

Evaluation

- Observe and interview for decreased nausea and vomiting.
- Observe and interview regarding ability to maintain adequate intake of food and fluids.
- Compare current weight with baseline weight.
- Observe and interview regarding appropriate use of antiemetic drugs.

CLIENT TEACHING GUIDELINES

Antiemetic Drugs

General Considerations

- Try to identify the circumstances that cause or aggravate nausea and vomiting and avoid them when possible.
- Drugs are more effective in preventing nausea and vomiting than in stopping them. Thus, they should be taken before the causative event when possible.
- Do not eat, drink, or take oral medications during acute vomiting episodes, to avoid aggravating the stomach upset.
- Lying down may help nausea and vomiting to subside; activity tends to increase stomach upset.
- Once your stomach has settled down, try to take enough fluids to prevent dehydration and potentially serious problems. Tea, broth, and gelatins are usually tolerated.
- Do not drive an automobile or operate dangerous machinery if drowsy from antiemetic drugs to avoid injury.
- If taking antiemetic drugs regularly, do not drink alcohol or take other drugs without consulting a health care provider. Several drugs interact with antiemetic agents, to increase adverse effects.
- Dronabinol, which is derived from marijuana and recommended only for nausea and vomiting associated with cancer chemotherapy, can cause dizziness, drowsiness, mood changes, and other mind-altering effects. You should avoid alcohol and other drugs that cause drowsiness. Also, do not drive or perform hazardous tasks requiring alertness, coordination, or physical dexterity, to decrease risks of injury.

Self- or Caregiver Administration

- Take the drugs as prescribed: Do not increase dosage, take more often, or take when drowsy, dizzy, or unsteady on your feet. Several of the drugs cause sedation and other adverse effects, which are more severe if too much is taken.
- To prevent motion sickness, take medication 30 minutes before travel and then every 4 to 6 hours, if necessary, to avoid or minimize adverse effects.
- Take or give antiemetic drugs 30 to 60 minutes before a nausea-producing event, when possible. This includes cancer chemotherapy, radiation therapy, painful dressings, or other treatments.
- Take dronabinol only when you can be supervised by a responsible adult because of its sedative and mind-altering effects.
2. Most antiemetic agents are available in oral, parenteral, and rectal dosage forms. As a general rule, oral dosage forms are preferred for prophylactic use and rectal or parenteral forms are preferred for therapeutic use.

3. Antiemetic drugs are often ordered PRN (as needed). As for any PRN drug, the client’s condition should be assessed before drug administration.

4. The use of antiemetic drugs is usually short term, from a single dose to a few days.

Timing of Drug Administration

When nausea and vomiting are likely to occur because of travel, administration of emetogenic anticancer drugs, diagnostic tests, or therapeutic procedures, an antiemetic drug should be given before the emetogenic event. Pretreatment usually increases client comfort and allows use of lower drug doses. It also may prevent aspiration and other potentially serious complications of vomiting.

Chemotherapy-Induced Nausea and Vomiting

Several anticancer drugs may cause severe nausea and vomiting and much discomfort for clients. Cisplatin is one of the most emetogenic drugs. For this reason, new antiemetics are usually compared with older drugs in the treatment of cisplatin-induced nausea and vomiting. Some general management guidelines include the following:

1. Chemotherapy may be given during sleeping hours.
2. Some clients may experience less nausea and vomiting if they avoid or decrease food intake for a few hours before scheduled chemotherapy.
3. Antiemetic drugs should be given before the emetogenic drug to prevent nausea and vomiting when possible. Most often, they are given intravenously for rapid effects and continued for 2 to 3 days. Continuous intravenous infusion may be more effective than intermittent bolus injections.
4. The 5-HT₃ receptor antagonists (eg, ondansetron) are usually considered the most effective antiemetics. They may be given in a single daily dose.
5. Metoclopramide, given intravenously in high doses, may be used alone or in combination with various other drugs. Diphenhydramine (Benadryl) may be given at the same time or PRN because high doses of metoclopramide often cause extrapyramidal effects (see Chap. 9).
6. Various combinations of antiemetic and sedative-type drugs are used, and research continues in this area. A commonly used regimen for prophylaxis is a corticosteroid (eg, dexamethasone 8 to 10 mg) and a 5-HT₃ receptor antagonist (eg, dolasetron 1.8 mg/kg, granisetron 10 mcg/kg, or ondansetron 16 to 32 mg).

Use in Children

Few studies of antiemetics have been done in children and their usage is not clearly defined. Thus, antiemetic drug therapy should be cautious and limited to prolonged vomiting of known etiology.

1. With the 5-HT₃ receptor antagonists, safety and efficacy of granisetron and dolasetron have not been established for children younger than 2 years of age, and there is little information available about the use of ondansetron in children 3 years of age and younger.
2. Phenothiazines are more likely to cause dystonias and other neuromuscular reactions in children than in adults. Promethazine is preferred because its action is more like that of the antihistamines than the phenothiazines. However, promethazine should not be used in children with hepatic disease, Reye’s syndrome, a history of sleep apnea, or a family history of sudden infant death syndrome. Excessive doses may cause hallucinations, convulsions, and sudden death.
3. Several antiemetics (eg, buclizine, cyclizine, scopolamine) are not recommended for use in children younger than 12 years of age.
4. Metoclopramide often causes extrapyramidal reactions (eg, dystonia) in children, even in small doses.
5. Dronabinol may be used to prevent or treat chemotherapy-induced nausea and vomiting in children who do not respond to other antiemetic drugs. However, the drug should be used cautiously in children because of its psychoactive effects.

Use in Older Adults

Most antiemetic drugs cause drowsiness, especially in older adults, and therefore should be used cautiously. Efforts should be made to prevent nausea and vomiting when possible. Older adults are at risk of fluid volume depletion and electrolyte imbalances with vomiting.

Nursing Notes: Apply Your Knowledge

Sally Roberts is being treated in an outpatient chemotherapy unit. She will be receiving cisplatin, a very emetogenic chemotherapeutic drug. The following drugs have been ordered IV 30 minutes before her treatment: ondansetron (Zofran), metoclopramide (Reglan), and lorazepam (Ativan). Explain the rationale for these orders.
Dronabinol should be used cautiously because older adults are usually more sensitive to the drug’s psychoactive effects than young or middle-aged adults.

**Use in Renal Impairment**

Several drugs are commonly used for clients with renal impairment who have nausea and vomiting.

1. Metoclopramide dosage should be reduced in clients with severe renal impairment to decrease drowsiness and extrapyramidal effects.
2. Phenothiazines are metabolized primarily in the liver, and dosage reductions are not usually needed for clients with renal impairment. However, these drugs have anticholinergic effects and can cause urinary retention and orthostatic hypotension. They also can cause extrapyramidal symptoms and sedation in clients with end-stage renal disease (ESRD).

**Use in Hepatic Impairment**

Most antiemetic drugs are metabolized in the liver and should be used cautiously in clients with impaired hepatic function.

1. With oral ondansetron, do not exceed an 8-mg dose; with IV use, a single, maximal daily dose of 8 mg is recommended.
2. Phenothiazines are metabolized in the liver and eliminated in urine. In the presence of liver disease (e.g., cirrhosis, hepatitis), metabolism may be slowed and drug elimination half-lives prolonged, with resultant accumulation and increased risk of adverse effects. Thus, the drugs should be used cautiously in clients with hepatic impairment. Cholestatic jaundice has been reported with promethazine.
3. Dronabinol normally undergoes extensive first-pass hepatic metabolism to active and inactive metabolites. Resultant plasma levels consist of approximately equal portions of the parent drug and the main active metabolite. In addition, the drug is eliminated mainly by biliary excretion, over several weeks. Thus, long-term use at recommended doses may lead to accumulation of toxic amounts of the drug and its metabolite, even in clients with normal liver function.

In clients with hepatic impairment, more of the parent drug and less of the active metabolite are likely to reach the bloodstream. Thus, therapeutic and adverse effects are less predictable. Also, impaired liver function can decrease metabolism and excretion in bile so that accumulation is likely and adverse effects may be increased and prolonged. The drug should be used very cautiously, if at all, in clients with moderate to severe hepatic impairment.

**Home Care**

Antiemetics are usually given orally or by rectal suppository in the home setting. The home care nurse may need to assess clients for possible causes of nausea and vomiting and assist clients and caregivers with appropriate use of the drugs and other interventions to prevent fluid and electrolyte depletion. Teaching safety precautions with sedating drugs may also be needed.

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>Antiemetics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td><strong>RATIONAL/EXPLANATION</strong></td>
</tr>
<tr>
<td>a. For prevention of motion sickness, give antiemetics 30 min before travel and q4–6h, if necessary.</td>
<td>To allow time for drug dissolution and absorption</td>
</tr>
<tr>
<td>b. For prevention of vomiting with cancer chemotherapy and radiation therapy, give antiemetic drugs 30–60 min before treatment.</td>
<td>Drugs are more effective in preventing than in stopping nausea and vomiting.</td>
</tr>
<tr>
<td>c. Inject intramuscular antiemetics deeply into a large muscle mass (e.g., gluteal area).</td>
<td>To decrease tissue irritation</td>
</tr>
<tr>
<td>d. In general, do not mix parenteral antiemetics in a syringe with other drugs.</td>
<td>To avoid physical incompatibilities</td>
</tr>
<tr>
<td>e. Omit antiemetic agents and report to the physician if the client appears excessively drowsy or is hypotensive.</td>
<td>To avoid potentiating adverse effects and central nervous system (CNS) depression</td>
</tr>
<tr>
<td>f. Mix intravenous (IV) ondansetron in 50 mL of 5% dextrose or 0.9% sodium chloride injection and infuse over 15 min.</td>
<td></td>
</tr>
</tbody>
</table>
### NURSING ACTIONS | RATIONALE/EXPLANATION
---|---
g. Mix granisetron in 20–50 mL of 5% dextrose or 0.9% sodium chloride injection and infuse over 5 min. | For oral administration to clients who cannot swallow tablets, dolasetron injection can be mixed in apple or apple–grape juice. Specific instructions should be obtained from a pharmacy. When kept at room temperature, the diluted oral solution should be used within 2 h.
h. With dolasetron:
   1. Give oral drug 1–2 h before chemotherapy; give IV drug about 30 min before chemotherapy. |  
   2. Give IV drug (up to 100-mg dose) by direct injection over 30 sec or longer or dilute up to 50 mL with 0.9% sodium chloride, 5% dextrose, or 5% dextrose and 0.45% sodium chloride and infuse over 15 min.

2. Observe for therapeutic effects
   a. Verbal reports of decreased nausea | Excessive sedation may occur with usual doses of antiemetics and is more likely to occur with high doses. This may be minimized by avoiding high doses and assessing the client’s level of consciousness before each dose.
   b. Decreased frequency or absence of vomiting

3. Observe for adverse effects
   a. Excessive sedation and drowsiness | These effects are common to many antiemetic agents and are more likely to occur with large doses.
   b. Anticholinergic effects—dry mouth, urinary retention | Most likely to occur with phenothiazines; may also occur with 5-HT₃ antagonists
   c. Hypotension, including orthostatic hypotension | These disorders may occur with phenothiazines and metoclopramide.
   d. Extrapyramidal reactions—dyskinesia, dystonia, akathisia, parkinsonism | These drugs are usually well tolerated, with mild to moderate adverse effects.
   e. With ondansetron and related drugs, observe for headache, diarrhea or constipation, dizziness, fatigue, and muscle aches. Bradycardia and hypotension may also occur.
   f. With dronabinol, observe for alterations in mood, cognition, and perception of reality, dysphoria, drowsiness, dizziness, anxiety, tachycardia, and conjunctivitis. | Tachycardia may be prevented with a beta-adrenergic blocking drug, such as propranolol (Inderal).

4. Observe for drug interactions
   a. Drugs that increase effects of antiemetic agents:
      1. CNS depressants (alcohol, sedative-hypnotics, anti-anxiety agents, other antihistamines or antipsychotic agents) | Additive CNS depression
      2. Anticholinergics (eg, atropine) | Additive anticholinergic effects. Some phenothiazines and antiemetic antihistamines have strong anticholinergic properties.
      3. Antihypertensive agents
   b. Drugs that alter effects of 5-HT₃ receptor antagonists:
      1. Atenolol and cimetidine increase effects of dolasetron | Additive hypotension
      2. Rifampin (and presumably other enzyme inducers) decreases effects of dolasetron and granisetron | The drugs decrease dolasetron metabolism and clearance.
      Enzyme inducers accelerate metabolism of affected drugs.
**Review and Application Exercises**

1. List common causes of nausea and vomiting or circumstances in which nausea and vomiting often occur.
2. How do antiemetic drugs prevent or relieve nausea and vomiting?
3. What are adverse effects of commonly used antiemetics?
4. Are antiemetics more effective if given before, during, or after nausea and vomiting?
5. Which antiemetics are usually given to control nausea and vomiting that occur with certain antineoplastic drugs?

---

**SELECTED REFERENCES**


section 11

Drugs Used in Special Conditions
chapter 64

Drugs Used in Oncologic Disorders

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Contrast normal and malignant cells.
2. Describe major types of antineoplastic drugs in terms of mechanism of action, indications for use, administration, and nursing process implications.
3. Discuss the rationales for using chemotherapeutic drugs in combination with each other, with surgical treatment, and with radiation therapy.
4. Discuss common and potentially serious adverse drug effects.
5. Describe pharmacologic and nonpharmacologic interventions to prevent or minimize adverse drug effects.
7. Manage or assist clients/caregivers in managing symptoms associated with chemotherapy regimens.

Critical Thinking Scenario
Georgia Sommers, a 39 year-old mother of 4, is diagnosed with breast cancer that was detected by routine mammography. She is recovering from a modified radical mastectomy when she comes to the clinic to discuss additional treatment with chemotherapy with the oncologist. He explains that she will receive combination therapy with three drugs on a cycle of every 4 weeks.

Reflect on:
- Possible reactions of Ms. Sommers to a diagnosis of cancer. What is the role of the nurse during the period of initial diagnosis?
- How will you assess Ms. Sommers concerns regarding chemotherapy?
- What are the benefits of combination (using more than one drug) therapy?
- What impact do you think chemotherapy might have on Ms. Sommers’ ability to function normally and meet normal demands of life?

OVERVIEW
Oncology is the study of malignant neoplasms and their treatment. Drugs used in oncologic disorders include those used to kill, damage, or slow the growth of cancer cells, and those used to prevent or treat adverse drug effects. Antineoplastic drug therapy, commonly called chemotherapy, is a major treatment modality for cancer, along with surgery and radiation therapy. To aid understanding of chemotherapy, selected characteristics of cancer are described below.

NORMAL AND MALIGNANT CELLS
Normal cells reproduce in response to a need for growth or tissue repair and stop reproduction when the need has been met. The normal cell cycle is the interval between the “birth” of a cell and its division into two daughter cells (Fig. 64–1). The daughter cells may then enter the resting phase (G0) or proceed through the reproductive cycle to form more new cells. Normal cells are also well differentiated in appearance and function and have a characteristic lifespan.

Malignant cells serve no useful purpose in the body. Instead, they occupy space and take blood and nutrients away from normal tissues. They grow in an uncontrolled fashion and avoid the restraints (eg, contact with other cells) that stop the growth of normal cells. They are undifferentiated, which means they have lost the structural and functional characteristics of the cells from which they originated. They are loosely connected, so that cells break off from the primary tumor and invade adjacent tissues. Loose cells also enter blood and lymph vessels, by which they circulate through the body.
The term cancer is used to describe many disease processes with the common characteristics of uncontrolled cell growth, invasiveness, and metastasis, as well as numerous etiologies, clinical manifestations, and treatments. One theory of carcinogenesis involves abnormal genes and cells, in which cancer may be caused by mutation of genes (abnormal structural changes in cellular genetic material), abnormal activation of genes that regulate cell growth and mitosis, or lack of tumor suppressor genes. The abnormal genes, called oncogenes, are

mutations of normal growth-regulating genes called proto-oncogenes, which are present in all body cells. Normally, proto-oncogenes are active for a brief period in the cell reproductive cycle. When exposed to carcinogens and genetically altered to oncogenes, however, they may operate continuously and cause abnormal, disordered, and unregulated cell growth. Unregulated cell growth and proliferation increases the probability of neoplastic transformation of the cell. Tumors of the breast, colon, lung, and bone have been linked to activation of oncogenes.

Tumor suppressor genes (anti-oncogenes) normally function to regulate and inhibit inappropriate cellular growth and proliferation. Abnormal tumor suppressor genes (ie, absent, damaged, mutated, or inactivated) may be inherited or result from exposure to carcinogens. When these genes are inactivated, a block to proliferation is removed and the cells begin unregulated growth. One tumor suppressor gene, p53, is present in virtually all normal tissues. When cellular deoxyribonucleic acid (DNA) is damaged, the p53 gene allows time for DNA repair and restricts proliferation of cells with abnormal DNA. Mutations of the p53 gene, a common genetic change in cancer, are associated with more than 90% of small-cell lung cancers and more than 50% of breast and colon cancers. Mutant p53 proteins can also form complexes with normal p53 proteins and inactivate the function of the normal suppressor gene.

Thus, activation of oncogenes and inactivation of anti-oncogenes probably both play roles in cancer development. Multiple genetic abnormalities are usually characteristic of cancer cells and may occur concurrently or sequentially.

Overall, evidence indicates that neoplastic transformation is a progressive process involving several generations of cells, with each new generation becoming more like malignant cells. Thus, malignancy probably results from a combination of factors experienced over a person’s lifetime. One factor may be a random cell mutation. However, mutations and malignancies are increased in people exposed to certain chemical, physical, or biologic factors, especially in large amounts or for long periods of time. Some carcinogens and risk factors are listed in Box 64–1. Once a cancer develops, factors influencing the growth rate include blood and nutrient supply, immune response, and hormonal stimulation (eg, in tumors of the breast, uterus, ovary, and prostate).

Classification of Malignant Neoplasms

Malignant neoplasms are classified according to the type of tissue involved, the rate of growth, and other characteristics. With the exception of the acute leukemias, they are considered chronic diseases.

Hematologic malignancies involve the bone marrow and lymphoid tissues; they include leukemias, lymphomas, and multiple myeloma. Leukemias are cancers of the bone marrow characterized by overproduction of abnormal white blood cells. The four main types are acute lymphocytic; acute myelo-
Despite extensive study, the cause of cancer is not clear. Because cancer is actually many diseases, many etiologic factors are probably involved. The factors that initiate the transformation of a single normal cell into a malignant cell and allow tumor growth are complex and overlapping, including the environmental and host factors described below.

**Environmental Carcinogens**

**Biologic carcinogens** include several infections, mainly viral. Viruses linked to cancer include Epstein-Barr (Burkitt lymphoma, Hodgkin’s disease); hepatitis B and C (liver cancer); herpes simplex II (cancer of cervix and vulva); human papilloma (cancer of the cervix, penis, oral cavity, esophagus, larynx); human immunodeficiency (Kaposi’s sarcoma); and human T-cell lymphotropic (T-cell leukemia or lymphoma). In addition, *Helicobacter pylori*, the bacterium that causes most gastric and duodenal ulcers, is also associated with gastric cancer and gastric lymphoma.

**Radiation** (eg, from sunlight and tanning beds) can damage DNA and cause mutations by changing cell structure or causing damage that interferes with transfer of genetic information during cell reproduction.

**Chemicals** include numerous substances that can damage cellular structures and interfere with cell replication and regulation.

**Industrial carcinogens** include benzene (bladder cancer), hydrocarbons (lung and skin cancer), polyvinyl chloride (liver cancer), and other substances used in the production of various products. Workers who manufacture the products and people who live in the plant vicinity are most likely to be affected. *Tobacco products* contain numerous carcinogens and are associated with cancers of the lungs, mouth, pharynx, larynx, esophagus, and bladder. Chemicals in cigarette smoke cause most lung cancer, in smokers and other people exposed to cigarette smoke. Children whose parents smoke have an increased risk of lung cancer, lymphomas, and acute lymphocytic leukemia. Smokeless tobacco products are also carcinogenic.

**Therapeutic drugs** are associated with both hematologic and solid neoplasms. The *alkylating antineoplastic drugs* are associated with leukemia, lymphoma, and other cancers. The drugs damage DNA and interfere with growth or replication of tumor cells. At the same time, they may damage the DNA of normal cells and transform some of them into malignant cells. Clients who are given these drugs and survive their illness have an increased risk of developing leukemia for 15 to 20 years. Antineoplastic drugs that cause bone marrow suppression or immunosuppression may also lead to secondary cancer. *Immunosuppressants* (eg, azathioprine and corticosteroids in renal transplant recipients) are associated with an increased risk of non-Hodgkin’s lymphoma, which may appear within months of transplantation, and for later skin cancer (eg, squamous cell carcinoma and malignant melanoma) and Kaposi’s sarcoma. Other clients on immunosuppressant drugs are at risk for lymphomas, squamous cell carcinoma of skin, and soft tissue sarcomas, but at lower rates than transplant recipients. For example, leukemia and solid tumors have been reported in clients who took azathioprine for rheumatoid arthritis.

**Sex hormones** are growth factors for certain cells. Estrogens are associated with cancer of the vagina in daughters of women who took the drugs during pregnancy and with endometrial cancer in women who took the drugs for menopausal symptoms. With breast cancer, endogenous estrogens are clearly causative, but the role of exogenous estrogens is less clear. *Oral contraceptives*, most of which contain an estrogen and a progestin, have been related to endometrial cancer and possibly to breast cancer. A progestin taken to prevent estrogen-induced endometrial cancer may increase risks of breast cancer. The antiestrogen tamoxifen, which is widely used to prevent or treat breast cancer, is associated with endometrial cancer. *Androgens and anabolic steroids*, especially with high doses and prolonged use, have been associated with hepatic neoplasms.

**Host Factors**

**Age.** Except for a few early childhood cancers, the risks of cancer increase with age.

**Alcohol use** may make carcinogens more soluble or enhance their tissue penetration. Cancers associated with alcohol use include those of the breast, head and neck, and liver.

**Diet.** A high-fat diet is associated with breast, colon, and prostate cancer; a low-fiber diet may increase risks of colon cancer.

**Sex.** Men are more likely to have leukemia and cancer of the urinary bladder, stomach, and pancreas; women are at risk of cancer of the breast, cervix, and endometrium. Lung and colon cancer occur equally in both sexes.

**Geography and ethnicity** are more environmental than hereditary or racial. Immigrants who adopt dietary and lifestyle habits of natives have similar risks and people who live in cities have greater risks because of greater exposure to air pollutants and other carcinogens. In the United States, African Americans have higher rates of multiple myeloma and cancers of the lung, prostate, esophagus, and pancreas than white people.

**Heredity.** In some families, there is a strong tendency toward development of cancer. For example, close relatives of premenopausal women with breast cancer are at high risk for breast cancer.

**Immunosuppression,** whether caused by disease or drug therapy, is associated with an increased risk of cancer. For example, clients with acquired immunodeficiency syndrome are at risk for Kaposi’s sarcoma, and clients who undergo organ transplantation and receive immunosuppressant drugs are at risk for lymphomas and skin cancers.

**Obesity** has been associated with increased risks of developing cancer of the breast, colon, endometrium, esophagus, liver, pancreas, and prostate gland.

**Previous cancer** is associated with a higher risk of other cancers in those who are treated and survive (eg, children with leukemia may develop other cancers; women with cancer in one breast have a higher risk of cancer in the other breast; female survivors of Hodgkin’s disease have a greater risk of developing breast cancer than the general population; patients who received radiation may develop bone and soft tissue sarcomas; those who received radiation to the neck area may develop thyroid cancer; and patients who received radiation to the head may develop brain tumors). Secondary cancers are usually attributed to treatments that damage DNA and eventually transform normal cells into malignant cells.

**Tobacco use** is a major lifestyle risk factor for cancers of the lung, esophagus, and head and neck.
**Antineoplastic Drugs**

### General Characteristics

1. Most drugs kill malignant cells by interfering with cell replication, with the supply and use of nutrients (eg, amino acids, purines, pyrimidines), or with the genetic materials in the cell nucleus (DNA or RNA).

2. The drugs act during the cell’s reproductive cycle (Fig. 64–2). Some, called cell cycle specific, act mainly during specific phases such as DNA synthesis or formation of the mitotic spindle. Others act during any phase of the cell cycle and are called cell cycle nonspecific.

3. Cytotoxic drugs are most active against rapidly dividing cells, both normal and malignant. Commonly damaged normal cells are those of the bone marrow, the lining of the gastrointestinal tract, and the hair follicles.

4. Each drug dose kills a specific percentage of cells. To achieve a cure, all malignant cells must be killed or reduced to a small number that can be killed by the person’s immune system.

5. Antineoplastic drugs may induce drug-resistant malignant cells. Mechanisms may include inhibiting drug uptake or activation, increasing the rate of drug inactivation, pumping the drug out of the cell before it can act, increasing cellular repair of DNA damaged by the drugs, or altering metabolic pathways and target enzymes of the drugs. Mutant cells also may emerge.

6. Most cytotoxic antineoplastic drugs are potential teratogens.

7. Most antineoplastic drugs are given orally or intravenously (IV); some are given topically, intrathecally, or by instillation into a body cavity.

8. A few drugs are available in liposomal preparations. These preparations increase drug concentration in malignant tissues and decrease concentration in normal tissues, thereby increasing effectiveness while decreasing toxicity. For example, liposomal doxorubicin and daunorubicin reduce the drugs’ cardiotoxic effects.

### Effects of Cancer on the Host

Effects vary according to the location and extent of the disease process. There are few effects initially. As the neoplasm grows, effects occur when the tumor becomes large enough to cause pressure, distortion, or deficient blood supply in surrounding tissues; interfere with organ function; obstruct ducts and organs; and impair nutrition of normal tissues. More specific effects include anemia, malnutrition, pain, infection, hemorrhagic tendencies, thromboembolism, hypercalcemia, cachexia, and various symptoms related to impaired function of affected organs and tissues.

---

**Grading and Staging of Malignant Neoplasms**

When a malignant neoplasm is identified, it is further “graded” according to the degree of malignancy and “staged” according to tissue involvement. Grades 1 and 2 are similar to the normal tissue of origin and show cellular differentiation; grades 3 and 4 are unlike the normal tissue of origin, less differentiated, and more malignant. Staging indicates whether the neoplasm is localized or metastasized and which organs are involved. These characteristics assist in treatment (eg, localized tumors are usually amenable to surgical or radiation therapy; metastatic disease requires systemic therapy).

---

**Figure 64–2  Cell cycle effects of cytotoxic antineoplastic drugs.**
Indications for Use

Cytotoxic antineoplastic drugs are used in the treatment of malignant neoplasms to cure the disease, relieve symptoms, or induce or maintain remissions (symptom-free periods that last for varying lengths of time). Chemotherapy is the treatment of choice for Hodgkin’s disease, leukemia, Wilms’ tumor, and Ewing’s sarcoma, but it is less effective in cancers of the lung, colon, and prostate gland.

In hematologic neoplasms, drug therapy is the treatment of choice because the disease is systemic rather than localized. In solid tumors, drug therapy is often used before or after surgery or radiation therapy.

Antineoplastic drugs are sometimes used in the treatment of nonmalignant conditions. For example, small doses of methotrexate (MTX) are used for rheumatoid arthritis and psoriasis.

Classifications

Cytotoxic antineoplastic drugs are usually classified in terms of their mechanisms of action (alkylating agents and antimetabolites) or their sources (plant alkaloids, antibiotics). Other drugs used in chemotherapy are immunostimulants (see Chap. 44), hormones, hormone inhibitors, and cytoprotectants.

Alkylating Agents

Alkylating agents include nitrogen mustard derivatives, nitrosoureas, and platinum compounds. Nitrogen mustard derivatives (eg, cyclophosphamide) interfere with cell division and the structure of DNA during all phases of the malignant cell cycle. As a result, they have a broad spectrum of activity. They are most effective in hematologic malignancies but also are used to treat breast, lung, and ovarian tumors. All of these drugs cause significant myelosuppression (bone marrow depression).

Nitrosoureas also interfere with DNA replication and RNA synthesis and may inhibit essential enzymatic reactions of cancer cells. They are cell cycle nonspecific and have been used in clients with gastrointestinal (GI), lung, and brain tumors. They are highly lipid soluble and therefore enter the brain and cerebrospinal fluid more readily than other antineoplastic drugs. They cause delayed bone marrow depression, with maximum leukopenia and thrombocytopenia occurring 5 to 6 weeks after drug administration. As a result, the drugs are given less often than other drugs, and complete blood counts (CBCs) are needed weekly for at least 6 weeks after a dose.

Platinum compounds are cell cycle–nonspecific agents that inhibit DNA, RNA, and protein synthesis. Cisplatin is widely used to treat both hematologic and solid cancers. Adverse effects include severe nausea and vomiting, nephrotoxicity, and ototoxicity. Carboplatin is most often used to treat endometrial and ovarian carcinomas and it produces bone marrow depression as a major adverse effect. Oxaliplatin (Eloxatin) was approved in 2002 for treatment of colorectal cancer in patients whose disease has recurred or worsened following standard therapy. It is used with 5-fluorouracil and leucovorin and given every 2 weeks by injection. Adverse effects include peripheral neuropathy, vomiting, diarrhea, and anemia.

Antimetabolites

Antimetabolites are substances that are structurally similar to normal metabolites. They are allowed to enter cancer cells because they are similar to nutrients needed by the cells for reproduction. Once inside the cell, the drugs may compete with, replace, or antagonize the normal metabolite. These actions deprive the cell of substances needed for formation of DNA or cause formation of abnormal DNA. The drugs are cell cycle specific because they exert their cytotoxic effects only during the S phase of the cell’s reproductive cycle, when DNA is being synthesized.

This group includes a folic acid antagonist (eg, methotrexate), purine antagonists (eg, mercaptopurine), and pyrimidine antagonists (eg, fluorouracil). These drugs have been used to treat many types of cancers, but they are most effective against rapidly growing tumors, and individual drugs vary in their effectiveness with different kinds of cancer. Toxic effects include bone marrow depression, mucositis and ulceration of the GI tract, and hair loss (alopecia).

Antitumor Antibiotics

These drugs (eg, doxorubicin) are active in all phases of the cell cycle and their cytotoxic effects are similar to those of the alkylating agents. They bind to DNA so that DNA and RNA transcription is blocked. Major toxicities are bone marrow depression and GI upset. Doxorubicin and related drugs also cause cardiotoxicity and tissue necrosis if extravasation occurs. Bleomycin may cause significant pulmonary toxicity. All of these drugs except bleomycin must be given IV.

Plant Alkaloids

Plant alkaloids include derivatives of camptothecin (eg, topotecan), podophyllotoxin (eg, etoposide), taxanes (eg, paclitaxel), and plants of the Vinca genus (eg, vincristine). These drugs vary in their characteristics and clinical uses.

Nursing Notes: Apply Your Knowledge

Your patient, Sally Moore is receiving an antineoplastic drug that is known to cause bone marrow depression, with a nadir (lowest point) 12 days after administration. Discuss the effects of bone marrow depression and appropriate nursing assessments. What teaching would be appropriate for this patient?
Camptothecins (also called DNA topoisomerase inhibitors) inhibit an enzyme required for DNA replication and repair. They have activity in several types of cancers, including colorectal, lung, and ovarian cancers. Dose-limiting toxicity is myelosuppression.

Podophyllotoxins act mainly in the G2 phase of the cell cycle and prevent mitosis. Etoposide is used mainly to treat testicular and small cell lung cancer; teniposide is used mainly for childhood acute lymphocytic leukemia. Dose-limiting toxicity is myelosuppression.

Taxanes inhibit cell division (antimitotic effects). They are used mainly for advanced breast and ovarian cancers. Dose-limiting toxicity is neutropenia.

Vinca alkaloids are cell cycle–specific agents that stop mitosis. These drugs have similar structures but different antineoplastic activities and adverse effects. Vincristine is used to treat Hodgkin’s disease, acute lymphoblastic leukemia, and non-Hodgkin’s lymphomas. Vinblastine is used to treat Hodgkin’s disease and choriocarcinoma; vinorelbine is used to treat non–small cell lung cancer. The drugs can cause severe tissue damage with extravasation (leaking of medication into soft tissues around the venipuncture site). In addition, vinblastine and vinorelbine are more likely to cause bone marrow depression, and vincristine is more likely to cause peripheral nerve toxicity.

Monoclonal Antibodies

Monoclonal antibodies (see Chap. 45) are produced from one cell line. For antitumor effects in cancer, they are designed to combine with growth factor receptors on malignant cell surfaces and inhibit tumor growth. Researchers also conjugate monoclonal antibodies with radioisotopes, toxins, chemotherapeutic agents, and drug-filled liposomes to increase their effectiveness and deliver antineoplastic drugs to specific areas of the body.

Cancer cells have more growth factor receptors than healthy cells. For example, 20% to 30% of women with breast cancer have an excessive number of HER2 receptors. A monoclonal antibody, trastuzumab (Herceptin), was developed specifically to bind with HER2 receptors and inhibit malignant cell growth. This antibody is used with other antineoplastic drugs to improve response in women with metastatic breast cancer. A major adverse effect is the development of congestive heart failure. The drug should not be used with doxorubicin or cyclophosphamide, because of increased risks of cardiovascular toxicity.

Other monoclonal antibodies available for clinical use include alemtuzumab (Campath IH), ibritumomab tiuxetan (Zevalin), gemtuzumab (Mylotarg), and rituximab (Rituxan). Alemtuzumab binds to molecules on T and B cells in lymphocytic leukemia. Major adverse effects include allergic reactions, leukopenia, and pancytopenia. Because of the high risk of infection, patients are treated prophylactically with antibiotic, antifungal, and antiviral drugs during and for 3 months after therapy. Gemtuzumab, an antibody conjugated with an antitumor antibiotic, is used to treat acute myeloid leukemia.

It may cause severe bone marrow depression. Ibritumomab is a conjugated antibody used to treat non-Hodgkin’s lymphoma. It is used with rituximab and may cause severe bone marrow depression and fatal infusion-related reactions. Rituximab is used to treat non-Hodgkin’s lymphoma. Common adverse effects include infusion reactions (hypoxia, acute respiratory distress syndrome, myocardial infarction, ventricular dysrhythmias, cardiogenic shock) and lymphopenia.

Miscellaneous Cytotoxic Agents

Miscellaneous agents vary in their sources, mechanisms of action, indications for use, and toxic effects. l-Asparaginase (Elspar) is an enzyme that inhibits cellular protein synthesis and reproduction by depriving cells of required amino acids. It is used to treat acute lymphocytic leukemia and can cause allergic reactions, including anaphylaxis. Pegaspargase (Onicaspar) is a modified formulation for people who are hypersensitive to Elspar. Hydroxyurea acts in the S phase of the cell cycle to impair DNA synthesis. It is used to treat leukemia, melanoma, and advanced ovarian cancer. A major adverse effect is myelosuppression. Procarbazine inhibits DNA, RNA, and protein synthesis. It is used to treat Hodgkin’s disease. It is a monoamine oxidase inhibitor and may cause hypertension if given with adrenergic drugs, tricyclic antidepressants, or foods with high tyramine content (see Chap. 10). Common adverse effects include leukopenia and thrombocytopenia.

Miscellaneous biotherapy agents include interferons (see Chap. 44) and imatinib (Gleevec). Interferon alfa (Roferon-A, Intron A) is used to treat hairy cell leukemia, chronic myelogenous leukemia, Kaposi’s sarcoma, and other cancers. Imatinib is a tyrosine kinase inhibitor that inhibits cell proliferation and increases cell death in chronic myelogenous leukemia. It is also used to treat a rare type of cancer called gastrointestinal stromal tumor and is being investigated for use in other cancers. It is given orally and its side effects include edema, cramps, nausea, and anemia.

Hormones and Hormone Inhibitors

Hormones interfere with protein synthesis and inhibit tumor growth in hormone-dependent tissues. The goal of therapy is control of tumor growth and palliation of symptoms rather than cure. Hormones are not cytotoxic and adverse effects are usually mild.

Sex hormones (estrogens, progestins, androgens) are useful in cancers of the breast, prostate gland, and other reproductive organs. Adrenal corticosteroids suppress formation and function of lymphocytes and therefore are most useful in the treatment of leukemia and lymphoma. They are also used for complications of cancer (eg, brain metastases, hypercalcemia) and with radiation therapy to reduce radiation-related edema in the mediastinum, brain, and spinal cord. Dexamethasone is commonly used in neurologic disorders.

Hormone inhibitors include aromatase inhibitors (eg, anastrozole) that inhibit estrogen synthesis, antiestrogens (eg, tamoxifen) that bind to estrogen receptors and block
estrogen action; amifostine, an adrenocorticosteroid-inhibiting agent that produces a “medical adrenalectomy”; and goserelin and leuprolide, which inhibit testosterone secretion in advanced prostatic cancer and inhibit production of estrogen in advanced breast cancer.

**INDIVIDUAL DRUGS**

Cytotoxic antineoplastic drugs are listed in Drugs at a Glance: Cytotoxic Antineoplastic Drugs; hormones and hormone inhibitors are listed in Drugs at a Glance: Antineoplastic Hormones and Hormone Inhibitors.

**CYTOPROTECTANT DRUGS**

Cytoprotectants reduce the adverse effects of cytotoxic drugs, which may be severe, debilitating, and life threatening (Box 64–2). Severe adverse effects may also limit drug dosage or frequency of administration, thereby limiting the effectiveness of chemotherapy. Several cytoprotectants are available to protect certain body tissues from one or more adverse effects and allow a more optimal dose and schedule of cytotoxic agents. To be effective, administration and scheduling must be precise in relation to administration of the cytotoxic agent. A cytoprotective agent does not prevent or treat all adverse effects of a particular cytotoxic agent and it may have adverse effects of its own.

Amifostine produces a metabolite that combines with cisplatin and ameliorates cisplatin-induced renal damage. Dexrazoxane decreases cardiac toxicity of doxorubicin. Erythropoietin, filgrastim, oprelvekin, and sargramostim are colony-stimulating factors (see Chap. 44) that stimulate the bone marrow to produce blood cells. Erythropoietin stimulates production of red blood cells and is used for anemia; oprelvekin stimulates production of platelets and is used to prevent thrombocytopenia; filgrastim and sargramostim stimulate production of white blood cells and are used to reduce neutropenia and the risk of severe infection. Leucovorin is used with high-dose MTX. Mesna is used with ifosfamide, which produces a metabolite that causes hemorrhagic cystitis. Mesna combines with and inactivates the metabolite and thereby decreases cystitis. Dosages and routes of administration for these medications are listed in Drugs at a Glance: Cytoprotective Agents.

**Nursing Process**

**Assessment**

Assess the client’s condition before chemotherapy is started and often during treatment. Useful information includes the type, grade, and stage of the tumor as well as the signs and symptoms of cancer. General manifestations include anemia, malnutrition, weight loss, pain, and infection; specific manifestations depend on the organs affected.

Assess for other diseases and organ dysfunctions (eg, cardiac, renal or hepatic) that influence response to chemotherapy.

Assess emotional status, coping mechanisms, family relationships, and financial resources. Anxiety and depression are common features during cancer diagnosis and treatment.

Assess laboratory test results before chemotherapy to establish baseline data and during chemotherapy to monitor drug effects:

- **Blood tests for tumor markers** (tumor-specific antigens on cell surfaces). Alpha-fetoprotein is a fetal antigen normally present during intrauterine and early postnatal life but absent in adulthood. Increased amounts may indicate hepatic or testicular cancer. Carcinoembryonic antigen (CEA) is secreted by several types of malignant cells (eg, CEA is present in approximately 75% of people with colorectal cancer). A rising level may indicate tumor progression and levels that are elevated before surgery and disappear after surgery indicate adequate tumor excision. If CEA levels rise later, it probably indicates tumor recurrence. In chemotherapy, falling CEA levels indicate effectiveness. Other tumor markers are immunoglobulins (elevated levels may indicate multiple myeloma) and prostate-specific antigen (elevated levels may indicate prostatic cancer).

- **Complete blood cell count** (CBC) to check for anemia, leukopenia, and thrombocytopenia because most cytotoxic antineoplastic drugs cause bone marrow depression. A CBC and white blood cell differential are done before each cycle of chemotherapy to determine dosage and frequency of drug administration, to monitor bone marrow function so fatal bone marrow depression does not occur, and to assist the nurse in planning care. For example, the client is very susceptible to infection when the leukocyte count is low, and bleeding is likely when the platelet count is low.

- **Other tests.** These include tests of kidney and liver function, serum calcium, uric acid, and others, depending on the organs affected by the cancer or its treatment.

**Nursing Diagnoses**

- Pain, nausea and vomiting, weakness, and activity intolerance related to disease process or chemotherapy
- Imbalanced Nutrition: Less Than Body Requirements related to disease process or chemotherapy
- Anxiety related to the disease, its possible progression, and its treatment
- Ineffective Family Coping related to illness and treatment of a family member
- Deficient Fluid Volume related to chemotherapy-induced nausea, vomiting, and diarrhea
- Risk for Injury: Infection related to drug-induced neutropenia; bleeding related to drug-induced thrombo-
cytopenia; stomatitis related to damage of GI mucosal cells
• Deficient Knowledge about cancer chemotherapy and managing adverse drug effects

Planning/Goals
The client will:
• Receive assistance in coping with the diagnosis of cancer
• Experience reduced anxiety and fear
• Receive chemotherapy accurately and safely
• Experience reduction of tumor size, change of laboratory values toward normal, or other therapeutic effects of chemotherapy
• Experience minimal bleeding, infection, nausea and vomiting, and other consequences of chemotherapy
• Maintain adequate food and fluid intake and body weight
• Receive assistance in activities of daily living when needed
• Be informed about community resources for cancer care (eg, hospice, Reach to Recovery, other support groups)

Interventions
Participate in and promote efforts to prevent cancer.
• Follow and promote the diet recommended by the American Cancer Society (ie, decrease fat; eat five or more servings of fruits and vegetables daily; increase intake of dietary fiber; minimize intake of salt-cured or smoked foods).
• Promote weight control. Obesity may contribute to the development of several cancers, including breast and endometrial cancer in women.
• Identify cancer-causing agents and strategies to reduce exposure to them when possible.
• Strengthen host defenses by promoting a healthful lifestyle (eg, good nutrition, adequate rest and exercise, stress management techniques, avoiding or minimizing alcohol and tobacco use).
• Avoid smoking cigarettes and being around smokers. Passive smoking increases risk of lung cancer in spouses of smokers and risks of brain, cervical, and acute lymphogenous leukemia in children of smokers.
• Minimize exposure to sunlight, use sunscreens liberally, and wear protective clothing to prevent skin cancer.

Participate in and promote cancer screening tests in nonsymptomatic people, especially those at high risk, to detect cancer before signs and symptoms occur. These tests include regular examination of breasts, testicles, and skin and tests for colon cancer such as hemoccult tests on stool and sigmoidoscopy. Early recognition of risk factors, premalignant tissue changes (dysplasia), biochemical tumor markers, and beginning malignancies may be lifesaving; early treatment can greatly reduce the suffering and problems associated with advanced cancer.

For clients receiving cytotoxic anticancer drugs, try to prevent or minimize the incidence and severity of adverse reactions (Box 64-2).

Provide supportive care to clients and families.

• Physiologic care includes pain management, comfort measures, and assistance with nutrition, hygiene, ambulation, and other activities of daily living as needed.
• Psychological care includes allowing family members or significant others to be with the client and participate in care when desired, and keeping clients and families informed.

Evaluation
• Monitor drug administration for accuracy.
• Observe and interview for therapeutic effects of chemotherapy.
• Compare current laboratory reports with baseline values for changes toward normal values.
• Compare weight and nutritional status with baseline values for maintenance or improvement.
• Observe and interview for adverse drug effects and interventions to prevent or manage them.

Observe and interview for adequate pain management and other symptom control.

PRINCIPLES OF THERAPY

Overview of Cancer Treatment

Most cancer treatment involves surgery, radiation, and chemotherapy. Optimal regimens maximize effectiveness (eg, attempt to eradicate tumor cells at primary, regional, and systemic sites) and minimize morbidity (eg, pain and treatment-related toxicity).

Surgery is used to excise small, localized tumors, which may be curative; to remove tumors that have been reduced in size by radiation therapy, chemotherapy, or both; and to treat complications of cancer, such as bowel obstruction. Surgical risks are greater in clients who have received preoperative radiation therapy or chemotherapy.

Radiation therapy is used to treat most types of cancer. It may be used alone to cure some malignancies such as Hodgkin’s disease or cervical cancer. It may be used with surgery to reduce the need for radical surgery (eg, in breast cancer, excision of small tumors plus radiation therapy is as effective as mastectomy). With soft tissue sarcomas of the limbs, wide excision plus radiation therapy can be used instead of amputation. Radiation is also used to eliminate local or regional malignant cells (eg, positive lymph nodes) that remain after surgery; with chemotherapy to cure or control growth of tumors; and as a palliative treatment in metastatic disease, such as relieving symptoms in clients with bone or brain involvement.

Cytotoxic chemotherapy is most effective when started before extensive tumor growth or when the tumor burden has been reduced by surgical excision or radiation therapy. Once metastasized, solid tumors become systemic diseases and are not accessible to surgical excision or radiation therapy.

(text continues on page 925)
## Drugs at a Glance: Cytotoxic Antineoplastic Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges*</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylating Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chlorambucil (Leukeran)</td>
<td>PO 0.1–0.2 mg/kg/d for 3–6 wk. Maintenance therapy, 0.03–0.1 mg/kg/d</td>
<td>Chronic lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s lymphomas</td>
<td>Bone marrow depression, hepatotoxicity, secondary leukemia</td>
</tr>
<tr>
<td><strong>Nitrogen Mustard Derivatives</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclophosphamide (Cytoxan)</td>
<td>Induction therapy, PO 1–5 mg/kg/d; IV 20–40 mg/kg in divided doses over 2–5 days. Maintenance therapy, PO 1–5 mg/kg daily</td>
<td>Hodgkin’s disease, non-Hodgkin’s lymphomas, leukemias, cancer of breast, lung or ovary, multiple myeloma, neuroblastoma</td>
<td>Bone marrow depression, nausea, vomiting, alopecia, hemorrhagic cystitis, hypersensitivity reactions, secondary leukemia or bladder cancer</td>
</tr>
<tr>
<td>Ifosfamide (Ifex)</td>
<td>IV 1.2 g/m²/d for 5 consecutive d. Repeat every 3 wk or after white blood cell and platelet counts return to normal after a dose.</td>
<td>Germ cell testicular cancer</td>
<td>Bone marrow depression, hemorrhagic cystitis, nausea and vomiting, alopecia, CNS depression, seizures</td>
</tr>
<tr>
<td>Melphalan (Alkeran)</td>
<td>PO 6 mg/d for 2–3 wk, then 28 drug-free days, then 2 mg daily; IV 16 mg/m² every 2 wk for 4 doses, then every 4 wk</td>
<td>Multiple myeloma, ovarian cancer</td>
<td>Bone marrow depression, nausea and vomiting, hypersensitivity reactions</td>
</tr>
<tr>
<td><strong>Nitrosoureas</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carmustine (BiCNU, Gliadel)</td>
<td>IV 150–200 mg/m² every 6 wk</td>
<td>Hodgkin’s disease, non-Hodgkin’s lymphomas, multiple myeloma, brain tumors</td>
<td>Bone marrow depression, nausea, vomiting</td>
</tr>
<tr>
<td>Lomustine (CCNU)</td>
<td>PO 130 mg/m² every 6 wk</td>
<td>Hodgkin’s disease, brain tumors</td>
<td>Nausea and vomiting, bone marrow depression</td>
</tr>
<tr>
<td><strong>Platinum Compounds</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carboplatin (Paraplatin)</td>
<td>IV infusion 360 mg/m² on day 1 every 4 wk</td>
<td>Palliation of ovarian cancer</td>
<td>Bone marrow depression, nausea and vomiting, nephrotoxicity</td>
</tr>
<tr>
<td>Cisplatin (Platinol)</td>
<td>IV 100 mg/m² once every 4 wk</td>
<td>Advanced carcinomas of testes, bladder, ovary</td>
<td>Nausea, vomiting, anaphylaxis, nephrotoxicity, bone marrow depression, ototoxicity</td>
</tr>
<tr>
<td>Oxaliplatin (Eloxatin)</td>
<td>IV infusion 85 mg/m² every 2 wk</td>
<td>Advanced colon cancer</td>
<td>Anaphylaxis, anemia, increased risk of bleeding or infection</td>
</tr>
<tr>
<td><strong>Antimetabolites</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capecitabine (Xeloda)</td>
<td>PO 1250 mg/m² q12h for 2 wk, then a rest period of 1 wk, then repeat cycle</td>
<td>Metastatic breast cancer, colorectal cancer</td>
<td>Bone marrow depression, nausea, vomiting, diarrhea, mucositis</td>
</tr>
<tr>
<td>Cladribine (Leustatin)</td>
<td>IV infusion 0.09 mg/kg/d for 7 consecutive d</td>
<td>Hairy cell leukemia</td>
<td>Bone marrow depression, nausea, vomiting</td>
</tr>
<tr>
<td>Cytarabine (Cytosar-U)</td>
<td>IV infusion 100 mg/m²/d for 7 d</td>
<td>Leukemias of adults and children</td>
<td>Bone marrow depression, nausea, vomiting, anaphylaxis, mucositis, diarrhea</td>
</tr>
<tr>
<td>Fludarabine (Fludara)</td>
<td>IV 25 mg/m²/d for 5 consecutive d; repeat every 28 d</td>
<td>Chronic lymphocytic leukemia</td>
<td>Bone marrow depression, nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td>Fluorouracil (5-FU) (Adrucil, Efudex, Fluoroplex)</td>
<td>IV 12 mg/kg/d for 4 d, then 6 mg/kg every other day for 4 doses</td>
<td>Carcinomas of the breast, colon, stomach, and pancreas</td>
<td>Bone marrow depression, nausea, vomiting, mucositis, pain, pruritus, burning at site of application</td>
</tr>
<tr>
<td>Gemcitabine (Gemzar)</td>
<td>IV 1000 mg/m² once weekly up to 7 wk or toxicity, withhold for 1 wk, then once weekly for 3 wk and withhold for 1 wk</td>
<td>Lung and pancreatic cancer</td>
<td>Bone marrow depression, nausea, vomiting, flu-like symptoms, skin rash</td>
</tr>
<tr>
<td>Mercaptopurine (Purinethol) (MTX) (Rheumatrex)</td>
<td>PO 2.5 mg/kg/d (100–200 mg for average adult)</td>
<td>Acute and chronic leukemias</td>
<td>Bone marrow depression, nausea, vomiting, mucositis</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Acute leukemia in children, induction, PO, IV 3 mg/m²/d; maintenance, PO 30 mg/m² twice weekly</td>
<td>Leukemias, non-Hodgkin’s lymphomas, osteosarcoma, chorionicarcinoma of testes, cancers of breast, lung, head and neck</td>
<td>Bone marrow depression, nausea, vomiting, mucositis, diarrhea, fever, alopecia</td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Cytotoxic Antineoplastic Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges *</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antitumor Antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bleomycin (Blenoxane)</td>
<td>IV, IM, SC 0.25–0.5 units/kg once or twice weekly</td>
<td>Squamous cell carcinoma, Hodgkin’s and non-Hodgkin’s lymphomas, testicular carcinoma</td>
<td>Pulmonary toxicity, mucositis, alopecia, nausea, vomiting, hypersensitivity reactions</td>
</tr>
<tr>
<td>Dactinomycin (Actinomycin D, Cosmegen)</td>
<td>IV 15 mcg/kg/d for 5 d and repeated every 2–4 wk</td>
<td>Rhabdomyosarcoma, Wilms’ tumor, choriocarcinoma, testicular carcinoma, Ewing’s sarcoma</td>
<td>Bone marrow depression, nausea, vomiting. Extravasation may lead to tissue necrosis.</td>
</tr>
<tr>
<td>Daunorubicin conventional</td>
<td>IV 25–45 mg/m² daily for 3 d every 3–4 wk</td>
<td>Acute leukemias, lymphomas</td>
<td>Same as doxorubicin, below</td>
</tr>
<tr>
<td>Daunorubicin liposomal (DaunoXome)</td>
<td>IV infusion, 40 mg/m² every 2 wk</td>
<td>AIDS-related Kaposi’s sarcoma</td>
<td>Bone marrow depression, nausea, vomiting</td>
</tr>
<tr>
<td>Doxorubicin conventional (Adriamycin)</td>
<td>Adults, IV 60–75 mg/m² every 21 d Children, IV 30 mg/m² daily for 3 d, repeated every 4 wk</td>
<td>Acute leukemias, lymphomas, carcinomas of breast, lung, and ovary</td>
<td>Bone marrow depression, alopecia, mucositis, GI upset, cardiomyopathy. Extravasation may lead to tissue necrosis.</td>
</tr>
<tr>
<td>Doxorubicin liposomal (Doxil)</td>
<td>IV infusion, 20 mg/m², once every 3 wk</td>
<td>AIDS-related Kaposi’s sarcoma</td>
<td>Bone marrow depression, nausea, vomiting, fever, alopecia</td>
</tr>
<tr>
<td>Epirubicin (Ellence)</td>
<td>IV infusion 120 mg/m² every 3–4 wk</td>
<td>Breast cancer</td>
<td>Cardiotoxicity</td>
</tr>
<tr>
<td>Idarubicin (Idamycin)</td>
<td>IV injection 12 mg/m²/d for 3 d, with cytarabine</td>
<td>Acute myeloid leukemia</td>
<td>Same as doxorubicin, above</td>
</tr>
<tr>
<td>Mitomycin (Mutamycin)</td>
<td>IV 20 mg/m² every 6–8 wk</td>
<td>Metastatic carcinomas of stomach and pancreas</td>
<td>Bone marrow depression, nausea, vomiting. Extravasation may lead to tissue necrosis.</td>
</tr>
<tr>
<td>Mitoxantrone (Novantrone)</td>
<td>IV infusion 12 mg/m² on days 1–3, for induction of remission in leukemia</td>
<td>Acute nonlymphocytic leukemia, prostate cancer</td>
<td>Bone marrow depression, congestive heart failure, nausea</td>
</tr>
<tr>
<td>Pentostatin (Nipent)</td>
<td>IV 4 mg/m² every other week</td>
<td>Hairy cell leukemia unresponsive to alpha-interferon</td>
<td>Bone marrow depression, hepatotoxicity, nausea, vomiting</td>
</tr>
<tr>
<td>Vairubicin (Valstar)</td>
<td>Intravesically, 800 mg once weekly for 6 wk</td>
<td>Bladder cancer</td>
<td>Dysuria, urgency, frequency, bladder spasms, hematuria</td>
</tr>
<tr>
<td><strong>Plant Alkaloids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CAMPTOTHECANS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irinotecan (Camptosar)</td>
<td>IV infusion, 125 mg/m² once weekly for 4 wk, then a 2-wk rest period; repeat regimen</td>
<td>Metastatic cancer of colon or rectum</td>
<td>Bone marrow depression, diarrhea</td>
</tr>
<tr>
<td>Topotecan (Hycamtin)</td>
<td>IV infusion 1.5 mg/m² daily for 5 consecutive days every 21 d</td>
<td>Advanced ovarian cancer, small-cell lung cancer</td>
<td>Bone marrow depression, nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td><strong>PODOPHYLLOTOXINS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etoposide (VePesid)</td>
<td>IV 50–100 mg/m²/d on days 1–5, or 100 mg/m²/d on days 1, 3, and 5, every 3–4 wk PO 2 times the IV dose</td>
<td>Testicular cancer, small-cell lung cancer</td>
<td>Bone marrow depression, allergic reactions, nausea, vomiting, alopecia</td>
</tr>
<tr>
<td>Teniposide (Vumon)</td>
<td>IV infusion 165 mg/m² twice weekly for 8–9 doses</td>
<td>Acute lymphocytic leukemia in children</td>
<td>Same as etoposide, above</td>
</tr>
<tr>
<td><strong>TAXANES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Docetaxel (Taxotere)</td>
<td>IV infusion 60–100 mg/m², every 3 wk</td>
<td>Advanced breast cancer, non–small cell lung cancer</td>
<td>Bone marrow depression, nausea, vomiting, hypersensitivity reactions</td>
</tr>
<tr>
<td>Paclitaxel (Taxol)</td>
<td>IV infusion 135 mg/m² every 3 wk</td>
<td>Advanced ovarian cancer, advanced breast cancer, non–small cell lung cancer, AIDS-related Kaposi’s sarcoma</td>
<td>Bone marrow depression, allergic reactions, hypotension, bradycardia, nausea, vomiting</td>
</tr>
<tr>
<td><strong>VINCA ALKALOIDS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vinblastine (Velban)</td>
<td>Adults, IV 3.7–11.1 mg/m² (average 5.5–7.4 mg/m²) weekly Children, IV 2.5–7.5 mg/m² weekly</td>
<td>Metastatic testicular carcinoma, Hodgkin’s disease</td>
<td>Bone marrow depression, nausea, vomiting. Extravasation may lead to tissue necrosis.</td>
</tr>
<tr>
<td>Vincristine (Oncovin)</td>
<td>Adults, IV 1.4 mg/m² weekly Children, IV 2 mg/m² weekly</td>
<td>Hodgkin’s and other lymphomas, acute leukemia, neuroblastoma, Wilms’ tumor</td>
<td>Peripheral neuropathy. Extravasation may lead to tissue necrosis.</td>
</tr>
</tbody>
</table>

(continued)
Drugs at a Glance: Cytotoxic Antineoplastic Drugs (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Routes and Dosage Ranges*</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vinorelbine (Navelbine)</td>
<td>IV injection 30 mg/m² once weekly</td>
<td>Non–small cell lung cancer</td>
<td>Bone marrow depression, peripheral neuropathy. Extravasation may lead to tissue necrosis.</td>
</tr>
</tbody>
</table>

Monoclonal Antibodies

<table>
<thead>
<tr>
<th>GENERIC/TRADE NAME</th>
<th>Routes and Dosage Ranges</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gemtuzumab ozoγamicin (Mylotarg)</td>
<td>IV infusion, 9 mg/m²; for 2 doses, 14 d apart</td>
<td>Acute myeloid leukemia</td>
<td>Chills, fever, nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td>Ibritumomab tiuxetan (Zevalin)</td>
<td>See literature</td>
<td>Non-Hodgkin’s lymphoma, with rituximab</td>
<td>Severe or fatal infusion reaction, severe bone marrow depression, hypersensitivity reactions, cardiac dysrhythmias</td>
</tr>
<tr>
<td>Rituximab (Rituxan)</td>
<td>IV infusion, 375 mg/m² once weekly for 4 doses</td>
<td>Non-Hodgkin’s lymphoma</td>
<td></td>
</tr>
<tr>
<td>Trastuzumab (Herceptin)</td>
<td>IV infusion, 4 mg/kg, then 2 mg/kg once weekly</td>
<td>Metastatic breast cancer</td>
<td>Cardiotoxicity (dyspnea, edema, heart failure)</td>
</tr>
</tbody>
</table>

Miscellaneous Agents

<table>
<thead>
<tr>
<th>GENERIC/TRADE NAME</th>
<th>Routes and Dosage Ranges</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-Asparaginase (Elspar)</td>
<td>IV 1000 IU/kg/d for 10 d</td>
<td>Acute lymphocytic leukemia</td>
<td>Hypersensitivity reactions, including anaphylaxis</td>
</tr>
<tr>
<td>Hydroxyurea (Hydrea)</td>
<td>PO 80 mg/kg as a single dose every third day or 20–30 mg/kg as a single dose daily</td>
<td>Chronic myelocytic leukemia, melanoma, ovarian cancer, head and neck cancer</td>
<td>Bone marrow depression, nausea, vomiting, peripheral neuropathy</td>
</tr>
<tr>
<td>Levamisole (Ergamisol)</td>
<td>PO 50 mg q8h for 3 d every 2 wk</td>
<td>Colon cancer, with fluorouracil Hodgkin’s disease</td>
<td>Nausea, vomiting, diarrhea</td>
</tr>
<tr>
<td>Procarbazine (Matulane)</td>
<td>PO 2–4 mg/kg/d for 1 wk, then 4–6 mg/kg/d</td>
<td></td>
<td>Bone marrow depression, mucositis, CNS depression</td>
</tr>
<tr>
<td>Temozolomide (Temodar)</td>
<td>PO 150 mg/m² once daily for 5 d, then 200 mg/m² every 28 d</td>
<td>Brain tumors</td>
<td>Bone marrow depression</td>
</tr>
</tbody>
</table>

*Dosages may vary significantly or change often, according to use in different types of cancer and in different combinations. AIDS, acquired immunodeficiency syndrome.

Drugs at a Glance: Antineoplastic Hormones and Hormone Inhibitors

<table>
<thead>
<tr>
<th>GENERIC/TRADE NAME</th>
<th>Routes and Dosage Ranges</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fulvestrant (Faslodex)</td>
<td>IM 250 mg once monthly (one 5-mL or two 2.5-mL injections)</td>
<td>Advanced breast cancer in postmenopausal women</td>
<td>GI upset, hot flashes, injection site reactions</td>
</tr>
<tr>
<td>Tamoxifen (Nolvadex)</td>
<td>PO 20 mg once or twice daily</td>
<td>Breast cancer: after surgery or radiation; prophylaxis in high-risk women; and treatment of metastatic disease</td>
<td>Hot flashes, nausea, vomiting, vaginal discharge, risk of endometrial cancer in nonhysterectomized women</td>
</tr>
<tr>
<td>Toremifene (Fareston)</td>
<td>PO 60 mg once daily</td>
<td>Metastatic breast cancer in postmenopausal women</td>
<td>Hot flashes, nausea, hypercalcemia, tumor flare</td>
</tr>
</tbody>
</table>

Aromatase Inhibitors

<table>
<thead>
<tr>
<th>GENERIC/TRADE NAME</th>
<th>Routes and Dosage Ranges</th>
<th>Clinical Uses</th>
<th>Adverse Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anastrazole (Arimidex)</td>
<td>PO 1 mg once daily</td>
<td>Advanced breast cancer in postmenopausal women</td>
<td>Nausea, hot flashes, edema</td>
</tr>
<tr>
<td>Exemestane (Aromasin)</td>
<td>PO 25 mg once daily</td>
<td>Advanced breast cancer in postmenopausal women</td>
<td>Hot flashes, nausea, depression, insomnia, anxiety, dyspnea, pain</td>
</tr>
<tr>
<td>Letrozole (Femara)</td>
<td>PO 2.5 mg once daily</td>
<td>Advanced breast cancer</td>
<td>Nausea, hot flashes</td>
</tr>
<tr>
<td>Goserelin (Zoladex)</td>
<td>SC implant, 3.6 mg every 28 d or 10.8 mg every 12 wk</td>
<td>Advanced prostatic or breast cancer, endometriosis</td>
<td>Hot flashes, transient increase in bone pain</td>
</tr>
<tr>
<td>Leuproline (Eligard, Lupron, Viadur)</td>
<td>SC 7.5 mg/mo; IM 7.5 mg/mo, 22.5 mg/3 mo, or 30 mg/4 mo</td>
<td>Advanced prostatic cancer</td>
<td>Same as for goserelin, above</td>
</tr>
<tr>
<td>Triptorelin (Trelstar LA, Trelstar Depot)</td>
<td>IM 3.75 mg/28 d or 11.25 mg/3 mo</td>
<td>Advanced prostatic cancer</td>
<td>Same as for goserelin and leuproline, above</td>
</tr>
</tbody>
</table>
Complications may range from minor to life threatening. Systematic efforts toward prevention or early detection and treatment are needed.

- **Nausea** and **vomiting** commonly occur. They are usually treated with antiemetics (see Chap. 63), which are most effective when started before chemotherapy and continued on a regular schedule for 24 to 48 hours afterward. An effective regimen is a serotonin receptor antagonist (eg, ondansetron) and a corticosteroid (eg, dexamethasone), given orally or intravenously (IV). Other measures include a benzodiazepine (eg, lorazepam) for anticipatory nausea and vomiting and limiting oral intake for a few hours.

- **Alopecia** occurs with several drugs, including cyclophosphamide, doxorubicin, methotrexate, and vincristine. Complete hair loss can be psychologically devastating, especially for women. Helpful measures include the following:
  - Counsel clients that hair loss is likely but that it is temporary and that hair may grow back a different color and texture.
  - Suggest the purchase of wigs, hats, and scarves before hair loss is expected to occur.
  - Suggest using a mild shampoo and avoiding rollers, hair dryers, permanent waves, hair coloring, and other treatments that damage the hair and may increase hair loss.

- **Mucositis** (also called stomatitis) occurs often with the antimetabolites, antibiotics, and plant alkaloids and usually lasts 7 to 10 days. It may interfere with nutrition; lead to oral ulcerations, infections, and bleeding; and cause pain. Nurse or client interventions to minimize or treat mucositis include:
  - Brush the teeth after meals and at bedtime with a soft toothbrush and floss once daily with unwaxed floss. Stop brushing and flossing if the platelet count drops below 20,000/mm³ because gingival bleeding is likely. Teeth may then be cleaned with soft, sponge-tipped or cotton-tipped applicators.
  - Rinse the mouth several times daily, especially before meals (to decrease unpleasant taste and increase appetite) and after meals (to remove food particles that promote growth of microorganisms). One suggested solution is 1 tsp of table salt and 1 tsp of baking soda in 1 quart of water.
  - Encourage the client to drink fluids. Systemic dehydration and local dryness of the oral mucosa contribute to the development and progression of mucositis. Pain and soreness contribute to dehydration. Fluids usually tolerated include tea, carbonated beverages, ices (eg, popsicles), and plain gelatin desserts. Fruit juices may be diluted with water, ginger ale, Sprite, or 7-Up to decrease pain, burning, and further tissue irritation. Drinking fluids through a straw may be more comfortable, because this decreases contact of fluids with painful ulcerations.
  - Encourage the client to eat soft, bland, cold, nonacidic foods. Although individual tolerances vary, it is usually better to avoid highly spiced or rough foods.
  - Remove dentures entirely or for at least 8 hours daily because they may irritate oral mucosa.

- **Fatigue**, which may be profound, is often caused or aggravated by anemia and can be prevented or treated with administration of erythropoietin. An adequate diet and light to moderate exercise, as tolerated, may also be helpful.

- **Anorexia** interferes with nutrition. Well-balanced meals, with foods the client is able and willing to eat, and nutritional supplements, to increase intake of protein and calories, are helpful.

- **Infection** is common because the disease and its treatment lower host resistance to infection.
  - Help the client maintain a well-balanced diet. Oral hygiene and analgesics before meals may increase food intake. High-protein, high-calorie foods and fluids can be given between meals. Nutritional supplements can be taken with or between meals. Provide fluids with high nutritional value (eg, milkshakes or nutritional supplements) if the client can tolerate them and has an adequate intake of water and other fluids.
  - Instruct the client to avoid exposure to infection by avoiding crowds, anyone with a known infection, and contact with fresh flowers, soil, animals, or animal excrement.
  - Frequent and thorough handwashing by the client and everyone involved in his or her care is necessary to reduce exposure to pathogenic microorganisms.
  - The client should take a bath daily and put on clean clothes. In addition, the perineal area should be washed with soap and water after each urination or defecation.
  - When venous access devices are used, take care to prevent them from becoming sources of infection. For implanted catheters, inspect and cleanse around exit sites according to agency policies and procedures. Use strict sterile technique when changing dressings or flushing the catheters. For peripheral venous lines, the same principles of care apply, except that sites should be changed every 3 days or if signs of phlebitis occur.
  - Avoid indwelling urinary catheters when possible. When they are necessary, cleanse the perineal area with soap and water at least once daily and provide sufficient fluids to ensure an adequate urine output.
  - If fever occurs, especially in a neutropenic client, possible sources of infection are usually cultured and antibiotics are started immediately.
  - Severe neutropenia can be prevented or its extent and duration minimized by administering filgrastim or sargramostim to stimulate the bone marrow to produce leukocytes. A protective environment may be needed to decrease exposure to pathogens.

- **Bleeding** may be caused by thrombocytopenia and may occur spontaneously or with minor trauma. Precautions should be instituted if the platelet count drops to 50,000/mm³ or below. Measures to avoid bleeding include:
  - Giving oprelvekin to stimulate platelet production and prevent thrombocytopenia.

(continued)
Chemotherapy regimens should be managed by oncologists experienced in use of the drugs; the consequences of inappropriate or erroneous drug therapy may be fatal for clients (from the disease or the treatment).

Adjuvant chemotherapy is used after surgery or radiation to destroy or reduce microscopic metastases. It is often used in the treatment of clients with carcinomas of the breast, colon, lung, ovaries, or testes. Palliative chemotherapy is used in advanced cancer to relieve symptoms and treat or prevent complications.

### Drug Selection Factors

Factors that determine drug choice include which drugs have been effective in similar types of cancer; primary tumor sites;...
effective drug combinations include the following:

- Each drug should have activity against the type of tumor being treated.
- Each drug should act by a different mechanism. Drugs can be combined to produce sequential or concurrent inhibition. For example, one drug can be chosen to damage the DNA, RNA, or proteins of the malignant cell, and another drug can be chosen to prevent their repair or synthesis.
- Drugs should act at different times in the reproductive cycle of the malignant cell. For example, more malignant cells are likely to be destroyed by combining cell cycle–specific and cell cycle–nonspecific drugs. The first group kills only dividing cells; the second group kills cells during any part of the life cycle, including the resting phase.
- Consecutive doses kill a percentage of the tumor cells remaining after earlier doses and further decrease the tumor burden.
- Toxic reactions of the various drugs should not overlap so that maximal tolerated doses may be given. It is

The goal of chemotherapy is to be as effective as possible with tolerable side effects. Particular side effects vary with the medications used; some increase risks of infection, some cause anemia, nausea, or hair loss. All of these can be managed effectively, and several medications can help prevent or minimize side effects. In addition, some helpful activities are listed below.

- Keep all appointments for chemotherapy, blood tests, and check-ups. This is extremely important. Chemotherapy effectiveness depends on its being given on time; blood tests help to determine when the drugs should be given and how the drugs affect your body tissues.
- Do everything you can to avoid infection, such as avoiding other people who have infections and washing your hands frequently and thoroughly. If you have a fever, chills, sore throat, or cough, notify your oncologist.
- Try to maintain or improve your intake of nutritious food and fluids; this will help you feel better. A dietician can be helpful in designing a diet to meet your needs.
- If your chemotherapy may cause bleeding, you can decrease the likelihood by shaving with an electric razor, avoiding aspirin and other nonsteroidal anti-inflammatory drugs (including over-the-counter Advil, Aleve, and others), and avoiding injections, cuts, and other injuries when possible. If you notice excessive bruising, bleeding gums when you brush your teeth, or blood in your urine or bowel movement, notify your oncologist immediately.
- If hair loss is expected with the medications you take, you can use wigs, scarves, and hats. These should be purchased before starting chemotherapy, if possible. Hair loss is temporary; your hair will grow back!
- Inform any other physician, dentist, or health care provider that you are taking chemotherapy before any diagnostic test or treatment is begun. Some procedures may be contraindicated or require special precautions.
- If you are of childbearing age, effective contraceptive measures should be carried out during and a few months after chemotherapy.
- A few chemotherapy medications and medications to prevent or treat side effects are taken at home. Instructions for taking the drugs should be followed exactly for the most beneficial effects.
- Although specific instructions vary with the drugs you are taking, the following are a few precautions with some commonly used drugs:
  - With cyclophosphamide, take the tablets on an empty stomach. If severe stomach upset occurs, take with food. Also, drink 2 or 3 quarts of fluid daily, if possible, and urinate often, especially at bedtime. If blood is seen in the urine or signs of cystitis occur (eg, burning with urination), report to a health care provider. The drug is irritating to the bladder lining and may cause cystitis. High fluid intake and frequent emptying of the bladder help to decrease bladder damage.
  - With doxorubicin, the urine may turn red for 1 to 2 days after drug administration. This discoloration is harmless; it does not indicate bleeding. Also, report to a health care provider if you have edema, shortness of breath, and excessive fatigue. Doxorubicin may need to be stopped if these symptoms occur.
  - With fluorouracil, drink plenty of liquids while taking.
  - With methotrexate, avoid alcohol, aspirin, and prolonged exposure to sunlight.
  - With vincristine, eat high-fiber foods, such as raw fruits and vegetables and whole cereal grains, if you are able, to prevent constipation. Also try to maintain a high fluid intake. A stool softener or bulk laxative may be prescribed for daily use.
preferable to use drugs that are not toxic to the same organ system (eg, bone marrow, kidney) and to use drugs that do not exert their toxic effects at the same time.

- Bleomycin is often combined with myelosuppressive drugs because it rarely causes myelosuppression. However, it can cause severe allergic reactions with hypotension and pulmonary toxicity (eg, interstitial pneumonitis and pulmonary fibrosis).

**Dosage Factors**

Dosage must be calculated and regulated carefully to minimize toxicity. The client’s age, nutritional status, blood count, kidney and liver function, and previous chemotherapy or radiation therapy must be considered. Additional guidelines include the following:

1. High doses, to the limits of tolerance of normal tissues (eg, bone marrow), are usually most effective.
2. Doses are usually calculated according to body surface area, which includes both weight and height, and expressed as milligrams of drug per square meter of body surface area (mg/m²). Doses also can be expressed as milligrams per kilogram of body weight (mg/kg). Because dosages based on body surface area consider the client’s size, they are especially important for children. If the client’s weight changes more than a few pounds during treatment, dosages should be recalculated.
3. Dosage may be reduced for neutropenia, thrombocytopenia, stomatitis, diarrhea, and renal or hepatic impairment that reduces the client’s ability to eliminate the drugs.
4. Total dose limits for doxorubicin (550 mg/m²) and bleomycin (450 units) should not be exceeded.

**Administration Factors**

1. Dosage schedules are largely determined by clinical trials and should be followed as exactly as possible.
2. Antineoplastic drugs are usually given in relatively high doses, on an intermittent or cyclic schedule. This regimen seems more effective than low doses given continuously or massive doses given once. It also produces less immunosuppression and provides drug-free periods during which normal tissues can repair themselves from damage inflicted by the drugs. Fortunately, normal cells repair themselves faster than malignant cells. Succeeding doses are given when tissue repair occurs, usually when leukocyte and platelet counts return to acceptable levels.
3. Each antineoplastic drug should be used in the schedule, route, and dosage judged to be most effective for a particular type of cancer. With combinations of drugs, the recommended schedule should be followed precisely because safety and effectiveness may be schedule dependent. When chemotherapy is used as an adjuvant to surgery, it usually should be started as soon as possible after surgery, given in maximal tolerated doses just as if advanced disease were present, and continued for several months.
4. Intravenous drug administration should be performed by experienced personnel who ensure free flow of fluid to the vein and verify adequate blood return before a drug is injected. Infusion should be through a large, upper extremity vein. When possible, veins of the antecubital fossa, wrist, dorsum of the hand, and the arm where an axillary lymph node dissection has been done should be avoided. An indwelling central venous catheter is often inserted for clients with poor peripheral venous access or who require many doses of chemotherapy.
5. With bleomycin, a test dose of 1 to 2 mg subcutaneously should be given before starting full doses. Severe allergic reactions with hypotension may occur.
6. With paclitaxel and docetaxel, premedication is needed to decrease severe hypersensitivity reactions with dyspnea, hypotension, angioedema, and urticaria. A few deaths have occurred despite premedication. With paclitaxel, one regimen is oral dexamethasone 20 mg at 12 and 6 hours before, with IV diphenhydramine 50 mg and cimetidine 300 mg, famotidine 20 mg, or ranitidine 50 mg 30 to 60 minutes before. Additional paclitaxel is contraindicated for clients who experience severe hypersensitivity reactions. With docetaxel, an oral corticosteroid (eg, dexamethasone 8 mg twice daily) is recommended for 3 days, starting 1 day before docetaxel administration. This reduces risk and severity of hypersensitivity reactions and fluid retention.

**Hormonal Therapy**

Hormonal therapy is often used to treat breast or prostate cancer. Decreasing the hormones that stimulate tumor growth in these tissues can decrease symptoms and prolong survival.

In some clients with breast cancer, the presence of receptors for estrogen indicates a likely response to hormonal therapy. Tamoxifen is often used to treat breast cancers with estrogen receptors because it inhibits the interaction between estrogen and estrogen receptors. However, tumors may be resistant to hormonal therapy because of mutations in receptors that alter receptor functions. In clients with prostate cancer, hormonal therapy involves drugs that decrease androgens.

When both hormonal and cytotoxic drug therapies are needed, they are not given concurrently because hormonal antagonists decrease malignant cell growth, and cytotoxic agents are most effective when the cells are actively dividing. In clients with breast cancer, hormonal therapy is usually given before cytotoxic chemotherapy in metastatic disease and after chemotherapy when used for adjuvant treatment.

**Planning With Client and Family**

Clients with cancer and their families should be provided with information about their disease, their treatment options,
and the preferred treatment. For those with Internet access, helpful information can be obtained at:

- Oncolink, http://cancer.med.upenn.edu

When cytotoxic chemotherapy is recommended, additional factors should be discussed, such as the following:

1. **What is the goal of chemotherapy?** Expected benefits may include curing the disease, decreasing tumor size, relieving symptoms, killing metastatic cells left after surgery or radiation therapy, or prolonging life. Chemotherapy is not justified unless expected benefits outweigh the potential hazards.

2. **What adverse reactions are likely to occur?** Which reactions should be reported to the physician? How will they be managed if they occur? Even if the realities of chemotherapy are unpleasant, it is usually better for the client to know what they are than to fear the unknown. Some specific effects that should be discussed, depending on the drugs to be used, include alopecia, amenorrhea, oligospermia, and possibly permanent sterility. Because most of these drugs are teratogenic, clients in the reproductive years are advised to avoid pregnancy during treatment.

3. **Who will administer the drugs, where, and for how long?** Chemotherapy is highly specialized. Because the drugs are toxic and require meticulous administration, they are preferably given at a cancer treatment center. Some clients undergo chemotherapy at a cancer center far from home; others undergo treatment at a nearby hospital, clinic, physician’s office, or at home. The duration of treatment varies, depending on the type of tumor and response.

Clients should be informed about the frequent venipunctures required for blood tests and drug administration. When CBC indicates excessive leukopenia or thrombocytopenia, chemotherapy is postponed.

### Guidelines for Handling Cytotoxic Antineoplastic Drugs

Exposure to chemotherapy drugs may lead to adverse effects such as contact dermatitis, cough, nausea, vomiting, diarrhea, and others. In addition, exposure during pregnancy increases risks of fetal abnormalities, ectopic pregnancy, and spontaneous abortions. Guidelines to avoid adverse effects include the following:

1. Avoid contact with solutions for injection by wearing gloves, eye protectors, and protective clothing (eg, disposable, liquid-impermeable gowns).
2. If handling a powder form of a drug, wear a mask to avoid inhaling the powder.
3. Do not prepare the drugs in eating areas (to decrease risks of oral ingestion).
4. Dispose of contaminated materials (eg, needles, syringes, ampules, vials, IV tubing and bags) in puncture-proof containers labeled “Warning: Hazardous Material.”
5. Wear gloves when handling clients’ clothing, bed linens, or excreta. Blood and body fluids are contaminated with drugs or metabolites for about 48 hours after a dose.
6. Wash hands thoroughly after exposure or potential exposure.
7. Follow recommended procedures for cleaning up spills.

### Use in Children

Children are at risk for a wide range of malignancies, including acute leukemias, lymphomas, brain tumors, Wilms’ tumor, and sarcomas of muscle and bone. Although chemotherapy drugs are widely used in children, few studies have been done and their safety and effectiveness are not established. As with adults, chemotherapy is often used with surgery or radiation therapy.

Chemotherapy should be designed and supervised by pediatric oncologists. Dosage of cytotoxic drugs should be based on body surface area because this takes size into account. Long-term effects on growth and development of survivors are not clear and special efforts are needed to maintain nutrition, organ function, psychological support, and other aspects of growth and development. After successful chemotherapy, children should be closely monitored because they are at increased risk for development of cancers in adulthood (eg, leukemia). After radiation therapy, they are at increased risk of developing breast, thyroid, or brain cancer. Children treated for Hodgkin’s disease seem to have the highest risk of developing a new cancer later.

### Use in Older Adults

Older adults are at risk for a wide range of cancers. Although they also are likely to have chronic cardiovascular, renal, and other disorders that increase their risks of serious adverse

### Nursing Notes: Ethical/Legal Dilemma

You are working on an oncology unit and have recently become certified to administer antineoplastic medications. You read a new study that documents significant cancer with contact exposure to a new antineoplastic agent.

**Reflect on:**

- Does a nurse have the right to refuse to administer this new medication if he or she feels it poses a personal health risk?
- The nurse’s responsibility for his or her own safety.
- The institution’s responsibility for the safety of the workers in this situation.
effects, they should not be denied the potential benefits of chemotherapy on the basis of age alone. Instead, greater vigilance is needed to maximize benefits and minimize hazards of chemotherapy. For example, older adults are more sensitive to the neurotoxic effects of vincristine and need reduced dosages of some drugs (eg, cyclophosphamide, MTX) if renal function is impaired. Creatinine clearance should be monitored; serum creatinine level is not a reliable indicator of renal function in older adults because of their decreased muscle mass.

Use in Renal Impairment

Some antineoplastic drugs are nephrotoxic (eg, cisplatin, MTX) and many are excreted through the kidneys. In the presence of impaired renal function, risks of further impairment or accumulation of toxic drug levels are increased. Thus, renal function should be monitored carefully during therapy and drug dosages are often reduced according to creatinine clearance (CrCl) levels. In advanced cancer, CrCl may not be reliable because these clients are often in catabolic states characterized by increased production of creatinine from breakdown of skeletal muscle and other proteins. Renal effects of selected drugs are as follows:

- **Carmustine** and **temozolomide** are associated with azotemia and renal failure, usually with long-term IV administration and large cumulative doses.
- **Cisplatin** is nephrotoxic, and acute overdosage can cause renal failure. Because nephrotoxicity is increased with repeated doses, cisplatin is given at 3- or 4-week intervals and renal function tests (eg, serum creatinine, blood urea nitrogen [BUN]) and serum electrolytes (eg, sodium, potassium, calcium) are measured before each course of therapy. Renal function is usually allowed to return to normal before another dose is given. Nephrotoxicity may be reduced by the use of amifostine or IV hydration and mannitol.
- **Cyclophosphamide** may cause hemorrhagic ureteritis and renal tubular necrosis with IV doses above 50 mg/kg. These effects usually subside when the drug is stopped.
- **Ifosfamide** may increase BUN and serum creatinine, but its major effect on the urinary tract is hemorrhagic cystitis, manifested by hematuria. Cystitis can be reduced by the use of mesna, vigorous hydration, and delaying drug administration if a predose urinalysis shows hematuria.
- **Irinotecan** dosage should be reduced (eg, 0.75 mg/m²) in clients with moderate impairment (CrCl 20 to 39 mL/minute). No dosage reduction is recommended with mild impairment (CrCl 40 to 60 mL/minute), and there are inadequate data for recommendations in severe impairment.
- **Melphalan** should be reduced in dosage when given IV, to reduce accumulation and increased bone marrow toxicity. It is unknown whether dosage reduction is needed with oral drug.
- **Mercaptopurine** should be given in smaller doses because the drug may be eliminated more slowly.
- **Methotrexate** is excreted mainly by the kidneys and its use in clients with impaired renal function may lead to accumulation of toxic amounts or additional renal damage. The client’s renal status should be evaluated before and during MTX therapy. If significant renal impairment occurs, the drug should be discontinued or reduced in dosage until renal function improves.

In clients who receive high doses for treatment of osteosarcoma, MTX may cause renal damage leading to acute renal failure. Nephrotoxicity is attributed to precipitation of MTX and a metabolite in renal tubules. Renal impairment may be reduced by monitoring renal function closely, ensuring adequate hydration, alkalinizing the urine, and measuring serum drug levels.

- **Procarbazine** may cause more severe adverse effects if given to clients with impaired renal function. Hospitalization is recommended for the first course of treatment.

Many other drugs should be used with caution in clients with renal impairment. **Asparaginase** often causes azotemia (eg, increased BUN); acute renal failure and fatal renal insufficiency have been reported. **Bleomycin** is rarely associated with nephrotoxicity but its elimination half-life is prolonged in clients with a CrCl of less than 35 mL/minute. **Cytarabine** is detoxified mainly by the liver. However, clients with renal impairment may have more CNS-related adverse effects, and dosage reduction may be needed. **Gemcitabine** should be used with caution, although it has not been studied in clients with preexisting renal impairment. Mild proteinuria and hematuria were commonly reported during clinical trials, and hemolytic-uremic syndrome (HUS) was reported in a few clients. HUS may be manifested by anemia, indications of blood cell breakdown (eg, elevated bilirubin and reticulocyte counts), and renal failure. The drug should be stopped immediately if HUS occurs; hemodialysis may be required.

Use in Hepatic Impairment

Some antineoplastic drugs are hepatotoxic and many are metabolized in the liver. In the presence of impaired hepatic function, risks of further impairment or accumulation of toxic drug levels are increased. Dosage reduction is needed with some drugs and hepatic function should be monitored with most. However, abnormal values for the usual liver function tests (eg, serum aminotransferases such as aspartate aminotransferase [AST] and alanine aminotransferase [ALT], bilirubin, alkaline phosphatase) may indicate liver injury but do not indicate decreased ability to metabolize drugs. Clients with metastatic cancer often have impaired liver function. Hepatotoxic drugs include the anthracyclines (eg, doxorubicin), mercaptopurine, MTX, paclitaxel, and vincristine. Hepatic effects of these and selected other drugs are as follows:

- **Asparaginase** is hepatotoxic in most clients and may increase preexisting hepatic impairment. It may also increase hepatotoxicity of other medications. Signs of
liver impairment, which usually subside when the drug is discontinued, include increased AST, ALT, alkaline phosphatase, and bilirubin and decreased serum albumin, cholesterol, and plasma fibrinogen.

- **Capetitabine** blood levels are significantly increased with hepatic impairment, and clients with mild to moderate impairment caused by liver metastases should be monitored closely. The effects of severe impairment have not been studied.

- **Carmustine** may increase AST, ALT, alkaline phosphatase, and bilirubin when given IV.

- **Chlorambucil** may be hepatotoxic and cause jaundice.

- **Cisplatin** may cause a transient increase in liver enzymes and bilirubin, which should be measured periodically during cisplatin therapy.

- **Cytoxan** is metabolized in the liver and clients with impaired liver function are more likely to have CNS-related adverse effects. The drug should be used with caution and dosage may need to be reduced.

- **Daunorubicin**, liposomal formulation, should be reduced in dosage according to the serum bilirubin (eg, bilirubin 1.2 to 3 mg/dL, give three fourths the normal dose; bilirubin >3 mg/dL, give one half the normal dose).

- **Doxorubicin** is excreted primarily in bile and toxicity is increased with impaired hepatic function. Liver function tests should be done before drug administration, and dosage of both regular and liposomal formulations should be reduced according to the serum bilirubin (eg, bilirubin 1.2 to 3 mg/dL, give one half the normal dose; bilirubin >3 mg/dL, give one fourth the normal dose).

- **Gemcitabine** has not been studied in clients with significant hepatic impairment but should be used with caution. Transient increases in serum aminotransferases occurred in most clients during clinical trials.

- **Idarubicin** should not be given to clients with a serum bilirubin above 5 mg/dL.

- **Irinotecan** has been associated with abnormal liver function tests in clients with liver metastases.

- **Mercaptopurine** causes hepatotoxicity, especially with higher doses (>2.5 mg/kg/day) and in combination with doxorubicin. Enocephalopathy and fatal liver necrosis have occurred. The drug should be stopped if signs of hepatotoxicity (eg, jaundice, hepatomegaly, liver function tests indicating toxic hepatitis or biliary stasis) occur. Serum aminotransferases, alkaline phosphatase, and bilirubin should be monitored weekly with initial therapy, then monthly. Liver function tests may be needed more often in clients who have pre-existing liver impairment or are receiving other hepatotoxic drugs.

- **Methotrexate** may cause acute (increased serum aminotransferases, hepatitis) and chronic (fibrosis and cirrhosis) hepatotoxicity. Chronic toxicity is potentially fatal. It is more likely to occur after prolonged use (eg, 2 years or longer) and after a total dose of at least 1.5 g. Cautious use of MTX is especially indicated in clients with pre-existing liver damage or impaired hepatic function. Liver function tests should be closely monitored.

- **Paclitaxel** is mainly metabolized by the liver and may cause more toxicity in clients with impaired hepatic function.

- **Procarbazine** causes more toxic effects in clients with hepatic impairment. Hospitalization is recommended for the first course of therapy.

- **Topotecan** is cleared from plasma more slowly in clients with hepatic impairment, but dosage reductions are not recommended.

- **Vinblastine** and **vincristine** may cause more toxicity with hepatic impairment and dosage should be reduced 50% for clients with a direct serum bilirubin value above 3 mg/dL.

Other drugs that should be used with caution because of their hepatic effects include the antineoplastic hormones and hormone antagonists. The antiandrogens include bicalutamide, flutamide, and nilutamide. **Bicalutamide** has a long serum half-life in clients with severe hepatic impairment. Excretion may be delayed and the drug may accumulate. The drug should be used with caution in clients with moderate to severe hepatic impairment, and liver function tests are needed periodically during long-term therapy. **Flutamide** is associated with serum aminotransferase abnormalities, cholestatic jaundice, hepatic encephalopathy, hepatic necrosis, and a few deaths. Liver function tests should be performed periodically and at the first sign or symptom of liver dysfunction (eg, pruritus, dark urine, jaundice). Flutamide should be discontinued if jaundice develops in clients who do not have liver metastases or if serum aminotransferase levels increase more than 2 to 3 times the upper limit of normal. Liver damage usually subsides if flutamide is discontinued or if dosage is reduced. **Nilutamide** may cause hepatitis or increases in liver enzymes. Liver enzymes should be checked at baseline and every 3 months. If symptoms of liver injury occur or if aminotransferases increase over 2 to 3 times the upper limits of normal, nilutamide should be discontinued.

**Medroxyprogesterone** should be stopped if any manifestations of impaired liver function develop. Tamoxifen and toremifene are antiestrogens. **Tamoxifen** is associated with changes in liver enzyme levels and occasionally more severe liver damage, including fatty liver, cholestasis, hepatitis, and hepatic necrosis. **Toremifene’s** elimination half-life is prolonged in clients with hepatic cirrhosis or fibrosis.

**Home Care**

Clients may receive parenteral cytotoxic drugs as outpatients and return home, or the drugs may be administered at home by the client or a caregiver. The home care nurse may be involved in a wide range of activities associated with chemotherapy, including administering antineoplastic drugs, administering...
drugs to prevent or manage adverse effects, and assessing client and family responses to therapy. In addition, a major role involves teaching about the disease process, management of pain and other symptoms, the anticancer drugs, prevention or management of adverse drug effects, preventing infection, maintaining food and fluid intake, and other aspects of care. If a client is receiving erythropoietin or oprelvekin subcutaneously, the client or a caregiver may need to be taught injection technique.

The home care nurse also needs to teach clients and caregivers about safe handling of chemotherapeutic agents, including items contaminated with the drugs and client body fluids or excreta. Precautions need to be similar to those used in health care agencies.

### Antineoplastic Drugs

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td>Cancer chemotherapy requires advanced knowledge and skills and most agencies require instruction and demonstration of competency. Current information is necessary because of the large number and varied characteristics of the drugs; differences in administration according to the drug and type of neoplasm; and continuing development of new drugs and treatment protocols.</td>
</tr>
<tr>
<td>a. If not accustomed to giving cytotoxic antineoplastic drugs regularly, read package inserts, research protocols, or other recent drug references for specific instructions on administration of individual drugs.</td>
<td>Many of the drugs must be reconstituted from a powder and further diluted in an IV solution. Drug solutions are usually prepared in the pharmacy; multiple checks may prevent errors.</td>
</tr>
<tr>
<td>b. For IV drug administration:</td>
<td>Because the drugs are highly toxic, every precaution must be taken to ensure accurate and safe administration.</td>
</tr>
<tr>
<td>(1) Compare labels on prepared solutions to medication orders in terms of the drug, concentration, expiration date, and instructions for administration. Do not give without checking further if there is any discrepancy.</td>
<td>Long-term devices decrease the number of venipunctures a client must undergo. These devices require special care to maintain patency and prevent infection.</td>
</tr>
<tr>
<td>(2) Follow instructions for administering each drug. Common methods include injecting the drug into the tubing of a rapidly flowing IV or infusing the drug over a specified period of minutes to hours.</td>
<td>These solutions are hazardous materials that require special handling.</td>
</tr>
<tr>
<td>(3) For clients with a long-term venous access device (eg, Hickman or Groshong catheter), follow agency protocols for drug administration and catheter care.</td>
<td>Therapeutic effects depend to a large extent on the type of malignancy being treated. They may not become evident for several weeks after chemotherapy is begun. Some clients experience anorexia, nausea, and vomiting for 2 to 3 wk after each cycle of drug therapy.</td>
</tr>
<tr>
<td>(4) Follow agency protocols for skin exposure or spills of cytotoxic drug solutions.</td>
<td>Antineoplastic drugs may have adverse effects on virtually any body tissue. These effects range from common to rare, from relatively mild to life threatening, and occur with usual dosage ranges. Myelosuppressive effects are used to guide drug therapy.</td>
</tr>
<tr>
<td>c. For drugs to be given orally, the total dose of most drugs can be given at one time.</td>
<td></td>
</tr>
</tbody>
</table>
### Nursing Actions

<table>
<thead>
<tr>
<th>Effect</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Hematologic effects:</td>
<td>(1) Bone marrow depression with leukopenia (decreased white blood cell [WBC] count), thrombocytopenia (decreased platelets), and anemia (decreased red blood cell [RBC] count, hemoglobin, and hematocrit) (2) Decreased antibodies and lymphocytes</td>
</tr>
<tr>
<td>b. Gastrointestinal (GI) effects—anorexia, nausea, vomiting, diarrhea, constipation, oral and intestinal mucositis and mucosal ulcerations, oral candidiasis</td>
<td></td>
</tr>
<tr>
<td>c. Integumentary effects—alopecia, dermatitis, tissue irritation at injection sites</td>
<td></td>
</tr>
<tr>
<td>d. Renal effects:</td>
<td>(1) Hyperuricemia and uric acid nephropathy (2) With cisplatin, nephrotoxicity (increased blood urea nitrogen [BUN] and serum creatinine; decreased creatinine clearance). (3) With cyclophosphamide or ifosfamide, hemorrhagic cystitis (blood in urine, dysuria, burning on urination)</td>
</tr>
<tr>
<td>e. Pulmonary effects—cough, dyspnea, chest x-ray changes</td>
<td></td>
</tr>
<tr>
<td>f. Cardiovascular effects—congestive heart failure (dyspnea, edema, fatigue), dysrhythmias, electrocardiographic changes</td>
<td></td>
</tr>
<tr>
<td>g. Central nervous system effects—peripheral neuropathy with vincristine, manifested by muscle weakness, numbness and tingling of extremities, foot drop, and decreased ability to walk</td>
<td></td>
</tr>
<tr>
<td>h. Endocrine effects—menstrual irregularities, sterility in men and women</td>
<td></td>
</tr>
</tbody>
</table>

### Rationale/Explanation

- For most drugs, WBC and platelet counts reach their lowest points (nadir) 7 to 14 days after drug administration and return toward normal after 21 days. Normal leukocyte and platelet counts indicate recovery of bone marrow function. Anemia may occur later because the red blood cell lives longer than white cells and platelets.
- Most of these drugs have immunosuppressant effects, which impair body defenses against infection.
- Nausea and vomiting are very common, usually occur within a few hours of drug administration, and often subside within 12 to 24 hours. Constipation is most likely to occur with vincristine. Nausea and vomiting may occur anywhere in the GI tract; may interfere with nutrition and cause significant discomfort; may lead to infection, hemorrhage, or perforation; and may require that drug therapy be stopped.
- Complete hair loss may take several weeks to occur. Alopecia may cause psychological discomfort. Several drugs may cause phlebitis and sclerosis of veins used for injections, as well as pain and tissue necrosis if allowed to leak into tissues around the injection site.
- When malignant cells are destroyed, they release uric acid into the bloodstream. Uric acid crystals may precipitate in the kidneys and cause impaired function or failure. Adverse effects on the kidneys are especially associated with methotrexate and cisplatin. Hyperuricemia can be decreased by an ample fluid intake or by administration of allopurinol.
- Nephrotoxicity is a major adverse effect. Decreasing the dose or frequency of administration, vigorous hydration, and amifostine administration can reduce the incidence.
- Hemorrhagic cystitis occurs in about 10% of clients. It is attributed to irritating effects of drug metabolites on the bladder mucosa. The drug is stopped if this occurs. Cystitis can be decreased by an ample fluid intake. In addition, mesna is given with ifosfamide.
- Adverse effects on the lungs are associated mainly with bleomycin and methotrexate. With bleomycin, pulmonary toxicity may be severe and progress to pulmonary fibrosis.
- Cardiomyopathy is associated primarily with doxorubicin and related drugs. This is a life-threatening adverse reaction. The heart failure may be unresponsive to digoxin.
- This common effect of vincristine may worsen for several weeks after drug administration. There is usually some recovery of function eventually.

(continued)
### NURSING ACTIONS

#### 4. Observe for drug interactions

a. Drugs that *increase* effects of cytotoxic antineoplastic drugs:
   - (1) Allopurinol
   - (2) Anticoagulants, oral
   - (3) Bone marrow depressants
   - (4) Other antineoplastic drugs

b. Drugs that *increase* effects of cyclophosphamide:
   - (1) Anesthetics, inhalation
   - (2) Carbamazepine, phenytoin, rifampin
   - (3) Other myelosuppressive antineoplastic drugs

c. Drugs that *increase* effects of methotrexate (MTX):
   - (1) Alcohol
   - (2) Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), phenytoin, procarbazine, sulfonamides
   - (3) Other hepatotoxic drugs
   - (4) Other antineoplastic drugs
   - (5) Trimethoprim-sulfamethoxazole (TMP-SMX, Bactrim)

d. Drug that *decreases* effects of methotrexate:
   - (1) Leucovorin (citrovorum factor, folinic acid)

e. Drugs that *increase* effects of vinca alkaloids:
   - (1) Erythromycin increases vinblastine toxicity; itraconazole increases vincristine toxicity

### RATIONALE/EXPLANATION

- **Allopurinol** is usually given to prevent or treat chemotherapy-induced hyperuricemia. When given with mercaptopurine, allopurinol facilitates the formation of the active metabolite. Consequently, doses of mercaptopurine must be reduced to one third to one fourth the usual dose.
- Increased risk of bleeding
- Increased bone marrow depression
- Additive cytotoxic effects, both therapeutic and adverse

- **Lethal combination.** Discontinue cyclophosphamide at least 12 h before general inhalation anesthesia is to be given.
- Potentiate cyclophosphamide by induction of liver enzymes, which accelerate transformation of the drug into its active metabolites
- Increased bone marrow depression

- **Additive liver toxicity.** Avoid concomitant use.
- Potentiate MTX by displacing it from protein-binding sites in plasma. Salicylates also block renal excretion of methotrexate. This may cause pancytopenia and liver toxicity.
- Additive liver toxicity
- Additive cytotoxic effects, both therapeutic and adverse. Cisplatin may induce renal damage that impairs MTX excretion, increases blood levels, and increases toxicity.
- Increased MTX toxicity; avoid concurrent administration if possible.
- Leucovorin antagonizes the toxic effects of methotrexate and is used as an antidote for high-dose methotrexate regimens or for overdose. It must be given exactly at the specified time, before affected cells become too damaged to respond.
- These drugs probably inhibit metabolism of vinblastine and vincristine.
Nursing Notes: Apply Your Knowledge

**Answer:** Platelets, red blood cells and white blood cells are produced in the bone marrow. The production of any of these cells can decrease when an antineoplastic agent with a side effect of bone marrow depression is given. The impact is greatest at nadir. When platelets decrease below 50,000/mm³ there is an increased risk of bleeding, which may manifest as increased bruising, blood in the stool, dark urine, or even seizures and confusion if the bleeding is intracranial. When red blood cells decrease, as evidenced by a hemoglobin of less than 9 g/dL, the patient will experience anemia and fatigue. White blood cell (WBC) count is a measure of the body’s ability to fight infection. Neutrophils are white blood cells that are especially helpful in fighting infection; thus when the WBC count is low, a neutrophil count is done. A patient with neutrophil counts of less than 500/mm³ is at significant risk for infection. Common signs of infection are often mediated by neutrophils. So the signs and symptoms of infection may be low in the neutropenic patient.

Patient teaching should focus on avoiding infection (good handwashing, avoiding contact with infected individuals), especially if the neutrophil count is low. The patient should report any fever, even low-grade fever. Fatigue can be managed with frequent rest, energy conservation measures, and good nutrition. When platelets are low, patients should be taught to avoid trauma. The importance of keeping appointments for monitoring should be stressed so that blood products can be given if values are critically low.

Review and Application Exercises

1. List major characteristics of malignant cells.
2. Which common cancers are attributed mainly to environmental factors? Which are attributed to genetic factors?
3. How do cytotoxic antineoplastic drugs destroy malignant cells?
4. Which cytotoxic antineoplastic drugs are associated with serious adverse effects (eg, bone marrow suppression, cardiotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity)?
5. Which drugs are associated with second malignancies?
6. What is the basis for the anticancer effects of hormones and antihormones?
7. For which cytotoxic drugs are cytoprotective drugs available?
8. List at least one intervention to prevent or minimize each of the following adverse effects of chemotherapy: alopecia, anemia, bleeding, infection, nausea and vomiting, stomatitis.

SELECTED REFERENCES


Drugs Used in Ophthalmic Conditions

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review characteristics of ocular structures that influence drug therapy of eye disorders.
2. Discuss selected drugs in relation to their use in ocular disorders.
3. Use correct techniques to administer ophthalmic medications.
4. Assess for ocular effects of systemic drugs and systemic effects of ophthalmic drugs.
5. Teach clients, family members, or caretakers correct administration of eye medications.
6. For a client with an eye disorder, teach about the importance of taking medications as prescribed to protect and preserve eyesight.

Critical Thinking Scenario
Jean Green, a 40-year-old accountant, has made an appointment to have her eyes examined because she has been having difficulty reading small print. She has not had her eyes tested for over 10 years. When she arrives at the office, you explain that the examination will include using medications to dilate her eyes and a test for glaucoma.

Reflect on:
- Age-related visual changes that often occur at midlife.
- Which drugs are used to dilate the eyes for examination, and how they work.
- Why glaucoma testing is important.
- What teaching is necessary for Mrs. Green.

OVERVIEW

The eye is the major sensory organ through which the person receives information about the external environment. Extensive discussion of vision and ocular anatomy is beyond the scope of this chapter, but some characteristics and functions are described to facilitate understanding of ocular drug therapy. These include the following:

- The eyelids and lacrimal system function to protect the eye. The eyelid is a covering that acts as a barrier to the entry of foreign bodies, strong light, dust, and other potential irritants. The conjunctiva is the mucous membrane lining of the eyelids. The canthi (singular, canthus) are the angles where the upper and lower eyelids meet. The lacrimal system produces a fluid that constantly moistens and cleanses the anterior surface of the eyeball. The fluid drains through two small openings in the inner canthus and flows through the nasolacrimal duct into the nasal cavity. When the conjunctiva is irritated or certain emotions are experienced (eg, sadness), the lacrimal gland produces more fluid than the drainage system can accommodate. The excess fluid overflows the eyelids and becomes tears.
- The eyeball is a spherical structure composed of the sclera, cornea, choroid, and retina, plus special refractive tissues. The sclera is a white, opaque, fibrous tissue that covers the posterior five sixths of the eyeball. The cornea is a transparent, special connective tissue that covers the anterior sixth of the eyeball. The cornea contains no blood vessels. The choroid, composed of blood vessels and connective tissue, continues forward to form the iris. The iris is composed of pigmented cells, the opening called the pupil, and muscles that control the size of the pupil by contracting or dilating in response to stimuli. The retina is the innermost layer of the eyeball.
Agnostic tests for glaucoma include ophthalmoscopic exami-


nation of the optic disk, measurement of intraocular pressure (tonometry), and testing of visual fields.

The most common type of glaucoma is called primary open-angle glaucoma. Its etiology is unknown, but contributing factors may include advanced age, a family history of glaucoma and elevated IOP, diabetes mellitus, hypertension, myopia, long-term use of corticosteroid drugs, and previous eye injury, inflammation, or infection. In addition, the incidence of glaucoma in African Americans is about three times higher than in non–African Americans. Closed-angle glaucoma is usually an acute situation requiring emergency surgery. It may occur when pupils are dilated and the outflow of aqueous humor is blocked. Darkness and drugs with anticholinergic effects (eg, atropine, antihistamines, tricyclic antidepressants) may dilate the pupil, reduce outflow of aqueous humor, and precipitate acute glaucoma.

Inflammatory or Infectious Conditions

Inflammation may be caused by bacteria, viruses, allergic reactions, or irritating chemicals. Infections may result from foreign bodies, contaminated hands, contaminated eye medications, or infections in contiguous structures (eg, nose, face, sinuses). Common inflammatory and infectious disorders include the following:

- **Conjunctivitis** is a common eye disorder that may be caused by allergens (eg, airborne pollens), bacterial or viral infection, or physical or chemical irritants. Symptoms include redness, tearing, itching, edema, and burning or gritty sensations. Bacterial conjunctivitis is often caused by *Staphylococcus aureus*, *Streptococcus pneumoniae*, or *Haemophilus influenzae* and produces mucopurulent drainage. Conjunctivitis with a purulent discharge is most often caused by the gonococcus; corneal ulcers and scarring may result.

- **Blepharitis** is a chronic infection of glands and lash follicles on the margins of the eyelids characterized by burning, redness, and itching. A hordeolum (commonly called a stye) is often associated with blepharitis. The most common causes are seborrhea and staphylococcal infections.

- **Keratitis** (inflammation of the cornea) may be caused by microorganisms, trauma, allergy, ischemia, and drying of the cornea (eg, from inadequate lacrimation). The major symptom is pain, which ranges from mild to severe. Vision may not be affected initially. However, if not treated effectively, corneal ulceration, scarring, and impaired vision may result.

- **Bacterial corneal ulcers** are most often caused by pneumococci and staphylococci. Pseudomonal ulcers are less common but may rapidly progress to perforation. Fungal ulcers may follow topical corticosteroid therapy or injury with plant matter, such as a tree branch. Viral ulcers are usually caused by the herpesvirus.

- **Fungal infections** commonly occur and may often be attributed to frequent use of ophthalmic antibiotics and corticosteroids.

**DISORDERS OF THE EYE**

The eye is subject to the development of many disorders that threaten its structure, function, or both. Some disorders in which ophthalmic drugs play a prominent role are discussed in the following sections.

**Refractive Errors**

Refractive errors include myopia (nearsightedness), hyperopia (farsightedness), presbyopia, and astigmatism. These conditions impair vision by interfering with the eye’s ability to focus light rays on the retina. Ophthalmic drugs are used only in the diagnosis of the conditions; treatment involves prescription of eyeglasses or contact lenses.

**Glaucoma**

Glaucoma, a common preventable cause of blindness, is a group of diseases characterized by optic nerve damage and changes in visual fields. It is often characterized by increased intraocular pressure (IOP, >22 mm Hg), but may also occur with normal IOP (<21 mm Hg; average 15–16 mm Hg). Diagnostic tests for glaucoma include ophthalmoscopic exami-
Types of Ophthalmic Drugs

Drugs used to diagnose or treat ophthalmic disorders represent numerous therapeutic classifications, most of which are discussed in other chapters. Major classes used in ophthalmology include the following:

- **Antihistamines** (H<sub>1</sub> receptor antagonists) and **mast cell stabilizers** are used to decrease redness and itching associated with allergic conjunctivitis.
- **Antimicrobials** are used to treat bacterial, viral, and fungal infections (see Chaps. 33 through 41). Bacterial infections include conjunctivitis, keratitis, blepharitis, and corneal ulcers. The drugs are usually applied topically but may be given orally or intravenously.
- **Autonomic drugs** are used for diagnostic and therapeutic purposes (see Chaps. 17 through 21). Some are used to dilate the pupil before ophthalmologic examinations or surgical procedures; some are used to decrease intraocular pressure in glaucoma. Ophthalmic beta-adrenergic blocking agents are the most commonly used drugs for treatment of glaucoma, in which they decrease IOP by decreasing formation of aqueous humor. Adrenergic vasoconstricting drugs are commonly used to decrease redness associated with allergic conjunctivitis.
- **Corticosteroids** (see Chap. 24) are often used to treat inflammatory conditions of the eye, thereby reducing scarring and preventing loss of vision. Corticosteroids are generally more effective in acute than chronic inflammatory conditions. Because these drugs are potentially toxic, they should not be used to treat minor disorders or disorders that can be effectively treated with safer drugs. When used, corticosteroids should be administered in the lowest effective dose and for the shortest effective time. Long-term use should be avoided when possible, because it may result in glaucoma, increased IOP, optic nerve damage, defects in visual acuity and fields of vision, cataract, or secondary ocular infections.
- **Nonsteroidal anti-inflammatory drugs**, in ophthalmic formulations for topical use, may be used in eye disorders (see Drugs at a Glance: Topical Ophthalmic Anti-Inflammatory Agents and Chap. 7).
- **Prostaglandin analogs** are newer antiglaucoma drugs that apparently reduce IOP by increasing the outflow of aqueous humor. The drugs may be used when a client’s IOP is not lowered adequately with a beta blocker or when a beta blocker is contraindicated for a client. When compared with twice-daily ophthalmic timolol, the drugs were considered as effective as timolol. The drugs may be used in conjunction with other antiglaucoma medications (eg, a beta blocker or carbonic anhydrase inhibitor) if multiple drugs are required.

In clinical trials, the incidence of systemic adverse effects was about the same as with placebo. The most common adverse effects were ocular burning, stinging, and itching. However, the drugs may cause a permanent darkening of eye color, especially in light-colored eyes, and alter eyelashes.

Nurses who are pregnant should be careful in handling prostaglandin analogs because they may be absorbed through the skin. If accidental contact occurs, the exposed area should be washed immediately with soap and water.

- **Carbonic anhydrase inhibitors** (CAIs) and **osmotic diuretics** are given to decrease IOP in glaucoma and before certain surgical procedures. CAIs lower IOP by decreasing production of aqueous humor.
- **Fluorescein** is a dye used in diagnosing lesions or foreign bodies in the cornea, fitting contact lenses, and studying the lacrimal system and flow of aqueous humor.

**Ophthalmic Drug Therapy**

Drug therapy of ophthalmic conditions is unique because of the location, structure, and function of the eye. Many systemic drugs are unable to cross the blood–eye barrier and achieve therapeutic concentrations in ocular structures. In general, penetration is greater if the drug achieves a high concentration in the blood, is fat soluble, and is poorly bound to serum proteins, and if inflammation is present.

Because of the difficulties associated with systemic therapy, various methods of administering drugs locally have been developed. The most common and preferred method is topical application of ophthalmic solutions (eye drops) to the conjunctiva. Drugs are distributed through the tear film covering the eye and may be used for superficial disorders (eg, conjunctivitis) or for relatively deep ocular disorders (eg, glaucoma). Topical ophthalmic ointments may also be used. In addition, ophthalmologists may inject medications (eg, antibiotics, corticosteroids, local anesthetics) into or around various eye structures.

**Individual Drugs**

See Drugs at a Glance: Drugs Used in Ocular Disorders, Drugs at a Glance: Ophthalmic Antimicrobial Agents, and Drugs at a Glance: Topical Ophthalmic Antiallergic and Anti-Inflammatory Agents.
**Nursing Process**

**Assessment**
Assess the client’s condition in relation to ophthalmic disorders.

- Determine whether the client has impaired vision and, if so, the extent or severity of the impairment. Minimal assessment includes the vision-impaired client’s ability to participate in activities of daily living, including safe ambulation. Maximal assessment depends on the nurse’s ability and working situation. Some nurses do vision testing and ophthalmoscopic examinations.
- Identify risk factors for eye disorders. These include trauma, allergies, infection in one eye (a risk factor for infection in the other eye), use of contact lenses, infections of facial structures or skin, and occupational exposure to chemical irritants or foreign bodies.
- Signs and symptoms vary with particular disorders:
  - Pain is usually associated with corneal abrasions or inflammation. Sudden, severe pain may indicate acute glaucoma, which requires immediate treatment to lower intraocular pressure and minimize damage to the optic nerve.
  - Signs of inflammation (redness, edema, heat, tenderness) are especially evident with infection or inflammation of external ocular structures, such as the eyelids and conjunctiva. A watery or mucoid discharge also often occurs.
  - Pruritus is most often associated with allergic conjunctivitis.
  - Photosensitivity commonly occurs with keratitis.

**Nursing Diagnoses**
- Disturbed Sensory Perception: Visual, related to eye disorders
- Risk for Injury: Blindness related to inadequately treated glaucoma or ophthalmic infections
- Deficient Knowledge related to prevention and treatment of ocular disorders

**Planning/Goals**

*The client will:*
- Take ophthalmic medications as prescribed
- Follow safety precautions to protect eyes from trauma and disease
- Experience improvement in signs and symptoms (eg, decreased drainage with infections, decreased eye pain with glaucoma)
- Avoid injury from impaired vision (eg, falls)
- Avoid systemic effects of ophthalmic drugs
- Have regular eye examinations to monitor effects of antiglaucoma drugs

**Interventions**
Use measures to minimize ocular disorders.

- Promote regular eye examinations. This is especially important among middle-aged and older adults, who are more likely to have several ocular disorders. They are also more likely to experience ocular disorders as adverse effects of drugs taken for nonocular disorders.
- Assist clients at risk of eye damage from increased intraocular pressure (eg, those with glaucoma; those who have had intraocular surgery, such as cataract removal) to avoid straining at stool (use laxatives or stool softeners if needed), heavy lifting, bending over, coughing, and vomiting when possible.
- Promote handwashing and keeping hands away from eyes to prevent eye infections.
- Cleanse contact lenses or assist clients in lens care, when needed.
- Treat eye injuries appropriately:
  - For chemical burns, irrigate the eyes with copious amounts of water as soon as possible (ie, near the area where the injury occurred). Do not wait for transport to a first aid station, hospital, or other health care facility. Damage continues as long as the chemical is in contact with the eye.
  - For thermal burns, apply cold compresses to the area.
  - Superficial foreign bodies may be removed by irrigation with water. Foreign bodies embedded in ocular structures must be removed by a physician.
  - Warm, wet compresses are often useful in ophthalmic inflammation or infections. They relieve pain and promote healing by increasing the blood supply to the affected area.

**Evaluation**

- Observe and interview for compliance with instructions regarding drug therapy and follow-up care.
- Observe and interview for relief of symptoms.
- Observe for systemic adverse effects of ophthalmic drugs (eg, tachycardia and dysrhythmias with adrenergics; bradycardia or bronchoconstriction with beta blockers).

---

**PRINCIPLES OF THERAPY**

**General Guidelines**

1. Topical application is the most common route of administration for ophthalmic drugs, and correct administration is essential for optimal therapeutic effects.
2. Systemic absorption of eye drops can be decreased by closing the eye and applying pressure over the tear duct (nasolacrimal occlusion) for 3 to 5 minutes after instillation.
3. When multiple eye drops are required, there should be an interval of 5 to 10 minutes between drops because of limited eye capacity and rapid drainage into tear ducts.

*(text continues on page 943)*
### Autonomic Drugs

**ADRENERGICS**
- Decreased production of aqueous humor
- Mydriasis
- Decreased IOP
- Vasoconstriction
- Photophobia

**ALPHA2 ADRENERGIC AGONISTS**
- Decreased IOP

**BETA BLOCKERS**
- Decreased production of aqueous humor
- Reduced IOP

**CHOLINERGICS**
- Increased outflow of aqueous humor
- Miosis

**ANTICHOLINESTERASE AGENT**
- Increased outflow of aqueous humor
- Miosis

**ANTICHOLINERGICS**
- Mydriasis
- Cycloplegia
- Photophobia

**Diuretics**

**CARBONIC ANHYDRASE INHIBITORS**
- Decreased production of aqueous humor
- Decreased IOP

### Drugs at a Glance: Drugs Used in Ocular Disorders*

<table>
<thead>
<tr>
<th>Classes of Drugs/Ocular Effects</th>
<th>Clinical Indications</th>
<th>Generic/Trade Name</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Autonomic Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ADRENERGICS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased production of</td>
<td>Glaucoma</td>
<td>Dipivefrin (0.1%</td>
<td>1 drop in</td>
</tr>
<tr>
<td>aqueous humor</td>
<td></td>
<td>solution) (Propine)</td>
<td>affected eye(s) q12h</td>
</tr>
<tr>
<td>Mydriasis</td>
<td></td>
<td>Epinephrine (0.5%,</td>
<td>1 drop in</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1%, and 2%</td>
<td>each eye once</td>
</tr>
<tr>
<td></td>
<td></td>
<td>solutions) (Epifrin,</td>
<td>or twice daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Glaucin)</td>
<td><em>Children: Same as adults</em></td>
</tr>
<tr>
<td>Decreased IOP</td>
<td></td>
<td>Hydroxyamphetamine</td>
<td>Before ophthalmoscopy, 1 drop in each eye</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(1% solution) (Paredrine)</td>
<td>Before ophthalmoscopy or refraction, 1 drop of 2.5% or 10% solution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenylephrine (2.5% and 10%</td>
<td>Preoperatively, 1 drop of 2.5% or 10% solution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>solutions) (Neo-Synephrine)</td>
<td>Postoperatively, 1 drop of 10% solution once or twice daily</td>
</tr>
<tr>
<td>Vasoconstriction</td>
<td></td>
<td></td>
<td>*Children: Refraction, 1 drop of 2.5% solution</td>
</tr>
<tr>
<td>Photophobia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALPHA2 ADRENERGIC AGONISTS</strong></td>
<td></td>
<td>Apraclonidine (Iopidine)</td>
<td>1–2 drops in affected eye(s) 3 times daily</td>
</tr>
<tr>
<td>Decreased IOP</td>
<td>Glaucoma</td>
<td>Brimonidine (Alphagan)</td>
<td>1 drop in affected eye(s) 3 times daily, q8h</td>
</tr>
<tr>
<td><strong>BETA BLOCKERS</strong></td>
<td></td>
<td>Betaxolol (Betoptic)</td>
<td>1–2 drops in affected eye(s) twice daily</td>
</tr>
<tr>
<td>Decreased production of</td>
<td>Glaucoma</td>
<td>Carteolol (Ocupress)</td>
<td>1 drop in affected eye(s) twice daily</td>
</tr>
<tr>
<td>aqueous humor</td>
<td></td>
<td>Levobunolol (Betagan)</td>
<td>1–2 drops in affected eye(s) once or twice daily</td>
</tr>
<tr>
<td>Reduced IOP</td>
<td></td>
<td>Metipranolol (OptiPranolol)</td>
<td>1 drop in affected eye(s) twice daily</td>
</tr>
<tr>
<td><strong>CHOLINERGICS</strong></td>
<td></td>
<td>Timolol maleate (Timoptic, Timoptic-XE)</td>
<td>1 drop in affected eye(s) twice daily; gel, 1 drop once daily</td>
</tr>
<tr>
<td>Increased outflow of aqueous</td>
<td>Glaucoma</td>
<td>Pilocarpine (0.25%–10% solutions) (Isopto Carpine, Pilocar)</td>
<td>Glaucoma, 1 drop of 1% or 2% solution in each eye 3–4 times daily</td>
</tr>
<tr>
<td>humor</td>
<td></td>
<td>Pilocarpine ocular system (Ocusert Pilo-20 or -40)</td>
<td>One system in conjunctival sac per week</td>
</tr>
<tr>
<td>Miosis</td>
<td></td>
<td>Carbachol (Caroptic)</td>
<td>2 drops of 0.75%–3% solution into eye(s) up to 3 times daily</td>
</tr>
<tr>
<td><strong>ANTICHOLINESTERASE AGENT</strong></td>
<td></td>
<td>Demecarium bromide (Humorsol)</td>
<td>1 drop of 0.125%–0.25% solution in each eye twice a day to twice a week</td>
</tr>
<tr>
<td>Increased outflow of aqueous</td>
<td>Glaucoma</td>
<td>Atropine sulfate (0.5%–3% solutions)</td>
<td>Before intraocular surgery, 1 drop</td>
</tr>
<tr>
<td>humor</td>
<td></td>
<td>Cyclopentolate hydrochloride (Cyclogyl)</td>
<td>After intraocular surgery, 1 drop once daily</td>
</tr>
<tr>
<td>Miosis</td>
<td></td>
<td>Homatropine hydrobromide (2% and 5% solutions)</td>
<td>For refraction, 1 drop of 0.5% or 2% solution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tropicamide (0.5% and 1% solutions) (Mydriacyl)</td>
<td>Before ophthalmoscopy, 1 drop of 0.5% solution</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td><em>Children: For refraction, 1 drop of 0.5%, 1%, or 2% solution, repeated in 10 min</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Refraction, 1 drop of 5% solution every 5 min for 2 or 3 doses or 1–2 drops of 2% solution every 10–15 min for 5 doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Uveitis, 1 drop of 2% or 5% solution 2–3 times daily</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Before refraction or ophthalmoscopy, 1 drop, repeated in 5 min, then every 20–30 min as needed to maintain mydriasis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mydriasis for refraction and other diagnostic purposes</td>
<td>Acetzolamide (Diamox, Diamox Sequels)</td>
<td>PO 250 mg q6h; sustained-release capsules, PO 500 mg q12h</td>
</tr>
<tr>
<td></td>
<td>Before and after intraocular surgery</td>
<td></td>
<td>IV, IM 5–10 mg/kg/d in divided doses, q6h</td>
</tr>
<tr>
<td></td>
<td>Treatment of uveitis</td>
<td></td>
<td><em>Children: PO 10–15 mg/kg/d in divided doses, q6–8h</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Acetzolamide (Diamox, Diamox Sequels)</td>
<td>IV, IM 5–10 mg/kg q6h</td>
</tr>
</tbody>
</table>

(continued)
### Drugs at a Glance: Drugs Used in Ocular Disorders* (continued)

<table>
<thead>
<tr>
<th>Classes of Drugs/Ocular Effects</th>
<th>Clinical Indications</th>
<th>Generic/Trade Name</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>OSMOTIC AGENTS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reduced volume of vitreous humor</td>
<td>treatment of acute glaucoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decreased IOP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prostaglandin Analogos</strong></td>
<td>Decreased IOP</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glaucoma</td>
<td>Bimatoprost (Lumigan)</td>
<td>1 drop once daily in the evening</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Latanoprost (Xalatan)</td>
<td>1 drop once daily in the evening</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Travoprost (Travatan)</td>
<td>1 drop once daily in the evening</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Unoprostone (Rescula)</td>
<td>1 drop twice daily</td>
</tr>
<tr>
<td><strong>Miscellaneous Agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ANESTHETICS, LOCAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surface anesthesia of conjunctiva and cornea</td>
<td>Tonometry</td>
<td>Proparacaine (Alcaine, Ophthaine)</td>
<td>Minor procedures, 1–2 drops of 0.5% solution</td>
</tr>
<tr>
<td></td>
<td>Removal of foreign bodies</td>
<td>Tetracaine (Pontocaine)</td>
<td>Minor procedures, 1–2 drops of 0.5% solution</td>
</tr>
<tr>
<td></td>
<td>Removal of sutures</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>LUBRICANTS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serve as “artificial tears”</td>
<td>Protect the cornea during keratitis or diagnostic procedures</td>
<td>Methylcellulose (Methulose)</td>
<td>1–2 drops as needed</td>
</tr>
<tr>
<td></td>
<td>Moisten contact lenses</td>
<td>Polyvinyl alcohol (Liquifilm)</td>
<td>1–2 drops as needed</td>
</tr>
</tbody>
</table>

IOP, intraocular pressure.

*Antimicrobial agents are listed in Drugs at a Glance: Ophthalmic Antimicrobial Agents; antiallergic and anti-inflammatory agents are listed in Drugs at a Glance: Topical Ophthalmic Antiallergic and Anti-inflammatory Agents.

### Drugs at a Glance: Ophthalmic Antimicrobial Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibacterial Agents</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Ciprofloxacin 3.5 mg/mL solution (Ciloxan)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comeal ulcer, day 1, 2 drops q15 min for 6 h, then q30 min for rest of day; day 2, 2 drops q1h; days 3–14, 2 drops q4h Conjunctivitis, 1–2 drops q2h while awake for 2 d, then 1–2 drops q4h while awake for 5 d</td>
</tr>
<tr>
<td><strong>Erythromycin 5% ointment (Ilotycin)</strong></td>
<td>Prevention of neonatal gonococcal or chlamydial conjunctivitis, 0.5–1 cm in each eye</td>
</tr>
<tr>
<td><strong>Gentamicin 3 mg/mL solution or 3 mg/g ointment (Garamycin)</strong></td>
<td>Safety and efficacy not established in infants &lt;1 y</td>
</tr>
<tr>
<td><strong>Levofloxacin 5 mg/mL solution (Quixin)</strong></td>
<td>Same as adults</td>
</tr>
<tr>
<td><strong>Norfloxacin 3 mg/mL solution (Chibroxin)</strong></td>
<td>Dosage not established</td>
</tr>
<tr>
<td><strong>Ofloxacin 3 mg/mL solution (Ocuflox)</strong></td>
<td>Same as adults for children 1 y and older</td>
</tr>
</tbody>
</table>
Drugs at a Glance: Ophthalmic Antimicrobial Agents (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sulfacetamide 10% solution or ointment</strong></td>
<td>Conjunctivitis, corneal ulcers, or other superficial infections caused by susceptible organisms: 1–2 drops q4h or 0.5 inch ointment 3–4 times daily, for 7–10 days</td>
</tr>
<tr>
<td><strong>Fluorometholone</strong></td>
<td>Safety and efficacy not established. Contraindicated in infants &lt;2 mo of age</td>
</tr>
<tr>
<td><strong>Loteprednol</strong> (Lotemax, Alrex)</td>
<td>Safety and efficacy not established. Contraindicated in infants &lt;2 mo of age</td>
</tr>
<tr>
<td><strong>Sulfisoxazole 4% solution</strong> (Gantrisin)</td>
<td>Safety and efficacy not established. Contraindicated in infants &lt;2 mo of age</td>
</tr>
<tr>
<td><strong>Trifluridine 1% solution</strong> (Viroptic)</td>
<td>1 drop q1–2h for 3–4 d, then q3–4h, for 14–21 d</td>
</tr>
</tbody>
</table>

### Antifungal Agents

**Natamycin 5% suspension** (Natacyn) 1 drop q1–2h for 3–4 d, then q3–4h, for 14–21 d

### Corticosteroids

**Dexamethasone** (Decadron, Maxidex) 1 drop in affected eye(s) twice daily

**Fluorometholone** (FML) Solution or suspension 1–2 drops q1h daytime, q2h nighttime until response; then 1 drop q4h Postoperative inflammation, 1–2 drops 4 times daily, starting 24 h after surgery, for 2 wk Ointment thin strip 3–4 times daily until response, then once or twice daily Solution 1 drop q1–2h until response, then less often Ointment thin strip 3–4 times daily until response, then once or twice daily Allergic conjunctivitis, 0.2%, 1 drop in affected eye(s) 4 times daily Keratitis, 0.5%, 1–2 drops in affected eye(s) 4 times daily Postoperative inflammation, 0.5%, 1–2 drops in affected eye(s) 4 times daily starting 24 h after surgery and continuing for 2 wk

### Antiallergic Agents

**Azelastine** (Optivar) 1 drop in affected eye(s) twice daily

**Cromolyn** (Crolom, Opticrom) 1–2 drops in each eye 4–6 times daily at regular intervals

**Emedastine** (Emadine) 1–2 drops twice daily

**Ketotifen** (Zaditor) 1 drop in affected eye(s) q8–12h

**Levocabastine** (Livostin) 1 drop in affected eye(s) 4 times daily, for up to 2 wk

**Lodoxamide** (Alomide) 1–2 drops in affected eye(s) 4 times daily, for up to 3 mo

**Olopatadine** (Patanol) 1–2 drops twice daily

### Antiviral Agent

**Trifluridine 1% solution** (Viroptic) Keratoconjunctivitis or corneal ulcers caused by herpes simplex virus: 1 drop q2h while awake (maximum, 9 drops/d) until corneal ulcer heals, then 1 drop q4h (minimum, 5 drops/d), for 7 d

**Antifungal Agent**

**Natamycin 5% suspension** (Natacyn) 1 drop q1–2h for 3–4 d, then q3–4h, for 14–21 d

Drugs at a Glance: Topical Ophthalmic Antiallergic and Anti-Inflammatory Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiallergic Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Azelastine</strong> (Optivar)</td>
<td>Allergic conjunctivitis</td>
<td>1 drop in affected eye(s) twice daily</td>
</tr>
<tr>
<td><strong>Cromolyn</strong> (Crolom, Opticrom)</td>
<td>Treatment of seasonal allergic conjunctivitis, keratitis, and keratoconjunctivitis</td>
<td>1–2 drops in each eye 4–6 times daily at regular intervals</td>
</tr>
<tr>
<td><strong>Emedastine</strong> (Emadine)</td>
<td>Allergic conjunctivitis</td>
<td>1–2 drops twice daily</td>
</tr>
<tr>
<td><strong>Ketotifen</strong> (Zaditor)</td>
<td>Allergic conjunctivitis</td>
<td>1 drop in affected eye(s) q8–12h</td>
</tr>
<tr>
<td><strong>Levocabastine</strong> (Livostin)</td>
<td>Treatment of seasonal allergic conjunctivitis</td>
<td>1–2 drops in affected eye(s) 4 times daily, for up to 3 mo</td>
</tr>
<tr>
<td><strong>Lodoxamide</strong> (Alomide)</td>
<td>Conjunctivitis</td>
<td>1–2 drops twice daily</td>
</tr>
<tr>
<td><strong>Olopatadine</strong> (Patanol)</td>
<td>Allergic conjunctivitis</td>
<td>1–2 drops twice daily</td>
</tr>
</tbody>
</table>

**Corticosteroids**

**Dexamethasone** (Decadron, Maxidex) 1 drop in affected eye(s) twice daily

**Fluorometholone** (FML) Solution or suspension 1–2 drops q1h daytime, q2h nighttime until response; then 1 drop q4h Postoperative inflammation, 1–2 drops 4 times daily, starting 24 h after surgery, for 2 wk Ointment thin strip 3–4 times daily until response, then once or twice daily Solution 1 drop q1–2h until response, then less often Ointment thin strip 3–4 times daily until response, then once or twice daily Allergic conjunctivitis, 0.2%, 1 drop in affected eye(s) 4 times daily Keratitis, 0.5%, 1–2 drops in affected eye(s) 4 times daily Postoperative inflammation, 0.5%, 1–2 drops in affected eye(s) 4 times daily starting 24 h after surgery and continuing for 2 wk

(continued)
Drugs at a Glance: Topical Ophthalmic Antiallergic and Anti-Inflammatory Agents (continued)

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medrysone (HMS)</td>
<td>Inflammatory disorders</td>
<td>1 drop q1–2h until response obtained, then less frequently</td>
</tr>
<tr>
<td>Prednisolone (Econopred, others)</td>
<td>Inflammatory disorders</td>
<td>Solution or suspension 1–2 drops q1–2h until response, then 1 drop q4h, then less frequently</td>
</tr>
<tr>
<td>Rimexolone (Vexol)</td>
<td>Treatment of anterior uveitis</td>
<td>Ointment thin strip 3–4 times daily until response, then once or twice daily</td>
</tr>
<tr>
<td></td>
<td>Treatment of inflammation after ocular surgery</td>
<td>Uveitis, 1–2 drops in affected eye q1h during waking hours for 1 wk, then 1 drop q2h for 1 wk, then taper until uveitis resolved</td>
</tr>
<tr>
<td></td>
<td>Postoperative inflammation, 1–2 drops in affected eye(s) 4 times daily starting 24 h after surgery and continuing for 2 wk</td>
<td></td>
</tr>
</tbody>
</table>

Nonsteroidal Anti-inflammatory Drugs

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indications for Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac (Voltaren)</td>
<td>Treatment of inflammation after cataract surgery</td>
<td>1 drop to affected eye 4 times daily, starting 24 h after surgery, for 2 wk</td>
</tr>
<tr>
<td>Flurbiprofen (Ocufen)</td>
<td>Inhibition of pupil constriction during eye surgery</td>
<td>1 drop every 30 min for 4 doses, starting 2 h before surgery</td>
</tr>
<tr>
<td>Ketorolac (Acular)</td>
<td>Treatment of ocular itching due to seasonal allergic conjunctivitis</td>
<td>1 drop 4 times daily for approximately 1 wk</td>
</tr>
<tr>
<td>Suprofen (Profenal)</td>
<td>Inhibition of pupil constriction during eye surgery</td>
<td>2 drops at 3, 2, and 1 h before surgery or q4h while awake the day before surgery</td>
</tr>
</tbody>
</table>

CLIENT TEACHING GUIDELINES

Topical Eye Medications

General Considerations

- Prevent eye disorders, when possible. For example, try to avoid long periods of reading and computer work; minimize exposure to dust, smog, cigarette smoke, and other eye irritants; wash hands often and avoid touching the eyes to decrease risks of infection.
- Do not use nonprescription eye drops (eg, Murine, Visine) on a regular basis for longer than 48 to 72 hours. Persistent eye irritation and redness should be reported to a physician.
- Have regular eye examinations and testing for glaucoma after 40 years of age.
- Eye drop preparations often contain sulfites, which can cause allergic reactions in some people.
- If you have glaucoma, do not take any drugs without the ophthalmologist’s knowledge and consent. Many drugs given for purposes other than eye disorders may cause or aggravate glaucoma. Also, wear a medical alert bracelet or carry identification that states you have glaucoma. This helps to avoid administration of drugs that aggravate glaucoma or to maintain treatment of glaucoma, in emergencies.
- If you have an eye infection, wash hands before and after contact with the infected eye to avoid spreading the infection to the unaffected eye or to other people. Also, avoid touching the unaffected eye.
- If you wear contact lenses, wash your hands before inserting them and follow instructions for care (eg, cleaning, inserting or removing, and duration of wear). Improper or infrequent cleaning may lead to infection. Overwearing is a common cause of corneal abrasion and may cause corneal ulceration. The lens wearer should consult a physician when eye pain occurs. Antibiotics are often prescribed for corneal abrasions to prevent development of ulcers.
- If you wear soft contact lenses, do not use any eye medication without consulting a specialist in eye care. Some eye drops contain benzalkonium hydrochloride, a preservative, which is absorbed by soft contacts. The medication should not be applied while wearing soft contacts and should be instilled 15 minutes or longer before inserting soft contacts.
- Never use eye medications used by someone else and never allow your eye medications to be used by anyone else. These preparations should be used by one person only and they are dispensed in small amounts for this purpose. Single-person use minimizes cross-contamination and risks of infection.
- Many eye drops and ointments cause temporary blurring of vision. Do not use such medications just before driving or operating potentially hazardous machinery.
- Avoid straining at stool (use laxatives or stool softeners if necessary), heavy lifting, bending over, coughing, and vomiting when possible. These activities increase intraocular pressure, which may cause eye damage in glaucoma and after eye surgery.
4. Absorption of eye medications is increased in eye disorders associated with hyperemia and inflammation.

5. Many ophthalmic drugs are available as eye drops (solutions or suspensions) and ointments. Ointments do not need to be administered as frequently and often produce higher concentrations of drug in target tissues. However, ointments also cause blurred vision, which limits their daytime use, at least for ambulatory clients. In some situations, drops may be used during waking hours and ointments at bedtime. However, the two formulations are not interchangeable.

6. Topical ophthalmic medications should not be used after the expiration date, and cloudy, discolored solutions should be discarded.

7. Topical eye medications contain a number of inactive ingredients, such as preservatives, buffers, tonicity agents, antioxidants, and so forth. Some contain sulfites, to which some people may have allergic reactions.

8. Some eye drops contain benzalkonium hydrochloride, a preservative, which is absorbed by soft contact lenses. The medications should not be applied while wearing soft contacts and should be instilled 15 minutes or longer before inserting soft contacts.

9. To increase safety and accuracy of ophthalmic drug therapy, the labels and caps of eye medications are color coded.

**Ocular Infections**

Guidelines for drug therapy of ocular infections include the following:

1. Drug therapy is usually initiated as soon as culture material (eye secretions) has been obtained, often with a broad-spectrum antibacterial agent or a combination of two or more antibiotics.

2. Topical administration is used most often, and recommended drugs include bacitracin, polymyxin B, and sulfacetamide. These agents are rarely given systemically. They do not cause sensitization to commonly used systemic antibiotics and do not promote growth of drug-resistant microorganisms. Other antibacterial drugs available in ophthalmic formulations include erythromycin, gentamicin, tobramycin, ciprofloxacin, norfloxacin, ofloxacin, and combination products.

3. In severe infections, antibacterial drugs may be given both topically and systemically. Because systemic antibiotics penetrate the eye poorly, large doses are required to attain therapeutic drug concentrations in ocular structures. Drugs that reach therapeutic levels in the eye when given in proper dosage include ampicillin and dicloxacillin. Gentamicin and other antibiotics penetrate the eye when inflammation is present.

4. Combination products containing two or more antibacterials are available for topical treatment of external ocular infections. These products are most useful when therapy must be initiated before the infecting microorganism is identified. Mixtures (eg, polymyxin B and bacitracin) provide a broader spectrum of antibacterial activity than a single drug.

5. Fixed-dose combinations of an antibacterial agent and a corticosteroid are available for topical use in selected conditions (eg, staphylococcal keratitis, blepharoconjunctivitis, allergic conjunctivitis, and some postoperative inflammatory reactions). Neomycin and corticosteroid mixtures include NeoDecadron. Neomycin, polymyxin B, and corticosteroid mixtures include Poly-Pred and Maxitrol. Neomycin, polymyxin B,
bacitracin, and corticosteroid mixtures include Cortisporin. Sulfacetamide and corticosteroid mixtures include Blephamide, Cetapred, Metimyd, and Vasocidin.

6. Trifluridine (Viroptic) is the drug of choice in eye infections caused by the herpes simplex virus.

7. Natamycin (Natacyn) is the drug of choice in fungal eye infections. It has a broad spectrum of antifungal activity and is nonirritating and nontoxic.

**Glaucoma**

For chronic glaucoma, the goal of drug therapy is to slow disease progression by reducing IOP. Topical beta blockers are first-line drugs and commonly used. They may be used alone or in combination with other antiglaucoma drugs. Several are available for ophthalmic use. Most adverse effects of systemic beta blockers may also occur with ophthalmic preparations and their use may be restricted in clients with respiratory or cardiac disease.

Other first-line drugs, which may be used with or instead of beta blockers, include brimonidine, prostaglandin analogs, and topical carbonic anhydrase inhibitors (CAIs). Apraclonidine, dipivefrin, epinephrine, and pilocarpine are second-line drugs, mainly because of more adverse effects than first-line agents. Oral CAIs are used only when topical CAIs are ineffective.

**Use in Children**

Topical ophthalmic drug therapy in children differs little from that in adults. Few studies of ophthalmic drug therapy in children have been reported, and many conditions for which adults need therapy (eg, cataract, glaucoma) rarely occur in children. A major use of topical ophthalmic drugs in children is to dilate the pupil and paralyze accommodation for ophthalmoscopic examination. As a general rule, the short-acting mydriatics and cycloplegics (eg, cyclopentolate, tropicamide) are preferred because they cause fewer systemic adverse effects than atropine and scopolamine. In addition, lower drug concentrations are usually given empirically because of the smaller size of children and the potential risk of systemic adverse effects.

**Use in Older Adults**

Older adults are at risk for development of ocular disorders, especially glaucoma and cataracts. General principles of ophthalmic drug therapy are the same as for younger adults. In addition, older adults are likely to have cardiovascular disorders, which may be aggravated by systemic absorption of topical eye medication. Thus, accurate dosage and occlusion of the nasolacrimal duct in the inner canthus of the eye are needed to prevent adverse drug effects (eg, hypertension, tachycardia, or dysrhythmias with adrenergic drugs and bradycardia, heart block, or bronchoconstriction with beta blockers).

**Home Care**

The home care nurse may be involved in the care of clients with acute or chronic eye disorders. As with other drug therapy, the nurse may need to teach clients and caregivers reasons for use, accurate administration, and assessment of therapeutic and adverse responses to eye medications. The nurse may also need to encourage periodic eye examinations and measurements of IOP to promote optimal vision and prevent blindness.

**Nursing Notes: Apply Your Knowledge**

Sylvia Jetson, an 82-year-old widow, is diagnosed in your clinic with open-angle glaucoma. She is given a prescription of timolol maleate (Timoptic) eye drops to decrease her intraocular pressure. Discuss teaching that is important before Mrs. Jetson leaves the clinic.

**How Can You Avoid This Medication Error?**

You are administering medications in a nursing home. A confused elderly resident has an order for chloramphenicol (Chloromycetin) 0.5% 1 drop OS, bid. When you enter her room, she asks, “Are you sure those eye drops are for me?” After rechecking the order, you proceed to administer 1 drop of Chloramycetin into each eye.
# NURSING ACTIONS

## Ophthalmic Drugs

### NURSING ACTIONS

1. **Administer accurately**
   - **a.** Read labels of ophthalmic medications carefully.
   - **b.** Read medication orders carefully and accurately.
   - **c.** For hospitalized clients, keep eye medications at the bedside.
   - **d.** Wash hands before approaching the client for instillation of eye medications.
   - **e.** To administer eye drops, have the client lie down or tilt the head backward and look upward. Then, pull down the lower lid to expose the conjunctival sac, and drop the medication into the sac. After instillation, have the client close the eyes gently, and apply pressure to the inner canthus.
   - **f.** When instilling ophthalmic ointments, position the client as above, and apply a 1/4-inch to 1/2-inch strip of ointment to the conjunctiva.
   - **g.** Do not touch the dropper tip or ointment top to the eye or anything else.
   - **h.** When crusts or secretions are present, cleanse the eye before administering medication.
   - **i.** When two or more eye drops are scheduled for the same time, they should be instilled at least 5 min apart, preferably 10 min.

2. **Observe for therapeutic effects**
   - **a.** With beta-blocking agents, observe for decreased intraocular pressure (IOP).
   - **b.** With mydriatics, observe for dilation of the pupil.
   - **c.** With miotics, observe for constriction of the pupil.
   - **d.** With antimicrobial drugs, observe for decreased redness, edema, and drainage.
   - **e.** With osmotic agents, observe for decreased IOP.

3. **Observe for adverse effects**
   - **a.** Local effects:
     1. Irritation, burning, stinging, blurred vision, discomfort, redness, itching, tearing, conjunctivitis, keratitis, allergic reactions
     2. With prostaglandin analogs—permanent darkening of eye color may occur, especially in light-colored eyes. Changes in the length and thickness of eyelashes may also occur.

### RATIONALE/EXPLANATION

- To avoid error, because many drugs are available in several concentrations.
- To avoid error. Avoid abbreviations (eg, OS, OD, OU) when possible.
- Eye medications should be used by one person only. They are dispensed in small amounts for this purpose. This minimizes cross-contamination and risk of infection.
- To reduce risks of infection
- Drug absorption and concentration in ocular tissues depend partly on the length of time the medication is in contact with ocular tissues. Contact time is increased by closing the eyes (delays outflow into the nasolacrimal duct) and pressure on the inner canthus (delays outflow and decreases side effects resulting from systemic absorption).
- To avoid contamination of the medication and infection
- If the eye is not cleansed, the drug may not be absorbed.
- To avoid drug loss by dilution and outflow into the nasolacrimal duct
- Therapeutic effects depend on the reason for use.
- Lowering of IOP usually occurs within a month; periodic measurements should be done.
- Mydriasis begins within 5 to 15 min after instillation.
- With oral glycerin, maximal decrease in IOP occurs approximately 1 h after administration, and effects persist for about 5 h. With intravenous (IV) mannitol, maximal decreased IOP occurs within 30 to 60 min and lasts 6 to 8 h.
- These effects may occur with any topical ophthalmic agent. Burning and stinging occur with instillation and are usually transient. Allergic reactions may occur with the active ingredient, preservatives, or other components.
- Changes in eye color and eyelashes may not be noticeable for months to years after starting drug use.
- These effects are most problematic in clients receiving treatment in one eye.

(continued)
### Nursing Actions and Rationale/Explanation

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(3) With antibacterial agents—superinfection or sensitization</td>
<td>Superinfection caused by drug-resistant organisms may occur. Sensitization means that topical application induces antibody formation. Therefore, if the same or a related drug is subsequently administered systemically, an allergic reaction may occur. Sensitization can be prevented or minimized by avoiding topical administration of antibacterial agents that are commonly given systemically.</td>
</tr>
<tr>
<td>(4) With anticholinergics, adrenergics, topical corticosteroids—glaucoma or increased IOP</td>
<td>Mydriatic drugs (anticholinergics and adrenergics) may cause an acute attack of angle closure in clients with closed-angle glaucoma by blocking outflow of aqueous humor. Topical corticosteroids raise IOP in some clients. The “glaucomatous” response occurs most often in clients with chronic, primary open-angle glaucoma and their relatives. It also may occur in clients with myopia or diabetes mellitus. The magnitude of increased IOP depends on the concentration, frequency of administration, duration of therapy, and anti-inflammatory potency of the corticosteroid. This effect can be minimized by checking IOP every 2 mo in clients receiving long-term therapy with topical corticosteroids.</td>
</tr>
<tr>
<td>(5) Cataract formation</td>
<td>This is most likely to occur with long-term use of anticholinesterase agents.</td>
</tr>
<tr>
<td>(6) With miotic drugs—decreased vision in dim light</td>
<td>These agents prevent pupil dilation, which normally occurs in dim light or darkness.</td>
</tr>
</tbody>
</table>

#### Systemic effects:

<table>
<thead>
<tr>
<th>Nursing Actions</th>
<th>Rationale/Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) With beta-blocking agents—bradycardia, bronchospasm, and others (see Chap. 19)</td>
<td>These agents may be absorbed systematically and cause all the adverse effects associated with oral or injected drugs.</td>
</tr>
<tr>
<td>(2) With miotics—sweating, nausea, vomiting, diarrhea, abdominal pain, bradycardia, hypotension, bronchoconstriction. Toxic doses produce ataxia, confusion, convulsions, coma, respiratory failure, and death.</td>
<td>These cholinergic or parasympathomimetic effects occur rarely with pilocarpine or carbachol. Acute toxicity may be reversed by an anticholinergic agent, atropine, given IV.</td>
</tr>
<tr>
<td>(3) With anticholinergic mydriatics—dryness of the mouth and skin, fever, rash, tachycardia, confusion, hallucinations, delirium</td>
<td>These effects are most likely to occur with atropine and in children and older adults. Tropicamide (Mydriacyl) rarely causes systemic reactions.</td>
</tr>
<tr>
<td>(4) With adrenergic mydriatics—tachycardia, hypertension, premature ventricular contractions, tremors, headache</td>
<td>Systemic effects are uncommon. They are more likely to occur with repeated instillations of high drug concentrations (eg, epinephrine 2%, phenylephrine [Neo-Synephrine] 10%).</td>
</tr>
<tr>
<td>(5) With carbonic anhydrase inhibitors—anorexia, nausea, vomiting, diarrhea, paresthesias, weakness, lethargy</td>
<td>Nausea, malaise, and paresthesias (numbness and tingling of extremities) commonly occur with oral drugs, which are given only when topical drugs are not effective.</td>
</tr>
<tr>
<td>(6) With osmotic diuretics—dehydration, nausea, vomiting, headache, hyperglycemia and glycosuria with glycerin (Osmoglyn)</td>
<td>These agents may produce profound diuresis and dehydration. Oral agents (eg, glycerin) are less likely to cause severe systemic effects than IV agents (eg, mannitol). These agents are usually given in a single dose, which decreases the risks of serious adverse reactions unless large doses are given.</td>
</tr>
<tr>
<td>(7) With corticosteroids, see Chapter 24.</td>
<td>Serious adverse effects may occur with long-term use of corticosteroids.</td>
</tr>
<tr>
<td>(8) With antibacterial agents, see Chapter 33 and the chapter on the individual drug group.</td>
<td>Adverse effects may occur with all antibacterial agents.</td>
</tr>
<tr>
<td>(9) With apraclonidine—bradycardia, orthostatic hypotension, headache, insomnia</td>
<td>This drug is related to clonidine, an alpha-adrenergic agonist anti-hypertensive agent (see Chaps. 19 and 55).</td>
</tr>
</tbody>
</table>

(continued)
## NURSING ACTIONS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(10) With ophthalmic nonsteroidal antiinflammatory drugs—potential for increased bleeding</td>
<td>Systemic absorption may interfere with platelet function and increase risks of bleeding with surgery or anticoagulant therapy.</td>
</tr>
<tr>
<td>(11) With prostaglandin analogs—headache, cold/flu/upper respiratory infection, bronchitis, sinusitis, muscle and joint pain, chest pain</td>
<td>These were the most commonly reported systemic adverse effects in clinical trials, similar in incidence to placebo.</td>
</tr>
</tbody>
</table>

### 4. Observe for drug interactions

**a. Drugs that increase effects of antiglaucoma drugs:**
- Other antiglaucoma drugs

**b. Drugs that increase effects of adrenergic (sympathomimetic) ophthalmic drugs:**
- Anticholinergic ophthalmic drugs
- Systemic adrenergic drugs

**c. Drugs that decrease effects of adrenergic ophthalmic preparations:**
- Cholinergic and anticholinesterase ophthalmic drugs

**d. Drugs that increase effects of antiadrenergic ophthalmic preparations:**
- Systemic antiadrenergics (eg, propranolol, atenolol, metoprolol, nadolol, timolol)

**e. Drugs that increase effects of anticholinergic ophthalmic drugs:**
- Adrenergic ophthalmic agents
- Systemic anticholinergic drugs (eg, atropine) and other drugs with anticholinergic effects (eg, some antihistamines, antipsychotic agents, and tricyclic antidepressants)

**f. Drugs that decrease effects of cholinergic and anticholinesterase ophthalmic drugs:**
- Anticholinergics and drugs with anticholinergic effects (eg, atropine, antipsychotic agents, tricyclic antidepressants, some antihistamines)
- Corticosteroids
- Sympathomimetic drugs

**RATIONAL/EXPLANATION**

- Antiglaucoma drugs may be used in various combinations for additive effects when a single drug does not decrease IOP sufficiently.
- The combination (eg, atropine and phenylephrine) produces additive mydriasis.
- Additive risks of adverse effects (eg, tachycardia, cardiac dysrhythmias, hypertension)
- Antagonize mydriatic effects of adrenergic drugs
- When the client is receiving a topical beta blocker in ocular disorders, administration of systemic beta-blocking agents in cardiovascular disorders may cause additive systemic toxicity.
- Additive mydriasis
- Additive anticholinergic effects (mydriasis, blurred vision, tachycardia). These drugs are hazardous in narrow-angle glaucoma.
- Antagonize antiglaucoma (miotic) effects of cholinergic and anticholinesterase drugs
- Long-term use of corticosteroids, topically or systemically, raises IOP and may cause glaucoma. Therefore, corticosteroids decrease effects of all drugs used for glaucoma.
- Antagonize miotic (antiglaucoma) effect
Nursing Notes: Apply Your Knowledge

Answer: Start by assessing what Mrs. Jetson knows about glaucoma and providing basic information about the condition. Review and write down the order for eye drops. Sometimes the small print on the medication container is difficult to read. Ask Mrs. Jetson if she has taken eye drops before. If so, watch her demonstrate this procedure, reinforcing proper technique (tilt head back, pull down lower lid, drop medication into sac, close eyes, occlude tear duct). Good aseptic technique should be stressed (wash hands, keep container clean, do not let dropper touch eye). Also caution Mrs. Jetson to notify her doctor before taking any medications or remedies.

How Can You Avoid This Medication Error?

Answer: The order indicates that this patient should receive 1 drop of Chloromycetin in her left eye. The abbreviations for ocular medications include OS, left eye; OD, right eye; and OU, both eyes. Chloromycetin is used to treat infection that may have been present only in the left eye. In general, it is safer to spell out right eye, etc., than to use abbreviations.

Review and Application Exercises

1. What is the main function of the eye?
2. List common disorders of the eye for which drug therapy is indicated.
3. Do ophthalmic medications need to be sterile? Why or why not?
4. What are important principles and techniques related to the nurse’s administration of ophthalmic drugs?
5. For a client with newly prescribed eye drops, how would you teach self-administration principles and techniques?

SELECTED REFERENCES


Drugs Used in Dermatologic Conditions

Objectives

AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Review characteristics of skin structures that influence drug therapy of dermatologic disorders.
2. Discuss antimicrobial, anti-inflammatory, and selected miscellaneous drugs in relation to their use in dermatologic disorders.
3. Use correct techniques to administer dermatologic medications.
4. Teach clients, family members, or caregivers correct administration of dermatologic medications.
5. For clients with “open lesion” skin disorders, teach about the importance and techniques of preventing infection.
6. Practice and teach measures to protect the skin from the damaging effects of sun exposure.

Critical Thinking Scenario

Fifteen-year-old Shawn Kelly stops by to talk when you are working in the teen clinic. For the last 6 months, he has had a severe problem with acne and his face is currently spotted with pimples and pustules.

Reflect on:

► Why acne is so common during adolescence.
► The impact acne has on the psychosocial development of an adolescent.
► How you will structure your intervention to be most therapeutic.
► Appropriate teaching for Shawn related to his acne.

OVERVIEW

The skin, the largest body organ, is the interface between the internal and external environments. The skin is composed of the epidermis and dermis. Epidermal or epithelial cells begin in the basal layer of the epidermis and migrate outward, undergoing degenerative changes in each layer. The outer layer, called the stratum corneum, is composed of dead cells and keratin. The dead cells are constantly being shed (desquamated) and replaced by newer cells. Normally, approximately 1 month is required for cell formation, migration, and desquamation. When dead cells are discarded, keratin remains on the skin. Keratin is a tough protein substance that is insoluble in water, weak acids, and weak bases. Hair and nails, which are composed of keratin, are referred to as appendages of the skin.

Melanocytes are pigment-producing cells located at the junction of the epidermis and the dermis. These cells produce yellow, brown, or black skin coloring in response to genetic influences, melanocyte-stimulating hormone released from the anterior pituitary gland, and exposure to ultraviolet (UV) light (eg, sunlight).

The dermis is composed of elastic and fibrous connective tissue. Dermal structures include blood vessels, lymphatic channels, nerves and nerve endings, sweat glands, sebaceous glands, and hair follicles. The dermis is supported underneath by subcutaneous tissue, which is composed primarily of fat cells.

The skin has numerous functions, most of which are protective, including the following:

- Serves as a physical barrier against loss of fluids and electrolytes and against entry of microorganisms, foreign bodies, and other potentially harmful substances
- Detects sensations of pain, pressure, touch, and temperature through sensory nerve endings
- Assists in regulating body temperature through production and elimination of sweat
• Serves as a source of vitamin D when exposed to sunlight or other sources of UV light. Skin contains a precursor for vitamin D.
• Serves as an excretory organ. Water, sodium, chloride, lactate, and urea are excreted in sweat.
• Inhibits growth of many microorganisms by its acidic pH (4.5 to 6.5)

Mucous membranes are composed of a surface layer of epithelial cells, a basement membrane, and a layer of connective tissue. They line body cavities that communicate with the external environment (ie, mouth, vagina, anus). They receive an abundant blood supply because capillaries lie just beneath the epithelial cells.

Dermatologic disorders may be primary (ie, originate in the skin or mucous membranes) or secondary (ie, result from a systemic condition, such as measles or adverse drug reactions). This chapter emphasizes selected primary skin disorders and the topical medications used to prevent or treat them.

### DISORDERS OF THE SKIN

Because the skin is constantly exposed to the external environment, it is susceptible to numerous disorders, including those described in the following sections.

#### Inflammatory Disorders

**Dermatitis**

*Dermatitis* is a general term denoting an inflammatory response of the skin to injuries from irritants, allergens, or trauma. *Eczema* is often used as a synonym for dermatitis. Whatever the cause, dermatitis is usually characterized by erythema, pruritus, and skin lesions. It may be acute or chronic.

- **Atopic dermatitis** is a common disorder characterized mainly by pruritus and lesions that vary according to the extent of inflammation, stages of healing, and scratching. Scratching damages the skin and increases the risks of secondary infection. Acute lesions are reddened skin areas containing papules and vesicles; chronic lesions are often thick, fibrotic, and nodular.

  The cause is uncertain but may involve allergic, hereditary, or psychological elements. Approximately 50% to 80% of clients have asthma or allergic rhinitis; some have a family history of these disorders. Thus, exposure to possible causes or exacerbating factors such as allergens, irritating chemicals, foods, and emotional stress should be considered. The condition may occur in all age groups but is more common in children.

- **Contact dermatitis** results from direct contact with irritants (eg, soaps, detergents) or allergens (eg, clothing materials or dyes, jewelry, cosmetics) that stimulate inflammation. Irritants cause tissue damage and dermatitis in anyone with sufficient contact or exposure. Allergens cause dermatitis only in sensitized or hypersensitive people. The location of the dermatitis may indicate the cause (eg, facial dermatitis may indicate an allergy to cosmetics).

- **Seborrheic dermatitis** is a disease of the sebaceous glands characterized by excessive production of sebum. It may occur on the scalp, face, or trunk. A simple form involving the scalp is dandruff, which is characterized by flaking and itching of the skin. More severe forms are characterized by greasy, yellow scales or crusts with variable amounts of erythema and itching.

- **Urticaria** (“hives”) is an inflammatory response characterized by a skin lesion called a wheal, a raised edematous area with a pale center and red border, which itches intensely. Histamine is the most common mediator of urticaria and it causes vasodilation, increased vascular permeability, and pruritus.

  Histamine is released from mast cells and basophils by both allergic (eg, insect bites, foods, drugs) and nonallergic (eg, radiocontrast media, opiates, and some antibiotics as well as heat, cold, pressure, UV light) stimuli. An important difference between allergic and nonallergic reactions is that many allergic reactions require prior exposure to the stimulus, whereas nonallergic reactions can occur with the first exposure.

- **Drug-induced skin reactions** can occur with virtually any drug and can resemble the signs and symptoms of virtually any skin disorder. Topical drugs usually cause a localized, contact dermatitis type of reaction and systemic drugs cause generalized skin lesions. Skin manifestations of serious drug reactions include erythema, facial edema, pain, blisters, necrosis, and urticaria. Systemic manifestations may include fever, enlarged lymph nodes, joint pain or inflammation, shortness of breath, hypotension, and leukocytosis. Drug-related reactions usually occur within the first or second week of drug administration and subside when the drug is discontinued.

**Psoriasis**

*Psoriasis* is a chronic skin disorder characterized by erythematous, dry, scaling lesions. The lesions may occur anywhere on the body but commonly involve the skin covering bony prominences, such as the elbows and knees. The disease is characterized by remissions and exacerbations. Exacerbating factors include infections, winter weather, some drugs (eg, beta blockers, lithium) and possibly stress, obesity, and alcoholism.

The cause of psoriasis is thought to be an inflammatory process. The pathophysiology involves excessively rapid turnover of epidermal cells. Instead of 30 days from formation to elimination of normal epidermal cells, epidermal cells involved in psoriasis are abnormal in structure and have a lifespan of about 4 days.

Skin lesions may be tender, but they do not usually cause severe pain or itching. However, the lesions are unsightly and usually cause embarrassment and mental distress.
Rosacea
Rosacea is characterized by erythema, flushing, telangiectases (fine, red, superficial blood vessels) and acne-like lesions of facial skin. Hyperplasia of the nose (rhinophyma) eventually develops. Rosacea is a chronic disease of unknown etiology that usually occurs in middle-aged and older people, more often in men than women.

Dermatologic Infections

Bacterial Infections

Bacterial infections of the skin are common; they are most often caused by streptococci or staphylococci.

- **Cellulitis** is characterized by erythema, tenderness, and edema, which may spread to subcutaneous tissue. Generalized malaise, chills, and fever may occur.
- **Folliculitis** is an infection of the hair follicles that most often occurs on the scalp or bearded areas of the face.
- **Furuncles** and **carbuncles** are infections usually caused by staphylococci. Furuncles (boils) may result from folliculitis. They usually occur in the neck, face, axillae, buttocks, thighs, and perineum. Furuncles tend to recur. Carbuncles involve many hair follicles and include multiple pustules. Carbuncles may cause fever, malaise, leukocytosis, and bacteremia. Healing of carbuncles often produces scar tissue.
- **Impetigo** is a superficial skin infection caused by streptococci or staphylococci. An especially contagious form is caused by group A beta-hemolytic streptococci. This form occurs most often in children.

Fungal Infections

Fungal infections of the skin and mucous membranes are most often caused by **Candida albicans**.

- **Oral candidiasis** (thrush) involves mucous membranes of the mouth. It often occurs as a superinfection after the use of broad-spectrum systemic antibiotics.
- **Candidiasis of the vagina and vulva** occurs with systemic antibiotic therapy and in women with diabetes mellitus.
- **Intertrigo** involves skin folds or areas where two skin surfaces are in contact (eg, groin, pendulous breasts).
- **Tinea** infections (ringworm) are caused by fungi (dermatophytes). These infections may involve the scalp (tinea capitis), the body (tinea corporis), the foot (tinea pedis), and other areas of the body. Tinea pedis, commonly called athlete’s foot, is the most common type of ringworm infection.

Viral Infections

Viral infections of the skin include verrucal (warts) and herpes infections. There are two types of herpes simplex infections. Type 1 usually involves the face or neck (eg, fever blisters or cold sores on the lips), and type 2 involves the genitalia. Other herpes infections include varicella (chickenpox) and herpes zoster (shingles).

Trauma

Trauma refers to a physical injury that disrupts the skin. When the skin is broken, it may not be able to function properly. The major problem associated with skin wounds is infection. Common wounds include lacerations (cuts or tears), abrasions (shearing or scraping of the skin), and puncture wounds; surgical incisions; and burn wounds.

Ulcerations

Cutaneous ulcerations are usually caused by trauma and impaired circulation. They may become inflamed or infected.

- **Pressure ulcers** (also called decubitus ulcers) may occur anywhere on the body when external pressure decreases blood flow. They are most likely to develop in clients who are immobilized, incontinent, malnourished, and debilitated. Common sites include the sacrum, trochanters, ankles, and heels. In addition, abraded skin is susceptible to infection and ulcer formation.
- **Venous stasis ulcers**, which usually occur on the legs, result from impaired venous circulation. Other signs of venous insufficiency include edema, varicose veins, stasis dermatitis, and brown skin pigmentation. Bacterial infection may occur in the ulcer.

Acne

Acne is a common disorder characterized by excessive production of sebum and obstruction of hair follicles, which normally carry sebum to the skin surface. As a result, hair follicles expand and form comedones (blackheads and whiteheads). Acne lesions vary from small comedones to acne vulgaris, the most severe form, in which follicles become infected and irritating secretions leak into surrounding tissues to form inflammatory pustules, cysts, and abscesses. Most clients have a variety of lesion types at one time.

Acne occurs most often on the face, upper back, and chest because large numbers of sebaceous glands are located in these areas. One etiologic factor is increased secretion of male hormones (androgens), which occurs at puberty in both sexes. This leads to increased production of sebum and proliferation of **Propionibacterium acnes** bacteria, which depend on sebum for survival. The P. acnes organisms contain lipase enzymes that break down free fatty acids and produce inflammation in acne lesions. Other causative factors may include medications (eg, phenytoin, corticosteroids) and stress, whose mechanism may involve stimulation of androgen secretion. There is no evidence that lack of cleanliness or certain foods (eg, chocolate) cause acne.
External Otitis

External otitis is an infection of the external ear characterized by pain, itching, and drainage. The external ear is lined with epidermal tissue, which is susceptible to the same skin disorders that affect other parts of the body. External otitis is most often caused by *Pseudomonas aeruginosa* and *Staphylococcus aureus* organisms and may be treated with antimicrobial ear drops for approximately 7 to 10 days.

Anorectal Disorders

Hemorrhoids and anal fissures are common anorectal disorders characterized by pruritus, bleeding, and pain. Inflammation and infection may occur.

### TYPES OF DERMATOLOGIC DRUGS

Many different agents are used to prevent or treat dermatologic disorders. Most agents fit into one or more of the following categories:

- **Antimicrobials** are used to treat infections caused by bacteria, fungi, and viruses (see Chaps. 33 through 41). When used in dermatologic infections, antimicrobials may be administered locally (topically) or systemically (orally or parenterally).
- **Antiseptics** kill or inhibit the growth of bacteria, viruses, or fungi. They are used primarily to prevent infection. They are occasionally used to treat dermatologic infections. Skin surfaces should be clean before application of antiseptics.
- **Astringents** (eg, dilute solutions of aluminum salts) are used for their drying effects on exudative lesions.
- **Corticosteroids** (see Chap. 24) are used to treat the inflammation present in many dermatologic conditions. They are most often applied topically, but also may be given orally or parenterally.
- **Emollients** or lubricants (eg, mineral oil, lanolin) are used to relieve pruritus and dryness of the skin.
- **Enzymes** are used to débride burn wounds, decubitus ulcers, and venous stasis ulcers. They promote healing by removing necrotic tissue.
- **Immunomodulators** are newer drugs with immunosuppressant and anti-inflammatory effects. They are not steroids, do not cause the adverse effects associated with corticosteroids, and may be used as corticosteroid substitutes. They are used to treat moderate to severe atopic dermatitis.
  
  Two of these drugs are currently available, tacrolimus (Protopic) ointment and pimecrolimus (Elidel) cream. Systemic tacrolimus is used to prevent organ rejection in kidney and liver transplantations. The topical drugs are considered safe and effective in adults and children as young as 2 years. They may cause increased burning and itching during the first week of use but they are not associated with significant systemic absorption or increased risk of infections.
- **Keratolytic agents** (eg, salicylic acid) are used to remove warts, corns, calluses, and other keratin-containing skin lesions.
- **Retinoids** are vitamin A derivatives that are active in proliferation and differentiation of skin cells. These agents are commonly used to treat acne, psoriasis, aging, and wrinkling of skin from sunlight exposure, and skin cancers. Retinoids (eg, etretinate and isotretinoin) are contraindicated in women of childbearing potential unless the women have negative pregnancy tests; agree to use effective contraception before, during, and after drug therapy; and agree to take the drugs as prescribed. These drugs have been associated with severe fetal abnormalities.
- **Sunscreens** are used to protect the skin from the damaging effects of UV radiation, thereby decreasing skin cancer and signs of aging, including wrinkles. Dermatologists recommend sunscreen preparations that block both UVA and UVB and have a “sun protection factor” value of 30 or higher. These highly protective sunscreens are especially needed by people who are fair skinned, allergic to sunlight, or using medications that increase skin sensitivity to sunlight (eg, estrogens, tetracycline).

Application of Dermatologic Drugs

Most dermatologic medications are applied topically. To be effective, topical agents must be in contact with the underlying skin or mucous membrane. Numerous dosage forms have been developed for topical application of drugs to various parts of the body and for various therapeutic purposes. Basic components of topical agents are one or more active ingredients and a usually inactive vehicle. The vehicle is a major determinant of the drug’s ability to reach affected skin and mucous membranes. Many topical preparations contain other additives (eg, emollients, dispersing agents) that further facilitate application to skin and mucous membranes. Commonly used vehicles and dosage forms include ointments, creams, lotions, aerosols, gels, otic solutions, and vaginal and rectal suppositories. Many topical drug preparations are available in several dosage forms.

Topical medications are used primarily for local effects; systemic effects are usually undesirable. Factors that influence percutaneous absorption of topical agents include the following:

- **Degree of skin hydration**. Drug penetration and percutaneous absorption are increased when keratin in the outermost layer of the epidermis is well hydrated.
- **Drug concentration**. Because percutaneous absorption occurs by passive diffusion, higher concentrations increase the amount of drug absorbed.
- **Skin condition**. Absorption from abraded, damaged, or inflamed skin is much greater than from intact skin.
- **Length of contact time**. Absorption is increased when drugs are left in place for prolonged periods.
• **Size of area.** Absorption is increased when topical medications are applied to large areas of the body.

• **Location of area.** Absorption from mucous membranes and facial skin is comparatively rapid. Absorption from thick-skinned areas (e.g., palms of hands and soles of feet) is comparatively slow.

---

**INDIVIDUAL DRUGS**

See Drugs at a Glance: Topical Antibacterial Agents, Drugs at a Glance: Topical Corticosteroids, and Drugs at a Glance: Miscellaneous Dermatologic Agents.

---

**Herbal and Dietary Supplements**

Many supplements are promoted for use in skin conditions. Most have not been tested adequately to ensure effectiveness. At the same time, however, topical use rarely causes serious adverse effects or drug interaction. Two topical agents for which there is some support of safety and effectiveness are aloes and oat preparations.

*Aloe* is often used as a topical remedy for minor burns and wounds (e.g., sunburn, cuts, abrasions) to decrease pain, itching, and inflammation and to promote healing. Its active ingredients are unknown. Wound healing is attributed to moisturizing (text continues on page 956)

### Drugs at a Glance: Topical Antimicrobial Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibacterial Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Azelaic acid (Azelex)</td>
<td>Acne</td>
<td>To lesions, twice daily</td>
</tr>
<tr>
<td>Bacitracin (Baciguent)</td>
<td>Bacterial skin infections</td>
<td>To affected area, after cleansing, 1–3 times daily, small amount. Cover with a sterile dressing, if desired. Do not use longer than 1 wk.</td>
</tr>
<tr>
<td><strong>Benzoyl peroxide</strong></td>
<td>Acne</td>
<td>To affected areas, after cleansing, 1–3 times daily</td>
</tr>
<tr>
<td>Clindamycin (Cleocin T)</td>
<td>Acne vulgaris</td>
<td>To affected areas, twice daily</td>
</tr>
<tr>
<td>Erythromycin (Aknemycin)</td>
<td>Acne vulgaris</td>
<td>To affected areas, after cleansing, twice daily, morning and evening</td>
</tr>
<tr>
<td>Gentamicin (Garamycin)</td>
<td>Skin infections caused by susceptible strains of streptococci, staphylococci, and gram-negative organisms</td>
<td>To infected areas, 3–4 times daily. Cover with dressing if desired.</td>
</tr>
<tr>
<td>Mafenide (Sulfamylon)</td>
<td>Treatment of burn wounds</td>
<td>To affected area, after cleansing, once or twice daily, using sterile technique</td>
</tr>
<tr>
<td>Metronidazole (MetroLotion)</td>
<td>Rosacea</td>
<td>To affected areas, after cleansing, twice daily, morning and evening</td>
</tr>
<tr>
<td>Mupirocin (Bactroban)</td>
<td>Impetigo caused by <em>Staphylococcus aureus</em>, beta-hemolytic streptococci, or <em>Streptococcus pyogenes</em></td>
<td>Impetigo: Ointment, to affected areas, 3 times daily. Cover with dressing, if desired. Other skin lesions: Cream, 3 times daily for 10 d. Cover with dressing, if desired. Eradication of nasal colonization: Ointment from single-use tube, one half in each nostril, morning and evening for 5 d</td>
</tr>
<tr>
<td><strong>Neomycin</strong> (Myciguent)</td>
<td>Bacterial skin infections</td>
<td>To affected area, after cleansing, 1–3 times daily, small, fingertip-size amount. Cover with a sterile dressing, if desired. Do not use longer than 1 wk.</td>
</tr>
<tr>
<td><strong>Silver sulfadiazine</strong> (Silvadene)</td>
<td>Prevent or treat infection in burn wounds caused by <em>Pseudomonas</em> and many other organisms</td>
<td>To affected area, after cleansing, once or twice daily, using sterile technique</td>
</tr>
<tr>
<td>Sulfacetamide sodium (Sebizon)</td>
<td>Bacterial skin infections</td>
<td>Skin infections: 2–4 times daily until infection clears Seborrhea: to scalp and adjacent skin areas, at bedtime</td>
</tr>
<tr>
<td>Tetracycline (Topicycline)</td>
<td>Acne vulgaris</td>
<td>To affected areas, twice daily, morning and evening</td>
</tr>
<tr>
<td><strong>Combination Products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bacitracin and polymyxin B (Polysporin)</td>
<td>Bacterial skin infections</td>
<td>To lesions, 2–3 times daily</td>
</tr>
<tr>
<td>Erythromycin/benzoyl peroxide (Benzamycin)</td>
<td>Acne</td>
<td>To affected areas, after cleansing, twice daily, morning and evening</td>
</tr>
<tr>
<td>Neomycin, polymyxin B and bacitracin (Neosporin)</td>
<td>Bacterial skin infections</td>
<td>To lesions, 2–3 times daily</td>
</tr>
</tbody>
</table>

(continued)
**Drugs at a Glance: Topical Antimicrobial Agents (continued)**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Indications for Use</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antifungal Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amphotericin B (Fungizone)</td>
<td>Cutaneous candidiasis</td>
<td>To affected areas, 2–4 times daily</td>
</tr>
<tr>
<td>Butenafine (Mentax)</td>
<td>Tinea pedis</td>
<td>To affected area, once daily for 4 wk</td>
</tr>
<tr>
<td>Ciclopirox (Loprox)</td>
<td>Tinea infections</td>
<td>To affected area, twice daily for 2–4 wk</td>
</tr>
<tr>
<td>Clioquinol (Vioform)</td>
<td>Fungal skin infection and inflammation</td>
<td>To affected areas, 2–3 times daily. Do not use for &gt;1 wk.</td>
</tr>
<tr>
<td>Clotrimazole (Lotrimin, Mycelex)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily, morning and evening</td>
</tr>
<tr>
<td>Econazole (Spectazole)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily for 2–4 wk</td>
</tr>
<tr>
<td>Haloprogin (Halotex)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily for 4 wk or until clinical clearing</td>
</tr>
<tr>
<td>Ketoconazole (Nizoral)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily for 1–4 wk</td>
</tr>
<tr>
<td>Miconazole (Micatin)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily for 2–4 wk</td>
</tr>
<tr>
<td>Naftifine (Naftin)</td>
<td>Tinea infections</td>
<td>To affected areas, once daily with cream, twice daily with gel</td>
</tr>
<tr>
<td>Nystatin (Mycostatin)</td>
<td>Candidiasis of skin and mucous membranes</td>
<td>To affected areas, after cleansing, 2–3 times daily until healing is complete</td>
</tr>
<tr>
<td>Oxiconazole (Oxistat)</td>
<td>Tinea infections</td>
<td>To affected areas, once or twice daily for 2–4 wk</td>
</tr>
<tr>
<td>Sulconazole (Exelderm)</td>
<td>Tinea infections</td>
<td>To affected areas, once or twice daily</td>
</tr>
<tr>
<td>Terbinafine (Lamisil)</td>
<td>Tinea infections</td>
<td>To affected areas, twice daily for 1–4 wk</td>
</tr>
<tr>
<td><strong>Antiviral Agents</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acyclovir (Zovirax)</td>
<td>Herpes genitalis</td>
<td>To lesions, q3h six times daily for 7 d</td>
</tr>
<tr>
<td>Penciclovir (Denavir)</td>
<td>Herpes labialis in immunosuppressed clients</td>
<td>To lesions, q2h while awake for 4 d</td>
</tr>
</tbody>
</table>

**Drugs at a Glance: Topical Corticosteroids**

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Dosage Forms</th>
<th>Potency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alclometasone (Aclovate)</td>
<td>Cream, ointment</td>
<td>Low</td>
</tr>
<tr>
<td>Amcinonide (Cyclocort)</td>
<td>Cream, lotion, ointment</td>
<td>High</td>
</tr>
<tr>
<td>Augmented betamethasone dipropionate (Diprolene)</td>
<td>Cream, gel, lotion, ointment</td>
<td>Ointment very high; cream high</td>
</tr>
<tr>
<td>Betamethasone dipropionate (Alphatrex, others)</td>
<td>Aerosol, cream, lotion, ointment</td>
<td>Cream and ointment high; lotion medium</td>
</tr>
<tr>
<td>Betamethasone valerate (Vailsone, others)</td>
<td>Cream, foam, lotion, ointment</td>
<td>Ointment high; cream medium</td>
</tr>
<tr>
<td>Clobetasol (Temovate)</td>
<td>Cream, gel, ointment, scalp application</td>
<td>Very high</td>
</tr>
<tr>
<td>Clocortolone (Clobertone)</td>
<td>Cream</td>
<td>Medium</td>
</tr>
<tr>
<td>Desonide (Tredeslon)</td>
<td>Cream, lotion, ointment</td>
<td>Low</td>
</tr>
<tr>
<td>Desoximetasone (Topicoet)</td>
<td>Cream, gel, ointment</td>
<td>Medium</td>
</tr>
<tr>
<td>Dexamethasone (Decaderm, Decadron)</td>
<td>Aerosol, cream</td>
<td>Low</td>
</tr>
<tr>
<td>Diflorasone (Florone, Maxifor)</td>
<td>Cream, ointment</td>
<td>Ointment, very high; cream, high</td>
</tr>
<tr>
<td>Fluocinolone (Synalar, others)</td>
<td>Cream, oil, ointment, shampoo, solution</td>
<td>High</td>
</tr>
<tr>
<td>Fluocinolone (Lex)</td>
<td>Cream, gel, ointment, solution</td>
<td>High</td>
</tr>
<tr>
<td>Flurandrenolide (Cordran)</td>
<td>Cream, lotion, ointment, tape</td>
<td>Medium</td>
</tr>
<tr>
<td>Fluticasone (Cultivate)</td>
<td>Cream, ointment</td>
<td>Medium</td>
</tr>
<tr>
<td>Halcinonide (Halog)</td>
<td>Cream, ointment, solution</td>
<td>High</td>
</tr>
<tr>
<td>Halobetasol (Ultravee)</td>
<td>Cream, ointment</td>
<td>Very high</td>
</tr>
<tr>
<td>Hydrocortisone (Cortril, Hydrocortone, others)</td>
<td>Cream, lotion, ointment, solution, spray, roll-on stick</td>
<td>Medium or low</td>
</tr>
<tr>
<td>Mometasone (Elocon)</td>
<td>Cream, lotion, ointment</td>
<td>Medium</td>
</tr>
<tr>
<td>Triamcinolone acetonide (Aristocort, Kenalog, others)</td>
<td>Aerosol, cream, lotion, ointment</td>
<td>0.5% cream and ointment, high; lower concentrations, medium</td>
</tr>
</tbody>
</table>
## Drugs at a Glance: Miscellaneous Dermatologic Agents

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Dermatologic Effects</th>
<th>Clinical Indications</th>
<th>Method of Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Enzymes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagenase (Santyl)</td>
<td>Débriding effects</td>
<td>Enzymatic débridement of infected wounds (eg, burn wounds, decubitus ulcers)</td>
<td>Topically once daily until the wound is cleansed of necrotic material</td>
</tr>
<tr>
<td>Papain (Panafil)</td>
<td>Débriding effects</td>
<td>Débridement of surface lesions</td>
<td>Topically 1 or 2 times daily</td>
</tr>
<tr>
<td>Trypsin (Granulex)</td>
<td>Débriding effects</td>
<td>Débridement of infected wounds (eg, decubitus and varicose ulcers)</td>
<td>Topically by spray twice daily</td>
</tr>
<tr>
<td><strong>Immunomodulators</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pimecrolimus (Elidel)</td>
<td>Anti-inflammatory</td>
<td>Atopic dermatitis</td>
<td>Topically to affected skin, once daily</td>
</tr>
<tr>
<td>Tacrolimus (Protopic)</td>
<td>Anti-inflammatory</td>
<td>Atopic dermatitis</td>
<td>Topically to affected skin, twice daily</td>
</tr>
<tr>
<td><strong>Retinoids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acitretin (Soriatane)</td>
<td>A metabolite of etretinate</td>
<td>Severe psoriasis</td>
<td>PO 25–50 mg/d</td>
</tr>
<tr>
<td>Adapalene (Differin)</td>
<td>Reportedly causes less burning, itching, redness, and dryness than tretinoin</td>
<td>Acne vulgaris</td>
<td>Topically to skin lesions once daily</td>
</tr>
<tr>
<td>Isotretinoin (Accutane)</td>
<td>Inhibits sebum production and keratinization</td>
<td>Severe cystic acne Disorders characterized by excessive keratinization (eg, pityriasis, ichthyosis)</td>
<td>PO 1–2 mg/kg/d, in 2 divided doses, for 15–20 wk</td>
</tr>
<tr>
<td><strong>Other Agents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tazarotene (Tazorac)</td>
<td>A prodrug, mechanism of action is unknown</td>
<td>Acne</td>
<td>Topically to skin, after cleansing, once daily in the evening</td>
</tr>
<tr>
<td>Tretinoin (Retin-A)</td>
<td>Irritant</td>
<td>Psoriasis</td>
<td>Topically to skin lesions once daily</td>
</tr>
<tr>
<td><strong>Anthralin</strong> (Anthra-Derm, others)</td>
<td>Slows the rate of skin cell growth and replication</td>
<td>Psoriasis</td>
<td>Topically to lesions once daily or as directed</td>
</tr>
<tr>
<td>Becaplermin (Regranex)</td>
<td>A recombinant human platelet-derived growth factor</td>
<td>Diabetic skin ulcers</td>
<td>Topically to ulcer, amount calculated according to size of the ulcer</td>
</tr>
<tr>
<td>Calcipotriene (Dovonex)</td>
<td>Synthetic analog of vitamin D that helps to regulate skin cell production and development</td>
<td>Psoriasis</td>
<td>Topically to lesions twice daily</td>
</tr>
<tr>
<td>Capsaicin (Zostrix)</td>
<td>Depletes substance P (which transmits pain impulses) in sensory nerves of the skin</td>
<td>Relief of pain associated with rheumatoid arthritis, osteoarthritis, and neuralgias</td>
<td>Topically to affected area, up to 3–4 times daily</td>
</tr>
<tr>
<td>Coal tar (Bainetar, Zetar, others)</td>
<td>Irritant</td>
<td>Psoriasis, Dermatitis</td>
<td>Topically to skin, in various concentrations and preparations (eg, creams, lotions, shampoos, bath emulsion). Also available in combination with hydrocortisone and other substances</td>
</tr>
<tr>
<td>Colloidal oatmeal (Aveeno)</td>
<td>Antipruritic</td>
<td>Pruritus</td>
<td>Topically as a bath solution (1 cup in bathtub of water)</td>
</tr>
<tr>
<td>Dextranomer (Debrisan)</td>
<td>Absorbs exudates from wound surfaces</td>
<td>Cleansing of ulcers (eg, venous stasis, decubitus) and wounds (eg, burn, surgical, traumatic)</td>
<td>Apply to a clean, moist wound surface q12h initially, then less often as exudate decreases</td>
</tr>
<tr>
<td>Fluorouracil (Efudex)</td>
<td>Antineoplastic</td>
<td>Actinic keratoses</td>
<td>Topically to skin lesions twice daily for 2–6 wk</td>
</tr>
<tr>
<td>Masoprocol (Actinex)</td>
<td>Inhibits proliferation of keratin-containing cells</td>
<td>Superficial basal cell carcinomas Actinic keratoses</td>
<td>Topically to skin lesions morning and evening for 28 d</td>
</tr>
<tr>
<td>Salicylic acid</td>
<td>Keratolytic, antifungal</td>
<td>Removal of warts, corns, calluses Superficial fungal infections Seborrheic dermatitis Acne Psoriasis</td>
<td>Topically to lesions</td>
</tr>
<tr>
<td>Selenium sulfide (Selsun)</td>
<td>Antifungal, antidandruff</td>
<td>Dandruff, Tinea versicolor</td>
<td>Topically to scalp as shampoo once or twice weekly</td>
</tr>
</tbody>
</table>
effects and increased blood flow to the area. Reduced inflammation and pain may result from inhibition of arachidonic acid metabolism and formation of inflammatory prostaglandins. Reduced itching may result from inhibition of histamine production.

Commercial products are available for topical use, but fresh gel from the plant may be preferred. When used for this purpose, a clear, thin, gel-like liquid can be squeezed directly from a plant leaf onto the burned or injured area several times daily if needed. Topical use has not been associated with severe adverse effects or drug interactions.

Aside from oral use as a cereal, good source of dietary fiber, and well-documented cholesterol-lowering product, oat preparations have long been used topically to treat minor skin irritation and pruritus associated with common skin disorders. Oats contain gluten, which forms a sticky mass that holds moisture in the skin when it is mixed with a liquid and has emollient effects. For topical use, oats are contained in bath products, cleansing bars, and lotions (eg, Aveeno products) that can be used once or twice daily. They should not be used near the eyes or on inflamed skin. After use, they should be washed off with water.

### Nursing Process

#### Assessment

Assess the client’s skin for characteristics or lesions that may indicate current or potential dermatologic disorders.

- **When a skin rash is present**, interview the client and inspect the area to determine the following:
  - **Appearance of individual lesions.** Lesions should be described as specifically as possible so changes can be identified. Terms commonly used in dermatology include macule (flat spot), papule (raised spot), nodule (small, solid swelling), vesicle (blister), pustule (pus-containing lesion), petechia (flat, round, purplish-red spot the size of a pinpoint, caused by intradermal or submucosal bleeding), and erythema (redness). Lesions also may be described as weeping, dry and scaly, or crusty.
  - **Location or distribution.** Some skin rashes occur exclusively or primarily on certain parts of the body (eg, face, extremities, trunk), and distribution may indicate the cause.
  - **Accompanying symptoms.** Pruritus occurs with most dermatologic conditions. Fever, malaise, and other symptoms may occur as well.
  - **Historic development.** Appropriate questions include
    - When and where did the skin rash appear?
    - How long has it been present?
    - Has it changed in appearance or location?
    - Has it occurred previously?
  - **Etiologic factors.** In many instances, appropriate treatment is determined by the cause. Some etiologic factors include the following:
    - **Drug therapy.** Many commonly used drugs may cause skin lesions, including antibiotics (eg, penicillins, sulfonamides, tetracyclines), narcotic analgesics, and thiazide diuretics. Skin rashes due to drug therapy are usually generalized and appear abruptly.
    - **Irritants or allergens** may cause contact dermatitis. For example, dermatitis involving the hands may be caused by soaps, detergents, or various other cleansing agents. Dermatitis involving the trunk may result from allergic reactions to clothing.
    - **Communicable diseases** (ie, measles, chickenpox) cause characteristic skin rashes and systemic signs and symptoms.
    - When skin lesions other than rashes are present, assess appearance, size or extent, amount and character of any drainage, and whether the lesion appears infected or contains necrotic material. Bleeding into the skin is usually described as petechiae (pinpoint hemorrhages) or ecchymoses (bruises). Burn wounds are usually described in terms of depth (partial or full thickness of skin) and percentage of body surface area. Burn wounds with extensive skin damage are rapidly colonized with potentially pathogenic microorganisms. Venous stasis, pressure, and other cutaneous ulcers are usually described in terms of diameter and depth.
    - When assessing the skin, consider the age of the client. Infants are likely to have “diaper” dermatitis, miliaria (heat rash), and tinea capitis (ringworm infection of the scalp). School-aged children have a relatively high incidence of measles, chickenpox, and tinea infections. Adolescents often have acne. Older adults are more likely to have dry skin, actinic keratoses (premalignant lesions that occur on sun-exposed skin), and skin neoplasms.
    - **Assess for skin neoplasms.** Basal cell carcinoma is the most common type of skin cancer. It may initially appear as a pale nodule, most often on the head and neck. Squamous cell carcinomas may appear as ulcerated areas. These lesions may occur anywhere on the body but are more common on sun-exposed parts, such as the face and hands. Malignant melanoma is the most serious skin cancer. It involves melanocytes, the pigment-producing cells of the skin. Malignant melanoma may occur in pigmented moles (moles) or previously normal skin. In nevi, malignant melanoma may be manifested by enlargement and ulceration. In previously normal skin, lesions appear as irregularly shaped pigmented areas. Although it can occur in almost any area, malignant melanoma is most likely to be located on the back in white people and in toe webs and soles of the feet in African-American or Asian people.
    - Color changes and skin rashes are more difficult to detect when assessing dark-skinned clients. Some guidelines include the following:
      - Adequate lighting is required; nonglare daylight is best. The illumination provided by overbed lights or flashlights is inadequate for most purposes.
      - Some skin rashes may be visible on oral mucous membranes.
• Petechiae are not visible on dark brown or black skin, but they may be visible on oral mucous membranes or the conjunctiva.
• When skin disorders are present, assess the client’s psychological response to the condition. Many clients, especially those with chronic disorders, feel self-conscious and depressed.

Nursing Diagnoses
• Disturbed Body Image related to visible skin lesions
• Anxiety related to potential for permanent scarring or disfigurement
• Pain related to skin lesions and pruritus
• Risk for Injury: Infection related to entry of microbes through damaged skin

Planning/Goals
The client will:
• Apply topical drugs correctly
• Experience relief of symptoms
• Use techniques to prevent or minimize skin damage and disorders
• Avoid scarring and disfigurement when possible
• Be encouraged to express concerns about acute and chronic body image changes

Interventions
Use measures to prevent or minimize skin disorders.
• Use general measures to promote health and increase resistance to disease (ie, maintain nutrition, rest, and exercise).
• Practice good personal hygiene, with at least once-daily cleansing of skin areas with high bacterial counts, such as underarms and perineum.
• Practice safety measures to avoid injury to the skin. Any injury, especially one that disrupts the integrity of the skin (eg, lacerations, puncture wounds, scratching of skin lesions) increases the likelihood of skin infections.
• Avoid known irritants or allergens. Have the client substitute nonirritating soaps or cleaning supplies for irritating ones; use hypoallergenic jewelry and cosmetics if indicated; wear cotton clothing if indicated.
• Use measures to relieve dry skin and pruritus. Dry skin causes itching, and itching promotes scratching. Scratching relieves itching only if it is strong enough to damage the skin and serve as a counterirritant. Skin damaged or disrupted by scratching is susceptible to invasion by pathogenic microorganisms. Thus, dry skin may lead to serious skin disorders. Older adults are especially likely to have dry, flaky skin. Measures to decrease skin dryness include the following:
  • Alternating complete and partial baths. For example, the client may alternate a shower or tub bath with a sponge bath (of face, hands, underarms, and perineal areas). Warm water, mild soaps, and patting dry are recommended because hot water, harsh soaps, and rubbing with a towel have drying effects on the skin.
  • Liberal use of lubricating creams, lotions, and oils. Bath oils, which usually contain mineral oil or lanolin oil and a perfume, are widely available. If bath oils are used, precautions against falls are necessary because the oils make bathtubs and shower floors slippery. Creams and lotions may be applied several times daily.
• Prevent pressure ulcers by avoiding trauma to the skin and prolonged pressure on any part of the body. In clients at high risk for development of pressure ulcers, major preventive measures include frequent changes of position and correct lifting techniques. Various pressure-relieving devices (eg, special beds and mattresses) also are useful. Daily inspection of the skin is needed for early detection and treatment of beginning pressure ulcers.
• Avoid excessive exposure to sunlight and other sources of ultraviolet (UV) light. Although controlled amounts of UV light are beneficial in some dermatologic disorders (ie, acne, psoriasis), excessive amounts cause wrinkling, dryness, and malignancies. If prolonged exposure is necessary, protective clothing and sunscreen lotions decrease skin damage.
• When skin rashes are present, cool, wet compresses or baths are often effective in relieving pruritus. Water or normal saline may be used alone or with additives, such as colloidal oatmeal (Aveeno) or baking soda. A cool environment also tends to decrease pruritus. The client’s fingernails should be cut short and kept clean to avoid skin damage and infection from scratching.
  For severe itching, a systemic antihistamine may be needed.

Evaluation
• Observe and interview regarding use of dermatologic drugs.
• Observe for improvement in skin lesions and symptoms.
• Interview regarding use of measures to promote healthy skin and prevent skin disorders.

PRINCIPLES OF THERAPY

Goals
General treatment goals for many skin disorders are to relieve symptoms (eg, dryness, pruritus, inflammation, infection), eradicate or improve lesions, promote healing and repair, restore skin integrity, and prevent recurrence. Specific goals often depend on the condition being treated.

General Aspects of Dermatologic Drug Therapy

1. Pharmacologic therapy may include a single drug or multiple agents used concurrently or sequentially.
2. For severe skin conditions, a dermatologist is best qualified to prescribe medications and other treatments.
General Considerations

- Severe dermatologic disorders should be treated by a dermatologist.
- Promote healthy skin by a balanced diet, personal hygiene measures, avoiding excessive exposure to sunlight, avoiding skin injuries, and lubricating dry skin. Healthy skin is less susceptible to inflammation, infections, and other disorders. It also heals more rapidly when disorders or injuries occur.
- Common symptoms of skin disorders are inflammation, infection, and itching. The goal of most drug therapy is to relieve these symptoms and promote healing. Systemic medications (eg, oral antihistamines, antibiotics and corticosteroids) may be used for severe disorders, at least initially, but most medications are applied directly to the skin. There is a wide array of topical products, both prescription and over-the-counter.
- It is extremely important to use the correct topical medication and the correct amount for the condition being treated. Topical corticosteroids, for example, come in many vehicles (eg, creams, lotions, ointments). These products cannot be used interchangeably. In addition, they should not be combined (ie, using a prescription and a nonprescription product) and should not be covered with occlusive dressings unless specifically instructed to do so. Correct use increases beneficial effects, decreases risks of worsening the condition being treated, and decreases risks of adverse effects.

Adverse effects of topical medications may involve the skin (eg, irritation, excessive drying, infection) where the drug is applied or the entire body, when the drug is absorbed into the bloodstream. Systemic absorption is increased when the drug is strong; applied to inflamed skin, over a large surface area, or frequently; or covered with an occlusive dressing (eg, plastic wrap). Systemic absorption is of most concern with corticosteroid preparations.

Some ways to prevent or decrease skin disorders include:

- Identifying and avoiding, when possible, substances that cause skin irritation and inflammation (eg, harsh cleaning products, latex gloves, cosmetics, wool fabrics, pet dander)
- Bathing in warm water with a mild cleanser (eg, Dove, Basis, Cetaphil), patting skin dry, and applying lotions or oils (eg, Aquaphor, Eucerin, mineral oil or baby oil) to lubricate skin and decrease dryness
- Avoiding scratching, squeezing, or rubbing skin lesions. These behaviors cause additional skin damage and increase risks of infection. Fingernails should be cut short; cotton gloves can be worn at night.
- Maintaining a cool environment; preventing sweating
- Applying cold compresses to inflamed, itchy skin
- Using baking soda or colloidal oatmeal (Aveeno) in bath water to relieve itching
- If you are taking an oral antihistamine to relieve itching, it should be taken on a regular schedule, around the clock, for greater effectiveness.

Misinformation about acne is common. Acne is not caused by dirt, washing does not improve acne, and vigorous scrubbing and squeezing may worsen acne lesions. There is also no evidence that acne is caused by eating chocolate or other foods. Recommendations for managing acne include using non–acne-producing cosmetics, moisturizers, and sunscreens; washing and bathing with a gentle, nonirritating cleanser (eg, Dove or Purpose bar); and avoiding sun exposure if taking a tetracycline or retinoid anti-acne medication. (The drugs increase risks of sunburn.) Once treatment is started, significant improvement in acne lesions may take as long as 6 to 12 weeks. It is very important to not give up or stop treatment prematurely.

People with psoriasis can obtain information and support from:
- National Psoriasis Foundation (NPF)
  6600 SW 92nd Avenue, Suite 300
  Portland, OR 97223
  Telephone: 1-800-723-9166
  E-mail: getinfo@npfusa.org
  Web site: http://www.psoriasis.org

Unavoidable skin lesions or scars can often be hidden or rendered less noticeable with makeup or clothing.

- Women can wear cosmetics over most topical medications. If unclear, ask a physician or pharmacist whether makeup is permissible. With acne, use noncomedogenic makeup, moisturizers, and sunscreens.
- If taking an oral retinoid (eg, Accutane), avoid vitamin supplements containing vitamin A and excessive exposure to sunlight, to decrease risks of excessive vitamin A intake and photosensitivity.
- Because adult household contacts of children with ringworm of the scalp may be asymptomatic carriers, they should use a shampoo containing ketoconazole daily until the infected child is clear of signs and symptoms.

Self-Administration

- Use topical medications only as prescribed or according to the manufacturer’s instructions (for over-the-counter products). Use the correct preparation for the intended area of application (ie, skin, ear, vagina).
- For topical application to skin lesions, cleanse the skin and remove previously applied medication to promote drug contact with the affected area of the skin.
- Wash the skin and pat it dry.
- Apply a small amount of the drug preparation and rub it in well. A thin layer of medication is effective and decreases the incidence and severity of adverse effects. With acne and rosacea, preventing skin lesions is easier than eliminating lesions that are already present. As a result, topical medications should be applied to the general area of involvement rather than individual lesions.
- For burn wounds, broken skin, or open lesions, apply the drug with sterile gloves or sterile cotton-tipped applicators to prevent infection.
Because many skin conditions are so visible, early and aggressive treatment may be needed to prevent additional tissue damage, repeated infections, scarring, and mental anguish.

3. Topical medications are preferred, when effective, and many preparations are available. Astringents and lotions are usually used as drying agents for “wet,” oozing lesions, and ointments and creams are used as “wetting” agents for dry, scaling lesions.

4. To relieve pruritus, a common symptom of inflammatory skin disorders, skin lubricants, systemic antihistamines, and topical corticosteroids are important elements.

5. Topical corticosteroids are used for both acute and chronic inflammatory and pruritic lesions. However, when acute lesions involve extensive areas or chronic lesions are resistant to topical drugs, systemic corticosteroid therapy may be needed. Prednisone 0.5 to 1 mg/kg/day is often used for 1 to 3 weeks.

**Use of Topical Corticosteroids**

Because of the extensive use of topical corticosteroids and the risks of potentially serious adverse effects, numerous precautions, guidelines, and recommendations have evolved to increase safety and effectiveness of these drugs.

**Drug Selection**

Choice of drug depends mainly on the acuity, severity, location, and extent of the condition being treated. For acute lesions, a more potent corticosteroid may be needed, at least initially; for chronic lesions, the least potent preparation that is effective is indicated (see Drugs at a Glance: Topical Corticosteroids).

- Low-potency drugs (eg, hydrocortisone) are preferred when likely to be effective. They are especially recommended for use in children, on large areas, and on body sites especially prone to corticosteroid damage (eg, face, scrotum, axillae, flexures and skin folds).

- Mid-potency drugs (eg, flurandrenolide) are usually effective in nonintertriginous areas in children and adults.

- High-potency drugs (eg, amcinonide) usually are effective in nonintertriginous areas in children and adults.

- Very–high-potency drugs (eg, clobetasol, halobetasol) usually are used for less absorptive areas such as soles of feet, palms of hands, and thick skin plaques. Usage should not exceed 2 consecutive weeks and total dosage should not exceed 50 g/week because of the potential for these drugs to suppress the hypothalamic–pituitary–adrenal (HPA) axis. Clobetasol suppresses the HPA axis at doses as low as 2 g/day. These drugs should not be used with occlusive dressings or for children younger than 12 years of age.

- Drug potency and clinical use vary with the dosage form, and many topical corticosteroids are available in...
creams, ointments, and other preparations. Creams are usually the most acceptable to clients; ointments penetrate the epidermis better and are often used for chronic dry or scaly lesions; lotions are recommended for intertriginous areas and the scalp. Some preparations are available in aerosol sprays, gels, and other dosage forms.

**Dosage**

Dosage depends on the drug concentration, the area of application, and the method of application.

- The skin covering the face, scalp, scrotum, and axillae is more permeable to corticosteroids than other skin surfaces, and these areas can usually be treated with less potent formulations, smaller amounts, or less frequent applications.
- Drug absorption and risks of systemic toxicity are significantly increased when the drug is applied to inflamed skin or covered by an occlusive dressing. Application should be less frequent and limited to isolated, resistant areas when occlusive dressings are used.
- The drug should be applied sparingly. Some clinicians recommend twice-daily applications until a clinical response is obtained, then decreasing to the least-frequent schedule needed to control the condition.
- With continuous use, one or two applications daily may be as effective as three or four applications, because the drugs have a repository effect.
- If an occlusive dressing is applied, leave it on overnight or at least 6 hours. However, do not leave it in place for more than 12 hours in a 24-hour period.
- After long-term use or after using a potent drug, taper dosage by switching to a less potent agent or applying the drug less frequently. Discontinuing the drug abruptly can cause a rebound effect, in which the skin condition worsens.

**Drug Selection in Selected Skin Conditions**

The choice of topical dermatologic agents depends primarily on the reason for use and client response.

**Acne**

Numerous prescription and nonprescription antiacne products are available.

- **Antimicrobial drugs** include both topical and systemic agents. Topical drugs usually are used for mild to moderate acne, often in combination with a topical retinoid to maximize effects. *Benzoyl peroxide* is an effective topical bactericidal agent that is available in numerous preparations (eg, gel, lotion, cream, wash) and concentrations (eg, 2.5% to 10%). Lotion and cream preparations are the least irritating. *Clindamycin* and *erythromycin* are also available in topical dosage forms. These drugs reduce *P. acnes* bacteria and are approximately equally effective. A prescription product combining benzoyl peroxide and erythromycin in a gel form (Benzamycin) is reportedly more effective than either agent alone.

Oral antimicrobials are useful with widespread or severe, disfiguring acne or when a rapid response is needed. Tetracyclines, which have both antibacterial and anti-inflammatory activity, are commonly used for long-term treatment. These drugs are usually given twice daily to increase compliance. Therapeutic effects usually occur within a few weeks, but maximal effects may require 2 to 3 months.

- **Retinoids**, in both systemic and topical forms, are commonly used for moderate to severe acne. When used alone, topical tretinoin may take several months to decrease acne lesions significantly. Thus, it is usually used in combination with other products. Adapalene and tazarotene are newer topical retinoids.

Isotretinoin is usually given to clients with severe acne who do not respond to safer drugs. Its antiacne effects include suppression of sebum production, inhibition of comedone formation, and inhibition of inflammation. Approximately 70% to 80% of clients treated appropriately (usually 1 mg/kg/day for 5 months) have a long-term remission. The main drawbacks are teratogenic and other adverse effects. This oral drug must never be given to a woman of childbearing age unless she agrees to practice adequate contraceptive measures.

**Anorectal Disorders**

In anorectal disorders, most preparations contain a local anesthetic, emollients, and perhaps a corticosteroid. These preparations relieve pruritus and pain but do not cure the underlying condition. Some preparations contain ingredients of questionable value, such as vasoconstrictors, astringents, and weak antiseptics. No particular mixture is clearly superior.

**Dermatitis**

Both systemic and topical agents are usually needed. Sedating, systemic antihistamines such as diphenhydramine or hydroxyzine are often used to relieve itching and promote rest and sleep. An oral antibiotic such as clindamycin, dicloxacillin, a cephalosporin, or a macrolide may be given for a week to treat secondary infections. An oral corticosteroid such as prednisone may be needed initially for severe inflammation, but topical corticosteroids are most often used.

Coal tar preparations have anti-inflammatory and antipruritic actions and can be used alone or with topical corticosteroids. However, these agents have an unpleasant odor and they stain clothing. They are usually applied at bedtime.

Additional preparations include moisturizers and lubricants (eg, Aquaphor) for dry skin and itching; mild skin cleansers (eg, Basis, Cetaphil) to avoid further skin irritation; and baking soda or colloidal oatmeal (Aveeno) in baths or soaks for pruritus.
**External Otitis**

Otic preparations of various dermatologic medications are used. Hydrocortisone is the corticosteroid most often included in topical otic preparations. It relieves pruritus and inflammation in chronic external otitis. Systemic analgesics are usually required.

**Pressure Ulcers**

In pressure ulcers, the only clear-cut guideline for treatment is avoiding further pressure on the affected area. Many topical agents are used, most often with specific procedures for dressing changes, skin cleansing, and so on. No one agent or procedure is clearly superior. Consistent implementation of a protocol (ie, position changes, inspection of current or potential pressure areas, dressing changes, use of alternating, pressure-relieving mattresses) may be more effective than drug therapy.

**Psoriasis**

Localized lesions are usually treated by a combination of topical agents, such as a corticosteroid during daytime hours and a coal tar ointment at night. Coal tar preparations work slowly but produce longer remissions. Newer antipsoriasis drugs such as calcipotriene or tazarotene may also be used. Calcipotriene is reportedly as effective as topical fluocinonide. However, its onset of action is slower than that of a topical corticosteroid. A combination of calcipotriene and a topical corticosteroid may be used initially for rapid improvement, after which the calcipotriene can be continued as monotherapy. Tazarotene is a topical retinoid that may cause cutaneous irritation.

Generalized psoriasis, which requires systemic treatment or body light therapy, should be managed mainly by dermatologists. Systemic therapy often involves oral retinoids or methotrexate. Acitretin has replaced etretinate as the oral retinoid of choice for treatment of severe psoriasis. Acitretin is a metabolite of etretinate that can be converted back to etretinate, especially in the presence of alcohol. The drug, like other oral retinoids, is teratogenic. Thus, women of childbearing potential who take acitretin should be instructed to avoid ingesting alcohol and to use adequate contraception while taking the drug and for at least 3 years thereafter. Methotrexate is an antineoplastic drug that may cause significant adverse effects.

Phototherapy can involve natural sunlight, which is highly effective. Most clients with psoriasis notice some remission during summer months. Office phototherapy treatments are usually performed three to five times weekly.

**Rosacea**

Mild skin cleansers (eg, Cetaphil), oral tetracycline, and topical metronidazole are commonly used; oral isotretinoin and topical metronidazole are also effective. These medications prevent or treat acneiform lesions; they have little to no effect on other aspects (eg, erythema, telangiectasia, hyperplasia of connective tissue and sebaceous glands).

**Urticaria**

Systemic drug therapy with antihistamines (H₁ receptor antagonists) is the major element of drug therapy. In addition, an epinephrine injection may be used initially and topical medications may be applied to relieve itching.

With chronic urticaria, the goal of treatment is symptom relief. Antihistamines are most effective when given before histamine-induced urticaria occurs and should be given around the clock, not just when lesions appear.

**Dosage Forms**

The choice of dosage form for topical drug therapy depends largely on the reason for use. Guidelines include the following:

- **Ointments** are oil-based substances that usually contain a medication in an emollient vehicle, such as petrolatum or lanolin. Ointments occlude the skin and promote retention of moisture. Thus, they are especially useful in chronic skin disorders characterized by dry lesions. Ointments should usually be avoided in hairy, moist, and intertriginous areas of the body because of potential maceration, irritation, and secondary infection.
- **Creams** (emulsions of oil in water, which may be greasy or nongreasy) and **gels** (transparent colloids, which dry and leave a film over the area) retain moisture in the skin but are less occlusive than ointments. These preparations are cosmetically acceptable for use on the face and other visible areas of the body. They also may be used in hairy, moist, intertriginous areas. Creams and gels are especially useful in subacute dermatologic disorders.
- **Lotions** are suspensions of insoluble substances in water. They cool, dry, and protect the skin. They are most useful in subacute dermatologic disorders. **Sprays** and **aerosols** are similar to lotions.
- **Powders** have absorbent, cooling, and protective effects. Powders usually should not be applied in acute, exudative disorders or on denuded areas because they tend to cake, occlude the lesions, and retard healing. Also, some powders (eg, cornstarch) may lead to secondary infections by promoting growth of bacteria and fungi.
- **Topical otic medications** are usually liquids. However, creams or ointments may be used for dry, crusted lesions, and powders may be used for drying effects.
- **Topical vaginal medications** may be applied as douche solutions, vaginal tablets, or vaginal creams used with an applicator.
- **Anorectal medications** may be applied as ointments, creams, foams, and rectal suppositories.
Use in Children

Children may develop a wide range of dermatologic disorders, including dermatitis and skin rashes in younger children and acne in adolescents. Few guidelines have been developed for drug therapy of these disorders. Infants, and perhaps older children, have more permeable skin and are more likely to absorb topical drugs than adults. In addition, absorption is increased in the presence of broken or damaged skin. Therefore, cautious use of topical agents is advised.

With topical corticosteroids, suppression of the HPA axis (see Chap. 24), Cushing’s disease, and intracranial hypertension have been reported in children. Signs of impaired adrenal function may include delayed growth and low plasma cortisol levels. Signs of intracranial hypertension may include headaches and swelling of the optic nerve (papilledema) on ophthalmoscopic examination. The latter may lead to blindness if pressure on the optic nerve is not relieved.

Because children are at high risk for development of systemic adverse effects with topical corticosteroids, these drugs should be used only if clearly indicated, in the smallest effective dose, for the shortest effective time, and usually without occlusive dressings. In addition, a low-potency agent should be used initially in infants and in intertriginous areas of older children. If a more potent drug is required for severe dermatitis, the child should be examined often and the strength of the drug reduced as skin lesions improve.

Use in Older Adults

Older adults often have thin, dry skin and are at risk of pressure ulcers if mobility, nutrition, or elimination is impaired. Principles of topical drug therapy are generally the same as for younger adults. In addition, topical corticosteroids should be used with caution on thinned or atrophic skin.

Home Care

Skin disorders are commonly treated at home by clients or caregivers. When a home care nurse is involved, responsibilities may include assessing clients, other members of the household, and the home environment for risks of skin disorders; teaching preventive or treatment measures; assisting with treatment; and assessing response to treatment.

Nursing Notes: Apply Your Knowledge

You are making a home visit to young parents of a 6-month-old baby. The teenage mother is home alone with the baby when you visit. You ask if she has any concerns. She states that the baby has had a severe diaper rash for the last 2 weeks. What assessment data do you need to collect? What general principles should you include in your teaching about diaper rash?

NURSING ACTIONS

Dermatologic Drugs

1. Administer actions accurately
   a. Use the correct preparation for the intended use (ie, dermatologic, otic, vaginal, anorectal)
   b. For topical application to skin lesions:
      (1) Wash the skin, and pat it dry.
      (2) Apply a small amount of the drug preparation, and rub it in well.
      (3) For burn wounds, broken skin, or open lesions, apply the drug with sterile gloves or sterile cotton-tipped applicators.
      (4) Use the drug only for the individual client.
      (5) Wash hands before and after application.

2. Observe for therapeutic effects
   a. With dermatologic conditions, observe for healing of skin lesions.
   b. With external otitis, observe for decreased pain and pruritus.

RATIONAL/EXPLANATION

Preparations may differ in drug contents and concentrations.

To cleanse the skin and remove previously applied medication. This facilitates drug contact with the affected area of the skin.

A thin layer of medication is effective and decreases the incidence and severity of adverse effects.

To prevent infection.

To avoid bacterial cross-contamination between clients.

Wash hands before to avoid exposing the client to infection; wash hands afterward to avoid transferring the drug to your own face or eyes and causing adverse reactions.

Therapeutic effects depend on the medication being used and the disorder being treated.

With acne and rosacea, improvement may require 6 to 12 wk of therapy.

(continued)
### NURSING ACTIONS

| c. With vaginal disorders, observe for decreased vaginal discharge and pruritus. |
| d. With anorectal disorders, observe for decreased pain and pruritus. |

### 3. Observe for adverse effects

| a. Local irritation or inflammation—burning on application, erythema, skin rash, pruritus. |
| b. With topical corticosteroids, observe for local and systemic effects. |

   1. Local effects include skin atrophy, striae, telangiectasia, hypopigmentation, rosacea, dermatitis, acne, and allergic and irritant reactions. |

   2. Systemic effects include suppression of adrenal function, hypertension, hyperglycemia, muscle weakness, osteoporosis, cataracts, glaucoma, and growth retardation in children. |

c. With topical antibiotics, superinfection and sensitization may occur. |

d. With oral retinoids, observe for hypervitaminosis A (nausea, vomiting, headache, blurred vision, eye irritation, conjunctivitis, skin disorders, abnormal liver function, musculoskeletal pain, increased plasma triglycerides, depression, and suicidal ideation). |

### 4. Observe for drug interactions

### RATIONALE/EXPLANATION

Incidence of adverse effects is low with topical agents. Local effects may occur with most topical agents but may be more likely with antiseptics, local anesthetics, and antimicrobials. |

These effects commonly occur with prolonged use, frequent application, and higher potency drugs. Atrophy or thinning of skin is more likely in the face, groin, and axillae. |

Allergic and irritant reactions to preservatives, fragrances, and other ingredients may prevent healing or worsen dermatitis. Systemic effects are more likely with more potent agents (eg, clobetasol can cause suppression of the hypothalamic–pituitary–adrenal axis with as little as 2 g daily), application over large areas of skin, prolonged use, and the use of occlusive dressings. In addition, children are at higher risk because they may absorb proportionally larger amounts and be more sensitive to systemic toxicity. |

Little adrenal suppression is likely to occur with doses less than 50 g weekly for an adult and 15 g weekly for a small child, unless occlusive dressings are used. |

Superinfection with drug-resistant organisms may occur with any antibacterial agent; diarrhea and pseudomembranous colitis may occur with topical clindamycin. Sensitization may cause serious allergic reactions if the same drug is given systemically at a later time. Adverse effects commonly occur with usual doses but are more severe with higher doses. |

Clinically significant drug interactions rarely occur with topical agents.

---

**How Can You Avoid This Medication Error?**

**Answer:** Never use a drug that is not labeled clearly. Even topical agents can cause serious adverse effects. When pouring liquids, always pour away from the label, so that accidental spillage will not impair the written drug label. Another concern in this situation is sterility. Using previously opened bottles, where sterility cannot be guaranteed, is not acceptable practice.

---

**Nursing Notes: Apply Your Knowledge**

**Answer:** Ask the mother to describe when the rash appeared and if its occurrence corresponded with diarrhea or new foods being introduced in the diet. Question the mother regarding the types of diapers she uses and how often the baby is changed. Inspect the baby’s skin for the severity of diaper rash and other skin irritation. Observe for any sign of fungal infection. Stress the importance of keeping the baby clean and dry by changing the diaper frequently and washing with gentle soap and water. If the area is excoriated, a protective barrier can be achieved by applying a thin coat of many commercially available products such as petroleum jelly (Vaseline) or Desitin.
Review and Application Exercises

1. What are the main functions of the skin?
2. Describe interventions to promote skin health and integrity.
3. During initial assessment of a client, what signs and symptoms may indicate common skin disorders?
4. Which client groups are at risk for development of common skin disorders (eg, skin infections, pressure ulcers)?
5. Compare topical and systemic corticosteroids in terms of adverse effects.
6. If an adolescent client with acne asks your advice about over-the-counter topical drugs, which would you recommend, and why?
7. List general principles of using topical agents for common skin disorders.

SELECTED REFERENCES


Drug Use During Pregnancy and Lactation

Objectives
AFTER STUDYING THIS CHAPTER, THE STUDENT WILL BE ABLE TO:

1. Discuss reasons for avoiding or minimizing drug therapy during pregnancy and lactation.
2. Describe selected teratogenic drugs.
3. Discuss guidelines for drug therapy of pregnancy-associated signs and symptoms.
4. Discuss guidelines for drug therapy of selected chronic disorders during pregnancy and lactation.
5. Discuss the safety of immunizations given during pregnancy.
6. Teach adolescent and young adult women to avoid prescribed and over-the-counter drugs when possible and to inform physicians and dentists if there is a possibility of pregnancy.
7. Discuss the role of the home care nurse working with the pregnant mother.
8. Discuss drugs used during labor and delivery in terms of their effects on the mother and newborn infant.
9. Describe abortifacients in terms of characteristics and nursing process implications.

Critical Thinking Scenario
Thirty-eight-year-old Susan Williams comes in for her first prenatal visit. Susan works as a corporate lawyer and is married to a university professor. Susan is very excited about this planned pregnancy, but seems somewhat anxious as she asks lots of questions.

Reflect on:
- The effects of drug use by the mother on the fetus during pregnancy.
- Do you make any assumptions about Susan’s knowledge level based on her profession and social class?
- How might such judgments assist you to individualize teaching? How might such judgments impair the teaching process?
- Essential information to provide Susan regarding the use of any prescription, nonprescription, or herbal drugs during pregnancy.

OVERVIEW

Drug use during pregnancy and lactation requires special consideration because both the mother and the fetus or nursing infant are affected. Few drugs are considered safe, and drug use is generally contraindicated. However, many pregnant or lactating women take drugs for various reasons, including acute disorders that may or may not be associated with pregnancy, chronic disorders that require continued treatment during pregnancy or lactation, and habitual use of nontherapeutic drugs (eg, alcohol, tobacco, others). The main purpose of this chapter is to describe potential drug effects on the fetus and maternal drug therapy to protect the fetus while providing therapeutic effects to the pregnant woman.

PREGNANCY AND LACTATION

Pregnancy is a dynamic state: Mother and fetus undergo physiologic changes that influence drug effects. In the pregnant woman, physiologic changes alter drug pharmacokinetics (Table 67–1), and drug effects are less predictable than in the nonpregnant state. Most of the drugs in this chapter are described elsewhere; they are discussed here in relation to
Drugs ingested by the pregnant woman reach the fetus through the maternal–placental–fetal circulation, which is completed about the third week after conception. On the maternal side, arterial blood pressure carries blood and drugs to the placenta. In the placenta, maternal and fetal blood are separated by a few thin layers of tissue over a large surface area. Drugs readily cross the placenta, mainly by passive diffusion. Placental transfer begins approximately the fifth week after conception. When drugs are given on a regular schedule, serum levels reach equilibrium, with fetal blood usually containing 50% to 100% of the amount in maternal blood.

After drugs enter the fetal circulation, relatively large amounts are pharmacologically active because the fetus has low levels of serum albumin and thus low levels of drug binding. Drug molecules are distributed in two ways. Most are transported to the liver, where they are metabolized. Metabolism occurs slowly because the fetal liver is immature in quantity and quality of drug-metabolizing enzymes. Drugs metabolized by the fetal liver are excreted by fetal kidneys into amniotic fluid. Excretion also is slow and inefficient owing to immature development of fetal kidneys. In addition, the fetus swallows some amniotic fluid, and some drug molecules are recirculated.

Other drug molecules are transported directly to the heart, which then distributes them to the brain and coronary arteries. Drugs enter the brain easily because the blood–brain barrier is poorly developed in the fetus. Approximately half of the drug-containing blood is then transported through the umbilical arteries to the placenta, where it reenters the maternal circulation. Thus, the mother can metabolize and excrete some drug molecules for the fetus.

The fetus, which is exposed to any drugs circulating in maternal blood, is very sensitive to drug effects because it is small, has few plasma proteins that can bind drug molecules, and has a weak capacity for metabolizing and excreting drugs. Once drug molecules reach the fetus, they may cause teratogenicity (anatomic malformations) or other adverse effects. The teratogenicity of many drugs is unknown. However, since 1984, the Food and Drug Administration (FDA) has required that new drugs be assigned a risk category (Box 67–1).

Drug teratogenicity is most likely to occur when drugs are taken during the first trimester of pregnancy, when fetal organs are formed (Fig. 67–1). For drugs taken during the second and third trimesters, adverse effects are usually manifested in the neonate (birth to 1 month) or infant (1 month to 1 year) as growth retardation, respiratory problems, infection, or bleeding. Overall, effects are determined mainly by the type and amount of drugs, the duration of exposure, and the level of fetal growth and development when exposed to the drugs. Both therapeutic and nontherapeutic drugs may affect the fetus.

Fetal effects of commonly used therapeutic drugs are listed in Box 67–2. Effects of nontherapeutic drugs are described in the following paragraphs.

Alcohol is contraindicated during pregnancy; no amount is considered safe. Heavy intake may cause fetal alcohol

### Table 67–1: Pregnancy: Physiologic and Pharmacokinetic Changes

<table>
<thead>
<tr>
<th>Physiologic Change</th>
<th>Pharmacokinetic Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased plasma volume and body water, approximately 50% in a normal pregnancy</td>
<td>Once absorbed into the bloodstream, a drug (especially if water soluble) is distributed and “diluted” more than in the nonpregnant state. Drug dosage requirements may increase. However, this effect may be offset by other pharmacokinetic changes of pregnancy.</td>
</tr>
<tr>
<td>Increased weight (average 25 lb) and body fat</td>
<td>Drugs (especially fat-soluble ones) are distributed more widely. Drugs that are distributed to fatty tissues tend to linger in the body because they are slowly released from storage sites into the bloodstream.</td>
</tr>
<tr>
<td>Decreased serum albumin. The rate of albumin production is increased. However, serum levels fall because of plasma volume expansion. Also, many plasma protein-binding sites are occupied by hormones and other endogenous substances that increase during pregnancy.</td>
<td>The decreased capacity for drug binding leaves more free or unbound drug available for therapeutic or adverse effects on the mother and for placental transfer to the fetus. Thus, a given dose of a drug is likely to produce greater effects than it would in the nonpregnant state. Some commonly used drugs with higher unbound amounts during pregnancy include dexamethasone (Decadron), diazepam (Valium), lidocaine (Xylocaine), meperidine (Demerol), phenobarbital, phenytoin (Dilantin), propranolol (Inderal), and sulfisoxazole (Gantrisin).</td>
</tr>
<tr>
<td>Increased renal blood flow and glomerular filtration rate secondary to increased cardiac output</td>
<td>Increased excretion of drugs by the kidneys, especially those excreted primarily unchanged in the urine. These include penicillins, digoxin (Lanoxin), and lithium. In late pregnancy, the increased size and weight of the uterus may decrease renal blood flow when the woman assumes a supine position. This may result in decreased excretion and prolonged effects of renally excreted drugs.</td>
</tr>
</tbody>
</table>
syndrome, a condition characterized by multiple congenital defects and mental retardation.

Caffeine is the most commonly ingested nontherapeutic drug during pregnancy. It is present in coffee, tea, cola drinks, over-the-counter analgesics, antiseize preparations, and chocolate. Although ingestion of moderate amounts has not been associated with birth defects, spontaneous abortions, preterm births, and low birth weights have occurred. In addition, high doses may cause cardiac dysrhythmias in the fetus.

Cigarette smoking (nicotine and carbon monoxide ingestion) is one of the few preventable causes of perinatal morbidity and mortality and is contraindicated. Effects include increased fetal, neonatal, and infant mortality; decreased birth weight and length; shortened gestation; and increased complications of pregnancy (eg, placental abruption, spontaneous abortion; preterm delivery). These effects are attributed to decreased flow of blood and oxygen to the placenta and uterus. Nicotine causes vasoconstriction and decreases blood flow to the fetus; carbon monoxide decreases the oxygen available to the fetus. Chronic fetal hypoxia from heavy smoking has been associated with mental retardation and other long-term effects on physical and intellectual development. Overall, effects of smoking are dose related, with light smoking (<1 pack/day) estimated to increase fetal deaths by 20% and heavy smoking (1 or more packs/day) increasing deaths by 35%.

Cocaine, marijuana, and heroin are illegal drugs of abuse, and their use during pregnancy is particularly serious. Cocaine may cause maternal vasoconstriction, tachycardia, hypertension, cardiac dysrhythmias, and seizures. These effects may impair fetal growth, impair neurologic development, and increase the risk of spontaneous abortion during the first and second trimesters. During the third trimester, cocaine causes increased uterine contractility, vasoconstriction and decreased blood flow in the placenta, fetal tachycardia, and increased risk of fetal distress and abruptio placentae. These life-threatening effects are no data from human studies. These drugs may be used when potential benefits outweigh the potential risks.

**Box 67–1 U.S. Food and Drug Administration Drug Categories Regarding Pregnancy**

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Adequate studies in pregnant women demonstrate no risk to the fetus.</td>
</tr>
<tr>
<td>B.</td>
<td>Animal studies indicate no risk to the fetus, but there are no adequate studies in pregnant women; or animal studies show adverse effects, but adequate studies in pregnant women have not demonstrated a risk.</td>
</tr>
<tr>
<td>C.</td>
<td>A potential risk, usually because animal studies have either not been performed or indicated adverse effects, and there are no data from human studies. These drugs may be used when potential benefits outweigh the potential risks.</td>
</tr>
<tr>
<td>D.</td>
<td>There is evidence of human fetal risk, but the potential benefits to the mother may be acceptable despite the potential risk.</td>
</tr>
<tr>
<td>X.</td>
<td>Studies in animals or humans or adverse reaction reports or both have demonstrated fetal abnormalities; the risk of use in a pregnant woman clearly outweighs any possible benefit.</td>
</tr>
</tbody>
</table>

**Figure 67–1** The gestational clock showing the classic teratogenic risk assessment. (Adapted from Niebyl, J. [1999]. Drugs and related areas in pregnancy. In J. Sciarra [Ed.], Obstetrics and gynecology. Philadelphia: Lippincott Williams & Wilkins.)
All drugs are relatively contraindicated and should be used only if necessary. For most drugs, adequate studies have not been done in pregnant women and effects on the fetus are unknown. They should be used only if potential benefit to the mother justifies potential harm to the fetus.

Adrenergics
Adrenergics are cardiac stimulants that increase rate and force of contractions and may increase blood pressure. Several were teratogenic and embryocidal in animal studies. These drugs are common ingredients in over-the-counter decongestants, cold remedies, and appetite suppressants.

Oral and parenteral adrenergics may inhibit uterine contractions during labor; cause hypokalemia, hypoglycemia, and pulmonary edema in the mother; and cause hypoglycemia in the neonate. These effects are unlikely with inhaled adrenergics (eg, albuterol). Oral albuterol and oral or intravenous terbutaline relax uterine muscles and inhibit preterm labor.

Analgesics, Opioid
Opioids rapidly cross the placenta and reach the fetus. Maternal addiction and neonatal withdrawal symptoms result from regular use. Use of codeine during the first trimester has been associated with congenital defects.

When given to women in labor, opioids may decrease uterine contractility and slow progress toward delivery. They may also cause respiratory depression in the neonate. Meperidine reportedly causes less neonatal respiratory depression than other opioids. Butorphanol is also used. If respiratory depression occurs, it can be reversed by administration of naloxone, an opioid antagonist.

Angiotensin-Converting Enzyme (ACE) Inhibitors
These drugs can cause fetal and neonatal morbidity and death; several dozen cases have been reported worldwide. Adverse fetal effects apparently do not occur during first trimester exposure. With exposure during the second and third trimesters, however, effects may include fetal and neonatal injury such as hypotension, neonatal skull hypoplasia, anuria, renal failure, and death. As a result, the drugs should be discontinued as soon as pregnancy is detected. Infants exposed to the drugs in utero should be closely observed for hypotension, oliguria, and hyperkalemia.

Angiotensin II Receptor Blockers (ARBs)
See ACE inhibitors, above. These drugs should be discontinued when pregnancy is detected.

Antianginal Agents (Nitrates)
The drugs lower blood pressure and may decrease blood supply to the fetus. Thus, they should be used only if necessary.

Antianxiety and Sedative-Hypnotic Agents
(Benzodiazepines)
These drugs should generally be avoided. They and their metabolites cross the placenta freely and accumulate in fetal blood. If taken during the first trimester, they may cause physical malformations. If taken during labor, they may cause sedation, respiratory depression, hypotonia, lethargy, tremors, irritability, and sucking difficulties in the neonate.

Antibacterials
Beta lactams. Penicillins cross the placenta but apparently produce no adverse effects on the fetus. They are considered safer than other antibiotics. Cephalosporins cross the placenta and seem to be safe, although they have not been studied extensively in pregnancy. They have shorter half-lives, lower serum concentrations, and a faster rate of elimination in pregnancy. Carbapenems and aztreonam have not been studied and fetal effects are unknown.

Aminoglycosides (FDA category D) cross the placenta and fetal serum levels may reach 15% to 50% of maternal levels. Otoxicity may occur with gentamicin. Serious adverse effects on the fetus or neonate have not been reported with other aminoglycosides, but there is potential harm because the drugs are nephrotoxic and ototoxic.

Clindamycin (Cleocin) should be used only when infection with Bacteroides fragilis is suspected.

Fluoroquinolones are contraindicated in pregnancy.

Macrolides. Erythromycin crosses the placenta to reach fetal serum levels up to 20% of maternal levels, but no fetal abnormalities have been reported. In animal studies, adverse fetal effects were reported with clarithromycin and dirithromycin but not with azithromycin. Clarithromycin is contraindicated if a safer alternative is available.

Nitrofurantoin should not be used during late pregnancy because of possible hemolytic anemia in the neonate.

Sulfonamides should not be used during the last trimester because they may cause kernicterus in the neonate.

Tetracyclines are contraindicated. They cross the placenta and interfere with development of teeth and bone in the fetus. Animal studies indicate embryotoxicity.

Trimethoprim, often given in combination with sulfamethoxazole (Bactrim), is contraindicated during the first trimester. It crosses the placenta to reach levels in fetal serum that are similar to those in maternal serum. It is a folate antagonist and may interfere with folic acid metabolism in the fetus. It was teratogenic in animals, but a few studies in pregnant women have not indicated teratogenic effects.

Vancomycin is not recommended because fetal effects are unknown.

Antifungals
Systemic antifungals are generally contraindicated.

Anticholinergics
Atropine crosses the placenta rapidly with IV injection; effects on the fetus depend on the maturity of its parasympathetic nervous system. Scopolamine may cause respiratory depression in the neonate and may contribute to neonatal hemorrhage by reducing vitamin K–dependent clotting factors in the neonate.

Anticoagulants
Heparin does not cross the placenta and has not been associated with congenital defects. It is the anticoagulant of choice during pregnancy. However, its use has been associated with 13% to 22% unfavorable outcomes, including stillbirths and prematurity. Warfarin crosses the placenta and fetal hemorrhage, spontaneous abortion, prematurity, stillbirth, and congenital anomalies may occur. Approximately 31% of fetuses exposed to warfarin may experience a problem related to the anticoagulant. If a woman becomes pregnant during warfarin therapy, inform her of the potential risks to the fetus, and discuss the possibility of terminating the pregnancy.
Anticonvulsants
Although more than 90% of women receiving antiseizure drugs deliver normal infants, the drugs (eg, carbamazepine, phenytoin, valproate) are known teratogens. After years of questioning whether teratogenesis resulted from epilepsy or antiepileptic drugs, a recent study confirms that anticonvulsant drug therapy in pregnant women causes physical abnormalities in their offspring. Moreover, infants exposed to one drug had a much higher rate of abnormalities than infants not exposed (20.6% vs. 8.5%) and infants exposed to two or more drugs had a still higher rate (28%). Infants whose nonepileptic mothers took the drugs for bipolar disorder also had higher rates of birth defects. In general, the fetal effects of newer drugs (eg, gabapentin, lamotrigine, oxcarbazepine, tiagabine, and topiramate) (Topamax) are unknown. They are FDA category C.

Antidepressants
Tricyclic antidepressants (eg, amitriptyline) have been associated with teratogenicity and embryotoxicity when given in large doses, and there have been reports of congenital malformations and neonatal withdrawal syndrome. Monoamine oxidase inhibitors (eg, phenelzine), were associated with fewer viable offspring and growth retardation in animal studies with large doses. The selective serotonin reuptake inhibitors were teratogenic in animals and, in one study of 228 women who took fluoxetine during the first trimester, 5.5% of the infants had major birth defects. In addition, late exposure to fluoxetine resulted in more preterm births than early exposure (14.3% vs. 4.1%).

Antidiabetic Drugs
Insulin is the only antidiabetic drug recommended for use during pregnancy. Sulfonylureas except glyburide are teratogenic in animals; fetal effects of other oral agents are largely unknown. Acarbose, metformin, and miglitol are FDA category B; nateglinide, pioglitazone, repaglinide, and rosiglitazone are category C.

Antihistamines
Histamine-1 receptor blocking agents (eg, diphenhydramine), have been associated with teratogenic effects, but the extent is unknown. The drugs should generally not be used during the third trimester because of possible adverse effects in the neonate. With histamine-2 receptor blocking agents, cimetidine and ranitidine are considered acceptable for treatment of gastroesophageal reflux disease that does not respond to dietary and other lifestyle changes.

Antihypertensives
Methyldopa crosses the placenta and reaches fetal concentrations similar to those of maternal serum. However, no teratogenic effects have been reported despite widespread use during pregnancy. Neonates of mothers receiving methyldopa may have decreased blood pressure for about 48 h. Hydralazine is considered safe. Clonidine, guanabenz, and guanfacine are not recommended because effects in pregnant women are unknown.

Antimanic Agent
Lithium crosses the placenta and fetal concentrations are similar to those of the mother. Cardiac and other birth defects may occur. In the neonate, lithium is eliminated slowly and may cause bradycardia, cyanosis, diabetes insipidus, hypotonia, hypothyroidism, and electrocardiogram (ECG) abnormalities. Most of these effects resolve within 1 to 2 wk.

Antipsychotics
Phenothiazines (eg, chlorpromazine) readily cross the placenta. Studies indicate that the drugs are not teratogenic, but animal studies indicate potential embryotoxicity, increased neonatal mortality, and decreased performance. The possibility of permanent neurologic damage cannot be excluded. Use near term may cause abnormal movements, abnormal reflexes, and jaundice in the neonate and hypotension in the mother. Fetal effects of newer drugs are unknown.

Antitubercular Drugs
These drugs are recommended for treatment of active tuberculosis; use for prophylaxis can usually be delayed until after delivery. Isoniazid, ethambutol, and rifampin were embryocidal or teratogenic in animal studies. The effects of drug combinations on the fetus are unknown.

Antivirals
Most systemic antivirals were teratogenic in animal studies. No well-controlled studies support their use in pregnancy, except for zidovudine and other anti–human immunodeficiency virus (HIV) drugs to prevent transmission of HIV infection to the fetus.

Aspirin
Aspirin is contraindicated because of potential adverse effects on the mother and fetus. Maternal effects include prolonged gestation, prolonged labor, and antepartum and postpartum hemorrhage. Fetal effects include constriction of the ductus arteriosus, low birth weight, and increased incidence of stillbirth and neonatal death. The drug is FDA category D.

Beta-Adrenergic Blocking Agents
Safety for use of these drugs (eg, propranolol) has not been established. Teratogenicity has not been reported in humans, but problems may occur during delivery. These include maternal bradycardia and neonatal bradycardia, hypoglycemia, apnea, low Apgar scores, and low birth weight. Neonatal effects may last up to 72 h.

Calcium Channel Blocking Agents
Teratogenic and embryotoxic effects occurred in small animals given large doses. Diltiazem caused fetal death, skeletal abnormalities, and increased incidence of stillbirths. Nifedipine caused developmental toxicity in animals. Fetal effects of most of the drugs are unknown. Because the drugs decrease maternal blood pressure, there is a potential risk of inadequate blood flow to the placenta and the fetus.

Corticosteroids
Systemic corticosteroids cross the placenta. Animal studies indicate that large doses of cortisol early in pregnancy may produce cleft palate, stillbirths, and decreased fetal size. Chronic maternal ingestion during the first trimester has shown a 1% incidence of cleft palate in humans. Infants of mothers who received substantial amounts of corticosteroids during pregnancy...
should be closely observed for signs of adrenal insufficiency. Be-
tamethasone is used to promote fetal production of surfactant
to increase lung maturity in the preterm infant. Inhaled cortico-
steroids (eg, those used to treat allergic rhinitis or asthma) are
less likely to cause adverse effects in the fetus because of less
systemic absorption.

**Digoxin**

*Digoxin* is apparently safe for use during pregnancy. It crosses
the placenta to reach fetal serum levels that are 50% to 80% those
of maternal serum. Fetal toxicity and neonatal death have occurred
with maternal overdose. Dosage requirements may be less predict-
table during pregnancy, and serum drug levels and other as-
seessment parameters must be closely monitored. Digoxin also has
been administered to the mother for treatment of fetal tachycardia
and heart failure.

**Diuretics**

Thiazides (eg, hydrochlorothiazide) cross the placenta. They are
not associated with teratogenesis, but they may cause other ad-
verse effects. Because the drugs decrease plasma volume, de-
creased blood flow to the uterus and placenta may occur with
resultant impairment of fetal nutrition and growth. Other adverse
effects may include fetal or neonatal jaundice, thrombocytopenia,
hyperbilirubinemia, hemolytic jaundice, fluid and electrolyte im-
balances, and impaired carbohydrate metabolism. These drugs are
not indicated for treatment of dependent edema caused by uterine
enlargement and restriction of venous blood flow. They also are
not effective in prevention or treatment of pregnancy-induced
hypertension (preeclampsia). They may be used for treatment of
pathologic edema.

Loop diuretics (eg, furosemide) are not considered teratogenic,
but animal studies indicated fetal toxicity and death. Like the thi-
azides, loop diuretics may decrease plasma volume and blood flow
to the placenta and fetus.

Potassium-conserving diuretics (eg, triamterene, an ingredient
in Dyazide and Maxide) cross the placenta in animal studies, but
effects on the human fetus are unknown.

**Dyslipidemics**

Cholestyramine and colestipol are considered safe because they
are not absorbed systemically. HMG-CoA reductase inhibitors or
“statins” (eg, lovastatin) are FDA category X and contraindicated
during pregnancy. They should be given to women of childbear-
ing age only if they are highly unlikely to become pregnant and
are informed of potential hazards. If a woman becomes pregnant
while taking one of these drugs, the drug should be stopped and
the patient informed of possible adverse drug effects on the fetus.

**Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)**

Use of NSAIDs (eg, ibuprofen) should generally be avoided, espe-
cially during the third trimester. All of the drugs are FDA category
D in the third trimester or near delivery. If these drugs are taken in
the third trimester, effects on human fetuses include constriction
of the ductus arteriosus prenatally, nonclosure of the ductus arteriosus
postnatally, impaired function of the tricuspid valve in the heart,
pulmonary hypertension, degenerative changes in the myocardium,
impaired platelet function with resultant bleeding, intracranial
bleeding, renal impairment or failure, oligohydramnios, gastro-
intestinal (GI) bleeding or perforation, and increased risk of
eutrophil infiltration and death. The newer COX-2 inhibitors (eg, celecoxib)
have not been studied in pregnant women; diclofenac is contraindicated in pregnant women.

**Thyroid Hormone**

Levothyroxine does not readily cross the placenta and it seems
safe in appropriate dosages. However, it may cause tachycardia
in the fetus. When given as replacement therapy in hypothyroid
women, the drug should be continued through pregnancy.

**Fetal Therapeutics**

Although the major concern about drugs ingested during
pregnancy is adverse effects on the fetus, a few drugs are
given to the mother for their therapeutic effects on the fetus.
These include digoxin for fetal tachycardia or heart failure,
levothyroxine for hypothyroidism, penicillin for exposure to
maternal syphilis, and prenatal corticosteroids to promote
surfactant production to improve lung function and decrease
respiratory distress syndrome in preterm infants.

**Maternal Therapeutics**

Thus far, the main emphasis on drug use during pregnancy
has related to actual or potential adverse effects on the fetus.
Despite the general principle that drug use should be avoided
when possible, pregnant women may require drug therapy
for various illnesses, increased nutritional needs, pregnancy-
associated problems, chronic disease processes, treatment
of preterm labor, induction of labor, and pain management
during labor.

**Herbal and Dietary Supplements**

Pregnancy increases nutritional needs and vitamin and min-
eral supplements are commonly used. Folic acid supplemen-
tation is especially important, to prevent neural tube birth
defects (eg, spina bifida). Such defects occur early in preg-
nancy, often before the woman realizes she is pregnant. For
this reason, it is recommended that all women of childbear-
ing potential ingest at least 400 mcg daily from food and/or a supplement. In addition, pregnancy increases folic acid requirements by 5- to 10-fold and deficiencies are common. A supplement is usually needed to supply adequate amounts. For deficiency states, 1 mg or more daily may be needed.

Herbal supplements are not recommended during pregnancy. Ginger has been used to relieve nausea and vomiting during pregnancy, with a few studies supporting its use. Overall, it has not been proven effective, but is probably safe for use.

Pregnancy-Associated Symptoms and Their Management

Anemias

Three types of anemia are common during pregnancy. One is physiologic anemia, which results from expanded blood volume. A second is iron-deficiency anemia, which is often related to long-term nutritional deficiencies. Iron supplements are usually given for prophylaxis (eg, ferrous sulfate 300 mg or ferrous gluconate 600 mg three times daily). Iron preparations should be given with food to decrease gastric irritation. Citrus juices enhance absorption. A third type is megaloblastic anemia, caused by folic acid deficiency. A folic acid supplement is often prescribed for prophylaxis.

Constipation

Constipation often occurs during pregnancy, probably from decreased peristalsis. Preferred treatment, if effective, is to increase exercise and intake of fluids and high-fiber foods. If a laxative is required, a bulk-producing agent (eg, Metamucil) is the most physiologic for the mother and safest for the fetus because it is not absorbed systemically. A stool softener (eg, docusate) or an occasional saline laxative (eg, milk of magnesia) may also be used. Mineral oil should be avoided because it interferes with absorption of fat-soluble vitamins. Reduced absorption of vitamin K can lead to bleeding in newborns. Castor oil should be avoided because it can cause uterine contractions. Strong laxatives or any laxative used in excess may initiate uterine contractions and labor.

Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD), of which heartburn (pyrosis) is the main symptom, often occurs in the later months of pregnancy. It develops when increased abdominal pressure and a relaxed esophageal sphincter allow gastric acid to splash into the esophagus and cause irritation, discomfort, and esophagitis. Nonpharmacologic interventions include eating small meals; not eating for 2 to 3 hours before bedtime; avoiding caffeine, gas-producing foods and constipation; and sitting in an upright position. For clients who do not obtain adequate relief with these measures, drug therapy may be needed. Antacids may be used if necessary. Because little systemic absorption occurs, the drugs are unlikely to harm the fetus if used in recommended doses. Cimetidine, ranitidine, or sucralfate may also be used.

Gestational Diabetes

Some women first show signs of diabetes during pregnancy. This is called gestational diabetes. Women with risk factors (eg, obesity, family history of diabetes, being Hispanic, Native American, Asian, or African American) should be screened at the first prenatal visit. Most women without risk factors, or whose initial test was normal, should be tested between 24 and 28 weeks of gestation.

For women with gestational diabetes, initial management includes nutrition and exercise interventions, calorie restriction for obese women, and daily self-monitoring of blood glucose levels. If these interventions are ineffective, recombinant human insulin is needed to keep blood sugar levels as nearly normal as possible. Oral antidiabetics are generally contraindicated, although acarbose, metformin, and miglitol seem to cause minimal fetal risk.

These women may revert to a nondiabetic state when pregnancy ends, but they are at increased risk for development of overt diabetes within 5 to 10 years. Gestational diabetes usually subsides within 6 weeks after delivery.

Nausea and Vomiting

Nausea and vomiting often occur, especially during early pregnancy. Dietary management (eg, eating a few crackers when awakening and waiting a few minutes before arising) and maintaining fluid and electrolyte balance are recommended. Antiemetic drugs should be given only if nausea and vomiting are severe enough to threaten the mother’s nutritional or metabolic status. Meclizine, 25 to 50 mg daily, and dimenhydrinate, 50 mg every 3 to 4 hours, are thought to have low teratogenic risks. Pyridoxine (vitamin B6) also may be helpful. If used, recommended dosage is 10 to 25 mg daily.

Pregnancy-Induced Hypertension

Pregnancy-induced hypertension includes preeclampsia and eclampsia, conditions that endanger the lives of mother and fetus. Preeclampsia is most likely to occur during the last 10 weeks of pregnancy, during labor, or within the first 48 hours after delivery. It is manifested by edema, hypertension, and proteinuria. Drug therapy includes intravenous hydralazine or labetalol for blood pressure control and magnesium sulfate for prevention or treatment of seizures. Eclampsia, characterized by severe symptoms and convulsions, occurs if preeclampsia is not treated effectively. Delivery of the fetus is the only known cure for preeclampsia or eclampsia. For women at risk of developing preeclampsia, aspirin 60 mg daily, from 24 to 28 weeks of gestation until onset of labor, may be used for prophylaxis.
Selected Infections

Group B streptococcal infections may affect the pregnant woman and the neonate. During late pregnancy, urinary tract infections (UTIs) or amnionitis may occur. After cesarean delivery, endometritis, bacteremia, or wound infection may occur. In the infant, sepsis, meningitis, or pneumonia may occur.

Because of the potentially serious consequences of infection with group B streptococci, pregnant women should have a vaginal culture at 35 to 37 weeks of gestation. A positive culture indicates infection that should be treated. However, antibiotics given at this time may not provide coverage during labor and delivery. Treatment should be initiated during labor, often with ampicillin 2 g intravenously (IV) as a loading dose, then 1 g IV every 4 hours until delivery.

Human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) can be transmitted to the fetus and neonate, and treatment is needed to reduce transmission. Oral zidovudine (AZT) monotherapy has been used for several years, after 14 weeks of gestation. During labor, IV AZT is given until delivery. After delivery, the infant should be given AZT for 6 weeks, with or without other anti-AIDS drugs. Increasingly, highly active antiretroviral therapy (HAART) is being used for pregnant women. HAART is a combination of drugs that may include a nucleoside reverse transcriptase inhibitor (eg, zidovudine, lamivudine, or didanosine), a non-nucleoside reverse transcriptase inhibitor (eg, nevirapine) and a protease inhibitor (eg, ritonavir, saquinavir, nelfinavir).

Women with HIV infection or AIDS should be encouraged to avoid pregnancy.

Urinary tract infections commonly occur during pregnancy and may include asymptomatic bacteriuria, cystitis, and pyelonephritis. Although treatment of asymptomatic bacteriuria is controversial in some populations, the condition should be treated in pregnant women because of its association with cystitis and pyelonephritis. Asymptomatic bacteriuria and UTIs are also associated with increased preterm deliveries and low birth weights. Amoxicillin, cephalaxin, and nitrofurantoin are commonly used drugs. Hospitalization and an IV cephalosporin may be needed for management of pyelonephritis.

Management of Chronic Diseases During Pregnancy

Asthma

Asthma is associated with a variety of complications in pregnancy, including preeclampsia, perinatal death, low birth weights, and congenital malformations. Poor asthma control during pregnancy is considered more detrimental to a fetus than treatment with available drugs. Thus, good control is essential. Commonly used drugs include orally inhaled beta2 agonists (eg, albuterol or metaproterenol) and anti-inflammatory agents (eg, cromolyn or beclomethasone).

Diabetes Mellitus

Diabetes increases the risks of pregnancy for both mother and fetus, and the hormonal changes of pregnancy have diabetogenic effects that may cause or aggravate diabetes. Some women first show signs of diabetes during pregnancy (gestational diabetes). Others, who were previously able to control diabetes with diet alone, may become insulin dependent during pregnancy. Still others, already insulin dependent, are likely to need larger doses as pregnancy advances. Overall, pregnancy makes diabetes more difficult to control. In addition, insulin requirements fluctuate during pregnancy. For diabetic women who become pregnant, maintaining normal or near-normal blood sugar levels is required for successful outcomes because poor glycemic control increases the risks of birth defects. Recommendations for management include the following:

- If oral antidiabetic drugs are taken by a woman of childbearing potential, they should be discontinued before conception, if possible (eg, for a planned pregnancy attempt), or as soon as pregnancy is suspected. Oral antidiabetic drugs are contraindicated in pregnancy, mainly because of fetal hypoglycemia. This recommendation may change in the future, because acarbose, miglitol, and metformin are thought to have little risk for the fetus. Glyburide has been used in some women after 11 weeks of gestation. However, its use is not recommended during the last few weeks of pregnancy. Most oral agents have not been studied in pregnant women.
- Insulin is the antidiabetic drug of choice during pregnancy. Human insulin should be used because it is least likely to cause an allergic response. Because insulin requirements vary according to the stage of pregnancy, the diabetic client’s blood glucose levels must be monitored closely and insulin therapy individualized. It is especially important that sufficient insulin is given to prevent maternal acidosis. Uncontrolled acidosis is likely to interfere with neurologic development of the fetus. At the same time, careful dietary control and other treatment measures are necessary.
- Insulin requirements usually decrease during the first trimester and increase during the second and third trimesters.
- During labor and delivery, short-acting insulin and frequent blood glucose tests are used to control diabetes, as during other acute situations.
- During the postpartum period, insulin requirements fluctuate because stress, trauma, infection, surgery, or other factors associated with delivery tend to increase blood glucose levels and insulin requirements. At the same time, termination of the pregnancy reverses the diabetogenic hormonal changes and decreases insulin requirements. Short-acting insulin is given, and dosage is based on frequent measurements of blood glucose. Once the insulin requirement is stabilized, the client may be able to return to the prepregnancy treatment program.
**Hypertension**

Chronic hypertension (hypertension beginning before conception or up to 20 weeks of pregnancy) is associated with increased maternal and fetal risks. Thus, appropriate management is mandatory. Nonpharmacologic interventions (e.g., avoiding excessive weight gain, sodium restriction, increased rest) should be emphasized. If drug therapy is required, methyldopa is the drug of first choice because it has not been associated with adverse effects on the fetus or neonate. Alternatives include labetalol and other beta blockers, clonidine, hydralazine, isradipine, nifedipine, and prazosin. With beta blockers, fetal and neonatal bradycardia, hypotension, hypoglycemia, and respiratory depression have been reported. As a result, some authorities recommend avoiding the drugs during the first trimester and stopping them 2 to 3 days before delivery.

Opinions seem divided on the use of angiotensin-converting enzyme (ACE) inhibitors. Some sources say the drugs are contraindicated during pregnancy; others say they can be used during the first trimester but should then be discontinued because of potential renal damage in the fetus. The same effects would probably occur with angiotensin II receptor blockers (ARBs), because they also act on the renin–angiotensin system.

Although diuretics are commonly used in the treatment of hypertension, they should not be given during pregnancy. They decrease blood volume, cardiac output, and blood pressure and may cause fluid and electrolyte imbalances, all of which may have adverse effects on the fetus.

**Seizure Disorders**

Although antiepileptic drugs (AEDs) are known teratogens, they must often be taken during pregnancy because seizures may also be harmful to mother and fetus. Fortunately, most pregnancies (90 to 95%) result in normal infants. Despite the usually good outcomes, the incidence of birth defects is 2 to 3 times higher in fetuses exposed to AEDs than in those not exposed. If an AED is required, monotherapy with the lowest dose that stops seizures should be used and plasma drug levels should be checked monthly. Women with epilepsy should take a folic acid supplement (at least 400 mcg daily) all the time and 800 mcg or more during pregnancy. Supplemental vitamin K is usually needed during the last month of pregnancy, to prevent bleeding in neonates. An injection of vitamin K is also given to the infant immediately after birth.

There has been controversy as to whether teratogenic effects stemmed from epilepsy or AEDs. A newer study indicates that the drugs are responsible. Moreover, the rate of birth defects in infants exposed to one AED was significantly higher than those not exposed (20.6% vs 8.5%) and 28% in infants exposed to two or more AEDs. Infants whose mothers took AEDs for bipolar disorder rather than epilepsy also had higher rates of birth defects.

**ABORTIFACIENTS**

Abortion is the termination of pregnancy before 20 weeks. It may occur spontaneously or be intentionally induced. Medical abortion may be induced by prostaglandins and an antiprogestin (Drugs at a Glance: Abortifacients, Prostaglandins, Tocolytics, and Oxytoics). Prostaglandins may be used to terminate pregnancy during the second trimester. In the female reproductive system, prostaglandins E and F are found in the ovaries, myometrium, and menstrual fluid. They stimulate uterine contraction and are probably important in initiating and maintaining the normal birth process. Drug preparations of prostaglandins are capable of inducing labor at any time during pregnancy. Misoprostol, a prostaglandin developed to prevent nonsteroidal anti-inflammatory drug–induced gastric ulcers (see Chap. 60), is being given orally or intravaginally for first or second trimester termination. It is not FDA approved for this use.

Mifepristone is a progesterone antagonist used to terminate pregnancy during the first trimester. A prostaglandin is given approximately 48 hours after the mifepristone to augment uterine contractions and ensure expulsion of the conceptus.

**TOCOLY蒂CS**

Drugs given to inhibit labor and maintain the pregnancy are called tocolytics. Uterine contractions with cervical changes between 20 and 37 weeks of gestation are considered premature labor. Nonpharmacologic treatment includes bed rest, hydration, and sedation. Drug therapy is most effective when the cervix is dilated less than 4 cm and membranes are intact.

Ritodrine, terbutaline, magnesium sulfate, and nifedipine are used as tocolytics (see Drugs at a Glance: Abortifacients, Prostaglandins, Tocolytics, and Oxytoics). Ritodrine and terbutaline are beta-adrenergic agents that relax uterine smooth muscle and thereby slow or stop uterine contractions. Terbutaline is not FDA approved for use in premature labor, but is used widely for that purpose. Magnesium sulfate is most often used as an anticonvulsant in the treatment of preeclampsia, but it also inhibits preterm labor. Hypermagnesemia may occur because tocolytic serum levels (4 to 7 mEq/L) are higher than normal levels (1.5 to 2.5 mEq/L). Close monitoring of serum
levels and signs of hypermagnesemia (eg, decreased respiratory rate and hypotonia) is required.

#### DRUGS USED DURING LABOR AND DELIVERY AT TERM

At the end of gestation, labor usually begins spontaneously and proceeds through delivery of the neonate. In some instances, prostaglandin preparations (eg, Prepidil or Cervidil formulations of dinoprostone) are administered intravaginally to promote cervical ripening and induce labor. Drugs often used during labor, delivery, and the immediate postpartum period include oxytocics, analgesics, and anesthetics.

### Oxytocics

Oxytocic drugs include oxytocin (Pitocin) and methylergonovine (see Drugs at a Glance Table). Oxytocin is a hormone produced in the hypothalamus and released by the posterior pituitary gland (see Chap. 23). Oxytocin stimulates uterine contractions to initiate labor and promotes letdown of breast milk to the nipples in lactation. Pitocin is a synthetic form used to induce labor at or near full-term gestation and to augment labor when uterine contractions are weak and ineffective. It also can be used to prevent or control uterine bleeding after delivery or to complete an incomplete abortion. It is contraindicated for antepartum use in the presence of fetal distress, cephalopelvic disproportion, preterm labor, placenta previa, previous uterine surgery, and severe preeclampsia. Methergine is used for management of postpartum hemorrhage related to uterine atony.

### Analgesics

Parenteral opioid analgesics are used to control discomfort and pain during labor and delivery. They may prolong labor and cause sedation and respiratory depression in the mother...
and neonate. Meperidine may cause less neonatal depression than other opioid analgesics. Butorphanol is widely used. If neonatal respiratory depression occurs, it can be reversed by naloxone (Narcan).

Duramorph is a long-acting form of morphine that provides analgesia up to 24 hours after injection into the epidural catheter at the completion of a cesarean section.

Regional analgesia is achieved by the epidural injection of opioids (eg, fentanyl) or preservative-free morphine. Possible side effects include maternal urinary retention, but no significant effects on the fetus.

**Anesthetics**

Local anesthetics also are used to control discomfort and pain. They are injected by physicians for regional anesthesia in the pelvic area. Epidural blocks involve injection into the epidural space of the spinal cord. Bupivacaine is commonly used. With regional anesthesia, the mother is usually conscious and comfortable, and the neonate is rarely depressed. Fentanyl may be combined with a small amount of an anesthetic drug for both analgesia and anesthesia. No significant effects on the fetus occurred in clinical studies.

**NEONATAL THERAPEUTICS**

In the neonate, any drug must be used cautiously. Drugs are usually given less often because they are metabolized and excreted slowly. Immature liver and kidney function prolongs drug action and increases risks of toxicity. Also, drug therapy should be initiated with low doses, especially with drugs that are highly bound to plasma proteins. Neonates have few binding proteins, which leads to increased amounts of free, active drug and increased risk of toxicity. When the health care provider is assessing the neonate, drugs received by the mother during pregnancy, labor and delivery, and lactation must be considered.

At birth, some drugs are routinely administered to prevent hemorrhagic disease of the newborn and opthalmia neonatorum. Hemorrhagic disease of the newborn occurs because the intestinal tract lacks the bacteria that normally synthesize vitamin K. Vitamin K is required for liver production of several clotting factors, including prothrombin. Thus, the neonate is at increased risk of bleeding during the first week of life. One dose of phytolactone 0.5 to 1 mg is injected at delivery or on admission to the nursery.

Ophthalmia neonatorum is a form of bacterial conjunctivitis that may cause ulceration and blindness. It may be caused by several bacteria, most commonly *Chlamydia trachomatis*, a sexually transmitted organism. Erythromycin ointment 0.5% is applied to each eye at delivery. It is effective against both chlamydial and gonococcal infections.

**Nursing Process**

**Assessment**
Assess each female client of reproductive age for possible pregnancy. If the client is known to be pregnant, assess status in relation to pregnancy, as follows:

- Length of gestation
- Use of prescription, over-the-counter, herbal, nontherapeutic, and illegal drugs
- Acute and chronic health problems that may influence the pregnancy or require drug therapy
- With premature labor, assess length of gestation, the frequency and quality of uterine contractions, the amount of vaginal bleeding or discharge, and the length of labor. Also determine whether any tissue has been expelled from the vagina. When abortion is inevitable, oxytocics may be given. When stopping labor is possible or desired, a tocolytic may be given.
- When spontaneous labor occurs in normal, full-term pregnancy, assess frequency and quality of uterine contractions, amount of cervical dilatation, fetal heart rate and quality, and maternal blood pressure.
- Assess antepartum women for intention to breastfeed.

**Nursing Diagnoses**

- Risk for Injury: Damage to fetus or neonate from maternal ingestion of drugs
- Noncompliance related to ingestion of nonessential drugs during pregnancy
- Risk for Injury related to possible damage to mother or infant during the birth process
- Deficient Knowledge: Drug effects during pregnancy and lactation

**Planning/Goals**
The client will:

- Avoid unnecessary drug ingestion when pregnant or likely to become pregnant
- Use nonpharmacologic measures to relieve symptoms associated with pregnancy or other health problems when possible
- Obtain optimal care during pregnancy, labor and delivery, and the postpartum period
- Avoid behaviors that may lead to complications of pregnancy and labor and delivery
- Breast-feed safely and successfully if desired

**Interventions**

- Use nondrug measures to prevent the need for drug therapy during pregnancy.
- Provide optimal prenatal care and counseling to promote a healthy pregnancy (eg, regular monitoring of blood pressure, weight, blood sugar, urine protein, and counseling about nutrition and other health-promoting activities).
- Help clients and families cope with complications of pregnancy, including therapeutic abortion.
Drug Use During Pregnancy and Lactation

CLIENT TEACHING GUIDELINES

Drug Use During Pregnancy and Lactation

Any systemic drug ingested by a pregnant woman reaches the fetus and may interfere with fetal growth and development. For most drugs, safety during pregnancy has not been established, and all drugs are relatively contraindicated. Therefore, any drug use must be cautious and minimal to avoid potential damage to the fetus.

Avoid drugs when possible and use them very cautiously when necessary. If women who are sexually active and not using contraception take any drugs, there is a high risk that potentially harmful agents may be ingested before pregnancy is suspected or confirmed.

Lifestyle or nontherapeutic drugs associated with problems during pregnancy include alcohol, caffeine, and cigarette smoking. Women should completely avoid alcohol when trying to conceive and throughout pregnancy; no amount is considered safe. Caffeine intake should be limited to about three caffeinated beverages per day; excessive intake should be avoided. Women who smoke should quit if possible during pregnancy, to avoid the effects of nicotine, carbon monoxide, and other chemicals on the fetus.

Herbal supplements are not recommended; their effects during pregnancy are largely unknown.

Measures to prevent the need for drug therapy include a healthful lifestyle (adequate nutrition, exercise, rest and sleep; avoiding alcohol and cigarette smoking) and avoiding infection (personal hygiene, avoiding contact with people known to have infections, maintaining indicated immunizations).

Nondrug measures to relieve common health problems include positioning, adequate food and fluid intake, and deep breathing.

See a health care provider as soon as pregnancy is suspected.

Inform any health care provider from whom treatment is sought if there is a possibility of pregnancy.

Many drugs are excreted in breast milk to some extent and reach the nursing infant. The infant’s health care provider should be informed about medications taken by the nursing mother and consulted about potential drug effects on the infant. Before taking over-the-counter medications, consult a health care provider. In regard to nontherapeutic drugs, recommendations include the following:

1. Alcohol should be used in moderation and nursing should be withheld temporarily after alcohol consumption (1–2 hours per drink). Alcohol reaches the baby through breast milk, with the highest concentration about 30 to 60 minutes after drinking (60–90 minutes if taken with food). The effects of alcohol on the baby are directly related to the amount of alcohol the mother consumes. Moderate to heavy drinking (2 or more drinks per day) can interfere with the ability to breast-feed, harm the baby’s motor development, and slow the baby’s weight gain. If you plan to drink (eg, wine with dinner), you can avoid breast-feeding for a few hours (until the alcohol has time to leave your system) or you can pump your milk before drinking and give it to the baby after you have had the alcohol. You can also pump and discard the milk that is most affected by the ingested alcohol.

2. Caffeine is considered compatible with breast-feeding. However, large amounts should be avoided because infants may be jittery and have difficulty sleeping.

3. Cigarette smoking is contraindicated. Nicotine and an active metabolite are concentrated in milk and the amounts reaching the infant are proportional to the number of cigarettes smoked by the mother. Ideally, the mother who smokes would stop. If unable or unwilling to stop, she should decrease the number of cigarettes as much as possible, avoid smoking before nursing, and avoid smoking (or allowing other people to smoke) in the same room with the infant. The risk for sudden infant death syndrome (SIDS) is greater when a mother smokes or when the baby is around second-hand (or passive) smoke. Maternal smoking and passive smoke may also increase respiratory and ear infections in infants.

PRINCIPLES OF THERAPY

General Guidelines: Pregnancy

1. Give medications only when clearly indicated, weighing anticipated benefits to the mother against the risk of harm to the fetus.

2. When drug therapy is required, the choice of drug should be based on the stage of pregnancy and available drug information (see Boxes 67–1 and 67–2). During the first trimester, for example, an older drug that has not been associated with teratogenic effects is usually preferred over a newer drug of unknown teratogenicity.

3. Any drugs used during pregnancy should be given in the lowest effective doses and for the shortest effective time.

1. Give medications only when clearly indicated, weighing anticipated benefits to the mother against the risk of harm to the fetus.

2. When drug therapy is required, the choice of drug should be based on the stage of pregnancy and available drug information (see Boxes 67–1 and 67–2). During the first trimester, for example, an older drug that has not been associated with teratogenic effects is usually preferred over a newer drug of unknown teratogenicity.

3. Any drugs used during pregnancy should be given in the lowest effective doses and for the shortest effective time.
General Guidelines: Lactation

1. Most systemic drugs taken by the mother reach the infant in breast milk. For some, the amount of drug is too small to cause significant effects; for others, effects on the nursing infant are unknown or potentially adverse. Drugs that are considered safe, those to be used with caution, and those that are contraindicated are listed in Box 67–3.

2. Give medications only when clearly indicated, weighing potential benefit to the mother against possible harm to the nursing infant. For contraindicated drugs, it is usually recommended that the mother stop the drug or stop breast-feeding.

3. Any drugs used during lactation should be given in the lowest effective dose for the shortest effective time.

4. The American Academy of Pediatrics (AAP) supports breast-feeding as optimal nutrition for infants and does not recommend stopping during maternal drug therapy unless necessary. In some instances, mothers may pump and discard breast milk while receiving therapeutic drugs, to maintain lactation.

5. Women with human immunodeficiency virus (HIV) infection should not breast-feed. The virus can be transmitted to the nursing infant.

Use of Oxytocin

Oxytocin is usually the drug of choice for induction or augmentation of labor because physiologic doses produce a rhythm...
mic uterine contraction–relaxation pattern that approximates the normal labor process. It is also the drug of choice for prevention or control of postpartum uterine bleeding because it is less likely to cause hypertension than the ergot alkaloids.

**Home Care**

Many obstetric clients with conditions such as preterm labor, hyperemesis, and elevated blood pressure are now being managed in the home. The home care nurse who assists in managing these clients should be an obstetric specialist who is knowledgeable about normal pregnancy and potential complications. The nurse should be aware of the drugs being used to treat the complicated obstetric client as well as maternal use of any nonprescription and nontherapeutic drugs. A systematic assessment of maternal and fetal responses should be made on each visit.

Home care visits also allow for assessment of compliance with the proposed management plan. Understanding of previous teaching should be evaluated on each visit. It is especially important for the client to know the danger signs and symptoms that may necessitate notifying a health care provider.

The overall goal of home care is to maintain the pregnancy to the most advanced gestational age possible. Home care follow-up by a nurse has been demonstrated to positively affect the outcome of a high-risk pregnancy.

---

### Nursing Actions

**Abortifacients, Tocolytics, and Oxytocics**

<table>
<thead>
<tr>
<th>NURSING ACTIONS</th>
<th>RATIONALE/EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. Administer accurately</strong></td>
<td></td>
</tr>
<tr>
<td>a. Give abortifacients orally (PO), intramuscularly (IM), or intravaginally.</td>
<td></td>
</tr>
<tr>
<td>b. Give tocolytics intravenously (IV) initially, via an infusion pump, then PO. With IV ritodrine, have the client lie in the left lateral position.</td>
<td>The side-lying position decreases risks of hypotension.</td>
</tr>
<tr>
<td>c. For IV oxytocin, dilute the drug in an IV sodium chloride solution, and piggyback the solution into a primary IV line. Use an infusion pump to administer.</td>
<td>Oxytocin may cause water intoxication, which is less likely to occur if the drug is given in a saline solution. Piggybacking allows regulation of the oxytocin drip without interrupting the main IV line. Infusion pumps deliver more accurate doses and minimize the risk of overdosage.</td>
</tr>
<tr>
<td>d. Give IM oxytocin immediately after delivery of the placenta.</td>
<td>To prevent excessive postpartum bleeding</td>
</tr>
<tr>
<td><strong>2. Observe for therapeutic effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. When an abortifacient is given, observe for the onset of uterine bleeding and the expulsion of the fetus and placenta.</td>
<td>Abortion usually occurs within 24 h after a prostaglandin is given and approximately 5 d after mifepristone administration.</td>
</tr>
<tr>
<td>b. When a tocolytic drug is given in threatened abortion or premature labor, observe for absent or decreased uterine contractions.</td>
<td>The goal of drug therapy is to stop the labor process.</td>
</tr>
<tr>
<td>c. When oxytocin is given to induce or augment labor, observe for firm uterine contractions at a rate of three to four per 10 min. Each contraction should be followed by a palpable relaxation period. Examine periodically for cervical dilatation and effacement.</td>
<td>Oxytocin is given to stimulate the normal labor process. Contractions should become regular and increase in duration and intensity.</td>
</tr>
<tr>
<td>d. When oxytocin or an ergot alkaloid is given to prevent or control postpartum bleeding, observe for a small, firm uterus and minimal vaginal bleeding.</td>
<td>These agents control bleeding by causing strong uterine contractions. The uterus can be palpated in the lower abdomen.</td>
</tr>
<tr>
<td><strong>3. Observe for adverse effects</strong></td>
<td></td>
</tr>
<tr>
<td>a. With mifepristone, observe for excessive uterine bleeding and abdominal pain</td>
<td>These effects are uncommon but may occur.</td>
</tr>
<tr>
<td>b. With prostaglandins, observe for:</td>
<td>These are the most common adverse effects. They result from drug-induced stimulation of gastrointestinal smooth muscle.</td>
</tr>
<tr>
<td>(1) Nausea, vomiting, diarrhea</td>
<td></td>
</tr>
</tbody>
</table>
**NURSING ACTIONS**

<table>
<thead>
<tr>
<th>(2) Fever, cardiac dysrhythmias, bronchospasm, convulsions, chest pain, muscle aches</th>
</tr>
</thead>
</table>

c. With ritodrine, observe for:
   (1) Change in fetal heart rate
   (2) Maternal effects, (eg, palpitations, dysrhythmias, changes in blood pressure, nausea and vomiting, hyperglycemia, dyspnea, chest pain, anaphylactic shock).

d. With oxytocin, observe for:
   (1) Excessive stimulation of uterine contractility (hypertonicity, tetany, rupture, cervical and perineal lacerations, fetal hypoxia, dysrhythmias, death or damage from rapid, forceful propulsion through the birth canal)
   (2) Hypotension or hypertension
   (3) Water intoxication (convulsions, coma)

e. With ergot preparations, observe for:
   (1) Nausea, vomiting, diarrhea
   (2) Symptoms of ergot poisoning—coolness, numbness and tingling of extremities, headache, vomiting, dizziness, thirst, convulsions, weak pulse, confusion, chest pain, and muscle weakness and pain
   (3) Hypertension

4. Observe for drug interactions

<table>
<thead>
<tr>
<th>a. Drugs that alter effects of prostaglandins:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Aspirin and other nonsteroidal anti-inflammatory agents, such as ibuprofen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>b. Drugs that alter effects of ritodrine:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Beta-adrenergic blocking agents (eg, propranolol)</td>
</tr>
<tr>
<td>(2) Corticosteroids</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>c. Drugs that alter effects of oxytocin:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Vasoconstrictors, such as epinephrine and other adrenergic drugs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>d. Drugs that alter effects of ergot alkaloids:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Propranolol (Inderal)</td>
</tr>
<tr>
<td>(2) Vasoconstrictors</td>
</tr>
</tbody>
</table>

**RATIONALE/EXPLANATION**

- These effects occur less often. Bronchospasm is more likely to occur in clients with asthma; seizures are more likely in clients with known epilepsy.

- This is a common adverse effect and may be significant if changes are extreme or prolonged.

- Most likely to occur when excessive doses are given to initiate or augment labor.

- Usual obstetric doses do not cause significant change in blood pressure. Large doses may cause an initial drop in blood pressure, followed by a sustained elevation.

- These drugs stimulate the vomiting center of the brain and stimulate contraction of gastrointestinal smooth muscle.

- The ergot alkaloids are highly toxic. Circulatory impairments may result from vasoconstriction and vascular insufficiency. Large doses also damage capillary endothelium and may cause thrombosis and occlusion.

- Hypertension may result from generalized vasoconstriction.

- These drugs inhibit effects of prostaglandins. When given concurrently with abortifacient prostaglandins, the abortive process is prolonged.

- Decreased effectiveness of ritodrine, which is a beta-adrenergic stimulating (agonist) agent.

- Increased risk of pulmonary edema

- Additive vasoconstriction with risks of severe, persistent hypertension and intracranial hemorrhage

- See oxytocin, above.
Review and Application Exercises

1. Why should drugs be avoided during pregnancy and lactation when possible?
2. How does insulin therapy for diabetes mellitus differ during pregnancy?
3. What is the rationale for using methyldopa and hydralazine to treat hypertension during pregnancy?
4. How are asthma and seizure disorders managed during pregnancy?
5. In a client receiving a tocolytic to inhibit uterine contractions, how and when would you assess the client for adverse drug effects?
6. In a client receiving an oxytocin infusion to induce or augment labor, what interventions are needed to increase safety and decrease adverse drug effects?
7. Which immunizations are safe to be administered during pregnancy? Which are contraindicated?
8. A pregnant client asks you about using herbal supplements. What would you tell her? Why?

SELECTED REFERENCES

## Recently Approved and Miscellaneous Drugs

<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Use</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adofovir dipivoxil (Hepsera)</td>
<td>Hepatitis B</td>
<td>Inhibits reproduction of the hepatitis B virus</td>
<td>PO 10 mg once daily</td>
</tr>
<tr>
<td>Alosetron (Lotronex)</td>
<td>Severe, diarrhea-dominant irritable bowel syndrome (IBS)</td>
<td>May cause severe adverse effects</td>
<td>See manufacturer’s literature</td>
</tr>
<tr>
<td>Alprostadil (Caverject, Muse)</td>
<td>Erectile dysfunction</td>
<td>A form of prostaglandin E</td>
<td>Restrictions on prescribing Caverject, injection into penis</td>
</tr>
<tr>
<td>Antithrombin III, Human (Thrombate III)</td>
<td>Antithrombin III deficiency in patients with thrombotic disorders</td>
<td>Replaces a substance normally found in plasma</td>
<td>PO 10–15 mg once daily</td>
</tr>
<tr>
<td>Aripiprazole (Abilify)</td>
<td>Schizophrenia</td>
<td>An atypical antipsychotic agent similar to risperidone in efficacy</td>
<td>PO 40–100 mg daily, in 1 or 2 doses</td>
</tr>
<tr>
<td>Atomoxetine (Strattera)</td>
<td>Attention deficit-hyperactivity disorder (ADHD)</td>
<td>Nonstimulant; not a controlled drug; low risk of abuse</td>
<td>PO 2250 mg 3 times daily for 8–12 wk</td>
</tr>
<tr>
<td>Balsalazide (Colazal)</td>
<td>Ulcerative colitis</td>
<td>Anti-inflammatory effects</td>
<td>Injection of infants at approximately 2, 4, and 6 months of age</td>
</tr>
<tr>
<td>Diphtheria &amp; Tetanus Toxoids &amp; Acellular Pertussis (DtaP), Hepatitis B (recombinant), &amp; Inactivated Poliovirus Vaccine (Pediarix)</td>
<td>Primary vaccination of children against diphtheria, tetanus, pertussis, polio, and hepatitis B virus infection</td>
<td>Reduces injections for comparable protection from 9 to 3</td>
<td></td>
</tr>
<tr>
<td>Dutasteride (Avodart)</td>
<td>Benign prostatic hypertrophy</td>
<td>Antiandrogen effects</td>
<td>PO 0.5 mg daily</td>
</tr>
<tr>
<td>Eplerenone (Inspra)</td>
<td>Hypertension</td>
<td>An aldosterone receptor antagonist</td>
<td>PO 50 mg once daily</td>
</tr>
<tr>
<td>Epoprostenol (Flolan)</td>
<td>Pulmonary hypertension</td>
<td>Adverse effects include hypotension, nausea, vomiting, diarrhea, flu-like symptoms</td>
<td>IV infusion via central venous catheter; see manufacturer’s instructions re: dosage</td>
</tr>
<tr>
<td>Escitalopram (Lexapro)</td>
<td>Major depression</td>
<td>Similar to other selective serotonin reuptake inhibitors (SSRIs)</td>
<td>PO 10 mg once daily, with or without food</td>
</tr>
<tr>
<td>Ezetimibe (Zetia)</td>
<td>Hypercholesterolemia</td>
<td>Stops absorption of cholesterol in intestines</td>
<td>Tablets, PO 800 mg 3 times daily for 6 wk</td>
</tr>
<tr>
<td>Mesalamine (Asacol, Pentasa, Rowasa)</td>
<td>Ulcerative colitis, Proctitis</td>
<td>Has anti-inflammatory effects</td>
<td>Capsules, PO 1 g 4 times daily for up to 8 wk</td>
</tr>
<tr>
<td>Metformin/glipizide (Metaglip)</td>
<td>Type 2 diabetes mellitus</td>
<td>Each tablet contains metformin 250 or 500 mg and glipizide 2.5 or 5 mg</td>
<td>Rectally 1 suppository (500 mg) twice daily or enema 60 mL once daily</td>
</tr>
<tr>
<td>Midodrine (ProAnatime)</td>
<td>Orthostatic hypotension</td>
<td>For severe symptoms only</td>
<td>PO 10 mg 3 times daily</td>
</tr>
<tr>
<td>Olsalazine (Dipentum)</td>
<td>Ulcerative colitis</td>
<td>Anti-inflammatory activity</td>
<td>PO 500 mg twice daily</td>
</tr>
<tr>
<td>Omalizumab (Xolair)</td>
<td>Asthma</td>
<td>Anti-IgE monoclonal antibody</td>
<td>IV 0.5 mg/kg intermittently</td>
</tr>
<tr>
<td>Pentosan polysulfate sodium (Emiron)</td>
<td>Bladder pain associated with interstitial cystitis</td>
<td>May prevent mucosal irritation</td>
<td>PO 100 mg 3 times daily</td>
</tr>
<tr>
<td>Rasburicase (Elitek)</td>
<td>Prevent elevated serum uric acid levels in children with malignancies</td>
<td>May cause anaphylaxis</td>
<td>IV infusion 0.15–0.2 mg/kg once daily for 5 d, 4–24 h before chemotherapy</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Generic/Trade Name</th>
<th>Clinical Use</th>
<th>Characteristics</th>
<th>Routes and Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riluzole (Rilutek)</td>
<td>Amyotrophic lateral sclerosis (ALS)</td>
<td>May cause nausea and increased liver enzymes</td>
<td>PO 50 mg q12h</td>
</tr>
<tr>
<td>Rosiglitazone/metformin (Avandamet)</td>
<td>Type 2 diabetes mellitus</td>
<td>Available in tablets with 1, 2, or 4 mg of rosiglitazone and 500 mg of metformin</td>
<td>PO variable dose; maximum daily dose 8 mg rosiglitazone and 1000 mg metformin</td>
</tr>
<tr>
<td>Sevelamer (Renagel)</td>
<td>Hyperphosphatemia</td>
<td>Reduces serum phosphorus levels</td>
<td>PO 2–4 capsules 3 times daily</td>
</tr>
<tr>
<td>Sildenafil (Viagra)</td>
<td>Erectile dysfunction</td>
<td>Associated with myocardial infarction</td>
<td>PO 50 mg 1 h before sexual activity</td>
</tr>
<tr>
<td>Sulfasalazine (Azulfidine)</td>
<td>Ulcerative colitis Rheumatoid arthritis</td>
<td>Anti-inflammatory effects</td>
<td>PO 2–4 g daily in divided doses</td>
</tr>
<tr>
<td>Tegaserod (Zelnorm)</td>
<td>Constipation-dominant irritable bowel syndrome (IBS)</td>
<td>May cause diarrhea and abdominal pain</td>
<td>PO 6 mg twice daily for 4–6 wk</td>
</tr>
</tbody>
</table>
The International System of Units

The International System of Units (Système International d’Unités or SI units), which is based on the metric system, has been adopted by many countries in an attempt to standardize reports of clinical laboratory data among nations and disciplines. A major reason for using SI units is that biologic substances react in the human body on a molar basis.

The international system, like the conventional system, uses the kilogram for measurement of mass or weight and the meter for measurement of length. The major difference is that the international system uses the mole for measurement of amounts per volume of a substance. A mole is the amount of a chemical compound of which its weight in grams equals its molecular weight. Thus, the concentration of solutions is expressed in moles, millimoles, or micromoles per liter (mol/L, mmol/L, µmol/L) rather than the conventional measurement of mass per volume, such as grams or milligrams per 100 mL or dL. A few laboratory values are the same in conventional and SI units, but many differ dramatically. Moreover, “normal values” in both systems often vary, depending on laboratory methodologies and reference sources. Thus, laboratory data should be interpreted in light of the client’s clinical status and with knowledge of the “normal values” of the laboratory performing the test.

In addition to other laboratory tests, measuring the amount of a drug in blood plasma or serum is often useful in the clinical management of various disorders. For example, serum drug levels may be used to guide drug dosage (eg, aminoglycoside antibiotics such as gentamicin), to evaluate an inadequate therapeutic response, and to diagnose drug toxicity.
**Therapeutic Serum Drug Concentrations for Selected Drugs**

Listed below are generally accepted therapeutic serum drug concentrations, in conventional and SI units, for several commonly used drugs. In addition, toxic concentrations are listed for selected drugs. SI units have not been established for some drugs.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Conventional Units</th>
<th>SI Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>0.2–0.6 mg/dL</td>
<td>13–40 µmol/L</td>
</tr>
<tr>
<td></td>
<td>Toxic &gt;5 mg/dL</td>
<td>&gt;300 µmol/L</td>
</tr>
<tr>
<td>Amikacin</td>
<td>(peak) 16–32 mcg/mL</td>
<td>20–30 mg/L</td>
</tr>
<tr>
<td></td>
<td>(trough) ≤8 mcg/mL</td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>110–250 ng/mL</td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>4–12 mcg/mL</td>
<td>375–900 nmol/L</td>
</tr>
<tr>
<td>Desipramine</td>
<td>125–300 ng/mL</td>
<td>17–50 µmol/L</td>
</tr>
<tr>
<td>Digoxin</td>
<td>0.5–2.2 ng/mL</td>
<td>1–2.6 nmol/L</td>
</tr>
<tr>
<td>Disopyramide</td>
<td>2–8 mcg/mL</td>
<td>6–18 µmol/L</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td>40–110 mcg/mL</td>
<td>280–780 µmol/L</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>(peak) 4–8 mcg/mL</td>
<td>5–10 mg/L</td>
</tr>
<tr>
<td></td>
<td>(trough) ≤2 mcg/mL</td>
<td></td>
</tr>
<tr>
<td>Imipramine</td>
<td>200–350 ng/mL</td>
<td>530–950 nmol/L</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>1.5–6 mcg/mL</td>
<td>6–21 µmol/L</td>
</tr>
<tr>
<td>Lithium</td>
<td>0.5–1.5 mEq/L</td>
<td>0.5–1.5 mmol/L</td>
</tr>
<tr>
<td>Maprotiline</td>
<td>50–200 ng/mL</td>
<td>180–270 µmol/L</td>
</tr>
<tr>
<td>Netilmicin</td>
<td>(peak) 6–10 mcg/mL</td>
<td>5–10 mg/L</td>
</tr>
<tr>
<td></td>
<td>(trough) ≤2 mcg/mL</td>
<td></td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>50–150 ng/mL</td>
<td>190–570 nmol/L</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>15–50 mcg/mL</td>
<td>65–170 µmol/L</td>
</tr>
<tr>
<td>Phenytoin</td>
<td>10–20 mcg/mL</td>
<td>40–80 µmol/L</td>
</tr>
<tr>
<td>Primidone</td>
<td>5–12 mcg/mL</td>
<td>25–45 µmol/L</td>
</tr>
<tr>
<td>Procainamide</td>
<td>4–8 mcg/mL</td>
<td>17–40 µmol/L</td>
</tr>
<tr>
<td>Propranolol</td>
<td>50–200 ng/mL</td>
<td>190–770 nmol/L</td>
</tr>
<tr>
<td>Protriptyline</td>
<td>100–300 ng/mL</td>
<td>380–1140 nmol/L</td>
</tr>
<tr>
<td>Quinidine</td>
<td>2–6 mcg/mL</td>
<td>4.6–9.2 µmol/L</td>
</tr>
<tr>
<td>Salicylate</td>
<td>100–200 mg/L</td>
<td>724–1448 µmol/L</td>
</tr>
<tr>
<td></td>
<td>Toxic &gt;200 mg/L</td>
<td>&gt;1450 µmol/L</td>
</tr>
<tr>
<td>Theophylline</td>
<td>10–20 mcg/mL</td>
<td>55–110 µmol/L</td>
</tr>
<tr>
<td></td>
<td>(peak) 4–8 mcg/mL</td>
<td>5–10 mg/L</td>
</tr>
<tr>
<td>Tobramycin</td>
<td>(trough) ≤2 mcg/mL</td>
<td></td>
</tr>
<tr>
<td>Valproic acid</td>
<td>50–100 mcg/mL</td>
<td>350–700 µmol/L</td>
</tr>
<tr>
<td>Vancomycin</td>
<td>(peak) 30–40 mg/mL</td>
<td>(peak) 20–40 mg/L</td>
</tr>
<tr>
<td></td>
<td>(trough) 5–10 mg/mL</td>
<td>(trough) 5–10 mg/L</td>
</tr>
</tbody>
</table>

mcg, microgram; ng, nanogram; µmol, micromole.
Two national laws, with their amendments, regulate drug-related standards and practices. The Health Protection Branch of the Department of National Health and Welfare is responsible for administering and enforcing the laws, which are described below.

The Food and Drugs Act, initially passed in 1953 and amended periodically since then, regulates the manufacture, distribution, advertising, labeling, and use of drugs. Specific provisions:

- Empower the government to control the marketing of drugs according to proof of safety and effectiveness
- Require that drugs comply with the standards under which the drugs are approved for sale or the standards listed in “specific pharmacopeiae”
- Direct the government to supervise the manufacturing processes of some drugs
- Classify drugs (e.g., antihypertensives, antimicrobials, hormones) that require a prescription and specify that refills must be designated on the original prescription and obtained within 6 months (Schedule F)
- Specify symbols to be placed on containers of the different classifications of drugs
- Require proof of appropriate drug release from oral dosage formulations
- Prohibit advertising of prescription and controlled drugs to the public
- Prohibit the sale of contaminated, adulterated, or unsafe drugs
- Establish requirements for labeling
- Prohibit false, misleading, or deceptive labeling of drug products

The Narcotic Control Act, originally passed in 1961 and amended periodically since then, restricts the sale, possession, and use of opiates, cocaine, marijuana, and methadone. Additional provisions:

- Restrict possession of the above drugs to authorized people
- Require people possessing the drugs to keep them in a secure place, maintain strict dispensing records, and promptly report any thefts or other losses
- Require prescriptions for dispensing narcotics
- Require that containers with prescribed narcotics be labeled with the symbol N
- Specify four levels of controlled drugs. The first level, narcotics, includes single drugs and preparations containing cocaine, codeine, heroin, hydrocodone, hydromorphone, methadone, morphine, oxycodone, and pentazocine. The second level, controlled drugs or Schedule G, includes non-narcotic prescription drugs, the use of which is restricted to treatment of certain disorders (e.g., amphetamines, methylphenidate, pentobarbital, and secobarbital). The third level restricts anabolic steroids, amobarbital, phenobarbital, diethylpropion, and nalbuphine. The fourth level (Schedule H) includes substances with no recognized medicinal uses (e.g., hallucinogens such as LSD).

Nurses in Canada are governed by these national laws; there also may be local and provincial laws. Legal possession of a narcotic by a nurse is restricted to the following circumstances:

- When administering to a client according to a physician’s order
- When performing custodial care of narcotics as an agent of a health care facility
- When receiving a prescribed narcotic for medical treatment
Canadian Drug Names

Many drugs are distributed by international pharmaceutical companies, and most names (generic and trade) are the same in the United States and Canada. To assist the Canadian reader in identifying the drugs discussed in this book, generic names, relevant chapter number(s), and Canadian trade names are listed below. Generic names used in Canada but not in the United States are designated by an asterisk.

Canadian trade names that include Alti, Apo, Novo, or Nu are drugs manufactured by Altimed, Apotex, Novo-Pharm, and Nu-Pharm companies, respectively. Some trade names consist of a company prefix and a generic name (eg, Alti-Ibuprofen, Apo-Cimetidine, Novo-Acebutolol, Nu-Clonidine). Because these names are easy to identify, they are not included in the accompanying list. However, some trade names consisting of a company prefix and a shortened version of the generic name (eg, Apo-Alpraz for alprazolam) are included.

Generic/Canadian Trade Names

Abacavir (39)
Ziagen
Abciximab (57)
ReoPro
Acetobutolol (19)
Monitan, Rhotral, Sectral
Acetaminophen (7), Paracetamol*
APAP, Abenol, Atasol, Tempra, Tylenol
Acetazolamide (65)
Diamox
Acetylcysteine (49)
Mucomyst, Parvolex
Acyclovir (39, 66)
Avirax, Zovirax
Adenosine (52)
Adenocard
Albuterol (18, 47), Salbutamol*
Airomir, Asmavent, Novo-Salmol, Ventolin
Amlodipine (53)
Norvasc
Amitriptyline (10)
Elavil
Amitriptiline (16, 47)
Phyllocontin
Amiodarone (52)
Cordarone
Amikacin (35)
Amikin
Aminocaproic acid (57)
Amicar
Aminophylline (16, 47)
Aminophylline (16, 47)
Ampicillin (34)
Apo-Ami, Nu-Ampi
Amifostine (64)
Ethyol
Anagrelide (10)
Agrylin
Asparaginase, (64) Colaspase*
Kidrolase
Atenolol (19, 53, 55)
Apo-Atenol, Novo-Atenol, Nu-Atenol, Tenormin
Atorvastatin (58)
Lipitor
Azatadine (48)
Optimine
Azathioprine (45)
Imuran
Azelastine (48)
Astelin
Azithromycin (37)
Zithromax
Bacitracin (65, 66)
Baciguent
Baclofen (13)
Lioresal, Liotec, Nu-Baclo
Beclomethasone (24, 47)
Beconase, Vancenase, Vanceril
Benzoyl peroxide (66)
Acetoxyl, Benoxyl, Benzac, Benzagel, Desquam-X, Panoxyl, Solugel
Benztropine (12, 21)
Cogentin
Betamethasone (24, 66)
Betaderm, Betnesol, Betnovate, Celestoderm, Tara-Sone
Betaxolol (19, 65)
Betoptic S
Bethanechol (20)
Duvoid, Mytonachol, Urecholine
Biperiden (12, 21)
Akineton
Bisacodyl (61)
Dulcolax
Bitolterol (47)
Tornalate
Bleomycin (64)
Blenoxane
Brimonidine (65)
Alphagan
Budesonide (47)
Pulmicort, Rhinocort
Bumetanide (56)
Burinex
Bupropion (10, 15)
Wellbutrin, Zyban
Buspirone (8)
Buspar, Buspirex, Bustab
Calcitriol (26)
Rocaltrol
Calcium carbonate (26)
Apo-Cal, Caltrate, Os-Cal
Candesartan (55)
Atacand
Carbamazepine (11)
Novo-Carbamaz, Tegretol
Carboplatin (64)
Paraplatin-AQ
Carisoprodol (13), Isomeprobamate *
Soma
Carmustine (64)
BiCNU
Cefaclor (34)
Cefadroxil (34)
Duricef
Cefazolin (34)
Ancef, Kefzol
Cefepime (34)
Maxipime
Cefixime (34)
Suprax
Cefoperazone (34)
Cefobid
Cefotaxime (34)
Clavoxan
Cromolyn (47), Sodium cromoglycate*
  Intal, Nalcrom, Opticrom
Cyclobenzaprine (13)
  Flexeril, Novo-Cycloprine
Cyclopentolate (65)
  Cyclogyl, Diopentolate
Cyclophosphamide (64)
  Cytoxan, Procytox
Cyclosporine (45)
  Neoral, Sandimmune
Cyproheptadine (48)
  Periactin
Cytarabine, cytosine arabinoside (64)
  Cytosar
Cyclophosphamide (64)
  Cytoxan, Procytox
Cyclosporine (45)
  Neoral, Sandimmune
Cyproheptadine (48)
  Periactin
Cyclosporine (45)
  Neoral, Sandimmune
Cyproheptadine (48)
  Periactin
Cytarabine, cytosine arabinoside (64)
  Cytosar
Cyclophosphamide (64)
  Cytoxan, Procytox
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Canadian Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethinyl estradiol/norgestrel (28)</td>
<td>Ovral</td>
</tr>
<tr>
<td>Ethosuximide (11)</td>
<td>Zarontin</td>
</tr>
<tr>
<td>Etidronate (26)</td>
<td>Didronel</td>
</tr>
<tr>
<td>Etodolac (7)</td>
<td>Ultradol</td>
</tr>
<tr>
<td>Etoposide (64)</td>
<td>Vepesid</td>
</tr>
<tr>
<td>Famciclovir (39)</td>
<td>Famvir</td>
</tr>
<tr>
<td>Famotidine (60)</td>
<td>Pepcid, Ulcidine</td>
</tr>
<tr>
<td>Felodipine (53)</td>
<td>Plendil, Renedil</td>
</tr>
<tr>
<td>Fenofibrate (58)</td>
<td>Lipidil</td>
</tr>
<tr>
<td>Fenoprofen (7)</td>
<td>Nalfon</td>
</tr>
<tr>
<td>Fentanyl (6)</td>
<td>Duragesic</td>
</tr>
<tr>
<td>Ferrous sulfate (32)</td>
<td>Fer-In-Sol, Ferodan</td>
</tr>
<tr>
<td>Fexofenadine (48)</td>
<td>Allegra</td>
</tr>
<tr>
<td>Filgrastim (44)</td>
<td>Neupogen</td>
</tr>
<tr>
<td>Flavoxate (21)</td>
<td>Urispas</td>
</tr>
<tr>
<td>Flecaïnid (52)</td>
<td>Tambocor</td>
</tr>
<tr>
<td>Fluconazole (40)</td>
<td>Diflucan</td>
</tr>
<tr>
<td>Fludarabine (64)</td>
<td>Fludara</td>
</tr>
<tr>
<td>Fluocortisone (24)</td>
<td>Florinef</td>
</tr>
<tr>
<td>Flumazenil (8)</td>
<td>Anexate</td>
</tr>
<tr>
<td>Flunisolide (24, 47)</td>
<td>Rhinalar</td>
</tr>
<tr>
<td>Fluocinolone (66)</td>
<td>Lidemol, Lidx, Synalar, Tiamol, Topsyn</td>
</tr>
<tr>
<td>Fluorometholone (65)</td>
<td>Flarex, FML</td>
</tr>
<tr>
<td>Fluorouracil, 5-FU (64)</td>
<td>Adrucil, Efudex</td>
</tr>
<tr>
<td>Fluoxetine (10)</td>
<td>Prozac</td>
</tr>
<tr>
<td>Fluoxymesterone (29)</td>
<td>Halostestin</td>
</tr>
<tr>
<td>Fluphenazine (9)</td>
<td>Moditen</td>
</tr>
<tr>
<td>Flurazepam (8)</td>
<td>Dalmane, Sonmol</td>
</tr>
<tr>
<td>Flurbiprofen (7, 65)</td>
<td>Ansaid, Froben, Ocuflu</td>
</tr>
<tr>
<td>Flutamide (64)</td>
<td>Euflex</td>
</tr>
<tr>
<td>Fluticasone (24)</td>
<td>Flonase, Flovent</td>
</tr>
<tr>
<td>Fluavastatin (58)</td>
<td>Lescol</td>
</tr>
<tr>
<td>Fluvoxamine (10)</td>
<td>Luvox</td>
</tr>
<tr>
<td>Fosfomycin (36)</td>
<td>Monurol</td>
</tr>
<tr>
<td>Fosinopril (55)</td>
<td>Monopril</td>
</tr>
<tr>
<td>Fosphenytoin (11)</td>
<td>Cerebyx</td>
</tr>
<tr>
<td>Furosemide (26, 56), Frusemide*</td>
<td>Lasix</td>
</tr>
<tr>
<td>Gabapentin (11)</td>
<td>Neurontin</td>
</tr>
<tr>
<td>Ganciclovir (39)</td>
<td>Cytovene</td>
</tr>
<tr>
<td>Gatifloxacin (35)</td>
<td>Tequin</td>
</tr>
<tr>
<td>Gemcitabine (64)</td>
<td>Gemzar</td>
</tr>
<tr>
<td>Gemfibrozil (58)</td>
<td>Lopid</td>
</tr>
<tr>
<td>Gentamicin (35, 65)</td>
<td>Alcomycin, Diogenet, Garamycin</td>
</tr>
<tr>
<td>Glimepiride (27)</td>
<td>Amaryl</td>
</tr>
<tr>
<td>Glyburide (27), Gilbenclamide*</td>
<td>DiaBeta, Euglucon, Gen-Glybe</td>
</tr>
<tr>
<td>Goserelain (64)</td>
<td>Zoladex</td>
</tr>
<tr>
<td>Granisetron (63)</td>
<td>Kytril</td>
</tr>
<tr>
<td>Guainifenesin (49), Glyceryl guaiacolate*</td>
<td>Balminil Expectorant, Benyl-E, Robitussin</td>
</tr>
<tr>
<td>Griseofulvin (40)</td>
<td>Fulvicin</td>
</tr>
<tr>
<td>Halcinonide (66)</td>
<td>Halog</td>
</tr>
<tr>
<td>Haloperidol (9)</td>
<td>Halodol, Peridol</td>
</tr>
<tr>
<td>Hydralazine (55)</td>
<td>Apresoline, Novo-Hylazin, Nu-Hydral</td>
</tr>
<tr>
<td>Hydrochlorothiazide (56)</td>
<td>Apo-Hydro, HydroDiuril</td>
</tr>
<tr>
<td>Hydrocodone (6, 49)</td>
<td>Hydcan, Robidone</td>
</tr>
<tr>
<td>Hydrocortisone (24, 47, 66)</td>
<td>Aquacort, Cortate, Cortef, Cortenema</td>
</tr>
<tr>
<td>Hydromorphone (6, 49)</td>
<td>Dilaudid, Hydromorph Contine</td>
</tr>
<tr>
<td>Hydroxyurea (64)</td>
<td>Hydrea</td>
</tr>
<tr>
<td>Hydroxyzine (8, 48, 63)</td>
<td>Atarax</td>
</tr>
<tr>
<td>Ibuprofen (7)</td>
<td>Advil, Motrin, Novo-Profen</td>
</tr>
<tr>
<td>Idaurubicin (64)</td>
<td>Idamycin</td>
</tr>
<tr>
<td>Ifosfamide (64)</td>
<td>Ifex</td>
</tr>
<tr>
<td>Imipenem/cilastatin (34)</td>
<td>Primaxin</td>
</tr>
<tr>
<td>Impiramine (10)</td>
<td>Tofranil</td>
</tr>
<tr>
<td>Indomethacin (7)</td>
<td>Indocid, Indotec, Novo-Methacin, Nu-Indo</td>
</tr>
<tr>
<td>Insulins (27)</td>
<td>Humalog, Humulin, Iletin, Lantus, Novolin</td>
</tr>
<tr>
<td>Interferons (44)</td>
<td>Alfa-2a (Roferon A); alfa-2b (Intron A); beta-1a (Avonex, Rebif); beta-1b (Betaseron)</td>
</tr>
<tr>
<td>Ipratropium (47)</td>
<td>Atrovent</td>
</tr>
<tr>
<td>Drug Name</td>
<td>Brand Name(s)</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Irbesartan</td>
<td>Avapro</td>
</tr>
<tr>
<td>Irinotecan</td>
<td>Camptosar</td>
</tr>
<tr>
<td>Isoproterenol</td>
<td>Isuprel</td>
</tr>
<tr>
<td>Isosorbide dinitrate</td>
<td>Apo-ISDN, Cedocard-SR, Isordil</td>
</tr>
<tr>
<td>Isosorbide mononitrate</td>
<td>Imdur, Ismo</td>
</tr>
<tr>
<td>Isotretinoin</td>
<td>Accutane, Isotrext</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Nizoral</td>
</tr>
<tr>
<td>Ketoprofen</td>
<td>Apo-Keto, Novo-Keto, Orafen, Orudis, Oruvail, Rhodis</td>
</tr>
<tr>
<td>Ketorolac</td>
<td>Acular, Toradol</td>
</tr>
<tr>
<td>Labetalol</td>
<td>Trandate</td>
</tr>
<tr>
<td>Lamivudine</td>
<td>Epivir</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>Lamictal</td>
</tr>
<tr>
<td>Lansoprazole</td>
<td>Prevacid</td>
</tr>
<tr>
<td>Leuproside</td>
<td>Lupron</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>Keppra</td>
</tr>
<tr>
<td>Levobunolol</td>
<td>Betagan</td>
</tr>
<tr>
<td>Levofoflaxacin</td>
<td>Levaquin</td>
</tr>
<tr>
<td>Levothyroxine</td>
<td>Eltroxin, Synthroid</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>Xylocaine, Xylocard</td>
</tr>
<tr>
<td>Linezolid</td>
<td>Zyxox</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>Prinivil, Zestril</td>
</tr>
<tr>
<td>Lithium</td>
<td>Carbolith, Duralith, Lithane</td>
</tr>
<tr>
<td>Loperamide</td>
<td>Imodium</td>
</tr>
<tr>
<td>Loratadine</td>
<td>Claritin</td>
</tr>
<tr>
<td>Lorazepam</td>
<td>Ativan, Novo-Lorazem, Nu-Loraz</td>
</tr>
<tr>
<td>Losartan</td>
<td>Cozaar</td>
</tr>
<tr>
<td>Lovastatin</td>
<td>Mevacor</td>
</tr>
<tr>
<td>Mannitol</td>
<td>Osmitrol</td>
</tr>
<tr>
<td>Mebendazole</td>
<td>Vermox</td>
</tr>
<tr>
<td>Mecloprine</td>
<td>Bonamine</td>
</tr>
<tr>
<td>Medroxyprogesterone</td>
<td>Depo-Provera, Novo-Medrone, Provera</td>
</tr>
<tr>
<td>Megestrol</td>
<td>Megace</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>Mobic</td>
</tr>
<tr>
<td>Melphalan</td>
<td>Alkeran</td>
</tr>
<tr>
<td>Meperidine</td>
<td>Demerol</td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>Purinethol</td>
</tr>
<tr>
<td>Meropenem</td>
<td>Merrem</td>
</tr>
<tr>
<td>Metanor/noretindrone</td>
<td>Ortho-Novum</td>
</tr>
<tr>
<td>Metaprotosterol</td>
<td>Alupent</td>
</tr>
<tr>
<td>Methimazole</td>
<td>Tapazole</td>
</tr>
<tr>
<td>Methocarbamol</td>
<td>Robaxin</td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Rheumatrex</td>
</tr>
<tr>
<td>Methyldopa</td>
<td>Aldomet, Novo-Medopa, Nu-Medopa</td>
</tr>
<tr>
<td>Methyphenidate</td>
<td>Ritalin</td>
</tr>
<tr>
<td>Metoprednisolone</td>
<td>Depo-Medrol, Medrol, Solu-Medrol</td>
</tr>
<tr>
<td>Metoclopramide</td>
<td>Apo-Metoclopop, Reglan</td>
</tr>
<tr>
<td>Metolazone</td>
<td>Zaroxolyn</td>
</tr>
<tr>
<td>Metoprol</td>
<td>Betaloc, Lopressor, Novo-Metoprol, Nu-Metop</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>Flagyl, Metrogel, Novo-Nidazol, Noritate</td>
</tr>
<tr>
<td>Miconazole</td>
<td>Micatin, Monistat, Micozole</td>
</tr>
<tr>
<td>Midazolam</td>
<td>Versed</td>
</tr>
<tr>
<td>Migliol</td>
<td>Glyset</td>
</tr>
<tr>
<td>Milrinone</td>
<td>Primacor</td>
</tr>
<tr>
<td>Minocycline</td>
<td>Minocin</td>
</tr>
<tr>
<td>Minoxidil</td>
<td>Apo-Gain, Loniten, Rogaine</td>
</tr>
<tr>
<td>Misoprostol</td>
<td>Cytotec</td>
</tr>
<tr>
<td>Moexapril</td>
<td>Univasac</td>
</tr>
<tr>
<td>Mometasone</td>
<td>Nasonex</td>
</tr>
<tr>
<td>Montelukast</td>
<td>Singulair</td>
</tr>
<tr>
<td>Morphine</td>
<td>Morphitec, MOS, MS Contin, MSIR, Oramorph, Statex</td>
</tr>
<tr>
<td>Moxiflaxacin</td>
<td>Avelox</td>
</tr>
<tr>
<td>Muromonab-CD3</td>
<td>Orthoclone OKT 3</td>
</tr>
<tr>
<td>Mycophenolate</td>
<td>CellCept</td>
</tr>
<tr>
<td>Nabumetone</td>
<td>CellCept</td>
</tr>
<tr>
<td>Nadolol</td>
<td>Relafen</td>
</tr>
<tr>
<td>Mobic</td>
<td>Appro-Pro, Corgard</td>
</tr>
<tr>
<td>Nalbuphine</td>
<td>Nubain</td>
</tr>
</tbody>
</table>
Naloxone (6)
Narcan
Naphazoline (18, 49)
Naphcon, Vasocon
Naproxen (7)
Anaprox, Naprosyn, Naxen, Synflex
Naratriptan (7)
Amerge
Nateglinide (27)
Starlix
Nedocromil (47)
Alocril, Tilade
Nefazodone (10)
Serzone
Nelfinavir (39)
Viracept
Neostigmine (20)
Prostigmin
Netilmicin (35)
Netromycin
Nevirapine (39)
Viramune
Nicardipine (53)
Cardene
Nifedipine (53)
Adalat PA, Apo-Nifed, Novo-Nifedin, Nu-Nifed
Nilutamide (64)
Anandron
Nitrofurantoin (36)
Macrodantin
Nitroprusside (55)
Nitropress
Nitroglycerin (53), Glyceryl trinitrate*
Minitran, Nitro-Dur, Nitrol, Nitrostat, Transderm-Nitro
Nitazidine (60)
Axid
Norepinephrine (18, 54), Noradrenaline*
Levophed
Northindrone (28)
Norlutate
Norfloxacin (35, 65)
Apo-Norflox, Noroxin
Nortriptyline (10)
Aventyl, Norventyl
Nystatin (40, 66)
Candidstatin, Mycostatin, Nilstat, Nyaderm
Ofloxacin (35, 65)
Apo-Oflox, Floxin, Ocuflox
Olanzapine (9)
Zyprexa
Olmesartan (55)
Benicar
Omeprazole (60)
Losec
Ondansetron (63)
Zofran
Orphenadrine (12, 13)
Disipal
Oseltamivir (39)
Tamiflu
Oxaprin (7)
Daypro
Oxazepam (8)
Serax
Oxycodeone (6)
OxyContin, Supeudol
Paclitaxel (64)
Taxol
Pamidronate (26)
Aredia
Pantoprazole (60)
Panto IV, Pantoloc
Paroxetine (10)
Paxil
Penicillin V (34), Phenoxymethyl penicillin*
Apo-Pen VK, Nadopen-V, Novo-V-Pen-VK, Nu-Pen-VK
Pentamidine (41)
Pentacarinat
Perphenazine (9)
Trilafon
Phenelzine (10)
Nardil
Phenobarbital (8, 11), Phenobarbitone*
Phenylephrine (18, 49)
Dioneprine, Mydfrin, Neo-Synephrine
Phenytoin (11)
Dilantin
Pindolol (19, 55)
Apo-Pindol, Novo-Pindol, Nu-Pindol, Visken
Piozilazine (27)
Actos
Piperacillin (34)
Pipracil
Piperacillin/tazobactam (34)
Tazocin
Piroxicam (7)
Feldene, Fexicam, Novo-Pirocam, Nu-Pirox
Potassium chloride (32)
Pramipexole (12)
Mirapex
Pravastatin (58)
Pravasol
Prazosin (55)
Apo-Prazo, Minipress, Novo-Prazin, Nu-Prazo
Prednisolone (24), Deltahydrocortisone*
Diopred, Inflamase, Ophtho-Tate, Pediapred
Prednisone (24), Deltacortisone*
Winpred
Procainamide (52)
Procan-SR, Pronestyl
Prochlorperazine (9)
Stemetil
Propylthiouracil (25)
Propyl-Thyracil
Promethazine (9, 48, 63)
Phenergan
Propranolol (19, 52, 53, 55)
Inderal
Propylthiouracil (25)
Propyl-Thyracil
Protriptyline (10)
Triptil
Quetiapine (9)
Seroquel
Quinapril (55)
Accupril
Quinidine (52)
Biquin, Cardioquin, QuinideX
Quinupristin/dalfopristin (37)
Synercid
Rabeprazole (60)
Aciphex
Raloxifene (26)
Evista
Ramipril (55)
Altace
Ranitidine (60)
Novo-Ranidine, Nu-Ranit, Zantac
Repaglinide (27)
GlucoNorm
Ribavirin (39)
Virazole
Rifampin (38)
Rifadin, Rofact
Risedronate (26)
Actonel
Risperidone (9)
Risperdal
Ritonavir (39)
Norvir
Rituximab (64)
Rituxan
Rizatriptan (7)
Maxalt
Rofecoxib (7)
Vioxx
Ropinirole (12)
ReQuip
Rosiglitazone (27)
Avandia
Salmeterol (47)
Serevent
Saquinavir (39)
Invirase
Scopolamine (21, 63)
Transderm-V
Selegiline (12)
Eldepryl
Sertraline (10)
Zoloft
Simvastatin (58)
Zocor
Sodium polystyrene sulfonate (32)
Kayexalate
Sotalol (19, 52)
Sotacor
Spiironolactone (56)
Aldactone, Novo-Spiroton
Stavudine (39)
Zerit
Streptokinase (57)
Kabikinase, Streptase
Succinylcholine (14)
Quelicin
Sucrafate (60)
Sulcrate
Sulfacetamide (65)
Cetamide, Diosulf, Sodium Sulamyd
Sulfamethoxazole/trimethoprim (36)
Apo-Sulfatrim, Novo-Trimel, Nu-Cotrimox, Septra
Sulindac (7)
Apo-Sulin, Novo-Sundac
Sumatriptan (7)
Imitrex
Tamoxifen (64)
Apo-Tamox, Novlavadex, Tamofen
Telemesartan (55)
Micardis
Temazepam (8)
Restoril
Teniposide (64)
Vumon
Tenofovir (39)
Viread
Terazosin (19, 55)
Hytrin
Terbutaline (18, 47)
Bricanyl
Terconazole (40)
Terazol
Testosterone (29)
Androderm, Delatestyl
Tetracycline (36, 65)
Apo-Tetra, Novo-Tetra, Nu-Tetra
Theophylline (16, 47)
Theochron, Theo-Dur, Theolair, Uniphyl
Thiabendazole (41)
Mintezol
Thiothixene (9)
Navane
Tiagabine (11)
Gabitril
Ticarcillin/clavulanate (34)
Timentin
Timolol (19, 55, 65)
Apo-Timol, Apo-Timop, Novo-Timol, Timoptic
Tioconazole (40)
Gynecure, Trosyd
Tirofiban (57)
Aggrastat
Tobramycin (35, 65)
Nebcin, Tobrex
Tocainide (52)
Tonocard
Tolcapone (12)
Tasmar
Tolmetin (7)
Tolectin
Tolnaftate (40, 66)
Pitrex
Topiramate (11)
Topamax
Topotecan (64)
Hycamtin
Torsemide (56)
Demadex
Trandolapril (55)
Mavik
Tranexamic acid (57)
Cyklokapron
Trastuzumab (64)
Herceptin
Tretinoin (retinoic acid) (66)
Rejuva-A, Renova, Retin-A
Triamcinolone (24, 47, 66)
Aristocort, Azmacort, Kenalog, Nasacort, Triaderm
Triamterene (56)
Dyrenium
Triazolam (8)
Apo-Triazo, Halcion
Vioptic
Trihexyphenidyl (12), Benzhexol*
Apo-Trihex
Trimethoprim (36)
Proloprim
Trimipramine (10)
Apo-Trimip, Novo-Tripramine, Surmontil
Tropicamide (65)
Diotrope, Mydriacyl
Valdecoxib (7)
Bextra
Valproic acid (11)
Depakene, Epiject
Valsartan (55)
Diovan
Vancomycin (37)
Vancocin
Venlafaxine (10)
Effexor
Verapamil (52, 53, 55)
Apo-Verap, Chronovera, Isoptin, Novo-Veramil, Verelan

Vinblastine (64)
Vincristine (64)
Warfarin (57)
Coumadin
Xylometazoline (18, 49)
Decongest
Zafirlukast (47)
Accolate
Zalcitabine (39)
Hivid
Zaleplon (8)
Sonata, Starnoc
Zanamivir (39)
Relenza
Zidovudine (39) Azidothymidine, AZT
Novo-AZT, Retrovir
Ziprasidone (9)
Geodon
Zoledronic acid (26)
Zometa
Zolmitriptan (7)
Zomig
